5 Aminosalicylic Acid (Mesalamine)	\n\n\tDrug International Ltd.\tCanasa TAB dr 400mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tMeslamin TAB dr   \n\tSun Pharmaceutical (Bangladesh) Ltd.\tMesacol TAB dr 400mg 50's pack 377.50\n\tIndication: Ulcerative colitis, Ulcerative proctitis, Crohn's Disease. \n\nDose: For the treatment of mildly to moderately active ulcerative colitis: The usual dosage in adults is two 400 mg tablets to be taken three times a day for a total daily dose of 2.4 grams for a duration of 6 weeks.For the maintenance of remission of ulcerative colitis: The recommended dosage in adults is 1.6 grams daily, in divided doses. Treatment duration in the prospective, well-controlled trial was 6 months.\n\nChild: Dose is dependant on preparation and brand used. Tablets: 5-15 yr: Acute attack: 15-20 mg/kg (max: 1 g) tid; maintenance of remission: 10 mg/kg (max: 500 mg) 2-3 times daily. \n\nCrohn`s disease: 800 mg 3 times daily. \n\nContra-indication: Hypersensitivity to salicylates, aminosalicylates, or any component of the product.- Severe renal impairment (GFR less than 30 mL per minute).- Severe liver impairment.- Gastric and duodenal ulcers- Children under the age of 2 years\n\nSide effects:  Abdominal pain (if new abdominal pain - consider pancreatitis); headache, nausea; flu; fatigue; fever, rash; sore throat; diarrhoea; joint pain; dizziness; bloating; back pain; haemorrhoids; itching; rectal pain, constipation; hair loss; intolerance syndrome; peripheral oedema; UTI; myocarditis, pre-existing pericarditis; pancreatitis; nephritis; hepatitis; lupus-like syndrome; alopecia; myalgia, arthralgia; increased liver enzyme values.Potentially Fatal: Blood dyscrasias, aplastic anaemia, agranulocytosis; renal toxicity.\n\nPrecaution: Mild to moderate impaired renal or hepatic function (test serum creatinine before treatment, every 3 mth for 1st yr, every 6 mth for next 4 yr, then annually). Elderly; active peptic ulcer; pregnancy, lactation; patients predisposed to pericarditis or myocariditis. Counsel patients to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise during treatment; perform blood count and stop treatment if blood dyscrasias suspected. Counsel patients taking delayed release tablets to report repeatedly unbroken or partially broken tablets in their faeces. Pyloric stenosis may delay release into colon.Patients with pulmonary disease, in particular asthma, should be very carefully monitored during a course of treatment.Hypersensitivity to Sulphasalazine.In patients with a history of hypersensitivity to sulphasalazine, therapy should be initiated only under close medical supervision. Treatment must be stopped immediately if acute symptoms of intolerance occur such as abdominal cramps, acute abdominal pain, fever, severe headache and rash.Paediatric populationThere is only limited documentation for an effect in children (age 6-18 years).\n\nMode of action: Do not give with lactulose or other drugs which lower pH for they prevent release of mesalazine. May decrease digoxin absorption.\n\nPregnancy category: B\n\nInteraction: Do not give with lactulose or other drugs which lower pH for they prevent release of mesalazine. May decrease digoxin absorption.
Abacavir + Lamivudine + Zidovudine	\n\n\tSquare\tTivizid TAB dr   10's pack 1405.28\n\tIndication: Acquired immunodeficiency syndrome (AIDS)\n\nDose:  Adults and Adolescents >12 years: Recommended Dose: 1 tablet twice daily.\nThis should not be administered to adolescents and adults who weigh &lt;40 kg because it is a fixed-dose tablet, therefore the dose cannot be reduced.\n\nRenal Impairment: Dosage reduction of lamivudine or zidovudine may be necessary in renally impaired patients. It is therefore recommended that separate preparations of abacavir, lamivudine and zidovudine should be administered to patients with reduced renal function (CrCl &lt;50 mL/min).\n\nHepatic Impairment: This drugs is contraindicated for use in hepatically impaired patients.\n\nAdministration: Trizivir can be taken with or without food.\n\nContra-indication: Hypersensitivity. Hepatic impairment, abnormally low neutrophil counts (&lt;0.75 x 10 9/L) or abnormally low Hb levels (&lt;7.5 g/dL or 4.65 mmol/L). Patient &lt;40 kg, CrCl &lt;50 mL/min.\n\nSide effects: Hypersensitivity reactions (discontinue immediately & do not rechallenge), GI disturbances, anorexia, headache, insomnia, muscle disorders, myalgia, cough, rash, alopecia, fever, malaise, fatigue, severe hepatomegaly w/ steatosis & lactic acidosis.\n\nPrecaution: Use of abacavir in patients known to carry HLA B*5701 allele is not recommended. Screening should be performed before initiating treatment or prior to reinitiation in patients w/ unknown HLA B*5701 status who have previously tolerated abacavir. Hypersensitivity reaction. Risk of lactic acidosis & hepatomegaly w/ steatosis in patients (esp obese women w/ hepatomegaly), pancreatitis, hepatitis or other known risk factors for hepatic disease. Due to haematological AR, monitor haematological parameters during treatment esp in patients w/ poor bone marrow reserve or advanced HIV disease. Discontinue immediately if pancreatitis is suspected. Co-infection w/ HBV or HCV. Immune reconstitution syndrome, opportunistic infections, transmission of infection, MI. Elderly. Pregnancy & lactation.\n\nMode of action: Abacavir: Alcohol may cause decreased elimination of abacavir. Lactic acidosis with nucleoside analogues concomitantly. Decreased serum concentrations of methadone.\n\nZidovudine: acyclovir and valacyclovir may increase CNS depression. Increased risk of haematologic toxicity with ganciclovir, valganciclovir, dapsone, doxorubicin, vincristine and vinblastine. Doxorubicin may reduce phophorylation; fluconazole may increase levels/effects; increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of pancreatitis and lactic acidosis). Methadone may increase effects/levels. Increased risk of myalgia, malaise and/or fever, maculopapular rash and effects/levels with probenecid. Stavudine may decrease antiviral activity; valproic acid may increase plasma levels (AUC increased by 80%).\n\nLamivudine: Increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of mitochondrial toxicity, pancreatitis and lactic acidosis). Ganciclovir and valganciclovir may increase effects and toxicity; sulfamethoxazole/trimethoprim may increase AUC and decrease clearance (increasing levels and effects).\n\nPregnancy category: C\n\nInteraction: Abacavir: Alcohol may cause decreased elimination of abacavir. Lactic acidosis with nucleoside analogues concomitantly. Decreased serum concentrations of methadone.\n\nZidovudine: acyclovir and valacyclovir may increase CNS depression. Increased risk of haematologic toxicity with ganciclovir, valganciclovir, dapsone, doxorubicin, vincristine and vinblastine. Doxorubicin may reduce phophorylation; fluconazole may increase levels/effects; increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of pancreatitis and lactic acidosis). Methadone may increase effects/levels. Increased risk of myalgia, malaise and/or fever, maculopapular rash and effects/levels with probenecid. Stavudine may decrease antiviral activity; valproic acid may increase plasma levels (AUC increased by 80%).\n\nLamivudine: Increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of mitochondrial toxicity, pancreatitis and lactic acidosis). Ganciclovir and valganciclovir may increase effects and toxicity; sulfamethoxazole/trimethoprim may increase AUC and decrease clearance (increasing levels and effects).
Acarbose	\n\n\tPacific\tSugatrol TAB dr 100mg 30's pack 760\n\tPacific\tSugatrol TAB dr 50mg 30's pack 450\n\tWhite Horse Pharma\tAcaril TAB dr 50mg 30's pack 390\n\tIndication: Type 2 DM\n\nDose:  Dosage 	Adult: PO Initial: 25 mg/day. May adjust gradually. Maintenance: 50-100 mg 3 times/day. Max: <60 kg: 50 mg 3 times/day; >60 kg: 100 mg 3 times/day.\n\nContra-indication: Patients <18 yr; diabetic ketoacidosis or cirrhosis; malabsorption; inflammatory bowel disease; with or pre-disposed to intestinal obstruction; intestinal diseases that affect digestion or absorption; conditions that worsen as a result of increased gas formation e.g. hernias; colonic ulcers; hepatic impairment; CrClr< 25 ml/min/1.73m2. Pregnancy, lactation.\n\nSide effects: Flatulence, abdominal pain, distension, diarrhoea, nausea, vomiting. Elevation of transaminases, hepatitis, jaundice. Rarely, skin reactions.\nPotentially Fatal: Hepatotoxicity.\n\nPrecaution: Monitor LFT every 3 mth for 1st yr and periodically thereafter especially for doses >50 mg tid. Reduce dose or withdraw therapy if transaminases elevations persist. If hypoglycaemia occurs, give glucose orally as a 1st aid measure. Adhere strictly to the prescribed diabetic diet to avoid intensification of GI symptoms.\n\nMode of action: May enhance effects of other antidiabetics including insulin. Diminished effects w/ GI adsorbents (e.g. charcoal) and digestive enzyme preparations containing carbohydrate splitting enzymes (e.g. amylase, pancreatin). Neomycin and colestyramine may enhance effects of acarbose. May inhibit absorption of digoxin.\n\nPregnancy category: B\n\nInteraction: May enhance effects of other antidiabetics including insulin. Diminished effects w/ GI adsorbents (e.g. charcoal) and digestive enzyme preparations containing carbohydrate splitting enzymes (e.g. amylase, pancreatin). Neomycin and colestyramine may enhance effects of acarbose. May inhibit absorption of digoxin.
Aceclofenac	\n\n\tACI\tCelofen TAB dr 100mg 50's pack 200.50\n\tAcme Ltd.\tApitac TAB dr 100mg 100's pack 400\n\tAd-din\tFleco TAB dr 100mg 100's pack 250\n\tAexim\tAclovix TAB dr 100mg 100's pack 250\n\tAlbion Ltd.\tAceclofenac TAB dr 100mg 100's pack \n\tAlco Pharma\tAclo TAB dr 100mg 100's pack 300\n\tAPC Pharma Ltd.\tPenac-AC TAB dr 100mg 100's pack 300\n\tApex\tApeclo TAB dr 100mg 100's pack 150\n\tApex\tApeclo SR Extended Release TAB dr 200mg  \n\tApollo Pharmaceutical Ltd.\tAcflam TAB dr  100 mg 100's pack 300\n\tAristopharma\tMervan TAB dr 100mg 100's pack 400\n\tAristopharma\tMervan SR Extended Release TAB dr 200mg 30's pack 600\n\tAsiatic Ltd.\tEna TAB dr 100mg 50's pack 150\n\tAstra Biopharmaceuticals Ltd.\tAceclofen TAB dr 100mg 30's pack 90\n\tBeacon\tAcebid TAB dr 100mg 50's pack 200\n\tBelsen\tAcegic TAB dr  100 mg 100's pack 300\n\tBenham\tAcecloben TAB dr 100mg 50's pack 150\n\tBenham\tA-Pak TAB dr 100mg  \n\tBeximco\tZolfin TAB dr 100mg 100's pack/150's pack 400 / 600\n\tBio Pharma Ltd.\tClof TAB dr 100mg 100's pack 400\n\tBristol Pharma Ltd.\tAcelock TAB dr 100mg 100's pack 300\n\tCentral.\tAcelon TAB dr  100 mg 100's pack 300\n\tChemist Ltd.\tPainex TAB dr 100mg 100's pack 150\n\tConcord\tAcedol TAB dr 100mg 100's pack 300\n\tCosmic Chemical Industries Ltd.\tDolonac TAB dr  100 mg 100's pack 300\n\tCosmo Pharma Ltd.\tAnalgen TAB dr 100mg 50's pack 150\n\tDecent Pharma Ltd.\tACF TAB dr 100mg 100's pack 400\n\tDelta Pharma\tXtrafen TAB dr 100mg  \n\tDelta Pharma\tXtrafen SR Extended Release TAB dr 200mg  \n\tDesh\tXe Fast TAB dr 100mg 40's pack/80's pack 100 / 200\n\tDoctor Tims\tHifenac TAB dr 100mg 50's pack 125\n\tDrug International Ltd.\tNofenac TAB dr 100mg 50's pack 200\n\tEdruc Ltd.\tEcena TAB dr 100mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tPaino TAB dr 100mg 100's pack 400\n\tEskayef Bangladesh Ltd.\tTuffox TAB dr  100 mg 100's pack 301.14\n\tEuro Pharma Ltd.\tFixonac TAB dr 100mg 100's pack 300\n\tEverest\tPankil TAB dr 100mg 100's pack 250\n\tEverest\tPankil TAB dr  100 mg 100's pack 250\n\tG. A. Company Ltd.\tXpain TAB dr 100mg 50's pack 150\n\tGeneral\tAcefenac TAB dr 100mg 50's pack 200\n\tGlobe\tAros TAB dr 100mg 50's pack 150\n\tGlobex\tEzemove TAB dr 100mg 50's pack 200\n\tHallmark\tMovon TAB dr 100mg 50's pack 150\n\tHealthcare\tTernilla TAB dr 100mg 50's pack 200\n\tHudson\tCeconac TAB dr 100mg 100's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tPreservin TAB dr  100 mg 50's pack 175\n\tIncepta\tReservix TAB dr 100mg 100's pack 300\n\tIncepta\tReservix SR Er TAB dr 200mg  \n\tIndobangla Pharmaceuticals\tRelise TAB dr 100mg 100's pack 250\n\tKemiko\tAlona TAB dr 100mg 50's pack 200\n\tKumudini Pharma Ltd.\tXeriflam TAB dr 100mg 50's pack 150\n\tLabaid\tLabenac TAB dr 100mg  \n\tLeon\tPolynac TAB dr 100mg  \n\tMarksman.\tAceclora TAB dr 100mg 50's pack 95\n\tMedicon\tAcenac TAB dr 100mg 50's pack 200\n\tMillat\tLofam TAB dr 100mg 100's pack 300\n\tModern\tACN TAB dr 100mg 100's pack 300\n\tMonicopharma\tNostrin TAB dr 100mg 50's pack 150\n\tMystic\tRheuma TAB dr 100mg 100's pack 280\n\tNavana\tZerodol TAB dr 100mg 50's pack 150.50\n\tNIPRO JMI Pharma\tFlexivan TAB dr 100mg 50's pack 151\n\tNIPRO JMI Pharma\tFlexivan ER Extended Release TAB dr 200mg  \n\tNovartis (Bangladesh) Ltd.\tVaxtin TAB dr 100mg 60's pack 300\n\tNovelta Bestway\tXerolin TAB dr 100mg 50's pack 150\n\tNovo Healthcare and Pharma Ltd.\tServex TAB dr 100mg 50's pack 200\n\tNovus\tRuclon TAB dr 100mg 100's pack 150\n\tNuvista Pharma Ltd\tFreemax TAB dr 100mg 50's pack 248\n\tOpsonin Pharma\tMovex TAB dr 100mg 100's pack 351.88\n\tOrganic Health Care\tOrcenac TAB dr 100mg 50's pack 200\n\tOrion Pharma Ltd.\tNoak TAB dr 100mg 50's pack 200\n\tOyster\tCeclonac TAB dr 100mg 50's pack 150.00\n\tPacific\tAc PR TAB dr  100 mg 50's pack 200\n\tPeoples Pharma Ltd.\tXerifen TAB dr 100mg 100's pack 300\n\tPharmadesh Ltd.\tMotifen TAB dr 100mg 50's pack 175\n\tPharmasia Ltd.\tAclonac TAB dr 100mg 50's pack 150\n\tPrime\tGrofenac TAB dr 100mg  \n\tRadiant.\tAvenac TAB dr 100mg 50's pack 250\n\tRAK\tAclopain TAB dr 100mg 100's pack 400\n\tReliance\tProtilez TAB dr 100mg 100's pack 400\n\tRenata\tCeclofen TAB dr 100mg 50's pack 200\n\tRephco\tRepidor TAB dr 100mg 100's pack 300\n\tS. N.\tVolfenac TAB dr 100mg 100's pack 300\n\tSanofi Aventis (BD) Ltd.\tQrip TAB dr  100 mg 100's pack 400\n\tSeba Ltd.\tSenac - A TAB dr 100mg 100's pack 300\n\tShamsul Al-Amin\tSapclo TAB dr  100 mg 50's pack 150\n\tSharif\tZolonac TAB dr 100mg 50's pack 200\n\tSilva\tOrifen TAB dr 100mg 100's pack 250.94\n\tSomatec\tOstoflex TAB dr 100mg 100's pack 400\n\tSquare\tFlexi TAB dr 100mg 100's pack 400\n\tSquare\tFlexi SR TAB dr 200mg 30's pack \n\tSupreme\tXyfen TAB dr 100mg 30's pack 90\n\tSyntho Ltd.\tSyclofen TAB dr 100mg 100's pack 300\n\tVeritas\tPainkil TAB dr 100mg  \n\tWhite Horse Pharma\tAcepro TAB dr  100 mg 50's pack 150\n\tZenith\tLofens TAB dr 100mg 100's pack 151\n\tZiska\tAcecol TAB dr 100mg 50's pack 100\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis;\n\nDose: Adult: PO Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis 100 mg twice daily.\n\nContra-indication: Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.\n\nSide effects: Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.\nPotentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.\n\nPrecaution: Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly.\n\nMode of action: May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.\n\nPregnancy category: Not Classified\n\nInteraction: May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.
Acemetacin	\n\n\tOrion Pharma Ltd.\tTendonil CAP 60mg 30's pack 240\n\tIndication: Rheumatoid arthritis,Osteoarthritis,Lower back pain,Ankylosing spondylitis,Post-operative pain,Musculoskeletal and joint pain\n\nDose: Adult: PO Pain and inflammation associated with musculoskeletal and joint disorders; Post-op pain 120-180 mg/day.\n\nContra-indication: Previous/active peptic ulcers; hypersensivity to aspirin/NSAIDs; severe liver disease; neonates with untreated infection, children, pregnancy, lactation.\n\nSide effects: Headaches, dizziness, GI disturbances; anaemia; acute interstitial nephritis; corneal deposits, retinal disturbances; rash, urticaria; alopoecia; CHF, tachycardia, arrhythmias, palpitations; jaundice.\nPotentially Fatal: Toxic hepatitis, Stevens-Johnson syndrome.\n\nPrecaution: Elderly; allergic disorders/coagulation defects; epilepsy; parkinsonism; psychiatric disturbances (prolonged therapy may require ophthalmic and blood examinations); renal, hepatic or cardiac impairment.\n\nMode of action: May reduce the antihypertensive effect of ?-blockers. May prolong bleeding when used with acenocoumarol. Increased risk of convulsion when used with quinolone. Concurrent use with aspirin, NSAIDs, SSRIs or corticosteroids may increase risk of GI bleeding. May increase serum levels of ciclosporin. May increase serum levels of lithium.\nPotentially Fatal: Increased risk of methotrexate toxicity when used together. \n\nPregnancy category: Not Classified\n\nInteraction: May reduce the antihypertensive effect of ?-blockers. May prolong bleeding when used with acenocoumarol. Increased risk of convulsion when used with quinolone. Concurrent use with aspirin, NSAIDs, SSRIs or corticosteroids may increase risk of GI bleeding. May increase serum levels of ciclosporin. May increase serum levels of lithium.\nPotentially Fatal: Increased risk of methotrexate toxicity when used together. 
Acetazolamide	\n\n\tAcme Ltd.\tAcemox TAB dr 250mg 100's pack 150\n\tAcme Ltd.\tAcemox TAB dr 250mg 100's pack 200\n\tReman Drug Ltd.\tRemox TAB dr 250mg 100's pack 131\n\tIndication: Glaucoma,Epilepsy,Idiopathic intracranial hypertension,Altitude sickness\n\nDose: Adult: PO Diuresis 250-375 mg/day. \nGlaucoma; Epilepsy 250-1,000 mg/day. \nProphylaxis of high altitude sickness 500-1,000 mg/day. \n\nChild: Glaucoma: 1 mth-12 yr: 10-20 mg/kg daily. Max: 750 mg daily, in 2-4 divided doses. Epilepsy: Neonates and up to 12 yr: Initially, 2.5 mg/kg bid-tid; maintenance: 5-7 mg/kg bid-tid. Max: 750 mg daily. \n\n\n\n\nContra-indication: Hypersensitivity to sulphonamides; sodium or potassium depletion, hepatic insufficiency; hepatic cirrhosis; hyperchloraemic acidosis; severe renal impairment; severe pulmonary obstruction; chronic noncongestive angle-closure glaucoma; adrenocortical insufficiency. Pregnancy, lactation.\n\nSide effects: Drowsiness, paraesthesia, ataxia, dizziness, thirst, anorexia, headache; confusion, malaise, depression; GI distress, metabolic acidosis, polyuria, hyperuricaemia, renal calculi, nephrotoxicity, hepatic dysfunction.\nPotentially Fatal: Rarely, skin reactions or blood dyscrasias.\n\nPrecaution: Potassium supplements may be required. Impaired hepatic or renal function; diabetes. Monitor plasma electrolytes and blood count regularly. IM route is not recommended. Caution when driving or operating machinery. Elderly.\n\nMode of action: Concomitant use w/ high-dose aspirin may cause anorexia, tachypnoea, lethargy, metabolic acidosis, coma and death. May increase serum levels of phenytoin, resulting to increased risk of osteomalacia. May decrease serum concentrations of primidone. Additive effects w/ other carbonic anhydrase inhibitors. May increase the effects of folic acid antagonists. May decrease urinary excretion of amphetamine and quinidine. May prevent the urinary antiseptic effect of methenamine. May increase lithium excretion. Increased risk of renal calculus formation w/ Na bicarbonate. May increase ciclosporin levels.\n\nPregnancy category: C\n\nInteraction: Concomitant use w/ high-dose aspirin may cause anorexia, tachypnoea, lethargy, metabolic acidosis, coma and death. May increase serum levels of phenytoin, resulting to increased risk of osteomalacia. May decrease serum concentrations of primidone. Additive effects w/ other carbonic anhydrase inhibitors. May increase the effects of folic acid antagonists. May decrease urinary excretion of amphetamine and quinidine. May prevent the urinary antiseptic effect of methenamine. May increase lithium excretion. Increased risk of renal calculus formation w/ Na bicarbonate. May increase ciclosporin levels.
Acetic Acid .469% + Calcium Chloride 1.008% + Magnessium Chloride .754% + Potassium Chloride .554% + Sodium Chloride 21.968%	\n\n\tIndication: Hemodialysis\n\nDose: 5 lit. concentrate per dialysis or as required. \n\nContra-indication: \n\nSide effects: \n\nPrecaution: Do not use sol A or sol B alone. It must be diluted immediately before use with water of suitable quality. \nDiscard container incase of visible solid particles inside. It's not for IV injection or infusion.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Acetylcysteine	\n\n\tBeximco\tMucomist-DT TAB dr 600mg 100's pack \n\tBeximco\tMucomist Inhalation Solution 600 mg/3 ml 30's pack 450\n\tNIPRO JMI Pharma\tNacsol DT Dispersible TAB dr 600mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tViscotin Effervescent granules for inhalation 100mg 20's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tViscotin Effervescent granules for inhalation 200mg 20's pack 360\n\tUnimed & Unihealth Manufacturers Ltd.\tViscotin Effervescent TAB dr 600mg 20's pack 500\n\tIndication: Tuberculosis, Chronic emphysema, Paracetamol poisoning, Bronchiectasis, Pneumonia, Atelectasis, Cystic fibrosis, Tracheostomy care, during anaesthesia\n\nDose: Oral\nAs a mucolytic\nAdult: As effervescent granules or tablets: 200 mg tid.\nChild: As effervescent granules or tablets: 2-7 yr: 200 mg bid; <2 yr: 200 mg daily.\n\nParacetamol poisoning\nAdult: After gastric lavage or induction of emesis with ipecac syrup, admin loading dose of 140 mg/kg, followed by maintenance doses of 70 mg/kg every 4 hr for a total of 17 doses. 1st maintenance dose to be given 4 hr after the loading dose. Repeat dose if the patient vomits within 1 hr of admin. Continue therapy until paracetamol levels are not detectable and there is no evidence of hepatotoxicity.\nChild: After gastric lavage or induction of emesis with ipecac syrup, admin loading dose of 140 mg/kg, followed by maintenance doses of 70 mg/kg every 4 hr for a total of 17 doses. 1st maintenance dose to be given 4 hr after the loading dose. Repeat dose if the patient vomits within 1 hr of admin. Continue therapy until paracetamol levels are not detectable and there is no evidence of hepatotoxicity.\n\nInhalation\nAs a mucolytic\nAdult: 3-5 ml of a 20% solution or 6-10 ml of a 10% solution 3-4 times daily by nebulising through a face mask, mouth piece or tracheostomy. May increase to 1-10 ml of a 20% solution or 2-20 ml of a 10% solution every 2-6 hr if needed.\nChild: 3-5 ml of a 20% solution or 6-10 ml of a 10% solution 3-4 times daily by nebulising through a face mask, mouth piece or tracheostomy. May increase to 1-10 ml of a 20% solution or 2-20 ml of a 10% solution every 2-6 hr if needed.\n\nEndotracheal\nAs a mucolytic\nAdult: Instill 1-2 ml of a 10-20% solution as often as every hrly.\nChild: Instill 1-2 ml of a 10-20% solution as often as every hrly.\n\nContra-indication: Acetylcysteine is contraindicated in those patients who are sensitive to it.\n\nSide effects: Flushing, fever, stomatitis, nausea, vomiting, rhinorrhoea, bronchospasm, anaphylactoid reactions, rashes. Rarely, blurred vision, bradycardia, syncope, thrombocytopenia, convulsions.\nPotentially Fatal: Rarely, respiratory or cardiac arrest.\n\nPrecaution: Asthmatic patients, history of bronchospasm, peptic ulceration. Pregnancy, lactation.\n\nMode of action: Drug stability and safety of acetylcysteine when mixed with other drugs in a nebulizer have not been established.\n\nPregnancy category: B\n\nInteraction: Drug stability and safety of acetylcysteine when mixed with other drugs in a nebulizer have not been established.
Acitretin	\n\n\tACI\tSoritec CAP 10mg 30's pack 1354.20\n\tACI\tSoritec CAP 25mg 10's pack 852.60\n\tIndication: Lichen planus, Psoriasis, Congenital icthyosis, Darier's disease					\n\n\nDose: Oral\nDarier's disease\nAdult: Initially, 10 mg daily for 2-4 wk. Max: 50 mg/day.\n\nCongenital icthyosis\nAdult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods.\n\nSevere psoriasis\nAdult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods.\n\nSevere lichen planus\nAdult: Initially, 25-30 mg daily for 2-4 wk before dose adjustments are done. Usual range: 25-50 mg daily for further 6-8 wk. Max: 75 mg daily for short periods.\n\nChild: 500 mcg/kg/day. Max: 35 mg daily.\n\nContra-indication: Pregnancy (before the start, during and at least 2-3 yr after cessation of therapy), lactation. Hepatic and renal impairment. Hyperlipidaemia.\n\nSide effects: Dryness of mucous membranes and skin; conjunctivitis, dry sore mouth; ophth disturbances; raised lipid level, pancreatitis; sticky skin, dermatitis. Severe headache; GI disturbances; dermatologic reactions, oedema, paronychia, granulomatous lesions, bullous eruptions; reversible hair thinning and alopoecia; CNS disturbances; sweating; taste disturbance, gingivitis; benign intracranial hypertension; photosensitivity; skeletal hyperostosis; extraosseous calcification; premature epiphyseal closure in child.\nPotentially Fatal: Phototoxicity, jaundice, hepatitis and hepatotoxity.\n\nPrecaution: Female patients to avoid alcohol during and 2 mth after treatment. Avoid blood donation during therapy or at least 1-3 yr after stopping therapy. Children. Radiographic treatment for prolonged therapy. Therapy should not last >6 mth. Monitor plasma lipid and glucose levels (especially diabetics) regularly. Monitor LFTs.\n\nMode of action: Concomitant use with keratolytics or high dose vitamin A. Reduces anticoagulant effect of coumarins e.g. warfarin. Concomitant use of microdised progestin oral contraceptives. Concomitant use of methotrexate can potentiate hepatotoxicty. Concomitant use with tetracycline.\n\nPregnancy category: X\n\nInteraction: Concomitant use with keratolytics or high dose vitamin A. Reduces anticoagulant effect of coumarins e.g. warfarin. Concomitant use of microdised progestin oral contraceptives. Concomitant use of methotrexate can potentiate hepatotoxicty. Concomitant use with tetracycline.
Activated Charcoal	\n\n\tMerck , Italy\tUltracarbon 				 	 TAB dr  50's pack \n\tIndication: Poisonings,Drug overdose,Gastrointestinal disorders\n\nDose: Oral\nAcute oral poisoning\nAdult: 25-100 g as a single dose. For multiple-dose treatment: 50-100 g as an initial dose followed by not <12.5 g every hr. Alternatively, 25 mg every 2 hr or 50 mg every 4 hr.\n\nChild: <1 yr: 1 g/kg/dose; 1-12 yr: 25-50 g/dose.\nOral\nGastrointestinal disorders\nAdult: 0.975 - 3.9 g tid.\n\nContra-indication: Cyanide, mineral acids, caustic alkalis, organic solvents, iron, ethanol, methanol poisoning; lithium, methionine; intestinal obstruction, anatomically-broken GI tract, haemorrhage or GI perforation. Concomitant use of charcoal with sorbitol: Patients with fructose intolerance; Childn <1 yr.\n\nSide effects: Vomiting, constipation, diarrhoea, black stools, swelling of abdomen, bowel obstruction; platelet aggregation, charcoal embolism, thrombocytopenia, haemorrhage, hypoglycaemia, hypocalcaemia, hypothermia, hypotension (haemoperfusion with activated charcoal); blackening of teeth and mouth; hypernatraemia, hypokalaemia, hypermagnesemia (with concomitant admin with cathartics).\n\nPrecaution: Decreased peristalsis: administer within 1 hr of ingestion. Induce vomiting of ipecac syr before admin of charcoal to prevent adsorption of ipecac. Petroleum distillate, caustic ingestions may harm gastric lining upon induction of vomiting by charcoal. Limit admin of charcoal in sorbitol doses to prevent loss of fluid and electrolyte. Monitor for active bowel sounds before administering charcoal. Pregnancy.\n\nMode of action: Reduces absorption of most drugs from GI tract. Decreases effectiveness of methionine via adsorption. Decreases ipecac effect.\n\nPregnancy category: Not Classified\n\nInteraction: Reduces absorption of most drugs from GI tract. Decreases effectiveness of methionine via adsorption. Decreases ipecac effect.
Acyclovir	\n\n\tAlbion Ltd.\tAcirux Cream 5g/100g 5g/100g \n\tAristopharma\tAcyvir IV Infusion 250mg 1 ampoule of 10 ml 264.02\n\tAristopharma\tAcyvir IV Infusion 500mg 1/2 ampoule of 10 ml 538.04\n\tBeacon\tXovir Injection 250mg/vial 1 vial's pack 400\n\tBeacon\tXovir Injection 500 mg/vial  \n\tBeacon\tXovir Injection 1 gm/vial  \n\tDrug International Ltd.\tNovirax TAB dr 200mg 30's pack 420\n\tDrug International Ltd.\tNovirax TAB dr 400mg 20's pack 440\n\tEskayef Bangladesh Ltd.\tViroxi TAB dr 200mg 20's pack 280\n\tGlobe\tVirunil Injection 250 mg/vial  \n\tGlobe\tVirunil Injection 500 mg/vial  \n\tGlobe\tVirunil TAB dr 200mg  \n\tGlobe\tVirunil TAB dr 400mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tClovir TAB dr 200mg 30's pack 420\n\tIbn Sina Pharmaceutical Ind. Ltd.\tClovir TAB dr 400mg 20's pack 440\n\tIncepta\tSimplovir TAB dr 200mg  \n\tIncepta\tSimplovir TAB dr 400mg  \n\tIncepta\tSimplovir Injection 250 mg/vial  \n\tIncepta\tSimplovir 500 IV Injection 500 mg/vial  \n\tOpsonin Pharma\tAcerux TAB dr 200mg 10x3's pack 370.79\n\tOpsonin Pharma\tAcerux TAB dr 400 10x2's pack 387.07\n\tOpsonin Pharma\tAcerux Injection 250mg 1's amps pack 351.88\n\tOpsonin Pharma\tAcerux Oral Solution  70 ml bot 125.47\n\tOpsonin Pharma\tAcerux Injection 500mg 5 amps pack 700\n\tSquare\tVirux Suspension 200mg/5ml 70ml bot 125.47\n\tSquare\tVirux TAB dr 200mg 30's pack 420\n\tSquare\tVirux TAB dr 400mg 20's pack 440\n\tSquare\tVirux 500 IV Injection 500mg 1's pack \n\tSquare\tVirux Injection 250 mg/vial  \n\tSquare\tVirux Injection 1 gm/vial  \n\tIndication: Herpes simplex infections,Varicella zoster (chickenpox),Herpes zoster (shingles),Genital herpes\n\nDose: Oral\nPrimary herpes simplex infections\nAdult: 200 mg 5 times daily every 4 hr for 5-10 days; for severely immuno compromised patients and those with impaired absorption: 400 mg 5 times daily for 5 days.\n\nSuppression of recurrent herpes simplex\nAdult: 800 mg daily in 2-4 divided doses. May reduce to 400-600 mg daily if necessary. Reassess the condition every 6-12 mth. For mild or infrequent recurrences: Episodic treatment may be used: 200 mg 5 times daily for 5 days, preferably begun during the prodromal period.\n\nProphylaxis of herpes simplex in immunocompromised patients\nAdult: 200-400 mg 4 times daily.\nChild: >2 yr: 200-400 mg 4 times daily; <2 yr: 100-200 mg 4 times daily.\n\nRenal impairment:\nCrCl (ml/min) \n<10:     200 mg every 12 hr.\n\nVaricella zoster\nAdult: >40 kg: 800 mg 4 times daily for 5 days.\nChild: >2 yr and <40 kg: 20 mg/kg (up to 800 mg) 4 times daily for 5 days.\n\nHerpes zoster (shingles)\nAdult: 800 mg 5 times daily for 7-10 days.\nChild: >6 yr: 800 mg 4 times daily; 2-5 yr: 400 mg 4 times daily; <2 yr: 200 mg 4 times daily.\n\nRenal impairment:\nCrCl (ml/min) \n10-25:    800 mg tid. \n<10   	800 mg every 12 hr.\n\nIntravenous\nMucocutaneous herpes simplex in immunocompromised patients\nAdult: 5 mg/kg every 8 hr for 7 days. Dose to be given as IV infusion over 1 hr.\nChild: 10 mg/kg every 8 hr for 7 days.\n\nHerpes simplex encephalitis\nAdult: 10 mg/kg every 8 hr for 10 days.\nChild: >3 mth: 20 mg/kg every 8 hr for 10 days.\n\nGenital herpes\nAdult: 5 mg/kg every 8 hr for 5-7 days.\nNeonatal herpes simplex virus infections\nChild: Birth - 3 mth: 10 mg/kg every 8 hr for 10 days.\n\nHerpes zoster in immunocompromised patients\nAdult: >12 yr: 10 mg/kg every 8 hr for 7 days.\nChild: 20 mg/kg every 8 hr for 7 days.\n\nRenal impairment: Peritoneal dialysis: Half the usual dose once daily. Haemodialysis: Half the usual dose every 24 hr and an additional half-dose after haemodialysis.\nCrCl (ml/min)	\n25-50	Increase dose interval to 12 hr.\n10-25	Increase dose interval to 24 hr.\n\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea, vomiting, headache, diarrhoea, rash, haematological changes (occasional), increase in liver enzymes, burning, itching or erythema (topical use). Eye application may produce stinging, superficial punctate keratopathy, blepharitis or conjunctivitis. IV administration: Local reaction, pain, inflammation, phlebitis, extravasation leads to ulceration. Increase in BUN and/or creatinine. Rarely, renal failure.\nPotentially Fatal: Occasionally neurotoxicity after IV use: Lethargy, confusion, agitation, tremors, seizures, coma.\n\nPrecaution: Renal impairment. Pregnancy, lactation. Neurological abnormalities with significant hypoxia, serious hepatic or electrolyte abnormalities. Maintain adequate hydration.\n\nMode of action: Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).\n\nPregnancy category: B\n\nInteraction: Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).
Acyclovir 3%	\n\n\tAristopharma\tAcyvir Eye Ointment   5 gm tube 100\n\tG. A. Company Ltd.\tSevirax Eye Ointment   5 gm tube 70\n\tGeneral\tCuvir Eye Ointment   5gm tube 100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tClovir Eye Ointment   5 gm tube 100\n\tNipa\tVirex Eye Ointment   3 gm tube/5 gm tube 40 / 100\n\tOpso Saline Ltd.\tCylcovex Eye Ointment   3 gm tube 45.17\n\tOpsonin Pharma\tAcerux Eye Ointment 3 gm/100 gm  \n\tReman Drug Ltd.\tAciclon Eye Ointment   3 gm tube 60\n\tIndication: Herpes simplex keratitis\n\nDose:  As 3% oint: Apply 5 times/day until 3rd day of complete healing.\n\nContra-indication: Hypersensitivity.\n\nSide effects:  Eye application may produce stinging, superficial punctate keratopathy, blepharitis or conjunctivitis.\n\nPrecaution: Renal impairment. Pregnancy, lactation. Neurological abnormalities with significant hypoxia, serious hepatic or electrolyte abnormalities. Maintain adequate hydration.\n\nMode of action: Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).\n\nPregnancy category: B\n\nInteraction: Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).
Acyclovir 5%	\n\n\tDrug International Ltd.\tNovirax Cream   5gm  tube 40\n\tEskayef Bangladesh Ltd.\tViroxi Cream  50mg/g 	 1's pack(5g) 	 40.15 	\n\tGlobe\tVirunil Cream 5 gm/100 gm  \n\tIncepta\tSimplovir Cream   5gm  tube 40\n\tOpsonin Pharma\tAcerux Cream 5 gm/100 gm  \n\tSquare\tVirux Cream 5 gm/100 gm  5gm  tube 40\n\tIndication: Herpes virus infections\n\nDose:  As 5% oint/cream: Apply 5-6 times/day for 5-10 days.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea, vomiting, headache, diarrhoea, rash, haematological changes (occasional), increase in liver enzymes, burning, itching or erythema\n\nPrecaution: Renal impairment. Pregnancy, lactation. Neurological abnormalities with significant hypoxia, serious hepatic or electrolyte abnormalities. Maintain adequate hydration.\n\nMode of action: Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).\n\nPregnancy category: B\n\nInteraction: Probenecid, cimetidine and mycophenolate mofetil may increase the plasma concentration of aciclovir. Increased nephrotoxic effects w/ drugs that affect renal physiology (e.g. ciclosporin, tacrolimus).
Adapalene 0.1%	\n\n\tACI\tAdgar 0.1% Gel  .1% 10g 60\n\tDrug International Ltd.\tAclene Cream   10gm tubex 1's pack 60\n\tHealthcare\tAdapel Cream  10 gm tube \n\tIncepta\tApalene 0.1% Cream  10gm 1's pack 60\n\tSquare\tFona Cream  1 mg/gm 10gm tube x 1 's pack 60\n\tIndication: Acne, Keratosis pilaris\n\nDose: Adult: Topical As 0.1% soln/cream/gel: Apply once daily at night.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Mild skin irritation, scaling, erythema, cutaneous dryness, sensations of stinging and burning, pruritus.\n\nPrecaution: Patients with sunburn, eczema. Pregnancy, lactation. Avoid excessive exposure to sunlight or UV irradiation. Keep away from the eyes, lips, nostrils and mucous membranes. Do not apply to cuts, abrasions, scaly or flaky skin, or patches of sunburned skin. Use with caution with preparations containing sulfur, resorcinol, or salicylic acid.\n\nMode of action: Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.\n\nPregnancy category: C\n\nInteraction: Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.
Adapalene 0.1% + Benzoyl Peroxide 2.5%	\n\n\tAcme Ltd.\tAcnegel Gel (0.1 gm + 2.5 gm)/100 gm  \n\tIncepta\tAdaben Duo Gel Gel  20gm tube 200\n\tOpsonin Pharma\tNomark Gel (0.1 gm + 2.5 gm)/100 gm  \n\tSquare\tFona Plus Gel  .1 gm + 2.5 gm/100 gm 10g 160\n\tZiska\tFreshlook Gel Gel  1x1's pack 160\n\tIndication: Acne\n\nDose: Apply a thin film of adapalene and benzoyle peroxide gel to affected areas of the face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). Avoid the eyes, lips and mucous membranes.\n\nContra-indication: Hypersensitive to any of the components.\n\nSide effects: Local adverse reactions that may be observed are dry skin, erythema, pruritus of skin, skin scaling, skin rash etc.\n\nPrecaution: Exposure to sunlight, including sunlamps, should be minimized during the use of adapalene and benzoyle peroxide gel. Patients with high levels of sun exposure and those with inherent sensitivity to sun should exercise particular caution. Use of sunscreen products and protective apparel, (e.g., hat) are recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, may be irritating to patients under treatment with adapalene and benzoyle peroxide gel.\nSafety and effectiveness of Adapalene and Benzoyl peroxide gel in pediatric patients under the age of 12\nyears have not been established.\n\nMode of action: Adapalene: Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.\n\nBenzoyl Peroxide: PABA sunscreens may transiently discolour fabric.\n\nPregnancy category: C\n\nInteraction: Adapalene: Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.\n\nBenzoyl Peroxide: PABA sunscreens may transiently discolour fabric.
Adapalene 0.3%	\n\n\tACI\tAdgar 0.3% Gel  .3% 10g 80\n\tSquare\tFona Gel  3 mg/gm 10gm tube x 1 's pack 80.30\n\tIndication: Acne\n\nDose: Adult: Topical As 0.3% soln/cream/gel: Apply once daily at night.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Mild skin irritation, scaling, erythema, cutaneous dryness, sensations of stinging and burning, pruritus.\n\nPrecaution: Patients with sunburn, eczema. Pregnancy, lactation. Avoid excessive exposure to sunlight or UV irradiation. Keep away from the eyes, lips, nostrils and mucous membranes. Do not apply to cuts, abrasions, scaly or flaky skin, or patches of sunburned skin. Use with caution with preparations containing sulfur, resorcinol, or salicylic acid.\n\nMode of action: Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.\n\nPregnancy category: C\n\nInteraction: Increased irritation may occur with medicated or abrasive soaps, products with a pronounced drying effect and those containing alcohol or astringents.
Adefovir Dipivoxil	\n\n\tIncepta\tInfovir TAB dr 10mg 20's pack 700\n\tRenata\tAdovir TAB dr 10mg 30's pack 300\n\tSquare\tAntiva TAB dr 10mg 10's pack 351.40\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAdfovir TAB dr 10mg 10's pack 251\n\tIndication: Herpes simplex virus, Chronic hepatitis B\n\nDose: Adult: PO: The recommended dose of Adefovir for the treatment of chronic hepatitis B in adolescent & adults (age > 12 year) with adequate renal function is 10 mg, once daily, taken orally, without regard to food. \n\nRenal impairment: Haemodialysis patients: 10 mg every 7 days after dialysis.\nCrCl (ml/min)	\n20-49	10 mg every 48 hr.\n10-19	10 mg every 72 hr.\n\n\nDose Adjustment in Renal Impairment: Significantly increased drug exposures are seen when Adefovir Dipivoxil is administered to patients with renal impairment. Therefore, the dosing interval of Adefovir Dipivoxil should be adjusted in patients with baseline creatinine clearance < 50 mL/min using the following suggested guidelines- Dosing interval adjustment of Adefovir in patients with renal impairment Creatinine clearance (mL/min) > 50 20 to 49 10 to 19 < 10 Hemodialysis or CAPD Recommended dose and dosing interval 10 mg every 24 hours 10 mg every 48 hours 10 mg every 72 hours 10 mg every 7 days.\n\n\nContra-indication: Adefovir Dipivoxil is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product.\n\nSide effects: Nausea, dyspepsia, abdominal pain, flatulence, diarrhoea, asthenia, headache. Pruritus, skin rashes, and respiratory effects e.g. cough, pharyngitis and sinusitis.Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis, hepatotoxicity, nephrotoxicity.\n\nPrecaution: Pregnancy; elderly; child; renal or hepatic impairment. HIV antibody testing to be performed before initiation due to possible resistance development in untreated HIV infection. Increased risk of hepatotoxicity in females, obese patients and with prolonged treatment. Monitor renal function every 3 mth; hepatitis B biochemical, viral and serological markers every 6 mth and LFTs. Discontinue therapy if liver function worsens, severe hepatomegaly, steatosis or unexplained metabolic or lactic acidosis. Monitor hepatic function for several mth in patients whose antihepatitis therapy is discontinued as acute exacerbations of hepatitis may occur.\n\nMode of action: Increased risk of nephrotoxicity with nephrotoxic drugs e.g. aminoglycosides, ciclosporin, NSAIDs, vancomycin, tacrolimus. Ibuprofen increases bioavailability of adefovir.\n\nPregnancy category: C\n\nInteraction: Increased risk of nephrotoxicity with nephrotoxic drugs e.g. aminoglycosides, ciclosporin, NSAIDs, vancomycin, tacrolimus. Ibuprofen increases bioavailability of adefovir.
Adenine .0275 % + Citric Acid Anhydrous .3 % + Dextrose	\n\n\tIndication: Blood preservation.\n\nDose: It consists of a whole blood collection system with 70 mL of citrate-phosphate-dextrose (CPD), an anticoagulant for the collection of 500 Â± 50 mL of whole blood, and 110 mL of adenine-dextrose-mannitol (AS-1), an RBC preservative solution. They are supplied with sterile, non-pyrogenic fluid pathways. \n\nContra-indication: \n\nSide effects: \n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Adenosine	\n\n\tPopular\tAdecard Injection 6mg/2ml 6mg(2m) amp X 5's pack 750\n\tSquare\tOsiden Injection 6mg/2ml 5's pack 200\n\tIndication: Paroxysmal supraventricular tachycardia,Supraventricular tachycardia\n\nDose: Intravenous\nDifferential diagnosis of supraventricular tachycardias\nAdult: Initially, 3 mg by rapid IV inj into a central or large peripheral vein over 2 sec with cardiac monitoring; 6 mg may be given after 1-2 minutes if necessary, then 12 mg after a further 1-2 minutes. Avoid increments if high level AV block occurs at any particular dose.\nChild: Initially, 50-100 mcg/kg; if necessary, may increase dose by 50-100 mcg/kg increments at 1-2 minute intervals or until arrhythmia is controlled. Max dose: 300 mcg/kg.\n\nParoxysmal supraventricular tachycardia\nAdult: Initially, 3 mg by rapid IV inj into a central or large peripheral vein over 2 sec with cardiac monitoring; 6 mg may be given after 1-2 minutes if necessary, then 12 mg after a further 1-2 minutes. Avoid increments if high level AV block occurs at any particular dose.\nChild: Initially, 50-100 mcg/kg; if necessary, may increase dose by 50-100 mcg/kg increments at 1-2 minute intervals or until arrhythmia is controlled. Max dose: 300 mcg/kg.\n\nMyocardial imaging\nAdult: 140 mcg/kg/minute by infusion for 6 minutes. Inject radionuclide 3 minute after infusion.\n\nContra-indication: 2nd or 3rd degree AV block and sick sinus syndrome (unless pacemaker fitted), asthma, hypersensitivity.\n\nSide effects: Facial flushing, palpitations, chest pain, bradycardia, sweating, hypotension, dyspnoea, choking sensation, headache, lightheadedness, tingling, numbness, neck and back pain, nausea, metallic taste. ECG changes suggestive of rhythm disturbances.\n\nPrecaution: Pregnancy; heart transplant patients; patients on dipyridamole (lower initial dose of adenosine 0.5-1 mg); atrial fibrillation or flutter with accessory pathway (conduction along anomalous pathway may increase).\n\nMode of action: Adenosine effects antagonised by methylxanthines like caffeine, theophylline, etc. Concomitant carbamazepine may increase the risk of heart block.\nPotentially Fatal: Adenosine effects are potentiated by dipyridamole. \n\nPregnancy category: C\n\nInteraction: Adenosine effects antagonised by methylxanthines like caffeine, theophylline, etc. Concomitant carbamazepine may increase the risk of heart block.\nPotentially Fatal: Adenosine effects are potentiated by dipyridamole. 
Adenosine 0.2% + Cytochrome C 0.05% + Nicotinamide eye prep	\n\n\tAcme Ltd.\tCatnil Eye Drops    5  ml drop 125\n\tApex\tCatavit Eye Drops   5  ml drop 120\n\tAristopharma\tPhacovit Eye Drops   5  ml drop 125\n\tGeneral\tVitalens Eye Drops   5ml drop 120\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRactovit Eye Drops   5  ml drop 125\n\tIncepta\tCatrix Eye Drops   5  ml drop 125\n\tPopular\tVitafol Eye Drops   5  ml drop 125\n\tIndication: Lens opacification\n\nDose: One drop into the affected eye twice daily.\n\nContra-indication:  Patients with known hypersensitivity to any ingredient of this product.\n\nSide effects: It may cause more or less discomfort\n\nPrecaution: Only for topical ophthalmic use. Do not inject or swallow. In case of concomitant treatment with another ophthalmic solution, wait 15 minutes between each instillation.\n\nMode of action: No specific drug interaction has been demonstrated.\n\nPregnancy category: C\n\nInteraction: No specific drug interaction has been demonstrated.
Adrenaline (Epinephrine)	\n\n\tG. A. Company Ltd.\tAdrin Injection 1mg/ml 1 amps pack 25\n\tIncepta\tAdrinor Injection 1mg/ml 5 amps pack 125\n\tTechno Drugs Ltd.\tAdrenaline Injection 1mg/ml 10 amps pack 250\n\tIndication: Cardiac arrest, Anaphylaxis, Superficial bleeding, Acute asthma\n\nDose: Parenteral\nAcute asthma\nAdult: 0.3-0.5 ml (300-500 mcg). Dose may be given via IM or SC inj. \nChild: 0.01 ml/kg (10 mcg/kg). Max: 0.5 ml (500 mcg). Dose may be given via IM or SC inj. \nIntravenous\nAdvanced cardiac life support (Cardiac Arrest)\nAdult: \n1. Intravenous injection: 1 mg injection repeated every 2-3 minutes as necessary.\n2. Endotracheal: 2-3 mg via an endotracheal tube, repeated as necessary.\n3. Intracardiac injection: 0.1 to 1 mg, direct into the atrium of the heart.\n4. Intraspinal use: Usual dose is 0.2 to 0.4 mg added to anesthetic spinal fluid mixture (to prolong anesthetic action by limiting absorption).\n\nChild: Initially, 10 mcg/kg, may repeat as often as every 2-3 minutes throughout the resuscitation process. Endotracheal doses: 100 mcg/kg. Intraosseous doses are the same as IV doses. \nMax Dosage: Intraosseous doses for adults and children are the same as IV doses. \n\nAnaphylactic shock\nAdult: 0.5 mg (5 mL) given at a slow rate of 100 mcg/minute, stopping when a response is achieved. \nChild: 10 mcg/kg. If auto injectors are used, doses are based on body wt: 15-30 kg: 150 mcg and >30 kg: 300 mcg. \n\nIntramuscular\nAnaphylactic shock\nAdult: 500 mcg (0.5 ml), repeat every 5 minutes as needed until improvement occurs. For emergency self-admin (e.g. via autoinjector): A dose of 300 mcg (0.3 ml) may be used.\nChild: Dose depends on age and weight. Usual dose: 10 mcg/kg.\n\n\nContra-indication: Preexisting hypertension; occlusive vascular disease; angle-closure glaucoma (eye drops); hypersensitivity; cardiac arrhythmias or tachycardia. When used in addition to local anaesthetics: Procedures involving digits, ears, nose, penis or scrotum.\n\nSide effects: CNS effects; GI disturbances; epigastric pain; CV disorders; difficulty in micturition with urinary retention; dyspnoea; hyperglycaemia; sweating; hypersalivation; weakness, tremors; coldness of extremities; hypokalaemia. Gangrene, tissue necrosis and sloughing (extravasation) when used in addition to local anaesthetics. Eye drops: Severe smarting, blurred vision, photophobia; naso-lachrymal ducts obstruction. Oedema, hyperaemia and inflammation of the eyes with repeated administration.\n\nPrecaution: CV diseases; hyperthyroidism; DM; Parkinson's disease; elderly; pregnancy, lactation.\n\nMode of action: Halogenated inhalation anaesthetics; alpha- or beta-blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce hypertension and arrhythmia.\n\nPregnancy category: C\n\nInteraction: Halogenated inhalation anaesthetics; alpha- or beta-blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce hypertension and arrhythmia.
Adrenaline + Lidocaine Hydrochloride	\n\n\tGonoshasthaya\tG Lignocaine 2% Injection   50 ml vial x 1's pack 28.42\n\tJayson\tJasocaine A Injection  2% 50ml vial 40\n\tJayson\tJasocaine A 1% Injection   5's pack 150\n\tJayson\tJasocaine-A 2% Injection   50 ml vial 28.32\n\tJayson\tJasocaine-A DC Injection   1.8 ml cartridge x 5's pack 150\n\tIndication: Local or regional anesthesia, nerve blocks, epidural and caudal anaesthesia\n\nDose: Adult: Per ml prep contains lidocaine HCl 20 mg and epinephrine 5 mcg. Dosage depends on several factors such as route, type and extent of surgical procedure, duration of anaesthesia and patient's condition and age. Max dose of lidocaine given with epinephrine: 7 mg/kg and not >500 mg.\n\nChild: 3 mth-12 yr: Per ml prep contains lidocaine HCl 20 mg and epinephrine 5 mcg. Dosage depends on several factors such as route, type and extent of surgical procedure, duration of anaesthesia and patient's condition and age. Max dose 3 mg/kg. Ideal body weight should be used in children with high body weight. Reconstitution: Can be diluted if necessary in glucose 5%, sodium chloride 0.9% and lactated Ringer's solution.\n\nContra-indication: Tachycardia, hypertension, cerebral arteriosclerosis, ischaemic heart disease, IV admin, anaesthetise digits or appendages, myasthenia gravis.\n\nSide effects: Severity of adverse effects in CNS and CVS are directly related to blood levels of lidocaine; the effects are more likely to occur after systemic administration rather than infiltration; dizziness; muscle twitching; local anaesthetic of mouth/throat impairs swallowing and increases the risk of aspiration (patients cautioned against eating or drinking for 3-4 hr after anaesthesia); transient effect on auditory system of neonate; erythema; pigmentation; pain; headache; palpitations; local necrosis; pulmonary oedema; hyperglycaemia; bradycardia; reduced cardiac output; anxiety. \n\nEpidural may cause hypotension, bradycardia, nausea and vomiting. Intraoral inj may cause stress reactions such as diaphoresis, palpitation, hyperventilation, generalised pallor and faintness. Topically: papules, burns, rash, skin irritation, burning sensation and blanching.\n\nPotentially Fatal: Severity of adverse effects in CNS and CVS related to blood levels of lidocaine; effects more likely to occur after systemic administration rather than infiltration. CNS toxicity (due to inadvertent IV admin), medullary depression with tonic & clonic convulsions; ventricular fibrillation; severe hypertension with cerebral haemorrhage and pulmonary oedema; unconsciousness; possibly respiratory arrest. Allergic reactions including anaphylactic symptoms and possibly life threatening asthmatic episodes in susceptible patients may occur due to sodium metabisulphate constituent. \n\nCentral nerve blocks may cause CV depression (especially in hypovolaemia). Retrobulbar inj may reach subarachnoid space causing CV collapse, apnoea, convulsions, temporary blindness. Paracervical block may cause foetal bradycardia/tachycardia (careful monitoring of foetal heart rate is necessary).\n\nPrecaution: Epilepsy, impaired cardiac conduction, CHF, DM, closed angle glaucoma, impaired liver function (if site of admin is likely to result in high blood levels), severe renal dysfunction. Local anaesthetic effect may be reduced if injected into an inflamed or infected area. Cerebrovascular insufficiency, hyperthyroidism. Neonates, elderly, patients in poor general condition (optimise patient's condition before major block), pregnancy.\n\nMode of action: Halogenated inhalation anaesthetics; alpha- or beta-blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce hypertension and arrhythmia.\n\nPregnancy category: A\n\nInteraction: Halogenated inhalation anaesthetics; alpha- or beta-blocking agents; methyldopa, guanethidine; drugs with vasoconstrictor and pressor effects; antihypertensives; adrenergic neuron blockers; potassium-depleting drugs; cardiac glycosides; ephedra, yohimbe. TCAs may induce hypertension and arrhythmia.
Adrenochrome Monosemicarbazone	\n\n\tNuvista Pharma Ltd\tAnaroxyl TAB dr 2.5mg 30's pack 592.50\n\tNuvista Pharma Ltd\tAnaroxyl Injection 5mg/ml 5 amp's pack 334.5\n\tRenata\tRenoxyl TAB dr 5mg  \n\tTechno Drugs Ltd.\tAdrinoxyl TAB dr 2.5mg  \n\tIndication: Capillary bleeding, Haemoptysis, Haematuria, Retinal hemorrhage,Secondary hemorrhage, Menorrhagia.\n\nDose: Oral As a haemostatic \nAdult: 10-30 mg tid. \nInjection As a haemostatic Adult: 10 mg daily by SC/IM inj. Alternatively, 25-100 mg daily by IV Inj or drip infusion.\nPre-operative: 2-6ml at suitable intervals. Post-operative: 1-2ml every 2hrs. Non-surgical: 2-4ml tid. Child <6yrs: 1-2ml tid.\n\nContra-indication: Should not be administered to patients with hypersensitivity.\n\nSide effects: Allergic reactions may occur like dyspnoea, bronchospasm, skin reaction etc\n\nPrecaution: Because of the content of diprophylline (90 mg/ml), the dosage to premature babies, infants and young children should not exceed 0.3 ml.\n\nMode of action: No specific drug interaction has been demonstrated.\n\nPregnancy category: Not Classified\n\nInteraction: No specific drug interaction has been demonstrated.
Agomelatine	\n\n\tBeacon\tAgotin TAB dr 25mg  \n\tIndication: Major depressive disorder\n\nDose: 25-50 mg at bedtime.\n\nContra-indication: Co-administration of potent CYP1A2 inhibitors (eg fluvoxamine or ciprofloxacin). Hepatic impairment.\n\nSide effects: Dizziness, somnolence, insomnia, migraine, headache, nausea, diarrhoea, constipation, upper abdominal pain, hyperhidrosis, back pain, tiredness, anxiety, elevated liver enzymes.\n\nPrecaution: Suicidal thoughts & worsening of depression. Mania, dementia, lactose intolerance. May affect ability to drive or operate machinery. Pregnancy & lactation. Childn & adolescent <18 yr.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Albendazole	\n\n\tACI\tSintel Suspension 200mg/5ml 10 ml bot 20.06\n\tACI\tSintel TAB dr 400mg 50's pack 251\n\tAcme Ltd.\tBen A TAB dr 400mg 50's pack 134\n\tAcme Ltd.\tBen-A Suspension 200mg/5ml 10 ml bot 15\n\tAd-din\tAldaben Suspension 200mg/5ml 10ml bot 15\n\tAd-din\tAldaben DS TAB dr 400mg 25's pack 100\n\tAexim\tAlbenda DS TAB dr 400mg 20's pack 68\n\tAlbion Ltd.\tAlbendazole TAB dr 400 mg 20's pack \n\tAlbion Ltd.\tAlbendazole Suspension 200 mg/ 5ml  10 ml \n\tAlco Pharma\tChuben TAB dr 400mg 50's pack 192.50\n\tAmbee\tTriben Suspension 200mg/5ml 10 ml bot 14\n\tAmbee\tTriben DS TAB dr 400mg 25's pack 83.50\n\tAmbee\tTriben TAB dr 200mg  \n\tAmico Ltd.\tZoben Suspension 200mg/5ml 10 ml bot 14\n\tAmico Ltd.\tZoben TAB dr 400mg 50's pack 150\n\tAristopharma\tAbentel TAB dr 400mg 50's pack 250\n\tAsiatic Ltd.\tAsiben Suspension 200mg/5ml 10 ml bot 14\n\tAsiatic Ltd.\tAsiben TAB dr 400mg 10's pack \n\tAstra Biopharmaceuticals Ltd.\tVerben TAB dr 400mg 20's pack 80\n\tBelsen\tBenz-24 TAB dr 400mg 50's pack 160\n\tBeximco\tAlphin DS TAB dr 400mg 50's pack 250\n\tBio Pharma Ltd.\tAzole Suspension 200mg/5ml 10 ml bot 15\n\tBio Pharma Ltd.\tAzole TAB dr 400mg  20's pack 120.60\n\tBristol Pharma Ltd.\tBenda DS TAB dr 400mg 50's pack 175\n\tCentral.\tAlbazol DS TAB dr 400mg 50's pack 200\n\tChemist Ltd.\tNematox DS TAB dr 400mg 50's pack 177\n\tConcord\tQ ben DS TAB dr 400mg 60's pack 240\n\tCosmic Chemical Industries Ltd.\tColaz Suspension 200mg/5ml 10 ml bot 15\n\tCosmic Chemical Industries Ltd.\tColaz TAB dr 400mg 30's pack 150\n\tCosmo Pharma Ltd.\tCosben TAB dr 400mg 50's pack 150\n\tDecent Pharma Ltd.\tAlarm TAB dr 400mg 30's pack 120\n\tDesh\tAldes Suspension 200mg/5ml 10ml bot 15\n\tDesh\tAldes-DS TAB dr 400mg 50's pack/100's pack 150/300\n\tDoctor's Chemicals Works Ltd.\tAldew TAB dr 400mg 50's pack 200\n\tDrug International Ltd.\tInfesen TAB dr 400mg 60's pack 210\n\tDrug International Ltd.\tInfesen Suspension 200mg 10ml bot/20ml bot 15\n\tDrug International Ltd.\tAH TAB dr 400mg  \n\tEdruc Ltd.\tE Ben TAB dr 400mg 25's pack 71.22\n\tEdruc Ltd.\tE Ben DS TAB dr 400mg 25's pack 100\n\tEdruc Ltd.\tEben Suspension 200mg 10ml bot 15\n\tEskayef Bangladesh Ltd.\tAlben Suspension 200mg/5ml 10ml 18\n\tEskayef Bangladesh Ltd.\tAlben DS TAB dr 400mg 100's pack 500\n\tEuro Pharma Ltd.\tParnil DS TAB dr 400mg 50's pack 250\n\tEverest\tAL Suspension 200mg/5ml 10 ml bot 15\n\tEverest\tAl TAB dr 400mg 30's pack 114\n\tG. A. Company Ltd.\tAldex Suspension 200mg/5ml 10 ml bot 15\n\tG. A. Company Ltd.\tAldex DS TAB dr 400mg 20's pack 80\n\tGeneral\tAlzed TAB dr 400mg 20's pack 66.20\n\tGlobe\tAl DS TAB dr 400mg 40's pack 152\n\tGlobex\tAlbendol TAB dr 400mg 50's pack 175\n\tGlobex\tAlbendol Suspension 200 mg/5 ml 10ml bot 15\n\tGonoshasthaya\tG Albendazole TAB dr 200mg 100's pack 325\n\tHudson\tH Ben TAB dr 400mg 40's pack 144\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEstazol Suspension 200mg/5ml 10 ml bot 20\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEstazol TAB dr 400mg 50's pack 200\n\tIndobangla Pharmaceuticals\tAlbendox TAB dr 400mg 50's pack 200\n\tJayson\tElmin TAB dr 400mg 25's pack 82.75\n\tKemiko\tAdze TAB dr 400mg 50's pack 200\n\tKumudini Pharma Ltd.\tAlmin Suspension 200mg/5ml 10 ml bot 14\n\tKumudini Pharma Ltd.\tAlmin TAB dr 400mg 50's pack 200\n\tLeon\tExworm TAB dr 400mg  \n\tLeon\tExworm Suspension 200 mg/5 ml  \n\tMedicon\tMebel Suspension 200mg/5ml 10 ml bot 20\n\tMedicon\tMebel DS TAB dr 400mg 50's pack 265\n\tMedimet\tAlbrex TAB dr 400mg 50's pack 175\n\tMillat\tDurazol Suspension 200mg/5ml 10 ml bot 15\n\tMillat\tDurazol TAB dr 400mg 50's pack 200\n\tModern\tHelben DS TAB dr 400mg 50's pack 152\n\tMystic\tKrimizole Suspension 200mg/5ml 10 ml bot 15\n\tMystic\tKrimizole DS TAB dr 400mg 25's pack 81.25\n\tNavana\tAlba TAB dr 400mg 50's pack 190.50\n\tNipa\tVermin DS TAB dr 400mg 25's pack 88.75\n\tNIPRO JMI Pharma\tVermikil Suspension 200mg/5ml 10 ml bot 15.06\n\tNIPRO JMI Pharma\tVermikil TAB dr 400mg 50's pack 176\n\tNovo Healthcare and Pharma Ltd.\tBenfast TAB dr 400mg 50's pack 200\n\tOpsonin Pharma\tAlbizol TAB dr 40mg 30's pack \n\tOrganic Health Care\tOlv TAB dr 400mg 50's pack 190\n\tPharmadesh Ltd.\tAlpro TAB dr 400mg 30's pack 120\n\tRAK\tXben TAB dr 400mg 50's pack 200\n\tRangs\tNT-Par Suspension 200mg/5ml 10 ml bot 15\n\tRangs\tNT-Par TAB dr 400mg 50's pack 200\n\tReliance\tChir-DS TAB dr 400mg 10's pack 51\n\tReman Drug Ltd.\tR-Zol TAB dr 400mg 25's pack 100\n\tRenata\tAlentin TAB dr 200mg 80's pack \n\tRenata\tAlentin DS TAB dr 400mg 25's pack 83.75\n\tSeema\tAnthel TAB dr 400mg 50's pack 210\n\tSomatec\tVermid TAB dr 400mg 25's pack 95.50\n\tSquare\tAlmex Suspension 200mg/5ml 10 ml bot 15.05\n\tSquare\tAlmex TAB dr 400mg 100's pack / 48's pack 500 / 240\n\tSupreme\tAlda Suspension 200mg/5ml 10ml bot 15\n\tSupreme\tAlda DS TAB dr 400mg 25's pack 100\n\tSyntho Ltd.\tWormex Suspension 200mg/5ml 10 ml bot 14\n\tSyntho Ltd.\tWormex TAB dr 400mg 26's pack 91\n\tTechno Drugs Ltd.\tAldin DS TAB dr 400mg 60's pack 180\n\tWhite Horse Pharma\tAlbicon DS TAB dr 400mg 100's pack 400\n\tZenith\tAlbezen TAB dr 400mg 60's pack 180\n\tZiska\tAlbamax DS TAB dr 400mg 100's pack 456\n\tIndication: Helminthiasis, Echinococcosis, Neurocysticercosis, Enterobiasis, Ascariasis, Hookworm infections, Strongyloidiasis, Giardiasis, Filariasis\n\nDose: Adult: PO Echinococcosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 28 days/cycle. Cystic echinococcosis: Up to 3 cycles w/ 14 treatment-free days in between cycles. Alveolar echinococcosis: Treatment cycles may need to be continued for mths or yrs w/ 14 treatment -free days in between cycles. Neurocysticerosis >60 kg: 400 mg twice daily; <60 kg: 15 mg/kg/day (max: 800 mg/day) in 2 divided doses. Duration: 8-30 days. Intestinal nematode infections 400 mg as a single dose. Strongyloidiasis 400 mg 1-2 times/day for 3 consecutive days, may repeat after 3 wk if needed. Giardiasis 400 mg/day for 5 days. Ascariasis; Enterobiasis; Hookworm infections 400 mg as a single dose.\n\nChild: >2 yr: 400 mg as a single dose; 1-2 yr: 200 mg as a single dose.\n\nContra-indication: Pregnancy and lactation. Neonates. Hypersensitivity, liver impairment.\n\nSide effects: GI discomfort, headache, nausea, dizziness, allergic reactions, pruritus, raised liver enzymes, alopecia and dry mouth.\nPotentially Fatal: Bone marrow depression.\n\nPrecaution: Monitor blood counts and liver function. Administer within 7 days of start of normal menstruation in women of childbearing age. Adequate nonhormonal contraceptive measures must be taken during and for 1 mth after therapy. Perform liver function tests and blood counts before and every 2 wk during high dose therapy of hydatid disease.\n\nMode of action: Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.\n\nPregnancy category: C\n\nInteraction: Increased serum concentrations w/ dexamethasone, praziquantel and cimetidine. Decreased serum concentrations w/ aminoquinoline (antimalarials), carbamazepine, phenobarbital, and phenytoin.
Alendronic Acid	\n\n\tACI\tMabone tablet 70mg 10's pack 250\n\tBeximco\tAlendon TAB dr 10mg 30's pack \n\tBeximco\tAlendon TAB dr 70mg 30's pack 750\n\tEskayef Bangladesh Ltd.\tOstomax TAB dr 10mg 40's pack 200\n\tIncepta\tBonemas TAB dr 70mg 10's pack 300\n\tSquare\tOstel 10 TAB dr 10mg 30's pack 150.30\n\tSquare\tOstel 70 TAB dr 70mg 12's pack 301.16\n\tIndication: Osteopetrosis, postmenopausal osteoporosis, Paget's disease of bone.\n\nDose: Adult: PO Osteoporosis 10 mg/day or 70 mg once wkly. Prevention of postmenopausal osteoporosis 5 mg/day or 35 mg once wkly. Corticosteroid-induced osteoporosis 5 mg/day; up to 10 mg/day in women not on HRT treatment. Paget's disease of bone 40 mg/day for 6 mth. May repeat after an interval of 6 mth if needed.\n\nRenal impairment:\nCrCl (ml/min)	\n<35	        Not recommended.\n\n\nContra-indication: Hypocalcaemia; oesophageal abnormalities and factors which delay oesophageal emptying; severe renal impairment; hypersensitivity; inability to stand or sit upright for ?30 min. Pregnancy, lactation.\n\nSide effects: Oesophagitis, oesophageal ulcers and erosions, dysphagia, heartburn, retrosternal pain, abdominal pain, distension, diarrhoea, constipation, flatulence, headache, rash, erythema, musculoskeletal pain, transient decreases in serum phosphate.\n\nPrecaution: Upper GI disorders (discontinue if symptoms worsen); history of ulcers, active GI bleeding. Correct vitamin D and calcium deficiency before starting therapy. To be taken half an hr before breakfast and remain upright for at least 30 minutes after admin. Not recommended for use in patients with CrCl <35 ml/min.\n\nMode of action: Concomitant iron, calcium supplements and antacids hinder alendronate absorption. Concomitant aspirin or NSAIDs may increase the incidence of adverse GI effects.\n\nPregnancy category: C\n\nInteraction: Concomitant iron, calcium supplements and antacids hinder alendronate absorption. Concomitant aspirin or NSAIDs may increase the incidence of adverse GI effects.
Alendronic Acid + Vitamin D3	\n\n\tEskayef Bangladesh Ltd.\tOstomax TAB dr  70 8's pack 200\n\tIncepta\tBonemass D TAB dr    10's pack 300\n\tSquare\tOstel D 10/400 TAB dr  10 mg + 400 IU (10 mg + 10 mcg or 400 IU)  x 30's pack 180.74\n\tSquare\tOstel D 70/2800 TAB dr  70 mg + 2800 IU (70 mg + 70 mcg or 2800 IU)  x 8's pack 240.89\n\tIndication: Osteopetrosis, postmenopausal osteoporosis, Paget's disease of bone							\n\n\nDose: Treatment of osteoporosis in postmenopausal women: One tablet once weekly.\nTreatment to increase bonemass in men with osteoporosis: One tablet once weekly.\n\nDosing in elderly and renal insufficiency: No dosage adjustment is necessary for the elderly or for patients with mild-to-moderate renal insufficiency (creatinine clearance 35 to 60 mL/min).  \nCrCl (ml/min)	\n<35	         Not recommended.\n\n\nContra-indication: Hypocalcaemia; oesophageal abnormalities and factors which delay oesophageal emptying; severe renal impairment; hypersensitivity; inability to stand or sit upright for ?30 min. Pregnancy, lactation.\n\nSide effects: The most common side-effect is digestive reactions from Bonemass D. These reactions include irritation, inflammation, or ulcers of the esophagus, which may sometimes bleed. This may occur especially if patients do not drink a full glass of water with Bonemass D or if they lie down in less than 30 minutes or before their first food of the day. Less common side-effects are nausea, vomiting, a full or bloated feeling in the stomach, constipation, diarrhea, black or bloody stools, gas, headache, a changed sense of taste, and bone, muscle, or joint pain.\n\nPrecaution: Upper GI disorders (discontinue if symptoms worsen); history of ulcers, active GI bleeding. Correct vitamin D and calcium deficiency before starting therapy. To be taken half an hr before breakfast and remain upright for at least 30 minutes after admin. Not recommended for use in patients with CrCl <35 ml/min.\n\nMode of action: Concomitant iron, calcium supplements and antacids hinder alendronate absorption. Concomitant aspirin or NSAIDs may increase the incidence of adverse GI effects.\n\nPregnancy category: C\n\nInteraction: Concomitant iron, calcium supplements and antacids hinder alendronate absorption. Concomitant aspirin or NSAIDs may increase the incidence of adverse GI effects.
Alfuzosin	\n\n\tEskayef Bangladesh Ltd.\tZatral TAB dr 10mg 24's pack 240\n\tIncepta\tAlfasin XR TAB dr 10mg  24's pack 240\n\tSquare\tUriten TAB dr 10mg 30's pack 301.24\n\tUnimed & Unihealth Manufacturers Ltd.\tAlfumax ER Extended Release TAB dr 10mg  \n\tIndication: Benign prostatic hyperplasia (BPH)\n\nDose: Oral\nBenign prostatic hyperplasia\nAdult: 2.5 mg tid. Max: 10 mg/day. 1st dose should be given before bedtime. Extended-release: 10 mg once daily.\n\nElderly: Initially, 2.5 mg bid. Acute urinary retention: Extended-release: 10 mg once daily to be taken from 1st day of catheterisation. Duration: 3-4 days.\n\nHepatic impairment: Mild to moderate: Initially, 2.5 mg daily, may increase to 2.5 mg bid according to response. Severe: Contraindicated.\n\nContra-indication: Severe hepatic impairment; history of postural hypotension and micturition syncope; intestinal occlusion; severe renal insufficiency; lactation.\n\nSide effects: Drowsiness, postural hypotension, syncope, asthenia, depression, headache, dry mouth, GI disturbances, edema, blurred vision, rhinitis, erectile disorders, tachycardia, palpitation, hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy.\n\nPrecaution: Elderly; hypertension; coronary insufficiency; angina (discontinue); renal or hepatic impairment. Monitor BP regularly. May affect ability to drive or operate machinery.\n\nMode of action: Additive effect on QT interval prolongation when used w/ QT-prolonging drugs. Concomitant admin w/ other ?1-adrenergic blocking agents, atenolol or diltiazem may result in additive CV effects. Increased plasma alfuzosin concentrations w/ cimetidine.\nPotentially Fatal: Concurrent use w/ potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir) increase plasma alfuzosin levels.\n\nPregnancy category: B\n\nInteraction: Additive effect on QT interval prolongation when used w/ QT-prolonging drugs. Concomitant admin w/ other ?1-adrenergic blocking agents, atenolol or diltiazem may result in additive CV effects. Increased plasma alfuzosin concentrations w/ cimetidine.\nPotentially Fatal: Concurrent use w/ potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir) increase plasma alfuzosin levels.
Aliskiren	\n\n\tNovartis Farma SpA, Italy\tRasilez TAB dr 150mg 7's pack 546\n\tNovartis Farma SpA, Italy\tRasilez TAB dr 300mg 7's pack 437.50\n\tIndication: Hypertension\n\nDose: Oral\nEssential hypertension\nAdult: >18 yr 150 mg once daily, increased to 300 mg once daily if needed.\nElderly: No dosage adjustment needed.\nHepatic impairment: No dosage adjustment needed.\n\nContra-indication: History of angioedema; severe renal impairment. Concomitant use w/ ACE inhibitors or angiotensin II receptor antagonists in patients w/ DM and renal impairment (GFR <60 mL/min). Concomitant use w/ ciclosporin, itraconazole and quinidine. Pregnancy.\n\nSide effects: Diarrhoea, dyspepsia, GERD, abdominal pain, hypotension, headache, fatigue, dizziness, back pain, cough, rashes, hyperuricaemia, gout, renal calculi, hyperkalaemia, decreases in Hb levels (dose-related), angioedema and seizures.\nPotentially Fatal: Anaphylactic reactions.\n\nPrecaution: Serious CHF, sodium or volume depletion. Discontinue if diarrhoea is severe and persistent. Lactation. Monitoring Parameters Periodically monitor serum potassium concentration and renal function.\n\nMode of action: Increased risk of hypotension w/ other antihypertensives. Increased risk of acute renal failure w/ ACE inhibitors, angiotensin II receptor antagonists or NSAIDs. Antihypertensive effect may be reduced w/ NSAIDs. Increased serum levels w/ atorvastatin, itraconazole, ketoconazole, verapamil. Significant decrease in furosemide concentrations w/ aliskiren. Increased risk of hyperkalaemia w/ potassium-sparing diuretics, potassium supplements or any substances that may increase serum potassium levels.\nPotentially Fatal: Increased risk of renal impairment, hypotension and hyperkalaemia w/ ACE inhibitors or angiotensin II receptor antagonists. Markedly increased plasma concentration w/ ciclosporin, itraconazole and quinidine. \n\nPregnancy category: D\n\nInteraction: Increased risk of hypotension w/ other antihypertensives. Increased risk of acute renal failure w/ ACE inhibitors, angiotensin II receptor antagonists or NSAIDs. Antihypertensive effect may be reduced w/ NSAIDs. Increased serum levels w/ atorvastatin, itraconazole, ketoconazole, verapamil. Significant decrease in furosemide concentrations w/ aliskiren. Increased risk of hyperkalaemia w/ potassium-sparing diuretics, potassium supplements or any substances that may increase serum potassium levels.\nPotentially Fatal: Increased risk of renal impairment, hypotension and hyperkalaemia w/ ACE inhibitors or angiotensin II receptor antagonists. Markedly increased plasma concentration w/ ciclosporin, itraconazole and quinidine. 
Allopurinol	\n\n\tBio Pharma Ltd.\tGoutex TAB dr 100mg 100's pack 402\n\tBio Pharma Ltd.\tGoutex TAB dr 300mg  \n\tDrug International Ltd.\tPurinol TAB dr 300mg 30's pack 360\n\tHealthcare\tUcorex TAB dr 100mg 50's pack 227.24\n\tIncepta\tAlurol TAB dr 100mg 100's pack 400\n\tOpsonin Pharma\tDuric TAB dr 100mg 50's pack 200\n\tOpsonin Pharma\tDuric TAB dr 300mg 30's pack 240\n\tSonear Ltd.\tAluric TAB dr 100mg 100's pack 410\n\tSquare\tEsloric TAB dr 100mg 100's pack 401.66\n\tSquare\tEsloric TAB dr 300mg 30's pack 241.20\n\tUnimed & Unihealth Manufacturers Ltd.\tPurinol TAB dr 100mg 30's pack 120\n\tIndication: Hyperuricaemia, Uric acid nephropathy, Cancer therapy-induced hyperuricaemia, Gout, Recurrent renal stones\n\nDose: Adult: PO Gout; Hyperuricaemia Initial: 100 mg/day, may adjust dose according to response. Max: 800 mg/day. \n\nPrevention of hyperuricaemia associated w/ chemotherapy treatment or enzyme disorders 600-800 mg/day, starting 2-3 days before cancer treatment. \n\nRenal impairment: Haemodialysis: Administer dose after session or administer 50% supplemental dose.\n\nCrCl (ml/min)	\n10-20	200 mg daily.\n<3	100 mg daily at extended intervals.\n3-10	 100 mg daily.\n\nHepatic impairment: Dose reduction may be needed. Monitor liver function regularly.\n\n\nContra-indication: Hypersensitivity; acute attack of gout.\n\nSide effects: Rash; alopoecia; GI disorders, taste disturbances, nausea, vomiting, abdominal pain, diarrhoea; paraesthesia, peripheral neuropathy, vertigo, headache, hepatic necrosis, drowsiness, neuritis, arthralgia; hypertension.\nPotentially Fatal: Stevens-Jonhson and/or Lyell's Syndrome (urticaria, fever, lymphadenopathy, arthralgia). Occasionally, thrombocytopaenia, agranulocytosis and aplastic anaemia.\n\nPrecaution: Ensure adequate fluid intake. Prophylactically with an anti-inflammatory or colchicine for at least 1 mth. Withdraw immediately when sensitivity (skin rash, etc) appears. Pregnancy, lactation. Hepatic and renal impairment.\n\nMode of action: May inhibit the metabolism of mercaptopurine and azathioprine; reduce dose of mercaptopurine and azathioprine when given w/ allopurinol. May increase effect of warfarin and other coumarin anticoagulants. Increased excretion of the oxipurinol (metabolite) w/ salicylates or uricosuric agents. Increased toxicity w/ thiazide diuretics, some antibacterials, other antineoplastics, ciclosporin, some sulfonylurea antidiabetics, theophylline and vidarabine.\n\nPregnancy category: C\n\nInteraction: May inhibit the metabolism of mercaptopurine and azathioprine; reduce dose of mercaptopurine and azathioprine when given w/ allopurinol. May increase effect of warfarin and other coumarin anticoagulants. Increased excretion of the oxipurinol (metabolite) w/ salicylates or uricosuric agents. Increased toxicity w/ thiazide diuretics, some antibacterials, other antineoplastics, ciclosporin, some sulfonylurea antidiabetics, theophylline and vidarabine.
Allystrenol	\n\n\tACI\tPrelab TAB dr 5mg 45's pack 360.90\n\tIncepta\tAlestor TAB dr 5 mg 30's pack 240\n\tNuvista Pharma Ltd\tAllygest TAB dr 5 mg 30's pack 231.60\n\tPopular\tAllynol TAB dr 5mg 45's pack 360\n\tRenata\tGestrenol TAB dr 5mg 30's pack 240.90\n\tSquare\tGeston TAB dr 5mg 30's pack 240\n\tIndication: Threatened miscarriage, Premature labor\n\nDose: Adult: PO 5 mg 3 times/day for 5-7 days.\n\nContra-indication: Hypersensitivity; thrombophleobitis; undiagnosed vag bleeding, incomplete abortion, hormone-dependent carcinoma, cerebral apoplexy, as a diagnostic test for pregnancy; severe hepatic impairment; pregnancy.\n\nSide effects: GI disturbances, appetite/weight change; fluid retention, oedema; acnes, skin rash, urticaria; depression, headache, fever, fatigue; breast changes, hirsutism, changes in libido, altered menstrual cycles or irregular menstrual bleeding (rare).\n\nPrecaution: Discontinue medications if there is sudden partial or complete loss of vision, proptosis or diplopia; migraine and embolic disorders; epilepsy, migraine, asthma, cardiac or renal dysfunction. History of depression, glucose tolerance and diabetic patients. My impair ability to drive operate machinery. Sudden withdrawal of allyloestrenol should be avoided as it leads to intermittent breakthrough bleeding; lactation.\n\nMode of action: Enhanced clearance with enzyme-inducing drugs eg, carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Ketoconazole may increase bioavailability of progesterone.\nPotentially Fatal: Increased ciclosporin concentration.\n\nPregnancy category: Not Classified\n\nInteraction: Enhanced clearance with enzyme-inducing drugs eg, carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Ketoconazole may increase bioavailability of progesterone.\nPotentially Fatal: Increased ciclosporin concentration.
Almitrine Bismesylate + Raubasine	\n\n\tDrug International Ltd.\tAlbasine TAB dr   30's pack 360\n\tOpsonin Pharma\tAruxil TAB dr  10x3 's pack 300\n\tSquare\tTruxil TAB dr   30's pack 300\n\tIndication: Cerebrovascular insufficiency, Functional rehabilitation after cerebrovascular accidents, Auditory, Vestibular and visual disorders of ischaemic aetiology, Stroke\n\nDose: Adult: PO Auditory, vestibular and visual disorders of ischaemic aetiology; Cerebrovascular insufficiency; Functional rehabilitation after cerebrovascular accidents Per tab contains almitrine 30 mg and raubasine 10 mg: 1 tab twice daily.\n\nContra-indication: Concurrent usage with MAOIs.\n\nSide effects: Mild GI disorders, sleep disturbances, palpitations, anxiety, dizziness. Rarely, wt loss, peripheral neuropathy with abnormal sensations in the lower limbs.\n\nPrecaution: Pregnancy. Long term treatment may result in numbness, prickling or formication effects in the lower limbs which may, in rare cases, lead to treatment withdrawal.\n\nMode of action: Not to be used concurrently with other almitrine-containing preparations.\nPotentially Fatal: MAOIs.\n\nPregnancy category: Not Classified\n\nInteraction: Not to be used concurrently with other almitrine-containing preparations.\nPotentially Fatal: MAOIs.
Almotriptan	\n\n\tNIPRO JMI Pharma\tAltrip TAB dr 6.25mg 10's pack 250\n\tOpsonin Pharma\tAlmitan TAB dr 6.5 mg 4x1's pack 25\n\tIndication: Migraine headache, Acute migraine attacks\n\nDose: Oral\nAcute migraine attacks\nAdult: Initially, 6.25-12.5 mg. May repeat 2 hr later if needed. Max: 2 doses/24 hr.\nHepatic impairment: Initially, 6.25 mg as a single dose. Max: 12.5 mg/24 hr. Avoid in severe impairment.\n\nContra-indication: Underlying CV disease e.g. ischaemic heart disease or coronary artery vasospasm. Uncontrolled hypertension. Severe hepatic or renal impairment. Prophylaxis of migraine, hemiplegic or basilar migraine; cluster headache. Use within 24 hr of another 5-HT1 agonist; use within 24 hr of ergotamine derivative; concurrent use or within 2 wk of discontinuing an MAOI.\n\nSide effects: Nausea, somnolence, headache, flushing, fatigue, paresthesia and dry mouth. Hypotension, bradycardia or tachycardia, palpitations, Raynaud's syndrome, ischaemic colitis and visual disturbances.\nPotentially Fatal: Serious cardiac events.\n\nPrecaution: Hypersensitivity to sulfonamides. Hepatic or moderate-severe renal impairment. Caution when used in patients with a history of seizures. May significantly increase BP. May cause drowsiness. Children <18 yr. Pregnancy, lactation.\n\nMode of action: Increased risk of serotonin syndrome when used with SSRIs or serotonin norepinephrine reuptake inhibitors. Increased plasma concentrations when used with verapamil, ketoconazole or other potent CYP450 inhibitors.\nPotentially Fatal: Severe vasospastic reactions may occur when given within 24 hr of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-like medication. Avoid usage with or within 2 wk of stopping treatment with a MAOI.\n\nPregnancy category: C\n\nInteraction: Increased risk of serotonin syndrome when used with SSRIs or serotonin norepinephrine reuptake inhibitors. Increased plasma concentrations when used with verapamil, ketoconazole or other potent CYP450 inhibitors.\nPotentially Fatal: Severe vasospastic reactions may occur when given within 24 hr of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-like medication. Avoid usage with or within 2 wk of stopping treatment with a MAOI.
Alprazolam	\n\n\tAlbion Ltd.\tAlprazolam TAB dr 0.25 mg/ 0.50 mg 100's / 100's pack \n\tAristopharma\tXolam XR TAB dr 0.5mg 50's pack 125\n\tAristopharma\tXolam XR TAB dr 1mg 50's pack 200\n\tAsiatic Ltd.\tAlpam TAB dr 0.25mg 100's pack 100\n\tAsiatic Ltd.\tAlpam TAB dr 0.5mg 50's pack 100\n\tBeximco\tZolax TAB dr 0.25mg 100's pack 100\n\tBeximco\tZolax TAB dr 0.5mg 100's pack 175\n\tGeneral\tSerelam TAB dr .25mg 100's pack 100\n\tGeneral\tSerelam TAB dr 0.5mg 100's pack 201\n\tGlobe\tXiotic TAB dr 0.5mg  \n\tIncepta\tZolium TAB dr 0.25mg 100's pack 150\n\tIncepta\tZolium TAB dr 0.5mg 100's pack 300\n\tMundipharma (Bangladesh) Pvt. Ltd.\tAlprocontin TAB dr 0.5mg 100's pack \n\tNavana\tXanax TAB dr 0.25mg 100's pack 100\n\tNavana\tXanax TAB dr 0.5mg 50's pack 100.50\n\tOpsonin Pharma\tAlprax TAB dr 0.25mg 50's pack 50\n\tOpsonin Pharma\tAlprax TAB dr 0.5mg 50's pack 100\n\tOpsonin Pharma\tAlprax XR TAB dr 2mg 30's pack 240\n\tOpsonin Pharma\tAlprax XR TAB dr 1mg 30's pack 120\n\tSquare\tNixalo TAB dr 0.25mg 100's pack 180.66\n\tSquare\tNixalo TAB dr 0.5mg 100's pack 200\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAlzolam 0.25 TAB dr 0.25mg 100's pack 112\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAlzolam 0.5 TAB dr 0.5mg 100's pack 203\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAlzolam SR 1 TAB dr 1mg 100's pack 400\n\tUnited Chemicals &\tAlaxen TAB dr 0.5mg  \n\tUnited Chemicals &\tAlaxen TAB dr 0.25mg  \n\tIndication: Anxiety disorders, Panic disorders, Nausea due to chemotherapy\n\nDose: Oral\nShort-term management of anxiety\nAdult: 0.25-0.5 mg tid, increased to 3-4 mg daily if necessary.\nElderly: Initially, 0.25 mg bid/tid.\nHepatic impairment: Avoid in severe impairment.\n\nPanic attacks\nAdult: Up to 10 mg daily.\n\nContra-indication: Acute narrow-angle glaucoma, preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; pregnancy, lactation.\n\nSide effects: Psychological and physical dependence, withdrawal syndrome; drowsiness, sedation, vertigo, headache, visual disturbances, GI disturbances, jaundice; fatigue, muscle weakness, ataxia, dizziness, confusion and depression.\nPotentially Fatal: Blood dyscrasias.\n\nPrecaution: Dosage reduction or gradual withdrawal. Dependence. Geriatric or debilitated patients. Muscle weakness, impaired hepatic or renal function; arteriosclerosis; obesity; depression particularly suicidal tendency; chronic pulmonary insufficiency. May impair ability to drive or operate machinery. Children <18 yr.\n\nMode of action: Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.\nPotentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. \n\nPregnancy category: D\n\nInteraction: Potentiates action of alcohol and CNS depressants. Reduced conc with cigarette smoking by 50%.\nPotentially Fatal: Cimetidine and fluoxetine reduce the clearance of alprazolam. Alprazolam enhances activity of imipramine and desipramine. 
Aluminium Chloride Hexahydrate 20%	\n\n\tZiska\tDricare Solution 20% 50ml bot 220\n\tIndication: Hyperhidrosis. \n\nDose: Topical\n\nApply solution to completely dry affected area (e.g., underarms, palms, soles, scalp) once daily at bedtime and washed off the following morning. Repeat applications for >2 consecutive nights until desired effect (lack of sweating) achieved.Thereafter, may apply additional treatments once or twice weekly as needed.\n\nApply only to affected areas you need to treat. It is usually used around the armpits, hands or feet, and is most effective when applied to small areas of skin, helping to prevent lasting side effects as a result of blocking too many sweat glands. \n\nContra-indication: Known hypersensitivity to aluminum chloride hexahydrate or any ingredient in the formulation.\n\nSide effects: Local skin irritation (burning, stinging, itching, tingling).\n\nPrecaution: Aluminium Chloride Hexahydrate is suitable for use only on small areas at a time and not for wide spread usage. Pregnancy and lactation. Avoid contact with eyes.Keep preparations out of reach of children.Risk of skin sensitivity increases with higher concentrations,\n\nThis medication may stain clothing or certain fabrics or harm metals. Use this medication cautiously to avoid contact with clothes, bed linens, other fabrics, or metals. Let this medication dry completely before putting clothing over the treated area.\n\nMode of action: There are no known drug interactions for aluminum chloride hexahydrate topical.\n\nPregnancy category: C\n\nInteraction: There are no known drug interactions for aluminum chloride hexahydrate topical.
Aluminium Hydroxide + Magnesium Hydroxide	\n\n\tACI\tAvlocid Suspension   200ml bot 75\n\tAcme Ltd.\tOxecone TAB dr  (250+400) mg 100's pack 53\n\tAd-din\tDuomeal TAB dr   200's pack 106\n\tAexim\tDolocid TAB dr   200's pack 120\n\tAlbion Ltd.\tPentocil Suspension 15g/100ml 200 ml \n\tAlco Pharma\tAntameal TAB dr   200's pack 100\n\tAmbee\tStomacid TAB dr   100's pack 53\n\tAmico Ltd.\tMagnogel TAB dr   200's pack 104\n\tAristopharma\tDigel TAB dr   200's pack 100\n\tBeximco\tLactameal TAB dr   200's pack 106\n\tBio Pharma Ltd.\tBiocid TAB dr   200's pack 400\n\tCentral.\tCytocid TAB dr   200's pack 100\n\tCosmic Chemical Industries Ltd.\tAlugel TAB dr   200's pack 100\n\tCrystal\tCrystacid TAB dr   200ml bot 32\n\tDoctor's Chemicals Works Ltd.\tAlgex TAB dr   200's pack 100\n\tEdruc Ltd.\tEpazel Suspension   200ml bot 75\n\tEskayef Bangladesh Ltd.\tStoma TAB dr   200's pack 108\n\tGeneral\tGenacid TAB dr   200's pack \n\tGonoshasthaya\tG Antacid MH TAB dr   200's pack 102\n\tHudson\tHi Gel TAB dr   200's pack 104\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAntanil TAB dr   200's pack 104\n\tIndobangla Pharmaceuticals\tTrialugel TAB dr   200's pack 80\n\tJayson\tJpdrox TAB dr   100's pack 140\n\tKumudini Pharma Ltd.\tTricid TAB dr   200's pack 104\n\tMedimet\tNocid TAB dr   200's pack 280\n\tOpsonin Pharma\tAlucil Suspension  (175 mg + 225 mg)/ 5ml 200ml bot 65.98\n\tOpsonin Pharma\tAlucil TAB dr 250 mg + 400 mg  100's pack \n\tOrion Pharma Ltd.\tGastrodyne TAB dr   200's pack \n\tPacific\tSugel TAB dr   200's pack 100\n\tPharmadesh Ltd.\tPharmacid TAB dr   200's pack 360\n\tReman Drug Ltd.\tRemacid Suspension  200ml bot 32.50\n\tRenata\tAncid Plus Suspension   200ml bot 46\n\tRephco\tRecocid Suspension   200ml bot 75\n\tSalton\tPlacid TAB dr   200's pack 204\n\tSquare\tEntacyd TAB dr  250 mg + 400 mg 200's pack 400\n\tSquare\tEntacyd Suspension   200ml bot 75\n\tSupreme\tApcocid TAB dr   100's pack 50\n\tZiska\tZ Antacid TAB dr   200's pack 100\n\tIndication: Heartburn, Reflux oesophagitis, Hyperacidity, Peptic ulcer, Constipation, Indigestion\n\nDose: Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.\n\nContra-indication: Hypersensitivity to aluminium salts.\n\nSide effects: Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.\n\nPrecaution: Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.\n\nMode of action: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.\n\nPregnancy category: C\n\nInteraction: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
Aluminium Hydroxide + Magnesium Hydroxide + Simethicon	\n\n\tAcme Ltd.\tOxecone S TAB dr (400+400+30) mg 100's pack 121\n\tAlbion Ltd.\tPentocil Plus Suspension (40g + 26.67g + 0.6g)/ 10 200ml \n\tAmico Ltd.\tPeptacid TAB dr   100's pack 100\n\tBeximco\tAntacid Max TAB dr   200's pack 400\n\tBeximco\tFlatameal TAB dr   200's pack 240\n\tBio Pharma Ltd.\tBiocid PLUS TAB dr   200's pack 180\n\tDrug International Ltd.\tGeludrox HS TAB dr   120's pack 94.80\n\tEskayef Bangladesh Ltd.\tStoma Gas TAB dr   200's pack \n\tG. A. Company Ltd.\tMagadrox PLUS TAB dr   100's pack 90\n\tHallmark\tNeutral S TAB dr   200's pack 158\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAntanil PLUS TAB dr   100's pack \n\tIbn Sina Pharmaceutical Ind. Ltd.\tAntanil PLUS Suspension  200ml bot 56\n\tIncepta\tAmacid Plus TAB dr   200's pack 240\n\tJayson\tJpdrox S TAB dr   100's pack 76\n\tMedimet\tNocid PLUS TAB dr   200's pack 180\n\tModern\tDroxigel PLUS TAB dr   200's pack 180\n\tOpsonin Pharma\tAlucil S TAB dr   10x10's pack 200\n\tPharmadesh Ltd.\tPharmacid PLUS TAB dr   200's pack 226\n\tPharmadesh Ltd.\tPharmacid PLUS Suspension  200ml bot 63\n\tReman Drug Ltd.\tRemacid PLUS TAB dr  400 mg + 400 mg + 30 mg 200's pack 156\n\tRephco\tRecocid Plus TAB dr  200's pack 200\n\tSquare\tEntacyd PLUS TAB dr  400 mg + 400 mg + 30 mg 200's pack 300\n\tSquare\tEntacyd PLUS Suspension  200ml bot 75\n\tIndication: Dyspepsia, Flatulence\n\nDose: Adult: PO Antacid Up to 1 g/day. Hyperphosphataemia in chronic renal failure Up to 10 g/day in divided doses w/ meals.\n\nContra-indication: Hypersensitivity to aluminium salts.\n\nSide effects: Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.\n\nPrecaution: Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.\n\nMode of action: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.\n\nSimethicon: None well documented.\n\nPregnancy category: C\n\nInteraction: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.\n\nSimethicon: None well documented.
Aluminium Hydroxide + Magnesium Trisilicate	\n\n\tGonoshasthaya\tG Antacid TAB dr   250's strip pack/1000's pot 127.50/310\n\tIndication: Heartburn, Indigestion, Gastric Hyperacidity, Peptic ulcer disease, Gastroesophageal reflux disorder (GERD)\n\nDose:  Chew 2 to 4 tablets after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. For best results, drink a half glass of water or other liquid after each dose. Do not take more than 16 tablets in 24 hours\n\nContra-indication: Hypophosphataemia.\n\nSide effects: Diarrhoea, constipation, nausea, vomiting.\n\nPrecaution: Renal dysfunction, low phosphate diet, prolonged use.\n\nMode of action: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Trisilicate: None well documented.\n\nPregnancy category: C\n\nInteraction: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Trisilicate: None well documented.
Aluminium Oxide + Magnesium Hydroxide	\n\n\tAcme Ltd.\tOxecone Suspension  (2G+125 mg)/5 ml 200ml bot 33.01\n\tAd-din\tDuomeal Suspension   200ml bot 32\n\tAexim\tDolocid Suspension   200ml bot 32\n\tAmbee\tStomacid Suspension   200ml bot 33\n\tAmico Ltd.\tMagnogel Suspension   200ml bot 32\n\tAPC Pharma Ltd.\tApedrox Suspension   200ml bot 30\n\tAristopharma\tDigel Suspension   200ml bot 32\n\tBelsen\tGastolin Suspension   200ml bot 30\n\tBeximco\tLactameal Suspension   200ml bot 33\n\tBio Pharma Ltd.\tBiocid MH Suspension   200ml bot 32.42\n\tCentral.\tCytocid Suspension   200ml bot 32\n\tDoctor's Chemicals Works Ltd.\tAlgex Suspension   200ml bot 32.3\n\tGeneral\tGenacid Suspension   200ml bot \n\tIbn Sina Pharmaceutical Ind. Ltd.\tAntanil Suspension   200ml bot 33\n\tKumudini Pharma Ltd.\tTricid Suspension (175 mg + 225 mg)/5 ml  \n\tMedicon\tMucogel Suspension   200ml bot 50\n\tMedimet\tNocid N Suspension   200ml bot 32.5\n\tMillat\tHydrocid Suspension   200ml bot 32.57\n\tModern\tDroxigel S Suspension   200ml bot 32.88\n\tOrion Pharma Ltd.\tGastrodyne Suspension   200ml bot \n\tPacific\tSugel Suspension   200ml bot 32\n\tPharmadesh Ltd.\tPharmacid Suspension   200ml bot 33\n\tSeema\tSeemacid MH Suspension   200ml bot 64\n\tSeema\tSeemacid Plus Suspension   200ml bot 65\n\tSyntho Ltd.\tAcidrox Suspension   200ml bot 32\n\tZenith\tAcedone Z Suspension   200ml bot 40\n\tZenith\tAcedone-Z TAB dr  250's pack 132.50\n\tZenith\tAcidrox-M Suspension  200ml bot 50\n\tIndication: Hyperacidity, Flatulence, Gastric ulcer, Duodenal ulcer, Gastritis, Stomach distension\n\nDose: Chew 1-2 tablets after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. For best results, drink a half glass of water or other liquid after each dose. Do not take more than 16 tablets in 24 hours\n\nContra-indication: Hypophosphataemia.\n\nSide effects: Diarrhoea, constipation, nausea, vomiting.\n\nPrecaution: Renal dysfunction, low phosphate diet, prolonged use.\n\nMode of action: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.\n\nPregnancy category: Not Classified\n\nInteraction: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
Aluminium Oxide + Magnesium Hydroxide + Simethicon	\n\n\tACI\tAvlocid Plus Suspension 400mg+400mg+30mg/5ml 200ml 75.23\n\tACI\tAvlocid Plus TAB dr 5mg 250's pack\n 502.50\n\tAcme Ltd.\tOxecone S Suspension (400+400+30) mg / 5 ml 200ml bot 55.21\n\tAmico Ltd.\tPeptacid Suspension   200ml bot 55\n\tBeximco\tFlatameal DS Oral suspension   200ml bot 65\n\tBio Pharma Ltd.\tBiocid Plus Suspension   200ml bot 55.21\n\tDrug International Ltd.\tGeludrox HS Suspension   200ml bot 60\n\tEdruc Ltd.\tEpazel Plus Suspension   200ml bot 65\n\tEskayef Bangladesh Ltd.\tStoma Gas Susp Suspension   200ml \n\tG. A. Company Ltd.\tMagadrox PLUS Suspension   200ml bot 55\n\tHallmark\tNeutral S Suspension   200ml bot 65\n\tIncepta\tAmacid Plus Susp Suspension   200ml 55\n\tMedimet\tNocid PLUS Suspension   200ml bot 50\n\tModern\tDroxigel PLUS Suspension   200ml bot 65\n\tOpsonin Pharma\tAlucil S Suspension   200ml bot 75\n\tReman Drug Ltd.\tRemacid PLUS Suspension  200 mg + 400 mg + 30 mg/ 200ml bot 55.21\n\tRenata\tAncid DS Plus Suspension   200ml bot 46\n\tRephco\tRecocid Plus Suspension   200ml bot 60\n\tZenith\tAcedone-Z Plus Suspension   200ml bot 65\n\tIndication: Hyperacidity, Gastric ulcer duodenal ulcer and gastritis\n\nDose: Chew1-2 tablets or 2-4 tsf after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. \n\nContra-indication: Hypophosphataemia. Simethicon is contrindicated in renal failure, severely debiliated patients, 1st trimester of pregnancy.\n\nSide effects: Diarrhoea, constipation, nausea, vomiting.\n\nPrecaution: Renal dysfunction, low phosphate diet, prolonged use.\n\nMode of action: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.\n\nSimethicon: None well documented.\n\n\nPregnancy category: Not Classified\n\nInteraction: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Hydroxide: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.\n\nSimethicon: None well documented.\n
Aluminium Oxide + Magnesium Trisilicate	\n\n\tGonoshasthaya\tG Antacid Suspension   200ml bot 28.1\n\tIndication: Heartburn, Indigestion, Gastric Hyperacidity, Peptic ulcer disease, Gastroesophageal reflux disorder (GERD)\n\nDose: Take 2-4 tsf after meals and at bedtime as needed (up to 4 times a day).\n\n\n\nContra-indication: Hypophosphataemia.\n\nSide effects: Diarrhoea, constipation, nausea, vomiting. 	\n\nPrecaution: Renal dysfunction, low phosphate diet, prolonged use.\n\nMode of action: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Trisilicate: None well documented.\n\nPregnancy category: Not Classified\n\nInteraction: Aluminium Hydroxide: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nMagnesium Trisilicate: None well documented.
Alverine Citrate	\n\n\tBeacon\tSpasverin TAB dr 60mg 50's pack 200.50\n\tIncepta\tSomolax TAB dr 60mg 30's pack 120\n\tOpsonin Pharma\tDismonal TAB dr 60mg 50's pack 176.82\n\tOrion Pharma Ltd.\tAlve TAB dr 60mg 50's pack 201\n\tRangs\tAlverin TAB dr 60mg 30's pack 150\n\tIndication: Dysmenorrhoea, Gastrointestinal tract spasm, Irritable bowel syndrome, Diverticular disease\n\nDose: Oral\nDysmenorrhoea, Gastrointestinal tract spasm\nAdult: 60-120 mg 1-3 times daily.\nChild: >12 yr: 60-120 mg 1-3 times daily.\n\nContra-indication: Hypersensitivity, intestinal obstruction, paralytic ileus; children <12 yr.\n\nSide effects: Nausea, headache; pruritus, rash; dizziness; allergic reactions.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Amantadine Hydrochloride	\n\n\tACI\tAmantril CAP 100mg 30's pack 300\n\tPeoples Pharma Ltd.\tInflu CAP 100mg 60's pack 180\n\tPeoples Pharma Ltd.\tInflu Syrup 50mg/5ml 100ml bot 35.17\n\tIndication:  Parkinson's disease, Influenza, herpes zoster, drug-induced extrapyramidal reactions							\n\n\nDose: Adult: PO Influenza A 100 mg/day for 5 days. Prophylaxis of influenza A 100 mg/day for up to 6 wk. W/ influenza vaccination: up to 3 wk after vaccination. \nElderly: >65 yr: Daily dose of <100 mg or 100 mg given at intervals >1 day.\nChild: 10-15 yr: 100 mg daily. \n\nHerpes zoster 100 mg twice daily for 14 days, may continue for another 14 days if pain persists. \nParkinson's disease100 mg/day, up to 100 mg twice daily 1 wk or more. Max: 400 mg/day.\n\nRenal impairment:\nCrCl (ml/min)	\n>35	100 mg daily.\n15-35	100 mg every 2-3 days.\n<15	  Not recommended. \n\nContra-indication: Hypersensitivity. Pregnancy and lactation. Epilepsy or other seizure disorders, severe renal impairment and gastric ulceration.\n\nSide effects: Seizures, psychosis, hallucinations, confusion, ataxia, heart failure, depression, orthostatic hypotension, blood dyscrasias, urinary retention, irritability, GI disturbances, anorexia, livedo reticularis, ankle oedema.\nPotentially Fatal: Congestive heart failure, convulsions.\n\nPrecaution: Patients with CV or liver disease, impaired renal function, recurrent eczema. Elderly. Withdrawal of the drug should be gradual.\n\nMode of action: Enhances the adverse effects of antimuscarinics and levodopa. CNS stimulants, drugs that raise urinary pH.\n\nThe concurrent use of Amantadine hydrochloride with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. \n\nPregnancy category: C\n\nInteraction: Enhances the adverse effects of antimuscarinics and levodopa. CNS stimulants, drugs that raise urinary pH.\n\nThe concurrent use of Amantadine hydrochloride with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. 
Ambroxol	\n\n\tACI\tMyrox Syrup 15mg/5ml 100ml bot 40.12\n\tACI\tMyrox S Paediatric Drops 6mg/ml 15ml bot 30.09\n\tAcme Ltd.\tX-Cold Syrup 15mg/5ml 100ml bot 30.11\n\tAcme Ltd.\tX-Cold Paediatric Drops 6mg/ml 15ml bot 20.07\n\tAd-din\tMucovan Syrup 15mg/5ml 100ml bot 28\n\tAlbion Ltd.\tAmbroxol Syrup 15 mg/5 ml 100 ml \n\tAmico Ltd.\tAmbrotil Syrup 15mg/5ml 100ml bot 35\n\tApex\tAcorex Syrup 15mg/5ml 100ml bot 300\n\tApex\tAcorex TAB dr 30mg 100's pack 200\n\tApollo Pharmaceutical Ltd.\tBronchosil Syrup 15mg/5ml 100ml bot 30\n\tAristopharma\tNexol Syrup 15mg/5ml 100ml bot 30\n\tAristopharma\tNexol Paediatric Drops 6mg/ml 15ml bot 20\n\tBeacon\tSafoxol CAP 75mg  \n\tBenham\tMbroxol Syrup 15mg/5ml 100ml bot 30\n\tBeximco\tMucosol Syrup 15mg/5ml 100ml bot 30\n\tBeximco\tMucosol Paediatric Drops 6mg/ml 15ml bot 20\n\tBio Pharma Ltd.\tAmbroxol Syrup 15mg/5ml 100ml bot 30\n\tBio Pharma Ltd.\tAmbroxol SR CAP 75mg 30's pack 150\n\tConcord\tNeobrox Syrup 15mg/5ml 100ml bot 30\n\tDelta Pharma\tAmsiv Syrup 15mg/5ml 100ml bot 30\n\tDesh\tKufflin Syrup 15mg/5ml 100ml bot 30\n\tDoctor's Chemicals Works Ltd.\tBilco Syrup 15mg/5ml 100ml bot 30\n\tDoctor's Chemicals Works Ltd.\tBilco Paediatric Drops 6mg/ml 15ml bot 20\n\tEdruc Ltd.\tRoxal Syrup 15mg/5ml 100ml bot 30\n\tEdruc Ltd.\tRoxal Paediatric Drops 6mg/ml 15ml bot 20\n\tEskayef Bangladesh Ltd.\tAmboten Syrup 15mg/5ml 100ml bot 30\n\tEskayef Bangladesh Ltd.\tAmboten PD Paediatric Drops 6mg/ml 15ml bot 20\n\tEverest\tProkof Paediatric Drops 6mg/ml 15ml bot 20\n\tEverest\tProkof Syrup 15mg/5ml 100ml bot 40.15\n\tGlaxoSmithKline Bangladesh Ltd.\tActicol Syrup 15mg/5ml 100ml bot 40\n\tGlobe\tFemex Syrup 15mg/5ml 100ml bot 30\n\tGlobex\tCofexin Syrup 15 mg/5 ml 100ml 35\n\tHallmark\tMubrox Syrup 15mg/5ml 100ml bot 30.11\n\tHallmark\tMubrox Paediatric Drops 6mg/ml 15ml bot 20\n\tHealthcare\tAroxol PD Paediatric Drops 6mg/ml 15ml bot 25\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLytex Paediatric Drops 15mg/5ml 15ml bot 25\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLytex Syrup 15mg/5ml 100ml bot 40\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLytex SR CAP 75mg 30's pack 165\n\tIncepta\tAmbolyt Syrup 15mg/5ml 100ml bot 30\n\tIncepta\tAmbolyt Paediatric Drops 6mg/ml 15ml bot 30\n\tJayson\tBroxolin Syrup 15mg/5ml 100ml bot 33\n\tKemiko\tHybrox Syrup 15 mg/5 ml  \n\tKemiko\tHybrox Paediatric Drops 6 mg/ml  \n\tKemiko\tHybrox SR CAP 75mg  \n\tKumudini Pharma Ltd.\tAmboxol Syrup 15mg/5ml 100ml bot 30\n\tKumudini Pharma Ltd.\tAmbroxol Paediatric Drops 6mg/ml 15ml bot 20\n\tLeon\tLeucofil syrup 50ml/ml  \n\tMedicon\tRixol Syrup 15mg/5ml 100ml bot 30\n\tModern\tAmbix Syrup 15mg/5ml 100ml bot 30\n\tMonicopharma\tRemap Syrup 15mg/5ml 100ml bot 30\n\tNavana\tBrox Syrup 15mg/5ml 100ml bot 30.11\n\tNIPRO JMI Pharma\tBroculyt Syrup 15mg/5ml 100ml bot 30\n\tNovelta Bestway\tAmbokof Syrup 15mg/5ml 100ml bot 300\n\tNovo Healthcare and Pharma Ltd.\tDilyt Syrup 15mg/5ml 100ml bot 30\n\tOpsonin Pharma\tBoxol Syrup 15mg/5ml 100ml bot 30\n\tOpsonin Pharma\tBoxol Paediatric Drops 6mg/ml 15ml bot 20\n\tOpsonin Pharma\tBoxol SR CAP 75mg  \n\tOrganic Health Care\tAmbroton Syrup 15 mg/5 ml  \n\tOrion Pharma Ltd.\tAmbronil Paediatric Drops 6mg/ml 12ml bot 25\n\tOrion Pharma Ltd.\tAmbronil Syrup 15mg/5ml 100ml bot 30.11\n\tOyster\tFlintex Syrup 15 mg/5 ml  28\n\tPacific\tBroxolit Paediatric Drops 6mg/ml 15ml bot 19\n\tPharmadesh Ltd.\tAmboral Syrup 15mg/5ml 100ml bot 30.11\n\tPharmadesh Ltd.\tAmboral Paediatric Drops 6mg/ml 15ml bot 20.06\n\tPharmasia Ltd.\tXerokof Syrup 15 mg/5 ml  \n\tPopular\tAmbrosol Syrup 15mg/5ml 100ml bot 30.11\n\tPopular\tAmbrosol CAP 75mg 30's pack \n\tRAK\tAmbryl Paediatric Drops 6mg/ml 100ml bot 30\n\tRAK\tAmbryl SF Syrup 15mg/5ml 100ml bot 30\n\tRenata\tRecof Syrup 15mg/5ml 100ml bot 40\n\tRephco\tAmbozin Syrup 15mg/5ml 100ml bot 40\n\tRephco\tAmbozin SR CAP 75mg 3x10's pack 150\n\tS. N.\tAmbolos Syrup 15mg/5ml 100ml bot 30.10\n\tSeema\tSeebrox Syrup 15mg/5ml 100ml bot 30\n\tSharif\tResol Syrup 15mg/5ml 100ml bot 30\n\tSilva\tAmbosil Syrup 15mg/5ml 100ml bot 30.11\n\tSilva\tAmbosil Paediatric Drops 6mg/ml 15ml bot 20.07\n\tSomatec\tMucobrox Syrup 15mg/5ml 100ml bot 30.11\n\tSomatec\tMucobrox Paediatric Drops 6mg/ml 15ml bot 20.08\n\tSquare\tAmbrox Syrup 15mg/5ml 100ml bot 30.11\n\tSquare\tAmbrox Paediatric Drops 6mg/ml 15ml bot 20.07\n\tSquare\tAmbrox SR 75 CAP 75mg 30's pack 150.43\n\tZiska\tBroxidil Syrup 15mg/5ml 100ml bot 40\n\tIndication: Mucolytic, Productive cough, Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis, laryngitis, Pharyngitis, sinusitis and rhinitis associated with viscid mucus, Asthmatic bronchitis, bronchial asthma with thick expectoration, Bronchiectasis, Chronic pneumonia.\n\nDose: Paediatric Drops : \n0 - 6 months old - 0.5 ml, 2 times a day, \n6 - 12 months old - 1 ml, 2 times a day, \n1 - 2 years old -1.25 ml, 2 times a day. \n\nSyrup : 2 -5 years old - 2.5 ml (1/2 teaspoonful), 2-3 times a day, \n5 - 10 years old - 5 ml (1 teaspoonful), 2-3 times a day, \n10 years old and adults - 10 ml (2 teaspoonful), 3 times a day. \n\nSR Capsule : Adults and children over 12 years old - 1 capsule, once daily \n\nContra-indication: Contraindicated in known hypersensitivity to Ambroxol or Bromhexine.\n\nSide effects: Mild GI effects and allergic reactions.\n\nPrecaution: Ambroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Amikacin	\n\n\tACI\tKacin Injection 100mg/2ml 10 amps pack/20 amps pack 160.60/322.20\n\tACI\tKacin Injection 500mg/2ml 10 amps pack 483.20\n\tApex\tAmikacin IV/IM Injection 500mg/2ml 5's pack 240\n\tAristopharma\tMikacin Injection 100mg/2ml 10 amps pack 160\n\tAristopharma\tMikacin Injection 500mg/2ml 5 amps pack 240\n\tBio Pharma Ltd.\tAmimax Injection 100mg/2ml 10 amps pack 160\n\tBio Pharma Ltd.\tAmimax Injection 500mg/2ml 10 amps pack 480\n\tDrug International Ltd.\tPsudonil Injection 250mg/2ml 5 amps pack 150\n\tDrug International Ltd.\tPsudonil Injection 500mg/2ml 5 amps pack 225\n\tIncepta\tAmikin Injection 100mg/2ml 10 amps pack 160\n\tIncepta\tAmikin Injection 500mg/2ml 10 amps pack 480\n\tPopular\tAmibac Injection 100mg/2ml 10 amps pack 160.60\n\tPopular\tAmibac Injection 500mg/2ml 10 amps pack 481.81\n\tSquare\tAmistar IM/IV inj Injection 100mg/2ml 10's pack 160\n\tSquare\tAmistar IM/IV inj Injection 500mg/2ml 10's pack 480\n\tTechno Drugs Ltd.\tCinamak Injection 250mg/2ml 10 amps pack 120\n\tTechno Drugs Ltd.\tCinamak Injection 500mg/2ml 10 amps pack 210\n\tIndication: Tuberculosis, Complicated and recurrent urinary tract infections, Severe Gram-negative infections, Non-tubercular mycobacterial infections, Bacterial septicemia, Infections of the respiratory tract, Bones and joints, Central nervous system and skin and soft tissue, Intra-abdominal infections, Burns, Postoperative infections, Meningitis, Peritonitis, Neonatal sepsis\n\nDose: Parenteral\nUncomplicated urinary tract infections\nAdult: 250 mg bid, given via IM, IV inj over 2-3 minutes or as IV infusion.\n\nSevere Gram-negative infections resistant to gentamicin and tobramycin\nAdult: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Max: Up to 500 mg every 8 hr in life-threatening infections. Max cumulative dose: 15 g. Doses may be given via IM, slow IV inj over 2-3 minutes or IV infusion.\n\nChild: 15 mg/kg daily in equally divided doses injected every 8 or 12 hr for 7-10 days. Neonates: 10 mg/kg daily in 2 divided doses.\n\nImpaired renal function: In patient with impaired renal function the daily dose should be reduced and/or the intervals between doses increased to avoid accumulation of the drug. Simple doses schedule for renal impairment is given below:\nRenal function Dosage schedule\nMild impairment 500 mg every 18 hours\nModerate impairment 500 mg every 24 hours\nSevere impairment 250 mg every 24 hours. \n\nContra-indication: Pregnancy, perforated ear drum, myasthenia gravis, hypersensitivity.\n\nSide effects: Tinnitus, vertigo; ataxia and overt deafness.\nPotentially Fatal: Ototoxicity, nephrotoxicity, neuromuscular blockade.\n\nPrecaution: Renal impairment; vertigo, tinnitus. Discontinue if signs of ototoxicity, neurotoxicity or hypersensitivity occurs; lactation. Safety has not been established for treatment period >14 days. Monitor renal function before and during treatment.\n\nMode of action: Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.\nPotentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.\n\nPregnancy category: D\n\nInteraction: Amphotericin B may lead to increased nephrotoxicity and reduced clearance of amikacin when used together.\nPotentially Fatal: Increased ototoxic or nephrotoxic effects with other nephrotoxic or ototoxic drugs. Enhanced neuromuscular blockade with neuromuscular blocking drugs. Increased risk of ototoxicity with potent diuretics.
Amiloride Hydrochloride + Hydrochlorothiazide	\n\n\tACI\tKaltide TAB dr   100's pack 201\n\tSanofi Aventis (BD) Ltd.\tAmizide TAB dr   200's pack 144.01\n\tIndication: Hypertension, Congestive heart failure, Hepatic cirrhosis with ascites and oedema\n\nDose: Adult: PO: \nHypertension Per tab contains amiloride 5 mg and hydrochlorothiazide 50 mg: 1/2  to 1 tab/day. \n\nCongestive heart failure Per tab contains amiloride 5 mg and hydrochlorothiazide 50 mg: 1/2  to 2 tabs/day. \n\nHepatic cirrhosis with ascites and oedema Per tab contains amiloride 5 mg and hydrochlorothiazide 50 mg: 1-2 tabs/day.\n\nContra-indication: Hyperkalaemia; anuria; acute renal failure, severe progressive renal disease; severe hepatic failure, precoma associated with hepatic cirrhosis; Addison's disease; hypercalcaemia; diabetic neuropathy; DM. Child <18 yr. Lactation.\n\nSide effects: Electrolyte imbalance e.g. hyponatraemia, hypochloraemic alkalosis, hypokalaemia and hypomagnesaemia. Anaphylaxis, back pain, chest pain, fatigue, fever, headache, malaise, neck/shoulder ache, pain in extremities, syncope, weakness; angina, arrhythmias, digitalis toxicity, orthostatic hypotension, necrotising angiitis, palpitation and tachycardia; \nGI disturbances; agranulocytosis, aplastic anaemia, haemolytic anaemia, leucopenia, neutropenia, purpura and thrombocytopenia; alopecia, diaphoresis, dry mouth, flushing, photosensitivity, pruritis, rash, sialadenitis and urticaria; glycosuria, gout, hyperglycaemia and hyperuricaemia; joint pain, leg ache and muscle cramps; dizziness, encephalopathy, paraesthesia, stupor, tremors, vertigo; decreased libido, depression, insomnia, mental confusion, nervousness, restlessness, sleepiness and somnolence; cough, dyspnoea and respiratory distress; bad taste, increased intraocular pressure, nasal congestion, tinnitus, visual disturbance and xanthopsia; bladder spasm, dysuria, impotence, incontinence, interstitial nephritis, nocturia, polyuria, renal dysfunction.\n\nPrecaution: Renal impairment; BUN >10 mmol/L, serum creatinine >130 mmol/L. Monitor serum electrolytes and blood urea levels in seriously ill patients e.g. those with hepatic cirrhosis with ascites and metabolic alkalosis, or those with resistant oedema. Pre-existing severe liver disease. May affect parathyroid function. Hyperuricaemia or gout may occur. Cholesterol and triglyceride levels may be increased. Thiazides may impair glucose tolerance. DM may be precipitated or aggravated. May activate or exacerbate SLE. Elderly. Hyponatraemia. Pregnancy.\n\nMode of action:  	Additive effects with other antihypertensives. May increase the responsiveness to tubocurarine. May reduce arterial responsiveness to pressor amines e.g. norepinephrine. Orthostatic hypotension may occur with alcohol, barbiturates and narcotics. Discontinue diuretics 2-3 days before initiation of an ACE inhibitor to reduce the likelihood of 1st dose hypotension. Increased hypokalaemia with corticosteroids or ACTH. Attenuation of diuretic, natriuretic and antihypertensive effects of diuretics with NSAIDs. Increased hyponatraemia with chlorpropamide. Increased hyperkalaemia with ciclosporin, tacrolimus, indometacin and angiotensin II receptor antagonists.\nPotentially Fatal: Increases risk of hyperkalaemia with other potassium-sparing diuretics (spironolactone or triamterene). Increases risk of lithium toxicity.\n\nPregnancy category: B\n\nInteraction:  	Additive effects with other antihypertensives. May increase the responsiveness to tubocurarine. May reduce arterial responsiveness to pressor amines e.g. norepinephrine. Orthostatic hypotension may occur with alcohol, barbiturates and narcotics. Discontinue diuretics 2-3 days before initiation of an ACE inhibitor to reduce the likelihood of 1st dose hypotension. Increased hypokalaemia with corticosteroids or ACTH. Attenuation of diuretic, natriuretic and antihypertensive effects of diuretics with NSAIDs. Increased hyponatraemia with chlorpropamide. Increased hyperkalaemia with ciclosporin, tacrolimus, indometacin and angiotensin II receptor antagonists.\nPotentially Fatal: Increases risk of hyperkalaemia with other potassium-sparing diuretics (spironolactone or triamterene). Increases risk of lithium toxicity.
Amino Acids 5 % & 10%	\n\n\tACI\tRepotyn 5% IV Infusion  5% 500 ml bot 352.38\n\tACI\tRepotyn max VI 10% Infusion  7%+10% 500ml bot 401.20\n\tBeacon\tXemocid IV Infusion  5 % 500 ml bot 350\n\tBeacon\tXemocid IV Infusion  10% 500ml bot  400\n\tBeximco\tNutrimin IV Infusion   500 ml bot 350\n\tBio Pharma Ltd.\tAmilac IV Infusion   500 ml bot 350\n\tEskayef Bangladesh Ltd.\tProtinex IV Infusion   500 ml bot 350\n\tEskayef Bangladesh Ltd.\tProtinex gold VI 10% Infusion   500ml bot  400\n\tGeneral\tPowersol IV Infusion   500ml 350\n\tGlobe\tAminomax Gold IV Infusion   500ml bot 351.32\n\tHealthcare\tNutrilive IV Infusion   500 ml bot 350\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAminosin 				 Infusion  500ml  350 \n\tIbn Sina Pharmaceutical Ind. Ltd.\tAminosin Plus 	 		 	 Infusion  500ml  400\n\tIncepta\tProsol IV Infusion  500ml  500 ml bot 350\n\tMonicopharma\tEsamin IV Infusion   500ml bot 350\n\tOpso Saline Ltd.\tAminosol 5 IV Infusion   500 ml bot 351.32\n\tOpso Saline Ltd.\tAminosol gold VI 10% Infusion    500ml bot 401.52\n\tOpsonin Pharma\tClinosol Infusion   500 ml bot 351.32\n\tOrion Pharma Ltd.\tProliv IV Infusion   100 ml bot/ 500 ml bot 260/ 350\n\tPopular\tAmisol IV Infusion  5 % 250 ml bot/500 ml bot 200.75 / 351.32\n\tPopular\tAmisol gold VI 10% Infusion   250ml bot / 500ml bot 260.98 / 401.51\n\tRenata\tProtemin IV Infusion 500ml 500ml bot \n\tUnimed & Unihealth Manufacturers Ltd.\tAminosyn 10% 			 	 	 Infusion  1's pack(500ml) 560.97\n\tIndication: Protein supply for parenteral nutrition. Prophylaxis & therapy of protein deficiency resulting from increased protein losses &/or increased protein requirements.\n\nDose: Adults:\n\nThe nitrogen requirement for maintenance of body protein mass depends on the patient's condition (nutritional state and degree of metabolic stress).\nNo or minor metabolic stress and normal nutritional state: 0.10-0.15 g nitrogen/kg/day,\nModerate metabolic stress with or without malnutrition: 0.15-0.20 g nitrogen/kg/day,\nSevere catabolism as in burns, sepsis and trauma: up to 0.20-0.25 g nitrogen/kg/day.\n\nThe dosage range 0.10-0.25 g nitrogen/kg/day corresponds to 15-35 ml amino acid IV/kg/day.\nIn obese patients, the dose should be based on the estimated ideal weight. Depending upon patients requirements, 1000-2000 ml amino acid may be infused intravenously per 24 hours. It should be infused slowly, at rates 1.4-2.8 ml (30-60 drops) per minute.\n\nInfants and Children:\nIn children and infants, the rate of infusion is 28-35 ml/kg body wt/day is recommended, with a stepwise increment in the rate of administration during the first week of treatment.\n\nContra-indication: Contraindicated in patients with inborn errors of amino acids metabolism. Moreover, amino acid should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.\n\nSide effects: It is usually well tolerated. Yet nausea, vomiting, flushing and sweating have been observed during infusion of amino acid IV at rates exceeding the recommended maximal rate. Hypersensitivity reactions have been reported. Like all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. The incidence may be reduced by the simultaneous infusion of 10% fat emulsion. If it is infused to severely ill patients, premature infants, hyperphenylalaninemia may occur.\n\nPrecaution: Hyperphenylalaninemia has been noted in severely ill, premature infants. In these patients, monitoring of the phenylalanine levels is recommended and the infusion rate adjusted as needed.\nDo not use if the solution is turbid or contains particles. Discard any unused portion.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Amino Acids 7 % + Glucose & Electrolytes 10 %	\n\n\tAcme Ltd.\tAminomix IV Infusion   \n\tBeximco\tNutrimin-D IV Infusion   500 ml bot 410\n\tGeneral\tPowersol Plus IV Infusion   500ml 400\n\tOpsonin Pharma\tClinosol Gold IV Infusion    500 ml bot 401.51\n\tOrion Pharma Ltd.\tProliv Plus IV Infusion   500 ml bot 400\n\tIndication: Prevent nitrogen loss, Negative nitrogen balance, Nutritional therapy\n\nDose: For peripheral intravenous infusion, 1 to 1.5 g/kg/day of total amino acids will reduce protein catabolism. Infusion or ingestion of carbohydrate or lipid will not reduce the nitrogen sparing effect of intravenous amino acid infusions at this dose.\nAs with all intravenous fluid therapy, the primary aim is to provide sufficient water to compensate for insensible, urinary, and other fluid losses (nasogastric suction, fistula drainage, and diarrhea).  Infused at a rate of 45 mL/kg/day, will meet the fluid and amino acid requirements of the stable adult patient.\nAs reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.\n\nContra-indication: This preparation should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.\n\nSide effects:  it can be infused through a peripheral vein paying great care to the possible occurrence of local reactions. Local reactions consisting of a warm sensation, erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids; in such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slower rates of infusion may reduce the incidence of local venous irritation. Electrolyte additives should be spread throughout the day. Irritating additive medications may need to be injected at another venous site.\n\nGeneralized flushing, fever and nausea have been reported during peripheral infusions of amino acid solutions.\n\nPrecaution: Special care must be taken when administering glucose solutions to provide calories in diabetic or prediabetic patients. To control and minimize possible hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and, if necessary, add insulin.\n\nBecause of its antianabolic activity, concurrent administration of tetracycline may reduce the nitrogen sparing effects of infused amino acids.\n\nFeeding regimens which include amino acids should be used with caution in patients with history of renal disease, pulmonary disease, or with cardiac insufficiency so as to avoid excessive fluid accumulation.\n\nNitrogen intake should be carefully monitored in patients with impaired renal function.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Aminocaproic Acid	\n\n\tACI\tMinocap Injection   94.32\n\tChemist Ltd.\tHemolysin Injection 1gm/5ml 10 amps pack 151.70\n\tEdruc Ltd.\tE-Capro Injection  6 amps pack 210\n\tPacific\tCaprolisin Injection  10 amps pack 437\n\tTechno Drugs Ltd.\tCaprolex Injection 1gm/5ml 5ml X 5 amps pack 73\n\tIndication: Haemorrhage, Missed abortion, Hereditary hemorrhagic telangiectasia,Traumatic hyphema, Dental bleeding, Hemophilia A, Postoperative bleeding, Systemic hyperfibrinolysis\n\nDose: Oral\nTreatment and prophylaxis of haemorrhage\nAdult: Initially, 4-5 g, followed by 1-1.25 g every hr for about 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. \n\nIV Treatment and prophylaxis of haemorrhage As 2% soln: Initial: 4-5 g over 1 hr, then continuous infusion of 1 g/hr for usually up to 8 hr or until bleeding is controlled. Max: 24 g/24 hr.\n\nContra-indication: Bleeding due to disseminated intravascular coagulation. Rapid IV administration.\n\nSide effects: Oedema, headache, malaise, allergic and anaphylactic reactions, anaphylaxis, bradycardia, hypotension, peripheral ischaemia, thrombosis, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopaenia, thrombocytopaenia, increased CPK, muscle damage, myalgia, myopathy, myositis, rhabdomyolysis, confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope, dyspnoea, nasal congestion, pulmonary embolism, pruritus, rash, tinnitus, decreased vision, watery eyes, increased BUN, dry ejaculation.\nPotentially Fatal: Cardiac and hepatic damage.\n\nPrecaution: Renal or cardiac disorders. Urinary tract bleeding, haematuria of upper urinary tract origin; veno-occlusive hepatic disease, skeletal myopathy, neonates. Monitor creatinine phosphokinase. Avoid admin with factor IX complex concentrates. Pregnancy and lactation.\n\nMode of action: Increased risk of hypercoagulability with OC and oestrogens.\n\nPregnancy category: C\n\nInteraction: Increased risk of hypercoagulability with OC and oestrogens.
Aminophylline	\n\n\tAmbee\tAminophylline TAB dr 100mg 500's pack 190\n\tAmbee\tAminophylline Injection 125mg/5ml 5 amps pack 27.30\n\tBeximco\tLarnox LA TAB dr 350mg 50's pack 111\n\tBristol Pharma Ltd.\tAminophylline TAB dr 100mg 200's pack 190\n\tChemist Ltd.\tAminophylline TAB dr 100mg 500's pack 190\n\tDelta Pharma\tBrolin Retard TAB dr 350mg 50's pack 111\n\tIndobangla Pharmaceuticals\tIndophyllin TAB dr 100mg 100's pack 42\n\tNovartis (Bangladesh) Ltd.\tAminophyllinum Retard TAB dr 350mg 50's pack 111\n\tOpsonin Pharma\tFilin Injection 125mg/5ml 10 amps pack 44\n\tOpsonin Pharma\tFilin TAB dr 100mg 100's pack 38\n\tPacific\tMinomal R TAB dr 350mg 50's pack 110\n\tPacific\tMinomal R TAB dr 175mg 100's pack 123\n\tPacific\tMinomal-R SR TAB dr 600mg 20's pack 72\n\tSanofi Aventis (BD) Ltd.\tCardophylin injection 125 mg/5ml  \n\tIndication: Asthma, Acute bronchospasm, Chronic bronchitis, Emphysema, COPD\n\nDose: Oral\nChronic bronchospasm\nAdult: As hydrate: Initially, 225-450 mg bid, increased if necessary.\nChild: >3 yr: As modified-release hydrate: 12 mg/kg daily increased to 24 mg/kg daily in 2 divided doses after 1 wk.\n\nIntravenous\nAcute severe bronchospasm\nAdult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min.\nChild: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.\n\nElderly: Dose reduction may be ncessary.\nHepatic impairment: Dose reduction may be ncessary.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness; tremor, palpitations.\nPotentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV injection.\n\nPrecaution: Neonates, elderly, lactation, pregnancy, cardiac/hepatic diseases, peptic ulceration, hyperthyroidism, hypertension, epilepsy, heart failure, chronic alcoholism, acute febrile illness.\n\nMode of action: Other xanthines. Clearance reduced by allopurinol, some antiarrhythmics, cimetidine, disulfiram, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, cigarette smoking. Corticosteroids, diuretics, ?2-agonists.\nPotentially Fatal: Increased risk of cardiac arrhythmias with sympathomimetics and halothane. Tachycardia with pancuronium. ?-blockers inhibit metabolism. Increased risk of convulsion with quinolones, ketamine.\n\nPregnancy category: C\n\nInteraction: Other xanthines. Clearance reduced by allopurinol, some antiarrhythmics, cimetidine, disulfiram, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, cigarette smoking. Corticosteroids, diuretics, ?2-agonists.\nPotentially Fatal: Increased risk of cardiac arrhythmias with sympathomimetics and halothane. Tachycardia with pancuronium. ?-blockers inhibit metabolism. Increased risk of convulsion with quinolones, ketamine.
Amiodarone Hydrochloride	\n\n\tACI\tAmidron IV Injection 50 mg/ml  \n\tACI\tAmidron TAB dr 200mg  \n\tACI\tAmidron TAB dr 100mg  \n\tBeximco\tPacet TAB dr 100mg 30's pack 150.60\n\tBeximco\tPacet TAB dr 200mg 30's pack 301.20\n\tDrug International Ltd.\tCardiron TAB dr 200mg 30's pack 210\n\tSanofi Aventis (BD) Ltd.\tCordarone TAB dr 100mg 30's pack 301.20\n\tSanofi Aventis (BD) Ltd.\tCordarone TAB dr 200mg 30's pack 542.10\n\tIndication: Ventricular arrhythmias, Ventricular fibrillation, Ventricular tachycardia, Atrial fibrillation, Hypertrophic cardiomyopathy, Supraventricular arrhythmias\n\nDose: Oral\nVentricular arrhythmias\nAdult: 800-1,600 mg/day in 1-2 divided doses for 1-3 wk until initial therapeutic response is achieved, then reduce dose to 600-800 mg/day in 1-2 divided doses for 1 mth. Maintenance: 400 mg/day; lower doses may be used for supraventricular arrhythmias. Daily doses may be divided. Close monitoring of the patient is recommended. Use the minimum effective dose.\nHepatic impairment: Dosage reduction may be necessary. \n\nContra-indication: Hypersensitivity to amiodarone or iodine. Severe sinus node dysfunction, 2nd and 3rd degree heart block (except in patients with a functioning artificial pacemaker), cardiogenic shock, pregnancy.\n\nSide effects: Blue-grey discolouration of skin, photosensitivity, peripheral neuropathy, paraesthesia, myopathy, ataxia, tremor, nausea, vomiting, metallic taste, hypothyroidism, hyperthyroidism, alopoecia, sleep disturbances, corneal microdeposits, hot flushes, sweating. Heart block, bradycardia, sinus arrest, hepatotoxicity, heart failure.\nPotentially Fatal: Pulmonary toxicity including pulmonary fibrosis and interstitial pneumonitis, hepatotoxicity, thyrotoxicity. Ventricular arrhythmias, pulmonary alveolitis, exacerbation of arrhythmias and rare serious liver injury. Generally in patients with high doses and having preexisting abnormalities of diffusion capacity.\n\nPrecaution: Close monitoring is recommended as amiodarone may worsen arrhythmia especially when used concurrently with other anti-arrhythmic drugs or drugs that prolong QT interval. May cause hypotension and bradycardia. May increase risk of liver toxicity. May cause visual disturbance/impairment; corneal refractive laser surgery is not recommended in patients on amiodarone treatment. May cause lung damage; monitor for pulmonary toxicity e.g. acute respiratory distress syndrome. Monitor liver functions regularly. May affect defibrillation or pacing thresholds of cardiac devices. Correct electrolyte imbalance before starting treatment. Caution when used in patients undergoing surgery. Avoid excessive sunlight exposure due to increased risk of photosensitivity. Hepatic impairment, thyroid disease, elderly. Lactation.\n\nMode of action: Potentiation of antiarrhythmic drugs. Possible increased risk of adverse effects when used with anaesthetic agents. Monitor plasma levels of amiodarone when used with HIV protease inhibitors. Cimetidine may increase serum levels of amiodarone. Concurrent use may increase serum levels of ciclosporin. May increase risk of myopathy or rhabdomyolysis when used with HMG-CoA reductase inhibitors. Rifampin may reduce the serum levels of amiodarone.\nPotentially Fatal: Potentiates the effect of warfarin and other anticoagulants hence dose of warfarin generally needs to be reduced approx half. Raised plasma concentrations of digoxin, phenytoin and quinidine. Additive effect with beta-blockers and calcium-channel blockers (e.g. verapamil and diltiazem).\n\nPregnancy category: D\n\nInteraction: Potentiation of antiarrhythmic drugs. Possible increased risk of adverse effects when used with anaesthetic agents. Monitor plasma levels of amiodarone when used with HIV protease inhibitors. Cimetidine may increase serum levels of amiodarone. Concurrent use may increase serum levels of ciclosporin. May increase risk of myopathy or rhabdomyolysis when used with HMG-CoA reductase inhibitors. Rifampin may reduce the serum levels of amiodarone.\nPotentially Fatal: Potentiates the effect of warfarin and other anticoagulants hence dose of warfarin generally needs to be reduced approx half. Raised plasma concentrations of digoxin, phenytoin and quinidine. Additive effect with beta-blockers and calcium-channel blockers (e.g. verapamil and diltiazem).
Amitriptyline Hydrochloride	\n\n\tAlbion Ltd.\tReptyline TAB dr 10 mg/ 25 mg 200's/100's pack \n\tEdruc Ltd.\tAmtylin TAB dr 10mg 100's pack 50\n\tEdruc Ltd.\tAmtylin TAB dr 25mg 100's pack 80\n\tGeneral\tAmit TAB dr 10mg 100's pack 56\n\tGeneral\tAmit TAB dr 25mg 100's pack 100\n\tGlaxoSmithKline Bangladesh Ltd.\tAmitriptyline TAB dr 10mg 200's pack 110\n\tGlaxoSmithKline Bangladesh Ltd.\tAmitriptyline TAB dr 25mg 500's bot 400.99\n\tMedicon\tTrip TAB dr 10mg 100's pack 50\n\tOpsonin Pharma\tAmilin TAB dr 10mg 100's pack 50\n\tOpsonin Pharma\tAmilin TAB dr 25mg 100's pack 80\n\tSquare\tTryptin TAB dr 10mg 100's pack 111.72\n\tSquare\tTryptin TAB dr 25mg 100's pack 199.50\n\tIndication: Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis\n\nDose: Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. \nChild: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses.\nElderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. \n\nNeuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. \nMigraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night.\nNocturnal enuresis\nChild: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.\n\nContra-indication: Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.\n\nSide effects: Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating.\nPotentially Fatal: Cardiac arrhythmias.\n\nPrecaution: Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.\n\nMode of action: Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.\n\nPregnancy category: C\n\nInteraction: Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
Amlexanox	\n\n\tACI\tAmlex Oral Paste 50mg/gm 5g 75.23\n\tEskayef Bangladesh Ltd.\tSorex Oral Paste 50mg/gm 5gm tube 75\n\tSquare\tApsol Oral Paste 50mg/gm 5gm tube 75\n\tIndication: Aphthous ulcer\n\nDose: Adult: Topical As a 5% oral paste: Apply approx 0.5 cm of oral paste directly on to each ulcer 4 times/day; following oral hygiene after meals and at bedtime. \n\nInitiate treatment at earliest symptom of an aphthous ulcer. Continue treatment until mouth ulcer is healed, not exceeding 10 days. \n\nChild: Not to be used in children below age 12.\n\nContra-indication: Known hypersensitivity to any of the ingredients.\n\nSide effects: Application site reactions e.g. transient pain, stinging, burning, irritation, contact mucositis, nausea and diarrhoea.\n\nPrecaution: For topical use on mouth ulcers only. Avoid contact with the eyes; rinse immediately if ocular contact occurs. Wash hands before and after every application. Discontinue treatment if rash or contact mucositis develops. Seek medical advice if mouth ulcers have not healed after 10 days of treatment. Effects have not been evaluated in immune-compromised patients. Use lower initial dose for elderly patients. Not recommended for use in children below <12 yr. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Amlodipine	\n\n\tACI\tCab TAB dr 5mg 50's pack 251\n\tAcme Ltd.\tAmlopin TAB dr 10mg 30's pack 180.60\n\tAcme Ltd.\tAmlopin TAB dr 5mg 30's pack 120.30\n\tAd-din\tNopidin TAB dr 5mg 50's pack 150\n\tAlbion Ltd.\tAmofast TAB dr 5 mg/ 10 mg 100's / 60's pack \n\tAlco Pharma\tAmdin TAB dr 10mg 30's pack 180\n\tAlco Pharma\tAmdin TAB dr 5mg 50's pack 200\n\tApex\tMcard TAB dr 5mg 50's pack\n 200\n\tApex\tCanvas-5 TAB dr 5mg 30's pack 105\n\tAristopharma\tLodipin-5 TAB dr 5mg 50's pack 250\n\tAsiatic Ltd.\tCalpress TAB dr 10mg 30's pack 180\n\tAsiatic Ltd.\tCalpress TAB dr 5mg 50's pack 200\n\tBeacon\tAmlowide TAB dr 5mg 50's pack 150.50\n\tBeximco\tAmdocal TAB dr 10mg 60's pack 360\n\tBeximco\tAmdocal TAB dr 5mg 100's pack 400\n\tBio Pharma Ltd.\tEmlon TAB dr 10mg 30's pack 210\n\tBio Pharma Ltd.\tEmlon TAB dr 5mg 50's pack 250\n\tBristol Pharma Ltd.\tDipine TAB dr 5mg 50's pack 200\n\tChemist Ltd.\tIpin TAB dr 5mg 30's pack 105\n\tConcord\tAcudipin TAB dr 5mg 30's pack \n\tCosmic Chemical Industries Ltd.\tHypoten TAB dr 5mg 30's pack 105\n\tDelta Pharma\tAmo TAB dr 10mg 30's pack 165\n\tDelta Pharma\tAmo TAB dr 5mg 50's pack 150\n\tDoctor's Chemicals Works Ltd.\tAmlosin TAB dr 5mg 30's pack 102.30\n\tDrug International Ltd.\tAmlocard TAB dr 10mg 50's pack 350\n\tDrug International Ltd.\tAmlocard TAB dr 5mg 100's pack 450\n\tEdruc Ltd.\tLopin TAB dr 5mg 30's pack 90\n\tEskayef Bangladesh Ltd.\tSidopin TAB dr 5mg 50's pack 200\n\tEuro Pharma Ltd.\tAmtinol TAB dr 5mg 30's pack 120\n\tGeneral\tCalchek TAB dr 5mg 50's pack 250\n\tGlobe\tCalpin TAB dr 5mg 50's pack 175\n\tGonoshasthaya\tG-Amlodipine TAB dr 5mg 30's pack 75.30\n\tGonoshasthaya\tG-Amlodipine TAB dr 10mg 30's pack 120.60\n\tHallmark\tAmdoper TAB dr 5mg 30's pack 90.30\n\tHealthcare\tXelcard TAB dr 5mg 30's pack 150\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDiplor TAB dr 10mg 30's pack 210.60\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDiplor TAB dr 5mg 30's pack 127.50\n\tIncepta\tAmlotab 5 TAB dr 5mg 50's pack 250\n\tJayson\tLocard TAB dr 5mg 50's pack 152.50\n\tKemiko\tNelod TAB dr 10mg 50's pack 400\n\tKemiko\tNelod TAB dr 5mg 50's pack 250\n\tKumudini Pharma Ltd.\tAmpre TAB dr 5mg 30's pack 150\n\tLabaid\tCardolab 5 TAB dr 5mg  5 x 10's pack 250\n\tMedicon\tDopin TAB dr 5mg 30's pack 120\n\tMedimet\tCalock TAB dr 10mg 50's pack 187.50\n\tMedimet\tCalock TAB dr 5mg 50's pack 175\n\tNavana\tCVnor TAB dr 10mg 30's pack 180.60\n\tNavana\tCVnor TAB dr 5mg 30's pack 120.60\n\tNovo Healthcare and Pharma Ltd.\tPristin TAB dr 10mg 30's pack 150\n\tNuvista Pharma Ltd\tCardifort TAB dr 5mg  \n\tOpsonin Pharma\tAmocal TAB dr 10mg 30's pack 180\n\tOpsonin Pharma\tAmocal TAB dr 5mg 30's pack 120\n\tOrion Pharma Ltd.\tCCB TAB dr 5mg 50's pack 150.50\n\tPacific\tHipre TAB dr 10mg 30's pack 180\n\tPacific\tHipre TAB dr 5mg 50's pack 250\n\tPharmadesh Ltd.\tAmlo TAB dr 5mg 50's pack 175\n\tPharmasia Ltd.\tCardosia TAB dr 5mg 30's pack 120.60\n\tPopular\tAmlovas TAB dr 10mg 30's pack 180.60\n\tPopular\tAmlovas TAB dr 5mg 50's pack 175.50\n\tRAK\tRaklopin TAB dr 10mg 30's pack 180\n\tRAK\tRaklopin TAB dr 5mg 50's pack 200\n\tRangs\tVesocal TAB dr 10mg 30's pack 240\n\tRangs\tVesocal TAB dr 5mg 50's pack 250\n\tRenata\tCardipin TAB dr 5mg 50's pack 200\n\tRephco\tImped TAB dr 5mg 30's pack 105\n\tSilco Pharmaceuticlas Ltd.\tAlopin TAB dr 5mg  \n\tSilva\tVasopin TAB dr 10mg 30's pack 150.97\n\tSilva\tVasopin TAB dr 5mg 30's pack 120.46\n\tSquare\tCamlodin TAB dr 10mg 30's pack 180.74\n\tSquare\tCamlodin TAB dr 5mg 60's pack 300\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAmlosun TAB dr 5mg 50's pack 202.50\n\tTechno Drugs Ltd.\tCordil TAB dr 5mg 30's pack 90\n\tUnimed & Unihealth Manufacturers Ltd.\tCalvase TAB dr 10mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tCalvase TAB dr 5mg 30's pack 150\n\tWhite Horse Pharma\tAmpil TAB dr 5mg 50's pack 200\n\tZenith\tM-Card TAB dr 5mg 50's pack 200\n\tIndication: Mild to moderate hypertension, Chronic stable and vasospastic angina, Raynaud's disease, Coronary Artery Disease, HTN, Stroke prevention\n\nDose: Adult: PO Stable angina; HTN; Prinzmetal's angina Initial: 5 mg once daily;  If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. \n\nChild: >12 yr Initially, 2.5 mg once daily, increased to 5 mg once daily if necessary.\nElderly: Initially, 2.5 mg once daily.\nHepatic impairment: Initially, 2.5 mg once daily.\n\nContra-indication: Hypersensitivity to Amlodipine or other calcium channel antagonist, Severe hypertension.\n\nSide effects: Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.Potentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.\n\nPrecaution: Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.  Use in renal failure: Although Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable. Use in patients with impaired hepatic function: Amlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients. Use in heart failure: An increased number of pulmonary oedema has been reported.\n\nMode of action: Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.\n\nPregnancy category: C\n\nInteraction: Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.
Amlodipine  +  Atenolol	\n\n\tACI\tTenocab 5/25 TAB dr  25mg+5mg 50's pack 263.50\n\tACI\tTenocab 5/50 TAB dr  50mg+5mg 50's pack 301\n\tAcme Ltd.\tAmloten 5/25 TAB dr   30's pack 128.10\n\tAcme Ltd.\tAmloten 5/50 TAB dr   30's pack 136.50\n\tAexim\tAmicard PLUS 5/50 TAB dr   50's pack 150\n\tAlbion Ltd.\tAmofast Plus TAB dr 5 mg + 25 mg/ 5 mg + 50 m 30's / 60's pack \n\tAlco Pharma\tAmdin PLUS 5/50 TAB dr   50's pack 225\n\tApex\tAngical 25 TAB dr   30's pack 105\n\tApex\tAngical 50 TAB dr   30's pack 180\n\tAristopharma\tLodicard 5/50 TAB dr   50's pack 230\n\tAsiatic Ltd.\tTenodin 25/5 TAB dr  5 mg + 25 mg 30's pack 126\n\tAsiatic Ltd.\tTenodin 50/5 TAB dr  5 mg + 50 mg 30's pack 135\n\tBeacon\tAmlocom TAB dr 5 mg + 25 mg  \n\tBeximco\tAmdocal PLUS 5/25 TAB dr   30's pack 127.50\n\tBeximco\tAmdocal PLUS 5/50 TAB dr   60's pack 270\n\tBio Pharma Ltd.\tEmlon PLUS 5/50 TAB dr   30's pack 135.60\n\tConcord\tAcudipin Plus TAB dr 5 mg + 50 mg 30's pack \n\tDelta Pharma\tBpnol PLUS 5/50 TAB dr   30's pack 120\n\tDoctor's Chemicals Works Ltd.\tAmlosin PLUS TAB dr   30's pack 120\n\tDrug International Ltd.\tAmlocard PLUS 5/25 TAB dr   50's pack 225\n\tDrug International Ltd.\tAmlocard PLUS 5/50 TAB dr   50's pack 250\n\tEdruc Ltd.\tLopin Plus 5/25 TAB dr   30's pack 135\n\tEskayef Bangladesh Ltd.\tSidoplus 5/25 TAB dr   40's pack 170\n\tEskayef Bangladesh Ltd.\tSidoplus 5/50 TAB dr   40's pack 180\n\tEuro Pharma Ltd.\tAmtinol Plus TAB dr   30's pack 135\n\tGeneral\tCalchek PLUS 5/50 TAB dr   30's pack 135.60\n\tGlobe\tCalpin Plus 50 TAB dr  30's pack 135\n\tHealthcare\tCombicard 5/50 TAB dr   30's pack 135\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDiplor PLUS 5/25 TAB dr   30's pack 120\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDiplor PLUS 5/50 TAB dr   30's pack 150\n\tIncepta\tFixocard 5/25 TAB dr   50's pack 262.50\n\tIncepta\tFixocard 5/50 TAB dr   50's pack 300\n\tJayson\tLocard PLUS 5/50 TAB dr   30's pack 90.60\n\tKemiko\tAloten 5/25 TAB dr   50's pack 212.50\n\tKemiko\tAloten Forte TAB dr   50's pack 225\n\tKumudini Pharma Ltd.\tAmpre Plus TAB dr  30's pack 120\n\tLeon\tDipicard Plus TAB dr  100's pack \n\tLeon\tDipicard 5 TAB dr 5mg 100's pack \n\tLeon\tDipicard 10 TAB dr 10mg 100's pack \n\tLeon\tDipicard Plus TAB dr 5mg + 50mg  \n\tMedimet\tCalock PLUS 5/25 TAB dr   42's pack 168\n\tMedimet\tCalock PLUS 5/50 TAB dr   42's pack 189\n\tNavana\tCVnor A 5/50 TAB dr   30's pack 135.6\n\tNovo Healthcare and Pharma Ltd.\tPristin OL 5/50 TAB dr   30's pack 120\n\tNuvista Pharma Ltd\tCardifort Plus TAB dr 5 mg + 25 mg  \n\tNuvista Pharma Ltd\tCardifort Plus TAB dr 5 mg + 50 mg  \n\tOpsonin Pharma\tAmocal AT 5/25 TAB dr   30's pack 128.10\n\tOpsonin Pharma\tAmocal AT 5/50 TAB dr   30's pack 135\n\tOpsonin Pharma\tAmosec TAB dr 5 mg + 50 mg 30's pack \n\tOrion Pharma Ltd.\tBetacal 5/50 TAB dr   50's pack 226\n\tPacific\tHipre PLUS 5/50 TAB dr   30's pack 150\n\tPeoples Pharma Ltd.\tDipicard-25 TAB dr  50's pack 175\n\tPharmadesh Ltd.\tAtepine 5/50 TAB dr   30's pack 135\n\tPharmasia Ltd.\tCardosia Plus TAB dr   30's pack 135.60\n\tPopular\tAmlovas PLUS 5/50 TAB dr   50's pack 201.03\n\tPopular\tAmlovas AT TAB dr 5mg+50mg 50's pack 201.03\n\tRangs\tVesocal PLUS 5/50 TAB dr   30's pack 135\n\tRenata\tCardipin PLUS 5/50 TAB dr   50's pack 226\n\tRephco\tImped Plus-25 TAB dr 5mg + 25mg 10x10's Pack 400\n\tRephco\tImped Plus-50 TAB dr 5mg + 50mg 10x10's Pack 500\n\tSanofi Aventis (BD) Ltd.\tBetanol-A 25 TAB dr  50's pack 213.50\n\tSanofi Aventis (BD) Ltd.\tBetanol-A 50 TAB dr  50's pack 226\n\tSharif\tTenopin TAB dr   30's pack 135\n\tSilva\tVasopin PLUS 5/50 TAB dr   30's pack 135.51\n\tSquare\tCamlodin 5/25 TAB dr  5 mg + 25 mg 30's pack 150\n\tSquare\tCamlodin PLUS 5/50 TAB dr  5 mg + 50 mg 50's pack 300\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAmlobet 5/50 TAB dr   50's pack 227.50\n\tUnimed & Unihealth Manufacturers Ltd.\tCalbeta 5/25 TAB dr   30's pack\n 180\n\tUnimed & Unihealth Manufacturers Ltd.\tCalbeta 5/50 TAB dr   30's pack 180\n\tWhite Horse Pharma\tAmpil Plus 5/25 TAB dr   50's pack 225\n\tZenith\tAtezen Plus TAB dr   50's pack 180\n\tIndication: Patients with essential hypertension; Patients with angina pectoris & hypertension as co-existing diseases; In post MI patients; In patients with refractory angina pectoris where nitrate therapy has failed.\n\nDose: Adult: PO HTN; Chronic stable angina Per tab contains amlodipine (besylate) 5 mg and atenolol 25 or 50 mg: 1 tab once daily, up to 2 tab/day if needed.\n\nContra-indication: Hypotension, sinus bradycardia, 2nd & 3rd degrees of heart block, cardiogenic shock, overt congestive failure, poor LV function, hypersensitivity to either component, pregnancy.\n\nSide effects: Headache, hypotension, dizziness, breathlessness, fatigue, muscle cramps, bradycardia, palpitations, flushing, oedema, dyspnoea, dyspepsia, cold extremities. Drowsiness, chestpain & impotence rarely. Hypersensitivity reactions.\n\nPrecaution: Excessive fall of BP may occur in elderly patients. Caution in patients with COPD, thyrotoxicosis, congestive failure, vasospastic angina, hepatic & renal impairment. Caution in diabetic patients as beta-blockers may mask tachycardia occurring with hypoglycaemia. Withdrawal should be gradual. Lactation. Safety and efficacy have not been established in children. Not to be used in untreated phaeochromocytoma.\n\nMode of action: Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.\n\nPregnancy category: A\n\nInteraction: Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.
Amlodipine 5mg + Atorvastatin 10mg	\n\n\tACI\tCardual 5/10 TAB dr   30's pack 331.20\n\tAlco Pharma\tAdvast TAB dr  30's pack 300\n\tBeacon\tAmovast TAB dr   20's pack 220\n\tBeximco\tAmdova TAB dr   30's pack 330\n\tDelta Pharma\tATV Plus TAB dr   10's pack 80\n\tDrug International Ltd.\tDivastin Plus TAB dr   30's pack 330\n\tEskayef Bangladesh Ltd.\tAmlip TAB dr   30's pack 330\n\tGeneral\tLipichek TAB dr   20's pack 220\n\tIncepta\tSyncard TAB dr   30's pack 330\n\tLeon\tLipiva Plus TAB dr  50's pack \n\tLeon\tLipiva Plus TAB dr 5mg + 10mg  \n\tOpsonin Pharma\tAmitor 5/10 TAB dr   30's pack 330\n\tOrion Pharma Ltd.\tCarditor 5/10 TAB dr   8's pack 1200\n\tPacific\tLipigent Plus TAB dr   30's pack 330\n\tPopular\tLocol Plus TAB dr   30's pack 331.20\n\tRAK\tRaklopin-AT 5/10 TAB dr   30's pack 300\n\tRenata\tTrovastin 5/10 TAB dr   30's pack 330\n\tSquare\tCamlotor 5/10 TAB dr  5 mg + 10 mg 30's pack 331.17\n\tIndication: Angina, Hyperlipidaemia, Hypertension, Stroke prevention\n\nDose: Adult: PO HTN or angina and hyperlipidaemia: \n\n Amlodipine: Initially 5 mg once daily, titrate over 1-2 wk; max: 10 mg/day. Atorvastatin: Initially 10-20 mg once daily (anytime of the day), patients who require >45 % reduction in LDL cholesterol may be initiated at 40 mg once daily. Titrate dose at intervals of at least 4 week; max: 80 mg/day.\n\nContra-indication: Active liver disease or unexplained persistent elevated hepatic transaminases. Pregnancy and lactation.\n\nSide effects: Amlodipine: Headache, dizziness, fatigue, somnolence, peripheral oedema, flushing, palpitations, nausea, abdominal pain; rarely pruritus, rash, dyspnoea, asthenia and muscle cramps. Atorvastatin: Nasopharyngitis, arthralgia, diarrhoea, pain in extremity, UTI, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, increased transaminases, abnormal liver function test, increased creatinine phosphokinase, thrombocytopenia, malaise, hepatitis, cholestasis, bullous rashes.\nPotentially Fatal: Rhabdomyolysis with acute renal failure.\n\nPrecaution: Atorvastatin may cause myopathy, and rarely rhabdomyolysis with acute renal failure secondary to myoglobinuria especially at high doses or in patients with history of renal impairment. Caution when used with CYP3A4 inhibitors which may increase plasma concentrations of Atorvastatin. Withhold/discontinue Atorvastatin if symptoms suggestive of myopathy or rhabdomyolysis are observed. Atorvastatin has been associated with biochemical abnormalities of liver; LFT should be monitored prior to and at 12 wk following treatment initiation and dosage increment; caution in patients who consume large amounts of alcohol or with history of liver disease. Worsening of angina and/or myocardial infarction has been reported with use of dihydrophyridine calcium channel blockers, especially in patients with severe obstructive coronary artery disease. Amlodipine may cause dose-dependent peripheral oedema. Caution in patients with severe aortic stenosis, symptomatic hypotension may occur. Elderly.\n\nMode of action: Rifamycins may increase the metabolism of both Amlodipine and Atorvastatin. Atorvastatin may increase AUC of norethindrone and ethinyl estradiol.\nPotentially Fatal: Atorvastatin: Increased risk of myopathy when used concurrently with fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYP3A4 inhibitors (e.g. clarithromycin, HIV protease inhibitors, itraconazole). Cyclosporine (OATP1B1 inhibitor) may significantly increase bioavailability of Atorvastatin.\n\nPregnancy category: X\n\nInteraction: Rifamycins may increase the metabolism of both Amlodipine and Atorvastatin. Atorvastatin may increase AUC of norethindrone and ethinyl estradiol.\nPotentially Fatal: Atorvastatin: Increased risk of myopathy when used concurrently with fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYP3A4 inhibitors (e.g. clarithromycin, HIV protease inhibitors, itraconazole). Cyclosporine (OATP1B1 inhibitor) may significantly increase bioavailability of Atorvastatin.
Amlodipine + Benazepril Hydrochloride	\n\n\tACI\tCacetor 2.5/10 CAP   24's pack 96\n\tACI\tCacetor 5/10 CAP   24's pack 144\n\tACI\tCacetor 5/20 CAP   24's pack 192\n\tBeacon\tAmlozep 5/10 CAP   30's pack 180\n\tBeximco\tAmdopril 10/20 CAP   30's pack 300\n\tBeximco\tAmdopril 2.5/10 CAP   60's pack 240\n\tBeximco\tAmdopril 5/10 CAP   60's pack 360\n\tBeximco\tAmdopril 5/20 CAP   30's pack 240\n\tEskayef Bangladesh Ltd.\tLodiben 2.5/10 CAP   36's pack 144\n\tEskayef Bangladesh Ltd.\tLodiben 5/10 CAP   24's pack 144\n\tEskayef Bangladesh Ltd.\tLodiben 5/20 CAP   16's pack 128\n\tIncepta\tBenadip 10/20 CAP   28's pack 280\n\tIncepta\tBenadip 2.5/10 CAP   20's pack 80\n\tIncepta\tBenadip 5/10 CAP   20's pack 120\n\tIncepta\tBenadip 5/20 CAP   20's pack 160\n\tOpsonin Pharma\tAmocal BZ 2.5/10 CAP   30's pack 120\n\tOpsonin Pharma\tAmocal BZ 5/10 CAP   30's pack 180.60\n\tOpsonin Pharma\tAmocal BZ 5/20 CAP   20's pack 160\n\tSquare\tCamlopril 10/20 CAP   30's pack 301.24\n\tSquare\tCamlopril 2.5/10 CAP   30's pack 120.50\n\tSquare\tCamlopril 5/10 CAP   30's pack 180.74\n\tSquare\tCamlopril Plus CAP  5mg + 50mg 30's pack 300\n\tIndication: Hypertension\n\nDose: Adult: PO Per combination cap contains Amlodipine 2.5-10 mg and benazepril 10-40 mg: Amlodipine component: 2.5-10 mg once daily; benazepril component: 10-40 mg once daily.\n\nContra-indication: Patients with history of angioedema; pregnancy, lactation.\n\nSide effects: Cough, oedema (including dependent oedema, angioedema, facial oedema, peripheral oedema), headache, dizziness, flushing, dry mouth, nausea, diarrhoea, constipation, asthenia, fatigue, hyperkalaemia, hypotension, orthostatic hypotension, musculoskeletal pain, skin rash, insomnia, anxiety, decreased libido, acute renal disease, palpitation, angina pectoris, bradycardia, chest pain, jaundice, hepatic enzymes elevations, increased creatinine and BUN, haemolytic anaemia, neutropenia, thrombocytopenia, pancreatitis, pemphigus.\nPotentially Fatal: Analphylactoid reactions, angioedema, Stevens-Johnson syndrome.\n\nPrecaution: Discontinue Amlodipine+Benazepril as soon as possible if pregnancy is detected. Caution in elderly, renal or hepatic impairment, congestive heart failure, severe aortic stenosis, unilateral or bilateral renal artery stenosis, use during surgery or anaesthesia. Amlodipine+Benazepril can cause symptomatic hypotension, especially in patients with salt/volume depletion. ACE inhibitors (ACEi) have been associated with cholestatic jaundice and fulminant hepatic necrosis; discontinue treatment if patient develops jaundice/marked elevation of liver enzymes. Monitor renal function and serum potassium periodically. Angioedema of the face, extremities, lips, tongue, glottis, larynx and intestinal angioedema have been reported in ACEi-treated patients. As with all ACEi, may cause persistent dry cough. Safety and efficacy in paediatric patients have not been established.\n\nMode of action: Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	\n\nPregnancy category: A\n\nInteraction: Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.	
Amlodipine + Olmesartan Medoxomil	\n\n\tACI\tAbecab 5/20 TAB dr  20mg+5mg 30's pack 241.50\n\tACI\tAbecab 5/40 TAB dr  40mg+5mg 30's pack 451.50\n\tAcme Ltd.\tOrbapin TAB dr 5 mg + 20 mg  \n\tAristopharma\tDuoblock TAB dr 5 mg + 20 mg  \n\tAristopharma\tDuoblock TAB dr 5 mg + 40 mg  \n\tBeximco\tBizoran TAB dr  5 mg + 20 mg 30's pack 240\n\tBeximco\tBizoran 5/40 TAB dr 5 mg + 40 mg  \n\tDrug International Ltd.\tDisartan TAB dr   30's pack 240\n\tGeneral\tOlmepres Plus TAB dr 5 mg + 20 mg  \n\tIncepta\tDuopres 5/40 TAB dr  30's pack 240\n\tIncepta\tDuopres 5/20 TAB dr  30's pack 420\n\tOpsonin Pharma\tCalnor 5/20 TAB dr  10x3's pack 211.20\n\tPopular\tOlmevas Plus TAB dr 5mg + 20mg  \n\tPopular\tOlmevas Plus TAB dr 5mg + 40mg  \n\tRadiant.\tDuovas TAB dr 5 mg + 20 mg  \n\tSquare\tAmlosart 5/20 TAB dr   30's pack 240\n\tSquare\tCamlosart 5/40 TAB dr 5mg + 40mg 2x10's pack 300\n\tSquare\tCamlosart 5/20 TAB dr 5mg + 20mg  \n\tSun Pharmaceutical (Bangladesh) Ltd.\tOlmezest AM TAB dr  5 mg + 20 mg 30's pack 255\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOlmezest AM TAB dr 5 mg + 40 mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tTenivasc 5/20 TAB dr  28's pack 224\n\tWhite Horse Pharma\tMesartin Plus TAB dr 5 mg + 20 mg  \n\tIndication: Hypertension\n\nDose: Adult: Initial: 10-20 mg once daily. Antihypertensive effect is substantially present within 2 wk of therapy initiation. Dose may be increased up to 40 mg once daily if needed. May consider a lower starting dose in patients with possible depletion of intravascular volume (e.g. patients receiving concomitant diuretics, especially those with renal impairment).\n \nChild: 6 to 16 yr: 20-35 kg: 10 mg once daily, may increase to maximum of 20 mg once daily. >35 kg: 20 mg once daily, may increase to maximum of 40 mg once daily.\n\nElderly: May consider lower starting dose of 5-10 mg daily.\n\nContra-indication: Pregnancy (2nd and 3rd trimesters); biliary obstruction.\n\nSide effects: Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.\nPotentially Fatal: Acute renal failure.\n\nPrecaution: Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.\n\nMode of action: Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.\n	Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.\n\nPregnancy category: A\n\nInteraction: Additive effect when used with catecholamine depleting drugs; monitor for hypotension and/or marked bradycardia. If used with clonidine, clonidine withdrawal should occur a few days after withdrawal of the beta-blocker to prevent rebound hypertension; if replacing clonidine by beta-blocker, beta-blocker should be introduced only after clonidine administration has stopped for several days. Concurrent use with prostaglandin synthase inhibiting drugs (e.g. indomethacin) may reduce the hypotensive effects of beta-blockers.\n	Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
Amlodipine + Telmisartan	\n\n\tPharmasia Ltd.\tCardotel TAB dr   30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tTelamlo TAB dr 40/5mg 2x7's pack 175\n\tIndication: Hypertension\n\nDose: Adult: PO Initiate with 5 mg/40 mg or 5mg/80 mg once daily.\nMay increase dose after at least 2 weeks, not to exceed 10 mg/80 mg once daily.\n\nDosage range: Amlodipine/Telmisartan 2.5-10 mg/ 20-80 mg once daily.\n\nContra-indication: Liver insufficiency. Pregnancy.\n\nSide effects: Headache, fatigue, insomnia, nausea, abdominal pain, flushing, dizziness, pruritus, skin rash, dyspnoea, weakness, muscular spasm, dyspepsia, oedema.\n\nPrecaution: Lactation. May increase frequency and/or severity of angina during treatment initiation or dosage increments. Heart failure or hepatic impairment.\n\nMode of action: Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.\n\nPregnancy category: A\n\nInteraction: Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina.
Amlodipine + Valsartan	\n\n\tAcme Ltd.\tCo-valtin TAB dr 5/80mg 3x10's pack 270\n\tAcme Ltd.\tCo-valtin TAB dr 5/160mg 3x10's pack 480\n\tDrug International Ltd.\tAV-5 TAB dr   20's pack 160\n\tDrug International Ltd.\tAV-10 TAB dr   20's pack 200\n\tHealthcare\tCo-Disys 160/5 TAB dr   30's pack 540\n\tHealthcare\tCo-Disys 80/5 TAB dr   30's pack 300\n\tIncepta\tAmlosartan 10/160 TAB dr   30's pack 480\n\tIncepta\tAmlosartan 5/160 TAB dr   30's pack 480\n\tIncepta\tAmlosartan 5/80 TAB dr   30's pack 270\n\tNovartis (Bangladesh) Ltd.\tExforge 10/ 160 TAB dr 10mg + 160mg 30's pack 2208\n\tNovartis (Bangladesh) Ltd.\tExforge 5/ 160 TAB dr 5mg + 160mg 30's pack 1975\n\tNovartis (Bangladesh) Ltd.\tExforge 5/80 TAB dr 5mg + 80mg 30's pack 1410\n\tOpsonin Pharma\tAvodil VL 5 TAB dr   30's pack 270\n\tOpsonin Pharma\tAvodil VL 160/5 TAB dr  20's pack 320\n\tOpsonin Pharma\tAvodil VL 320/5 TAB dr  20's pack 440\n\tOpsonin Pharma\tAvodil VL 10/320 TAB dr  20's pack 640\n\tPopular\tAmlovas VS 160/5 TAB dr   30's pack 481.81\n\tPopular\tAmlovas VS 5/80 TAB dr   30's pack 270.90\n\tPopular\tAmlovas VS 160/10 TAB dr  30's pack 481.80\n\tRAK\tReovan A 80/5 TAB dr   30's pack 270\n\tRAK\tReovan A 160/5 TAB dr   30's pack 450\n\tRenata\tValdipin TAB dr 5 mg + 80 mg  \n\tRenata\tValdipin TAB dr 5 mg + 160 mg  \n\tSquare\tCamoval 5/160 TAB dr   20's pack 321.33\n\tSquare\tCamoval 5/80 TAB dr   30's pack 270.92\n\tIndication: Hypertension\n\nDose: Adult: PO Initiate with 5 mg/160 mg once daily.\n\nMay increase dose after at least 2 weeks, not to exceed 10 mg/day amlodipine and 320 mg/day valsartan once daily if needed.\n\nContra-indication: Known hypersensitivity to dihydropyridines.\n\nSide effects: Headache, peripheral oedema, fatigue, somnolence, nausea, abdominal pain, flushing, dyspepsia, palpitations, dizziness. Rarely pruritus, rash, dyspnoea, asthenia, muscle cramps.\nPotentially Fatal: Hypotension, bradycardia, conductive system delay and CCF.\n\nPrecaution: Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. Pregnancy, lactation.\n\nMode of action: Amlodipine : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.\n\nValsartan : May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.\nPotentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).\n\nPregnancy category: A\n\nInteraction: Amlodipine : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan.\n\nValsartan : May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.\nPotentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Amoxicillin	\n\n\tACI\tAvlomox Paediatric Drops 125mg/1.2ml 15ml bot 30.29\n\tACI\tAvlomox Powder for Suspension 125mg/5ml 100ml bot 46.32\n\tACI\tAvlomox CAP 250mg 100's pack 345\n\tACI\tAvlomox CAP 500mg 40's pack 244.80\n\tACI\tAvlomox Injection 500mg 500mg Vial+water 32.10\n\tACI\tAvlomox DS Powder for Suspension 250mg/5ml 100ml bot 65.45\n\tAcme Ltd.\tMoxilin Paediatric Drops 125mg/1.2ml 15ml bot 30.19\n\tAcme Ltd.\tMoxilin Powder for Suspension 125mg/5ml 100ml bot 47.46\n\tAcme Ltd.\tMoxilin CAP 250mg 100's pack 362\n\tAcme Ltd.\tMoxilin Injection 250mg 5 vials 106\n\tAcme Ltd.\tMoxilin CAP 500mg 50's pack 337.50\n\tAcme Ltd.\tMoxilin Injection 500mg 5 vials 114.25\n\tAcme Ltd.\tMoxilin DS Powder for Suspension 250mg/5ml 100ml bot 68.25\n\tAd-din\tJ Mox Paediatric Drops 125mg/1.2ml 15ml bot 28.32\n\tAd-din\tJ Mox Powder for Suspension 125mg/5ml 100ml bot 45\n\tAd-din\tJ Mox CAP 250mg 100's pack 286\n\tAd-din\tJ Mox CAP 500mg 50's pack 285\n\tAexim\tAlmoxil Powder for Suspension 125mg/5ml 100ml bot 45\n\tAexim\tAlmoxil CAP 250mg 100's pack 330\n\tAexim\tAlmoxil CAP 500mg 50's pack 330\n\tAlbion Ltd.\tMimox TAB dr 500mg/ 250mg 50's/ 100's pack \n\tAlbion Ltd.\tMimox CAP 500mg/ 250mg 50's/ 100's pack \n\tAlbion Ltd.\tMimox Powder for Suspension 125 mg/5 ml 100 ml \n\tAlbion Ltd.\tMimox Paediatric Drops 125 mg/1.25 ml 15 ml \n\tAlco Pharma\tSapox DS Powder for Suspension 250mg/5ml 100ml bot 65\n\tAlco Pharma\tSapox CAP 250mg  100's pack 344\n\tAlco Pharma\tSapox Suspension 125mg 100ml bot 45.05\n\tAlco Pharma\tSapox-DS CAP 500mg 100's pack 607\n\tAlco Pharma\tSapox Drops 125mg 15ml bot 28.32\n\tAmbee\tAmbeexin Paediatric Drops 125mg/1.2ml 15ml bot 28.42\n\tAmbee\tAmbeexin Powder for Suspension 125mg/5ml 100ml bot 46.55\n\tAmbee\tAmbeexin CAP 250mg 100's pack 355\n\tAmico Ltd.\tMonamox Powder for Suspension 125mg/5ml 100ml bot 47.40\n\tAmico Ltd.\tMonamox CAP 250mg 100's pack 300\n\tAmico Ltd.\tMonamox CAP 500mg 50's pack 300\n\tAmico Ltd.\tMonomox Paediatric Drops 125mg/1.2ml 15ml bot 28\n\tAmico Ltd.\tMonamox DS Suspension 250mg  100ml bot 60\n\tAPC Pharma Ltd.\tPemox Paediatric Drops 125mg/1.2ml 15ml bot 28\n\tAPC Pharma Ltd.\tPemox Powder for Suspension 125mg/5ml 100ml bot 45\n\tAPC Pharma Ltd.\tPemox CAP 500mg 50's pack 300\n\tApex\tApoxy Powder for Suspension 125mg/5ml 100ml bot 47.47\n\tApex\tApoxy CAP 250mg 50's pack 211\n\tApex\tApoxy CAP 500mg 50's pack 275\n\tApex\tApoxy DS Powder for Suspension 250mg/5ml 100ml bot 47.47\n\tApollo Pharmaceutical Ltd.\tApimox Powder for Suspension 125mg/5ml 100ml bot 45\n\tApollo Pharmaceutical Ltd.\tApimox CAP 250mg 100's pack 300\n\tApollo Pharmaceutical Ltd.\tApimox CAP 500mg 50's pack 300\n\tApollo Pharmaceutical Ltd.\tApimox Drops 100mg 15 ml bot 28\n\tAristopharma\tAristomox Powder for Suspension 125mg/5ml 100ml bot 45\n\tAristopharma\tAristomox CAP 250mg 100's pack 350\n\tAristopharma\tAristomox CAP 500mg 50's pack 300\n\tAsiatic Ltd.\tLoxyl Powder for Suspension 125mg/5ml 100ml bot 47.46\n\tAsiatic Ltd.\tLoxyl CAP 250mg 100's pack 361\n\tAsiatic Ltd.\tLoxyl CAP 500mg 50's pack 338\n\tBelsen\tMoci CAP 250mg 100's pack 356\n\tBenham\tBenoxil Paediatric Drops 125mg/1.2ml 15ml bot 27\n\tBenham\tBenoxil Powder for Suspension 125mg/5ml 100ml bot 45\n\tBenham\tBenoxil CAP 250mg 100's pack 217\n\tBenham\tBenoxil CAP 500mg 100's pack 550\n\tBenham\tBenoxil DS Powder for Suspension 250mg/5ml 100ml bot 67\n\tBeximco\tTycil Paediatric Drops 125mg/1.2ml 15ml bot 30.20\n\tBeximco\tTycil Powder for Suspension 125mg/5ml 100ml bot 65.25\n\tBeximco\tTycil CAP 250mg 100's pack 361\n\tBeximco\tTycil CAP 500mg 50's pack 338.50\n\tBeximco\tTycil DS Powder for Suspension 250mg/5ml 100ml bot 65\n\tBio Pharma Ltd.\tAmotid Paediatric Drops 125mg/1.2ml 15ml bot 40\n\tBio Pharma Ltd.\tAmotid Powder for Suspension 125mg/5ml 100ml bot 46.17\n\tBio Pharma Ltd.\tAmotid CAP 250mg 100's pack 361\n\tBio Pharma Ltd.\tAmotid CAP 500mg 100's pack 602\n\tBio Pharma Ltd.\tAmotid F Powder for Suspension 250mg/5ml 100ml bot 65.25\n\tBristol Pharma Ltd.\tBpmox Paediatric Drops 125mg/1.2ml 15ml bot 28.4\n\tBristol Pharma Ltd.\tBpmox Powder for Suspension 125mg/5ml 100ml bot 45\n\tBristol Pharma Ltd.\tBpmox CAP 250mg 100's pack 225\n\tBristol Pharma Ltd.\tBpmox CAP 500mg 50's pack 300\n\tCentral.\tCemoxin Powder for Suspension 125mg/5ml 100ml bot 45\n\tCentral.\tCemoxin CAP 250mg 100's pack 340\n\tCentral.\tCemoxin CAP 500mg 50's pack 325\n\tCosmic Chemical Industries Ltd.\tBrodamox Powder for Suspension 125mg/5ml 100ml bot 48\n\tCosmic Chemical Industries Ltd.\tBrodamox CAP 250mg 100's pack 360\n\tCosmic Chemical Industries Ltd.\tBrodamox DS CAP 500mg 50's pack 328\n\tCosmo Pharma Ltd.\tAmoxic Powder for Suspension 125mg/5ml 100ml bot 40\n\tCosmo Pharma Ltd.\tAmoxic CAP 250mg 100's pack 323\n\tCosmo Pharma Ltd.\tAmoxic CAP 500mg 100's pack 500\n\tDecent Pharma Ltd.\tMoxa Powder for Suspension 125mg/5ml 100ml bot 47\n\tDecent Pharma Ltd.\tMoxa CAP 250mg 100's pack 350\n\tDecent Pharma Ltd.\tMoxa CAP 500mg 50's pack 335\n\tDesh\tDemox Powder for Suspension 125mg/5ml 100ml bot 44\n\tDesh\tDemox CAP 250mg 100's pack 320\n\tDesh\tDemox CAP 500mg 50's pack 300\n\tDoctor's Chemicals Works Ltd.\tAmox Paediatric Drops 125mg/1.2ml 15ml bot 26.86\n\tDoctor's Chemicals Works Ltd.\tAmox Powder for Suspension 125mg/5ml 100ml bot 45\n\tDoctor's Chemicals Works Ltd.\tAmox CAP 250mg 100's pack 300\n\tDoctor's Chemicals Works Ltd.\tAmox CAP 500mg 40's pack 227.6\n\tDrug International Ltd.\tDemoxil Injection 1gm 1gm Vial+water 45\n\tDrug International Ltd.\tDemoxil Powder for Suspension 125mg/5ml 100ml bot 47\n\tDrug International Ltd.\tDemoxil CAP 250mg 100's pack 350\n\tDrug International Ltd.\tDemoxil Injection 250mg 250mg Vial+water 19\n\tDrug International Ltd.\tDemoxil Injection 500mg 500mg Vial+water 26\n\tDrug International Ltd.\tDemoxil DS Powder for Suspension 250mg/5ml 100ml bot 65\n\tEdruc Ltd.\tE Mox Paediatric Drops 125mg/1.2ml 15ml bot 30\n\tEdruc Ltd.\tE Mox Powder for Suspension 125mg/5ml 100ml bot 44\n\tEdruc Ltd.\tE Mox CAP 250mg 100's pack 339\n\tEdruc Ltd.\tE Mox CAP 500mg 50's pack 303.5\n\tEskayef Bangladesh Ltd.\tSk Mox Paediatric Drops 125mg/1.2ml 15ml bot 28.32\n\tEskayef Bangladesh Ltd.\tSk Mox Powder for Suspension 125mg/5ml 100ml bot 46.40\n\tEskayef Bangladesh Ltd.\tSk Mox CAP 250mg 100's pack 354\n\tEskayef Bangladesh Ltd.\tSk Mox CAP 500mg 48's pack 291.36\n\tEskayef Bangladesh Ltd.\tSk Mox DS Powder for Suspension 250mg/5ml 100ml bot 65\n\tG. A. Company Ltd.\tUnimox Paediatric Drops 125mg/1.2ml 15ml bot 28.32\n\tG. A. Company Ltd.\tUnimox Powder for Suspension 125mg/5ml 100ml bot 47.29\n\tG. A. Company Ltd.\tUnimox CAP 250mg 100's pack 360\n\tG. A. Company Ltd.\tUnimox CAP 500mg 20's pack 134.60\n\tGeneral\tGenamox Paediatric Drops 125mg/1.2ml 15ml bot 30.11\n\tGeneral\tGenamox Powder for Suspension 125mg/5ml 100ml bot 47.45\n\tGeneral\tGenamox CAP 250mg 100's pack 361\n\tGeneral\tGenamox CAP 500mg 50's pack 338\n\tGlaxoSmithKline Bangladesh Ltd.\tAmoxil CAP 250mg  \n\tGlaxoSmithKline Bangladesh Ltd.\tAmoxil Powder For Suspension 125 mg/5 ml  \n\tGlaxoSmithKline Bangladesh Ltd.\tAmoxil CAP 500mg  \n\tGlaxoSmithKline Bangladesh Ltd.\tAmoxil FORTE Powder For Suspension 250 mg/5 ml  \n\tGlobe\tUltramox Powder for Suspension 125mg/5ml 100ml bot 45\n\tGlobe\tUltramox CAP 250mg 100's pack 350\n\tGlobe\tUltramox CAP 500mg 50's pack 303.50\n\tGonoshasthaya\tG Amoxicillin Powder for Suspension 125mg/5ml 100ml bot 40.1\n\tGonoshasthaya\tG Amoxicillin CAP 250mg 100's pack 276\n\tGonoshasthaya\tG Amoxicillin Injection 500mg 1's pack 24.1\n\tGonoshasthaya\tG Amoxycillin Paediatric Drops 125mg/1.2ml 15ml bot 24.1\n\tGonoshasthaya\tG Amoxycillin CAP 500mg 50's pack 300\n\tHallmark\tDopen Powder for Suspension 125mg/5ml 100ml bot 45.67\n\tHallmark\tDopen CAP 500mg 50's pack 338\n\tHudson\tHi Mox Powder for Suspension 125mg/5ml 100ml bot 47\n\tHudson\tHi Mox CAP 250mg 100's pack 350\n\tHudson\tHi Mox CAP 500mg 50's pack 300\n\tHudson\tMox PLUS Powder for Suspension 250mg/5ml 100ml bot 65\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinamox Powder for Suspension 125mg/5ml 100ml bot 47.46\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinamox CAP 250mg 100's pack 360\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinamox CAP 500mg 80's pack 540\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinamox DS Powder for Suspension 250mg/5ml 100ml bot 69\n\tIndobangla Pharmaceuticals\tIndomoxin Paediatric Drops 125mg/1.2ml 15ml bot 30\n\tIndobangla Pharmaceuticals\tIndomoxin Powder for Suspension 125mg/5ml 100ml bot 45\n\tIndobangla Pharmaceuticals\tIndomoxin CAP 250mg 100's pack 250\n\tIndobangla Pharmaceuticals\tIndomoxin CAP 500mg 100's pack 600\n\tIndobangla Pharmaceuticals\tIndomoxin TAB dr 250mg 100's pack 300\n\tJalalabad\tJamoxil CAP 250mg  \n\tJalalabad\tJamoxil CAP 500mg  \n\tJalalabad\tJamoxil Powder For Suspension 125 mg/5 ml  \n\tJayson\tAmoxon Paediatric Drops 125mg/1.2ml 15ml bot 30.19\n\tJayson\tAmoxon Powder for Suspension 125mg/5ml 100ml bot 47.47\n\tJayson\tAmoxon CAP 250mg 100's pack 361\n\tJayson\tAmoxon Injection 250mg 5 Vial 87.4\n\tJayson\tAmoxon CAP 500mg 50's pack 338\n\tJayson\tAmoxon Injection 500mg 5 Vial 122.95\n\tKemiko\tKamoxy Paediatric Drops 125mg/1.2ml 15ml bot 28\n\tKemiko\tKamoxy Powder for Suspension 125mg/5ml 100ml bot 47.46\n\tKemiko\tKamoxy CAP 250mg 100's pack 300\n\tKemiko\tKamoxy CAP 500mg 80's pack 480\n\tKumudini Pharma Ltd.\tKumumox Powder for Suspension 125mg/5ml 100ml bot 45\n\tKumudini Pharma Ltd.\tKumumox CAP 250mg 100's pack 300\n\tKumudini Pharma Ltd.\tKumumox CAP 500mg 50's pack 275\n\tMarksman.\tMoxatid Paediatric Drops 125mg/1.2ml 15ml bot 28\n\tMarksman.\tMoxatid Powder for Suspension 125mg/5ml 100ml bot 45\n\tMarksman.\tMoxatid CAP 250mg 100's pack 350\n\tMarksman.\tMoxatid CAP 500mg 50's pack 300\n\tMedicon\tAmoxicon Powder for Suspension 125mg/5ml 100ml bot 45\n\tMedicon\tAmoxicon CAP 250mg 100's pack 360\n\tMedicon\tAmoxicon CAP 500mg 50's pack 300\n\tMedimet\tHiconcil Powder for Suspension 125mg/5ml 100ml bot 47\n\tMedimet\tHiconcil CAP 250mg 100's pack 345\n\tMedimet\tHiconcil CAP 500mg 50's pack 300\n\tMedimet\tHioncil Drops 125mg 15 ml bot 27\n\tMillat\tHectamox Paediatric Drops 125mg/1.2ml 15ml bot 30\n\tMillat\tHectamox Powder for Suspension 125mg/5ml 100ml bot 47\n\tMillat\tHectamox CAP 250mg 100's pack 364\n\tMillat\tHectamox CAP 500mg 50's pack 335\n\tMillat\tHectamox DS Powder for Suspension 250mg/5ml 100ml bot 65\n\tModern\tAmoxima Paediatric Drops 125mg/1.2ml 15ml bot 30.2\n\tModern\tAmoxima CAP 500mg 50's pack 334\n\tMystic\tMymoxcil Suspension 250mg 100's pack 350\n\tMystic\tMymoxcil CAP 500mg 50's pack 300\n\tMystic\tMymoxcil Suspension 125mg  100ml bot  45.60\n\tNavana\tNavamox Powder for Suspension 125mg/5ml 100ml bot 45.17\n\tNavana\tNavamox CAP 250mg 100's pack 351\n\tNavana\tNavamox CAP 500mg 50's pack 326.50\n\tNipa\tMoxapen Paediatric Drops 125mg/1.2ml 15ml bot 28.33\n\tNipa\tMoxapen Powder for Suspension 125mg/5ml 100ml bot 45.52\n\tNipa\tMoxapen CAP 250mg 100's pack 350\n\tNipa\tMoxapen CAP 500mg 30's pack 180\n\tNIPRO JMI Pharma\tAMX Powder for Suspension 125mg/5ml 100ml bot 47.47\n\tNIPRO JMI Pharma\tAMX CAP 500mg 50's pack 300\n\tNIPRO JMI Pharma\tAMX CAP 250mg 100's pack 330\n\tNovartis (Bangladesh) Ltd.\tServimox Powder for Suspension 125mg/5ml 100ml bot 45.66\n\tNovartis (Bangladesh) Ltd.\tServimox CAP 250mg 10's pack 360\n\tOpsonin Pharma\tMoxin Paediatric Drops 125mg/1.2ml 15ml bot 28\n\tOpsonin Pharma\tMoxin Powder for Suspension 125mg/5ml 100ml bot 45\n\tOpsonin Pharma\tMoxin Injection 250mg 4 vial 70\n\tOpsonin Pharma\tMoxin TAB dr 250mg 100's pack 325\n\tOpsonin Pharma\tMoxin CAP 500mg 50's pack 337\n\tOpsonin Pharma\tMoxin Injection 500mg 4 vial 98\n\tOpsonin Pharma\tMoxin TAB dr 875mg 20's pack 170\n\tOpsonin Pharma\tMoxin PR Powder for Suspension 250mg/5ml 100ml bot 65\n\tOrion Pharma Ltd.\tOrixyl Paediatric Drops 125mg/1.2ml 15ml bot \n\tOrion Pharma Ltd.\tOrixyl Powder for Suspension 125mg/5ml 100ml bot \n\tOrion Pharma Ltd.\tOrixyl CAP 250mg 100's pack \n\tOrion Pharma Ltd.\tOrixyl CAP 500mg 50's pack \n\tPacific\tAmocin Powder for Suspension 125mg/5ml 100ml bot 40\n\tPacific\tAmocin CAP 250mg 100's pack 330\n\tPacific\tAmocin CAP 500mg 50's pack 335\n\tPeoples Pharma Ltd.\tPamoxil Powder for Suspension 125mg/5ml 100ml bot 35\n\tPeoples Pharma Ltd.\tPamoxil CAP 250mg 100's pack 230\n\tPeoples Pharma Ltd.\tPamoxil CAP 500mg 50's pack 230\n\tPharmadesh Ltd.\tPharmoxyl Paediatric Drops 125mg/1.2 15ml bot 30.11\n\tPharmadesh Ltd.\tPharmoxyl Powder for Suspension 125mg/5 m 100ml bot 47.43\n\tPharmadesh Ltd.\tPharmoxyl CAP 250mg 100's pack 303\n\tPharmadesh Ltd.\tPharmoxyl CAP 500mg 50's pack 293\n\tPopular\tFimox Powder for Suspension 125mg/5ml 100ml bot 47.28\n\tPopular\tFimox CAP 250mg 100's pack 360.96\n\tPopular\tFimox CAP 500mg 50's pack 338.02\n\tRAK\tAmoxirak CAP 500mg 50's pack 325\n\tRangs\tAntif Paediatric Drops 125mg/1.2ml 15ml bot 28\n\tRangs\tAntif Powder for Suspension 125mg/5ml 100ml bot 45\n\tRangs\tAntif CAP 250mg 100's pack 361\n\tRangs\tAntif CAP 500mg 50's pack 337\n\tReman Drug Ltd.\tRemamox Powder for Suspension 125mg/5ml 100ml bot 45.50\n\tReman Drug Ltd.\tRemamox CAP 250mg 100's pack 250\n\tReman Drug Ltd.\tRemamox CAP 500mg 40's pack 220\n\tRenata\tAmoxicap CAP 250mg 100's pack 360\n\tRenata\tBactamox Paediatric Drops 125mg/1.2ml 15ml bot 28.32\n\tRenata\tBactamox Powder for Suspension 125mg/5ml 100ml bot 45.52\n\tRenata\tBactamox Injection 250mg/ vial 250mg Vial+water 18.03\n\tRenata\tBactamox Injection 500mg/ vial 500mg Vial+water 25.52\n\tRenata\tBactamox TAB dr 250mg 100's pack 338\n\tRenata\tBactamox TAB dr 500mg 50's pack 290.5\n\tRenata\tBactamox IM/IV Injection 250mg/ vial 1's pack 18.03\n\tRenata\tBactamox IM/IV Injection 500mg/ vial 1's pack 25.52\n\tRenata\tAmoxi Injection 500mg 50mg vial + water 25.52\n\tRephco\tRemoxin Powder for Suspension 125mg/5ml 100ml bot 46\n\tRephco\tRemoxin CAP 500mg 50's pack 325\n\tSalton\tAmoxipan CAP 250mg 100's pack 351\n\tSalton\tAmoxipan CAP 500mg 50's pack 304.5\n\tSalton\tAmoxipan Suspension 125mg 100 ml bot 45.17\n\tSanofi Aventis (BD) Ltd.\tFimoxyl Paediatric Drops 125mg/1.2ml 15ml bot 30.2\n\tSanofi Aventis (BD) Ltd.\tFimoxyl Powder for Suspension 125mg/5ml 100ml bot 47.46\n\tSanofi Aventis (BD) Ltd.\tFimoxyl Injection 250mg 1 combi pack 19.19\n\tSanofi Aventis (BD) Ltd.\tFimoxyl TAB dr 250mg 100's pack 347.99\n\tSanofi Aventis (BD) Ltd.\tFimoxyl Injection 500mg 1 combipack 26.29\n\tSanofi Aventis (BD) Ltd.\tFimoxyl TAB dr 500mg 50's pack 301\n\tSanofi Aventis (BD) Ltd.\tFimoxyl DS Powder for Suspension 250mg/5ml 100ml bot 68.26\n\tSanofi Aventis (BD) Ltd.\tFimoxyl CAP 500mg 50's pack 338\n\tSanofi Aventis (BD) Ltd.\tFimoxyl CAP 250mg 100's pack 360.96\n\tSeema\tSeemaxyl Powder for Suspension 125mg/5ml 100ml bot 45\n\tSeema\tSeemaxyl CAP 250mg 100's pack 340\n\tSeema\tSeemaxyl DS CAP 500mg 50's pack 338\n\tShamsul Al-Amin\tMumox CAP 250mg 100's pack 300\n\tShamsul Al-Amin\tMumox CAP 500mg 50's pack 300\n\tShamsul Al-Amin\tMumoxs Powder for Suspension 125mg/5ml 100ml bot 45\n\tSilva\tSimox Powder for Suspension 125mg/5ml 100ml bot 45.17\n\tSilva\tSimox CAP 250mg 100's pack 351.32\n\tSilva\tSimox CAP 500mg 50's pack 301.14\n\tSilva\tSimox DS Powder for Suspension 250mg/5ml 100ml bot 65.25\n\tSilva\tSimox S Paediatric Drops 125mg/1.2ml 15ml bot 27.11\n\tSomatec\tTymox Powder for Suspension 125mg/5ml 100ml bot 44.67\n\tSomatec\tTymox CAP 250mg 100's pack 341\n\tSomatec\tTymox CAP 500mg 50's pack 301\n\tSomatec\tTymox Drops 125mg 15ml bot 30.11\n\tSonear Ltd.\tAmocap CAP 250mg 100's pack 359\n\tSonear Ltd.\tAmocap CAP 500mg 40's pack 246\n\tSquare\tMoxacil Paediatric Drops 125mg/1.2ml 15ml bot 30.11\n\tSquare\tMoxacil Powder for Suspension 125mg/5ml 100ml bot 47.47\n\tSquare\tMoxacil CAP 250mg 100's pack 360.43\n\tSquare\tMoxacil CAP 500mg 50's pack 338.48\n\tSquare\tMoxacil Injection 500mg 5's pack 126.09\n\tSquare\tMoxacil DT TAB dr 250mg 100's pack 348.46\n\tSquare\tMoxacil FORTE Powder for Suspension 250mg/5ml 100ml bot 65.25\n\tSquare\tMoxacil 875 TAB dr 875mg 30's pack 301.24\n\tSupreme\tMoxico Powder for Suspension 125mg/5ml 100ml bot 46\n\tSupreme\tMoxico CAP 250mg 100's pack 360\n\tSupreme\tMoxico DS Powder for Suspension 250mg/5ml 100ml bot 65\n\tSupreme\tMoxico CAP 500mg 50's pack 300\n\tSyntho Ltd.\tAmocil Powder for Suspension 125mg/5ml 100ml bot 50\n\tSyntho Ltd.\tAmocil CAP 250mg 100's pack 300\n\tSyntho Ltd.\tAmocil CAP 500mg 50's pack 275\n\tTechno Drugs Ltd.\tPenmox Powder for Suspension 125mg/5ml 100ml bot 58\n\tTechno Drugs Ltd.\tPenmox Injection 250mg 1 vial 22\n\tTechno Drugs Ltd.\tPenmox CAP 500mg 50's pack 293\n\tTechno Drugs Ltd.\tPenmox Injection 500mg 1 vial 26\n\tZenith\tAmoxizen Powder for Suspension 125mg/5ml 100ml bot 45.52\n\tZenith\tAmoxizen CAP 250mg 100's pack 350\n\tZenith\tAmoxizen DS CAP 500mg 50's pack 303.5\n\tElixir\tElimox CAP 250mg 100's pack 350\n\tElixir\tElimox CAP 500mg 50's pack 300\n\tIndication: Bacterial infections,Pharyngitis,Acute otitis media,Acute bacterial sinusitis,Endocarditis,Anthrax,Chlamydial cervicitis,Chlamydial urethritis,Lyme disease,Dental abscess,Salmonellosis,Typhoid fever,Acute Uncomplicated gonorrhea,Infections of the Lower Respiratory Tract,Skin and Skin Structure,Genitourinary Tract,Ear,Nose,Throat\n\nDose: Adult: PO Susceptible infections 250-500 mg 8 hrly. Uncomplicated gonorrhoea W/ probenecid: 3 g as a single dose. Dental abscesses 3 g, repeat once 8 hr later. \n\nUncomplicated acute UTI 3 g, repeat once 10-12 hr later. Prophylaxis of endocarditis 2 or 3 g as a single dose, 1 hr before dental procedure. \n\nSevere or recurrent resp tract infections 3 g twice daily. \n\nH.pylori infection W/ either metronidazole or clarithromycin and a bismuth compound or an antisecretory drug: 500 mg 3 times/day. \n\nChild:  <10 yr: 125-250 mg every 8 hr; <40 kg: 20-40 mg/kg daily in divided doses every 8 hr. Max dose: Infant <3 mth: 30 mg/kg daily in divided doses every 12 hr.\n\nIV/IM Susceptible infections 500 mg 8 hrly. Listerial meningitis W/ other antibiotics: 2 g 4 hrly for 10-14 days.\n\nChild: >10 yr: 50-100 mg/kg daily in divided doses.\n\nRenal impairment: Patients on haemodialysis should receive 250-500 mg every 24 hr and an additional dose during and after each dialysis session.\nCrCl (ml/min)	\n10-30	250-500 mg every 12 hr.\n<10	        250-500 mg every 24 hr. \n\nContra-indication: Hypersensitivity\n\nSide effects: Hyperactivity, agitation, insomnia, dizziness; maculopapular rash, exfoliative dermatitis, urticaria, hypersensitivity vasculitis; diarrhoea, nausea, vomiting; anaemia, thrombocytopenia, leucopenia, agranulocytosis.\nPotentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis.\n\nPrecaution: Renal and hepatic disease; pregnancy, lactation; infectious mononucleosis.\n\nMode of action: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.\n\nPregnancy category: B\n\nInteraction: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
Amoxicillin + Clarithromycin + Lansoprazole Kit	\n\n\tGeneral\tHelicon KIT Kit   14's pack 772.94\n\tSquare\tPylotrip Kit  7's pack 386.46\n\tIndication: H. pylori infection, Peptic ulcer disease\n\nDose: One strip twice daily for 7-14 days or as per the physicians advice. \n\nContra-indication: Contraindicated in patients with known severe hypersensitivity to any component. Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes. \n\nA history of severe hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or other beta-lactam antibiotics (e.g., penicillins and cephalosporins) is a contraindication.\n\nClarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics.\n\nClarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin.\n\nClarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes.\n\nAmoxicillin/clarithromycin/lansoprazole is not recommended in patients with CrCl less than 30 mL/min.\n\nSide effects: Adverse reactions which were reported as possibly or probably related to treatment (<3%) in clinical trials when all three components of this therapy were given concomitantly are listed below and divided by body systems. Digestive system : nausea, vomiting, diarrhoea, dark stool, glossitis, oral moniliasis, stomatitis, tongue discoloration, Musculoskeletal System : myalgia, Nervous System : confusion, headache, dizziness, Skin : skin reactions, Urological System : vaginitis, vaginal moniliasis. \n\nPrecaution:  Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.\n\nMode of action: Amoxicillin: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.\n\nClarithromycin: Serious adverse reactions have been reported in patients taking Clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older.\n\nLansoprazole: Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.\nPotentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.\n\n\nPregnancy category: A\n\nInteraction: Amoxicillin: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.\n\nClarithromycin: Serious adverse reactions have been reported in patients taking Clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older.\n\nLansoprazole: Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.\nPotentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.\n
Amoxicillin + Clarithromycin + Rabeprazole Sodium kit	\n\n\tOpsonin Pharma\tPylocure TAB dr   7's pack 386.46\n\tIndication: H. pylori infection, Peptic ulcer disease\n\nDose: Eradication of H. pylori infection: One strip twice daily for 7-14 days.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Headache, diarrhoea, rash, infection and flu-like syndrome. Dizziness, fatigue, constipation, nausea and vomiting.\nPotentially Fatal: Anaphylaxis, agranulocytosis.\n\nPrecaution: Severe hepatic impairment, gastric malignancy. May increase the risk of GI infections due to acid suppressive effects. Pregnancy.\n\nMode of action: Amoxicillin: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.\n\nClarithromycin: Serious adverse reactions have been reported in patients taking Clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older.\n\nRabeprazole: May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.\n\n\nPregnancy category: A\n\nInteraction: Amoxicillin: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.\n\nClarithromycin: Serious adverse reactions have been reported in patients taking Clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older.\n\nRabeprazole: May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.\n
Amoxicillin + Clavulanic Acid	\n\n\tAlbion Ltd.\tMimoxclav Dry Powder for Syrup (125 mg + 31.25 mg)/ 5ml  100 ml  \n\tAlbion Ltd.\tMimoxclav TAB dr 500 mg+125 mg  18's pack \n\tAlbion Ltd.\tMimoxclav TAB dr 250 mg+125 mg 18's pack \n\tBeximco\tTyclav 1gm TAB dr  875 mg + 125 mg 12's pack 420\n\tBeximco\tTyclav 375 TAB dr  250 mg + 125 mg 18's pack 360\n\tBeximco\tTyclav 625 TAB dr  500 mg + 125 mg 12's pack 450\n\tBeximco\tTyclav 0.6 Injection 500 mg + 100 mg  \n\tBeximco\tTyclav 1.2 Injection 1 gm + 200 mg  \n\tBeximco\tTyclav Powder For Suspension (125 mg + 31.25 mg)/5 ml  \n\tBeximco\tTyclav BID Powder For Suspension (400 mg + 57.5 mg)/5 ml  \n\tDrug International Ltd.\tDemoxiclave-375 TAB dr  21's pack 336\n\tDrug International Ltd.\tDemoxiclave-625 TAB dr  21's pack 960\n\tDrug International Ltd.\tDemoxiclave Suspension  100ml bot 150\n\tDrug International Ltd.\tDemoxiclave Forte Suspension  35ml bot 90\n\tIncepta\tCefaclav TAB dr 500 mg + 125 mg  \n\tJams\tAmoxiclav 375 TAB dr 250 mg + 125 mg	  \n\tOpsonin Pharma\tClamox 1gm TAB dr   12's pack 264.97\n\tOpsonin Pharma\tClamox 1.2gm Injection   1's pack 275\n\tOpsonin Pharma\tClamox 125/31 Powder for Suspension   100ml bot 150\n\tOpsonin Pharma\tClamox 375 TAB dr   18's pack 262.22\n\tOpsonin Pharma\tClamox Injection 600mg 1's pack 123.62\n\tOpsonin Pharma\tClamox 625 TAB dr   12's pack 211.97\n\tOpsonin Pharma\tClamox DS Powder for Suspension   35ml bot 79.47\n\tRenata\tClavoxil 375 TAB dr   18's pack 297\n\tRenata\tClavoxil 625 TAB dr   18's pack 360\n\tSanofi Aventis (BD) Ltd.\tFimoxyclav 1gm TAB dr   20's pack 900\n\tSanofi Aventis (BD) Ltd.\tFimoxyclav 375 TAB dr   30's pack 722.70\n\tSanofi Aventis (BD) Ltd.\tFimoxyclav 600 Injection   1 combipack 140.53\n\tSanofi Aventis (BD) Ltd.\tFimoxyclav 625 TAB dr   30's pack 960\n\tSanofi Aventis (BD) Ltd.\tFimoxyclav Bid Powder for Suspension   50ml bot 245\n\tSanofi Aventis (BD) Ltd.\tFimoxyclav Suspension  100 ml bot 220\n\tSanofi Aventis (BD) Ltd.\tFimoxyclav-1200 I.V Injection  1 combi pack 300\n\tSquare\tMoxaclav 1.2 IV Injection 1 gm + 200 mg 1's pack 275\n\tSquare\tMoxaclav 125/31 Powder for Suspension (125 mg + 31.25 mg)/5 ml 60ml bot/ 100ml bot 135.51/ 150.57\n\tSquare\tMoxaclav 375 TAB dr  250 mg + 125 mg 24's pack 480\n\tSquare\tMoxaclav 625 TAB dr  500 mg + 125 mg 18's pack 450\n\tSquare\tMoxaclav 1gm TAB dr  12's pack 360\n\tSquare\tMoxaclav Forte Suspension (250 mg + 31.25 mg)/5 ml 35ml bot 90.34\n\tSquare\tMoxaclav-600 Suspension  1's pack 140\n\tSquare\tMoxaclav 0.6 IV Injection 500 mg + 100 mg  \n\tTechno Drugs Ltd.\tAmoclav 125/31 Powder for Suspension  60ml bot/ 100ml bot 130/ 190\n\tTechno Drugs Ltd.\tAmoclav 375 TAB dr   20's pack 325\n\tTechno Drugs Ltd.\tAmoclav 0.6 IV Injection  500/100 1's pack 110\n\tTechno Drugs Ltd.\tAmoclav 625 TAB dr   18's pack 360\n\tTechno Drugs Ltd.\tAmoclav FORTE Powder for Suspension 400/57 35ml bot 90\n\tTechno Drugs Ltd.\tAmoclav 1 gm TAB dr  6's pack 138\n\tTechno Drugs Ltd.\tAmoclav 1.2 IV Injection 1000/200 1's pack 200\n\tIndication: Bacterial infections, Acute otitis media, Acute bacterial sinusitis, Endocarditis, Dental abscess, H. pylori infection, Community-acquired pneumonia, Acute uncomplicated UTI, Uncomplicated gonorrhea, Severe or recurrent resp tract infections\n\nDose: Adults and children over 12 years: One 375 mg tablet 3 times a day. In severe infection one 625mg tablet 3 times a day or one 1gm tablet two times a day. \n\nChildren of 6-12 years:  2 teaspoonful Powder for Suspension every 8 hours. \nChildren of 1-6 years: 1 teaspoonful Powder for Suspension every 8 hours. \nChildren below 1 year: 25 mg/kg/day in divided doses every 8 hours. \n\nAdults and children over 12 years: IV Injection: 1.2 g every 6-8 hours, \nChildren up to 3 months: 30 mg/kg every 8 hours (every 12 hours in the perinatal period and in premature infants); \nchild 3 months-12 years, 30 mg/kg every 6-8 hours.\n\n\nContra-indication: Penicillin allergy.\n\nSide effects: Nausea, vomiting, diarrhoea, indigestion, rash and urticaria, candida superinfection.\nPotentially Fatal: Anaphylactic reaction with CV collapse esp with parenteral use.\n\nPrecaution: History of allergy especially to cephalosporins, infectious mononucleosis, severe renal impairment.\n\nMode of action: Allopurinol may reduce renal tubular secretion of amoxicillin thus increasing the serum levels of amoxicillin. Concurrent use may reduce the efficacy of oral contraceptives.\n\nPregnancy category: B\n\nInteraction: Allopurinol may reduce renal tubular secretion of amoxicillin thus increasing the serum levels of amoxicillin. Concurrent use may reduce the efficacy of oral contraceptives.
Amoxicillin Pedriatric	\n\n\tDesh\tDemox Powder for Pedriatric Drop 125mg/1.2ml 15ml bot 28\n\tIndication: Bacterial infections, Pharyngitis, Acute otitis media, Acute bacterial sinusitis, Endocarditis, Anthrax, Chlamydial cervicitis, Chlamydial urethritis, Dental abscess, Salmonellosis, Typhoid fever, Acute Uncomplicated gonorrhea, Infections of the Lower Respiratory Tract, Skin and Skin Structure, Genitourinary Tract, Ear, Nose, Throat, H. pylori infection\n\nDose: Ear/Nose/Throat Skin/Skin Structure Genitourinary Tract:  Usual Dose for Children > 3 Months. PO: 20-40 mg/kg/day in divided doses every 8 hours. Children < 3 Months. 20 to 30 mg/kg/day in divided doses every 12 hours.\nLower Respiratory Tract:  40-50 mg/kg/day in divided doses every 8 hours.	\n\n\nContra-indication: Contraindicated in patients who have experienced a serious hypersensitivity reaction.\n\nSide effects: The most common adverse reactions ( > 1%) observed in clinical trials  capsules, tablets or oral suspension were diarrhea, rash, vomiting, and nausea.\n\n\n\n\n\nPrecaution: Hypersensitivity Reactions: Anaphylaxis  Serum sicknessâlike reactions, erythematous maculopapular rashes, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and urticaria have been reported.\nLiver: A moderate rise in AST and/or ALT has been noted, but the significance of this finding is unknown. Hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.\n\nMode of action: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.\n\nPregnancy category: B\n\nInteraction: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin.
Amphotericin B	\n\n\tIndication: Endocarditis, Systemic fungal infections, Visceral leishmaniasis, Primary amoebic meningoencephalitis, Thrush, Cryptococcal meningitis, Candidiasis, Aspergillosis, Candidal cystitis\n\nDose: Adult: Dosing regimens are applicable to amphotericin B (conventional). PO Oral candidiasis Per loz contains amphotericin B 10 mg: Suck 1 loz 4 times/day, up to 8 loz/day if needed. \n\nIV Severe systemic fungal infections Test dose of 1 mg if needed. Initiate w/ 250 mcg/kg/day. Max: 1.5 mg/kg/day. Aspergillosis, disseminated Test dose of 1 mg if needed. 0.6-0.7 mg/kg/day for 3-6 mth. Endocarditis Test dose of 1 mg if needed. 0.6-1 mg/kg/day for 1 wk, then 0.8 mg/kg/day every other day for 6-8 wk post-op. \n\nIntrathecal Severe meningitis Test dose of 1 mg if needed. Initial: 25 mcg, may increase gradually to the max that can be tolerated. Usual: 0.25-1 mg 2-4 times/wk. \n\nIrrigation Candiduria 50 mg/day via continuous bladder irrigation for 5-10 days or until cultures are clear.\n\nContra-indication: Hypersensitivity; lactation; do not give to patients receiving antineoplastics.\n\nSide effects: Topical: Local irritation, pruritus and skin rash. IV infusion: Fever, chills, convulsions, malaise; nausea, vomiting, diarrhoea, anorexia; tinnitus, vertigo, hearing loss; hypotension, hypertension, cardiac arrhythmias; peripheral neuropathy; phloebitis, pain at Inj site, disturbances in renal function and renal toxicity.\nPotentially Fatal: Anaphylactic reaction; leucoencephalopathy. Overdosage can result in cardio-respiratory arrest.\n\nPrecaution: Renal and hepatic impairment; pregnancy; monitor renal and liver function changes.\n\nMode of action:  	Increased toxicity with flucytosine. Drug induced renal toxicity enhanced in presence of other nephrotoxic medications. Antagonises effects of azole antifungals.\nPotentially Fatal: Potentiates K loss by corticosteroids. Avoid diuretics. Enhances digitalis toxicity and neuromuscular blocker effects.\n\nPregnancy category: B\n\nInteraction:  	Increased toxicity with flucytosine. Drug induced renal toxicity enhanced in presence of other nephrotoxic medications. Antagonises effects of azole antifungals.\nPotentially Fatal: Potentiates K loss by corticosteroids. Avoid diuretics. Enhances digitalis toxicity and neuromuscular blocker effects.
Ampicillin	\n\n\tACI\tAvlocillin CAP 250mg 100's pack \n\tACI\tAvlocillin Powder for Suspension 125mg/5ml 100ml \n\tACI\tAvlocillin Paediatric Drops 125mg/ml 15ml \n\tAcme Ltd.\tAcmecilin Powder for Suspension 125mg/5ml 100ml bot 39.59\n\tAcme Ltd.\tAcmecilin CAP 250mg 100's pack 332\n\tAcme Ltd.\tAcmecilin IV/IM Injection 250mg 5's pack 81.2\n\tAcme Ltd.\tAcmecilin IV/IM Injection 500mg 5's pack 114.25\n\tAlbion Ltd.\tAmpi cap CAP 250 mg 100's pack \n\tJayson\tAmpirex Powder for Suspension 125mg/5ml 100ml bot 33.8\n\tJayson\tAmpirex IV/IM Injection 500mg 5 Vial 112.1\n\tJayson\tAmpirex Injection 250mg 5 vial (combi pack) 82\n\tMedimet\tAmpimet CAP 250mg 100's pack 325\n\tMedimet\tAmpimet CAP 500mg 50's pack 250\n\tMedimet\tAmpimet DS Powder for Suspension 125mg/5ml 100ml bot 43.75\n\tOpsonin Pharma\tAmpexin Paediatric Drops 125mg/ml 15ml bot 26.50\n\tOpsonin Pharma\tAmpexin Powder for Suspension 125mg/5ml 100ml bot 40\n\tOpsonin Pharma\tAmpexin CAP 250mg 100's pack \n\tOpsonin Pharma\tAmpexin IV/IM Injection 250mg 4 Vial 64\n\tOpsonin Pharma\tAmpexin CAP 500mg 100's pack 270\n\tOpsonin Pharma\tAmpexin IV/IM Injection 500mg 4 Vial 90\n\tRenata\tPen A IV/IM Injection 250mg 1's pack 20.36\n\tRenata\tPen-A Powder for Suspension 125mg/5ml 100ml bot \n\tRenata\tPen-A CAP 250mg 100's pack 218\n\tRenata\tPen-A IV/IM Injection 500mg 1's pack 20.36\n\tSquare\tAmpicin Paediatric Drops 125mg/1.2ml 15ml bot \n\tSquare\tAmpicin Powder for Suspension 125mg/5ml 100ml bot \n\tSquare\tAmpicin CAP 250mg 100's pack \n\tSquare\tAmpicin IV/IM Injection 500mg 5's pack \n\tIndication: Bacterial infections, Endocarditis, Typhoid fever, Community-acquired pneumonia, Uncomplicated gonorrhea, Susceptible infections, Bacterial meningitis, Paratyphoid fever, Septicaemia, Intrapartum prophylaxis against group B streptococcal infections\n\nDose: Adult: PO Susceptible infections 0.25-0.5 g 6 hrly. Typhoid and paratyphoid fever 1-2 g 6 hrly. Duration: 2 wk (acute infections); 4-12 wk (carriers). Uncomplicated gonorrhoea W/ probenecid: 2 g as single dose. \n\nIV Intrapartum prophylaxis against group B streptococcal infections Initial, 2 g, then 1 g 4 hrly until delivery. Septicaemia 150-200 mg/kg/day. Start with IV admin for 3 days, then IM inj 3-4 hrly. Continue treatment for at least 48-72 hr after patient has become asymptomatic or when there is evidence of bacterial eradication. IV/IM Susceptible infections 250-500 mg 6 hrly. Meningitis 2-3 g 4-6 hrly, may start w/ IV admin, then continue w/ IM inj. Inj Supplement to systemic therapy For intrapleural/intraperitoneal/intra-articular admin: 500 mg/day.\n\nChild: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. \n\nRenal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.\nCrCl (ml/min)\n<10	  Dose reduction or increase in dose interval.\n\nContra-indication: Hypersensitivity; infectious mononucleosis.\n\nSide effects: GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis.\nPotentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance.\n\nPrecaution: Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation.\n\nMode of action: May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.\n\nPregnancy category: B\n\nInteraction: May reduce the efficacy of OC. May alter INR while on warfarin and phenindione. May reduce the efficacy of oral typhoid vaccines. May reduce the excretion of methotrexate. Reduced excretion w/ probenecid and sulfinpyrazone, resulting to increased risk of toxicity. Allopurinol increases ampicillin-induced skin reactions. Reduced absorption w/ chloroquine. Bacteriostatic antibacterials (e.g. erythromycin, chloramphenicol, tetracycline) may interfere w/ the bactericidal action of ampicillin.
Anastrozole	\n\n\tTechno Drugs Ltd.\tArodex TAB dr 1mg 30's pack 1500\n\tIndication: Breast cancer, Ovulation induction\n\nDose: Oral\nAdvanced or locally advanced breast cancer, Adjuvant treatment in early breast cancer\nAdult: In postmenopausal women: 1 mg daily. Adjuvant treatment may be continued for up to 5 yr.\n\nContra-indication: Pregnancy. Hypersensitivity, premenopausal women.\n\nSide effects: Hot flushes, vaginal dryness, vaginal bleeding, hair thinning, anorexia, nausea, vomiting, diarrhoea, headache, arthralgia, bone fractures, rash, oedema, myalgia, fever, weight gain, leucopenia, flu-like syndrome, asthenia, dizziness, drowsiness, abnormal liver enzyme values, thrombophloebitis, anaphylaxis.\n\nPrecaution: Lactation. Moderate or severe hepatic impairment, hyperlipidaemias. Laboratory test for menopause if status is doubtful. Bone mass density test should be conducted at the start of the therapy and at regular intervals thereafter.\n\nMode of action: Efficacy decreased by oestrogens. Plasma concentrations decreased by tamoxifen.\n\nPregnancy category: X\n\nInteraction: Efficacy decreased by oestrogens. Plasma concentrations decreased by tamoxifen.
Anhydrous Glucose + Citric Acid + Potassium Chloride	\n\n\tIndication: Diarrhea, Gastro-enteritis with dehydration\n\nDose: For oral administration only.\nReconstitution: The powder contents of one sachet or two effervescent tablets should be made up to 200ml with fresh drinking water. (For infants, the water should be freshly boiled and cooled before mixing with Gastrolyte Electrolyte Rehydration Formula). An infant's feeding bottle is a convenient measure of this volume. The solution should be made up immediately prior to feeding and any solution remaining an hour after reconstitution should be discarded. However, the solution may be used for up to 24 hours if stored in a refrigerator immediately after reconstitution. The reconstituted solution must not be boiled.\n\nContra-indication: There are no known contraindications to Gastrolyte Electrolyte Rehydration Formula. However, there may be a number of conditions where treatment with Gastrolyte Electrolyte Rehydration Formula will be inappropriate, e.g. intestinal obstruction requiring surgical intervention.\n\nSide effects: None reported.\n\nPrecaution: Use water ONLY to mix Gastrolyte Electrolyte Rehydration Formula powder or effervescent tablets. Never dilute with lemonade, soft drinks, cordials or any other fluid than water.\nGastrolyte Electrolyte Rehydration Formula powder is available with either sodium saccharin or aspartame as a sweetening agent. Phenylketonurics are warned that this product, in some forms, contains phenylalanine. Please refer to the packaging for information relating to the sweetening agent used.\nFor oral administration only. The contents of one sachet or two effervescent tablets should always be made up to 200ml with water (the product must not be reconstituted in diluents other than water, e.g. must not be included in milk solutions). A weaker solution than recommended will fail to provide adequate sugar and electrolytes and a stronger solution than recommended may give rise to hypernatraemia. Intravenous rehydration is required for dehydrated children with shock, very large stool losses (>10mL/kg/hour), severe vomiting that interferes with oral fluid replacement, or glucose malabsorption. Patients with gastroenteritis should be monitored carefully to ensure that their condition does not deteriorate. In particular, young infants may become severely dehydrated in a short time.\nPatients and/or parents should be advised to seek medical advice if the condition worsens. Clinicians should particularly ensure patients are aware of the risk of dehydration in young children and infants. Early warning signs of impending dehydration should be discussed.\nSeek medical advice if diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children aged 6 months to 3 years, 24 hours in children aged 3 to 6 years and 48 hours in children over 6 years of age.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Anhydrous Glucose + Potassium Chloride + Sodium Chloride + Sodium Bicarbonate	\n\n\tAmico Ltd.\tSuper Saline Oral Saline   20 sachets  pack 91.40\n\tBristol Pharma Ltd.\tORSALINE Saline   20 sachets pack 60\n\tEdruc Ltd.\tE-Saline 	 Oral Saline  20's pack 60\n\tIndobangla Pharmaceuticals\tI B Oral Saline Oral Saline   20 sachets pack 64\n\tMedicon\tOralsaline Saline   25 sachets pack 75\n\tPopular\tORS Saline   25 sachets pack 114.50\n\tRenata\tORS-N Saline   1 sachets pack 3.06\n\tRenata\tORS saline plus Saline   20 sachets pack 86\n\tRenata\tORS saline-R Saline   20 sachets pack 61.20\n\tSharif\tZeosaline Oral Saline    20 sachets  pack 91.60\n\tIndication: Diarrhea,Gastro-enteritis with dehydration,Prolonged vomiting,Burns with a gastric fistula,Pulmonary hemorrhage,Intestinal bleeding\n\nDose: Children less than 2 years: After each loose stool or vomiting 10 to 20 spoonful (50-100 ml).\nChildren 2 to 10 years: After each loose stool or vomiting 100-200 ml of prepared oral saline.\nAdult and children above 10 years: After each loose stool or vomiting 200-400 ml of prepared saline.\n\nContra-indication: None known.\n\nSide effects: \n\nPrecaution: Depressed renal function, severe continuing diarrhoea or other critical fluid losses may need supplementation with parenteral fluids along with oral saline.\n\nSolutions containing acetate or gluconate ions should be used with caution, as excess administration may result in metabolic alkalosis.\n\nSolutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.\n\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Antazoline Hydrochloride 0.05% + Tetryzoline Hydrochloride 0.04%	\n\n\tHealthcare\tZocare Eye Drops  1's pack 115\n\tNovartis (Bangladesh) Ltd.\tSpersallerg Eye Drops 0.5mg 10ml drop 113.78\n\tIndication: Conjunctivitis, Keratitis, Inflammatory eye conditions, Hay-fever\n\nDose: Adult: Ophth As soln containing antazoline 0.5% and xylometazoline HCI 0.05%: Apply 1-2 drops 2-3 times/day. \n\nAdult: Ophth Conjunctival decongestant As 0.01-0.05% soln: Instill 1-2 drops up to 4 times/day for 3-4 days unless directed. \n\nNasal Nasal congestion As 0.1% soln: Instill 2-4 drops/sprays not more often than 3 hrly. Max duration: 3-5 days.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Hypersensitivity reactions. Skin sensitization. Headache, hypertension, tremors, weakness, sweating, rebound congestion with prolonged use. Nasal: transient burning, stinging, sneezing, dryness of mucosa. Eye: blurred vision, irritation, mydriasis.\n\nPrecaution: Do not use on infants, young child. Prolonged use can cause rebound congestion. Discontinue if ocular pain or visual changes occur. Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Aripiprazole	\n\n\tAcme Ltd.\tSizopra TAB dr 10mg 30's pack 150.30\n\tAcme Ltd.\tSizopra TAB dr 15mg 20's pack 140.40\n\tGeneral\tAriprazole TAB dr 10mg 30's pack 150.60\n\tGeneral\tAriprazole TAB dr 5mg 50's pack 175.50\n\tIncepta\tAripra 10 TAB dr 10mg 50's pack 250\n\tIncepta\tAripra 15 TAB dr 15mg 50's pack 350\n\tOpsonin Pharma\tAripen TAB dr 10mg 30's pack 150\n\tOpsonin Pharma\tAripen TAB dr 15mg 20's pack 140\n\tOrion Pharma Ltd.\tSiznil TAB dr 10mg 50's pack 251\n\tSquare\tAriprex 10 TAB dr 10 mg 30's pack \n\tSquare\tAriprex 15 TAB dr 15 mg 30's pack \n\tSquare\tAriprex Oral Solution 300 mg/100 ml  \n\tSquare\tAriprex 2 TAB dr 2mg  \n\tIndication: Major depressive disorder, Schizophrenia, Acute manic episodes of bipolar disorder, Agitation, Irritability in autism\n\nDose: Adult: PO Schizophrenia Initial: 10-15 mg once daily. Maintenance: 15 mg once daily. Max: 30 mg once daily without regard to food. Dose increment should not be made before 2 weeks, the time needed to achieve steady state.  \n\nBipolar mania 30 mg once daily. May reduce to 15 mg once daily according to tolerability.\n\nContra-indication: Hypersensitivity. Lactation. Children <18 yr.\n\nSide effects: Headache, agitation, insomnia, somnolence; dyspepsia, constipation, pain, nausea, vomiting; asthaenia, dizziness, abdominal pain; dry mouth; anxiety, akathisia; orthostatic hypotension; hypertonia, tremor and blurred vision.\n\nPrecaution: Patients with known CV diseases (e.g. history of MI, IHD, CCF or conduction abnormalities), cerebrovascular diseases or conditions which would predispose patients to hypotension; Alzheimer's disease and dementia. Caution when operating hazardous machinery, including automobiles when taking aripiprazole. Pregnancy.\n\nMode of action: Drugs that induce CYP3A4 (e.g. carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g. ketoconazole) or CYP2D6 (e.g. quinidine, fluoxetine or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Increased CNS depression with ethanol.\n\nPregnancy category: C\n\nInteraction: Drugs that induce CYP3A4 (e.g. carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels. Inhibitors of CYP3A4 (e.g. ketoconazole) or CYP2D6 (e.g. quinidine, fluoxetine or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels. Increased CNS depression with ethanol.
Artemether	\n\n\tJayson\tArex-80 Injection 80mg/1mL 5mL/10mL  \n\tJayson\tArex-40 Injection 40mg/ml 5ml/10ml\n \n\tJayson\tArex-160 Injection 160mg/1mL 5x2mL, 10x2mL Ampoules \n\tSanofi Aventis (BD) Ltd.\tPaluther Injection 80mg/ml 6's pack \n\tIndication: Malaria, Schistosomiasis\n\nDose: Adult(IM) 80 mg twice daily for 1 day followed by 80 mg once daily for 4 days. Maximum dose: 480 mg for 5 days. \nChildren (IM): 3.2 mg/kg body weight /day in 2 divided doses followed by 1.6 mg/kg/day once daily for 4 days. Maximum dose: 9.6 mg/kg for 5 days.\n\n\nContra-indication:  	Hypersensitivity.\n\nSide effects: Mild GI disturbance, dizziness, tinnitus, reduction in reticulocyte and leucocyte counts, nausea, vomiting, abdominal pain, bradycardia, 1st-degree heart block, transient increase in serum transaminases.\n\nPrecaution: Pregnancy and lactation. Avoid concomitant use of drugs known to prolong QT interval or monitor such patients.\n\nMode of action: Artemether causes QT prolongation in some patients. Thus concomitant use of erythromycin, terfenadine, procainamide, quinidine, disopyramide, amiodarone, bretylium, bepridil, sotalol, astemizole, probucol, tricyclic antidepressants, phenothiazines may be avoided.\n\nPregnancy category: C\n\nInteraction: Artemether causes QT prolongation in some patients. Thus concomitant use of erythromycin, terfenadine, procainamide, quinidine, disopyramide, amiodarone, bretylium, bepridil, sotalol, astemizole, probucol, tricyclic antidepressants, phenothiazines may be avoided.
Artemether + Lumefantrine	\n\n\tACI\tCoavlon TAB dr   24's pack 481.92\n\tAexim\tArtem TAB dr 20mg 16's pack 320\n\tAexim\tArtem Syrup 15mg / 90 mg 60 ml bot 220\n\tIncepta\tArtemet TAB dr   24's pack 480\n\tJayson\tArexel TAB dr 20mg 24's pack 409.44\n\tSquare\tLumertam TAB dr  20 mg + 120 mg 24's pack 481.68\n\tNovartis Pharma SA, China\tCoartem TAB dr  120/20mg 16's pack / 24's pack 346.40 / 519.60\n\tIndication: Acute uncomplicated malaria, Falciparum malaria\n\nDose: Oral\nAdults and children (weighing 35 kg and above or more than 12 years of age): Administer 24 tablets over 3 days; use a 3-day treatment schedule with total of 6 doses.\nDay 1: 4 tablets initially and 4 tablets again after 8 hours.\nDays 2 & 3: 4 tablets BID (morning & evening).\n\nChildren: < 12 years\n5 to <15 kg: Administer 6 tablets over 3 days; 1 tablet initially and again after 8 hours on first day; follow by 1 tablet BID (morning & evening) for the next 2 days.\n15 to <25 kg: Administer 12 tablets over 3 days; 2 tablets initially and again after 8 hours on first day; follow by 2 tablets BID (morning & evening) for the next 2 days.\n25 to <35 kg: Administer 18 tablets over 3 days; 3 tablets initially and again after 8 hr on 1st day; follow by 3 tablets BID (morning & evening) for the next 2 days.\n\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Mild GI disturbance, dizziness, tinnitus, reduction in reticulocyte and leucocyte counts, nausea, vomiting, abdominal pain, bradycardia, 1st-degree heart block, transient increase in serum transaminases.\n\nPrecaution: Pregnancy and lactation. Avoid concomitant use of drugs known to prolong QT interval or monitor such patients.\n\nMode of action: Artemether causes QT prolongation in some patients. Thus concomitant use of erythromycin, terfenadine, procainamide, quinidine, disopyramide, amiodarone, bretylium, bepridil, sotalol, astemizole, probucol, tricyclic antidepressants, phenothiazines may be avoided.\n\nPregnancy category: C\n\nInteraction: Artemether causes QT prolongation in some patients. Thus concomitant use of erythromycin, terfenadine, procainamide, quinidine, disopyramide, amiodarone, bretylium, bepridil, sotalol, astemizole, probucol, tricyclic antidepressants, phenothiazines may be avoided.
Artesunate	\n\n\tAexim\tArtesunet TAB dr 50mg 12's pack 144\n\tAlco Pharma\tArinet TAB dr 50mg 20's pack 200\n\tJayson\tArtex TAB dr 50mg 12's pack 144.60\n\tIndication: Malaria, Schistosomiasis\n\nDose: Parenteral\nFalciparum malaria especially in quinidine-resistant patients\nAdult: PO: 4 mg/kg once daily x3 days (with mefloquine)\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Hepatic or renal insufficiency. Pregnancy and lactation.\n\nPrecaution: Hepatic or renal insufficiency. Pregnancy and lactation.\n\nMode of action:  	Antimalarial potentiating action seen with mefloquine, primaquine and tetracycline. Additive effect with chloroquine. Antagonistic effect with pyrimethamine and sulphonamides.\n\nPregnancy category: Not Classified\n\nInteraction:  	Antimalarial potentiating action seen with mefloquine, primaquine and tetracycline. Additive effect with chloroquine. Antagonistic effect with pyrimethamine and sulphonamides.
Articaine Hydrochloride + Epinephrine	\n\n\tJayson\tArocaine-A DC Injection   1.8ml cratridge x 5's pack 241.50\n\tIndication: Local anesthesia\n\nDose: Dosage depends on several factors such as route, type and extent of surgical procedure, duration of anaesthesia and patient's condition and age.\n\nLocal Infiltration: 0.5-2.5 mL injection of 4% solution; 20-100 mg total dose\n\nNerve block: 0.5-3.4 mL injection of 4% solution; 20-136 mg total dose\n\nOral surgery: 1-5.1 mL injection of 4% solution; 40-204 mg total dose\n\nNo more than 7 mg/kg (0.175 mL/kg)\n\nContra-indication: Tachycardia, hypertension, cerebral arteriosclerosis, ischaemic heart disease, IV admin, anaesthetise digits or appendages, myasthenia gravis.\n\nSide effects: Severity of adverse effects in CNS and CVS are directly related to blood levels of lidocaine; dizziness; muscle twitching; \nlocal anaesthetic of mouth/throat impairs swallowing and increases the risk of aspiration (patients cautioned against eating or drinking for 3-4 hr after anaesthesia); transient effect on auditory system of neonate; erythema; pigmentation; pain; headache; palpitations; local necrosis; pulmonary oedema; hyperglycaemia; bradycardia; reduced cardiac output; anxiety. \nEpidural may cause hypotension, bradycardia, nausea and vomiting. Intraoral inj may cause stress reactions such as diaphoresis, palpitation, hyperventilation, generalised pallor and faintness. \nTopically: papules, burns, rash, skin irritation, burning sensation and blanching.\nPotentially Fatal: CNS toxicity (due to inadvertent IV admin), medullary depression with tonic & clonic convulsions; ventricular fibrillation; severe hypertension with cerebral haemorrhage and pulmonary oedema; unconsciousness; possibly respiratory arrest. Allergic reactions including anaphylactic symptoms and possibly life threatening asthmatic episodes in susceptible patients may occur due to sodium metabisulphate constituent. Central nerve blocks may cause CV depression (especially in hypovolaemia). Retrobulbar inj may reach subarachnoid space causing CV collapse, apnoea, convulsions, temporary blindness. Paracervical block may cause foetal bradycardia/tachycardia (careful monitoring of foetal heart rate is necessary).\n\nPrecaution: Epilepsy, impaired cardiac conduction, CHF, DM, closed angle glaucoma, impaired liver function (if site of admin is likely to result in high blood levels), severe renal dysfunction. Local anaesthetic effect may be reduced if injected into an inflamed or infected area. Cerebrovascular insufficiency, hyperthyroidism. Neonates, elderly, patients in poor general condition (optimise patient's condition before major block), pregnancy.\n\nMode of action: The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should be avoided; however, in situations when concurrent therapy is necessary, careful patient monitoring is essential.\n\nPregnancy category: C\n\nInteraction: The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should be avoided; however, in situations when concurrent therapy is necessary, careful patient monitoring is essential.
Multivitamin and Multimineral A-Z Gold preparations	\n\n\tACI\tRevital 32 TAB dr  32 Ingredients  15's pack / 30's pack 90.30 / 181.20\n\tAcme Ltd.\tNutrum GOLD TAB dr   15's pack / 30's pack 90.30 / 180.60\n\tAlco Pharma\tLifegold TAB dr   15's pack / 30's pack 90 / 180\n\tAmbee\tVitex gold TAB dr  30's pack 180 	\n\tAmico Ltd.\tVitan GOLD TAB dr   30's pack 180\n\tAmulet\tVolta Gold TAB dr   15's pack / 30's pack 90 / 180\n\tAPC Pharma Ltd.\tOstium Gold TAB dr   15's pack / 30's pack 90 / 180\n\tApex\tAztrum GOLD TAB dr   15's pack / 30's pack 90 / 180\n\tAristopharma\tAristo GOLD TAB dr   15's pack / 30's pack 90/180\n\tAsiatic Ltd.\tAsitrum GOLD TAB dr   15's pack / 30's pack 90/180\n\tBeacon\tAllion TAB dr     30's pack 195\n\tBeximco\tBextram GOLD TAB dr   15's pack / 30's pack 90 / 180\n\tBio Pharma Ltd.\tBiovit GOLD TAB dr   15's pack / 30's pack 90.30 / 180.60\n\tCentral.\tCentral Gold TAB dr   30's pack 195\n\tDelta Pharma\tActivit GOLD TAB dr   15's pack / 30's pack 90 / 180\n\tDrug International Ltd.\tSupravit G soft CAP   50's pack 300\n\tDrug International Ltd.\tSupravit soft CAP   100'pack 200\n\tEdruc Ltd.\tVita-Gold TAB dr   15's pack / 30's pack 90 / 180\n\tEskayef Bangladesh Ltd.\tVitrum TAB dr   15's pack / 30's pack 90 / 180\n\tEskayef Bangladesh Ltd.\tVitrum GOLD TAB dr    15's pack / 30's pack 90 / 180\n\tEverest\tMygold TAB dr   15's pack / 30's pack 90 / 180\n\tGeneral\tSuper GOLD TAB dr   15's pack / 30's pack 90.30 / 180.60\n\tGlobe\tXtrum GOLD TAB dr   15's pack / 30's pack 90 / 175\n\tGlobex\tGlovit Gold TAB dr  30's pack 180\n\tHealthcare\tSantogen TAB dr    30's pack 225\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSina GOLD TAB dr   15's pack / 30's pack 97.50 / 180\n\tIncepta\tProviten A-Z TAB dr   15's pack / 30's pack 90 / 180\n\tIncepta\tProviten GOLD TAB dr   \n\tInnova Phrmaceutical Ltd.\tIntrum Gold TAB dr   \n\tJayson\tVitamin Z TAB dr   30's pack/100's pack 180.60 / 602\n\tKemiko\tKvit Gold TAB dr  15's pack / 30's pack 90 / 180\n\tMedicon\tMedi-Gold TAB dr   15's pack / 30's pack 90 / 180\n\tMystic\tMystrum TAB dr     30's pack 144.90\n\tNavana\tRevam GOLD TAB dr   15's pack / 30's pack/ 100's pack 85.20/ 170.40 /560.98\n\tNIPRO JMI Pharma\tNipro Gold TAB dr   30's pack 180\n\tNovelta Bestway\tVitora Gold TAB dr   30's pack 180\n\tNovo Healthcare and Pharma Ltd.\tAzovit GOLD TAB dr   15's pack / 30's pack 90 / 180\n\tNovo Healthcare and Pharma Ltd.\tNovavit Gold TAB dr   \n\tOpsonin Pharma\tZovia GOLD TAB dr   15's pack / 30's pack 90.30 / 180.60\n\tOrganic Health Care\tVM Gold TAB dr  15's pack / 30's pack 90 / 180\n\tOrion Pharma Ltd.\tGoldage TAB dr   15's pack / 30's pack 90.30 / 180.60\n\tPacific\tSilverpac TAB dr    15's pack / 30's pack 90/180\n\tPharmasia Ltd.\tLolly GOLD TAB dr   15's pack / 30's pack 90 /180\n\tPharmasia Ltd.\tXperia gold Syrup   \n\tPharmasia Ltd.\tXperia gold TAB dr   \n\tPopular\tVidalin GOLD TAB dr  60 mg + 30 mcg + 150 mcg 15's pack / 30's pack 90.30 / 180.60\n\tRadiant.\tATOZ Premium TAB dr     35's pack 420\n\tRephco\tReoplex Gold TAB dr  30's pack 180\n\tSharif\tS-32 Gold TAB dr   15's pack / 30's pack 90 / 180\n\tSilva\tMulti Gold TAB dr     30's pack 180.68\n\tSomatec\tHygea Gold TAB dr   15's pack / 30's pack 90.30 / 180.60\n\tSquare\tFilwel GOLD TAB dr   15's pack / 30's pack 90.37/ 180.74\n\tSupreme\tVitalex GOLD TAB dr   30's pack 90 / 180\n\tUnimed & Unihealth Manufacturers Ltd.\tCentury Forte TAB dr   30's pack 180\n\tWhite Horse Pharma\tPower Gold TAB dr  30's pack 180\n\tIndication: Vitamin/mineral deficiency\n\nDose: 1 tablet daily or as recommended by the physician.\n\nContra-indication:  Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. \n\nPrecaution: Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Multivitamin and Multimineral A-Z Silver preparations	\n\n\tACI\tRevital 30 TAB dr  30 Ingredients  30's pack 181.20\n\tAcme Ltd.\tNutrum 50+ TAB dr    15's pack / 30's pack 90.30 / 180.60\n\tAlco Pharma\tLifesilver TAB dr   15's pack / 30's pack 90 / 180\n\tAmico Ltd.\tVitan TAB dr   30's pack 135\n\tApex\tAztrum SILVER TAB dr     30's pack 165\n\tAsiatic Ltd.\tAsitrum SILVER TAB dr   15's pack / 30's pack 90/180\n\tBeximco\tBextram Silver TAB dr     30's pack 180\n\tBio Pharma Ltd.\tBiovit SILVER TAB dr   15's pack / 30's pack 90.30 / 180.60\n\tDelta Pharma\tActivit SILVER TAB dr   15's pack 90\n\tEdruc Ltd.\tVita Silver TAB dr   15's pack / 30's pack 90/180\n\tEskayef Bangladesh Ltd.\tVitrum SILVER TAB dr   15's pack / 30's pack 90/180\n\tGeneral\tSuper silver TAB dr   30's pack 180.60\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSina SILVER TAB dr   15's pack / 30's pack 97.50 / 180\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinasilver TAB dr  15's pack/30's pack 79.50/159\n\tIncepta\tProviten A-Z SILVER TAB dr     30's pack 180\n\tInnova Phrmaceutical Ltd.\tIntrum SILVER TAB dr   \n\tNavana\tRevam Silver TAB dr   15's pack / 30's pack 90 / 180\n\tOpsonin Pharma\tZovia SILVER TAB dr    30's pack 180.60\n\tOrion Pharma Ltd.\tSilvage TAB dr   15's pack / 30's pack 90.30 / 180.60\n\tPacific\tGoldpac TAB dr   15's pack / 30's pack 90 / 180\n\tPopular\tVidalin silver TAB dr     30's pack 180.60\n\tRadiant.\tATOZ Senior TAB dr    35's pack 420\n\tRephco\tReoplex Silver TAB dr  30's pack 180\n\tSilva\tMulti SILVER TAB dr     30's pack 180.68\n\tSquare\tFilwel silver TAB dr     30's pack 180.74\n\tUnimed & Unihealth Manufacturers Ltd.\tCentury Select TAB dr   30's pack 180\n\tVirgo\tRestor Silver TAB dr  15's pack / 30's pack 90 / 180\n\tWhite Horse Pharma\tPower Silver TAB dr  15's pack / 30's pack 90 / 180\n\tIndication: Vitamin/mineral deficiency\n\nDose: 1 tablet daily or as recommended by the physician.\n\nContra-indication: patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. \n\nPrecaution: Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Multivitamin and Multimineral A-Z Syrup preparations	\n\n\tAcme Ltd.\tNutrum junior Syrup   100ml bot  85.32\n\tApex\tAztrum Kidz Syrup   100ml bot 85\n\tAristopharma\tAristo Kid Syrup    100ml bot / 200 ml bot 86 /152\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVitalgin Syrup    100ml bot / 200 ml bot 85 / 150\n\tMedicon\tMedi-Gold Syrup    100ml bot / 200 ml bot 85 / 150\n\tNovelta Bestway\tVitora Syrup   100ml bot / 200ml bot 85 / 150\n\tOpsonin Pharma\tZovia GOLD Syrup    100ml bot / 200 ml bot 90 / 160\n\tSilva\tMultitonic Syrup    100ml bot / 200 ml bot 85.32 / 150.57\n\tSquare\tLivwel Syrup 			 100ml/200ml bot 90.34/160.60 \n\tVirgo\tKiditonic Syrup   100ml bot 85\n\tIndication: Vitamin/mineral deficiency\n\nDose: Infants up to 1 year: 1 tea-spoon daily\nChildren 1-4 years: 1-2 tea-spoons daily\nChildren 4-12 years: 2-3 tea-spoons daily\nAdult : 3-4 tea-spoons daily\n\nContra-indication: Known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Over dose is prohibited or the physicians should adjust doses.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ascorbic Acid + Biotin + Cholecalciferol (Vit. D3)	\n\n\tIndication: Vitamin/mineral deficiency\n\nDose:  Before, during and/or after pregnancy, one softgel daily or as directed by a licensed healthcare practitioner.\n\nContra-indication: This medicines are contraindicated in patients with a known hypersensitivity to any of the ingredients. Do not take this product if you are presently taking mineral oil, unless directed by a healthcare practitioner.\n\nSide effects: Anorexia, nausea, vomitting, diarrhoea. Raised concentration of calcium & phosphate.\n\nPrecaution: Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Vitamin B complex + Vitamin C	\n\n\tIncepta\tAritone IV Injection  	 1's pack (10ml) 270 	\n\tLeon\tSerobion TAB dr   \n\tLeon\tSerobion Injection   \n\tPopular\tVidalin IV Injection   10 ml vial x 1's pack 200\n\tIndication: Supplement for intravenous nutrition in order to meet the daily requirements of the water-soluble vitamins in infants, adults and children. \n\nDose: Adults and children age 11 years and above: One vial (10 ml) daily. 1-2 Capsule daily.\nChildren below 11 years of age: Children weighing less than 10 kg should be given 1 ml of the dissolved mixture per kg body weight /day.\nChildren weighing 10 kg or more should be given 10 ml (one vial) of the dissolved mixture /day.\n\nContra-indication: Hypersensitivity to any of the ingredients of the preparation.\n\nSide effects: The unwanted effects of nutrient solutions are a rise in the body temperature, shivering, chills and nausea and vomiting. Adverse reactions that may be expected based on experience with other water-soluble vitamin compounds administered intravenously include: allergic reactions, including anaphylaxis; dermatological reactions including flushing, erythema and pruritus and CNS reactions including headache, dizziness and agitation etc.\n\nPrecaution: Folic acid may mask the symptoms of pernicious anemia in that hematologic remission may occur while neurologic manifestations remain progressive. Administering folic acid may obscure pernicious anemia. Recommended doses are insufficient to correct severe vitamin deficiency states and may be insufficient in patients with markedly increased vitamin requirements. In patients receiving total parenteral nutrition (TPN), routine supplementation with both fat-soluble and water-soluble vitamins is recommended to prevent deficiency states and to obviate the need to speculate on individual vitamin status. Daily vitamin requirements must be calculated to avoid over dosage and toxic effects, especially with regards to vitamins A & D and particularly in pediatric patients. \n\nIn patients for whom total parenteral nutrition is continued for prolonged periods (months or years), periodic monitoring of blood vitamin levels should be considered. To prevent excessive excretion of water-soluble vitamins and for reasons of safety, daily dosage should be administered over a number of hours. \n\nMode of action: Decreased GI tract absorption with neomycin, aminosalicylic acid, H2-blockers and colchicine. Reduced serum concentrations with oral contraceptives. Reduced effects in anaemia with parenteral chloramphenicol.\n\nPregnancy category: Not Classified\n\nInteraction: Decreased GI tract absorption with neomycin, aminosalicylic acid, H2-blockers and colchicine. Reduced serum concentrations with oral contraceptives. Reduced effects in anaemia with parenteral chloramphenicol.
Calcium  +  Vitamin  (D3  +  C +  E)  +  Minerals	\n\n\tAristopharma\tCalbon PLUS TAB dr   15's pack / 30's pack 82.50 / 165\n\tOpsonin Pharma\tOstogen Bone TAB dr   30x1's pack 150\n\tOrion Pharma Ltd.\tMaxical Plus TAB dr   30's pack 150.60\n\tIndication: Vitamin/mineral deficiency, Osteoporosis, post-menopausal osteoporosis\n\nDose: One tablet daily or as recommended by the physician.\n\nContra-indication:  Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated.\n\nPrecaution:  Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Calcium Carbonate + Calcium Gluconate + Vitamin-C	\n\n\tACI\tAcical-C Eff TAB dr  1000mg+327mg+500mg 10's pack 110.30\n\tAlco Pharma\tC 4 TAB dr   10's pack 80\n\tEskayef Bangladesh Ltd.\tOstocal-C TAB dr 327 mg + 1 gm + 500 mg  \n\tIncepta\tCavic C TAB dr   10's pack 79\n\tKemiko\tCasalt-C TAB dr 500 mg + 327 mg + 578 mg   \n\tNovartis (Bangladesh) Ltd.\tCac-1000 	 TAB dr    12's pack 180\n\tOpsonin Pharma\tOstogen C TAB dr  10's pack 78.30\n\tPopular\tUltracal C TAB dr 327 mg + 1 gm + 500 mg 9's pack  94.86  \n\tSquare\tCalbo-C TAB dr 327 mg + 1 gm + 500 mg 10's pack 78.60\n\tIndication: Osteoporosis, Calcium and vitamin C deficiency, Premenstrual syndrome, Postmenopausal problems, Increased demand for Calcium and Vitamin C,  pregnancy, Lactation, Periods of rapid growth (childhood,Adolescence), In old age, During infectious disease and convalescence.\n\nDose: Adults and children above 7 years: 1 effervescent tablet daily.\nChildren 3 to 7 years : 1/2 effervescent tablet daily, \nInfants : As prescribed by the physician. Dissolve one tablet in half glass (100 ml) of water.\n\nContra-indication: Absolute contraindications are hypercalcaemia resulting from myeloma, bone metastases or other malignant bone disease, sarcoidosis; primary hyperparathyroidism and Vitamin-D overdosage. It is also contraindicated in severe renal failure and hypersensitivity to any of the tablet ingredients.\n\nSide effects: The use of Calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. \n\nPrecaution: Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. Periodic checks of plasma Calcium levels and urinary Calcium excretion should be made in patients with mild to moderate renal failure or mild hypercalciuria. In patients with a history of renal stones urinary Calcium excretion should be measured to exclude hypercalciuria. \nWith long-term treatment it is advisable to monitor serum and urinary Calcium levels and kidney function, and reduce or stop treatment temporarily if urinary Calcium exceeds 7.5 mmol/24 hours. \n\nMode of action: Calcium Carbonate: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nCalcium Gluconate: Co-admin of high calcium doses with thiazide diuretics may result in milk-alkali syndrome and hypercalcaemia. May potentiate digoxin toxicity. Decreases effects of calcium-channel blockers. Enhanced absorption with calcitriol (a vitamin D metabolite).\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\nPregnancy category: C\n\nInteraction: Calcium Carbonate: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nCalcium Gluconate: Co-admin of high calcium doses with thiazide diuretics may result in milk-alkali syndrome and hypercalcaemia. May potentiate digoxin toxicity. Decreases effects of calcium-channel blockers. Enhanced absorption with calcitriol (a vitamin D metabolite).\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.
Multivitamins + Multiminerals	\n\n\tAcme Ltd.\tV Plex PLUS TAB dr   30's pack / 1000's pack 45 / 740\n\tAexim\tMultivita Forte TAB dr   30's pack 45\n\tAmbee\tVitex M TAB dr   30's pack 30.30\n\tAmico Ltd.\tFlavit M TAB dr   30's pack 45\n\tApollo Pharmaceutical Ltd.\tMulti M TAB dr   30's pack 54\n\tAristopharma\tUnivit PLUS TAB dr   30's pack 45\n\tAristopharma\tAristo Silver TAB dr  15's pack/30's pack/50's pack/60's pack/100's pack 184.81\n\tAsiatic Ltd.\tEquate TAB dr   30's pack 30\n\tBeximco\tAristovit M TAB dr   30's pack 45\n\tBio Pharma Ltd.\tBiovit M TAB dr   30's pack 54\n\tBristol Pharma Ltd.\tBpfort M TAB dr   30's pack 45\n\tCentral.\tCytaplex M TAB dr   30's pack 45\n\tCosmic Chemical Industries Ltd.\tSuplivit M TAB dr   30's pack 45\n\tDoctor's Chemicals Works Ltd.\tBeforte M TAB dr   30's pack 33\n\tDrug International Ltd.\tSupravit M CAP   120's pack 420\n\tEdruc Ltd.\tEdruvit M TAB dr   30's pack 45\n\tEskayef Bangladesh Ltd.\tSolvit M TAB dr   30's pack 54\n\tG. A. Company Ltd.\tVimin PLUS TAB dr   30's pack 45\n\tGlobe\tStano M CAP   50's pack 150\n\tGlobe\tStanovit M TAB dr   30's pack 24.30\n\tHallmark\tVigor M TAB dr   30's pack 45\n\tHudson\tBecoson M TAB dr   30's pack 45\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEnvit M TAB dr   30's pack 45\n\tJayson\tJasovit M TAB dr   30's pack 39.9\n\tKemiko\tKvit M TAB dr   30's pack 45\n\tKumudini Pharma Ltd.\tVicon M TAB dr   30's pack 50\n\tMedicon\tMedivit M TAB dr   30's pack 45\n\tMedimet\tAllbeevit-M CAP   100's pack 97\n\tMedimet\tAllbeevit-M TAB dr   24' pack 36\n\tMillat\tMicoplex-M TAB dr   30's pack 54\n\tNavana\tPlacent M TAB dr   30's pack 45.30\n\tNipa\tNipavit M TAB dr   30's pack 30\n\tNovelta Bestway\tNovacal-M TAB dr   \n\tOpsonin Pharma\tOpsovit MM TAB dr   30's pack 45\n\tOpsonin Pharma\tOpsovit C CAP   \n\tOrion Pharma Ltd.\tOrioplex M TAB dr   30's pack 45.30\n\tPharmadesh Ltd.\tVita PLUS TAB dr   30's pack 44.56\n\tPharmasia Ltd.\tSimvit -M TAB dr   30's pack 54\n\tPopular\tVitachild Syrup 100/200ml 1's pack 75/130\n\tReman Drug Ltd.\tRemavit M TAB dr   30's pack 41.10\n\tRenata\tBecnox M TAB dr   30's pack/ 100's pack 32.70 / 109\n\tSalton\tExtravit M TAB dr   30's pack 42.90\n\tSeema\tSeemavit M TAB dr   30's pack 45\n\tSilco Pharmaceuticlas Ltd.\tViton TAB dr   \n\tSilva\tVitasil M TAB dr   30's pack 45.17\n\tSomatec\tMegavit M TAB dr   30's pack 27.90\n\tSquare\tMultivit PLUS TAB dr   30's pack 54\n\tSquare\tFilwel Teen Hm TAB dr   \n\tSquare\tFilwel TAB dr   \n\tSquare\tFilwel PRENAT TAB dr   \n\tSquare\tFilwel Teen Hr TAB dr   \n\tSupreme\tVitalex M TAB dr   30's pack 45\n\tSyntho Ltd.\tPlexivit M TAB dr   30's pack 30\n\tZenith\tRestovit M TAB dr   30's pack 43\n\tZiska\tZiskavit M TAB dr   30's pack 45\n\tIndication: Vitamin/mineral deficiency\n\nDose: One tablet/capsule daily or as directed by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated.\n\nPrecaution: Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Multivitamins	\n\n\tDrug International Ltd.\tSupravit CAP   100's pack 195\n\tGlobex\tCodmin Syrup  100ml 80\n\tIndication: Vitamin/mineral deficiency\n\nDose: 1-2 tablet/capsule daily or as recommended by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated.\n\nPrecaution: Should not use in over dosage. Patients with mild to moderate renal failure. Diabetes, patients prone to recurrent renal calculi.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Multivitamin & Multimineral Prenatal (Ascorbic Acid + Chromium + Copper + Elemental Iron)	\n\n\tACI\tRevigor TAB dr  20 Ingredients 30's pack 151.20\n\tAcme Ltd.\tNutrum PN TAB dr   30's pack/ 100's pack 150.30 / 501\n\tApex\tAztrum PN TAB dr   30's pack 150\n\tAsiatic Ltd.\tVerve TAB dr   30's pack 150\n\tBeximco\tBextram TAB dr   30's pack 150\n\tBio Pharma Ltd.\tBiovit PN TAB dr   15's pack / 30's pack 75.30/150.60\n\tDrug International Ltd.\tSupravit PN CAP   50's pack 250\n\tIncepta\tPrecare TAB dr     30's pack 150\n\tOrion Pharma Ltd.\tNewage TAB dr    15's pack / 30's pack 75.30 / 150.60\n\tIndication: Improving the nutritional status of women throughout the pregnancy and in the postnatal period for both lactating and non-lactating mothers.  improving the nutritional status of women prior to conception. Anemia, Iron deficiency\n\nDose: Premature or low-birth weight infants: 2-4 mg/kg daily starting preferably at 1 month, but at least by 2 months, of age. Do not exceed 15 mg daily.\n\nNormal full-term infants who are not breast-fed or are only partially breast-fed: 1 mg/kg daily, preferably as iron-fortified formula, starting at birth and continuing during the first year of life.Do not exceed 15 mg daily.\n\nChildren 10 years of age who have begun their pubertal growth spurt may require daily iron supplementation of 2 or 5 mg daily in males or females, respectively.\n\n\n\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.  Primary hemochromatosis. Peptic ulcer, regional enteritis, or ulcerative colitis.\n\n\nSide effects: Constipation, diarrhea, dark stools, nausea, epigastric pain.\n\nPrecaution: Possible increased pathogenicity of certain microorganisms, including possible adverse effects on prognosis in HIV-infected individuals; not recommended for use in individuals without documented iron deficiency.\nUse of Fixed Combination.\n\nWhen used in fixed combination with other agents, consider the cautions, precautions, and contraindications associated with the concomitant agents.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Vitamin A, D, B1, B2, B6, C, E, Nicotinamide, Cod liver oil (Multivitamin with Cod Liver Oil)	\n\n\tACI\tHeptaseas Syrup   100ml bot/200ml bot 80.54/150\n\tAlco Pharma\tVitcod Syrup   100ml bot/200ml bot 75/140\n\tAmico Ltd.\tCodvita Syrup  100ml bot 80\n\tApex\tCod plus Syrup  100ml bot / 200ml bot 80 / 145\n\tAristopharma\tNine Seas Syrup   100ml bot/200ml bot 80/150\n\tAsiatic Ltd.\tAsitrum cod Syrup  100ml bot 80\n\tBeximco\tBextram kidz Syrup  100ml bot 80\n\tCosmic Chemical Industries Ltd.\tLicod-M Syrup   100ml bot/200ml bot 80/145\n\tDelta Pharma\tCNV Syrup  100ml bot 80\n\tDrug International Ltd.\tSupracod Syrup  100ml bot 80\n\tEdruc Ltd.\tV-Cod Syrup   100ml bot 80\n\tEskayef Bangladesh Ltd.\tMixavit Syrup   100ml bot 80\n\tEverest\tMicod Syrup   100ml bot/200ml bot 80/145\n\tGeneral\tMulti Seas Syrup   100ml bot/200ml bot 80.30/145.54\n\tGeneral\tMultigen Syrup  100ml bot / 200ml bot \n\tGlobe\tSeas plus Syrup  100ml bot / 200ml bot 80 / 145\n\tHealthcare\tPogo Syrup   100ml bot 80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tJunivit Syrup   100ml bot 90\n\tIncepta\tVitagrow Syrup  100ml bot 80\n\tJayson\tMulticod Syrup   100ml bot 100\n\tJayson\tCodomix Syrup  100ml bot 80.30\n\tKemiko\tKvit Seas Syrup   200ml bot 145\n\tMillat\tKidoplex Syrup   100ml bot 80\n\tMonicopharma\tKidivit Syrup   100ml bot 80\n\tNavana\tRivam KIDS Syrup   50ml bot/100ml bot 45.17/80.30\n\tNIPRO JMI Pharma\tNipro Seas Syrup (17.5 mg + 100 mg + 9 mg   \n\tNovo Healthcare and Pharma Ltd.\tE-Cod Syrup   100ml bot 80\n\tOpsonin Pharma\tZovia KIDS Syrup   100ml bot / 200ml bot 80.30 / 145.54\n\tOrganic Health Care\tVita Seas Syrup   100ml bot 80\n\tOrion Pharma Ltd.\tGold Kid Syrup   100ml bot 80.30\n\tPharmadesh Ltd.\tSeven VIT Syrup    100ml bot 80\n\tPharmasia Ltd.\tSimcod Syrup   100ml bot 80\n\tReliance\tIQ Vit Syrup   100ml bot 80\n\tRenata\tKiddi Syrup   50ml bot/100ml bot/200ml bot 40.15/ 80.31/ 140.53\n\tSharif\tNewseas Syrup   100ml bot 80\n\tSilva\tCodlivit Syrup   100ml bot/200ml bot 80.31/150.57\n\tSomatec\tAquavit Syrup   100ml bot 80.30\n\tSquare\tFilwel kids Syrup  100ml bot / 200ml bot 80.30 / 145.54\n\tUnimed & Unihealth Manufacturers Ltd.\tPediavit Syrup   100ml bot 80\n\tZenith\tMinicod Syrup    100ml bot 80\n\tZiska\tSuperseas Syrup   100ml bot 80\n\tIndication: Vitamin/mineral deficiency. Prevention of vitamin lacking symptom for growing child, lack of appetite child, including patient under rehabilitating period.\n\nDose: Infants (<1 year): Half teaspoonful daily. Children (1 - 4 years): One teaspoonful daily. Children (> 4 years): One & half teaspoonful daily. Adults: Two teaspoonful daily. Women of child bearing age (including pregnancy & lactation): One teaspoonful daily. It can be taken with water or milk if desired.\n\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: This medicine may accumulate in the body, which cause danger. So, it should not use over dosage or use continuously except recommended by physicians\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Vitamin C   +  Vitamin E  +  Zinc  +  Copper  + Lutein (Antioxidant and Anti Cataract Preparations)	\n\n\tACI\tTioxil CAP   32's pack 156.96\n\tAcme Ltd.\tNutrum Eye CAP 60 mg + 2 mg + 6 mg + 30   \n\tApex\tAztrum-I CAP   28's pack 224\n\tAristopharma\tI-Gold CAP 60mg + 30mg+ 15mg + 6mg + 30's pack 240\n\tAsiatic Ltd.\tOcuvit CAP   30's pack 300\n\tBeximco\tVivis CAP   20's pack/ 30's pack 200 / 300\n\tDrug International Ltd.\tLunox CAP   30's pack 240\n\tGeneral\tLutin Plus CAP   32's pack 320\n\tIbn Sina Pharmaceutical Ind. Ltd.\tOptagold CAP   32's pack 320\n\tIncepta\tAzecol CAP   28's pack 280\n\tKemiko\tKvit-I CAP   \n\tNavana\tVitared CAP   \n\tOpso Saline Ltd.\tSigvit CAP   \n\tOpsonin Pharma\tI-Vita CAP   30's pack 240\n\tOpsonin Pharma\tI-Care CAP 60mg + 30mg + 6mg + 2mg + 30's pack \n\tPacific\tIcare Soft Gelatin CAP   30's pack 300\n\tPopular\tOptavit CAP 60 mg + 2 mg + 6 mg + 30  60's pack 600\n\tReman Drug Ltd.\tR-Vit CAP   28's pack 280\n\tSquare\tEyevi CAP   30's pack 241.20\n\tIndication: Age-related Eye Disease., Vitamin/mineral deficiency. Immune system support. Eye health. \n\nDose: One tablet/capsule daily or as recommended by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen. Diarrhea and other gastrointestinal disturbances may occur.\n\nPrecaution: Caution should be taken during the concomitant use of anticoagulant.\n\nMode of action: Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\nVit E: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.\n\nPregnancy category: Not Classified\n\nInteraction: Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\nVit E: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.
Super Antioxidant Vitamins & Multimineral (Vitamin A + C + E + K ) + Copper  + Zinc + Manganese + Selenium	\n\n\tAcme Ltd.\tNutrum SUPER TAB dr   30's pack 120.30\n\tAmbee\tAces PLUS TAB dr   30's pack 120.60\n\tAmico Ltd.\tSynergy TAB dr   20's pack 80\n\tAristopharma\tVitace M TAB dr   20's pack 80\n\tBeximco\tAristovit X TAB dr   30's pack 120\n\tBio Pharma Ltd.\tVitaforce S TAB dr   15's pack/ 30's pack 60.30 / 120.60\n\tDrug International Ltd.\tTanox plus CAP   50's pack 200\n\tEverest\tOxiden TAB dr   30's pack 120\n\tHealthcare\tSantox TAB dr   20's pack 80\n\tIncepta\tEvagren TAB dr   30's pack 120\n\tKemiko\tAvista TAB dr   30's pack 120\n\tMystic\tAGE PLUS TAB dr   20's pack 75\n\tOpsonin Pharma\tBec PLUS TAB dr   30's pack 120\n\tPacific\tNorad plus SG CAP   50's pack 250\n\tSilva\tAlvital TAB dr   30's pack 120.46\n\tSomatec\tLogeva TAB dr   30's pack 120\n\tIndication: To develop immune system.To prevent aging.Prevent certain types of cancer. Vitamin/mineral deficiency\n\nDose: One tablet daily or as recommended by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.\n\nPrecaution: Hypervitaminosis, Should not use in over dosage or use continiously.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Iron + Folic acid + B Complex + Vitamin C + Zinc	\n\n\tAd-din\tAd - All CAP   100'pack 300\n\tApex\tIrof BC TR CAP   30's pack 90\n\tChemist Ltd.\tPregneed CAP   50's pack 150\n\tDelta Pharma\tFeona CAP   30's pack 93\n\tDelta Pharma\tFeona Z CAP   30's pack 105\n\tEskayef Bangladesh Ltd.\tFolvit CAP   90's pack 270\n\tEskayef Bangladesh Ltd.\tFolvit CI CAP   60's pack 195\n\tEverest\tVifol-Z CAP   30's pack 99\n\tIncepta\tAlneed PLUS CAP   100'pack 350\n\tMarksman.\tProviron CAP   50's pack 150\n\tMonicopharma\tVitamom CAP   50's pack 175\n\tNavana\tPregnid CAP   28's pack 98.28\n\tOpsonin Pharma\tVizicon 	 CAP    60's pack 210 	\n\tPeoples Pharma Ltd.\tRecova PLUS CAP   100's pack 275\n\tS. N.\tFerocom CAP   30's pack 90\n\tSalton\tExtravit PLUS CAP   100's pack 301\n\tSilva\tFamina CAP   60's pack 195.74\n\tIndication: Vitamin/mineral deficiency during pregnancy and lactation\n\nDose: Adults (persons over 12 years of age), One (1) capsule daily, between meals, or as prescribed by a physician. Do not exceed recommended dosage. Do not administer to children under the age of 12.\n\nContra-indication:  Patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. Pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.\n\nSide effects:  Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy. Reducing the dose and administering it with meals will minimize these effects in the sensitive patient. Increasing fiber in the diet can relieve constipation. Iron may turn stools black. This is a harmless effect that is a result of unabsorbed iron. Although the absorption of iron is best when taken between meals, giving Integra FTM after meals may control occasional G.I. disturbances. Integra FTM is best absorbed when taken at bedtime.\n\nPrecaution: General: Anemia is a manifestation that requires appropriate investigation to determine its cause or causes. No single regimen fits all cases and the status of the patient observed in follow-up is the final criterion for adequacy of therapy. Periodic clinical and laboratory studies are considered essential. Blood examinations including hemoglobin and hematacrit should be done at the usual intervals to make certain that therapy is adequate. Use with care in the presence of peptic ulcer, regional enteritis, and ulcerative colitis. Folic acid, especially in doses above 0.1 mg -0.4 mg daily may obscure pernicious anemia, in that hematological remission can occur while neurological manifestations remain progressive.\n\nMode of action: Iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\n\n\nPregnancy category: C\n\nInteraction: Iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\n
Iron + Folic Acid + Zinc + Vitamin A + Vitamin C	\n\n\tRenata\tSprinkles Sachet   30's pack 67.50\n\tRenata\tPushtikona 5 Sachet 0.3mg+30mg+0.16mg+12.5mg+ 30's pack 75\n\tIndication: Vitamin/mineral deficiency, Iron deficiency during pregnancy and lactation\n\nDose: Once daily or as directed by physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Allergic sensitization has been reported following oral administration of folic acid.  Diarrhea and other gastrointestinal disturbances may occur.\n\nPrecaution: Precautions should be exercised if hypersensitivity to any of its ingredients is manifested. \n\nMode of action: Iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\n\n\nPregnancy category: Not Classified\n\nInteraction: Iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\n
Aspartame	\n\n\tAcme Ltd.\tSucrol TAB dr 18mg 100's pack 69\n\tSonear Ltd.\tPep Sweet TAB dr 25mg 50's pack 35\n\tWhite Horse Pharma\tDiasweet TAB dr 18mg 100's pack 90\n\tIndication: Sugar substitute\n\nDose: According to individual taste. 1 pellet is equiv. in sweetness to 1 tsp of sugar or 2 calories.\n\nContra-indication: Complete biliary obstruction; hypersensitivity.\n\nSide effects: Constipation; faecal impaction; haemorrhoids; abdominal discomfort or pain; heartburn; flatulence; nausea; vomiting; diarrhoea; increased bleeding tendency (chronic use); osteoporosis; steatorrhoea (high doses); skin rashes; pruritus of the tongue, skin and perianal region; hyperchloraemic acidosis.\n\nPrecaution: If pregnant or breast-feeding, seek advice of a health professional before use.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Aspirin	\n\n\tACI\tAciprin CV TAB dr 75mg 100's pack 38\n\tAcme Ltd.\tEcosprin TAB dr 300mg 100's pack 172\n\tAcme Specialized\tEcosprin TAB dr 75mg 100's pack 75\n\tAlbion Ltd.\tAspirin TAB dr 75 mg/ 300 mg 100's/' 100's pack \n\tEdruc Ltd.\tNeospin TAB dr 75mg 100's pack 37\n\tGonoshasthaya\tG Aspirin 100 TAB dr 100mg 100's pack 33\n\tGonoshasthaya\tG Aspirin 300 TAB dr 300mg 100's pack/1000's pack 21 / 210\n\tJayson\tCaid TAB dr 100mg 100's pack 37\n\tJayson\tCaid TAB dr 75mg 100's pack 50\n\tKemiko\tAsorin TAB dr 75mg 100's pack 50\n\tMedimet\tEncoprin LD TAB dr 75mg 70's pack 35\n\tNavana\tS-Pirin TAB dr 100mg 100's pack 50\n\tOpsonin Pharma\tSolrin TAB dr 75mg 100's pack 50\n\tPacific\tMysprin TAB dr 75mg 100's pack 50\n\tPharmadesh Ltd.\tAngin TAB dr 75mg 100's pack 50\n\tReckitt & Benckiser Bangladesh Ltd.\tDisprin TAB dr 300mg  \n\tReckitt & Benckiser Bangladesh Ltd.\tDisprin CV TAB dr 100mg  \n\tSanofi Aventis (BD) Ltd.\tGenasprin TAB dr 100mg 100's pack\n 30\n\tSanofi Aventis (BD) Ltd.\tGenasprin S TAB dr 300mg 100's pack 20\n\tSquare\tCarva 75 TAB dr 75mg 200's pack 114\n\tUnimed & Unihealth Manufacturers Ltd.\tEras 75 TAB dr 75 mg 100's pack 58\n\tIndication: Fever, Headache, Pain/inflammation, Acute coronary syndrome, TIA,  MI, Stroke\n\nDose: Oral\nAcute symptoms \n150-300 mg PO; (within minutes of symptoms)\nProphylaxis of myocardial infarction\nAdult: 75-300 mg once daily. Lower doses should be used in patients receiving ACE inhibitors.\nStent implantation\nAdult: 300 mg 2 hr before procedure followed by 150-300 mg/day thereafter.\nJuvenile rheumatoid arthritis\nChild: 80-100 mg/kg daily in 5 or 6 divided doses. Up to 130 mg/kg daily in acute exacerbations if necessary.\nMild to moderate pain and fever\nAdult: 150-300 mg repeated every 4-6 hr according to response. Max: 4 g/day. \nPain and inflammation associated with musculoskeletal and joint disorders\nAdult: Initial: 2.4-3.6 g/day in divided doses. Usual maintenance: 3.6-5.4 g/day. Monitor serum concentrations.\n\n\nContra-indication: Hypersensitivity (attacks of asthma, angioedema, urticaria or rhinitis), active peptic ulceration; pregnancy (3rd trimester), children <12 yr, patients with haemophilia or haemorrhagic disorders, gout, severe renal or hepatic impairment, lactation.\n\nSide effects: GI disturbances; prolonged bleeding time, rhinitis, urticaria and epigastric discomfort; angioedema, salicylism, tinnitus; bronchospasm.\nPotentially Fatal: Gastric erosion, ulceration and bleeding; severe, occasionally fatal exacerbation of airway obstruction in asthma; Reye's syndrome (children <12 yr). Hepatotoxicity; CNS depression which may lead to coma; CV collapse and resp failure; paroxysmal bronchospasm and dyspnoea.\n\nPrecaution: Patients with history  of asthma, angioedema, urticaria or rhinitis, nasal polyp, severe renal or hepatic impairment, lactation.\n\nMode of action: Alcohol, corticosteroids, analgin, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Aspirin increases phenytoin levels. May antagonize actions of uricosurics and spironolactone.\nPotentially Fatal: May potentiate effects of anticoagulants, methotrexate and oral hypoglycaemics.\n\nPregnancy category: D\n\nInteraction: Alcohol, corticosteroids, analgin, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Aspirin increases phenytoin levels. May antagonize actions of uricosurics and spironolactone.\nPotentially Fatal: May potentiate effects of anticoagulants, methotrexate and oral hypoglycaemics.
Aspirin + Clopidogrel	\n\n\tACI\tClorel A TAB dr  75mg+75mg 30's pack 361.20\n\tAcme Ltd.\tDclot TAB dr  75 30's pack 300\n\tAcme Ltd.\tEcosprin PLUS TAB dr 75 mg + 75 mg 20's pack 220\n\tAlbion Ltd.\tPlator Plus TAB dr 75 mg + 75 mg  \n\tAlco Pharma\tClopidol PLUS TAB dr   20's pack 240\n\tAristopharma\tAspin PLUS TAB dr   30's pack 330\n\tBeacon\tCombiplat TAB dr   30's pack 331.20\n\tBeximco\tOdrel PLUS TAB dr   30's pack 330\n\tBio Pharma Ltd.\tAsclop TAB dr   30's pack 330\n\tDelta Pharma\tClas TAB dr   20's pack 160\n\tDrug International Ltd.\tClopid PLUS TAB dr  75mg + 75mg 20's pack  240\n\tDrug International Ltd.\tClopid-As TAB dr  50's pack 600\n\tEskayef Bangladesh Ltd.\tNoclog PLUS TAB dr   20's pack 220\n\tGeneral\tDorel PLUS TAB dr   20's pack 220.80\n\tGlobe\tAnlet PLUS TAB dr   30's pack 240\n\tHealthcare\tReplet PLUS TAB dr   30's pack 330\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAspirel TAB dr 75 mg + 75 mg  \n\tIncepta\tLopirel PLUS TAB dr   30's pack 360\n\tKemiko\tLoplate PLUS TAB dr   30's pack 330\n\tLeon\tAsiplug TAB dr 75 mg + 75 mg  \n\tNavana\tPlavix PLUS TAB dr   20's pack 241\n\tOpsonin Pharma\tClontas TAB dr   30's pack 330\n\tOrion Pharma Ltd.\tClognil PLUS TAB dr   30's pack 331.20\n\tPacific\tClopigel PLUS TAB dr   30's pack 300\n\tPharmasia Ltd.\tCardogrel PLUS TAB dr   20's pack 220.80\n\tPopular\tPreclot TAB dr  75 mg + 75 mg 30's pack 331.21\n\tPopular\tPreclot AS TAB dr 75mg + 75mg 30's pack 331.21\n\tRenata\tPlagrin PLUS TAB dr   20's pack 220.80\n\tSilva\tLirel PLUS TAB dr   30's pack 331.25\n\tSquare\tAnclog PLUS TAB dr  75 mg + 75 mg 30's pack 331.17\n\tSun Pharmaceutical (Bangladesh) Ltd.\tClopilet A TAB dr  30's pack 330\n\tUnimed & Unihealth Manufacturers Ltd.\tPladex A PLUS TAB dr   30's pack 375\n\tWhite Horse Pharma\tLivocard PLUS TAB dr   30's pack 360\n\tZenith\tZesprin TAB dr   30's pack 330\n\tIndication: Acute coronary syndrome, TIA, Ischaemic events, MI, Stroke\n\nDose: Adult: PO Prevention of ischaemic events Per tab contains clopidogrel 75 mg and aspirin 75 mg: 1 tab once daily. Acute coronary syndrome Per tab contains clopidogrel 75 mg and aspirin 75 mg: Loading dose: 4 tab; maintenance: 1 tab/day.\n\nRenal impairment:\nCrCl (ml/min)	\n<10	   Avoid use.\nHepatic impairment: Severe hepatic impairment: Avoid use.\n\nContra-indication: Hypersensitivity to aspirin, NSAIDs or clopidogrel; active peptic ulceration; children <12 yr; patients with haemophilia or haemorrhagic disorders; gout; severe renal or hepatic impairment; lactation.\n\nSide effects: Aspirin: GI disturbances, epigastric discomfort, prolonged bleeding time, rhinitis, urticaria; angioedema, salicylism, tinnitus. Clopidogrel: Dyspepsia, abdominal pain, nausea, vomiting, flatulence, constipation, gastritis, gastric and duodenal ulcers. Serious events include bleeding and GI haemorrhage. GI upset, diarrhoea, paraesthesia, vertigo, headache, dizziness, leucopaenia, eosinophilia, rash and pruritus.\nPotentially Fatal: Aspirin: Gastric erosion, ulceration and bleeding; severe, occasionally fatal exacerbation of airway obstruction in asthma; Reye's syndrome (childn <12 yrs). Hepatotoxicity; CNS depression, which may lead to coma; CV collapse, resp failure; paroxysmal bronchospasm and dyspnoea. Clopidogrel: Bleeding disorders including GI intracranial haemorrhage and thrombotic thrombocytopenic purpura.\n\nPrecaution: History of peptic ulcer or those prone to dyspepsia and those with gastric mucosal lesion or heavy ethanol consumption; asthma or allergic disorders; tinnitus; dehydrated patients; uncontrolled hypertension; impaired renal or hepatic function; children and elderly; pregnancy. Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions. Increased risk of Reye's syndrome when used in patients with chicken pox, influenza or flu symptoms. Caution when used in patients with nasal allergies or nasal polyps. For patients undergoing elective surgery and an antiplatelet effect is not needed, clopidogrel should be discontinued 7-10 days before surgery.\n\nMode of action: Aspirin: Corticosteroids, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Use with coumarins, anagrelide, agatroban, LMWH, bivalirudin, dasatinib, iloprost, lepirudin and tenecteplase may increase the risk of bleeding. Clopidogrel: Co-administration of clopidogrel with NSAIDs may increase the risk of stomach and intestinal bleeding. There is an increased risk of bleeding with coumarins, agatroban, dasatinib, heparin, LMWH, gingko biloba and iloprost. Increased risk of bleeding if clopidogrel and drotrecogin alfa are given within 7 days. May increase bupropion level and side effects (lightheadedness , GI discomfort).\nPotentially Fatal: Aspirin and clopidogrel: Increased risk of bleeding with dabigatran.\n\nPregnancy category: A\n\nInteraction: Aspirin: Corticosteroids, phenylbutazone and oxyphenbutazone may increase risk of GI ulceration. Use with coumarins, anagrelide, agatroban, LMWH, bivalirudin, dasatinib, iloprost, lepirudin and tenecteplase may increase the risk of bleeding. Clopidogrel: Co-administration of clopidogrel with NSAIDs may increase the risk of stomach and intestinal bleeding. There is an increased risk of bleeding with coumarins, agatroban, dasatinib, heparin, LMWH, gingko biloba and iloprost. Increased risk of bleeding if clopidogrel and drotrecogin alfa are given within 7 days. May increase bupropion level and side effects (lightheadedness , GI discomfort).\nPotentially Fatal: Aspirin and clopidogrel: Increased risk of bleeding with dabigatran.
Astaxanthin	\n\n\tGeneral\tAstagen CAP 2mg 30's pack 360\n\tGeneral\tAstagen CAP 4mg 20's pack 440\n\tIncepta\tAztaCap CAP 4mg 20's 440\n\tSquare\tZanthin 2 CAP 2 mg 30's pack \n\tSquare\tZanthin 4 CAP 4 mg 20's pack \n\tJulphar Bangladesh Ltd.\tGreenox CAP 4mg  \n\tIndication: Food supplement, Protects eyes from cataract and age-related macular degeneration (AMD), Improves recovery from central nervous system injuries, Protects from Parkinson's disease, Dementia and Alzheimer's disease, Improving recovery after stroke, Protecting against cancer, Improves Cardiovascular health (Atherosclerosis, reduce cholesterol), Reducing skin damage from ultraviolet (UV) light, Reduces wrinkles, pimples and other signs of aging , Strength and endurance & immune system, Reduce risk of infertility, Stabilize blood sugar.\n\n\n\nDose: The recommended daily dosage is fairly standardized at a 2-4 mg per day. \n\n4 mg daily: As a strong antioxidant, improves cardiovascular health (Atherosclerosis, reduce cholesterol), improves immune function; 4-8 mg daily: Improves condition of skin, protects skin from sun damage (Reduce wrinkles, pimples and other signs of aging), improves recovery from central nervous system injuries and protects eyes from cataracta and macular degeneration; 8-12 mg daily: Reduces inflammation (Arthritis); 16 mg daily: reduces risk of infertility.\n\n\nContra-indication: Astaxanthin is contraindicated in those hypersensitive to any component of an Astaxanthin containing supplement.\n\nSide effects: Astaxanthin is safe when it is consumed in amounts found in food. The safety of using astaxanthin supplements and astaxanthin in skin products is unknown.\n\nPrecaution: Pregnant women and nursing mothers should avoid Astaxanthin containing supplements.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Atenolol	\n\n\tACI\tTenoren TAB dr 100mg 100's pack 138\n\tACI\tTenoren TAB dr 25mg 50's pack 22.50\n\tACI\tTenoren TAB dr 50mg 150's pack 115.50\n\tAcme Specialized\tTenoloc TAB dr 100mg 100's pack 137\n\tAcme Specialized\tTenoloc TAB dr 50mg 100's pack 77\n\tAlbion Ltd.\tAtenolol TAB dr 50 mg / 100 mg 100's/100's pack \n\tAlco Pharma\tCardilock TAB dr 50mg 100's pack 77\n\tAmbee\tAnetol TAB dr 50mg 100's pack 80\n\tAPC Pharma Ltd.\tApcard TAB dr 50mg 100's pack\n 75\n\tAristopharma\tTenocard TAB dr 50mg 100's pack 75\n\tAsiatic Ltd.\tAtebit TAB dr 100mg 100's pack 138\n\tAsiatic Ltd.\tAtebit TAB dr 50mg 100's pack 77\n\tBeximco\tLonet TAB dr 100mg 100's pack 137\n\tBeximco\tLonet TAB dr 50mg 100's pack 77\n\tBio Pharma Ltd.\tEtnol TAB dr 100mg 100's pack 138\n\tBio Pharma Ltd.\tEtnol TAB dr 50mg 100's pack 77\n\tCipla Ltd.\tBetapress TAB dr 50mg 100's pack 67.73\n\tDelta Pharma\tBpnol TAB dr 50mg 100's pack 76.06\n\tDoctor's Chemicals Works Ltd.\tPrecinol TAB dr 50mg 100's pack 73\n\tEdruc Ltd.\tEnol TAB dr 50mg 100's pack 77\n\tEuro Pharma Ltd.\tAnolol TAB dr 100mg 100's pack 138\n\tEuro Pharma Ltd.\tAnolol TAB dr 50mg 100's pack 77\n\tJayson\tAtin TAB dr 50mg 100's pack 76\n\tKemiko\tNorpress TAB dr 50mg 100's pack 75\n\tKemiko\tNorpress TAB dr 100mg 60's pack 75\n\tMedimet\tCarsec TAB dr 100mg 140's pack 189\n\tMedimet\tCarsec TAB dr 50mg 140's pack 105\n\tModern\tAnol TAB dr 50mg 100's pack 77\n\tMystic\tAtol TAB dr 100mg 100's pack 75\n\tMystic\tAtol TAB dr 50mg 100's pack 75\n\tNavana\tNormaten TAB dr 50mg 100's pack 76\n\tNipa\tB Card TAB dr 50mg 100's pack 77\n\tOpsonin Pharma\tBetasec TAB dr 50mg 100's pack 76\n\tOrion Pharma Ltd.\tLopres TAB dr 50mg 100's pack 70\n\tPacific\tTenomin TAB dr 50mg 100's pack 77\n\tSanofi Aventis (BD) Ltd.\tBetanol TAB dr 100mg 100's pack 136.99\n\tSanofi Aventis (BD) Ltd.\tBetanol TAB dr 25mg 200's pack 90.44\n\tSanofi Aventis (BD) Ltd.\tBetanol TAB dr 50mg 200's pack 154.28\n\tSquare\tCardipro TAB dr 100mg 100's pack 143.64\n\tSquare\tCardipro TAB dr 50mg 100's pack 77.14\n\tSupreme\tCardisef TAB dr 50mg 100's pack 77\n\tSupreme\tCardisef TAB dr 100mg 100's pack 136\n\tVirgo\tTenovir TAB dr 50mg 100's pack 75\n\tZenith\tAtezen TAB dr 100mg 100's pack 136\n\tZenith\tAtezen TAB dr 50mg 100's pack 77\n\tIndication: Hypertension, Migraine, Arrhythmias, MI, Angina pectoris\n\nDose: Adult: PO HTN 25-100 mg/day. \nAngina pectoris; Migraine prophylaxis 50-100 mg/day. Max for angina pectoris: 200 mg/day.\n\nRenal impairment:\nCrCl (ml/min)	\n<15	  25 mg or 50 mg on alternate days.\n15-35	50 mg/day.\nDialysis patients	25-50 mg after each dialysis.\n\nContra-indication: Hypersensitivity. Sinus bradycardia, sinus node dysfunction, heart block >1st degree, compensated cardiac failure, cardiogenic shock, bronchospastic diseases, peripheral vascular diseases. Pregnancy.\n\nSide effects: Bronchospasm; cold extremities, fatigue, dizziness, insomnia, lethargy, confusion, headache, depression, nightmares, nausea, diarrhoea, constipation, impotence and paraesthesia.\nPotentially Fatal: Heart failure, 2nd or 3rd degree AV block.\n\nPrecaution: Compensated heart failure. Variant angina, acute MI, DM; peripheral vascular disorders; hepatic and renal dysfunction; elderly patients, children. Lactation. If atenolol and clonidine are co-admin, then gradual withdrawal of clonidine should take place a few days after withdrawal of atenolol.\n\nMode of action: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment.\n\n\nPregnancy category: D\n\nInteraction: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment.\n
Atenolol + Chlorthalidone	\n\n\tACI\tTenoren PLUS 50/25 TAB dr  50mg+25mg 50's pack 151\n\tApex\tTenoclor 50/25 TAB dr   30's pack 75\n\tSilva\tAtechlor 100 TAB dr   50's pack 150.57\n\tSilva\tAtechlor 50/25 TAB dr   50's pack 125.47\n\tSquare\tCardipro PLUS 100 TAB dr  100 mg 30's pack 90.18\n\tSquare\tCardipro PLUS 50/25 TAB dr  50 mg + 25 mg 30's pack 82.99\n\tIndication: Hypertension\n\nDose: Adult: Per tab contains Atenolol (mg)/Chlorthalidone (mg): 50/25 or 100/25. Initially one tab of 50/12.5 once daily; may increase to one tab of 100/25 based on response.\n\nRenal impairment:\nCrCl (ml/min)	\n15-35	Max dose of Atenolol component: 50 mg/day\n<15 	Max dose of Atenolol component: 50 mg every other day.\n\nContra-indication: Sinus bradycardia, 2nd or 3rd degree heart block, cardiogenic shock, anuria, hypersentivity to either product or sulphonamide derivatives.\n\nSide effects: Atenolol: Dyspnoea, wheeziness, bradycardia, hypotension, cold extremities, fatigue, dizziness, insomnia, lethargy, confusion, headache, depression, nightmares, nausea, diarrhoea, constipation, impotence, paraesthesia, rash, Raynaud's phenomenon. Chlorthalidone: Orthostatic hypotension, GI disturbances, jaundice, pancreatitis, vertigo, lethargy, paraesthesia, photosensitivity, rash, muscle cramps, hypokalaemia, hyponatraemia, hyperglycaemia, hyperuricaemia or gout, leucopenia, agranulocytosis, aplastic anaemia, thrombocytopenia.\nPotentially Fatal: Atenolol: Heart failure, 2nd or 3rd degree AV block. Chlorthalidone: Hypersensitivity reaction including toxic epidermal necrolysis.\n\nPrecaution: Bronchospastic disease, renal or hepatic impairment, elderly. May aggravate peripheral arterial circulatory disorder. Beta-blocker can depress myocardial contractility; continued use in patients without history of cardiac failure may in some cases, lead to cardiac failure. Caution in patients receiving anaesthetic agents that may depress myocardium. In patients with coronary artery disease, abrupt withdrawal may cause angina pectoris exacerbation, MI. Atenolol may mask signs (tachycardia) of hypoglycaemia and thyrotoxicosis. Latent DM may manifest with Chlorthalidone therapy. Chlorthalidone can cause hyperuricaemia and precipitate gout. Monitor renal functions, potassium levels, and signs of fluid and electrolytes imbalance. Discontinue if progressive renal impairment is evident. Not recommended in pregnancy and lactation. Safety and efficacy in paediatric patients have not been established.\n\nMode of action: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment. \n\nPregnancy category: D\n\nInteraction: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive w/ Ca channel blockers, hydralazine, methyldopa. Increased risk of bradycardia and heart block w/ verapamil and diltiazem. May decrease hypotensive effects w/ NSAIDs (e.g. indometacin). Enhanced bradycardic effect w/ disopyramide, amiodarone or digitalis glycosides. May exacerbate rebound HTN upon discontinuance of clonidine treatment. 
Atenolol + Nifedipine	\n\n\tSquare\tNidipro CAP 50mg/20mg 50's pack 134.99\n\tIndication: Hypertension, Angina pectoris\n\nDose: Adult: PO Angina pectoris Per cap contains atenolol 50 mg and nifedipine (sustained release) 20 mg: 1 cap 2 times/day. \nHypertension Per cap contains atenolol 50 mg and nifedipine (sustained release) 20 mg: 1 cap 1-2 times/day.\n\nRenal impairment: Dose reduction may be required. Max dose: 1 capsule daily.\nCrCl (ml/min)	\n<15 	Contraindicated.\n\nHepatic impairment: Dose reduction may be required. Max dose: 1 capsule daily.\n\nContra-indication: History of wheezing, asthma, obstructive respiratory disease, pronounced bradycardia (resting heart rate <50 beats/min prior to treatment), 2nd or 3rd degree heart block, sick sinus syndrome, SA block, systolic pressure <90 mmHg, overt or decompensated cardiac failure (NYHA grades III & IV), aortic stenosis, unstable angina, acute attacks of angina, acute MI or within 1 mth of MI, or for secondary prevention of MI, cardiogenic shock, severe peripheral arterial circulatory disorders, acidosis, severe renal impairment, untreated phaeochromocytoma, malignant hypertension. Lactation, pregnancy, women of child-bearing age.\n\nSide effects: Headache, flushing, purpura, impotence, dizziness, GI upsets, oedema, fatigue.\n\nPrecaution: Conduction defects, poor cardiac reserve, controlled CHF, peripheral circulatory disorders, 1st degree heart block, mild heart failure (NYHA grade II), Prinzmetal's angina, renal or hepatic impairment. Discontinue use if heart rate is reduced at a dose of 1 capsule daily or if there is ischaemic pain within 1-4 hr of initiation of therapy. Withdraw gradually in patients with ischaemic heart disease. Adjustment in diabetic control may be required; may mask signs of thyrotoxicosis and modifies tachycardia of hypoglycaemia. Family history of psoriasis.\n\nMode of action: Potentiate effects of other antihypertensives. Atenolol: Reduced hypotensive effect with pseudoephedrine, xylometazoline or NSAIDs. Additive effect with calcium antagonist and catecholamine-depleting drugs e.g. reserpine. Increase risk of bradycardia with amisulpride, flecainide, digitalis glycosides. Increase risk of hypotension with alprostadil, baclofen. Withdrawal of clonidine in patients receiving ?-blockers may result in rebound hypertension. Chlorthalidone: May alter insulin and dosage of oral hypoglycaemic agents required in diabetics. May reduce renal clearance of lithium and increases risk of lithium toxicity. May cause hypokalaemia therefore increase risk of digitalis toxicity. Risk of hypercalcaemia with paricalcitol. Increased risk of hypokalaemia with ritodrine, amphotericin B. Increased responsiveness to tubocurarine.\nPotentially Fatal: Atenolol: Bradycardia, heart block may occur when used with verapamil or diltiazem. Severe bradycardia, asystole and heart failure have been reported when used with disopyramide. High degree of cardiac depression may occur with methoxyflurane. Chlorthalidone: Risk of cardiac arrhythmias with ketanserin.\n\nPregnancy category: D\n\nInteraction: Potentiate effects of other antihypertensives. Atenolol: Reduced hypotensive effect with pseudoephedrine, xylometazoline or NSAIDs. Additive effect with calcium antagonist and catecholamine-depleting drugs e.g. reserpine. Increase risk of bradycardia with amisulpride, flecainide, digitalis glycosides. Increase risk of hypotension with alprostadil, baclofen. Withdrawal of clonidine in patients receiving ?-blockers may result in rebound hypertension. Chlorthalidone: May alter insulin and dosage of oral hypoglycaemic agents required in diabetics. May reduce renal clearance of lithium and increases risk of lithium toxicity. May cause hypokalaemia therefore increase risk of digitalis toxicity. Risk of hypercalcaemia with paricalcitol. Increased risk of hypokalaemia with ritodrine, amphotericin B. Increased responsiveness to tubocurarine.\nPotentially Fatal: Atenolol: Bradycardia, heart block may occur when used with verapamil or diltiazem. Severe bradycardia, asystole and heart failure have been reported when used with disopyramide. High degree of cardiac depression may occur with methoxyflurane. Chlorthalidone: Risk of cardiac arrhythmias with ketanserin.
Atomoxetine	\n\n\tSquare\tSuev TAB dr 10mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tAttentin-10 TAB dr 10mg 10's pack 240\n\tIndication: Attention deficit hyperactivity disorder (ADHD)\n\nDose: Oral\nAttention deficit hyperactivity disorder\nAdult: Initially, 40 mg/day may increase gradually after at least 7 days to 80 mg/day, up to 100 mg/day may be used after 2-4 wk.\nChild: >6 yr ?70 kg: Initially, 0.5 mg/kg/day, may increase gradually to approx 1.2 mg/kg/day. Max: 1.4 mg/kg or 100 mg, whichever is lower; >70 kg: Initially, 40 mg/day, may increase gradually after at least 7 days to 80 mg/day, up to100 mg/day may be used after 2-4 wk.\n\nHepatic impairment: Moderate: Reduce dose by 50%. Severe: Reduce dose by 75%.\n\n\nContra-indication: Angle-closure glaucoma. Not to be used with or within 14 days of discontinuing treatment with MAOIs.\n\nSide effects: GI disturbances, anorexia and wt loss, fatigue. CNS symptoms e.g. headache, insomnia, sleep disturbances, dizziness, irritability and emotional lability. Cough, sinusitis or rhinorrhoea, urinary hesitancy or retention. Reduced libido and sexual dysfunction. Skin rashes, increased sweating and hot flushes.\n\nPrecaution: Monitor height and wt gain especially during the initial period of treatment; dose reduction or treatment interruption may be needed in children whose growth or wt gain is not satisfactory. Patients with high BP or cardiovascular conditions that may be worsened by increases in BP or heart rate. Caution when used in patients with a history of psychotic illness or bipolar disorder. May increase the risk of urinary obstruction or hesitancy. Monitor for signs of clinical worsening, suicidality or unusual behavioural changes especially during the start of treatment and during dose changes. Safety and efficacy have not been established in patients <6 yr. Not recommended for use in pregnancy.\n\nMode of action: May cause additive effect when used w/ drugs that increase BP. May potentiate the effect of salbutamol on the CVS. May increase risk of cardiac events when used w/ drugs that affect cardiac conduction or electrolyte balance, or that inhibit CYP2D6 (e.g. fluoxetine, paroxetine, quinidine). Increased risk of QT prolongation w/ QT prolonging drugs (e.g. class Ia and III antiarrhythmics, moxifloxacin, erythromycin, TCAs, lithium, cisapride). Increased risk of seizures w/ drugs that are known to lower seizure threshold (e.g. phenothiazines, neuroleptics, mefloquine, bupropion, tramadol).\nPotentially Fatal: Increased neurotoxic effect w/ MAOIs.\n\nPregnancy category: C\n\nInteraction: May cause additive effect when used w/ drugs that increase BP. May potentiate the effect of salbutamol on the CVS. May increase risk of cardiac events when used w/ drugs that affect cardiac conduction or electrolyte balance, or that inhibit CYP2D6 (e.g. fluoxetine, paroxetine, quinidine). Increased risk of QT prolongation w/ QT prolonging drugs (e.g. class Ia and III antiarrhythmics, moxifloxacin, erythromycin, TCAs, lithium, cisapride). Increased risk of seizures w/ drugs that are known to lower seizure threshold (e.g. phenothiazines, neuroleptics, mefloquine, bupropion, tramadol).\nPotentially Fatal: Increased neurotoxic effect w/ MAOIs.
Atorvastatin	\n\n\tACI\tAtasin TAB dr 10mg 30's pack 302.10\n\tACI\tAtasin TAB dr 20mg 20's pack 362.40\n\tACI\tAtasin TAB dr 40mg 10's pack 241.60\n\tACI\tAtasin TAB dr 80mg 12's pack 481.44\n\tACI\tAtrovast F.C TAB dr 10mg 30's pack \n\tACI\tAtrovast F.C TAB dr 20mg 20's pack \n\tACI\tAtasin 40 TAB dr 40mg 10's pack 241.60\n\tAcme Ltd.\tLiptor TAB dr 40mg 10's pack 240.90\n\tAcme Ltd.\tLiptor TAB dr 10mg 20's pack 200\n\tAcme Ltd.\tLiptor TAB dr 20mg 10's pack 180\n\tAlbion Ltd.\tAltovas TAB dr 10 mg/ 20mg 30's / 20's pack \n\tAlco Pharma\tAtovin TAB dr 10mg 10's pack 100\n\tApex\tZapitor TAB dr 10mg 30's pack 300\n\tApex\tZapitor TAB dr 20mg 30's pack 360\n\tAristopharma\tTCL-R TAB dr 10mg 30's pack 300\n\tAristopharma\tTCL R TAB dr 20mg 10's pack 180\n\tAsiatic Ltd.\tAtonor TAB dr 10mg 30's pack 300\n\tAsiatic Ltd.\tAtonor TAB dr 20mg 20's pack 360\n\tBeacon\tXerova TAB dr 10mg 30's pack 300.90\n\tBeacon\tXerova TAB dr 20mg 20's pack 360\n\tBeximco\tAtova TAB dr 10mg 30's pack 300\n\tBeximco\tAtova TAB dr 20mg 20's pack 360\n\tBeximco\tAtova TAB dr 40mg 20's pack 480\n\tBio Pharma Ltd.\tTrova TAB dr 10mg 30's pack 240.90\n\tBio Pharma Ltd.\tTrova TAB dr 20mg 10's pack 150.60\n\tConcord\tOptivas TAB dr 10mg 30's pack \n\tConcord\tOptivas TAB dr 20mg 20's pack \n\tDelta Pharma\tATV TAB dr 10mg 30's pack 150\n\tDelta Pharma\tATV TAB dr 20mg 10's pack/30's pack 100/300\n\tDoctor's Chemicals Works Ltd.\tCloles TAB dr 10mg 10's pack 240\n\tDrug International Ltd.\tDivastin TAB dr 10mg 30's pack 300\n\tDrug International Ltd.\tDivastin TAB dr 20mg 20's pack 360\n\tDrug International Ltd.\tDivastin TAB dr 40mg 20's pack 480\n\tDrug International Ltd.\tAngitor TAB dr 10mg 3x10's pack 300\n\tEdruc Ltd.\tAvastatin TAB dr 10mg 10's pack 80\n\tEskayef Bangladesh Ltd.\tLipicon TAB dr 10mg 40's pack 400\n\tEskayef Bangladesh Ltd.\tLipicon TAB dr 20mg 20's pack 360\n\tEskayef Bangladesh Ltd.\tLipicon TAB dr 40mg 10's pack 240\n\tGeneral\tLipitin TAB dr 10mg 30's pack 301.20\n\tGeneral\tLipitin TAB dr 20mg 20's pack 180.70\n\tGeneral\tLipitin TAB dr 40mg 10's pack 240\n\tGlobe\tLiplo TAB dr 10mg 10's pack 100\n\tGlobe\tLiplo TAB dr 20mg 10's pack 150\n\tGonoshasthaya\tG-Atorvastatin TAB dr 10mg 30's pack 210.30\n\tGonoshasthaya\tG-Atorvastatin TAB dr 20mg 30's pack 361.80\n\tHealthcare\tXelpid TAB dr 10mg 30's pack 300\n\tHealthcare\tXelpid TAB dr 20mg 10's pack 180\n\tHealthcare\tXelpid TAB dr 40mg 10's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tColostat TAB dr 10mg 30's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tColostat TAB dr 20mg 30's pack 451.80\n\tIncepta\tTiginor 10 TAB dr 10mg 30's pack 300\n\tIncepta\tTiginor 20 TAB dr 20mg 20's pack 360\n\tIncepta\tTiginor 40 TAB dr 40mg 20's pack 480\n\tJayson\tAstin TAB dr 10mg 30's pack 241.20\n\tJayson\tAstin TAB dr 20mg 10's pack 150.50\n\tKemiko\tOrvatin TAB dr 10mg 20's pack 160\n\tKemiko\tOrvatin TAB dr 20mg 20's pack 340\n\tKumudini Pharma Ltd.\tTorvas TAB dr 10mg 30's pack 270\n\tLabaid\tTigilo TAB dr 10mg 30's pack 360\n\tLabaid\tTigilo TAB dr 20mg 30's pack 600\n\tLeon\tLipiva 10 TAB dr 10mg 100's pack \n\tLeon\tLipiva 20 TAB dr 20mg 50's pack \n\tLeon\tLipiva TAB dr 10mg  \n\tLeon\tLipiva TAB dr 20mg  \n\tMedimet\tAtorvast TAB dr 10mg 30's pack 240\n\tNavana\tLipostat TAB dr 10mg 30's pack 210\n\tNavana\tLipostat TAB dr 20mg 30's pack 360\n\tNipa\tLipobi TAB dr 10mg 30's pack 240\n\tNIPRO JMI Pharma\tAvator TAB dr 20mg 20's pack 360\n\tNovartis (Bangladesh) Ltd.\tVass TAB dr 10mg 30's pack 360\n\tNovartis (Bangladesh) Ltd.\tVass TAB dr 20mg 10's pack 200\n\tNovartis (Bangladesh) Ltd.\tVass TAB dr 40mg 10's pack 250\n\tNovo Healthcare and Pharma Ltd.\tXelitor TAB dr 10mg 30's pack 240\n\tNovo Healthcare and Pharma Ltd.\tXelitor TAB dr 20mg 30's pack 450\n\tNovus\tTorva TAB dr 10mg 30's pack 300\n\tOpsonin Pharma\tAvas TAB dr 10mg 30's pack 300\n\tOpsonin Pharma\tAvas TAB dr 20mg 10's pack 180\n\tOpsonin Pharma\tAvas TAB dr 40mg 10's pack 240\n\tOrion Pharma Ltd.\tLipex TAB dr 10mg 30's pack 270\n\tOrion Pharma Ltd.\tLipex TAB dr 20mg 20's pack 301.20\n\tPacific\tLipigent TAB dr 10mg 30's pack 300\n\tPacific\tLipigent TAB dr 20mg 20's pack 360\n\tPharmadesh Ltd.\tVastin TAB dr 10mg 20's pack 160.60\n\tPharmasia Ltd.\tLipiles TAB dr 10mg  \n\tPharmasia Ltd.\tLipiles TAB dr 20mg  \n\tPopular\tLocol TAB dr 10mg 30's pack 301\n\tPopular\tLocol TAB dr 20mg 20's pack 361\n\tPopular\tLocol TAB dr 40mg 20's pack 481\n\tRadiant.\tFrenvas TAB dr 10mg 28's pack 338\n\tRadiant.\tFrenvas TAB dr 20mg  \n\tRAK\tAtovex TAB dr 10mg 30's pack 300\n\tRAK\tAtovex TAB dr 20mg 20's pack 320\n\tRAK\tAtovex TAB dr 40mg 10's pack 220\n\tRangs\tLipicut TAB dr 10mg 30's pack 240\n\tRangs\tLipicut TAB dr 20mg 20's pack 300\n\tRenata\tTaven TAB dr 10mg 30's pack 301\n\tRenata\tTaven TAB dr 20mg 30's pack 541.80\n\tRenata\tTaven TAB dr 40mg 30's pack 720\n\tRephco\tLipinor TAB dr 10mg 30's pack 210\n\tSanofi Aventis (BD) Ltd.\tOrva TAB dr 10mg 30's pack 301\n\tSanofi Aventis (BD) Ltd.\tOrva TAB dr 20mg 30's pack 542\n\tSanofi Aventis (BD) Ltd.\tOrva TAB dr 40mg 30's pack 750\n\tSharif\tLipovast TAB dr 10mg 30's pack 300\n\tSquare\tAnzitor TAB dr 10mg 50's pack 502\n\tSquare\tAnzitor TAB dr 20mg 30's pack 541.80\n\tSquare\tAnzitor TAB dr 40mg 10's pack 240.90\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAztor TAB dr 10mg 50's pack 502.50\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAztor TAB dr 20mg 30's pack 543\n\tSun Pharmaceutical (Bangladesh) Ltd.\tAztor TAB dr 40mg 30's pack 720\n\tSupreme\tAstiva TAB dr 10mg 10's pack 75\n\tTechno Drugs Ltd.\tLivas TAB dr 10mg 30's pack 300\n\tTechno Drugs Ltd.\tLivas TAB dr 20mg 20's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tStacor TAB dr 10mg 30's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tStacor TAB dr 20mg 20's pack 360\n\tUnimed & Unihealth Manufacturers Ltd.\tStacor TAB dr 40mg 10's pack 240\n\tVeritas\tLipistat TAB dr 10mg 30's pack 300\n\tVeritas\tLipistat TAB dr 20mg 30's pack 540\n\tWhite Horse Pharma\tAvocard TAB dr 10mg 30's pack 300\n\tWhite Horse Pharma\tAvocard TAB dr 20mg 20's pack 320\n\tWhite Horse Pharma\tAvocard TAB dr 40mg 30's pack 660\n\tIndication:  Primary hypercholesterolemia (heterozygous familial and nonfamilial), Mixed Dyslipidemia, Homozygous familial hypercholesterolemia, Hypertriglyceridemia, Familial hypercholesterolemia, Cardiovascular event prevention, Primary dysbetalipoproteinemia\n\nDose: Oral\nMixed dyslipidaemia, Heterozygous familial hypercholesterolaemia, Nonfamilial hypercholesterolaemia\nAdult: Initially, 10 or 20 mg once daily, may be adjusted at 4-wk interval. May initiate 40 mg once daily in patients who require >45% reduction in LDL-cholesterol. Max: 80 mg/day.\n\nChild: Heterozygous familial hypercholesterolaemia: 10-17 yr 10 mg once daily, may increase at intervals of at least 4 wk to max 20 mg/day.\nElderly: No dosage adjustment needed.\n\nAtorvastatin can be administered as a single dose at any time of the day, with or without food. Therapy should be individualized according to goal of therapy and response. After initiation and/or upon titration of Atorvastatin, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. Since the goal of treatment is to lower LDL-C, the LDL-C levels should be used to initiate and assess treatment response. Only if LDL-C levels are not available, should total-C be used to monitor therapy. \n\nHomozygous Familial Hypercholesterolemia: The dosage of Atorvastatin in patients with homozygous FH is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) in these patients or if such treatments are unavailable. \n\nDosage in Patients with Renal Insufficiency: Renal disease does not affect the plasma concentrations or LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary. \n\nPediatric Use: Treatment experience in a pediatric population is limited to doses of Atorvastatin up to 80 mg/day for 1 year in 8 patients with homozygous FH. No clinical or biochemical abnormalities were reported in these patients. None of these patients was below 9 years of age. \n\nGeriatric Use: Treatment experience in adultâs age 70 years with doses of Atorvastatin up to 80 mg/day has been evaluated. The safety and efficacy of Atorvastatin in this population were similar to those of patients <70 years of age.\n\n\nContra-indication: Hypersensitivity, active liver disease or unexplained persistent elevations of serum transaminase, porphyria, pregnancy, lactation.\n\nSide effects: Headache, flatulence, diarrhoea, nausea, vomiting, anorexia, xerostomia, angioedema, myalgia, rash/pruritus, alopecia, allergy, infection, chest pain.Potentially Fatal: Thrombocytopenia. Rhabdomyolysis with acute renal failure.\n\nPrecaution: Patients who consume substantial quantities of alcohol. History of liver disease. Patients with risk factors for myopathy or rhabdomyolysis. Hypothyroidism should be properly managed prior to starting statin therapy. Children <10 yr. Premenarcheal females.\n\nMode of action: May increase risk of myopathy and rhabdomyolysis w/ CYP3A4 potent inhibitor (e.g. HIV or HCV protease inhibitors, itraconazole, clarithromycin), fenofibrate, colchicines, fixed combination of lopinavir/ritonavir. May decrease plasma concentration w/ CYP3A4 inducer (e.g. rifampicin, efavirenz). May significantly increase AUC and peak plasma concentration of digoxin. Increased AUC for norethindrone and ethinyl estradiol.\nPotentially Fatal: Increased risk of myopathy or rhabdomyolysis w/ ciclosporin, gemfibrozil, telaprevir, tipranavir.\n\nPregnancy category: X\n\nInteraction: May increase risk of myopathy and rhabdomyolysis w/ CYP3A4 potent inhibitor (e.g. HIV or HCV protease inhibitors, itraconazole, clarithromycin), fenofibrate, colchicines, fixed combination of lopinavir/ritonavir. May decrease plasma concentration w/ CYP3A4 inducer (e.g. rifampicin, efavirenz). May significantly increase AUC and peak plasma concentration of digoxin. Increased AUC for norethindrone and ethinyl estradiol.\nPotentially Fatal: Increased risk of myopathy or rhabdomyolysis w/ ciclosporin, gemfibrozil, telaprevir, tipranavir.
Atracurium Besylate	\n\n\tChemist Ltd.\tAtrium Injection 25mg/2.5ml 2.5 ml amp x 5's pack 400\n\tGlaxoSmithKline Bangladesh Ltd.\tTracrium Injection 10mg/ml 2.5mlx5's pack 722.95\n\tTechno Drugs Ltd.\tRelaston Injection 25mg/2.5ml 2.5 ml amp x 5's pack 375\n\tTechno Drugs Ltd.\tRelaxtion Injection 25mg/2.5ml 5's pack 375\n\tTechno Drugs Ltd.\tRelaxton Injection 10mg/ml 2.5ml amp x 5's pack 375\n\tIndication: General anaesthesia, Endotracheal intubation, Aid controlled ventilation\n\nDose: Intravenous\nMuscle relaxant in general anaesthesia, Endotracheal intubation, Aid controlled ventilation\nAdult: Initially, 300-600 mcg/kg as inj. Subsequently, 100-200 mcg/kg when necessary or every 15-25 minutes for maintenance in prolonged procedures. Alternatively, maintenance can also be achieved by continuous infusion at 5-10 mcg/kg/minute. Initial dose should be given over 60 seconds in patients with CV disease. Dose should be calculated based on ideal body-weight in obese patients.\n\nChild: >2 mth: Initially, 400-500 mcg/kg as inj. Maintenance dose: 80-100 mcg/kg; first maintenance dose may be given 20-45 min after the initial dose, subsequently, may be repeated every 15-25 min. \n\nFor children 1 mth-2 yr: 300-400 mcg/kg may be used as initial dose in those who are under halothane anaesthesia. Maintenance doses may be admin more frequently in infant and children than adults.\n\nSpecial Populations: For patients with significant CV disease or any history (e.g. severe anaphylactoid reactions or asthma) suggesting a greater risk of histamine release, an initial dose of 0.3-0.4 mg/kg should be given slowly or in divided doses over 1 min. For adults receiving atracurium following the use of succinylcholine for intubation under balanced anesthesia, an initial dose of 0.3-0.4 mg/kg is recommended. Dosage reductions may be necessary in patients with neuromuscular disease, severe electrolyte disorders or carcinomatosis in which potentiation of neuromuscular block or difficulties with reversal have been demonstrated.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Cutaneous reactions; bradycardia, transient hypotension in patients with CVS disorders; dyspnoea, bronchospasm; rash and urticaria.\n\nPrecaution: Neonates; severe CVS disorders; renal or hepatic dysfunction; myasthenia gravis and other neuromuscular disorders; severe electrolyte imbalances; respiratory insufficiency or pulmonary disease, asthma; burns; cardiopulmonary bypass; smoking; pregnancy and lactation. Dosage for obese patients should be based on ideal body-weight to prevent overdosing.\n\nMode of action:  Mixed block with suxamethonium which is difficult to reverse with anticholinergic drugs. Ketamine may potentiate the effects of atracurium. Concurrent use with tamoxifen or danazol may prolong effects of atracurium.\nPotentially Fatal: Neuromuscular blockade potentiated by parenteral Mg salts, anaesthetics, aminoglycosides and polypeptide antibiotics, botulinum A toxin. Malignant hyperthermia with halogenated anaesthetics and succinylcholine. MAOIs.\n\nPregnancy category: C\n\nInteraction:  Mixed block with suxamethonium which is difficult to reverse with anticholinergic drugs. Ketamine may potentiate the effects of atracurium. Concurrent use with tamoxifen or danazol may prolong effects of atracurium.\nPotentially Fatal: Neuromuscular blockade potentiated by parenteral Mg salts, anaesthetics, aminoglycosides and polypeptide antibiotics, botulinum A toxin. Malignant hyperthermia with halogenated anaesthetics and succinylcholine. MAOIs.
Atropine Sulphate	\n\n\tChemist Ltd.\tAtropine Injection 0.6mg/ml 50 amps pack 126\n\tEdruc Ltd.\tAtropin Injection 0.6mg/ml 10 amps pack 30\n\tGeneral\tAtrogen Eye Drops 1 gm/100 ml  \n\tGonoshasthaya\tG Atropine Injection 0.6mg/ml 10 amps pack 31\n\tJayson\tAtropine Injection 1mg/ml 10 amps pack 50 IP\n\tS. N.\tAtropin Injection 0.6mg/ml 50's pack 126\n\tIndication: Bradycardia, Organophosphorus poisoning,  Anesthesia adjunct\n\nDose: Adult: IV Bradycardia 500 mcg every 3-5 mins. Total: 3 mg. \n\nIV/IM Organophosphorus poisoning 2 mg every 10-30 mins until muscarinic effects disappear or atropine toxicity appears. \nChild: 20 mcg/kg given every 5-10 minutes. \n\nIM/SC Premed in anesth 300-600 mcg 30-60 mins before anesth. \nChild: >20 kg: 300-600 mcg; 12-16 kg: 300 mcg; 7-9 kg: 200 mcg; >3 kg: 100 mcg. Doses to be given via IM/SC admin 30-60 minutes before anaesthesia. \n\nIV/IM/SC Poisoning or overdosage w/ compd having muscarinic actions 0.6-1 mg, repeat 2 hrly. \n\nContra-indication: Glaucoma, chronic respiratory disease, sick sinus syndrome, thyrotoxicosis, cardiac failure, pyloric stenosis, prostatic hypertrophy.\n\nSide effects: Dry mouth, dysphagia, constipation, flushing and dryness of skin, tachycardia, palpitations, arrhythmias, mydriasis, photophobia, cycloplegia, raised intraocular pressure. Toxic doses cause tachycardia, hyperpyrexia, restlessness, confusion, excitement, hallucinations, delirium and may progress to circulatory failure and resp depression. Eye drops: Systemic toxicity esp in children, on prolonged use may lead to irritation, hyperaemia, oedema and conjunctivitis. Increased intraocular pressure. Inhalation: Dryness of mouth, throat.\nPotentially Fatal: Atrial arrhythmias, AV dissociation, multiple ventricular ectopics.\n\nPrecaution: Reflux oesophagitis, elderly, infants and children. Pregnancy.\n\nMode of action: Additive anticholinergic effects with quinidine, antidepressants and some antihistamines.\n\nPregnancy category: C\n\nInteraction: Additive anticholinergic effects with quinidine, antidepressants and some antihistamines.
Atropine Sulphate 1%	\n\n\tG. A. Company Ltd.\tMydripine Eye Drops   10 ml bot 25.89\n\tG. A. Company Ltd.\tMydripine Eye Ointment  5 gm tube  14.31 \n\tGonoshasthaya\tG Atropine Eye Drops   10 ml bot 27.31\n\tKDH Ltd.\tAtropine Eye Drops   5ml drop 25.95\n\tKDH Ltd.\tAtropine Eye Ointment 1 % 4 gm tube  25\n\tNipa\tItropin Eye Drops   10 ml bot 25.29\n\tOpso Saline Ltd.\tAtropine OSL Eye Drops   5  ml vial 25.95\n\tOpso Saline Ltd.\tAtropine OSL Eye Ointment   3 gm tube 14.05\n\tReman Drug Ltd.\tMydri Atropine Eye Drops   5ml bot/10 ml bot 25 / 35\n\tReman Drug Ltd.\tMydri Atropine Eye Ointment  4 gm tube  25\n\tIndication: Keratitis, iritis, cyclitis, & refractive procedure in children. Mydriatic & cyclopplegic.\n\nDose: Ophthalmic\nInflammatory eye disorders\nAdult: Instill 1-2 drops of a 1% solution up to 4 times daily.\nChild: As sulfate: Instill 1 drop of a 1% solution up to tid.\n\nOintment: as required.\n\nEye refraction\nAdult: Instill 1 drop of a 1% solution bid for 1-2 days before the procedure, or on a single occasion 1 hr before the procedure.\nChild: As sulfate: Instill 1 or 2 drops of a 0.5% soln (or 1 drop of a 1% solution) bid for 1-3 days before the procedure, with a further dose given 1 hr before the procedure.\n\nContra-indication: Narrow angle glaucoma.\n\nSide effects: May precipitate glaucoma, contact dermatitis. \n\nPrecaution: Toxic systemic reaction may occur in the very young & very old.\n\nMode of action: Additive anticholinergic effects with quinidine, antidepressants and some antihistamines.\n\nPregnancy category: C\n\nInteraction: Additive anticholinergic effects with quinidine, antidepressants and some antihistamines.
Avobenzone 2% + Oxybenzone 3% + Padimate O 8% + Titanium dioxide	\n\n\tIncepta\tSolascren Lotion   400 1's pack\n\tIndication: Sunblock, Solar urticaria, Acute solar dermatitis, Acute lupus erythematosus, Herpes simplex, Polymorphic light eruption, Cutaneous albinism, Vitiligo, Drug-induced photosensitivity\n\nDose: Apply 45 minutes before swimming or sweat producing exercise. A single application may give day-long protection but the product should be re-applied during prolonged periods of sunning and after swimming or excessive sweating.\n\nContra-indication: The drug is contraindicated in individuals with a history of sensitivity reactions to any of the components of the preparation.\n\nSide effects: Signs of irritations (including erythema, burning or rash) may appear when applied to sensitive or broken skin.\n\nPrecaution: Application to broken skin should be avoided. Contact with the eyes and other mucous membranes should be avoided.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Azelaic Acid 20%	\n\n\tAcme Ltd.\tAzelec 20% Cream   10gm tube 75.28\n\tUnimed & Unihealth Manufacturers Ltd.\tAcnezac Cream 20 gm/100 gm  \n\tIndication: Acne vulgaris, Rosacea, Rosacea melasma, Post inflammatory hyperpigmentation\n\nDose: Adult: Topical Acne As a 20% cream: Apply twice daily onto the affected areas. \nRosacea: Apply twice daily onto the affected areas.\n\nContra-indication: Hypersensitivity to any of the ingredients.\n\nSide effects: Local skin irritation (e.g. erythema, scaling, itching or burning). Hypopigmentation and rarely, photosensitivity reactions.\n\nPrecaution: Pregnancy, lactation. Avoid contact with eyes, mouth or other mucous membranes. Occlusive dressings or wrappings should not be used. Recommend patient to use only very mild soaps or soapless cleansing lotions for facial washing. Monitor for hypopigmentation in patients with dark complexion. Safety and efficacy not established in children <12 yr.\n\nMode of action: There have been no formal studies of the interaction of Azelaic Acid Gel with other drugs.\n\nPregnancy category: B\n\nInteraction: There have been no formal studies of the interaction of Azelaic Acid Gel with other drugs.
Azelastin Hydrochloride Nasal prep	\n\n\tIncepta\tAzelast Nasal Spray 137mcg 120 dose (spray) unit 180\n\tOpsonin Pharma\tZelanex Nasal Spray 137mcg 120md drop 180\n\tSquare\tSnizex Nasal Spray 137mcg 120 dose (spray) unit 180.68\n\tIndication: Allergic rhinitis, vasomotor rhinitis.\n\nDose: Nasal Rhinitis: Children 5 years to 11 years of age: One spray into each nostril twice daily.\nAdults and children 12 years of age and older: Two sprays per nostril twice daily.\n\nContra-indication:  Known hypersensitivity to Azelastine Hydrochloride or any of its components.\n\nSide effects: Irritation, stinging and itching of the nasal mucosa. Sneezing, nosebleeds, headache; nausea, taste disturbances, somnolence, dry mouth.\n\nPrecaution: In clinical trials, the occurrence of somnolence has been reported in some patients taking Azelastine Hydrochloride Nasal Spray; due caution should therefore be exercised when driving a car or operating potentially dangerous machinery. Concurrent use of Azelastine Hydrochloride Nasal Spray with Alcohol or other CNS depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Azithromycin	\n\n\tACI\tOdazyth Powder for Suspension 200mg/5ml 15ml bot/30ml bot/50ml bot 85.58/130.88/186.26\n\tACI\tOdazyth TAB dr 500mg 12's pack 421.32\n\tACI\tOdazyth CAP 250mg 12's pack 300.96\n\tACI\tOdazyth SR Powder For Suspension 2g 75ml bot 250.75\n\tAcme Ltd.\tAzin Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85.32/130.49\n\tAcme Ltd.\tAzin CAP 250mg 6's pack 120.42\n\tAcme Ltd.\tAzin TAB dr 500mg 3's pack/6's pack 90.33/180.66\n\tAcme Ltd.\tAzin Injection 500mg  \n\tAd-din\tVinzam TAB dr 500 mg  \n\tAd-din\tVinzam Powder For Suspension 200 mg/5 ml  \n\tAlco Pharma\tZinex TAB dr 250mg 6's pack 120\n\tAlco Pharma\tZinex TAB dr 500mg 8's pack 240\n\tAlco Pharma\tZinexs Powder for Suspension 200mg/5ml 15ml bot/30ml bot 80/130\n\tAmbee\tMyzid TAB dr 500mg  \n\tAmbee\tMyzid TAB dr 250mg  \n\tAmico Ltd.\tAzix Powder for Suspension 200mg/5ml 15ml bot 85\n\tAmico Ltd.\tAzix TAB dr 500mg 6's pack 180\n\tAmulet\tAmzith Powder for Suspension 200mg/5ml 30ml bot\n 130\n\tAmulet\tAmzith TAB dr 500mg 12's pack 360\n\tAmulet\tAmzith CAP 250mg  \n\tAPC Pharma Ltd.\tZiocin-500 TAB dr 500mg 3's pack 90\n\tApex\tAzinil Powder for Suspension 200mg/5ml 20ml bot/35ml bot 80/130\n\tApex\tAzinil TAB dr 250mg 6's pack 120\n\tApex\tAzinil TAB dr 500mg 6's pack 180\n\tApollo Pharmaceutical Ltd.\tApozyth TAB dr 500mg 12's pack 360\n\tAristopharma\tAZ Powder for Suspension 200mg/5ml 20ml bot/35ml bot/50ml bot 100/140/200\n\tAristopharma\tAz CAP 250mg 10's pack 200\n\tAristopharma\tAz CAP 500mg 9's pack 270\n\tAristopharma\tAz TAB dr 500mg 9's pack 315\n\tAsiatic Ltd.\tAsizith Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tAsiatic Ltd.\tAsizith TAB dr 250mg 6's pack 120\n\tAsiatic Ltd.\tAsizith TAB dr 500mg 6's pack 180\n\tBeacon\tSimpli Injection 500mg 1 amps pack 460\n\tBeacon\tSimpli TAB dr 500mg 8's pack 280.88\n\tBeacon\tSimpli-3 Suspension 200mg 15ml bot  / 35 ml bot 85 / 130.49\n\tBelsen\tAzirex TAB dr 500mg 6's pack 180\n\tBenham\tBenzith Powder for Suspension 200mg/5ml 15ml bot 90\n\tBenham\tBenzith CAP 500mg 8' pack 240\n\tBeximco\tAzithrocin Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tBeximco\tAzithrocin CAP 250mg 10's pack 200\n\tBeximco\tAzithrocin TAB dr 500mg 9's pack 270\n\tBeximco\tAzithrocin IV IV Injection 500mg 1's combipack 460\n\tBio Pharma Ltd.\tMaczith Powder for Suspension 200mg/5ml 15ml bot/25ml bot 85.32/130.49\n\tBio Pharma Ltd.\tMaczith CAP 250mg 6's pack 120.48\n\tBio Pharma Ltd.\tMaczith TAB dr 250mg 6's pack 120.48\n\tBio Pharma Ltd.\tMaczith TAB dr 500mg 12's pack 361.32\n\tBristol Pharma Ltd.\tBP-Z Powder for Suspension 200mg/5ml 15ml bot 85\n\tBristol Pharma Ltd.\tBP-Z TAB dr 500mg 6's pack 180\n\tBristol Pharma Ltd.\tBp-Z CAP 500mg 3' pack 90\n\tCentral.\tAzitor TAB dr 500mg 5's pack 150\n\tChemist Ltd.\tAzithin Powder for Suspension 200mg/5ml 15ml bot/35ml bot 85/130\n\tChemist Ltd.\tAzithin CAP 500mg 8's pack 240\n\tConcord\tMacrobac Powder for Suspension 200mg/5ml 15ml bot/25ml bot/35ml bot 85/120/135\n\tConcord\tMacrobac TAB dr 500mg 6's pack 180\n\tCosmic Chemical Industries Ltd.\tAzitel CAP 500mg 8's pack 240\n\tCosmic Chemical Industries Ltd.\tAzitel Suspension 200mg 15 ml bot / 30 ml bot  85 / 130\n\tDecent Pharma Ltd.\tDemacro Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/120\n\tDecent Pharma Ltd.\tDemacro TAB dr 500mg 8's pack 240\n\tDelta Pharma\tAzo Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tDelta Pharma\tAzo TAB dr 500mg 9's pack 270\n\tDesh\tAzilit Powder for Suspension 200mg/5ml 15ml bot 85\n\tDesh\tAzilit TAB dr 500mg 3's pack 90\n\tDoctor Tims\tMy-Azi Powder For Suspension 200 mg/5 ml  \n\tDoctor Tims\tMy-Azi TAB dr 500mg  \n\tDoctor's Chemicals Works Ltd.\tIlozin TAB dr 500mg 8's  pack 240\n\tDoctor's Chemicals Works Ltd.\tIlozin Suspension 200mg 15ml bot  / 30 ml bot 85 / 130\n\tDrug International Ltd.\tAzimex Powder for Suspension 200mg/5ml 15ml bot/30ml bot 90/130\n\tDrug International Ltd.\tAzimex TAB dr 250mg 20's pack 400\n\tDrug International Ltd.\tAzimex TAB dr 500mg 9's pack 270\n\tDrug International Ltd.\tAzimex CAP 250mg  \n\tDrug International Ltd.\tAzimex CAP 500mg  \n\tDrug International Ltd.\tAzimex Injection 500mg  \n\tEdruc Ltd.\tEzith Powder for Suspension 200mg/5ml 15ml bot 85\n\tEdruc Ltd.\tEzith TAB dr 500mg 3's pack 90\n\tEskayef Bangladesh Ltd.\tZithrox Powder for Suspension 200mg/5ml 20ml bot/35ml bot/50ml bot 85/130/180\n\tEskayef Bangladesh Ltd.\tZithrox TAB dr 250mg 6's pack 120\n\tEskayef Bangladesh Ltd.\tZithrox TAB dr 500mg 12's pack 363.96\n\tEuro Pharma Ltd.\tAdiz Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tEuro Pharma Ltd.\tAdiz TAB dr 500mg 8's pack 240\n\tEuro Pharma Ltd.\tAdiz Suspension 200mg/5 ml 35ml  130\n\tEverest\tATM Powder for Suspension 200mg/5ml 15ml bot/35ml bot 85/130\n\tEverest\tATM TAB dr 500mg 6's pack 180\n\tEverest\tAtm Suspension 200mg 35ml bot 130\n\tF N F\tNuzith TAB dr 500mg  \n\tF N F\tNuzith Powder For Suspension 200 mg/5 ml  \n\tG. A. Company Ltd.\tZemycin Powder for Suspension 200mg/5ml 15ml bot 85\n\tG. A. Company Ltd.\tZemycin TAB dr 500mg 3's pack 90\n\tGeneral\tAzomac Powder for Suspension 200mg/5ml 15ml bot/35ml bot 85.32/130.49\n\tGeneral\tAzomac TAB dr 500mg 6's pack 180.66\n\tGlobe\tZycin Powder for Suspension 200mg/5ml 15ml bot/30ml bot 80/120\n\tGlobe\tZycin TAB dr 500mg 6's pack 180\n\tGlobex\tAzithral TAB dr 500mg 12's pack 360\n\tGlobex\tAzithral Powder For Suspension 200 mg/5 ml 30 ml 130\n\tGuardian Healthcare Ltd.\tAzee TAB dr 500mg  \n\tHallmark\tMazith Powder for Suspension 200mg/5ml 15ml bot/25ml bot 85.32/110.42\n\tHallmark\tMazith TAB dr 500mg 5's pack/12's pack 140/336\n\tHealthcare\tRozith Powder for Suspension 200mg/5ml 15ml bot/22.5ml bot/35ml bot/50ml bot 85/90/130/185\n\tHealthcare\tRozith TAB dr 250mg 6's pack 120\n\tHealthcare\tRozith TAB dr 500mg 3's pack 90\n\tHealthcare\tRozith IV Injection 500mg 1 amps pack 460\n\tHudson\tSoto A TAB dr 500mg 8's pack 240\n\tHudson\tSoto Suspension 200mg 15ml bot 85 \n\tIbn Sina Pharmaceutical Ind. Ltd.\tRomycin Powder for Suspension 200mg/5ml 15ml bot/20ml bot/35ml bot/50ml bot 90/100/135/190\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRomycin CAP 250mg 8's pack 160\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRomycin TAB dr 500mg 12's pack 420\n\tIncepta\tTridosil Powder for Suspension 200mg/5ml 15ml bot/30ml bot/35ml bot/50ml bot 85/130/140/185\n\tIncepta\tTridosil Injection 500mg 1 amps pack 460\n\tIncepta\tTridosil TAB dr 250mg 6's pack 150\n\tIncepta\tTridosil TAB dr 500mg 12's pack 420\n\tIndobangla Pharmaceuticals\tIndozith CAP 250mg 6's pack 180\n\tIndobangla Pharmaceuticals\tIndozith TAB dr 500mg 6's pack 180\n\tIndobangla Pharmaceuticals\tIndozith Suspension 200mg 15ml bot  / 35 ml bot 85 / 120\n\tJayson\tCinalid Powder for Suspension 200mg/5ml 15ml bot 75.29\n\tJayson\tCinalid TAB dr 500mg 3's pack 75.30\n\tKemiko\tZita Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tKemiko\tZita TAB dr 500mg 3's pack/6's pack 90/180\n\tKumudini Pharma Ltd.\tThiza Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tKumudini Pharma Ltd.\tThiza TAB dr 500mg 8's pack 240\n\tLabaid\tAzilab 500 TAB dr 500mg 2x3's pack 300\n\tLabaid\tAzilab Powder for suspension  35 ml bot 165\n\tLeon\tNovazith TAB dr 500mg 2x5's pack \n\tLeon\tNovazith Powder for suspension 200mg/5ml 15ml bot \n\tLeon\tNovazith Suspension 200mg/5ml  \n\tMarksman.\tNeozith TAB dr 500mg 3's pack 90\n\tMarksman.\tNeozith Suspension 200mg 15ml bot  85 \n\tMedicon\tZitrex Powder for Suspension 200mg/5ml 20ml bot/35ml bot 85/130\n\tMedicon\tZitrex TAB dr 500mg 8's pack 240\n\tMedimet\tAzimete TAB dr 500mg 4's pack 120\n\tMedimet\tAzimet Suspension 200mg 15ml bot/30ml bot 85 / 130\n\tMillat\tHyzith Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tMillat\tHyzith TAB dr 500mg 3's pack/6's pack 90/180\n\tModern\tAzmin TAB dr 500mg 8's pack 224\n\tMonicopharma\tAzimon Powder for Suspension 200mg/5ml 15ml bot/30ml bot 90/130\n\tMonicopharma\tAzimon TAB dr 500mg 8's pack 240\n\tMystic\tZithrolex Powder for Suspension 200mg/5ml 15ml bot 84\n\tMystic\tZithrolex TAB dr 250mg 6's pack 114\n\tMystic\tZithrolex TAB dr 500mg 3's pack 84\n\tNavana\tAzirox Powder for Suspension 200mg/5ml 20ml bot/35ml bot 85/130\n\tNavana\tAzirox TAB dr 500mg 9's pack 270.99\n\tNipa\tAzro TAB dr 500mg 12's pack 360\n\tNipa\tAzro Powder For Suspension 200 mg/5 ml  \n\tNIPRO JMI Pharma\tAzaltic Powder for Suspension 200mg/5ml 15ml bot/35ml bot 85/130\n\tNIPRO JMI Pharma\tAzaltic TAB dr 500mg 6's pack 180\n\tNovartis (Bangladesh) Ltd.\tAzyth Powder for Suspension 200mg/5ml 15ml bot/30ml bot 100/140\n\tNovartis (Bangladesh) Ltd.\tAzyth CAP 250mg 10's pack 300\n\tNovartis (Bangladesh) Ltd.\tAzyth TAB dr 500mg 6's pack 300\n\tNovo Healthcare and Pharma Ltd.\tThromax TAB dr 250mg 6's pack 120\n\tNovo Healthcare and Pharma Ltd.\tThromax TAB dr 500mg 6's pack 180\n\tNovo Healthcare and Pharma Ltd.\tThromax Suspension 200mg 15ml bot/ 25ml bot / 35ml bot 90 / 110 / 130\n\tNovus\tN Zith TAB dr 500mg 6's pack 180\n\tNovus\tN-zith Suspension 200mg 15ml bot  85 \n\tNuvista Pharma Ltd\tZunami TAB dr 500 mg 5's pack 275.85\n\tOpso Saline Ltd.\tZixin TAB dr 500mg  \n\tOpsonin Pharma\tAzicin Powder for Suspension 200mg/5ml 20ml bot/35ml bot/50ml bot 85.32/130.49/185.70\n\tOpsonin Pharma\tAzicin CAP 250mg 6's pack 120\n\tOpsonin Pharma\tAzicin TAB dr 250mg 6's pack 120\n\tOpsonin Pharma\tAzicin CAP 500mg 6's pack 180\n\tOpsonin Pharma\tAzicin TAB dr 500mg 6's pack 180\n\tOpsonin Pharma\tAzicin Dry Powder Sachet 1gm  \n\tOpsonin Pharma\tAzicin Powder For Suspension 2gm  \n\tOrganic Health Care\tOrgazith CAP 500mg  \n\tOrganic Health Care\tOrgazith CAP 250mg  \n\tOrganic Health Care\tOrgazith Powder For Suspension 200 mg/5 ml  \n\tOrion Pharma Ltd.\tAzalid Powder for Suspension 200mg/5ml 15ml bot/35ml bot/50ml bot 85.32/130/160\n\tOrion Pharma Ltd.\tAzalid CAP 250mg 6's pack 120.48\n\tOrion Pharma Ltd.\tAzalid CAP 500mg 8's pack 240.88\n\tOyster\tXerion TAB dr 500mg  \n\tPacific\tMacazi Powder for Suspension 200mg/5ml 15ml bot/35ml bot 64/118\n\tPacific\tMacazi TAB dr 500mg 3's pack/6's pack 89.40/178.80\n\tPeoples Pharma Ltd.\tFizyth TAB dr 500mg 8's  pack / 12's pack 176 / 280\n\tPharmadesh Ltd.\tZithro Powder for Suspension 200mg/5ml 15ml bot/30ml bot 86.11/125.47\n\tPharmadesh Ltd.\tZithro CAP 250mg 6's pack 120.36\n\tPharmasia Ltd.\tAzexia Powder for Suspension 200mg/5ml 20ml bot/35ml bot 80.31/130\n\tPharmasia Ltd.\tAzexia TAB dr 500mg 3's pack/6's pack 90.33/180.66\n\tPopular\tZibac Powder for Suspension 200mg/5ml 15ml bot/20ml bot/25ml bot/35ml bot/50ml bot 85.32/100/115/130.48/185.\n\tPopular\tZibac Injection 500mg 1 amps pack 461.74\n\tPopular\tZibac TAB dr 250mg 8's pack 160.64\n\tPopular\tZibac TAB dr 500mg 18's pack 541.98\n\tPrime\tPrizyth TAB dr 500mg  \n\tPrime\tPrizyth Powder For Suspension 200 mg/5 ml  \n\tRadiant.\tAcos TAB dr 500mg 6's pack 330\n\tRadiant.\tXolide Powder for Suspension 200mg/5ml 30ml bot 145\n\tRadiant.\tXolide CAP 250mg 6's pack 162\n\tRadiant.\tXolide CAP 500mg 6's pack 240\n\tRadiant.\tAcos Suspension 30ml 30ml bot \n\tRAK\tRazithro Powder for Suspension 200mg/5ml 15ml bot/35ml bot 85/130\n\tRAK\tRazithro TAB dr 500mg 6's pack 180\n\tRangs\tRanzith Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tRangs\tRanzith CAP 250mg 6's pack 120\n\tRangs\tRanzith TAB dr 500mg 6's pack 180\n\tReliance\tAM Powder for Suspension 200mg/5ml 30ml bot 85\n\tReliance\tAM TAB dr 500mg 10's pack 300\n\tRenata\tZithrin Powder for Suspension 200mg/5ml 15ml bot/20ml bot/35ml bot/50ml bot 80.30/85.32/130/185\n\tRenata\tZithrin CAP 250mg 12's pack 240.84\n\tRenata\tZithrin TAB dr 250mg 12's pack 216.84\n\tRenata\tZithrin TAB dr 500mg 12's pack 361.32\n\tRenata\tZithrin IV Infusion 500mg 1's pack 460\n\tRephco\tPenalox Powder for Suspension 200mg/5ml 15ml bot/30ml bot 95/130\n\tRephco\tPenalox CAP 500mg 6's pack 180\n\tS. N.\tAzebac TAB dr 500mg 12's pack 361.32\n\tSanofi Aventis (BD) Ltd.\tCurazith Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tSanofi Aventis (BD) Ltd.\tCurazith TAB dr 250mg 6's pack 120\n\tSanofi Aventis (BD) Ltd.\tCurazith TAB dr 500mg 12's pack 360\n\tSeema\tAzi-S 500 TAB dr 500mg 6's pack 160\n\tSeema\tAzi-S Suspension 200mg 15 ml bot 100\n\tShamsul Al-Amin\tPhagocin Powder for Suspension 200mg/5ml 15ml bot/35ml bot 85/130\n\tShamsul Al-Amin\tPhagocin TAB dr 500mg 8's pack 240\n\tSharif\tAzasite Powder for Suspension 200mg/5ml 20ml bot/35ml bot 85/130\n\tSharif\tAzasite TAB dr 500mg 8's pack 240\n\tSilva\tMacrozith Powder for Suspension 200mg/5ml 15ml bot/25ml bot 85.32/115.43\n\tSilva\tMacrozith CAP 250mg 6's pack 120.44\n\tSilva\tMacrozith TAB dr 500mg 6's pack 180.68\n\tSomatec\tRespazit Powder for Suspension 200mg/5ml 15ml bot/20ml bot/30ml bot 80.30/85.32/130.49\n\tSomatec\tRespazit CAP 250mg 6's pack 120.48\n\tSomatec\tRespazit TAB dr 500mg 3's pack/6's pack 84.30/168.60\n\tSquare\tZimax Powder for Suspension 200mg/5ml 15ml bot/30ml bot/50ml bot 85.32/130.49/185.69\n\tSquare\tZimax CAP 250mg 12's pack 300\n\tSquare\tZimax TAB dr 500mg 12's pack 420\n\tSquare\tZimax IV Injection 500mg 1's pack 460\n\tStandard Ltd.\tAzocin TAB dr 500mg  \n\tStandard Ltd.\tAzocin Powder For Suspension 200 mg/5 ml  \n\tSunypun.\tSunzith TAB dr 500mg  \n\tSunypun.\tSunzith Powder For Suspension 200 mg/5 ml  \n\tSyntho Ltd.\tAzitra 500 TAB dr 500mg 3' pack 75\n\tTechno Drugs Ltd.\tAvalon Powder for Suspension 200mg/5ml 15ml bot/30ml bot 85/130\n\tTechno Drugs Ltd.\tAvalon Injection 500mg 1 amps pack 240\n\tTechno Drugs Ltd.\tAvalon TAB dr 500mg 6's pack 180\n\tTechno Drugs Ltd.\tAvalon Suspension 200mg 30ml bot 130\n\tUnimed & Unihealth Manufacturers Ltd.\tOdaz Powder for Suspension 200mg/5ml 15ml bot/30ml bot 90/140\n\tUnimed & Unihealth Manufacturers Ltd.\tOdaz TAB dr 500mg 6's pack 210\n\tVeritas\tVerizith CAP 250mg  \n\tVeritas\tVerizith TAB dr 500mg  \n\tVeritas\tVerizith Powder For Suspension 200 mg/5 ml  \n\tVirgo\tVirzith Powder For Suspension 200 mg/5 ml  \n\tWhite Horse Pharma\tTruzith TAB dr 500mg 8's pack 240\n\tZenith\tZenicin Powder for Suspension 200mg/5ml 15ml bot/50ml bot 82/200\n\tZenith\tZenicin TAB dr 500mg 6's pack 168\n\tZiska\tAzithromax TAB dr 500mg 2x5's pack 150\n\tZiska\tAzithromax Suspension 200mg/5ml 15 ml bot / 35 ml bot / 50 ml bot 85 / 130/185\n\tAllied\tZylomax TAB dr 500mg  \n\tAllied\tZylomax Powder For Suspension 200 mg/5 ml  \n\tOne Pharma Ltd.\tAzikil TAB dr 500mg  \n\tOne Pharma Ltd.\tAzikil Powder 10 gm/100 gm  \n\tOne Pharma Ltd.\tAzikil Powder For Suspension 200 mg/5 ml  \n\tMedRx Life Science Ltd.\tMedzith Powder For Suspension 200 mg/5 ml  \n\tIndication: Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,							\n\n\nDose: Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose. \n\nProphylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials. \nUncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely. \nActive immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days. \n\nIV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy. \n\nPelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.\n\nChild: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days. \n\nContra-indication: Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.\n\nSide effects: GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.\nPotentially Fatal: Angioedema and cholestatic jaundice.\n\nPrecaution: May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.\n\nMode of action: Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.\nPotentially Fatal: Increased risk of cardiotoxicity w/ pimozide.\n\nPregnancy category: B\n\nInteraction: Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.\nPotentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
Azithromycin 1%  Eye drop	\n\n\tACI\tOdazyth Eye Drops   2.5 ml drop 110.41\n\tAcme Ltd.\tAzin Eye Drops 1 gm/100 ml  \n\tApex\tAzinil Eye Drops   2.5ml bot 110\n\tAristopharma\tAZ Eye Drops   2.5 ml drop 120\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRomycin Eye Drops   2.5 ml drop 115\n\tKemiko\tZita Eye Drops   2.5ml drop 120\n\tOpsonin Pharma\tAzicin Eye Drops 1 gm/100 ml  \n\tPopular\tZibac Eye Drops  1 gm/100 ml 2.5 ml drop 110.41\n\tSquare\tZimax Eye Drops  1 gm/100 ml  5 ml drop 110\n\tIndication: Bacterial Conjunctivitis, Neonatal Conjunctivitis, Blepharitis\n\nDose: Adult: Instill 1 drop in the affected eye(s) bid for 2 days, then once daily for the next 5 days.\n\n\n\nContra-indication: Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.\n\nSide effects: GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.\nPotentially Fatal: Angioedema and cholestatic jaundice.\n\nPrecaution: Anaphylaxis and hypersensitivity have been reported with systemic use of azithromycin . Growth of resistant organisms may occur with prolonged use. patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.\n\nMode of action: Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.\nPotentially Fatal: Increased risk of cardiotoxicity w/ pimozide.\n\nPregnancy category: B\n\nInteraction: Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.\nPotentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
Aztreonam	\n\n\tIncepta\tAzonam Injection 1gm/vial 1's pack 400\n\tSquare\tAtreon Injection 0.5g 1's pack 300\n\tSquare\tAtreon Injection 1g 1's pack 450\n\tSquare\tAtreon Injection 2g 1's pack 650\n\tIndication: Cystic fibrosis, Peritonitis, Bacterial infections, UTI, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Septicemia, Skin and Skin-Structure Infections, Endometritis, Pelvic cellulitis\n\nDose: Adult: IV/IM Gm-ve infections 1-8 g/day in divided doses depending on severity. Max: 8 g/day. \nUTI 0.5-1 g 8-12 hrly. \nIM Cystitis; Gonorrhoea 1 g as a single dose.\n\nChild: and infants >1 wk: 30 mg/kg every 6 or 8 hr; >2 yr: 50 mg/kg every 6 or 8 hr for severe infections. Dose may be given via deep IM inj or slow IV inj or infusion. Doses >1 g should be given via IV route. Max (>2 yr): 8 g/day. \n\nRenal impairment: Moderate to severe impairment: Same initial doses, adjust maintenance doses according to the patient's CrCl. Haemodialysis: A supplementary dose of 1/8 of the initial dose may be given after each session.\nCrCl (ml/min)	\n10-30	Maintenance dose: Half of initial dose.\n<10 	Maintenance dose: One-quarter of initial dose.\n\nContra-indication:  Hypersensitivity; lactation.\n\nSide effects: IV: Phloebitis and thrombophloebitis. IM: Pain and swelling at inj site; diarrhoea, nausea, vomiting, altered taste; jaundice, hepatitis, high liver enzymes; long prothrombin time, partial thromboplastin time; rash, urticaria, eosinophilia.\nPotentially Fatal: Thrombocytopenia, neutropenia; overgrowth of susceptible organisms; pseudomembranous colitis.\n\nPrecaution: Hypersensitivity to other beta-lactams; renal and hepatic impairment; pregnancy.\n\nMode of action: Concurrent use with oral anticoagulants may increase prothrombin time.\n\nPregnancy category: B\n\nInteraction: Concurrent use with oral anticoagulants may increase prothrombin time.
Bacitracin Zinc + Neomycin Sulphate Topical	\n\n\tACI\tNeocitrin Powder  5mg+4.56mg/g 10gm powder 20.14\n\tAcme Ltd.\tNeotracin Powder   5's pack/10's pack 10.15 / 20.07\n\tAcme Ltd.\tNeotracin Ointment  10 gm tube 17.42\n\tAlco Pharma\tNenol Powder   5gm powder 10\n\tBio Pharma Ltd.\tNuba Ointment   20gm  tube 40.15\n\tCosmic Chemical Industries Ltd.\tBioderm Ointment   15gm  tubex 12's pack 384\n\tDrug International Ltd.\tNeo-B Ointment 10mg/gm 10 gm tube 14.50\n\tEdruc Ltd.\tDerma Aid Powder   5gm powder4.56gm powder 10 IP\n\tEdruc Ltd.\tDerma Aid Ointment   5gm pack 10\n\tG. A. Company Ltd.\tB Mycin Powder   5gm pack 10\n\tGlaxoSmithKline Bangladesh Ltd.\tNeobacrin Ointment   20gm  tube 44.06\n\tIncepta\tNebazin Ointment   20gm  tube 43.90\n\tJayson\tNebason Ointment   10gm  tube 17.36\n\tKemiko\tNeobacin Ointment   10gm  tube/20gm  tube 12.80 / 43.90\n\tMedicon\tMebalon Powder   4.56gm powder / 10gm powder 10.20 / 20\n\tMystic\tNSB Ointment   10gm  tube 12.55\n\tNovartis (Bangladesh) Ltd.\tBivacyn Spray  150ml bot 244.95\n\tOpsonin Pharma\tNeocin Powder  25's pack 253.75\n\tOpsonin Pharma\tNeocin Ointment   10gm  tube 17.36\n\tPharmadesh Ltd.\tNebacin Ointment   10gm  tube 18.25\n\tRephco\tNeobac Ointment   10gm  tube 25\n\tSomatec\tTybac Powder   5gm  tube 10.04\n\tSquare\tNebanol Powder  250 IU + 5 mg/gm 6's pack / 1's pack 120.42 / 20.7\n\tSquare\tNebanol Ointment  500 IU + 5 mg/gm 20gm  tube 44.06\n\tIndication: Bacterial skin infections\n\nDose: Adult: Topical: Cream: Apply 3 times/day. \nPowder: Apply 2-4 times/day.\n\nContra-indication: Hypersensitivity to aminoglycosides. Pre-existing nerve deafness. Neonates and infants <2 yr.\n\nSide effects: Hypersensitivity reactions. Possibility of ototoxicity and nephrotoxicity if used in large quantities or on large areas for prolonged use.\n\nPrecaution: Neuromuscular disorders, hearing impaired, extensive skin damage. Avoid application in large quantities and prolonged use. Do not use if tympanic membrane is perforated. Pregnancy and lactation. Liver and renal impairment.\n\nMode of action: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\nNeomycin Sulphate: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\n\n\nPregnancy category: A\n\nInteraction: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\nNeomycin Sulphate: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\n
Bacitracin Zinc + Neomycin Sulphate + Polymixin B	\n\n\tBio Pharma Ltd.\tNuba Plus Ointment   10gm  tube 30.11\n\tGeneral\tNeogen PLUS Ointment   10gm  tube 30.11\n\tOpsonin Pharma\tNeocin Plus Ointment   10gm  tube 30\n\tSquare\tNebanol PLUS Ointment  400 IU + 3.5 mg + 5000 I 10gm  tube 30.11\n\tIndication: Minor cuts, Scrapes, Burns, Eczematoid dermatitis, Neurodermatitis, Eczema, Anogenital pruritus, Impetigo, Contact dermatitis, Bacterial skin infections\n\nDose: Apply the ointment in the affected eye every 3 or 4 hours, depending on the severity of the condition. Not more than 8 grams should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in precaution above.\n\nContra-indication: Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is contraindicated in most viral diseases of the cornea and conjunctiva including: epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is also contraindicated in individuals who have shown hypersensitivity to any of its components. Hypersensitivity to the antibiotic component occurs at a higher rate than for other components.\n\nSide effects: Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. The exact incidence is not known. Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitization reactions including itching, swelling, and conjunctival erythema . \n\nMore serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. The reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.\n\nSecondary Infection: The development of the secondary ocular infection has occurred after use of combinations containing corticosteroids and antimicrobials. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of a corticosteroid. The possibility of fungal invasion must be considered in any persistent corneal ulceration where corticosteroid treatment has been used . Local irritation on installation has been reported.\n\nPrecaution:  The initial prescription and renewal of the medication order beyond 8 grams should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated. \n\nAs fungal infections of the cornea are particularly prone to develop coincidentally with long-term corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate. If this product is used for 10 days or longer, intraocular pressure should be monitored. \n\nThere have been reports of bacterial keratitis associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface. \n\nAllergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.\n\nMode of action: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\nNeomycin Sulphate: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\nPolymixin B: Potentially Fatal: Additive neurotoxic or nephrotoxic effect w/ bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, colistin. Increased risk of resp paralysis w/ neuromuscular blockers (e.g. anaesthetics, muscle relaxants).\n\nPregnancy category: C\n\nInteraction: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\nNeomycin Sulphate: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\nPolymixin B: Potentially Fatal: Additive neurotoxic or nephrotoxic effect w/ bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, colistin. Increased risk of resp paralysis w/ neuromuscular blockers (e.g. anaesthetics, muscle relaxants).
Bacitracin Zinc + Neomycin Sulphate Eye prep	\n\n\tAcme Ltd.\tNeotracin Eye Ointment   5gm tube 17.42\n\tOpso Saline Ltd.\tNeobac Eye Ointment   3gm tube 12.85\n\tIndication: Bacterial ocular infections\n\nDose: Before use, the area for application should be cleaned gently. Debris such as pus or crusts should be removed from the affected area.\nA thin film to be applied 2 to 4 times daily\n\nContra-indication: Not for use in the eyes or in the external ear canal if the eardrum is perforated. This product is contraindicated in those individuals who have shown hypersensitivity to any of its components.\n\nSide effects: Generally this preparation is well tolerated. However, a low order of toxicity may be occurred like rashes and allergic anaphylactoid reactions in some patients. If itching, burning, inflammation or other signs of sensitivity occur during therapy, patients should be advised to discontinue the drug and consult a physician. \n\nPrecaution: Patients considering self-medication with a topical anti-infective for deep or puncture wounds, animal bites, or serious burns should be advised to first consult a physician. Patients using the preparations for the prevention of infection in minor skin injuries (e.g., cuts, scrapes, burns) should be advised to discontinue the topical anti-infective preparation and consult a physician if the condition persists or worsens; it should not be used for longer than 1 week unless directed by a physician.\n\nMode of action: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\nNeomycin Sulphate: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\n\n\nPregnancy category: A\n\nInteraction: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\nNeomycin Sulphate: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\n
Bacitracin Zinc + Polymixin B Sulphate Eye prep	\n\n\tIbn Sina Pharmaceutical Ind. Ltd.\tPolytracin Eye Ointment   5gm tube 65\n\tOpso Saline Ltd.\tPolymix Eye Ointment   5gm tube 35.13\n\tIndication: Bacterial ocular infections\n\nDose: Adult: Ophth Ocular infections; Prevention of ocular infection following surgical procedure: Apply Â½ inch 3-4 hrly for acute infections or 2-3 times/day for mild-to-moderate infections for 7-10 days. Topical Superficial infections: Apply 1-4 times/day.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Rash, itching, burning, anaphylactic reactions, swelling, conjunctival erythema.\n\nPrecaution: Excessive use of the topical preparation may lead to substantial systemic absorption which may lead to nephrotoxicity (polymyxin B sulfate) and neurotoxicity (bacitracin). Prolonged use of the antibacterial preparation may cause overgrowth of non-susceptible organisms, including fungi. Pregnancy and lactation.\n\nMode of action: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\n\nPolymixin B: Potentially Fatal: Additive neurotoxic or nephrotoxic effect w/ bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, colistin. Increased risk of resp paralysis w/ neuromuscular blockers (e.g. anaesthetics, muscle relaxants).\n\nPregnancy category: C\n\nInteraction: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\n\nPolymixin B: Potentially Fatal: Additive neurotoxic or nephrotoxic effect w/ bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, colistin. Increased risk of resp paralysis w/ neuromuscular blockers (e.g. anaesthetics, muscle relaxants).
Baclofen	\n\n\tACI\tLiorel TAB dr 10mg 30's pack 241.50\n\tACI\tLiorel TAB dr 5mg 50's pack 226.50\n\tAcme Ltd.\tSkelofen TAB dr 10mg 30's pack 240\n\tAcme Ltd.\tSkelofen TAB dr 5mg 30's pack 135\n\tAd-din\tRelofen TAB dr 10mg 30's pack 240\n\tAlbion Ltd.\tFelo TAB dr 5 mg/10 mg 50's pack \n\tAmico Ltd.\tBaclofen TAB dr 10mg 20's pack 120\n\tAPC Pharma Ltd.\tSlaken TAB dr 10mg  \n\tApex\tBaclofen TAB dr 10mg 20's pack 120\n\tAristopharma\tBaclovan TAB dr 10mg 30's pack 240\n\tAristopharma\tBeclovan TAB dr 10mg 30's pack 240\n\tBeacon\tFlexibac TAB dr 10mg 50's pack 401.50\n\tBeacon\tFlexibac TAB dr 25mg 50's pack 400\n\tBeacon\tFlexibac TAB dr 5mg 50's pack 225.50\n\tBeximco\tLospan TAB dr 25 mg 30's pack 480\n\tBeximco\tLospan TAB dr 10 mg 30's pack 240\n\tBio Pharma Ltd.\tBacifen TAB dr 10mg 30's pack 240\n\tChemist Ltd.\tC-Bac TAB dr 10mg 30's pack 240\n\tDelta Pharma\tLiosal TAB dr 10mg 20's pack 160\n\tDrug International Ltd.\tBacmax TAB dr 5mg 50's pack \n\tDrug International Ltd.\tBacmax TAB dr 10mg 30's pack \n\tDrug International Ltd.\tBacmax Syrup 100 mg/100 ml  \n\tEskayef Bangladesh Ltd.\tFenobac TAB dr 5mg 50's pack 225\n\tEskayef Bangladesh Ltd.\tFenobac TAB dr 10mg 30's pack 240\n\tEskayef Bangladesh Ltd.\tFenobac TAB dr 25mg  \n\tEskayef Bangladesh Ltd.\tFenobac Syrup 100 mg/100 ml  \n\tGeneral\tRestobac TAB dr 10mg 30's pack 240.90\n\tGlobe\tSpinafen TAB dr 10mg 30's pack 240\n\tHallmark\tBaclomark TAB dr 10mg 30's pack 180\n\tHealthcare\tMyorel TAB dr 25mg 30's pack 600\n\tHealthcare\tMyorel TAB dr 5mg 30's pack 150\n\tHealthcare\tMyorel TAB dr 5mg	 30's pack 247.50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBacofen TAB dr 10mg 30's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBacofen TAB dr 5mg 50's pack 225\n\tIncepta\tFlexifen TAB dr 10mg 30's pack 240\n\tIncepta\tFlexifen TAB dr 25mg 20's pack 320\n\tIncepta\tFlexifen TAB dr 5mg 50's pack 225\n\tLabaid\tBacaid 10 TAB dr 10mg 3x10's pack 270\n\tLeon\tStarbac 5 TAB dr 5mg  \n\tLeon\tStarbac 10 TAB dr 10mg  \n\tMonicopharma\tRembac TAB dr 10mg 30's pack 240\n\tNavana\tMyobac TAB dr 10mg 30's pack 210\n\tNavana\tMyobac TAB dr 5mg 30's pack 150\n\tNIPRO JMI Pharma\tReflexen TAB dr 10mg 30's pack 240\n\tNIPRO JMI Pharma\tReflexen TAB dr 25mg 30's pack 600\n\tNovelta Bestway\tLirosal TAB dr 10mg 30's pack 240\n\tNovus\tAxant TAB dr 10 mg 30's pack  135\n\tNovus\tAxant TAB dr 25 mg 20's pack  160\n\tOpsonin Pharma\tBeclo TAB dr 10mg 30's pack 240\n\tOpsonin Pharma\tBeclo TAB dr 25mg 20's pack 400\n\tOpsonin Pharma\tBeclo TAB dr 5mg 30's pack 135\n\tOpsonin Pharma\tBeklo TAB dr 5mg  \n\tOpsonin Pharma\tBeklo TAB dr 10mg  \n\tOpsonin Pharma\tBeklo TAB dr 25mg  \n\tOrion Pharma Ltd.\tBaclon TAB dr 10mg 30's pack 240.90\n\tPacific\tBaclof TAB dr 5mg 30's pack \n\tPacific\tBaclof TAB dr 10mg 30's pack 285\n\tPharmacil Ltd.\tBacktone TAB dr 5mg  \n\tPharmacil Ltd.\tBacktone TAB dr 10mg  \n\tPharmacil Ltd.\tBacktone TAB dr 25mg  \n\tPharmasia Ltd.\tBaclobac TAB dr 10mg 30's pack 240.90\n\tPharmasia Ltd.\tBaclobac TAB dr 5mg 30's pack 135.60\n\tPopular\tMylofen TAB dr 5mg 50's pack 198.55\n\tRAK\tSpafen TAB dr 10mg 30's pack 240\n\tRangs\tBactab TAB dr 10mg  \n\tRenata\tMaxolax TAB dr 10mg 30's pack 240\n\tRenata\tMaxolax TAB dr 5mg 30's pack 150\n\tSharif\tSpinofen TAB dr 10mg 30's pack 240\n\tSomatec\tBacloflex TAB dr 10mg 30's pack 240\n\tSquare\tFlexilax TAB dr 10mg 50's pack 402\n\tSquare\tFlexilax TAB dr 5mg 30's pack 135.66\n\tSun Pharmaceutical (Bangladesh) Ltd.\tLiofen TAB dr 5mg  \n\tSun Pharmaceutical (Bangladesh) Ltd.\tLiofen TAB dr 10mg  \n\tSyntho Ltd.\tXanbac TAB dr 10mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tSpakem TAB dr 10mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tSpakem TAB dr 5mg 30's pack 135\n\tVirgo\tBaclium TAB dr 10mg 30's pack 240\n\tNovartis Farma SpA, Italy\tLioresal TAB dr 10mg 50's pack 648\n\tNovartis Farmaceutica S.A., Spain\tLioresal TAB dr 25mg 50's pack 1123\n\tIndication: Pain, Chronic muscle spasticity, Multiple sclerosis, Spasm, Stiffness, Low back pain\n\nDose: Oral\nSevere chronic spasticity\nAdult: Initially, 5 mg tid for 3 days increased to 10 mg tid for 3 days, then in similar increments and intervals until either 20 mg tid is reached or until desired effect is obtained. Max: 100 mg daily.\nChild: 0.75-2 mg/kg daily. May initiate with 2.5 mg 4 times daily, increased gradually every 3 days until desired effect is obtained. Maintenance: 6-10 yr: 30-60 mg daily; 2-6 yr: 20-30 mg daily; 12 mth-2 yr: 10-20 mg daily. Max: >10 yr: 2.5 mg/kg daily.\nElderly: Initiate with lower doses.\n\nContra-indication: Hypersensitivity. Active peptic ulcer disease.\n\nSide effects: Sedation, drowsiness, ataxia, dizziness, headache, confusion, hallucinations, skin reactions, GI symptoms, enuresis.\nPotentially Fatal: Respiratory or CV depression, seizures.\n\nPrecaution: Cerebrovascular disorders, epilepsy, severe psychotic disorders, confusional states, history of peptic ulcer, resp depression, diabetes (DM), hepatic or renal impairment, elderly, pregnancy. Avoid sudden withdrawal.\n\nMode of action: Hypotensive effect may be increased with antihypertensives. Concomittant use with levodopa in Parkinson patients may result in confusion, agitation, hallucinations.\nPotentially Fatal: CNS depressants and alcohol may potentiate CNS effects.\n\nPregnancy category: C\n\nInteraction: Hypotensive effect may be increased with antihypertensives. Concomittant use with levodopa in Parkinson patients may result in confusion, agitation, hallucinations.\nPotentially Fatal: CNS depressants and alcohol may potentiate CNS effects.
Bambuterol Hydrochloride	\n\n\tACI\tButerol Syrup 5mg/5ml 60ml 35\n\tACI\tButerol TAB dr 10mg 100's pack 150\n\tAcme Ltd.\tMuterol Syrup 5mg/5ml 60ml bot 20.07\n\tAcme Ltd.\tMuterol TAB dr 20mg 50's pack 150\n\tAcme Ltd.\tMuterol TAB dr 10mg 100's pack 150\n\tChemist Ltd.\tBambutol TAB dr 10mg 100's pack 150\n\tEskayef Bangladesh Ltd.\tDilator Syrup 5mg/5ml 60ml bot 30\n\tEskayef Bangladesh Ltd.\tDilator TAB dr 10mg 100's pack 300\n\tEskayef Bangladesh Ltd.\tDilator TAB dr 20mg 100's pack 400\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVenterol Syrup 5mg/5ml 60ml bot 35.14\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVenterol TAB dr 10mg 100's pack 150\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVenterol TAB dr 20mg 50's pack 150.50\n\tIncepta\tBambelor Syrup 5mg/5ml 60ml bot 25\n\tIncepta\tBambelor TAB dr 10mg 100's pack 150\n\tIncepta\tBambelor TAB dr 20mg 100's pack 300\n\tSilva\tAerodyl Syrup 5mg/5ml 60ml bot 20.07\n\tSilva\tAerodyl TAB dr 10mg 100's pack 150.57\n\tSilva\tAerodyl TAB dr 20mg 100's pack 301.13\n\tSquare\tOptiven Syrup 5mg/5ml 60ml bot 30\n\tSquare\tOptiven TAB dr 10mg 30's pack 60.25\n\tSquare\tOptiven TAB dr 20mg 30's pack 105.33\n\tIndication: Chronic obstructive pulmonary disease (COPD), Asthma.\n\nDose: Adult: PO 10-20 mg/day at bedtime.\n\nRenal impairment:\nCrCl (ml/min)	\n<50	 Initial dose should be halved. \n\nContra-indication: Severe hepatic impairment; cirrhosis.\n\nSide effects: Fine tremor of skeletal muscle (e.g. hands), palpitations and muscle cramps; tachycardia, tenseness and peripheral vasodilation.\n\nPrecaution: DM, hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation. Pregnancy.\n\nMode of action: Risk of hypokalaemia increased by co-admin of corticosteroids, diuretics or xanthines. Prolong the action of drugs e.g. suxamethonium.\n\nPregnancy category: Not Classified\n\nInteraction: Risk of hypokalaemia increased by co-admin of corticosteroids, diuretics or xanthines. Prolong the action of drugs e.g. suxamethonium.
Barium Sulphate	\n\n\tPopular\tViewgut powder 150gm 1's pack 176.60\n\tIndication: X-ray imaging,Diagnostic procedures,Imaging of the GI tract\n\nDose: It  will depend on the degree and extent of contrast required in the area(s) under examination and on the equipment and technique employed.\n\nContra-indication: This product should not be used in patients with known gastric or intestinal perforation or hypersensitivity to barium sulfate products.\n\nSide effects: Adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. Severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, barium sulfate impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. It is of the utmost importance to be completely prepared to treat any such occurrence.\n\nPrecaution: Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease.\n\nIngestion of this product is not recommended in patients with a history of food aspiration. If barium studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. If this product is aspirated into the larynx, further administration should be immediately discontinued.\n\nAfter any barium study of the GI tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of the bowel by barium sulfate. To prevent barium sulfate impaction in the bowel, the use of mild laxatives such as milk of magnesia or lactulose, following completion of the examination may also be required. These mild laxatives are recommended on a routine basis and in patients with a history of constipation unless contraindicated.\n\nUse with caution in patients with complete or nearly complete obstruction of the GI tract.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Beclomethasone Dipropionate	\n\n\tACI\tSteradin HFA Inhalation Solution 100mcg 200 doses unit 271.84\n\tACI\tSteradin HFA Inhaler 250mcg 200 doses unit 352.38\n\tAcme Ltd.\tAscon Inhalation Solution 250mcg 200 doses unit 250.94\n\tAcme Ltd.\tAscon Inhalation Inhalation Solution 100mcg 200 doses unit 200.75\n\tAcme Ltd.\tBeclod Inhaler 100mcg 30 doses unit 45\n\tAcme Ltd.\tBeclod Dry powder inhalation capsule 200mcg 30 doses unit 63.90\n\tAristopharma\tBeclocort 100 HFA Inhalation Solution 100mcg 200 doses unit 270\n\tAristopharma\tBeclocort-250 HFA Inhaler 250mcg 200 doses unit 350\n\tAristopharma\tBeclocort 50 HFA	 	 Inhaler 50 mcg 200 doses unit Inhalation Solution 	\n\tBeximco\tDecomit Inhaler 100mcg 200 doses unit 200\n\tBeximco\tDecomit Inhaler 200mcg 200 doses unit 250\n\tBeximco\tDecomit-50 HFA Inhaler 50mcg 200 doses unit 220\n\tBeximco\tDecomit-100 HFA Inhaler 100mcg 200 doses unit 270\n\tDrug International Ltd.\tBecovent HFA Inhalation Aerosol 100 mcg/Metered Inhalatio  \n\tEskayef Bangladesh Ltd.\tAzbec 100 Inhaler 100mcg 200 puffs 200\n\tEskayef Bangladesh Ltd.\tAzbec Inhaler 250mcg 200 puffs 250\n\tSquare\tBeclomin Inhaler 100mcg 200 doses unit 270\n\tSquare\tBeclomin Inhaler 50mcg 200 doses unit 200\n\tSquare\tBeclomin HFA Inhalation Solution 100mcg 200 doses unit 271.01\n\tSquare\tBeclomin Inhaler 250mcg 200 doses unit 320\n\tSquare\tBeclomin HFA Inhalation Solution 250mcg 200 doses unit 321.25\n\tSquare\tBeclomin-50 HFA Inhaler 50mcg 200 doses unit 220.840\n\tIndication: Asthma, Chronic obstructive pulmonary disease (COPD),\n\nDose: Management of chronic asthma\nAdults & children over 12 years: 100-400 mcg twice daily.\n\nChildren (5-12 years): 100-200 mcg twice daily. Maximum 200-400 mcg twice daily.\n\nProphylaxis of asthma\nAdults & children over 12 years: 50-200 mcg twice daily. Increased if necessary to maximum 400 mcg twice daily.\n\nChildren (5-12 years): The usual starting dose is 100 mcg twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 mcg administered in 2-4 divided doses.\n\nWhen patient's symptoms remain under satisfactory control, the dose should be titrated to the lowest dose at which effective control of asthma is maintained.\n\n\n\nContra-indication: Hypersensitivity to any of the ingredients of this preparation contraindicates its use. Child under 6 years not recommended. \n\nSide effects: Loss of skin collagen and SC atrophy; local hypopigmentation of deeply pigmented skin; dryness, irritation, epistaxis, rarely ulceration or perforation of the nasal septum; smell and taste disturbances; hoarseness and candidiasis of the mouth or throat.\n\n\n\nPrecaution: Patients should be instructed to use inhaler properly to ensure that the drug reaches the target areas within the lungs. They should also be made aware of the prophylactic nature of therapy with Beclometasone Dipropionate HFA inhaler and that they should use it regularly, even when they are asymptomatic.\nIntranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. \nBeclometasone dipropionate is not suitable for the treatment of an acute asthma attack. \n\n\nMode of action: Inhibitors of CYP3A4: potential pharmacokinetic interaction (increased plasma beclomethasone dipropionate concentrations).\nInducers of CYP3A4: potential pharmacokinetic interaction (decreased plasma beclomethasone dipropionate concentrations).\nAntidiabetic agents\nMay increase blood glucose concentrations in patients with diabetes mellitus.\nNSAIDs\nPossible increased risk of GI ulcerationa\nDecreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication\n\nVaccines and Toxoids\nMay cause a diminished response to toxoids and live or inactivated vaccines.\nMay potentiate replication of some organisms contained in live, attenuated vaccines.\nCan aggravate neurologic reactions to some vaccines (supraphysiologic dosages).\n\n\nPregnancy category: C\n\nInteraction: Inhibitors of CYP3A4: potential pharmacokinetic interaction (increased plasma beclomethasone dipropionate concentrations).\nInducers of CYP3A4: potential pharmacokinetic interaction (decreased plasma beclomethasone dipropionate concentrations).\nAntidiabetic agents\nMay increase blood glucose concentrations in patients with diabetes mellitus.\nNSAIDs\nPossible increased risk of GI ulcerationa\nDecreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication\n\nVaccines and Toxoids\nMay cause a diminished response to toxoids and live or inactivated vaccines.\nMay potentiate replication of some organisms contained in live, attenuated vaccines.\nCan aggravate neurologic reactions to some vaccines (supraphysiologic dosages).\n
Beclomethasone Dipropionate Nasal prep	\n\n\tBeximco\tDecomit Nasal Spray 50mcg/ Spray  200 dose spray unit 146\n\tGlaxoSmithKline Bangladesh Ltd.\tBeconase Nasal Spray 50mcg/ Spray  200 dose ( spray) unit 235.54\n\tSquare\tBecospary Nasal Spray 50mcg/ Spray  200 dose spray unit 125.47\n\tIndication: Sinusitis, Hay fever,  Allergic and non-allergic rhinitis\n\nDose: Adults and Children 12 Years of Age and Older: The usual dosage is one or two inhalations in each nostril twice a day .\n\nChildren 6 to 12 Years of Age: Patients should be started with one inhalation in each nostril twice a day; patients with more severe symptoms may use two inhalations in each nostril. \n\nBeclomethasone dipropionate nasal spray is not recommended for children below 6 years of age.\n\nContra-indication: patients with a history of hyper-sensitivity to any of the components\n\nSide effects: Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. Such effects may include hypothalmic-pituitary-adrenal (HPA) suppression and growth retardation in children.\nRare cases of nasal septal perforation have been reported following the use of intranasal corticosteroids.\nRare cases of raised intra-ocular pressure or glaucoma have been reported.\nAs with other nasal sprays, dryness and irritation of the nose and throat, unpleasant taste and smell and epistaxis have been reported rarely.\n\nPrecaution: Nasal passage infections and paranasal sinuses should be appropriately treated.\n\nCaution should be exercised whilst transferring patients from systemic steroid treatment to Beclometasone Dipropionate Aqueous Nasal Spray if there is doubt that their adrenal function is impaired.\n\nSystemic effects of nasal corticosteroids may occur particularly at high doses prescribed for prolonged periods. Growth retardation has been reported in children receiving nasal corticosteroids at licensed doses.\n\nTreatment with higher than recommended doses may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Benzathine Penicillin	\n\n\tGonoshasthaya\tG Benzathine Penicil Injection 12 Lac Unit 1 Vial 22.1\n\tGonoshasthaya\tG Benzathine Penicil Injection 6 Lac Unit 1 Vial 15.05\n\tOpsonin Pharma\tB Pen Injection 12 Lac Unit 4's pack 96\n\tOpsonin Pharma\tB Pen Injection 6 Lac Unit 5's pack 82\n\tOpsonin Pharma\tBpen Injection 0.6MU 5's pack 82.50\n\tOpsonin Pharma\tBpen Injection 1.2MU 4's pack 96\n\tRenata\tDiamine Penicillin Injection 12 Lac Unit 12 Lac Unit Vial 24.21\n\tSquare\tBenzapen Injection 12 Lac Unit 5's pack 139.79\n\tIndication: Anthrax, Group A Strep. infections, Neurosyphilis, Fusobacterium infections, Diphtheria, Erysipeloid, Uncomplicated pneumococcal pneumonia, Rat bite fever, Rheumatic fever, Syphilis, Streptococcal pharyngitis\n\nDose: Adult: IM: 0.3 to 1.2 million units up to 2.4 million units as a single dose repeated every five to seven days.\n\nSpecific dosage schedule:\nTreatment of group-A beta-haemolytic streptococcal infections: \nA single intramuscular dose of 600,000 units.\nPrevention of rheumatic fever: Monthly injection of a single dose of 1.2 million units is the most effective regimen for preventing further attacks of rheumatic fever.\nTreatment of acute otitis media: A single injection of 600,000 units.\nTreatment of syphilis:\nEarly syphilis- 2.4 million units as a single dose.\nLate syphilis- 2.4 million units weekly for three successive weeks.\nNeurosyphilis- Benzylpenicillin, intravenously, 2 to 4 million units every 4 hours for 10 days, followed by benzathine penicillin intramuscularly, 2.4 million units weekly for three successive weeks.\nCongenital syphilis: Asymptomatic infants with normal cerebrospinal fluid, intramuscularly 50,000 units per kg in a single dose.\nPrimary and secondary syphilis have been treated with single injections of 2.4 million units of long acting benzathine penicillin (Benzapen) weekly for 2 to 4 weeks with satisfactory results.\n\n\n\nContra-indication: Hypersensitivity to penicillins or cephalosporins. IM inj (ischaemic reactions may occur).\n\nSide effects: Hypersensitivity reactions including uticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis.\nPotentially Fatal: Anaphylaxis\n\nPrecaution: Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route.\n\nMode of action: Probenecid prolongs T1/2 of benzathine benzylpenicillin. Bacteriostatic drugs e.g. chloramphenicol, tetracyclines; other antibacterials; anticoagulants.\n\nPregnancy category: B\n\nInteraction: Probenecid prolongs T1/2 of benzathine benzylpenicillin. Bacteriostatic drugs e.g. chloramphenicol, tetracyclines; other antibacterials; anticoagulants.
Benzocaine	\n\n\tAcme Ltd.\tOratics Oral Gel 200mg  \n\tSquare\tOrogel 	 Oro-dental Gel 20gm/100ml 5gm tube 50\n\tIndication: For the temporary relief of pain due to minor injury or irritation of the mouth and gums like- toothache, sore gums, canker sores, braces, minor dental procedures, dentures.\n\nDose: Apply to the affected area up to 4 times daily or as directed by a doctor/dentist. Children under 12 years of age should be supervised in the use of this product.\n\nContra-indication:  Hypersensitivity.\n\nSide effects: Allergies, swelling in the mouth or throat etc.\n\nPrecaution:  Avoid: Contact with  eyes; prolonged use or application on extensive areas. Avoid eating or drinking for at least 1 hr after use; \n\nMode of action: Antagonism with sulfonamides; aminosalicylic acid; anticholinesterases; suxamethonium; antiarrhythmics; MAOIs; TCAs.\n\nPregnancy category: C\n\nInteraction: Antagonism with sulfonamides; aminosalicylic acid; anticholinesterases; suxamethonium; antiarrhythmics; MAOIs; TCAs.
Benzocaine 0.065% + Camphor 0.25% + Methanol 0.25%	\n\n\tIndication: Sore throat,toothaches, gum pain, canker sores. \n\nDose: Adults and children 2 years of age and older: apply to the affected area not more than 3 to 4 times daily\nChildren under 12 years of age: adult supervision should be given in the use of this product\n\n\nContra-indication: Do not use this product if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine, or other "caine" anesthetics.\n\nSide effects: Benzocaine are more likely to cause contact sensitization. Slight burning, tingling, or stinging may occur.\n\nPrecaution: Do not use over deep or puncture wounds, infections, or lacerations. Consult a doctor. Do not use for more than 7 days unless directed by a doctor/dentist\nWhen using this product avoid contact with the eyes, do not exceed recommended dosage. Keep out of reach of children.\n\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Benzocaine 0.20% + Camphor 0.25% + Methanol 0.25%	\n\n\tIndication: Sore throat,toothaches, gum pain, canker sores\n\nDose: Adults and children 2 years of age and older: apply to the affected area not more than 3 to 4 times daily Children under 12 years of age: adult supervision should be given in the use of this product \n\nContra-indication: Do not use this product if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine, or other "caine" anesthetics.\n\nSide effects: Benzocaine are more likely to cause contact sensitization. Slight burning, tingling, or stinging may occur.  \n\nPrecaution: Do not use over deep or puncture wounds, infections, or lacerations. Consult a doctor. Do not use for more than 7 days unless directed by a doctor/dentist When using this product avoid contact with the eyes, do not exceed recommended dosage. Keep out of reach of children. \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Benzocaine + Oxytetracycline + Polymiyxin B Eye prep	\n\n\tRenata\tRenamycin Eye Drops   5 ml bot 24.27\n\tIndication: Bacterial eye infections, Inflammation of the Cornea\n\nDose: Opthalmic: 1-2 drops 2-4 times daily.\n\n\nContra-indication: Known hypersensitivity to any of the components.\n\nSide effects: Local sensitivity. Lid itching, swelling, conjunctival erythema.\n\nPrecaution: Prolonged use. perforated ear drum.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Benzoic Acid 6% + Salicylic Acid 3%	\n\n\tAsiatic Ltd.\tWhitfield Ointment   30gm x 1 's pack 13\n\tCentral.\tBenzalic Ointment   20gm  tube 14\n\tCosmic Chemical Industries Ltd.\tDarmol Ointment   12 's pack 72\n\tEdruc Ltd.\tBexsul Ointment   25gm  tube 15\n\tG. A. Company Ltd.\tBensal Ointment   10gm  tube 5.54\n\tGonoshasthaya\tG Benzosal Ointment   25gm pot 12.50\n\tJayson\tDermin Ointment   25gm pack 13.30\n\tMedicon\tTifield Ointment   30gm tube \n\tMillat\tWhitfield Ointment   10gm pack 12\n\tModern\tModern's White fields Ointment   15gm pot/25gm pot 8 / 16.65\n\tOpsonin Pharma\tSalben Ointment (60mg + 30 mg)/g 25g Tube \n\tRenata\tEnsal Ointment   1kg pack  265\n\tUnique.\tUnique's Whitefild Ointment   10gm x 12 's pack 101\n\tIndication: Fungal infections, athlete's foot, barber's itch.\n\nDose: Adult & Child: Apply locally on the affected area 2-3 times/day. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Irritation, sensitivity, excessive drying; systemic effects on prolonged use.\n\nPrecaution: Not for prolonged use in high concentrations and on large areas of the body. Avoid broken skin, mouth, eyes, mucous membranes and anogenital region.\n\nMode of action: It is not known if this interacts with other topical medications applied to the treatment area. The use of this drug with other topical drugs has not been studied.\n\nPregnancy category: C\n\nInteraction: It is not known if this interacts with other topical medications applied to the treatment area. The use of this drug with other topical drugs has not been studied.
Benzoyl Peroxide	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tBrevoxyl Cream 4% 1's pack(40g) 332.41\n\tRenata\tCaress 2.5% Cream 2.5gm/100ml 15gm tube 43.50\n\tRenata\tCaress 5% Cream  5gm/100ml 15gm tube 45\n\tIndication: Acne vulgaris, Dyeing hair, Teeth whitening, Decubitus or Stasis ulcers\n\nDose: Adult: Topical Acne As 2.5-10% cream: Apply 1-2 times/day. \n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Excessive drying of skin, allergic dermatitis. May bleach fabrics or hair. Skin discoloration; skin rash, peeling, transient local oedema.\n\nPrecaution: Discontinue if severe irritation develops. Restart with tolerable levels of treatment after irritiation has cleared. Do not use occlusive dressing. May cause dermatitis in allergic patients. Apply carefully near the eyes, mouth, neck and other mucous membranes as well as other sensitive areas.\n\nMode of action: PABA sunscreens may transiently discolour fabric.\n\nPregnancy category: C\n\nInteraction: PABA sunscreens may transiently discolour fabric.
Benzoyl Peroxide 5%	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tOxigel Gel   20gm tube 100\n\tIndication: Acne vulgaris\n\nDose: Adult: Topical Gel: Apply 1-2 times/day. \n\nContra-indication: Hypersensitivity\n\nSide effects: Excessive drying of skin, allergic dermatitis. May bleach fabrics or hair. Skin discoloration; skin rash, peeling, transient local oedema.\n\nPrecaution: Discontinue if severe irritation develops. Restart with tolerable levels of treatment after irritiation has cleared. Do not use occlusive dressing. May cause dermatitis in allergic patients. Apply carefully near the eyes, mouth, neck and other mucous membranes as well as other sensitive areas.\n\nMode of action: PABA sunscreens may transiently discolour fabric.\n\nPregnancy category: C\n\nInteraction: PABA sunscreens may transiently discolour fabric.
Benzoyl Peroxide 5% + Erythromycin 3%	\n\n\tIndication: Acne vulgaris\n\nDose: Adult: Topical Acne : Apply 1-2 times/day.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Excessive drying of skin, allergic dermatitis. Skin discoloration; skin rash, peeling, transient local oedema.\n\nPrecaution: Apply carefully near the eyes, mouth, neck and other mucous membranes as well as other sensitive areas.Discontinue if severe irritation develops.\n\nMode of action: Benzoyl Peroxide: PABA sunscreens may transiently discolour fabric.\n\nErythromycin: Potentially Fatal: QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, torsades de pointes w/ cisapride, pimozide, astemizole or terfenadine. Acute ergot toxicity w/ ergotamine and dihydroergotamine.\n\n\n\nPregnancy category: B\n\nInteraction: Benzoyl Peroxide: PABA sunscreens may transiently discolour fabric.\n\nErythromycin: Potentially Fatal: QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, torsades de pointes w/ cisapride, pimozide, astemizole or terfenadine. Acute ergot toxicity w/ ergotamine and dihydroergotamine.\n\n
Benzyl Alcohol	\n\n\tIndication: Head lice, Pediculosis capitis\n\nDose: Apply lotion to dry hair, using enough to completely saturate hair & scalp, rinse off with water after 10 minutes\n\nRepeat treatment in 7 days\n\nContra-indication: Hypersensitivity to any of the active ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen. Irritation, itching, redness, tingling, or numbness at the application site may occur. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.\n\nPrecaution: Constant or forceful scratching of the skin/scalp may lead to a bacterial skin infection. \n\nThis drug is not recommended for use in children younger than 6 months.\n\nMode of action: No formal drug interaction studies to date.\n\nPregnancy category: B\n\nInteraction: No formal drug interaction studies to date.
Benzyl Benzoate 25%	\n\n\tAexim\tScabicid Emulsion   60ml bot 12.13\n\tAmico Ltd.\tBenosol Emulsion   100ml bot 25\n\tGonoshasthaya\tG-B.Benzoate Lotion 25% 100ml bot  25\n\tHudson\tAscab Emulsion   60ml bot/100ml bot 12.13 / 18\n\tHudson\tViola 25% Solution   60ml pack/100ml pack 12/22\n\tJayson\tScabisol Emulsion   100ml bot 32.10\n\tMedicon\tScabicon Emulsion   100ml bot 32\n\tRenata\tScanil 25% Emulsion   450ml bot 115\n\tSanofi Aventis (BD) Ltd.\tAscabiol Emulsion   100ml bot 32.07\n\tSupreme\tScabex Emulsion  1.25 gm/5 ml 100ml bot 18\n\tIndication: Scabies\n\nDose: Adult: Topical As 25% emulsion: Apply 3 times at 12-hrly intervals, over the whole body. Wash off 12 hr after the last application.\n\nContra-indication: Broken or irritated skin; neonates; pregnancy.\n\nSide effects: Irritant to eyes and mucous membranes, allergic dermatitis reactions, drying effects in the elderly.\n\nPrecaution: Prevent drug from entering the eyes, elderly (drying effects).\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Benzyl Penicillin	\n\n\tOpsonin Pharma\tPen G Injection 10 LacIU 10's pack 167.40\n\tOpsonin Pharma\tPen G Injection 5 LacIU 10's pack 112.90\n\tRenata\tPenicillin G Sodium Injection 10 LacIU 1 vial 9.21\n\tRenata\tPenicillin G Sodium Injection 5 LacIU 1 vial 6.23\n\tIndication: Meningitis, Anthrax, Community-acquired pneumonia, Bacterial endocarditis, Septicemia, Diphtheria, Syphilis, Cellulitis, Infective endocarditis, Gonorrhea, Aspiration pneumonia, Lung abscess, Septic Arthritis, Gangrene, Meningococcal meningitis, Pneumococcal meningitis, Botulism\n\nDose: Adult: IV Bacterial endocarditis W/ aminoglycoside: 1.2 g 4 hrly. Intrapartum prophylaxis against group B streptococcal infection Initial: 3 g, then 1.5 g 4 hrly until delivery. \nMeningococcal meningitis; Pneumococcal meningitis 2.4 g 4 hrly. Up to 18 g/day in meningococcal meningitis. \nIV/IM Susceptible infections 0.6-4.8 g/day in divided doses.\n\nInfant & Children: Bacterial Infection \n\nModerate Infection: 25,000-50,000 units/kg/day IV/IM divided 6hourly  \n\nSevere Infection: 250,000-400,000 units/kg/day IV/IM divided 4-6 hourly\n\nContra-indication: Hypersensitivity to penicillins.\n\nSide effects: Hypersensitivity reactions including uticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route. Lactation.\n\nMode of action: Probenecid\nIncreases and prolongs serum penicillin levels.\n\nTetracycline\nMay antagonize the bactericidal effect of penicillin.\n\nPregnancy category: B\n\nInteraction: Probenecid\nIncreases and prolongs serum penicillin levels.\n\nTetracycline\nMay antagonize the bactericidal effect of penicillin.
Benzyl Penicillin + Procaine Penicillin	\n\n\tAcme Ltd.\tCombipen 4 LAC Injection  300k+100k units per Vial 5 vials pack 70.25\n\tG. A. Company Ltd.\tEupen Injection 2 Lac IU + 6 Lac IU  \n\tOpsonin Pharma\tPropen 4 LAC Injection   4's pack 30.40\n\tOpsonin Pharma\tPropen 8 LAC Injection   4's pack 40\n\tRenata\tPronapen 4 LAC Injection   1 vial pack 6.03\n\tRenata\tPronapen 8 LAC Injection   1 vial pack 9.10\n\tIndication: Meningitis, Peritonitis, Anthrax, Non-gonococcal urethritis, Diphtheria, Syphilis, Infections caused by Staphylococcus (susceptible strains), Streptococcus, Pneumococcus species gonorrhoea, Subacute bacterial endocarditis, Upper respiratory tract, Erysipelas, Skin and soft tissue infections, Moderately severe pneumonia and otitis media, Empyema, Bacteremia, Pericarditis, Arthritis\n\nDose:  Streptococcal Infections Group A-Infections of the upper-respiratory tract, skin and soft-tissue infections, scarlet fever, and erysipelas.\n\nThe following doses are recommended:\n\nAdults and pediatric patients over 60 lbs. in weight: 2,400,000 units.\n\nPediatric patients from 30 to 60 lbs.: 900,000 units to 1,200,000 units.\n\nPediatric patients under 30 lbs.: 600,000 units.\n\nNOTE: Treatment with the recommended dosage is usually given at a single session using multiple IM sites when indicated. An alternative dosage schedule may be used, giving one-half (1/2) the total dose on day 1 and one-half (1/2) on day 3. \n\nPneumococcal Infections (except pneumococcal meningitis)\n\n600,000 units in pediatric patients and 1,200,000 units in adults, repeated every 2 or 3 days until the temperature is normal for 48 hours. Other forms of penicillin may be necessary for severe cases.\n\n\nContra-indication: A previous hypersensitivity reaction to any penicillin or to procaine is a contraindication.\n\nSide effects: As with other penicillins, untoward reactions of the sensitivity phenomena are likely to occur, particularly in individuals who have previously demonstrated hypersensitivity to penicillins or in those with a history of allergy, asthma, hay fever, or urticaria.\n\nThe following have been reported with parenteral penicillin G:\n\nGeneral: Hypersensitivity reactions including the following: skin eruptions (maculopapular to exfoliative dermatitis), urticaria, laryngeal edema, fever, eosinophilia; other serum sickness-like reactions (including chills, fever, edema, arthralgia, and prostration); and anaphylaxis including shock and death. \n\nGastrointestinal: Pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment.\n\nPrecaution: Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma.\n\nCare should be taken to avoid intravenous or intra-arterial administration, or injection into or near major peripheral nerves or blood vessels, since such injections may produce neurovascular damage\n\nMode of action: Probenecid\nIncreases and prolongs serum penicillin levels.\n\nTetracycline\nMay antagonize the bactericidal effect of penicillin.\n\nPregnancy category: B\n\nInteraction: Probenecid\nIncreases and prolongs serum penicillin levels.\n\nTetracycline\nMay antagonize the bactericidal effect of penicillin.
Bepotastine Besilate 1.5%  Eye prep	\n\n\tAristopharma\tBepotas Eye Drops 1.5 5ml bot 300\n\tGeneral\tBepogen Eye Drops 1.5 gm/100 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tBetasil Eye Drops 1.5 gm/100 ml  \n\tIncepta\tBetastin Eye Drops   5ml 300\n\tPopular\tOcustin Eye Drops 15mg 5 ml plastic dropper bottle 300\n\tIndication: Allergic conjunctivitis\n\nDose: Instill one drop  into the affected eye(s) twice a day.\nPediatric Use: Safety and effectiveness in children below the age of 2 years have not been established. \n\nContra-indication: Hypersensitivity.\n\nSide effects: The most common reported side effect occurring in approximately 25% of subjects was a mild taste following instillation. Other side effects occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.\n\nPrecaution: To minimize the risk of contamination, do not touch dropper tip to any surface.\nIt should not be used to treat contact lens-related irritation.\nPatients should be advised not to wear contact lens when using this drop. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Besifloxacin 0.6%  Eye prep	\n\n\tAristopharma\tBesiflox Eye Drops   5ml drop 350\n\tGeneral\tBesigen Eye Drops 0.6 gm/100 ml  \n\tIncepta\tBesiven Eye Drops Eye Drops  0.6% 1'sx5ml bot 350\n\tPopular\tBesibac Eye Drops  .6 gm/100 ml 5ml drop 350\n\tIndication: Bacterial Conjunctivitis\n\nDose: Adults and children (1 year of age and older): Instill one drop in the affected eye(s) 3 times a day for 7 days.\n\nContra-indication: This drug is contraindicated in patients with a history of hypersensitivity to Besifloxacin, to other Quinolones or to any of the components in this formulation. \n\nSide effects: The most frequently reported ocular adverse event was conjunctival redness, reported in approximately 2% of patients. Other adverse events reported in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.\n\nPrecaution: â¢ This drug is for topical ophthalmic use only and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.\nâ¢ As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy.\nâ¢ To prevent contamination do not touch the tip of the dropper to eye, eyelid or any surface of the affected eye.\nâ¢ Patients should not wear contact lenses during the course of therapy with this drug.\nâ¢ Shake well before use.\n\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Beta Carotene + Calcium + Cholecalciferol (Vit D3)	\n\n\tIndication: Postmenopausal osteoporosis, Osteoporosis, Osteomalacia/rickets, Hypoparathyroidism, Latent tetany, Calcium deficiency, Increased calcium demand in pregnancy & lactation\n\nDose:  As a dietary adjunct before, during and after pregnancy, take one tablet daily with a meal, or as directed by a physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients of this preparation.\n\nSide effects: Generally well tolerated.\n\nPrecaution: If any pregnant woman has a baby with neural tube defect she is advised to consult with her physician.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Beta Carotene + Copper + Manganese + Selenium + Vit C	\n\n\tIndication: Vitamin/mineral supplement\n\nDose: One tablet daily or as directed by a physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.\n\nPrecaution: Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Betacarotene + Vitamin C + Vitamin E  (Anti-Oxidant Vitamins and Minerals)	\n\n\tACI\tTasti TAB dr   20's pack 50.20\n\tAcme Ltd.\tAntox TAB dr  (6 + 200 + 50) mg 20's pack/100'pack 50.80 / 254\n\tAexim\tD'Tox TAB dr  20's pack  50\n\tAlco Pharma\tNox TAB dr  20's pack   50.60\n\tApex\tEba TAB dr   20's pack 45\n\tAristopharma\tVitace- M TAB dr   30's pack 90\n\tAsiatic Ltd.\tA Care TAB dr   20's pack 50\n\tBeximco\tCarocet TAB dr   20's pack 50.80\n\tBio Pharma Ltd.\tVitaforce TAB dr   20's pack 50.80\n\tBristol Pharma Ltd.\tAX TAB dr  30's pack  75\n\tCentral.\tPerex TAB dr   20's pack 50\n\tChemist Ltd.\tCetox plus TAB dr  20's pack  80\n\tConcord\tMaxvit-ACE TAB dr   20's pack 50\n\tCosmic Chemical Industries Ltd.\tVecarot TAB dr   30's pack 75\n\tDesh\tVitoxi-3 TAB dr   20's pack 50\n\tDoctor's Chemicals Works Ltd.\tEnergin TAB dr   20's pack 50\n\tDrug International Ltd.\tTanox CAP   100'pack 300\n\tEdruc Ltd.\tCare TAB dr   20's pack 50\n\tEskayef Bangladesh Ltd.\tPriovit TAB dr   20's pack 50\n\tG. A. Company Ltd.\tECA TAB dr   20's pack 50.62\n\tGeneral\tCeto TAB dr   20's pack 50.20\n\tHallmark\tVigor Ace TAB dr   20's pack 60\n\tHudson\tHax TAB dr   30's pack 75\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRace TAB dr   20's pack 50\n\tJayson\tZest TAB dr   50's pack 150\n\tKemiko\tVroot TAB dr   20's pack 50\n\tKumudini Pharma Ltd.\tHiprex TAB dr   20's pack 50\n\tMarksman.\tNutriace TAB dr   20's pack 50\n\tMedicon\tOxid TAB dr   20's pack 50\n\tMedimet\tAgedefy TAB dr   20's pack 50\n\tMillat\tDonor TAB dr   20's pack 50\n\tModern\tBetanic TAB dr   20's pack 75\n\tMystic\tAge M TAB dr   20's pack 50\n\tNavana\tNoxid TAB dr   20's pack 50.20\n\tNipa\tSafe TAB dr   20's pack 50.80\n\tNovartis (Bangladesh) Ltd.\tRenbo TAB dr   50's pack 150\n\tOpsonin Pharma\tBec TAB dr   20's pack 45\n\tPacific\tNorad TAB dr   20's pack 80\n\tPacific\tNorad SG CAP  50's pack  250\n\tPharmadesh Ltd.\tOxivt TAB dr   20's pack 55.86\n\tReman Drug Ltd.\tOxforte TAB dr   20's pack 50\n\tRenata\tProxid TAB dr   20's pack 50.60\n\tRephco\tCeb TAB dr   30's pack 105\n\tSalton\tExtravit X TAB dr   20's pack 50\n\tShamsul Al-Amin\tRotex TAB dr   20's pack 51\n\tSilco Pharmaceuticlas Ltd.\tViton TAB dr 6 mg + 200 mg + 50 mg  \n\tSilva\tPrentox TAB dr   20's pack 50.19\n\tSquare\tRex TAB dr   30's pack 76.21\n\tSyntho Ltd.\tOxitab TAB dr   20's pack 50.60\n\tUnimed & Unihealth Manufacturers Ltd.\tAnoxiv TAB dr   30's pack 75.90\n\tWhite Horse Pharma\tActive PLUS TAB dr   30's pack 75\n\tZenith\tEC - Vit TAB dr   20's pack/30's pack 50/75\n\tIndication: Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair.\n\n\nDose: One tablet/capsule daily or as directed by a physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.\n\nPrecaution: Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Betahistine Mesilate	\n\n\tSquare\tMerison TAB dr 6mg 100's pack 200.83\n\tIndication: Meniere's disease, tinnitus, vertigo, dizziness				\n\n\nDose: Adults : 1 to 2 tablets three times per day after meals.\n\n\nContra-indication: Phaeochromocytoma. Porphyria.\n\nSide effects: Rash, pruritus, urticaria, dyspepsia, nausea, peptic ulcer disease, headache, insomnia.\n\nPrecaution: Active peptic ulcer, bronchial asthma, pregnancy and lactation.\n\nMode of action: May antagonise antihistamines. May decrease bronchodilator effects of beta-2 agonists.\n\nPregnancy category: C\n\nInteraction: May antagonise antihistamines. May decrease bronchodilator effects of beta-2 agonists.
Betamethasone	\n\n\tAcme Ltd.\tBet-A TAB dr 500mcg 100's pack 72\n\tGlaxoSmithKline Bangladesh Ltd.\tBetnelan TAB dr 500mcg 500's pack 359.10\n\tIndication: Ulcerative colitis, Rheumatoid arthritis, Ankylosing spondylitis, Lichen planus, Psoriasis, Asthma, Eczema, Contact dermatitis, Multiple sclerosis, Drug hypersensitivity reactions, Perennial or seasonal allergic rhinitis, Serum sickness, Transfusion reactions, Severe erythema multiforme (Stevens-Johnson syndrome), Leukemias, Lymphomas, Acute gouty arthritis, Acute rheumatic carditis, Psoriatic arthritis, Including juvenile rheumatoid arthritis, Dermatomyositis, Polymyositis, Systemic lupus erythematosus, Psoriatic plaques, Allergic and inflammatory disorders, Congenital adrenal hyperplasia\n\nDose: Oral\nAllergic and inflammatory disorders\nAdult: 0.5-5 mg daily.\nChild: For inflammatory conditions: >12 yr: 0.0175-0.125 mg base/kg daily, dose may be divided every 6-12 hr. \n\n\nContra-indication: Hypersensitivity; systemic fungal or acute infections.\n\nSide effects: Sodium and fluid retention, potassium and calcium depletion. Muscle wasting, weakness, osteoporosis. GI disturbances and bleeding. Increased appetite and delayed wound healing; hirsutism, bruising, striae, acne; raised intracranial pressure, headache, depression, psychosis, menstrual irregularities. Hyperglycaemia, DM. Suppression of pituitary-adrenocortical axis. Growth retardation in children (prolonged therapy). Increased susceptibility for infections. Topical use: Dermal atrophy, local irritation, folliculitis, hypertrichosis. Inhalation: Hoarseness, candidiasis of mouth and throat. Topical application to the eye: Corneal ulcers, raised IOP and reduced visual acuity. Intradermal injection: Local hypopigmentation of deeply pigmented skin. Intra-articular injection: Joint damage, fibrosis, esp in load bearing joints.\nPotentially Fatal: Abrupt withdrawal leading to acute adrenal insufficiency manifesting as malaise, weakness, mental changes, muscle and joint pains, dystonia, hypoglycaemia, hypotension, dehydration and death. Rapid IV inj may cause CV collapse.\n\nPrecaution: Uncontrolled diabetes, peptic ulcer, osteoporosis, psychosis, psychoneurosis, pregnancy and lactation. Congestive heart failure, hypertension, epilepsy, CRF, elderly, regular monitoring of patients on long term therapy, withdraw gradually, glaucoma, hypothyroidism, cirrhosis, ocular herpes simplex, ulcerative colitis, infants and children.\n\nMode of action: Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents.\n\nPotentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.\n\nPregnancy category: C\n\nInteraction: Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents.\n\nPotentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.
Betamethasone valerate 0.01% Topical	\n\n\tAcme Ltd.\tBet A Cream   15gm  tube 33\n\tAcme Ltd.\tBeta-A Ointment   15gm  tube 35\n\tAristopharma\tDiprosal Lotion Cream   30gm  tube 150\n\tBio Pharma Ltd.\tMexiderm Cream   15gm  tube 25.09\n\tBio Pharma Ltd.\tMexiderm Ointment   15gm  tube 30.11\n\tDrug International Ltd.\tBetavet Cream  1's pack 19.30\n\tGlaxoSmithKline Bangladesh Ltd.\tBetnovate Cream   15gm  tube/20gm  tube 33.56 / 44.74 \n\tGlaxoSmithKline Bangladesh Ltd.\tBetnovate Ointment   15gm  tube/ 20gm  tube 36 / 48\n\tHealthcare\tBetaval Cream   15gm  tube 33\n\tHealthcare\tBetaval Ointment   15gm  tube 35\n\tHudson\tBetnoson Ointment   15gm  tube 30\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinacort Cream   10gm  tube 20\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinacort Ointment   10gm  tube 20\n\tIncepta\tBetaderm Ointment  15gm 1 's pack 35\n\tPharmadesh Ltd.\tBesone Ointment   5gm  tube 13.04\n\tIndication: Lichen planus, Psoriasis, Eczema, Contact dermatitis, Systemic lupus erythematosus, Lichen simplex, Prurigo nodularis, Plaque psoriasis.\n\nDose:  As valerate (0.1%): Apply sparingly 2-3 times daily. Cream for moist & ointment for dry surface.\n\nContra-indication: Hypersensitivity; systemic fungal or acute infections.\n\nSide effects: Dermal atrophy, local irritation, folliculitis, hypertrichosis. Inhalation: Hoarseness, candidiasis of mouth and throat. Topical application to the eye: Corneal ulcers, raised IOP and reduced visual acuity. Intradermal injection: Local hypopigmentation of deeply pigmented skin. Intra-articular injection: Joint damage, fibrosis, esp in load bearing joints.\n\nPrecaution: Uncontrolled diabetes, peptic ulcer, osteoporosis, psychosis, psychoneurosis, pregnancy and lactation. Congestive heart failure, hypertension, epilepsy, CRF, elderly, regular monitoring of patients on long term therapy, withdraw gradually, glaucoma, hypothyroidism, cirrhosis, ocular herpes simplex, ulcerative colitis, infants and children.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Betamethasone 0.05% + Calcipotriol 0.005%	\n\n\tSquare\tDyvon Plus Ointment  .05 gm + .005 gm/100 gm 20gm pack 380\n\tSquare\tDyvon Plus Topical Suspension 50 mg + 5 mg/100 gm 25ml bot 380\n\tIndication: Psoriasis\n\nDose: Adult: Topical : >18 yr: Apply once daily up to 4 wk. Max: 100 g/wk.\n\nContra-indication: Known or suspected disorders of calcium metabolism. Patients with erythrodermic, exfoliative and pustular psoriasis.\n\nSide effects: Pruritus, rash, burning sensation of the skin, dry skin, erythema, rash, dermatitis, eczema, photosensitivity and hypersensitivity reactions. May aggravate psoriasis.\n\nPrecaution: Not to be used on face, axillae or groin. Not to be applied to more than 30% of the body surface area. Monitor serum calcium levels; treatment should be temporarily discontinued if levels exceeded normal range. Prolonged usage or concurrent use with occlusive dressings may increase absorption of the drugs into the systemic circulation. Regular monitoring for evidence of hypothalamic-pituitary-adrenal axis suppression is recommended. Efficacy and safety have not been evaluated in patients with severe renal or hepatic impairment. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Betamethasone 0.05% + Clotrimazole 1% Topical	\n\n\tACI\tDermasim Cream 1% 15g tube 40.12\n\tAcme Ltd.\tBET-CL Cream   10gm  tube 29\n\tEskayef Bangladesh Ltd.\tGenobat Cream (50 mg + 100 mg)/100 gm  \n\tMedicon\tCloson Cream   10gm  tube 25\n\tOpsonin Pharma\tBetson-CL Cream   10gm  tube 25\n\tSquare\tOni Cream   10gm  tube 29.11\n\tIndication: Inflammed tinea pedis, tinea cruris and tinea corporis.\n\nDose: Adult: Topical: Apply twice daily. Recommended duration: Up to 2 wk (tinea corporis and tinea cruris) and 4 wk (tinea pedis). Max: 45 g/wk.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Dry skin, burning sensation at the site of application, paresthesia, oedema, rash, secondary infections, stinging, skin atrophy.\n\nPrecaution: Systemic absorption of betamethasone may result in suppression of the hypothalmic-pituitary-adrenal axis; prolonged or excessive use may increase systemic absorption of the drug. Monitor for signs of infection. Safety and efficacy have not been established in children <17 yr. Elderly. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Betamethasone 0.05% + Gentamicin 0.1%	\n\n\tIndication: Ocular and ear inflammation with bacterial infection\n\nDose: Adult: Ophth Ocular inflammation with suspected or confirmed bacterial infection As soln containing gentamicin 0.3% and betamethasone 0.1%: Instill 2 drops 3-4 times/day; acute stage: 2 drops 2 hrly. Per g oint contains gentamicin 3 mg and betamethasone 1 mg: Apply Â¼ inch 3-4 times/day. \nOtic Otic inflammation w/ suspected or confirmed bacterial infection As soln containing gentamicin 0.3% and betamethasone 0.1%: Instill 3-4 drops 3 times/day.\n\nContra-indication: Hypersensitivity. Ophthalmic preparations should not be used in epithelial herpes simplex keratitis (dendritic keratitis), varicella, and many other viral diseases of the cornea and conjunctiva, mycobacterial infections of the eye, trachoma, fungal diseases of ocular structures. Not to be used after removal of a corneal foreign body or in the presence of acute local viral lesions e.g. herpes, and in patients with absent or perforated tympanic membranes.\n\nSide effects: Ophthalmic: Increased ocular pressure, increased ocular hyperemia, oedema and burning sensation. May also cause anterior uveitis or perforation of the globe. Otic: May cause ototoxicity.\n\nPrecaution: Prolonged ophthalmic usage may increase the intraocular pressure. Monitor intraocular pressure if treatment lasts for >10 days. Prolonged use of ophthalmic corticosteroid may increase the risk of cataract formation. Increases the risk of perforation in diseases causing thinning of the cornea or sclera. Use of topical corticosteroids may lead to reactivation of disease in patients with a history of herpetic infection of the cornea. Steroid use after cataract surgery may increase risk of filtering blebs and delay healing. Prolonged use may also suppress immune response and increase risk of secondary infections. Safety and efficacy have not been established in children <8 yr. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Betamethasone 0.05% + Lidocaine Hydrochloride 2.5%+ Phenylephrine Hydrochloride 0.1% (Rectal prep)	\n\n\tDrug International Ltd.\tRelitch Rectal Ointment   15gm tube 30\n\tG. A. Company Ltd.\tMethovate R Rectal Ointment   15gm tube 28.33\n\tIndication: Discomfort, pain, itchiness or irritation around the anus, Haemorrhoids (piles)\n\nDose: Apply to perianal region or rectally \nMay apply up to 2-4 times/day, especially at night, in the morning, or after bowel movement that may exacerbate hemorrhoid(s).\n\n\nContra-indication: Hypersensitivity; systemic fungal or acute infections.\n\nSide effects: Topical application to the eye: Corneal ulcers, raised IOP and reduced visual acuity. Intradermal injection: Local hypopigmentation of deeply pigmented skin. Intra-articular injection: Joint damage, fibrosis, esp in load bearing joints.\n\nPrecaution: Uncontrolled diabetes, peptic ulcer, osteoporosis, psychosis, psychoneurosis, pregnancy and lactation. Congestive heart failure, hypertension, epilepsy, CRF, elderly, regular monitoring of patients on long term therapy, withdraw gradually, glaucoma, hypothyroidism, cirrhosis, ocular herpes simplex, ulcerative colitis, infants and children.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Betamethasone 0.05% + Salicylic Acid 2%	\n\n\tIncepta\tBetamesal Scalp Lotion Lotion   30ml 150\n\tSquare\tProsalic Solution  .05 gm + 2 gm/100 ml 25ml 150\n\tIndication: Scalp and non-scalp psoriasis\n\nDose: Apply few drops of Betamesal Scalp Lotion to the affected area and massage gently and thoroughly onto the scalp or skin. The usual frequency of application is twice daily, in the morning and at night.\n\nContra-indication: Viral skin infections e.g. vaccinia, varicella and herpes simplex. Tuberculosis, acne rosacea, fungal skin infections (moniliasis), perioral dermatitis and ulcerative conditions.\n\nSide effects: Pruritus, irritation, folliculitis, maceration of skin, skin atrophy, hypertrichosis, acneiform eruptions, secondary infection, hypopigmentation, perioral dermatitis, allergic contact dermatitis, striae and miliaria.\n\nPrecaution: Not to be used in or near the eyes. Avoid contact with mucous membranes. Prolonged topical corticosteroid treatment may result in systemic corticosteroid effects; may also lead to formation of striae or atrophy of the skin or subcutaneous tissue. Absorption of corticosteroid through the skin is increased when used with occlusive dressings. Caution when used in patients with stasis dermatitis or other skin diseases with impaired blood circulation. Treatment should be re-evaluated on a 4-wkly basis. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Betamethasone 0.1%  E/E & Nasal prep	\n\n\tDrug International Ltd.\tCeludex Drops   10 ml drop 60\n\tG. A. Company Ltd.\tMethasol Drops   5  ml drop 31.80\n\tIncepta\tEyebet Drops  5ml 30\n\tNipa\tBetricin Drops   5  ml drop 29.33\n\tIndication:  Allergic and inflammatory conditions of the eye, ear & nose.\n\nDose: Adults and children\nEye: 1 or 2 drops to each affected eye every 1 or 2 hours until control is achieved, then the frequency may be reduced.\nEar: 2 or 3 drops to each affected ear every 2 or 3 hours until control is achieved, then the frequency may be reduced.\nNose: 2 or 3 drops instilled into each nostril 2 or 3 times daily.\n\nContra-indication: Hypersensitivity; systemic fungal or acute infections.\n\nSide effects: Corneal ulcers, raised IOP and reduced visual acuity. Intradermal injection: Local hypopigmentation of deeply pigmented skin. Intra-articular injection: Joint damage, fibrosis, esp in load bearing joints.\n\nPrecaution: Uncontrolled diabetes, peptic ulcer, osteoporosis, psychosis, psychoneurosis, pregnancy and lactation. Congestive heart failure, hypertension, epilepsy, CRF, elderly, regular monitoring of patients on long term therapy, withdraw gradually, glaucoma, hypothyroidism, cirrhosis, ocular herpes simplex, ulcerative colitis, infants and children.\n\nMode of action: Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents.\nPotentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.\n\nPregnancy category: D\n\nInteraction: Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents.\nPotentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.
Betamethasone 0.1% + Clotrimazole 1% Topical	\n\n\tAcme Ltd.\tBet-CL Ointment   10gm  tube 29\n\tDrug International Ltd.\tBetavate CL Ointment   10gm  tube 25\n\tEskayef Bangladesh Ltd.\tTopibet CL Cream   10g 25\n\tEskayef Bangladesh Ltd.\tTopibet CL Ointment   10gm  tube 25\n\tGlaxoSmithKline Bangladesh Ltd.\tBetnovate CL 				 Ointment   	10gm tube  29.10\n\tIbn Sina Pharmaceutical Ind. Ltd.\tFungin B Cream   10gm  tube 35\n\tOpsonin Pharma\tBetson-CL Ointment   10gm  tube 29.20\n\tUnimed & Unihealth Manufacturers Ltd.\tClozosone Cream 0.05% 1's pack (10g)  25\n\tIndication: Tinea pedis, tinea cruris, tinea corporis, ringworm, athlete's foot, jock itch.							\n\n\nDose: Gently massage sufficient Clotrimazole and Betamethasone Dipropionate Cream into the affected skin areas twice a day, in the morning and evening.\n\nContra-indication: Patients who are sensitive to clotrimazole, betamethasone dipropionate, other corticosteroids or imidazoles, or to any ingredient in these preparations.\n\nSide effects: Adverse reactions reported for Clotrimazole and Betamethasone Dipropionate Cream in clinical trials were paresthesia in 1.9% of patients, and rash, edema, and secondary infection, each in less than 1% of patients.\n\nThe following local adverse reactions have been reported with topical corticosteroids and may occur more frequently with the use of occlusive dressings. \nIn the pediatric population, reported adverse events for Clotrimazole and Betamethasone Dipropionate Cream include growth retardation, benign intracranial hypertension, Cushing's syndrome (HPA axis suppression), and local cutaneous reactions, including skin atrophy.\n\nSystemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.\n\nAdverse reactions reported with the use of clotrimazole are as follows: erythema, stinging, blistering, peeling, edema, pruritus, urticaria, and general irritation of the skin.\n\nPrecaution: Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.\n\nConditions which augment systemic absorption include use over large surface areas, prolonged use, and use under occlusive dressings. \n\nIf HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid.\n\nPediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios \n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Betamethasone 0.1% + Fusidic Acid 2% Topical	\n\n\tEskayef Bangladesh Ltd.\tFacid BT Cream   10gm  tube 135\n\tOrion Pharma Ltd.\tXzema Cream   10gm  tube 200.75\n\tSharif\tFusigal Cream   15gm  tube 135\n\tLeo Pharmaceutical Products,Denmark\tFucicort Cream 0.1% 15gm tube 376.73\n\tIndication: Lichen planus, Psoriasis, Eczema, Contact dermatitis, Seborrhoeic dermatitis, Systemic lupus erythematosus, Lichen simplex, Prurigo nodularis, Sunburns\n\nDose: Adult: Topical As cream containing fusidic acid 2% and betamethasone valerate 0.1%: Apply twice daily. Usual duration: Up to 2 wk/course.\n\nContra-indication: Skin lesions of viral, fungal or bacterial origin, acne rosacea and perioral dermatitis.\n\nSide effects: Prolonged intensive treatment may cause local atrophic changes in the skin e.g. striae, thining and dilatation of superficial blood vessels. Dryness, itching, irritation, hypopigmentation, burning sensation at the site of application or miliaria.\n\nPrecaution: Avoid prolonged continuous treatment especially in infants and children. Extended treatment may increase the risk of contact sensitisation and development of antibiotic resistance. Not to be used for >7 days if there is no clinical improvement. Increased risk of glaucoma if preparation enters the eye(s). Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Betamethasone 0.1% + Neomycin Sulphate 0.5% Topical	\n\n\tAcme Ltd.\tNeobet 5 Cream  (5 + 1) mg / g 5gm  tube/ 10gm  tube/ 15gm  tube 15.28 / 18.28 / 27\n\tBio Pharma Ltd.\tMexiderm N Cream   5gm  tube 15.06\n\tBio Pharma Ltd.\tMexiderm N Ointment   5gm  tube 18\n\tDrug International Ltd.\tBetavate N Cream   10gm  tube 21.55\n\tEdruc Ltd.\tBetanosol-N Cream   5gm  tube 15\n\tEdruc Ltd.\tBetanosol-N Ointment   5gm  tube 18\n\tG. A. Company Ltd.\tMethovate N Cream   5gm  tube/ 10gm  tube 15.34 / 22\n\tG. A. Company Ltd.\tMethovate N Ointment   5gm  tube 18.53\n\tGlaxoSmithKline Bangladesh Ltd.\tBetnovate N Cream   5gm  tube 18.51\n\tGlaxoSmithKline Bangladesh Ltd.\tBetnovate N Ointment   5gm  tube 18.54\n\tHealthcare\tBetaval-N Cream   5gm  tube 18.51\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeocort Cream   5gm  tube 18.53\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeocort Ointment   5gm  tube 18.53\n\tIncepta\tBetaderm N Ointment   10gm  tube 22\n\tOpsonin Pharma\tBetson N Cream   5gm  tube 15.22\n\tPharmadesh Ltd.\tBesone N Ointment   5gm  tube 18\n\tRAK\tBactovate Cream   10gm  tube 22\n\tReman Drug Ltd.\tBetason N Ointment   5gm  tube 18\n\tSquare\tBetameson N Cream   10gm  tube 22.08\n\tSupreme\tBetamycin Ointment   5gm  tube 15.30\n\tIndication: Lichen planus, Psoriasis, Eczema, Contact dermatitis, Seborrhoeic dermatitis, Systemic lupus erythematosus, Lichen simplex, Prurigo nodularis\n\nDose: Adult: Topical  Apply 2-3 times/day. Usual duration: Up to 7 days/course.\n\nContra-indication: Hypersensitivity. Rosacea, acne vulgaris, perioral dermatitis, perianal and genital pruritus and primary cutaneous viral infections. Not to be used in otitis externa complicated by ear-drum perforation. Treatment of primary infected skin lesions caused by fungi or bacteria; primary or secondary infections due to yeast; or secondary infections due to Pseudomonas or Proteus species. Children <2 yr. Ophthalmic preparation: Not to be used in patients with glaucoma or herpetic keratitis.\n\nSide effects: Prolonged use may cause local atrophic changes in the skin e.g. thining, striae and dilatation of superficial blood vessels. Local skin burning sensation, pruritus, pigmentation changes, allergic contact dermatitis and hypertrichosis. Ophthalmic preparation: Corneal ulceration, increased intraocular pressure, mydriasis, ptosis, epithelial punctate keratitis.\n\nPrecaution: Avoid prolonged treatment as it may lead to systemic corticosteroid effects even withour occlusion. Avoid prolonged excessive application to the facial areas. Withdraw treatment if there is spread of the infection. Risk of glaucoma development if preparation enters eye(s). Regular monitoring is recommended when used in psoriasis due to treatment tolerance, rebound relapses, generalised pustular psoriasis or systemic toxicity. Increased risk of contact sensitisation when used for extended period or recurrently. Pregnancy and lactation. Ophthalmic preparation: Monitor intraocular pressure, cataract formation of unsuspected infections; evaluate treatment if there is no clinical improvement after 7 days. Not to be used for undiagnosed red eye.\n\nMode of action: If there is significant systemic absorption, neomycin sulfate may increase the respiratory depressant effects of neuromuscular blockers.\n\nPregnancy category: B\n\nInteraction: If there is significant systemic absorption, neomycin sulfate may increase the respiratory depressant effects of neuromuscular blockers.
Betamethasone  0.1% + Neomycin Sulphate 0.5 E/E prep	\n\n\tAcme Ltd.\tNeobet E Eye Ointment (5 + 1) mg / g 2.5 gm tube/5 gm tube 12.39  / 18.23\n\tAristopharma\tAristobet N Eye/Ear Drops   5  ml drop 32.30\n\tAristopharma\tAristobet-N Eye Ointment 0.1% / 0.5% 5gm tube 10.80\n\tAsiatic Ltd.\tBn Sterile Eye/Ear Drops   5  ml drop 32\n\tG. A. Company Ltd.\tMethasol N Eye Ointment   5 gm tube 12.67 \n\tG. A. Company Ltd.\tMethasol N Eye/Ear Drops   5  ml drop 35\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBetacin N Eye/Ear Drops   5  ml drop 35\n\tNipa\tBetricin N Eye/Ear Drops   5  ml drop 35\n\tNipa\tBetricin-N Eye Ointment 0.1% / 0.5% 3gm tube 10.77\n\tOpso Saline Ltd.\tOptison N Eye Ointment   3 gm tube 10.54\n\tOpso Saline Ltd.\tOptison N Eye/Ear Drops   5  ml drop 30.41\n\tReman Drug Ltd.\tBetasone N Eye Ointment   3 gm tube 10.81\n\tReman Drug Ltd.\tBetasone N Eye/Ear Drops   5  ml drop 32.44\n\tIndication: Allergic and inflammatory conditions of the eye & ear, otitis externa, uveitis, marginal keratitis, allergic conjunctivitis, blepharitis and episcleritis\n\nDose: Eye, Ear & Nasal Drops: Eye: 1 drop instilled into the eye every one or two hours until control is achieved, when the frequency may be reduced. Ear: 2 or 3 drops instilled into the ear, every two or three hours until control is achieved, when the frequency can be reduced. Nose: 2 or 3 drops instilled into each nostril two or three times daily.\n\nEye Ointment: It should be applied thinly and evenly to the conjunctival sac at night (If eye drops used during day) or 3-4 times daily (if ointment used alone).\n\nContra-indication: Skin lesions of viral, fungal or bacterial origin, acne rosacea and perioral dermatitis.\n\nSide effects: Prolonged intensive treatment may cause local atrophic changes in the skin e.g. striae, thining and dilatation of superficial blood vessels. Dryness, itching, irritation, hypopigmentation, burning sensation at the site of application or miliaria.\n\nPrecaution: Avoid prolonged continuous treatment especially in infants and children. Extended treatment may increase the risk of contact sensitisation and development of antibiotic resistance. Not to be used for >7 days if there is no clinical improvement. Increased risk of glaucoma if preparation enters the eye(s). Pregnancy and lactation.\n\nMode of action: If there is significant systemic absorption, neomycin sulfate may increase the respiratory depressant effects of neuromuscular blockers.\n\nPregnancy category: Not Classified\n\nInteraction: If there is significant systemic absorption, neomycin sulfate may increase the respiratory depressant effects of neuromuscular blockers.
Betaxolol 0.25%  Eye prep	\n\n\tAristopharma\tBetaxol 0.25% Eye Drops   5  ml drop 150\n\tBeximco\tGlucovis Eye Drops   5ml bot 200\n\tJayson\tOptibet 0.25% Eye Drops   5  ml drop 150.56\n\tIndication: Glaucoma, Ocular hypertension\n\nDose: Ophthalmic\nOpen-angle glaucoma\nAdult: Instil 1 drop of 0.25% or 0.5% solution bid.\n\nOcular hypertension\nAdult: Instil 1 drop of 0.25% or 0.5% solution bid.\n\n\n\nContra-indication: Hypersensitivity. Sinus bradycardia, cardiogenic shock, overt cardiac failure. Pregnancy .\n\nSide effects: Topical use in eye: Mild ocular stinging and discomfort, usually transient and well-tolerated. Rarely, decreased corneal sensitivity, erythema, itching, keratitis and photophobia reported;\n\nPrecaution: DM, renal or hepatic impairment. May mask signs of hypoglycemia & hyperthyroidism. Gradual withdrawal is recommended. Children. Lactation.\n\nMode of action: Increased risk of bradycardia w/ digitalis glycosides. May cause mydriasis w/ epinephrine. Potential additive effect w/ oral Ca channel blockers, ?-adrenergic blockers, antiarrhythmics (including amiodarone), parasympathomimetics, guanethidine. Increased risk of myocardial depression and hypotension w/ peripheral muscle relaxants (e.g. tubocurarine).\n\nPregnancy category: C\n\nInteraction: Increased risk of bradycardia w/ digitalis glycosides. May cause mydriasis w/ epinephrine. Potential additive effect w/ oral Ca channel blockers, ?-adrenergic blockers, antiarrhythmics (including amiodarone), parasympathomimetics, guanethidine. Increased risk of myocardial depression and hypotension w/ peripheral muscle relaxants (e.g. tubocurarine).
Betaxolol 0.5%  Eye prep	\n\n\tPopular\tOptaloc 0.5% Eye Drops  500 mg/100 ml 5  ml drop 200.75\n\tIndication: Glaucoma, Ocular hypertension\n\nDose: Ophthalmic\nOpen-angle glaucoma\nAdult: Instil 1 drop of 0.25% or 0.5% solution bid.\n\nOcular hypertension\nAdult: Instil 1 drop of 0.25% or 0.5% solution bid.\n\n\n\nContra-indication: Hypersensitivity.Sinus bradycardia, cardiogenic shock, overt cardiac failure. Pregnancy .\n\nSide effects: Topical use in eye: Mild ocular stinging and discomfort, usually transient and well-tolerated. Rarely, decreased corneal sensitivity, erythema, itching, keratitis and photophobia reported; \n\nPrecaution: DM, renal or hepatic impairment. May mask signs of hypoglycemia & hyperthyroidism. Gradual withdrawal is recommended. Children. Lactation.\n\nMode of action: Increased risk of bradycardia w/ digitalis glycosides. May cause mydriasis w/ epinephrine. Potential additive effect w/ oral Ca channel blockers, alpha-adrenergic blockers, antiarrhythmics (including amiodarone), parasympathomimetics, guanethidine. Increased risk of myocardial depression and hypotension w/ peripheral muscle relaxants (e.g. tubocurarine).\n\nPregnancy category: C\n\nInteraction: Increased risk of bradycardia w/ digitalis glycosides. May cause mydriasis w/ epinephrine. Potential additive effect w/ oral Ca channel blockers, alpha-adrenergic blockers, antiarrhythmics (including amiodarone), parasympathomimetics, guanethidine. Increased risk of myocardial depression and hypotension w/ peripheral muscle relaxants (e.g. tubocurarine).
Bimatoprost 0.03% Eye prep	\n\n\tEskayef Bangladesh Ltd.\tLumigan Eye Drops 0.03%  \n\tIncepta\tBimast Eye Drops 0.03 gm/100 ml  \n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: Adult: Ophth Open-angle glaucoma; Ocular HTN As 0.03% soln: Instill 1 drop once nightly.\n\nContra-indication: Known hypersensitivity.\n\nSide effects: Ocular irritation, conjunctival hyperaemia, transient punctate epithelial erosions and eyelid oedema. Darkening and thickening of the eye lashes may occur.\n\nPrecaution: May increase pigmentation of the iris, periorbital tissue and eyelashes. Active intraocular inflammation. Safety and efficacy have not been evaluated in the treatment of inflammatory, neovascular or angle closure glaucoma. Ensure at least an interval of 5 minutes between admin of ophthalmic preparations. Contact lenses should be removed prior to admin. Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Multivitamin-Multimineral A-Z preparations for Teen Girls	\n\n\tBeximco\tBextram Teen Hr			 TAB dr   30's pack 180 \n\tOpsonin Pharma\tZovia Teen G TAB dr   \n\tIndication: Vitamin/Mineral supplement\n\nDose: Adult :1 tab daily or as prescribed by the physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematological remission can occur while neurological manifestations remain progressive. \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Multivitamin-Multimineral A-Z preparations for Teen Boys	\n\n\tBeximco\tBextram Teen Hm TAB dr   30's pack 180\n\tOpsonin Pharma\tZovia Teen B TAB dr   \n\tIndication: Vitamin/mineral supplement \n\nDose: One tablet daily or as recommended by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematological remission can occur while neurological manifestations remain progressive. \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Bisacodyl	\n\n\tAlbion Ltd.\tBisacodyl TAB dr 5 mg 200's pack \n\tOpsonin Pharma\tDuralax TAB dr 5mg 200's pack 140\n\tUnimed & Unihealth Manufacturers Ltd.\tDilax Solution 3.33gm/5ml 1's pack(100ml) 75\n\t Boehringer Ingelheim Pharmaceutical\tDulcolax TAB dr 5mg 100's pack \n\tIndication: Constipation, Bowel evacuation\n\nDose: Oral\nConstipation\nAdult: 5-10 mg at night.\nChild: >4 yr: 5 mg at night time.\nElderly:\nOral\nBowel evacuation\nAdult: Initially, 10-20 mg the night before the procedure followed by 10 mg suppository admin rectally the next morning.\nChild: >10 yr: Same as adult dose. 4-10 yr: 5 mg the night before the procedure and 5 mg suppository admin rectally the following morning. \n\nContra-indication: Acute surgical abdomen or intestinal obstruction, severe dehydration, faecal impaction, chronic use.\n\nSide effects: Abdominal discomfort (colic, cramps). Suppositories may cause irritation and proctitis.\n\nPrecaution: Swallow the tab whole. Pregnancy; inflammatory bowel disease.\n\nMode of action: Do not give antacids or milk within 1 hr of taking the drug (enteric coated).\n\nPregnancy category: C\n\nInteraction: Do not give antacids or milk within 1 hr of taking the drug (enteric coated).
Bismuth Subcitrate	\n\n\tIndication: Gastric and duodenal ulceration, H.pylori infection, Peptic ulcers\n\nDose: Adult: PO Benign gastric and duodenal ulceration 240 mg twice daily for 4-8 wk. H.pylori infection W/ other drugs: 120 mg 4 times/day for 2 wk.\n\nContra-indication: Moderate-severe renal insufficiency. Pregnancy, child <14 yr.\n\nSide effects: Darkening of tongue or stools. Nausea, vomiting, bone and joint toxicity.\nPotentially Fatal: Possibility of bismuth poisoning and fatal encephalopathy in patients with renal impairment or if given over prolonged periods. Renal failure and liver damage.\n\nPrecaution: Lactation. Monitor renal function regularly.\n\nMode of action: Food, milk, antacids, tetracyclines and H2-receptor antagonists reduce activity of drug.\n\nPregnancy category: Not Classified\n\nInteraction: Food, milk, antacids, tetracyclines and H2-receptor antagonists reduce activity of drug.
Bisoprolol  + Hydrochlorothiazide	\n\n\tACI\tProbis Plus TAB dr  2.5/6.25mg 30's pack 180.60\n\tACI\tProbis Plus TAB dr  5/6.25mg 30's pack 300.90\n\tAristopharma\tAncor Plus 2.5 TAB dr   30's pack 180\n\tAristopharma\tAncor Plus 5 TAB dr   30's pack 300\n\tDrug International Ltd.\tTenobis Plus TAB dr 10 mg + 6.25 mg  \n\tEskayef Bangladesh Ltd.\tCardobis Plus TAB dr 2.5 mg + 6.25 mg  \n\tEskayef Bangladesh Ltd.\tCardobis Plus TAB dr 5 mg + 6.25 mg  \n\tIncepta\tBisopro Plus TAB dr 2.5mg + 6.25mg 30's pack \n\tIncepta\tBisopro Plus TAB dr 5mg + 6.25mg 30's pack \n\tOpsonin Pharma\tBislol Plus 5/6.25 TAB dr  30's pack 300\n\tOpsonin Pharma\tBislol Plus 2.5/6.25 TAB dr  30's pack 180\n\tOpsonin Pharma\tBislol Plus 10/6.25 TAB dr  20's pack 480\n\tSquare\tBisocor Plus 10/6.25 TAB dr  10 mg + 6.25 mg 20's pack 320\n\tSquare\tBisocor Plus 2.5/6.25 TAB dr  2.5 mg + 6.25 mg 30's pack 180\n\tSquare\tBisocor Plus 5/6.25 TAB dr  5 mg + 6.25 mg 30's pack 300\n\t Boehringer Ingelheim Pharmaceutical\tProbis-2.5/6.25 TAB dr  30's pack 180\n\t Boehringer Ingelheim Pharmaceutical\tProbis-5/6.25 TAB dr  30's pack 300\n\tIndication: Hypertension, Congestive heart failure, HTN, Angina pectoris\n\nDose: Adult: PO Initial: 2.5 mg/6.25 mg tablet once daily.\n\nIncrease based on clinical response in 2 weeks, Maximum: bisoprolol 20 mg/hydrochlorothiazide 12.5 mg once daily.\n\nContra-indication: Low cardiac output and uncompensated cardiac failure; sinus bradycardia, 1st Â° heart block, cardiogenic shock, bronchospasm; severe haemorrhage. Pregnancy.\n\nSide effects: Giddiness, headache, fatigue, bradycardia. Nausea, vomiting, diarrhoea or constipation, stomach discomfort, mild ocular stinging, photophobia, keratitis, decreased sexual ability. GI disturbances, dyspnoea, cold extremities, insomnia, hallucination, drowsiness and mood alterations.\nPotentially Fatal: AV block, bradycardia. Rare but may occur in patients with preexisting cardiac disease. Includes severe bronchospasm, hypoglycaemia, hypotension, orthostatic hypotension, bradyarrhythmias. 'Rebound phenomenon' leading to unstable angina or MI on sudden withdrawal.\n\nPrecaution: Bronchospastic disease, hyperthyroidism, peripheral vascular disease, undergoing anaesthesia. Monitor blood glucose regularly. May mask symptoms of hypoglycaemia. Elderly. Gradual withdrawal is advised. Lactation.\n\nMode of action: Bisoprolol : May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.\n\nHydrochlorothiazide: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.\n\nPregnancy category: A\n\nInteraction: Bisoprolol : May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.\n\nHydrochlorothiazide: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
Black Seed Oil	\n\n\tIndication: Constipation, Asthma, Diarrhea, Hemorrhoids, Gas, Colic, Dysentery, Allergies, Cough, Bronchitis, Flu, Swine flu, Congestion, Hyperlipidemia, Cancer, Emphysema, HTN\n\nDose: The appropriate dose of black seed depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for black seed. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Black seed, when used in small quantities, such as a flavoring for foods, appears to be safe for most people. There isn't enough information to know if larger, medicinal quantities are safe. Black seed can cause allergic rashes when applied to the skin. \n\nPrecaution: Black seed seems to be safe in food amounts during pregnancy. But taking larger medicinal amounts is UNSAFE. Black seed can slow down or stop the uterus from contracting.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Boric Acid 2% + Dithranol 0.1% + Salicylic Acid 1%	\n\n\tG. A. Company Ltd.\tGacozema Ointment   6gm  tube 120\n\tMillat\tRing Fight Ointment  6.5gm 12's pack 72\n\tIndication: Psoriasis, Eczema.\n\nDose: Apply on the skin  2 times daily. The preparation is applied to the lesion, covered with a dressing & left for 1 hour.\n\nContra-indication: Hypersensitivity, acute & pustular psoriasis.\n\nSide effects: Local burning sensation & irritation, stains skin, hair and fabrics.\n\nPrecaution: Avoid contact of eyes & sensitive areas of skin.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Calcium + Vitamin D + Minerals	\n\n\tACI\tAcical M TAB dr   30's pack 150.60\n\tACI\tAcical-M TAB dr 600mg+200 IU+Minerals 30's pack 151.20\n\tAcme Ltd.\tNutrum Bone TAB dr   30's pack 120.30\n\tAlbion Ltd.\tCalcium Forte Plus M TAB dr 600 mg+200 IU 30's pack \n\tAlco Pharma\tCalmi-M TAB dr   15's pack / 30's pack 60 / 120\n\tAmico Ltd.\tOracal-M TAB dr   15's pack 60\n\tApex\tApocal-DM TAB dr   15's pack / 30's pack  60 / 120\n\tAristopharma\tCalbon M TAB dr   15's pack / 30's pack 75/ 150\n\tBeacon\tProtebon M TAB dr   30's pack 150\n\tBeximco\tAristocal M TAB dr   20's pack 110\n\tDecent Pharma Ltd.\tCZM TAB dr   15's pack / 30's pack 60 / 120\n\tDelta Pharma\tBoni M TAB dr   15's pack / 30's pack 60 / 120\n\tEskayef Bangladesh Ltd.\tOstocal M TAB dr   30's pack 150\n\tEverest\tEvecal D M TAB dr   30's pack 120\n\tGeneral\tCadmin PLUS TAB dr   15's pack / 30's pack 60.30 / 120.60\n\tGlobe\tCarbocal M TAB dr   30's pack 120\n\tGlobex\tBontonic TAB dr  30's pack 150\n\tHealthcare\tRocal M TAB dr   32's pack 224\n\tIbn Sina Pharmaceutical Ind. Ltd.\tIpical M TAB dr   30's pack 150\n\tIncepta\tCalvimax PLUS TAB dr   30's pack 150\n\tNavana\tMiracal M TAB dr   50's pack 80\n\tNavana\tCalcium-M TAB dr   30's pack 120\n\tOpsonin Pharma\tOstogen Plus Chewable TAB dr  30's pack 150\n\tPacific\tCal D PLUS TAB dr   15's pack / 30's pack  69 / 138\n\tPharmasia Ltd.\tXtracal M TAB dr   15's pack / 30's pack 60.30 / 120.60\n\tRenata\tCalcin-M TAB dr   30's pack / 40's pack 150 / 200.40\n\tSilva\tCalsil M TAB dr   30's pack 164\n\tSomatec\tCalmet M TAB dr   15's pack / 30's pack 60.15 / 120.30\n\tSquare\tCalboplex TAB dr   30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tOscal-M TAB dr   30's pack 150\n\tZenith\tMultical TAB dr   30's pack 120\n\tIndication: Osteoporosis, Calcium deficiency, Post-menopausal osteoporosis, Rickets, Osteocalcaemia, Mineral supplement\n\nDose: Adults and Elderly and children above 12 years of age: 2 tablets per day, preferably one tablet each morning and evening.\n\nChildren: Not recommended for children under 12 years.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Mild and transient effects of gastrointestinal disturbances, like constipation, flatulence, nausea, diarrhoea may be seen in some individuals. Following administration of vitamin D supplements may cause skin rash in some rare cases. Hypercalciuria have been seen with long term use at high dosage.\n\nPrecaution: Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. Periodic checks of plasma calcium levels and urinary calcium excretion should be made in patients with mild to moderate renal failure or mild hypercalciuria. \n\nUrinary calcium excretion should also be measured. In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria. With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5mmol/24 hours. \n\nMode of action: May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.\n\nPregnancy category: C\n\nInteraction: May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
Bosentan	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tPulmoten TAB dr 62.5mg 7's pack\n 1050\n\tIndication: Pulmonary Arterial Hypertension (PAH)\n\nDose: Adult Dosage:\nInitiate treatment at 62.5 mg twice daily for 4 weeks and then increase to the maintenance dose of 125 mg twice daily. Doses above 125 mg twice daily did not appear to confer additional benefit sufficient to offset the increased risk of hepatotoxicity.\n\nBosentan should be administered in the morning and evening with or without food.\n\nContra-indication: Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of hepatotoxicity in WHO Class II patients, which may preclude future use as their disease progresses.\n\nSide effects: More common\n\n    Blurred vision\n    confusion\n    dizziness\n    dark urine\n    faintness or lightheadedness when getting up from a lying or sitting position\n    fever with or without chills\n    light-colored stools\n    loss of appetite\n    nausea and vomiting\n    stomach pain\n    sudden sweating\n    unusual tiredness or weakness\n    yellow eyes or skin\n\n\nPrecaution: Hepatotoxicity and teratogenicity. Elevations of AST or ALT associated with Bosentan are dose-dependent, occur both early and late in treatment, usually progress slowly, are typically asymptomatic, and usually have been reversible after treatment interruption or cessation. Aminotransferase elevations also may reverse spontaneously while continuing treatment with Tracleer.\n\nLiver aminotransferase levels must be measured prior to initiation of treatment and then monthly and therapy adjusted accordingly .Discontinue Bosentan if liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2 \n\nMode of action: Increased bosentan levels w/ CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, diltiazem), CYP2C9 inhibitors (e.g. amiodarone, fluconazole), tacrolimus. Rifampicin initially increases but subsequently decreases bosentan concentration. May decrease plasma levels of warfarin, statins (e.g. simvastatin, lovastatin), hormonal contraceptives, sildenafil, tadalafil.\nPotentially Fatal: Increased risk of hepatotoxicity may occur w/ glibenclamide. Ciclosporin markedly increases bosentan concentration.\n\nPregnancy category: X\n\nInteraction: Increased bosentan levels w/ CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, diltiazem), CYP2C9 inhibitors (e.g. amiodarone, fluconazole), tacrolimus. Rifampicin initially increases but subsequently decreases bosentan concentration. May decrease plasma levels of warfarin, statins (e.g. simvastatin, lovastatin), hormonal contraceptives, sildenafil, tadalafil.\nPotentially Fatal: Increased risk of hepatotoxicity may occur w/ glibenclamide. Ciclosporin markedly increases bosentan concentration.
Brimonidine Tartrate (0.2 %, 0.15%)  Eye prep	\n\n\tAristopharma\tAlphaten Eye Drops  5ml bot 80\n\tEskayef Bangladesh Ltd.\tAlphagan Eye Drops 0.15%  \n\tG. A. Company Ltd.\tRocular Eye Drops   5ml drop 80\n\tIncepta\tBrimodin Eye Drops   5  ml drop 80\n\tOpsonin Pharma\tBricoma Eye Drops 0.2%  \n\tPopular\tBrimo Eye Drops  .2 % 5  ml drop 80.30\n\tSquare\tLocular Eye Drops   5  ml drop 80.30\n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: The recommended dose is 1 drop of ophthalmic solution in the affected eye(s) twice daily (doses taken approximately 12 hours apart).\n\n\nContra-indication: This eye drops are contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication.This product is also contraindicated in patients receiving monoaminase oxidase inhibitor therapy.\n\nSide effects: Headache; itching of eye; redness of eye or inner lining of eyelid; swelling of eyelid; tearing of eye. \n\nPrecaution: General\nBrimonidine ophthalmic solution should be used with caution in patients with known hypersensitivity to other alpha-adrenoceptor agonists.\n\nAlthough brimonidine had minimal effect on blood pressure and heart rate of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.\n\nBrimonidine has not been studied in patients with hepatic or renal impairment; caution should be exercised in treating such patients.\n\nBrimonidine should be used with caution in patients with depression, cerebral or coronary insufficiency.\n\nMode of action: Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with beta-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.\n\nPregnancy category: B\n\nInteraction: Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with beta-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.
Brimonidine Tartrate 0.2% + Timolol Maleate 0.5%  Eye prep	\n\n\tApex\tBrimolol Eye Drops   5  ml drop 110\n\tAristopharma\tCombipres Eye Drops   5  ml drop 110\n\tEskayef Bangladesh Ltd.\tCombigan Eye Drops   \n\tGeneral\tCombat Eye Drops   5ml drop 110\n\tGlobe\tGlumol Plus Eye Drops 200 mg + 500 mg/100 ml  \n\tHealthcare\tWigan Eye Drops (200 mg + 500 mg)/100 ml  \n\tIncepta\tBrimodin Plus Eye Drops   5ml 110\n\tPopular\tBrimopres Eye Drops 0.2% + 0.5% 5ml bot 110.42\n\tReman Drug Ltd.\tTimo-plus Eye Drops   5ml drop 110\n\tSquare\tLocular Plus Eye Drops 0.2% + 0.5% 5ml bot 110\n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: Adult: Ophth: Instill 1 drop 2 times/day approximately 12 hours apart.\n\nContra-indication: Hypersensitivity. Patients receiving MAO inhibitor therapy.\n\nSide effects: Ocular dryness; ocular hyperaemia, burning and stinging; headache, blurring of vision; foreign body sensation, fatigue or drowsiness; conjunctival follicles, ocular allergic reactions and ocular pruritus. Corneal staining or erosion, photophobia, eyelid erythema, ocular ache and pain, ocular dryness, tearing; upper respiratory symptoms; eyelid oedema, conjunctival oedema, dizziness, blepharitis, ocular irritation; GI symptoms; asthaenia; conjunctival blanching, abnormal vision and muscular pain.\n\nPrecaution: Patients wearing soft contact lenses should wait for at least 15 min after instilling brimonidine tartrate before inserting soft contact lenses. Renal or hepatic impairment. CV disease. Use with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangitis obliterans. Pregnancy, lactation.\n\nMode of action: Brimonidine Tartrate: Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with ?-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.\n\nTimolol: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).\n\nPregnancy category: A\n\nInteraction: Brimonidine Tartrate: Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with ?-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.\n\nTimolol: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).
Bromazepam	\n\n\tACI\tZepam TAB dr 3mg 50's pack/100's pack 251/402\n\tAcme Specialized\tTenil TAB dr 3mg 100's pack 401\n\tAlbion Ltd.\tBromazepam TAB dr 3 mg 50's pack \n\tAlco Pharma\tBrozep TAB dr 3mg 100's pack 300\n\tAmbee\tRem TAB dr 3mg 30's pack 60.30\n\tAmico Ltd.\tRelaxium TAB dr 3mg 30's pack 75\n\tAristopharma\tNotens TAB dr 3mg 50's pack 200\n\tAsiatic Ltd.\tLexnil TAB dr 3mg 50's pack 200\n\tBenham\tBenzopam TAB dr 3mg  \n\tBeximco\tNightus TAB dr 3mg 100's pack 300\n\tBio Pharma Ltd.\tBroze TAB dr 3mg 50's pack 150.50\n\tDelta Pharma\tFreten TAB dr 3mg 45's pack 135\n\tDoctor's Chemicals Works Ltd.\tBronium TAB dr 3mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tRestol TAB dr 3mg 30's pack 120\n\tGeneral\tTenapam TAB dr 3mg 30's pack 120.60\n\tHealthcare\tLexopil TAB dr 3mg 50's pack 225\n\tIncepta\tSiesta TAB dr 3mg 30's pack 120\n\tKemiko\tKpam TAB dr 3mg  \n\tKumudini Pharma Ltd.\tMapez TAB dr 3mg 50's pack 175\n\tNavana\tTynaxie TAB dr 3mg 30's pack \n\tNIPRO JMI Pharma\tAnxionil TAB dr 3mg 50's pack 150\n\tNovartis (Bangladesh) Ltd.\tXionil TAB dr 3mg 50's pack 250\n\tNovo Healthcare and Pharma Ltd.\tAnxirel TAB dr 3mg 30's pack 90\n\tNuvista Pharma Ltd\tTarbo TAB dr 3mg  \n\tOpsonin Pharma\tBopam TAB dr 3mg 50's pack 225\n\tOrion Pharma Ltd.\tBromazep TAB dr 3mg 50's pack 150.50\n\tPopular\tAnxopam TAB dr 3mg 30's pack 90.30\n\tRadiant.\tLexotanil TAB dr 3mg 70's pack 420\n\tRAK\tBromapam TAB dr 3mg 50's pack 200\n\tRangs\tAncotil TAB dr 3mg 50's pack 150\n\tRenata\tNorry TAB dr 3mg 50's pack 200\n\tRephco\tLaxonil TAB dr 3mg 50's pack 150\n\tSquare\tLaxyl TAB dr 3mg 50's pack 200.50\n\tSupreme\tLaten TAB dr 3mg 30's pack 75\n\tUnimed & Unihealth Manufacturers Ltd.\tAnxio TAB dr 3mg 30's pack 135\n\tIndication: Anxiety, Panic attacks\n\nDose: Adult: PO Initial: 6-18 mg/day in divided doses. Higher doses  have occasionally been given to hospitalized patients. Dose should be reduced at least half in elderly patients and those with hepatic and renal impairment.\n\nContra-indication: Preexisting CNS depression or coma, resp depression, acute pulmonary insufficiency or sleep apnea; severe hepatic impairment; not indicated for chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behavior, not used alone to treat depression or anxiety associated with depression; glaucoma.\n\nSide effects: Drowsiness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia; rarely, jaundice, blood disorders and hypersensitivity reactions; pain and thrombophlebitis; raised liver enzyme values; paradoxical excitation.\n\nPrecaution: Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; patients with personality disorders or organic brain changes; pregnancy and lactation; history of alcohol or drug addiction due to risk of dependence. resp depression and hypotension with parenteral administration, therefore this route should only be used when facilities for reversing resp depression are available.\n\nMode of action: May enhance the activity w/ CYP450 inhibitor (e.g. azole antifungals, macrolides, HIV protease inhibitors, Ca channel blockers). Elevated plasma levels w/ disulfiram or cimetidine. Additive CNS depressant effects w/ barbiturates, sedatives, anaeasth, anxiolytics, hypnotics, phenothiazines, other antipsychotics, skeletal muscle relaxants. May potentiate anticholinergic effects of atropine, antihistamines and antidepressants. Increased psychic drug dependence w/ narcotic analgesics.\n\nPregnancy category: Not Classified\n\nInteraction: May enhance the activity w/ CYP450 inhibitor (e.g. azole antifungals, macrolides, HIV protease inhibitors, Ca channel blockers). Elevated plasma levels w/ disulfiram or cimetidine. Additive CNS depressant effects w/ barbiturates, sedatives, anaeasth, anxiolytics, hypnotics, phenothiazines, other antipsychotics, skeletal muscle relaxants. May potentiate anticholinergic effects of atropine, antihistamines and antidepressants. Increased psychic drug dependence w/ narcotic analgesics.
Bromfenac Sodium 0 .09 %  eye prep	\n\n\tACI\tRotarac Eye Drops  0.09% 5  ml drop 95.65\n\tAcme Ltd.\tEyefen Eye Drops 90 mg/100 ml  \n\tApex\tXirofen Eye Drops   5ml bot 95\n\tAristopharma\tXirom Eye Drops   5  ml drop 100\n\tEskayef Bangladesh Ltd.\tRomfen Eye Drops  0.9mg/ml 5ml 100\n\tGeneral\tAcunac Eye Drops   5ml drop 100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBromofen Eye Drops   5  ml drop 100\n\tIncepta\tXibrofen Eye Drops   5  ml drop 100\n\tNavana\tInarom Eye Drops 0.09% 5ml bot \n\tOpso Saline Ltd.\tBSH Eye Drops   5  ml drop 100\n\tOpsonin Pharma\tBromnac Eye drops .09% 1's pack 88.33\n\tPopular\tBfenac Eye Drops  90 mg/100 m 5  ml drop 100\n\tReman Drug Ltd.\tRe-Fenac Eye Drops   5  ml drop 100\n\tSquare\tOcufen 0.09% Eye Drops   5  ml drop/10 ml drop 100.38/100.38\n\tSquare\tOcubrom Eye Drops 0.09% 5ml bot 100\n\tIndication: Postoperative ocular inflammation, Ocular pain\n\nDose: One drop should be applied to the affected eye(s) once daily beginning 1 day prior to surgery,continued on the day of surgery and through 2 weeks after surgery.\n\nContra-indication: Bromfenac ophthalmic solution is contraindicated in patients with known hypersensitivity to any ingredients of the formulation.\n\nSide effects: Abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache and iritis.\n\nPrecaution: Bromfenac ophthalmic solution should be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.\nPatients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Bromhexine Hydrochloride	\n\n\tAcme Ltd.\tA Cold Syrup 4mg/5ml 1'spack(100ml) 40 	\n\tAcme Ltd.\tA-Cold Syrup 4 mg / 5 ml 100ml bot 30.11\n\tAexim\tDe-Cold Syrup 4mg/5ml 100ml bot 30\n\tAlbion Ltd.\tMytil Syrup 4 mg/5 ml 100 ml \n\tAlco Pharma\tBrolyt Syrup 4mg/5ml 100ml bot 27\n\tAlco Pharma\tBrolyt TAB dr 4mg 50's pack 35\n\tAlco Pharma\tBrolyt TAB dr 8mg 50's pack 50\n\tAmico Ltd.\tMucola Syrup 4mg/5ml 100ml bot 25\n\tAristopharma\tExpecto Syrup 4mg/5ml 100ml bot 30\n\tAsiatic Ltd.\tCoflyt Syrup 4mg/5ml 100ml bot 30\n\tBeximco\tSpulyt Syrup 4mg/5ml 100ml bot 30\n\tBio Pharma Ltd.\tMucut Syrup 4mg/5ml 100ml bot 30.11\n\tCosmic Chemical Industries Ltd.\tMucopront Syrup 4mg/5ml 100ml bot 31\n\tDelta Pharma\tMusis Syrup 4mg/5ml 100ml bot 30\n\tDrug International Ltd.\tBroncomet Syrup 4mg/5ml 100ml bot 30\n\tEskayef Bangladesh Ltd.\tMucoten TAB dr 8mg  \n\tEskayef Bangladesh Ltd.\tMucoten Syrup 4 mg/5 ml  \n\tEthical Drug Ltd.\tEhexin Syrup 4 mg/5 ml  \n\tG. A. Company Ltd.\tMulyt Syrup 4mg/5ml 100ml bot 30\n\tGeneral\tBroxine Syrup 4mg/5ml 100ml bot 30.11\n\tHealthcare\tBromoxol DS Syrup 4mg/5ml 100ml bot 60\n\tHealthcare\tBromoxol Syrup 4mg/5ml 100ml bot 35\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBromotex Syrup 4mg/5ml 100ml bot 40\n\tIncepta\tMucolyt Syrup 4mg/5ml 100ml bot 50\n\tIncepta\tMucolyt TAB dr 8mg 100's pack 200\n\tKumudini Pharma Ltd.\tNaxcel Syrup 4mg/5ml 100ml bot 30\n\tMedimet\tCold B TAB dr 4mg 100's pack 70\n\tMillat\tBrohexin Syrup 4mg/5ml 100ml bot 30\n\tNipa\tN Hexin Syrup 4mg/5ml 100ml bot 30\n\tNIPRO JMI Pharma\tMucodil Syrup 4mg/5ml 100ml bot 30\n\tOpsonin Pharma\tMunil Syrup 4mg/5ml 100ml bot 30\n\tPeoples Pharma Ltd.\tBromolit Syrup 4mg/5ml 100ml bot 25\n\tPharmadesh Ltd.\tMexilyt Syrup 4mg/5ml 60ml bot/100ml bot 18.06/25.09\n\tRangs\tX-Pectoran Syrup 4mg/5ml 100ml bot 30\n\tRangs\tX-Pectoran TAB dr 8mg 50's pack 100\n\tRephco\tBrostin Syrup 4mg/5ml 100ml bot 30\n\tRephco\tBrostin DS TAB dr 8mg 10x10's pack 200\n\tSalton\tMucof Syrup 4mg/5ml 100ml bot 30.11\n\tSilva\tSputen Syrup 4mg/5ml 100ml bot 30.11\n\tSomatec\tBromex Syrup 4mg/5ml 100ml bot 27.10\n\tSomatec\tBromex TAB dr 8mg 100's pack 101\n\tSquare\tMucospel Syrup 4mg/5ml 50ml bot 22.08\n\tSquare\tMucospel TAB dr 8mg 100's pack 200.83\n\tSquare\tMucospel 100ml Syrup 4mg/5ml 100ml bot 40\n\tZenith\tTopsil TAB dr 4mg 100's pack 70\n\tZenith\tTopsil Syrup 4mg/5ml 100ml bot 30\n\tZiska\tMuconil Syrup 4mg/5ml 100ml bot 30\n\tIndication: Productive cough, Acute sore throat, Mucolytic\n\nDose: Tablet:\nAdults and children over 10 years: 8-16 mg 3 times daily. Children 5-10 years: 4 mg 3 times daily.\n\nSyrup:\nAdults: The recommended daily dose is 2 to 4 teaspoonful 3 times. Initially 4 teaspoonful 3 times daily and then as required.\n\nChildren: Suggested dosage for children under 2 years is 1/4 teaspoonful 3 times daily, \n2-5 years 1/2 teaspoonful 3 times daily \n5-10 years 1 teaspoonful 3 times daily.\n\nContra-indication: Contraindicated to those who are hypersensitive to Bromhexine Hydrochloride.\n\nSide effects: GI side effects; headache, dizziness, sweating, skin rashes. Inhalation: Cough or bronchospasm.\n\nPrecaution: History of peptic ulceration; asthmatic patients. Severe hepatic or renal impairment.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Budesonide	\n\n\tAcme Ltd.\tBudeson Dry powder inhalation capsule 200mcg 30 doses unit 90\n\tBeximco\tAeronid Inhaler 200mcg 120 doses unit 400\n\tBeximco\tAeronid HFA Inhaler 200mcg 30's pack 420\n\tIncepta\tBudicort 0.5 Nebuliser Suspension 0.5mg/2ml 5's pack 350\n\tSquare\tZycort Dry powder inhalation capsule 200mcg 30's pack \n\tIndication:  Asthma, COPD.				\n\nDose: Adult: Inhalation Asthma As metered dose inhaler: 400 mcg/day in 2 divided doses, up to 1.6 mg/day in severe cases. Maintenance: 200-400 mcg/day. As dry powd inhaler: 200-800 mcg/day. As nebulised soln: Inhale. Adults and elderly: 1 - 2 mg twice daily. \n\nChildren 3 months to 12 years of age: 0.5 - 1 mg twice daily.\n\nContra-indication: Hypersensitivity to any of the ingredients of this preparation.\n\nSide effects: Sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects. hoarseness and candidiasis of the mouth or throat.\n\nPrecaution: Active or doubtfully quiescent tuberculosis, paradoxical bronchospasm; untreated fungal, bacterial, or systemic viral infections, or ocular herpes simplex infection. Pregnancy, lactation.\n\nMode of action: Increased systemic exposure w/ potent CYP3A4 inhibitors (e.g. ketoconazole). Decreased systemic exposure w/ CYP3A4 inducers (e.g. carbamazepine).\n\nPregnancy category: B\n\nInteraction: Increased systemic exposure w/ potent CYP3A4 inhibitors (e.g. ketoconazole). Decreased systemic exposure w/ CYP3A4 inducers (e.g. carbamazepine).
Budesonide + Formoterol Fumarate	\n\n\tACI\tOxycort 160/4.5 HFA Inhaler   1's pack 800\n\tACI\tOxycort 80/4.5 HFA Inhaler   1's pack 600\n\tACI\tOxycort 12/400 Acucap Dry Powder Inhaler 12Âµg+400Âµg/Cap 32's pack 429.28\n\tACI\tOxycort 6/100 Acucap Dry Powder Inhaler 6Âµg+100Âµg/Cap 32's pack 224.64\n\tACI\tOxycort 6/200 Acucap Dry Powder Inhaler 6Âµg+200Âµg/Cap 32's pack 288.96\n\tAcme Ltd.\tBudefort Cozycap 400 mcg + 12 mcg  \n\tAcme Ltd.\tBudefort Cozycap 200 mcg + 6 mcg  \n\tAristopharma\tBudison F 160 Inhaler   1's pack 500\n\tAristopharma\tBudison F 80 Inhaler   1's pack 400\n\tBeximco\tSymbion 4.5/160 Inhaler   1's pack 960\n\tBeximco\tSymbion 6/100 Bexicap Cozycap   30's pack 210\n\tBeximco\tSymbion 6/200 Bexicap Cozycap   30's pack 270\n\tIncepta\tBudemet 100 ConviCap Cozycap  100/6 Âµg  30's pack 210\n\tIncepta\tBudemet 200 Convicap Cozycap  200/6 Âµg  30's pack 270\n\tIncepta\tBudemet 400 Convicap Cozycap 400/12 Âµg  30's pack 420\n\tSquare\tBufocort 100 Cozycap  100 mcg + 6 mcg 100 cozycap X 30's pack 210\n\tSquare\tBufocort 200 Cozycap  200 mcg + 6 mcg 200 cozycap X 30's pack 270\n\tSquare\tBufocort 400 Cozycap  400 mcg + 12 mcg 400 cozycap X 30's pack 420\n\tIndication: Asthma, COPD\n\nDose: Asthma Maintenance and reliever therapy: Adults and adolescents (12 years and older) -\n\nAs both maintenance and reliever therapy:\nAdults and adolescents (12 years and older): The recommended maintenance dose is 1 puff twice daily or 2 puffs once daily. For some patients a maintenance dose of 2 puffs twice daily may be appropriate (for 160/4.5 mcg/inhalation only). Patients should take 1 additional puff as needed in response to symptoms. If symptoms persist after a few minutes, the additional puff should be taken. Not more than 6 puffs should be taken on any single occasion.\nChildren: The usual maintenance dose is 1-2 puffs once or twice daily. Patients should take 1 additional puff as needed in response to symptoms. If symptoms persist after a few minutes, the additional puff should be taken. Not more than 4 puffs should be taken on any single occasion. \n\nConvicap/cozycap: Maintenance dose: 100 Convicap twice daily. 200 Convicap twice daily. Reliever dose: 1 additional Convicap as needed in response to symptoms. If symptoms persist after a few minutes, an additional Convicap should be taken.  \n\nChildren-Maintenance dose: 100 Convicap: 1-2 ConviCaps once daily. Reliever dose: 1 additional Convicap as needed in response to symptoms. If symptoms persist after a few minutes, an additional Convicap should be taken. \n\nCOPD 200 Convicap: 2 Convicaps twice daily. 400 Convicap: 1 Convicap twice daily\n\nContra-indication: Primary treatment of status asthmaticus or other acute episodes of asthma. Hypersensitivity to Budesonide, Formoterol or to Lactose.\n\nSide effects: The most common drug related adverse reactions are pharmacologically predictable side effects of beta 2-agonist therapy, such as tremor and palpitations. Adverse events which have been associated with Budesonide and Formoterol are Palpitations, Candida infections in oropharynx, Headache, Tremor, Coughing, Hoarseness and Tachycardia.\n\nPrecaution: Treatment with Budesonide and Formoterol combination should not be initiated to treat a severe exacerbation or if patients have significantly worsening or acutely deteriorating asthma. May produce paradoxical bronchospasm which is life-threatening. Caution when used in patients with CV diseases, especially coronary insufficiency, cardiac arrhythmias and hypertension. Chronic use may further decrease bone mineral content when used in patients with advanced age, osteoporosis, poor nutrition, sedentary lifestyle or tobacco use. May reduce growth velocity when used in paediatric patients. Caution when used in patients with active or quiescent tuberculosis infection of the respiratory tract, untreated systemic fungal, bacterial, viral or parasitic infections, or ocular herpes simplex. Pregnancy and lactation.\n\nMode of action: Concomitant admin with CYP3A4 inhibitor e.g. itraconazole, clarithromycin, erythromycin may inhibit the metabolism of budesonide. Concurrent use with nonpotassium-sparing diuretics may lead to ECG changes and/or hypokalaemia.\n\nPregnancy category: A\n\nInteraction: Concomitant admin with CYP3A4 inhibitor e.g. itraconazole, clarithromycin, erythromycin may inhibit the metabolism of budesonide. Concurrent use with nonpotassium-sparing diuretics may lead to ECG changes and/or hypokalaemia.
Budesonide 0.1%  Nasal spray	\n\n\tACI\tBudenide Nasal Spray  100mcg/spray 120 sprays 250\n\tIncepta\tBudicort Nasal Spray 100mcg  120mtered dose 250\n\tOpsonin Pharma\tPulmicort Nasal Spray    120 dose ( spray) unit 250\n\tIndication: Hay fever, nasal polyposis, seasonal and perennial allergic rhinitis, vasomotor rhinitis , \n\nDose: Adults and children 6 years of age and older: 100 mcg per day administered as one spray per nostril once daily.\n\nThe maximum recommended dose for adults (12 years of age and older) is 400 mcg per day administered as four sprays per nostril once daily.\n\nContra-indication: Hypersensitivity to any of the ingredients of this preparation.\n\nSide effects: Adverse local reactions following budesonide use are mild and usually transient. Systemic side effects have not been reported during clinical studies of budesonide nasal preparations. Sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects.\n\nLoss of skin collagen and SC atrophy;  dryness, irritation, epistaxis, rarely ulceration or perforation of the nasal septum; smell and taste disturbances; \n\nPrecaution: Active or doubtfully quiescent tuberculosis, paradoxical bronchospasm; children, elderly; pregnancy, lactation.\n\nMode of action: The main route of metabolism of corticosteroids, including budesonide, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of CYP3A4 may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the co-administration of Budesonide Nasal Spray with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin).\n\nPregnancy category: B\n\nInteraction: The main route of metabolism of corticosteroids, including budesonide, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of CYP3A4 may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the co-administration of Budesonide Nasal Spray with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin).
Bumetanide	\n\n\tACI\tConart TAB dr 1mg 30's pack 150.60\n\tIncepta\tBumecard TAB dr 1mg 30's pack 150\n\tIncepta\tBumecard Injection 2mg/4ml 5's pack 150\n\tIncepta\tBumecard TAB dr 5mg 30's pack 540\n\tNavana\tUrinide TAB dr 1mg 20's pack 200.80\n\tIndication: Hypertension, Heart failure, Oedema, Nephrotic syndrome\n\nDose: Adult: PO Oedema 1 mg once daily, 2nd dose 6-8 hr later if needed. Refractory oedema Initial: 5 mg/day, may increase dose depending on response. Max: 10 mg/day. HTN 0.5-1 mg/day. Max: 5 mg/day. \n\nIV Pulmonary oedema 1-2 mg, repeat 20 mins later if needed. IV/IM Emergency oedema 0.5-1 mg, then adjust according to response.\n\nContra-indication: Hypersensitivity, progressive renal failure and anuria, hepatic coma, severe electrolyte depletion.\n\nSide effects: Muscle cramps, dizziness, hypotension, headache, nausea, impaired hearing, pruritus, ECG changes, musculoskeletal pain, rash, chest discomfort, renal failure, premature ejaculation, thrombocytopenia, hypokalaemia, hypomagnesaemia, hyponatraemia, hyperuricaemia, hyperglycaemia, hypocalcaemia.\nPotentially Fatal: Encephalopathy (in patients with preexisting liver disease).\n\nPrecaution: Pregnancy, lactation; regular monitoring of serum electrolytes (especially potassium, calcium, magnesium); in case of hypokalemia, potassium supplements/potassium-sparing diuretics added. Monitor blood-glucose, BUN, creatinine levels as well as blood counts. Sulfonamide allergy. CHF patients on digitalis, K losing nephropathy, hepatic cirrhosis and ascitis, diarrhoeal states.\n\nMode of action: Reduced diuretic and natriuretic actions by probenecid. Indometacin blunts action of bumetanide; concurrent usage with antihypertensives may increase risk of orthostatic hypotension.\nPotentially Fatal: Avoid concurrent usage with ototoxic drugs such as aminoglycoides and nephrotoxic drugs. Reduced lithium excretion via kidneys.\n\nPregnancy category: C\n\nInteraction: Reduced diuretic and natriuretic actions by probenecid. Indometacin blunts action of bumetanide; concurrent usage with antihypertensives may increase risk of orthostatic hypotension.\nPotentially Fatal: Avoid concurrent usage with ototoxic drugs such as aminoglycoides and nephrotoxic drugs. Reduced lithium excretion via kidneys.
Bupivacaine	\n\n\tACI\tPivacain 0.25% Injection 2.5% 20ml 45\n\tACI\tPivacain 0.5% Injection 5% 1's pack 60\n\tBeximco\tNerkein Injection 5 mg/ ml  \n\tJayson\tUltracaine Injection 2.5mg/5ml 0.25% x 20 ml vial 35.53\n\tJayson\tUltracaine Injection 5mg/ml 0.5% x 30 ml vial 60.23\n\tPopular\tBupi Injection 5mg/ml 0.5% x 30 ml vial 60.23\n\tSquare\tBucain Injection 2.5 mg/5ml  \n\tUnimed & Unihealth Manufacturers Ltd.\tBbocain Injection .5% 50's pack 231.30\n\tIndication: Local anesthesia, Epidural, Intrathecal anesthesia, Epidural analgesia\n\nDose: Adult: Inj Percutaneous infiltration anesth For prolonged action: 9 mg w/ adrenaline (1 in 200,000), may repeat 2-10 mins later if needed. Max: 90 mg per dental sitting. \n\nPeripheral nerve block 12.5 mg (as 0.25% soln) or 25 mg (as 0.5% soln) . Max: 150 mg/dose. \nSympathetic nerve block As 0.25% soln: 50-125 mg. \nRetrobulbar block As 0.75% soln: 15-30 mg. \nCaudal block In surgery: 37.5-75 mg (as 0.25% soln) or 75-150 mg (as 0.5% soln). \nLumbar epidural block In surgery: 25-50 mg (as 0.25% soln) and 50-100 mg (as 0.5% soln).\n\nContra-indication: Hypersensitivity to local anaesthetics of amide type. IV regional anaesthesia; paracervical block in obstetrics; spinal anaesthesia <18 yr. Lactation. Solutions containing preservatives for caudal or epidural block.\n\nSide effects: CNS excitation may be followed by depression. Hypotension, bradycardia, arrhythmias and cardiac arrest; methaemoglobinaemia; seizures, restlessness, dizziness. Hypersensitivity. Prolonged block.\nPotentially Fatal: Cardiac and sudden respiratory arrest.\n\nPrecaution: Hepatic disease; CV disease; children <12 yr; pregnancy. Elderly and debilitated patients.\n\nMode of action: Additive systemic toxic effect w/ other local anaesth or agents structurally related to amide-type local anaesth (e.g. lidocaine and mexiletine). Increased risk of myocardial depression w/ antiarrhythmics. Enhanced adverse effects w/ hyaluronidase. Decreased clearance resulting to increased plasma concentrations w/ cimetidine and ranitidine. Increased risk of adverse effects w/ ?-blockers and Ca channel blockers.\n\nPregnancy category: C\n\nInteraction: Additive systemic toxic effect w/ other local anaesth or agents structurally related to amide-type local anaesth (e.g. lidocaine and mexiletine). Increased risk of myocardial depression w/ antiarrhythmics. Enhanced adverse effects w/ hyaluronidase. Decreased clearance resulting to increased plasma concentrations w/ cimetidine and ranitidine. Increased risk of adverse effects w/ ?-blockers and Ca channel blockers.
Bupivacaine + Dextrose	\n\n\tACI\tPivacain D Injection   4 ml amps x 10's pack 301.10\n\tChemist Ltd.\tBupicaine Heavy Injection   4 ml amps x 10's pack 280\n\tGonoshasthaya\tG-Bupivacaine Heavy Injection 4ml 5's pack 140\n\tIncepta\tSpino Injection   4 ml amps x 5's pack 150\n\tJayson\tUltracaine Heavy Injection   4 ml amps x 10's pack 301.10\n\tPopular\tBupi Heavy Injection  20 mg + 320 mg/4 ml 4 ml amps x 5's pack 150.55\n\tRenata\tSivicaine Heavy Injection   4 ml amps x 5's pack 150.55\n\tSquare\tAnespine Injection  20 mg + 320 mg/4 m 4 ml amps x 10's pack 301.11\n\tTechno Drugs Ltd.\tDuracain Injection  20mg/4ml 5's pack 150\n\tIndication: Intrathecal anesthesia, Spinal anesthesia, Epidural anesthesia, Subarachnoid anesthesia\n\nDose: Adult: Inj Percutaneous infiltration anesth For prolonged action: 9 mg w/ adrenaline (1 in 200,000), may repeat 2-10 mins later if needed. Max: 90 mg per dental sitting. \nPeripheral nerve block 12.5 mg (as 0.25% soln) or 25 mg (as 0.5% soln) . Max: 150 mg/dose. \nSympathetic nerve block As 0.25% soln: 50-125 mg. \nRetrobulbar block As 0.75% soln: 15-30 mg. \nCaudal block In surgery: 37.5-75 mg (as 0.25% soln) or 75-150 mg (as 0.5% soln). \nLumbar epidural block In surgery: 25-50 mg (as 0.25% soln) and 50-100 mg (as 0.5% soln).\n\nContra-indication: Hypersensitivity to local anaesthetics of amide type. IV regional anaesthesia; paracervical block in obstetrics; spinal anaesthesia <18 yr. Lactation. Solutions containing preservatives for caudal or epidural block.\n\nSide effects: CNS excitation may be followed by depression. Hypotension, bradycardia, arrhythmias and cardiac arrest; methaemoglobinaemia; seizures, restlessness, dizziness. Hypersensitivity. Prolonged block.\nPotentially Fatal: Cardiac and sudden respiratory arrest.\n\nPrecaution: Hepatic disease; CV disease; children <12 yr; pregnancy. Elderly and debilitated patients.\n\nMode of action: Additive systemic toxic effect w/ other local anaesth or agents structurally related to amide-type local anaesth (e.g. lidocaine and mexiletine). Increased risk of myocardial depression w/ antiarrhythmics. Enhanced adverse effects w/ hyaluronidase. Decreased clearance resulting to increased plasma concentrations w/ cimetidine and ranitidine. Increased risk of adverse effects w/ ?-blockers and Ca channel blockers.\n\nPregnancy category: C\n\nInteraction: Additive systemic toxic effect w/ other local anaesth or agents structurally related to amide-type local anaesth (e.g. lidocaine and mexiletine). Increased risk of myocardial depression w/ antiarrhythmics. Enhanced adverse effects w/ hyaluronidase. Decreased clearance resulting to increased plasma concentrations w/ cimetidine and ranitidine. Increased risk of adverse effects w/ ?-blockers and Ca channel blockers.
Buprenorphine	\n\n\tACI\tAcron TAB dr 200 mcg  \n\tBeximco\tBugesic TAB dr 200 mcg  \n\tSquare\tNalgesic Injection 300 mcg/ml  \n\tSquare\tNalgesic TAB dr 200 mcg  \n\tIndication: Pain, Anaesthesia, Opioid dependence\n\nDose: Adult: Sublingual Moderate to severe pain 200-400 mcg 6-8 hrly. IV Perioperative analgesia 300-450 mcg via slow inj. IV/IM Moderate to severe pain 300-600 mcg 6-8 hrly. IM Anesth premed 300 mcg.\n\nContra-indication: Acute alcoholism; convulsive disorders; head injuries; increased intracranial pressure; comatose patients; resp depression and obstructive airway disease; patients on established opioid agonists.\n\nSide effects: Sedation, nausea, dizziness, vertigo, hypotension, miosis, headache, hypoventilation, resp or CNS depression; tachycardia, bradycardia, urinary retention, coma, vomiting, drowsiness, sweating, confusion, dry mouth, diaphoresis, withdrawal syndrome.\n\nPrecaution: Hepatic or renal disease; pregnancy, lactation; hypothyroidism; adrenocortical insufficiency; asthma; prostatic hyperplasia; shock; hypotension; inflammatory or obstructive bowel disorders; myasthaenia gravis; infants/neonates. Reduce dose in elderly and debilitated patients. May precipitate withdrawal symptoms in narcotic addicts.\n\nMode of action:  	Plasma-buprenorphine concentrations may be affected when co-administered with drugs that induce or inhibit cytochrome P450 isoenzyme CYP3A4. Enhanced depressant effects with other CNS depressants e.g. alcohol, anaesthetics, anxiolytics, hypnotics, TCAs and antipsychotics.\nPotentially Fatal: Diazepam may produce resp and cardiac collapse.\n\nPregnancy category: C\n\nInteraction:  	Plasma-buprenorphine concentrations may be affected when co-administered with drugs that induce or inhibit cytochrome P450 isoenzyme CYP3A4. Enhanced depressant effects with other CNS depressants e.g. alcohol, anaesthetics, anxiolytics, hypnotics, TCAs and antipsychotics.\nPotentially Fatal: Diazepam may produce resp and cardiac collapse.
Buspirone	\n\n\tKumudini Pharma Ltd.\tBusper TAB dr 10mg 30's pack 210\n\tKumudini Pharma Ltd.\tBusper TAB dr 5mg 30's pack 120\n\tIndication: Anxiety\n\nDose: Oral\nShort-term management of anxiety\nAdult: Initially, 5 mg bid/tid increased by 5-mg increments at intervals of 2-3 days. Max: 45 mg daily in divided doses.\nMax Dosage: 45 mg daily in divided doses.\n\nContra-indication: Hypersensitivity. Epilepsy; severe renal or hepatic impairment; children <18 yr; pregnancy, lactation.\n\nSide effects: Dizziness, nausea, headache, nervousness, lightheadedness, excitement, paraesthesia, sleep disturbances, chest pain, tinnitus, nasal congestion, sore throat. Less sedation and lower potential for dependence compared to other anxiolytics.\n\nPrecaution: Preceding co-administration of MAOIs, decreased hepatic or renal function. In patients on benzodiazepines, withdraw the drug gradually. May impair ability to drive or operate machinery.\n\nMode of action: Enhanced sedative effects with alcohol or CNS depressants. Increases serum haloperidol. Concurrent admin with MAOIs may lead to increase in BP.\nPotentially Fatal: Elevation of BP when taken concomitantly with MAOIs.\n\nPregnancy category: B\n\nInteraction: Enhanced sedative effects with alcohol or CNS depressants. Increases serum haloperidol. Concurrent admin with MAOIs may lead to increase in BP.\nPotentially Fatal: Elevation of BP when taken concomitantly with MAOIs.
Butamirate Citrate	\n\n\tACI\tKofnix TAB dr 50mg  30's pack 300.90\n\tBeacon\tBukof TAB dr 50mg 30's pack 300\n\tBeacon\tBukof Syrup 150 mg/100 ml  \n\tEskayef Bangladesh Ltd.\tMiraten Syrup 150 mg/100 ml  \n\tEuro Pharma Ltd.\tCofof Syrup 150 mg/100 ml  \n\tEuro Pharma Ltd.\tCofof TAB dr 50mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinakof TAB dr 50mg 30's pack 300\n\tIncepta\tAskorel Syrup 150 mg/100 ml  1's pack 80\n\tIncepta\tButaret TAB dr 50mg  \n\tIncepta\tAskorel SR TAB dr 50mg  \n\tNovartis (Bangladesh) Ltd.\tSinecod SR TAB dr 50mg 50's pack 600\n\tOpsonin Pharma\tButaret Syrup 100 ml 1's pack 80\n\tOpsonin Pharma\tButaret Paediatric Drops 15 ml 1's pack 50\n\tOrion Pharma Ltd.\tDeconil SR TAB dr 50mg 30's pack 300\n\tOrion Pharma Ltd.\tDeconil Syrup 150 mg/100 ml  \n\tPharmasia Ltd.\tButacod Syrup 150 mg/100 ml  \n\tPharmasia Ltd.\tButacod TAB dr 50mg  \n\tRenata\tBurat SR TAB dr 50mg 30's pack 300\n\tSharif\tBucod SR TAB dr 50mg 30's pack 150\n\tSquare\tMirakof SR TAB dr 50mg 30's pack 300\n\tSquare\tMirakof Syrup 150 mg/100 ml  \n\tIndication: Cough (non-productive), Whooping cough, Pre-post operative cough\n\nDose: Tablet: Adolescents over 12 years old: 1-2 tablets daily. Adults: 2-3 tablets daily at 8 to 12 hours intervals. \n\nSyrup: Adult: 15 ml 4 times daily; Adolescent: 15 ml 4 times daily\nChildren (6-12 years): 10 ml 3 times daily, Children (3-6 years): 5 ml 3 times daily. \n\nContra-indication: Hypersensitivity. \n\nSide effects: Rarely, skin rash, nausea, diarrhoea or dizziness.\n\nPrecaution: Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Butenafine 1 %	\n\n\tBeximco\tTenafin Cream   15gm  tube 50\n\tDrug International Ltd.\tFintop Cream 10gm 10gm tube 35.10\n\tSquare\tButefin Cream  1 % 10gm  tube 40.15\n\tIndication: Skin fungal infections.\n\nDose: Adult: Topical As 1% cream: For tinea pedis: Apply twice daily for 7 days. For tinea corporis, tinea cruris and tinea versicolor: Apply once daily for 2 wk.\n\nContra-indication: Application to eye area.\n\nSide effects: Mild burning sensation at the site of application.\n\nPrecaution: Avoid occlusive dressings. Avoid contact with mouth, eyes and other mucous membranes. Affected areas should be thoroughly cleansed with soap and dried prior to application. Hands should always be washed after applying cream. Child <12 yr.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Cabergoline	\n\n\tOpsonin Pharma\tArgolin TAB dr 500 mcg  \n\tPopular\tCabergol TAB dr 0.5mg 6's pack 480\n\tRenata\tCabolin TAB dr 0.5mg 4's pack 320\n\tIndication: Hyperprolactinemia, prolactinomas, parkinson's disease, uterine fibroids, acromegaly, cushing's disease, pituitary adenomas, lactation suppression							\n\n\nDose: Adult: PO Inhibition of physiological lactation 1 mg as a single dose on 1st day postpartum.\nLactation suppression 250 mcg 12 hrly for 2 days. \nHyperprolactinemia-associated disorders Initial: 500 mcg/wk, may increase slowly according to response. Usual: 1 mg (up to 4.5 mg)/wk. Doses >1 mg should be given as divided doses. \nMonotherapy in Parkinson's disease; Adjunct in Parkinsons's disease Initial: 0.5 mg/day in monotherapy and 1 mg/day as adjunct therapy. May increase slowly. Max: 3 mg/day.\n\nContra-indication: Hypersensitivity to ergot derivatives. Uncontrolled hypertension.\n\nSide effects: Decrease in BP, dizziness, vertigo, headache, nausea, sleeplessness, abdominal pain, dyspepsia, gastritis, weakness, fatigue, constipation, vomiting, breast pain, hot flushes, depression, tingling, leg cramps, Raynaud's syndrome, psychosis with hallucinations, delusions and confusion.\nPotentially Fatal: Risk of serotinin syndrome with sibutramine; avoid combination.\n\nPrecaution: CV disease, Raynaud's syndrome, renal or hepatic impairment, peptic ulcer, GI bleeding, history of psychosis, hypertension. May affect ability to drive or operate machinery. Pregnancy, lactation. Prolonged use and/or usage of high doses may lead to psychiatric disorders, pleural/retroperitoneal fibrosis or cardiac valvular fibrosis. Monitor serum prolactin level mthly until normalisation. Monitor hepatic function regularly in patients with hepatic impairment.\n\nMode of action: Increased risk of orthostatic hypotension when used with antihypertensives. May increase vasoconstriction effect of dopamine. May reduce vasodilation effect of nitroglycerin. Concurrent use with SSRIs or TCAs may increase the risk of serotonin syndrome.\nPotentially Fatal: Risk of serotonin syndrome with sibutramine.\n\nPregnancy category: B\n\nInteraction: Increased risk of orthostatic hypotension when used with antihypertensives. May increase vasoconstriction effect of dopamine. May reduce vasodilation effect of nitroglycerin. Concurrent use with SSRIs or TCAs may increase the risk of serotonin syndrome.\nPotentially Fatal: Risk of serotonin syndrome with sibutramine.
Caffeine + Ergotamine Tartrate	\n\n\tSkylab Ltd.\tMigrin TAB dr   50's pack 250\n\tIndication: Acute Migraine\n\nDose: Adult: Each tablet contains ergotamine tartrate 2 mg, cyclizine hydrochloride 50 mg and caffeine hydrate 100 mg. Initially, 1 tablet, additional doses of  Â½-1 tablet may be taken at half-hrly intervals, if needed. To be taken as soon as possible at the 1st warning of a migraine attack. \n\nMax: 3 tablets in 24 hr, 4 tablets per attack, 6 tablets per wk and 2 courses of treatment per mth. Ensure an interval of at least 4 days between successive treatment courses.\n\nContra-indication: Not to be used with potent inhibitors of CYP3A4 and protease inhibitors. Hyperthyroidism, renal or hepatic impairment. Pre-existing vascular disease including coronary disease, obliterative vascular disease, angina, claudication, peripheral ischaemia, Raynaud's syndrome and hypertension. Not to be used when there is sepsis. Pregnancy and lactation.\n\nSide effects: Increased BP, hypotension, rapid and weak pulse, palpitations, arrhythmias, precordial pain, coronary infarction, fibrotic thickening of the heart valves. Cerebral ischaemia and thrombosis, blurred vision, sleep disturbances, urinary retention, muscle cramps and joint pains. GI symptoms such as nausea, vomiting, constipation, abdominal pain. Dysaesthesia, paraesthesia, formication, tremor, convulsions, headache, extrapyramidal effects. Anxiety, depression, confusion, hallucinations, psychomotor impairment.\n\nPrecaution: Not to be taken regularly or used for migraine prophylaxis. Increased risk of arterial constriction and other symptoms of ergotism. Discontinue treatment when symptoms of arterial occlusion occur e.g. numbness and tingling of the extremities. Caution when used in patients with infective hepatitis, cardiac disease or anaemia. GI tract obstructive disease, glaucoma, prostatic hypertrophy or urinary retention may be worsened by cyclizine. May increase risk of retroperitoneal and/or pleuropulmonary fibrosis. Not recommended for use with other vasoconstrictors. Elderly.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Paracetamol + Caffeine	\n\n\tACI\tXcel Plus TAB dr 500mg+65mg  200's pack 384\n\tAcme Ltd.\tFast PLUS TAB dr  500 mg + 65 mg 100's pack 190\n\tAd-din\tFeva PLUS TAB dr   100's pack 150\n\tAlbion Ltd.\tParactamol - Extra TAB dr 500 mg+65 mg 100's pack \n\tAlco Pharma\tP + C TAB dr   100's pack 190\n\tAmbee\tArchi Extra TAB dr 500mg/ 60mg  100's pack 150\n\tAmico Ltd.\tPara-C TAB dr 500mg/ 65mg  100's pack 190\n\tAmulet\tTempanil Extra TAB dr   200's pack 380\n\tAPC Pharma Ltd.\tPara Fast TAB dr   100's pack 160\n\tApex\tTamol PLUS TAB dr   100's pack 150\n\tApollo Pharmaceutical Ltd.\tPromel Plus TAB dr 500mg/ 65mg  100's pack 190\n\tAristopharma\tXpa C TAB dr   200's pack 400\n\tAsiatic Ltd.\tTempol PLUS TAB dr  65 mg + 500 mg 100's pack 190\n\tAstra Biopharmaceuticals Ltd.\tReliv Plus TAB dr   100's pack 190\n\tBeacon\tFap PLUS TAB dr   200's pack 300\n\tBengal Drugs & Chemical Works Pharm. Ltd.\tBepol PLUS TAB dr  65mg 100's pack 150\n\tBenham\tBenalgin PLUS TAB dr   100's pack 146\n\tBeximco\tNapa EXTRA TAB dr  200's pack 500\n\tBio Pharma Ltd.\tAceta X TAB dr 65 mg + 500 mg 100's pack 191\n\tBristol Pharma Ltd.\tNeopara Plus TAB dr   100's pack 150\n\tCentral.\tCentamol Plus TAB dr  65mg 100's pack 190\n\tConcord\tPyrex Plus TAB dr   200's pack 360\n\tCosmic Chemical Industries Ltd.\tNova Plus TAB dr   100's pack 180\n\tCosmo Pharma Ltd.\tCpmol plus TAB dr 500mg/ 65mg  100's pack 150\n\tDecent Pharma Ltd.\tDC-Plus TAB dr   100's pack 200\n\tDelta Pharma\tPyrenol TAB dr   200's pack 380\n\tDesh\tDepol Extra TAB dr  65mg 100's pack / 200's pack 160 / 320\n\tDoctor's Chemicals Works Ltd.\tCetadol PLUS TAB dr   200's pack 300\n\tEdruc Ltd.\tTy Plus TAB dr   100's pack 190\n\tEskayef Bangladesh Ltd.\tTamen C TAB dr  65 mg + 500 mg 100's pack 190\n\tEskayef Bangladesh Ltd.\tTamen X TAB dr 65 mg + 500 mg  150's pack 285\n\tEuro Pharma Ltd.\tEnyl plus TAB dr 500mg/ 65mg  100's pack 200\n\tEverest\tPcaf TAB dr   100's pack 190\n\tG. A. Company Ltd.\tTimidal-Plus TAB dr   100's pack 200\n\tGeneral\tCafenol TAB dr   100's pack 191\n\tGlaxoSmithKline Bangladesh Ltd.\tPanadol EXTRA TAB dr   200's pack 381.42\n\tGlobe\tPol PLUS TAB dr   100's pack 150\n\tGlobex\tCaf-N TAB dr 65 mg + 500 mg 100's pack 200\n\tHealthcare\tCafedon TAB dr   200's pack 380\n\tHudson\tHepa plus TAB dr 500mg/ 65mg  100's pack 150\n\tIbn Sina Pharmaceutical Ind. Ltd.\tPac 2 TAB dr   200's pack 400\n\tIncepta\tReset PLUS TAB dr   100's pack 190\n\tIndobangla Pharmaceuticals\tIndomol plus TAB dr 500mg/ 65mg  100's pack 150\n\tJayson\tZerin XP TAB dr   100's pack 190\n\tKemiko\tAtopen plus TAB dr 500mg/ 65mg  100's pack 190\n\tKumudini Pharma Ltd.\tPainil PLUS TAB dr   200's pack 400\n\tLeon\tCaface TAB dr  5x 10's pack\n \n\tLeon\tCaface TAB dr 500mg + 65mg  \n\tMarksman.\tPace TAB dr   200's pack 300\n\tMedicon\tDual TAB dr 500mg/ 65mg  100's pack 150\n\tMillat\tDola Extra TAB dr   100's pack 190\n\tModern\tK-Pol TAB dr   100's pack 190\n\tMonicopharma\tTemrif Plus TAB dr   100's pack 150\n\tNavana\tFea PLUS TAB dr  500 mg + 65 mg 100's pack 200\n\tNIPRO JMI Pharma\tTamino Plus TAB dr   100's pack 150\n\tNovelta Bestway\tNor Plus 	 	 	 TAB dr   500mg + 65mg  200's pack  380\n\tNovo Healthcare and Pharma Ltd.\tCapdol TAB dr  65mg 50's pack 100\n\tNovus\tFevrex plus TAB dr 500mg/ 65mg  100's pack 200\n\tOpsonin Pharma\tRenova Plus TAB dr   100's pack 167.15\n\tOrganic Health Care\tTemfin TAB dr   100's pack 180\n\tOrion Pharma Ltd.\tHedax TAB dr   100's pack 151\n\tOrion Pharma Ltd.\tZita 	 TAB dr   500mg + 65mg  100's pack 150\n\tOyster\tParet Plus TAB dr Paracetamol 500mg+ Caffei 100's pack 200\n\tPacific\tCetam PLUS TAB dr   200's pack 470\n\tPharmadesh Ltd.\tParacin TAB dr 500mg/ 65mg  200's pack 300\n\tPharmasia Ltd.\tParaxia PLUS TAB dr   100's pack 190\n\tPharmik Ltd.\tAnapol TAB dr 65 mg + 500 mg  \n\tPopular\tGesic PLUS TAB dr   100's pack 151\n\tPrime\tPricet Plus TAB dr 65 mg + 500 mg  \n\tRAK\tTylen Plus TAB dr   100's pack 150\n\tRangs\tTacs TAB dr   200's pack 380\n\tReliance\tPM Plus TAB dr   100's pack 150\n\tReman Drug Ltd.\tRemalgin PLUS TAB dr   100's pack 150\n\tRenata\tPyra Plus PLUS TAB dr   250's pack 300\n\tRephco\tAsta PLUS TAB dr   100's pack 200\n\tS. N.\tPanalgin Plus TAB dr   100's pack 180\n\tSeema\tPara Caf TAB dr   100's pack 190\n\tShamsul Al-Amin\tPax TAB dr   200's pack 300\n\tSharif\tAsmol Plus TAB dr   100's pack 150\n\tSilva\tDuet TAB dr   200's pack 381.43\n\tSomatec\tCaffo TAB dr   100's pack 190\n\tSquare\tAce PLUS TAB dr  65 mg + 500 mg 200's pack 380.38\n\tSupreme\tCetal Plus TAB dr  65 100's pack 190\n\tSyntho Ltd.\tFibi PLUS TAB dr  65mg 100's pack 200\n\tVirgo\tPanol Plus TAB dr  65 mg + 500 mg 200's pack 380\n\tWhite Horse Pharma\tParacet TAB dr   100's pack 150\n\tZenith\tAcep Plus TAB dr   100's pack 151\n\tZiska\tClofamol TAB dr 500mg/ 65mg  200's pack 300\n\tAllied\tAlpara-C TAB dr 65 mg + 500 mg  \n\tIndication: Pain,Fever,Headache,Influenza,Migraine,Sore throat,Backache,Toothache,Rheumatic pain,Dysmenorrhea,Colds\n\nDose: Adults : 1-2 tablets every 4-6 hours. Maximum dose: 8 tablets daily. Not recommended for children below 12 years.\n\nContra-indication: History of hypersensitivity to any of the components.\n\nSide effects: Skin rash, diarrhoea, anorexia, GI disturbances, epistaxis (rare).\n\nPrecaution: Severe hepatic or renal disorder.\n\nMode of action: May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.\n\nPregnancy category: C\n\nInteraction: May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
Calamine 15% + Zinc Oxide 5%	\n\n\tAmico Ltd.\tCalamine Lotion   100ml bot 38\n\tEverest\tCalam 			 Lotion 15gm 	 100ml bot  40.15 \n\tUnited Chemicals &\tCalamilon Lotion (15 gm + 5 gm)/100 ml  \n\tIndication: Pruritus, Discomfort from minor skin irritations such as Poison ivy, Poison oak, Poison sumac. Itching, Psoriasis, eczema, urticaria.\n\nDose: Adult:  Apply 3-4 times daily for 3-5 days.\n\nContra-indication: History of hypersensitivity to any of the components\n\nSide effects: May cause rash or irritation.\n\nPrecaution: For external use only. Not to be used on open wounds or burns.\n\nMode of action: There are no known drug interactions for calamine / zinc oxide topical.\n\nPregnancy category: Not Classified\n\nInteraction: There are no known drug interactions for calamine / zinc oxide topical.
Calcitriol	\n\n\tACI\tCaloren IV Injection 1mcg/ml 1ml amp x 1's pack 156.05\n\tBeacon\tLiquical CAP .25mcg 0.25mcg x 30'spack 300\n\tDrug International Ltd.\tDicaltrol CAP .25mcg 0.25mcg x 50'spack 350\n\tGlobe\tEncatrol CAP 0.25 mcg  \n\tIncepta\tColitrol CAP 0.25mcg 30's pack 300\n\tIncepta\tColitrol Injection 1mcg/ml 1ml amp x 1's pack 155\n\tNavana\tPromocal Injection 1mcg/ml 1ml ampul 155\n\tNIPRO JMI Pharma\tOstriol CAP .25mcg 50's pack 500\n\tOpsonin Pharma\tImprocal CAP 0.25mcg 50's pack 351.50\n\tPacific\tCaltrol CAP  30's pack 300\n\tRadiant.\tRocaltrol CAP .25mcg 0.25mcg x 30'spack 420\n\tRenata\tLucent Soft Gelatin CAP .25mcg 0.25mcg x 30'spack 300\n\tSquare\tCalcitrol Licap CAP 0.25mcg 0.25mcg x 30'spack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tCalcijex Injection 1mgcg/ml 5's pack 1719\n\tIndication: Osteoporosis, Hypoparathyroidism, Hypocalcaemia, Osteomalacia rickets, Renal osteodystrophy, Chronic kidney dialysis.\n\nDose:  Adult: Capsule: The optimal daily dose of Calcitriol must be carefully determined for each patient on the basis of the serum calcium level. Calcitriol  can be administered orally either 0.25 mcg or 0.50 mcg.\n\nPostmenopausal osteoporosis\nThe recommended dosage is 0.25 mcg twice daily or 0.50 mcg once daily. Serum creatinine levels should be determined at 4 weeks, 3 and 6 months and 6 monthly intervals thereafter.\n\nRenal osteodystrophy (Dialysis patients)\nThe recommended initial dose of Calcitriol is 0.25 mcg/day. Patients with normal or only slightly reduced serum calcium levels may respond to Calcitriol doses of 0.25 mcg every other day. Most patients undergoing hemodialysis respond to doses between 0.5 and 1 mcg/day.\n\nHypoparathyroidism & Rickets\nThe recommended initial dosage of Calcitriol is 0.25 mcg/day given in the morning. If a satisfactory response is not observed, the dose may be increased at 2 to 4 week intervals.\n\nPredialysis patients:\nThe recommended initial dosage of Calcitriol is 0.25 mcg/day in adults and pediatric patients 3 years of age and older. This dosage may be increased if necessary to 0.5 mcg/day.\nChild dose: 1 month - 3 years of age, the recommended initial dosage of Calcitriol is 10 to 15 ng/kg/day.\n\nInjection\nThe recommended intravenous initial dose of Calcitriol injection, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals. \n\nContra-indication: Hypercalcaemia; evidence of vitamin D toxicity. Pregnancy (dose exceeding RDA). Lactation.\n\nSide effects: Adverse events associated with Calcitriol therapy are similar to those encountered with excess vitamin D intake, i.e. hypercalcemia syndrome, or calcium intoxication.\n\nOccasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation.\n\nPrecaution: Idiopathic hypercalcaemia. Pediatric doses must be individualised and monitored under close medical supervision. Coronary disease, renal function impairment and arteriosclerosis, especially in the elderly. Hypoparathyroidism.\nExcessive dosage of Calcitriol induces hypercalcemia and in some instances hypercalciuria; therefore, early in treatment during dosage adjustment, serum calcium should be determined twice weekly. \nPatients with normal renal function who are taking Calcitriol should avoid dehydration. Adequate fluid intake should be maintained.\n\nMode of action: Hypermagnesaemia may develop in patients on chronic renal dialysis. Hypercalcaemia in patients on digitalis may precipitate cardiac arrhythmias. Intestinal absorption of calcitriol may be reduced by cholestyramine and colestipol. Phenytoin, barbiturates may decrease the T1/2 of calcitriol. May develop hypercalcaemia with thiazide diuretics.\n\nPregnancy category: C\n\nInteraction: Hypermagnesaemia may develop in patients on chronic renal dialysis. Hypercalcaemia in patients on digitalis may precipitate cardiac arrhythmias. Intestinal absorption of calcitriol may be reduced by cholestyramine and colestipol. Phenytoin, barbiturates may decrease the T1/2 of calcitriol. May develop hypercalcaemia with thiazide diuretics.
Calcitriol + Calcium	\n\n\tDrug International Ltd.\tDicaltrol Plus TAB dr 0.25 mcg + 252 mg  \n\tIndication: Osteoporosis, Hypoparathyroidism, Hypocalcaemia, Osteomalacia rickets, Renal osteodystrophy, Chronic kidney dialysis\n\nDose: Adult: PO Hyperparathyroidism in renal failure 0.25 mcg/day or alternate day. May increase slowly. Hypoparathyroidism/pseudohypoparathyroidism 0.5-2 mcg once daily. Vit D-dependent rickets 0.015-0.02 mcg/kg/day. Maintenance: 0.03-0.06 mcg/kg/day. Max: 2 mcg/day. \n\nIV Hyperparathyroidism in dialysis patients 0.5-4 mcg 3 times/wk. Max: 8 mcg 3 times/wk. Hyperparathyroidism in renal failure 0.5 mcg 3 times/wk, may increase by 0.25-0.5 mcg at 2-4 wk intervals. Maintenance: 0.5-3 mcg 3 times/wk.\n\nContra-indication: Hypercalcaemia; evidence of vitamin D toxicity. Pregnancy (dose exceeding RDA). Lactation.\n\nSide effects: Weakness; headache; somnolence; nausea; vomiting; dry mouth; constipation; muscle pain; bone pain; metallic taste; polyuria; polydipsia; anorexia; irritability; weight loss; nocturia; mild acidosis; reversible azotemia; generalized vascular calcification; nephrocalcinosis; conjunctivitis (calcific); pancreatitis; photophobia; rhinorrhoea; pruritus; hyperthermia; decreased libido; elevated BUN; albuminuria; hypercholesterolaemia; elevated AST and ALT; ectopic calcification; hypertension; cardiac arrhythmias.\n\nPrecaution: Idiopathic hypercalcaemia. Pediatric doses must be individualised and monitored under close medical supervision. Coronary disease, renal function impairment and arteriosclerosis, especially in the elderly. Hypoparathyroidism.\n\nMode of action: Calcium: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\n\nCalcitriol : Hypermagnesaemia may develop in patients on chronic renal dialysis. Hypercalcaemia in patients on digitalis may precipitate cardiac arrhythmias. Intestinal absorption of calcitriol may be reduced by cholestyramine and colestipol. Phenytoin, barbiturates may decrease the T1/2 of calcitriol. May develop hypercalcaemia with thiazide diuretics.\n\nPregnancy category: C\n\nInteraction: Calcium: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\n\nCalcitriol : Hypermagnesaemia may develop in patients on chronic renal dialysis. Hypercalcaemia in patients on digitalis may precipitate cardiac arrhythmias. Intestinal absorption of calcitriol may be reduced by cholestyramine and colestipol. Phenytoin, barbiturates may decrease the T1/2 of calcitriol. May develop hypercalcaemia with thiazide diuretics.
Calcium + Vitamin D3	\n\n\tACI\tAcical D TAB dr   30's pack 150\n\tACI\tAcical-D TAB dr 500mg+200 IU 30s\n 150.60\n\tACI\tCora-DX TAB dr 600 mg + 400 IU  \n\tAcme Ltd.\tA-Cal D TAB dr 500 mg+200 IU 15's pack/30's pack  60/120\n\tAcme Ltd.\tA Cal DX TAB dr 500mg +400 iu  \n\tAd-din\tCalcium A&D TAB dr   30's pack 90\n\tAlbion Ltd.\tCalcium Forte-D TAB dr 500 mg+200 IU 30's pack \n\tAlbion Ltd.\tCalcium-D TAB dr 500 mg+200 IU 60's pack \n\tAmbee\tAmbeecal-D TAB dr   15's pack 50\n\tAmico Ltd.\tOracal-D TAB dr   30's pack 150\n\tAmulet\tAdcal D TAB dr   15's pack / 30's pack 60 /120\n\tAPC Pharma Ltd.\tOstium-D TAB dr   30's pack 120\n\tApex\tApocal-D TAB dr   15's pack/30's pack 52.50/ 105\n\tAristopharma\tCalbon D TAB dr    15's pack / 30's pack 75 / 150\n\tAristopharma\tFossical-D TAB dr 500mg+200 IU 30's pack 300\n\tAsiatic Ltd.\tCalfor D TAB dr   15's pack / 30's pack 60 / 120\n\tAstra Biopharmaceuticals Ltd.\tCalcibo D TAB dr   15's pack 60\n\tBeacon\tProtebon D TAB dr   30's pack 150\n\tBeacon\tProtebon DX TAB dr 600 mg + 400 IU  \n\tBengal Drugs & Chemical Works Pharm. Ltd.\tCardiben D TAB dr   15's pack / 30's pack 60 / 120\n\tBenham\tCarben D TAB dr   30's pack 97.50\n\tBeximco\tAristocal D TAB dr   50's pack 250\n\tBio Pharma Ltd.\tOrthocal D TAB dr   15's pack / 30's pack 75 / 150\n\tBristol Pharma Ltd.\tBPCAL D TAB dr   30's pack/50's pack 99/165\n\tCentral.\tDOS TAB dr   30's pack 120\n\tConcord\tMonocal-D TAB dr   50's pack 200\n\tCosmic Chemical Industries Ltd.\tSuplical D TAB dr    15's pack / 30's pack 60 / 120\n\tDelta Pharma\tBoni D TAB dr   15's pack/30's pack 60/120\n\tDesh\tOstoplus D TAB dr   30's pack/ 50's pack 90 / 150\n\tDoctor's Chemicals Works Ltd.\tIsocal D TAB dr   30's pack 90\n\tDrug International Ltd.\tCaldil PLUS TAB dr   100's pack 400\n\tDrug International Ltd.\tCaldil TAB dr 500 mg + 200 IU  \n\tEdruc Ltd.\tEdical D TAB dr   15's pack / 30's pack 48 / 96\n\tEskayef Bangladesh Ltd.\tOstocal D TAB dr  500 mg + 200 IU 15's pack/20's pack / 30's pack 100 / 150 / 300\n\tEskayef Bangladesh Ltd.\tOstocal DX TAB dr 600 mg + 400 IU  \n\tEskayef Bangladesh Ltd.\tOstocal GX TAB dr 600 mg + 400 IU  \n\tEuro Pharma Ltd.\tEurocal-D TAB dr   30's pack / 50's pack 120 / 200\n\tEverest\tEvecal-D TAB dr   30's pack 99\n\tG. A. Company Ltd.\tCalcifil-D TAB dr   50's pack 200\n\tGeneral\tCadmin TAB dr   30's pack 99.30\n\tGlaxoSmithKline Bangladesh Ltd.\tCaldivit TAB dr   30's pack 120\n\tGlobex\tCaltonic-D TAB dr  30's pack 150\n\tHallmark\tOstim-D TAB dr   15's pack / 30's pack 75 / 150\n\tHealthcare\tRocal D TAB dr 500 mg + 200 IU  40's pack 180\n\tHudson\tCalmax-D TAB dr   30's pack 120\n\tIbn Sina Pharmaceutical Ind. Ltd.\tIpical D TAB dr   15's pack / 30's pack 75 /120\n\tIncepta\tCalvimax-D TAB dr   15's pack / 30's pack 75 / 150\n\tIncepta\tMarinCal-D TAB dr 500mg  \n\tJayson\tCadolin TAB dr   30's pack 99.30\n\tKumudini Pharma Ltd.\tOssi D TAB dr   15's pack 49.50\n\tLabaid\tLabcal D TAB dr   30's pack 210\n\tLeon\tNovacal D TAB dr 500 mg + 200 IU  \n\tMedicon\tCalpo D TAB dr   15's pack / 30's pack 60 /120\n\tMillat\tM.Cal_D TAB dr   30's pack 120\n\tModern\tCalos-D TAB dr   15's pack / 30's pack 60 /120\n\tMonicopharma\tCalsto-D TAB dr   30's pack 150\n\tNavana\tCalcium D TAB dr   30's pack / 100's pack 150 / 500\n\tNavana\tMiracal-D			 TAB dr   15's / 30's pack  75 / 150 \n\tNIPRO JMI Pharma\tStarcal D TAB dr   30's pack 240\n\tNIPRO JMI Pharma\tStarcal D Forte TAB dr 500 mg + 400 IU  \n\tNovartis (Bangladesh) Ltd.\tSandocal D TAB dr   50's pack 300\n\tNovelta Bestway\tBonmax-D TAB dr  15's / 30's pack 60 /120\n\tNovelta Bestway\tNovacal-DX TAB dr 500 mg + 400 IU  \n\tNovo Healthcare and Pharma Ltd.\tRejuven D TAB dr   15's pack / 30's pack / 50's pack 60 / 120 / 200\n\tNovus\tMaxcal-D TAB dr   30's pack 150\n\tNuvista Pharma Ltd\tCorabon-D TAB dr 500 mg + 200 IU  \n\tOpsonin Pharma\tOstogen D TAB dr   30's pack 131.95\n\tOrganic Health Care\tMycal-D TAB dr   50's pack 200\n\tOrion Pharma Ltd.\tMaxical TAB dr   15's pack / 30's pack 60.30 / 120.60\n\tOrion Pharma Ltd.\tMaxical-DX TAB dr 600 mg + 400 IU  \n\tPacific\tCal D TAB dr   30's pack/100's pack 150/ 500\n\tPeoples Pharma Ltd.\tPeocal D TAB dr   15's pack / 30's pack 45 / 90\n\tPharmadesh Ltd.\tCalium plus TAB dr   30's pack 120\n\tPharmasia Ltd.\tXtracal-D TAB dr    15's pack / 30's pack 49.65 / 99.30\n\tPopular\tUltracal D TAB dr  500 mg + 200 IU 15's pack / 30's pack / 60's pack 60.32 / 120.62 / 241.24\n\tPremier Pharmaceuticals\tPrecal-D TAB dr 500 mg + 200 IU  \n\tPrime\tSancal-D TAB dr 500 mg + 200 IU  \n\tRadiant.\tCoralcal-D TAB dr  500 mg + 200 IU 50's pack 500\n\tRadiant.\tCoralcal-DX TAB dr 600 mg + 400 IU  \n\tRAK\tBeucal D TAB dr   30's pack 150\n\tRangs\tOstacid-D TAB dr   15's pack / 30's pack 60 / 120\n\tRenata\tCalcin D TAB dr   15's pack / 30's pack/60's pack 60.15/ 120.30/240.60\n\tRephco\tCalci D Plus TAB dr   15's pack 49.50\n\tS. N.\tCarmo D TAB dr   30's pack 99\n\tSeema\tSeecal Plus TAB dr   30's pack 120\n\tShamsul Al-Amin\tOsmin D TAB dr   15's pack / 30's pack 50 / 100\n\tSharif\tCalcibost D TAB dr   15's pack / 30's pack 60/120\n\tSilva\tCalsil PLUS TAB dr   15's pack / 30's pack 74 / 149\n\tSomatec\tCalmet D TAB dr   15's pack / 30's pack 49.20 / 98.40\n\tSquare\tCalbo D TAB dr   15's pack / 30's pack 75 / 150\n\tSyntho Ltd.\tSycal D TAB dr   15's pack  / 30's pack 60 / 120\n\tTechno Drugs Ltd.\tCalcical D TAB dr   30's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tOscal D TAB dr   30's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tOscal-D Forte TAB dr   30's pack 150\n\tVeritas\tNutribon TAB dr 500 mg + 200 IU  \n\tWhite Horse Pharma\tNeocal D TAB dr   30's pack 120\n\tZiska\tCaldical-D TAB dr   50's pack 200\n\tAllied\tCalvox-D TAB dr 500 mg + 200 IU  \n\tMedihealth Pharmaceutical\tOsteomin CAP 400mg + 200iu  \n\tOne Pharma Ltd.\tOnecal-D TAB dr 500 mg + 200 IU  \n\tIndication: Postmenopausal osteoporosis, Osteoporosis, Osteomalacia/rickets, Hypoparathyroidism, Latent tetany, Hypocalcaemia, Calcium and vitamin D deficiency\n\nDose: Adult: PO Per tab contains Ca carbonate 1,500 mg and vitamin D3 10 mcg: 1 tab twice daily.\n\nContra-indication: Patients with hypercalcaemia and/or hypercalciuria. Nephrolithiasis, hypervitaminosis D, hypophosphataemia.\n\nSide effects: Constipation, flatulence, nausea, abdominal pain and diarrhoea, pruritus, rash and urticaria.\n\nPrecaution: Impaired calcium absorption in achlorhydria which is common in elderly. Increased risk of hypercalcaemia and hypercalciuria in hypoparathyroid patients receiving high doses of vitamin D. Caution when using in patients with history of kidney stones. Renal impairment; frequent monitoring of serum calcium and phosphorus is recommended.\n\nMode of action: May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.\n\nPregnancy category: C\n\nInteraction: May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
Calcium Acetate	\n\n\tACI\tRemophos TAB dr 667mg 50's pack 301\n\tPopular\tHypophos TAB dr 667mg 60's pack 331.20\n\tIndication: Hyperphosphatemia\n\nDose: Adult: PO Initial: 3-4 g/day. Usual range: 6-12 g/day. Increase dose gradually according to serum phosphate conc, provided hypercalcaemia does not occur.\n\nContra-indication: Patients with hypercalcaemia. \n\nSide effects: GI irritations. Excessive amounts may lead to hypercalcaemia.\n\nPrecaution: Patients undergoing chronic hemodialysis. Renal impairment, diseases associated with hypercalcaemia such as sarcoidosis & some malignancies. Avoid in patients with calcium renal calculi or a history of renal calculi.\n\nMode of action: Tetracycline antibiotics, thiazide diuretics, vit D, corticosteroids, bisphosphonates, fluoride, some fluoroquinolones.\n\nPregnancy category: C\n\nInteraction: Tetracycline antibiotics, thiazide diuretics, vit D, corticosteroids, bisphosphonates, fluoride, some fluoroquinolones.
Calcium Carbonate	\n\n\tACI\tAcical 500 TAB dr 1250mg 100's pack 301\n\tACI\tAcical Jr. TAB dr 625mg 100's pack 301\n\tACI\tAcical Jr. TAB dr 250mg 50's pack\n 150.50\n\tACI\tAcical TAB dr 500mg 100's pack 401\n\tAcme Ltd.\tA Cal 500 TAB dr 1250mg 100's pack 350\n\tAcme Ltd.\tA Cal Chewable 250 TAB dr 625mg  30's pack 45\n\tAcme Ltd.\tKidcal 250 TAB dr 625mg 30's pack 45\n\tAcme Ltd.\tKidcal TAB dr 250mg 3x10's pack 75\n\tAcme Specialized\tA-Cal 250 TAB dr 625mg 100's pack 100\n\tAd-din\tCalcium A TAB dr 1250mg 100's pack 250\n\tAexim\tOstocurb 500 TAB dr 1250mg 50's pack 80\n\tAlbion Ltd.\tCalcium DS TAB dr 500mg 50's pack \n\tAlbion Ltd.\tCalcium (Chewable) TAB dr 250 mg 60's pack \n\tAlbion Ltd.\tBoncal TAB dr 1250mg  \n\tAlco Pharma\tCalcarb 500 TAB dr 1250mg 50's pack 100\n\tAmbee\tAmbeecal TAB dr 1250mg  50's pack 100.50\n\tAmico Ltd.\tOracal 500 TAB dr 1250mg 50's pack 100\n\tApex\tApocal 500 TAB dr 1250mg 50's pack 150\n\tApex\tApocal Chewable 250 TAB dr 625mg 50's pack 75\n\tApollo Pharmaceutical Ltd.\tCalfeed TAB dr 125mg 50's pack 100\n\tAristopharma\tCalbon 500 TAB dr 1250mg 45's pack 157.50\n\tAristopharma\tCaljuven Chewable 250 TAB dr 625mg 50's pack 100\n\tAsiatic Ltd.\tCalfor TAB dr 500mg 50's pack 125\n\tBeacon\tProtebon 500 TAB dr 1250mg 30's pack 60\n\tBelsen\tCinet TAB dr 1250mg 30's pack 60\n\tBenham\tCarben 500 TAB dr 1250mg 50's pack 125\n\tBeximco\tAristocal 500 TAB dr 1250mg 100's pack 400\n\tBio Pharma Ltd.\tOrthocal 500 TAB dr 1250mg 50's pack 125.50\n\tBristol Pharma Ltd.\tBpcal 500 TAB dr 1250mg 100's pack 200\n\tCentral.\tCenet TAB dr 1250mg 50's pack 80\n\tChemist Ltd.\tCalciton 500 TAB dr 1250mg 30's pack 60\n\tConcord\tMonocal TAB dr 500mg 50's pack \n\tCosmic Chemical Industries Ltd.\tSuplecal 500 TAB dr 1250mg 30's pack 61.80\n\tCosmo Pharma Ltd.\tCpcal 500 TAB dr 1250mg 100's pack 200\n\tDelta Pharma\tBoni 500 TAB dr 1250mg 16's pack 48\n\tDelta Pharma\tCanta TAB dr 625mg 30's pack 45\n\tDesh\tOstoplus 500 TAB dr 1250mg 50's pack 125\n\tDoctor's Chemicals Works Ltd.\tIsocal 500 TAB dr 1250mg 30's pack 55.80\n\tDrug International Ltd.\tCaldil 500 TAB dr 1250mg 100's pack 300\n\tDrug International Ltd.\tCaldil TAB dr 1250mg  \n\tEdruc Ltd.\tEdical 500 TAB dr 1250mg 50's pack 100\n\tEskayef Bangladesh Ltd.\tOstocal 500 TAB dr 1250mg 100's pack 350\n\tEskayef Bangladesh Ltd.\tOstocal JR 250 TAB dr 625mg 50's pack 100\n\tEskayef Bangladesh Ltd.\tTumy 250 TAB dr 625mg 100's pack 150\n\tEskayef Bangladesh Ltd.\tOstocal Family TAB dr 250mg 30's pack 90\n\tEuro Pharma Ltd.\tEurocal TAB dr 1250mg 50's pack 150\n\tEverest\tEvecal 500 TAB dr 1250mg 50's pack 100\n\tG. A. Company Ltd.\tCalcifil TAB dr 1250mg 20's pack 65\n\tGeneral\tCostin 250MG TAB dr 250mg 100's pack 100\n\tGeneral\tCostin 500 TAB dr 1250mg 100's pack 201\n\tGlobe\tCarbocal 500 TAB dr 1250mg 100's pack 220\n\tGlobex\tCaltonic TAB dr 1250mg 100's pack 400\n\tHallmark\tOstim 500 TAB dr 1250mg 50's pack 125.50\n\tHealthcare\tRocal 500 TAB dr 1250mg 40's pack 160\n\tHudson\tCalmax 250 TAB dr 625mg 100's pack 200\n\tIbn Sina Pharmaceutical Ind. Ltd.\tIpical 500 TAB dr 1250mg 50's pack 175\n\tIncepta\tCalcicar 250 TAB dr  250mg 100's pack 150\n\tIncepta\tCalcicar 500 TAB dr 500mg 100's pack 250\n\tIndobangla Pharmaceuticals\tIndocal 500 TAB dr 1250mg 30's pack 60\n\tJayson\tJasocal 250 TAB dr 625mg 50's pack 75\n\tJayson\tJasocal 500 TAB dr 1250mg 50's pack 100.50\n\tKemiko\tCasalt 500 TAB dr 1250mg 50's pack 125\n\tKumudini Pharma Ltd.\tOssi 500 TAB dr 1250mg 50's pack 150\n\tMarksman.\tBonacal 500 TAB dr 1250mg 30's pack 60\n\tMedicon\tCalpo 500 TAB dr 1250mg 50's pack 125\n\tMedimet\tMed Cal 500 TAB dr 1250mg 50's pack 100\n\tMillat\tCabonate 500 TAB dr 1250mg 30's pack 105\n\tModern\tCalos 500 TAB dr 1250mg 50's pack 100\n\tMonicopharma\tCalsto 500 TAB dr 1250mg 50's pack 100\n\tMystic\tMystocal TAB dr 1250mg 50's pack 125\n\tNavana\tMiracal J TAB dr 625mg 50's pack 100\n\tNavana\tCalcium-500 TAB dr 125mg 100's pack 250\n\tNavana\tCalcium-J TAB dr 125mg 50's pack 75.50\n\tNavana\tMiracal-500 TAB dr 500mg 50's pack 200\n\tNipa\tMyocal TAB dr 1250mg 30's pack 90\n\tNIPRO JMI Pharma\tStarcal TAB dr 1250mg  \n\tNovartis (Bangladesh) Ltd.\tCalcium Sandoz 250 TAB dr 625mg 50's pack 200\n\tNovartis (Bangladesh) Ltd.\tSandocal 500 TAB dr 1250mg 100's pack 500\n\tNovartis (Bangladesh) Ltd.\tCalsan TAB dr 250mg 50's pack 100\n\tNovo Healthcare and Pharma Ltd.\tRejuven 500 TAB dr 1250mg 50's pack 150\n\tNovus\tMaxcal TAB dr 1250mg  50's pack 162.50\n\tOpsonin Pharma\tOstogen TAB dr 500mg 100's pack 326\n\tOrganic Health Care\tMycal TAB dr 1250mg 50's pack 150\n\tOrion Pharma Ltd.\tBonec 500 TAB dr 1250mg 100's pack 351\n\tPacific\tCal 250 TAB dr 625mg 30's pack/ 100's pack 60 / 200\n\tPacific\tCal 500 TAB dr 1250mg 30's pack/100's pack 105 / 350\n\tPeoples Pharma Ltd.\tPeocal 500 TAB dr 1250mg 50's pack 100\n\tPharmadesh Ltd.\tCalium-500 TAB dr 125mg 50's pack 125\n\tPharmasia Ltd.\tXtracal TAB dr 1250mg 50's pack 175\n\tPremier Pharmaceuticals\tPrecal TAB dr 1250mg  \n\tPrime\tSancal TAB dr 1250mg  \n\tRangs\tOstacid 500 TAB dr 1250mg 50's pack 175\n\tRenata\tCalcin 500 TAB dr 1250mg 50's pack 175\n\tRephco\tCalci-D TAB dr 125mg  50's pack 100\n\tSalton\tSaltonate 500 TAB dr 1250mg 50's pack 150.50\n\tSeema\tSee-Cal 500 TAB dr 1250mg 100's pack 325\n\tShamsul Al-Amin\tProcala 500 TAB dr 1250mg 50's pack 100\n\tSharif\tCalcibost TAB dr 1250mg 50's pack 150\n\tSilco Pharmaceuticlas Ltd.\tSilcal TAB dr 1250mg  \n\tSilva\tCalsil 500 TAB dr 1250mg 60's pack 239\n\tSomatec\tCalmet 500 TAB dr 1250mg 50's pack 100.50\n\tSonear Ltd.\tCal Up TAB dr 1250mg  \n\tSquare\tCalbo JR 250 TAB dr 250mg 60's pack 180\n\tSquare\tCalboral-D TAB dr 500 mg + 200 IU 30's pack 300\n\tSquare\tCalbo-D TAB dr 1250mg 15's pack/30's pack 70/150\n\tSupreme\tSucal 500 TAB dr 1250mg 30's pack 97.50\n\tSyntho Ltd.\tSycal 500 TAB dr 1250mg 100's pack 250\n\tUnimed & Unihealth Manufacturers Ltd.\tOscal 500 TAB dr 1250mg 30's pack 105\n\tWhite Horse Pharma\tNeocal 500 TAB dr 1250mg 50's pack 125\n\tZenith\tCalcizen DS TAB dr 1250mg 50's pack 100\n\tZiska\tCaldical 500 TAB dr 1250mg 50's pack 125\n\tOne Pharma Ltd.\tOnecal TAB dr 1250mg  \n\tIndication: Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset\n\nDose: Adult: PO Hyperacidity: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets. \n\nHyperphosphataemia in chronic renal failure Initial: 2.5 g/day, up to 17 g/day in divided doses.\n\nRenal impairment:\nCrCl (ml/min)	\n<25	Dosage adjustments may be needed depending on serum calcium levels. \n\nContra-indication: Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.\n\nSide effects: Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).\n\nPrecaution: Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.\n\nMode of action: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nPregnancy category: C\n\nInteraction: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
Calcium Carbonate + Calcium Lactate Gluconate +  Vitamin-C + Vitamin D3	\n\n\tEskayef Bangladesh Ltd.\tOstovit TAB dr   10's pack 80\n\tHealthcare\tSante T TAB dr   10's pack 120\n\tIncepta\tCavic C PLUS TAB dr   10's pack 80\n\tMillat\tMicac-3 TAB dr   10's pack 78\n\tNovartis (Bangladesh) Ltd.\tCac EFF TAB dr   12's pack 160\n\tRenata\tCalcefer EFF TAB dr   10's pack 60\n\tSquare\tCalbo FORTE TAB dr  327 mg + 1 gm + 500 mg + 10's pack 80.40\n\tIndication: Osteoporosis, Calcium deficiency, Rickets, Hypocalcaemia, Calcium supplement, Osteomalacia\n\nDose: Dosage  should be individualized based on the demands in age, sex and various physiological (pregnancy & lactation) & disease conditions. In general the dosage is-\nAdults and children above 7 years: 1  effervescent tablet daily\nChildren 3-7 years: Half effervescent tablet daily\n\nContra-indication: Absolute contraindications are hypercalcaemia resulting from myeloma, bone metastases or other malignant bone disease, sarcoidosis; primary hyperparathyroidism and Vitamin-D overdosage. It is also contraindicated in severe renal failure and hypersensitivity to any of the tablet ingredients.\n\nSide effects: The use of Calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea. Following administration of Vitamin-D supplements occasional skin rash has been reported. Hypercalciuria, and in rare cases hypercalcaemia have been seen in long-term treatment with Vitamin-D at high doses.\n\nPrecaution: Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. Periodic checks of plasma Calcium levels and urinary Calcium excretion should be made in patients with mild to moderate renal failure or mild hypercalciuria. In patients with a history of renal stones urinary Calcium excretion should be measured to exclude hypercalciuria. With long-term treatment it is advisable to monitor serum and urinary Calcium levels and kidney function, and reduce or stop treatment temporarily if urinary Calcium exceeds 7.5 mmol/24 hours. Allowances should be made for Calcium and Vitamin-D supplements from other sources.\n\nMode of action: Calcium Carbonate: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nCalcium Lactate: May reduce the efficacy of calcium-channel blockers. Concurrent admin of IV calcium salt with cardiac glycosides may lead to serious adverse events. Increased risk of hypercalcaemia when used with thiazide diuretics. May reduce absorption of tetracycline, alendronate, atenolol, iron, quinolone antibiotics, sodium fluoride and zinc.\n\nCalcium Gluconate: Co-admin of high calcium doses with thiazide diuretics may result in milk-alkali syndrome and hypercalcaemia. May potentiate digoxin toxicity. Decreases effects of calcium-channel blockers. Enhanced absorption with calcitriol (a vitamin D metabolite).\n\nVit D3: Increased risk of hypercalcaemia if given with thiazide diuretics, calcium or phosphate. Antiepileptics (e.g. carbamazepine, phenobarbitone, phenytoin & primidone) may increase vitamin D requirements. Rifampicin & isoniazid may reduce efficacy of vitamin D. Corticosteroids may counteract the effect of vitamin D. Digoxin or any cardiac glycoside. Reduced absorption when taken with cholestyramine, colestipol, mineral oil, orlistat. Ketoconazole.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\nPregnancy category: Not Classified\n\nInteraction: Calcium Carbonate: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nCalcium Lactate: May reduce the efficacy of calcium-channel blockers. Concurrent admin of IV calcium salt with cardiac glycosides may lead to serious adverse events. Increased risk of hypercalcaemia when used with thiazide diuretics. May reduce absorption of tetracycline, alendronate, atenolol, iron, quinolone antibiotics, sodium fluoride and zinc.\n\nCalcium Gluconate: Co-admin of high calcium doses with thiazide diuretics may result in milk-alkali syndrome and hypercalcaemia. May potentiate digoxin toxicity. Decreases effects of calcium-channel blockers. Enhanced absorption with calcitriol (a vitamin D metabolite).\n\nVit D3: Increased risk of hypercalcaemia if given with thiazide diuretics, calcium or phosphate. Antiepileptics (e.g. carbamazepine, phenobarbitone, phenytoin & primidone) may increase vitamin D requirements. Rifampicin & isoniazid may reduce efficacy of vitamin D. Corticosteroids may counteract the effect of vitamin D. Digoxin or any cardiac glycoside. Reduced absorption when taken with cholestyramine, colestipol, mineral oil, orlistat. Ketoconazole.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n
Calcium Carbonate Chewable	\n\n\tSquare\tCalbo 500 TAB dr 500mg 100's pack 400\n\tSquare\tXcid TAB dr 1000mg 50's pack 100.50\n\tIndication: Heartburn, Indigestion, Calcium deficiency, Hypocalcaemia, Hyperphosphatemia, Calcium supplement, Stomach upset\n\nDose: Adult: PO Hyperacidity Per tab contains 500 mg calcium carbonate: Take 1-2 tab as needed, up to a max of 16 tab/day. May suck or chew tablets.\n\nContra-indication: Patients with Ca renal calculi or history of renal calculi; hypercalcaemia; hypophosphataemia. Patients with suspected digoxin toxicity.\n\nSide effects: Constipation, flatulence; hypercalcaemia; metabolic alkalosis; milk-alkali syndrome, tissue-calcification. Gastric hypersecretion and acid rebound (with prolonged use).\n\nPrecaution: Renal impairment, hypoparathyroid disease, hypercalcaemia-associated diseases. Calcium absorption is impaired in achlorhydria; use an alternate salt and take with food. Caution when used in patients with a history of kidney stones.\n\nMode of action: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nPregnancy category: C\n\nInteraction: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
Calcium Chloride + Dextrose Anhydrous + Potassium	\n\n\tLibra Pharmaceuticls Ltd.\tHartsol Plus IV Infusion   500 ml bag  / 1000 ml bag 62.77 / 81.05\n\tOrion Pharma Ltd.\tDextrolac IV Infusion    500 ml bag  / 1000 ml bag 62.54 / 80.74\n\tPopular\tGlucohart I.V Infusion  20 mg + 5 gm + 30 mg + 6 500ml bag/1000ml bag 62.78 / 81.04\n\tIndication: Source of water, electrolyte and calories or as an alkalinizing agent. Used as a fluid and electrolyte replenisher in hypovolaemia caused by trauma, surgery, haemorrage and burn.\n\nDose: Generally 30-75 drops/min are given or according to physician's recommendation.\n\n\nContra-indication: Solution containing dextrose may be contraindicated in patients with known allergy to corn or corn products.\n\n\nSide effects: \n\nPrecaution: Do not uses if the solution is cloudy contain particles or date expired. Infusion of fluid should be immediately discontinued if rigor arises for any reason during the process.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Calcium Chloride + Magnessium Chloride + Potassium chloride + Sodium chloride + Sodium acetate + Sodium citrate	\n\n\tGeneral\tBSS GV Ocular Irrigation Solution   500ml bot 250\n\tOpso Saline Ltd.\tOpso Rinse Irrigation Solution   100ml bot 35\n\tPopular\tB-Sol Irrigation Solution 48 mg + 30 mg + 75 mg + 3 500 ml bot 250\n\tIndication: Irrigation Solution:  For irrigation during various ocular surgical procedures. For use as an extraocular and intraocular irrigating solution during ocular surgical procedure involving perfusion of the eye with an expected maximum duration of less than 60 minutes.\n\nDose: This irrigating solution should be used according to standard format for each surgical procedure.\n\nContra-indication: Known hypersensitivity to any of the ingredients of this preparation.\n\nSide effects: Irrigation or any other trauma may result in corneal swelling or bullous keratopathy. Post-operative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported.\n\nPrecaution: Use with caution in diabetic patients undergoing vitrectomy since intraoperative lens changes have been observed. There have been reports of corneal clouding and edema following ocular surgery in which Irrigating Solution was used as an irrigating solution.\nNot for injection or intravenous infusion. Do not uses unless product is clear, seal is intact, vacuum is present & container is undamaged. Do not use if product is discolored or contains a precipitate.\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Calcium Chloride + Potassium Chloride + Sodium Chloride + Sodium Lactate	\n\n\tBeximco\tLactoride IV Infusion   500 ml bag  / 1000 ml bag 46.70 / 58.72\n\tLibra Pharmaceuticls Ltd.\tHartsol IV Infusion   500 ml bag  / 1000 ml bag 52.64 / 60.74\n\tOpso Saline Ltd.\tHartmann IV Infusion   500 ml bag  / 1000 ml bag 46.70 / 58.78\n\tOrion Pharma Ltd.\tHartman IV Infusion    500 ml bag  / 1000 ml bag 52 / 60\n\tPopular\tElectrosal IV Infusion    500 ml bag  / 1000 ml bag 52.64 / 60.74\n\tSquare\tLactoring IV Infusion (27 mg + 40 mg + 600 mg +  \n\tIndication: Mainly used as a fluid and electrolyte replenisher in hypovolaemia caused by trauma, surgery, haemorrage and burn. Diarrhea, dehydration,Water and electrolytes imbalance, Alkalinizing agent, Diabetic coma, Cholera\n\nDose: As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.\n\nThe recommended flow rate is up to 100-drops/minute/70 kg body weight. In burn patients the dose is according to the Parkland formula : 4ml/kg body weight/% of Body surface area (BSA) burn (e.g. for a 30% BSA burn of a person having 60 kg body weight, 4 x 60x30ml = 7200 ml of Lactoride would be required in 24 hours). Half of this within 8 hr, the remainder over 16 hr.\n\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.\n\nIf an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.\n\nPrecaution: It should not be administered rapidly or for prolonged periods. Since the solution contains different electrolytes, it should be infused with caution in patients where electrolyte imbalance may cause detrimental effects; e.g. in pregnancy, renal impairment, heart failure, pulmonary congestion, etc. or to patients receiving potassium sparing diuretics.\nPressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.\n\nUse of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.\n\nClinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.\n\nCaution must be exercised in the administration of Ringerâs Injection, USP to patients receiving corticosteroids or corticotropin.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Calcium Chloride .514 % + Magnessium Chloride .356 + Potassium Chloride .521 % + Sodium Acetate 18.088 % + Sodium Chloride 19.84 % (Hemodialysis solutions)	\n\n\tPopular\tDialyte AC Dialysis Solution  10 liters containers 562.10\n\tIndication: Hemodialysis.\n\nDose: Recommended dose: 5 litres concentrate per dialysis or as required. \n\nContra-indication: Known hypersensitivity to any of the ingredients of this preparation.\n\nSide effects: \n\nPrecaution: It is used for hemodialysis purposes only.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Calcium Chloride  + Potassium Chloride + Sodium Chloride	\n\n\tOpso Saline Ltd.\tRingers Solution Osl IV Infusion   500 ml bag  45.17\n\tIndication: Diarrhea, Dehydration,Water and electrolytes imbalance, Alkalinizing agent, Diabetic coma, Cholera\n\nDose: As required and advised by the physician.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.\n\nPrecaution: IV infusion is obsolettc  in metabolic acidosis and carries the risk of producing  lactic acidosis, particularly in seriously ill patients with poor tissue perfusion and on impaired hepatic function.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Calcium Chloride  + Dextrose Anhydrous + Magnessium Chloride  + Sodium Acetate + Sodium Chloride  (Peritoneal Dialysis solutions)	\n\n\tOpso Saline Ltd.\tPeritoneal Dialysis Solution  1000ml bag 70.80\n\tIndication: Peritoneal Dialysis.\n\nDose: In case of intermittent peritoneal dialysis (IPD): 2 litres solution is instill into the abdominal cavity over a period of 1 hour then drained from the cavity. \n\nThe exchange should be continued for 8-36 hours.\n\nContra-indication: Patients with excessive obesity and in pregnancy. \n\nSide effects: During dialysis amino acids and water soluble vitamins may be lost. Fluid and electrolyte imbalance, hypovolemia, hypotension or muscle cramping may occur. \n\nPrecaution: It is used for peritoneal dialysis purposes only.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Calcium Chloride  + Glacial Acetic Acid  + Magnessium Chloride  + Potassium Chloride  +  Sodium Chloride (Hemodialysis solutions)	\n\n\tPopular\tDialyte A Dialysis Solution   10 litres container 516.90\n\tIndication: Hemodialysis.\n\nDose: Recommended dose: 5 litres concentrate per dialysis or as required. \n\nContra-indication: Known hypersensitivity to any of the ingredients of this preparation.\n\nSide effects: \n\nPrecaution: It is used for hemodialysis purposes only. Do not use solution A or B alone. Discard container in case visible solid particles inside.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Calcium Gluconate	\n\n\tAmbee\tCalcium Ambee Injection 500mg/5ml 5 amps x 5's pack 31.10\n\tEdruc Ltd.\tCalcium Gluconate Injection 500mg/5ml 5 amps x 10's pack 52\n\tGonoshasthaya\tG Calcium Gluconate Injection 500mg/5ml 5 amps x 10's pack/10 amps x 10's pack 61 /71\n\tJayson\tCalcium Jayson Injection 1gm/10ml 5 amps x 10's pack/10 amps x 10's pack 511.50 / 63.70\n\tIndication: Postmenopausal osteoporosis, Osteoporosis, Hypoparathyroidism, Latent tetany, Rickets, Osteomalacia, Hyperkalemia, Hypocalcemia, Magnesium sulfate overdose\n\nDose: Adult: PO Hypocalcaemia 10-50 mmol/day. \n\nIV Severe acute hypocalcaemia; Hypocalcaemic tetany 2.25 mmol via slow inj , then 58-77 mL of 10% soln diluted and administered as a continuous IV infusion. \n\nAntidote in severe hypermagnesaemia; Severe hyperkalaemia 10 mL of 10% soln, repeat every 10 mins if needed.\n\nContra-indication: Patients with calcium renal calculi or history of renal calculi. Conditions associated with hypercalcaemia and hypercalciuria.\n\nSide effects: GI irritation; soft-tissue calcification, skin sloughing or necrosis after IM/SC inj. Hypercalcaemia characterised by anorexia, nausea, vomiting, constipation, abdominal pain, muscle weakness, mental disturbances, polydipsia, polyuria, nephrocalcinosis, renal calculi; chalky taste, hot flushes and peripheral vasodilation.\nPotentially Fatal: Cardiac arrhythmias and coma.\n\nPrecaution: Impaired renal function; cardiac disease; hypercalcaemia-associated diseases, e.g. sarcoidosis; other malignancies. Pregnancy.\n\nMode of action: Calcium Gluconate: Co-admin of high calcium doses with thiazide diuretics may result in milk-alkali syndrome and hypercalcaemia. May potentiate digoxin toxicity. Decreases effects of calcium-channel blockers. Enhanced absorption with calcitriol (a vitamin D metabolite).\n\nPregnancy category: C\n\nInteraction: Calcium Gluconate: Co-admin of high calcium doses with thiazide diuretics may result in milk-alkali syndrome and hypercalcaemia. May potentiate digoxin toxicity. Decreases effects of calcium-channel blockers. Enhanced absorption with calcitriol (a vitamin D metabolite).
Calcium Lactate	\n\n\tAmbee\tCalcitate TAB dr 300mg 120'pack 34.80\n\tDesh\tDecal TAB dr 300mg 100'pack 29\n\tDoctor's Chemicals Works Ltd.\tD Lactate TAB dr 300mg 100's pack 29\n\tG. A. Company Ltd.\tCaltate TAB dr 300mg 100'pack 30\n\tGonoshasthaya\tG Calcium Lactate TAB dr 300mg 100's strip100's pot100's tin 30 / 21 / 100\n\tHudson\tCalson TAB dr 300mg 100'pack 29\n\tIndobangla Pharmaceuticals\tCaltab TAB dr 300mg 100'pack 27\n\tOpsonin Pharma\tCalac TAB dr 300mg 100'pack 30\n\tPharmadesh Ltd.\tCalate TAB dr 300mg 100'pack 40\n\tSalton\tCalton TAB dr 300mg 100'pack 29\n\tIndication: Heartburn, Calcium supplement, Calcium deficiencies\n\nDose: Adult: PO 19-50 yr: 1,000 mg elemental Ca/day and >50 yr: 1,200 mg elemental Ca/day.\n\nContra-indication: Conditions associated with hypercalcaemia and hypercalciuria.\n\nSide effects: GI discomfort e.g. nausea, vomiting, constipation; bradycardia, arrhythmias. Dry mouth, increased thirst or increased urination. Mental confusion, milk-alkali syndrome.\n\nPrecaution: Renal impairment (frequent monitoring of serum calcium and phosphorus is recommended); sarcoidosis; history of nephrolithiasis. Avoid IV admin of calcium in patients on cardiac glycosides. Increased risk of hypercalcaemia and hypercalciuria in hypoparathyroid patients receiving high doses of vitamin D. Caution when used in patients with history of kidney stones. Patients should be advised to administer vitamin D concurrently to optimise calcium absorption. Pregnancy.\n\nMode of action: May reduce the efficacy of calcium-channel blockers. Concurrent admin of IV calcium salt with cardiac glycosides may lead to serious adverse events. Increased risk of hypercalcaemia when used with thiazide diuretics. May reduce absorption of tetracycline, alendronate, atenolol, iron, quinolone antibiotics, sodium fluoride and zinc.\n\nPregnancy category: C\n\nInteraction: May reduce the efficacy of calcium-channel blockers. Concurrent admin of IV calcium salt with cardiac glycosides may lead to serious adverse events. Increased risk of hypercalcaemia when used with thiazide diuretics. May reduce absorption of tetracycline, alendronate, atenolol, iron, quinolone antibiotics, sodium fluoride and zinc.
Calcium Orotate	\n\n\tACI\tRotacal TAB dr 400mg 50's 400\n\tBeacon\tProtebon P TAB dr 400mg  \n\tBeacon\tProtebon P TAB dr 740mg  \n\tBeximco\tCalorate TAB dr 400mg 30's pack 240\n\tBeximco\tCalorate Kit TAB dr  1's pack 990\n\tConcord\tMonocal Gold TAB dr 400mg  \n\tDrug International Ltd.\tCaldil-OT TAB dr 400mg 30's pack \n\tDrug International Ltd.\tCaldil OT TAB dr 400mg  \n\tEskayef Bangladesh Ltd.\tCalofast TAB dr 400mg 30's pack \n\tGlobe\tEffical TAB dr 400mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\torcical TAB dr 400mg  \n\tIncepta\tIntraCal TAB dr 400mg 30's pack 240\n\tIncepta\tIntraCal TAB dr 740mg  \n\tNovelta Bestway\tDavycal TAB dr 400mg  \n\tOpsonin Pharma\tOrtical TAB dr 400mg 30's pack 240\n\tRenata\tCalcin-O TAB dr 400mg  \n\tSquare\tCalborate TAB dr 400mg 30's pack 240\n\tSquare\tCalborate TAB dr 740mg 30's pack 360\n\tIndication: Calcium supplement\n\nDose: As an addition to the daily diet, 2-3 tablets are usually recommended with meal or as directed by health care professional. \n\nContra-indication: Its contraindicated in conditions like kidney stone, kidney disease, increased activity of the parathyroid gland, high amount of calcium in urine, high amount of calcium in the blood, extreme loss of body water. \n\nSide effects: Bloating and swelling in the abdomen are common side effects of Calcium Orotate. Constipation, nausea, vomiting, headache, increased thirst/urination, may occur infrequently. \n\nPrecaution: Precaution is needed if the patient is allergic to calcium orotate. Before using this product in kidney disease, kidney stones, little or no stomach acid (achlorhydria), disease of the pancreas, a certain lung disease (sarcoidosis), difficulty absorbing nutrition from food (malabsorption syndrome) precaution is needed.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Calcium Pantothenate	\n\n\tG. A. Company Ltd.\tCalcinate Injection 100mg/2ml 5 amps  pack 3.50\n\tOpsonin Pharma\tCalci Injection 100mg/2ml 5 amps  pack 175\n\tIndication: Calcium supplement, Dietary supplements, Burning feet syndrome, Greying hair, Peripheral neuritis, Muscular cramps.\n\nDose: Slow IV or deep IM as required or as directed by physician.\n\nContra-indication: Hypercalcaemia, hypercalciuria\n\nSide effects: Mild G. I. disturbances, bradicardia, arrythmia and irritation after IV injection\n\nPrecaution: Renal impairment, sarcoidosis, concurrent administration of thiazide diuretics may increase the risk of hypercalcaemia.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Camphor 2.5% + Menthol 2% + Oil Clove 2.5% + Oil Eucalyptus	\n\n\tCosmic Chemical Industries Ltd.\tSinex Ointment  10mg  12s pack 144\n\tHallmark\tVaporex Ointment   30gm tube 35\n\tIndication: Stiffness, Congestion, Muscle aches, Sprains, Strains, Back pain, Joint pain, Cold, Flu, Catarrh, Headache, \n\nDose: Topical: Rub gently 3-4 mintues on the chest and back 2-3 times daily. Cover the rubbed area with warm clothes. \nInhalation: 1 tsf of ointment tobe dissolved in boiled water and inhale the steam by mouth or nose as required.\n\nContra-indication: Children under 3 years. History of convulsion.\n\nSide effects: Redness, irritation, rash or pruritis may occur with sensitive skin.\n\nPrecaution: Avoid contact with eyes. Should not be applied to wounds or damaged skin. Wash hand thoroughly after applying.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Camphor  + Menthol + Oil Eucalyptus + Thymol	\n\n\tG. A. Company Ltd.\tGacorub Ointment   25gm pack 17\n\tIndication: Cold, Flu, Catarrh, Headache, Stiffness, Congestion, Muscle aches, Sprains, Strains, Back pain, Joint pain, \n\nDose: Topical: Rub gently 3-4 mintues on the chest and back 2-3 times daily. Cover the rubbed area with warm clothes. \nInhalation: 1 tsf of ointment tobe dissolved in boiled water and inhale the steam by mouth or nose as required.\n\n\nContra-indication: Children under 3 years. History of convulsion. Hypersensitivity.\n\nSide effects: Redness, irritation, rash or pruritis may occur with sensitive skin.\n\nPrecaution: Avoid contact with eyes. Should not be applied to wounds or damaged skin. Wash hand thoroughly after applying.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Candesartan Cilexetil	\n\n\tAristopharma\tGiran TAB dr 16mg 30's pack 330\n\tAristopharma\tGiran TAB dr 8mg 30's pack 180\n\tRangs\tVesotan TAB dr 16mg 30's pack 330\n\tRangs\tVesotan TAB dr 8mg 30's pack 180\n\tSquare\tArb TAB dr 16mg 30's pack 300\n\tSquare\tArb TAB dr 8mg 30's pack 180.74\n\tIndication: Hypertension, Congestive heart failure\n\nDose: Oral\nHypertension\nAdult: Initially, 8 mg once daily adjusted according to response. Maintenance: 8 mg once daily. Max: 32 mg/day as single or in 2 divided doses. Patients w/ intravascular volume depletion: Initially, 4 mg once daily.\nChild: 1 to <6 yr Initially, 200 mcg/kg/day. May increase according to response to 50-400 mcg/kg/day. >6 yr <50 kg: 4-8 mg/day, adjusted according to response to 2-16 mg/day; >50 kg: 8-16 mg/day, adjusted according response to 4-32 mg/day. All doses may be given as single or in 2 divided doses.\nHepatic impairment: Mild to moderate: Initially, 4 mg once daily. Severe: Contraindicated.\n\nHeart failure\nAdult: Initially, 4 mg once daily, may be doubled at intervals of not <2 wk. Max: 32 mg once daily.\nHepatic impairment: Severe: Contraindicated.\n\nContra-indication: Hypersensitivity. Pregnancy (2nd and 3rd trimester) and lactation.\n\nSide effects: Dizziness, headache, vertigo, depression, somnolence, fever, back pain, upper respiratory tract infections, 1st dose orthostatic hypotension, rash, diarrhoea, decreased haemoglobin, renal impairment, hepatitis.\n\nPrecaution: Volume or sodium depletion, preexisting renal insufficiency; aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy, renal artery stenosis, primary hyperaldosteronism. Patients with a history of angioedema, urticaria. Monitor serum potassium levels especially in elderly and renally impaired patients. Hypotension may occur during major surgery and anaesthesia due to suppression of the renin-angiotensin system.\n\nMode of action: NSAIDs may reduce antihypertensive effect and result in deterioration of renal function including possible acute renal failure. May increase serum lithium concentration. K-sparing diuretics, K supplements or salt substitutes containing K may increase risk of hyperkalaemia.\nPotentially Fatal: Coadministration w/ aliskiren in diabetic patients may increase risk of renal impairment, hypotension and hyperkalaemia.\n\nPregnancy category: D\n\nInteraction: NSAIDs may reduce antihypertensive effect and result in deterioration of renal function including possible acute renal failure. May increase serum lithium concentration. K-sparing diuretics, K supplements or salt substitutes containing K may increase risk of hyperkalaemia.\nPotentially Fatal: Coadministration w/ aliskiren in diabetic patients may increase risk of renal impairment, hypotension and hyperkalaemia.
Candesartan Cilexetil + Hydrochlorothiazide	\n\n\tAristopharma\tGiran H TAB dr   30's pack 180\n\tIndication: Hypertension, Congestive heart failure\n\nDose: Adult: PO HTN Initial: 8 mg once daily.Max: 32 mg/day. Heart failure Initial: 4 mg once daily. May double dose at intervals of not <2 wk. Max: 32 mg/day.\n\nContra-indication: Hypersensitivity. Pregnancy (2nd and 3rd trimester) and lactation.\n\nSide effects: Dizziness, headache, vertigo, depression, somnolence, fever, back pain, upper respiratory tract infections, 1st dose orthostatic hypotension, rash, diarrhoea, decreased haemoglobin, renal impairment, hepatitis.\n\nPrecaution: Volume or sodium depletion, preexisting renal insufficiency; aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy, renal artery stenosis, primary hyperaldosteronism. Patients with a history of angioedema, urticaria. Monitor serum potassium levels especially in elderly and renally impaired patients. Hypotension may occur during major surgery and anaesthesia due to suppression of the renin-angiotensin system.\n\nMode of action: NSAIDs may reduce antihypertensive effect and result in deterioration of renal function including possible acute renal failure. May increase serum lithium concentration. K-sparing diuretics, K supplements or salt substitutes containing K may increase risk of hyperkalaemia.\nPotentially Fatal: Coadministration w/ aliskiren in diabetic patients may increase risk of renal impairment, hypotension and hyperkalaemia.\n\nPregnancy category: D\n\nInteraction: NSAIDs may reduce antihypertensive effect and result in deterioration of renal function including possible acute renal failure. May increase serum lithium concentration. K-sparing diuretics, K supplements or salt substitutes containing K may increase risk of hyperkalaemia.\nPotentially Fatal: Coadministration w/ aliskiren in diabetic patients may increase risk of renal impairment, hypotension and hyperkalaemia.
Capecitabine	\n\n\tBeacon\tXitabin TAB dr 500mg 1's pack 125\n\tTechno Drugs Ltd.\tCaptabine TAB dr 150mg 30's pack 900\n\tTechno Drugs Ltd.\tCaptabine TAB dr 500mg 30's pack 2700\n\tF. Hoffmann La Roche,Switzerland\tXeloda TAB dr 500mg  260\n\tF. Hoffmann La Roche,Switzerland\tXeloda TAB dr 150mg  60\n\tIndication: Breast cancer, Colorectal cancer, Gastric cancer, Oesophageal cancer\n\nDose: Adult: PO Colorectal cancer; Breast cancer 1.25 g/m2 twice daily for 14 days followed by a 7-day rest period. Treatment duration for colorectal cancer: 6 mth. Gastric cancer W/ platinum-based compd: 1 g/m2 twice daily for 14 days, followed by a 7-day rest period.\n\nRenal impairment:\nCrCl (ml/min)	\n51-80	No adjustment needed.\n30-50	Reduce dose to 950 mg/m2 bid when starting dose is 1.25 g/m2 bid. No dose adjustment is needed when starting dose is 1 g/m2.\n<30	Avoid use. \n\nContra-indication: History of severe and unexpected reactions to fluoropyrimidine therapy; severe renal impairment; pregnancy, lactation. Hypersensitivity.\n\nSide effects: Diarrhoea, nausea and vomiting, stomatitis, palmar-plantar syndrome, dermatitis. Fatigue, mucosal inflammation, pyrexia, asthenia and lethargy; headache, dizziness and insomnia; lower limb oedema, anorexia, dehydration.\nPotentially Fatal: Cardiotoxicity, bone-marrow depression and hyperbilirubinaemia.\n\nPrecaution: Hepatic dysfunction, bone marrow suppression, poor nutritional status, warfarin therapy. Child, elderly, prior extensive pelvic radiation or alkylating therapy. Moderate renal impairment; CBC with differential; monitor hepatic and renal function. Discontinue use if intractable diarrhoea, stomatitis, bone marrow suppression or MI develops.\n\nMode of action: Antacids containing aluminum and magnesium, leucovorin, anticoagulants, phenytoin, allopurinol.\n\nPregnancy category: D\n\nInteraction: Antacids containing aluminum and magnesium, leucovorin, anticoagulants, phenytoin, allopurinol.
Capsaicin 0.025%	\n\n\tGeneral\tOstocin Cream   20gm tube 50.19\n\tIncepta\tTopicacin Cream   20gm tube 50\n\tSquare\tCapsi Cream   20gm tube 50.20\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Psoriasis, Post-herpetic neuralgia, Anogenital pruritus, Sprains, Stiff neck, Low back pain, Trigeminal neuralgia, Spondylitis, Peripheral neuralgias:, Diabetic neuropathy, Post-surgical pains\n\nDose: Persons 18 years of age and older apply a thin film of Capsaicin cream to affected area 3 to 4 times daily. A burning sensation may occur upon application, but generally disappears with regular use. \n\nApplication schedules of 3 to 4 times a day for 2 weeks provides optimum pain relief. \n\nContra-indication: Capsaicin cream is contraindicated for use on broken or irritated skin or known hypersensitivity to this medication.\n\nSide effects: Capsaicin may cause transient burning on application. This burning is observed more frequently when the application schedules are more than 3-4 times daily. The burning can be enhanced if too much cream is used and if it is applied just before or after a bath or shower.\n\nPrecaution: Capsaicin cream should not be applied to broken or irritated skin. Applied area should not be tightly bandaged. Do not get on mucous membranes and into eyes or on contact lenses. If this occurs, rinse the affected area thoroughly with water. Do not apply the cream on the heat treated area as this may increase the burning sensation. In case of accidental ingestion, seek physician advice immediately.\n\nMode of action: Capsaicin, including topical use, may cause or exacerbate coughing associated with ACE inhibitor treatment and vice versa. If a severe cough develops in patients taking an ACE inhibitor and using capsaicin, 1 or both drugs may need to be discontinued.\n\nPregnancy category: B\n\nInteraction: Capsaicin, including topical use, may cause or exacerbate coughing associated with ACE inhibitor treatment and vice versa. If a severe cough develops in patients taking an ACE inhibitor and using capsaicin, 1 or both drugs may need to be discontinued.
Captopril	\n\n\tAlbion Ltd.\tCaptopril TAB dr 25 mg 100's pack \n\tAlco Pharma\tCapotril TAB dr 25mg 40's pack 120\n\tBeximco\tCardopril TAB dr 25mg 100's pack 301\n\tBeximco\tCardopril TAB dr 50mg 100's pack 600\n\tDrug International Ltd.\tAcetor TAB dr 25mg 100's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAngiten TAB dr 25mg 100's pack 325\n\tJayson\tTopril TAB dr 50mg 50's pack 139.50\n\tOpsonin Pharma\tCapril TAB dr 25mg 50's pack \n\tOpsonin Pharma\tCapril TAB dr 50mg 30's pack \n\tZenith\tCatopil TAB dr 12.5mg 100's pack 175\n\tZenith\tCatopil TAB dr 25mg 100's pack 300\n\tIndication: Hypertension, Congestive heart failure, Post Myocardial infarction, Diabetic nephropathy\n\nDose: Adult: PO HTN Initial: 12.5 mg twice daily. Maintenance: 25-50 mg twice daily. Max: 50 mg 3 times/day. \n\nHeart failure Initial: 6.25-12.5 mg 2-3 times/day. Max: 50 mg 3 times/day. \n\nPost MI Start 3 days after MI. Initial: 6.25 mg/day, may increase after several wk to 150 mg/day in divided doses if needed and tolerated. \n\nDiabetic nephropathy 25 mg 3 times/day.\n\nRenal impairment:\nCrCl (ml/min)	\n<10	Initially, 6.25 mg/day. Max: 37.5 mg/day.\n10-20	Initially, 12.5 mg/day. Max: 75 mg/day.\n21-40	Initially, 25 mg/day. Max: 100 mg/day.\n\nContra-indication: Known hypersensitivity to the drug. Bilateral renal artery stenosis, hereditary angioedema; renal impairment; pregnancy.\n\nSide effects: Hypotension, tachycardia, chest pain, palpitations, pruritus, hyperkalaemia. Proteinuria; angioedema, skin rashes; taste disturbance, nonproductive cough, headache.\nPotentially Fatal: Neutropenia, usually occurs within 3 mth of starting therapy especially in patients with renal dysfunction or collagen diseases. Hyperkalaemia. Anaphylactic reactions.\n\nPrecaution: Patients on diuretics or with sodium depletion should discontinue diuretics or increase sodium intake prior to initiation of therapy. Renal impairment, SLE and other autoimmune collagen disorders and during concurrent use of immunosuppressant or leucopenic drugs, monitor WBC count and urinary protein before and during therapy. Lactation. Porphyria. Severe CHF.\n\nMode of action: Concurrent treatment w/ NSAIDs reduces hypotensive action and increases the risk of nephrotoxicity. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. heparin). May increase risk of leucopenia w/ procainamide, allopurinol, cytostatic or immunosuppressants. May increase risk of lithium toxicity. Increased risk of nitritoid reactions w/ gold (Na aurothiomalate).\nPotentially Fatal: Increased risk of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) w/ aliskiren in diabetic patients.\n\nPregnancy category: D\n\nInteraction: Concurrent treatment w/ NSAIDs reduces hypotensive action and increases the risk of nephrotoxicity. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. heparin). May increase risk of leucopenia w/ procainamide, allopurinol, cytostatic or immunosuppressants. May increase risk of lithium toxicity. Increased risk of nitritoid reactions w/ gold (Na aurothiomalate).\nPotentially Fatal: Increased risk of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) w/ aliskiren in diabetic patients.
Carbamazepine	\n\n\tACI\tCepilep TAB dr 200mg 50's pack \n\tAristopharma\tCarmaz TAB dr 200mg 50's pack 200\n\tBeximco\tEpilep TAB dr 200mg 50's pack 175.50\n\tBeximco\tEpilep CR TAB dr 200mg 50's pack 226\n\tEskayef Bangladesh Ltd.\tCarbazin TAB dr 200mg 50's pack 225\n\tEskayef Bangladesh Ltd.\tCarbazin CR TAB dr 200mg 50's pack 203\n\tEskayef Bangladesh Ltd.\tCarbazin-CR TAB dr 200mg 50's pack 202.50\n\tIncepta\tCarmapine Suspension 100mg/5ml 100ml bot 250\n\tIncepta\tCarmapine TAB dr 200mg 50's pack 200\n\tIncepta\tCarmapine CR TAB dr 200mg 50's pack 250\n\tMundipharma (Bangladesh) Pvt. Ltd.\tCarbocontin TAB dr 200mg 100's pack \n\tNovartis (Bangladesh) Ltd.\tTegretol TAB dr 200mg 50's pack 326.50\n\tNovartis (Bangladesh) Ltd.\tTegretol CR TAB dr 200mg 50's pack 351.50\n\tNovartis (Bangladesh) Ltd.\tTegretol Syrup 100mg/5ml 100ml bot 379\n\tOpsonin Pharma\tCazep TAB dr 200mg 50's pack 200\n\tRenata\tCabretol Suspension 100mg/5ml 100ml bot 301.13\n\tRenata\tCabretol TAB dr 200mg 50's pack 195.50\n\tRenata\tCabretol CR TAB dr 200mg 50's pack 195\n\tSquare\tAnleptic Suspension 100mg/5ml 100ml bot 250.94\n\tSquare\tAnleptic TAB dr 200mg 50's pack 175.50\n\tSquare\tAnleptic CR TAB dr 200mg 50's pack 226\n\tSun Pharmaceutical (Bangladesh) Ltd.\tZeptol TAB dr 200mg 100's pack 550\n\tSun Pharmaceutical (Bangladesh) Ltd.\tZeptol CR TAB dr 200mg 100's pack 550\n\tSun Pharmaceutical (Bangladesh) Ltd.\tZeptol CR TAB dr 400mg 50's pack 425\n\tNovartis Pharma SA, France\tTegretol 2% Syrup 2gm/100ml 100ml bot\n 379\n\tShire\tCarbatrol CAP 200mg  \n\tIndication: Epilepsy,Schizophrenia,Bipolar disorder,Trigeminal neuralgia\n\nDose: Epilepsy: Adults and children over 12 years of age - Initial: Either 200 mg b.i.d. for tablets and XR tablets, or 1 teaspoon q.i.d. for suspension (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. \n\nDosage generally should not exceed 1000 mg daily in children 12-15 years of age, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. \n\nMaintenance: usually 800-1200 mg daily. Children 6-12 years of age - Initial: Either 100 mg b.i.d. for tablets or XR tablets, or 1/2 teaspoon q.i.d. for suspension (200 mg/day). Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. or a t.i.d. or q.i.d. regimen of the either formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily. Maintenance: usually 400-800 mg daily. \n\nChildren under 6 years of age - Initial: 10-20 mg/kg/day b.i.d. or t.i.d. as tablets, or q.i.d. as suspension. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of Carbamazepine for use at doses above 35 mg/kg/24 hours can be made. \n\nCombination therapy: Carbamazepine may be used alone or with other anticonvulsants. When added to existing anticonvulsant therapy, the drug should be added gradually while the other anticonvulsants are maintained or gradually decreased, except phenytoin, which may have to be increased. \n\nTrigeminal Neuralgia: Initial: On the first day, either 100 mg b.i.d. for tablets or XR tablets, or 1/2 teaspoon q.i.d. for suspension, for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets or XR tablets, or 50 mg (1/2 teaspoon) q.i.d. for suspension, only as needed to achieve freedom from pain. A total dose of 1200 mg daily shouldn't be exceeded. \nMaintenance: Control of pain can be maintained in most patients with 400-800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug. The tablets or syrup can be taken without regards to meal.\n\n\nContra-indication: Hypersensitivity; bone marrow depression; porphyria, pregnancy.\n\nSide effects: Dizziness, drowsiness, ataxia; dry mouth, abdominal pain, nausea, vomiting, anorexia; leucopenia, proteinuria, renal failure, heart failure and hyponatraemia.\nPotentially Fatal: Agranulocytosis, aplastic anaemia, hepatic failure, severe exfoliative dermatitis and Stevens-Johnson syndrome.\n\nPrecaution: Lactation; CV disease, hepatic or renal disorders, history of blood disorders or haematological reactions to other drugs; glaucoma; skin disorders; elderly, patients on MAO inhibitors; abrupt withdrawal of treatment.\n\nMode of action: Increased plasma levels w/ CYP3A4 inhibitors (e.g. cimetidine). Decreased plasma levels w/ CYP3A4 inducers (e.g. cisplatin). Increased risk of neurotoxic side effects w/ lithium. May decrease the effect of hormonal contraceptives. Increased plasma levels of active metabolite carbamazepine-10, 11-epoxide w/ loxapine, quetiapine, primidone, progabide, valproic acid and valpromide. May increase cyclophosphamide levels. May reduce exposure of aripiprazole. May reduce plasma levels of tacrolimus, temsirolimus and lapatinib. May increase risk of isoniazid-induced hepatotoxicity. Risk of symptomatic hyponatraemia w/ diuretics (e.g. hydrochlorothiazide, furosemide).\nPotentially Fatal: May decrease serum concentrations of nefazodone and its active metabolites. Toxic reactions may develop when taken concurrently w/ MAOIs.\n\nPregnancy category: D\n\nInteraction: Increased plasma levels w/ CYP3A4 inhibitors (e.g. cimetidine). Decreased plasma levels w/ CYP3A4 inducers (e.g. cisplatin). Increased risk of neurotoxic side effects w/ lithium. May decrease the effect of hormonal contraceptives. Increased plasma levels of active metabolite carbamazepine-10, 11-epoxide w/ loxapine, quetiapine, primidone, progabide, valproic acid and valpromide. May increase cyclophosphamide levels. May reduce exposure of aripiprazole. May reduce plasma levels of tacrolimus, temsirolimus and lapatinib. May increase risk of isoniazid-induced hepatotoxicity. Risk of symptomatic hyponatraemia w/ diuretics (e.g. hydrochlorothiazide, furosemide).\nPotentially Fatal: May decrease serum concentrations of nefazodone and its active metabolites. Toxic reactions may develop when taken concurrently w/ MAOIs.
Carbidopa + Entacapone + Levodopa	\n\n\tACI\tTridopa 50 TAB dr 50mg+12.5mg+200mg 20's Pack 301\n\tACI\tTridopa 100 TAB dr 100mg+25mg+200mg 20's pack 501.60\n\tACI\tTridopa 200 TAB dr 200mg+50mg+200mg 20's pack 802.40\n\tACI\tTridopa 150 TAB dr 150mg+37.5mg+200mg 20's pack 601.80\n\tIndication: Parkinson's disease and 'end of dose' motor fluctuations \n\nDose: Adult: PO  Initial: 1 tab/day. Titrate dose according to patient's response. Recommended to take only 1 tab per dose administration. Max: 8 tabs/day.\n\nContra-indication: Hypersensitivity. Narrow angle glaucoma. Should not be used in patients with suspicious, undiagnosed skin lesions or a history ot melanoma.\n\nSide effects: Diarrhoea, nausea, vomiting, hypotension, hallucinations, hyperpyrexia and confusion. Fibrotic complications. Dark colour (red, brown or black) may appear in bodily secretions such as sweat, saliva and urine. Possible increase in dyskinesia. Chest pain, asthenia, cardiac irregularities, angioedema, urticaria, pruritus, back pain, shoulder pain and muscle cramps.\nPotentially Fatal: Rhabdomyolysis.\n\nPrecaution: Periodic monitoring of hepatic, renal, haematopoietic and CV functions in patients on prolonged therapy. Monitor for changes in IOP in patients with chronic wide-angle glaucoma. Caution when used in patients with biliary obstruction. Caution when interpreting plasma and urine levels of catecholamines and their metabolites. Withdrawal should be gradual.\n\nMode of action: Increased risk of postural hypotension when used concurrently with hypotensive drugs. Severe orthostatic hypotension may result from concurrent usage with MAOIs. Dopamine D2 receptor antagonists, phenytoin or papaverine may reduce the efficacy of levodopa. Iron salts may reduce the bioavailability. Concurrent usage with drugs that interfere with biliary excretion may lead to increased plasma levels of entacapone. May depress prolactin secretion and increase growth hormone levels.\n\nPregnancy category: C\n\nInteraction: Increased risk of postural hypotension when used concurrently with hypotensive drugs. Severe orthostatic hypotension may result from concurrent usage with MAOIs. Dopamine D2 receptor antagonists, phenytoin or papaverine may reduce the efficacy of levodopa. Iron salts may reduce the bioavailability. Concurrent usage with drugs that interfere with biliary excretion may lead to increased plasma levels of entacapone. May depress prolactin secretion and increase growth hormone levels.
Carbidopa + Levodopa	\n\n\tACI\tCinemet CR Continued Release TAB dr 50 mg + 200 mg  \n\tACI\tCinemet CR Half Continued Release TAB dr 25 mg + 100 mg  \n\tAcme Ltd.\tLevopa 110 TAB dr   100 (100 + 10)  30's pack 120\n\tAcme Ltd.\tLevopa 275 TAB dr  275 (250 + 25) 30's pack 225\n\tAlbion Ltd.\tAldopa TAB dr 25 mg + 250 mg  \n\tAlbion Ltd.\tAldopa TAB dr 10 mg + 100 mg  \n\tDrug International Ltd.\tD-Dopa 110 TAB dr   30's pack 150\n\tDrug International Ltd.\tD-Dopa 275 TAB dr   50's pack 300\n\tDrug International Ltd.\tD-Dopa Plus TAB dr  50's pack 300\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSyndopa 110 TAB dr   50's pack 225\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSyndopa 275 TAB dr   100's pack 900\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSyndopa CR 125 TAB dr  50's pack 375\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSyndopa CR TAB dr  100's pack \n\tUnimed & Unihealth Manufacturers Ltd.\tCo Dopa 110 TAB dr   30's pack 210\n\tUnimed & Unihealth Manufacturers Ltd.\tCo Dopa 275 TAB dr   30's pack 300\n\tIndication:  Parkinson's disease.\n\nDose: Adult: PO Initial: 1 tab 3 times/day. Adjust dose according to response. Max: 8 tab/day. If patient has been taking L-dopa alone, combination therapy may only be started at least 8 hr after stopping L-dopa.\n\nContra-indication: Lactation, narrow angle glaucoma, melanoma, psychosis, severely decompensated endocrine.\n\nSide effects: Nausea, vomiting, anorexia, increased risk of GI bleeding in peptic ulcer patients. Orthostatic hypotension, cardiac arrhythmias. Psychiatric symptoms (depression with or without suicidal tendency). Abnormal involuntary movements or dyskinesias, delirium, hallucinations (elderly). Slight elevation of liver enzymes, leucopenia and thrombocytopenia.\nPotentially Fatal: Severe postural hypotension in elderly.\n\nPrecaution: Heart disease, liver disease, dementia, psychosis, pregnancy, elderly, heart disease. Regular monitoring of renal and hepatic function is reccomended.\n\nMode of action: Pyridoxine reverses effects of levodopa. Type-B MAOIs have synergistic effect. Effect reduced by phenothiazines, haloperidol, reserpine, pyridoxine, diazepam, oxazepam, chlordiazepoxide, phenobarbitone. Effects of levodopa enhanced by carbidopa, amantadine, anticholinergics, amphetamine. Effects of sympathomimetic agents enhanced.\nPotentially Fatal: Enhances hypotensive effects of bethanidine, bretylium, guanethidine. Hypertensive crises with furazolidone or MAO inhibitors.\n\nPregnancy category: C\n\nInteraction: Pyridoxine reverses effects of levodopa. Type-B MAOIs have synergistic effect. Effect reduced by phenothiazines, haloperidol, reserpine, pyridoxine, diazepam, oxazepam, chlordiazepoxide, phenobarbitone. Effects of levodopa enhanced by carbidopa, amantadine, anticholinergics, amphetamine. Effects of sympathomimetic agents enhanced.\nPotentially Fatal: Enhances hypotensive effects of bethanidine, bretylium, guanethidine. Hypertensive crises with furazolidone or MAO inhibitors.
Carbimazole	\n\n\tRenata\tMercazole TAB dr 5mg  \n\tSquare\tCarbizol TAB dr 5mg 60's pack 180.35\n\tWhite Horse Pharma\tCarbiroid TAB dr 5mg 100's pack 480\n\tIndication: Grave's disease, Hyperthyroidism, Diabetic nephropathy, Preparation for thyroidectomy\n\nDose: Oral\nHyperthyroidism, Adjunct to radio-iodine therapy, Grave's disease, Preparation for thyroidectomy\nAdult: Initially, 20-60 mg daily as a single or divided dose, reduced gradually once euthyroidism is achieved. Maintenance: 5-15 mg daily for at least 1 yr or 18 mth.\n\nChild: 4-12 yr: Initially, 15 mg daily.\n\nContra-indication: Hyperthyroidism due to nodular goitre.\n\nSide effects: Mild leucopaenia, sore throat, mouth ulcers, fever, bruising, malaise; rarely cholestatic jaundice; nephrotic syndrome. Nausea, loss of taste, headache, arthralgia, alopoecia.\nPotentially Fatal: Agranulocytosis, aplastic anaemia, hypoprothrombinaemia, neutropaenia; hypothyroidism and goitre.\n\nPrecaution: Liver diseases, pregnancy, lactation.\n\nMode of action: Potentially Fatal: Increased sensitivity to warfarin in hyperthyroidism and careful control required as patient is rendered euthyroid.\n\nPregnancy category: D\n\nInteraction: Potentially Fatal: Increased sensitivity to warfarin in hyperthyroidism and careful control required as patient is rendered euthyroid.
Carbocisteine	\n\n\tAmico Ltd.\tCarboten DS 10 Syrup 250mg/5ml 100ml bot 40\n\tBeximco\tNokof Syrup 125mg/5ml 100ml bot 30\n\tBeximco\tNokof CAP 375mg 30's pack \n\tBeximco\tNokof DS Syrup 250mg/5ml 100ml bot 40\n\tEskayef Bangladesh Ltd.\tCarbolin Syrup 125mg/5ml 100ml bot 30\n\tEskayef Bangladesh Ltd.\tCarbolin CAP 375mg 30's pack 75\n\tEskayef Bangladesh Ltd.\tCarbolin DS Syrup 250mg/5ml 100ml bot 40\n\tEuro Pharma Ltd.\tTulsi Syrup 125mg/5ml 100ml bot 28\n\tGeneral\tMucolex Syrup 125mg/5ml 30's pack \n\tOrion Pharma Ltd.\tFlegnil Syrup 125mg/5ml 100ml bot 30.11\n\tOrion Pharma Ltd.\tFlegnil DS Syrup 250mg/5ml 100ml bot 40.15\n\tIndication: Bronchiectasis, Mucolytic, Chronic obstructive pulmonary disorder (COPD)\n\nDose: Oral\nAs a mucolytic\nAdult: Initially, 750 mg tid, then 1.5 g daily in divided doses.\n\nChild: 2-5 yr: 62.5-125 mg 4 times daily; 6-12 yr: 250 mg tid.\n\nContra-indication: Active peptic ulceration.\n\nSide effects: Nausea, gastric discomfort, GI bleeding, skin rash.\n\nPrecaution: History of peptic ulceration.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Carbonyl Iron	\n\n\tIndication: Dietary supplement, Iron deficiencies, Iron deficiency anemia\n\nDose: One capsule daily. In more severe cases, 2 capsules a day may be required \n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: Antacids may decrease the absorption of carbonyl iron.\n\nPregnancy category: Not Classified\n\nInteraction: Antacids may decrease the absorption of carbonyl iron.
Carbonyl Iron + Folic Acid	\n\n\tEskayef Bangladesh Ltd.\tFeofol CI CAP   30's pack 75\n\tEskayef Bangladesh Ltd.\tFeofol CL CAP   30's pack 75\n\tRangs\tPregmin CAP   50's pack 120\n\tIndication: Iron deficiency anemia\n\nDose: One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: Carbonyl iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nPregnancy category: Not Classified\n\nInteraction: Carbonyl iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
Carbonyl Iron + Folic Acid + Zinc	\n\n\tAcme Ltd.\tDfaz-CI CAP  30's pack  90\n\tAmico Ltd.\tFeropreg TR CAP   30's pack 90\n\tAsiatic Ltd.\tAnimet CAP   30's pack 90\n\tBeximco\tCarofol Z CAP   50's pack 150\n\tDrug International Ltd.\tFerozi-CI CAP 50 mg + 500 mcg + 22.5 mg  \n\tEskayef Bangladesh Ltd.\tZeefol CI CAP   60's pack 180\n\tHealthcare\tPrenat CI CAP   60's pack 240\n\tIncepta\tPreneed-CI CAP  50's pack  150\n\tJayson\tBiofez CAP   50's pack 150.50\n\tKumudini Pharma Ltd.\tZifonyl CAP  50's pack 150\n\tNovo Healthcare and Pharma Ltd.\tFeocron CAP   60's pack 120\n\tNuvista Pharma Ltd\tZifocap CAP  56's pack 301.28\n\tOrganic Health Care\tFer-Z CAP  30's pack 90\n\tOrion Pharma Ltd.\tGlory CAP   50's pack 150\n\tPharmasia Ltd.\tItop CI CAP 50 mg + 500 mcg + 22.5 mg  \n\tRangs\tPregmin Z CAP   50's pack 150\n\tRenata\tFerix CAP   60's pack 180\n\tRephco\tFezin CR CAP   50's pack 150\n\tSilva\tPrenatal CAP   30's pack 87.33\n\tSquare\tZif-CI TR CAP   60's pack 180.35\n\tVirgo\tEnazif TAB dr  50's pack 200\n\tZenith\tHemo Plus CAP   30's pack 90\n\tIndication: Iron,Folic acid and zinc deficiency during pregnancy and lactation\n\nDose: One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: Carbonyl iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\n\n\nPregnancy category: Not Classified\n\nInteraction: Carbonyl iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\n
Carboplatin	\n\n\tBeacon\tCarboplat Injection 150mg/15ml 15 ml vial x 1's pack 1200\n\tBeacon\tCarboplat Injection 450mg/45ml 45 ml vial x 1's pack 2900\n\tBeacon\tDuratocin Injection 100mg/ml 5 amps pack \n\tNovartis (Bangladesh) Ltd.\tCarboplatin Hexal Injection 50mg 1's pack 500\n\tNovartis (Bangladesh) Ltd.\tCarboplatin Hexal Injection 150mg 1's pack 1378\n\tNovartis (Bangladesh) Ltd.\tCarboplatin Hexal Injection 450mg 1's pack 3627\n\tTechno Drugs Ltd.\tCarbotin Injection 450mg/45ml 1's pack 3500\n\tTechno Drugs Ltd.\tCarbotin Injection 150mg/15ml 1's pack 1300\n\tHexal ag, Germany\tCarboplatin Hexal Injection 50mg/Vial 5 ml vial x 1's pack 423\n\tHexal ag, Germany\tCarboplatin Hexal Injection 150mg/Vial 15 ml vial x 1's pack 1166\n\tHexal ag, Germany\tCarboplatin Hexal Injection 450mg/Vial 45 ml vial x 1's pack 3069\n\tIndication: Ovarian carcinoma, Lung cancer\n\nDose: Adult: IV As single agent in treatment-naive patients: 400 mg/m2; As single agent in previously treated patients: 360 mg/m2; W/ cyclophosphamide in treatment-naive patients: 300 mg/m2. Doses to be given not more frequently than every 4 wk. Adjust subsequent doses based on nadir of WBC and platelet counts.\n\nRenal impairment:\nCrCl (ml/min)	\n>40	Recommended dose: 400 mg/m2.\n20-39	Recommended dose: 250 mg/m2.\n\nContra-indication: Previous allergy; pregnancy, lactation; allergy to other platinum compounds; severe bone marrow depression; significant bleeding, aluminium containing needles and IV sets.\n\nSide effects: Thrombocytopenia, neutropenia, leukopenia, anaemia; nausea, vomiting, central neurotoxicity, peripheral neuropathies, ototoxicity; elevation of ALT, AST, blood urea and bilirubin levels, electrolyte disturbances; alopecia; asthenia, pain; cardiac failure, embolism and cerebrovascular accidents may occur; mucositis.\nPotentially Fatal: Bone marrow suppression and anaphylactic reactions.\n\nPrecaution: Neonates; diminished renal function; neurotoxicity; liver function impairment.\n\nMode of action: Increased risk of ototoxicity when used with aminoglycosides.\n\nPregnancy category: D\n\nInteraction: Increased risk of ototoxicity when used with aminoglycosides.
Carboxymethylcellulose Sodium +  Glycerine  Eye prep	\n\n\tAristopharma\tNeotear Eye Drops   10 ml drop 190\n\tIndication: Dry eye, Burning, Irritation and discomfort of the eye\n\nDose: Instill 1 drop in the affected eyes as needed.\n\nContra-indication: It is contraindicated in patients with known hypersensitivity to any ingredient of this formulation.\n\nSide effects: Vision may be temporarily blurred when this product is first used. Also, minor burning/stinging/irritation may temporarily occur.\n\nPrecaution: Irritation, eye pain or visual changes may worsen.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Carboxypolymethylene  + Hydroxy Ethyl Cellulose	\n\n\tIndication: Surgical lubricant, Sexual lubricant\n\nDose: Use as required or as directed by the physician.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Irritation.\n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Carvedilol	\n\n\tACI\tKarvedil TAB dr 12.5mg 30's pack 120\n\tACI\tKarvedil TAB dr 25mg 30's pack 240\n\tACI\tKarvedil TAB dr 6.25mg 50's pack 150\n\tAcme Ltd.\tCarvipress TAB dr 12.5mg 30's pack 150.30\n\tAcme Ltd.\tCarvipress TAB dr 25mg 30's pack 241.20\n\tAcme Ltd.\tCarvipress TAB dr 6.25mg 30's pack 90\n\tAd-din\tAvidol TAB dr 6.25mg 60's pack 180\n\tBeximco\tDilapress TAB dr 12.5mg 30's pack 150\n\tBeximco\tDilapress TAB dr 25mg 30's pack 240\n\tBeximco\tDilapress TAB dr 6.25mg 30's pack 90\n\tBio Pharma Ltd.\tCarved TAB dr 12.5mg 30's pack 150.60\n\tBio Pharma Ltd.\tCarved TAB dr 25mg 30's pack 240.90\n\tBio Pharma Ltd.\tCarvedilol TAB dr 6.25mg 30's pack 90.30\n\tBio Pharma Ltd.\tCravex TAB dr 6.5mg 100's pack \n\tBio Pharma Ltd.\tCravex TAB dr 12.5mg 50's pack \n\tBio Pharma Ltd.\tCravex TAB dr 25mg 50's pack \n\tDelta Pharma\tCarvida TAB dr 12.5mg 30's pack 150\n\tDelta Pharma\tCarvida TAB dr 6.25mg 30's pack 90\n\tDrug International Ltd.\tCavelon TAB dr 12.5mg 50's pack 300\n\tDrug International Ltd.\tCavelon TAB dr 6.25mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tVedilol TAB dr 12.5mg 40's pack 200\n\tEskayef Bangladesh Ltd.\tVedilol TAB dr 25mg 20's pack 160\n\tEskayef Bangladesh Ltd.\tVedilol TAB dr 6.25mg 40's pack 120\n\tGeneral\tDilgard TAB dr 12.5mg 30's pack 150.60\n\tGeneral\tDilgard TAB dr 25mg 30's pack 240.90\n\tGeneral\tDilgard TAB dr 6.25mg 30's pack 90.30\n\tHealthcare\tRovedilol TAB dr 12.5mg 30's pack 210\n\tHealthcare\tRovedilol TAB dr 6.25mg 30's pack 120\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRevodil TAB dr 6.25mg 40's pack 120\n\tIncepta\tCarvista TAB dr 12.5mg 50's pack 250\n\tIncepta\tCarvista TAB dr 25mg 30's pack 240\n\tIncepta\tCarvista TAB dr 6.25mg 100's pack 300\n\tMedimet\tCarvetab TAB dr 12.5mg 50's pack 250\n\tMedimet\tCarvetab TAB dr 6.25mg 50's pack 150\n\tMystic\tDilol TAB dr 12.5mg 50's pack 250\n\tMystic\tDilol TAB dr 6.25mg 100's pack 300\n\tNovartis (Bangladesh) Ltd.\tDiola TAB dr 12.5mg 30's pack 285\n\tNovartis (Bangladesh) Ltd.\tDiola TAB dr 25mg 30's pack 360\n\tNovartis (Bangladesh) Ltd.\tDiola TAB dr 6.25mg 30's pack 187.50\n\tOpsonin Pharma\tExepress TAB dr 12.5mg 30's pack 150\n\tOpsonin Pharma\tExepress TAB dr 25mg 20's pack 160\n\tOpsonin Pharma\tExepress TAB dr 3.125mg 100's pack 151\n\tOpsonin Pharma\tExepress TAB dr 6.25mg 50's pack 150\n\tOpsonin Pharma\tCardex TAB dr 12.5mg 10x3's pack 132.48\n\tOpsonin Pharma\tCardex TAB dr 3.12mg 100's pack 132.83\n\tOpsonin Pharma\tCardex TAB dr 6.25mg 10x5's pack 132.40\n\tPacific\tArilol TAB dr 12.5mg 30's pack 150\n\tPacific\tArilol TAB dr 25mg 30's pack 240\n\tPacific\tArilol TAB dr 6.25mg 30's pack 90\n\tRadiant.\tDilatrend TAB dr 25mg 30's pack 660\n\tRadiant.\tDilatrend TAB dr 6.25mg 30's pack 285\n\tRAK\tCarvicor TAB dr 12.5mg 30's pack 150\n\tRAK\tCarvicor TAB dr 25mg 30's pack 240\n\tRAK\tCarvicor TAB dr 6.25mg 30's pack 90\n\tRangs\tVesodil TAB dr 12.5mg 30's pack 150\n\tRangs\tVesodil TAB dr 25mg 30's pack 240\n\tRangs\tVesodil TAB dr 6.25mg 30's pack 90\n\tRoche Bangladesh Pharmaceutical\tDilatrend TAB dr 6.25mg 30's pack 285\n\tRoche Bangladesh Pharmaceutical\tDilatrend TAB dr 25mg 30's pack 660\n\tSilva\tKoreg TAB dr 12.5mg 30's pack 150.57\n\tSilva\tKoreg TAB dr 25mg 30's pack 240.90\n\tSilva\tKoreg TAB dr 6.25mg 30's pack 90.33\n\tSquare\tDurol TAB dr 12.5mg 30's pack 150.43\n\tSquare\tDurol TAB dr 25mg 30's pack 210.67\n\tSquare\tDurol TAB dr 6.25mg 30's pack 90.18\n\tSquare\tDurol-CR CAP 10mg 30's pack 270\n\tSquare\tDurol-CR CAP 20mg 30's pack 450\n\tSun Pharmaceutical (Bangladesh) Ltd.\tCardivas TAB dr 12.5mg 30's pack 195.60\n\tSun Pharmaceutical (Bangladesh) Ltd.\tCardivas TAB dr 6.25mg 30's pack 227.50\n\tUnimed & Unihealth Manufacturers Ltd.\tUcardol TAB dr 12.5mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tUcardol TAB dr 25mg 30's pack 270\n\tUnimed & Unihealth Manufacturers Ltd.\tUcardol TAB dr 6.25mg 30's pack 90\n\tWhite Horse Pharma\tDilocard TAB dr 12.5mg 30's pack 150\n\tWhite Horse Pharma\tDilocard TAB dr 6.25mg 50's pack 150\n\tIndication: Hypertension, Congestive heart failure, Myocardial infarction, Left ventricular dysfunction, Angina pectoris\n\nDose: Hypertension\nAdult: Initially, 12.5 mg once daily increased to 25 mg once daily after 2 days. Alternatively, initial dose of 6.25 mg bid increased to 12.5 mg bid after 1-2 wk, increased further if necessary to 50 mg once daily or in divided doses.\nElderly: 12.5 mg once daily.\nAngina pectoris\nAdult: Initially, 12.5 mg bid increased to 25 mg bid after 2 days.\nHeart failure\nAdult: Initially, 3.125 mg bid, doubled to 6.25 mg bid after 2 wk if tolerated, then gradually increased to the max dose the patient can tolerate at intervals of not <2>85 kg: 50 mg bid; &lt;85 kg: 25 mg bid.\nLeft ventricular dysfunction post myocardial infarction\nAdult: Initially: 6.25 mg bid, if tolerated, after 3-10 days, increase to 12.5 mg bid and then to a target dose of 25 mg bid.\n\nContra-indication: Hypersensitivity; severe chronic heart failure, bronchial asthma or related bronchospastic conditions; severe hepatic impairment. Patients with NYHA class IV cardiac failure, 2nd or 3rd Â° AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia. Lactation.\n\nSide effects: Bradycardia, AV block, angina pectoris, hypervolaemia, leucopenia, hypotension, peripheral oedema, allergy, malaise, fluid overload, melena, periodontitis, hyperuricaemia, hyponatraemia, increased alkaline phosphatase, glycosuria, prothrombin time, SGPT and SGOT levels, purpura, somnolence, impotence, albuminuria, hypokinesia, nervousness, sleep disorder, skin reaction, tinnitus, dry mouth, anaemia, sweating, fatigue, arthralgia, aggravation, dizziness. Diarrhoea, nausea, vomiting, insomnia, hypercholesterolaemia, weight gain, abnormal vision, rhinitis, pharyngitis and hypertriglyceridaemia.\n\nPrecaution: Avoid abrupt withdrawal as it may precipitate thyroid storm or exacerbate hyperthyroidism. Liver injury; vascular disease, renal failures, suspected phaeochromocytoma and prinzmetal's variable angina; worsening cardiac failure or fluid retention during increase in dosage of carvedilol; diabetic patients. Pregnancy.\n\nMode of action: Decreased serum levels w/ rifampicin. Combination w/ Ca channel blockers (e.g. verapamil and diltiazem) can lead to bradycardia and myocardial depression. Potentiates insulin-induced hypoglycaemic action. May increase hypoglycaemic effects of antidiabetic agents. Increased risk of bradycardia w/ digoxin. Increased risk of hypotension and bradycardia w/ reserpine, MAOIs, clonidine. May increase ciclosporin concentrations. Concurrent use w/ ether, cyclopropane, trichloroethylene may increase the risk of hypotension and heart failure.\n\nPregnancy category: D\n\nInteraction: Decreased serum levels w/ rifampicin. Combination w/ Ca channel blockers (e.g. verapamil and diltiazem) can lead to bradycardia and myocardial depression. Potentiates insulin-induced hypoglycaemic action. May increase hypoglycaemic effects of antidiabetic agents. Increased risk of bradycardia w/ digoxin. Increased risk of hypotension and bradycardia w/ reserpine, MAOIs, clonidine. May increase ciclosporin concentrations. Concurrent use w/ ether, cyclopropane, trichloroethylene may increase the risk of hypotension and heart failure.
Cefaclor	\n\n\tACI\tAbaclor Pd Paediatric Drops 125mg/1.2ml 15ml 125\n\tACI\tAbaclor Powder for Suspension 125mg/5ml 100ml 201.35\n\tACI\tAbaclor CAP 250mg 20's pack 412\n\tACI\tAbaclor CAP 500mg 100ml 481\n\tACI\tAbaclor PD Paediatric Drops 100 mg/ml 15ml 125.85\n\tACI\tAbaclor 250 CAP 250 mg 20s 422.80\n\tACI\tAbaclor 500 CAP 500mg 12's pack 483.24\n\tAcme Ltd.\tAlclor Paediatric Drops 125mg/1.2ml 1's pack 125\n\tAcme Ltd.\tAlclor Powder for Suspension 125mg/5ml 1's pack 190\n\tAcme Ltd.\tAlclor CAP 500mg 20's pack 800\n\tAcme Ltd.\tAlclor Powder for Drops  15 ml bot \n\tAcme Ltd.\tAlclor Suspension  100 ml bot \n\tAlco Pharma\tOticef CAP 250mg  \n\tAlco Pharma\tOticef CAP 500mg  \n\tAlco Pharma\tOticef Powder For Suspension 125 mg/5 ml  \n\tAlco Pharma\tOticef Paediatric Drops 125 mg/1.25 ml  \n\tEskayef Bangladesh Ltd.\tCeflon Paediatric Drops 100mg/ml 15ml 125\n\tEskayef Bangladesh Ltd.\tCeflon Powder for Suspension 125mg/5ml 100ml 200\n\tEskayef Bangladesh Ltd.\tCeflon CAP 250mg 16's pack 256\n\tEskayef Bangladesh Ltd.\tCeflon CAP 500mg 8's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tClorocef CAP 250mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tClorocef CAP 500mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tClorocef Powder For Suspension 125 mg/5 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tClorocef Paediatric Drops 125 mg/1.25 ml  \n\tIncepta\tOticlor Paediatric Drops 125mg/1.2ml 15ml 115\n\tIncepta\tOticlor Powder for Suspension 125mg/5ml 100ml 180\n\tIncepta\tOticlor CAP 500mg 12's pack 480\n\tLeon\tUniclor Paediatric Drops 125 mg/1.25 ml  \n\tNavana\tNavacef Paediatric Drops 125mg/1.2ml 15ml bot 125\n\tNavana\tNavacef Powder for Suspension 125mg/5ml 100ml bot 190\n\tNavana\tNavacef CAP 250mg 20's pack 420\n\tNavana\tNavacef CAP 500mg 12's pack 480\n\tNovartis (Bangladesh) Ltd.\tBiocef Powder for Suspension 125mg/5ml 100ml bot 295\n\tNovartis (Bangladesh) Ltd.\tBiocef CAP 250mg 20's pack 500\n\tNovartis (Bangladesh) Ltd.\tBiocef CAP 500mg 20's pack 920\n\tOpsonin Pharma\tClobac Paediatric Drops 125mg/1.2ml 15ml bot 125.47\n\tOpsonin Pharma\tClobac Powder for Suspension 125mg/5ml 100ml bot 180.64\n\tOrion Pharma Ltd.\tXclor Powder For Suspension 125 mg/5 ml  \n\tRenata\tCefticlor Paediatric Drops 125mg/1.2ml 15ml bot 125\n\tRenata\tCefticlor Powder for Suspension 125mg/5ml 100ml bot \n\tRenata\tCefticlor TAB dr 350mg 12's pack \n\tRenata\tCefticlor CAP 250mg 12's pack 252\n\tRenata\tCefticlor CAP 500mg 12's pack 456\n\tRenata\tCefticlor Drops 100mg 15 ml bot 125.47\n\tSharif\tCFL Powder For Suspension 125 mg/5 ml  \n\tSharif\tCFL Paediatric Drops 125 mg/1.25 ml  \n\tSquare\tLoracef Paediatric Drops 125mg/1.2ml 15ml 125.47\n\tSquare\tLoracef Powder for Suspension 125mg/5ml 100ml 190\n\tSquare\tLoracef CAP 500mg 6's pack 228.90\n\tEli Lilly and Company USA\tCeclor CAP 250mg 15's pack \n\tEli Lilly and Company USA\tCeclor CAP 500mg 15's pack \n\tEli Lilly and Company USA\tCeclor CD TAB dr 375mg 10's pack \n\tIndication: Pneumonia, Meningitis, Peritonitis, Otitis media, Septicaemia, Biliary-tract infections, Urinary-tract infections, Skin and skin structure infections, Upper and lower respiratory tract infections, Pharyngitis and Tonsillitis\n\nDose:  	Oral\nUrinary tract infections, Upper and lower respiratory tract infections, Skin infections, Otitis media\nAdult: As monohydrate: 250-500 mg every 8 hr. Max: 4 g daily.\nChild: >1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid.\n\nSuspension  & Paediatric Drops:\n1 month - 1 year 2.5 ml t.i.d. 0.625 ml t.i.d\n1 year - 5 year 5 ml t.i.d. 1.25 ml t.i.d\nover 5 years 10 ml t.i.d 2.5 ml t.i.d\n\nContra-indication: Known hypersensitivity to cephalosporins.\n\nSide effects: Allergic reactions; diarrhoea, nausea, vomiting; candidiasis, eosinophilia; elevated transaminases.\nPotentially Fatal: Anaphylactic reaction; pseudomembranous colitis.\n\nPrecaution: Severe renal impairment; history of allergy to penicillin; pregnancy, lactation.\n\nMode of action: May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.\n\nPregnancy category: B\n\nInteraction: May enhance the nephrotoxic effect of aminoglycosides. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. Concomitant use w/ warfarin may increase prothrombin time. Probenecid inhibits renal excretion of cefaclor.
Cefadroxil	\n\n\tACI\tCedril Powder for Suspension 125mg/5ml 100ml 70\n\tACI\tCedril CAP 500mg 30's pack 360\n\tAcme Ltd.\tTwicef Paediatric Drops 125mg/1.2ml 15ml bot 50.20\n\tAcme Ltd.\tTwicef Powder for Suspension 125mg/5ml 100ml bot 70.26\n\tAcme Ltd.\tTwicef CAP 500mg 20's pack 241\n\tAcme Ltd.\tTwicef DS Powder for Suspension 250mg/5ml 100ml bot 120.46\n\tDrug International Ltd.\tSefanid Powder for Suspension 125mg/5ml 100ml bot 70\n\tDrug International Ltd.\tSefanid CAP 500mg 50's pack 600\n\tEskayef Bangladesh Ltd.\tArocef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tEskayef Bangladesh Ltd.\tArocef Powder for Suspension 125mg/5ml 100ml bot 70\n\tEskayef Bangladesh Ltd.\tArocef CAP 500mg 24's pack 288\n\tIncepta\tAdora Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tIncepta\tAdora Suspension 125mg/5ml 100ml bot 70\n\tIncepta\tAdora CAP 500mg 20's pack 300\n\tIncepta\tAdora DS Powder for Suspension 250mg/5ml 100ml 120\n\tIncepta\tAdora CAP 500 mg 20's pack 300\n\tKemiko\tAdocil Powder for Suspension 125mg/5ml 100ml bot 70\n\tKemiko\tAdocil CAP 500mg 20's pack 240\n\tNavana\tCefcare Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tNavana\tCefcare Powder for Suspension 125mg/5ml 100ml bot 70.26\n\tNavana\tCefcare CAP 500mg 12's pack 144.60\n\tNIPRO JMI Pharma\tBexen CAP 500mg  \n\tNIPRO JMI Pharma\tBexen Powder For Suspension 125 mg/5 ml  \n\tOpsonin Pharma\tTrubid Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tOpsonin Pharma\tTrubid Powder for Suspension 125mg/5ml 60ml bot/ 100ml bot 50/ 70\n\tOpsonin Pharma\tTrubid CAP 500mg 24's pack 254\n\tOpsonin Pharma\tTrubid DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tRangs\tDroxil Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tRangs\tDroxil Powder for Suspension 125mg/5ml 100ml bot 70\n\tRangs\tDroxil CAP 500mg 20's pack 240\n\tSomatec\tCefador Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tSomatec\tCefador Powder for Suspension 125mg/5ml 100ml bot 70.26\n\tSomatec\tCefador CAP 500mg 20's pack 241\n\tSquare\tFodexil CAP 500mg 18's pack 270\n\tTechno Drugs Ltd.\tSefadol Powder for Suspension 125mg/5ml 100ml bot 65\n\tTechno Drugs Ltd.\tSefadol CAP 500mg 18's pack 216\n\tUnimed & Unihealth Manufacturers Ltd.\tFicef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tUnimed & Unihealth Manufacturers Ltd.\tFicef Powder for Suspension 125mg/5ml 100ml bot 70\n\tUnimed & Unihealth Manufacturers Ltd.\tFicef CAP 500mg 20's pack 240\n\tJMI Pharma\tBexan CAP 500mg 20's pack 241\n\tJMI Pharma\tBexan Suspension 125mg 100ml bot 70\n\tIndication: Pharyngitis, Susceptible infections, Sore throat, Tonsillitis, Urinary tract infection, Reproductive tract infection and skin infections\n\nDose:  Adult: PO 1-2 g/day as a single dose or in 2 divided doses. \nChildren: 30 mg/kg/day in equally divided doses every 12 hours.\n\nRenal impairment:\nCrCl (ml/min)	\n26-50	0.5-1 g bid.\n11-25	0.5-1 g once daily.\n<10	0.5-1 g every 36 hr. \n\nContra-indication: Hypersensitivity to cephalosporins.\n\nSide effects: Nausea, vomiting, diarrhoea, abdominal discomfort; skin rash, angioedema; elevated liver enzyme values; superinfection with resistant organisms especially candida.\nPotentially Fatal: Anaphylactic reaction; pseudomembranous colitis.\n\nPrecaution: Impaired renal function; pregnancy and lactation.\n\nMode of action: Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.\n\nPregnancy category: B\n\nInteraction: Concomitant use w/ bacteriostatic antibiotics (e.g. tetracycline, erythromycin, sulfonamides, chloramphenicol) may cause antagonistic effect. May potentiate nephrotoxic effects of aminoglycoside antibiotics, polymyxin B, colistin or high-dose loop diuretics. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May attenuate the effect of oral contraceptives. Increased serum concentration w/ probenecid. Reduced bioavailability w/ colestyramine.
Cefdinir	\n\n\tAcme Ltd.\tAdinir Powder for Suspension 125mg/5ml 60ml bot 175.66\n\tAcme Ltd.\tAdinir CAP 300mg 8's pack 361.28\n\tBeximco\tCefida Powder for Suspension 125mg/5ml 60ml bot 176\n\tBeximco\tCefida CAP 300mg 8's pack 360\n\tEskayef Bangladesh Ltd.\tCednir CAP 300mg 4's pack 160\n\tEskayef Bangladesh Ltd.\tCednir DS Powder for Suspension 250mg/5ml 30ml bot 160\n\tIncepta\tEfdinir Powder for Suspension 125mg/5ml 60ml bot 175\n\tIncepta\tEfdinir CAP 300mg 8's pack 360\n\tNavana\tRidicef Powder for Suspension 125mg/5ml 60ml bot 175.65\n\tNavana\tRidicef CAP 300mg 12's pack 541.92\n\tRenata\tPalcef Powder for Suspension 125mg/5ml 60ml bot 175\n\tRenata\tPalcef CAP 300mg 10's pack 450\n\tRenata\tPalcef TAB dr 300mg 10's pack 175\n\tRenata\tPalcef DS Powder for Suspension 250mg/5ml 30ml bot 160\n\tUnimed & Unihealth Manufacturers Ltd.\tCefexta CAP 300mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tCefexta Dry Powder for Suspension  60ml \n\tUnimed & Unihealth Manufacturers Ltd.\tCefexta Forte Dry Powder for Suspension  30ml \n\tIndication: Community-acquired pneumonia, Susceptible infections, Sinusitis, Otitis media, Sore throat, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Acute Maxillary Sinusitis\n\nDose: Adult: PO 600 mg once daily.  Once-daily dosing for 10 days is as effective as BID dosing.\nChild:\nThe total daily dose for all infections is 14 mg/kg, up to a maximum dose of 600 mg per day.\n\nRenal impairment:\nCrCl (ml/min)	\n<30	 300 mg once daily. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Headache, dizziness, fever; nausea, vomiting, diarrhoea, abdominal pain; rash; leukopaenia, thrombocytopaenia, haemolytic anaemia.\nPotentially Fatal: Anaphylaxis; renal and hepatic failure.\n\nPrecaution: Penicillin-sensitive patients; superinfection; seizure; pseudomembranous colitis; pregnancy, lactation; renal or hepatic insufficiency.\n\nMode of action: Concomitant admin w/ antacids or Fe supplements reduce the rate and extent of absorption. Admin w/ Fe supplements may cause reddish stools. Decreased renal elimination w/ probenecid.\n\nPregnancy category: B\n\nInteraction: Concomitant admin w/ antacids or Fe supplements reduce the rate and extent of absorption. Admin w/ Fe supplements may cause reddish stools. Decreased renal elimination w/ probenecid.
Cefditoren	\n\n\tACI\tCeftoren TAB dr 200mg  \n\tGeneral\tSpacef TAB dr 200mg  \n\tGeneral\tSpacef TAB dr 400mg  \n\tOrion Pharma Ltd.\tCefditor TAB dr 200mg 8's pack 1200\n\tOrion Pharma Ltd.\tCefditor TAB dr 400mg  \n\tSanofi Aventis (BD) Ltd.\tCeftor TAB dr 200mg  \n\tIndication: Pharyngitis, Community-acquired pneumonia, Susceptible infections, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis\n\nDose: Adult: PO Community-acquired pneumonia; Acute bacterial exacerbation of chronic bronchitis 400 mg twice daily. Treatment duration: 10-14 days. \n\nPharyngitis; Tonsilitis; Uncomplicated skin and skin structure infections 200 mg twice daily for 10 days.\n\nRenal impairment:\nCrCl (ml/min)	\n30-49	Maximum: 200 mg bid\n<30 	Maximum: 200 mg once daily\n\nContra-indication: Hypersensitivity to Cefditoren, other cephalosporins; or milk proteins. Carnitine deficiency.\n\nSide effects: Diarrhoea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, haematuria, increased urine white blood cells, decreased haematocrit, increased glucose, interstitial pneumonia, acute eosinophilic pneumonia, acute renal failure, arthralgia, thrombocytopenia, erythema multiforme. Pseudomembranous colitis symptoms may occur during or after antibiotic treatment.\nPotentially Fatal: Hypersensitivity, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis.\n\nPrecaution: Pregnancy and lactation. Patients with penicillin allergy. Avoid prolonged use as pivalate-containing compounds may cause carnitine deficiency over time; greater risk of carnitine deficiency in patients with renal impairment or decreased muscle mass. May decrease prothrombin activity especially in patients with renal or hepatic impairment, poor nutritional status, prolonged antibiotic treatment or patients previously stabilised on anticoagulant therapy. Long term use may result in development of drug-resistant bacteria, or superinfection including Clostridium difficile-associated diarrhoea and pseudomembranous colitis.\n\nMode of action: Reduced oral bioavailability when coadministered with antacids or H2-receptor antagonists. Probenecid may increase plasma concentration and prolong half-life of Cefditoren. May enhance anticoagulant effect of vitamin K antagonists (e.g. warfarin).\n\nPregnancy category: B\n\nInteraction: Reduced oral bioavailability when coadministered with antacids or H2-receptor antagonists. Probenecid may increase plasma concentration and prolong half-life of Cefditoren. May enhance anticoagulant effect of vitamin K antagonists (e.g. warfarin).
Cefepime	\n\n\tACI\tPime-4 IV/IM Injection 1gm/vial 1gm vial with water 553.73\n\tACI\tPime-4 IV/IM Injection 2gm/vial 2gm vial with water 1104.15\n\tACI\tPime-4 IV/IM Injection 500mg/vial 500mg vial with water 302.04\n\tAcme Ltd.\tSuperpime IV/IM Injection 1gm/vial 1's pack 552.07\n\tAcme Ltd.\tSuperpime IV/IM Injection 2gm/vial 1's pack 1100\n\tAcme Ltd.\tSuperpime IV/IM Injection 500mg/vial 1's pack 300\n\tAristopharma\tForgen IV/IM Injection 1gm/vial 1gm vial with water 550\n\tAristopharma\tForgen IV/IM Injection 2gm/vial 2gm vial with water 1100\n\tAristopharma\tForgen IV/IM Injection 500mg/vial 500mg vial with water 300\n\tBeximco\tTetracef IV/IM Injection 1gm/vial 1gm vial with water 550\n\tBeximco\tTetracef IV/IM Injection 2gm/vial 2gm vial with water 1100\n\tBeximco\tTetracef IV/IM Injection 500mg/vial 500mg vial with water 300\n\tDrug International Ltd.\tUnipim IV/IM Injection 1gm/vial 1gm vial with water 401\n\tDrug International Ltd.\tUnipim IV/IM Injection 500mg/vial 500mg vial with water 230\n\tEskayef Bangladesh Ltd.\tMegapime IV/IM Injection 1gm/vial 1gm vial with water 550\n\tEskayef Bangladesh Ltd.\tMegapime IV/IM Injection 2gm/vial 2gm vial with water 1100\n\tEskayef Bangladesh Ltd.\tMegapime IV/IM Injection 500mg/vial 500mg vial with water 300\n\tGlobe\tXimepime IV/IM Injection 1gm/vial 1gm vial with water 550\n\tGlobe\tXimepime IV/IM Injection 500mg/vial 500mg vial with water 300\n\tHealthcare\tZopime Injection 1gm  550\n\tHealthcare\tZopime Injection 500mg  300\n\tHealthcare\tZopime IV/IM Injection 2 gm/vial  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tGen 4 IV/IM Injection 1gm/vial 1gm vial with water 555\n\tIbn Sina Pharmaceutical Ind. Ltd.\tGen 4 IV/IM Injection 2gm/vial 2gm vial with water 1010\n\tIbn Sina Pharmaceutical Ind. Ltd.\tGen 4 IV/IM Injection 500mg/vial 500mg vial with water 305\n\tIncepta\tUltrapime IV/IM Injection 1gm/vial 1gm vial with water 550\n\tIncepta\tUltrapime IV/IM Injection 500mg/vial 500mg vial with water 300\n\tJayson\tJapime IM / IV Injection 1 gm 1 gm  vial combi pack 526.98\n\tKemiko\tTupime IV/IM Injection 1gm/vial 1gm vial with water 550\n\tOpsonin Pharma\tXenim IV/IM Injection 1gm/vial 1gm vial with water 550\n\tOpsonin Pharma\tXenim IV/IM Injection 500mg/vial 500mg vial with water 300\n\tOrion Pharma Ltd.\tMagnova IV/IM Injection 500 mg/vial  \n\tOrion Pharma Ltd.\tMagnova IV/IM Injection 1 gm/vial  \n\tOrion Pharma Ltd.\tMagnova IV/IM Injection 2 gm/vial  \n\tPharmasia Ltd.\tXemimax IV/IM Injection 500 mg/vial  \n\tPharmasia Ltd.\tXemimax IV/IM Injection 1 gm/vial  \n\tPopular\tCefa 4 IV/IM Injection 1gm/vial 1gm vial with water 550\n\tPopular\tCefa 4 IV/IM Injection 2gm/vial 2gm vial with water 1100\n\tPopular\tCefa 4 IV/IM Injection 500mg/vial 500mg vial with water 300\n\tRenata\tCeftipime IV/IM Injection 1gm/vial 1gm vial with water 552.08\n\tRenata\tCeftipime IV/IM Injection 2gm/vial 2gm vial with water 1104.15\n\tRenata\tCeftipime IV/IM Injection 500mg/vial 500mg vial with water 301.13\n\tSanofi Aventis (BD) Ltd.\tWinnipime IV/IM Injection 1gm/vial 1gm vial (combipack) 550\n\tSanofi Aventis (BD) Ltd.\tWinnipime IV/IM Injection 2gm/vial 2gm vial (combipack) 1100\n\tSanofi Aventis (BD) Ltd.\tWinnipime IV/IM Injection 500mg/vial 500mg vial combipack 300\n\tSquare Cephalosporins Ltd.\tMaxpime IV/IM Injection 1gm/vial 1gm vial with water 550\n\tSquare Cephalosporins Ltd.\tMaxpime IV/IM Injection 2gm/vial 2gm vial with water 1100\n\tSquare Cephalosporins Ltd.\tMaxpime IV/IM Injection 500mg/vial 500mg vial with water 300\n\tZiska\tEfepime IV/IM Injection 1gm/vial 1gm vial with water 550\n\tZiska\tEfepime IV/IM Injection 500mg/vial 500mg vial with water 300\n\tZiska\tEfepime IV/IM Injection 2gm 1's pack 1100\n\tIndication: Skin and skin structure infections, Urinary tract infection, Nosocomial pneumonia, Multiple drug resistant pneumonia, Neutropenia\n\nDose:  Adult: IV UTI 0.5-1 g 12 hrly for 7-10 days. \nEmpirical therapy for febrile neutropenia 2 g 8 hrly for 7 days or until resolution of neutropenia. \nModerate to severe pneumonia 1-2 g 12 hrly for 10 days. \nComplicated intra-abdominal infections 2 g 12 hrly for 7-10 days. \nUncomplicated skin and skin structure infections 2 g 12 hrly for 10 days.\n\nChild: 2 mth - 16 yr: ?40 kg: 50 mg/kg every 12 hr for 7-10 days for Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis),\nUncomplicated Skin and Skin Structure Infections and Pneumonia.. May be given via direct inj over 5 minutes or infuse over 30 minutes.\n\nFor empiric therapy for febrile neutropenic patients  2 mth - 16 yr: <40 kg: 50 mg/kg every 8 hr for 7 days or until neutropenia resolves.\n\nRenal impairment: Haemodialysis: 1 g on the 1st day of treatment, followed by 0.5 g 24 hrly; dose should be given after haemodialysis on dialysis days and preferably at the same time each day. CAPD: Adult dose 48 hrly.\n\nCrCl (ml/min)	\n<10	        0.25-0.5 g 24 hrly.\n11-29	0.5-1 g 24 hrly.\n30-60	0.5-2 g 24 hrly.\n\nContra-indication: Hypersensitivity to cefepime or other cephalosporins.\n\nSide effects: Positive Coombs' test without haemolysis; rash, pruritus; diarrhoea, nausea, vomiting; fever, headache; pain and erythema at inj site; agranulocytosis; anaphylactic shock; leucopenia; neutropenia; thrombocytopenia.\n\nPrecaution: Renal impairment; history of penicillin or cephalosporin allergy; lactation, pregnancy. Caution when used in patients with history of GI diseases, especially colitis. May decrease prothrombin activity; monitor prothrombin time in patients with poor nutritional state, renal or hepatic impairment and those on prolonged treatment. Prolonged treatment may result in overgrowth of nonsusceptible organisms, resulting in superinfection. Consider the possibility of Clostridium difficile associated diarrhoea in patients who present with diarrhoea after treatment. Caution when used in patients with a history of seizures.\n\nMode of action: Increased potential for nephrotoxicity and ototoxicity of aminoglycosides. Increased risk of nephrotoxicity w/ potent diuretics (e.g. furosemide).\n\nPregnancy category: B\n\nInteraction: Increased potential for nephrotoxicity and ototoxicity of aminoglycosides. Increased risk of nephrotoxicity w/ potent diuretics (e.g. furosemide).
Cefetamet Pivoxil Hydrochloride	\n\n\tIncepta\tTenafet TAB dr 250mg 12's pack 240\n\tIncepta\tTenafet TAB dr 500mg 12's pack 420\n\tIncepta\tTenafet Suspension 125mg/5ml 50ml bot 120\n\tIncepta\tTenafet Suspension 125mg 50 ml bot 120\n\tIndication: Pneumonia, Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis\n\nDose: Adults and children over 12 years:\n500 mg twice daily.\nChildren under 12 years:\nUsual dosage is 10 mg/kg twice daily.\n<15 kg (approximately 6 months - 3 years) 125 mg twice daily\n16 - 30 kg (approximately 3 - 9 years) 250 mg twice daily\n31 - 40 kg (approximately 9 - 12 years) 375 mg twice daily\n>40 kg (approximately over 12 years) 500 mg twice daily\n\nContra-indication: Known hypersensitivity to cephalosporins.\n\nSide effects: Diarrhoea, nausea, vomiting, hypersensitivity reactions.\n\nPrecaution: Hypersensitivity to penicillins. Renal insufficiency; lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Cefixime	\n\n\tACI\tCefim Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot/ 75ml bot 120.45/ 195/ 240.90\n\tACI\tCefim-3 Powder for Suspension 200mg/5ml 50ml bot 300.90\n\tACI\tCefim-3 CAP 200mg 12's pack 421.32\n\tACI\tCefim-3 DS CAP 400mg 6's pack 302.04\n\tACI\tCefim-3 Powder For Suspension 100mg/5ml 30ml bot/75ml bot/50ml bot 130.39/241.62/210.63\n\tACI\tCefim-3 TAB dr 200mg 14's pack 421.26\n\tACI\tCefim-3 DS TAB dr 400mg 7's pack 351.05\n\tAcme Ltd.\tFix A Powder for Suspension 100mg/5ml 37.5ml bot/ 50ml bot 130.49/ 175.66\n\tAcme Ltd.\tFix A CAP 200mg 12's pack 361.32\n\tAcme Ltd.\tFix A DS CAP 400mg 8's pack 401\n\tAd-din\tCefixime A Powder for Suspension 100mg/5ml 50ml bot 160\n\tAd-din\tCefixime A CAP 200mg 5's pack 125\n\tAexim\tCeferon-3 CAP 200mg 12's pack 300\n\tAexim\tCeferon-3 Suspension 100mg 37.5 ml bot / 50 ml bot 130 / 160\n\tAlbion Ltd.\tCefiac Powder For Suspension 100 mg/5 ml  \n\tAlbion Ltd.\tCefiac CAP 200mg  \n\tAlbion Ltd.\tCefiac CAP 400mg  \n\tAlbion Ltd.\tCefixime CAP 200 mg/ 400 mg 12's / 6's pack \n\tAlco Pharma\tSaver CAP 200mg 12's pack 360\n\tAlco Pharma\tSaver CAP 400mg 8's pack 400\n\tAlco Pharma\tSaver Suspension 100mg 30ml bot / 50 ml bot 120 / 195\n\tAmbee\tTricef Powder for Suspension 100mg/5ml 50ml bot 160.61\n\tAmbee\tTricef M CAP 200mg 4's pack 100.40\n\tAmico Ltd.\tGen - 3 Powder for Suspension 100mg/5ml 50ml bot 175\n\tAmico Ltd.\tGen - 3 CAP 200mg 5's pack 135\n\tAmulet\tAmucef CAP 400mg  \n\tAmulet\tAmucef CAP 200mg  \n\tAmulet\tAmucef Powder For Suspension 100 mg/5 ml  \n\tAPC Pharma Ltd.\tCefesta Powder for Suspension 100mg/5ml 50ml bot 160\n\tAPC Pharma Ltd.\tCefesta CAP 200mg 8's pack 240\n\tApex\tTexit Powder for Suspension 100mg/5ml 50ml bot 160\n\tApex\tTexit CAP 200mg 8's pack 240\n\tApex\tTexit CAP 400mg 4's pack 180\n\tApollo Pharmaceutical Ltd.\tCefixime Powder for Suspension 100mg/5ml 50ml bot 160\n\tApollo Pharmaceutical Ltd.\tCefixime CAP 200mg 12's pack 360\n\tAristopharma\tAfix Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot 120/ 195\n\tAristopharma\tAfix CAP 200mg 10's pack 300\n\tAristopharma\tAfix TAB dr 200mg 10's pack 300\n\tAristopharma\tAfix CAP 400mg 6's pack 300\n\tAristopharma\tAfix TAB dr 400mg 6's pack 300\n\tAristopharma\tAfix DS Powder for Suspension 200mg/5ml 30ml bot/ 50ml bot 195/ 280\n\tAsiatic Ltd.\tAfixime Powder for Suspension 100mg/5ml 50ml bot 160.60\n\tAsiatic Ltd.\tAfixime CAP 200mg 8's pack 200\n\tAsiatic Ltd.\tAfixim CAP 400mg  \n\tAstra Biopharmaceuticals Ltd.\tC-3 CAP 200mg  \n\tAstra Biopharmaceuticals Ltd.\tC-3 Powder For Suspension 100 mg/5 ml  \n\tBeacon\tStarcef Powder for Suspension 100mg/5ml 50ml bot 195\n\tBeacon\tStarcef CAP 200mg 8's pack 240\n\tBenham\tExiben Powder for Suspension 100mg/5ml 50ml bot 160\n\tBenham\tExiben CAP 200mg 4's pack 116\n\tBeximco\tTriocim Powder for Suspension 100mg/5ml 50ml bot 195\n\tBeximco\tTriocim CAP 200mg 16's pack 480\n\tBeximco\tTriocim CAP 400mg 6's pack 300\n\tBeximco\tTriocim DS Powder for Suspension 200mg/5ml 50ml bot 320\n\tBio Pharma Ltd.\tBestcef Powder for Suspension 100mg/5ml 37.5ml bot/ 50ml bot 130.49/ 195.74\n\tBio Pharma Ltd.\tBestcef CAP 200mg 15's pack 451.65\n\tBio Pharma Ltd.\tBestcef CAP 400mg 8's pack 401.52\n\tBio Pharma Ltd.\tCefimax PFS Powder For Suspension 200 mg/5 ml  \n\tBristol Pharma Ltd.\tXifim CAP 200mg 12's pack 360\n\tBristol Pharma Ltd.\tXifim Suspension 125mg 50 ml bot 160\n\tChemist Ltd.\tExcef Powder for Suspension 100mg/5ml 50ml bot 160\n\tChemist Ltd.\tExcef CAP 200mg 8's pack 200\n\tConcord\tMicrocef CAP 200mg 12's pack \n\tConcord\tMicrocef CAP 400mg 8's pack \n\tConcord\tMicrocef Powder For Suspension 100 mg/5 ml 30ml bot/50ml bot \n\tCosmic Chemical Industries Ltd.\tSuprax CAP 200mg 12's pack 360\n\tCosmic Chemical Industries Ltd.\tSuprax PFS Powder for Suspension 100mg/5ml 50ml bot 180\n\tCosmic Chemical Industries Ltd.\tSuprax-DS CAP 400mg 8's pack 400\n\tDecent Pharma Ltd.\tDefim 3 Powder for Suspension 100mg/5ml 60ml bot 156\n\tDecent Pharma Ltd.\tDefim 3 CAP 200mg 8's pack 240\n\tDelta Pharma\tOfex Powder for Suspension 100mg/5ml 50ml bot 170\n\tDelta Pharma\tOfex CAP 200mg 12's pack 300\n\tDelta Pharma\tOfex CAP 400mg 4's pack 160\n\tDesh\tD-Fix Powder for Suspension 100mg/5ml 50ml bot 180\n\tDesh\tD-Fix CAP 200mg 6's pack 180\n\tDoctor's Chemicals Works Ltd.\tNeofexim CAP 200mg 8's pack 200\n\tDoctor's Chemicals Works Ltd.\tNeofexim Suspension 100mg 50ml bot 175\n\tDrug International Ltd.\tT Cef Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot 130/ 175\n\tDrug International Ltd.\tT Cef CAP 200mg 14's pack 420\n\tDrug International Ltd.\tT Cef CAP 400mg 7's pack 350\n\tDrug International Ltd.\tT-Cef DS Powder for Suspension 200mg/5ml 50ml bot 280\n\tEdruc Ltd.\tC - 3 CAP 200mg 4's pack 100\n\tEdruc Ltd.\t3-C Suspension 125mg 50 ml bot 160\n\tEskayef Bangladesh Ltd.\tRoxim Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot/ 70ml bot 120/ 195/ 225\n\tEskayef Bangladesh Ltd.\tRoxim CAP 200mg 12's pack/ 14's pack 360/ 420\n\tEskayef Bangladesh Ltd.\tRoxim TAB dr 200mg 16's pack 560\n\tEskayef Bangladesh Ltd.\tRoxim CAP 400mg 6's pack/ 7's pack 400\n\tEskayef Bangladesh Ltd.\tRoxim TAB dr 400mg 7's pack 350\n\tEskayef Bangladesh Ltd.\tRoxim XL Powder for Suspension 200mg/5ml 37.5ml bot/ 60ml bot 225/ 320\n\tEskayef Bangladesh Ltd.\tRoxim-L Powder for suspension 100mg/5ml 75ml 225\n\tEskayef Bangladesh Ltd.\tRoxim-M Powder for suspension 100mg/5ml 50ml 195\n\tEskayef Bangladesh Ltd.\tRoxim-S Powder for suspension 100mg/5ml 30ml 130\n\tEthical Drug Ltd.\tTrixim CAP 400mg  \n\tEthical Drug Ltd.\tTrixim Powder For Suspension 100 mg/5 ml  \n\tEuro Pharma Ltd.\tCeficap CAP 200mg 8's pack 240\n\tEuro Pharma Ltd.\tCeficap CAP 400mg 8's pack 400\n\tEuro Pharma Ltd.\tCeficap Suspension 100mg 50 ml bot 195\n\tEverest\tEvexim Powder for Suspension 100mg/5ml 50ml bot 155\n\tEverest\tEvexim CAP 200mg 6's pack 144\n\tG. A. Company Ltd.\tG Fix Powder for Suspension 100mg/5ml 50ml bot 195\n\tG. A. Company Ltd.\tG Fix CAP 200mg 4's pack 120\n\tGeneral\tTocef Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot 130.49/ 195.74\n\tGeneral\tTocef CAP 200mg 12's pack 361.22\n\tGeneral\tTocef CAP 400mg 8's pack 401.52\n\tGeneral\tTocef DS Powder For Suspension 200 mg/5 ml  \n\tGlaxoSmithKline Bangladesh Ltd.\tCexime Powder for Suspension 100mg/5ml 50ml bot 195.74\n\tGlaxoSmithKline Bangladesh Ltd.\tCexime CAP 200mg 14's pack 490\n\tGlaxoSmithKline Bangladesh Ltd.\tCexime CAP 400mg 7's pack 350\n\tGlobe\tCefix Powder for Suspension 100mg/5ml 50ml bot 160\n\tGlobe\tCefix CAP 200mg 8's pack 200\n\tGlobe\tCefix CAP 400mg 4's pack 180\n\tGlobex\tGlobexim CAP 200mg 8's pack 240\n\tGlobex\tGlobexim Powder For Suspension 200 mg/5 ml 50ml 190\n\tGonoshasthaya\tG-Cefixime Suspension 100mg 50 ml bot 130.50\n\tGonoshasthaya\tG-Cefixime CAP 200mg 8's pack 160.64\n\tGuardian Healthcare Ltd.\tCefimax CAP 200mg  \n\tHallmark\t3-Geocef Suspension 125mg 50 ml bot 175\n\tHealthcare\tDenvar Powder for Suspension 100mg/5ml 50ml bot 195\n\tHealthcare\tDenvar CAP 200mg 12's pack 420\n\tHealthcare\tDenvar CAP 400mg 6's pack 300\n\tHealthcare\tDenver DS Powder for Suspension 200mg/5ml 37.5ml bot/ 50ml bot 225/ 280\n\tHudson\tCef PLUS Powder for Suspension 100mg/5ml 50ml bot 160\n\tHudson\tCef PLUS CAP 200mg 12's pack 400\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCefixim Powder for Suspension 100mg/5ml 30ml bot/ 40ml bot/ 50ml bot 130/ 150/ 200\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCefixim CAP 200mg 12's pack 360\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCefixim CAP 400mg 8's pack 400\n\tIncepta\tEmixef Powder for Suspension 100mg/5ml 30ml bot\n 130\n\tIncepta\tEmixef CAP 420mg 12's pack 300\n\tIncepta\tEmixef CAP 400mg 4's pack 180\n\tIncepta\tEmixef DS Powder for Suspension 200mg/5ml 50ml bot 280\n\tIndobangla Pharmaceuticals\tFixim Suspension 100mg 50 ml bot 195\n\tJayson\tAntima Powder for Suspension 100mg/5ml 50ml bot 160\n\tJayson\tAntima CAP 200mg 4's pack 100\n\tJayson\tAntima CAP 400mg 1x4's pack 200\n\tKemiko\tKefim Powder for Suspension 100mg/5ml 37.5ml bot/ 50ml bot 130/ 195\n\tKemiko\tKefim CAP 200mg 8's pack  240\n\tKemiko\tKefim CAP 400mg 4's pack 220\n\tKumudini Pharma Ltd.\tCefadyl Powder for Suspension 100mg/5ml 50ml bot 160\n\tKumudini Pharma Ltd.\tCefadyl CAP 200mg 8's pack 240\n\tLabaid\tCephoral-200 CAP 200mg 2x7's pack 490\n\tLabaid\tCephoral-400 CAP 400mg 7's pack 385\n\tLabaid\tCephoral Powder for suspension  50ml bot 200\n\tLeon\tPolyxim CAP 200mg  \n\tLeon\tPolyxim CAP 400mg  \n\tLeon\tPolyxim Powder For Suspension 100 mg/5 ml  \n\tLeon\tPolyxim Powder For Suspension 200 mg/5 ml  \n\tLibra Pharmaceuticls Ltd.\tXylocef Powder for Suspension 100mg/5ml 50ml bot 160.61\n\tLibra Pharmaceuticls Ltd.\tXylocef CAP 200mg 8's pack 200.80\n\tMarksman.\tRescure Powder for Suspension 100mg/5ml 50ml bot 165\n\tMarksman.\tRescure CAP 200mg 6's pack 180\n\tMedicon\tProfix Powder for Suspension 100mg/5ml 50ml bot 175\n\tMedicon\tProfix CAP 200mg 8's pack 240\n\tMedimet\t3rd Cef TAB dr 400mg 4's pack 200\n\tMillat\tHyxim Powder for Suspension 100mg/5ml 50ml bot 195\n\tMillat\tHyxim CAP 200mg 6's pack 180\n\tModern\tNeofix Powder for Suspension 100mg/5ml 50ml bot 160\n\tModern\tNeofix CAP 200mg 8's pack 200\n\tMonicopharma\tCefmix Powder for Suspension 100mg/5ml 50ml bot 180\n\tMonicopharma\tCefmix CAP 200mg 12's pack 360\n\tMystic\tOrfix Powder for Suspension 100mg/5ml 50ml bot 160\n\tMystic\tOrfix CAP 200mg 4's pack 100\n\tNavana\tDuracef Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot 120.44/ 160.60\n\tNavana\tDuracef CAP 200mg 12's pack 361.32\n\tNavana\tDuracef CAP 400mg 12's pack 602.28\n\tNipa\tTriocef-200 CAP 200mg 12's pack  360\n\tNipa\tTriocef-200 Suspension 100mg 37.5 ml bot / 50 ml bot  135 / 195\n\tNIPRO JMI Pharma\tFixpro Powder for Suspension 100mg/5ml 50ml bot 195.74\n\tNIPRO JMI Pharma\tFixpro 200 CAP 200mg 12's pack 361.44\n\tNIPRO JMI Pharma\tFixpro 400 CAP 400mg 8's pack 401.52\n\tNovartis (Bangladesh) Ltd.\tSetic Powder for Suspension 100mg/5 m 50ml bot 195\n\tNovartis (Bangladesh) Ltd.\tSetic CAP 200mg 14's pack 490\n\tNovartis (Bangladesh) Ltd.\tSetic CAP 400mg 14's pack 700\n\tNovelta Bestway\tInfa-3 CAP 200mg  \n\tNovelta Bestway\tInfa-3 CAP 400mg  \n\tNovelta Bestway\tInfa-3 Powder For Suspension 100 mg/5 ml  \n\tNovo Healthcare and Pharma Ltd.\tCebex Powder for Suspension 100mg/5ml 50ml bot 160\n\tNovo Healthcare and Pharma Ltd.\tCebex CAP 200mg 8's pack 240\n\tNovo Healthcare and Pharma Ltd.\tCebex CAP 400mg 4's pack 200\n\tNovus\tNovacef-200 CAP 200mg 12's pack 360\n\tNovus\tNovacef-200 Suspension 100mg 50 ml bot 195\n\tNuvista Pharma Ltd\tSanfix CAP 200 mg 14's pack 491.54\n\tNuvista Pharma Ltd\tSanfix CAP 400mg  \n\tOpsonin Pharma\tCeftid Powder for Suspension 100mg/5ml 37.5ml bot/ 50ml bot 130/ 160\n\tOpsonin Pharma\tCeftid CAP 200mg 12's pack 360\n\tOpsonin Pharma\tCeftid TAB dr 200mg 12's pack 361.44\n\tOpsonin Pharma\tCeftid CAP 400mg 6's pack 300\n\tOpsonin Pharma\tCeftid TAB dr 400mg 6's pack 301.14\n\tOpsonin Pharma\tCeftid DS Powder for Suspension 200mg/5ml 50ml bot 320\n\tOpsonin Pharma\tCeftid Paediatric drops Paediatric Drops 25mg/ml 1x1's Pack 98\n\tOrganic Health Care\tOrgaxim Powder For Suspension 100 mg/5 ml  \n\tOrganic Health Care\tOrgaxim CAP 200mg  \n\tOrganic Health Care\tOrgaxim CAP 400mg  \n\tOrganic Health Care\tOrgaxim CAP 100mg  \n\tOrion Pharma Ltd.\tTruso CAP 200mg 16's pack 480\n\tOrion Pharma Ltd.\tTruso CAP 400mg 8's pack 400\n\tOrion Pharma Ltd.\tTruso DS Powder for Suspension 200mg/5ml 50ml bot 280\n\tOrion Pharma Ltd.\tTruso Suspension 125mg 37.5ml bot / 50 ml bot 130.49 / 160\n\tPacific\tTrifix Powder for Suspension 100mg/5ml 50ml bot 150\n\tPacific\tTrifix CAP 200mg 6's pack 210\n\tPacific\tTrifix Paediatric Drops 2.5 gm/100 ml  \n\tPacific\tTrifix DS Powder For Suspension 200 mg/5 ml  \n\tPacific\tTrifix CAP 400mg  \n\tPharmadesh Ltd.\tCefocef Powder for Suspension 100mg/5ml 50ml bot 175\n\tPharmadesh Ltd.\tCefocef DS CAP 400mg 8's pack 361.28\n\tPharmadesh Ltd.\tCefocef M CAP 200mg 8's pack 200.72\n\tPharmasia Ltd.\tVelofix Powder for Suspension 100mg/5ml 50ml bot 195\n\tPharmasia Ltd.\tVelofix CAP 200mg  12's pack 360\n\tPharmasia Ltd.\tVelofix CAP 400mg 8's pack 400\n\tPharmasia Ltd.\tVelofix DS Powder for Suspension 200mg/5ml 37.5ml bot 225.85\n\tPopular\tZemicef Powder for Suspension 100mg/5ml 30ml bot/ 40ml bot/ 50ml bot 120.45/ 150.57/ 195.74\n\tPopular\tZemicef CAP 200mg 14's pack 421.54\n\tPopular\tZemicef CAP 400mg 8's pack 401.52\n\tPopular\tZemicef DS Powder for Suspension 200mg/5ml 50ml bot 321.21\n\tPrime\tPrixim CAP 200mg  \n\tPrime\tPrixim Powder For Suspension 100 mg/5 ml  \n\tRadiant.\tRofixim Powder for Suspension 100mg/5ml 50ml bot 200\n\tRadiant.\tRofixim CAP 200mg 8's pack 280\n\tRadiant.\tRofixim CAP 400mg 8's pack 440\n\tRadiant.\tRofixim DS Powder For Suspension 200 mg/5 ml  \n\tRAK\tFixbac Powder for Suspension 100mg/5ml 30ml bot/50ml bot 140/200\n\tRAK\tFixbac CAP 200mg 12's pack 420\n\tRangs\tNgcef Powder for Suspension 100mg/5ml 50ml bot 195\n\tRangs\tNgcef CAP 200mg 12's pack 168\n\tRangs\tNgcef CAP 400mg  \n\tRangs\tNgcef DS Powder For Suspension 200 mg/5 ml  \n\tReliance\tElexime Powder for Suspension 100mg/5ml 50ml bot 160\n\tReliance\tElexime CAP 200mg 12's pack 360\n\tReman Drug Ltd.\tFixim CAP 200mg 4's pack 120.80\n\tRenata\tOrcef Powder for Suspension 100mg/5ml 50ml bot 170\n\tRenata\tOrcef TAB dr 200mg 6's pack/ 12's pack 180/ 361.32\n\tRenata\tOrcef CAP 200mg 16's pack 481.76\n\tRenata\tOrcef TAB dr 400mg 6's pack 300\n\tRenata\tOrcef DS Oral drops 100mg/5ml 30ml bot/ 40ml bot/ 50ml bot/ 70ml bot 135/ 155/ 195/  225\n\tRephco\tKeor CAP 200mg 10's pack 300\n\tRephco\tKeorsp Powder for Suspension 100mg/5ml 50ml bot 160\n\tRephco\tKeor DS CAP 400mg 2x4's pack 400\n\tS. N.\tSonexim Powder for Suspension 100mg/5ml 50ml bot 160.60\n\tS. N.\tSonexim CAP 200mg 12's pack 361.29\n\tSanofi Aventis (BD) Ltd.\tKuracef Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot 120.46/ 195.74\n\tSanofi Aventis (BD) Ltd.\tKuracef TAB dr 200mg 12's pack 361.32\n\tSanofi Aventis (BD) Ltd.\tKuracef TAB dr 400mg 8's pack 401.52\n\tSeema\tCemix-3 CAP 200mg 8's pack 240\n\tSeema\tCemix-3 Suspension 100mg 50 ml bot 195\n\tShamsul Al-Amin\tSuffix Suspension 100mg 50 ml bot 160\n\tShamsul Al-Amin\tSuffix-200 CAP 200mg 6's pack / 12's pack 150 / 300\n\tSharif\tBioxim Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot 120/ 160\n\tSharif\tBioxim CAP 200mg 8's pack 240\n\tSharif\tBioxim CAP 400mg 8's pack 400\n\tSilco Pharmaceuticlas Ltd.\tBactazim CAP 200mg  \n\tSilco Pharmaceuticlas Ltd.\tBactazim Powder For Suspension 100 mg/5 ml  \n\tSilva\tSupraxim Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot 135.51/ 160.60\n\tSilva\tSupraxim CAP 200mg 6's pack 210\n\tSomatec\tTgocef Powder for Suspension 100mg/5ml 50ml bot 150.57\n\tSomatec\tTgocef CAP 200mg 12's pack 301.20\n\tSomatec\tTgocef CAP 400mg 4's pack 180.68\n\tSquare Cephalosporins Ltd.\tCef-3 Powder for Suspension 100mg/5ml 30ml bot/ 40ml bot/ 50ml bot 120.46/ 150.57/ 195.74\n\tSquare Cephalosporins Ltd.\tCef-3 TAB dr 200mg 10's pack 301.33\n\tSquare Cephalosporins Ltd.\tCef-3 CAP 200mg 12's pack / 10's pack 420 / 350\n\tSquare Cephalosporins Ltd.\tCef-3 DS TAB dr 400mg 6's pack 300\n\tSquare Cephalosporins Ltd.\tCef-3 DS CAP 400mg 6's pack 301.16\n\tSquare Cephalosporins Ltd.\tCef-3 forte Powder for Suspension 200mg/5ml 50ml bot 280\n\tSupreme\tAdexim Powder for Suspension 100mg/5ml 50ml bot 155\n\tSupreme\tAdexim CAP 200mg 6's pack 180\n\tSyntho Ltd.\tUnifix CAP 200mg 8's pack 240\n\tSyntho Ltd.\tUnifix Suspension 125mg 50 ml bot 160\n\tTechno Drugs Ltd.\tLoxim Powder for Suspension 100mg/5ml 50ml bot 190\n\tTechno Drugs Ltd.\tLoxim TAB dr 200mg 12's pack 300\n\tTechno Drugs Ltd.\tLoxim DS TAB dr 400mg 6's pack 270\n\tUnimed & Unihealth Manufacturers Ltd.\tOdacef Powder for Suspension 100mg/5ml 30ml bot/ 50ml bot 120/ 195\n\tUnimed & Unihealth Manufacturers Ltd.\tOdacef CAP 200mg 8's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tOdacef CAP 400mg 4's pack 200\n\tVeritas\tVerixim Powder For Suspension 100 mg/5 ml  \n\tVeritas\tVerixim CAP 200mg  \n\tVeritas\tVerixim CAP 400mg  \n\tWhite Horse Pharma\tTyfax Powder for Suspension 100mg/5ml 100ml bot 295\n\tWhite Horse Pharma\tTyfax CAP 200mg 12's pack 300\n\tWhite Horse Pharma\tTyfax CAP 400mg 4's pack 180\n\tZenith\tZenicef Powder for Suspension 100mg/5ml 50ml bot 160\n\tZenith\tZenicef CAP 200mg 4's pack 120\n\tZiska\tPrexim CAP 200mg 12's pack 360\n\tZiska\tPrexim Suspension 100mg 30 ml bot / 50 ml bot 120 / 195\n\tZiska\tPrexim CAP 400mg 7's pack 315\n\tAllied\tAlfixim CAP 200mg  \n\tAllied\tAlfixim CAP 400mg  \n\tAllied\tAlfixim Powder For Suspension 100 mg/5 ml  \n\tIndication: Pneumonia, Pharyngitis, Typhoid fever, Susceptible infections , Sinusitis, Otitis media, Tonsillitis, Soft tissue infections, Respiratory tract infections, Acute Exacerbations of Chronic bronchitis, Gonococcal urethritis, Acute bronchitis\n\nDose: Adult and child over 12 years: 200 or 400 mg daily as a single dose or in two divided doses\nGonorrhea: 400 mg as a single dose.\nPowder for Suspension & DS Powder for Suspension:\nChildren above 6 months: 8 mg/kg daily in 1-2 divided doses or\n6 months-1year: 75 mg daily\n1-4 years: 100 mg daily\n5-10 years: 200 mg daily\nTyphoid fever: 20 mg/kg body weight daily in two divided dose for 8 days.\nThe usual treatment of Cefixime is 7 days. This may be continued for up to 14 days according to the severity of infection.\n\nRenal impairment: Dose reduction is necessary.\nCrCl (ml/min)	\n<20	     Max: 200 mg daily. \n\nContra-indication: Hypersensitivity to cephalosporin.\n\nSide effects: Diarrhoea, nausea, vomiting, abdominal pain; headache, dizziness, thrombocytopenia, eosinophilia.\nPotentially Fatal: Pseudomembranous colitis.\n\nPrecaution: History of allergy to penicillins; pregnancy, lactation; renal failure; GI disease.\n\nMode of action: Increased concentrations with probenecid.\nPotentially Fatal: May increase prothrombin time with anticoagulants.\n\nPregnancy category: B\n\nInteraction: Increased concentrations with probenecid.\nPotentially Fatal: May increase prothrombin time with anticoagulants.
Cefotaxime	\n\n\tACI\tCefot IV/IM Injection 1gm/vial 1's pack 132.40\n\tACI\tCefot IV/IM Injection 2gm/vial 1's pack 250.75\n\tACI\tCefot IV/IM Injection 250mg/vial 1's pack 50.15\n\tACI\tCefot IV/IM Injection 500mg/vial 1's pack 76.23\n\tAcme Ltd.\tTaxim IV/IM Injection 1gm/vial 1's pack 132\n\tAcme Ltd.\tTaxim IV/IM Injection 250mg/vial 1's pack 50.20\n\tAcme Ltd.\tTaxim IV/IM Injection 500mg/vial 1's pack 76.29\n\tDrug International Ltd.\tDiabac Injection 1gm/vial 1's pack \n\tDrug International Ltd.\tDiabac IV/IM Injection 250mg/vial 1's pack \n\tDrug International Ltd.\tDiabac IV/IM Injection 500mg/vial 1's pack \n\tGlobe\tCetaxim IV/IM Injection 1gm/vial 1's pack 116.56\n\tGlobe\tCetaxim IV/IM Injection 500mg/vial 1's pack 76\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTaxceph IV/IM Injection 1gm/vial 1's pack 140\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTaxceph IV/IM Injection 500mg/vial 1's pack 76\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTaxceph IV/IM Injection 250mg/vial 1's pack 52\n\tIncepta\tCefotime IV/IM Injection 1gm/vial 1's pack 132\n\tIncepta\tCefotime IV/IM Injection 250mg/vial 1's pack 50\n\tIncepta\tCefotime IV/IM Injection 500mg/vial 1's pack 76\n\tOpsonin Pharma\tCeftax IV/IM Injection 1gm/vial 1's pack 132.50\n\tOpsonin Pharma\tCeftax IV/IM Injection 250mg/vial 1's pack 44.16\n\tOpsonin Pharma\tCeftax IV/IM Injection 500mg/vial 1's pack 67.11\n\tOrion Pharma Ltd.\tTorped IV/IM Injection 1gm/vial 1's pack 130.49\n\tOrion Pharma Ltd.\tTorped IV/IM Injection 250mg/vial 1's pack 50.19\n\tOrion Pharma Ltd.\tTorped IV/IM Injection 500mg/vial 1's pack 75.28\n\tRenata\tCefotax IV/IM Injection 1gm/vial 1's pack 132.50\n\tRenata\tCefotax IV/IM Injection 250mg/vial 1's pack 75\n\tRenata\tCefotax IV/IM Injection 500mg/vial 1's pack 100\n\tSquare Cephalosporins Ltd.\tMaxcef IV/IM Injection 250mg/vial 1's pack 50.20\n\tSquare Cephalosporins Ltd.\tMaxcef IV/IM Injection 500mg/vial 1's pack 76.29\n\tSquare\tMaxcef IV/IM Injection 1gm/vial 1's pack 132.50\n\tIndication: Pneumonia, Meningitis, Peritonitis, Pelvic inflammatory disease, Endometritis, Pelvic cellulitis, Gonorrhea, Skin and skin structure infections, Respiratory tract infections, Urinary tract infections, Bacteremia/Septicemia, Bone and/or joint infections\n\nDose: Adult: IV/IM Susceptible infections 1-2 g 4-12 hrly. Max: 12 g/day. \nSurgical prophylaxis 1 g 30-90 mins before procedure. \nGonorrhoea 0.5-1 g as a single dose.\n\nChildren:\nThe usual dosage range is 100-150 mg/kg/day in 2 to 4 divided doses. However, in very severe infections doses of up to 200 mg/kg/day may be required.\nNeonates:\nThe recommended dosage is 50 mg/kg/day in 2 to 4 divided doses. In severe infections 150-200 mg/kg/day in divided doses have been given.\n\nContra-indication: Hypersensitivity to cephalosporins.\n\nSide effects: Pain at inj site; hypersensitivity reactions, rash, pruritus; diarrhoea, nausea, vomiting; candidiasis; eosinophilia, neutropenia, leucopenia, thrombocytopenia.\nPotentially Fatal: Anaphylactic reaction; nephrotoxicity.\n\nPrecaution: History of penicillin allergy; colitis; impaired renal function; pregnancy, lactation.\n\nMode of action: Probenecid decreases cefotaxime elimination.\nPotentially Fatal: Nephrotoxicity with furosemide and aminoglycosides.\n\nPregnancy category: B\n\nInteraction: Probenecid decreases cefotaxime elimination.\nPotentially Fatal: Nephrotoxicity with furosemide and aminoglycosides.
Cefoxitin	\n\n\tIndication: Pneumonia, Intra-abdominal infections, UTI, Pelvic inflammatory disease, Lower Respiratory Tract Infections, Endometritis, Pelvic cellulitis, Gonorrhea, Lung abscess, Skin and skin structure infections, Bone and/or joint infections, Prophylaxis of surgical infections, Gynecological infections\n\nDose: Adult: IV Prophylaxis of endometritis at caesarean section 2 g as a single dose as soon as the umblical cord is clamped. May be repeated 4 and 8 hr later if needed. IV/IM Susceptible infections 1-2 g 4-8 hrly. Up to 12 g/day for severe infections. Surgical prophylaxis 2 g 30-60 mins pre-op, then 6 hrly, usually for <24 hr. IM Uncomplicated UTI 1 g twice daily. Uncomplicated gonorrhoea W/ oral probenecid: 2 g as a single dose.\n\nRenal impairment: Loading dose: 1-2 g. Maintenance dose: According to CrCl. Haemodialysis patients: Repeat loading dose after each dialysis session.\nCrCl (ml/min)	\n<5	0.5-1 g every 24-48 hr.\n5-9	   0.5-1 g every 12-24 hr.\n10-29	1-2 g every 12-24 hr.\n30-50	1-2 g every 8-12 hr.\n\nContra-indication: Hypersensitivity to cephalosporins.\n\nSide effects: Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use. Headache.\nPotentially Fatal: Pseudomembranous collitis.\n\nPrecaution: Hypersensitivity to penicillins; renal impairment; Porphyria. Monitor renal and haematologic status.\n\nMode of action: Enhanced nephrotoxicity with aminoglycosides and loop diuretics e.g. furosemide. Renal excretion inhibited by probenecid. Bacteriostatic antibacterials.\n\nPregnancy category: B\n\nInteraction: Enhanced nephrotoxicity with aminoglycosides and loop diuretics e.g. furosemide. Renal excretion inhibited by probenecid. Bacteriostatic antibacterials.
Cefpirome	\n\n\tSquare Cephalosporins Ltd.\tForce Injection 1gm/vial 1gm vial with water 401.15\n\tSquare Cephalosporins Ltd.\tForce 1 G Injection 1 gm/vial  \n\tSquare\tForce 1 gm IV Injection 1 gm/vial  \n\tIndication: Susceptible infections\n\nDose: Adult: IV 1-2 g 12 hrly.\n\nRenal impairment: Loading dose: 1-2 g followed by a maintenance dose adjusted according to CrCl.\nCrCl (ml/min)	\n20-50	0.5-1 g bid.\n5-20	0.5-1 g once daily.\n<5 (in haemodialysis patients)	0.5 or 1 g once daily with half-dose after each dialysis session. \n\nContra-indication: Hypersensitivity; porphyria.\n\nSide effects: Rash, pruritus, urticaria; nausea, vomiting, abdominal pain, diarrhoea; increased plasma levels of ASAT, ALAT, gamma-GT, LDH, bilirubin and/or alkaline phosphatase; interstitial nephritis, acute renal failure; thrombocytopaenia, eosinophilia, haemolytic anaemia, neutropaenia, agranulocytosis; thrombophloebitis, pain at Inj site; convulsions, fever; haemorrhage.\nPotentially Fatal: Pseudomembranous colitis.\n\nPrecaution: Allergy to penicillin or to cephalosporins; renal impairment, monitor renal and haematological status; pregnancy and lactation.\n\nMode of action: Reduced clearance with probenecid.\n\nPregnancy category: Not Classified\n\nInteraction: Reduced clearance with probenecid.
Cefpodoxime	\n\n\tACI\tCefdox Paediatric Drops 20mg/ml 15ml 60\n\tACI\tCefdox Powder for Suspension 40mg/5ml 50ml bot 98.67\n\tACI\tCefdox CAP 100mg 6's pack 132\n\tACI\tCefdox TAB dr 200mg 12's pack 504\n\tACI\tCefdox DS Powder for Suspension 80mg/5ml 80ml 175\n\tAcme Ltd.\tCp TAB dr 200mg 8's pack 337.28\n\tAcme Ltd.\tCP Paediatric Drops Paediatric Drops 20mg/ml 15ml bot 60.22\n\tAcme Ltd.\tCP-DS Powder for Suspension 80mg/5ml 50ml 175\n\tAcme Ltd.\tCP Suspension 40mg 50 ml bot 98.36\n\tAcme Ltd.\tCp P-Dps Paediatric Drops 20mg/ml 1's pack(15ml) 60.22\n\tAlco Pharma\tCepdoxim CAP 100mg 16's pack 320\n\tAlco Pharma\tCepdoxim Suspension 40mg 50 ml bot / 100 ml bot 90 / 175\n\tAlco Pharma\tCepdoxim CAP 200mg 16's pack 480\n\tApex\tCepoxid Paediatric Drops 20mg/ml 15ml bot 60\n\tApex\tCepoxid Powder for Suspension 40mg/5ml 50ml bot 98\n\tApex\tCepoxid CAP 100mg 16's pack 320\n\tApex\tCepoxid TAB dr 200mg 16's pack 560\n\tApex\tCepoxid DS Powder for Suspension 80mg/5ml 50ml bot 145\n\tAristopharma\tTaxetil Paediatric Drops 20mg/ml 15ml bot 62\n\tAristopharma\tTaxetil Powder for Suspension 40mg/5ml 50ml bot/ 100ml bot 99/ 195\n\tAristopharma\tTaxetil CAP 100mg 18's pack 396\n\tAristopharma\tTaxetil CAP 200mg 8's pack 320\n\tAristopharma\tTaxetil DS Powder for Suspension 80mg/5ml 50ml bot 175\n\tAsiatic Ltd.\tCefipod Paediatric Drops 20mg/ml 15ml bot 60\n\tAsiatic Ltd.\tCefipod Powder for Suspension 40mg/5ml 50ml bot 98\n\tAsiatic Ltd.\tCefipod Powder for Suspension 80mg/5ml 50ml bot 175\n\tAsiatic Ltd.\tCefipod CAP 100mg 8's pack 112\n\tAsiatic Ltd.\tCefipod CAP 200mg 6's pack 150\n\tBeacon\tKidcef Suspension 50mg 50 ml bot 98\n\tBeximco\tVercef Paediatric Drops 20mg/ml 15ml bot 60\n\tBeximco\tVercef Powder for Suspension 40mg/5ml 50ml bot/ 100ml bot 98/ 195\n\tBeximco\tVercef DS Powder for Suspension 80mg/5ml 50ml bot 175\n\tBristol Pharma Ltd.\tCefodox CAP 100mg 4's pack 88\n\tBristol Pharma Ltd.\tCefodox Suspension 125mg 50 ml bot 95\n\tChemist Ltd.\tPodoxi Powder for Suspension 40mg/5ml 50ml bot 90\n\tChemist Ltd.\tPodoxi CAP 100mg 8's pack 160\n\tCosmic Chemical Industries Ltd.\tXpotil Powder for Suspension 40mg/5ml 50ml bot 95\n\tDelta Pharma\tToraxim Paediatric Drops 20mg/ml 15ml bot 60\n\tDelta Pharma\tToraxim Powder for Suspension 40mg/5ml 50ml bot 98\n\tDrug International Ltd.\tCeforan Powder for Suspension 40mg/5ml 50ml bot/ 100ml bot 75/ 120\n\tDrug International Ltd.\tCeforan CAP 100mg 14's pack 238\n\tDrug International Ltd.\tCeforan TAB dr 100mg 16's pack 192\n\tDrug International Ltd.\tCeforan CAP 200mg 14's pack 392\n\tDrug International Ltd.\tCeforan TAB dr 200mg 16's pack 400\n\tDrug International Ltd.\tCeforan-DS Powder for Suspension 80mg/5ml 50ml bot 175\n\tEdruc Ltd.\tE - Pod CAP 200mg 12's pack 480\n\tEdruc Ltd.\tE-Pod Suspension 40mg 50 ml bot 96\n\tEskayef Bangladesh Ltd.\tStarin Powder for Suspension 40mg/5ml 100ml 195\n\tEskayef Bangladesh Ltd.\tStarin CAP 100mg 16's pack 352\n\tEskayef Bangladesh Ltd.\tStarin CAP 200mg 8's pack 320\n\tEskayef Bangladesh Ltd.\tStarin DS Powder for Suspension 80mg/5ml 50ml bot 150\n\tEskayef Bangladesh Ltd.\tStarin Paediatric Drops 20mg/ml 15ml 60\n\tEuro Pharma Ltd.\tCefokid DS Powder For Suspension 80 mg/5 ml  \n\tEuro Pharma Ltd.\tCefokid Powder For Suspension 40 mg/5 ml  \n\tEverest\tEvedoxim Paediatric Drops 20mg/ml 15ml bot 60\n\tEverest\tEvedoxim Powder for Suspension 40mg/5ml 50ml bot 85\n\tEverest\tEvedoxim CAP 100mg 12's pack 264\n\tGeneral\tDesbac Paediatric Drops 20mg/ml 15ml bot 60\n\tGeneral\tDesbac Powder for Suspension 40mg/5ml 50ml bot 98.37\n\tGeneral\tDesbac CAP 100mg 12's pack 264.72\n\tGlobe\tZedoxim Suspension 40mg 50 ml bot 95\n\tHealthcare\tRoxetil Powder for Suspension 40mg/5ml 50ml bot 95\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDofixim CAP 100mg 8's pack 168\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDofixim TAB dr 200mg 12's pack 480\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDofixim Suspension 40mg 50 ml bot 100\n\tIncepta\tXimeprox Paediatric Drops 20mg/ml 15ml bot 60\n\tIncepta\tXimeprox Powder for Suspension 40mg/5ml 50ml bot/ 100ml bot 98/ 195\n\tIncepta\tXimeprox Powder for Suspension 80mg/5ml 50ml bot 175\n\tIncepta\tXimeprox CAP 100mg 20's pack 440\n\tIncepta\tXimeprox TAB dr 100mg 24's pack 440\n\tIncepta\tXimeprox TAB dr 200mg 12's pack 504\n\tIncepta\tXimeprox DS Suspension 80mg/5ml 1's pack 175\n\tKemiko\tPodo Powder for Suspension 40mg/5ml 50ml bot/ 100ml bot 98/ 190\n\tKemiko\tPodo TAB dr 100mg 10's pack 220\n\tKumudini Pharma Ltd.\tXimocef Powder for Suspension 40mg/5ml 50ml bot 95\n\tKumudini Pharma Ltd.\tXimocef CAP 200mg 8's pack 320\n\tKumudini Pharma Ltd.\tXimocef Drops 20mg 50 ml bot 150\n\tLeon\tCefoprox Powder for suspension 40mg/5ml  \n\tLeon\tCefoprox Suspension 40mg/5ml  \n\tMedicon\tProctil Suspension 40mg 50 ml bot 98\n\tMonicopharma\tDxproxil Powder for Suspension 40mg/5ml 50ml bot 98\n\tNavana\tSefox Powder for Suspension 40mg/5ml 50ml bot 95.35\n\tNavana\tSefox CAP 100mg 12's pack 264.96\n\tNavana\tSefox DS Oral Suspension 80mg/5ml 50ml bot \n\tNovartis (Bangladesh) Ltd.\tMetoxim Powder for Suspension 40mg/5ml 50ml bot 100\n\tNovo Healthcare and Pharma Ltd.\tVictorin Paediatric Drops 20mg/ml 15ml bot 60\n\tNovo Healthcare and Pharma Ltd.\tVictorin Powder for Suspension 40mg/5ml 50ml bot 98\n\tNovo Healthcare and Pharma Ltd.\tVictorin CAP 200mg 8's pack 320\n\tOpsonin Pharma\tRovantin Paediatric Drops 20mg/ml 15ml bot 60\n\tOpsonin Pharma\tRovantin Powder for Suspension 40mg/5ml 50ml bot 98\n\tOpsonin Pharma\tRovantin TAB dr 100mg 10's pack 140\n\tOpsonin Pharma\tRovantin TAB dr 200mg 10's pack 250\n\tOpsonin Pharma\tRovantin DS Powder for Suspension 80mg/5ml 50ml bot 175\n\tOrion Pharma Ltd.\tPedicef Powder for Suspension 40mg/5ml 50ml bot 98.37\n\tOrion Pharma Ltd.\tPedicef DS Powder for Suspension 80mg/5ml 50ml bot 175.66\n\tOrion Pharma Ltd.\tPedicef PD Paediatric Drops 20mg/ml 15ml bot 60.23\n\tPacific\tCefodim Powder for Suspension 40mg/5ml 50ml bot 80\n\tPacific\tCefodim CAP 100mg 20's pack 440\n\tPacific\tCefodim CAP 200mg 10's pack 400\n\tPeoples Pharma Ltd.\tEpoxim Powder for Suspension 40mg/5ml 50ml bot 90\n\tPeoples Pharma Ltd.\tEpoxim TAB dr 100mg 12's pack 211.02\n\tPeoples Pharma Ltd.\tEpoxim TAB dr 200mg 8's pack 246.19\n\tPopular\tCefomin Powder for Suspension 40mg/5ml 50ml bot 96.36\n\tPopular\tCefomin TAB dr 100mg 10's pack 200.80\n\tPopular\tCefomin TAB dr 200mg 10's pack 381.40\n\tPopular\tCefomin Suspension 5ml 50ml bot \n\tRangs\tXepodox Paediatric Drops 20mg/ml 15ml bot 60\n\tRangs\tXepodox Powder for Suspension 40mg/5ml 50ml bot 98\n\tRenata\tTrucef Paediatric Drops 20mg/ml 15ml bot 60.23\n\tRenata\tTrucef Powder for Suspension 40mg/5ml 50ml bot/ 100ml bot 90.37/ 190.72\n\tRenata\tTrucef TAB dr 100mg 10's pack 220.80\n\tRenata\tTrucef TAB dr 200mg 10's pack 421.60\n\tRenata\tTrucef DS Powder for Suspension 80mg/5ml 50ml bot 175.66\n\tS. N.\tSudoxim Powder for Suspension 40mg/5ml 50ml bot 95.36\n\tSanofi Aventis (BD) Ltd.\tSarelox Paediatric Drops 20mg/ml 15ml bot 60.23\n\tSanofi Aventis (BD) Ltd.\tSarelox TAB dr 100mg 12's pack 264.96\n\tSanofi Aventis (BD) Ltd.\tSarelox TAB dr 200mg 12's pack 505.92\n\tSanofi Aventis (BD) Ltd.\tSarelox Suspension 40mg 50 ml bot  98.37\n\tSanofi Aventis (BD) Ltd.\tSarelox DS Suspension 80mg 50 ml bot 175.66\n\tSomatec\tNeoprox Paediatric Drops 20mg/ml 15ml bot 60.23\n\tSomatec\tNeoprox Powder for Suspension 40mg/5ml 50ml bot 98.37\n\tSomatec\tNeoprox CAP 200mg 8's pack 321.20\n\tSomatec\tNeoprox DS Powder for Suspension 80mg/5ml 50ml bot 175.66\n\tSquare Cephalosporins Ltd.\tVanprox Paediatric Drops 20mg/ml 15ml bot 60.22\n\tSquare Cephalosporins Ltd.\tVanprox CAP 100mg 12's pack 264.93\n\tSquare Cephalosporins Ltd.\tVanprox CAP 200mg 6's pack 252.96\n\tSquare\tVanprox Powder for Suspension 40mg/5ml 50ml bot 98.35\n\tSquare\tVanprox Forte Powder For Suspension 80mg/5ml 1's pack(50ml) 175.66\n\tUnimed & Unihealth Manufacturers Ltd.\tCefobid Powder for Suspension 40mg/5ml 50ml bot 98\n\tWhite Horse Pharma\tCedofax CAP 100mg 12's pack 204\n\tWhite Horse Pharma\tCedofax CAP 200mg 8's pack 224\n\tZiska\tInstina Powder for Suspension 40mg/5ml 50ml bot 98\n\tIndication: Pharyngitis, Acute otitis media, Community-acquired pneumonia, Sinusitis, UTI, Cystitis, Gonorrhea, Skin and skin structure infections, Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Acute bacterial exacerbation of chronic bronchitis\n\nDose: Adult: PO Resp tract infections; UTI 100-200 mg 12 hrly. Skin infections 200-400 mg 12 hrly. Uncomplicated gonorrhoea 200 mg as a single dose.\n\nRenal impairment: Patients on haemodialysis: Dose should be given after each dialysis session.\nCrCl (ml/min)	Dosage Recommendation\n10-39	Increase dosing intervals to 24 hrly.\n<10	Increase dosing intervals to 48 hrly. \n\nChild :\n15 days - 6 months : 4 mg/kg every 12 hours\n6 months - 2 years : 40 mg every 12 hours\n3 - 8 years : 80 mg every 12 hours\nover 9 years : 100 mg every 12 hours\n\nContra-indication: Hypersensitivity.\n\nSide effects: Anaphylactic shock; purpuric nephritis, skin rash, pruritus; diarrhoea, nausea, abdominal pain, vomiting.\nPotentially Fatal: Pseudomembranous colitis; nephrotoxicity.\n\nPrecaution: History of allergy to penicillin; severe renal impairment; pregnancy and lactation.\n\nMode of action: Antacids or H2-blockers may decrease the absorption of cefpodoxime. Probenecid inhibits renal excretion.\nPotentially Fatal: Monitor renal function during admin. Additive nephrotoxic effects with furosemide.\n\nPregnancy category: B\n\nInteraction: Antacids or H2-blockers may decrease the absorption of cefpodoxime. Probenecid inhibits renal excretion.\nPotentially Fatal: Monitor renal function during admin. Additive nephrotoxic effects with furosemide.
Cefpodoxime + Clavulanic Acid	\n\n\tACI\tCombocef TAB dr 100mg+62.5mg 12s\n 361.08\n\tACI\tCombocef TAB dr 200mg+125mg 12's pack 601.80\n\tDrug International Ltd.\tCefuran TAB dr 100mg  \n\tDrug International Ltd.\tClavuran TAB dr 100 mg + 62.5 mg  \n\tDrug International Ltd.\tClavuran TAB dr 200 mg + 125 mg  \n\tEskayef Bangladesh Ltd.\tTrioclav TAB dr 100 mg + 62.5 mg  \n\tEskayef Bangladesh Ltd.\tTrioclav TAB dr 200 mg + 125 mg  \n\tIncepta\tDuo-5 LS TAB dr 100mg+62.5mg 12's pack 300\n\tIncepta\tDuo-5 TAB dr 200mg + 125mg 12's pack 480\n\tOpsonin Pharma\tXtabac 100 TAB dr  4x3's pack 100.20\n\tOpsonin Pharma\tXtabac 200 TAB dr  4x3's pack 200.35\n\tIndication: Pharyngitis, Acute otitis media, Community-acquired pneumonia, Sinusitis, UTI, Cystitis, Gonorrhea, Skin and skin structure infections, Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Acute bacterial exacerbation of chronic bronchitis, Enteric fever\n\nDose: Adult: PO Resp tract infections; UTI 100-200 mg 12 hrly. Skin infections 200-400 mg 12 hrly. Uncomplicated gonorrhoea 200 mg as a single dose.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Anaphylactic shock; purpuric nephritis, skin rash, pruritus; diarrhoea, nausea, abdominal pain, vomiting.\nPotentially Fatal: Pseudomembranous colitis; nephrotoxicity.\n\nPrecaution: History of allergy to penicillin; severe renal impairment; pregnancy and lactation.\n\nMode of action: Antacids or H2-blockers may decrease the absorption of cefpodoxime. Reduced renal excretion w/ probenecid.\n\nPregnancy category: B\n\nInteraction: Antacids or H2-blockers may decrease the absorption of cefpodoxime. Reduced renal excretion w/ probenecid.
Cefprozil	\n\n\tApex\tZilcef TAB dr 250mg 8's pack \n\tApex\tZilcef TAB dr 500mg 8's pack \n\tBeximco\tZilapro Powder for Suspension 250mg/5ml 56ml bot 276\n\tPopular\tCefozil TAB dr 250mg 10's pack 301.10\n\tPopular\tCefozil TAB dr 500mg 8's pack 441.48\n\tPopular\tCefozil Suspension 125mg 50 ml bot 230.87\n\tSquare\tAnca Oral Suspension 250mg/5ml 50ml bot 275\n\tSquare\tAnca TAB dr 250mg  300\n\tSquare\tAnca TAB dr 500mg  330\n\tIndication: Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections, Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Acute bacterial exacerbation of chronic bronchitis\n\nDose: Oral\nSkin and soft tissue infections, Susceptible infections\nAdult: 500 mg/day as a single dose or in 2 divided doses, increased to 500 mg bid if necessary.\nChild: 20 mg/kg/day once or twice daily, up to a max dose of 500 mg once daily, if necessary, bid for otitis media.\nRenal impairment:\nCrCl (ml/min)	\n<30	  Half normal dose. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.\nPotentially Fatal: Pseudomembranous colitis.\n\nPrecaution: Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. Pregnancy, lactation.\n\nMode of action: Renal excretion delayed by probenecid. Decreases contraceptive effect of oestrogen-containing oral contraceptives.\n\nPregnancy category: B\n\nInteraction: Renal excretion delayed by probenecid. Decreases contraceptive effect of oestrogen-containing oral contraceptives.
Ceftazidime	\n\n\tACI\tZitum IV/IM Injection 1gm/vial  1 vial 226.53\n\tACI\tZitum IV/IM Injection 250mg/vial  1 vial 70.47\n\tACI\tZitum IV/IM Injection 500mg/vial  1 vial 115.78\n\tAcme Ltd.\tTrizidim IV/IM Injection 1gm/vial  1 vial 215.80\n\tAcme Ltd.\tTrizidim IV/IM Injection 250mg/vial  1 vial 70.26\n\tAcme Ltd.\tTrizidim IV/IM Injection 500mg/vial  1 vial 115.43\n\tAristopharma\tCeftazim IV/IM Injection 1gm/vial  1 vial 220\n\tAristopharma\tCeftazim IV/IM Injection 250mg/vial  1 vial 75\n\tAristopharma\tCeftazim IV/IM Injection 500mg/vial 1 vial 115.43\n\tBeximco\tMaxidim IV/IM Injection 1gm/vial  1 vial 215\n\tBeximco\tMaxidim IV/IM Injection 250mg/vial  1 vial 70\n\tBeximco\tMaxidim IV/IM Injection 500mg/vial  1 vial 115\n\tBio Pharma Ltd.\tZidimax IV/IM Injection 1gm/vial  1 vial 225\n\tBio Pharma Ltd.\tZidimax IV/IM Injection 250mg/vial  1 vial 70\n\tBio Pharma Ltd.\tZidimax IV/IM Injection 500mg/vial  1 vial 115\n\tDrug International Ltd.\tTrum-3 IV/IM Injection 1gm/vial  1 vial 225\n\tDrug International Ltd.\tTrum-3 Injection 500mg 500 mg vial 120\n\tDrug International Ltd.\tTrum-3 Injection 250mg 250 mg vial 70\n\tEskayef Bangladesh Ltd.\tTazimax IV/IM Injection 1 gm/vial  \n\tEskayef Bangladesh Ltd.\tTazimax IV/IM Injection 250 mg/vial  \n\tGlobe\tTizime IV/IM Injection 1gm/vial  1 vial 210\n\tGlobe\tTizime IV/IM Injection 250mg/vial  1 vial 70\n\tGlobe\tTizime IV/IM Injection 500mg/vial  1 vial 115\n\tIncepta\tSidobac IV/IM Injection 1gm/vial  1 vial 189.84\n\tIncepta\tSidobac IV/IM Injection 250mg/vial  1 vial 70\n\tIncepta\tSidobac IV/IM Injection 500mg/vial  1 vial 115\n\tNavana\tCefzon IV/IM Injection 250mg/vial  1 vial 70.26\n\tNavana\tCefzon IV/IM Injection 1gm/vial  1 vial 215.80\n\tNavana\tCefzon IV/IM Injection 500mg/vial  1 vial 115.43\n\tOpsonin Pharma\tSerozid IV/IM Injection 1gm/vial  1 vial 215\n\tOpsonin Pharma\tSerozid IV/IM Injection 250mg/vial  1 vial 61.81\n\tOpsonin Pharma\tSerozid IV/IM Injection 500mg/vial  1 vial 101.54\n\tOrion Pharma Ltd.\tZidim IV/IM Injection 1gm/vial  1 vial 215.81\n\tOrion Pharma Ltd.\tZidim IV/IM Injection 250mg/vial  1 vial 70.26\n\tOrion Pharma Ltd.\tZidim IV/IM Injection 500mg/vial  1 vial 115.43\n\tPopular\tZidicef IV/IM Injection 1gm/vial  1 vial 215.81\n\tPopular\tZidicef IV/IM Injection 250mg/vial  1 vial 70.26\n\tRangs\tMaxbac IV/IM Injection 1gm/vial  1 vial 240\n\tRangs\tMaxibac IV/IM Injection 250mg/vial  1 vial 70\n\tRangs\tMaxibac IV/IM Injection 500mg/vial  1 vial 115\n\tRenata\tCefazid IV/IM Injection 1gm/vial  1 vial 215.81\n\tRenata\tCefazid IV/IM Injection 250mg/vial 1 vial 85\n\tRenata\tCefazid IV/IM Injection 500mg/vial  1 vial 130\n\tSquare Cephalosporins Ltd.\tTazid IV/IM Injection 1gm/vial  1 vial 240\n\tSquare\tTazid IV/IM Injection 250mg/vial  1 vial 85\n\tSquare\tTazid IV/IM Injection 500mg/vial  1 vial 130\n\tZiska\tLesero IV/IM Injection 1gm/vial  1 vial 215\n\tZiska\tLesero IV/IM Injection 250mg/vial  1 vial 70\n\tZiska\tLesero IV/IM Injection 500mg/vial  1 vial 115\n\tIndication: Pneumonia, Cystic fibrosis, Bacterial septicemia, Meningitis, Peritonitis, Skin and Skin-Structure Infections, Endometritis, Pelvic cellulitis, Respiratory tract infections, Urinary tract infections, Febrile neutropenia, Melioidosis, Bone and Joint Infections,G ynecologic Infections, Biliary tract infections, Endophthalmitis\n\nDose:  Adults: The adult dosage range for ceftazidime is 1 to 6 gm per day 8 or 12 hourly (IM/IV) in the majority of infections, 1 gm 8 hourly or 2 gm 12 hourly should be given. \n\nIn urinary tract infections and many less serious infections, 500 mg or 1 gm 12 hourly is usually adequate. \n\nIn severe infections, especially immunocompromised patients, including those with neutropenia, 2 gm 8 or 12 hourly should be administered. When used as a prophylactic agent in prostatic surgery 1gm should be given at the induction of anesthesia. A second dose should be considered at the time of catheter removal.\n\nNeonates (0 - 2 months): 25-60 mg/kg/day IV Q 12h\nInfants & Children (2 months - 12 years): 30-100 mg/kg/day IV to a maximum of 6 grams per day Q 8-12h.\n\nElderly: Max dose: 3 g daily.\nRenal impairment: Loading dose: 1 g; maintenance doses based on CrCl. May need to increase doses by 50% in severe infections. Peritoneal dialysis: Loading dose is followed by 500 mg every 24 hr; may add ceftazidime to the dialysis fluid (usually 125-250 mg for 2 litres of dialysis fluid). Haemodialysis: Admin loading dose then 0.5-1 g after each dialysis period.\n\nCrCl (ml/min)	\n31-50	1 g every 12 hr.\n16-30	1 g every 24 hr.\n6-15	500 mg every 24 hr.\n<5	500 mg every 48 hr. \n\nContra-indication: Hypersensitivity to cephalosporins.\n\nSide effects: Hypersensitivity, dizziness, diarrhoea, nausea, vomiting, renal impairment, rash, erythema multiforme, thrombocytopaenia, superinfection, phloebitis and thrombophloebitis at the site of injection.\nPotentially Fatal: Anaphylactic reactions, nephrotoxicity, pseudomembranous colitis.\n\nPrecaution: History of penicillin allergy; severe renal impairment; pregnancy, lactation.\n\nMode of action: May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.\n\nPregnancy category: B\n\nInteraction: May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.
Ceftriaxone	\n\n\tACI\tAciphin IM Injection 1gm  191.29\n\tACI\tAciphin IM Injection 250mg 1 vial with lidocaine 100.30\n\tACI\tAciphin IM Injection 500mg 1 vial with lidocaine 130.39\n\tACI\tAciphin IV Injection 1gm 1 vial with water 191.29\n\tACI\tAciphin IV Injection 2gm 1 vial with water 302.04\n\tACI\tAciphin IV Injection 250mg 1 vial with water 100.30\n\tACI\tAciphin IV Injection 500mg 1 vial with water 130.39\n\tAcme Ltd.\tTrizon IM Injection 250mg 1 vial with lidocaine 90.34\n\tAcme Ltd.\tTrizon IV Injection 1gm 1's pack 190\n\tAcme Ltd.\tTrizon IV Injection 2gm 1's pack 300\n\tAcme Ltd.\tTrizon IV Injection 250mg 1's pack 100\n\tAcme Ltd.\tTrizon IV Injection 500mg 1's pack 130\n\tAcme Ltd.\tTrizon I.M Injection 500 mg 500 mg  vial with lidocaine 120.46\n\tAcme Ltd.\tTrizon I.M Injection 1 gm 1 gm  vial with lidocaine 160.60\n\tAlco Pharma\tInfecef IM Injection 250mg  \n\tAlco Pharma\tInfecef IM Injection 500mg  \n\tAlco Pharma\tInfecef IM Injection 1gm  \n\tAlco Pharma\tInfecef IV Injection 250mg  \n\tAlco Pharma\tInfecef IV Injection 500mg  \n\tAlco Pharma\tInfecef IV Injection 1gm  \n\tAlco Pharma\tInfecef IV Injection 2gm  \n\tApex\tKeptrix I.M/IV Injection 2gm 1 vial with water 300\n\tApex\tKeptrix I.M/IV Injection 250 mg 250 mg vial with lidocaine 90\n\tApex\tKeptrix I.M/IV Injection 500 mg 500 mg vial with lidocaine 120\n\tApex\tKeptrix I.M/IV Injection 1 gm 1 gm vial with lidocaine 160\n\tAristopharma\tAxon IM Injection 1gm 1 vial with lidocaine 150\n\tAristopharma\tAxon IM Injection 250mg 1 vial with lidocaine 90\n\tAristopharma\tAxon IM Injection 500mg 1 vial with lidocaine 120\n\tAristopharma\tAxon IV Injection 1gm 1 vial with water 150\n\tAristopharma\tAxon IV Injection 2gm 1 vial with water 260\n\tAristopharma\tAxon IV Injection 250mg 1 vial with water 90\n\tAristopharma\tAxon IV Injection 500mg 1 vial with water 120\n\tAsiatic Ltd.\tAsixone IV IV Injection 2gm  \n\tAstra Biopharmaceuticals Ltd.\tCefaz IV Injection 1gm  \n\tAstra Biopharmaceuticals Ltd.\tCefaz IV Injection 2gm  \n\tBeacon\tTraxef IM Injection 250mg  \n\tBeacon\tTraxef IM Injection 500mg  \n\tBeacon\tTraxef IV Injection 1gm  \n\tBeximco\tArixon IM Injection 1gm 1 vial with lidocaine 160\n\tBeximco\tArixon IM Injection 250mg 1 vial with lidocaine 90\n\tBeximco\tArixon IM Injection 500mg 1 vial with lidocaine 125\n\tBeximco\tArixon IV Injection 1gm 1 vial with water 160\n\tBeximco\tArixon IV Injection 250mg 1 vial with water 90\n\tBeximco\tArixon IV Injection 500mg 1 vial with water 125\n\tBio Pharma Ltd.\tWinner IV Injection 2gm 1 vial with water 300\n\tBio Pharma Ltd.\tWinner IM Injection 1gm 1 vial with lidocaine 180.68\n\tBio Pharma Ltd.\tWinner IM Injection 250mg 1 vial with lidocaine 90.34\n\tBio Pharma Ltd.\tWinner IM Injection 500mg 1 vial with lidocaine 120.45\n\tBio Pharma Ltd.\tWinner IV Injection 1gm 1 vial with water 180.68\n\tBio Pharma Ltd.\tWinner IV Injection 250mg 1 vial with water 90.34\n\tBio Pharma Ltd.\tWinner IV Injection 500mg 1 vial with water 120.45\n\tChemist Ltd.\tPowercef IV Injection 1gm 1 vial with water 160\n\tChemist Ltd.\tPowercef IM Injection 250mg 1 vial with lidocaine 80\n\tChemist Ltd.\tPowercef IM Injection 500mg 1 vial with lidocaine 130\n\tChemist Ltd.\tPowercef IV Injection 500mg 1 vial with water 130\n\tChemist Ltd.\tPowercef I.M Injection 1 gm 1 gm vial with lidocaine 160\n\tConcord\tHolicef IM Injection 500mg  \n\tConcord\tHolicef IM Injection 250mg  \n\tConcord\tHolicef IV Injection 500mg  \n\tConcord\tHolicef IM Injection 1gm  \n\tConcord\tHolicef IV Injection 1gm  \n\tConcord\tHolicef IV Injection 2gm  \n\tDelta Pharma\tXone-3 IM Injection 250mg 1's pack 90\n\tDelta Pharma\tXone-3 IM Injection 500mg 1's pack 120\n\tDelta Pharma\tXone-3 IV Injection 1gm 1's pack 160\n\tDrug International Ltd.\tDicephin IM Injection 1gm 1 vial with lidocaine 160\n\tDrug International Ltd.\tDicephin IM Injection 2gm 1's pack\n 220\n\tDrug International Ltd.\tDicephin IM Injection 250mg 1 vial with lidocaine 90\n\tDrug International Ltd.\tDicephin IM Injection 500mg 1 vial with lidocaine 125\n\tDrug International Ltd.\tDicephin IV Injection 1gm 1 vial with water 160\n\tDrug International Ltd.\tDicephin IV Injection 2gm 1 vial with water 280\n\tDrug International Ltd.\tDicephin IV Injection 250mg 1 vial with water 90\n\tDrug International Ltd.\tDicephin IV Injection 500mg 1 vial with water 125\n\tEskayef Bangladesh Ltd.\tTriject IV Injection 2gm 1 vial with water 260\n\tEskayef Bangladesh Ltd.\tTriject IM Injection 1gm 1 vial with lidocaine 160\n\tEskayef Bangladesh Ltd.\tTriject IM Injection 250mg 1 vial with lidocaine 90\n\tEskayef Bangladesh Ltd.\tTriject IM Injection 500mg 1 vial with lidocaine 120\n\tEskayef Bangladesh Ltd.\tTriject IV Injection 1gm 1 vial with water 160\n\tEskayef Bangladesh Ltd.\tTriject IV Injection 250mg 1 vial with water 90\n\tEskayef Bangladesh Ltd.\tTriject IV Injection 500mg 1 vial with water 120\n\tGeneral\tImacef IV Injection 2gm 1 vial with water 301.13\n\tGeneral\tImacef IM Injection 1gm 1 vial with lidocaine 160.60\n\tGeneral\tImacef IM Injection 250mg 1 vial with lidocaine 90.34\n\tGeneral\tImacef IM Injection 500mg 1 vial with lidocaine 120.48\n\tGeneral\tImacef IV Injection 1gm 1 vial with water 160.60\n\tGeneral\tImacef IV Injection 250mg 1's pack 90\n\tGeneral\tImacef IV Injection 500mg 1's pack 120\n\tGlobe\tTribac IM Injection 1gm 1 vial with lidocaine 160\n\tGlobe\tTribac IM Injection 250mg 1 vial with lidocaine 90\n\tGlobe\tTribac IM Injection 500mg 1 vial with lidocaine 120\n\tGlobe\tTribac IV Injection 1gm 1 vial with water 160\n\tGlobe\tTribac IV Injection 2gm 1 vial with water 300\n\tGlobe\tTribac IV Injection 250mg 1 vial with water 90\n\tGlobe\tTribac IV Injection 500mg 1 vial with water 120\n\tGlobex\tSeftimax IM/IV Injection 1gm 1's pack 190\n\tGlobex\tSeftimax IV Injection 2gm 1's pack 300\n\tGlobex\tSeftimax IM Injection 250mg 1's pack 90\n\tGlobex\tSeftimax IM Injection 500mg 1's pack 130\n\tGonoshasthaya\tG Ceftriax IM Injection 1gm 1 vial with lidocaine 150\n\tGonoshasthaya\tG Ceftriax IM Injection 250mg 1 vial with lidocaine 75\n\tGonoshasthaya\tG Ceftriax IM Injection 500mg 1 vial with lidocaine 120\n\tGonoshasthaya\tG Ceftriax IV Injection 1gm 1 vial with water 150\n\tGonoshasthaya\tG Ceftriax IV Injection 250mg 1 vial with water 75\n\tGonoshasthaya\tG Ceftriax IV Injection 500mg 1 vial with water 120\n\tHealthcare\tOricef IM Injection 1gm 1 vial with lidocaine 320\n\tHealthcare\tOricef IM Injection 250mg 1 vial with lidocaine 130\n\tHealthcare\tOricef IM Injection 500mg 1 vial with lidocaine 200\n\tHealthcare\tOricef IV Injection 1gm 1 vial with water 320\n\tHealthcare\tOricef IV Injection 250mg 1 vial with water 130\n\tHealthcare\tOricef IV Injection 500mg 1 vial with water 200\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAxosin IM Injection 250mg 1 vial with lidocaine 90\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAxosin IM Injection 500mg 1 vial with lidocaine 120.46\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAxosin IV Injection 1gm 1 vial with water 180\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAxosin IV Injection 2gm 1 vial with water 290\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAxosin IV Injection 250mg 1 vial with water 90\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAxosin IV Injection 500mg 1 vial with water 120.46\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAxosin I.V Injection 1 gm  1 mg vial 180\n\tIncepta\tExephin 250 IM Injection 250 mg 1's 100\n\tIncepta\tExephin 500 IM Injection 500 mg 1's 130\n\tIncepta\tExephin 250 IV Injection 250 mg 1's 100\n\tIncepta\tExephin 500 IV Injection 500 mg 1's 130\n\tIncepta\tExephin 2 gm IV Injection 2 gm 1's 300\n\tIncepta\tExephin 1 gm IM Injection 1 gm 1's 190\n\tJayson\tParcef IM Injection 1gm 1 vial with lidocaine 189.71\n\tJayson\tParcef IM Injection 250mg 1 vial with lidocaine 90.34\n\tJayson\tParcef IM Injection 500mg 1 vial with lidocaine 125.47\n\tJayson\tParcef IV Injection 1gm 1 vial with water 189.71\n\tJayson\tParcef IV Injection 250mg 1 vial with water 90.34\n\tJayson\tParcef IV Injection 500mg 1 vial with water 125.47\n\tKemiko\tRIT IV Injection 2gm 1 vial with water 300\n\tKemiko\tRIT IM Injection 1gm 1 vial with lidocaine 160\n\tKemiko\tRIT IM Injection 250mg 1 vial with lidocaine 85\n\tKemiko\tRIT IM Injection 500mg 1 vial with lidocaine 120\n\tKemiko\tRIT IV Injection 1gm 1 vial with water 160\n\tKemiko\tRIT IV Injection 250mg 1 vial with water 85\n\tKemiko\tRIT IV Injection 500mg 1 vial with water 120\n\tLibra Pharmaceuticls Ltd.\tXylab IM Injection 1gm 1 vial with lidocaine 160.61\n\tLibra Pharmaceuticls Ltd.\tXylab IM Injection 250mg 1 vial with lidocaine 90.34\n\tLibra Pharmaceuticls Ltd.\tXylab IM Injection 500mg 1 vial with lidocaine 120.45\n\tLibra Pharmaceuticls Ltd.\tXylab IV Injection 1gm 1 vial with water 160.61\n\tLibra Pharmaceuticls Ltd.\tXylab IV Injection 250mg 1 vial with water 90.34\n\tLibra Pharmaceuticls Ltd.\tXylab IV Injection 500mg 1 vial with water 120.45\n\tMedimet\tTrax IM Injection 1gm 1 vial with lidocaine 160\n\tMedimet\tTrax IM Injection 250mg 1 vial with lidocaine 90\n\tMedimet\tTrax IM Injection 500mg 1 vial with lidocaine 120\n\tMedimet\tTrax IV Injection 1gm 1 vial with water 160\n\tMedimet\tTrax IV Injection 250mg 1 vial with water 90\n\tMedimet\tTrax IV Injection 500mg 1 vial with water 120\n\tMonicopharma\tPerix IM Injection 1gm 1 vial with lidocaine 160\n\tMonicopharma\tPerix IV Injection 1gm 1 vial with water 160\n\tMonicopharma\tPerix IV Injection 2gm 1 vial with water 300\n\tMonicopharma\tPerix IV Injection 250mg 1 vial with water 90\n\tMonicopharma\tPerix IM Injection 250mg 1 vial with lidocaine 90\n\tMonicopharma\tPerix IM Injection 500mg 1 vial with lidocaine 120\n\tMonicopharma\tPerix IV Injection 500mg 1 vial with water 120\n\tNavana\tTopcef IV Injection 1gm 1 vial with water 185.69\n\tNavana\tTopcef IV Injection 2gm 1 vial with water 301.12\n\tNavana\tTopcef IV Injection 250mg 1 vial with water 90.33\n\tNavana\tTopcefÂ I.M Injection 250mg  250mg  vial with lidocaine 9o.33\n\tNavana\tTopcefÂ I.M Injection 500mg  500 mg  vial with lidocaine 130.48\n\tNavana\tTopcef I.M Injection 1 gm 1 gm  vial with lidocaine 185.69\n\tNavana\tTopcefÂ I.V Injection  500 mg 500 mg   vial with water 130.48\n\tNIPRO JMI Pharma\tNixon IV/IM Injection 250 mg  \n\tNIPRO JMI Pharma\tNixon IV/IM Injection 500mg  \n\tNIPRO JMI Pharma\tNixon IV/IM Injection 1gm  \n\tNIPRO JMI Pharma\tNixon IV Injection 2gm  \n\tNovartis (Bangladesh) Ltd.\tMegacin IV/IM Injection 500mg 1's pack \n\tNovartis (Bangladesh) Ltd.\tMegion IM Injection 1gm 1 vial with lidocaine 190\n\tNovartis (Bangladesh) Ltd.\tMegion IM Injection 250mg 1 vial with lidocaine 100\n\tNovartis (Bangladesh) Ltd.\tMegion IM Injection 500mg 1 vial with lidocaine 140\n\tNovartis (Bangladesh) Ltd.\tMegion IV Injection 1gm 1 vial with water 190\n\tNovartis (Bangladesh) Ltd.\tMegion I.V Injection 250mg 250mg vial with Water 100\n\tNovartis (Bangladesh) Ltd.\tMegion I.V Injection 500mg 500mg vial with Water 140\n\tNovo Healthcare and Pharma Ltd.\tCeftrix IM Injection 250mg 1 vial with lidocaine 90\n\tNovo Healthcare and Pharma Ltd.\tCeftrix IM Injection 500mg 1 vial with lidocaine 130\n\tNovo Healthcare and Pharma Ltd.\tCeftrix IV Injection 2gm 1 vial with water 300\n\tNovo Healthcare and Pharma Ltd.\tCeftrix IV Injection 1gm 1 vial with water 190\n\tOpso Saline Ltd.\t3GC I.M Injection 500 mg 500mg   vial with lidocaine 120.44\n\tOpso Saline Ltd.\t3GC I.V Injection 1 gm 1 gm  vial with lidocaine 160.60\n\tOpso Saline Ltd.\t3GC I.V Injection 2 gm 2 gm  vial with water 301.13\n\tOpso Saline Ltd.\tBakticef IV Injection 1gm  \n\tOpso Saline Ltd.\tBakticef IV Injection 2gm  \n\tOpso Saline Ltd.\tBakticef IM Injection 500mg  \n\tOpsonin Pharma\tTraxon IM Injection 1gm 1 vial with lidocaine 160\n\tOpsonin Pharma\tTraxon IM Injection 250mg 1 vial with lidocaine 90\n\tOpsonin Pharma\tTraxon IM Injection 500mg 1 vial with lidocaine 120\n\tOpsonin Pharma\tTraxon IV Injection 1gm 1 vial with water 160\n\tOpsonin Pharma\tTraxon IV Injection 2gm 1 vial with water 300\n\tOpsonin Pharma\tTraxon IV Injection 250mg 1 vial with water 90\n\tOpsonin Pharma\tTraxon IV Injection 500mg 1 vial with water 120\n\tOrganic Health Care\tCeftobac IM Injection 500 mg  \n\tOrganic Health Care\tCeftobac IM Injection 1 gm  \n\tOrganic Health Care\tCeftobac IV Injection 500 mg  \n\tOrganic Health Care\tCeftobac IV Injection 1 gm  \n\tOrganic Health Care\tCeftobac IV Injection 2 gm  \n\tOrion Pharma Ltd.\tVertex IM Injection 1gm 1 vial with lidocaine 160.60\n\tOrion Pharma Ltd.\tVertex IM Injection 250mg 1 vial with lidocaine 90.34\n\tOrion Pharma Ltd.\tVertex IM Injection 500mg 1 vial with lidocaine 120.45\n\tOrion Pharma Ltd.\tVertex IV Injection 1gm 1 vial with water 160.60\n\tOrion Pharma Ltd.\tVertex IV Injection 250mg 1 vial with water 90.34\n\tOrion Pharma Ltd.\tVertex IV Injection 500mg 1 vial with water 120.45\n\tOrion Pharma Ltd.\tVertex I.V Injection 2 gm 2 gm  vial with lidocaine 231.14\n\tPharmacil Ltd.\tOrizone IV Injection 500mg  \n\tPharmacil Ltd.\tOrizone IV Injection 1gm  \n\tPharmacil Ltd.\tOrizone IV Injection 2gm  \n\tPharmasia Ltd.\tTrimax IM Injection 1gm 1 vial with lidocaine 160\n\tPharmasia Ltd.\tTrimax IV Injection 1gm 1 vial with water 160\n\tPharmasia Ltd.\tTrimax IV Injection 2gm 1 vial with water 300\n\tPharmasia Ltd.\tTrimax IM Injection 250mg 1 vial with lidocaine 90\n\tPharmasia Ltd.\tTrimax IV Injection 250mg 1 vial with water 90\n\tPharmasia Ltd.\tTrimax IM Injection 500mg 1 vial with lidocaine 120\n\tPharmasia Ltd.\tTrimax IV Injection 500mg 1 vial with water 120\n\tPopular\tEracef IM Injection 1gm 1 vial with lidocaine 180.68\n\tPopular\tEracef IM Injection 250mg 1 vial with lidocaine 85.32\n\tPopular\tEracef IM Injection 500mg 1 vial with lidocaine 120.45\n\tPopular\tEracef IV Injection 1gm 1 vial with water/10 vial with water 180.68/1806.81\n\tPopular\tEracef IV Injection 2gm 1 vial with water 301.13\n\tPopular\tEracef IV Injection 250mg 1 vial with water 85.32\n\tPopular\tEracef IV Injection 500mg 1 vial with water 120.45\n\tRadiant.\tRofecin IV Injection 2gm 1 vial with water 788\n\tRadiant.\tRofecin IM Injection 1gm 1 vial with lidocaine 415\n\tRadiant.\tRofecin IM Injection 250mg 1 vial with lidocaine 170\n\tRadiant.\tRofecin IM Injection 500mg 1 vial with lidocaine 250\n\tRadiant.\tRofecin IV Injection 1gm 1 vial with water 415\n\tRadiant.\tRofecin IV Injection 250mg 1 vial with water 170\n\tRadiant.\tRofecin IV Injection 500mg 1 vial with water 250\n\tRAK\tRakxon IM Injection 1gm 1 vial with lidocaine 180\n\tRAK\tRakxon IV Injection 1gm 1 vial with water 180\n\tRAK\tRakxon IV Injection 250mg 1's pack 95\n\tRAK\tRakxon IV Injection 2gm 1 vial with water 300\n\tRAK\tRakxon IM Injection 500mg 1 vial with lidocaine 130\n\tRAK\tRakxon IM Injection 250mg  250mg  vial with lidocaine 95\n\tRangs\tOryx IM Injection 1gm 1 vial with lidocaine 200\n\tRangs\tOryx IM Injection 250mg 1 vial with lidocaine 80\n\tRangs\tOryx IM Injection 500mg 1 vial with lidocaine 150\n\tRangs\tOryx IV Injection 1gm 1 vial with water/10 vial with water 200/1000\n\tRangs\tOryx IV Injection 2gm 1 vial with water 350\n\tRangs\tOryx IV Injection 250mg 1 vial with water 80\n\tRangs\tOryx IV Injection 500mg 1 vial with water 150\n\tRenata\tCeftizone IM Injection 1gm 1 vial with lidocaine 200.75\n\tRenata\tCeftizone IM Injection 250mg 1 vial with lidocaine 100.34\n\tRenata\tCeftizone IM Injection 500mg 1 vial with lidocaine 140.53\n\tRenata\tCeftizone IV Injection 1gm 1 vial with water 200.75\n\tRenata\tCeftizone IV Injection 2gm 1 vial with water 341.28\n\tRenata\tCeftizone IV Injection 250mg 1 vial with water 100.38\n\tRenata\tCeftizone IV Injection 500mg 1 vial with water 140.53\n\tRephco\tInoxon IV Injection 2gm 1 vial with water 300\n\tRephco\tInoxon IM Injection 1gm 1 vial with lidocaine 160\n\tRephco\tInoxon IM Injection 250mg 1 vial with lidocaine 80\n\tRephco\tInoxon IM Injection 500mg 1 vial with lidocaine 120\n\tRephco\tInoxon IV Injection 1gm 1 vial with water 160\n\tRephco\tInoxon IV Injection 250mg 1 vial with water 80\n\tRephco\tInoxon IV Injection 500mg 1 vial with water 120\n\tSanofi Aventis (BD) Ltd.\tEnocef IM Injection 1gm 1 vial with lidocaine 200.75\n\tSanofi Aventis (BD) Ltd.\tEnocef IM Injection 250mg 1 vial with lidocaine 100.38\n\tSanofi Aventis (BD) Ltd.\tEnocef IM Injection 500mg 1 vial with lidocaine 150.57\n\tSanofi Aventis (BD) Ltd.\tEnocef IV Injection 1gm 1 vial with water 200.75\n\tSanofi Aventis (BD) Ltd.\tEnocef IV Injection 250mg 1 vial with water 100.38\n\tSanofi Aventis (BD) Ltd.\tEnocef IV Injection 500mg 1 vial with water 150.57\n\tSharif\tCefone IM Injection 250mg  \n\tSharif\tCefone IM Injection 500mg  \n\tSharif\tCefone IV Injection 1gm  \n\tSharif\tCefone IV Injection 2gm  \n\tSquare\tCeftron IM Injection 1gm 1 vial with lidocaine 160.60\n\tSquare\tCeftron IM Injection 250mg 1 vial with lidocaine 90.34\n\tSquare\tCeftron IM Injection 500mg 1 vial with lidocaine 120.46\n\tSquare\tCeftron IV Injection 1gm 1 vial with water 160.60\n\tSquare\tCeftron IV Injection 2gm 1 vial with water 301.14\n\tSquare\tCeftron IV Injection 250mg 1 vial with water 90.34\n\tSquare\tCeftron IV Injection 500mg 1 vial with water 120.46\n\tTechno Drugs Ltd.\tCefixon IM Injection 1gm 1 vial with lidocaine 160\n\tTechno Drugs Ltd.\tCefixon IM Injection 250mg 1 vial with lidocaine 80\n\tTechno Drugs Ltd.\tCefixon IM Injection 500mg 1 vial with lidocaine 120\n\tTechno Drugs Ltd.\tCefixon IV Injection 1gm 1 vial with water 160\n\tTechno Drugs Ltd.\tCefixon IV Injection 2gm 1 vial with water 250\n\tTechno Drugs Ltd.\tCefixon IV Injection 250mg 1 vial with water 80\n\tTechno Drugs Ltd.\tCefixon IV Injection 500mg 1 vial with water 120\n\tUnimed & Unihealth Manufacturers Ltd.\tOdatrix IM Injection 1gm 1 vial with lidocaine 160\n\tUnimed & Unihealth Manufacturers Ltd.\tOdatrix IM Injection 250mg 1 vial with lidocaine 90\n\tUnimed & Unihealth Manufacturers Ltd.\tOdatrix IM Injection 500mg 1 vial with lidocaine 120\n\tUnimed & Unihealth Manufacturers Ltd.\tOdatrix IV Injection 1gm 1 vial with water 160\n\tUnimed & Unihealth Manufacturers Ltd.\tOdatrix IV Injection 2gm 1 vial with water 300\n\tUnimed & Unihealth Manufacturers Ltd.\tOdatrix IV Injection 250mg 1 vial with water 90\n\tUnimed & Unihealth Manufacturers Ltd.\tOdatrix IV Injection 500mg 1 vial with water 120\n\tVeritas\tCeftrimax IM Injection 1gm  \n\tVeritas\tCeftrimax IV Injection 1gm  \n\tVeritas\tCeftrimax IV Injection 2gm  \n\tVeritas\tCeftrimax IM/IV Injection 250mg  \n\tVeritas\tCeftrimax IM/IV Injection 500mg  \n\tZiska\tTriphin IV Injection 2gm 1 vial with water 260.99\n\tZiska\tTriphin IM Injection 500mg 1 vial with lidocaine 120\n\tZiska\tTriphin I.M Injection  250 mg 250 mg   vial with water 80\n\tZiska\tTriphin I.M Injection  500 mg 500 mg   vial with water 120\n\tZiska\tTriphin I.M Injection 1 gm 1 gm   vial with lidocaine 160\n\tIndication: Pneumonia, Meningitis, Acute otitis media, Lyme disease, Typhoid fever, Otitis media, Pelvic inflammatory disease, Septicemia, Skin and Skin-Structure Infections, Gonorrhea, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Chlamydia infection, Surgical Prophylaxis\n\nDose: Adult: IV Typhoid fever 2 g once daily for 14 days. \nIV/IM Susceptible infections 1-2 g/day, up to 4 g/day for severe infections. \nSurgical prophylaxis 1 g as a single dose 0.5-2 hr pre-op. \nIM Uncomplicated gonorrhoea; Prevention of secondary meningococcal meningitis 250 mg as a single dose.\n\nChildren under 12 years: The recommended total daily dose is 50 to 75 mg/kg once daily (or twice daily in equally divided doses). In severe infections, up to 80 mg/kg body weight daily may be given. \n\nThe total daily dose should not exceed 2 gm. In the treatment of meningitis, the initial dose of 100 mg/kg body weight (not to exceed 4 gm daily) once daily (or twice daily in equally divided doses), is recommended. \nAs soon as the causative organism has been identified and its sensitivity, the doses can be reduced accordingly. The usual duration of therapy in meningitis is 7 to 14 days. \n\nRenal impairment:\nCrCl (ml/min)	\n<10	     Max: 2 g daily. \n\nContra-indication: Hypersensitivity to cephalosporins; hyperbilirubinaemic neonates. Do not use calcium or calcium-containing solutions or products with or within 48 hr of ceftriaxone administration due to risk of calcium-ceftriaxone precipitate formation.\n\nSide effects: History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.\n\nPrecaution: History of penicillin allergy; severe renal impairment; pregnancy and lactation; superinfection.\n\nMode of action: May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.\n\nPotentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.\n\nPregnancy category: B\n\nInteraction: May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.\n\nPotentially Fatal: Admin w/ Ca-containing IV soln may cause precipitation of a crystalline material in the lungs and kidneys.
Cefuroxime	\n\n\tACI\tCerox A Powder for Suspension 125mg/5ml 70ml bot 198.75\n\tACI\tCerox A TAB dr 250mg 16's pack 401.44\n\tACI\tCerox A IV/IM Injection 250mg/vial 1 vial combipack 55.21\n\tACI\tCerox A TAB dr 500mg 8's pack 361.36\n\tACI\tCerox A IV/IM Injection 750mg/vial 1 vial combipack 125.47\n\tACI\tCerox-A Powder for Suspension 125mg/5ml 70ml bot 199.35\n\tACI\tCerox-A IV/IM Injection 1.5gm/vial 1 vial pack 201.35\n\tACI\tCerox-A IM/IV Injection 250mg 1's pack 55.38\n\tACI\tCerox-A TAB dr 250 mg 16's pack 402.72\n\tACI\tCerox-A TAB dr 500 mg 8's pack 362.48\n\tACI\tCerox-A IM/IV Injection 750mg 1's pack 126.12\n\tAcme Ltd.\tFamicef Powder for Suspension 125mg/5ml 70ml bot 198.74\n\tAcme Ltd.\tFamicef Powder for Suspension 250mg/5ml 35ml bot 185.69\n\tAcme Ltd.\tFamicef IV/IM Injection 1.5gm/vial 1 vial pack 200.75\n\tAcme Ltd.\tFamicef TAB dr 250mg 20's pack 502\n\tAcme Ltd.\tFamicef TAB dr 500mg 8's pack 361.28\n\tAcme Ltd.\tFamicef IV/IM Injection 750mg/vial 1 vial pack 120.46\n\tAd-din\tAdrox Suspension 125mg 70 ml bot 181\n\tAlco Pharma\tAxetil TAB dr 125mg 12's pack 144\n\tAlco Pharma\tAxetil TAB dr 250mg 8's pack 176\n\tAlco Pharma\tAxetil TAB dr 500mg 8's pack 320\n\tAlco Pharma\tAxetil Suspension 125mg 70 ml bot 190\n\tAmico Ltd.\tLepath TAB dr 250mg 10's pack 220\n\tApex\tTil Powder for Suspension 125mg/5ml 70ml bot 198\n\tApex\tTil TAB dr 125mg 8's pack 120\n\tApex\tTil TAB dr 250mg 8's pack 200\n\tAristopharma\tAxim Powder for Suspension 125mg/5ml 70ml bot 198\n\tAristopharma\tAxim TAB dr 125mg 10's pack 150\n\tAristopharma\tAxim TAB dr 250mg 20's pack 500\n\tAristopharma\tAxim TAB dr 500mg 10's pack 450\n\tAristopharma\tAxim IV/IM Injection 750mg/vial 1 vial pack 125\n\tAsiatic Ltd.\tCeroxime Powder for Suspension 125mg/5ml 70ml bot 198\n\tAsiatic Ltd.\tCeroxime TAB dr 250mg 8's pack 200\n\tAsiatic Ltd.\tCeroxime TAB dr 500mg 8's pack 360\n\tAsiatic Ltd.\tCeroxime TAB dr 125mg  \n\tAstra Biopharmaceuticals Ltd.\tC-2 TAB dr 250mg  \n\tAstra Biopharmaceuticals Ltd.\tC-2 TAB dr 500mg  \n\tAstra Biopharmaceuticals Ltd.\tC-2 Powder For Suspension 125 mg/5 ml  \n\tBeacon\tXefrim Powder for Suspension 125mg/5ml 70ml bot 198\n\tBeacon\tXefrim TAB dr 250mg 10's pack 250\n\tBeximco\tTurbocef IV/IM Injection 1.5gm/vial 1 vial pack 200\n\tBeximco\tTurbocef TAB dr 250mg 14's pack 350\n\tBeximco\tTurbocef TAB dr 500mg 7's pack 315\n\tBeximco\tTurbocef IV/IM Injection 750mg/vial 1 vial pack 125\n\tBeximco\tTurbocef Suspension 125mg 70 ml bot 198\n\tBio Pharma Ltd.\tMextil IV/IM Injection 1.5gm/vial 1 combipack 200\n\tBio Pharma Ltd.\tMextil Powder for Suspension 125mg/5ml 70ml bot 200.75\n\tBio Pharma Ltd.\tMextil TAB dr 125mg 20's pack 301.20\n\tBio Pharma Ltd.\tMextil TAB dr 250mg 20's pack 501.80\n\tBio Pharma Ltd.\tMextil IV/IM Injection 250mg/vial 1's pack 55\n\tBio Pharma Ltd.\tMextil TAB dr 500mg 12's pack 542.04\n\tBio Pharma Ltd.\tMextil IV/IM Injection 750mg/vial 1's pack 125\n\tBio Pharma Ltd.\tMextil DS Powder for Suspension 250mg/5ml 50ml bot 250.94\n\tChemist Ltd.\tCefuxet TAB dr 250mg 16's pack 400\n\tChemist Ltd.\tCefuxet Suspension 125mg 70 ml bot 198\n\tConcord\tPicocef TAB dr 250mg 30's pack \n\tConcord\tPicocef TAB dr 500mg 16's pack \n\tConcord\tPicocef Powder For Suspension 125 mg/5 ml  \n\tDelta Pharma\tStaxim TAB dr 250mg 12's pack 264\n\tDelta Pharma\tStaxim TAB dr 500mg 6's pack 240\n\tDelta Pharma\tStaxim IV/IM Injection 750mg/5ml 70ml 170\n\tDelta Pharma\tStaxim TAB dr 250mg 12's pack 264\n\tDoctor's Chemicals Works Ltd.\tDexatil Powder for Suspension 125mg/5ml 70ml bot 198\n\tDoctor's Chemicals Works Ltd.\tDexatil TAB dr 250mg 12's pack 300\n\tDrug International Ltd.\tFurex Powder for Suspension 125mg/5ml 70ml bot 225\n\tDrug International Ltd.\tFurex TAB dr 250mg 14's pack 350\n\tDrug International Ltd.\tFurex IV/IM Injection 250mg/vial 1 vial pack 50\n\tDrug International Ltd.\tFurex TAB dr 500mg 8's pack 360\n\tDrug International Ltd.\tFurex IV/IM Injection 750mg/vial 1 vial pack 125\n\tDrug International Ltd.\tFurex IV/IM Injection 1.5gm/vial 1 vial pack 200\n\tDrug International Ltd.\tHemosaf Syrup 1.5g 1's pack 200\n\tEdruc Ltd.\tBactikil Powder for Suspension 125mg/5ml 70ml bot 198\n\tEdruc Ltd.\tBactikil TAB dr 250mg 18's pack 450\n\tEdruc Ltd.\tBactikil TAB dr 500mg 8's pack 360\n\tEskayef Bangladesh Ltd.\tKilmax TAB dr 125mg 10's pack/14's pack 150/210\n\tEskayef Bangladesh Ltd.\tKilmax Powder for Suspension 125mg/5ml 70ml bot 198\n\tEskayef Bangladesh Ltd.\tKilmax IV/IM Injection 1.5gm/vial 1's pack 200\n\tEskayef Bangladesh Ltd.\tKilmax TAB dr 250mg 12's pack/14's pack 300/350\n\tEskayef Bangladesh Ltd.\tKilmax IV/IM Injection 250mg/vial 1's pack 55\n\tEskayef Bangladesh Ltd.\tKilmax TAB dr 500mg 7's pack/12's pack 315/540\n\tEskayef Bangladesh Ltd.\tKilmax IV/IM Injection 750mg/vial 1's pack 125\n\tEuro Pharma Ltd.\tUroxime Suspension 125mg 70 ml bot 198\n\tEuro Pharma Ltd.\tUroxime TAB dr 250mg 12's pack 300\n\tEverest\tZinatil Powder for Suspension 125mg/5ml 70ml bot 185\n\tEverest\tZinatil TAB dr 250mg 12's pack 300\n\tEverest\tZinatil TAB dr 500mg 6's pack 270\n\tGeneral\tSecomax TAB dr 250mg 12's pack 301.08\n\tGeneral\tSecomax TAB dr 500mg 8's pack 361.36\n\tGeneral\tSecomax Suspension 125mg 70 ml bot 200.75\n\tGlaxoSmithKline Bangladesh Ltd.\tZinnat Powder for Suspension 125mg/5ml 70ml 360\n\tGlaxoSmithKline Bangladesh Ltd.\tZinnat TAB dr 125mg 14's pack 210\n\tGlaxoSmithKline Bangladesh Ltd.\tZinnat TAB dr 250mg 14's pack 350\n\tGlaxoSmithKline Bangladesh Ltd.\tZinnat TAB dr 500mg 14's pack 630\n\tGlobe\tXimetil IV/IM Injection 1.5gm/vial 1 combipack 200\n\tGlobe\tXimetil TAB dr 250mg 16's pack 400\n\tGlobe\tXimetil IV/IM Injection 750mg/vial 1 vial pack 125\n\tGlobe\tXimetil TAB dr 500mg 12's pack 540\n\tGlobex\tGimrox TAB dr 250mg 8's pack 200\n\tGlobex\tGimrox TAB dr 500mg  \n\tGlobex\tGimrox IV/IM Injection 750 mg/vial  \n\tGlobex\tGimrox Powder For Suspension 125 mg/5 ml 70ml 190\n\tHallmark\tCefroxil Powder for Suspension 125mg/5ml 70ml bot 195.74\n\tHallmark\tCefroxil TAB dr 250mg 8's pack/ 12's pack 200/ 300\n\tHealthcare\tFurotil Powder for Suspension 125mg/5ml 70ml bot 200\n\tHealthcare\tFurotil TAB dr 125mg 12's pack 180\n\tHealthcare\tFurotil TAB dr 250mg 18's pack 450\n\tHealthcare\tFurotil TAB dr 500mg 12's pack 540\n\tHealthcare\tFurotil DS Powder For Suspension 250 mg/5 ml  \n\tHealthcare\tFurotil IV/IM Injection 750 mg/vial  \n\tHealthcare\tFurotil IV/IM Injection 1.5 gm/vial  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tMerocef TAB dr 250mg 8's pack 208\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMerocef TAB dr 500mg 8's pack 368\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMerocef IV/IM Injection 750mg/vial 1's pack 130\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMerocef Suspension 125mg 70 ml bot 200\n\tIncepta\tKilbac Powder for Suspension 125mg/5ml 70ml bot 198\n\tIncepta\tKilbac IV/IM Injection 1.5gm/vial 1 vial combipack 200\n\tIncepta\tKilbac TAB dr 125mg 24's pack 360\n\tIncepta\tKilbac TAB dr 250mg 18's pack 450\n\tIncepta\tKilbac IV/IM Injection 250mg/vial 1 vial combipack 55\n\tIncepta\tKilbac TAB dr 500mg 8's pack 360\n\tIncepta\tKilbac IV/IM Injection 750mg/vial 1 vial combipack 125\n\tIncepta\tKilbac DS Powder for Suspension 250mg/5ml 70ml bot 250\n\tKemiko\tKfore TAB dr 250mg 16's pack 400\n\tKemiko\tKfore TAB dr 500mg 8's pack 360\n\tKumudini Pharma Ltd.\tXimorox Powder for Suspension 125mg/5ml 70ml bot 195\n\tKumudini Pharma Ltd.\tXimorox TAB dr 500mg 8's pack 360\n\tKumudini Pharma Ltd.\tXimorox TAB dr 250mg 12's pack 300\n\tLabaid\tRoxilab-250 TAB dr 250mg 2x7's pack 350\n\tLabaid\tRoxilab 500 TAB dr 500mg 7's pack 350\n\tLabaid\tRoxilab Powder for suspension 70ml 70ml bot 270\n\tLeon\tCefuact TAB dr 250mg  \n\tLeon\tCefuact TAB dr 500mg  \n\tLeon\tCefuact PFS Powder For Suspension 125 mg/5 ml  \n\tLibra Pharmaceuticls Ltd.\tLibotil Powder for Suspension 125mg/5ml 70ml bot 198.75\n\tMedicon\tCexitil Powder for Suspension 125mg/5ml 70ml bot 198\n\tMedicon\tCexitil TAB dr 250mg 12's pack 300\n\tMedicon\tCexitil TAB dr 500mg 8's pack 360\n\tMedimet\tCefu M IV/IM Injection 750mg/vial 1's pack 125\n\tMonicopharma\tOrextil 500 TAB dr 250mg 12's pack 300\n\tMonicopharma\tOrextil TAB dr 500mg 12's pack 540\n\tMystic\tMenat Powder for Suspension 125mg/5ml 70ml bot 198\n\tMystic\tMenat TAB dr 125mg 8's pack 120\n\tMystic\tMenat TAB dr 250mg 8's pack 200\n\tNavana\tFixcef IV/IM Injection 1.5gm/vial 1 vial combipack 200\n\tNavana\tFixcef IV/IM Injection 250mg/vial 1 vial combipack 55\n\tNavana\tFixcef IV/IM Injection 750mg/vial 1 vial combipack 125\n\tNavana\tFixcef Suspension 125mg 70 ml bot 190\n\tNavana\tFixcef TAB dr 250mg 14's pack 350\n\tNavana\tFixcef TAB dr 500mg 14's pack 630\n\tNIPRO JMI Pharma\tRoxcef TAB dr 250mg  \n\tNIPRO JMI Pharma\tRoxcef TAB dr 500mg  \n\tNovartis (Bangladesh) Ltd.\tXorimax TAB dr 250mg 14's pack 420\n\tNovartis (Bangladesh) Ltd.\tXorimax TAB dr 500mg 14's pack 770\n\tNovartis (Bangladesh) Ltd.\tXorimax Powder For Suspension 125 mg/5 ml  \n\tNovelta Bestway\tInfanil TAB dr 250mg  \n\tNovelta Bestway\tInfanil TAB dr 500mg  \n\tNovelta Bestway\tInfanil PFS Powder For Suspension 125 mg/5 ml  \n\tNovo Healthcare and Pharma Ltd.\tPrimocef Powder for Suspension 125mg/5ml 70ml bot 198\n\tNovo Healthcare and Pharma Ltd.\tPrimocef TAB dr 250mg 12's pack 300\n\tNovo Healthcare and Pharma Ltd.\tPrimocef TAB dr 500mg 8's pack 360\n\tNuvista Pharma Ltd\tAxibid TAB dr 250mg  \n\tNuvista Pharma Ltd\tAxibid TAB dr 500mg 7's pack 305\n\tOpsonin Pharma\tSefur Powder for Suspension 125mg/5ml 70ml bot 198\n\tOpsonin Pharma\tSefur IV/IM Injection 1.5gm/vial 1 combipack 200\n\tOpsonin Pharma\tSefur TAB dr 125mg 12's pack 180\n\tOpsonin Pharma\tSefur TAB dr 250mg 12's pack 300\n\tOpsonin Pharma\tSefur TAB dr 500mg 6's pack 270\n\tOpsonin Pharma\tSefur IV/IM Injection 750mg/vial 1 vial combipack 125\n\tOpsonin Pharma\tSefur DS Powder for Suspension 250mg/5ml 50ml bot 250\n\tOrganic Health Care\tVexotil TAB dr 250mg 12's pack  300\n\tOrion Pharma Ltd.\tAxet Powder for Suspension 125mg/5ml 70ml bot 215.81\n\tOrion Pharma Ltd.\tAxet TAB dr 125mg 20's pack 301.20\n\tOrion Pharma Ltd.\tAxet TAB dr 250mg 20's pack 501.80\n\tOrion Pharma Ltd.\tAxet IV/IM Injection 250mg/vial 1's pack 60\n\tOrion Pharma Ltd.\tAxet TAB dr 500mg 12's pack 542.04\n\tOrion Pharma Ltd.\tAxet IV/IM Injection 750mg/vial 1's pack 125.47\n\tPacific\tSefatil Powder for Suspension 125mg/5ml 70ml bot 150\n\tPacific\tSefatil TAB dr 125mg 20's pack 300\n\tPacific\tSefatil TAB dr 250mg 20's pack 500\n\tPacific\tSefatil TAB dr 500mg 12's pack 540\n\tPharmadesh Ltd.\tCefstar Powder for Suspension 125mg/5ml 70ml bot 190\n\tPharmadesh Ltd.\tCefstar TAB dr 125mg 10's pack 150.50\n\tPharmadesh Ltd.\tCefstar TAB dr 250mg 8's pack 200.64\n\tPharmadesh Ltd.\tCefstar TAB dr 500mg 8's pack 361.28\n\tPharmasia Ltd.\tFuxtil Powder for Suspension 125mg/5ml 70ml bot 198.74\n\tPharmasia Ltd.\tFuxtil TAB dr 500mg  \n\tPharmasia Ltd.\tFuxtil TAB dr 250mg  \n\tPopular\tCefobac Powder for Suspension 125mg/5ml 70ml bot 198.75\n\tPopular\tCefobac IV/IM Injection 1.5gm/vial 1 vial pack 200.75\n\tPopular\tCefobac TAB dr 250mg 20's pack 501.81\n\tPopular\tCefobac TAB dr 500mg 8's pack 361.36\n\tPopular\tCefobac IV/IM Injection 750mg/vial 1 vial pack 125.47\n\tRadiant.\tRofurox Powder for Suspension 125mg/5ml 70ml bot 270\n\tRadiant.\tRofurox TAB dr 250mg 10's pack 350\n\tRadiant.\tRofurox TAB dr 500mg 8's pack 440\n\tRadiant.\tRofuroxÂ IM / IV Injection 750mg 1's pack 200\n\tRAK\tRoxibac TAB dr 250mg 10's pack 250\n\tRAK\tRoxibac TAB dr 500mg 8's pack 360\n\tRangs\tRecofast IV/IM Injection 750mg/vial 1's pack 125\n\tRangs\tRicofast TAB dr 125mg 70ml bot 198\n\tRangs\tRicofast TAB dr 250mg 12's pack 300\n\tRangs\tRicofast TAB dr 500mg 8's pack 360\n\tRangs\tRecofast TAB dr 125mg 8's pack 120\n\tRangs\tRecofast TAB dr 250mg 12's pack 300\n\tRangs\tRecofast TAB dr 500mg 8's pack 360\n\tRangs\tRecofast Suspension 125mg 70 ml bot 198\n\tReliance\tEliroxime Powder for Suspension 125mg/5ml 70ml bot 170.34\n\tReliance\tEliroxime TAB dr 250mg 12's pack 300\n\tRenata\tFurocef TAB dr 125mg 10's pack 150.60\n\tRenata\tFurocef Powder for Suspension 125mg/5ml 70ml bot 198.75\n\tRenata\tFurocef TAB dr 250mg 16's pack 401.44\n\tRenata\tFurocef TAB dr 500mg 12's pack 542.04\n\tRenata\tFurocef IV/IM Injection 1.5gm/vial 1 vial pack 230\n\tRenata\tFurocef IV/IM Injection 250mg/vial 1 vial pack 55.21\n\tRenata\tFurocef IV/IM Injection 750mg/vial 1 vial pack 125.47\n\tRephco\tCefoxil Dry Syrup Powder for Suspension  70ml bot 200\n\tRephco\tCefoxil-500 TAB dr  1x10's Pack 450\n\tRephco\tCefoxil-250 TAB dr  2x10's Pack 500\n\tSanofi Aventis (BD) Ltd.\tSefurox Powder for Suspension 125mg/5ml 70ml bot 198.74\n\tSanofi Aventis (BD) Ltd.\tSefurox IV/IM Injection 1.5gm/vial 1 combipack 200.01\n\tSanofi Aventis (BD) Ltd.\tSefurox TAB dr 125mg 12's pack 180.72\n\tSanofi Aventis (BD) Ltd.\tSefurox TAB dr 250mg 20's pack 501.80\n\tSanofi Aventis (BD) Ltd.\tSefurox TAB dr 500mg 12's pack 542.04\n\tSanofi Aventis (BD) Ltd.\tSefurox IV/IM Injection 750mg/vial 1 vial combipack 125.47\n\tSharif\tFurotixol Powder for Suspension 125mg/5ml 70ml bot 198\n\tSharif\tFurotixol TAB dr 500mg 8's pack 360\n\tSharif\tFurotixol TAB dr 250mg 8's pack 200\n\tSilva\tProbac Powder for Suspension 125mg/5ml 70ml bot 198.74\n\tSilva\tProbac TAB dr 250mg 16's pack 401.51\n\tSilva\tProbac TAB dr 500mg 8's pack 361.36\n\tSomatec\tCefurim Powder for Suspension 125mg/5ml 70ml bot 190.72\n\tSomatec\tCefurim TAB dr 250mg 12's pack 301.20\n\tSomatec\tCefurim TAB dr 500mg 8's pack 361.36\n\tSquare Cephalosporins Ltd.\tCefotil Powder for Suspension 125mg/5ml 70ml bot 198.74\n\tSquare Cephalosporins Ltd.\tCefotil IV/IM Injection 1.5gm/vial 1's pack 200.75\n\tSquare Cephalosporins Ltd.\tCefotil TAB dr 125mg 20's pack 301.11\n\tSquare Cephalosporins Ltd.\tCefotil TAB dr 250mg 20's pack 501.94\n\tSquare Cephalosporins Ltd.\tCefotil TAB dr 500mg 6's pack 270.92\n\tSquare Cephalosporins Ltd.\tCefotil IV/IM Injection 750mg/vial 1's pack 125.47\n\tSupreme\tAdetil TAB dr 250mg 10's pack 250\n\tSupreme\tAdetil TAB dr 500mg 6's pack 270\n\tSyntho Ltd.\tXtil TAB dr 250mg 20's pack 480\n\tVeritas\tRoximax TAB dr 250mg  \n\tVeritas\tRoximax TAB dr 500mg  \n\tWhite Horse Pharma\tWinfax TAB dr 500mg 12's pack 360\n\tZiska\tXitil TAB dr 250mg 14's pack 350\n\tZiska\tXitil TAB dr 500mg 7's pack 315\n\tZiska\tXitil Suspension 125 mg / 5 ml 70ml bot 198\n\tFerring GmbH, Germany\tZinacef Injection 789mg  290\n\tIndication: Pharyngitis, Acute otitis media, Lyme disease, Susceptible infections, Sinusitis, Otitis media, Skin and skin structure infections,Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Urinary tract infections, Acute bacterial exacerbation of chronic bronchitis, Surgical Prophylaxis\n\nDose: Adult: PO Uncomplicated UTI 125 mg twice daily. \nResp tract infections 250-500 mg twice daily. \nUncomplicated gonorrhoea W/ oral probenecid: 1 g as a single dose.\n IV Meningitis 3 g 8 hrly. \nIM Gonorrhoea W/ oral probenecid: 1.5 g as a single dose. \nIV/IM Surgical prophylaxis 1.5 g IV per-op, then 750 mg IM 8 hrly for up to 24-48 hr. \nSusceptible infections 750 mg 8 hrly, up to 1.5 g 6-8 hrly for severe infections.\n\nChildren (above 3 months of age): 30 - 100 mg/kg/day given in 3 or 4 equally divided doses. A dose of 60mg/kg/day is appropriate for most infections.\n\nNeonate: 30 - 100 mg/kg/day given in 2 or 3 equally divided doses.\n\nRenal impairment: Patients undergoing haemodialysis should receive an additional 750-mg dose after each dialysis; those undergoing continuous peritoneal dialysis may be given 750 mg bid.\nCrCl (ml/min)	\n10-20	750 mg bid.\n<10	750 mg once daily. \n\nContra-indication: Hypersensitivity to cephalosporins.\n\nSide effects: Large doses can cause cerebral irritation and convulsions; nausea, vomiting, diarrhoea, GI disturbances; erythema multiforme, Stevens-Johnson syndrome, epidermal necrolysis.\nPotentially Fatal: Anaphylaxis, nephrotoxicity, pseudomembranous colitis.\n\nPrecaution: Severe renal impairment; pregnancy, lactation; hypersensitivity to penicillins.\n\nMode of action: May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.\n\nPregnancy category: B\n\nInteraction: May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.
Cefuroxime + Clavulanic Acid	\n\n\tACI\tCerox CV 125 TAB dr 125mg+31.25mg 12's pack 252.72\n\tACI\tCerox CV 250 TAB dr 250mg + 62.50mg 12's pack 361.08\n\tACI\tCerox CV 500 TAB dr 500mg + 125mg 8's pack 401.20\n\tACI\tCerox CV Powder For Suspension (125mg+31.25mg)/5ml 70 ml bot\n 250.75\n\tAcme Ltd.\tFamiclav TAB dr 500 mg + 125 mg  \n\tAcme Ltd.\tFamiclav TAB dr 250 mg + 62.5 mg  \n\tAcme Ltd.\tFamiclav Powder For Suspension (125 mg + 31.25 mg)/5 ml  \n\tBio Pharma Ltd.\tMexclav TAB dr 250 mg + 62.5 mg  \n\tBio Pharma Ltd.\tMexclav TAB dr 500 mg + 125 mg  \n\tDrug International Ltd.\tFurex CV Powder for Suspension   70ml 250\n\tDrug International Ltd.\tFurex CV 250 TAB dr  250mg 20's pack 360\n\tDrug International Ltd.\tFurex-CV 500 TAB dr  500mg 8's pack 400\n\tDrug International Ltd.\tFuclav-125 TAB dr 125mg & 31.25mg 14's Pack 252\n\tDrug International Ltd.\tFuclav-250 TAB dr 250mg & 62.50mg 14's Pack 420\n\tDrug International Ltd.\tFuclav-500 TAB dr 500mg & 125mg 14's Pack 700\n\tEskayef Bangladesh Ltd.\tKefuclav TAB dr 250mg 14's pack 369.47\n\tEskayef Bangladesh Ltd.\tKefuclav TAB dr 500mg 7's pack 307.89\n\tEskayef Bangladesh Ltd.\tKefuclav TAB dr 250 mg + 62.5 mg  \n\tEskayef Bangladesh Ltd.\tKefuclav TAB dr 500 mg + 125 mg  \n\tGeneral\tSecoclav TAB dr 250 mg + 62.5 mg  \n\tGeneral\tSecoclav TAB dr 500 mg + 125 mg  \n\tGlobe\tXimeclav Powder For Suspension (125 mg + 31.25 mg)/5 ml  \n\tGlobe\tXimeclav TAB dr 125 mg + 31.25 mg  \n\tGlobe\tXimeclav TAB dr 250 mg + 62.5 mg  \n\tGlobe\tXimeclav TAB dr 500 mg + 125 mg  \n\tIncepta\tCefaclav 125 TAB dr 125 mg + 31.25 mg 18's pack 324\n\tIncepta\tCefaclav 250 TAB dr 250 mg + 62.5 mg 12's 360\n\tIncepta\tCefaclav 500 TAB dr 500 mg + 125 mg 8's 400\n\tIncepta\tCefaclav Powder for Suspension (125 mg + 31.25 mg)/5 ml 70ml bot 250\n\tOpso Saline Ltd.\tClacef TAB dr 125 mg + 31.25 mg  \n\tOpso Saline Ltd.\tClacef TAB dr 250 mg + 62.5 mg  \n\tOpso Saline Ltd.\tClacef TAB dr 500 mg + 125 mg  \n\tOpsonin Pharma\tClavusef TAB dr  6x2's pack 216\n\tOrion Pharma Ltd.\tCo-Axet TAB dr 125 mg + 31.25 mg  \n\tOrion Pharma Ltd.\tCo-Axet TAB dr 250 mg + 62.5 mg  \n\tOrion Pharma Ltd.\tCo-Axet TAB dr 500 mg + 125 mg  \n\tOrion Pharma Ltd.\tCo-Axet Powder For Suspension (125 mg + 31.25 mg)/5 ml  \n\tPharmasia Ltd.\tFuxtil CV TAB dr 250 mg + 62.5 mg  \n\tPharmasia Ltd.\tFuxtil CV TAB dr 500 mg + 125 mg  \n\tPharmasia Ltd.\tFuxtil CV Powder For Suspension (125 mg + 31.25 mg)/5 ml  \n\tPopular\tClavurox TAB dr 500 mg + 125 mg  \n\tPopular\tClavurox TAB dr 250 mg + 62.5 mg  \n\tRenata\tFuroclav TAB dr 250mg 12's pack 316.70\n\tRenata\tFuroclav TAB dr 500mg 8's pack 351.88\n\tSharif\tCeclav TAB dr 250 mg + 62.5 mg  \n\tSharif\tCeclav TAB dr 500 mg + 125 mg  \n\tSharif\tCeclav Powder For Suspension (125 mg + 31.25 mg)/5 ml  \n\tSquare\tCefotil Plus 500 TAB dr 500 mg + 125 mg 6's pack 300\n\tSquare\tCefotil Plus 250 TAB dr 250 mg + 62.5 mg 10's pack 300\n\tSquare\tCefotil Plus 125 TAB dr 125 mg + 31.25 mg 10's pack 503\n\tTechno Drugs Ltd.\tCefuclav TAB dr  30's pack\n \n\tZiska\tXiclav 250 TAB dr  10's pack 300\n\tZiska\tXiclav 500 TAB dr  8's pack 400\n\tZiska\tXiclav GFS Suspension  1's pack 250\n\tIndication: Pharyngitis, Acute otitis media, Lyme disease, Susceptible infections, Sinusitis,Otitis media, Skin and skin structure infections,Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Urinary tract infections, Acute bacterial exacerbation of chronic bronchitis, Surgical Prophylaxis\n\nDose: Adolescents & adults:\nPharyngitis or Tonsillitis: 250 mg twice daily 5-10 days\nAcute bacterial maxillary sinusitis: 250 mg twice daily 10 days\nAcute bacterial exacerbation of chronic bronchitis: 250-500 mg twice daily 10 days\nSecondary bacterial infections of acute bronchitis: 250-500 mg twice daily 5-10 days\nCommunity acquired pneumonia: 250-500 mg twice daily 5-10 days\nUncomplicated skin & skin-structure infections: 250-500 mg twice daily 10 days\nMDR Typhoid fever: 500 mg twice daily 10-14 days\nUncomplicated urinary tract infection: 250 mg twice daily 7-10 days\nUncomplicated gonorrhea: 1000 mg single dose\nLyme disease: 500 mg twice daily 20 days\n\nPaediatric patients (3 months to 12 years)\nPharyngitis or Tonsillitis: 20 mg/kg/day in two divided doses 5-10 days\nAcute otitis media: 30 mg/kg/day in two divided doses 10 days\nAcute bacterial maxillary sinusitis: 30 mg/kg/day in two divided doses 10 days\nCommunity acquired pneumonia: 30 mg/kg/day in two divided doses 5-10 days\nMDR Typhoid fever: 30 mg/kg/day in two divided doses 10-14 days\nUncomplicated skin & skin-structure infections: 30 mg/kg/day in two divided doses 10 days\nUncomplicated urinary tract infection: 20 mg/kg/day in two divided doses 7-10 days\n\n\n\nContra-indication: Hypersensitivity to cephalosporins.\n\nSide effects: Large doses can cause cerebral irritation and convulsions; nausea, vomiting, diarrhoea, GI disturbances; erythema multiforme, Stevens-Johnson syndrome, epidermal necrolysis.\nPotentially Fatal: Anaphylaxis, nephrotoxicity, pseudomembranous colitis.\n\nPrecaution: Severe renal impairment; pregnancy, lactation; hypersensitivity to penicillins.\n\nMode of action: May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.\n\nPregnancy category: B\n\nInteraction: May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.
Celecoxib	\n\n\tACI\tAcicox 100 CAP  100mg 30's pack 120\n\tAlco Pharma\tCoxib CAP 100mg 50's pack 202.50\n\tAlco Pharma\tCoxib CAP 200mg 50's pack 352.50\n\tBeximco\tCox B CAP 100mg 50's pack 225\n\tBeximco\tCox B CAP 200mg 50's pack 400\n\tEskayef Bangladesh Ltd.\tEzy CAP 100mg 30's pack 135\n\tEskayef Bangladesh Ltd.\tEzy CAP 200mg 20's pack 160\n\tIncepta\tCelenta CAP 100mg 50's pack 225\n\tIncepta\tCelenta CAP 200mg 40's pack 320\n\tMedimet\tCeleco CAP 100mg 50's pack 225\n\tMedimet\tCeleco CAP 200mg 30's pack 240\n\tSquare\tSelecox CAP 100mg 48's pack 144\n\tSquare\tSelecox CAP 200mg 48's pack 240\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Dysmenorrhea, Acute pain, Familial adenomatous polyposis\n\nDose: Adult: PO Osteoarthritis 200 mg 1-2 times/day. May increase to 200 mg 2 times daily if needed. Rheumatoid arthritis 100-200 mg 2 times daily. \nJuvenile idiopathic arthritis\nChild: >2 yr ?10 kg to <25 kg: 50 mg bid; >25 kg: 100 mg bid.\n\nPain relief; Dysmenorrhea Initial: 400 mg followed by 200 mg on the 1st day if needed. Maintenance: 200 mg 2 times daily. Familial adenomatous polyposis 400 mg 2 times daily.\n\nHepatic impairment: Moderate (Child-Pugh category B): Reduce dose by 50%. Severe (Child-Pugh category C or >10 score): Contraindicated.\n\nContra-indication: Hypersensitivity including those in whom attacks of angioedema, rhinitis and urticaria have been precipitated by aspirin, NSAIDs or sulfonamides. Severe hepatic impairment; severe heart failure; inflammatory bowel disease; peptic ulcer; renal impairment (creatinine clearance <30 mL/min); pregnancy and lactation.\n\nSide effects: Abdominal pain, diarrhea, nausea, oedema, dizziness, headache, insomnia, upper respiratory tract infections (URTI); rash.\nPotentially Fatal: Serious skin reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.\n\nPrecaution: History of GI bleeding; renal/hepatic insufficiency; asthma or allergic disorders; hypertension; monitor Hb or haematocrit levels for signs of anaemia. History of cerebrovascular disease or ischaemic heart disease (IHD).\n\nMode of action: May increase plasma level w/ CYP2C9 isoenzymes (e.g. fluconazole). May increase serum level of lithium. May reduce effect of antihypertensives and diuretics. May increase anticoagulant effect of warfarin.\n\nPregnancy category: D\n\nInteraction: May increase plasma level w/ CYP2C9 isoenzymes (e.g. fluconazole). May increase serum level of lithium. May reduce effect of antihypertensives and diuretics. May increase anticoagulant effect of warfarin.
Celiprolol Hydrochloride	\n\n\tEskayef Bangladesh Ltd.\tCelipress TAB dr 200mg 20's pack 160\n\tEskayef Bangladesh Ltd.\tCelipress TAB dr 400mg 10's pack 150\n\tIndication: Hypertension, Angina pectoris\n\nDose: Oral\nHypertension\nAdult: 200-400 mg once daily.\n\nRenal impairment:\nCrCl (ml/min)	\n15-40	100-200 mg/day.\n<15	         Avoid.\n\nContra-indication: Hypersensitivity, sinus bradycardia, >1st degree heart block, cardiogenic shock, uncompensated heart failure, hypotensive patients. Pregnancy (2nd and 3rd trimesters).\n\nSide effects: Nausea, abdominal discomfort, diarrhoea; CHF, AV nodal block and bradycardia, palpitations; headache, fatigue, dizziness, insomnia; Raynaud's phenomenon; orthostatic hypotension; bronchial obstruction; tremor, rash, muscle cramps; impotence.\n\nPrecaution: Asthma. Lactation.\n\nMode of action: May exacerbate rebound HTN upon withdrawal of clonidine. May increase AV conduction time w/ digitalis glycosides. Reduced bioavailability w/ concomitant hydrochlorothiazide, chlorthalidone or theophylline. Concomitant dihydropyridine Ca channel blockers (e.g. nifedipine) may increase the risk of hypotension and heart failure.\n\nPregnancy category: D\n\nInteraction: May exacerbate rebound HTN upon withdrawal of clonidine. May increase AV conduction time w/ digitalis glycosides. Reduced bioavailability w/ concomitant hydrochlorothiazide, chlorthalidone or theophylline. Concomitant dihydropyridine Ca channel blockers (e.g. nifedipine) may increase the risk of hypotension and heart failure.
Cephalexin	\n\n\tACI\tAvloxin Powder for Suspension 125mg/5ml 100ml 69\n\tACI\tAvloxin CAP 500mg 20's pack 210\n\tAcme Ltd.\tAcelex Paediatric Drops 125mg/1.2ml 15ml bot 42.66\n\tAcme Ltd.\tAcelex Powder for Suspension 125mg/5ml 100ml bot 77.29\n\tAcme Ltd.\tAcelex CAP 250mg 20's pack/ 50's pack 132.60/ 330\n\tAcme Ltd.\tAcelex CAP 500mg 20's pack/ 40's pack 250.80/ 500\n\tAlbion Ltd.\tCehalexine CAP 250 mg 20's pack \n\tAlbion Ltd.\tPorex CAP 500 mg 20's pack \n\tAlbion Ltd.\tCephalexine Dry Powder for Syrup 125 mg/5ml 100ml \n\tBeximco\tCephalen Powder for Suspension 125mg/5ml 100ml bot 81.81\n\tBeximco\tCephalen CAP 250mg 100's pack 673\n\tBeximco\tCephalen CAP 500mg 50's pack 630\n\tBio Pharma Ltd.\tSulpralex CAP 500mg 30's pack 361.50\n\tBio Pharma Ltd.\tSupralex Powder for Suspension 125mg/5ml 100ml bot 77.29\n\tBio Pharma Ltd.\tSupralex CAP 250mg 30's pack 195.60\n\tChemist Ltd.\tAbac CAP 500mg 20's pack 252.80\n\tDoctor's Chemicals Works Ltd.\tCefex Powder for Suspension 125mg/5ml 100ml 81\n\tDoctor's Chemicals Works Ltd.\tCefex CAP 250mg 100's pack 650\n\tDoctor's Chemicals Works Ltd.\tCefex CAP 500mg 50's pack 600\n\tDrug International Ltd.\tCefalex Powder for Suspension 125mg/5ml 100ml bot 81\n\tDrug International Ltd.\tCefalex CAP 500mg 50's pack 400\n\tEdruc Ltd.\tEdicef Powder for Suspension 125mg/5ml 100ml 77\n\tEdruc Ltd.\tEdicef CAP 250mg 50's pack 328.50\n\tEdruc Ltd.\tEdicef CAP 500mg 30's pack 364.20\n\tEskayef Bangladesh Ltd.\tNeorex Powder for Suspension 125mg/5ml 100ml bot 83.50\n\tEskayef Bangladesh Ltd.\tNeorex CAP 250mg 100's pack 660\n\tEskayef Bangladesh Ltd.\tNeorex CAP 500mg 50's pack 625\n\tGeneral\tNufex Powder for Suspension 125mg/5ml 100ml bot 78.29\n\tGeneral\tNufex CAP 500mg 20's pack 180.60\n\tGlaxoSmithKline Bangladesh Ltd.\tCeporex Powder for Suspension 125mg/5ml 100ml bot 84.27\n\tGlaxoSmithKline Bangladesh Ltd.\tCeporex CAP 250mg 100's pack 688.41\n\tGlaxoSmithKline Bangladesh Ltd.\tCeporex CAP 500mg 50's pack 634.54\n\tGonoshasthaya\tG Cephalexin Powder for Suspension 125mg/5ml 100ml bot 75.79\n\tGonoshasthaya\tG Cephalexin CAP 250mg 50's pack 201\n\tHudson\tHi Cef Powder for Suspension 125mg/5ml 100ml bot 70\n\tHudson\tHi Cef CAP 500mg 50's pack 525\n\tMedimet\tCeporal Powder for Suspension 125mg/5ml 100ml bot 78\n\tMedimet\tCeporal CAP 250mg 40's pack 220\n\tMedimet\tCeporal CAP 500mg 20's pack 200\n\tNavana\tNavalexin Powder for Suspension 125mg/5ml 100ml bot 80\n\tNavana\tNavalexin CAP 250mg 100's pack 500\n\tNavana\tNavalexin CAP 500mg 50's pack 450\n\tNavana\tSefro CAP 250mg 24's pack 156.72\n\tNavana\tSefro CAP 500mg 24's pack 300.76\n\tOpsonin Pharma\tKeflin Powder for Suspension 125mg/5ml 100ml bot 77\n\tOpsonin Pharma\tKeflin CAP 250mg 50's pack 275\n\tOpsonin Pharma\tKeflin CAP 500mg 30's pack 330\n\tOrion Pharma Ltd.\tSelex Powder for Suspension 125mg/5ml 100ml bot \n\tOrion Pharma Ltd.\tSelex CAP 500mg 30's pack \n\tPharmadesh Ltd.\tCephaxin Powder for Suspension 125mg/5ml 100ml bot 72.27\n\tPharmadesh Ltd.\tCephaxin CAP 500mg 20's pack 210.60\n\tRenata\tAlexin CAP 500mg 50's pack 571\n\tRenata\tAlexin CAP 250mg 50's pack 279\n\tRenata\tAlexin Oral Suspension 500mg 100ml bot \n\tRenata\tAlsporin Powder for Suspension 125mg/5ml 100ml bot 82.24\n\tRenata\tAlsporin TAB dr 250mg 100's pack 660\n\tRenata\tAlsporin TAB dr 500mg 50's pack 609.50\n\tSquare\tCeporin Powder for Suspension 125mg/5ml 100ml bot 84.27\n\tSquare\tCeporin DT TAB dr 250mg 50's pack 326.50\n\tTheraputics (BD) Ltd.\tCeflex CAP 500mg 50's pack 400\n\tIndication: Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis\n\nDose: Adults\n1 to 4 g/day in divided doses. Usual dose is 250 mg every 6 hours.\nStreptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis in patients>15 years 500 mg every 12 hours. May need larger doses for more severe infections or less susceptible organisms.\n\nChildren\n25 to 50 mg/kg/day in divided doses. For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours. In sever infections, double the dose.\nOtitis media: 75 to 100 mg/kg/day in 4 divided doses.\nbeta-hemolytic streptococcal infections: Continue treatment for at least 10 days.\n\nRenal impairment:\nCrCl (ml/min)	\n40-50	Max: 3 g daily.\n10-40	Max: 1.5 g daily.\n<10	        Max: 750 mg daily. \n\nContra-indication: Hypersensitivity to cephalosporins.\n\nSide effects: Pain at inj site; hypersensitivity; GI disturbances; eosinophilia, neutropenia, leucopenia, thrombocytopenia.\nPotentially Fatal: Anaphylactic reactions; nephrotoxicity.\n\nPrecaution: Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.\n\nMode of action: Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.\n\nPregnancy category: B\n\nInteraction: Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
Cephradine	\n\n\tACI\tAvlosef Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tACI\tAvlosef Powder for Suspension 125mg/5ml 100ml bot 90.27\n\tACI\tAvlosef IV/IM Injection 1gm/vial 1's pack 95.29\n\tACI\tAvlosef CAP 250mg 32's pack 256.64\n\tACI\tAvlosef CAP 500mg 32's pack 481.60\n\tACI\tAvlosef IV/IM Injection 500mg/vial 1's pack 65.20\n\tACI\tAvlosef DS Powder for Suspension 250mg/5ml 100ml bot 135.41\n\tACI\tAvlosef PD Paediatric Drops 125mg/1.25ml 15ml bot 65.20\n\tAcme Ltd.\tSefril Powder for Suspension 125mg/5ml 100ml bot 80.30\n\tAcme Ltd.\tSefril IV/IM Injection 1gm/vial 1's pack 80.30\n\tAcme Ltd.\tSefril CAP 250mg 20's pack 130.60\n\tAcme Ltd.\tSefril CAP 500mg 20's pack 250.80\n\tAcme Ltd.\tSefril IV/IM Injection 500mg/vial 5's pack 251\n\tAcme Ltd.\tSefril DS Powder for Suspension 250mg/5ml 100ml bot 120.46\n\tAd-din\tJedine Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tAd-din\tJedine Powder for Suspension 125mg/5ml 100ml bot 80\n\tAd-din\tJedine CAP 500mg 30's pack 375\n\tAexim\tNovadin Powder for Suspension 125mg/5ml 100ml bot 80\n\tAexim\tNovadin CAP 500mg 20's pack 240\n\tAlbion Ltd.\tCephradine CAP 500 mg 24's pack \n\tAlbion Ltd.\tCephradine Dry Powder for Syrup 125 mg/5 ml 100 ml \n\tAlbion Ltd.\tCephradine Dry Powder for Syrup 250 mg/5 ml 100 ml \n\tAlbion Ltd.\tCephradine Paediatric Drops 125 mg/1.25 ml 15 ml \n\tAlco Pharma\tBetasef DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tAlco Pharma\tBetasef CAP 250mg 20's pack 132\n\tAlco Pharma\tBetasef Suspension 500mg 20's pack 253\n\tAlco Pharma\tBetasef Drops 100mg 15ml bot 51\n\tAlco Pharma\tBetasef Suspension 125mg 100ml bot 79\n\tAmbee\tMycef Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tAmbee\tMycef Powder for Suspension 125mg/5ml 100ml bot 80.31\n\tAmbee\tMycef CAP 500mg 40's pack 250\n\tAmico Ltd.\tBelocef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tAmico Ltd.\tBelocef Powder for Suspension 125mg/5ml 100ml bot 80\n\tAmico Ltd.\tBelocef CAP 250mg 20's pack 130\n\tAmico Ltd.\tBelocef CAP 500mg 20's pack 250\n\tAmico Ltd.\tBelocef DS Powder for Suspension 250mg/5ml 100ml bot 110\n\tAPC Pharma Ltd.\tSeftec Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tAPC Pharma Ltd.\tSeftec Powder for Suspension 125mg/5ml 100ml bot 86\n\tAPC Pharma Ltd.\tSeftec CAP 500mg 20's pack 300\n\tApex\tAphrin Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tApex\tAphrin CAP 500mg 20's pack 240\n\tApex\tAphrin DS Powder for Suspension 250mg/5ml 100ml bot 80\n\tApex\tAphrin IV/IM Injection 1gm/vial 1's pack 80\n\tApex\tAphrin IV/IM Injection 500mg/vial 1's pack 45\n\tApex\tAphrin PFS Powder for Suspension 125mg/5ml 100ml bot 80\n\tApollo Pharmaceutical Ltd.\tAcefra Powder for Suspension 125mg/5ml 100ml bot 78\n\tApollo Pharmaceutical Ltd.\tAcefra CAP 500mg 20's pack 240\n\tAristopharma\tExtracef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tAristopharma\tExtracef Powder for Suspension 125mg/5ml 100ml bot 82\n\tAristopharma\tExtracef IV/IM Injection 1gm/vial 1's pack 80\n\tAristopharma\tExtracef CAP 250mg 30's pack 195\n\tAristopharma\tExtracef IV/IM Injection 250mg/vial 5's pack 175\n\tAristopharma\tExtracef CAP 500mg 28's pack 350\n\tAristopharma\tExtracef IV/IM Injection 500mg/vial 5's pack 250\n\tAristopharma\tExtracef DS Powder for Suspension 250mg/5ml 100ml bot 125\n\tAsiatic Ltd.\tVecef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tAsiatic Ltd.\tVecef Powder for Suspension 125mg/5ml 100ml bot 80\n\tAsiatic Ltd.\tVecef CAP 500mg 24's pack 300\n\tAsiatic Ltd.\tVecef DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tBengal Techno Pharma Ltd.\tBT-Cef CAP 500mg  \n\tBengal Techno Pharma Ltd.\tBT-Cef Powder For Suspension 125 mg/5 ml  \n\tBenham\tBenocef Powder for Suspension 125mg/5ml 100ml bot 79\n\tBenham\tBenocef CAP 250mg 20's pack 131.20\n\tBenham\tBenocef CAP 500mg 20's pack 250\n\tBenham\tBenocef DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tBeximco\tIntracef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tBeximco\tIntracef Powder for Suspension 125mg/5ml 100ml bot 80\n\tBeximco\tIntracef CAP 250mg 48's pack/ 50's pack 312/ 325\n\tBeximco\tIntracef IV/IM Injection 250mg/vial 10 vials 350\n\tBeximco\tIntracef CAP 500mg 40's pack 500\n\tBeximco\tIntracef IV/IM Injection 500mg/vial 10 vials 500\n\tBeximco\tIntracef DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tBio Pharma Ltd.\tSupracef Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tBio Pharma Ltd.\tSupracef Powder for Suspension 125mg/5ml 100ml bot 80.30\n\tBio Pharma Ltd.\tSupracef CAP 250mg 28's pack 188.44\n\tBio Pharma Ltd.\tSupracef Inj Injection 250mg/vial 1's pack 35.13\n\tBio Pharma Ltd.\tSupracef CAP 500mg 28's pack 351.40\n\tBio Pharma Ltd.\tSupracef Inj Injection 500mg/vial 1's pack 50.19\n\tBio Pharma Ltd.\tSupracef F DS Powder for Suspension 250mg/5ml 100ml bot 120.45\n\tBristol Pharma Ltd.\tSefrate Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tBristol Pharma Ltd.\tSefrate Powder for Suspension 125mg/5ml 100ml bot 80\n\tBristol Pharma Ltd.\tSefrate CAP 500mg 20's pack 250\n\tCentral.\tCeodin CAP 250mg 30's pack 195\n\tCentral.\tCeodin CAP 500mg 20's pack 245\n\tCentral.\tCeodin Suspension 125mg 100ml bot 80\n\tChemist Ltd.\tAbac Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tChemist Ltd.\tAbac Powder for Suspension 125mg/5ml 100ml bot 81.92\n\tConcord\tSefcon CAP 500mg 28's pack \n\tConcord\tSefcon-DS Powder For Suspension 250 mg/5 ml 100ml bot \n\tCosmic Chemical Industries Ltd.\tZenaf Paediatric Drops 125mg/1.2ml 15ml bot 55\n\tCosmic Chemical Industries Ltd.\tZenaf Powder for Suspension 125mg/5ml 100ml bot 80\n\tCosmic Chemical Industries Ltd.\tZenaf CAP 250mg 30's pack 195\n\tCosmic Chemical Industries Ltd.\tZenaf CAP 500mg 20's pack 260\n\tCosmo Pharma Ltd.\tCoscef CAP 500mg 20's pack 240\n\tCosmo Pharma Ltd.\tCoscef Suspension 125mg 100ml bot 80\n\tDecent Pharma Ltd.\tRad Powder for Suspension 125mg/5ml 100ml bot 78\n\tDecent Pharma Ltd.\tRad CAP 500mg 32's pack 408\n\tDelta Pharma\tCusef P/D Paediatric Drops 125mg/1.2ml 15ml 50\n\tDelta Pharma\tCusef Powder for Suspension 125mg/5ml 100ml bot 80\n\tDelta Pharma\tCusef CAP 250mg 20's pack 130\n\tDelta Pharma\tCusef CAP 500mg 24's pack 300\n\tDelta Pharma\tCusef DS Inhaler 250mg/5ml 60ml 80\n\tDesh\tMulticef Paediatric Drops 125mg/1.2ml 15ml bot 55\n\tDesh\tMulticef Powder for Suspension 125mg/5ml 100ml bot 75\n\tDesh\tMulticef CAP 250mg 30's pack 210\n\tDesh\tMulticef CAP 500mg 20's pack 261\n\tDoctor's Chemicals Works Ltd.\tSepta Paediatric Drops 125mg/1.2ml 15ml bot 48.90\n\tDoctor's Chemicals Works Ltd.\tSepta Powder for Suspension 125mg/5ml 100ml bot 80\n\tDoctor's Chemicals Works Ltd.\tSepta CAP 500mg 20's pack 240\n\tDolphin\tDolcef Powder for Suspension 125mg/5ml 100ml bot 86\n\tDolphin\tDolcef CAP 500mg 18's pack 225\n\tDrug International Ltd.\tDicef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tDrug International Ltd.\tDicef Powder for Suspension 125mg/5ml 100ml bot 81\n\tDrug International Ltd.\tDicef IV/IM Injection 1gm/vial 1's pack 85\n\tDrug International Ltd.\tDicef CAP 250mg 50's pack 350\n\tDrug International Ltd.\tDicef IV/IM Injection 250mg/vial 1's pack 30\n\tDrug International Ltd.\tDicef CAP 500mg 30's pack 390\n\tDrug International Ltd.\tDicef IV/IM Injection 500mg/vial 1's pack 45\n\tDrug International Ltd.\tDicef Forte Suspension 250mg 100ml bot 120\n\tEdruc Ltd.\tEfrad Powder for Suspension 125mg/5ml 100ml bot 82\n\tEdruc Ltd.\tEfrad CAP 250mg 20's pack 130\n\tEdruc Ltd.\tEfrad CAP 500mg 20's pack 250\n\tEskayef Bangladesh Ltd.\tSk Cef Paediatric Drops 125mg/1.2ml 15ml bot 51\n\tEskayef Bangladesh Ltd.\tSk Cef Powder for Suspension 125mg/5ml 100ml bot 82\n\tEskayef Bangladesh Ltd.\tSk Cef IV/IM Injection 1gm/vial 1's pack 80\n\tEskayef Bangladesh Ltd.\tSk Cef CAP 250mg 48's pack 315.36\n\tEskayef Bangladesh Ltd.\tSk Cef CAP 500mg 30's pack/ 48's pack 390/ 624\n\tEskayef Bangladesh Ltd.\tSk Cef IV/IM Injection 500mg/vial 1's pack 50\n\tEskayef Bangladesh Ltd.\tSk Cef DS Powder for Suspension 250mg/5ml 60ml bot/ 100ml bot 80/ 140\n\tEuro Pharma Ltd.\tCephracap Powder for Suspension 125mg/5ml 100ml bot 80\n\tEuro Pharma Ltd.\tCephracap CAP 500mg 20's pack 250\n\tEuro Pharma Ltd.\tCephracap DS Powder For Suspension 250 mg/5 ml  \n\tEverest\tEvecef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tEverest\tEvecef Powder for Suspension 125mg/5ml 100ml bot 70\n\tEverest\tEvecef CAP 500mg 30's pack 300\n\tG. A. Company Ltd.\tZecef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tG. A. Company Ltd.\tZecef Powder for Suspension 125mg/5ml 100ml bot 80\n\tG. A. Company Ltd.\tZecef CAP 500mg 20's pack 250\n\tGeneral\tVelogen Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tGeneral\tVelogen Powder for Suspension 125mg/5ml 100ml bot 82.31\n\tGeneral\tVelogen CAP 250mg 30's pack 195.60\n\tGeneral\tVelogen CAP 500mg 20's pack 251\n\tGlaxoSmithKline Bangladesh Ltd.\tKefdrin Powder for Suspension 125mg/5ml 100ml bot 86.30\n\tGlaxoSmithKline Bangladesh Ltd.\tKefdrin CAP 250mg 20's pack 141.80\n\tGlaxoSmithKline Bangladesh Ltd.\tKefdrin CAP 500mg 20's pack 272.12\n\tGlobe\tEusef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tGlobe\tEusef Powder for Suspension 125mg/5ml 100ml bot 75\n\tGlobe\tEusef IV/IM Injection 1gm/vial 1's pack 80\n\tGlobe\tEusef CAP 500mg 30's pack 360\n\tGlobe\tEusef IV/IM Injection 500mg/vial 1's pack 50\n\tGlobe\tEusefs DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tGlobex\tGlovocef CAP 500mg 20's pack 250\n\tGlobex\tGlovocef Powder For Suspension 125 mg/5 ml 100ml 80\n\tGonoshasthaya\tG Cefradine Paediatric Drops 125mg/1.2ml 15ml bot 40.15\n\tGonoshasthaya\tG Cefradine Powder for Suspension 125mg/5ml 100ml bot 65.25\n\tGonoshasthaya\tG Cefradine CAP 500mg 20's pack 210.80\n\tHallmark\tBrace Powder for Suspension 125mg/5ml 100ml bot 80\n\tHallmark\tBrace CAP 250mg 28's pack 182.84\n\tHallmark\tBrace CAP 500mg 20's pack/ 28's pack 241/ 337.40\n\tHealthcare\tRocef Powder for Suspension 125mg/5ml 100ml bot 75\n\tHealthcare\tRocef CAP 250mg 30's pack 195\n\tHealthcare\tRocef CAP 500mg 24's pack 300\n\tHealthcare\tRocef DS FORTE Powder for Suspension 250mg/5ml 100ml bot 120\n\tHudson\tMega Cef Powder for Suspension 125mg/5ml 100ml bot 81\n\tHudson\tMega Cef CAP 500mg 30's pack 357\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaceph Paediatric Drops 125mg/1.2ml 15ml bot 55\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaceph Powder for Suspension 125mg/5ml 100ml bot 85\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaceph IV/IM Injection 1gm/vial 1's pack 85\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaceph CAP 250mg 20's pack 136\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaceph CAP 500mg 30's pack 390\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaceph IV/IM Injection 500mg/vial 1's pack 55\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaceph DS Powder for Suspension 250mg/5ml 100ml bot 125\n\tIncepta\tProcef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tIncepta\tProcef Powder for Suspension 125mg/5ml 100ml bot 80\n\tIncepta\tProcef IV/IM Injection 1gm/vial 1's pack 80\n\tIncepta\tProcef CAP 250mg 20's pack 130\n\tIncepta\tProcef IV/IM Injection 250mg/vial 4's pack 120\n\tIncepta\tProcef CAP 500mg 20's pack 250\n\tIncepta\tProcef IV/IM Injection 500mg/vial 4's pack 200\n\tIncepta\tProcef DS FORTE Powder for Suspension 250mg/5ml 100ml bot 120\n\tIndobangla Pharmaceuticals\tIndocef Powder for Suspension 125mg/5ml 100ml bot 80\n\tJayson\tUltrasef Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tJayson\tUltrasef Powder for Suspension 125mg/5ml 100ml bot 80.30\n\tJayson\tUltrasef CAP 250mg 20's pack 135.40\n\tJayson\tUltrasef CAP 500mg 20's pack 250.80\n\tKemiko\tVelox Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tKemiko\tVelox Powder for Suspension 125mg/5ml 100ml bot 80\n\tKemiko\tVelox CAP 250mg 30's pack 195\n\tKemiko\tVelox CAP 500mg 20's pack 260\n\tKumudini Pharma Ltd.\tSefacin Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tKumudini Pharma Ltd.\tSefacin Powder for Suspension 125mg/5ml 100ml bot 85\n\tKumudini Pharma Ltd.\tSefacin CAP 250mg 20's pack 155\n\tKumudini Pharma Ltd.\tSefacin CAP 500mg 20's pack 250\n\tLeon\tLidocef CAP 500mg  \n\tLeon\tLidocef Powder For Suspension 125 mg/5 ml  \n\tLibra Pharmaceuticls Ltd.\tLibradin Powder for Suspension 125mg/5ml 100ml bot 80.30\n\tLibra Pharmaceuticls Ltd.\tLibradin 500 CAP 500mg 28's pack 351.12\n\tMarksman.\tSporin Paediatric Drops 125mg/1.2ml 15ml bot 60\n\tMarksman.\tSporin Powder for Suspension 125mg/5ml 100ml bot 80\n\tMarksman.\tSporin CAP 500mg 20's pack 240\n\tMedicon\tMedicef Powder for Suspension 125mg/5ml 100ml bot 80\n\tMedicon\tMedicef CAP 500mg 20's pack 250\n\tMedimet\tCeframed Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tMedimet\tCeframed Powder for Suspension 125mg/5ml 100ml bot 80\n\tMedimet\tCeframed IV/IM Injection 1gm/vial 1's pack 75\n\tMedimet\tCeframed CAP 250mg 50's pack 350\n\tMedimet\tCeframed IV/IM Injection 250mg/vial 1's pack 33\n\tMedimet\tCeframed CAP 500mg 20's pack 240\n\tMedimet\tCeframed IV/IM Injection 500mg/vial 1's pack 46.50\n\tMillat\tEdin Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tMillat\tEdin Powder for Suspension 125mg/5ml 100ml bot 86\n\tMillat\tEdin CAP 250mg 30's pack 195\n\tMillat\tEdin CAP 500mg 20's pack 250\n\tMillat\tEdin DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tModern\tMefrad Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tModern\tMefrad CAP 500mg 40's pack 251\n\tModern\tMefrad DS Powder for Suspension 250mg/5ml 100ml bot 81\n\tMonicopharma\tSefnin Powder for Suspension 125mg/5ml 100ml bot 80\n\tMonicopharma\tSefnin CAP 250mg 50's pack 325\n\tMonicopharma\tSefnin CAP 500mg 24's pack 300\n\tMystic\tCefad Powder for Suspension 125mg/5ml 100ml bot 86\n\tMystic\tCefad CAP 500mg 20's pack 235\n\tNavana\tSefro Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tNavana\tSefro Powder for Suspension 125mg/5ml 100ml bot 80.29\n\tNavana\tSefro IV/IM Injection 1gm/vial 1's pack 80\n\tNavana\tSefro IV/IM Injection 500mg/vial 1's pack 50\n\tNavana\tSefro HS Powder for Suspension 250mg/5ml 100ml bot 120.44\n\tNipa\tCeflin Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tNipa\tCeflin Powder for Suspension 125mg/5ml 100ml bot 80\n\tNipa\tCeflin CAP 500mg 20's pack 253.20\n\tNIPRO JMI Pharma\tCefracef Powder for Suspension 125mg/5ml 100ml bot 80.31\n\tNIPRO JMI Pharma\tCefracef CAP 250mg 30's pack 195.90\n\tNIPRO JMI Pharma\tCefracef CAP 500mg 24's pack 301.20\n\tNovartis (Bangladesh) Ltd.\tMegacin Paediatric Drops 125mg/ml 15ml drop \n\tNovartis (Bangladesh) Ltd.\tMegacin Syrup 125mg/5ml 100ml bot \n\tNovartis (Bangladesh) Ltd.\tMegacin IV/IM Injection 1gm/vial 1's pack \n\tNovartis (Bangladesh) Ltd.\tMegacin CAP 250mg 20's pack 140\n\tNovartis (Bangladesh) Ltd.\tMegacin CAP 500mg 20's pack 260\n\tNovo Healthcare and Pharma Ltd.\tRevoc Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tNovo Healthcare and Pharma Ltd.\tRevoc Powder for Suspension 125mg/5ml 100ml bot 80\n\tNovo Healthcare and Pharma Ltd.\tRevoc CAP 500mg 24's pack 288\n\tNovo Healthcare and Pharma Ltd.\tRevoc DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tNovus\tCefranov CAP 500mg 24's pack 300\n\tNovus\tCefranov Suspension 125mg 100ml bot 80\n\tOpsonin Pharma\tCephran Paediatric Drops 125mg/ml 15ml bot 50.19\n\tOpsonin Pharma\tCephran Powder for Suspension 125mg/5ml 100ml bot 80\n\tOpsonin Pharma\tCephran IV/IM Injection 1gm/vial 1's pack 80\n\tOpsonin Pharma\tCephran CAP 500mg 30's pack 375\n\tOpsonin Pharma\tCephran IV/IM Injection 500mg/vial 4's pack 216\n\tOpsonin Pharma\tCephran DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tOrganic Health Care\tOrgacef Powder For Suspension 125 mg/5 ml  \n\tOrganic Health Care\tOrgacef CAP 500mg  \n\tOrganic Health Care\tOrgacef CAP 250mg  \n\tOrion Pharma Ltd.\tSefin Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tOrion Pharma Ltd.\tSefin IV/IM Injection 1gm/vial 1's pack 80.25\n\tOrion Pharma Ltd.\tSefin CAP 250mg 20's pack 130.60\n\tOrion Pharma Ltd.\tSefin 250 IV/IM Injection 250mg/vial 1's pack 35.13\n\tOrion Pharma Ltd.\tSefin CAP 500mg 20's pack 251\n\tOrion Pharma Ltd.\tSefin IV/IM Injection 500mg/vial 1's pack 50.19\n\tOrion Pharma Ltd.\tSefin DS Powder for Suspension 250mg/5ml 50ml bot/ 100ml bot 60.23/ 120.45\n\tOrion Pharma Ltd.\tSefin Suspension 125mg 100 ml bot 80.30\n\tPacific\tGigacef Powder for Suspension 125mg/5ml 100ml bot 64\n\tPacific\tGigacef CAP 500mg 20's pack 254\n\tPacific\tGigacef Drops 100mg 15 ml bot 46\n\tPeoples Pharma Ltd.\tCeproval Powder for Suspension 125mg/5ml 100ml bot 70\n\tPeoples Pharma Ltd.\tCeproval CAP 500mg 20's pack 210\n\tPharmadesh Ltd.\tP Cef Paediatric Drops 125mg/1.2ml 15ml bot 50.18\n\tPharmadesh Ltd.\tP Cef Powder for Suspension 125mg/5ml 100ml bot 75.27\n\tPharmadesh Ltd.\tP Cef CAP 500mg 20's pack 241\n\tPharmadesh Ltd.\tP-Cef DS Powder for Suspension 250mg/5ml 100ml bot 120.45\n\tPharmasia Ltd.\tCefasia Powder for Suspension 125mg/5ml 100ml bot 80.31\n\tPharmasia Ltd.\tCefasia CAP 500mg 20's pack 260\n\tPharmasia Ltd.\tCefasia DS Powder for Suspension 250mg/5ml 100ml bot 120.46\n\tPopular\tRoxicef Paediatric Drops 125mg/1.2ml 15ml bot 50.19\n\tPopular\tRoxicef Powder for Suspension 125mg/5ml 100ml bot 80.30\n\tPopular\tRoxicef IV/IM Injection 1gm/vial 1's pack 80.30\n\tPopular\tRoxicef CAP 500mg 20's pack 251\n\tPopular\tRoxicef IV/IM Injection 500mg/vial 1's pack 50.19\n\tPopular\tRoxicef DS Powder for Suspension 250mg/5ml 100ml bot 120.45\n\tPrime\tPricef CAP 500mg  \n\tPrime\tPricef Powder For Suspension 125 mg/5 ml  \n\tRAK\tSephar CAP 500mg 30's pack 375\n\tRAK\tSephar DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tRAK\tSephar PFS Powder for Suspension 125mg/5ml 100ml bot 80\n\tRangs\tLindex Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tRangs\tLindex Powder for Suspension 125mg/5ml 100ml bot 80\n\tRangs\tLindex IV/IM Injection 1gm/vial 1's pack 80\n\tRangs\tLindex CAP 250mg 20's pack 130\n\tRangs\tLindex CAP 500mg 20's pack 250\n\tRangs\tLindex IV/IM Injection 500mg/vial 5's pack 250\n\tRangs\tLindex DS Suspension 250mg 100 ml bot 120\n\tReliance\tRecepra Powder for Suspension 125mg/5ml 100ml bot 75\n\tReliance\tRecepra CAP 500mg 20's pack 240\n\tReman Drug Ltd.\tRecef Paediatric Drops 125mg/1.2ml 15ml bot 55.50\n\tReman Drug Ltd.\tRecef Powder for Suspension 125mg/5ml 100ml bot 85.50\n\tReman Drug Ltd.\tRecef CAP 500mg 20's pack 250\n\tRenata\tPolycef Paediatric Drops 125mg/1.2ml 15ml bot 50.57\n\tRenata\tPolycef Powder for Suspension 125mg/5ml 100ml bot 80.30\n\tRenata\tPolycef CAP 250mg 20's pack 130.40\n\tRenata\tPolycef CAP 500mg 28's pack 351.12\n\tRenata\tPolycef IV/IM Injection 500mg/vial 500ml vial+water 56.52\n\tRenata\tPolycef IV/IM Injection 1gm/vial 1gm vial+water 78.29\n\tRenata\tPolycef IV/IM Injection 250mg/vial 250ml vial+water 38.10\n\tRenata\tPolycef DS Powder for Suspension 250mg/5ml 60ml bot/ 100ml bot 80/ 120.45\n\tRephco\tReocef Powder for Suspension 125mg/5ml 100ml bot 81\n\tRephco\tReocef CAP 500mg 40's pack 560\n\tS. N.\tSeptacef Powder for Suspension 125mg/5ml 100ml bot 78.29\n\tS. N.\tSeptacef CAP 500mg 30's pack 361.50\n\tSanofi Aventis (BD) Ltd.\tSefrad Paediatric Drops 125mg/1.2ml 15ml bot 60.91\n\tSanofi Aventis (BD) Ltd.\tSefrad Powder for Suspension 125mg/5ml 100ml bot 87.31\n\tSanofi Aventis (BD) Ltd.\tSefrad IV/IM Injection 1gm/vial 1gm vaial combipack X 1's pack 90.33\n\tSanofi Aventis (BD) Ltd.\tSefrad CAP 250mg 20's pack 162.20\n\tSanofi Aventis (BD) Ltd.\tSefrad IV/IM Injection 250mg/vial 250mg vaial combipack X 1's pack 35.14\n\tSanofi Aventis (BD) Ltd.\tSefrad CAP 500mg 20's pack 304.60\n\tSanofi Aventis (BD) Ltd.\tSefrad IV/IM Injection 500mg/vial 500mg vaial combipack X 1's pack 50.19\n\tSanofi Aventis (BD) Ltd.\tSefrad DS Powder for Suspension 250mg/5ml 100ml bot 120.45\n\tSeema\tSepra-S Powder for Suspension 125mg/5ml 100ml bot 82\n\tSeema\tSepra-S CAP 500mg 20's pack 300\n\tShamsul Al-Amin\tCephradex CAP 500mg 20's pack 250\n\tShamsul Al-Amin\tCephradex DS Powder for Suspension 250mg/5ml 100ml bot 80\n\tSilco Pharmaceuticlas Ltd.\tBactacef CAP 500mg  \n\tSilco Pharmaceuticlas Ltd.\tBactacef Powder For Suspension 125 mg/5 ml  \n\tSilva\tSicef Powder for Suspension 125mg/5ml 100ml bot 80.31\n\tSilva\tSicef CAP 500mg 20's pack 250.94\n\tSilva\tSicef DS Powder for Suspension 250mg/5ml 60ml bot/ 100ml bot 70.26/ 120.46\n\tSilva\tSicef S Paediatric Drops 125mg/1.2ml 15ml bot 45.17\n\tSomatec\tTydin Paediatric Drops 125mg/1.2ml 15ml bot 48.18\n\tSomatec\tTydin Powder for Suspension 125mg/5ml 100ml bot 78.29\n\tSomatec\tTydin CAP 250mg 20's pack 129.60\n\tSomatec\tTydin CAP 500mg 20's pack 250\n\tSomatec\tTydin DS Powder for Suspension 250mg/5ml 100ml bot 120.46\n\tSonear Ltd.\tKeprad CAP 250mg 40's pack 328\n\tSonear Ltd.\tKeprad CAP 500mg 20's pack 307.60\n\tSquare Cephalosporins Ltd.\tLebac Paediatric Drops 125mg/1.2ml 15ml bot 50.20\n\tSquare Cephalosporins Ltd.\tLebac Powder for Suspension 125mg/5ml 100ml bot 80.30\n\tSquare Cephalosporins Ltd.\tLebac IV/IM Injection 1gm/vial 1's pack 80.30\n\tSquare Cephalosporins Ltd.\tLebac CAP 250mg 18's pack 117.54\n\tSquare Cephalosporins Ltd.\tLebac CAP 500mg 18's pack 376.25\n\tSquare Cephalosporins Ltd.\tLebac IV/IM Injection 500mg/vial 1's pack 50.20\n\tSquare Cephalosporins Ltd.\tLebac Forte Powder for Suspension 250mg/5ml 100ml bot 120.36\n\tSquare\tCephadin Infusion 500mg 1's pack \n\tSupreme\tAdecef Powder for Suspension 125mg/5ml 100ml bot 80\n\tSupreme\tAdecef CAP 500mg 24's pack 300\n\tSupreme\tAdecef DS Powder for Suspension 250mg/5ml 100ml bot 120\n\tSyntho Ltd.\tCefrasyn Powder for Suspension 125mg/5ml 100ml bot 78\n\tSyntho Ltd.\tCefrasyn CAP 500mg 20's pack 260\n\tTechno Drugs Ltd.\tDolocef Powder for Suspension 125mg/5ml 100ml bot 70\n\tTechno Drugs Ltd.\tDolocef IV/IM Injection 1gm/vial 1's pack 80\n\tTechno Drugs Ltd.\tDolocef CAP 250mg 18's pack 108\n\tTechno Drugs Ltd.\tDolocef IV/IM Injection 250mg/vial 1's pack 30\n\tTechno Drugs Ltd.\tDolocef CAP 500mg 18's pack 180\n\tTechno Drugs Ltd.\tDolocef IV/IM Injection 500mg/vial 1's pack 45\n\tUnimed & Unihealth Manufacturers Ltd.\tAncef Paediatric Drops 125mg/1.2ml 15ml bot 50\n\tUnimed & Unihealth Manufacturers Ltd.\tAncef Powder for Suspension 125mg/5ml 100ml bot 85\n\tUnimed & Unihealth Manufacturers Ltd.\tAncef CAP 250mg 20's pack 130\n\tUnimed & Unihealth Manufacturers Ltd.\tAncef CAP 500mg 20's pack 250\n\tUnimed & Unihealth Manufacturers Ltd.\tAncef Forte Powder for Suspension 250mg/5ml 100ml bot 120\n\tWhite Horse Pharma\tWincef CAP 500mg 20's pack 250\n\tZenith\tCephid Powder for Suspension 125mg/5ml 100ml bot 80\n\tZenith\tCephid CAP 250mg 30's pack 195\n\tZenith\tCephid CAP 500mg 20's pack 250\n\tZiska\tCefadin Powder for Suspension 125mg/5ml 100ml bot 80\n\tZiska\tCefadin 1gm IV/IM Injection 1gm/vial 1's pack 80\n\tZiska\tCefadin CAP 500mg 28's pack 336\n\tZiska\tCefadin 500 IV/IM Injection 500mg 1's pack 50\n\tAllied\tAlfradin CAP 500mg  \n\tAllied\tAlfradin DS Powder For Suspension 250 mg/5 ml  \n\tIndication: Pneumonia, Pharyngitis, Susceptible infections, Otitis media, Skin and Skin-Structure Infections, Rheumatic fever, Tonsillitis, Respiratory tract infections, Urinary tract infections, Surgical Prophylaxis, Genitourinary tract infections, Acute prostatitis\n\nDose: Adult: PO Susceptible infections 1-2 g/day in 2-4 divided doses. Max: 4 g/day. \n\nIV/IM Severe infections 2-4 g/day in divided doses. Max: 8 g/day. \n\nSurgical prophylaxis 1-2 g pre-op. Subsequent doses may be given as needed. \nSkin and skin structures and respiratory tract infection: Usual dose is 250 mg every 6 hours or 500 mg every 12 hours. \n\nLobar pneumonia: 500 mg every 6 hours or 1 gm every 12 hours. \nUrinary tract infection: Usual dose is 500 mg every 12 hours. \nGastro-intestinal tract infection: 500 mg three to four times daily. \n\nChildren: Oral: The usual total dose is 25 to 50 mg/kg/day given in 2 to 4 equally divided doses. \n\nInjection: 50 to 100 mg/kg/day in 4 equally divided doses. The usual total dose may be increased up to 200-300 mg/kg/day. \nPerioperative prophylaxis: Recommended dose is 1-2 gm by intramuscular or intravenous route; subsequent parenteral or oral doses are given as appropriate. \n\nRenal impairment: For patients undergoing chronic intermittent haemodialysis: 250 mg may be given at the start of the session, repeated after 6-12 hr, then again 36-48 hr after the initial dose, and again at the start of the next haemodialysis if >30 hr have elapsed since the previous dose.\n\nCrCl (ml/min)	\n>20	        500 mg every 6 hr.\n5-20        250 mg every 6 hr.\n<5	        250 mg every 12 hr. \n\nContra-indication: Hypersensitivity to cefradine or other cephalosporins; porphyria.\n\nSide effects: Diarrhoea, nausea, vomiting; leukopenia, neutropenia, eosinophilia, rash, pruritus; joint pain; increased BUN and creatine; dizziness.\nPotentially Fatal: Pseudomembranous colitis.\n\nPrecaution: Renal impairment; history of penicillin sensitivity; pregnancy; lactation.\n\nMode of action: Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.\n\nPregnancy category: B\n\nInteraction: Increased risk of nephrotoxicity w/ loop diuretics. Decreased renal clearance w/ probenecid.
Cetalkonium Chloride  + Choline Salicylate	\n\n\tGeneral\tBongel Oral Gel   10gm tube 80\n\tIndication: Mouth ulcers, Cold sores, Denture sores, Gum swelling, Apthous ulcer\n\nDose: Adult:Apply 1/2 inch of gel on the sore area. Repeat every 3 hours or as directed.\n\nContra-indication: Haemophilia, haemorrhagic disorders, gout, history of hypersensitivity to salicylates. Severe renal or hepatic impairment; childn <12 yrs. Pregnancy and lactation.\n\nSide effects: Hypersensitivity reactions, skin eruptions, Paroxysmal bronchospasm;  mild chronic salicylate intoxication.\n\nPrecaution: Peptic ulcers, errosive gastritis; asthma, allergic disorders; renal and hepatic impairment; dehydrated patients; \n\nMode of action: Increased toxicity of warfarin. Antacids may reduce salicylate effects. Increased risk of GI bleeding when used with corticosteroids.\n\nPregnancy category: Not Classified\n\nInteraction: Increased toxicity of warfarin. Antacids may reduce salicylate effects. Increased risk of GI bleeding when used with corticosteroids.
Cetirizine Dihydrochloride	\n\n\tACI\tAcitrin TAB dr 10mg 100's pack 301\n\tACI\tAcitrin Paediatric Drops 2.5mg/ml 15 ml bot 25\n\tACI\tAcitrin Syrup 5mg/5ml 60ml bot 25\n\tACI\tAcitrin PD Paediatric Drops 2.5mg/1ml 15ml\n 25.08\n\tAcme Ltd.\tCetizin TAB dr 10mg 100's pack 201\n\tAd-din\tCirizin TAB dr 10mg 100's pack 200\n\tAd-din\tCirizin Syrup 5mg 60 ml bot 18\n\tAexim\tNo-Trol TAB dr 10mg 100's pack 150\n\tAlbion Ltd.\tCetirizine TAB dr 10 mg 100's pack \n\tAlbion Ltd.\tCetirizine Syrup 5 mg/5 ml 60 ml \n\tAlco Pharma\tNoler Syrup 5mg/5ml 60ml bot 16\n\tAlco Pharma\tNoler TAB dr 10mg 50's pack 125\n\tAmbee\tActizen Syrup 5mg/5ml 60ml bot 16.07\n\tAmbee\tActizen TAB dr 10mg 100's pack 203\n\tAmico Ltd.\tDyzin Syrup 5mg/5ml 60ml bot 16\n\tAmico Ltd.\tDyzin TAB dr 10mg 50's pack 125\n\tAmulet\tSetir TAB dr 10mg 100's pack 200\n\tAPC Pharma Ltd.\tCetirizine Syrup 5mg/5ml 60ml bot 16\n\tAPC Pharma Ltd.\tCetirizine TAB dr 10mg 100's pack 250\n\tAristopharma\tRhinil Syrup 5mg/5ml 60ml bot 20\n\tAristopharma\tRhinil TAB dr 10mg 100's pack 250\n\tAsiatic Ltd.\tAsitrol Syrup 5mg/5ml 60ml bot 16\n\tAsiatic Ltd.\tAsitrol TAB dr 10mg 100's pack 200\n\tAstra Biopharmaceuticals Ltd.\tCetriz TAB dr 10mg 30's pack 60\n\tBelsen\tB-cet TAB dr 10mg 100's pack 250\n\tBelsen\tB-cet Syrup 5mg 60 ml bot 25\n\tBengal Drugs & Chemical Works Pharm. Ltd.\tAlater TAB dr 10mg  \n\tBenham\tCetriben TAB dr 10mg  \n\tBeximco\tAtrizin Paediatric Drops 2.5mg/ml 15ml bot 22\n\tBeximco\tAtrizin Syrup 5mg/5ml 60ml bot 16\n\tBeximco\tAtrizin TAB dr 10mg 100's pack/150's pack 250 / 375\n\tBristol Pharma Ltd.\tBptrol TAB dr 10mg 100's pack 200\n\tCentral.\tAntrin TAB dr 10mg 100's pack 250\n\tChemist Ltd.\tCetril Syrup 5mg/5ml 60ml bot 17.19\n\tChemist Ltd.\tCetril TAB dr 10mg 100's pack 252\n\tConcord\tAlatin TAB dr 10mg 50's pack 100\n\tCosmic Chemical Industries Ltd.\tCetzin Syrup 5mg/5ml 60ml bot 15\n\tCosmic Chemical Industries Ltd.\tCetzin TAB dr 10mg 100's pack 250\n\tCosmo Pharma Ltd.\tCetra TAB dr 10mg 100's pack 202\n\tDecent Pharma Ltd.\tFlustat Syrup 5mg/5ml 60ml bot 16\n\tDecent Pharma Ltd.\tFlustat TAB dr 10mg 100's pack 200\n\tDelta Pharma\tCTZ Tab TAB dr 10mg 100's pack 100\n\tDesh\tZyrtec TAB dr 10mg 100's pack 150\n\tDoctor Tims\tCetrol TAB dr 10mg  \n\tDrug International Ltd.\tCetrin Syrup 5mg/5ml 60ml \n\tDrug International Ltd.\tCetrin TAB dr 10mg 100's pack 300\n\tEdruc Ltd.\tEtizin Syrup 5mg/5ml 60ml bot 16\n\tEdruc Ltd.\tEtizin TAB dr 10mg 100's pack 252\n\tEskayef Bangladesh Ltd.\tOntin Syrup 5mg/5ml 60ml bot 20\n\tEskayef Bangladesh Ltd.\tOntin TAB dr 10mg 100's pack 250\n\tEskayef Bangladesh Ltd.\tOntin F/C TAB dr 10mg 100's pack 250\n\tEuro Pharma Ltd.\tTiz TAB dr 10mg 100's pack 275\n\tEuro Pharma Ltd.\tTiz Syrup 5mg/5ml 60ml bot 20\n\tG. A. Company Ltd.\tRizin Syrup 5mg/5ml 60ml bot 16\n\tG. A. Company Ltd.\tRizin TAB dr 10mg 50's pack 125\n\tGlobe\tTrin Syrup 5mg/5ml 60ml bot 15\n\tGlobe\tTrin TAB dr 10mg 100's pack 250\n\tGlobex\tRinzin Syrup 5mg/5ml  \n\tGlobex\tRinzin TAB dr 10mg 100's pack 300\n\tHallmark\tProler Syrup 5mg/5ml 60ml bot 16.07\n\tHallmark\tProler TAB dr 10mg 50's pack 125.50\n\tHudson\tHI-Trol Syrup 5mg/5ml 60ml bot 16\n\tHudson\tHi-Trol TAB dr 10mg 100's pack 150\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNosemin Syrup 5mg/5ml 60ml bot 20\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNosemin TAB dr 10mg 100's pack 300\n\tIndobangla Pharmaceuticals\tI-Cet Syrup 5mg/5ml 60ml bot 16\n\tIndobangla Pharmaceuticals\tI-Cet TAB dr 10mg 100's pack 250\n\tInnova Phrmaceutical Ltd.\tInozin F/C TAB dr 10mg  \n\tKemiko\tAllernil Syrup 5mg/5ml 60ml bot 25\n\tKemiko\tAllernil TAB dr 10mg 100's pack 250\n\tKumudini Pharma Ltd.\tOrgy Syrup 5mg/5ml 60ml bot 20\n\tKumudini Pharma Ltd.\tOrgy TAB dr 10mg 100's pack 250\n\tLeon\tCelozin TAB dr 10mg  \n\tLeon\tCelozin Syrup 5 mg/5 ml  \n\tMarksman.\tAllercet Syrup 5mg/5ml 60ml bot 14.80\n\tMarksman.\tAllercet TAB dr 10mg 100's pack 250\n\tMedicon\tCezin Syrup 5mg/5ml 60ml bot 16\n\tMedicon\tCezin TAB dr 10mg 100's pack 250\n\tMedimet\tHistacet Syrup 5mg/5ml 50ml bot 16\n\tMedimet\tHistacet TAB dr 10mg 100's pack 200\n\tMonicopharma\tMoset TAB dr 10mg 50's pack 125\n\tMonicopharma\tMoset Syrup 5mg/5ml 60ml bot 16\n\tMystic\tMystacin TAB dr 10mg 100's pack 250\n\tNavana\tTrizin Syrup 5mg/5ml 60ml bot 16.06\n\tNavana\tTrizin TAB dr 10mg 100's pack 251\n\tNipa\tCizin Syrup 5mg/5ml 60ml bot 15.17\n\tNipa\tCizin TAB dr 10mg 100's pack 200\n\tNIPRO JMI Pharma\tArcet TAB dr 10mg 100's pack 200\n\tNIPRO JMI Pharma\tArcet Syrup 5mg/5ml 60ml bot 25\n\tNovus\tCetrimax TAB dr 10mg 100's pack 250\n\tOpsonin Pharma\tCitin Syrup 5mg/5ml 60ml bot 16\n\tOpsonin Pharma\tCitin TAB dr 10mg 100's pack 250\n\tOrganic Health Care\tCZ TAB dr 10mg 100's pack 250\n\tOrion Pharma Ltd.\tRiz Syrup 5mg/5ml 60ml bot 20\n\tOrion Pharma Ltd.\tRiz TAB dr 10mg 100's pack 300\n\tOyster\tTerzin TAB dr 10mg  \n\tPharmadesh Ltd.\tOpzin TAB dr 10mg 100's pack 150\n\tPharmadesh Ltd.\tOpzin Syrup 5mg  60ml bot 22\n\tPopular\tAlarex Syrup 5mg/5ml 60ml bot 16.07\n\tRangs\tSartec Syrup 5mg/5ml 60ml bot 20\n\tRangs\tSartec TAB dr 10mg 50's pack 125\n\tReliance\tCetjet TAB dr 10mg 100's pack 200\n\tReman Drug Ltd.\tAletrin TAB dr 10mg 100's pack 250\n\tRenata\tTiramin TAB dr 10mg 100's pack 254\n\tRephco\tDyno TAB dr 10mg 100's pack 200\n\tS. N.\tCeritec TAB dr 10mg 100's pack 250\n\tSeema\tCipzin Syrup 5mg/5ml 60ml bot 20\n\tSeema\tCipzin TAB dr 10mg 100's pack 200\n\tShamsul Al-Amin\tSatrol TAB dr 10mg 100's pack 200\n\tSilva\tCesil Syrup 5mg/5ml 60ml bot 16.07\n\tSilva\tCesil TAB dr 10mg 100's pack 250.94\n\tSomatec\tProcet Syrup 5mg/5ml 60ml bot 20\n\tSomatec\tProcet TAB dr 10mg 100's pack 201\n\tSquare\tAlatrol Paediatric Drops 2.5mg/ml 15 ml bot 25\n\tSquare\tAlatrol Syrup 5mg/5ml 60ml bot 25\n\tSquare\tAlatrol TAB dr 10mg 100's pack 300\n\tSyntho Ltd.\tSytrol Syrup 5mg/5ml 60ml bot 16\n\tSyntho Ltd.\tSytrol TAB dr 10mg 100's pack 250\n\tUnimed & Unihealth Manufacturers Ltd.\tZinal Syrup 5mg/5ml 60ml bot 16\n\tUnimed & Unihealth Manufacturers Ltd.\tZinal TAB dr 10mg 50's pack 125\n\tVirgo\tVircet Syrup 5mg/5ml 60ml bot 20\n\tWhite Horse Pharma\tSarcet-10 TAB dr 10mg 100's pack 250\n\tZenith\tCitizen TAB dr 10mg 100's pack 200\n\tIndication: Allergic rhinitis, Hay fever, Allergies, Urticaria\n\nDose: Tablet:\nOral\nAllergic conditions\nAdult: 10 mg once daily or 5 mg bid.\nChild: 6-23 mth 2.5 mg once daily increased to max of 2.5 mg bid in childn >12 mth; 2-5 yr 5 mg once daily or in 2 divided doses; >6 yr 10 mg once daily or in 2 divided doses.\n\nElderly: Initially, 5 mg once daily.\nHepatic impairment: Initially, 5 mg once daily.\n\nSyrup:\nAdults and children over 6 years: 2 teaspoon once daily or 1 teaspoon twice daily.\nChildren 2-6 years: 1 teaspoonful once daily or 1/2 teaspoon twice daily.\n\nContra-indication: Hypersensitivity; lactation.\n\nSide effects: Somnolence, insomnia, malaise, headache, dizziness; GI discomfort, dry mouth, abdominal pain, diarrhoea, nausea, vomiting; occasional hypersensitivity; epistaxis, pharyngitis, bronchospasm.\n\nPrecaution: Hepatic or renal impairment; elderly; tasks requiring mental alertness eg, driving or operating heavy machinery; pregnancy.\n\nMode of action: Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).\n\nPregnancy category: B\n\nInteraction: Additive CNS depression when administered concomitantly w/ other CNS depressants (e.g. sedatives, tranquilisers).
Cetrimide 0.5% + Chlorhexidine Hydrochloride 0.1%	\n\n\tACI\tSavlon Cream   15gm tube/30ml tube 12 /22\n\tMillat\tHyginol Cream   30ml tube/60ml tube 22 / 30\n\tMystic\tClenol Cream   30ml tube 19\n\tOpsonin Pharma\tKevilon Cream  12.5mg/1mg 30ml tube 18\n\tIndication: Insect bites, Sunburn, Disinfection, Cuts, Scratches, Blisters, Grazes, Nappy rash, Cracked and itchy skin, Cleansing and irrigating the skin or dirty wounds\n\nDose: Adult and children: Apply 2-3 times daily or as directed.\n\nContra-indication: Not to be used in the eye, ear, mucous membrane or body cavities.\n\nSide effects: Repeated application may lead to skin irritation.\n\nPrecaution: Prolonged and repeated use may increase risk of hypersensitivity reactions. Blood, soap, cotton or other organic matter may decrease antibacterial efficacy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Cetrimide  + Chlorhexidine Gluconate	\n\n\tACI\tSavlon Solution   112ml bot/1 liter 23/110\n\tApex\tHibisol Solution   56ml bot / 112ml bot \n\tEskayef Bangladesh Ltd.\tWelon Solution   500ml bot/1 liter bot 85/145\n\tGonoshasthaya\tG Antiseptic Solution   100ml bot 16.08\n\tGreenland\tDecon Hospitla Solution (15 gm + 1.5 gm)/100 ml  \n\tGreenland\tDecon Liquid Solution 3 gm + 300 mg/100 ml  \n\tIndobangla Pharmaceuticals\tSeplon Solution   56ml bot / 110ml bot  18 / 21\n\tMillat\tHyginol Solution   50ml bot/100ml bot 17/26\n\tSquare\tSepnil Solution   50ml bot/100ml bot 11/16.63\n\tIndication: Disinfection,Cleansing and irrigating the skin or dirty wounds\n\nDose: Adult: Topical Per mL of liquid contains cetrimide 30 mg and chlorhexidine 3 mg: Use as directed.\n\nContra-indication: Not to be used in the eye, ear, mucous membrane or body cavities.\n\nSide effects: Repeated application may lead to skin irritation.\n\nPrecaution: Prolonged and repeated use may increase risk of hypersensitivity reactions. Blood, soap, cotton or other organic matter may decrease antibacterial efficacy.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Chloramphenicol	\n\n\tEastern\tEpamycetin CAP 250mg 100's pack 250\n\tEdruc Ltd.\tEdrumycetin CAP 250mg 100's pack 250\n\tHudson\tChloramphenicol CAP 250mg 100's pack 220\n\tNipa\tChlorphen CAP 250mg 100's pack 200\n\tOpsonin Pharma\tOpsomycetin Suspension 125mg/5ml 60ml bot 16\n\tOpsonin Pharma\tOpsomycetin CAP 250mg 100's pack\n 250\n\tIndication: Tetracycline-resistant cholera, typhoid, brain abscesses, meningitis, Granuloma inguinale, Anthrax, Listeriosis, Gas gangrene, Whipple's disease, gastroenteritis, melioidosis, Plague, Psittacosis, Q fever, Tularaemia							\n\n\nDose: Adult: PO Susceptible infections 50 mg/kg/day in 4 divided doses, may increase to 100 mg/kg/day in more severe infections. \n\nChild: Premature and full-term neonates: 25 mg/kg/day in 4 divided doses. Full-term infants >2 wk: 50 mg/kg/day in 4 divided doses. Children: 50 mg/kg/day in 4 divided doses increased to 100 mg/kg/day for meningitis or severe infections.\nElderly:\nHepatic impairment: Dose reduction may be required. \n\nContra-indication: History of hypersensitivity or toxic reaction to the drug; pregnancy, lactation; porphyria; parenteral admin for minor infections or as prophylaxis; preexisting bone marrow depression or blood dyscrasias.\n\nSide effects: GI symptoms; bleeding; peripheral and optic neuritis, visual impairment, blindness; encephalopathy, confusion, delirium, mental depression, headache. Haemolysis in patients with G6PD deficiency. \nPotentially Fatal: Bone marrow suppression and irreversible aplastic anaemia. Neutropenia, thrombocytopenia. Grey baby syndrome. Rarely, anaphylaxis.\n\nPrecaution: Impaired renal or hepatic function; premature and full-term neonates. Monitor plasma concentrations to avoid toxicity.\n\nMode of action: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.\n\nPregnancy category: C\n\nInteraction: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
Chloramphenicol 0.5%  Eye drops	\n\n\tACI\tIcol E/E Eye/Ear Drops  0.5% 10 ml bot 34.50\n\tAcme Ltd.\tA Phenicol Eye Drops   10 ml bot 34\n\tApex\tOcubac Eye Drops   10 ml bot 25\n\tAristopharma\tAristophen Eye Drops   10 ml bot 34.40\n\tAsiatic Ltd.\tOpticol Eye Drops   10 ml bot 34.39\n\tBeximco\tOcutrex Eye Drops   10 ml bot 34.39\n\tChemist Ltd.\tChemophenicol Eye Drops   10 ml bot 34\n\tDrug International Ltd.\tOpthacol Eye Drops   10 ml bot 30\n\tEdruc Ltd.\tEdrumycetin Eye Drops   10 ml bot 34\n\tG. A. Company Ltd.\tSupraphen Eye Drops   10 ml bot 34.27\n\tGeneral\tOcuclor Eye Drops   10ml bot 34.27\n\tGlobe\tGlophen Eye Drops 5 mg/ml  \n\tGonoshasthaya\tG Chloramphenicol E/E Eye Drops   10 ml bot 20.08\n\tHealthcare\tEyephen Eye Drops 5 mg/ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tCloram Eye Drops  5 mg/ml 10 ml bot 34.39\n\tIncepta\tI-Guard 0.5 Eye Drops  0.5% 10 ml bot 34.40\n\tJayson\tOptichlor Eye Drops   10 ml bot 20.23\n\tKemiko\tRamphen Eye Drops   10 ml bot 34.27\n\tNavana\tOcuram Eye Drops   10ml drop 34\n\tNipa\tChlorphen Eye Drops   10 ml bot 30\n\tNovartis (Bangladesh) Ltd.\tSpersanicol E/E Eye/Ear Drops   10ml bot 25.81\n\tOpso Saline Ltd.\tOpsophenicol Eye Drops   10 ml bot 34.30\n\tOpsonin Pharma\tConicol Eye/Ear Drops 5 mg/ml  \n\tPopular\tOptabac Eye Drops  5 mg/ml 10 ml bot 34.27\n\tReman Drug Ltd.\tOptaphenicol Eye Drops   10 ml bot 34\n\tRenata\tChloramex E/E Eye/Ear Drops 0.5% 10ml bot 25.29\n\tRephco\tNicol Eye Drops   10ml bot 25\n\tSquare\tSQ-Mycetin Eye Drops 5 mg/ml 10 ml drop 34.40\n\tIndication: Bacterial Conjunctivitis\n\nDose: Ocular infections\nAdult: Instill 1 drop of a 0.5% solution every 2 hr. Increase dosage interval upon improvement. To continue treatment for at least 48 hr after complete healing. Reduce dose once symptoms are controlled or apply a 1% ointment 3-4 times daily.\nRenal impairment: Dose reduction may be required.\nHepatic impairment: Dose reduction may be required.\n\n\nContra-indication: History of hypersensitivity or toxic reaction to the drug; Herpes simplex and other virul conditions of the eye or ear, mycosis.\n\nSide effects: Ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. \n\nPrecaution: Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. \n\nMode of action: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.\n\nPregnancy category: C\n\nInteraction: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
Chloramphenicol 0.5% + Dexamethasone 0.1%  Eye/Ear drop	\n\n\tACI\tDenicol E/E Drops 0.1%+0.5% 5ml drop 65.45\n\tAcme Ltd.\tA-Phenicol-D E/E Drops   5  ml drop 70\n\tAcme Ltd.\tA- Phenical D Eye drops  5ml \n\tApex\tOcubac-D E/E Drops   5  ml drop 60\n\tAristopharma\tSonexa-C E/E Drops  5ml drop 70\n\tAsiatic Ltd.\tOpticol-D E/E Drops  5ml drop 70\n\tBeximco\tChlormet E/E Drops   5ml bot 70\n\tDrug International Ltd.\tStenicol E/E Drops  5ml drop 70\n\tG. A. Company Ltd.\tDexchlor E/E Drops   5ml bot 70\n\tGeneral\tDexagen C E/E Drops  5ml drop 70\n\tGlobe\tGlophen-D Eye Drops (5 mg + 1 mg)/ml  \n\tHealthcare\tEyephen Plus Eye Drops (5 mg + 1 mg) / ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tCloram D E/E Drops  500 mg + 100 mg/100 ml 5  ml drop 70\n\tIncepta\tDexagurd E/E Drops  5ml drop 60\n\tJayson\tDecalor E/E Drops  5ml drop 50 .20\n\tKemiko\tRamdex E/E Drops   5  ml drop 70\n\tNavana\tCloradex E/E Drops   5ml drop 70\n\tNavana\tStedex-C Eye Drops 5mg + 1mg 5ml bot \n\tNipa\tChlorodex E/E Drops  5ml drop 70 \n\tOpso Saline Ltd.\tDexacol E/E Drops   5  ml drop 65\n\tPopular\tOrbidex C Eye Drops 0.5% + 0..1% 5ml drop 61.60\n\tReman Drug Ltd.\tOptadex E/E Drops  5ml drop 70\n\tRephco\tNicodex E/E Drops  5ml drop 70\n\tSquare\tDexonex-C E/E Drops  5ml bot 70\n\tIndication: Allergic conjunctivitis, Acute purulent conjunctivitis, Corneal ulceration, Keratitis disciformis, Post-herpetic keratitis, Allergic blepharitis, Acute and chronic iritis, Iridocyclitis, Otitis externa, infective and inflammatory ear infections.\n\nDose: Ocular infections Adult: Instill 1 drop of asolution every 2 hr. Increase dosage interval upon improvement. To continue treatment for at least 48 hr after complete healing. \n\n Otic/Aural Otitis externa Adult: Instill 2-3 drops into the ear bid-tid. \n\nContra-indication: History of hypersensitivity or toxic reaction to the drug; Perforated ear drum. Herpes simplex and other virul conditions of the eye or ear, mycosis.\n\nSide effects: Ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. Ear drops: Ototoxicity.\n\nPrecaution: Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. \n\nMode of action: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.\n\nPregnancy category: C\n\nInteraction: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
Chloramphenicol 5% + Lidocaine Hydrochloride 1%  Ear drops	\n\n\tEdruc Ltd.\tOto Plus Ear Drops   10 ml drop 20\n\tG. A. Company Ltd.\tSupraphen PLUS Ear Drops   10 ml drop 20\n\tNipa\tChlorphen 			 Ear Drops  10 ml bot  30 	\n\tIndication: Acute bacterial ear infections\n\nDose: Otic/Aural Otitis externa Adult: Instill 2-3 drops into the ear bid-tid. \n\nContra-indication: History of hypersensitivity or toxic reaction to the drug; Perforated ear drum. Herpes simplex and other virul conditions of the eye or ear, mycosis.\n\nSide effects: Ear drops: Ototoxicity.\n\nPrecaution: Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. \n\nMode of action: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.\nMay increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.\n\nPregnancy category: A\n\nInteraction: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.\nMay increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
Chloramphenicol 1%  Eye prep	\n\n\tAcme Ltd.\tA Phenicol Eye Ointment   5gm tube 11.67\n\tApex\tOcubac Eye Ointment   10ml bot 25\n\tAristopharma\tAristophen Eye Ointment   3gm tube 8.37\n\tAsiatic Ltd.\tOpticol Eye Ointment   3gm tube 8.34\n\tG. A. Company Ltd.\tSupraphen Eye Ointment   5gm tube 12.50\n\tGeneral\tOcuclor Eye Ointment   3gm tube 8.50\n\tGonoshasthaya\tG Chloramphenicol Eye Ointment   5gm tube 8.03\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCloram Eye Ointment  1 gm/100 gm 5gm tube 13\n\tJayson\tOptichlor Eye Ointment   5gm tube 12.04\n\tNipa\tChlorphen Eye Ointment   3gm tube 8.50\n\tOpso Saline Ltd.\tOpsophenicol Eye Ointment   3gm tube 8.53\n\tReman Drug Ltd.\tOptaphenicol Eye Ointment   3gm tube 10\n\tIndication: Bacterial Conjunctivitis\n\nDose: Ocular infections Adult: Apply a 1% ointment 3-4 times daily. \nRenal impairment: Dose reduction may be required. Hepatic impairment: Dose reduction may be required. \n\nContra-indication: History of hypersensitivity to the drug; Herpes simplex and other virul conditions of the eye, mycosis.\n\nSide effects:  Ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. \n\nPrecaution: Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. \n\nMode of action: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.\n\nPregnancy category: C\n\nInteraction: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
Chloramphenicol  Ear drops	\n\n\tACI\tIcol E/E 	 Ear Drops 0.5% 10ml bot  34.40 \n\tBeximco\tOcutrex Ear Drops 0.5% 10ml bot  34.39\n\tG. A. Company Ltd.\tSupraphen 5% Ear Drops 5%/10% 10 ml drop 20\n\tIncepta\tI-Guard 0.5 Ear Drops 0.5% 10ml bot  34.40 \n\tNavana\tOcuram Ear Drops 0.5% 10ml bot  34\n\tOpso Saline Ltd.\tOpsophenicol E/E Ear Drops 5% 10ml bot  20\n\tRenata\tChloramex E/E Ear Drops 0.5% 10ml bot  25.29 	\n\tSquare\tSQ-Mycetin Ear Drops 0.5% 10ml bot  34.40\n\tIndication: Bacterial Ear infections\n\nDose:  Otic/Aural Otitis externa Adult: Instill 2-3 drops of a 5% solution into the ear bid-tid. \n\nRenal impairment: Dose reduction may be required. Hepatic impairment: Dose reduction may be required.\n\nContra-indication: History of hypersensitivity to the drug; Perforated ear drum. Herpes simplex and other virul conditions of the ear, mycosis.\n\nSide effects: Ear drops: Ototoxicity.\n\nPrecaution: Avoid prolonged use. Discontinue immediately if local hypersensitivity reactions occur. \n\nMode of action: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.\n\nPregnancy category: C\n\nInteraction: Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of chloramphenicol. Impairs the action of oral contraceptives.\nPotentially Fatal: Increases the effect of oral anticoagulants, oral hypoglycaemic agents, phenytoin. Avoid concomitant administration with drugs that depress bone marrow function.
Chlorhexidine Gluconate 0.2% Gargle	\n\n\tACI\tOralon Solution  0.2% 100ml bot 50.15\n\tUnimed & Unihealth Manufacturers Ltd.\tOral-C Mouthwash  125ml bot 75\n\tIndication: Gingivitis, Mouth sore\n\nDose: Adult: Mouth/throat Oral hygiene; Gingivitis As 0.2% soln: Rinse w/ 10 mL for about 1 min bid. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Skin sensitivity; mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Avoid contact w/ middle ear or sensitive tissues and eyes. Do not inject or use in body cavities.Avoid eating, drinking, or brushing your teeth just after using this medication\n\nMode of action: Soaps, other anionic agents, borates, bicarbonates, carbonates, chlorides, citrates, nitrates, phosphates & sulfates.\n\nPregnancy category: B\n\nInteraction: Soaps, other anionic agents, borates, bicarbonates, carbonates, chlorides, citrates, nitrates, phosphates & sulfates.
Chlorhexidine Gluconate 0.25% + Lidocaine Hydrochloride	\n\n\tIndication: Acute sore throats\n\nDose: Adult: Mouth/throat Oral hygiene;  As gel: Brush teeth w/ 1 inch of gel once or bid for about 1 min. \n\nContra-indication: Hypersensitivity to any of the ingredients.\n\nSide effects: Skin sensitivity; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Avoid contact w/ sensitive tissues and eyes. Do not use in body cavities.Avoid eating, drinking, or brushing your teeth just after using this medication\n\nMode of action: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.\n\nPregnancy category: B\n\nInteraction: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
Chlorhexidine Gluconate	\n\n\tACI\tHexisol Hand Rub  0.5% 50ml bot/250ml bot 40.12/130.39\n\tACI\tHexiscrub Solution 4% 250ml 300\n\tACI\tHexisol (with Dispenser) Solution 0.5% 500ml bot/250ml bot 215.65/140.42\n\tACI\tHexicord Solution 7.1% 10ml bot 30.09\n\tAristopharma\tXisol Hand Rub   50ml bot / 250ml bot 30 / 105\n\tEskayef Bangladesh Ltd.\tHandirub Hand Rub   50ml bot/200ml bot 30/80\n\tGeneral\tHandiwash Solution 0.5% 50ml bot / 250ml bot  30.11 / 105.40\n\tGreenland\tHandisol Liquid Solution 2.5 gm/100 ml  \n\tGreenland\tHandscrub Solution 4 gm/100 ml  \n\tGreenland\tDecon Mother Solution 1 gm/100 ml  \n\tMedicon\tOtsol Hand Rub   50ml bot/250ml bot 30 / 105\n\tMedimet\tSafwash Hand Rub   50ml bot/250ml bot 31/105\n\tOpsonin Pharma\tKevirub Hand Rub   50ml bot/250ml bot 31/105\n\tPharmasia Ltd.\tHexasia Hand Rub   50ml bot/250ml bot 30 /100.38\n\tSilva\tSafetisol Hand Rub 0.5% 50ml bot / 200ml bot  125.47 / 105.40\n\tSquare\tGermisol Hand Rub  500 mg/100 ml 50ml bot / 250ml bot 31.12 / 105.40\n\tUnimed & Unihealth Manufacturers Ltd.\tOragel C Gel 1%  \n\tIndication: Disinfection of clean and intact skin. Pre-operative hand disinfection\n\nDose:  For external use only. Adults: Pre-operative surgical hand disinfection: Dispense 5 ml of solution and spread thoroughly over both hands and forearms, rubbing vigorously. When dry apply a further 5 ml and repeat the procedure. \n\nAntiseptic hand disinfection on the ward: Dispense 3 ml of solution and spread thoroughly over the hands and wrists rubbing vigorously until dry. Disinfection of patients' skin: Prior to surgery apply the solution to a sterile swab and rub vigorously over the operation site for a minimum of 2 minutes. \n\nChlorhexidine Gluconate is also used for preparation of the skin prior to invasive procedures such as venepuncture. Elderly and children: There are no special dosing regimes for children and the elderly. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Skin sensitivity; irritation. \n\nPrecaution: Avoid contact w/ middle ear or sensitive tissues and eyes. Do not inject or use in body cavities.\n\nMode of action: Soaps, other anionic materials, K iodide.\n\nPregnancy category: B\n\nInteraction: Soaps, other anionic materials, K iodide.
Chlorhexidine Gluconate 1 %  Oral prep	\n\n\tACI\tHexitane Cream  1% 60ml bot 90\n\tACI\tOralon Gel  1% 30ml tube 55.17\n\tIndication: Dental and gum infection.\n\nDose: Adult: As cream/gel: Apply to the affected area 2-3 times daily or as directed by physician.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Local irritation. Chlorhexidine gluconate can stain teeth, dentures, tooth restorations, your tongue, or the inside of your mouth.\n\nPrecaution: Avoid eating, drinking, or brushing your teeth just after using this medicationAvoid contact w/ eyes. Do not inject or use in body cavities.\n\nMode of action: Soaps, other anionic agents, borates, bicarbonates, carbonates, chlorides, citrates, nitrates, phosphates & sulfates.\n\nPregnancy category: B\n\nInteraction: Soaps, other anionic agents, borates, bicarbonates, carbonates, chlorides, citrates, nitrates, phosphates & sulfates.
Chloroquine Phosphate	\n\n\tACI\tAvloquin TAB dr 250mg 100's pack 122\n\tACI\tAvloquin Syrup 125mg/5ml 60ml bot 14.91\n\tAexim\tUniquin TAB dr 250mg 100's pack 100\n\tAlbion Ltd.\tMalorine Syrup 1 mg/ 100 ml 60 ml \n\tGlobe\tQuinolex TAB dr 250mg 100's pack 100\n\tGlobe\tQuinolex Syrup 80mg/5ml 60ml bot 12\n\tGonoshasthaya\tG Chloroquine TAB dr 250mg 100's pack/100o's pot 100/910\n\tGonoshasthaya\tG Chloroquine Syrup 80mg/5ml 60ml bot 14.87\n\tHudson\tClit Syrup 125mg/5ml 60ml bot/100ml bot 12/22\n\tHudson\tClit TAB dr 250mg 100's pack 120\n\tJayson\tJasochlor TAB dr 250mg 100's pack 121\n\tJayson\tJasochlor Syrup 80mg/5ml 60ml bot 14.87\n\tOpsonin Pharma\tC-quin TAB dr 250mg 50's pack \n\tOpsonin Pharma\tC-quin Syrup 50 mg/5ml 60ml bot \n\tZenith\tZenoquine TAB dr 250mg 100's pack 130\n\tZenith\tZenoquine Syrup 80mg/5ml 60ml bot 14.65\n\tIndication: Rheumatoid arthritis, Malaria, Systemic lupus erythematosus, SLE, Amoebiasis\n\nDose: Adult: PO Acute malaria As base: Initial: 600 mg, then 300 mg 6-8 hr later on day 1. Continue w/ 300 mg/day on days 2 and 3. \n\nMalaria prophylaxis As base: 300 mg/wk, starting 1 wk before exposure, continue throughout on a wkly basis and for at least 4 wk after exposure. \n\nDiscoid and SLE; Rheumatoid arthritis As base: Initial: 150 mg/day. Max: 2.5 mg/kg/day. \n\nHepatic amoebiasis As base: W/ emetine or dehydroemetine: 600 mg/day for 2 days then 300 mg/day for 2-3 wk. \n\nIV Severe malaria As base: 25 mg/kg given in several infusions over 30-32 hr.\n\nContra-indication: Hypersensitivity, known or suspected resistant P. falciparum infection, porphyria, retinal damage, concurrent hepatotoxic drugs.\n\nSide effects: Retinopathy, hair loss, photosensitivity, tinnitus, myopathy (long-term therapy). Psychosis, seizures, leucopenia and rarely aplastic anaemia, hepatitis, GI upsets, dizziness, hypokalaemia, headache, pruritus, urticaria, difficulty in visual accommodation.\nPotentially Fatal: Cardiac and respiratory arrest, CV collapse, convulsions, coma.\n\nPrecaution: Psoriasis, diseases of the haematopoietic or CNS systems, myasthenia gravis, hepatic or renal impairment, G6PD deficiency, epilepsy, childn. Pregnancy and lactation. Slow infusion is used upon IV admin to prevent cardiotoxicity.\n\nMode of action: Concomitant therapy with phenylbutazone predisposes to dermatitis, antagonises effect of neostigmine and pyridostigmine, reduces bioavailability of ampicillin. Cimetidine inhibits metabolism of chloroquine raising plasma levels.\nPotentially Fatal: Increased risks of inducing ventricular arrhythmias with halofantrine or other arrhythmogenic drugs eg, amiodarone. Increased risk of convulsions with mefloquine. Antacids reduce absorption of chloroquine hence admin should be separated by 4 hrs. Rarely Stevens-Johnson syndrome, when administered with pyrimethamine/sulphadoxine. Increased toxicity with quinacrine\n\nPregnancy category: C\n\nInteraction: Concomitant therapy with phenylbutazone predisposes to dermatitis, antagonises effect of neostigmine and pyridostigmine, reduces bioavailability of ampicillin. Cimetidine inhibits metabolism of chloroquine raising plasma levels.\nPotentially Fatal: Increased risks of inducing ventricular arrhythmias with halofantrine or other arrhythmogenic drugs eg, amiodarone. Increased risk of convulsions with mefloquine. Antacids reduce absorption of chloroquine hence admin should be separated by 4 hrs. Rarely Stevens-Johnson syndrome, when administered with pyrimethamine/sulphadoxine. Increased toxicity with quinacrine
Chloroxylenol 0.3% + Triclosan 0.3%	\n\n\tReckitt & Benckiser Bangladesh Ltd.\tDettol Cream   56ml bot 18\n\tIndication: Insect bites, Sunburn, Cuts, Scratches, Abrasions, Disinfection of the skin, Minor burns, Sore lips, Minor skin infections ,Chapped roughened hands,Cracked itchy skin\n\nDose:     Adults and children 2 years of age and older: apply to the affected area no more than 3 to 4 times daily\n    children under 2 years of age; consult a doctor\n\n\nContra-indication: Hypersensitivity, \n\nSide effects: Skin sensitivity; irritation of conjunctiva, mucosal irritation; reversible brown staining of the teeth; tongue discoloration and burning sensation; transient taste disturbance; parotid gland swelling.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Condition worsens or symptoms persist for more than 7 days or clear up and occur again within a few days\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Chloroxylenol 4.8%	\n\n\tIndication: Disinfection of the  hands, Wound cleansing, Cuts, Disinfection of skin lesions, Abrasions, Bites, Insect stings.\n\nDose: Wash with 1 table spoonful to a tumber of water (1 in 13) for urgent application, \n\nContra-indication: Hypersensitivity, \n\nSide effects: Skin sensitivity;, mucosal irritation;  burning sensation; \n\nPrecaution: Avoid contact w/ brain, meninges, middle ear or sensitive tissues and eyes. Do not inject or use in body cavities.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Chlorpheniramine Maleate	\n\n\tACI\tAcira TAB dr 4mg 200's pack 40\n\tAcme Ltd.\tHistalex Syrup 2mg/5ml 100ml bot 21.78\n\tAcme Ltd.\tHistalex TAB dr 4mg 100's pack 20\n\tAd-din\tAlerjess Syrup 2mg/5ml 100ml bot 20\n\tAd-din\tAlerjess TAB dr 4mg 200's pack 20\n\tAexim\tHistosin Syrup 2mg/5ml 100ml bot 12\n\tAexim\tHistosin TAB dr 4mg 500's pack 80\n\tAlbion Ltd.\tCytacin TAB dr 4 mg 500's pack \n\tAmico Ltd.\tPheramin Syrup 2mg/5ml 60ml bot 11.70\n\tAmico Ltd.\tPheramin TAB dr 4mg 500's pack 100\n\tAPC Pharma Ltd.\tPenamin TAB dr 4mg 500's pack 100\n\tApollo Pharmaceutical Ltd.\tHistin TAB dr 4mg 500's pack 105\n\tBenham\tSafamin Syrup 2mg/5ml 100ml bot 13.65\n\tBio Pharma Ltd.\tBiocin Syrup 2mg/5ml 100ml bot 21.78\n\tBio Pharma Ltd.\tBiocin TAB dr 4mg 100's pack 20\n\tBristol Pharma Ltd.\tHistalab TAB dr 4mg 500's pack 100\n\tCentral.\tCentagan Syrup 2mg/5ml 100ml bot 12\n\tChemist Ltd.\tHistanol Syrup 2mg/5ml 100ml bot 13.30\n\tChemist Ltd.\tHistanol TAB dr 4mg 500's pack 105\n\tDesh\tDenamine Syrup 2mg/5ml 60ml bot 8.75\n\tDesh\tDenamine TAB dr 4mg 500's pack 80\n\tDoctor's Chemicals Works Ltd.\tDistamin Syrup 2mg/5ml 100ml bot 14\n\tG. A. Company Ltd.\tExpilin Syrup 2mg/5ml 60ml bot 11\n\tG. A. Company Ltd.\tExpilin TAB dr 4mg 100's pack/ 500's pack 20 / 100\n\tGeneral\tHitagen Syrup 2mg/5ml 60ml bot/ 100ml bot 8.03 / 14.03\n\tGeneral\tHitagen TAB dr 4mg 500's pack 100\n\tGlaxoSmithKline Bangladesh Ltd.\tPiriton Syrup 2mg/5ml 100ml bot 21.75\n\tGlaxoSmithKline Bangladesh Ltd.\tPiriton TAB dr 4mg 500's pack 101.74\n\tGlobe\tWinkol Syrup 2mg/5ml 60ml bot / 100ml bot 8 / 12\n\tGonoshasthaya\tG Antihistamine Syrup 2mg/5ml 60ml bot / 100ml bot 11.70 / 17\n\tGonoshasthaya\tG Antihistamine TAB dr 4mg 100's pack/ 1000's pot 21 / 80\n\tHallmark\tPhenomark Syrup 2mg/5ml 100ml bot 22\n\tHallmark\tPhenomark TAB dr 4mg  \n\tHudson\tHistason Syrup 2mg/5ml 100ml bot 12\n\tHudson\tHistason TAB dr 4mg 500's pack 90\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinamin Syrup 2mg/5ml 100ml bot 21.78\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinamin TAB dr 4mg 500's pack 100\n\tJayson\tHistacin Injection 10mg/ml 10 amps pack 33.40\n\tJayson\tHistacin Syrup 2mg/5ml  60ml bot / 100 ml bot 11.70 / 21.78\n\tJayson\tHistacin TAB dr 4mg 500's pack 100\n\tMedimet\tChlorpheniramine TAB dr 4 mg 100's pack 18\n\tModern\tSedilux M Syrup 2mg/5ml  60ml bot / 100 ml bot 11.70 / 21.70\n\tModern\tSedilux M TAB dr 4mg 500's pack 100\n\tMystic\tMycentra Syrup 2mg/5ml 100ml bot 14.14\n\tOpsonin Pharma\tHistal Syrup 2mg/5ml 60ml bot 12.10\n\tOpsonin Pharma\tHistal TAB dr 4mg 60ml bot 13.75\n\tOrion Pharma Ltd.\tCloramin Syrup 2mg/5ml 100ml bot 13.05\n\tOrion Pharma Ltd.\tCloramin TAB dr 4mg 250's pack 50\n\tPharmadesh Ltd.\tEramin Syrup 2mg/5ml 60ml bot/100ml bot 11.70 / 21.50\n\tPharmadesh Ltd.\tEramin TAB dr 4mg 500's pack 100\n\tReliance\tHistamin Syrup 2mg/5ml 60ml bot 10\n\tReliance\tHistamin TAB dr 4mg 100's pack 20\n\tReman Drug Ltd.\tRemacin TAB dr 4mg 200's pack 40\n\tRenata\tAllermine Syrup 2mg/5ml  100ml bot 14.14\n\tRephco\tHistadyl Syrup 2mg/5ml 60ml bot 11.70\n\tRephco\tHistadyl TAB dr 4mg 500's pack 100\n\tSalton\tSaltamin Syrup 2mg/5ml 100ml bot 13\n\tSalton\tSaltamin TAB dr 4mg 500's pack 100\n\tSilco Pharmaceuticlas Ltd.\tAntismin Syrup 2 mg/5 ml  \n\tSomatec\tHisnul Syrup 2mg/5ml 60ml bot/ 100ml bot 8.03 / 14.10\n\tSquare\tAntista Syrup 2mg/5ml 100ml bot 21.78\n\tSupreme\tHistaco Syrup 2mg/5ml 60ml bot 11.70\n\tSupreme\tHistaco TAB dr 4mg 500's pack 100\n\tSyntho Ltd.\tSymin Syrup 2mg/5ml 60ml bot 9.50\n\tZenith\tZistacin Syrup 2mg/5ml  60ml bot / 100 ml bot 9 / 13.90\n\tIndication: Urticaria, Sneezing, Watery eyes,  Allergic conditions, Anaphylactic shock, Rhinitis, Itching\n\nDose: Adult: 4 mg every 4-6 hr. Max: 24 mg daily. \nChild: 1-2 yr: 1 mg bid, 2-5 yr: 1 mg every 4-6 hr, 6-12 yr: 2 mg every 4-6 hr. Max: 6 mg daily (1-5 yr); 12 mg daily (6-12 yr). \n\nParenteral\nAdjunct in the emergency treatment of anaphylactic shock\nAdult: 10-20 mg IM, SC, or slow IV inj over 1 min. Max dose: 40 mg daily.\nChild: 87.5 mcg/kg SC 4 times daily\n\n\n\nContra-indication: Hypersensitivity, Neonates.\n\nSide effects: CNS depression, sedation, drowsiness, lassitude, dizziness. GI upsets, anorexia, or increased appetite, epigastric pain, blurring of vision, dysuria, dryness of mouth, tightness in chest, hypotension, muscular weakness, tinnitus, euphoria, headache, paradoxical CNS stimulation.\nPotentially Fatal: CV collapse and respiratory failure.\n\nPrecaution: Elderly, pylori duodenal obstruction, angle-closure glaucoma, urinary retention, prostatic hyperplasia, epilepsy, renal and hepatic impairment. May affect performance of skilled tasks. BPH, bladder neck obstruction, hypertension. Pregnancy, lactation.\n\nMode of action: Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).\n\nPregnancy category: B\n\nInteraction: Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).
Chlorpheniramine Maleate 0.5% + Dexamethasone 0.1%	\n\n\tIndication: Steroid responsive bacterial allergic conditions of eye and ear. Otitis externa.\n\nDose: Adult and Child: 2-4 drop, 3 to 4 times daily,\n\nContra-indication: Known hypersensitivity. Fresh herpes simplex cornealis, tubercular processes involving the conjunctiva, the cornea and the anterior uvea. Perforated ear drum. Herpes simplex of ear, mycosis.\n\nSide effects: The local use of dexamethasone over a prolonged period may lead in some cases to secondary glaucoma and the development of complicated cataract. Ototoxicity.\n\nPrecaution: Dexamethasone and Chloramphenicol Eye drops must be used under strict medical supervision. Because of the possibility of inducing corneal abscess, fungal keratopathy or glaucoma the patient should be referred to an ophthalmologist if the eye has not responded within 48 hours.\n\nMode of action: Chlorpheniramine Maleate: Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).\n\n\nDexamethasone: Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\n\n\nPregnancy category: C\n\nInteraction: Chlorpheniramine Maleate: Potentiates sedative effect of psychotropic drugs e.g. barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Interaction with alcohol could be dangerous (sedation/excitation).\n\n\nDexamethasone: Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\n
Chlorpromazine Hydrochloride	\n\n\tAlbion Ltd.\tGevirl Syrup 25 mg/5 ml 100 ml \n\tOpsonin Pharma\tOpsonil Injection 50mg/2ml 25 amps pack 100\n\tOpsonin Pharma\tOpsonil TAB dr 100mg 100's pack 170\n\tOpsonin Pharma\tOpsonil TAB dr 50mg 100's pack 60\n\tOpsonin Pharma\tOpsonil TAB dr 25mg  \n\tSanofi Aventis (BD) Ltd.\tLargactil TAB dr 100mg 100's pack 101.01\n\tSanofi Aventis (BD) Ltd.\tLargactil TAB dr 25mg 500's pack 206.15\n\tSanofi Aventis (BD) Ltd.\tLargactil TAB dr 50mg 100's pack 59.85\n\tIndication: Schizophrenia, Bipolar disorder, Anxiety, Psychoses, Delirium, Porphyria, Hiccups, Nausea,Vomiting\n\nDose: Oral\nIntractable hiccup\nAdult: Initially, 25-50 mg 3-4 times daily for 2-3 days; if unresponsive, may admin 25-50 mg via IM inj. If still necessary, 25-50 mg in 500-1000 ml of normal saline may be given via slow IV infusion.\nChild: 1-12 yr: 500 mcg/kg every 4-6 hr. Max: >5 yr: 75 mg daily; 1-5 yr: 40 mg daily.\n\nPsychoses\nAdult: 25 mg tid; may be given as a single 75 mg dose at night. Maintenance: 25-100 mg tid increased to ?1 g daily as required in psychotic patients.\nChild: 1-12 yr: 500 mcg/kg every 4-6 hr. Max: >5 yr: 75 mg daily; 1-5 yr: 40 mg daily.\n\nIntramuscular\nPsychoses\nAdult: 25-50 mg repeated every 6-8 hr. Substitute with oral therapy as soon as possible. \nChild: 1-12 yr: 500 mcg/kg every 4-6 hr. Max: >5 yr: 75 mg daily; 1-5 yr: 40 mg daily. \n\nIntramuscular\nNausea and vomiting\nAdult: Initially, 25 mg via IM inj, followed by 25-50 mg every 3-4 hr until vomiting stops. \nChild: 1-12 yr: 500 mcg/kg every 4-6 hr. Max: >5 yr: 75 mg daily; 1-5 yr: 40 mg daily.\n\nElderly: Initially, 1/3-Â½ the normal adult dose.\n\n\nContra-indication: Do not use in patients with known hypersensitivity to phenothiazines.\n\nDo not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.).\n\nSide effects: Note: Some adverse effects of chlorpromazine may be more likely to occur, or occur with greater intensity, in patients with special medical problems, e.g., patients with mitral insufficiency or pheochromocytoma have experienced severe hypotension following recommended doses.\n\nPrecaution: Some patients exposed chronically to antipsychotics will develop tardive dyskinesia,\n\nChlorpromazine should be administered cautiously to persons with cardiovascular, liver or renal disease. There is evidence that patients with a history of hepatic encephalopathy due to cirrhosis have increased sensitivity to the CNS effects of chlorpromazine (i.e., impaired cerebration and abnormal slowing of the EEG).\n\nBecause of its CNS depressant effect, chlorpromazine should be used with caution in patients with chronic respiratory disorders such as severe asthma, emphysema and acute respiratory infections, particularly in children (1 to 12 years of age).\n\nBecause chlorpromazine can suppress the cough reflex, aspiration of vomitus is possible.\n\nMode of action: Potentiation of anticholinergic effects of antiparkinson agents and TCAs may lead to an anticholinergic crisis. Additive orthostatic hypotensive effect in combination with MAOIs. Reverses antihypertensive effect of guanethidine, methyldopa and clonidine.\nPotentially Fatal: Additive depressant effect with sedatives, hypnotics, antihistamines, general anaesthetics, opiates and alcohol.\n\nPregnancy category: C\n\nInteraction: Potentiation of anticholinergic effects of antiparkinson agents and TCAs may lead to an anticholinergic crisis. Additive orthostatic hypotensive effect in combination with MAOIs. Reverses antihypertensive effect of guanethidine, methyldopa and clonidine.\nPotentially Fatal: Additive depressant effect with sedatives, hypnotics, antihistamines, general anaesthetics, opiates and alcohol.
Chlorthalidone	\n\n\tBeximco\tThalin TAB dr 25mg 60's pack 300\n\tPopular\tThalidon TAB dr 25mg 30's pack 150.60\n\tPopular\tThalidon TAB dr 50mg 30's pack 150.60\n\tIndication: Hypertension, Oedema, Diabetes insipidus, Congestive heart failure\n\nDose: Adult: PO HTN 25 mg/day, up to 50 mg/day. \nOedema Initial: 25-50 mg/day up to 100-200 mg/day in severe cases. Maintenance: 25-50 mg/day or on alternate days. \nDiabetes insipidus Initial: 100 mg twice daily. Maintenance: 50 mg/day.\n\nContra-indication: Severe renal impairment or anuria. Severe hepatic impairment, addison's disease, preexisting hypercalcaemia, asthma; hypersensitivity; severe allergy. Pregnancy and lactation.\n\nSide effects: Dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, seizures, oliguria, hypotension, fatigue, muscle cramps and GI disturbances, nausea, vomiting, constipation, diarrhoea, anorexia. Diabetes and gout may be precipitated. Impotence. Raised blood levels of glucose, urates, lipids and calcium. Reduced levels of K and magnesium. Raised CPK levels.\nPotentially Fatal: Rare. Severe hyponatraemia and idiosyncratic hypersensitivity.\n\nPrecaution: Existing fluid and electrolyte disturbances, hepatic cirrhosis, severe heart failure, hyperuricaemia, mild to moderate renal impairment. Elderly. Monitor fluid and electrolyte balance. Kidney or liver disease; diabetes; gout; hyperlipidaemia and ventricular extra systoles.\n\nMode of action:  	NSAIDs antagonise hypotensive action. Suppresses action of oral anticoagulants due to reduced prothrombin activity. Increased risk of hypokalaemia when corticosteroids are given concurrently.\nPotentially Fatal: Potentiates bone marrow suppression caused by anticancer drugs. Diuretic-induced vol depletion can potentiate aminoglycoside nephrotoxicity. Impairs action of oral hypoglycaemic agents. Enhances digitalis toxicity due to hypokalaemia. vol depletion enhances lithium toxicity, conversely, sudden withdrawal of diuretics may result in subtherapeutic levels of circulating lithium. Prolonged paralysis with tubocurarine due to hypokalaemia.\n\nPregnancy category: D\n\nInteraction:  	NSAIDs antagonise hypotensive action. Suppresses action of oral anticoagulants due to reduced prothrombin activity. Increased risk of hypokalaemia when corticosteroids are given concurrently.\nPotentially Fatal: Potentiates bone marrow suppression caused by anticancer drugs. Diuretic-induced vol depletion can potentiate aminoglycoside nephrotoxicity. Impairs action of oral hypoglycaemic agents. Enhances digitalis toxicity due to hypokalaemia. vol depletion enhances lithium toxicity, conversely, sudden withdrawal of diuretics may result in subtherapeutic levels of circulating lithium. Prolonged paralysis with tubocurarine due to hypokalaemia.
Cholecalciferol (Vit. D3)	\n\n\tAcme Ltd.\tDefrol TAB dr 1000 IU  \n\tChemist Ltd.\tDebolin Injection 200000 IU 1ml amp x 1's pack 270\n\tDrug International Ltd.\tCalcirol Injection 5mg/ml 1ml amp ( 200000 i.u/ml) x 1's pack 120\n\tIncepta\tOsteo-D Injection 200000IU 1ml amp ( 200000 i.u/ml) x 1's pack 90\n\tIncepta\tOsteo D Solution 200IU/ml 15ml amp ( 200 i.u/ml) x 1's pack 75\n\tKemiko\tKvit-D Injection 5mg/ml 1ml amp ( 200000 i.u/ml) x 1's pack 90\n\tOpsonin Pharma\tColical Injection 5 mg/ml  \n\tRenata\tCalciferol Injection 5mg/ml 1ml amp ( 200000 i.u/ml) x 1's pack 90\n\tRephco\tDeon 3 Injection 5mg/ml 1amp vial 90\n\tZiska\tMax D TAB dr 1000 IU 50's pack 100\n\tMedac Gesellschaft fur Klinischespezialpraparate Germany\tUvedose Injection 2.5mg/2ml  220\n\tIndication: Osteoporosis, Hypoparathyroidism, Rickets, Osteomalacia,Vitamin D Deficiency, Pseudohypoparathyroidism, Familial hypophosphatemia\n\nDose: Oral /IM solution:\nColecalciferol (Vitamin D3) is recommended 5-10 mcg or 1-2ml (200-400 IU)/day or as directed by the physician.\n\nMay also be given via IM inj.\n\nContra-indication: Colecalciferol is contraindicated in all diseases associated with hypercalcaemia. It is also contraindicated in patients with known hypersensitivity to Colecalciferol (or medicines of the same class) and any of the constituent excipients. Colecalciferol is contraindicated if there is evidence of vitamin D toxicity.\n\nSide effects: Generally all nutritional supplements are considered to be safe and well tolerable. However, few side-effects can generally occur including hypercalcaemia syndrome or Calcium intoxication (depending on the severity and duration of hypercalcaemia), occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation with the administration of Colecaciferol.\n\nPrecaution: People with the following conditions should exercise caution when considering taking vitamin D supplements:\nHigh blood Calcium or Phosphorus level\nHeart problems\nKidney disease\n\nVitamin D must be taken with adequate amounts of both Calcium and Magnesium supplementation. When Calcium level is low (due to insufficient vitamin D and calcium intake), the body activates the parathyroid gland, which produces PTH (parathyroid hormone). This hormone kick starts vitamin D hormone production and assists removal of Calcium from the bones to be used in more important functions such as neutralizing body acidity.\n\nMode of action: Increased risk of hypercalcaemia if given with thiazide diuretics, calcium or phosphate. Antiepileptics (e.g. carbamazepine, phenobarbitone, phenytoin & primidone) may increase vitamin D requirements. Rifampicin & isoniazid may reduce efficacy of vitamin D. Corticosteroids may counteract the effect of vitamin D. Digoxin or any cardiac glycoside. Reduced absorption when taken with cholestyramine, colestipol, mineral oil, orlistat. Ketoconazole.\n\nPregnancy category: A\n\nInteraction: Increased risk of hypercalcaemia if given with thiazide diuretics, calcium or phosphate. Antiepileptics (e.g. carbamazepine, phenobarbitone, phenytoin & primidone) may increase vitamin D requirements. Rifampicin & isoniazid may reduce efficacy of vitamin D. Corticosteroids may counteract the effect of vitamin D. Digoxin or any cardiac glycoside. Reduced absorption when taken with cholestyramine, colestipol, mineral oil, orlistat. Ketoconazole.
Chondroitin + Glucosamine	\n\n\tACI\tCartilex TAB dr  200mg+250mg 50's pack 402.50\n\tAcme Ltd.\tArth A TAB dr   48's pack 385.92\n\tAmbee\tNostis TAB dr   50's pack  401.50\n\tApex\tJorix TAB dr   30's pack 210\n\tAristopharma\tRejoin TAB dr   50's pack 400\n\tBeximco\tJointec PLUS TAB dr   60's pack 480\n\tBio Pharma Ltd.\tGlucium TAB dr 200 mg + 250 mg  \n\tDoctor Tims\tArthrocare TAB dr 200 mg + 250 mg  \n\tDrug International Ltd.\tGlucotin Plus TAB dr  200 mg + 250 mg 50's pack 300\n\tEskayef Bangladesh Ltd.\tBonflex TAB dr   40's pack 320\n\tEuro Pharma Ltd.\tArthofix TAB dr 200 mg + 250 mg  \n\tGeneral\tGlustin PLUS TAB dr   50's pack 401.50\n\tGlobe\tCartifit TAB dr   48's pack 336\n\tGlobex\tJointin TAB dr 200 mg + 250 mg 30's pack 240\n\tHallmark\tAustomin TAB dr   30's pack 240\n\tHealthcare\tSynflex TAB dr   30's pack 255\n\tIbn Sina Pharmaceutical Ind. Ltd.\tArticulex TAB dr   48's pack 396\n\tIncepta\tJoinix PLUS TAB dr   50's pack 400\n\tKemiko\tMaso PLUS TAB dr   50's pack 350\n\tOpsonin Pharma\tCarticel Plus TAB dr   30's pack 240\n\tRadiant.\tCarticare TAB dr 200 mg + 250 mg  \n\tRangs\tArtiflex TAB dr   30's pack 240\n\tRenata\tCartilage PLUS TAB dr   30's pack 240.90\n\tSilva\tCartil TAB dr   30's pack 240.90\n\tSomatec\tCartigen TAB dr   30's pack 240.90\n\tSquare\tContilex TAB dr   30's pack 241.20\n\tUnimed & Unihealth Manufacturers Ltd.\tArthrosin TAB dr   30's pack 240\n\tVirgo\tCartimax TAB dr   30's pack 180\n\tWhite Horse Pharma\tOstofid PLUS TAB dr   30's pack 210\n\tIndication: Osteoarthritis, rheumatoid arthritis, sport injuries, migraine, different skin problems (e.g., psoriasis), vascular complications (e. g., atherosclerosis), kidney stones, and inflammatory bowel disease (e.g., ulcerative colitis, leaky gut syndrome), Nutritional supplement, Dietary supplement\n\nDose: 1 to 2 tablets three times daily or as directed by the physician. Obese individuals may need higher doses, based on body weight.\n\nContra-indication: Proven hypersensitivity (e. g. allergic to shellfish or sulfur) to Glucosamine and Chondroitin is a contraindication.\n\nSide effects: Side effects are rare and are limited to stomach upset, nausea or diarrhea. These usually disappear when the tablet is taken with meals.\n\nPrecaution: Diabetic patients, patients on heparin. Pregnancy and lactation.\n\nMode of action: May increase insulin resistance & affect glucose tolerance; reduce antidiabetic agent effectiveness. Increase INR value w/ warfarin & potentiates anticoagulant effect.\n\nPregnancy category: Not Classified\n\nInteraction: May increase insulin resistance & affect glucose tolerance; reduce antidiabetic agent effectiveness. Increase INR value w/ warfarin & potentiates anticoagulant effect.
Ciclesonide	\n\n\tBeximco\tCesonide 160 HFA Inhaler 160mcg 120 doses unit 350\n\tBeximco\tCesonide 80 HFA Inhaler 80mcg 120 doses unit 250\n\tIncepta\tCicloson Nasal Spray 50mcg 120 metered dose 350\n\tSquare\tEzonide Inhaler 160mcg 120 doses unit 351.31\n\tSquare\tEzonide Inhaler 80mcg 120 doses unit 250.94\n\tIndication: Asthma, seasonal allergic rhinitis, perennial allergic rhinitis\n\nDose: Inhalation\nAsthma\nAdult: Usual dose 160 mcg once daily, preferably in the evening from a metered-dose inhaler; reduced to 80 mcg once daily for maintenance.\n\nChild: >12 yr: Usual dose 160 mcg once daily, preferably in the evening from a metered-dose inhaler; \nreduced to 80 mcg once daily for maintenance.\n\nNasal Spray: \n1 spray (50 micrograms/spray) in each nostril once a day. The maximum total daily dosage should not exceed 2 sprays in each nostril (200 micrograms/day).\n\nContra-indication: Not for status asthmaticus or severe acute asthma where intensive measures are needed. Ciclesonide nasal spray is contraindicated in patients with a hypersensitivity to any of its ingredients.\n\nSide effects: Bad taste, hoarse voice, paradoxical bronchospasm, rash and eczema. Dryness, burning, inflammation and irritation at application site. Cough after inhalation. Systemic effects after prolonged use e.g. Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, bone mineral density decrease, cataract, glaucoma.\n\nCiclesonide nasal spray is absorbed less into the rest of the body; therefore fewer side effects are seen. However, few side-effects like headache, dizziness, nosebleed, stuffy nose, earache may occur.\n\nPrecaution: Active or quiescent pulmonary TB, fungal, viral or bacterial infections, unless adequately treated. Severe hepatic impairment. Monitor height of children and adolescents on long term treatment with inhaled corticosteroids; reduce dose if growth is slow. Pregnancy, lactation.\n\nCiclesonide nasal spray should be used with caution in patients with active or quiescent tuberculosis infection of the respiratory tract or in patients with untreated fungal, bacterial or systemic viral infections or ocular herpes simplex. Rare instances of nasal septal perforation, cataract, and glaucoma have been reported following intranasal application. Development of localized infections of the nose and pharynx with Candida albcans has rarely occurred. Although systemic effects have been minimal with recommended doses of Ciclesonide nasal spray, potential risk increases with larger doses. Therefore, larger than recommended doses of Ciclesonide nasal spray should be avoided.\n\nMode of action:  Increased ciclesonide concentrations with concomitant ketoconazole, itraconazole, ritonavir, nelfinavir or other potent CYP3A4 inhibitors.\n\nPregnancy category: C\n\nInteraction:  Increased ciclesonide concentrations with concomitant ketoconazole, itraconazole, ritonavir, nelfinavir or other potent CYP3A4 inhibitors.
Cilastatin + Imipenem	\n\n\tACI\tIminem IV/IM Injection  500mg+500mg 500mg vial X 1's pack 1203.12\n\tBio Pharma Ltd.\tImilast 500 IV/IM Injection 500 mg + 500 mg  \n\tIncepta\tCispenam 500 IV Injection   500mg vial X 1's pack 1195\n\tIncepta\tCispenam 250 IV Injection  1's bot 650\n\tOpsonin Pharma\tMaxipen IV IM/IV Injection 500 mg + 500 mg  \n\tPopular\tIMBAC IV/IM Injection   500mg vial X 1's pack 1199.51\n\tRenata\tIropen IV/IM Injection   500mg vial X 1's pack 1195\n\tTechno Drugs Ltd.\tImipen 500 IV/IM Injection   500mg vial X 1's pack 1195\n\tIndication: Cystic fibrosis, Bacterial septicemia, Endocarditis, Susceptible infections, Lower Respiratory Tract Infections, Gonorrhea, Skin and skin structure infections, Urinary tract infections, Bone and Joint Infections, Surgical Prophylaxis\n\nDose: Adult: IV Susceptible infections As imipenem: 1-2 g/day in divided doses 6-8 hrly. Surgical prophylaxis As imipenem: 1 g on induction of anesth, followed by 1 g 3 hr later. Additional doses of 500 mg may be given at 8 and 16 hr after induction if needed. \n\nChild: >40 kg: same as adult dose. >3 mth and <40 kg: 15-25 mg/kg every 6 hr by IV infusion. Up to 90 mg/kg may be given to older children with cystic fibrosis. Neonates and infants <3 mth: 4 wk-3 mth, 25 mg/kg every 6 hr; 1-4 wk, 25 mg/kg every 8 hr; up to 1 wk, 25 mg/kg every 12 hr.\nMax Dosage: Adults and children >40 kg: 4 g/day or 50 mg/kg. Children <40 kg: 2 g/day.\nRenal impairment:\nCrCl (ml/min)\n31-70	500 mg every 6-8 hr\n21-30	500 mg every 8-12 hr\n6-20	250 mg or 3.5 mg/kg (whichever is lower) every 12 hr\n<5	Only give if haemodialysis started within 48 hr\n\nIM Susceptible infections As imipenem: 500 or 750 mg 12 hrly. Uncomplicated gonorrhoea As imipenem: 500 mg as single dose.\n\nMild infection: 250 mg 6 hourly (1 gm/day)\nModerate infection: 500 mg 8 hourly or 1 gm 12 hourly (1.5-2 gm/day)\nSevere infection with fully susceptible microorganism: 500 mg 6 hourly (2gm/day)\nSevere infection with less susceptible organisms (primarily some strains of P. aeruginosa): 1 gm 3-4 times daily (3-4 gm/day)\n\nContra-indication: Hypersensitivity.\n\nSide effects: Skin rashes, urticaria, eosinophilia, fever, nausea, vomiting, diarrhoea, tooth or tongue discoloration and altered taste. Erythema multiforme, exfoliative dermatitis. Pain and thrombophlebitis may occur at the inj site.\nPotentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis.\n\nPrecaution: Caution when used in patients with known hypersensitivity to other beta-lactams due to possibility of cross-sensitivity. CNS disorders such as epilepsy; renal, hepatic impairment; pregnancy, lactation.\n\nMode of action: Concurrent admin with probenecid may increase the half-life of cilastatin. Increased risk of generalised seizures when used concurrently with ganciclovir.\n\nPregnancy category: C\n\nInteraction: Concurrent admin with probenecid may increase the half-life of cilastatin. Increased risk of generalised seizures when used concurrently with ganciclovir.
Cilostazol	\n\n\tACI\tInclaud TAB dr 100mg 20's pack 240.80\n\tBeximco\tZocil TAB dr 100mg 20's pack 240\n\tBeximco\tZocil TAB dr 50mg 30's pack 210\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVasocil TAB dr 100mg 20's pack 500\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVasocil TAB dr 50mg 30's pack 450\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVasosil TAB dr 50mg 30's pack 210\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVasosil TAB dr 100mg 20's pack 240\n\tSquare\tCilosta TAB dr 100mg 30's pack 361.49\n\tIndication: Peripheral vascular disease, Intermittent claudication\n\nDose: Adult: PO 100 mg twice daily.\n\nContra-indication: Heart failure; known predisposition to bleeding; history of ventricular arrhythmias; QT interval prolongation; severe renal impairment; moderate to severe hepatic impairment.\n\nSide effects: Headache, dizziness, palpitations, diarrhoea, abnormal stools; pain, infection; peripheral oedema, nausea, vomiting, other cardiac arrhythmias, chest pain, rhinitis, pharyngitis, ecchymosis and skin rash.\n\nPrecaution: Congestive heart disease. Concurrent therapy with clopidogrel has not been studied for safety or efficacy. Pregnancy and lactation.\n\nMode of action: Co-admin with drugs that affect CYP3A4 (erythromycin, other macrolides, diltiazem) or CYP2C19 (omeprazole) may influence the pharmacokinetics of cilostazol.\n\nPregnancy category: C\n\nInteraction: Co-admin with drugs that affect CYP3A4 (erythromycin, other macrolides, diltiazem) or CYP2C19 (omeprazole) may influence the pharmacokinetics of cilostazol.
Cimetidine	\n\n\tGonoshasthaya\tG Cimetidine Injection 200mg/2ml 25 amps pack 107.25\n\tIndication: Heartburn, Dyspepsia, Peptic ulcers, Benign gastric and duodenal ulceration, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Pancreatic insufficiency\n\nDose: Intravenous\nBenign gastric and duodenal ulceration\nAdult: Intermittent infusion: 300 mg 6-8 hrly infused over 15-20 min. Max: 2400 mg/day. Continuous infusion: 37.5 mg/hr (900 mg/day). A 150 mg IV loading dose may be given in patients requiring rapid elevation of gastric pH.\n\nZollinger-Ellison syndrome\nAdult: Intermittent infusion: 300 mg 6-8 hrly infused over 15-20 min. Max: 2400 mg/day. Continuous infusion: 37.5 mg/hr (900 mg/day). A 150 mg IV loading dose may be given in patients requiring rapid elevation of gastric pH.\n\nContra-indication: Hypersensitivity, lactation.\n\nSide effects: Diarrhoea, dizziness, tiredness, rash, headache, CNS disturbances, arthralgia, myalgia, gynaecomastia, alopoecia, blood dyscrasias, nephritis, hepatitis, pancreatitis, granulocytopenia, hypersensitivity reactions.\n\nPrecaution: Impaired renal and hepatic function. Age >50 yr; CV impairment. Pregnancy.\n\nMode of action: Reduces absorption of dasatinib, ketoconazole, itraconazole and posaconazole. May increase serum levels of phenytoin, theophylline, lidocaine, hydroxyzine and oral anticoagulants. Absorption may be reduced by antacids. Decreased bioavailability w/ metoclopramide, sucralfate or propantheline. May potentiate the myelosuppressive effects (e.g. agranulocytosis, neutropenia) of myelosuppressive drugs (e.g. antimetabolites, alkylating agents) or therapies (e.g. radiation).\n\nPregnancy category: B\n\nInteraction: Reduces absorption of dasatinib, ketoconazole, itraconazole and posaconazole. May increase serum levels of phenytoin, theophylline, lidocaine, hydroxyzine and oral anticoagulants. Absorption may be reduced by antacids. Decreased bioavailability w/ metoclopramide, sucralfate or propantheline. May potentiate the myelosuppressive effects (e.g. agranulocytosis, neutropenia) of myelosuppressive drugs (e.g. antimetabolites, alkylating agents) or therapies (e.g. radiation).
Cinacalcet	\n\n\tACI\tTyrodin TAB dr 30mg 10's pack 451.70\n\tIndication: Hyperparathyroidism, Hypercalcemia, Parathyroid carcinoma\n\nDose: Adult: PO Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis >18 yr: Initially 30 mg once daily; titrate dose every 2-4 wk in steps of 30 mg as necessary to achieve intact parathyroid hormone (iPTH) levels of 150-300pg/mL. Max: 180 mg/day. \n\nHypercalcaemia associated w/ parathyroid carcinoma >18 yr: Initially 30 mg bid; titrate dose every 2-4 wk in sequential doses of 60 mg bid, 90 mg bid, and 90 mg 3-4 times daily as needed until serum calcium levels normalise. Max: 90 mg 4 times/day.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea, vomiting, diarrheoa, anorexia, dizziness, myalgia, paraesthesia, asthenia, chest pain (non-cardiac), rash, urticaria, seizure, decreased testosterone levels, hypocalcaemia, hypotension, hypertension.\nPotentially Fatal: Hypersensitivity reaction including angioedema.\n\nPrecaution: Moderate-to-severe hepatic impairment, CV diseases. Not indicated for chronic kidney disease patients who are not receiving dialysis. Do not initiate Cinacalcet in hypocalcaemic patients. For secondary hyperparathyroidism, measure serum calcium and phosphorus (prior to- and within 1 wk after initiation/dose adjustment; mthly during maintenance) and iPTH (prior to- and within 1-4 wk after initiation/dosage adjustment; every 1-3 mth during maintenance). iPTH levels should drawn at least 12 hr after Cinacalcet dosing. \n\nFor parathyroid carcinoma and primary parathyroidism, measure serum calcium prior-to and within 1 wk after initiation/dose adjustment; and every 2-3 mth during maintenance. Vitamin D sterols, calcium-containing phosphate binder and/or adjustment of calcium contents of dialysis fluid can be used to raise serum calcium in the event of hypocalcaemia. Reduce dose or withhold therapy if hypocalcaemia persists; may reinstate treatment at the next lowest dose after calcium levels normalised. Significant reduction in serum calcium may lower seizure threshold. Adynamic bone disease may develop if iPTH level is suppressed to < 100 pg/mL. May decrease total and free testosterone levels. Safety and efficacy not established in patients ?18 yr. Pregnancy and lactation.\n\nMode of action: Cinacalcet is a strong CYP2D6 inhibitor and may increase serum concentrations of amitriptyline, nortriptyline and desipramine. Cinacalcet may decrease serum concentrations of tacrolimus. CYP3A4 inhibitors such as ketoconazole, erythromycin may increase plasma concentrations of Cinacalcet.\n\nPregnancy category: C\n\nInteraction: Cinacalcet is a strong CYP2D6 inhibitor and may increase serum concentrations of amitriptyline, nortriptyline and desipramine. Cinacalcet may decrease serum concentrations of tacrolimus. CYP3A4 inhibitors such as ketoconazole, erythromycin may increase plasma concentrations of Cinacalcet.
Cinchocaine Hydrochloride 0.5% + Esculin 1% + Hydrocortisone + Neomycin Sulphate (Rectal prep)	\n\n\tAcme Ltd.\tCinoplus Suppository  10's pack 60.20\n\tAristopharma\tAriproct Suppository 15mg 10 suppositories in PVC / PE strip pack 61.60\n\tBeximco\tAnustat Ointment   15gm tube 60\n\tPopular\tAnorel Ointment  15 g 1 tube 80.30\n\tSquare\tErian Ointment  500 mg + 1 gm + 500 mg + 15gm tube 68\n\tSquare\tErian Suppository  5 mg + 10 mg + 5 mg + 10 10's pack 60.25\n\tIndication: Pruritus ani, Haemorrhoids, Anal fissure, Proctitis\n\nDose: Adult: Up to 1% in cream and ointment.Adult: As 0.05% w/w ointment (in combination with hydrocortisone): Apply onto the affected area in the morning and evening and after each stool. \n\nAs suppository containing 5 mg/unit (in combination with hydrocortisone): Insert 1 suppository in the morning and evening and after each stool.\n\nContra-indication: Complete heart block; pyogenic infection at or near the skin. Application to inflamed or infected tissues or to damaged skin mucosa; instillation into the middle ear.\n\nSide effects: Restlessness; excitement; nervousness; paraesthesias; dizziness; tinnitus; blurred vision; nausea; vomiting; muscle twitching; tremors; convulsions; hypotension; bradycardia; arrhythmias; cardiac arrest.\n\nPrecaution: Elderly; debilitated patients; child; epilepsy; impaired cardiac conduction or respiratory function; shock; hepatic impairment; myasthenia gravis. Do not to rub or touch the eye while anaesthesia persists. Avoid application for prolonged periods and to extensive areas. Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Cinnarizine	\n\n\tAcme Ltd.\tCinazin TAB dr 15 mg 100's pack 70\n\tAlbion Ltd.\tCinnarizine TAB dr 15 mg 200's pack \n\tAristopharma\tZincin TAB dr 15mg 250's pack 250\n\tBeximco\tInarzin TAB dr 15mg 100's pack 90\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCinarzin TAB dr 15mg 100's pack 100\n\tMystic\tCinomyst TAB dr 15mg 100's pack 70\n\tNipa\tCinarin TAB dr 15mg 100's pack 100\n\tOpsonin Pharma\tCinaryl TAB dr 15mg 100's pack 87.92\n\tRephco\tSuzaron TAB dr 15mg 100's pack 50\n\tSquare\tCinaron TAB dr 15mg 200's pack 200\n\tIndication: Nausea and vomiting, motion sickness, vertigo, meniere's disease, peripheral vascular diseases, cerebrovascular disorders, vestibular disorders							\n\n\nDose: Adult: PO 15 to 30 mg three times daily. Peripheral vascular diseases 75 mg 2-3 times/day. Motion sickness 30 mg 2 hr before travel and 15 mg 8 hrly during travel if needed. Cerebrovascular disorders 75 mg 1-3 times/day. Vertigo and vestibular disorders 30 mg 3 times/day.\n\nChildren (5 to 12 years): Half of the adult dose.\n\nContra-indication: Proven hypersensitivity to the drug. Parkinson's disease. Childn and neonates.\n\nSide effects: Extrapyramidal symptoms sometimes associated with severe depression. Drowsiness, headache, GI upsets, unsteadiness, headache; rarely skin and hypersensitivity reactions, dry mouth, blurred vision, urinary difficulty or retention, constipation and increased gastric reflux, fatigue. Hypolipidaemic effect.\n\nPrecaution: Hypotension; pregnancy; lactation; elderly. May impair ability to drive or operate machineries.\n\nMode of action: CNS depressant effect enhanced with alcohol. Action potentiated by domperidone.\n\nPregnancy category: C\n\nInteraction: CNS depressant effect enhanced with alcohol. Action potentiated by domperidone.
Cinnarizine + Dimenhydrinate	\n\n\tACI\tArtigo TAB dr 20mg+40mg 50's pack 100.50\n\tAcme Ltd.\tCinazin Plus TAB dr  20mg+40mg 50's pack 75\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCinarzin Plus TAB dr   100's pack 150\n\tIncepta\tRevert TAB dr   50's pack 100\n\tOpsonin Pharma\tCinaryl Plus TAB dr  10x10's pack 175.94\n\tSquare\tCinaron Plus TAB dr  20mg + 40mg 100's pack 200\n\tIndication: Nausea and vomiting, motion sickness, vertigo, meniere's disease, peripheral vascular diseases, cerebrovascular disorders, vestibular disorders							\n\n\nDose: Oral\nAdult: 75 mg bid or tid.\nElderly: \n\nMotion sickness\nAdult: 30 mg taken 2 hr before travel and 15 mg every 8 hr during the journey if necessary. \nChild: 5-12 yr: 1/2 of adult dose.\n\nCerebrovascular disorders\nAdult: 75 mg 1-3 times daily. \n\nContra-indication: Proven hypersensitivity to the drug. Parkinson's disease. Childn and neonates.\n\nSide effects: Extrapyramidal symptoms sometimes associated with severe depression. Drowsiness, headache, GI upsets, unsteadiness, headache; rarely skin and hypersensitivity reactions, dry mouth, blurred vision, urinary difficulty or retention, constipation and increased gastric reflux, fatigue. Hypolipidaemic effect.\n\nPrecaution: Hypotension; pregnancy; lactation; elderly. May impair ability to drive or operate machineries.\n\nMode of action: Cinnarizine: CNS depressant effect enhanced with alcohol. Action potentiated by domperidone.\n\nDimenhydrinate: Physically incompatible with aminophylline, hydrocortisone, phenothiazines and some barbiturates in solution.\nPotentially Fatal: Potentiates the sedative effects of CNS depressants including alcohol, barbiturates, opioid analgesics, sedatives and neuroleptics. MAOIs, atropine, TCAs enhance antimuscarinic effect. Masks ototoxicity produced by aminoglycoside antibiotics.\n\nPregnancy category: C\n\nInteraction: Cinnarizine: CNS depressant effect enhanced with alcohol. Action potentiated by domperidone.\n\nDimenhydrinate: Physically incompatible with aminophylline, hydrocortisone, phenothiazines and some barbiturates in solution.\nPotentially Fatal: Potentiates the sedative effects of CNS depressants including alcohol, barbiturates, opioid analgesics, sedatives and neuroleptics. MAOIs, atropine, TCAs enhance antimuscarinic effect. Masks ototoxicity produced by aminoglycoside antibiotics.
Ciprofloxacin	\n\n\tACI\tFloxabid Powder for Suspension 250mg/5ml 60ml bot 100.30\n\tACI\tFloxabid TAB dr 250mg 50's pack 428\n\tACI\tFloxabid TAB dr 500mg 30's pack 451.50\n\tACI\tFloxabid TAB dr 750mg 20's pack 362.40\n\tACI\tFloxabid IV Infusion 250mg/5ml 60ml 90.34\n\tACI\tFloxabid SR TAB dr 1000gm 8's pack 161.04\n\tAcme Ltd.\tCipro A Powder for Suspension 250mg/5ml 60ml bot 90\n\tAcme Ltd.\tCipro A IV Infusion 200mg/100ml 100ml bot 90.34\n\tAcme Ltd.\tCipro A TAB dr 250mg 30's pack 255.90\n\tAcme Ltd.\tCipro A TAB dr 500mg 20's pack 281.20\n\tAcme Ltd.\tCipro A TAB dr 750mg 20's pack 361.20\n\tAd-din\tCiproxen TAB dr 250mg 30's pack 210\n\tAd-din\tCiproxen TAB dr 500mg 14's pack 196\n\tAexim\tUniflox TAB dr 500mg 30's pack 240\n\tAlbion Ltd.\tCiprofloxacin TAB dr 500mg/ 250mg 20's / 30's pack \n\tAlbion Ltd.\tCiprofloxacin Powder For Suspension 250 mg/5 ml 60 ml \n\tAlco Pharma\tDumaflox Powder for Suspension 250mg/5ml 60ml bot 65\n\tAlco Pharma\tDumaflox TAB dr 750mg 20's pack 240\n\tAlco Pharma\tDumaflox TAB dr 250mg  30's pack 225\n\tAlco Pharma\tDumaflox TAB dr 500mg  30's pack 300\n\tAmbee\tHiflox TAB dr 500mg 30's pack 261\n\tAmbee\tHiflox TAB dr 750mg 20's pack 241\n\tAmbee\tHiflox Suspension 250mg  60ml bot 70.26\n\tAmico Ltd.\tAmiflox TAB dr 250mg 30's pack 180\n\tAmico Ltd.\tAmiflox TAB dr 500mg 30's pack 300\n\tAmico Ltd.\tAmiflox TAB dr 750mg 10's pack 160\n\tAmico Ltd.\tAmiflox DS Powder for Suspension 250mg/5ml 60ml bot 85\n\tAmulet\tFlocip TAB dr 500mg  \n\tAmulet\tFlocip Powder For Suspension 250 mg/5 ml  \n\tAPC Pharma Ltd.\tCiprotec Powder for Suspension 250mg/5ml 60ml bot 80\n\tAPC Pharma Ltd.\tCiprotec TAB dr 500mg 20's pack 160\n\tApex\tLox TAB dr 500mg 30's pack 300\n\tApex\tLox TAB dr 750mg 20's pack 280\n\tApex\tLox DS Powder for Suspension 250mg/5ml 60ml bot 60\n\tApollo Pharmaceutical Ltd.\tCipro TAB dr 500mg 30's pack 300\n\tApollo Pharmaceutical Ltd.\tCipro Suspension 250mg 60ml bot 80\n\tAristopharma\tAprocin Powder for Suspension 250mg/5ml 60ml bot 100\n\tAristopharma\tAprocin TAB dr 250mg 30's pack 255\n\tAristopharma\tAprocin TAB dr 500mg 30's pack 420\n\tAristopharma\tAprocin TAB dr 750mg 20's pack 360\n\tAsiatic Ltd.\tCip TAB dr 500mg 30's pack 420\n\tAsiatic Ltd.\tCip TAB dr 750mg 12's pack 216\n\tBeacon\tXbac Powder for Suspension 250mg/5ml 60ml bot 90\n\tBeacon\tXbac TAB dr 500mg 30's pack 420\n\tBeacon\tXbac TAB dr 750mg 20's pack 360\n\tBeacon\tXbac IV Infusion 200mg/100ml 100ml bot 145\n\tBelsen\tCipro B TAB dr 500mg 20's pack 240\n\tBenham\tBenprox TAB dr 500mg 30's pack 421.80\n\tBenham\tBenprox TAB dr 750mg 20's pack 360\n\tBeximco\tNeofloxin Infusion 200mg/100ml 1's pack 146.50\n\tBeximco\tNeofloxin Powder for Suspension 250mg/5ml 60ml bot 80\n\tBeximco\tNeofloxin IV Infusion 200mg/100ml 100ml bot 146.50\n\tBeximco\tNeofloxin TAB dr 250mg 50's pack 425\n\tBeximco\tNeofloxin TAB dr 500mg 20's pack 280\n\tBeximco\tNeofloxin TAB dr 750mg 30's pack 540\n\tBeximco\tNeofloxin XR TAB dr 1gm 10's pack 250\n\tBeximco\tNeofloxin XR TAB dr 500mg 20's pack 220\n\tBio Pharma Ltd.\tCipcin IV Infusion 200mg/100ml 100ml bot 100\n\tBio Pharma Ltd.\tCipcin Powder for Suspension 250mg/5ml 60ml bot 90.34\n\tBio Pharma Ltd.\tCipcin TAB dr 250mg 30's pack 255.90\n\tBio Pharma Ltd.\tCipcin TAB dr 500mg 30's pack 421.50\n\tBio Pharma Ltd.\tCipcin TAB dr 750mg 12's pack 216.84\n\tBristol Pharma Ltd.\tCiprobac 500 TAB dr 500mg  20's pack 200\n\tBristol Pharma Ltd.\tCiprobac DS Suspension 250mg  60ml bot 80\n\tCentral.\tNeoflox TAB dr 500mg 30's pack 360\n\tChemist Ltd.\tCipro C TAB dr 500mg 50's pack 500\n\tConcord\tCeprocon-500 TAB dr 500mg 30's pack 360\n\tConcord\tCeprocon Powder For Suspension 250 mg/5 ml 60ml bot \n\tCosmic Chemical Industries Ltd.\tCiprolyn Powder for Suspension 250mg/5ml 60ml bot 90\n\tCosmic Chemical Industries Ltd.\tCiprolyn TAB dr 250mg 50's pack 300\n\tCosmic Chemical Industries Ltd.\tCiprolyn TAB dr 500mg 30's pack 360\n\tCosmo Pharma Ltd.\tCpflox TAB dr 500mg 20's pack 202.20\n\tDecent Pharma Ltd.\tQnol TAB dr 500mg 30's pack 330\n\tDelta Pharma\tDFX Powder for Suspension 250mg/5ml 60ml bot 90\n\tDelta Pharma\tDFX TAB dr 500mg 32's pack 320\n\tDelta Pharma\tDFX TAB dr 750mg 8's pack 112\n\tDesh\tDeflox TAB dr 500mg 30's pack 315\n\tDesh\tDeflox TAB dr 750mg 20's pack 260\n\tDesh\tDeflox DS Powder for Suspension 250mg/5ml 60ml bot 80\n\tDoctor's Chemicals Works Ltd.\tD Floxin TAB dr 250mg 30's pack 136.50\n\tDoctor's Chemicals Works Ltd.\tD Floxin TAB dr 500mg 30's pack 360\n\tDoctor's Chemicals Works Ltd.\tD-Floxin Powder for Suspension 250mg/5ml 60ml 65\n\tDrug International Ltd.\tCiprozid Powder for Suspension 250mg/5ml 60ml bot 90\n\tDrug International Ltd.\tCiprozid IV Infusion 200mg/100ml 100ml bot 70\n\tDrug International Ltd.\tCiprozid TAB dr 250mg 50's pack 400\n\tDrug International Ltd.\tCiprozid TAB dr 750mg 30's pack 480\n\tDrug International Ltd.\tCiprozid DS TAB dr 500mg 30's pack 420\n\tDrug International Ltd.\tCiprozid XR TAB dr 1gm 12's pack 280\n\tEdruc Ltd.\tCipron Powder for Suspension 250mg/5ml 60ml bot 90\n\tEdruc Ltd.\tCipron TAB dr 500mg 30's pack 364.50\n\tEskayef Bangladesh Ltd.\tQuinox IV Infusion 200mg/100ml 100ml bot 100\n\tEskayef Bangladesh Ltd.\tQuinox TAB dr 250mg 30's pack 255\n\tEskayef Bangladesh Ltd.\tQuinox TAB dr 500mg 20's pack/40's pack 280/560\n\tEskayef Bangladesh Ltd.\tQuinox TAB dr 750mg 10's pack 180\n\tEskayef Bangladesh Ltd.\tQuinox DS Powder for Suspension 250mg/5ml 60ml bot 90\n\tEuro Pharma Ltd.\tCibact TAB dr 500mg 30's pack 420\n\tEverest\tCiptec Powder for Suspension 250mg/5ml 60ml bot 80\n\tEverest\tCiptec TAB dr 500mg 30's pack 360\n\tEverest\tCiptec TAB dr 750mg 24's pack 336\n\tG. A. Company Ltd.\tCero TAB dr 500mg 20's pack 280\n\tGeneral\tGeflox Powder for Suspension 250mg/5ml 60ml bot 80.30\n\tGeneral\tGeflox TAB dr 500mg 30's pack 255\n\tGeneral\tGeflox XR TAB dr 500mg 30's pack 421.50\n\tGeneral\tGeflox IV Infusion 200 mg/100 ml  \n\tGeneral\tGeflox TAB dr 250mg  \n\tGeneral\tGeflox Pellets For Suspension 250 mg/5 ml  \n\tGlaxoSmithKline Bangladesh Ltd.\tGlaxipro TAB dr 500mg 30's pack 421.58\n\tGlobe\tKapron Powder for Suspension 250mg/5ml 60ml bot 80\n\tGlobe\tKapron TAB dr 250mg 30's pack 180\n\tGlobe\tKapron TAB dr 500mg 30's pack 360\n\tGlobe\tKapron TAB dr 750mg 20's pack 300\n\tGlobex\tPancipro TAB dr 500mg 30's pack 420\n\tGlobex\tPancipro Powder For Suspension 250 mg/5 ml 60ml 100\n\tGonoshasthaya\tG- Cipro TAB dr 500mg  30's pack 180.60\n\tGonoshasthaya\tG- Cipro I.V TAB dr 250mg  100ml bot 50.18\n\tGuardian Healthcare Ltd.\tCiproguard TAB dr 500mg  \n\tGuardian Healthcare Ltd.\tCiproguard TAB dr 1gm  \n\tHallmark\tDoquin TAB dr 500mg 30's pack 361.50\n\tHealthcare\tRocipro TAB dr 500mg 30's pack 420\n\tHealthcare\tRocipro TAB dr 750mg 16's pack 288\n\tHealthcare\tRocipro XR TAB dr 500mg  \n\tHudson\tHi-floxin TAB dr 500mg  30's apck 360\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBactin TAB dr 250mg 20's pack 170.80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBactin TAB dr 500mg 20's pack 281.20\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBactin TAB dr 750mg 20's pack 361.20\n\tIncepta\tBeuflox IV Infusion 200mg/100ml 100ml bot/200ml bot 70/130\n\tIncepta\tBeuflox TAB dr 250mg 18's pack 153\n\tIncepta\tBeuflox TAB dr 500mg 20's pack 280\n\tIncepta\tBeuflox TAB dr 750mg 20's pack 360\n\tIncepta\tBeuflox Susp Powder for Suspension 250mg/5ml 60ml 90\n\tIncepta\tBeuflox 125 Granules for Suspension 125mg 14's 112\n\tIncepta\tBeuflox Granules for Suspension 250mg/100ml 14's pack 168\n\tIndobangla Pharmaceuticals\tCipro-I TAB dr 750mg 30's pack 360\n\tIndobangla Pharmaceuticals\tCipro-I Suspension 250mg  60ml bot 90\n\tJayson\tSpectra TAB dr 500mg 20's pack 203.20\n\tKemiko\tProcin Powder for Suspension 250mg/5ml 60ml bot 90\n\tKemiko\tProcin TAB dr 250mg 30's pack 255\n\tKemiko\tProcin TAB dr 500mg 30's pack 420\n\tKemiko\tProcin TAB dr 750mg 20's pack 360\n\tKumudini Pharma Ltd.\tProflox TAB dr 250mg 30's pack 180\n\tKumudini Pharma Ltd.\tProflox TAB dr 500mg 30's pack 360\n\tLabaid\tCiproaid-500 TAB dr 500mg 2x10's pack 300\n\tLeon\tNovaflox TAB dr 500mg  \n\tLeon\tNovaflox Powder For Suspension 250 mg/5 ml  \n\tLibra Pharmaceuticls Ltd.\tLibracin IV Infusion 200mg/100ml 100ml bot 70.26\n\tLibra Pharmaceuticls Ltd.\tLibracin IV Infusion 400mg/100ml 100ml bot 146.30\n\tMarksman.\tCiproquin TAB dr 500mg 30's pack 360\n\tMedicon\tCiprol Powder for Suspension 250mg/5ml 60ml bot 90\n\tMedicon\tCiprol TAB dr 500mg 30's pack 360\n\tMedimet\tCipromet TAB dr 250mg 30's pack 180\n\tMedimet\tCipromet TAB dr 500mg 20's pack 200\n\tMillat\tCiprom TAB dr 250mg 30's pack 150\n\tMillat\tCiprom TAB dr 500mg 20's pack 240\n\tMillat\tCiprom DS Powder for Suspension 250mg/5ml 100ml bot 80\n\tModern\tCipro M TAB dr 500mg 40's pack 400\n\tModern\tCipro M TAB dr 750mg 20's pack 280\n\tMonicopharma\tMonipro TAB dr 500mg 24's pack 336\n\tMystic\tCiprolex TAB dr 250mg 30's pack 210\n\tMystic\tCiprolex TAB dr 500mg 20's pack 240\n\tNavana\tFloxacin TAB dr 250mg 50's pack 301\n\tNavana\tFloxacin TAB dr 500mg 30's pack 301.20\n\tNipa\tCiprin TAB dr 500mg 30's pack 360\n\tNIPRO JMI Pharma\tFlorocin Powder for Suspension 250mg/5ml 60ml bot 90\n\tNIPRO JMI Pharma\tFlorocin TAB dr 500mg 30's pack 361.50\n\tNovartis (Bangladesh) Ltd.\tServiflox TAB dr 250mg 30's pack 242.70\n\tNovartis (Bangladesh) Ltd.\tServiflox TAB dr 500mg 30's pack 420\n\tNovartis (Bangladesh) Ltd.\tServiflox TAB dr 750mg 20's pack 360\n\tNovelta Bestway\tCipronor Oral Suspension 250mg/5ml 60ml bot 90\n\tNovelta Bestway\tCipronor TAB dr 500mg 20's pack 280\n\tNovo Healthcare and Pharma Ltd.\tXirocip Powder for Suspension 250mg/5ml 60ml bot/100ml bot 90/140\n\tNovo Healthcare and Pharma Ltd.\tXirocip TAB dr 1gm 8's pack 200\n\tNovo Healthcare and Pharma Ltd.\tXirocip IV Infusion 200mg/100ml 100ml bot 70\n\tNovo Healthcare and Pharma Ltd.\tXirocip TAB dr 500mg 20's pack 280\n\tNovus\tNovacin TAB dr 500mg 20's pack 280\n\tNuvista Pharma Ltd\tQuinobid TAB dr 500mg  \n\tNuvista Pharma Ltd\tQuinobid TAB dr 750mg  \n\tOpso Saline Ltd.\tCiproxy IV Infusion 200mg/100ml 100ml bot 65.25\n\tOpsonin Pharma\tCiprox Powder for Suspension 125mg/5ml 1's pack 90\n\tOpsonin Pharma\tCiprox IV Infusion 200mg/100ml 100ml bot 70\n\tOpsonin Pharma\tCiprox TAB dr 250mg 30's pack 225\n\tOpsonin Pharma\tCiprox TAB dr 500mg 20's pack 280\n\tOpsonin Pharma\tCiprox TAB dr 750mg 20's pack 360\n\tOpsonin Pharma\tCiprox DS Powder for Suspension 250mg/5ml 60ml bot 90\n\tOpsonin Pharma\tCiprox XR TAB dr 1gm 6's pack 120\n\tOrion Pharma Ltd.\tMaprocin Powder for Suspension 250mg/5ml 60ml bot 90.34\n\tOrion Pharma Ltd.\tMaprocin IV Infusion 200mg/100ml 100ml bot 130\n\tOrion Pharma Ltd.\tMaprocin TAB dr 250mg 30's pack 421.50\n\tOrion Pharma Ltd.\tMaprocin TAB dr 500mg 20's pack 361.20\n\tOrion Pharma Ltd.\tMaprocin TAB dr 750mg 10's pack 360\n\tOrion Pharma Ltd.\tMaprocin DS IV Infusion 400mg/100ml 100ml bot 70\n\tOrion Pharma Ltd.\tOrlev IV Injection 500mg  100ml bot 100\n\tOyster\tXeoflox TAB dr 500mg 30's pack 361\n\tPacific\tCilocin TAB dr 500mg 20's pack/50's pack 160 / 400\n\tPacific\tCilocin XR TAB dr 500mg 30's pack 240\n\tPacific\tCilocin DS Suspension 250mg 60ml bot 100\n\tPeoples Pharma Ltd.\tPeoflox TAB dr 500mg 30's pack 360\n\tPharmadesh Ltd.\tFloxin TAB dr 250mg 50's pack 250\n\tPharmadesh Ltd.\tFloxin TAB dr 500mg 30's pack 330\n\tPharmadesh Ltd.\tFloxin DS Powder for Suspension 250mg/5ml 60ml bot 85\n\tPharmasia Ltd.\tCipoxia-500 TAB dr 500mg 20's pack 280\n\tPharmasia Ltd.\tCipoxia-500 Suspension 250mg 60ml bot 100\n\tPopular\tCivox Powder for Suspension 250mg/5ml 60ml bot 90.34\n\tPopular\tCivox TAB dr 500mg 24's pack 337.20\n\tPopular\tCivox XR TAB dr 1gm 12's pack 301.09\n\tPopular\tCivox Infusion 200mg  100ml bot 100\n\tPrime\tSupercin TAB dr 500mg  \n\tRadiant.\tWinbac TAB dr 500mg 20's pack/28's pack 320/448\n\tRAK\tRaciprox Powder for Suspension 250mg/5ml 60ml bot 80\n\tRAK\tRaciprox TAB dr 500mg 20's pack 280\n\tRangs\tRanflox TAB dr 500mg 20's pack 280\n\tRangs\tRanflox TAB dr 750mg 20's pack 360\n\tReliance\tEliprox TAB dr 500mg 30's pack 421\n\tReman Drug Ltd.\tCiflox TAB dr 500mg 20's pack 250\n\tRenata\tFlontin 0.2% 200 IV Infusion 200mg/100ml 100ml bot 145.54\n\tRenata\tFlontin TAB dr 250mg 20's pack 170.60\n\tRenata\tFlontin TAB dr 500mg 30's pack 421.80\n\tRenata\tFlontin TAB dr 750mg 20's pack 361.20\n\tRenata\tFlontin Suspension 250mg/5ml 60ml bot 90\n\tRephco\tOctabid TAB dr 500mg 30's pack 360\n\tS. N.\tC-Flox TAB dr 500mg 30's pack 361.50\n\tSalton\tSaflox TAB dr 500mg 30's pack 367.20\n\tSanofi Aventis (BD) Ltd.\tFiprox TAB dr 250mg 30's pack 255.90\n\tSanofi Aventis (BD) Ltd.\tFiprox TAB dr 500mg 30's pack 421.50\n\tSanofi Aventis (BD) Ltd.\tFiprox TAB dr 750mg 20's pack 361.40\n\tSeema\tCipro S Powder for Suspension 250mg/5ml 60ml bot 90\n\tSeema\tCipro S TAB dr 500mg 50's pack 700\n\tShamsul Al-Amin\tAngyr TAB dr 250mg 50's pack 425\n\tShamsul Al-Amin\tAngyr TAB dr 500mg 30's pack 360\n\tSharif\tProquin TAB dr 500mg 30's pack 420\n\tSharif\tProquin Powder For Suspension 250 mg/5 ml  \n\tSilco Pharmaceuticlas Ltd.\tSilflox TAB dr 500mg  \n\tSilva\tCipronil Powder for Suspension 250mg/5ml 60ml bot 90.33\n\tSilva\tCipronil TAB dr 500mg 30's pack 451.58\n\tSilva\tCipronil TAB dr 750mg 12's pack 216.82\n\tSomatec\tTyflox TAB dr 250mg 30's pack 255.90\n\tSomatec\tTyflox TAB dr 500mg 30's pack 361.20\n\tSomatec\tTyflox TAB dr 750mg 10's pack 180.70\n\tSomatec\tTyflox DS Powder for Suspension 250mg/5ml 60ml bot 90.34\n\tSonear Ltd.\tCiprocap Suspension 250mg  30's pack 261.30\n\tSonear Ltd.\tCiprocap Suspension 500mg  16's pack 229.60\n\tSquare\tCiprocin IV Infusion 200mg/100ml 100ml bot 100\n\tSquare\tCiprocin TAB dr 250mg 30's pack 256.16\n\tSquare\tCiprocin Powder for Suspension 250mg/5ml 60ml bot 90.34\n\tSquare\tCiprocin TAB dr 500mg 30's pack 421.75\n\tSquare\tCiprocin TAB dr 750mg 20's pack 361.23\n\tSquare\tCiprocin XR TAB dr 1gm 12's pack 240.83\n\tSupreme\tAdecin TAB dr 500mg 30's pack 420\n\tSyntho Ltd.\tSypron TAB dr 500mg 30's pack 375\n\tTechno Drugs Ltd.\tCiplon IV Infusion 200mg/100ml 100ml bot 75\n\tTechno Drugs Ltd.\tCiplon TAB dr 500mg 30's pack 420\n\tTechno Drugs Ltd.\tCiplos DS IV Infusion 400mg/100ml 100ml bot 145\n\tUnimed & Unihealth Manufacturers Ltd.\tAncipro TAB dr 250mg 20's pack 170\n\tUnimed & Unihealth Manufacturers Ltd.\tAncipro TAB dr 500mg 20's pack 280\n\tUnimed & Unihealth Manufacturers Ltd.\tAncipro TAB dr 750mg 20's pack 360\n\tWhite Horse Pharma\tCiproxim TAB dr 250mg 40's pack 333\n\tWhite Horse Pharma\tCiproxim TAB dr 500mg 14's pack 288\n\tZenith\tCiprozen Powder for Suspension 250mg/5ml 60ml bot 75\n\tZenith\tCiprozen TAB dr 250mg 50's pack 400\n\tZenith\tCiprozen DS TAB dr 500mg 50's pack 700\n\tZiska\tQuintor IV Infusion 200mg/100ml 100ml bot 70\n\tZiska\tCiproz TAB dr 500mg  30's pack 300\n\tZiska\tCiproz TAB dr 750mg  20's pack 280\n\tZiska\tCiproz Suspension 250mg  60ml bot 60\n\tZiska\tQuintor TAB dr 500mg 24's pack 240\n\tZiska\tQuintor Suspension 250 mg/ 5 ml 60ml bot 60\n\tAllied\tBactiflox TAB dr 250mg  \n\tAllied\tBactiflox TAB dr 500mg  \n\tOne Pharma Ltd.\tOcimax TAB dr 500mg  \n\tOne Pharma Ltd.\tOcimax Solution 10 gm/100 ml  \n\tIndication: Cystic fibrosis, Intra-abdominal infections, Meningitis, Peritonitis, Endocarditis, Anthrax, Otitis media, Septicaemia, Lower Respiratory Tract Infections, Cystitis, Gonorrhoea, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Enteric fever, Bone and Joint Infections, Biliary tract infections, Surgical Prophylaxis, Gastroenteritis, Q fever, Acute Sinusitis, Cat scratch disease, Spotted fever, Typhus, Chanroid, Brucellosis, Typhoid and paratyphoid fever, Superficial ophthalmic infections, Otitis externa\n\nDose: Adult Dose: For oral dosage & suspension: Urinary Tract infection: Acute uncomplicated: 250 mg twice daily for 3 days; Mild/Moderate: 250 mg twice daily for 7 to 14 days; Severe/Complicated: 500 mg twice daily for 7 to 14 days; \n\nChronic Bacterial Prostitis : 500 mg twice daily for 28 days; \n\nLower Respiratory Tract infection: Mild/Moderate: 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days; \n\nAcute Sinusitis : 500 mg twice daily for 10 days; Skin and Skin Structure infection: Mild/Moderate : 500 mg twice daily for 7 to 14 days, Severe/Complicated : 750 mg twice daily for 7 to 14 days, \n\nBone and joint infection: Mild/Moderate 500 mg twice daily for 4 to 6 weeks, Severe/Complicated : 750 mg twice daily for 4 to 6 weeks, \n\nIntra Abdominal Infection: 500 mg twice daily for 7 to 14 days, Infectious Diarrhea: Mild/Moderate/Severe: 500 mg twice daily for 5 to 7 days, Typhoid Fever : 500 mg twice daily for 10 days, \n\nUrethral & Cervical Gonococcal Infections: Uncomplicated: 250 mg Single dose. \n\nFor IV infusion : Urinary Tract Infection: Mild to Moderate: 200 mg 12 hourly for 7-14 days;Severe or Complicated: 400 mg 12 hourly for 7-14 days; \n\nLower Respiratory Tract infection: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Nosocomial Pneumonia: Mild/Moderate/Severe: 400 mg 8 hourly for 10-14 days; \n\nSkin and Skin Structure: Mild to Moderate: 400 mg 12 hourly for 7-14 days; Severe or Complicated: 400 mg 8 hourly for 7-14 days; Bone and Joint Infection: Mild to Moderate: 400 mg 12 hourly for more than 4-6 weeks; Severe/Comlicated: 400 mg 8 hourly for more than 4-6weeks; \n\nIntra abdominal (Acute abdomen): Complicated: 400 mg 12 hourly for 7-14 days; Acute Sinusitis: Mild/Moderate: 400 mg 12 hourly for10 days: \nChronic Bacterial Prostatitis: Mild/Moderate: 400 mg 12 hourly for 28 Days. \n\nChildren and adolescents: RTI & GI infections: Neonate-15mg/kg twice daily, Child (1 month -18 years)-20mg/kg (max 750 mg) twice daily; \nUTI: Neonate-10 mg/kg twice daily, Child (1 month -18 years)-10mg/kg (max 750 mg) twice daily; \n\nPseudomonal lower respiratory tract infection in cystic fibrosis: Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily; Anthrax (treatment & post exposure prophylaxis): Child (1 month -18 years) - 20mg/kg (max 750 mg) twice daily.\n\nContra-indication: Hypersensitivity. Not to be used concurrently with tizanidine. Avoid exposure to strong sunlight or sun lamps during treatment.\n\nSide effects: GI disturbances; headache, tremor, confusion, convulsions; rashes; joint pain; phototoxicity. Transient increases in serum creatinine. Haematological, hepatic and renal disturbances. Vasculitis, pseudomembranous colitis and tachycardia. Phototoxicity.\nPotentially Fatal: Anaphylactoid reaction; cardiopulmonary arrest.\n\nPrecaution: Epilepsy, history of CNS disorders; severe renal or hepatic dysfunction; G6PD deficiency; maintain adequate hydration; myasthaenia gravis. Caution when used in patients with QT prolongation or risk factors e.g. bradycardia, pre-existing cardiac disease or uncorrected electrolyte disturbances. Discontinue treatment if patients experience tendon pain, inflammation or rupture. Avoid usage in methicillin-resistant staphylococcus aureus (MRSA) infections due to high level of resistance. May impair ability to drive or operate machinery. Safety and efficacy have not been established in pregnant and lactating women. Not to be used in children <18 yr; except where benefit clearly exceeds risk.\n\nMode of action: May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.\nPotentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.\n\nPregnancy category: C\n\nInteraction: May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.\nPotentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
Ciprofloxacin 0.3% E/E prep	\n\n\tACI\tFloxabid Eye Drops 0.3% 5ml drop 40.12\n\tAcme Ltd.\tCipro A E/E Drops   5  ml bot 35.14\n\tApex\tLox E/E Drops   5  ml bot 35\n\tAristopharma\tAprocin E/E Drops   10 ml bot 50\n\tAristopharma\tAprocin Eye Ointment   3gm tube 32\n\tAsiatic Ltd.\tCip E/E Drops   10 ml bot 35\n\tAsiatic Ltd.\tCip Eye Ointment   3gm tube 20\n\tBeximco\tNeofloxin E/E Drops   5  ml bot 40\n\tChemist Ltd.\tCipro C E/E Drops   5  ml bot 30\n\tDrug International Ltd.\tCiprozid E/E Drops   10 ml bot 35\n\tG. A. Company Ltd.\tCero E/E Drops   5  ml bot/ 10 ml bot 40 / 50\n\tG. A. Company Ltd.\tCero Eye Ointment   5gm tube 32\n\tHealthcare\tRocipro E/E Drops  300 mg/100 ml 5ml drop 45\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBactin E/E Drops   5  ml bot/10 ml bot 35.14 / 50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBactin Eye Ointment  300 mg/100 gm 3gm tube 35\n\tIncepta\tBeuflox E/E Drops  5  ml bot 40\n\tJayson\tSpectra E/E Drops   5  ml bot 15.05\n\tKemiko\tProcin E/E Drops   10 ml bot 35\n\tNavana\tFloxacin E/E Drops   10ml drop 50\n\tNipa\tCiprin E/E Drops   5  ml bot / 10 ml bot  40 / 50\n\tNipa\tCiprin Eye Ointment   3gm tube 35\n\tOpso Saline Ltd.\tCiproxy E/E Drops   10 ml bot 30\n\tOpso Saline Ltd.\tCiproxy Eye Ointment   3gm tube 20\n\tOpsonin Pharma\tCiprox Eye/Ear Drops 300 mg/100 ml  \n\tPopular\tCivox E/E Drops  300 mg/100 ml 5  ml bot 35.13\n\tReman Drug Ltd.\tCiflox E/E Drops   5  ml bot / 10 ml bot  24.50 / 50\n\tReman Drug Ltd.\tCiflox Eye Ointment   5gm tube 35\n\tRenata\tFlontin E/E Drops   10 ml bot 25.39\n\tSquare\tCiprocin E/E Drops   5  ml bot 40.15\n\tIndication: Otitis media, Superficial ophthalmic infections, Otitis externa\n\nDose: Eye drops: \nCorneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is 2 drops into the affected eye every 15 minutes for the first 6 hours and then 2 drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill 2 drops in the affected eye hourly. On the third through the fourteenth day, place 2 drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.\nConjunctivitis: The recommended dosage regimen for the treatment of bacterial conjunctivitis is 1 or 2 drops instilled into the conjunctival sac(s) every 2 hours while awake for 2 days and one or 2 drops every 4 hours while awake for the next 5 days.\n\nEye ointment: A thin film of Aprocin Sterile Eye Ointment should evenly be applied either directly to the affected part or inside the lower conjunctival sac at night (if eye drops used during the day) or 3-4 times daily depending on the severity of the condition (if eye ointment used alone).\n\nEar drops: \nFor all infections, 2-3 drops every 2-3 hours initially, reducing the frequency of the instillation with control of infection. Treatment should be continued at least 7 days. \n\nContra-indication: Ciprofloxacin is contraindicated in patients who have hypersensitivity to Ciprofloxacin or other quinolones.\n\nSide effects: Local burning or discomfort, itching, foreign body sensation, crystalline precipitates, lid margin crusting, conjunctival hyperemia and a bad taste following administration. Photophobia and nausea may be reported.\n\nPrecaution: Prolonged use of Ciprofloxacin may result in overgrowth of nonsusceptible organisms including fungi. Ciprofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction. Not for injection into the eye.\n\nMode of action: May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.\nPotentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.\n\nPregnancy category: C\n\nInteraction: May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.\nPotentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
Ciprofloxacin 0.3% + Dexamethasone 0.1% E/E prep	\n\n\tAcme Ltd.\tCipro-D Eye/Ear Drops   5ml 75\n\tApex\tLox-D Eye/Ear Drops   5ml bot 75\n\tAristopharma\tAprodex Eye/Ear Drops   5  ml drop 75\n\tAsiatic Ltd.\tCip-D Eye/Ear Drops   5  ml drop 75\n\tBeximco\tNeofloxin-D Eye/Ear Drops   5  ml drop 75\n\tDrug International Ltd.\tCiprozid DX Eye/Ear Drops   5ml drop 75\n\tG. A. Company Ltd.\tCerodex Eye/Ear Drops   5ml bot 75.28\n\tGeneral\tDexaflox E/E drops Eye/Ear Drops   5ml bot 75\n\tHealthcare\tRocipro Eye Drops (300 mg + 100 mg)/100 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tBactin D Eye/Ear Drops  300 mg + 100 mg/100 ml 5  ml drop 75.28\n\tIncepta\tBeuflox D Eye/Ear Drops   5  ml drop 75\n\tKemiko\tProcin-D Eye/Ear Drops   5ml drop 75\n\tNavana\tQuidex Eye/Ear Drops   5ml bot 75\n\tNipa\tOpdex Eye/Ear Drops  300 mg + 100 mg/100 ml 5  ml drop 75\n\tPopular\tCivodex Eye/Ear Drops  300 mg + 100 mg/100 ml 5  ml drop 75.28\n\tIndication: Steroid responsive inflammatory ocular conditions, Otitis media, Otitis externa, Ocular inflammation associated with infection, Post-operative inflammation of ear and eye.\n\nDose: For Eye: 1 drop to be instilled into conjunctival sac(s) every four to six hours. During the initial 24 to 48 hours, the dosage may be increased to 1 drop every two hours.\n\nFor Ear: Acute otitis media in pediatric patients with typanastomy tube: 4 drops instilled into the affected ear 2 times daily for 7 days. Acute otitis externa: 4 drops instilled into the affected ear 2 times daily for 7 days.\nFrequency should be decreased gradually or warranted in clinical signs. Care should be taken not to discontinue therapy prematurely.\n\nContra-indication: Known hypersensitivity to any ingredient of the product. Herpes simplex and other viral conditions, mycosis, glaucoma, newborn babies, fungal diseases of ocular or auricular structures.\n\nSide effects: The most frequently reported drug-related adverse reactions seen with Ciprofloxacin are transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, conjunctivitis/keratitis, periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain. Rare reports of dizziness have been received.\n\nThe reactions due to the steroid component are elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage, posterior sub capsular cataract formation, and delayed wound healing.\n\nPrecaution: Prolonged use may result in overgrowth of nonsusceptible organisms including fungi; in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision and posterior sub capsular cataract formation.\n\nPatients wearing contact lenses must not use the drops during the time the lenses are worn.\n\nMode of action: May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.\nPotentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.\n\nPregnancy category: C\n\nInteraction: May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.\nPotentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
Ciprofloxacin 0.3% + Hydrocortisone Acetate 1% E/E prep	\n\n\tAristopharma\tAprocin HC Eye/Ear Drops   10ml bot 50\n\tDrug International Ltd.\tCiprocort Eye/Ear Drops   10 ml drop 90\n\tG. A. Company Ltd.\tCero HC Eye/Ear Drops   10 ml drop 55\n\tIndication: Steroid responsive inflammatory ocular conditions, Otitis media, Otitis externa, Ocular inflammation associated with infection, Post-operative inflammation of ear and eye, Corneal Ulcers, Bacterial Conjunctivitis\n\nDose: Eye:\nCorneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcer is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.\nBacterial Conjunctivitis:\nThe recommended dosage regimen for the treatment of bacterial conjunctivitis is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.\n\nEar:\nFour drops instilled into the affected ear twice daily for seven days. The suspension should be warmed by holding the bottle in the hand for one or two minutes to avoid dizziness, which may result from the instillation of a cold suspension. The patient should lie with the affected ear upward, and then the suspension should be instilled. This position should be maintained for 60 seconds. Repeat, if necessary, for the opposite ear.\n\nPaediatric Use:\nEar: Safety and effectiveness of this suspension in pediatric (6 months of age and older) patients for ear application have been established.\nEye:\nSafety and effectiveness of this suspension in pediatric patients for eye application have not been established.\n\n\n\nContra-indication: Known hypersensitivity to any ingredient of the product. Herpes simplex and other viral conditions, mycosis, glaucoma, newborn babies, fungal diseases of ocular or auricular structures.\n\nSide effects: The most frequently reported drug-related adverse reactions seen with Ciprofloxacin are transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness and eye pain. Rare reports of dizziness have been received.\n\nThe reactions due to the steroid component are elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior sub-capsular cataract formation and delayed wound healing.\n\nPrecaution: Prolonged use may result in overgrowth of nonsusceptible organisms including fungi; in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision and posterior sub capsular cataract formation. Patients wearing contact lenses must not use the drops during the time the lenses are worn.\n\nMode of action: May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.\nPotentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.\n 	Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.\n\nPregnancy category: A\n\nInteraction: May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin.\nPotentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.\n 	Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.
Cisplatin	\n\n\tBeacon\tPlatinex Injection 10mg/ml 10 mgl vial x 1's pack 165\n\tGlobex\tCisplatin Injection 50mg 1's  pack 630.87\n\tNovartis (Bangladesh) Ltd.\tCisplathin Hexal Injection 10mg/20ml 1's vial 313\n\tNovartis (Bangladesh) Ltd.\tCisplathin Hexal Injection 50mg/100ml 1's vial 853\n\tTechno Drugs Ltd.\tCesalin Injection  50mg/ml 1's pack 800\n\tTechno Drugs Ltd.\tCesalin Injection 10mg/ml 1's pack 220\n\tHexal ag, Germany\tCisplatin Hexal PI Injection 10mg/Vial 20 ml vial x 1's pack 313\n\tHexal ag, Germany\tCisplatin Hexal PI Injection 50mg/Vial 100 ml vial x 1's pack 853\n\tPharmachemie B.V., Holland\tPlatosin Injection  10mg 10 mg vial x 1's pack 1687\n\tIndication: Lymphomas, Sarcomas, Carcinomas, Small cell lung cancer, Ovarian cancer, Germ cell tumors, Metastatic Testicular Tumors, Metastatic Ovarian Tumors, Advanced Bladder Cancer\n\nDose: Adult: IV Metastatic ovarian cancer As monotherapy: 100 mg/m2 per cycle, given as a single dose once every 4 wk. For combination therapy w/ cyclophosphamide: 75-100 mg/m2 on day 1 of every 4-wk cycle. \n\nMetastatic testicular tumours 20 mg/m2/day for 5 days per cycle. Advanced bladder cancer 50-70 mg/m2 per cycle once every 3-4 wk.\n\nContra-indication: Patients with severe renal or auditory disorder, known hypersensitivity, severe bone marrow suppression, peripheral neuropathy, pregnancy, lactation.\n\nSide effects: Severe nausea and vomiting. Serious toxic effects on the kidneys, bone marrows and ears. Hypomagnesaemia, hypocalcaemia, hyperuricaemia. Peripheral neuropathies, papilloedema, optic neuritis, seizures. Ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity.\nPotentially Fatal: Rarely, renal damage due to inadequate hydration during therapy. Very rarely life-threatening myelosuppression. Anaphylactoid reactions (rare) and cardiac abnormalities.\n\nPrecaution: Patients with renal or hepatic disorder, myelosuppression. Monitor renal, neurological and auditory function. Perform blood counts regularly. Maintain adequate hydration before and 24 hr after admin to minimise nephrotoxicity.\n\nMode of action:  	Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ?100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression.\nPotentially Fatal: Potentiates nephrotoxicity with aminoglycosides. Increased toxicity when combined with other cytotoxic drugs.\n\nPregnancy category: D\n\nInteraction:  	Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ?100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression.\nPotentially Fatal: Potentiates nephrotoxicity with aminoglycosides. Increased toxicity when combined with other cytotoxic drugs.
Citalopram Hydrobromide	\n\n\tGeneral\tCitapram TAB dr 10mg 50's pack 251\n\tGeneral\tCitapram TAB dr 20mg 30's pack 240.90\n\tIncepta\tArpolax TAB dr 20mg 30's pack 240\n\tIndication: Depressive illness, Bipolar disorder, Panic disorder, Substance abuse disorders, Alcohol dependence, Anxiety disorders including obsessive-compulsive disorder and social phobia, Post-traumatic stress disorder, Premenstrual syndrome, Idiopathic Parkinson's disease and Eating disorder.\n\nDose: Adult: Initially, 20 mg daily, increased to 40 mg once daily after at least 1 wk or 60 mg daily if necessary. \nHepatic impairment: Recommended dose: 20 mg daily. \n\nOral Depressive phase of bipolar disorder: Adult: Initially, 20 mg daily, increased to 40 mg once daily after at least 1 wk or 60 mg daily if necessary.\nHepatic impairment: Recommended dose: 20 mg daily. \n\nOral Panic disorder with or without agoraphobia: Adult: Initially, 10 mg daily, increased to 20 mg daily after 1 wk. Max: 60 mg daily. \nHepatic impairment: Recommended dose: 20 mg daily. Special Populations: Patients with reduced hepatic function should receive dosages of no more than 30 mg/day.\n\nElderly maximum 40 mg daily.\n\n\nContra-indication:  Hypersensitivity, concomitant admin with MAOIs or within 14 days of discontinuing MAOI treatment; children and adolescents <18 yr; treatment of depressive illness; lactation.\n\nSide effects:  Increased sweating, headache, tremor, fatigue, asthenia, dizziness, abnormal accommodation, somnolence, insomnia, agitation, nervousness, nausea, dry mouth, constipation, diarrhoea, palpitation, rash, pruritus, abnormal vision, decreased libido, anxiety, increased appetite, anorexia, apathy, impotence, suicide attempt, confusion, yawning, dyspepsia, vomiting, abdominal pain, flatulence, increased saliva, weight decrease or increase, postural hypotension, tachycardia, rhinitis, ejaculation failure, fatigue, extrapyramidal disorders.Potentially Fatal: Increased risk of suicidal thinking and behaviour especially in child and adolescents. Monitor closely for signs of clinical worsening, suicidality or unusual changes in behaviour.\n\nPrecaution:  Caution should be taken in patients with epilepsy, concurrent electroconvulsive therapy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, history of bleeding disorders, hepatic and renal impairment. Abrupt withdrawal of Citalopram should be avoided. Gradual discontinuation of treatment if patient enters into manic phase; pregnancy. Increased risk of hyponatraemia and SIADH. May reduce convulsant threshold thus, citalopram should be used with care in epileptic patients.\n\nMode of action:  	May increase anticoagulant effect w/ drugs affecting haemostatis (e.g. warfarin). Increased risk of hypomania w/ sibutramine. Increased lowering seizure threshold w/ TCAs and other SSRIs.\nPotentially Fatal: Increased risk of severe adverse effects (e.g. serotonin syndrome) w/ MAOI. QT interval prolongation w/ subsequent risk of torsade de pointes w/ QT-prolonging drugs (e.g. pimozide, quinidine, procainamide, chlorpromazine, thioridazine, amiodarone, sotalol, moxifloxacin, pentamidine, levomethadyl, methadone).\n\nPregnancy category: C\n\nInteraction:  	May increase anticoagulant effect w/ drugs affecting haemostatis (e.g. warfarin). Increased risk of hypomania w/ sibutramine. Increased lowering seizure threshold w/ TCAs and other SSRIs.\nPotentially Fatal: Increased risk of severe adverse effects (e.g. serotonin syndrome) w/ MAOI. QT interval prolongation w/ subsequent risk of torsade de pointes w/ QT-prolonging drugs (e.g. pimozide, quinidine, procainamide, chlorpromazine, thioridazine, amiodarone, sotalol, moxifloxacin, pentamidine, levomethadyl, methadone).
Citicoline	\n\n\tBeximco\tCiticol Injection 500mg/4ml 5's pack 700\n\tUnimed & Unihealth Manufacturers Ltd.\tCognilin TAB dr 500mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tCogniz TAB dr 500mg  \n\tIndication:  	Attention deficit disorder, Ischemic stroke, glaucoma, amblyopia, Parkinson's disease, Cerebrovascular disorders; Head injury,  Alzheimer's Disease, 							\n\n\nDose: Adult:  IV/IM Parkinson's disease; Cerebrovascular disorders; Head injury Up to 1 g/day.\n\nContra-indication: Known hypersensitivity \n\nSide effects: Citicoline seems to be safe when taken short-term (up to 90 days). The safety of long-term use is not known. Most people who take citicoline don't experience problematic side effects. But some people can have side effects such as trouble sleeping (insomnia), headache, diarrhea, low or high blood pressure, nausea, blurred vision, chest pains, and others. \n\nPrecaution:  Not enough is known about the use of citicoline during pregnancy and breast-feeding. Stay on the safe side and avoid use.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Citric Acid Monohydrate 5% + Potassium Citrate 30%	\n\n\tEskayef Bangladesh Ltd.\tUrokit Plus Oral Solution (5 gm + 30 gm) / 100 ml  \n\tIncepta\tUrikal Oral Solution   200ml 200\n\tNovelta Bestway\tUrinor Oral Solution   200ml bot 200\n\tSquare\tUriset Oral Solution 5 gm + 30 gm/100 ml  \n\tUnimed & Unihealth Manufacturers Ltd.\tCitra-K Syrup  200ml bot 180\n\tIndication: Prevention of gout and kidney stones, Urine alkalinization, Renal tubular acidosis\n\nDose: To relieve discomfort in UTI:\nAdults & children over 6 years: 10 ml 3 times daily, diluted with 1 glass of water.\nChildren 1-6 years: 5 ml 3 times daily, diluted with 1/2 glass of water.\n\nTo prevent kidney stones, acidosis caused by kidney diseases, with uricosuric agent to prevent gout:\nAdults: 10-15 ml 4 times daily; or as directed by the physician, diluted with 1 glass of water.\nPediatric: 5-10ml 4 times daily; or as directed by the physician, diluted with 1/2 glass of water.\n\nContra-indication: The drug is contraindicated in severe renal impairment with oliguria or azotemia, untreated Addison's disease, acute dehydration, severe myocardial damage, and hyperkalemia from any cause.\n\nSide effects: This solution is generally well tolerated without any unpleasant side effect when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis. Potassium intoxication causes listlessness, weakness, mental confusion, tingling of extremities, and other symptoms associated with a high concentration of potassium in the serum. \n\nPrecaution: The solution should be used with caution in patients with low urinary output. It should be diluted adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations; and preferably, to take each dose after meals. Large doses may cause hyperkalemia and alkalosis, especially in the presence of renal disease.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Clindamycin 1%	\n\n\tACI\tDaclin Lotion  1% 25ml bot 125.38\n\tAristopharma\tClinex Lotion   25ml bot 125\n\tEskayef Bangladesh Ltd.\tLindamax Lotion  10mg/ml 25ml bot 125\n\tIncepta\tClindacin Lotion Lotion  1% 25ml bot 125\n\tOpsonin Pharma\tClindax Lotion Lotion   25ml bot 125\n\tIndication: Acne vulgaris, erythrasma, rosacea, periorificial dermatitis, folliculitis, stasis, chronic lymphaedema and familial pemphigus, dermal ulcers.\n\nDose: Clean the face or affected area gently with warm water or soap as recommended by the physician. After the skin is dried, apply a thin film of lotion to the affected areas twice daily, in the morning and in the evening. \n\nDo not wash within three hours after using lotion. The treatment period is usually 6 weeks or as advised by the physician.\n\nHowever, 8 to 12 weeks of treatment may be required for maximum benefit.\n\nContra-indication: Contraindicated in patients with hypersensitivity to clindamycin.\n\nSide effects: Side effects are usually rare. Possible side-effects may includes skin rash, itching, oily skin, dryness, erythema, burning, change in skin color, diarrhea, colitis, GI disturbance etc.\n\nPrecaution: It is not for oral, ophthalmic, or Intravaginal use.\nAvoid exposure to sunlight and sunlamps. Wear sunscreen daily.\n\nMode of action:  	May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).\n\nPregnancy category: B\n\nInteraction:  	May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).
Clindamycin 2% Vaginal prep	\n\n\tBeximco\tClinacyn Vaginal Cream 20 mg/gm  \n\tHealthcare\tCleocin Vaginal Cream 20mg/gm 20gm tube 70\n\tIncepta\tClindacin Vaginal Cream   1's pack 70\n\tOpsonin Pharma\tClindax Vaginal Cream    20gm tube 70\n\tIndication: Bacterial vaginosis\n\nDose: Adult: As 2% cream: One applicator full (approximately 5 gram) intravaginally at bedtime for 7 consecutive days. In patients in whom a shorter treatment course is desirable, a 3 day regimen has been shown to be effective.\n\nContra-indication: Hypersensitivity.Clindamycin cream is also contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or a history of "antibiotic-associated" colitis.\n\nSide effects: Genital tract: vaginitis, vulvo-vaginal irritation Central nervous system: dizziness, headache, vertigo.Gastro-intestinal: heartburn, nausea, vomiting, diarrhea, constipation, abdominal pain. Dermatological: rash, exanthema. Hypersensitivity: urticaria.\n\nPrecaution: The patient should be instructed not to engage in vaginal intercourse, or use other vaginal products during treatment with this product. This cream contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, use of such products within 72 hours following treatment with Clindacin cream is not recommended.\n\nClindacin cream is not recommended in children under 12 years of age.\n\nMode of action:  	May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).\n\nPregnancy category: B\n\nInteraction:  	May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).
Clindamycin Phosphate 1.2% + Tretinoin 0.025% Topical	\n\n\tACI\tDaclin Plus Gel  15gm tube x 1 's pack 150\n\tAristopharma\tClinex Plus Gel   15gm tube x 1 's pack 150\n\tBeximco\tClinacyn T Gel (1.2 gm + 0.025 gm)/100 g  \n\tDrug International Ltd.\tDalacin Plus Gel   15gm tube x 1 's pack 150\n\tEskayef Bangladesh Ltd.\tLindamax Plus Gel (1.2 gm + .025 gm)/100 gm  \n\tIncepta\tClindacin Plus Gel   15gm tube x 1 's pack 150\n\tOpsonin Pharma\tClindax Plus Gel   10gm tube x 1 's pack 120\n\tSquare\tClinface Gel 1.2 gm + .025 gm/100 gm  15gm tube x 1 's pack 150.57\n\tIndication: Acne vulgaris\n\nDose: At first wash the face or affected area gently with warm water or soap.\nClindacin plus gel: When the skin is completely dried (about 30 minutes later) apply a pea-size amount of Clindacin plus gel to your fingertip and spread it over your face once daily preferably at bed time. Treatment should be continued for 12 weeks or as directed by the physician.\nEye, lip or nose contact should be avoided while applying Clindacin plus gel.\n\nContra-indication: Contraindicated in patients with hypersensitivity to clindamycin or tretinoin or any of the ingredients of these medicine.\n\nSide effects: Side effects are usually rare. Possible side-effects may includes skin rash, itching, oily skin, dryness, erythema, burning, change in skin color, diarrhea, colitis, GI disturbance etc.\n\nPrecaution: Clindacin plus gel is not for oral, ophthalmic, or Intravaginal use.\nAvoid exposure to sunlight and sunlamps. Wear sunscreen daily.\n\nMode of action: Clindamycin: May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).\n\nTretinoin: Enhances percutaneous absorption of minoxidil. Increased risk of fatal thrombotic complications with antifibrinolytic. Increased tretinoin concentrations with azole antifungals. Enhances peeling action of sulphur, resorcinol, benzoyl peroxide, salicylic acid. Increased photosensitivity with photosensitising medications eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides.\nPotentially Fatal: Increased risk of intracranial pressure with tetracyclines.\n\nPregnancy category: A\n\nInteraction: Clindamycin: May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).\n\nTretinoin: Enhances percutaneous absorption of minoxidil. Increased risk of fatal thrombotic complications with antifibrinolytic. Increased tretinoin concentrations with azole antifungals. Enhances peeling action of sulphur, resorcinol, benzoyl peroxide, salicylic acid. Increased photosensitivity with photosensitising medications eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides.\nPotentially Fatal: Increased risk of intracranial pressure with tetracyclines.
Clioquinol 1% + Flumetasone Pivalate 0.02% Ear prep	\n\n\tAristopharma\tFlumetanol Ear Drops   5  ml drop 100\n\tIncepta\tCliomet Ear Drops  5ml 100\n\tIndication: Inflammation of the external ear\n\nDose: Adult: Otic As soln containing flumetasone pivalate 0.02% w/v and clioquinol 1% w/v: Instill 2-3 drops twice daily into the auditory canal. Recommended duration: 7-10 days.\n\nContra-indication: Hypersensitivity to any component of the formulation or iodine. Primary bacterial, viral or fungal infections of the outer ear. Tympanic membrane perforation. Children <2 yr.\n\nSide effects: May cause irritation at the site of application such as burning sensation, itching or skin rash. May cause hair discolouration.\n\nPrecaution: Prolonged use may lead to adrenal suppression. Preparation should not come into contact with the conjunctiva. Discontinue treatment if there is severe irritation or sensitisation or if there is no improvement after 1 wk of application. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Clobazam	\n\n\tAcme Ltd.\tCosium TAB dr 10mg 100's pack 351\n\tAlbion Ltd.\tAlsium TAB dr 10 mg 100's pack \n\tAlco Pharma\tTensnil TAB dr 10mg 100's pack 400\n\tBeximco\tKeolax TAB dr 10mg 100's pack 277\n\tBio Pharma Ltd.\tCalm TAB dr 10mg 100's pack 276\n\tDoctor's Chemicals Works Ltd.\tDanium TAB dr 10mg 100's pack 290\n\tEdruc Ltd.\tEbazam TAB dr 10mg 100's pack 300\n\tGlobe\tNebium TAB dr 10mg 100's pack 255\n\tHudson\tVenium TAB dr 10mg 100's pack 270\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTranquil TAB dr 10mg 100's pack 400\n\tKemiko\tProcalm TAB dr 10mg 100's pack 300\n\tMedimet\tClobid TAB dr 10mg 100's pack 275\n\tNavana\tClozam TAB dr 10mg 100's pack 285\n\tNipa\tPrezium TAB dr 10mg 100's pack 250\n\tOpsonin Pharma\tClob TAB dr 10mg 100's pack 242.80\n\tOrion Pharma Ltd.\tDetens TAB dr 10mg 30's pack 75\n\tPharmadesh Ltd.\tColax TAB dr 10mg 50's pack 137.50\n\tRephco\tNoanxit TAB dr 10mg  \n\tSanofi Aventis (BD) Ltd.\tFrisium TAB dr 10mg 100's pack 400\n\tSquare\tClobam TAB dr 10mg 100's pack 400\n\tZenith\tEpson TAB dr 10mg 100's pack 280\n\tIndication: Anxiety, tension, irritability, restlessness, epilepsy.\n\nDose: Oral\nShort-term management of anxiety, Adjunct in epilepsy\nAdult: 20-30 mg as a single dose at night or as daily divided doses, increased to 60 mg/day in severe conditions.\nChild: 3-12 yr: 125 mcg/kg bid increased every 5 days. Usual maintenance dose: 250 mcg/kg bid. Max: 500 mcg/kg bid.\nElderly: or debilitated patients: 10-20 mg daily.\nHepatic impairment: Dose adjustment may be needed.\n\nContra-indication: Hypersensitivity; history of drug dependence; myasthaenia gravis; pregnancy (1st trimester), lactation; serious liver damage; sleep apnoea syndrome; impaired respiratory function.\n\nSide effects: Constipation, anorexia, nausea; dizziness, fine tremors; worsening of respiratory symptoms in predisposed individuals; ataxia, drowsiness, headache, confusion; loss of libido, motor dysfunction; dependence; visual disturbances and weight gain.\nPotentially Fatal: Respiratory depression.\n\nPrecaution: May impair ability to perform skilled tasks and hazardous activities; elderly; renal or hepatic impairment; alcoholics; obesity; withdrawal should be gradual.\n\nMode of action: Increased hepatic clearance of clobazam when administered with phenytoin, phenobarbital or carbamazepine. Cimetidine may increase levels of clobazam.\nPotentially Fatal: Concurrent alcohol, hypnotics and sedative antidepressants can potentiate CNS side effects of clobazam\n\nPregnancy category: C\n\nInteraction: Increased hepatic clearance of clobazam when administered with phenytoin, phenobarbital or carbamazepine. Cimetidine may increase levels of clobazam.\nPotentially Fatal: Concurrent alcohol, hypnotics and sedative antidepressants can potentiate CNS side effects of clobazam
Clobetasol Propionate 0.05%	\n\n\tACI\tClovate Cream  0.05% 10gm  tube 58.17\n\tACI\tClovate Ointment  0.05% 10gm  tube 68.20\n\tACI\tClovate Scalp Solution 0.05% 30ml  200.60\n\tAcme Ltd.\tAclobet Cream   10gm  tube 45\n\tAcme Ltd.\tAclobet Ointment   10gm  tube 50\n\tAristopharma\tClobesol Cream   10gm  tube 45\n\tAristopharma\tClobesol SA Ointment   10gm  tube 50\n\tAristopharma\tClobesol Ointment 50 mg/100 gm  \n\tAsiatic Ltd.\tProtasol Cream   10gm tube / 20gm tube 45 / 70\n\tAsiatic Ltd.\tProtasol Ointment   10gm tube 50\n\tBeximco\tExovate Cream   10gm  tube 45\n\tBeximco\tExovate Ointment   10gm  tube 50\n\tBio Pharma Ltd.\tXderm Cream   10gm  tube 45.17\n\tBio Pharma Ltd.\tXderm Ointment   10gm  tube 50.19\n\tDrug International Ltd.\tClobederm Cream 50 mg/100 gm  10gm  tube 50\n\tDrug International Ltd.\tClobederm Ointment 50 mg/100 gm  \n\tEskayef Bangladesh Ltd.\tTopiclo Cream   10gm  tube 45\n\tEskayef Bangladesh Ltd.\tTopiclo Ointment   10gm  tube 50\n\tG. A. Company Ltd.\tSkinovate Cream   10gm  tube 50.19\n\tGeneral\tEclo Cream   10gm  tube 45.17\n\tGeneral\tEclo Ointment   10gm  tube 40.19\n\tGlaxoSmithKline Bangladesh Ltd.\tDermovate Cream   10gm  tube 58.21\n\tGlaxoSmithKline Bangladesh Ltd.\tDermovate Ointment   10gm  tube 68.26\n\tHealthcare\tTemovate Ointment   10 gm tube 68\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDermacort Cream   10gm  tube 50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDermacort Ointment   10gm  tube 52\n\tIncepta\tNyclobate Ointment 10mg/20mg 1's pack 50/75\n\tIncepta\tNyclobate Shampoo  60 ml 1's pack 350\n\tIncepta\tNyclobate Scalp Application Scalp Lotion  30ml bot 1's pack 200\n\tIncepta\tNyclobate Cream 10mg/20mg 10gm tube/ 20gm tube 45/70\n\tKemiko\tClonate Ointment 50 mg/100 gm  \n\tKumudini Pharma Ltd.\tDermatas Cream   10gm  tube 45\n\tMillat\tBederm Cream   10gm  tube 35\n\tOpsonin Pharma\tDermex Cream   10gm  tube 43.80\n\tOpsonin Pharma\tDermex Ointment   10gm  tube 48.70\n\tOrion Pharma Ltd.\tXenocort Cream   10gm  tube 40.15\n\tOrion Pharma Ltd.\tXenocort Ointment   10gm  tube 50.19\n\tPharmasia Ltd.\tCobesol Cream   10gm  tube 45.17\n\tPharmasia Ltd.\tCobesol Ointment   10gm  tube 50.19\n\tPopular\tSynovate Ointment  50 mg/100 gm 10gm  tube 50.19\n\tRAK\tClobenate Cream   10gm  tube 45\n\tRAK\tClobenate Ointment   10gm  tube 50\n\tSanofi Aventis (BD) Ltd.\tComol Ointment 50 mg/100 gm  \n\tSharif\tDersole Cream   10gm  tube 45\n\tSharif\tDersole Ointment   10gm  tube 50\n\tSquare\tDermasol Cream  50 mg/100 gm 10gm  tube/20gm  tube 45.16 / 70.26\n\tSquare\tDermasol Ointment  50 mg/100 gm 10gm  tube/ 20gm  tube 50.20 / 75.28\n\tSquare\tDermasol-S Scalp Solution 0.05% 30ml bot 200\n\tUnimed & Unihealth Manufacturers Ltd.\tXenovate Ointment   10gm/30gm  tube 68/131.95\n\tUnimed & Unihealth Manufacturers Ltd.\tXenovate Scalp Lotion   10gm  tube 58\n\tAspen Bad Oldesloe, Germany\tDermovate Scalp Application Solution 0.50mg/gm 30ml bot 250	\n\tIndication: Corticosteroid-responsive Dermatoses, Psoriasis, Scalp Psoriasis, Plaque-type Psoriasis, Vitiligo, Eczema, Alopecia areata, Herpes labialis, Lichen sclerosus, Lichen, Mycosis fungoides, Corticosteroid-responsive dermatoses\n\nDose: Adults and children over 1 year:\nApply sparingly to cover the affected area, and gently rub into the skin. Frequency of application is 2 to 3 times daily according to the severity of the condition. The total dose applied should not exceed 50 g weekly.\n\nTreatment should not be continued for more than 7 days without medical supervision. If a longer course is necessary, it is recommended that treatment should not be continued for more than 4 weeks without the patient's condition being reviewed.\n\nRepeated short courses of Clobetasol may be used to control exacerbations\nChildren below 1 year: Under 1 year this preparation is not recommended.\n\nScalp Application\n It should be applied to the affected scalp areas twice daily, once in morning and once at night.\nTotal dosage should not exceed 50 ml per week.\nAs with other highly active topical steroid preparations, therapy should be discontinued when control is achieved\nChildren: Under 1 year this preparation is not recommended.\n\nShampoo\nIt should be applied to the dry (not wet) scalp once a day to the affected areas only.\nIt should be massaged gently into the lesions and left in place for 15 minutes before lathering and rinsing.\nTreatment should be limited to 4 consecutive weeks.\nTotal dosage of shampoo should not exceed 50 g per week.\nUnder 18 years this preparation is not recommended.\n\nContra-indication: Childn <12 yrs. Long-term treatment of ulcerative conditions, rosacea, pruritus; It is contraindicated in rosacea, acne vulgaris, perioral dermatitis, primary cutaneous viral infections (eg. herpes simplex, chickenpox), otitis externa with a perforated eardrum, hypersensitivity to the preparations. Scalp application is contraindicated in infection of the scalp.\n\nSide effects: Perioral dermatitis, striae esp in flexures. Dermal and epidermal atrophy esp on the face, steroid purpura. Potentially Fatal: Prolonged usage of large amount of clobetasol propionate can lead to sufficient systemic levels to produce adrenal suppression, Cushing's syndrome, diabetes and hypertension.\n\nPrecaution: Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even without occlusion. If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye. If used in psoriasis careful patient supervision is important.\nScalp Application: Keep away from eye. Flammable. Do not use or dry the hair near a fire or flame.\nScalp Shampoo: Do not use on areas other than the scalp. Keep away from eye.\n\nMode of action: Increased systemic exposure w/ CYP3A4 inhibitors (eg ritonavir & itraconazole).\n\nPregnancy category: C\n\nInteraction: Increased systemic exposure w/ CYP3A4 inhibitors (eg ritonavir & itraconazole).
Clobetasol Propionate 0.05% + Neomycin Sulphate 0.5% + Nystatin BP 1,00,000 IU.	\n\n\tACI\tClovate N Cream  0.05%+0.5%+100000 units/ 10gm  tube 60.20\n\tACI\tClovate N Ointment  0.05%+0.5%+100000 units/ 15gm  tube 70.21\n\tAcme Ltd.\tAclobet-N Cream   10gm  tube 60\n\tAcme Ltd.\tAclobet-N Ointment   15gm  tube 65.25\n\tAcme Ltd.\tAclobet N Ointment .5mg 1's pack(15g) 65.25\n\tAcme Ltd.\tAclobet N Cream 5mg 1's pack(15g) 60\n\tBeximco\tExovate N Cream   25gm  tube 75\n\tEskayef Bangladesh Ltd.\tTopiclo NN Cream  .5mg/g 10g 45\n\tEskayef Bangladesh Ltd.\tTopiclo NN Ointment  .5% 10g 50\n\tIncepta\tNyclobate NN Cream 10gm/20gm 1's pack 60/80\n\tKemiko\tClonate NN Cream (50 mg + 500 mg + 1 Lac I  \n\tNovo Healthcare and Pharma Ltd.\tVesol-N Cream   10gm  tube 60\n\tOpsonin Pharma\tDermex-NN Cream  10gm tube 55\n\tOpsonin Pharma\tTopivate-NN Cream  10mg Tube \n\tRAK\tClobeon Cream   10gm  tube 60\n\tSanofi Aventis (BD) Ltd.\tComol-NN Ointment (50 mg + 500 mg + 100 Lac  \n\tSquare\tDermasol N Cream  50 mg + 500 mg + 100 Lac 15gm  tube 60.22\n\tSquare\tDermasol N Ointment  50 mg + 500 mg + 100 Lac 15gm  tube 65.25\n\tIndication: Psoriasis, Eczema, Severe inflammatory skin disorders\n\nDose: Adults and children over 2 years:\nApply sparingly to the affected area once or twice daily until improvement occurs. As with other highly active topical steroid preparations therapy should be discontinued when control is achieved. \n\nTreatment should not be continued for more than 7 days without medical supervision. If a longer course is necessary, it is recommended that treatment should not be continued for more than 4 weeks without the patient's condition being reviewed. \n\nElderly: This preparation is suitable for use in the elderly. Caution should be exercised in cases where a decrease in renal function exists and significant systemic absorption of Neomycin Sulphate may occur.\n\nChildren: Under 2 years this preparation is not recommended.\n\nContra-indication: Childn <12 yrs. Long-term treatment of ulcerative conditions, rosacea, pruritus; presence of acute infections. Hypersensitivity.\n\nSide effects: Perioral dermatitis, striae esp in flexures. Dermal and epidermal atrophy esp on the face, steroid purpura.\nPotentially Fatal: Prolonged usage of large amount of clobetasol propionate can lead to sufficient systemic levels to produce adrenal suppression, Cushing's syndrome, diabetes and hypertension.\n\nPrecaution: Long-term continuous topical therapy should be avoided where possible, particularly in infants and children, as adrenal suppression can occur readily even without occlusion. If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye. If used in psoriasis careful patient supervision is important. Scalp Application: Keep away from eye. Flammable. Do not use or dry the hair near a fire or flame.\n\nMode of action: If there is substantial systemic absorption, neomycin may prolong and intensify respiratory depressant effects of neuromuscular blockers.\n\nPregnancy category: C\n\nInteraction: If there is substantial systemic absorption, neomycin may prolong and intensify respiratory depressant effects of neuromuscular blockers.
Clobetasol Propionate 0.05% + Salicylic Acid 3%	\n\n\tEskayef Bangladesh Ltd.\tTopiclo-S Ointment   10gm  tube 70\n\tGeneral\tEclo Plus Ointment  .05% 10g \n\tUnimed & Unihealth Manufacturers Ltd.\tXenosal Ointment (0.05 gm + 3 gm)/100 gm  \n\tZiska\tClosalic Ointment Ointment 10gm 1's pack 70\n\tIndication: Psoriasis, Burns, Acne vulgaris, Eczema, Dyskeratosis, Ichthyosis, Warts, Hyperkeratosis, Corn, Callus, Seborrhea, Scaly skin disease, Hair loss, Sweating feet, Dermatitis\n\nDose: Adult: Topical Acne; Hyperkeratotic and scaling skin conditions As 2-6% preparation: Apply >3 times/day. Warts and calluses As 60% preparation: Apply as directed.\n\nContra-indication: Hypersensitivity\n\nSide effects: Prolonged usage of large amount of clobetasol propionate can lead to sufficient systemic levels to produce adrenal suppression, Cushing's syndrome, diabetes and hypertension.Dermal and epidermal atrophy esp on the face, steroid purpura\n\nPrecaution: Not for prolonged use in high concentrations and on large areas of the body. Impaired peripheral circulation or diabetes. Avoid broken skin, mouth, eyes, mucous membranes and anogenital region.\n\nMode of action: Clobetasol Propionate: Increased systemic exposure w/ CYP3A4 inhibitors (eg ritonavir & itraconazole).\n\n\n\nPregnancy category: C\n\nInteraction: Clobetasol Propionate: Increased systemic exposure w/ CYP3A4 inhibitors (eg ritonavir & itraconazole).\n\n
Clobetasone butyrate 0.05% Topical	\n\n\tAd-din\tAmobet Cream   10gm  tube 30\n\tGeneral\tMiclo Cream   10gm  tube 40.15\n\tGeneral\tMiclo Ointment   10gm  tube 40.15\n\tGlaxoSmithKline Bangladesh Ltd.\tEumovate Cream   10gm  tube 40.15\n\tGlaxoSmithKline Bangladesh Ltd.\tEumovate Ointment   10gm  tube 40.17\n\tSquare\tEzex Ointment  50 mg/100 gm 25gm  tube 75.28\n\tSquare\tEzex Cream 50 mg/100 gm  \n\tIndication: Eczema, Inflammatory skin disorders, Dermatitis\n\nDose: Topical/Cutaneous\nCorticosteroid-responsive dermatoses\nAdult: Use as 0.05% cream or ointment to be applied thinly once or bid on affected areas.\n\nContra-indication: Pregnancy (in high doses). Presence of acute infections. Treatment of rosacea; leg ulcers; acne vulgaris; widespread plaque psoriasis. Child <1 yr.\n\nSide effects:  Increased liability to infection. Infections may be masked. Acute adrenal insufficiency. Growth retardation in child. Cushingoid symptoms. Amenorrhoea, hyperhidrosis, skin thinning,\n\nPrecaution: May be absorbed in sufficient amounts to cause systemic effects when applied topically to large areas, broken skin or under occlusive dressings. Peptic ulcer, osteoporosis, psychoses or severe psychoneuroses. Not to be used indiscriminately for pruritus. CHF or hypertension. Diabetes mellitus, epilepsy, glaucoma, infectious diseases, ocular herpes simplex, chronic renal failure and uraemia. Active or doubtfully quiescent tuberculosis. Local treatment of eye disorders. Elderly. Prolonged use on the face.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Clomiphene Citrate	\n\n\tAristopharma\tClovul TAB dr 50mg 30's pack 150\n\tBeximco\tFertil TAB dr 50mg 50's pack 251\n\tEskayef Bangladesh Ltd.\tReomen TAB dr 100mg 10's pack 180\n\tEskayef Bangladesh Ltd.\tReomen TAB dr 25mg 25's pack 125\n\tEskayef Bangladesh Ltd.\tReomen TAB dr 50mg 20's pack 200\n\tG. A. Company Ltd.\tFermid TAB dr 50mg 10's pack 85\n\tIncepta\tOvuclon TAB dr 100mg 20's pack 360\n\tIncepta\tOvuclon TAB dr 50mg 30's pack 300\n\tPacific\tComipen TAB dr 50mg 30's pack 500\n\tRenata\tOvulet TAB dr 100mg 5's pack 90.30\n\tRenata\tOvulet TAB dr 50mg 10's pack 100.40\n\tIndication: Ovulation induction, Female infertility, Polycystic ovary syndrome, Amenorrhea-galactorrhea syndrome, Psychogenic amenorrhea\n\nDose: Adult: PO: Ovulatory failure:  50 mg/day for 5 days starting on the 5th day of menstrual cycle or at any time if there is amenorrhoea. May increase to 100 mg/day for the 2nd course as early as 30 days after previous therapy, if needed. If this dose induces ovulation there is no need to increase the dose in the following courses. \n\nIf this dose induces ovulation but not pregnancy, stimulation with Clomiphene citrate is to be continued up to 6  stimulative courses.  For other indications: The recommended dose for other gynaecological problems is 50 mg (1 tab) for 5 days, starting from the 5th day of menstruation or according to the physician's recommendation, but never more than 6 cycles in total.\n\nContra-indication: Clomiphene citrate is contraindicated during pregnancy, in patients with liver diseases, ovarian cysts, bleeding of undetermined origin, patients with neoplasm of endometrium, hypersensitivity; abnormal bleeding; lactation; uncontrolled thyroid or adrenal dysfunction, patient with an organic intracranial lesions such as pituitary tumor.\n\nSide effects: Ovarian enlargement; abdominal pain and bloating; blurred vision; hot flushes; breast discomfort; depression; multiple or ectopic pregnancies; weight gain, nausea, vomiting; endometriosis; headache, convulsions, dizziness, fatigue, vertigo, insomnia; rash.\n\nPrecaution: Clomiphene citrate should be used with caution in the following conditions: longer maintenance therapy, with alcoholic drinks & antidepressants. Polycystic ovaries, evaluate presence of ovarian cyst before each cycle treatment. Uterine fibroids; visual disturbances may develop which will impair ability to drive or operate machinery. There is a minimal chance of multiple pregnancies, about which the patient should be warned. \n\nMode of action:  	Decreased response with danazol.\n\nPregnancy category: X\n\nInteraction:  	Decreased response with danazol.
Clomipramine Hydrochloride	\n\n\tNovartis (Bangladesh) Ltd.\tAnafranil TAB dr 25mg 50's pack 276.50\n\tOrion Pharma Ltd.\tTimex TAB dr 25mg 30's pack 150\n\tSun Pharmaceutical (Bangladesh) Ltd.\tClofranil TAB dr 25mg 50's pack 252.50\n\tIndication: Depression, Panic disorder, Obsessive compulsive disorder, Cataplexy, Narcolepsy, Phobias, Premature ejaculation, Enuresis, Trichotillomania\n\nDose:  Adult: PO Adjunct in cataplexy associated w/ narcolepsy Initial: 10 mg/day, up to 75 mg/day. \nObsessive-compulsive disorder; Panic disorder; Phobias Initial: 25 mg/day, gradually increase up to 100-150 mg/day if needed. Max: 250 mg/day. \nDepression Initial: 10 mg/day, up to 30-150 mg/day if needed. >250 mg/day may be needed in severe cases. \n\nContra-indication:  Hypersensitivity. Concomitant use of MAOIs; recovery phase following MI, heartblock or other arrhythmias; mania; childn.\n\nSide effects:  Dryness of mouth; disturbances in micturition; drowsiness, increased sweating; sexual dysfunction; confusion, paraesthesia, ataxia, tremors; extrapyramidal symptoms; tinnitus, dizziness, fatigue, headache; wt gain esp in women; gynaecomastia and galactorrhoea.\nPotentially Fatal: Death, rare (except in patients with preexisting significant heart block and patients on MAOI therapy). Induction of mania in individuals with underlying manic-depressive illness or worsening of psychoses in already psychotic individuals.\n\nPrecaution:  Cardiovascular insufficiency; narrow-angle glaucoma; urinary retention; history of epilepsy; renal or hepatic dysfunction; electroconvulsive therapy; hypotension; hyperthyroidism or concomitant treatment with thyroid preparations; suicidal tendencies; surgery; pregnancy and lactation; tasks requiring mental alertness; elderly; avoid abrupt withdrawal.\n\nMode of action: Barbiturates increase metabolism of tricyclic antidepressants; conversely cimetidine, guanethidine, haloperidol and phenothiazines block the tricyclic metabolism. CNS effects of alcohol enhanced.\nPotentially Fatal: If clomipramine is to be substituted for MAOIs, at least 3 wk should elapse after discontinuing MAOIs. Risk of hypertension and arrhythmias if co-administered with adrenaline and noradrenaline.\n\nPregnancy category: C\n\nInteraction: Barbiturates increase metabolism of tricyclic antidepressants; conversely cimetidine, guanethidine, haloperidol and phenothiazines block the tricyclic metabolism. CNS effects of alcohol enhanced.\nPotentially Fatal: If clomipramine is to be substituted for MAOIs, at least 3 wk should elapse after discontinuing MAOIs. Risk of hypertension and arrhythmias if co-administered with adrenaline and noradrenaline.
Clonazepam	\n\n\tACI\tClonium TAB dr 0.5mg 100's pack 401\n\tACI\tClonium TAB dr 1mg 50's pack 251\n\tACI\tClonium TAB dr 2mg 50's pack 301\n\tAcme Ltd.\tLeptic TAB dr 0.5mg 100's pack 300\n\tAcme Ltd.\tLeptic TAB dr 2mg 50's pack 250\n\tAlbion Ltd.\tClonazepam TAB dr 0.5 mg/ 2 mg 100's /50's pack \n\tAlbion Ltd.\tDipan TAB dr 2 mg 100's pack \n\tAlco Pharma\tEpizam TAB dr 0.5mg  \n\tAlco Pharma\tEpizam TAB dr 1mg  \n\tAlco Pharma\tEpizam TAB dr 2mg  \n\tApex\tClonapex TAB dr 2mg  \n\tApex\tClonapex TAB dr 0.5 mg  \n\tAristopharma\tArotril TAB dr 1mg 50's pack 250\n\tAristopharma\tArotril TAB dr 0.5mg 100's pack 300\n\tAristopharma\tArotril TAB dr 2mg 30's pack 150\n\tBenham\tClonaben TAB dr 0.5 mg  \n\tBeximco\tXetril TAB dr 0.5mg 100's pack 300\n\tBeximco\tXetril TAB dr 2mg 50's pack 250\n\tBio Pharma Ltd.\tCloma TAB dr 0.5mg 50's pack 100.50\n\tBio Pharma Ltd.\tCloma TAB dr 2mg 30's pack 120.60\n\tDelta Pharma\tLonapam TAB dr 0.5mg 30's pack 60\n\tDelta Pharma\tLonapam TAB dr 2mg 30's pack 120\n\tEskayef Bangladesh Ltd.\tCloron TAB dr 0.5mg 100's pack 300\n\tEskayef Bangladesh Ltd.\tCloron TAB dr 2mg 50's pack 250\n\tEskayef Bangladesh Ltd.\tCloron PD Paediatric Drops 2.5mg/ml 10ml drop 80\n\tGeneral\tEpiclon TAB dr 0.5mg 50's pack 150.50\n\tGeneral\tEpiclon TAB dr 2mg 30's pack 150\n\tGeneral\tEpiclon TAB dr 1mg 50's pack \n\tGlobe\tClon TAB dr 0.5mg 100's pack 200\n\tGlobe\tClon TAB dr 2mg 100's pack 200\n\tHealthcare\tClonatril TAB dr 0.5mg 50's pack 250\n\tHealthcare\tClonatril TAB dr 1mg 30's pack 180\n\tHealthcare\tClonatril TAB dr 2mg 30's pack 180\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMyotril TAB dr 0.5mg 50's pack 125\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMyotril TAB dr 2mg 30's pack 135\n\tIncepta\tDisopan TAB dr 0.5mg 100's pack 500\n\tIncepta\tDisopan 2 TAB dr 2mg 50's pack 300\n\tIncepta\tDisopan 1 TAB dr 1 mg  50's pack 250\n\tIncepta\tDisopan 1 Injection Clonazepam 1 mg/ml 1's pack 150\n\tNovartis (Bangladesh) Ltd.\tEpnil TAB dr .5mg 50's pack 200\n\tNovartis (Bangladesh) Ltd.\tEpnil TAB dr 2mg 30's pack 240\n\tNovartis (Bangladesh) Ltd.\tEpnil 1 TAB dr 1mg  \n\tOpsonin Pharma\tPase Paediatric Drops 2.5mg/ml 10ml drop 80\n\tOpsonin Pharma\tPase TAB dr 0.5mg 50's pack 131.95\n\tOpsonin Pharma\tPase TAB dr 1mg 30's pack 105.57\n\tOpsonin Pharma\tPase TAB dr 2mg 30's pack 131.95\n\tOpsonin Pharma\tPase Injection 1 mg/ml  \n\tOrion Pharma Ltd.\tRivo TAB dr 0.5mg 50's pack 150\n\tOrion Pharma Ltd.\tRivo TAB dr 2mg 30's pack 150\n\tPharmasia Ltd.\tClonzy TAB dr 0.5 mg  \n\tPharmasia Ltd.\tClonzy TAB dr 2mg  \n\tPopular\tClonapin TAB dr 0.5mg 30's pack 90\n\tPopular\tClonapin TAB dr 2mg 30's pack 130\n\tRadiant.\tRivotril TAB dr .5mg 50's pack 350\n\tRadiant.\tRivotril TAB dr 2mg 50's pack 600\n\tRAK\tClonil TAB dr 0.5mg 100's pack 300\n\tRAK\tClonil TAB dr 2mg 50's pack 250\n\tRangs\tDepanil TAB dr 0.5mg 50's pack 150\n\tRangs\tDepanil TAB dr 2mg 30's pack 250\n\tRenata\tDenixil TAB dr 0.5mg 50's pack 200\n\tRenata\tDenixil TAB dr 2mg 30's pack 180\n\tSharif\tClopam TAB dr 0.5mg  \n\tSharif\tClopam TAB dr 2mg  \n\tSilva\tEsypan Paediatric Drops 2.5mg/ml 10ml drop 80\n\tSilva\tEsypan TAB dr 0.5mg 50's pack 100.38\n\tSilva\tEsypan TAB dr 2mg 50's pack 200.75\n\tSomatec\tXioclon TAB dr 2mg  \n\tSomatec\tXioclon TAB dr 0.5mg  \n\tSomatec\tXioclon TAB dr 1mg  \n\tSquare\tEpitra Drops 2.5 mg/ml 1's pack(10ml) 80.30\n\tSquare\tEpitra 1 TAB dr 1mg 60's pack 240\n\tSquare\tEpitra 2 TAB dr 2mg 50's pack 300\n\tSquare\tEpitra 	 		 TAB dr 0.5 mg 100's pack 300 \n\tSun Pharmaceutical (Bangladesh) Ltd.\tLonazep TAB dr 0.5mg 100's pack 400\n\tSun Pharmaceutical (Bangladesh) Ltd.\tLonazep TAB dr 2mg 50's pack 300\n\tIndication: Epilepsy, Anxiety disorders, Panic disorder, Status epilepticus, Social phobia, Migraines, Parasomnia, Restless legs syndrome, Rapid eye movement, Behavior disorder, Spasticity, Resistant depression, Trigeminal neuralgia, Nocturnal myoclonus, Post traumatic stress disorder, Insomnia and sleep disturbances, Burning Mouth Syndrome\n\n\nDose: Adults :1 mg (elderly 500 micrograms) initially at night for 4 nights, increased according to response over 2-4 weeks to usual maintenance dose of 4-8 mg usually at night (may be given in 3-4 divided doses if necessary). \n\nDosage may be increased in increments of 0.5 to 1 mg every three days until seizures are adequately controlled.\n\nChildren: The initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day and should not exceed 0.05 mg/kg/day given in two or three divided doses. \n\nDosage should be increased by not more than 0.25 to 0.50 mg every third day until a maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the larger dose should be given before retiring.\n\n\nIV Emergency treatment of status epilepticus 1 mg as inj or infusion, repeat if needed.\n\nContra-indication: Hypersensitivity to benzodiazepines, acute pulmonary insufficiency, acute narrow angle glaucoma.\n\nSide effects: Drowsiness, fatigue, muscular hypotonia, coordination disturbances, dizziness, vertigo, anorexia, visual disturbances, libido changes.\nPotentially Fatal: Salivary or bronchial hypersecretion leading to respiratory problems (children). May produce diminished reflexes or coma. Rarely, blood dyscrasias.\n\nPrecaution: Neonates, chronic pulmonary insufficiency, hepatic/renal dysfunction, porphyria, elderly; pregnancy and lactation.\n\nMode of action: Additive depressant effect w/ TCAs, MAOIs, sedative and hypnotics, barbiturates, anxiolytics, antipsychotics, opiate agonists. May increase serum phenytoin levels.\n\nPregnancy category: D\n\nInteraction: Additive depressant effect w/ TCAs, MAOIs, sedative and hypnotics, barbiturates, anxiolytics, antipsychotics, opiate agonists. May increase serum phenytoin levels.
Clonidine Hydrochloride	\n\n\tNavana\tCatapres 0.1 TAB dr 100mcg 50's pack 301\n\tIndication: Hypertension, Anxiety disorders, Migraine, Panic disorder, Menopausal flushing, Hypertensive crisis, Cancer pain\n\nDose: Adult: PO HTN Initial: 50-100 mcg 3 times/day. Max: 2,400 mcg/day. \n\nMenopausal flushing; Migraine prophylaxis 50 mcg twice daily, up to 75 mg twice daily.\n\nRenal impairment: Supplemental doses after haemodialysis are not necessary.\nCrCl (ml/min)	\n<10	      50-75% of usual dose. \n\nContra-indication: Hypersensitivity. Disorders of cardiac pacemaker activity and conduction. Pregnancy and lactation.\n\nSide effects: Dry mouth, drowsiness, dizziness, headache, constipation, impotence, vivid dreams, urinary retention; dry, itching, burning sensation in the eye; fluid or electrolyte imbalance, GI upset, paralytic ileus, orthostatic hypotension, weakness, sedation, pruritus, myalgia, urticaria, nausea, insomnia, arrhythmias, agitation. Reduced GI motility at times may cause paralytic ileus.\nPotentially Fatal: Transient hypertension or profound hypotension, respiratory depression, convulsion. Clonidine withdrawal syndrome could be life threatening. Bradycardia, coma and disturbances in conduction (in individuals with preexisting diseases of SA/AV nodes, overdose or on digitalis).\n\nPrecaution: Withdraw gradually, renal impairment, tasks that require mental alertness. Cerebrovascular disease, ischaemic heart disease, MI. IV inj should be administered slowly. Occlusive peripheral vascular disorders, history of depression.\n\nMode of action:  	Hypotensive action may be potentiated by diuretics and vasodilators. Effects of clonidine antagonised by TCAs and centrally-acting alpha-blockers. May enhance toxicity due to digitalis, lithium. May antagonise oral hypoglycaemics.\nPotentially Fatal: Hypnosedatives, antihistamines and alcohol may cause excessive drowsiness in patients on clonidine. Withdrawal of clonidine in patients receiving noncardioselective ?-blockers may result in rebound BP. Acute severe hypotension following concomitant administration of clonidine and chlorpromazine or haloperidol.\n\nPregnancy category: C\n\nInteraction:  	Hypotensive action may be potentiated by diuretics and vasodilators. Effects of clonidine antagonised by TCAs and centrally-acting alpha-blockers. May enhance toxicity due to digitalis, lithium. May antagonise oral hypoglycaemics.\nPotentially Fatal: Hypnosedatives, antihistamines and alcohol may cause excessive drowsiness in patients on clonidine. Withdrawal of clonidine in patients receiving noncardioselective ?-blockers may result in rebound BP. Acute severe hypotension following concomitant administration of clonidine and chlorpromazine or haloperidol.
Clopidogrel	\n\n\tACI\tClorel TAB dr 75mg 30's pack 301.20\n\tAcme Ltd.\tDclot TAB dr 75mg 30's pack 301.20\n\tAd-din\tClogrel TAB dr 75mg 45's pack 405\n\tAlbion Ltd.\tPlator TAB dr 75mg  \n\tAlco Pharma\tClopidol TAB dr 75mg 30's pack 300\n\tAstra Biopharmaceuticals Ltd.\tDogrel TAB dr 75mg 10's pack 100\n\tBeximco\tOdrel TAB dr 75mg 10's pack/30's pack 100/300\n\tDrug International Ltd.\tClopid TAB dr 75mg 50's pack 600\n\tEskayef Bangladesh Ltd.\tNoclog TAB dr 75mg 20's pack 200\n\tGeneral\tDorel TAB dr 75mg 30's pack 301.20\n\tGlobe\tAnlet TAB dr 75mg 30's pack 240\n\tHealthcare\tReplet TAB dr 75mg 30's pack 300\n\tIncepta\tLopirel TAB dr 75mg 30's pack 360\n\tNavana\tPlavix TAB dr 75mg 20's pack 200.80\n\tNipa\tFree TAB dr 75mg 20's pack 200\n\tNovartis (Bangladesh) Ltd.\tPlatrel TAB dr 75mg 30's pack 375\n\tNovo Healthcare and Pharma Ltd.\tClopirel TAB dr 75mg 30's pack 300\n\tOpsonin Pharma\tClont TAB dr 75mg 30's pack 300\n\tOrion Pharma Ltd.\tClognil TAB dr 75mg 30's pack 301.20\n\tPacific\tClopigel TAB dr 75mg 30's pack 273\n\tPharmasia Ltd.\tCardogrel TAB dr 75mg 20's pack 200.80\n\tPopular\tPreclot TAB dr 75mg 20's pack 200.80\n\tRAK\tAnplat TAB dr 75mg 30's pack 300\n\tRangs\tAntiplet TAB dr 75mg 30's pack 300\n\tRenata\tPlagrin TAB dr 75mg 20's pack 200.80\n\tRephco\tClotinil TAB dr 75mg 30's pack 330\n\tSharif\tAPT TAB dr 75mg 20's pack 200\n\tSilva\tLirel TAB dr 75mg 20's pack 200.75\n\tSquare\tAnclog TAB dr 75mg 30's pack 301.24\n\tSun Pharmaceutical (Bangladesh) Ltd.\tClopilet TAB dr 75mg 50's pack 552\n\tTechno Drugs Ltd.\tClavix TAB dr 75mg 30's pack 420\n\tUnimed & Unihealth Manufacturers Ltd.\tPladex TAB dr 75mg 30's pack 360\n\tWhite Horse Pharma\tLivocard TAB dr 75mg 30's pack 270\n\tIndication: Coronary Artery Disease, Acute coronary syndrome, Myocardial infarction, Peripheral vascular disease, Cerebrovascular disease, Atherosclerosis, Thromboembolic disorders, Unstable angina, Stroke\n\nDose: Adult: PO Prophylaxis of thromboembolic events 75 mg once daily. \n\nAcute coronary syndrome For ST-elevation myocardial infarction: W/ aspirin: 75 mg once daily. Continue treatment for up to 28 days. \n\nFor unstable angina, non-ST-elevation myocardial infarction: Initial: 300 mg loading dose, followed by 75 mg once daily (w/ aspirin 75-325 mg once daily).\n\nContra-indication: Hypersensitivity. Active pathological bleeding. admin within 7 days after MI and ischaemic stroke, coagulation disorders. Lactation.\n\nSide effects: Dyspepsia, abdominal pain, nausea, vomiting, flatulence, constipation, gastritis, gastric and duodenal ulcers. GI upset, diarrhoea, paraesthesia, vertigo, headache, dizziness, pruritus and rashes.\nPotentially Fatal: Bleeding disorders including GI and intracranial haemorrhage. Blood dyscrasias.\n\nPrecaution: Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions; ulcer; renal and hepatic impairment; history of bleeding or haemostatic disorders. Pregnancy.\n\nMode of action:  	Co-admin with NSAIDs may increase the risk of stomach and intestinal bleeding. High-dose clopidogrel may lead to increased warfarin levels thus increasing the risk of bleeding. High-dose clopidogrel may also inhibit P450 (2C9), thus interfering with the metabolism of phenytoin, tamoxifen, torasemide, fluvastatin and some NSAIDs. Avoid concurrent use of drugs that inhibit CYP2C19, including omeprazole, esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine and ticlopidine.\n\nPregnancy category: B\n\nInteraction:  	Co-admin with NSAIDs may increase the risk of stomach and intestinal bleeding. High-dose clopidogrel may lead to increased warfarin levels thus increasing the risk of bleeding. High-dose clopidogrel may also inhibit P450 (2C9), thus interfering with the metabolism of phenytoin, tamoxifen, torasemide, fluvastatin and some NSAIDs. Avoid concurrent use of drugs that inhibit CYP2C19, including omeprazole, esomeprazole, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, felbamate, fluoxetine, fluvoxamine and ticlopidine.
Clotrimazole VT	\n\n\tACI\tDermasim 500 VT Vaginal TAB dr 500mg 1's pack 60.23\n\tACI\tDermasim VT Vaginal TAB dr 500mg 1's pack 60\n\tAcme Ltd.\tClotrim VS Vaginal Suppository 200mg 3's pack 60.21\n\tAcme Ltd.\tClotrim VT Vaginal TAB dr 200mg 3's pack 60.21\n\tBeximco\tNeosten VT Vaginal TAB dr 200mg 3's pack 60\n\tChemist Ltd.\tClozol VT Vaginal TAB dr 200 mcg 3's pack 60\n\tSquare\tAfun VT Vaginal TAB dr 100mg 6's pack 60.25\n\tSquare\tAfun VT Vaginal TAB dr 500mg 1's pack 60\n\tSquare\tAfun VT Vaginal TAB dr 200mg 3's pack 60\n\tIndication: Vaginal itching, burning and discharge associated with recurrent vaginal yeast infections Vulvovaginal candidiasis (Vagonal thrush).\n\nDose: Adult: Vaginal Vulvovaginal candidiasis:\nClotrimazole VT 100 & 200- First infections: In general, a 3-day treatment is sufficient for Candida vaginitis. On 3 consecutive nights, Clotrimazole VT 100  or 1  Clotrimazole VT 200 are inserted as deeply as possible into the vagina. This is best achieved when lying on oneâs back with the knees slightly bent. \n\nRe-infections: In general, a 6-day treatment is sufficient. This applies also to mixed infections with the above-mentioned causative organisms. On six consecutive nights, 1 Clotrimazole VT 100 is inserted as deeply as possible into the vagina. If necessary, 2 Clotrimazole VT 100 (1 in the morning and 1 in the evening) or 1 Clotrimazole VT 200 daily can be used for 6-12 days. \n\nTreatment should be timed so as to avoid the menstrual period and be finished before the onset of menstruation. To avoid re-infection, the partner should undergo local treatment with Clotrimazole Cream at the same time. \n\nClotrimazole VT 500- Single dose, complete treatment with one vaginal tablet. The tablet should be inserted as deeply as possible in to the vagina. This is best achieved when lying on oneâs back with the knees slightly bent. It is recommended that the treatment should be timed so as to avoid the menstrual period. \nFor prevention of re-infection the partner should be treated locally with Clotrimazole Cream at the same time.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Topical: Erythema, stinging, irritation; hypersensitivity reactions; contact dermatitis. \n\nPrecaution: Avoid contact with eyes upon topical application. Childn <3 yrs. Pregnancy, lactation.\n\nMode of action: Antagonism with polyene antibiotics.\n\nPregnancy category: B\n\nInteraction: Antagonism with polyene antibiotics.
Clotrimazole 1% + Hydrocortisone 1%	\n\n\tBeximco\tNeosten HC Cream   10gm tube/20gm tube 35/ 55\n\tBio Pharma Ltd.\tClotison Cream   10gm tube 30.11\n\tOpsonin Pharma\tH Trimazole Cream   10gm tube 35.50\n\tIndication: Athlete's foot, Tinea pedis, Candida nappy rash, Fungal infections, Jock itch, Ringworm, Tinea cruris, Tinea corporis							\n\n\nDose: Topical/Cutaneous\nSkin fungal infections\nAdult: Apply a 1% cream/lotion/solution bid-tid for 2-4 wk, \n\nContra-indication: Hypersensitivity.\n\nSide effects: Topical: Erythema, stinging, irritation; hypersensitivity reactions; contact dermatitis. \n\nPrecaution: Avoid contact with eyes upon topical application. Childn <3 yrs. Pregnancy, lactation.\n\nMode of action: Antagonism with polyene antibiotics.\n 	Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.\n\nPregnancy category: A\n\nInteraction: Antagonism with polyene antibiotics.\n 	Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.
Cloxacillin	\n\n\tAcme Ltd.\tA Clox Powder for suspension 125mg/1.2ml 100ml 44\n\tAcme Ltd.\tA Clox Injection 500mg/vial 5 Vials 121.75\n\tAcme Ltd.\tA Clox Injection 250mg/vial 5 Vials 68.55\n\tAcme Ltd.\tA Clox CAP 500mg 100's pack 596\n\tAcme Ltd.\tA-Clox Powder for Suspension 125mg 100ml bot 44.83\n\tAcme Ltd.\tA-Clox Drops 100mg 15 ml bot 26.38\n\tAlbion Ltd.\tLoxa CAP 500 mg 60's pack \n\tAmbee\tAmbeeclox CAP 500mg 100's pack 596\n\tBeximco\tClobex Powder for Suspension 125mg/5ml 100ml bot 43.85\n\tBeximco\tClobex CAP 500mg 100's pack 595\n\tBristol Pharma Ltd.\tBpclox Powder for Suspension 125mg/5ml 100ml bot 44\n\tBristol Pharma Ltd.\tBpclox CAP 500mg 100's pack 400\n\tCentral.\tPenclox Powder for Suspension 125mg/5ml 100ml bot 43\n\tCentral.\tPenclox CAP 500mg 100's pack 580\n\tCosmo Pharma Ltd.\tCosclox CAP 500mg 40's pack 218.40\n\tDoctor's Chemicals Works Ltd.\tCloxil Powder for Suspension 125mg/5ml 100ml 42.65\n\tDoctor's Chemicals Works Ltd.\tCloxil CAP 500mg 100's pack 594\n\tDrug International Ltd.\tCloxpen CAP 500mg 40's pack 200\n\tGonoshasthaya\tG Cloxacillin Powder for Suspension 125mg/5ml 100ml bot 42.48\n\tGonoshasthaya\tG Cloxacillin Injection 500mg/vial 10's pack 200\n\tGonoshasthaya\tG Cloxacillin CAP 500mg 100's pack 462\n\tHudson\tHi Clox Powder for Suspension 125mg/5ml 100ml bot 45\n\tHudson\tHi Clox CAP 500mg 40's pack 200\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaclox Powder for Suspension 125mg/5ml 100ml bot 43\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaclox CAP 500mg 48's pack 276\n\tMedimet\tCloxamet CAP 500mg 50's pack 287.50\n\tMillat\tMiclocin Powder for Suspension 125mg/5ml 100ml bot 43\n\tMillat\tMiclocin CAP 500mg 100's pack 595\n\tModern\tCloxima CAP 500mg 50's pack 253\n\tNavana\tNavaclox Powder for Suspension 125mg/5ml 100ml bot 43.2\n\tNavana\tNavaclox CAP 500mg 100's pack 588\n\tOpsonin Pharma\tCloxin Powder for Suspension 125mg/5ml 100ml bot 39\n\tOpsonin Pharma\tCloxin Injection 500mg/vial 4's pack 89\n\tOpsonin Pharma\tCloxin CAP 500mg 52's pack 270\n\tRenata\tCloxicap CAP 500mg 100's pack 585\n\tSalton\tSalclox Powder for Suspension 125mg/5ml 100ml bot 43.66\n\tSanofi Aventis (BD) Ltd.\tFiclox Paediatric Drops 125mg/1.2ml 15ml bot 27.25\n\tSanofi Aventis (BD) Ltd.\tFiclox Powder for Suspension 125mg/5ml 100ml bot 44.85\n\tSanofi Aventis (BD) Ltd.\tFiclox CAP 500mg 100's pack 595.84\n\tSanofi Aventis (BD) Ltd.\tFiclox Injection 500mg/vial 1's pack 25.39\n\tSanofi Aventis (BD) Ltd.\tFiclox Drops 100mg 15 ml bot 27.25\n\tSonear Ltd.\tCyclox CAP 500mg 40's pack 238.4\n\tSquare\tLoxacin Injection 250mg/vial 5'sb pack \n\tSquare\tLoxacin CAP 500mg  5's pack\n\tSquare\tLoxacin Injection 500mg/vial 5's pack \n\tIndication: Bacterial infections, Staphylococcal infections resistant to benzylpenicillin, Bacterial Meningitis caused by Staphylococcus, Bacterial Pneumonia caused by Staphylococcus, Lower Respiratory Tract Infection, Urinary Tract Infection caused by Staphylococcus Aureus\n\nDose: Adult: PO 250-500 mg 4 times/day. \nChild: 50-100 mg/kg in divided doses every 6 hr.\n\nContra-indication: Hypersensitivity to penicillins.\n\nSide effects: Neutropenia, agranulocytosis; GI upsets; rash. Sore mouth or tongue. Black hairy tongue.\nPotentially Fatal: Neuromuscular hypersensitivity; pseudomembranous colitis; anaphylaxis.\n\nPrecaution: Renal impairment; pregnancy and lactation. Porphyria.\n\nMode of action:  	May diminish the effect of BCG and typhoid vaccine. May increase risk of methotrexate toxicity. May diminish the therapeutic effect of Na picosulfate. May decrease serum concentrations of mycophenolate. May prolong bleeding time w/ anticoagulants. Increased serum concentrations w/ probenecid. Tetracycline may antagonise the bactericidal effect of cloxacillin.\n\nPregnancy category: B\n\nInteraction:  	May diminish the effect of BCG and typhoid vaccine. May increase risk of methotrexate toxicity. May diminish the therapeutic effect of Na picosulfate. May decrease serum concentrations of mycophenolate. May prolong bleeding time w/ anticoagulants. Increased serum concentrations w/ probenecid. Tetracycline may antagonise the bactericidal effect of cloxacillin.
Clozapine	\n\n\tBeximco\tSensipin TAB dr 25mg 30's pack 115.20\n\tIncepta\tZapenia 100 TAB dr 100mg 30's pack 270\n\tIncepta\tZapenia 25 TAB dr 25mg 50's pack 125\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSizopin TAB dr 100mg 50's pack 477.50\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSizopin TAB dr 25mg 50's pack 127.50\n\tIndication:  Schizophrenia in people for whom other antipsychotic medicines are ineffective or not tolerated.\n Psychotic disorders in people with Parkinson's disease, when standard treatment has failed to control symptoms.		\n\nDose: Adult over 16 years: PO: Schizophrenia 12.5 mg 1-2 times on day 1(elderly 12.5 mg once), followed by 25-50 mg 1-2 times on day 2(elderly 25-37.5 mg). Increase gradually according to response over 14-21 days up to 300 mg daily in divided doses (larger dose at night, up to 200 mg daily may be taken as a single dose at bedtime); if necessary may be further increased in steps of 50-100 mg once (preferably) or twice weekly;  Usual range: 200-450 mg/day. Max: 900 mg/day.  \n\nPsychoses in Parkinson's disease Initial: 12.5 mg/day at night, increase gradually in steps of 12.5 mg up to twice weekly. Usual range: 25-37.5 mg/day at bedtime. Max: 100 mg/day in 1-2 divided doses.\n\nElderly: Initially, 12.5 mg on day 1 increased subsequently by increments of 25 mg.\nHepatic impairment: Use with caution and avoid in symptomatic or progressive liver disease or hepatic failure. \n\n\nContra-indication: History of bone marrow disorders including agranulocytosis, circulatory collapse, alcoholic or toxic psychosis, drug intoxication, uncontrolled epilepsy, severe renal, hepatic or cardiac disease; paralytic ileus. Pregnancy and lactation.\n\nSide effects: Drowsiness, dizziness, headache; nausea, vomiting, constipation; anxiety, confusion, fatigue, transient fever. Rarely, dysphagia, acute pancreatitis, cholestatic jaundice; orthostatic hypotension, tachycardia; seizures; hypersalivation.Potentially Fatal: Rarely, thromboembolism. Reversible neutropenia which may progress to a potentially fatal agranulocytosis. Fatal myocarditis.\n\nPrecaution: Medication should not be stopped abruptly; should be tapered off over 1-2 weeks. If conditions warrant abrupt discontinuation (leukopenia, myocarditis, cardiomyopathy), monitor patient for psychosis and cholinergic rebound (headache, nausea, vomiting, diarrhea). Elderly patients are more susceptible to adverse effects (including agranulocytosis, cardiovascular, anticholinergic, and tardive dyskinesia). Significant risk of agranulocytosis, potentially life-threatening. Leucocyte counts should be monitored regularly and for at least 4 wk after treatment discontinuation. Renal, hepatic or cardiac impairment; prostatic enlargement, narrow-angle glaucoma; elderly; immobilised patients\n\nMode of action:  	Increased risk and/or severity of bone marrow suppression w/ bone marrow suppressants (e.g. carbamazepine, chloramphenicol), sulfonamides (e.g. co-trimoxazole), pyrazolone analgesics (e.g. phenylbutazone), penicillamine, cytotoxic agents or long-acting depot inj of antipsychotics. Concomitant use w/ benzodiazepines may increase risk of circulatory collapse which may lead to cardiac and/or resp arrest. Additive CNS depression and cognitive and motor performance interference w/ MAOIs and CNS depressants including antihistamines, benzodiazepines and opioid analgesics. May potentiate effects of anticholinergics or antihypertensives. Increased plasma concentration of highly protein bound substances (e.g. warfarin, digoxin). Decreased plasma concentrations w/ phenytoin. Concomitant use w/ lithium can increase the risk of development of neuroleptic malignant syndrome. Decreased clozapine levels w/ CYP1A2 inducers (e.g. omeprazole). Increased clozapine levels w/ CYP1A2 inhibitors (e.g. fluvoxamine, caffeine, ciprofloxacin).\n\nPregnancy category: B\n\nInteraction:  	Increased risk and/or severity of bone marrow suppression w/ bone marrow suppressants (e.g. carbamazepine, chloramphenicol), sulfonamides (e.g. co-trimoxazole), pyrazolone analgesics (e.g. phenylbutazone), penicillamine, cytotoxic agents or long-acting depot inj of antipsychotics. Concomitant use w/ benzodiazepines may increase risk of circulatory collapse which may lead to cardiac and/or resp arrest. Additive CNS depression and cognitive and motor performance interference w/ MAOIs and CNS depressants including antihistamines, benzodiazepines and opioid analgesics. May potentiate effects of anticholinergics or antihypertensives. Increased plasma concentration of highly protein bound substances (e.g. warfarin, digoxin). Decreased plasma concentrations w/ phenytoin. Concomitant use w/ lithium can increase the risk of development of neuroleptic malignant syndrome. Decreased clozapine levels w/ CYP1A2 inducers (e.g. omeprazole). Increased clozapine levels w/ CYP1A2 inhibitors (e.g. fluvoxamine, caffeine, ciprofloxacin).
Coal Tar + Precipitated Sulpher + Salicylic Acid	\n\n\tIndication: Psoriasis, Seborrheic dermatitis, Dandruff\n\nDose: Adult: PO Dandruff; Seborrhoeic dermatitis As 5% shampoo: Use as directed. Psoriasis As 40% emulsion: Use as directed. As 1% emulsion: Apply 2-3 times/day.\n\nContra-indication: Application to inflamed or broken skin.\n\nSide effects: Skin irritation and acne-like skin eruptions. Photosensitivity.\n\nPrecaution: Use with caution on the face, near eyes and mucous membranes. Do not apply to genital or rectal areas. Avoid use in patient with exacerbation of psoriasis. Avoid exposure to direct sunlight and sunlamps for at least 24-72 hr after application. May stain clothes and hair. If undergoing Goeckerman treatment, all coal tar preparation should be removed from skin before exposure to radiation. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Cod Liver Oil (Vitamin A + D)	\n\n\tDrug International Ltd.\tCod Liver Oil 	 		 CAP   120's pack 240 	\n\tGeneral\tMultiseas CAP 300mg 100'pack 201\n\tIncepta\tCodcap CAP 300mg 100'pack 200\n\tOpsonin Pharma\tCodvit CAP 300mg 100'pack 100\n\tPacific\tCodliv SG CAP  100's pack 200\n\tRangs\tCod Oil CAP 300mg 50's pack 50\n\tSquare\tOlicod CAP 300mg 50's pack 100.41\n\tIndication: Nutritional supplements, Vitamin A , D & E deficiency, Osteoarthritis, Glaucoma, Hypertension, Depression, Multiple sclerosis, Pain and joint stiffness, Kidney disease, High triglycerides, Heart disease, Systemic lupus erythematosus (SLE), Middle ear infections (otitis media).\n\nDose:  Adult and child over 6 years: 1-2 capsule 3 times daily with meals. \n\nContra-indication: Hypersensitivity.\n\nSide effects:  Hypervitaminosis;hypercalcemia, myopathy; thrombophloebitis; fatigue, weakness, nausea, headache, dizziness, blurred vision, flatulence, diarrhoea, abdominal pain.\n\nPrecaution: Chronic renal failure, Patients having hepatomegaly & raised ESR\n\nMode of action: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.\n\nPregnancy category: A\n\nInteraction: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.
Cod Liver Oil 30.5%	\n\n\tDrug International Ltd.\tCod'S Emulsion Emulsion   200ml 114.29\n\tIndication: Dietary supplements, Vitamin A & D deficiency, Pain and joint stiffness,Kidney disease, High triglycerides, Heart disease, Systemic lupus erythematosus (SLE), Middle ear infections (otitis media)\n\nDose: Infant: 1/2 tsf daily. Child (1-4 yrs): 1 tsf daily. Child over 4 yrs: 1 1/2 tsf daily.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Hypervitaminosis;hypercalcemia, myopathy; thrombophloebitis; fatigue, weakness, nausea, headache, dizziness, blurred vision, flatulence, diarrhoea, abdominal pain.\n\nPrecaution: Chronic renal failure, Patients having hepatomegaly & raised ESR\n\nMode of action: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.\n\nPregnancy category: A\n\nInteraction: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.
Colchicine	\n\n\tIncepta\tKolchin TAB dr 0.5mg 30's pack 120\n\tIncepta\tKolchin TAB dr 0.6mg 30's pack 150\n\tSquare\tColimax TAB dr 0.6mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tColuric TAB dr 0.6mg 14's pack 105\n\tIndication: Acute gout, Familial Mediterranean Fever, Behcet's disease, Gouty arthritis							\n\n\nDose: Adult: PO Acute gout Initial: 1 mg, reduce to 0.5 mg 2-3 hrly until pain relief is achieved or GI toxicity occurs. Max: 6 mg/course. \n\nMay repeat course after at least 3 drug-free days. Prophylaxis of recurrent gouty arthritis 0.5-0.6 mg once daily. \n\nContra-indication: Hypersensitivity; blood dyscrasias, severe renal impairment, pregnancy, debilitated patients; SC/IM admin.\n\nSide effects: Nausea, vomiting and abdominal pain; diarrhoea, GI haemorrhage, rashes, renal and hepatic damage in excessive doses. Rarely peripheral neuritis, myopathy, alopecia and with chronic therapy blood disorders like agranulocytosis, aplastic anaemia.\n\nPrecaution: Elderly; GI disease. Cardiac, renal and hepatic impairment; prolonged therapy not recommended; lactation.\n\nMode of action: Reversible malabsorption of vitamin B12 may occur because of ileal mucosal function alteration. Response to CNS depressants and sympathomimetics may increase when used concurrently with colchicine. Increased risk of myopathy when used concurrently with simvastatin.\nPotentially Fatal: With ciclosporin, increased risk of nephrotoxicity and myotoxicity. Risk of colchicine toxicity when used with macrolides.\n\nPregnancy category: D\n\nInteraction: Reversible malabsorption of vitamin B12 may occur because of ileal mucosal function alteration. Response to CNS depressants and sympathomimetics may increase when used concurrently with colchicine. Increased risk of myopathy when used concurrently with simvastatin.\nPotentially Fatal: With ciclosporin, increased risk of nephrotoxicity and myotoxicity. Risk of colchicine toxicity when used with macrolides.
Conjugated Oestrogens	\n\n\tRenata\tEstracon TAB dr 625mcg 28's pack 420\n\tTechno Drugs Ltd.\tPremicon TAB dr 625mcg 28's pack 420\n\tAyerst Wyeth PharmaceuticalsInc.,\tPremarin IV 	 Injection 25mg 	 1 amp  173.50 		\n\tAyerst Wyeth PharmaceuticalsInc.,\tPremarin TAB dr 1.25mg 	 1.25mg x 100's pack  349.70\n\tLaboratorio Aldo-Union, Spain\tEquin 		 TAB dr 0.625mg  28's pack  450 	\n\tIndication: Osteoporosis, Fungal infections, Itching, Burning, Hot flashes, Vaginal dryness, Vaginal atrophy, Menopausal symptoms, Female hypogonadism, Metastatic breast carcinoma, Ovarian failure, Prostate carcinoma, Primary ovarian failure, Hormone replacement therapy, Oral contraceptives\n\nDose: Adult: PO Menopausal vasomotor symptoms 0.45 mg/day, up to 1.25 mg/day. Attempt to discontinue medication at 3-6-mth intervals. \nVulvular and vag atrophy 0.3 mg/day. \nFemale hypogonadism 0.3-0.625 mg/day in a cyclical regimen. Add progestin treatment once skeletal maturity is achieved. \nFemale castration; Primary ovarian failure 1.25 mg/day in a cyclical regimen. \nPalliation in prostate carcinoma 1.25-2.5 mg 3 times/day. \nOsteoporosis prophylaxis in postmenopausal women Initial: 0.3 mg/day in a cyclical or continuous regimen depending on patient's condition. \n\nIV/IM Abnormal uterine bleeding 25 mg, may repeat in 6-12 hr if needed.\n\nContra-indication: Severe liver impairment; breast carcinoma; thromboembolic disorders; CV disease; undiagnosed vag bleeding; estrogen-dependent neoplasms; hypersensitivity; pregnancy.\n\nSide effects: Abnormal bleeding; vomiting, nausea; tender breasts, wt gain, fluid retention; headache, depression. Males: Gynaecomastia, impotence.\nPotentially Fatal: Unopposed replacement therapy in postmenopausal women associated with increased risk of endometrial and breast cancer.\n\nPrecaution: Asthma, epilepsy, migraine; heart or kidney dysfunction; CV disease; cerebrovascular disorders; diabetes, hypercalcaemia; gall bladder disease; porphyria. Childn. Lactation.\n\nMode of action: Rifampicin, barbiturates increase rate of metabolism.\nPotentially Fatal: May reduce the efficacy of anticoagulants.\n\nPregnancy category: Not Classified\n\nInteraction: Rifampicin, barbiturates increase rate of metabolism.\nPotentially Fatal: May reduce the efficacy of anticoagulants.
Copper + Folic Acid + Iodine + Iron + Niacin + Pyridoxine Hydrochloride	\n\n\tIndication: Nutritional supplement\n\nDose: One tablet daily or as recommended by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated.\n\nPrecaution:  Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematological remission can occur while neurological manifestations remain progressive.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Crotamiton 10%	\n\n\tG. A. Company Ltd.\tCrodex Cream   20gm  tube 55\n\tKumudini Pharma Ltd.\tCurex 10 Cream   10gm  tube 30\n\tOpsonin Pharma\tLorix Plus Lotion   60ml bot 80\n\tUnimed & Unihealth Manufacturers Ltd.\tCronix Lotion 10% 60ml pack 80\n\tIndication: Scabies, Pruritic skin\n\nDose: Adult: Topical Scabies As 10% cream/lotion: Apply to the whole body from below the chin. 2nd application is applied 24 hr later. May need to use once daily for up to 5 days. \nPruritic skin disorders As 10% cream/lotion: Apply 2-3 times/day.\n\nContra-indication: Hypersensitivity; acute exudative dermatitis. Application to the eye, mouth, other mucous membranes or on excoriated skin.\n\nSide effects: Topical: Pruritus, contact dermatitis, rash, irritation, warm sensation.\n\nPrecaution: For external use only. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Crotamiton  + Permethrin	\n\n\tIncepta\tElimate Plus Lotion   60ml bot 80\n\tUnimed & Unihealth Manufacturers Ltd.\tUnix C Lotion   60ml bot 100\n\tIndication: Pruritus, Scabies\n\nDose: Adults: Apply once. If necessary, a second application may be given not less than 7 days after the initial application. \n\nChildren aged 2 months to 2 years: Apply over whole body under doctor supervision.\n\nHOW TO USE:\nLotion should be applied to clean, dry skin. If the body is hot due to warm bath or any other reason, skin should be allowed to cool. It should be applied to the whole body excluding head. The whole body should be washed thoroughly 8-12 hours after treatment. On the next day cloths and bed sheets should be cleaned with warm water. The lotion should be applied if lotion is washed out by water. Other members of the family should use this lotion as preventive in the same way due to its highly contagious effects. The lotion should not be applied to the vicinity of mouth and areas close to eyes.\n\nContra-indication: Permethrin is contraindicated in subjects with known hypersensitivity to the Product.\n\nSide effects: Generally mild and transient burning and stinging are followed by application of lotion. Other temporary symptoms of irritation including pruritus, erythema, numbness, eczema and rash may occur. In patients itching may persist for up to 4 weeks Post-treatment. This is generally regarded as due to an allergic reaction to the dead mites under the skin and is not necessarily indicative of a treatment failure.\n\nPrecaution: Avoid contact with eyes and mucous membranes. Cross-sensitivity may occur with ragweed or chrysanthemums. History of asthma. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Cyanocobalamin	\n\n\tChemist Ltd.\tCynovit Injection 1mg/ml 25 amps pack 101\n\tJayson\tCynomin Injection 250mcg/ml 1ml (250mcg) amp x 10's pack/1ml (100mcg) amp x 10's pack/10ml (1000mcg) amp x 1's pack 35.10/30.30/35\n\tRephco\tVitamin Injection 1mg/ml 25 amps pack 125\n\tSquare\tCynavit 1 Injection 1 mg/ml  \n\tSquare\tCynavit 250 Injection 250 mcg/ml  \n\tIndication: Pernicious anemia,Vitamin B12 deficiency due to low intake from food,Thyrotoxicosis, Hemorrhage, Malignancy, Liver or kidney disease,Gastric bypass surgery, Total or partial gastrectomy, Gluten enteropathy or sprue, Folic acid deficiency, Macrocytic anaemia\n\nDose: Adult: IM 250-1,000 mcg on alternate days for 1-2 wk, then 250 mcg wkly. Maintenance: 1,000 mcg mthly.\n\nContra-indication: Leber's disease, tobacco amblyopia.\n\nSide effects: \n\nPrecaution: \n\nMode of action: Absorption reduced by antibiotics, aminosalicylic acid, anticonvulsants, biguanides, cholestyramine, cimetidine, colchicine, K salts, methyldopa.\n\nPregnancy category: C\n\nInteraction: Absorption reduced by antibiotics, aminosalicylic acid, anticonvulsants, biguanides, cholestyramine, cimetidine, colchicine, K salts, methyldopa.
Cyanocobalamin + Elemental Iron + Folic Acid	\n\n\tACI\tPolyron PLUS CAP  100mg+1mg+25mcg 48's pack 132.96\n\tACI\tPolyron plus Syrup  200mg/5ml 100ml bot 40.12\n\tEdruc Ltd.\tEdiplex ZI Syrup   100ml bot/200ml bot 50100/\n\tZenith\tZimon Plus Syrup   60ml bot 30\n\tIndication: Iron deficiency anemia, Megaloblastic anemias\n\nDose:  Adults: 1-2 capsules daily. Child: 1 capsule daily.\n\nContra-indication: Hypersensitivity to folic acid, cyanocobalamin, pyridoxine, or any component of the formulation\n\nSide effects: Allergic sensitization has been reported  following oral administration of folic acid. Oral iron preparation may cause constipation, particularly in older patients.\n\nPrecaution: Iron chelates with antacidd and tetra cycline, so there absorption may be impaired if use concurrently.\n\nMode of action: Cyanocobalamin: Absorption reduced by antibiotics, aminosalicylic acid, anticonvulsants, biguanides, cholestyramine, cimetidine, colchicine, K salts, methyldopa.\n\nElemental iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\n\nPregnancy category: Not Classified\n\nInteraction: Cyanocobalamin: Absorption reduced by antibiotics, aminosalicylic acid, anticonvulsants, biguanides, cholestyramine, cimetidine, colchicine, K salts, methyldopa.\n\nElemental iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n
Folic Acid + Vitamin B6 + Vitamin B12	\n\n\tAristopharma\tPFC TAB dr   30's pack 180\n\tBeximco\tHeart Plus 	 TAB dr   1's pack  3 	\n\tNavana\tFolicard TAB dr   30's pack 120.60\n\tNovo Healthcare and Pharma Ltd.\tVita-Heart TAB dr   30's pack 90\n\tOpsonin Pharma\tVgard TAB dr   30's pack 120\n\tPacific\tFolbion TAB dr   30's pack 237\n\tPopular\tVicard TAB dr  2 mg + 2.5 mg + 25 mg 30's pack/60's pack 120.45 / 240.90\n\tIndication: Dialysis, Nutritional supplement, Peripheral vascular disease, Restless legs syndrome, End-stage renal failure, Hyperhomocysteinemia, Age-related macular degeneration, Cardiovascular disease, Artherosclerotic vascular disease, Neurological disorders, Renal disease and vitamin B12 deficiency\n\nDose: Adult dose is 1-2 tablets daily or as directed by a physician. \n\nContra-indication: Known hypersensitivity to any of the components in the product is a contraindication. \n\nSide effects: Allergic sensitization has been reported following both oral and parenteral administration of folic acid. Paresthesia, somnolence, nausea and headache have been reported with pyridoxine hydrochlloride. Mild transient diarrhea, polycythemia vera, itching, transitory exanthema, and the feeling of swelling of the entire body has been associated with cyanocobalamin. \n\nPrecaution: Folic acid when administered as a single agent in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Unmetabolized Folic Acid has the potential to reduce natural killer cells' cytotoxicity, which may result in an impaired immune response. \n\nMode of action: Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit B12: Absorption reduced by antibiotics, aminosalicylic acid, anticonvulsants, biguanides, cholestyramine, cimetidine, colchicine, K salts, methyldopa.\n\n\nPregnancy category: Not Classified\n\nInteraction: Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit B12: Absorption reduced by antibiotics, aminosalicylic acid, anticonvulsants, biguanides, cholestyramine, cimetidine, colchicine, K salts, methyldopa.\n
Vitamin B1 + Vitamin B6 + Vitamin B12	\n\n\tACI\tPovital Injection  100mg+200mg+200mcg 3ml amp x 10's pack 251.70\n\tACI\tPovital TAB dr  100mg+200mg+200mcg 50's pack 251\n\tAcme Ltd.\tTPC Injection   3ml amp x6's pack 150.60\n\tAcme Ltd.\tTPC TAB dr   32's pack 128.32\n\tAcme Ltd.\tTPC TAB dr 50mg + 100Mg + 200mg + 20 32's pack 128.32\n\tAcme Ltd.\tTPC Injection Injection 100mg 6's pack 150.60\n\tAd-din\tCombomin TAB dr 200 mcg + 200 mg + 100 mg  \n\tAlbion Ltd.\tAlvita TAB dr 100 mg+200 mg+ 200 mcg 50's pack \n\tAlco Pharma\tRenep TAB dr  30's pack 120\n\tAmico Ltd.\tBig-B TAB dr   30's pack 120\n\tAmulet\tNopath TAB dr   \n\tApex\tNervo B TAB dr   50's pack 200\n\tAristopharma\tNeobion Injection   3ml amp x 10's pack 260\n\tAristopharma\tNeobion TAB dr   60's pack 240\n\tAsiatic Ltd.\tAsibion TAB dr   30's pack 120\n\tBeacon\tRejubion Injection   3ml amp x 5's pack 125\n\tBeacon\tRejubion TAB dr   30's pack 120.30\n\tBeximco\tNeurocare TAB dr   30's pack 120\n\tBeximco\tMyolin 	 TAB dr   1's pack  4 \n\tBio Pharma Ltd.\tNeurep TAB dr   60's pack 241.20\n\tBristol Pharma Ltd.\tB 3 TAB dr  50's pack 200\n\tCentral.\tOST TAB dr   50's pack 200\n\tChemist Ltd.\tNurobix Plus Injection   3ml amp x 10's pack 125\n\tChemist Ltd.\tNurobix Plus TAB dr 100mg  \n\tConcord\tNeuroprax TAB dr 100mg + 200mg + 200mcg 60's pack \n\tConcord\tNeuroprax Injection (100mg + 100mg + 1000mcg)  \n\tDecent Pharma Ltd.\tVt - 3 TAB dr   32's pack 128\n\tDelta Pharma\tDebion TAB dr   30's pack 120\n\tDesh\tUnibion TAB dr   30's pack 120\n\tDoctor's Chemicals Works Ltd.\tD-Vital TAB dr   40's pack 160\n\tDrug International Ltd.\tSupra B Injection   3ml amp x 5's pack 125\n\tDrug International Ltd.\tSupra B TAB dr   50's pack 250\n\tEdruc Ltd.\tEdruplex Injection   3ml amp x 3's pack 75\n\tEdruc Ltd.\tEdruplex TAB dr   30's pack 120\n\tEskayef Bangladesh Ltd.\tSolbion Injection   3ml amp x 10's pack 250\n\tEskayef Bangladesh Ltd.\tSolbion TAB dr   50's pack 200\n\tEuro Pharma Ltd.\tNenvit TAB dr   30's pack 120\n\tEverest\tEon TAB dr   30's pack 120\n\tGeneral\tBost TAB dr   50's pack 120.60\n\tGeneral\tBost Inj Injection   10's pack 250\n\tGlaxoSmithKline Bangladesh Ltd.\tBerin Plus TAB dr   30's pack 120\n\tGlobe\tTribion Injection   3ml amp x 10's pack 250\n\tGlobe\tTribion TAB dr   30's pack 120\n\tGlobex\tNeurotonic Injection (1 mg + 100 mg + 100 mg)/  \n\tGlobex\tNeurotonic TAB dr 200 mcg + 200 mg + 100 mg 30's pack 150\n\tHallmark\tVigor-3 TAB dr   30's pack 120\n\tHealthcare\tRenovit TAB dr   30's pack 128\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeuralgin Injection   3ml amp x 10's pack 260\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeuralgin TAB dr  60's pack 140\n\tIncepta\tVitabion Injection   3ml amp x5's pack 125\n\tIncepta\tVitabion TAB dr   50's pack 400\n\tJayson\tNerviplex Injection   3ml amp x 5's pack/3ml amp x 10's pack 125.50/ 251\n\tJayson\tNerviplex TAB dr   30's pack 120.30\n\tKemiko\tKvit-N TAB dr   30's pack 200\n\tKemiko\tKvit-N IM Injection   3ml amp x 10's pack 250\n\tLabaid\tNeuromate TAB dr 200 mcg + 200 mg + 100 mg  \n\tMedicon\tMedibion TAB dr   30's pack 120\n\tMonicopharma\tV-Nerve Injection   3ml amp x 10's pack 250\n\tMonicopharma\tV-Nerve TAB dr   30's pack 120\n\tNavana\tMylo TAB dr   50's pack 201\n\tNIPRO JMI Pharma\tV3N TAB dr   30's pack 120\n\tNovelta Bestway\tNeurocon TAB dr   50's pack  200 	\n\tNovo Healthcare and Pharma Ltd.\tNeuroaid TAB dr   30's pack 120\n\tNovus\tSpine-B TAB dr  50's pack 200\n\tOpsonin Pharma\tMyelin Injection   3ml amp x x5's pack 125\n\tOpsonin Pharma\tMyelin TAB dr   50's pack 200\n\tOrion Pharma Ltd.\tNugesic Injection   3ml amp x 10's pack 250\n\tOrion Pharma Ltd.\tNugesic TAB dr   30's pack 120.60\n\tPacific\tPacibion TAB dr   30's pack/ 100'pack 150/500\n\tPharmasia Ltd.\tBionic TAB dr   30's pack 120.60\n\tPopular\tB126 TAB dr  60's pack 240\n\tRadiant.\tNeucos b TAB dr  30's pack 550\n\tRangs\tNeurodol TAB dr   30's pack 120\n\tReliance\tVN TAB dr   15's pack 60\n\tRenata\tNeurobest Injection   3ml amp x 10's pack 251\n\tRenata\tNeurobest TAB dr   60's pack 240.60\n\tRephco\tRebion TAB dr   30's pack 135\n\tSharif\tNerbo TAB dr   50's pack 200\n\tSilva\tNeurex-B TAB dr   50's pack 200\n\tSomatec\tMiovit TAB dr   30's pack 120.30\n\tSquare\tNeuro B Injection   3ml amp x 10's pack 250.97\n\tSquare\tNeuro B TAB dr   30's pack 150\n\tSyntho Ltd.\tN-Vit TAB dr   30's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tNeuvital TAB dr   30's pack 150\n\tWhite Horse Pharma\tTri-B TAB dr   50's pack 250\n\tZiska\tNeubin Injection    10's pack 250\n\tZiska\tNeubin TAB dr  30's pack 120\n\tOne Pharma Ltd.\tNevrona TAB dr 200 mcg + 200 mg + 100 mg  \n\tIndication: B1, B6 and B12 deficiency syndrome, sciatica, lumbago, trigeminal neuralgia, facial paralysis, optic neuritis, Diabetic neuropathy,  Peripheral neuralgia, Myalgia \n\nDose: Tablet: 1-2 tablets three times daily.\n\nInjection: In severe cases, 1 ampoule daily until the acute symptoms subsides. For milder cases, & follow up therapy 2 or 3 should be injected weekly.\n\nContra-indication: Should not be used in the patients on Levodopa therapy and hypersensitivity to any of the active ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Cyanocobalamin should not be given before a diagnosis has been fully established because of the possibility of masking symptoms of subacute degeneration of the spinal cord. Cyanocobalamin is not a suitable form of Vitamin B12 for the treatment of optic neuropathies associated with raised plasma concentrations of cyanocobalamin.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Cyclobenzaprine Hydrochloride	\n\n\tHallmark\tCyrin TAB dr 10mg 50's pack 150\n\tIncepta\tFlexor TAB dr 10mg 100's pack 300\n\tIncepta\tFlexor TAB dr 5mg 100's pack 200\n\tOpsonin Pharma\tLaxirin TAB dr 10mg 100's pack 300\n\tOpsonin Pharma\tLaxirin TAB dr 5mg 100's pack 200\n\tSomatec\tFlexerin TAB dr 10mg 100's pack 301\n\tIndication: Fibromyalgia, Muscle spasm\n\nDose: Adult: PO 5 mg 3 times/day for not >2-3 wk. May increase to 10 mg 3 times/day if needed.\n\nContra-indication: Recent MI, arrhythmias, severe liver disease.\n\nSide effects: Antimuscarinic effects, neurological adverse effects, GI disorders, orthostatic hypotension, tachycardia, hypersensitivity reactions. Rarely, cholestatic jaundice and blood disorders. Endocrine effects, sexual dysfunction, changes in blood sugar. Increased appetite with wt gain, sweating.\n\nPrecaution: Cardiac disease, history of epilepsy, hepatic impairment, hyperthyroidism, pheochromocytoma, history of mania, psychoses, close-angle glaucoma, history of urinary retention, concurrent electroconvulsive therapy, diabetes. Pregnancy and lactation; elderly, child. Unsafe for use in patients with porphyria. Avoid abrupt withdrawal. May cause drowsiness; do not drive or operate machinery. Treatment for more than 2-3 wk is not recommended.\n\nMode of action:  	Plasma concentration may be increased with the use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir, and verapamil. Side-effects are increased by adrenaline, amiodarone, general anesthetics, SSRIs, antihistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, clozapine, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, phenothiazine, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine, and tramadol. Effects of adrenergic neurone blockers, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics, and thyroid hormones are enhanced with concomitant use of cyclobenzaprine. Carbamazepine and rifampicin may increase metabolism of cyclobenzaprine. Effects may be antagonized by oestrogens. Avoid use with brimonidine, entacapone, artemether with lumefantrine, or sibutramine. CNS effects may be enhanced by other CNS depressants.\n\nPregnancy category: B\n\nInteraction:  	Plasma concentration may be increased with the use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir, and verapamil. Side-effects are increased by adrenaline, amiodarone, general anesthetics, SSRIs, antihistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, clozapine, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, phenothiazine, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine, and tramadol. Effects of adrenergic neurone blockers, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics, and thyroid hormones are enhanced with concomitant use of cyclobenzaprine. Carbamazepine and rifampicin may increase metabolism of cyclobenzaprine. Effects may be antagonized by oestrogens. Avoid use with brimonidine, entacapone, artemether with lumefantrine, or sibutramine. CNS effects may be enhanced by other CNS depressants.
Cyclopentolate Hydrochloride 1% Eye prep	\n\n\tBeximco\tMydrate Eye Drops   5  ml drop 120\n\tIndication: Pediatric eye examinations, Mydriasis,Cycloplegia, Uveitis, Iritis\n\nDose: The normal adult dose is 1 or 2 drops of solution in each eye, as required. The administration of the drops can be repeated every 6-8 hours, depending on the treatment.\n\nThe normal child dose (over 3 months old) is 1 drop of Cyclopentolate Hydrochloride 0.5% w/v in each eye. \nChildren should be observed for 45 minutes after the administration of the drops.\n\nContra-indication: Children under 3 months of age, Glaucoma, or people with a tendency to glaucoma because of a shallow anterior chamber, Conditions where the gut is not functioning properly, resulting in an obstruction in the bowel (paralytic ileus), Children with organic brain syndromes, including congenital or neuro-developmental abnormalities such as epilepsy.\n\nThis medicine should not be used if history of allergies to one or any of its ingredients.\n\nSide effects: Eye irritation such as mild stinging, and sensitivity to light, Blurred vision. Other less common effects: dry mouth, flushing, dry skin, constipation, difficulties passing urine, a fast heartbeat, feeling sick, skin rash, giddiness and other changes in behaviour\n\nPrecaution: This medicine is for use in the eyes only and must not be taken by mouth. \n\nThese eye drops can cause blurred vision, difficulty focusing and sensitivity to light. The effects can last for up to 24 hours. You must not drive or take part in hazardous activities unless you can see clearly.\nYou should not wear soft contact lenses during treatment with these eye drops. This is because they contain a preservative called benzalkonium chloride, which can be absorbed by soft contact lenses and cause eye irritation.\n\nMode of action:  	Plasma concentration may be increased with the use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir, and verapamil. Side-effects are increased by adrenaline, amiodarone, general anesthetics, SSRIs, antihistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, clozapine, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, phenothiazine, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine, and tramadol. Effects of adrenergic neurone blockers, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics, and thyroid hormones are enhanced with concomitant use of cyclobenzaprine. Carbamazepine and rifampicin may increase metabolism of cyclobenzaprine. Effects may be antagonized by oestrogens. Avoid use with brimonidine, entacapone, artemether with lumefantrine, or sibutramine. CNS effects may be enhanced by other CNS depressants.\n\nPregnancy category: C\n\nInteraction:  	Plasma concentration may be increased with the use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir, and verapamil. Side-effects are increased by adrenaline, amiodarone, general anesthetics, SSRIs, antihistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, clozapine, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline, phenothiazine, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine, and tramadol. Effects of adrenergic neurone blockers, clonidine, barbiturates, nitrates, and primidone are reduced while effects of baclofen, opioid analgesics, and thyroid hormones are enhanced with concomitant use of cyclobenzaprine. Carbamazepine and rifampicin may increase metabolism of cyclobenzaprine. Effects may be antagonized by oestrogens. Avoid use with brimonidine, entacapone, artemether with lumefantrine, or sibutramine. CNS effects may be enhanced by other CNS depressants.
Cyclosporine	\n\n\tIncepta\tSporium Solution 100mg/ml 50ml bot 2385\n\tNovartis (Bangladesh) Ltd.\tSandimmum Neoral CAP 25mg 50's pack \n\tNovartis (Bangladesh) Ltd.\tSandimmum Neoral CAP 50mg 50's pack \n\tNovartis (Bangladesh) Ltd.\tSandimmum Neoral CAP 100mg 50's pack \n\tNovartis (Bangladesh) Ltd.\tNeoral 100 mg TAB dr 100 mg 50's pack 11750\n\tNovartis (Bangladesh) Ltd.\tNeoral  25 mg TAB dr 25mg 50's pack 2962.50\n\tNovartis (Bangladesh) Ltd.\tNeoral  50 mg TAB dr 50mg 50's pack 5875\n\tTechno Drugs Ltd.\tImural CAP 100mg 30's pack 3750\n\tIndication: Ulcerative colitis, Rheumatoid arthritis, Psoriasis, Missed abortion, Nephrotic syndrome ,Urticaria, Bone marrow transplantation, Organ transplantation, atopic dermatitis\n\nDose: Oral\nImmunosuppression in organ transplantation\nAdult: Initially, 10-15 mg/kg/day, starting 4-12 hr before procedure and continued for 1-2 wk; usual maintenance: 2-6 mg/kg/day. Lower doses may be used when combined with other immunosuppressants.\n\nSevere atopic dermatitis\nAdult: Initially, 2.5 mg/kg/day, in 2 divided doses. Reduce to lowest effective dose once remission is achieved. Stop treatment if there is no sufficient improvement to max dose within 6 wk. Max: 5 mg/kg/day.\n\nPsoriasis\nAdult: Initially, 2.5 mg/kg/day, in 2 divided doses. Reduce to lowest effective dose once remission is achieved. Stop treatment if there is no sufficient improvement to max dose within 6 wk. Max: 5 mg/kg/day.\n\nRheumatoid arthritis\nAdult: 2.5 mg/kg/day, in 2 divided doses. Treatment should continue for 6-8 wk. If response is insufficient, may increase dose gradually. Max: 4 mg/kg/day.\n\nNephrotic syndrome\nAdult: 5 mg/kg daily, given in 2 divided doses.\nChild: 6 mg/kg daily, given in 2 divided doses.\n\nIntravenous\nProphylaxis of graft rejection in bone marrow transplantation\nAdult: Intially, 3-5 mg/kg/day starting on the day before transplantation and continue for up to 2 wk or until oral therapy can be initiated at a maintenance of 12.5 mg/kg/day. Continue maintenance dose for at least 3-6 mth.\n\nImmunosuppression in organ transplantation\nAdult: Initially: 5-6 mg/kg/day as a single dose, infuse dose over 2-6 hr. Switch to an oral dosage form as soon as possible.\n\nContra-indication: Hypersensitivity; malignant neoplasms; uncontrolled hypertension; psoriasis; lactation.\n\nSide effects: Hypertension; hepatoxicity; tremor; paraesthesia, hypertrichosis, facial oedema, acne; gingival hypertrophy; hyperkalaemia, fluid retention; increased susceptibility to infections; GI symptoms. Potentially Fatal: Nephrotoxicity; convulsions.\n\nPrecaution:  Cyclosporine increases the risk of developing lymphomas and other malignancies, particularly those of the skin. So patients should be warned to avoid excess ultraviolet light exposure. Cyclosporine may develop bacterial, fungal, parasitic and viral infections. So therapeutic strategies should be employed for long-term immunosuppressive therapy. A reversible increase in serum creatinine and urea may occur during the first few weeks of Cyclosporine therapy and usually responding to dose reduction. In elderly patients, renal function should be monitored with particular care. Regular monitoring of blood pressure is required during Cyclosporine therapy; if hypertension develops, appropriate antihypertensive treatment must be instituted.  Cyclosporine enhances the risk of hyperkalaemia, especially in patients with renal dysfunction. Caution is also required when Cyclosporine is co-administered with potassium sparing drugs. Cyclosporine enhances the clearance of magnesium. If considered necessary, magnesium supplementation should be given. Caution should be observed in treating patients with hyperuricaemia. During treatment with Cyclosporine, vaccination may be less effective; the use of live-attenuated vaccines should be avoided. Non-transplant patients with impaired renal function, uncontrolled hypertension, uncontrolled infections, or any kind of malignancy should not receive Cyclosporine. Renal and hepatic impairment; hyperuricaemia; anaphylaxis; history of allergic reactions; pregnancy; monitor BP, serum electrolytes, renal and hepatic function.\n\nMode of action: Increased ciclosporin level by diltiazem, doxycycline, erythromycin, ketoconazole, methylprednisolone (high doses), nicardipine, verapamil, oral contraceptives. Drugs which reduce ciclosporin level are carbamazepine, isoniazid, phenobarbitone, phenytoin and rifampicin. Increased risk of convulsion when used concurrently with high-dose methylprednisolone.\nPotentially Fatal: Additive nephrotoxicity when used with aminoglycosides, amphotericin B, ciprofloxacin, colchicine, melphalan, co-trimoxazole and NSAIDs.\n\nPregnancy category: C\n\nInteraction: Increased ciclosporin level by diltiazem, doxycycline, erythromycin, ketoconazole, methylprednisolone (high doses), nicardipine, verapamil, oral contraceptives. Drugs which reduce ciclosporin level are carbamazepine, isoniazid, phenobarbitone, phenytoin and rifampicin. Increased risk of convulsion when used concurrently with high-dose methylprednisolone.\nPotentially Fatal: Additive nephrotoxicity when used with aminoglycosides, amphotericin B, ciprofloxacin, colchicine, melphalan, co-trimoxazole and NSAIDs.
Cyclosporine 0.05% Eye prep	\n\n\tApex\tRestor Eye Drops   5ml bot 200\n\tAristopharma\tCyporin Eye Drops   5  ml drop 210\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCyclorin Eye Drops   5  ml drop 210\n\tIndication: Dry eye\n\nDose: One drop of Cyclosporine eye drop should be instilled twice a day in each eye approximately 12 hours apart. Cyclosporine eye drop can be used concomitantly with artificial tears, allowing a 15-minute interval between products.\n\nContra-indication: Cyclosporine is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.\n\nSide effects: The most common adverse event was ocular burning. Other events reported included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring). \n\nPrecaution: Cyclosporine eye drop should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. If contact lenses are worn, they should be removed prior to the administration of this formulation. Lenses may be reinserted 15 minutes following administration of Cyclosporine eye drop. \n\nMode of action: Increased ciclosporin level by diltiazem, doxycycline, erythromycin, ketoconazole, methylprednisolone (high doses), nicardipine, verapamil, oral contraceptives. Drugs which reduce ciclosporin level are carbamazepine, isoniazid, phenobarbitone, phenytoin and rifampicin. Increased risk of convulsion when used concurrently with high-dose methylprednisolone.\nPotentially Fatal: Additive nephrotoxicity when used with aminoglycosides, amphotericin B, ciprofloxacin, colchicine, melphalan, co-trimoxazole and NSAIDs.\n\nPregnancy category: C\n\nInteraction: Increased ciclosporin level by diltiazem, doxycycline, erythromycin, ketoconazole, methylprednisolone (high doses), nicardipine, verapamil, oral contraceptives. Drugs which reduce ciclosporin level are carbamazepine, isoniazid, phenobarbitone, phenytoin and rifampicin. Increased risk of convulsion when used concurrently with high-dose methylprednisolone.\nPotentially Fatal: Additive nephrotoxicity when used with aminoglycosides, amphotericin B, ciprofloxacin, colchicine, melphalan, co-trimoxazole and NSAIDs.
Cyproterone Acetate + Ethinylestradiol	\n\n\tRenata\tGiane 35 TAB dr   1 x 21 's pack 150.78\n\tIndication: Acne, Contraception, Hirsutism, Prostatic carcinoma, Libido, Hot flushes\n\nDose: Adult: PO Acne; Contraception; Hirsutism 2 mg/day (w/ ethinylestradiol) for 21 days of the menstrual cycle. \n\nPalliative treatment for prostatic carcinoma Initial: 300 mg/day in 2-3 divided doses. Maintenance: 200-300 mg/day. \n\nControl of libido 50 mg twice daily. Hot flushes 50mg/day, may increase to 150 mg/day in 3 divided doses if needed.\n\nContra-indication: Markedly impaired liver function or cholestasis; Dubin-Johnson or Rotor syndrome, hepatic adenoma; malignant or wasting diseases; severe chronic depression; severe diabetes with vascular changes; sickle-cell anaemia; history of thromboembolic disorders; renal impairment. Youths <18 yr.\n\nSide effects: Inhibits spermatogenesis, reduces volume of ejaculate, causes infertility, produces abnormal spermatozoa, gynecomastia and enlargement of mammary glands; galactorrhoea and benign nodules. Depressive mood changes. Alterations in hair pattern, skin reactions. Fatigue and lassitude, breathlessness, wt changes.\n\nPrecaution: Prostate cancer, hepatic impairment, DM, history of depression, familial defects in lipoprotein metabolism, CV diseases. Monitor LFT, adrenocortical function, LDL and HDL levels, and RBC count during treatment. In women: Interrupt treatment if persistent or recurrent bleeding occurs to exclude the possibility of organic diseases. May increase risk of thrombo-embolic diseases. Ineffective for male hypersexuality in chronic alcoholism. May impair ability to drive or operate machinery. Pregnancy, lactation.\n\nMode of action:  	Metabolism may be reduced by inhibitors of CYP3A4 e.g. ketoconazole, itraconazole, clotrimazole, ritonavir. Inducers of CYP3A4 e.g. rifampicin, phenytoin may reduce the levels of cyproterone.\nCYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol.\nPotentially Fatal: Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs.\n\nPregnancy category: X\n\nInteraction:  	Metabolism may be reduced by inhibitors of CYP3A4 e.g. ketoconazole, itraconazole, clotrimazole, ritonavir. Inducers of CYP3A4 e.g. rifampicin, phenytoin may reduce the levels of cyproterone.\nCYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol.\nPotentially Fatal: Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs.
Vitamin B Complex Inj	\n\n\tAcme Ltd.\tV Plex Injection   \n\tOrion Pharma Ltd.\tCombivit Injection   10's pack 40\n\tSanofi Aventis (BD) Ltd.\tFidaplex Injection   \n\tSquare\tB 50 FORTE Injection   20's pack 200\n\tIndication: Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.Nutritional supplement\n\nDose: Injection : 2 ml daily IV or IM. High concentrations given intravenously may be diluted using parenteral infusion solutions. \n\nContra-indication: Contraindicated in patients hypersensitive to any of its components.\n\nSide effects: Adverse reactions have been reported with specific vitamins and minerals, but generally at levels substantially higher than the usual dose. However, allergic and idiosyncratic reactions are possible at lower levels. \nMild transient diarrhea, polycythemia vera, peripheral vascular thrombosis, itching transitory exanthema, feeling of swelling of entire body, anaphylactic shock.\n\nPrecaution: The usual precautions for parenteral administration should be observed. Do not inject if precipitation occurs. Inject slowly by the intravenous route. High concentrations should be diluted using Normal Saline Injection when given intravenously.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Danazol	\n\n\tDelta Pharma\tDana CAP 100mg  \n\tDelta Pharma\tDana CAP 200mg  \n\tDrug International Ltd.\tDazol CAP 100mg  \n\tDrug International Ltd.\tDazol CAP 200mg  \n\tEskayef Bangladesh Ltd.\tDanamet CAP 100mg 18's pack 360\n\tEskayef Bangladesh Ltd.\tDanamet CAP 200mg 18's pack 684\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDanazol CAP 100mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tDanazol CAP 200mg  \n\tIncepta\tLozana CAP 100mg 20's pack 400\n\tIncepta\tLozana CAP 200mg 16's pack 608\n\tRenata\tDanzol CAP 100mg 30's pack 600\n\tRenata\tDanzol CAP 200mg 20's pack 760\n\tIndication: Endometriosis, Benign breast disorders, Gynaecomastia, Hereditary angioedema, Menorrhagia.\n\nDose: Adult: PO: 200-800 mg/day in 2 divided doses for 3-6 mth, up to 9 mth if needed. It is recommended that danazol therapy in adult females should start on the first day of the menstrual cycle with an adjustment of dosage made subsequently to achieve amenorrhoea or the desired effect.  \n\nIn endometrosis : The initial dose is 400 mg daily usually continued for 6 months. If symptoms do not resolve, the dose can be increased to 800 mg daily but the total course should not exceed 9 months.  \n\nBenign breast disease: Severe cyclical mastalgia. The recommended initial dose for severe cyclical mastalgia is 200-300 mg daily for 3-6 month. In several studies, the initial dose was either 200 mg or 300 mg daily, which was reduced after either 1 or 2 months if a clinically useful response had occurred.  \n\nBenign, multiple or recurrent breast disease: The recommended initial dose for this indication is 300 mg daily for 3-6 months.  \n\nMenorrhagia: In menorrhagia, daily doses of 100-200 mg have been found effective but 200 mg daily is usually sufficient to reduce menstrual blood flow to acceptable levels. The recommended initial dose is 200 mg daily for 3 months.  \n\nGynecomastia: Adults, 300-600 mg daily. Adolescents, 200-300 mg daily.  \n\nPreoperative thinning of the endometrium before hysteroscopic endometrial ablation: Danazol induces endometrial atrophy and is currently recommended at doses of 400-800 mg daily for up to 3 months preoperatively.\n\nContra-indication: Hypersensitivity, pregnancy, lactation, porphyria, thromboembolic disorders; undiagnosed genital bleeding, markedly impaired renal, cardiac or hepatic dysfunction.\n\nSide effects: Oedema, wt gain, sweating, acne, hirsutism, flushing, oily skin or hair, deepening of the voice, clitoral hypertrophy, amenorrhoea, hepatic dysfunction, CNS or GI disturbances, benign intracranial hypertension, reduction in breast size, visual disturbances, elevated LFT values.   Other adverse effects: Include menstrual disturbances, hypo-estrogenic symptoms, such as flushing, vaginal dryness and irritation and a modest reduction of spermatogenesis in the male. Maculopapular, petechial, purpuric and urticarial rashes have been reported. Cardiovascular reactions may include exacerbation of hypertension, palpitations and tachycardia. Various psychological reactions such as increased appetite, emotional lability, anxiety, depression, nervousness, changes in libido, dizziness, vertigo, nausea, headache and fatigue have been described. Potentially Fatal: Thromboembolic events and fatal strokes have been reported.\n\nPrecaution: Danazol may cause some degree of fluid retention, conditions that might be influenced by this factor, such as epilepsy, migraine, or cardiac or renal dysfunction, polycythemia and hypertension require careful observation. Use with caution in patients with diabetes mellitus.  Since hepatic dysfunction manifested by modest increases in serum transaminases levels has been reported in patients treated with Danazol, periodic liver function tests should be performed  Administration of danazol has been reported to cause exacerbation of the manifestations of acute intermittent porphyria. \n\nMode of action: Increased serum levels of ciclosporin, warfarin, carbamazepine and tacrolimus.\nPotentially Fatal: Increased incidence of insulin resistance in diabetic patients.\n\nPregnancy category: X\n\nInteraction: Increased serum levels of ciclosporin, warfarin, carbamazepine and tacrolimus.\nPotentially Fatal: Increased incidence of insulin resistance in diabetic patients.
Dapsone	\n\n\tEDCL (Dhaka)\tDapsone TAB dr 100mg  \n\tEDCL (Dhaka)\tDapsone TAB dr 50mg  \n\tG. A. Company Ltd.\tLepsone TAB dr 100mg  \n\tIndication: Pneumonia, Acne, Leprosy, Dermatitis herpetiformis\n\nDose: Adult: PO Prophylaxis of Pneumocystis (carinii) jiroveci pneumonia50 mg/day (w/ pyrimethamine once wkly). \nMultibacillary leprosy 100 mg/day (w/ clofazimine and rifampicin in different dosage regimens) for 12 mth. \nPaucibacillary leprosy 100 mg/day (w/ rifampicin once mthly) for 6 mth. \nDermatitis herpetiformis Initial: 50 mg/day, up to 300 mg/day if needed. T\n\nContra-indication: Hypersensitivity. Severe anaemia, porphyria.\n\nSide effects: Anaemia, peripheral neuropathy, haemolysis and methaemoglobinaemia (dose-related), nephrotic syndrome, psychological changes, hepatitis. Others: Nausea, vomiting, anorexia, headache, maculopapular rash, toxic epidermal necrolysis, Stevens-Johnson syndrome. Topical: Dryness, redness, oiliness and peeling at application site.\nPotentially Fatal: Agranulocytosis, serious cutaneous hypersensitivity reactions, exfoliative dermatitis.\n\nPrecaution: G6PD deficiency, methaemoglobin or Hb M. Perform regular blood counts and monitor liver function regularly. Pregnancy and lactation.\n\nMode of action: Decreased serum conc of dapsone when used with rifampicin. Increased plasma conc with probenecid, trimethoprim. Antagonize clofazimine.\n\nPregnancy category: C\n\nInteraction: Decreased serum conc of dapsone when used with rifampicin. Increased plasma conc with probenecid, trimethoprim. Antagonize clofazimine.
Darifenacin	\n\n\tAcme Ltd.\tDarifen ER TAB dr 7.5mg 7's pack 280\n\tAcme Ltd.\tDarifen TAB dr 7.5 mg 1x7's pack 154\n\tIncepta\tDarifenacin ER TAB dr 15mg 30's pack 1200\n\tIncepta\tDarilax 15 ER TAB dr 15mg 30's pack 1200\n\tIncepta\tDarilax 7.5 ER TAB dr 7.5mg 30's pack 660\n\tNovartis (Bangladesh) Ltd.\tEnablex TAB dr 7.5mg 28's pack 1752.80\n\tNovartis (Bangladesh) Ltd.\tEnablex TAB dr 15mg 28's pack 1808.52\n\tIndication: Urge incontinence, Urinary frequency and urgency, Overactive bladder\n\nDose: Adult: PO Initial: 7.5 mg once daily; may increase dose to 15 mg once daily if no adequate response after 2 wk of therapy. Daily dose should not exceed 7.5 mg/day if use concurrently w/ strong CYP3A4 inhibitors.\n\nContra-indication: Patient with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients who are at risk for these conditions.\n\nSide effects: Dry mouth, nausea, abdominal pain, constipation, diarrhoea, dyspepsia, dizziness, headache, asthaenia, pain, weight gain, dry skin, rash, pruritus, dry eyes, abnormal vision, arthralgia, bronchitis, pharyngitis, rhinitis, sinusitis, flu-like syndrome, UTI, vaginitis, acute urinary retention, hypertension and peripheral oedema.\nPotentially Fatal: Hypersensitivity reactions, including angioedema.\n\nPrecaution: Anticholinergic agents including Darifenacin, may cause urinary retention and decreased GI motility. Caution when used in patients with clinically significant bladder outflow obstruction, GI obstructive disorder (e.g. pyloric stenosis), severe constipation, ulcerative colitis, and myasthenia gravis. For patients being treated for narrow-angle glaucoma, caution and only use where potential benefits outweigh the risks. May cause heat prostration when used in a hot environment. May cause dizziness and blurred vision; caution when operating machinery or driving vehicle. Not recommended in severe hepatic impairment. Safety and efficacy have not been established in paediatric patients. Pregnancy and lactation.\n\nMode of action: Concurrent use of CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) or CYP2D6 inhibitors (e.g. quinidine, paroxetine) may increase serum levels of Darifenacin. CYP3A4 inducers (e.g. barbiturates, phenytoin, rifampicin) may likely decrease Darifenacin serum concentrations. Darifenacin may act as a moderate inhibitor of CYP2D6, caution when used concomitantly with CYP2D6 substrates that have narrow therapeutic index (e.g. flecainide, thioridazine, imipramine). Concurrent use of another agent with antimuscarinic properties may potentiate the side effects of Darifenacin.\n\nPregnancy category: C\n\nInteraction: Concurrent use of CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) or CYP2D6 inhibitors (e.g. quinidine, paroxetine) may increase serum levels of Darifenacin. CYP3A4 inducers (e.g. barbiturates, phenytoin, rifampicin) may likely decrease Darifenacin serum concentrations. Darifenacin may act as a moderate inhibitor of CYP2D6, caution when used concomitantly with CYP2D6 substrates that have narrow therapeutic index (e.g. flecainide, thioridazine, imipramine). Concurrent use of another agent with antimuscarinic properties may potentiate the side effects of Darifenacin.
Daunorubicin	\n\n\tIndication: Acute leukaemia, AIDS-related Kaposi's sarcoma				\n\n\nDose: Adult: IV Acute leukaemia 30-45 mg/m2/day on days 1-3 of the induction regimen and days 1 and 2 of subsequent courses. May repeat course 3-6 wk later. Max total cumulative dose: 550 mg/m2 in patients w/o risk factors for cardiotoxicity and 400 mg/m2 in patients who have received chest radiotherapy. \n\nChild: For acute lymphoblastic leukaemia: 25 mg/m2 BSA once wkly in combination with other regimens. <2 yr old or BSA <0.5 m2: 1 mg/kg once wkly. Max (total cumulative dose): 300 mg/m2 and in children <2 yr: 10 mg/kg.\nHepatic impairment: Based on serum bilirubin concentrations of 12-30 mcg/ml: 75% of the usual dose; >30 mcg/ml: 50% of the usual dose. \n\nAIDS-related Kaposi's sarcoma As liposomal formulation: Initial: 40 mg/m2 every 2 wk. Continue treatment for as long as disease control is maintained.\n\nHepatic impairment: Based on serum bilirubin concentrations of 12-30 mcg/ml: 75% of the usual dose; >30 mcg/ml: 50% of the usual dose.\n\nContra-indication: Heart failure. Pregnancy, lactation.\n\nSide effects: GI disturbances; stomatitis; alopoecia and dermatological reactions. Extravasation of daunorubicin may cause severe local tissue necrosis damaging surrounding muscles, tendons and nerves. IV infusion, back pain, flushing and chest tightness.\nPotentially Fatal: Bone marrow suppression, cardiac toxicity, cardiomyopathy and congestive heart failure.\n\nPrecaution: Regular blood count and ECG monitoring; elderly, children. Hepatic or renal impairment may increase risk of toxicity. Pre-existing cardiac disease and previous treatment with doxorubicin. Myocardial toxicity leading to potentially fatal congestive heart failure may occur during therapy or mth to yr after therapy cessation. Incidence of myocardial toxicity increases after total cumulative dose exceeds 400-550 mg/m2 in adults, 300 mg/m2 in children >2 yr, or 10 mg/kg in children <2 yr. Risk of severe myelosuppression leading to infection or haemorrhage.\n\nMode of action: Increased risk of cardiotoxicity when used with cyclophosphamide. Increased risk of hepatic toxicity when used with hepatotoxic drugs e.g. high-dose methotrexate.\nPotentially Fatal: Immunisation with live vaccines is not recommended. Concurrent radiation may lead to increased radiation reaction.\n\nPregnancy category: D\n\nInteraction: Increased risk of cardiotoxicity when used with cyclophosphamide. Increased risk of hepatic toxicity when used with hepatotoxic drugs e.g. high-dose methotrexate.\nPotentially Fatal: Immunisation with live vaccines is not recommended. Concurrent radiation may lead to increased radiation reaction.
Deferiprone	\n\n\tCipla Ltd.\tKelfer CAP 500mg 50's pack 700\n\tCipla Ltd.\tKelfer CAP 250mg 50's pack 500\n\tDrug International Ltd.\tFeripon TAB dr 500mg 500mg x 10's pack 180\n\tIndication: Thalassaemia,Iron overload\n\nDose: Oral\nIron overload in patients with thalassaemia\nAdult: 25 mg/kg tid. Doses >100 mg/kg daily are not recommended.\nChild: >6 yr: 25 mg/kg tid.\n\nContra-indication: Agranulocytosis, pregnancy and lactation.\n\nSide effects: Musculoskeletal and joint pain; GI disturbances; red-brown discoloration of urine; transient liver enzyme abnormalities; zinc deficiency; neutropenia and agranulocytosis.\n\nPrecaution: Hepatic and renal impairment. Neutropenia, monitor neutrophil count wkly and discontinue treatment if neutropenia develops. Limited experience in children 6-10 yr.\n\nMode of action: Avoid using deferiprone with aluminium-containing antacids as it can chelates trivalent metal ions.\n\nPregnancy category: D\n\nInteraction: Avoid using deferiprone with aluminium-containing antacids as it can chelates trivalent metal ions.
Demeclocycline Hydrochloride	\n\n\tIndication: Atypical pneumonia, Hyponatraemia\n\nDose: Adult: PO Susceptible infections 150 mg 4 times/day. Atypical pneumonia 300 mg 3 times/day. Chronic hyponatraemia associated w/ SIADH Initial: 900-1,200 mg/day in divided doses. Maintenance: 600-900 mg/day in divided doses.\n\nContra-indication: Hypersensitivity. Pregnancy and lactation.\n\nSide effects: Photosensitivity. Reversible nephrogenic diabetes insipidus. Permanent staining of teeth; nausea; rash; GI upsets; dysphagia; enterocolitis; anogenital inflammation (moniliasis). Hypersensitivity; haemolytic anaemia, thrombocytopenia, neutropenia and eosinophilia; raised blood urea and liver enzymes.\nPotentially Fatal: Anaphylaxis (rare).\n\nPrecaution: Children <12 yr; SLE; renal or hepatic disease.\n\nMode of action: Reduced absorption w/ antacids containing Al, Mg, or Ca, Fe-containing preparations, zinc, kaolin, quinapril, strontium ranelate, sucralfate, tripotassium dicitratobismuthate. May reduce the efficacy of oral contraceptives and penicillins. Increased risk of benign intracranial HTN w/ retinoids (e.g. acitretin, isotretinoin, tretinoin). Increased risk of ergotism w/ ergotamine and methysergide. May inactivate oral typhoid vaccine. May potentiate the effect of anticoagulants.\nPotentially Fatal: Concurrent use w/ methoxyflurane may result to fatal renal toxicity.\n\nPregnancy category: D\n\nInteraction: Reduced absorption w/ antacids containing Al, Mg, or Ca, Fe-containing preparations, zinc, kaolin, quinapril, strontium ranelate, sucralfate, tripotassium dicitratobismuthate. May reduce the efficacy of oral contraceptives and penicillins. Increased risk of benign intracranial HTN w/ retinoids (e.g. acitretin, isotretinoin, tretinoin). Increased risk of ergotism w/ ergotamine and methysergide. May inactivate oral typhoid vaccine. May potentiate the effect of anticoagulants.\nPotentially Fatal: Concurrent use w/ methoxyflurane may result to fatal renal toxicity.
Desferrioxamine Mesilate	\n\n\tNovartis (Bangladesh) Ltd.\tKelfer Injection 500mg 10's pack 2709\n\tIndication: Iron overload, Aluminum overload, Iron poisoning\n\nDose: Adult: IV Aluminum overload Patients w/ end stage renal failure or on haemodialysis or haemofiltration: 5 mg/kg once a wk during the last hr of dialysis or 5 hr before dialysis in severe cases. \n\nPatients on peritoneal dialysis: 5 mg/kg once a wk (via slow IV infusion/SC/IM/intraperitoneally) before the final exchange of the day. \n\nDiagnosis of aluminum overload 5 mg/kg during the last hr of the dialysis session. \n\nAcute iron poisoning Initial: 15 mg/kg/hr, reduce 4-6 hr later. Total dose: <80 mg/kg in 24 hr. IV/IM/SC Chronic iron overload Initial: 500 mg via IV/SC infusion. Usual: 20-60 mg/kg/day for 3-7 times/wk depending on extent of overload. Alternatively, initial: 0.5-1 g/day via IM administration, maintenance dose depends on response. \n\nIM Acute iron poisoning 2 g as a single dose. Diagnosis of iron storage disease 500 mg as a single dose.\n\nContra-indication: Severe renal disease or anuria.\n\nSide effects: Rapid IV injection: Flushing, urticaria, hypotension and shock. SC or IM injection: Local pain. Prolonged SC: Pruritus, erythema and swelling. GI disorders, dysuria, fever, allergic skin rashes, tachycardia, cardiac arrhythmias, convulsions and leg cramps; visual disturbances, cataract formation, hearing loss; may retard growth in very young childn. Pulmonary syndrome with high IV doses.\n\nPrecaution: Impaired renal function; may color the urine reddish-brown, exacerbate aluminum-related encephalopathy and precipitate seizure (prophylactic with antiepileptic if at risk); susceptible to infection; monitor urinary excretion of iron, ophthalmological, audiological and cardiac function examinations; pregnancy.\n\nMode of action: Increased risk of neurological symptoms when used concurrently with phenothiazines. Ascorbic acid improves Fe excretion but it should not be given during the 1st mth of starting deferoxamine treatment as it may worsen Fe toxicity. May affect imaging results if given together with gallium-67.\n\nPregnancy category: C\n\nInteraction: Increased risk of neurological symptoms when used concurrently with phenothiazines. Ascorbic acid improves Fe excretion but it should not be given during the 1st mth of starting deferoxamine treatment as it may worsen Fe toxicity. May affect imaging results if given together with gallium-67.
Desloratadine	\n\n\tACI\tDeslorin Syrup 2.5mg/5ml 60ml bot 25.17\n\tACI\tDeslorin TAB dr 5mg 100's pack 251\n\tAcme Ltd.\tOrinex TAB dr 5mg 100's pack 251\n\tAd-din\tAdlorin TAB dr 5mg  100's pack 250\n\tAlbion Ltd.\tDesloratadine TAB dr 5 mg 100's pack \n\tAlco Pharma\tAloran TAB dr 5mg 50's pack 125\n\tAmulet\tDesolet TAB dr 5mg 100's pack 250\n\tApex\tDelot Syrup 2.5mg/5ml 60ml bot 25\n\tApex\tDelot TAB dr 5mg  50's pack 100\n\tAsiatic Ltd.\tClarex TAB dr 5mg 50's pack 125\n\tBeacon\tAlertadin TAB dr 5mg 100's pack 250\n\tBeximco\tMomento Syrup 2.5mg/5ml 60ml bot 25\n\tBeximco\tMomento TAB dr 5mg 100's pack 250\n\tBristol Pharma Ltd.\tPerilor TAB dr 5mg 100's pack 250\n\tConcord\tUnilor TAB dr 5mg  \n\tConcord\tUnilor Syrup 2.5 mg/5 ml  \n\tDelta Pharma\tSarinex Syrup 2.5mg/5ml 60ml bot 25\n\tDelta Pharma\tSarinex TAB dr 5mg 50's pack 125\n\tDrug International Ltd.\tAslor TAB dr 5mg 100's pack 250\n\tEskayef Bangladesh Ltd.\tDesodin Syrup 2.5mg/5ml 60ml bot 25\n\tEskayef Bangladesh Ltd.\tDesodin TAB dr 5mg 50's pack 150\n\tEuro Pharma Ltd.\tDesmin TAB dr 5mg 100's pack 250\n\tGeneral\tRelergy Syrup 2.5mg/5ml 50's pack \n\tGeneral\tRelergy TAB dr 5mg 50's pack 125.50\n\tGlobe\tDeslona Syrup 2.5mg/5ml 60ml bot 25\n\tGlobe\tDeslona TAB dr 5mg 100's pack 250\n\tHallmark\tDesmark TAB dr 5mg 50's pack 100.50\n\tHudson\tLara TAB dr 5mg 100's pack 250\n\tIncepta\tNeocilor Syrup 2.5mg/5ml 60ml bot 25\n\tIncepta\tNeocilor TAB dr 5mg 100's pack 250\n\tKemiko\tDeen TAB dr 5mg 50's pack 125\n\tLeon\tDesgud TAB dr 5mg  \n\tMystic\tDora Syrup 2.5mg/5ml 60ml bot 25.75\n\tMystic\tDora TAB dr 5mg 50's pack 125\n\tNavana\tDesatrol Syrup 2.5mg/5ml 50ml bot 25\n\tNavana\tDesatrol TAB dr 5mg 100's pack 251\n\tNovo Healthcare and Pharma Ltd.\tLorades Syrup 2.5mg/5ml 60ml bot 25\n\tNovo Healthcare and Pharma Ltd.\tLorades TAB dr 5mg 50's pack 125\n\tOpsonin Pharma\tDes Syrup 2.5mg/5ml 60ml bot 25\n\tOpsonin Pharma\tDes TAB dr 5mg 50's pack 125\n\tOrion Pharma Ltd.\tDeslor Syrup 2.5mg/5ml 60ml bot 30\n\tOrion Pharma Ltd.\tDeslor TAB dr 5mg 100's pack 350\n\tOrion Pharma Ltd.\tDeslor Kidz Paediatric Drops 0.5mg/ml 50ml bot 25\n\tPacific\tDerat TAB dr 5mg 50's pack 125\n\tPharmasia Ltd.\tDelosia Syrup 2.5mg/5ml 60ml bot 28\n\tPharmasia Ltd.\tDelosia TAB dr 5mg 50's pack 125.50\n\tPrime\tDestadin TAB dr 5mg  \n\tRangs\tDestacin TAB dr 5mg 50's pack 125\n\tSquare\tSedno Syrup 2.5mg/5ml 60ml bot 25.10\n\tSquare\tSedno TAB dr 5mg 100's pack 251.37\n\tSupreme\tNeolor TAB dr 5mg 50's pack 150\n\tSyntho Ltd.\tReelart TAB dr 5mg 50's pack 125\n\tUnimed & Unihealth Manufacturers Ltd.\tDestin Syrup 2.5mg/5ml 60ml bot 25\n\tUnimed & Unihealth Manufacturers Ltd.\tDestin TAB dr 5mg 30's pack 75\n\tWhite Horse Pharma\tDesta TAB dr 5mg 50's pack 125\n\tZenith\tDesol Syrup 2.5mg/5ml 60ml bot 25\n\tCosmic Pharma Ltd.\tRhinexe TAB dr 5mg  \n\tIndication: Itching, Sneezing, Watery eyes, Allergic conditions, Runny nose, Hives, Skin rash, Common cold\n\nDose: Adults and adolescent of 12 years or over : 5 mg once daily.\nChild 6-11 years : 2.5 mg once daily.\nChild 12 months-5 years : 1.25 mg (2.5 ml syrup) once daily.\nChild 6 months-11 months : 1 mg (2 ml syrup) once daily.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Headache, fatigue, somnolence, dizziness; nausea, dyspepsia; xerostomia, dysmenorrhoea; pharyngitis.\n\nPrecaution: Severe renal or hepatic failure; children <6 mth, elderly, epilepsy, pregnancy and lactation.\n\nMode of action:  	Potential increase in plasma concentrations w/ drugs affecting hepatic microsomal enzymes (e.g. azithromycin, cimetidine, erythromycin, fluoxetine, ketoconazole).\n\nPregnancy category: C\n\nInteraction:  	Potential increase in plasma concentrations w/ drugs affecting hepatic microsomal enzymes (e.g. azithromycin, cimetidine, erythromycin, fluoxetine, ketoconazole).
Desloratadine + Pseudoephedrine Sulphate	\n\n\tACI\tDeslorin 5 PLUS 5/240 TAB dr 5 mg + 240 mg 50's pack 276\n\tACI\tDeslorin PLUS 2.5/120 TAB dr  2.5 mg + 120 mg 50's pack 175.50\n\tDelta Pharma\tSarinex D TAB dr  5/240  20's pack 100\n\tDelta Pharma\tSerinex D 2.5 TAB dr   30's pack 90\n\tOrion Pharma Ltd.\tDeslor Plus TAB dr 2.5 mg + 120 mg  \n\tOrion Pharma Ltd.\tDeslor PLUS TAB dr 5 mg + 240 mg  \n\tIndication: Allergic rhinitis, Itching, Sneezing, Watery eyes, Runny nose, Hives, Skin rash, Common cold, Nasal congestion\n\nDose: PO:  Adults and adolescent of 12 years or over : 1 tablet (2.5 mg desloratadine/120 mg pseudoephedrine)  12 hourly.\n1 tablet (5 mg desloratadine/240 mg pseudoephedrine) 24 hourly. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Mild GI effects and allergic reactions.\n\nPrecaution: Severe renal or hepatic failure; children <6 mth, elderly, epilepsy, pregnancy and lactation.\n\nMode of action:  	Potential increase in plasma concentrations w/ drugs affecting hepatic microsomal enzymes (e.g. azithromycin, cimetidine, erythromycin, fluoxetine, ketoconazole).\nIncreased risk of hypertension and arrhythmias if given with cardiac glycosides, quinidine or TCAs. Increased risk of vasoconstrictor effects if given with ergot alkaloids or oxytocin. Co-admin with MAOIs may cause hypertensive crisis. Anaesthetics e.g. cyclopropane, halothane and other halogenated anaesthestics; antihypertensive agents.\n\nPregnancy category: C\n\nInteraction:  	Potential increase in plasma concentrations w/ drugs affecting hepatic microsomal enzymes (e.g. azithromycin, cimetidine, erythromycin, fluoxetine, ketoconazole).\nIncreased risk of hypertension and arrhythmias if given with cardiac glycosides, quinidine or TCAs. Increased risk of vasoconstrictor effects if given with ergot alkaloids or oxytocin. Co-admin with MAOIs may cause hypertensive crisis. Anaesthetics e.g. cyclopropane, halothane and other halogenated anaesthestics; antihypertensive agents.
Desogestrel + Ethinylestradiol	\n\n\tNuvista Pharma Ltd\tMarvelon TAB dr   21's pack 105\n\tRenata\tDesolon TAB dr  150 mcg + 30 mcg 1 X 21's pack/10 X 21's pack 60.06/600.60\n\tIndication: Oral contraception\n\nDose: Adult: PO Dosing instruction may vary according to the brand. For 21-day pack: Start on 1st day of menses. 1 tab/day for 21 days followed by 7 pill-free days. Start new pack on the 8th day after the last tab is taken. For 28-day pack: Start on 1st day of menses. 1 tab/day w/o interruption. Take dose at the same time everyday.\n\nContra-indication: History of or current thrombophlebitis or venous thromboembolic disorders; active or recent (within 1 yr) arterial thromboembolic disease e.g. stroke, MI; cerebral vascular disease, coronary artery disease, valvular heart disease with complications. Severe hypertension; DM with vascular involvement; severe headache with focal neurological symptoms. Known or suspected breast carcinoma, endometrial cancer, oestrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding; hepatic dysfunction or tumor. Cholestatic jaundice of pregnancy, jaundice with prior combined hormonal contraceptive use. Major surgery with prolonged immobilisation. Pregnancy.\n\nSide effects: Intermenstrual bleeding, post-medication amenorrhoea, changes in cervical secretion, increase in size of uterine fibromyomata, aggravation of endometriosis and certain vaginal infections. Breast tenderness, pain, enlargement or secretion. Nausea, vomiting, cholelithiasis, cholestatic jaundice. Headache, migraine, mood changes, depression. Fluid retention, change in body wt, reduced glucose tolerance.\n\nPrecaution: May increase risk of breast cancer, glucose intolerance and thromboembolism. May affect serum levels of triglyceride and lipoprotein. Caution when used in patients with familial defects of lipoprotein metabolism. Discontinue treatment if papilledema or retinal vascular lesions are observed on eye examination. Patients with risk factors for coronary artery disease. Patients with depression or history of migraine. Renal impairment. Increased cardiovascular risk in smoking women especially those >35 yr. Treatment should be stopped for 4 wk prior to and for 2 wk after surgery associated with increased risk of thromboembolism or during periods of prolonged immbolisation.\n\nMode of action: Serum levels may be increased when used with paracetamol, ascorbic acid, atorvastatin. Serum levels may be reduced by aprepitant, griseofulvin, modafinil, troglitazone, rifampicin, topiramate, nevirapine, amprenavir, lopinavir, nelfinavir and ritonavir. May affect the efficacy of coumarin derivatives. Concurrent use with aminoglutethimide, carbamazepine, felbamate, phenobarbital, phenytoin or topiramate may lead to decrease in contraceptive effectiveness. May reduce the clearance of alprazolam, chlordiazepoxide and diazepam. May increase the clearance of lorazepam, oxazepam, temazepam, clofibric acid, morphine, salicylic acid. May inhibit the metabolism of theophylline, ciclosporin and prednisolone. May decrease the serum levels of lamotrigine. May increase serum levels of selegiline and TCAs e.g. amitriptyline, imipramine.\n\nPregnancy category: X\n\nInteraction: Serum levels may be increased when used with paracetamol, ascorbic acid, atorvastatin. Serum levels may be reduced by aprepitant, griseofulvin, modafinil, troglitazone, rifampicin, topiramate, nevirapine, amprenavir, lopinavir, nelfinavir and ritonavir. May affect the efficacy of coumarin derivatives. Concurrent use with aminoglutethimide, carbamazepine, felbamate, phenobarbital, phenytoin or topiramate may lead to decrease in contraceptive effectiveness. May reduce the clearance of alprazolam, chlordiazepoxide and diazepam. May increase the clearance of lorazepam, oxazepam, temazepam, clofibric acid, morphine, salicylic acid. May inhibit the metabolism of theophylline, ciclosporin and prednisolone. May decrease the serum levels of lamotrigine. May increase serum levels of selegiline and TCAs e.g. amitriptyline, imipramine.
Desonide 0.05%	\n\n\tACI\tDesotop Gel  0.05% 15gm  tube 50.34\n\tIndication: Psoriasis, Eczema, Contact dermatitis, Corticosteroid-responsive dermatoses, Seborrheic dermatitis\n\nDose: Adult: Topical As 0.05% cream/oint/lotion: Apply 2-4 times/day.\n\nContra-indication: Hypersensitivity to any of the components. Primary infective skin conditions.\n\nSide effects: Burning, itching, irritation, scaling, folliculitis, hypertrichosis, contact dermatitis, skin peeling, transient erythema.\n\nPrecaution: Caution when using in paed patients. Evaluate periodically for evidence of HPA-axis suppression. In the event of secondary infections use appropriate antibiotics and discontinue topical steroid. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dexamethasone 0.05%  Eye prep	\n\n\tAristopharma\tSonexa Eye Ointment   3 gm tube 60\n\tBio Pharma Ltd.\tInfladex Eye Ointment 0.05 gm/100 gm  \n\tGeneral\tDexagen Eye Ointment 0.05 gm/100 gm  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tDexon Eye Ointment    3 gm tube 60\n\tIndication: Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as conjunctivitis, keratitis, iritis, scleritis, corneal injury from chemical or thermal burns, or penetration of foreign bodies. It is also effective post-operatively.\n\nDose: As 0.05% ointment: Apply 0.5-1 inch ribbon of ointment into the conjunctival sac(s) up to 4 times daily. Reduce to once daily dosing once conditon has improved.\n\nContra-indication: Patients wearing contact lenses, herpes simplex & other virus conditions, mycosis, glaucoma, new born babies, fungal diseases of ocular or auricular structures, hypersensitivity to any component of this product.\n\nSide effects: Topical application to eye: Corneal ulcers, glaucoma and reduced visual ability. A slight burning sensation may occur for a short time after instilling  into the eye. After several weeks of administration to predisposed patients there may be a reversible increase in intraocular pressure. Regular pressure checks are advisable. Systemic adverse reactions may also occur after long-term topical application of corticosteriod in children. Others include cataract and corneal softening.\n\nPrecaution: Patients with hypothyroidism; cirrhosis, hypertension, CHF, ulcerative colitis, thromboembolic disorders, osteoporosis, glaucoma, cataracts or TB of the eye, diabetes, peptic ulcer. Monitor blood glucose levels in diabetics and coagulation indices in patients on warfarin. Elderly, children and adolescent; pregnancy and lactation.\n\nMode of action:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\n\nPregnancy category: C\n\nInteraction:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.
Dexamethasone 0.1%  E/E prep	\n\n\tACI\tAcicot Eye/Ear Drops  0.1% 5 ml bot 61.18\n\tBeximco\tInflavis Eye/Ear Drops   5 ml bot 60\n\tG. A. Company Ltd.\tMeradexon Eye/Ear Drops   5 ml bot 50\n\tIncepta\tMetadaxan Eye/Ear Drops 1 mg/ml 5 ml bot 70\n\tJayson\tDexamin Eye/Ear Drops   5 ml pack 50.20\n\tOpso Saline Ltd.\tDexacort Eye/Ear Drops   5 ml bot 70\n\tReman Drug Ltd.\tDexadron Eye/Ear Drops   4 ml pack 60.23\n\tSquare\tDexonex Eye/Ear Drops   5 ml bot 60\n\tIndication: Allergic conjunctivitis, Ocular inflammation, Superficial punctate keratitis , Herpes zoster keratitis, 	Iritis , Cyclitis, Otic inflammation, Steroid responsive inflammatory conditions of the external auditory meatus,  Allergic otitis externa, Infective otitis externa.\n\nDose: Eye:\n1 or 2 drops in conjunctival sac.\nSevere or acute inflammation: Every 30 to 60 minutes as initial therapy, reducing the dosage when favourable response is observed to every two to four hours. Further reduction may be made to one drop three or four times daily if sufficient to control inflammation.\nChronic inflammation: Every three to six hours, or as necessary.\nAllergic inflammation: Every three to four hours until the desired response is obtained.\nEar :\nInstill two or three drops to the ear at two or three hours interval.The frequency of dosage and duration of treatment may vary with the type of lession and severity.\n\nContra-indication: Hypersensitivity; Contraindicated in epithelial herpes simplex, vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; tuberculosis of the eye; fungal disease of ocular structures; other diseases caused by micro-organisms, may be enhanced by the presence of the steroid. It is contraindicated in patients with perforated ear drum membrane.\n\nSide effects:  Topical application to eye: Corneal ulcers, glaucoma and reduced visual ability. The following side effects are common for patients taking Dexamethasone\nâ¢ Increased appetite\nâ¢ Insomnia\nâ¢ Fluid retention\nâ¢ Heartburn\nâ¢ Muscle weakness\n\nPrecaution: Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity, and posterior subcapsular cataract formation.Elderly, children and adolescent; pregnancy and lactation.\n\nMode of action:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\n\nPregnancy category: C\n\nInteraction:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.
Dexamethasone 0.1% + Gatifloxacin 0.3%	\n\n\tAristopharma\tGatison Eye Drops   5ml bot 120\n\tGeneral\tDexagen Eye Drops (100 mg + 300 mg)/100 ml  \n\tOpso Saline Ltd.\tGatidex Eye Drops   5  ml drop 120\n\tPopular\tOrbidex G Eye Drops 0.1% + 0.3% 5 ml plastic dropper bottle 120\n\tIndication: Steroid responsive ocular inflammatory conditions with involvement of bacteria like blepharitis, scleritis, episcleritis, iritis, cyclitis, iridocyclitis, choroiditis, optic neuritis and chronic anterior uveitis, disciform and interstitial keratitis, allergic corneal marginal ulcers, corneal injury from chemical radiation or thermal burns, allergic conjunctivitis.\n\nDose: Adult: : Instill 1 drop 2 hrly into affected eye(s) up to 8 times daily for the 1st 2 days, then reduce to 1 drop 4 times daily on days 3-7.\n\n\nContra-indication: Contraindicated in fungal disease of ocular structures, viral conjunctivitis and in patients who are hypersensitive to any of the components of this preparation.\n\nSide effects: Mild burning, chemosis, redness may occur.\n\nPrecaution: For ophthalmic use only. If the product is used for 10 days or more, intraocular pressure should be monitored routinely. \n\nMode of action:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\nAdditive effect w/ drugs that prolong QT interval e.g. antiarrhythmic agents (amiodarone, quinidine, sotalol), arsenic trioxide, cisapride, chlorpromazine, droperidol, mefloquine, dolasetron, mesoridazine, moxifloxacin, pimozide, tacrolimus, pentamidine, thioridazine, ziprasidone. Increased risk of blood glucose disturbances w/ drugs that alter blood glucose concentrations (e.g. antidiabetics). Systemic admin may elevate plasma concentrations of theophylline, interfere caffeine metabolism, enhance effects of oral anticoagulant (warfarin and its derivatives), and transient elevations in serum creatinine w/ ciclosporin.\n\nPregnancy category: C\n\nInteraction:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\nAdditive effect w/ drugs that prolong QT interval e.g. antiarrhythmic agents (amiodarone, quinidine, sotalol), arsenic trioxide, cisapride, chlorpromazine, droperidol, mefloquine, dolasetron, mesoridazine, moxifloxacin, pimozide, tacrolimus, pentamidine, thioridazine, ziprasidone. Increased risk of blood glucose disturbances w/ drugs that alter blood glucose concentrations (e.g. antidiabetics). Systemic admin may elevate plasma concentrations of theophylline, interfere caffeine metabolism, enhance effects of oral anticoagulant (warfarin and its derivatives), and transient elevations in serum creatinine w/ ciclosporin.
Dexamethasone 0.1% + Neomycin 0.35% + Polymixin B (Eye prep)	\n\n\tAristopharma\tPolydex N Eye Drops   5  ml drop 90\n\tDrug International Ltd.\tNEO DP Eye Drops    5  ml drop 90\n\tS.A. Alcon Couvreur.,N.V., Belgium\tMaxitrol Eye drops   90\n\tIndication: Bacterial eye infections, Ocular inflammation\n\nDose: Eye drops: One drop topically into the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides. In mild disease, drops may be used up to four to six times daily.\n\nEye ointment: It should be applied thinly and evenly to the conjunctival sac(s) at night (if eye drops used during the day) or 3-4 times daily (if eye ointment used alone).\n\n\n\nContra-indication: Hypersensitivity. Epithelial herpes simplex keratitis (dentritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Hypersensitivity to a component of the medication (Hypersensitivity to the antibiotic component occurs at a higher rate than other component).\n\nThe use of these combinations is always contraindicated after uncomplicated removal of a corneal foreign body.\n\nSide effects: Allergic sensitisations. Increased intraocular pressure and delayed wound healing. Irritation, burning, stinging, itching and dermatitis.Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. \n\nPrecaution: Prolonged use may cause glaucoma, damage to the optic nerve, defects in visual acuity and fields of vision, posterior subcapsular cataract formation and increased risk of secondary ocular infections. Increased risk of perforations in diseases which can cause thinning of the cornea or sclera. Corticosteroids may mask infection or worsen existing infections in acute purulent conditions of the eye. Regular monitoring of the intraocular pressure is recommended if product is used for ?10 days. Long term application of topical corticosteroids may also increase the risk of ocular fungal infections. Neomycin sulfate may cause cutaneous sensitisation. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Dexamethasone 0.1% + Tobramycin 0.3% Eye prep	\n\n\tAristopharma\tT Mycin PLUS Eye Ointment   3.5 gm tube 90\n\tAristopharma\tT-Mycin PLUS Eye Drops   5  ml drop 150\n\tAsiatic Ltd.\tTobicort Eye Drops   5  ml drop 150\n\tBeximco\tCinarex-D Eye Drops   5  ml drop 150\n\tBio Pharma Ltd.\tInfladex-TN Eye Drops (100 mg + 300 mg)/100 ml  \n\tBio Pharma Ltd.\tInfladex-TN Eye Ointment (100 mg + 300 mg)/100 gm  \n\tDrug International Ltd.\tTexa Eye Drops  5ml drop 125\n\tG. A. Company Ltd.\tTobidex Eye Drops   5  ml drop 130\n\tG. A. Company Ltd.\tTobidex Eye Ointment   3.5 gm tube 90\n\tGeneral\tDexagen T Eye Drops (100 mg + 300 mg)/100 ml  \n\tGeneral\tDexagen T Eye Ointment (100 mg + 300 mg)/100 gm  \n\tGlobe\tDexatob Eye Drops (100 mg + 300 mg)/100 ml  \n\tHealthcare\tTobrel Plus Eye Drops (100 mg + 300 mg)/100 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tTomycin D Eye Drops   5  ml drop 150\n\tIncepta\tDextrobac Eye Drops   5  ml drop 130\n\tNavana\tStedex-T Eye Drops 3mg + 1 mg 5ml bot \n\tNipa\tEytex Eye Drops   5  ml drop/ 3 gm tube 125 / 90\n\tOpso Saline Ltd.\tTobracin-D Eye Drops (100 mg + 300 mg)/100 ml  \n\tOpso Saline Ltd.\tTobracin-D Eye Ointment (100 mg + 300 mg)/100 gm  \n\tPopular\tOrbidex T Eye Drops 0.1% + 0.3% 5  ml drop 132.01\n\tReman Drug Ltd.\tT Dex Eye Drops   5  ml drop 150\n\tReman Drug Ltd.\tT Dex Eye Ointment   4 gm tube 90\n\tIndication: Bacterial eye infections, Ocular inflammation, Pink eye\n\nDose: Adult: Ophth As susp containing tobramycin 0.3% and dexamethasone 0.1%: Instill 1-2 drops 4-6 hrly. May increase to 2 hrly during the initial 24-48 hr, reduce frequency gradually as improvement seen. As oint containing tobramycin 0.3% and dexamethasone 0.1%: Apply half an inch ?3-4 times/day.\n\nContra-indication: Viral infections of corneal and conjunctiva (e.g. epithelial herpes simplex keratitis, vaccinia, varicella). Mycobacterial or fungal infection of the eye.\n\nSide effects: Hypersensitivity reactions, lid itching and swelling, conjunctival erythema, increase in intraocular pressure, glaucoma, optic nerve damage, posterior subcapsular cataract formation and delayed wound healing. Secondary infections especially after prolonged use.\n\nPrecaution: Pregnancy and lactation. Avoid prolonged use, monitor intraocular pressure routinely. Safety and effectiveness in children <2 yr not established.\n\nMode of action: Enhanced neurotoxic and nephrotoxic effects w/ other aminoglycosides (e.g. amikacin, streptomycin), cefaloridine, viomycin, polymyxin B, colistin, cisplatin and vancomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). Prolonged secondary apnoea may occur when given to anaesthetised patients receiving neuromuscular blocking agents (e.g. succinylcholine, tubocurarine, decamethonium). Increased risk of nephrotoxicity w/ ciclosporin and other antibacterials (e.g. cephalosporins). Antagonistic effect w/ neostigmine and pyridostigmine. May potentiate the effect of warfarin and phenindione.\n\nPregnancy category: A\n\nInteraction: Enhanced neurotoxic and nephrotoxic effects w/ other aminoglycosides (e.g. amikacin, streptomycin), cefaloridine, viomycin, polymyxin B, colistin, cisplatin and vancomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). Prolonged secondary apnoea may occur when given to anaesthetised patients receiving neuromuscular blocking agents (e.g. succinylcholine, tubocurarine, decamethonium). Increased risk of nephrotoxicity w/ ciclosporin and other antibacterials (e.g. cephalosporins). Antagonistic effect w/ neostigmine and pyridostigmine. May potentiate the effect of warfarin and phenindione.
Dexamethasone Sodium Phosphate	\n\n\tACI\tDexcor Injection 5mg/ml 10's pack\n \n\tAristopharma\tSonexa 500 Injection 5mg/ml 10 amps pack 150\n\tBeximco\tOdeson Injection 4mg/ml 10's pack 150\n\tChemist Ltd.\tDexan Injection 5mg/ml 20 amps pack 267\n\tG. A. Company Ltd.\tMeradexone Injection 5mg/ml 10 amps pack 9.81\n\tGeneral\tDexagen Injection 5 mg/ml  \n\tGlobe\tD Cort Injection 5mg/ml 10 amps pack 130\n\tGonoshasthaya\tG Dexamtthasone Injection 5mg/ml 10 amps pack 99\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDexon Injection 5mg/ml 10 amps pack 160\n\tIncepta\tMetadaxan Injection 5 mg/ml  \n\tJayson\tDexamin Injection 5mg/ml 10 amps pack 120.50\n\tKemiko\tGludex IM/IV Injection 5mg/ml 10 amps pack 100\n\tMedimet\tDexam Injection 5mg/ml 10 amps pack 100\n\tNavana\tStedex Injection 5mg/ml 12's pack 264\n\tNuvista Pharma Ltd\tRoxadex Injection 5mg/ml 10 amps pack 290.20\n\tOpsonin Pharma\tDecason Injection 5mg/ml 10 amps pack 220.80\n\tRenata\tDexa Injection 5mg/ml 10 amp's pack 150.50\n\tRephco\tDexamet Injection 5mg/ml 10 amps pack 100\n\tSquare\tDexonex IM/IV Injection 5 mg/ml 2x5's pack 200\n\tTechno Drugs Ltd.\tDecafog Injection 5mg/ml 10 amps pack 90\n\tZiska\tDextason Injection 5mg/ml 10 amps pack 120\n\tIndication: Ulcerative colitis, Rheumatoid arthritis, Multiple sclerosis, Nausea and vomiting, Multiple myeloma, Cerebral oedema, Shock, Inflammatory joint diseases, Idiopathic thrombocytopenic purpura, Dental surgery, Allergic anaphylactic shock, Brain tumors, Status asthmaticus\n\nDose: Dexamethasone sodium phosphate injection,  â For intravenous, intramuscular, intra-articular, intralesional, and soft tissue injection.\nDexamethasone can be given parenterally at doses of 0.5-20 mg daily, either as a single IV/IM injection or by IV infusion. \n\nChild: 200-500 mcg/kg daily. \nCerebral oedema: 10 mg IV initially, then 4 mg IM every 6 hours as required for 2-10 days. Large IV doses should be given slowly to reduce the possibility of cardiovascular collapse. \nShock: By intravenous or intramascular injection or infusion 2-6 mg/kg, repeated if necessary after 2-6 hours. The total daily intake of Dexamethasone, even in acute conditions should not exceed 80 mg except in certain very special circumstances.\n\nContra-indication: Systemic fungal infections .  Hypersensitivity to any component of this product, including sulfites\n\nSide effects: Fluid and electrolyte disturbances:\n\n     Sodium retention\n\n     Fluid retention\n\n     Congestive heart failure in susceptible patients\n\n     Potassium loss\n\n     Hypokalemic alkalosis\n\n     Hypertension\n\nMusculoskeletal:\n\n     Muscle weakness\n\n     Steroid myopathy\n\n     Loss of muscle mass\n\n     Osteoporosis\n\n     Pathologic fracture of long bones\n\n     Vertebral compression fractures\n\n     Aseptic necrosis of femoral and humeral heads\n\n     Tendon rupture\n\nGastrointestinal:\n\n     Peptic ulcer with possible subsequent perforation and hemorrhage\n\n     Perforation of the small and large bowel, particularly in patients with inflammatory bowel disease\n\n     Pancreatitis\n\n     Abdominal distention\n\n     Ulcerative esophagitis\n\nDermatologic:\n\n     Impaired wound healing\n\n     Thin fragile skin\n\n     Petechiae and ecchymoses\n\n     Erythema\n\n     Increased sweating\n\n     May suppress reactions to skin tests\n\n     Burning or tingling, especially in the perineal area (after IV injection)\n\n     Other cutaneous reactions, such as allergic dermatitis, urticaria, angioneurotic edema\n\nNeurologic:\n\n     Convulsions\n\n     Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment\n\n     Vertigo\n\n     Headache\n\n     Psychic disturbances\n\nEndocrine:\n\n     Menstrual irregularities\n\n     Development of cushingoid state\n\n     Suppression of growth in children\n\n     Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness\n\n     Decreased carbohydrate tolerance\n\n     Manifestations of latent diabetes mellitus\n\n     Increased requirements for insulin or oral hypoglycemic agents in diabetics\n\n     Hirsutism\n\nOphthalmic:\n\n     Posterior subcapsular cataracts\n\n     Increased intraocular pressure\n\n     Glaucoma\n\n     Exophthalmos\n\nMetabolic:\n\n     Negative nitrogen balance due to protein catabolism\n\nCardiovascular:\n\n     Myocardial rupture following recent myocardial infarction.\n\nOther:\n\n     Anaphylactoid or hypersensitivity reactions\n\n     Thromboembolism\n\n     Weight gain\n\n     Increased appetite\n\n     Nausea\n\n     Malaise\n\n     Hiccups\n\n     The following additional adverse reactions are related to parenteral corticosteroid therapy:\n\n     Rare instances of blindness associated with intralesional therapy around the face and head\n\n     Hyperpigmentation or hypopigmentation\n\n     Subcutaneous and cutaneous atrophy\n\n     Sterile abscess\n\n     Post-injection flare (following intra-articular use)\n\n     Charcot-like arthropathy\n\nPrecaution: This product, like many other steroid formulations, is sensitive to heat.  Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial.\n\nFollowing prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including fever, myalgia, arthralgia, and malaise.  This may occur in patients even without evidence of adrenal insufficiency.\n\nThere is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.\n\nCorticosteroids should be used cautiously in patients with ocular herpes simplex for fear of corneal perforation.\n\nThe lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction must be gradual.\n\nPsychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations.  Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.\n\nAspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.\n\nSteroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess, or other pyogenic infection, also in diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, and myasthenia gravis.  \n\nWhen large doses are given, some authorities advise that antacids be administered between meals to help to prevent peptic ulcer.\n\nGrowth and development of infants and children on prolonged corticosteroid therapy should be carefully followed.\n\nSteroids may increase or decrease motility and number of spermatozoa in some patients.\n\nPhenytoin, phenobarbital, ephedrine, and rifampin may enhance the metabolic clearance of corticosteroids resulting in decreased blood levels and lessened physiologic activity, thus requiring adjustment in corticosteroid dosage.  These interactions may interfere with dexamethasone suppression tests which should be interpreted with caution during administration of these drugs.\n\nWhen corticosteroids are administered concomitantly with potassium-depleting diuretics, patients should be observed closely for development of hypokalemia.\n\nIntra-articular injection of a corticosteroid may produce systemic as well as local effects.\n\n\n\n\n\n\n\n\nMode of action:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\n\nPregnancy category: C\n\nInteraction:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.
Dexibuprofen	\n\n\tACI\tFlamex DX TAB dr 300mg 50's pack 201.50\n\tAlbion Ltd.\tDexibuprofen TAB dr 300 mg 100's pack \n\tAlco Pharma\tDip TAB dr 200mg 50's pack 150\n\tAlco Pharma\tDip TAB dr 400mg 30's pack 150\n\tApex\tDexbru TAB dr 200mg 42's pack 126.42\n\tApex\tDexbru TAB dr 300mg 35's pack 140.70\n\tApex\tDexbru TAB dr 400mg 28's pack 140.56\n\tAsiatic Ltd.\tFendex TAB dr 300mg 30's pack 120\n\tAsiatic Ltd.\tFendex TAB dr 400mg 20's pack 100\n\tBeximco\tDexifen TAB dr 200mg 100's pack 300\n\tBeximco\tDexifen TAB dr 300mg 100's pack 400\n\tBeximco\tDexifen TAB dr 400mg 100's pack 500\n\tBeximco\tDexifen Suspension  100 mg 100ml bot 40\n\tEdruc Ltd.\tDex I TAB dr 300mg  20's pack 60\n\tGeneral\tDexibu TAB dr 200mg 42's pack 126.42\n\tGeneral\tDexibu TAB dr 300mg 35's pack 140.70\n\tGeneral\tDexibu TAB dr 400mg 28's pack 140.56\n\tIncepta\tPurifen Suspension 100mg/5ml 100ml bot 40\n\tIncepta\tPurifen TAB dr 200mg 20's pack 60\n\tIncepta\tPurifen TAB dr 300mg 20's pack 80\n\tIncepta\tPurifen TAB dr 400mg 20's pack 100\n\tOpsonin Pharma\tArtoflex TAB dr 300mg 30's pack 120\n\tOpsonin Pharma\tArtoflex TAB dr 400mg 30's pack 150\n\tOrion Pharma Ltd.\tDexpro TAB dr 300mg 50's pack 201\n\tOrion Pharma Ltd.\tDexpro TAB dr 400mg 30's pack 150.60\n\tRAK\tXibu TAB dr 300mg 30's pack 120\n\tSilva\tSerifen TAB dr 300mg 50's pack 200.75\n\tSilva\tSerifen TAB dr 400mg 50's pack 250.94\n\tSquare\tXflam TAB dr 300mg 48's pack 192.48\n\tSquare\tXflam TAB dr 400mg 48's pack 240.48\n\tIndication: Osteoarthritis, Pain, Fever, Pericarditis, Dysmenorrhea, Rheumatic disorders, Patent ductus arteriosus\n\nDose: Adult: PO Pain and inflammation associated w/ musculoskeletal and joint disorders; Dysmenorrhoea 600-900 mg/day in 2-3 divided doses, up to 1,200 mg/day in acute exacerbations.\n\nHepatic impairment: Dose reduction is recommended.\n\nContra-indication: Hypersensitivity to aspirin or NSAIDs; active or suspected GI ulcer or history of recurrent GI ulcer; GI bleeding or other active bleedings or bleeding disorders; active Crohn's disease or ulcerative colitis; haemorrhagic diasthesis and other coagulation disorders, or patients receiving anticoagulant therapy; severe heart failure, renal or hepatic impairment; child <18 yrs; pregnancy (third trimester).\n\nSide effects: GI bleeding, heartburn, epigastric pain; dyspepsia, peptic ulcer; nausea, vomiting, diarrhoea; jaundice, hepatitis; rash; thrombocytopaenia; visual disturbances; tinnitus; depression; fatigue, headache, dizziness, vertigo.\n\nPrecaution: History of bronchial asthma; renal or hepatic disorders; bleeding disorders; CV disease; elderly; lactation.\n\nMode of action: Avoid concomitant use with anticoagulants, other NSAIDs and salicylates. Increases risk of methotrexate and lithium toxicity.\n\nPregnancy category: Not Classified\n\nInteraction: Avoid concomitant use with anticoagulants, other NSAIDs and salicylates. Increases risk of methotrexate and lithium toxicity.
Dexketoprofen	\n\n\tAcme Ltd.\tKeto-D 	 TAB dr  25mg 	 30's pack 	 120.30 	\n\tAlbion Ltd.\tKetoprofen TAB dr 100 mg/ 50mg 50's pack \n\tEskayef Bangladesh Ltd.\tKynol D TAB dr 25mg 60's pack 240\n\tIncepta\tActidex TAB dr 25mg 50's pack 200\n\tSquare\tKitex TAB dr 25mg 50's pack 200.83\n\tIndication: Pain, Dysmenorrhea, Rheumatic disorders\n\nDose: Adult: PO Rheumatic disorders 100-200 mg/day in 2-4 divided doses. Max: 300 mg/day in divided doses. Pain and inflammation 25-50 mg 6-8 hrly. Max: 300 mg/day. \n\nIM Pain and inflammation associated w/ musculoskeletal and joint disorders; Pain following orthopaedic surgery 50-100 mg by deep inj into the gluteal muscle 4 hrly. Max: 200 mg/24 hr for up to 3 days. \n\nContra-indication: Dexketoprofen tablets are not recommended to use in patients who are:\n\n- Allergic to this product or any of its components, aspirin or other non-steroidal anti-inflammatory medicines.\n\n- Have suffered attacks of asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria, angioedema (swollen face, eyes, lips, or tongue, or difficulty in breathing), after taking aspirin or other non-steroidal anti-inflammatory medicines.\n\n- Have or have previously suffered from a peptic ulcer or chronic gastro-intestinal disorders.\n\n- Have had previously gastro-intestinal haemorrhage (bleeding).\n\n- Have suffered from bronchial asthma.\n\n- Have severe heart failure, moderate to severe renal dysfunction or severely impaired hepatic function.\n\n- Have a bleeding disorder, a blood clotting disorder or taking an anticoagulant.\n\n- Pregnant or breast-feeding.\n\nSide effects: As with all medicines, Dexketoprofen may cause some unwanted effects in some patients. These are described below and are characteristic of non steroidal anti-inflammatory drugs:\n\n- Common (1 - 10%): nausea, vomiting, diarrhoea, stomach pain or heartburn.\n\n- Uncommon (0.1 - 1%): sleep disorders, nervousness, headache, dizziness,vertigo, palpitations, constipation, dry mouth, flatulence, skin rash, fatigue, hot flushes, shivering, general malaise.\n\n- Rare (0.01-0.1%): stomach ulceration, gastric haemorrhage or perforation, pins and needles, high blood pressure, water retention, slowed breathing rate, increased hepatic enzymes, increased sweating.\n\n- Very rare / isolated cases (<0.01%): blurred vision, ringing in the ear, low blood pressure, haematological reactions, hepatic or renal damage, dermatological and photosensitivity reactions, bronchospasm or anaphylaxis.\n\n- In patients with systemic lupus erythematosus or mixed connective tissue disease, anti-inflammatory medicines may rarely cause isolated cases of fever, headache and rigidity of the nape (back of the neck).\n\nPrecaution: The medicine should be used with caution in conditions mentioned below:\n- Allergic to any other medicines.\n- Kidney disease, liver disease, heart disease or fluid retention conditions.\n- Blood disorder, systemic lupus erythematosus or mixed connective tissue disease.\n\nMode of action: Increased risk of GI ulcers & bleeding (synergistic effect) w/ other NSAIDs. Increased risk of haemorrhagic effect of oral anticoagulants. Increased risk of haemorrhage w/ heparin. Increased blood lithium levels, which may reach toxic values, w/ lithium. Increased haematological toxicity of methotrexate at high dose of ?15 mg/wk. Increased toxic effects of hydantoins & sulphonamides. Increase risk of bleeding & damage of GI mucosal w/ anticoagulant. Increase hypoglycemic effect of sulfonylurea agents.\n\nPregnancy category: D\n\nInteraction: Increased risk of GI ulcers & bleeding (synergistic effect) w/ other NSAIDs. Increased risk of haemorrhagic effect of oral anticoagulants. Increased risk of haemorrhage w/ heparin. Increased blood lithium levels, which may reach toxic values, w/ lithium. Increased haematological toxicity of methotrexate at high dose of ?15 mg/wk. Increased toxic effects of hydantoins & sulphonamides. Increase risk of bleeding & damage of GI mucosal w/ anticoagulant. Increase hypoglycemic effect of sulfonylurea agents.
Dexlansoprazole	\n\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDexlan CAP 30mg 50's pack 750\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDexlan CAP 60mg 30's pack 750\n\tZiska\tDexilant 30 CAP 30mg 32's pack 256\n\tZiska\tDexilant 60 CAP 60mg 24's pack 384\n\tIndication: Oesophagitis, Gastro-oesophageal reflux disease (GERD)\n\nDose: Adult: PO Peptic ulcer 30 mg once in the morning for 4 wk (duodenal ulcer) or 8 wk (gastric ulcer). Hypersecretory conditions Initial: 60 mg/day. Daily doses >120 mg should be given in 2 divided doses. \n\nAcid-related dyspepsia 15-30 mg once in the morning for 2-4 wk. Gastro-oesophageal reflux disease 30 mg once in the morning for 4-8 wk. Maintenance: 15-30 once daily. \n\nPrevention and treatment of NSAID-related ulcers 15-30 mg/day for 4-8 wk. H.pylori infection 30 mg twice daily, usually w/ clarithromycin and amoxicillin or metronidazole. IV Erosive oesophagitis 30 mg/day for up to 7 days.\n\nContra-indication: Hypersensitivity. \n\nSide effects: Diarrhoea, abdominal pain, nausea, constipation, headache, dizziness, eosinophilia, myalgia, glossitis, stomatitis, rash.\n\nPrecaution: Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation.\n\nMode of action:  	Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.\nPotentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.\n\nPregnancy category: B\n\nInteraction:  	Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.\nPotentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.
Dextran 40 10% + Dextrose 5%	\n\n\tInstitute of Public Health\tDextran 40 IV Infusion   500ml bag \n\tIndication: Thromboembolic disorders, Hypovolaemic shock, Pulmonary embolism, Venous thrombosis\n\nDose: Adult: IV Hypovolaemic shock As dextran 40 (10% soln): 10 mL/kg/day for up to 5 days. \n\nThromboembolic disorders As dextran 40 (10% soln): Initial: 500 mL on day 1, followed by 500 mL on day 2 and subsequently on alternate days up to 10 days. Prophylaxis of post-op thromboembolic disorders As dextran 40 (10% soln): 500 mL during or at the end of surgery. May repeat dose next day and continue treatment on alternate days for up to 10 days in high-risk patients. \n\nChild: As dextran 40: Up to 5 ml/kg in infants and 10 ml/kg in children. \n\nContra-indication: Hypersensitivity. Severe renal disease with oliguria or anuria. Marked cardiac decompensation. Pregnancy.\n\nSide effects: GI disturbances; headache, dizziness; allergic reactions; raised liver enzyme values; alopecia; bone marrow suppression.\n\nPrecaution: Lactation.\n\nMode of action: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine. Sodium Chloride: May affect serum concentrations of lithium.\n\nPregnancy category: C\n\nInteraction: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine. Sodium Chloride: May affect serum concentrations of lithium.
Dextran 40 10% + Sodium Chloride 0.9%	\n\n\tInstitute of Public Health\tDextran IV Infusion   500ml bag \n\tIndication: Thromboembolic disorders, Hypovolaemic shock, Pulmonary embolism, Venous thrombosis\n\nDose: Adult: IV Hypovolaemic shock As dextran 40 (10% soln): 10 mL/kg/day for up to 5 days. \n\nThromboembolic disorders As dextran 40 (10% soln): Initial: 500 mL on day 1, followed by 500 mL on day 2 and subsequently on alternate days up to 10 days. \n\nProphylaxis of post-op thromboembolic disorders As dextran 40 (10% soln): 500 mL during or at the end of surgery. May repeat dose next day and continue treatment on alternate days for up to 10 days in high-risk patients. \n\nChild: As dextran 40: Up to 10 ml/kg in children.\n\nContra-indication: Hypersensitivity. Severe renal disease with oliguria or anuria. Marked cardiac decompensation. Pregnancy.\n\nSide effects: GI disturbances; headache, dizziness; allergic reactions; raised liver enzyme values; alopecia; bone marrow suppression.\n\nPrecaution: Lactation.\n\nMode of action: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine.\n\nSodium Chloride: May affect serum concentrations of lithium.\n\nPregnancy category: C\n\nInteraction: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine.\n\nSodium Chloride: May affect serum concentrations of lithium.
Dextran 70 + Sodium Chloride	\n\n\tInstitute of Public Health\tDextran 70 IV Infusion   500ml bag \n\tIndication: Peritonitis, Thromboembolic disorders, Hypovolaemic shock, Pulmonary embolism, Venous thrombosis, Open heart surgery, Paralytic ileus,Pancreatitis\n\nDose: Adult: IV Dose depends on age, wt and clinical condition of the patient.\nIntravenous\nHypovolaemic shock\nAdult:  As dextran 70: Initially, 500-1000 mL of a 6% solution in sodium chloride 0.9% or glucose 5% infused at a rate of 20-40 mL/min. Maintenance: 10 ml/kg/day for3 days (Dextran 70).\n\nProphylaxis of pulmonary embolism or venous thrombosis in moderate- to high-risk patients undergoing surgery\nAdult: As dextran 70: Initially, 500-1000 mL of a 6% solution in sodium chloride 0.9% or glucose 5% infused over 4-6 hr during or immediately after surgery, followed by 500 mL on the next day and on subsequent alternate days for up to 2 wk after surgery in high-risk patients.\n\nIntrauterine\nAs an aid in hysteroscopy\nAdult: As dextran 70: 50-100 mL of a 32% solution instilled into the uterus as a rinsing and dilatation fluid.\n\nContra-indication: Allergy to corn products.\n\nSide effects: Fever, infection at the site of inj, venous thrombosis or phlebitis extending from the site of inj, extravasation and hypervolaemia.\n\nPrecaution: May cause fluid and/or solute overload. Caution when used in patients with CHF, severe renal impairment or clinical conditions whereby there is sodium retention with oedema. Monitor serum potassium levels. Not to be administered concurrently with blood through the same infusion set due to risk of agglomeration. Patients with overt or known subclinical DM, or carbohydrate intolerance. Risk of hypokalaemia during parenteral admin of hypertonic dextrose solutions. Paediatric patients especially neonates and very low birth weight infants. Caution when used in patients receiving corticosteroids or corticotropin. Pregnancy.\n\nMode of action: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine.\n\nSodium Chloride: May affect serum concentrations of lithium.\n\nPregnancy category: C\n\nInteraction: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine.\n\nSodium Chloride: May affect serum concentrations of lithium.
Dextran 70 0.1% + Hypromellose 0.3% Eye prep	\n\n\tDrug International Ltd.\tSyntar Eye Drops   10 ml drop 65\n\tIbn Sina Pharmaceutical Ind. Ltd.\tGlamor Eye Drops   10 ml drop 90\n\tIncepta\tLubric D Eye Drops (100 mg + 300 mg)/100 ml  \n\tOpsonin Pharma\tLacrima Eye Drops (100 mg + 300 mg)/100 ml  \n\tSquare\tLubtear Eye Drops  100 mg + 300 mg/100 ml 10 ml drop 70\n\tIndication: Dry eye, Burning and irritation of the eye\n\nDose: 1 drop 4 times daily or as required, depending upon the severity of the disease, to be instilled into the conjunctival sac.\n\nContra-indication: Eye Drops is contraindicated in patients with known hypersensitivity to any ingredient of the product.\n\n\nSide effects: Occasionally mild-transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions reported. Blurred vision after application may occur.\n\nPrecaution: Patients who experience blurred vision after application of the product should not drive or use machinery until their vision has cleared.\nContact lenses should not be worn during instillation of the product. After instillation there should be an interval of at least 30 minutes before reinsertion of contact lenses.\n\n\nMode of action: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine.\n\nPregnancy category: C\n\nInteraction: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine.
Dextran 70 0.2% + Hypromellose 0.2% Eye prep	\n\n\tApex\tOptafresh Eye Drops   10 ml drop 80\n\tIndication: Dry eye, Burning and irritation of the eye\n\nDose: 1 drop 4 times daily or as required, depending upon the severity of the disease, to be instilled into the conjunctival sac.\n\nContra-indication: Eye Drops is contraindicated in patients with known hypersensitivity to any ingredient of the product. \n\nSide effects: Occasionally mild-transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions reported. Blurred vision after application may occur.\n\nPrecaution: Patients who experience blurred vision after application of the product should not drive or use machinery until their vision has cleared. Contact lenses should not be worn during instillation of the product. After instillation there should be an interval of at least 30 minutes before reinsertion of contact lenses.\n\nMode of action: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine. Sodium Chloride: May affect serum concentrations of lithium.\n\nPregnancy category: Not Classified\n\nInteraction: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine. Sodium Chloride: May affect serum concentrations of lithium.
Dextran 70 6% + Dextrose 5%	\n\n\tIndication: Hypovolaemic shock, Pulmonary embolism, Venous thrombosis, Open heart surgery\n\nDose: DextranI/V should be administered prior to administration of clinical dextran solutions.\n\n    In shock, it is suggested that total dosage not exceed 20 mL/kg for adults and adolescents, during the first 24 hours. The first 10 mL/kg may be infused as rapidly as necessary to effect improvement. It is strongly recommended that central venous pressure be monitored frequently during the initial infusion of the drug. Should therapy continue beyond 24 hours, subsequent dosage should not exceed 10 mL/kg per day and therapy should not continue beyond five days.\n\n  In prophylaxis of venous thrombosis and thromboembolism, the dosage  for adults and adolescents, should be chosen according to the risk of thromboembolic complications, e.g., type of surgery and duration of immobilization. In general, treatment should be initiated during surgery; 500 to 1000 mL (approximately 10 mL/kg of body weight) should be administered on the day of operation. Treatment should be continued at a dose of 500 mL daily for an additional two to three days; then, according to the risk of complications, 500 mL may be given every second or third day during the period of risk, for up to two weeks.\n\n    Infants may be given 5 mL per kg body weight and children 10 mL per kg.\n\n\n\nContra-indication: Patients with known hypersensitivity to dextran, in those with marked hemostatic defects of all types (thrombocytopenia, hypofibrinogenemia, etc.) including those caused by drugs (heparin, warfarin, etc.), marked cardiac decompensation and in renal disease with severe oliguria or anuria.\n\nSide effects: Because of the seriousness of anaphylactoid reactions, it is recommended that the infusion of intravenous dextran be stopped at the first sign of an allergic reaction provided that other means of sustaining the circulation are available. Resuscitative measures should be readily available for emergency administration in the event such a reaction occurs. In circulatory collapse due to anaphylaxis, rapid volume substitutions with an agent other than dextran should be instituted.\n\nPrecaution: The possibility of circulatory overload should be kept in mind. Special care should be exercised in patients with impaired renal clearance of dextran. When the risk of pulmonary edema and/or congestive heart failure may be increased, dextran should be used with caution.\n\nIn patients with normal hemostasis, dosage of LMD (dextran 40) approximating 15 mL/kg of body weight may prolong bleeding time and depress platelet function. Dosages in this range also markedly decrease factor VIII, and decrease factors V and IX to a greater degree than would be expected to occur from hemodilution alone. Since these changes tend to be more pronounced following trauma or major surgery, patients should be observed for early signs of bleeding complications.\n\nSince increased rouleaux formation may occur in the presence of dextran, it is recommended that blood samples be drawn for typing and cross-matching prior to the infusion of dextran and reserved for subsequent use if necessary. If blood is drawn after infusion of dextran, the saline agglutination and indirect antiglobulin methods may be used for typing and cross-matching. Difficulty may be encountered when proteolytic enzyme techniques are used to match blood.\n\nConsideration should be given to withdrawal of blood for chemical laboratory tests prior to initiating therapy with dextran because of the following:\n\n    Blood sugar determinations that employ high concentrations of acid may result in hydrolysis of dextran, yielding falsely elevated glucose assay results. This has been observed both with sulfuric acid and with acetic acid.\n\n    In other laboratory tests, the presence of dextran in the blood may result in the development of turbidity, which can interfere with the assay. This has been observed in bilirubin assays in which alcohol is employed and in total protein assays employing biuret reagent.\n\nSolutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.\n\nCaution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.\n\nDo not administer unless solution is clear and container is undamaged. Discard unused portion. \n\nMode of action: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine. Sodium Chloride: May affect serum concentrations of lithium.\n\nPregnancy category: C\n\nInteraction: Dextran: Enzyme inducers e.g. phenytoin or carbamazepine and enzyme inhibitors e.g. cimetidine. Sodium Chloride: May affect serum concentrations of lithium.
Dextromethorphan + Pseudoephedrine Hydrochloride +Triprolidine Hydrochloride	\n\n\tACI\tDixxar Syrup  10mg+30mg+1.25mg/5ml 100ml bot 70.21\n\tAcme Ltd.\tA-Cof Syrup   100ml bot 50.20\n\tAlbion Ltd.\tAlpoten Syrup 5 ml 100 ml \n\tAlco Pharma\tCofno Syrup   100ml bot 50\n\tAmbee\tNilkof Syrup  100ml bot 50.19\n\tAmico Ltd.\tKoftex D Syrup   100ml bot 50\n\tAristopharma\tFreecof Syrup   100ml bot 50\n\tBeximco\tPrudex Syrup   100ml bot 50\n\tDelta Pharma\tDexodel Syrup   100ml bot 50\n\tDoctor's Chemicals Works Ltd.\tCoprin Syrup   100ml bot 55\n\tEdruc Ltd.\tDextrop Syrup  100ml bot 50\n\tEskayef Bangladesh Ltd.\tDexpoten Syrup   100ml bot 55\n\tGeneral\tAnkof Syrup   100ml bot 50.19\n\tGeneral\tDekof Syrup  1's pack(100ml) \n\tGlobe\tTexco Syrup   100ml bot 50\n\tHudson\tDecoff Syrup  50ml bot/100ml bot 27/50\n\tIncepta\tSudocof Syrup   100ml bot 60\n\tMillat\tExordrin Syrup   100ml bot 50\n\tNovo Healthcare and Pharma Ltd.\tDexitra Syrup   100ml bot 50\n\tOpsonin Pharma\tTusiva Syrup   100ml bot 50\n\tPharmadesh Ltd.\tCasica Syrup  100ml bot 51.38\n\tPopular\tDelkof Syrup (10 mg + 30 mg + 1.25 mg)  \n\tRenata\tDetus Syrup (10 mg + 30 mg + 1.25 mg)  \n\tSomatec\tDexdin Syrup   100ml bot 50.19\n\tSquare\tOfkof Syrup  10 mg + 30 mg + 1.25 mg/ 100ml bot 70\n\tIndication: Flu, Colds, Runny nose, Dry coughs, Non-productive cough, Nasal congestion\n\nDose: Adult 2 teaspoonful three times a day.\n\nChildren\nOver 12 years 2 teaspoonful three times a day\n6-12 years 1 teaspoonful three times a day\n2-6 years 1/2 teaspoonful three times a day or\nas directed by the physician\n\nContra-indication: Patients at risk of developing resp failure. During an acute attack. Patients receiving MAOI or for 2 wk after discontinuing them. Persistent or chronic cough.\n\nSide effects: Dizziness, GI disturbances.\n\nPrecaution: 3rd trimester of pregnancy; atopic childn; child <1 yr; sedated or debilitated patients; patients confined to supine position; history of asthma. Moderate to severe renal impairment; liver disease.\n\nMode of action: Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol.\nPotentially Fatal: Memantine, moclobemide.\n\nTriprolidine + Pseudoephedrine: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine.\nPotentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.\n\nPregnancy category: C\n\nInteraction: Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol.\nPotentially Fatal: Memantine, moclobemide.\n\nTriprolidine + Pseudoephedrine: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine.\nPotentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.
Dextromethorphan Hydrobromide	\n\n\tAd-din\tMetodex Syrup 10mg/5ml 100ml bot 25\n\tAlbion Ltd.\tDextromethorphan Syrup 200 mg/100 ml 100 ml \n\tAmbee\tDextromethorphan Syrup 10mg/5ml 100ml bot 24.37\n\tAmico Ltd.\tColdflu 100 Syrup 10mg/5ml 100ml bot 23\n\tApollo Pharmaceutical Ltd.\tExophan Syrup 10mg/5ml 100ml bot 24\n\tBeximco\tDextromethorphan Syrup 10mg/5ml 100ml bot 25\n\tDelta Pharma\tDextrodel Syrup 10mg/5ml 60ml 35\n\tG. A. Company Ltd.\tDexsol Syrup 10mg/5ml 100ml bot 25\n\tIncepta\tTomephen Syrup 10mg/5ml 100ml bot 40\n\tLeon\tLeocof Syrup 10 mg/5 ml  \n\tOpsonin Pharma\tD Cough Syrup 10mg/5ml 100ml bot 25\n\tSomatec\tDexophan Syrup 10mg/5ml 100ml bot 24.09\n\tSquare\tBrofex Syrup 10mg/5ml 100ml bot 35\n\tIndication: Cough suppression, Flu, Common cold\n\nDose: Adults (>12 years of age): 10-20 mg (1-2 teaspoonful) every 4 hours, or 30 mg (3 teaspoonful) every 6-8 hours. Do not exceed 120 mg (12 teaspoonful) in 24 hours.\n\nChildren\n6 to 12 years of age: 5-10 mg (1/2-1 teaspoonful) every 4 hours, or 15 mg (11/2 teaspoonful) every 6-8 hours. Do not exceed 60 mg (6 teaspoonful) in 24 hours.\n2 to 6 years of age: 2.5-5 mg (1/4-1/2 teaspoonful) every 4 hours, or 7.5 mg (3/4 teaspoonful) every 6-8 hours. Do not exceed 30 mg (3 teaspoonful) in 24 hours.\n<2 years of age: Use only as directed by the physician.\n\nContra-indication: Hypersensitivity to Dextromethorphan or any other component.\n\nSide effects: Adverse effects with Dextromethorphan appear to be rare and may include dizziness and gastrointestinal disturbances.\n\nPrecaution: Do not use Dextromethorphan to control a cough that is associated with smoking, asthma, or emphysema, or a cough that is productive (produces sputum or phlegm).\n\nMode of action: Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol.\nPotentially Fatal: Memantine, moclobemide.\n\nPregnancy category: C\n\nInteraction: Dextromethorphan: Tricyclic antidepressants (TCAs), antipsychotics, anxiolytics and hypnotics, cimetidine, ciprofloxacin, domperidone, metoclopramide, mexiletine, CYP2D6 inhibitors, ritonavir, alcohol.\nPotentially Fatal: Memantine, moclobemide.
Dextrose + Lidocaine Hydrochloride	\n\n\tIndication: Ventricular fibrillation, Ventricular tachycardia, Arrhythmias, Spinal anesthesia, Epidural anesthesia, Haemorrhoids, Surface anesthesia, Regional anesthesia, Cataract surgery, Sympathetic nerve block, Peripheral nerve block, Perianal pain and itching\n\nDose: Adult: Mouth/Throat Surface anesth For pain: As 2% soln: 300 mg, not more often than 3 hrly. Before procedures in the mouth and throat: As 4% soln: 40-300 mg. \n\nFor dentistry and otorhinolaryngology procedures: As 10% soln: 10-50 mg. For laryngotracheal anesth: As 4% soln: 160 mg as a single dose. \n\nIV Ventricular arrhythmias As HCl: In advanced cardiac life support: 1-1.5 mg/kg, repeat if needed. Max total: 3 mg/kg. In more stable patients: 50-100 mg. May repeat once or twice if needed, up to a max of 200-300 mg in 1 hr, then 1-4 mg/min via continuous infusion. \n\nRegional anesth 50-300 mg (0.5% soln w/o adrenaline). Max: 4 mg/dose. IM Ventricular arrhythmia emergency 300 mg, repeat after 60-90 mins if needed. \n\nEpidural Epidural anesth 2-3 mL soln for each dermatome to be anaesthesized. Lumbar epidural: 250-300 mg (1% soln) for analgesia and 225-300 mg (1.5% soln) or 200-300 mg (2% soln) for anesth and thoracic epidural: 200-300 mg (1% soln). In obstetric caudal analgesia, up to 300 mg (0.5 or 1% soln). \n\nFor surgical caudal analgesia: 225-300 mg (1.5% soln). For continuous epidural anaesthesia, not to repeat max doses more often than 1.5 hrly. Parenteral Sympathetic nerve block As 1% soln: 50 mg for cervical block; 50-100 mg for lumbar block. Peripheral nerve block Brachial plexus block: 225-300 mg (1.5% soln). Intercostal nerve block: 30 mg (1% soln). Paracervical block: 100 mg (1% soln) on each side, repeated not more often than 1.5 hrly. Paravertebral block: 30-50 mg (1% soln). Pudendal block: 100 mg (1% soln) on each side. Retrobulbar block: 120-200 mg (4% soln). Percutaneous infiltration anesth 5-300 mg (0.5 or 1% soln). \n\nIntraspinal Spinal anesth Normal vag delivery: 50 mg (5% hyperbaric soln) or 9-15 mg (1.5% hyperbaric soln). Caesarean operation: Up to 75 mg (5% hyperbaric soln). Other surgical procedures: 75-100 mg. \n\nOphth Pupil dilatation during phacoemulsification cataract surgery As 1% soln: (often used w/ phenylephrine and cyclopentolate): Inject into anterior chamber of the eye at the start of the procedure. Surface anesth As 4% soln w/ fluorescein : 1 drops if needed. \n\nContra-indication: Hypovolaemia; heart block or other conduction disturbances.\n\nSide effects: Dizziness, paraesthesia, drowsiness, confusion, respiratory depression and convulsions.\nPotentially Fatal: Hypotension and bradycardia leading to cardiac arrest; anaphylaxis.\n\nPrecaution: Hepatic or renal impairment; CHF and following cardiac surgery; bradycardia; respiratory depression; porphyria; elderly or debilitated patients; pregnancy.\n\nMode of action: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.\n\nPregnancy category: B\n\nInteraction: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
Dextrose 10%	\n\n\tAcme Ltd.\tAcme's Destrose DS IV Infusion  500 ml bag / 1000 ml bag \n\tBeximco\tDexaqua DS IV Infusion   500 ml bag  x 1000 ml bag 77.96 / 105.48\n\tLibra Pharmaceuticls Ltd.\tLibott 10 IV Infusion   500 ml bag  x 1000 ml bag 77.96 / 105.48\n\tOpso Saline Ltd.\tDextrose 10% IV Infusion 500 ml bag x 1000 ml bag  500ml bag / 100ml bag 51.75 / 75\n\tOrion Pharma Ltd.\tDextropac 10 IV Infusion   500 ml bag  x 1000 ml bag 75.50 / 96.50\n\tPopular\tGlucolin DS IV Infusion  10 gm/100 ml 500 ml bag  x 1000 ml bag 60.49 / 77.45\n\tIndication: Parenteral Nutrition and Hydration, Jaundice, General weakness, Eclampsia, Pre-eclampsia, During pregnancy & after delivery and post surgical intervention\n\nDose: Adult: 10-20 g as single dose; may repeat in 10 min if needed. \nChild: >2 yr: 10-20 g as single dose; may repeat in 10 min if needed. \nIntravenous\nHypoglycaemia\nAdult: 10-25 g (40-100 ml of 25% solution or 20-50 ml of 50% solution). Doses may be repeated in severe cases. \nChild: <6 mth: 0.25-0.5 g/kg/dose; >6 mth: 0.5-1 g/kg/dose. Doses may be repeated in severe cases. Max: 25 g/dose. \nIntravenous\nHyperkalaemia\nAdult: 25-50 g combined with 10 units of regular insulin, administered over 30-60 minutes; may repeat if necessary. Alternatively, 25 g combined with 5-10 units of regular insulin infused over 5 minutes; may repeat if necessary. \nChild: and infants: 0.5-1 g/kg (using 25% or 50% solution) combined with regular insulin (1 unit for every 4-5 g dextrose given); infuse over 2 hr, may repeat if necessary.\n\nContra-indication: Known allergy to corn or corn products. Diabetic coma with hyperglycaemia. Use of hypertonic solutions in patients with intracranial or intraspinal haemorrhage. Patients with delirium tremens and dehydration. Anuria, hepatic coma, or glucose-galactose malabsorption syndrome.\n\nSide effects: Venous thrombosis, phlebitis, hypovolemia, hypervolemia, dehydration, oedema, fever, mental confusion, unconsciousness, hyperosmolar syndrome, hyperglycaemia, hypokalaemia, acidosis, hypophosphataemia, hypomagnesemia, polyuria, glycosuria, ketonuria, nausea, diarrhoea, polydipsia, vein irritation, tissue necrosis, pulmonary oedema, tachypnoea.\n\nPrecaution: Overt or known subclinical DM. Patients with carbohydrate intolerance. IV admin of dextrose may result in hypokalaemia, hypophosphataemia and hypomagnesemia. Prolonged infusion of isotonic dextrose solutions may cause water intoxication. Production of insulin may be adversely affected by prolonged parenteral nutrition with dextrose solutions. Rapid admin of hypertonic dextrose solutions may result in hyperglycaemia and hyperosmolar syndrome. Monitor for signs of mental confusion or loss of consciousness. Monitor blood and urinary glucose regularly. Caution when used in very low birth weight infants. Abrupt withdrawal may lead to rebound hypoglycaemia. Risk of thrombosis when hypertonic (>10%) solutions are administered through peripheral veins. Caution when used parenterally in pregnant women.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 10% + Sodium Chloride 0.9%	\n\n\tIndication: Dehydration, Fluid and Electrolytes imbalance\n\nDose: These solutions are for intravenous use only.\n\nDosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.\n\nWhen a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. Carefully avoid infiltration.\n\nIn the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of fluid containing 0.9% sodium chloride (154 mEq each of sodium and chloride).\n\nFluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.\n\nSome additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.\n\nParenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.\n\nContra-indication: These solutions are contraindicated where the administration of sodium or chloride could be clinically detrimental.\n\nSolutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.\n\nSide effects: Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.\n\nToo rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended. \n\nSymptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential.\n\nHypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect.\n\n\n\n\n\nPrecaution: These solutions should be used with care in patients with hypervolemia, renal insufficiency, urinary tract obstruction, or impending or frank cardiac decompensation. \n\nSodium-containing solutions should be administered with caution to patients receiving corticosteroids or corticotropin, or to other salt-retaining patients. Care should be exercised in administering solutions containing sodium to patients with renal or cardiovascular insufficiency, with or without congestive heart failure, particularly if they are postoperative or elderly.\n\nInfusion of more than one liter of isotonic (0.9%) sodium chloride per day  can exceed normal tolerance, resulting in hypernatremia; this may also cause a loss of bicarbonate ions, resulting in an acidifying effect.\n\nSolutions containing dextrose should be used with caution in patients with overt or known subclinical diabetes mellitus, or carbohydrate intolerance for any reason. Hypokalemia may develop during parenteral administration of hypertonic dextrose solutions. Sufficient amounts of potassium should be added to dextrose solutions administered to fasting patients with good renal function, especially those on digitalis therapy.\n\nThese solutions are intended for intravenous administration using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Dextrose 10% + Sodium Chloride 0.225%	\n\n\tLibra Pharmaceuticls Ltd.\tBaby Saline IV Infusion   250 ml bag / 500 ml bag 55.04 / 64.50\n\tLibra Pharmaceuticls Ltd.\tADS-10 Injection   500ml bag /1000ml bag 65.87 / 87.25\n\tOpso Saline Ltd.\tAPN IV Infusion   500ml bot / 1000 ml bot 65.25 / 86.32\n\tOrion Pharma Ltd.\tElectrodox 10 IV Infusion   500 ml bag  / 1000 ml bag 65.62 / 86.93\n\tPopular\tPeclisol DS IV Infusion   500 ml bag  50.61\n\tPopular\tPedisol DS Injection 5 gm + 225 mg/100 ml 500ml bag 65.87\n\tIPH\tBaby saline saline   500ml bag \n\tIndication: Dehydration, Fluid and Electrolytes imbalance\n\nDose: The dose is dependent upon the age, weight and clinical condition of the patient.\n\nAs reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.\n\nParenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.\n\nIf an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.\n\nPrecaution: Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.\n\nSolutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.\n\nCaution must be exercised in the administration of parenteral fluids, especially those containing sodium ions to patients receiving corticosteroids or corticotropin.\n\nDo not administer unless solution is clear and container is undamaged. Discard unused portion.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 100 %	\n\n\tEskayef Bangladesh Ltd.\tNRG Powder  20 sachets box 100\n\tIndication: Hypoglycemia, Nutrition, Hydration\n\nDose: As directed by a physician. Dosage should be adjusted to meet the requirements of each individual patient.Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.\n\n\n\nContra-indication: Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.\n\nA concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present nor in the presence of delirium tremens if the patient is already dehydrated.\n\nSide effects: Hypersensitivity reactions, including anaphylaxis and chills.\n\nReactions which may occur because of the injection or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.\n\nIf an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.\n\nPrecaution: Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions. Blood electrolyte monitoring is essential, and fluid and electrolyte imbalances should be corrected. Essential vitamins and minerals also should be provided as needed. Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus. \n\n Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly. Do not administer unless solution is clear and container is undamaged. Discard unused portion.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 20%	\n\n\tBeximco\tNutridex Infusion 20% 100 ml bot \n\tIndication: Parenteral Nutrition and Hydration, Hypoglycemia, Hyperkalaemia\n\nDose: Adult: 10-20 g as single dose; may repeat in 10 min if needed.\nChild: >2 yr: 10-20 g as single dose; may repeat in 10 min if needed. \n\nContra-indication: Known allergy to corn or corn products. Diabetic coma with hyperglycaemia. Use of hypertonic solutions in patients with intracranial or intraspinal haemorrhage. Patients with delirium tremens and dehydration. Anuria, hepatic coma, or glucose-galactose malabsorption syndrome.\n\nSide effects: Venous thrombosis, phlebitis, hypovolemia, hypervolemia, dehydration, oedema, fever, mental confusion, unconsciousness, hyperosmolar syndrome, hyperglycaemia, hypokalaemia, acidosis, hypophosphataemia, hypomagnesemia, polyuria, glycosuria, ketonuria, nausea, diarrhoea, polydipsia, vein irritation, tissue necrosis, pulmonary oedema, tachypnoea.\n\nPrecaution: Overt or known subclinical DM. Patients with carbohydrate intolerance. IV admin of dextrose may result in hypokalaemia, hypophosphataemia and hypomagnesemia. Prolonged infusion of isotonic dextrose solutions may cause water intoxication. Production of insulin may be adversely affected by prolonged parenteral nutrition with dextrose solutions. Rapid admin of hypertonic dextrose solutions may result in hyperglycaemia and hyperosmolar syndrome. Monitor for signs of mental confusion or loss of consciousness. Monitor blood and urinary glucose regularly. Caution when used in very low birth weight infants. Abrupt withdrawal may lead to rebound hypoglycaemia. Risk of thrombosis when hypertonic (>10%) solutions are administered through peripheral veins. Caution when used parenterally in pregnant women.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 25%	\n\n\tBeximco\tNutridex 25 IV Infusion   100ml ampoule / 250ml ampoule 35.40 / 60.90\n\tBeximco\tNutridex 25 Infusion 25% 250 ml bot 60.90\n\tLibra Pharmaceuticls Ltd.\tLibott 25 IV Infusion   100ml ampoule / 250ml ampoule  35.55 / 58.90\n\tOpso Saline Ltd.\tDextrose 25 IV Infusion   100ml ampoule / 250ml ampoule 28.86 / 60.23\n\tOrion Pharma Ltd.\tDextropac 25 IV Infusion    100ml ampoule /250ml ampoule  38 / 60\n\tIndication: Parenteral Nutrition and Hydration, Hypoglycemia, Hyperkalaemia, Energy malnutrition\n\nDose: Adult: 10-25 g (40-100 ml of 25% solution or 20-50 ml of 50% solution). Doses may be repeated in severe cases.\nChild: <6 mth: 0.25-0.5 g/kg/dose; >6 mth: 0.5-1 g/kg/dose. Doses may be repeated in severe cases. Max: 25 g/dose.\n \nHyperkalaemia\nAdult: 25-50 g combined with 10 units of regular insulin, administered over 30-60 minutes; may repeat if necessary. Alternatively, 25 g combined with 5-10 units of regular insulin infused over 5 minutes; may repeat if necessary.\nChild: and infants: 0.5-1 g/kg (using 25% or 50% solution) combined with regular insulin (1 unit for every 4-5 g dextrose given); infuse over 2 hr, may repeat if necessary.\n\nContra-indication: Known allergy to corn or corn products. Diabetic coma with hyperglycaemia. Use of hypertonic solutions in patients with intracranial or intraspinal haemorrhage. Patients with delirium tremens and dehydration. Anuria, hepatic coma, or glucose-galactose malabsorption syndrome.\n\nSide effects: Venous thrombosis, phlebitis, hypovolemia, hypervolemia, dehydration, oedema, fever, mental confusion, unconsciousness, hyperosmolar syndrome, hyperglycaemia, hypokalaemia, acidosis, hypophosphataemia, hypomagnesemia, polyuria, glycosuria, ketonuria, nausea, diarrhoea, polydipsia, vein irritation, tissue necrosis, pulmonary oedema, tachypnoea.\n\nPrecaution: Overt or known subclinical DM. Patients with carbohydrate intolerance. IV admin of dextrose may result in hypokalaemia, hypophosphataemia and hypomagnesemia. Prolonged infusion of isotonic dextrose solutions may cause water intoxication. Production of insulin may be adversely affected by prolonged parenteral nutrition with dextrose solutions. Rapid admin of hypertonic dextrose solutions may result in hyperglycaemia and hyperosmolar syndrome. Monitor for signs of mental confusion or loss of consciousness. Monitor blood and urinary glucose regularly. Caution when used in very low birth weight infants. Abrupt withdrawal may lead to rebound hypoglycaemia. Risk of thrombosis when hypertonic (>10%) solutions are administered through peripheral veins. Caution when used parenterally in pregnant women.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 30%	\n\n\tBeximco\tNutridex 30 Infusion 30% 100ml \n\tIndication: Parenteral Nutrition and Hydration, Hypoglycemia\n\nDose: Following suitable admixture of prescribed drugs, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. \n\n\n\n\n\n\nContra-indication: The infusion of hypertonic dextrose injections is contraindicated in patients having intracranial or intraspinal hemorrhage, in patients who are severely dehydrated, in patients who are anuric, and in patients in hepatic coma.\n\nSolutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.\n\nSide effects: Too rapid infusion of a hypertonic dextrose solution may result in diuresis, hyperglycemia, glycosuria, and hyperosmolar coma. Continual clinical monitoring of the patient is necessary in order to identify and initiate measures for these clinical conditions.\n\nReactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.\n\nIf an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.\n\nPrecaution: Administration of hypertonic dextrose and amino acid solutions via central venous catheter may be associated with complications which can be prevented or minimized by careful attention to all aspects of the procedure. This includes attention to solution preparation, administration and patient monitoring.\nDo not administer unless solution is clear and seal is intact.\n\nThese admixed injections are intended for intravenous administration using sterile equipment.\n\nIt is essential that a carefully prepared protocol, based upon current medical practice, be followed, preferably by an experienced team. The package insert of the protein (nitrogen) source should be consulted for dosage and all precautionary information.\n\nClinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.\n\nCare should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency.\n\nCaution must be exercised in the administration of these injections to patients receiving corticosteroids or corticotropin.\n\nThese injections should be used with caution in patients with overt or subclinical diabetes mellitus.\n\nDrug product contains no more than 25 Âµg/L of aluminum.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 4.3% + Sodium Chloride 0.18%	\n\n\tBeximco\tIsoride IV Infusion   500 ml bag  / 1000 ml bag 45.17 / 60.22\n\tLibra Pharmaceuticls Ltd.\tLibott M IV Infusion   500 ml bag  / 1000 ml bag 71.09 / 93.80\n\tOpso Saline Ltd.\tIDS IV Infusion     1000 ml bag 60.23\n\tOrion Pharma Ltd.\tDextrose ISO IV Infusion   500 ml bag  / 1000 ml bag 47 / 61\n\tPopular\tGlucosal M IV Infusion  4.3 gm + 180 mg/100 ml 500 ml bag  / 1000 ml bag 47.72 / 61.93\n\tIndication: Dehydration, Fluid and Electrolytes imbalance\n\nDose: Adult: Dose depends on age, weight and clinical condition of the patient. Child: Dose depends on age, weight and clinical condition of the patient.\n\nContra-indication: Allergy to corn products.\n\nSide effects: Fever, infection at the site of inj, venous thrombosis or phlebitis extending from the site of inj, extravasation and hypervolaemia.\n\nPrecaution: May cause fluid and/or solute overload. Caution when used in patients with CHF, severe renal impairment or clinical conditions whereby there is sodium retention with oedema. Monitor serum potassium levels. Not to be administered concurrently with blood through the same infusion set due to risk of agglomeration. Patients with overt or known subclinical DM, or carbohydrate intolerance. Risk of hypokalaemia during parenteral admin of hypertonic dextrose solutions. Paediatric patients especially neonates and very low birth weight infants. Caution when used in patients receiving corticosteroids or corticotropin. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 5%	\n\n\tAcme Ltd.\tAcme's Destrose Saline IV Infusion  500 ml bag / 1000 ml bag \n\tBeximco\tDexaqua IV Infusion   500 ml bag  x 1000 ml bag 71.09 / 91.72\n\tLibra Pharmaceuticls Ltd.\tLibott IV Infusion   500 ml bag  x 1000 ml bag 71.09 / 91.72\n\tOpso Saline Ltd.\tDextrose 5% IV Infusion   500 ml bag  x 1000 ml bag 48.73 / 61.92\n\tOrion Pharma Ltd.\tDextropac IV Infusion   500 ml bag  x 1000 ml bag 62 / 79\n\tPopular\tGlucolin IV Infusion  5 gm/100 ml 500 ml bag  x 1000 ml bag 48.73 / 61.93\n\tIndication: Parenteral Nutrition and Hydration, Hypoglycemia, Hyperkalaemia\n\nDose: As water replacement: Replacement should be to recover losses and maintenance therapy.\n\nContra-indication: Known allergy to corn or corn products. Diabetic coma with hyperglycaemia. Use of hypertonic solutions in patients with intracranial or intraspinal haemorrhage. Patients with delirium tremens and dehydration. Anuria, hepatic coma, or glucose-galactose malabsorption syndrome.\n\nSide effects: Venous thrombosis, phlebitis, hypovolemia, hypervolemia, dehydration, oedema, fever, mental confusion, unconsciousness, hyperosmolar syndrome, hyperglycaemia, hypokalaemia, acidosis, hypophosphataemia, hypomagnesemia, polyuria, glycosuria, ketonuria, nausea, diarrhoea, polydipsia, vein irritation, tissue necrosis, pulmonary oedema, tachypnoea.\n\nPrecaution: Overt or known subclinical DM. Patients with carbohydrate intolerance. IV admin of dextrose may result in hypokalaemia, hypophosphataemia and hypomagnesemia. Prolonged infusion of isotonic dextrose solutions may cause water intoxication. Production of insulin may be adversely affected by prolonged parenteral nutrition with dextrose solutions. Rapid admin of hypertonic dextrose solutions may result in hyperglycaemia and hyperosmolar syndrome. Monitor for signs of mental confusion or loss of consciousness. Monitor blood and urinary glucose regularly. Caution when used in very low birth weight infants. Abrupt withdrawal may lead to rebound hypoglycaemia. Risk of thrombosis when hypertonic (>10%) solutions are administered through peripheral veins. Caution when used parenterally in pregnant women.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 5% + Sodium Chloride 0.18%	\n\n\tIndication: Parenteral nutrition, Dehydration, Fluid and Electrolytes imbalance\n\nDose: Adult: IV Dose depends on age, wt and clinical condition of the patient.\n\nContra-indication: Allergy to corn products.\n\nSide effects: Fever, infection at the site of inj, venous thrombosis or phlebitis extending from the site of inj, extravasation and hypervolaemia.\n\nPrecaution: May cause fluid and/or solute overload. Caution when used in patients with CHF, severe renal impairment or clinical conditions whereby there is sodium retention with oedema. Monitor serum potassium levels. Not to be administered concurrently with blood through the same infusion set due to risk of agglomeration. Patients with overt or known subclinical DM, or carbohydrate intolerance. Risk of hypokalaemia during parenteral admin of hypertonic dextrose solutions. Paediatric patients especially neonates and very low birth weight infants. Caution when used in patients receiving corticosteroids or corticotropin. Pregnancy\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 5% + Sodium Chloride 0.225%	\n\n\tLibra Pharmaceuticls Ltd.\tBaby Saline IV Infusion Infusion 250ml bag / 500ml bag 55.04 / 64.50\n\tLibra Pharmaceuticls Ltd.\tLibott S IV Infusion 500 ml bag  500ml bag 73.38\n\tOpso Saline Ltd.\tBabysol IV Infusion   500 ml bag  45.17\n\tOrion Pharma Ltd.\tDextrosal BABY IV Infusion   500 ml bag  64\n\tPopular\tPedisol IV Infusion  10 gm + 225 mg/100 ml  500 ml bag   50.61\n\tIndication: Parenteral nutrition, Dehydration, Fluid and Electrolytes imbalance\n\nDose: Adult: IV Dose depends on age, wt and clinical condition of the patient.\n\nContra-indication: Allergy to corn products.\n\nSide effects: Fever, infection at the site of inj, venous thrombosis or phlebitis extending from the site of inj, extravasation and hypervolaemia.\n\nPrecaution: May cause fluid and/or solute overload. Caution when used in patients with CHF, severe renal impairment or clinical conditions whereby there is sodium retention with oedema. Monitor serum potassium levels. Not to be administered concurrently with blood through the same infusion set due to risk of agglomeration. Patients with overt or known subclinical DM, or carbohydrate intolerance. Risk of hypokalaemia during parenteral admin of hypertonic dextrose solutions. Paediatric patients especially neonates and very low birth weight infants. Caution when used in patients receiving corticosteroids or corticotropin. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 5% + Sodium Chloride 0.25%	\n\n\tIndication: Parenteral nutrition, Dehydration, Fluid and Electrolytes imbalance\n\nDose: Adult: IV Dose depends on age, wt and clinical condition of the patient.\n\nContra-indication: Allergy to corn products.\n\nSide effects: Fever, infection at the site of inj, venous thrombosis or phlebitis extending from the site of inj, extravasation and hypervolaemia.\n\nPrecaution: May cause fluid and/or solute overload. Caution when used in patients with CHF, severe renal impairment or clinical conditions whereby there is sodium retention with oedema. Monitor serum potassium levels. Not to be administered concurrently with blood through the same infusion set due to risk of agglomeration. Patients with overt or known subclinical DM, or carbohydrate intolerance. Risk of hypokalaemia during parenteral admin of hypertonic dextrose solutions. Paediatric patients especially neonates and very low birth weight infants. Caution when used in patients receiving corticosteroids or corticotropin. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 5% + Sodium Chloride 0.45%	\n\n\tBeximco\tNeosol DS IV Infusion   250 ml bag  / 500 ml bag 55.04 / 73.34\n\tOpso Saline Ltd.\tBabysol JUNIOR IV Infusion   500 ml bag  45.17\n\tOrion Pharma Ltd.\tDextrose MINI IV Infusion   500 ml bag  55.02\n\tIndication: Parenteral nutrition, Dehydration, Fluid and Electrolytes imbalance\n\nDose: Adult: IV Dose depends on age, wt and clinical condition of the patient.\n\nContra-indication: Allergy to corn products.\n\nSide effects: Fever, infection at the site of inj, venous thrombosis or phlebitis extending from the site of inj, extravasation and hypervolaemia.\n\nPrecaution: May cause fluid and/or solute overload. Caution when used in patients with CHF, severe renal impairment or clinical conditions whereby there is sodium retention with oedema. Monitor serum potassium levels. Not to be administered concurrently with blood through the same infusion set due to risk of agglomeration. Patients with overt or known subclinical DM, or carbohydrate intolerance. Risk of hypokalaemia during parenteral admin of hypertonic dextrose solutions. Paediatric patients especially neonates and very low birth weight infants. Caution when used in patients receiving corticosteroids or corticotropin. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 5% + Sodium Chloride 0.9%	\n\n\tAcme Ltd.\tAcme's DNS IV Infusion  500 ml bag / 1000 ml bag \n\tBeacon\tInfusol Plus IV Infusion   500ml bot 115\n\tBeximco\tDexoride IV Infusion   500 ml bag  / 1000 ml bag 75.66 / 100.89\n\tBeximco\tNeosol IV Infusion   250 ml bag  55.04\n\tLibra Pharmaceuticls Ltd.\tLibott-S IV Infusion   76/100\n\tOpso Saline Ltd.\tDextrose 5% in Normal Saline IV Infusion   500 ml bag  / 1000 ml bag 49/ 63\n\tOrion Pharma Ltd.\tDextrosal IV Infusion   500 ml bag  / 1000 ml bag 64 / 82\n\tPopular\tGlucosal IV Infusion  5 gm + 900 mg/100 ml 500 ml bag  / 1000 ml bag 48.73 / 62.95\n\tSquare\tSolodex IV Infusion (5 gm + 900 mg) / 100 ml  \n\tIndication: Dehydration, Fluid and Electrolytes imbalance\n\nDose: Adult: IV Dose depends on age, wt and clinical condition of the patient.\n\nContra-indication: Allergy to corn products.\n\nSide effects: Fever, infection at the site of inj, venous thrombosis or phlebitis extending from the site of inj, extravasation and hypervolaemia.\n\nPrecaution: May cause fluid and/or solute overload. Caution when used in patients with CHF, severe renal impairment or clinical conditions whereby there is sodium retention with oedema. Monitor serum potassium levels. Not to be administered concurrently with blood through the same infusion set due to risk of agglomeration. Patients with overt or known subclinical DM, or carbohydrate intolerance. Risk of hypokalaemia during parenteral admin of hypertonic dextrose solutions. Paediatric patients especially neonates and very low birth weight infants. Caution when used in patients receiving corticosteroids or corticotropin. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose 50%	\n\n\tBeximco\tNutridex 50 Injection 50% 100 ml bot \n\tIndication: Parenteral Nutrition and Hydration, Hypoglycemia, Hyperkalaemia\n\nDose: The dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. See directions accompanying drugs. \n\nContra-indication: The infusion of hypertonic dextrose injections is contraindicated in patients having intracranial or intraspinal hemorrhage, in patients who are severely dehydrated, in patients who are anuric, and in patients in hepatic coma. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.\n\nSide effects: Too rapid infusion of a hypertonic dextrose solution may result in diuresis, hyperglycemia, glycosuria, and hyperosmolar coma. Continual clinical monitoring of the patient is necessary in order to identify and initiate measures for these clinical conditions. Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.\n\nPrecaution: Care should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency. Caution must be exercised in the administration of these injections to patients receiving corticosteroids or corticotropin. These injections should be used with caution in patients with overt or subclinical diabetes mellitus. \n\nParenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless solution is clear and seal is intact. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dextrose Anhydrous + Fructose + Potassium Chloride + Sodium Bicarbonate + Sodium Chloride + Sucrose (Fruity/Tasty ORS)	\n\n\tACI\tACI ORS Fruity Dry Powder Sachet  20's pack 100\n\tApex\tAsaline Fruty 	 Oral Saline   20's pack 	 100 	 \n\tSocial Marketing Company\tORSaline Fruity Oral Saline   1's pack 5\n\tIndication: Diarrhea, Dehydration, Vomiting, Fluid and Electrolytes imbalance\n\nDose:  Daily dose should be equivalent to patients' fluid requirement for maintenance and replenishment of losses. During saline therapy mother should not stop breast-feeding to their child and normal food should be continued in case of adults.\n\nChildren less than 2 years: After each loose stool or vomiting 10 to 20 spoonful (50-100 ml) of prepared saline.\nChildren 2 to 10 years: After each loose stool or vomiting 100-200 ml of prepared oral saline.\nAdult and children above 10 years: After each loose stool or vomiting 200-400 ml of prepared saline.\n\nContra-indication: Patients with known hypersensitivity.\n\nSide effects: No significant side effects.\n\nPrecaution: Depressed renal function, severe continuing diarrhoea or other critical fluid losses may need supplementation with parenteral fluids along with oral saline.\n\nReconstitue saline should be used within 6 hours.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Dextrose Anhydrous + Potassium Chloride + Sodium citrate +  Sodium chloride (ORS)	\n\n\tACI\tACI ORS Dry Powder Sachet  20's pack 92\n\tAd-din\tO R S A Oral Saline   20 sachets  pack 80\n\tAPC Pharma Ltd.\tO R S N Oral Saline   20 sachets  pack 60\n\tCentral.\tEasy ORS Oral Saline   20sachets pack 91.60\n\tEdruc Ltd.\tE-Saline Oral Saline   20sachets pack 91.60\n\tEskayef Bangladesh Ltd.\tNeosaline Oral Saline   20sachets pack / 50sachets pack 91.60 / 229\n\tGonoshasthaya\tG Oral Saline Oral Saline   20 sachets  pack 60.80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tUnisaline Oral Saline   20 sachets  pack 68.80\n\tKemiko\tK-Saline N Oral Saline   20sachets pack 91.60\n\tMedicon\tMedicon Oral Saline   25's pack 125\n\tMedimet\tMedimet's ORS Oral Saline   12 sachets  pack 41.28\n\tMillat\tMillat's ORS Oral Saline   20 sachets  pack 60.60\n\tNovo Healthcare and Pharma Ltd.\tNovo Saline Oral Saline   20 sachets  pack 68.60\n\tPharmadesh Ltd.\tPharma Saline Oral Saline   20 sachets  pack 90\n\tRenata\tOrs Rena Saline Oral Saline   1  sachets  pack 3.20\n\tRenata\tRenasaline Oral Saline   1  sachets  pack 3.20\n\tRenata\tRenasaline N Oral Saline   1  sachets  pack 4.30\n\tRenata\tSaline R Oral Saline   20's pack 61.20\n\tRephco\tR-Saline N Oral Saline   20 sachets  pack 68.80\n\tSeema\tSR Saline Oral Saline   20 sachets  pack 78\n\tSocial Marketing Company\tORSaline N Oral Saline   1  sachets  pack 3.44\n\tSonear Ltd.\tOrasol Oral Saline   10 sachets  pack 32\n\tSupreme\tSOS Oral Saline   20 sachets  pack 61\n\tZenith\tOÂ Saline N Oral Saline   20 sachets  pack 85\n\tZenith\tO Saline Oral Saline   20 sachets  pack 90\n\tIndication: Diarrhea, Dehydration, Vomiting, Fluid and Electrolytes imbalance\n\nDose: Daily dose should be equivalent to patients' fluid requirement for maintenance and replenishment of losses. During ORS therapy mother should not stop breast-feeding to their child and normal food should be continued in case of adults. Children less than 2 years: After each loose stool or vomiting 10 to 20 spoonful (50-100 ml) of prepared saline. Children 2 to 10 years: After each loose stool or vomiting 100-200 ml of prepared oral saline. Adult and children above 10 years: After each loose stool or vomiting 200-400 ml of prepared saline.\n\nContra-indication: Patients with known hypersensitivity.\n\nSide effects: No significant side effects.\n\nPrecaution: Depressed renal function, severe continuing diarrhoea or other critical fluid losses may need supplementation with parenteral fluids along with oral saline. Reconstitue saline should be used within 6 hours.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Diabasic Sodium Phosphate  +  Monobasic Sodium Phosphate	\n\n\tIndication: Cleansing of the colon\n\nDose: Sodium Phosphates Injection, USP is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage.\n\nWithdraw the calculated volume aseptically and transfer to appropriate intravenous fluid to provide the desired number of millimoles (mM) of phosphorus and milliequivalents (mEq) of sodium. \n\nContra-indication: Sodium Phosphates Injection, USP is contraindicated in diseases where high sodium, high phosphorus or low calcium levels may be encountered. \n\nSide effects: Adverse reactions involve the possibility of combined sodium and phosphorus intoxication from overdosage.\n\nSodium replacement therapy should be guided primarily by the serum sodium level. Use with caution in patients with renal impairment, cirrhosis, cardiac failure or other edematous or sodium retaining states. Phosphorus intoxication results in a reduction of serum calcium, and the symptoms are those of hypocalcemic tetany\n\nPrecaution: Phosphorus replacement therapy with sodium phosphates should be guided primarily by the serum inorganic phosphorus levels and the limits imposed by the accompanying sodium (Na+) ion. Frequent monitoring of serum calcium and sodium as well as renal function is recommended.\n\nUse with caution in patients with renal impairment, cirrhosis, cardiac failure or in conjunction with other edema causing medications. It should not be used with sodium retaining medications.\n\nCaution must be exercised in the administration of parenteral fluids especially those containing sodium ion, to patients receiving corticosteroids or corticotropin. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Diacerein + Glucosamine Sulphate	\n\n\tACI\tCartilex D TAB dr 50 mg + 750 mg  \n\tAcme Ltd.\tArth-A Max TAB dr 50 mg + 750 mg  \n\tBeacon\tDiacer Plus TAB dr 50 mg + 750 mg  \n\tBeximco\tJointec Max TAB dr  50mg+750mg 30's pack 360\n\tDrug International Ltd.\tGlucotin Max TAB dr 50 mg + 750 mg 21's pack \n\tEskayef Bangladesh Ltd.\tOsticare TAB dr 50 mg + 750 mg  \n\tGeneral\tGlustin Max TAB dr  100's pack 360\n\tIncepta\tJoinix D TAB dr 50/750mg 30's 360\n\tNovelta Bestway\tDuogard TAB dr 50 mg + 750 mg  \n\tOpsonin Pharma\tCosarin TAB dr  6x5's pack 316.50\n\tOrion Pharma Ltd.\tArthrocare TAB dr 50 mg + 750 mg  \n\tPharmasia Ltd.\tCartiplus TAB dr 50 mg + 750 mg  \n\tSquare\tTilex Max TAB dr 50 mg + 750 mg  \n\tIndication: Rheumatoid arthritis, Osteoarthritis, Chronic low back pain\n\nDose: Adults and children over 12 years and older: \n1 tablet twice daily (12 hourly) taken with food. \n\nContra-indication: Absorption of Diacerein is reduced if taken with aluminium and/or magnesium hydroxide antacid. Diacerein also increases risk of diarrhea if taken with laxatives, antibiotics. Avoid co-administration with fibers and phytic acids. Diacerein has shown hypersensitivity to anthraquinone derivatives. \n\nSide effects: Diarrhea, constipation,\n epigastric pain, heart burn, nausea, vomiting, headache, skin rashes, drowsiness, intense yellow coloring of urine.\n\nPrecaution: Caution should be practiced when administering Diacerein + Glucosamine Sulphate in those patients who are allergic to Glucosamine and/or Diacerein or to shellfish (e.g., shrimp, crab); who have diabetes, asthma, alcohol dependence or liver disease. Before taking Diacerein + Glucosamine Sulphate complete blood count, liver function and urinalysis should be monitored regularly. \n\nMode of action: Diacerein: Decreased absorption with aluminium and/or magnesium hydroxide antacids. Increased risk of diarrhoea with laxatives, antibiotics. Avoid co-admin with fibres and phytates.\n\n Glucosamine: May reduce effect of antidiabetic agents, doxorubicin, etoposide, tenoposide. May enhance anticoagulant activity of warfarin.\n\nPregnancy category: A\n\nInteraction: Diacerein: Decreased absorption with aluminium and/or magnesium hydroxide antacids. Increased risk of diarrhoea with laxatives, antibiotics. Avoid co-admin with fibres and phytates.\n\n Glucosamine: May reduce effect of antidiabetic agents, doxorubicin, etoposide, tenoposide. May enhance anticoagulant activity of warfarin.
Diazepam	\n\n\tAcme Ltd.\tAzepam TAB dr 5mg 50's pack/200's pack 11/44\n\tAlbion Ltd.\tDiazem TAB dr 5 mg 200's pack \n\tAlbion Ltd.\tDiazepam TAB dr 5mg  \n\tAmbee\tSeduxen Injection 10mg/2ml 10 amps pack 36\n\tAmbee\tSeduxen TAB dr 5mg 200's pack 46\n\tAmico Ltd.\tSedapen TAB dr 5mg 100's pack 21\n\tAristopharma\tEvalin TAB dr 5mg 500's pack 105\n\tGeneral\tD Pam TAB dr 5mg 100's pack 22\n\tGonoshasthaya\tG Diazepam Injection 10mg/2ml 10 amps pack 30\n\tGonoshasthaya\tG Diazepam TAB dr 5mg 100's pot/100's strip 15/25\n\tIndobangla Pharmaceuticals\tTensareal TAB dr 5mg 100's pack 25\n\tMedimet\tDiazimet TAB dr 5mg 100's pack 22\n\tNavana\tRozam TAB dr 5mg 200's pack 42\n\tOpsonin Pharma\tEasium Suppository 10mg 10's pack 30\n\tOpsonin Pharma\tEasium Injection 10mg/2ml 25 amps pack 75\n\tOpsonin Pharma\tEasium TAB dr 5mg 200's pack 42\n\tPharmadesh Ltd.\tPharmapam TAB dr 5mg 250's pack 62.50\n\tSonear Ltd.\tRelaxen TAB dr 5mg 100's pack 68\n\tSquare\tSedil Injection 10mg/2ml 10 amps pack 30.45\n\tSquare\tSedil TAB dr 5mg 500's pack 345\n\tSupreme\tSedatab TAB dr 5mg 100's pack 22\n\tIndication: Agitation, Anxiety, Anaesthesia, Seizures, Insomnia, Muscle spasms, Alcohol withdrawal syndrome\n\nDose: Adult: PO Severe anxiety 2 mg 3 times/day. Max: 30 mg/day. \nInsomnia 5-15 mg/day at bedtime. \nAnesth premed 5-20 mg before general anesth. \nAdjunct in management of seizures 2-60 mg/day in divided doses. \nMuscle spasms 2-15 mg/day in divided doses, up to 60 mg/day in severe spastic disorders. \nAlcohol w/drawal syndrome 5-20 mg, repeat 2-4 hr later if needed. \n\nIV Anesth premed 100-200 mcg/kg. Sedation in minor surgical and medical procedures 10-20 mg. Adjunct in the management of seizures 10-20 mg, repeat if needed after 30-60 min.\n\n IV/IM Muscle spasms 10 mg, repeat 4 hr later if needed. \nAlcohol w/drawal syndrome 10-20 mg. Severe anxiety Up to 10 mg, repeat if needed after 4 hr. \n\nRectal Severe anxiety As rectal soln: 500 mcg/kg, repeat 12 hr later if needed. As supp: 10-30 mg. Anesth premed As rectal soln: 500 mcg/kg. \n\nAdjunct in the management of seizures As rectal gel: 200-500 mcg/kg, repeat 4-12 hr later if needed. Muscle spasms As rectal soln: 500 mcg/kg, repeat 12 hrly if needed.\n\nChildren:\nStatus epileptius, convulsions, due to poisoning, febrile convulsions 0.2 to 0.3 mg/kg body weight, IV / IM or 1 mg per year of life\nTetanus As for adultâs dose\nPre-operative medication 0.2 mg/kg body weight\n\n\nContra-indication: Hypersensitivity; myasthenia gravis, preexisting CNS depression or coma, respiratory depression; acute pulmonary insufficiency or sleep apnoea syndrome; severe hepatic impairment; acute narrow angle glaucoma; children <6 mth (oral); pregnancy and lactation.\n\nSide effects: Psychological and physical dependence with withdrawal syndrome, fatigue, drowsiness, sedation, ataxia, vertigo, confusion, depression, GI disturbances, changes in salivation, amnesia, jaundice, paradoxical excitation, elevated liver enzyme values; muscle weakness, visual disturbances, headache, slurring of speech and dysarthria, mental changes, incontinence, constipation, hypotension, tachycardia, changes in libido, pain and thrombophlebitis at inj site (IV).\nPotentially Fatal: Respiratory and CNS depression, coma.\n\nPrecaution: mpaired renal and hepatic function, respiratory disease, organic cerebral changes, elderly, psychotic patients, epileptics, history of alcohol or drug addiction, impaired gag reflux, obese patients. May cause CNS depression. Discontinue treatment if patient develops psychiatric and paradoxical reactions. Caution when used in patients with depression or anxiety associated with depression, especially if patient has suicidal risk. May increase risk of falls. Safety and efficacy of the inj have not been established in children <1 mth of age. Safety and efficacy of oral use have not been established in children <6 mth of age. Safety and efficacy of rectal gel have not been established in children <2 yr of age. Abrupt withdrawal or large dose reduction may cause rebound or withdrawal symptoms.\n\nMode of action:  May significantly enhance CNS depressant effect w/ antivirals (e.g. amprenavir, ritonavir). May enhance CNS depressant effect w/ anaesth, narcotic analgesics, antidepressants, antipsychotics, anxiolytics, antiepileptics, antihistamines, antihypertensives, muscle relaxants (e.g. tizanidine, baclofen), nabilone. May decrease clearance w/ antibacterials that interfere w/ metabolism by hepatic enzymes (e.g. isoniazid and erythromycin), OC, cimetidine, omeprazole. May increase clearance w/ antibacterials which are known inducers of hepatic enzymes (e.g. rifampicin). May increase serum level w/ disulfiram. May reduce clearance of digoxin. May reduce therapeutic effect w/ theophylline. Reversible deterioration of parkinsonism w/ levodopa.\n\nPregnancy category: D\n\nInteraction:  May significantly enhance CNS depressant effect w/ antivirals (e.g. amprenavir, ritonavir). May enhance CNS depressant effect w/ anaesth, narcotic analgesics, antidepressants, antipsychotics, anxiolytics, antiepileptics, antihistamines, antihypertensives, muscle relaxants (e.g. tizanidine, baclofen), nabilone. May decrease clearance w/ antibacterials that interfere w/ metabolism by hepatic enzymes (e.g. isoniazid and erythromycin), OC, cimetidine, omeprazole. May increase clearance w/ antibacterials which are known inducers of hepatic enzymes (e.g. rifampicin). May increase serum level w/ disulfiram. May reduce clearance of digoxin. May reduce therapeutic effect w/ theophylline. Reversible deterioration of parkinsonism w/ levodopa.
Dibromopropamidine Isethionate 0.15%	\n\n\tIndication: Conjunctivitis, Keratitis, Blepharitis\n\nDose: Apply ointment to eyelids or conjunctival sacs once or twice daily for 2 days. \n\nContra-indication: known allergy (sensitivity) \n\nSide effects:  Allergic reaction is possible.\n\nPrecaution: Limit or avoid use in pregnancy and if breast feeding; an eye examination should be arranged if there is not significant improvement in condition after two days of use. Do not drive or operate machinery after using ointment until it is clear that vision is not affected. Do not use with soft or gas-permeable contact lenses.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Diclofenac + Lidocaine Hydrochloride	\n\n\tACI\tMobifen PLUS IM Injection  2ml 10 amps pack 95.70\n\tAcme Ltd.\tA Fenac PLUS IM Injection   10's pack 140.60\n\tApex\tDIX Plus IM Injection   10 amps pack 95\n\tAristopharma\tErdon PLUS Injection   10 amps pack 150\n\tBeximco\tUltrafen extra Injection  75mg 10 amps pack 150\n\tChemist Ltd.\tC Fenac PLUS IM Injection   10 amps pack 119.30\n\tDrug International Ltd.\tNopain PLUS IM Injection   1's pack \n\tEdruc Ltd.\tEdifenac PLUS IM Injection   10 amps pack 100\n\tGeneral\tRonac Plus IM Injection (75 mg + 20 mg)/2 ml  \n\tGlobe\tGenac PLUS IM Injection   10 amps pack 100\n\tGlobex\tTolfenac Plus IM Injection (75 mg + 20 mg)/2 ml  \n\tHealthcare\tArthrofen Plus IM Injection (75 mg + 20 mg) / 2 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tAnodyne IM Injection   10's pack 120\n\tIncepta\tIntafenac PLUS IM Injection   10 amps pack 95\n\tJayson\tMegafen PLUS IM Injection   10 amps pack 101.60\n\tKemiko\tApain Plus IM Injection   10 amps pack 100\n\tNovo Healthcare and Pharma Ltd.\tProflam Lido IM Injection   5  amps pack 75\n\tOpsonin Pharma\tDiclofen PLUS IM Injection   15 amps pack 225\n\tOrion Pharma Ltd.\tOrfenac PLUS IM Injection   10 amps pack 90.30\n\tPopular\tProfenac L IM Injection   5 amps pack 47.70\n\tRangs\tOrafen PLUS IM Injection   10 amps pack 150\n\tRephco\tDifenac PLUS IM Injection   10 amps pack 100\n\tSquare\tClofenac Injection  10 amps pack 150\n\tSquare\tClofenac PLUS IM Injection   10 amps pack 150.55\n\tZiska\tDiclonac PLUS IM Injection   10 amps pack 95\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Acute gout, Inflammation, Tendinitis, Actinic keratoses, Bursitis\n\nDose: Adults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours.\n\nChildren: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.\nElderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.\n\nContra-indication: In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.\n\nLidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide-type.\n\nSide effects: Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.\nThe adverse effects due to Lidocaine mainly involve the CNS, are usually of short duration, and are dose related. The CNS reaction may be manifested by drowsiness, dizziness, disorientation, confusion, lightheadness, etc. Incase of eye drops ocular burning sensation or allergic reaction may occur in 5-10% patients. \n\n\nPrecaution: History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued.\n\nMode of action:  	May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.\nMay increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.\n\nPregnancy category: A\n\nInteraction:  	May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.\nMay increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
Diclofenac Potassium	\n\n\tAcme Ltd.\tA Fenac K TAB dr 50mg 50's pack 150\n\tDrug International Ltd.\tNopain TAB dr 50mg 50's pack 200\n\tIncepta\tIntafenac K TAB dr 50mg 50's pack 150\n\tNovartis (Bangladesh) Ltd.\tCataflam TAB dr 25mg 50's pack 200\n\tNovartis (Bangladesh) Ltd.\tCataflam TAB dr 50mg 50's pack 325\n\tNovartis (Bangladesh) Ltd.\tAnuva TAB dr 50mg  \n\tSquare\tKalinac TAB dr 50mg  50's pack 200.83\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Allergic conjunctivitis, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic, Miosis, Tendinitis, Actinic keratosis, Backaches, Dental pain, Menstrual cramps, Bursitis\n\nDose: Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.\n\nChildren: 1- 3 mg/kg body weight per day in divided doses. Migraine As K: Initial: 50 mg taken at 1st sign of attack, repeat 2 hr later if needed and subsequently 4-6 hrly if needed. Max: 200 mg/day. \n\nContra-indication:  It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.\n\nSide effects: Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.\n\nPrecaution: History of GI ulceration; impaired cardiac, renal or hepatic function; hypertension; lactation. IV admin in patients with moderate or severe renal impairment; hypovolaemia or dehydration; asthma, porphyria. Monitor LFTs in patients on prolonged therapy. May prolong bleeding time; caution when used in patients with coagulation disorders or on anticoagulants. Prolonged therapy may increase risk of anaemia. 1st and 2nd trimester of pregnancy. Elderly, debilitated patients.\n\nMode of action:  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.\n\nPregnancy category: D\n\nInteraction:  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
Diclofenac Sodium	\n\n\tACI\tMobifen TAB dr 50mg 100's pack 88\n\tACI\tMobifen SR CAP 100mg 100's pack 250\n\tACI\tMobifen SR CAP 75mg 100's pack 250\n\tAcme Ltd.\tA Fenac Injection 75mg/3ml 10 amps pack 140.60\n\tAcme Ltd.\tA Fenac Suppository 12.5mg 10's   pack 80.40\n\tAcme Ltd.\tA Fenac TAB dr 25mg 100's pack 55\n\tAcme Ltd.\tA Fenac Suppository 50mg 10's   pack 140.60\n\tAcme Ltd.\tA Fenac TAB dr 50mg 100's pack 84\n\tAcme Ltd.\tA Fenac SR TAB dr 100mg 100's pack 300\n\tAd-din\tJefenac TR CAP 100mg 100's pack 300\n\tAexim\tAlcofen TAB dr 50mg 100's pack 70\n\tAexim\tAlcofen SR CAP  100 mg 100's pack 150\n\tAlbion Ltd.\tDiclofenac TR Timed Release CAP 100 mg 50's pack \n\tAlbion Ltd.\tDiclofenac SR Sustained Release TAB dr 100ml 100's pack \n\tAlbion Ltd.\tDiclofenac TAB dr 50 mg 100's pack \n\tAlco Pharma\tProladin TR CAP 100mg 50's pack 150\n\tAlco Pharma\tProladin TAB dr 50 mg 100's pack 75\n\tAmbee\tHitflam Injection 75mg/3ml 10 amps pack 76.20\n\tAmbee\tHitflam TAB dr 50mg 100's pack 84\n\tAmbee\tHitflam SR TAB dr 100mg 50's pack 152.50\n\tAmico Ltd.\tNovarin SR CAP 100mg 100's pack 250\n\tAmulet\tDFC TAB dr 50mg 100's pack 250\n\tAmulet\tDFC TR CAP 100mg 100's pack 250\n\tAmulet\tDFC Injection 75 mg/3 ml  \n\tAPC Pharma Ltd.\tPenac TAB dr 50mg 100's pack 85\n\tAPC Pharma Ltd.\tPenac TR CAP 100mg 50's pack 150\n\tApex\tDix TR CAP 100mg 100's pack 150\n\tApollo Pharmaceutical Ltd.\tDiclo TAB dr 50mg 100's pack 125\n\tApollo Pharmaceutical Ltd.\tDiclo-TR CAP 100 mg 100's pack 300\n\tAristopharma\tErdon Suppository 50mg 20's pack 300\n\tAristopharma\tErdon Injection 75mg/3ml 10's pack 150\n\tAristopharma\tErdon TR CAP 100mg 100's pack 300\n\tAsiatic Ltd.\tLocopain TAB dr 50mg 100's pack 40\n\tAsiatic Ltd.\tLocopain TR CAP 100mg 100's pack 300\n\tAstra Biopharmaceuticals Ltd.\tMoov SR CAP 100mg 50's pack 75\n\tBelsen\tFenum TR CAP 100 mg 50's pack 150\n\tBenham\tBeonac TAB dr 50mg 100's pack 80\n\tBeximco\tUltrafen Injection 75mg/3ml 10's pack 150\n\tBeximco\tUltrafen Suppository 12.5mg 10's pack 90\n\tBeximco\tUltrafen TAB dr 25mg 100's pack/200's pack 54 / 108\n\tBeximco\tUltrafen Suppository 50mg 10's pack 150\n\tBeximco\tUltrafen TAB dr 50mg 200's pack 166\n\tBeximco\tUltrafen SR TAB dr 100mg 100's pack 300\n\tBio Pharma Ltd.\tVolcan TAB dr 50mg 100's pack 80\n\tBio Pharma Ltd.\tVolcan SR TAB dr 100mg 50's pack 150.50\n\tBio Pharma Ltd.\tVolcan TR CAP 100mg 100's pack 301\n\tBristol Pharma Ltd.\tDilock TAB dr 50mg  100's pack 50\n\tBristol Pharma Ltd.\tDilock TR CAP 100mg 50's pack /100's pack 150 / 300\n\tCentral.\tDiclon TAB dr 50mg 100's pack 85\n\tCentral.\tDiclon SR CAP  100 mg 100's pack 300\n\tChemist Ltd.\tC Fenac Injection 75mg/3ml 10 amps pack 111.30\n\tChemist Ltd.\tC Fenac TAB dr 50mg 100's pack 30\n\tChemist Ltd.\tC-Fenac TR CAP 100mg 50's pack 200\n\tConcord\tDidol TAB dr 50mg 10 amps pack 80\n\tCosmic Chemical Industries Ltd.\tClofen TAB dr 50mg 100's pack 76\n\tCosmo Pharma Ltd.\tCosfenac SR CAP 100mg 50's pack 150\n\tDecent Pharma Ltd.\tDcf TAB dr 50mg 100's pack 60\n\tDelta Pharma\tNasida CAP 100mg 100's pack 150\n\tDelta Pharma\tNasida SR CAP 100mg 100's pack 150\n\tDesh\tDenac TAB dr 50mg 100's pack 80\n\tDesh\tLardon TR CAP 100mg 100's pack 200\n\tDoctor's Chemicals Works Ltd.\tD Fenac TAB dr 50mg 100's pack 50\n\tDrug International Ltd.\tNopain TAB dr 25mg 100's pack 200\n\tEdruc Ltd.\tEdifenac Injection 75mg/3ml 8 amps pack 120\n\tEdruc Ltd.\tEdifenac TAB dr 50mg 100's pack 83\n\tEdruc Ltd.\tEdifenac TR CAP 100mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tNortid TAB dr 25mg 100's pack \n\tEskayef Bangladesh Ltd.\tNortid TAB dr 50mg 100's pack \n\tEskayef Bangladesh Ltd.\tNortid TAB dr 100mg 50's pack \n\tEskayef Bangladesh Ltd.\tVolmax SR CAP 100mg 60's pack 180\n\tEuro Pharma Ltd.\tAlterin TAB dr 50mg 100's pack 100\n\tEuro Pharma Ltd.\tAlterin TR CAP 100mg 50's pack 150\n\tEverest\tNiro SR TAB dr 100mg 50's pack 150\n\tEverest\tNiro TR CAP 100mg 50's pack 106.26\n\tG. A. Company Ltd.\tReutren Injection 75mg/3ml 1 amps pack 7.74\n\tG. A. Company Ltd.\tReutren SR TAB dr 100mg 50's pack 150\n\tGeneral\tRonac 75 IM Injection 75mg/3ml 10amp's pack 150\n\tGeneral\tRonac TR CAP 100mg 50's pack  \n\tGlobe\tGenac Injection 75mg/3ml 10 amps pack 95\n\tGlobe\tGenac TAB dr 50mg 100's pack 60\n\tGlobex\tTolfenac TAB dr 50mg  \n\tGlobex\tTolfenac SR TAB dr 100mg  \n\tGlobex\tTolfenac-SR Capsul  50's pack 150\n\tGonoshasthaya\tG Diclofenac Injection 75mg/3ml 5 amps pack 47.50\n\tGonoshasthaya\tG Diclofenac TAB dr 50mg 100's pack 61\n\tHallmark\tPronac SR TAB dr 100mg 50's pack 125.50\n\tHudson\tHi-Fenac TAB dr 50 mg 100's pack 50\n\tHudson\tHi-Fenac-TR TAB dr 100 mg 100's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAnodyne TAB dr 50mg 100's pack 100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAnodyne SR CAP 100mg 50's pack 162.50\n\tIncepta\tIntafenac Injection 75mg/3ml 10 amps pack 95\n\tIncepta\tIntafenac TAB dr 50mg 100's pack 75\n\tIndobangla Pharmaceuticals\tIndofenac TAB dr 50 mg 100's pack 50\n\tJayson\tMegafen Injection 75mg/3ml 20 amps pack 203\n\tJayson\tMegafen TAB dr 50mg 100's pack 81\n\tJayson\tMegafen SR TAB dr 100mg 50's pack 151\n\tJMI Syringes & Medical Devices Ltd.\tDSR SR CAP 100 mg 50's pack 150\n\tKemiko\tApain TAB dr 50mg 100's pack 75\n\tKemiko\tApain IM Injection 75mg/3ml 10 amps pack 150\n\tKemiko\tApain TR CAP 100mg 50's pack 150\n\tKumudini Pharma Ltd.\tNorfen TAB dr 50mg 100's pack 80\n\tKumudini Pharma Ltd.\tNorfen SR TAB dr 50mg 50's pack 200\n\tLeon\tVelofen TR CAP 100mg  \n\tMarksman.\tDiclora TR CAP 100mg 50's pack 150\n\tMarksman.\tDiclora TAB dr  50 mg 100's pack 80\n\tMedicon\tMedifen TAB dr 50mg 100's pack 100\n\tMedicon\tMedifen TR TAB dr 100mg 50's pack 150\n\tMedimet\tDiclorex Injection 75mg/3ml 10 amps pack 95\n\tMedimet\tDiclorex TAB dr 25mg 100's pack 54\n\tMedimet\tDiclorex TAB dr 50mg 100's pack 70\n\tMedimet\tDiclorex TAB dr 100 mg 50's pack 150\n\tMillat\tMiclofen TAB dr 50mg 100's pack 83\n\tMillat\tMiclofen TR CAP 100mg 50's pack 151.50\n\tModern\tNeofenac TAB dr 50mg 100's pack 84\n\tModern\tNeofenac SR CAP 100mg 40's pack 120\n\tMonicopharma\tRefain TAB dr 50mg 100's pack 83\n\tMonicopharma\tRefain TR CAP 100mg 48's pack 144\n\tMonicopharma\tRefain Injection 75 mg 3 ml amps x 10's pack 95\n\tMystic\tVolpro TAB dr 50mg 100's pack 80\n\tNavana\tDinac TR CAP 100mg 100's pack 300\n\tNIPRO JMI Pharma\tVurdon SR CAP 100mg 50's pack 150\n\tNovartis (Bangladesh) Ltd.\tVoltalin Injection 75mg/3ml 5 amps pack 550\n\tNovartis (Bangladesh) Ltd.\tVoltalin Suppository 12.5mg 10's pack 260\n\tNovartis (Bangladesh) Ltd.\tVoltalin TAB dr 25mg 100's pack 400\n\tNovartis (Bangladesh) Ltd.\tVoltalin Suppository 50mg 10's pack 500\n\tNovartis (Bangladesh) Ltd.\tVoltalin D TAB dr 50mg 100's pack 650\n\tNovartis (Bangladesh) Ltd.\tVoltalin SR TAB dr 100mg 50's pack 750\n\tNovartis (Bangladesh) Ltd.\tVoltalin Forte TAB dr  50 mg 100's pack 700\n\tNovartis (Bangladesh) Ltd.\tVoltalin SR TAB dr 75 mg 50's pack 550\n\tNovo Healthcare and Pharma Ltd.\tProflam TAB dr 50mg 100's pack 50\n\tNovo Healthcare and Pharma Ltd.\tProflam SR CAP 100mg 100's pack 140\n\tNovus\tNodinac SR CAP 100 mg 100's pack 300\n\tOpsonin Pharma\tDiclofen Injection 75mg/3ml 10's pack 150\n\tOpsonin Pharma\tDiclofen Suppository 12.5mg 25's pack 225\n\tOpsonin Pharma\tDiclofen Suppository 25mg 10's pack 120\n\tOpsonin Pharma\tDiclofen TAB dr 25mg 100's pack 52\n\tOpsonin Pharma\tDiclofen Suppository 50mg 25's pack 375\n\tOpsonin Pharma\tDiclofen TAB dr 50mg 100's pack 88\n\tOpsonin Pharma\tDiclofen SR TAB dr 100mg 100's pack 300\n\tOrganic Health Care\tOrgafen TR CAP 100mg 100's pack 300\n\tOrion Pharma Ltd.\tOrfenac TAB dr 50mg 100's pack 80\n\tOrion Pharma Ltd.\tOrfenac TR CAP 100mg 50's pack 150.50\n\tOyster\tXyfenac TAB dr 50mg 50's pack 150\n\tPacific\tPanfre SR CAP 100mg 50's pack 150\n\tPeoples Pharma Ltd.\tDifen TAB dr 50mg   100's pack 38\n\tPharmadesh Ltd.\tFentab TAB dr 50mg 100's pack 100\n\tPharmadesh Ltd.\tFentab SR TAB dr 100mg 50's pack 150\n\tPharmasia Ltd.\tVoltid TAB dr 50mg 100's pack 60\n\tPharmasia Ltd.\tVoltid SR CAP 100mg 50's pack 151\n\tPharmik Ltd.\tHipain TR CAP 100mg  \n\tPopular\tProfenac L Injection 75mg/3ml 5's pack 47.70\n\tPremier Pharmaceuticals\tAid 50 TAB dr 50mg  \n\tPremier Pharmaceuticals\tAid 100 CAP 100mg  \n\tRAK\tDiclopain TAB dr 50mg 100's pack 85\n\tRangs\tOrafen SR TAB dr 100mg  50's pack 150\n\tReliance\tE Fenac TAB dr 50mg 100's pack 50\n\tReliance\tPain Zero TR CAP 100mg 50's pack 150\n\tReman Drug Ltd.\tRenac TR CAP 100mg 50's pack 150\n\tRenata\tDecafen TAB dr 50mg 100's pack 84\n\tRenata\tDecafen SR TAB dr 100mg 100's pack 289\n\tRephco\tDifenac Injection 75mg/3ml 10 amps pack 100\n\tRephco\tDifenac TAB dr 50mg 100's pack 90\n\tRephco\tDifenac CR CAP 100mg 100's pack 250\n\tS. N.\tVolfast TR CAP 100mg 100's pack 300\n\tSalton\tRotafen TAB dr 50mg 200's pack 166\n\tSalton\tRotafen SR CAP 100mg 100's pack 301\n\tSanofi Aventis (BD) Ltd.\tFiclon Injection 75mg/3ml 10 amps pack 152.29\n\tSanofi Aventis (BD) Ltd.\tFiclon Suppository 50mg 10's pack 120.46\n\tSeema\tS-Fenac TR CAP 100mg 50's pack 150\n\tShamsul Al-Amin\tSafenac TR CAP 100mg 50's pack 125\n\tSharif\tMovonac TAB dr 50mg 100's pack 80\n\tSharif\tMovonac TR CAP 100mg 50's pack 150\n\tSilva\tSifen TR CAP 100mg 100's pack 250.94\n\tSomatec\tClonac TAB dr 50mg 100's pack 83\n\tSomatec\tClonac TR CAP 100mg 50's pack 150.50\n\tSquare\tClofenac Injection 75mg/3ml  10 amps pack 150.55\n\tSquare\tClofenac Suppository 100mg 10's pack 200\n\tSquare\tClofenac Suppository 12.5mg 10  pack 90.30\n\tSquare\tClofenac Suppository 25mg 10's  pack 120.50\n\tSquare\tClofenac TAB dr 25mg 100's pack 100\n\tSquare\tClofenac Suppository 50mg 20 's pack  301\n\tSquare\tClofenac TAB dr 50mg 200's pack 300\n\tSquare\tClofenac DT TAB dr 50mg 100's pack 400\n\tSquare\tClofenac SR TAB dr 100mg 100's pack 400\n\tSquare\tClofenac TR CAP 100mg 50's pack 200\n\tSupreme\tApnac TAB dr 50mg  100's pack 80\n\tSupreme\tApnac SR CAP 100mg 50's pack 150\n\tSyntho Ltd.\tSunac TAB dr 50mg 150's pack 120\n\tTechno Drugs Ltd.\tVoltarol Injection 75mg/3ml 5 amps pack 75\n\tVirgo\tDiclovir TAB dr 50mg 100's pack 75\n\tWhite Horse Pharma\tVolton TAB dr 50mg 100's pack 84\n\tZenith\tDiclonil CAP  50 mg 100's pack 80\n\tZiska\tDiclonac Injection 75mg/3ml 10 amps pack 85\n\tZiska\tDiclonac TAB dr 50mg 100's pack 83\n\tZiska\tDiclonac TR CAP 100mg 50's pack 100\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Pain, Migraine, Dysmenorrhea, Muscle aches, Acute gout, Inflammation, Renal colic,Tendinitis, Backaches, Dental pain, Menstrual cramps, Bursitis\n\nDose: Adults: 1- 3 tablet (50 -150 mg) daily in divided doses preferably with food or after food.\n\nChildren: 1- 3 mg/kg body weight per day in divided doses.\n\n Injections are intended for intramuscular injection.\n\nAdults: The dosage is generally one 75 mg ampoule daily. In severe cases (e.g. colic) the daily dose can exceptionally be increased to two ampoules of 75 mg, separated by an interval of a few hours. Alternatively, one ampoule of 75 mg can be combined with other dosage forms (tablets, suppositories) up to a maximum daily dosage of 150 mg.\n\nIn migraine attacks, clinical experience is limited to initial use of 1 ampoule of 75 mg administered as soon as possible, followed by suppositories up to 100 mg on the same day if required. The total dosage should not exceed 175 mg on the first day.\n\nChildren: In juvenile chronic arthritis, 1-3 mg of Diclofenac sodium/kg body weight daily in divided doses.\n\nElderly patients: The lowest effective dosage is recommended, commensurate with age and physical status or as prescribed by the physician.\n\nSuppository: For adults: 50 mg suppository 2-3 times daily. Maximum daily dose is 150 mg. \n\nContra-indication: It is contra-indicated for those patients who are hypersensitive to Diclofenac. In patients with active or suspected peptic ulcer or gastrointestinal bleeding, or for those patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs possessing prostaglandin synthetase inhibitinig activity, it is also contraindicated.\nBecause of the presence of Lidocaine, it is also contraindicated for those patients who are hypersensitive to local anaesthetics of the amide type, although the incidence is very rare. \n\nSide effects: Side-effects of Diclofenac is usually mild and transient. It is generally well tolerated. At the starting of the treatment, however, patients may sometimes complain of gastrointestinal discomfort, epigastria pain, eructation, nausea and Diarrhoea, headache and bleeding sometime may occur. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminase have been reported.Very rarely reported side effects include activation of peptic ulcer, haematemesis or melena, blood dyscrasia (extensive usage). There have been isolated reports of anaphylactoid reactions.\n\n\nPrecaution: History of gastrointestinal ulceration, haematemesis or melaena, ulcerative colitis, Asthma or history of asthma, Crohn's disease, bleeding diathesis or haematological abnormalities. Patients with severe hepatic, cardiac or renal insufficiency or the elderly people, Current or previous high blood pressure ( hypertension) should be kept under close surveillance. All patients who are receiving long-term treatment with NSAID agents should be monitored as a precautionary measure (e.g., renal, hepatic function and blood counts).If abnormal liver function tests persist or worsen, clinical signs and symptoms consistent with liver disease develop or if other manifestations occur, Diclofenac sodium should be discontinued. Use of Diclofenac tablet in patients with hepatic porphyria may trigger an attack.\n\nMode of action:  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.\n\nPregnancy category: D\n\nInteraction:  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
Diclofenac Sodium + Misoprostol	\n\n\tAcme Ltd.\tMisofenac 50/200 TAB dr  200 mcg 30's pack 301.20\n\tApex\tDix Extra 50/200 TAB dr   30's pack \n\tAristopharma\tErdon SUPER 50/200 TAB dr   30's pack 300\n\tBeximco\tUltrafen PLUS 50/200 TAB dr   30's pack/50's pack 330/500\n\tDrug International Ltd.\tNopain Extra 50 TAB dr   20's pack 200\n\tDrug International Ltd.\tNopain Extra 75 TAB dr   30's pack 330\n\tEverest\tDimis 50/200 TAB dr   30's pack 300\n\tGeneral\tMisoclo 50/200 TAB dr   20's pack 200.80\n\tGeneral\tMisoclo 75/200 TAB dr   20's pack 220.80\n\tHealthcare\tArthrofen 50/200 TAB dr   30's pack 300\n\tHealthcare\tArthrofen 75/200 TAB dr   30's pack 360\n\tKemiko\tApain MS TAB dr   30's pack 330\n\tPacific\tPanfre PLUS 50/200 TAB dr   30's pack 300\n\tPopular\tProfenac PLUS 50/200 TAB dr  50 mg + 200 mcg 20's pack 200.80\n\tRAK\tClofina TAB dr   30's pack 300\n\tSomatec\tMisofen 75/200 TAB dr   30's pack 331.20\n\tSquare\tMiclofenac 50/200 TAB dr  50 mg + 200 mcg 30's pack 301.24\n\tSquare\tMiclofenac 75/200 TAB dr  75 mg + 200 mcg 30's pack 331.17\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Joint and muscular pains\n\nDose: Osteoarthritis: 50 mg tablet thrice daily. For patients who experience intolerance, 75 mg tablet or 50 mg tablet twice daily.\nRheumatoid arthritis:50 mg tablet hrice or four times daily. For patients who experience intolerance, 75 mg tablet or 50 mg tablet twice daily.\n\nContra-indication:  Diclofenac Sodium and Misoprostol combination is contraindicated in women who are pregnant because of the abortive property of the Misoprostol component.\n\nSide effects: The most common reported side effects are abdominal pain, diarrhoea and other GI symptoms. Diarrhoea and abdominal pain developed early in the course of therapy and were usually self-limited (resolved after 2-7 days).\n\nPrecaution: Patients with an underlying condition such as inflammatory bowel disease or those in whom dehydration should be monitored carefully if Diclofenac Sodium 50 mg plus Misoprostol 200 mcg is prescribed. \n\nThe pharmacological activity   in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.\n\nMode of action:  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.\nMay increase effects of oxytocin. Increased risk of misoprostol-induced diarrhoea with magnesium-containing antacids.\n\nPregnancy category: B\n\nInteraction:  May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.\nMay increase effects of oxytocin. Increased risk of misoprostol-induced diarrhoea with magnesium-containing antacids.
Diclofenac Sodium 0.1% Eye prep	\n\n\tACI\tMobifen Eye Drops  0.10% 5  ml drop 75.51\n\tAristopharma\tErdon Eye Drops   5  ml drop 80\n\tAsiatic Ltd.\tLocopain Eye Drops   5  ml drop 80\n\tChemist Ltd.\tC Fenac Eye Drops   5  ml drop 65\n\tDrug International Ltd.\tNopain Eye Drops   5  ml drop 75\n\tG. A. Company Ltd.\tReutren Eye Drops   5  ml drop 70\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAnodyne Eye Drops   5  ml drop 80\n\tIncepta\tIntafenac Eye Drops   5  ml drop 80\n\tNavana\tDinac Eye Drops   5ml drop 80\n\tNipa\tAnfenac Eye Drops   5  ml drop 80\n\tOpso Saline Ltd.\tDiclofenac Eye Drops   5  ml drop 75.28\n\tPopular\tProfenac Eye Drops  1 mg/ml 5  ml drop 75.28\n\tReman Drug Ltd.\tDiclon Eye Drops   5  ml drop 78.50\n\tSquare\tClofenac 0.1% Eye Drops   5  ml drop 75.28\n\tIndication: Allergic conjunctivitis, Ocular inflammation, Miosis\n\nDose: Adults\nPre-operatively: Instill 1 drop in the conjunctival sac up to 5 times over the 3 hours preceding surgery\n\nPost-operatively: Instill 1 drop in the conjunctival sac after 15, 30 & 45 minutes following surgery; then 3-5 times daily for as long as required.\n\nInflammatory conditions: Instill 1 drop in the conjunctival sac 4-5 times daily depending upon the severity of the diseases.\n\nContra-indication: Contraindicated to patients hypersensitive to Diclofenac Sodium or any other of its ingredients. Diclofenac sodium is also contraindicated in patients who may have NSAID induced asthma, urticaria, or acute rhinitis.\n\nSide effects: Mild to moderate burning sensation in 5-15% patients which is transient in nature and almost never necessitated discontinuation of treatment. Other less common side-effects are sensitivity to light, bad taste, feeling of pressure, allergic reactions etc. \n\nPrecaution: Diclofenac eye drops may mask the signs of infection. So physicians should be alert to the development of infections in patients receiving the drug. During prolonged use, it is recommended that physicians conduct periodic examinations of the eye, including measurement of the intraocular pressure. Contact lenses should not be worn during treatment.\n\nMode of action: May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.\n\nPregnancy category: C\n\nInteraction: May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
Diclofenac Sodium 1% Topical	\n\n\tAcme Ltd.\tA Fenac 1% Gel   10gm tube 13.05\n\tAcme Ltd.\tA-Fenac Gel Cream 1%  1's pack 13.05\n\tAd-din\tNeofenac Gel   25 gm tube 12.90\n\tAmbee\tHitflam 1% Gel   10 gm tube 12.95\n\tAmico Ltd.\tNovarin 1% Gel   10gm tube 12.90\n\tAristopharma\tErdon GEL 1% Gel   10 gm tube 12.90\n\tAstra Biopharmaceuticals Ltd.\tMoov 1% Gel   10gm tube 60\n\tBeximco\tUltrafen 1% Gel   10gm tube/ 25gm tube 13 / 35\n\tBeximco\tVoligel Gel 50gm 50gm tube / 30gm tube 97 / 80\n\tDoctor's Chemicals Works Ltd.\tD Fenac 1% Gel   20gm tube 25\n\tEdruc Ltd.\tEmov 1% Gel   25 gm tube 25\n\tG. A. Company Ltd.\tReutren 1% Gel   10gm tube 12.14\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAnodyne 1% Gel   10 gm tube 13\n\tNovartis (Bangladesh) Ltd.\tVoltalin Emulgel Gel   20gm tube \n\tOpsonin Pharma\tDiclofen 1% Gel   10 gm tube 12.90\n\tPharmadesh Ltd.\tFengel 1% Gel   15gm tube 19.68\n\tPharmasia Ltd.\tVoltid Gel 1% Gel   10gm tube 12.95\n\tPopular\tProfenac 1% Gel 1 gm/100 gm 10gm tube 12.95\n\tSquare\tClofenac 1% Gel   20gm tube 40.15\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Joint and muscular pains\n\nDose: Gel: For external use only. Depending on the size of area to be treated, 2-4 g of  Gel should be applied to the skin 3-4 times daily. To the affected area gel should be rubbed in lightly.  \nGel may also be given in addition to further treatment with other dosage forms of Diclofenac.\n\n\n\nContra-indication: Contraindicated to the patients hypersensitive to any ingredient of the products. Peptic ulcer, hypersensitivity to Diclofenac like other non-steroid anti-inflammatory agents, Diclofenac is also contra-indicated in asthmatic patient in whom attack with asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or by other drugs with prostaglandin synthetase inhibitor.  Gel should not be used under occlusive airtight dressings.\n\nSide effects: Generally well tolerated. Adverse effects are mild, rare and transient. At the starting of the treatment, however, patients may be sometimes complaining of epigastric pain, eructation, nausea and diarrhea or dizziness or headache. These effects are usually mild in nature. Peripheral edema and skin reactions, such as rash and eczema have also been encountered. Gel may cause local irritation and reddening of the skin and skin rash.\n\nPrecaution: In rare instances where peptic ulceration or gastro-intestinal bleeding occurs in patients under treatment with Diclofenac. In patients with advanced age should be kept under close observation.Gel should not be allowed to come in contact with the eyes or mucus membranes, after application the hands should be washed properly and not to be taken by mouth.\n\nMode of action: May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.\n\nPregnancy category: C\n\nInteraction: May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.
Dicloxacillin	\n\n\tEskayef Bangladesh Ltd.\tBetaclox CAP 250mg 100's pack \n\tNovartis (Bangladesh) Ltd.\tDiclox CAP 250mg 40's pack 242\n\tNovartis (Bangladesh) Ltd.\tDiclox CAP 500mg 40's pack 445.20\n\tIndication: Pneumonia, Endocarditis, Impetigo, Cellulitis, Septic Arthritis, Surgical Prophylaxis, Otitis externa, Staphylococcal skin infections, Folliculitis, Boils, Carbuncles, Mastitis, Osteomyelitis, Throat infections, Streptococcus Septicaemia\n\nDose: Adult: PO 125-250 mg 6 hrly, may double dose in severe infections.\nChild: 12.5-25 mg/kg/day in 4 divided doses.\n\nContra-indication: Hypersensitivity to penicillins.\n\nSide effects: Hypersensitivity reactions including uticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; hemolytic anemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Skin sensitization may occur on direct contact. Monitor serum K concentration, renal and hematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly; porphyria.\n\nMode of action: Probenecid prolongs serum levels of dicloxacillin. Bacteriostatic drugs (e.g. chloramphenicol, tetracyclines) may antagonise the bactericidal effect of dicloxacillin. May reduce anticoagulant response to dicumarol and warfarin. May increase risk of methotrexate toxicity. May diminish the effect of live vaccines (e.g. typhoid vaccine).\n\nPregnancy category: B\n\nInteraction: Probenecid prolongs serum levels of dicloxacillin. Bacteriostatic drugs (e.g. chloramphenicol, tetracyclines) may antagonise the bactericidal effect of dicloxacillin. May reduce anticoagulant response to dicumarol and warfarin. May increase risk of methotrexate toxicity. May diminish the effect of live vaccines (e.g. typhoid vaccine).
Dicycloverine Hydrochloride	\n\n\tACI\tDiverin Syrup 10mg/5ml 50ml bot 30.11\n\tACI\tDiverin TAB dr 20mg 50's pack 176\n\tACI\tDiverin TAB dr 10mg 50's pack 101\n\tAlco Pharma\tDirin TAB dr 10mg 100's pack 200\n\tAlco Pharma\tDirin Syrup 10mg/5ml 50ml bot 40\n\tApex\tWinspa TAB dr 10mg 50's pack 100\n\tApex\tWinspa Syrup 10mg/5ml 50ml bot 30\n\tBeximco\tLoverin TAB dr 10mg 50's pack 100.50 IP\n\tBeximco\tLoverin Syrup 10mg/5ml 50ml bot 30 IP\n\tHealthcare\tRobentyl TAB dr 10mg 100's pack 200\n\tHealthcare\tRobentyl Syrup 10mg/5ml 50ml bot 30\n\tIncepta\tCyclopan TAB dr 10mg 100's pack 200\n\tIncepta\tCyclopan Syrup 100mg/5ml 50ml bot 30\n\tIncepta\tCyclopan Injection 20mg/2ml 5 amps pack 40\n\tNavana\tSpalax TAB dr 10mg 60's pack 120.60\n\tNavana\tSpalax Syrup 10mg/5ml 50ml bot 30.11\n\tOpsonin Pharma\tAbdorin TAB dr 10mg 50's pack 88.41\n\tOpsonin Pharma\tAbdorin Syrup 10mg/5ml 50ml bot 26.49\n\tPacific\tIbspa TAB dr 10mg 100's pack 200\n\tPacific\tIBSPA Syrup 10mg/5ml 50ml bot 25\n\tSomatec\tCyclovin TAB dr 10mg 100's pack 201\n\tSomatec\tCyclovin Suspension 10mg/5ml 50ml bot 30.11\n\tSquare\tColicon TAB dr 10mg 100's pack 200.83\n\tSquare\tColicon Syrup 10mg/5ml 50ml bot 30.11\n\tSquare\tColicon Injection 20mg/2ml 10 amps pack 60.25\n\tSquare\tColicon Syrup 10 mg/5 ml  \n\tSyntho Ltd.\tEraspa TAB dr 10mg 50ml bot 30.11\n\tIndication: Gastrointestinal tract spasm, Intestinal hypermotility, Irritable bowel syndrome (IBS)\n\nDose: Adults : 10 to 20 mg three to four times a day. Maximum recommended oral dose is 160 mg daily in divided dose. \n\nChildren : Children over 6 months of age- 5 to 10 mg three times a day. IM injection : Usual recommended injectable dose is 80 mg daily by IM route in 4 divided dose.\n\n\nContra-indication: Intestinal obstruction; intestinal atony; myasthenia gravis; glaucoma; reflux oesophagitis; infants <6 mth; lactation.\n\nSide effects: Difficulty in accommodation, exacerbation of glaucoma; tachycardia, palpitations, arrhythmias; urinary retention; restlessness; confusion, excitement, hallucination and delirium.\nPotentially Fatal: Respiratory arrest in infants <10 wk.\n\nPrecaution:  Hepatic or renal disease, urinary retention, paralytic ileus, hyperthyroidism, hypertension, congestive heart failure, cardiac tachyarrhythmia, children, elderly, pregnancy.\n\nMode of action: Antagonise the effect of drugs that affect GI motility e.g. metoclopramide. Absorption affected by concurrent admin with antacids.\n\nPregnancy category: B\n\nInteraction: Antagonise the effect of drugs that affect GI motility e.g. metoclopramide. Absorption affected by concurrent admin with antacids.
Diethylcarbamazine Citrate	\n\n\tCipla Ltd.\tDicazin TAB dr 50mg  \n\tHudson\tFilazine TAB dr 100mg 100's pack 130\n\tReman Drug Ltd.\tRemazin TAB dr 50mg 100's pack 75\n\tIndication: Filariasis, Lymphatic filariasis, Pulmonary eosinophilia, Loiasis, Toxocariasis\n\nDose: Adult: PO Filariasis; Loiasis; Toxocariasis Inital: 1 mg/kg/day, may increase to 6 mg/kg/day over 3 days, then maintain for 3 wk. Prophylaxis of loiasis 300 mg/wk.\n\nContra-indication: Pregnancy, hypersensitivity; lactation; infants, elderly or debilitated patients; impaired renal function; cardiac disease.\n\nSide effects: Fever, headache, vomiting, dizziness, drowsiness, nausea, chills.\nPotentially Fatal: Severe hypersensitivity reactions may occur especially in the treatment of onchocerciasis where rare Mazzotti reaction characterised by rash, itching, headache, muscle and joint pains, tachycardia, postural hypotension may start within 2 hr of drug administration. Encephalitis and retinal haemorrhage.\n\nPrecaution: Patients with poor health.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Diflorasone Diacetate 0.05% Topical	\n\n\tSquare\tEczena Cream  .05 gm/100 gm 10gm  tube 70.26\n\tSquare\tEczena Ointment  .05 gm/100 gm 10gm  tube 70.26\n\tIndication: Psoriasis, Corticosteroid-responsive dermatoses\n\nDose: Adult: Topical As 0.05% oint/cream: Apply 1-4 times/day.\n\nContra-indication: Hypersensitivity. \n\nSide effects: Burning sensation, itching, redness, dryness. Folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin atrophy, striae, miliaria.\n\nPrecaution: Substantial systemic absorption may lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycaemia and glucosuria. Treatment should be discontinued if there is irritation. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Difluprednate Eye prep	\n\n\tAristopharma\tNeopred Eye Solution .05gm/100ml 5ml bot 180\n\tGeneral\tDiflupred Ophthalmic Emulsion 0.05 gm/100 ml  \n\tOpso Saline Ltd.\tDipred 0.05% Ophthalmic Emulsion 0.05 gm/100 ml  \n\tPopular\tDipred Ophthalmic Emulsion 0.05 gm/100 ml  180\n\tIndication: Ocular inflammation and pain\n\nDose: Ocular Surgery\n\nInstill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response.\n\n Endogenous Anterior Uveitis\n\nInstill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated.\n\n\nContra-indication: Contraindicated in most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures.\n\nSide effects: Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.\n\nPrecaution: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, intraocular pressure should be monitored.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Digoxin	\n\n\tAristopharma\tAgoxin TAB dr 250mcg 100's pack 109\n\tDrug International Ltd.\tDigoxen CAP 100mcg 100's pack 94\n\tDrug International Ltd.\tDigoxen CAP 200mcg 50's pack 67\n\tGlaxoSmithKline Bangladesh Ltd.\tLanoxin TAB dr 250mcg 100's pack 236\n\tOpsonin Pharma\tCentoxin TAB dr 250mcg 50's pack 47.95\n\tOpsonin Pharma\tCentoxin-60 Elixir 0.05mg/ml 60ml bot 75.28\n\tIndication: Heart failure, Supraventricular arrhythmias, Atrial fibrillation and Atrial flutter\n\nDose: Adult: PO Heart failure; Supraventricular arrhythmias Rapid digitalisation: Loading dose: 0.75-1.5 mg in the 1st 24 hr. Slow digitilisation: 250 mcg 1-2 times/day. Uusal maintenance: 125-250 mcg/day. \n\nChild: Neonate <1.5 kg: Initial: 25 mcg/kg/day in 3 divided doses for 24 hr, then 4-6 mcg/kg/day in 1-2 divided doses; neonate 1.5-2.5 kg: Initial: 30 mcg/kg/day in 3 divided doses for 24 hr, then 4-6 mcg/kg/day in 1-2 divided doses; Neonate >2.5 kg and child 1 mth-2 yr: Initial: 45 mcg/kg/day in 3 divided doses for 24 hr, then 10 mcg/kg/day in 1-2 divided doses. 2-5 yr: Initial: 35 mcg/kg/day in 3 divided doses for 24 hr, then 10 mcg/kg/day in 1-2 divided doses. 5-10 yr: Initial: 25 mcg/kg/day (max: 750 mcg/day) in 3 divided doses for 24 hr, then 6 mcg/kg/day (max: 250 mcg/day) in 1-2 divided doses. 10-18 yr: Initial: 0.75-1.5 mg/day in 3 divided doses for 24 hr, then 62.5-750 mcg/day in 1-2 divided doses. Reduce doses if patient has been given cardiac glycoside in the preceding 2 wk. \n\nAdult: IV Emergency heart failure For patients who have not received cardiac glycosides in the previous 2 wk: 0.5-1 mg via infusion as a single dose or in divided doses. Maintenance: Usually via oral admin.\n\nContra-indication: Digitalis toxicity, ventricular tachycardia/fibrillation, obstructive cardiomyopathy. Arrhythmias due to accessory pathways (e.g. Wolff-Parkinson-White syndrome).\n\nSide effects: Extra beats, anorexia, nausea and vomiting. Diarrhoea in elderly, confusion, dizziness, drowsiness, restlessness, nervousness, agitation and amnesia, visual disturbances, gynaecomastia, local irritation (IM/SC inj), rapid IV admin may lead to vasocostriction and transient hypertension.\nPotentially Fatal: Cardiac arrhythmias in combination with heart block.\n\nPrecaution: Cardiac dysrhythmias, hypokalaemia, hypertension, IHD, hypercalcaemia, hypomagnesaemia, electroconversion, chronic cor pulmonale, aortic valve disease, acute myocarditis, congestive cardiomyopathies, constrictive pericarditis, heart block, elderly, renal impairment, abnormalities in thyroid function; pregnancy. IV digoxin can only be given to patients who have not received cardiac glycosides in the preceding 2 wk.\n\nMode of action: Effectiveness reduced by phenytoin, neomycin, sulphasalazine, kaolin, pectin, antacids and in patients receiving radiotherapy. Metoclopramide may alter the absorption of solid dosage forms of digoxin. Blood levels increased by calcium channel blockers, spironolactone, quinidine and calcium salts.\nPotentially Fatal: Electrolyte imbalances such as hypokalaemia and hypomagnesemia (e.g. admin of potassium-losing diuretics, corticosteroids) can increase the risk of cardiac toxicity.\n\nPregnancy category: C\n\nInteraction: Effectiveness reduced by phenytoin, neomycin, sulphasalazine, kaolin, pectin, antacids and in patients receiving radiotherapy. Metoclopramide may alter the absorption of solid dosage forms of digoxin. Blood levels increased by calcium channel blockers, spironolactone, quinidine and calcium salts.\nPotentially Fatal: Electrolyte imbalances such as hypokalaemia and hypomagnesemia (e.g. admin of potassium-losing diuretics, corticosteroids) can increase the risk of cardiac toxicity.
Diloxanide Furoate	\n\n\tAcme Ltd.\tDiloxide TAB dr 500mg 100's pack 186\n\tPharmadesh Ltd.\tDilamide Suspension 250mg/5ml 60ml bot 60\n\tPharmadesh Ltd.\tDilamide TAB dr 500mg 100's pack 500\n\tIndication: Intestinal amoebiasis\n\nDose: Adult: PO- The recommended dose is 500 mg 3 times/day for 10 days. May repeat course if needed.\nChild: >25 kg: 20 mg/kg daily in 3 divided doses for 10 days, repeated if necessary.\n\nContra-indication: Hypersensitivity. \n\nSide effects: The frequency of these side-effects is unknown\n\n1. flatulence    2.  itching\n 3. urticaria      4. vomiting\n\n\nPrecaution:  Caution should be exercised in pregnant and breastfeeding women.  Avoid excess dosage.\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Diltiazem Hydrochloride	\n\n\tAlbion Ltd.\tDiltiazem TAB dr 30 mg/ 60 mg 100's / 100's pack \n\tBeximco\tNeocard TAB dr 30mg 100's pack \n\tBeximco\tNeocard TAB dr 60mg 100's pack \n\tDelta Pharma\tTizem TAB dr 30mg 100's pack 200\n\tDelta Pharma\tTizem TAB dr 60mg 50's pack 190\n\tDrug International Ltd.\tCardizem TAB dr 30mg 100's pack 300\n\tDrug International Ltd.\tCardizem TAB dr 60mg 100's pack 500\n\tDrug International Ltd.\tCardizem SR CAP 120mg 50's pack 400\n\tDrug International Ltd.\tCardizem SR TAB dr 120mg 50's pack 400\n\tDrug International Ltd.\tCardizem SR CAP 90mg 50's pack 250\n\tEdruc Ltd.\tDilti SR CAP 90mg 30's pack 90\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCardil TAB dr 30mg 100's pack 225\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCardil TAB dr 60mg 100's pack 400\n\tIncepta\tLitizem TAB dr 30mg 50's pack 100\n\tIncepta\tLitizem TAB dr 60mg 30's pack 114\n\tMundipharma (Bangladesh) Pvt. Ltd.\tDilcontin XL TAB dr 90mg  \n\tNipa\tDial TAB dr 60mg 100's pack 380\n\tRenata\tEvascon TAB dr 30mg 100's pack 202\n\tRenata\tEvascon TAB dr 60mg 100's pack 385\n\tSquare\tDiltizem SR TAB dr 90mg 40's pack 224.40\n\tIndication: Supraventricular tachycardia, Hypertension, Angina, Atrial fibrillation, Arrhythmias, Atrial flutter\n\nDose: Adult: PO Angina pectoris Initial: 60 mg 3 times/day, up to 480 mg/day if needed. HTN Initial: 60-120 mg twice daily. Max: 360 mg/day. \n\nContra-indication: Sick-sinus syndrome; 2nd or 3rd Â° AV block; porphyria. Severe congestive cardiac failure; marked bradycardia. Pregnancy and lactation.\n\nSide effects: Headache, ankle oedema, hypotension, dizziness, fatigue, flushing, nausea, GI discomfort, gingival hyperplasia, rashes, erythema multiforme, exfoliative dermatitis, photosensitivity, occasionally hepatitis.\nPotentially Fatal: AV block, bradycardia, asystole, sinus arrest.\n\nPrecaution: Elderly. Hepatic or renal impairment; impaired left ventricular function; prolonged AV periods; DM; hypotension. Avoid abrupt withdrawal and long-term use. Patients with sick-sinus syndrome, preexisting AV block, bradycardia and those taking beta-blockers or digitalis are at risk of developing AV block, bradycardia, asystole or sinus arrest.\n\nMode of action: Increased AV blocking effect w/ clonidine. May increase serum levels of statins (e.g. atorvastatin, lovastatin), carbamazepine, phenytoin. May increase bradycardic affect of amiodarone, digoxin, mefloquine. May enhance antihypertensive effect w/ other antihypertensives (e.g. aldesleukin), antipsychotic. Increased serum levels w/ cimetidine. Decreased serum levels w/ rifampicin, phenobarbital.\nPotentially Fatal: IV: May enhance hypotensive effect of IV ?-blockers.\n\nPregnancy category: C\n\nInteraction: Increased AV blocking effect w/ clonidine. May increase serum levels of statins (e.g. atorvastatin, lovastatin), carbamazepine, phenytoin. May increase bradycardic affect of amiodarone, digoxin, mefloquine. May enhance antihypertensive effect w/ other antihypertensives (e.g. aldesleukin), antipsychotic. Increased serum levels w/ cimetidine. Decreased serum levels w/ rifampicin, phenobarbital.\nPotentially Fatal: IV: May enhance hypotensive effect of IV ?-blockers.
Dimethothiazine Mesylate	\n\n\tIndication: Migraine\n\nDose: Oral: 20 mg 3-4 times daily.\n\nContra-indication: Hypersensitivity.\n\nSide effects: \n\nPrecaution: \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Diosmin + Hesperidin	\n\n\tACI\tDaflon TAB dr 450 mg + 50 mg  30's pack 364.50\n\tAcme Ltd.\tPilestop TAB dr 450mg + 50mg 20's pack 160.80\n\tApex\tHemonor TAB dr   30's pack 240\n\tAristopharma\tHemoral TAB dr   30's pack 240\n\tHealthcare\tSangril TAB dr   30's pack 255\n\tIncepta\tDiorin TAB dr   30's pack 240\n\tOpsonin Pharma\tDiohes TAB dr   30's pack 240\n\tRAK\tPilof TAB dr  30's pack 240\n\tRenata\tNormanal TAB dr   30's pack 240.90\n\tSquare\tHemorif TAB dr  450 mg + 50 mg 30's pack 240.99\n\tUnimed & Unihealth Manufacturers Ltd.\tAvonoid TAB dr   30's pack 240\n\tLes Servier Industrie,France\tDaflon TAB dr 450 mg + 50 mg 30's pack 360\n\tIndication: Hemorrhoids, Piles, Chronic venous disease\n\nDose: Adult: PO Chronic venous disease : 2 tab/day. \nHaemorrhoids : Acute attack: 6 tab/day for 1st 4 days, followed by 4 tab/day for next 3 days; Chronic haemorrhoids: 2 tab/day.\n\nContra-indication: It is contra-indicated in patients, who have shown hypersensitivity to any of the substances present in the drug.\n\nSide effects: Possible side-effects to be observed: cutaneous allergies, gastrointestinal disorders, headaches and flushes.\n\nPrecaution:  Pregnancy & Lactation.\n\nMode of action: Metabolism of metronidazole may be reduced by concurrent admin of diosmin.\n\nPregnancy category: Not Classified\n\nInteraction: Metabolism of metronidazole may be reduced by concurrent admin of diosmin.
Dioxybenzone 0.3% + Hydroquinone 0.4% + Octyldimet p-aminobenzoate 0.8% + Oxybenzone 0.2%	\n\n\tIncepta\tSpotclen Plus Cream   10gm pack 80\n\tUnimed & Unihealth Manufacturers Ltd.\tDepiquin Forte Cream (300 mg + 400 mg + 800 mg  \n\tIndication: Chloasma, Melasma, Freckles, Senile lentigines, Hyperpigmentation\n\nDose: Hyperpigmentated skin conditions\nAdult: Apply and rub in a thin layer  to affected area bid.\n\nAfter desired bleaching, use only as needed to maintain results of treatment. After reduction of hyperpigmentation, use of sunscreen agents and/or protective clothing should continue on bleached skin to prevent repigmentation.\n\nContra-indication: Hydroquinone is contraindicated to patients with prior history of hypersensitivity or allergic reaction to hydroquinone or other ingredients in the preparation. Sunburn or depilatory usage. Children <12 yr.\n\nSide effects: Transient erythema, mild burning sensations; hyperpigmentation. Staining and corneal opacities. Tremors and convulsions after systemic absorption. Occasionally, hypersensitivity.\n\nPrecaution: Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin to check in 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, further treatment is not advised. If no bleaching or lightening effect is noted after 2 months of treatment, the medication should be discontinued.Contact with the eyes and lips should be avoided. Hydroquinone should not be applied to cut or abraded skin. Avoid contact with eyes and on abraded or sunburnt skin. Avoid unnecessary exposure to sunlight. Limit application to area no larger than face and neck or hands and arms. Not advised to use when itching, vesicle formation, or excessive inflammation occurs. Discontinue application if there is no improvement after 2 mth of treatment.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Diphenhydramine Hydrochloride	\n\n\tAcme Ltd.\tPhenadryl Syrup 10mg/5ml 100ml bot 22.59\n\tAlbion Ltd.\tDiphenhydramin Syrup 200 mg/100 ml 100 ml \n\tBeximco\tPedeamin Syrup 10mg/5ml 100ml bot 38\n\tCosmic Chemical Industries Ltd.\tBena-Flu Syrup 12.5mg/5ml 100ml bot 26\n\tEskayef Bangladesh Ltd.\tDorenta Syrup 10mg/5ml 100ml bot 30\n\tEskayef Bangladesh Ltd.\tDorenta TAB dr 50mg 50's pack 125\n\tG. A. Company Ltd.\tDidryl Syrup 10mg/5ml 100ml bot 30\n\tNipa\tDifin Syrup 10mg/5ml 100ml bot 30\n\tOpsonin Pharma\tRymin Syrup 10mg/5ml 100ml bot 20\n\tOyster\tPedryl Syrup 10 mg/5 ml 100ml bot 20\n\tPopular\tPedilar Syrup 10mg/5ml 100ml bot 45.17\n\tSalton\tPhendrin Syrup 10mg/5ml 100ml bot 22.08\n\tSomatec\tPediphen Syrup 10mg/5ml 100ml bot 20.08\n\tSquare\tAdryl Syrup 10mg/5ml 100ml bot 22.59\n\tIndication: Allergic rhinitis, Allergic conditions, Motion sickness, Common cold, Insomnia, Extrapyramidal symptoms\n\nDose: Oral\nAdult: As hydrochloride: 25-50 mg 3-4 times daily. Max: 300 mg/day. \nChild: 6.25-25 mg 3-4 times daily, up to 5 mg/kg in divided doses. Max: 300 mg/day. \n\nTreatment and prophylaxis of motion sickness\nAdult: As diphenhydramine di (acefyllinate): Usual dose: 90-135 mg, may repeat if needed at intervals of at least 6 hr. Max: 540 mg daily. For prevention, dose to be given at least 30 min before travelling. \n\n\nContra-indication: Hypersensitivity ; neonates, lactation.\n\nSide effects: CNS depression, dizziness, headache, sedation; paradoxical stimulation in children; dryness of mouth, thickened respiratory secretion, blurring of vision, urinary retention; GI disturbances; blood dyscrasias.\n\nPrecaution: Epilepsy; elderly; performing tasks which require mental alertness; angle-closure glaucoma; pyroduodenal obstruction; urinary tract obstruction; hyperthyroidism; raised intraocular pressure; CV disease; acute asthma; pregnancy.\n\nMode of action:  	Masks ototoxicity produced by aminoglycosides. Increases gastric degradation of levodopa and decreases its absorption by reduction of gastric emptying. Antagonises therapeutic effects of cholinergic agents e.g. tacrine, donezepil and neuroleptics. Valerian, St. John's wort, Kava Kava and gotu kola may increase CNS depression.\nPotentially Fatal: Potentiates CNS depression with alcohol, barbiturates, analgesics, sedatives and neuroleptics. Additive antimuscarinic action with MAOIs, atropine and TCAs.\n\nPregnancy category: B\n\nInteraction:  	Masks ototoxicity produced by aminoglycosides. Increases gastric degradation of levodopa and decreases its absorption by reduction of gastric emptying. Antagonises therapeutic effects of cholinergic agents e.g. tacrine, donezepil and neuroleptics. Valerian, St. John's wort, Kava Kava and gotu kola may increase CNS depression.\nPotentially Fatal: Potentiates CNS depression with alcohol, barbiturates, analgesics, sedatives and neuroleptics. Additive antimuscarinic action with MAOIs, atropine and TCAs.
Diphenhydramine Hydrochloride 2% + Zinc Acetate 0.1% Topical	\n\n\tAlco Pharma\tBendil Cream  5gm tube / 10gm tube / 30gm tube 20 / 35 / 55\n\tSquare\tTogent Cream  20 mg + 1 mg/gm 10 gm tube 35.14\n\tIndication: Pruritus, Insect bites, Rashes, Allergic skin conditions\n\nDose: Adults & children above 2 years: Apply to the affected area 3 to 4 times daily. Before application ofcream, the skin should be clean, cool and dry. Should not have a hot shower or bath before applying. Apply the cream lightly on the skin until the cream disappears. It is important to include all skin surfaces, such as between the fingers and toes, under the nails and on the soles of the feet.\n\nContra-indication: Use of cream is contraindicated in individuals with a known allergy\nto its components, other pyrethroids or pyrethrins.\n\nSide effects: Contact dermatitis with mild erythematous vesicular lesions and papules has occasionally been reported.\n\nPrecaution: For external use only. Flammable, keep away from fire or flame.\nDo not use on large areas of the body with any other product\ncontaining diphenhydramine, even once taken by mouth. Consult\nwith the physician before use on chicken pox, on measles. When\nusing this product, avoid contact of eyes.\n\nMode of action:  	Masks ototoxicity produced by aminoglycosides. Increases gastric degradation of levodopa and decreases its absorption by reduction of gastric emptying. Antagonises therapeutic effects of cholinergic agents e.g. tacrine, donezepil and neuroleptics. Valerian, St. John's wort, Kava Kava and gotu kola may increase CNS depression.\nPotentially Fatal: Potentiates CNS depression with alcohol, barbiturates, analgesics, sedatives and neuroleptics. Additive antimuscarinic action with MAOIs, atropine and TCAs.\n\nPregnancy category: A\n\nInteraction:  	Masks ototoxicity produced by aminoglycosides. Increases gastric degradation of levodopa and decreases its absorption by reduction of gastric emptying. Antagonises therapeutic effects of cholinergic agents e.g. tacrine, donezepil and neuroleptics. Valerian, St. John's wort, Kava Kava and gotu kola may increase CNS depression.\nPotentially Fatal: Potentiates CNS depression with alcohol, barbiturates, analgesics, sedatives and neuroleptics. Additive antimuscarinic action with MAOIs, atropine and TCAs.
Dipyridamole	\n\n\tOpsonin Pharma\tPyrintin TAB dr 100mg 50's pack \n\tIndication: Stroke, Thromboembolism, Transient ischaemic attack\n\nDose: Adult: PO Prophylaxis of thromboembolism following cardiac valve replacementW/ an anticoagulant: 300-600 mg/day in divided doses. Secondary prevention of stroke or transient ischaemic attack Extended release 200 mg twice daily.\n\nContra-indication: Hypersensitivity. Peptic ulcer.\n\nSide effects: GI disturbances, headache, dizziness, faintness, facial flushing, skin rash, liver dysfunction, angina. Large doses may lower BP.\nPotentially Fatal: Risk of worsening angina and cardiac arrhythmias when given IV.\n\nPrecaution: In patients with rapidly worsening angina, subvalvular aortic stenosis, haemodynamic instability associated with recent MI or coagulation disorders esp when given IV during myocardial imaging. Hypotension, unstable angina, aortic stenosis. Pregnancy and lactation. Safety and efficacy are not established in childn < 12 yrs.\n\nMode of action: Aminophylline may reverse vasodilatation effect. Useful combination with aspirin in prevention of thromboembolism. Efficacy reduced by concurrent admin of antacids. Concurrent use may increase the cardiotoxic effects of adenosine.\nPotentially Fatal: Potentiates effects of oral anticoagulants and antiarrhythmic agents.\n\nPregnancy category: B\n\nInteraction: Aminophylline may reverse vasodilatation effect. Useful combination with aspirin in prevention of thromboembolism. Efficacy reduced by concurrent admin of antacids. Concurrent use may increase the cardiotoxic effects of adenosine.\nPotentially Fatal: Potentiates effects of oral anticoagulants and antiarrhythmic agents.
Disodium Hydrogen Phosphate Dodecahydrate 24% + Sodium Dihydrogen Phosphate Dihydrate 54.22%	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tPhosphoprep Oral Solution   45ml bot 230\n\tIndication: Constipation, Colonoscopy preparation\n\nDose: It should be prepared when needed by diluting the contents of one bottle of the medicine (45ml) in half a glass (120ml) of cold water. Take  first dose of Fleet phospho-soda  followed by at least one full glass (240ml) of cold water. Take the second dose of Fleet phospho-soda after 12 hours, followed by at least one full glass (240ml) of cold water. Drink more water or clear liquids if you want to, up to midnight.\n\nThe recommended dose as Tablets for colon cleansing for adult patients is 32 tablets (48 grams of sodium phosphate) taken orally with a total of 2 quarts of clear liquids in the following manner:\n\n    The evening before the colonoscopy procedure: Take 4  Tablets with 8 ounces of clear liquids every 15 minutes for a total of 20 tablets.\n\n    On the day of the colonoscopy procedure: Starting 3-5 hours before the procedure, take 4  Tablets with 8 ounces of clear liquids every 15 minutes for a total of 12 tablets.\n\nContra-indication: Contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients.\n\nSide effects: Renal Disease, Acute Phosphate Nephropathy, and Electrolyte Disorders, Seizures, Cardiac Arrhythmias.\n\n\nPrecaution: Each bottle of Fleet phospho-soda must be diluted with water before taking. To avoid dehydration you should make sure that you drink plenty of fluids while taking this medicine and after the procedure.\n\n    It is important to make sure that you will always have access to a toilet after taking a dose of Fleet phospho-soda, as loose bowel motions can start half an hour after taking it.\n    If you don't have a bowel movement within six hours of your first dose if this medicine you should not take any more and consult your doctor immediately.\n\nPatients should be instructed to drink 8 ounces of clear liquids with each 4-tablet dose of  Patients should take a total of 2 quarts of clear liquids with this oral prep. Inadequate fluid intake, as with any effective purgative, may lead to excessive fluid loss, hypovolemia, and dehydration. Dehydration from purgation may be exacerbated by inadequate oral fluid intake, vomiting, and/or use of diuretics.\n\nAdministration of sodium phosphate products prior to colonoscopy for colon cleansing has resulted in fatalities due to significant fluid shifts, severe electrolyte abnormalities, and cardiac arrhythmias. These fatalities have been observed in patients with renal insufficiency, in patients with bowel perforation, and in patients who misused or overdosed sodium phosphate products. It is recommended that patients receiving this be advised to adequately hydrate before, during, and after the use of OsmoPrep.\n\nConsiderable caution should be advised before OsmoPrep Tablets are used in patients with the following illnesses: severe renal insufficiency (creatinine clearance less than 30 mL/minute), congestive heart failure, ascites, unstable angina, gastric retention, ileus, acute bowel obstruction, pseudo-obstruction of the bowel, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome.\n\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Disopyramide	\n\n\tIncepta\tNorbit CAP 100mg 30's pack 240\n\tIndication: Ventricular tachycardia, Supraventricular and Ventricular arrhythmias\n\nDose: Oral\nSupraventricular and ventricular arrhythmias\nAdult: 300-800 mg daily in divided doses (as conventional capsules every 6 hr; as extended-release capsules every 12 hr), adjusted according to patient's response.\n\nChild: 12-18 yr: 6-15 mg/kg daily; 4-12 yr: 10-15 mg/kg daily; 1-4 yr: 10-20 mg/kg daily; <1 yr: 10-30 mg/kg daily.\n\nRenal impairment:\nCrCl (ml/min)	\n>40	        400 mg daily in divided doses.\n30-40	100 mg every 8 hr; avoid modified release preparations.\n15-30	100 mg every 12 hr; avoid modified release preparations.\n<15	        100 mg every 24 hr; avoid modified release preparations.\n\nHepatic impairment: 400 mg daily in divided doses. Liver cirrhosis: consider a therapeutic range 50% lower than in patients with normal hepatic function. \n\nContra-indication: Patients with complete heart block; glaucoma; predisposition to urinary retention; myasthenia gravis. Sinus node disease in absence of pacemaker. Cardiomyopathy. Cardiogenic shock. Hypotension. Hypersensitivity. Children.\n\nSide effects: Impotence, constipation, difficulty in micturition, dry mouth, blurred vision, nausea, bloating, abdominal pain, vomiting, diarrhoea, colic. Psychosis, depression, skin rashes, dizziness, fatigue, muscle weakness, headache, cholestatic jaundice, elevated liver enzymes, thrombocytopenia, agranulocytosis, ventricular tachycardia and fibrillation, heart failure, hypotension, conduction disturbances.\nPotentially Fatal: Urinary retention, severe cardiovascular depression if given as rapid IV inj. High risk of recurrence of failure in patients with history of congestive cardiac failure. Negative inotropic effect especially prominent in patients with cardiomyopathy, hypertension and uncompensated cardiac failure.\n\nPrecaution: Conduction disorders or uncompensated heart failure. Pregnancy and lactation. Renal and hepatic failure. Family history of glaucoma. Correct potassium deficiency.\n\nMode of action: Avoid other Class I antiarrhythmics and other cardiac depressants including ?-blockers except in life-threatening arrhythmias. Risk of worsening of arrhythmias, precipitation of new arrhythmias and ventricular fibrillation when used with other anti-arrhythmics. Reduced efficacy when co-admin with phenytoin.\nPotentially Fatal: Enhanced antimuscarinic effects with other antimuscarinic drugs. Potentiates negative chronotropic and inotropic effects of ?-blockers and verapamil. Potentiates inhibitory effect on the conduction system produced by digitalis. Potentiates QT interval prolongation produced by TCAs and amiodarone.\n\nPregnancy category: C\n\nInteraction: Avoid other Class I antiarrhythmics and other cardiac depressants including ?-blockers except in life-threatening arrhythmias. Risk of worsening of arrhythmias, precipitation of new arrhythmias and ventricular fibrillation when used with other anti-arrhythmics. Reduced efficacy when co-admin with phenytoin.\nPotentially Fatal: Enhanced antimuscarinic effects with other antimuscarinic drugs. Potentiates negative chronotropic and inotropic effects of ?-blockers and verapamil. Potentiates inhibitory effect on the conduction system produced by digitalis. Potentiates QT interval prolongation produced by TCAs and amiodarone.
Dithranol 1% Topical	\n\n\tSquare\tMicanol Cream 1% 1's pack(50g) \n\tIndication: Psoriasis\n\nDose: Adult: Topical As 0.1% oint/paste: Apply for a few hr before washing off once daily.\n\nContra-indication: Acute or pustular psoriasis. Inflamed skin. Hypersensitivity.\n\nSide effects: Burning sensation and irritation esp on perilesional skin. Hair and skin discoloration.\n\nPrecaution: Avoid use on face, skin flexures, inner thighs, upper arms and genitals. Avoid contact with eyes and mucous membranes.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Dobutamine	\n\n\tACI\tDobumin Injection 12.5mg/ml 1's pack 251.69\n\tIncepta\tDobutin Injection 250mg/20ml 1's pack 250\n\tUnimed & Unihealth Manufacturers Ltd.\tDobutamine Hcl Injection 250mg/20ml 1's pack 375\n\tLaboratories Panpharma, France\tDobutamine Panpharma Infusion 250mg/20ml 1 vial 285\n\tIndication: Heart failure, Cardiac stress test\n\nDose: Adult: IV Acute heart failure 2.5-10 mcg/kg, up to 0.5-40 mcg/kg according to response. \n\nCardiac stress test As 1 mg/mL soln: 5 mcg/kg/min for 8 mins, increase dose at 5 mcg/kg/min until 20 mcg/kg/min, w/ each dose being infused for 8 mins before the next increase.\n\nBecause of its short half-life, Dobutamine Hydrochloride must be administered as a continuous intravenous infusion. Following the initiation of a constant rate infusion, or upon changing the rate, a steady-state dobutamine plasma concentration is achieved within approximately 10 minutes. Thus, loading doses or bolus injections are not necessary and are not recommended. \n\nRecommended Dosage The rate of infusion needed to increase cardiac output has ranged from 2.5 to 10 mcg/kg/min in the majority of patients. Frequently, doses up to 20 mcg/kg/min are required for adequate haemodynamic improvement. \n\nThe rate of administration and the duration of therapy should be adjusted according to the patient's response, The indicators are: haemodynamic parameters such as heart rate and rhythm, arterial pressure, and, whenever possible, cardiac output and measurements of ventricular filling pressures and signs of pulmonary congestion. \n\nConcentrations up to 5,000 mg/L have been administered to humans. The final volume administered should be determined by the fluid requirements of the patient. Rather than abruptly discontinuing therapy with Dobutamine Hydrochloride, it is often advisable to decrease the dosage gradually. Rates of Infusion Based on Concentration of Dobutamine Hydrochloride The rates of fluid infusion that are required to deliver specific dosages are a function of the concentration of Dobutamine Hydrochloride in the infusate.\n\n\nContra-indication: Hypersensitivity; idiopathic hypertrophic subaortic stenosis (IHSS).\n\nSide effects: Increased heart rate and BP, ectopic beats, palpitation. Nausea, headache, chest pain, palpitation, dyspnoea, paraesthesia, leg cramps. Tissue necrosis at site of extravasation.\nPotentially Fatal: Cardiac arrhythmias, allergy (rare), MI and hypotension.\n\nPrecaution: Correct hypovolaemia prior to treatment. Increased risk of rapid ventricular response in patients with atrial fibrillation. Insufficient data to determine the safety and efficacy of dobutamine use after acute MI. Elderly. Neonates. Pregnancy.\n\nMode of action: Increased cardiac output when used with nitroprusside. Increased vasopressor effect of dobutamine when used with bretylium, guanethidine, oxytocic drugs or TCAs.\n\nPregnancy category: B\n\nInteraction: Increased cardiac output when used with nitroprusside. Increased vasopressor effect of dobutamine when used with bretylium, guanethidine, oxytocic drugs or TCAs.
Docetaxel	\n\n\tBeacon\tDocexan Injection 20mg/0.5ml 0.5 ml vial with solvent 4000\n\tBeacon\tDocexan Injection 80mg/2ml 2 ml vial with solvent 14500\n\tSanofi Aventis (BD) Ltd.\tTexotere Injection 20mg 1's pack 6991\n\tTechno Drugs Ltd.\tDocetax Injection 80mg/2ml 1's pack 14000\n\tTechno Drugs Ltd.\tDocetax Injection 20mg/0.5ml 1's pack 4000\n\tAventis Pharma, UK\tTaxotere Infusion 20mg/0.5ml 0.5 ml vial with solvent 6305\n\tIndication: Breast cancer, Lung cancer, Prostate cancer, Stomach cancer, Head/neck cancer\n\nDose: Adult: IV Breast cancer Initial: 60-100 mg/m2 once 3 wkly as a single agent. \nGastric adenocarcinoma; Head and neck cancer; Non-small cell lung cancer; Prostate cancer 75 mg/m2 once 3 wkly.\n\nContra-indication: Previous severe hypersensitivity reaction to docetaxel, the solvent or polysorbate 80. Severe neutropenia; pregnancy, severe liver impairment.\n\nSide effects: Erythematous patches, eruptions, scleroderma, onycholysis, alopoecia, nausea, vomiting, diarrhoea, stomatitis; increases in hepatic transaminases, bilirubin and alkaline phosphatase; mucositis, asthenia, arthralgia, myalgia, paroxysmal atrial tachycardia, atrial flutter, dysrrhythmia, hypertension and heart failure.\nPotentially Fatal: Neutropenia; fluid retention syndrome; anaemia.\n\nPrecaution: Lactation. Hepatic impairment. Monitor liver blood function and blood counts regularly. Premedication with oral dexamethsaone at 16 mg daily for 3 days, starting one day before docetaxel treatment is recommended.\n\nMode of action: CYP3A4 inducers, inhibitors, or substrates may alter docetaxel metabolism.\n\nPregnancy category: D\n\nInteraction: CYP3A4 inducers, inhibitors, or substrates may alter docetaxel metabolism.
Docosanol 10%	\n\n\tIncepta\tLafrost Cream   5gm  tube 50\n\tIndication: Cold sores, Herpes labialis, Fever blisters\n\nDose: Apply docosanol topical in a quantity sufficient to cover the affected lesions and immediately surrounding skin 5 times a day until the lesions are healed\n\nContra-indication: Hypersensitivity.\n\nSide effects:  Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).\n\nPrecaution: Do not share this product with anyone. This may spread infection.\nStop using docosanol  if  cold sore gets worse or is not healed within 10 days.\nDocosanol is not recommended for use in CHILDREN younger than 12 years of age. Safety and effectiveness in this age group have not been confirmed.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Domperidone	\n\n\tACI\tVave TAB dr 10mg 150's pack 303\n\tACI\tVave Suspension 5mg/5ml 60ml bot/100ml bot 35.11/40.12\n\tACI\tVave Paediatric Drops 5mg/ml 15ml drop 25.08\n\tACI\tVave ODT TAB dr 10mg 100's pack 502\n\tAcme Ltd.\tDon A Suspension 5mg/5ml 30ml bot/60ml bot 25.10/28.10\n\tAcme Ltd.\tDon A Paediatric Drops 5mg/ml 15ml drop 20.07\n\tAcme Ltd.\tDon A TAB dr 10mg 100's pack 201\n\tAcme Ltd.\tDon A Suppository 15mg 10's pack 50.10\n\tAcme Ltd.\tDon A Suppository 30mg 10's pack 80.4\n\tAd-din\tGutset TAB dr 10mg 100's pack 171\n\tAd-din\tGutset Suspension 5mg/5ml 15ml  20\n\tAd-din\tGutset Paediatric Drops 5mg/ml 15ml drop 18.28\n\tAlbion Ltd.\tDomp TAB dr 10 mg 100's pack \n\tAlbion Ltd.\tDomp Suspension 5 mg/ 5 ml 100 ml \n\tAlco Pharma\tDompi Suspension 5mg/5ml 60ml bot 28\n\tAlco Pharma\tDompi TAB dr 10mg 100's pack 200\n\tAmbee\tAdorex TAB dr 10mg 100's pack 96\n\tAmbee\tAdorex Suspension 5mg/5ml 60ml bot/100ml bot 28.10/38.14\n\tAmbee\tAdorex Paediatric Drops 5mg/ml 15ml drop 20.07\n\tAmico Ltd.\tXepadon Suspension 5mg/5ml 60ml bot 25\n\tAmico Ltd.\tXepadon TAB dr 10mg 50's pack 100\n\tAmico Ltd.\tXepadon Paediatric Drops 5mg/ml 15ml drop 18\n\tAPC Pharma Ltd.\tDomstal TAB dr 10mg 50's pack 100\n\tAPC Pharma Ltd.\tDomstal Suspension 5mg/5ml 60ml bot 28\n\tApex\tProtix TAB dr 10mg 100's pack 100\n\tApex\tProtix Suspension 5mg/5ml 100ml bot 25\n\tApex\tProtix Paediatric Drops 5mg/ml 15ml bot 20\n\tApex\tFixgut TAB dr 10mg  \n\tApex\tFixgut Suspension 5 mg/5 ml  \n\tApollo Pharmaceutical Ltd.\tApedom TAB dr 10mg 100's pack 200\n\tApollo Pharmaceutical Ltd.\tApedom Suspension 5mg/5ml 60ml bot 27\n\tAristopharma\tApuldon TAB dr 10mg 100's pack 200\n\tAristopharma\tApuldon Suspension 5mg/5ml 60ml bot 35\n\tAristopharma\tApuldon Paediatric Drops 5mg/ml 15ml drop 25\n\tAristopharma\tApuldon Suppository 15mg 10's pack 60\n\tAristopharma\tApuldon Suppository 30mg 10's pack 90\n\tAsiatic Ltd.\tAtidon TAB dr 10mg 50's pack 100\n\tAsiatic Ltd.\tAtidone Suspension 5mg/5ml 60ml bot 28\n\tAstra Biopharmaceuticals Ltd.\tPeridone TAB dr 10mg 30's pack 60\n\tBeacon\tNoburn TAB dr 10mg 100's pack 200\n\tBelsen\tBeridom TAB dr 10mg 100's pack 200\n\tBelsen\tBeridom Syrup 5mg/5ml 60ml bot 28\n\tBengal Drugs & Chemical Works Pharm. Ltd.\tBedom TAB dr 10mg 100's pack 200\n\tBengal Drugs & Chemical Works Pharm. Ltd.\tBedom Suspension 5mg/5ml 60ml bot 28\n\tBeximco\tDeflux TAB dr 10mg 150's pack 375\n\tBeximco\tDeflux Suspension 5mg/5ml 100ml bot 38\n\tBeximco\tDeflux Paediatric Drops 5mg/ml 15ml drop 20\n\tBeximco\tDeflux DT TAB dr 20mg 100's pack 200\n\tBio Pharma Ltd.\tEsogut TAB dr 10mg 100's pack 201\n\tBio Pharma Ltd.\tEsogut Suspension 5mg/5ml 60ml bot 28.11\n\tBio Pharma Ltd.\tEsogut Paediatric Drops 5mg/ml 15ml drop 20.08\n\tBristol Pharma Ltd.\tBpdon TAB dr 10mg 100's pack 100\n\tCentral.\tDP DONE TAB dr 10mg 100's pack 200\n\tCentral.\tDP DONE Suspension 5mg/5ml 60ml bot 28\n\tChemist Ltd.\tAvomit TAB dr 10mg 100's pack 200\n\tChemist Ltd.\tAvomit Suspension 5mg/5ml 60ml bot 28\n\tConcord\tDopagut TAB dr 10mg 50's pack 100\n\tConcord\tDopagut Suspension 5mg/5ml 60ml bot 28\n\tCosmic Chemical Industries Ltd.\tEmedon TAB dr 10mg 100's pack 154\n\tCosmo Pharma Ltd.\tCpdom TAB dr 10mg 100's pack 200\n\tDecent Pharma Ltd.\tDedom TAB dr 10mg 100's pack 190\n\tDecent Pharma Ltd.\tDedom Suspension 5mg/5ml 60ml bot 28\n\tDelta Pharma\tDegut TAB dr 10mg 100's pack 200\n\tDelta Pharma\tDegut Suspension 5mg/5ml 60ml bot 28\n\tDesh\tOmid TAB dr 10mg 100's pack 150\n\tDesh\tOmid Suspension 5mg/5ml 60ml bot 28\n\tDoctor's Chemicals Works Ltd.\tEridon Suspension 5mg/5ml 60ml bot 25\n\tDoctor's Chemicals Works Ltd.\tEridon TAB dr 10mg 100's pack 100\n\tDrug International Ltd.\tParidon Suspension 5mg/5ml 100ml bot 32\n\tDrug International Ltd.\tParidon TAB dr 10mg 100's pack 200\n\tEdruc Ltd.\tMerin TAB dr 10mg 100's pack 150\n\tEdruc Ltd.\tMerin Suspension 5mg/5ml 100ml bot 38\n\tEskayef Bangladesh Ltd.\tRidon TAB dr 10mg 100's pack 200\n\tEskayef Bangladesh Ltd.\tRidon Suspension 5mg/5ml 60ml bot 28\n\tEskayef Bangladesh Ltd.\tRidon Paediatric Drops 5mg/ml 15ml drop 20\n\tEthical Drug Ltd.\tMotilium TAB dr 10mg 100's pack 200\n\tEuro Pharma Ltd.\tEgut TAB dr 10mg 100's pack 200\n\tEuro Pharma Ltd.\tEgut Suspension 5mg/5ml 60ml bot 35\n\tEverest\tEvdom TAB dr 10mg 100's pack 150\n\tEverest\tEvdom Suspension 5mg/5ml 60ml bot 28\n\tGeneral\tDomilin TAB dr 10mg 100's pack 201\n\tGeneral\tDomilin Suspension 5mg/5ml 100ml bot 40.15\n\tGlobe\tPerion TAB dr 10mg 100's pack 200\n\tGlobe\tPerion Suspension 5mg/5ml 60ml bot/100ml bot 28/38\n\tGlobex\tMotistat Suspension 5 mg/5 ml 60ml 30\n\tGlobex\tMotistat TAB dr 10mg 100's pack 250\n\tHallmark\tMotil TAB dr 10mg 100's pack 201\n\tHallmark\tMotil Suspension 5mg/5ml 100ml bot 28\n\tHudson\tPeri TAB dr 10mg 100's pack 200\n\tHudson\tPeri Suspension 5mg/5ml 100ml bot 35\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDopadon TAB dr 10mg 100's pack 225\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDopadon Suspension 5mg/5ml 60ml bot 30\n\tIncepta\tOmidon TAB dr 10mg 100's pack 200\n\tIncepta\tOmidon Suspension 5mg/5ml 60ml bot/100ml bot 28/38\n\tIncepta\tOmidon Paediatric Drops 5mg/ml 15ml drop 20\n\tIncepta\tOmidon D TAB dr 20mg 100's pack 200\n\tIndobangla Pharmaceuticals\tI-Pedom TAB dr 10mg 100's pack 150\n\tIndobangla Pharmaceuticals\tI-Pedom Suspension 5mg/5ml 60ml bot 28\n\tJayson\tLoval TAB dr 10mg 100's pack 201\n\tJayson\tLoval Suspension 5mg/5ml 60ml bot/100ml bot 28.10/38.15\n\tKemiko\tAnet TAB dr 10mg 100's pack 200\n\tKemiko\tAnet Suspension 5mg/5ml 60ml bot 35\n\tKumudini Pharma Ltd.\tDudon TAB dr 10mg 100's pack 200\n\tKumudini Pharma Ltd.\tDudon 100 Suspension 5mg/5ml 60ml bot 28\n\tLabaid\tDomaid TAB dr 10mg  \n\tMarksman.\tMotilant Suspension 5mg/5ml 60ml bot 27\n\tMarksman.\tMotilant TAB dr 10mg 100's pack 100\n\tMedicon\tDoridon TAB dr 10mg 100's pack 200\n\tMedicon\tDoridon Paediatric Drops 5mg/ml 15ml drop 25\n\tMedimet\tMotidom TAB dr 10mg 50's pack 75\n\tMillat\tDompen TAB dr 10mg 100's pack 200\n\tModern\tLoridon TAB dr 10mg 100's pack 200\n\tModern\tLoridon Suspension 5mg/5ml 60ml bot 28\n\tModern\tLoridon Paediatric Drops 5mg/ml 15ml drop 20\n\tMonicopharma\tVomino TAB dr 10mg 100's pack 200\n\tMonicopharma\tVomino Suspension 5mg/5ml 60ml bot 28\n\tMystic\tMotiper TAB dr 10mg 50's pack 100\n\tMystic\tMotiper Suspension 5mg/5ml 60ml bot 28\n\tNavana\tVomitop TAB dr 10mg 100's pack 120\n\tNavana\tVomitop Suspension 5mg/5ml 60ml bot 24.09\n\tNavana\tVomitop Paediatric Drops 5mg/ml 15ml drop 20.08\n\tNipa\tDominat TAB dr 10mg 100's pack 200\n\tNipa\tDominat Suspension 5mg/5ml 60ml bot 27\n\tNIPRO JMI Pharma\tProkinet Suspension 5mg/5ml 60ml bot 35\n\tNIPRO JMI Pharma\tProkinet TAB dr 10mg 100's pack 201\n\tNovelta Bestway\tGidonic TAB dr 10mg 10's pack 200\n\tNovelta Bestway\tGidonic Suspension 5mg/5ml 60ml bot 28\n\tNovo Healthcare and Pharma Ltd.\tMotigen TAB dr 10mg 100's pack 100\n\tNuvista Pharma Ltd\tSagdon TAB dr 10mg  \n\tOpsonin Pharma\tDomin TAB dr 10mg 100's pack 200\n\tOpsonin Pharma\tDomin Suspension 5mg/5ml 60ml bot 28\n\tOpsonin Pharma\tDomin Paediatric Drops 5mg/ml 15ml drop 20\n\tOpsonin Pharma\tDomin Suppository 15mg 10's pack 50.20\n\tOpsonin Pharma\tDomin Suppository 30mg 10's pack 80.30\n\tOrganic Health Care\tNudon TAB dr 10mg 100's pack 200\n\tOrion Pharma Ltd.\tCosy TAB dr 10mg 100's pack 201\n\tOrion Pharma Ltd.\tCosy Suspension 5mg/5ml 60ml bot/100ml bot 28.10/38.14\n\tOyster\tDomider Suspension 5 mg/5 ml 1's pack 28\n\tPacific\tDomar TAB dr 10mg 100's pack 300\n\tPacific\tDomar Suspension 5mg/5ml 60ml bot/100ml bot 25/40\n\tPeoples Pharma Ltd.\tMyodon TAB dr 10mg 100's pack 150\n\tPharmadesh Ltd.\tP Don Suspension 5mg/5ml 60ml bot 27\n\tPharmadesh Ltd.\tP Don TAB dr 10mg 100's pack 150\n\tPharmasia Ltd.\tVegadon TAB dr 10mg 100's pack 200\n\tPharmasia Ltd.\tVegadon Suspension 5mg/5ml 60ml bot 28.10\n\tPopular\tDomilux TAB dr 10mg 200's pack 301.91\n\tPopular\tDomilux Suspension 5mg/5ml 60ml bot 35\n\tPrime\tPridon TAB dr 10mg  \n\tRadiant.\tEfodio TAB dr 10mg  \n\tRAK\tXeridon TAB dr 10mg 100's pack 200\n\tRAK\tXeridon Suspension 5mg/5ml 100's pack 200\n\tRangs\tNormogut TAB dr 10mg 50's pack 100\n\tRangs\tNormogut Suspension 5mg/5ml 100ml bot 38\n\tReliance\tRegut TAB dr 10mg 100's pack 206\n\tReman Drug Ltd.\tRemadon TAB dr 10mg 100's pack 195\n\tRenata\tDomiren Suspension 5mg/5ml 100ml 38\n\tRenata\tDomiren Paediatric Drops 5mg/ml 15ml drop 25\n\tRenata\tDomiren TAB dr 10mg 100's pack 201\n\tRephco\tGidora TAB dr 10mg 100's pack 200\n\tRephco\tGidora Suspension 5mg/5ml 60ml bot 28\n\tS. N.\tPerigut TAB dr 10mg 50's pack 100\n\tSanofi Aventis (BD) Ltd.\tSandom Suspension 5mg/5ml 60ml bot 28.10\n\tSanofi Aventis (BD) Ltd.\tSandom Paediatric Drops 5mg/ml 15ml drop 20.07\n\tSanofi Aventis (BD) Ltd.\tSandom TAB dr 10mg 100's pack 201\n\tSeema\tDompa S TAB dr 10mg 100's pack 200\n\tSeema\tDompa S Suspension 5mg/5ml 60ml bot 28\n\tShamsul Al-Amin\tDopon TAB dr 10mg 50's pack 50\n\tSharif\tMotinorm TAB dr 10mg 100's pack 200\n\tSilva\tDomsil TAB dr 10mg 100's pack 200.75\n\tSilva\tDomsil Suspension 5mg/5ml 60ml bot/100ml bot 28.10/38.14\n\tSilva\tDomsil DT TAB dr 20mg 100's pack 200.75\n\tSkylab Ltd.\tSkydon TAB dr 10mg 100's pack 200\n\tSomatec\tEmidom TAB dr 10mg 100's pack 201\n\tSomatec\tEmidom Suspension 5mg/5ml 60ml bot/100ml bot 28.11/38\n\tSomatec\tEmidom Paediatric Drops 5mg/ml 15ml drop 20.08\n\tSquare\tMotifast TAB dr 10mg 100's pack 250\n\tSquare\tMotigut TAB dr 10mg 150's pack 375\n\tSquare\tMotigut Suspension 5mg/5ml 60ml bot 28.10\n\tSquare\tMotigut Paediatric Drops 5mg/ml 15ml drop 20.08\n\tSupreme\tAdegut TAB dr 10mg 50's pack 100\n\tSupreme\tAdegut Suspension 5mg/5ml 60ml bot 28\n\tSyntho Ltd.\tSydon TAB dr 10mg 100's pack 200\n\tSyntho Ltd.\tSydon Suspension 5mg/5ml 60ml bot 27\n\tTechno Drugs Ltd.\tMotilex TAB dr 10mg 50's pack 75\n\tTechno Drugs Ltd.\tMotilex Suspension 5mg/5ml 60ml bot 35\n\tUnimed & Unihealth Manufacturers Ltd.\tDysnov TAB dr 10mg 50's pack 100\n\tUnimed & Unihealth Manufacturers Ltd.\tDysnov Suspension 5mg/5ml 100ml bot 38\n\tUnimed & Unihealth Manufacturers Ltd.\tDysnov Paediatric Drops 5mg/ml 15ml drop 20\n\tUnited Chemicals &\tDoperon TAB dr 10mg 100's pack 200\n\tUnited Chemicals &\tDoperon Suspension 5mg/5ml 15ml bot 25\n\tWhite Horse Pharma\tDominol TAB dr 10mg 100's pack 200\n\tZenith\tEdone TAB dr 10mg 100's pack 200\n\tZenith\tEdone 100 Suspension 5mg/5ml 60ml bot/100ml bot 28/38\n\tZiska\tDomidon TAB dr 10mg 100's pack 200\n\tZiska\tDomidon Syrup 5mg/5ml 60ml bot 28\n\tIndication: Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia\n\nDose: Adults : 10 - 20 mg every 4 - 8 hours daily\nChildren : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.\n\nNausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day. \nNon ulcer dyspepsia 10-20 mg 3 times/day and at night. \nMigraine 20 mg 4 hrly. Max: 4 doses/24 hr. \n\nRectal: Nausea and vomiting 60 mg twice daily.\n\nContra-indication: Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.\n\nSide effects: Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.\nPotentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.\n\nPrecaution: Phaeochromocytoma; children<2 yr, elderly; renal or hepatic impairment. Risk of cardiac arrhythmias and hypokalaemia if administered IV. Pregnancy and lactation.\n\nMode of action: May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.\nPotentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.\n\nPregnancy category: C\n\nInteraction: May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.\nPotentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
Donepezil Hydrochloride	\n\n\tBeximco\tMemorin TAB dr 5mg 30's pack 300\n\tIncepta\tAmeloss 5 TAB dr 5mg 30's pack 300\n\tSquare\tElzer TAB dr 5mg 30's pack 301.24\n\tIndication: Mild to moderately severe dementia in Alzheimer's disease.\n\nDose: Adult: PO Initial: 5 mg/day in the evening, up to 10 mg/day after 4-6 wk. The 5 mg (1 tab)/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. \n\nFollowing a one-month clinical assessment of treatment at 5 mg/day, the dose can be increased to 10 mg/day (once-a-day dosing). Since food does not affect the rate or extent of absorption of donepezil, it can be administered with or without food. \n\nIn case of renal & hepatic impairment: A similar dose schedule can be followed for patients with renal or mild to moderate hepatic impairment as clearance of donepezil hydrochloride is not affected by these conditions. \n\nIn case of children: There are no adequate and well controlled trials in document to safety and efficacy of donepezil hydrochloride in any illness occurring in children. Donepezil is not recommended for use in children.\n\n\nContra-indication: Donepezil is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.\n\nSide effects: Nausea, vomiting, anorexia, wt loss, diarrhoea, insomnia, fatigue, muscle cramps; headache and dizziness; syncope, bradycardia; convulsions; increased liver transaminases; sinoatrial and atrioventricular block; hallucinations, agitation and aggressive behavior; minor increases in plasma creatine kinase; potentially bladder outflow obstruction.\n\nPrecaution: Caution when used in patients with sick sinus syndrome or cardiac conduction abnormalities. May increase secretion of gastric acid; caution when used in patients at risk of ulcer disease. Patients with COPD, asthma, history of epilepsy, bladder obstruction, prostatic hypertrophy. May cause dose-related diarrhoea, nausea and/or vomiting which usually resolves after 1-3 wk. Safety and efficacy have not been established in children. Pregnancy, lactation.\n\nMode of action: May increase the neurotoxic effect of antipsychotics. Concurrent use with systemic corticosteroids may increase the adverse effects of donepezil. May increase the neuromuscular-blocking effect of succinylcholine. May increase the adverse effects of cholinergic agonists. May increase the bradycardic effect of ?-blockers.\n\nPregnancy category: C\n\nInteraction: May increase the neurotoxic effect of antipsychotics. Concurrent use with systemic corticosteroids may increase the adverse effects of donepezil. May increase the neuromuscular-blocking effect of succinylcholine. May increase the adverse effects of cholinergic agonists. May increase the bradycardic effect of ?-blockers.
Dopamine Hydrochloride	\n\n\tACI\tCardopa Injection 200mg/5ml 5 amps pack 226.55\n\tDrug International Ltd.\tD-Dopamine Injection 200mg/5ml 3 amps pack 135\n\tIncepta\tMyomine Injection 200mg/5ml 5 amps pack 225\n\tLes Servier Industrie,France\tSterile Dopamine Concentrate Infusion 200mg/5ml  .70\n\tRotexmedica GmbH, Germany\tDopamine-Rotex Injection 200mg/5ml 10 amps pack 600\n\tIndication: Shock, Acute heart failure, Hypotension\n\nDose: Adult: IV Initial: 1-5 mcg/kg/min, up to 5-10 mcg/kg/min according to patient's response. For seriously ill patients: up to 20-50 mcg/kg/min may be used.\n\nContra-indication: Pheochromocytoma, uncorrected tachyarrhythmias, ventricular fibrillation. Hypersensitivity.\n\nSide effects: Nausea, vomiting, tachycardia, ectopic beats, palpitation, anginal pain, hypotension, vasoconstriction, bradycardia, hypertension, dyspnoea, headache, widened QRS complexes, azotaemia.\n\nPrecaution: Shock secondary to MI, history of peripheral vascular disease. Correct hypovolaemia before infusion. History of occlusive vascular disease e.g, atherosclerosis, Raynaud's disease, Buerger's disease, diabetic endarteritis; disproportionate increase in diastolic pressure. Pregnancy.\n\nMode of action: Cyclopropane and halogenated hydrocarbon anaesthetics may sensitise myocardium to dopamine and precipitate ventricular arrhythmias. MAO inhibitors prolong and increase dopamine effects. Ergots potentiate vasoconstriction action of dopamine. Alpha-blockers unmask dopamine's beta action.\n\nPregnancy category: C\n\nInteraction: Cyclopropane and halogenated hydrocarbon anaesthetics may sensitise myocardium to dopamine and precipitate ventricular arrhythmias. MAO inhibitors prolong and increase dopamine effects. Ergots potentiate vasoconstriction action of dopamine. Alpha-blockers unmask dopamine's beta action.
Doripenem	\n\n\tACI\tDorinem Injection 500mg/vial 1's pack 2006.02\n\tEskayef Bangladesh Ltd.\tDoripen Injection 500mg 1's pack 2000\n\tUnimed & Unihealth Manufacturers Ltd.\tDoribax Injection  10's amps pack 25953\n\tIndication: Intra-abdominal infections, Bacterial infections, Septicemia, Nosocomial pneumonia, Urinary tract infections, Pyelonephritis\n\nDose: Adult: IV Complicated intra-abdominal infections; Complicated urinary tract infection; Pyelonephritis; Nosocomial pneumonia. 500 mg 8 hrly. Treatment duration: May range from 5-14 days.\n\nRenal impairment:\nCrCl (ml/min)	\n30-50	250 mg every 8 hr by IV infusion over 1 hr\n11-29	250 mg every 12 hr by IV infusion over 1 hr \n\nContra-indication: Hypersensitivity; anaphylactic reactions to beta-lactams.\n\nSide effects: Headache, nausea, diarrhoea, rash, phlebitis, elevated hepatic enzymes, oral candidiasis, anaemia, vulvomycotic infection, renal impairment, neutropenia, leucopenia, thrombocytopenia.\nPotentially Fatal: Anaphylaxis, toxic epidermal necrolysis, Stevens-Johnson Syndrome, interstitial pneumonia, seizure.\n\nPrecaution: May decrease serum concentration of valproic acid to below therapeutic range thus increasing risk of breakthrough seizure; consider alternative antimicrobial agents or additional anti-seizure medications if concurrent usage is necessary. Prolonged use may result in Clostridium difficile-associated diarrhoea (CDAD). May cause development of drug-resistant bacteria when used in the absence of proven or strongly suspected bacterial infection. Renal impairment. Safety and efficacy have not been established in patients <18 yr old.\n\nMode of action: Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.\n\nPregnancy category: B\n\nInteraction: Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
Dorzolamide 2% + Timolol 0.5% Eye prep	\n\n\tAristopharma\tCozopt Eye Drops   5ml bot 550\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAzopt Eye Drops (2 gm + 500 mg)/100 ml  \n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: Adult: As soln containing timolol 0.5% and dorzolamide 2%: Instill 1 drop twice daily.\n\nRenal impairment:\nCrCl (ml/min)	\n<30 	Not recommended. \n\nContra-indication: Hypersensitivity to any of the components or sulphonamide. History or current bronchial asthma, severe COPD, sinus bradycardia, 2nd or 3rd degree AV block, overt cardiac failure, cardiogenic shock, CrClr <30 ml/min and hyperchloraemic acidosis.\n\nSide effects: Ocular irritation, burning, stinging, itching and tearing; conjunctival inj, eyelid inflammation or irritation, corneal erosion, blurred vision, headache, sinusitis, taste perversion, nausea, fatigue.\nPotentially Fatal: Cardiac failure, bronchospasm.\n\nPrecaution: Hepatic impairment, mild to moderate renal impairment, children <2 yr. Avoid use in pregnancy and lactation. Prinzmetal's angina, cardiac disease, hypotension, myasthenia gravis, history of renal calculi, history of intra-ocular surgery, pre-existing chronic corneal defects. May worsen severe peripheral and central circulatory disorders. May mask symptoms of hypoglycaemia and hyperthyroidism. Withdraw gradually, especially in patients with coronary heart disease. Discontinue treatment at the first signs or symptoms of cardiac failure. Contact lenses to be removed before eyedrop application and wait at least 15 minutes before reinsertion. Apply other eyedrops 10 minutes apart. May affect ability to drive or operate machinery as it may cause blurred vision.\n\nMode of action: Additive hypotension and bradycardia with oral calcium channel blockers, catecholamine-depleting drugs or ?-blockers, antiarrhythmics (e.g. amiodarone), digitalis glycosides, parasympathomimetics, narcotics and MAOIs. Additive systemic side effects with oral carbonic anhydrase or ?-blockers; avoid concurrent use. Additive systemic ?-blockade with CYP2D6 inhibitors (e.g. quinidine, SSRIs) and timolol.\n\nPregnancy category: C\n\nInteraction: Additive hypotension and bradycardia with oral calcium channel blockers, catecholamine-depleting drugs or ?-blockers, antiarrhythmics (e.g. amiodarone), digitalis glycosides, parasympathomimetics, narcotics and MAOIs. Additive systemic side effects with oral carbonic anhydrase or ?-blockers; avoid concurrent use. Additive systemic ?-blockade with CYP2D6 inhibitors (e.g. quinidine, SSRIs) and timolol.
Doxepin	\n\n\tApex\tAdnor CAP 75mg 28's pack 140\n\tBeacon\tSlipaid TAB dr 3mg  \n\tBeacon\tSlipaid TAB dr 6mg  \n\tIndication: Anxiety disorders, Depression, Insomnia\n\nDose: Adult: PO Initial: 75 mg/day, up to 300 mg/day in severely depressed patients. Total daily dose >100 mg should be given in divided doses\n\nContra-indication: Hypersensitivity; mania, glaucoma, neonates (topical); lactation.\n\nSide effects: Drowsiness, dizziness, confusion, headache, dry mouth, constipation, blurring of vision, hypotension, tachycardia, rashes. Topical: Burning, stinging, scaling, oedema and dryness.\n\nPrecaution: Epilepsy, CV disease, pregnancy, history of urinary retention, glaucoma; gradual withdrawal. May impair ability to drive or operate machinery.\n\nMode of action: Methylphenidate may increase plasma doxepin levels.\nPotentially Fatal: Potentiates hypertensive action of sympathomimetics. Increased anticholinergic effects with MAOIs. Additive CNS effects with anticholinergics, CNS depressants and alcohol.\n\nPregnancy category: C\n\nInteraction: Methylphenidate may increase plasma doxepin levels.\nPotentially Fatal: Potentiates hypertensive action of sympathomimetics. Increased anticholinergic effects with MAOIs. Additive CNS effects with anticholinergics, CNS depressants and alcohol.
Doxepin 5% Topical	\n\n\tIncepta\tDoxiderm Cream  50mg/1g 30g 120\n\tIndication: Pruritus, Chronic idiopathic urticaria (hives), Atopic dermatitis, lichen simplex chronicus\n\nDose: Adult and child over 12 years: apply thinly 3-4 times daily; usual max. 3 g per application; usual total max. 12 g daily; coverage should be less than 10% of body surface area.\n\nUse in Children:\nThe use of Doxiderm cream in pediatric patients is not recommended. Safe conditions for use of cream in children have not been established.\n\nUse in Elderly Patients:\nDose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.\n\nContra-indication: Patients with untreated narrow angle glaucoma or a tendency to urinary retention because doxepin HCl has an anticholinergic effect\n\nIndividuals who have shown previous sensitivity to any of its components\n\nSide effects: Drowsiness, local burning, stinging, irritation, tingling, rash; systemic side-effects such as antimuscarinic effects, headache, fever, dizziness, gastro-intestinal disturbances has been reported.\n\nPrecaution: Cautions should be exercised if there is susceptibility to angle-closure glaucoma, urinary retention, severe liver impairment, mania and also in pregnancy and breast-feeding. Drowsiness may affect performance of skilled tasks (e.g. driving) so patient should be careful.\n\nMode of action: Methylphenidate may increase plasma doxepin levels.\nPotentially Fatal: Potentiates hypertensive action of sympathomimetics. Increased anticholinergic effects with MAOIs. Additive CNS effects with anticholinergics, CNS depressants and alcohol.\n\nPregnancy category: B\n\nInteraction: Methylphenidate may increase plasma doxepin levels.\nPotentially Fatal: Potentiates hypertensive action of sympathomimetics. Increased anticholinergic effects with MAOIs. Additive CNS effects with anticholinergics, CNS depressants and alcohol.
Doxycycline	\n\n\tACI\tImpedox CAP 100mg 100's pack 217\n\tAcme Ltd.\tDoxy A CAP 100mg 100's pack 219\n\tAexim\tDelacin CAP 100mg 100's pack 150\n\tAlbion Ltd.\tDycap CAP 100 mg 100's pack \n\tAlco Pharma\tDoxcline CAP 100mg 100's pack 200\n\tAmbee\tDoxilin CAP 100mg 100's pack 213\n\tAmico Ltd.\tMonadox CAP 100mg 100's pack 250\n\tApex\tApdox CAP 100mg 100's pack 200\n\tAsiatic Ltd.\tAsidox CAP 100mg 100's pack 200\n\tBeximco\tMegadox CAP 100mg 100's pack 216\n\tBristol Pharma Ltd.\tBpdox CAP 100mg 100's pack 150\n\tCentral.\tDoxicen CAP 100mg 100's pack 220\n\tCosmic Chemical Industries Ltd.\tDoxycin CAP 100mg 100's pack 210\n\tCosmo Pharma Ltd.\tCosdox CAP 100mg 100's pack 200\n\tDesh\tDoxacin CAP 100mg 100's pack 215\n\tDoctor's Chemicals Works Ltd.\tVelacin CAP 100mg 100's pack 102\n\tEdruc Ltd.\tE Doxy CAP 100mg 100's pack 215\n\tGeneral\tDoxigen CAP 100mg 100's pack 216\n\tGlobe\tUnidox CAP 100mg 100's pack 200\n\tHudson\tDoxyson CAP 100mg 100's pack 190\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDoxysina CAP 100mg 100's pack 203\n\tIncepta\tIpadox CAP 100mg 100's pack \n\tIndobangla Pharmaceuticals\tIndox CAP 100mg 100's pack 200\n\tJayson\tVidox CAP 100mg 50's pack 89\n\tMarksman.\tMardox CAP 100mg 100's pack 200\n\tMedicon\tDoxicon CAP 100 mg  100's pack 220\n\tMedimet\tDoximet CAP 100mg 100's pack 220\n\tModern\tVib CAP 100mg 100's pack 200\n\tMystic\tMydox CAP 100mg 100's pack 200\n\tNipa\tVitrocin CAP 100mg 100's pack 200\n\tNovartis (Bangladesh) Ltd.\tServidoxyne CAP 100mg 100's pack 217\n\tOpsonin Pharma\tDoxin CAP 100mg 100's pack 220\n\tOpsonin Pharma\tDoxin CAP 50mg 50's pack 71.50\n\tOrion Pharma Ltd.\tOriodox CAP 100mg 100's pack 211\n\tPacific\tDopac CAP 100mg 100's pack 200\n\tPharmadesh Ltd.\tFardox CAP 100mg 100's pack 200\n\tReliance\tElidox CAP 100mg 100's pack 200\n\tRenata\tDoxicap CAP 100mg 100's pack 220\n\tRenata\tDoxicap CAP 50mg 50's pack 71\n\tSalton\tDoxipan CAP 100mg 100's pack 216\n\tSeema\tDoxseem CAP 100mg 100's pack 250\n\tSomatec\tTydox CAP 100mg 100's pack 201\n\tSquare\tDoxacil CAP 100mg 100's pack 200\n\tSupreme\tDoxico CAP 100mg 100's pack 215\n\tSyntho Ltd.\tDoxisyn CAP 100mg 100's pack 200\n\tZenith\tDoxyzen CAP 100mg 100's pack 215\n\tIndication: Acne, Susceptible infections, Syphilis, Uncomplicated gonorrhoea, Relapsing fever and louse-borne typhus, Scrub typhus\n\nDose: Adults: Two capsules at a time or one capsule every 12 hours for the first day followed by one capsule per day.\n\nChildren: Over 8 years or weighing 45 Kg or less: 4.4 mg/Kg on the first day followed by 2.2 mg/Kg daily.\n\nAcute gonococcal urethritis: 1 capsule twice daily for 2 to 4 days in male and until a cure has been obtained in female.\nChlamydial infections: 1 capsule twice daily for 7 days.\nSyphilis: 3 capsules in divided doses for 10 days.\n\nContra-indication: It is contraindicated to patients with known hypersensitivity to any of the tetracyclines. It is also contraindicated in severe hepatic disorder and patients with systemic lupas erythematosus. Concomitant intake of alkalis, antacids and iron may interfere with the absorption of Doxycycline. It is advisable to avoid giving doxycycline in conjunction with penicillin. Doxycycline should not be used in pregnant women unless, in the judgment of the physician, it is essential for the welfare of the patient.\n \n\nSide effects: Epigastric distress, abdominal discomfort, nausea, and vomiting may occur. Long term therapy with DoxacilÂ® may produce changes in the peripheral blood. Various skin reactions including rashes, urticaria,\nexfoliative dermatitis.\n\nPrecaution: The use of drugs of tetracycline group during tooth development (last half of pregnancy, infancy and childhood to the age of 12 years) may cause permanent discoloration of the teeth. Tetracyclines, therefore, should not be used in this age group unless other drugs are not likely to be effective or are contraindicated.\n\nMode of action: Concomitant use w/ isotretinoin is known to cause pseudotumour cerebri. Prolonged prothrombin time w/ anticoagulants (e.g. warfarin). May interfere w/ the bactericidal action of penicillin. Impaired absorption w/ antacids containing Al, Ca, or Mg, oral Zn, Fe salts, and bismuth preparations. Increased metabolism w/ phenobarbital, carbamazepine, primidone and phenytoin. Risk of breakthrough bleeding w/ oral contraceptives. Increased plasma concentration of ciclosporin. Decreased half-life w/ hepatic enzymes inducers (e.g. rifampicin).\nPotentially Fatal: Concurrent use w/ methoxyflurane may result to fatal renal toxicity.\n\nPregnancy category: D\n\nInteraction: Concomitant use w/ isotretinoin is known to cause pseudotumour cerebri. Prolonged prothrombin time w/ anticoagulants (e.g. warfarin). May interfere w/ the bactericidal action of penicillin. Impaired absorption w/ antacids containing Al, Ca, or Mg, oral Zn, Fe salts, and bismuth preparations. Increased metabolism w/ phenobarbital, carbamazepine, primidone and phenytoin. Risk of breakthrough bleeding w/ oral contraceptives. Increased plasma concentration of ciclosporin. Decreased half-life w/ hepatic enzymes inducers (e.g. rifampicin).\nPotentially Fatal: Concurrent use w/ methoxyflurane may result to fatal renal toxicity.
Doxylamine Succinate	\n\n\tACI\tDoxamil TAB dr 25mg 100's pack 201\n\tIndication: Itching, Sneezing, Watery eyes, Runny nose, Common cold, Insomnia, Hypersensitivity reactions\n\nDose: Adult: PO Hypersensitivity reactions 25 mg 4-6 hrly. Max: 150 mg/day. Insomnia 25 mg 30 mins before bedtime.\n\nContra-indication: Severe liver disease; avoid alcohol; premature infants or full-term neonates.\n\nSide effects: Acute dystonic reactions and long-lasting impaired consciousness in child. CNS depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. Headache, psychomotor impairment and antimuscarinic effects. Rarely rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, extrapyramidal effects, tremor, confusion, tinnitus, hypotension, hair loss.\n\nPrecaution: May impair ability to drive and operate machinery. Angle-closure galucoma, urinary retention, prostatic hypertrophy or pyloroduodenal obstruction; epilepsy; hepatic impairment. Elderly. Lactation.\n\nMode of action: Doxylamine enhances effects of CNS depressants eg alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and antipsychotics. Atropine, tricyclic antidepressants (TCAs), MAOIs. It can mask signs of ototoxicity caused by aminoglycosides. INH, penicillamine and OC require greater pyridoxine dose. Pyridoxine reduces the effects of levodopa, phenobarb and phenytoin.\n\nPregnancy category: A\n\nInteraction: Doxylamine enhances effects of CNS depressants eg alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and antipsychotics. Atropine, tricyclic antidepressants (TCAs), MAOIs. It can mask signs of ototoxicity caused by aminoglycosides. INH, penicillamine and OC require greater pyridoxine dose. Pyridoxine reduces the effects of levodopa, phenobarb and phenytoin.
Drospirenone + Ethinylestradiol	\n\n\tIncepta\tRosen 28 TAB dr  0.030 mg/3 mg 28's pack 399\n\tIncepta\tRosen Gold TAB dr 3 mg + 20 mcg  \n\tRenata\tNovelon TAB dr 3 mg/20 mcg 1x21's pack 343.98	\n\tIndication: Acne, Oral contraception, Premenstrual dysphoric disorder.\n\nDose: Adult: PO OC; Premenstrual dysmorphic disorder 1 tab/day for 21 days followed by 7 pill-free days before starting on a new pack or after taking 21 light yellow tablets for 21 days, then continue taking one white placebo tablet every day from the last row in the pack for next 7 days. . \n\nTake dose at the same time each day. Women should be instructed to take the tablets at about the same time every day, preferably after the evening meal or at bedtime. \n\nRenal impairment:\nCrCl (ml/min)	\n<50  	Avoid use.\n\nHepatic impairment: Avoid use.\n\nContra-indication: Pregnancy. Undiagnosed abnormal genital bleeding. Renal insufficiency, hepatic dysfunction or tumor. Adrenal insufficiency, cholestatic jaundice of pregnancy, jaundice with prior oral contraceptive use. Major surgery with prolonged immobilisation. Heavy smoking (>15 cigarettes/day) in patients >35 y. \n\nHistory of or current thrombophlebitis or venous thromboembolic disorders. Active or recent (within 1 yr) arterial thromboembolic disease; cerebral vascular disease, coronary artery disease, severe hypertension, valvular heart disease with thrombogenic complications. Diabetes with vascular involvement; headache with focal neurological symptoms. Known or suspected breast carcinoma, endometrial cancer, oestrogen-dependent neoplasms. \n\nSide effects: Enlarged abdomen, abdominal pain, diarrhoea, dyspepsia, gastroenteritis, nausea, tooth disorder, vomiting, wt gain. Depression, dizziness, emotional lability, fever, headache, migraine, nervousness, pain. Acne, pruritus, rash. Amenorrhoea, breast pain, dysmenorrhoea, hyperlipidaemia, intermenstrual bleeding, reduced libido, irregular menstrual cycles. Bronchitis, cough, pharyngitis, rhinitis, sinusitis, upper respiratory infection.\n\nPrecaution: May increase risk of breast cancer, thromboembolism and glucose intolerance. May lead to hyperkalaemia in patients with adrenal insufficiency. May affect serum triglycerides and lipoprotein levels. May cause retinal vascular thrombosis; discontinue treatment if papilloedema or retinal vascular lesions occur. Caution when used in patients with depression, history of migraines or risk factors for coronary arterial diseases. Patients with diseases which may be worsened by fluid retention. \n\nMay have dose-related risk of gall bladder disease. Increased risk of CV side effects when used in smokers, especially if they are >35 yr of age. Recommended to stop treatment 4 wk before and for 2 wk after elective surgery associated with high risk of thromboembolism or periods of immobilisation. Lactation.\n\nMode of action: Increased risk of hyperkalaemia when used with ACE inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, potassium salts or NSAIDs. Aminoglutethimide may increase hepatic metabolism of progestins. Increased risk of systemic acidosis when used with ammonium chloride. Serum concentrations may be reduced by aprepitant, topiramate, rifampin or protease inhibitors. \n\nEfficacy may be reduced by concurrent use of acitretin, carbamazepine, felbamate, oxcarbazepine, phenobarbital, phenytoin, topiramate, barbiturates, griseofulvin, modafinil. Oestrogens may decrease the clearance of benzodiazepines that undergo oxidative metabolism. Concurrent use may increase the serum levels of systemic corticosteroids, ciclosporin, tizanidine, voriconazole and selegiline. May affect the efficacy of coumarin derivativesl; thus combined use is not recommended. May reduce the efficacy of protease inhibitors and lamotrigine.\n\nPregnancy category: X\n\nInteraction: Increased risk of hyperkalaemia when used with ACE inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, potassium salts or NSAIDs. Aminoglutethimide may increase hepatic metabolism of progestins. Increased risk of systemic acidosis when used with ammonium chloride. Serum concentrations may be reduced by aprepitant, topiramate, rifampin or protease inhibitors. \n\nEfficacy may be reduced by concurrent use of acitretin, carbamazepine, felbamate, oxcarbazepine, phenobarbital, phenytoin, topiramate, barbiturates, griseofulvin, modafinil. Oestrogens may decrease the clearance of benzodiazepines that undergo oxidative metabolism. Concurrent use may increase the serum levels of systemic corticosteroids, ciclosporin, tizanidine, voriconazole and selegiline. May affect the efficacy of coumarin derivativesl; thus combined use is not recommended. May reduce the efficacy of protease inhibitors and lamotrigine.
Drotaverine Hydrochloride	\n\n\tACI\tDrovin TAB dr 40mg 100's pack 176\n\tAcme Ltd.\tDot TAB dr 40mg 100's pack 176\n\tAcme Ltd.\tDot Injection 40mg/2ml 10 amps pack 70.20\n\tAlbion Ltd.\tN-Aspa TAB dr 40 mg 200's pack \n\tAmbee\tNo Spa TAB dr 40mg 200's pack 364\n\tAmbee\tNo Spa Injection 40mg/2ml 10 amps pack 79.80\n\tBeximco\tTaverin TAB dr 40mg 100's pack 175\n\tChemist Ltd.\tNospasm TAB dr 40mg  \n\tChemist Ltd.\tNospasm Injection 40 mg/2 ml  \n\tHallmark\tDrota TAB dr 40mg 100's pack 176\n\tIncepta\tDrotapan TAB dr 40mg 100's pack 175\n\tKemiko\tRova TAB dr 40mg 100's pack 200\n\tNipa\tDover TAB dr 40mg 100's pack 175\n\tOpsonin Pharma\tSpan TAB dr 40mg 100's pack 154\n\tRenata\tRenapa TAB dr 40mg 100's pack 180\n\tSquare\tEspa TAB dr 40mg 100's pack 175.56\n\tSquare\tEspa Injection 40mg/2ml 10 amps pack 70.23\n\tIndication: Gastrointestinal tract spasm, Irritable bowel syndrome, Dysmenorrhea, Biliary colics, Renal colics\n\nDose: Adults: 1 to 2 tablets, 3 times daily.\nChildren (over 6 years): 1/2 to 1 tablet, 1-2 times daily.\nChildren (1-6 years): 1/4 to 1/2 tablet, 1-2 times daily.\n\nInjection: Adults: 1 to 2 ampoules, intramuscularly or subcutaneously, 1-3 times daily. For the management of acute stone colics: 1 or 2 ampoules by slow intravenous injection.\n\nContra-indication: Severe renal/hepatic/cardiac dysfunction. Porphyria.\n\nSide effects: Vertigo, nausea, vomiting, dry mouth.\n\nPrecaution: Exercise caution in patients with renal/hepatic/cardiac dysfunction. Pregnacy, lactation.\n\nMode of action: May attenuate the action of levodopa. Concurrent use of analgesics, antimuscarinics or benzodiazepines. Additive beneficial effect with concurrent use of analgesics, antimuscarinics or benzodiazepines.\n\nPregnancy category: C\n\nInteraction: May attenuate the action of levodopa. Concurrent use of analgesics, antimuscarinics or benzodiazepines. Additive beneficial effect with concurrent use of analgesics, antimuscarinics or benzodiazepines.
Duloxetine	\n\n\tAcme Ltd.\tDulox TAB dr 20mg 10's pack 70.20\n\tAcme Ltd.\tDulox TAB dr 30mg 10's pack 100.40\n\tEskayef Bangladesh Ltd.\tDeloxi CAP 20mg 36's pack 252\n\tEskayef Bangladesh Ltd.\tDeloxi CAP 60mg 16's pack 288\n\tIncepta\tDuloxen 20 TAB dr 20mg 30's pack 210\n\tIncepta\tDuloxen 30 TAB dr 30mg 30's pack 300\n\tOpsonin Pharma\tXinolax DR CAP 20mg 30's pack 210\n\tOpsonin Pharma\tXinolax DR CAP 30mg 30's pack 300\n\tOpsonin Pharma\tXinolax DR CAP 60mg 20's pack 320\n\tSquare\tDiliner-DR 30 CAP 30mg 18's pack 180.74\n\tSquare\tDiliner-DR 60 CAP 60mg 18's pack 289.08\n\tSquare\tDiliner DR 60 CAP 60mg 18's pack \n\tSquare\tDiliner DR 30 CAP 30mg 18's pack \n\tSun Pharmaceutical (Bangladesh) Ltd.\tDuzela CAP 20mg 25's pack 352.50\n\tUnimed & Unihealth Manufacturers Ltd.\tStresin CAP 20mg 30's pack 240\n\tIndication: Major Depressive Disorder (MDD), Fibromyalgia, Diabetic neuropathy, Stress urinary incontinence, Generalized anxiety disorder, Interstitial cystitis, Musculoskeletal pain\n\nDose: Adult: PO Major Depressive Disorder (MDD): 20-30 mg twice daily. Max: 60 mg/day. \n\nDiabetic neuropathy 60 mg once daily. Max: 120 mg/day. \n\nModerate to severe stress incontinence in women 40 mg twice daily. \n\nChronic Musculoskeletal Pain: 30 mg/day. Max: 60 mg once daily\n\nContra-indication: Duloxetine is contraindicated in patients with a known hypersensitivity to this drug or any of the inactive ingredients.. Uncontrolled narrow-angle glaucoma. Concomitant use or within 2 wk of MAOIs. Renal and hepatic impairment.\n\nSide effects: Nausea, dry mouth, constipation, decreased appetite, somnolence, fatigue, increased sweating.\n\nPrecaution: Avoid alcohol and abrupt cessation. May impair ability to drive or engage in task requiring alertness. Increased risk of suicidal thinking and behaviour when used in children and adolescents. Pregnancy, lactation.\n\nMode of action: Increased risk of serotonin syndrome w/ TCA, SSRI, SNRI, lithium. May increase bleeding risk w/ aspirin, NSAIDs, warfarin and other anticoagulants.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue. Increased serum levels and risk of toxicity w/ potent CYP1A2 inhibitors (e.g. ciprofloxacin, enoxacin).\n\nPregnancy category: C\n\nInteraction: Increased risk of serotonin syndrome w/ TCA, SSRI, SNRI, lithium. May increase bleeding risk w/ aspirin, NSAIDs, warfarin and other anticoagulants.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue. Increased serum levels and risk of toxicity w/ potent CYP1A2 inhibitors (e.g. ciprofloxacin, enoxacin).
Dutasteride	\n\n\tDrug International Ltd.\tDutamax CAP 0.5mg 21's pack 252\n\tUnimed & Unihealth Manufacturers Ltd.\tUrodart CAP 500mcg 28's pack 280\n\tIndication: Benign prostatic hyperplasia (BPH)\n\nDose: Adult: PO 500 mcg/day.\n\nContra-indication: Severe liver impairment; pregnant women, children, adolescent.\n\nSide effects: Impotence; decreased libido; ejaculation disorders; breast tenderness and enlargement.\n\nPrecaution: Excreted in semen therefore use of condom is recommended. Women of childbearing potential should avoid handling dutasteride capsules. Advisable to exclude other causes of benign prostatic hypertrophy (e.g. prostate cancer, infection) before initiating therapy.\n\nMode of action: Plasma concentrations may be increased when used concomitantly w/ moderate or potent CYP3A4 inhibitors.\n\nPregnancy category: X\n\nInteraction: Plasma concentrations may be increased when used concomitantly w/ moderate or potent CYP3A4 inhibitors.
Ebastine	\n\n\tAcme Ltd.\tRhitin TAB dr 10mg  \n\tDelta Pharma\tEbatrol TAB dr 10mg 30's pack 250\n\tEskayef Bangladesh Ltd.\tStiba TAB dr 10mg 30's pack 180\n\tEuro Pharma Ltd.\tEbtin TAB dr 10mg  \n\tEuro Pharma Ltd.\tEbtin Syrup 5 mg/5 ml  \n\tGlobe\tEbahist TAB dr 10mg  \n\tGlobe\tEbahist Syrup 5 mg/5 ml  \n\tIncepta\tEbaril 10 TAB dr 10mg 30's pack 180\n\tIncepta\tEbaril Syrup 5mg/5ml 1's pack 60\n\tNovelta Bestway\tAlestin TAB dr 10mg 50's pack 300\n\tNovelta Bestway\tAlestin Syrup 5mg/5ml 50ml bot 80\n\tOpso Saline Ltd.\tEbanil TAB dr 10mg  \n\tOpsonin Pharma\tEbanex TAB dr 10mg 30's pack 158.35\n\tPopular\tEbatin TAB dr 10mg 50's pack 301\n\tPopular\tEbatin Syrup 5mg/5ml 30ml bot/ 50ml bot 60 / 80\n\tRadiant.\tExler TAB dr 10mg 50's pack 400\n\tRAK\tRinobas TAB dr 10mg 30's pack 300\n\tSquare\tTebast TAB dr 10mg 30's pack 180\n\tSquare\tTebast Syrup 5mg/5ml 50ml bot 80\n\tIndication: Allergic rhinitis, Allergic conditions, Chronic idiopathic urticaria\n\nDose: Adult: PO 10-20 mg once daily.\nChild: >6 yr: 5 mg once daily.\n\nContra-indication: Hypersensitivity, cardiac arrhythmias.\n\nSide effects: Headache, dry mouth, drowsiness, pharyngitis, abdominal pain, dyspepsia, asthenia, epistaxis, rhinitis, sinusitis, nausea, insomnia.\n\nPrecaution: Caution is advised when used in hepatic impairment, renal insufficiency, QTc interval prolongation. Pregnancy, lactation.\n\nMode of action: Concomitant use of ketoconazole, itraconazole, clarithromycin or erythromycin may increase plasma levels of ebastine and cause QTc interval prolongation.\n\nPregnancy category: Not Classified\n\nInteraction: Concomitant use of ketoconazole, itraconazole, clarithromycin or erythromycin may increase plasma levels of ebastine and cause QTc interval prolongation.
Econazole Nitrate (Vaginal prep)	\n\n\tACI\tEcoren VT Vaginal TAB dr 150mg 3 tabs pack 72.27\n\tIncepta\tEconate G Vaginal Cream  30gm 30gm tube 70\n\tIncepta\tEconate VT Vaginal TAB dr 150mg 3 tabs pack 70\n\tOpsonin Pharma\tEcozol VT Vaginal TAB dr 150mg 3 tabs pack 70\n\tIndication: Vaginal thrush, , Vulvo-vaginal candidiasis or any other fungal infection of vagina.\n\nDose: Vag candidiasis As VT: 150 mg/day at bedtime for 3 consecutive nights. \nVaginal infection As Vaginal cream: Applied with the applicator par vaginally once or twice daily.\n\nContra-indication: Hypersensitivity. Porphyria; pregnancy.\n\nSide effects: Vulvar/vaginal burning; erythema; itching;\n\nPrecaution: Avoid contact with eyes and mucous membranes. May damage latex contraceptives. Pregnancy.\n\nMode of action: Theoretical potential for compd metabolized by CYP3A4/2C9, oral anticoagulants eg warfarin & acenocoumarol.\n\nPregnancy category: C\n\nInteraction: Theoretical potential for compd metabolized by CYP3A4/2C9, oral anticoagulants eg warfarin & acenocoumarol.
Econazole Nitrate 1%	\n\n\tACI\tEcoren Cream  1% 10gm  tube 30.20\n\tHealthcare\tSpectazole Cream   10gm  tube 30\n\tIncepta\tEconate Cream   10gm  tube 32\n\tKemiko\tEconal Cream   10gm  tube 32\n\tMedimet\tEcomet Cream   10gm  tube 28\n\tOpsonin Pharma\tEcozol Cream   10gm  tube/30gm  tube 32 / 70\n\tRephco\tEcoderm Cream   10gm  tube 28\n\tSanofi Aventis (BD) Ltd.\tPevaryl Cream   10gm  tube 32.49\n\tIndication: Tinea pedis, Tinea cruris, Tinea corporis, Jock itch, Athlet's foot, Pityriasis versicolor, Cutaneous candidiasis, Onychomycoses.\n\nDose: Adult: Topical Skin fungal infections As 1% cream: Apply up to 3 times/day for 2-4 wk. \n\nNail fungal infections As 1% cream/lotion: Apply once daily w/ occlusive dressing. \n\n\n\nContra-indication: Hypersensitivity. \n\nSide effects: Skin irritation, erythema; itching; contact dermatitis.\n\nPrecaution: Avoid contact with eyes and mucous membranes. Pregnancy.\n\nMode of action: May enhance anticoagulant effect of warfarin or acenocoumarol.\n\nPregnancy category: C\n\nInteraction: May enhance anticoagulant effect of warfarin or acenocoumarol.
Econazole Nitrate 1% + Triamcinolone Acetonide 0.1 Topical	\n\n\tACI\tEcoren T Cream  1%+0.1% 10gm tube 41.27\n\tAcme Ltd.\tExinil Cream (1 gm + 100 mg)/100 gm  \n\tAlbion Ltd.\tPelsone Cream (1 gm + 100 mg)/100 gm  \n\tAmico Ltd.\tElocon Cream   10gm tube 40\n\tAristopharma\tAristocort PLUS Cream   5gm tube/10gm tube 20/ 35\n\tAsiatic Ltd.\tPevisia Cream   10gm tube 34\n\tBeximco\tEcotrim Cream   10gm tube 34.50\n\tBio Pharma Ltd.\tEnazol PLUS Cream   10gm tube 34.13\n\tChemist Ltd.\tFungison Cream   10gm tube 31.80\n\tCosmic Chemical Industries Ltd.\tPevicort Cream   10gm tube 34\n\tDrug International Ltd.\tDicot Cream   10gm tube 35\n\tEdruc Ltd.\tTriamace Cream   10gm tube 34\n\tEverest\tEcton Cream   10gm tube 37.14\n\tGeneral\tTricoderm Cream   10gm tube 34.13\n\tGeneral\tTricoderma Cream  10gm tube 34.13\n\tHealthcare\tSpectazole-N Cream   10gm tube 35\n\tIbn Sina Pharmaceutical Ind. Ltd.\tPevisina Cream   35\n\tIbn Sina Pharmaceutical Ind. Ltd.\tFungicort Cream (1 gm + 100 mg)/100 gm  \n\tIncepta\tEconate PLUS Cream   10gm tube 40\n\tKemiko\tTinacort Cream   10gm tube 34\n\tMedicon\tEcot Cream 10gm 1's Pack 40\n\tNovo Healthcare and Pharma Ltd.\tTriozol Cream   10gm tube 34\n\tOpsonin Pharma\tEcozol PLUS Cream   10gm tube 34\n\tOrion Pharma Ltd.\tAvison Cream (1 gm + 100 mg)/100 gm  \n\tPharmadesh Ltd.\tEcosone Cream   10gm tube 32\n\tPharmasia Ltd.\tPeviderm Cream   10gm tube 34\n\tRephco\tEcoderm TA Cream   10gm tube 35\n\tSanofi Aventis (BD) Ltd.\tPevisone Cream   10gm tube 41.15\n\tSanofi Aventis (BD) Ltd.\tPevisone Ointment (1 gm + 100 mg)/100 gm  \n\tShamsul Al-Amin\tSecotal Cream   10gm tube 34\n\tSharif\tEcostat Cream   10gm tube 34\n\tSquare\tPevitin Cream  1 gm + 100 mg/100 gm 10gm tube 40.15\n\tIndication:  Steroid-responsive inflammatory dermatoses, Tinea pedis, Tinea cruris, Tinea corporis, Pityriasis versicolor, Cutaneous candidiasis, Onychomycoses\n\nDose: For topical administration only.Adults: Apply twice daily to the affected area and rub on the skin gently with the finger. Continue the applications for 14 days or as directed by the doctor.Children: Suitable for topical application to children.\n\nContra-indication: Not to be used in the treatment of tuberculous lesions and viral diseases of the skin (herpes, vaccinia, varicella).True hypersensitivity.\n\nSide effects: Rarely, transient local mild irritation, itching & redness may occur immediately after application. Econazole has minimal allergenic effect and is well tolerated, even by delicate skin. Adrenal suppression on long term continuous topical steroid therapy may occur, particularly in infants or children, or when occlusive dressings are applied. It should be noted that an infant's napkin may act as an occlusive dressing.\n\nPrecaution: Hypersensitivity has rarely been recorded. If it occurs, application of the product should be discontinued. The infected area should be kept clean and dry during treatment.\n\nMode of action: Econazole: Theoretical potential for compd metabolized by CYP3A4/2C9, oral anticoagulants eg warfarin & acenocoumarol.\n\nTriamcinolone: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.\n\n\nPregnancy category: C\n\nInteraction: Econazole: Theoretical potential for compd metabolized by CYP3A4/2C9, oral anticoagulants eg warfarin & acenocoumarol.\n\nTriamcinolone: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.\n
Efavirenz	\n\n\tBeximco\tAvifanz TAB dr 600mg 10's pack 2000\n\tSquare\tAdiva TAB dr 600mg 10's pack 2007.49\n\tIndication: HIV infection\n\nDose: Oral\nHIV infection\nAdult: Combined with other antiretrovirals: 600 mg once daily. Dosing at bedtime recommended during 1st 2-4 wk of therapy to improve tolerability.\n\nChild: Combined with other antiretrovirals: >3 yr, 10-14 kg: 200 mg; 15-19 kg: 250 mg; 20-24 kg: 300 mg; 25-32.4 kg: 350 mg; 32.5-39 kg: 400 mg; ?40 kg: 600 mg. To be taken once daily.\n\nContra-indication: Severe hepatic impairment; hypersensitivity; lactation.\n\nSide effects: Rash including Stevens-Johnson syndrome and erythema multiforme; CNS effects e.g. dizziness, headache, insomnia, somnolence, abnormal dreams, fatigue, impaired concentration. Nausea, less frequently, vomiting, diarrhoea, hepatitis, depression, anxiety, psychosis, amnesia and ataxia, stupor, vertigo, abdominal pain, hepatic failure, pancreatitis, convulsions, gynaecomastia, pruritus, blurred vision.\n\nPrecaution: Mild to moderate liver disease; renal impairment. Monitor liver enzymes and cholesterol. Discontinue if severe skin rash or fever develops; known or suspected hepatitis B or infection. History of mental illness or seizures; elderly. Pregnancy. Children.\n\nMode of action: Hormonal contraceptives; antibacterial e.g. rifampicin, rifabutin, clarithromycin; enzyme inducers. St. John's wort may decrease serum level. Ethanol (hepatic and CNS adverse effects).\nPotentially Fatal: Life-threatening adverse effects when used with terfenadine, astemizole, cisapride, midazolam, triazolam and ergot alkaloids.\n\nPregnancy category: D\n\nInteraction: Hormonal contraceptives; antibacterial e.g. rifampicin, rifabutin, clarithromycin; enzyme inducers. St. John's wort may decrease serum level. Ethanol (hepatic and CNS adverse effects).\nPotentially Fatal: Life-threatening adverse effects when used with terfenadine, astemizole, cisapride, midazolam, triazolam and ergot alkaloids.
Elemental Iron (carbonyl iron) + Folic Acid	\n\n\tEskayef Bangladesh Ltd.\tFeofol-CI CAP  30's pack 75\n\tIndication: Dietary supplement,Iron deficiency anemia,Chronic or acute blood loss,Pregnancy & lactation\n\nDose: One capsule daily or as directed by the physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Folic Acid is contraindicated in untreated cobalamine deficiency. Haemolytic anemia.\n\nSide effects: This tablet is well tolerated. Sometimes gastrointestinal disturbance like abdominal pain, dyspepsia, nausea, vomiting, constipation.\n\nPrecaution: Iron chealates with antacid and tetracycline and absorption of all these may be impaired if taken concurrently.\n\nMode of action: Elemental iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\n\nPregnancy category: Not Classified\n\nInteraction: Elemental iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n
Elemental Iron (Iron Polymaltose Complex) + Folic Acid + Zinc + Vitamin B-Complex	\n\n\tACI\tMylovit Z CAP   100's pack 300\n\tACI\tMylovit-Z CAP  50's pack  176\n\tAd-din\tRed plus extra CAP  100's pack 350\n\tAmico Ltd.\tPregnacare CAP  50's pack  150\n\tAristopharma\tIpec SUPER CAP 47 mg + 500 mcg + 20 mg + 30's pack 180\n\tBio Pharma Ltd.\tFivita CAP  30's pack/100's pack  105.30/263.91\n\tHealthcare\tPrenat XL CAP   60's pack 210\n\tIncepta\tAlneed Gold CAP   30's pack 6\n\tOpsonin Pharma\tVizicon Gold CAP   60's pack 237.39\n\tPopular\tFeviz PLUS CAP   30's pack 180.59\n\tSharif\tMerivit CAP   50's pack 175\n\tSquare\tZiliron B CAP   30's pack 135.66\n\tIndication: Dietary supplement, Iron, Folic Acid and Zinc deficiency, Vitamin-B Deficiency especially during pregnancy and lactation.\n\nDose: One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: Iron: Absorption decreased w/ antacids. May reduce effects of penicillamine. Concurrent use with psychotropic drugs may worsen constipation. Increased systemic side effects with concomitant ACE inhibitors and parenteral iron admin.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nPregnancy category: Not Classified\n\nInteraction: Iron: Absorption decreased w/ antacids. May reduce effects of penicillamine. Concurrent use with psychotropic drugs may worsen constipation. Increased systemic side effects with concomitant ACE inhibitors and parenteral iron admin.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
Elemental Iron + Folic Acid + Vitamin C + Zinc	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tOrofer TAB dr  30's pack 140.75\n\tIndication: Iron, Vitamin-B, Folic acid, Vitamin-C deficiency, Pregnancy and lactation\n\nDose: Adults: 2-3 tablets daily or as directed by the physician. \nThe tablet should be chewed to get flavour and taste. It can be taken with meals.\n\nContra-indication: Contraindicated in patients with a known hypersensitivity to any of the ingredients of this product.\n\nSide effects: A few side-effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur.\n\nPrecaution: Caution should be taken in the conditions where there is a risk of iron overload, such as haemochromatosis, thalassemia, haemosiderosis or haemolytic anaemia.\n\nMode of action: Elemental iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\nPregnancy category: Not Classified\n\nInteraction: Elemental iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n
Ferrous Ascorbate + Folic Acid + Zinc	\n\n\tBeximco\tHemofix FZ TAB dr 48mg + 0.5mg + 22.5mg 30's Pack 150\n\tIndication: Iron, Folic Acid and Zinc deficiency, Dietary supplement,Pregnancy and lactation,\n\nDose: Adults: 1-2 capsule daily or as directed by the physician.\nChild: Over 1 year: 1 capsule daily.\n\nContra-indication:  Contraindicated in patients with a known hypersensitivity to any of the ingredients. Folic Acid is contraindicated in untreated cobalamine deficiency.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen. Sometimes gastrointestinal disturbance like abdominal pain, dyspepsia, nausea, vomiting,constipation may occur.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Iron Polymaltose  +  Vitamin B Complex  +  Zinc	\n\n\tACI\tLivita Syrup  1g+0.2g+0.1g+0.04g+0.4g+ 100ml bot 50.34\n\tAcme Ltd.\tFeziplex Syrup   5ml 100ml bot/200ml bot 50.20/80.30\n\tAlco Pharma\tZivit- I Syrup  100ml  bot / 200ml bot 50 / 90\n\tAmico Ltd.\tIrotrex PLUS Syrup   100ml bot 50\n\tApex\tPolyfer Z Syrup   50ml bot/100ml bot/200ml bot 35/45/75\n\tAristopharma\tVitazin I Syrup   100ml bot 50\n\tAsiatic Ltd.\tAsivit-ZI Syrup  100ml bot / 200ml ot 50 / 90\n\tBeximco\tVitonic Syrup   50ml bot/100ml bot/200ml bot 30/50/80\n\tBio Pharma Ltd.\tBiovit Plus Syrup   100ml bot 50.19\n\tDelta Pharma\tActivit ZI Syrup   100ml bot 50\n\tDoctor's Chemicals Works Ltd.\tFezovit Syrup   100ml 50\n\tDrug International Ltd.\tSupra Z Syrup   100ml bot 50\n\tGlobe\tBizi Syrup  100ml bot 50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBiozine-I Syrup   100ml bot 50.19\n\tIncepta\tAritone ZI Syrup  50/100/200ml 	 30/50/90\n\tJMI Syringes & Medical Devices Ltd.\tV4Z Syrup  100ml bot 45\n\tMedicon\tIrovit Z 	 		 	 Syrup   100ml bot/200ml bot 50/85\n\tNavana\tOrazinc B 			 Syrup   50ml bot/100ml bot 	 30.11/50.19 \n\tNIPRO JMI Pharma\tPolytamin Syrup (50 mg + 20 mg + 2 mg + 2  \n\tOpsonin Pharma\tOpsovit ZI Syrup   100ml bot 50\n\tOpsonin Pharma\tZitaron Syrup 50mg + 5mg+2mg+2mg+20mg 1 100ml bot \n\tOrion Pharma Ltd.\tZimplex Syrup   100ml bot 	 50.19 \n\tPharmasia Ltd.\tItop-BZ Syrup   100ml bot/200ml bot 50.19/80.31\n\tPopular\tFeviz Syrup   100ml bot 50.19\n\tRenata\tBeconex ZI Syrup  30ml/50ml 	 1's pack 30.10/50.19\n\tRephco\tReoplex Syrup   100ml bot 50\n\tSeema\tSeemaplex ZI Syrup   100ml bot 50\n\tSilva\tXinoplex I Syrup  100ml  bot 45\n\tSomatec\tMaltovit Syrup   50ml bot/100ml bot/200ml bot 30.11/50.19/90.34\n\tSquare\tBicozin I Syrup   100ml bot/200ml bot 50.20/90.34\n\tIndication: Iron, Vitamin-B,  Zinc deficiency\n\nDose: Adults: 10 ml (2 teaspoonful) twice daily or as recommended by the physician.\nChildren: 5 ml (1 teaspoonful) once or twice daily or as recommended by the physician.\nInfants: 0.33 ml/Kg body weight daily or as recommended by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients of this product. Iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, and hemolytic anemias.\n\nSide effects: A few side-effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur.\n\nPrecaution: Caution should be taken in the conditions where there is a risk of iron overload, such as haemochromatosis, thalassemia, haemosiderosis or haemolytic anaemia.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Enalapril Maleate	\n\n\tAlbion Ltd.\tEnalapril TAB dr 5mg 100's pack 202\n\tAlbion Ltd.\tEnalapril TAB dr 5 mg/ 10 mg 100's / 100's pack \n\tBeximco\tEnaril TAB dr 5mg 100's pack 100\n\tEskayef Bangladesh Ltd.\tAnapril TAB dr 10mg 100's pack 270\n\tEskayef Bangladesh Ltd.\tAnapril TAB dr 5mg 100's pack 151\n\tOrion Pharma Ltd.\tEril TAB dr 10mg 50's pack \n\tOrion Pharma Ltd.\tEril TAB dr 5mg 50's pack \n\tRenata\tMinipril TAB dr 10mg 100's pack 202\n\tRenata\tMinipril TAB dr 5mg 100's pack 152\n\tSquare\tVasopril TAB dr 10mg 50's pack 113.05\n\tSquare\tVasopril TAB dr 5mg 100's pack 125.02\n\tIndication: Hypertension, Heart failure\n\nDose: Adult: PO HTN Initial: 5 mg/day at bedtime. Maintenance: 10-20 mg once daily. Severe: Up to 40 mg/day in divided doses. Max: 40 mg/day. \n\nHeart failure Initial: 2.5 mg/day. Maintenance: 20 mg once daily, up to 40 mg/day in 2 divided doses. \n\nContra-indication: Hypersensitivity. History of angioedema due to previous treatment with ACE inhibitors; bilateral renal artery stenosis. Pregnancy.\n\nSide effects: Initial hypotension may be severe and prolonged. Dizziness, headache, fatigue, persistent dry cough, abnormal taste, lassitude, rash, neutropenia, renal impairment or failure.\nPotentially Fatal: Angioedema.\n\nPrecaution: Impaired renal function. Hyperkalaemia, hypovolaemia, collagen vascular disease, valvular stenosis, during or immediately before or after anaesthesia, unilateral renal artery stenosis. Hypotension due to volume depletion, diuretic therapy. Monitor WBC count. Lactation, children.\n\nMode of action: May potentiate hypotensive action w/ diuretics, other antihypertensives, TCAs, nitrates or anaesth. Concomitant admin w/ lithium carbonate may cause lithium toxicity. Increased risk of renal impairment w/ NSAIDs. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.\n\nPregnancy category: D\n\nInteraction: May potentiate hypotensive action w/ diuretics, other antihypertensives, TCAs, nitrates or anaesth. Concomitant admin w/ lithium carbonate may cause lithium toxicity. Increased risk of renal impairment w/ NSAIDs. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.
Enoxaprin	\n\n\tAristopharma\tIntravas Injection 40mg/0.4ml 0.4ml ampoule 325\n\tAristopharma\tIntravas Injection 60mg/0.6ml 0.6ml ampoule 475\n\tAristopharma\tIntravax Injection 80mg/0.8ml 0.8ml ampoule 525\n\tBeacon\tEparin 60 Injection 60mg/0.6ml 60mg prefilled syringe 473\n\tBeximco\tCleven Injection 20mg/0.2ml 0.2ml prefilled syringe 200\n\tBeximco\tCleven Injection 40mg/0.4ml 0.4ml prefilled syringe 350\n\tBeximco\tCleven Injection 60mg/0.6ml 0.6ml prefilled syringe 500\n\tBeximco\tCleven Injection 80mg/0.8ml 0.8ml prefilled syringe 550\n\tDrug International Ltd.\tCardinex Injection 40mg/0.4ml 40mg ampoule 326\n\tDrug International Ltd.\tCardinex Injection 60mg/0.6ml 60mg ampoule 476\n\tDrug International Ltd.\tCardinex Injection 80mg/0.8ml 80mg ampoule 526\n\tGeneral\tClaxo Injection 40 mg/0.4 ml  \n\tGeneral\tClaxo Injection 60 mg/0.6 ml  \n\tIncepta\tParinox Injection 20mg/.2ml 20mg ampoule 175\n\tIncepta\tParinox Injection 40mg/.4ml 40mg ampoule 350\n\tIncepta\tParinox Injection 60mg/.6ml 60mg ampoule 500\n\tIncepta\tParinox Injection 80mg/.8ml 80mg ampoule 525\n\tPopular\tEnoparin Injection 40mg/0.4ml 40mg prefilled syringe 326.23\n\tPopular\tEnoparin Injection 60mg/0.6ml 60mg prefilled syringe 476.79\n\tPopular\tEnoparin Injection 80mg/0.8ml 80mg prefilled syringe 526.98\n\tSanofi Aventis (BD) Ltd.\tClexane 200 Anti-XaIU Injection 20mg/0.2ml 0.2ml prefilled syringe 425.06\n\tSanofi Aventis (BD) Ltd.\tClexane 4000 anti-XaIU Injection 40mg/0.4ml 0.4ml prefilled syringe 743.06\n\tSanofi Aventis (BD) Ltd.\tClexane 600 anti-XaIU Injection 60mg/0.6ml 0.6ml prefilled syringe 1049.52\n\tSanofi Aventis (BD) Ltd.\tClexane 8000 anti-XaIU Injection 80mg/0.8ml 0.8ml prefilled syringe 1343.38\n\tSquare\tClotinex Injection 40mg/0.4ml 40mg prefilled syringe 450\n\tSquare\tClotinex Injection 60mg/0.6ml 60mg prefilled syringe 575\n\tSquare\tClotinex Injection 80mg/0.8ml 80mg prefilled syringe 650\n\tIndication: Myocardial infarction, Unstable angina, Venous thromboembolism, Deep vein thrombosis\n\nDose: Adult: SC Prophylaxis of venous thromboembolism during surgery Low-moderate risk: 20 mg once daily, start 2 hr before start of procedure. High risk: 40 mg once daily, start 12 hr before start of procedure. \n\nChild: <2 mth 750 mcg/kg (75 u/kg) 12 hrly; >2 mth 500 mcg/kg (50 u/kg) 12 hrly.\n\nFor hip replacement surgery: 40 mg once daily for a further 3 wk. For immobilised patients: 40 mg once daily for at least 6 days or until patient is ambulant, up to a max of 14 days. \n\nDeep vein thrombosis 1 mg/kg 12 hrly for 5 days and until oral anticoagulation is established. \n\nPrevention of clotting in extracorporeal circulation during haemodialysis 1 mg/kg into the arterial line of the circuit at the start of the dialysis session. Give a further dose of 0.5-1 mg/kg if needed. \n\nUnstable angina 1 mg/kg 12 hrly for 2-8 days w/ low dose aspirin.\n\nParenteral\nAcute ST-elevation myocardial infarction\nAdult: Initially, 30 mg (3000 u) via IV w/ 1 mg/kg (100 u/kg) via SC given at the same time. Dose should be followed by 1 mg/kg (100 u/kg) via SC 12 hrly for 8 days or until hospital discharge. The 1st 2 SC doses should not exceed 100 mg (10,000 u) each. \nPatients who undergo PCI: An additional 300 mcg/kg (30 u/kg) via IV given at the time of the procedure if the last SC dose was given >8 hr ago.\n\nElderly: >75 yr SC: 750 mcg/kg (75 u/kg) 12 hrly, w/ max 75 mg (7500 u) for each of the 1st 2 doses.\n\n\nContra-indication: Hyper-sensitivity to either Enoxaparin, heparin or other low molecular weight heparins; major clotting disorders like history of thrombocytopenia, active gastro-intestinal ulcer or organic lesion likely to bleed, recent haemorrhagic vascular cerebral stroke. Although rare, cutaneous or systemic allergic reactions may occur.\n\nSide effects: Haemorrhage (bleeding), Thrombocytopenia, elevations of serum aminotransferase. Pain, bluish marks at injection sites to skin rash at injection sites. Cases of neuraxial hematomas with the concurrent use of Enoxaparin and spinal/epidural anesthesia or spinal puncture have resulted in varying degrees of neurologic injuries.\n\nPrecaution: Enoxaparin injection should not be administered by intramuscular route. Enoxaparin should be used with caution in conditions with increased potential for bleeding, such as impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retinopathy, recent neuro or opthalmologic surgery and low weight patients. It is recommended that the platelet count be measured befored the initiation of the treatment and regularly thereafter during treatment.\n\nMode of action: Increased risk of bleeding w/ anticoagulants, platelet aggregation inhibitors (e.g. dipyridamole, salicylates, NSAIDs, sulfinpyrazone). May increase bleeding w/ vit E.\n\nPregnancy category: B\n\nInteraction: Increased risk of bleeding w/ anticoagulants, platelet aggregation inhibitors (e.g. dipyridamole, salicylates, NSAIDs, sulfinpyrazone). May increase bleeding w/ vit E.
Entacapone	\n\n\tNovartis (Bangladesh) Ltd.\tComtan 200 mg TAB dr 200mg 30's pack 2484.90\n\tIndication: Adjunct to levodopa treatment in Parkinson's disease.\n\nDose: Adult: PO 200 mg w/ each levodopa/dopa decarboxylase inhibitor dose. Max: 200 mg 10 times/day.\n\nContra-indication: History of neuroleptic malignant syndrome and nontraumatic rhabdomyolysis. Phaeochromocytoma. Hepatic impairment.\n\nSide effects: Dyskinesia, GI symptoms, reddish brown urine discoloration, fatigue, insomnia, paroniria, confusion, hallucinations, dizziness, orthostatic/postural hypotension, vertigo, headache, leg cramps, hyperkinesia, tremor and increased sweating.\n\nPrecaution: Levodopa-induced orthostatic hypotension may be aggravated. Abrupt withdrawal. Concomitant use with a selective MAO-A and MAO-B inhibitor, or concomitant use with a selective MAO-A plus a selective MAO-B inhibitor. Biliary obstruction. Impairs ability to drive and operate machinery. Pregnancy and lactation. Children and elderly.\n\nMode of action: Drugs metabolised by COMT e.g. adrenaline, apomorphine, dobutamine, dopamine, isoprenaline, methyldopa, noradrenaline and remiterol. Iron preparations and levodopa. Avoid ethanol.\n\nPregnancy category: C\n\nInteraction: Drugs metabolised by COMT e.g. adrenaline, apomorphine, dobutamine, dopamine, isoprenaline, methyldopa, noradrenaline and remiterol. Iron preparations and levodopa. Avoid ethanol.
Entecavir	\n\n\tACI\tTeviral TAB dr 0.5mg 10's pack 483.20\n\tACI\tTeviral TAB dr 1mg 10's pack 1003\n\tAcme Ltd.\tVIR TAB dr 0.5mg 1x10's pack 480\n\tAristopharma\tTecavir TAB dr 0.5mg 10's pack 600\n\tAristopharma\tTecavir TAB dr 1mg 10's pack 1000\n\tBeacon\tCaviral TAB dr 0.5mg 10's pack 600\n\tDrug International Ltd.\tEntavir TAB dr 0.5mg 10's pack 600\n\tDrug International Ltd.\tEntavir TAB dr .5mg 10's pack 450\n\tEskayef Bangladesh Ltd.\tVirenta TAB dr .5mg 10's pack 422.25\n\tGeneral\tGenevir TAB dr 0.5mg 10's pack 480\n\tGeneral\tGenevir TAB dr 1mg 10's pack 900\n\tIncepta\tBarcavir 0.5 TAB dr 0.5mg 10's pack 480\n\tIncepta\tBarcavir 1 TAB dr 1mg 10's pack 900\n\tOpsonin Pharma\tEnviral TAB dr 0.5mg 10's pack 481.80\n\tOpsonin Pharma\tEnviral TAB dr 1mg 10's pack 903.40\n\tOpsonin Pharma\tAntavir TAB dr 0.5 mg 10's pack \n\tRenata\tEnteca TAB dr 0.5mg 10's pack 480\n\tSquare\tCavir 0.5 TAB dr 0.5mg 5's pack 240\n\tSquare\tCavir TAB dr 1mg 5's pack 450\n\tIndication: Chronic hepatitis B\n\nDose: The recommended dose of Entecavir for chronic hepatitis B virus infection in nucleoside-treatment-naive adults and adolescents 16 years of age is 0.5 mg once daily. \n\nFor Lamivudine-refractory or known Lamivudine or Telbivudine resistance mutations, the recommended dose of Entecavir is 1 mg once daily. \n\nFor patients with decompensated liver disease (adult) the recommended dose of Entecavir is 1 mg once daily. Entecavir should be administered on an empty stomach (at least 2 hours after a meal or 2 hours before the next meal). \n\nDose Adjustment in Renal impairment: Dose adjustment is recommended for patients with creatinine clearance <50 mL/min.  Dosing interval adjustment of Entecavir in patients with renal impairment Creatinine clearance(mL/min) >= 50 30 to < 50 10 to < 30 < 10 Hemodialysis or CAPD Recommended dose and dosing interval 0.5 mg every 24 hours 0.5 mg every 48 hours 0.5 mg every 72 hours 0.5 mg every 7 days  \n\nPediatric Use: Safety and effectiveness of Entecavir in pediatric patients below the age of 16 years have not been established. \n\nGeriatric Use: Clinical studies of Entecavir did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. But care should be taken in dose selection, and it may be useful to monitor renal function.\n\n\nContra-indication: Entecavir is contraindicated in patients with previously demonstrated hypersensitivity to Entecavir or any component of the product.\n\nSide effects: The most common adverse events are headache, fatigue, dizziness and nausea.\n\nPrecaution: Lactic acidosis: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported with the use of nucleoside analogues alone or in combination with antiretrovirals.Exacerbations of hepatitis after discontinuation of treatment: Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including Entecavir.\n\nMode of action: Drugs that reduce renal function or compete for active tubular secretion may increase serum conc of either entecavir or co-administered drug.\n\nPregnancy category: C\n\nInteraction: Drugs that reduce renal function or compete for active tubular secretion may increase serum conc of either entecavir or co-administered drug.
Entecavir 0.005%	\n\n\tOpsonin Pharma\tEnviral Oral Solution   100ml bot 301.14\n\tIndication: Chronic hepatitis B\n\nDose: The recommended dose of Entecavir for chronic hepatitis B virus infection in nucleoside-treatment-naive adults and adolescents 16 years of age is 0.5 mg once daily. \n\nFor Lamivudine-refractory or known Lamivudine or Telbivudine resistance mutations, the recommended dose of Entecavir is 1 mg once daily. \n\nFor patients with decompensated liver disease (adult) the recommended dose of Entecavir is 1 mg once daily. Entecavir should be administered on an empty stomach (at least 2 hours after a meal or 2 hours before the next meal). \n\nRenal impairment (nucleoside-naive): CrCl 30-49mL/min: 0.25mg once daily or 0.5mg every 48 hours; CrCl 10-29mL/min: 0.15mg once daily or 0.5mg every 72 hours; CrCl <10mL/min or on hemodialysis: 0.05mg once daily or 0.5mg every 7 days; (lamivudine-refractory or decompensated liver disease): CrCl 30-49mL/min: 0.5mg once daily or 1mg every 48 hours; CrCl 10-29mL/min: 0.3mg once daily or 1mg every 72 hours; CrCl <10mL/min or on hemodialysis: 0.1mg once daily or 1mg every 7 days. For doses <0.5mg: use oral soln. If on hemodialysis day, give after session Children;.<16yrs: not recommended.\n\nContra-indication: Entecavir is contraindicated in patients with previously demonstrated hypersensitivity to Entecavir or any component of the product.\n\nSide effects: Headache, fatigue, dizziness, GI upset; rare: lactic acidosis, severe hepatomegaly with steatosis (may be fatal), post-treatment severe, acute exacerbation of hepatitis.\n\nPrecaution: HIV/HBV co-infected patients not receiving highly active antiretroviral therapy (HAART): not recommended. HIV antibody testing recommended before starting therapy. Monitor hepatic function during and for several months after ending therapy (risk of hepatitis B reactivation). Renal impairment (see Dose). Liver transplant. Reevaulate periodically. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.\n\nMode of action: Drugs that reduce renal function or compete for active tubular secretion may increase serum conc of either entecavir or co-administered drug.\n\nPregnancy category: C\n\nInteraction: Drugs that reduce renal function or compete for active tubular secretion may increase serum conc of either entecavir or co-administered drug.
Epalrestat	\n\n\tEskayef Bangladesh Ltd.\tAldorin TAB dr 50mg 24's pack 192\n\tIndication: Diabetic neuropathy\n\nDose:     In general, for adults, take 1 tablet (50mg of the active ingredient) at a time, three times daily, before meal. The dosage may be adjusted according to the age or symptoms. Strictly follow the instructions.\n\n  \n\nContra-indication:     If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.\n\n    If you are pregnant or breastfeeding.\n\n    If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)\n\nSide effects:  The most commonly reported adverse reactions include abdominal pain, nausea, rash, itch, erythema and blister. If any of these symptoms occur, consult with your doctor or pharmacist.\n\nPrecaution: If you find your urine yellowish brown or reddish after taking the medicine, take it as usual, because the yellowish brown or reddish color is attributed to components of this medicine.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Eperisone Hydrochloride	\n\n\tNovartis (Bangladesh) Ltd.\tEpirison SDZ TAB dr 50mg 50's pack 150\n\tOrion Pharma Ltd.\tEprel TAB dr 50mg 50's pack 150.50\n\tSquare\tMyonil TAB dr 50mg 50's pack 150.29\n\tIndication: Muscle spasms\n\nDose: Adult: PO 50 mg 3 times/day.\n\nContra-indication: \n\nSide effects: Weakness, dizziness, insomnia, drowsiness, numbness or trembling in the extremities, hepatic and renal dysfunction, haematological changes, skin rashes, itching, GI disturbances, urinary disorders, Rarely, shock.\n\nPrecaution: Hepatic impairment. May impair ability to drive and operate machines.\n\nMode of action: Avoid concomitant use with tolperisone HCl and methocarbamol.\n\nPregnancy category: Not Classified\n\nInteraction: Avoid concomitant use with tolperisone HCl and methocarbamol.
Ephedrine Hydrochloride	\n\n\tBangladesh Immunity Co.\tEphedrin Syrup 15mg/5ml 10 amps pack 120.50\n\tGonoshasthaya\tG-Ephedrine Injection 25mg/5ml 5 amps pack 60.25\n\tIncepta\tNordrine Injection 25mg/5ml 10 amps pack 120\n\tJayson\tFedrin Injection 25mg/5ml 10 amps pack 120.50\n\tPopular\tEphidin Injection 25mg/5ml 10 amps pack 120.50\n\tRenata\tEpidron Injection 25mg/5ml 5 amps pack 60.25\n\tIndication: Bronchial asthma, Hypotension, Diabetic neuropathic oedema, Nasal congestion\n\nDose: Adult: PO Diabetic neuropathic oedema 30-60 mg 3 times/day. \n\nIV Reversal of spinal or epidural anesth-induced hypotension As 3 mg/mL soln: 3-6 mg, up to 9 mg, may repeat every 3-4 mins if needed.\n\nContra-indication: Hypersensitivity. Hypertension, thyrotoxicosis, BPH. Lactation.\n\nSide effects: Anxiety, tachycardia, tremor, dry mouth, hypertension, cardiac arrhythmias, impaired circulation to the extremities, nervousness, insomnia, palpitations. Difficulty in micturition in patients with prostatic enlargement. Nasal drops: Local irritation, rebound nasal congestion and drug-induced rhinitis on prolonged use.\nPotentially Fatal: Delusions, hallucinations. Seen with hypersensitivity and overdosage. Acute CNS and CVS stimulation presenting as vomiting, fever, hypertension, psychosis. Cardiac arrhythmias.\n\nPrecaution: Ischaemic heart disease, hyperthyroidism, diabetes mellitus, hypertension, angle-closure glaucoma, renal impairment; prostatic enlargement; pregnancy, elderly.\n\nMode of action: Reduces antihypertensive effect of bethanidine and guanethidine. May increase clearance of dexamethasone. Increased incidence of adverse effects when used with theophylline.\nPotentially Fatal: Severe HTN when combined with MAOIs or withi 2 wk of discontinuance of MAOI treatment. Increased risk of arrhythmias with cardiac glycosides, quinidine or tricyclic antidepressants. Increased vasoconstriction or pressor effects with ergot alkaloids or oxytocin.\n\nPregnancy category: C\n\nInteraction: Reduces antihypertensive effect of bethanidine and guanethidine. May increase clearance of dexamethasone. Increased incidence of adverse effects when used with theophylline.\nPotentially Fatal: Severe HTN when combined with MAOIs or withi 2 wk of discontinuance of MAOI treatment. Increased risk of arrhythmias with cardiac glycosides, quinidine or tricyclic antidepressants. Increased vasoconstriction or pressor effects with ergot alkaloids or oxytocin.
Ephedrine Hydrochloride 0.5%	\n\n\tIndication: Nasal congestion\n\nDose: Adults, the elderly and children over 12 years: Use 1 or 2 drops in each nostril as required but no more than 4 times a day, unless your doctor tells you otherwise.\nChildren under 12 years: Not suitable unless advised by your doctor.\n\n\nContra-indication: Hypersensitivity. Hypertension, thyrotoxicosis, BPH. Lactation.\n\nSide effects: Nasal drops: Local irritation, rebound nasal congestion and drug-induced rhinitis on prolonged use.\n\nPrecaution: Ischaemic heart disease, hyperthyroidism, diabetes mellitus, hypertension, angle-closure glaucoma, renal impairment; prostatic enlargement; pregnancy, elderly.\n\nMode of action: Reduces antihypertensive effect of bethanidine and guanethidine. May increase clearance of dexamethasone. Increased incidence of adverse effects when used with theophylline.\nPotentially Fatal: Severe HTN when combined with MAOIs or withi 2 wk of discontinuance of MAOI treatment. Increased risk of arrhythmias with cardiac glycosides, quinidine or tricyclic antidepressants. Increased vasoconstriction or pressor effects with ergot alkaloids or oxytocin.\n\nPregnancy category: C\n\nInteraction: Reduces antihypertensive effect of bethanidine and guanethidine. May increase clearance of dexamethasone. Increased incidence of adverse effects when used with theophylline.\nPotentially Fatal: Severe HTN when combined with MAOIs or withi 2 wk of discontinuance of MAOI treatment. Increased risk of arrhythmias with cardiac glycosides, quinidine or tricyclic antidepressants. Increased vasoconstriction or pressor effects with ergot alkaloids or oxytocin.
Epinastine Hydrochloride 0.05% Eye prep	\n\n\tAristopharma\tEpinast Eye Drops    5  ml drop 150\n\tBeximco\tAlpatin Eye Drops 0.44mg 5ml bot 150\n\tEskayef Bangladesh Ltd.\tRelestat Eye Drops 0.05% 5ml bot 296\n\tIndication: Allergic conjunctivitis\n\nDose: Adult: Ophth As 0.05% soln: Instill 1 drop twice daily.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Headache; burning sensation, folliculosis, hyperaemia, pruritus; cough, pharyngitis, rhinitis, sinusitis.\n\nPrecaution: Pregnancy, lactation. Contact lenses should be removed prior to use since the formulation may contain benzalkonium chloride. It may be re-inserted after 10 min. Childn <3 yrs.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Eplerenone	\n\n\tIncepta\tEpleron TAB dr 25mg 20's pack 600\n\tUnimed & Unihealth Manufacturers Ltd.\tAldonist TAB dr 25mg 28's pack 1260\n\tUnimed & Unihealth Manufacturers Ltd.\tAldonist TAB dr 50mg  \n\tIndication: Hypertension, Heart failure, Congestive heart failure, Left ventricular dysfunction, Acute myocardial infarction\n\nDose: Adult: PO CHF Post-MI Initial: 25 mg once daily; titrate to recommended dose of 50 mg once daily w/in 4 wk as tolerated. Adjust dose based on serum potassium level; reduce or w/draw therapy if hyperkalaemia develops. \n\nHTN Initial: 50 mg once daily; may increase to 50 mg twice daily based on response. Initiate at lower dose of 25 mg once daily if used concurrently w/ moderate CYP3A4 inhibitors.\n\nContra-indication: For all patients: Serum potassium >5.5 mEq/L at initiation; CrCl ?30 mL/min; concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir). For patients treated for hypertension: Patients with type 2 DM with microalbuminuria; serum creatinine >2 mg/dL (male), or >1.8 mg/dL (female); CrCl <50 mL/min; concomitant use of potassium supplements or potassium-sparing diuretics (e.g. amiloride, spironolactone, or triamterene).\n\nSide effects: Hyperkalaemia, hyponatraemia, dizziness, headache, abdominal pain, diarrhoea, cough, fatigue, influenza-like symptoms, abnormal vaginal bleeding, gynaecomastia, mastodynia, myocardial infarction, angina pectoris, hypercholesterolaemia, hypertriglyceridaemia, albuminuria, increased creatinine, elevated liver enzymes, increased uric acid, rash and angioneurotic oedema.\n\nPrecaution: Measure serum potassium levels before starting therapy, within the first wk, and periodically thereafter. Increased risk of hyperkalaemia in patients with impaired renal functions; diabetic patients with CHF post-MI (especially those with proteinuria); or concurrent use of agents affecting the rennin-angiotensin-aldosterone system. Safety and efficacy not established in patients with severe hepatic impairment; or paediatric patients <18 yr. Elderly. Pregnancy and lactation.\n\nMode of action: Concomitant use with CYP3A4 Inhibitors (e.g. ketoconazole, voriconazole, itraconazole, fluconazole, clarithromycin, diltiazem saquinavir, verpamil, ritonavir) may increase serum concentrations of Eplerenone. CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital) may decrease Eplerenone efficacy. Eplerenone may enhance hyperkalaemic effect of ACE inhibitors, angiotensin II receptor blockers, potassium-sparing diuretics or potassium salts. Concomitant use with diazoxide, MAOIs, pentoxifylline, prostacyclin analogues may enhance hypotensive effect of antihypertensives. NSAIDs may possibly reduce the antihypertensive and/or diuretic effects of potassium-sparing diuretics and may increase risk of hyperkalaemia. Lithium toxicity has been reported when used with ACE inhibitors or diuretics; monitor lithium levels when used with Eplerenone.\n\nPregnancy category: B\n\nInteraction: Concomitant use with CYP3A4 Inhibitors (e.g. ketoconazole, voriconazole, itraconazole, fluconazole, clarithromycin, diltiazem saquinavir, verpamil, ritonavir) may increase serum concentrations of Eplerenone. CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital) may decrease Eplerenone efficacy. Eplerenone may enhance hyperkalaemic effect of ACE inhibitors, angiotensin II receptor blockers, potassium-sparing diuretics or potassium salts. Concomitant use with diazoxide, MAOIs, pentoxifylline, prostacyclin analogues may enhance hypotensive effect of antihypertensives. NSAIDs may possibly reduce the antihypertensive and/or diuretic effects of potassium-sparing diuretics and may increase risk of hyperkalaemia. Lithium toxicity has been reported when used with ACE inhibitors or diuretics; monitor lithium levels when used with Eplerenone.
Eptifibatide	\n\n\tIncepta\tIntegril 0.75 Injection 75mg/100ml 100ml vial 9000\n\tIncepta\tIntegril 2 Injection 20mg/10ml 10ml vial 3000\n\tIndication: Myocardial infarction, Unstable angina, Angioplasty, Percutaneous coronary intervention (PCI)\n\nDose: Adult: IV:\nAcute Coronary Syndrome \nâ¢ In patients with normal renal function: The recommended adult dosage is an IV bolus of 180 mcg/kg as soon as possible following diagnosis, followed by a continuous infusion of 2.0 mcg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a PCI the infusion should be continued up to hospital discharge, or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. \n\nâ¢ In patients with creatinine clearance <50 mL/min: The recommended adult dosage is an IV bolus of 180 mcg/kg as soon as possible following diagnosis, immediately followed by a continuous infusion of 1.0 mcg/kg/min. \n\nPercutaneous Coronary Intervention (PCI) \nâ¢ In patients with normal renal function: The recommended adult dosage is IV bolus of 180 mcg/kg administered immediately before the initiation of PCI followed by a continuous infusion of 2.0 mcg/kg/min and a second 180-mcg/kg bolus 10 minutes after the first bolus. Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended. \n\nâ¢ In patients with creatinine clearance <50 mL/min: The recommended adult dose is an IV bolus of 180 mcg/kg administered immediately before the initiation of the procedure, immediately followed by a continuous infusion of 1.0 mcg/kg/min and a second 180-mcg/kg bolus administered 10 minutes after the first. \n\nIn patients who undergo CABG surgery, Eptifibatide  infusion should be discontinued prior to surgery.\n\nRenal impairment: Dose reduction may be needed. \nCrCl (ml/min)	\n<30  	Contraindicated.\n\n\nContra-indication: Active bleeding, increased risk of haemorrhage including hemorrhagic disorders, cerebrovascular disorders, history of stroke, uncontrolled hypertension, severe trauma, severe renal impairment, recent major surgery. Lactation.\n\nSide effects: Bleeding, hypotension; localised Injection site reaction; thrombocytopaenia; back pain; anaphylaxis; GI, intracranial or pulmonary haemorrhage.\n\nPrecaution: Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic therapy is required. Hepatic impairment, platelet counts <100,000 mm3; hemorrhagic retinopathy, drugs affecting haemostasis. Check APTT or ACT prior to sheath removal. Severe renal impairment, vasculitis, haemorrhagic retinopathy, acute pericarditis or aortic dissection. Pregnancy.\n\nMode of action: Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.\n\nPregnancy category: B\n\nInteraction: Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.
Ergometrine Maleate	\n\n\tChemist Ltd.\tUrgotin Injection .2mg/1ml 10 amps pack 30\n\tGonoshasthaya\tG-ergometrine TAB dr .125mg 100's pack 55\n\tGonoshasthaya\tG-ergometrine Injection .2mg/1ml 5 amps pack 19.50\n\tOpsonin Pharma\tMetherspan TAB dr .125mg 100's pack 48.36\n\tOpsonin Pharma\tMetherspan Injection .2mg/1ml 25 amps pack 66.20\n\tIndication: Postpartum and post-abortion bleeding, 3rd stage of labour, Uterine bleeding, Postpartum haemorrhage\n\nDose: Adult: PO Post-partum and post-abortion bleeding 0.2-0.4 mg 2-4 times/day until danger of uterine atony and haemorrhage has passed. Max duration: 1 wk postpartum. \n\nIV Excessive uterine bleeding 200 mcg over at least 1 min, followed by oral doses of 200-400 mcg 2-4 times/day until the danger of atony or haemorrhage has passed. \n\nIM Active management of 3rd stage of labour 500 mcg w/ oxytocin after delivery of the anterior shoulder of the infant or immediately after delivery. Postpartum haemorrhage 200 mcg, may repeat in severe bleeding 2-4 hrly if needed.\n\nContra-indication: Pregnancy, 1st and 2nd stage of labour, patients with preeclampsia, eclampsia or threatened spontaneous abortion; porphyria.\n\nSide effects: Nausea, vomiting, abdominal pain, diarrhoea; headache, dizziness; tinnitus; chest pain, palpitation, bradycardia, transient hypertension and other cardiac arrhythmias; dyspnoea, sometimes rashes, shock.\nPotentially Fatal: MI, pulmonary oedema.\n\nPrecaution: Breech and abnormal foetal presentation; hypertension; chronic anaemia; hepatic, renal, respiratory or cardiac impairment; toxemia; lactation; hypocalcaemia. Monitor BP, pulse and uterine response.\n\nMode of action:  	Halothane causes relaxation of uterine muscle and may interfere with ergometrine action. Enhanced uterotonic effect with prostaglandins and oxytocin. Concurrent admin with CYP3A4 inhibitors may lead to vasospasm, cerebral ischaemia and/or ischaemia of extremities.\nPotentially Fatal: Enhanced vasoconstrictive effects with sympathomimetics and other vasoconstrictors.\n\nPregnancy category: X\n\nInteraction:  	Halothane causes relaxation of uterine muscle and may interfere with ergometrine action. Enhanced uterotonic effect with prostaglandins and oxytocin. Concurrent admin with CYP3A4 inhibitors may lead to vasospasm, cerebral ischaemia and/or ischaemia of extremities.\nPotentially Fatal: Enhanced vasoconstrictive effects with sympathomimetics and other vasoconstrictors.
Erlotinib	\n\n\tBeacon\tErlonix TAB dr 100mg 1's pack 600\n\tBeacon\tErlonix TAB dr 150mg 1's pack 750\n\tRadiant.\tTarceva TAB dr 100mg 1's  pack 5661\n\tRadiant.\tTarceva TAB dr 150mg 1's  pack 7875\n\tTechno Drugs Ltd.\tTarcenib TAB dr 100mg  \n\tTechno Drugs Ltd.\tTarcenib TAB dr 150mg  \n\tPfizer (perth) Pty. Ltd. Australia\tTarceva TAB dr 25mg  18\n\tIndication: Small cell lung cancer, Pancreatic cancer\n\nDose: Adult: PO Locally advanced or metastatic non small cell lung carcinoma 150 mg once daily. Locally advanced, unresectable or metastatic pancreatic cancer W/ gemcitabine: 100 mg/day. Dose modifications may be required when used with strong CYP3A4 inhibitors/inducers; or in cigarette smoking patients.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Adverse reactions reported with monotherapy: Fatigue, diarrhoea, anorexia, nausea, abdominal pain, stomatitis, weight loss, rash, pruritus, acne, dermatitis acneiform, dry skin, cough, dyspnoea, infection, conjunctivitis, conjunctivitis sicca, liver function test abnormalities. Adverse reactions reported when used with gemcitabine: Fatigue, rash, nausea, anorexia, diarrhoea, abdominal pain, vomiting, weight decreased, infection, oedema, pyrexia, constipation, bone pain, dyspnoea, stomatitis, myalgia, depression, dyspepsia, cough, dizziness, headache, insomnia, alopecia, anxiety, neuropathy, flatulence, rigors.\n\nPrecaution: Pregnancy and lactation. Interrupt Erlotinib therapy if patient develops unexplained pulmonary symptoms e.g. dyspnoea, cough, fever; discontinue therapy if interstitial lung disease is diagnosed. Monitor liver functions periodically; extreme caution is needed if total bilirubin is 3x >ULN; close monitoring is required in patients with hepatic impairment. Interrupt/discontinue therapy if severe changes in liver functions (doubling of total bilirubin and/or tripling of transaminases) occur. Interrupt therapy in the event of dehydration especially in patients with predisposing factors to renal failure. Monitor renal function and serum electrolytes in patients at risk of dehydration. Interrupt or discontinue therapy if patient develops severe bullous and exfoliative skin disorders; eye pain or other acute/worsening ocular disorders. If patient develops GI perforation, discontinue therapy permanently. Patients with CV disorders. Monitor prothrombin time/INR in patients taking warfarin or other coumarin-derivative anticoagulants.\n\nMode of action: Increased serum levels w/ potent CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, atazanavir). CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital) may reduce exposure of erlotinib. Increased serum levels w/ potent inhibitors of CYP1A2 (e.g. ciprofloxacin) or capecitabine. Use w/ P-glycoprotein inhibitors (e.g. ciclosporin, verapamil) may cause altered distribution or elimination of erlotinib. Drugs that increase the pH of the GI tract (e.g. antacids, H2-receptor antagonists, or PPIs) may reduce the solubility of erlotinib thus lowering its bioavailability. Concomitant use w/ warfarin or other coumarin derivates may increase INR and bleeding events.\n\nPregnancy category: D\n\nInteraction: Increased serum levels w/ potent CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, atazanavir). CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital) may reduce exposure of erlotinib. Increased serum levels w/ potent inhibitors of CYP1A2 (e.g. ciprofloxacin) or capecitabine. Use w/ P-glycoprotein inhibitors (e.g. ciclosporin, verapamil) may cause altered distribution or elimination of erlotinib. Drugs that increase the pH of the GI tract (e.g. antacids, H2-receptor antagonists, or PPIs) may reduce the solubility of erlotinib thus lowering its bioavailability. Concomitant use w/ warfarin or other coumarin derivates may increase INR and bleeding events.
Ertapenem	\n\n\tIndication: Intra-abdominal infections, Community-acquired pneumonia, Skin and skin structure infections, Urinary tract infections, Pyelonephritis, Surgical infections, Diabetic foot infections, Septic abortion\n\nDose: Adult: IV Surgical prophylaxis 1 g as a single dose, 1 hr before start of procedure. IV/IM Susceptible infections 1 g once daily.\n\nContra-indication: Hypersensitivity; lactation.\n\nSide effects: GI effects, injection-site reactions, raised platelet count; less frequently dry mouth, taste disturbances; hypotension, chest pain, oedema, pharyngeal discomfort, dyspnoea, dizziness, sleep disturbances, confusion, asthenia, seizures, vaginitis, raised glucose; headache; hypersensitivity reactions; antibiotic-associated colitis; dysphagia, cholecystitis; liver disorder; arrhythmia; increase in blood pressure; syncope; nasal congestion; cough; wheezing; CNS effects; pelvic peritonitis; renal impairment; muscle cramp, scleral disorder; blood disorders, hypoglycaemia; electrolyte disturbances. Local site reactions such as pain and thrombophlebitis may occur.\nPotentially Fatal: Pseudomembranous colitis, Stevens-Johnson syndrome.\n\nPrecaution: Hypersensitivity to penicillins, cephalosporins or other beta-lactams (possibility of cross-sensitivity). Renal impairment; CNS disorders e.g. epilepsy. Pregnancy.\n\nMode of action: May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.\n\nPregnancy category: B\n\nInteraction: May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
Erythromycin	\n\n\tACI\tErythin Powder for Suspension 125mg/5ml 100ml bot 61.47\n\tACI\tErythin TAB dr 500mg 30's pack 240\n\tAcme Ltd.\tErocin Powder for Suspension 125mg/5ml 100ml bot 60.22\n\tAcme Ltd.\tErocin TAB dr 250mg 50's pack 243.50\n\tAcme Ltd.\tErocin TAB dr 500mg 30's pack 258.90\n\tAcme Ltd.\tErocin Suspension 125mg  100 ml bot 60.22\n\tAd-din\tErythromycin A Powder for Suspension 250mg/5ml 100ml bot 60\n\tAexim\tEromed Powder for Suspension 125mg/5ml 100ml bot 55\n\tAlbion Ltd.\tErythromycin TAB dr 500 mg/ 250 mg 30's / 100's pack \n\tAlbion Ltd.\tErythromycin Dry Powder for Syrup 125 mg/5 ml 100 ml \n\tAlbion Ltd.\tErythromycin Paediatric Drops 200 mg/5 ml 60 ml \n\tAlbion Ltd.\tErythromycin Dry Powder for Syrup 250 mg/5 ml 100 ml \n\tAlco Pharma\tEry Powder for Suspension 125mg/5ml 100ml bot 50\n\tAlco Pharma\tEry TAB dr 250mg 50's pack 200\n\tAlco Pharma\tEry TAB dr 500mg 50's pack 350\n\tAmbee\tMycin TAB dr 500mg  50's pack 401\n\tAmbee\tMycin Suspension 125mg 100ml bot 60.22\n\tAmico Ltd.\tErixin Powder for Suspension 125mg/5ml 100ml bot 60\n\tAmico Ltd.\tErixin Drops 200mg  60 ml bot 60\n\tApex\tRhythm Powder for Suspension 125mg/5ml 100ml bot 52\n\tApex\tRhythm TAB dr 250mg 50's pack 200\n\tApex\tRhythm TAB dr 500mg 30's pack 210\n\tAristopharma\tA Mycin Powder for Suspension 125mg/5ml 100ml bot 61.29\n\tAristopharma\tA Mycin Paediatric Drops 50mg/1.25ml 60ml bot 60\n\tAristopharma\tA Mycin TAB dr 250mg 100's pack 480\n\tAristopharma\tA Mycin TAB dr 500mg 50's pack 450\n\tAristopharma\tA Mycin DS Powder for Suspension 250mg/5ml 100ml bot 104.20\n\tAsiatic Ltd.\tMacas Powder for Suspension 125mg/5ml 100ml bot 56.85\n\tAsiatic Ltd.\tMacas TAB dr 500mg 24's pack 194.88\n\tBeximco\tEtrocin Powder for Suspension 125mg/5ml 100ml bot 60.25\n\tBeximco\tEtrocin TAB dr 250mg 100's pack 480\n\tBeximco\tEtrocin TAB dr 500mg 50's pack 450\n\tBio Pharma Ltd.\tErosa Powder for Suspension 125mg/5ml 100ml bot 55.21\n\tBio Pharma Ltd.\tErosa TAB dr 250mg 100's pack 452\n\tBio Pharma Ltd.\tErosa TAB dr 500mg 50's pack 401.50\n\tBristol Pharma Ltd.\tErynet Powder for Suspension 125mg/5ml 100ml bot 60\n\tCentral.\tArigram Suspension 125mg 100 ml bot 60\n\tChemist Ltd.\tZerobac Powder for Suspension 250mg/5ml 100ml bot 55\n\tCosmic Chemical Industries Ltd.\tErylin Powder for Suspension 125mg/5ml 100ml bot 60\n\tCosmo Pharma Ltd.\tCpmycin TAB dr 250mg 100's pack 400\n\tDelta Pharma\tErona TAB dr 500mg 50's pack 454.50\n\tDelta Pharma\tErona DS Powder for Suspension 250mg/5ml 100ml 103\n\tDelta Pharma\tEronas Powder for Suspension 125mg/5ml 100ml bot 61.29\n\tDesh\tE-Rox 500 TAB dr 500mg 50's pack 350\n\tDesh\tE-Rox 500 Suspension 125mg  100ml bot 60\n\tDoctor's Chemicals Works Ltd.\tIlocin Powder for Suspension 125mg/5ml 100ml bot 60\n\tDoctor's Chemicals Works Ltd.\tIlocin TAB dr 500mg 20's pack 160\n\tDrug International Ltd.\tErybac Powder for Suspension 125mg/5ml 100ml bot 55\n\tDrug International Ltd.\tErybac TAB dr 250mg 50's pack 200\n\tDrug International Ltd.\tErybac TAB dr 500mg 30's pack 210\n\tEdruc Ltd.\tEdry Powder for Suspension 125mg/5ml 100ml bot 55\n\tEskayef Bangladesh Ltd.\tPriocin Powder for Suspension 125mg/5ml 100ml bot 60\n\tEskayef Bangladesh Ltd.\tPriocin TAB dr 500mg 40's pack 280\n\tEverest\tEres TAB dr 500mg 30's pack 240\n\tG. A. Company Ltd.\tEcin Powder for Suspension 125mg/5ml 100ml bot 60\n\tGeneral\tEromac Powder for Suspension 125mg/5ml 100ml bot 61.33\n\tGlobe\tThrocin Powder for Suspension 125mg/5ml 100ml bot 56\n\tGlobex\tGlomycin Powder For Suspension 125 mg/5 ml 100ml 60\n\tHallmark\tMacin Powder for Suspension 125mg/5ml 100ml bot 60\n\tHudson\tEro Powder for Suspension 125mg/5ml 100ml bot 60\n\tIbn Sina Pharmaceutical Ind. Ltd.\tErymex Powder for Suspension 125mg/5ml 100ml bot 60.50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tErymex TAB dr 500mg 30's pack 243\n\tIncepta\tFirmac Powder for Suspension 125mg/5ml 100ml bot 60\n\tIncepta\tFirmac TAB dr 250mg 50's pack 225\n\tIncepta\tFirmac TAB dr 500mg 30's pack 258\n\tKemiko\tErom Powder for Suspension 125mg/5ml 100ml bot 60\n\tKemiko\tErom TAB dr 250mg 100's pack 485\n\tKemiko\tErom TAB dr 500mg 50's pack 430\n\tKumudini Pharma Ltd.\tKumucin Powder for Suspension 125mg/5ml 100ml bot 55\n\tMarksman.\tEryth Powder for Suspension 125mg/5ml 100ml bot 55\n\tMedicon\tErythro Powder for Suspension 125mg/5ml 100ml bot 57\n\tMedicon\tErythro TAB dr 500mg 30's pack 240.90\n\tMedimet\tEmycin Powder for Suspension 125mg/5ml 100ml bot 61\n\tMedimet\tEmycin TAB dr 250mg 50's pack 237.50\n\tMillat\tMitrocin Powder for Suspension 125mg/5ml 100ml bot 60\n\tMillat\tMitrocin DS Powder for Suspension 250mg/5ml 100ml bot 103\n\tMillat\tMitrocin TAB dr 250mg 30's pack 136.50\n\tMillat\tMitrocin TAB dr 500mg 20's pack 170.20\n\tModern\tEM Powder for Suspension 125mg/5ml 100ml bot 60\n\tModern\tEm TAB dr 500mg 20's pack 160\n\tMonicopharma\tAcryth Powder for Suspension 125mg/5ml 100ml bot 60\n\tMystic\tEthrolex Suspension 125mg 100ml bot 54.50\n\tMystic\tEthrolex 500 TAB dr 500mg  30's pack 217.50\n\tNavana\tEryrox Powder for Suspension 125mg/5ml 100ml bot 60.22\n\tNavana\tEryrox TAB dr 500mg 30's pack 240.90\n\tNipa\tEuro Powder for Suspension 125mg/5ml 100ml bot 60\n\tNipa\tEuro TAB dr 250mg 50's pack 212.50\n\tNipa\tEuro TAB dr 500mg 30's pack 240\n\tNovartis (Bangladesh) Ltd.\tServitrocin Powder for Suspension 125mg/5ml 100ml bot 60.68\n\tNovartis (Bangladesh) Ltd.\tServitrocin TAB dr 250mg 100's pack 485\n\tNovartis (Bangladesh) Ltd.\tServitrocin TAB dr 500mg 50's pack 430\n\tOpsonin Pharma\tErmac Powder for Suspension 125mg/5ml 100ml bot 61.30\n\tOrion Pharma Ltd.\tMac Powder for Suspension 125mg/5ml 100ml bot 60.27\n\tOrion Pharma Ltd.\tMac Suspension 50mg/1.25ml 100ml bot \n\tOrion Pharma Ltd.\tMac DS Powder for Suspension 250mg/5ml 70ml bot/100ml bot 74.27/103.39\n\tPacific\tMacery Powder for Suspension 125mg/5ml 100ml bot 46\n\tPacific\tMacery TAB dr 250mg 50's pack 225\n\tPacific\tMacery TAB dr 500mg 30's pack 246\n\tPharmadesh Ltd.\tEthro Suspension 125mg 100ml bot 75\n\tRadiant.\tErrin Powder for Suspension 125mg/5ml 100ml bot 60\n\tRangs\tPedicin Powder for Suspension 125mg/5ml 100ml bot 60\n\tRenata\tErythrox Powder for Suspension 125mg/5ml 100ml bot 61.07\n\tRenata\tErythrox TAB dr 250mg 50's pack 242.50\n\tRenata\tErythrox TAB dr 500mg 50's pack 429.50\n\tRephco\tZuracyn Powder for Suspension 125mg/5ml 100ml bot 61.07\n\tSanofi Aventis (BD) Ltd.\tMacrocin Powder for Suspension 125mg/5ml 100ml bot 61.23\n\tSanofi Aventis (BD) Ltd.\tMacrocin TAB dr 250mg 100's pack 488.11\n\tSanofi Aventis (BD) Ltd.\tMacrocin TAB dr 500mg 50's pack 432.92\n\tSharif\tErosite Powder for Suspension 125mg/5ml 100ml bot 69.32\n\tSomatec\tErycin Powder for Suspension 125mg/5ml 100ml bot 56.21\n\tSomatec\tErycin TAB dr 250mg 50's pack 216\n\tSomatec\tErycin TAB dr 500mg 30's pack 240.90\n\tSquare\tEromycin Powder for Suspension 125mg/5ml 100ml bot 56.86\n\tSquare\tEromycin Paediatric Drops 50mg/1.25ml 60ml Drop 60.22\n\tSquare\tEromycin TAB dr 250mg 50's pack 218.12\n\tSquare\tEromycin DS TAB dr 500mg 30's pack 243.79\n\tSyntho Ltd.\tE-Lid Suspension 125mg 100 ml bot 54\n\tTechno Drugs Ltd.\tMakcin Powder for Suspension 125mg/5ml 100ml bot 50\n\tZenith\tEryzen Powder for Suspension 125mg/5ml 100ml bot 56.64\n\tZenith\tEryzen TAB dr 250mg 60's pack 261\n\tZenith\tEryzen TAB dr 500mg 20's pack 172\n\tIndication: Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.						\n\n\nDose: Adults: Usually 250 mg every 6 hours, or 500 mg every 12 hours. May increase up to 4 g/day, according to severity of infection. \n\nUpper respiratory tract infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.\nLower respiratory infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.\nRespiratory tract infections due to Mycoplasma pneumoniae:  500 mg 6 hours for 5 to 10 days, treat severe infections for up to 3 weeks.\n\nSkin and soft tissue infections of mild to moderate severity:	250 to 500 mg 4 times a day for 10 days.\nPelvic inflammatory diseases (PID), acute due to Neisseria gonorrhoeae:  500 mg 4 times a day for 10 to 14 days.\nUrogenital infection during pregnancy caused by Chlamydia trachomatis:  500 mg 4 times daily for 7 days or\n250 mg 4 times daily for 14 days.\n\nUrethral, endocervical or rectal infections, uncomplicated:  500 mg 4 times daily for 7 days or\n250 mg 4 times daily for 14 days.\n\nNon-gonococcal urethritis:  500 mg 4 times daily for at least 7 days.\nNeisseria gonorrhoeae: Uncomplicated urethral, endocervical or rectal infections and in penicillinase producing N. gonorrhoeae(PPNG):  500 mg 4 times a day for 7 days.\n\nEarly syphillis (primary, secondary or latent syphillis of < 1 year duration):  500 mg 4 times a day for 14 days.\nSevere or chronic diarrhoea: 500 mg 4 times a day for 7 days. Rheumatic fever:	250 mg 2 times daily.\n\nBacterial endocarditis:	1 g 2 hours prior to procedures, then 500 mg 6 hours after initial dose.\nAcne:	500 mg twice daily for 3 months reduced to 250 mg twice for 3 months.\n\nChildren:\nThe usual oral dose is 30-50 mg/kg body weight per day in divided doses. For more severe infections, the dose may be doubled. \n\nContra-indication: Hypersensitivity; porphyria; hepatic impairment; pregnancy.\n\nSide effects: Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.\nPotentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.\n\nPrecaution: Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.\n\nMode of action: May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.\n\nPregnancy category: B\n\nInteraction: May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
Erythromycin solution	\n\n\tAristopharma\tA Mycin Lotion   25ml bot 120\n\tSanofi Aventis (BD) Ltd.\tMacrocin-T Solution  30ml bot 200\n\tSquare\tEromycin 2%, 3% Lotion  100 mg/5 m, 150 mg/5 ml 25ml bot 100.38\n\tIndication: Acne\n\nDose: As  cream/solution: Apply onto affected areas 1-2 times daily. \nDiscontinue treatment if condition worsens or if there is no improvement after 6-8 wk of continuous usage.\n\nContra-indication: Hypersensitivity; porphyria; hepatic impairment; pregnancy.\n\nSide effects: Rash, urticaria; nausea, vomiting, GI discomfort; ototoxicity; central neurotoxicity; agranulocytosis; arrhythmias; pancreatitis.\nPotentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.\n\nPrecaution: Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis.\n\nMode of action: Rhabdomyolysis w/ or w/o renal impairment w/ HMG-CoA reductase inhibitors (e.g. simvastatin). Increased risk of colchicine toxicity. Increased sedation w/ triazolobenzodiazepines and related benzodiazepines (e.g. alprazolam, midazolam). Theophylline may decrease and cimetidine may increase erythromycin concentration. Hypotension, bradyarrhythmia and lactic acidosis w/ Ca channel blockers (e.g. verapamil, amlodipine, diltiazem). Increased systemic exposure of sildenafil. Increased or prolonged adverse effects w/ ciclosporin, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine and bromocriptine. Increased risk of digoxin toxicity. Increased bleeding w/ oral anticoagulants.\nPotentially Fatal: QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, torsades de pointes w/ cisapride, pimozide, astemizole or terfenadine. Acute ergot toxicity w/ ergotamine and dihydroergotamine.\n\nPregnancy category: B\n\nInteraction: Rhabdomyolysis w/ or w/o renal impairment w/ HMG-CoA reductase inhibitors (e.g. simvastatin). Increased risk of colchicine toxicity. Increased sedation w/ triazolobenzodiazepines and related benzodiazepines (e.g. alprazolam, midazolam). Theophylline may decrease and cimetidine may increase erythromycin concentration. Hypotension, bradyarrhythmia and lactic acidosis w/ Ca channel blockers (e.g. verapamil, amlodipine, diltiazem). Increased systemic exposure of sildenafil. Increased or prolonged adverse effects w/ ciclosporin, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine and bromocriptine. Increased risk of digoxin toxicity. Increased bleeding w/ oral anticoagulants.\nPotentially Fatal: QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, torsades de pointes w/ cisapride, pimozide, astemizole or terfenadine. Acute ergot toxicity w/ ergotamine and dihydroergotamine.
Erythropoietin	\n\n\tAristopharma\tNipotin Injection 2000IU/0.5ml 1's pack 900\n\tAristopharma\tNipotin Injection 3000IU/0.7ml 1's pack 1250\n\tAristopharma\tNipotin Injection 4000IU/0.4ml 1's pack 1700\n\tAristopharma\tNipotin Injection 5000IU/.5ml 1's pack 2150\n\tBeacon\tEposis Injection 2000IU/0.5ml 2000 IU pre-filled syringe x 1's  900\n\tBeacon\tEposis Injection 3000IU/0.7ml  3000 IU pre-filled syringe x 1's  1300\n\tBeacon\tEposis Injection 5000IU/0.5ml  5000 IU pre-filled syringe x 1's  1900\n\tHealthcare\tIniter Injection 5000IU/0.5ml pre-filled syringe x 1's 2100\n\tHealthcare\tIniter Injection 3000IU/0.7ml pre-filled syringe x 1's 1400\n\tHealthcare\tIniter Injection 2000IU/0.5ml pre-filled syringe x 1's 1100\n\tHealthcare\tIniter Injection 10000IU/ml pre-filled syringe x 1's 5100\n\tIncepta\tEpoetin Injection 2000IU/0.5ml pre-filled syringe x 1's 900\n\tIncepta\tEpoetin Injection 3000IU/0.7ml pre-filled syringe x 1's 1250\n\tIncepta\tEpoetin Injection 5000IU/0.5ml pre-filled syringe x 1's 2160\n\tUnimed & Unihealth Manufacturers Ltd.\tEprex Injection 2000IU 6's pack 10704\n\tUnimed & Unihealth Manufacturers Ltd.\tEprex Injection 4000IU 6's pack 214909.38\n\tUnimed & Unihealth Manufacturers Ltd.\tEprex Injection 10000IU 6's pack 30543\n\tIndication: Anemia associated with Chronic Renal Failure, including patients on dialysis (ESRD) and patients not on dialysis, Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy, Anemic patients (hemoglobin > 10 to < 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions, Anemia related to therapy with zidovudine in HIV-infected patients.\n\nDose: Treatment of anemia in chronic renal failure: Erythropoietin is administered to maintain hemoglobin concentration between 11 to 12 g/dl and hematocrit of 33 -36 % in adults.\n\nStarting dose:\nAdult: usually 50 to 100 IU/kg three times in a week (TIW) by IV or Subcutaneous route\nPediatric: 50 IU/kg TIW by IV or Subcutaneous route\n\nDose adjustment: Dose should be increased if hematocrit doses not increase by 5 to 6 points after 8 weeks therapy, and hematocrit is below suggested target range. Dose should be reduced when hematocrit approaches 36% or hematocrit increases >4 points in any 2-week period.\n\nMaintenance dose: Maintenance dose must be individualized for each patient. In patients undergoing dialysis, the median maintenance dose is 75 IU/kg TIW, with a range from 12.5 to 525 IU/kg TIW as directed by the physician. In CRF patients not on dialysis, maintenance dose is 75 to 150 IU/kg/week.\n\nTreatment of Anemia in Cancer Patients on Chemotherapy\nStarting dose:\nAdult: 150 IU/kg TIW by Subcutaneous route or 40,000 IU Subcutaneous route weekly\nPediatric: 25 to 300 IU/kg 3 to 7 times per week by Subcutaneous or IV route\n\nDose adjustment: If the response is not satisfactory, the dose should be increased to 300 IU/kg TIW. If the hematocrit exceeds 40%, the dose should be withheld until the hematocrit falls to 36%. The dose should be reduced to 25% when treatment is resumed and titrated to maintain the desired hematocrit.\n\nSurgery Patients\nThe recommended dose is 300 IU/kg/day subcutaneously for 10 days before surgery, on the day of surgery, and for 4 days after surgery. An alternate dose schedule is 600 IU/kg subcutaneously in once weekly dose (21, 14, and 7 days before surgery) plus a fourth dose on the day of surgery.\n\nZidovudine-treated HIV-infected Patients\nStarting dose:\nAdult: 100 IU/kg as an IV or Subcutaneous injection TIW for 8 weeks\nPediatric: 50 to 400 IU/kg 2 to 3 times per week by Subcutaneous or IV route\n\nDose adjustment: If the response is not satisfactory, the dose should be increased by 50-100 IU/kg TIW. Response should be evaluated every 4 to 8 weeks thereafter and the dose adjusted accordingly by 50 to 100 IU/kg increments TIW.\n\nMaintenance dose: The dose is titrated to maintain the hematocrit between 33-36%.\n\nContra-indication: Uncontrolled hypertension, hypersensitivity to mammalian cell products and human albumin.\n\nSide effects: General: Headache, dizziness, fever, malaise, arthralgia and occasionally hyperkalemia CVS: Hypertension is the most common side effect, palpitations. Gastrointestinal: Nausea, vomiting, anorexia and diarrhea may occur occasionally. Allergic reactions.Potentially Fatal: Hypertensive crisis with encephalopathy-like symptoms e.g. headache, confusion, generalised seizures. Thrombosis.\n\nPrecaution: Erythropoietin should be used with caution in those patients with controlled hypertension, ischaemic vascular disease, history of seizures, or suspected allergy to the product. Iron evaluation: Prior to and during Epoetin therapy, the patient's iron stores, including transferrin saturation and serum ferritin, should be evaluated. Transferrin saturation should be at least 20%, and ferritin should be at least 100 ng/mL. Virtually all patients will require supplemental iron to increase or maintain transferrin saturation to levels that will adequately support erythropoiesis.\n\nMode of action:  	Haematinics enhance efficiency. Increased dose of heparin in patients undergoing dialysis.\n\nPregnancy category: C\n\nInteraction:  	Haematinics enhance efficiency. Increased dose of heparin in patients undergoing dialysis.
Escitalopram	\n\n\tACI\tCitalam TAB dr 5mg 30's pack 210\n\tACI\tCitalam TAB dr 10mg 30's pack 360\n\tAcme Ltd.\tElodep TAB dr 5mg  \n\tAcme Ltd.\tElodep TAB dr 10mg  \n\tBeximco\tSeropam TAB dr 5mg 30's pack 165\n\tEskayef Bangladesh Ltd.\tLosita TAB dr 10mg 20's pack 200\n\tEskayef Bangladesh Ltd.\tLosita TAB dr 5mg 40's pack 240\n\tGeneral\tS-Citapram TAB dr 10mg 20's pack 200.80\n\tGeneral\tS-Citapram TAB dr 5mg 30's pack 210\n\tHealthcare\tEsita TAB dr 10mg 20's pack 360\n\tHealthcare\tEsita TAB dr 5mg 20's pack 110\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAcipam TAB dr 5mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tAcipam TAB dr 10mg  \n\tIncepta\tEsipram 10 TAB dr 10mg 30's pack 300\n\tIncepta\tEsipram 5 TAB dr 5mg 30's pack 165\n\tJayson\tMeliva TAB dr 10mg 30's pack 240.90\n\tNavana\tTalopram TAB dr 5mg  \n\tNavana\tTalopram TAB dr 10mg  \n\tNovartis (Bangladesh) Ltd.\tEstarex TAB dr 5mg  \n\tNovartis (Bangladesh) Ltd.\tEstarex TAB dr 10mg  \n\tOpsonin Pharma\tCitalex TAB dr 10mg 20's pack 141\n\tOpsonin Pharma\tCitalex 5 TAB dr 5mg 10x3's pack 165\n\tPopular\tCitalon TAB dr 10mg 30's pack 240.92\n\tSquare\tOxapro TAB dr 10mg 30's pack 300\n\tSquare\tOxapro TAB dr 5mg 30's pack 165.59\n\tSun Pharmaceutical (Bangladesh) Ltd.\tNexito TAB dr 5mg 50's pack 275\n\tUnimed & Unihealth Manufacturers Ltd.\tNexcital TAB dr 10mg 30's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tNexcital TAB dr 5mg 30's pack 165\n\tIndication: Major depressive disorder, Depression, Panic disorder, Obsessive compulsive disorder, Anxiety disorder\n\nDose: Adult: PO Depression; Anxiety; Obsessive compulsive disorder 10 mg once daily. Max: 20 mg/day. \nPanic disorder Initial: 5 mg/day, up to 10 mg/day after 7 days if needed. Max: 20 mg/day.\n\nElderly: Half the adult dose.\nHepatic impairment: Dosage adjustments may be required. \n\nContra-indication: Concomitant use with or within 2 wk of MAOI withdrawal.\n\nSide effects: Nausea, diarrhoea, increased sweating, insomnia, impotence, ejaculation disorder, fatigue, somnolence; postural hypotension, sinusitis, taste disturbances. Increased appetite and wt gain.\n\nPrecaution: History of mania or seizure disorders; work requiring mental alertness; renal and hepatic impairment; pregnancy, lactation; withdraw gradually. Children and adolescents <18 yr\n\nMode of action: Increased risk of bleeding when used with aspirin, NSAIDs or drugs that affect coagulation. Serum levels may be reduced by CYP2C19 inducers (e.g. carbamazepine, rifampin, phenytoin) or CYP3A4 inducers (e.g. nafcillin, nevirapine). Serum levels may also be increased by CYP2C19 inhibitors (e.g. fluconazole, fluvoxamine, omeprazole) or CYP3A4 inhibitors (e.g. azole antifungals, clarithromycin). May increase serum levels of desipramine or metoprolol. Increased risk of serotonin syndrome when used with linezolid or sibutramine. Escitalopram may enhance the sedative effects of alcohol.\nPotentially Fatal: Concomitant administration with MAOIs may lead to serious or fatal reactions; should not be started until at least 2 wk after stopping escitalopram or vice versa. Moclobemide may increase the risk of serotonin syndrome.\n\nPregnancy category: C\n\nInteraction: Increased risk of bleeding when used with aspirin, NSAIDs or drugs that affect coagulation. Serum levels may be reduced by CYP2C19 inducers (e.g. carbamazepine, rifampin, phenytoin) or CYP3A4 inducers (e.g. nafcillin, nevirapine). Serum levels may also be increased by CYP2C19 inhibitors (e.g. fluconazole, fluvoxamine, omeprazole) or CYP3A4 inhibitors (e.g. azole antifungals, clarithromycin). May increase serum levels of desipramine or metoprolol. Increased risk of serotonin syndrome when used with linezolid or sibutramine. Escitalopram may enhance the sedative effects of alcohol.\nPotentially Fatal: Concomitant administration with MAOIs may lead to serious or fatal reactions; should not be started until at least 2 wk after stopping escitalopram or vice versa. Moclobemide may increase the risk of serotonin syndrome.
Esomeprazole Magnesium Trihydrate BP	\n\n\tACI\tEsomep CAP 20mg 50's pack 351\n\tACI\tEsomep TAB dr 20mg 50's pack 251\n\tACI\tEsomep CAP 40mg 40's pack 361.20\n\tACI\tEsomep TAB dr 40mg 30's pack 240.60\n\tAcme Ltd.\tMaxima TAB dr 20mg  \n\tAcme Ltd.\tMaxima TAB dr 40mg  \n\tAcme Specialized\tMaxima CAP 20mg 40's pack 200.40\n\tAcme Specialized\tMaxima CAP 40mg 20's pack 160.80\n\tAd-din\tSomazole CAP 20mg 100's pack 400\n\tAlco Pharma\tEsopra 20 TAB dr 20mg 50's pack 200\n\tAlco Pharma\tEsopra 40 TAB dr 40mg 30's Pack 270\n\tAmico Ltd.\tPrazia TAB dr 20mg  \n\tAmico Ltd.\tPrazia TAB dr 40mg  \n\tAmulet\tEsomo CAP 20mg 60's pack 360\n\tAmulet\tEsomo CAP 40mg 30's pack 240\n\tApex\tNexe TAB dr 20mg 50's pack 250\n\tApex\tNexe TAB dr 40mg 30's pack 240\n\tApex\tNexe CAP 20mg 30's pack 150\n\tAristopharma\tEmep TAB dr 20mg 60's pack 300\n\tAristopharma\tEmep E/C CAP 20mg 60's pack 420\n\tAristopharma\tEmep E/C CAP 40mg 40's pack 360\n\tAsiatic Ltd.\tEso TAB dr 20mg 30's pack 150\n\tAstra Biopharmaceuticals Ltd.\tEsoz TAB dr 20mg 30's pack 150\n\tAstra Biopharmaceuticals Ltd.\tEsoz TAB dr 40mg  \n\tAstra Biopharmaceuticals Ltd.\tEsoz CAP 40mg  \n\tBeacon\tEsoprex CAP 20mg 40's pack 200\n\tBeacon\tEsoprex CAP 40mg 30's pack 240\n\tBeximco\tOpton TAB dr 20mg 30's pack 150\n\tBeximco\tOpton TAB dr 40mg 30's pack 240\n\tBio Pharma Ltd.\tEsocon CAP 20mg 60's pack 360\n\tBio Pharma Ltd.\tEsocon CAP 40mg 40's pack 281.20\n\tBio Pharma Ltd.\tEsocon TAB dr 40mg 40's pack 281.20\n\tBio Pharma Ltd.\tEsocon TAB dr 20mg 60's pack 241.20\n\tChemist Ltd.\tExome TAB dr 20mg 50's pack 200\n\tConcord\tEsmax CAP 20mg 30's pack 150\n\tConcord\tEsmax TAB dr 20mg 60's pack 360\n\tConcord\tEsmax CAP 40mg 20's pack 160\n\tDelta Pharma\tAlenia CAP 20mg 64's pack 320\n\tDelta Pharma\tAlenia TAB dr 20mg 30's pack 120\n\tDelta Pharma\tAlenia-40 CAP 40mg 30's pack 210\n\tDelta Pharma\tImax TAB dr 20mg  \n\tDelta Pharma\tImax CAP 20mg  \n\tDelta Pharma\tImax CAP 40mg  \n\tDoctor Tims\tE-Proton CAP 20mg  \n\tDoctor's Chemicals Works Ltd.\tEsru TAB dr 20mg 50's pack 200\n\tDrug International Ltd.\tPronex TAB dr 20mg 50's pack 250\n\tDrug International Ltd.\tPronex TAB dr 40mg 50's pack 400\n\tDrug International Ltd.\tPronex CAP 20mg  \n\tDrug International Ltd.\tPronex CAP 40mg  \n\tEdruc Ltd.\tEsom-E TAB dr 20mg 30's pack 120\n\tEskayef Bangladesh Ltd.\tEsoral CAP 20mg 80's pack 400\n\tEskayef Bangladesh Ltd.\tEsoral TAB dr 20mg 50's pack 200\n\tEskayef Bangladesh Ltd.\tEsoral CAP 40mg 30's pack 270\n\tEskayef Bangladesh Ltd.\tEsoral TAB dr 40mg 20's pack/30's pack 140/210\n\tEthical Drug Ltd.\tGaspro CAP 20mg  \n\tEthical Drug Ltd.\tGaspro CAP 40mg  \n\tEuro Pharma Ltd.\tEsogap TAB dr 20mg 50's pack 200\n\tEuro Pharma Ltd.\tEsogap TAB dr 40mg 30's pack 210\n\tEverest\tEzoom TAB dr 20mg 50's pack 200\n\tG. A. Company Ltd.\tEsmotac TAB dr 20mg 30's pack 120\n\tG. A. Company Ltd.\tEsmotac TAB dr 40mg 20's pack 140\n\tGeneral\tAloton TAB dr 5mg 30's pack \n\tGeneral\tAlton TAB dr 40mg 30's pack 210\n\tGeneral\tAlton TAB dr 20mg 30's pack 150\n\tGlobe\tEma TAB dr 20mg 30's pack 142\n\tGlobe\tEma CAP 20mg  \n\tGlobex\tEsoking CAP 40mg  \n\tGlobex\tEsoking CAP 20mg 60's pack 360\n\tHallmark\tEsopin TAB dr 20mg 30's pack/50's pack 126.60/201\n\tHealthcare\tSergel CAP 20mg 90's pack 630\n\tHealthcare\tSergel CAP 40mg 30's pack 270\n\tHealthcare\tSergel TAB dr 40mg 50's pack 270\n\tHealthcare\tSergel TAB dr 20mg 30's pack 210\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEsolok TAB dr 20mg 100's pack 650\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEsolok TAB dr 40mg 48's pack 384\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEsolok- CAP 20mg 100's pack 650\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEsolok- CAP 40mg 48's pack 384\n\tIncepta\tEsonix 20 tablet TAB dr 20mg 	 	 50's pack 250\n\tIncepta\tEsonix 40 tablet TAB dr 40mg 	 	 30's pack 240\n\tIncepta\tEsonix 20 capsule CAP 20mg 	 	 56's pack 392 	\n\tIncepta\tEsonix 40 capsule CAP 40mg 	 	 30's pack 270\n\tKemiko\tErazole TAB dr 20mg 30's pack 120\n\tKemiko\tErazole CAP 20mg  \n\tKemiko\tErazole TAB dr 40mg  \n\tKumudini Pharma Ltd.\tEsomiloc TAB dr 20mg 50's pack 250\n\tLabaid\tEprazol CAP 20mg 60's pack 420\n\tLabaid\tEprazol CAP 40mg 60's pack \n\tLeon\tPepzol CAP 20mg  \n\tLeon\tPepzol CAP 40mg  \n\tMedicon\tEsozol CAP 20mg 50's pack 225\n\tMedicon\tEsozol CAP 40mg  \n\tModern\tEz CAP 20mg 30's pack 150\n\tMonicopharma\tNuloc TAB dr 20mg  \n\tMystic\tEspram TAB dr 20mg 30's pack 120\n\tNavana\tEsotac CAP 20mg 100's pack 500\n\tNavana\tEsotac TAB dr 20mg 60's pack/100's pack 241/402\n\tNavana\tEsotac CAP 40mg 30's pack 210.90\n\tNavana\tEsotac TAB dr 40mg 30's pack 210.90\n\tNipa\tEpizol Capsul 20mg  \n\tNipa\tEpizol CAP 40mg  \n\tNIPRO JMI Pharma\tEsotor TAB dr 20mg  \n\tNIPRO JMI Pharma\tEsotor TAB dr 40mg  \n\tNIPRO JMI Pharma\tEsotor CAP 20mg  \n\tNIPRO JMI Pharma\tEsotor CAP 40mg  \n\tNovartis (Bangladesh) Ltd.\tNeptor CAP 20mg 60's pack 480\n\tNovartis (Bangladesh) Ltd.\tNeptor CAP 40mg 30's pack 360\n\tNovelta Bestway\tEsocare CAP 20mg 50's pack 300\n\tNovelta Bestway\tEsocare CAP 40mg 30's pack 270\n\tNovo Healthcare and Pharma Ltd.\tAscetor CAP 20mg 60's pack 420\n\tNovo Healthcare and Pharma Ltd.\tAsector CAP 40mg 28's pack 252\n\tNovo Healthcare and Pharma Ltd.\tAsector TAB dr 20mg 60's pack 420\n\tOpsonin Pharma\tEsotid CAP 20mg 90's pack 540\n\tOpsonin Pharma\tEsotid TAB dr 20mg 50's pack 250\n\tOpsonin Pharma\tEsotid Sachet 20mg 90's pack 476\n\tOpsonin Pharma\tEsotid TAB dr 40mg 50's pack 350\n\tOpsonin Pharma\tEsotid CAP 40mg 30's pack 270\n\tOrion Pharma Ltd.\tExor 20 CAP 20mg 50's pack 300\n\tOrion Pharma Ltd.\tExor 40 CAP 40mg 30's pack 270\n\tOrion Pharma Ltd.\tPreso TAB dr 20mg 30's pack \n\tOrion Pharma Ltd.\tPreso TAB dr 40mg 30's pack \n\tPacific\tEzoom TAB dr 40mg 20's pack\n 180\n\tPacific\tEsprazo CAP 20mg 30's pack 150\n\tPharmadesh Ltd.\tEmo TAB dr 20mg 30's pack 135\n\tPharmasia Ltd.\tXelpro CAP 20mg 50s pack 250\n\tPharmasia Ltd.\tXelpro CAP 40mg 30's pack 240\n\tPharmasia Ltd.\tXelpro TAB dr 20mg  \n\tPharmasia Ltd.\tXelpro TAB dr 40mg  \n\tPopular\tProgut TAB dr 20mg 100's pack 700\n\tPopular\tProgut TAB dr 40mg 32's pack 256.96\n\tPrime\tEsomiz CAP 20mg  \n\tPrime\tEsomiz CAP 40mg  \n\tRadiant.\tExium CAP 20mg 100's pack 750\n\tRadiant.\tExium CAP 40mg 24's pack 198\n\tRAK\tEsomenta CAP 20mg 30's pack 150\n\tRAK\tEsomenta CAP 40mg 30's pack 300\n\tRangs\tCuracid CAP 20mg 28's pack 168\n\tRangs\tCuracid CAP 40mg 20's pack 180\n\tRangs\tCuracid TAB dr 20mg 28's pack 140\n\tRangs\tCuracid TAB dr 40mg 20's pack 140\n\tRenata\tMaxpro CAP 20mg 42's pack 294\n\tRenata\tMaxpro TAB dr 20mg 100's pack 500\n\tRenata\tMaxpro CAP 40mg 30's pack 300\n\tRenata\tMaxpro TAB dr 40mg 30's pack 240\n\tRenata\tMaxpro Powder For Suspension 20mg  \n\tS. N.\tEsofast TAB dr 20mg 30's pack 136.50\n\tSharif\tSomprazol CAP 20mg 60's pack 360\n\tSharif\tSomprazol CAP 40mg 50's pack 400\n\tSharif\tSomprazol TAB dr 40mg 20's pack 160\n\tSharif\tSomprazol TAB dr 20mg 40's pack 200\n\tSomatec\tS-Ome TAB dr 20mg 50's pack 200.50\n\tSomatec\tS-Ome CAP 40mg 30's pack 210.90\n\tSquare\tNexum CAP 20mg 60's pack 361.20\n\tSquare\tNexum TAB dr 20mg 50's pack 250.70\n\tSquare\tNexum CAP 40mg 30's pack 270.92\n\tSquare\tNexum TAB dr 40mg 30's pack 241\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSompraz TAB dr 20mg 50's pack 250\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSompraz TAB dr 40mg 50's pack 400\n\tSyntho Ltd.\tExmart TAB dr 20mg 30's pack 150\n\tTechno Drugs Ltd.\tEsmosec TAB dr 20mg 40's pack 160\n\tUnimed & Unihealth Manufacturers Ltd.\tNexcap DR CAP 20mg 28's pack 140\n\tUnimed & Unihealth Manufacturers Ltd.\tNexcap DR CAP 40mg 28's pack 224\n\tVeritas\tEsover CAP 20mg  \n\tVeritas\tEsover CAP 40mg  \n\tWhite Horse Pharma\tAsozit CAP 20mg 30's pack 210\n\tZenith\tEpa 20 TAB dr 20mg 50's pack 200\n\tZiska\tEsoprol CAP 20mg 56's pack 280\n\tZiska\tEsoprol CAP 40mg 28's pack 224\n\tAllied\tEsiguard CAP 20mg  \n\tOne Pharma Ltd.\tOnepro TAB dr 20mg  \n\tOne Pharma Ltd.\tOnepro TAB dr 40mg  \n\tIndication: Heartburn, Acid Related Dyspepsia, Peptic ulcer disease, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Helicobacter pylori infection, Erosive Esophagitis, Gouty arthritis, Duodenal and Gastric Ulcer.\n\nDose: Adult: PO: Erosive oesophagitis: 40 mg once daily for 4 wk, up to 8 wk if needed. Maintenance: 20 mg/day.  \n\nPeptic ulcer: 20 mg twice daily for 7 days. NSAID-associated ulceration 20 mg once daily for 4-8 wk.  \n\nZollinger-Ellison syndrome Initial: 40 mg twice daily. Usual range: 80-160 mg/day.  \n\nGastro-oesophageal reflux disease: 20 mg once daily for 4 wk.  The majority of patients are healed within 4 to 8 weeks. For patients who do not heal after 4-8 weeks, an additional 4-8 weeks of treatment may be considered.  Delayed release tablet/capsule should be swallowed whole and taken at least one hour before eating. \n\nContra-indication: Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.\n\nSide effects: The most frequently occurring adverse events ( >1%) are headache, diarrhoea, abdominal pain, nausea, flatulence, dry mouth, constipation.\n\nPrecaution: Paediatric; pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia. For patients with severe liver impairment, a dose of 20 mg should not be exceeded.\n\nMode of action: Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.\n\nPotentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.\n\nPregnancy category: C\n\nInteraction: Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.\n\nPotentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
Esomeprazole + Naproxen	\n\n\tACI\tAnaflex Max 375 TAB dr  375mg+20mg 50's pack 401.50\n\tACI\tAnaflex 500 TAB dr  500mg 30's pack 271.80\n\tACI\tAnaflex Max 500 TAB dr 500mg+20mg 50s\n 501.50\n\tAcme Ltd.\tNapro-A Plus 375 TAB dr  375mg 30's pack 240\n\tAcme Ltd.\tNapro-A Plus 500 TAB dr  500mg 30's pack 300\n\tAlco Pharma\tNapren ES 375 TAB dr   12's pack 96\n\tAlco Pharma\tNapren ES 500 TAB dr   12's pack 300\n\tAristopharma\tNeso 375/20 TAB dr   40's pack 320\n\tAristopharma\tNeso 500/20 TAB dr   40's pack 400\n\tAstra Biopharmaceuticals Ltd.\tEsoz-N TAB dr 20 mg + 375 mg  \n\tAstra Biopharmaceuticals Ltd.\tEsoz-N TAB dr 20 mg + 500 mg  \n\tBeximco\tDinovo TAB dr  375 50's pack 400\n\tBeximco\tDinovo TAB dr  500 50's pack 500\n\tDelta Pharma\tDemovo 375 TAB dr   24's pack 192\n\tDelta Pharma\tDemovo 500 TAB dr   24's pack 240\n\tDrug International Ltd.\tNapsec 375 TAB dr   30's pack 240\n\tDrug International Ltd.\tNapsec 500 TAB dr   30's pack 300\n\tEskayef Bangladesh Ltd.\tNaprox Plus 375 TAB dr   30's pack 240\n\tEskayef Bangladesh Ltd.\tNaprox Plus 500 TAB dr   30's pack 300\n\tEuro Pharma Ltd.\tEprox Plus TAB dr 20 mg + 500 mg  \n\tGeneral\tNaprozol TAB dr 375mg 5x8's pack 240.60\n\tGeneral\tNaprozol TAB dr 500mg 5x8's pack 300\n\tGlobe\tEmaprox TAB dr 20 mg + 500 mg  \n\tGlobe\tEmaprox TAB dr 20 mg + 375 mg  \n\tHealthcare\tSolivo 375 TAB dr   30's pack 390\n\tHealthcare\tSolivo 500 TAB dr   30's pack 450\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNupralgin Plus 375 TAB dr   30's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNupralgin Plus 500 TAB dr   30's pack 300\n\tIncepta\tProgesic 375 TAB dr  30's pack 240\n\tIncepta\tProgesic 500 TAB dr   28's pack 280\n\tKemiko\tInflect 375 TAB dr   20's pack 160\n\tKemiko\tInflect 500 TAB dr   20's pack 200\n\tLabaid\tPaincare TAB dr 20 mg + 375 mg  \n\tLabaid\tPaincare TAB dr 20 mg + 500 mg  \n\tLeon\tNovaxen Plus TAB dr 20 mg + 500 mg  \n\tLeon\tNovaxen Plus 375 TAB dr 20 mg + 375 mg  \n\tMedicon\tEnar TAB dr 20 mg + 500 mg  \n\tMedicon\tEnar TAB dr 20 mg + 375 mg  \n\tNavana\tEsona 375/20 TAB dr   30's pack 240\n\tNavana\tEsona 500/20 TAB dr   30's pack 300\n\tNIPRO JMI Pharma\tNimovo TAB dr 20 + 500mg  \n\tNovelta Bestway\tNaprogard TAB dr 20 mg + 375 mg  \n\tNovelta Bestway\tNaprogard TAB dr 20 mg + 500 mg  \n\tOpso Saline Ltd.\tDuofix TAB dr 20 mg + 375 mg  \n\tOpso Saline Ltd.\tDuofix TAB dr 20 mg + 500 mg  \n\tOpsonin Pharma\tNameso 375 TAB dr   30's pack 240\n\tOpsonin Pharma\tNameso 500 TAB dr   30's pack 300\n\tOrion Pharma Ltd.\tNovoxen 375 TAB dr   20's pack 160\n\tOrion Pharma Ltd.\tNovoxen 500 TAB dr   20's pack 200\n\tPharmasia Ltd.\tNapronil Plus TAB dr 20 mg + 375 mg  \n\tPharmasia Ltd.\tNapronil Plus TAB dr 20 mg + 500 mg  \n\tPopular\tProgut-N 500 TAB dr  20 mg + 500 mg 28's pack 300\n\tPopular\tProgut-N TAB dr 20 mg + 375 mg 100's pack 500.00\n\tRadiant.\tNaprosyn Plus 375/20mg TAB dr   48's pack 768\n\tRadiant.\tNaprosyn Plus 500/20mg TAB dr   24's pack 480\n\tRAK\tNasopain 375/20 TAB dr   30's pack 300\n\tRAK\tNasopain 500/20 TAB dr   30's pack 360\n\tRangs\tRanoxen Plus TAB dr 20 mg + 500 mg  \n\tRenata\tMaxpro-N TAB dr 20 mg + 375 mg  \n\tRenata\tMaxpro-N TAB dr 20 mg + 500 mg  \n\tSharif\tNaprotec 375 TAB dr   30's pack 240\n\tSharif\tNaprotec 500 TAB dr   30's pack 300\n\tSomatec\tNaproflex 375 TAB dr   32's pack 256\n\tSomatec\tNaproflex 500 TAB dr   30's pack 320\n\tSquare\tXenole 375 TAB dr   30's pack 240\n\tSquare\tXenole 500 TAB dr   30's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tNapexa TAB dr 20 mg + 375 mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tNapexa TAB dr 20 mg + 500 mg  \n\tZenith\tNaproxen Plus 375/20 TAB dr   30's pack 240\n\tZenith\tNaproxen Plus 500/20 TAB dr   30's pack 300\n\tZiska\tNapxon 375 TAB dr  20 mg + 375 mg 32's pack 256\n\tZiska\tNapxon 500 TAB dr  20 mg + 500 mg 32's pack 320\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Joint stiffness\n\nDose: Rheumatoid Arthritis, Osteoarthritis, Alkylosing Spondylitis, and dysmenorrhoea: 375 or 500 mg, one tablet twice daily.\n\n\n\nContra-indication: â¢ Known hypersensitivity to any component of Progesic or substituted benzimidazoles\nâ¢ History of asthma, urticaria or other allergic-type reactions after taking aspirin or other NSAIDs\nâ¢ Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery\nâ¢ Late pregnancy\n\nSide effects: In general,The most common adverse reactions in clinical trials (>5%): erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain, nausea etc.\n\nPrecaution: Patients with known CV disease/risk factors may be at greater risk. Progesic should be used with caution in patients with fluid retention or heart failure.\n\nMode of action: Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.\nPotentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.\n\nPregnancy category: D\n\nInteraction: Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.\nPotentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
Estradiol 0.06%	\n\n\tIndication: Vulvular and vaginal atrophy, Atrophic vaginitis \n\nDose: Vaginal\nVulvular and vaginal atrophy\nAdult: Insert 2-4 g/day of vag cream intravaginally for 2 wk, then reduce gradually to half the initial dose for 2 wk followed by a maintenance dose of 1 g 1-3 times/wk.\n\nPostmenopausal vaginal atrophy\nAdult: Insert a vag ring containing 2 mg of estradiol and keep in place for 90 days.\n\nUrogenital symptoms\nAdult: Insert a vag ring containing 2 mg of estradiol and keep in place for 90 days.\n\nAtrophic vaginitis\nAdult: Initial: Insert 1 tab (20 mcg) once daily for 2 wk. Maintenance: Insert 1 tab twice wkly. Attempt to discontinue or taper medication at 3-6 mthly intervals.\n\nContra-indication: Hypersensitivity; undiagnosed vag bleeding; thrombophloebitis or thromboembolic disorders; breast carcinoma except in selected patients being treated for metastatic disease; oestrogen-dependent tumor; porphyria; pregnancy.\n\nSide effects: GI disturbances, genitourinary changes, haematologic disorders, CV and CNS effects, endocrine and metabolic disorders, cholestatic jaundice, local skin reactions, chorea, contact lens intolerance, steeping of corneal curvature, pulmonary thromboembolism, carbohydrate intolerance.\n\nPrecaution: Conditions exacerbated by fluid retention; hypercalcaemia, cerebrovascular diorders, coronary artery disease, gall bladder diseases; lipid effects; familial defects of lipoprotein metabolism. May increase BP, risk of venous thromboembolism, breast cancer, benign hepatic adenoma, endometrial cancer and size of preexisting uterine leiomyomata. Dosage should be reduced in hepatic impairment. Lactation. Child.\n\nMode of action: CYP1A2 and CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together.\n\nPregnancy category: X\n\nInteraction: CYP1A2 and CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together.
Estriol	\n\n\tIncepta\tDefogen TAB dr 1mg 30's pack 240\n\tNuvista Pharma Ltd\tOvestin TAB dr 1 mg 30's pack 297.90\n\tNuvista Pharma Ltd\tOvestin Cream Cream 15 gm 1 tube 1114\n\tSquare\tFemastin TAB dr 1mg 30's pack 240\n\tSquare\tFemastin Forte TAB dr 1mg 30's pack 240\n\tSquare\tFemastin TAB dr 2mg  \n\tSquare\tFemastin Cream 100 mg/100 gm 15gm tube 1000\n\tOrganon (Ireland) Ltd., Ireland\tOvestin Cream 1mg/gm 15gm tube with applicator 1114\n\tIndication: Infertility due to cervical hostility, Menopausal atrophic vaginitis, Menopausal hormone replacement therapy, Dyspareunia, Dryness and itching of vagina due to Oestrogen deficiency, Prevention of recurrent infections of the vagina and lower urinary tract, Micturition complaints (such as frequency and dysuria), Urinary incontinence.  \n                                                                                                                                                                                                  \nPre- and postoperative therapy in postmenopausal women undergoing vaginal surgery, Climacteric complaints such as hot flushes and night sweating, a diagnostic aid in case of a doubtful atrophic cervical smear.\n\n\nDose: Adult: PO Menopausal HRT 0.5-3 mg/day for 1 mth, then 0.5-1 mg/day.  \n\nDiagnostic aid in atrophic cervical smear: 2-4 mg/day for 7 days before taking the next smear.  \n\nInfertility due to cervical hostility: 0.25-1 mg/day on days 6-15 of the menstrual cycle.  \n\nAtrophy of the lower urogenital tract related to oestrogen deficiency: 4-8 mg/day for the 1st wk, then taper down to 1-2 mg/day.  \n\nVag Menopausal atrophic vaginitis: As cream (0.01 or 0.1%) or pessary (500 mcg): Apply 500 mcg once daily, reduce to twice wkly subsequently. \n\nPre- and postoperative therapy in postmenopausal women undergoing vaginal surgery: 4-8mg per day in the 2 weeks before surgery; 1-2mg per day in the 2 weeks after surgery. \n\nClimacteric complaints such as hot flushes and night sweating:  4-8mg per day during the first weeks, followed by a gradual reduction. The lowest effective dosage should be used.   \n\n\n\n\nContra-indication: â¢ Pregnancy â¢ Known, past or suspected breast cancer â¢ Known or suspected oestrogen-dependent malignant tumours (e.g. endometrial cancer) â¢ Undiagnosed genital bleeding â¢ Untreated endometrial hyperplasia â¢ Previous idiopathic or current venous thromboembolism (deep venous thrombosis, pulmonary embolism) â¢ Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction) â¢ Acute liver disease, or a history of liver disease as long as liver function tests failed to return to normal\n\nSide effects: Breast tension or pain, nausea, spotting. Fluid retention, cervical hypersecretion.\n\nPrecaution: In order to prevent endometrial stimulation, the daily dose should not exceed 8 mg nor should this maximum dose be used for longer than several weeks. As for all hormone replacement therapies, yearly medical examination is advisable. With vaginal infections, a concomitant specific treatment is recommended. Patients with any of the following conditions should be monitored; thrombosis, severe liver disorders; porphyria; a history during pregnancy or previous use of steroids of severe pruritus, cholestatic jaundice, herpes gestationis, or otosclerosis.\n\nMode of action: Reduced efficacy may occur when used with activated charcoal, barbiturates, carbamazepine, griseofulvin, hydantoin and rifampicin. May possibly change efficacy of oral anticoagulants and increase pharmacologic effects of succinylcholine, theophyllines and troleandromycin.\n\nPregnancy category: X\n\nInteraction: Reduced efficacy may occur when used with activated charcoal, barbiturates, carbamazepine, griseofulvin, hydantoin and rifampicin. May possibly change efficacy of oral anticoagulants and increase pharmacologic effects of succinylcholine, theophyllines and troleandromycin.
Eszopiclone	\n\n\tAcme Ltd.\tSono TAB dr 1mg 30's pack 60.30\n\tAcme Ltd.\tSono TAB dr 2mg 30's pack 90\n\tAristopharma\tSleepil TAB dr 1mg 50's pack 100\n\tAristopharma\tSleepil TAB dr 2mg 30's pack 90\n\tBeximco\tS-Clon TAB dr 1mg 50's pack 120.60\n\tBeximco\tS-Clon TAB dr 2mg 30's pack 90.30\n\tEskayef Bangladesh Ltd.\tSominex TAB dr 1mg 50's pack 100\n\tEskayef Bangladesh Ltd.\tSominex TAB dr 2mg 30's pack 90\n\tIncepta\tZopilone TAB dr 1mg 50's pack 100\n\tIncepta\tZopilone TAB dr 2mg 30's pack 150\n\tOpsonin Pharma\tEsleep TAB dr 1mg 50's pack 100\n\tOpsonin Pharma\tEsleep TAB dr 2mg 30's pack 90\n\tPopular\tSleepwel TAB dr 2mg 30's pack 90\n\tSilva\tSleepon TAB dr 1mg 50's pack 100.38\n\tSilva\tSleepon TAB dr 2mg 50's pack 150\n\tIndication: Insomnia\n\nDose: Oral\nInsomnia\nAdult: Initial: 2 mg immediately before bedtime. If clinically indicated, may initiate treatment at or increase dosage to 3 mg immediately before bedtime.\nElderly: Difficulty falling asleep: Initial: 1 mg immediately before bedtime; may increase to 2 mg at bedtime if clinically indicated. Difficulty staying asleep: 2 mg immediately before bedtime. Dosages exceeding 2 mg daily are not recommended.\nHepatic impairment: Severe hepatic impairment: Initial: 1 mg immediately before bedtime. Dosages exceeding 2 mg daily are not recommended.\n\nContra-indication: Hypersensitivity\n\nSide effects: Headache, dizziness, somnolence, nervousness, depression, confusion, hallucination, anxiety, abnormal dreams, pain, migraine, neuralgia, rash, pruritus, dry mouth, unpleasant taste, nausea, vomiting, diarrhoea, dyspepsia, peripheral oedema, chest pain, urinary tract infection, viral infection, dysmenorrhoea, gynecomastia, decreased libido, dyspnoea, agitation, and memory impairment.\nPotentially Fatal: Anaphylaxis reactions, angioedema involving the tongue, glottis or larynx.\n\nPrecaution: Initiate treatment only after careful evaluation of patients; failure of insomnia to remit after 7-10 days of treatment may indicate presence of primary psychiatric and/or medical illness requiring evaluation. May be associated with abnormal thoughts and behaviour changes e.g. bizarre behavior, agitation, hallucinations, depersonalization, decreased inhibition. Complex sleep-related behaviours with no memory of the incident such as "sleep-driving", preparing and eating food, making phone calls, having sex while not fully awake have been reported. Caution in patients with history of drug or alcohol dependence and/or abuse. Worsening of depression, emergence of suicidality have been reported. Eszopiclone has rapid onset of action and must be taken immediately before bedtime or after experiencing difficulty sleeping. May impair ability to drive or operate machinery. Hypersensitivity reaction including angioedema involving the tongue, glottis or larynx, and symptoms suggestive of anaphylaxis have been reported. Abrupt discontinuance or rapid dose reduction may cause withdrawal symptoms. Caution in hepatic impairment; elderly/debilitated patients. Safety and efficacy have not been established in children <18 yr. Pregnancy and lactation.\n\nMode of action: Concurrent use of CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) may decrease metabolism and increase plasma concentrations of Eszopiclone; dosage reduction of Eszopiclone may be needed. Concurrent use with CYP3A4 inducers (e.g. rifampicin) may reduce concentrations of Eszopiclone. \n\nMay enhance adverse CNS effects when used with alcohol, anticonvulsants, antihistamines, or other psychotropic drugs. Concurrent use with flumazenil may diminish the sedative effect of nonbenzodiazepine hypnotics.\n\nPregnancy category: C\n\nInteraction: Concurrent use of CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) may decrease metabolism and increase plasma concentrations of Eszopiclone; dosage reduction of Eszopiclone may be needed. Concurrent use with CYP3A4 inducers (e.g. rifampicin) may reduce concentrations of Eszopiclone. \n\nMay enhance adverse CNS effects when used with alcohol, anticonvulsants, antihistamines, or other psychotropic drugs. Concurrent use with flumazenil may diminish the sedative effect of nonbenzodiazepine hypnotics.
Ethambutol	\n\n\tAmbee\tSural TAB dr 400mg 100's pack 166\n\tNovartis (Bangladesh) Ltd.\tServambutol TAB dr 400mg 100's pack 344\n\tSanofi Aventis (BD) Ltd.\tFiambutol L TAB dr 400mg 100's pack 341.28\n\tIndication: Tuberculosis\n\nDose: Oral\nPrimary treatment of pulmonary and extrapulmonary tuberculosis\nAdult: As hydrochloride: Initial 8 wk: 15 mg/kg/day or 30 mg/kg thrice wkly given with isoniazid, rifampicin and pyrazinamide. For patients with history of antimycobacterial therapy: Initial doses: 25 mg/kg/day for 60 days, thereafter reduce to 15 mg/kg/day.\nChild: For treatment of drug-resistant tuberculosis: 15-25 mg/kg daily or 50 mg/kg twice wkly. For congenitally acquired tuberculosis: Neonates: 15 mg/kg once daily and >1 mth: 15 mg/kg once daily or 30 mg/kg 3 times wkly for 2 mth initial treatment phase. \n\nContra-indication: Hypersensitivity; optic neuritis. Lactation.\n\nSide effects: Retrobulbar neuritis with a reduction in visual acuity, constriction of visual field, central or peripheral scotoma and green-red colour blindness. Retinal haemorrhage (rare); reduced renal clearance of urates (acute gout); GI disturbances eg, nausea, vomiting, abdominal pain, anorexia; rash, headache, dizziness, confusion, hallucinations, malaise, jaundice; thrombocytopenia; pulmonary infiltrates.\n\nPrecaution: Impaired pre-treatment visual acuity, elderly, children. Perform liver, kidney and visual acuity tests regularly. Caution when assessing visual acuity in patients with cataracts, DM, recurrent eye inflammation to make sure that changes are not due to the underlying causes.\n\nMode of action:  	Delayed or reduced absorption w/ Al hydroxide.\n\nPregnancy category: C\n\nInteraction:  	Delayed or reduced absorption w/ Al hydroxide.
Ethambutol + Isoniazid + Pyrazinamide + Rifampicin	\n\n\tNovartis (Bangladesh) Ltd.\tRimstar 4- FDC TAB dr   50's pack 500\n\tIndication: Tuberculosis\n\nDose: Rimstar 4-FDC presents- Rifampicin 150mg + Isoniazid 75mg + Pyrazinamide 400mg + Ethambutol 275mg tablet. Patients should be given the following single daily dose of either 1 hour before or 2 hours after a meal with a full glass of water.\n\nThe total dosage requirement of rifampicin is 10 (8 to 12) mglkg/day, of isoniazid 5 (4 to 6) mglkglday, of pyrazinamide 25 (20 to 30) mglkg/day and of ethambutol 15 (15-20) mglkg/day.\n\nNew patients:\nBody weight < 50kg, initial 2â¢months- Rimstar 4-FDC 3 tablets at a time daily; next 4 months- continuation dose Rifampicin 450mg + Isoniazid 300mg daily.\n\nBody weight >50kg, initial 2 months- Rimstar 4-FDC 4 tablets at a time daily; next 4 months- continuation dose Rifampicin 600mg + Isoniazid 300mg at a time daily.\n\nRe-treatment patients:\nBody weight < 50kg, initial 2 months- Rimstar 4-FDC 3 tablets at a time daily, & Streptomycin 15mg/kg daily; next 1 month Rimstar 4-FDC 3 tablets at a time daily; next 5 months- continuation dose Rifampicin 450mg + Isoniazid 300mg daily, & Ethambutol 400mg 2 tablets (800mg) at a time daily.\n\nBody weight >50kg, initial 2 months- Rimstar 4-FDC 4 tablets at a time daily, & Streptomycin 15mg/kg daily; next 1 month Rimstar 4-FDC 4 tablets at a time daily; next 5 months- continuation dose Rifampicin 600mg + Isoniazid 300mg at a time daily, & Ethambutol 400mg 2 1/2 tablets (1000mg) at a time daily.\n\n\nContra-indication: Patients with a history of hypersensitivity to rifampin, isoniazid, pyrazinamide or any of the components, or to any of the rifamycins. \n\nSide effects: No serious adverse events were reported in the patients receiving   tablets. Three serious adverse events were reported in the patients given isoniazid, rifampin, and pyrazinamide as separate tablets and capsules. The three serious adverse events were two general hypersensitivity reactions and one jaundice reaction.\n\nPrecaution: For treatment of tuberculosis, rifampin is usually administered on a daily basis. Doses of rifampin (>600 mg) given once or twice weekly have resulted in a higher incidence of adverse reactions, including the "flu syndrome" (fever, chills and malaise); hematopoietic reactions (leukopenia, thrombocytopenia, or acute hemolytic anemia); cutaneous, gastrointestinal, and hepatic reactions; shortness of breath; shock, anaphylaxis, and renal failure. Recent studies indicate that regimens using twice-weekly doses of rifampin 600 mg plus isoniazid 15 mg/kg are much better tolerated.\n\nRifampin is not recommended for intermittent therapy; the patient should be cautioned against intentional or accidental interruption of the daily dosage regimen since rare renal hypersensitivity reactions have been reported when therapy was resumed in such cases.\n\nMode of action: Rifampicin: Induces microsomal enzymes (accelerates clearance of methadone, oral anticoagulants, glucocorticoids, oestrogen, oral hypoglycaemic agents, digitoxin, antiarrhythmics, theophylline, anticonvulsants, ?-blockers, azole antifungal, cyclosporin). \nINH: Inhibits metabolism of antiepileptics, benzodiazepines, warfarin, theophylline. Increases metabolism of enflurane. Alcohol, ASA, Al-containing antacids, corticosteroids, ketoconazole, propranolol. \nPZA: Decreases efficacy of gout therapy agents. \nEthambutol: Neurotoxic agents.\n\nPregnancy category: C\n\nInteraction: Rifampicin: Induces microsomal enzymes (accelerates clearance of methadone, oral anticoagulants, glucocorticoids, oestrogen, oral hypoglycaemic agents, digitoxin, antiarrhythmics, theophylline, anticonvulsants, ?-blockers, azole antifungal, cyclosporin). \nINH: Inhibits metabolism of antiepileptics, benzodiazepines, warfarin, theophylline. Increases metabolism of enflurane. Alcohol, ASA, Al-containing antacids, corticosteroids, ketoconazole, propranolol. \nPZA: Decreases efficacy of gout therapy agents. \nEthambutol: Neurotoxic agents.
Ethinylestradiol + Ferrous Fumarate + Norgestrel	\n\n\tRenata\tConrena-R TAB dr   28's pack 30\n\tSocial Marketing Company\tFemicon TAB dr  28's pack 25.06\n\tSocial Marketing Company\tFemipil TAB dr  28's pack 13.21\n\tIndication: Contraception\n\nDose: Adult: PO  1 tab once daily. \n\n\n\nContra-indication: Pregnancy, undiagnosed vaginal bleeding, severe arterial disease (or family history of atherogenic lipid profile); liver adenoma; porphyria; after evacuation of hydatidiform mole; history of breast cancer; hepatic impairment; thrombophloebitis or thromboembolic disorders; breast carcinoma except in selected patients being treated for metastatic disease; oestrogen-dependent tumour; smoking ?40 cigarettes daily; >50 yr; diabetes complications present; BMI >39 kg/m2; migraine with typical focal aura, lasting >72 hr despite treatment or migraine treated with ergot derivatives; BP >160 mmHg systolic and 100 mmHg diastolic; transient ischaemic attacks without headaches; SLE; gallstones; history of haemolytic uraemic syndrome, pruritis during pregnancy; cholestatic jaundice; chorea or deterioration of otosclerosis pemphigoid; breast feeding during 1st 6 mth after delivery.\n\nSide effects: Menstrual irregularities; headache, dizziness; breast discomfort; gynaecomastia; depression; disturbance of appetite; wt changes; fluid retention; oedema; changes in libido; hair loss or hirsutism; GI disturbances (nausea and vomiting); genitourinary changes; haematologic disorders; endocrine and metabolic disorders; cholestatic jaundice; local skin reactions; chorea; contact lens intolerance; steeping of corneal curvature; pulmonary thromboembolism; carbohydrate and/or glucose intolerance; depression; chloasma; BP increase, liver impairment; reduced menstrual loss, 'spotting' in early cycles, absence of withdrawal bleeding; rarely photosensitivity; increased risk in breast cancer; elevation of plasma bound iodine, cortisol and thyroid binding, erythrocyte sedimentation may be accelerated; increases in plasma copper, iron and alkaline phosphatase; may affect serum triglyceride and lipoprotein levels; retinal vascular thrombosis.\nPotentially Fatal: Hepatic tumours; increased risk of thromboembolism.\n\nPrecaution: Sex-steroid dependent cancer; past ectopic pregnancy; malabsorption syndromes; functional ovarian cysts; active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy; history of CV or renal impairment; DM; asthma; epilepsy; migraine; depression; lactation; conditions exacerbated by fluid retention; hypercalcaemia; CV and gall bladder diseases; lipid effects; familial defects of lipoprotein metabolism; patients at risk of venous thromboembolism, breast cancer, preexisting uterine leiomyomata and benign hepatic adenoma; family history of arterial disease in 1st degree relative <45 yr; BP > systolic 140 mmHg and diastolic 90 mmHg; >35 yr; BMI 30-39 kg/m2; migraine without focal aura, controlled with 5HT1; GI upset (vomiting and diarrhoea), missed pills and interaction with other drugs may require additional contraceptive precautions. Should be taken at same time each day.\n\nMode of action: Reduced contraceptive effectiveness with antibiotics, anticonvulsants and drugs that may increase contraceptive steroids clearance (e.g. bosentan, rifampicin, rifabutin, barbiturates, primidone, phenytoin, carbamazepine, oxcarbazepine, topiramate, griseofulvin, aprepitant). Severe pruritus and jaundice with troleandomycin, avoid concurrent use. Decreased effectiveness of ursodeoxycholic acid by increasing the elimination of cholesterol in bile. Effects of danazol or gestrinone and hormonal contraceptives might be altered or reduced by concurrent use, avoid concomittant use. \n\nDecreased contraceptive effectiveness with anti-HIV protease inhibitors. Increased tacrolimus levels with ethinyl estradiol. May increase theophylline, selegiline and tizanidine levels with oral contraceptives.\n\nPregnancy category: Not Classified\n\nInteraction: Reduced contraceptive effectiveness with antibiotics, anticonvulsants and drugs that may increase contraceptive steroids clearance (e.g. bosentan, rifampicin, rifabutin, barbiturates, primidone, phenytoin, carbamazepine, oxcarbazepine, topiramate, griseofulvin, aprepitant). Severe pruritus and jaundice with troleandomycin, avoid concurrent use. Decreased effectiveness of ursodeoxycholic acid by increasing the elimination of cholesterol in bile. Effects of danazol or gestrinone and hormonal contraceptives might be altered or reduced by concurrent use, avoid concomittant use. \n\nDecreased contraceptive effectiveness with anti-HIV protease inhibitors. Increased tacrolimus levels with ethinyl estradiol. May increase theophylline, selegiline and tizanidine levels with oral contraceptives.
Ethinylestradiol + Gestodene	\n\n\tIncepta\tGestop 28 TAB dr   28's pack 99.75\n\tIncepta\tMini 28 TAB dr 0.15mg+0.03mg & 75mg 280's pack 235.20\n\tIndication: Contraception\n\nDose: Adult: PO As combination product containing gestodene and ethinylestradiol in varying concentrations and pack sizes depending on brand. Use as directed. Generally, for a 21-day pack: 1 tab/day for 21 days starting on day 1 of cycle followed by 7 pill-free days. Start 2nd pack immediately on the day after the pill-free period.\n\nContra-indication: Severe hepatic impairment, jaundice or persistent itching during a previous pregnancy, Dubin-Johnson syndrome, Rotor syndrome, previous or existing liver tumours. Personal or family history of venous thromboembolism (VTE). Risk factors for VTE. Sickle-cell anaemia, severe DM with vascular changes, lipid metabolism disorders, undiagnosed abnormal vaginal bleeding, history of herpes gestationis, worsening of otosclerosis during pregnancy. Exisiting or history of mammary or endometrial carcinoma. Pregnancy.\n\nSide effects: Headaches, body wt changes, depressed/altered moods, breast pain or tenderness, changes in libido. GI disturbance such as nausea and abdominal pain.\n\nPrecaution: May increase risk of arterial and venous thrombotic and thromboembolic diseases e.g. MI, stroke, deep venous thrombosis and pulmonary embolism. Caution when used in patients who are obese (BMI >30 kg/m2, have hypertension or dyslipoproteinaemia, vavular heart disease or atrial fibrillation. Heavy smokers >35 yr of age. Recommended to discontinue use at least 6 wk before and for 2 wk after elective surgery that may involve prolonged immobilisation. May increase severity and frequency of migraines. May increase risk of cervical carcinoma. May affect glucose tolerance. Efficacy of oral contraceptive may be reduced in the event of severe diarrhoea or vomiting. Lactation.\n\nMode of action: Concurrent use with hepatic enzyme inducers e.g. barbiturates, primidone, phenobarbitone, phenytoin, phenylbutazone, rifampicin, carbamazepine and griseofulvin may affect contraceptive efficacy. Short courses of broad-spectrum antibiotics may also reduce the efficacy of the oral contraceptive. Concurrent use with HIV protease and non-nucleoside reverse transcriptase inhibitors may affect hepatic metabolism of gestodene and/or ethinylestradiol. May increase plasma concentrations of ciclosporin and decrease the serum levels of lamotrigine. Concurrent use with felbamate may increase the clearance of gestodene. Gestodene may increase serum levels of buprenorphine. Co-trimoxazole, miconazole and etoricoxib may increase serum levels of ethinylestradiol. Aprepitant, modafinil and bosentan may reduce the serum levels of ethinylestradiol. Metabolism of omeprazole may be inhibited by ethinylestradiol. GI absorption of ethinylestradiol may be increased by concurrent admin of paracetamol.\n\nPregnancy category: X\n\nInteraction: Concurrent use with hepatic enzyme inducers e.g. barbiturates, primidone, phenobarbitone, phenytoin, phenylbutazone, rifampicin, carbamazepine and griseofulvin may affect contraceptive efficacy. Short courses of broad-spectrum antibiotics may also reduce the efficacy of the oral contraceptive. Concurrent use with HIV protease and non-nucleoside reverse transcriptase inhibitors may affect hepatic metabolism of gestodene and/or ethinylestradiol. May increase plasma concentrations of ciclosporin and decrease the serum levels of lamotrigine. Concurrent use with felbamate may increase the clearance of gestodene. Gestodene may increase serum levels of buprenorphine. Co-trimoxazole, miconazole and etoricoxib may increase serum levels of ethinylestradiol. Aprepitant, modafinil and bosentan may reduce the serum levels of ethinylestradiol. Metabolism of omeprazole may be inhibited by ethinylestradiol. GI absorption of ethinylestradiol may be increased by concurrent admin of paracetamol.
Ethinylestradiol + Levonorgestrel	\n\n\tACI\tMini-28 TAB dr   28's pack 235.20\n\tIncepta\tLyta-28 TAB dr   28's pack 23.52\n\tIndication: Contraception\n\nDose: Adult: PO Monophasic combined OC: As tab containing levonogestrel 150-250 mcg and ethinylestradiol 30 mcg: 1 tab once daily. \n\nTriphasic combined OC: Levonorgestrel 50-125 mcg + ethinylestradiol 30-40 mcg: 1 tab once daily.\n\nContra-indication: Pregnancy, undiagnosed vaginal bleeding, severe arterial disease (or family history of atherogenic lipid profile); liver adenoma; porphyria; after evacuation of hydatidiform mole; history of breast cancer; hepatic impairment; thrombophloebitis or thromboembolic disorders; breast carcinoma except in selected patients being treated for metastatic disease; oestrogen-dependent tumour; smoking ?40 cigarettes daily; >50 yr; diabetes complications present; BMI >39 kg/m2; migraine with typical focal aura, lasting >72 hr despite treatment or migraine treated with ergot derivatives; BP >160 mmHg systolic and 100 mmHg diastolic; transient ischaemic attacks without headaches; SLE; gallstones; history of haemolytic uraemic syndrome, pruritis during pregnancy; cholestatic jaundice; chorea or deterioration of otosclerosis pemphigoid; breast feeding during 1st 6 mth after delivery.\n\nSide effects: Menstrual irregularities; headache, dizziness; breast discomfort; gynaecomastia; depression; disturbance of appetite; wt changes; fluid retention; oedema; changes in libido; hair loss or hirsutism; GI disturbances (nausea and vomiting); genitourinary changes; haematologic disorders; endocrine and metabolic disorders; cholestatic jaundice; local skin reactions; chorea; contact lens intolerance; steeping of corneal curvature; pulmonary thromboembolism; carbohydrate and/or glucose intolerance; depression; chloasma; BP increase, liver impairment; reduced menstrual loss, 'spotting' in early cycles, absence of withdrawal bleeding; rarely photosensitivity; increased risk in breast cancer; elevation of plasma bound iodine, cortisol and thyroid binding, erythrocyte sedimentation may be accelerated; increases in plasma copper, iron and alkaline phosphatase; may affect serum triglyceride and lipoprotein levels; retinal vascular thrombosis.\nPotentially Fatal: Hepatic tumours; increased risk of thromboembolism.\n\nPrecaution: Sex-steroid dependent cancer; past ectopic pregnancy; malabsorption syndromes; functional ovarian cysts; active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy; history of CV or renal impairment; DM; asthma; epilepsy; migraine; depression; lactation; conditions exacerbated by fluid retention; hypercalcaemia; CV and gall bladder diseases; lipid effects; familial defects of lipoprotein metabolism; patients at risk of venous thromboembolism, breast cancer, preexisting uterine leiomyomata and benign hepatic adenoma; family history of arterial disease in 1st degree relative <45 yr; BP > systolic 140 mmHg and diastolic 90 mmHg; >35 yr; BMI 30-39 kg/m2; migraine without focal aura, controlled with 5HT1; GI upset (vomiting and diarrhoea), missed pills and interaction with other drugs may require additional contraceptive precautions. Should be taken at same time each day.\n\nMode of action:  	CYP3A4 inducers may decrease levels/effects eg aminoglutethimide, carbamazepine, nafcillin, nevirapine, atazanavir, nelfinavir, phenobarbital, phenytoin, lamotrigine, rifamycins, griseofulvin and ritonavir; ampicillin, tetracycline and other antibiotics may reduce efficacy; oestrogens may antagonise anticoagulant effect of coumarins; may inhibit metabolism of prednisolone and ciclosporin; may reduce clearance of alprazolam, chlordiazepoxide, diazepam; may increase clearance of lorazepam, oxazepam, temazepam.\n\nPregnancy category: X\n\nInteraction:  	CYP3A4 inducers may decrease levels/effects eg aminoglutethimide, carbamazepine, nafcillin, nevirapine, atazanavir, nelfinavir, phenobarbital, phenytoin, lamotrigine, rifamycins, griseofulvin and ritonavir; ampicillin, tetracycline and other antibiotics may reduce efficacy; oestrogens may antagonise anticoagulant effect of coumarins; may inhibit metabolism of prednisolone and ciclosporin; may reduce clearance of alprazolam, chlordiazepoxide, diazepam; may increase clearance of lorazepam, oxazepam, temazepam.
Ethinylestradiol + Lynestrenol	\n\n\tNuvista Pharma Ltd\tLynes TAB dr   22's pack 115.72\n\tNuvista Pharma Ltd\tOvostat Gold TAB dr   22's pack 65.12\n\tRenata\tRegumen TAB dr  21's pack 75.39\n\tIndication: Contraception\n\nDose: One pill is to be taken daily. \n\nWomen should be instructed to take the pills at about the same time every day, preferably after the evening meal or at bedtime. \n\nEach subsequent pack is started on the day after the current pack is completed.Continue taking one pill each day.It is most likely that your menstruation will start while taking the brown pills. Do not discontinue taking the brown pills. \n\nIn addition to giving you iron supplementation regular taking of the brown tablets for 7 days will help you keep your pill taking routine.When pt wish period to begin, just stop tablet taking. \n\nWhile using the second pack woman may have some breakthrough bleeding or spotting. Start with your next pack after the usual 7 day red inactive pill interval.\n\n The advice concerning Management of Missed Pills is applicable. The woman must take the extra active pill(s) needed from a back up pack after vomiting.   \n\nContra-indication:     Pregnancy\n\n    Cardiovascular diseases\n\n    Thromboembolic disorders\n\n    Severe hypertension\n\n    Severe liver disease\n\n    Known or suspected estrogen dependent tumor\n\n    Endometrial hyperplasia\n\n\n\n\nSide effects:     Nausea, vomiting\n\n    Cholestatic jaundice\n\n    Thrombosis, BP rise\n\n    Rash\n\n     Headache, migraine, mood change\n\n    Breast tenderness, pain, enlargement, secretion\n\n \n\nPrecaution: Some medications may interfere with the efficacy of the pill. Contact your doctor if you are taking any drugs, such as antibiotics, rifampicin or medicines for seizures. You may have to use another method of contraception during this time.\n\nMode of action:  \nCYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol.\nPotentially Fatal: Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs.	Increased metabolism and subsequent reduction in efficacy with enzyme-inducing agents e.g. carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Adjustment in antidiabetic dose may be required.\nPotentially Fatal: May increase plasma levels and toxicity of ciclosporin.\n\nPregnancy category: B\n\nInteraction:  \nCYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol.\nPotentially Fatal: Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs.	Increased metabolism and subsequent reduction in efficacy with enzyme-inducing agents e.g. carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Adjustment in antidiabetic dose may be required.\nPotentially Fatal: May increase plasma levels and toxicity of ciclosporin.
Ethosuximide	\n\n\tACI\tSerontin Syrup 250mg/5ml 70ml bot 130.39\n\tIndication: Absence seizures\n\nDose: Adult: PO Initial: 500 mg/day, may increase slowly. Usual: 1-1.5 g/day. Max: Up to 2 g in some patients.\n\nContra-indication: Hypersensitivity. Pregnancy and lactation.\n\nSide effects: Blood toxicities and disorders; headache, fatigue, lethargy, drowsiness, dizziness, ataxia, hiccup and mild euphoria; more rarely, psychotic states, rashes, hepatic and renal changes, and haematological disorders. SLE, erythema multiforme. Gum hypertrophy, swelling of tongue, irritability, hyperactivity, sleep disturbances, night terrors, inability to concentrate, aggressiveness, increased libido, myopia, vag bleeding.\n\nPrecaution: Hepatic or renal impairment, porphyria. Complete blood cell count, liver function tests, and urinalysis should be performed periodically. May increase the risk of grand mal seizures when used alone in mixed types of epilepsy. Avoid sudden withdrawal. May impair ability to drive or operate machinery.\n\nMode of action: Isoniazid may increase the serum concentration of ethosuximide, leading to toxicity. Antipsychotics, antidepressants, MAOIs, and mefloquine may antagonise anticonvulsant effects of ethosuximide. Plasma conc of ethosuximide may be reduced by carbamazepine, phenobarbital, phenytoin, and primidone; and affected by valproate. Chloroquine or hydroxychloroquine may increase risk of convulsions. Isoniazid.\n\nPregnancy category: C\n\nInteraction: Isoniazid may increase the serum concentration of ethosuximide, leading to toxicity. Antipsychotics, antidepressants, MAOIs, and mefloquine may antagonise anticonvulsant effects of ethosuximide. Plasma conc of ethosuximide may be reduced by carbamazepine, phenobarbital, phenytoin, and primidone; and affected by valproate. Chloroquine or hydroxychloroquine may increase risk of convulsions. Isoniazid.
Etodolac	\n\n\tAcme Ltd.\tEtogesic SR TAB dr 600mg 2x10's pack \n\tIncepta\tEdopain CAP 300mg 30's pack 240\n\tIncepta\tEdopain ER TAB dr 600mg 20's pack 360\n\tOpsonin Pharma\tEdolac CAP 300mg 30's pack 240\n\tOpsonin Pharma\tEdolac ER TAB dr 600mg 12's pack 216\n\tSquare\tPanodin SR TAB dr 600 mg 30's pack 451.67\n\tIndication: Rheumatoid arthritis, Pain, Osetoarthritis\n\nDose: Adult: 600-1000 mg/day in divided doses adjusted according to response. Max: 1200 mg/day.\n\nER tablet: Once daily\n\nContra-indication: Peptic ulcer, hypersensitivity to etodolac/NSAIDs. Childn; pregnancy (3rd trimester) and lactation.\n\nSide effects: GI disturbances; CNS effects; hypersensitivity reactions. Rash, pruritus; neuromuscular and skeletal weaknesses; blurred vision.\nPotentially Fatal: Acute renal failure; blood disorder; nephrotoxicity; angioedema, arrhythmia, bone marrow suppression, CHF, dyspnoea, erythema multiforme, exfoliative dermatitis, hepatitis, hypertension, peripheral neuropathy, Stevens-Johnson syndrome, syncope, tachycardia, toxic amblyopia, toxic epidermal necrolysis, urticaria.\n\nPrecaution: CHF, dehydration, impaired renal, hepatic function, history of GI disease. Elderly, patients receiving anticoagulant.\n\nMode of action:  	Increased effect of warfarin, lithium, methotrexate, digoxin, cyclosporin, aspirin. Effect may be reduced with aspirin. Reduced effect of some diuretics and ?-blockers. Alcohol enhances gastric mucosal irritation.\n\nPregnancy category: D\n\nInteraction:  	Increased effect of warfarin, lithium, methotrexate, digoxin, cyclosporin, aspirin. Effect may be reduced with aspirin. Reduced effect of some diuretics and ?-blockers. Alcohol enhances gastric mucosal irritation.
Etomidate	\n\n\tPopular\tEtomid Injection 2mg/ml 10 ml amp x 5's pack 752.85\n\tIndication: Anaesthesia\n\nDose: Intravenous\nInduction of anaesthesia\nAdult: 300 mcg/kg given slowly over 30-60 seconds into a large vein in the arm.\nChild: Up to 30% more than the standard adult dose.\nElderly: 150-200 mcg/kg, subsequently adjusted according to effects.\n\nContra-indication: Hypersensitivity. Reduced or at risk of reduced adrenocortical function. Porphyria.\n\nSide effects: Excitatory phenomena eg, involuntary myoclonic muscle movements, convulsions; hypersensitivity reactions, pain on injection; postoperative nausea and vomiting.\n\nPrecaution: Opioid analgesics or benzodiazepines may be given as premedications to reduce risk of convulsions. Not to be admin by prolonged infusion. Pre-existing epilepsy. Elderly and child <10 yrs. Pregnancy and lactation.\n\nMode of action: Antipsychotics, sedatives or opioids; calcium-channel blockers.\n\nPregnancy category: C\n\nInteraction: Antipsychotics, sedatives or opioids; calcium-channel blockers.
Etoposide	\n\n\tBeacon\tTopoxin Injection 100mg/5ml 5 ml vial x 1's pack 400\n\tTechno Drugs Ltd.\tEposide Injection 100mg/5ml 1's pack 400\n\tTechno Drugs Ltd.\tEposide CAP 50mg  \n\tTechno Drugs Ltd.\tEposide CAP 100mg  \n\tNippon Kayaku Co Ltd,.Japan\tLastet Injection  100mg 1's  pack 404\n\tPharmachemie B.V., Holland\tEposin IV Injection 20mg/ml  5 ml vial x 1's pack 560\n\tIndication: Lung cancer, Testicular cancer\n\nDose: Adult: IV Testicular cancer Combination therapy: 50-100 mg/m2/day from days 1-5. May repeat course 3-4 wkly. Small cell lung cancer 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days. May repeat course 3-4 wkly.\n\nRenal impairment:\nCrCl (ml/min)	\n15-50	75% of the recommended dose. \n\nContra-indication: Hypersensitivity, pregnancy, lactation.\n\nSide effects: Nausea, vomiting, anorexia, diarrhoea, stomatitis; reversible alopoecia; rarely, disturbances of liver dysfunction, peripheral neuropathy, CNS effects, anaphylactoid reactions; hypotension with IV injection. Local irritation and thrombophloebitis at the site of inj.\nPotentially Fatal: Severe myelosuppression, characterised by leucopaenia and thrombocytopaenia. Cardiotoxicity. Anaphylaxis.\n\nPrecaution: Skin reactions may occur with accidental exposure; renal or hepatic disease. Periodic CBCs should be done before, during and after therapy. Increased risk of etoposide-toxicity in patients with low serum albumin. Acrylic material has been shown to crack and leak when used with undiluted etoposide inj.\n\nMode of action: Synergism with other cytotoxic drugs. Caution when admin with drugs that inhibit phosphatase activity. Cyclosporin A may reduce the clearance of etoposide.\n\nPregnancy category: D\n\nInteraction: Synergism with other cytotoxic drugs. Caution when admin with drugs that inhibit phosphatase activity. Cyclosporin A may reduce the clearance of etoposide.
Etoricoxib	\n\n\tACI\tCoxia TAB dr 120mg 20's pack 281.80\n\tACI\tCoxia TAB dr 60mg 30's pack 211.50\n\tACI\tCoxia TAB dr 90mg 30's pack 362.70\n\tAcme Ltd.\tSetorib TAB dr 60mg 40's pack 280\n\tAcme Ltd.\tSetorib TAB dr 120mg 20's pack 281.20\n\tAcme Ltd.\tSetorib TAB dr 90mg 30's pack 361.50\n\tAd-din\tAroxia TAB dr 60 mg 30's pack 210\n\tAd-din\tAroxia TAB dr 90 mg 20's pack 240\n\tAd-din\tAroxia TAB dr 120 mg 20's pack 285\n\tAlbion Ltd.\tEtoricoxib TAB dr 60mg  \n\tAlbion Ltd.\tEtoricoxib TAB dr 90mg  \n\tAlbion Ltd.\tEtoricoxib TAB dr 120mg  \n\tAlbion Ltd.\tEtoricoxib TAB dr 60mg/90mg/120mg 40's/30's/20's pack \n\tAlco Pharma\tEcox TAB dr 120mg 20's pack 280\n\tAlco Pharma\tEcox TAB dr 60mg 30's pack 210\n\tAlco Pharma\tEcox TAB dr 90mg 20's pack 240\n\tAmulet\tCoxetori TAB dr 60mg 30's pack 210\n\tAmulet\tCoxetori TAB dr 120mg 20's pack 280\n\tApex\tEflam TAB dr 60mg 30's pack 210\n\tApex\tEflam TAB dr 90mg 20's pack 240\n\tAristopharma\tXibra TAB dr 120mg 20's pack 280\n\tAristopharma\tXibra TAB dr 60mg 30's pack 210\n\tAristopharma\tXibra TAB dr 90mg 30's pack 360\n\tAristopharma\tEtovan TAB dr 60mg  \n\tAristopharma\tEtovan TAB dr 90mg  \n\tAristopharma\tEtovan TAB dr 120mg  \n\tAsiatic Ltd.\tArtorix TAB dr 60 mg 30's pack 210\n\tAsiatic Ltd.\tArtorix TAB dr 90 mg 20's pack 240\n\tBeacon\tCoxitor TAB dr 60mg 30's pack 210.90\n\tBenham\tEtoben TAB dr 60mg  \n\tBenham\tEtoben TAB dr 90mg  \n\tBenham\tEtoben TAB dr 120mg  \n\tBeximco\tRibox TAB dr 120mg 20's pack 280\n\tBeximco\tRibox TAB dr 60mg 30's pack 210\n\tBeximco\tRibox TAB dr 90mg 30's pack 360\n\tBio Pharma Ltd.\tBiocox TAB dr 90mg  \n\tConcord\tX Dol TAB dr 120mg 20's pack 280\n\tConcord\tX Dol TAB dr 90mg 30's pack 360\n\tConcord\tX Dol TAB dr 60mg 30's pack 210\n\tDelta Pharma\tEto TAB dr 120mg 20's pack 240\n\tDelta Pharma\tEto TAB dr 60mg 50's pack 350\n\tDelta Pharma\tEto TAB dr 90mg 30's pack 300\n\tDrug International Ltd.\tE Coxib TAB dr 60mg 30's pack 210\n\tDrug International Ltd.\tE Coxib TAB dr 90mg 20's pack 240\n\tEskayef Bangladesh Ltd.\tEtorix TAB dr 120mg 20's pack 280\n\tEskayef Bangladesh Ltd.\tEtorix TAB dr 60mg 40's pack 280\n\tEskayef Bangladesh Ltd.\tEtorix TAB dr 90mg 30's pack 360\n\tGeneral\tEtocox TAB dr 120mg 20's pack 181\n\tGeneral\tEtocox TAB dr 60mg 50's pack 350.50\n\tGeneral\tEtocox TAB dr 90mg 30's pack 361.50\n\tGlobe\tEtoxib TAB dr 60 mg 30's pack 210\n\tGlobe\tEtoxib TAB dr 90 mg 30's pack 360\n\tHallmark\tEtox TAB dr 60mg 30's pack 210.60\n\tHallmark\tEtox TAB dr 90mg 30's pack 360\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAlgirex TAB dr 120mg 20's pack 285\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAlgirex TAB dr 60mg 30's pack 210\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAlgirex TAB dr 90mg 20's pack 240\n\tIncepta\tOricox TAB dr 120mg 20's pack 280\n\tIncepta\tOricox TAB dr 60mg 30's pack 210\n\tIncepta\tOricox TAB dr 90mg 30's pack 360\n\tKemiko\tCoxfree TAB dr 120mg 20's pack 280\n\tKemiko\tCoxfree TAB dr 60mg 30's pack 210\n\tKemiko\tCoxfree TAB dr 90mg 30's pack 360\n\tMedicon\tKingcox TAB dr 60mg 30's pack 210\n\tMedicon\tKingcox TAB dr 90mg 30's pack 360\n\tNIPRO JMI Pharma\tEtrib TAB dr 60mg 30's pack 210\n\tNIPRO JMI Pharma\tEtrib TAB dr 90mg 30's pack 360\n\tNovartis (Bangladesh) Ltd.\tVargus TAB dr 120mg 20's pack 340\n\tNovartis (Bangladesh) Ltd.\tVargus TAB dr 60mg 28's pack 252\n\tNovartis (Bangladesh) Ltd.\tVargus TAB dr 90mg 30's pack 450\n\tNovo Healthcare and Pharma Ltd.\tCoxpain TAB dr 120mg 10's pack 140\n\tNovo Healthcare and Pharma Ltd.\tCoxpain TAB dr 60mg 30's pack 180\n\tNovo Healthcare and Pharma Ltd.\tCoxpain TAB dr 90mg 20's pack 180\n\tNovus\tEtonov TAB dr 60 mg 30's pack 210\n\tNovus\tEtonov TAB dr 90 mg 30's pack 360\n\tNuvista Pharma Ltd\tTorimon TAB dr 120mg 20's pack 280.80\n\tNuvista Pharma Ltd\tTorimon TAB dr 90mg 30's pack 361.20\n\tOpsonin Pharma\tRito TAB dr 120mg 20's pack 280\n\tOpsonin Pharma\tRito TAB dr 60mg 30's pack 210\n\tOpsonin Pharma\tRito TAB dr 90mg 30's pack 360\n\tOrganic Health Care\tEtosis TAB dr 60mg  \n\tOrganic Health Care\tEtosis TAB dr 90mg  \n\tOrganic Health Care\tEtosis TAB dr 120mg  \n\tOrion Pharma Ltd.\tEroflam TAB dr 60mg 30's pack 210\n\tOrion Pharma Ltd.\tEroflam TAB dr 90mg 30's pack 360\n\tPacific\tCoxet TAB dr 120mg 20's pack 280\n\tPharmasia Ltd.\tEtonil 60 TAB dr 60mg  \n\tPharmasia Ltd.\tEtonil 90 TAB dr 90mg  \n\tPharmasia Ltd.\tEtonil 120 TAB dr 120mg  \n\tPopular\tCox-E TAB dr 120mg 30's pack 420\n\tPopular\tCox-E TAB dr 60mg 30's pack 210\n\tPopular\tCox-E TAB dr 90mg 30's pack 360\n\tRAK\tEtoflam TAB dr 120mg 20's pack 240\n\tRAK\tEtoflam TAB dr 60mg 30's pack 210\n\tRAK\tEtoflam TAB dr 90mg 30's pack 300\n\tRenata\tRecox TAB dr 60mg/ 90mg/ 120mg 20's pack/30's pack \n\tSharif\tCoxsafe TAB dr 60mg  \n\tSharif\tCoxsafe TAB dr 90mg  \n\tSharif\tCoxsafe TAB dr 120mg  \n\tSomatec\tEtoriflex TAB dr 60mg 30's pack 180\n\tSomatec\tEtoriflex TAB dr 90mg 30's pack 270\n\tSquare\tTory TAB dr 120mg 20's pack 281.16\n\tSquare\tTory TAB dr 60mg 30's pack 210.67\n\tSquare\tTory TAB dr 90mg 30's pack 361.49\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Gout\n\nDose: Adult: PO Osteoarthritis 60 mg once daily. Rheumatoid arthritis 90 mg once daily. Acute gout 120 mg once daily. Max duration: 8 days.\n\nChild: <16 yr Contraindicated.\nHepatic impairment: Mild (Child-Pugh score of 5-6): 60 mg once daily. Moderate (Child-Pugh 7-9): Max 60 mg every other day or 30 mg once daily. Severe (Child-Pugh >10): Avoid.\n\nContra-indication: Inflammatory bowel disease, severe congestive heart failure, active peptic ulceration, cerebrovascular disease, CrCL <30 ml/min; lactation. Children and adolescent < 16 yr.\n\nSide effects: GI disorders; ischemic cardiac events; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity; blood disorders, fluid retention, hypertension; dry mouth, taste disturbance, mouth ulcers; appetite and wt changes; chest pain, fatigue, paraesthesia, influenza-like syndrome, myalgia. Renal toxicity.\n\nPrecaution: Allergic disorders, coagulation defects; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, renal, cardiac or hepatic impairment. Withdraw treatment if GI lesions develop; caution when admin to dehydrated patients. Regular BP monitoring is advisable. May mask fever and other signs of infection. Pregnancy.\n\nMode of action: May increase INR w/ oral anticoagulants. May decrease effects of ACE inhibitors, angiotensin II antagonist and diuretics. May increase lithium plasma concentrations. May reduce plasma levels w/ rifampicin. Increased serum concentrations of ethinylestradiol.\n\nPregnancy category: Not Classified\n\nInteraction: May increase INR w/ oral anticoagulants. May decrease effects of ACE inhibitors, angiotensin II antagonist and diuretics. May increase lithium plasma concentrations. May reduce plasma levels w/ rifampicin. Increased serum concentrations of ethinylestradiol.
Eucalypytol 0.092% + Menthol 0.042% + Methyl Salicylate 0.06% + Thymol 0.064%	\n\n\tACI\tListoral Original Solution  0.060%+0.092%+0.042%+0.0 120 ml bot/250ml bot 75.51 / 140.95\n\tACI\tListoral Cool Mint Solution 0.060%+0.092%+0.042%+0.06 120ml/250ml\n 75.51/140.95\n\tAristopharma\tOromint Mouthwash   120ml bot 75\n\tAristopharma\tOromint Original Mouthwash   250ml bot 140\n\tGeneral\tListacare Gold Mouthwash (92 mg + 42 mg + 60 mg +   \n\tGeneral\tListacare Zero Mouthwash   \n\tIncepta\tOroclean Mouthwash   120ml bot/250ml bot 75.28/ 140.53\n\tIncepta\tOroclean Coolmint Mouthwash  250ml 140\n\tSquare\tOrostar Original Antiseptic Mouthwash  92mg+42mg+60mg+64mg/100m 250ml bot 140\n\tSquare\tOrostar Coolmint Mouthwash 92mg+42mg+60mg+64mg/100ml 1's pack(120ml)  75 \n\tZiska\tAlconil Mouthwash  120 ml bot 85\n\tIndication: Gingivitis, Oral hygiene, Cavities, Bad breath, Plaque, Gum disease, Teeth cleaner & brighter\n\nDose: Rinse with 20 ml Antiseptic Mouthwash for 30 seconds, twice daily (morning and\nevening). Then rinse with water. Do not swallow. Not indicated below 12 years of age.\n\nContra-indication: Hypersensitivity; \n\nSide effects: Do not rinse, eat, or smoke for thirty minutes after using a mouthwash. Doing so will diminish the effects of the mouthwash.\n\nPrecaution: Do not swallow. It is not indicated below 12 years of age. Keep out of the reach of children. Keep in a cool and dry palace. Do not use if cap seal is broken. \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Everolimus	\n\n\tBeacon\tXevirol TAB dr 10mg  \n\tBeacon\tXevirol TAB dr 5mg  \n\tNovartis Pharma AG, Switzerland\tCertican TAB dr 0.25mg 60's pack 6854.40\n\tNovartis Pharma AG, Switzerland\tCertican TAB dr 0.50mg 60's pack 13707.60\n\tNovartis Pharma AG, Switzerland\tCertican TAB dr 0.75mg 60's pack 20562\n\tIndication: Breast cancer, Kidney cancer, Renal transplant, Liver transplant, Neuroendocrine tumors, Renal cell carcinoma, Astrocytoma, Renal angiomyolipoma,Tuberous sclerosis\n\nDose: PO: Advanced HR+ BC, advanced PNET, advanced RCC, or renal angiomyolipoma with TSC:\n10 mg once daily with or without food\n\nContra-indication: Patients with hypersensitivity to the active substance, to other rapamycin derivatives, or to any of the excipients. Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis, dyspnea, flushing, chest pain, or angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) have been observed with everolimus and other rapamycin derivatives\n\nSide effects: Management of severe or intolerable adverse reactions may require temporary dose reduction and/or interruption of  therapy. If dose reduction is required, the suggested dose is approximately 50% lower than the daily dose previously administered [see Warnings and Precautions (5)].\n\nTable 1 summarizes recommendations for dose reduction, interruption or discontinuation of  in the management of adverse reactions. General management recommendations are also provided as applicable. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.\n\nPrecaution: Non-infectious pneumonitis is a class effect of rapamycin derivatives,   . Non-infectious pneumonitis was reported in up to 19% of patients treated  in clinical trials. The incidence of Common Terminology Criteria (CTC) grade 3 and 4 non-infectious pneumonitis was up to 4.0% and up to 0.2%, respectively \n\nMode of action: CYP3A4 inhibitors &/or inducers, CYP2D6 substrates w/ narrow therapeutic index, PgP inhibitors, rifampicin, ACE inhibitors, grapefruit juice & live vaccines.\n\nPregnancy category: D\n\nInteraction: CYP3A4 inhibitors &/or inducers, CYP2D6 substrates w/ narrow therapeutic index, PgP inhibitors, rifampicin, ACE inhibitors, grapefruit juice & live vaccines.
Ezetimibe	\n\n\tBeximco\tEzeta TAB dr 10mg 20's pack 200.80\n\tIncepta\tEzetim TAB dr 10mg 30's pack 300\n\tSquare\tCholinor TAB dr 10mg 30's pack 301.34\n\tUnimed & Unihealth Manufacturers Ltd.\tEzetrol TAB dr 10mg 30's pack 300\n\tIndication: Hyperlipidaemias, Homozygous familial sitosterolaemia, Hypercholesterolaemia\n\nDose: Adult: PO Homozygous familial sitosterolaemia; Hyperlipidaemias 10 mg once daily.\n\nContra-indication: Hypersensitivity; moderate to severe liver disease or unexplained serum transaminase elevation. Children <10 yr, lactation.\n\nSide effects: Abdominal discomfort, headache, dizziness, sinusitis, pharyngitis; diarrhoea, chest pain, arthralgia, myalgia, resp infection and fatigue.\n\nPrecaution: Renal or mild hepatic impairment. Monitor LFTs. Immediately discontinue ezetimibe and any HMG-CoA reductase inhibitor or fibrate if myopathy is diagnosed or suspected. Exclude or treat secondary causes of dyslipidaemia prior to initiating therapy.\n\nMode of action: Reduced absorption w/ colestyramine. Increased plasma concentrations w/ ciclosporin. Concomitant use w/ oral anticoagulants may result in increased INR.\n\nPregnancy category: C\n\nInteraction: Reduced absorption w/ colestyramine. Increased plasma concentrations w/ ciclosporin. Concomitant use w/ oral anticoagulants may result in increased INR.
Famotidine	\n\n\tACI\tNovatac TAB dr 20mg 100's pack 225\n\tACI\tNovatac TAB dr 40mg 100's pack 412\n\tAcme Ltd.\tFamodin TAB dr 20mg 100's pack 150\n\tAcme Ltd.\tFamodin TAB dr 40mg 100's pack 300\n\tAlbion Ltd.\tFamotidine TAB dr 40 mg/ 20 mg 50's / 100's pack \n\tBeximco\tYamadin TAB dr 20mg 200's pack 380\n\tBeximco\tYamadin TAB dr 40mg 100's pack 382\n\tDoctor's Chemicals Works Ltd.\tFamotin TAB dr 20mg 100's pack 142\n\tDoctor's Chemicals Works Ltd.\tFamotin TAB dr 40mg 100's pack 380\n\tDrug International Ltd.\tFamotid TAB dr 20mg 100's pack 200\n\tDrug International Ltd.\tFamotid TAB dr 40mg 100's pack 400\n\tNovartis (Bangladesh) Ltd.\tServipep TAB dr 20mg 50's pack 200\n\tNovartis (Bangladesh) Ltd.\tServipep TAB dr 40mg 50's pack 300\n\tOpsonin Pharma\tPeptid TAB dr 20mg 100's pack 190\n\tPeoples Pharma Ltd.\tZactrol TAB dr 20mg 100's pack 115\n\tPeoples Pharma Ltd.\tZactrol TAB dr 40mg 100's pack 300\n\tSonear Ltd.\tNacid TAB dr 20mg 100's pack 205\n\tSquare\tFamotack TAB dr 20mg 100's pack 200\n\tSquare\tFamotack TAB dr 40mg 50's pack 200\n\tIndication: Heartburn, Peptic ulcer, Dyspepsia, Urticaria, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD)\n\nDose: Benign peptic ulceration: 40 mg at night for 4-8 weeks. Maintenance: 20 mg at night.\nReflux oesophagitis: 20-40 mg twice daily for  6-12 weeks.\nZollinger Ellison syndrome: 20 mg every 6 hours.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Occassional diarrhoea, dizziness & rashes.Rarely gynecomastia.\n\nPrecaution: Impaired renal function. Long term treatment should be avoided.\n\nMode of action: Antacids slightly decrease the bioavailability of famotidine. May reduce serum concentration of ketoconazole and itraconazole.\n\nPregnancy category: B\n\nInteraction: Antacids slightly decrease the bioavailability of famotidine. May reduce serum concentration of ketoconazole and itraconazole.
Febuxostat	\n\n\tACI\tFebus TAB dr 40mg 30's pack 361.20\n\tACI\tFebus TAB dr 80mg 30's pack 662.10\n\tAcme Ltd.\tGoustat TAB dr 40mg 20's pack 240\n\tAcme Ltd.\tGaustat TAB dr 40mg 2x10's pack \n\tAristopharma\tFebux TAB dr 40mg 30's pack 360\n\tAristopharma\tFebux TAB dr 80mg 10's pack 220\n\tBeximco\tEeburic TAB dr 40mg 30's pack 360\n\tBeximco\tFeburic 40 TAB dr 40mg 30's pack 360\n\tDelta Pharma\tFebulas TAB dr 40mg  \n\tDelta Pharma\tFebulas TAB dr 80mg  \n\tEskayef Bangladesh Ltd.\tGoutil TAB dr 40mg  \n\tEskayef Bangladesh Ltd.\tGoutil TAB dr 80mg  \n\tGeneral\tUrostat TAB dr 40mg 20's pack 240\n\tGeneral\tUrostat TAB dr 80mg 10's pack 220\n\tHealthcare\tFeluric TAB dr 40mg 30's pack 360\n\tHealthcare\tFeluric TAB dr 80mg 20's pack 440\n\tIbn Sina Pharmaceutical Ind. Ltd.\tUristat TAB dr 40mg 30's pack 360\n\tIbn Sina Pharmaceutical Ind. Ltd.\tUristat TAB dr 80mg 20's pack 240\n\tIncepta\tFebustat TAB dr 40mg 30's pack 360\n\tIncepta\tFebustat 80 TAB dr 80mg 30's pack 660\n\tMonicopharma\tFebux 40 TAB dr 40 mg 20's pack 240\n\tOrion Pharma Ltd.\tFostat TAB dr 40mg 30's pack 300\n\tRenata\tFeburen TAB dr 40mg 30's pack 360\n\tRenata\tFeburen TAB dr 80mg 10's pack 220\n\tSquare\tBarif TAB dr 40mg 30's pack 360\n\tSquare\tBarif TAB dr 80mg 10's pack 220\n\tIndication: Gout, Hyperuricemia\n\nDose: For treatment of hyperuricemia in patients with gout, Febuxostat is recommended at 40 mg or 80 mg once daily.\n\nThe recommended starting dose of Febuxostat is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg per dL after 2 weeks with 40 mg, Febuxostat 80 mg is recommended.\n\nNo dose adjustment is necessary when administering Febuxostat to patients with mild to moderate renal or hepatic impairment.\n\nUse in Children\nSafety and efficacy in children below the age of 12 years have not been studied.\n\nContra-indication: Patients being treated with azathioprine, mercaptopurine, or theophylline.\n\nSide effects: The most common side effects of Febustat are liver problems, nausea, gout flares, joint pain and rash.\n\nPrecaution: Gout Flare: An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including Febustat. If a gout flare occurs during treatment, Febustat need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti-inflammatory drug (NSAID) or colchicine upon initiation of treatment) may be beneficial\nfor up to six months. \n\nMode of action: May increase plasma conc of mercaptopurine, azathioprine. Alteration of metabolism of xanthine oxidase substrate drugs (eg theophylline).\n\nPregnancy category: C\n\nInteraction: May increase plasma conc of mercaptopurine, azathioprine. Alteration of metabolism of xanthine oxidase substrate drugs (eg theophylline).
Fenofibrate	\n\n\tACI\tTizabet CAP 200mg 30's pack 210\n\tAcme Ltd.\tLipidof CAP 200mg 20's pack 140.40\n\tAristopharma\tTigicon CAP 200mg 30's pack 210\n\tBeximco\tLofat CAP 200mg 30's pack 210\n\tDrug International Ltd.\tFenatrol TAB dr 145mg 30's pack 240\n\tDrug International Ltd.\tFenatrol CAP 200mg 30's pack 210\n\tEskayef Bangladesh Ltd.\tNoficon CAP 200mg 40's pack 280\n\tGeneral\tFenolid CAP 200mg 40's pack 210.90\n\tIncepta\tNofiate CAP 200mg 30's pack 210\n\tOpsonin Pharma\tTigirate CAP 200mg 30's pack 210\n\tOrion Pharma Ltd.\tFenocap CAP 200mg 30's pack 210.90\n\tPacific\tFenorat CAP 200mg 30's pack 210.90\n\tPeoples Pharma Ltd.\tFenocol CAP 200mg 30's pack 184.64\n\tRenata\tFenobate CAP 200mg 30's pack 210\n\tSquare\tLipired TAB dr 160mg 30's pack 150\n\tSquare\tLipired CAP 200mg 30's pack 210.67\n\tUnimed & Unihealth Manufacturers Ltd.\tTrigent CAP 200mg 30's pack 210\n\tWhite Horse Pharma\tFibre CAP 200mg 30's pack 350\n\tIndication: Hyperlipidemia,Hypercholesterolaemia,Hypertriglyceridaemia\n\nDose: Adult: PO : Standard micronised formulation: Initially, 200 mg once daily.\n\nFor non-micronised formulations: Initial: 200-300 mg/day in divided doses. Usual range: 200-400 mg/day.\n\nFormulation w/ improved bioavailability: 40-160 mg once daily may be used.\n\nContra-indication: Hypersensitivity; severe hepatic and renal impairment. Unexplained persistent liver function abnormality and primary biliary cirrhosis; preexisting gall bladder disease. Pregnancy, lactation.\n\nSide effects: Headache, dizziness, asthaenia, fatigue, arrhythmia, photosensitivity, eczema, dizziness, vaginitis, paraesthesia, rhinitis, cough, sinusitis, allergic pulmonary alveolitis, polyuria, myopathy, myositis, arthralgia, myalgia, myasthenia.\nPotentially Fatal: Hepatitis, cholecystitis.\n\nPrecaution: Renal or hepatic impairment. Monitor LFTs and blood counts regularly. Increased risk of cholelithiasis, pancreatitis, skeletal muscle effects. Withdraw treatment if no adequate response after 2 mth of treatment at max recommended dose.\n\nMode of action: Decreased absorption w/ bile acid sequestrants (e.g. colestyramine). May increase risk of ciclosporin-induced nephrotoxicity. Increased risk of muscle toxicity w/ HMG-CoA reductase inhibitors (e.g. simvastatin). May increase risk of bleeding w/ oral anticoagulants.\n\nPregnancy category: C\n\nInteraction: Decreased absorption w/ bile acid sequestrants (e.g. colestyramine). May increase risk of ciclosporin-induced nephrotoxicity. Increased risk of muscle toxicity w/ HMG-CoA reductase inhibitors (e.g. simvastatin). May increase risk of bleeding w/ oral anticoagulants.
Fentanyl	\n\n\tIncepta\tOpifen TAB dr 100mcg 30's pack 750\n\tIncepta\tOpifen Injection 50mcg/2ml 2ml amp x 5's pack 200\n\tIncepta\tOpifen TAB dr 200mcg 30's pack 1350\n\tPopular\tfentyl Injection 50mcg/2ml 2ml amp x 5's pack 200.75\n\tRenata\tFentanyl IM/IV Injection 2 mL (100mcg/2 mL) 5's pack 200.75\n\tHexal ag, Germany\tFentanyl Hexal Mat 25mcg/h Patch 5.78mg/hr 25 mcg/h x 5's pack 1850\n\tJanseen Pharmaceutica, Belgium\tDurogesic Transdermal Patch 50mcg/h 5's pack 5456,50\n\tJanseen Pharmaceutica, Belgium\tDurogesic Transdermal Patch 25mcg/h 5's pack 2754.25\n\tRotexmedica GmbH, Germany\tFentanyl 0.1mg- Rotexmedica Injection 0.05mg/ml 2ml amp x 10's pack 700\n\tIndication: Pain, Cancer pain, Anesthesia, Analgesia, Breakthrough pain\n\nDose: Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. \n\nIV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response. \n\nIM Premed before anesth 50-100 mcg 30-60 mins before induction of anesth. \n\nTransdermal Intractable cancer pain Initial: Apply patch that delivers ?25 mcg/hr of fentanyl in opioid-naive patients. Adjust dose according to response. For patients who have been receiving a strong opioid, initial dose should be based on the previous 24-hr opioid requirement. Replace patch 72 hrly and apply new patch to a different site.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea, vomiting; bradycardia, oedema, CNS depression, confusion, dizziness,drowsiness, headache, sedation, transient hypotension, peripheral vasodilation; increased intracranial pressure. High IV dose may cause chest wall rigidity. Transdermal: Rash, erythema and itching.\nPotentially Fatal: Respiratory depression, trunk rigidity, laryngospasm, bronchoconstriction.\n\nPrecaution: Myasthaenia gravis. Head injury; increased intracranial pressure; intracranial lesions; renal or hepatic impairment; neonates; opioid-nontolerant patients. Increased risk of respiratory depression in elderly, debilitated patients, patient with hypoxia or hypercapnia. Hypothyroidism, prostatic hyperplasia, inflammatory bowel disorders, bradycardia or bradyarrhythmias. Rapid IV infusion may cause skeletal muscle and chest wall rigidity, impaired ventilation or respiratory distress/arrest. Prolonged use may cause tolerance, psychological and physical dependence. Abrupt withdrawal after prolonged admin may lead to withdrawal symptoms. Lactation. Pregnancy (avoid high doses or prolonged usage).\n\nMode of action: Concomitant use w/ CYP3A4 inhibitors (e.g. erythromycin, clarithromycin, troleandomycin, azole antifungals, ritonavir, amiodarone, nefazodone, aprepitant, diltiazem and verapamil) increases serum levels of fentanyl and may potentiate fatal resp depression. Increased risk of life-threatening serotonin syndrome w/ SSRIs, SNRIs and MAOIs. May reduce serum levels w/ rifamycin derivatives. Enhanced depressant effect w/ general anaesth, tranquilisers, barbiturates and narcotics. May increase excretion w/ ammonium Cl. May increase hypotensive effect w/ phenothiazines. May reduce efficacy of pegvisomant.\n\nPregnancy category: C\n\nInteraction: Concomitant use w/ CYP3A4 inhibitors (e.g. erythromycin, clarithromycin, troleandomycin, azole antifungals, ritonavir, amiodarone, nefazodone, aprepitant, diltiazem and verapamil) increases serum levels of fentanyl and may potentiate fatal resp depression. Increased risk of life-threatening serotonin syndrome w/ SSRIs, SNRIs and MAOIs. May reduce serum levels w/ rifamycin derivatives. Enhanced depressant effect w/ general anaesth, tranquilisers, barbiturates and narcotics. May increase excretion w/ ammonium Cl. May increase hypotensive effect w/ phenothiazines. May reduce efficacy of pegvisomant.
Fenticonazole Nitrate 2% Topical	\n\n\tSharif\tFentigal Cream   30gm tube 195\n\tSquare\tFentizol VT 600 TAB dr 600 mg 1's pack 120\n\tIndication: Candidiasis,Fungal skin infections\n\nDose: Adult: Apply 2% cream once daily.\nChild: Apply 2% cream once daily.\n\nContra-indication: Hypersensitivity; hepatic impairment (oral gel). Porphyria.\n\nSide effects: Nausea, vomiting, febrile reactions, rash, drowsiness, diarrhoea, anorexia and flushing, hepatitis. Local irritation and sensitisation, contact dermatitis.\nPotentially Fatal: IV: Anaphylactic reaction and cardiac arrest.\n\nPrecaution: For external use only; discontinue if sensitization or irritation occurs. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Ferrous Ascorbate	\n\n\tBeximco\tHemofix TAB dr 275mg 30's pack 120\n\tIndication: Iron deficiency anemia\n\nDose: One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.\n\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ferrous Fumarate	\n\n\tGeneral\tIrofol Suspension 100mg/5ml 200ml bot 32.18\n\tHudson\tFeroson Suspension 100mg/5ml 200ml bot 27\n\tRenata\tFecap CAP   100 's pack 57\n\tIndication: Iron deficiency anemia, Iron supplement\n\nDose: Oral\nIron-deficiency anaemia\nAdult: Usual dose range: Up to 600 mg daily. May increase up to 1.2 g daily if necessary.\nChild: As syrup containing 140 mg(45 mg iron)/5ml. Preterm neonate: 0.6-2.4 ml/kg daily; up to 6 yr: 2.5-5 ml bid.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: GI disturbance including constipation, diarrhoea, dark stools. Nausea and epi-gastric pain.\n\nPrecaution: Patients with intestinal strictures and diverticular disease. May worsen diarrhoea in patients with inflammatory bowel disease. May cause constipation and faecal impaction in elderly. Avoid prolonged admin (>6 mth) except in patients with continued bleeding, menorrhagia or repeated pregnancies. Not for routine use in treatment of haemolytic anaemia unless an iron-deficient state exists. Parenteral iron should not be used concurrently with oral iron treatment. Avoid use in patients receiving repeated blood tranfusions. Pregnancy.\n\nMode of action: Oral absorption of iron may be increased when taken with ascorbic acid. May reduce the absorption of quinolones and tetracyclines when taken concurrently via the oral route. Concurrent admin with antacids may reduce the absorption of ferrous fumarate from the GI tract. May reduce the absorption of penicillamine in the gut when taken concurrently.\n\nPregnancy category: Not Classified\n\nInteraction: Oral absorption of iron may be increased when taken with ascorbic acid. May reduce the absorption of quinolones and tetracyclines when taken concurrently via the oral route. Concurrent admin with antacids may reduce the absorption of ferrous fumarate from the GI tract. May reduce the absorption of penicillamine in the gut when taken concurrently.
Ferrous Fumarate + Folic Acid	\n\n\tACI\tFeridex + CAP   100's pack \n\tAcme Ltd.\tFerocit TAB dr  (200+0.2) mg 100's pack 18\n\tAexim\tFerofe Z TR CAP   30's pack 87\n\tAlbion Ltd.\tDicalat-M CAP CAP  30's pack \n\tAmico Ltd.\tFero TR CAP   30's pack 71.10\n\tBenham\tHemofol-TR CAP   50's pack 118\n\tBeximco\tAristofol Fe TAB dr   100's pack 47\n\tGeneral\tIrofol CAP   100's pack 53\n\tGonoshasthaya\tG Iron Folic Acid TAB dr   100's pack 19\n\tHudson\tAlic TAB dr   100's pack 25\n\tHudson\tKelfer CAP   100's pack 2100\n\tHudson\tFeroson-TR CAP   100's pack 2100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaferon CAP   100's pack 57\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaferon TAB dr   100's pack 19\n\tIndobangla Pharmaceuticals\tI-Fol TAB dr   100's pack 30\n\tJayson\tFemicap CAP   100's pack 51\n\tKumudini Pharma Ltd.\tFerron TR CAP   100's pack 240\n\tMedimet\tFerigun CAP   100's pack 57\n\tPacific\tFeroplus TR CAP   30 's pack 71.09\n\tPharmasia Ltd.\tITOP CAP   30's pack 60.30\n\tRenata\tChewrol Chewable TAB dr   30's pack 90\n\tRephco\tFit Plus TAB dr   60 's pack 15\n\tSquare\tFe Plus CAP  200 mg + 200 mcg 100's pack 54.53\n\tSupreme\tSuprafol TR CAP   30's pack 69\n\tIndication: Iron deficiency anemia, Iron supplement, Iron deficiency in pregnancy\n\nDose: Adult: PO Each tab contains ferrous fumurate 322 mg and folic acid 0.35 mg: 1 tab/day starting from the 13th wk of gestation.\n\nContra-indication: Paroxysmal nocturnal haemoglobinuria, haemosiderosis, haemochromatosis.\n\nSide effects: GI discomfort, anorexia, nausea, vomiting, constipation, diarrhoea. Stool darkening may occur.\n\nPrecaution: Avoid use in patients with active peptic ulcer, repeated blood transfusion, regional enteritis and ulcerative colitis. Caution when used in patients with folate-dependent tumours. Not recommended for use during 1st trimester of pregnancy.\n\nMode of action: Ferrous Fumarate:  Oral absorption of iron may be increased when taken with ascorbic acid. May reduce the absorption of quinolones and tetracyclines when taken concurrently via the oral route. Concurrent admin with antacids may reduce the absorption of ferrous fumarate from the GI tract. May reduce the absorption of penicillamine in the gut when taken concurrently.\n\nFolic Acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nPregnancy category: Not Classified\n\nInteraction: Ferrous Fumarate:  Oral absorption of iron may be increased when taken with ascorbic acid. May reduce the absorption of quinolones and tetracyclines when taken concurrently via the oral route. Concurrent admin with antacids may reduce the absorption of ferrous fumarate from the GI tract. May reduce the absorption of penicillamine in the gut when taken concurrently.\n\nFolic Acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
Ferrous Gluconate	\n\n\tACI\tFeridex Syrup 300mg 200ml 32\n\tEdruc Ltd.\tFerronat Syrup 300mg/5ml 200ml 32\n\tIndication: Iron deficiency anemia\n\nDose:  	Oral\nIron-deficiency anaemia\nAdult: Expressed in terms of elemental iron. Treatment: 60 mg bid up to 60 mg 4 times daily. Prevention: 60 mg daily.\nChild: Expressed in terms of elemental iron. Treatment: Severe: 4-6 mg/kg/day in 3 divided doses; Mild to moderate: 3 mg/kg/day in 1-2 divided doses. Prevention: 1-2 mgkg/day.\n\nContra-indication: Haemochromatosis, haemolytic anemia.\n\nSide effects: GI symptoms e.g. stomach cramping, constipation, nausea, vomiting, dark stools, heartburn, diarrhea, teeth staining, urine discoloration.\n\nPrecaution: Avoid in patients with peptic ulcer, enteritis, or ulcerative colitis and those who receive frequent blood transfusions. Not to be used in premature infants until the vitamin E stores (deficient at birth) are replenished. Avoid prolonged treatment (>6 mth) except in patients with continuous menorrhagia or bleeding.\n\nMode of action: Concurrent admin with antacids/H2 antagonists may reduce absorption of iron. Chloramphenicol may delay response to iron. Iron may reduce the absorption of levodopa, methyldopa and penicillamine when given together. Absorption may be reduced when used with quinolones or tetracyclines. Concurrent admin with vitamin C may increase iron absorption.\n\nPregnancy category: Not Classified\n\nInteraction: Concurrent admin with antacids/H2 antagonists may reduce absorption of iron. Chloramphenicol may delay response to iron. Iron may reduce the absorption of levodopa, methyldopa and penicillamine when given together. Absorption may be reduced when used with quinolones or tetracyclines. Concurrent admin with vitamin C may increase iron absorption.
Ferrous Sulphate	\n\n\tAcme Ltd.\tFerroglobin Syrup 200mg 100ml bot  /200ml bot 23 / 26.10\n\tAlbion Ltd.\tDicalat Syrup Syrup 4mg/100 ml 200 ml bot \n\tApollo Pharmaceutical Ltd.\tApitone Syrup 200 mg/5 ml  \n\tBeximco\tAristoferon Syrup 200mg/5ml 250ml bot 26\n\tBio Pharma Ltd.\tBioron Syrup 200mg/5ml 200ml bot 26.10\n\tDoctor's Chemicals Works Ltd.\tDyaferon Syrup 200mg/5ml 200ml 25\n\tGonoshasthaya\tG Iron Syrup 200mg/5ml 200ml bot 25.10\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaferon Syrup 200mg/5ml 200ml bot 26.75\n\tJayson\tFerocin Syrup 200 mg/ 5 ml 200mL bot \n\tMedimet\tFerigun S Syrup 200mg/5ml 200ml bot 26.50\n\tModern\tFerrum Syrup 200mg/5ml 200ml bot 24.89\n\tMonicopharma\tAscoferon Syrup 200mg/5ml 200ml bot 26.75\n\tOrion Pharma Ltd.\tFerrolin Syrup 200mg/5ml 200ml bot \n\tPacific\tFeroplus Syrup 200mg/5ml 200ml bot 26\n\tPharmadesh Ltd.\tFeromat Syrup 200mg/5ml 200ml bot 25\n\tSalton\tSalferon Syrup 200mg/5ml 200ml bot 24.09\n\tZenith\tHimobin Syrup 200mg 100ml bot  /200ml bot  18 / 24\n\tIndication: Iron deficiency anemia\n\nDose: Adult: PO 400-600 mg/day in divided doses. Prevention: 200 mg/day.\n\nContra-indication: Patients receiving repeated blood transfusions; anaemia not due to iron deficiency.\n\nSide effects: GI irritation, abdominal pain and cramps, nausea, vomiting, constipation, diarrhoea, dark stool and discoloration of urine; heartburn.\n\nPrecaution: Elderly. Avoid admin for >6 mth except in patients with continuous bleeding. Avoid concomitant oral and parenteral iron therapy. Iron-storage or iron-absorption diseases (e.g. haemochromatosis), haemoglobinopathies); existing GI diseases (e.g. inflammatory bowel disease, intestinal strictures, diverticulae, peptic ulcer disease, enteritis or ulcerative colitis). Liquid preparations may stain teeth.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ferrous Sulphate + Folic Acid	\n\n\tAcme Ltd.\tFerocit-TR CAP  (150+0.5) mg 50's pack 120\n\tAlbion Ltd.\tIfol Plus CAP  60's pack \n\tAlco Pharma\tFecon-TR CAP   30's pack 72\n\tAmbee\tFerritin TR CAP   30's pack 66.90\n\tAristopharma\tUnifol TR CAP   50's pack 118.50\n\tBeximco\tHefolin SR CAP   100's pack \n\tCosmo Pharma Ltd.\tCpefro TR CAP   50 's pack 116\n\tDesh\tDifol TR CAP   60 's pack 144\n\tDrug International Ltd.\tFerospan CAP   100's pack 240\n\tEskayef Bangladesh Ltd.\tFeofol TR CAP   90 's pack 216\n\tGeneral\tFolex-TR CAP   50's pack 118.50\n\tJayson\tFemitab TAB dr   500's pack 160\n\tMillat\tMeta Plus TR CAP   50's pack 120\n\tNavana\tFef TR CAP   60 's pack 138\n\tSomatec\tFolin SR CAP   30's pack 71.40\n\tSquare\tCaron Cap CAP   30's pack 72\n\tSquare\tCaron Syrup  200ml bot 25.29\n\tZenith\tF+F CAP   100's pack 119.50\n\tIndication: Iron and folic acid deficiency in pregnancy\n\nDose: The usual therapeutic dose for Adult: 50-100 mg 2-3 times daily.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients, haemolytic anemia.\n\nSide effects: Allergic sensitization has been reported following oral administration. May cause constipation.\n\nPrecaution: Iron chelates with antacid and tetracycline and absorption of all these may be impaired. \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Iron +  Folic Acid  +   Vitamin B  +  Vitamin C	\n\n\tACI\tMylovit CAP  100's pack 302\n\tAcme Ltd.\tFerocit CAP   100's pack 18\n\tAlco Pharma\tFecon-BC CAP  50's pack 150\n\tBeximco\tPregvit CAP   50's pack 150.50\n\tCosmo Pharma Ltd.\tCosvit TR CAP   50's pack 150\n\tDecent Pharma Ltd.\tVic CAP   100's pack 300\n\tDesh\tMoriamin M CAP   60's pack 180\n\tEverest\tVifol CAP   30's pack 90\n\tGeneral\tBic F CAP   50's pack 175.50\n\tGlaxoSmithKline Bangladesh Ltd.\tFefovit CAP  100's pack 301.12\n\tGlobe\tEPL CAP   30's pack 90\n\tHealthcare\tPrenat Plus CAP  60's pack 240\n\tHudson\tFerovit TR CAP   100's pack 300\n\tIncepta\tAlneed CAP   100's pack 300\n\tJayson\tNatavit CAP  30's pack 90.30\n\tKemiko\tVitafol CAP   40's pack 120\n\tMedicon\tUneed CAP   28's pack 84\n\tModern\tBestal CAP   50's pack 150\n\tNovartis (Bangladesh) Ltd.\tMomcap CAP   100's pack 350\n\tNovus\tNuovit F CAP   50's pack 150\n\tOrion Pharma Ltd.\tHeptamin CAP   50's pack 150.50\n\tPacific\tFBC CAP   30's pack 90\n\tPharmadesh Ltd.\tIrovit CAP  50's pack 137.50\n\tPharmasia Ltd.\tItop-BC CAP  30's pack 105.30\n\tReliance\tFerolet-BC CAP  50's pack 150\n\tShamsul Al-Amin\tAlfil CAP   30's pack 90\n\tSquare\tServin CAP   100's pack 300.58\n\tSquare\tMymix Powder  30'spack 60.30\n\tSupreme\tRuneed CAP  50's pack 150\n\tIndication: Nutritional deficiency in pregnancy & lactation.\n\nDose: 1 capsule daily or in more severe cases 2 capsules daily or as directed by the physician.\n\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients, haemolytic anemia.\n\nSide effects: Allergic sensitization has been reported following oral administration. May cause constipation.\n\nPrecaution: Iron chelates with antacid and tetracycline and absorption of all these may be impaired. \n\nMode of action: Iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\n\n\nPregnancy category: Not Classified\n\nInteraction: Iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\n
Ferrous Sulphate + Folic Acid + Zinc	\n\n\tACI\tFemizin TR CAP   30's pack 69.90\n\tAcme Ltd.\tFerocit Z CAP  Dried Ferrous Sulphate B 30's pack 88.20\n\tAd-din\tRed plus CAP  100's pack 300\n\tAlbion Ltd.\tAlfol TR CAP  30's pack \n\tAlco Pharma\tFecon Z CAP   30's pack 87.90\n\tAmico Ltd.\tFeraz CAP   30's pack 75\n\tAPC Pharma Ltd.\tApefol TR CAP   50's pack 145\n\tApollo Pharmaceutical Ltd.\tZimobin CAP  30's pack  90\n\tAsiatic Ltd.\tFecel TR CAP   45's pack 135\n\tBelsen\tFerofolin TR CAP  50's pack 150\n\tBenham\tBtiron TR CAP  30's pack 87.\n\tBeximco\tEfol ER CAP   50's pack 125.50\n\tBio Pharma Ltd.\tBiron PLUS CAP   30 's pack 87.30\n\tBio Pharma Ltd.\tBioron Plus CAP  3x10's pack 87\n\tBristol Pharma Ltd.\tZ Fol CAP   60's pack 175.80\n\tCentral.\tFerofol Z CAP   100'pack 290\n\tCosmic Chemical Industries Ltd.\tZiron F CAP   50's pack 150\n\tCosmo Pharma Ltd.\tCosfez TR CAP   50's pack 145\n\tDecent Pharma Ltd.\tZilic TR CAP   50's pack 150\n\tDesh\tTrifol TR CAP   30's pack 87\n\tDoctor's Chemicals Works Ltd.\tHaemozin TR CAP  40's pack 108\n\tDrug International Ltd.\tFerozi CAP  100's pack 293\n\tEdruc Ltd.\tFerro Z TR CAP   30's pack 87\n\tEskayef Bangladesh Ltd.\tZeefol TR CAP   60's pack 175.80\n\tEuro Pharma Ltd.\tFozifol CAP   30's pack 87.90\n\tGeneral\tFolized CAP   50's pack 155.50\n\tHallmark\tFeelbe TR CAP   50's pack 145.50\n\tHudson\tIron Z TR CAP  100's pack 250\n\tIbn Sina Pharmaceutical Ind. Ltd.\tIfozin SR CAP   50's pack 152.50\n\tKemiko\tFeolet TR PLUS CAP   40's pack 116\n\tMedicon\tFeol TR Plus CAP   30 's pack 90\n\tMedimet\tFeriz TR CAP   50's pack 145\n\tMillat\tMeta Z TR CAP   30's pack 87.90\n\tModern\tFE-Z CAP  150 mg + 500 mcg + 22.5  24' pack 87\n\tMystic\tFoliron TR CAP   30's pack 90\n\tNavana\tZifef TR CAP   30's pack 84.30\n\tNipa\tFefa TR CAP   30's pack 82.50\n\tOpsonin Pharma\tFerol TR CAP   30's pack 81\n\tOrion Pharma Ltd.\tFerrolin TR CAP   30's pack 87\n\tPacific\tFeroplus Z SR CAP   30's pack 87\n\tPharmadesh Ltd.\tIfel TR CAP   30's pack 83.10\n\tPharmasia Ltd.\tITOP-Z CAP   30's pack 90.60\n\tReliance\tFerolet CAP  50's pack 142\n\tS. N.\tFerogurd CAP   30's pack 75\n\tSalton\tZifex SR CAP   50's pack 150.50\n\tShamsul Al-Amin\tSakti TR CAP   30's pack 87\n\tSilva\tFeosil Z CAP   30's pack 87.33\n\tSomatec\tFolin Z TR CAP  30's pack 87.30\n\tSquare\tZif CAP   100'pack 300.58\n\tSupreme\tSuprafol Z TR CAP   30's pack 81\n\tSyntho Ltd.\tAstro Z CAP  150 mg + 500 mcg + 22.5  50's pack 130\n\tWhite Horse Pharma\tFizz-TR CAP   50's pack 150\n\tZiska\tFozi TR CAP   50's pack 146\n\tIndication: Iron, Zinc & Folic acid deficiency\n\nDose: One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.\n\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Fexofenadine Hydrochloride	\n\n\tACI\tRitch Suspension 30mg/5ml 50ml 48.14\n\tACI\tRitch TAB dr 120mg 30's pack/50's pack 210.90/352.50\n\tACI\tRitch TAB dr 180mg 30's pack 2741.80\n\tACI\tRitch TAB dr 60mg 30's pack 150.20\n\tAcme Ltd.\tAlanil Suspension 30mg/5ml 50ml bot 48\n\tAcme Ltd.\tAlanil TAB dr 120mg 3x10's pake 195\n\tAcme Ltd.\tAlanil TAB dr 180mg 3x10's pack 240\n\tAd-din\tXofast TAB dr 120mg 20's pack 120\n\tAd-din\tXofast TAB dr 60mg 30's pack 105\n\tAlbion Ltd.\tFexofenadine TAB dr 120 mg/ 180 mg 50's / 20's pack \n\tAlco Pharma\tAlagra Suspension 30mg/5ml 50ml bot 48\n\tAlco Pharma\tAlagra TAB dr 120mg 30's pack 180\n\tAlco Pharma\tAlagra TAB dr 180mg 30's pack 255\n\tAlco Pharma\tAlagra TAB dr 30mg 30's pack 90\n\tAlco Pharma\tAlagra TAB dr 60mg 30's pack 105\n\tAmulet\tXofedin TAB dr 120mg 30's pack 195\n\tAmulet\tXofedin TAB dr 180mg 30's pack 240\n\tApex\tAlafree TAB dr 120mg 50's pack 325\n\tApex\tAlafree TAB dr 180mg 30's pack 240\n\tAristopharma\tAxofen Suspension 30mg/5ml 50ml bot 48\n\tAristopharma\tAxofen TAB dr 120mg 30's pack 210\n\tAristopharma\tAxofen TAB dr 180mg 20's pack 180\n\tAsiatic Ltd.\tXofena TAB dr 120mg 3x10's pack 210\n\tAsiatic Ltd.\tXofena TAB dr 180mg 2x10's pack 180\n\tAsiatic Ltd.\tXofena Suspension 30 mg/5 ml  \n\tAsiatic Ltd.\tXofena TAB dr 120 mg  \n\tAsiatic Ltd.\tXofena TAB dr 60mg  \n\tAstra Biopharmaceuticals Ltd.\tFexon TAB dr 120mg 10's pack 65\n\tAstra Biopharmaceuticals Ltd.\tFexon TAB dr 180mg 10's pack 80\n\tBeximco\tAxodin Suspension 30mg/5ml 50ml bot 48\n\tBeximco\tAxodin TAB dr 120mg 30's pack 195\n\tBeximco\tAxodin TAB dr 180mg 30's pack 240\n\tBeximco\tAxodin TAB dr 60mg  50's pack 250\n\tBio Pharma Ltd.\tAlerfast TAB dr 120mg 30's pack 180\n\tChemist Ltd.\tFegra Suspension 30 mg/5 ml  \n\tChemist Ltd.\tFegra TAB dr 120mg  \n\tConcord\tFexocon Suspension 30mg/5ml 50ml bot 48\n\tConcord\tFexocon TAB dr 120mg 30's pack 195\n\tConcord\tFexocon TAB dr 180mg 20's pack 160\n\tDrug International Ltd.\tFexofast TAB dr 120mg 30's pack 210\n\tDrug International Ltd.\tFexofast TAB dr 180mg 20's pack 180\n\tDrug International Ltd.\tFexofast Oral Suspn Suspension 30mg/5ml 50ml bot 48\n\tDrug International Ltd.\tFexofast TAB dr 30mg  \n\tDrug International Ltd.\tFexofast TAB dr 60mg  \n\tEdruc Ltd.\tNolargy TAB dr 120mg 30's pack 195\n\tEdruc Ltd.\tNolargy TAB dr 180mg 30's pack 240\n\tEdruc Ltd.\tNolargy Suspension 30mg/5ml 50ml bot 48\n\tEskayef Bangladesh Ltd.\tDinafex Suspension 30mg/5ml 50ml bot 48\n\tEskayef Bangladesh Ltd.\tDinafex TAB dr 120mg 30's pack 195\n\tEskayef Bangladesh Ltd.\tDinafex TAB dr 180mg 30's pack 240\n\tEskayef Bangladesh Ltd.\tDinafex TAB dr 60mg 30's pack 105\n\tGlobe\tFexona Suspension 30mg/5ml 50ml bot 48\n\tGlobe\tFexona TAB dr 120mg 20's pack 130\n\tGlobe\tFexona TAB dr 180mg 20's pack 160\n\tGlobe\tFexona TAB dr 60mg 30's pack 105\n\tGlobex\tFastact TAB dr 120mg 30's pack 195\n\tGlobex\tFastact Suspension 30 mg/5 ml  \n\tHealthcare\tVifas TAB dr 120mg 30's pack 240\n\tHealthcare\tVifas TAB dr 180mg 30's pack 300\n\tHealthcare\tVifas TAB dr 60mg 30's pack 150\n\tHealthcare\tVifas Suspension 30 mg/5 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tFexomin Suspension 30mg/5ml 50ml bot 48\n\tIbn Sina Pharmaceutical Ind. Ltd.\tFexomin TAB dr 120mg 30's pack 210\n\tIbn Sina Pharmaceutical Ind. Ltd.\tFexomin TAB dr 60mg 50's pack 250\n\tIncepta\tFenofex TAB dr 120mg 20's pack 140\n\tIncepta\tFenofex TAB dr 60mg 30's pack 105\n\tIncepta\tFenofex TAB dr 180mg 20's pack 180\n\tIncepta\tFenofex Suspension 30mg/5ml 1's pack 48\n\tKemiko\tFenaxo TAB dr 60mg  \n\tKumudini Pharma Ltd.\tAlerfex Suspension 30mg/5ml 50ml bot 48\n\tKumudini Pharma Ltd.\tAlerfex TAB dr 120mg  30's pack 210\n\tKumudini Pharma Ltd.\tAlerfex TAB dr 180mg 20's pack 160\n\tLabaid\tSardin TAB dr 120mg 30's pack 210\n\tLabaid\tSardin TAB dr 180 30's pack 270\n\tLeon\tElfexo TAB dr 120mg  \n\tLeon\tElfexo 180 TAB dr 180mg  \n\tLeon\tElfexo Suspension 30 mg/5 ml  \n\tMedicon\tAlfex Oral Suspension 50ml 50ml bot 48\n\tMedicon\tAlfex TAB dr 120mg 3x10's pack 210\n\tMonicopharma\tFesler Suspension 30mg/5ml 50ml bot 48\n\tMonicopharma\tFesler TAB dr 180mg 20's pack 180\n\tNavana\tOdafen Oral Suspension 30mg/5ml 50ml bot 48\n\tNavana\tOdafen TAB dr 120mg 30's pack 195\n\tNavana\tOdafen TAB dr 180mg 30's pack 240\n\tNIPRO JMI Pharma\tFexten TAB dr 120mg 30's pack 180.90\n\tNIPRO JMI Pharma\tFexten Suspension 30mg/5ml 50ml bot 48\n\tNovus\tFexomax TAB dr 60mg 30's pack 150\n\tNovus\tFexomax TAB dr 120mg 30's pack 210\n\tOpsonin Pharma\tFixal Suspension 30mg/5ml 50ml bot 48\n\tOpsonin Pharma\tFixal TAB dr 120mg 20's pack 140\n\tOpsonin Pharma\tFixal TAB dr 180mg 20's pack 180\n\tOpsonin Pharma\tFixal TAB dr 30mg 50's pack 175\n\tOpsonin Pharma\tFixal TAB dr 60mg 30's pack 150\n\tOrion Pharma Ltd.\tNosedex TAB dr 120mg 30's pack 195.90\n\tPacific\tFexodin TAB dr 120mg 30's pack 210\n\tPacific\tFexodin Suspension 30mg/5ml 50ml bot 48\n\tPharmasia Ltd.\tTelfex TAB dr 120mg 30's pack 195\n\tPharmasia Ltd.\tTelfex TAB dr 60mg  \n\tPharmasia Ltd.\tTelfex Suspension 30mg/ 5ml  \n\tRAK\tRinofen TAB dr 120mg 30's pack 195\n\tRAK\tRinofen TAB dr 180mg 30's pack 240\n\tRenata\tFenadin Suspension 30mg/5ml 50ml bot 48.19\n\tRenata\tFenadin TAB dr 120mg 50's pack 351\n\tRenata\tFenadin TAB dr 180mg 20's pack 180.60\n\tRenata\tFenadin TAB dr 30mg 50's pack 125.50\n\tRenata\tFenadin TAB dr 60mg 30's pack 105\n\tRephco\tFenodil-120 TAB dr 120mg 3x10's Pack 210\n\tRephco\tFenodil-180 TAB dr 180mg 3x10's Pack 240\n\tSanofi Aventis (BD) Ltd.\tTelfast Suspension 30mg/5ml 50ml bot 58\n\tSanofi Aventis (BD) Ltd.\tTelfast TAB dr 120mg 30's pack 240\n\tSanofi Aventis (BD) Ltd.\tTelfast TAB dr 180mg 20's pack 200\n\tSharif\tFixen TAB dr 120mg 30's pack 210\n\tSomatec\tFexofen Suspension 30mg/5ml 50ml bot 48.18\n\tSomatec\tFexofen TAB dr 120mg 30's pack 180.60\n\tSomatec\tFexofen TAB dr 180mg 20's pack 140.60\n\tSquare\tFexo Suspension 30mg/5ml 50ml bot 48.19\n\tSquare\tFexo TAB dr 120mg 50's pack 326.50\n\tSquare\tFexo TAB dr 180mg 30's pack 240.90\n\tSquare\tFexo TAB dr 60mg 50's pack 175.50\n\tVeritas\tFexotab TAB dr 120mg  \n\tVeritas\tFexotab TAB dr 180mg  \n\tAllied\tFexotis TAB dr 120mg  \n\tOne Pharma Ltd.\tTelfadin Suspension 30 mg/5 ml  \n\tOne Pharma Ltd.\tTelfadin TAB dr 60mg  \n\tOne Pharma Ltd.\tTelfadin TAB dr 120mg  \n\tOne Pharma Ltd.\tTelfadin TAB dr 180mg  \n\tIndication: Allergic rhinitis, Hay fever, Urticaria, Allergy\n\nDose: Adults:\nAllergic rhinitis: 120 mg once daily or 60 mg twice daily\nUrticaria: 180 mg once daily\n\nChildren:\n2-11 years: 30 mg (1 spoonful) or 5 ml twice daily\n6 months-2 years: 15 mg (1/2 spoonful) or 2.5 ml twice daily\n\nContra-indication: Hypersensitivity.\n\nSide effects: Viral infection (cold/flu); headache, dizziness, drowsiness, fatigue; nausea, dyspepsia, dysmenorrhoea.\n\nPrecaution: Renal impairment. Pregnancy, lactation; children <6 yr.\n\nMode of action:  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.\n\nPregnancy category: C\n\nInteraction:  Co-admin with ketoconazole or erythromycin may increase plasma levels of fexofenadine. May increase adverse effects of other anticholinergics and CNS depressants. May increase arrhythmogenic effect of antipsychotic agents (phenothiazines); avoid concurrent usage. May reduce the efficacy of betahistine. Pramlintide may increase the anticholinergic effect of fexofenadine. Bioavailability may be increased by verapamil. Efficacy may be reduced by rifampin.
Fexofenadine Hydrochloride + Pseudoephedrine Hydrochloride	\n\n\tACI\tRitch Plus TAB dr Fexofenadine HCl 60mg+Pse 56's pack 449.12\n\tOpsonin Pharma\tFixal Plus 60 TAB dr   30's pack 165\n\tSquare\tFexo Plus TAB dr  60 mg + 120 mg 50's pack 400\n\tVeritas\tFexotab Plus ER Extended Release TAB dr 60 mg + 120 mg  \n\tIndication: Allergic rhinitis, Hay fever, Urticaria, Sneezing, Runny nose, Hives, Skin rash, Common cold, Allergy, Itchy or watery eyes, Nasal congestion\n\nDose: Adults and children 12 years of age and older: 1 tablet twice daily administered on an empty stomach with water.\n\nContra-indication: Severe hypertension, phaeochromocytoma.\n\nSide effects: Anginal pain; rebound congestion and rhinorrhoea; fear, anxiety, restlessness, tremor, insomnia, confusion, irritability and psychotic states; reduced appetite, nausea, vomiting; gangrene; cerebral haemorrhage and pulmonary oedema; reflex bradycardia, tachycardia and cardiac arrhythmias, palpitations and cardiac arrest, hypotension and dizziness, fainting and flushing. Tissue necrosis and sloughing; myocardial and arterial necrosis.\n\nPrecaution: Hyperthyroidism; ischaemic heart disease, arrhythmia or tachycardia; occlusive vascular disorders e.g. arteriosclerosis, hypertension or aneurysms; DM and closed-angle glaucoma; renal impairment, prostatic enlargement. Pregnancy; lactation.\n\nMode of action: Increased risk of hypertension and arrhythmias if given with cardiac glycosides, quinidine or TCAs. Increased risk of vasoconstrictor effects if given with ergot alkaloids or oxytocin. Co-admin with MAOIs may cause hypertensive crisis. Anaesthetics e.g. cyclopropane, halothane and other halogenated anaesthestics; antihypertensive agents.\n\nPregnancy category: C\n\nInteraction: Increased risk of hypertension and arrhythmias if given with cardiac glycosides, quinidine or TCAs. Increased risk of vasoconstrictor effects if given with ergot alkaloids or oxytocin. Co-admin with MAOIs may cause hypertensive crisis. Anaesthetics e.g. cyclopropane, halothane and other halogenated anaesthestics; antihypertensive agents.
Finasteride	\n\n\tBeximco\tProsfin TAB dr 5mg 30's pack 301.20\n\tBeximco\tRecur TAB dr 1mg 30's pack 120.60\n\tSquare\tAlopec TAB dr 1mg 100 \n\tSquare\tPronor TAB dr 5mg 30's pack 301.24\n\tIndication: Male pattern baldness, Benign prostatic hyperplasia\n\nDose: Adult: PO Benign prostatic hyperplasia 5 mg once daily. Male pattern baldness 1 mg once daily\n\nContra-indication: Children, exposure of pregnant women to finasteride either via direct contact with crushed tab or through semen of male sexual partners who are taking finasteride; pregnancy, lactation.\n\nSide effects: Gynaecomastia, decreased libido, impotence, reduction in the volume of ejaculate, testicular pain. Hypersensitivity reactions e.g. swelling of lips and face, urticaria, rashes.\n\nPrecaution: Undiagnosed prostate cancer, liver dysfunction, obstructive uropathy.\n\nMode of action: No drug interactions of clinical importance have been identified. Proscar does not appear to affect significantly the cytochrome P-450-linked drug metabolizing enzyme system. Compounds which have been tested in man have included propranolol, digoxin, glyburide, warfarin, theophylline and antipyrine, and no clinically meaningful interactions were found.\n\nOther Concomitant Therapy: Although specific interaction studies were not performed, in clinical studies Proscar was used concomitantly with angiotensin converting-enzyme (ACE) inhibitors, acetaminophen, acetylsalicylic acid, ?-blockers, ?-blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2-antagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), quinolones and benzodiazepines without evidence of clinically significant adverse interactions.\n\nPregnancy category: X\n\nInteraction: No drug interactions of clinical importance have been identified. Proscar does not appear to affect significantly the cytochrome P-450-linked drug metabolizing enzyme system. Compounds which have been tested in man have included propranolol, digoxin, glyburide, warfarin, theophylline and antipyrine, and no clinically meaningful interactions were found.\n\nOther Concomitant Therapy: Although specific interaction studies were not performed, in clinical studies Proscar was used concomitantly with angiotensin converting-enzyme (ACE) inhibitors, acetaminophen, acetylsalicylic acid, ?-blockers, ?-blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2-antagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), quinolones and benzodiazepines without evidence of clinically significant adverse interactions.
Flavoxate Hydrochloride	\n\n\tIncepta\tUrilax TAB dr 100mg 30's pack 300\n\tIncepta\tUrilax TAB dr 200mg 30's pack 540\n\tOpsonin Pharma\tAvox TAB dr 100mg  30's pack 300\n\tOpsonin Pharma\tAvox TAB dr 200mg 20's pack 360\n\tSomatec\tFlavox TAB dr 100mg 30's pack 210.90\n\tSomatec\tFlavox TAB dr 200mg 20's pack  261\n\tIndication: Cystitis, Urinary incontinence, Urgency and frequency, Bladder spasms, Dysuria, Nocturia, Suprapubic pain, Prostatitis, Urethritis\n\nDose: Adult: PO Bladder spasms due to catheterisation; Dysuria; Urinary incontinence, urgency and frequency 200 mg 3 times/day.\n\nContra-indication: Pyloric or duodenal obstruction; obstructive intestinal lesions or ileus; achalasia; GI haemorhrage or obstructive uropathies of the lower urinary tract; myasthenia gravis; severe ulcerative colitis; toxic megacolon; glaucoma; children <12.\n\nSide effects: Increased intraocular pressure; difficulty in ocular accommodation; blurred vision; dry mouth and throat; GI disturbances; nervousness; vertigo; headache; fatigue; confusion; hypersensitivity reactions; dysuria; tachycardia; palpitation; hyperpyrexia; eosinophilia; leukopenia, abdominal pain, constipation and difficulty in concentrating.\n\nPrecaution: May affect ability to drive or operate machinery. May worsen hyperthyroidism, coronary artery disease, congestive heart failure, prostatic hypertrophy, arrhythmias, tachycardia. Pregnancy; lactation; elderly; autonomic neuropathy; hiatus hernia with reflux esophagitis, hepatic and renal impairment.\n\nMode of action: Amantadine, some antihistamines, phenothiazine antipsychotics, tricyclic antidepressants, MAOIs; parasympathomimetics. May decrease gastric motility thus decreasing absorption of certain drugs. May antagonise the GI effects of cisapride, domperidone, metoclopramide.\n\nPregnancy category: B\n\nInteraction: Amantadine, some antihistamines, phenothiazine antipsychotics, tricyclic antidepressants, MAOIs; parasympathomimetics. May decrease gastric motility thus decreasing absorption of certain drugs. May antagonise the GI effects of cisapride, domperidone, metoclopramide.
Flucloxacillin	\n\n\tACI\tFluclox Powder for Suspension 125mg/5ml 100ml bot 61.41\n\tACI\tFluclox CAP 250mg 100's pack 579\n\tACI\tFluclox Injection 250mg 250mg Vial 35.24\n\tACI\tFluclox CAP 500mg 40's pack 422.80\n\tACI\tFluclox Injection 500mg 1's pack 45.28\n\tACI\tFluclox DS Powder for Suspension 250mg/5ml 100ml bot 110.74\n\tAcme Ltd.\tA Flox Powder for Suspension 125mg/5ml 100ml bot 61.42\n\tAcme Ltd.\tA Flox CAP 250mg 48's pack 270.72\n\tAcme Ltd.\tA Flox Injection 250mg/vial 5's pack 175.7\n\tAcme Ltd.\tA Flox CAP 500mg 48's pack 506.4\n\tAcme Ltd.\tA Flox Injection 500mg/vial 5's pack 225.85\n\tAd-din\tOxacol CAP 500mg 30's pack 270\n\tAexim\tFlumark Powder for Suspension 125mg/5ml 100ml bot 60\n\tAexim\tFlumark CAP 500mg 20's pack 200\n\tAlbion Ltd.\tAlfux CAP 500 mg/ 250 mg 24's / 60's pack \n\tAlbion Ltd.\tAlfux Dry Powder for Syrup 125 mg/5 ml 100 ml \n\tAlco Pharma\tCapflu DS Powder for Suspension 125mg/5ml 100ml bot 110\n\tAlco Pharma\tCapflu CAP 500mg 28's pack 280\n\tAlco Pharma\tFlusyrup Suspension 125mg 100 ml bot 60\n\tAlco Pharma\tStaflu CAP 500mg  \n\tAlco Pharma\tStaflu CAP 250mg  \n\tAlco Pharma\tStaflu Powder For Suspension 125 mg/5 ml  \n\tAlco Pharma\tStaflu DS Powder For Suspension 125 mg/5 ml  \n\tAmbee\tFluxin Powder for Suspension 125mg/5ml 100ml bot 58.88\n\tAmbee\tFluxin CAP 250mg 60's pack 335.4\n\tAmbee\tFluxin CAP 500mg 20's pack 200.8\n\tAmico Ltd.\tMonaclox DS Powder for Suspension 125mg/5ml 100ml bot 100\n\tAmico Ltd.\tMonaclox F Powder for Suspension 125mg/5ml 100ml bot 65\n\tAmico Ltd.\tMonaclox F CAP 250mg 30's pack 165\n\tAPC Pharma Ltd.\tFlutec Powder for Suspension 125mg/5ml 100ml bot 60\n\tAPC Pharma Ltd.\tFlutec CAP 250mg 40's pack 230\n\tAPC Pharma Ltd.\tFlutec CAP 500mg 40's pack 400\n\tApex\tLuf Powder for Suspension 125mg/5ml 100ml bot 60\n\tApex\tLuf CAP 250mg 40's pack 220\n\tApex\tLuff CAP 500mg 28's pack 280\n\tApollo Pharmaceutical Ltd.\tSofa CAP 250mg 48's pack 252\n\tApollo Pharmaceutical Ltd.\tSofa Suspension 125mg 100ml bot 60\n\tAristopharma\tStafoxin Powder for Suspension 125mg/5ml 100ml bot 60\n\tAristopharma\tStafoxin CAP 250mg 48's pack 264\n\tAristopharma\tStafoxin CAP 500mg 28's pack 280\n\tAsiatic Ltd.\tClox F Powder for Suspension 125mg/5ml 100ml bot 60\n\tAsiatic Ltd.\tClox F CAP 250mg 48's pack 240\n\tAsiatic Ltd.\tClox F CAP 500mg 48's pack 480\n\tAsiatic Ltd.\tClox-F Powder for Suspension 250mg/5ml 100ml bot 110\n\tAstra Biopharmaceuticals Ltd.\tFluc CAP 500mg 15's pack  150\n\tBenham\tBelox CAP 250mg 20's pack 110\n\tBenham\tBelox CAP 500mg 20's pack 200\n\tBenham\tBeloxs Powder for Suspension 125mg/5ml 100ml bot 60\n\tBeximco\tFlubex Powder for Suspension 125mg/5ml 100ml bot 60\n\tBeximco\tFlubex cap CAP 250mg 50's pack \n\tBeximco\tFlubex CAP 250mg 50's pack 275\n\tBeximco\tFlubex CAP 500mg 30's pack 315\n\tBeximco\tFlubex DS Powder for Suspension 125mg/5ml 100ml bot 110\n\tBio Pharma Ltd.\tRevistar Powder for Suspension 125mg/5ml 100ml bot 60.23\n\tBio Pharma Ltd.\tRevistar CAP 250mg 28's pack 154.56\n\tBio Pharma Ltd.\tRevistar CAP 500mg 28's pack 281.12\n\tBristol Pharma Ltd.\tFlac CAP 250mg 60's pack 300\n\tBristol Pharma Ltd.\tFlac CAP 500mg 40's pack 400\n\tBristol Pharma Ltd.\tFlacsp Powder for Suspension 125mg/5ml 100ml bot 50\n\tCentral.\tIsoflu Powder for Suspension 125mg/5ml 100ml bot 60\n\tCentral.\tIsoflu CAP 500mg 40's pack 400\n\tConcord\tDoribac CAP 250mg 28's pack \n\tConcord\tDoribac CAP 500mg 28's pack \n\tConcord\tDoribac Dry Powder for Syrup 125 mg/5ml 100ml bot \n\tCosmic Chemical Industries Ltd.\tSurgeflox Powder for Suspension 125mg/5ml 100ml bot 60\n\tCosmic Chemical Industries Ltd.\tSurgeflox CAP 250mg 40's pack 240\n\tCosmic Chemical Industries Ltd.\tSurgeflox ES CAP 500mg 20's pack 200\n\tCosmo Pharma Ltd.\tFlucil Powder for Suspension 125mg/5ml 100ml bot 60\n\tCosmo Pharma Ltd.\tFlucil CAP 250mg 50's pack 273\n\tCosmo Pharma Ltd.\tFlucil CAP 500mg 20's pack 200\n\tDecent Pharma Ltd.\tFlonex-500 CAP 500mg 32's pack 320\n\tDesh\tFlucloxi Powder for Suspension 125mg/5ml 100ml bot 60.5\n\tDesh\tFlucloxi CAP 250mg 50's pack 330\n\tDesh\tFlucloxi CAP 500mg 20's pack 200\n\tDoctor's Chemicals Works Ltd.\tAuxil Powder for Suspension 125mg/5ml 100ml bot 60\n\tDoctor's Chemicals Works Ltd.\tAuxil CAP 250mg 20's pack 110\n\tDoctor's Chemicals Works Ltd.\tAuxil CAP 500mg 40's pack 400\n\tDrug International Ltd.\tFlupen Powder for Suspension 125mg/5ml 100ml bot 60\n\tDrug International Ltd.\tFlupen CAP 250mg 70's pack 350\n\tDrug International Ltd.\tFlupen Injection 250mg/vial 1's pack 42\n\tDrug International Ltd.\tFlupen CAP 500mg 40's pack 420\n\tDrug International Ltd.\tFlupen Injection 500mg/vial 1's pack\n 62\n\tEdruc Ltd.\tE Flu Powder for Suspension 125mg/5ml 100ml bot 60.68\n\tEdruc Ltd.\tE Flu CAP 500mg 20's pack 222\n\tEdruc Ltd.\tEflu CAP 250mg 40's pack 220\n\tEskayef Bangladesh Ltd.\tFlucloxin Powder for Suspension 125mg/5ml 100ml bot 61\n\tEskayef Bangladesh Ltd.\tFlucloxin CAP 250mg 100's pack 556\n\tEskayef Bangladesh Ltd.\tFlucloxin CAP 500mg 60's pack 378\n\tEskayef Bangladesh Ltd.\tFlucloxin DS Powder For Suspension 125 mg/5 ml  \n\tG. A. Company Ltd.\tFcx Powder for Suspension 125mg/5ml 100ml bot 60\n\tG. A. Company Ltd.\tFcx CAP 250mg 28's pack 154\n\tG. A. Company Ltd.\tFcx CAP 500mg 20's pack 200\n\tGeneral\tFloxapen Powder for Suspension 125mg/5ml 100ml bot 61.23\n\tGeneral\tFloxapen CAP 250mg 50's pack 288\n\tGeneral\tFloxapen CAP 500mg 20's pack 210.8\n\tGlobe\tIsoclox Powder for Suspension 125mg/5ml 100ml bot 60\n\tGlobe\tIsoclox CAP 250mg 20's pack 110\n\tGlobe\tIsoclox CAP 500mg 24's pack 240\n\tGonoshasthaya\tG-Flucloxacillin Injection 500mg/vial 1's pack 25\n\tGonoshasthaya\tG-flucloxacillin CAP 500mg 20's pack 140.60\n\tHallmark\tFlox Powder for Suspension 125mg/5ml 100ml bot 60.22\n\tHallmark\tFlox CAP 250mg 28's pack 154.56\n\tHallmark\tFlox CAP 500mg 20's pack 210\n\tHealthcare\tSkilox Powder for Suspension 125mg/5ml 100ml bot 60\n\tHealthcare\tSkilox CAP 250mg 50's pack 275\n\tHealthcare\tSkilox CAP 500mg 30's pack 300\n\tHudson\tFloxason Powder for Suspension 125mg/5ml 100ml bot 60\n\tHudson\tFloxason CAP 250mg 40's pack 200\n\tHudson\tFloxason CAP 500mg 20's pack 200\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaflox Powder for Suspension 125mg/5ml 100ml bot 65\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaflox CAP 250mg 32's pack 179.2\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinaflox CAP 500mg 28's pack 294\n\tIncepta\tInclox CAP 250mg 50's pack 275\n\tIncepta\tInclox CAP 500mg 50's pack 500\n\tIncepta\tInclox DS Syrup 125mg/5ml 100ml 60\n\tIndobangla Pharmaceuticals\tIndoflox Powder for Suspension 125mg/5ml 100ml bot 60\n\tIndobangla Pharmaceuticals\tIndoflox CAP 250mg 30's pack 154\n\tIndobangla Pharmaceuticals\tIndoflox CAP 500mg 30's pack 300\n\tJalalabad\tF Clox CAP 500mg 20's pack 210\n\tJayson\tEflucin Powder for Suspension 125mg/5ml 100ml bot 61.24\n\tJayson\tEflucin CAP 250mg 20's pack 115.4\n\tJayson\tEflucin Injection 250mg/vial 5 Vial 120.45\n\tJayson\tEflucin CAP 500mg 20's pack 200.6\n\tJayson\tEflucin Injection 500mg/vial 5 Vial 175.65\n\tKemiko\tFlu K Powder for Suspension 125mg/5ml 100ml bot 60\n\tKemiko\tFlu-K CAP 250mg 60's pack 330\n\tKemiko\tFlu-K CAP 500mg 20's pack 200\n\tKumudini Pharma Ltd.\tFaxilin Powder for Suspension 125mg/5ml 100ml bot 60\n\tKumudini Pharma Ltd.\tFaxilin CAP 250mg 48's pack 154\n\tKumudini Pharma Ltd.\tFaxilin CAP 500mg 28's pack 280\n\tLeon\tFlutam CAP 250mg  \n\tLeon\tFlutam CAP 500mg  \n\tLeon\tFlutam Powder For Suspension 250 mg/5 ml  \n\tMarksman.\tActinase Powder for Suspension 125mg/5ml 100ml bot 55\n\tMarksman.\tActinase CAP 500mg 20's pack 160\n\tMedicon\tFlumed Powder for Suspension 125mg/5ml 100ml bot 60\n\tMedicon\tFlumed CAP 250mg 30's pack 165\n\tMedicon\tFlumed CAP 500mg 20's pack 200\n\tMedimet\tFlucillin Powder for Suspension 125mg/5ml 100ml bot 60\n\tMedimet\tFlucillin CAP 250mg 40's pack 220\n\tMedimet\tFlucillin CAP 500mg 20's pack 200\n\tMillat\tFlucin Powder for Suspension 125mg/5ml 100ml bot 61.14\n\tMillat\tFlucin CAP 250mg 48's pack 276\n\tMillat\tFlucin CAP 500mg 30's pack 315\n\tMillat\tFlucin DS Powder for Suspension 125mg/5ml 100ml bot 110\n\tModern\tEnoclox Powder for Suspension 125mg/5ml 100ml bot 60\n\tModern\tEnoclox CAP 500mg 20's pack 200\n\tMystic\tFlora Powder for Suspension 125mg/5ml 100ml bot 59\n\tMystic\tFlora CAP 250mg 20's pack 100\n\tMystic\tFlora CAP 500mg 20's pack 200\n\tNavana\tFlubiotic Powder for Suspension 125mg/5ml 100ml bot 60.23\n\tNavana\tFlubiotic CAP 250mg 20's pack 110.4\n\tNavana\tFlubiotic CAP 500mg 20's pack 150\n\tNipa\tFucil Powder for Suspension 125mg/5ml 100ml bot 60\n\tNipa\tFucil CAP 250mg 60's pack 220\n\tNipa\tFucil CAP 500mg 20's pack 200\n\tNIPRO JMI Pharma\tHalopen Powder for Suspension 125mg/5ml 100ml bot 60.23\n\tNIPRO JMI Pharma\tHalopen CAP 500mg 28's pack 280\n\tNIPRO JMI Pharma\tHalopen CAP 250mg 40's pack 221.2\n\tOpsonin Pharma\tFlux Powder for Suspension 125mg/5ml 100ml bot 61\n\tOpsonin Pharma\tFlux CAP 250mg 28's pack 161\n\tOpsonin Pharma\tFlux CAP 500mg 28's pack 294\n\tOpsonin Pharma\tFlux Injection 500mg/vial 4's pack 180\n\tOpsonin Pharma\tFlux DS Powder for Suspension 250mg/5ml 100ml bot 110\n\tOrganic Health Care\tOrgaflu Powder For Suspension 125 mg/5 ml  \n\tOrganic Health Care\tOrgaflu CAP 250mg  \n\tOrganic Health Care\tOrgaflu CAP 500mg  \n\tOrion Pharma Ltd.\tFlustaph Powder for Suspension 125mg/5ml 100ml bot \n\tOrion Pharma Ltd.\tFlustaph CAP 250mg 28's pack \n\tOrion Pharma Ltd.\tFlustaph CAP 500mg 28's pack \n\tPacific\tStapkil Powder for Suspension 125mg/5ml 100ml bot 46\n\tPacific\tStapkil CAP 250mg 50's pack 275\n\tPacific\tStapkil CAP 500mg 30's pack 300\n\tPharmadesh Ltd.\tStaphylox Powder for Suspension 125mg/5ml 100ml bot 61.18\n\tPharmadesh Ltd.\tStaphylox CAP 500mg 28's pack 294\n\tPharmasia Ltd.\tFlukin Powder for Suspension 125mg/5ml 100ml bot 60\n\tPharmasia Ltd.\tFlukin CAP 250mg 28's pack 154.56\n\tPharmasia Ltd.\tFlukin CAP 500mg 28's pack 281.12\n\tPharmasia Ltd.\tFlukin DS Powder for Suspension 250mg/5ml 100ml bot 110\n\tPopular\tFlubac Powder for Suspension 125mg/5ml 100ml bot 61.23\n\tPopular\tFlubac CAP 250mg 52's pack 300.04\n\tPopular\tFlubac CAP 500mg 32's pack 321.28\n\tPopular\tFlubac DS Powder for Suspension 125mg/5ml 100ml bot 110.42\n\tRAK\tFloxirak CAP 500mg 32's pack 320\n\tRangs\tPerpen Powder for Suspension 125mg/5ml 100ml bot 60\n\tRangs\tPerpen CAP 250mg 40's pack 220\n\tRangs\tPerpen CAP 500mg 28's pack 280\n\tRenata\tFlustar Powder for Suspension 125mg/5ml 100ml bot 60\n\tRenata\tFlustar CAP 250mg 48's pack 264\n\tRenata\tFlustar CAP 500mg 28's pack 280\n\tRenata\tFlustar Dry Powder for Syrup 125mg/5mL 100ml bot \n\tRephco\tSoftapen Powder for Suspension 125mg/5ml 100ml bot 70\n\tRephco\tSoftapen CAP 500mg 50's pack 440\n\tSalton\tPenflu Powder for Suspension 125mg/5ml 100ml bot 60.23\n\tSalton\tPenflu CAP 250mg 60's pack 331.8\n\tSalton\tPenflu CAP 500mg 20's pack 200.6\n\tSeema\tS Fluclox CAP 250mg 40's pack 280\n\tSeema\tS-Fluclox CAP 500mg 40's pack 400\n\tShamsul Al-Amin\tAncoc CAP 250mg 30's pack 165\n\tShamsul Al-Amin\tAncoc CAP 500mg 20's pack 200\n\tShamsul Al-Amin\tAncoc PFS Powder for Suspension 125mg/5ml 100ml bot 60\n\tSilva\tSilox CAP 250mg 30's pack 173.15\n\tSilva\tSilox CAP 500mg 20's pack 200.75\n\tSilva\tSiloxs Powder for Suspension 125mg/5ml 100ml bot 60.22\n\tSomatec\tFlucopen Powder for Suspension 125mg/5ml 100ml bot 60.23\n\tSomatec\tFlucopen CAP 250mg 28's pack 154.84\n\tSomatec\tFlucopen CAP 500mg 20's pack 200.6\n\tSonear Ltd.\tCloxafu CAP 250mg 40's pack 225.6\n\tSonear Ltd.\tCloxafu CAP 500mg 20's pack 205\n\tSquare\tPhylopen Powder for Suspension 125mg/5ml 100ml bot 60.22\n\tSquare\tPhylopen CAP 250mg 50's pack 275.97\n\tSquare\tPhylopen Injection 500mg/vial 5's pack 225.83\n\tSquare\tPhylopen DS CAP 500mg 30's pack 316.01\n\tSquare\tPhylopen FORTE Powder for Suspension 125mg/5ml 100ml bot 110.41\n\tSupreme\tFulcin Powder for Suspension 125mg/5ml 100ml bot 60\n\tSupreme\tFulcin CAP 250mg 30's pack 165\n\tSupreme\tFulcin CAP 500mg 24's pack 240\n\tSyntho Ltd.\tSyflu Powder for Suspension 125mg/5ml 100ml bot 60\n\tSyntho Ltd.\tSyflu CAP 250mg 50's pack 262.5\n\tSyntho Ltd.\tSyflu CAP 500mg 30's pack 285\n\tTechno Drugs Ltd.\tDolopen CAP 250mg 30's pack 315\n\tTechno Drugs Ltd.\tDolopen Injection 250mg/vial 1 Vial 18\n\tTechno Drugs Ltd.\tDolopen CAP 500mg 30's pack 315\n\tTechno Drugs Ltd.\tDolopen Injection 500mg/vial 1 Vial 30\n\tTechno Drugs Ltd.\tDolopen DS Powder for Suspension 125mg/5ml 100ml bot 55\n\tZenith\tFlxzen Powder for Suspension 125mg/5ml 100ml bot 60\n\tZenith\tFlxzen CAP 250mg 60's pack 300\n\tZenith\tFlxzen CAP 500mg 20's pack 160\n\tZiska\tFluxicap CAP 250mg 40's pack 184\n\tZiska\tFluxicap CAP 500mg 56's pack 560\n\tZiska\tFluxi Suspension 125mg 100 ml bot 60\n\tIndication: Pneumonia, Burns, Meningitis, Endocarditis, Sinusitis, Septicaemia, Tonsillitis, Surgical Prophylaxis, Staphylococcal skin infections, Boils, Osteomyelitis, Enteritis,Wounds, Abscesses, Infected eczema, Infected acne\n\nDose: Adults (including elderly patients):\nOral:\n250-500mg three to four times a day. Oral doses should be administered 1 hour before meal\n\nChildren\n2-10 years: Half of adult dose\nUnder 2 years: One fourth of adult dose\n\nChildren have been given doses of 12.5-25 mg/kg body weight four times a day.\n\nIV 0.25-1 g 4 times/day, may double in severe cases. Up to 8 g/day in 3-4 divided doses may be given for osteomyelitis. Up to 8 g/day in 4 divided doses for endocarditis in patients weighing <85 kg and 12 g/day in 6 divided doses for patients weighing >85 kg.\n\nRenal impairment:\nCrCl (ml/min)	\n<10	     Dosage adjustment may be necessary.\n\nContra-indication: Hypersensitivity to penicillins. Porphyria.\n\nSide effects: Hypersensitivity reactions including urticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropenia; thrombocytopenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis; hepatitis, cholestatic jaundice; agranulocytosis; phlebitis (IV infusion).\nPotentially Fatal: Anaphylaxis. Stevens-Johnson syndrome\n\nPrecaution: Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum potassium concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route; elderly. Hepatic impairment.\n\nMode of action: May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.\n\nPregnancy category: B\n\nInteraction: May increase the risk of methotrexate toxicity. May decrease the efficacy of oestrogen-containing OC. Enhanced plasma concentrations w/ probenecid. Bacteriostatic drugs (e.g. chloramphenicol, tetracycline) may interfere w/ the bactericidal effect of flucloxacillin. May prolong bleeding time in patients on oral anticoagulants.
Fluconazole	\n\n\tACI\tCanazole Powder for Suspension 50mg/5ml 35ml bot 78.53\n\tACI\tCanazole TAB dr 150mg 10's pack 221.50\n\tACI\tCanazole TAB dr 200mg 10's pack 250.80\n\tACI\tCanazole TAB dr 50mg 30's pack 241.50\n\tAcme Ltd.\tFluconal Powder for Suspension 50mg/5ml 35ml bot 78.30\n\tAcme Ltd.\tFluconal TAB dr 150mg 10's pack/12's pack 220.80/264.96\n\tAcme Specialized\tFluconal TAB dr 50mg 20's pack 160.80\n\tAexim\tDiflucon CAP 50mg 50's pack 250\n\tAlbion Ltd.\tFluconazole CAP 150 mg/ 50 mg 10's / 30's pack \n\tAlbion Ltd.\tFluconazole Powder For Suspension 50 mg/5 ml 35 ml \n\tAlco Pharma\tDerma CAP 50mg 20's pack 192\n\tAlco Pharma\tDarma CAP 150mg  \n\tAmbee\tAfluzole CAP 50mg 30's pack 240.90\n\tAmbee\tAfluzole CAP 150mg 10's pack 220\n\tAmbee\tAfluzole Suspension 50mg 35ml bot 78.30\n\tAmico Ltd.\tCandid TAB dr 150mg 10's pack 220\n\tAmico Ltd.\tCandid TAB dr 50mg 30's pack 210\n\tApex\tZolen CAP 150mg 10's pack 180\n\tApex\tZolen CAP 50mg 50's pack 400\n\tAristopharma\tDiflu CAP 150mg 12's pack 264\n\tAristopharma\tDiflu CAP 200mg 12's pack 300\n\tAristopharma\tDiflu CAP 50mg 48's pack 384\n\tAristopharma\tDiflus Powder for Suspension 50mg/5ml 35ml bot 78\n\tAristopharma\tDiflu Oral Suspension  35ml bot 68.58\n\tAsiatic Ltd.\tDermicon CAP 150mg 1x10's pack 220\n\tAsiatic Ltd.\tDermicon 50 CAP 50mg 3x10's in Blister Strip 240.00\n\tAvert Pharma Ltd.\tFcon TAB dr 50mg 30's pack 240\n\tBeacon\tXeroder CAP 150mg 8's pack 176\n\tBeacon\tXeroder CAP 50mg 30's pack 240\n\tBelsen\tKenazol CAP 50mg 30's pack 240\n\tBeximco\tOmastin Powder for Suspension 50mg/5ml 35ml bot 78\n\tBeximco\tOmastin CAP 150mg 20's pack 440\n\tBeximco\tOmastin CAP 50mg 50's pack 400\n\tBio Pharma Ltd.\tFungata Powder for Suspension 50mg/5ml 35ml bot 78.29\n\tBio Pharma Ltd.\tFungata CAP 150mg 10's pack 220.80\n\tBio Pharma Ltd.\tFungata CAP 50mg 30's pack 240.90\n\tBristol Pharma Ltd.\tFluconazole CAP 50mg 30's pack 240\n\tBristol Pharma Ltd.\tFluconazole CAP 150mg 10's pack 220\n\tChemist Ltd.\tLeucodar TAB dr 50mg 20's pack 120\n\tCosmic Chemical Industries Ltd.\tFungard CAP 50mg 30's pack 240\n\tCosmo Pharma Ltd.\tCosflu TAB dr 50mg 30's pack 240\n\tDesh\tFlumart CAP 150mg 12's pack 240\n\tDesh\tFlumart CAP 50mg 30's pack 210\n\tDoctor's Chemicals Works Ltd.\tFunga 50 CAP 150mg 20's pack 360\n\tDoctor's Chemicals Works Ltd.\tFunga CAP 50mg 50's pack 325\n\tDrug International Ltd.\tFlunac Powder for Suspension 50mg/5ml 35ml bot 70\n\tDrug International Ltd.\tFlunac CAP 150mg 20's pack 400\n\tDrug International Ltd.\tFlunac CAP 50mg 50's pack 400\n\tEdruc Ltd.\tFungi-F CAP 50mg 30's pack 240\n\tEskayef Bangladesh Ltd.\tFlucoder Suspension 50mg/5ml 36ml 78\n\tEskayef Bangladesh Ltd.\tFlucoder CAP 150mg 10's pack 220\n\tEskayef Bangladesh Ltd.\tFlucoder CAP 50mg 30's pack 243\n\tEuro Pharma Ltd.\tFlumyc CAP 150mg 10's pack 220\n\tEverest\tFcon TAB dr 150mg 12's pack 240\n\tGeneral\tGalfin CAP 150mg 10's pack 220.80\n\tGeneral\tGalfin CAP 50mg 30's pack 240.90\n\tGlaxoSmithKline Bangladesh Ltd.\tFluvin OD TAB dr 150mg 10's pack 200.75\n\tGlaxoSmithKline Bangladesh Ltd.\tFluvin OD TAB dr 50mg 30's pack 240.90\n\tGlobe\tFluzole TAB dr 150mg 20's pack 280\n\tGlobe\tFluzole TAB dr 50mg 30's pack 150\n\tGlobex\tCandiflu 50 CAP 50mg 30's pack 240\n\tGlobex\tCandiflu Powder For Suspension 50 mg/5 ml 35ml 70\n\tHallmark\tOraf Powder for Suspension 50mg/5ml 35ml bot 70\n\tHallmark\tOraf CAP 150mg 20's pack 400\n\tHallmark\tOraf CAP 50mg 30's pack 240\n\tHealthcare\tCandinil Powder for Suspension 50mg/5ml 35ml bot 78\n\tHealthcare\tCandinil CAP 150mg 12's pack 264\n\tHealthcare\tCandinil CAP 50mg 30's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tIluca CAP 150mg 12's pack 276\n\tIbn Sina Pharmaceutical Ind. Ltd.\tIluca CAP 50mg 20's pack 180\n\tIncepta\tNispore 50mg/5ml Powder for Suspension 50mg/5ml 35ml bot 78\n\tIncepta\tNispore CAP 150mg 10's pack 220\n\tIncepta\tNispore CAP 200mg 10's pack 250\n\tIncepta\tNispore CAP 50mg 30's pack 240\n\tKemiko\tOlif CAP 150mg 10's pack 200\n\tKemiko\tOlif CAP 50mg 50's pack 400\n\tKumudini Pharma Ltd.\tNogal TAB dr 50mg 20's pack 160\n\tLeon\tFluact CAP 50mg  \n\tLeon\tFluact Powder For Suspension 50 mg/5 ml  \n\tLeon\tFluact CAP 150mg  \n\tMarksman.\tMycorest CAP 50mg 30's pack 180\n\tMedicon\tFludex CAP 50mg 30's pack 200\n\tMedicon\tFludex CAP 150mg  \n\tModern\tFluma CAP 150mg 12's pack 240\n\tMonicopharma\tFunzol CAP 50mg 30's pack 240\n\tMonicopharma\tFunzole Powder for Suspension 50mg/5ml 35ml bot 78\n\tMonicopharma\tFunzole CAP 150mg 12's pack 264\n\tNavana\tLucon CAP 150mg 10's pack 220.80\n\tNavana\tLucon CAP 50mg 30's pack 240.90\n\tNIPRO JMI Pharma\tDefungi CAP 150mg 10's pack 220.90\n\tNIPRO JMI Pharma\tDefungi CAP 50mg 30's pack 241.20\n\tNovartis (Bangladesh) Ltd.\tFlucess CAP 150mg 10's pack 220\n\tNovartis (Bangladesh) Ltd.\tFlucess CAP 50mg 30's pack 243\n\tNovo Healthcare and Pharma Ltd.\tFluda Powder for Suspension 50mg/5ml 35ml bot 78\n\tNovo Healthcare and Pharma Ltd.\tFluda CAP 50mg 30's pack 240\n\tOpsonin Pharma\tFlucon CAP 150mg 10's pack 220\n\tOpsonin Pharma\tFlucon CAP 200mg 10's pack 200\n\tOpsonin Pharma\tFlucon CAP 50mg 30's pack 240\n\tOrion Pharma Ltd.\tConaz CAP 150mg 12's pack 264.96\n\tOrion Pharma Ltd.\tConaz CAP 50mg 20's pack 160.60\n\tOyster\tLimastin CAP 50 mg  \n\tPacific\tFluzo TAB dr 150mg 10's pack 220\n\tPacific\tFluzo TAB dr 50mg 30's pack 240\n\tPharmadesh Ltd.\tFlunazol Powder for Suspension 50mg/5ml 35ml bot 75\n\tPharmadesh Ltd.\tFlunazol CAP 150mg 12's pack 240\n\tPharmadesh Ltd.\tFlunazol CAP 50mg 30's pack 210\n\tPharmasia Ltd.\tFlugard CAP 150mg 12's pack 264\n\tPharmasia Ltd.\tFlugard CAP 50mg 30's pack 240\n\tPopular\tF-Zol CAP 200mg 12's pack 300\n\tPopular\tF-Zol Powder for Suspension 50mg/5ml 20ml bot/35ml bot 60/78.29\n\tPopular\tF-Zol CAP 150mg 12's pack 264.96\n\tPopular\tF-Zol CAP 50mg 30's pack 240.90\n\tRadiant.\tCandidal CAP 150mg 12's pack 270\n\tRadiant.\tCandidal CAP 50mg 30's pack 240\n\tRadiant.\tCandidal TAB dr 50mg  \n\tRadiant.\tCandidal TAB dr 150mg  \n\tRAK\tFlucanex CAP 150mg 6's pack 132\n\tRAK\tFlucanex CAP 50mg 30's pack 240\n\tRangs\tFungitrol Powder for Suspension 50mg/5ml 35ml bot 70\n\tRangs\tFungitrol CAP 150mg 12's pack 240\n\tRangs\tFungitrol CAP 50mg 20's pack 140\n\tReliance\tCon TAB dr 50mg 30's pack 241.50\n\tRenata\tLucan R CAP 150mg 10's pack 220.80\n\tRenata\tLucan R CAP 50mg 40's pack 321.20\n\tRenata\tLucan R Powder for Suspension 50mg/5ml 35ml bot 78.30\n\tS. N.\tCandizol CAP 50mg 30's pack 211.50\n\tSeema\tFluco-S CAP 150mg 10's pack 220\n\tSeema\tFluco-S CAP 50mg 30's pack 240\n\tShamsul Al-Amin\tSacona 50 CAP 50mg 30's pack 240\n\tSharif\tFlukzol CAP 50mg 30's pack 240\n\tSilva\tAnfasil Powder for Suspension 50mg/5ml 35ml bot 75.28\n\tSilva\tAnfasil CAP 150mg 12's pack 240.90\n\tSilva\tAnfasil CAP 50mg 30's pack 210.79\n\tSomatec\tFlunol Powder for Suspension 50mg/5ml 35ml bot 75.28\n\tSomatec\tFlunol CAP 150mg 10's pack 200.80\n\tSomatec\tFlunol CAP 50mg 32's pack 224.96\n\tSquare\tFlugal Powder for Suspension 50mg/5ml 35ml bot 78.30\n\tSquare\tFlugal CAP 150mg 10's pack 220.78\n\tSquare\tFlugal CAP 50mg 30's pack 241.39\n\tSquare\tFlugal CAP 200mg  \n\tSupreme\tSegal Powder for Suspension 50mg/5ml 35ml bot 65\n\tSupreme\tSegal CAP 150mg 10's pack 150\n\tSupreme\tSegal CAP 50mg 20's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tMycoder TAB dr 150mg 10's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tMycoder TAB dr 50mg 30's pack 210\n\tWhite Horse Pharma\tFlusaf CAP 150mg 30's pack 660\n\tWhite Horse Pharma\tFlusaf CAP 50mg 50's pack 400\n\tZenith\tOnicon Powder for Suspension 50mg/5ml 35ml bot 65\n\tZenith\tOnicon TAB dr 50mg 50's pack 300\n\tZiska\tFlucostan CAP 50mg 20's pack 100\n\tIndication: Cryptococcal meningitis, Candidiasis, Tinea pedis, Tinea cruris, Tinea corporis, Vaginal candidiasis, Onychomycosis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Mucosal candidiasis, Candidal balanitis, Dermatophytosis\n\nDose: Adult: PO Superficial mucosal candidiasis 50 mg/day, up to 100 mg/day. Treatment duration: 7-30 days depending on condition. \nCandidal balanitis; Vag candidiasis 150 mg as a single dose. \nDermatophytosis; Pityriasis versicolor; Cutaneous candidiasis 50 mg/day, for up to 6 wk. \nSystemic candidiasis; Cryptococcal infections Initial: 400 mg, then 200-400 mg/day. Max: 800 mg/day in severe cases. \nPrevention of relapse after a primary course of antifungal treatment for acute cryptococcal infections in AIDS patients 100-200 mg/day. \nProphylaxis of fungal infections in immunocompromised patients 50-400 mg/day.\n\nChild over 1 year - superficial candidal infections, 1-2 mg/kg daily; systemic candidiasis and cryptococcal infections (including meningitis) - 3-6 mg/kg daily (in serious life threatening infections up to 12 mg/kg daily has been given to children aged 5-13 years - max. 400 mg daily).\n\nRenal impairment: Haemodialysis patients: Usual dose given after each session.\nCrCl (ml/min)	\n<50  and not receiving dialysis	50% of the usual dose.\n>50	     Usual dose.\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea, abdominal pain, vomiting, diarrhoea, flatulence; elevated liver function values; headache; rash, exfoliative dermatitis. Rarely, angioedema, anaphylactic reactions and thrombocytopenia.\nPotentially Fatal: Hepatotoxicity; rarely anaphylaxis; Stevens-Johnson syndrome.\n\nPrecaution: Renal or hepatic impairment. May prolong QT interval. Pregnancy, lactation.\n\nMode of action: May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).\nPotentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.\n\nPregnancy category: D\n\nInteraction: May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).\nPotentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.
Fluconazole 0.2% IV	\n\n\tBeacon\tXeroder IV Infusion   100ml bot 199\n\tBeximco\tOmastin IV Infusion  2mg/ml 1's pack 200\n\tPopular\tF-Zol IV Infusion   100ml bot 200\n\tSquare\tFlugal IV Infusion 200 mg/100 ml  \n\tIndication: Systemic fungal infections, Cryptococcal meningitis, Disseminated candidiasis, Fungal UTIs, Oral or vaginal thrush\n\nDose: Invasive candidal infections including candidaemia and disseminated candidiasis and cryptococcal infections including meningitis, by IV, 400 mg initially then 200 mg daily, increased if necessary to 400 mg daily, treatment continued according to response (at least 6-8 weeks for cryptococcal meningitis); Child 6-12 mg/kg daily (every 72 hours in neonate up to 2 weeks old, every 48 hours in neonate 2-4 weeks old); maximum 400 mg daily.\n\nPrevention of relapse of cryptococcal meningitis, by IV, 100-200 mg daily.\n\nPrevention of fungal infections in immunocompromised patients following cytotoxic chemotherapy or radiotherapy, by mouth 50-400 mg daily adjusted according to risk; \n\nChild according to extent and duration of neutropenia, 3-12 mg/kg daily (every 72 hours in neonate up to 2 weeks old, every 48 hours in neonate 2-4 weeks old); maximum 400 mg daily.\n\nContra-indication: - Known hypersensitivity\n- Advanced liver disease\n\nSide effects: Nausea, abdominal discomfort, diarrhoea, flatulence, headache, rash; less frequently dyspepsia, vomiting, abnormalities in liver enzymes, seizures, alopecia and Stevens Johnson syndrome reported.\n\nPrecaution: Cautions should be taken in renal impairment; in hepatic disease liver function should be monitored and should be discontinued if signs or symptoms of hepatic disease appear.\n\nMode of action: May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).\nPotentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.\n\nPregnancy category: D\n\nInteraction: May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).\nPotentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.
Fluconazole 0.3%  Eye prep	\n\n\tAristopharma\tDiflu Eye Drops   5  ml drop 80\n\tIncepta\tNispore Eye Drops   5  ml drop 80\n\tReman Drug Ltd.\tNaz Eye Drops   5  ml drop 100.50\n\tIndication: Fungal corneal ulcers, Fungal keratitis, Fungal eye infections\n\nDose: 1 - 2 drops to be instilled into the affected eye 5 times daily.\n\nContra-indication: The drug is contraindicated in patients with hypersensitivity to azoles. \n\nSide effects: This drug is generally well tolerated. Eosinophillia has been reported in some patients.\n\nPrecaution: Use of fluconazole may result in overgrowth of non-susceptible strains of candida other than C. albicans. \n\nMode of action: May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).\nPotentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.\n\nPregnancy category: D\n\nInteraction: May increase plasma concentrations of oral hypoglycaemics (e.g. tolbutamide, glyburide, glipizide), phenytoin, theophylline, tofacitinib, rifabutin. May increase prothrombin time w/ anticoagulants. May cause significant increase in ciclosporin levels in renal transplant patients w/ or w/o renal impairment. Rifampicin reduces fluconazole levels. May increase risk of nephrotoxicity w/ tacrolimus. May increase the effect of short-acting benzodiazepines (e.g. midazolam).\nPotentially Fatal: Increased risk of cardiac arrhythmias or QT prolongation w/ terfenadine, cisapride, astemizole, pimozide, quinidine, halofantrine and erythromycin.
Flunarizine	\n\n\tACI\tFluver TAB dr 10mg 80's pack 401.60\n\tACI\tFluver TAB dr 5mg 100's pack 351\n\tAcme Ltd.\tFluzin TAB dr 10mg 50's pack 250\n\tAcme Ltd.\tFluzin TAB dr 5mg 50's pack 150\n\tAcme Ltd.\tFluzin 5 TAB dr 5mg 5x10's pack 150\n\tAcme Ltd.\tFluzin 10 TAB dr 10mg 5x10's pack 250\n\tAlco Pharma\tVertig TAB dr 5mg 30's Pack 105\n\tAlco Pharma\tVertig TAB dr 10mg 30's pack 150\n\tApex\tFlunarin TAB dr 10mg 30's pack 90\n\tApex\tFlunarin TAB dr 5mg 50's pack 100\n\tBeximco\tFlurium TAB dr 10mg 30's pack 150\n\tBeximco\tFlurium TAB dr 5mg 30's pack 90\n\tEskayef Bangladesh Ltd.\tNorium TAB dr 10mg 60's pack 300\n\tEskayef Bangladesh Ltd.\tNorium TAB dr 5mg 100's pack 350\n\tNavana\tImigra CAP 10mg 30's pack 150\n\tNavana\tImigra CAP 5mg 50's pack 200\n\tOpso Saline Ltd.\tMigrium TAB dr 5mg  \n\tOpso Saline Ltd.\tMigrium TAB dr 10mg  \n\tOpsonin Pharma\tMinium TAB dr 10mg 50's pack 176.82\n\tOpsonin Pharma\tMinium TAB dr 5mg 50's pack 132.40\n\tSquare\tFlurizin TAB dr 10mg 50's pack 200.83\n\tSquare\tFlurizin TAB dr 5mg  50's pack 150.29\n\tUnimed & Unihealth Manufacturers Ltd.\tRizelium CAP 10mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tRizelium CAP 5mg 30's pack 105\n\tIndication: Migraine, Vertigo, Peripheral vascular disease, Cerebrovascular disorders, Vestibular disorders\n\nDose: Adult: PO Migraine prophylaxis; Prophylaxis of peripheral and cerebrovascular disorders; Prophylaxis of vertigo and vestibular disorders 5-10 mg/day at bedtime.\n\nContra-indication: Pregnancy, lactation, GI or urinary tract obstruction, acute porphyrias.\n\nSide effects: Drowsiness. Rarely wt gain, headache, depression, gastric pain, dry mouth, insomnia, extrapyramidal reactions, galactorrhoea.\n\nPrecaution: Driving or operating machinery, epilepsy, elderly, CVS disease, glaucoma.\n\nMode of action:  Plasma levels reduced by phenytoin, carbamazepine, valproic acid.\n\nPregnancy category: Not Classified\n\nInteraction:  Plasma levels reduced by phenytoin, carbamazepine, valproic acid.
Fluocinolone 0.01% + Hydroquinone 4% + Tretinoin 0.05% Topical	\n\n\tChemist Ltd.\tMelacare Cream (0.01 gm + 4 gm +0 .05 gm  \n\tEskayef Bangladesh Ltd.\tNospot Cream (0.01 gm + 4 gm +0 .05 gm  \n\tIncepta\tTrimela Cream  30gm tube 200\n\tPharmasia Ltd.\tMelasin Cream   15gm tube 110\n\tIndication: Melasma\n\nDose:  It should be applied at least 30 minutes before bedtime. A thin film of the cream should be applied to the hyperpigmented areas of melasma including about Â½ inch of normal appearing skin surrounding each lesion.\n\nCream is for short-term (up to 8 weeks) treatment of moderate to severe melasma of the face. It is not for long-term (more than 8 weeks) or maintenance (continuous) treatment of melasma.\n\n\nContra-indication:  A history of hypersensitivity, allergy, or intolerance to this product or any of its components.\n\nSide effects: The most frequently reported events were erythema, desquamation, burning, itching, irritation, dryness, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and skin atrophy at the site of application. The majority of these events were mild to moderate in severity.\n\nPrecaution: Cream contains hydroquinone and tretinoin that may cause mild to moderate irritation such as skin reddening, peeling, mild burning sensation, dryness, and pruritus. Transient skin reddening or mild burning sensation does not preclude treatment. If a reaction suggests hypersensitivity or chemical irritation, the use of the medication should be discontinued.\n Cream also contains the corticosteroid fluocinolone acetonide. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushingâs syndrome, hyperglycemia, and glucosuria can also be produced by systemic absorption of topical corticosteroid while on treatment. If HPA axis suppression is noted, Cream should be discontinued.\n\nMode of action: Medicated or abrasive soaps & cleansers, soaps & cosmetics w/ drying effects, products w/ high conc of alcohol & astringent, & other irritants or keratolytic drugs. Medications w/ photosensitizing effects.\n\nPregnancy category: C\n\nInteraction: Medicated or abrasive soaps & cleansers, soaps & cosmetics w/ drying effects, products w/ high conc of alcohol & astringent, & other irritants or keratolytic drugs. Medications w/ photosensitizing effects.
Fluocinolone 0.025% + Neomycin Sulphate 0.5% Topical	\n\n\tACI\tSkinalar N Cream  0.025%+0.5% 5gm  tube 40.12\n\tACI\tSkinalar N Ointment  0.025%+0.5% 5gm  tube 40.12\n\tIndication: Psoriasis, Eczema, Tularaemia, Dermatitis,\n\nDose: Adult: Topical  cream/gel/lotion/oint/scalp lotion: Apply 3-4 times/day.\n\nContra-indication: Primary infectious (bacterial, viral, fungal) ulcers, hypersensitivity, acne vulgaris. Neonates.\n\nSide effects: Dry skin, pruritus, irritation, mild to moderate transient burning/stinging. Local atrophic changes in the skin (prolonged & intensive treatment). Hypercorticism (systemic absorption on prolonged use). Itching, folliculitis, hypertrichoses, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of skin, secondary infections, striae & miliaria. Ototoxicity & nephrotoxicity.\nProlonged admin causes epidermal thinning, telangiectasia and striae (especially face and flexures). Application on eyelid and surrounding skin can cause raised intraocular pressure, cataracts, glaucoma, corneal ulcers and raised intracranial pressure. Systemic absorption with adrenal suppression may be seen when applied over large areas, when skin is broken or under occlusive dressing. \n\nPrecaution: Children, elderly, hepatic failure. Prolonged use on the face; contact with eyes. Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluocinolone 0.1% + Neomycin Sulphate 0.5%	\n\n\tIndication: Inflammatory eye disorders\n\nDose: Adult: Apply onto affected area(s) 3-4 times daily.\n\nContra-indication: Primary infectious (bacterial, viral, fungal) ulcers, hypersensitivity, acne vulgaris. Neonates.\n\nSide effects: Prolonged admin causes epidermal thinning, telangiectasia and striae (especially face and flexures). Application on eyelid and surrounding skin can cause raised intraocular pressure, cataracts, glaucoma, corneal ulcers and raised intracranial pressure. Systemic absorption with adrenal suppression may be seen when applied over large areas, when skin is broken or under occlusive dressing. Contact dermatitis, perioral dermatitis, papular disorder, mild depigmentation.\n\nPrecaution: Children, elderly, hepatic failure. Prolonged use on the face; contact with eyes. Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluocinolone Acetonide 0.025% Topical	\n\n\tACI\tSkinalar Cream  0.025% 5gm  tube 38.12\n\tACI\tSkinalar Ointment  0.025% 5gm  tube 38.12\n\tAmbee\tFungakil Ointment   5gm  tube 28.10\n\tAmbee\tFungkil Cream   5gm  tube 28.10\n\tAmico Ltd.\tDermidex Cream   5 gm  tube 30\n\tDrug International Ltd.\tCinoderm Cream   5gm  tube x 5 's pack/10gm  tube x 1 's pack 150 / 45\n\tG. A. Company Ltd.\tAlor Cream   5gm  tube 30\n\tPharmadesh Ltd.\tDarmalar N Ointment 25 mg/100 gm  \n\tIndication: Psoriasis, Eczema, Tularaemia, Dermatitis,\n\nDose: Adult: Topical  cream/gel/lotion/oint/scalp lotion: Apply 3-4 times/day.\n\nContra-indication: Primary infectious (bacterial, viral, fungal) ulcers, hypersensitivity, acne vulgaris. Neonates.\n\nSide effects: Prolonged admin causes epidermal thinning, telangiectasia and striae (especially face and flexures). Application on eyelid and surrounding skin can cause raised intraocular pressure, cataracts, glaucoma, corneal ulcers and raised intracranial pressure. Systemic absorption with adrenal suppression may be seen when applied over large areas, when skin is broken or under occlusive dressing. Contact dermatitis, perioral dermatitis, papular disorder, mild depigmentation.\n\nPrecaution: Children, elderly, hepatic failure. Prolonged use on the face; contact with eyes. Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluorescein Sodium 2% Eye prep	\n\n\tReman Drug Ltd.\tFlurocin Eye Drops   5 ml bot/10 ml bot 34 / 79\n\tIndication: Fitting of hard contact lenses, Diagnostic ophthalmic procedures\n\nDose:  Ophth Aid in fitting hard contact lenses; Detection of corneal lesions and foreign bodies; Diagnostic ophth procedures As 1 or 2% soln as eye drops or as sterile papers impregnated w/ fluorescein Na: Use as directed.\n\nContra-indication: Acute necrotising pancreatitis (oral fluorescein dilaurate).\n\nSide effects: Transient yellow coloration of skin and urine; staining of the skin, clothing and soft contact lenses.\n\n\nPrecaution: \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluormetholone 0.1% + Neomycin Sulphate 0.5% Eye prep	\n\n\tReman Drug Ltd.\tFlumelone N Eye Drops    5  ml drop 95.50\n\tIndication: Allergic and inflammatory conditions of the eye\n\nDose: Adult: Ophth As 0.1% oint: Apply half an inch ribbon 1-3 times/day. As 0.1% soln: Instil 1-2 drops 2-4 times/day. May increase dose to 4 hrly in severe cases during the initial 24-48 hr.\n\nContra-indication: Viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), Vaccinia and Varicella, mycobacterial eye infection, ocular fungal infections, untreated eye infections; hypersensitivity.\n\nSide effects: Elevated intraocular pressure, optic nerve damage, postsubcapsular cataract formation, delayed wound healing, uveitis, perforation of the globe, keratitis, conjunctivitis, corneal ulcers, loss of accommodation, secondary ocular infections, rarely systemic hypercorticoidism.\n\nPrecaution: Glaucoma (check intraocular pressure periodically), history of herpes simplex fungal or bacterial infections. Not to be used in mustard gas keratitis and Sjogren's keratoconjunctivitis. May cause corneal and scleral thinning which may lead to perforation in serious cases. Use of steroids after cataract surgery may prolong healing time and increase bleb formation. Pregnancy, lactation; children <2 yr.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluorometholone 0.1 % Eye prep	\n\n\tApex\tFlurom Eye Drops   5  ml drop 80\n\tAristopharma\tAfm Eye Drops   5  ml drop 100\n\tBeximco\tRubalon Eye Drops   5ml bot 90\n\tBio Pharma Ltd.\tFlurone Eye Drops 0.1 %  \n\tG. A. Company Ltd.\tFlucort Eye Drops   5  ml drop 90\n\tGeneral\tFlurolon Eye Drops 0.1%  \n\tIncepta\tMetalone Eye Drops   5  ml drop 90\n\tKemiko\tMetholone Eye Drops   5ml drop 90\n\tNavana\tOtholon Eye Drops   5ml drop 90\n\tNipa\tFlumeth Eye Drops   5  ml drop 100\n\tOpso Saline Ltd.\tNGS Eye Drops   5  ml drop 90\n\tPopular\tFluromet Eye Drops  .1 % 5  ml drop 100\n\tIndication: Allergic and inflammatory conditions of the eye\n\nDose: Adults and children (above 2 years of age):\nInstill 1-2 drops into conjunctivalsac 2-3 times daily. Dose may be increased to 1 drop hourly during first 24-48 hr.\n\nContra-indication: This medication is contraindicated in following cases-\nâ¢ Viral infection of cornea & conjunctiva caused by Herpes simplex etc\nâ¢ Fungal infection of the cornea & conjunctiva\nâ¢ Tuberculous infections\nâ¢ Ulcerous processes of the cornea\nâ¢ Hypersensitivity to any ingredients of this formulation.\n\nSide effects: Mild burning sensation, reversible increase in intra ocular pressure (IOP), reactive hyperemia/rebound effect, cataract & corneal defects, glaucoma, systemic effects (chronic use).\n\nPrecaution: â¢ Prolonged use in pregnant women and infants should be avoided\nâ¢ This medication should be used with caution in patients under treatment with MAO inhibitors\nâ¢ Do not apply while wearing soft contact lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.\nâ¢ Shake well before use.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluorometholone 0.1% + Gentamicin 0.3% Eye prep	\n\n\tAristopharma\tAFM plus Eye Ointment   3 gm tube 100\n\tAristopharma\tAFM PLUS Eye Drops   5  ml drop 110\n\tAsiatic Ltd.\tInflagen Eye Drops   5ml drop 130\n\tIndication: Allergic and inflammatory conditions of the eye\n\nDose: Sterile Ophthalmic Suspension:\nBacterial infection: The dosage depends on the severity of the disease. The application of 1 drop 5 times daily into the conjunctival sac of the affected eye is recommended. In severe cases the dosage can be increased up to 1 drop per hour for 1 to 2 days.\nOcular postoperative infection: 1 drop 4 times daily into the conjunctival sac for 1 week. Then a reduced application frequency is recommended for the remaining part of the treatment.\nSterile Eye Ointment:\nBacterial infection: Apply 3-4 times daily into the affected eye.\nOcular postoperative infection: To support the therapy with Ophthalmic Suspension during the night apply ointment before retiring.\n\nContra-indication: Hypersensitivity to any of the components. Injuries and ulceration of the cornea. Viral infections (e.g. Herpes simplex, Vaccinia) or mycosis.\n\nEye tuberculosis.\n\nGlaucoma.\n\nSide effects: A transient burning sensation may occur after instillation. Rare: Hypersensitivity reactions including eczema of the eyelid and puncture keratitis. Prolonged use of topical steroids may delay wound healing, increase of IOP, develop cataract and cause thinning of cornea & sclera.\n\nPrecaution: Steroids can mask, activate or aggravate ocular infections.\n\nLong term treatment with steroid may enhance thinning of cornea and sclera and rarely perforation of the cornea has been reported.\n\nIn case no improvement is observed after 7-8 days of treatment, other therapeutical means should be considered.\n\nPatients experiencing blurred vision after application of the product, particularly the ointment, should refrain from driving vehicles or operating machinery.\n\nContact lenses should be removed before each application.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluorometholone 0.1% + Tetrahydrozoline Hydrochloride 0.025% Eye prep	\n\n\tApex\tFlurom Plus Eye Drops   5ml bot 80\n\tAristopharma\tAFM-T Eye Drops   5  ml drop 100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEylon Eye Drops   5  ml drop 100\n\tIncepta\tMetalone Plus Eye Drops   5ml 110\n\tReman Drug Ltd.\tRefemoline Eye Drops   5  ml drop 100\n\tIndication: Keratitis, Allergic and inflammatory conditions of the eye, Iridocyclitis, Iritis, Acute & chronic conjunctivitis, Scleritis, Episcleritis, Myositis. Post-op conditions after strabotomy, Cataract & glaucoma operations\n\nDose: Adults and children (above 2 years of age):\nInstill 1-2 drops into conjunctivalsac 2-3 times daily. Dose may be increased to 1 drop hourly during first 24-48 hr.\n\nContra-indication: This medication is contraindicated in following cases-\nâ¢ Viral infection of cornea & conjunctiva caused by Herpes simplex etc\nâ¢ Fungal infection of the cornea & conjunctiva\nâ¢ Tuberculous infections\nâ¢ Ulcerous processes of the cornea\nâ¢ Hypersensitivity to any ingredients of this formulation.\n\nSide effects: Mild burning sensation, reversible increase in intra ocular pressure (IOP), reactive hyperemia/rebound effect, cataract & corneal defects, glaucoma, systemic effects (chronic use).\n\nPrecaution: â¢ Prolonged use in pregnant women and infants should be avoided\nâ¢ This medication should be used with caution in patients under treatment with MAO inhibitors\nâ¢ Do not apply while wearing soft contact lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.\nâ¢ Shake well before use.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluorometholone Acetate 0.1% Eye prep	\n\n\tS. A. Alcon Couvreur N.V.,Belgium\tFlarex 0.1% Eye Drops 1.0mg/ml  5 ml drop  163.50 \n\tIndication: Allergic and inflammatory conditions of the eye\n\nDose: Adult: Ophth As 0.1% soln: Instil 1-2 drops 2-4 times/day. May increase dose to 4 hrly in severe cases during the initial 24-48 hr.\n\nContra-indication: Viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), Vaccinia and Varicella, mycobacterial eye infection, ocular fungal infections, untreated eye infections; hypersensitivity.\n\nSide effects: Elevated intraocular pressure, optic nerve damage, postsubcapsular cataract formation, delayed wound healing, uveitis, perforation of the globe, keratitis, conjunctivitis, corneal ulcers, loss of accommodation, secondary ocular infections, rarely systemic hypercorticoidism.\n\nPrecaution: Glaucoma (check intraocular pressure periodically), history of herpes simplex fungal or bacterial infections. Not to be used in mustard gas keratitis and Sjogren's keratoconjunctivitis. May cause corneal and scleral thinning which may lead to perforation in serious cases. Use of steroids after cataract surgery may prolong healing time and increase bleb formation. Pregnancy, lactation; children <2 yr.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Fluoxetine	\n\n\tAlbion Ltd.\tFluoxetine CAP 20 mg 50's pack \n\tBeximco\tModipran CAP 20mg 100's pack 289\n\tDecent Pharma Ltd.\tOxetin CAP 20mg 50's pack 144\n\tGeneral\tNodep CAP 20mg 50's pack 140\n\tKemiko\tNodepress CAP 20mg 50's pack 130\n\tOpsonin Pharma\tDepil CAP 20 mg 50's pack \n\tSonear Ltd.\tSeren CAP 20mg 30's pack 86.10\n\tSquare\tProlert CAP 20mg 50's pack 150\n\tSun Pharmaceutical (Bangladesh) Ltd.\tProdep CAP 20mg 50's pack 150\n\tEli Lilly and Company USA\tProzac 20 TAB dr 20mg 7's pack \n\tIndication: Panic disorder, Obsessive compulsive disorder, Trichotillomania, Premenstrual dysphoric disorder, Major depression, Post-traumatic stress disorder, Bulimia nervosa, Body dysmorphic disorder, Binge eating disorder\n\nDose: Adults only; without regard to meals.\nDepression: Adults and elderly: A dose of 20 mg/day is recommended.\nBulimia nervosa: Adults and elderly: A dose of 60 mg/day is recommended.\nObsessive compulsive disorder: The recommended starting dose is 20mg/day which can be gradually increased to 60 mg/day. Child: 7-18 yr: Initially, 10 mg daily; may increase to 20 mg daily after 2 wk in adolescents and higher-wt children. Usual range: 10-60 mg daily.\n\nIn premenstrual syndrome: usual dose is 20 mg/day or as directed by the physician.\n\n\nContra-indication: Severe renal or hepatic failure; hypersensitivity; lactation; concomitant MAOIs or within 2 wk of MAOI withdrawal.\n\nSide effects: Nervousness, insomnia, anxiety, headache, tremor, drowsiness, dry mouth, nausea, vomiting, sweating, diarrhoea. Seizures, mania, hypomania or mixed manic states reported. Hyponatraemia; elevation of hepatic enzymes.\nPotentially Fatal: Rarely, systemic events possibly related to vasculitis have been reported in patients with rash but may be serious involving lungs, kidney and liver.\n\nPrecaution: Unstable epilepsy, liver and renal impairment, cardiac disease, diabetes, electroconvulsive therapy, bleeding disorders, closed-angle glaucoma; pregnancy. May impair performace of skilled tasks; withdraw gradually. Close monitoring of clinical worsening and behavioural changes during the 1st few mth of treatment or when there are dose changes.\n\nMode of action:  	May cause transient shift in plasma conc of tightly protein bound drugs e.g. warfarin and digoxin, resulting in adverse effects. T1/2 of diazepam is prolonged. Avoid concurrent use with clopidogrel.\nPotentially Fatal: Serious reactions when combined with MAOIs; at least 14 days should elapse after MAOIs withdrawal before starting fluoxetine treatment or at least 5 wk should elapse after fluoxetine treatment before starting MAOIs therapy. Two-fold increase in plasma levels of other antidepressants when combined with fluoxetine. Monitor lithium levels when combined.\n\nPregnancy category: C\n\nInteraction:  	May cause transient shift in plasma conc of tightly protein bound drugs e.g. warfarin and digoxin, resulting in adverse effects. T1/2 of diazepam is prolonged. Avoid concurrent use with clopidogrel.\nPotentially Fatal: Serious reactions when combined with MAOIs; at least 14 days should elapse after MAOIs withdrawal before starting fluoxetine treatment or at least 5 wk should elapse after fluoxetine treatment before starting MAOIs therapy. Two-fold increase in plasma levels of other antidepressants when combined with fluoxetine. Monitor lithium levels when combined.
Flupenthixol	\n\n\tEskayef Bangladesh Ltd.\tSentix TAB dr 0.5mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tSentix TAB dr 1mg 30's pack 150\n\tIndication: Depression, Schizophrenia, Psychoses\n\nDose: Adult: PO Psychoses Initial: 3-9 mg twice daily. Max: 18 mg/day. Depression Initial: 1 mg/day, increase to 2 mg/day after 1 wk, then to 3 mg/day. Max: 3 mg/day. \n\nIM Psychoses As decanoate: Initial: 20 mg as a test dose. After at least 7 days and depending on response: Subsequent doses of 20-40 mg may be given 2-4 wkly. Usual maintenance: 50 mg 4 wkly to 300 mg 2 wkly, up to 400 mg/wk in severe cases.\n\nContra-indication: Hypersensitivity. Extremely excitable and overactive patients; mania; porphyria; coma; preexisting CNS depression; bone-marrow supression; phaeochromocytoma. Lactation.\n\nSide effects: Rigidity, tremors, restlessness, tardive dyskinesia, insomnia, dryness of mouth, wt gain, sexual dysfunction, galactorrhoea and menstrual disturbances.\n\nPotentially Fatal: Neuroleptic malignant syndrome (hyperthermia, hypertonicity of skeletal muscles, unconsciousness and autonomic nervous system instability).\n\nPrecaution: Patients with convulsive disorders; advanced hepatic, renal, CV or resp disease; tasks requiring mental alertness; elderly (especially with dementia), and debilitated patients; neuroleptics with sedative effect must be withdrawn gradually; history of angle-closure glaucoma; urinary retention; prostatic hyperplasia; breast cancer, prolactin dependent tumours; parkinsonism; myasthenia gravis; pregnancy; Avoid direct sunlight.\n\nMode of action:  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).\nPotentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.\n\nPregnancy category: C\n\nInteraction:  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).\nPotentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.
Flupenthixol + Melitracen	\n\n\tACI\tAdelax TAB dr  0.5mg+10mg 80's pack 401.60\n\tAcme Ltd.\tLeanxit TAB dr 0.5 mg + 10 mg 100's pack 400\n\tAlbion Ltd.\tFulimet TAB dr (0.5+10) mg 150's pack \n\tAlco Pharma\tTixol TAB dr 500 mcg + 10 mg 50's pack 150\n\tAmico Ltd.\tAmilax TAB dr  50's pack 160\n\tApex\tMixit TAB dr   50's pack 175\n\tAristopharma\tAnfree TAB dr   100's pack 400\n\tAsiatic Ltd.\tAntison TAB dr   30's pack 105\n\tAstra Biopharmaceuticals Ltd.\tDanxit TAB dr 500 mcg + 10 mg  \n\tBeacon\tXolitra TAB dr   50's pack 175\n\tBeximco\tFrenxit TAB dr   750's pack 525\n\tBio Pharma Ltd.\tBenzit TAB dr   100's pack 351\n\tBristol Pharma Ltd.\tBP-Xit TAB dr  100's pack 350\n\tChemist Ltd.\tDinxi TAB dr   50's pack 150\n\tDelta Pharma\tStimo TAB dr   50's pack 175\n\tDoctor's Chemicals Works Ltd.\tAnotic TAB dr   50's pack 175\n\tDrug International Ltd.\tDiconten TAB dr  0.5mg + 10mg 50's pack 200\n\tEskayef Bangladesh Ltd.\tSensit TAB dr   50's pack 200\n\tEskayef Bangladesh Ltd.\tSensit FC TAB dr   50's pack 200\n\tEverest\tXit TAB dr   50's pack 175\n\tGeneral\tDeleta TAB dr   50's pack 200\n\tGlobe\tRadex TAB dr   30's pack 120\n\tHealthcare\tAngenta TAB dr   100's pack 500\n\tHudson\tHenxit TAB dr   100's pack 350\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRemood TAB dr   50's pack 200\n\tIncepta\tTenaxit TAB dr   50's pack 175\n\tKemiko\tFemanol TAB dr   50's pack 200\n\tKumudini Pharma Ltd.\tLumexit TAB dr   50's pack 200\n\tMedicon\tInspra TAB dr  50's pack 200\n\tMonicopharma\tFemixit TAB dr   50's pack 175\n\tNavana\tMeltix TAB dr   50's pack 175.50\n\tNIPRO JMI Pharma\tThixtra TAB dr 500 mcg + 10 mg  \n\tNovo Healthcare and Pharma Ltd.\tNeoxit TAB dr   30's pack 120\n\tOpsonin Pharma\tFluxit TAB dr   50's pack 175.50\n\tOrion Pharma Ltd.\tU 4 TAB dr   50's pack 175.50\n\tPacific\tThenxet TAB dr   100's pack 400\n\tPeoples Pharma Ltd.\tPenxit TAB dr   50's pack 130\n\tPharmadesh Ltd.\tExuten TAB dr   30's pack 105.30\n\tPharmasia Ltd.\tFraxit TAB dr  50's pack 200\n\tPopular\tAnzet FC TAB dr  0.5+10mg 50's pack 400\n\tRAK\tFMR TAB dr   50's pack 200\n\tRangs\tDepresil TAB dr   50's pack 162.50\n\tReliance\tNoanxit TAB dr 500 mcg + 10 mg  \n\tRenata\tRenxit TAB dr   100's pack 400\n\tRephco\tRelux TAB dr   50's pack 150\n\tShamsul Al-Amin\tTensa TAB dr   50's pack 175\n\tSharif\tTixocin TAB dr  500 mcg + 10 mg 30's pack 105\n\tSomatec\tDormir TAB dr   50's pack 175.50\n\tSquare\tMelixol TAB dr  500 mcg + 10 mg 50's pack 200\n\tSun Pharmaceutical (Bangladesh) Ltd.\tExzilor TAB dr   50's pack 175\n\tTechno Drugs Ltd.\tPentixol TAB dr   30's pack 90\n\tUnimed & Unihealth Manufacturers Ltd.\tDexit TAB dr   50's pack 200\n\tVeritas\tAnxicon TAB dr 500 mcg + 10 mg  \n\tWhite Horse Pharma\tTensicon TAB dr   50's pack 175\n\tZenith\tZenxit TAB dr   100's pack 325\n\tZiska\tMelxit TAB dr  50's pack 175\n\tIndication: Depression, Anxiety, Apathy, Dysphoria\n\nDose: Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets.\nElderly: 1 tablet in the morning.\nMaintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.\n\nContra-indication: The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.\n\nSide effects: In the recommended doses side effects are rare. These could be transient restlessness and insomnia.\n\nPrecaution: If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.\n\nMode of action:  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).\nPotentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.\n 	Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.\n\nPregnancy category: C\n\nInteraction:  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).\nPotentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.\n 	Additive toxicity with antimuscarinics, CNS depressants. Response to TCA may be accelerated with thyroid hormones; pressor effects of sympathomimetics may be enhanced; risk of serotonin syndrome when taken with other antidepressants. Antidiabetic dosage may need to be adjusted.
Fluphenazine Hydrochloride + Nortriptyline	\n\n\tAcme Ltd.\tNorflu TAB dr 10 mg + 0.5 mg 100's pack 80\n\tAlco Pharma\tAnflu TAB dr   100's pack 75\n\tAmico Ltd.\tAmival TAB dr   100's pack 80\n\tAmico Ltd.\tAmival F TAB dr   100's pack 201\n\tAristopharma\tNorzin TAB dr   250's pack 200\n\tBeximco\tApresin TAB dr   100's pack 105\n\tBio Pharma Ltd.\tEuphor TAB dr   100's pack 80\n\tGeneral\tFlutrip TAB dr   100's pack 71\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMoodon TAB dr   200's pack 170\n\tNipa\tFresh TAB dr   100's pack 80\n\tOpsonin Pharma\tPermival TAB dr   200's pack 131.89\n\tSomatec\tTripnor TAB dr   100's pack 75\n\tSquare\tSanit TAB dr  500 mcg + 10 mg 100's pack 80\n\tZiska\tAteval TAB dr   100's pack 100\n\tIndication: Headache, Depression, Anxiety, Emotional disturbance, Tension, Fatigue, Sleep disorder, Bodyache, Gastric problems\n\nDose: Adult: 1 tablet 2 to 3 times daily.\nChild: Not recommended.\n\nContra-indication: Patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. The presence of blood dyscrasia or liver damage precludes the use of fluphenazine hydrochloride. Fluphenazine hydrochloride is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross sensitivity to phenothiazine derivatives may occur.\n\nSide effects: Dryness of mouth, drowsiness, constipation, tachycardia, nasal congestion, blurred vision and excitement.\n\nPrecaution: Patients with glaucoma, prostate enlargement, cardiac failure and myocardial infarction. The drug may impair alertness and abilities to drive a car or operating machinery.\n\nBecause of the possibility of cross-sensitivity, fluphenazine hydrochloride should be used cautiously in patients who have developed cholestatic jaundice, dermatoses or other allergic reactions to phenothiazine derivatives.\n\nPsychotic patients on large doses of a phenothiazine drug who are undergoing surgery should be watched carefully for possible hypotensive phenomena. Moreover, it should be remembered that reduced amounts of anesthetics or central nervous system depressants may be necessary.\n\nThe effects of atropine may be potentiated in some patients receiving fluphenazine because of added anticholinergic effects.\n\nMode of action: Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics.\nPotentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.\n\nPregnancy category: C\n\nInteraction: Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics.\nPotentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.
Flurazepam	\n\n\tAlbion Ltd.\tFlurazepam TAB dr 30 mg 100's pack \n\tAmbee\tAluctin CAP 30mg 100's pack 355\n\tG. A. Company Ltd.\tFuramane CAP 15mg 100's pack 299.45\n\tGeneral\tSlipam CAP 15mg 30's pack 105.30\n\tGeneral\tSlipam CAP 30mg 30's pack 180.60\n\tIndication: Insomnia\n\nDose: Oral\nShort-term management of insomnia\nAdult: 15-30 mg at night.\nChild: >15 yr 15 mg at night.\nElderly: Max: 15 mg at night.\n\nContra-indication: Hypersensitivity; porphyria. Pregnancy (3rd trimester); neonates.\n\nSide effects: Drowsiness and lightheadedness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia.\n\nPrecaution: Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; personality disorders or organic brain changes; history of alcohol or drug addiction. Respiratory depression and hypotension with parenteral admin. Dependence; lactation. Safety and efficacy are not proven in children <15 yr.\n\nMode of action: May enhance CNS depressant effect w/ antidepressants, antipsychotics, general anaesth, hypnotics or sedatives, opioid analgesics. Flurazepam clearance may be reduced by cimetidine, and may be increased by rifampicin.\n\nPregnancy category: X\n\nInteraction: May enhance CNS depressant effect w/ antidepressants, antipsychotics, general anaesth, hypnotics or sedatives, opioid analgesics. Flurazepam clearance may be reduced by cimetidine, and may be increased by rifampicin.
Flurbiprofen	\n\n\tGeneral\tUrbifen TAB dr 50mg 30's pack 150.60\n\tIndication: Dysmenorrhoea, Sore throat, Ocular inflammation, Pain and inflammation associated w/ musculoskeletal and joint disorders, Prophylaxis of miosis during ocular surgery\n\nDose: Adult: PO Pain and inflammation associated w/ musculoskeletal and joint disorders 150-200 mg/day in divided doses, up to 300 mg/day in severe cases.\n Dysmenorrhoea Initial: 100 mg, then 50-100 mg 4-6 hrly. Max: 300 mg/day. \nSore throat Per loz contains 8.75 mg flurbiprofen: 1 loz 3-6 hrly, up to a max of 3 days. Max: 5 loz/day. \nOphth Prevention of miosis during ocular surgery As 0.03% flurbiprofen Na soln: Instill 1 drop every 30 mins starting 2 hr before and ending not <30 mins before surgery. \nPost-op ocular inflammation As 0.03% flurbiprofen Na soln: Instill 1 drop 4 times/day for 1-3 wk starting 24 hr post-op.\n\nContra-indication: Peptic ulcer, GI haemorrhage, asthma, bronchospasm, rhinitis, angioedema, hypersensitivity; aspirin intolerance; pregnancy (3rd trimester); lactation.\n\nSide effects: Fluid retention, oedema; allergic nephritis, allergic reactions; GI upsets; dizziness, tinnitus, blurring of vision; local irritation, transient burning and stinging (ophthalmic).\nPotentially Fatal: Peptic ulceration, haemorrhage and perforation.\n\nPrecaution: 	Hypertension; impaired renal function.\n\nMode of action:  	Reduced antihypertensive effect of ACE inhibitors, angiotensin II receptor antagonists and ?-blockers. Slight reduction in blood glucose concentration in patients w/ DM receiving certain antidiabetic agents (e.g. glyburide, metformin). Reduced diuretic effect of furosemide and thiazides. May increase toxicity of lithium and methotrexate. May increase risk of bleeding w/ antiplatelets, anticoagulants, SSRIs, corticosteroids.\n\nPregnancy category: C\n\nInteraction:  	Reduced antihypertensive effect of ACE inhibitors, angiotensin II receptor antagonists and ?-blockers. Slight reduction in blood glucose concentration in patients w/ DM receiving certain antidiabetic agents (e.g. glyburide, metformin). Reduced diuretic effect of furosemide and thiazides. May increase toxicity of lithium and methotrexate. May increase risk of bleeding w/ antiplatelets, anticoagulants, SSRIs, corticosteroids.
Flutamide	\n\n\tRenata\tProscan TAB dr 250mg 30's pack 360\n\tIndication: Prostate cancer\n\nDose: Adult: PO 250 mg 3 times/day.\n\nContra-indication: Hypersensitivity, severe hepatic impairment, pregnancy and lactation.\n\nSide effects: Hot flushes, loss of libido, impotence, gynaecomastia, nausea, vomiting, diarrhoea, increased appetite, sleep disturbances, skin reactions, anaemias, headache, dizziness, malaise, anxiety, hypertension, gastric and chest pain, oedema, blurred vision, hepatitis, jaundice, rash, thirst, pruritus, SLE-like syndrome, drowsiness, confusion, depression, nervousness.\n\nPrecaution: Perform liver function tests before starting treatment and at regular intervals. Treatment is not recommended in patients whose ALT values exceed twice the upper limit of normal. Regular assessment of prostate specific antigen level may help to monitor disease progression. Advise patient against discontinuing drug on their own. Exercise caution in patients with cardiac disease.\n\nMode of action:  	Increased prothrombin time in patients on long-term warfarin treatment.\n\nPregnancy category: D\n\nInteraction:  	Increased prothrombin time in patients on long-term warfarin treatment.
Fluticasone Furoate Nasal prep	\n\n\tAristopharma\tFlutica Nasal Spray 27.5 mcg 1's pack 220.02\n\tGlaxoSmithKline Bangladesh Ltd.\tAvamys Nasal Spray 27.5mcg/puff  1's pack(120md) 354\n\tIncepta\tNeotison Nasal Spray 27.5mcg/1 spray 1's pack 250\n\tIncepta\tNeotisone Nasal Spray  1's pack 250\n\tIndication: Allergic rhinitis\n\nDose: Adults & Children over 12 years: 2 sprays in each nostril once a day. In some cases 2 sprays into each nostril twice daily, not exceeding 4 sprays.\n\nChildren under 12 years (2 - 11 Years): 1 spray in each nostril once a day\n\nPatients should use Neotison (Fluticasone Furoate) nasal spray at regular intervals as directed since its effectiveness depends on its regular use.\n\nChildren (under 2 years of age): There are no data to recommend use of Fluticasone Furoate Nasal Spray for the treatment of seasonal or perennial allergic rhinitis in children under 2 years of age.\n\n\n\n\nContra-indication: Fluticasone Furoate nasal spray is contraindicated in patients with a hypersensitivity to any of its ingredients.\n\nSide effects: Fluticasone Furoate nasal spray is absorbed less into the rest of the body, therefore fewer side effects are seen. With the nasal spray, drying of the nose and an increase in the incidence of nosebleeds may occur. \n\nPrecaution: Rarely, immediate hypersensitivity reactions or contact dermatitis may occur after the administration of Fluticasone Furoate nasal spray. Rare instances of wheezing, nasal septum perforation, cataracts, glaucoma and increased intraocular pressure have been reported following the intranasal application of corticosteroids, including Fluticasone Furoate. Although systemic effects have been minimal with recommended doses of Fluticasone Furoate nasal spray, potential risk increases with larger doses. Therefore, larger than recommended doses of Fluticasone Furoate nasal spray should be avoided.\n\nMode of action:  	May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir.\n\nPregnancy category: C\n\nInteraction:  	May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir.
Fluticasone Propionate Nasal prep	\n\n\tACI\tFluvent Nasal Spray 50mcg/spray 1's pack 250.75\n\tAcme Ltd.\tFluticon Nasal Spray 50mcg/ Spray 120 dose ( spray) unit 250\n\tBeximco\tPerinase Nasal Spray 50mcg/ Sp 120 dose ( spray) unit 250\n\tGlaxoSmithKline Bangladesh Ltd.\tFlixonase Nasal Spray 50mcg/ Spray 120 dose ( spray) unit 275\n\tIncepta\tLutisone Nasal Spray 50mcg/ Spray 120 dose ( spray) unit 250\n\tOpsonin Pharma\tFluvate Nasal Spray 50mcg/ Spray 120 dose ( spray) unit 250\n\tSquare\tFlonaspray Nasal Spray 50mcg/ Spray 120 dose ( spray) unit 250.95\n\tIndication:  Seasonal and Perennial allergic and nonallergic rhinitis, Nasal polyps.\n\nDose: Adults & Children over 12 years: 2 sprays in each nostril once a day, preferably in the morning. In some cases 2 sprays into each nostril twice daily, not exceeding 4 sprays.Children under 12 years (4 - 11 Years): 1 spray in each nostril once a day. The maximum total daily dosage should not exceed 4 sprays.\n\nContra-indication: Hypersensitivity.\n\nSide effects: With the nasal spray, drying of the nose and an increase in the incidence of nosebleeds may occur.\n\nPrecaution: Rarely, immediate hypersensitivity reactions or contact dermatitis may occur after the administration of Fluticasone Propionate nasal spray. Rare instances of wheezing, nasal septum perforation, cataracts, glaucoma and increased intraocular pressure have been reported following the intranasal application of corticosteroids, including Fluticasone Propionate. Although systemic effects have been minimal with recommended doses of Fluticasone Propionate nasal spray, potential risk increases with larger doses. Therefore, larger than recommended doses of Fluticasone Propionate nasal spray should be avoided.\n\nMode of action:  	May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir.\n\nPregnancy category: C\n\nInteraction:  	May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir.
Fluticasone Propionate 0.005% Topical	\n\n\tAmico Ltd.\tFlupion 0.005% Ointment   10gm  tube 50\n\tAsiatic Ltd.\tTicason 0.005% Ointment   10gm  tube 40\n\tDrug International Ltd.\tFlutiderm 0.005% Ointment   10gm  tube 90\n\tGeneral\tCutisone 0.005% Ointment   10gm  tube 50.19\n\tGlaxoSmithKline Bangladesh Ltd.\tCutivate 0.005% Ointment   10gm  tube 76.14\n\tIncepta\tLutisone 0.005% Ointment   10gm  tube 50\n\tOpsonin Pharma\tFuvate Ointment   10gm  tube 50\n\tSquare\tTicas 0.005% Ointment   10gm  tube 40.15\n\tIndication: Psoriasis, Eczema, Corticosteroid-responsive dermatoses\n\nDose: Apply a thin film of Fluticasone Propionate ointment to the affected skin areas twice daily. Rub in gently.\n\nContra-indication: Fluticasone Propionate ointment is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.\n\nSide effects: The adverse reactions of Fluticasone Propionate ointment are usually mild, self-limiting, and consist primarily of pruritus, burning, hypertrichosis, increased erythema, hives, irritation, and lightheadedness. Each of these events occurred individually in less than 1% of patients. The following additional local adverse reactions have been reported infrequently with Fluticasone Propionate ointment - dryness, folliculitis, acneiform, eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.\n\nPrecaution: Fluticasone Propionate ointment may cause local cutaneous adverse reactions. If irritation develops, Fluticasone Propionate ointment should be discontinued. Fluticasone Propionate ointment should not be used in the presence of preexisting skin atrophy and should not be used where infection is present at the treatment site. This should not be used in the treatment of rosacea and perioral dermatitis.\n\nMode of action:  	May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir.\n\nPregnancy category: C\n\nInteraction:  	May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir.
Fluticasone Propionate 0.05% Topical	\n\n\tAsiatic Ltd.\tTicason 0.05% Cream   10gm  tube 90\n\tGeneral\tCutisone 0.05% Cream   10gm  tube 96.36\n\tGlaxoSmithKline Bangladesh Ltd.\tCutivate 0.05% Cream   10gm  tube 115.43\n\tRAK\tFlutivate Cream   10gm  tube 96\n\tSquare\tTicas 0.05% Cream   10gm  tube 90.34\n\tIndication: Psoriasis, Eczema, Corticosteroid-responsive dermatoses\n\nDose:  Apply a thin layer of  cream to the affected skin areas once daily.\n\nContra-indication: Hypersensitivity. Acne vulgaris, rosacea, perioral dermatitis, skin atrophy; hypersensitivity. Primary cutaneous viral infections (e.g. herpes simplex, chicken pox), perianal and genital pruritus, primary fungal or bacterial skin infections. Inhalation: Status asthmaticus.\n\nSide effects: Topical: Pruritus, hypertrichosis, dryness, numbness of fingers, burning, eruptions, hypopigmentation, allergic contact dermatitis, secondary infection, skin atrophy, Cushing's syndrome, reversible HPA-axis suppression. Inhalation: Oropharyngeal candidiasis, pharyngitis, dysphoria, cough, rhinitis, nasal congestion and headache. Systemic absorption may be seen when applied to large areas, when skin is broken or under occlusive dressings.\nPotentially Fatal: Suppression of immune system.\n\nPrecaution: Children, pregnancy, lactation, concomitant skin infections. Concomitant skin/lung/systemic infections. Advised to rinse mouth with water every time after inhalation. Application to large areas, broken skin or under occlusive dressings.\n\nMode of action: May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir.\n\nPregnancy category: C\n\nInteraction: May lead to increased plasma concentrations of fluticasone when used with CYP4503A4 inhibitors such as ritonavir.
Fluvoxamine Maleate	\n\n\tGeneral\tRelafin TAB dr 50mg 30's pack 451.80\n\tIndication: Major depressive disorder, Anxiety disorders, Depression, Panic disorder, Obsessive-compulsive disorder, Posttraumatic stress disorder\n\nDose: Adult: PO Depression Initial: 50-100 mg/day, up to 300 mg/day if needed. Obsessive compulsive disorder 50 mg once daily, may increase slowly. Max: 300 mg/day. Social anxiety disorder Extended release Initial: 100 mg once daily. Max: 300 mg/day.\nObsessive compulsive disorder\nChild: >8 yr: 25 mg once daily, may increase by 25 mg every 4-7 days. Doses >50 mg should be given in 2 divided doses. Reassess if no improvement after 10 wk of treatment. Max: 200 mg daily. \n\nContra-indication: Hypersensitivity. Not to be used with thioridazine, terfenadine, astemizole, cisapride, pimozide, aloestron, tizanidine. Lactation.\n\nSide effects: Headache, asthenia, tremor, palpitations, nausea, diarrhoea, constipation, anorexia, vomiting, flatulence, somnolence, insomnia, dry mouth, nervousness, dizziness, tremor, anxiety, agitation, decreased libido, depression, CNS stimulation, dyspnoea, yawn, sweating, abnormal ejaculation, urinary frequency, anorgasmia, urinary retention.\n\nPrecaution: History of mania or seizures; liver dysfunction; presence of depressive symptoms; smokers. Treatment with MAOI should only be started at least 2 wk after stopping fluvoxamine treatment. Increased risk of suicidal ideation and behaviour when used in children, adolescents and young adults <24 yr. Pregnancy, elderly; operating hazardous machinery; withdraw gradually. Monitor prothrombin time in patients who are taking oral anticoagulants concurrently.\n\nMode of action: Co-admin with fluvoxamine may increase carbamazepine toxicity and serum levels of theophylline. Lithium enhances the serotonergic effects of fluvoxamine. Anticoagulants may require dosage adjustments. Diltiazem with fluvoxamine may lead to bradycardia. Avoid alcohol.\nPotentially Fatal: Fluvoxamine should not be used in combination with MAOIs, or within 14 days of discontinuing treatment with MAOIs.\n\nPregnancy category: C\n\nInteraction: Co-admin with fluvoxamine may increase carbamazepine toxicity and serum levels of theophylline. Lithium enhances the serotonergic effects of fluvoxamine. Anticoagulants may require dosage adjustments. Diltiazem with fluvoxamine may lead to bradycardia. Avoid alcohol.\nPotentially Fatal: Fluvoxamine should not be used in combination with MAOIs, or within 14 days of discontinuing treatment with MAOIs.
Folic Acid	\n\n\tAd-din\tFolate TAB dr 5mg 100'pack 30\n\tAmbee\tFolac TAB dr 5mg 200'pack 48\n\tBristol Pharma Ltd.\tFolic-son TAB dr 5mg 100's pack 27\n\tG. A. Company Ltd.\tTerovit TAB dr 5mg 100'pack 27\n\tJayson\tFolison TAB dr 5mg 500'pack 135\n\tMonicopharma\tFolus TAB dr 5mg 100'pack 30\n\tPharmasia Ltd.\tFolicasia TAB dr 5mg 200'pack 54\n\tReliance\tRefolic TAB dr 5mg 100'pack 27\n\tIndication: Anemia, Nutritional supplement, Folic acid deficiency, Megaloblastic anemia, Neural tube defect\n\nDose: Adult: PO Folate-deficient megaloblastic anaemia 5 mg/day for 4 mth, up to 15 mg/day in malabsorption states. Prophylaxis of megaloblastic anaemia in pregnancy 0.2-0.5 mg/day. Prophylaxis of neural tube defect in pregnancy 4 or 5 mg/day. Supplement for women of child-bearing potential 0.4 mg/day. \n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Folic Acid is contraindicated in untreated cobalamine deficiency.\n\nSide effects: This tablet is well tolerated. Sometimes gastrointestinal disturbance like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur.\n\nPrecaution: N/A\n\nMode of action: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nPregnancy category: A\n\nInteraction: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.
Folic Acid  +  Vitamin C  +  Vitamin D3	\n\n\tBeximco\tAscofol D TAB dr   30's pack 90\n\tIncepta\tCardivit TAB dr   30's pack 90\n\tIndication: Dental bleeding, Lactation, Vitamin C, Vitamin D and Folic acid Deficiency\n\nDose: Once daily or as directed by physician. \n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: This tablet is well tolerated. Vitamin C & Vitamin D are well tolerated and side-effects are very rare at the recommended dose. Allergic sensitization has been reported following oral administration of folic acid. \n\nPrecaution: Precautions should be exercised if hypersensitivity to any of its ingredients is manifested. \n\nMode of action: Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\nVit D3: Increased risk of hypercalcaemia if given with thiazide diuretics, calcium or phosphate. Antiepileptics (e.g. carbamazepine, phenobarbitone, phenytoin & primidone) may increase vitamin D requirements. Rifampicin & isoniazid may reduce efficacy of vitamin D. Corticosteroids may counteract the effect of vitamin D. Digoxin or any cardiac glycoside. Reduced absorption when taken with cholestyramine, colestipol, mineral oil, orlistat. Ketoconazole.\n\n\nPregnancy category: Not Classified\n\nInteraction: Folic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\nVit D3: Increased risk of hypercalcaemia if given with thiazide diuretics, calcium or phosphate. Antiepileptics (e.g. carbamazepine, phenobarbitone, phenytoin & primidone) may increase vitamin D requirements. Rifampicin & isoniazid may reduce efficacy of vitamin D. Corticosteroids may counteract the effect of vitamin D. Digoxin or any cardiac glycoside. Reduced absorption when taken with cholestyramine, colestipol, mineral oil, orlistat. Ketoconazole.\n
Folic Acid + Zinc	\n\n\tACI\tOral Z 20 TAB dr 20mg 50's pack 75.50\n\tACI\tOral-Z Syrup  10mg/5ml 100ml 26.18\n\tAcme Ltd.\tDefaz TAB dr   100's pack 150\n\tAristopharma\tZnF TAB dr   100's pack 200\n\tConcord\tHemax-PG CAP   50's pack 100\n\tEskayef Bangladesh Ltd.\tFeozin FC TAB dr   100's pack 150\n\tIncepta\tFolneed TAB dr   100's pack 200\n\tOpsonin Pharma\tFolic Z TAB dr   100's pack 150\n\tOrion Pharma Ltd.\tESP CAP   30's pack 67.80\n\tPacific\tFolzin TAB dr   100's pack 190\n\tRadiant.\tPreMum F/C TAB dr 5 mg + 20 mg  \n\tSomatec\tZincfol CAP   30's pack 90\n\tSquare\tZifolet TAB dr   100's pack 150.29\n\tSupreme\tFosul CAP   30's pack 67.50\n\tIndication: Folic acid & zinc Deficiency\n\nDose: One tablet daily or as directed by the physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Folic Acid is contraindicated in untreated cobalamine deficiency.\n\nSide effects: This tablet is well tolerated. Sometimes gastrointestinal disturbance like abdominal pain, dyspepsia, nausea, vomiting, fever and respiratory distress may occur.\n\nPrecaution: N/A\n\nMode of action: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\nPregnancy Category (US FDA) 	\nQuinoloneTetracyclineCisplatinPenicillamine Amiloride may interact with zinc\n\nPregnancy category: A\n\nInteraction: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\nPregnancy Category (US FDA) 	\nQuinoloneTetracyclineCisplatinPenicillamine Amiloride may interact with zinc
Folinic Acid	\n\n\tBeacon\tFolinex Injection 50mg/ml 1  amps pack 500\n\tIncepta\tBiofol TAB dr 15mg 30's pack \n\tPharmachemie B. V. Netherlands\tRescuvolin TAB dr  15mg 10's  pack 680\n\tPharmachemie B. V. Netherlands\tRescuvolin Injection  50mg 10 amps  pack 4700\n\tIndication: Colorectal cancer, Methotrexate toxicity, Megaloblastic anaemia\n\nDose: Oral\nAdult: a) Reduction of harmful effects of folic acid antagonists such as. Methotrexate, Trimethoprime etc.:\nThe dose is usually one 15 mg tablet every 6 hours for 2 to 3 days.\n\nb)Megaloblastic anemia\nIn the treatment of Megaloblastic anemia, the dose is one 15 mg tablet daily.\n\nIntravenous\nAdjunct to fluorouracil in colorectal cancer\nAdult: 200 mg/m2 BSA by slow IV inj over at least 3 min followed by 370 mg/m2 fluorouracil by IV inj. Treatment is given for 5 consecutive days and repeated at intervals of 28 days for 2 courses. Subsequently, may repeat at 4-5 wkly intervals if the patient has recovered completely from the toxic effects of the prior treatment course.\nIntramuscular\nFolate-deficient megaloblastic anaemia\nAdult: Up to 1 mg/day.\n\nContra-indication: Undiagnosed megaloblastic anaemia; pernicious, aplastic or normocytic anaemias.\n\nSide effects: GI disturbances, hypersensitivity reactions; bronchospasm.\n\nPrecaution: Treatment resistance may occur in patients with depressed haematopoiesis, alcoholism, deficiencies of other vitamins. Neonates.\n\nMode of action: Fluorouracil: Folinic acid may increase the toxicity associated with fluorouracil if the two are administered together. Some adverse effects that have occurred, particularly in elderly patients, include severe enterocolitis, diarrhea, and dehydration.[12]\n\nSulfamethoxazole-trimethoprim: A potential drug interaction exists with concomitant use of sulfamethoxazole-trimethoprim and folinic acid. Folinic acid has been shown to decrease the efficacy of sulfamethoxazole-trimethoprim in the treatment of pneumocystis carinii, a common cause of pneumonia in AIDs patients\n\nPregnancy category: C\n\nInteraction: Fluorouracil: Folinic acid may increase the toxicity associated with fluorouracil if the two are administered together. Some adverse effects that have occurred, particularly in elderly patients, include severe enterocolitis, diarrhea, and dehydration.[12]\n\nSulfamethoxazole-trimethoprim: A potential drug interaction exists with concomitant use of sulfamethoxazole-trimethoprim and folinic acid. Folinic acid has been shown to decrease the efficacy of sulfamethoxazole-trimethoprim in the treatment of pneumocystis carinii, a common cause of pneumonia in AIDs patients
Formoterol Fumarate	\n\n\tSquare\tEFO Dry powder inhalation capsule 12mcg 30's pack 99.90\n\tIndication: Asthma,Chronic bronchitis, Emphysema, COPD\n\nDose: Adult:  Inhalation Acute bronchospasm; Reversible airways obstruction As inhalation cap: 12 mcg twice daily, up to 24 mcg twice daily in severe cases. \n\nAs dry powd inhaler: 6 or 12 mcg 1-2 times/day, up to to 24 mcg twice daily in sever cases. As metered doses from aerosol inhaler: 12 or 24 mcg twice daily.  \n\nPrevention of exercise-induced bronchospasm 6 or 12 mcg at least 15 mins before exercise. Additional doses may be given 12 hr later.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Tremor, headache, tiredness, restlessness, dizziness, dry mouth, palpitation, tachycardia, muscle cramps, nausea.\n\nPrecaution: Thyrotoxicosis; severe CV disorders e.g. ischaemic heart disease, tachyarrhythmias or severe heart burn; prolonged QT-interval. DM; pregnancy; lactation; children <5 yr; do not initiate or increase the dose during an exacerbation. May produce paradoxical bronchospasm.\n\nMode of action: Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypokalaemic effect of ?-agonists. Increased susceptibility to cardiac arrhythmias in patients treated with digitalis. Concomitant use with quinidine, disopyramide, procainamide, phenothiazines, antihistamines, MAOI or TCAs can prolong the QT-interval and increase the risk of ventricular arrhythmias. L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards ?2-sympathomimetics. ?-adrenergic blockers can inhibit the effect of formoterol. Increased risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.\n\nPregnancy category: C\n\nInteraction: Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypokalaemic effect of ?-agonists. Increased susceptibility to cardiac arrhythmias in patients treated with digitalis. Concomitant use with quinidine, disopyramide, procainamide, phenothiazines, antihistamines, MAOI or TCAs can prolong the QT-interval and increase the risk of ventricular arrhythmias. L-dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards ?2-sympathomimetics. ?-adrenergic blockers can inhibit the effect of formoterol. Increased risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.
Fructose 10%	\n\n\tBeximco\tFructin 10 IV Infusion   500ml pack 97\n\tOrion Pharma Ltd.\tFructose 10 IV Infusion   500ml pack / 100ml pack 97 / 175\n\tIndication: Carbohydrate nutrient in diabetic patients, Fluid replacement, Caloric feeding\n\nDose: It should not exceed 0.5-1 g/kg body weight per hour. The usual recommended flow rate for adult is 30-75 drops per minute infused intravenously.\n\n\nContra-indication: contraindicated in certain inborn errors of fructose metabolism, methyl alcohol poisoning, hyperuricemia, liver failure, and lactic acidosis.\n\nSide effects: Intravenous administration  may cause lactic acidosis and hyperuricemia. The rapid infusion results in facial flushing, abdominal pain and sweating.\n\nPrecaution:  It should be given with caution to patients with impaired kidney function or severe liver damage. Infusion of fluid should be immediately discontinued if rigor arises for any reason during the process. Do not use if the solution is cloudy, contains particles, or after expiry date.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Frusemide (Furosemide)	\n\n\tAlbion Ltd.\tFrusemide TAB dr 40 mg 100's pack \n\tAmbee\tTrofurit Injection 20mg/2ml 10 amps pack 35.30\n\tAmbee\tTrofurit TAB dr 40mg 100's pack 53\n\tDelta Pharma\tDirusid-Plus TAB dr  30's pack 180\n\tDoctor's Chemicals Works Ltd.\tUteric TAB dr 40mg 100's pack 52\n\tGonoshasthaya\tG Frusemide Injection 20mg/2ml 25's pack 75.50\n\tGonoshasthaya\tG Frusemide TAB dr 40mg 100's pack 52\n\tOpsonin Pharma\tFrusin Injection 20mg/2ml 25's pack 82.50\n\tOpsonin Pharma\tFrusin TAB dr 40mg 100's pack 50\n\tPacific\tFrudema TAB dr 40mg 100's pack 53\n\tSanofi Aventis (BD) Ltd.\tLasix TAB dr 40mg 100's pack 64.24\n\tSanofi Aventis (BD) Ltd.\tLaxis Injection 20mg/2ml 25's pack 200\n\tSquare\tFusid Injection 20mg/2ml 10's pack 80\n\tSquare\tFusid TAB dr 40mg 100's pack 128\n\tUnimed & Unihealth Manufacturers Ltd.\tFrunep 40 TAB dr 40mg 50's pack 140.75\n\tIndication: Hypertension, Congestive heart failure, Nephrotic syndrome, Hypercalcemia, Edema, Cirrhosis, Renal impairment, Cerebral/pulmonary edema, Pulmonary oedema, Acute renal failure, Chronic renal failure\n\nDose: Adult: PO HTN 40-80 mg/day. Oedema Initial: 20 mg/day. Max: 600 mg/day in severe cases. \n\nIV Pulmonary oedema 40 mg, if response is inadequate w/in 1 hr, a further dose of 80 mg may be given. \n\nOliguria in acute or chronic renal failure For GFR: 5-20 mL/min: Infuse 250 mg over 1 hr. If urine output is insufficient w/in the next hr, may follow by 500 mg infused over 2 hr. If urine output is still unsatisfactory w/in 1 hr after the 2nd infusion, a 3rd dose of 1 g may be infused over 4 hr. Rate of infusion: <4 mg/min. If the response is satisfactory, may repeat the effective dose (of up to 1 g) every 24 hr. \n\nIM/IV Oedema 20-50 mg, may increase in steps of 20 mg 2 hrly if needed. Doses >50 mg must be given as IV infusion.\n\nContra-indication: Severe sodium and water depletion, hypersensitivity to sulphonamides and furosemide, hypokalaemia, hyponatraemia, precomatose states associated with liver cirrhosis, anuria or renal failure. Addison's disease.\n\nSide effects: Fluid and electrolyte imbalance. Rashes, photosensitivity, nausea, diarrhoea, blurred vision, dizziness, headache, hypotension. Bone marrow depression (rare), hepatic dysfunction. Hyperglycaemia, glycosuria, ototoxicity.\nPotentially Fatal: Rarely, sudden death and cardiac arrest. Hypokalaemia and magnesium depletion can cause cardiac arrhythmias.\n\nPrecaution: Prostatic hyperplasia. Hepatic or renal impairment, gout, DM, impaired micturition. Infusion rate should not exceed 4 mg/min to reduce the risk of ototoxicity. Monitor fluid and electrolyte balance and renal function. May lower serum levels of calcium and magnesium, thus serum levels should be monitored. Pregnancy and lactation.\n\nMode of action: Analgesics reduce natriuretic action of furosemide. Antagonises hypoglycaemic agents and drugs used for gout. Hyperglycaemia with antihypertensive agent diazoxide. Antagonises muscle relaxants. Increased risk of ototoxicity when used with aminoglycosides especially in renal impairment. May enhance nephrotoxicity of cephalosporins. Effects of antihypertensives enhanced. Action antagonised by corticosteroids. Phenytoin and indometacin may reduce effects of furosemide.\nPotentially Fatal: May provoke severe hypotensive response with ACE inhibitors. NSAIDs inhibit diuretic and antihypertensive effects. Increased incidence of premature beats with cardiac glycosides.\n\nPregnancy category: C\n\nInteraction: Analgesics reduce natriuretic action of furosemide. Antagonises hypoglycaemic agents and drugs used for gout. Hyperglycaemia with antihypertensive agent diazoxide. Antagonises muscle relaxants. Increased risk of ototoxicity when used with aminoglycosides especially in renal impairment. May enhance nephrotoxicity of cephalosporins. Effects of antihypertensives enhanced. Action antagonised by corticosteroids. Phenytoin and indometacin may reduce effects of furosemide.\nPotentially Fatal: May provoke severe hypotensive response with ACE inhibitors. NSAIDs inhibit diuretic and antihypertensive effects. Increased incidence of premature beats with cardiac glycosides.
Frusemide + Spironolactone	\n\n\tACI\tDilup 20/50 TAB dr   30's pack 180.60\n\tACI\tDilup 40/50 TAB dr   30's pack 240.90\n\tAcme Ltd.\tEdemide 20/50 TAB dr   30's pack 180.60\n\tAcme Ltd.\tEdemide 40 TAB dr   30's pack 241.20\n\tAmbee\tVerospiron PLUS 20/50 TAB dr   30's pack 150.60\n\tAristopharma\tFruselac 20/50 TAB dr   30's pack 180\n\tAristopharma\tFruselac PLUS 40/50 TAB dr   30's pack 240\n\tBeacon\tFuro PLUS 20/50 TAB dr   30's pack 180\n\tBeximco\tResitone 20/50 TAB dr   30's pack 180.60\n\tBeximco\tResitone Plus TAB dr   30's pack 240.90\n\tBio Pharma Ltd.\tUrospin 20/50 TAB dr   30's pack 180.60\n\tDelta Pharma\tDirusid PLUS 20/50 TAB dr   30's pack 180\n\tDrug International Ltd.\tDiretic 20/50 TAB dr   50's pack 300\n\tDrug International Ltd.\tDiretic DS 40/50 TAB dr   50's pack 400\n\tEskayef Bangladesh Ltd.\tEdenil 20/50 TAB dr   30's pack 180\n\tEskayef Bangladesh Ltd.\tEdenil 40/50 TAB dr   30's pack 240\n\tGeneral\tLacitone 20/50 TAB dr   30's pack 180.60\n\tHealthcare\tLaxur 20/50 TAB dr   30's pack 180\n\tIbn Sina Pharmaceutical Ind. Ltd.\tFruson 20/50 TAB dr   30's pack 180\n\tIncepta\tEdeloss 20/50 TAB dr   50's pack 300\n\tIncepta\tEdeloss PLUS 40/50 TAB dr   50's pack 400\n\tNovo Healthcare and Pharma Ltd.\tFurotone 20/50 TAB dr   30's pack 180\n\tOpsonin Pharma\tFrusin Plus 20 TAB dr   30's pack 180\n\tOpsonin Pharma\tFrusin Plus 40 TAB dr   30's pack 240\n\tOrion Pharma Ltd.\tFrulac 20/50 TAB dr   50's pack / 30's pack 301 /180\n\tOrion Pharma Ltd.\tFrulac 40/50 TAB dr   30's pack 240.90\n\tPacific\tTonemide 20/50 TAB dr   30's pack 180\n\tPopular\tDirucom 20/50 TAB dr   30's pack 180.59\n\tPopular\tSpirocard Plus TAB dr 20mg + 50mg 30'spack 158.94\n\tRangs\tRedema 20/50 TAB dr   30's pack 180\n\tRangs\tRedema 40/50 TAB dr   30's pack 240\n\tRenata\tUritone-20 TAB dr   30's pack \n\tRenata\tUritone-40 TAB dr   30's pack \n\tSanofi Aventis (BD) Ltd.\tLasilactone 20/50 TAB dr   50's pack 301\n\tSquare\tFusid 40/50 TAB dr  40 mg + 50 mg 40's pack 400\n\tSquare\tFusid PLUS 20/50 TAB dr  20 mg + 50 mg 30's pack 320\n\tWhite Horse Pharma\tLaxicon TAB dr   30's pack 180\n\tZenith\tFrusapa TAB dr  50 30's pack 180\n\tIndication: Hypertension, Congestive heart failure, Oedema, Ascites\n\nDose: Adult: Per tab contains furosemide 20 mg and spironolactone 50 mg. 1-4 tabs/day.\n\nContra-indication: Hypersensitivity, anuria or severe oliguria, hypovolaemia, hyponatraemia, hypotension, urinary retention due to prostatic hypertrophy, Addison's disease, renal impairment, hyperkalaemia, acute or severe liver failure. Pregnancy and lactation.\n\nSide effects: Fluid and electrolyte imbalance, nausea, diarrhoea, blurred vision, headache, dizziness, hypotension, photosensitisation, hepatic dysfunction, hyperglycaemia and glycosuria, rarely bone marrow depression, gynaecomastia, hirsutism, hoarseness, menstrual irregularities, loss of libido, impotence.\nPotentially Fatal: Severe hyperkalaemia in patients with preexisting renal impairment or taking ACE inhibitors, agranulocytosis, cardiac arrhythmias.\n\nPrecaution: Concomitant use with ACE inhibitors, monitor fluids and electrolytes including changes in serum K levels. Dilutional hyponatraemia or even a true low-salt syndrome may develop. General anaesthesia.\n\nMode of action: 1.frusemide ..--.Aminoglycosides and ethacrynic acid (increased ototoxicity), tubocurazine, succinylcholine (effects enhanced). Sucralfate reduces effects of furosemide. Should be given 2 hr apart. NSAIDs reduce natriuretic and antihypertensive effects of furosemide. Corticosteroids may antagonise action. Digoxin levels may be increased. Warfarin effects may be reduced.\nPotentially Fatal: Potassium supplements or potassium-rich diet, ACE inhibitors, general anaesthetics (reduced vascular responsiveness to catecholamines), lithium toxicity. 2.spironolactone....Sodium excretion effect may be inhibited by aspirin. May reduce ulcer-healing properties of carbenoxolone. Increased risk of nephrotoxicity when used with NSAIDs or ciclosporin. Hyperkalaemia may occur if given with potassium supplements, ACE inhibitors, angiotensin II antagonists, NSAIDs, ciclosporin or trilostane. May increase risk of orthostatic hypotension when used with barbiturates, narcotics or alcohol. May reduce vascular responsiveness to pressor amines. May increase half-life of digoxin.\nPotentially Fatal: Increased risk of lithium toxicity when used concurrently.\n\n\nPregnancy category: A\n\nInteraction: 1.frusemide ..--.Aminoglycosides and ethacrynic acid (increased ototoxicity), tubocurazine, succinylcholine (effects enhanced). Sucralfate reduces effects of furosemide. Should be given 2 hr apart. NSAIDs reduce natriuretic and antihypertensive effects of furosemide. Corticosteroids may antagonise action. Digoxin levels may be increased. Warfarin effects may be reduced.\nPotentially Fatal: Potassium supplements or potassium-rich diet, ACE inhibitors, general anaesthetics (reduced vascular responsiveness to catecholamines), lithium toxicity. 2.spironolactone....Sodium excretion effect may be inhibited by aspirin. May reduce ulcer-healing properties of carbenoxolone. Increased risk of nephrotoxicity when used with NSAIDs or ciclosporin. Hyperkalaemia may occur if given with potassium supplements, ACE inhibitors, angiotensin II antagonists, NSAIDs, ciclosporin or trilostane. May increase risk of orthostatic hypotension when used with barbiturates, narcotics or alcohol. May reduce vascular responsiveness to pressor amines. May increase half-life of digoxin.\nPotentially Fatal: Increased risk of lithium toxicity when used concurrently.\n
Fusidic Acid 2% Topical	\n\n\tAristopharma\tFusidate 2% Ointment   20gm  tube 85\n\tEskayef Bangladesh Ltd.\tFacid Cream   15gm  tube 85\n\tEskayef Bangladesh Ltd.\tFacid Ointment   15gm  tube 85\n\tLeo Pharmaceutical Products,Denmark\tFucidin Cream 20mg 	 15gm tube 275.94 	\n\tIndication: Acne vulgaris, Skin infections, Staphylococcal infections\n\nDose: Topical/Cutaneous Skin infections Adult: As a 2% ointment/cream/gel: Apply onto affected area 3-4 times daily until there is improvement. \nIf gauze dressing is used, then frequency of application may be reduced to 1-2 times daily. \n\nChild: As a 2% ointment/cream/gel: Apply onto affected area 3-4 times daily until there is improvement. If gauze dressing is used, then frequency of application may be reduced to 1-2 times daily.\n\nContra-indication: *Topical hydrocortisone is contraindicated in viral, tuberculosis and fungal skin infections.\n*Hypersensitivity to any of the components.\n\nSide effects: Hypersensitivity has rarely been encountered. As with other topical steroids, prolonged and intensive treatment may cause local atrophic changes of the skin, such as striae, thinning and dilatation of the superficial blood vessels, particularly when occlusive dressing is used or when skin folds are involved. Systemic absorption, sufficient to produce adrenal suppression, can occur with prolonged or extensive use, specially when napkin is used. Infants and children are particularly at risk. Caution should be exercised if a topical steroid is used near the eye. Glaucoma might be the result if the preparation enters the eye.\n\nPrecaution: Long term continuous therapy should be avoided, particularly in the face, on flexures, and intertrigenous areas, and in infants and children\n\nMode of action: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.\n\nPregnancy category: C\n\nInteraction: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.
Fusidic Acid 2% + Hydrocortisone Acetate 1% Topical	\n\n\tAristopharma\tFusidate H Cream   10gm tube 125\n\tAsiatic Ltd.\tFusitrim Cream   10gm tube 125\n\tBeximco\tFusidic Plus Ointment   10gm tube 125.47\n\tDrug International Ltd.\tFusibac H Cream   10gm tube 110\n\tEskayef Bangladesh Ltd.\tFacid HC Cream   10gm tube 125\n\tIncepta\tFortison Cream  10gm 1's pack 125\n\tNovo Healthcare and Pharma Ltd.\tFucort Cream   10gm tube 125\n\tOpsonin Pharma\tFusicort Cream   10gm tube 125\n\tSquare\tFusitop-HC Cream (2 gm + 1 gm)/100 gm  \n\tIndication: Eczema, Seborrhoeic dermatitis, Atopic dermatitis with secondary Bacterial infections, Allergic dermatitis, Irritant dermatitis.\n\nDose: Uncovered lesions : 3-4 times daily applicationsCovered lesions : Less frequent application may be adequate\n\nContra-indication: *Topical hydrocortisone is contraindicated in viral, tuberculosis and fungal skin infections.*Hypersensitivity to any of the components.\n\nSide effects: Hypersensitivity has rarely been encountered. As with other topical steroids, prolonged and intensive treatment may cause local atrophic changes of the skin, such as striae, thinning and dilatation of the superficial blood vessels, particularly when occlusive dressing is used or when skin folds are involved. Systemic absorption, sufficient to produce adrenal suppression, can occur with prolonged or extensive use, specially when napkin is used. Infants and children are particularly at risk. Caution should be exercised if a topical steroid is used near the eye. Glaucoma might be the result if the preparation enters the eye.\n\nPrecaution: Long term continuous therapy should be avoided, particularly in the face, on flexures, and intertrigenous areas, and in infants and children\n\nMode of action: Fusidic Acid: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.\n\nHydrocortisone : Clearance may be increased by hepatic enzyme inducers eg phenobarb, phenytoin & rifampin. Metabolism may be inhibited by troleandomycin & ketoconazole. May increase clearance of chronic high dose aspirin. Risk of enhanced or diminished effects of anticoagulant.\n\nPregnancy category: C\n\nInteraction: Fusidic Acid: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.\n\nHydrocortisone : Clearance may be increased by hepatic enzyme inducers eg phenobarb, phenytoin & rifampin. Metabolism may be inhibited by troleandomycin & ketoconazole. May increase clearance of chronic high dose aspirin. Risk of enhanced or diminished effects of anticoagulant.
Gabapentin	\n\n\tAcme Ltd.\tGabon TAB dr 300mg 30's pack 480\n\tAlbion Ltd.\tGabapentin TAB dr 300 mg/ 600mg 30's/ 18's pack \n\tAristopharma\tAlgia TAB dr 300mg 30's pack \n\tBeacon\tGabamax TAB dr 300mg 20's pack 320\n\tBeximco\tEpipen TAB dr 300mg 30's pack 541.80\n\tDrug International Ltd.\tNeuropen TAB dr 300mg 30's pack 480\n\tEskayef Bangladesh Ltd.\tNepsy TAB dr 300mg 20's pack 320\n\tIncepta\tGabapen 300 TAB dr 300mg 30's pack 480\n\tIncepta\tGabapen 600 TAB dr 600mg 20's pack 600\n\tIncepta\tGabapen Solution 250gm/5ml 100ml 170\n\tIncepta\tGabapen 100 TAB dr 100 mg 30's 180\n\tNovartis (Bangladesh) Ltd.\tGaboton TAB dr 300mg 30's pack 483\n\tOpsonin Pharma\tGpentin TAB dr 100mg 30's pack 180\n\tOpsonin Pharma\tGpentin TAB dr 300mg 30's pack 480\n\tOpsonin Pharma\tGpentin TAB dr 600mg 20's pack 600\n\tRenata\tGaba TAB dr 300mg 30's pack 482.10\n\tRenata\tGaba TAB dr 600mg 18's pack 541.98\n\tSilva\tNeurotin TAB dr 300mg 30's pack 451.69\n\tSilva\tNeurotin TAB dr 600mg 20's pack 562.11\n\tSquare\tGabastar Syrup 5gm/100ml 50ml bot 100\n\tSquare\tGabastar TAB dr 100mg 30's pack 180.74\n\tSquare\tGabastar TAB dr 300mg 30's pack 481.99\n\tSquare\tGabastar TAB dr 600mg 10's pack 301.11\n\tSun Pharmaceutical (Bangladesh) Ltd.\tGabantin TAB dr 300mg 30's pack 480\n\tSun Pharmaceutical (Bangladesh) Ltd.\tGabantin CAP 100mg 50's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tGabatin TAB dr 300mg 20's pack 300\n\tIndication:  Epilepsy, Neuropathic pain, Partial Seizures, Hot flashes, Fibromyalgia, Postherpetic Neuralgia, Pain from diabetic neuropathy.\n\nDose: Adult: PO: Neuropathic pain: 300 mg on day-1, then 300 mg twice on day-2, then 300 mg thrice on day-3, then increase the dose according to response in steps of 300 mg daily to maximum 1800 mg daily in three divided doses.  \n\nPartial seizure/epilepsy: 300 mg on day-1, then 300 mg twice on day-2, then 300 mg thrice on day-3, then increase the dose according to response in steps of 300 mg daily to maximum 2400 mg daily in three divided doses.  \n\nIn case of children: For 6-12 years - 10 mg/kg on day-1, then 20 mg/kg on day-2, then 25-35 mg/kg daily in 3 divided doses. Maintenance dose is 900 mg daily (body weight 26-36 Kg) or 1.2 gm daily (body weight 37-50 Kg).\n\nRenal impairment: Haemodialysis: Loading dose: 300-400 mg followed by 200-300 mg after each 4 hr of haemodialysis.\nCrCl (ml/min)	\n<15 	300 mg on alternate days to 300 mg daily.\n15-29	300 mg on alternate days to 600 mg daily.\n30-49	300-900 mg daily.\n50-79	600-1,800 mg daily.\n\n\nContra-indication: Hypersensitivity. Lactation.\n\nSide effects: Somnolence, dizziness, ataxia, weakness, paraesthesia, fatigue, headache; nystagmus, diplopia; nausea, vomiting, wt gain, dyspepsia; rhinitis; tremor; leucopenia; altered LFTs; Stevens-Johnson syndrome.\n\nPrecaution: Discontinuation or transfer from other antiepileptics, history of psychotic illness; renal impairment; pregnancy. Gradual withdrawal over at least 7 days to prevent an increase in seizure frequency.\n\nMode of action: May increase plasma level w/ morphine. Reduced absorption w/ antacids.\n\nPregnancy category: C\n\nInteraction: May increase plasma level w/ morphine. Reduced absorption w/ antacids.
Galantamine	\n\n\tACI\tAntial TAB dr 8mg 10's pack 201.40\n\tACI\tAntial TAB dr 4mg 20's pack 241.80\n\tIndication: Dementia in Alzheimer's disease.\n\nDose: Adult: PO Initial: 4 mg twice daily for 4 wk, then increase to 8 mg twice daily for at least 4 wk. Up to 12 mg twice daily based on response and tolerance.\n\nRenal impairment: Moderate: Max: 16 mg daily.\nCrCl (ml/min)	\n<9	Avoid.\n\nHepatic impairment: Child-Pugh category C: Avoid.\n\nContra-indication: Hypersensitivity; severe liver or kidney dysfunction; lactation; disorders of galactose metabolism; urinary retention or GI obstruction. Lactation.\n\nSide effects: GI disturbances; bradycardia, CNS disturbances; tremor, anorexia, wt loss; urinary tract infection; anaemia; rhinitis.\nPotentially Fatal: CV effects; convulsion; delirium; rectal haemorrhage; thrombocytopenia.\n\nPrecaution: Mild-moderate hepatic impairment; supraventricular conduction abnormalities; asthma; COPD; pregnancy; peptic ulcers. May increase gastric acid production.\n\nMode of action: ncreased serum concentrations when used with drugs that inhibit CYP2D6 (e.g. quinidine, fluoxetine, fluvoxamine, and paroxetine) and CYP3A4 (e.g. ketoconazole and ritonavir). Cimetidine may increase the bioavailability of galantamine. Increased risk of gastric ulcer when used with NSAIDs.\nPotentially Fatal: Amiodarone, ?-blockers, diltiazem or verapamil; NSAIDs; digoxin.\n\nPregnancy category: B\n\nInteraction: ncreased serum concentrations when used with drugs that inhibit CYP2D6 (e.g. quinidine, fluoxetine, fluvoxamine, and paroxetine) and CYP3A4 (e.g. ketoconazole and ritonavir). Cimetidine may increase the bioavailability of galantamine. Increased risk of gastric ulcer when used with NSAIDs.\nPotentially Fatal: Amiodarone, ?-blockers, diltiazem or verapamil; NSAIDs; digoxin.
Gallamine Triethiodide	\n\n\tIndication: Aid controlled ventilation, Muscle relaxant\n\nDose: Adult: IV Muscle relaxant in general anesth; Aid controlled ventilation Test dose may be given before anesth to determine drug sensitivity. Initial: 80-120 mg, further doses of 20-40 mg may be given as needed.\n\nContra-indication: Severe renal impairment. Hypersensitivity to iodine. Mysasthenia gravis.\n\nSide effects: Tachycardia, increased BP.\n\nPrecaution: Careful dose titration and monitoring of the degree of block are required to prevent overdosage.\n\nMode of action: Lidocaine, procainamide, quinidine, and verapamil may enhance the block. Clindamycin can prolong the action of muscle relaxants. Apnoea may be prolonged when used with polymyxins. Anticholinesterases or long-term treatment with corticosteroids may antagonise the action of gallamine.\n\nPregnancy category: Not Classified\n\nInteraction: Lidocaine, procainamide, quinidine, and verapamil may enhance the block. Clindamycin can prolong the action of muscle relaxants. Apnoea may be prolonged when used with polymyxins. Anticholinesterases or long-term treatment with corticosteroids may antagonise the action of gallamine.
Gatifloxacin	\n\n\tACI\tGatilon TAB dr 200mg 20's pack 120\n\tACI\tGatilon TAB dr 400mg 20's pack 200\n\tAcme Ltd.\tGatox TAB dr 400mg 20's pack 200.80\n\tAlco Pharma\tGatfo TAB dr 400mg  20's pack 200\n\tAmico Ltd.\tAmiquin TAB dr 400mg  20's pack 200\n\tApex\tTequin TAB dr 200mg 8's pack 60\n\tApex\tTequin TAB dr 400mg 8's pack 80\n\tBeximco\tXegal TAB dr 400mg 30's pack 302.10\n\tDesh\tGatpro TAB dr 400mg 30's pack 300\n\tDrug International Ltd.\tGaticin TAB dr 400mg 30's pack 300\n\tEskayef Bangladesh Ltd.\tGatinox TAB dr 400mg 20's pack 200\n\tGeneral\tGatigen TAB dr 400mg 20's pack 200\n\tHealthcare\tGf-4 TAB dr 400mg 24's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tGatsina TAB dr 400mg 20's pack 220\n\tIncepta\tGatiflox TAB dr 400mg 20's pack 200\n\tIncepta\tGatiflox Eye Drops Drops .3% 5ml 100\n\tKemiko\tLogat TAB dr 400mg 20's pack 200\n\tMedimet\tGatimet TAB dr 400mg 50's pack 500\n\tMystic\tGatilex TAB dr 400mg 20's pack 200\n\tNavana\tGataxin TAB dr 400mg 28's pack 180.72\n\tOpsonin Pharma\tTget TAB dr 400mg 20's pack 200\n\tOrion Pharma Ltd.\tAtaq TAB dr 200mg 20's pack 120\n\tOrion Pharma Ltd.\tAtaq TAB dr 400mg 20's pack 200.80\n\tRangs\tGatiquin TAB dr 400mg 20's pack 200\n\tRenata\tGatlin TAB dr 400mg  10's pack /30's pack 100 / 300\n\tSquare\tGati TAB dr 200mg 14's pack 84\n\tSquare\tGati TAB dr 400mg 20's pack 200.83\n\tZenith\tGatizen TAB dr 400mg  18's pack 180\n\tZenith\tGatizen TAB dr 200mg  20's pack 180\n\tIndication: Uncomplicated gonorrhea, Susceptible infections, Respiratory tract infections, Urinary tract infections\n\nDose: Adult: PO Susceptible infections 400 mg once daily for 7-14 days. Uncomplicated gonorrhoea; Uncomplicated UTI 400 mg as a single dose. IV Susceptible infections 400 mg once daily.\n\nContra-indication: Hypersensitivity; children <18 yr; concurrent use of class IA or III antiarrhythmics, QT-prolongation drugs; diabetics; pregnancy, lactation.\n\nSide effects: Rapid heartbeat, mental confusion, hallucinations, agitation, nightmares, depression; photophobia; tendon rupture; headache, dizziness, insomnia, chills, fever; back pain, abdominal pain; constipation, nausea, vomiting, diarrhoea, inflammation of the tongue, mouth sores; abnormal vision, ringing in the ears, vaginitis.\nPotentially Fatal: Hyperosmolar nonketotic hyperglycaemic coma, diabetic ketoacidosis, hypoglycaemic coma, convulsions and mental status changes.\n\nPrecaution: May prolong QT interval; uncorrected hypokalaemia; known or suspected CNS disorders, renal and hepatic impairment. Elderly.\n\nMode of action: Additive effect w/ drugs that prolong QT interval e.g. antiarrhythmic agents (amiodarone, quinidine, sotalol), arsenic trioxide, cisapride, chlorpromazine, droperidol, mefloquine, dolasetron, mesoridazine, moxifloxacin, pimozide, tacrolimus, pentamidine, thioridazine, ziprasidone. Increased risk of blood glucose disturbances w/ drugs that alter blood glucose concentrations (e.g. antidiabetics). Systemic admin may elevate plasma concentrations of theophylline, interfere caffeine metabolism, enhance effects of oral anticoagulant (warfarin and its derivatives), and transient elevations in serum creatinine w/ ciclosporin.\n\nPregnancy category: C\n\nInteraction: Additive effect w/ drugs that prolong QT interval e.g. antiarrhythmic agents (amiodarone, quinidine, sotalol), arsenic trioxide, cisapride, chlorpromazine, droperidol, mefloquine, dolasetron, mesoridazine, moxifloxacin, pimozide, tacrolimus, pentamidine, thioridazine, ziprasidone. Increased risk of blood glucose disturbances w/ drugs that alter blood glucose concentrations (e.g. antidiabetics). Systemic admin may elevate plasma concentrations of theophylline, interfere caffeine metabolism, enhance effects of oral anticoagulant (warfarin and its derivatives), and transient elevations in serum creatinine w/ ciclosporin.
Gatifloxacin Eye prep	\n\n\tAristopharma\tTag Eye Drops  0.3%  5  ml drop 100\n\tBeximco\tXegal Eye Drops  0.3%  5  ml drop 90\n\tIncepta\tGatiflox Eye Drops  0.3%  5  ml drop 100\n\tIncepta\tGatiflox ES Eye Drops 0.5%  5ml 125\n\tPopular\tGatibac Eye Drops  0.3%  5  ml drop 100\n\tPopular\tLotenol G Eye Drops (300 mg + 500 mg)/100 ml  \n\tAllergan Inc, USA\tZymar Eye Drops 3mg/ml 5ml bot 208\n\tIndication: Bacterial conjunctivitis\n\nDose: The recommended dosage regimen for the treatment of bacterial conjunctivitis is:\nDays 1 and 2 : Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily.\nDays 3 through 7 : Instill one drop up to 4 times daily while awake. \n\nChild: >1 yr Same as adult dose.\n\nContra-indication: Patients with a history of hypersensitivity to Gatifloxacin, to other quinolones, or to any of the components in this medication.  Eye drops should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.\n\nSide effects: The most frequently reported adverse events in the overall study population were conjunctival irritation, increased lacrimation etc. \n\nPrecaution: Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. Avoid contaminating the applicator tip with material from the eye, fingers or other source.\n\nMode of action: Additive effect w/ drugs that prolong QT interval e.g. antiarrhythmic agents (amiodarone, quinidine, sotalol), arsenic trioxide, cisapride, chlorpromazine, droperidol, mefloquine, dolasetron, mesoridazine, moxifloxacin, pimozide, tacrolimus, pentamidine, thioridazine, ziprasidone. Increased risk of blood glucose disturbances w/ drugs that alter blood glucose concentrations (e.g. antidiabetics). Systemic admin may elevate plasma concentrations of theophylline, interfere caffeine metabolism, enhance effects of oral anticoagulant (warfarin and its derivatives), and transient elevations in serum creatinine w/ ciclosporin.\n\nPregnancy category: C\n\nInteraction: Additive effect w/ drugs that prolong QT interval e.g. antiarrhythmic agents (amiodarone, quinidine, sotalol), arsenic trioxide, cisapride, chlorpromazine, droperidol, mefloquine, dolasetron, mesoridazine, moxifloxacin, pimozide, tacrolimus, pentamidine, thioridazine, ziprasidone. Increased risk of blood glucose disturbances w/ drugs that alter blood glucose concentrations (e.g. antidiabetics). Systemic admin may elevate plasma concentrations of theophylline, interfere caffeine metabolism, enhance effects of oral anticoagulant (warfarin and its derivatives), and transient elevations in serum creatinine w/ ciclosporin.
Gemefloxacin	\n\n\tAlco Pharma\tGeminy TAB dr 320mg 12's Pack 720\n\tApex\tGemifix TAB dr 320mg  \n\tBeacon\tGemif TAB dr 320mg 8's pack 520\n\tBio Pharma Ltd.\tGefcin TAB dr 320mg 2x4's pack 457.44\n\tDrug International Ltd.\tGelcin TAB dr 320mg 7's pack 455\n\tEskayef Bangladesh Ltd.\tGeminox TAB dr 320mg 8's pack 520\n\tEuro Pharma Ltd.\tGeloxin TAB dr 320mg  \n\tHealthcare\tGemicin TAB dr 320mg 7's pack 455\n\tIbn Sina Pharmaceutical Ind. Ltd.\tGemitab TAB dr 320mg 10's pack 350\n\tIncepta\tOrasquin TAB dr 320mg 8's pack 65/tab\n\tMonicopharma\tFactiq TAB dr 320mg 8's pack 520\n\tNavana\tGemelon TAB dr 320mg 6's pack 390\n\tNovelta Bestway\tRtnor TAB dr 320mg 6's pack 390\n\tOpsonin Pharma\tFlogem TAB dr 320mg 6's pack 390\n\tOrion Pharma Ltd.\tXemi TAB dr 320mg 8's pack 400\n\tPopular\tGemifloy TAB dr 320mg 10's pack 552.50\n\tRAK\tGemiquin TAB dr 320mg 8's pack 520\n\tRenata\tToplon TAB dr 320mg 6's pack 390\n\tSharif\tGeoflox TAB dr 320mg  \n\tSquare\tFacticin TAB dr 320mg 6's pack 390\n\tIndication: Chronic bronchitis, Community-acquired pneumonia\n\nDose: Adult: PO Acute bacterial exacerbation of chronic bronchitis 320 mg once daily for 5 days. \nCommunity-acquired pneumonia 320 mg once daily for 7 days.\n\nRenal impairment:\nCrCl (ml/min)	\n<40 (or patient on haemodialysis/CAPD)	160 mg once daily.\n\nContra-indication: Hypersensitivity. Patients receiving class IA or III antiarrhythmics.\n\nSide effects: Diarrhoea, nausea, vomiting; headache, dizziness; rash, urticaria. May cause elevation of liver enzymes.\n\nPrecaution: History of prolongation of QT interval, uncorrected electrolyte disorders, CNS diseases such as epilepsy. Maintain adequate hydration. Increased risk of rash when treatment duration is prolonged. Children <18 yr. Pregnancy, lactation.\n\nMode of action: Additive effect on QT interval prolongation w/ class IA (e.g. quinidine) or class III (e.g. amiodarone) antiarrhythmics and other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Renal clearance reduced w/ probenecid. Decreased absorption w/ Al or Mg-containing antacids, buffered didanosine, sucralfate or dietary supplements containing metal cations (e.g. Zn, Mg, Fe). Increased risk of severe tendon disorders esp in elderly (>60 yr) w/ corticosteroids. May increase prothrombin time, INR and/or bleeding w/ warfarin.\n\nPregnancy category: C\n\nInteraction: Additive effect on QT interval prolongation w/ class IA (e.g. quinidine) or class III (e.g. amiodarone) antiarrhythmics and other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Renal clearance reduced w/ probenecid. Decreased absorption w/ Al or Mg-containing antacids, buffered didanosine, sucralfate or dietary supplements containing metal cations (e.g. Zn, Mg, Fe). Increased risk of severe tendon disorders esp in elderly (>60 yr) w/ corticosteroids. May increase prothrombin time, INR and/or bleeding w/ warfarin.
Gemfibrozil	\n\n\tBeximco\tFibril CAP 300mg 30's pack 210\n\tEskayef Bangladesh Ltd.\tGelicon CAP 300mg 24's pack 168\n\tSquare\tDelipid CAP 300mg 30's pack 210.28\n\tIndication: Hypertriglyceridemia, Hyperlipidemia\n\nDose: Adult: PO 1.2 g/day in 2 divided doses. Maintenance: 0.9-1.5 g/day.\n\nContra-indication: Hypersensitivity. Severe hepatic or renal dysfunction; gall stones; neonates, children, pregnancy, lactation.\n\nSide effects: Myositic syndrome, cholelithiasis, GI disturbances, rash, headache, blood dyscrasias, myalgia. Impotence, painful extremities, blurred vision; pruritus, urticaria; impotence; dizziness; cholestatic jaundice.\nPotentially Fatal: Bone marrow hypoplasia; intracranial haemorrhage; nephrotoxicity; peripheral neuritis.\n\nPrecaution: Causes of secondary hyperlipidaemia such as hypothyroidism and diabetes must be treated before initiating therapy. Renal impairment; blood disorders. Periodic monitoring of the serum lipids should be done; if no adequate response after 3 mth, treatment should be withdrawn. May increase risk of cholelithiasis.\n\nMode of action: Co-admin with repaglinide may increase serum levels of repaglinide. May enhance effects of oral anticoagulants. May also increase the plasma concentrations of ciclosporin and associated nephrotoxicity when used concurrently.\nPotentially Fatal: Increased risk of myopathy and rhabdomyolysis when used with HMG-CoA reductase inhibitors.\n\nPregnancy category: C\n\nInteraction: Co-admin with repaglinide may increase serum levels of repaglinide. May enhance effects of oral anticoagulants. May also increase the plasma concentrations of ciclosporin and associated nephrotoxicity when used concurrently.\nPotentially Fatal: Increased risk of myopathy and rhabdomyolysis when used with HMG-CoA reductase inhibitors.
Gentamicin	\n\n\tAristopharma\tOptimycin Injection 20mg/2ml 10amps pack 100\n\tAristopharma\tOptimycin Injection 80mg/2ml 10 amps pack 100\n\tBeximco\tInvigen IV Injection 80mg/100ml 100ml bot 47.03\n\tEdruc Ltd.\tEgen Injection 80mg/2ml 5 amps pack 47.50\n\tGonoshasthaya\tG Gentamycin Injection 80mg/2ml 10 amps pack 90.30\n\tIncepta\tIntamycin Injection 20mg/2ml 10 amps pack 100\n\tIncepta\tIntamycin Injection 80mg/2ml 10 amps pack 100\n\tOpsonin Pharma\tGentin Injection 20mg/2ml 25 amps pack 150\n\tOpsonin Pharma\tGentin Injection 80mg/2ml 25 amps pack 250\n\tSanofi Aventis (BD) Ltd.\tMicinagen Injection 20mg/2ml 25's pack \n\tSanofi Aventis (BD) Ltd.\tMicinagen Injection 80mg/2ml 25's pack \n\tSquare\tGenacyn Injection 20mg/2ml 10 amps pack 60.92\n\tSquare\tGenacyn Injection 80mg/2ml 10 amps pack 101.48\n\tTechno Drugs Ltd.\tGentasol 80 Injection 80mg/2ml 10 amps pack 95\n\tIndication: Pneumonia, Cystic fibrosis, Meningitis, Peritonitis, Endocarditis, Susceptible infections, Septicaemia, Pelvic inflammatory disease, Endometritis, Biliary tract infections, Granuloma inguinale, Listeriosis, Gastroenteritis, Plague, Cat scratch disease, Brucellosis, Otitis externa, Surgical infections, Skin infections.\n\nDose: Adult: IM Susceptible infections 3-5 mg/kg/day in divided doses 8 hrly for 7-10 days. Surgical prophylaxis 120 mg before induction of anesth, w/ penicillin, vancomycin or teicoplanin. \n\nPediatric\nUp to 2 weeks: 3 mg/kg/every 12 hours\n2 weeks to 12 years: 2 mg/kg/every 8 hours or as directed by the physician.\n\nRenal impairment: Haemodialysis: Administer dose after dialysis session and monitor levels.\n\nCrCl (ml/min)	\n>60	Administer every 8 hr.\n40-60	Administer every 12 hr.\n20-40	Administer every 24 hr.\n<20 	Loading dose, monitor levels. \n\n\nContra-indication: History of hypersensitivity to aminoglycoside; pregnancy; hepatic impairment, perforated ear drum.\n\nSide effects: Dizziness or vertigo; acute renal failure, interstitial nephritis, acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea, vomiting; convulsions, mental depression, hallucinations. Atrophy or rat necrosis at inj sites.\nPotentially Fatal: Nephrotoxicity, ototoxicity and neuromuscular blockade (may unmask or aggravate myasthaenia gravis).\n\nPrecaution: History of hypersensitivity to aminoglycoside; pregnancy; hepatic impairment, perforated ear drum.\n\nMode of action: Synergistic with ampicillin, benzylpenicillin and other beta-lactam antibiotics. Increased risk of severe respiratory depression when used concurrently with anaesthetics or opioids. May reduce renal clearance of zalcitabine and induce hypocalcaemia when used with biphosphonates. Not to be used with agalsidase alfa or beta as it may inhibit ?-galactosidase activity.\nPotentially Fatal: Increased incidence of ototoxicity when combined with ethacrynic acid and furosemide. Cephalosporins, ciclosporin, cisplatin, vancomycin, hydrocortisone and indometacin potentiate nephrotoxicity. Potentiates neuromuscular blocking agents.\n\nPregnancy category: D\n\nInteraction: Synergistic with ampicillin, benzylpenicillin and other beta-lactam antibiotics. Increased risk of severe respiratory depression when used concurrently with anaesthetics or opioids. May reduce renal clearance of zalcitabine and induce hypocalcaemia when used with biphosphonates. Not to be used with agalsidase alfa or beta as it may inhibit ?-galactosidase activity.\nPotentially Fatal: Increased incidence of ototoxicity when combined with ethacrynic acid and furosemide. Cephalosporins, ciclosporin, cisplatin, vancomycin, hydrocortisone and indometacin potentiate nephrotoxicity. Potentiates neuromuscular blocking agents.
Gentamicin 0.1% Topical	\n\n\tSquare\tGenacyn Ointment  100 mg/100 gm 10gm  tube 12.05\n\tIndication: Bacterial skin infections, Burns, eczema, seborrheic dermatitis, ecthyma, excoriation, folliculitis, furunculosis, insect bites and stings, lacerations and abrasions, paronychia, pyoderma gangrenosum, skin cysts and abscesses, stasis ulcers and infected skin ulcers, bacterial, fungal or viral superinfection, sycosis barbae, minor surgical wounds, infected contact dermatitis caused by susceptible organisms.\n\n\nDose: Adult: As a 0.1% cream; Apply to the affected area 3-4 times daily.\n\nContra-indication: History of hypersensitivity to aminoglycoside; pregnancy; hepatic impairment, perforated ear drum.\n\nSide effects: Dizziness or vertigo; acute renal failure, interstitial nephritis, acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea, vomiting; convulsions, mental depression, hallucinations. Atrophy or rat necrosis at inj sites.\nPotentially Fatal: Nephrotoxicity, ototoxicity and neuromuscular blockade (may unmask or aggravate myasthaenia gravis).\n\nPrecaution: Concurrent use of neuromuscular blocking agents; myasthenia gravis, parkinsonism; conditions predisposing to ototoxicity and nephrotoxicity; lactation. Monitor plasma concentrations of gentamicin in patients receiving high doses or prolonged courses, in infants, elderly, patients with renal impairment, cystic fibrosis or significant obesity. Monitor auditory and renal functions.\n\nMode of action: Synergistic with ampicillin, benzylpenicillin and other beta-lactam antibiotics. Increased risk of severe respiratory depression when used concurrently with anaesthetics or opioids. May reduce renal clearance of zalcitabine and induce hypocalcaemia when used with biphosphonates. Not to be used with agalsidase alfa or beta as it may inhibit ?-galactosidase activity.\n\nPotentially Fatal: Increased incidence of ototoxicity when combined with ethacrynic acid and furosemide. Cephalosporins, ciclosporin, cisplatin, vancomycin, hydrocortisone and indometacin potentiate nephrotoxicity. Potentiates neuromuscular blocking agents.\n\nPregnancy category: C\n\nInteraction: Synergistic with ampicillin, benzylpenicillin and other beta-lactam antibiotics. Increased risk of severe respiratory depression when used concurrently with anaesthetics or opioids. May reduce renal clearance of zalcitabine and induce hypocalcaemia when used with biphosphonates. Not to be used with agalsidase alfa or beta as it may inhibit ?-galactosidase activity.\n\nPotentially Fatal: Increased incidence of ototoxicity when combined with ethacrynic acid and furosemide. Cephalosporins, ciclosporin, cisplatin, vancomycin, hydrocortisone and indometacin potentiate nephrotoxicity. Potentiates neuromuscular blocking agents.
Gentamicin 0.3%  E/E prep	\n\n\tACI\tIgen E/E Drops   10 ml bot 32.02\n\tAcme Ltd.\tGentacin Eye Ointment   3.5 gm tube 9.75\n\tDrug International Ltd.\tGentum E/E Drops  .3% 10ml bot 31.50\n\tG. A. Company Ltd.\tGento E/E Drops   10 ml bot 31.50\n\tG. A. Company Ltd.\tGento Eye Ointment   5gm tube 10.10\n\tGonoshasthaya\tG Gentamicine E/E Drops   10 ml bot 25.10\n\tNipa\tGisin E/E Drops   10 ml bot 30.36\n\tOpso Saline Ltd.\tGentin E/E Drops   10 ml bot 31.37\n\tOpso Saline Ltd.\tGentin Eye Ointment   3gm tube 9.03\n\tPopular\tGentabac E/E Drops   10 ml bot 32.03\n\tReman Drug Ltd.\tRecin E/E Drops   10 ml pack 50\n\tRenata\tGenta E/E Drops   10 ml bot 31.93\n\tSquare\tGenacyn E/E Drops  300 mg/100 ml 10 ml bot 32.02\n\tIndication: Superficial ophthalmic infections, Otitis externa,\n\nDose: Adult: Instil 1-2 drops of a 0.3% soln into the infected eye/s every 4 hr or up to 2 drops every hr in severe infections. Alternatively, apply a small amount of 0.3% oint bid-tid into the affected eye. \n\n\nContra-indication: History of hypersensitivity to aminoglycoside; pregnancy; hepatic impairment, perforated ear drum.\n\nSide effects: Dizziness or vertigo; acute renal failure, interstitial nephritis, acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea, vomiting; convulsions, mental depression, hallucinations. Atrophy or rat necrosis at inj sites.\nPotentially Fatal: Nephrotoxicity, ototoxicity and neuromuscular blockade (may unmask or aggravate myasthaenia gravis).\n\nPrecaution: Concurrent use of neuromuscular blocking agents; myasthenia gravis, parkinsonism; conditions predisposing to ototoxicity and nephrotoxicity; lactation. Monitor plasma concentrations of gentamicin in patients receiving high doses or prolonged courses, in infants, elderly, patients with renal impairment, cystic fibrosis or significant obesity. Monitor auditory and renal functions.\n\nMode of action: Additive effect w/ other neurotoxic and/or nephrotoxic drugs including cephalosporins, methicillin, amphotericin B, ciclosporin, cisplatin, potent diuretics (e.g. ethacrynic acid, furosemide) and neuromuscular blocking agents (e.g. succinylcholine, tubocurarine). May potentiate the effect of anticoagulants (e.g. warfarin, phenindione). May antagonise the effect of neostigmine and pyridostigmine. Increased risk of hypocalcaemia w/ bisphosphonates. Increased risk of neuromuscular blockade w/ botulinum toxin. Indometacin may increase the plasma concentration of gentamicin in neonates.\n\nPregnancy category: C\n\nInteraction: Additive effect w/ other neurotoxic and/or nephrotoxic drugs including cephalosporins, methicillin, amphotericin B, ciclosporin, cisplatin, potent diuretics (e.g. ethacrynic acid, furosemide) and neuromuscular blocking agents (e.g. succinylcholine, tubocurarine). May potentiate the effect of anticoagulants (e.g. warfarin, phenindione). May antagonise the effect of neostigmine and pyridostigmine. Increased risk of hypocalcaemia w/ bisphosphonates. Increased risk of neuromuscular blockade w/ botulinum toxin. Indometacin may increase the plasma concentration of gentamicin in neonates.
Gentamicin 0.3% + Hydrocortisone Acetate 1% Eye prep	\n\n\tG. A. Company Ltd.\tGento HC Eye Cream   10gm tube 55\n\tNipa\tGisin H Eye Drops   5  ml drop 50\n\tOpso Saline Ltd.\tGentin HC Eye Drops   5 ml drop 55.21\n\tPopular\tGentabac HC Eye Drops   10 ml drop 51.05\n\tNicholas\tGenticin HC Eye Cream  15gm tube 111.10\n\tIndication: Susceptible infections, Keratitis, Allergic conjunctivitis, Blepharitis, Allergic and inflammatory conditions of the eye, Chronic conjunctivitis, Spring catarrh, \n\nDose: Ophth Superficial ophth infections As 0.3% soln: Instill 1-2 drops 4 hrly, up to 2 drops hrly in severe cases. \n\nContra-indication: History of hypersensitivity to aminoglycoside; pregnancy; hepatic impairment.\n\nSide effects: Dizziness or vertigo; acute renal failure, interstitial nephritis, acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea, vomiting; convulsions, mental depression, hallucinations. Atrophy or rat necrosis at inj sites.\nPotentially Fatal: Nephrotoxicity, ototoxicity and neuromuscular blockade (may unmask or aggravate myasthaenia gravis).\n\nPrecaution: Concurrent use of neuromuscular blocking agents; myasthenia gravis, parkinsonism; conditions predisposing to ototoxicity and nephrotoxicity; lactation. Monitor plasma concentrations of gentamicin in patients receiving high doses or prolonged courses, in infants, elderly, patients with renal impairment, cystic fibrosis or significant obesity. Monitor auditory and renal functions.\n\nMode of action: Gentamicin: Additive effect w/ other neurotoxic and/or nephrotoxic drugs including cephalosporins, methicillin, amphotericin B, ciclosporin, cisplatin, potent diuretics (e.g. ethacrynic acid, furosemide) and neuromuscular blocking agents (e.g. succinylcholine, tubocurarine). May potentiate the effect of anticoagulants (e.g. warfarin, phenindione). May antagonise the effect of neostigmine and pyridostigmine. Increased risk of hypocalcaemia w/ bisphosphonates. Increased risk of neuromuscular blockade w/ botulinum toxin. Indometacin may increase the plasma concentration of gentamicin in neonates.\n\nHydrocortisone: Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.\n\n\nPregnancy category: C\n\nInteraction: Gentamicin: Additive effect w/ other neurotoxic and/or nephrotoxic drugs including cephalosporins, methicillin, amphotericin B, ciclosporin, cisplatin, potent diuretics (e.g. ethacrynic acid, furosemide) and neuromuscular blocking agents (e.g. succinylcholine, tubocurarine). May potentiate the effect of anticoagulants (e.g. warfarin, phenindione). May antagonise the effect of neostigmine and pyridostigmine. Increased risk of hypocalcaemia w/ bisphosphonates. Increased risk of neuromuscular blockade w/ botulinum toxin. Indometacin may increase the plasma concentration of gentamicin in neonates.\n\nHydrocortisone: Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.\n
Gentian Violet	\n\n\tEDCL (Dhaka)\tGention Violet Topical Solution 2 gm/100 ml  \n\tKawser Chemicals\tViola Lotion 1% 1 fl. oz \n\tKawser Chemicals\tViola Lotion 2% 1 fl. oz \n\tM.R Chemicals\tViola Lotion 1% 28ml soln \n\tM.R Chemicals\tViola Lotion 2% 28ml soln \n\tKazi Chemicals\tViolete Lotion 1% 28ml soln \n\tIndication: Topical antiseptic as first aid to help prevent infection in minor cuts, scrapes and burns\n\nDose: Clean the affected area and apply a small amount of this product on the area 1 to 3 times daily.  May be covered with a sterile bandage.\n\nContra-indication: Do not apply to an ulcerative lesion as this may cause tattoing of the skin. \n\nSide effects: Redness, irritation, swelling or pain persists or increases of if infection occurs.\n\nPrecaution: Stop use if the condition persists or gets worse.\nDo not use longer than 1 week unless directed by a  doctor.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Glibenclamide	\n\n\tAcme Ltd.\tGluconil TAB dr 5mg 100's pack 28\n\tAlbion Ltd.\tGlibenol TAB dr 5 mg 300's pack \n\tAmico Ltd.\tGliden TAB dr 5mg  \n\tJayson\tDicon TAB dr 5 mg 100's pack \n\tOpsonin Pharma\tGlucon TAB dr 5mg 100's pack 29.91\n\tSanofi Aventis (BD) Ltd.\tDaonil TAB dr 5mg 500's pack 139.65\n\tSquare\tDibenol TAB dr 5mg 300's pack 102\n\tIndication: Type 2 DM\n\nDose: Adult: PO Initial: 2.5-5 mg/day, up to 15 mg/day. Max: 20 mg/day.\n\nContra-indication: Severe or life-threatening hyperglycaemia, severe liver or renal failure, type 1 diabetes, diabetic ketoacidosis with or without coma, patients with severe infection or trauma.\n\nSide effects: Hypoglycaemia; cholestatic jaundice; agranulocytosis; aplastic anaemia; haemolytic anaemia. Blood dyscrasias (reversible), liver dysfunction, hypoglycaemia, GI symptoms, allergic skin reactions.\nPotentially Fatal: Prolonged hypoglycaemia seen in elderly or debilitated patients with hepatic or renal diseases.\n\nPrecaution: Elderly; malnourished; mild to moderate renal and hepatic disorders. Impaired alertness. Avoid alcohol. Careful monitoring of blood-glucose concentration. Adrenocortical insufficiency. Changes in diet or prolonged exercise may also provoke hypoglycaemia. Increased risk of hypoglcaemia due to its long half-life. Avoid in severe hepatic impairment. Pregnancy, lactation.\n\nMode of action: Serum levels may be reduced by colesevelam. May increase hypoglycaemic effect w/ MAOIs, chloramphenicol, fluoroquinolones (e.g. ciprofloxacin), probenecid, NSAIDs, ACE inhibitors, fluoxetine, disopyramide, clarithromycin, salicylates, sulfonamides, ?-blockers. Increased serum levels w/ antifungal antibiotics (e.g. miconazole, fluconazole). May decrease hypoglycaemic effect w/ nonthiazide (e.g. furosemide) and thiazide diuretics, corticosteroids, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetic agents, rifampicin, Ca channel blockers, isoniazid.\nPotentially Fatal: May increase hepatotoxic effect of bosentan.\n\nPregnancy category: C\n\nInteraction: Serum levels may be reduced by colesevelam. May increase hypoglycaemic effect w/ MAOIs, chloramphenicol, fluoroquinolones (e.g. ciprofloxacin), probenecid, NSAIDs, ACE inhibitors, fluoxetine, disopyramide, clarithromycin, salicylates, sulfonamides, ?-blockers. Increased serum levels w/ antifungal antibiotics (e.g. miconazole, fluconazole). May decrease hypoglycaemic effect w/ nonthiazide (e.g. furosemide) and thiazide diuretics, corticosteroids, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetic agents, rifampicin, Ca channel blockers, isoniazid.\nPotentially Fatal: May increase hepatotoxic effect of bosentan.
Gliclazide	\n\n\tACI\tLozide TAB dr 80mg 40's pack 280.80\n\tACI\tDiamicron MR TAB dr 30mg  \n\tACI\tDiamicron MR TAB dr 60mg  \n\tAcme Ltd.\tGliclid TAB dr 80mg 50's pack 350\n\tAd-din\tSugred TAB dr 80mg 30's pack 180\n\tAexim\tDiagle TAB dr 80mg 50's pack 225\n\tAlbion Ltd.\tGlirol TAB dr 80 mg  50's pack \n\tAlco Pharma\tDiaprid TAB dr 80mg 30's pack 180\n\tAristopharma\tGlucozid TAB dr 80mg 50's pack 300\n\tBeximco\tDiapro MR TAB dr 30mg 30's pack 210\n\tBeximco\tDiapro TAB dr 80mg 50's pack 350\n\tBio Pharma Ltd.\tGlucostat TAB dr 80mg 50's pack 301\n\tCentral.\tGL TAB dr 80mg 50's pack 350\n\tDelta Pharma\tXido TAB dr 80mg 50's pack 350\n\tDoctor's Chemicals Works Ltd.\tDelazide TAB dr 80mg 50's pack 300\n\tDrug International Ltd.\tDimerol TAB dr 80mg 50's pack 350\n\tDrug International Ltd.\tDimerol MR TAB dr 30mg 50's pack 300\n\tEdruc Ltd.\tEzide TAB dr 80mg 50's pack 300\n\tEskayef Bangladesh Ltd.\tGlikazid MR TAB dr 60mg  \n\tEskayef Bangladesh Ltd.\tGlikazid TAB dr 80mg  \n\tEuro Pharma Ltd.\tEucron TAB dr 80mg 50's pack 300\n\tGeneral\tGored TAB dr 80mg 50's pack 350\n\tGeneral\tGored MR TAB dr 30mg 28's pack 247.24\n\tGlobe\tSucotab TAB dr 80mg 50's pack 300\n\tHudson\tGlitab TAB dr 80mg 100's pack 450\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSina Zid TAB dr 80mg 50's pack 325\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinazid TAB dr 80mg 50's pack 300\n\tIncepta\tConsucon TAB dr 80mg 50's pack 350\n\tIncepta\tConsucon MR TAB dr 30mg 50's pack 300\n\tIncepta\tConsucon TAB dr 60mg 50's pack 300\n\tKemiko\tKezid TAB dr 80mg 50's pack 400\n\tKemiko\tKezid MR TAB dr 30mg  \n\tLeon\tOnzid TAB dr 80mg  \n\tMedicon\tGide TAB dr 80mg 50's pack 300\n\tMillat\tDiacon TAB dr 80mg 50's pack 300\n\tModern\tGlica TAB dr 80mg 40's pack 200\n\tNavana\tGlix TAB dr 80mg 30's pack 180\n\tNipa\tDigreen TAB dr 80mg 50's pack 225\n\tNIPRO JMI Pharma\tDiazid TAB dr 80mg  \n\tNovartis (Bangladesh) Ltd.\tGlad TAB dr 80mg 50's pack 350\n\tOpsonin Pharma\tGlizid TAB dr 80mg 30's pack 210\n\tOpsonin Pharma\tGlizid MR TAB dr 30mg 30's pack 180\n\tOpsonin Pharma\tGlizid MR TAB dr 60mg  \n\tOrganic Health Care\tGlagin TAB dr 80mg 50's pack 350\n\tOrion Pharma Ltd.\tOclazid TAB dr 80mg 50's pack 350\n\tOrion Pharma Ltd.\tOclazid MR TAB dr 30mg 30's pack 180\n\tPacific\tDiatrol TAB dr 80mg 50's pack/100's pack 400/800\n\tPacific\tDiatrol MR TAB dr 30mg 50's pack 400\n\tPharmadesh Ltd.\tZide TAB dr 80mg 50's pack 350\n\tPopular\tGluzit TAB dr 80mg 50's pack 350\n\tRAK\tSucleer MR TAB dr 30mg 30's pack 180\n\tRAK\tSucleer TAB dr 80mg 50's pack 300\n\tRenata\tGlicron TAB dr 80mg 30's pack 210\n\tRenata\tGlicron CR CAP 30mg 30's pack 180.60\n\tSharif\tGlitz TAB dr 80mg 30's pack 210\n\tSilva\tGlicasil TAB dr 80mg 50's pack 250.94\n\tSomatec\tOrazid TAB dr 80mg 30's pack 210\n\tSquare\tComprid TAB dr 80mg 60's pack 420\n\tSquare\tComprid XR TAB dr 30mg 30's pack 180.74\n\tSquare\tComprid XR TAB dr 60mg  \n\tSupreme\tProglid TAB dr 80mg 30's pack 150\n\tTechno Drugs Ltd.\tGlazide TAB dr 80mg 50's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tAdmira TAB dr 80mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tAdmira MR TAB dr 30mg 30's pack 180\n\tUnited Chemicals &\tGleek TAB dr 80mg  \n\tVeritas\tGlucoact TAB dr 80mg  \n\tWhite Horse Pharma\tGlimicron TAB dr 80mg 50's pack 350\n\tWhite Horse Pharma\tGlimicron MR TAB dr 30mg 50's pack 300\n\tZenith\tZenzide TAB dr 80mg 100's pack 600\n\tIndication: Type 2 DM\n\nDose: Adult: PO Initial: 40-80 mg/day, increase slowly if needed. Doses >160 mg/day may be given in 2 divided doses.\n\nContra-indication: Type 1 DM, diabetes complicated with ketoacidosis; hypersensitivity; severe renal and hepatic impairment. Pregnancy and lactation.\n\nSide effects: GI disturbances, skin reaction, leucopenia, thrombocytopenia, agranulocytosis, haemolytic anaemia, cholestatic jaundice, vomiting, diarrhoea, gastritis, increased transaminases.\n\nPrecaution: Monitor blood glucose concentration. May require insulin during metabolic stress. Care when transferring from combination therapy. Increased risk of severe hypoglycaemia in elderly, debilitated patients, patients with hepatic or renal impairment. Risk of hypogylcaemia when caloric intake is deficient, after strenuous exercise, when taken with ethanol or when >1 antidiabetic drug is used.\n\nMode of action: May increase hypoglycaemic effect w/ phenylbutazone. Potentiation of blood glucose lowering effect w/ other antidiabetics (e.g. acarbose, insulins, metformin), ?-blockers, ACE inhibitors, H2-receptor antagonists, MAOIs, sulfonamides, clarithromycin and NSAIDs. Chlorpromazine, glucocorticoids, ritodrine, salbutamol and terbutaline may cause increases in blood glucose levels. May diminish hypoglycaemic effect w/ danazol. May increase anticoagulant effect of warfarin.\nPotentially Fatal: Increased hypoglycaemic effect w/ miconazole\n\nPregnancy category: C\n\nInteraction: May increase hypoglycaemic effect w/ phenylbutazone. Potentiation of blood glucose lowering effect w/ other antidiabetics (e.g. acarbose, insulins, metformin), ?-blockers, ACE inhibitors, H2-receptor antagonists, MAOIs, sulfonamides, clarithromycin and NSAIDs. Chlorpromazine, glucocorticoids, ritodrine, salbutamol and terbutaline may cause increases in blood glucose levels. May diminish hypoglycaemic effect w/ danazol. May increase anticoagulant effect of warfarin.\nPotentially Fatal: Increased hypoglycaemic effect w/ miconazole
Glimepiride	\n\n\tACI\tGlimirid TAB dr 1mg 30's pack 135.30\n\tACI\tGlimirid TAB dr 2mg 30's pack 240.60\n\tACI\tGlimirid TAB dr 3mg 30's pack 300.90\n\tACI\tGlimirid TAB dr 4mg 30's pack 361.20\n\tAcme Ltd.\tDactus TAB dr 1mg 50's pack 150\n\tAcme Ltd.\tDactus TAB dr 2mg 30's pack 200\n\tAcme Ltd.\tDactus TAB dr 3mg 30's pack 210.60\n\tAlco Pharma\tGipid TAB dr 1mg 30's pack 90\n\tAlco Pharma\tGipid TAB dr 2mg 30's pack 150\n\tAristopharma\tGluconor TAB dr 1mg 50's pack 150\n\tAristopharma\tGluconor TAB dr 2mg 30's pack 150\n\tBeximco\tDiaryl TAB dr 1mg 30's pack 135\n\tBeximco\tDiaryl TAB dr 2mg 30's pack 240\n\tBeximco\tDiaryl TAB dr 3mg 30's pack 300\n\tBio Pharma Ltd.\tGlucorid TAB dr 1mg 30's pack 90\n\tBio Pharma Ltd.\tGlucorid TAB dr 2mg 30's pack 150\n\tDrug International Ltd.\tLimpet TAB dr 1mg 50's pack 150\n\tDrug International Ltd.\tLimpet TAB dr 2mg 50's pack 250\n\tDrug International Ltd.\tLimpet TAB dr 3mg 30's pack 210\n\tDrug International Ltd.\tLimpet TAB dr 4mg 30's pack 237.52\n\tEskayef Bangladesh Ltd.\tDialon TAB dr 1mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tDialon TAB dr 2mg 30's pack 150\n\tEskayef Bangladesh Ltd.\tDialon TAB dr 4mg 20's pack 160\n\tGeneral\tGlirid TAB dr 1mg 30's pack 90.30\n\tGeneral\tGlirid TAB dr 2mg 30's pack 150.60\n\tGlobe\tSucorid-2 TAB dr 2mg  \n\tGlobe\tSucorid-4 TAB dr 4mg  \n\tGlobex\tAmynil TAB dr 1mg 30's pack 207\n\tGlobex\tAmynil TAB dr 2mg 30's pack 387\n\tHealthcare\tGlemep TAB dr 1mg 30's pack 90\n\tHealthcare\tGlemep TAB dr 2mg 30's pack 150\n\tIncepta\tLosucon 1 TAB dr 1mg 50's pack 225\n\tIncepta\tLosucon 2 TAB dr 2mg 50's pack 400\n\tIncepta\tLosucon 3 TAB dr 3mg 30's pack 300\n\tIncepta\tLosucon 4 TAB dr 4mg 30's pack 360\n\tKemiko\tLimep TAB dr 1mg 50's pack 150\n\tKemiko\tLimep TAB dr 2mg 50's pack 250\n\tMonicopharma\tGifon TAB dr 2mg 30's pack 150\n\tNavana\tSenride 1 TAB dr 1 mg 6Ã10's pack \n\tNavana\tSenride 2 TAB dr 2 mg 3Ã10's  pack \n\tOpsonin Pharma\tGlims TAB dr 1mg 30's pack 79.43\n\tOpsonin Pharma\tGlims TAB dr 2mg 30's pack 132.48\n\tOrion Pharma Ltd.\tStimulin TAB dr 1mg 30's pack 90.30\n\tOrion Pharma Ltd.\tStimulin TAB dr 2mg 30's pack 150.60\n\tPacific\tDieta TAB dr 1mg 30's pack 150\n\tPacific\tDieta TAB dr 2mg 30's pack 240\n\tPacific\tDieta TAB dr 3mg 30's pack 300\n\tPacific\tDieta TAB dr 4mg 30's pack 360\n\tPopular\tLimaryl TAB dr 1mg 30's pack 90.33\n\tPopular\tLimaryl TAB dr 2mg 30's pack 150.57\n\tPopular\tLimaryl TAB dr 3mg 30's pack 210.90\n\tPopular\tLimaryl TAB dr 4mg 30's pack 240.90\n\tRAK\tCondia TAB dr 1mg 30's pack 90\n\tRAK\tCondia TAB dr 2mg 30's pack 150\n\tRAK\tCondia TAB dr 3mg 30's pack 210\n\tRAK\tCondia TAB dr 4mg 30's pack 240\n\tRenata\tMepid TAB dr 1mg 30's pack 75.30\n\tRenata\tMepid TAB dr 2mg 30's pack 120.30\n\tRenata\tMepid TAB dr 4mg 30's pack 210.60\n\tSanofi Aventis (BD) Ltd.\tAmaryl TAB dr 1mg 30's pack 207\n\tSanofi Aventis (BD) Ltd.\tAmaryl TAB dr 2mg 30's pack 387\n\tSanofi Aventis (BD) Ltd.\tAmaryl TAB dr 3mg 30's pack 495\n\tSanofi Aventis (BD) Ltd.\tAmaryl TAB dr 4mg 30's pack 630\n\tSquare\tSecrin TAB dr 1mg 30's pack/60's pack 90.18/270\n\tSquare\tSecrin TAB dr 2mg 30's pack/60's pack 150.43/480\n\tSquare\tSecrin TAB dr 3mg 30's pack 300\n\tSquare\tSecrin TAB dr 4mg 30's pack 360\n\tSupreme\tLimerid TAB dr 1mg 30's pack 90\n\tSupreme\tLimerid TAB dr 2mg 30's pack 150\n\tTechno Drugs Ltd.\tGlutim TAB dr 1mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tAdglim TAB dr 1mg 30's pack 90\n\tUnimed & Unihealth Manufacturers Ltd.\tAdglim TAB dr 2mg 30's pack 150\n\tVirgo\tDiavir TAB dr 1mg 50's pack\n 150\n\tVirgo\tDiavir TAB dr 2mg 50's pack 250\n\tWhite Horse Pharma\tPride TAB dr 1mg 50's pack 250\n\tWhite Horse Pharma\tPride TAB dr 2mg 50's pack 350\n\tIndication: Type 2 DM\n\nDose: Oral\nType 2 diabetes mellitus\nAdult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.\nElderly: Initially, 1 mg once daily.\nHepatic impairment: Severe: Contraindicated.\n\nContra-indication: Diabetic ketoacidosis with or without coma.\n\nSide effects: Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.\n\nPrecaution: Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.\n\nMode of action: Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.\n\nPregnancy category: C\n\nInteraction: Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
Glimepiride + Pioglitazone	\n\n\tACI\tDiatag Plus F/C 2 TAB dr   30's pack 391.50\n\tPacific\tDieta Plus 2 TAB dr   20's pack 250\n\tPacific\tDieta Plus 4 TAB dr   20's pack 300\n\tSquare\tTosirin 30/2 TAB dr   15's pack 240\n\tSquare\tTosirin 30/4 TAB dr   15's pack 270\n\tIndication: Type 2 DM\n\nDose:  	Oral\nType 2 diabetes mellitus\nAdult: Each tab contains pioglitazone 15 mg or 30 mg and glimepiride 2 mg or 4 mg: Initially, 1 tab once daily then titrate gradually as needed.\n\nFor patients inadequately controlled on glimepiride monotherapy: 30 mg/2 mg or 30 mg/4 mg once daily and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability,\n\nFor patients inadequately controlled on pioglitazone monotherapy: 30 mg/2 mg once daily and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability,\n\nContra-indication:     Initiation in patients with established NYHA Class III or IV heart failure \n\n    Use in patients with known hypersensitivity to pioglitazone, glimepiride or any other component. \n\n    Use in patients with known history of an allergic reaction to sulfonamide derivatives. \n\nSide effects:     Congestive Heart Failure \n    Hypoglycemia \n\n    Edema \n\n    Fractures\n\n    Hemolytic Anemia \n\nPrecaution: Pioglitazone, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when  is used in combination with insulin. Fluid retention may lead to or exacerbate congestive heart failure. Patients should be observed for signs and symptoms of congestive heart failure. If congestive heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of  must be considered \n\nMode of action: Increased plasma levels w/ CYP2C8 inhibitors (e.g. gemfibrozil) and CYP2C9 inhibitors (e.g. fluconazole). Decreased plasma levels w/ CYP2C8 inducers (e.g. rifampicin). Colesevelam may reduce the max plasma concentration and total exposure of glimepiride. Concominant use w/ oral miconazole may lead to severe hypoglycaemia.\n\nPregnancy category: C\n\nInteraction: Increased plasma levels w/ CYP2C8 inhibitors (e.g. gemfibrozil) and CYP2C9 inhibitors (e.g. fluconazole). Decreased plasma levels w/ CYP2C8 inducers (e.g. rifampicin). Colesevelam may reduce the max plasma concentration and total exposure of glimepiride. Concominant use w/ oral miconazole may lead to severe hypoglycaemia.
Glimepiride + Rosiglitazone	\n\n\tACI\tRoglim 1 TAB dr   30's pack 301.20\n\tACI\tRoglim 2 TAB dr   30's pack 331.20\n\tGeneral\tRosiglim 1 TAB dr   30's pack 301.20\n\tGeneral\tRosiglim 2 TAB dr   30's pack 331.20\n\tPacific\tSugana 1/4 TAB dr   30's pack 300\n\tPacific\tSugana 2/4 TAB dr   30's pack 360\n\tSquare\tGlyros 1 TAB dr   30's pack 301.24\n\tSquare\tGlyros 2 TAB dr   30's pack 331.17\n\tIndication: Type 2 DM\n\nDose: The usual starting dose of 1mg/4 mg or 2 mg/4 mg once daily.\nThe maximum recommended daily dose of is 4 mg of Glimepiride and 8 mg of Rosiglitazone.\nThe dosage of anti-diabetic therapy should be individualized on the basis of effectiveness and tolerability. \n\n\nContra-indication: Patients with established Class III or IV heart failure is contraindicated.\n\nSide effects: Hypoglycemia, dizziness, asthenia, headache, nausea, allergic skin reactions, e.g., pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions.\n\nRosiglitazone:The mostcommon adverse experiences with Rosiglitazone are upper\nrespiratory tract infection, injury, and headache. Events of anemia and edema tended to be reported more frequently at higher doses, angioedema and urticaria have been reported rarely.\n\n\nPrecaution: Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes. Debilitated or malnourished patients and those with adrenal, pituitary\n, renal, or hepatic insufficiency are particularly susceptible to the hypoglycemic action of glucose lowering drugs.\nLoss of Control of Blood Glucose:\nWhen a patient stabilized on any antidiabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur.\n\nEdema:\nCombination of Glimepiride and Rosiglitazone should be used with caution in patients with edema.\nSince thiazolidinediones, including Rosiglitazone can cause fluid retention, which can exacerbate or lead to congestive heart failure, Combination of Glimepiride and Rosiglitazone should be used with caution in patients at risk for heart failure.\nWeight Gain:\nDose-related weight gain was seen with Rosiglitazone alone and in combination with other hypoglycemic agents. \nHepatic Effects:\nLiver enzymes should be checked prior to the initiation of therapy with combination of Glimepiride and Rosiglitazone in all patients and periodically thereafter per the clinical\njudgment of the healthcare professional. \n\nMode of action: Glimepiride: Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.\n\nRosiglitazone: Increased plasma conc w/ gemfibrozil. Decreased plasma conc w/ rifampicin.\n\n\n\nPregnancy category: C\n\nInteraction: Glimepiride: Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.\n\nRosiglitazone: Increased plasma conc w/ gemfibrozil. Decreased plasma conc w/ rifampicin.\n\n
Glipizide	\n\n\tAlbion Ltd.\tGlipizide TAB dr 5 mg 100's pack \n\tAristopharma\tActine TAB dr 5mg 50's pack 100\n\tBeximco\tDiactin TAB dr 5mg 100's pack 150\n\tDrug International Ltd.\tGlimerol TAB dr 5mg 100's pack 150\n\tKemiko\tPizide TAB dr 5mg 100's pack 200\n\tMedimet\tDiapizi TAB dr 2.5mg 100's pack 100\n\tMedimet\tDiapizi TAB dr 5mg 50's pack 100\n\tPacific\tDiaplus TAB dr 5mg 50's pack 100\n\tPacific\tDiaplus XR TAB dr 5mg 30's pack 84\n\tWhite Horse Pharma\tTicozid TAB dr 5mg 50's pack 100\n\tIndication: Type 2 DM\n\nDose: Adult: PO Initial: 2.5-5 mg/day as a single dose, may increase slowly. Doses >15 mg may be given in 2 divided doses. Max: 40 mg/day.\n\nHepatic impairment: Severe: Contraindicated.\n\nContra-indication: Hypersensitivity. Type 1 DM; ketoacidosis; severe renal or hepatic insufficiency. Pregnancy, lactation.\n\nSide effects: GI upsets, diarrhoea, nausea; allergic skin reactions, leucopenia, thrombocytopenia, agranulocytosis, hyponatraemia; jaundice; haemolytic anaemia, pancytopenia.\nPotentially Fatal: Hypoglycaemia in presence of renal or hepatic damage and alcohol.\n\nPrecaution: Hypoglycaemia, stress, elderly. Thyroid impairment; moderate hepatic or renal impairment. Monitor blood glucose concentration.\n\nMode of action: Increased plasma concentration w/ certain antifungals (e.g. miconazole, fluconazole). Protein-bound drugs (e.g. NSAIDs, other sulfonamides, oral anticoagulants, hydantoins), probenecid, MAOIs, and chloramphenicol may potentiate hypoglycaemic action of glipizide. Diminished therapeutic effect w/ thiazides, other diuretics, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers, rifampicin and isoniazid. Concomitant use w/ ?-blockers may impair glucose tolerance, increase frequency or severity of hypoglycaemia and block hypoglycaemia-induced tachycardia. Decreased serum concentration w/ colesevelam.\n\nPregnancy category: C\n\nInteraction: Increased plasma concentration w/ certain antifungals (e.g. miconazole, fluconazole). Protein-bound drugs (e.g. NSAIDs, other sulfonamides, oral anticoagulants, hydantoins), probenecid, MAOIs, and chloramphenicol may potentiate hypoglycaemic action of glipizide. Diminished therapeutic effect w/ thiazides, other diuretics, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers, rifampicin and isoniazid. Concomitant use w/ ?-blockers may impair glucose tolerance, increase frequency or severity of hypoglycaemia and block hypoglycaemia-induced tachycardia. Decreased serum concentration w/ colesevelam.
Glipizide + Metformin Hydrochloride	\n\n\tApex\tGlumin 2.5/250 TAB dr   50's pack 80\n\tApex\tGlumin PLUS 5/500 TAB dr   50's pack 140\n\tHealthcare\tGlymin PLUS 2.5/500 TAB dr  500mg 30's pack 97.50\n\tIncepta\tMefoglip 2.5/250 TAB dr   50's pack 95\n\tIncepta\tMefoglip 2.5/500 TAB dr   30's pack 84\n\tIncepta\tMefoglip DS 5/500 TAB dr   30's pack 111\n\tPacific\tMetglip 2.5/250 TAB dr   50's pack 95\n\tPacific\tMetglip 2.5/500 TAB dr   30's pack 89.40\n\tPacific\tMetglip DS 5/500 TAB dr   30's pack 150\n\tWhite Horse Pharma\tTicozid Plus TAB dr   50's pack 200\n\tIndication: Type 2 DM\n\nDose: Adult: PO Per tab contains glipizide 2.5 mg and metformin 250 mg. As initial therapy: Start w/ 1 tab once daily. May increase slowly to lowest effective dose to a max of 4 tab/day in divided doses. \n\nFor patients previously treated w/ glibenclamide/sulphonylurea or metformin alone: Recommended starting dose: 2 tab twice daily; starting dose should not exceed the daily doses of glipizide or metformin already being taken. \n\nTitrate subsequent doses based on blood glucose levels and patient's response. Daily max: 20 mg glipizide/2000 mg metformin.\n\nContra-indication: Hypersensitivity. Type 2 diabetes mellitus; ketoacidosis; severe renal or hepatic insufficiency, diabetic coma, cardiac failure, recent MI, CHF. IDDM; severe infection; acute or chronic metabolic acidosis with or without coma; stress, trauma; severe impairment of thyroid function; dehydration, acute or chronic alcoholism. Pregnancy, lactation.\n\nSide effects: Glipizide: GI upsets, diarrhoea, nausea; allergic skin reactions, leucopaenia, thrombocytopaenia, agranulocytosis, hyponatraemia; jaundice; haemolytic anaemia, pancytopaenia. Metformin: Anorexia, nausea, vomiting, diarrhoea, wt loss, flatulence, occasional metallic taste; weakness; hypoglycaemia; rash, malabsorption of Vitamin\nPotentially Fatal: Glipizide: Hypoglycaemia in presence of renal or hepatic damage and alcohol. Metformin: Lactic acidosis in presence of renal failure and alcoholism.\n\nPrecaution: Hypoglycaemia, stress, elderly. Thyroid impairment, monitor blood-glucose conc and renal function regularly.\n\nMode of action: Glipizide: Decreased effect with beta-blockers, cholestyramine, hydantoins, thiazide diuretics and urinary alkalinizers.\nMetformin: Additive effect with sulphonylureas. Antagonistic effects with diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers and isoniazid.\n\nPotentially Fatal: Glipizide: Increased glipizide levels and effects with fluconazole, gemfibrozil, ketoconazole, NSAIDs, pioglitazone and sulfonamides. Increased hypoglycaemic effects with H2 antagonists, anticoagulants, androgens, cimetidine, salicylates, tricyclic antidepressants, probenecid, MAOIs, methyldopa, digitalis glycosides and urinary acidifiers.\n\nMetformin: Lactic acidosis with alcohol and potentiation of hypoglycaemic effect. Cimetidine and furosemide may increase plasma-metformin levels. Drugs eliminated via renal tubular secretion may increase metformin levels.\n\nPregnancy category: C\n\nInteraction: Glipizide: Decreased effect with beta-blockers, cholestyramine, hydantoins, thiazide diuretics and urinary alkalinizers.\nMetformin: Additive effect with sulphonylureas. Antagonistic effects with diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers and isoniazid.\n\nPotentially Fatal: Glipizide: Increased glipizide levels and effects with fluconazole, gemfibrozil, ketoconazole, NSAIDs, pioglitazone and sulfonamides. Increased hypoglycaemic effects with H2 antagonists, anticoagulants, androgens, cimetidine, salicylates, tricyclic antidepressants, probenecid, MAOIs, methyldopa, digitalis glycosides and urinary acidifiers.\n\nMetformin: Lactic acidosis with alcohol and potentiation of hypoglycaemic effect. Cimetidine and furosemide may increase plasma-metformin levels. Drugs eliminated via renal tubular secretion may increase metformin levels.
Glucosamine	\n\n\tBeximco\tReflon TAB dr 500mg 100's pack 300\n\tGeneral\tGlustin TAB dr 500mg 50's pack 175.50\n\tIncepta\tJoinix TAB dr 500mg 100's pack 300\n\tOpsonin Pharma\tCarticel TAB dr 500mg 50's pack 150\n\tOrion Pharma Ltd.\tGlucart TAB dr 500mg 100's pack \n\tRadiant.\tCarticare Max TAB dr 500mg  \n\tSquare\tTilex500 TAB dr 500mg 30's pack 90\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Nutritional supplement, Low back pain, Acute gout, Degenerative joint disease\n\nDose: Adult: PO One (500 mg) tablet three times daily or as directed by the physician. A single dose of 1500 mg daily may also be effective. Obese individuals may need higher doses, based on body weight.\n\nContra-indication: Allergy to shellfish.\n\nSide effects: Heart burn, epigastric pain/tenderness, diarhea, nausea, dyspepsia, constipation, abdominal pain, palpitations, drowsiness, skin reaction, headache, indigestion.\n\nPrecaution: Diabetic patients, patients on heparin. Pregnancy and lactation.\n\nMode of action: Glucosamine: May reduce effect of antidiabetic agents, doxorubicin, etoposide, tenoposide. May enhance anticoagulant activity of warfarin.\n\nPregnancy category: C\n\nInteraction: Glucosamine: May reduce effect of antidiabetic agents, doxorubicin, etoposide, tenoposide. May enhance anticoagulant activity of warfarin.
Glycerine .75 ml + Liquid Sugar 1.93 ml	\n\n\tEskayef Bangladesh Ltd.\tHunny Syrup   100ml bot 30\n\tIncepta\tHunycof Syrup   100ml 50\n\tRenata\tHonycol Linctus Syrup   100ml bot 35.14\n\tSquare\tNectar Syrup  .75 ml + 1.93 ml/5 ml 100ml bot 40.15\n\tIndication: Dry coughs, Sore throats\n\nDose: Children 3 months â under 1 years, 2.5-5 ml; Children 1-5 years, 5 ml; Children 5 years and over and Adult, 10 ml 3 -4 times daily as required.\n\nContra-indication: Hypersensitivity or intolerance to any of the ingredients.\n\nSide effects: \n\nPrecaution: Diabetics should take note of the carbohydrate content of this product.\nDo not give to children under one year.\nKeep all medicines out of the reach of children.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Glycerine 100 %	\n\n\tIndication: Constipation, Dry skin, Lubrication, Skin care\n\nDose: Apply thoroughly to the affected part or as directed by the physician.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Generally well tolerated. Local skin irritation.\n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Glycerol	\n\n\tSquare\tGlysup Suppository 1.15gm 30's pack 90\n\tSquare\tGlysup Suppository 2.3gm 20's pack 100\n\tIndication: Constipation, Lubrication\n\nDose:  As supp: Children under 2 years: Consult a physician.\nChildren (2 to 6 years): only one 1.15 Suppository per 24 hours or as directed by a physician.\nAdults and Children (From 6 years): only one  2.30 Suppository per 24 hours or as directed by a physician\n\nInsert suppository well up into rectum. Suppository need to melt completely to produce laxative action. \n\nContra-indication: Hypersensitivity.\n\nSide effects:  Local irritation e.g. rectal discomfort and burning sensation.\n\n\nPrecaution: Hypervolaemia, cardiac failure or renal disease, dehydrated patients, DM.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Glycerol 0.2% + Hypromellose 0.36% + Polyethylene Glycol 400 1%	\n\n\tIncepta\tVisitear Eye Drops (200 mg + 360 mg + 1 gm)   \n\tOpso Saline Ltd.\tLubrex Eye Drops (200 mg + 360 mg + 1 gm)   \n\tPopular\tVisin Eye drops  200 mg + 360 mg + 1 gm/1 10ml drop 250\n\tIndication: Dry eye, Red eye, Eye irritation, Eye allergy, Watery eye\n\nDose: 1 to 2 drops in the affected eye(s) up to 4 times daily.  \n\nContra-indication: Eye pain, changes in vision, redness or irritation of the eye worsens or lasts more than 72 hours.\n\n\nSide effects: Pupils may become enlarged temporarily over use may cause more eye redness, feel eye pain.\n\nPrecaution:  If swallowed, get medical help.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Glyceryl Trinitrate (nitroglycerine)	\n\n\tACI\tPactorin TAB dr 10mg 30's pack 180\n\tACI\tPactorin Retard TAB dr 2.6mg 50's pack 201.50\n\tAcme Ltd.\tAngist SR TAB dr 2.6mg 30's pack 120.30\n\tAristopharma\tNitrocard TAB dr 2.6mg 50's pack 200\n\tAristopharma\tNitrocard spray 0.40mg 1's pack 250\n\tBeximco\tNitrosol Spray 400mcg 200 doses unit 225\n\tDrug International Ltd.\tAngicard TAB dr 0.5mg 100's pack 300\n\tDrug International Ltd.\tNidocard Spray 400mcg 200 doses unit 200\n\tDrug International Ltd.\tNidocard Injection 5mg/ml 1's pack 100\n\tDrug International Ltd.\tNidocard RETARD TAB dr 6.4mg 50's pack 350\n\tDrug International Ltd.\tNidocard SR TAB dr 2.6mg 100's pack 400\n\tDrug International Ltd.\tNidocard Spray Spray 0.40mg/dose 1's pack 200\n\tEskayef Bangladesh Ltd.\tGTN SR TAB dr 2.6mg 50's pack 200\n\tHealthcare\tNitrin SR CAP 2.6mg 60's pack 279\n\tHealthcare\tNitrin SR TAB dr 2.6mg  \n\tIncepta\tTrocer Spray Spray 400 mcg / spray 1's pack 225\n\tIncepta\tTrocer 2.6 SR CAP 2.6mg 30's pack 120\n\tIncepta\tTrocer 2.6 SR TAB dr 2.6mg 30's pack 120\n\tMedimet\tNitrodil CAP 2.6mg 50's pack 232.50\n\tMundipharma (Bangladesh) Pvt. Ltd.\tNitrocontin TAB dr 2.6mg 25's pack 134\n\tMundipharma (Bangladesh) Pvt. Ltd.\tNitrocontin TAB dr 6.4mg 25's pack 200\n\tNIPRO JMI Pharma\tNitrogina SR TAB dr 2.6mg  \n\tOpsonin Pharma\tNitrofix SR TAB dr 2.6mg  \n\tOrion Pharma Ltd.\tNitrocap CAP 2.6mg 30's pack 150.60\n\tPopular\tNitrovas SR TAB dr 2.6mg 30's pack 120.62\n\tSquare\tAnril TAB dr 0.5mg 30's pack 90.18\n\tSquare\tAnril SR TAB dr 2.6mg 50's pack 200\n\tSquare\tAnril Spray 400mcg 200 doses unit 215.80\n\tSquare\tAnril Injection 5mg/ml 		 4's pack 301.12\n\tSquare\tGlytrin Mouth Spray 400mcg/dose 1's pack(200 doses) \n\tUnimed & Unihealth Manufacturers Ltd.\tNitro SR TAB dr 2.6mg 30's pack 120\n\tWhite Horse Pharma\tXynocard SR TAB dr 2.6mg 50's pack 150\n\tCity overseas\tNitromint Retard TAB dr 2.6mg 30's pack 147\n\tCity overseas\tNitromint Spray Spray 400mcg 180 doses unit 205\n\tIndication: Angina pectoris, Acute myocardial infarction, Severe hypertension, Pulmonary edema.\n\nDose: Usual dosage for adults and elderly patients:  PO: 1 capsule/tablet: 2 times a day before meal (e.g. at 8 AM & 2 PM, with a daily nitrate-free interval of 10-12 hours). If necessary the dosage may be raised gradually to 2 or 3 capsules/tablets: 2 times daily. But dosage should be individualized depending on the Nitroglycerin sensitivity of the patient, the severity of illness and the occurrence of side-effects. Use in Children: Not recommended for children. Spray: In case of attack 1 or 2 doses should be administered under the tongue to a sitting patient. If necessary, more doses can be given but not more than 3 doses within 15 minutes.  For prevention 1 dose should be applied 5-10 minutes before physical exercise.         Use in Children: Nitroglycerin Spray is not recommended for children.\n\nContra-indication: Hypersensitivity. Severe hypotension, heart failure, marked anaemia, hypertrophic obstructive cardiomyopathy, cerebral haemorrhage or head trauma, low cardiac output secondary to hypovolaemia, inferior MI with right ventricular involvement, raised intracranial pressure. Concomitant use with phosphodiesterase type-5 inhibitors.\n\nSide effects:  Headache, facial flashing, dizziness, nausea, vomiting, sweating, palpitation, sensation of heat, postural hypotension and reflex tachycardia. Large doses can cause vomiting, restlessness, hypotension, syncope, rarely cyanosis and methaemoglobinaemia, impaired respiration, bradycardia. Sublingual Tabs/Spray: Dry mouth, localised burning sensation. Buccal tablets: Delayed dissolution, may be swallowed by mistake. Potentially Fatal: Hypotension, paradoxical bradycardia, impaired respiration, syncope and collapse.\n\nPrecaution: Severe hepatic or renal impairment, hypothyroidism, malnutrition, hypothermia. Cerebrovascular disease, lung disease or cor pulmonale. Pregnancy, lactation, glaucoma, mitral valve prolapse, cardiac tamponade, syncope. Gradual withdrawal in patients who have received prolonged high dose infusions. Avoid prolonged excessive hypotension. Nitrate-free interval is recommended in patients on continuous treatment with nitrates to reduce risk of tolerance.\n\nMode of action: Enhances bioavailability of dihydroergotamine. Glyceryl trinitrate infusion may prolong pancuronium-induced neuromuscular blockade. May reduce the efficacy of heparin, alteplase and noradrenaline when used together. Efficacy of buccal and sublingual preparations may be reduced by drugs that can cause dry mouth due to decreased dissolution. Aspirin and other NSAIDs may reduce the therapeutic response to glyceryl trinitrate.\nPotentially Fatal: Orthostatic hypotension may be produced by combined use of calcium channel blockers, antihypertensives, phenothiazines and TCAs. Alcohol may cause severe hypotension and collapse.\n\nPregnancy category: C\n\nInteraction: Enhances bioavailability of dihydroergotamine. Glyceryl trinitrate infusion may prolong pancuronium-induced neuromuscular blockade. May reduce the efficacy of heparin, alteplase and noradrenaline when used together. Efficacy of buccal and sublingual preparations may be reduced by drugs that can cause dry mouth due to decreased dissolution. Aspirin and other NSAIDs may reduce the therapeutic response to glyceryl trinitrate.\nPotentially Fatal: Orthostatic hypotension may be produced by combined use of calcium channel blockers, antihypertensives, phenothiazines and TCAs. Alcohol may cause severe hypotension and collapse.
Glyceryl Trinitrate 0.4%  (nitroglycerine ) Rectal prep	\n\n\tHealthcare\tNitrin Sublingual Spray 400 mcg/Metered Inhalatio  \n\tIncepta\tRepane Ointment  0.4% 1's pack 200\n\tPopular\tNitrovas Ointment .4 gm/100 gm 30gm pack 130.49\n\tSquare\tRectocare 	 Ointment  0.4% 	 15g 	 65.25 	\n\tIndication: Chronic anal fissure\n\nDose: Rectal Anal fissure As 0.4% oint: Apply 1.5 mg 12 hrly up to 8 wk applied to the anal canal.\n\nGently insert the ointment into the anal canal using the finger. The finger with the ointment must be inserted to the first finger joint (approximately 1 cm) into the anus. Treatment may be continued until the pain goes away, or for up to a maximum 8 weeks. \n\nContra-indication: Do not use Glyceryl Trinitrate 0.4% ointment if the patients:\nare allergic to glyceryl trinitrate or to similar medicines\nsuffer from low blood pressure\nsuffer from heart or blood vessel disorders\nsuffer from closed-angle glaucoma\nsuffer from migraine or recurrent headaches\nsuffer from increased intracranial pressure or high pressure within your skull\nsuffer from anaemia\nare taking any of the following medicines: sildenafil citrate, tadalafil, vardenafil, medicines for angina or heart pain such as glyceryl trinitrate (GTN), isosorbide dinitrate, amyl or butyl nitrite, medicines for high blood pressure or depression (tricyclic anti-depressants), acetyl cysteine or alteplase \n\nSide effects: Headache is the most common side-effect when glyceryl trinitrate 0.4% ointment is used. Other side-effects include dizziness, faintness on standing, light-headedness, blurred vision and tiredness & nausea. \n\nPrecaution: Take special care with Glyceryl Trinitrate 0.4% ointment if patient has:\nliver or kidney disease\nto be given heparin\nhaemorrhoids (piles) and notice more bleeding than usual,\nsevere headaches when using ointment,\nThe ointment may lower blood pressure. Blood pressure is more likely to be lowered if drink alcohol whilst you are using ointment.\nOintment is not indicated for patients under the age of 18 years.\n\nMode of action: Enhances bioavailability of dihydroergotamine. Glyceryl trinitrate infusion may prolong pancuronium-induced neuromuscular blockade. May reduce the efficacy of heparin, alteplase and noradrenaline when used together. Efficacy of buccal and sublingual preparations may be reduced by drugs that can cause dry mouth due to decreased dissolution. Aspirin and other NSAIDs may reduce the therapeutic response to glyceryl trinitrate.\nPotentially Fatal: Orthostatic hypotension may be produced by combined use of calcium channel blockers, antihypertensives, phenothiazines and TCAs. Alcohol may cause severe hypotension and collapse.\n\nPregnancy category: C\n\nInteraction: Enhances bioavailability of dihydroergotamine. Glyceryl trinitrate infusion may prolong pancuronium-induced neuromuscular blockade. May reduce the efficacy of heparin, alteplase and noradrenaline when used together. Efficacy of buccal and sublingual preparations may be reduced by drugs that can cause dry mouth due to decreased dissolution. Aspirin and other NSAIDs may reduce the therapeutic response to glyceryl trinitrate.\nPotentially Fatal: Orthostatic hypotension may be produced by combined use of calcium channel blockers, antihypertensives, phenothiazines and TCAs. Alcohol may cause severe hypotension and collapse.
Glycine 1.5% Irrigation solution	\n\n\tBeximco\tIrigin Irrigation Solution   1000 ml bag 70.80\n\tBeximco\tIrigon Infusion 1.5% 1000ml bot \n\tOpso Saline Ltd.\tGlycine Irrigation Solution   1000 ml bag 80\n\tPopular\tSterisol Irrigation Solution 1.5 gm/100 ml 2000 ml bag 165\n\tIndication: Prostatic or bladder surgery, Orthopedics Surgery\n\nDose: Irrigation solution is administered as drip through the bi-luminal catheter and can be continued as required.\n\nContra-indication: Patients with anuria. \n\nSide effects: Nausea, salivation, electrolyte loss, diuresis, edaema, thirst, dehydration, cardiovascular and pulmonary disorders.\n\nPrecaution: Cardiovuscular disease, impaired renal & liver function.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Glycopyrrolate 0.02%	\n\n\tACI\tGlycolate Injection .2mg/ml 1's pack\n 100\n\tIncepta\tSupotaria Injection 200 mcg/ml  \n\tIndication: Hyperhidrosis, Peptic ulcer, Anesthesia, Sialorrhea, Cerebral palsy, Reversal of neuromuscular blockade\n\nDose: Parenteral\nReduction of secretions\nAdult: Preoperative: 4 mcg/kg via IM admin 30-60 minutes before procedure. Intraoperative: 0.1 mg via IV admin, repeat at 2-3 minute intervals when needed. Max: 400 mcg/dose.\nChild: Preoperative: IM admin: <2 yr: 4-9 mcg/kg; >2 yr: 4 mcg/kg, dose to be given 30-60 minutes before procedure. Intraoperative: IV admin: 4 mcg/kg (Max: 0.1 mg); repeat at 2-3-minute intervals as needed.\nMax Dosage: Adult: 400 mcg/dose. Child >1 mth: 200 mcg/dose.\nIntravenous\nReversal of neuromuscular blockade\nAdult: 200 mcg for each 1 mg of neostigmine or 5 mg of pyridostigmine. Alternatively, 5-15 mcg/kg with 50 mcg/kg neostigmine with 25-70 mcg/kg of neostigmine or 0.1-0.3 mg/kg of pyridostigmine.\nChild: 10 mcg/kg with 50 mcg/kg neostigmine.\nParenteral\nPeptic ulcer\nAdult: 0.1-0.2 mg 3-4 times daily via IM/IV admin.\n\nContra-indication: Hypersensitivity. Glaucoma; obstructive uropathy; obstructive GI diseases; intestinal atony; paralytic ileus; pyloric stenosis; myasthenia gravis. Unstable CV status in acute haemorrhage. Injectable not recommended in new borns <1 mth if benzyl alcohol is present in the preparation.\n\nSide effects: Xerostomia; loss of taste, nausea, vomiting, constipation, reduced sweating; urinary hesitancy and retention; blurred vision; cycloplegia; increased ocular tension; tachycardia; palpitation; headache, anxiety, bloated feeling, impotence, skin reactions.\nPotentially Fatal: Severe anaphylaxis.\n\nPrecaution: Pregnancy, lactation. CV disease, hyperthyroidism, hepatic or renal impairment. Enlarged prostate, diarrhoea, fever. May cause ileus or megacolon in patients with ulcerative colitis. Children and elderly.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Gramacidin + Neomycin + Polymixin B (Eye prep)	\n\n\tNipa\tPolymycin Eye Drops   5  ml drop 30.35\n\tOpso Saline Ltd.\tPolymix G Eye Drops   5  ml drop 30.11\n\tIndication: Conjunctivitis, Keratitis, Blepharitis, Superficial bacterial infections, Corneal ulcer, Keratoconjunctivitis\n\nDose: Instill one or two drops into the affected eye every 4 hours for 7 to 10 days. In severe infections, dosage may be increased to as much as two drops every hour.\n\nContra-indication: This product is contraindicated in those persons who have shown hypersensitivity to any of its components.\n\nSide effects: Adverse reactions have occurred with the anti-infective components of this product. The exact incidence is not known. Reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema . More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely.\n\nLocal irritation on instillation has also been reported.\n\nPrecaution: As with other antibiotic preparations, prolonged use of this product may result in overgrowth of nonsusceptible organisms including fungi. If superinfection occurs, appropriate measures should be initiated.\n\nBacterial resistance to this product may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.\n\nThere have been reports of bacterial keratitis associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface .\n\nAllergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Gramicidin  + Neomycin Sulphate  + Nystatin  + Triamcinolone Acetonide (Topical)	\n\n\tAmico Ltd.\tMonacom Cream   5gm tube/10gm tube 30/40\n\tDrug International Ltd.\tFungistat Cream   10gm tube 40\n\tDrug International Ltd.\tFungistat Ointment   5gm tube/10gm tube 18.90/ 40\n\tG. A. Company Ltd.\tGanacomb Cream   5gm tube 18.80\n\tPharmasia Ltd.\tTetracomb Cream   5gm tube/10gm tube 22/35\n\tPharmasia Ltd.\tTetracomb Ointment   5gm tube/10gm tube 22/35\n\tIndication: Infected eczema, Skin infection, Corticosteriod-responsive dermatoses, Cuteneous candidiasis with superficial bacterial infection.\n\nDose: Apply a thin layer of film to the affected areas 2-3 times daily. \n\nContra-indication: Should not be used for prolonged period of time. Tuberculous, viral lesions of the skin (e.g. herpes simplex and varicella); fungal lesions not susceptible to nystatin, facial rosacea, acne vulgaris or perioral dermatitis. \n\nSide effects: Prolonged use may cause sensitivity reactions, impaired wound healing, thinning of skin, striae, telangiectasia, hirsutism, hypothalamic-pituitary-adrenal axis suppression, Cushing's syndrome. \n\nPrecaution: Patients with established hearing loss. Avoid occlusive dressing and prolonged or recurrent use. Avoid contact with eyes or mucous membranes. If there is no clinical improvement after 7 days, discontinue use as the infection may be masked by the steroid. Limit use to 5 days if used on the face or on children ?1 yr. Use with caution and sparingly on inflamed or damaged skin (e.g extensive burns, trophic ulceration). Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Granisetron	\n\n\tSquare\tNaurif Injection 1mg/ml 5 amps pack 240.93\n\tSquare\tNaurif TAB dr 1mg 20's pack 562.06\n\tIndication: Nausea and vomiting,Chemotherapy-induced nausea and vomiting,Post-operative nausea and vomiting\n\nDose: Adult: PO Nausea and vomiting associated with cancer chemotherapy 1-2 mg w/in 1 hr before start of chemotherapy, then 2 mg/day. Nausea and vomiting associated w/ radiotherapy 2 mg/day, w/in 1 hr of irradiation. \n\nIV Nausea and vomiting associated with cancer chemotherapy 3 mg before the start of chemotherapy. May repeat up to twice w/in 24 hr. Doses should be at least 10 mins apart. Max: 9 mg/day. \n\nPost-op nausea and vomiting 1 mg, to be completed before induction of anesth. May be given up to twice daily for treatment.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Headache; sensation of flushing; constipation; hypersensitivity reactions; chest pain; CV disturbances; dizziness; transient visual disturbances. Rarely, liver disorders; development of seizures; extrapyramidal reactions.\n\nPrecaution: Subacute intestinal obstruction or ileus. Moderate to severe hepatic impairment. Congenital long QT syndrome or other risk factors for QT prolongation (e.g. electrolyte abnormalities and cumulative high-dose anthracycline therapy). Pregnancy, lactation.\n\nMode of action: Phenobarbital may induce metabolism of granisetron.\n\nPregnancy category: B\n\nInteraction: Phenobarbital may induce metabolism of granisetron.
Griseofulvin	\n\n\tACI\tFulcinex TAB dr 500mg 100's pack 556\n\tAlbion Ltd.\tGriseofulvin TAB dr 500 mg 100's pack \n\tAlbion Ltd.\tGriseofulvin Suspension 2.5 mg/ 100 ml 60 ml \n\tAmbee\tAfuvin TAB dr 500mg 100's pack 532\n\tBristol Pharma Ltd.\tGriseofulvin FP TAB dr 500mg 100's pack 500\n\tGlaxoSmithKline Bangladesh Ltd.\tGrisovin FP TAB dr 500mg 100's pack 558.33\n\tGonoshasthaya\tG G G Vin TAB dr 500mg 50's pack 201\n\tModern\tGrisofulvin M TAB dr 500mg 100's pack 694\n\tNipa\tGrovin TAB dr 500mg 100's pack 556\n\tZenith\tGrisozen TAB dr 500mg 100's pack 334\n\tIndication: Dermatophytosis\n\nDose: Adult: PO 0.5-1 g/day. Hair and skin infecions: 2-8 wk. Fingernail infections: 6 mth. Toenail infections: 12 mth or more.\n\nChild: 10 mg/kg daily.\n\nContra-indication: Severe liver disease; porphyria; monilial infection; SLE; pregnancy.\n\nSide effects: Oral thrush; GI distress, taste perversion; dizziness, confusion, headache, depression, insomnia, fatigue; peripheral neuritis, photosensitivity; skin rashes, urticaria, erythema multiforme; leucopenia, proteinuria.\nPotentially Fatal: Hepatotoxicity; angioedema.\n\nPrecaution: Lactation; may impair ability to drive or operate machinery; avoid exposure to intense sunlight or artificial light. Regular monitoring of the renal, hepatic and blood tests should be done.\n\nMode of action: Antagonises oral anticoagulants and oral contraceptives. Decreased GI absorption with phenobarbital. Reduced plasma concentrations with enzyme inducers e.g. phenylbutazone and hypnotics.\nPotentially Fatal: Enhances effects of alcohol and causes disulfiram-like reaction.\n\nPregnancy category: C\n\nInteraction: Antagonises oral anticoagulants and oral contraceptives. Decreased GI absorption with phenobarbital. Reduced plasma concentrations with enzyme inducers e.g. phenylbutazone and hypnotics.\nPotentially Fatal: Enhances effects of alcohol and causes disulfiram-like reaction.
Guaiphenesin + Pseudoephedrine Hydrochloride + Triprolidine Hydrochloride	\n\n\tACI\tResyp Syrup   100ml 31\n\tACI\tTyrex Syrup 100mg+30mg+1.25mg/5ml 100ml bot 55.17\n\tAcme Ltd.\tCofrid Syrup   100ml bot 40.15\n\tAmbee\tCodex Syrup   100ml bot 30.46\n\tAmico Ltd.\tKoftex Syrup   100ml bot 50\n\tBeximco\tTripec Syrup   100ml bot 35\n\tBio Pharma Ltd.\tKofed Syrup   100ml bot 35.13\n\tCentral.\tCofdil Surup Syrup   100ml bot 50\n\tDelta Pharma\tExodel Syrup   60ml bot/100ml bot 22/30\n\tDoctor's Chemicals Works Ltd.\tTriphan Syrup   100ml bot 50\n\tEdruc Ltd.\tE Cof Syrup   100ml bot 50\n\tEskayef Bangladesh Ltd.\tExpoten Syrup   100ml bot 50\n\tG. A. Company Ltd.\tAntuss Syrup   100ml bot 40\n\tGeneral\tCofnil Syrup   100ml bot 35.13\n\tGlaxoSmithKline Bangladesh Ltd.\tActifed Syrup   100ml bot 40\n\tHudson\tCofdil Syrup   100ml bot\n 50\n\tHudson\tCofson Syrup  100ml bot 50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAbex Syrup   100ml bot 50\n\tIncepta\tAquaphen Syrup   100ml bot 42\n\tKemiko\tLurex Syrup   100ml bot 50\n\tKumudini Pharma Ltd.\tGPT-Cough Syrup   100ml bot 45\n\tMedicon\tTrinil Syrup   100ml bot 45\n\tMedimet\tCodyl Syrup   100ml bot 40\n\tMillat\tColdex Syrup   100ml bot 50\n\tNavana\tTridex Syrup   100ml bot 50.19\n\tNipa\tSmile Syrup   100ml bot 35\n\tNovo Healthcare and Pharma Ltd.\tExitra Syrup  100ml bot 35\n\tOpsonin Pharma\tCophilex Syrup   100ml bot 30\n\tOrion Pharma Ltd.\tTussin Syrup   100ml bot 30\n\tPharmadesh Ltd.\tCophyl Syrup   100ml bot 48\n\tPopular\tEzykof Syrup (100 mg + 30 mg + 1.25 mg  \n\tRenata\tTopex Syrup   100ml bot 30.34\n\tSharif\tPhendyl Syrup (100 mg + 30 mg + 1.25 mg  \n\tSomatec\tTussy Syrup   100ml bot 35.13\n\tSquare\tTusca Syrup  100 mg + 30 mg + 1.25 mg 100ml bot 55\n\tSupreme\tTriex Syrup   100ml bot 32\n\tSyntho Ltd.\tEfin Syrup   100ml bot 35\n\tVirgo\tKofta Syrup (100 mg + 30 mg + 1.25 mg  \n\tZenith\tTusscoff Syrup   100ml bot 30\n\tIndication: Pneumonia, Productive cough, Allergic rhinitis, Sneezing, Respiratory tract disorders, Cough & runny nose, Nasal congestion\n\nDose: Adult and Children over 12 years: 10 ml (2 teaspoonful) three times a day.\nChildren 6-12 years: 5 ml (1 teaspoonful) three times a day.\nChildren 2-5 years: 2.5 ml (1/2 teaspoonful) three times a day.\n\n\nContra-indication: Patients with a known hypersensitivity to guaiphenesin, psedoephedrine or triprolidine. Contraindicated in persons under treatment with monoamine oxidase inhibitors within 2 weeks of stopping such treatment.\nPatients with severe hypertension or severe coronary artery disease\n\nSide effects: Central nervous system (CNS) depression or excitation may occur. Sleep disturbance and rarely hallucination have been reported. Skin rashes, tachycardia, dryness of mouth, nose and throat have occasionally been reported. Urinary retention has been reported occasionally in men receiving pseudoephedrine; prostatic enlargement could have been an important predisposing factor.\n\nPrecaution:  It may cause drowsiness and impair performance in tests of auditory vigilance. It may also impair the patients ability to drive and also to use machineries. So, driving and operation of machineries should be avoided during treatment with Aquaphen. Although there are no objective data, Avoid the concomitant use of alcohol or other centrally acting sedatives.\nAlthough Pseudoephedrine has virtually no pressor effect in patients with normal blood pressure, Aquaphen should be used with caution in patients taking antihypertensive agents, tricyclic antidepressants or other sympathomimetic agents such as decongestant, appetite suppressants and amphetamine-like psychostimulants.  It effects   on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment.\nAs with other sympathomimetic agents, caution should be exercised in patients with hypertension, heart disease, diabetes, hyperthyroidism, elevated intraocular pressure and prostatic enlargement.  It should not be used for persistent or chronic cough such as occurs with smoking, asthma or emphysema or where cough is accompanied by excessive secretions unless directed by a physician.\n\nMode of action: Sympathomimetics eg decongestants, TCAs, appetite suppressants, amphetamine-like psychostimulants; may increase BP w/ MAOIs. Bretylium, bethanidine, guanethidine, debrisoquine, methyldopa, ?- & ?-adrenergic blocker; furazolidone, alcohol, sedatives.\n\nPregnancy category: C\n\nInteraction: Sympathomimetics eg decongestants, TCAs, appetite suppressants, amphetamine-like psychostimulants; may increase BP w/ MAOIs. Bretylium, bethanidine, guanethidine, debrisoquine, methyldopa, ?- & ?-adrenergic blocker; furazolidone, alcohol, sedatives.
Halazone	\n\n\tSonear Ltd.\tHalotab TAB dr 15mg 100's pack 77\n\tSonear Ltd.\tHalotab TAB dr 7.5mg 100's pack 51\n\tSonear Ltd.\tHalotab TAB dr 50mg 100's pack 154\n\tIndication: Water disinfection,Water purification\n\nDose: Dissolve 7.5 mg tablet in 1.5 litres, 15 mg tablet in 3 litres, & 50 mg tablet in 10 litres drinking water and use half to 1 hour after preparation.\n\nContra-indication: Hypersensitivity.\n\nSide effects: \n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Halcinonide 0.1% Topical	\n\n\tAmbee\tCinon 0.1% Cream   5gm tube 16.07\n\tG. A. Company Ltd.\tZemalog 0.1% Cream   5gm tue 18\n\tJayson\tDermalog 0.1% Cream   10gm tube 30.45\n\tIndication: Psoriasis, Eczema, Skin infection, Corticosteriod-responsive dermatoses\n\nDose: A thin layer should be applied to the affected skin 2-3 times daily or as directed by physician, and rub in gently and completely. Treatment beyond two consecutive weeks is not recommended.\n\nContra-indication: Contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.\n\nSide effects: The following adverse effects have been reported infrequently with topical corticosteroids. These reactions include burning, itching, dryness, folliculitis acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin atrophy, secondary infections, striae and miliaria.\n\nPrecaution: Systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitaryadrenal (HPA) axis suppression, manifestations of cushing's syndrome, hyperglycemia, and glucosuria. Patients receiving large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Halobetasol Propionate 0.05% Topical	\n\n\tACI\tHalocort 0.05% Ointment  10g  90.27\n\tACI\tHalocort Cream 0.05% 10g tube 90.27\n\tIncepta\tUlticort Cream .05% 15 gm tube \n\tIncepta\tUlticort Ointment .05% 30 gm tube 120\n\tPharmasia Ltd.\tHebasol Ointment   10gm tube 90\n\tSquare\tHalobet Ointment  50 mg/100 gm 10gm tube 90\n\tSquare\tHalobet Cream Cream  50 mg/100 gm 10gm tube 90\n\tIndication: Psoriasis, Eczema, Corticosteroid-responsive dermatoses\n\nDose: A thin layer should be applied to the affected skin once or twice daily, as directed by physician, and rub in gently and completely. \n\nTreatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. \n\nUse in children under 12 years of age is not recommended. Halobetasol Propionate Cream should not be used with occlusive dressings. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.\n\nUse in pediatric patients\nSafety and effectiveness of Halobetasol Propionate cream & ointment in paediatric patients have not been established. Paediatric patients are at greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids.\n\nContra-indication: Halobetasol Propionate Cream/Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.\n\nSide effects: The following adverse effects have been reported infrequently with topical corticosteroids. These reactions include burning, itching, dryness, folliculitis acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin atrophy, secondary infections, striae and miliaria.\n\nPrecaution: Systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitaryadrenal (HPA) axis suppression, manifestations of cushing's syndrome, hyperglycemia, and glucosuria. Patients receiving large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Haloperidol	\n\n\tAlbion Ltd.\tHaloperidol TAB dr 5 mg 100's pack \n\tAmbee\tPerol Injection 5mg/ml 10 amps pack 100.40\n\tAmbee\tPerol TAB dr 5mg 100's pack 51\n\tGeneral\tPerigen TAB dr 5mg 100's pack 100\n\tGeneral\tPerigen IM Injection 5mg/ml 10's pack 120\n\tIncepta\tHalopid Injection 5mg/ml 10's pack 108\n\tIncepta\tHalopid 5 TAB dr 5mg 100's pack 100\n\tOpsonin Pharma\tHalop TAB dr 5mg 100's pack 43\n\tSquare\tPeridol TAB dr 5mg 100's pack 99.75\n\tIndication: Schizophrenia, Delirium, Hiccups, Acute psychosis, Hyperactivity, Aggression, Agitation and confusion, Tic disorders, Tourette syndrome, Chorea, Nausea and vomiting, Dementia.\n\nDose: Adult: PO Psychoses 0.5-5 mg 2-3 times/day, up to 100 mg/day in severe cases. Maintenance: 3-10 mg/day. \n\nSevere tics; Tourette's syndrome Initial: 0.5-1.5 mg 3 times/day, up to 10 mg/day in Tourette's syndrome. \n\nAdjunct in severe anxiety or behavioral disturbances 0.5 mg twice daily. \n\nRestlessness and confusion 1-3 mg 8 hrly. \n\nIntractable hiccup 1.5 mg 3 times/day. \n\nIntramuscular:\n\nAcute psychosis 2-10 mg hrly or 4-8 hrly until symptoms are controlled. Max: 18 mg/day. \n\nNausea and vomiting 0.5-2 mg/day. \n\n\n\nContra-indication: Severe toxic CNS depression; preexisting coma; Parkinson's disease; lactation.\n\nSide effects: Tardive dyskinesia; extrapyramidal reactions. Anxiety, drowsiness, depression, anorexia, transient tachycardia, postural hypotension, leukopenia; anticholinergic side effects.Potentially Fatal: Neuroleptic malignant syndrome\n\nPrecaution: Parkinsonism; epilepsy, allergy, angle-closure glaucoma, benign prostatic hyperplasia; severe cardiac or hepatic disease; extremes in temp (hot and cold weather); presence of acute infections or leucopenia; hyperthyroidism; pregnancy, elderly, children. Patients receiving anticoagulants. Discontinue upon signs of neurological toxicity in patients taking haloperidol and lithium.\n\nMode of action: Carbamazepine and rifampicin reduce plasma concentrations. Symptoms of CNS depression may be enhanced by CNS depressants e.g. alcohol, hypnotics, general anaesthetics, anxiolytics and opioids. May reduce antihypertensive action of guanethidine. May increase risk of arrhythmia when used with drugs that prolong QT interval or diuretics that can cause electrolyte imbalance. May increase plasma levels of haloperidol when used with clozapine or chlorpromazine.\nPotentially Fatal: Increases lithium blood levels and may predispose to neuroleptic malignant syndrome.\n\nPregnancy category: C\n\nInteraction: Carbamazepine and rifampicin reduce plasma concentrations. Symptoms of CNS depression may be enhanced by CNS depressants e.g. alcohol, hypnotics, general anaesthetics, anxiolytics and opioids. May reduce antihypertensive action of guanethidine. May increase risk of arrhythmia when used with drugs that prolong QT interval or diuretics that can cause electrolyte imbalance. May increase plasma levels of haloperidol when used with clozapine or chlorpromazine.\nPotentially Fatal: Increases lithium blood levels and may predispose to neuroleptic malignant syndrome.
Halothane 0.187%	\n\n\tACI\tHalosin Solution  1.87g/ml 250ml pack 1890.45\n\tAstrazeneca Pharmaceutical company\tFluothane Solution  250ml bot \n\tIndication: General anesthesia\n\nDose: Adult: Inhalation Induction: 2-4% v/v in O2 or mixtures of nitrous oxide and O2. Maintenance: 0.5-2% v/v depending on the flow rate used.\n\nContra-indication: Obstetrics; malignant hyperthermia; porphyria.\n\nSide effects: Bradycardia, hypotension, cardiac arrhythmias, respiratory depression, shivering during recovery (occasional), hepatitis (multiple exposure).\nPotentially Fatal: Fulminant hepatic failure, malignant hyperpyrexia and pulmonary oedema.\n\nPrecaution: Phaeochromocytoma; poor cardiac/liver function, early pregnancy. Premedication with atropine is recommended to decrease vagal tone and prevent bradycardia and severe hypotension. May trigger malignant hyperthermia and increase intracranial pressure. Increased risk of hyperkalaemia in paediatrics with underlying neuromuscular disorders. May reduce hepatic, renal and splenic blood flow.\n\nMode of action: Adrenaline, other sympathomimetics, and theophylline can produce cardiac arrhythmias. Morphine and chlorpromazine may increase depressant effects of halothane on respiration. Increased risk of phenytoin intoxication when used together. Midazolam may potentiate the anaesthetic action of halothane.\nPotentially Fatal: Dopaminergics increase the risk of ventricular arrhythmias. Neuromuscular blocking drugs are potentiated by halothane.\n\nPregnancy category: C\n\nInteraction: Adrenaline, other sympathomimetics, and theophylline can produce cardiac arrhythmias. Morphine and chlorpromazine may increase depressant effects of halothane on respiration. Increased risk of phenytoin intoxication when used together. Midazolam may potentiate the anaesthetic action of halothane.\nPotentially Fatal: Dopaminergics increase the risk of ventricular arrhythmias. Neuromuscular blocking drugs are potentiated by halothane.
Heparin Sodium	\n\n\tBeacon\tHeparon Injection 5000IU/ml  5ml vial X 1's pack 397.72\n\tLeo Pharmaceutical Products,Denmark\tHeparin Leo Injection 5000IU/ml  5ml vial X 1's pack 639 	\n\tRotexmedica GmbH, Germany\tHeparin Rotex Injection  5000IU/ml 5ml vial X 1's pack 300\n\tIndication: Atrial fibrillation,  Acute coronary syndrome, Unstable angina, Pulmonary embolism, Thromboembolism, Deep-vein thrombosis, Cardiopulmonary bypass, Hemofiltration, Peripheral arterial embolism\n\nDose: Subcutaneous\nVenous thromboembolism\nAdult: 15,000 u injected every 12 hr.\nChild: 250 u/kg every 12 hr.\n\nProphylaxis of postoperative venous thromboembolism\nAdult: 5000 u given 2 hr before surgery then every 8-12 hr for 7 days or until the patient is ambulant, may increase to 10,000 u every 12 hr during the 3rd trimester of pregnancy.\n\nProphylaxis of mural thrombosis\nAdult: 12,500 u every 12 hr for at least 10 days.\n\nIntravenous\nUnstable angina\nAdult: 5000 u (10,000 u in severe pulmonary embolism) IV loading dose followed by 1000-2000 u/hr continuous infusion. Alternatively, intermittent inj of 5000-10,000 u every 4-6 hr.\nChild: Administer a lower loading dose. Maintenance: 15-25 u/kg/hr continuous infusion.\n\nVenous thromboembolism\nAdult: 5000 u (10,000 u in severe pulmonary embolism) IV loading dose followed by 1000-2000 u/hr continuous infusion. Alternatively, intermittent inj of 5000-10,000 u every 4-6 hr.\nChild: Administer a lower loading dose. Maintenance: 15-25 u/kg/hr continuous infusion.\n\nPeripheral arterial embolism\nAdult: 5000 u (10,000 u in severe pulmonary embolism) IV loading dose followed by 1000-2000 u/hr continuous infusion. Alternatively, intermittent inj of 5000-10,000 u every 4-6 hr.\nChild: Administer a lower loading dose. Maintenance: 15-25 u/kg/hr continuous infusion.\n\nProphylaxis of re-occlusion of the coronary arteries following thrombolytic therapy in myocardial infarction\nAdult: 5000 u IV followed by 1000 u/hr IV with alteplase.\n\nContra-indication: Patients predisposed to active bleeding including thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, haemorrhagic blood disorders, bacterial endocarditis, severe hypertension, oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage, abdominal or thoracic bleeding into closed space, severe traumatic bleed, hepatic, renal, splenic or arterial injury, severe haemostatic defect, arterial thrombosis with heparin-associated thrombocytopenia. IM admin.\n\nSide effects: Slight fever, headache, chills, nausea, vomiting, constipation, epistaxis, bruising, slight haematuria, skin necrosis (SC inj), osteoporosis, alopecia. Hypersensitivity reactions include urticaria, conjunctivitis, rhinitis, asthma, angioedema and anaphylactic shock. Priapism.\nPotentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding.\n\nPrecaution: Monitor platelet counts. Discontinue treatment if thrombocytopenia occurs. Hypersensitivity, elderly, pregnancy.\n\nMode of action: Enhanced anticoagulant effect w/ other drugs affecting platelet function or the coagulation system (e.g. platelet aggregation inhibitors, thrombolytic agents, salicylates, NSAIDs, vit K antagonists, dextrans, activated protein C). Decreased anticoagulant effect w/ gyceryl trinitrate infusion. Increased risk of hyperkalaemia w/ ACE inhibitors or angiotensin II antagonists.\n\nPregnancy category: C\n\nInteraction: Enhanced anticoagulant effect w/ other drugs affecting platelet function or the coagulation system (e.g. platelet aggregation inhibitors, thrombolytic agents, salicylates, NSAIDs, vit K antagonists, dextrans, activated protein C). Decreased anticoagulant effect w/ gyceryl trinitrate infusion. Increased risk of hyperkalaemia w/ ACE inhibitors or angiotensin II antagonists.
Homatropine Hydrobromide	\n\n\tAristopharma\tMatropin Drops 2gm/100ml 10ml bot 56\n\tNipa\tHemomin 2% Drops 2gm/100ml 10 ml drop 56.55\n\tOpso Saline Ltd.\tHomatropine OSL 2% Drops 2gm/100ml 10 ml drop 29.11\n\tReman Drug Ltd.\tHomatropine 2% Drops 2gm/100ml 10 ml drop 56.55\n\tIndication: Mydriasis and cycloplegia for refraction, Dilatation of pupil\n\nDose: Adult: Ophth Mydriasis and cycloplegia for refraction As 2% soln: Instill 1-2 drops immediately before procedure, repeat at 5-10 min intervals if needed. Uveitis As 2% soln: Instill 1-2 drops 2-3 times/day, up to 3-4 hrly if needed.\n\nChild: 3 mth- 2 yr: instill 1 drop of 0.5% soln once daily or on alternate days. >2 yr: instill 1 drop of 1% or 2% soln bid.\n\nContra-indication: Acute haemorrhage; narrow-angle glaucoma; primary glaucoma; predisposition to glaucoma; hypersensitivity.\n\nSide effects: Blurred vision; photophobia; increased intraocular pressure. Prolonged use may cause local irritation characterized by follicular conjunctivitis, vascular congestion, oedema, exudate and eczematoid dermatitis.\n\nPrecaution: Hypertension; cardiac disease; unstable CV status in acute haemorrhage; increased intraocular pressure; obstructive uropathy; paralytic ileus; ulcerative colitis; elderly; infants; young child; pregnancy. Finger pressure should be applied on the lachrymal sac for 1-2 minutes after instillation to reduce systemic absorption.\n\nMode of action: Effects may be increased by drugs with antimuscarinic effect such as; some antihistamines; phenothiazines; antipsychotics; TCAs; MAOIs or parasympathomimetics.\n\nPregnancy category: C\n\nInteraction: Effects may be increased by drugs with antimuscarinic effect such as; some antihistamines; phenothiazines; antipsychotics; TCAs; MAOIs or parasympathomimetics.
Hydrochlorothiazide	\n\n\tIncepta\tAcuren TAB dr 25mg 100's pack 70\n\tIncepta\tAcuren TAB dr 50mg 100's pack 100\n\tPacific\tHypezide TAB dr 50mg 100's pack 100\n\tUnimed & Unihealth Manufacturers Ltd.\tHtz TAB dr 25mg 100's pack 70\n\tIndication: Hypertension, Congestive heart failure, Oedema, Diabetes insipidus, Renal tubular acidosis\n\nDose: Oral\nHypertension\nAdult: Initially, 12.5 mg, may increase to 25-50 mg once daily as necessary either alone or w/ other antihypertensives.\nChild: <6>2-12 yr 1-2 mg/kg/day in 1-2 divided doses Max: 100 mg daily.\nElderly: 12.5-25 mg once daily, titrate as necessary in increments of 12.5 mg.\nOedema associated w/ heart failure Usual: 25-100 mg/day in the morning, may reduce based on response. Severe: Up to 200 mg/day. \nChild: <6>2-12 yr 1-2 mg/kg/day in 1-2 divided doses Max: 100 mg daily.\nElderly: 12.5-25 mg once daily, titrate as necessary in increments of 12.5 mg.\n\nNephrogenic diabetes insipidus Initial: Up to 100 mg/day.\n\nContra-indication: Severe hepatic and renal impairment, Addison's disease, preexisting hypercalcaemia, anuria, sulphonamide allergy. Pregnancy, lactation.\n\nSide effects: Volume depletion and electrolyte imbalance, dry mouth, thirst, lethargy, drowsiness, muscle pain and cramps, hypotension, hypersensitivity reactions e.g. rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence, hyperglycaemia; anorexia, gastric irritation, nausea, vomiting, constipation, diarrhoea, sialadenitis, dizziness, raised Ca concentration.\nPotentially Fatal: Hypersensitivity reactions.\n\nPrecaution: Existing electrolyte disturbances, hepatic cirrhosis, severe heart failure, oedema, elderly, renal impairment. Monitor for signs of fluid and electrolyte disturbance. Hepatic impairment, DM, gout, hyperlipidaemia, hypercalcaemia, hyperuricaemia; ECG: LVH and/or ventricular ectopics (extrasystoles). May exacerbate or activate SLE in susceptible patients.\n\nMode of action: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.\n\nPregnancy category: B\n\nInteraction: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
Hydrochlorothiazide + Irbesartan	\n\n\tOpsonin Pharma\tArbitain Plus 75 TAB dr   30's pack 180.90\n\tOpsonin Pharma\tArbitan PLUS 150 TAB dr   30's pack 360\n\tOpsonin Pharma\tArbitan Plus 300 TAB dr   20's pack 482\n\tUnimed & Unihealth Manufacturers Ltd.\tCavazide 150/12.5 TAB dr   30's pack 360\n\tUnimed & Unihealth Manufacturers Ltd.\tCavazide 300/12.5 TAB dr   10's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tCavazide 75/12.5 TAB dr   30's pack 180\n\tIndication: Diabetic nephropathy, Hypertension\n\nDose: Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.\n\nContra-indication: Hypersensitivity; pregnancy and lactation.\n\nSide effects: Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.\n\nPrecaution: Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.\n\nMode of action: Other antihypertensives, lithium, K-sparing diuretics, K supplements, salt substitutes containing K. CNS depressants, antidiabetics, cholestyramine & colestipol resins, corticosteroids, ACTH, digitalis glycosides, antiarrhythmics, NSAIDs, tubocurarine, antigout medications, Ca salts. Alcohol; ?-blockers, diazoxide, atropine, beperiden, amantadine, cyclophosphamide, methotrexate.\n\nPregnancy category: D\n\nInteraction: Other antihypertensives, lithium, K-sparing diuretics, K supplements, salt substitutes containing K. CNS depressants, antidiabetics, cholestyramine & colestipol resins, corticosteroids, ACTH, digitalis glycosides, antiarrhythmics, NSAIDs, tubocurarine, antigout medications, Ca salts. Alcohol; ?-blockers, diazoxide, atropine, beperiden, amantadine, cyclophosphamide, methotrexate.
Hydrochlorothiazide + Losartan Potassium	\n\n\tACI\tRosatan H 12.5/50 TAB dr   50's pack 301\n\tACI\tRosatan H 25/12.5 TAB dr   50's pack 201\n\tAcme Ltd.\tLosart Plus 100/12.50 TAB dr   30's pack 360\n\tAcme Ltd.\tLosart PLUS 12.5/50 TAB dr   30's pack 180.60\n\tAexim\tHypanil TAB dr  30's pack 150\n\tAlbion Ltd.\tLosapot-H TAB dr 12.5 mg + 50 mg  \n\tAlbion Ltd.\tLosartan-50 Plus TAB dr 50 mg + 12.5 mg 30's pack \n\tAlco Pharma\tLosa 50 Plus TAB dr   30's pack 240\n\tAmbee\tLotas Plus TAB dr  30's pack 150.60\n\tAristopharma\tOsartan HZ 12.5/50 TAB dr   30's pack 180\n\tAsiatic Ltd.\tArbium Plus 100/12.50 TAB dr   30's pack 300\n\tAsiatic Ltd.\tArbium Plus 100/25 TAB dr   30's pack 300\n\tAsiatic Ltd.\tArbium Plus 50/12.5 TAB dr   30's pack 300\n\tBeacon\tCardisan Plus TAB dr   30's pack 195\n\tBeximco\tProsan HZ 12.5/100 TAB dr   30's pack 270\n\tBeximco\tProsan HZ 12.5/50 TAB dr   30's pack 180\n\tBeximco\tProsan HZ 25/100 TAB dr   30's pack 300\n\tBio Pharma Ltd.\tLopo Plus TAB dr   30's pack 240\n\tChemist Ltd.\tAngitan Plus TAB dr 12.5 mg + 50 mg  \n\tConcord\tAcusan Plus TAB dr   30's pack\n 240\n\tDelta Pharma\tAnin Plus TAB dr   20's pack 120\n\tDelta Pharma\tAnin 50 Plus TAB dr   20's pack 120\n\tDrug International Ltd.\tLosardil Plus 100/25 TAB dr   20's pack 200\n\tDrug International Ltd.\tLosardil Plus 100/12.5 TAB dr 12.5 mg + 100 mg  20's pack 180\n\tDrug International Ltd.\tLosardil Plus TAB dr 25 mg + 100 mg  \n\tDrug International Ltd.\tLosardil H PLUS TAB dr 12.5 mg + 25 mg  \n\tEskayef Bangladesh Ltd.\tCardoplus TAB dr   20's pack 160\n\tEskayef Bangladesh Ltd.\tCardoplus 12.5/50 TAB dr   20's pack 120\n\tGeneral\tAnreb PLUS 12.5/50 TAB dr  12.5 mg + 50 mg 30's pack 180.60\n\tGeneral\tAnreb PLUS 100 TAB dr 12.5 mg + 100 mg 20's pack 200.80\n\tGlobe\tLok-50 Plus TAB dr  30's pack 180\n\tHealthcare\tLosacor PLUS 12.5/50 TAB dr   30's pack 195\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLosium PLUS 12.5/50 TAB dr   30's pack 195\n\tIncepta\tOsartil 100/12.5 TAB dr  100 mg + 12.5 mg 30's pack 360\n\tIncepta\tOsartil 50 PLUS TAB dr  50 mg + 12.5 mg 50's pack 400\n\tJayson\tParten Plus TAB dr   30's pack 180.60\n\tLabaid\tPreslo-H TAB dr  3x10's pack 240\n\tLeon\tRenosart Plus TAB dr 12.5 mg + 50 mg  \n\tMedimet\tLosarcar PLUS 12.5/50 TAB dr   50's pack 300\n\tNavana\tPartilos Plus TAB dr   30's pack 180\n\tNavana\tPertilos Plus TAB dr  30's pack 180\n\tNavana\tPertilos TAB dr 12.5 mg + 50 mg  \n\tNovo Healthcare and Pharma Ltd.\tLosacard HZ 12.5/50 TAB dr   30's pack 180\n\tOpsonin Pharma\tLarb PLUS 12.5/50 TAB dr   30's pack 180\n\tOpsonin Pharma\tLarb-100 25/100 TAB dr   30's pack 300\n\tOrion Pharma Ltd.\tLosan-D 12.5/50 TAB dr  12.5 mg + 50 mg 30's pack 180.80\n\tPacific\tLK PLUS 12.5/50 TAB dr   30's pack 180\n\tPharmasia Ltd.\tXelotan Plus TAB dr   30's pack 180.60\n\tPopular\tLosatan HZ 12.5/50 TAB dr  12.5 mg + 50 mg 30's pack 180.59\n\tRadiant.\tPrecon Plus TAB dr 12.5 mg + 50 mg  \n\tRenata\tOstan Plus TAB dr  30's pack 180.60\n\tRenata\tOstan 100 Plus TAB dr  30's pack 300\n\tSharif\tOscard 50/12.5 TAB dr   30's pack 180\n\tSquare\tAngilock PLUS 100/12.5 TAB dr  12.5 mg + 100 mg 30's pack 330\n\tSquare\tAngilock 25/100 TAB dr   30's pack 360\n\tSquare\tAngilock PLUS 100/25 TAB dr 25 mg + 100 mg 30's pack 360\n\tSquare\tAngilock PLUS 50/12.5 TAB dr 12.5 mg + 50 mg 50's pack 400\n\tSun Pharmaceutical (Bangladesh) Ltd.\tRepace H 12.5/50 TAB dr   50's pack 352.50\n\tUnimed & Unihealth Manufacturers Ltd.\tAraten PLUS 12.5/50 TAB dr   30's pack 240\n\tWhite Horse Pharma\tLospil Plus TAB dr  50's pack 300\n\tZenith\tLopos Plus TAB dr Losartan Potassium 50mg + 50's pack 500\n\tIndication: Hypertension, Stroke risk reduction of hypertensive or LVH patients\n\nDose: Adult: PO Hypertension: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.50 mg once daily. Maximum dose- Losartan 100 mg & Hydrochlorothiazide 25 mg once daily.\n\nStroke risk reduction of hypertensive or LVH patients: Starting dose- Losartan 50 mg & Hydrochlorothiazide 12.5 mg once daily. Maximum dose- Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily.\n\nRenal impairment: Dialysis patients: Avoid.\nCrCl (ml/min)	\n<20	Avoid.\n\nContra-indication: Pregnancy, lactation; intravascular volume depletion.\n\nSide effects: Volume depletion and electrolyte imbalance (especially hyperkalaemia); dry mouth, thirst; lethargy, drowsiness; muscle pain and cramps; rashes, photosensitivity, thrombocytopenia, jaundice, pancreatitis; fatigue, weakness; may precipitate an attack of gout; impotence; hyperglycaemia; anorexia, nausea, vomiting, constipation, diarrhoea; sialdenitis; raised urinary calcium concentration; headache, dizziness; back pain, myalgia; first-dose hypotension; angiodema; neutropenia; GI disturbances; transient elevation of liver enzymes; taste disturbances, cough; exacerbation or activation of systemic lupus erythematous; palpitations; xanthopsia; leucopenia, agranulocytosis, aplastic anaemia; necrotising angiitis; glucosuria; renal dysfunction, interstitial nephritis, renal failure; migraine; hyponatraemia; UTI; chest pain; gastritis, wt gain, dyspepsia, abdominal pain; bronchitis, upper respiratory infection, nasal congestion, sinusitis; rise in cholesterol and/or triglycerides.\nPotentially Fatal: Hypersensitivity reactions; hemolytic anaemia; toxic epidermal necrolysis.\n\nPrecaution: Existing electrolyte disturbances; hepatic cirrhosis; severe hepatic failure; oedema; elderly (>75 yr); renal impairment; hepatic impairment; diabetes, gout, hyperlipidaemia; hyperuricaemia; ECG: LVH and/or ventricular ectopics extrasystoles); volume depleted patients; patients on diuretics and salt restriction; renal artery stenosis; aortic and mitral stenosis. Monitor potassium concentration. Discontinue before performing tests for parathyroid function.\n\nMode of action: Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. \n\nLosartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. \n\nHydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.\n\nPregnancy category: D\n\nInteraction: Reduced excretion of lithium; effect of diuretic, natriuretic & other antihypertensive w/ NSAIDs including selective COX-2 inhibitors. Do not co-administer w/ aliskiren in patients w/ diabetes & renal impairment. \n\nLosartan: Rifampin & fluconazole. Increased serum potassium w/ K-sparing diuretics (eg spironolactone, triamterene, amiloride), K supplements or salt substitutes containing K. \n\nHydrochlorothiazide: Potentiate orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs (oral agents, insulin), other antihypertensive drugs. Impaired absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroids, ACTH, glycyrrhizin (liquorice). Possible decreased response to pressor amines (eg adrenaline); increased response to nondepolarizing skeletal muscle relaxants (eg tubocurarine). May interfere w/ parathyroid function test.
Hydrochlorothiazide + Olmesartan Medoxomil	\n\n\tACI\tAbetis Plus TAB dr  20+12.5 mg 30's pack 241.50\n\tAcme Ltd.\tOrbas Plus TAB dr 12.5 mg + 20 mg  \n\tBeximco\tOlmesan Plus TAB dr  12.5 mg + 20 mg 30's pack 240\n\tDrug International Ltd.\tOlmetic Plus TAB dr   30's pack 240\n\tIncepta\tXyotil 20 plus TAB dr  12.5mg/20mg 30's pack 240\n\tOpsonin Pharma\tOlsart HZ 20 TAB dr   30's pack 240\n\tOpsonin Pharma\tOlsart HZ 40 TAB dr   30's pack 451.80\n\tRadiant.\tSevitan HTZ TAB dr 12.5 mg + 20 mg  \n\tSquare\tOlmecar Plus 20/12.5 TAB dr  12.5 mg + 20 mg 30's pack 240\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOlmezest H 20 TAB dr   30's pack 255\n\tUnimed & Unihealth Manufacturers Ltd.\tTenizide 12.5/20 TAB dr  28's pack 224\n\tIndication: Hypertension, Diabetic nephropathy\n\nDose: Adult: PO Initial: 20 mg/12.5 mg once daily, may be increased to 40 mg/25 mg once daily if needed.\n\nContra-indication: Pregnancy (2nd and 3rd trimesters); biliary obstruction.\n\nSide effects: Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.\nPotentially Fatal: Acute renal failure.\n\nPrecaution: Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.\n\nMode of action: Olmesartan medoxomil: Increased risk of hypotension, hyperkalemia & changes in renal function w/ aliskiren. May result in deterioration of renal function w/ NSAIDs. May attenuate the antihypertensive effect of angiotensin II receptor antagonists. Reduces systemic exposure & peak plasma conc w/ colosevelam HCl. \n\nHydrochlorothiazide: Potentiation of orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs. Potentiation effect w/ other antihypertensives. Reduced absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroid, ACTH. Decreased response to pressor amines (eg norepinephrine). Increased responsiveness to skeletal muscle relaxants (eg tubocurarine). Reduce the renal clearance of lithium.\n\nPregnancy category: D\n\nInteraction: Olmesartan medoxomil: Increased risk of hypotension, hyperkalemia & changes in renal function w/ aliskiren. May result in deterioration of renal function w/ NSAIDs. May attenuate the antihypertensive effect of angiotensin II receptor antagonists. Reduces systemic exposure & peak plasma conc w/ colosevelam HCl. \n\nHydrochlorothiazide: Potentiation of orthostatic hypotension w/ alcohol, barbiturates or narcotics. Antidiabetic drugs. Potentiation effect w/ other antihypertensives. Reduced absorption w/ cholestyramine & colestipol resins. Intensified electrolyte depletion w/ corticosteroid, ACTH. Decreased response to pressor amines (eg norepinephrine). Increased responsiveness to skeletal muscle relaxants (eg tubocurarine). Reduce the renal clearance of lithium.
Hydrochlorothiazide + Ramipril	\n\n\tDrug International Ltd.\tRamicard 2.5 Plus TAB dr   50's pack 150\n\tDrug International Ltd.\tRamicard 5 Plus TAB dr   30's pack 150\n\tEskayef Bangladesh Ltd.\tMypril Plus TAB dr  160  20's pack\n\tIncepta\tRamoril PLUS 2.5/12.5 TAB dr   30's pack 150\n\tIncepta\tRamoril PLUS 5/25 TAB dr   30's pack 240\n\tNovartis (Bangladesh) Ltd.\tPiramil PLUS 2.5/12.5 TAB dr   28's pack 196\n\tNovartis (Bangladesh) Ltd.\tPiramil PLUS 5/25 TAB dr   28's pack 280\n\tSanofi Aventis (BD) Ltd.\tTritazid 10/25 TAB dr  28's pack 561.96\n\tSquare\tRipril PLUS 2.5/12.5 TAB dr  12.5 mg + 2.5 mg 30's pack 150\n\tSquare\tRipril PLUS 5/25 TAB dr  25 mg + 5 mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tProtace H 2.5/12.5 TAB dr   30's pack 150\n\tIndication: Hypertension, Diabetic nephropathy, Congestive heart failure\n\nDose: Adult: PO Per tab contains ramipril 2.5 mg and hydrochlorthiazide 12.5 mg: 1 tab/day. Max: 4 tab/day.\n\nContra-indication: Anuria, hypersensitivity, history of angioedema, bilateral renal artery stenosis, unilateral renal artery stenosis\n\nSide effects: Pancreatitis, jaundice, diarrhoea, nausea, vomiting, cramps, constipation, gastric irritation, anorexia, aplastic anaemia, agranulocytosis, leukopaenia, haemolytic anaemia, thrombocytopaenia, vasculitis, resp distress, including pneumonitis and pulmonary oedema, photosensitivity, fever, urticaria, rash, hyperglycaemia, glycosuria, hyperuricaemia, muscle spasm, vertigo, paraesthesias, dizziness, headache, restlessness, renal failure, renal dysfunction, interstitial nephritis, erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopoecia, transient blurred vision, xanthopsia, impotence, dizziness, fatigue, headache, abdominal pain, cough, rarely symptomatic hypotension, angioneurotic oedema of face, lips, tongue, glottis and larynx, syncope, renal impairment, hypersensitivity reactions.\nPotentially Fatal: Anaphylactic reactions, electrolyte imbalance, hypotension.\n\nPrecaution: Severe renal disease, impaired hepatic, allergy or bronchial asthma, systemic lupus erythematosus, acute gout, diabetes mellitus, elderly, collagen vascular diseases, should be discontinued before carrying out tests for parathyroid function. Pregnancy and lactation.\n\nMode of action: Hydrochlorthiazide in combination with alcohol, barbiturates, or narcotics potentiates orthostatic hypotension. When coadministered with other antihypertensive gives additive effect. Absorption is reduced with cholestyramine and colestipol resins. Hypokalemia is observed with corticosteroids, tubocurarine responsiveness to the muscle relaxant is increased. It decreases the renal clearance of lithium and increases the risk of lithium toxicity. Non-steroidal anti-inflammatory agents can reduce the diuretic and natriuretic effect of hydrochlorthiazide. \n\nRamipril with potassium-sparing diuretics results in severe hyperkaelemia. May increase serum lithium concentration, NSAIDs may reduce the effect of the drug and cause deterioration of renal function.\n\nPregnancy category: D\n\nInteraction: Hydrochlorthiazide in combination with alcohol, barbiturates, or narcotics potentiates orthostatic hypotension. When coadministered with other antihypertensive gives additive effect. Absorption is reduced with cholestyramine and colestipol resins. Hypokalemia is observed with corticosteroids, tubocurarine responsiveness to the muscle relaxant is increased. It decreases the renal clearance of lithium and increases the risk of lithium toxicity. Non-steroidal anti-inflammatory agents can reduce the diuretic and natriuretic effect of hydrochlorthiazide. \n\nRamipril with potassium-sparing diuretics results in severe hyperkaelemia. May increase serum lithium concentration, NSAIDs may reduce the effect of the drug and cause deterioration of renal function.
Hydrochlorothiazide + Telmisartan	\n\n\tNovartis (Bangladesh) Ltd.\tMitosan 80 PLUS 80/12.5 TAB dr   20's pack 420\n\tNovartis (Bangladesh) Ltd.\tMitosan PLUS 40/12.5 TAB dr   20's pack 260\n\tUnimed & Unihealth Manufacturers Ltd.\tTelcardis Plus 40 TAB dr   14's pack\n 175\n\tUnimed & Unihealth Manufacturers Ltd.\tTelcardis Plus 80 TAB dr   14's pack 280\n\tIndication: Hypertension, Diabetic nephropathy\n\nDose: Adult: PO 80-160 mg telmisartan/12.5-25 mg once daily. \n\nContra-indication: Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.\n\nSide effects: URTI, dizziness, back pain, sinusitis, pharyngitis and diarrhoea. Slight elevations in liver enzymes.\nPotentially Fatal: Rarely angioedema, rash, pruritus and urticaria.\n\nPrecaution: Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients.\n\nMode of action: Lithium, kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G, salicylates, K-sparing diuretics, K supplements, K salt substitutes drugs that cause hyperkalaemia, digitalis glycosides, antiarrhythmic agents, drugs known to induce torsades de pointes, alcohol, barbiturates, narcotics, oral antidiabetics, insulin, anion-exchange resins, NSAIDs, nondepolarising skeletal muscle relaxants, pressor amines, allopurinol, Ca salts, ?-blockers, diazoxide, anticholinergics, amantadine, cytotoxics.\n\nPregnancy category: D\n\nInteraction: Lithium, kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G, salicylates, K-sparing diuretics, K supplements, K salt substitutes drugs that cause hyperkalaemia, digitalis glycosides, antiarrhythmic agents, drugs known to induce torsades de pointes, alcohol, barbiturates, narcotics, oral antidiabetics, insulin, anion-exchange resins, NSAIDs, nondepolarising skeletal muscle relaxants, pressor amines, allopurinol, Ca salts, ?-blockers, diazoxide, anticholinergics, amantadine, cytotoxics.
Hydrochlorothiazide + Triamterene	\n\n\tEskayef Bangladesh Ltd.\tDezide TAB dr   100's pack 75\n\tGonoshasthaya\tG-Thiazide T TAB dr  100's pack 52\n\tIndication: Hypertension, Oedema\n\nDose: Oedema\nAdult: 150-250 mg/day in 2 divided doses, after breakfast and lunch. Maintenance: doses may be given on alternate days. Max: 300 mg/day.\nRenal impairment: Use with caution. Severe: avoid.\nHepatic impairment: Severe: avoid.\nHypertension\nAdult: In combination with other diuretics e.g. hydrochlorothiazide: Initially, 50 mg daily.\nRenal impairment: Use with caution. Severe: avoid.\nHepatic impairment: Severe: avoid.\n\nContra-indication: severe renal or hepatic impairment, preexisting or drug-induced hyperkalemia, patients at risk of respiratory or metabolic acidosis. Lactation.\n\nSide effects: Photosensitivity reactions; increase in uric acid concentrations; megaloblastic anaemia; thrombocytopenia; hyperkalaemia; nephrolithiasis; renal failure; GI disturbances such as nausea, vomiting, diarrhoea; dry mouth; fatigue; dizziness; skin rash, muscle cramps; headache; orthostatic hypotension; increased BUN concentrations, LFT abnormalities.\n\nPrecaution: Renal and hepatic impairment; cirrhosis; DM; hyponatraemia; hyperuricaemia; history of nephrolithiasis; depleted folic acid stores. Monitor electrolyte concentrations closely, especially potassium levels. Observe for signs of liver damage, blood dyscrasias or other idiosyncratic reactions. Discontinue treatment if urinary calculus is passed. Pregnancy and elderly.\n\nMode of action: May enhance toxicity of digitalis glycosides, neuromuscular-blocking action of competitive muscle relaxants, effect of antihypertensives. Increased risk of postural hypotension w/ alcohol, barbiturates, opioids. K-depleting effect enhanced by corticosteroids, lithium, ACTH, carbenoxolone.\n\nPregnancy category: C\n\nInteraction: May enhance toxicity of digitalis glycosides, neuromuscular-blocking action of competitive muscle relaxants, effect of antihypertensives. Increased risk of postural hypotension w/ alcohol, barbiturates, opioids. K-depleting effect enhanced by corticosteroids, lithium, ACTH, carbenoxolone.
Hydrochlorothiazide + Valsartan	\n\n\tDrug International Ltd.\tCardival Plus 160 TAB dr   10's pack 160\n\tDrug International Ltd.\tCardival Plus 80 TAB dr   20's pack 160\n\tHealthcare\tDisys S PLUS 80/12.5 TAB dr   30's pack 273\n\tIncepta\tValsaril 160/12.5 TAB dr   30's pack 480\n\tIncepta\tValsaril PLUS 160/25 TAB dr   30's pack 480\n\tIncepta\tValsartil PLUS 80/12.5 TAB dr   30's pack 270\n\tNovartis (Bangladesh) Ltd.\tCo-Diovan 80/12.5 TAB dr  28's pack 1344\n\tNovartis (Bangladesh) Ltd.\tCo-Diovan 160/12.5 TAB dr  28's pack 1848\n\tRAK\tReovan H TAB dr   30's pack 360\n\tRenata\tValzide 160/12.5 TAB dr 12.5 mg + 160 mg  20's pack 321.20\n\tRenata\tValzide 80/12.5 TAB dr 12.5 mg + 80 mg  20's pack 180\n\tRenata\tValzide 160/25 TAB dr 25 mg + 160 mg  \n\tIndication: Hypertension, Diabetic nephropathy\n\nDose: Adult: PO : Initial: 80/12.5 mg once daily, up to 320/25 mg if needed.\n\nRenal impairment:\nCrCl (ml/min)	\n<30 	Not recommended. \n\nContra-indication: Hypersensitivity to valsartan, hydrochlorothiazide or sulphonamides. Severe hepatic impairment, creatinine clearance <30ml/min, anuria, cirrhosis, biliary obstruction, conditions where there is increased potassium loss (e.g. salt losing nephropathies and pre-renal impairment of kidney function), refractory hypokalaemia, hyponatraemia, hypercalcaemia, hyperuricaemia, history of gout and uric acid stones, untreated Addison's disease. Pregnancy and lactation.\n\nSide effects: Headache, asthenia, fatigue, dizziness, somnolence, insomnia, orthostatic hypotension, paraesthesia, nasopharyngitis, tachycardia, palpitations, tinnitus, vertigo, dyspepsia, diarrhoea, flatulence, dry mouth, nausea, vomiting, abdominal pain, peripheral oedema, pyrexia, increased BUN, elevated LFT, anxiety, erectile dysfunction, glucose intolerance, increased serum cholesterol, triglycerides, uric acid. Electrolyte imbalances e.g. hypomagnesaemia, hypercalcaemia, hyponatraemia, hypochloraemic alkalosis.\n\nPrecaution: DM, postsympathectomy patients. May exacerbate SLE. Monitor serum potassium regularly. Observe for signs of fluid or electrolyte imbalance. Discontinue before testing for parathyroid function. May affect ability to drive or operate machinery. Elderly.\n\nMode of action: Increased antihypertensive effect with other antihypertensive drugs. Monitor potassium frequently if used with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or drugs that may affect potassium levels (e.g. heparin, ciclosporin, drospirenone, amphotericin, corticosteroids, carbenoxolone). Reduced antihypertensive effect of valsartan and increased risk of renal impairment with NSAIDs. May reduce renal clearance of cytotoxic drugs (e.g. cyclophosphamide, methotrexate). Increased serum calcium with vitamin D or calcium salts.\n\nPotentially Fatal: Increased lithium levels with valsartan, monitor lithium levels. Increased risk of cardiac arrhythmia with dofetilide, avoid use.\n\nPregnancy category: D\n\nInteraction: Increased antihypertensive effect with other antihypertensive drugs. Monitor potassium frequently if used with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or drugs that may affect potassium levels (e.g. heparin, ciclosporin, drospirenone, amphotericin, corticosteroids, carbenoxolone). Reduced antihypertensive effect of valsartan and increased risk of renal impairment with NSAIDs. May reduce renal clearance of cytotoxic drugs (e.g. cyclophosphamide, methotrexate). Increased serum calcium with vitamin D or calcium salts.\n\nPotentially Fatal: Increased lithium levels with valsartan, monitor lithium levels. Increased risk of cardiac arrhythmia with dofetilide, avoid use.
Hydrocortisone	\n\n\tACI\tHison Injection 100mg/vial 1's pack 50.34\n\tAristopharma\tCortef IV/IM Injection 100mg/vial 100mg vial 50\n\tChemist Ltd.\tHycort Injection 100mg/vial 100mg vial 50\n\tGonoshasthaya\tG Hydrocortisone Injection 100mg/vial 100mg vial X 5's pack 201.25\n\tIncepta\tIntasone Injection 100mg/vial 100mg vial 50\n\tIncepta\tIntasone TAB dr 20mg  \n\tNavana\tInflanil Injection 100mg/2ml 1's pack 50\n\tNovo Healthcare and Pharma Ltd.\tCortaid IV/IM Injection 100mg/vial 100mg vial 50\n\tOpsonin Pharma\tCotson Injection 100mg/vial 100mg vial 50\n\tOpsonin Pharma\tCotson TAB dr 10mg 100's pack 219\n\tTechno Drugs Ltd.\tAnacort Injection 100mg/vial 5's pack 225\n\tZiska\tCortinex IV/IM Injection 100mg/vial 100mg vial 50\n\tRotexmedica GmbH, Germany\tHydrocortisone Injection 100mg/vial 2ml vial 72\n\tIndication: Corticosteroid-responsive dermatoses, hypersensitivity reactions such as angioedema, status asthmaticus,  Soft tissue inflammation, Joint inflammations, Primary or secondary adrenocortical insufficiency, Acute adrenocortical insufficiency, Shock unresponsive to conventional therapy, Congenital adrenal hyperplasia, Hypercalcemia associated with cancer, Nonsuppurative thyroiditis, Rheumatic Disorders, Dermatologic Diseases (Allergic States, Severe seborrheic dermatitis, Severe psoriasis, Pemphigus, Severe erythema multiforme), Control of severe or incapacitating allergic conditions (Bronchial asthma, Contact dermatitis, Atopic dermatitis, Serum sickness, Seasonal or perennial allergic rhinitis, Drug hypersensitivity reactions, Urticarial transfusion reactions, Acute noninfectious laryngeal edema), Ophthalmic Diseases (Herpes zoster ophthalmicus, Iritis, iridocyclitis, Chorioretinitis, Diffuse posterior uveitis and choroiditis, Optic neuritis), Gastrointestinal Diseases, Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, Loeffler's syndrome, Aspiration pneumonitis, Hematologic Disorders (Acquired, autoimmune hemolytic anemia, Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia, Erythroblastopenia), Neoplastic Diseases (Leukemias and lymphomas in adults, Acute leukemia of childhood), Edematous States, Acute exacerbations of multiple sclerosis\n\nDose: Adult: By IM injection or slow IV injection or infusion, 100-500 mg, 3-4 times in 24 hours or as required; \nChild: by slow IV Injection, up to 1 year: 25 mg, 1-5 years: 50 mg, 6-12 years: 100 mg.\n\nPO Adrenocortical insufficiency 20-30 mg/day in 2 divided doses. \n\nIV Supplement in adrenal insufficiency during surgery under general anesth Patients taking >10 mg/day prednisolone or its equivalent by mouth: 25-50 mg at induction. \n\nAcute adrenocortical insufficiency 100-500 mg 3-4 times/24 hr depending on severity and response. \n\nInj Soft-tissue inflammation As Na phosphate or Na succinate esters: 100-200 mg as local inj. \n\nIntra-articular Joint inflammations As acetate: 5-50 mg depending on size of affected joint.\n\nChildren: By slow IV injection, up to 1 year 25 mg, 1-5 years 50 mg, 6-12 years 100 mg.\n\nContra-indication: Viral/fungal infections, tubercular or syphilitic lesions, bacterial infections unless used in conjunction with appropriate chemotherapy.\n\nSide effects: Sodium and fluid retention. Potassium and calcium depletion. Muscle wasting, weakness, osteoporosis. GI disturbances and bleeding. Increased appetite and delayed wound healing. Bruising, striae, hirsutism, acne, flushing. Raised intracranial pressure, headache, depression, psychosis, menstrual irregularities. Hyperglycaemia, glycosuria, DM, obesity, moon-face, buffalo hump. Suppression of pituitary-adrenocortical system. Growth retardation in childn (prolonged therapy). Increased susceptibility for infection. Topical use: Dermal atrophy, local irritation, folliculitis, hypertrichosis. Inhaled corticosteroids: May cause hoarseness, candidiasis of mouth and throat. Topical application to the eye: Can produce corneal ulcers, raised IOP and reduced visual function. Intralesional injection: Local hypopigmentation of deeply pigmented skin. Intra-articular injection: Joint damage, fibrosis esp in load bearing joints.\nPotentially Fatal: Abrupt withdrawal leading to acute adrenal insufficiency. Rapid IV Inj may cause CV collapse.\n\nPrecaution: CHF, hypertension, DM, epilepsy, elderly, patients on prolonged therapy. Gradual withdrawal, pregnancy and lactation.\n\nMode of action: Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. \n\nReduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.\n\nPregnancy category: D\n\nInteraction: Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. \n\nReduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.
Hydrocortisone 1% Topical	\n\n\tACI\tZocort 1% Cream   15gm tube 38.25\n\tAlco Pharma\tHydrocort Cream   10gm tube 28\n\tEskayef Bangladesh Ltd.\tCortider Cream   10gm tube 28\n\tG. A. Company Ltd.\tUnicort Cream   5gm tue 16\n\tGeneral\tGenacort Ointment   5gm tue 15.06\n\tIncepta\tIntasone Cream Cream  1% 10gm tube 28\n\tMedimet\tCortimet Cream   10gm tube 28\n\tSquare\tTopicort Cream   10gm tube 28.10\n\tIndication: Corticosteroid-responsive dermatoses,  Contact allergic dermatitis,  Eczema - atopic; infantile; discoid; stasis, Seborrheic dermatitis,  Skin irritations, itching and rashes, for example those caused by insect bites, minor thermal burns, sunburn, etc. \n\nDose: Adult: Apply a thin film onto affected area 2-3 times daily.\n\nContra-indication: Viral/fungal infections, tubercular or syphilitic lesions, bacterial infections unless used in conjunction with appropriate chemotherapy.\n\nSide effects: Topical use: Dermal atrophy, local irritation, folliculitis, hypertrichosis. \n\nPrecaution:  DM, elderly, patients on prolonged therapy.  Pregnancy and lactation.\n\nMode of action: Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.\n\nPregnancy category: C\n\nInteraction: Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.
Hydrocortisone 1% + Miconazole Nitrate 2% Topical	\n\n\tACI\tMicosone Cream  2%+1% 10gm tube 40.27\n\tACI\tMicosone Ointment  2%+1% 10gm tube 40.27\n\tEdruc Ltd.\tFungi-MH Cream   10gm tube 40\n\tG. A. Company Ltd.\tMicozol HC Cream   10gm tube 38\n\tGeneral\tGemison Cream   10gm tube 40.15\n\tGlobe\tMic HC Cream   10gm tube 37\n\tIncepta\tTopicazole Plus Cream   10gm tube 40\n\tNipa\tMiconil Cream   10gm tube 40\n\tOpsonin Pharma\tUnigal HC Cream   10gm tube 40\n\tOrion Pharma Ltd.\tMiki H Cream   10gm tube 40.15\n\tPharmasia Ltd.\tMyco-HC Cream   10gm tube 40.15\n\tSharif\tMHC Cream Cream   10gm tube 40.15\n\tSquare\tFungidal HC Cream  1 gm + 2 gm/100 gm 10gm tube 40.15\n\tIndication: Topical application to inflammatory skin condition where fungal infecton is present.\n\nDose: Topical Skin fungal infections As 2% cream/ointment: Apply twice daily, not exceeding more than 7 days.\n\nContra-indication: The drug is contraindicated in individuals with a history of sensitivity reactions to Miconazole or any of the components of the preparation, viral disease of the skin (herpes, chickenpox), perioral dermatitis, rosaceae, ulcerative conditions, tuberculous or syphilitic processes. \n\nSide effects: Generally it is well tolerated. An allergic reaction to any of the ingredient of the cream may occur. Rarely, irritation & burning may occur.\n\nPrecaution: For external use only; discontinue if sensitization or irritation occurs. It should be used with caution when applied to extensive surface areas or under occlusive dressings including baby napkins. Application to the face should be avoided. \n\nMode of action: Oral anticoagulants eg, warfarin. Certain oral hypoglycemics & phenytoin. Hydrocortisone.\n\nPregnancy category: C\n\nInteraction: Oral anticoagulants eg, warfarin. Certain oral hypoglycemics & phenytoin. Hydrocortisone.
Hydrocortisone + Neomycin Sulphate + Polymixin B Eye prep	\n\n\tG. A. Company Ltd.\tPolycort Eye Drops   5 ml bot 45\n\tGlaxoSmithKline Bangladesh Ltd.\tOtosporin Eye Drops   5 ml vial 60\n\tOpso Saline Ltd.\tPolymix H Eye Drops   5  ml drop 40.15\n\tReman Drug Ltd.\tNPH Eye Drops   5  ml drop 60.23\n\tIndication: Ocular inflammation\n\nDose: Ophthalmic\nOcular inflammation with suspected or confirmed bacterial infection\nAdult: 1-2 drops every 3-4 hrly as indicated. \n\n\nContra-indication: Hypersensitivity to aminoglycosides and any of its components. Pre-existing nerve deafness. TB, fungal or viral infections. \n\nSide effects: Ophthalmic: Irritation, increased intraocular pressure, glaucoma, posterior subcapsular cataract formation, delayed wound healing, secondary infections.\n\nPrecaution: Ophthalmic: Glaucoma; monitor intraocular pressure regularly if used for >10 days.\n\nMode of action: Additive toxicity with neurotoxic, ototoxic or nephrotoxic drugs. Increased neuromuscular blockade and possibly respiratory depression with neuromuscular blocking agents if significant amounts of neomycin absorbed significantly.\n\nPregnancy category: C\n\nInteraction: Additive toxicity with neurotoxic, ototoxic or nephrotoxic drugs. Increased neuromuscular blockade and possibly respiratory depression with neuromuscular blocking agents if significant amounts of neomycin absorbed significantly.
Hydrocortisone Acetate 0.5% + Neomycin Sulphate 0.5%	\n\n\tReman Drug Ltd.\tRemacort N Cream   15gm tube 18.92\n\tIndication: Burns, Eczema, Infected wounds & ulcers, Anal or vulvar pruritus, Pyogenic & seborrhoeic dermatitis\n\nDose: Topical/Cutaneous\nCorticosteroid-responsive dermatoses\nAdult: Apply  cream/ointment/lotion onto affected area as directed.\n\nContra-indication: Viral/fungal infections, tubercular or syphilitic lesions, bacterial infections unless used in conjunction with appropriate chemotherapy.\n\nSide effects: Topical application to the eye: Can produce corneal ulcers, raised IOP and reduced visual function. Intralesional injection: Local hypopigmentation of deeply pigmented skin. Intra-articular injection: Joint damage, fibrosis esp in load bearing joints.\n\nPrecaution: CHF, hypertension, DM, epilepsy, elderly, patients on prolonged therapy. Gradual withdrawal, pregnancy and lactation.\n\nMode of action: Hydrocortisone: Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.\n\n Neomycin: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\nPregnancy category: C\n\nInteraction: Hydrocortisone: Thiazides may enhance hyperglycaemia and hypokalaemia caused by corticosteroids. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents. Ethanol may enhance gastric mucosal irritation. Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Mutual inhibition of metabolism between ciclosporin and corticosteroids increase plasma conc of both drugs. Enhanced effect in women taking oestrogens or oral contraceptives.\n\n Neomycin: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.
Hydrocortisone Acetate 2.5% + Pramoxine 1% Topical	\n\n\tSquare\tPracort Cream    55\n\tSquare\tPracort Ointment    60\n\tIndication: Hemorrhoids, Insect bites, Skin irritations, Corticosteroid-responsive dermatoses, Anal itching\n\nDose: Topical corticosteroids are generally applied to the affected area as a thin film three to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.\n\nContra-indication: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.\n\nSide effects:  If the drug is absorbed in the system patient may feel blurred vision, halos around lights, irregular heart rate, insomnia. Redness, burning, itching and irritation may occur in application site.\n\nPrecaution: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.\n\nTherefore, patients receiving a large dose of a potent topical steroid applied to a large surface area and under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.\n\nRecovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity.  \n\nIf irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.\n\nIn the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Hydroquinone	\n\n\tIncepta\tSpotclen Cream 4% 10gm pack 50\n\tPharmasia Ltd.\tNoir Cream  40mg/gm 10gm pack 50.19\n\tUnimed & Unihealth Manufacturers Ltd.\tDepiquin Cream 40 mg/gm  \n\tJanata Pharma\tEldopaque Forte Cream 4% 1's pack 402.05\n\tIndication: Chloasma, Melasma, Freckles, Senile lentigines, Hyperpigmentation\n\nDose: Hydroquinone should be applied to the affected area and rubbed in well twice daily or as directed by a physician. Most discolorations begin to lighten after 4 weeks of treatment but it may take longer. After desired bleaching, use only as needed to maintain results of treatment. Hydroquinone bleaching is faster, more dependable and easier if the treated area is protected from ultraviolet light. Therefore, exposure to sunlight should be minimized at the period of treatment. During day, an effective broad-spectrum sunscreen should be used, unnecessary solar exposure should be avoided and protective clothing should be used to prevent repigmentation of treated areas. After reduction of hyperpigmentation, use of sunscreen agents and/or protective clothing should continue.Use in children: Safety and efficacy in paediatric patients below the age of 12 years have not been established.\n\nContra-indication: Hydroquinone is contraindicated to patients with prior history of hypersensitivity or allergic reaction to hydroquinone or other ingredients in the preparation.\n\nSide effects: No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur in which case the medication should be discontinued.\n\nPrecaution: Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin to check in 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, further treatment is not advised. If no bleaching or lightening effect is noted after 2 months of treatment, the medication should be discontinued.Contact with the eyes and lips should be avoided. Hydroquinone should not be applied to cut or abraded skin.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Hydrous Benzoyl Peroxide 6.5%	\n\n\tIndication: Acne, Decubitus/Stasis ulcers, \n\nDose: Adult: Apply a 2.5-10% preparation once or twice daily, often used with other antimicrobials. \nTopical/Cutaneous\nDecubitus/stasis ulcers\nAdult: Apply a 20% lotion every 8-12 hr.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Excessive drying of skin, allergic dermatitis. May bleach fabrics or hair. Skin discoloration; skin rash, peeling, transient local oedema.\n\nPrecaution: Discontinue if severe irritation develops. Restart with tolerable levels of treatment after irritiation has cleared. Do not use occlusive dressing. May cause dermatitis in allergic patients. Apply carefully near the eyes, mouth, neck and other mucous membranes as well as other sensitive areas.\n\nMode of action: PABA sunscreens may transiently discolour fabric.\n\nPregnancy category: C\n\nInteraction: PABA sunscreens may transiently discolour fabric.
Hydroxocobalamin	\n\n\tJayson\tCynomin H Injection 1mg/ml 10 amps pack 70.30\n\tIndication: Vitamin B12 deficiency, Cyanide poisoning\n\nDose: Thirty mcg daily for 5 to 10 days followed by 100 to 200 mcg monthly injected intramuscularly. If the patient is critically ill, or has neurologic disease, an infectious disease or hyperthyroidism, considerably higher doses may be indicated. However, current data indicate that the optimum obtainable neurologic response may be expected with a dosage of vitamin B12 sufficient to produce good hematologic response. Children may be given a total of 1 to 5 mg over a period of 2 or more weeks in doses of 100 mcg, then 30 to 50 mcg every 4 weeks for maintenance.\n\nContra-indication: Hypersensitivity to any component of this medication.\n\nSide effects: Mild transient diarrhea, itching, transitory exanthema, feeling of swelling of entire body, and anaphylaxis.\n\nA few patients may experience pain after injection of hydroxocobalamin.\n\nPrecaution: General\n\nThe validity of diagnostic vitamin B12 or folic acid blood assays could be compromised by medications, and this should be considered before relying on such tests for therapy.\n\nVitamin B12 is not a substitute for folic acid and since it might improve folic acid deficient megaloblastic anemia, indiscriminate use of vitamin B12 could mask the true diagnosis.\n\nHypokalemia and thrombocytosis could occur upon conversion of severe megaloblastic to normal erythropoiesis with B12 therapy. Therefore, serum potassium levels and the platelet count should be monitored carefully during therapy.\n\nVitamin B12 deficiency may suppress the signs of polycythemia vera. Treatment with vitamin B12 may unmask this condition.\n\nMode of action: history of interaction with ARI Sodium Iodide (I123) 1-12 MBq (sodium iodide i-123)\nARI Sodium Iodide (I123) 100-750 MBq (sodium iodide i-123)\narsenic trioxide\nChloracol (chloramphenicol)\nchloramphenicol\nChloromycetin (chloramphenicol)\nChloromycetin Sodium Succinate (chloramphenicol)\nHicon (sodium iodide-i-131)\nIodotope (sodium iodide-i-131)\nsodium iodide i-123\nsodium iodide-i-131\nTrisenox (arsenic trioxide)\n\nPregnancy category: C\n\nInteraction: history of interaction with ARI Sodium Iodide (I123) 1-12 MBq (sodium iodide i-123)\nARI Sodium Iodide (I123) 100-750 MBq (sodium iodide i-123)\narsenic trioxide\nChloracol (chloramphenicol)\nchloramphenicol\nChloromycetin (chloramphenicol)\nChloromycetin Sodium Succinate (chloramphenicol)\nHicon (sodium iodide-i-131)\nIodotope (sodium iodide-i-131)\nsodium iodide i-123\nsodium iodide-i-131\nTrisenox (arsenic trioxide)
Hydroxychloroquine Sulphate	\n\n\tIncepta\tReconil TAB dr 200mg 30's pack 360\n\tZenith\tRoquin TAB dr 200mg 30's pack 360\n\tIndication: i) Acute and chronic rheumatoid arthritis,\n\nii) Systemic Lupus Erythematosus (SLE),\n\niii) Malaria\n\nDose: Hydroxychloroquine Sulphate tablets are for oral administration and are taken with food to avoid stomach upset.\ni) Acute and chronic rheumatoid arthritis: 400 to 600 mg daily. When good response is obtained (usually 4 to 8 weeks), dose can be reduced to 50%.\nii) Systemic Lupus Erythematosus (SLE): 400 mg once or twice daily for several weeks or months depending on response of the patients. Maintenance dose is 200 to 400 mg daily.\niii) Malaria: In adults, an initial dose of 800 mg followed by 400 mg in 6-8 hours and 400 mg on each of two consecutive days. For children a total dose representing 25 mg/kg is administered in 3 days as follows. First dose: 10 mg base/kg (but not exceeding a single dose of 620 mg base). Second dose: 5 mg base/kg (but not exceeding a single dose of 310 mg base) 6 hours after first dose. Third dose: 5 mg base/kg 18 hours after second dose. Fourth dose: 5 mg base/kg 24 hours after third dose.\n* Hydroxychloroquine Sulphate BP 200 mg equivalent to 155 mg of base. \n\nContra-indication: The presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, patients with known hypersensitivity to 4-aminoquinoline compounds, long term therapy in children.\n\nSide effects: Generally Hydroxychloroquine Sulphate is well tolerated. However, few side effects like nausea, vomiting, stomach upset, loss of appetite, diarrhea, tiredness, weakness or headache and visual problem may occur the first several days.\n\nPrecaution: Children are especially sensitive to the 4-aminoquinoline compounds. Patients should be strongly warned to keep these drugs out of the reach of children. Opthalmologic examination requires in every 12 months.\n\nMode of action: Cimetidine may increase serum levels of hydroxychloroquine. Its absorption may be decreased by kaolin or Mg trisilicate. Avoid digoxin and alcohol. Increased risk of ventricular arrhythmias when used with halofantrine. Concurrent use with mefloquine may increase the risk of convulsions.\n\nPregnancy category: C\n\nInteraction: Cimetidine may increase serum levels of hydroxychloroquine. Its absorption may be decreased by kaolin or Mg trisilicate. Avoid digoxin and alcohol. Increased risk of ventricular arrhythmias when used with halofantrine. Concurrent use with mefloquine may increase the risk of convulsions.
Hydroxyurea	\n\n\tBeacon\tHydronix CAP 500mg  \n\tIndication: Chronic myeloid leukaemia, Psoriasis, Myeloproliferative disorders, Sickle-cell disease, Essential thrombocythemia, AIDS\n\nDose: Adult: PO Malignancies Chronic myeloid leukaemia: 20-30 mg/kg/day. Solid tumours: 80 mg/kg every third day. With radiotherapy, start treatment 7 days before initiation of radiotherapy. Sickle-cell disease Initial: 15 mg/kg/day. Max: 35 mg/kg/day. Adjust based on response and blood counts. Essential thrombocythemia 15 mg/kg/day. Adjust based on platelet counts.\n\nContra-indication: Severe bone-marrow suppression, severe anaemia, WBC <3000/mm3 or platelet count <100,000/mm3. Pregnancy and lactation. Hypersensitivity.\n\nSide effects: GI disturbances, renal impairment, pulmonary oedema, dermatological reactions, headache, dizziness. Disorientation, drowsiness, hallucinations, convulsions, alopecia.\nPotentially Fatal: Bone marrow suppression.\n\nPrecaution: Regular monitoring of uric acid concentrations, blood counts, renal and hepatic function is recommended. Prior irradiation therapy. Elderly. Avoid use of live vaccines.\n\nMode of action: Other antineoplastic drugs or irradiation, cytarabine (ara-C) & fluoropyrimidines.\n\nPregnancy category: D\n\nInteraction: Other antineoplastic drugs or irradiation, cytarabine (ara-C) & fluoropyrimidines.
Hydroxyzine Hydrochloride	\n\n\tACI\tArtica Suspension 10mg/5ml 100ml bot 40.15\n\tACI\tArtica TAB dr 10mg 250's pack 312.50\n\tACI\tArtica TAB dr 25mg 200's pack 402\n\tACI\tArtica Syrup 10mg/5ml 100ml\n 40.27\n\tGeneral\tHytis TAB dr 25mg 100's pack \n\tOpsonin Pharma\tXyril Suspension 10mg/5ml 100ml bot 35\n\tOpsonin Pharma\tXyril TAB dr 10mg 100's pack 102\n\tOpsonin Pharma\tXyril TAB dr 25mg 100's pack 174\n\tIndication: Pruritus, Allergic conditions, Generalized anxiety disorder, Psychoneurosis, Chronic urticaria, Atopic or contact dermatoses, Pre- or post-operative sedation\n\nDose: Adult: PO Anxiety 50-100 mg 4 times/day. Pruritus Initial: 25 mg at night, up to 25 mg 3-4 times/day. Adjunct to pre- or post-op sedation 50-100 mg. IM Prompt control of anxiety or agitation Initial: 50-100 mg, may repeat 4-6 hrly if needed.\n\nContra-indication: Porphyria, neonates, pregnancy, lactation.\n\nSide effects: CNS depression, paradoxical CNS stimulation, dry mouth, thickened respiratory secretions, constipation, blurring of vision, tachycardia, GI disturbances, headache, hypotension, tinnitus.\n\nPrecaution: Renal and hepatic impairment; narrow-angle glaucoma; epilepsy; prostatic hypertrophy; bladder neck obstruction; asthma; COPD. May impair ability to drive or operate machinery.\n\nMode of action: Additive or may potentiate CNS depressant effects of opiates or other analgesics, barbiturates or other sedatives, and anaesth. MAOIs and TCAs potentiate antimuscarinic effects.\n\nPregnancy category: C\n\nInteraction: Additive or may potentiate CNS depressant effects of opiates or other analgesics, barbiturates or other sedatives, and anaesth. MAOIs and TCAs potentiate antimuscarinic effects.
Hyoscine Butyl Bromide	\n\n\tACI\tColik Injection 20mg/ml 1ml amp X 5's pack 39.40\n\tACI\tColik TAB dr 10mg 100's pack 345\n\tACI\tColik TAB dr 20mg 100's pack 351\n\tACI\tByspa tablet 10mg 100's pack \n\tAlbion Ltd.\tAltapan TAB dr 10 mg 100's pack \n\tBeximco\tSpanil TAB dr 10mg 100's pack 344\n\tBristol Pharma Ltd.\tAncopan TAB dr 20mg 50's pack 175\n\tChemist Ltd.\tRelapan Injection 20mg/ml 10 amps pack 60.70\n\tChemist Ltd.\tRelapan TAB dr 10mg 100's pack 152\n\tDelta Pharma\tHyosin TAB dr 10mg 100's pack 180\n\tDesh\tButalpen TAB dr 10mg 100's pack 300\n\tDoctor's Chemicals Works Ltd.\tSpasmin TAB dr 10mg 100's pack 154\n\tEdruc Ltd.\tHysin Injection 20mg/ml 10 amps pack 77.50\n\tEdruc Ltd.\tHysin TAB dr 10mg 100's pack 348\n\tEskayef Bangladesh Ltd.\tBromid TAB dr 10mg 100's pack 180\n\tEskayef Bangladesh Ltd.\tBromid TAB dr 20mg 50's pack 175\n\tG. A. Company Ltd.\tBrospan Injection 20mg/ml 1 amp 7.84\n\tG. A. Company Ltd.\tBrospan TAB dr 10mg 100's pack 182\n\tGeneral\tResopan TAB dr 10mg 100's pack \n\tGlaxoSmithKline Bangladesh Ltd.\tAntispam TAB dr 10mg  \n\tGonoshasthaya\tG Hyoscine Injection 20mg/ml 10 amps pack 61\n\tGonoshasthaya\tG Hyoscine TAB dr 10mg 100's pack 335\n\tHudson\tButason TAB dr 10mg 100's pack 175\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBuscon Injection 20mg/ml 10 amps pack 71\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBuscon TAB dr 10mg 100's pack 344\n\tIndobangla Pharmaceuticals\tButabrom TAB dr 10mg 100's pack 220\n\tJayson\tSpasmoson Injection 20mg/ml 1 ml amp X 10's pack 78.80\n\tJayson\tSpasmoson TAB dr 10mg 100's pack 163\n\tMedimet\tColipan Injection 20mg/ml 10 amps pack 78.50\n\tMedimet\tColipan TAB dr 10mg 100's pack 300\n\tMedimet\tColipan TAB dr 20mg 50's pack 282.50\n\tModern\tHysoma TAB dr 10mg 100's pack 167\n\tNavana\tLopan TAB dr 10mg 100's pack 343\n\tNipa\tAntipen TAB dr 10mg 100's pack 162\n\tOpsonin Pharma\tHysomide Injection 20mg/ml 25 amps pack 187.50\n\tOpsonin Pharma\tHysomide TAB dr 10mg 100's pack 180\n\tOpsonin Pharma\tHysomide TAB dr 20mg 100's pack 350\n\tPharmadesh Ltd.\tHysocin TAB dr 10mg 100's pack 344\n\tS. N.\tPasmodil TAB dr 20mg 50's pack 170\n\tSanofi Aventis (BD) Ltd.\tButapan Injection 20mg/ml 1 ml amp X 10's pack 78.87\n\tSanofi Aventis (BD) Ltd.\tButapan TAB dr 10mg 500's pack 1709.05\n\tSanofi Aventis (BD) Ltd.\tButapan TAB dr 20mg 100's pack 600\n\tShamsul Al-Amin\tSapen TAB dr 10mg 100's pack 180\n\tSomatec\tHyo TAB dr 10mg 100's pack 161\n\tSquare\tBelcopan TAB dr 10mg 100's pack \n\tSupreme\tHybucin TAB dr 10mg 100's pack 160\n\tZenith\tSpasmozen TAB dr 10mg 100's pack 180\n\tIndication: Gastrointestinal tract spasm, Abdominal pain, Genitourinary spasm\n\nDose: Adult: PO Genito-urinary spasm; GI tract spasm As butylbromide: 20 mg 4 times/day.\n\nIV/IM Genito-urinary spasm; GI tract spasm As butylbromide: 20 mg, repeat 30 mins later if needed. Max: 100 mg/day. \n\n\n\nContra-indication: Narrow-angle glaucoma, acute haemorrhage, paralytic ileus, tachycardia due to cardiac insufficiency, myasthenia gravis.\n\nSide effects: Flushing, postural hypotension, tachycardia, fibrillation. Rarely psychotic reactions. Dizziness, drowsiness, fatigue, headache, memory loss. Dry skin, erythema, increased sensitivity to light, rash. Bloatedness, constipation, dry throat, dysphagia, nausea, vomiting, xerostomia. Dysuria, urinary retention. Tremor, weakness. Impaired accommodation, blurred vision, cycloplegia, dryness, narrow-angle glaucoma, increased intraocular pain, itching, photophobia, pupil dilation. Dry nose. Decreased diaphoresis, heat intolerance. Ophthalmic: Somnolence, dermatitis, oedema, exudate, follicular conjunctivitis, increased IOP, local irritation, photophobia, vascular and respiratory congestion.\nPotentially Fatal: CNS depression, coma, circulatory and respiratory failure.\n\nPrecaution: Hepatic/renal disease, pyloric stenosis, urinary retention, prostatic hyperplasia, psychosis, seizure disorders, ulcerative colitis, coronary artery disease, tachyarrhythmias, heart failure, hypertension. Elderly, children, pregnancy, lactation.\n\nMode of action: Additive sedative effects with alcohol or other CNS depressants. Reduced effects with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine).\nPotentially Fatal: Effect potentiated by other anticholinergic drugs and TCAs.\n\nPregnancy category: C\n\nInteraction: Additive sedative effects with alcohol or other CNS depressants. Reduced effects with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine).\nPotentially Fatal: Effect potentiated by other anticholinergic drugs and TCAs.
Hypromellose 0.3 % Eye prep	\n\n\tACI\tAtier 0.3% Eye Drops   10 ml drop 65.45\n\tAsiatic Ltd.\tOcutear 0.3% Eye Drops   10 ml drop 65\n\tBeximco\tHyprosol Eye Drops   10 ml drop 65\n\tBio Pharma Ltd.\tTearin Eye Drops 0.3 %  \n\tNavana\tIclear 0.3% Eye Drops   10ml drop 70\n\tOpso Saline Ltd.\tEyefresh 0.3% Eye Drops   10 ml drop 70.26\n\tReman Drug Ltd.\tTearsol 0.3% Eye Drops   10 ml drop 80\n\tIndication: Dry eye, Ophthalmic surgery, Corneal protection\n\nDose: For dry eyes:\nAdults and children-Use 1 drop three or four times a day.\nChildren: This drug does not cause different side effects or problems in children than it does in adults.\n\nContra-indication: Known sensitivity or allergy to any ingredient of the product.\n\nSide effects: Blurred vision.\nMatting or stickiness of eyelashes\n\nPrecaution: If you experience eye pain, changes in vision, continued redness or irritation of the eye or if your symptoms continue for more than 3 days or become worse, check with your doctor .\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Hypromellose 0.5 % Eye prep	\n\n\tBio Pharma Ltd.\tTearin Eye Drops 0.5 %  \n\tG. A. Company Ltd.\tTear 0.5% Eye Drops    10 ml drop 80\n\tIncepta\tLubric 0.5% Eye Drops   10 ml drop 80\n\tNipa\tHypro 0.5% Eye Drops   5  ml drop 60\n\tIndication: Dry eye, Ophthalmic surgery, Corneal protection\n\nDose: For dry eyes:\nAdults and children-Use 1 drop three or four times a day.\nChildren: This drug does not cause different side effects or problems in children than it does in adults.\n\nContra-indication: Known sensitivity or allergy to any ingredient of the product.\n\nSide effects: Blurred vision.\nMatting or stickiness of eyelashes\n\nPrecaution: If you experience eye pain, changes in vision, continued redness or irritation of the eye or if your symptoms continue for more than 3 days or become worse, check with your doctor .\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Hypromellose 2% Eye prep	\n\n\tAristopharma\tOcugel 2% Eye gel   3  ml  120\n\tAristopharma\tHypomer Gel Eye gel 0.3gm/100gm  10gm tube 250\n\tGeneral\tViscogel Eye Drops 20 mg/ml  \n\tIncepta\tLubric 2% Eye gel   3  ml  120\n\tOpso Saline Ltd.\tEyegel 2% Eye gel   3  ml  120.45\n\tPopular\tOptagel 2% Eye gel  20 mg/ml 3ml syringe / 5 ml in glass 120.45 / 120.45\n\tIndication: Dry eye, Ophthalmic surgery, Corneal protection\n\nDose: Each pre-filled glass syringe is for single intraocular use only. The quantity injected into the anterior chamber of the eye must be adjusted according to the volume of the aqueous humour and the anatomical structure to be protected.\n\nContra-indication: There are no contraindication if used as instructed.\n\nSide effects: Post operative inflammatory reactions are not related with this product. \n\nPrecaution: Before use ensure the sterility of the product.\nRemove all the product by irrigation and/ or aspiration at the end of the procedure.\n Eye solution should be injected with the provided angled cannula.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ibandronic Acid	\n\n\tAristopharma\tIbandron TAB dr 150mg 1's pack 1056.07\n\tHealthcare\tBondrova TAB dr 150mg 1 's pack 1960\n\tIncepta\tBone Guard TAB dr 150 mg 1's pack   510\n\tLabaid\tBonaid TAB dr 150mg  \n\tOpsonin Pharma\tBonfix TAB dr 150mg  \n\tOrion Pharma Ltd.\tBoncare TAB dr 150mg  \n\tPharmacil Ltd.\tIbanova TAB dr 150mg  \n\tRadiant.\tBonova TAB dr 150mg  \n\tRenata\tIvana TAB dr 150mg 1 tab 99.5\n\tSun Pharmaceutical (Bangladesh) Ltd.\tIdrofos TAB dr 150mg 1's pack 1500\n\tF. Hoffmann La Roche,Switzerland\tBondronat Vials Injection 2.25mg 1ml x 5's pack \n\tF.Hoffmann La Roche, Switzerland\tBonviva TAB dr  1's pack 5063\n\tRoche Diagnostic, GermanyUnder Licence Roche, Swiss\tBondronat Vials Injection 1.125mg 1ml x 5's pack \n\tRoche Diagnostics GmbH,Germany\tBondronat vials Injection 6mg/6ml 6mg vial x 1's pack 25990\n\tIndication: Post-menopausal osteoporosis, Hypercalcaemia of malignancy, Breast cancer and bone metastases\n\nDose: Adult: PO Prevention and treatment of postmenopausal osteoporosis As ibandronic acid: 150 mg once mthly on the same date each mth or 2.5 mg/day. Prevention of skeletal events in breast cancer and bone metastases As ibandronic acid: 50 mg/day. IV Hypercalcaemia of malignancy As ibandronic acid: 2-4 mg as a single dose. Max: 6 mg/dose. Prevention and treatment of postmenopausal osteoporosis As ibandronic acid: 3 mg once 3 mthly. Prevention of skeletal events in breast cancer and bone metastases As ibandronic acid: 6 mg 3-4 wkly.\n\nContra-indication: Severe renal impairment, uncorrected hypocalcaemia, acute upper GI inflammation, inability to stand or sit upright for at least 60 min (oral).\n\nSide effects: Fever; influenza-like syndrome; electrolyte disturbances; GI disturbances; musculoskeletal pain; headache; rash, allergic dermatitis; anaemia; decreased alkaline phosphatase; hypercholesterolaemia; UTI; local reactions (parenteral); renal impairment (parenteral).\n\nPrecaution: History of bone/joint/muscle pain; dysphagia, oesophageal disease, gastritis, duodenitis, ulcers. Risk factors for osteonecrosis of the jaw. Pregnancy and lactation.\n\nMode of action: Impaired absorption with aluminium, calcium, iron, magnesium compounds. Increased risk of GI or renal adverse effects with NSAIDs. Additive hypocalcaemic effects with aminoglycosides.\n\nPregnancy category: C\n\nInteraction: Impaired absorption with aluminium, calcium, iron, magnesium compounds. Increased risk of GI or renal adverse effects with NSAIDs. Additive hypocalcaemic effects with aminoglycosides.
Ibuprofen	\n\n\tACI\tFlamex Suspension 100mg/5ml 100ml bot 33.81\n\tACI\tFlamex TAB dr 200mg 100's pack 88\n\tACI\tFlamex SR CAP 300mg 50's pack 200.50\n\tACI\tFlamex TAB dr 400mg 100's pack 143\n\tAcme Ltd.\tProfen Suspension 100mg/5ml 100ml bot 33.70\n\tAcme Ltd.\tProfen TAB dr 400mg 100's pack 142\n\tAexim\tNeoflam TAB dr 400mg 100ml bot 140\n\tAlbion Ltd.\tAlflam TAB dr 400 mg 100's pack \n\tAlbion Ltd.\tAlflam Suspension 100 mg/5 ml 100ml bot \n\tAlco Pharma\tFlampen TAB dr 400mg 100's pack 130\n\tBengal Drugs & Chemical Works Pharm. Ltd.\tBeflam TAB dr 400mg 100's pack 182\n\tBeximco\tReumafen Suspension 100mg/5ml 100ml bot 33.71\n\tBeximco\tReumafen TAB dr 200mg 100's pack 88\n\tBeximco\tReumafen TAB dr 400mg 100's pack 142\n\tBristol Pharma Ltd.\tUniflam TAB dr 400mg 100's pack 100\n\tCosmic Chemical Industries Ltd.\tIfen TAB dr 400mg 100's pack 140\n\tCosmo Pharma Ltd.\tCpfen TAB dr 400mg 100's pack 131\n\tDecent Pharma Ltd.\tIbf TAB dr 400mg 100's pack 125\n\tDesh\tDeflam TAB dr 400mg 100's pack 140\n\tDoctor's Chemicals Works Ltd.\tDeprofen TAB dr 200mg 100's pack \n\tDoctor's Chemicals Works Ltd.\tDeprofen TAB dr 400mg 100's pack 69\n\tDrug International Ltd.\tBufen SR CAP 300mg 100's pack 405\n\tEdruc Ltd.\tErofen TAB dr 400mg 100's pack 135\n\tGlobe\tNeorofen TAB dr 400mg  100's pack 100\n\tGonoshasthaya\tG Ibuprofen TAB dr 400mg 100's pack 121\n\tHudson\tArafa TAB dr 400mg 100's pack 100\n\tIndobangla Pharmaceuticals\tIndoflam Suspension 100mg/5ml 100ml bot 18\n\tMedimet\tIburex TAB dr 200mg 100's pack 80\n\tMedimet\tIburex TAB dr 400mg 100's pack 120\n\tModern\tTrufen TAB dr 400mg 100's pack 126\n\tNipa\tAnafen TAB dr 400mg  100's pack 142\n\tNovartis (Bangladesh) Ltd.\tServiprofen TAB dr 400mg 100's pack \n\tOpsonin Pharma\tAdvel Suspension 100mg/5ml 100 ml bot 29.66\n\tOpsonin Pharma\tAdvel TAB dr 200mg 100's pack 88\n\tOpsonin Pharma\tAdvel TAB dr 400mg 100's pack 142\n\tPharmadesh Ltd.\tRapofen TAB dr 400mg  100's pack 133\n\tRenata\tRebuprofen TAB dr 400mg 100's pack 145\n\tSanofi Aventis (BD) Ltd.\tInflam Suspension 100mg/5ml 100ml bot 18.65\n\tSanofi Aventis (BD) Ltd.\tInflam TAB dr 200mg 100's pack 301\n\tSanofi Aventis (BD) Ltd.\tInflam TAB dr 400mg 50's pack 251\n\tSanofi Aventis (BD) Ltd.\tInflam TAB dr 300 mg 100's pack 402.01\n\tSilva\tSiflam TAB dr 400mg 100's pack 120.44\n\tZenith\tIben TAB dr 400mg 100's pack 130\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Pain, Fever, Pericarditis, Dysmenorrhea, Patent ductus arteriosus, Inflammation, Musculoskeletal and joint disorders\n\nDose: Adult: PO Pain and inflammation 1.2-1.8 g/day in divided doses. Maintenance: 0.6-1.2 g/day. Max: 2.4 g/day. \nFever 200-400 mg 4-6 hrly. Max: 1.2 g/day. \n\n\n\nContra-indication: Active peptic ulcer; hypersensitivity. Neonates with congenital heart disease, suspected necrotising enterocolitis and active bleeding (parenteral).\n\nSide effects: Oral: Dyspepsia, vomitting, abdominal pain, heart burn, nausea, diarrhoea, epigastric pain, edema, fluid retention, dizziness, rash, tinnitus. Parenteral: Intraventricular hemorrhage, skin irritation, hypocalcemia, hypoglycemia, GI disorders, anemia, apnea, respiratory infection, sepsis.\nPotentially Fatal: Severe CV thrombotic events. Severe GI bleeding, ulceration and perforation.\n\nPrecaution: Asthma; renal or hepatic disorders; bleeding disorders; CV disease. Pregnancy, lactation.\n\nMode of action: Increased risk of GI bleeding w/ warfarin, corticosteroids, SSRIs and aspirin. May reduce the natriuretic effects of diuretics. Reduced antihypertensive effect of ACE inhibitors and angiotensin II receptor antagonists. May increase toxicity of lithium and methotrexate. Increased nephrotoxicity w/ ciclosporin and tacrolimus.\n\nPregnancy category: D\n\nInteraction: Increased risk of GI bleeding w/ warfarin, corticosteroids, SSRIs and aspirin. May reduce the natriuretic effects of diuretics. Reduced antihypertensive effect of ACE inhibitors and angiotensin II receptor antagonists. May increase toxicity of lithium and methotrexate. Increased nephrotoxicity w/ ciclosporin and tacrolimus.
Idoxuridine 0.1% Eye prep	\n\n\tOpso Saline Ltd.\tHerplex Eye Drops   10 ml drop 60.23\n\tIndication: Herpes simplex keratitis\n\nDose: Adult: As 0.1% soln: Instill 1 drop in the affected eye(s) every hr. Taper to every 2 hr or 4 times daily. Continue treatment for at least 7 days.\n\nContra-indication: Hypersensitivity.\n\nSide effects:  Ophthalmic: Irritation; inflammation of the eye or eyelids; pain; photophobia; pruritus; conjunctivitis; oedema. Rarely, lachrymal duct occlusion and hypersensitivity reactions. Corneal damage (prolonged use).\n\nPrecaution: Deep ulceration of the stromal layers of the cornea. Avoid prolonged use. Pregnancy and lactation.\n\nMode of action: Corticosteroids may accelerate spread of viral infection.\n\nPregnancy category: C\n\nInteraction: Corticosteroids may accelerate spread of viral infection.
Ifosfamide	\n\n\tSanofi Aventis (BD) Ltd.\tHoloxan Injection 2gm 1's pack 4810.55\n\tSanofi Aventis (BD) Ltd.\tHoloxan Injection 1gm 1's pack 3049.80\n\tTechno Drugs Ltd.\tIfamide Injection 1gm/vial 1's pack 1800\n\tTechno Drugs Ltd.\tIfamide Injection 2gm/vial 1's pack 3200\n\tIndication: Breast cancer, Lung cancer, Ovarian cancer, Lymphoma, Testicular cancer, Soft tissue sarcoma, Osteogenic sarcoma, Cervical cancer\n\nDose: Adult: IV Lymphoma; Sarcoma; Solid tumours Different licensed dosage regimens are available. 8-12 g/m2 divided over 3-5 days, repeat course 2-4 wkly. \nGerm cell testicular carcinoma W/ mesna and adequate hydration: 1.2 g/m2/day for 5 days, repeat treatment 3 wkly or after recovery from haematological toxicity.\n\nRenal impairment:\nCrCl (ml/min)	\n<10 	Administer 75% of dose. \n\nContra-indication: Hypersensitivity; severe bone-marrow depression. Pregnancy, lactation.\n\nSide effects: Confusion, alopoecia, nausea, vomiting, phloebitis, somnolence, depression, hallucinations. Wound healing may be impaired during ifosfamide use.\nPotentially Fatal: Severe myelosuppression, haemorrhagic cystitis, nephrotoxicity, cardiotoxicity, coma.\n\nPrecaution: Hepatic or renal dysfunction, compromised bone marrow reserve. Use with mesna and ensure high oral/IV fluid intake to reduce urotoxic effects.\n\nMode of action: Causes enhanced toxicity with allopurinol, cisplatin. Ifosfamide enhances the anticoagulant effect of warfarin. CYP2A6 inducers (e.g. amobarbital, pentobarbital, phenobarbital, rifampin and secobarbital) may reduce serum levels of ifosfamide while the inhibitors (e.g. isoniazid, methoxsalen and miconazole) may increase its serum levels. CYP3A4 inducers (e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins) may reduce serum levels of ifosfamide while the inhibitors (e.g. azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid) may increase its serum levels.\n\nPregnancy category: D\n\nInteraction: Causes enhanced toxicity with allopurinol, cisplatin. Ifosfamide enhances the anticoagulant effect of warfarin. CYP2A6 inducers (e.g. amobarbital, pentobarbital, phenobarbital, rifampin and secobarbital) may reduce serum levels of ifosfamide while the inhibitors (e.g. isoniazid, methoxsalen and miconazole) may increase its serum levels. CYP3A4 inducers (e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins) may reduce serum levels of ifosfamide while the inhibitors (e.g. azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid) may increase its serum levels.
Imatinib	\n\n\tBeacon\tImanix TAB dr 100mg 30's pack 3000\n\tBeacon\tImanix 400 TAB dr 400mg  \n\tOrion Pharma Ltd.\tEnliven CAP 100mg 28's pack 3513.16\n\tTechno Drugs Ltd.\tImatin TAB dr 400mg  \n\tNovartis Pharma AG, Switzerland\tGlivec CAP 100mg 120's pack 16872\n\tIndication: Chronic myeloid leukaemia, Acute lymphoblastic leukaemia, Myelodysplastic disease, Hypereosinophilic syndrome, Mastocytosis, Dermatofibrosarcoma protuberans, Malignant gastrointestinal stromal tumours\n\nDose: Adult: PO Chronic myeloid leukaemia Chronic phase: 400 mg/day, up to 600 mg/day. Blast crisis or aceelerated phase: 600 mg/day, up to 400 mg twice daily if needed. \n\nAcute lymphoblastic leukaemia; Monotherapy in relapsed or refractory acute lymphoblastic leukaemia 600 mg/day w/ induction, maintenance or consolidation therapy. \n\nHypereosinophilic syndrome; Myelodysplastic disease 400 mg/day. Unresectable, metastatic GI stromal tumours 400 or 600 mg/day. \n\nMastocytosis 400 mg/day. Start w/ 100 mg/day if there is associated eosinophilia. Dermatofibrosarcoma protuberans 400 mg twice daily.\n\nContra-indication: Lactation.\n\nSide effects: Fluid retention/oedema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhoea, rash. Fatigue, asthenia, headache, dizziness, insomnia, depression, anxiety, joint pain, arthralgia, myalgia, back pain, abdominal pain, flatulence, dyspepsia, loose stools, anorexia, constipation, taste disturbance, nasopharyngitis, cough, pharyngolaryngeal pain, pharyngitis, sinusitis, upper respiratory tract infection, pneumonia, influenza, dyspnoea, haemorrhage, pyrexia, increased wt, night sweats, rigors, hepatotoxi\n\nPrecaution: Cardiac disease or increased risk for CHF. Monitor for signs of severe fluid retention. Monitor CBC regularly. Renal and hepatic impairment. Monitor LFTs. Pregnancy.\n\nMode of action: Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.\n\nPregnancy category: D\n\nInteraction: Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.
Imipramine Hydrochloride	\n\n\tAristopharma\tPinor TAB dr 25mg 100's pack 400\n\tIncepta\tPramin TAB dr 25mg 50's pack 100\n\tIncepta\tPramin TAB dr 75 mg 100's 200\n\tNovartis (Bangladesh) Ltd.\tTofranil TAB dr 25mg 100's pack 460\n\tSquare\tDepram TAB dr 25mg 50's pack 150.29\n\tIndication: Depression,Nocturnal enuresis\n\nDose: Depression, initially up to 75 mg daily in divided doses increased gradually to 150-200 mg (up to 300 mg in hospital patients); up to 150 mg may be given as a single dose at bedtime; elderly initially 10 mg daily, increased gradually to 30-50 mg daily; child not recommended for depression.\nNocturnal enuresis, child 7-8 years 25 mg, 8-11 years 25-50 mg, over 11 years 50-75 mg at bedtime; max. period of treatment (including gradual withdrawal) 3 months-full physical examination before further course.\n\nContra-indication: Imipramine should not be given in conjunction with, or within 14 days of treatment with a MAO inhibitor. Combined therapy of this type could lead to the appearance of serious interactions such as hypertensive crises, hyperactivity, hyperpyrexia, spasticity, severe convulsions or coma and death may occur. Imipramine is contraindicated in patients with existing severe hepatic or renal damage, and those with a history of blood dyscrasias. Imipramine is contraindicated in patients who have shown hypersensitivity to the drug or hypersensitivity to tricyclic antidepressants belonging to the dibenzazepine group. Imipramine is contraindicated for use during the acute recovery phase following a myocardial infarction. It should not be used in patients with convulsive disorders or glaucoma. \n\nSide effects: The most frequent of side effects are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, dizziness, and decreased coordination. Dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. Imipramine usage has been linked to both increases and decreases in blood pressure and heart rate. Heart attacks, congestive heart failure, and strokes have been reported. Confusion, disorientation, delusions, insomnia, and anxiety have also been reported as side effects in a small percentage of people taking imipramine. Problems associated with the skin (loss of sensation, numbness and tingling, rashes, spots, itching and puffiness), seizures, and ringing in the ears have also been reported. Nausea, vomiting, loss of appetite, diarrhea, and abdominal cramping are all side effects associated with imipramine usage in a small number of people.\n\nPrecaution: Imipramine should be used cautiously and with close physician supervision in people, especially the elderly, who have benign prostatic hypertrophy, urinary retention, and glaucoma, especially angle-closure glaucoma. The sedative effect is increased when imipramine is taken with other central nervous system depressants, such as alcoholic beverages, sleeping medications, other sedatives, or antihistamines. Imipramine may increase heart rate and stress on the heart. It may be dangerous for people with cardiovascular disease, especially those who have recently had a heart attack, to take this drug or other antidepressants in the same pharmacological class. Older people and persons with a history of heart disease may develop heart arrhythmias, heart conduction abnormalities, congestive heart failure, heart attack, abnormally rapid heart rates and strokes. Until a therapeutic dosage has been determined, people starting imipramine should be closely watched for signs of suicide. The risk of suicide is increased when imipramine is taken in overdose or combined with alcohol. Manic episodes and the emergence of symptoms of pre-existing psychotic states have been reported when imipramine therapy is started.\n\nMode of action: Increased plasma levels and effects with quinidine, cimetidine, SSRIs, propafenone, flecainide. Reduced plasma levels with barbiturates, phenytoin. May increase effects of anticholinergic drugs. Severe orthostatic hypotension with altretamine. Causes drowsiness and impaired performance in combination with alcohol.\nPotentially Fatal: Severe hypertension with adrenaline, noradrenaline and methylphenidate. Reduces hypotensive effects of guanethidine, bethanidine, debrisoquine, bretylium, methyldopa and clonidine. Possible serotonin syndrome with MAOIs, separate admin by 3 wk.\n\nPregnancy category: D\n\nInteraction: Increased plasma levels and effects with quinidine, cimetidine, SSRIs, propafenone, flecainide. Reduced plasma levels with barbiturates, phenytoin. May increase effects of anticholinergic drugs. Severe orthostatic hypotension with altretamine. Causes drowsiness and impaired performance in combination with alcohol.\nPotentially Fatal: Severe hypertension with adrenaline, noradrenaline and methylphenidate. Reduces hypotensive effects of guanethidine, bethanidine, debrisoquine, bretylium, methyldopa and clonidine. Possible serotonin syndrome with MAOIs, separate admin by 3 wk.
Indapamide	\n\n\tACI\tNatrilex SR TAB dr 1.5mg 30's pack 264.90\n\tAristopharma\tXelix SR TAB dr 1.5mg 30's pack 150\n\tBeximco\tIndelix SR TAB dr 1.5mg 30's pack 180\n\tDrug International Ltd.\tIndapa SR TAB dr 1.5mg 50's pack 250\n\tHealthcare\tIndimide SR TAB dr 1.5mg 30's pack 195\n\tIncepta\tIdatix TAB dr 2.5mg 30's pack 150\n\tIncepta\tIdatix SR TAB dr 1.5mg 30's pack 150\n\tMundipharma (Bangladesh) Pvt. Ltd.\tIndicontin TAB dr 1.5mg 30's pack \n\tNovartis (Bangladesh) Ltd.\tDihert SR TAB dr 1.5mg 28's pack 224\n\tOpsonin Pharma\tHypen TAB dr 2.5mg 30's pack 150\n\tOpsonin Pharma\tHypen SR TAB dr 1.5mg 30's pack 150\n\tOrion Pharma Ltd.\tMicturex SR TAB dr 1.5mg 20's pack 150\n\tRenata\tIpide SR TAB dr 1.5mg 30's pack 150\n\tRenata\tNatri-SR TAB dr 1.5mg 30's pack 150\n\tSharif\tIndamid SR TAB dr 1.5mg 30's pack 150\n\tSilva\tTrilix TAB dr 1.5mg 20's pack\n 100\n\tSilva\tTrilix SR TAB dr 1.5mg 20's pack 100.38\n\tSquare\tRepres SR TAB dr 1.5mg 30's pack 150.43\n\tLes Servier Industrie,France\tNatrilix SR TAB dr 1.5mg 30's pack 264\n\tLes Servier Industrie,France\tNatrilix 	 	 	 	 TAB dr 2.5 mg 10's pack 105.60\n\tIndication: Hypertension, Congestive heart failure\n\nDose: Hypertension\nAdult: 1.25-2.5 mg once daily, alone or in conjunction with other antihypertensives.\nOedema\nAdult: 2.5 mg once daily increased to 5 mg daily after 1 wk if needed.\n\nContra-indication: Anuria, severe hepatic impairment.\n\nSide effects: Headache, dizziness, weakness, drowsiness, fatigue, agitation, nervousness, anorexia, nausea, vomiting, pain, diarrhoea, constipation, orthostatic hypotension, palpitations, hypokalaemia, hyponatraemia, metabolic alkalosis.\n\nPrecaution: Pregnancy, lactation, elderly, renal impairment, fluid or electrolyte imbalance, hyperuricaemia, DM, lupus erythematosus.\n\nMode of action: Additive effect with other antihypertensive agents and diuretics. Increased chance of hypokalaemia with corticosteroids, corticotropin and amphotericin.\nPotentially Fatal: Increased risk of lithium toxicity. Hypokalaemia enhances digitalis toxicity with cardiac gycosides.\n\nPregnancy category: D\n\nInteraction: Additive effect with other antihypertensive agents and diuretics. Increased chance of hypokalaemia with corticosteroids, corticotropin and amphotericin.\nPotentially Fatal: Increased risk of lithium toxicity. Hypokalaemia enhances digitalis toxicity with cardiac gycosides.
Indapamide + Perindopril Erbumine	\n\n\tAsiatic Ltd.\tPericard Plus1.25/4 TAB dr   10's pack 120\n\tAsiatic Ltd.\tPericard Plus 0.625/2 TAB dr   30's pack 210\n\tBeximco\tInduric Plus 2/625 TAB dr   1's pack 7\n\tDelta Pharma\tInopil PLUS 2/625 TAB dr  20's pack 160\n\tDelta Pharma\tInopil PLUS 4/1.25 TAB dr   20's pack 160\n\tIncepta\tIndapril TAB dr   30's pack 210\n\tIncepta\tIndapril- 4 TAB dr   20's pack 240\n\tOpsonin Pharma\tPerindal 2 + 2/625 TAB dr   30's pack 210\n\tOpsonin Pharma\tPerindal 4 + 4/1.25 TAB dr   20's pack 240\n\tRenata\tPendoril PLUS 2/625 TAB dr   10's pack 80.30\n\tRenata\tPendoril PLUS 4/1.25 TAB dr   10's pack 130.50\n\tSquare\tRepres PLUS 4/1.25 TAB dr  1.25 mg + 4 mg 20's pack 240.99\n\tSquare\tRepress PLUS 2/625 TAB dr  625 mcg + 2 mg 30's pack 210.67\n\tIndication: Hypertension\n\nDose: Adult: PO Per tab contains perindopril 4 mg and indapamide 1.25 mg: 1 tab once daily.\n\nRenal impairment:\nCrCl (ml/min)	\n<30	        Avoid use.\n30-60	Dose adjustment may be needed. \n\nContra-indication: Hypersensitivity. Severe renal impairment (CrCl <30 ml/min), hypokalaemia, severe hepatic impairment or hepatic encephalopathy, history of angioedema associated with treatment with an ACE inhibitor, children. Dialysis patients or patients with untreated decompensated heart failure. Hereditary/idiopathic angioneurotic oedema. Pregnancy and lactation.\n\nSide effects: Dry cough, headache, bradycardia, dizziness, asthenia, hypokalaemia and orthostatic hypotension. GI effects such as constipation, dry mouth, nausea, epigastric pain, anorexia, abdominal pain and taste disturbance.\n\nPrecaution: Impaired renal function, risk of hypotension and electrolyte imbalance. Regular monitoring of renal function and plasma levels of potassium are recommended. Blood glucose levels should be monitored in diabetic patients especially in those with low serum potassium levels. Increased risk of neutropenia/agranulocytosis in immunosuppressed patients. Treatment should be discontinued immediately if there is angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx.\n\nMode of action: Additive effect with other antihypertensive agents and diuretics. Increased chance of hypokalaemia with corticosteroids, corticotropin and amphotericin.\nPotentially Fatal: Increased risk of lithium toxicity. Hypokalaemia enhances digitalis toxicity with cardiac gycosides.\n\nPregnancy category: D\n\nInteraction: Additive effect with other antihypertensive agents and diuretics. Increased chance of hypokalaemia with corticosteroids, corticotropin and amphotericin.\nPotentially Fatal: Increased risk of lithium toxicity. Hypokalaemia enhances digitalis toxicity with cardiac gycosides.
Indomethacin	\n\n\tACI\tInsaid CAP 25mg  \n\tACI\tInsaid SR CAP 75mg  \n\tAcme Ltd.\tIndo-A Suppository 100mg 10's pack 70\n\tAcme Ltd.\tIndo-A CAP 25mg 10's pack 87.97\n\tAlbion Ltd.\tIndomethacin CAP 25 mg 100's  pack \n\tAristopharma\tReumacap CAP 25mg 100's pack 100\n\tAristopharma\tReumacap SR CAP 75mg 100's pack 400\n\tAristopharma\tReumacid Suppository 100mg 20's pack 180\n\tAsiatic Ltd.\tIndocap CAP 25mg 100's pack 60\n\tBristol Pharma Ltd.\tIndomethacin CAP 25mg 100's pack 50\n\tIndobangla Pharmaceuticals\tI-Cin CAP 25mg  100's pack 60\n\tJayson\tIndoxyl CAP 25mg 100's pack 63\n\tMedimet\tIndorex CAP 25mg 100's pack 100\n\tNipa\tMethacin CAP 25mg 100's pack 61\n\tNovartis (Bangladesh) Ltd.\tServimeta CAP 25mg 100's pack 180\n\tOpsonin Pharma\tIndomet Suppository 100mg 25's pack 175\n\tOpsonin Pharma\tIndomet CAP 25mg 100's pack 100\n\tOpsonin Pharma\tIndomet SR CAP 75mg 50's pack 200\n\tPacific\tImet CAP 25mg 100's pack 100\n\tPacific\tImet SR CAP 75mg 50's pack 200\n\tPharmadesh Ltd.\tRheumet CAP 25mg 100's pack 62\n\tReliance\tIndomin CAP 25mg 100's pack 100\n\tSalton\tMetrocin CAP 25mg 100's pack 60\n\tIndication: Rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis (degenerative joint disease), gout, acute non-articular rheumatism (bursitis, synovitis, tendinitis). \n\nDose: By mouth, rheumatic disease, 50-200 mg daily in divided doses, with food. Acute gout, 150-200 mg daily in divided doses. Dismenorrhea, upto 75 mg daily.\nChildren: Not recommended\n\nRectal\nPain and inflammation associated with musculoskeletal and joint disorders\nAdult: As supp: 100 mg to be inserted at night and repeated in the morning if necessary.\n\n\nContra-indication: Indomethacin is contraindicated in patients with ulcer, gastritis, active ulcerative colitis, and should be used with caution in patients with a history of these disorders. It is also contraindicated in previously hypersensitive patient.\n\nSide effects: Headaches, usually in the morning and mild vertigo may occur during the early weeks of therapy. These symptoms are transient and usually disappear with continued use or by reduction of the dose. Gastrointestinal reactions such as nausea, vomiting, diarrhoea, epigastric and abdominal pain are often due to large doses of the drug and disappear when the dose is reduced.\n\nPrecaution: Patient w/ known CV disease or risk factors for CV disease, fluid retention, history of GI disease (e.g. bleeding or ulcers), history of mental depression or other psychiatric disorder, epilepsy, or parkinsonian syndrome; existing infection that is adequately controlled. May mask signs and symptoms of infection. Hepatic and renal impairment. Elderly, childn. Pregnancy and lactation. \n\nMode of action: May increase plasma levels of methotrexate. Increased risk of GI bleeding w/ warfarin. May reduce hypotensive effects of hydralazine, furosemide, ?-blockers (e.g. atenolol, propranolol, oxprenolol), or thiazide diuretics. Increased risk of hyperkalaemia w/ K-sparing diuretics, ACE inhibitors, K supplements. May increase nephrotoxic effects of ciclosporin or triamterene. Increase plasma concentration w/ probenecid. May increase plasma levels of aminoglycoside (e.g. amikacin, gentamicin) in premature neonates. May enhance antipsychotic effect (e.g. severe drowsiness and confusion) of haloperidol. Al- or Mg-containing antacids may reduce GI disorders of indometacin.\nPotentially Fatal: Diflunisal decreases renal clearance and increases plasma concentrations of indometacin which leads to fatal GI haemorrhage.\n\nPregnancy category: D\n\nInteraction: May increase plasma levels of methotrexate. Increased risk of GI bleeding w/ warfarin. May reduce hypotensive effects of hydralazine, furosemide, ?-blockers (e.g. atenolol, propranolol, oxprenolol), or thiazide diuretics. Increased risk of hyperkalaemia w/ K-sparing diuretics, ACE inhibitors, K supplements. May increase nephrotoxic effects of ciclosporin or triamterene. Increase plasma concentration w/ probenecid. May increase plasma levels of aminoglycoside (e.g. amikacin, gentamicin) in premature neonates. May enhance antipsychotic effect (e.g. severe drowsiness and confusion) of haloperidol. Al- or Mg-containing antacids may reduce GI disorders of indometacin.\nPotentially Fatal: Diflunisal decreases renal clearance and increases plasma concentrations of indometacin which leads to fatal GI haemorrhage.
Inositol nicotinate	\n\n\tIncepta\tNicosit TAB dr 500mg 20's pack 100\n\tIncepta\tNicosit TAB dr 750mg 20's pack 140\n\tIndication: Adjunct treatment to Hyperlipidemia, raynaud's disease, intermittent claudication. May use in stasis ulcers, dysmenorrhea, dermatitis herpetiformis, alcoholism, diabetes, cancer prevention and hypertension.\n\nDose: Recommended dosage for lipid-lowering and improving conditions related to peripheral vascular insufficiency ranges from 1500 mg to 4 grams daily, in divided dosages of two to three times daily.\n\nContra-indication: Contraindicated to children, early stage of stroke & people who have recently had a heart attack. It should not be used if anyone is allergic to one or any of its ingredients\n\nSide effects: The most common side effects are headache, rash, paraesthesia, dizziness, nausea and vomiting, flushing, excessive fluid retention in the body tissues, postural hypotension, fainting\n\nPrecaution: Cautions should be exercised in patients with angina not well controlled by medical treatment and decreased blood supply through the vessels of the brain (cerebrovascular insufficiency).\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Insulin (Human) Regular + Insulin (Human) Isophane (pre mixed)	\n\n\tACI\tDiasulin 30/70 100 IU SC Injection 100 IU/ml 10ml bot 415\n\tACI\tDiasulin 50/50 100 IU SC Injection 100 IU/ml 10ml bot\n 415\n\tAristopharma\tInsulet 30/70 Injection  100IU/ml 4ml vial / 10ml vial 169.70 / 415\n\tIncepta\tMaxsulin 30/70 Injection  100IU 10ml X 1's pack 888\n\tIncepta\tMaxsulin 30/70 40 Injection  40IU 10ml pack 140	\n\tIncepta\tMaxsulin 50/50 Injection 100IU/ml  10ml X 1's pack 422.15\n\tIncepta\tMaxsulin 50/50 Injection  100 IU/ml 10ml vial 888\n\tIncepta\tMaxsulin 30/70 100 Injection 100IU 3ml X 4's pack 888\n\tIncepta\tMaxsulin 50/50 Penset Injection 100IU 3ml X 4's pack 888\n\tPopular\tInsul 30/70 100IU Injection   10 ml vial/ 3ml cartridge X 5's pack 415/1110\n\tPopular\tInsul 30/70 40IU Injection   10 ml vial 195\n\tPopular\tInsul 50/50 Injection 100IU/ml  10ml	vial / 3ml x 5's pack 415/1110\n\tSquare\tAnsulin 30/70 Injection 100 IU / 40 IU 10 ml vial  415 / 195\n\tSquare\tAnsulin 50/50 Injection 100IU/ml  10ml vial 415\n\tEli Lilly France SA, France\tHumulin 70/30 Injection  100IU/ml 4ml vial/ 10ml vial/ 3ml cartridge x 5's pack 310/680/2210\n\tNovo Nordisk A/S Denmark\tMixtard 30 Injection 100 IU/ml, 40 IU/ml 10 ml vial  570, 260\n\tNovo Nordisk A/S Denmark\tMixtard 30 NovoLet Injection 100IU/ml 3ml (prefilled syringe) x 5s pack 2720\n\tNovo Nordisk A/S Denmark\tMixtard 50 Injection 100IU/ml  10ml vial \n\tNovo Nordisk A/S Denmark\tMixtard 50 Penfill Injection 100IU/ml  3ml cartridge X 5's pack 1830\n\tNovo Nordisk A/S Denmark\tMixtard 30 Penfill Injection  100IU/ml 3ml cartridge X 5's pack 1830\n\tNovo Nordisk A/S Denmark\tMixtard 50 NovoLet Injection 100IU/ml 3ml (prefilled syringe) x 5s pack 2720\n\tSanofi Aventis, Germany\tInsuman Comb 25 Injection 100 IU/ml 5 ml vial  281.70 \n\tIndication: Diabetes mellitus\n\nDose: Adult: SC DM Dosage should be individualised and adjusted based on patient's glycaemic response. Usual range: 0.5-1 u/kg/day.\nMorning: Give 2/3rds of daily insulin SC\n    Ratio of regular insulin to NPH (isophane) insulin 1:2\n\nEvening: Give 1/3 of daily insulin SC\n\n\nContra-indication: Hypoglycaemia.Hypersensitivity to any of the components. \n\nSide effects: Adverse events commonly associated with human insulin therapy include the following: Allergic reactions. Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance\n\nPrecaution: Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. Regular monitoring of HbA1c and blood glucose concentrations.\n\nMode of action: Oral hypoglycemic agents, MAOIs, nonselective ?-blocker, ACE inhibitors, salicylates, alcohol, anabolic steroids & sulphonamides may reduce insulin requirement. OCs, thiazides, glucocorticoids, thyroid hormones, ?-sympathomimetics & danazol may increase insulin requirements. \n\nOctreotide/lanreotide may both decrease & increase insulin requirement. ?-blockers may mask symptoms of hypoglycemia. Alcohol may intensify or reduce hypoglycemic effect of insulin.\n\nPregnancy category: B\n\nInteraction: Oral hypoglycemic agents, MAOIs, nonselective ?-blocker, ACE inhibitors, salicylates, alcohol, anabolic steroids & sulphonamides may reduce insulin requirement. OCs, thiazides, glucocorticoids, thyroid hormones, ?-sympathomimetics & danazol may increase insulin requirements. \n\nOctreotide/lanreotide may both decrease & increase insulin requirement. ?-blockers may mask symptoms of hypoglycemia. Alcohol may intensify or reduce hypoglycemic effect of insulin.
Insulin (Human) N	\n\n\tAristopharma\tInsulet N Injection  100IU/ml 4ml vial 169.70\n\tIbn Sina Pharmaceutical Ind. Ltd.\tH-Insulin50/50 Injection  1's pack(100IU) \n\tIbn Sina Pharmaceutical Ind. Ltd.\tH-Insulin N Injection  1's pack(100IU) \n\tIncepta\tMaxsulin N 100 Injection 100IU/ml 10ml X 1's pack 415\n\tIncepta\tMaxsulin N 40 Injection 40IU/ml 10ml X 1's pack 195\n\tPopular\tInsul N Injection 100IU/ml 10 ml vial/ 3ml cartridge X 5's pack 415/1110\n\tPopular\tInsul N Injection 40IU/ml 10 ml vial 195\n\tSquare\tAnsulin N Injection 100IU/ml 10 ml vial 415\n\tSquare\tAnsulin N Injection 40IU/ml 10 ml vial 195\n\tEli Lilly France SA, France\tHumulin N Injection  100IU/ml 316 4ml vial\n\tSanofi Aventis, Germany\tInsuman Basal Injection  100IU/ml 5 ml vial \n\tNovo Nordisk\tInsulin Insulatard Injection 40IU/ml, 100IU/ml 10 ml vial 260 / 580\n\tNovo Nordisk\tInsulatard Penfill Injection 100IU/ml 3ml x 5's pack 1775\n\tIndication: Diabetes mellitus\n\nDose: Adult:  SC DM Dosage should be individualised and adjusted based on patient's glycaemic response. Usual range: 0.5-1 u/kg/day.\n\nContra-indication: Hypoglycaemia. Hypersensitivity to any of the components. \n\nSide effects: Adverse events commonly associated with human insulin therapy include the following:  Allergic reactions.  Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance\n\nPrecaution: Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. During infection.\n\nMode of action: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.\n\nPregnancy category: B\n\nInteraction: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
Insulin (Human) R	\n\n\tAristopharma\tInsulet R Injection  100IU/ml 4ml vial/10ml vial 169/415 	\n\tIbn Sina Pharmaceutical Ind. Ltd.\tH Insulin 30/70 Injection  1's pack(100IU) \n\tIbn Sina Pharmaceutical Ind. Ltd.\tH-Insulin R Injection  1's pack(100IU) \n\tIncepta\tMaxsulin R 100 Injection 100IU/ml 10ml X 1's pack 415\n\tIncepta\tMaxsulin R 40 Injection 40IU/ml 10ml X 1's pack 195\n\tIncepta\tMaxsulin R Penset Injection 100IU 3ml X 4's pack 888\n\tPopular\tInsul R Injection 100IU/ml 100 i.u X 3ml cartridge 1110\n\tPopular\tInsul R Injection 40IU/ml 40 i.u X 10ml vial 195\n\tSquare\tAnsulin R Injection 100IU/ml 100 i.u X 10ml vial 415\n\tSquare\tAnsulin R Injection 40IU/ml 40 i.u X 10ml vial 195\n\tEli Lilly France SA, France\tHumulin R Injection  100IU/ml 4ml vial/10ml vial/3ml Cartridge X 5's pack  316/666/1957 \n\tSanofi Aventis, Germany\tInsuman Rapid Injection  100IU/ml 5 ml vial 281.70\n\tNovo Nordisk\tActrapid Insulin Injection 40IU/ml 10ml vial 250\n\tNovo Nordisk\tActrapid Penfill Injection  100IU/ml 3ml x 5's pack 1775\n\tNovo Nordisk\tActrapid Insulin Injection 100IU/ml 10ml vial 560\n\tNovo Nordisk\tActrapid HM Injection 100IU/ml 3ml x 5'spack 1830\n\t Boehringer Ingelheim Pharmaceutical\tAnsulin 30/70 pen Injection 100IU/ml 3ml vial 222\n\tIndication: Diabetic ketoacidosis, Diabetes mellitus\n\nDose: Adult: SC DM Dosage should be individualised and adjusted based on patient's glycaemic response. Usual range: 0.5-1 u/kg/day.\n\nIV Diabetic ketoacidosis As soluble insulin at a concentration of 1 u/mL via an infusion pump: Initial: Infuse at a rate of 6 u/hr, double or quadruple the rate if blood glucose concentration do not decrease by about 5 mmol/L/hr. If blood glucose concentrations have decreased to 10 mmol/L, reduce infusion rate to 3 u/hr and continue w/ 5% glucose until the patient can eat orally. \n\nIM Diabetic ketoacidosis As soluble insulin: Loading dose: 20 u, then 6 u/hr until blood glucose drops to 10 mmol/L, when the dose is given 2 hrly. SC DM Dosage should be individualised and adjusted based on patient's glycaemic response.\n\nContra-indication: Hypoglycaemia.Hypersensitivity to any of the components. \n\nSide effects: Adverse events commonly associated with human insulin therapy include the following: Allergic reactions. Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance\n\nPrecaution: Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. Regular monitoring of HbA1c and blood glucose concentrations.\n\nMode of action: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.\n\nPregnancy category: B\n\nInteraction: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
Insulin Lispro	\n\n\tPopular\tInsul Lispro Injection 100IU/ml  3ml vial X 1's pack/ 3ml cartridge X 3's pack 500/1500\n\tPopular\tINSUL LISPRO Injection 100 IU/ml 3ml x1's/3ml cartridge x3's 1500.00\n\tEli Lilly France SA, France\tHumalog Kwikpen Injection 100u/ml 3ml 570\n\tIndication: Diabetes mellitus\n\nDose: Adult: SC Dosing regimen should be individualised and adjusted based on patient's glycaemic response. Adult: SC Usual range: 0.5-1 u/kg/day. \n\nType 1 diabetes mellitus\n\n    Approximately one third of the total daily insulin requirements SC; rapid-acting or short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements\n    Usual daily maintenance range is 0.5-1 unit/kg/day in divided doses; nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.8-1.2 units/kg/day\n\nType 2 diabetes mellitus\n\n    Type 2 diabetes mellitus inadequately controlled with oral medication\n    10 units/day SC (or 0.1-0.2 unit/kg/day) of intermediate- or long-acting insulin given at bedtime generally recommended; as an alternative, rapid-acting formulations, such as insulin lispro, given before meals have also been used; dose must be adjusted carefully.\n\n\nContra-indication: Hypoglycaemia.Hypersensitivity to any of the components.\n\nSide effects: Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj.\n\nPrecaution: Renal or hepatic impairment; pregnancy, lactation; transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections.\n\nMode of action: Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by ?-blockers, clonidine.\n\nPregnancy category: B\n\nInteraction: Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by ?-blockers, clonidine.
Interferon Alfa-2a	\n\n\tBeacon\tInteron 	 Injection   4.5 MIU/0.5ml  1's pack 1200\n\tHoffman-La Roche Ltd.Switzerland\tRoferon-A Injection 3 MIU, 4.5 MIU 1's pack / 1's pack 1750 / 2550\n\tIndication: Renal cell carcinoma, Chronic hepatitis B, Chronic hepatitis C, Hairy cell leukaemia, AIDS related Kaposi's sarcoma, Chronic myeloid leukaemia, Follicular lymphoma, Cutaneous T-cell lymphoma, Melanoma \n\nDose: Adult: SC Renal cell carcinoma In an escalating dose of 3 million u 3 times/wk for 1 wk, then 9 million u 3 times/wk for 1 wk, then 18 million u 3 times/wk thereafter for 3-12 mth. \n\nChronic hepatitis B 2.5-5 million u/m2 3 times/wk for 4-6 mth. Chronic hepatitis C W/ ribavirin: 3-4.5 million u 3 times/wk for 6 mth. Monotherapy: 3 million u 3 times/wk for 12 mth. Hairy cell leukaemia 3 million u/day for 16-24 wk. Maintenance: 3 million u 3 times/wk, up to 24 wk. \n\nAIDS related Kaposi's sarcoma In an escalating dose of 3 million u/day for 3 days, 9 million u/day for 3 days, 18 million u/day for 3 days, and 36 million u/day (if tolerated) on days 10-84. thereafter max tolerated dose (up to 36 million u) 3 times/wk. \n\nChronic myeloid leukaemia In an escalating dose of 3 million u/day for 3 days, 6 million u/day for 3 days, and 9 million u/day thereafter. For responders after 12 wk: Continue treatment until haematological response is complete or up to 18 mth. Follicular lymphoma As adjunct to chemotherapy: 6 million u/ m2/day on days 22-26 of each 28-day cycle. \n\nCutaneous T-cell lymphoma In an escalating dose of 3 million u/day for 3 days, then 9 million u/day for 3 days, and then 18 million u/day to complete 12 wk of treatment. Thereafter, max tolerated dose (up to 18 million u) 3 times/wk for at least 12 mth in responders. \n\nMelanoma 3 million u 3 times/wk for 18 mth. Start treatment no later than 6 wk after surgery.\n\nContra-indication: Hypersensitivity. Autoimmune hepatitis, hepatic decompensation.\n\nSide effects: Depressive illness, suicidal behaviour, irritability, insomnia, anxiety. Flu-like symptoms. Headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. GI disturbances. Dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. Inj site reaction, alopecia, rash, dry skin or pruritus. Conjunctivitis, menstrual irregularity, visual disturbances. Coughing, dyspnoea. Myalgia, joint or bone pain, arthritis or polyarthritis. Bone marrow depression.\nPotentially Fatal: Marked increase in triglyceride levels, GI haemorrhage, severe infections, pulmonary infiltrates or pulmonary function impairment.\n\nPrecaution: History of depression (monitor for signs). Perform regular neuropsychiatric monitoring. Seizure disorders and/or compromised CNS function. Preexisting or any history of cardiac disease. Monitor CBC prior to and during therapy. Myelosuppression or concurrent use of myelosuppressive drugs. Hypothyroidism, hyperthyroidism, DM. Perform ophthalmological exam on patients with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy). Monitor patients with impaired renal function. Creatinine clearance <50 ml/min. May impair ability to drive or operate machinery. Pregnancy and lactation.\n\nMode of action: Reduces clearance of theophylline. Enhanced myelosuppression with other myelosuppressive drugs (e.g. zidovudine). Drugs metabolised by CYP450 pathway (monitor for changes in pharmacologic or adverse effects of concomitant drug). Increased risk of toxicity of centrally acting drugs. Increased risk of renal failure with interleukin-2.\n\nPregnancy category: Not Classified\n\nInteraction: Reduces clearance of theophylline. Enhanced myelosuppression with other myelosuppressive drugs (e.g. zidovudine). Drugs metabolised by CYP450 pathway (monitor for changes in pharmacologic or adverse effects of concomitant drug). Increased risk of toxicity of centrally acting drugs. Increased risk of renal failure with interleukin-2.
Iodine	\n\n\tDrug International Ltd.\tI Cap CAP 200mg 50's pack 450\n\tPopular\tImiro Injection 350mg 50ml bot/100ml bot 880.06/1672.11\n\tIndication: Grave's disease, Iodine deficiency disorders, Wound and ulcer cleansing, hyperthyroidism, Superficial wounds, Thyroid storm							\n.\n\nDose: Preoperative reduction of vascularity of the thyroid gland\nAdult: As potassium iodide: 50-250 mg (approx 1-5 drops of a solution containing 1 g/ml) tid for 10-14 days before surgery.\nChild: As potassium iodide: 50-250 mg (approx 1-5 drops of a solution containing 1 g/ml) tid for 10-14 days before surgery. As strong iodine solution: 0.1-0.3 ml (or approx 3-5 drops) tid.\n\nGrave's disease\nChild: Neonates: 1 drop of strong iodine solution every 8 hr.\n\nRadiation protection against radioactive iodine\nAdult: As potassium iodide: 100-150 mg 24 hr before procedure and daily for up to 10 days after procedure.\nChild: As potassium iodide: Infants from birth to 1 mth with a predicted thyroid exposure of >5 centigrays (cGy): 16 mg. >1 mth to 3 yr with a predicted thyroid exposure of >5 cGy: 32 mg. >3 yr to 18 yr (except adolescents approaching adult size) with a predicted thyroid exposure of >5 cGy: 65 mg. Do not exceed once-daily doses.\n\nCutaneous or lymphocutaneous sporotrichosis\nAdult: As potassium iodide solution containing 1 g/mL: Initially, 1 mL tid, should continue for at least 1 mth after disappearance or stabilisation of the lesions.\nChild: As potassium iodide: Initially, 250 mg (approx 5 drops of a solution containing 1 g/ml) tid. Max: 1.25-2 g (approx 25-40 drops) tid. Duration: 3-6 mth.\n\nIodine deficiency disorders\nAdult: As iodised oil (poppyseed/peanut/rapeseed oil containing about 38% w/w or 480 mg/ml of iodine): 400 mg iodine once yrly. Pregnant patient: 200 mg iodine as a single dose. Moderate to severe: 300-480 mg iodine each yr or 100-300 mg iodine every 6 mth and for at least 1 yr postpartum.\nChild: As iodised oil (poppyseed/peanut/rapeseed oil containing about 38% w/w or 480 mg/ml of iodine): Infants up to 1 yr: Single dose of 100 mg iodine; 1-5 yr: 200 mg iodine; >6 yr: 400 mg iodine.\n\nThyroid storm\nAdult: As potassium iodide: Up to 500 mg every 4 hr. \n\nContra-indication: Hypersensitivity. Acute bronchitis (potassium iodide).\n\nSide effects: Oral/Topical: Hypersensitivity reactions (urticaria, angioedema, cutaneous haemorrhage, purpura, fever, arthralgia, lymphadenopathy, eosinophilia); goitre, hypothyroidism and hyperthyroidism. Iodism on prolonged use (metallic taste, increased salivation, swelling and inflammation of throat, swollen and irritated eyes, pulmonary oedema, nausea, vomiting, diarrhoea).\nPotentially Fatal: Fatal periarteritis, ioderma.\n\nPrecaution: Children. Adult >45 yr. Topical applications should not be covered with occlusive dressings. Nodular goitre. Renal impairment. Hypocomplemetemic vasculitis. TB (potassium iodide). Pregnancy and lactation.\n\nMode of action: Additive or synergistic hypothyroid effect with lithium salts, antithyroid agents. Additive hyperkalaemia with combined use of potassium iodide and potassium-containing drugs or potassium-sparing diuretics.\n\nPregnancy category: D\n\nInteraction: Additive or synergistic hypothyroid effect with lithium salts, antithyroid agents. Additive hyperkalaemia with combined use of potassium iodide and potassium-containing drugs or potassium-sparing diuretics.
Iodine 10%	\n\n\tIndication: Wound and ulcer cleansing, Superficial wounds\n\nDose: Gargle and Mouth-Wash: Adults and children over 6 years, gargle with up to 10 ml undiluted or diluted with an equal quantity of warm water for up to 30 seconds, up to 4 times daily for up to 14 days. \n\nSolution: Apply the full strength as often as required as a paint or wet soak. For minor wounds and infection apply directly to the affected area. The site may be covered with gauze or adhesive bandage. Ointment: Apply ointment directly to the affected area after being cleaned and dried. May be covered with a dressing or bandage.\n\nContra-indication: Avoid regular use in patients with thyroid disorders or those receiving lithium therapy and who shows hypersensitivity to Iodine.\n\nSide effects: Idiosyncratic mucosal irritation and hypersensitivity reactions rarely, may interfere with thyroid-function tests.\n\nPrecaution: Children. Adult >45 yr. Topical applications should not be covered with occlusive dressings. Nodular goitre. Renal impairment. Hypocomplemetemic vasculitis. TB (potassium iodide). Pregnancy and lactation.\n\nMode of action: Additive or synergistic hypothyroid effect with lithium salts, antithyroid agents. Additive hyperkalaemia with combined use of potassium iodide and potassium-containing drugs or potassium-sparing diuretics.\n\nPregnancy category: D\n\nInteraction: Additive or synergistic hypothyroid effect with lithium salts, antithyroid agents. Additive hyperkalaemia with combined use of potassium iodide and potassium-containing drugs or potassium-sparing diuretics.
Iodine 2.5 %	\n\n\tIndication: Wound and ulcer cleansing, Superficial wounds\n\nDose: Adult: As 2% or 2.5% solution/ointment: Apply small amount to the affected area 1-3 times daily.\nChild: As 2% or 2.5% solution/ointment: Apply small amount to the affected area 1-3 times daily.\n\nContra-indication: Hypersensitivity. Acute bronchitis (potassium iodide).\n\nSide effects: Topical: Hypersensitivity reactions (urticaria, angioedema, cutaneous haemorrhage, purpura, fever, arthralgia, lymphadenopathy, eosinophilia); goitre, hypothyroidism and hyperthyroidism. Iodism on prolonged use (metallic taste, increased salivation, swelling and inflammation of throat, swollen and irritated eyes, pulmonary oedema, nausea, vomiting, diarrhoea).\nPotentially Fatal: Fatal periarteritis, ioderma.\n\nPrecaution: Children. Adult >45 yr. Topical applications should not be covered with occlusive dressings. Nodular goitre. Renal impairment. Hypocomplemetemic vasculitis. TB (potassium iodide). Pregnancy and lactation.\n\nMode of action: Additive or synergistic hypothyroid effect with lithium salts, antithyroid agents. Additive hyperkalaemia with combined use of potassium iodide and potassium-containing drugs or potassium-sparing diuretics.\n\nPregnancy category: D\n\nInteraction: Additive or synergistic hypothyroid effect with lithium salts, antithyroid agents. Additive hyperkalaemia with combined use of potassium iodide and potassium-containing drugs or potassium-sparing diuretics.
Iodixanol	\n\n\tIndication: Radiographic contrast medium for diagnostic procedures\n\nDose: Intravenous Administration for Contrast Enhanced Computerized Tomography or Excretory Urography\n\n  1 to 2 mL/kg. The recommended total dose   should not exceed 2 mL/kg.\n\nContra-indication: In the pediatric population prolonged fasting and the administration of a laxative before  injection are contraindicated.\n\nSide effects:  Body as a WholeâGeneral Disorders: back pain, fatigue, malaise.\n\nCardiovascular Disorders: arrhythmias, cardiac failure, conduction abnormalities, hypotension, myocardial infarction.\n\nNervous System: cerebral vascular disorder, convulsions, hypoesthesia, stupor, confusion.\n\nGastrointestinal System Disorders: dyspepsia.\n\nHypersensitivity Disorders: pharyngeal edema.\n\nRespiratory System Disorders: asthma, bronchitis, dyspnea, pulmonary edema, rhinitis.\n\nRenal System Disorders: abnormal renal function, acute renal failure, hematuria.\n\nPeripheral Vascular Disorders: flushing, peripheral ischemia.\n\nSkin and Appendage Disorders: hematoma, increased sweating.\n\nSpecial Senses, Other Disorders: tinnitus.\n\nVision Disorders: abnormal vision.\n\nPrecaution: CONTRAST AGENTS ARE ASSOCIATED WITH RISK AND INCREASED RADIATION EXPOSURE, AND THE DECISION TO USE ENHANCEMENT SHOULD BE BASED UPON A CAREFUL EVALUATION OF CLINICAL, OTHER RADIOLOGIC DATA, AND THE RESULTS OF UNENHANCED CT FINDINGS.\n\nPatients receiving contrast agents, and especially those who are medically unstable, must be closely supervised. Diagnostic procedures which involve the use of iodinated intravascular contrast agents should be carried out under the direction of personnel skilled and experienced in the particular procedure to be performed. A fully equipped emergency cart, or equivalent supplies and equipment, and personnel competent in recognizing and treating adverse reactions of all types should always be available. Since severe delayed reactions have been known to occur, emergency facilities and competent personnel should be available for at least 30 to 60 minutes.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Iohexol	\n\n\tTechno Drugs Ltd.\tDiapac 350 Injection 350mg/ml 50ml 970\n\tIndication: Radiographic contrast medium for diagnostic procedures\n\nDose: Adult: Inj As iohexol soln containing 6-350 mg iodine/mL: Dose and strength used depends on the procedure and route of administration.\n\nContra-indication: Procedure-specific. Intrathecal: Myelography in significant local or systemic infection where bacteremia is likely; concurrent use with corticosteroids; repeat myelography in the event of technical failure (risk of overdosage). Hysterosalpingography: During menstrual period or when menstrual flow in imminent; presence of infection; pregnancy, 6 mth after termination of pregnancy or 30 days after conization or curettage.\n\nSide effects: Flushing or a sensation of heat; pain, extravasation, thrombophlebitis at the inj site; nausea, vomiting, headache, and dizziness; urticaria, pruritus, pallor, sweating, metallic taste, weakness, coughing, rhinitis, sneezing, lachrymation, visual disturbances; hypotension, tachycardia, bradycardia, transient ECG abnormalities, haemodynamic disturbances; dyspnoea, bronchospasm, angioedema, severe urticaria; convulsions, paraesthesia, paralysis; acute renal failure; thromboembolism, disseminated intravascular coagulation, thrombocytopenia; hyperthyroidism, thyroid storm thyrotoxicosis.\nPotentially Fatal: Profound hypotension, pulmonary oedema, respiratory arrest, ventricular fibrillation, circulatory failure, cardiac arrest, coma.\n\nPrecaution: Asthma or a history of allergies (risk of anaphylactoid reactions is increased); compromised blood-brain barrier (severe neurotoxicity after intrathecal use); epilepsy and brain tumour (higher risk of convulsions); severe hepatic or renal impairment, diabetics with renal impairment, dehydration and others who may be at increased risk of renal failure; multiple myeloma (dehydration from use may cause precipitation of protein in the renal tubules, leading to anuria and fatal renal failure); severe hypertension; advanced cardiac disease; phaeochromocytoma; sickle-cell disease; hyperthyroidism; debilitated, severely ill, very old, or very young patients; occlusive vascular disease. Special care to ensure that 140 and 350 mg iodine/ml solutions are not given intrathecally. Adequate resuscitative facilities should be available when radiographic procedures are undertaken, and patients should be kept under observation for a suitable period after the procedure.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Iopamidol	\n\n\tBeximco\tLopidam Injection 370mg/ml 1's pack 850\n\tIncepta\tAmidol 300 Injection 300mg/ml 1's pack 750\n\tIncepta\tAmidol 370 Injection 370mg/50ml 100ml 1650\n\tPopular\tLmiro Injection 350mg/ml 50ml 879.70\n\tTechno Drugs Ltd.\tDiapamiro 370 	 			 	 Injection 370 mg/ml  1's pack(50ml) 1100 \n\tIndication: Radiographic contrast medium for diagnostic procedures\n\nDose: Adult: Inj As soln containing 41-76% of iopamidol. Dose and strength used depends on the procedure and route of administration used.\n\nContra-indication: Not for intrathecal use.\n\nSide effects: Arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.\nPotentially Fatal: Severe anaphylactoid reactions.\n\nPrecaution: May inhibit blood coagulation. Multiple myeloma or other paraproteinaemia. Sickle-cell disease. Known or suspected phaeochromocytoma (monitor closely). Hyperthyroidism. Ensure adequate hydration. History of a previous sensitivity to a contrast medium, sensitivity to iodine, bronchial asthma, hay fever and food allergy. Monitor patients with CHF. Avoid angiography in patients with homocystinuria. Severe arterial or venous disease. Severe renal impairment, combined renal and hepatic disease or anuria, especially when large doses are used. Pregnancy and lactation.\n\nMode of action: Arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.\nPotentially Fatal: Severe anaphylactoid reactions.\n\nPregnancy category: B\n\nInteraction: Arrhythmias, arterial spasm, flushing, vasodilatation, angina, cardiopulmonary arrest; dizziness, confusion, paraesthesia, visual disturbances, seizure, paralysis, coma, temporary amnesia; inj site pain, pallor, periorbital and facial oedema; coughing, sneezing, rhinitis, asthma, apnoea, laryngeal oedema, chest tightness; watery itchy eyes, lachrymation, conjunctivitis; muscle spasm, involuntary leg movement; tremors, malaise; severe retching and choking, abdominal pain; urogenital pain, haematuria.\nPotentially Fatal: Severe anaphylactoid reactions.
Iopanoic Acid	\n\n\tIndication: Iopanoic Acid is primarily indicated in conditions like Epilepsy (monotherapy), Radiological contrast agent, Vestibular disorders. \n\nDose:  Adult Dosage  42.857 mg/kg 	  43 (42.857) As recommended. 	  PO 	  Once,as required\n\nContra-indication: Iopanoic Acid is contraindicated in conditions like Cardiovascular disease, Malabsorption. \n\nSide effects:  Dizziness, Headache, Diarrhea, Rashes, Urticaria, Pruritus, Dysuria, Cramps, Nausea and vomiting, Heart burn, Sore throat.\n\nPrecaution: Avoid use of iopanoic acid in patients with severe renal (kidney) or hepatic (liver) disease. Dose higher than 3gm should not be given to patients with renal impairment. Avoid use in presence of acute gastro-intestinal disease, as it may impair the absorption. It should be used with caution in patients with history of hypersensitivity to iodine, or other contrast media, hyperthyroidism, hyperuricaemia\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Ipratropium Bromide	\n\n\tACI\tRinase Respiratory Solution Solution 250mcg/ml 20ml 130.39\n\tBeximco\tIpramid Inhaler 20mcg 200 puffs inhaler 200\n\tBeximco\tIpramid HFA Inhaler 20mcg 200md 250\n\tGonoshasthaya\tG-Ipra Nebuliser Solution 250mcg/ml 20ml vial 60.25\n\tIncepta\tIpratop Nebuliser Solution 250mcg/ml 20ml bot 130\n\tSquare\tIprex Inhaler 20mcg 200 puffs inhaler 200.75\n\tSquare\tIprex Respiratory Solution 250mcg/ml 20ml pack 130.49\n\tSquare\tIprex Nebuliser Solution 500mcg/2ml 10 amps pack 140\n\tIndication: Asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema.\n\nDose: As Inhaler: Adults: 1-2 puffs (20 mg/puff) 3-4 times daily.  Children: 1-2 puffs 2-3 times daily.  \n\nAs nebulized soln:  Adults (including elderly and adolescents) over 12 years of age: The usual dose is 0.4-2.0 ml Ipratropium Bromide Solution (100-500 micrograms) up to four times daily. \n\nChildren over 3 years: The usual dose is 0.4-2.0 ml Ipratropium Bromide Solution (100-500 micrograms) up to three times daily.\n\nContra-indication: Ipratropium Bromide solution should not be taken by patients with known hypersensitivity to atropine or its derivatives or to any other component of the product. \n\nSide effects: Dry mouth, urinary retention, buccal ulceration, paralytic ileus, headache, nausea, constipation, paradoxical bronchospasm, immediate hypersensitivity reactions (urticaria, angioedema), acute angle-closure glaucoma.Potentially Fatal: Anaphylactic reactions, atrial fibrillation, supraventricular tachycardia.\n\nPrecaution: Bladder neck obstruction, narrow-angle glaucoma or patients susceptible to glaucoma, prostatic hyperplasia. Protect patient's eyes from nebulised drug. Renal and hepatic impairment. Pregnancy, lactation, children, elderly.\n\nMode of action: Increased toxicity with other anticholinergic drugs.\n\nPregnancy category: B\n\nInteraction: Increased toxicity with other anticholinergic drugs.
Ipratropium Bromide + Salbutamol	\n\n\tACI\tCombair Resp Sol Respirator Solution 0.5mg+2.5mg/ml 20ml bot 226.38\n\tACI\tCombair HFA Refill Inhaler 100mcg+20mcg/puff 1's pack 230.69\n\tACI\tCombair HFA Inhaler  100mcg+20mcg/puff 1's pack 250.75\n\tAcme Ltd.\tSalpium Inhaler 100 mcg + 20 mcg 200 puffs unit 230.86\n\tAristopharma\tIpralin HFA Inhaler   200 puffs unit 250\n\tBeximco\tIprasol Inhaler   200 puffs unit 230\n\tBeximco\tIprasol HFA Inhaler 100mcg + 20mcg 1's pack 230\n\tDrug International Ltd.\tVentil Plus Inhalation Aerosol 20 mcg + 100 mcg/Metered   \n\tHealthcare\tCombiver-AF Inhalation Aerosol (20 mcg + 100 mcg)/Metere  \n\tSquare\tSulprex 20mcg/100mcg Inhaler  20 mcg + 100 mcg/Metered 200 puffs unit 230.86\n\tSquare\tSulprex HFA Aerosol Inhalation 20 mcg + 100 mcg/Metered   \n\tIndication: Asthma, Chronic obstructive pulmonary disease\n\nDose: Adult: Inhalation Per inhalation contains ipratropium bromide 18 mcg and salbutamol sulfate 103 mcg: 2 inhalations 4 times/day. Max: 12 inhalations/24 hr. \n\nFor nebulising solution (each 3 ml contains ipratropium bromide 0.5 mg and salbutamol base 2.5 mg): Initially, 3 ml every 6 hr. Max: 3 ml every 4 hr.\n\nContra-indication: Hypersensitivity to soy lecithin or related food products e.g. peanuts.\n\nSide effects: Bronchitis, respiratory tract infections. Chest pain, arrhythmia, oedema, hypertension, hypokalaemia, palpitation, tachycardia. Headache, dizziness, fatigue, insomnia, tremor, nervousness. GI symptoms e.g. nausea, vomiting, diarrhoea, dyspepsia and constipation.\nPotentially Fatal: Anaphylactic reactions such as angioedema of tongue, lips or face and laryngospasm.\n\nPrecaution: May cause paradoxical bronchospasm. Caution when used in patients who are sensitive to sympathomimetic agents.  Caution when used in patients with CV disease as ?-agonists may increase BP, heart rate and risk of arrhythmias. Monitor blood glucose in diabetics. Monitor serum potassium levels especially in patients who are on concurrent treatment with xanthine derivatives, steroids or diuretics. Caution when used in patients with narrow angle glaucoma, hyperthyroidism, prostatic hyperplasia, bladder neck obstruction, seizure disorders, renal or hepatic impairment. Safety and efficacy have not been established in children <12 yr. Increased risk of GI motility disturbance in patients with cystic fibrosis. Pregnancy and lactation.\n\nMode of action: May have additive anticholinergic effects when used with psychotropics; may decrease effect of propranolol. Increased CV effects (tachycardia, palpitations) when used with MAOIs, TCAs and amphetamines.\n\nPregnancy category: C\n\nInteraction: May have additive anticholinergic effects when used with psychotropics; may decrease effect of propranolol. Increased CV effects (tachycardia, palpitations) when used with MAOIs, TCAs and amphetamines.
Ipratropium Bromide 0.04% + Salbutamol 0.12%	\n\n\tIncepta\tWindel Plus Nebuliser Solution   10 amps pack 150\n\tSquare\tSulprex Nebuliser Solution  500 mcg + 2.5 mg/2.5 ml 10 amps pack 150\n\tIndication: Asthma,Chronic obstructive pulmonary disease\n\nDose: Adults (including elderly): Per 3 mL nebulising soln contains ipratropium bromide 0.5 mg and salbutamol base 2.5 mg: Initial: 3 mL 6 hrly. Max: 3 mL 4 hrly.\n\nOne ampoule as required for the relief of symptoms or as directed. Up to three to four ampoules daily.\n\nPatients should be advised to consult a doctor or the nearest hospital immediately in the case of acute or rapidly worsening dyspnoea if additional inhalations do not produce an adequate improvement.\n\nContra-indication: The combination of Salbutamol & Ipratropium Bromide is contraindicated in patients with hypertrophic obstructive cardiomyopathy and tachyarrhythmia and in patients with a history of hypersensitivity to atropine or its derivatives, or to any other component of the product.\n\nSide effects: Adverse Effects: In common with other beta-agonists containing products, side effects of Windel Plus can include fine tremor of skeletal muscles and nervousness and less frequently, tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.\nPotentially serious hypokalaemia may result from prolonged and / or high dose beta2-agonist therapy.\nAs with use of other inhalation therapy, cough, local irritation and, less commonly, inhalation induced bronchospasm can occur.\nAs with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. In rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.\nIn individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.\nThe most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia.\nThere have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle-closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2-agonist, has escaped into the eyes. Ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible.\n\nPrecaution: May cause paradoxical bronchospasm. Caution when used in patients who are sensitive to sympathomimetic agents.\n\nMode of action: May have additive anticholinergic effects when used with psychotropics; may decrease effect of propranolol. Increased CV effects (tachycardia, palpitations) when used with MAOIs, TCAs and amphetamines.\n\nPregnancy category: C\n\nInteraction: May have additive anticholinergic effects when used with psychotropics; may decrease effect of propranolol. Increased CV effects (tachycardia, palpitations) when used with MAOIs, TCAs and amphetamines.
Irbesartan	\n\n\tACI\tIsart TAB dr 150mg 10's pack 140\n\tAcme Ltd.\tIbsan TAB dr 75mg 20's pack 100\n\tAcme Ltd.\tIbsan TAB dr 100mg 10's pack 100\n\tBeximco\tArbit TAB dr 150mg 30's pack \n\tBeximco\tArbit TAB dr 75mg 30's pack \n\tEskayef Bangladesh Ltd.\tIrbes TAB dr 150mg 30's pack 270\n\tEskayef Bangladesh Ltd.\tIrbes TAB dr 75mg 50's pack 250\n\tOpsonin Pharma\tArbitan TAB dr 150mg 30's pack 360\n\tOpsonin Pharma\tArbitan TAB dr 300mg 20's pack 480\n\tOpsonin Pharma\tArbitan TAB dr 75mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tCavapro TAB dr 150mg 30's pack 360\n\tUnimed & Unihealth Manufacturers Ltd.\tCavapro TAB dr 300mg 10's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tCavapro TAB dr 75mg 30's pack 180\n\tIndication: Diabetic nephropathy, Hypertension\n\nDose: Adult: PO HTN; Diabetic nephropathy in Type 2 DM 150 mg once daily, up to 300 mg once daily if needed.\n\nContra-indication: Hypersensitivity; pregnancy and lactation.\n\nSide effects: Diarrhoea, dizziness, fatigue, headache, hyperkalaemia. Dyspepsia, oedema, myalgia, insomnia, nasal congestion, 1st dose orthostatic hypotension, rash, pharyngitis, urticaria, angioedema, anxiety/nervousness, tachycardia.\n\nPrecaution: Child <6 yr. Unilateral or bilateral renal artery stenosis; vol or Na depletion; aortic or mitral valve stenosis, hypertrophic cardiomyopathy.\n\nMode of action: May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.\nPotentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).\n\nPregnancy category: D\n\nInteraction: May antagonise hypotensive effect and increase risk of nephrotoxicity w/ NSAIDs. May increase serum lithium levels and toxicity. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.\nPotentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Iron Hydroxide Polymaltose	\n\n\tACI\tPolyron Syrup 50mg/5ml 100ml bot 25.09\n\tAristopharma\tIpec Syrup 50mg/5ml 100ml bot 40\n\tAsiatic Ltd.\tPolimine Syrup 50mg/5ml 50ml bot 20\n\tChemist Ltd.\tPolyferon Syrup 50mg/5ml 200ml bot 50\n\tIncepta\tCompiron Syrup  200ml bot 50\n\tIncepta\tCompiron Drops Paediatric Drops 200mg 30 ml drop 30\n\tOpsonin Pharma\tIromia Syrup 50mg/5ml 1x1's pack 50\n\tOrion Pharma Ltd.\tAneron Syrup 50mg/5ml 200ml bot / 100ml bot 50/30\n\tIndication: Iron-deficiency anemia\n\nDose: Dosage and duration of therapy are dependent upon the extent of iron deficiency and should be taken as directed by the physician.\n\nAdults: 10 ml once or twice daily\nChildren (6 - 12 years): 10 ml daily\nChildren (2 - 6 years): 5 ml daily\nPremature infants & Infants: 3.33 mg of elemental iron/kg body weight (0.06 ml  drops/kg body weight) daily.\n\nContra-indication: * In conditions where there is a risk of iron overload e.g. Haemochromatosis, thalassemia or haemosiderosis.\n* In case of hypersensitivity to iron or any other ingredients of the syrup.\n\nSide effects: This preparation is well tolerated. However, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur.\n\nPrecaution: Avoid concomitant parenteral and oral iron admin, oral iron therapy should start at least 1 wk after last iron inj. Parenteral: Pregnancy (2nd and 3rd trimester), allergies, hepatic and liver insufficiency, low iron binding capacity and or folic acid deficiency. Facilities for CPR should be available during admin. Excessive IV infusion rate may cause nausea and epigastric upset. IV infusion route should be used only if IM route is unacceptable and when there is no stored iron in the bone marrow.\n\nMode of action: Concurrent use with psychotropic drugs may worsen constipation. Increased systemic side effects with concomitant ACE inhibitors and parenteral iron admin.\n\nPregnancy category: Not Classified\n\nInteraction: Concurrent use with psychotropic drugs may worsen constipation. Increased systemic side effects with concomitant ACE inhibitors and parenteral iron admin.
Elemental Iron (Iron sucrose)	\n\n\tAristopharma\tInofar IV Injection 100mg/5ml 100mg (5ml) ampoule x 2's pack 600\n\tBeacon\tXenofer Injection 100mg/5ml 100mg (5ml) ampoule x2's pack 602.26\n\tBeacon\tXenofer 50 Infusion 50 mg/2.5 ml 50mg ampoule x 1's pack 274\n\tBeximco\tVeniron IV Injection 100mg/5ml 1's pack 300\n\tEskayef Bangladesh Ltd.\tFeofer Injection 100 mg/5 ml  \n\tGeneral\tKidifer IV Injection 100mg/5ml 1's pack 326/.27\n\tGlobe\tMaxifer Injection 100 mg/5 ml  \n\tIncepta\tFerimax IV Injection 100mg/5ml 100mg (5ml) ampoule x 1's pack 300\n\tOpsonin Pharma\tAnefer Injection 100mg/5ml 1x1's pack 301.13\n\tOrion Pharma Ltd.\tFeroven Injection 100mg/5ml 100mg (5ml) ampoule x 1's pack 301.14\n\tOrion Pharma Ltd.\tFeroven I.V Infusion 20mg 1's pack 326.27\n\tPopular\tHemofer Injection 100mg/5ml 100mg (5ml) ampoule x2's pack 602.26\n\tPopular\tHemofer I.V Infusion 100mg/5ml 5ml amp. with 100ml Normal Saline 325.00\n\tRenata\tFeristar Injection 100mg/5ml 1's pack 325\n\tSquare\tDefiron Injection 100mg/5ml 100mg (5ml) ampoule x 1's pack 301.14\n\tUnimed & Unihealth Manufacturers Ltd.\tVenofer Injection 100mg/5ml  5ml amp. x 2's pack 1617.55\n\tZiska\tUnifer Injection 100mg/5ml 100mg (5ml) ampoule x 1's pack 300\n\tVifor (International) Inc.,Switzerland\tVenofer Injection 100mg 100mg (5ml) ampoule x 5's pack 1610.75\n\tIndication: Iron deficiency anemia in pregnancy and in non-dialysis dependent chronic kidney disease (CKD) patients, hemodialysis dependent CKD patients  or peritoneal dialysis CKD patients.\n\nDose: Adults and the Elderly: \nAs injection: Iron Sucrose can also be administered undiluted by slow IV injection at a rate of 1 ml Iron Sucrose (20 mg Iron) in at least 1 minute a maximum of 10 ml Iron Sucrose (200 mg Iron) can be administered per injection in at least 10 minutes.\n\nIron-deficiency Anemia in Chronic Kidney Disease\nHemodialysis-dependent CKD: 100 mg elemental iron IV (injection or infusion over 2-5 min) per dialysis session not to exceed total cumulative dose of 1000 mg divided in 3 doses/week.\n\nNon-dialysis-dependent CKD: 200 mg IV injection for 5 doses in over 14 days (cumulative 1000 mg in 14-day period).\n\nPeritoneal dialysis-dependent CKD: 300 mg IV infusion (1.5 hr) for 2 doses 14 days apart, THEN 400 mg IV infusion (2.5 hr) 14 days later (cumulative 1000 mg divided in 3 doses/week).\n\nAs infusion: Iron Sucrose should preferably be administered by drip infusion ( in order to reduce hypotensive episodes) in a dilution of 1 ml Iron Sucrose in maximum 20 ml 0.9% NaCl etc up to 25 ml Iron Sucrose in maximum 500 ml 0.9% NaCl. Dilution must take place immediately prior to infusion and solution must be administered as follows: 100 mg Iron in at least 15 minutes; 200 mg Iron in at least 30 minutes ete. Normal posology is to use 5-10 ml Iron Sucrose 1-3 times a week depending on the Hemoglobin level. For the administration of the maximum tolerable dose of 7 mg Iron/kg body weight an infusion time of at least 3.5 hours has to be respected, independently of the total dose.\n\nChildren: There is limited data on children under study conditions. If there is a clinical need, it is recommended not to exceed 0.15 ml Iron Sucrose (3 mg Iron) per kg body weight 1-3 times a week depending on the hemoglobin level.\n\nIron-deficiency Anemia in Chronic Kidney Disease\nIndicated for maintenance treatment of iron-deficient anemia associated with chronic kidney disease\n<2 years: Safety and efficacy not established.\n\nHemodialysis-dependent: 0.5 mg/kg IV q2weeks for 12 weeks; not to exceed 100 mg/dose.\n\nNon-dialysis dependent or peritoneal-dependent (on erythropoietin): 0.5 mg/kg IV q4weeks for 12 weeks; not to exceed 100 mg/dose.\n\nBefore administering a slow intravenous injection, a test dose of 1 ml (20 mg of iron) should be injected slowly over a period of 1 to 2 minutes. If no adverse events occur within 15 minutes of completing the test dose, then the remaining portion of the injection may be given.\n\n\nContra-indication: The use of Iron Sucrose is contraindicated in patients with evidence of Iron overload e.g. Haemochromatosis, thalassemia or haemosiderosis and in patients with known hypersensitivity to Iron preparations or any components preparation, in patients with anemia not caused by Iron deficiency.\n\nSide effects: Iron Sucrose is generally well tolerated. However, occasionally metallic taste, headache, nausea, vomiting and hypotension may occur. Less frequently side-effects are paresthesia, abdominal disorders, muscular pain, fever, urticaria, flushing, edema of the extremities, anaphylactic (pseudoallergic) reactions and in the region of the punctured vein, phlebitis and venous spasm have been observed.\n\nPrecaution: Iron Sucrose should be administered with caution in patients with asthma, eczema, other atopic allergies or allergic reaction to other parenteral Iron preparations, low binding capacity and/or folic acid deficiency, liver dysfunction, acute or chronic infection.\n\nBaseline tests: Ensure Hgb, Hct, serum ferritin and transferrin saturation is determined before starting therapy and periodically during treatment. Note that serum Iron levels may be reliably obtained 48 hours after IV dosing.\n\nBlood Pressure: Monitor Blood Pressure during infusion. If hypotension occurs, slow the rate of infusion. If hypotension continues, discontinue infusion and be prepared to treat appropriately.\n\nDiscontinue oral Iron preparations before administering parenteral Iron products. Co-administration of parenteral Iron preparations may reduce absorption of oral Iron.The dose will be in terms of elemental Iron. For IV administration only. Not for intradermal, subcutaneous, IM, or intra-arterial administration. Medication is administered 1 to 3 times/ week. Do not administer more than 3 times/week. Discard any unused diluted solution. Do not save unused solution for future use. Do not administer if particulate matter or discoloration noted.\n\nMode of action: May reduce the serum levels of cefdinir; stools may appear red due to the formation of an insoluble iron-cefdinir complex. May reduce the serum levels of eltrombopag. May decrease absorption of phosphate supplements. Concurrent use with trientine may result in reduction of serum levels of iron sucrose and/or trientine.\nPotentially Fatal: Dimercaprol may increase the nephrotoxic effect of iron salts when used concurrently.\n\nPregnancy category: B\n\nInteraction: May reduce the serum levels of cefdinir; stools may appear red due to the formation of an insoluble iron-cefdinir complex. May reduce the serum levels of eltrombopag. May decrease absorption of phosphate supplements. Concurrent use with trientine may result in reduction of serum levels of iron sucrose and/or trientine.\nPotentially Fatal: Dimercaprol may increase the nephrotoxic effect of iron salts when used concurrently.
Isoflurane	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tForane 	 			 	 		 Solution  1's pack(100ml) 3666\n\tAbbott, UK\tForane 					 Volatile liquid  100 ml bot  2961.16 \n\tIndication: General anaesthesia\n\nDose: Adult: Inhalation Induction: Initial: 0.5% v/v w/ oxygen or oxygen and nitrous oxide, increase to 1.5-3% v/v. Maintenance: 1-2.5% v/v w/ oxygen and nitrous oxide mixtures or 1.5-3.5% v/v w/ oxygen only. \n\nFor maintenance of anesth during caesarean section: 0.5-0.75% v/v w/ oxygen and nitrous oxide mixtures.\n\nContra-indication: Known or suspected susceptibility to malignant hyperthermia. Porphyria.\n\nSide effects: Respiratory depression, hypotension, arrhythmias, malignant hyperthermia. Shivering, nausea, vomiting, ileus. Breath holding, coughing and laryngospasm. Rarely, postoperative hepatic dysfunction and hepatitis. Hypersensitivity reactions. Transient WBC elevation.\n\nPrecaution: Perioperative hyperkalaemia; raised intracranial pressure. May impair ability to drive or operate machinery. Pregnancy and lactation. Do not allow carbon dioxide absorbents in anaesthetic apparatus to dry out when delivering isoflurane to minimise the risk of developing elevated carboxyhaemoglobin levels.\n\n\nMode of action: nhances effects of neuromuscular blockers. May sensitise the myocardium to adrenaline and other sympathomimetics. Enhances hypotensive effects of ACE inhibitors, TCAs, MAOIs, antihypertensives, antipsychotics or ?-blockers. May have synergistic effects with CNS depressants.\n\nPregnancy category: C\n\nInteraction: nhances effects of neuromuscular blockers. May sensitise the myocardium to adrenaline and other sympathomimetics. Enhances hypotensive effects of ACE inhibitors, TCAs, MAOIs, antihypertensives, antipsychotics or ?-blockers. May have synergistic effects with CNS depressants.
Isoniazid	\n\n\tNovartis (Bangladesh) Ltd.\tServizid TAB dr 300mg 500's pack 305\n\tIndication: Tuberculosis\n\nDose: Adult: PO Active tuberculosis 5 mg/kg/day. Max: 300 mg/day or 15 mg/kg up to 900 mg/day, 2 or 3 times wkly. Latent tuberculosis 300 mg/day for 6 mth. \nNontuberculous mycobacterial infections 5 mg/kg/day for at least 12 mth of culture-negative sputum. Max: 300 mg/day.\n\nChild: 10-15 mg/kg up to 300 mg daily as a single dose or 20-40 mg/kg up to 900 mg/day, 2 or 3 times wkly.\n\nContra-indication: Acute liver disease or history of hepatic damage during INH therapy; hypersensitivity.\n\nSide effects: Peripheral neuritis, optic neuritis; psychotic reactions, convulsions, nausea, vomiting, fatigue, epigastric distress, visual disturbances, fever, rash, pyridoxine deficiency.\nPotentially Fatal: Hepatotoxicity.\n\nPrecaution: Renal or hepatic impairment; convulsive disorders; history of psychosis; patients at risk of neuropathy or pyridoxine deficiency eg, diabetic, alcoholic, malnourished, uraemic, infected with HIV. Careful monitoring of hepatic function is necessary for black and hispanic women. Check hepatic function before and during treatment. Pregnancy and lactation.\n\nMode of action: Inhibit the hepatic metabolism of antiepileptics (e.g. carbamazepine, ethosuximide, primidone, phenytoin), benzodiazepines (e.g. diazepam, triazolam), chlorzoxazone, theophylline, disulfiram, sometimes leading to increased toxicity. Increased metabolism of enflurane, resulting in potentially nephrotoxic levels of fluoride. Increased concentrations and enhanced effects or toxicity of clofazimine, cycloserine and warfarin. Reduced absorption w/ Al-containing antacids. Increased risk of peripheral neuropathy w/ zalcitabine and stavudine.\n\nPregnancy category: C\n\nInteraction: Inhibit the hepatic metabolism of antiepileptics (e.g. carbamazepine, ethosuximide, primidone, phenytoin), benzodiazepines (e.g. diazepam, triazolam), chlorzoxazone, theophylline, disulfiram, sometimes leading to increased toxicity. Increased metabolism of enflurane, resulting in potentially nephrotoxic levels of fluoride. Increased concentrations and enhanced effects or toxicity of clofazimine, cycloserine and warfarin. Reduced absorption w/ Al-containing antacids. Increased risk of peripheral neuropathy w/ zalcitabine and stavudine.
Isoniazid + Pyrazinamide + Rifampicin	\n\n\tNovartis (Bangladesh) Ltd.\tRimactazid Z 150 TAB dr   10's pack \n\tNovartis (Bangladesh) Ltd.\tRimactazid Z 300 TAB dr   60's pack 247.20\n\tNovartis (Bangladesh) Ltd.\tRimactazid Z 450 TAB dr   40's pack 186.80\n\tNovartis (Bangladesh) Ltd.\tRimcure FDC 3 TAB dr   100's pack 553\n\tSanofi Aventis (BD) Ltd.\tRifazid 450 +Z TAB dr    186.80\n\tSanofi Aventis (BD) Ltd.\tRifazid 300 +Z TAB dr   247.20\n\tIndication: Tuberculosis\n\nDose: Total Dosage Requirement: Rifampicin: 10 (8-12) mg/kg body mass/day.\nIsoniazid: 5 (4-6) mg/kg body mass/day.\nPyrazinamide: 25 (20-30) mg/kg body mass/day.\n\nPatients weighing <44 kg â 4 tablets\nPatients weighing between 45-54 kg â 5 tablets\nPatients weighing > 55 kg â 6 tablets\n\nPediatric Patients\n\nThe ratio of the drugs may not be appropriate in pediatric patients under the age of 15 (e.g., higher mg/kg doses of isoniazid are usually given in pediatric patients than adults).\n\nThe tablets should be given as a single dose, preferably on an empty stomach, at least 30 min before breakfast to ensure a high peak serum concentration.\nTablets are recommended in the initial intensive phase of the short course treatment of tuberculosis. During this phase which lasts for 2 months,\n\nContra-indication: Known or suspected hypersensitivity to rifamycins and/or to isoniazid and to pyrazinamide and/or to any of the excipients including a history of drug-induced hepatitis, acute liver diseases regardless of their origin, and peripheral neuritis.\n\nSide effects: Unwanted effects which may occur during continuous daily or intermittent therapy: Rifampicin: Rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. It may permanently discolour soft contact lenses.\nHepatic Effects: Very common (>10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (>0.1% and <1%). In isolated cases (<0.01%), a fatal outcome was observed.\nRenal Effects: Elevations of BUN and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency.\nGastrointestinal Effects: Nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis.\nCentral and Peripheral Nervous System Effects: Tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances.\nHaematological Changes: Leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura.\nEffects on Skin and Appendages: Flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, Lyell's syndrome and pemphigoid reactions.\nEndocrine Effects: Disturbances in the menstrual cycle, induction of crisis in Addison patients.\nUnwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption:\n\nPrecaution: Caution is advised in patients with impaired renal or liver function, diabetes mellitus, chronic alcoholism and undernourished patients, patients with a history of gout and patients suffering from convulsive disorders and acute porphyria. Precautions need to be taken: Blood counts and liver function tests (SGPT, SGOT) should be performed periodically (especially in prolonged treatment) and at baseline, if possible.\nPatients with current chronic liver disease or impaired liver function should be treated with caution and under strict medical supervision. Careful monitoring of liver function should be carried out and attention should be paid to possible prodromal symptoms of hepatitis eg, fatigue, weakness, malaise, anorexia, nausea or vomiting. If these symptoms appear or if signs suggestive of hepatic damage are detected, treatment should be discontinued promptly. The occurrence of severe and sometimes fatal hepatitis associated may develop even after many months of treatment.\n\nMode of action: Rifampicin may reduce effectivity of hormonal contraceptives, ACE inhibitors (e.g. enalapril, imidapril), antiemetics (e.g. aprepitant), antineoplastics (e.g. imatinib), diuretics (e.g. eplerenone), drugs for erectile dysfunction (e.g. tadalafil), oral hypoglycaemics (e.g. nateglinide, repaglinide), NSAIDs (e.g. etoricoxib). Rifampicin may reduce serum levels of atovaquone, ketoconazole. Antacids may reduce absorption of rifampicin. Anaesthetics and halothane may increase risk for hepatotoxicity w/ rifampicin and isoniazid. \n\nIsoniazid may increase serum levels of phenytoin and theophylline; and may decrease carbamazepine metabolism. Stavudine may increase risk of distal sensory neuropathy w/ isoniazid. Antacids may reduce isoniazid absorption. May increase plasma levels of isoniazid w/ para-aminosalicylic acid. Increased risk of CNS toxicity when isoniazid is used concomitantly w/ cycloserine. \n\nPyrazinamide antagonizes the effects of probenecid and sulfinpyrazone.\n\nPotentially Fatal: Concominant use w/ saquinavir/ritonavir may increase risk of severe hepatotoxicity. May reduce antiviral efficacy of atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir\n\nPregnancy category: C\n\nInteraction: Rifampicin may reduce effectivity of hormonal contraceptives, ACE inhibitors (e.g. enalapril, imidapril), antiemetics (e.g. aprepitant), antineoplastics (e.g. imatinib), diuretics (e.g. eplerenone), drugs for erectile dysfunction (e.g. tadalafil), oral hypoglycaemics (e.g. nateglinide, repaglinide), NSAIDs (e.g. etoricoxib). Rifampicin may reduce serum levels of atovaquone, ketoconazole. Antacids may reduce absorption of rifampicin. Anaesthetics and halothane may increase risk for hepatotoxicity w/ rifampicin and isoniazid. \n\nIsoniazid may increase serum levels of phenytoin and theophylline; and may decrease carbamazepine metabolism. Stavudine may increase risk of distal sensory neuropathy w/ isoniazid. Antacids may reduce isoniazid absorption. May increase plasma levels of isoniazid w/ para-aminosalicylic acid. Increased risk of CNS toxicity when isoniazid is used concomitantly w/ cycloserine. \n\nPyrazinamide antagonizes the effects of probenecid and sulfinpyrazone.\n\nPotentially Fatal: Concominant use w/ saquinavir/ritonavir may increase risk of severe hepatotoxicity. May reduce antiviral efficacy of atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir
Isoniazid + Rifampicin	\n\n\tAcme Ltd.\tIsorifam 150 CAP 100/150 100's pack 397\n\tAcme Ltd.\tIsorifam 450 CAP   40's pack 266\n\tAmbee\tMyzid CAP 100 mg + 150 mg  \n\tAmbee\tMyzid CAP 150 mg + 300 mg  \n\tNovartis (Bangladesh) Ltd.\tRimactazid 100 TAB dr  50/100 100's pack 398\n\tNovartis (Bangladesh) Ltd.\tRimactazid 150 TAB dr 100/150 100's pack 400\n\tNovartis (Bangladesh) Ltd.\tRimactazid 300 TAB dr 150/300 50's pack 384\n\tNovartis (Bangladesh) Ltd.\tRimactazid 450 TAB dr 300/450 50's pack 583\n\tPharmadesh Ltd.\tRifagen 450 TAB dr  300/450 20's pack 349.80\n\tSanofi Aventis (BD) Ltd.\tRifazid 150 TAB dr  100/150 100's pack 423.47\n\tSanofi Aventis (BD) Ltd.\tRifazid 300 TAB dr  150/300 60's pack 462.52\n\tSanofi Aventis (BD) Ltd.\tRifazid 450 CAP 300/450 30's pack 351.12\n\tIndication: Tuberculosis\n\nDose: Oral\nTuberculosis\nAdult: Each tab contains rifampicin and isoniazid (mg): \n<50 kg: 3 tab of 150/100 once daily or 1 tab of 450/300 once daily, \n>50 kg: 2 tab of 300/150 once daily. \nHepatic impairment: Max: 8 mg/kg daily.\n\n\n\nContra-indication: Known or suspected hypersensitivity to rifamycins and/or to INH, and/or to any of the excipients including a history of drug-induced hepatitis; acute liver diseases, regardless of their origin; peripheral neuritis.\n\nSide effects: Unwanted effects which may occur during continuous daily or intermittent therapy: Rifampicin: Rifampicin may cause reddish discolouration of body fluids and occasionally other body secretions eg, urine, sputum, lacrimal fluid, faeces, saliva and sweat. It may permanently discolour soft contact lenses. Hepatic Effects: Very common (>10%) is an asymptomatic increase in liver enzymes; severe life-threatening hepatic reactions eg, hepatic failure and acute fulminant hepatitis are uncommon (>0.1% and <1%). In isolated cases (<0.01%), a fatal outcome was observed. Renal Effects: Elevations of BUN and serum uric acid, haemolysis, haematuria, interstitial nephritis, renal insufficiency. Gastrointestinal Effects: Nausea, abdominal pains, vomiting or diarrhoea, pseudomembranous colitis. Central and Peripheral Nervous System Effects: Tiredness, drowsiness, headache, dizziness, ataxia, mental confusion, muscular weakness, visual disturbances. Haematological Changes: Leucopenia, eosinophilia, thrombocytopenia and thrombocytopenic purpura. Effects on Skin and Appendages: Flushing, itching with or without skin rash, urticaria, reddening of the eyes, exudative conjunctivitis or generalised hypersensitivity reactions involving the skin eg, exfoliative dermatitis, Lyell's syndrome and pemphigoid reactions. Endocrine Effects: Disturbances in the menstrual cycle, induction of crisis in Addison patients. Unwanted effects chiefly occurring during intermittent therapy or upon resumption of treatment after temporary interruption:\n\nPrecaution: All drugs should be stopped and an evaluation made at the first sign of a hypersensitivity reaction. If isoniazid therapy must be reinstituted, the drug should be given only after symptoms have cleared. The drug should be restarted in very small and gradually increasing doses and should be withdrawn immediately if there is any indication of recurrent hypersensitivity reaction.\n\nUse of isoniazid should be carefully monitored in the following:\n\n    Daily users of alcohol. Daily ingestion of alcohol may be associated with a higher incidence of isoniazid hepatitis.\n    Patients with active chronic liver disease or severe renal dysfunction.\n    Age > 35.\n    Concurrent use of any chronically administered medication.\n    History of previous discontinuation of isoniazid.\n    Existence of peripheral neuropathy or conditions predisposing to neuropathy.\n    Pregnancy.\n    Injection drug use.\n    Women belonging to minority groups, particularly in the post-partum period.\n    HIV seropositive patients.\n\n\nMode of action: May reduce effectivity of hormonal contraceptives. Reduced absorption w/ antacids. May decrease plasma concentrations of antivirals (e.g. atazanavir, darunavir, fosamprenavir), atovaquone w/ rifampicin. Rifampicin may reduce serum levels of anticonvulsants (e.g. phenytoin), antiarrhythmics (e.g. disopyramide), oral anticoagulants, antifungals (e.g. ketoconazole), barbiturates, ?-blockers, Ca channel blockers (e.g. diltiazem), chloramphenicol, clarithromycin, corticosteroids, ciclosporin, cardiac glycosides, clofibrate, dapsone, diazepam, doxycycline, fluoroquinolones (e.g. ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas), levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus, theophylline, TCAs (e.g. amitriptyline, nortriptyline) and zidovudine. Increased risk of hepatotoxicity w/ halothane. \nIsoniazid may inhibit the metabolism of anticonvulsants (e.g. carbamazepine, phenytoin), benzodiazepines (e.g. diazepam), haloperidol, ketoconazole, theophylline, and warfarin. May enhance the CNS effects of meperidine, cycloserine, and disulfiram w/ isoniazid. Loss of glucose control in patients on oral hypoglycaemics w/ isoniazid.\n\nPotentially Fatal: Concurrent treatment w/ saquinavir/ritonavir combination may result to severe hepatoxicity.\n\nPregnancy category: C\n\nInteraction: May reduce effectivity of hormonal contraceptives. Reduced absorption w/ antacids. May decrease plasma concentrations of antivirals (e.g. atazanavir, darunavir, fosamprenavir), atovaquone w/ rifampicin. Rifampicin may reduce serum levels of anticonvulsants (e.g. phenytoin), antiarrhythmics (e.g. disopyramide), oral anticoagulants, antifungals (e.g. ketoconazole), barbiturates, ?-blockers, Ca channel blockers (e.g. diltiazem), chloramphenicol, clarithromycin, corticosteroids, ciclosporin, cardiac glycosides, clofibrate, dapsone, diazepam, doxycycline, fluoroquinolones (e.g. ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas), levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus, theophylline, TCAs (e.g. amitriptyline, nortriptyline) and zidovudine. Increased risk of hepatotoxicity w/ halothane. \nIsoniazid may inhibit the metabolism of anticonvulsants (e.g. carbamazepine, phenytoin), benzodiazepines (e.g. diazepam), haloperidol, ketoconazole, theophylline, and warfarin. May enhance the CNS effects of meperidine, cycloserine, and disulfiram w/ isoniazid. Loss of glucose control in patients on oral hypoglycaemics w/ isoniazid.\n\nPotentially Fatal: Concurrent treatment w/ saquinavir/ritonavir combination may result to severe hepatoxicity.
Isoniazid + Thiacetazone	\n\n\tIndication: Tuberculosis\n\nDose: Adult: PO/IM Active tuberculosis 5 mg/kg/day. Max: 300 mg/day. Latent tuberculosis 300 mg/day for 6 mth. Nontuberculous mycobacterial infections 5 mg/kg/day for at least 12 mth of culture-negative sputum. Max: 300 mg/day.\n\nContra-indication: Acute liver disease or history of hepatic damage during INH therapy; hypersensitivity.\n\nSide effects: Peripheral neuritis, optic neuritis; psychotic reactions, convulsions, nausea, vomiting, fatigue, epigastric distress, visual disturbances, fever, rash, pyridoxine deficiency.\nPotentially Fatal: Hepatotoxicity.\n\nPrecaution: Renal or hepatic impairment; convulsive disorders; history of psychosis; patients at risk of neuropathy or pyridoxine deficiency eg, diabetic, alcoholic, malnourished, uraemic, infected with HIV. Careful monitoring of hepatic function is necessary for black and hispanic women. Check hepatic function before and during treatment. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Isopropamide + Trifluoperazine	\n\n\tEskayef Bangladesh Ltd.\tTelabid 1 TAB dr   50's pack 100\n\tEskayef Bangladesh Ltd.\tTelabid 2 TAB dr   30's pack 150\n\tEskayef Bangladesh Ltd.\tTelabid FORTE TAB dr   30's pack 150\n\tIndication: Gastrointestinal disorders, Peptic ulcer, Gastritis, Anxiety, Tension, Genitourinary spasm, Hyperchlorhydria, Functional diarrhea, Irritable or spastic colon, Pylorospasm, Acute nonspecific gastroenteritis, Biliary dyskinesia, Chronic cholelithiasis, Duodenitis, Gastrointestinal spasm\n\nDose: Adult: PO Psychoses 2-5 mg twice daily, up to 15-20 mg/day. Severe or resistant: 40 mg/day. \nNausea and vomiting; Short-term management of anxiety 1-2 mg twice daily. Max: 6 mg/day. \nFor anxiety: Max duration: 12 wk. \n\nContra-indication: Preexisting CNS depression and coma; bone marrow depression, blood dyscrasias, liver disease, hypersensitivity to phenothiazines, prolactin dependent tumours. Pregnancy (1st trimester), lactation.\n\nSide effects: Drowsiness, dry mouth, blurred vision, dizziness, sedation, antimuscarinic affects, postural hypotension, akathisia, muscle weakness, anorexia, insomnia, rash, amenorrhoea, fatigue, increased prolactin levels, extrapyramidal side effects.\nPotentially Fatal: Neuroleptic malignant syndrome, blood dyscrasias.\n\nPrecaution: Cardiovascular disease, epilepsy, angle-closure glaucoma, exposure to extreme temperatures, elderly, parkinson's disease, myasthenia gravis, benign prostatic hyperplasia, DM, renal amd hepatic impairment. Discontinue trifluoperazine at least 48 hr before myelography and do not resume for at least 24 hr after procedure. Do not use trifluoperazine in control of nausea and vomiting occurring either prior to myelography or postprocedure with metrizamide. Pregnancy.\n\nMode of action: Increased CNS depression with CNS depressants such as opiates or other analgesics, barbiturates or other sedatives, general anaesthetics, or alcohol. Increased risk of side effects with drugs with antimuscarinic properties e.g. TCA, antiparkinsonian drugs. Antagonised effects of dopaminergic drugs such as levodopa. Increased risk of hypotension with antihypertensives, trazodone. Reverses antihypertensive effect of guanethidine. Increased risk of severe extrapyramidal side-effects or severe neurotoxicity with lithium. Possible decrease in absorption with antacids.\n\nPregnancy category: C\n\nInteraction: Increased CNS depression with CNS depressants such as opiates or other analgesics, barbiturates or other sedatives, general anaesthetics, or alcohol. Increased risk of side effects with drugs with antimuscarinic properties e.g. TCA, antiparkinsonian drugs. Antagonised effects of dopaminergic drugs such as levodopa. Increased risk of hypotension with antihypertensives, trazodone. Reverses antihypertensive effect of guanethidine. Increased risk of severe extrapyramidal side-effects or severe neurotoxicity with lithium. Possible decrease in absorption with antacids.
Isosorbide Dinitrate	\n\n\tSquare\tEsordin TAB dr 10mg 100's pack 35\n\tIndication: Heart failure, Angina, Percutaneous transluminal coronary angioplasty\n\nDose: Adult: PO Long term management of angina 20-120 mg/day in divided doses. Max: 240 mg/day. Heart failure 30-160 mg/day in divided doses. Max: 240 mg/day. \n\nSublingual Heart failure 5-15 mg 2-3 hrly. Acute angina As tab: 2.5-10 mg. As spray: 1-3 sprays (1.25 mg/spray).\n\nContra-indication: Severe hypotension or anaemia, hypovolaemia, heart failure due to obstruction, or raised intracranial pressure due to head trauma or cerebral haemorrhage.\n\nSide effects: Hypotension, tachycardia, flushing, headache, dizziness, palpitation, syncope, confusion. Nausea, vomiting, abdominal pain. Apprehension, restlessness, weakness and vertigo.\nPotentially Fatal: Severe hypotension, circulatory collapse.\n\nPrecaution: Raised intracranial pressure, hypotension, hypovolaemia. Mitral valve prolapse, arterial hypoxaemia, glaucoma, elderly, hypothyroidism, malnutrition, pregnancy, lactation\n\nMode of action: Increased hypotensive effects with alcohol or vasodilators. Marked orthostatic hypotension may occur when used with calcium channel blockers. Vasodilatory effect may be reduced with dihydroergotamine. Ergotamine effects may be enhanced. Reduced effectiveness of sublingual form with disopyramide.\nPotentially Fatal: Significant hypotension may occur with phosphodiesterase-5 inhibitors.\n\nPregnancy category: C\n\nInteraction: Increased hypotensive effects with alcohol or vasodilators. Marked orthostatic hypotension may occur when used with calcium channel blockers. Vasodilatory effect may be reduced with dihydroergotamine. Ergotamine effects may be enhanced. Reduced effectiveness of sublingual form with disopyramide.\nPotentially Fatal: Significant hypotension may occur with phosphodiesterase-5 inhibitors.
Isosorbide Mononitrate	\n\n\tACI\tMoniten TAB dr 20mg 100's pack 142\n\tAcme Ltd.\tA Card TAB dr 20mg 100's pack 142\n\tAristopharma\tISM TAB dr 20mg 100's pack 140\n\tBeximco\tMonate TAB dr 20mg 100's pack 142\n\tDrug International Ltd.\tMonocard TAB dr 20mg 100's pack 150\n\tDrug International Ltd.\tMonocard SR CAP 50mg 40's pack 280\n\tGeneral\tPentabid TAB dr 20mg 100's pack \n\tIncepta\tAngifix TAB dr 20mg 50's pack 70\n\tMundipharma (Bangladesh) Pvt. Ltd.\tMonocontin TAB dr 25mg 100's pack \n\tMundipharma (Bangladesh) Pvt. Ltd.\tMonocontin TAB dr 50mg 28's pack \n\tOpsonin Pharma\tMonit TAB dr 20mg 100's pack 140\n\tSquare\tEsmo TAB dr 20mg 100's pack 142.31\n\tSquare\tEsmo LA CAP 50mg 30's pack 210.67\n\tSun Pharmaceutical (Bangladesh) Ltd.\tMonotate TAB dr 20mg 50's pack 71\n\tSun Pharmaceutical (Bangladesh) Ltd.\tMonotrate TAB dr 50mg 30's pack 123.90\n\tWhite Horse Pharma\tIsocontin TAB dr 20mg 50's pack 71\n\tIndication: Heart failure,  Angina pectoris\n\nDose: Adult: PO 20 mg 2-3 times/day. Usual range: 20-120 mg/day.\nAs LA form: One capsule once daily.\n\nContra-indication: Severe hypotension or anaemia, hypovolaemia, heart failure due to obstruction, or raised intracranial pressure due to head trauma or cerebral haemorrhage.\n\nSide effects: Hypotension, tachycardia, flushing, headache, dizziness, palpitation, syncope, confusion. Nausea, vomiting, abdominal pain. Restlessness, weakness and vertigo. Dry mouth, chest pain, back pain, oedema, fatigue, abdominal pain, constipation, diarrhoea, dyspepsia and flatulence.\nPotentially Fatal: Severe hypotension and cardiac failure.\n\nPrecaution: Severe renal or severe hepatic impairment, hypothyroidism, malnutrition, or hypothermia. Caution in patients who are already hypotensive. May aggravate angina caused by hypertrophic cardiomyopathy. Tolerance may develop after long-term treatment. Lactation.\n\nMode of action: Hypotensive effects may be increased when used with alcohol or vasodilators. Concurrent use with calcium channel blockers may lead to marked orthostatic hypotension.\nPotentially Fatal: Significant hypotension may occur when used with phosphodiesterase-5 inhibitors.\n\nPregnancy category: C\n\nInteraction: Hypotensive effects may be increased when used with alcohol or vasodilators. Concurrent use with calcium channel blockers may lead to marked orthostatic hypotension.\nPotentially Fatal: Significant hypotension may occur when used with phosphodiesterase-5 inhibitors.
Isotretinoin 0.05% Topical	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tIsotrex Gel 0.05mg/100ml  10gm tube  296.94\n\tIncepta\tAknil Gel 0.05 gm/100 gm  \n\tUnimed & Unihealth Manufacturers Ltd.\tRetigel Gel   20gm tube 100\n\tIndication: Acne\n\nDose: Adult: As 0.05% gel: Apply sparingly once or twice daily. Effect may not be evident for 6-8 wk.\n\nContra-indication: Pregnancy, lactation.\n\nSide effects: Dryness of mucous membranes, dryness of skin with scaling, fragility, erythema, cheilitis, pruritus, epistaxis, conjunctivitis, dry sore mouth and palmo-plantar exfoliation. Corneal opacities, dry eyes, visual disturbances, skeletal hyperostosis and musculoskeletal symptoms. Elevation of serum triglycerides, LFTs, ESR and blood glucose. Hair thinning, photosensitivity, changes in skin pigmentation, paronychia. GI disturbances, hepatitis. Headache, drowsiness, sweating, mood changes, psychotic symptoms, depression, suicidal tendencies, benign intracranial hypertension, seizures. Vasculitis, hypersensitivity reactions, IBS.\nPotentially Fatal: Anaphylaxis. Haemorrhagic pancreatitis.\n\nPrecaution: Preexisting or predisposition to hypertriglyceridaemia (e.g. DM, obesity or increased alcohol intake). Monitor triglyceride levels. Monitor blood lipids and LFTs at wkly or bi-wkly intervals. Monitor blood glucose in known or suspected DM patients. Genetic predisposition for age-related osteoporosis, history of childhood osteoporosis, osteomalacia or other bone metabolism disorders. Anorexia nervosa. History of psychiatric disorder. May impair night vision. Avoid wax epilation and skin resurfacing procedures for at least 6 mth. Avoid prolonged exposure to UV light or sunlight. Discontinue if hearing impairment, abdominal pain, rectal bleeding, severe diarrhoea or adverse ocular effects occur. Patient should not donate blood during therapy and for at least 1 mth following drug discontinuation.\n\nMode of action: Additive toxicity with vitamin A or its derivatives. Decreased efficacy of microdosed progesterone (use 2 forms of contraception). May increase risk of bone loss with phenytoin. May increase risk of osteoporosis with systemic corticosteroids. Reduces plasma levels of carbamazepine.\nPotentially Fatal: Increased risk of pseudotumor cerebri with tetracyclines.\n\nPregnancy category: X\n\nInteraction: Additive toxicity with vitamin A or its derivatives. Decreased efficacy of microdosed progesterone (use 2 forms of contraception). May increase risk of bone loss with phenytoin. May increase risk of osteoporosis with systemic corticosteroids. Reduces plasma levels of carbamazepine.\nPotentially Fatal: Increased risk of pseudotumor cerebri with tetracyclines.
Ispaghula Husk	\n\n\tAlbion Ltd.\tAlbi-Tasty Ispaghula Sachet 3.5 g/Sachet 20's pack \n\tDrug International Ltd.\tLaxadil Sachet 3.5gm 15's pack 105\n\tIncepta\tFiberlax Powder 400gm  \n\tMedimet\tLaxate Sachet 3.5gm 12's pack 84\n\tRadiant.\tFibogel Effervescent powder   \n\tRephco\tLite Sachet 3.5gm 12's pack 70\n\tSquare\tIspergul Sachet 3.5mg 15âs sachet/box  120\n\tSquare\tIspergul Dry Powder 100mg 1's pack 185\n\tIndication: Constipation\n\nDose: Adult: PO Constipation Initial: 10-20 g (15-30 mL)/day. Max: 45 mL (or 40 g of the reconstituted oral formulation)/day. Hepatic encephalopathy 60-100 g (90-150 mL)/day in 3 divided doses; adjust accordingly. Rectal Hepatic encephalopathy Mix 200 g (300 mL w/ 700 mL water or 0.9% NaCl as a retention enema. Retain enema for 30-60 mins; repeat 4-6 hrly until oral medication can be administered.\n\nContra-indication: Galactosaemia, intestinal obstruction. Patients on low galactose diet.\n\nSide effects: Diarrhoea (dose-related), nausea, vomiting, hypokalaemia, bloating and abdominal cramps.\nPotentially Fatal: Dehydration and hypernatraemia on aggressive treatment.\n\nPrecaution: Monitor electrolyte imbalance. Lactose intolerance; diabetics.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Itraconazole	\n\n\tKemiko\tIconal CAP 100mg 12's pack 180\n\tNavana\tItracon CAP 100mg 12's pack 180.72\n\tPopular\tI-Zol CAP 100mg 20's pack 301.20\n\tSquare\tItra CAP 100mg 24's pack 361.20\n\tIndication: Candidiasis, Fungal infections, Tinea pedis, Tinea cruris, Tinea corporis, Pityriasis versicolor\n\nDose: Adult: PO: Oropharyngeal candidiasis As cap: 100 mg/day for 15 days. \nVulvovaginal candidiasis As cap: 200 mg twice daily for 1 day. \nPityriasis versicolor As cap: 200 mg/day for 7 days. \nTinea corporis; Tinea cruris As cap: 100 mg/day for 15 days. \nFungal nail infections As cap: 200 mg/day for 3 mth. \nSystemic fungal infections As cap: 100-200 mg once daily, up to 200 mg twice daily for invasive or disseminated infections. \nProphylaxis of infections in neutropenic or AIDS patients As cap: 200 mg/day, up to 200 mg twice daily if needed. \nTinea pedis; Tinea manuum As cap: 100 mg/day for 30 days. \n\nContra-indication: Hypersensitivity to azole antifungals; pregnancy and lactation; hepatic disease. IV: CrCl: <30 ml/min.\n\nSide effects: Dyspepsia, abdominal pain, nausea, vomiting, diarrhoea; menstrual disorders; constipation, rash, pruritus, urticaria; angioedema, anaphylaxis. Increased liver enzyme values, jaundice, Stevens-Johnson syndrome, hypokalaemia.\nPotentially Fatal: Liver failure; heart failure; pulmonary oedema; CV disease.\n\nPrecaution: Renal insufficiency; CHF, history of CHF, COPD; monitor liver function.\n\nMode of action: May increase the plasma concentrations of oral anticoagulants, digoxin, cilostazol, alprazolam, midazolam (IV), repaglinide, corticosteroids (e.g. budesonide, dexamethasone, fluticasone, methylprednisolone). May increase plasma concentration w/ HIV protease inhibitors (e.g. ritonavir, indinavir, saquinavir), erythromycin, clarithromycin. May reduce plasma concentration w/ isoniazid, carbamazepine, nevirapine, phenytoin, Phenobarbital, rifampicin, rifabutin. May reduce absorption w/ PPIs, antacids, antimuscarinics, histamine H2 receptor antagonists. Concomitant use w/ dihydropyridines may cause oedema. May increase negative inotropic effects of verapamil. May increase risk of potentially fatal resp depression w/ fentanyl.\nPotentially Fatal: May increase risk of QT prolongation or torsades de pointes w/ astemizole, bepridil, cisapride, dofetilide, levacetylmethadol (levomethadyl), mizolastine, pimozide, quinidine, sertindole, terfenadine, methadone, ranolazine, dronedarone, halofantrine. May increase risk of myopathy including rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. atorvastatin, lovastatin, simvastatin). May increase risk of ergotism w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergometrine, methylergometrine). May potentiate hypnotic and sedative effect of triazolam and oral midazolam. May increase plasma concentration of eletriptan, nisoldipine, felodipine, disopyramide, irinotecan, lurasidone; colchicine (patient w/ renal or hepatic failure). May increase risk of hypotension and hyperkalaemia w/ eplerenone.\n\nPregnancy category: C\n\nInteraction: May increase the plasma concentrations of oral anticoagulants, digoxin, cilostazol, alprazolam, midazolam (IV), repaglinide, corticosteroids (e.g. budesonide, dexamethasone, fluticasone, methylprednisolone). May increase plasma concentration w/ HIV protease inhibitors (e.g. ritonavir, indinavir, saquinavir), erythromycin, clarithromycin. May reduce plasma concentration w/ isoniazid, carbamazepine, nevirapine, phenytoin, Phenobarbital, rifampicin, rifabutin. May reduce absorption w/ PPIs, antacids, antimuscarinics, histamine H2 receptor antagonists. Concomitant use w/ dihydropyridines may cause oedema. May increase negative inotropic effects of verapamil. May increase risk of potentially fatal resp depression w/ fentanyl.\nPotentially Fatal: May increase risk of QT prolongation or torsades de pointes w/ astemizole, bepridil, cisapride, dofetilide, levacetylmethadol (levomethadyl), mizolastine, pimozide, quinidine, sertindole, terfenadine, methadone, ranolazine, dronedarone, halofantrine. May increase risk of myopathy including rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. atorvastatin, lovastatin, simvastatin). May increase risk of ergotism w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergometrine, methylergometrine). May potentiate hypnotic and sedative effect of triazolam and oral midazolam. May increase plasma concentration of eletriptan, nisoldipine, felodipine, disopyramide, irinotecan, lurasidone; colchicine (patient w/ renal or hepatic failure). May increase risk of hypotension and hyperkalaemia w/ eplerenone.
ivabradine	\n\n\tDrug International Ltd.\tIvaten-5 TAB dr 5mg 10's Pack 250\n\tDrug International Ltd.\tIvaten-7.5 TAB dr 7.5mg 10's Pack 350\n\tIncepta\tIvaprex TAB dr 5mg 10's pack 300\n\tIncepta\tIvaprex TAB dr 7.5mg 10's pack 450\n\tSquare\tIvanor TAB dr 5mg 10's pack 300\n\tSquare\tIvanor TAB dr 7.5mg 10's pack 450\n\tUnimed & Unihealth Manufacturers Ltd.\tCorabid TAB dr 5mg 14's pack 490\n\tUnimed & Unihealth Manufacturers Ltd.\tCorabid TAB dr 7.5mg 14's pack 700\n\tIndication: Chronic stable angina \n\nDose: Adult: PO Chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm who are unable to tolerate or has a contraindication to beta-blockers; or used with beta-blockers in patients inadequately controlled with an optimal dose of beta-blockers and whose heart rate is >60 beats/min Initial: 5 mg twice daily. Increase if necessary to 7.5 mg twice daily after 3-4 weeks. Titrate downward to 2.5-5 mg twice daily if develop bradycardia (resting heart rate < 50 beats/min) or experience symptoms of bradycardia (dizziness, fatigue, hypotension) or resting heart rate is persistently <50 beats/min).\nElderly: >75 yr old: Initiate treatment at 2.5 mg bid. Titrate up if necessary.\n\nContra-indication: Pregnancy, lactation, resting heart rate <60 beats/min prior to treatment, cardiogenic shock, acute myocardial infarction, severe hypotension (<90/50 mmHg), severe hepatic insufficiency, sick sinus syndrome, sino-atrial block, heart failure patients with NYHA class III-IV, pacemaker dependent, unstable angina, 3rd degree AV-block, concurrent use with potent CYP3A4 inhibitors.\n\nSide effects: Luminous phenomena (phosphena), blurred vision, bradycardia, 1st degree AV-block, ventricular extrasystole, supraventricular extrasystoles, palpitations, headache, dizziness, nausea, constipation, diarrhoea, vertigo, dyspnoea, muscle cramps, hyperuricaemia, eosinophilia, elevated blood-creatinine.\n\nPrecaution: Reduce dose if resting heart rate is persistently <50 beats/min or patient develops bradycardia symptoms during treatment; discontinue if heart rate <50 beats/min and symptoms persist. Not recommended in patient with AF or other cardiac arrhythmias that interfere with sinus node rhythm; monitor regularly for AF occurrence. Not recommended for concomitant use with heart rate reducing calcium channel blockers (e.g. diltiazem or verapamil), immediate use after a stroke or in patients with 2nd degree AV-block. Severe renal insufficiency, Moderate hepatic insufficiency. Stop treatment if visual field deteriorates unexpectedly. Patients with retinitis pigmentosa.\n\nMode of action: Concomitant use with QT-prolonging drugs (e.g. quinidine, disopyramide, bepridil, sotalol, ibutilide, amiodarone, pimozide, ziprasidone, sertinole, mefloquine, halofantrine, pentamide, cisapride, erythromycin IV) is not recommended as QT prolongation may be enhanced by heart rate reduction. Concentrations may increase when used with CYP3A4 inhibitors. Use with verapamil or diltiazem (moderate CYP3A4 inhibitors) is not recommended. If used with other moderate CYP3A4 inhibitors (e.g. fluconazole), may consider starting at lower dose and with heart rate monitoring if resting heart rate >60 beats/min. Concentration may be reduced with CYP3A4 inducers (e.g. rifampicin, barbiturates, phenytoin, St John's Wort) and may require Ivabradine dose adjustment.\nPotentially Fatal: Concurrent use with potent CYP3A4 inhibitors is contraindicated; e.g. azole antifungals (ketoconazole, itraconazole), macrolides (clarithromycin, erythromycin PO, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone.\n\nPregnancy category: Not Classified\n\nInteraction: Concomitant use with QT-prolonging drugs (e.g. quinidine, disopyramide, bepridil, sotalol, ibutilide, amiodarone, pimozide, ziprasidone, sertinole, mefloquine, halofantrine, pentamide, cisapride, erythromycin IV) is not recommended as QT prolongation may be enhanced by heart rate reduction. Concentrations may increase when used with CYP3A4 inhibitors. Use with verapamil or diltiazem (moderate CYP3A4 inhibitors) is not recommended. If used with other moderate CYP3A4 inhibitors (e.g. fluconazole), may consider starting at lower dose and with heart rate monitoring if resting heart rate >60 beats/min. Concentration may be reduced with CYP3A4 inducers (e.g. rifampicin, barbiturates, phenytoin, St John's Wort) and may require Ivabradine dose adjustment.\nPotentially Fatal: Concurrent use with potent CYP3A4 inhibitors is contraindicated; e.g. azole antifungals (ketoconazole, itraconazole), macrolides (clarithromycin, erythromycin PO, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone.
Ivermectin	\n\n\tAristopharma\tIvactin TAB dr 3mg 10 's pack 60\n\tBeximco\tIvera TAB dr 6mg 10's pack 150\n\tDelta Pharma\tScabo TAB dr 3mg 10's pack 30\n\tDelta Pharma\tScabo TAB dr 6mg 10 's pack 50\n\tIndication: Ascariasis, Strongyloidiasis, Filariasis, Scabies, Onchocerciasis, Gnathostomiasis\n\nDose: Oral\nOnchocerciasis\nAdult: >15 kg: 150 mcg/kg as a single dose; retreatment may be given every 6-12 mth until adult worms die.\nChild: >5 yr and >15kg: 150 mcg/kg as a single dose every 6-12 mth until adult worms die.\n\nStrongyloidiasis\nAdult: 200 mcg/kg as a single dose for 1-2 days.\nChild: >15 kg: 200 mcg/kg as a single dose for 1-2 days.\n\nFilariasis\nAdult: Dosing regimen depends on the causative agent. Mansonella streptocerca 150 mcg/kg as a single dose; Mansonella ozzardi 200 mcg/kg as a single dose.\nChild: >15 kg: Dosing regimen depends on the causative agent. Mansonella streptocerca 150 mcg/kg as a single dose; Mansonella ozzardi 200 mcg/kg as a single dose.\n\nAscariasis\nAdult: Ascaris lumbricoides 150-200 mcg/kg as a single dose.\nChild: >15 kg: Ascaris lumbricoides 150-200 mcg/kg as a single dose.\n\nGnathostomiasis\nAdult: Gnathostoma spinigerum: 200 mcg/kg once daily for 2 days.\nChild: >15 kg: Gnathostoma spinigerum: 200 mcg/kg once daily for 2 days.\n\nScabies\nAdult: Sarcoptes scabiei 200 mcg/kg as a single dose, repeat dose in 2 wk.\nChild: >15 kg: Sarcoptes scabiei 200 mcg/kg as a single dose, repeat dose in 2 wk.\n\nContra-indication: Hypersensitivity. Pregnancy and lactation. Childn <15 kg body weight.\n\nSide effects: Diarrhoea, nausea, vomiting, dizziness, pruritus, urticaria, rash, arthralgia, fever, myalgia, asthenia, postural hypotension, tachycardia, oedema, lymphadenopathy, sore throat, cough, headache, somnolence, transient eosinophilia, raised liver enzyme values.\n\nPrecaution: Concurrent Loa loa infection, impaired blood-brain barrier function due to infection.\n\nMode of action: Bioavailability may be increased by alcohol, levamisole.\n\nPregnancy category: C\n\nInteraction: Bioavailability may be increased by alcohol, levamisole.
Ketoconazole 1.9%, 2%	\n\n\tAristopharma\tKetozol Shampoo   60ml pack 175\n\tBeximco\tResolve Shampoo 2% 100ml 250\n\tIncepta\tDancel Shampoo Shampoo  2% (60ml/100ml) 1's pack  175/230\n\tOpsonin Pharma\tKetocon 2% Shampoo   60ml pack 175\n\tSanofi Aventis (BD) Ltd.\tNizoral 			 	 	 Shampoo 2%  1's pack(60ml) 345\n\tSquare\tSelect-Plus shampoo Shampoo  75ml bot 175\n\tUnimed & Unihealth Manufacturers Ltd.\tNizoder Shampoo   100ml pack 230\n\tUnimed & Unihealth Manufacturers Ltd.\tNizoder 2 % Cream 20mg/gm 15gm tube 50\n\tIndication: Dandruff, Seborrheic dermatitis of the scalp, Pityriasis versicolor\n\nDose: To use the Ketoconazole  shampoo, follow these steps: Use a small amount of water to wet the area where Ketoconazole  shampoo is to be applied. Apply the shampoo to the affected skin/scalp and a large area around it. Use fingers to rub the shampoo until it forms lather. Leave the shampoo on skin/scalp for 5 minutes. Rinse the shampoo off skin/scalp with water. \n\nTreatment: Pityriasis versicolor: once daily for 5 days. \nSeborrhoeic dermatitis and Pityriasis capitis: twice weekly for 2 to 4 weeks.\n\nProphylaxis: Pityriasis versicolor: once daily for 3 days during a single treatment course before the summer. Seborrhoeic dermatitis and Pityriasis capitis: once every 1 or 2 weeks.\n\nContra-indication: Known hypersensitivity to ketoconazole or any of the excipients.\n\nSide effects: Topical treatment with Ketoconazole 2% shampoo is generally well tolerated. As with other shampoos, a local burning sensation, itching, or contact dermatitis (due to irritation or allergy), may occur on exposed areas. In rare instances, mainly in patients with chemically damaged hair or gray hair, a discoloration of the hair has been observed with the use of Ketoconazole 2% shampoo.\n\nPrecaution: In patients who have been on prolonged treatment with topical corticosteroids, it is recommended that the steroid therapy be gradually withdrawn over a period of 2 to 3 weeks, while using Ketoconazole 2% shampoo to prevent any potential rebound effect. Avoid contact with the eyes. If the shampoo enters the eyes, rinse immediately with plenty of water.\n\nMode of action: Reduced absorption w/ antimuscarinics, antacids, H2-blockers, PPIs, sucralfate. Reduced plasma concentrations w/ rifampicin, isoniazid, efavirenz, nevirapine, phenytoin. May also reduce concentrations of isoniazid and rifampicin. May reduce efficacy of oral contraceptives. May increase serum levels of CYP3A4 substrates e.g. digoxin, oral anticoagulants, sildenafil, tacrolimus.\nPotentially Fatal: May potentiate and prolong sedative and hypnotic effects of midazolam and triazolam. Increased plasma levels and prolonged QT intervals of astemizole, cisapride, dofetilide, pimozide, quinidine and terfenadine which may lead to torsade de pointes. Increased risk of myopathy w/ HMG-CoA reductase inhibitors (e.g. lovastatin, simvastatin). Markedly increased plasma levels of nisoldipine. Increased risk of hyperkalaemia and hypotension w/ eplerenone. Increased risk of vasospasm potentially leading to cerebral ischaemia w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine).\n\nPregnancy category: C\n\nInteraction: Reduced absorption w/ antimuscarinics, antacids, H2-blockers, PPIs, sucralfate. Reduced plasma concentrations w/ rifampicin, isoniazid, efavirenz, nevirapine, phenytoin. May also reduce concentrations of isoniazid and rifampicin. May reduce efficacy of oral contraceptives. May increase serum levels of CYP3A4 substrates e.g. digoxin, oral anticoagulants, sildenafil, tacrolimus.\nPotentially Fatal: May potentiate and prolong sedative and hypnotic effects of midazolam and triazolam. Increased plasma levels and prolonged QT intervals of astemizole, cisapride, dofetilide, pimozide, quinidine and terfenadine which may lead to torsade de pointes. Increased risk of myopathy w/ HMG-CoA reductase inhibitors (e.g. lovastatin, simvastatin). Markedly increased plasma levels of nisoldipine. Increased risk of hyperkalaemia and hypotension w/ eplerenone. Increased risk of vasospasm potentially leading to cerebral ischaemia w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine).
Ketoprofen 2.5% Topical	\n\n\tNovo Healthcare and Pharma Ltd.\tKetofast Gel 25 mg/gm  \n\tPacific\tFestam Gel 25 mg/gm  \n\tSanofi Aventis (BD) Ltd.\tProfenid Gel   30gm tube 101.53\n\tSquare\tKop 2.5% Gel  25 mg/gm 20gm tube 58.21\n\tIndication: Rheumatic disorders, Musculoskeletal pain, Pain and inflammation\n\nDose: Adult: As 2.5% gel: Apply onto affected areas 2-4 times daily for up to 10 days. As 30 mg plaster: Apply 1 plaster bid.\n\nContra-indication: For all routes: Hypersensitivity to aspirin or other NSAIDs or those suffering from asthma, angioedema, urticaria or rhinitis. Active GI disease (e.g. bleeding or ulcer). Severe heart failure, and renal insufficiency. Treatment of perioperative pain in the setting CABG surgery. Rectal: Patients w/ history of proctitis or haemorrhoids.\n\nSide effects: HTN; GI symptoms e.g. dyspepsia, discomfort, nausea, diarrhoea; pain and tissue damage at inj site (IM). Cardiovascular toxicity (chest pain, dyspnea, weakness, slurred speech). May mask the usual signs and symptoms of infection. NSAID-induced liver dysfunction, anaphylactoid reaction (e.g. difficulty breathing, swelling of the face or throat); photosensitivity reactions (topical).\n\nPrecaution: History of GI disease (e.g. bleeding or ulcer). Hypertensive patients; renal or hepatic impairment. Pregnancy, lactation, elderly. Monitoring Parameters Close monitoring of BP during initiation and throughout the therapy. Complete blood cell count, chemistry profile, liver and renal function test performed periodically for patients receiving long-term ketoprofen therapy.\n\nMode of action: Increases plasma concentrations of lithium and methotrexate. Reduces effects of antihypertensives (e.g. ACE inhibitors, angiotensin II receptor antagonists). Increased risk of GI bleeding w/ warfarin. Decreased protein binding of ketoprofen and increased risk for serious GI events w/ aspirin and other NSAIDs. Increased risk of developing renal failure w/ diuretics. Increased risk of GI bleeding and ulceration w/ corticosteroids. Increased plasma levels w/ probenecid. Salicylate reduces conjugation and renal elimination of ketoprofen.\n\nPregnancy category: B\n\nInteraction: Increases plasma concentrations of lithium and methotrexate. Reduces effects of antihypertensives (e.g. ACE inhibitors, angiotensin II receptor antagonists). Increased risk of GI bleeding w/ warfarin. Decreased protein binding of ketoprofen and increased risk for serious GI events w/ aspirin and other NSAIDs. Increased risk of developing renal failure w/ diuretics. Increased risk of GI bleeding and ulceration w/ corticosteroids. Increased plasma levels w/ probenecid. Salicylate reduces conjugation and renal elimination of ketoprofen.
Ketorolac Tromethamine	\n\n\tACI\tMinolac TAB dr 10mg 40's pack 402.80\n\tACI\tMinolac Injection 10mg/ml 1ml amp x 1's pack 33\n\tACI\tMinolac Injection 30mg/ml 5's pack 276.90\n\tACI\tMinolac Injection 60mg/2ml 5's pack 478.25\n\tAcme Ltd.\tWinop TAB dr 10mg 20's pack 200.80\n\tAcme Ltd.\tWinop Injection 10mg/ml 1ml amp x 5's pack 150.55\n\tAcme Ltd.\tWinop Injection 30mg/ml 1ml amp x 1's pack/1ml amp x 5's pack 55.21 / 250\n\tAcme Ltd.\tWinop Injection 60mg/2ml 2ml amp x 1's pack 95.36\n\tAd-din\tLacor TAB dr 10mg 20's pack 180\n\tAlbion Ltd.\tKorac TAB dr 10mg  \n\tAlbion Ltd.\tKetorolac TAB dr 10 mg 40's pack \n\tAlco Pharma\tTolec TAB dr 10mg 20's pack 200\n\tAlco Pharma\tTolec IM/IV Injection 30 mg/ml  \n\tAlco Pharma\tTolec IM/IV Injection 60 mg/2 ml  \n\tAmbee\tArolak TAB dr 10mg 20's pack 200.80\n\tAmbee\tArolak Injection 10mg 5's pack 150.60\n\tAmbee\tArolak Injection 30mg 5's pack 276.50\n\tAmbee\tE-ket Injection 30mg 5's pack 250\n\tAmico Ltd.\tTroy TAB dr 10mg 30's pack 300\n\tAmulet\tToro TAB dr 10mg 20's pack 200\n\tAmulet\tToro Injection 60 mg/2 ml  \n\tAPC Pharma Ltd.\tApilac TAB dr 10mg 30's pack 200\n\tAPC Pharma Ltd.\tKetorolac TAB dr 10mg 30's pack 200\n\tApex\tKflam TAB dr 10mg 20's pack 200\n\tApex\tKflam IV/IM Injection 30mg/ml 1ml amp x 5's pack 275\n\tApollo Pharmaceutical Ltd.\tApoket TAB dr 10mg 30's pack 300\n\tAristopharma\tOradol TAB dr 10mg 20's pack/30's pack 200 / 300\n\tAristopharma\tOradol Injection 30mg/ml 1ml amp x 1's pack/1ml amp x 5's pack 55 /275\n\tAristopharma\tOradol Injection 60mg/ml 2ml amp x 1's pack 95\n\tAsiatic Ltd.\tSurpim TAB dr 10mg 20's pack 200\n\tAstra Biopharmaceuticals Ltd.\tKetoroz TAB dr 10mg 10's pack 100\n\tAstra Biopharmaceuticals Ltd.\tKetoroz Injection 30mg/ml 1's pack 55\n\tBeacon\tAcupain TAB dr 10mg 30's pack 300.90\n\tBeacon\tAcupain Injection 30mg/ml 30 mg  amp x 5's pack 276\n\tBenham\tKetobe TAB dr 10mg 30's pack 298.20\n\tBeximco\tXidolac TAB dr 10mg 20's pack 200\n\tBeximco\tXidolac Injection 10mg/ml 1ml amp x 5's pack 150\n\tBeximco\tXidolac Injection 30mg/ml 1ml amp x 1's pack 55\n\tBio Pharma Ltd.\tPerilac TAB dr 10mg 20's pack 200.80\n\tBio Pharma Ltd.\tPerilac Injection 10mg/ml 1ml amp x 5's pack 150.55\n\tBio Pharma Ltd.\tPerilac Injection 30mg/ml 1ml amp x 5's pack 276.05\n\tBristol Pharma Ltd.\tKetorolac. TAB dr 10mg 40's pack 400\n\tCentral.\tKPR TAB dr 10mg 20's pack 200\n\tChemist Ltd.\tKelac TAB dr 10mg 20's pack 160\n\tChemist Ltd.\tKelac Injection 30mg/ml 1ml amp x 5's pack 175\n\tConcord\tMaxdol TAB dr 10mg 20's pack 300\n\tConcord\tMaxdol IV/IM Injection 30 mg/ml  \n\tConcord\tMaxdol IV/IM Injection 60 mg/2 ml  \n\tCosmic Chemical Industries Ltd.\tLixidol TAB dr 10mg 30's pack 300\n\tDecent Pharma Ltd.\tKilpan TAB dr 10mg 20's pack 200\n\tDelta Pharma\tKet TAB dr 10mg 20's pack 160\n\tDesh\tDetolac TAB dr 10mg 30's pack / 50's pack 180 / 300\n\tDoctor Tims\tKetofenac IM/IV Injection 30 mg/ml  \n\tDrug International Ltd.\tPair TAB dr 10mg 30's pack 300\n\tDrug International Ltd.\tPair Injection 30mg/ml 5's pack 275\n\tEdruc Ltd.\tEket TAB dr 10mg 20's pack 200\n\tEskayef Bangladesh Ltd.\tKetonic TAB dr 10mg 30's pack 300\n\tEskayef Bangladesh Ltd.\tKetonic Injection 30mg/ml 4's pack  220 \n\tEskayef Bangladesh Ltd.\tKetonic Injection 60mg/2ml 2ml amp x 1's pack 95\n\tEuro Pharma Ltd.\tEurolac TAB dr 10mg 30's pack 300\n\tEuro Pharma Ltd.\tEurolac Injection 60 mg/2 ml  \n\tEuro Pharma Ltd.\tEurolac Injection 30 mg/ml  \n\tEverest\tEcolac TAB dr 10mg 20's pack 200\n\tG. A. Company Ltd.\tKerolac TAB dr 10mg 20's pack 200\n\tGeneral\tToroaid TAB dr 10mg 20's pack 300\n\tGeneral\tToroaid IV/IM Injection 30mg/ml 1's pack 55\n\tGeneral\tToroaid IV/IM Injection 60mg/2ml 1's pack 95\n\tGlobe\tRoket TAB dr 10mg 20's pack 200\n\tGlobe\tRoket Injection 30mg/ml 1ml amp x 5's pack 250\n\tGlobex\tSurgidol TAB dr 10mg 30's pack 300\n\tGlobex\tSurgidol Injection 30 mg/ml  \n\tHealthcare\tZeropain TAB dr 10mg 20's pack 240\n\tHealthcare\tZeropain Injection 30mg/ml 1ml amp x 5's pack 300\n\tHealthcare\tZeropain Injection 60mg/2ml 2ml amp x 2's pack 200\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEtolac TAB dr 10mg 20's pack 210\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEtolac Injection 30mg/ml 1ml amp x 5's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEtolac Injection 60mg/2ml 2ml amp x 1's pack 100\n\tIncepta\tEtorac TAB dr 10mg 30's pack 300\n\tIncepta\tEtorac Injection 10mg/ml 10's pack 320\n\tIncepta\tEtorac Injection 30mg/ml 1ml amp x 1's pack 55\n\tIncepta\tEtorac Injection 60mg/2ml 2ml amp x 1's pack 95\n\tIndobangla Pharmaceuticals\tInket TAB dr 10mg 40's pack 400\n\tJayson\tEmodol TAB dr 10mg 20's pack  203\n\tJayson\tEmodol Injection 10mg/ml 1ml amp x10's pack 332.50\n\tJayson\tEmodol Injection 30mg/ml 1ml amp x 5's pack 250.95\n\tJMI Syringes & Medical Devices Ltd.\tKtmet TAB dr 10mg 30's pack 301.20\n\tKemiko\tOfpain TAB dr 10mg 20's pack 200\n\tKemiko\tOfpain Injection 30mg/ml 1ml amp x 1's pack 55\n\tKumudini Pharma Ltd.\tDoloket TAB dr 10mg 30's pack 300\n\tLabaid\tKetolab 10 TAB dr 10mg 2x10's pack 240\n\tLabaid\tKetolab 30 Injection 30 mg/ml	  \n\tLabaid\tKetolab 60 Injection 60 mg/2 ml  \n\tLeon\tKetoact TAB dr 10mg  \n\tLeon\tKetoact Injection 30mg/ml  \n\tMedicon\tKetora TAB dr 10mg 20's pack 200\n\tMonicopharma\tKepros TAB dr 10mg 30's pack 300\n\tMonicopharma\tKepros Injection 30mg/ml 1ml amp x 5's pack 275\n\tNavana\tOrc TAB dr 10mg 20's pack 301.20\n\tNavana\tORC Injection 30mg/ml 3's pack 165\n\tNavana\tORC Injection 60mg/2ml 2's pack 190\n\tNipa\tKitolac TAB dr 10mg 30's pack 300\n\tNIPRO JMI Pharma\tToralin TAB dr 10mg  \n\tNovartis (Bangladesh) Ltd.\tZepac TAB dr 10mg 30's pack 300\n\tNovartis (Bangladesh) Ltd.\tZepac Injection 30mg/ml 1ml amp x 5's pack 300\n\tNovelta Bestway\tLupelac TAB dr 10mg 20's pack 200\n\tNovo Healthcare and Pharma Ltd.\tRotek TAB dr 10mg 20's pack 200\n\tNovo Healthcare and Pharma Ltd.\tRotek Injection 30mg/ml 1ml amp x 5's pack 250\n\tNovus\tPainlok TAB dr 10mg 20's pack 200\n\tOpso Saline Ltd.\tTorosic TAB dr 10mg  \n\tOpso Saline Ltd.\tTorosic Injection 30 mg/ml  \n\tOpso Saline Ltd.\tKetorolac Injection 60 mg/2 ml  \n\tOpsonin Pharma\tTodol TAB dr 10mg 30's pack 300\n\tOpsonin Pharma\tTodol Injection 30mg/ml 1ml amp x 5's pack 280\n\tOpsonin Pharma\tTodol Injection 30mg/2ml 2ml amp x 1's pack 95.36\n\tOrganic Health Care\tRepopain TAB dr 10mg 30's pack 300\n\tOrion Pharma Ltd.\tKetorin TAB dr 10mg 20's pack 200.80\n\tOrion Pharma Ltd.\tKetorin 30 Injection 30mg/ml 1ml amp x 5's pack 250.95\n\tOyster\tSurgin TAB dr 10mg  \n\tPacific\tKetromin TAB dr 10mg 20's pack 200\n\tPharmacil Ltd.\tKetogate IM/IV Injection 30 mg/ml  \n\tPharmasia Ltd.\tRotalac TAB dr 10mg 20's pack 200.80\n\tPharmasia Ltd.\tRotalac Injection 30mg/ml 1ml amp x 1's pack 55\n\tPharmasia Ltd.\tRotalac Injection 60mg/2ml 2ml amp x 1's pack 95\n\tPopular\tLopadol Injection 60mg/2ml 2ml amp x 1's pack 95.36\n\tPopular\tLopadol TAB dr 10mg 50's pack 502\n\tPopular\tLopadol Injection 30mg/ml 1ml amp x 5's pack 276.05\n\tPrime\tPetrolac TAB dr 10mg  \n\tRadiant.\tToradol TAB dr 10mg 20's pack 460.20\n\tRadiant.\tToradol Injection 30mg/ml 1ml amp x 5's pack 600\n\tRadiant.\tToradolin Injection 30mg/1ml 5's amps pack \n\tRAK\tKeteks TAB dr 10mg 30's pack 360\n\tRAK\tKeteks Injection 30mg/ml 1ml amp x 5's pack 275\n\tRAK\tKeteks Injection 60mg/2ml 2ml amp x 1's pack 95\n\tRangs\tKenodol TAB dr 10mg 20's pack 240\n\tRangs\tKenodol Injection 30mg/ml 1ml amp x 6's pack 300\n\tRasa\tKT TAB dr 10mg  \n\tReliance\tVeslac TAB dr 10mg 30's pack 309.15\n\tRenata\tRolac TAB dr 10mg 40's pack 400\n\tRenata\tRolac Injection 10mg/ml 1ml amp x 1's pack 32.13\n\tRenata\tRolac Injection 30mg/ml 1ml amp x 1's pack 55.21\n\tRephco\tKnil TAB dr 10mg 30's pack 300\n\tRephco\tKnil Injection 30mg/ml 1ml amp x 1's pack 60\n\tRephco\tKnil Injection 60mg/2ml 1's pack 95\n\tS. N.\tKitorex TAB dr 10mg 30's pack 301.50\n\tSalton\tKetosal TAB dr 10mg  \n\tSanofi Aventis (BD) Ltd.\tSanoket TAB dr 10mg 30's pack 270.90\n\tSanofi Aventis (BD) Ltd.\tSanoket Injection 10mg 5's pack 150.55\n\tSanofi Aventis (BD) Ltd.\tSanoket Injection 30mg 5's pack 276.05\n\tSanofi Aventis (BD) Ltd.\tSanoket Injection 60mg/2ml 1's ampule 95\n\tSeema\tKetoseem TAB dr 10mg 30's pack 300\n\tShamsul Al-Amin\tXenolac TAB dr 10mg 20's pack 200\n\tSharif\tKetoprix TAB dr 10mg 30's pack 300\n\tSilva\tTorolac TAB dr 10mg 20's pack 200.75\n\tSomatec\tKetoflex TAB dr 10mg 20's pack 200.60\n\tSquare\tTorax TAB dr 10mg 50's pack 302\n\tSquare\tTorax Injection 10mg/ml 1ml amp x 5's pack 150.55\n\tSquare\tTorax Injection 30mg/ml 1ml amp x 5's pack 276.04\n\tSquare\tTorax Injection 60mg/2ml 2ml amp x 1's pack 95.36\n\tTechno Drugs Ltd.\tRomilac TAB dr 10mg 30's pack 300\n\tTechno Drugs Ltd.\tRomilac Injection 30mg/ml 1ml amp x 10's pack 560\n\tUnimed & Unihealth Manufacturers Ltd.\tDoltro TAB dr 10mg 20's 200\n\tVeritas\tKetofast TAB dr 10mg  \n\tVeritas\tKetofast Injection 30 mg/ml  \n\tWhite Horse Pharma\tAngesic TAB dr 10mg 30's pack 300\n\tZenith\tLactro TAB dr 10mg 20's pack 200\n\tZiska\tAnalac TAB dr 10mg 20's pack 200\n\tZiska\tAnalac Injection 30mg/ml 5's pack 275\n\tZiska\tAnalac Injection 60mg/2ml 2ml amp x 1's pack 95\n\t Boehringer Ingelheim Pharmaceutical\tketlac Injection 30mg/ml 5a's pack \n\tAllied\tAltorec TAB dr 10mg  \n\tOne Pharma Ltd.\tKelorac TAB dr 10mg  \n\tIndication: Moderate to severe pain\n\nDose: Oral\nModerate to severe pain\nAdult: 10 mg every 4-6 hr. Max: 40 mg/day. Max duration: 7 days.\nElderly: 10 mg every 6-8 hr. Max duration: 7 days.\nParenteral\nModerate to severe pain\nAdult: 60 mg as a single dose via IM inj or 30 mg as a single IV dose. Alternatively, 30 mg every 6 hr via IM or IV admin up to a max of 120 mg daily. Halve the doses in patients weighing <50 kg. Max duration: 2 days; patient should be transferred to oral therapy as soon as possible.\nElderly: 30 mg as a single dose via IM inj or 15 mg as a single IV dose. Alternatively, 15 mg every 6 hr via IM or IV admin up to a max of 60 mg daily.\n\nPediatric Patients (2 to 16 years of age):\nIM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.\nIV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.\n\n\nContra-indication: Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.\n\nSide effects: GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic).\nPotentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.\n\nPrecaution: Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.\n\nMode of action: May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.\nPotentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.\n\nPregnancy category: D\n\nInteraction: May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.\nPotentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
Ketorolac Tromethamine 0.5% Eye prep	\n\n\tAcme Ltd.\tWinop 0.5% Eye Drops   5  ml drop 80\n\tAristopharma\tOradol Eye Drops   5  ml drop 80\n\tAsiatic Ltd.\tSurpim Eye Drops   5ml drop 80\n\tBeximco\tXidolac Eye Drops   5  ml drop 80\n\tDrug International Ltd.\tPair Eye Drops   5ml drop 70\n\tG. A. Company Ltd.\tKerolac Eye Drops   5  ml drop 60\n\tGeneral\tToroaid Eye Drops   5ml drop 80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEtolac Eye Drops   5  ml drop 85\n\tIncepta\tEtorac Eye Drops  5 mg/ml 5  ml drop 80\n\tJayson\tEmodol Eye Drops   5  ml drop 60.92\n\tKemiko\tOfpain Eye Drops   5  ml drop 80\n\tMonicopharma\tKepronol Eye Drops 5 mg/ml  \n\tOpsonin Pharma\tTodol Eye Drops  1's pack 80.30\n\tPopular\tLopadol Eye Drops  5 mg/ml 5  ml drop 80.30\n\tReman Drug Ltd.\tRecular Eye Drops  5ml drop 80.30\n\tIndication: Allergic conjunctivitis, Postoperative eye inflammation, Cystoid macular oedema\n\nDose: Ophth Ocular itching As 0.5% soln: Instill 1 drop 4 times/day. \nPost-op eye inflammation As 0.5% soln: Instill 1 drop 4 times/day for 2 wk, starting 24 hr after surgery for 2 wk. \nCystoid macular oedema As 0.5% soln: Instill 1-2 drops 6-8 hrly starting 24 hr before surgery, continue for 3-4 wk after surgery. \nPain and photophobia after incisional refractive surgery As 0.5% soln: Instill 1 drop 4 times/day for up to 3 days after surgery.\n\nThe recommended dose of eye drop is one drop four times a day for relief of ocular itching due to seasonal allergic conjunctivitis.\n\n\n\nContra-indication: Ketorolac Tromethamine is contraindicated in patients with known hypersensitivity to NSAIDs and any of the components of Ketorolac Tromethamine. Moreover, the patient with the history of asthma, nasal polyp, angioedema, peptic ulcer and bleeding, bleeding disorders are contraindicated for this drug.\n\nSide effects: The most frequent adverse events reported with the use of Ketorolac Tromethamine eye drops have been transient stinging and burning on instillation. Other less frequent adverse events include allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis and superficial ocular infections. Other adverse events reported rarely with the use of Ketorolac Tromethamine ophthalmic solutions included: corneal infiltrates, corneal ulcer, eye dryness, headaches, and visual disturbance (blurry vision).\n\nPrecaution: Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.\n\nMode of action: May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.\nPotentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.\n\nPregnancy category: D\n\nInteraction: May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.\nPotentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
Ketorolac Tromethamine 15.8% Nasal prep	\n\n\tIndication: Allergic rhinitis\n\nDose: 1 spray in each nostrils 2-3 times daily or as directed by the physician.\n\nContra-indication: Hypersensitivity to aspirin or other NSAIDs, asthma.  Nasal polyps, angioedema, bronchospasm.Moderate to severe renal impairment. Pregnancy, lactation.\n\nSide effects: Transient stinging and local irritation. \n\n\nPrecaution: Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.\n\nMode of action: May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.\nPotentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.\n\nPregnancy category: D\n\nInteraction: May reduce effects of antihypertensives eg ACE inhibitors or angiotensin II receptor antagonists (AIIA). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam.\nPotentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate (MTX) and lithium. Increased plasma concentrations with probenecid.
Ketotifen	\n\n\tACI\tProsma Syrup 1mg/5ml 100ml bot 50.15\n\tACI\tProsma TAB dr 1mg 100's pack 201\n\tAcme Ltd.\tKetifen TAB dr 1mg 100's pack 150\n\tAcme Ltd.\tKetifen Syrup 1mg/5ml 100ml bot 40.15\n\tAristopharma\tStafen TAB dr 1mg 100's pack 160\n\tAristopharma\tStafen Syrup 1mg/5ml 100ml bot 51\n\tBeximco\tTofen TAB dr 1mg 100's pack/200's pack 150/300\n\tBeximco\tTofen Syrup 1mg/5ml 100ml bot 42\n\tBio Pharma Ltd.\tKetorif TAB dr 1mg 100's pack 150\n\tBio Pharma Ltd.\tKetorif Syrup 1mg/5ml 100ml bot 35\n\tChemist Ltd.\tTicofen Syrup 1 mg/5 ml  \n\tChemist Ltd.\tTicofen TAB dr 1mg  \n\tDelta Pharma\tKetotif TAB dr 1mg 100's pack 150\n\tDelta Pharma\tKetotif Syrup 1mg/5ml 100ml bot 35.01\n\tDrug International Ltd.\tFenat TAB dr 1mg 100's pack 155\n\tDrug International Ltd.\tFenat Syrup 1mg/5ml 100ml bot 40\n\tEskayef Bangladesh Ltd.\tToti TAB dr 1mg 100's pack 150\n\tEskayef Bangladesh Ltd.\tToti Syrup 1mg/5ml 100ml bot 38\n\tEthical Drug Ltd.\tEthifen Syrup 1 mg/5 ml  \n\tEthical Drug Ltd.\tEthifen TAB dr 1mg  \n\tGeneral\tOrotifen TAB dr 1mg  \n\tGeneral\tOrotifen Syrup 1 mg/5 ml  \n\tGlobe\tAsmafen TAB dr 1mg 100's pack 150\n\tGlobe\tAsmafen Syrup 1mg/5ml 100ml bot 35\n\tGlobe\tAsmafen syrup  100ml \n\tIbn Sina Pharmaceutical Ind. Ltd.\tKetof Syrup 1mg/5ml 100ml bot 50\n\tIncepta\tKetomar TAB dr 1mg 100's pack 200\n\tIncepta\tKetomar Syrup 1mg/5ml 100ml bot 40\n\tKemiko\tKtin t 1mg  \n\tKemiko\tKtin Syrup 1 mg/5 ml  \n\tLeon\tKetosma Syrup 1 mg/5 ml  \n\tLeon\tKetosma TAB dr 1mg  \n\tMonicopharma\tAllerkit Syrup 1 mg/5 ml  \n\tNavana\tToma TAB dr 1mg 100's pack 151\n\tNavana\tToma Syrup 1mg/5ml 50ml bot/100ml bot 20.08/35.13\n\tNovartis (Bangladesh) Ltd.\tSanketo TAB dr 1mg 100's pack 250\n\tNovo Healthcare and Pharma Ltd.\tMinia Syrup 1mg/5ml 100ml bot 40\n\tOpso Saline Ltd.\tMasfen TAB dr 1mg  \n\tOpsonin Pharma\tKofen Syrup 1mg/5ml 100ml bot 35\n\tOpsonin Pharma\tKofen TAB dr 1mg 100's pack 150\n\tOrion Pharma Ltd.\tBroket TAB dr 1mg 100's pack 151\n\tOrion Pharma Ltd.\tBroket Syrup 1mg/5ml 100ml bot 40.15\n\tPacific\tKetopac TAB dr 1mg 100's pack 150\n\tPacific\tKetopac Syrup 1mg/5ml 100ml bot 40\n\tPopular\tZadit TAB dr 1mg 100's pack 150.96\n\tPopular\tZadit Syrup 1mg/5ml 100ml bot 40.15\n\tRenata\tTotifen Syrup 1mg/5ml 100ml bot 40\n\tRenata\tTotifen TAB dr 1mg 100's pack 150\n\tSharif\tS-Kit TAB dr 1mg 50's pack 75\n\tSharif\tS-Kit Syrup 1mg/5ml 100ml bot 40\n\tSilva\tAerofen TAB dr 1mg 50's pack 75.29\n\tSilva\tAerofen Syrup 1mg/5ml 100ml bot 35.14\n\tSomatec\tTifen TAB dr 1mg 100's pack 151\n\tSomatec\tTifen Syrup 1mg/5ml 100ml bot 37.14\n\tSquare\tAlarid TAB dr 1mg 100's pack 150.29\n\tSquare\tAlarid Syrup 1mg/5ml 100ml bot 40.15\n\tTechno Drugs Ltd.\tKetodil CAP 1mg 50's pack 75\n\tTechno Drugs Ltd.\tKetodil Syrup 1mg/5ml 100ml bot 45\n\tUnimed & Unihealth Manufacturers Ltd.\tZadifen TAB dr 1mg 50's pack 75\n\tUnimed & Unihealth Manufacturers Ltd.\tZadifen Syrup 1mg/5ml 100ml bot 35\n\tIndication: Allergic conjunctivitis,  Allergic conditions,  Asthma prophylaxis\n\nDose: Adult: PO: Tablet:\n Asthma prophylaxis; Allergic conditions 1 mg twice daily, up to 2 mg twice daily if needed. \n\nSyrup:\n6 months to 3 years:\n0.25 ml / kg body weight, twice daily (Once in the morning & once in the evening).\n\n\nContra-indication: Acute asthma attack.\n\nSide effects: Sedation, drowsiness, dizziness, dry mouth, weight gain, increased appetite, CNS stimulation. Rarely, cystitis. Conjunctival injection, headaches and rhinitis (ophthalmic).\n\nPrecaution: May impair tasks requring mental alertness e.g. driving or operating machinery. History of epilepsy. Pregnancy and lactation. Children <3 yr.\n\nMode of action: Reduced platelet count with oral antidiabetics.\nPotentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.\n\nPregnancy category: C\n\nInteraction: Reduced platelet count with oral antidiabetics.\nPotentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.
Ketotifen 0.25 % Eye prep	\n\n\tACI\tProsma 0.025% Drops  0.025% 5  ml drop 95.65\n\tApex\tAljen Drops   5  ml drop 95\n\tAristopharma\tStafen 0.025% Drops   5  ml drop 100\n\tAsiatic Ltd.\tOcutif 0.025% Drops   5  ml drop 95\n\tBeximco\tTofen Drops   5  ml drop 95\n\tDrug International Ltd.\tFenat 0.025% Drops  0.025% w/v 5  ml drop 95\n\tGeneral\tOcutifen Drops   5ml drop 95\n\tIbn Sina Pharmaceutical Ind. Ltd.\tKetof 0.025% Drops   5  ml drop 100\n\tIncepta\tKetomar 0.025% Drops  0.025% 5  ml drop 100\n\tKemiko\tKtin Eye Drops 0.025 %  \n\tMonicopharma\tAllerkit-E Eye Drops 0.025 %  \n\tOpso Saline Ltd.\tMasfen Eye Drops 0.025 %  \n\tPopular\tZadit 0.025% Drops  .025 % 5  ml drop 95.36\n\tReman Drug Ltd.\tKetotifen Drops   5  ml drop 100\n\tSquare\tAlarid 0.025% Drops  .025 % 5  ml drop 95.36\n\tIndication: Allergic conjunctivitis\n\nDose: Adults and children over 3 years of age: 1 drop Ketotifen eye drop into the conjunctival sac of the affected eye(s) twice a day or as directed by the physician.\n\nChildren below 3 years of age: Not recommended.\n\nContra-indication: Patients with known hypersensitivity to ketotifen or to any of the excipients of the preparation.\n\nSide effects: Generally side effects of Ketotifen are localized ocular toxicity and hypersensitivity such as burning or stinging, punctate corneal epithelial erosion, dry eyes, eyelid disorder, photophobia, keratitis, lacrimation etc. Systemic side effects are very rare, there may be headache, urticaria, dry mouth and allergic reaction.\n\nPrecaution: Eye drops contains benzalkonium chloride as a preservative, which may be deposited in soft contact lenses; thereforeKetotifen eye drops should not be instilled while the patient is wearing contact lenses. The lenses should be removed before application of the drops and not reinserted earlier than 15 minutes after use.\n\nMode of action: Reduced platelet count with oral antidiabetics.\nPotentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.\n\nPregnancy category: C\n\nInteraction: Reduced platelet count with oral antidiabetics.\nPotentially Fatal: May potentiate CNS effects of sedatives, hypnotics, antihistamines and alcohol.
L-Lysine HCl 15% Topical	\n\n\tBeximco\tLimogel Ointment   25gm tube 80\n\tIncepta\tColagel Gel 15% 1's Pack 80\n\tIndication: Burns, Cuts, Wounds, Abrasion, Surgical incisions, Decubitus or stasis ulcers\n\nDose: Gel may be used as often as required, preferably at an interval of 24, 48, 72 hrs. The affected areas should be cleaned with normal saline and/or surgically if necessary till the wound bed looks red/few bleeding points appear in the cleaned wound bed. Then gel should be applied liberally. The areas may be covered with a moist dressing and/or a bandage. \n\nContra-indication: Hypersensitivity to the amino acid. No other known contraindication is known for this essential amino acid.\n\nSide effects: Slight itching sensation might be there on application.\n\nPrecaution: \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Labetalol Hydrochloride	\n\n\tBeximco\tLabeta TAB dr 100mg 60's pack 361.20\n\tBeximco\tLabeta TAB dr 200mg 30's pack 301.20\n\tPopular\tLabecard Injection 5mg/ml 1 amps pack 100.38\n\tPopular\tLabecard TAB dr 100mg 30's pack 180.60\n\tPopular\tLabecard TAB dr 200mg 30's pack 301.20\n\tIndication: Hypertension, Hypotensive anaesthesia\n\nDose: Adult: PO HTN Initial: 100 mg twice daily, up to 200-400 mg twice daily. Max: 2.4 g/day in 2-4 divided doses. \n\nIV Emergency treatment of HTN 50 mg, repeat at 5-min intervals if needed, up to a total dose of 200 mg. HTN in pregnancy Initial: 20 mg/hr, double dose every 30 mins until a favourable response or a dose of 160 mg/hr is reached. \n\nHTN after MI Initial: 15 mg/hr, may increase slowly until a favourable response or a dose of 120 mg/hr is achieved. \n\nHypotensive anesth Initial: 10-20 mg, may increase slowly if satisfactory hypotension is not reached after 5 mins.\n\nContra-indication: 2nd and 3rd degree heart block, cardiogenic shock, obstructive airway disease e.g. bronchial asthma, uncompensated heart failure, severe bradycardia, sick sinus syndrome, Prinzmetal's angina, severe peripheral arterial disease.\n\nSide effects: Orthostatic hypotension, dizziness, fatigue, vertigo, paraesthesia, headache, nasal stuffiness, dyspnoea, diarrhoea, abdominal pain, sexual dysfunction, dyspepsia, nausea, vomiting, scalp tingling, rash, increased transaminases, nightmares, worsening of intermittent claudication.\nPotentially Fatal: Hepatic injury.\n\nPrecaution: Phaeochromocytoma, compensated heart failure, nonallergic bronchospasm. Avoid abrupt withdrawal. DM. Hepatic impairment. Perform LFTs. Elderly. Pregnancy and lactation.\n\nMode of action: Synergistic hypotensive effect w/ halothane. Increased absolute bioavailability w/ cimetidine. Decreased absolute bioavailability w/ glutethimide. Additive hypotensive effect w/ nitroglycerin. Increased incidence of tremor w/ TCAs. Increased risk of bradycardia and heart block w/ Ca channel blocker (e.g. verapamil, diltiazem).\n\nPregnancy category: C\n\nInteraction: Synergistic hypotensive effect w/ halothane. Increased absolute bioavailability w/ cimetidine. Decreased absolute bioavailability w/ glutethimide. Additive hypotensive effect w/ nitroglycerin. Increased incidence of tremor w/ TCAs. Increased risk of bradycardia and heart block w/ Ca channel blocker (e.g. verapamil, diltiazem).
Lacidipine	\n\n\tAcme Ltd.\tLactitab TAB dr 4mg 30's pack 180.60\n\tAcme Ltd.\tLacitab-2 TAB dr 2mg 50's pack 200.50\n\tAristopharma\tLacicard-2 TAB dr 2mg 50's pack 200\n\tAristopharma\tLacicard-4 TAB dr 4mg 30's pack 180\n\tDrug International Ltd.\tL-Cardin TAB dr 2mg 50's pack 150\n\tDrug International Ltd.\tl-cardin TAB dr 4mg 50's pack 131.95\n\tIncepta\tLacidip TAB dr 2mg 50's pack 200\n\tIncepta\tLacidip TAB dr 4mg 30's pack 180\n\tRAK\tLacipin TAB dr 2mg 50's pack 200\n\tRAK\tLacipin TAB dr 4mg 30's pack 180\n\tSquare\tLaciten TAB dr 2mg 28's pack 112\n\tSquare\tLaciten TAB dr 4mg 28's pack 168\n\tIndication: Hypertension,  Storke prevention\n\nDose: Adult: PO Initial: 2 mg once daily, up to 4-6 mg/day if needed.\n\nContra-indication: Within 1 mth of MI, cardiogenic shock, unstable angina, aortic stenosis.\n\nSide effects: Headache, flushing, oedema, dizziness, palpitations, aggravation of angina, increased alkaline phosphatase. Rarely asthenia, rash (e.g. erythema and itching), gastric upset, nausea, gum hyperplasia, polyuria, muscle cramps, mood disturbances.\n\nPrecaution: Conduction abnormalities, congenital or acquired QT prolongation, poor cardiac reserve. Hepatic impairment. Pregnancy and lactation.\n\nMode of action: Additive effect w/ diuretics, ACE inhibitors and ?-blockers. May increase plasma level w/ cimetidine. Metabolism may be affected by CYP3A4 inhibitors (e.g. itraconazole) and inducers (e.g. rifampicin). May attenuate antihypertensive effect w/ corticoids or tetracosactid\n\nPregnancy category: Not Classified\n\nInteraction: Additive effect w/ diuretics, ACE inhibitors and ?-blockers. May increase plasma level w/ cimetidine. Metabolism may be affected by CYP3A4 inhibitors (e.g. itraconazole) and inducers (e.g. rifampicin). May attenuate antihypertensive effect w/ corticoids or tetracosactid
Lactitol	\n\n\tEskayef Bangladesh Ltd.\tLaxitol Syrup 66.67gm/1ml 10's pack 120\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinalax Powder 10gm 10's pack 130\n\tOpsonin Pharma\tMaxilax Powder 10gm 10's pack 120\n\tRadiant.\tFibolac Powder 10gm  \n\tRenata\tTitolax Sachet 10gm 10's pack 120\n\tIndication: Constipation, Hepatic encephalopathy\n\nDose: 2 teaspoonfuls (20g) once or twice daily with plenty of water\n\nContra-indication: Patients with known hypersensitivity to any of the active substance.\nGastro-intestinal obstruction. Galactosaemia.\n\n\nSide effects: Abdominal distension, flatulance and abdominal cramp. \n\nPrecaution: Lactose intolerance.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Lactulose 68 %	\n\n\tACI\tRelacs Syrup 3.35mg/ml 1's pack(1000ml) 65\n\tAcme Ltd.\tTulos Oral Solution  3.35 g / 5 ml 100ml bot/200ml bot 100.83/200.75\n\tAlbion Ltd.\tVeelac Syrup 100 ml/100 ml 100ml/200ml bot \n\tAlco Pharma\tLeaxe Oral Solution   100ml bot 90\n\tAmico Ltd.\tLoctoz Syrup 3.4gm 100ml bot 100\n\tAPC Pharma Ltd.\tComfort Oral Solution   100ml bot 80\n\tAristopharma\tAvolac Oral Oral Solution   100ml bot/200ml bot 120/230\n\tAsiatic Ltd.\tAsilac Oral Solution   100ml bot 100\n\tBeximco\tSerelose Oral Solution   100ml bot 100\n\tBio Pharma Ltd.\tLactu Oral Solution   100ml bot/200ml bot 120/200\n\tChemist Ltd.\tDulac Oral Solution Oral Solution   100ml bot 100\n\tConcord\tIsolac Oral Solution   100ml bot 120\n\tDelta Pharma\tXylose Oral Solution   100ml bot 100\n\tDesh\tDevolac Oral Solution   100ml bot/200ml bot 100/195\n\tDrug International Ltd.\tDlac Oral Solution   100ml bot/200ml bot 100/150\n\tDrug International Ltd.\tD-Lac Suspension  200ml/100ml/50ml 193.52/105.57/61.58\n\tEdruc Ltd.\tE-Lax Oral Solution   100ml bot 100\n\tEskayef Bangladesh Ltd.\tTulac Oral Solution   100ml bot 100\n\tGeneral\tRegulose Oral Solution   100ml bot/200ml bot 100.83/200.75\n\tGlobe\tLaxolac 100 Oral Solution   100ml bot 95\n\tGlobex\tGlovolac Oral Solution 68% 100ml 120\n\tHealthcare\tActilac Oral Solution   100ml bot/200ml bot 120/230\n\tHudson\tLactulose H Oral Solution   100ml bot 60\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinalac Oral Solution   60ml bot/100ml bot/200ml bot/450ml bot 60/100/200/425\n\tIncepta\tInolac Oral Solution  3.35/5ml 100ml bot 95\n\tKemiko\tLivoton Oral Solution   50ml bot/100ml bot/200ml bot 50/100/200\n\tKumudini Pharma Ltd.\tRewat Oral Solution   100ml bot 95\n\tLeon\tLeolac Oral Solution 68%  \n\tMedicon\tLax Oral Solution   100ml bot 120\n\tMonicopharma\tLactomose Oral Solution   100ml bot 100\n\tMystic\tMylac Oral Solution   100ml bot/200ml bot 75/140\n\tNavana\tLaxol Oral Solution   50ml bot/100ml bot/200ml bot 50.19/100.38/200.75\n\tNIPRO JMI Pharma\tNiprolac Oral Solution 68%  \n\tOpsonin Pharma\tLaclose Oral Solution   100ml bot/200ml bot 100/200\n\tOpsonin Pharma\tEzylax Syrup  3.35gm/ml 1's pack 100\n\tOrion Pharma Ltd.\tEzylax Oral Solution  3.35gm/ml 50ml bot 50\n\tPacific\tLivax Oral Solution   100ml bot/200ml bot 120/230\n\tPharmadesh Ltd.\tP Lac Oral Solution   100ml bot 93.12\n\tPharmasia Ltd.\tLactolax Oral Solution   100ml bot 100.38\n\tRangs\tLaxativ Oral Solution   100ml bot/200ml bot 75/140\n\tRenata\tConstilac Oral Solution   100ml bot 100\n\tSharif\tSivolac Oral Solution   100ml bot 100\n\tSilva\tActulose Oral Solution   100ml bot/200ml bot 60.22/120.46\n\tSomatec\tOralax Oral Solution   100ml bot 100.38\n\tSquare\tOsmolax Oral Solution  3.4gm/5ml 100ml bot 120\n\tSquare\tOsmolax Solution 3.4mg/5ml 200ml bot 230\n\tUnimed & Unihealth Manufacturers Ltd.\tConlax Oral Solution   100ml bot/200ml bot 100/200\n\tZenith\tZenilac Oral Solution   100ml bot/200ml bot 70/130\n\tJMI Pharma\tLublac Oral Solution  100ml bot 100\n\tIndication: Constipation, Hepatic encephalopathy\n\nDose: Constipation:\nAdults: Initially 15 ml twice daily, adjusted according to patient's need.\nChildren: Under 1 year: 2.5 ml twice daily\n1-5 years: 5 ml twice daily\n5-10 years: 10 ml twice daily\n\nHepatic encephalopathy: 30-50 ml 3 times daily, subsequently adjusted to produce 2-3 soft stools daily.\n\nContra-indication: Lactulose is contraindicated in patients with galactosaemia and intestinal obstruction.\n\nSide effects: Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhoea.\n\nPrecaution: It should be used with caution in patients with lactose intolerance and diabetes.\n\nMode of action: May prevent release of mesalazine in the colon. Decreased effect with oral neomycin, antacids.\n\nPregnancy category: B\n\nInteraction: May prevent release of mesalazine in the colon. Decreased effect with oral neomycin, antacids.
Lamivudine	\n\n\tBeximco\tAvilam TAB dr 150mg 10's pack 250\n\tEskayef Bangladesh Ltd.\tLamidin TAB dr 100mg 10's pack 253\n\tGlaxoSmithKline Bangladesh Ltd.\tZeffix TAB dr 100mg 10's pack 903.40\n\tIncepta\tLamivir TAB dr 100mg 20's pack 500\n\tSquare\tHepavir TAB dr 100mg 20's pack 502\n\tSquare\tHivarif TAB dr 150mg 10's pack 501.94\n\tSquare\tHivarif Syrup 50mg/5ml 100ml bot 110.41\n\tIndication: HIV infection, Chronic hepatitis B\n\nDose: Oral\nHIV infection\nAdult: 150 mg bid or 300 mg once daily, in combination with other antiretrovirals.\nChild: 3 mth-12 yr: 4 mg/kg bid. Max: 300 mg/day.\n\nRenal impairment: Dialysis patients: Not recommended.\nCrCl (ml/min)	\n30-49	1st dose 150 mg, then 150 mg once daily.\n15-29	1st dose 150 mg, then 100 mg once daily.\n5-14	1st dose 150 mg, then 50 mg once daily.\n<5	1st dose 50 mg, then 25 mg once daily.\n\n\nChronic hepatitis B\nAdult: 100 mg once daily. For patients with concomitant HIV infection: 300 mg once daily or in 2 divided doses.\nChild: >2 yr: 3 mg/kg once daily. Max: 100 mg/day.\n\nRenal impairment: Haemodialysis patients: Dose adjustment in accordance with CrCl. Peritoneal dialysis patients: Not recommended.\nCrCl (ml/min)	\n30-49	1st dose 100 mg, then 50 mg once daily.\n15-29	1st dose 100 mg, then 25 mg once daily.\n5-14	1st dose 35 mg, then 15 mg once daily.\n<5	        1st dose 35 mg, then 10 mg once daily.\n\nContra-indication: Hypersensitivity. Lactation.\n\nSide effects: Abdominal pain, nausea, vomiting, diarrhoea, insomnia, cough, nasal symptoms, arthralgia, muscle pain, headache, fever, rash, alopecia, malaise, increased creatinine phosphokinase and alanine aminotransferase, peripheral neuropathy. Rarely rhabdomyolysis, pancreatitis, hepatitis. Neutropenia and anaemia (in combination with zidovudine), thrombocytopenia, increases in LFTs. Paronychia. Angioedema, urticaria, and anaphylactoid reaction.Potentially Fatal: Lactic acidosis associated with severe hepatomegaly and hepatic steatosis.\n\nPrecaution: Discontinue use if there is rapid increase in aminotransferase levels, progressive hepatomegaly, or metabolic or lactic acidosis of unknown origin. Discontinue use if clinical signs, symptoms or lab abnormalities suggestive of pancreatitis develop. Hepatomegaly or other risk factors for hepatic impairment. Monitor hepatic function in chronic hepatitis B patients. Exclude HIV infection prior to hepatitis B therapy. Renal impairment. Pregnancy.\n\nMode of action: Renal excretion may be inhibited by high doses of trimethoprim (co-trimoxazole). May antagonise the antiviral action of zalcitabine.\n\nPregnancy category: C\n\nInteraction: Renal excretion may be inhibited by high doses of trimethoprim (co-trimoxazole). May antagonise the antiviral action of zalcitabine.
Lamivudine + Nevirapine + Zidovudine	\n\n\tBeximco\tTriovix TAB dr   10's pack 700\n\tIndication: HIV infection\n\nDose: Adult: PO: One tablet twice daily. \n\nRenal impairment:\nCrCl (ml/min)	\n<50	 n   Avoid\nHepatic impairment: In severe impairment use separate formulations.\n\nContra-indication: Neutrophil count <0.75 x 109/l; haemoglobin levels <7.5 g/dl or 4.65 mmol/l. Lactation.\n\nSide effects: Headache, malaise and fatigue, fever or chills, nausea, diarrhoea, anorexia, abdominal pain, neuropathy, insomnia and other sleep disorders, dizziness, depressive disorders, nasal signs and symptoms, skin rashes, musculoskeletal pain, myalgia, arthralgia; anaemia, neutropenia and leucopenia (particularly at high doses of zidovudine; 1200-1500 mg/day), usually seen 4-5 wk after therapy commencing; respiratory symptoms eg rapid and/or deep breathing; if symptomatic hyperlactatemia, metabolic/lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels occur, withdraw treatment; mitochondrial damage leading to hyperlactatemia and hyperlipasemia; lipodystrophy; immune reactivation syndrome, osteonecrosis.\nPotentially Fatal: Lactic acidosis associated with liver failure and pancreatitis (normally after several mth of treatment); haematological toxicity (eg neutropenia and severe anaemia).\n\nPrecaution: Renal and hepatic impairment; poor bone marrow reserve prior to treatment; risk of opportunistic infection; patients (especially obese women) with risk factors for or active liver disease. Patients with low body wt should avoid the combined formulation. Separate formulations of lamivudine or zidovudine should not be given at the same time as the combined formulation. If dose adjustment is necessary for either component, separate formulations should be used. Monitor haematological parameters (advanced disease: 2 wkly for 1st 3 mth of treatment, then monthly; early disease: 1-3 mthly), LFTs, mean cell volume, serum creatinine kinase, viral load, CD4 counts and blood lactate levels. Patient to report any sore throat, nausea, vomiting, unexplained bruising or bleeding. Maintain adequate hydration (2-3 L/day) unless fluid restricted. Withdraw treatment if symptomatic hyperlactaemia, metabolic/lactic acidosis, progressive heptomegaly or rapidly elevating aminotransferase levels occur. Cases of lactic acidosis and hepatic steatosis syndrome have been reported in pregnancy. Monitor hepatic enzymes and electrolytes regularly during 3rd trimester.\n\nMode of action: Zidovudine: acyclovir and valacyclovir may increase CNS depression. Increased risk of haematologic toxicity with ganciclovir, valganciclovir, dapsone, doxorubicin, vincristine and vinblastine. Doxorubicin may reduce phophorylation; fluconazole may increase levels/effects; increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of pancreatitis and lactic acidosis). Methadone may increase effects/levels. Increased risk of myalgia, malaise and/or fever, maculopapular rash and effects/levels with probenecid. Stavudine may decrease antiviral activity; valproic acid may increase plasma levels (AUC increased by 80%). \n\nLamivudine: Increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of mitochondrial toxicity, pancreatitis and lactic acidosis). Ganciclovir and valganciclovir may increase effects and toxicity; sulfamethoxazole/trimethoprim may increase AUC and decrease clearance (increasing levels and effects).\n\nPregnancy category: C\n\nInteraction: Zidovudine: acyclovir and valacyclovir may increase CNS depression. Increased risk of haematologic toxicity with ganciclovir, valganciclovir, dapsone, doxorubicin, vincristine and vinblastine. Doxorubicin may reduce phophorylation; fluconazole may increase levels/effects; increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of pancreatitis and lactic acidosis). Methadone may increase effects/levels. Increased risk of myalgia, malaise and/or fever, maculopapular rash and effects/levels with probenecid. Stavudine may decrease antiviral activity; valproic acid may increase plasma levels (AUC increased by 80%). \n\nLamivudine: Increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of mitochondrial toxicity, pancreatitis and lactic acidosis). Ganciclovir and valganciclovir may increase effects and toxicity; sulfamethoxazole/trimethoprim may increase AUC and decrease clearance (increasing levels and effects).
Lamivudine + Zidovudine	\n\n\tBeximco\tDiavix TAB dr   10's pack 450\n\tSquare\tAvudin TAB dr   10's pack 451.67\n\tIndication: HIV infection\n\nDose: Adult: The recommended oral dose for adults and adolescents is one tablet twice daily. \n\nContra-indication: Neutrophil count <0.75 x 109/l; haemoglobin levels <7.5 g/dl or 4.65 mmol/l. Lactation.\n\nSide effects: Headache, malaise and fatigue, fever or chills, nausea, diarrhoea, anorexia, abdominal pain, neuropathy, insomnia and other sleep disorders, dizziness, depressive disorders, nasal signs and symptoms, skin rashes, musculoskeletal pain, myalgia, arthralgia; anaemia, neutropenia and leucopenia (particularly at high doses of zidovudine; 1200-1500 mg/day), usually seen 4-5 wk after therapy commencing; respiratory symptoms eg rapid and/or deep breathing; if symptomatic hyperlactatemia, metabolic/lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels occur, withdraw treatment; mitochondrial damage leading to hyperlactatemia and hyperlipasemia; lipodystrophy; immune reactivation syndrome, osteonecrosis.\nPotentially Fatal: Lactic acidosis associated with liver failure and pancreatitis (normally after several mth of treatment); haematological toxicity (eg neutropenia and severe anaemia).\n\nPrecaution: Renal and hepatic impairment; poor bone marrow reserve prior to treatment; risk of opportunistic infection; patients (especially obese women) with risk factors for or active liver disease. Patients with low body wt should avoid the combined formulation. Separate formulations of lamivudine or zidovudine should not be given at the same time as the combined formulation. If dose adjustment is necessary for either component, separate formulations should be used. Monitor haematological parameters (advanced disease: 2 wkly for 1st 3 mth of treatment, then monthly; early disease: 1-3 mthly), LFTs, mean cell volume, serum creatinine kinase, viral load, CD4 counts and blood lactate levels. Patient to report any sore throat, nausea, vomiting, unexplained bruising or bleeding. Maintain adequate hydration (2-3 L/day) unless fluid restricted. Withdraw treatment if symptomatic hyperlactaemia, metabolic/lactic acidosis, progressive heptomegaly or rapidly elevating aminotransferase levels occur. Cases of lactic acidosis and hepatic steatosis syndrome have been reported in pregnancy. Monitor hepatic enzymes and electrolytes regularly during 3rd trimester.\n\nMode of action: Zidovudine: acyclovir and valacyclovir may increase CNS depression. Increased risk of haematologic toxicity with ganciclovir, valganciclovir, dapsone, doxorubicin, vincristine and vinblastine. Doxorubicin may reduce phophorylation; fluconazole may increase levels/effects; increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of pancreatitis and lactic acidosis). Methadone may increase effects/levels. Increased risk of myalgia, malaise and/or fever, maculopapular rash and effects/levels with probenecid. Stavudine may decrease antiviral activity; valproic acid may increase plasma levels (AUC increased by 80%). \n\nLamivudine: Increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of mitochondrial toxicity, pancreatitis and lactic acidosis). Ganciclovir and valganciclovir may increase effects and toxicity; sulfamethoxazole/trimethoprim may increase AUC and decrease clearance (increasing levels and effects).\n\nPregnancy category: C\n\nInteraction: Zidovudine: acyclovir and valacyclovir may increase CNS depression. Increased risk of haematologic toxicity with ganciclovir, valganciclovir, dapsone, doxorubicin, vincristine and vinblastine. Doxorubicin may reduce phophorylation; fluconazole may increase levels/effects; increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of pancreatitis and lactic acidosis). Methadone may increase effects/levels. Increased risk of myalgia, malaise and/or fever, maculopapular rash and effects/levels with probenecid. Stavudine may decrease antiviral activity; valproic acid may increase plasma levels (AUC increased by 80%). \n\nLamivudine: Increased risk of hepatic decompensation or haematologic toxicities with interferon-? and ribavirin (also increases risk of mitochondrial toxicity, pancreatitis and lactic acidosis). Ganciclovir and valganciclovir may increase effects and toxicity; sulfamethoxazole/trimethoprim may increase AUC and decrease clearance (increasing levels and effects).
Lamotrigine	\n\n\tACI\tLamitrin TAB dr 50mg 30's pack 541.50\n\tACI\tLamitrin TAB dr 25mg 30's pack 300.90\n\tGlaxoSmithKline Bangladesh Ltd.\tLamictal TAB dr 50mg 30's pack 1575.90\n\tNovartis (Bangladesh) Ltd.\tLameptil TAB dr 25mg  \n\tNovartis (Bangladesh) Ltd.\tLameptil TAB dr 50mg  \n\tNovartis (Bangladesh) Ltd.\tLamotrigine TAB dr 100mg  \n\tNovartis (Bangladesh) Ltd.\tLameptil TAB dr 200mg  \n\tIndication: Epilepsy, Bipolar disorder\n\nDose: Oral\nEpilepsy\nAdult: Initially, 25 mg once daily for 2 wk followed by 50 mg once daily for 2 wk; thereafter, increase the dose by a max of 50-100 mg every 1-2 wk to usual maintenance doses of 100-200 mg daily, as a single dose or in 2 divided doses. Some patients may require up to 500 mg daily.\n\nChild: >12 yr: Initially, 25 mg once daily for 2 wk followed by 50 mg once daily for 2 wk; thereafter, increase the dose by a max of 50-100 mg every 1-2 wk to usual maintenance doses of 100 -200 mg daily, as a single dose or in 2 divided doses. Some patients may require up to 500 mg daily. <12 yr: Not recommended.\nMax Dosage: Adult: 500 mg daily.\n\nAdjunct in epilepsy\nAdult: With valproate: Initially, 25 mg on alternate days for 2 wk followed by 25 mg once daily for 2 wk; thereafter, increase by a max of 25-50 mg every 1-2 wk; usual maintenance doses: 100-200 mg daily in 1-2 divided doses. With enzyme-inducing antiepileptics but not with valproate: 50 mg once daily for 2 wk followed by 50 mg bid for 2 wk; thereafter, increase by a max of 100 mg every 1-2 wk; usual maintenance doses: 200-400 mg/day in 2 divided doses; up to 700 mg/day in some patients. With oxcarbazepine but no enzyme-inducing or -inhibiting antiepileptics: 25 mg once daily for 2 wk followed by 50 mg once daily for 2 wk; thereafter increase dose by a max of 50-100 mg every 1-2 wk; usual maintenance doses: 100-200 mg daily in 1-2 divided doses; up to 500 mg daily in some patients.\n\nChild: With valproate: Initially, 0.15 mg/kg once daily for 2 wk followed by 0.3 mg/kg once daily for 2 wk; thereafter, increase by a max of 0.3 mg/kg every 1-2 wk to usual maintenance doses of 1-5 mg/kg once daily or in 2 divided doses.\n\nBipolar disorder\nAdult: Monotherapy: Initially, 25 mg once daily for 2 wk followed by 50 mg once daily for 2 wk; thereafter, double the daily dose at wkly intervals to usual maintenance dose of 200 mg daily. Max dose: 200 mg/day. With valproate: Initially, 25 mg every other day for 2 wk followed by 25 mg once daily for 2 wk; thereafter, double the daily dose at wkly intervals to usual maintenance dose of 100 mg daily. With enzyme-inducing antiepileptics but not with valproate: Initially, 50 mg once daily for 2 wk followed by 100 mg daily in 2 divided doses for 2 wk; thereafter, increase in 100-mg increments wkly to usual maintenance dose of 400 mg daily in 2 divided doses.\n\nHepatic impairment: Moderate impairment (Child-Pugh category B): Reduce dose by about 50%. Severe impairment (Child-Pugh category C): Reduce dose by about 75%.\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Skin eruptions usually maculopapular in nature, nausea, headache, tiredness, dizziness, ataxia, irritability/aggression, tremor, agitation, confusion, hallucination, diplopia, blurred vision. Haematological abnormalities e.g. leucopenia and thrombocytopenia. Elevations of LFTs. Arthralgia, pain and back pain.\nPotentially Fatal: Stevens-Johnson syndrome and toxic epidermal necrolysis.\n\nPrecaution: Hepatic or renal impairment. Closely monitor patient. Monitor children's body wt. Advise patient to report any hypersensitivity reaction. Avoid abrupt withdrawal unless severe skin reactions have developed. May impair ability to drive or operate machinery. Pregnancy and lactation.\n\nMode of action: Metabolism enhanced by enzyme-inducing drugs e.g. phenytoin, carbamazepine, phenobarbitone, primidone, rifampicin, ethinyloestradiol/levonorgestrel combination. Metabolism reduced by sodium valproate.\n\nPregnancy category: C\n\nInteraction: Metabolism enhanced by enzyme-inducing drugs e.g. phenytoin, carbamazepine, phenobarbitone, primidone, rifampicin, ethinyloestradiol/levonorgestrel combination. Metabolism reduced by sodium valproate.
Lansoprazole	\n\n\tACI\tLanz CAP 15mg 60's pack 180\n\tACI\tLanz CAP 30mg 28's pack 140\n\tAcme Ltd.\tLansodin CAP 15mg 28's pack 98.28\n\tAcme Ltd.\tLansodin CAP 30mg 28's pack 168.56\n\tAlbion Ltd.\tLanzopra CAP 15 mg/15 mg 50's/30's pack \n\tAmbee\tLap CAP 30mg 28's pack 140.28\n\tAmico Ltd.\tLansopril CAP 30mg 30's pack 150\n\tBeximco\tProtolan CAP 15mg 30's pack 120\n\tBeximco\tProtolan CAP 30mg 30's pack 180\n\tBio Pharma Ltd.\tLasocon CAP 30mg 28's pack 168\n\tChemist Ltd.\tLansozol CAP 30mg 50's pack 250\n\tDesh\tLazo CAP 30mg 30's pack 150\n\tDoctor's Chemicals Works Ltd.\tLanzol CAP 30mg 40's pack 200\n\tDrug International Ltd.\tLansec CAP 15mg 60's pack 210\n\tDrug International Ltd.\tLansec CAP 30mg 70's pack 420\n\tGeneral\tZoton CAP 15mg 30's pack 105.30\n\tGeneral\tZoton CAP 30mg 20's pack 120.40\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLansina CAP 30mg 25's pack 150\n\tKemiko\tEnso CAP 15mg 20's pack 60\n\tKemiko\tEnso CAP 30mg 20's pack 100\n\tMedimet\tLanozole CAP 15mg 40's pack 120\n\tMedimet\tLanozole CAP 30mg 20's pack 100\n\tOpsonin Pharma\tLantid CAP 15mg 20's pack 58\n\tOpsonin Pharma\tLantid CAP 30mg 18's pack 90\n\tSquare\tLanso CAP 15mg 50's pack 175.56\n\tSquare\tLanso CAP 30mg 30's pack 180.74\n\tUnimed & Unihealth Manufacturers Ltd.\tAslan CAP 15mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tAslan CAP 30mg  \n\tIndication: Peptic ulcer, H.pylori infection, Gastro-oesophageal reflux disease, Hypersecretory conditions, Acid-related dyspepsia, NSAID-induced ulcers, Erosive oesophagitis\n\nDose: Adult: PO Peptic ulcer 30 mg once in the morning for 4 wk (duodenal ulcer) or 8 wk (gastric ulcer). Hypersecretory conditions Initial: 60 mg/day. Daily doses >120 mg should be given in 2 divided doses. \n\nAcid-related dyspepsia 15-30 mg once in the morning for 2-4 wk. Gastro-oesophageal reflux disease 30 mg once in the morning for 4-8 wk. Maintenance: 15-30 once daily. Prevention and treatment of NSAID-related ulcers 15-30 mg/day for 4-8 wk.\n\nChild: 1-11 yr <30 kg: 15 mg once daily in the morning for up to 12 wk; >30 kg: 30 mg once daily in the morning for up to 12 wk. May increase doses up to 30 mg bid if patient is still symptomatic after 2 or more wk of treatment. 12-17 yr 30 mg once daily for up to 8 wk.\n\n H.pylori infection 30 mg twice daily, usually w/ clarithromycin and amoxicillin or metronidazole. IV Erosive oesophagitis 30 mg/day for up to 7 days.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Diarrhoea, abdominal pain, nausea, constipation, headache, dizziness, eosinophilia, myalgia, glossitis, stomatitis, rash.\n\nPrecaution: Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation.\n\nMode of action: Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.\nPotentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir. \n\nPregnancy category: B\n\nInteraction: Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.\nPotentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir. 
Latanoprost .005% + Timolol 0.5% Eye prep	\n\n\tACI\tLotensin Plus Eye Drops   2.5  ml drop 401.51\n\tBeximco\tXalanol Eye Drops   2.5  ml drop 495\n\tPfizer Manufacturing, Belgium\tXalacom Eye Drops 2.5ml 2.5ml drop 781.94\n\tIndication: Open-angle glaucoma, Ocular HTN\n\nDose: Adult: Ophth Ocular HTN; Open-angle glaucoma: Instill 1 drop once daily.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Increased iris pigmentation, eye irritation, eye pain, stinging and burning sensation. Rarely, bradycardia, arrhythmia, CHF, bronchospasm and allergic reactions.\n\nPrecaution:  Prolonged treatment with latanoprost may change eye colour by increasing the amount of brown pigment in the iris especially in patients with mixed coloured irides; regular eye examination is recommended. Caution when used in aphakic patients due to risk of macular oedema. Contact lenses should be removed during application and reinserted at least 15 minutes after application. May cause transient blurring of vision; patients should not drive or operate machinery until this resolves. Pregnancy and lactation.\n\nMode of action: Additive effect on the intraocular pressure and other systemic effects may occur when used with oral beta-blockers, calcium channel blockers, guanethidine, antiarrhythmics, digitalis glycosides or parasympathomimetics. Concurrent use of >2 ophthalmic prostaglandin analogues may lead to paradoxical increase in intraocular pressure. Mydriasis may occur when used concurrently with epinephrine. beta-blocker may increase hypoglycaemic effect of antidiabetic agents.\n\nPregnancy category: C\n\nInteraction: Additive effect on the intraocular pressure and other systemic effects may occur when used with oral beta-blockers, calcium channel blockers, guanethidine, antiarrhythmics, digitalis glycosides or parasympathomimetics. Concurrent use of >2 ophthalmic prostaglandin analogues may lead to paradoxical increase in intraocular pressure. Mydriasis may occur when used concurrently with epinephrine. beta-blocker may increase hypoglycaemic effect of antidiabetic agents.
Latanoprost 0.005% Eye prep	\n\n\tBeximco\tXalaprost Eye Drops   2.5  ml drop 460\n\tNavana\tOcuprost Eye Drops   5ml drop 475\n\tReman Drug Ltd.\tRemaprost Eye Drops   2.5  ml drop 497\n\tIndication: Open-angle glaucoma, Ocular HTN\n\nDose: Adult: As 0.005% soln: Instill 1 drop every evening.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Brown pigmentation particularly in those with mixed-color irides; blepharitis, ocular irritation and pain; darkening, thickening and lengthening of eyelashes; localised oedema; conjunctival hyperaemia; transient punctate epithelial erosions; dyspnoea; exacerbation of asthma; local skin reactions; iritis; uveitis; darkening of palpebral skin.\n\nPrecaution: Do not use within 5 min of thiomersal-containing preparations. Aphakia or pseudophakia with torn posterior lens cap or anterior chamber lenses; risk factors for cystoid macular oedema; brittle or severe asthma; history of intraocular inflammation; inflammatory, neovascular, angle-closure or congenital glaucoma; pregnancy, lactation. Remove contact lenses during use.\n\nMode of action: Paradoxical elevations in IOP w/ other prostaglandins, prostaglandin analogs or prostaglandin derivatives.\n\nPregnancy category: C\n\nInteraction: Paradoxical elevations in IOP w/ other prostaglandins, prostaglandin analogs or prostaglandin derivatives.
Levocarnitine	\n\n\tACI\tCartine TAB dr 330mg 30's pack 150\n\tACI\tCartine Oral Solution 500mg/5ml 100ml 100.68\n\tBeximco\tCarnitab TAB dr 330mg 30's pack 150\n\tDelta Pharma\tLenit TAB dr 330mg 30's pack 150\n\tDrug International Ltd.\tCarniten TAB dr 330mg 48's pack 245\n\tGeneral\tL - Carni TAB dr 330mg 30's pack 150\n\tIncepta\tOcarnix TAB dr 330mg 20's pack 100\n\tOpsonin Pharma\tEnvitor TAB dr 330mg 30's pack 150\n\tSquare\tLevocar TAB dr 330mg 30's pack 150\n\tIndication: Congestive heart failure, Diabetic nephropathy, Intermittent claudication, Kidney disease, Chronic Fatigue Syndrome, Heart Diseases, High Cholesterol, Dementia and Memory impairment, Down Syndrome, Male infertility\n\nDose: Adults: Tablet: 330 mg two or three times daily. \nInfants and children: 50 to 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response.\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Generally Levocarnitine is well tolerated. However, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur\n\nPrecaution: Gastrointestinal reactions may result from a too rapid consumption of Levocarnitine.\nThe safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Leflunomide	\n\n\tACI\tMotoral TAB dr 100mg 10's pack 200\n\tACI\tMotoral TAB dr 20mg 50's pack 250\n\tGeneral\tArolef TAB dr 100mg 3's pack \n\tGeneral\tArolef TAB dr 20mg 50's pack \n\tIncepta\tNodia TAB dr 10mg 100's pack 300\n\tIncepta\tNodia TAB dr 100mg 3's pack 60\n\tIncepta\tNodia TAB dr 20mg 50's pack 250\n\tIndication: Rheumatoid arthritis, Psoriatic arthritis\n\nDose: Adult: PO Rheumatoid arthritis; Psoriatic arthritis: Loading dose of 100 mg once daily for 3 days, the maintenance dose is 20 mg once daily. Leflunomide does not require stepwise dose increment over time. The dose may be decreased to 10 mg daily if tolerability issues arise.\n\nContra-indication: Significant hepatic impairment, compromised immune function including bone marrow dysplasia or severe uncontrolled infection; concurrent vaccination with live vaccines. Pregnancy, lactation.\n\nSide effects: Thrombocytopenia, anaphylaxis, eosinophilia, leukopenia, pancytopenia. Headache, dizziness, weakness, bronchitis, urinary tract infection, alopecia, rash, dry skin, eczema, pruritus, hypokalaemia, weight loss, arthralgia, joint disorder, leg cramps, rhinitis, sinusitis, hypertension, diarrhoea, nausea, abdominal pain, synovitis, tenosynovitis, paraesthesia, pharyngitis, anorexia, vomiting, oral thrush, stomatitis.Potentially Fatal: Hepatotoxicity.\n\nPrecaution: Renal and hepatic impairment; Women with childbearing potential. Caution should be taken for those female with child bearing potential who are not using reliable contraception and for the subject of renal insufficiency. Leflunomide should be stopped before becoming pregnant. Liver function should be monitored before starting treatment. Monitor blood counts and BP regularly. Avoid alcohol.\n\nMode of action: Cholestyramine and activated charcoal may decrease plasma concentration of active metabolite. Concurrent use of methotrexate and other hepatotoxic drugs may increase the risk of hepatotoxicity. Rifampicin increases serum levels of the active metabolite.\nPotentially Fatal: May enhance the adverse effects of live vaccines. \n\nPregnancy category: X\n\nInteraction: Cholestyramine and activated charcoal may decrease plasma concentration of active metabolite. Concurrent use of methotrexate and other hepatotoxic drugs may increase the risk of hepatotoxicity. Rifampicin increases serum levels of the active metabolite.\nPotentially Fatal: May enhance the adverse effects of live vaccines. 
Lercanidipine Hydrochloride	\n\n\tACI\tCanider TAB dr 10mg 30's pack 150\n\tIncepta\tLarcadip TAB dr 10mg 30's pack 150\n\tOpsonin Pharma\tLarcan TAB dr 10mg 30's pack 150\n\tSun Pharmaceutical (Bangladesh) Ltd.\tLotensyl TAB dr 10mg 50's pack 272.50\n\tIndication: Mild to moderate essential hypertension, Stroke prevention.\n\nDose: Adult: PO As HCl: 10 mg once daily, increase to 20 mg daily after 2 wk if needed. \n\nUse in the elderly: The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient's response.  \n\nUse in children: Since there is no clinical data in patients under the age of 18 years, use in children is not currently recommended. \n\nUse in renal or hepatic dysfunction: Special care should be exercised in patients with mild to moderate renal or hepatic dysfunction. Dosage above 20 mg daily must be approached with caution. Lercanidipine is not recommended for use in patients with severe hepatic or renal dysfunction.\n\nContra-indication: Severe hepatic or renal impairment; aortic stenosis, unstable angina, uncontrolled heart failure, within 1 mth of MI; and known hypersensitivity to any dihydropyridine. Lercanidipine should not be taken with grapefruit juice. lactation, pregnancy.\n\nSide effects: Tachycardia, oedema, flushing, headache, dizziness, asthenia, rash, diarrhoea, polyuria, palpitations, hypotension, drowsiness, myalgia.\n\nPrecaution:  Left ventricular dysfunction, sick sinus syndrome (if pacemaker not fitted), left ventricular dysfunction and ischaemic heart disease.\n\nMode of action: Plasma concentration reduced by inducers of CYP3A4 eg rifampicin, phenytoin, carbamazepine. Bioavailability also reduced by metoprolol and possibly propranolol. Plasma concentrations increased by inhibitors of CYP3A4 eg imidazole antifungals, erythromycin, ritonavir, fluoxetine. Alcohol may potentiate vasodilating effect.\nPotentially Fatal: Significantly increased plasma levels of both lercanidipine and ciclosporin when administered together. \n\nPregnancy category: C\n\nInteraction: Plasma concentration reduced by inducers of CYP3A4 eg rifampicin, phenytoin, carbamazepine. Bioavailability also reduced by metoprolol and possibly propranolol. Plasma concentrations increased by inhibitors of CYP3A4 eg imidazole antifungals, erythromycin, ritonavir, fluoxetine. Alcohol may potentiate vasodilating effect.\nPotentially Fatal: Significantly increased plasma levels of both lercanidipine and ciclosporin when administered together. 
Levamisole	\n\n\tACI\tEtrax TAB dr 40mg 100's pack 100\n\tACI\tEtrax Syrup 40mg/5ml 30ml bot 24.07\n\tAcme Ltd.\tNeo Trax TAB dr 40mg 200's pack 86\n\tAcme Ltd.\tNeo Trax Syrup 40mg/5ml 30ml bot /40ml bot 12.06 / 70.26\n\tAcme Ltd.\tNeotrax TAB dr 40mg 200's pack 86\n\tAcme Ltd.\tNeotrax Syrup 40mg/5ml 1's pack(9.28) 9.28\n\tAlbion Ltd.\tAltex Syrup 40 mg/ 5 ml  30 ml \n\tBengal Drugs & Chemical Works Pharm. Ltd.\tLemox Syrup 40mg/5ml 15ml bot / 30ml bot 9 / 15\n\tBio Pharma Ltd.\tBiotrex Syrup 40mg/5ml 15 ml bot/ 30ml bot 8.03 / 15\n\tDesh\tDeotrex TAB dr 40mg 100's pack 35\n\tDesh\tDeotrex Syrup 40mg/5ml 30ml bot 11\n\tG. A. Company Ltd.\tHelmisole TAB dr 40mg 100's pack 41.08\n\tG. A. Company Ltd.\tHelmisole Syrup 40mg/5ml 30ml bot 15\n\tGonoshasthaya\tG Levamisole Syrup 40mg/5ml 30ml bot 9.54\n\tModern\tLevamisole M TAB dr 40mg 100's pack 40\n\tOpsonin Pharma\tVermicom TAB dr 40mg 100's pack 40\n\tOpsonin Pharma\tVermicom Syrup 40mg 30ml bot 8.17\n\tPharmadesh Ltd.\tLevamin TAB dr 40mg 100's pack 46\n\tPharmadesh Ltd.\tLevamin Syrup 40mg/5ml 30ml bot 13.87\n\tPremier Pharmaceuticals\tPremisol Syrup 40 mg/5 ml  \n\tIndication: Ascariasis, Ancylostomiasis\n\nDose: Oral\nAscariasis\nAdult: 150 mg as a single dose.\nChild: 3 mg/kg as a single dose.\n\nMixed ascariasis-hookworm infections\nAdult: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases.\nChild: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases.\n\nAncylostomiasis\nAdult: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases.\nChild: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases.\n\nContra-indication: Preexisting blood disorders; pregnancy and lactation; rheumatoid arthritis; severe renal impairment.\n\nSide effects: Nausea, vomiting, diarrhoea, abdominal pain, dizziness and headache. Fever, influenza-like syndrome, arthralgia, muscle pain, rash, taste disturbances and cutaneous vasculitis.\nPotentially Fatal: Agranulocytosis, leucopenia, thrombocytopenia.\n\nPrecaution: Hepatic impairment, Sjogren's syndrome.\n\nMode of action: May increase toxicity of phenytoin. Increases bioavailability of ivermectin; decreases bioavailability of albendazole. Alcohol causes disulfiram-like reaction.\n\nPregnancy category: C\n\nInteraction: May increase toxicity of phenytoin. Increases bioavailability of ivermectin; decreases bioavailability of albendazole. Alcohol causes disulfiram-like reaction.
Levetiracetam	\n\n\tACI\tCitazar TAB dr 250mg 20's pack 302.20\n\tACI\tCitazar TAB dr 500mg 10's pack 251.70\n\tNovartis (Bangladesh) Ltd.\tErata TAB dr 250mg 30's pack 483\n\tNovartis (Bangladesh) Ltd.\tErata TAB dr 500mg 30's pack 906\n\tSanofi Aventis (BD) Ltd.\tLeveron TAB dr 250mg  \n\tSanofi Aventis (BD) Ltd.\tLeveron TAB dr 500mg  \n\tSquare\tIracet Injection 500mg/5ml 6's pack 240\n\tSquare\tIracet TAB dr 250mg 20's pack 300\n\tSquare\tIracet TAB dr 500mg 10's pack 250\n\tSquare\tIracet Oral Solution 500mg/5ml 50ml bot 200\n\tSun Pharmaceutical (Bangladesh) Ltd.\tLevipil TAB dr 500mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tEletam Suspension 100mg/ml 100ml bot 400\n\tUnimed & Unihealth Manufacturers Ltd.\tEletam TAB dr 250mg 20's pack 320\n\tUnimed & Unihealth Manufacturers Ltd.\tEletam TAB dr 500mg 20's pack 600\n\tIndication: Partial seizures\n\nDose: Adult: PO/IV Adjunct in partial seizures\nAdult: Initially, 500 mg bid on the 1st day. May increase in steps of 1 g at 2-4 wk intervals until effective antiepileptic control is achieved. Max: 3 g/day.\n\nChild: 4-15 yr (<50 kg): Initially 10 mg/kg bid. May be increased by 10 mg/kg bid at 2-wk intervals. Adolescents >16 yr or 50 kg initially 500 mg bid. May be increased by 500 mg bid at 2-4 wk intervals. Max: 60 mg/kg/day.\n\nMonotherapy for partial seizures with or without secondary generalisation\nAdult: Initially 500 mg daily, increased after 2 wk to 1 g daily. May further increase in steps of 500 mg at 2 wk intervals. Max: 3 g/day.\n\nRenal impairment: Suitable total daily dose (given as 2 divided doses) based on CrCl.\nCrCl (ml/min)	\n50-79	1 - 2 g\n30-50	500 mg - 1.5 g\n<30 	500 mg - 1 g\n\nContra-indication: Hypersensitivity.\n\nSide effects: Somnolence, asthenia, dizziness, vertigo, depression, emotional instability, hostility, nervousness, ataxia, tremor, amnesia, headache, nausea, dyspepsia, diarrhoea, anorexia, rash, diplopia.\n\nPrecaution: Renal and hepatic impairment; pregnancy, lactation; patients undergoing haemodialysis. If psychotic symptoms (eg hallucination) and behavioural symptoms (eg agitation, anxiety) occur, reduce dosage. Abrupt withdrawal may result in increased seizure frequency. May impair ability to drive or operate machinery during initial therapy.\n\nMode of action: Enzyme-inducing antiepiletic drugs.\n\nPregnancy category: C\n\nInteraction: Enzyme-inducing antiepiletic drugs.
Levonorgestrel	\n\n\tACI\tE-Plan TAB dr 750mcg 10's pack 225\n\tPopular\tI-Pill TAB dr 750mcg 2's pack 45.15\n\tRenata\tEmcon TAB dr 750mcg 2's pack 45.16\n\tSquare\tNorpill TAB dr 750mcg 10's pack 225\n\tSquare\tNorpill TAB dr 1.5mg 5's pack 300\n\tCity overseas\tPostinor-2 	 	 		 TAB dr 0.75mg 2 tabs pack  52 \n\tIndication: Contraception , Emergency contraception , Menopausal hormone replacement therapy , Menorrhagia,\n\nDose: Adult: PO Contraception Monotherapy: 30 or 37.5 mcg/day. Monophasic combined oral contraceptive (COC): 150-250 mcg/day. Triphasic COC: 50-125 mcg/day. \n\nEmergency contraception 1.5 mg w/in 72 hr of coitus or 750 mcg immediately or w/in 72 hr of coitus, then a 2nd dose 12 hr later. \n\nMenopausal HRT As progestogenic component: 75-250 mcg/day for 10-12 days of 28-day cycle. \n\nContra-indication: Pregnancy, undiagnosed vaginal bleeding, severe arterial disease; liver adenoma, porphyria; after recent evacuation of hydatidiform mole; history of breast cancer; hepatic impairment.\n\nSide effects: Menstrual irregularities; nausea, vomiting, headache, dizziness, breast discomfort, gynaecomastia, depression, skin disorders, disturbance of appetite, wt changes, fluid retention, oedema, changes in libido, cholestatic jaundice, hair loss or hirsutism. Benign intracranial hypertension, thrombocytopenic purpura.\nPotentially Fatal: Thrombocytopenia, stroke.\n\nPrecaution: Sex-steroid dependent cancer, past ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy, CV or renal impairment, DM, asthma, epilepsy, migraine, conditions aggravated by fluid retention, depression and thromboembolism (high doses); lactation.\n\nMode of action: Reduced efficacy with enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism.\n\nPregnancy category: X\n\nInteraction: Reduced efficacy with enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism.
Levobunolol Hydrochloride	\n\n\tIndication: Open-angle glaucoma, Ocular HTN\n\nDose: Adult : As 0.5% soln: Apply 1-2 drops once daily, up to twice daily in severe cases. As 0.25% soln: 1-2 drops twice daily.\n\nContra-indication: Bronchial asthma, severe COPD; sinus bradycardia; 2nd and 3rd degree heart block; overt cardiac failure; cardiogenic shock.\n\nSide effects: Ocular stinging, burning, blepharoconjunctivitis, decreased heart rate, decreased BP, iridocyclitis, headache, transient ataxia, dizziness, lethargy, decreased corneal sensitivity, tearing, visual disturbances, urticaria and pruritus.\n\nPrecaution: Patients at risk of developing hypoglycaemia. DM. Thyrotoxicosis. Known diminished pulmonary function. Cerebrovascular insufficiency. Do not drive or operate machinery until vision is clear. Pregnancy and lactation.\n\nMode of action: Additive hypotensive effect w/ catecholamine-depleting drug (e.g. reserpine), Ca channel blockers, beta-adrenergic blockers, digitalis glycosides, antiarrhythmics, guanethidine, parasympathomimetics. Mydriasis may occur when used w/ epinephrine.\n\nPregnancy category: C\n\nInteraction: Additive hypotensive effect w/ catecholamine-depleting drug (e.g. reserpine), Ca channel blockers, beta-adrenergic blockers, digitalis glycosides, antiarrhythmics, guanethidine, parasympathomimetics. Mydriasis may occur when used w/ epinephrine.
Levobupivacaine Hydrochloride	\n\n\tACI\tPivacain-L Injection 2.5mg/ml  20 ml vial x 1's pack 50.19\n\tACI\tPivacain-L Injection 5mg/ml 20 ml vial x 1's pack 70.26\n\tIndication: Acute pain, Peripheral nerve block, Surgical anaesthesia, Infiltration anaesthesia\n\nDose: Adult: Inj Surgical anesth Epidural block: 50-100 mg (using 0.5% soln) or 75-150 mg (using 0.75% soln). \n\nCaesarean section: 75-150 mg (using 0.5% soln). \nSpinal block: 15 mg (using 0.5% soln). Max: 150 mg/dose; 400 mg/day. \nPeripheral nerve block 2.5-150 mg or 1-2 mg/kg (0.4 mL/kg) of a 0.25 or 0.5% soln. Not to exceed 40 mL. Max: 150 mg/dose; 400 mg/day. \nInfiltration anesth Up to 150 mg (using 0.25% soln). For peribulbar block in ophth procedures: 37.5-112.5 mg (using 0.75% soln). Max: 150 mg/dose; 400 mg/day. \n\nAcute pain Pain relief during labour: 15-50 mg (using 0.25% soln), given as a bolus dose. Post-op pain: 10-25 mg/hr (using 0.25% soln), given as an epidural infusion. Max: 150 mg/dose; 400 mg/day.\n\nContra-indication: Not to be used in IV regional anesth (Bier's block) and paracervical block in obstetrics. Do not use 0.75% solution for epidural block in obstetrics. Hypovolaemia, complete heart block.\n\nSide effects: CNS effects such as restlessness, anxiety, dizziness, confusion, respiratory depression and convulsions. Neuromuscular and skeletal weakness, blurred vision, pupillary constriction, tinnitus. Hypotension, bradycardia and CV collapse which may lead to cardiac arrest. Rarely, hypersensitivity reactions.\n\nPrecaution: Epilepsy, respiratory impairment, impaired cardiac conduction, bradycardia, severe shock, acute porphyria, myasthenia gravis, renal or hepatic impairment. Pregnancy, lactation. Reduce dose in elderly or debilitated patients. Resuscitative equipment should be available. Do not use solutions containing adrenaline for anesth in appendages. Do not use solutions containing preservatives for caudal or epidural block.\n\nMode of action: Plasma levels may be reduced when used with enzyme-inducing drugs such as rifampicin. Substrates for or inhibitors of CYP3A4 and CYP1A2 may affect the plasma levels of levobupivacaine.\n\nPregnancy category: B\n\nInteraction: Plasma levels may be reduced when used with enzyme-inducing drugs such as rifampicin. Substrates for or inhibitors of CYP3A4 and CYP1A2 may affect the plasma levels of levobupivacaine.
Levocarnitine Syrup	\n\n\tACI\tCartine Syrup   100ml bot 100\n\tBeximco\tCarnitab Oral solution  100mg/ml 100ml bot 100\n\tIncepta\tOcarnix Syrup   100ml bot 100\n\tSquare\tLevocar Solution  10 gm/100 ml 100ml bot 100.38\n\tIndication: Congestive heart failure,Diabetic nephropathy,Intermittent claudication,Kidney disease,Chronic Fatigue Syndrome,Heart Diseases,High Cholesterol,Dementia and memory impairment,Down Syndrome,Male infertility\n\nDose: Adults: Syrup: 10-30 ml per day. Depending on clinical response\nInfants and children: 50 to 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response.\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Generally Levocarnitine is well tolerated. However, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur\n\nPrecaution: Gastrointestinal reactions may result from a too rapid consumption of Levocarnitine.\nThe safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Levocetirizine Hydrochloride	\n\n\tACI\tAcitrin-L TAB dr 5mg 100's pack 301\n\tAd-din\tCevozin TAB dr 5mg 100's pack 200\n\tAlco Pharma\tLevocet TAB dr 5mg 50's pack 100\n\tApex\tVocet TAB dr 5mg 50's pack 100\n\tAristopharma\tRehaf TAB dr 5mg 100's pack 200\n\tAsiatic Ltd.\tLerex TAB dr 5mg 50's pack 100\n\tBeximco\tCurin TAB dr 5mg 100's pack 350\n\tBio Pharma Ltd.\tRinotin TAB dr 5mg 100's pack 201\n\tChemist Ltd.\tLevocetril TAB dr 5mg 100's pack 200\n\tDelta Pharma\tLecetrin TAB dr 5mg 100's pack 200\n\tDrug International Ltd.\tClarigen TAB dr 5mg 100's pack 200\n\tEuro Pharma Ltd.\tLevotiz TAB dr 5mg 100's pack 250\n\tEverest\tLacer TAB dr 5mg 50's pack 100\n\tGlobe\tPolan TAB dr 5mg 50's pack 100\n\tHealthcare\tAlcet TAB dr 5mg  100's pack 350\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLevomin TAB dr 5mg 100's pack 460\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLevomin Syrup 2.5mg/5ml 1's pack(50ml) 50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinacet TAB dr 5mg  \n\tIncepta\tSeasonix TAB dr 5mg 100's pack 350\n\tKemiko\tLozin TAB dr 5mg 100's pack 300\n\tKumudini Pharma Ltd.\tLupron TAB dr 5mg 100's pack 250\n\tNovartis (Bangladesh) Ltd.\tLingin TAB dr 5mg 50's pack 160\n\tOrganic Health Care\tLVC TAB dr 5mg 100's pack 300\n\tPacific\tLecet TAB dr 5mg 50's pack 100\n\tPeoples Pharma Ltd.\tMegatrol TAB dr 5mg 100's pack 200\n\tPopular\tLevorex TAB dr 5mg 100's pack 201\n\tRAK\tRinocet TAB dr 5mg 100's pack 200\n\tSharif\tVerizin TAB dr 5mg 50's pack 100\n\tSomatec\tEnacet TAB dr 5mg 100's pack 201\n\tSquare\tPurotrol TAB dr 5mg 50's pack 175\n\tSyntho Ltd.\tLiset TAB dr 5mg 50's pack 100\n\tZenith\tLecitin TAB dr 5mg 100's pack 200\n\tIndication: Allergic rhinitis,  Allergic conditions, Chronic idiopathic urticaria\n\nDose: â¢ Adult and children 12 years of age and older: 5mg once daily\nâ¢ Children 6 to 11 years of age: 2.5mg (1/2 tablet or 1 teaspoon oral solution) once daily\nâ¢ Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) once daily\n\nRenal impairment:\nCrCl (ml/min)	\n<10 and patients undergoing dialysis	Contraindicated.\n10-29	5 mg once every 3 days.\n30-49	5 mg every other day.\n50-79	5 mg once daily.\nHepatic impairment: No dosage adjustment needed.\n\nContra-indication: Patients who are hypersensitive to this medication or to any of its ingredients.\n\nSide effects: Generally Levocetirizine is well tolerated. However, a few side effects like headache, dry mouth, fatigue and skin rash have been reported rarely.\n\nPrecaution: N/A\n\nMode of action: Possible additive adverse CNS effects w/ CNS depressants (e.g. sedatives, tranquilizers).\n\nPregnancy category: B\n\nInteraction: Possible additive adverse CNS effects w/ CNS depressants (e.g. sedatives, tranquilizers).
Levocetrizine Dihydrochloride 0.1%	\n\n\tACI\tAcitrin-L Oral Solution  2.5mg/5ml 60ml bot 40.12\n\tHealthcare\tAlcet Oral Solution   60ml bot 50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinacet Syrup 50 mg/100 ml  \n\tIncepta\tSeasonix Oral Solution   60ml bot 40\n\tSquare\tPurotrol Oral Solution 500 mcg/ml 50ml bot 35.14\n\tIndication: Allergic rhinitis, Chronic idiopathic urticaria\n\nDose: â¢ Adult and children 12 years of age and older: 5mg once daily\nâ¢ Children 6 to 11 years of age: 2.5mg (1/2 tablet or 1 teaspoon oral solution) once daily\nâ¢ Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) once daily\n\nContra-indication: Lactation. End-stage renal disease (CrCl <10 ml/min) or haemodialysis patients. Child 6-11 yr with renal impairment.\n\nSide effects: Fatigue, somnolence, dry mouth, nasopharyngitis, pyrexia, cough, epistaxis.\n\nPrecaution: Renal impairment. May impair ability to drive or operate machinery.\n\nMode of action: Possible additive adverse CNS effects w/ CNS depressants (e.g. sedatives, tranquilizers).\n\nPregnancy category: B\n\nInteraction: Possible additive adverse CNS effects w/ CNS depressants (e.g. sedatives, tranquilizers).
Levofloxacin	\n\n\tACI\tLeflox TAB dr 500mg 20's pack 302.20\n\tACI\tLeflox TAB dr 750mg 10's pack 201.30\n\tAcme Ltd.\tLeo TAB dr 250mg 32's pack 257.28\n\tAcme Ltd.\tLeo IV Infusion 500mg/100ml 1's pack 100\n\tAcme Ltd.\tLeo Eye Drops Eye Drops .5% 1's pack(5ml) 80.30\n\tAcme Specialized\tLeo TAB dr 500mg 20's pack 301\n\tAcme Specialized\tLeo TAB dr 750mg 12's pack 240.84\n\tAexim\tLevostin TAB dr 500mg 20's pack 260\n\tAlbion Ltd.\tLevoflxacim TAB dr 500 mg 20's pack \n\tAlco Pharma\tLeoflox TAB dr 250mg 10's pack 70\n\tAlco Pharma\tLeoflox TAB dr 500mg 20's pack 300\n\tAmbee\tLexlo TAB dr 500mg 20's pack 261\n\tAmbee\tLexlo TAB dr 250mg 20's pack 160.60\n\tAmico Ltd.\tLevin TAB dr 500mg 10's pack 140\n\tApex\tLequin TAB dr 250mg I20's pack 100\n\tApex\tLequin TAB dr 500mg 20's pack 200\n\tApollo Pharmaceutical Ltd.\tLevodon TAB dr 500mg  16's pack 240\n\tAristopharma\tOvel TAB dr 500mg 30's pack 450\n\tAsiatic Ltd.\tLee 500 TAB dr 500mg  24's pack 360\n\tAsiatic Ltd.\tAsilee TAB dr 500mg  \n\tBeacon\tQuixin TAB dr 500mg 30's pack 450\n\tBelsen\tBeloxin TAB dr 500mg  20's pack 300\n\tBenham\tBenfloxin 500 CAP 500mg  20's pack 238.60\n\tBeximco\tEvo Oral Solution 125mg/5ml 100ml bot 75\n\tBeximco\tEvo TAB dr 250mg 30's pack 270\n\tBeximco\tEvo TAB dr 500mg 20's pack 320\n\tBeximco\tEvo TAB dr 750mg 10's pack 200\n\tBeximco\tEvo Infusion 500mg  1's pack 100\n\tBio Pharma Ltd.\tLifcin Oral Solution 125mg/5ml 100ml bot 75.28\n\tBio Pharma Ltd.\tLifcin IV Infusion 500mg/100ml 1's pack 100\n\tBio Pharma Ltd.\tLifcin TAB dr 500mg 20's pack 301.20\n\tBio Pharma Ltd.\tLifcin TAB dr 750mg 12's pack 240.96\n\tBristol Pharma Ltd.\tLevonce TAB dr 500mg 20's pack 300\n\tChemist Ltd.\tLetab TAB dr 500mg 20's pack 200\n\tConcord\tRadibac TAB dr 500mg 20's pack 300\n\tCosmic Chemical Industries Ltd.\tLevocos TAB dr 500mg 30's pack 420\n\tCosmo Pharma Ltd.\tCoslev TAB dr 500mg 20's pack 280\n\tDecent Pharma Ltd.\tFlovo TAB dr 500mg 20's pack 300\n\tDelta Pharma\tOlcin TAB dr 500mg 20's pack 240\n\tDelta Pharma\tOlcin TAB dr 750mg 10's pack 160\n\tDesh\tLevocin TAB dr 500mg 30's pack 420\n\tDoctor's Chemicals Works Ltd.\tLefex TAB dr 500mg 30's pack 420\n\tDrug International Ltd.\tLevoflox TAB dr 500mg 20's pack 300\n\tDrug International Ltd.\tLevoflox IV Infusion 500mg/100ml 1's pack 100\n\tDrug International Ltd.\tLevoflox TAB dr 750mg 10's pack 200\n\tEskayef Bangladesh Ltd.\tLevomax TAB dr 500mg 20's pack 300\n\tEskayef Bangladesh Ltd.\tLevomax TAB dr 750mg 10's pack 200\n\tEuro Pharma Ltd.\tLezon TAB dr 500mg 20's pack 300\n\tEverest\tLoce TAB dr 500mg 24's pack 288\n\tG. A. Company Ltd.\tLivacin TAB dr 500mg 20's pack 300\n\tGeneral\tLevogen TAB dr 250mg 30's pack 240.90\n\tGeneral\tLevogen TAB dr 500mg 20's pack 301.20\n\tGlobe\tLocin TAB dr 250mg 20's pack 140\n\tGlobe\tLocin TAB dr 500mg 20's pack 240\n\tGlobex\tLexa TAB dr 500mg 30's pack 450\n\tHallmark\tEvoloxin TAB dr 500mg 20's pack 261\n\tHealthcare\tResquine TAB dr 250mg 30's pack 240\n\tHealthcare\tResquine TAB dr 500mg 24's pack 360\n\tHealthcare\tResquine TAB dr 750mg 18's pack 360\n\tHudson\tEvocin TAB dr 500mg 20's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLevosina TAB dr 250mg 20's pack 160\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLevosina TAB dr 500mg 20's pack 310\n\tIncepta\tLevoxin Oral Solution 125mg/5ml 100ml 80\n\tIncepta\tLevoxin TAB dr 250mg 30's pack 240\n\tIncepta\tLevoxin TAB dr 500mg 20's pack 300\n\tIncepta\tLevoxin IV Infusion 500mg/100ml 1's pack 100\n\tIncepta\tLevoxin TAB dr 750mg 10's pack 200\n\tIncepta\tLevoxin IV Infusion 250 mg/50 ml  \n\tJayson\tEvonex TAB dr 250mg 30's pack 210.90\n\tJayson\tEvonex TAB dr 500mg 20's pack 261\n\tKemiko\tLin TAB dr 250mg 30's pack 300\n\tKemiko\tLin TAB dr 500mg 20's pack 300\n\tKumudini Pharma Ltd.\tNivoloc TAB dr 500mg 20's pack 300\n\tLeon\tLotor 500 TAB dr 500mg  \n\tMarksman.\tNeolev TAB dr 500mg 20's pack 240\n\tMedicon\tLoxin TAB dr 250mg 30's pack 210\n\tMedicon\tLoxin TAB dr 500mg 20's pack 300\n\tMedimet\tLevomet TAB dr 250mg 20's pack 160\n\tMillat\tLaxod TAB dr 500mg 30's pack 450\n\tMonicopharma\tQuilev TAB dr 500mg 24's pack 360\n\tNavana\tLevoquin TAB dr 250mg 20's pack 160.60\n\tNavana\tLevoquin TAB dr 500mg 24's pack 361.46\n\tNipa\tLovicin TAB dr 500mg 30's pack 450\n\tNIPRO JMI Pharma\tToplevo TAB dr 500mg 30's pack 450\n\tNovartis (Bangladesh) Ltd.\tExolev TAB dr 250mg 30's pack 300\n\tNovartis (Bangladesh) Ltd.\tExolev TAB dr 500mg 20's pack 320\n\tNovartis (Bangladesh) Ltd.\tExolev TAB dr 750mg 10's pack 200\n\tNovelta Bestway\tLevonor TAB dr 500mg  \n\tNovelta Bestway\tLevonor TAB dr 750mg  \n\tNovo Healthcare and Pharma Ltd.\tCorbic TAB dr 500mg 10's pack 150\n\tNovus\tMaxlev TAB dr 500mg 20's pack 240\n\tOpsonin Pharma\tLevox Oral Solution 125mg/5ml 100ml bot 75\n\tOpsonin Pharma\tLevox TAB dr 250mg 30's pack 240\n\tOpsonin Pharma\tLevox TAB dr 500mg 20's pack 300\n\tOpsonin Pharma\tLevox IV Infusion 500mg/100ml 1's pack 100\n\tOpsonin Pharma\tLevox TAB dr 750mg 10's pack/12's pack 200/240\n\tOrion Pharma Ltd.\tOrlev TAB dr 250mg 20's pack 80\n\tOrion Pharma Ltd.\tOrlev TAB dr 500mg 20's pack 301.20\n\tPacific\tLevolo TAB dr 500mg  \n\tPeoples Pharma Ltd.\tLevolon TAB dr 250mg 20's pack 150\n\tPeoples Pharma Ltd.\tLevolon TAB dr 500mg 30's pack 420\n\tPharmadesh Ltd.\tLevolex TAB dr 500mg 20's pack 280\n\tPharmasia Ltd.\tXelevo TAB dr 500mg 20's pack 300\n\tPopular\tLevobac TAB dr 500mg 24's pack 358.53\n\tPopular\tLevobac TAB dr 750mg 24's pack 481.92\n\tPrime\tLecocin TAB dr 500mg  \n\tRAK\tNeovox TAB dr 500mg 20's pack 300\n\tRangs\tLethiquin 500 TAB dr 500mg  20's pack 300\n\tRenata\tLevoking TAB dr 250mg 30's pack 240.90\n\tRenata\tLevoking TAB dr 500mg 30's pack 451.80\n\tRenata\tLevoking TAB dr 750mg 18's pack 361.26\n\tRenata\tLevoking Oral Solution 125mg 100ml bot 75.28\n\tRephco\tBacnil TAB dr 500mg 20's pack 300\n\tSeema\tLevoseem TAB dr 500mg 20's pack 320\n\tShamsul Al-Amin\tAvelox TAB dr 500mg 20's pack 240\n\tSilva\tTivanik TAB dr 250mg 30's pack 240.90\n\tSilva\tTivanik TAB dr 500mg 20's pack 301.14\n\tSomatec\tLevora Oral Solution 125mg/5ml 100ml bot 75.28\n\tSomatec\tLevora TAB dr 250mg 20's pack 160.60\n\tSomatec\tLevora TAB dr 500mg 20's pack 281\n\tSomatec\tLevora TAB dr 750mg 10's pack 180.70\n\tSquare\tTrevox Oral Solution 125mg/5ml 100ml 80\n\tSquare\tTrevox TAB dr 500mg 30's pack 451.67\n\tSquare\tTrevox IV Infusion 500mg/100ml 100ml 100\n\tSquare\tTrevox TAB dr 750mg 20's pack 401.39\n\tSquare\tTrevox Syrup 125mg  100ml bot 75.28\n\tSyntho Ltd.\tLeevotin TAB dr 500mg 30's pack 450\n\tTechno Drugs Ltd.\tUrilev TAB dr 250mg 20's pack 170\n\tTechno Drugs Ltd.\tUrilev TAB dr 500mg 20's pack 300\n\tTechno Drugs Ltd.\tUrilev IV Infusion 500mg/100ml 1's pack 100\n\tTechno Drugs Ltd.\tUrilev TAB dr 750mg 18's pack 360\n\tTechno Drugs Ltd.\tLevonic Injection 25mg 1's pack 430\n\tVeritas\tLevoday 500 TAB dr 500mg  \n\tWhite Horse Pharma\tTrilon-500 TAB dr 500mg 24's pack 360\n\tZenith\tLexazen TAB dr 250mg 30's pack 240\n\tZenith\tLexazen TAB dr 500mg 18's pack 252\n\tZiska\tLevonix 500 TAB dr 500mg 21's pack 294\n\tUniDerma\tAnlev TAB dr 500mg  10's pack 150\n\tIndication: Chronic bronchitis, Acute bacterial sinusitis, Anthrax, Community-acquired pneumonia, Skin and skin structure infections, Nosocomial pneumonia, Urinary tract infections, Complicated skin and skin structure infections, Acute pyelonephritis, Chronic bacterial prostatitis\n\nDose: Adult: PO/IV Acute sinusitis 500 mg once daily for 10-14 days. Acute bacterial exacerbation of chronic bronchitis 500 mg once daily for 7 days. \n\nCommunity-acquired pneumonia 500 mg once daily for 7-14 days. Uncomplicatd skin infections 500 mg once daily for 7-10 days. Nosocomial pneumonia; Complicated skin infections 750 mg once daily for 7-14 days. \n\nUncomplicated UTI 250 mg once daily for 3 days. Acute pyelonephritis; Complicated UTI 250 mg once daily for 10 days. Chronic bacterial prostatitis 500 mg once daily for 28 days. Treatment and postexposure prophylaxis of inhalation anthrax 500 mg once daily for 60 days. \n\nChildren\n- Children 6 months to <5 years: 10 mg/kg every 12 hours\n- Children > 5 years:10 mg/kg every 24 hours\n\nRenal impairment: Haemodialysis/CAPD: Initially, 500 mg daily, then 250 mg every 48 hr. Alternatively: Initially, 750 mg daily, then 500 mg every 48 hr.\n\nCrCl (ml/min)	\n20-49	Initially, 500 mg daily, then 250 mg every 24 hr. Alternatively: Initially, 750 mg daily, then 750 mg every 48 hr.\n10-19	Initially, 500 mg daily, then 250 mg every 48 hr. Alternatively: Initially, 750 mg daily, then 500 mg every 48 hr.\n\nContra-indication: Hypersensitivity to levofloxacin or other quinolones. Child <18 yr.\n\nSide effects: Oral/IV: Nausea, diarrhoea, constipation, headache, insomnia, inj site reactions (IV). Ophthalmic: Transient decrease in vision, ocular burning, ocular pain or discomfort, foreign body sensation, headache, fever, pharyngitis, photophobia.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Known or suspected CNS disorders (e.g. severe cerebral arteriosclerosis, epilepsy) or other risk factors that predispose to seizures. Avoid unnecessary exposure to sunlight or artificial UV light. History of prolonged QT interval, uncorrected electrolyte disturbances. DM (carefully monitor blood glucose levels). Periodically monitor renal, hepatic and haematopoietic functions during treatment. Pregnancy and lactation. Elderly. May impair ability to drive or operate machinery.\n\nMode of action: Additive effects on QT interval prolongation w/ class IA (e.g. quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmics, fluoxetine or imipramine. Reduced absorption w/ sucralfate, didanosine, antacids containing Mg or Al, dietary supplements containing Zn, Ca, Mg or Fe. Altered glucose levels w/ antidiabetic agents (e.g. insulin, glibenclamide). Increased risk of severe tendon disorders w/ corticosteroids. Increased risk of CNS stimulation and seizures w/ NSAIDs. Increased prothrombin time w/ warfarin.\n\nPregnancy category: C\n\nInteraction: Additive effects on QT interval prolongation w/ class IA (e.g. quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmics, fluoxetine or imipramine. Reduced absorption w/ sucralfate, didanosine, antacids containing Mg or Al, dietary supplements containing Zn, Ca, Mg or Fe. Altered glucose levels w/ antidiabetic agents (e.g. insulin, glibenclamide). Increased risk of severe tendon disorders w/ corticosteroids. Increased risk of CNS stimulation and seizures w/ NSAIDs. Increased prothrombin time w/ warfarin.
Levofloxacin 0.5% Eye prep	\n\n\tACI\tLeflox Eye Drops  0.5% 5  ml drop 80.54\n\tAcme Ltd.\tLeo 0.5% Eye Drops   5  ml drop 80.30\n\tApex\tLequin Eye Drops   5  ml drop 80\n\tAristopharma\tOvel Eye Drops   5  ml drop 90\n\tBeximco\tEvo Eye Drops   5  ml drop 80\n\tDrug International Ltd.\tLevoflox Eye Drops   5  ml drop 80\n\tEskayef Bangladesh Ltd.\tLevomax Solution  .5%/ml 5ml 90\n\tG. A. Company Ltd.\tLivacin Eye Drops   5  ml drop 80\n\tGeneral\tLevogen Eye Drops   5ml drop 90\n\tGlobe\tLocin Eye Drops 5 mg/ml  \n\tHealthcare\tResquine Eye Drops   5ml drop 90\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLevosina Eye Drops   5  ml drop 90\n\tIncepta\tLevoxin Eye Drops 5mg/ml 5ml 80\n\tKemiko\tLin Eye Drops   5ml drop 90\n\tNavana\tLevoquin Eye Drops   5ml drop 90\n\tNipa\tLovicin Eye Drops   5  ml drop 80\n\tOpso Saline Ltd.\tFlovix Eye Drops 5 mg/ml  \n\tPopular\tLevobac Eye Drops  5 mg/ml 5  ml drop 90\n\tReman Drug Ltd.\tRevacin Eye Drops   5ml drop 100\n\tIndication: Bacterial conjunctivitis, Ocular infections\n\nDose: Adults and children 1 year of age and older:\nDays 1 and 2: Instill 1-2 drops in the affected eye(s) every 2 hours while awake, up to 8 times per day.\nDays 3 through 7: Instill 1-2 drops in the affected eye(s) every 4 hours while awake, up to 4 times per day.\n\nChildren up to 1 year of age:\nUse and dose must be determined by the physician.\n\nContra-indication: Levofloxacin is contraindicated in patients with a history of hypersensitivity to levofloxacin, quinolone antimicrobial agents, or any other components of this product.\n\nSide effects: Levofloxacin is generally well tolerated. However, a few side-effects can usually be seen. Side-effects include: nausea, vomiting, diarrhea, abdominal pain, flatulence and rare occurrence of phototoxicity (0.1%). Side-effects that may be seen very rarely include tremors, depression, anxiety, confusion etc.\n\nPrecaution: Contaminating the applicator tip with material from the eye, fingers or other source.\n\nMode of action: Additive effects on QT interval prolongation w/ class IA (e.g. quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmics, fluoxetine or imipramine. Reduced absorption w/ sucralfate, didanosine, antacids containing Mg or Al, dietary supplements containing Zn, Ca, Mg or Fe. Altered glucose levels w/ antidiabetic agents (e.g. insulin, glibenclamide). Increased risk of severe tendon disorders w/ corticosteroids. Increased risk of CNS stimulation and seizures w/ NSAIDs. Increased prothrombin time w/ warfarin.\n\nPregnancy category: C\n\nInteraction: Additive effects on QT interval prolongation w/ class IA (e.g. quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmics, fluoxetine or imipramine. Reduced absorption w/ sucralfate, didanosine, antacids containing Mg or Al, dietary supplements containing Zn, Ca, Mg or Fe. Altered glucose levels w/ antidiabetic agents (e.g. insulin, glibenclamide). Increased risk of severe tendon disorders w/ corticosteroids. Increased risk of CNS stimulation and seizures w/ NSAIDs. Increased prothrombin time w/ warfarin.
Levofloxacin 1.5% Eye prep	\n\n\tACI\tLeflox TS Eye Drops   5  ml drop 120\n\tAristopharma\tOvel TS Eye Drops   5  ml drop 120\n\tAsiatic Ltd.\tAsilee-TS Eye Drops 15 mg/ml  \n\tBeximco\tEvo TS Eye Drops   5  ml drop 130\n\tGeneral\tLevogen TS Eye Drops   5ml drop 130\n\tIncepta\tLevoxin TS Eye Drops 5mg/ml 5  ml drop 130\n\tOpso Saline Ltd.\tFlovix TS Eye Drops 15 mg/ml  \n\tPopular\tLevobac TS Eye Drops   5  ml drop 130\n\tReman Drug Ltd.\tRevacin 1.5% Eye Drops   5  ml drop 150\n\tIndication: Corneal ulcer\n\nDose: Adults and children 6 year of age and older:\nDays 1 through 3: Instill one to two drops in the affected eye(s) every 30 minutes to 2 hours while awake and approximately 4 and 6 hours after retiring.\nDay 4 through treatment completion: Instill one to two drops in the affected eye(s) every 1 to 4 hours while awake.\n\nContra-indication: Levofloxacin is contraindicated in patients with a history of hypersensitivity to Levofloxacin, quinolone, or any other components of this product.\n\nSide effects: The most common side-effects are transient decreased vision, fever, headache, transient ocular burning, ocular pain or discomfort, pharyngitis, allergic reactions, lid edema, ocular dryness and ocular itching.\n\nPrecaution: This drug should not be injected subconjunctially, nor should it be introduced directly into the anterior chamber of the eye. Avoid contaminating the applicator tip with material from the eye, fingers or other source.\n\nMode of action: Additive effects on QT interval prolongation w/ class IA (e.g. quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmics, fluoxetine or imipramine. Reduced absorption w/ sucralfate, didanosine, antacids containing Mg or Al, dietary supplements containing Zn, Ca, Mg or Fe. Altered glucose levels w/ antidiabetic agents (e.g. insulin, glibenclamide). Increased risk of severe tendon disorders w/ corticosteroids. Increased risk of CNS stimulation and seizures w/ NSAIDs. Increased prothrombin time w/ warfarin.\n\nPregnancy category: C\n\nInteraction: Additive effects on QT interval prolongation w/ class IA (e.g. quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmics, fluoxetine or imipramine. Reduced absorption w/ sucralfate, didanosine, antacids containing Mg or Al, dietary supplements containing Zn, Ca, Mg or Fe. Altered glucose levels w/ antidiabetic agents (e.g. insulin, glibenclamide). Increased risk of severe tendon disorders w/ corticosteroids. Increased risk of CNS stimulation and seizures w/ NSAIDs. Increased prothrombin time w/ warfarin.
Levosalbutamol	\n\n\tACI\tBrodil Levo Syrup 1mg/5ml 50ml bot/100ml bot 30.09/45.14\n\tACI\tBrodil Levo TAB dr 1mg 100's pack 110\n\tACI\tBrodil Levo TAB dr 2mg 100's pack 191\n\tAcme Ltd.\tSalmolin-L Syrup 1mg/5ml 60ml bot 25.10\n\tAcme Ltd.\tSalmolin-L TAB dr 1mg 100's pack 91\n\tAcme Ltd.\tSalmolin-L TAB dr 2mg 100's pack 170\n\tAlco Pharma\tLebrod Syrup 1mg/5ml 100ml bot 35\n\tAlco Pharma\tLebrod TAB dr 1mg 100's pack 75\n\tAlco Pharma\tLebrod TAB dr 2mg 100's pack 140\n\tApex\tLesal Syrup 1mg/5ml 60ml bot/100ml bot 25/35\n\tApex\tLesal TAB dr 1mg 50's pack 45\n\tApex\tLesal TAB dr 2mg 50's pack 75\n\tAristopharma\tAsmolex L TAB dr 1mg 100's pack 80\n\tAristopharma\tAsmolex L TAB dr 2mg 50's pack 75\n\tAristopharma\tAsmolex L 	 Syrup 1mg/5ml 	100ml bot 	 35 \n\tBeximco\tRespira Syrup 1mg/5ml 100ml bot 38\n\tBeximco\tRespira TAB dr 1mg 100's pack 90\n\tBeximco\tRespira TAB dr 2mg 100's pack 170\n\tBeximco\tRespira 	 Inhaler 50mcg 	 	 200 doses unit  200\n\tDelta Pharma\tAire Syrup 1mg/5ml 50ml bot 25\n\tDelta Pharma\tAire TAB dr 1mg 50's pack 45\n\tDelta Pharma\tAire TAB dr 2mg 50's pack 85\n\tEskayef Bangladesh Ltd.\tBrizy Syrup 1mg/5ml 60ml bot 28\n\tEskayef Bangladesh Ltd.\tBrizy TAB dr 1mg 50's pack 43\n\tEskayef Bangladesh Ltd.\tBrizy TAB dr 2mg 50's pack 85\n\tGeneral\tLavair TAB dr 1mg 100's pack 90\n\tGeneral\tLavair TAB dr 2mg 50's pack 85\n\tGeneral\tLevairÂ Syr Syrup 1mg/5ml 100ml bot 	 35\n\tHealthcare\tPulmocare-L Aerosol Inhalation 50 mcg/Metered Inhalation  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tVentisal-L Syrup 1mg/5ml 50ml bot/100ml bot 30/40\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVentisal-L TAB dr 2mg 100's pack 200\n\tIncepta\tPurisal Syrup 1mg/5ml 50ml bot/100ml bot 30/45\n\tIncepta\tPurisal Nebuliser Solution 1.25mg/3ml 10's pack 200\n\tIncepta\tPurisal Nebuliser Solution 360mcg/3ml 10's pack 150\n\tIncepta\tPurisal Nebuliser Solution 630mcg/3ml 10's pack 150\n\tIncepta\tPurisal TAB dr 1mg 100's pack 100\n\tIncepta\tPurisal TAB dr 2mg 100's pack 200\n\tNavana\tArolax Syrup 1mg/5ml 60ml bot/100ml bot 25.09/35.13\n\tNavana\tArolax TAB dr 1mg 100's pack 90\n\tNavana\tArolax TAB dr 2mg 100's pack 171\n\tNIPRO JMI Pharma\tIsosal Syrup 1 mg/5 ml  \n\tNIPRO JMI Pharma\tIsosal TAB dr 1mg  \n\tNIPRO JMI Pharma\tIsosal TAB dr 2mg  \n\tNovartis (Bangladesh) Ltd.\tSanlev TAB dr 1mg 100's pack 150\n\tNovartis (Bangladesh) Ltd.\tSanlev TAB dr 2mg 100's pack 250\n\tOpsonin Pharma\tPurilin Syrup 1mg/5ml 50ml bot/100ml bot 25/35\n\tOpsonin Pharma\tPurilin TAB dr 1mg 100's pack 90\n\tOpsonin Pharma\tPurilin TAB dr 2mg 100's pack 170\n\tPacific\tLebutal Syrup 1mg/5ml 100ml bot 40\n\tPacific\tLebutal TAB dr 1mg 100's pack 100\n\tPacific\tLebutal TAB dr 2mg 100's pack 190\n\tPharmasia Ltd.\tComfil Syrup 1mg/5ml 100ml bot 35\n\tPharmasia Ltd.\tComfil TAB dr 2mg 50's pack 85.50\n\tPopular\tLivodel Syrup 1mg/5ml 100ml bot 35.13\n\tPopular\tLivodel TAB dr 1mg 100's pack 90.04\n\tPopular\tLivodel TAB dr 2mg 100's pack 171.04\n\tRenata\tTrulax Syrup 1mg/5ml 100ml bot 	 45\n\tSilva\tActisal Syrup 1mg/5ml 50ml bot/100ml bot 25.10/35.14\n\tSilva\tActisal TAB dr 1mg 100's pack 90.33\n\tSilva\tActisal TAB dr 2mg 100's pack 170.64\n\tSomatec\tBromol Syrup 1mg/5ml 100ml bot 35.13\n\tSomatec\tBromol TAB dr 1mg 100's pack 91\n\tSomatec\tBromol TAB dr 2mg 100's pack 171\n\tSquare\tLevostar Syrup 1mg/5ml 50ml bot/100ml bot 25.10/38.15\n\tSquare\tLevostar Inhaler 50mcg 200 doses unit 200.75\n\tSquare\tLevostar TAB dr 1mg 100's pack 90.44\n\tSquare\tLevostar TAB dr 2mg 50's pack 85.72\n\tMST Pharma and Healthcare Ltd.\tWinzc-2 TAB dr 2mg  \n\tIndication: Asthma, Chronic obstructive pulmonary disease (COPD)\n\nDose: Children (2 -5 years): Up to 0.1 mg/kg body weight (not more than 1 mg) three times daily.\nChildren (6 -11 years): 5 ml (1 mg), three times daily.\nAdults and adolescents above 12 years: 1-2 mg, three times daily. \n\nContra-indication: Levosalbutamol is contraindicated in patients with a history of hypersensitivity to Levosalbutamol or any of its components.\n\nSide effects: Hypocalcaemia, palpitation, fine tremors of the skeletal muscle and muscle cramps may occur. The other likely side effects are nausea, vomiting, burning substernal or epigastric pain and diarrhoea. \n\nPrecaution: Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Thyroxine/Levothyroxine Sodium	\n\n\tACI\tTyroid TAB dr 50mcg 100's pack 135\n\tAcme Ltd.\tThyrolar TAB dr 50mcg 90's pack 108\n\tAcme Ltd.\tThyrotron TAB dr 25mg + 50mg + 100mg 30's pack \n\tAristopharma\tThormon TAB dr 50mg  \n\tBeximco\tSynroid TAB dr 50 mcg  160\n\tEskayef Bangladesh Ltd.\tThynor TAB dr 50mcg 90's pack 135\n\tIbn Sina Pharmaceutical Ind. Ltd.\tThyrotab TAB dr 50mcg 100's pack \n\tIncepta\tEuthycin TAB dr 50mcg 100's pack 120\n\tJayson\tJaroxin TAB dr 50mcg 100's pack 120\n\tNuvista Pharma Ltd\tThyronor TAB dr 0.05 mg 100's pack 228\n\tPopular\tLeroxin-50 TAB dr 50mcg 100's pack 120\n\tRenata\tThyrox TAB dr 100mcg 90's pack 144\n\tRenata\tThyrox TAB dr 50mcg 90's pack 135\n\tSquare\tThyrin TAB dr 50mcg 90's pack 144\n\tSquare\tThyrin TAB dr 25mcg 4x15's pack 66\n\tGlaxo Wellcome GmbH, Germany\tEltroxin 	 TAB dr 50mcg 	 100's pack  255.60 	\n\tIndication: Hypothyroidism, TSH suppression, Myxoedema coma\n\nDose: Adult: PO Hypothyroidism Inital: 50-100 mcg/day. Maintenance: 100-200 mcg/day. Severe and chronic hypothyroidism Initial: 12.5-25 mcg/day, increase gradually if needed. \n\nTSH supression For thyrotropin-dependent well-differentiated thyroid cancer: Doses >2 mcg/kg/day may be used to achieve TSH target of <0.1 MIU/L. \n\nFor benign nodules and nontoxic multinodular goitre: Target TSH suppresion to 0.1-0.5 MIU/L for nodules and 0.5-1.0 MIU/L for multinodular goitre. \n\nContra-indication: Untreated hyperthyroidism; uncorrected adrenal failure; recent MI.\n\nSide effects: Nervousness, excitability, tremor, muscle weakness, cramps; sweating, flushing, heat intolerance, headache, insomnia, tachycardia, palpitations, angina pectoris, excessive wt loss; menstrual irregularities; diarrhoea, vomiting.Potentially Fatal: Convulsions, cardiac arrhythmia, heart failure, coma.\n\nPrecaution: Angina, heart failure; DM; diabetes insipidus; elderly; long-standing hypothyroidism; adrenal insufficiency; myxoedema. Do not use for treatment of obesity or for wt loss. Pregnancy, lactation.\n\nMode of action: Reduced absorption w/ iron, antacids, bile acid sequestrants, colestyramine, simeticone, Ca carbonate, sucralfate, cation exchange resins. Reduced tri-iodothyronine serum levels w/ amiodarone and propranolol. Reduced serum levels of thyroxine w/ carbamazepine, phenytoin, phenobarbital, rifampicin, lithium, oestrogens, sertraline. Androgens may decrease levothyroxine-binding globulins serum levels. May alter requirements of antidiabetic drugs. Increased risk of significant HTN and tachycardia w/ ketamine. Increased metabolic demands w/ sympathomimetics (e.g. epinephrine). May increase anticoagulant effect of warfarin.\n\nPregnancy category: A\n\nInteraction: Reduced absorption w/ iron, antacids, bile acid sequestrants, colestyramine, simeticone, Ca carbonate, sucralfate, cation exchange resins. Reduced tri-iodothyronine serum levels w/ amiodarone and propranolol. Reduced serum levels of thyroxine w/ carbamazepine, phenytoin, phenobarbital, rifampicin, lithium, oestrogens, sertraline. Androgens may decrease levothyroxine-binding globulins serum levels. May alter requirements of antidiabetic drugs. Increased risk of significant HTN and tachycardia w/ ketamine. Increased metabolic demands w/ sympathomimetics (e.g. epinephrine). May increase anticoagulant effect of warfarin.
Lidocaine + Prilocaine	\n\n\tACI\tXylone Plus Cream  2.5%. 5g 130\n\tPopular\tTopican Cream  2.5 gm + 2.5 gm/100 gm  5gm tube 130.49\n\tUnimed & Unihealth Manufacturers Ltd.\tEmprila Cream   5gm tube 100\n\tIndication: Local anaesthesia\n\nDose: Adult: Topical As eutectic mixture containing lidocaine base 2.5% and prilocaine base 2.5%: \nFor minor procedures: Apply 2.5 g over 20-25 cm2 of skin surface for at least 1 hr. \nFor major dermal procedures involving a larger skin area: Apply 2 g per 10 cm2 of skin and allow to remain in contact with the skin for at least 2 hr. \nAs adjunct to local infiltration anesth in genital mucous membranes: Apply 1 g per 10 cm2 of the skin surface for 15 mins. \nFor superficial minor surgery of genital mucous membranes in adult females: Apply 5-10 g for 5-10 mins.\n\nContra-indication: Neonates with gestational age <37 wk. Infants <12 mth of age who are receiving treatment with methaemoglobin-inducing agents or children who are receiving medications associated with drug-induced methaemoglobinemia. Children with congenital or idiopathic methaemoglobinemia. Application on mucous membranes, broken or inflamed skin.\n\nSide effects: Hyperpigmentation, erythema, itching, rash, burning, urticaria, stinging, oedema.\n\nPrecaution: Caution when used over large areas and leaving on for >2 hr. Severe hepatic impairment. Caution when used in patients who are receiving class I and III antiarrhythmics. Dose reduction may be necessary in acutely ill, debilitated patients and elderly. Avoid using on open wounds or near the eyes. Pregnancy and lactation.\n\nMode of action: Increased risk of toxicity when used with drugs that are known to cause methaemoglobinaemia. Concurrent use with class III antiarrhythmics may lead to additive cardiac effects. Toxic effects may be additive when used with class I antiarrhythmics.\n\nPregnancy category: B\n\nInteraction: Increased risk of toxicity when used with drugs that are known to cause methaemoglobinaemia. Concurrent use with class III antiarrhythmics may lead to additive cardiac effects. Toxic effects may be additive when used with class I antiarrhythmics.
Lidocaine Hydrochloride	\n\n\tGonoshasthaya\tG Lignocaine 2% Injection 20mg/ml 2ml amp x 10's pack/50 ml vial x 1's pack 27.60 / 18.27\n\tJayson\tJasocaine 1% Injection 10mg/ml 50 ml vial x 1's pack 16.81\n\tJayson\tJasocaine 2% Injection 20mg/ml 50 ml vial x 1's pack  18.20\n\tJayson\tJasocaine 4% Injection 40mg/ml 2 ml vial x 10's pack 32.80\n\tIndication: Ventricular arrhythmias, Haemorrhoids, Sympathetic nerve block, Peripheral nerve block, Perianal pain and itching, Ventricular fibrillation or ventricular tachycardia, Epidural anaesthesia, Spinal anaesthesia, Regional anaesthesia, Surface anaesthesia, Pupil dilatation\n\nDose: Adult:\n\nIV Ventricular arrhythmias As HCl: In advanced cardiac life support: 1-1.5 mg/kg, repeat if needed. Max total: 3 mg/kg. In more stable patients: 50-100 mg. May repeat once or twice if needed, up to a max of 200-300 mg in 1 hr, then 1-4 mg/min via continuous infusion. \n\nRegional anesth 50-300 mg (0.5% soln w/o adrenaline). Max: 4 mg/dose. \n\nIM Ventricular arrhythmia emergency 300 mg, repeat after 60-90 mins if needed. \n\nEpidural anesth 2-3 mL soln for each dermatome to be anaesthesized. Lumbar epidural: 250-300 mg (1% soln) for analgesia and 225-300 mg (1.5% soln) or 200-300 mg (2% soln) for anesth and thoracic epidural: 200-300 mg (1% soln). \n\nIn obstetric caudal analgesia, up to 300 mg (0.5 or 1% soln). For surgical caudal analgesia: 225-300 mg (1.5% soln). For continuous epidural anaesthesia, not to repeat max doses more often than 1.5 hrly. \n\nParenteral Sympathetic nerve block As 1% soln: 50 mg for cervical block; 50-100 mg for lumbar block. Peripheral nerve block Brachial plexus block: 225-300 mg (1.5% soln). \n\nIntercostal nerve block: 30 mg (1% soln). Paracervical block: 100 mg (1% soln) on each side, repeated not more often than 1.5 hrly. Paravertebral block: 30-50 mg (1% soln). \n\nPudendal block: 100 mg (1% soln) on each side. Retrobulbar block: 120-200 mg (4% soln). Percutaneous infiltration anesth 5-300 mg (0.5 or 1% soln). \n\nIntraspinal Spinal anesth Normal vag delivery: 50 mg (5% hyperbaric soln) or 9-15 mg (1.5% hyperbaric soln). Caesarean operation: Up to 75 mg (5% hyperbaric soln). Other surgical procedures: 75-100 mg. \n\nOphth Pupil dilatation during phacoemulsification cataract surgery As 1% soln: (often used w/ phenylephrine and cyclopentolate): Inject into anterior chamber of the eye at the start of the procedure. \n\nContra-indication: Hypovolaemia; heart block or other conduction disturbances.\n\nSide effects: Dizziness, paraesthesia, drowsiness, confusion, respiratory depression and convulsions.\nPotentially Fatal: Hypotension and bradycardia leading to cardiac arrest; anaphylaxis.\n\nPrecaution: Hepatic or renal impairment; CHF and following cardiac surgery; bradycardia; respiratory depression; porphyria; elderly or debilitated patients; pregnancy.\n\nMode of action: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.\n\nPregnancy category: C\n\nInteraction: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
Lidocaine Hydrochloride + Tolperisone Hydrochloride	\n\n\tIncepta\tMyolax PLUS Injection  2.5 mg + 100 mg 1ml amp x 5's pack 150\n\tOpsonin Pharma\tTolson Plus Injection   1ml amp x 5's pack 150\n\tIndication: Increased tone of skeletal muscles due to organic neurological disorders (e.g. injury of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis etc.), muscular hypertension, muscular spasm, muscular contracture, rigidity, spinal automatism and discopathy. Obliterative vascular diseases (obliterative arteriosclerosis, diabetic angiopathy, obliterative thromboangitis, raynaud's disease, diffuse scleroderma) and disorders due to injured innervation of the vessels (acrocyanosis, intermittent angioneurotic dysbasia). In individual cases post-thrombotic venous and lymphatic circulation disorders, crural ulcer\n\nDose: The usual dose is one ampoule twice daily by intramuscularly. Injection should be given slowly.\nAccordingly to age and symptom, the dosage may be changed.\n\nContra-indication: Hypersensitivity to any component of the product\nMyasthenia gravis\nNursing mother\n\nSide effects: Sometimes, muscular weakness, headache, nausea, vomiting and rarely hypersensitivity reactions may occur as side effects\n\nPrecaution: In case of children, the prescribed dose and duration of treatment should closely be observed\n\nMode of action: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.\n\nPregnancy category: C\n\nInteraction: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
Lidocaine Hydrochloride 1%	\n\n\tIndication: Local & Regional anaesthesia.\n\nDose:  Intercostal nerve block: 30 mg (1% soln). Paracervical block: 100 mg (1% soln) on each side, repeated not more often than 1.5 hrly. Paravertebral block: 30-50 mg (1% soln). Pudendal block: 100 mg (1% soln) on each side. Retrobulbar block: 120-200 mg (4% soln). Percutaneous infiltration anesth 5-300 mg (0.5 or 1% soln).\n\nContra-indication: Hypovolaemia; heart block or other conduction disturbances.\n\nSide effects: Dizziness, paraesthesia, drowsiness, confusion, respiratory depression and convulsions. Potentially Fatal: Hypotension and bradycardia leading to cardiac arrest; anaphylaxis.\n\nPrecaution: Hepatic or renal impairment; CHF and following cardiac surgery; bradycardia; respiratory depression; porphyria; elderly or debilitated patients; pregnancy.\n\nMode of action: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.\n\nPregnancy category: C\n\nInteraction: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
Lidocaine Hydrochloride 2%, 10%	\n\n\tJayson\tJasocaine Gel  2% 30 gm tube 65\n\tOpsonin Pharma\tXyloken Spray 10 gm/100 ml  \n\tSquare\tLido Spray 10% 30ml 300\n\tIndication: Hemorrhoids, Itching, Perianal pain and itching, Postherpetic Neuralgia, Surface anaesthesia, Burning and pain and skin inflammations, Anorectal disorders\n\nDose: Adult: Mouth/Throat Surface anesth For pain: As 2% soln: 300 mg, not more often than 3 hrly. Each spray delivers 10 mg of Lidocaine. The maximum dose is 20 sprays (200mg). \n\nIn dentistry, the normal dose is 1-5 sprays. Two sprays per quarter of the mouth is recommended, with a maximum of 3 sprays per quarter of the mouth over 30 minutes. In sinus procedures 3 sprays are used. Up to 20 sprays may be necessary in childbirth and procedures of the throat and windpipe. Lower doses are used for children aged 3-12 years. \n\nLidocaine 10% Spray is not recommended for children under 3 years. \n\nGel: Apply locally 2-3 times daily. \n\nContra-indication: Hypovolaemia; heart block or other conduction disturbances.\n\nSide effects: Dizziness, paraesthesia, drowsiness, confusion, respiratory depression and convulsions. Potentially Fatal: Hypotension and bradycardia leading to cardiac arrest; anaphylaxis.\n\nPrecaution: Hepatic or renal impairment; CHF and following cardiac surgery; bradycardia; respiratory depression; porphyria; elderly or debilitated patients; pregnancy.\n\nMode of action: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.\n\nPregnancy category: C\n\nInteraction: May increase serum levels w/ cimetidine and propranolol. Increased risk of cardiac depression w/ ?-blockers and other antiarrhythmics. Additive cardiac effects w/ IV phenytoin. Hypokalaemia caused by acetazolamide, loop diuretics and thiazides may antagonise effect of lidocaine. Dose requirements may be increased w/ long-term use of phenytoin and other enzyme-inducers.
Light Paraffin + White Paraffin	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tOilatum Bar cleanser 7.5% 1's pack (100g) 291\n\tGlaxoSmithKline Bangladesh Ltd.\tOilatum Cream Cream 6%, 15% 1's pack (40g) 314\n\tSquare\tEmolent Cream  60mg +150mg 25gm 100\n\tIndication: Dry skin, Cracked feet, Infantile eczema\n\nDose:  Topical Hydrate and soften skin Apply when needed, esp after bath. Light liquid paraffin and White soft paraffin cream is used as often as required. Apply to the affected area and rub in well. It is specially effective after washing body areas because the sebum content of the stratum corneum may be depleted after washing resulting in excessive moisture loss.\n\nContra-indication: Abdominal pain, nausea and vomiting is present; children <3 yr.\n\nSide effects:  Foreign-body granulomatous reactions; vasospasm; lipoid pneumonia; interference with absorption of fat-soluble vitamins. \n\nPrecaution: Oral: not recommended for use in patients with difficulty swallowing or impaired neurodevelopment. \n\nMode of action: May impair absorption of fat-soluble vitamins and possibly other compounds.\n\nPregnancy category: Not Classified\n\nInteraction: May impair absorption of fat-soluble vitamins and possibly other compounds.
Linagliptin	\n\n\tACI\tGlitin TAB dr 5mg  \n\tAcme Ltd.\tLino TAB dr 5mg  \n\tAristopharma\tLinaglip TAB dr 5mg 20's Pack 400\n\tBeximco\tTraneta TAB dr 5mg  \n\tDelta Pharma\tLinatin TAB dr 5mg  \n\tDrug International Ltd.\tLinarol TAB dr 5mg 30's pack \n\tEskayef Bangladesh Ltd.\tLigazid TAB dr   \n\tGeneral\tLinaptin 5 TAB dr 5 mg 10's pack 150\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLinax TAB dr 5mg  \n\tIncepta\tLinatab TAB dr 5mg 20's pack 300\n\tMedicon\tLinago TAB dr 5mg  \n\tNIPRO JMI Pharma\tLijenta TAB dr 5 mg 10's pack 150\n\tOpsonin Pharma\tLinadus TAB dr 5mg 20's 300\n\tPacific\tLinadi TAB dr 5mg  \n\tPharmasia Ltd.\tLinaxitin TAB dr 5mg  \n\tPopular\tLinajen TAB dr 5mg 1's pack 132.01\n\tPopular\tLinajen TAB dr 5 mg 10's pack \n\tSquare\tLinita TAB dr 5mg 20's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tAdlina-5 TAB dr 5mg 10's pack 300\n\tWhite Horse Pharma\tLinalit TAB dr 5mg  \n\tIndication: Type 2 Diabetes Mellitus \n\nDose: Adults: Recommended Dose: 5 mg once daily. \n\nWhen linagliptin is added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly.\n\nWhen linagliptin is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.\n\nSpecial Population: Renal Impairment: No dose adjustment. \nHepatic Impairment: Pharmacokinetics studies suggest that no dose adjustment is required for patients with hepatic impairment. \nElderly: No dose adjustment is necessary based on age. However, clinical experience in patients >75 years is limited.\nChildren: The safety and efficacy of linagliptin in paediatric population has not yet been established. No data are available.\nAdministration:It can be taken with or without a meal at any time of the day. \n\nContra-indication: Patients with a history of a hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyperreactivity. Type 1 DM. Treatment of diabetic ketoacidosis.\n\nSide effects: Hypoglycaemia. Uncommonly, nasopharyngitis, hypersensitivity, cough.\nHypoglycemia was more commonly reported in patients treated with the combination  and sulfonylurea compared with those treated with the combination of placebo and sulfonylurea\n\nPrecaution: Concomitant use w/ sulphonylureas which are known to cause hypoglycemia; dose reduction of sulphonylureas may be considered. May affect ability to drive or operate machinery. Childn. Elderly >75 yr. Pregnancy & lactation.\n\nMode of action: Decreased steady-state AUC & Cmax w/ rifampicin.\n\nPregnancy category: B\n\nInteraction: Decreased steady-state AUC & Cmax w/ rifampicin.
Linezolid	\n\n\tBeximco\tArlin Powder for Suspension 100mg/5ml 100ml bot 280\n\tBeximco\tArlin TAB dr 400mg 20's pack 1200\n\tBeximco\tArlin TAB dr 600mg 20's pack 1700\n\tIncepta\tLinzolid Powder for Suspension 100mg/5ml 100ml bot 280\n\tIncepta\tLinzolid TAB dr 600mg 1's pack 450\n\tIncepta\tLinzolid TAB dr 400mg  \n\tOpsonin Pharma\tLinexil TAB dr 600mg 10's pack 85\n\tOpsonin Pharma\tLinexil Powder for suspension 100mg/5ml 100ml bot 280\n\tOrion Pharma Ltd.\tLinozid Powder for Suspension 100mg/5ml 100ml bot \n\tOrion Pharma Ltd.\tLinozid TAB dr 400mg 12's pack \n\tOrion Pharma Ltd.\tLinozid TAB dr 600mg 12's pack \n\tRenata\tLinez Powder for Suspension 100mg/5ml 60ml bot/100ml bot/150ml bot 175/280/420\n\tRenata\tLinez TAB dr 400mg 10's pack 600\n\tRenata\tLinez TAB dr 600mg 10's pack 850\n\tZenith\tLizen Powder for Suspension 100mg/5ml 100ml bot 280\n\tZenith\tLizen TAB dr 600mg 30's pack 2550\n\tIndication: Community-acquired pneumonia, Skin and skin structure infections, Nosocomial pneumonia\n\nDose: Adults and Adolescents (12 Years and Older): PO Uncomplicated skin infections 400 mg 12 hrly for 10-14 days. \n\nPO/IV Community-acquired pneumonia; Complicated skin and skin structure infections; Nosocomial pneumonia 600 mg 12 hrly for 10-14 days. \n\nFor Pediatric Patients (Birth through 11 Years of Age):\nâ¢ Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV or oral b.i.d. for 10 to 14 days.\nâ¢ Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV or oral b.i.d.for 14-28.\nNeonates < 7 days: Most pre-term neonates < 7 days of age (gestational age < 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg in every eight hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg t.i.d. by 7 days of life.\n\nMethicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococci infections 600 mg 12 hrly. Treatment duration for vancomycin-resistant enterococci: 14-28 day.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Diarrhoea (antibiotic associated colitis reported), headache, nausea, vomiting, constipation, abnormal liver function tests, fever, vaginal and oral candidiasis, skin rash, pruritus, dizziness, insomnia, anaemia, tongue discoloration, taste disturbance, lactic acidosis, optic and peripheral neuropathy (particularly if used > 28 days).\nPotentially Fatal: Reversible myelosuppression including anaemia, leukopenia, pancytopenia and thrombocytopenia (particularly if using > 10-14 days), transient ischaemic attacks, renal failure, Stevens-Johnson syndrome.\n\nPrecaution: Preexisting myelosuppression, renal impairment (CrCl < 30ml/min), uncontrolled hypertension, phaeochromocytoma, carcinoid syndrome, untreated hyperthyroidism, chronic infection, history of seizures, bipolar depression, schizophrenia or acute confusional states. Pregnancy and lactation. Monitor complete blood counts weekly. Give after haemodialysis. Not known if linezolid or metabolites removed during peritoneal dialysis.\n\nMode of action: May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).\n\nPregnancy category: C\n\nInteraction: May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).
Linezolid 0.2%	\n\n\tIncepta\tLinzolid IV Infusion   1 amp's pack 450\n\tIndication: Community-acquired pneumonia, Skin and skin structure infections, Nosocomial pneumonia\n\nDose: Patients who commence treatment on the parenteral formulation may be switched to either oral presentation when clinically indicated. In such circumstances, no dose adjustment is required as Linzolid (Linezolid) has an oral bioavailability of approximately 100%. The injection should be administered over a period of 30 to 120 minutes. \n\nAdults and Adolescents (12 Years and Older):\n\nâ¢ Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV b.i.d. for 10 to 14 days.\nâ¢ Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV  b.i.d. for 14-28\n\nFor Pediatric Patients (Birth through 11 Years of Age):\nâ¢ Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV b.i.d. for 10 to 14 days.\nâ¢ Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV  b.i.d.for 14-28.\n\nNeonates < 7 days: Most pre-term neonates < 7 days of age (gestational age < 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg in every eight hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg t.i.d. by 7 days of life.\n\nContra-indication: Linzolid formulations are contraindicated for use in patients who have known hypersensitivity to Linzolid or any of the other product components. Linzolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. Linzolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome and/or patients taking directly and indirectly acting sympathomimetic agents (e.g. pseudoephedrine), vasopressive agents (e.g. epinephrine, norepinephrine), dopaminergic agents (e.g. dopamine, dobutamine), serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), meperidine or buspirone.\n\nSide effects: Most of the adverse events reported with Linzolid were mild to moderate in intensity. The most common adverse events in patients treated with Linzolid were diarrhea, headache and nausea. Other adverse included oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration.\n\nPrecaution: Patients who develop recurrent nausea or vomiting, unexplained acidosis, or low bicarbonate level while receiving Linzolid should receive immediate medical evaluation. Where administration of Linzolid and concomitant serotonergic agents is clinically appropriate, patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyper reflexia and incoordination. If signs or symptoms occur physicians should consider discontinuation of either one or both agents. If the concomitant serotonergic agent is withdrawn, discontinuation symptoms can be observed. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmic evaluation is recommended. Convulsions have been reported in patients when treated with Linzolid. In some of these cases, a history of seizures or risk factors for seizures was reported.\n\nMode of action: May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).\n\nPregnancy category: C\n\nInteraction: May reduce serum levels w/ rifampicin and phenytoin. May cause hypoglycaemia w/ insulin or oral antidiabetics. May increase risk of seizures w/ tramadol.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, TCAs, SNRIs, or other serotonergic drugs (e.g. bupropion, vilazodone, mirtazapine, amoxapine, buspirone, maprotiline, meperidine, trazodone, nefazodone). Significant increase in BP w/ vasopressive agents (e.g. epinephrine, norepinephrine), sympathomimetic agents (e.g. pseudoephedrine) and dopaminergic agents (e.g. dopamine, dobutamine).
Liquid Paraffin + Magnesium Hydroxide	\n\n\tAcme Ltd.\tAcme's Milk of Magnesia Plus Suspension   120ml bot 65.25\n\tBeximco\tFrelax Oral Emulsion  100ml \n\tIncepta\tMagfin Emulsion Suspension   100ml bot 95\n\tNovelta Bestway\tNormocon Oral Emulsion Suspension (30 ml + 5 gm + 7.06 gm)/  \n\tOpsonin Pharma\tNesifin Suspension   100ml bot 95\n\tOrion Pharma Ltd.\tMegalax Suspension   1's pack 85\n\tSharif\tLaxefin Suspension (1.25 ml + 300 mg)/5 ml  \n\tSquare\tDuolax Oral Solution 1.25 ml + 300 mg/5 ml 100ml bot 95\n\tIndication: Constipation\n\nDose: Adult: PO Constipation Up to 45 mL/day. Max duration: 1 wk.\n\nThe recommended oral dose are as follows-\n\nAdults:\n15-30ml before breakfast or at bedtime.\n\nChildren:\nOver 7 years: 7.5ml-15ml at bedtime.\n\n3-7 years: 5-10ml at bedtime.\n\nThe dose may be mixed with milk or half a glass of water if desired.\n\nContra-indication: Abdominal pain, nausea and vomiting is present; children <3 yr.\n\nSide effects: Anal irritation (excessive dose) and seepage. Foreign-body granulomatous reactions; vasospasm; lipoid pneumonia; interference with absorption of fat-soluble vitamins. \n\nPrecaution: Oral: not recommended for use in patients with difficulty swallowing or impaired neurodevelopment. Avoid prolonged use as a laxative or faecal softener. \n\nMode of action: May impair absorption of fat-soluble vitamins and possibly other compounds.\n\nPregnancy category: Not Classified\n\nInteraction: May impair absorption of fat-soluble vitamins and possibly other compounds.
Lisinopril	\n\n\tACI\tStril TAB dr 5mg 28's pack 84.56\n\tAcme Ltd.\tLipril TAB dr 10mg 30's pack 165\n\tAcme Ltd.\tLipril TAB dr 5mg 50's pack 150\n\tAmbee\tNop TAB dr 2.5mg 50's pack 177.50\n\tAmbee\tNop TAB dr 5mg 50's pack 177.50\n\tBeximco\tNeopril TAB dr 10mg 50's pack \n\tBeximco\tNeopril TAB dr 5mg 100's pack 301\n\tDrug International Ltd.\tAcepril TAB dr 10mg 30's pack 210\n\tDrug International Ltd.\tAcepril TAB dr 5mg 50's pack 200\n\tGonoshasthaya\tG Lisinopril TAB dr 5mg 50's pack 100.50\n\tMedimet\tLispril TAB dr 5mg 50's pack/100's pack 112.5/301\n\tRAK\tHyporil TAB dr 10mg 30's pack 202\n\tRAK\tHyporil TAB dr 5mg 30's pack 120\n\tAstrazeneca Pharmaceutical company\tZestril TAB dr 5mg 28's pack \n\tAstrazeneca Pharmaceutical company\tZestril TAB dr 10mg 28's pack \n\tAstrazeneca Pharmaceutical company\tZestril TAB dr 20mg 28's pack \n\tIndication: Heart failure, Myocardial infarction, Diabetic nephropathy, Hypertension\n\nDose: Oral\nHypertension\nAdult: Initially, 10 mg/day, 1st dose given preferably at bedtime to avoid precipitous fall in BP. Patient w/ renovascular HTN, volume depletion, severe HTN: Initially, 2.5-5 mg once daily. Patient on diuretic: Initially, 5 mg once daily. Maintenance: 20 mg once daily, up to 80 mg/day may be given if needed.\nChild: >6 yr Initially, 0.07 mg/kg, up to 5 mg once daily.\n\nRenal impairment: Adult: CrCl <10 mL/min or on dialysis: Initially, 2.5 mg once daily. CrCl 10-30 mL/min: Initially, 2.5-5 mg once daily. CrCl 31-80 mL/min: Initially, 5-10 mg once daily. Dose can be adjusted up to max 40 mg once daily based on patient's response. Child: Do not give if GFR <30 mL/min/1.73 m2.\n\nCrCl (ml/min)	\n<10 	Initially, 2.5 mg once daily.\n10-30	Initially 2.5-5 mg once daily.\n31-80	Initially, 5-10 mg once daily.\n\n\nHeart failure\nAdult: As adjunct: Initially, 2.5 or 5 mg/day, increased by increments of >10 mg at intervals of at least 2 wk to max maintenance dose of 40 mg/day.\n\nPost myocardial infarction\nAdult: Initially, 5 mg once daily for 2 days started w/in 24 hr of the onset of symptoms. Increase to 10 mg once daily. Patients w/ low systolic BP: Initially, 2.5 mg once daily.\n\nDiabetic nephropathy\nAdult: Hypertensive type 2 diabetics w/ microalbuminuria: 10 mg once daily, may increase to 20 mg once daily to achieve a sitting diastolic BP <90 mmHg.\n\nContra-indication: History of angioedema related to previous treatment with ACE inhibitors, hereditary or idiopathic angioedema. Bilateral renal artery stenosis. Pregnancy (2nd or 3rd trimester), lactation.\n\nSide effects: Dizziness, headache, fatigue; cough, upper respiratory tract infection; rash; diarrhoea, nausea, vomiting, abdominal pain; chest pain, weakness; orthostatic effects; hypotension; hyperkalaemia; impotence; decreased haemoglobin; increased serum creatinine.\nPotentially Fatal: Severe hypotension, angioedema.\n\nPrecaution: Hypovolaemia, hyperkalaemia, collagen vascular disease, valvular stenosis; before, during or immediately after anaesthesia, preexisting renal insufficiency, unilateral renal artery stenosis. Children <6 yr. Assess renal function. May impair ability to drive or operate machinery.\n\nMode of action: May enhance hypotensive effect w/ diuretics. May increase risk of renal function deterioration and decrease antihypertensive effect w/ NSAIDs. May increase serum levels and toxicity of lithium. Increased risk of hyperkalaemia w/ K-sparing diuretics and K supplements. May increase nitritoid reactions of gold Na thiomalate.\nPotentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function w/ aliskiren in patients w/ diabetes or renal impairment.\n\nPregnancy category: D\n\nInteraction: May enhance hypotensive effect w/ diuretics. May increase risk of renal function deterioration and decrease antihypertensive effect w/ NSAIDs. May increase serum levels and toxicity of lithium. Increased risk of hyperkalaemia w/ K-sparing diuretics and K supplements. May increase nitritoid reactions of gold Na thiomalate.\nPotentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function w/ aliskiren in patients w/ diabetes or renal impairment.
Lithium Carbonate	\n\n\tACI\tLitiam ER TAB dr 400mg 40's pack 200.80\n\tIncepta\tLithin SR TAB dr 400mg 50's pack 250\n\tSun Pharmaceutical (Bangladesh) Ltd.\tLithosun SR TAB dr 400mg 50's pack 252.50\n\tIndication: Bipolar disorder, Mania, Recurrent unipolar depression\n\nDose: Oral: Adult:\nExtended release: 900-1800 mg/day PO divided 12 hourly\n\nLower initial dosage may be used to minimize adverse drug reactions\n\nSerum lithium should be monitored 12 hours after dose, twice weekly until serum concentration and clinical condition stabilize, and every other month thereafter\n\nDesirable range for serum lithium: 0.6-1.2 mEq/L; although higher serum concentrations may be needed, not to exceed 1.5 mEq/L\n\nContra-indication: Renal insufficiency, cardiovascular insufficiency, Addison's disease and untreated hypothyroidism are all contraindications to lithium therapy.\n\nSide effects: Tiredness, loss of appetite, nausea, vomiting, diarrhoea, hands shaking, memory problems, increased thirst and consequently passing urine more often by day, and perhaps also by night.\n\nPrecaution: Decreased tolerance to lithium has been reported to ensue from protracted sweating or diarrhoea and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved. \n\nMode of action: Reduced serum levels with carbonic anhydrase inhibitors, chlorpromazine, sodium-containing preparations, theophylline, urea. Enhanced hypothyroid effects with iodine salts. Enhanced effects of neuromuscular-blocking agents. Reduced pressor response to sympathomimetics.\nPotentially Fatal: Increased risk of lithium toxicity with ACE inhibitors, angiotensin receptor antagonists, loop diuretics, metronidazole, phenytoin. Increased risk of neurotoxicity with carbamazepine, calcium-channel blockers, haloperidol, methyldopa, phenothiazines, SSRIs, TCAs. Increased serum levels with COX-2 inhibitors, NSAIDs (except sulindac, aspirin), tetracyclines, thiazide diuretics. Increased risk of encephalopathy with haloperidol. Increased risk of serotonin syndrome with sibutramine. Fatal malignant hyperpyrexia may occur when used with MAOIs.\n\nPregnancy category: D\n\nInteraction: Reduced serum levels with carbonic anhydrase inhibitors, chlorpromazine, sodium-containing preparations, theophylline, urea. Enhanced hypothyroid effects with iodine salts. Enhanced effects of neuromuscular-blocking agents. Reduced pressor response to sympathomimetics.\nPotentially Fatal: Increased risk of lithium toxicity with ACE inhibitors, angiotensin receptor antagonists, loop diuretics, metronidazole, phenytoin. Increased risk of neurotoxicity with carbamazepine, calcium-channel blockers, haloperidol, methyldopa, phenothiazines, SSRIs, TCAs. Increased serum levels with COX-2 inhibitors, NSAIDs (except sulindac, aspirin), tetracyclines, thiazide diuretics. Increased risk of encephalopathy with haloperidol. Increased risk of serotonin syndrome with sibutramine. Fatal malignant hyperpyrexia may occur when used with MAOIs.
Lomefloxacin	\n\n\tAristopharma\tLomeflox TAB dr 400mg 20's pack 300\n\tNipa\tNamicin TAB dr 400mg 20's pack 300\n\tSquare\tMexlo TAB dr 400mg 20's pack 301.11\n\tIndication: Chronic bronchitis, Otitis media, Bacterial Conjunctivitis, Urinary tract infections, Surgical Prophylaxis, Otitis externa\n\nDose: Adult: PO Acute bacterial exacerbations of chronic bronchitis 400 mg once daily for 10 days. Surgical prophylaxis 400 mg as a single dose 1-6 hr pre-op. Uncomplicated UTI 400 mg once daily. \n\nTreament duration depends on bacterial strains: E. coli: 3 days. K. pneumoniae, P. mirabilis or S. saprophyticus : 10 days. Complicated UTI 400 mg once daily for 14 days. \n\nRenal impairment: Haemodialysis: Initially, 400 mg daily. Maintenance: 200 mg daily.\n\nCrCl (ml/min)	\n10-40	Initially, 400 mg daily. Maintenance: 200 mg daily.\n\nContra-indication: Hypersensitivity to the drug or other quinolones; children <18 yr; pregnancy and lactation.\n\nSide effects: Nausea, abdominal pain or discomfort, diarrhoea; headache, dizziness, insomnia; rash, pruritus, photosensitivity; thrombocytopenia.\nPotentially Fatal: Anaphylactic or anaphylactoid reactions.\n\nPrecaution: Avoid prolonged exposure to sunlight or artificial UV light. Known or suspected CNS disorders e.g. severe cerebral arteriosclerosis, epilepsy or other factors that predispose to seizures. Avoid in patients with known QT prolongation, uncorrected hypokalaemia. May impair ability to drive or operate machinery. Renal impairment.\n\nMode of action: Reduced bioavailability with sucralfate, antacids containing magnesium or aluminium, vitamin or mineral supplements containing iron. Increased serum levels with cimetidine. Potential increase in serum levels of ciclosporin. Renal elimination reduced with probenecid.\nPotentially Fatal: Increased risk of ventricular arrhythmias with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents.\n\nPregnancy category: C\n\nInteraction: Reduced bioavailability with sucralfate, antacids containing magnesium or aluminium, vitamin or mineral supplements containing iron. Increased serum levels with cimetidine. Potential increase in serum levels of ciclosporin. Renal elimination reduced with probenecid.\nPotentially Fatal: Increased risk of ventricular arrhythmias with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents.
Lomefloxacin 0.3% E/E prep	\n\n\tACI\tOmeflox E/E Drops  0.3% 5  ml drop 50.34\n\tApex\tSafquin E/E Drops   5  ml drop 60\n\tAristopharma\tLomeflox 0.3% E/E Drops   5  ml drop 70\n\tAsiatic Ltd.\tMeflocin E/E Drops   5  ml drop 70\n\tBeximco\tContra E/E Drops    5  ml drop 60\n\tDrug International Ltd.\tOpthaflox E/E Drops   5  ml drop 60\n\tG. A. Company Ltd.\tLumex E/E Drops   5  ml drop 60.50\n\tGeneral\tLomegen E/E Drops   5ml drop 70\n\tHealthcare\tOptilom E/E Drops   5ml drop 80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLyflox E/E Drops   5  ml drop 70\n\tIncepta\tLomequin E/E Drops  5  ml drop 70\n\tJayson\tOptiflox E/E Drops   5  ml drop 50.20\n\tNipa\tNamicin E/E Drops   5  ml drop 70\n\tOpso Saline Ltd.\tLoflox E/E Drops   5  ml drop 70\n\tPopular\tLomebec E/E Drops 0.3% 5  ml drop 70\n\tReman Drug Ltd.\tLomecin E/E Drops   5  ml drop 70\n\tReman Drug Ltd.\tLomecin Eye Ointment 0.3% 3gm tube 60\n\tSquare\tMexlo E/E Drops  .3 gm/100 ml 5  ml drop 60.22\n\tIndication: Otitis media, Bacterial Conjunctivitis, Otitis externa\n\nDose: Adults and children (above 1 year of age)\nAt the beginning of therapy on day one instill 5 drops into the conjunctival sac within 20 minutes. Thereafter, until day 7-9 instill 1 drop 3 times daily into the conjunctival sac.\n\nOtic Otitis externa; Otitis media As .3% soln: Use as diected. \n\nContra-indication: Lomefloxacin is contraindicated in patients with a history of hypersensitivity to Lomefloxacin, quinolone or any other components of this product.\n\nSide effects: Mild, transient sensation of burning, irritation or pain may be experienced on instillation.\n\nPrecaution: Long term treatment with antibiotics may enhance development of secondary fungal infections or may support growth of non-susceptible bacteria. Contact lenses should not be worn in the presence of infectious eye diseases and the product should not be instilled while wearing contact lenses. During prolonged use, it is recommended that physicians conduct periodic examinations of the eye, including measurement of the intraocular pressure.\n\nMode of action: Reduced bioavailability with sucralfate, antacids containing magnesium or aluminium, vitamin or mineral supplements containing iron. Increased serum levels with cimetidine. Potential increase in serum levels of ciclosporin. Renal elimination reduced with probenecid.\nPotentially Fatal: Increased risk of ventricular arrhythmias with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents.\n\nPregnancy category: C\n\nInteraction: Reduced bioavailability with sucralfate, antacids containing magnesium or aluminium, vitamin or mineral supplements containing iron. Increased serum levels with cimetidine. Potential increase in serum levels of ciclosporin. Renal elimination reduced with probenecid.\nPotentially Fatal: Increased risk of ventricular arrhythmias with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents.
Lomustine	\n\n\tGonoshasthaya\tG-Lomustin CAP 10mg 10mg x 18's pack 1260\n\tIndication: Brain tumours;  Hodgkin's disease;  Lung cancer;  Malignant melanoma						\n\n\nDose: Oral\nBrain tumours, Hodgkin's disease, resistant or relapsed, Malignant melanoma, Lung cancer\nAdult: 100-130 mg/m2 as a single dose every 6 wk. Adjust dose according to platelet and leukocyte counts. Compromised marrow function: 100 mg/m2 as a single dose every 6 wk.\nChild: 75-150 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts.\n\nRenal impairment:\nCrCl (ml/min)	\n10-50	Admin 75% of normal dose.\n<10	        Admin 25-50% of normal dose.\n\nContra-indication: Pregnancy and lactation.\n\nSide effects: Pulmonary infiltrates, pulmonary fibrosis, nausea, vomiting, hepatotoxicity, nephrotoxicity, stomatitis, alopecia, disorientation, lethargy, dysarthria, ataxia, visual disturbances.\nPotentially Fatal: Delayed bone marrow suppression and permanent marrow damage following prolonged use.\n\nPrecaution: Monitor CBC with differential platelet count wkly for at least 6 wk after a dose. Periodically perform pulmonary function studies and LFTs.\n\nMode of action: Increased levels/effects with CYP2D6 inhibitors.\n\nPregnancy category: D\n\nInteraction: Increased levels/effects with CYP2D6 inhibitors.
Loperamide	\n\n\tACI\tLomosec CAP 2mg 200's pack 200\n\tAcme Ltd.\tLopamid CAP 2mg 100's pack 100\n\tBeximco\tNormotil CAP 2mg 200's pack 120\n\tBristol Pharma Ltd.\tLoramide CAP 2mg 200's pack 100\n\tOpsonin Pharma\tLoperin CAP 2mg 100's pack 87.97\n\tSquare\tImotil CAP 2mg 200's pack 200\n\tZiska\tNomotil CAP 2mg 200's pack 120\n\tIndication: Diarrhea\n\nDose: Adult:\nAcute Diarrhea\n4 mg initially, then 2 mg after each loose stool; not to exceed 16 mg/day (8 mg/day for self-medication); discontinue if no improvement seen within 48 hours.\n\nChronic Diarrhea\n4 mg initially, then 2 mg after each loose stool until controlled, and then 4-8 mg/day in divided doses\nTraveler's Diarrhea.\n\n4 mg after first loose stool, then 2 mg after each subsequent stool; not to exceed 8 mg/day\n\nChildren:\nAcute Diarrhea\nFirst Day of Treatment\n\n    2-6 years (13-20 kg): 1 mg q8hr PO\n    6-8 years: (20-30 kg): 2 mg q12hr PO\n    8-12 years (>30 kg): 2 mg q8hr PO\n\nSecond & Subsequent Doses\n\n    0.1 mg/kg PO after each loose stool; not to exceed dose recommended for first 24 hours \n\nChronic Diarrhea\n0.08-0.24 mg/kg/day PO divided q12hr \n\nTraveler's Diarrhea\n<6 years: Safety and efficacy not established\n\n6-8 years: 2 mg after first loose stool, then 1 mg after each subsequent stool; not to exceed 4 mg/day\n\n8-12 years: 2 mg after first loose stool, then 1 mg after each subsequent stool; not to exceed 6 mg/day\n\n>12 years: 4 mg after first loose stool, then 2 mg after each subsequent stool; not to exceed 8 mg/day\n\n\n\nContra-indication: Conditions when inhibition of peristalsis is undesirable (e.g. ileus or megacolon); antibiotic induced colitis; active inflammatory bowel disease; if abdominal distention develops during use; abdominal pain in the absence of diarrhoea.\n\nSide effects: Abdominal pain, distention, and discomfort; paralytic ileus; constipation, dry mouth, drowsiness, dizziness, fatigue, rash.\nPotentially Fatal: Toxic megacolon.\n\nPrecaution: Concomitant specific therapy must be given in those with infectious diarrhoea; hepatic dysfunction; infants; pregnancy, lactation.\n\nMode of action: Bioavailability increased by co-trimoxazole, ritonavir, saquinavir. Respiratory depression reported when administered with quinidine. Loperamide increases GI absorption of desmopressin and decreases exposure to saquinavir.\n\nPregnancy category: B\n\nInteraction: Bioavailability increased by co-trimoxazole, ritonavir, saquinavir. Respiratory depression reported when administered with quinidine. Loperamide increases GI absorption of desmopressin and decreases exposure to saquinavir.
Loratadine	\n\n\tACI\tAlaron TAB dr 10mg 100's pack 301\n\tACI\tAlaron Suspension 5mg/5ml 60ml bot 30.11\n\tAcme Ltd.\tOrin TAB dr 10mg 100's pack 300\n\tAcme Ltd.\tOrin Suspension 5mg/5ml 60ml bot 26.10\n\tAd-din\tCladin TAB dr 10mg 100's pack 225\n\tAlbion Ltd.\tLoratadine TAB dr 10 mg 100 mg \n\tAlbion Ltd.\tLoratadine Suspension 5 mg/5 ml 60 ml \n\tAmico Ltd.\tLodin TAB dr 10mg 100's pack 300\n\tApollo Pharmaceutical Ltd.\tAlert TAB dr 10mg 100's pack 273\n\tAristopharma\tLoradin TAB dr 10mg 100's pack 300\n\tBeximco\tPretin TAB dr 10mg 100's pack 300\n\tBio Pharma Ltd.\tLorfast TAB dr 10mg 100's pack 150.50\n\tBio Pharma Ltd.\tLorfast Suspension 5mg/5ml 60ml bot 26.10\n\tBio Pharma Ltd.\tLorfast Suspension 10mg  60ml bot 26.10\n\tDesh\tLoratec TAB dr 10mg 100's pack 200\n\tDoctor's Chemicals Works Ltd.\tEradex TAB dr 10mg 50's pack 136.50\n\tDrug International Ltd.\tLorat TAB dr 10mg 100's pack 300\n\tEdruc Ltd.\tElo TAB dr 10mg 100's pack 250\n\tEskayef Bangladesh Ltd.\tOradin TAB dr 10mg 100's pack 400\n\tEskayef Bangladesh Ltd.\tOradin Suspension 5mg/5ml 40's pack 30\n\tEskayef Bangladesh Ltd.\tOradin FT TAB dr 10mg 40's pack 160\n\tGeneral\tLorin TAB dr 10mg 100's pack 301\n\tGeneral\tLorin Suspension 5mg/5ml 60ml bot 30.11\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSilora TAB dr 10mg 50's pack 125\n\tIncepta\tEncilor TAB dr 10mg 100's pack 300\n\tJayson\tEladin TAB dr 10mg  50's pack 152.50\n\tJayson\tEladin Suspension 5mg/5ml 60ml bot 26.40\n\tKemiko\tKevil TAB dr 10mg 100's pack 300\n\tKemiko\tKevil Suspension 5mg/5ml 60ml bot 30\n\tMillat\tDin TAB dr 10mg 100's pack 300\n\tModern\tLtdin TAB dr 10mg 100's pack 301\n\tNIPRO JMI Pharma\tItchlor TAB dr 10mg 30's pack 90.60\n\tNIPRO JMI Pharma\tItchlor Suspension 5mg/5ml 60ml bot 30.12\n\tNovartis (Bangladesh) Ltd.\tTirlor TAB dr 10mg 50's pack 151\n\tOpsonin Pharma\tLora TAB dr 10mg 100's pack 250\n\tOpsonin Pharma\tLora Suspension 5mg/5ml 60ml bot 25\n\tPeoples Pharma Ltd.\tNoseral TAB dr 10mg 50's pack 150\n\tPharmadesh Ltd.\tLoren TAB dr 10mg 100's pack 200\n\tShamsul Al-Amin\tSalora TAB dr 10mg 50's pack 150\n\tSquare\tLoratin TAB dr 10mg 100's pack 301\n\tSquare\tLoratin Suspension 5mg/5ml 60ml bot 30.11\n\tSquare\tLoratin FAST TAB dr 10mg 100's pack 301\n\tTechno Drugs Ltd.\tAnalor TAB dr 10mg 100's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tAleze TAB dr 10mg 50's pack 125\n\tUnimed & Unihealth Manufacturers Ltd.\tAleze Suspension 5mg/5ml 60ml bot 26\n\tIndication: Pneumonia, Allergic rhinitis, Pruritus, Urticaria, Sneezing, Allergic conditions, Rhinorrhea, Lacrimation\n\nDose: Adult and child over 6 years: One 10 mg tablet or two teaspoonful (10 ml) suspension once daily. or 5 mg 12 hrly.\nChildren aged 2-5 years: 5 ml or 1 teaspoonful (5 mg) suspension once daily. \nLoratadine is not recommended for children under 2 years of age.\n\nContra-indication: Pregnancy, lactation, children <2 yr.\n\nSide effects: Fatigue, giddiness, dizziness, dry mouth, headache, nausea, somnolence.\n\nPrecaution: Severe hepatic damage, epilepsy, renal insufficiency.\n\nMode of action: May increase plasma concentrations w/ inhibitors of CYP3A4 and/or CYP2D6 (e.g. cimetidine, erythromycin, ketoconazole, clarithromycin, quinidine, fluconazole, fluoxetine).\n\nPregnancy category: B\n\nInteraction: May increase plasma concentrations w/ inhibitors of CYP3A4 and/or CYP2D6 (e.g. cimetidine, erythromycin, ketoconazole, clarithromycin, quinidine, fluconazole, fluoxetine).
Loratadine + Pseudoephedrine Hydrochloride	\n\n\tACI\tCoderin 5 TAB dr  5mg 50's pack 201\n\tACI\tCoderin 10 TAB dr 10mg 50's pack 301\n\tAlbion Ltd.\tLoratidine Plus TAB dr 10 mg + 240 mg 40's pack \n\tAmico Ltd.\tLodin Plus TAB dr   30's pack 180\n\tBeximco\tPretin D 10/240 TAB dr   50's pack 300\n\tEdruc Ltd.\tElo Plus TAB dr   50's pack 261.66\n\tEskayef Bangladesh Ltd.\tOradin PLUS 10/240 TAB dr   40's pack 280\n\tGeneral\tEphedrol 10/240 TAB dr   30's pack 180.60\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSudamin TAB dr  50's pack 300\n\tIncepta\tSudolor 10/240 TAB dr   50's pack 300\n\tIncepta\tSudolor 5/120 TAB dr   50's pack 175\n\tOpsonin Pharma\tLora Plus 5/120 TAB dr   50's pack 200\n\tOpsonin Pharma\tLora PLUS 10/240 TAB dr   30's pack 180\n\tOpsonin Pharma\tDecontin TAB dr 10mg+240mg 30's pack \n\tSquare\tLoratin PLUS 10/240 TAB dr  10 mg + 240 mg 50's pack 400\n\tIndication: Pneumonia, Allergic rhinitis, Pruritus, Sneezing, Allergic conditions, Rhinorrhea, Lacrimation, Nasal congestion\n\nDose: Adults and Children 12 years of age and over: PO: loratadine 5 mg and pseudoephedrine sulfate 120 mg: 1 tab twice daily. \nLoratadine 10 mg and pseudoephedrine sulfate 240 mg: 1 tab once daily.\n(Safety and effectiveness of this drug in children below the age of 12 years have not been established).\n\nContra-indication: Lactation. Narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism. Patients on MAOI therapy or within 14 days of discontinuing MAOI.\n\nSide effects: Insomnia, dry mouth, headache, nervousness, epistaxis, pharyngitis, dizziness, fatigue, tachycardia, postural hypotension, transient abnormal hepatic function, urinary retention, CNS stimulation, excitability.\n\nPrecaution: Glaucoma, increased intraocular pressure, stenosing peptic ulcer and pyloroduodenal obstruction, prostatic hypertrophy, bladder neck obstruction, CV disease, DM, severe liver impairment. Not recommended for use in pregnancy. Elderly. Tablets to be swallowed whole and patients should be instructed not to break, chew, or dissolve such tablets.\n\nMode of action: Loratadine: Increased loratadine levels with ritonavir, amprenavir; increased loratadine levels with erythromycin, cimetidine and ketoconazole without evidence of clinical significance or toxicity; may block effects of betahistine. \n\nPseudoephedrine: Increased adverse effects (e.g. somnolence, agitation) with atomoxetine; increased BP or heart rate with sibutramine.\n\nPotentially Fatal: Pseudoephedrine: Increased risk of psychosis with bromocriptine; increased risk of fatal hypertensive crisis with MAOI, avoid concurrent use during and for 2 wk after stopping the MAOI; increased BP with linezolid and selegiline.\n\nPregnancy category: B\n\nInteraction: Loratadine: Increased loratadine levels with ritonavir, amprenavir; increased loratadine levels with erythromycin, cimetidine and ketoconazole without evidence of clinical significance or toxicity; may block effects of betahistine. \n\nPseudoephedrine: Increased adverse effects (e.g. somnolence, agitation) with atomoxetine; increased BP or heart rate with sibutramine.\n\nPotentially Fatal: Pseudoephedrine: Increased risk of psychosis with bromocriptine; increased risk of fatal hypertensive crisis with MAOI, avoid concurrent use during and for 2 wk after stopping the MAOI; increased BP with linezolid and selegiline.
Lorazepam	\n\n\tAlbion Ltd.\tLorazem TAB dr 1 mg/ 2.5 mg 100's pack \n\tIncepta\tLozicum TAB dr 1mg 100's pack 200\n\tPopular\tLorapam Injection 4mg/ml 5 amps pack 376.40\n\tSun Pharmaceutical (Bangladesh) Ltd.\tTrapex TAB dr 1mg 50's pack 100\n\tIndication: Anxiety, Status epilepticus, Sedation, psychosomatic, organic or psychotic illness, insomnia associated with anxiety, nervousness, restlessness, nausea and vomiting related to chemotherapy and anticonvulsants, and as a premedicant before dental or general surgery or prior to investigative procedures where there may be discomfort.\n\nDose: Adult: PO Anxiety 1-6 mg/day in 2 or 3 divided doses, up to 10 mg/day. \nInsomnia associated w/ anxiety 1-4 mg/day at bedtime. \nProphylaxis of nausea and vomiting associated with cytotoxic therapy For moderately emetogenic chemotherapy: May add 1-2 mg to the antiemetic therapy. \nPremed in surgery 2-3 mg the night before operation, then a smaller dose in the morning if needed. \nFor elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended, to be adjusted as needed and tolerated.\n\nIV Status epilepticus 4 mg, repeat once after 10-15 mins if needed. \nSedation in critical care 0.02-0.06 mg/kg 2-6 hrly as inj or 0.01-0.1 mg/kg/hr as continuous infusion. \n\nIV/IM Acute anxiety 25-30 mcg/kg 6 hrly if needed. \nPremed in surgery 50 mcg/kg, to be given 30-45 minutes before the operation if given via IV inj or 1-1.5 hr before operation if given via IM inj.\n\n\nContra-indication: Severe hepatic impairment; respiratory depression; acute narrow-angle glaucoma; pregnancy and lactation.\n\nSide effects: Drowsiness, headache, dizziness, confusion; blurred vision; nausea; weakness; unsteadiness.Potentially Fatal: Respiratory depression.\n\nPrecaution: Hepatic and renal dysfunction; pulmonary insufficiency; myasthenia gravis; may impair ability to drive or operate machinery; elderly or debilitated patients.\n\nMode of action: Drugs that affect the CNS (e.g. barbiturates, phenothiazines, antidepressants, MAOIs) may have additive CNS effects. Scopolamine may increase sedation, hallucinations and irrational behaviour. May reduce sedative and anxiolytic effect w/ caffeine, theophylline or aminophylline. May increase plasma level w/ Na valproate or probenecid.\n\nPregnancy category: D\n\nInteraction: Drugs that affect the CNS (e.g. barbiturates, phenothiazines, antidepressants, MAOIs) may have additive CNS effects. Scopolamine may increase sedation, hallucinations and irrational behaviour. May reduce sedative and anxiolytic effect w/ caffeine, theophylline or aminophylline. May increase plasma level w/ Na valproate or probenecid.
Losartan Potassium	\n\n\tACI\tRosatan TAB dr 25mg 30's pack 20\n\tACI\tRosatan TAB dr 50mg 30's pack 180.20\n\tAcme Ltd.\tLosart TAB dr 100mg 30's pack 360\n\tAcme Ltd.\tLosart TAB dr 25mg 30's pack 105.30\n\tAcme Ltd.\tLosart TAB dr 50mg 30's pack 180.60\n\tAlbion Ltd.\tLosapot TAB dr 50mg  \n\tAlbion Ltd.\tLosapot TAB dr 100mg/50mg/25mg 30's/50's/50's pack \n\tAlco Pharma\tLosa TAB dr 25mg 30's pack 105\n\tAlco Pharma\tLosa TAB dr 50mg 30's pack 180\n\tAmbee\tLotas TAB dr 50mg 30's pack 170.70\n\tAmico Ltd.\tLosaron TAB dr 50mg 30's pack 150\n\tApex\tLosarpex TAB dr 25mg 30's pack 105\n\tApex\tLosarpex TAB dr 50mg 30's pack 180\n\tApex\tGitox TAB dr 25mg 30's pack \n\tApex\tGitox TAB dr 50mg 30's pack \n\tAristopharma\tOsartan TAB dr 25mg 50's pack 175\n\tAristopharma\tOsartan TAB dr 50mg 30's pack 180\n\tAsiatic Ltd.\tArbium TAB dr 100mg 30's pack 300\n\tAsiatic Ltd.\tArbium TAB dr 25mg 50's pack 175\n\tAsiatic Ltd.\tArbium TAB dr 50mg 50's pack 300\n\tBeacon\tCardisan TAB dr 50mg 30's pack 180\n\tBeacon\tCardisan TAB dr 25mg 30's pack\n 240\n\tBeximco\tProsan TAB dr 25mg 50's pack 175\n\tBeximco\tProsan TAB dr 50mg 50's pack 300\n\tBio Pharma Ltd.\tLopo TAB dr 25mg 30's pack 135\n\tBio Pharma Ltd.\tLopo TAB dr 50mg 30's pack 240\n\tChemist Ltd.\tAngitan TAB dr 50 mg  \n\tConcord\tAcusan TAB dr 50mg 30's pack 240\n\tDelta Pharma\tAnin TAB dr 50mg 30's pack 150\n\tDoctor Tims\tLosark TAB dr 50mg  \n\tDoctor's Chemicals Works Ltd.\tLosap TAB dr 50mg 30's pack 150\n\tDrug International Ltd.\tLosardil TAB dr 100mg 20's pack 200\n\tDrug International Ltd.\tLosardil TAB dr 25mg 50's pack 175\n\tDrug International Ltd.\tLosardil TAB dr 50mg 30's pack 180\n\tEdruc Ltd.\tEtan TAB dr 50mg 30's pack 150\n\tEskayef Bangladesh Ltd.\tCardon TAB dr 100mg 20's pack 200\n\tEskayef Bangladesh Ltd.\tCardon TAB dr 25mg 30's pack 105\n\tEskayef Bangladesh Ltd.\tCardon TAB dr 50mg 40's pack 240\n\tEuro Pharma Ltd.\tLopoten TAB dr 25mg 30's pack 105\n\tEuro Pharma Ltd.\tLopoten TAB dr 50mg 30's pack 180\n\tGeneral\tAnreb TAB dr 25mg 50's pack 175.50\n\tGeneral\tAnreb TAB dr 50mg 30's pack 180.6\n\tGlobe\tLok TAB dr 50mg 30's pack 150\n\tHallmark\tCozaril TAB dr 50mg 30's pack 120.60\n\tHealthcare\tLosacor TAB dr 50mg 30's pack 195\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLosium TAB dr 25mg 30's pack 105\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLosium TAB dr 50mg 30's pack 180\n\tIncepta\tOsartil 100 TAB dr 100mg 30's pack 360\n\tIncepta\tOsartil 25 TAB dr 25mg 50's pack 225\n\tIncepta\tOsartil 50 TAB dr 50mg 50's pack 400\n\tJayson\tParten TAB dr 25mg 30's pack 90.60\n\tJayson\tParten TAB dr 50mg 30's pack 150.60\n\tKemiko\tTaran TAB dr 25mg 50's pack 175\n\tKemiko\tTaran TAB dr 50mg 50's pack 300\n\tKumudini Pharma Ltd.\tLospre TAB dr 50mg 30's pack 120\n\tLabaid\tPreslo TAB dr 50mg  \n\tLeon\tRenosart TAB dr 50mg  \n\tMedimet\tLosarcar TAB dr 25mg 50's pack 175\n\tMedimet\tLosarcar TAB dr 50mg 30's pack 180\n\tNavana\tVasotan TAB dr 25mg 30's pack 105.30\n\tNavana\tVasotan TAB dr 50mg 30's pack 180.60\n\tNavana\tPertilos TAB dr 25mg  \n\tNavana\tPertilos TAB dr 50mg  \n\tNipa\tLosar TAB dr 50mg 30's pack 165\n\tNIPRO JMI Pharma\tLosarva TAB dr 50mg  \n\tNIPRO JMI Pharma\tLosarva TAB dr 25mg  \n\tNovo Healthcare and Pharma Ltd.\tLosacard TAB dr 25mg 30's pack 105\n\tNovo Healthcare and Pharma Ltd.\tLosacard TAB dr 50mg 30's pack 150\n\tNuvista Pharma Ltd\tNusartan TAB dr 25mg  \n\tNuvista Pharma Ltd\tNusartan TAB dr 50mg  \n\tOpsonin Pharma\tLarb TAB dr 100mg 30's pack 360\n\tOpsonin Pharma\tLarb TAB dr 25mg 30's pack 105\n\tOpsonin Pharma\tLarb TAB dr 50mg 30's pack 180\n\tOrion Pharma Ltd.\tLosan TAB dr 25mg 30's pack 105.30\n\tOrion Pharma Ltd.\tLosan TAB dr 50mg 30's pack 180.60\n\tOrion Pharma Ltd.\tLosan TAB dr 100mg  \n\tPacific\tLk TAB dr 25mg 30's pack 105\n\tPacific\tLk TAB dr 50mg 30's pack 180\n\tPharmadesh Ltd.\tOsartek TAB dr 25mg 50's pack 175\n\tPharmadesh Ltd.\tOsartek TAB dr 50mg 30's pack 180\n\tPharmasia Ltd.\tXelotan TAB dr 50mg 30's pack 180.60\n\tPopular\tLosatan TAB dr 100mg 30's pack 301.20\n\tPopular\tLosatan TAB dr 50mg 30's pack 180.59\n\tRadiant.\tPrecon TAB dr 50 mg  \n\tRAK\tRaklok TAB dr 25mg 30's pack 105\n\tRAK\tRaklok TAB dr 50mg 30's pack 180\n\tRenata\tOstan TAB dr 25mg 30's pack 105.30\n\tRenata\tOstan TAB dr 50mg 30's pack 182.70\n\tSquare\tAngilock TAB dr 100mg 30's pack 360\n\tSquare\tAngilock TAB dr 25mg 50's pack 225\n\tSquare\tAngilock TAB dr 50mg 50's pack 400\n\tSun Pharmaceutical (Bangladesh) Ltd.\tRepace TAB dr 25mg 50's pack 175\n\tSun Pharmaceutical (Bangladesh) Ltd.\tRepace TAB dr 50mg 50's pack 302.50\n\tUnimed & Unihealth Manufacturers Ltd.\tAraten TAB dr 50mg 30's pack\n 240\n\tWhite Horse Pharma\tLospil TAB dr 50mg 50's pack 300\n\tZenith\tLopos TAB dr 25mg 30's pack/100's pack 105/350\n\tZenith\tLopos TAB dr 50mg 30's pack/100's pack 180/600\n\tIndication: Diabetic nephropathy, Hypertension, Stroke risk reduction of hypertensive or LVH patients, Heart Failure\n\nDose: Hypertension: The usual starting dose is 50 mg once daily. In patients with possible depletion of intravascular volume or patients with a history of hepatic impairment, starting dose is 25 mg once daily. \n\nLosartan can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg. No initial dosage adjustment is necessary for elderly or renal impairment patients. \n\nStroke risk reduction of hypertensive or LVH patients: Starting dose of Losartan is 50 mg  once daily. Maximum dose upto 100 mg  once daily.\n\nDiabetic Nephropathy: Starting dose of Losartan is 50 mg once daily. Maximum dose: 100 mg once daily.\n\nHeart Failure: Starting dose 12.5 mg once daily. The dose should generally be titrated at weekly intervals to maximum dose of 50 mg once daily.\n\nIf blood pressure is not controlled by Losartan, a low dose of a diuretic (Hydrochlorothiazide) may be added. \n\nChronic heart failure: 12.5 mg once daily, increased at weekly intervals to 50 mg once daily if tolerated, Stroke risk reduction in hypertension & LVH: 50 mg once daily. Hydrochlorothiazide 12.5 mg daily should added.\nMaximum dose-Losartan 100 mg followed by Hydrochlorothiazide 25 mg once daily. \n\nNephropathy in type 2 Diabetes: 50 mg once daily. Maximum dose-100 mg once daily.\n\nContra-indication: Losartan potassium is contraindicated in patients who are hypersensitive to the active ingredient or any component of the drug.\n\nSide effects: The most common adverse events occuring with Losartan are upper respiratory infection, dizziness and leg pain.\n\nPrecaution: Patients with known hypersensitivity to the drugs that act through renin-angiotensin system. Special precaution should be taken when it is administered to the patients with renal and hepatic impairment. Safety and effectivenss of Losartan in pediatric patients have not been established.\n\nMode of action: May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.\nPotentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).\n\nPregnancy category: C\n\nInteraction: May decrease plasma levels / fluconazole and rifampicin. May increase serum lithium levels and toxicity. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, triamterene, spironolactone), K supplements or K-containing salt substitutes.\nPotentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Loteprednol Etabonate 0.5% Eye prep	\n\n\tAristopharma\tLotepred Eye Drops   5  ml drop 175\n\tBeximco\tLacrison Eye Drops 0.5 gm/100 ml  \n\tEskayef Bangladesh Ltd.\tLotrel Eye Drops 0.5 gm/100 ml  \n\tGeneral\tLoteflam Eye Drops 0.5 gm/100 ml 5ml drop 175\n\tGeneral\tLoteflam Eye Ointment 500 mg/100 gm  \n\tIncepta\tLotepro Eye Drops   5  ml drop 150\n\tPopular\tLotenol Eye Drops  .5 gm/100 ml 5  ml drop 175\n\tIndication: Allergic conjunctivitis, Ocular inflammation\n\nDose: Steroid responsive disease treatment:\nApply 1 to 2 drops of Lotepro into the conjunctival sac of the affected eye(s) four times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary. Care should be taken not to discontinue therapy prematurely.\n\nPost-Operative Inflammation:\nApply 1 to 2 drops of Lotepro into the conjunctival sac of the operated eye(s) four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.\n\nContra-indication: As with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.\nLotepro is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.\n\nSide effects: Local reactions (e.g. blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. Prolonged use may increase IOP, which may be associated with possible development of glaucoma and infrequent optic nerve damage; posterior sub-capsular cataract formation and perforation of the globe where there is thinning of the cornea or sclera.\n\nPrecaution: â¢ Shake the bottle well before use\nâ¢ Patients should be advised not to allow the dropper tip to touch the eye, eyelid, fingers, or any other surface to prevent contamination\nâ¢ Patients should be advised not to wear soft contact lenses when using this drug\nâ¢ If this product is used for 10 days or longer, intraocular pressure should be monitored.\nâ¢ The possibility of fungal infections of the cornea should be considered after long-term steroid dosing\nâ¢ The use of steroids may delay wound healing.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Loteprednol Etabonate 0.5% + Tobramycin 0.3% Eye prep	\n\n\tAcme Ltd.\tLotemycin Eye Drops (0.5 gm + 0.3 gm)/100 ml  \n\tAristopharma\tLotepred Plus Eye Drops   5  ml drop 200\n\tBeximco\tLacrison T Eye Drops (0.5 gm + 0.3 gm)/100 ml   \n\tEskayef Bangladesh Ltd.\tLotrel T Eye Drops (0.5 gm + 0.3 gm)/100 ml  \n\tGeneral\tLoteflam T Eye Drops (0.5 gm + 0.3 gm)/100 ml 5ml drop 200\n\tIncepta\tLotepro Plus Eye Drops   5  ml drop 200\n\tNavana\tLoteba Eye Drops   5ml drop 200\n\tPopular\tLotenol T Eye Drops   5  ml drop 200.75\n\tIndication: Keratitis, Allergic conjunctivitis, Iritis, Ocular inflammation, Bacterial ocular infection, Cyclitis\n\nDose: Shake the bottle vigorously before using.\nApply 1 or 2 drops of Lotepro plus into the conjunctival sac of the affected eye(s) every 4 to 6 hours.\nDuring the initial 24 to 48 hours, the dosing may be increased, to every 1 to 2 hours. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.\nPediatric Use: Safety and effectiveness in pediatric patients have not been established.\n\nContra-indication: This drop, as with other steroid anti-infective ophthalmic combination drugs, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. It is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.\n\nSide effects: Prolonged use may increase: IOP, which may be associated with possible development of glaucoma and infrequent optic nerve damage; posterior sub-capsular cataract formation and perforation of the globe where there is thinning of the cornea or sclera.\nThe most frequent adverse reactions to topical tobramycin are hypersensitivity and localized ocular toxicity, including lid itching and swelling and conjunctival erythema.\n\nPrecaution: â¢ Shake the bottle well before use\nâ¢ Patients should be advised not to allow the dropper tip to touch the eye, eyelid, fingers, or any other surface to prevent contamination\nâ¢ Patients should be advised not to wear soft contact lenses when using this drug\nâ¢ If this product is used for 10 days or longer, intraocular pressure should be monitored\nâ¢ The possibility of fungal infections of the cornea should be considered after long-term steroid dosing\nâ¢ The use of steroids after cataract surgery may delay healing\nâ¢ If super infection occurs, appropriate therapy should be initiated.\n\nMode of action: Enhanced neurotoxic and nephrotoxic effects w/ other aminoglycosides (e.g. amikacin, streptomycin), cefaloridine, viomycin, polymyxin B, colistin, cisplatin and vancomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). Prolonged secondary apnoea may occur when given to anaesthetised patients receiving neuromuscular blocking agents (e.g. succinylcholine, tubocurarine, decamethonium). Increased risk of nephrotoxicity w/ ciclosporin and other antibacterials (e.g. cephalosporins). Antagonistic effect w/ neostigmine and pyridostigmine. May potentiate the effect of warfarin and phenindione.\n\nPregnancy category: C\n\nInteraction: Enhanced neurotoxic and nephrotoxic effects w/ other aminoglycosides (e.g. amikacin, streptomycin), cefaloridine, viomycin, polymyxin B, colistin, cisplatin and vancomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). Prolonged secondary apnoea may occur when given to anaesthetised patients receiving neuromuscular blocking agents (e.g. succinylcholine, tubocurarine, decamethonium). Increased risk of nephrotoxicity w/ ciclosporin and other antibacterials (e.g. cephalosporins). Antagonistic effect w/ neostigmine and pyridostigmine. May potentiate the effect of warfarin and phenindione.
Lovastatin	\n\n\tIndication: Coronary Artery Disease, Hyperlipidaemias\n\nDose: Adult: PO Hyperlipidaemias; Primary prevention of coronary artery disease Initial: 10-20 mg/day at bedtime, may increase 4-wkly if needed. Max: 80 mg/day (immediate-release); 60 mg/day (extended-release).\n\nContra-indication: Active liver disease; unexplained persistently elevated serum transaminases. Pregnancy and lactation.\n\nSide effects: Increased creatine phosphokinase; flatulence, nausea, dyspepsia, constipation or diarrhoea, abdominal pain; muscle cramps, myalgia, weakness; blurred vision; headache, dizziness; rash.\nPotentially Fatal: Rhabdomyolysis and acute renal failure.\n\nPrecaution: Renal impairment; inadequately controlled hypothyroidism; history of liver disease; alcoholism; patients at risk of rhabdomyolysis. Elderly. Monitor LFTs.\n\nMode of action: Increased risk of myopathy/rhabdomyolysis w/ amiodarone, colchicine, ranolazine, danazol, diltiazem and verapamil. May increase anticoagulant effect of warfarin.\nPotentially Fatal: Increased risk of myopathy and rhabdomyolysis w/ concomitant CYP3A4 inhibitors (e.g. nefazodone, erythromycin, boceprevir, clarithromycin, telithromycin, HIV protease inhibitors, itraconazole, ketoconazole, posaconazole, telaprevir), gemfibrozil, ciclosporin.\n\nPregnancy category: X\n\nInteraction: Increased risk of myopathy/rhabdomyolysis w/ amiodarone, colchicine, ranolazine, danazol, diltiazem and verapamil. May increase anticoagulant effect of warfarin.\nPotentially Fatal: Increased risk of myopathy and rhabdomyolysis w/ concomitant CYP3A4 inhibitors (e.g. nefazodone, erythromycin, boceprevir, clarithromycin, telithromycin, HIV protease inhibitors, itraconazole, ketoconazole, posaconazole, telaprevir), gemfibrozil, ciclosporin.
Lubiprostone	\n\n\tBeacon\tLubilax CAP 8mcg 20's pack 300\n\tBeacon\tLubilax 24 CAP 24 mcg  \n\tIncepta\tLubistone 8 CAP 8mcg 20's 300\n\tIncepta\tLubistone 24 CAP 24mcg 20's 800\n\tIndication: Irritable Bowel Syndrome with Constipation (IBS-C), Chronic idiopathic constipation\n\nDose: Adult: PO \nIrritable Bowel Syndrome with Constipation (IBS-C)\n8 mcg twice daily\n\nChronic idiopathic constipation\n24 mcg twice daily.\n\nContra-indication: History of mechanical GI obstruction.\n\nSide effects: Dose-dependent nausea. Diarrhoea, abdominal distension, pain, flatulence and vomiting. Headache, dizziness, fatigue, dyspnoea, and peripheral oedema.\n\nPrecaution: Safety has not been established in pregnant women. Not to be used in patients with severe diarrhoea.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Lynestrenol	\n\n\tNuvista Pharma Ltd\tOrgatril TAB dr 5 mg 30's pack 347.40\n\tIndication: Contraception, Menstrual disorders\n\nDose: Adult: PO Contraception 0.5 mg/day when used alone or 0.75-2.5 mg/day when used w/ an oestrogen. \nMenstrual disorders 5-10 mg/day as cyclic regimen.\n\nContra-indication: Undiagnosed vaginal bleeding, active venous thromboembolic disorders or severe arterial disease, hepatic impairment, progestogen-dependent tumours, porphyria. Pregnancy.\n\nSide effects: GI disturbances, changes in appetite or weight, fluid retention, oedema, rashes, urticaria, mental depression, breast tenderness and pain, gynaecomastia, changes in libido, headache, migraine, altered menstrual cycle, irregular menstrual bleeding, changes in LFTs and serum lipid profile.\nPotentially Fatal: Anaphylaxis or anaphylactoid reactions.\n\nPrecaution: CV or renal dysfunction, hypertension, epilepsy, migraine, asthma, DM, conditions which may be exacerbated by fluid retention, malabsorption syndrome, post ectopic pregnancy, functional ovarian cysts, thromboembolism. Lactation.\n\nMode of action: Increased metabolism and subsequent reduction in efficacy with enzyme-inducing agents e.g. carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Adjustment in antidiabetic dose may be required.\nPotentially Fatal: May increase plasma levels and toxicity of ciclosporin.\n\nPregnancy category: D\n\nInteraction: Increased metabolism and subsequent reduction in efficacy with enzyme-inducing agents e.g. carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Adjustment in antidiabetic dose may be required.\nPotentially Fatal: May increase plasma levels and toxicity of ciclosporin.
Magaldrate	\n\n\tAcme Ltd.\tOxecone M Suspension 400mg/5ml 200ml bot 54.2\n\tAcme Ltd.\tOxecone M Chewable TAB dr 400mg 100's pack 100\n\tAexim\tMagadrate PLUS Suspension 400mg/5ml 200ml bot 50\n\tIncepta\tMarlox TAB dr 400mg 200's pack 200\n\tKemiko\tMagaplus Suspension 400mg/5ml 200ml bot 54.2\n\tOpsonin Pharma\tMagacil Suspension  200ml bot 50\n\tOpsonin Pharma\tMegacil Oral Suspension 400mg/ml 200ml bot 50\n\tSyntho Ltd.\tAcidrox M TAB dr 400mg 150's pack 150\n\tIndication: Peptic ulcers, GERD, Heartburn, Gastritis\n\nDose: Adult: PO: 1-3 tablets, after meals and at bed time. \n5-10 mL (1-2 teaspoonfuls) between meals and not to exceed 80 mL (16 teaspoonfuls) in 24-hour period\n\nContra-indication: Magaldrate is contraindicated in patients with known hypersensitivity to magnesium and aluminium. It is also contraindicated in patients with impaired renal functions.\n\nSide effects: Constipation and diarrhea may occur.\n\nPrecaution: Care should be taken in decreased kidney function, hypophosphataemia and weak people.\n\nMode of action: Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.\n\nPregnancy category: C\n\nInteraction: Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
Magaldrate + Simethicone	\n\n\tACI\tAvlocid MS TAB dr 480mg+20mg 100's pack 301\n\tACI\tAvlocid MS Suspension 480mg+20mg/5ml 200ml\n 100.30\n\tAcme Ltd.\tOxecone MS Suspension  480mg + 20mg/ 5ml 200ml bot 85.32\n\tBeximco\tDigecid Plus suspension 480 mg + 20 mg/5 ml  110\n\tEskayef Bangladesh Ltd.\tGastid Suspension   200ml bot 100\n\tEthical Drug Ltd.\tMagalcon Suspension (480 mg + 20 mg)/5 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tMegalrat Plus Syrup  100's pack 100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMegalrat Plus TAB dr  100's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMagalrate Plus Suspension 480 mg + 20 mg/5 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tMagalrate Plus Chewable TAB dr 480 mg + 20 mg  \n\tIncepta\tMarlox Plus Suspension   200ml bot 100\n\tIncepta\tMarlox Plus TAB dr  100's pack 300\n\tKemiko\tMagaplus-X Suspension   200ml bot 85\n\tLeon\tPepcon Plus Suspension (480 mg + 20 mg)/5 ml  \n\tLeon\tPepcon Plus Chewable TAB dr 480 mg + 20 mg  \n\tMedicon\tMegasim Suspension (480 mg + 20 mg)/5 ml  \n\tOpsonin Pharma\tMagacil Plus Suspension   200ml bot 85\n\tOpsonin Pharma\tMegacil Plus Oral Suspension  200ml bot 100\n\tOrion Pharma Ltd.\tNovelta Suspension   100ml bot/200ml bot 55 / 85\n\tSquare\tMaganta Plus Suspension  480 mg + 20 mg/5 ml 200ml bot 100\n\tIndication: Heartburn, Hyperacidity, Indigestion, Dyspepsia, Gastritis, Peptic ulcers, GERD\n\nDose: Suspension: 2-4 teaspoonfuls after 20-60 minutes of meal and before sleep or on the basis of physicianâs prescription.\n\nContra-indication: Magaldrate is contraindicated in patients with known hypersensitivity to magnesium and aluminium. It is also contraindicated in patients with impaired renal functions.\n\nSide effects: GI side-effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur.\n\nPrecaution: Care should be taken in decreased kidney function, hypophosphataemia and weak people.\n\nMode of action: Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.\n\nPregnancy category: C\n\nInteraction: Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
Magaldrate + Simethicone Chewable	\n\n\tBeximco\tDigecid Plus Chewable TAB dr 480 mg + 20 mg  \n\tEskayef Bangladesh Ltd.\tGastid TAB dr   60's pack 180\n\tOrion Pharma Ltd.\tNovelta TAB dr   100's pack 200\n\tSquare\tMaganta Plus TAB dr  480 mg + 20 mg 100's pack 300\n\tIndication: Heartburn, Indigestion, Dyspepsia, Gastritis, Peptic ulcers, GERD\n\nDose: Adult: 100-250 mg 3-4 times daily as required. May be given with an antacid. \nOral\nInfant colic\nChild: Infant: 20-40 mg to be given with feeds.\n\nContra-indication: Patients with known hypersensitivity to magnesium and aluminium. It is also contraindicated in patients with impaired renal functions.\n\nSide effects: GI side-effects are uncommon. Occasionally, if excessive amount is consumed, diarrhea, constipation or regurgitation may occur\n\nPrecaution: Care should be taken in decreased kidney function, hypophosphataemia and weak people.\n\nMode of action: Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.\n\nPregnancy category: C\n\nInteraction: Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
Magnesium Hydroxide	\n\n\tAcme Ltd.\tAcme's Milk Of Magnesia Suspension 400mg/5ml 114ml bot 60\n\tAexim\tMilk Of Magnesia AL Suspension 400mg/5ml 114ml bot 13\n\tAlbion Ltd.\tMilk of Magnesia Suspension 26.67 g/100 ml 60 ml \n\tDoctor's Chemicals Works Ltd.\tDoctor's Milk Of Magnesia Suspension 412mg/5ml 114ml bot 28\n\tJayson\tMagnason Suspension 400mg/5ml 100ml bot 50\n\tMillat\tMilk Of Magnesia Suspension 400mg/5ml 100ml bot 28\n\tModern\tModern's Milk of Magnesia Suspension 400mg/5ml 100ml bot/200ml bot 28/50\n\tOpsonin Pharma\tMom Suspension 400mg/5ml 114ml bot 28\n\tOrion Pharma Ltd.\tMilk Of Magnesia Suspension 400mg/5ml 100ml bot \n\tPacific\tMagmil Suspension 400mg/5ml 50ml bot/100ml bot/200ml bot 25/60/100\n\tPharmadesh Ltd.\tMilk Of Megnesia Suspension 400mg/5ml 114ml bot/200ml bot 27.10/50.19\n\tSeema\tMilk Of Magnesia Suspension 400mg/5ml 114ml bot 15\n\tUnited Chemicals &\tMagnamilk Suspension 400 mg/5 ml  \n\tIndication: Heartburn, Constipation, Indigestion, Gastrointestinal hyperacidity, Osmotic laxative\n\nDose: Adult: PO: \nConstipation\nMagnesium hydroxide (400 mg/5 mL): 30-60 mL/day PO at bedtime or in divided doses\n\nMagnesium hydroxide (800 mg/5 mL): 15-30 mL/day PO at bedtime or in divided doses\n\nChild: \n 2-6 years: 5-15 mL/day of regular-strength liquid PO at bedtime or in divided doses\n 6-12 years: 15-30 mL/day (400 mg/5 mL) or 7.5-15 mL/day (800 mg/5 mL) PO at bedtime or in divided doses\n  >12 years: 30-60 mL/day (400 mg/5 mL) or 15-30 mL/day (800 mg/5 mL) PO at bedtime or in divided doses\n\nAdult:\nAcid Indigestion\nMagnesium hydroxide (400 mg/5 mL): 5-15 mL PO q4hr; no more than 4 doses per 24-hour period.\n\nChild: \n<12 years: Not recommended\n>12 years: 5-15 mL (400 mg/5 mL) PO q4hr; no more than 4 doses per 24-hour period\n\n\nContra-indication: Intestinal obstruction, faecal impaction; renal failure; appendicitis.\n\nSide effects: GI irritation, diarrhoea, abdominal cramps; hypermagnesaemia (in patients with renal impairment). Paralytic ileus.\n\nPrecaution: Colostomy, ileostomy; electrolyte imbalance. Monitor for toxicity in patients with impaired renal function. Pregnancy.\n\nMode of action: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.\n\nPregnancy category: A\n\nInteraction: Decreases absorption of tetracyclines and biphosphonates. Separate administration of these and other drugs by around 2 hr.
Magnesium Sulphate	\n\n\tOpsonin Pharma\tEclamsil Injection 2.5gm/5ml 5's pack 125\n\tRenata\tMagsum Injection 2.5gm/5ml 5 amps x1's pack 18.06\n\tIndication: Eclampsia, Cerebral palsy, Hypomagnesemia, Torsades de pointes, Barium poisoning\n\nDose: Adult:  IV Hypomagnesaemia Symptomatic deficiency: 1-2 g over 5-60 mins, then maintain at 0.5-1 g/hr if needed. Severe: 1-2 g/hr for 3-6 hr, then 0.5-1 g/hr as needed to correct deficiency. \n\nTorsades de pointes W/ pulses: Loading dose: 1-2 g over 5-60 mins, then maintain at 0.5-1 g/hr as needed. Pulseless: 1-2 g over 5-20 mins. Barium poisoning 1-2 g. \n\nCerebral oedema 2.5 g. Eclampsia Loading dose: 4-5 g over 10-15 mins, followed by either a continuous infusion of 1 g/hr or deep IM doses of 4-5 g into alternate buttocks 4 hrly. If seizure recurs, an additional IV dose of 2-4 g may be given. Not to exceed 30-40 g/24 hr. \n\nIM Hypomagnesaemia Mild deficiency: 1 g 6 hrly for 4 doses. Severe deficiency: Up to 250 mg/kg w/in 4 hr. \n\nContra-indication: Parenteral: Heart block, severe renal impairment, myocardial damage.\n\nSide effects: Oral: GI irritation, watery diarrhoea. Parenteral: Hypermagnesaemia characterised by nausea, vomiting, flushing, thirst, hypotension, drowsiness, confusion, slurred speech, double vision, bradycardia, muscle weakness. Hypocalcaemia; paralytic ileus.\n\nPrecaution: Renal impairment, myasthaenia gravis, digitalised patients; pregnancy. Monitor serum-magnesium concentrations.\n\nMode of action: Enhances neuromuscular blockers, digitalis glycosides.\n\nPregnancy category: B\n\nInteraction: Enhances neuromuscular blockers, digitalis glycosides.
Magnesium Sulphate 4%	\n\n\tBeximco\tNalepsin IV Infusion   100 ml bot 70.80\n\tGonoshasthaya\tG Magsulph IV Infusion   100ml vial 55.25\n\tRenata\tMagsum Infusion 100ml 1's pack \n\tIndication: Convulsions of eclampsia, pre-eclampsia\n\nDose: In Eclampsia\n\nIn severe pre-eclampsia or eclampsia, the total initial dose is 10 to 14 g of magnesium sulfate. To initiate therapy, 4 g of Magnesium Sulfate in 5% Dextrose Injection, USP may be administered intravenously. The rate of I.V. infusion should generally not exceed 150 mg/minute, or 7.5 mL of a 2% concentration (or its equivalent) per minute, except in severe eclampsia with seizures. Simultaneously, 4 to 5 g (32.5 to 40.6 mEq) of magnesium sulfate may be administered intramuscularly into each buttock using undiluted 50% Magnesium Sulfate Injection, USP. After the initial I.V. dose, some clinicians administer 1-2 g/hour by constant I.V. infusion.\n\nSubsequent intramuscular doses of 4 to 5 g of magnesium sulfate may be injected into alternate buttocks every four hours, depending on the continuing presence of the patellar reflex, adequate respiratory function, and absence of signs of magnesium toxicity. Therapy should continue until paroxysms cease.\n\nContra-indication: Parenteral: Heart block, severe renal impairment, myocardial damage.\n\nSide effects: Oral: GI irritation, watery diarrhoea. Parenteral: Hypermagnesaemia characterised by nausea, vomiting, flushing, thirst, hypotension, drowsiness, confusion, slurred speech, double vision, bradycardia, muscle weakness. Hypocalcaemia; paralytic ileus.\n\nPrecaution: Renal impairment, myasthaenia gravis, digitalised patients; pregnancy. Monitor serum-magnesium concentrations.\n\nMode of action: Enhances neuromuscular blockers, digitalis glycosides.\n\nPregnancy category: B\n\nInteraction: Enhances neuromuscular blockers, digitalis glycosides.
Mannitol 20%	\n\n\tBeximco\tOsmosol 20% IV Infusion   500ml bot with set 126.40\n\tOpso Saline Ltd.\tMannitol 20% IV Infusion   500ml bot with set 125.47\n\tOrion Pharma Ltd.\tManisol 20% IV Infusion   500ml bot 125\n\tIndication: Chronic bronchitis, Cerebral oedema, Oliguric phase of renal failure, Raised intracranial pressure, Renal function testing, Transurethral prostatic resection\n\nDose: Intravenous\nOliguric phase of renal failure\nAdult: 50-100 g in a 24-hr period by IV infusion of a 5-25% solution. Adjust rate of administration to maintain a urine flow of at least 30-50 mL/hr.\nChild: 0.25-2 g/kg.\n\nCerebral oedema\nAdult: 0.25-2 g/kg by IV infusion of a 15-25% solution given over 30-60 minutes.\n\nReduction of raised intraocular pressure\nAdult: 0.25-2 g/kg by IV infusion of a 15-25% solution given over 30-60 minutes.\n\nRenal function testing\nAdult: 0.2 g/kg infused over 3-5 min.\n\nIrrigation\nTransurethral prostatic resection\nAdult: Use 2.5-5% solution for bladder irrigation.\n\nContra-indication: Pulmonary congestion or oedema; intracranial bleeding; CHF; metabolic oedema with abnormal capillary fragility; anuria due to severe renal disease; severe dehydration.\n\nSide effects: Fluid and electrolyte imbalance; acidosis (with high doses). Nausea, vomiting, thirst; headache, dizziness, convulsions, chills, fever; tachycardia, chest pain; blurred vision; urticaria and hypotension or hypertension; acute renal failure; skin necrosis; thrombophloebitis.\n\nPrecaution: Hypervolaemia; urinary tract obstruction; check for signs of fluid and electrolyte imbalance. Should not be administered with whole blood. Pregnancy, lactation.\n\nMode of action: Fluid and electrolyte imbalance; acidosis (with high doses). Nausea, vomiting, thirst; headache, dizziness, convulsions, chills, fever; tachycardia, chest pain; blurred vision; urticaria and hypotension or hypertension; acute renal failure; skin necrosis; thrombophloebitis.\n\nPregnancy category: C\n\nInteraction: Fluid and electrolyte imbalance; acidosis (with high doses). Nausea, vomiting, thirst; headache, dizziness, convulsions, chills, fever; tachycardia, chest pain; blurred vision; urticaria and hypotension or hypertension; acute renal failure; skin necrosis; thrombophloebitis.
Maprotiline Hydrochloride	\n\n\tNovartis (Bangladesh) Ltd.\tLudiomil TAB dr 25mg 50's pack 255\n\tIndication: Depression\n\nDose: Oral\nDepression\nAdult: As hydrochloride: 25-75 mg daily in 3 divided doses, gradually increased in 25 mg increments at 1-2 wk intervals to 150 mg/day if necessary. Up to 225 mg/day in severely depressed patients.\nElderly: Initial: 25 mg daily. May increase slowly according to response to 50-75 mg daily if needed.\n\nContra-indication: Preexisting CV insufficiency; epilepsy or lowered seizure threshold.\n\nSide effects: Dry mouth, constipation, blurred vision, drowsiness, dizziness, tremor, nervousness, anxiety, insomnia, agitation, confusion, nausea, weakness and fatigue, headache, CV disorders, altered liver function, changes in blood glucose concentrations, allergic skin manifestations.\nPotentially Fatal: Seizures\n\nPrecaution: Urinary retention, prostatic hyperplasia, chronic constipation, untreated angle-closure glaucoma; hyperthyroidism; risk of suicide; may precipitate mania or psychotic symptoms; withdraw gradually; may impair ability to operate machinery. Pregnancy and lactation; elderly.\n\nMode of action: MAOIs. Increase in sedative effect with alcohol. Increased effect of antidiabetics. Maprotiline concentrations and toxicity increased by propranolol, risperidone. Risk of seizures increased with phenothiazines.\n\nPregnancy category: B\n\nInteraction: MAOIs. Increase in sedative effect with alcohol. Increased effect of antidiabetics. Maprotiline concentrations and toxicity increased by propranolol, risperidone. Risk of seizures increased with phenothiazines.
Mebendazole	\n\n\tAd-din\tHelben Suspension 100mg/5ml 30ml bot 14.80\n\tAlbion Ltd.\tMisole Suspension 2 mg/100 ml 30 ml \n\tDoctor's Chemicals Works Ltd.\tMebendol Suspension 100mg/5ml 30ml bot 13.65\n\tDoctor's Chemicals Works Ltd.\tMebendol TAB dr 100mg 60's pack 42\n\tG. A. Company Ltd.\tBendex Suspension 100mg/5ml 30ml bot 14.83\n\tG. A. Company Ltd.\tBendex TAB dr 100mg 30's pack 22.20\n\tG. A. Company Ltd.\tBendex TAB dr 500mg 30's pack 165\n\tGonoshasthaya\tG Mebendazole TAB dr 500mg 100mg x 500's tin 660\n\tIndobangla Pharmaceuticals\tMebendox Suspension 100mg/5ml 30ml bot 14.50\n\tIndobangla Pharmaceuticals\tMebendox TAB dr 100mg 30's pack 22\n\tJayson\tPanamox Suspension 100mg/5ml 30ml bot 14.75\n\tJayson\tPanamox TAB dr 100mg 120's pack 88.80\n\tMedimet\tMebrex Suspension 100mg/5ml 30ml bot 14.83\n\tMedimet\tMebrex TAB dr 100mg 60's pack 44.40\n\tOpsonin Pharma\tSolas Suspension 100mg/5ml 30ml bot 13.50\n\tOpsonin Pharma\tSolas TAB dr 100mg 30's pack 42\n\tPharmadesh Ltd.\tMebantrin Suspension 100mg/5ml 30ml bot 15\n\tPharmadesh Ltd.\tMebantrin TAB dr 100mg 30's pack 22.50\n\tSalton\tSarmox TAB dr 100mg  \n\tSquare\tErmox Suspension 100mg/5ml 30ml bot 14.88\n\tSquare\tErmox TAB dr 100mg 150's pack 111.72\n\tZenith\tVermizole TAB dr 100mg 30's pack 22.23\n\tIndication: Enterobiasis, Hookworm infections, Filariasis, Toxocariasis, Ascarisis, Trichuriasis, Trichostrongyliasis, Trichinellosis, Dracunculiasis\n\nDose: 100 mg tablet and suspension have the same dosage schedule applies to Adults & Children: Enterobiasis : A single tablet or 1 teaspoonful (5 ml) of the suspension. \n\nAscariasis, Ancylostomiasis, Trichuriasis : 2 tablets in two divided doses for 3 consecutive days or 2 teaspoonful (10 ml) in two divided doses for 3 consecutive days. \n\nTaeniasis & strongyloidiasis : Adults : 2 tablets twice daily for 3 consecutive days. Children: 1 tablet or 1 teaspoonful (5 ml) twice daily for 3 consecutive days.\n\nContra-indication: Hypersensitivity. Infants and children <2 yr.\n\nSide effects: Transient diarrhoea, abdominal pain, nausea, vomiting, headache, tinnitus, numbness, fever and dizziness.\nPotentially Fatal: Myelosuppression (high doses).\n\nPrecaution: Monitor blood counts and hepatic function especially in patients receiving high doses. Pregnancy and lactation.\n\nMode of action: Decreased plasma concentrations w/ carbamazepine and phenytoin. Increased plasma concentrations w/ cimetidine.\n\nPregnancy category: C\n\nInteraction: Decreased plasma concentrations w/ carbamazepine and phenytoin. Increased plasma concentrations w/ cimetidine.
Mebeverine Hydrochloride	\n\n\tAcme Ltd.\tAmeb TAB dr 135mg  \n\tAlbion Ltd.\tMebeverine TAB dr 135 mg 50's pack \n\tAmbee\tMespa TAB dr 135mg 50's pack 301\n\tBeximco\tRostil TAB dr 135mg 50's pack 350\n\tBeximco\tRostil SR CAP 200mg  \n\tDelta Pharma\tEvarin TAB dr 135mg 50's pack 300\n\tDrug International Ltd.\tMeverine TAB dr 135mg 50's pack 300\n\tDrug International Ltd.\tMeverine SR CAP 200mg 30's pack 300\n\tEskayef Bangladesh Ltd.\tVeron TAB dr 135mg 50's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tIrisyn TAB dr 135mg 50's pack 350\n\tIncepta\tIriban TAB dr 135mg 50's pack 300\n\tIncepta\tIriban SR CAP 200mg 30's pack 300\n\tOpsonin Pharma\tMave TAB dr 135mg 50's pack 264.97\n\tOpsonin Pharma\tMave SR CAP 200mg 30's pack 300\n\tSquare\tMevin TAB dr 135mg 50's pack 300\n\tSquare\tMevin SR Sr CAP 200mg  \n\tSun Pharmaceutical (Bangladesh) Ltd.\tMebiz SR TAB dr 200mg 30's pack 241.50\n\tZiska\tMevelum Dry Powder Sachet  8's Sachet pack  112\n\tIndication: Irritable bowel syndrome [IBS], GI tract spasm\n\nDose: Adults, elderly and children over 10 years: 1 tablet three times, or 1 capsule twice daily\n\n\n\nContra-indication: Not known\n\nSide effects: Generally Mebeverine is well tolerated. However, few side-effects like skin rash, urticaria and angioedema may appear.\n\nPrecaution: Caution should be exercised in porphyria or allergic reaction to this or any other medicine of this group.\n\nMode of action: No interaction studies have been performed except with alcohol. In vitro and in vivo studies in animals have demonstrated the absence of any interaction between Duspatalin Retard and ethanol.\nIncompatibilities: Not applicable.\n\nPregnancy category: Not Classified\n\nInteraction: No interaction studies have been performed except with alcohol. In vitro and in vivo studies in animals have demonstrated the absence of any interaction between Duspatalin Retard and ethanol.\nIncompatibilities: Not applicable.
Mebhydrolin	\n\n\tAcme Ltd.\tMebolin TAB dr 50mg 100's pack 200\n\tBeximco\tBexidal TAB dr 50mg 200's pack 400\n\tEskayef Bangladesh Ltd.\tMebidal TAB dr 50mg 200's pack 400\n\tIncepta\tMebastin TAB dr 50mg 100's pack 200\n\tMedimet\tDayhista TAB dr 50mg 100's pack 250\n\tOpsonin Pharma\tMedrolin TAB dr 50mg 100's pack 150\n\tSquare\tIncidal TAB dr 50mg 200's pack \n\tIndication: Allergic conditions\n\nDose: Adults and children over 10 years: 2-6 tablets daily\nChildren 5-10 years: 2-4 tablets daily\nChildren 2-5 years: 1-3 tablets daily\nChildren upto 2 years: 1-2 tablets daily\n\n\nContra-indication: Premature infants and neonates. Acute asthmatic attack.\n\nSide effects: CNS depression; paradoxical stimulation (high doses, children or elderly); headache, psychomotor impairment; dry mouth, thickened respiratory tract secretions, blurred vision; urinary difficulty or retention, constipation, increased gastric reflux; nausea, vomiting, diarrhoea, epigastric pain. Rarely, blood disorders. Convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, tremor, sleep disturbances, depression, confusion, tinnitus, hypotension, hair loss.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Closed-angle glaucoma; urinary retention, prostatic hyperplasia or pyloroduodenal obstruction; epilepsy. Elderly. Pregnancy. May impair ability to drive or operate machinery.\n\nMode of action: Enhanced sedation with alcohol or other CNS depressants. Additive antimuscarinic effects with MAOIs, atropine, TCAs. May mask warning symptoms caused by ototoxic agents e.g. aminoglycoside antibiotics.\n\nPregnancy category: Not Classified\n\nInteraction: Enhanced sedation with alcohol or other CNS depressants. Additive antimuscarinic effects with MAOIs, atropine, TCAs. May mask warning symptoms caused by ototoxic agents e.g. aminoglycoside antibiotics.
Meclizine Hydrochloride	\n\n\tAd-din\tMeczin TAB dr 50mg 50's pack 125\n\tAd-din\tMelizin TAB dr 10mg 50's pack 125\n\tAristopharma\tAcliz TAB dr 50mg 100's pack 250\n\tBeximco\tVomec TAB dr 50mg 50's pack 125\n\tBio Pharma Ltd.\tAvert TAB dr 50mg 50's pack 125.50\n\tChemist Ltd.\tAntivert TAB dr 50mg 100's pack 250\n\tDrug International Ltd.\tNomosic TAB dr 50mg 50's pack 125\n\tEskayef Bangladesh Ltd.\tEmezin TAB dr 50mg 50's pack 125\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAnosea TAB dr 50mg 50's pack 130\n\tIncepta\tEmenil TAB dr 50mg 100's pack 250\n\tOpsonin Pharma\tEmego TAB dr 50mg 50's pack 110\n\tPeoples Pharma Ltd.\tClizin TAB dr 50mg 100's pack 250\n\tSquare\tVertina TAB dr 50mg 50's pack 125.69\n\tIndication: Motion sickness, Vertigo and Vestibular disorders\n\nDose: Adult and Children 12 years of age & over: Nausea and vomiting: 25-50 mg daily or as directed by a physician.\nMotion sickness: Take an initial dose of 25-50 mg, 1 hour prior to travel. May repeat the dose every 24 hours for the duration of the journey.\nRadiation sickness: 50 mg administered 2-12 hours prior to radiation treatment.\nVertigo: 25-100 mg daily in divided doses.\nPrevention of nausea and vomiting associated with emergency contraceptive pill (ECP) : 25-50 mg, 1 hour before first ECP dose; repeat if needed in 24 hours.\nThe safety and efficacy for use in children less than 12 years of age have not been established. \n\nContra-indication: Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.\n\nSide effects: Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.\n\nPrecaution: Patients should be warned that Meclizine Hydrochloride may impair their ability to perform hazardous activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle). Patients should avoid alcoholic beverages while taking this drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.\n\nMode of action: Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.\n\nPregnancy category: B\n\nInteraction: Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
Meclizine Hydrochloride + Pyridoxine Hydrochloride	\n\n\tACI\tPyrimac TAB dr  50mg+25mg 50's pack 151\n\tAcme Ltd.\tNVP TAB dr  25 mg + 50 mg 50's pack 150\n\tAlco Pharma\tV-Nil TAB dr   50's pack 150\n\tAmulet\tPyrizin TAB dr   50's pack 150\n\tApex\tEmenor TAB dr   50's pack 125\n\tAristopharma\tAcliz PLUS TAB dr   100's pack 300\n\tAsiatic Ltd.\tAsivert 50 TAB dr   5x10's pack 150\n\tBeacon\tXmec TAB dr   50's pack 150.50\n\tBeximco\tVomic Plus TAB dr   50's pack 150\n\tBio Pharma Ltd.\tAvert Plus TAB dr   50's pack 150\n\tCosmic Chemical Industries Ltd.\tOptimin TAB dr   50's pack 150\n\tEskayef Bangladesh Ltd.\tEmezin Plus TAB dr   50's pack 150\n\tGeneral\tMeclixine TAB dr   50's pack 125\n\tGeneral\tMaclixine TAB dr  50's pack 150.50\n\tHealthcare\tNomesis TAB dr   50's pack 175\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAnosea Plus TAB dr   50's pack 150\n\tIncepta\tEmenil PLUS TAB dr   100's pack 300\n\tMedicon\tMecpy TAB dr   50's pack 150\n\tMonicopharma\tAncliz TAB dr   50's pack 150\n\tNavana\tMEC-P TAB dr   50's pack 150.50\n\tNIPRO JMI Pharma\tMecliz Plus TAB dr 25 mg + 50 mg  \n\tNovo Healthcare and Pharma Ltd.\tAvonex TAB dr   30's pack 75\n\tOpsonin Pharma\tEmego PLUS TAB dr   50's pack 150\n\tOrion Pharma Ltd.\tAnvert TAB dr 25 mg + 50 mg  \n\tPharmasia Ltd.\tAntinos TAB dr   50's pack 175\n\tSharif\tS-Vom TAB dr   50's pack 150\n\tSilva\tDevomit TAB dr  50's pack 150.57\n\tSquare\tVertina Plus TAB dr   50's pack 150.29\n\tIndication: Nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of vestibular motion sickness, radiation sickness and vertigo associated with diseases of vestibular system, morning sickness during pregnancy, drug induced nausea, vomiting induced by oral contraceptives or Estrogen preparations. \n\nDose: Adult: PO: As combination preparation containing meclozine 25 mg and pyridoxine 50 mg per tablet: 1 tablet at night.\n\nContra-indication: Meclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.\n\nSide effects: Drowsiness, thickening of bronchial secretions, dry mouth, fatigue, blurred vision.\n\nPrecaution: Prostate hypertrophy, obstruction of bladder neck, narrow angle glaucoma, pyloric stenosis. May impair ability to drive or operate machinery. Pregnancy.\n\nMode of action: Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.\n\nPregnancy category: A\n\nInteraction: Additive effects with CNS depressants, neuroleptics, anticholinergics, alcohol.
Mecobalamin	\n\n\tACI\tPhyton TAB dr .5mg 50's pack 201\n\tACI\tPhyton Injection .5mg/ml 50's pack 150.55\n\tAcme Ltd.\tMB 12 Injection 0.5mg/ml 5 amps pack 150.55\n\tAcme Ltd.\tMB 12 TAB dr 0.5mg 30's pack 120.30\n\tApex\tNervo 12 TAB dr 0.5mg  50's pack 200\n\tAristopharma\tMecol TAB dr 0.5mg 50's pack 200\n\tDrug International Ltd.\tMecolin TAB dr 0.5mg 50's pack 200\n\tEskayef Bangladesh Ltd.\tMecopen F/C TAB dr 0.5mg 50's pack 200\n\tGeneral\tMecobal TAB dr 0.5mg 50's pack 175\n\tGlobe\tPedial TAB dr .5mg 50's pack 200\n\tHealthcare\tNeural TAB dr .5mg 30's pack 127.50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRemylin TAB dr .5mg 30's pack 135\n\tIncepta\tMecolagin TAB dr 0.5mg 60's pack 240\n\tIncepta\tMecolagin Injection 0.5mg/ml 5 amps pack 150\n\tOpsonin Pharma\tNerviton TAB dr 0.5mg 50's pack 200\n\tOpsonin Pharma\tNerviton Injection 0.5mg/ml 5 amps pack 150\n\tOrion Pharma Ltd.\tNervex TAB dr 0.5mg 50's pack 201\n\tOrion Pharma Ltd.\tNervex Injection 0.5mg/ml 50's pack \n\tPeoples Pharma Ltd.\tMecomin TAB dr 0.5mg 50's pack 175.05\n\tSquare\tMethicol TAB dr 0.5mg 60's pack 241\n\tSquare\tMethicol 10 Injection 0.5mg/ml  5 amps pack 150.55\n\tWhite Horse Pharma\tMeclon TAB dr 0.5mg 50's pack 200\n\tIndication: Megaloblastic anaemia, Peripheral neuropathies\n\nDose:  Tablet :The usual adult dosage is one 500 mcg tablet three times daily. The dosage should be adjusted according to the age of patient and the severity of symptoms.\n\nInjection :Peripheral neuropathies: The usual adult dosage is one ampoule equivalent to 500 mcg of Mecobalamin, administered intramuscularly or intravenously three times a week.The dosage should be adjusted according to the age of patient and the severity of symptoms.\n\nMegaloblastic anemia: The usual adult dosage is one ampoule equivalent to 500 mcg of Mecobalamin, administered intramuscularly or intravenously three times a week. After about two months of administration, dosage should be changed to one ampoule equivalent to 500 mcg of Mecobalamin every one to three months as maintenance therapy\n\nContra-indication: Hypersensitivity to any component of this product.\n\nSide effects:  Generally Mecobalamin is well tolerated. However, a few side effects like GI discomfort (including anorexia, nausea or diarrhea) & rash may be seen after administration of Mecobalamin.\n\nPrecaution: The medicine should not be used for months if there is no response at all after its use for a certain period of time.\n\nMode of action: Decreased GI tract absorption with neomycin, aminosalicylic acid, H2-blockers and colchicine. Reduced serum concentrations with oral contraceptives. Reduced effects in anaemia with parenteral chloramphenicol.\n\nPregnancy category: Not Classified\n\nInteraction: Decreased GI tract absorption with neomycin, aminosalicylic acid, H2-blockers and colchicine. Reduced serum concentrations with oral contraceptives. Reduced effects in anaemia with parenteral chloramphenicol.
Mefenamic Acid	\n\n\tBeximco\tFenamic CAP 250mg 100's pack 201\n\tBeximco\tFenamic Suspension 50mg/5ml 60ml bot 15\n\tBeximco\tFenamic TAB dr 500mg 30's pack 114.60\n\tCosmic Chemical Industries Ltd.\tMefalgin Suspension 50mg/5ml 60ml bot 22\n\tCosmic Chemical Industries Ltd.\tMefalgin TAB dr 250mg 100's pack 175\n\tCosmic Chemical Industries Ltd.\tMefalgin TAB dr 500mg 100's pack 250\n\tDrug International Ltd.\tFenaton TAB dr 500mg 100's pack 150\n\tEverest\tNam TAB dr 250mg 100's pack 120\n\tEverest\tNam TAB dr 500mg 50's pack 117.50\n\tGlobe\tFlamic Suspension 50mg/5ml 60ml bot 22\n\tGlobe\tFlamic TAB dr 250mg 100's pack 125\n\tGlobe\tFlamic TAB dr 500mg 50's pack 125\n\tOpsonin Pharma\tAmifen Suspension 50mg/5ml 60ml bot 80\n\tOpsonin Pharma\tAmifen TAB dr 250mg 100's pack 280\n\tOpsonin Pharma\tAmifen TAB dr 500mg 50's pack 250\n\tPacific\tHPR Suspension 50mg/5ml 60ml bot 40\n\tPacific\tHPR TAB dr 250mg 100's pack 280\n\tPacific\tHPR DS TAB dr 500mg 50's pack 290\n\tRAK\tMefepain TAB dr 250mg 100's pack 200\n\tRAK\tMefepain TAB dr 500mg 50 150\n\tRenata\tDysmen TAB dr 250mg 100's pack 280\n\tRenata\tDysmen TAB dr 500mg 50's pack 250\n\tRephco\tflunil Suspension 50 mg/5 ml  \n\tSalton\tMefa Suspension 50mg/5ml 100ml bot 28.10\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Dysmenorrhoea, Menorrhagia, Dental pain, Pain and inflammation, Mild to moderate pain, Postoperative pain\n\nDose: Oral\nRheumatoid arthritis, Mild to moderate pain, Dental pain, Postoperative pain, Dysmenorrhoea, Osteoarthritis, Menorrhagia\nAdult: 500 mg tid.\nChild: >6 mth 25 mg/kg daily in divided doses for up to 7 days.\n\nContra-indication: Inflammatory bowel disease; peptic ulcer; neonates; pregnancy (3rd trimester), lactation. Coronary artery bypass graft surgery, severe renal impairment, severe heart failure.\n\nSide effects: Abdominal pain, dyspepsia, constipation, diarrhoea, nausea, GI ulcers; oedema; bronchospasm; headache, drowsiness, insomnia, visual disturbances; CHF, hypertension, tachycardia, syncope; urticaria, rash; thrombocytopenia, aplastic anaemia, agranulocytosis; tinnitus; elevated liver enzymes; abnormal renal function.\nPotentially Fatal: Autoimmune haemolytic anaemia; convulsions (overdosage).\n\nPrecaution:  	Renal and hepatic impairment, asthma. Monitor blood counts and liver function during long-term therapy. Drowsiness may affect ability to perform skilled tasks. Elderly.\n\nMode of action: Concomitant use w/ CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events w/ aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.\n\nPregnancy category: D\n\nInteraction: Concomitant use w/ CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events w/ aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.
Mefloquine	\n\n\tACI\tMeflon TAB dr 250mg 100's pack 3961\n\tRenata\tMef-Q TAB dr 250mg  100's pack 3200\n\tIndication: Malaria\n\nDose: Adult: PO Malaria As base: 20-25 mg/kg as a single dose or in 2-3 divided doses 6-8 hrly. Max: 1.5 g/dose. Malaria prophylaxis 250 mg/wk taken 1-3 wk before exposure and continuing for 4 wk after leaving the malarious area.\n\nContra-indication: Treatment with quinine during the preceding 12 hr. Prophylaxis in patients with history of psychiatric illness, seizure, hepatic disorder. Co-admin with halofantrine due to increased risk of cardiac arrhythmias.\n\nSide effects: Nausea, vomiting, abdominal pain, diarrhoea; dysphoria, dizziness; headache; sleep disorders; vertigo; neuropsychiatric reactions; bradycardia; visual/auditory disturbances; pruritus; sialorrhea, arthralgia and fatigue; syncope; extrasystole.\nPotentially Fatal: Seizures, thrombocytopenia, leucopenia, AV block, encephalopathy.\n\nPrecaution: Epilepsy; delay admin until at least 12 hr after the last dose of quinine/quinine-related compounds (monitoring of cardiac and neurological functions is warranted). Avoid driving or operating machines during and up to 3 wk after mefloquine use. Pregnancy, lactation; cardiac conduction disturbances; children <3 mth or 5 kg.\n\nMode of action: Increased risk of ECG abnormalities w/ quinine or chloroquine, antihistamines, TCAs and phenothiazines. May increase risk of seizure w/ quinidine or quinine. Concomitant use w/ valproic acid, phenobarbital, carbamazepine and phenytoin may cause loss of seizure control and lower plasma levels of anticonvulsants. Increased risk of QT prolongation and arrhythmia w/ ketoconazole. Concomitant use w/ digoxin, Ca-channel blockers, antiarrhythmics and ?-blockers may increase the risk of cardiotoxicity. Increased risk of ventricular arrhythmias w/ amiodarone. Concomitant use w/ TCAs, SSRIs, buprion, antipsychotic, tramadol may increase the risk of convulsions. Increased plasma levels w/ metoclopromide. May compromise adequate immunisation by live typhoid vaccine. Vaccinations w/ attenuated live bacteria should be completed at least 3 days prior the 1st dose of mefloquine.\nPotentially Fatal: Avoid concomitant use w/ halofantrine as potentially fatal cardiac arrhythmias may occur.\n\nPregnancy category: C\n\nInteraction: Increased risk of ECG abnormalities w/ quinine or chloroquine, antihistamines, TCAs and phenothiazines. May increase risk of seizure w/ quinidine or quinine. Concomitant use w/ valproic acid, phenobarbital, carbamazepine and phenytoin may cause loss of seizure control and lower plasma levels of anticonvulsants. Increased risk of QT prolongation and arrhythmia w/ ketoconazole. Concomitant use w/ digoxin, Ca-channel blockers, antiarrhythmics and ?-blockers may increase the risk of cardiotoxicity. Increased risk of ventricular arrhythmias w/ amiodarone. Concomitant use w/ TCAs, SSRIs, buprion, antipsychotic, tramadol may increase the risk of convulsions. Increased plasma levels w/ metoclopromide. May compromise adequate immunisation by live typhoid vaccine. Vaccinations w/ attenuated live bacteria should be completed at least 3 days prior the 1st dose of mefloquine.\nPotentially Fatal: Avoid concomitant use w/ halofantrine as potentially fatal cardiac arrhythmias may occur.
Melatonin	\n\n\tSquare\tFilfresh TAB dr 3mg 20's pack 90.18\n\tIndication: Disturbed biorhythms, Sleep disorders, Insomnia, Osteoporosis, In menopause to regulate sleep patterns in peri or postmenopausal women, To correct the symptoms of anorexia, Attention Deficit Hyperactivity Disorder in Children, In sarcoidosis and jet lag.\n\nDose: Adult: Insomnia: 3-6 mg one hour before bedtime Jet lag: 0.5 to 5 mg one hour prior to bedtime at final destination or, 1 to 5 mg 1 hour before bedtime for 2 days prior to departure and for 2 to 3 days upon arrival at final destination.\n\nSarcoidosis: 20 mg per day for 4 to 12 months. \n\nDepression: 0.125 mg twice in the late afternoon, each dose 4 hours apart. Difficulty falling asleep: 5 mg 3 to 4 hours before an imposed sleep period over a 4-week period. Children (6 months to 14 years of age with sleep disorders): 0.3 mg/day \n\nContra-indication: Pregnancy and lactation.\n\nSide effects: Increased seizure activity; drowsiness, headache. Disruption of normal circadian rhythm. May worsen symptoms for individuals with depression.\n\nPrecaution:  May impair ability to drive or operate machinery. Epilepsy\n\nMode of action: Quinolones; carbamazepine, rifampicin; fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, cigarette smoking, oestrogens. Alcohol; zalepon, zolpidem, zopiclone; thioridazine, imipramine.\n\nPregnancy category: Not Classified\n\nInteraction: Quinolones; carbamazepine, rifampicin; fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, cigarette smoking, oestrogens. Alcohol; zalepon, zolpidem, zopiclone; thioridazine, imipramine.
Meloxicam	\n\n\tSquare\tMelcam TAB dr 15mg 50's pack 200.83\n\tSquare\tMelcam TAB dr 7.5mg 100's pack 251.37\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis\n\nDose: Rheumatoid arthritis\nAdult: 15 mg daily as a single dose. Patients with increased risk of adverse effects: Initially 7.5 mg.\nElderly: 7.5 mg daily for long-term treatment.\n \nAnkylosing spondylitis\nAdult: 15 mg daily as a single dose. Patients with increased risk of adverse effects: Initially 7.5 mg.\nElderly: 7.5 mg daily for long-term treatment.\n \nAcute exacerbations of osteoarthritis\nAdult: 7.5 mg daily up to a max of 15 mg as a single dose.\nElderly: 7.5 mg daily.\n \nJuvenile rheumatoid arthritis\nChild: >2 yr: 125 mcg/kg ocne daily. Max dose: 7.5 mg daily.\n\n\nContra-indication: Hypersensitivity to meloxicam, aspirin or other NSAIDs; severe hepatic impairment; bleeding disorders; renal failure without dialysis. Rectal admin in patients with proctitis, haemorrhoids or rectal bleeding.\n\nSide effects: Dyspepsia, headache, nausea, diarrhoea, upper respiratory tract infection, abdominal pain, dizziness, oedema, flatulence, influenza-like symptoms, back pain, muscle spasms, musculoskeletal pain, rash, anaemia. GI perforation, ulceration and/or bleeding. In children: Abdominal pain, vomiting, diarrhoea, headache, pyrexia.\nPotentially Fatal: Stevens Johnson syndrome, thrombocytopenia, interstitial nephritis and idiosyncratic liver abnormality.\n\nPrecaution: History of GI disease, asthma, hypertension, CVD or risk factors, fluid retention or heart failure. Monitor patients with advanced renal disease. May impair ability to drive or operate machinery. Elderly. Pregnancy (avoid in the 3rd trimester) and lactation.\n\nMode of action: Increased risk of severe GI effects w/ aspirin or warfarin. May antagonise antihypertensive effects of ACE inhibitors and angiotensin II receptor antagonists. May reduce natriuretic effects of furosemide and thiazides. Enhanced toxicity of methotrexate. May increase plasma lithium concentration.\n\nPregnancy category: D\n\nInteraction: Increased risk of severe GI effects w/ aspirin or warfarin. May antagonise antihypertensive effects of ACE inhibitors and angiotensin II receptor antagonists. May reduce natriuretic effects of furosemide and thiazides. Enhanced toxicity of methotrexate. May increase plasma lithium concentration.
Memantine Hydrochloride	\n\n\tACI\tAbixa TAB dr 10mg 20's pack 200.60\n\tIncepta\tRemtin TAB dr 5mg 30's pack 300\n\tOrion Pharma Ltd.\tMemogen TAB dr 5mg 30's pack 240\n\tZiska\tDementa TAB dr 5mg 20's pack 200\n\tIndication: Alzheimer's dementia.\n\nDose: Oral\nModerate to severe dementia in Alzheimer's disease\nAdult: As hydrochloride: Initially, 5 mg daily in the morning for the 1st wk; increase dose wkly in steps of 5 mg. Max: 20 mg daily. Wait for at least 1 wk between dose changes. Doses >10 mg/day should be given in 2 divided doses. \n\nSuggested titration: 5 mg daily for >1 wk; 5 mg bid for >1 wk; 15 mg daily given in 5- and 10-mg separated doses for >1 wk; then 10 mg bid.\n\nRenal impairment:\nCrCl (ml/min)	\n40-60	Per 1.73 m2: Max dose: Reduce to 10 mg daily.\n\nContra-indication: Severe renal impairment.\n\nSide effects: Dizziness, confusion, headache, constipation, somnolence, hallucinations, tiredness, vomiting, anxiety, abnormal gait, hypertonia, cystitis and increased libido. Rarely, psychotic reactions, pancreatitis.\n\nPrecaution: Renal impairment; epilepsy. Pregnancy and lactation. Closely monitor patients with recent MI, uncompensated CHF, uncontrolled hypertension. Predisposition to convulsions; conditions that increase urinary pH.\n\nMode of action: May increase effects of antimuscarinics and dopaminergics. May reduce effects of antipsychotics and barbiturates. May alter effects of dantrolene, baclofen. Reduced clearance with carbonic anhydrase inhibitors and sodium bicarbonate.\nPotentially Fatal: Increased risk of adverse effects with amantadine, dextromethorphan or ketamine.\n\nPregnancy category: B\n\nInteraction: May increase effects of antimuscarinics and dopaminergics. May reduce effects of antipsychotics and barbiturates. May alter effects of dantrolene, baclofen. Reduced clearance with carbonic anhydrase inhibitors and sodium bicarbonate.\nPotentially Fatal: Increased risk of adverse effects with amantadine, dextromethorphan or ketamine.
Menthol 1% + Pramoxine Hydrochloride 1% Topical	\n\n\tIndication: Burns, Eczema, Contact dermatitis, Hemorrhoids, Insect bites, Skin irritations, Itching and pain, Anal pruritus\n\nDose:  Adults and children 2 years and older: apply to affected area up to 3 or 4 times daily\n\nchildren under 2 years: consult a doctor\n\nContra-indication:     Deep or puncture wounds\n    animals bites\n    serious burns\n    large areas of the body\n\n\nSide effects:   Redness, irritation, swelling or pain.\n\n\nPrecaution:     Do not get into eyes or nose and not for prolonged use.\n\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Menthol 10% + Methyl Salicylate 15% Topical	\n\n\tACI\tViscon 15 Cream  15%+10% 20gm tube 40.27\n\tACI\tViscon 30 Cream 30%+8% 20g tube 60.41\n\tAlco Pharma\tP-Cool Cream 15% / 10% 10gm tube / 25gm tube 25 / 40\n\tBeximco\tIcykool Cream   25 gm tube 40\n\tIncepta\tSalinix 15 Cream    20gm tube 40\n\tOpsonin Pharma\tKoolmint 15 Cream  1tube 35.19\n\tPopular\tSalirub Cream   20gm tube 35.13\n\tSquare\tPenrif 15 Cream   20gm tube 40.15\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Post-herpetic neuralgia, Anogenital pruritus, Congestion, Muscle aches, Sprains, Cold, Catarrh, Stiff neck, Low back pain, Spondylitis. Peripheral neuralgias: Diabetic neuropathy, Trigeminal neuralgia, Post surgical pains, Headache, Backache, Sprains, Rheumatism Strains, Tendonitis, Leg cramps\n\nDose: For external use only.\nAdult and children 2 years of age and older : Apply a thin layer to the affected area and gently massage until cream disappears. Apply to affected area not more than 3 to 4 times daily.\n\n\nContra-indication: Hypersensitivity to salicylate or any of its ingredients\n\nSide effects: Redness or irritation may occur, especially in persons with sensitive skin. Adverse reactions possibly involved are mild to moderate local irritation, erythema, rash, desquamation, pruritis and relative local reaction at the application site.\n\nPrecaution: Avoid contact with the eyes and mucous membranes. Do not bandage tightly, wrap or cover until washing the area. It should not be applied to wounds or damaged skin. It should not be used immediately after bath. Wash hand thoroughly after applying.\n\nMode of action: Warfarin.\n\nPregnancy category: C\n\nInteraction: Warfarin.
Menthol 10% + Methyl Salicylate 30% Topical	\n\n\tBeximco\tIcykool Max Cream   25 gm tube 60\n\tEskayef Bangladesh Ltd.\tXenthol 30 Cream   15gm tube 40\n\tIncepta\tSalinix 30 Cream  20gm tube  60\n\tMedicon\tInsta Cool Cream   25 gm tube 60\n\tOpsonin Pharma\tKoolmint 30 Cream  1tube 52.78\n\tPacific\tFastcut Cream Cream   20gm tube 60\n\tSharif\tBangay Cream (10 gm + 30 gm)/100 gm  \n\tSquare\tPenrif 30 Cream   20gm tube 60.22\n\tIndication: Headache, Backache, Sprains, Rheumatism Strains, Tendonitis, Leg cramps\n\nDose: For external use only.\nAdult and children 2 years of age and older : Apply a thin layer to the affected area and gently massage until cream disappears. Apply to affected area not more than 3 to 4 times daily.\n\n\nContra-indication: Hypersensitivity to salicylate or any of its ingredients\n\nSide effects: Redness or irritation may occur, especially in persons with sensitive skin. Adverse reactions possibly involved are mild to moderate local irritation, erythema, rash, desquamation, pruritis and relative local reaction at the application site.\n\nPrecaution: Avoid contact with the eyes and mucous membranes. Do not bandage tightly, wrap or cover until washing the area. It should not be applied to wounds or damaged skin. It should not be used immediately after bath. Wash hand thoroughly after applying.\n\nMode of action: Warfarin.\n\nPregnancy category: C\n\nInteraction: Warfarin.
Mepyramine Maleate 2% Topical	\n\n\tSanofi Aventis (BD) Ltd.\tAnthisan Cream   15gm  tube 35.03\n\tIndication: Pruritic skin disorders\n\nDose: Adult: Apply 2% cream on affected areas.\n\nContra-indication: Severe liver disease; premature infants or full-term neonates; eczema (topical).\n\nSide effects: Sedation; antimuscarinic effects, CNS depression and disturbances; occasionally, paradoxical CNS stimulation; psychomotor impairment; headache; palpitations and arrhythmias; convulsions, sweating, myalgia, paraesthesias, extrapyramidal symptoms, tremor, sleep and GI disturbances, hypersensitivity reactions and blood dyscrasias; hypotension; hair loss; tinnitus.\n\nPrecaution: Pregnancy; lactation; severe CV disorders; asthma; drowsiness; angle-closure glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction; renal and hepatic impairment; elderly; epilepsy. May affect ability to drive and operate machinery. Broken skin (topical).\n\nMode of action: increased effects with CNS depressants (e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and neuroleptics). Additive effects with other antimuscarinics (e.g. TCAs, atropine).\n\nPregnancy category: Not Classified\n\nInteraction: increased effects with CNS depressants (e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and neuroleptics). Additive effects with other antimuscarinics (e.g. TCAs, atropine).
Mercaptopurine	\n\n\tBeacon\tLeukin TAB dr 50mg 30's pack 600\n\tGlaxoSmithKline Bangladesh Ltd.\tPurinethol TAB dr 50mg 25's pack 1019\n\tExcella, Germany\tPuri-Nethol TAB dr 50mg 25's pack 1019\n\tIndication: Acute lymphatic leukaemia, Crohn's disease				\n\n\nDose: Oral\nAcute lymphatic leukaemia\nAdult: Usual maintenance dose: Initially, 1.5-2.5 mg/kg daily as a single dose, usually used in combination with methotrexate. Dose may vary individually based on response and tolerance. Monitor blood counts at least once wkly. Withdraw treatment immedietely if there is a sharp drop in the white cell count or severe bone-marrow depression. May resume treatment slowly and carefully if white cell count remains constant for 2-3 days or rises. Reduce dose when used with allopurinol.\nChild: Usual maintenance dose: Initially, 1.5-2.5 mg/kg daily as a single dose, usually used in combination with methotrexate. Dose may vary individually based on response and tolerance. Monitor blood counts at least once wkly. Withdraw treatment immedietely if there is a sharp drop in the white cell count or severe bone-marrow depression. May resume treatment slowly and carefully if white cell count remains constant for 2-3 days or rises. Reduce dose when used with allopurinol.\nHepatic impairment: Dosage may need to be reduced\n\nCrohn's disease\nAdult: Initially 1-1.5 mg/kg daily, may increase to 125 mg daily.\nChild: Initially 1-1.5 mg/kg daily increased to a max of 75 mg daily\n\nHepatic impairment: Dosage may need to be reduced.\n\n\nContra-indication: Pregnancy and lactation. Prior resistance to mercaptopurine or thioguanine; severe liver disease; severe bone marrow suppression.\n\nSide effects: Hyperuricaemia, bone marrow toxicity, hypoplasia, anorexia, diarrhoea, leukopenia, thrombocytopenia, intestinal ulceration, crystalluria with haematuria, immunosuppression, interstitial pneumonitis. Cutaneous hyperpigmentation, alopecia.\nPotentially Fatal: Myelosuppression; hepatotoxicity, cholestatic jaundice.\n\nPrecaution: Hepatic or renal dysfunction; monitor hepatic function periodically. Mercaptopurine is potentially carcinogenic. Thiopurine S-methyl transferase (TPMT) deficiency; porphyria.\n\nMode of action: Anticoagulant action of warfarin may be inhibited by mercaptopurine. Enhanced toxicity with myelosuppressive drugs.\nPotentially Fatal: Effects enhanced by allopurinol (reduce dose of mercaptopurine). Other hepatotoxic drugs (e.g. doxorubicin) potentiate toxicity.\n\nPregnancy category: D\n\nInteraction: Anticoagulant action of warfarin may be inhibited by mercaptopurine. Enhanced toxicity with myelosuppressive drugs.\nPotentially Fatal: Effects enhanced by allopurinol (reduce dose of mercaptopurine). Other hepatotoxic drugs (e.g. doxorubicin) potentiate toxicity.
Meropenem	\n\n\tACI\tAronem Injection 1gm/vial 1gm vial X 1's pack 1208.14\n\tACI\tAronem Injection 500mg/vial 500mg vial X 1's pack 654.41\n\tACI\tMeronem Injection 1g 1's pack 2113.50\n\tACI\tMeronem Injection 500mg 1's pack 1115\n\tAcme Ltd.\tFulspec IV Injection 1gm/vial 1gm vial X 1's pack 1204.53\n\tAcme Ltd.\tFulspec IV Injection 500mg/vial 500mg vial X 1's pack 652.46\n\tAristopharma\tAropen Injection 1gm/vial 1gm vial X 1's pack 1200\n\tAristopharma\tAropen IV Injection 500mg/vial 500mg vial X 1's pack 650\n\tBeacon\tMerocon Injection 1 gm/vial  \n\tBeacon\tMerocon Injection 500 mg/vial  \n\tBio Pharma Ltd.\tMepen Injection 1 gm/vial  \n\tBio Pharma Ltd.\tMepen Injection 500 mg/vial  \n\tConcord\tRosebac Injection 1 gm/vial  \n\tConcord\tRosebac Injection 500 mg/vial  \n\tDrug International Ltd.\tRopenem Injection 1gm/vial 1gm vial X 1's pack 960\n\tDrug International Ltd.\tRopenem Injection 500mg/vial 500mg vial X 1's pack 501.64\n\tEskayef Bangladesh Ltd.\tMeroject Injection 1gm/vial 1gm vial X 1's pack 1300\n\tEskayef Bangladesh Ltd.\tMeroject Injection 500mg/vial 500mg vial X 1's pack 700\n\tGeneral\tIntrapen Injection 500 mg/vial  \n\tGeneral\tIntrapen Injection 1 gm/vial  \n\tGlobe\tMerocar Injection 1gm/vial 1gm vial X 1's pack 1200\n\tGlobe\tMerocar Injection 500mg/vial 500mg vial X 1's pack 650\n\tHealthcare\tNeopenem Injection 1gm/vial 1gm vial X 1's pack 1250\n\tHealthcare\tNeopenem Injection 500mg/vial 500mg vial X 1's pack 650\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMeerotrax Injection .5g 1's pack \n\tIbn Sina Pharmaceutical Ind. Ltd.\tMeerotrax Injection 1g 1's pack \n\tIncepta\tI-Penam 1gm Injection 1gm/vial 1's pack 1300\n\tIncepta\tI-Penam 500mg Injection  1's pack 700\n\tNovo Healthcare and Pharma Ltd.\tMeronix IV Injection 1gm/vial 1gm vial X 1's pack 1200\n\tNovo Healthcare and Pharma Ltd.\tMeronix IV Injection 500mg/vial 500mg vial X 1's pack 650\n\tOpsonin Pharma\tRonem Injection 1gm/vial 1gm vial X 1's pack 1250\n\tOpsonin Pharma\tRonem Injection 500mg/vial 500mg vial X 1's pack 650\n\tOrion Pharma Ltd.\tMeromax I.V 	 Injection 500mg, 1 gm 1's pack / 1's pack 650 / 1200\n\tPharmacil Ltd.\tMerocil Injection 1 gm/vial  \n\tPharmacil Ltd.\tMerocil Injection 500 mg/vial  \n\tPharmasia Ltd.\tCarbabac IV Injection 500 mg/vial  \n\tPharmasia Ltd.\tCarbabac IV Injection 1 gm/vial  \n\tPopular\tMerobac Injection 1gm/vial 1gm vial X 1's pack 1204.53\n\tPopular\tMerobac Injection 500mg/vial 500mg vial X 1's pack 652.45\n\tRAK\tR-Penem Injection 1gm/vial 1's amps pack 1300\n\tRenata\tMeropen Injection 1gm/vial 1gm vial X 1's pack 1300\n\tRenata\tMeropen Injection 500mg/vial 500mg vial X 1's pack 700\n\tSanofi Aventis (BD) Ltd.\tCarbanem IV Injection 1gm/vial 1gm vial X 1's pack 1300\n\tSanofi Aventis (BD) Ltd.\tCarbanem IV Injection 500mg/vial 500mg vial X 1's pack 700\n\tSquare\tSpecbac Injection 1gm/vial 1gm vial X 1's pack 1204.53\n\tSquare\tSpecbac Injection 500mg/vial 500mg vial X 1's pack 652.45\n\tTechno Drugs Ltd.\tMerom Injection 1gm/vial 1gm vial X 1's pack 1200\n\tTechno Drugs Ltd.\tMerom Injection 500mg/vial 500mg vial X 1's pack 650\n\tVeritas\tVeronem Injection 1 gm/vial  \n\tVeritas\tVeronem Injection 500 mg/vial  \n\tIndication: Cystic fibrosis, Intra-abdominal infections, Meningitis, Skin and skin structure infections, Diabetic foot infection\n\nDose: Adult: IV Susceptible infections 0.5-1 g 8 hrly. Meningitis 2 g 8 hrly. Cystic fibrosis Up to 2 g 8 hrly. Skin infections 500 mg 8 hrly. Diabetic foot; Intra-abdominal infections 1 g 8 hrly.\n\nChildren: 3 months to 12 years. 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogen(s) and the condition of the patient.\nIntra-abdominal infections: 20 mg/kg every 8 hours.\nCystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours.\nMeningitis: 40 mg/kg IV every 8 hours.\n\nChildren over 50 kg weight: use adult dosage.\n\nRenal impairment:\nCrCl (ml/min)	\n26-50	Usual dose 12 hrly.\n10-25	Half the usual dose 12 hrly.\n<10	        Half the usual dose 24 hrly.\n\nHepatic impairment: No dosage adjustment needed.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment.\nPotentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome.\n\nPrecaution: History of hypersensitivity to carbapenem, pencillins or other ?-lactam antibiotics; infants <3 mth; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.\n\nMode of action: Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.\n\nPregnancy category: B\n\nInteraction: Increased plasma concentration w/ probenecid. May decrease plasma levels of valproic acid thus, increasing the risk of seizures.
Mesalazine	\n\n\tPharmasia Ltd.\tMesamin CAP 250mg 28's pack 280\n\tIndication: Ulcerative colitis, Hairy cell leukaemia\n\nDose: Adult: PO Ulcerative colitis Dose is dependant on preparation and brand used. Acute attack: Initially, up to 4 g/day in 2-3 divided doses; maintenance of remission: Initially, 1.5 g/day in 2-3 divided doses, adjust subsequently based on response. \n\nRenal impairment:\nCrCl (ml/min)	\n<20	 Avoid.\n\nHepatic impairment: Avoid in severe impairment.\n\n\n\nContra-indication: Hypersensitivity to mesalazine, salicylates and sulfasalazine. Severe impaired renal (CrCl < 20 ml/min) or hepatic function. Children <2 yr.\n\nSide effects: Abdominal pain (if new abdominal pain - consider pancreatitis); headache, nausea; flu; fatigue; fever, rash; sore throat; diarrhoea; joint pain; dizziness; bloating; back pain; haemorrhoids; itching; rectal pain, constipation; hair loss; intolerance syndrome; peripheral oedema; UTI; myocarditis, pre-existing pericarditis; pancreatitis; nephritis; hepatitis; lupus-like syndrome; alopecia; myalgia, arthralgia; increased liver enzyme values.\nPotentially Fatal: Blood dyscrasias, aplastic anaemia, agranulocytosis; renal toxicity.\n\nPrecaution: Mild to moderate impaired renal or hepatic function (test serum creatinine before treatment, every 3 mth for 1st yr, every 6 mth for next 4 yr, then annually). Elderly; active peptic ulcer; pregnancy, lactation; patients predisposed to pericarditis or myocariditis. Counsel patients to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise during treatment; perform blood count and stop treatment if blood dyscrasias suspected. Counsel patients taking delayed release tablets to report repeatedly unbroken or partially broken tablets in their faeces. Pyloric stenosis may delay release into colon.\n\nMode of action: Do not give with lactulose or other drugs which lower pH for they prevent release of mesalazine. May decrease digoxin absorption.\n\nPregnancy category: B\n\nInteraction: Do not give with lactulose or other drugs which lower pH for they prevent release of mesalazine. May decrease digoxin absorption.
Mesna Disulfide	\n\n\tSanofi Aventis (BD) Ltd.\tUromitexan Injection 400mg/4ml 15's pack 4474.50\n\tTechno Drugs Ltd.\tMesna Injection 400mg/4ml 4's pack 760\n\tBaxter Oncology Gmbh, Germany\tUromitexan Injection 400mg 15 amps pack 3628.25\n\tIndication: Urothelial toxicity\n\nDose: Intravenous\nProphylaxis against urothelial toxicity\nAdult: Refer to individual and local protocol. Dose calculated according to cytotoxic dose. Normally given at a dose >cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall. Administered either by short (15-30 minutes) or continuous (24 hr) infusion.\n\nContra-indication: Hypersensitivity to thiol-containing compounds.\n\nSide effects: Nausea, vomiting, colic, diarrhoea, anorexia, dyspepsia, unpleasant taste, constipation; headache, malaise, fatigue, depression, irritability, somnolence, hyperaesthesia, dizziness, confusion; rash, pruritus, generalised urticaria, alopecia, inj site reactions, flushing; leucopenia, thrombocytopenia, anaemia, granulocytopenia, chest pain, oedema (peripheral, facial and periorbital), hypotension, tachycardia, hypertension, increased heart rate, ST-segment elevation; dyspnoea, coughing, pneumonia, tachypnea; fever; hypocalcaemia; increased sweating; back pain, limb pain, myalgia; increased hepatic enzyme concentrations; pharyngitis; ulceration of mucous membranes. In patients receiving oral and/or IV mesna and were specifically not treated with concurrent cytotoxic therapy: flatulence; rhinitis; rigors; back pain; rash; conjunctivitis; arthralgia. Inhalation: bronchospasm.\nPotentially Fatal: May cause haemorrhagic cystitis, systemic anaphylactic reactions.\n\nPrecaution: Protective effect applies only to the urinary tract; pregnancy, lactation. Patients with auto-immune disorders. IV formulation may contain benzyl alcohol as a preservative; avoid in neonates or infants. Instruct patients to seek medical attention if discolouration of urine occurs. During treatment, monitor urine for erythrocytes and haematuria. Maintain adequate hydration in all patients. Patients who vomit within 2 hr of oral dose should repeat dose or receive IV dose.\n\nMode of action: Mesna is incompatible in vitro with cisplatin and nitrogen mustard.\n\nPregnancy category: B\n\nInteraction: Mesna is incompatible in vitro with cisplatin and nitrogen mustard.
Metamizol	\n\n\tSanofi Aventis (BD) Ltd.\tNovalgin Injection 1gm/2ml 2ml amp x 25's pack 253.70\n\tIndication: Pain, Fever\n\nDose: Adults and children over 18 years: The usual dose is 1.25 g (2.5 ml) or 2.5 g (5 ml) once daily. The maximum daily dose is 4 g.\n\nContra-indication:     If you are allergic to metamizole and other pyrazolone derivatives\n    If you suffer from hepatic porphyria (an inherited disorder of porphyrin metabolism)\n    If you have a blood disorder (granulocytopenia)\n    If you have a congenital deficiency of the enzyme glucose-6 -phosphate dehydrogenase\n    During pregnancy and lactation\n    In children under 18 years\n\n\nSide effects: Allergic reactions that may occur are usually skin reactions: rash, redness, itching, swelling, gradually swelling of the face and tongue, and a lot more dangerous anaphylactic shock which has the following symptoms: itching, cold sweat, dizziness, lethargy, nausea, redness or paleness of skin and shortness of breath.\n\nMetamizole can cause damage to the bone marrow (granulocytopenia, agranulocytosis, hemolytic anemia, aplastic anemia). Cases of agranulocytosis are rare, but they are still very serious. Symptoms of agranulocytosis include: high fever, chills, sore throat, difficulty swallowing, inflammation of the mouth, nose, throat.\n\nMetamizole can cause digestive disorders such as nausea, vomiting, dry mouth, irritation of the digestive system. You can contact drowsiness, fatigue, weakness, headache, and hypotension, and wheezing.\n\nPrecaution:     Allergic reactions to aspirin and nonsteroidal anti-inflammatory drugs\n    asthma or chronic inflammation of the airways\n    Anaemia\n    The weakness of the kidney or liver\n    An ulcer in the stomach or duodenum\n    Heart disease and systolic blood pressure less than 100 mmHg and unstable circulation disorder (initial shock or heart attack)\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Metformin Hydrochloride	\n\n\tACI\tMetform TAB dr 500mg 100's pack 400\n\tACI\tMetform TAB dr 850mg 50's pack 300\n\tACI\tMetform ER 1000 TAB dr 1000mg 32's pack 288\n\tACI\tMetform ER 500 Extended Release TAB dr 500mg 50's pack 300\n\tAcme Ltd.\tDaomin TAB dr 500mg 100's pack 299\n\tAcme Ltd.\tDaomin TAB dr 850mg 40's pack 199.20\n\tAcme Ltd.\tDaomin XR TAB dr 500mg 50's pack 250\n\tAd-din\tGuamin TAB dr 850mg 50's pack 150\n\tAlbion Ltd.\tMetformin TAB dr 500 mg/ 850 mg  50's / 100's pack \n\tAlco Pharma\tMetmin TAB dr 850mg 100's pack 400\n\tAlco Pharma\tMetmin TAB dr 500mg 50's pack 100\n\tAmico Ltd.\tRuzmet TAB dr 500mg 30's pack 250\n\tApex\tPreform Oral Solution 500mg/5ml 100ml bot 60\n\tApex\tPreform TAB dr 850mg 100's pack 250\n\tApex\tPreform SR TAB dr 500mg 50's pack 200\n\tAristopharma\tGlucomet TAB dr 500mg 100's pack 300\n\tAristopharma\tGlucomet TAB dr 850mg 50's pack 200\n\tAristopharma\tGlucomet 500 XR TAB dr 500mg 50's pack 250\n\tAristopharma\tGlucomet 750 XR TAB dr 750mg 30's pack 210\n\tAsiatic Ltd.\tDiout TAB dr 850mg 50's pack 112.50\n\tBeximco\tInformet TAB dr 500mg 100's pack 250\n\tBeximco\tInformet TAB dr 850mg 60's pack 210\n\tBeximco\tInformet LA TAB dr 500mg 100's pack 500\n\tBeximco\tInformet LA 750 TAB dr 750mg  \n\tBeximco\tInformet LA 1000 TAB dr 1gm  \n\tBio Pharma Ltd.\tFormet TAB dr 500mg 100's pack 300\n\tBio Pharma Ltd.\tFormet TAB dr 850mg 50's pack 250\n\tBio Pharma Ltd.\tFormet XR TAB dr 500mg 50's pack 300\n\tBristol Pharma Ltd.\tInfo TAB dr 500mg 50's pack 100\n\tBristol Pharma Ltd.\tInfo TAB dr 850mg 50's pack 150\n\tConcord\tPolimet TAB dr 850mg 50's pack \n\tConcord\tPolimet TAB dr 500mg  \n\tDecent Pharma Ltd.\tD-Fo TAB dr 850mg 30's pack 75\n\tDelta Pharma\tObid TAB dr 500mg 100's pack 300\n\tDelta Pharma\tObid TAB dr 850mg 30's pack 150\n\tDoctor's Chemicals Works Ltd.\tMetfen TAB dr 500mg 100's pack 250\n\tDoctor's Chemicals Works Ltd.\tMetfen TAB dr 850mg 50's pack 175\n\tDrug International Ltd.\tOramet TAB dr 500mg 100's pack 250\n\tDrug International Ltd.\tOramet SR TAB dr 500mg 50's pack 210\n\tDrug International Ltd.\tOramet TAB dr 850mg 100's pack 400\n\tEdruc Ltd.\tG Phase TAB dr 850mg 30's pack 90\n\tEskayef Bangladesh Ltd.\tGlunor TAB dr 500mg 50's pack 100\n\tEskayef Bangladesh Ltd.\tGlunor TAB dr 850mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tGlunor XR TAB dr 500mg 50's pack 200\n\tEuro Pharma Ltd.\tObemet TAB dr 500mg 100's pack 200\n\tEuro Pharma Ltd.\tObemet TAB dr 850mg 50's pack 200\n\tGeneral\tSugamet TAB dr 500mg 100's pack 300\n\tGeneral\tSugamet TAB dr 850mg 100's pack 450\n\tGlobe\tSucomet TAB dr 500mg 100's pack 250\n\tGlobe\tSucomet TAB dr 850mg 50's pack 150\n\tGonoshasthaya\tG-Metformin TAB dr 500mg 30's pack 48\n\tGonoshasthaya\tG-Metformin TAB dr 850mg 30's pack 75\n\tGuardian Healthcare Ltd.\tMetguard TAB dr 500mg  \n\tHealthcare\tGlymin TAB dr 500mg 50's pack 75\n\tHealthcare\tGlymin TAB dr 850mg 40's pack 120\n\tHealthcare\tGlymin XR TAB dr 500mg 50's pack 230\n\tHudson\tHi-Met TAB dr 850mg 100's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tInsimet TAB dr 500mg 100's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tInsimet TAB dr 850mg 50's pack 200\n\tIbn Sina Pharmaceutical Ind. Ltd.\tInsimet 500 XR TAB dr 500mg 5x10's Pack 5\n\tIncepta\tNobesit TAB dr 500mg 50's pack 125\n\tIncepta\tNobesit TAB dr 850mg 60's pack 270\n\tIncepta\tNobesit XR 1 TAB dr 1gm 30's pack 210\n\tIncepta\tNobesit XR TAB dr 500mg 50's pack 250\n\tJayson\tMeforex TAB dr 500mg 50's pack 150\n\tJayson\tMeforex TAB dr 850mg 50's pack 250\n\tKemiko\tKemin TAB dr 500mg 50's pack 125\n\tKemiko\tKemin TAB dr 850mg 50's pack 200\n\tLeon\tOnmet 500 TAB dr 500mg  150\n\tLeon\tOnmet 850 TAB dr 850mg  150\n\tMedicon\tMetnil TAB dr 500mg 100's pack 200\n\tMedimet\tDia M TAB dr 500mg 50's pack 55\n\tMedimet\tDia M TAB dr 850mg 50's pack 125\n\tMedimet\tDia M SR TAB dr 500mg 50's pack 100\n\tMillat\tGlimet TAB dr 850mg 30's pack 120\n\tMystic\tDiafre TAB dr 500mg 100's pack 150\n\tMystic\tDiafre TAB dr 850mg 50's pack 150\n\tNational Ltd.\tHimet TAB dr 850mg 100's pack 300\n\tNavana\tNV-Met TAB dr 500mg 50's pack 150\n\tNavana\tNV-Met TAB dr 850mg 50's pack 200\n\tNavana\tNV-Met 500 SR TAB dr 500mg 50's pack 200\n\tNIPRO JMI Pharma\tGlucomin 500 TAB dr 500mg 50's pack 200\n\tNIPRO JMI Pharma\tGlucomin 850 TAB dr 850mg 50's pack 300\n\tNovartis (Bangladesh) Ltd.\tEtform TAB dr 500mg 100's pack 320\n\tNovartis (Bangladesh) Ltd.\tEtform TAB dr 850mg 50's pack 275\n\tOpsonin Pharma\tMet TAB dr 500mg 30's pack 79.17\n\tOpsonin Pharma\tMet XR TAB dr 500mg 50's pack 200\n\tOpsonin Pharma\tMet XR TAB dr 750mg 30's pack 158.87\n\tOpsonin Pharma\tMet TAB dr 850mg 30's pack 131.95\n\tOrion Pharma Ltd.\tOrmin TAB dr 500mg 50's pack 150\n\tOrion Pharma Ltd.\tOrmin TAB dr 850mg 50's pack 250.50\n\tPacific\tMetfo TAB dr 500mg 100's pack 400\n\tPacific\tMetfo TAB dr 850mg 30's pack 180\n\tPacific\tMetfo XR TAB dr 500mg 50's pack 350\n\tPacific\tMetfo XR TAB dr 750mg  \n\tPharmadesh Ltd.\tPimin TAB dr 500mg 100's pack 250\n\tPharmadesh Ltd.\tPimin TAB dr 850mg 30's pack 105.30\n\tPopular\tMetarin TAB dr 500mg 30's pack 75.29\n\tPopular\tMetarin TAB dr 850mg 30's pack 120.62\n\tPrime\tDiaformin TAB dr 500mg  \n\tPrime\tDiaformin TAB dr 850mg  \n\tRAK\tMeforin TAB dr 500mg 50's pack 100\n\tRAK\tMeforin TAB dr 850mg 50's pack 200\n\tRAK\tMeforin XR TAB dr 500mg 30's pack 150\n\tRenata\tBigmet TAB dr 500mg 100's pack 300\n\tRenata\tBigmet TAB dr 850mg 100's pack 400\n\tSanofi Aventis (BD) Ltd.\tMetsa TAB dr 500mg 100's pack 299.99\n\tSanofi Aventis (BD) Ltd.\tMetsa TAB dr 850mg 50's pack 250\n\tSharif\tM-Min TAB dr 500mg 50's pack 150\n\tSharif\tM-Min TAB dr 850mg 30's pack 135\n\tSilva\tGluphage XR TAB dr 500mg 50's pack 185.69\n\tSilva\tMetlife TAB dr 850mg 50's pack 200.75\n\tSilva\tMetlife TAB dr 500mg 100's pack 301\n\tSomatec\tMetomin TAB dr 850mg 50's pack 250\n\tSquare\tComet TAB dr 500mg 100's pack 300\n\tSquare\tComet TAB dr 750mg 60's pack 210\n\tSquare\tComet TAB dr 850mg 50's pack 225\n\tSquare\tComet XR TAB dr 1gm 30's pack 210\n\tSquare\tComet 1gm TAB dr 1gm 30's pack 150\n\tSquare\tComet XR TAB dr 500mg 50's pack 250\n\tSquare\tComet XR 1gm TAB dr 1gm 30's pack 210\n\tSupreme\tMetin TAB dr 500mg 50's pack 75\n\tSupreme\tMetin TAB dr 850mg 30's pack 148.80\n\tTechno Drugs Ltd.\tGlutec TAB dr 500mg 50's pack 150\n\tTechno Drugs Ltd.\tGlutec TAB dr 850mg 50's pack 250\n\tUnimed & Unihealth Manufacturers Ltd.\tMeglu ER TAB dr 500mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tMeglu TAB dr 850mg 30's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tMeglu TAB dr 500mg 30's pack 90\n\tUnimed & Unihealth Manufacturers Ltd.\tMeglu TAB dr 750mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tMeglu ER TAB dr 1gm  \n\tVirgo\tDiamin TAB dr 500mg 30's pack 150\n\tVirgo\tDiamin TAB dr 850mg 30's pack 90\n\tWhite Horse Pharma\tMetfar TAB dr 500mg 200's pack 150\n\tWhite Horse Pharma\tMetfar TAB dr 850mg 50's pack 250\n\tWhite Horse Pharma\tMetfar SR TAB dr 500mg 30's pack 120\n\tIndication: Polycystic ovarian syndrome, Type 2 DM\n\nDose: The usual starting dose is 500 mg twice daily or 850 mg once a day, given with meals. Dosage increase should be made in increments of 500 mg weekly or 850 mg every 2 weeks up to a total of 2000 mg per day, given in divided doses. \n\nPatients can be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For these patients requiring additional glycaemic control, metformin may be given to a maximum daily dose of 2550 mg per day. \n\nDoses above 2000 mg may be better tolerated when given three times a day with meals. The usual starting dose of Metformin HCl extended - release tablet is 500 mg once daily with the evening meal. Dosage increase may be made up to a max. of 2000 mg once daily with the evening meal.\n\nPolycystic ovary syndrome Initial: 500 mg/day in the morning for 1 wk, then 500 mg twice daily for 1 wk, then 1.5-1.7 g/day in 2-3 divided doses.\n\nContra-indication: Acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis). Renal failure, severe renal or hepatic impairment, acute conditions which may affect renal function e.g. dehydration, severe infection or shock. Cardiac failure, CHF, IDDM, severe impairment of thyroid function; acute or chronic alcoholism. Acute or chronic diseases which may cause tissue hypoxia e.g. cardiac or respiratory failure, recent MI or shock. Pregnancy, lactation. 	Adult: PO Type 2 DMInitial: 500 mg 2-3 times/day, may increase slowly. Max:2.25 g/day. Polycystic ovary syndrome Initial: 500 mg/day in the morning for 1 wk, then 500 mg twice daily for 1 wk, then 1.5-1.7 g\n\nSide effects: Anorexia, nausea, vomiting, diarrhoea, wt loss, flatulence, occasional metallic taste; weakness; hypoglycaemia; rash, malabsorption of vit B12. Chest discomfort, flushing, palpitation, chills, headache, lightheadedness, indigestion, abdominal discomfort. Potentially Fatal: Lactic acidosis in presence of renal failure and alcoholism. Patients may experience a metallic taste and there may be weight loss, which in some diabetics could be an advantage.\n\nPrecaution: Caution when used in patients with CHF especially in those with unstable or acute heart failure. Risk of lactic acid accumulation increases with the degree of renal impairment. May need to discontinue treatment in patients with stress-related states e.g. fever, trauma, infection or surgery. Metformin should be temporarily discontinued for 48 hr in patients undergoing radiologic studies involving intravascular admin of iodinated contrast materials. Elderly. Monitor renal function regularly. Because of possibility of hypoglycemia in combination therapy with a sulphonylurea or insulin, diabetic control should be monitored by blood sugar readings.\n\nMode of action: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.\n\nPregnancy category: B\n\nInteraction: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
Metformin Hydrochloride + Pioglitazone	\n\n\tACI\tPolitor 500 TAB dr   30's pack 270.90\n\tACI\tPolitor 850 TAB dr   30's pack 301.20\n\tBeximco\tCoDiaglit 500 TAB dr   30's pack 300\n\tBeximco\tCoDiaglit 850 TAB dr   30's pack 345\n\tIncepta\tCompimet 500 TAB dr   30's pack 270\n\tIncepta\tCompimet 850 TAB dr   30's pack 300\n\tOpsonin Pharma\tPiol M 500 TAB dr   20's pack 158\n\tOpsonin Pharma\tPiol M 850 TAB dr   20's pack 271\n\tPacific\tPiomin 500 TAB dr   30's pack 330\n\tPacific\tPiomin 850 TAB dr   30's pack 375\n\tSilva\tPiomet 500 TAB dr   30's pack 271.01\n\tSilva\tPiomet 850 TAB dr   30's pack 301.14\n\tSquare\tRezulin 500 TAB dr   30's pack 300\n\tSquare\tRezulin 850 TAB dr   30's pack 330\n\tUnimed & Unihealth Manufacturers Ltd.\tActomeg 500 TAB dr   20's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tActomeg 850 TAB dr   20's pack 200\n\tWhite Horse Pharma\tGlitamin 500 TAB dr   30's pack 270\n\tWhite Horse Pharma\tGlitamin 850 TAB dr   30's pack 300\n\tIndication: Type 2 DM\n\nDose: Dosage of this preparation must be individualized on the basis of effectiveness and tolerability while not exceeding the maximum recommended daily dose of Pioglitazone 45 mg and Metformin 2550 mg.  \n\nIt may be initiated at either the 15 mg/500 mg twice daily or 15 mg/850 mg once daily with meals to reduce the gastrointestinal side effects associated with Metformin and gradually titrated after assessing adequacy of therapeutic response.\n\nThe initial and maintenance dose of  it should be carefully selected in patients with advanced age due to the potential for decreased renal function in these populations. \n\nMonitoring of renal function is necessary to aid in prevention of Metformin associated lactic acidosis, particularly in the elderly.  It should not be initiated if the patients exhibit clinical evidence of active liver disease. Liver enzyme monitoring is recommended in all patients prior to initiation of therapy with combination of Pioglitazone and Metformin and periodically thereafter. \n\nContra-indication: 1. Renal disease or renal dysfunction (e.g. as suggested by serum creatinine levels >1.5 mg/dl in male, >1.4 mg/dl in females or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction and septicemia.\n2. Known hypersensitivity to Pioglitazone, Metformin or any other component of this combination.\n3. Acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma.\n\nSide effects: Generally this combined preparation is well tolerated. However, the most common side effects are upper respiratory tract infection, diarrhea, peripheral edema and headache, respectively. These are mild in severity.\n\nPrecaution: Pioglitazone exerts its antihyperglycemic effect only in the presence of insulin. Therefore, Pioglitazone should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Pioglitazone should be used with caution in combination especially with insulin, hepatic insufficiency and heart diseases.\n\nMetformin is known to be substantially excreted by the kidney and the risk of Metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus patients with serum creatinine levels above the upper limit of normal for their age should not receive this combination.\n\nMode of action: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.\n\nPregnancy category: A\n\nInteraction: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
Metformin Hydrochloride + Rosiglitazone	\n\n\tACI\tRotamin 2 TAB dr   30's pack 180\n\tACI\tRotamin 4 TAB dr   32's pack 255\n\tACI\tRotamin DS 2 TAB dr   32's pack 240\n\tACI\tRotamin DS 4 TAB dr   32's pack 320\n\tAristopharma\tArmomet 1 TAB dr   30's pack 120\n\tAristopharma\tArmomet 2 TAB dr   30's pack 180\n\tAristopharma\tAromet-1 TAB dr 500mg + 1mg 30's pack 120\n\tAristopharma\tAromet-2 TAB dr 500mg + 2mg 30's pack 180\n\tDelta Pharma\tRosimet 500/1 TAB dr   30's pack 120\n\tDrug International Ltd.\tOramet Plus TAB dr   50's pack 350\n\tGeneral\tMetiglit 500/1 TAB dr   30's pack 120.60\n\tGeneral\tMetiglit 2 TAB dr  30's pack 180.60\n\tPacific\tRogmet 2 TAB dr   30's pack 180\n\tPopular\tMetarin Plus 500/1 TAB dr  Rosiglitazone 1mg+ Metfo 30's pack 120.62\n\tSquare\tSensimet 4 TAB dr   30's pack 256.16\n\tSquare\tSensimet 500/1 TAB dr   30's pack 120.50\n\tSquare\tSensimet 500/2 TAB dr   30's pack 180.74\n\tSquare\tSensimet DS 1 TAB dr   30's pack 225.83\n\tSquare\tSensimet DS 2 TAB dr   30's pack 301.24\n\tWhite Horse Pharma\tRosimin 500/1 TAB dr   30's pack 120\n\tIndication: Type 2 DM\n\nDose: The dosage  should be individualized on the basis of effectiveness and tolerability while not exceeding the maximum recommended daily dose of 8mg/2000 mg (Rosiglitazone/Metformin).\n\n In Drug-Naive Patients: The recommended starting dose of  is 2 mg/500 mg once or twice daily. \n\nFor patients with HbA1c >11% or FPG>270 mg/dL, a starting dose of 2 mg/500 mg twice daily may be considered. The dose may be increased by increment of 2 mg/500 mg per day to a maximum of 8 mg/2,000 mg per day in divided doses if patients are not adequately controlled after 4 weeks.\n\nFor patients inadequately controlled on Metformin monotherapy, the usual starting dose  is 4 mg Rosiglitazone (daily dose) plus the dose of Metformin already being taken.\n\nFor patients inadequately controlled on Rosiglitazone monotherapy, the usual starting dose is 1000 mg Metformin (daily dose) plus the dose of Rosiglitazone already being taken.\n\nWhen switching from combination therapy of Rosiglitazone plus Metformin as separate tablets, the usual starting dose  is the dose of Rosiglitazone and Metformin already being taken. If additional glycemic control is needed, the daily dose may be increased by increment of 4 mg Rosiglitazone and/or 500 mg Metformin, up to the maximum recommended total daily dose of 8 mg/2000 mg.\n\nContra-indication: It is contraindicated in patients with renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels .1.5 mg/dl (males), 1.4 mg/dl (females), or abnormal creatinine clearance), acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma & known hypersensitivity to rosiglitazone maleate or metformin HCl.\n\nSide effects: Rosiglitazone: The commonly reported adverse events are upper respiratory tract infections, injury, headache, back pain, fatigue, sinusitis, diarrhoea and hypoglycemia. There were a small number of patients who had anemia and edema. All these events were generally mild to moderate in severity and usually do not require discontinuation of treatment with Rosiglitazone.\nMetformin: Some patients may develop asymptomatic subnormal levels of serum vitamin B12.\nIncidence of lactic acidosis is also very rare. Diarrhoea, nausea, vomiting, abdominal bloating, flatulence and anorexia are common reactions to Metformin.\n\nPrecaution: Rosiglitazone: should not be used in patients with type 1 diabetes. This should be used with caution in patients with edema. Dose-related weight gain was seen with rosiglitazone alone and rosiglitazone together with other hypoglycemic agents.\n\nMetformin: Monitoring of renal function: Patients with serum creatinine levels above the upper limit of normal should not receive this tablet. In patients with advanced age, the dose should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. \n\nMode of action: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.\n\nPregnancy category: A\n\nInteraction: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
Metformin Hydrochloride + Sitagliptin	\n\n\tACI\tSitomet TAB dr 50mg+1000mg 10's pack 180.50\n\tACI\tSitomet TAB dr 50mg+500mg 30's pack 481.50\n\tAcme Ltd.\tJanmet 1000 TAB dr   6's pack 108\n\tAcme Ltd.\tJanmet 500 TAB dr   6's pack 96\n\tBeximco\tGlipita M 1000/50 TAB dr   10's pack 420\n\tBeximco\tGlipta M 50/500 TAB dr   10's pack 390\n\tBeximco\tGlipita M 50/500 TAB dr  10's pack 250\n\tDelta Pharma\tSitalia M TAB dr 500 mg + 50 mg  \n\tDelta Pharma\tSitalia M TAB dr 1000 mg + 50 mg  \n\tDrug International Ltd.\tSliptin-M TAB dr  1000 mg + 50 mg 14's pack 280\n\tDrug International Ltd.\tSliptin-M 500 TAB dr  500 mg + 50 mg 12's pack 261\n\tDrug International Ltd.\tSliptin M-1000 ER Extended Release TAB dr 1000 mg + 50 mg  \n\tDrug International Ltd.\tSliptin M-500 ER Extended Release TAB dr 500 mg + 50 mg  \n\tIncepta\tSitagil M 50/1000 ER TAB dr 50 mg/1000 mg 18's pack 324\n\tIncepta\tSitagil M 50/500 ER TAB dr 50 mg/500 mg 20's pack 320\n\tIncepta\tSitagil M Extended Release TAB dr 1000 mg + 100 mg  \n\tPacific\tSGN Plus 500 TAB dr   12's pack\n 300\n\tPacific\tSGN 1000 TAB dr 1000mg  \n\tRenata\tSitamet TAB dr  3x10's pack \n\tSanofi Aventis (BD) Ltd.\tIncrit M TAB dr 50 mg/500 mg  400\n\tSanofi Aventis (BD) Ltd.\tIncrit M TAB dr 50 mg/1000 mg 30's pack 400\n\tSharif\tSitavia-M 50/1000 TAB dr 1000 mg + 50 mg  \n\tSharif\tSitavia-M 50/500 TAB dr 500 mg + 50 mg  \n\tSquare\tSiglimet 50/1000 TAB dr 1000 mg + 50 mg 10's pack  220\n\tSquare\tSiglimet 50/500 TAB dr  500 mg + 50 mg 10's pack 200\n\tSquare\tSiglimet XR Er TAB dr 500 mg + 50 mg  \n\tSquare\tSiglimet XR Er TAB dr 1000 mg + 50 mg  \n\tSquare\tSiglimet XR Er TAB dr 1000 mg + 100 mg  \n\tWhite Horse Pharma\tSigtil-M TAB dr  500 mg + 50 mg 20's pack 360\n\tWhite Horse Pharma\tSigtil TAB dr 1000 mg + 50 mg  \n\tIndication: Type 2 DM\n\nDose: Dose of this combination should be individualized on the basis of the patientâs current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg Sitagliptin and 2000 mg Metformin.\n\nSitagliptin/Metformin combination should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal (GI) side effects due to Metformin. \n\nThe recommended starting dose in patients not currently treated with Metformin is 50 mg Sitagliptin/500 mg Metformin hydrochloride twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with Metformin.\n\nThe starting dose in patients already treated with Metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of Metformin already being taken. \n\nFor patients taking Metformin 850 mg twice daily, the recommended starting dose of this combination is 50 mg Sitagliptin/1000 mg Metformin hydrochloride twice daily. May adjust the dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 100 mg Sitagliptin and 2000 mg Metformin extended release. Administer once daily with a meal preferably in the evening. Gradually escalate the dose to reduce the gastrointestinal side effects due to Metformin. \n\nMaintain the same total daily dose of Sitagliptin and Metformin when changing between Sitagliptin + Metformin ER, without exceeding the maximum recommended daily dose of 2000 mg Metformin extended release.\n\n\nContra-indication: â¢ Renal dysfunction, e.g., serum creatinine >1.5 mg/dL [males], >1.4 mg/dL [females] or abnormal creatinine clearance.â¢ Metabolic acidosis, including diabetic ketoacidosis.â¢ History of a serious hypersensitivity reaction (e.g., anaphylaxis or angioedema) to Sitagliptin + Metformin or to one of its components. \n\nSide effects: Headache, diarrhoea, upper respiratory tract infection, nasopharyngitis. Angioedema, exfoliative dermatitis, hypoglycaemia.\n\nPrecaution: Do not use the combination of Sitagliptin & Metformin in patients with hepatic disease. Before initiating the combination and at least annually thereafter, assess renal function and verify as normal. May need to discontinue the combination and temporarily use insulin during periods of stress and decreased intake of fluids and food as may occur with fever, trauma, infection or surgery.\n\nMode of action: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.\n\nPregnancy category: B\n\nInteraction: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
Metformin Hydrochloride + Vildagliptin	\n\n\tAcme Ltd.\tVildapin Plus TAB dr  500 mg + 50 mg 2x10's pack 320\n\tAcme Ltd.\tVildapin Plus TAB dr  850 mg + 50 mg 2x10's pack 340\n\tAlbion Ltd.\tRecleveus MET TAB dr 50 mg + 500 mg 30's pack \n\tAristopharma\tGalvan Plus 500 TAB dr   20's pack 420\n\tAristopharma\tGalvan Plus 850 TAB dr   20's pack 440\n\tAristopharma\tGluvan Plus 500 TAB dr 500mg 20's pack 420\n\tAristopharma\tGluvan Plus 850 TAB dr 850mg 20's pack \n\tDrug International Ltd.\tDialiptin M 850 TAB dr   14's pack 238\n\tDrug International Ltd.\tDialiptin-M 500 TAB dr   14's pack 224\n\tEskayef Bangladesh Ltd.\tVigamet TAB dr 850 mg + 50 mg  \n\tGeneral\tViptin Plus TAB dr 500mg 30's pack \n\tGeneral\tViptin Plus TAB dr 850 30's pack \n\tOpsonin Pharma\tVildamet TAB dr 50/500mg 20's pack 240\n\tOpsonin Pharma\tVildamet TAB dr 50/850mg 18 414\n\tPacific\tVida Plus 500 TAB dr   18's pack 396\n\tPacific\tVida Plus 850 TAB dr   20's pack\n 480\n\tPacific\tVida Plus 500 TAB dr 500 mg  \n\tPacific\tVida Plus 850 TAB dr 850 mg  \n\tSharif\tVildagil M 500 TAB dr   20's pack 400\n\tSharif\tVildagil M 850 TAB dr   20's pack 240\n\tSquare\tViglimet 50/500 TAB dr   20's pack\n 440\n\tSquare\tViglimet 50/850 TAB dr   20's pack 460\n\tWhite Horse Pharma\tGalet-M TAB dr   20's pack 360\n\tIndication: Type 2 DM\n\nDose: Adults: Based on the patient's current dose of Metformin, Combination of Vildagliptin & Metformin may be initiated at either 50 mg/500 mg or 50 mg/850 mg twice daily, 1 tab in the morning and the other in the evening. \n\nThe recommended daily dose is 100 mg Vildagliptin plus 2000 mg Metformin HCl. Patients receiving Vildagliptin and Metformin from separate tablets may be switched to Combination of Vildagliptin & Metformin containing the same doses of each component. Doses higher than 100 mg of Vildagliptin are not recommended. There is no clinical experience of Vildagliptin and Metformin in triple combination with other antidiabetic agents. \n\nTaking Combination of Vildagliptin & Metformin with or just after food may reduce gastrointestinal symptoms associated with Metformin.\n\n\nContra-indication: This combination is contraindicated in patients with known hypersensitivity to Vildagliptin or Metformin Hydrochloride or to any of the excipients. It is contraindicated in patients with renal disease or renal dysfunction, acute myocardial infarction, and septicaemia. It is also contraindicated in patients with congestive heart failure patients and in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. It should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function.\n\nSide effects: Hypoglycaemia, delayed gastric emptying, nausea and vomiting. Flu-like symptoms, headache and dizziness may occur.\nPotentially Fatal: Stevens-Johnson syndrome.\n\nPrecaution: Lactic acidosis can occur due to Metformin accumulation. If metabolic acidosis is suspected, treatment should be discontinued and the patient should be hospitalized immediately. \n\nPatients with renal impairment:\nThis combination should not be used in patients with renal failure or renal dysfunction, e.g. serum creatinine levels > 1.5 mg/dL (>135 micro mol/L) in males and > 1.4 mg/dL (>110 micro mol/L) in females.\n\nPatients with hepatic impairment:\nThis combination is not recommended in patients with hepatic impairment including patients with a pre-treatment ALT or AST >3 X the upper limit of normal. \n\nMode of action: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.\n\nPregnancy category: Not Classified\n\nInteraction: Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.\nPotentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
Methyl Ergometrine Maleate	\n\n\tChemist Ltd.\tUrgotin Injection 200mcg/ml 10 amps pack 30\n\tGonoshasthaya\tG Methyl Ergometrine TAB dr 125mcg 100's pack 57\n\tOpsonin Pharma\tMetherspan TAB dr 125mcg 100's pack 55\n\tOpsonin Pharma\tMetherspan Injection 200mcg/ml 25 amps pack 75\n\tIndication: Migraine, Miscarriage, Uterine hemorrhage, Spontaneous or elective abortion, Uterine atony, Second stage of labor\n\nDose: Oral:\nProphylaxis of postpartum haemorrhage\nAdult: 200 mcg 3-4 times daily in the puerperium for 2-7 days. \n\nIntramuscular\nTreatment and prophylaxis of postpartum and postabortal haemorrhage\nAdult: 200 mcg. May repeat every 2-4 hr. Max: 5 doses.\n\nIntravenous\nTreatment and prophylaxis of postpartum and postabortal haemorrhage\nAdult: As an emergency measure: 200 mcg by slow inj over at least 1 minute, may repeat every 2-4 hr, up to a max of 5 doses.\n\nContra-indication: Hypertension, eclamptic or previously hypertensive patients, heart disease, venoatrial shunts, mitral valve stenosis, obliterative vascular disease. Do not use in cases of threatened spontaneous abortion. Pregnancy.\n\nSide effects: Headache, dizziness, hallucinations; tinnitus; nausea, vomiting, foul taste, diarrhoea; hypertension, temporary chest pain, palpitations, bradycardia; nasal congestion, dyspnoea; diaphoresis; thrombophlebitis; haematuria; water intoxication; leg cramps; allergic reactions.\nPotentially Fatal: Shock.\n\nPrecaution: Captivation of the placenta may occur if given during the 2nd or 3rd stage of labour prior to delivery of the placenta; use in this situation should only be done by a qualified personnel. Avoid prolonged use. Caution in patients with sepsis, hepatic or renal impairment. Lactation.\n\nMode of action: None\n\nPregnancy category: X\n\nInteraction: 
Methylprednisolone	\n\n\tGeneral\tMethipred TAB dr 2mg 60's pack 180\n\tGeneral\tMethipred TAB dr 4mg 45's pack 225\n\tGeneral\tMethipred TAB dr 8mg  \n\tGeneral\tMethipred TAB dr 16mg  \n\tOpsonin Pharma\tDepodrol TAB dr 2mg  \n\tOpsonin Pharma\tDepodrol TAB dr 4mg  \n\tPharmasia Ltd.\tMelpred TAB dr 2mg  \n\tPharmasia Ltd.\tMelpred TAB dr 4mg  \n\tPharmasia Ltd.\tMelpred TAB dr 8mg  \n\tPharmasia Ltd.\tMelpred TAB dr 16mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tPredixa TAB dr 4mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tPredixa TAB dr 16mg 10's pack 240\n\tZiska\tSolupred TAB dr 4 mg 30's pack 150\n\tZiska\tSolupred TAB dr 16 mg 10's pack 150\n\tIndication: Methylprednisolone Tablets are indicated in the following conditions:\n\n1.Endocrine Disorders\n\n2.Rheumatic Disorders\n\n3.Collagen Diseases\n \n4.Dermatologic Diseases\n \n5.Allergic States\n\n6.Ophthalmic Diseases\n\n7.Respiratory Diseases\n\n8.Hematologic Disorders\n \n9.Neoplastic Diseases\n \n10.Edematous States \n\n11.Gastrointestinal Diseases\n\n12.Nervous System\n\n13.Miscellaneous\n   \n\nDose: The initial dosage of Methylprednisolone may vary from 5 mg to 60 mg of methylprednisolone per day depending on the specific disease entity being treated. \n\nIn situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Methylprednisolone should be discontinued and the patient transferred to other appropriate therapy.\n\nUse in children\nCorticosteroids cause growth retardation in infancy, childhood and adolescence, which may be irreversible. Treatment should be administered where possible as a single dose on alternate days.\n\nContra-indication: Systemic fungal infections and known hypersensitivity to components.\n\nSide effects:   Fluid and Electrolyte Disturbances\n\nSodium retention\n\nCongestive heart failure in susceptible patients\n\nHypertension\n\nFluid retention\n\nPotassium loss\n\nHypokalemic alkalosis\n\n \n\nMusculoskeletal\n\nMuscle weakness\n\nLoss of muscle mass\n\nSteroid myopathy\n\nOsteoporosis\n\nVertebral compression fractures\n\nAseptic necrosis of femoral and humeral heads\n\nPathologic fracture of long bones\n\n \n\nGastrointestinal\n\nPeptic ulcer with possible perforation and hemorrhage\n\nPancreatitis\n\nAbdominal distention\n\nUlcerative esophagitis\n\n \n\nDermatologic\n\nImpaired wound healing\n\nPetechiae and ecchymoses\n\nMay suppress reactions to skin tests\n\nThin fragile skin\n\nFacial erythema\n\nIncreased sweating\n\n \n\nNeurological\n\nIncreased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment\n\nConvulsions\n\nVertigo\n\nHeadache\n\n \n\nEndocrine\n\nDevelopment of Cushingoid state\n\nSuppression of growth in children\n\nSecondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness\n\nMenstrual irregularities\n\nDecreased carbohydrate tolerance\n\nManifestations of latent diabetes mellitus\n\nIncreased requirements for insulin or oral hypoglycemic agents in diabetics\n\n \n\nOphthalmic\n\nPosterior subcapsular cataracts\n\nIncreased intraocular pressure\n\nGlaucoma\n\nExophthalmos\n\n \n\nMetabolic\n\nNegative nitrogen balance due to protein catabolism\n\nThe following additional reactions have been reported following oral as well as parenteral therapy:\n\nUrticaria and other allergic, anaphylactic or hypersensitivity reactions.\n\nPrecaution: Caution is necessary when oral corticosteroids, including Prednisolone, are prescribed in patients with the following conditions like-Tuberculosis, Hypertension, Congestive heart failure, Liver failure, Renal insufficiency, Diabetes mellitus or in those with a family history of diabetes, Osteoporosis, Patients with a history of severe affective disorders and particularly those with a previous history of steroid-induced psychoses, Epilepsy, Peptic ulceration, Previous Steroid Myopathy.\n\nUndesirable effects may be minimized by using the lowest effective dose for the minimum period and by administering the daily requirement as a single morning dose on alternate days. Frequent patient review is required to titrate the dose appropriately against disease activity.\n\nMode of action: Decreases effect of anticholinesterases in myasthenia gravis. May decrease the hypoglycaemic effects of antidiabetic agents. Decreases serum concentrations of salicylates. Increased hypokalemic effects of potassium-depleting diuretics (thiazides or furosemide), amphotericin B, bronchodilator therapy with xanthines or ?2 agonists. Increase incidence of GI bleeding and ulceration with NSAIDs. May increase the anticoagulant effects of warfarin. Decreased levels/effects with CYP3A4 inducers (aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins). Increased levels/effects with CYP3A4 inhibitors (azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil). May decrease the effects of vaccines (dead organism) or increase the risk of vaccinal infection (live organism). Antacids and bile sequestrants may decrease the absorption of corticosteroids, separate admin by 2 hr. Increased risk of myopathy with neuromuscular-blocking agents, tendinopathies with fluoroquinolones.\n\nPregnancy category: C\n\nInteraction: Decreases effect of anticholinesterases in myasthenia gravis. May decrease the hypoglycaemic effects of antidiabetic agents. Decreases serum concentrations of salicylates. Increased hypokalemic effects of potassium-depleting diuretics (thiazides or furosemide), amphotericin B, bronchodilator therapy with xanthines or ?2 agonists. Increase incidence of GI bleeding and ulceration with NSAIDs. May increase the anticoagulant effects of warfarin. Decreased levels/effects with CYP3A4 inducers (aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins). Increased levels/effects with CYP3A4 inhibitors (azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil). May decrease the effects of vaccines (dead organism) or increase the risk of vaccinal infection (live organism). Antacids and bile sequestrants may decrease the absorption of corticosteroids, separate admin by 2 hr. Increased risk of myopathy with neuromuscular-blocking agents, tendinopathies with fluoroquinolones.
Methylprednisolone Acetate	\n\n\tAristopharma\tSolumed 40 Injection 40mg/ml 2's pack 150\n\tAristopharma\tSolumed 80 Injection 80mg/ml 2's pack 200\n\tChemist Ltd.\tUni-Medrol Injection 40mg/ml 2 vial's pack 130\n\tChemist Ltd.\tUni-Medrol Injection 80mg/ml 2ml vial x 2's pack 180\n\tDrug International Ltd.\tDepomed Injection 40mg/ml 3 vial's pack 225\n\tDrug International Ltd.\tDepomed Injection 80mg/ml 3 vial's pack 300\n\tIncepta\tCortan M Injection 40 mg/ml  \n\tIncepta\tCortan M Injection 80 mg/ml  \n\tOpsonin Pharma\tDepodrol Injection 40 mg/ml  \n\tTechno Drugs Ltd.\tMedrol Injection 40mg/ml 1ml vial x 5's pack 325\n\tTechno Drugs Ltd.\tMedrol Injection 80mg/ml 2ml vial x 1's pack 90\n\tZiska\tDepo-pred 40 Injection 40 mg/ml 3's pack 225\n\tJanata Pharma\tDepo-Medrol Injection 40mg/ml 1ml vial 176.30\n\tJanata Pharma\tDepo-Medrol Injection 80mg/ml 2ml vial 215\n\tIndication: Cardiac arrest, Multiple sclerosis, Systemic lupus erythematosus, Acute bronchitis, Vestibular neuritis\n\nDose: The initial dosage of parenterally administered Methyl Prednisolone Acetate will vary from 4 to 120 mg, depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.\n\nIt Should Be Emphasized that Dosage Requirements Are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.\n\nA. Administration for Local Effect\n\n1. Rheumatoid Arthritis and Osteoarthritis. The dose for intra-articular administration depends upon the size of the joint and varies with the severity of the condition in the individual patient. In chronic cases, injections may be repeated at intervals ranging from one to five or more weeks, depending upon the degree of relief obtained from the initial injection. The doses in the following table are given as a general guide:\n\nLarge Joint: Knees, Ankles & Shoulders:	20 to 80 mg\nMedium joint: Elbows & Wrists:	 10 to 40 mg\nSmall joint:  Metacarpophalangeal, Interphalangeal, Sternoclavicular & Acromioclavicular:  4 to 10 mg\n\n2. The dose in the treatment of the various conditions of the tendinous or bursal structures varies with the condition being treated and ranges from 4 to 30 mg. In recurrent or chronic conditions, repeated injections may be necessary.\n\n3. Injections for Local Effect in Dermatologic Conditions. Following cleansing with an appropriate antiseptic such as 70% alcohol, 20 to 60 mg of the suspension is injected into the lesion. It may be necessary to distribute doses ranging from 20 to 40 mg by repeated local injections in the case of large lesions. \n\nB. Administration for Systemic Effect\n\nThe intramuscular dosage will vary with the condition being treated. When employed as a temporary substitute for oral therapy, a single injection during each 24-hour period of a dose of the suspension equal to the total daily oral dose of methylprednisolone tablets is usually sufficient. When a prolonged effect is desired, the weekly dose may be calculated by multiplying the daily oral dose by 7 and given as a single intramuscular injection.\n\nIn pediatric patients, the initial dose of methylprednisolone may vary depending on the specific disease entity being treated. Dosage must be individualized according to the severity of the disease and response of the patient. The recommended dosage may be reduced for pediatric patients, but dosage should be governed by the severity of the condition rather than by strict adherence to the ratio indicated by age or body weight.\n\nIn patients with the adrenogenital syndrome, a single intramuscular injection of 40 mg every two weeks may be adequate. For maintenance of patients with rheumatoid arthritis, the weekly intramuscular dose will vary from 40 to 120 mg. The usual dosage for patients with dermatologic lesions benefited by systemic corticoid therapy is 40 to 120 mg of methylprednisolone acetate administered intramuscularly at weekly intervals for one to four weeks. In acute severe dermatitis due to poison ivy, relief may result within 8 to 12 hours following intramuscular administration of a single dose of 80 to 120 mg. In chronic contact dermatitis, repeated injections at 5 to 10 day intervals may be necessary. In seborrheic dermatitis, a weekly dose of 80 mg may be adequate to control the condition.\n\nFollowing intramuscular administration of 80 to 120 mg to asthmatic patients, relief may result within 6 to 48 hours and persist for several days to two weeks. Similarly, in patients with allergic rhinitis (hay fever), an intramuscular dose of 80 to 120 mg may be followed by relief of coryzal symptoms within six hours persisting for several days to three weeks.\n\nIf signs of stress are associated with the condition being treated, the dosage of the suspension should be increased. If a rapid hormonal effect of maximum intensity is required, the intravenous administration of highly soluble methylprednisolone sodium succinate is indicated.\n\nIn treatment of acute exacerbations of multiple sclerosis, daily doses of 160 mg of methylprednisolone for a week followed by 64 mg every other day for 1 month have been shown to be effective.\n\n\nContra-indication: Methylprednisolone acetate is contraindicated in patients with known hypersensitivity to the product and its constituents.\n\nIntramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.\n\nMethylprednisolone acetate injectable suspension is contraindicated for intrathecal administration. This formulation of methylprednisolone acetate has been associated with reports of severe medical events when administered by this route.\n\nMethylprednisolone acetate is contraindicated in systemic fungal infections, except when administered as an intra-articular injection for localized joint conditions\n\nSide effects: The following adverse reactions have been reported with methylprednisolone acetate or other corticosteroids:\n\nAllergic Reactions\n\nAllergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema.\n\nCardiovascular\n\nBradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopthy in premature infants, myocardial rupture following recent mycocardial infarction , pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis.\n\nDermatologic\n\nAcne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increase sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria.\n\nEndocrine\n\nDecreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients.\n\nFluid and Electrolyte Disturbances\n\nCongestive heart failure in susceptible patients, Fluid retention, hypokalemic alkalosis, potassium loss, sodium retention.\n\nGastrointestinal\n\nAbdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzymes levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible subsequent perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis.\n\nMusculoskeletal\n\nAseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intra-lesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, postinjection flare (following intra-articular use), steroid myopathy, tendon rupture, vertebral compression fractures.\n\nNeurologic/Psychiatric\n\nConvulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo.\n\nOphthalmic\n\nExophthalmoses, glaucoma, increased intraocular pressure, posterior subcapsular cataracts.\n\n\n\n\n\nPrecaution: General\n\nThe lowest possible dose of corticosteroid should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual.\n\nSince complications of treatment with glucocorticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.\n\nKarposis sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.\n\nMode of action: Decreases effect of anticholinesterases in myasthenia gravis. May decrease the hypoglycaemic effects of antidiabetic agents. Decreases serum concentrations of salicylates. Increased hypokalemic effects of potassium-depleting diuretics (thiazides or furosemide), amphotericin B, bronchodilator therapy with xanthines or ?2 agonists. Increase incidence of GI bleeding and ulceration with NSAIDs. May increase the anticoagulant effects of warfarin. Decreased levels/effects with CYP3A4 inducers (aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins). Increased levels/effects with CYP3A4 inhibitors (azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil). May decrease the effects of vaccines (dead organism) or increase the risk of vaccinal infection (live organism). Antacids and bile sequestrants may decrease the absorption of corticosteroids, separate admin by 2 hr. Increased risk of myopathy with neuromuscular-blocking agents, tendinopathies with fluoroquinolones.\n\nPregnancy category: C\n\nInteraction: Decreases effect of anticholinesterases in myasthenia gravis. May decrease the hypoglycaemic effects of antidiabetic agents. Decreases serum concentrations of salicylates. Increased hypokalemic effects of potassium-depleting diuretics (thiazides or furosemide), amphotericin B, bronchodilator therapy with xanthines or ?2 agonists. Increase incidence of GI bleeding and ulceration with NSAIDs. May increase the anticoagulant effects of warfarin. Decreased levels/effects with CYP3A4 inducers (aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins). Increased levels/effects with CYP3A4 inhibitors (azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil). May decrease the effects of vaccines (dead organism) or increase the risk of vaccinal infection (live organism). Antacids and bile sequestrants may decrease the absorption of corticosteroids, separate admin by 2 hr. Increased risk of myopathy with neuromuscular-blocking agents, tendinopathies with fluoroquinolones.
Methylprednisolone Sodium Succinate	\n\n\tGlobe\tMepcort Injection 1 gm/vial  \n\tGlobe\tMepcort Injection 500 mg/vial  \n\tPharmasia Ltd.\tMelpred IV/IM Injection 1 gm/vial  \n\tPharmasia Ltd.\tMelpred IV/IM Injection 500 mg/vial  \n\tTechno Drugs Ltd.\tPro-Medrol Injection 1gm/vial 1's pack 1200\n\tTechno Drugs Ltd.\tPro-Medrol Injection 500mg/vial 1's pack 800\n\tZiska\tSolupred IM/IV Injection 1gm/vial 1 vial's pack 1000\n\tZiska\tSolupred IM/IV Injection 500mg/vial 1 vial's pack 600\n\tPfizer, Belgium\tSolu-Medrol 40mg Act-O- vial Injection 40mg/ml 1 vial's pack 359.26\n\tPfizer, Belgium\tSolu-Medrol 125mg ACTO- Vial Injection 125mg/2ml vial 1 vial's pack 1170.53\n\tJanata Pharma\tSolu-Medrol 500mg Injection 500mg/ml 500mg vial x 1's pack 1753.22\n\tJanata Pharma\tSolu-Medrol 1gm Injection 1gm/ml 1gm vial x 1's pack 3360.36\n\tCity overseas\tMethyl Prednisolone Sodium Succinate Injection 500mg 500mg vial / 1's pack 760\n\tIndication:    1. Endocrine Disorders\n\n    Acute adrenocortical insufficiency\n    Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful\n    Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected\n    Congenital adrenal hyperplasia\n    Hypercalcemia associated with cancer\n    Nonsuppurative thyroiditis\n\n    2. Rheumatic Disorders\n\n    As adjunctive therapy for short-term administration in:\n    Post-traumatic osteoarthritis\n    Synovitis of osteoarthritis\n    Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)\n    Acute and subacute bursitis\n    Epicondylitis\n    Acute nonspecific tenosynovitis\n    Acute gouty arthritis\n    Psoriatic arthritis\n    Ankylosing spondylitis\n    3. Collagen Diseases\n\n    During an exacerbation or as maintenance therapy in selected cases of:\n    Systemic lupus erythematosus\n    Systemic dermatomyositis (polymyositis)\n    Acute rheumatic carditis\n    4. Dermatologic Diseases\n\n    Pemphigus\n    Severe erythema multiforme (Stevens-Johnson syndrome)\n    Exfoliative dermatitis\n    Bullous dermatitis herpetiformis\n    Severe seborrheic dermatitis\n    Severe psoriasis\n    Mycosis fungoides\n    5. Allergic States\n\n    Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:\n    Bronchial asthma\n    Contact dermatitis\n    Atopic dermatitis\n    Serum sickness\n    Seasonal or perennial allergic rhinitis\n    Drug hypersensitivity reactions\n    Urticarial transfusion reactions\n    Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)\n    6. Ophthalmic Diseases\n\n    Severe acute and chronic allergic and inflammatory processes involving the eye, such as:\n    Herpes zoster ophthalmicus\n    Iritis, iridocyclitis\n    Chorioretinitis\n    Diffuse posterior uveitis and choroiditis\n    Optic neuritis\n    Sympathetic ophthalmia\n    Anterior segment inflammation\n    Allergic conjunctivitis\n    Allergic corneal marginal ulcers\n    Keratitis\n    7. Gastrointestinal Diseases\n\n    To tide the patient over a critical period of the disease in:\n    Ulcerative colitis (systemic therapy)\n    Regional enteritis (systemic therapy)\n    8. Respiratory Diseases\n\n    \n    9. Hematologic Disorders\n\n    Acquired (autoimmune) hemolytic anemia\n    Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)\n    Secondary thrombocytopenia in adults\n    Erythroblastopenia (RBC anemia)\n    Congenital (erythroid) hypoplastic anemia\n    10. Neoplastic Diseases\n\n    For palliative management of:\n    Leukemias and lymphomas in adults\n    Acute leukemia of childhood\n    11. Edematous States\n\n    To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus\n    12. Nervous System\n\n    Acute exacerbations of multiple sclerosis\n    \n\nDose: This preparation may be administered by intravenous injection, by intravenous infusion, or by intramuscular injection, the preferred method for initial emergency use being intravenous injection. Following the initial emergency period, consideration should be given to employing a longer acting injectable preparation or an oral preparation.\n\nWhen high dose therapy is desired, the recommended dose of Methyl prednisolone sodium succinate Sterile Powder is 30 mg/kg administered intravenously over at least 30 minutes. This dose may be repeated every 4 to 6 hours for 48 hours.\n\nIn general, high dose corticosteroid therapy should be continued only until the patient's condition has stabilized; usually not beyond 48 to 72 hours.\n\nIn other indications, initial dosage will vary from 10 to 40 mg of methylprednisolone depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.\n\nIt should be emphasized that Dosage Requirements are Variable and Must Be Individualized on the Basis of the Disease under Treatment and the Response of the Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. \nIf after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.\n\nTo prepare solutions for intravenous infusion, first prepare the solution for injection as directed. This solution may then be added to indicate amounts of 5% dextrose in water, isotonic saline solution, or 5% dextrose in isotonic saline solution.\n\nIn pediatric patients, the initial dose of methylprednisolone may vary depending on the specific disease entity being treated. The range of initial doses is 0.11 to 1.6 mg/kg/day in three or four divided doses (3.2 to 48 mg/m2bsa/day).\n\nThe National Heart, Lung, and Blood Institute (NHLBI) recommended dosing for systemic prednisone, prednisolone, or methylprednisolone in pediatric patients whose asthma is uncontrolled by inhaled corticosteroids and long-acting bronchodilators is 1â2 mg/kg/day in single or divided doses. It is further recommended that short course, or "burst" therapy, be continued until the patient achieves a peak expiratory flow rate of 80% of his or her personal best or until symptoms resolve. This usually requires 3 to 10 days of treatment, although it can take longer. There is no evidence that tapering the dose after improvement will prevent a relapse.\n\nDosage may be reduced for infants and children but should be governed more by the severity of the condition and response of the patient than by age or size. It should not be less than 0.5 mg per kg every 24 hours.\n\nIn treatment of acute exacerbations of multiple sclerosis, daily doses of 160 mg of methylprednisolone for a week followed by 64 mg every other day for 1 month have been shown to be effective.\n\n\nContra-indication: Powder is also contraindicated in systemic fungal infections and patients with known hypersensitivity to the product and its constituents. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Methylprednisolone acetate injectable suspension is contraindicated for intrathecal administration. This formulation of methylprednisolone acetate has been associated with reports of severe medical events when administered by this route. Methylprednisolone acetate is contraindicated in systemic fungal infections, except when administered as an intra-articular injection for localized joint conditions\n\nSide effects: The following adverse reactions have been reported with methylprednisolone acetate or other corticosteroids: Allergic Reactions Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema. Cardiovascular Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopthy in premature infants, myocardial rupture following recent mycocardial infarction , pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. Dermatologic Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increase sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. \n\nEndocrine Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients. Fluid and Electrolyte Disturbances Congestive heart failure in susceptible patients, Fluid retention, hypokalemic alkalosis, potassium loss, sodium retention. \n\nGastrointestinal Abdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzymes levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible subsequent perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis. \n\nMusculoskeletal Aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intra-lesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, postinjection flare (following intra-articular use), steroid myopathy, tendon rupture, vertebral compression fractures. Neurologic/Psychiatric Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Ophthalmic Exophthalmoses, glaucoma, increased intraocular pressure, posterior subcapsular cataracts. \n\nPrecaution: General The lowest possible dose of corticosteroid should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual. Since complications of treatment with glucocorticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. Karposis sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.\n\nSteroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency;  hypertension; osteoporosis; and myasthenia gravis.\n\nGrowth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.\n\nMode of action: Decreases effect of anticholinesterases in myasthenia gravis. May decrease the hypoglycaemic effects of antidiabetic agents. Decreases serum concentrations of salicylates. Increased hypokalemic effects of potassium-depleting diuretics (thiazides or furosemide), amphotericin B, bronchodilator therapy with xanthines or ?2 agonists. Increase incidence of GI bleeding and ulceration with NSAIDs. May increase the anticoagulant effects of warfarin. Decreased levels/effects with CYP3A4 inducers (aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins). Increased levels/effects with CYP3A4 inhibitors (azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil). May decrease the effects of vaccines (dead organism) or increase the risk of vaccinal infection (live organism). Antacids and bile sequestrants may decrease the absorption of corticosteroids, separate admin by 2 hr. Increased risk of myopathy with neuromuscular-blocking agents, tendinopathies with fluoroquinolones.\n\nPregnancy category: C\n\nInteraction: Decreases effect of anticholinesterases in myasthenia gravis. May decrease the hypoglycaemic effects of antidiabetic agents. Decreases serum concentrations of salicylates. Increased hypokalemic effects of potassium-depleting diuretics (thiazides or furosemide), amphotericin B, bronchodilator therapy with xanthines or ?2 agonists. Increase incidence of GI bleeding and ulceration with NSAIDs. May increase the anticoagulant effects of warfarin. Decreased levels/effects with CYP3A4 inducers (aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins). Increased levels/effects with CYP3A4 inhibitors (azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil). May decrease the effects of vaccines (dead organism) or increase the risk of vaccinal infection (live organism). Antacids and bile sequestrants may decrease the absorption of corticosteroids, separate admin by 2 hr. Increased risk of myopathy with neuromuscular-blocking agents, tendinopathies with fluoroquinolones.
Methyldopa	\n\n\tAmbee\tDopegyt TAB dr 250mg 100's pack 309\n\tIncepta\tSardopa TAB dr 250mg 56's pack 172\n\tIncepta\tSardopa 500 TAB dr 500mg 28's pack 165\n\tOpsonin Pharma\tDopamet TAB dr 250mg 10x5's pack 135.47\n\tCosmic Pharma Ltd.\tAldomet TAB dr 250mg  \n\tIndication: Hypertension\n\nDose: Oral\nHypertension\nAdult: Monotherapy: Initially, 250 mg bid-tid for 2 days; adjust according to response not more than every 2 days. Maintenance: 0.5-2 g daily. Max: 3 g daily. Combination therapy: Initial dose should not exceed 500 mg daily in divided doses.\nChild: Initially, 10 mg/kg or 300 mg/m2 daily in 2-4 divided doses; increase as necessary. Max: 65 mg/kg, 2 g/m2 or 3 g daily, whichever is least.\nElderly: Initially, 125 mg bid; gradually increase according to response. Max: 2 g daily.\n\nContra-indication: Methyldopa is contraindicated in patients:\n\n- with active hepatic disease, such as acute hepatitis and active cirrhosis.\n\n- with liver disorders previously associated with Methyldopa therapy.\n- with hypersensitivity to any component of these products.\n- on therapy with monoamine oxidase (MAO) inhibitors.\n\nSide effects: Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. Headache, asthenia, or weakness may be noted as early and transient symptoms. The following systemic side effects may rarely occurs with the use of Methyldopa - angina pectoris, congestive heart failure, orthostatic hypotension, edema or weight gain, bradycardia, pancreatitis, colitis, vomiting, diarrhea, nausea, constipation, dryness of mouth, hyperprolactinemia, bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; rheumatoid factor, hepatitis, jaundice, myocarditis, pericarditis, vasculitis, eosinophilia, parkinsonism, bell's palsy, nightmares and reversible mild psychoses or depression, dizziness, lightheadedness, paresthesias, arthralgia, myalgia, nasal stuffiness, rash, amenorrhea, gynecomastia, lactation, impotence. However, significant adverse effects due to Methyldopa have been infrequent and this agent usually is well tolerated.\n\nPrecaution: Methyldopa should be used with caution in patients with a history of previous liver disease or dysfunction.\nSome patients taking Methyldopa experience clinical edema or weight gain, which may be controlled by use of a diuretic. Methyldopa should not be continued if edema progresses or signs of heart failure appear.\nHypertension has recurred occasionally after dialysis in patients given Methyldopa because the drug is removed by this procedure.\nRarely involuntary choreoathetotic movements have been observed during therapy with Methyldopa in patients with severe bilateral cerebrovascular disease. If these movements occur, stop therapy\n\nMode of action: Reduced hypotensive effects with phenothiazines, TCAs and possibly, amphetamines. Additive hypotensive effects with levodopa; psychosis may also occur. Reduced absorption and effects with oral iron preparations. Reduced doses of general anaesthetics may be required. Effect of ephedrine may be reduced.\nPotentially Fatal: Increased risk of severe hypertension with MAOIs. Increased lithium toxicity\n\nPregnancy category: B\n\nInteraction: Reduced hypotensive effects with phenothiazines, TCAs and possibly, amphetamines. Additive hypotensive effects with levodopa; psychosis may also occur. Reduced absorption and effects with oral iron preparations. Reduced doses of general anaesthetics may be required. Effect of ephedrine may be reduced.\nPotentially Fatal: Increased risk of severe hypertension with MAOIs. Increased lithium toxicity
Methylphenidate Hydrochloride	\n\n\tNovartis (Bangladesh) Ltd.\tRitalin TAB dr 10mg  \n\tIndication: Narcolepsy, Hyperactivity disorders\n\nDose: Adult: PO Narcolepsy 20-30 mg/day in divided doses. Effective range: 10-60 mg/day.\n\nContra-indication: Marked anxiety, tension, agitation; glaucoma; Tourette's syndrome or tics. Known severe structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac disorders that could increase the risk of sudden death. Extended-release form: Severe hypertension, heart failure, arrhythmia, hyperthyroidism, recent MI or angina.\n\nSide effects: Angina, arrhythmia, cerebral arteritis, cerebral occlusion, changes in BP, MI, necrotising vasculitis, palpitation, pulse changes, tachycardia; depression, dizziness, drowsiness, fever, headache, insomnia, nervousness, neuroleptic malignant syndrome (NMS), Tourette's syndrome, toxic psychosis; erythema multiforme, exfoliative dermatitis, hair loss, rash, urticaria; growth retardation; abdominal pain, anorexia, diarrhoea, nausea, vomiting, weight loss; anaemia, leukopenia, thrombocytopenic purpura, thrombocytopenia; abnormal LFTs, hepatic coma, increased transaminases; arthralgia, dyskinesia; blurred vision, visual accommodation disturbance; cough, pharyngitis, sinusitis, upper respiratory tract infection; accidental injury, hypersensitivity. Transdermal: Insomnia, decreased appetite; nausea; tic, emotional instability; vomiting, anorexia; nasal congestion, nasopharyngitis; weight loss.\n\nPrecaution: Pregnancy and lactation. History of alcohol or drug abuse. Hypertension and other CV disorders that might be exacerbated by increases in BP or heart rate. Pre-existing psychosis or bipolar disorder; monitor for symptoms of aggression or hostility. History of seizure disorder. Children <6 yr (growth suppression); monitor growth during therapy. May impair ability to drive or operate machinery. Transdermal: Avoid exposure of application site to any direct external heat source\n\nMode of action: May reduce effects of antihypertensive agents. Reduced serum level with carbamazepine. Increased serum levels or effects with CYP2D6 inhibitors e.g. chlorpromazine, delavirdine, fluoxetine, miconazole, paroxetine, pergolide, quinidine, quinine, ritonavir, ropinirole. May increase serum levels of phenytoin, TCAs. Possible severe hypertension and tachycardia with sibutramine. CNS depression with alcohol.\nPotentially Fatal: Severe toxic reactions with clonidine. Increased risk of hypertensive crisis with MAOIs.\n\nPregnancy category: C\n\nInteraction: May reduce effects of antihypertensive agents. Reduced serum level with carbamazepine. Increased serum levels or effects with CYP2D6 inhibitors e.g. chlorpromazine, delavirdine, fluoxetine, miconazole, paroxetine, pergolide, quinidine, quinine, ritonavir, ropinirole. May increase serum levels of phenytoin, TCAs. Possible severe hypertension and tachycardia with sibutramine. CNS depression with alcohol.\nPotentially Fatal: Severe toxic reactions with clonidine. Increased risk of hypertensive crisis with MAOIs.
Metoclopramide Hydrochloride	\n\n\tAcme Ltd.\tNutramid Drops 1mg/ml 15ml bot 9.64\n\tAcme Ltd.\tNutramid TAB dr 10mg 100's pack 34\n\tAcme Ltd.\tNutramid Syrup 5mg/5ml 60ml bot 10.65\n\tAlbion Ltd.\tMigen Syrup 100 mg/100 ml 100 ml \n\tBeximco\tMeclomid Suppository 10mg 10's pack \n\tBeximco\tMeclomid TAB dr 10mg 100's pack \n\tJayson\tMeclid TAB dr 10mg 100's pack 32\n\tJayson\tMeclid Injection 10mg/2ml 10 amps pack 35.50\n\tMedimet\tMaxocol TAB dr 10mg 100's pack 34\n\tMedimet\tMaxocol Syrup 5mg/5ml 100ml bot 15.77\n\tNipa\tMaxil TAB dr 10mg 100's pack 34\n\tNipa\tMaxil Syrup 5mg/5ml 100ml bot 14.11\n\tOpsonin Pharma\tMetocol Syrup 5mg/5ml 100ml bot 13\n\tOpsonin Pharma\tMetocol Paediatric Drops 1mg/ml 15ml bot 9.50\n\tSanofi Aventis (BD) Ltd.\tMotilon TAB dr 10mg 500's pack 169.97\n\tSanofi Aventis (BD) Ltd.\tMotilon Injection 10mg/2ml 10 amps pack 37.64\n\tSanofi Aventis (BD) Ltd.\tMotilon Syrup 5mg/5ml 100ml bot 15.83\n\tSanofi Aventis (BD) Ltd.\tMotilon Paediatric Drops 1mg/ml 15ml bot 9.80\n\tIndication: Gastro-oesophageal reflux disease, Diabetic gastric stasis, Nausea and vomiting associated w/ cancer chemotherapy or radiotherapy, Postoperative nausea and vomiting\n\nDose: Adult: PO Diabetic gastric stasis 10 mg 4 times/day. Usual duration: 2-8 wk. Nausea and vomiting associated w/ cancer chemotherapy or radiotherapy 2 mg/kg 1 hr before start of treatment. Repeat dose 3 times at 2-hrly intervals. May repeat 2 additional doses at 3-hrly intervals if needed. Max: 12 mg/kg/day. Gastro-oesophageal reflux disease 10-15 mg up to 4 times/day, depending on severity of symptoms. Delayed emesis following chemotherapy 20-40 mg 2-4 times/day for 3-4 days. \n\nIV Nausea and vomiting associated w/ cancer chemotherapy Highly emetogenic regimens: 2 mg/kg 30 mins before start of treatment. Repeat twice at 2-hrly intervals. Less emetogenic regimens: 1 mg/kg. If vomiting is not well-controlled, 3 additional doses at 2 mg/kg/dose 3-hrly. If vomiting is well-controlled w/ the 1st 3 doses, may reduce dose to 1 mg/kg 3-hrly for 3 additional doses. Intubation of the small intestine; Premed for radiologic examination of the upper GI tract 10 mg as a single direct inj. \n\nIV/IM Diabetic gastric stasis 10 mg 4 times/day. Convert to PO when possible. Usual duration: 2-8 wk. IM Post-op nausea and vomiting 10 mg near the end of the procedure. Repeat 4-6 hrly when needed.\n\nRenal impairment: Moderate to severe: Reduce dose by at least 50%\nCrCl (ml/min)	\n<40	 Reduce dose by at least 50% \n\nContra-indication: GI haemorrhage, mechanical obstruction and perforation; phaeochromocytoma; history of seizures.\n\nSide effects: Extrapyramidal symptoms, restlessness, drowsiness, anxiety, diarrhoea, hypotension, hypertension, headache, depression, blood disorders (e.g. aganulocytosis, methaemoglobinaemia), hypersensitivity reactions (e.g. bronchospasm, rash), galactorrhoea or related disorders, transient increase in plasma aldosterone levels.\nPotentially Fatal: Neuroleptic malignant syndrome; cardiac conduction disorders may occur with IV dosage form.\n\nPrecaution: Children, elderly. Renal or hepatic impairment, porphyria, epilepsy, Parkinson's disease, history of depression. Ability to drive or operate machineries may be impaired. Pregnancy and lactation. Monitor patients on prolonged therapy. Increased risk of tardive dyskinesia in patients on prolonged or high-dose treatment.\n\nMode of action: Increased sedative effects with CNS depressants. GI effects antagonised by antimuscarinics and opioids. Reduces absorption of digoxin. Increases absorption of ciclosporin, levodopa, aspirin, paracetamol. Interferes with hypoprolactinaemic effect of bromocriptine. Inhibits serum cholinesterase and prolongs neuromuscular blockade produced by suxamethonium and mivacurium.\nPotentially Fatal: Serotonin syndrome with sertraline (SSRI). \n\nPregnancy category: B\n\nInteraction: Increased sedative effects with CNS depressants. GI effects antagonised by antimuscarinics and opioids. Reduces absorption of digoxin. Increases absorption of ciclosporin, levodopa, aspirin, paracetamol. Interferes with hypoprolactinaemic effect of bromocriptine. Inhibits serum cholinesterase and prolongs neuromuscular blockade produced by suxamethonium and mivacurium.\nPotentially Fatal: Serotonin syndrome with sertraline (SSRI). 
Metolazone	\n\n\tNavana\tMetolaz 0.5 TAB dr 500mcg 30's pack 150.60\n\tUnimed & Unihealth Manufacturers Ltd.\tMerozolyn TAB dr 500mcg  \n\tUnimed & Unihealth Manufacturers Ltd.\tMerozolyn TAB dr 5mg  \n\tIndication: Oedema, Hypertension\n\nDose: Oral\nHypertension\nAdult: Initially, 1.25 mg daily, adjusted after 3-4 wk according to response. Usual dose: 2.5-5 mg daily, either alone or with other antihypertensives. Maintenance dose: 5 mg on alternate days. Formulations with enhanced bioavailability: 0.5-1 mg daily.\nElderly: Initially, 2.5 mg/day or every other day.\n\nOedema\nAdult: 5-10 mg daily, increased if necessary to 20 mg daily. Max: 80 mg in 24 hr.\nElderly: Initially, 2.5 mg/day or every other day.\n\nContra-indication: Anuria; hepatic coma or pre-coma. Pregnancy.\n\nSide effects: Chest pain, palpitation, necrotising angiitis, orthostatic hypotension, syncope, venous thrombosis, vertigo, volume depletion; depression, dizziness, chills, drowsiness, fatigue, restlessness, headache, lightheadedness; petechiae, photosensitivity, hypersensitivity reactions; gout attacks, electrolyte disturbances; abdominal bloating, diarrhoea, abdominal pain, anorexia, constipation, epigastric distress, nausea, xerostomia, pancreatitis, vomiting; impotence; aplastic anaemia, thrombocytopenia, haemoconcentration, leukopenia; cholestatic jaundice, hepatitis; joint pain, muscle cramps, weakness, neuropathy, paraesthesia; blurred vision; increased BUN, glucosuria.\nPotentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis.\n\nPrecaution: Pre-diabetes or DM; gout; SLE; hepatic and renal impairment; hypercholesterolaemia. Correct electrolyte disturbances prior to therapy. Risk of cross-sensitivity with sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides and loop diuretics. Lactation.\n\nMode of action: Hypotensive and nephrotoxic effects of ACE inhibitors may be enhanced. Absorption may be reduced with bile acid sequestrants. Hyperglycaemic effect may be enhanced with diazoxide. May increase serum concentration and QTc-prolonging effect of dofetilide. May reduce lithium excretion. Hypotensive effect may be increased with alcohol.\nPotentially Fatal: Increased risk of nephrotoxicity with ciclosporin. Severe electrolyte disturbances may occur with furosemide.\n\nPregnancy category: B\n\nInteraction: Hypotensive and nephrotoxic effects of ACE inhibitors may be enhanced. Absorption may be reduced with bile acid sequestrants. Hyperglycaemic effect may be enhanced with diazoxide. May increase serum concentration and QTc-prolonging effect of dofetilide. May reduce lithium excretion. Hypotensive effect may be increased with alcohol.\nPotentially Fatal: Increased risk of nephrotoxicity with ciclosporin. Severe electrolyte disturbances may occur with furosemide.
Metoprolol Tartrate	\n\n\tACI\tAngilat Injection 1mg/ml 5 mg (ml) amp X 5's pack 600\n\tACI\tAngilat TAB dr 25mg 100's pack 150\n\tACI\tAngilat TAB dr 50mg 100's pack 201\n\tAcme Ltd.\tBetaone TAB dr 50mg 100's pack 200\n\tAristopharma\tBetacard TAB dr 50mg 100's pack 200\n\tBeximco\tMetoprol XL TAB dr 100mg 50's pack 250\n\tBeximco\tMetoprol XL TAB dr 50mg 50's pack 150\n\tBristol Pharma Ltd.\tLopresor TAB dr 50mg 100's pack 131\n\tDrug International Ltd.\tBetaloc TAB dr 25mg 100's pack 150\n\tDrug International Ltd.\tBetaloc TAB dr 50mg 100's pack 200\n\tDrug International Ltd.\tBetaloc XR TAB dr 100mg 50's pack 300\n\tDrug International Ltd.\tBetaloc XR TAB dr 50mg 100's pack 400\n\tDrug International Ltd.\tBetaloc Injection 1 mg/ml  \n\tEskayef Bangladesh Ltd.\tTopress TAB dr 100mg 100's pack 200\n\tEskayef Bangladesh Ltd.\tTopress TAB dr 50mg 100's pack 200\n\tIncepta\tPresonil TAB dr 50mg 100's pack 130\n\tOpsonin Pharma\tPreloc TAB dr 50mg 50's pack 100\n\tOpsonin Pharma\tPreloc TAB dr 100mg 50's pack 88\n\tOpsonin Pharma\tPreloc TAB dr 25mg 100's pack 150\n\tPopular\tMetocard Injection 1mg/ml 5 mg (ml) amp X 5's pack 602.25\n\tRenata\tMetaloc TAB dr 100mg 50's pack 125.50\n\tRenata\tMetaloc TAB dr 50mg 100's pack 132\n\tSharif\tM-Loc TAB dr 50mg 50's pack 100\n\tUnimed & Unihealth Manufacturers Ltd.\tSelomet TAB dr 50mg 30's pack 60\n\tUnimed & Unihealth Manufacturers Ltd.\tSelomet SR TAB dr 50mg 30's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tSelomet TAB dr 25mg 30's pack 45\n\tWhite Horse Pharma\tAngipro TAB dr 50mg 50's pack 65\n\tIndication: Heart failure, Migraine, Acute MI, Diabetic nephropathy, Hypertension, Cardiac arrhythmias, Angina pectoris\n\nDose: Hypertension: initially 100mg daily, maintenance 100-200mg daily in 1-2 divided doses\nAngina Pectoris: 50-100mg 2-3 times daily.\nMyocardial Infarction: After early intravenous treatment for 48 hours, patients should receive a maintenance dose of 100mg twice daily.\nArrhythmias: usually 50mg 2-3 times daily; up to 300mg daily in divided doses if necessary.\nHyperthyroidism: (adjunct), 50mg 4 times daily\nMigraine Prophylaxis: 100-200mg daily in divided doses.\n\nContra-indication: Hypertension and Angina: Metoprolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure.\n\nMyocardial Infarction: Metoprolol is contraindicated in patients with a heart rate<45 beats/min; second and third-degree heart block; significant first-degree heart block; systolic blood pressure <100 mmHg; or moderate-to-severe cardiac failure.\n\nSide effects: Bradycardia, Heart failure, hypotension, Conduction disorder, Bronchospasm, Peripheral vasoconstriction, Gastrointestinal disturbances, Fatigue, Sleep disturbance, Rare reports of rashes and dry eyes, Sexual dysfunction, and Exacerbation of psoriasis.\n\nPrecaution: Gereral: Metoprolol should be used with caution in patients with impaired hepatic function.\nInformation for Patients: Patients should be advised to take Metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose missed, the patient should take only the next scheduled dose (without doubling it). Patient should not discontinue Metoprolol without consulting the physician. Patients should be advised to\navoid operating automobiles and machinery or engaging in other tasks requiring alertness until the\npatient's response to therapy with Metoprolol has been determined.\ncontact the physician if any difficulty in breathing occurs.\ninform the physician or dentist before any type of surgery that he or she is taking Metoprolol.\n\nMode of action: Additive effect w/ catecholamine-depleting drugs (e.g. reserpine) and MAOIs. May antagonise ?1-adrenergic stimulating effects of sympathomimetics. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. Paradoxical response to epinephrine may occur. Increased plasma concentrations w/ CYP2D6 inhibitors (e.g. bupropion, cimetidine). Increased risk of hypotension and heart failure w/ myocardial depressant general anaesth (e.g. diethyl ether). Risk of pulmonary HTN w/ vasodilators (e.g. hydralazine) in uraemic patients. Reduced plasma levels w/ rifampicin. May increase negative inotropic and negative dromotropic effect of antiarrhythmic drugs (e.g. quinidine, amiodarone). May reduce antihypertensive efficacy w/ indometacin. May increase effects of hypoglycaemics.\n\nPregnancy category: D\n\nInteraction: Additive effect w/ catecholamine-depleting drugs (e.g. reserpine) and MAOIs. May antagonise ?1-adrenergic stimulating effects of sympathomimetics. Additive negative effects on SA or AV nodal conduction w/ cardiac glycosides, nondihydropyridine Ca channel blockers. Paradoxical response to epinephrine may occur. Increased plasma concentrations w/ CYP2D6 inhibitors (e.g. bupropion, cimetidine). Increased risk of hypotension and heart failure w/ myocardial depressant general anaesth (e.g. diethyl ether). Risk of pulmonary HTN w/ vasodilators (e.g. hydralazine) in uraemic patients. Reduced plasma levels w/ rifampicin. May increase negative inotropic and negative dromotropic effect of antiarrhythmic drugs (e.g. quinidine, amiodarone). May reduce antihypertensive efficacy w/ indometacin. May increase effects of hypoglycaemics.
Metronidazole	\n\n\tACI\tAmotrex Suspension 200mg/5ml 60ml bot 29.90\n\tACI\tAmotrex TAB dr 200mg 100's pack 69\n\tACI\tAmotrex TAB dr 400mg 100's pack 127\n\tACI\tAmotrex DS TAB dr 800mg 100's pack 200\n\tAcme Ltd.\tDirozyl Suspension 200mg/5ml 60ml bot 25.10\n\tAcme Ltd.\tDirozyl TAB dr 200mg 100's pack 67\n\tAcme Ltd.\tDirozyl TAB dr 500mg 500's pack 400\n\tAcme Ltd.\tDirozyl Suppository 500mg 10 sticks pack 120.50\n\tAcme Ltd.\tDirozyl IV Infusion 500mg/100ml 100ml bot 50.20\n\tAcme Specialized\tDirozyl TAB dr 400mg 100's pack 101\n\tAd-din\tMetra Suspension 200mg/5ml 60ml bot 24\n\tAd-din\tMetra TAB dr 400mg 100's pack 105\n\tAexim\tQugyl Suspension 200mg/5ml 60ml bot 24\n\tAexim\tQugyl TAB dr 400mg 100's pack 100\n\tAlbion Ltd.\tMetronidazole TAB dr 400 mg 100's pack \n\tAlbion Ltd.\tDylin Suspension 4 mg/100 ml  60 ml \n\tAlco Pharma\tMenilet TAB dr 400mg 100's pack 101\n\tAlco Pharma\tMenilet Suspension 200mg 60ml bot 21.24\n\tAmbee\tKlion Suspension 200mg/5ml 60ml bot 23.35\n\tAmbee\tKlion TAB dr 200mg 100's pack 67\n\tAmbee\tKlion TAB dr 400mg 100's pack 109\n\tAmico Ltd.\tMecozol Suspension 200mg/5ml 60ml bot 25\n\tAmico Ltd.\tMecozol TAB dr 400mg 100's pack 100\n\tAPC Pharma Ltd.\tApetryl Suspension 200mg/5ml 60ml bot 20\n\tAPC Pharma Ltd.\tApetryl TAB dr 400mg 100's pack 113\n\tApex\tRibazole Suspension 200mg/5ml 60ml bot 21.50\n\tApex\tRibazole TAB dr 400mg 100's pack 100\n\tApollo Pharmaceutical Ltd.\tApzyl Suspension 200mg/5ml 60ml bot 24\n\tAsiatic Ltd.\tStrazyl Suspension 200mg/5ml 60ml bot 24.84\n\tAsiatic Ltd.\tStrazyl TAB dr 400mg 100's pack 102\n\tBelsen\tOrmet Suspension 200mg/5ml 60ml bot 20\n\tBelsen\tOrmet TAB dr 400mg 100's pack 112\n\tBeximco\tFilmet Suspension 200mg/5ml 60ml bot 25.15\n\tBeximco\tFilmet TAB dr 200mg 200's pack 138\n\tBeximco\tFilmet TAB dr 400mg 100's pack/250's pack 101/252.50\n\tBeximco\tFilmet Injection 0.5% 100ml bot 52\n\tBeximco\tFilmet IV Infusion 500mg/100ml 100ml bot 53.40\n\tBeximco\tFilmet DS TAB dr 800mg 100's pack 201\n\tBio Pharma Ltd.\tBiozyl Suspension 200mg/5ml 60ml bot 25.09\n\tBio Pharma Ltd.\tBiozyl IV Infusion 500mg/100ml 100ml bot 52.29\n\tBio Pharma Ltd.\tBiozyl TAB dr 400mg 100's pack 100\n\tBristol Pharma Ltd.\tMetfil TAB dr 400mg 100's pack 100\n\tCentral.\tCedol Suspension 200mg/5ml 60ml bot 22\n\tCentral.\tCedol TAB dr 400mg 100's pack 100\n\tCity Chemicals & Pharmaceuticals Works Ltd.\tMetrolin TAB dr 400mg 100's pack 114\n\tConcord\tMetrocon-400 TAB dr 400mg 100's pack 200\n\tCosmic Chemical Industries Ltd.\tAmezol Suspension 200mg/5ml 60ml bot 24.21\n\tCosmic Chemical Industries Ltd.\tAmezol TAB dr 400mg 100's pack 100\n\tCosmo Pharma Ltd.\tMetrizol TAB dr 400mg 100's pack 101\n\tDecent Pharma Ltd.\tDecagyl Suspension 200mg/5ml 60ml bot 25.50\n\tDecent Pharma Ltd.\tDecagyl TAB dr 400mg 100's pack 100\n\tDelta Pharma\tDanidazol Suspension 200mg/5ml 60ml 22\n\tDelta Pharma\tDanidazol TAB dr 400mg 100's pack 114\n\tDesh\tD Metro Suspension 200mg/5ml 60ml bot 21\n\tDesh\tD Metro TAB dr 400mg 100's pack 100\n\tDoctor's Chemicals Works Ltd.\tAmobin Suspension 200mg/5ml 60ml bot 24\n\tDoctor's Chemicals Works Ltd.\tAmobin TAB dr 200mg 100's pack 53\n\tDoctor's Chemicals Works Ltd.\tAmobin TAB dr 400mg 100's pack 114\n\tDrug International Ltd.\tVarizil TAB dr 400mg 100's pack 86\n\tDrug International Ltd.\tVarizil IV Infusion 500mg/100ml 100ml bot 45\n\tEdruc Ltd.\tTricozyl Suspension 200mg/5ml 60ml bot 25\n\tEdruc Ltd.\tTricozyl TAB dr 400mg 100's pack 126\n\tEskayef Bangladesh Ltd.\tMetco Suspension 200mg/5ml 60ml bot 25.12\n\tEskayef Bangladesh Ltd.\tMetco IV Infusion 5mg/ml 1's pack 60\n\tEskayef Bangladesh Ltd.\tMetco TAB dr 400mg 100's pack 114\n\tEuro Pharma Ltd.\tEGYL Suspension 200mg/5ml 60ml bot 24.85\n\tEuro Pharma Ltd.\tEGYL TAB dr 400mg 100's pack 114\n\tGeneral\tMetrion Suspension 200mg/5ml 60ml bot 25.76\n\tGeneral\tMetrion TAB dr 400mg 100's pack 114\n\tGlobe\tMicogyl Suspension 200mg/5ml 60ml bot 22\n\tGlobe\tMicogyl TAB dr 400mg 100's pack 100\n\tGonoshasthaya\tG Metronidazole Suspension 200mg/5ml 50ml bot/60ml bot/100ml bot 17.26/21/30.45\n\tGonoshasthaya\tG Metronidazole TAB dr 200mg 100's pack 102\n\tGonoshasthaya\tG Metronidazole IV Infusion 500mg/100ml 100ml bot 35.53\n\tHallmark\tProtec Suspension 200mg/5ml 60ml bot 21.08\n\tHallmark\tProtec TAB dr 400mg 100's pack 108\n\tHudson\tMetroson Suspension 200mg/5ml 60ml bot 18\n\tHudson\tMetroson TAB dr 400mg 100's pack 105\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMetsina Suspension 200mg/5ml 60ml bot 25.75\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMetsina TAB dr 200mg 100's pack 63\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMetsina TAB dr 400mg 100's pack 115\n\tIncepta\tFlamyd Suspension 200mg/5ml 60ml 25\n\tIncepta\tFlamyd TAB dr 250mg 100's pack 78\n\tIncepta\tFlamyd TAB dr 400mg 150's pack 200\n\tIncepta\tFlamyd TAB dr 500mg 100's pack 135\n\tIncepta\tFlamyd IV Infusion 500mg/100ml 100ml bot 53.18\n\tIndobangla Pharmaceuticals\tMetrol Suspension 200mg/5ml 60ml bot 21\n\tIndobangla Pharmaceuticals\tMetrol TAB dr 400mg 100's pack 100\n\tJayson\tMetason Suspension 200mg/5ml 60ml bot 25.10\n\tJayson\tMetason TAB dr 400mg 100's pack 115\n\tKemiko\tKemet Suspension 200mg/5ml 60ml bot 25\n\tKemiko\tKemet TAB dr 400mg 100's pack 112\n\tLeon\tMetron Suspension 200 mg/5 ml  \n\tLeon\tMetron TAB dr 400mg  \n\tLibra Pharmaceuticls Ltd.\tLibrazol IV Infusion 500mg 100ml bot  49.76\n\tMarksman.\tAmogit TAB dr 400mg 100's pack 95\n\tMedicon\tMedizol Suspension 200mg/5ml 60ml bot 21\n\tMedicon\tMedizol TAB dr 400mg 100's pack 110\n\tMedimet\tMetropill TAB dr 200mg 100's pack 60\n\tMedimet\tMetropill TAB dr 400mg 100's pack 110\n\tMedimet\tMetropill S Suspension 200mg/5ml 60ml bot 22\n\tMillat\tNeogyl Suspension 200mg/5ml 60ml bot 24.88\n\tMillat\tNeogyl TAB dr 400mg 100's pack 114\n\tModern\tM Dazole Suspension 200mg/5ml 60ml bot 25.67\n\tModern\tM-Dazole TAB dr 200mg 100's pack 66\n\tModern\tM-Dazole TAB dr 400mg 100's pack 114\n\tMonicopharma\tAnzole Suspension 200mg/5ml 60ml bot 25\n\tMonicopharma\tAnzole TAB dr 400mg 100's pack 101\n\tMystic\tOnida Suspension 200mg/5ml 60ml bot 21\n\tMystic\tOnida TAB dr 400mg 100's pack 100\n\tNavana\tAnamet Suspension 200mg/5ml 60ml bot 25.50\n\tNavana\tAnamet TAB dr 400mg 100's pack 114\n\tNIPRO JMI Pharma\tFlorazol Suspension 200mg/5ml 60ml bot 24\n\tNIPRO JMI Pharma\tFlorazol TAB dr 400mg 200's pack 228\n\tNovartis (Bangladesh) Ltd.\tServizol TAB dr 200mg 100's pack \n\tNovartis (Bangladesh) Ltd.\tServizol TAB dr 400mg 100's pack \n\tNovo Healthcare and Pharma Ltd.\tMetromax IV Infusion 500mg/100ml 100ml bot 52\n\tNovo Healthcare and Pharma Ltd.\tMetromax-500 TAB dr  100's pack 135\n\tOpso Saline Ltd.\tMetro IV Infusion 500mg/100ml 100ml bot 35.13\n\tOpsonin Pharma\tMetryl Suspension 200mg/5ml 60ml bot 24\n\tOpsonin Pharma\tMetryl TAB dr 200mg 100's pack 62\n\tOpsonin Pharma\tMetryl TAB dr 400mg 100's pack 108\n\tOpsonin Pharma\tMetryl TAB dr 500mg 100's pack 135\n\tOpsonin Pharma\tMetryl IV Infusion 500mg/100ml 100ml bot 53\n\tOrganic Health Care\tOrzyl TAB dr 400mg 200's pack 228\n\tOrion Pharma Ltd.\tNidazyl Suspension 200mg/5ml 60ml bot 21.08\n\tOrion Pharma Ltd.\tNidazyl TAB dr 200mg 100's pack \n\tOrion Pharma Ltd.\tNidazyl TAB dr 400mg 100's pack 114\n\tOrion Pharma Ltd.\tNidazyl IV Infusion 500mg/100ml 100ml bot 52\n\tOyster\tMenida TAB dr 400mg 100's pack 100\n\tOyster\tMenida Suspension 200 mg/5 ml 60ml bot 25\n\tPacific\tBenmet Suspension 200mg/5ml 60ml bot 20\n\tPacific\tBenmet TAB dr 400mg 100's pack 114\n\tPharmadesh Ltd.\tPhidazole Suspension 200mg/5ml 60ml bot 24.50\n\tPharmadesh Ltd.\tPhidazole TAB dr 400mg 200's pack 220\n\tPharmasia Ltd.\tM TAB dr 400mg 100's pack 114\n\tPopular\tMetonid Suspension 200mg/5ml 60ml bot 25.24\n\tPopular\tMetonid TAB dr 400mg 100's pack 114\n\tPopular\tMetonid IV Infusion 500mg/100ml 100ml bot 52.79\n\tRangs\tAntipro Suspension 200mg/5ml 60ml bot 24\n\tRangs\tAntipro TAB dr 400mg 100's pack 114\n\tReliance\tMelagyl Suspension 200mg/5ml 60ml bot 25\n\tReliance\tMelagyl TAB dr 400mg 100's pack 102\n\tReman Drug Ltd.\tRemagyl Suspension 200mg/5ml 60ml bot 21.50\n\tRenata\tMez TAB dr 400mg 100's pack 125\n\tRenata\tMez IV Infusion 500mg/100ml 100ml bot 70\n\tRephco\tMetrogyl Suspension 200mg/5ml 60ml bot 25\n\tRephco\tMetrogyl TAB dr 400mg 100's pack 110\n\tS. N.\tElygyl Suspension 200mg/5ml 60ml bot 22.08\n\tS. N.\tElygyl TAB dr 400mg 100's pack 100\n\tSalton\tVigil Suspension 200mg/5ml 60ml bot 22.08\n\tSalton\tVigil TAB dr 400mg 100's pack 100\n\tSanofi Aventis (BD) Ltd.\tFlagyl Suspension 200mg/5ml 60ml bot 24.94\n\tSanofi Aventis (BD) Ltd.\tFlagyl TAB dr 200mg 500's pack 332.50\n\tSanofi Aventis (BD) Ltd.\tFlagyl TAB dr 400mg 250's pack 285.95\n\tSanofi Aventis (BD) Ltd.\tFlagyl IV Infusion 500mg/100ml 100ml bot 85.22\n\tSeema\tSeemagyl Suspension 200mg/5ml 60ml bot 24\n\tShamsul Al-Amin\tProzol TAB dr 400mg 100's pack 100\n\tSilco Pharmaceuticlas Ltd.\tSilmet Suspension 200 mg/5 ml  \n\tSilco Pharmaceuticlas Ltd.\tSilmet TAB dr 400mg  \n\tSilva\tMetrosil Suspension 200mg/5ml 60ml bot 19.07\n\tSilva\tMetrosil TAB dr 400mg 100's pack 100.38\n\tSomatec\tSomet Suspension 200mg/5ml 60ml bot 18.81\n\tSonear Ltd.\tNida TAB dr 400mg 100's pack 82\n\tSquare\tAmodis Suspension 200mg/5ml 60ml bot 24.85\n\tSquare\tAmodis TAB dr 400mg 200's pack 202.16\n\tSquare\tAmodis TAB dr 500mg 100's pack 135\n\tSquare\tAmodis IV Infusion 500mg/100ml 100ml bot 53.40\n\tSupreme\tMenol Suspension 200mg/5ml 60ml bot 25.75\n\tSupreme\tMenol TAB dr 400mg 100's pack 114\n\tSyntho Ltd.\tDymet Suspension 200mg/5ml 60ml bot 22\n\tSyntho Ltd.\tDymet TAB dr 400mg 100's pack 100\n\tTechno Drugs Ltd.\tKilpro TAB dr 400mg 100's pack 114\n\tTechno Drugs Ltd.\tKilpro IV Infusion 500mg/100ml 100ml bot 65\n\tWhite Horse Pharma\tTilomet TAB dr 400mg 100's pack 114\n\tWhite Horse Pharma\tTilomet TAB dr 200mg 100's pack 66\n\tZenith\tMetrozen Suspension 200mg/5ml 60ml bot 21.30\n\tZenith\tMetrozen TAB dr 400mg 200's pack 214\n\tZiska\tMetro TAB dr 400mg 100's pack 105\n\tZiska\tMetrobac IV Infusion 500mg/100ml 100ml bot 53\n\tZiska\tMetro Suspension 200mg 60ml bot 25\n\tZiska\tMetro 400 TAB dr 400mg 100's pack 105\n\tZiska\tMetro Suspension 200 mg / 5 ml  60 ml bot 25\n\tZiska\tMetrobac 100 IV Injection 500 mg /100 ml 1's pack 53\n\tIndication: Pneumonia, Giardiasis, Peptic ulcer disease, Peritonitis, H. pylori infection, Rosacea, Septicemia, Endometritis, Aspiration pneumonia, Lung abscess, Empyema, Bone and Joint Infections, Surgical Prophylaxis, Amoebiasis, Bacterial vaginosis, Balantidiasis, Blastocystis hominis infection, Trichomoniasis, Acute dental infections, Acute necrotising ulcerative gingivitis, Anaerobic bacterial infections, Antibiotic-associated colitis, Fungating tumours, Leg ulcers and pressure sores, Diverticulitis, Diabetic foot ulcer, Meningitis and brain abscesses, endocarditis\n\nDose: Adults & Children (over 10 years): PO Amoebiasis; Balantidiasis; Blastocystis hominis infection 400-800 mg 3 times/day for 5-10 days. Trichomoniasis 2 g as a single dose for 2 days or 0.6-1 g/day in 2-3 divided doses for 7 days.\n\nRepeat 4-6 wk later if needed. Giardiasis 2 g once daily for 3 consecutive days. Acute dental infections; Acute necrotising ulcerative gingivitis 200 mg 3 times/day. Anaerobic bacterial infections Initial: 800 mg, then 400 mg 8 hrly for about 7 days. \n\nSurgical prophylaxis 400 mg 8 hrly in the 24 hr before surgery followed post-op by IV or rectal route until PO is possible.\n\n Eradication of H. pylori associated w/ peptic ulcer disease W/ omeprazole and amoxicillin: 400 mg 3 times/day for 1 wk. Leg ulcers and pressure sores 400 mg 3 times/day for 7 days. Antibiotic-associated colitis 250-500 mg 2-3 times/day for 10-14 days. Change to oral vancomycin if no clear response after 2 days. \n\nIV: Anaerobic bacterial infections 500 mg 8 hrly. Surgical prophylaxis 500 mg shortly pre-op and repeat 8 hrly. Substitute w/ oral doses at 200 or 400 mg 8 hrly as soon as possible. \n\nChildren: IV: 7.5 mg/kg (1.5 ml/kg) 8 hourly. \n\n\nContra-indication: History of hypersensitivity to metronidazole or other nitroimidazole derivatives. Pregnancy (1st trimester) and lactation.\n\nSide effects: GI disturbances e.g. nausea, unpleasant metallic taste, vomiting, diarrhoea or constipation. Furred tongue, glossitis, and stomatitis due to overgrowth of Candida. Rarely, antibiotic-associated colitis. Weakness, dizziness, ataxia, headache, drowsiness, insomnia, changes in mood or mental state. Numbness or tingling in the extremities, epileptiform seizures (high doses or prolonged treatment). Transient leucopenia and thrombocytopenia. Hypersensitivity reactions. Urethral discomfort and darkening of urine. Raised liver enzyme values, cholestatic hepatitis, jaundice. Thrombophlebitis (IV).\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Patients with CNS diseases; discontinue IV therapy if abnormal neurologic symptoms occur. History of seizure disorder. Evidence or a history of blood dyscrasias; perform total and differential leukocyte counts before and after treatment. Severe hepatic impairment; monitor plasma levels. Predisposition to oedema (inj contains sodium). Prolonged use may result in fungal or bacterial superinfection.\n\nMode of action: Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.\n\nPregnancy category: B\n\nInteraction: Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
Metronidazole + Miconazole Nitrate Vag prep	\n\n\tAmbee\tAmetrol VT Vaginal TAB dr   10's pack 110.40\n\tIndication: Vaginal candidiasis, Bacterial and trichomonal vaginitis\n\nDose: Adult: Vag candidiasis As pessary: 100 mg every night for 7-14 days. As 2% cream: 5 g every night for 7-14 days. \n\nContra-indication: Hypersensitivity; hepatic impairment (oral gel). Porphyria.\n\nSide effects: Nausea, vomiting, febrile reactions, rash, drowsiness, diarrhoea, anorexia and flushing, hepatitis. Local irritation and sensitisation, contact dermatitis.\nPotentially Fatal: IV: Anaphylactic reaction and cardiac arrest.\n\nPrecaution: For external use only; discontinue if sensitization or irritation occurs. Pregnancy and lactation\n\nMode of action: Metronidazole: Disulfiram-like reaction w/ alcohol. Increased oral anticoagulant effect, blood levels of phenytoin, lithium toxicity, plasma conc of astemizole & terfenadine; blood conc of carbamazepine. Decreased blood levels w/ phenobarb. Risk of CNS-related effects (eg psychotic reactions) w/ disulfiram. Increased blood levels & neurologic effects w/ cimetidine. May increase blood levels & toxicity of fluorouracil; toxicity of cyclosporine. Increased cardiotoxicity w/ amiodarone. Interference w/ blood levels of liver enzymes, glucose (hexokinase method), theophylline & procainamide. Decreased levels w/ phenytoin. \n\nMiconazole: Increased risk of bleeding w/ acenocoumarol, anisindione, dicumarol, phenindione, phenprocoumon, warfarin; plasma conc & exposure to oxybutinin. May increase risk of phenytoin, phosphenytoin, cyclosporine, trimetrexate toxicity & cardiotoxicity w/ pimozide. May inhibit metabolism of astemizole, cisapride & terfenadine. Reduced carbamazepine metabolism. Increased or prolonged effects of opioid (fentanyl). May cause hypoglycemia w/ glimepiride. Reduced clearance & increased plasma conc of oxycodone. May increase bioavailability of tolterodine (in patients w/ deficient CYP2D6 activity).\n\nPregnancy category: A\n\nInteraction: Metronidazole: Disulfiram-like reaction w/ alcohol. Increased oral anticoagulant effect, blood levels of phenytoin, lithium toxicity, plasma conc of astemizole & terfenadine; blood conc of carbamazepine. Decreased blood levels w/ phenobarb. Risk of CNS-related effects (eg psychotic reactions) w/ disulfiram. Increased blood levels & neurologic effects w/ cimetidine. May increase blood levels & toxicity of fluorouracil; toxicity of cyclosporine. Increased cardiotoxicity w/ amiodarone. Interference w/ blood levels of liver enzymes, glucose (hexokinase method), theophylline & procainamide. Decreased levels w/ phenytoin. \n\nMiconazole: Increased risk of bleeding w/ acenocoumarol, anisindione, dicumarol, phenindione, phenprocoumon, warfarin; plasma conc & exposure to oxybutinin. May increase risk of phenytoin, phosphenytoin, cyclosporine, trimetrexate toxicity & cardiotoxicity w/ pimozide. May inhibit metabolism of astemizole, cisapride & terfenadine. Reduced carbamazepine metabolism. Increased or prolonged effects of opioid (fentanyl). May cause hypoglycemia w/ glimepiride. Reduced clearance & increased plasma conc of oxycodone. May increase bioavailability of tolterodine (in patients w/ deficient CYP2D6 activity).
Metronidazole + Neomycin Sulphate + Nystatin + Polmyxin B Vag prep	\n\n\tAcme Ltd.\tGynastin Vaginal suppository  1's \n\tAristopharma\tGynoxin Suppository   12's pack 288\n\tDrug International Ltd.\tGynomix CAP   6 caps pack 150\n\tGlobe\tGynoheal Soft Gelatin CAP 200 mg + 35000 IU + 1 Lac  \n\tOpsonin Pharma\tGynoril Suppository   12's pack 289.08\n\tPacific\tGyned Soft Gelatin CAP 200 mg + 35000 IU + 1 Lac  \n\tRenata\tV Cap CAP   6's pack 144\n\tSquare\tGynepro Suppository  200 mg + 35000 IU + 1 La  12's pack 288\n\tIndication: Vaginal trichomoniasis, Vaginal leucorrhoea, Bacterial or fungal vaginal infection\n\nDose: Per Vagina: One suppository to be inserted into vagina at bedtime for 12 days, or as directed by the physician. As Capsule: 100 mg every night for 7-14 days.\n\nContra-indication: Contraindicated in patients who are hypersensitive to any component of this product.\n\nSide effects: Skin rash and urticaria may occur rarely.\n\nPrecaution: Caution should be taken in case of renal impaired patients.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Metronidazole 0.75% Vag prep	\n\n\tIncepta\tFlamyd Gel Gel  .75% 30gm tube  50\n\tSquare\tCresac Vaginal Gel   25gm tube 35.14\n\tIndication: Bacterial vaginosis (also known as non-specific vaginitis, anaerobic vaginosis or gardnerella vaginitis).\n\nDose: GEL (approximately 5 grams containing approximately 37.5 mg of Metronidazole) intravaginally once or twice a day for 5 days.  For once a day dosing,  GEL should be administered at bedtime.\n\nContra-indication: Metronidazole is contraindicated in patients with a history of hypersensitivity to Metronidazole or other Nitroimidazole derivatives.\n\nSide effects: Vaginal irritation or discharge.\n\nPrecaution: Metronidazole should be given with caution in the following conditions- anaemia or other blood disorders, liver disease, disease of the nervous system, seizures etc.\n\nMode of action: Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.\n\nPregnancy category: B\n\nInteraction: Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.
Miconazole 2% Oral	\n\n\tACI\tMicoral Oral Gel  2% 15 gm tube/30gm tube 60.18/100.30\n\tAcme Ltd.\tA-Migel Oral Gel  2% 15 gm tube 50.20\n\tAristopharma\tMycon Oral Gel   15 gm tube 60\n\tBeximco\tCandoral Oral Gel   15 gm tube 52\n\tDrug International Ltd.\tMicoderm Oral Gel  15ML BOT 50\n\tEskayef Bangladesh Ltd.\tOrogurd Oral Gel Oral Gel   15 gm tube 50\n\tEverest\tMiral Gel Oral Gel   15 gm tube 48\n\tGeneral\tDakrin Oral Gel   15 gm tube 50.19\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMikogel Oral Gel 15g  60\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMicosina Oral Gel 20 mg/gm  \n\tIncepta\tOroconazole Oral Gel   15 gm tube 50\n\tMedicon\tMyzol Oral Gel   15 gm tube 50\n\tNovo Healthcare and Pharma Ltd.\tOrocare Oral Gel   15 gm tube 50\n\tOpsonin Pharma\tUnigal Oral Gel   1's pack 50.19\n\tPacific\tOrmico Oral Gel 20 mg/gm  \n\tPharmasia Ltd.\tMyco-OG Oral Gel   15 gm tube 50\n\tSquare\tGelora Oral Gel  20 mg/gm 15 gm tube 60\n\tUnimed & Unihealth Manufacturers Ltd.\tOragel-M Oral Gel  15ml tube 50\n\tIndication: Oropharyngeal candidiasis, Oral thrush, Denture stomatitis, Fungal infections of the mouth, Throat and gut, Angular cheilitis, Dermatomycoses, Tinea pedis, Tinea corporis, Tinea cruris, Tinea versicolor\n\nDose: For oral administration: The usual dose is 15 mg/kg/day in divided doses. \n\nAdults : 1-2 tea-spoonfuls of gel 4 times daily. \n\nChildren aged 6 years and over : 1 tea-spoonful of gel 4 times daily. \n\nChildren aged 2-6 years : 1 tea-spoonful of gel twice daily1 month - 2 years : 1/2 tea-spoonful of gel twice daily. Localised lesions of mouth:Smear small amount on affected area with clean finger 4 times daily for 5-7 days.\n\nContra-indication: Miconazole Oral Gel is contraindicated in patients with known hypersensitivity to any of its components and in patients with liver dysfunction.\n\nSide effects: Nausea, vomiting, diarrhoea (with long-term treatment); rarely allergic reactions; isolated reports of hepatitis.\n\nPrecaution: Caution is required particularly in infants & young children to ensure that the gel does not obstruct the throat.\n\nMode of action: May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.\nPotentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.\n\nPregnancy category: B\n\nInteraction: May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.\nPotentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.
Miconazole Nitrate	\n\n\tSquare\tFungidal DT TAB dr 10mg 30 's pack 150.43\n\tIndication: Oropharyngeal & Esophageal Candidiasis.\n\nDose: 1 tablet daily (apply in the morning) for 7 days. Miconazole should be applied to the gingiva in the morning, i.e. above the eye tooth, once daily, for one week. Do not swallow. A second week of treatment may be indicated. The use of Miconazole in children below the age of 7 is not recommended.\n\nContra-indication: Hypersensitivity; hepatic impairment (oral gel). Porphyria.\n\nSide effects: Nausea, vomiting, febrile reactions, rash, drowsiness, diarrhoea, anorexia and flushing, hepatitis. \nPotentially Fatal: IV: Anaphylactic reaction and cardiac arrest.\n\nPrecaution: Discontinue if sensitization or irritation occurs. Pregnancy and lactation.\n\nMode of action: May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.\nPotentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.\n\nPregnancy category: C\n\nInteraction: May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.\nPotentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.
Midazolam	\n\n\tACI\tDormilat Injection 5mg/5ml 1's pack 55\n\tACI\tDormilat TAB dr 15mg 5's pack 375\n\tACI\tDormilat Injection 15mg/3ml 5's pack 376.15\n\tAcme Ltd.\tMizolam TAB dr 7.5mg 30's pack 241.20\n\tAlbion Ltd.\tOmicum TAB dr 15 mg/ 7.5 mg 100's pack \n\tAristopharma\tDormax Injection 15mg/3ml 1 amps pack 150\n\tAristopharma\tDormax TAB dr 7.5mg 30's pack 240\n\tBio Pharma Ltd.\tBenquil TAB dr 7.5mg 30's pack 240\n\tBio Pharma Ltd.\tGaren TAB dr 7.5mg 30's pack \n\tBio Pharma Ltd.\tGaren TAB dr 15mg 30's pack \n\tEskayef Bangladesh Ltd.\tMilam Injection 15mg/3ml 1 amps pack 75\n\tEskayef Bangladesh Ltd.\tMilam TAB dr 15mg 20's pack 400\n\tEskayef Bangladesh Ltd.\tMilam TAB dr 7.5mg 30's pack 240\n\tEskayef Bangladesh Ltd.\tMilam Injection 1 mg/ml  \n\tGeneral\tAnquil TAB dr 15mg 10's pack 150.60\n\tGeneral\tAnquil IV/IM Injection 15mg/3ml 30's pack \n\tGeneral\tAnquil TAB dr 7.5mg 30's pack 240.90\n\tHealthcare\tHypnocum TAB dr 7.5mg 30's pack 300\n\tIncepta\tHypnofast Injection 5mg/5ml 1 amps pack 90\n\tIncepta\tHypnofast Injection 15mg/3ml 1 amps pack 150\n\tIncepta\tHypnofast TAB dr 15mg 10's pack 150\n\tIncepta\tHypnofast TAB dr 7.5mg 30's pack 240\n\tOpsonin Pharma\tMidolam Injection 15mg/3ml 1 amps pack/5 amps pack 75/375\n\tOpsonin Pharma\tMidolam TAB dr 15mg 10's pack 150\n\tOpsonin Pharma\tMidolam 5mg/5ml Injection 1mg/ml 1 amps pack 55\n\tOpsonin Pharma\tMidolam TAB dr 7.5mg 30's pack 240\n\tRadiant.\tDormicum TAB dr 7.5mg 30's pack \n\tRangs\tSedaquil TAB dr 7.5mg 30's pack 240\n\tRenata\tMidzo TAB dr 7.5mg 30's pack 240\n\tRenata\tMidzo IM/IV Injection 15mg/3ml 1's pack 75\n\tRoche Bangladesh Pharmaceutical\tDormicum Injection 5mg/5ml 10 amps pack 1700\n\tSquare\tDormitol Injection 15mg/3ml 1 amps pack 75\n\tSquare\tDormitol TAB dr 7.5mg 30's pack 240.99\n\tSquare\tDormitol TAB dr 15mg 20'S Pack 401\n\tRoche Fontenay, France\tDormicum Injection 15mg/3ml 5 amps pack 1147.52\n\tIndication: Insomnia, Sedation, Induction of anesthesia\n\nDose: Oral dosage: For adults 7.5-15 mg daily. In elderly and debilitated patients, the recommended dose is 7.5 mg. In premedication, 15 mg of Midazolam should be given 30-60 minutes before the procedure.\n\nIntravenous administration:\nEndoscopic or Cardiovascular Procedures\nIn healthy adults the initial dose is approximately 2.5 mg. In cases of severe illness and in elderly patients, the initial dose must be reduced to 1 to 1.5 mg.\n\nInduction of Anesthesia\nThe dose is 10-15 mg I. V.\n\nIntramuscular administration:\nAdult: 0.07-0.1 mg/kg bodyweight i. m. Usual dose is about 5 mg.\nChildren: 0.15-0.20 mg/kg.\nElderly and debilitated patients: 0.025-0.05 mg/kg\n\nRectal administration in children:\nFor preoperative sedation, rectal administration of the ampoule solution (0.35-0.45 mg/kg) 20-30 min before induction of general anesthesia. \n\nContra-indication: Midazolam must not be given to patients with severe respiratory insufficiency, severe hepatic insufficiency, myasthenia gravis, sleep apnea syndrome and with known hypersensitivity to benzodiazepines or to any component of the product.\n\nSide effects: At the start of therapy, drowsiness during daytime, confusion, fatigue, headache and muscle weakness may occur which usually disappear with repeated administration. Following parenteral (IV or IM) administration of Midazolam, fluctuations in vital signs have been noted including respiratory depression, apnoea, variations in blood pressure and pulse rate.\n\nPrecaution: Midazolam IV should be administered very slowly.\n\nMode of action: Increased CNS depression with alcohol, opioids, barbiturates, other sedatives and anaesthetics. Increased respiratory depression with opiates, phenobarbital, other benzodiazepines. Plasma concentrations increased by CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, diltiazem, verapamil, ketoconazole and itraconazole, antiretroviral agents, quinupristin with dalfopristin. Midazolam concentration decreased by phenytoin, carbamazepine, phenobarbital, rifampicin. Halothane, thiopental requirements may be reduced during concurrent use.\n\nPregnancy category: D\n\nInteraction: Increased CNS depression with alcohol, opioids, barbiturates, other sedatives and anaesthetics. Increased respiratory depression with opiates, phenobarbital, other benzodiazepines. Plasma concentrations increased by CYP3A4 inhibitors such as cimetidine, erythromycin, clarithromycin, diltiazem, verapamil, ketoconazole and itraconazole, antiretroviral agents, quinupristin with dalfopristin. Midazolam concentration decreased by phenytoin, carbamazepine, phenobarbital, rifampicin. Halothane, thiopental requirements may be reduced during concurrent use.
Mifepristone	\n\n\tIncepta\tMifeston TAB dr 200mg 3's pack 525\n\tRenata\tMIF TAB dr 200mg 3's pack 525\n\tIndication: Termination of pregnancy, Labour induction, Cervical softening and dilatation,  Postcoital contraception.\n\nDose: 1. As a medical alternative to surgical termination of intra-uterine pregnancy in early pregnancy: 600 mg Mifepristone (3 tablets) in a single oral dose followed 36-48 hrs later, by the administration of a prostaglandin analogue Misoprostol 400 mcg orally (up to 49 days).  \n\n2. Softening and dilatation of the cervix uteri prior to surgical pregnancy termination: 200 mg Mifepristone (one tablet), followed 36-48 hrs later (but not beyond) by a surgical termination of pregnancy. \n\n3. Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (to reduce the doses of prostaglandin): 600 mg of Mifepristone (3 tablets) taken in a single oral dose, 36-48 hrs prior to scheduled prostaglandin administration which will be repeated as often as indicated. \n\n4. Labour induction for expulsion of a dead fetus (fetal death in utero): 600 mg of Mifepristone in a single oral daily dose for 2 consecutive days. Mifepristone alone leads to expulsion in about 60%. Labour should be induced by the usual methods if it has not started within 72 hrs following the first administration of Mifepristone. \n\n5. Postcoital contraception 600 mg as a single dose w/in 72 hr of unprotected intercourse.\n\n\nContra-indication: Confirmed or suspected ectopic pregnancy, chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, misoprostol or other prostaglandin, haemorrhagic disorders or concurrent anticoagulant therapy, porphyria, hepatic or renal impairment; pregnancy and lactation; IUD in place; undiagnosed adnexal mass.\n\nSide effects: Excessive vaginal bleeding; UTI; uterine haemorrhage; uterine infections; unusual tiredness or weakness; back pain; diarrhoea, nausea, vomiting; fever; dizziness; headache; anxiety; GI cramps.\n\nPrecaution: Mifepristone must not be administered if there is doubt as to the existence or age of the pregnancy or if an extra-uterine pregnancy is suspected. An ultrasound scan and/or measurement of Beta-hCG must be performed before administration. For first trimester abortions, Mifepristone is contraindicated if the pregnancy is beyond 49 days of amenorrhoea when used with Misoprostol.  Mifepristone should never be prescribed in patients with chronic adrenal failure, known allergy to Mifepristone or to any component of the product, severe asthma uncontrolled by corticosteroid therapy, porphyrias and renal failure, liver failure or malnutrition, or during breast feeding. Mifepristone is a lipophilic compound and may theoretically be excreted in the mother's breast milk, however no data is available.\n\nMode of action: Decreased efficacy with aspirin and NSAIDs. Efficacy of corticosteroids (including inhaled) decreased, monitor patients during co-admin and for several days afterwards.\n\nPregnancy category: X\n\nInteraction: Decreased efficacy with aspirin and NSAIDs. Efficacy of corticosteroids (including inhaled) decreased, monitor patients during co-admin and for several days afterwards.
Miglitol	\n\n\tACI\tDiaset TAB dr 25mg 30's pack 302.10\n\tACI\tDiaset TAB dr 50mg 30's pack 453.30\n\tIndication: Type 2 DM\n\nDose: Adult: PO Initial:25 mg 3 times/day. May increase after 4-8 wk. Maintenance: 50 mg 3 times/day. Max:100 mg 3 times/day.\n\nContra-indication: Renal clearance <25 ml/min, GI motility disorders or the presence of inflammatory bowel disease, diabetic ketoacidosis, colonic ulceration, or partial intestinal obstruction. Lactation.\n\nSide effects: Abdominal pain, diarrhoea, flatulence, skin rash. To minimise GI effects, treatment may be initiated at 25 mg once daily and increased gradually to three times daily.\n\nPrecaution: Hypoglycaemia, renal impairment.\n\nMode of action: Concomitant use w/ insulin increases the risk of hypoglycaemia. Intestinal adsorbents (e.g. charcoal) and carbohydrate-splitting digestive enzyme supplements (e.g. amylase, pancreatin) may reduce glycaemic effects. May significantly reduce the bioavailability of ranitidine and propranolol.\n\nPregnancy category: B\n\nInteraction: Concomitant use w/ insulin increases the risk of hypoglycaemia. Intestinal adsorbents (e.g. charcoal) and carbohydrate-splitting digestive enzyme supplements (e.g. amylase, pancreatin) may reduce glycaemic effects. May significantly reduce the bioavailability of ranitidine and propranolol.
Milnacipran Hydrochloride	\n\n\tBeacon\tMilran TAB dr 50mg 20's pack 300\n\tBeacon\tMilran TAB dr 12.5mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeocipran TAB dr 50mg 30's pack 450\n\tIndication: Depression, Fibromyalgia\n\nDose: Based on efficacy and tolerability dosing may be titrated according to the following schedule:\n\nDay 1: 12.5 mg once\n\nDays 2-3: 25 mg/day (12.5 mg twice daily)\n\nDays 4-7: 50 mg/day (25 mg twice daily)\n\nAfter Day 7: 100 mg/day (50 mg twice daily)\n\nBased on individual patient response, the dose may be increased to 200 mg/day (100 mg twice daily).\n\nDoses above 200 mg/day have not been studied. \n\nContra-indication: 1. Monoamine Oxidase Inhibitors (MAOIs)\n 2. Uncontrolled Narrow-Angle Glaucoma \n\nSide effects: The most frequently occurring adverse reactions (? 5% and greater than placebo) were nausea, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, vomiting, palpitations, heart rate increased, dry mouth, and hypertension  . \n\nPrecaution: 1 Suicide Risk\n2 Serotonin Syndrome\n3 Elevated Blood Pressure\n4 Elevated Heart Rate\n5 Seizures\n6 Hepatotoxicity\n7 Discontinuation of Treatment with Savella\n8 Hyponatremia\n9 Abnormal Bleeding\n10 Activation of Mania\n11 Patients with a History of Dysuria\n12 Controlled Narrow-Angle Glaucoma\n13 Concomitant Use with Alcohol \n\nMode of action: Iproniazide, nialamide, selegiline, digitalis, sumatriptan, parenteral epinephrine or norepinephrine, clonidine, moclobemide, toloxantone.\n\nPregnancy category: C\n\nInteraction: Iproniazide, nialamide, selegiline, digitalis, sumatriptan, parenteral epinephrine or norepinephrine, clonidine, moclobemide, toloxantone.
Minoxidil 2%	\n\n\tIncepta\tXenogrow 2% Scalp Lotion   60ml bot 500\n\tRenata\tRegain 2% Scalp Lotion   60ml bot 348\n\tSquare\tSplendora 2% Scalp Lotion 2% 1's pack(60ml) 500\n\tTechno Drugs Ltd.\tRegrow 2% Scalp Lotion   60ml bot 175\n\tZiska\tTrugain 2% Scalp Lotion  60ml bot 348\n\tIndication: Male pattern baldness, Alopecia androgenetica\n\nDose: Apply 1 ml solution to the scalp bid. 4 mth of treatment may be necessary.\n\nHair and scalp should be thoroughly dry prior to topical application of Minoxidil. A dose of 1 ml Minoxidil cutaneous solution should be applied to the total affected areas of the scalp twice daily. The total dosage should not exceed 2 ml. If fingertips are used to facilitate drug application, hands should be washed afterwards.\n\nIt should be used twice daily for four months or more before evidence of hair growth can be expected.\n\nContra-indication: Minoxidil topical solution is contraindicated in patients with a history of hypersensitivity to Minoxidil or any of the other ingredients in the formulation such as propylene glycol or ethanol.\n\nSide effects: Minoxidil is well tolerated. However few side effects such as hypertrichosis (unwanted non-scalp hair including facial hair growth in women), local erythema, itching, dry skin/scalp flaking, and exacerbation of hair loss have been reported commonly.\n\nPrecaution: Before using Minoxidil, the user should determine that the scalp is normal and healthy. Patients with known cardiovascular disease or cardiac arrhythmia should contact a physician before using Minoxidil. Minoxidil contains alcohol, which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin and mucous membranes) the area should be bathed with large amount of cool tap water.\n\nMode of action: Antihypertensive effect may be enhanced by other hypotensive drugs. Topical: Absorption may be increased with corticosteroids, retinoids, occlusive ointment bases.\nPotentially Fatal: Severe orthostatic hypotension may occur with guanethidine.\n\nPregnancy category: C\n\nInteraction: Antihypertensive effect may be enhanced by other hypotensive drugs. Topical: Absorption may be increased with corticosteroids, retinoids, occlusive ointment bases.\nPotentially Fatal: Severe orthostatic hypotension may occur with guanethidine.
Minoxidil 5%	\n\n\tIncepta\tXenogrow 5% Scalp Lotion   60ml bot 600\n\tRenata\tRegain 5% Scalp Lotion   60ml bot 398\n\tSquare\tSplendora 5% Scalp Lotion  50 mg/ml 60ml bot 600\n\tZiska\tTrugain 5% Scalp Lotion  60ml bot 398\n\tIndication: Male pattern baldness, Alopecia androgenetica\n\nDose: Apply 1 ml  solution to the scalp bid. 4 mth of treatment may be necessary.\nHair and scalp should be thoroughly dry prior to topical application of Minoxidil. A dose of 1 ml Minoxidil cutaneous solution should be applied to the total affected areas of the scalp twice daily. The total dosage should not exceed 2 ml. If fingertips are used to facilitate drug application, hands should be washed afterwards.\nIt should be used twice daily for four months or more before evidence of hair growth can be expected.\n\nContra-indication: Minoxidil topical solution is contraindicated in patients with a history of hypersensitivity to Minoxidil or any of the other ingredients in the formulation such as propylene glycol or ethanol.\n\nSide effects: Minoxidil is well tolerated. However few side effects such as hypertrichosis (unwanted non-scalp hair including facial hair growth in women), local erythema, itching, dry skin/scalp flaking, and exacerbation of hair loss have been reported commonly.\n\nPrecaution: Before using Minoxidil, the user should determine that the scalp is normal and healthy. Patients with known cardiovascular disease or cardiac arrhythmia should contact a physician before using Minoxidil. Minoxidil contains alcohol, which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin and mucous membranes) the area should be bathed with large amount of cool tap water.\n\n\n\nMode of action: Antihypertensive effect may be enhanced by other hypotensive drugs. Topical: Absorption may be increased with corticosteroids, retinoids, occlusive ointment bases.\nPotentially Fatal: Severe orthostatic hypotension may occur with guanethidine.\n\nPregnancy category: C\n\nInteraction: Antihypertensive effect may be enhanced by other hypotensive drugs. Topical: Absorption may be increased with corticosteroids, retinoids, occlusive ointment bases.\nPotentially Fatal: Severe orthostatic hypotension may occur with guanethidine.
Mirtazapine	\n\n\tACI\tRapine TAB dr 15 mg 30's pack 240\n\tACI\tRapine TAB dr 30mg  \n\tACI\tRapine TAB dr 7.5mg  \n\tAlbion Ltd.\tTrazapin TAB dr 15 mg 100's pack \n\tBeacon\tMirapin TAB dr 15mg  \n\tGeneral\tMitrazin TAB dr 15mg 30's pack 240.90\n\tGeneral\tMitrazin TAB dr 30mg  \n\tHealthcare\tMirez TAB dr 15mg  \n\tHealthcare\tMirez TAB dr 30mg  \n\tIncepta\tMitaprex 15 TAB dr 15mg 30's pack 240\n\tIncepta\tMitaprex 30 TAB dr 30mg 30's pack 450\n\tSun Pharmaceutical (Bangladesh) Ltd.\tMirtaz TAB dr 15mg 50's pack 402.50\n\tSun Pharmaceutical (Bangladesh) Ltd.\tMirtaz TAB dr 30mg  \n\tSun Pharmaceutical (Bangladesh) Ltd.\tMirtaz TAB dr 7.5mg  \n\tSandoz GmbH, Austria\tMirzalux TAB dr 15mg 40's pack 320\n\tSandoz GmbH, Austria\tMirzalux TAB dr 30mg 30's pack 540\n\tIndication: Depression, Major depressive disorder\n\nDose: Adult: PO Initial: The recommended starting dose for (mirtazapine) Tablets is 15 mg/day, administered in a single dose, preferably in the evening prior to sleep. In the treatment of major depressive disorder, the effective dose range was generally  15-45 mg/day as 1-2 divided doses.\n\nContra-indication: Mirtazapine Tablets are contraindicated in patients with a known hypersensitivity to mirtazapine or to any of the excipients. \n\nSide effects: Increase in appetite and wt, oedema; drowsiness or sedation; dizziness, headache, increased liver enzyme levels; jaundice. Orthostatic hypotension, rash, nightmares, agitation, mania, hallucinations, paraesthesia, convulsions, tremor, myoclonus, akathisia, restless legs syndrome, arthralgia, myalgia, reversible agranulocytosis, leucopenia, granulocytopenia, hyponatraemia.\n\nPrecaution: Epilepsy or history of seizures; avoid completely in unstable cases. Hepatic or renal impairment, cardiac disorders e.g. conduction disturbances, angina pectoris, recent MI. Hypotension, DM, psychoses, history of bipolar disorder. Stop treatment if jaundice develops. Micturition disturbances, angle-closure glaucoma, raised intraocular pressure. Monitor patient for signs of bone marrow depression. Monitor patient for suicidal tendency. Avoid abrupt withdrawal. May impair ability to drive or operate machinery. Pregnancy and lactation. Elderly.\n\nMode of action: Potentiation of sedative effects with alcohol or benzodiazepines. Increased plasma levels with potent CYP3A4 inhibitors (e.g. HIV-protease inhibitors, azole antifungals including ketoconazole, erythromycin, nefazodone). Reduced plasma levels with carbamazepine and other inducers of CYP3A4. Increased bioavailability with cimetidine.\nPotentially Fatal: Do not use with or within 2 wk of stopping an MAOI; at least 1 wk should elapse between discontinuing mirtazapine and initiating any drug which may provoke a serious reaction (e.g. phenelzine).\n\nPregnancy category: C\n\nInteraction: Potentiation of sedative effects with alcohol or benzodiazepines. Increased plasma levels with potent CYP3A4 inhibitors (e.g. HIV-protease inhibitors, azole antifungals including ketoconazole, erythromycin, nefazodone). Reduced plasma levels with carbamazepine and other inducers of CYP3A4. Increased bioavailability with cimetidine.\nPotentially Fatal: Do not use with or within 2 wk of stopping an MAOI; at least 1 wk should elapse between discontinuing mirtazapine and initiating any drug which may provoke a serious reaction (e.g. phenelzine).
Misoprostol	\n\n\tAcme Ltd.\tMisoclear TAB dr 200mcg 30's pack 450\n\tAcme Ltd.\tMisoclear TAB dr 600 mcg 10's pack 400\n\tAcme Specialized\tMisoclear TAB dr 200 mcg  \n\tBeximco\tMisopa TAB dr 100mcg 30's pack 240\n\tBeximco\tMisopa TAB dr 200mcg 30's pack 450\n\tBeximco\tMisopa TAB dr 600mcg 10's pack 400\n\tEuro Pharma Ltd.\tMisotab TAB dr 200mcg 30's pack 450\n\tGonoshasthaya\tG- Misoprostol TAB dr 200 mcg 30's pack 301.20\n\tGonoshasthaya\tG-Misoprostol TAB dr 200mcg 30's pack 301.20\n\tIncepta\tCytomis TAB dr 100mcg 30's pack 240\n\tIncepta\tCytomis TAB dr 200mcg 30's pack 450\n\tRenata\tIndula TAB dr 200mcg 3x10's pack \n\tSquare\tIsovent TAB dr 200mcg 30's pack 451.67\n\tSquare\tIsovent TAB dr 600mcg 10's pack 400\n\tSquare\tIsovent TAB dr 100 mcg 30's pack 240.99\n\tZiska\tMisotol TAB dr 200mcg 20's pack 300\n\tIndication: NSAID-induced ulcers, Termination of pregnancy, Benign gastric and duodenal ulcers\n\nDose: Adult: Benign gastric and duodenal ulceration and NSAID associated ulceration: 800 mcg daily (in 2-4 divided doses) with breakfast or main meals and at bedtime; treatment should be continued for at least 4 weeks and may be continued for up to 8 weeks if required. \n\nProphylaxis of NSAID induced gastric and duodenal ulcer: 200 mcg 2-4 times daily taken with NSAID. If this dose cannot be tolerated, a dose of 100 mcg can be used. Misoprostol should be taken for the duration of NSAID therapy as prescribed by the physician. \n\nInduction of labor: Place 25 mcg in the posterior fornix of the vagina. Repeat after every 6 hours if necessary until the maximum dosage of 200 mcg total misoprostol is reached. Fetal heart rate and uterus contractions should be monitored.  Alternatively, 100 mcg taken orally. If cervical ripening or active labor does not occur, repeated dose of 100- 200 mcg of oral misoprostol is given every 4 hourly until labor is established (as evidenced by a Bishop score of 7 or more). Maximum number of dose is 6. \n\nMaternal vital signs, fetal heart rate and contractions should be monitored. Oxytocin can be started 4 hours after last dose of misoprostol. Physician should be notified for signs of fetal distress or tetanic uterine contractions. Oral misoprostol therapy should be monitored by Physician. \n\nPrevention of postpartum haemorrhage: 600 mcg orally immediately following delivery. Treatment of postpartum haemorrhage: 600 mcg orally or 1000 mcg per rectally. \n\nTermination of pregnancy (<49 days of duration) 400 mcg as a single dose 36-48 hr after mifepristone. \n\nUse in children: Safety and effectiveness of Misoprostol in children below the age of 18 years have not been established.\n\nContra-indication: Misoprostol is contraindicated to anyone with a history of allergy to prostaglandins. Women of childbearing potential. Pregnancy and lactation. \n\nSide effects: Diarrhoea, abdominal pain, dyspepsia, constipation, flatulence, nausea and vomiting; abnormal vaginal bleeding, cramps, increased uterine contractility, headache.\n\nPrecaution: In case of prevention and treatment of NSAID induced gastric and duodenal ulcer: Misoprostol is contraindicated in women who are pregnant, and should not be used in women of child bearing potential unless the patient requires NSAID therapy. Women of child bearing potential should be told that they must not be pregnant when Misoprostol therapy is initiated and they must use an effective contraception method while taking misoprostol. Conditions where hypotension might precipitate severe complications e.g. cerebrovascular or CV disease. Inflammatory bowel disease. Patients prone to dehydration. Elderly. Renal impairment.\n\nMode of action: May increase effects of oxytocin. Increased risk of misoprostol-induced diarrhoea with magnesium-containing antacids.\n\nPregnancy category: X\n\nInteraction: May increase effects of oxytocin. Increased risk of misoprostol-induced diarrhoea with magnesium-containing antacids.
Mizolastine	\n\n\tACI\tMastel MR TAB dr 10mg 30's pack 195.60\n\tOpsonin Pharma\tRhinor MR TAB dr 10mg 50's pack 250\n\tIndication: Allergic conditions\n\nDose: Oral\nAllergic conditions\nAdult: 10 mg daily.\nChild: >12 yr: 10 mg daily.\nElderly: 10 mg daily.\n\nContra-indication: Significant cardiac or hepatic disease; electrolyte imbalance, particularly hypokalaemia; known or suspected QT prolongation. Clinically significant bradycardia.\n\nSide effects: Dry mouth, diarrhoea, abdominal pain, nausea; transient drowsiness, headache, dizziness; anxiety and depression; raised liver enzymes: low neutrophil count; transient asthenia, increased appetite associated with wt gain; allergic reactions e.g. angioedema, generalised rash/urticaria, pruritus and hypotension; tachycardia, palpitations; vasovagal attack; arthralgia and myalgia.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: May impair ability to drive or operate machinery. Elderly. Pregnancy (avoid in 1st trimester) and lactation.\n\nMode of action: Antidepressants and anxiolytics may enhance sedative effect. Potent inhibitors of or substrates for the hepatic metabolism of mizolastine (e.g. cimetidine, ciclosporin, nifedipine) may alter its metabolism.\nPotentially Fatal: Increased risk of cardiac arrhythmias with drugs known to prolong the QT interval e.g. class I and III antiarryhthmics. Increased plasma concentrations with macrolide antibiotics and imidazole antifungals.\n\nPregnancy category: Not Classified\n\nInteraction: Antidepressants and anxiolytics may enhance sedative effect. Potent inhibitors of or substrates for the hepatic metabolism of mizolastine (e.g. cimetidine, ciclosporin, nifedipine) may alter its metabolism.\nPotentially Fatal: Increased risk of cardiac arrhythmias with drugs known to prolong the QT interval e.g. class I and III antiarryhthmics. Increased plasma concentrations with macrolide antibiotics and imidazole antifungals.
Mometasone Furoate	\n\n\tBeximco\tNasomet Nasal Spray 50mcg 120 dose ( spray) unit 250\n\tIncepta\tMomeson Nasal Spray 50mcg 120 dose ( spray) unit 250\n\tIncepta\tMomeson Convicap Dry powder inhalation capsule 220mcg 30's pack 300\n\tOpsonin Pharma\tNasonex Nasal Spray 50mcg 120 dose ( spray) unit 250\n\tSquare\tMetaspray Nasal Spray 50mcg  120 dose ( spray) unit 259.94\n\tIndication: Allergic rhinitis, Nasal polyps, Asthma prophylaxis\n\nDose: Nasal Treatment and prophylaxis of allergic rhinitis Adults: 100 mcg (2 sprays) in each nostril once daily, increased to 200 mcg into each nostril once daily if needed. Maintenance: 50 mcg in each nostril daily. \n\nChild: 2-11 yr: 50 mcg (1 spray) in each nostril daily; Child: >12 yr: 100 mcg in each nostril daily. \n\nNasal polyps Adult: 100 mcg (2 sprays) in each nostril once daily; may increase to bid after 5-6 wk if needed. \n\nInhalation Asthma prophylaxis Adult: Mild to moderate: Initially, 400 mcg once daily in the evening. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled. \n\nChild: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.\n\nContra-indication: Hypersensitivity to any of the ingredients of this preparation contraindicates its use.\n\nSide effects: Nasal/Oral inhalation: Headache, fatigue, depression; musculoskeletal pain, arthalgia; sinusitis, rhinitis, upper respiratory infection, pharyngitis, cough, epistaxis; viral infection, nasal and oral candidiasis; chest pain; abdominal pain, dry throat, vomiting, diarrhoea, dyspepsia, flatulence, gastroenteritis, nausea, vomiting; dysmenorrhoea; back pain, myalgia; conjunctivitis; earache, otitis media; asthma, bronchitis, dysphonia; nasal irritation, burning and septal perforation; wheezing; nasal ulcers; growth suppression. \n\nPrecaution: Use with caution in active or inactive tuberculosis infection, herpes simplex virus infection of the eye, untreated infections affecting the body as a whole etc.\n\nMode of action: Increased risk of hypokalaemia with amphotericin B, potassium-wasting diuretics. Decreases hypoglycaemic effects of antidiabetic drugs. Increased serum levels with antifungals (imidazole). Increased risk of tendinopathies with fluoroquinolones.\n\nPregnancy category: C\n\nInteraction: Increased risk of hypokalaemia with amphotericin B, potassium-wasting diuretics. Decreases hypoglycaemic effects of antidiabetic drugs. Increased serum levels with antifungals (imidazole). Increased risk of tendinopathies with fluoroquinolones.
Mometasone Furoate 0.1% Topical	\n\n\tACI\tMeloderm Cream  .1% 5g 100.30\n\tACI\tMeloderm Ointment  .1% 5g 100.30\n\tAristopharma\tSoneta Cream   5gm tube 100\n\tAristopharma\tSoneta Ointment   5gm tube 100\n\tGeneral\tElocan Ointment   5gm tue 100.38\n\tIncepta\tMomeson Cream   5gm tue 100\n\tPopular\tMometa Cream  100 mg/100 gm 10gm tube 180.68\n\tRAK\tMomevate 0.1% Cream   5gm tube 100\n\tSanofi Aventis (BD) Ltd.\tMomtec Cream 5GM Cream 5gm 1's Pack 100\n\tSanofi Aventis (BD) Ltd.\tMomtec Cream 10GM Cream 10gm 1's Pack 180\n\tIndication: Psoriasis, Corticosteroid- responsive dermatoses\n\nDose: A thin film of Mometasone Furoate cream should be applied to the affected skin areas once daily.\nSafety and effectiveness in paediatric patients below 2 years of age have not been established.\n\nContra-indication: The drug is contraindicated in individuals with a history of sensitivity reactions to Mometasone or any of the components of the preparation. \n\nSide effects: Mometasone Furoate cream is generally well tolerated. Burning, Pruritus and skin atrophy may occur. \n\nPrecaution: If irritation develops with the use of Mometasone Furoate cream, treatment should be discontinued. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Monosulfiram 25%	\n\n\tACI\tTetrasol Solution  25% 30ml bot 68.20\n\tG. A. Company Ltd.\tMonosol Solution   30ml bot 50.58\n\tIndication: Scabies\n\nDose: It used in place of ordinary toilet soap for the prophylaxis of scabies. Ideally, the person should bathe in hot water and soap themselves liberally with  Soap paying particular attention to the folded areas of the skin. After bathing, the body should be allowed to dry naturally or dried with a towel using a 'blotting' action.   Soap should be used daily for as long as the danger of infection remains.\n\nContra-indication: Patients who have previously shown an idiosyncratic response to its application.\n\n\nSide effects: Cases of erythematous rash have been reported.\n\nPrecaution: Cases of erythematous rash have been reported.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Montelukast	\n\n\tACI\tReversair TAB dr 10mg 20's pack 302.20\n\tACI\tReversair TAB dr 4mg 20's pack 141\n\tACI\tReversair TAB dr 5mg 20's pack 161\n\tAcme Ltd.\tMonas TAB dr 10mg 5's pack/15's pack 75.25/225.75\n\tAcme Ltd.\tMonas TAB dr 4mg 5's pack/30's pack 30.10/180.60\n\tAcme Ltd.\tMonas TAB dr 5mg 5's pack/30's pack 40.20/241.20\n\tAlbion Ltd.\tMonkon TAB dr 4mg  \n\tAlbion Ltd.\tMonkon TAB dr 5mg  \n\tAlbion Ltd.\tMonkon TAB dr 10mg  \n\tAlco Pharma\tMokast TAB dr 10mg 10's pack 100\n\tAlco Pharma\tMokast TAB dr 4mg 20's pack 120\n\tApex\tMontelon TAB dr 10mg 20's pack 300\n\tApex\tMolus TAB dr 4mg 10's pack 70\n\tApex\tMolus TAB dr 10mg 10's pack 150\n\tAristopharma\tMontril TAB dr 10mg 20's pack 300\n\tAristopharma\tMontril TAB dr 4mg 30's pack 210\n\tAristopharma\tMontril TAB dr 5mg 30's pack 240\n\tAsiatic Ltd.\tLiam TAB dr 10mg 10's pack 150\n\tAsiatic Ltd.\tLiam Chewable TAB dr 5mg  \n\tBeximco\tMonocast TAB dr 10mg 10's pack 140\n\tBeximco\tMonocast TAB dr 4mg 20's pack 110\n\tBeximco\tMonocast TAB dr 5mg 20's pack 150\n\tBeximco\tMonocast Sachet 4mg  \n\tBio Pharma Ltd.\tFreegest TAB dr 10mg 20's pack 300\n\tBio Pharma Ltd.\tFreegest TAB dr 4mg 30's pack 180\n\tBio Pharma Ltd.\tFreegest TAB dr 5mg 30's pack 240\n\tConcord\tBrocast TAB dr 10mg 20's pack \n\tDelta Pharma\tMontela TAB dr 10mg 20's pack 200\n\tDelta Pharma\tMontela-5 TAB dr 5mg 20's pack 120\n\tDoctor Tims\tMontemax TAB dr 5mg  \n\tDoctor Tims\tMontemax TAB dr 10mg  \n\tDrug International Ltd.\tM Kast TAB dr 10mg 20's pack 240\n\tDrug International Ltd.\tM Kast TAB dr 4mg 30's pack 150\n\tDrug International Ltd.\tM Kast TAB dr 5mg 30's pack 210\n\tDrug International Ltd.\tM Kast Chewable TAB dr 10mg 20's pack \n\tEdruc Ltd.\tEdron TAB dr 10mg 10's pack 150\n\tEskayef Bangladesh Ltd.\tLumona TAB dr 10mg 10's pack/20's pack 100/200\n\tEskayef Bangladesh Ltd.\tLumona TAB dr 4mg 10's pack/30's pack 60/180\n\tEskayef Bangladesh Ltd.\tLumona TAB dr 5mg 10's pack/30's pack 60/180\n\tEuro Pharma Ltd.\tMontica Chewable TAB dr 4mg  \n\tEuro Pharma Ltd.\tMontica TAB dr 5mg  \n\tEuro Pharma Ltd.\tMontica TAB dr 10mg  \n\tGeneral\tTelukast TAB dr 10mg 20's pack 281\n\tGeneral\tTelukast TAB dr 4mg 30's pack 165\n\tGeneral\tTelukast TAB dr 5mg 20's pack 150.60\n\tGlobe\tMontifast TAB dr 4mg 20's pack 140\n\tGlobe\tMontifast TAB dr 10mg 20's pack 300\n\tHallmark\tMonark TAB dr 10mg 20's pack 400\n\tHealthcare\tAeron TAB dr 10mg 12's pack 180\n\tHealthcare\tAeron FT TAB dr 5mg 30's pack 240\n\tHealthcare\tAeron FT TAB dr 4mg 30's pack 180\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMontex TAB dr 10mg 10's pack 160\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMontex TAB dr 5mg 20's pack 160\n\tIncepta\tMontair TAB dr 10mg 20's pack/30's pack 450\n\tIncepta\tMontair TAB dr 4mg 30's pack 180\n\tIncepta\tMontair TAB dr 5mg 30's pack 240\n\tKemiko\tMolukat TAB dr 10mg 20's pack 240\n\tKemiko\tMolukat TAB dr 4mg 20's pack 120\n\tKemiko\tMolukat TAB dr 5mg 20's pack 160\n\tLabaid\tMontilab 10 TAB dr 10mg 2x10's pack 300\n\tLeon\tMedikast TAB dr 4mg  \n\tLeon\tMedikast TAB dr 5mg  \n\tLeon\tMedikast TAB dr 10mg  \n\tMedicon\tMTS TAB dr 10mg  \n\tMonicopharma\tRecast TAB dr 10mg  \n\tNavana\tArokast TAB dr 10mg 10's pack 100\n\tNavana\tArokast TAB dr 4mg 30's pack 150\n\tNavana\tArokast TAB dr 5mg 30's pack 210\n\tNIPRO JMI Pharma\tMontiva 5 TAB dr 5mg 30's pack 180\n\tNIPRO JMI Pharma\tMontiva 10 TAB dr 10mg 30's pack 300\n\tNIPRO JMI Pharma\tMontiva TAB dr 4mg  \n\tNovartis (Bangladesh) Ltd.\tLumenta TAB dr 10mg 28's pack 448\n\tNovartis (Bangladesh) Ltd.\tLumenta TAB dr 5mg 20's pack 180\n\tNuvista Pharma Ltd\tPulmont TAB dr 10mg  \n\tOpsonin Pharma\tTrilock Oral Granules Sachet 4mg 1x10's pack 80.30\n\tOpsonin Pharma\tTrilock TAB dr 10mg 30's pack 450\n\tOpsonin Pharma\tTrilock TAB dr 5mg 30's pack 240\n\tOpsonin Pharma\tTrilock TAB dr 4mg 30's pack 180\n\tOrion Pharma Ltd.\tArovent TAB dr 10mg 10's pack 200.80\n\tOrion Pharma Ltd.\tArovent TAB dr 5mg 20's pack 140\n\tPacific\tMontekast TAB dr 10mg 20's pack 300\n\tPharmasia Ltd.\tMonkast TAB dr 5mg  \n\tPharmasia Ltd.\tMonkast TAB dr 10mg  \n\tPharmasia Ltd.\tMonkast Chewable TAB dr 5mg  \n\tPopular\tM-Lukas TAB dr 4mg 30's pack 180\n\tPopular\tM-Lukas TAB dr 5mg 30's pack 240\n\tPopular\tM-Lukas TAB dr 10mg 10's pack 150\n\tRadiant.\tXyflo TAB dr 10mg  \n\tRadiant.\tXyflo TAB dr 5mg  \n\tRAK\tArotel TAB dr 5mg 30's pack 240\n\tRAK\tArotel TAB dr 10mg 20's pack 300\n\tRangs\tMonprox TAB dr 10mg 10's pack 200\n\tRenata\tOdmon TAB dr 10mg 10's pack 300\n\tRenata\tOdmon TAB dr 5mg 10's pack 150\n\tRenata\tOdmon Chewable TAB dr 4mg  \n\tSharif\tCroma TAB dr 10mg 30's pack 450\n\tSharif\tCroma TAB dr 4mg  \n\tSharif\tCroma Chewable TAB dr 5mg \n \n\tSilco Pharmaceuticlas Ltd.\tMoneka TAB dr 5mg  \n\tSomatec\tAsmont TAB dr 10mg 10's pack 150.50\n\tSomatec\tAsmont TAB dr 5mg 10's pack 85.30\n\tSquare\tMontene Sachet 4mg 20's pack 120\n\tSquare\tMontene TAB dr 10mg 30's pack 300\n\tSquare\tMontene TAB dr 4mg 20's pack 120.40\n\tSquare\tMontene TAB dr 5mg 20's pack 160.80\n\tSun Pharmaceutical (Bangladesh) Ltd.\tMontek TAB dr 10mg 30's pack 450\n\tSun Pharmaceutical (Bangladesh) Ltd.\tMontek TAB dr 4mg 30's pack 210\n\tUnimed & Unihealth Manufacturers Ltd.\tProvair TAB dr 10mg 20's pack 450\n\tUnimed & Unihealth Manufacturers Ltd.\tProvair TAB dr 4mg 20's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tProvair TAB dr 5mg 20's pack 240\n\tVeritas\tAsmatab TAB dr 10mg  \n\tOne Pharma Ltd.\tAirway TAB dr 5mg  \n\tOne Pharma Ltd.\tAirway TAB dr 10mg  \n\tJulphar Bangladesh Ltd.\tMaxair TAB dr 5mg  \n\tJulphar Bangladesh Ltd.\tMaxair TAB dr 10mg  \n\tIndication: Asthma, Allergic rhinitis\n\nDose: Adults (15 years of age or over): 10 mg daily to be taken in the evening.\n\nChronic asthma; Allergic rhinitis 10 mg/day once in the evening. Prophylaxis of exercise-induced asthma 10 mg at least 2 hr before exercise; do not admin additional doses w/in 24 hr.\n\nChildren (6-14 years of age): 5 mg daily to be taken in the evening.\nChildren (2-5 years of age): 4 mg daily to be taken in the evening\n\nContra-indication: Hypersensitivity.\n\nSide effects: Dizziness, fatigue, fever; rash; abdominal pain, dyspepsia, dental pain, gastroenteritis; increased AST; weakness; cough, nasal congestion. Aggression, agitation, angioedema, arthralgia, bleeding tendency, bruising, cholestasis, diarrhoea, dream abnormalities, drowsiness, oedema, eosinophilia, hallucinations, hepatic eosinophilic infiltration (rare), hepatitis, hypersensitivity, hypoaesthesia, insomnia, irritability, muscle cramps, myalgia, nausea, palpitation, pancreatitis, paraesthesia, pruritus, restlessness, seizure, urticaria, vasculitis, vomiting.\nPotentially Fatal: Anaphylaxis, Churg-Strauss syndrome.\n\nPrecaution: Not for the relief of acute bronchospasm. Not to be used as monotherapy for the prevention of exercise-induced bronchospasm. Patients in whom asthma is precipitated by aspirin or other NSAIDs should continue to avoid aspirin and NSAIDs. Do not abruptly substitute for oral or inhaled corticosteroids. Be alert for any signs of Churg-Strauss syndrome. Pregnancy and lactation. Children <6 mth.\n\nMode of action: nduced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).\n\nPregnancy category: B\n\nInteraction: nduced hepatic metabolism resulting to decreased plasma concentration w/ potent inducers of cytochrome P450 isoenzymes (e.g. phenobarbital, phenytoin, rifampicin).
Morphine Sulphate	\n\n\tGonoshasthaya\tG Morphine Injection 15mg/ml 5 amps pack 200\n\tGonoshasthaya\tG Morphine SR TAB dr 15mg 30's pack 300\n\tRenata\tMorphine Injection 15mg/ml 5amps pack 111.55\n\tRenata\tMorphin-R Injection 1ml 1x5's pack 89.33\n\tUnimed & Unihealth Manufacturers Ltd.\tMSL-10 TAB dr 10 mg  \n\tIndication: Pain, MI, Unstable angina, Intractable cough, Acute pulmonary oedema, Analgesia during labour\n\nDose: Adult: PO Pain relief 5-20 mg 4 hrly. Intractable cough associated w/ lung cancer As oral soln: Initial: 5 mg 4 hrly. \n\nIV Pain associated w/ MI 10 mg, then a further dose of 5-10 mg if needed. \nAcute pulmonary oedema 5-10 mg. Unstable angina unresponsive to anti-ischaemic therapy 2-5 mg repeated every 5-30 mins as needed. Acute pain Initial: 2.5 mg 4 hrly, adjust according to response. \n\nIM/SC Acute pain 10 mg 4 hrly, adjust according to response. Premed in surgical procedures Up to 10 mg 60-90 mins pre-op. Analgesia during labour 10 mg. Intrathecal Moderate to severe pain 0.2-1 mg on a single occasion. Intraspinal Moderate to severe pain Initial: 5 mg epidural inj; after 1 hr, additional doses of 1-2 mg may be given if needed. Total dose: 10 mg/24 hr. \n\nContra-indication: Respiratory depression, acute or severe asthma; paralytic ileus; obstructive airway disease; acute liver disease; comatose patients; increased intracranial pressure; acute alcoholism. Pulmonary oedema resulting from a chemical respiratory irritant.\n\nSide effects: Convulsions; nausea, vomiting, dry mouth, constipation; urinary retention; headache, vertigo; palpitations; hypothermia; pruritus, urticaria; tachycardia, bradycardia; blurred vision; miosis; dependency; drowsiness; lightheadedness; dizziness; sweating; dysphoria; euphoria.\nPotentially Fatal: Respiratory depression; circulatory failure; hypotension; deepening coma; anaphylactic reactions.\n\nPrecaution: Elderly; hypothyroidism; renal and liver disease; head injury, intracranial lesions; hypotension, circulatory shock; adrenocortical insufficiency; asthma; prostatic hyperplasia; inflammatory or obstructive bowel disease; myasthaenia gravis; infants <3 mth; pregnancy, lactation; hypovolaemia, biliary tract disorders.\n\nMode of action: Additive depressant effects w/ other CNS depressants (e.g. sedatives, hypnotics, general anaesth, phenothiazines, other tranquilisers). May enhance the neuromuscular blocking action of skeletal muscle relaxants. Reduced analgesic effect w/ mixed agonist/antagonist opioid analgesics (e.g. pentazocine, nalbuphine, buprenorphine). Increased plasma concentrations w/ cimetidine. May reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. May delay the absorption of mexiletine. May antagonise the GI effect of cisapride, domperidone and metoclopramide. May produce hyperpyrexia and CNS toxicity w/ dopaminergics.\nPotentially Fatal: MAOIs intensify the effect of morphine resulting to severe and even fatal events (e.g. anxiety, confusion, resp depression, sometimes leading to coma).\n\nPregnancy category: D\n\nInteraction: Additive depressant effects w/ other CNS depressants (e.g. sedatives, hypnotics, general anaesth, phenothiazines, other tranquilisers). May enhance the neuromuscular blocking action of skeletal muscle relaxants. Reduced analgesic effect w/ mixed agonist/antagonist opioid analgesics (e.g. pentazocine, nalbuphine, buprenorphine). Increased plasma concentrations w/ cimetidine. May reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. May delay the absorption of mexiletine. May antagonise the GI effect of cisapride, domperidone and metoclopramide. May produce hyperpyrexia and CNS toxicity w/ dopaminergics.\nPotentially Fatal: MAOIs intensify the effect of morphine resulting to severe and even fatal events (e.g. anxiety, confusion, resp depression, sometimes leading to coma).
Moxifloxacin	\n\n\tACI\tMaxiflox TAB dr 400mg 10's pack 500\n\tAcme Ltd.\tCubimox TAB dr 400mg  \n\tAlco Pharma\tMoxiflox TAB dr 400mg 8's pack 680\n\tAristopharma\tOptimox TAB dr 400mg 10's pack 400\n\tBeximco\tOdycin TAB dr 400mg 20's pack 1400\n\tDrug International Ltd.\tFloxalone TAB dr 400mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tFloromox TAB dr 400mg  \n\tIncepta\tMoxquin TAB dr 400mg 8's pack 320\n\tLeon\tTopomox TAB dr 400mg  \n\tNIPRO JMI Pharma\tTopmox TAB dr 400mg  \n\tOrion Pharma Ltd.\tMaximox TAB dr 400mg 12's pack \n\tPopular\tMoxibac TAB dr 400mg  \n\tSomatec\tRespamox TAB dr 400mg  \n\tSquare\tIventi TAB dr 400mg  \n\tIndication: Intra-abdominal infections, Chronic bronchitis, Acute bacterial sinusitis, Community-acquired pneumonia, Skin and skin structure infections, Typhoid Fever\n\nDose: â¢ The dose of Moxifloxacin is 400 mg once every 24 hours. The duration of therapy depends on the type of infection as described bellow-â¢\n\n In Acute Bacterial Sinusitis Moxifloxacin 400 mg is given once daily for 10 days.â¢ In Acute Bacterial Exacerbation of Chronic Bronchitis Moxifloxacin 400 mg is given once daily for 5 days.\n\nâ¢ In Community Acquired Pneumonia Moxifloxacin 400 mg is given once daily for 7-14 days.\n\nâ¢ In Uncomplicated Skin & Skin Structure infections Moxifloxacin 400 mg is given once daily for 7 days.â¢ In Complicated Skin & Skin Structure infections Moxifloxacin 400 mg is given once daily for 7-21 days.â¢ In Complicated Intra-Abdominal infections Moxifloxacin 400 mg is given once daily for 5-14 days.\n\nâ¢ In Typhoid Fever Moxifloxacin 400 mg is given once daily for 10-14 days.\n\nContra-indication: Hypersensitivity; child, adolescent; pregnancy, lactation.\n\nSide effects: GI disturbances, CNS effects, hypersensitivity-type reactions, reversible arthralgia, abnormal liver function tests, hepatitis, haematological disturbances, tachycardia, superinfection, pain and irritation at the Inj site, tendon damage, phloebitis and thrombophloebitis, peripheral neuropathy, photosensitivity, abdominal pain, headache, vaginitis.\n\nPrecaution: Maintain adequate fluid intake; exposure to strong sunlight/sunlamp. Epilepsy, history of CNS disorders, DM. Not recommended in severe hepatic impairment. May worsen myasthenia gravis. Discontinue in case of tendon pain, inflammation or rupture. High level of resistance with S. aureus infections. Increased risk of tendon inflammation/rupture especially in elderly taking corticosteroids. Caution in patients with proarrhythmic conditions e.g. clinically significant bradycardia or acute MI. Existing QT prolongation, bradycardia, heart failure with reduced left ventricular ejection fraction; uncorrected hypokalaemia. Avoid concomitant usage with drugs that are known to prolong QT interval. Prolonged use may increase risk of fungal or bacterial superinfection.\n\nMode of action: Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine.\nPotentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.\n\nPregnancy category: C\n\nInteraction: Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine.\nPotentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.
Moxifloxacin IV	\n\n\tIncepta\tMoxquin 400 IV Infusion 400mg/250ml 1's pack 350\n\tOpso Saline Ltd.\tFlomox IV Infusion  160mg/100ml 250ml bot 120\n\tPopular\tMoxibac IV Infusion  160 mg/100 ml 250ml  x 1's pack 350\n\tSquare\tIventi 400 IV Infusion  160 mg/100 ml 1's pack 175\n\tIndication: Intra-abdominal infections, Chronic bronchitis, Acute bacterial sinusitis, Community-acquired pneumonia, Skin and skin structure infections\n\nDose: Moxifloxacin 400 mg IV infusion can be administered intravenously  once daily for  5-21 days, depending on the condition. The duration of therapy depends on the type of infection as described bellow-\n\nâ¢ In Community Acquired Pneumonia Moxifloxacin 400 mg is given once daily for7-14 days\nâ¢ In Acute Bacterial Exacerbation of Chronic Bronchitis Moxifloxacin 400 mg is given once daily for 5 days\nâ¢ In Acute Bacterial Sinusitis Moxifloxacin 400 mg is given once daily for 10 days\nâ¢ In Complicated Intra-Abdominal Infections Moxifloxacin 400 mg is given once daily for 5-14 days\nâ¢ In Uncomplicated Skin and Skin Structure Infections (SSSI) Moxifloxacin 400 mg is given once daily for7 days\nâ¢ In Complicated SSSI Moxifloxacin 400 mg is given once daily for7-21 days\nâ¢ In Typhoid Fever Moxifloxacin 400 mg is given once daily for 10-14 days\n\n Alternatively, therapy may be initial intravenous administration, followed by oral administration when clinically indicated. The recommended duration of treatment for the indication being treated should not be exceeded. The solution for infusion should be infused intravenously over 60 minutes.\n\nElderly:\nNo adjustment of dosage is required in the elderly.\n\nChildren:\nEfficacy and safety of Moxquin IV infusion in children and adolescent have not been established. \n\nContra-indication: Moxifloxacin is contraindicated in persons with a history of hypersensitivity to Moxifloxacin or any member of the quinolone class of antimicrobial agents and any component of this formulation.\n\nSide effects: The following one or more side effects may be observed: tendinopathy and tendon rupture, QT prolongation, hypersensitivity reactions, clostridium difficile-associated diarrhea, peripheral neuropathy, photosensitivity, phototoxicity etc. \n\nPrecaution: Moxifloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Moxifloxacin should be discontinued if the patient experiences pain, swelling, inflammation or rupture of a tendon.\n\nMode of action: Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine.\nPotentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.\n\nPregnancy category: C\n\nInteraction: Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine.\nPotentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.
Moxifloxacin 0.5% Eye prep	\n\n\tACI\tMaxiflox Eye Drops  0.5% 5  ml drop 100.68\n\tAcme Ltd.\tEyemox Eye Drops   5  ml drop 100.38\n\tApex\tMoxigram Eye Drops   5  ml drop 100\n\tAristopharma\tOptimox Eye Drops  5 mg/ml 5  ml drop 100\n\tAristopharma\tOptimox XG Eye Drops  1's pack 150\n\tAsiatic Ltd.\tFloximox Eye Drops   5  ml drop 100\n\tBeximco\tOdycin Eye Drops   5  ml drop 100\n\tBio Pharma Ltd.\tMoxif Eye Drops 5 mg/ml  \n\tDrug International Ltd.\tFloxalone Eye Drops  5 mg/ml 5  ml drop 100\n\tEskayef Bangladesh Ltd.\tVisomox Eye Drops  5mg/ml 5ml 100\n\tG. A. Company Ltd.\tKilgen 0.5% Eye Drops   5ml drop 100\n\tGeneral\tMoxigen Eye Drops   5ml drop 100\n\tGlobe\tGlomox Eye Drops 5 mg/ml  \n\tHealthcare\tMoxivin Eye Drops 0.5% 5ml 100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tFloromox Eye Drops   5  ml drop 100\n\tIncepta\tMoxquin Eye Drops   1's pack 100\n\tIncepta\tMoxquin XG Eye Drops  1's pack 140\n\tKemiko\tMoxikem Eye Drops   5  ml drop 100\n\tMonicopharma\tFomox Eye Drops 5 mg/ml  \n\tNavana\tCinagen Eye Drops   5ml bot 100\n\tNipa\tMFC Eye Drops   5  ml drop 100\n\tOpso Saline Ltd.\tFlomox Eye Drops   5  ml drop 100\n\tOpsonin Pharma\tMoxilocin Eye Drops 5 mg/ml  \n\tPopular\tMoxibac Eye Drops   5  ml drop 100.38\n\tPopular\tMoxibac XG Eye Drops 0.5% 5ml bot 150\n\tReman Drug Ltd.\tOcumox Eye Drops  5 mg/ml 5  ml drop 100.38\n\tSquare\tIventi 0.5% Eye Drops  5 mg/ml 5  ml drop 100.38\n\tIndication: Bacterial Conjunctivitis\n\nDose: Adults and children (1 year of age and older)\n1 drop in infected eye(s) 3 times a day for 7 days.\n\nChildren up to 1 year of age\nUse and dose must be determined by doctor. \n\n\n\nContra-indication: Patients with a history of hypersensitivity to Moxifloxacin, to other Quinolones or to any of the components in this medication\n\nSide effects: Burning, dry or itching eyes; change in vision; eye discharge; pain in eye; redness of eye; swelling of eye, eyelid, or inner lining of eyelid; tearing.\n\nPrecaution: As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. To prevent contamination do not touch the tip of the dropper to eye, eyelid or any surface of of the affected eye. Keep the bottle tightly closed after use.\n\nMode of action: Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine.\nPotentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.\n\nPregnancy category: C\n\nInteraction: Additive effect on QT interval prolongation w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Decreased absorption and bioavailability w/ Al- or Mg-containing antacids, or Fe or Zn preparations. Concomitant use of corticosteroids increases the risk of severe tendon disorders esp in elderly (>60 yr). Decreased absorption w/ sucralfate or didanosine.\nPotentially Fatal: Concurrent use of class Ia (e.g. quinidine, procainamide) or III (e.g. amiodarone, sotalol) antiarrhythmic drugs or w/ other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents) may cause additive effect on QT interval prolongation.
Moxonidine	\n\n\tIndication: Hypertension\n\nDose: Adult: PO Initial: 200 mcg once daily, up to 400 mcg/day in 1-2 divided doses if needed after 3 wk. May further increase to 600 mcg/day in 2 divided doses after another 3 wk. Max: 600 mcg/day.\n\nRenal impairment:\nCrCl (ml/min)	\n30-60	Single dose should not exceed 200 mcg. Max daily dose 400 mcg.\n<30	        Avoid\n\nContra-indication: Conduction disorders; bradycardia; severe arrhythmias; severe heart failure; severe ischaemic heart disease; history of angioedema; severe liver or renal impairment; Raynaud's syndrome; intermittent claudication; epilepsy; depression; Parkinson's disease; glaucoma. Pregnancy and lactation.\n\nSide effects: Dry mouth; headache; fatigue; dizziness; nausea; sleep disturbances; asthenia; vasodilatation; skin reactions; constipation; depression; anxiety; anorexia; parotid pain; vivid dreams; impotence and loss of libido; urinary retention or incontinence; slight orthostastic hypotension; fluid retention.\n\nPrecaution: Renal impairment; avoid abrupt withdrawal (if concomitant treatment with ?-blocker has to be stopped, discontinue ?-blocker first, then moxonidine after few days).\n\nMode of action: Additive effects with other antihypertensives; may increase sedative effects of benzodiazepines. Effects may be antagonised by TCAs.\n\nPregnancy category: Not Classified\n\nInteraction: Additive effects with other antihypertensives; may increase sedative effects of benzodiazepines. Effects may be antagonised by TCAs.
Mupirocin 2% Topical	\n\n\tACI\tSystop Ointment  2% 10g 140.42\n\tAcme Ltd.\tDermupin Ointment   10gm tube 130\n\tAlco Pharma\tMupi 2% Ointment   5gm tube / 10gm  tube 80 / 140\n\tBio Pharma Ltd.\tBacron 2% Ointment   10gm  tube 125.47\n\tDrug International Ltd.\tMuron Ointment 2% 15gm  tube 130\n\tEskayef Bangladesh Ltd.\tMupiron Ointment   10gm  tube 140\n\tGeneral\tMuroderm Ointment   10gm  tube 140.53\n\tGlaxoSmithKline Bangladesh Ltd.\tBactroban 2% Ointment   15gm  tube 140.53\n\tHealthcare\tMupiderm Ointment   10gm  tube 140\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBactromen Ointment  10gm tube 140\n\tIncepta\tTrego 2% Ointment   10gm  tube 140\n\tMedicon\tPirocin Ointment 100 mg/5 gm  \n\tOpsonin Pharma\tDermoban 2% Ointment   10gm tube 114.79\n\tPacific\tTigocin Ointment   10gm tube 140\n\tPharmasia Ltd.\tMupibac Ointment   10gm  tube 130\n\tSquare\tBactrocin 2% Ointment  100 mg/5 gm 10gm  tube 140\n\tUnimed & Unihealth Manufacturers Ltd.\tBactoderm 2% Ointment   10gm  tube 140\n\tIndication: Impetigo, Folliculitis, Secondary skin infections, Furunculosis\n\nDose: For children and adults: A small amount of  ointment should be applied to the affected area three times daily for up to 10 days. The area treated may be covered with a dressing if desired.\n\nContra-indication: This drug is contraindicated in individuals with a history of sensitivity reactions to Mupirocin or any of the components of the preparation.\n\nSide effects: Burning, stinging, pain, itching, erythema, dryness, tenderness, dermatitis and rash.\n\nPrecaution: Mupirocin is not suitable for ophthalmic or intra-nasal use. When Mupirocin ointment is used on the face, care should be taken to avoid the eyes. In common with other polyethylene-based ointments, this drug should be used with caution if there is evidence of moderate or severe renal impairment. As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Nalbuphine Hydrochloride	\n\n\tACI\tNalbutin 2 Injection 10mg/ml 5's pack 300\n\tACI\tNalbutin 2 Injection 20mg/2ml 5's pack 501.50\n\tAcme Ltd.\tNalphin Injection 20mg/2ml 2ml amp  x  5's pack 501.90\n\tGeneral\tNabulex IV/IM Injection 20 mg/2 ml  \n\tIncepta\tNalbun Injection 10mg/ml 1 ml amp x 5 's pack 300\n\tIncepta\tNalbun Injection 20mg/2ml 2 ml amp  x 5's pack 500\n\tOpsonin Pharma\tRaltrox Injection 10mg/ml 1ml amp  x  3's pack 158.96\n\tOpsonin Pharma\tRaltrox Injection 20mg/2ml 2ml amp  x1's pack 88.30\n\tRenata\tNalbufin Injection 10 mg/ml  \n\tRenata\tNalbufin Injection 20 mg/2 ml  \n\tSquare\tRadirif Injection 20mg/2ml 4's pack 401.52\n\tIndication: Moderate to severe pain, Pain associated with MI, Balanced anaesthesia\n\nDose: Adult: IV Adjunct in balanced anesth Induction: 0.3-1 mg/kg, up to 3 mg/kg. Maintenance: 250-500 mcg/kg every 30 mins. Pain associated w/ MI 10-30 mg via slow inj, then 20-mg 30 min later if needed.\n\nIV/IM/SC Moderate to severe pain 10-20 mg 3-6 hrly as needed. Nonopioid-tolerant patients: Max: 20 mg/dose and 160 mg/day. Anesth premed 100-200 mcg/kg.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Sedation, dizziness, vertigo, miosis, headache; nausea, vomiting, dry mouth; itching, burning, urticaria. Respiratory depression, dyspnoea, asthma; speech difficulty, urinary urgency, blurred vision, flushing, warmth; clamminess.\nPotentially Fatal: Anaphylactic or anaphylactoid and other serious hypersensitivity reactions e.g. shock, respiratory distress, respiratory arrest, bradycardia, cardiac arrest, hypotension, laryngeal oedema.\n\nPrecaution: May impair ability to drive or operate machinery. Emotionally unstable patients or patients with history of opiate abuse; closely monitor these patients during long-term therapy. Impaired respiration due to other drugs, uraemia, bronchial asthma, severe infection, cyanosis, respiratory obstruction. MI patients who exhibit nausea and vomiting and in those about to undergo biliary tract surgery. Head injury, intracranial lesions or pre-existing increased intracranial pressure. Renal or hepatic impairment. Elderly and debilitated patients. Pregnancy and lactation.\n\nMode of action: Additive CNS depressant effects may occur with other CNS depressants e.g. alcohol, anaesthetics, anxiolytics, hypnotics, TCAs and antipsychotics.\n\nPregnancy category: B\n\nInteraction: Additive CNS depressant effects may occur with other CNS depressants e.g. alcohol, anaesthetics, anxiolytics, hypnotics, TCAs and antipsychotics.
Nalidixic Acid	\n\n\tAcme Ltd.\tNaligram Powder for Suspension 300mg/5ml 50ml bot/100ml bot 30.46 / 56.86\n\tAcme Ltd.\tNaligram TAB dr 500mg 100's pack 487\n\tAmbee\tNalidex Powder for Suspension 300mg/5ml 50ml bot 30.46\n\tAmbee\tNalidex TAB dr 500mg 100's pack 407\n\tAristopharma\tNalix Powder for Suspension 300mg/5ml 50ml bot 30\n\tBeximco\tNebactil Oral suspension 300mg/5ml 50ml bot 30.79\n\tBeximco\tNebactil TAB dr 500mg 100's pack 406\n\tBeximco\tNebactil Oral suspension 250mg/5ml 50ml 41.73\n\tDoctor's Chemicals Works Ltd.\tDegram TAB dr 500mg 100's pack 387\n\tJayson\tDixicon Powder for Suspension 300mg/5ml 50ml bot 30.45\n\tJayson\tDixicon TAB dr 500mg 100's pack 384\n\tOpsonin Pharma\tUtirex Powder for Suspension 300mg/5ml 50ml bot 30\n\tPharmadesh Ltd.\tNalidixin Powder for Suspension 300mg/5ml 50ml bot 30.75\n\tPharmadesh Ltd.\tNalidixin TAB dr 500mg 50's pack 233.50\n\tSalton\tNalitrum Powder for Suspension 300mg/5ml 50ml bot 30\n\tSquare\tNalid Powder for Suspension 300mg/5ml 50ml bot 41.74\n\tSquare\tNalid TAB dr 500mg 60's pack 292.20\n\tIndication: Lower urinary tract infections, Shigellosis\n\nDose: ral\nUncomplicated lower urinary tract infections\nAdult: 1 g 4 times daily for 1-2 wk. Long-term therapy: Reduce daily dose to 2 g.\nChild: >3 mth: 50 mg/kg daily in 4 equally divided doses. Long-term therapy: Reduce dose to 30 mg/kg daily. Prophylaxis: 15 mg/kg bid.\n\n\nShigellosis\nAdult: 1 g 4 times daily for 5 days.\nChild: >3 mth: 15 mg/kg 4 times daily for 5 days.\nHepatic impairment: Reduced doses should be considered.\n\nContra-indication: Hypersensitivity. History of convulsive disorders or porphyria. Infants <3 mth. Severe renal impairment.\n\nSide effects: Nausea, vomiting, diarrhoea, abdominal pain; photosensitivity reactions, allergic rash, urticaria, pruritus; visual disturbances, headache, dizziness or vertigo, drowsiness, confusion, depression, excitement, hallucinations, toxic psychoses or convulsions (especially after large doses), intracranial hypertension (especially in infants and young children), metabolic acidosis; peripheral neuropathies, muscular weakness, myalgia; arthralgia, tendon damage; cholestatic jaundice, thrombocytopenia, leucopenia.\nPotentially Fatal: Erythema multiforme and Stevens-Johnson syndrome; anaphylactoid reactions. Auto-immune haemolytic anaemia (particularly in elderly patients).\n\nPrecaution: Hepatic or moderate renal impairment, severe cerebral arteriosclerosis, G6PD deficiency. Monitor blood counts, renal and hepatic function for treatment >2 wk. Children <18 yr. Elderly. Avoid exposure to sunlight or sunlamps. Pregnancy and lactation.\n\nMode of action: Absorption reduced by sucralfate, and divalent and trivalent cations e.g. aluminium, calcium, iron, magnesium, zinc. Excretion reduced and plasma concentrations increased with probenecid. Reduced effects with chloramphenicol, nitrofurantoin, tetracycline.\nPotentially Fatal: Fatal haemorrhagic enterocolitis may occur when used with high-dose melphalan in children. Increased risk of nephrotoxicity with ciclosporin. May increase effects of oral anticoagulants e.g. warfarin.\n\nPregnancy category: C\n\nInteraction: Absorption reduced by sucralfate, and divalent and trivalent cations e.g. aluminium, calcium, iron, magnesium, zinc. Excretion reduced and plasma concentrations increased with probenecid. Reduced effects with chloramphenicol, nitrofurantoin, tetracycline.\nPotentially Fatal: Fatal haemorrhagic enterocolitis may occur when used with high-dose melphalan in children. Increased risk of nephrotoxicity with ciclosporin. May increase effects of oral anticoagulants e.g. warfarin.
Naloxone Hydrochloride	\n\n\tIndication: Opioid dependence, Opioid overdosage, Opioid-induced depression\n\nDose: Adult: As hydrochloride: 200 mg to 3 g daily.\nIntravenous\nOpioid overdosage\nAdult: As hydrochloride: 0.4-2 mg repeated if necessary at 2-3 min intervals. If there is no response after a total of 10 mg has been given, consider the possibility of overdosage with other drugs. Reduce dose for opioid-dependent patients: 0.1-0.2 mg. IM/SC routes may be used (at IV doses) if IV admin is not feasible. \nChild: As hydrochloride: Initially 10 mcg/kg IV followed by 100 mcg/kg IV if necessary. Alternatively, 0.4-0.8 mg IM or SC, repeated as necessary, if IV admin is not feasible.\nParenteral\nOpioid-induced depression in neonates due to obstetric analgesia\nChild: As hydrochloride: 10 mcg/kg IV, IM or SC repeated at 2-3 min intervals if necessary or 60 mcg/kg as a single IM dose.\nIntravenous\nReversal of central depression from opioid use during surgery\nAdult: As hydrochloride: 100-200 mcg at intervals of 2-3 minute, titrate dose according to response while maintaining analgesia.\nChild: As hydrochloride: 5-10 mcg IV at 2-3 min intervals.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Occur secondarily to reversal (withdrawal) of narcotic analgesia and sedation. Mental depression, apathy, inability to concentrate, sleepiness, irritability, anorexia, nausea, and vomiting in high oral doses during initial treatment of opiate addiction.\nPotentially Fatal: Severe cardiopulmonary effects (e.g. hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnoea, pulmonary oedema, cardiac arrest) in postoperative patients, most frequently in those with preexisting CV disease. Recurrence of respiratory depression in long-acting opioids.\n\nPrecaution: Patients physically dependent on opioids, or who have received large doses of opioids (acute withdrawal syndrome may be precipitated). Pregnancy and lactation.\n\nMode of action: Decreased effect of opioid analgesics.\nPotentially Fatal: Acute withdrawal reaction in physically dependent patients may occur with opioid analgesics. Severe cardiopulmonary effects may occur with cardiotoxic drugs.\n\nPregnancy category: C\n\nInteraction: Decreased effect of opioid analgesics.\nPotentially Fatal: Acute withdrawal reaction in physically dependent patients may occur with opioid analgesics. Severe cardiopulmonary effects may occur with cardiotoxic drugs.
Naltrexone	\n\n\tNavana\tNaltrax TAB dr 50mg 10's pack 1405.30\n\tNavana\tNalTax TAB dr 50mg 10's pack 650\n\tIndication: Opioid dependence, Alcohol dependence\n\nDose: Adult: PO Opioid dependence Initial: 25 mg, then up to 50 mg/day if no withdrawal signs. Maintenance: 350 mg/wk given as 50 mg/day or divided in 3 doses (given on 3 days of the wk) for improved compliance. \n\nAdjunct in alcohol dependence 50 mg/day. \n\nContra-indication: Patients concurrently dependent on opioids; acute hepatitis or hepatic failure; acute opioid withdrawal; patients on therapeutic opioid analgesics.\n\nSide effects: Abdominal pain, nausea, vomiting; anxiety, insomnia, lethargy, headache, musculoskeletal pain; anorexia, diarrhoea, constipation; increased thirst; chest pain; chills, dizziness; sexual dysfunction; rash, liver function abnormalities and reversible idiopathic thrombocytopenia. Inj-site reactions.\n\nPrecaution: Hepatic or renal impairment. Monitor LFTs regularly. Patients should be opioid-free for at least 7-10 days prior to initiating naltrexone therapy. Strictly warn patients against the use of opioids while on naltrexone. Monitor for inj-site reactions. Pregnancy, lactation. History of bleeding disorders (including thrombocytopenia).\n\nMode of action: May reduce effects of opiate-containing preparations e.g. those used for cough and cold, diarrhoea and pain. Increased or decreased serum levels with drugs that alter hepatic metabolism. Potentially increased hepatotoxic effects with disulfiram. Increased risk of naltrexone-induced lethargy and somnolence with thioridazine. May increase insulin requirements.\n\nPregnancy category: C\n\nInteraction: May reduce effects of opiate-containing preparations e.g. those used for cough and cold, diarrhoea and pain. Increased or decreased serum levels with drugs that alter hepatic metabolism. Potentially increased hepatotoxic effects with disulfiram. Increased risk of naltrexone-induced lethargy and somnolence with thioridazine. May increase insulin requirements.
Nandrolone	\n\n\tChemist Ltd.\tHydeca Injection 50mg/ml 1 amps pack 110\n\tChemist Ltd.\tHyvolin Injection 25mg/ml 5 amps pack 190\n\tNuvista Pharma Ltd\tDeca Durabolin Injection 50mg/ml 2 amps pack 436.92\n\tNuvista Pharma Ltd\tDurabolin Injection 25mg/ml 5 amps pack 435.8\n\tRenata\tNandron 	 Injection 25mg/ml 	 5 amps pack 	 250.95 	\n\tRenata\tNandron Injection 50mg/ml 1's amps pack 140.75\n\tTechno Drugs Ltd.\tAnabolin Injection 25mg/ml 5 amps pack 200\n\tTechno Drugs Ltd.\tDecabolon Injection 50mg/ml 1 amps pack 112\n\tIndication: Postmenopausal osteoporosis, Metastatic breast cancer, Anaemia of chronic renal failure, Anaemia in chemotherapy patients\n\nDose: Adult: IM Anabolic after debilitating illness; Metastatic breast carcinoma; Postmenopausal osteoporosis As decanoate: 25-100 mg 3-4 wkly. Anaemia of chronic renal failure As decanoate: 50-200 mg/wk. Aplastic anaemia As decanoate: 50-150 mg/wk.\n\nContra-indication: Prostatic or breast carcinoma (male); nephrosis, porphyria; infants, pregnancy and lactation.\n\nSide effects: Male: Postpubertal: Acne, gynaecomastia, bladder irritability, priapism, insomnia, chills, decreased libido, hepatic dysfunction, nausea, diarrhoea, prostatic hyperplasia. Prepubertal: Acne, virilism, chills, insomnia, hyperpigmentation, diarrhoea, nausea. Female: Virilism, hypercalcaemia, nausea, diarrhoea, chills, insomnia, iron deficiency anaemia, hepatic dysfunction.\n\nPrecaution: Monitor diabetic patients carefully. Conditions influenced by oedema (e.g. CV disease, migraine, seizure disorder, renal impairment). Hepatic impairment. Elderly. Discontinue if signs of virilisation in women occur. Monitor skeletal maturation in children.\n\nMode of action: May increase effects of oral anticoagulants, insulin, oral antidiabetic agents, adrenal steroid, adrenocorticotropic hormone (ACTH).\n\nPregnancy category: X\n\nInteraction: May increase effects of oral anticoagulants, insulin, oral antidiabetic agents, adrenal steroid, adrenocorticotropic hormone (ACTH).
Naphazoline Nitrate 0.005% + Zinc Sulphate 0.02% Eye prep	\n\n\tAristopharma\tNazin Eye Drops    10 ml drop 80\n\tGeneral\tOculogen Eye Drops   10ml drop 80\n\tReman Drug Ltd.\tNaphalon Eye Drops   10 ml drop 80\n\tIndication: Conjunctival decongestant, Acute and chronic non-infectious conjunctivitis, Nonspecific conjunctival irritation, Bacterial and viral conjunctivitis, Irrigation of the tear ducts\n\nDose: Adults: 1 drop in the conjunctival sac, three to 4 times per day.\n\nChildren: Naphazoline nitrate and Zinc sulphate drops has not been studied in children. Generally, in children the dosage of vasoconstrictors should be low and selected with caution.\n\n\nContra-indication: Hypersensitivity to zinc sulphate, Naphazoline and other ingredients. Nazin is contraindicated in patients suffering from narrow-angle glaucoma, dry eye and especially keratoconjunctivits sicca (SjÃ¶gren's syndrome). Nazin must not be used in infants.\n\nSide effects: Mydriasis and a slight increase of intraocular pressure in isolated cases. A slight and transient burning sensation may occur after instillation, which does not affect the success of the treatment. Long term use may result in reactive redness of the eye (rebound effect).\nIn very rare cases systemic cardiovascular effects, such as hypertension and arrhythmia, may occur. Nonspecific fatigue has been observed in some patients.\n\nPrecaution:  patients with predisposition to glaucoma and in patients suffering from hypertension, cardiovascular diseases, pheochromocytoma, aneurysm, hyperglycemia, and hyperthyroidism.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Naproxen	\n\n\tACI\tAnaflex TAB dr 250mg 50's pack 252\n\tACI\tAnaflex TAB dr 500mg 30's pack 270.90\n\tACI\tAnaflex SR TAB dr 500mg 20's pack 281.80\n\tACI\tAnaflex Gel Gel 10% 15g\n 62.42\n\tAcme Ltd.\tNapro A TAB dr 250mg 100's pack 101\n\tAcme Ltd.\tNapro A Suppository 500mg  50ml bot  35.14\n\tAcme Ltd.\tNapro A TAB dr 500mg 30's pack 210.60\n\tAd-din\tUltranax TAB dr 500mg 30's pack 240\n\tAlbion Ltd.\tNaproxen TAB dr 500mg/250mg 30's/100's pack \n\tAlco Pharma\tNapren TAB dr 250mg 30's pack 150\n\tAlco Pharma\tNapren TAB dr 500mg 30's pack 270\n\tAmbee\tNaproxin TAB dr 250mg 30's pack 127.80\n\tAmbee\tNaproxin TAB dr 500mg 30's pack 207.60\n\tAmico Ltd.\tNaproxen TAB dr 500mg 30's pack 210\n\tApex\tXpro TAB dr 500mg 30's pack 210\n\tAristopharma\tNapro TAB dr 250mg 50's pack 210\n\tAristopharma\tNapro TAB dr 500mg 30's pack 210\n\tAsiatic Ltd.\tPairox TAB dr 250mg 50's pack 250\n\tAsiatic Ltd.\tPairox TAB dr 500mg 30's pack 240\n\tBenham\tNaproben TAB dr 500mg  30's pack 180\n\tBeximco\tNuprafen TAB dr 250mg 100's pack 420\n\tBeximco\tNuprafen TAB dr 500mg 50's pack 392.50\n\tBristol Pharma Ltd.\tBpxen TAB dr 250mg 50's pack 200\n\tBristol Pharma Ltd.\tBpxen TAB dr 500mg 30's pack 255\n\tConcord\tNapier TAB dr 500mg 30's pack 210\n\tCosmo Pharma Ltd.\tCosnap TAB dr 250mg 50's pack 150\n\tDelta Pharma\tDemovo TAB dr 500mg 24's pack 240\n\tDesh\tNaptodin TAB dr 500mg 50's pack 450\n\tDoctor's Chemicals Works Ltd.\tRepro TAB dr 500mg 30's pack 210\n\tDrug International Ltd.\tDiproxen TAB dr 250mg 100's pack 425\n\tDrug International Ltd.\tDiproxen TAB dr 500mg 50's pack 350\n\tDrug International Ltd.\tDiproxen CR TAB dr 500mg 30's pack 300\n\tEdruc Ltd.\tNaproxen TAB dr 250mg 50's pack 200\n\tEdruc Ltd.\tNapoxen TAB dr 250 mg 50's pack 200\n\tEdruc Ltd.\tNapoxen TAB dr 500 mg 30's pack 210\n\tEskayef Bangladesh Ltd.\tNaprox Powder for Suspension 125mg/5ml 50ml bot 50\n\tEskayef Bangladesh Ltd.\tNaprox TAB dr 250mg 50's pack 250\n\tEskayef Bangladesh Ltd.\tNaprox TAB dr 500mg 50's pack 450\n\tEuro Pharma Ltd.\tEprox TAB dr 500mg  50's pack 400\n\tEverest\tNoxen TAB dr 500mg 30's pack 210\n\tG. A. Company Ltd.\tNaprocid TAB dr 250mg 30's pack 120.05\n\tG. A. Company Ltd.\tNaprocid TAB dr 500mg 30's pack 210\n\tGeneral\tReleve TAB dr 500mg 50's pack 350\n\tGlobe\tGloxen TAB dr 500mg 30's pack 210\n\tHallmark\tRoxen TAB dr 250mg 50's pack 201\n\tHallmark\tRoxen TAB dr 500mg 30's pack 210\n\tHealthcare\tNapryn TAB dr 500mg 30's pack 550\n\tHealthcare\tNapryn TAB dr 250mg 50's pack 350\n\tHealthcare\tNapryn Powder For Suspension 125 mg/5 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tNupralgin TAB dr 250mg 48's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNupralgin TAB dr 500mg 24's pack 216\n\tIncepta\tTiclofex Powder for Suspension 125mg/5ml 50ml bot 35\n\tIncepta\tTicoflex TAB dr 250mg 50's pack 200\n\tIncepta\tTicoflex TAB dr 500mg 50's pack 350\n\tIncepta\tTicoflex SR TAB dr 500mg 30's pack 240\n\tIncepta\tTicoflex Suspension 125mg/5ml 50ml 35\n\tIndobangla Pharmaceuticals\tIndoprox TAB dr 250mg 30's pack 160\n\tIndobangla Pharmaceuticals\tIndoprox TAB dr 500mg 30's pack 210\n\tJayson\tNaproson TAB dr 250mg 50's pack 203\n\tJayson\tNaproson TAB dr 500mg 30's pack 210.90\n\tKemiko\tTofa TAB dr 500mg 50's pack 400\n\tKumudini Pharma Ltd.\tNapium TAB dr 250mg 50's pack 200\n\tKumudini Pharma Ltd.\tNapium TAB dr 500mg 30's pack 204\n\tLeon\tNovaxen TAB dr 500mg  \n\tModern\tNapix TAB dr 500mg 20's pack 140\n\tMonicopharma\tProxen TAB dr 500mg 50's pack 350\n\tNavana\tNaxo TAB dr 250mg 50's pack 201\n\tNavana\tNaxo TAB dr 500mg 50's pack 351.50\n\tNIPRO JMI Pharma\tNipoxen TAB dr 250mg 50's pack 250\n\tNIPRO JMI Pharma\tNipoxen SR TAB dr 500mg 30's pack 420\n\tNovartis (Bangladesh) Ltd.\tServinaprox TAB dr 250mg 50's pack 350\n\tNovartis (Bangladesh) Ltd.\tServinaprox TAB dr 500mg 30's pack 360\n\tNovus\tNax-N 250 TAB dr 250 mg 50's pack 200\n\tNovus\tNax-N 500 TAB dr 500 mg 30's pack 210\n\tOpsonin Pharma\tNaxin TAB dr 250mg 50's pack 219.92\n\tOpsonin Pharma\tNaxin TAB dr 500mg 30's pack 237.39\n\tOpsonin Pharma\tNaxin Suppository 500mg  \n\tOrion Pharma Ltd.\tVenoxen TAB dr 500mg 30's pack \n\tPacific\tNaid TAB dr 250mg 50's pack 200\n\tPacific\tNaid TAB dr 500mg 50's pack 376\n\tPharmasia Ltd.\tNapronil TAB dr 500mg 30's pack 210.90\n\tPopular\tNaspro TAB dr 250mg 50's pack 251\n\tPopular\tNaspro TAB dr 500mg 30's pack 270.90\n\tRadiant.\tNaprosyn Powder for Suspension 125mg/5ml 50ml bot 120\n\tRadiant.\tNaprosyn TAB dr 250mg 50's pack 400\n\tRadiant.\tNaprosyn TAB dr 500mg 50's pack 750\n\tRAK\tNapropain TAB dr 250mg 50's pack 300\n\tRAK\tNapropain TAB dr 500mg 30's pack 240\n\tRangs\tRanoxen TAB dr 250mg 50's pack 200\n\tRangs\tRanoxen SR TAB dr 500mg 30's pack 210\n\tReliance\tNAN TAB dr 500mg 50's pack 386.50\n\tRenata\tXenapro TAB dr 250mg 50's pack 250\n\tRenata\tXenapro TAB dr 500mg 30's pack 240.90\n\tSeema\tNasox TAB dr 500mg 20's pack 300\n\tSharif\tZenosyn TAB dr 500mg 30's pack 210\n\tSilva\tArnex TAB dr 500mg 30's pack 180.68\n\tSomatec\tFritt TAB dr 250mg 50's pack 200.50\n\tSomatec\tFritt TAB dr 500mg 50's pack 351.50\n\tSquare\tSonap TAB dr 250mg 50's pack 200.83\n\tSquare\tSonap Suppository 500mg 10's pack 120.50\n\tSquare\tSonap TAB dr 500mg 30's pack 210.67\n\tSyntho Ltd.\tNozee TAB dr 500mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tNapsod TAB dr 275mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tNapsod TAB dr 550mg 30's pack 270\n\tUnimed & Unihealth Manufacturers Ltd.\tNapec TAB dr 250mg 30' pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tNapec TAB dr 500mg 30' pack 270\n\tWhite Horse Pharma\tTicolax TAB dr 250mg 50's pack 250\n\tWhite Horse Pharma\tTicolax TAB dr 500mg 30's pack 240\n\tZenith\tNaproxen SR TAB dr 500mg 30's pack 210\n\tIndication: Rheumatoid arthritis, Ankylosing spondylitis, Post-operative pain, Dysmenorrhea, Acute gout, Acute migraine attacks, Renal colic, Cutaneous candidiasis, Mild to moderate pain, Tendonitis, Osteoarthritis (degenerative arthritis), Acute musculoskeletal disorders, Bursitis\n\nDose: Adults\nOral:\nFor rheumatoid arthritis, osteoarthritis and ankylosing spondylitis\nThe usual dose is 500-1000 mg per day taken in 2 doses at 12 hours intervals after meals.\nFor acute gout\n750 mg should be given initially, followed in 8 hours with 500 mg, and thereafter 250 mg at 12 hours intervals until the attack has passed.\nFor dysmennorhoea\n500 mg should be given initially, followed by 250 mg at 6-8 hour intervals for up to 5 days.\nFor analgesia and acute muscular skeletal disorders\n500 mg should be given initially, followed by 250 mg at 6-8 hour intervals.\n\nChildren over 5 years\nFor juvenile rheumatoid arthritis\n10mg/kg/day given as 2 divided doses at 12 hour intervals.\nSR tablet: For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis\n500mg or 1000mg (500mg Ã 2) SR tablet once daily (morning or evening) after meals.\nSR tablet is also indicated after the acute condition is subsided for long term use.\n\nNaproxen suspension\nAdults\nDosage is the same as Naproxen tablet.\nChildren over 5 years\n10 mg/kg/day given as 2 divided doses at 12 hours intervals.\n\n\n\nContra-indication: Hypersensitivity. Aspirin or NSAID allergy. Perioperative pain in the setting of CABG surgery. Pregnancy (3rd trimester).\n\nSide effects: Oedema, palpitation, dizziness, drowsiness, headache, light headedness, vertigo, pruritus, skin eruption, ecchymosis, purpura, rash, fluid retention, abdominal pain, constipation, nausea, heartburn, diarrhoea, dyspepsia, stomatitis, flatulence, gross bleeding/perforation, indigestion, ulcers, vomiting, abnormal renal function, haemolysis, anaemia, increased bleeding time, elevated LFTs, visual disturbances, tinnitus, hearing disturbances, dyspnoea, diaphoresis, thirst.\nPotentially Fatal: Anaphylactic/anaphylactoid reactions. Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).\n\nPrecaution: Pre-existing CV risk factors or disease e.g. fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment. Elderly. Lactation.\n\nMode of action: May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. \n\nDelayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.\n\nPregnancy category: D\n\nInteraction: May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. \n\nDelayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.
Naproxen 10%	\n\n\tACI\tAnaflex Gel   15gm tube/ 30gm tube 62.23 / 116.\n\tDrug International Ltd.\tDiproxen Gel   15gm tube 60\n\tDrug International Ltd.\tDeproxen Gel Gel 10% w/w 1's pack(15g) 60\n\tEskayef Bangladesh Ltd.\tNaprox Gel   15gm tube 60\n\tHealthcare\tNapryn Gel   15gm tube 70\n\tIncepta\tTiclofex Gel   15gm tube 60\n\tIncepta\tTicoflex Gel Gel 100mg/1gm 15g 60\n\tSquare\tSonap Gel  10 gm/100 gm 15gm tube 60.22\n\tSupreme\tSuxen Gel   15gm tube 62\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Renal colic, Mild to moderate pain, Tendonitis, Acute musculoskeletal disorders, Bursitis\n\nDose: Adult: Apply Naproxen gel 2-6 times a day as required.\n\nContra-indication: Hypersensitivity. Aspirin or NSAID allergy. Perioperative pain in the setting of CABG surgery. Pregnancy (3rd trimester)\n\nSide effects: Oedema, palpitation, dizziness, drowsiness, headache, light headedness, vertigo, pruritus, skin eruption, ecchymosis, purpura, rash, fluid retention, abdominal pain, constipation, nausea, heartburn, diarrhoea, dyspepsia, stomatitis, flatulence, gross bleeding/perforation, indigestion, ulcers, vomiting, abnormal renal function, haemolysis, anaemia, increased bleeding time, elevated LFTs, visual disturbances, tinnitus, hearing disturbances, dyspnoea, diaphoresis, thirst. Potentially Fatal: Anaphylactic/anaphylactoid reactions. Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).\n\nPrecaution: Pre-existing CV risk factors or disease e.g. fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment. Elderly. Lactation.\n\nMode of action: May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. Delayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.\n\nPregnancy category: D\n\nInteraction: May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. Delayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of ?-blockers (e.g. propranolol). May increase serum levels w/ probenecid.
Natamycin 5% Eye prep	\n\n\tAristopharma\tN Mycin Eye Drops   5  ml drop 100\n\tG. A. Company Ltd.\tNatacin Eye Drops    5  ml drop 80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNatoph Eye Drops   5  ml drop 100\n\tNipa\tNicin Eye Drops   5  ml drop 100\n\tPopular\tNatapro Eye Drops  50 mg/ml 5  ml drop 100\n\tReman Drug Ltd.\tNatadrop Eye Drops   5  ml drop 100\n\tIndication: Conjunctivitis, Keratitis, Blepharitis\n\nDose: For fungal keratitis: The preferred initial dosage is 1 drop instilled in the conjuntival sac (s) at 1-2 hours interval. The frequency of application can usually be reduced to 1 drop 6-8 times daily after the first 3-4 days. \n\nTherapy should generally be continued for 14 to 21 days or until there is resolution of active fungal keratitis. In many cases, it may be helpful to reduce the dosage gradually at 4 to 7 days intervals to assure the replicating fungus has been eliminated. \n\nFor fungal blepharitis & conjunctivitis: Less frequent initial dosage, 1 drop 4-6 times daily may be sufficient. \n\nContra-indication: Natamycin sterile ophthalmic suspension is contraindicated in individuals with a known hypersensitivity to any of its components.\n\n\nSide effects: Local irritation, conjunctival chemosis, hyperemia, etc.\n\n\nPrecaution: For topical eye use only. Failure of improvement of keratitis following 7-10 days of administration of the drug suggests that the infection may be caused by a microorganism not susceptible to natamycin. \n\nMode of action: Potentially Fatal: May increase spread of fungal eye infection when used w/ topical corticosteroid.\n\nPregnancy category: C\n\nInteraction: Potentially Fatal: May increase spread of fungal eye infection when used w/ topical corticosteroid.
Nateglinide	\n\n\tSquare\tNopik TAB dr 120mg 30's pack 300\n\tNovartis Farma SpA, Italy\tStarlix TAB dr 120mg 84's pack 2352\n\tIndication: Type 2 DM\n\nDose: Adult: PO 60-120 mg 3 times/day, up to 180 mg 3 times/day if needed.\n\nContra-indication: Diabetic ketoacidosis; IDDM. Lactation.\n\nSide effects: Dizziness; back pain; arthropathy; upper respiratory tract infection; flu-like symptoms; bronchitis; cough; hypoglycaemia; accidental trauma; diarrhoea.\n\nPrecaution: Geriatric patients, debilitated and malnourished patients; adrenal or pituitary insufficiency, moderate to severe hepatic impairment; severe renal impairment. Monitor glycaemic levels during periods of stress. Pregnancy.\n\nMode of action: Increased levels/effects with enzyme inhibitors (e.g. fluconazole). Increased hypoglycaemic effects with salicylates, MAOIs, nonselective ?-blockers, alcohol, NSAIDs. Decreased levels/effects with enzyme inducers (e.g. rifampicin). Decreased hypoglycaemic effects with thiazide diuretics, corticosteroids, thyroid products and sympathomimetic agents.\n\nPregnancy category: C\n\nInteraction: Increased levels/effects with enzyme inhibitors (e.g. fluconazole). Increased hypoglycaemic effects with salicylates, MAOIs, nonselective ?-blockers, alcohol, NSAIDs. Decreased levels/effects with enzyme inducers (e.g. rifampicin). Decreased hypoglycaemic effects with thiazide diuretics, corticosteroids, thyroid products and sympathomimetic agents.
Nebivolol	\n\n\tACI\tBipinor TAB dr 2.5mg 30's pack 151.20\n\tACI\tDipinor TAB dr 5mg 30's pack 240.90\n\tACI\tBipinor TAB dr 5mg 30's pack 241.50\n\tDelta Pharma\tNebinor TAB dr 5mg 30's pack \n\tOpsonin Pharma\tNebilol TAB dr 2.5mg/5mg 30's 150/300\n\tSquare\tNebita TAB dr 5 mg 30's pack 300\n\tSquare\tNebita TAB dr 2.5 mg 30's pack 210\n\tUnimed & Unihealth Manufacturers Ltd.\tNebicard TAB dr 2.5mg 28's pack 196\n\tUnimed & Unihealth Manufacturers Ltd.\tNebicard TAB dr 5mg 28's pack 336\n\tIndication: Heart failure, Hypertension\n\nDose: Adult: PO HTN 5 mg/day. Max: 40 mg once daily. Heart failure Initial: 1.25 mg once daily. May double dose 1-2 wkly up to a max of 10 mg once daily.\n\nContra-indication: Hepatic impairment, sick sinus syndrome, 2nd and 3rd degree heart block (without a pacemaker), history of asthma, metabolic acidosis, severe peripheral arterial disease, severe bradycardia, cardiogenic shock or decompensated heart failure, untreated phaeochromocytoma. Pregnancy and lactation.\n\nSide effects: Peripheral oedema, bradycardia, chest pain; headache, fatigue, dizziness, insomnia; rash; hypercholesterolaemia, decreased HDL levels, hyperuricaemia, increased triglyceride levels, increased uric acid levels; diarrhoea, nausea, abdominal pain; thrombocytopenia; paraesthesia, weakness; increased BUN; dyspnoea.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Elderly. History of anaphylaxis to various allergens, 1st degree AV block, peripheral arterial disease, DM, compensated heart failure, myasthenia gravis, history of psychiatric illness, renal impairment. May mask signs of hyperthyroidism (e.g. tachycardia).\n\nMode of action: Increased plasma concentrations w/ potent CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, propafenone, thioridazine, quinidine). Concomitant use w/ antiarrhythmic drugs (e.g. amiodarone, disopyramide) or nondihydropyridine Ca channel blockers (e.g. diltiazem, verapamil) may cause conduction disturbance. Additive negative effects on AV conduction and heart rate w/ other beta-adrenergic blocking agents or digoxin. Concurrent admin w/ catecholamine-depleting agents (e.g. reserpine) may result in additive hypotension or bradycardia. Abrupt withdrawal of clonidine may increase risk of rebound HTN.\n\nPregnancy category: C\n\nInteraction: Increased plasma concentrations w/ potent CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, propafenone, thioridazine, quinidine). Concomitant use w/ antiarrhythmic drugs (e.g. amiodarone, disopyramide) or nondihydropyridine Ca channel blockers (e.g. diltiazem, verapamil) may cause conduction disturbance. Additive negative effects on AV conduction and heart rate w/ other beta-adrenergic blocking agents or digoxin. Concurrent admin w/ catecholamine-depleting agents (e.g. reserpine) may result in additive hypotension or bradycardia. Abrupt withdrawal of clonidine may increase risk of rebound HTN.
Nefopam Hydrochloride	\n\n\tACI\tAcuten Injection 20mg/ml 60's pack 180\n\tACI\tAcuten TAB dr 30mg 60's pack 180.60\n\tEskayef Bangladesh Ltd.\tEfopam TAB dr 30mg 60's pack 180\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAcupain 30 TAB dr 30mg 50's pack \n\tIbn Sina Pharmaceutical Ind. Ltd.\tAcupain Inj Injection 20mg/ml 10's pack \n\tIncepta\tNeforex Injection 20mg/ml 5's pack 75\n\tIncepta\tNeforex TAB dr 30mg 30's pack 90\n\tSquare\tXripa Injection 20mg/ml 10's pack 150.55\n\tSquare\tXripa TAB dr 30mg 60's pack 180.35\n\tIndication: Acute and chronic pain\n\nDose: Adult: PO Initial: 60 mg 3 times/day. Usual range: 30-90 mg 3 times/day. Max: 300 mg/day. \n\nIV 20 mg 4 hrly. Max:120 mg/day. IM 20 mg 6 hrly if needed.\n\nChildren: Not recommended for children under the age of 12 years. \n\nContra-indication: History of convulsive disorders.\n\nSide effects: Nausea, vomiting, sweating, drowsiness, insomnia, urinary retention, dizziness, hypotension, tremor, paraesthesia, palpitations, lightheadedness, nervousness, mental confusion, blurred vision, headache, dry mouth, angioedema, tachycardia, euphoria, hallucinations, convulsions, temporary pink discolouration of the urine.\n\nPrecaution: Glaucoma, urinary retention, hepatic or renal impairment. Elderly. Pregnancy.\n\nMode of action: Adverse effects increased with antimuscarinic or sympathomimetic drugs. Increased risk of seizures with TCAs. Increased CNS depressant effects with other sedatives.\nPotentially Fatal: Additive sympathomimetic effects with MAOIs.\n\nPregnancy category: Not Classified\n\nInteraction: Adverse effects increased with antimuscarinic or sympathomimetic drugs. Increased risk of seizures with TCAs. Increased CNS depressant effects with other sedatives.\nPotentially Fatal: Additive sympathomimetic effects with MAOIs.
Nelfinavir	\n\n\tBeximco\tAvifix TAB dr 250mg 10's pack 450\n\tSquare\tNelvir TAB dr 250mg 10's pack 451.67\n\tIndication: HIV infection\n\nDose: Oral\nHIV infection\nAdult: Combined with other antiretrovirals: 1.25 g bid or 0.75 g tid.\nChild: Combined with other antiretrovirals: 2-13 yr: 45-55 mg/kg bid or 25-35 mg/kg tid. Max: 0.75 g tid.\nMax Dosage: Child: 0.75 g tid.\nHepatic impairment: Dose reduction may be required.\n\nContra-indication: Hypersensitivity; lactation.\n\nSide effects: Hyperglycaemia, dyslipidaemia and redistribution of body fat (protease paunch, buffalo hump, facial atrophy and heart engorgement); hypertriglyceridaemia, hypercholesterolaemia. Diarrhoea, rash, nausea, flatulence, decreased lymphocytes, decreased neutrophils, decreased haemoglobin, increased creatine kinase, increased transaminases.\n\nPrecaution: Pregnancy. Hepatic and renal impairment; haemophilia A or B; diabetes. Monitor for signs of lipodystrophy.\n\nMode of action: Reduced levels/effects with antacids, phenobarbital, carbamazepine, aminoglutethimide, phenytoin, rifampicin, nafcillin, nevirapine, omeprazole, nevirapine. Increased serum levels/effects with azole antifungal agents, cimetidine, efavirenz. Increased serum levels/effects of azithromycin, calcium channel blockers, clarithromycin, corticosteroids (e.g. fluticasone), mirtazapine, nateglinide, nefazodone, ciclosporin, sirolimus, tacrolimus, venlafaxine, eplerinone, fentanyl, atorvastatin, phosphodiesterase-5 (PDE-5) inhibitors, rifabutin, trazodone, TCAs. Reduced serum levels/effects of hormonal contraceptives, methadone, theophylline derivatives.\nPotentially Fatal: Increased serum levels/toxicity of amiodarone, cisapride, pimozide, midazolam, triazolam, ergot alkaloids, lovastatin, simvastatin, quinidine.\n\nPregnancy category: B\n\nInteraction: Reduced levels/effects with antacids, phenobarbital, carbamazepine, aminoglutethimide, phenytoin, rifampicin, nafcillin, nevirapine, omeprazole, nevirapine. Increased serum levels/effects with azole antifungal agents, cimetidine, efavirenz. Increased serum levels/effects of azithromycin, calcium channel blockers, clarithromycin, corticosteroids (e.g. fluticasone), mirtazapine, nateglinide, nefazodone, ciclosporin, sirolimus, tacrolimus, venlafaxine, eplerinone, fentanyl, atorvastatin, phosphodiesterase-5 (PDE-5) inhibitors, rifabutin, trazodone, TCAs. Reduced serum levels/effects of hormonal contraceptives, methadone, theophylline derivatives.\nPotentially Fatal: Increased serum levels/toxicity of amiodarone, cisapride, pimozide, midazolam, triazolam, ergot alkaloids, lovastatin, simvastatin, quinidine.
Neomycin Sulphate 0.35% + Polymixin B Sulphate 0.127% + Prednisolone 0.5% Eye prep	\n\n\tAristopharma\tPolyforte Eye Drops   5ml bot 150\n\tIncepta\tCortan Plus Eye Drops (350 mg + 127 mg + 500 mg  \n\tIndication: Conjunctivitis, Keratitis, Bacterial ocular infection, Steroid-responsive inflammatory ocular conditions, Corneal ulcerations\n\nDose: Instill one drop into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue the therapy before completing the course.\nPaediatric Use: Safety and effectiveness in pediatric patients have not been established.\n\nContra-indication: Prednisolone Acetate is contraindicated in viral diseases of the cornea, conjunctiva and known hypersensitivity to any of the ingredients of this preparation or other corticosteroids.\n\nSide effects: Elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation and delayed wound healing.\nFungal and viral infections of the cornea are particularly may develop coincidentally with long-term applications of steroid\n\nPrecaution: Shake the bottle well before use. Prolonged use of corticosteroids may result in damage to the optic nerve and defects in vision. If this product is used for longer period of time, intraocular pressure should be routinely monitored.\n\nMode of action: Synergistic effects with penicillins. Additive toxicity with neurotoxic, ototoxic or nephrotoxic drugs. May decrease absorption of digoxin and methotrexate. May increase effects of oral anticoagulants.	\n\nPregnancy category: C\n\nInteraction: Synergistic effects with penicillins. Additive toxicity with neurotoxic, ototoxic or nephrotoxic drugs. May decrease absorption of digoxin and methotrexate. May increase effects of oral anticoagulants.	
Neomycin Sulphate 0.4% + Polymixin B Sulphate + Pramoxine 1% Topical	\n\n\tAlco Pharma\tNuprin Cream    5gm  tube/10gm  tube/30gm  tube 40 / 75 / 140\n\tSquare\tNepranol Cream  3.5 mg + 10000 IU + 10 m 10gm  tube 75.28\n\tIndication: Burns, Scrapes, Skin and skin structure infections, Cuts\n\nDose:     Adults and children 2 years of age and older:\n        clean the affected area\n        apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily\n        may be covered with a sterile bandage\n    children under 2 years of age: consult a doctor\n\n\nContra-indication: Hypersensitivity to aminoglycosides and any of its components. Pre-existing nerve deafness. TB, fungal or viral infections. Do not use in external eardrum if tympanic membrane is perforated.\n\nSide effects:  Skin sensitisation. Cream: Burning, itching, irritation, hypopigmentaion, skin atrophy, striae. Ophthalmic: Irritation, increased intraocular pressure, glaucoma, posterior subcapsular cataract formation, delayed wound healing, secondary infections.\n\nPrecaution: : Possibility of ototoxicity, nephrotoxicity and exogenous hyperadrenocorticism if used in large quantities or on large areas for prolonged use\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Neomycin Sulphate 0.5% Eye prep	\n\n\tIndication: Otitis externa, Bacterial ocular infection, Otic infections\n\nDose: Apply sparingly to the affected area 2 to 3 times daily until an improvement occurs. In children, course should be limited to 5 days\n\nContra-indication: - Acne vulgaris.\n- Perioral dermatitis.\n- Perianal and genital pruritus.\n- Primary cutaneous viral infections (e.g. herpes simplex, chickenpox).\n- Hypersensitivity to any component of the preparation.\n\nSide effects: Burning, itching, irritation, dryness, folliculitis, hypertrychosis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria may be reported.\n\nPrecaution: Long-term continuous topical therapy should be avoided where possible, particularly in infants and children. Infants and children up to four years should not be treated with topical steroids for longer than 3 weeks without medical review. \n\nMode of action: Synergistic effects with penicillins. Additive toxicity with neurotoxic, ototoxic or nephrotoxic drugs. May decrease absorption of digoxin and methotrexate. May increase effects of oral anticoagulants.\n\nPregnancy category: C\n\nInteraction: Synergistic effects with penicillins. Additive toxicity with neurotoxic, ototoxic or nephrotoxic drugs. May decrease absorption of digoxin and methotrexate. May increase effects of oral anticoagulants.
Neomycin Sulphate 0.5% + Prednisolone 0.5% E/E prep	\n\n\tRenata\tDeltasone N Eye/Ear Drops   5  ml drop 39.98\n\tIndication: Bacterial ocular infection, otitis externa\n\nDose:  Instill 1 or 2 drops every 3 or 4 hours, or more frequently as required. Acute infections may require administration every 30 minutes, with frequency of administration reduced as the infection is brought under control. \n\n\n\nContra-indication: Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of the ocular structures. Hypersensitivity to a component of the medication. (Hypersensitivity to the antibiotic component occurs at a higher rate than for other components.)\n\nThe use of these combinations is always contraindicated after uncomplicated removal of a corneal foreign body.\n\nSide effects: Adverse reactions have occurred with steroid/anti-infective combination drugs which can be attributed to the steroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.\n\nReactions occurring most often from the presence of the anti-infective ingredients are allergic sensitizations including itching, swelling, and conjunctival erythema . More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. The reactions due to the steroid component in decreasing order of frequency are: elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.\n\nAlthough systemic effects are extremely uncommon, there have been rare occurences of systemic hypercorticoidism after use of topical steroids.\n\nCorticosteroid-containing preparations have also been reported to cause perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following local use of steroids.\n\nSecondary infection: The development of secondary infection has occurred after use of combinations containing steroids and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion must be considered in any persistent corneal ulceration where steroid treatment has been used.\n\nSecondary bacterial ocular infection following suppression of host responses also occurs.\n\nPrecaution: The initial prescription and renewal of the medication order beyond 20 milliliters should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.\n\nThe possibility of persistent fungal infections of the cornea should be considered after prolonged steroid dosing.\n\nAs with other antimicrobial preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.\n\n . If purulent discharge, inflammation, or pain becomes aggravated, the patient should discontinue use of the medicatioin and consult a physician.\n\nAllergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.\n\nMode of action: Synergistic effects with penicillins. Additive toxicity with neurotoxic, ototoxic or nephrotoxic drugs. May decrease absorption of digoxin and methotrexate. May increase effects of oral anticoagulants.\n\nPregnancy category: C\n\nInteraction: Synergistic effects with penicillins. Additive toxicity with neurotoxic, ototoxic or nephrotoxic drugs. May decrease absorption of digoxin and methotrexate. May increase effects of oral anticoagulants.
Nepafenac 0.1% Eye prep	\n\n\tAristopharma\tNevan Eye Drops   5ml bot 150\n\tBeximco\tOpanac Eye Drops 0.1% 3ml bot 119\n\tPopular\tOptafenac Eye Drops 0.1% 5 ml plastic dropper bottle  150\n\tIndication: Occular pain and inflammation, Cystoid macular edema\n\nDose: For post-operative pain & inflammation: Instill 1 drop 3 times daily 1 day prior to cataract surgery and continued on the day of surgery and through the first 2 weeks of the post-operative period.\n\nFor surgery induced miosis: Instill 1 drop 3 times daily 1 day before surgery & on the day of surgery.\n\nFor prevention of post-operative CME: Instill 1 drop 3 times daily 1 day before surgery and continued on the day of surgery and through the first 6 weeks of the post-operative period.\n\nContra-indication: Contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation or to other NSAIDs.\n\nSide effects: Reported side effects are foreign body sensation, lid margin crusting, ocular discomfort, ocular hyperemia etc.\n\nPrecaution: Nepafenac should be used with caution in patients with known bleeding tendencies or who are receiving medications which may prolong bleeding time.\n\nMode of action: Topical NSAIDs & corticosteroids.\n\nPregnancy category: C\n\nInteraction: Topical NSAIDs & corticosteroids.
Nevirapine	\n\n\tIndication: HIV infection\n\nDose: Oral\nHIV infection\nAdult: Combined with other antiretrovirals: 200 mg once daily for the first 14 days; increase to 200 mg bid if rash does not develop. Interrupting the treatment for >7 days necessitate reintroduction at a lower dose for the first 14 days.\nChild: Combined with other antiretrovirals: 2 mth to 8 yr: 4 mg/kg once daily for the first 14 days; increase to 7 mg/kg bid if no rash is present. 8-16 yr: 4 mg/kg once daily for 14 days followed by 4 mg/kg bid. Max: 400 mg daily. Interrupting the treatment for >7 days necessitate reintroduction at a lower dose for the first 14 days.\n\nContra-indication: Hypersensitivity. Lactation. Severe hepatic impairment.\n\nSide effects: Skin rash, nausea, vomiting, headache, abnormal LFT, fatigue, diarrhoea, abdominal pain.\nPotentially Fatal: Severe and life-threatening hepatotoxic and skin reactions\n\nPrecaution: Pregnancy. Interrupt treatment if severe hepatotoxicity or life-threatening skin reactions develop. Renal or hepatic insufficiency. Monitor liver function periodically.\n\nMode of action: Mutually increased levels effects when used with drugs extensively metabolised by CYP3A. Reduced levels/effects of methadone.\n\nPregnancy category: B\n\nInteraction: Mutually increased levels effects when used with drugs extensively metabolised by CYP3A. Reduced levels/effects of methadone.
Niacin (nicotinic acid)	\n\n\tDrug International Ltd.\tNiapid TAB dr 500mg 30's pack 180\n\tDrug International Ltd.\tNiapid XR TAB dr 500mg 30's pack\n 180\n\tEskayef Bangladesh Ltd.\tVanila-E TAB dr 200mg 15's pack 57\n\tIncepta\tRidel ER TAB dr 500mg 20's pack 160\n\tJayson\tNicoson TAB dr 50mg 100'pack 35\n\tJayson\tNicoson TAB dr 500mg  \n\tIndication: Ischaemic events, Hyperlipidaemias, Nicotinic acid deficiency\n\nDose: Oral\nTreatment and prophylaxis of nicotinic acid deficiency\nAdult: Up to 500 mg daily in divided doses. May also be given by IM or slow IV inj.\n\nHyperlipidaemias\nAdult: As immediate-release preparation: Initially, 600 mg daily in 3 divided doses, gradually increased over 2-4 wk to max 6 g daily (usual dose 1-2 g bid-tid). As modified-release preparation: Initially, 375 or 500 mg at night gradually increased by no more that 500 mg in 4 wk according to patient's response. Maintenance: 1-2 g at bedtime.\n\nVasodilation\nAdult: As immediate-release preparation: 100-150 mg 3-5 times daily. As extended release preparation: 300-400 mg 12 hrly.\n\n\n\nContra-indication: Niacin is contraindicated in patients with a known hypersensitivity to Niacin or any component of this medication, significant or unexplained hepatic dysfunction, active peptic ulcer disease or arterial bleeding.\n\nSide effects: Niacin is generally well tolerated; adverse reactions have been mild and transient.The most frequent advers effects were flushing, itching, pruritis, nausea and GI upset, jaundice ,hypotension, tachycardia, increased serum blood glucose and uric acid levels, myalgia.\n\nPrecaution: Before instituting therapy with Niacin, an attempt should be made to control hyperlipidemia with appropriate diet, exercise, and weight reduction in obese patients and to treat other underlying medical problems. Patients with a past history of jaundice, hepatobiliary disease, or peptic ulcer should be observed closely during Niacin therapy. Frequent monitoring of liver function tests and blood glucose should be performed to ascertain that the drug is producing no adverse effects on these organ systems. Diabetic patients may experience a dose-related rise in glucose intolerance, the clinical significance of which is unclear. Diabetic or potentially diabetic patients should be observed closely. Adjustment of diet and/or hypoglycemic therapy may be necessary.\n\nCaution should also be used when Niacin is used in patients with unstable angina or in the acute phase of MI, particularly when such patients are also receiving vasoactive drugs such as nitrates, calcium channel blockers or adrenergic blocking agents. Elevated uric acid levels have occurred with Niacin therapy, therefore use with caution in patients predisposed to gout. Niacin has been associated with small but statistically significant dose-related reductions in platelet count and increases in prothrombin time. Caution should be observed when Niacin is administered concomitantly with anticoagulants; prothrombin time and platelet counts should be monitored closely in such patients. Niacin has been associated with small but statistically significant, dose-related reductions in phosphorus levels (mean of -13% with 2000 mg). So phosphorus levels should be monitored periodically in patients at risk.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Vitamin B-complex + Zinc	\n\n\tACI\tOral-ZB Syrup 10mg/5ml+Vit B Complex 100ml bot 45.31\n\tAcme Ltd.\tZ-Plex Syrup    100ml bot / 200 ml bot 45.16 / 85.32\n\tAlbion Ltd.\tPolyvit Plus Z Syrup  100 ml bot \n\tAlco Pharma\tZivit Syrup   100ml bot / 200ml bot 60 / 100\n\tAmico Ltd.\tZn-B Syrup   100ml bot 50\n\tAPC Pharma Ltd.\tApevit Z Syrup   100ml bot 45\n\tApex\tZipol plus Syrup   100ml bot 45\n\tApollo Pharmaceutical Ltd.\tZincaplex Syrup   100ml bot 50\n\tAstra Biopharmaceuticals Ltd.\tAstra-Z TAB dr  15's pack 60\n\tConcord\tConvit Z Syrup (400 mg + 40 mg + 50 mg +  \n\tDelta Pharma\tActivit Z Syrup    100ml bot / 200 ml bot 45 / 85\n\tDesh\tLysozinc Syrup  100ml bot / 200ml bot 45 / 80\n\tEskayef Bangladesh Ltd.\tXinc B Syrup    100ml bot / 200 ml bot 50 / 85\n\tEskayef Bangladesh Ltd.\tXinc B TAB dr   30's pack 60\n\tEuro Pharma Ltd.\tEuroplex-Z Syrup   100ml bot 45\n\tGeneral\tZico plus Syrup   100ml bot 45.17\n\tGlobex\tZicovit-B Syrup  100ml 45\n\tIncepta\tAritone Z Syrup  100/200ml 45/85\n\tKemiko\tZismo B Syrup    100ml bot / 200 ml bot 45 / 85\n\tKumudini Pharma Ltd.\tVicon-Z Syrup  100ml bot 45\n\tLeon\tLeozinc-B syrup (20 mg + 2 mg + 2 mg + 5   \n\tModern\tZinofa-B Syrup    100ml bot / 200 ml bot 45 / 85\n\tMonicopharma\tHizin Syrup   100ml bot 45\n\tNovo Healthcare and Pharma Ltd.\tZido B Syrup   100ml bot 45\n\tOpsonin Pharma\tOpsovit Z Syrup   1's pack 85.32\n\tOpsonin Pharma\tOpsovit Z TAB dr  30's pack 52.78\n\tOrganic Health Care\tVitaflower-Z Syrup  100ml bot 50\n\tOrion Pharma Ltd.\tPep PLUS Syrup   100ml bot 45.17\n\tOrion Pharma Ltd.\tPep-plus TAB dr   30's pack 60.30\n\tPeoples Pharma Ltd.\tZbvit Syrup   100ml bot 45\n\tPharmadesh Ltd.\tVitaplex-Z Syrup   100ml bot 40\n\tPopular\tVizinc TAB dr  20 mg + 2 mg + 2.75 mg + 30's pack 60.29\n\tRangs\tBabiz Syrup    100ml bot / 200 ml bot 45 / 85\n\tSilva\tXinoplex Syrup    100ml bot / 200 ml bot 45.17 / 85.32\n\tSomatec\tZinc Plus Syrup   100ml bot 45\n\tSquare\tBicozin Syrup     100ml bot / 200 ml bot 45.16 / 85.32\n\tSquare\tBicozin TAB dr   30's pack 60.30\n\tVirgo\tKidizinc-B Syrup  100ml bot 50\n\tZenith\tMonovit Syrup    100ml bot / 200 ml bot 45/80\n\tIndication: Vitamin B and Zinc deficiencies\n\nDose: Adults: 10 ml (2 teaspoonful) 2 to 3 times daily or as recommended by the physician.\nChildren: 10 ml (2 teaspoonful) 1 to 3 times daily or as recommended by the physician.\nInfants: 5 ml (1 teaspoonful) 1 to 2 times daily or as recommended by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients of this product.\n\nSide effects: Generally well tolerated.\n\nPrecaution: \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Nicorandil	\n\n\tGeneral\tNicoral TAB dr 10mg 50's pack \n\tGeneral\tNicoral TAB dr 5mg 50's pack \n\tOrion Pharma Ltd.\tNicor TAB dr 10mg 50's pack \n\tUnimed & Unihealth Manufacturers Ltd.\tCorangi TAB dr 10mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tCorangi TAB dr 20mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tCorangi TAB dr 5mg  \n\tIndication: Angina pectoris\n\nDose: Adult: PO Initial:10 mg twice daily. Usual dose: 10-20 mg twice daily. Max: 30 mg twice daily.\n\nContra-indication: Cardiogenic shock; hypotension; left ventricular failure with low filling pressure; lactation.\n\nSide effects: Headache (usually transitory), flushing, dizziness, nausea, vomiting and weakness. Hypotension and reflex tachycardia at high doses.\n\nPrecaution: Hypovolaemia, low systolic BP, acute pulmonary oedema, pregnancy. May impair ability to drive or operate machinery.\n\nMode of action: Hypotensive interaction may occur with alcohol, TCAs, antihypertensives and other vasodilators.\nPotentially Fatal: Enhanced hypotensive effect with sildenafil and other phosphodiesterase type-5 inhibitors.\n\nPregnancy category: Not Classified\n\nInteraction: Hypotensive interaction may occur with alcohol, TCAs, antihypertensives and other vasodilators.\nPotentially Fatal: Enhanced hypotensive effect with sildenafil and other phosphodiesterase type-5 inhibitors.
Multivitamin Paediatric preparations	\n\n\tACI\tNutrivit MV Paediatric Drops  15 ml bot  16.06\n\tAPC Pharma Ltd.\tApevit M Paediatric Drops   15 ml bot 15\n\tApollo Pharmaceutical Ltd.\tMulti 7 Paediatric Drops   15 ml bot 14.37\n\tBeximco\tTynisol Paediatric Drops   15 ml bot 16.04\n\tBio Pharma Ltd.\tBiovit Paediatric Drops   15 ml bot 15.06\n\tDoctor's Chemicals Works Ltd.\tHeptavit Paediatric Drops   15ml 15\n\tEdruc Ltd.\tEdruvit Paediatric Drops   15 ml bot 20\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMultisina 	 Paediatric Drops 15 ml bot   15.95\n\tKemiko\tKvit M Paediatric Drops   15 ml bot 15\n\tOpsonin Pharma\tVita M Paediatric Drops  15 ml bot 14.75 \n\tOrion Pharma Ltd.\tMultivin Paediatric Drops   15ml bot \n\tSomatec\tNeoplus Paediatric Drops   15 ml bot 15.05\n\tSquare\tPanvit Paediatric Drops   15ml bot 15.17\n\tZenith\tRestovit M Paediatric Drops   15 ml bot 15\n\tIndication: Vitamin deficiencies\n\nDose: Below 1 year : 9-10 drops (0.3 ml), 1 year and above : 23-25 drops (1.0 ml) once daily or as advised by the physicians. \n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients. Supplemental vitamins should not be prescribed for patients with haemochromatosis or Wilsonâs disease.\n\nSide effects:  Generally well tolerated. \n\nPrecaution: Multivitamin preparation with ordinary doses of component are usually nontoxic.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Vitamin B complex	\n\n\tACI\tNutrivit-B 	 TAB dr    45's pack 22.95 	\n\tACI\tNutrivit-B Syrup 5mg+2mg+20mg+2mg/5ml 200ml bot   62.19\n\tAcme Ltd.\tV Plex CAP   250's pack 142.50\n\tAcme Ltd.\tV Plex TAB dr   100'pack 44\n\tAcme Ltd.\tV Plex Syrup    100ml bot x 200 ml bot 20.91/ 38.17\n\tAcme Ltd.\tV Plex Paediatric Drops   \n\tAd-din\tB Plex TAB dr   45's pack 20.70\n\tAd-din\tB Plex Syrup   100ml bot 20.84\n\tAexim\tAlbaplex Syrup   100ml bot/200ml bot 20.60 / 37.60\n\tAexim\tAlbatab TAB dr   100'pack 44\n\tAlbion Ltd.\tPolyvit B-Forte Syrup  100ml/200ml \n\tAlbion Ltd.\tPolyvit B CAP  200's pack \n\tAlbion Ltd.\tPolyvit B TAB dr  100's pack \n\tAmbee\tVitex CAP   200's pack 106\n\tAmbee\tVitex Syrup    100ml bot x 200 ml bot 20.92/38.18\n\tAmico Ltd.\tFlavit TAB dr   45's pack 19.80\n\tAmico Ltd.\tFlavit Syrup    100ml bot x 200 ml bot 20.65 / 38\n\tAPC Pharma Ltd.\tApevit Syrup   100ml bot/200ml bot 20 /37.60\n\tAPC Pharma Ltd.\tApevit B TAB dr   45's pot/100's box 18 / 40\n\tApex\tRibaplex CAP   100's pack 53\n\tApex\tRibaplex TAB dr   45's pack 20.25\n\tApex\tRibaplex Syrup   200's pack 38.17\n\tAristopharma\tUniplex Syrup    100ml bot x 200 ml bot 20.90 / 38\n\tAristopharma\tUnivit B TAB dr   45's pack 22.95\n\tAristopharma\tVitazin Syrup   100ml bot 46\n\tAsiatic Ltd.\tAsivit TAB dr   60's pack 31.20\n\tAsiatic Ltd.\tNutrovita Syrup    100ml bot x 200 ml bot 20.91 / 38.17\n\tBelsen\tProvit B TAB dr   30's pack / 100'pack 18.19/36.80\n\tBelsen\tProvit B Syrup    100ml bot x 200 ml bot 23/41\n\tBenham\tBenvit B TAB dr   45's pack 18.90\n\tBenham\tBenvit B Syrup   100ml bot/200ml bot 20.23 / 37.42\n\tBeximco\tAristoplex Syrup   100ml bot/200ml bot 20.92 / 33.58\n\tBeximco\tAristovit B TAB dr   45's pack 23.40\n\tBio Pharma Ltd.\tBiovit CAP   200's pack 114\n\tBio Pharma Ltd.\tBiovit Syrup    100ml bot x 200 ml bot  20.88 / 38.14\n\tBristol Pharma Ltd.\tBp Fort CAP   250's pack 125\n\tBristol Pharma Ltd.\tVitatab TAB dr   200's pack 80\n\tCentral.\tCytaplex CAP   200's pack 110\n\tCentral.\tCytaplex Syrup    100ml bot x 200 ml bot 22/ 37.60\n\tChemist Ltd.\tVita-S TAB dr   10 amps pack 40.40\n\tCipla Ltd.\tCiplavit Syrup (20 mg + 2 mg + 2 mg + 5   \n\tConcord\tConvit B Syrup (20 mg + 2 mg + 2 mg + 5   \n\tCosmic Chemical Industries Ltd.\tB Vit 4 TAB dr   45's pack/ 200's pack 19.80 / 88\n\tCosmic Chemical Industries Ltd.\tB Vit 4 Syrup   200ml bot 38\n\tCosmo Pharma Ltd.\tCpvit B CAP   45's pack 19\n\tDecent Pharma Ltd.\tDeplex CAP   250's pack 140\n\tDecent Pharma Ltd.\tDeplex Syrup    100ml bot x 200 ml bot 20.84 /38.14\n\tDelta Pharma\tActivit B Syrup   100ml 20.85\n\tDesh\tLysovita B CAP   200's pack 120\n\tDesh\tLysovita B TAB dr   45's pack/ 100'pack 19.80/ 44\n\tDesh\tLysovita B Syrup   200'ml bot 37.60\n\tDoctor's Chemicals Works Ltd.\tBeforte CAP  114  200's pack\n\tDoctor's Chemicals Works Ltd.\tBeforte TAB dr   45's pack 19.35\n\tDoctor's Chemicals Works Ltd.\tBeforte Syrup    100ml bot x 200ml bot 20 / 37\n\tDoctor's Chemicals Works Ltd.\tBeforte Z Syrup   100ml bot 45\n\tDrug International Ltd.\tSupraplex Syrup    100ml bot x 200 ml bot 20.87 / 38.16\n\tEdruc Ltd.\tEdiplex TAB dr   45's pack 19.80\n\tEdruc Ltd.\tEdiplex Syrup    100ml bot x 200 ml bot 20.84 / 38.17\n\tEskayef Bangladesh Ltd.\tSolvit B TAB dr   45's pack 22.96\n\tEskayef Bangladesh Ltd.\tSolvitone Syrup     100ml bot x 200 ml bot 21/38\n\tEuro Pharma Ltd.\tEuroplex Syrup   200ml bot 37\n\tEverest\tBicom TAB dr   45's pack 19.80\n\tG. A. Company Ltd.\tHiposul CAP   100'pack 50\n\tG. A. Company Ltd.\tHiposul TAB dr   45's pack 19.35\n\tG. A. Company Ltd.\tHiposul Syrup    100ml bot x 200 ml bot 20.86 / 38.03\n\tGeneral\tGenaplex CAP   250's pack 140\n\tGeneral\tGenaplex Syrup    100ml bot x 200 ml bot 20.75 / 37.75\n\tGlaxoSmithKline Bangladesh Ltd.\tComplavit Syrup   100ml bot 20.92\n\tGlaxoSmithKline Bangladesh Ltd.\tComplavit TAB dr   \n\tGlobe\tStanoplex Syrup    100ml bot x 200 ml bot 20.60/ 37.60\n\tGlobe\tStanovit B TAB dr   45's pack 19.80\n\tGonoshasthaya\tG Vitamin B COMP TAB dr   100'pack 45\n\tHallmark\tVigor B TAB dr   45's pack 19.80\n\tHallmark\tVigor B Syrup    100ml bot x 200 ml bot 20.64 / 38.17\n\tHudson\tBecoson CAP   200's pack 112\n\tHudson\tBecoson Syrup   100ml bot/200ml bot 20.60 / 37.60\n\tHudson\tBevit TAB dr   100'pack 43\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBiozine-B Syrup   100ml bot 45.17\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinafort B CAP   250's pack 142.50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinafort B TAB dr   45's pack 22.95\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinafort B Syrup    100ml bot x 200 ml bot 20.92/ 38.17\n\tIndobangla Pharmaceuticals\tIndoplex Syrup    100ml bot x 200 ml bot 23 / 38\n\tIndobangla Pharmaceuticals\tIndoplex B TAB dr   45's pack 18\n\tJayson\tHexaplex Syrup    100ml bot x 200 ml bot 19.80 / 38.17\n\tJayson\tOrabex CAP   200's pack 114\n\tJayson\tOrabex TAB dr   100'pack 44\n\tKemiko\tKvit B TAB dr   45's pack 22.95\n\tKemiko\tKvit B Syrup   200's pack 37\n\tKumudini Pharma Ltd.\tVicon TAB dr   45's pack 22.95\n\tKumudini Pharma Ltd.\tVicon Syrup   200'ml bot 38\n\tMarksman.\tVitacare Syrup    100ml bot x 200 ml bot 20 / 37\n\tMedicon\tMedivit TAB dr   45's pack / 100'pack 19.80 /44\n\tMedicon\tVitacon Syrup    100ml bot x 200 ml bot 23 / 42\n\tMedimet\tAllbeevit CAP   100'pack 57\n\tMedimet\tAllbeevit TAB dr   100'pack/200's pack 44/ 88\n\tMedimet\tAllbeevit Syrup    100ml bot/200ml bot 20.90 / 38\n\tMillat\tMicoplex Syrup    100ml bot x 200 ml bot 20.92 / 38\n\tMillat\tMicoplex B TAB dr   45's pack 22.50\n\tModern\tM-Plex TAB dr   45's pack / 100'pack 23.40 / 45\n\tModern\tM-Plex Syrup    100ml bot x 200 ml bot 20.84 / 38.04\n\tMonicopharma\tMonoplex TAB dr   45's pack 20.25\n\tMystic\tComvit B Syrup    100ml bot x 200 ml bot 20.70 / 38.03\n\tNavana\tPlacent B TAB dr   45's pack 20.25\n\tNavana\tPlacent B Syrup    100ml bot x 200 ml bot 20.67 / 38.14\n\tNipa\tNipaplex CAP    100'pack 58\n\tNipa\tNipaplex Syrup    100ml bot x 200 ml bot 20 / 37\n\tNIPRO JMI Pharma\tV4 Syrup   100ml bot 20.84\n\tNovo Healthcare and Pharma Ltd.\tEnplex B TAB dr   45's pack 20.25\n\tOpsonin Pharma\tOpsovit TAB dr   45's pack / 100'pack 19.80 / 88\n\tOpsonin Pharma\tOpsovit Syrup    100ml bot x 200 ml bot 23 / 42.50\n\tOrion Pharma Ltd.\tOrioplex TAB dr   45's pack 19.80\n\tOrion Pharma Ltd.\tOrioplex M Syrup    100ml bot x 200 ml bot 20.91 / 38.17\n\tPacific\tAduvit CAP   200's pack 104\n\tPacific\tAduvit Syrup   100ml bot/200ml bot 20/ 37\n\tPeoples Pharma Ltd.\tPeoplex Syrup    100ml bot x 200 ml bot 17 / 30\n\tPharmadesh Ltd.\tVitaplex TAB dr   45's pack 22.94\n\tPharmadesh Ltd.\tVitaplex Syrup    100ml bot x 200 ml bot 20.90 / 38\n\tPharmasia Ltd.\tSimvit -B TAB dr   45's pack 19.80\n\tPharmasia Ltd.\tSimvit-B Syrup    100ml bot x 200 ml bot 20.88 / 38.14\n\tPopular\tVizinc Syrup   100ml bot 45.17\n\tPrime\tP-Plex Syrup   \n\tPrime\tP-Plex TAB dr   \n\tRAK\tRakplex Syrup   100mn bot/ 200ml bot 20/ 38\n\tRangs\tRanvit B TAB dr   45's pack 20.25\n\tRangs\tRanvit B Syrup    100ml bot x 200 ml bot 20 / 38\n\tReliance\tEv Plex-B Syrup   200ml bot 43\n\tReliance\tEV-Plex-B TAB dr  B1 5mg + B2 2mg + B8 2mg 45's pack 19\n\tReman Drug Ltd.\tRemaplex CAP   100'pack 50\n\tReman Drug Ltd.\tRemaplex Syrup    100ml bot x 200 ml bot 20.92 / 37.17\n\tRenata\tBeconex CAP   30's pack 17.10\n\tRenata\tBeconex Syrup   100ml bot/200ml bot 20.85 / 38.03\n\tRephco\tReoplex FORTE TAB dr   40's pot / 250's pack 20.80 / 125\n\tRephco\tReoplex FORTE Syrup    100ml bot x 200 ml bot 20 / 38.04\n\tSalton\tExtravit B TAB dr   45's pack 19.80\n\tSalton\tSG-Plus Syrup    100ml bot x 200 ml bot 20.64 / 37.74\n\tSeema\tSeemaplex Syrup    100ml bot x 200 ml bot 23/43\n\tShamsul Al-Amin\tVitsa CAP   100'pack 49\n\tSilco Pharmaceuticlas Ltd.\tViton Syrup (20 mg + 2 mg + 2 mg + 5   \n\tSilco Pharmaceuticlas Ltd.\tViton B TAB dr 20 mg + 2 mg + 2 mg + 5 m  \n\tSilva\tVitasil B TAB dr   45's pack 19.87\n\tSilva\tVitasil B Syrup    100ml bot x 200 ml bot 20.07/ 38.14\n\tSomatec\tB Plus TAB dr   45's pack 19.80\n\tSomatec\tB Plus Syrup    100ml bot x 200 ml bot 20.58 / 37.64\n\tSquare\tB 50 FORTE CAP   250's pack 250\n\tSquare\tB 50 FORTE TAB dr   45's pack 22.95\n\tSquare\tB 50 FORTE Syrup   100ml bot / 200ml bot 22.59 /42.77\n\tSupreme\tVitalex Syrup    100ml bot x 200 ml bot 20/ 36\n\tSyntho Ltd.\tPlexivit Syrup    100ml bot x 200 ml bot 20.80/ 38\n\tSyntho Ltd.\tPlexvit CAP   30's pack 17.10\n\tZenith\tRestovit Syrup    100ml bot x 200 ml bot 20.85 / 37.60\n\tZenith\tRestovit B TAB dr   45's pack 19.80\n\tZiska\tZiskavit CAP   200's pack 137\n\tZiska\tZiskavit TAB dr   100'pack 50\n\tZiska\tZiskavit Syrup  200 ml 38\n\tIndication: Vitamin B deficiency. Glossitis, stomatitis, cheilosis, beriberi polyneuritis.\n\nDose: Tablet/Capsule : 1-2, 3 times daily or as directed by the physician. Syrup : 2-3 teaspoonful daily. Injection : 2 ml daily IV or IM. \n\nContra-indication: Contraindicated in patients hypersensitive to any of its components.\n\nSide effects: Generally well tolerated.\n\nPrecaution: Should be given cautiously to patients taking Levodopa as Pyridoxine reduces the effect of Levodopa.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Nicotine	\n\n\tIndication: Smoking cessation\n\nDose: Adult: Buccal Chewing gum: Smokers of >20 cigarettes/day: Initial: Chew 4 mg gum when the urge to smoke occurs; reduce to 2 mg gum when possible. Smokers of >20 cigarettes/day: Start w/ 2 mg gum. \n\nMax: >15 pieces of either strengths/day. Loz: Initial: 1 loz 1-2 hrly. Max: 30 mg/day. Sublingual tabs: Per tab contains 2 mg of nicotine as ?-cyclodextrin complex): 1-2 tab/hr. Max: 40 tab/day. Reduce dose gradually until no longer needed. Smoking reduction As 2 or 4 mg gum: Chew 1 piece when urge occurs between smoking episodes; reduce smoking w/in 6 wk and attempt smoking cessation w/in 6 mth. \n\nTransdermal 1 patch for 16 or 24 hr daily. Start w/ the highest strength and reduce gradually over several wk to lower strengths. Lighter smokers may start w/ lower strength patches. \n\nNasal As 500 mcg spray: 1 spray into each nostril when needed. Max: Twice/hr and 64 sprays/day. Reduce usage gradually until no longer needed. Inhalation As inhaler w/ 10 mg catridge: Inhale when urge occurs. Initial: 6-12 cartridges/day, reduce gradually till no longer needed. \n\nAs inhaler w/ 10 mg cartridge: Inhale when urge to smoke occurs between smoking episodes; reduce smoking w/in 6 wk and attempt smoking cessation w/in 6 mth.\n\nContra-indication: Nonsmokers, children and occasional smokers. Recent cerebrovascular accident, acute MI, unstable or worsening angina pectoris, severe cardiac arrhythmias, active temporomandibular joint disease (gum).\n\nSide effects: Headache, cold and flu-like symptoms; insomnia; nausea; myalgia and dizziness; palpitations; dyspepsia, hiccups; vivid dreams; chest pain; anxiety and irritability; somnolence and impaired concentration; abnormal hunger; dysmenorrhoea; rash. Patches: Skin reactions (discontinue if severe), vasculitis. Spray: Nasal irritation, nose bleeds, watery eyes, ear sensations. Gum, lozenges, SL tab or inhalator: Apthous ulceration, throat irritation. Inhalator: Cough, rhinitis, pharyngitis, stomatitis, sinusitis, dry mouth.\n\nPrecaution: Use with caution in oropharyngeal inflammation and in patients with cerebrovascular disease, heart failure and renal impairment. History of oesophagitis, peptic ulcer, CV disease, hyperthyroidism, hepatic dysfunction; myasthenia gravis; DM (monitor blood glucose concentrations); pregnancy, lactation; peripheral vascular disease; skin disease (should not be applied on broken skin).\n\nMode of action: Nicotine increases the haemodynamic and AV blocking effects of adenosine. Monitor for treatment-emergent hypertension in patients treated with combination of nicotine patch and bupropion. Smoking cessation may increase response to various drugs e.g. theophylline, imipramine, oxazepam, pentazocine, some beta-blockers; monitor for increased toxicity.\n\nPregnancy category: D\n\nInteraction: Nicotine increases the haemodynamic and AV blocking effects of adenosine. Monitor for treatment-emergent hypertension in patients treated with combination of nicotine patch and bupropion. Smoking cessation may increase response to various drugs e.g. theophylline, imipramine, oxazepam, pentazocine, some beta-blockers; monitor for increased toxicity.
Nifedipine	\n\n\tAcme Ltd.\tNifin TAB dr 10mg 100's pack 34\n\tAlbion Ltd.\tNifedipine TAB dr 10 mg 100's pack \n\tDrug International Ltd.\tNifecap CAP 10mg 30's pack 63\n\tSquare\tNidipine TAB dr 10mg 200's pack 66.50\n\tSquare\tNidipine SR TAB dr 20mg 100's pack 63.84\n\tIndication: Hypertension, Angina pectoris, Raynaud's syndrome, Stroke prevention\n\nDose: Adult: PO HTN Extended release 10-40 mg twice daily or 20-90 mg once daily. Angina pectoris Extended release 10-40 mg twice daily or 30-90 mg once daily. Liquid-filled cap: 5-20 mg 3 times/day. Raynaud's syndrome Liquid-filled cap: 5-20 mg 3 times/day.\n\nContra-indication: Acute MI, cardiogenic shock, acute unstable angina, treatment of anginal attack in chronic stable angina.\n\nSide effects: Peripheral oedema, hypotension, palpitations, tachycardia, flushing, dizziness, headache, nausea, increased micturition frequency, lethargy, eye pain, mental depression, visual disturbances, gingival hyperplasia, myalgia, tremor, impotence, fever, paradoxical increase in ischaemic chest pain during initiation of treatment, rashes, abnormalities in liver function (including cholestasis), GI obstruction in some tablets covered in indigestable membrane.\n\nPrecaution: Hypotension, poor cardiac reserve, heart failure (deterioration has been noted), severe aortic stenosis, hepatic impairment, DM, porphyric patients, pregnancy. Avoid abrupt withdrawal (associated with exacerbation of angina). Discontinue if with ischaemic pain following administration.\n\nMode of action: Enhanced antihypertensive effects w/ other antihypertensives, aldesleukin, and antipsychotics. Concomitant use w/ fentanyl during surgery caused severe hypotension. May modify insulin and glucose responses. Attenuation of tachycardic effect when used w/ benazerpril. Prothrombin time may be increased w/ coumarin anticoagulants. Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, cimetidine, erythromycin, HIV-protease inhibitors, nefazodone, fluoxetine, quinupristin/dalfopristin).\nPotentially Fatal: Decreased bioavailability and efficacy w/ strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine).\n\nPregnancy category: C\n\nInteraction: Enhanced antihypertensive effects w/ other antihypertensives, aldesleukin, and antipsychotics. Concomitant use w/ fentanyl during surgery caused severe hypotension. May modify insulin and glucose responses. Attenuation of tachycardic effect when used w/ benazerpril. Prothrombin time may be increased w/ coumarin anticoagulants. Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, cimetidine, erythromycin, HIV-protease inhibitors, nefazodone, fluoxetine, quinupristin/dalfopristin).\nPotentially Fatal: Decreased bioavailability and efficacy w/ strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine).
Nikethamide	\n\n\tJayson\tNikethamide Injection 500mg/2ml 10 amps pack 50.70\n\tIndication: Energy malnutrition, Central respiratory depression, Tranquilizer overdoses\n\nDose:  Adult Dosage;\n\n1.500 g as Single Dose.\n\nContra-indication:  Nikethamide is contraindicated in conditions like Porphyria, Hypersensitivity to any component of product.\n\n\nSide effects: The symptomatic adverse reactions produced by Nikethamide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Itching, Breathlessness, Paresthesias, Heat sensation.\n\nPrecaution: \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Nimodipine	\n\n\tEskayef Bangladesh Ltd.\tNimodi TAB dr 30mg 30's pack 150\n\tSquare\tNimocal TAB dr 30mg 30's pack 150.43\n\tUnimed & Unihealth Manufacturers Ltd.\tNims TAB dr 100mg 100's pack 100\n\tIndication: Subarachnoid haemorrhage, Stroke prevention\n\nDose: Adult: PO Prophylaxis of neurological deficit following subarachnoid haemorrhage 60 mg 4 hrly for 21 days beginning w/in 4 days of onset of haemorrhage. \n\nIV Ischaemic neurological deficits following subarachnoid haemorrhage Initial: 1 mg/hr for 2 hr, up to 2 mg/hr if no severe decrease in BP is observed. Start treatment at once and continue for 5-14 days. Total duration should not exceed 21 days if patient has received oral treatment.\n\nContra-indication: \n\nSide effects: Peripheral oedema, hypotension, palpitations, tachycardia, flushing, dizziness, headache, nausea, increased micturition frequency, lethargy, eye pain, mental depression, visual disturbances, gingival hyperplasia, myalgia, tremor, impotence, fever, paradoxical increase in ischaemic chest pain during initiation of treatment, rashes, abnormalities in liver function (including cholestasis), GI obstruction in some tablets covered in indigestable membrane.\nPotentially Fatal: Angina/MI, symptomatic hypotension.\n\nPrecaution: Cerebral oedema, severely raised intracranial pressure, idiopathic hypertrophic subaortic stenosis (IHSS), elderly, severe liver disease. Inadvertent IV admin of the contents of capsules has resulted in CV collapse, hypotension, bradycardia and death. Tablets should not be administered concomitantly with IV solution.\n\nMode of action: Plasma concentration and efficacy may be significantly reduced when administered w/ strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin). May increase serum levels and toxicity of phenytoin. Increased plasma concentrations w/ cimetidine or sodium valproate.\nPotentially Fatal: Increased risk of significant hypotension w/ concomitant potent CYP3A4 inhibitors (e.g. clarithromycin, ritonavir, ketoconazole, nefazodone).\n\nPregnancy category: C\n\nInteraction: Plasma concentration and efficacy may be significantly reduced when administered w/ strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin). May increase serum levels and toxicity of phenytoin. Increased plasma concentrations w/ cimetidine or sodium valproate.\nPotentially Fatal: Increased risk of significant hypotension w/ concomitant potent CYP3A4 inhibitors (e.g. clarithromycin, ritonavir, ketoconazole, nefazodone).
Nitazoxanide	\n\n\tACI\tDiar Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35.24/50.34\n\tACI\tDiar TAB dr 500mg 10's pack 100.70\n\tAcme Ltd.\tNidozox Suspension 100mg/ml 1's pack 50\n\tAcme Specialized\tNidozox Powder for Suspension 100mg/5ml 30ml bot 35.14\n\tAcme Specialized\tNidozox TAB dr 500mg 18's pack 180.72\n\tAd-din\tProxa-A Powder for Suspension 100mg/5ml 20's pack 180\n\tAd-din\tProxa-A TAB dr 500mg 20's pack 180\n\tAlbion Ltd.\tAlbizox Powder For Suspension 100 mg/5 ml 60 ml \n\tAlco Pharma\tAdnix Powder for Suspension 100mg/5ml 30ml bot 35\n\tAlco Pharma\tAdnix TAB dr 500mg 12's pack 120\n\tAmulet\tNitalet TAB dr 500mg 12's pack 120\n\tApex\tNiazid Powder for Suspension 100mg/5ml 30ml bot 35\n\tApex\tNiazid TAB dr 500mg 28's pack 280\n\tAristopharma\tNitoxin Powder for Suspension 100mg/5ml 30ml bot/60ml bot 36/50\n\tAristopharma\tNitoxin TAB dr 500mg 30's pack 300\n\tAsiatic Ltd.\tNTZ PFS Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tBeximco\tNitaxide Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tBeximco\tNitaxide TAB dr 500mg 20's pack 200\n\tBio Pharma Ltd.\tAtinid Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35.16/50.19\n\tBio Pharma Ltd.\tAtinid TAB dr 500mg 20's pack 200.80\n\tDelta Pharma\tNitax Powder for Suspension 100mg/5ml 30ml bot 30\n\tDelta Pharma\tNitax TAB dr 500mg 10's pack 80\n\tDrug International Ltd.\tNitanid Powder for Suspension 100mg/5ml 60ml bot 50\n\tDrug International Ltd.\tNitanid TAB dr 500mg 20's pack 200\n\tEskayef Bangladesh Ltd.\tToza Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tEskayef Bangladesh Ltd.\tToza TAB dr 500mg 12's pack 120\n\tEthical Drug Ltd.\tNIZ TAB dr 500mg  \n\tEthical Drug Ltd.\tNIZ Powder For Suspension 100 mg/5 ml  \n\tGeneral\tDianide Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tGeneral\tDianide TAB dr 500mg 6's pack 60.24\n\tGlobe\tXanide Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tGlobe\tXanide TAB dr 500mg 12's pack 120\n\tHealthcare\tAlinix Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35.14/50.19\n\tHealthcare\tAlinix TAB dr 500mg 30's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNitasol Powder for Suspension 100mg/5ml 30ml bot/60ml bot 36/50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNitasol TAB dr 500mg 12's pack 132\n\tIncepta\tNitazox Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tIncepta\tNitazox TAB dr 500mg 30's pack 300\n\tKumudini Pharma Ltd.\tDiazox Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tKumudini Pharma Ltd.\tDiazox TAB dr 500mg 24's pack 240\n\tLeon\tNitaxen TAB dr 500mg  \n\tLeon\tNitaxen PFS Powder For Suspension 100 mg/5 ml  \n\tMedicon\tNizonid Powder for Suspension 100mg/5ml 30ml bot 35\n\tMedicon\tNizonid TAB dr 500mg 12's pack 120\n\tMonicopharma\tNicud Suspension 100mg/5ml 30ml bot 35\n\tNIPRO JMI Pharma\tNitide Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tNIPRO JMI Pharma\tNitide TAB dr 500mg 30's pack 300\n\tNovo Healthcare and Pharma Ltd.\tTazox Powder for Suspension 100mg/5ml 30ml bot 35\n\tNovo Healthcare and Pharma Ltd.\tTazox TAB dr 500mg 12's pack 120\n\tOpsonin Pharma\tZoxan Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35/50\n\tOpsonin Pharma\tZoxan TAB dr 500mg 18's pack 180\n\tOrganic Health Care\tNitazet TAB dr 500mg 30's pack 300\n\tOrion Pharma Ltd.\tZoana Powder for Suspension 100mg/5ml 32ml bot/62ml bot 35.13/50.19\n\tOrion Pharma Ltd.\tZoana TAB dr 500mg 12's pack 120.48\n\tPharmasia Ltd.\tNidor Powder for Suspension 100mg/5ml 30ml bot/60ml bot 30/50\n\tPharmasia Ltd.\tNidor TAB dr 500mg 18's pack 180.72\n\tPopular\tTazonid Powder for Suspension 100mg/5ml 30ml bot 32.12\n\tPopular\tTazonid TAB dr 500mg 30's pack 301.20\n\tRAK\tAntizoa Suspension 100mg/5ml 30ml bot 35\n\tRAK\tAntizoa TAB dr 500mg 30's pack 300\n\tRenata\tXanita TAB dr 500mg 18's pack 180.72\n\tRenata\tXanita Suspension 100mg/5ml 30ml bot/60ml bot 35.18/50\n\tRephco\tNixonid TAB dr  2x10's pack 200\n\tSharif\tNixar Powder for Suspension 100mg/5ml 30ml bot 35\n\tSharif\tNixar TAB dr 500mg 20's pack 200\n\tSilva\tZoxanid Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35.14/50.19\n\tSilva\tZoxanid TAB dr 500mg 12's pack/30's pack 120.46/301.13\n\tSomatec\tNizox Powder for Suspension 100mg/5ml 30ml bot/60ml bot 30.11/50.19\n\tSomatec\tNizox TAB dr 500mg 12's pack 120.36\n\tSquare\tZox Powder for Suspension 100mg/5ml 30ml bot/60ml bot 35.14/50.20\n\tSquare\tZox TAB dr 500mg 30's pack 301.24\n\tIndication: Giardiasis, Cryptosporidiosis\n\nDose: Age 1 - 3 years : 5 ml (100 mg) twice daily for 3 days, Age 4 - 11 years : 10 ml (200 mg) twice daily for 3 days, Age >12 years : 25 ml or 1 tablet (500 mg) twice daily for 3 days. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Headache, abdominal pain, diarrhoea, nausea, vomiting, allergic reactions, anaemia, anorexia, increased appetite, increased creatinine and LFT, diaphoresis, dizziness, eye and urine discolouration, fever, flatulence, hypertension, infection, malaise, nausea, pruritus, rhinitis, enlarged salivary glands, tachycardia.\n\nPrecaution: Renal and hepatic impairment. Pregnancy and lactation. Children <1 yr.\n\nMode of action: May possibly interact with highly protein-bound drugs e.g. warfarin.\n\nPregnancy category: B\n\nInteraction: May possibly interact with highly protein-bound drugs e.g. warfarin.
Nitrazepam	\n\n\tAlbion Ltd.\tNectum TAB dr 5 mg 100's pack \n\tAmbee\tNoctin TAB dr 5mg 100's pack 69\n\tOpsonin Pharma\tEpam TAB dr 5mg 200's pack 150\n\tIndication: Insomnia\n\nDose: Adult: PO 5 mg at bedtime; increase to 10 mg if needed.\n\nContra-indication: Myasthenia gravis, narrow-angle glaucoma, severe respiratory insufficiency, sleep apnoea syndrome, severe hepatic impairment, porphyria.\n\nSide effects: Hypotension, palpitation; agitation, aggressiveness, amnesia, ataxia, confusion, delusions, disorientation, dizziness, fatigue, hallucination, hangover, headache, irritability, nightmares, psychoses, rage, restlessness, sedation; rash; changes in libido; constipation, diarrhoea, excessive salivation, heartburn, nausea, vomiting; granulocytopenia, leukopenia; falling, muscle weakness; blurred or double vision; tinnitus (associated with withdrawal); aspiration, increased bronchial secretion, dyspnoea.\n\nPrecaution: May induce anterograde amnesia; caution patients to have uninterrupted sleep of 7-8 hr after ingestion of dose. May impair ability to drive or operate machinery. Depression, especially if suicidal risk may be present. History of drug abuse or acute alcoholism. Hepatic and renal impairment. Respiratory disease. Debilitated patients. Patients who are at risk of falls. Children, elderly. Pregnancy and lactation.\n\nMode of action: CNS depressant effect increased with alcohol, barbiturates, TCAs, phenothiazines, morphine derivatives. Effects may be antagonised by theophylline. Increased levels/effects with probenecid. Reduced levels/effects with rifampicin. May reduce effects of levodopa.\n\nPregnancy category: Not Classified\n\nInteraction: CNS depressant effect increased with alcohol, barbiturates, TCAs, phenothiazines, morphine derivatives. Effects may be antagonised by theophylline. Increased levels/effects with probenecid. Reduced levels/effects with rifampicin. May reduce effects of levodopa.
Nitrofurantoin	\n\n\tIncepta\tNintoin TAB dr 100mg 30's pack 180\n\tIncepta\tNintoin SR CAP 100mg 20's pack 400\n\tIncepta\tNintoin Suspension 25 mg/5 ml 1's pack 80\n\tOpsonin Pharma\tUrobak TAB dr 100mg  30's pack \n\tOpsonin Pharma\tUrobak Oral Suspension  25mg/5ml 100ml bot \n\tPacific\tOfuran SR TAB dr 100mg 30's pack 600\n\tSquare\tUrocure 100 SR CAP 100mg 20's pack 400\n\tSquare\tUrocure Suspension 100ml 100ml bot \n\tUnimed & Unihealth Manufacturers Ltd.\tUmactin CAP 100mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tUmactin CAP 50mg 30's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tUmactin Suspension 500 mg/100 ml  \n\tIndication: Uncomplicated UTI\n\nDose: Oral\nAcute uncomplicated urinary tract infections\nAdult: 50-100 mg 4 times daily for 7 days. Dual-release preparation: 100 mg bid.\nChild: >3 mth and older children: 3 mg/kg daily in 4 divided doses.\n\nProphylaxis of uncomplicated urinary tract infections\nAdult: 50-100 mg at bedtime.\nChild: >3 mth and older children: 1 mg/kg once daily.\n\nContra-indication: Severe renal impairment (anuria, oliguria, significantly elevated serum creatinine, CrCl <60 ml/min). Hypersensitivity to nitrofurans, G6PD deficiency, infants <3 mth. Pregnancy at term, during labour and delivery, or when the onset of labour is imminent.\n\nSide effects: Nausea, vomiting, anorexia, abdominal pain, diarrhoea; headache, drowsiness, vertigo, dizziness, nystagmus, benign intracranial hypertension; rash, urticaria, pruritus, fever, sialadenitis, angioedema, erythema multiforme, exfoliative dermatitis, pancreatitis, lupus-like syndrome, myalgia, arthralgia; acute pulmonary sensitivity reactions; megaloblastic anaemia, leucopenia, granulocytopenia or agranulocytosis, thrombocytopenia, aplastic anaemia, haemolytic anaemia (in G6PD-deficient patients); transient alopecia; brownish discolouration of urine.\nPotentially Fatal: Peripheral polyneuropathy, hepatotoxicity, anaphylaxis, Stevens-Johnson syndrome, interstitial pneumonitis, pulmonary fibrosis.\n\nPrecaution: Elderly. Monitor hepatic and pulmonary function during prolonged therapy. Pre-existing pulmonary, hepatic, neurological, or allergic disorders, predisposition to peripheral neuropathy e.g. renal impairment, anaemia, DM, electrolyte imbalance, debility, vitamin B deficiency. Withdraw if signs of peripheral neuropathy occur. Lactation.\n\nMode of action: Reduced excretion with probenecid or sulfinpyrazone. Absorption reduced by magnesium trisilicate. Antagonistic effects with quinolone antibacterials. Reduced effects with carbonic anhydrase inhibitors or urinary alkalinisers.\n\nPregnancy category: B\n\nInteraction: Reduced excretion with probenecid or sulfinpyrazone. Absorption reduced by magnesium trisilicate. Antagonistic effects with quinolone antibacterials. Reduced effects with carbonic anhydrase inhibitors or urinary alkalinisers.
Nitrofurazone 0.2% Topical	\n\n\tBeximco\tFurasep Cream   20gm  tube 17\n\tSupreme\tNifura Cream   20gm  tube 17\n\tIndication: Burns, Wounds, Skin infections, Skin grafting, Ulcers\n\nDose: Adult: Apply as 0.2% topical preparation in a water-soluble or water-miscible basis to the affected area.\n\nContra-indication: Hypersensitivity. Cross-sensitation may occur with other nitrofuran derivatives.\n\nSide effects: Oral: Severe peripheral neuropathy. Topical: Sensitisation, generalised allergic skin reactions.\n\nPrecaution: G6PD deficiency (oral). Renal impairment.\n\nMode of action: Reduced excretion with probenecid or sulfinpyrazone. Absorption reduced by magnesium trisilicate. Antagonistic effects with quinolone antibacterials. Reduced effects with carbonic anhydrase inhibitors or urinary alkalinisers.\n\nPregnancy category: B\n\nInteraction: Reduced excretion with probenecid or sulfinpyrazone. Absorption reduced by magnesium trisilicate. Antagonistic effects with quinolone antibacterials. Reduced effects with carbonic anhydrase inhibitors or urinary alkalinisers.
Nitrous Oxide 50 % + Oxygen 50 % Gas	\n\n\tIndication: Sedation, Short-term pain relief, Acute trauma, Tooth extraction, Wound and burn dressing, Wound debribement and suturing, Fracture and joint manipulation, Colonoscopy, Labour\n\nDose: This is used for more than a total of 24 hours, or more frequently than every 4 days, it must be used with close clinical supervision with haematological monitoring. \n\nContra-indication:     Pneumothorax, \n\n    abdominal distension,\n\n    suspected intestinal obstruction,\n\n    bullous emphysema,\n\n    middle ear procedures,\n\n    following a recent dive,\n\nIt should also be avoided where the patient is unable to effectively make use of the gas delivery equipment such as maxillo-facial injuries, impaired consciousness, sedation or intoxication. \n\nSide effects: Minimal side-effects\n\nPrecaution: It may cause vitamin B12 deficiency in susceptible patients (usually related to prolonged use of the gas or where an existing deficiency is present).  Prolonged inhalation can also result in dryness of the mouth and discomfort.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Nitrous Oxide 98 % Gas	\n\n\tIndication: Anaesthesia, Pain relief\n\nDose: The gas must be used with close clinical supervision with haematological monitoring as required.\n\nContra-indication: Pneumothorax, abdominal distension, suspected intestinal obstruction, bullous emphysema. It should also be avoided where the patient is unable to effectively make use of the gas delivery equipment such as maxillo-facial injuries, impaired consciousness, sedation or intoxication. \n\nSide effects: Generally well tolerated.\n\nPrecaution: Prolonged inhalation can also result in dryness of the mouth and discomfort.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Nizatidine	\n\n\tIndication: Benign gastric and duodenal ulceration, Gastro-oesophageal reflux disease\n\nDose: Adult: PO Benign gastric and duodenal ulceration 300 mg at bedtime for 4 wk, up to 8 wk if needed. Maintenance: 150 mg at bedtime. Dyspepsia 75 mg/day. Max: 150 mg/day for 2 wk. GERD 150-300 mg twice daily for 12 wk. \n\nIV Benign gastric and duodenal ulceration 10 mg/hr as continuous infusion. Max total: 480 mg/day. To be used on a short-term basis only.\n\nRenal impairment:\nCrCl (ml/min)	\n<20 	150 mg every other day. Maintenance: 150 mg every 3 days.\n20-50	150 mg/day. Maintenance: 150 mg every other day.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Headache, anxiety, dizziness, insomnia, somnolence, nervousness, pruritus, rash, abdominal pain, anorexia, constipation, diarrhoea, dry mouth, flatulence, heartburn, nausea, vomiting, increased liver enzymes, anaemia, bronchospasm, confusion, eosinophilia, gynaecomastia, hepatitis, jaundice, laryngeal oedema, serum-sickness like reactions, thrombocytopenia, vasculitis, ventricular tachycardia. Reported in children: Fever, irritability, cough, nasal congestion, nasopharyngitis.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Exclude the presence of gastric malignancy. Renal and hepatic impairment. Pregnancy and lactation. Child <12 yr.\n\nMode of action: May increase absorption of aspirin when used in high-doses. May decrease bioavailability w/ antacids.\n\nPregnancy category: B\n\nInteraction: May increase absorption of aspirin when used in high-doses. May decrease bioavailability w/ antacids.
Norethisterone	\n\n\tACI\tMenogia TAB dr 5mg 60's pack 300\n\tBeximco\tNorestin TAB dr 5 mg  300\n\tBeximco\tNorestin TAB dr 5mg 60's pack 300\n\tEskayef Bangladesh Ltd.\tEthinor TAB dr 5mg 45's pack 225\n\tIncepta\tNoteron TAB dr 5mg 60's pack 300\n\tNuvista Pharma Ltd\tRontril TAB dr 5mg  \n\tPopular\tRemens TAB dr 5mg 5mg x 60's pack 300\n\tRenata\tNormens TAB dr 5mg 60's pack 301.20\n\tSquare\tMenoral TAB dr 5mg 30's pack 150\n\tCity overseas\tNorcolut TAB dr 5mg 5mg x 20's pack 145\n\tIndication: Breast cancer, Metropathia haemorrhagica (dysfunctional uterine bleeding), Premenstrual syndrome, Contraception, Endometriosis, Menorrhagia, Menopausal HRT\n\nDose: Adult: PO Metropathia haemorrhagica (dysfunctional uterine bleeding): 1 tablet 3 times daily for 10 days. Menstruation occurs within 2-4 days after discontinuing treatment. \n\nProphylaxis against recurrence of dysfunctional bleeding: If there are no signs of resumption of normal ovarian function recurrence must be anticipated. Cyclical bleeding can be established with 1 tablet twice daily from the 19th to the 26th day of the cycle.\n\nPremenstrual syndrome (including premenstrual mastalgia): 2-3 tablets daily from the 19th to the 26th day of the cycle. Treatment should be repeated for several cycles. \n\nPostponement of menstruation: 1 tablet three times daily, starting 3 days before the expected onset of menstruation. A normal period should occur 2-3 days after the patient has stopped taking tablets. \n\nEndometriosis (pseudo-pregnancy therapy): Long-term treatment is commenced on the 5th day of the cycle with 2 tablets daily for the first few weeks. In the event of spotting, the dosage is increased to 4, and, if necessary, 5 tablets daily. After bleeding has ceased, the initial dose is usually sufficient. \n\nMenorrhagia (hypermenorrhoea): 1 tablet 2-3 times a day from the 19th to the 26th day of the cycle (counting the first day of menstruation as day 1).\n\nContra-indication: Severe hepatic dysfunction; undiagnosed vaginal bleeding; porphyria; pregnancy; previous idiopathic or current thromboembolism; thromboembolic disease; DVT.\n\nSide effects: Mental depression, cholestatic jaundice, porphyria, epilepsy, migraine, headache, breast discomfort, dizziness, nausea and vomiting, changes in libido, appetite and weight, breakthrough bleeding, changes in menstrual flow, amenorrhoea, oedema, rash, melasma or cholasma, acne, urticaria, abnormal LFTs, moodswings, insomnia, thrombotic and thromoembolic events, optic neuritis, altered lipid profile.\n\nPrecaution: Hypertension; CVS disease; hepatic impairment; epilepsy; lactation; new onset of migraine-type headache; asthma; renal impairment; history of clinical depression.\n\nMode of action: Concentration may be reduced by CYP450 inducers (e.g. phenobarbital, phenytoin, carbamazepine, rifampicin, rifabutin, nevirapine, efavirenz, tetracyclines, ampicillin, oxacillin, co-trimoxazole) and ritonavir, nelfinavir (usually inhibitors of CYP450 but have inducing properties when used with steroid hormones). May cause additive fluid retention with NSAIDs, vasodilators. Adjustment in antidiabetic, thyroid hormone and anticoagulant therapy may be required.\nPotentially Fatal: May increase ciclosporin concentration.\n\nPregnancy category: X\n\nInteraction: Concentration may be reduced by CYP450 inducers (e.g. phenobarbital, phenytoin, carbamazepine, rifampicin, rifabutin, nevirapine, efavirenz, tetracyclines, ampicillin, oxacillin, co-trimoxazole) and ritonavir, nelfinavir (usually inhibitors of CYP450 but have inducing properties when used with steroid hormones). May cause additive fluid retention with NSAIDs, vasodilators. Adjustment in antidiabetic, thyroid hormone and anticoagulant therapy may be required.\nPotentially Fatal: May increase ciclosporin concentration.
Norgestrel	\n\n\tRenata\tRenatrel TAB dr 0.075mg 28's pack 25\n\tSocial Marketing Company\tMinicon TAB dr 0.075mg 28's pack 30\n\tIndication: Contraception, Menorrhagia, Menopausal HRT\n\nDose: Adult: PO Contraception Monotherapy: 30 or 37.5 mcg/day. Monophasic combined oral contraceptive (COC): 150-250 mcg/day. Triphasic COC: 50-125 mcg/day. \n\nEmergency contraception 1.5 mg w/in 72 hr of coitus or 750 mcg immediately or w/in 72 hr of coitus, then a 2nd dose 12 hr later. Menopausal HRT As progestogenic component: 75-250 mcg/day for 10-12 days of 28-day cycle.\n\nContra-indication: Pregnancy, undiagnosed vaginal bleeding, severe arterial disease; liver adenoma, porphyria; after recent evacuation of hydatidiform mole; history of breast cancer; hepatic impairment.\n\nSide effects: Menstrual irregularities; nausea, vomiting, headache, dizziness, breast discomfort, gynaecomastia, depression, skin disorders, disturbance of appetite, wt changes, fluid retention, oedema, changes in libido, cholestatic jaundice, hair loss or hirsutism. Benign intracranial hypertension, thrombocytopenic purpura.\nPotentially Fatal: Thrombocytopenia, stroke.\n\nPrecaution: Sex-steroid dependent cancer, past ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy, CV or renal impairment, DM, asthma, epilepsy, migraine, conditions aggravated by fluid retention, depression and thromboembolism (high doses); lactation.\n\nMode of action: None\n\nPregnancy category: X\n\nInteraction: 
Nortriptyline	\n\n\tIncepta\tNortilin TAB dr 10mg 100's pack \n\tIncepta\tNortilin TAB dr 25mg 100's pack \n\tNavana\tNortin CAP 10mg 100's pack 63\n\tNavana\tNortin CAP 25mg 100's pack 85\n\tIndication: Depression, Nocturnal enuresis\n\nDose: Oral\nDepression\nAdult: 75-100 mg/day in 3 or 4 divided doses. Max: 150 mg/day in severe depression.\nChild: Adolescent: 30-50 mg/day in divided doses.\nElderly: 30-50 mg/day in divided doses.\n\nNocturnal enuresis\nChild: 6-7 yr (20-25 kg): 10 mg; 8-11 yr (25-35kg): 10-20 mg; >11 yr (35-54 kg): 25-35 mg. All doses are given 30 minutes before bedtime and treatment should continue for not >3 mth.\n\nContra-indication: Mania, recent MI, arrhythmias (particularly heart block); severe liver disease; children <6 yr.\n\nSide effects: Tachycardia, slows conduction and prolongation of PR interval, lowers seizure threshold, peripheral neuropathy, dry mouth, constipation, urinary hesitancy, confusion and blurred vision, nausea, sweating, tremor, rashes, hypersensitivity reactions, hypomania or mania, headache, hyponatraemia, abnormal LFT, endocrine disorders, movement disorders, taste disturbances.\nPotentially Fatal: Rare, blood dyscrasias.\n\nPrecaution: Elderly; hepatic or renal dysfunction; benign prostatic hypertrophy; angle closure glaucoma; phaeochromocytoma; CVS disease; epilepsy; history of bowel obstruction; withdraw gradually; monitor for suicidal tendencies during early treatment; DM; thyroid disease; psychoses (may aggravate psychotic symptoms); urinary retention. Pregnancy, lactation.\n\nMode of action: Increased risk of serotonin syndrome w/ SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone. May reduce antihypertensive effect of bethanidine, guanethidine, debrisoquine, clonidine. May increase metabolism w/ barbiturates. Increased risk of arrhythmias and hypotension w/ anaesth. Increased plasma level w/ fluoxetine.\n\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.\n\nPregnancy category: C\n\nInteraction: Increased risk of serotonin syndrome w/ SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone. May reduce antihypertensive effect of bethanidine, guanethidine, debrisoquine, clonidine. May increase metabolism w/ barbiturates. Increased risk of arrhythmias and hypotension w/ anaesth. Increased plasma level w/ fluoxetine.\n\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
Nystatin	\n\n\tACI\tNyscan Suspension 1 Lac Unit 12ml \n\tAcme Ltd.\tNystat Ointment 1 Lac Unit 10gm  tube 20.23\n\tAcme Ltd.\tNystat Drops 1 Lac Unit 12ml bot 22.50\n\tAcme Ltd.\tNystat TAB dr 5 Lac Unit 50's pack 287.28\n\tAcme Ltd.\tNystat VT TAB dr 1 Lac Unit 15's pack 29.25\n\tAmico Ltd.\tFefun Drops 1 Lac Unit 12ml bot 21\n\tBeximco\tFungistin Drops 1 Lac Unit 12ml bot 22.74\n\tEdruc Ltd.\tNysol Drops 1 Lac Unit 12ml bot 22\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMycocin Drops 1 Lac Unit 12ml bot 21\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMycocin TAB dr 5 Lac Unit 28's pack 141.40\n\tJayson\tCanstat Drops 1 Lac Unit 10ml bot 17.20\n\tJayson\tCanstat TAB dr 5 Lac Unit 100's pack 278\n\tKemiko\tOrnys Drops 1 Lac Unit 12ml bot 20\n\tOpsonin Pharma\tNaf Drops 1 Lac Unit 12ml bot 20\n\tSomatec\tNyst Drops 1 Lac Unit 12ml bot 20.59\n\tSquare\tCandex Suspension 1 Lac Unit 12ml bot 22.73\n\tZenith\tZenistin Drops 1 Lac Unit 12ml bot 20.11\n\tIndication: Fungal infections, Oropharyngeal candidiasis, Vaginal candidiasis, Intestinal candidiasis\n\nDose: Adult & Child: PO Intestinal or oropharyngeal candidiasis 500,000 or 1,000,000 u 3-4 times/day. Oral candidiasis As pastilles or oral susp: 100,000 u 4 times/day. Continue for 48 hr after lesions have healed. Prophylaxis of intestinal candidiasis 1,000,000 u/day in divided doses. \n\nVag Tablet: Vag candidiasis As pessaries/vag cream: 100,000-200,000 u/day for 14 days. \n\nTopical Susceptible fungal infections Per g cream/gel/oint/dusting powd contains 100,000 u/g: Apply 2-4 times/day.\n\n Infants: 2 ml (200, 000 units) four times daily. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Diarrhoea, GI distress, nausea and vomiting. vaginal pessaries/cream: May damage latex contraceptives (e.g. diaphragms, condoms), additional contraceptive measures should be taken. Topical application: Irritation.\n\nPrecaution: Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ofloxacin	\n\n\tDrug International Ltd.\tOflacin TAB dr 200mg 20's pack 240\n\tDrug International Ltd.\tOflacin TAB dr 400mg 20's pack 400\n\tOpsonin Pharma\tFlocet TAB dr 200mg 20's pack 240\n\tOpsonin Pharma\tFlocet TAB dr 400mg 10's pack 220\n\tOpsonin Pharma\tFlocet IV Infusion 200mg/100ml 100ml bot \n\tSquare\tRutix TAB dr 200mg 30's pack 361.49\n\tSquare\tRutix TAB dr 400mg 20's pack 441.60\n\tIndication: Leprosy,chronic bronchitis; Community-acquired pneumonia; Uncomplicated skin infections,anthrax,Legionnaire's disease,Nongonococcal cervicitis; Urethritis, Uncomplicated cystitis, Complicated UTI, Traveller's diarrhea, bacterial prostatis, Typhoid fever, Skin and soft tissue infections, Uncomplicated gonorrhea, Pelvic inflammatory disease, Lower respiratory tract infections, Septicaemia							\n\n\nDose: Adult: PO Part of multidrug therapy in leprosy 400 mg/day or intermittently, depending on regimen. Uncomplicated gonorrhoea Single dose of 400 mg. Acute bacterial exacerbation of chronic bronchitis; \n\nCommunity-acquired pneumonia; Uncomplicated skin infections 400 mg twice daily for 10 days. Pelvic inflammatory disease 400 mg twice daily for 14 days. Postexposure prophylaxis following exposure to inhalational anthrax 400 mg twice daily for 60 days. \n\nLegionnaire's disease 400 mg twice daily for 2-3 wk. Mixed infection of the urethra and cervix due to C. trachomatis and Neisseria gonorrhoeae; Nongonococcal cervicitis; Urethritis due to Chlamydia trachomatis 200-300 mg twice daily for 7 days. \n\nUncomplicated cystitis 200 mg twice daily for 3-7 days. Duration depends on causative agent. Complicated UTI 200 mg twice daily for 10 days. Traveller's diarrhoea 300 mg twice daily for 1-3 days. Chronic bacterial prostatis 300 mg twice daily for 6 wk. Typhoid fever 200-400 mg twice daily for 7-14 days. \n\nIntravenous\nAdult: 200 mg daily by IV infusion over at least 30 min. Max: 400 mg bid infused over at least 1 hr.\n\nRenal impairment: Initial dose as normal then reduce.\nCrCl (ml/min)	\n20-50	Reduce dose by half or give usual dose only every 24 hr.\n<20	         100 mg every 24 hr.\n\nHepatic impairment: Clearance is reduced in severe hepatic impairment, lower doses should be used. Max: 400 mg daily.\n\nContra-indication: Hypersensitivity to quinolones; pregnancy and lactation; prolongation of the QT interval; uncorrected hypokalaemia.\n\nSide effects: Nausea, vomiting, abdominal pain, diarrhoea; headache, dizziness, insomnia, hallucinations; leucopenia and eosinophilia; vaginitis; dysgeusia; tendon damage and rupture; anorexia; tremor; photosensitivity; hypersensitivity reactions. Discontinue if psychiatric, neurological or hypersensitivity reactions occur.\nPotentially Fatal: Anaphylaxis; rarely seizures.\n\nPrecaution: Epilepsy or other predisposition to seizures; known or suspected CNS disorders; renal, hepatic impairment; myasthaenia gravis; superinfection; children <18 yr; exposure to strong sunlight and UV light; ensure adequate hydration; elderly.\n\nMode of action: Concomitant use of class IA (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) antiarrhythmic agents may increase risk of QT interval prolongation. Decreased serum and urine concentrations w/ antacids containing Mg, Al or Ca. Additive antibacterial activity w/ aminoglycosides (e.g. amikacin, tobramycin). Corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation (e.g. seizures) w/ NSAIDs. Higher and prolonged serum theophylline concentrations and increased risk of theophylline-related adverse effects.\n\nPregnancy category: C\n\nInteraction: Concomitant use of class IA (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) antiarrhythmic agents may increase risk of QT interval prolongation. Decreased serum and urine concentrations w/ antacids containing Mg, Al or Ca. Additive antibacterial activity w/ aminoglycosides (e.g. amikacin, tobramycin). Corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation (e.g. seizures) w/ NSAIDs. Higher and prolonged serum theophylline concentrations and increased risk of theophylline-related adverse effects.
Ofloxacin 0.3%  E/E drops	\n\n\tAristopharma\tVista Eye Drops   5  ml drop 85\n\tIbn Sina Pharmaceutical Ind. Ltd.\tObactin Eye Drops   5  ml drop 85\n\tIndication: Bacterial Conjunctivitis, Otic infections, Bacterial corneal ulcer\n\nDose: Otitis Externa: The recommended dosage regimen for the treatment of otitis externa is:\n\nFor pediatric patients (from 6 months to 13 years old): Five drops (0.25 ml, 0.75 mg ofloxacin) instilled into the affected ear once daily for seven days.\n\nFor patients 13 years and older: Ten drops (0.5 ml, 1.5 mg ofloxacin) instilled into the affected ear once daily for seven days.\n\nAcute Otitis Media in pediatric patients  (from 1 to 12 years old) with tympanostomy tubes is:\n\nFive drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affected ear twice daily for ten days. \n\nChronic Suppurative Otitis Media with perforated tympanic membranes:  patients 12 years and older is:\n\nTen drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear twice daily for fourteen days. \n\nEye: Instill 1 drop in the affected eye(s) every 2 to 4 hours for the first two days and then 4 times daily. The length of treatment should not exceed ten days.\n\nContra-indication: Patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.\n\nSide effects: Nausea, vomiting, diarrhoea, abdominal pain, dizziness and headache. Fever, influenza-like syndrome, arthralgia, muscle pain, rash, taste disturbances and cutaneous vasculitis.\nPotentially Fatal: Agranulocytosis, leucopenia, thrombocytopenia.\n\nPrecaution: As with other anti-infective preparations, prolonged use may result in over-growth of nonsusceptible organisms, including fungi. If the infection is not improved after one week, cultures should be obtained to guide further treatment. If otorrhea persists after a full course of therapy, or if two or more episodes of otorrhea occur within six months, further evaluation is recommended to exclude an underlying condition such as cholesteatoma, foreign body, or a tumor.\n\nThe systemic administration of quinolones, including ofloxacin at doses much higher than given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species.\n\n\n\nMode of action: Concomitant use of class IA (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) antiarrhythmic agents may increase risk of QT interval prolongation. Decreased serum and urine concentrations w/ antacids containing Mg, Al or Ca. Additive antibacterial activity w/ aminoglycosides (e.g. amikacin, tobramycin). Corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation (e.g. seizures) w/ NSAIDs. Higher and prolonged serum theophylline concentrations and increased risk of theophylline-related adverse effects.\n\nPregnancy category: C\n\nInteraction: Concomitant use of class IA (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) antiarrhythmic agents may increase risk of QT interval prolongation. Decreased serum and urine concentrations w/ antacids containing Mg, Al or Ca. Additive antibacterial activity w/ aminoglycosides (e.g. amikacin, tobramycin). Corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation (e.g. seizures) w/ NSAIDs. Higher and prolonged serum theophylline concentrations and increased risk of theophylline-related adverse effects.
Olanzapine	\n\n\tACI\tXytrex TAB dr 10mg 50's pack 226.50\n\tACI\tXytrex TAB dr 5mg 50's pack 126\n\tBeximco\tPericam TAB dr 5mg 100's pack 150\n\tBeximco\tPericam TAB dr 10mg 100's pack 251\n\tGeneral\tLopez TAB dr 10mg 50's pack 200\n\tGeneral\tLopez TAB dr 5mg 50's pack 125.50\n\tIncepta\tOlanap 10 TAB dr 10mg 50's pack 225\n\tIncepta\tOlanap 5 TAB dr 5mg 50's pack 125\n\tRenata\tLanzep TAB dr 10mg 50's pack \n\tRenata\tLanzep TAB dr 5mg 50's pack \n\tSquare\tDeprex TAB dr 10mg 100's pack 450\n\tSquare\tDeprex TAB dr 5mg 100's pack 250\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOleanz TAB dr 10mg 50's pack 227.50\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOleanz TAB dr 5mg 50's pack 127.50\n\tIndication: Schizophrenia, Bipolar disorder, Agitation, Mania\n\nDose: Adult: PO Schizophrenia Initial: 5-10 mg/day adjust according to response. Usual: 5-20 mg/day. Max: 20 mg/day. Acute mixed or manic episodes in bipolar disorder Initial: 10 or 15 mg/day as monotherapy or 10 mg/day as part of combination therapy. Usual: 5-20 mg/day. \n\nFor prevention of recurrence: Start w/ 10 mg/day. \n\nContra-indication: Angle-closure glaucoma; lactation. IM: History of CVS disease, heart surgery.\n\nSide effects: Postural hypotension; constipation; dizziness; wt gain; agitation; insomnia; akathisia; tremor; personality disorders; oedema; somnolence; increased appetite; antimuscarinic effects; speech difficulty; exacerbation of Parkinson's disease; hallucinations; asthenia; increased body temperature; bradycardia; hyperprolactinaemia; QT prolongation (uncommon); asymptomatic elevations of hepatic transaminases.\nPotentially Fatal: Exacerbation of preexisting diabetes sometimes leading to ketoacidosis. Neuroleptic malignant syndrome.\n\nPrecaution: Impaired renal, hepatic, cardiovascular function; prostatic hypertrophy; paralytic ileus; DM; parkinsonism; pregnancy. History of blood dyscrasias, myelosuppression, seizures; dementia; dyslipidaemia. IM: Hypotension, bradyarrhythmia, hypoventilation; monitor BP carefully. Caution when used in adolescents due to increased risk of weight gain and hyperlipidaemia. Efficacy and safety have not been established in paediatric patients <13 yr.\n\nMode of action: Olanzapine may antagonise the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucuronyl transferase enzymes e.g. omeprazole and rifampicin, may increase olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit olanzapine elimination. Carbamazepine may increase the clearance of olanzapine. Concomitant admin of activated charcoal reduced the oral bioavailability of olanzapine by 50-60%. Caution should be taken when olanzapine is administered with centrally acting drugs and alcohol.\n\nPregnancy category: C\n\nInteraction: Olanzapine may antagonise the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucuronyl transferase enzymes e.g. omeprazole and rifampicin, may increase olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit olanzapine elimination. Carbamazepine may increase the clearance of olanzapine. Concomitant admin of activated charcoal reduced the oral bioavailability of olanzapine by 50-60%. Caution should be taken when olanzapine is administered with centrally acting drugs and alcohol.
Olmesartan Medoxomil	\n\n\tACI\tAbetis TAB dr 10mg 30's pack 151.20\n\tACI\tAbetis TAB dr 20mg 30's pack 241.50\n\tACI\tAbetis TAB dr 40mg 30's pack 453.30\n\tAcme Ltd.\tOrbas TAB dr 20mg 30's pack 211.20\n\tAcme Ltd.\tOrbas TAB dr 40mg 30's pack 396\n\tBeximco\tOlmesan TAB dr 20mg 30's pack 240\n\tBeximco\tOlmesan TAB dr 40mg 30's pack 450\n\tBeximco\tOlmesan TAB dr 10mg  \n\tDrug International Ltd.\tOlmetic TAB dr 20mg 30's pack 240\n\tGeneral\tOlmepres TAB dr 40mg  \n\tHealthcare\tRansys TAB dr 10mg  \n\tHealthcare\tRansys TAB dr 20mg  \n\tHealthcare\tRansys TAB dr 40mg  \n\tIncepta\tXyotil TAB dr 20mg 30's pack 240\n\tIncepta\tXyotil TAB dr 40mg 30's pack 15\n\tOpsonin Pharma\tOlsart TAB dr 20mg 30's pack 240\n\tOpsonin Pharma\tOlsart TAB dr 40mg 20's pack 450\n\tPopular\tOlmevas TAB dr 10mg  \n\tPopular\tOlmevas TAB dr 20mg  \n\tRadiant.\tSevitan TAB dr 20mg  \n\tSharif\tOlmesart TAB dr 20mg 30's pack 240\n\tSharif\tOlmesart TAB dr 40mg 20's pack 300\n\tSquare\tOlmecar TAB dr 20mg 30's pack 240\n\tSquare\tOlmecar TAB dr 40mg 30's pack 450\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOlmezest TAB dr 10mg 30's pack 150\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOlmezest TAB dr 20mg 30's pack 241.50\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOlmezest TAB dr 40mg 30's pack 450\n\tUnimed & Unihealth Manufacturers Ltd.\tTenicar 20 TAB dr 20mg 28's pack 224\n\tUnimed & Unihealth Manufacturers Ltd.\tTenicar 40 TAB dr 40mg 14's pack 210\n\tWhite Horse Pharma\tMesartin TAB dr 20mg  \n\tIndication: Hypertension, Diabetic nephropathy, \n\nDose:  	Oral\nHypertension\nAdult: Initial: 10-20 mg once daily may then be increased up to max 40 mg once daily if needed.\nChild: 6-16 yr <35 kg: 10 mg once daily; >35 kg: 20 mg once daily. Doses may be doubled once if necessary after 2 wk.\nElderly: No dosage adjustment needed.\nHepatic impairment: Moderate: Initial: 10 mg once daily may increase up to max 20 mg once daily.\n\nContra-indication: Pregnancy (2nd and 3rd trimesters); biliary obstruction.\n\nSide effects: Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.\nPotentially Fatal: Acute renal failure.\n\nPrecaution: Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation.\n\nMode of action: Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.\n\nPregnancy category: D\n\nInteraction: Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.
Olopatadine 0.1% Eye prep	\n\n\tACI\tContova 0.1% Eye Drops  0.1% 5  ml drop 100.68\n\tAcme Ltd.\tAlercon Eye Drops   5  ml drop 100\n\tApex\tAlchek Eye Drops   5  ml drop 100\n\tAristopharma\tOlpadin 0.1% Eye Drops   5  ml drop 100\n\tAsiatic Ltd.\tOptadin Eye Drops   5ml bot 100\n\tBeximco\tOlopan Eye Drops   5  ml drop 100\n\tBeximco\tOpopan Eye Drops 0.1% 5ml bot 100\n\tBio Pharma Ltd.\tOlarif Eye Drops 1 mg/ml  \n\tEskayef Bangladesh Ltd.\tAladay Eye Drops  5ml 100\n\tG. A. Company Ltd.\tOlopta 0.1% Eye Drops   5ml drop 100\n\tGeneral\tOlogen Eye Drops   5ml drop 100\n\tGlobe\tConrif Eye Drops 1 mg/ml  \n\tHealthcare\tAllet Eye Drops 1 mg/ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tPatalon 0.1% Eye Drops   5  ml drop 110\n\tIncepta\tLopadine 0.1% Eye Drops  1 mg/ml 5  ml drop 100\n\tKemiko\tOlon Eye Drops 1 mg/ml  \n\tNavana\tAlleloc Eye Drops   5ml drop 100\n\tPopular\tPatadin 0.1% Eye Drops   5  ml drop 100.38\n\tReman Drug Ltd.\tOlodin 0.1% Eye Drops   5  ml drop 100.38\n\tSquare\tAlacot 0.1% Eye Drops  1 mg/ml 5  ml drop 100.38\n\tIndication: Allergic conjunctivitis\n\nDose: Adults and children (above 3 years of age). One drop   in the conjunctival sac of the affected eye(s) twice daily.\n \n\nContra-indication: It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.\n\nSide effects: Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.\nNon-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.\n\nPrecaution: To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.\n\nMode of action: May result in additive CNS depression w/ CNS depressants.\n\nPregnancy category: C\n\nInteraction: May result in additive CNS depression w/ CNS depressants.
Olopatadine 0.2% Eye prep	\n\n\tAristopharma\tOlpadin DS Eye Drops   5  ml drop 150\n\tBeximco\tOlopan DS Eye Drops    5  ml drop 150\n\tBio Pharma Ltd.\tOlarif DS Eye Drops 0.2 gm/100 ml  \n\tEskayef Bangladesh Ltd.\tAladay DS Eye Drops  30's pack 180\n\tGeneral\tOlogen DS Eye Drops   5ml drop 150\n\tGlobe\tConrif Eye Drops 0.2 gm/100 ml  \n\tHealthcare\tAllet DS Eye Drops 0.2 gm/100 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tPatalon DS Eye Drops   5  ml drop 150\n\tIncepta\tLopadine DS Eye Drops 0.2 gm/100 ml  \n\tNavana\tAlleloc DS Eye Drops .2% 5 ml bot \n\tPopular\tPatadin DS Eye Drops  5ml drop 150.57\n\tSquare\tAlacot DS Eye Drops  .2 gm/100 ml 5ml bot 150\n\tIndication: Allergic conjunctivitis\n\nDose:  Adults and children (above 2 years of age). One drop in each affected eye once a day.\n\nContra-indication: It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.\n\nSide effects: Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.\nNon-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.\n\nPrecaution: To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Patients should be advised not to wear a contact lens if their eye is red. Lopadine should not be used to treat contact lens related irritation.\n\nMode of action: May result in additive CNS depression w/ CNS depressants.\n\nPregnancy category: C\n\nInteraction: May result in additive CNS depression w/ CNS depressants.
Olopatadine 0.6% Nasal prep	\n\n\tAcme Ltd.\tAlercon Nasal Spray    400\n\tBeximco\tOlopan Nasal Spray    400\n\tIncepta\tLopadine Nasal Spray 0.6 gm/100 gm 120 metered dose (spray) in bot 400\n\tIndication: Allergic rhinitis\n\nDose: Adults and Adolescents 12 years of age and older: Two sprays per nostril twice daily.\nChildren 6 to 11 years of age: One spray per nostril twice daily.\n\nContra-indication: It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.\n\nSide effects: Side Effects\nA bitter taste in the mouth, nosebleeds, or irritation/soreness in the nose may occur. Drowsiness may rarely occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.\n\nPrecaution: Priming: Before initial use, prime   Nasal Spray by releasing 5 sprays or until a fine mist appears. When  Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays. Avoid spraying   Nasal Spray into the eyes.\nPatients should be informed to avoid spraying  Nasal Spray in their eyes.\n\nMode of action: May result in additive CNS depression w/ CNS depressants.\n\nPregnancy category: C\n\nInteraction: May result in additive CNS depression w/ CNS depressants.
Omega-3 Acid Ethyl Esters	\n\n\tDrug International Ltd.\tOMG-3 CAP 1gm Omg-3 180\n\tPacific\tOmesoft CAP 1gm 30's pack/50's pack 300/500\n\tUnimed & Unihealth Manufacturers Ltd.\tMaxOmega Soft Gelatin CAP 1gm  \n\tIndication: Dyslipidemia, Hypertriglyceridaemin,\n\nDose: The daily dose is 4 grams per day. The daily dose may be taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily). \n\nContra-indication:  Patients with known hypersensitivity (e.g., anaphylactic reaction) to LOVAZA or any of its components.\n\nSide effects: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n\nPrecaution: In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy . In some patients, increases in ALT levels without a concurrent increase in AST levels were observed.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Omeprazole	\n\n\tACI\tXeldrin CAP 10mg 48's pack/50's pack 96.48/101\n\tACI\tXeldrin CAP 40mg 40's pack 320.80\n\tACI\tXeldrin IV Injection 40mg/vial 40mg vial X 1's pack 80.24\n\tACI\tXeldrin CAP 20mg 100's pack 502\n\tAcme Ltd.\tPPI CAP 20mg 40's pack/100's pack 160.40/401\n\tAcme Ltd.\tPPI CAP 40mg 20's pack 140.40\n\tAcme Ltd.\tPPI IV Injection 40mg/vial 40mg vial X 1's pack 70.26\n\tAd-din\tOmrazol CAP 40mg 20's pack 140\n\tAexim\tLomesec CAP 20mg 60's pack 180\n\tAlbion Ltd.\tLotil CAP 20mg 60's pack \n\tAlbion Ltd.\tLotil CAP 40mg 100's pack \n\tAlco Pharma\tOmepra CAP 20mg 50's pack 200\n\tAlco Pharma\tOmepra CAP 40mg 30's pack 210\n\tAmbee\tOm CAP 20mg 40's pack 120.80\n\tAmbee\tOm CAP 40mg 20's pack 100.20\n\tAmico Ltd.\tHealer CAP 20mg 50's pack 200\n\tAmulet\tOmelet CAP 20mg 60's pack 300\n\tAmulet\tOmelet CAP 40mg 30's pack 210\n\tAPC Pharma Ltd.\tOmeprazole CAP 20mg 60's pack 150\n\tApex\tAspra CAP 20mg 40's pack 200\n\tApex\tAspra SR TAB dr 20mg 40's pack 200\n\tApex\tAspra CAP 40mg 28's pack 168\n\tApollo Pharmaceutical Ltd.\tHk CAP 20mg 100's pack 500\n\tAristopharma\tOmep CAP 10mg 48's pack 96\n\tAristopharma\tOmep CAP 20mg 100 500\n\tAristopharma\tOmep CAP 40mg 30's pack 210\n\tAristopharma\tOmep IV Injection 40mg/vial 40mg vial X 1's pack 80\n\tAsiatic Ltd.\tO-40 CAP 40mg 20's pack 140\n\tAsiatic Ltd.\tO-20 CAP 20mg 100's pack 500\n\tAstra Biopharmaceuticals Ltd.\tOmetor CAP 20mg 28's pack 112\n\tBeacon\tXelopes Injection 40mg/vial 40mg vial X 1's pack 70.26\n\tBeacon\tXelopes CAP 20mg 120's pack 600\n\tBeacon\tXelopes TAB dr 20mg 120's pack 600\n\tBeacon\tXelopes CAP 40mg 30's pack 209\n\tBenham\tOmeben CAP 20mg 60's pack 234\n\tBeximco\tProceptin CAP 20mg 100's pack 400\n\tBeximco\tProceptin CAP 40mg 30's pack 150\n\tBeximco\tProceptin IV Injection 40mg/vial 1's pack 100\n\tBeximco\tProceptin CAP 10mg 30's pack 60\n\tBio Pharma Ltd.\tInpro CAP 20mg 96's pack 385.92\n\tBio Pharma Ltd.\tInpro CAP 40mg 20's pack 140.620\n\tBio Pharma Ltd.\tInpro Injection 40mg/vial 1 amp's pack 70\n\tBristol Pharma Ltd.\tLosek CAP 20mg 60's pack 240\n\tCentral.\tOC-20 CAP 20mg 60's pack 240\n\tChemist Ltd.\tOmecap CAP 20mg 100's pack 400\n\tChemist Ltd.\tOmecap CAP 40mg 100's pack 400\n\tConcord\tOpmax CAP 20mg 60's pack 240\n\tConcord\tOpmax CAP 40mg 40's pack \n\tCosmic Chemical Industries Ltd.\tSectil CAP 20mg 100's pack 400\n\tCosmo Pharma Ltd.\tOpra CAP 20mg 60's pack 242\n\tDecent Pharma Ltd.\tAu CAP 20mg 100's pack 400\n\tDelta Pharma\tInhibita CAP 20mg 60's pack 240\n\tDelta Pharma\tInhibita CAP 40mg 20's pack 140\n\tDesh\tRoceptin CAP 20mg 30's pack/60's pack 120/240\n\tDoctor Tims\tI-Proton CAP 20mg  \n\tDoctor's Chemicals Works Ltd.\tOmaprin CAP 20mg 40's pack 120\n\tDrug International Ltd.\tCosec CAP 20mg 100's pack 500\n\tDrug International Ltd.\tCosec CAP 40mg 42's pack 336\n\tDrug International Ltd.\tCosec Injection 40mg/vial 1 amp's pack 70\n\tEdruc Ltd.\tEmez CAP 20mg 60's pack 240\n\tEdruc Ltd.\tEmez CAP 40mg 60's pack 240\n\tEskayef Bangladesh Ltd.\tLosectil Dry Powder Sachet 20mg 20mg pack X 20's pack/20mg pack X 30's pack 100/150\n\tEskayef Bangladesh Ltd.\tLosectil Dry Powder Sachet 40mg 40mg pack X20 's pack/40mg pack X 20's pack 160/240\n\tEskayef Bangladesh Ltd.\tLosectil CAP 10mg 48's pack 96\n\tEskayef Bangladesh Ltd.\tLosectil CAP 20mg 100's pack 400\n\tEskayef Bangladesh Ltd.\tLosectil CAP 40mg 24's pack/48's pack 168/336\n\tEskayef Bangladesh Ltd.\tLosectil DR TAB dr 20mg 60's pack 240\n\tEskayef Bangladesh Ltd.\tLosectil IV Injection 40mg/vial 1 amp's pack 70\n\tEskayef Bangladesh Ltd.\tLosectil V CAP 20mg  \n\tEskayef Bangladesh Ltd.\tLosectil V CAP 40mg  \n\tEthical Drug Ltd.\tGastril CAP 20mg  \n\tEthical Drug Ltd.\tGastril Injection 40 mg/vial  \n\tEuro Pharma Ltd.\tGap CAP 20mg 60's pack 240\n\tEverest\tZoom CAP 20mg 50's pack 175\n\tEverest\tZoom CAP 40mg 30's pack 210\n\tG. A. Company Ltd.\tOmitac CAP 20mg 48's pack 144\n\tGeneral\tPrevas CAP 20mg 50's pack 201\n\tGeneral\tPrevas CAP 40mg 30's pack 210.90\n\tGlaxoSmithKline Bangladesh Ltd.\tNorain CAP 20mg 60's pack 300\n\tGlobe\tOp CAP 20mg 60's pack 240\n\tGlobe\tOp CAP 40mg 40's pack 280\n\tGlobe\tOP-20 Sachet Powder 20mg  \n\tGlobe\tOP-40 Injection 40 mg/vial  \n\tGlobe\tOP-40 Sachet Powder 40mg  \n\tGlobex\tPiazol CAP 20mg 60's pack 300\n\tGlobex\tPiazol CAP 40mg  \n\tGonoshasthaya\tG-Omeprazole Injection 40mg/vial 1 amps pack 65\n\tGonoshasthaya\tG-Omeprazole CAP 20mg 40's pack 120.40\n\tGuardian Healthcare Ltd.\tOmilant CAP 20mg  \n\tHallmark\tPropin CAP 20mg 28's pack/40's pack 98.28/140.40\n\tHallmark\tPropin CAP 40mg 20's pack 150.60\n\tHealthcare\tOpal CAP 20mg 60's pack 250\n\tHealthcare\tOpal CAP 40mg 30's pack/60's pack 240/300\n\tHealthcare\tOpal Injection 40 mg/vial  \n\tHudson\tAumi CAP 20mg 60's pack 240\n\tHudson\tAumi CAP 40mg 20's pack 150\n\tIbn Sina Pharmaceutical Ind. Ltd.\tProlok CAP 20mg 100's pack 400\n\tIbn Sina Pharmaceutical Ind. Ltd.\tProlok CAP 40mg  \n\tIncepta\tOmenix CAP 20mg 60's pack 300\n\tIncepta\tOmenix Dry Powder Sachet 20mg 30's pack 150\n\tIncepta\tOmenix CAP 40mg 20's pack 160\n\tIncepta\tOmenix Dry Powder Sachet 40mg 30's pack 240\n\tIncepta\tOmenix Injection 40mg/vial 40mg vial X 1's pack 90\n\tIncepta\tOmenix-20 TAB dr 20mg 80's pack 400\n\tIndobangla Pharmaceuticals\tProtobit CAP 20mg 60's pack 240\n\tJayson\tOmirex CAP 20mg 160's pack 118.40\n\tJayson\tOmirex CAP 40mg 20's pack 101.40\n\tKemiko\tOmex CAP 20mg 60's pack 300\n\tKemiko\tOmex CAP 40mg 20's pack 140\n\tKumudini Pharma Ltd.\tOmiloc CAP 40mg 100's pack 400\n\tLabaid\tPeptral CAP 20mg 60's pack 300\n\tLabaid\tPeptral CAP 40mg  \n\tLeon\tPerizol 20 CAP 20mg 2x10's pack \n\tLeon\tPerizol 40 CAP 40mg 2x10's pack \n\tMarksman.\tMepra CAP 20mg 60's pack 240\n\tMedicon\tOmel CAP 20mg 100's pack 500\n\tMedimet\tOmezole CAP 20mg 50's pack/56's pack/100's pack 200/224/400\n\tMillat\tGem CAP 20mg 60's pack 240\n\tModern\tOmidex CAP 20mg 100's pack 300\n\tMonicopharma\tDeu Injection 40mg/vial 1 amp's pack 70\n\tMonicopharma\tDEU- CAP 20mg 48's pack 192\n\tNavana\tOmetac CAP 20mg 100's pack 402\n\tNavana\tOmetac CAP 40mg 24's pack 144.48\n\tNipa\tOmitin CAP 20mg 60's pack 240\n\tNipa\tOmitin CAP 40mg 30's pack 210\n\tNIPRO JMI Pharma\tOmecron CAP 20mg 50's pack 300\n\tNIPRO JMI Pharma\tOmecron CAP 40mg 40's pack 320\n\tNovartis (Bangladesh) Ltd.\tProbitor CAP 20mg 60's pack 360\n\tNovartis (Bangladesh) Ltd.\tProbitor CAP 40mg 28's pack 252\n\tNovartis (Bangladesh) Ltd.\tProbitor CAP 10mg  \n\tNovelta Bestway\tOmecare CAP 40mg 60's pack 240\n\tNovo Healthcare and Pharma Ltd.\tAnasec TAB dr 20mg 60's pack 300\n\tNovo Healthcare and Pharma Ltd.\tAnasec CAP 20mg 60's pack 300\n\tNovo Healthcare and Pharma Ltd.\tAnasec Injection 40mg/vial 1 amp's pack 70\n\tNovus\tOmetop CAP 20mg 30's pack 120\n\tNuvista Pharma Ltd\tNuprazol CAP 20mg 50's pack 343\n\tOpso Saline Ltd.\tNIL90 I.V. Injection 40mg/vial 40mg vial X 1's pack 70.26\n\tOpso Saline Ltd.\tStosec CAP 20mg  \n\tOpso Saline Ltd.\tStosec IV Injection 40mg  \n\tOpsonin Pharma\tOmetid Injection 40mg/vial 40mg vial X 1's pack 70\n\tOpsonin Pharma\tOmetid CAP 20mg 90's pack 396\n\tOpsonin Pharma\tOmetid Dry Powder Sachet 20mg 90's pack 396\n\tOpsonin Pharma\tOmetid CAP 40mg 30's pack 186\n\tOrion Pharma Ltd.\tProcap CAP 20mg 100's pack 402\n\tOrion Pharma Ltd.\tProcap CAP 40mg 20's pack 140.60\n\tOrion Pharma Ltd.\tProcap IV Injection 40mg/vial 40mg vial X 1's pack 70.26\n\tOyster\tRanzo CAP 20mg 60's pack  240\n\tPacific\tPrazo CAP 20mg 100's pack/200's pack 200/400\n\tPacific\tPrazo TAB dr 20mg 100's pack 200\n\tPacific\tPrazo Plus CAP 20mg 32's pack 160\n\tPeoples Pharma Ltd.\tOzole CAP 20mg 60's pack 150\n\tPharmadesh Ltd.\tOmet CAP 20mg 60's pack 180\n\tPharmasia Ltd.\tEupi IV Injection 40mg/vial 1's amp pack 80\n\tPharmasia Ltd.\tEupi CAP 20mg 60's pack 300\n\tPharmasia Ltd.\tProvoxia-20 CAP 20mg 30's pack/60's pack 120.60/241.20\n\tPharmasia Ltd.\tProvoxia I.V. Injection 40mg/vial 40mg vial X 1's pack 80\n\tPharmasia Ltd.\tEupi CAP 40mg  \n\tPopular\tOmegut Injection 40mg/vial 1 amp's pack 80\n\tPopular\tOmegut CAP 20mg 100's pack 500\n\tPopular\tOmegut CAP 40mg 32's pack 351\n\tPrime\tPear CAP 20mg  \n\tRadiant.\tZilon CAP 20mg 60's pack 300\n\tRadiant.\tZilon CAP 40mg 24's pack 180\n\tRAK\tOmenta Injection 40mg/vial 40mg vial X 1's pack 90\n\tRAK\tOmenta CAP 20mg 60's pack 240\n\tRAK\tOmenta CAP 40mg 30's pack 210\n\tRangs\tOmag-DR TAB dr 20mg 100's pack 200\n\tRangs\tPrevencid CAP 20mg  \n\tRangs\tPrevencid CAP 40mg  \n\tReliance\tRomilok CAP 20mg 60's pack 240\n\tReman Drug Ltd.\tRe CAP 20mg 40's pack 124\n\tReman Drug Ltd.\tRe CAP 40mg 20's pack 110\n\tReman Drug Ltd.\tEPZ-40 CAP 40mg 20's pack 150.40\n\tRenata\tPrazole CAP 20mg 60's pack 241.20\n\tRephco\tRome CAP 20mg 100's pack 400\n\tSalton\tOsecton CAP 20mg 60's pack 210\n\tSanofi Aventis (BD) Ltd.\tXerosec CAP 10mg 30's pack 75.30\n\tSanofi Aventis (BD) Ltd.\tXerosec CAP 20mg 100's pack 401\n\tSanofi Aventis (BD) Ltd.\tXerosec CAP 40mg 30's pack 210.90\n\tSeema\tOmpa CAP 20mg 60's pack 300\n\tShamsul Al-Amin\tSom CAP 20mg 60's pack 240\n\tSharif\tPromisec CAP 20mg 40's pack 160\n\tSharif\tPromisec CAP 40mg 20's pack 140\n\tSilco Pharmaceuticlas Ltd.\tPeplo CAP 20mg  \n\tSilva\tOmesil CAP 20mg 60's pack 300\n\tSilva\tOmesil TAB dr 20mg 60's pack 240.90\n\tSilva\tOmesil CAP 40mg 20's pack 140.53\n\tSilva\tOmesil TAB dr 40mg 30's pack 210.79\n\tSilva\tOmesil Fast Dry Powder Sachet 20mg 30's pack 150.57\n\tSilva\tOmesil Fast Dry Powder Sachet 40mg 30's pack 240.90\n\tSilva\tOmesil IR 20 CAP 20mg 60's pack 240.90\n\tSilva\tOmesil IR 40 CAP 40mg 28's pack 196.73\n\tSomatec\tOme CAP 20mg 60's pack 240\n\tSomatec\tOme CAP 40mg 20's pack 160\n\tSquare\tSeclo CAP 20mg 100's pack 500\n\tSquare\tSeclo CAP 40mg 30's pack 240\n\tSquare\tSeclo Injection 40mg/vial 40mg vial X 1's pack 80\n\tSquare\tSeclo DR TAB dr 20mg 60's pack 300\n\tSupreme\tNeopra CAP 20mg 30's pack 105\n\tSyntho Ltd.\tOsyn TAB dr 20mg 60's pack 240\n\tSyntho Ltd.\tOsyn-20 CAP 20mg 30's pack 120\n\tTechno Drugs Ltd.\tOmsec Injection 40mg/vial 40mg vial X 1's pack 70\n\tTechno Drugs Ltd.\tOmsec CAP 20mg 60's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tPresec CAP 20mg 28's pack 112\n\tUnimed & Unihealth Manufacturers Ltd.\tPresec CAP 40mg 28's pack 196\n\tVeritas\tPrazover CAP 40mg  \n\tVeritas\tPrazover CAP 20mg  \n\tVeritas\tPrazover DR TAB dr 20mg  \n\tVirgo\tOmevir CAP 20mg 60's pack\n 240\n\tWhite Horse Pharma\tOmizit CAP 20mg 30's pack 120\n\tZenith\tOpezen TAB dr 20mg 60's pack 240\n\tZenith\tOpezen TAB dr 40mg 20's pack 140\n\tZiska\tOmeprol CAP 20mg 56's pack 224\n\tZiska\tOmeprol Injection 40mg 1's amps pack 70\n\tZiska\tOmeprol CAP 40 mg 28's pack 196\n\tAllied\tOmixen CAP 20mg  \n\tOne Pharma Ltd.\tOmelock CAP 40mg  \n\tIndication: Peptic ulcer, H. pylori infection, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Oesophagitis, Acid-related dyspepsia, NSAID-associated ulceration\n\nDose: Adult: PO Peptic ulcer 20 mg once daily. Severe: 40 mg/day. Duration: Duodenal ulcers: 4 wk; Gastric ulcers: 8 wk. Maintenance: 10-20 mg once daily. NSAID-associated ulceration 20 mg/day. \n\nEradication of H. pylori infection Dose varies w/ regimen: 20 mg once daily or 40 mg/day in 1-2 divided doses. To use w/ antibiotics. GERD 20 mg once daily for 4 wk, may continue for another 8 wk if needed. Maintenance: 10 mg/day. Zollinger-Ellison syndrome Initial: 60 mg once daily. Maintenance: 20-120 mg/day. Give doses >80 mg in 2 divided doses. \n\nProphylaxis of acid aspiration during general anesth Initial: 40 mg the evening before surgery and another 40 mg 2-6 hr pre-op. Acid-related dyspepsia 10 or 20 mg/day 2-4 wkly. Erosive oesophagitis 20 mg/day for 4-8 wk. Maintenance: 20 mg/day for up to 12 mth of total therapy inclusive of treatment period. \n\nIV Gastric and duodenal ulcers; Reflux oesophagitis 40 mg once daily. Prophylaxis of acid aspiration during general anesth 40 mg, to be completed 1 hr before the surgery.\n\nContra-indication: Known hypersensitivity to any of its component.\n\nSide effects: Diarrhoea, nausea, fatigue, constipation, vomiting, flatulence, acid regurgitation, taste perversion, arthralgia, myalgia, urticaria, dry mouth, dizziness, headache, paraesthesia, abdominal pain, skin rashes, weakness, back pain, upper respiratory infection, cough.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Exclude malignancy, prolonged use, hepatic impairment. Pregnancy, lactation, children <1 yr. Elderly and Asians (increased bioavailability).\n\nMode of action: Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.\n\nPregnancy category: C\n\nInteraction: Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.
Ondansetron	\n\n\tACI\tOsetron Syrup 4mg/5ml 50ml bot 30.20\n\tACI\tOsetron TAB dr 8mg 30's pack 302.10\n\tACI\tOsetron Injection 8mg/4ml 5 amps pack 125.45\n\tACI\tOsetron IM/IV Injection 2mg/ml 5's pack 125.85\n\tAcme Ltd.\tPeriset TAB dr 8mg 30's pack 300\n\tAcme Ltd.\tPeriset Injection 8mg/4ml 5's pack 150\n\tAcme Ltd.\tPeriset Oral Solution Syrup 4mg/5ml 50ml bot 40\n\tAlbion Ltd.\tOndansetron TAB dr 8 mg 30's pack \n\tAristopharma\tApulset-4 TAB dr 4mg 30's pack \n\tAristopharma\tApulset-8 TAB dr 8mg 30's pack \n\tAristopharma\tApulset Injection 8mg/4ml 5 amps pack \n\tAristopharma\tApulset Oral Solution  50ml bot \n\tBeximco\tOnsat Injection 4mg/2ml 4ml X 5 amps pack 125\n\tBeximco\tOnsat TAB dr 8mg 30's pack 300\n\tBeximco\tOnsat OSF Oral Soluble Film 4mg/8mg 10 Oral Soluble Film 120/180\n\tBio Pharma Ltd.\tOnstar ODT Orodispersible TAB dr 8mg  \n\tBio Pharma Ltd.\tOnstar Syrup 4 mg/5 ml  \n\tDelta Pharma\tSeton TAB dr 8mg 30's pack 240\n\tDrug International Ltd.\tOndason TAB dr 8mg 3's pack 90\n\tDrug International Ltd.\tOndason Oral Liquid Syrup 4mg/5ml 30's pack 30\n\tEskayef Bangladesh Ltd.\tZofra Injection 8mg/4ml 5 amps pack 150\n\tEskayef Bangladesh Ltd.\tZofra DT TAB dr 8mg 30's pack 300\n\tEskayef Bangladesh Ltd.\tZofra ODT TAB dr 4mg 30's pack 150\n\tEskayef Bangladesh Ltd.\tZofra Oral Solution Syrup 4mg/5ml 50ml bot 30\n\tEskayef Bangladesh Ltd.\tZofra ODT 8 TAB dr 8mg 20's pack/30's pack 160/240\n\tEuro Pharma Ltd.\tOsedan TAB dr 8mg  \n\tGeneral\tOndagen Injection 8 mg/4 ml  \n\tGeneral\tOndagen 8 TAB dr 8mg  \n\tGlobe\tPremesis TAB dr 4mg 30's pack 135\n\tGlobe\tPremesis TAB dr 8mg 30's pack 240\n\tGlobe\tPremesis IM/IV Injection 2mg/ml 5's pack 125\n\tGlobex\tSeroset TAB dr 8mg 30's pack 210\n\tGlobex\tSeroset Injection 8 mg/4 ml  \n\tHealthcare\tEmistat Syrup 4mg/5ml 50ml bot 35\n\tHealthcare\tEmistat TAB dr 8mg 30's pack 300\n\tHealthcare\tEmistat Injection 8mg/4ml 5 amps pack 150\n\tHealthcare\tEmistat FT TAB dr 4mg 30's pack 180\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEmiston TAB dr 8mg 30's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tEmiston Syrup 4mg/5ml 50ml bot 30\n\tIncepta\tOnaseron Syrup 4mg/5ml 50ml bot 40\n\tIncepta\tOnaseron TAB dr 8mg 30's pack 300\n\tIncepta\tOnaseron Injection 8mg/4ml 5 amps pack 125\n\tIncepta\tOnaseron ODT TAB dr 4mg 30's pack 5tk/tab\n\tJayson\tOncodex Injection 4mg/2ml 5's pack 125.50\n\tJayson\tOncodex TAB dr 4mg 30's pack 135.60\n\tJayson\tOncodex TAB dr 8mg 30's pack 240.90\n\tJayson\tOncodex Injection 8mg/4ml 5 amps pack 125.50\n\tLeon\tLeofran TAB dr 8mg  \n\tLeon\tLeofran Syrup 4 mg/5 ml  \n\tLeon\tLeofran Injection 2 mg/ml  \n\tMonicopharma\tSetronax TAB dr 8mg 30's pack 300\n\tNavana\tNauset TAB dr 8mg 30's pack \n\tNavana\tNauset Syrup 4mg/5ml 50ml bot \n\tNovartis (Bangladesh) Ltd.\tOndantor TAB dr 4mg  \n\tNovartis (Bangladesh) Ltd.\tOndantor TAB dr 8mg  \n\tNovelta Bestway\tOnatron TAB dr 8mg  \n\tNovelta Bestway\tOnatron Syrup 4 mg/5 ml  \n\tNovus\tOndanov-4 TAB dr 4mg 30's pack 90\n\tNovus\tOndanov-8 TAB dr 8mg 30's pack 150\n\tOpsonin Pharma\tAnset Syrup 4mg/5ml 50ml bot 39\n\tOpsonin Pharma\tAnset TAB dr 8mg 30's pack 300\n\tOpsonin Pharma\tAnset Suppository 16mg 10's pack 131\n\tOpsonin Pharma\tAnset ODT TAB dr 4mg 30's pack 135\n\tOpsonin Pharma\tAnset ODT Injection 8mg/4ml 5 amps pack 125\n\tOrion Pharma Ltd.\tOnasia Syrup 4mg/5ml 50ml bot 30\n\tOrion Pharma Ltd.\tOnasia Injection 8mg/4ml 5 amps pack 125\n\tOrion Pharma Ltd.\tOnasia TAB dr 8mg 30's pack 150\n\tPopular\tAvona Solution syrup 4mg 5ml bot 30.79\n\tPopular\tAvona 8 TAB dr 8mg 30's pack 263.91\n\tPopular\tAvona Injection 4ml 5's amps pack 131.95\n\tRAK\tVomiset TAB dr 8mg 30's pack 300\n\tRAK\tVomiset Oral Solution Syrup 4mg/5ml 50ml bot 30\n\tRAK\tEmiset TAB dr 4mg 30's pack 150\n\tRAK\tEmiset TAB dr 8mg 30's pack 300\n\tRAK\tEmiset Oral Solution 4mg/5ml 50ml bot 30\n\tRenata\tEmeren TAB dr 4mg 30's pack 150\n\tRenata\tEmeren TAB dr 8mg 30's pack 300\n\tRenata\tEmeset FC TAB dr 4mg 3x10's pack 92.37\n\tRenata\tEmeset FC TAB dr 8mg 3x10's pack  184.74\n\tRenata\tEmeset IM/IV Injection 8mg/4ml 1x5's pack 109.97\n\tRenata\tEmeren IM/IV Injection 8mg 5's pack \n\tSomatec\tOndamax 4 TAB dr 4mg  \n\tSomatec\tOndamax 8 TAB dr 8mg  \n\tSomatec\tOndamax Syrup 4 mg/5 ml  \n\tSquare\tOfran Suppository 16mg 10's pack 200\n\tSquare\tOfran Injection 2mg/ml 6's pack 180\n\tSquare\tOfran Syrup 4mg/5ml 50ml bot 40\n\tSquare\tOfran TAB dr 8mg 30's pack 301.24\n\tSquare\tOfran Injection 8mg/4ml 6 amps pack 180\n\tSun Pharmaceutical (Bangladesh) Ltd.\tZofer MD TAB dr 4mg 30's pack 165\n\tIndication: Post-op nausea and vomiting, Nausea and vomiting associated w/ cancer chemotherapy\n\nDose: 1. Prevention of nausea-vomiting associated with chemotherapy\n\n1 a. Adult\n\nParenteral: 32 mg single dose infused over 15 minutes by diluting with 50 ml saline (5% dextrose or 0.9% NaCl) 30 minutes before starting chemotherapy. Alternative therapy: Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before the starting chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.\n\nOral: Highly emetogenic cancer chemotherapy: 24 mg (three 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy\n\nModerate emetogenic cancer chemotherapy: 8 mg (one 8 mg tablet/oral film) administered 30 minutes before start of emetogenic chemotherapy. A further 8 mg dose should be administered after 8 hours of the first dose. One 8 mg tablet/oral film should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.\n\n\n1 b. Pediatric\n\nParenteral (6 months onwards): Three dose of 0.15 mg/kg body weight. The first dose is infused over 15 minutes beginning 30 minutes before starting moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose of administration.\n\nOral (4-11 years): 4 mg tablet/oral film should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 4 mg tablet/oral film should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.\n\n\n2. Prevention of nausea-vomiting associated with radiotherapy\n\nAdults/ Geriatric/ Child of 12 years or over\nThe recommended dose is 8 mg tablet/oral film 3 times a day.\n\nFor total body irradiation: One 8 mg tablet/oral film should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.\n\nFor single high-dose fraction radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.\n\nFor daily fractionated radiotherapy to the abdomen: One 8 mg tablet/oral film should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day.\n\n\n3. Prevention of post-operative nausea-vomiting\n\n3 a. Adults/ Geriatric/ Child of 12 years or over\n\nParenteral : Undiluted 4 mg intravenously or intramuscularly immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes. Alternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery\n\nOral: 16 mg (two 8 mg tablets/oral film) 1 hour before induction of anesthesia.\n\n\n3 b. Pediatric (1 months to12 years)\n\nParenteral : Weighing less than 40 kg: 0.1-mg/kg body weight in a Single dose . Weighing more than 40 kg: 4mg single dose The dose should be immediately before induction of anesthesia. The rate of administration should not be less than 30 seconds, preferably over 2 to 5 minutes.\n\nAlternatively, the dose can be administered post-operatively if the patient experiences nausea and/or vomiting shortly after surgery.\n\n4. Nausea-vomiting in gastroenteritis\n\n4 a. Adult: 8 mg three times daily.\n\n4 b. Pediatric (1 month or over): 0.15 mg/kg body weight three times daily.\n\n\n5. Nausea vomiting in pregnancy\n8 mg (1 tablet) 2-3 times daily\n\n\nContra-indication: Use with apomorphine (profound hypotension).\n\nSide effects: Headache, malaise/fatigue, constipation; drowsiness, fever, dizziness, anxiety, cold sensation; pruritus, rash; diarrhoea; gynaecological disorder, urinary retention; elevated transaminase; local inj site reaction (pain, redness, burning); paresthesia; hypoxia. Rarely: Anaphylaxis, angina, bronchospasm, ECG changes, extrapyramidal symptoms, grand mal seizure, hypokalaemia, tachycardia, vascular occlusive events.\n\nPrecaution: May cause QT prolongation; caution when used in cardiac diseases, patients who are on medications that can prolong QT or patients with electrolyte abnormalities. Severe hepatic impairment. May mask progressive ileus and/or gastric distension. Pregnancy, lactation.\n\nMode of action: May reduce analgesic effect of tramadol. Rifampicin and other CYP3A4 inducers may reduce levels/effects of ondansetron. Concomitant use of QT-prolonging agents (e.g. antiarrhythmics) may cause additive prolongation of QT interval. May increase the risk of arrhythmias w/ cardiotoxic drugs (e.g. anthracyclines).\nPotentially Fatal: May increase the hypotensive effect of apomorphine.\n\nPregnancy category: B\n\nInteraction: May reduce analgesic effect of tramadol. Rifampicin and other CYP3A4 inducers may reduce levels/effects of ondansetron. Concomitant use of QT-prolonging agents (e.g. antiarrhythmics) may cause additive prolongation of QT interval. May increase the risk of arrhythmias w/ cardiotoxic drugs (e.g. anthracyclines).\nPotentially Fatal: May increase the hypotensive effect of apomorphine.
Orlistat	\n\n\tACI\tOrnical CAP 120mg  \n\tEskayef Bangladesh Ltd.\tDietil CAP 120mg 10's pack 400\n\tHealthcare\tSlimfast CAP 120mg 12's pack 500\n\tHealthcare\tSlimfast CAP 60mg  \n\tIncepta\tAdiponil CAP 120mg 10's pack 400\n\tRadiant.\tXenobese CAP 120mg 21's pack 12.63\n\tSquare\tOlistat CAP 120mg 20's pack 1100\n\tSquare\tOlistat CAP 60mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tSlimi CAP 60mg 21's pack 630\n\tRoche SpA, Italy\tXenical CAP 120mg 84's pack 6525\n\tIndication: Obesity\n\nDose: Adult: PO 120 mg 3 times/day with each main meal. (Should be taken with food. Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted).\n\nContra-indication: Chronic malabsorption syndrome. Cholestasis. Lactation\n\nSide effects: Faecal urgency and incontinence, flatulence, fatty stools or discharge, increased defecation; headache, anxiety, fatigue, menstrual irregularities; abdominal pain/discomfort.\nPotentially Fatal: Anaphylaxis; angioedema.\n\nPrecaution: Distribute daily intake of fat over 3 main meals. Fat-soluble vitamins supplements may be required during long-term therapy. Discontinue use if 5% body wt loss is not achieved during the first 12 wk. History of hyperoxaluria or calcium oxalate nephrolithiasis. DM. Pregnancy.\n\nMode of action: May decrease absorption of oral fat-soluble vitamins, amiodarone, propafenone. May decrease plasma levels of ciclosporin. May alter the effects of warfarin (monitor INR). May elevate plasma levels of pravastatin.\n\nPregnancy category: B\n\nInteraction: May decrease absorption of oral fat-soluble vitamins, amiodarone, propafenone. May decrease plasma levels of ciclosporin. May alter the effects of warfarin (monitor INR). May elevate plasma levels of pravastatin.
Ornidazole	\n\n\tAlco Pharma\tOrnizol TAB dr 500mg 30's pack 180\n\tBeximco\tXynor TAB dr 500mg 30's pack 195\n\tDrug International Ltd.\tOrnid TAB dr 500mg 50's pack 350\n\tOpsonin Pharma\tOrnil TAB dr 500mg 20's pack 130\n\tSquare\tRobic TAB dr 500mg 30's pack 195\n\tUnimed & Unihealth Manufacturers Ltd.\tTroniz TAB dr 500mg 30's pack 195\n\tZenith\tOR TAB dr 500mg 30's pack 195\n\tIndication: Surgical Prophylaxis, Amoebiasis, Hereditary angioedema, Trichomoniasis, Anaerobic bacterial infections, Amoebic dysentery\n\nDose: Adult: PO Amoebiasis 0.5 g twice daily for 5-10 days. Amoebic dysentery 1.5 g once daily for 3 days. Giardiasis 1-1.5 g once daily for 1-2 days. Trichomoniasis 1.5 g once daily for 5 days. Treat sexual partners concomitantly. \n\nContra-indication: Hypersensitivity to ornidazole or to other nitroimidazole derivatives.\n\nSide effects: Somnolence, headache, nausea, vomiting, dizziness, tremor, rigidity, poor coordination, seizures, tiredness, vertigo, temporary loss of consciousness and signs of sensory or mixed peripheral neuropathy, taste disturbances, abnormal LFTs, skin reactions.\n\nPrecaution: Renal and hepatic impairment. CNS diseases e.g. epilepsy or multiple sclerosis. May impair ability to drive or operate machinery. Pregnancy and lactation.\n\nMode of action: May decrease absorption of oral fat-soluble vitamins, amiodarone, propafenone. May decrease plasma levels of ciclosporin. May alter the effects of warfarin (monitor INR). May elevate plasma levels of pravastatin.\n\nPregnancy category: Not Classified\n\nInteraction: May decrease absorption of oral fat-soluble vitamins, amiodarone, propafenone. May decrease plasma levels of ciclosporin. May alter the effects of warfarin (monitor INR). May elevate plasma levels of pravastatin.
Oseltamivir	\n\n\tACI\tPandeflu CAP 75mg 8's pack 1440\n\tBeximco\tOseflu CAP 75mg 10's pack 1500\n\tEskayef Bangladesh Ltd.\tSk Flu CAP 75mg 10's pack 1800\n\tGonoshasthaya\tG-Oseltamivir CAP 75mg 30's pack 2256.30\n\tGonoshasthaya\tG-Oseltamivir Syrup 60mg 25ml  bot 351.32\n\tIncepta\tFlutavir CAP 75mg 10's pack 1500\n\tSquare\tAviflu CAP 75mg 10's pack 1505.69\n\tIndication: Influenza\n\nDose: Oral\nInfluenza A and B\nAdult: 75 mg bid for 5 days. Initiate treatment within 2 days of onset of symptoms.\nChild: 1-12 yr: Wt <15 kg: 30 mg bid; >15-23 kg: 45 mg bid; >23-40 kg: 60 mg bid; >40 kg: 75 mg bid. Initiate treatment within 2 days of onset of symptoms. Duration of treatment: 5 days.\n\n\nProphylaxis of influenza A and B\nAdult: 75 mg once daily for 10 days. Initiate treatment within 2 days of exposure. For community outbreak: May continue dosing for up to 6 wk.\nChild: 1-12 yr: Wt <15 kg: 30 mg once daily; >15-23 kg: 45 mg once daily; >23-40 kg: 60 mg once daily; >40 kg: 75 mg once daily. Initiate treatment within 2 days of contact with an infected individual. Duration of treatment: 10 days.\n\nRenal impairment: Dialysis: Not recommended.\nCrCl (ml/min)	\n10-30	75 mg on alternate days or 30 mg daily.\n<10	        Not recommended.\n\nContra-indication: Hypersensitivity. Severe renal impairment.\n\nSide effects: Nausea, vomiting, abdominal pain, bronchitis, insomnia, vertigo, diarrhoea, dizziness, headache, cough, fatigue, unstable angina, anaemia, pseudomembranous colitis, pneumonia, pyrexia, peritonsillar abscess, elevated liver enzymes, hepatitis, aches and pains, dyspepsia, rhinorrhoea, upper respiratory-tract infections. In children: Vomiting, other GI disturbances, asthma, bronchitis, conjunctivitis, dermatitis, epistaxis, ear disorders, otitis media, lymphadenopathy, pneumonia, sinusitis.\nPotentially Fatal: Anaphylaxis, severe dermatologic reactions.\n\nPrecaution: Moderate renal impairment. Pregnancy and lactation. Chronic cardiac disease, hepatic impairment, respiratory disease, immunocompromised patients.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Oxaliplatin	\n\n\tBeacon\tXaloplat Injection 50mg/vial 10 ml vial x 1's pack 3000\n\tTechno Drugs Ltd.\tOxalotin Injection 50mg/vial 1's pack 3000\n\tTechno Drugs Ltd.\tOxalotin Injection 100mg/vial 1's pack 5500\n\tAventis Pharma, Dagenham, UK\tEloxatin 	 Infusion 5mg/ml vial 	 1's pack 6230.74\n\tIndication: Colorectal cancer, Colon cancer\n\nDose: Intravenous\nAdvanced colorectal cancer\nAdult: In combination with fluorouracil/leucovorin: 85 mg/m2 every 2 wk until disease progression or unacceptable toxicity. Dose to be given by IV infusion over 2-6 hr, dissolved in 250-500 ml of glucose 5%, . After recovery from toxicity, reduce dose to 65 mg/m2. Administer before fluoropyrimidines.\n\nAdjuvant therapy in stage III colon cancer\nAdult: In combination with fluorouracil/leucovorin: 85 mg/m2 every 2 wk for 12 cycles. Dose to be given by IV infusion over 2-6 hr, dissolved in 250-500 ml of glucose 5%, every 2 wk; given for 12 cycles. After recovery from toxicity, reduce dose to 75 mg/m2. Administer before fluoropyrimidines.\n\nContra-indication: Pregnancy. Peripheral neuropathy with functional impairment. Severe renal impairment.\n\nSide effects: Fatigue, fever, pain, headache, insomnia, nausea, diarrheoa, vomiting, abdominal pain, constipation, anorexia, stomatitis, anemia, thrombocytopenia, leukopenia, aspartate and alanine transaminases increased, total bilirubin increased, peripheral neuropathy, back pain, dyspnoea, cough, oedema, chest pain, peripheral oedema, flushing , thromboembolism, dizziness, rash, alopecia , hand-foot syndrome dehydration, hypokalaemia, dyspepsia, taste perversion, flatulence, mucositis, gastroesophageal reflux, dysphagia, dysuria, neutropenia, inj site reaction, rigors, arthralgia, abnormal lacrimation, serum creatinine increased, rhinitis, epistaxis, pharyngitis, pharyngolaryngeal dysesthesia, allergic reactions, hiccup.\nPotentially Fatal: Anaphylaxis, pulmonary fibrosis.\n\nPrecaution: Should be administered under the supervision of an experienced cancer chemotherapy physician. Use appropriate precautions for handling and disposal. Monitor neurological status and dose should be reduced if symptoms are prolonged or severe. Monitor blood counts during treatment and courses should not be repeated until blood counts have recovered. Caution in elderly, moderate degrees of renal impairment. Avoid using aluminum-containing needles or IV admin sets that may come into contact with oxaliplatin as aluminum has been reported to cause degradation of platinum compounds. Lactation.\n\nMode of action: May decrease plasma levels of digoxin. May increase risk of toxicity with nephrotoxic drugs. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before oxaliplatin to limit myelosuppression and enhance efficacy.\n\nPregnancy category: D\n\nInteraction: May decrease plasma levels of digoxin. May increase risk of toxicity with nephrotoxic drugs. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before oxaliplatin to limit myelosuppression and enhance efficacy.
Oxaprozin	\n\n\tACI\tDemarin TAB dr 600mg 30's pack 210.90\n\tEskayef Bangladesh Ltd.\tDayprox TAB dr 600mg 30's pack 210\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Juvenile rheumatoid arthritis\n\nDose: Adult: PO Osteoarthritis 1.2 g once daily. Patients w/ low body wt or mild disease: Initial: 600 mg once daily. Max: 1.8 g or 26 mg/kg (whichever is lower) in divided doses. \n\nRheumatoid arthritis 1.2 g once daily. Max: 1.8 g or 26 mg/kg (whichever is lower) in divided doses.\n\nJuvenile rheumatoid arthritis\nChild: >6 yr: Wt 22-31 kg: 600 mg; 32-54 kg: 900 mg; >55 kg: 1200 mg. All doses to be given once daily.\n\nContra-indication: Previous or active peptic ulceration, known hypersensitivity to NSAIDs. Perioperative pain in CABG setting.\n\nSide effects: Depression, sedation, somnolence, confusion, disturbance of sleep, weakness, malaise; rash, prutitus, urticaria, photosensitivity; abdominal pain/distress, anorexia, flatulence, vomiting, constipation, diarrhoea, dyspepsia, nausea, peptic ulcer and/or GI bleeding, abnormalities in LFTs, stomatitis, haemorrhoidal or rectal bleeding; tinnitus; dysuria or frequency; oedema, BP changes; haematuria, renal insufficiency, decreased menstrual flow; anaemia, thrombocytopenia, leukopenia, ecchymoses; wt gain/loss; blurred vision, conjunctivitis.\nPotentially Fatal: Anaphylactoid reactions, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, severe hepatic reactions.\n\nPrecaution: Be alert for ulceration and bleeding in patients treated chronically. History of serious GI events, alcoholism, smoking, other factors known to be associated with peptic ulcer. Elderly or debilitated patients. Uncompensated cardiac failure, history of hypertension, cardiac decompensation, chronic diuretic therapy, conditions predisposing to fluid retention. Renal and hepatic impairment. Underlying coagulation defects or patients who are undergoing surgical procedures where a high degree of haemostasis is required. Pregnancy (avoid in 3rd trimester) and lactation.\n\nMode of action: Increased risk of salicylate toxicity with aspirin. May increase effects of oral anticoagulants. May reduce effects of ?-blockers, diuretics and other antihypertensive agents. May increase risk of methotrexate and lithium toxicity.\n\nPregnancy category: D\n\nInteraction: Increased risk of salicylate toxicity with aspirin. May increase effects of oral anticoagulants. May reduce effects of ?-blockers, diuretics and other antihypertensive agents. May increase risk of methotrexate and lithium toxicity.
Oxazepam	\n\n\tAlbion Ltd.\tOxapam TAB dr 10 mg 100's pack \n\tSquare\tAnoxa TAB dr 10mg 30's pack 105.30\n\tIndication: Anxiety, Insomnia, Alcohol withdrawal syndrome\n\nDose: Adult: PO Alcohol withdrawal syndrome; Anxiety 15-30 mg 3-4 times/day. Insomnia associated w/ anxiety 15-25 mg 1 hr before bedtime. Up to 50 mg may be used.\n\nContra-indication: Not for the treatment of psychoses. Pregnancy and lactation.\n\nSide effects: Syncope (rare), oedema; drowsiness, ataxia, dizziness, vertigo, memory impairment, headache, paradoxical reactions (excitement, stimulation of effect), lethargy, amnesia, euphoria; rash; decreased libido, menstrual irregularities; incontinence; leukopenia, blood dyscrasias; jaundice; dysarthria, tremor, reflex slowing; blurred vision, diplopia; drug dependence.\n\nPrecaution: Cross-sensitivity with other benzodiazepines may occur. Hepatic and renal impairment. Respiratory disease. Debilitated patients, elderly, patients at risk of falls. Withdraw gradually. Porphyria; impaired gag reflex. History of drug abuse or acute alcoholism. May impair ability to drive or operate machinery. CV or cerebrovascular disease, intolerance to transient decreases in BP. Depression or if suicidal risk is present.\n\nMode of action: Additive CNS depressant effects w/ barbiturates, antipsychotics, sedatives/hypnotics, anxiolytics, antidepressants, sedative antihistamines, anticonvulsants, and anaesth. Increased psychic dependence w/ narcotic analgesics. CYP450 inhibitors may enhance benzodiazepine activity.\n\nPregnancy category: D\n\nInteraction: Additive CNS depressant effects w/ barbiturates, antipsychotics, sedatives/hypnotics, anxiolytics, antidepressants, sedative antihistamines, anticonvulsants, and anaesth. Increased psychic dependence w/ narcotic analgesics. CYP450 inhibitors may enhance benzodiazepine activity.
Oxcarbazepine	\n\n\tIncepta\tOxazep Suspension 300mg/5ml 100ml bot 250\n\tIncepta\tOxazep TAB dr 300mg 30's pack 360\n\tIncepta\tOxazep TAB dr 600mg 20's pack 400\n\tNovartis (Bangladesh) Ltd.\tTrileptal TAB dr 300mg 50's pack 1000\n\tNovartis (Bangladesh) Ltd.\tTrileptal TAB dr 600mg 50's pack 1750\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOxetol TAB dr 150mg 50's pack 350\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOxetol TAB dr 300mg 50's pack 590\n\tNovartis Pharma, France\tTrileptal Suspension 60mg/ml 100ml bot 934\n\tIndication: Partial seizures, Generalised tonic-clonic seizures\n\nDose: Oral\nMonotherapy or adjunctive therapy in the treatment of partial seizures with or without secondary generalised tonic-clonic seizures\nAdult: Initially, 600 mg daily in 2 divided doses; increase at a max increments of 600 mg daily at wkly intervals depending on response. Maintenance: 600-1,200 mg daily. Adjunctive therapy/refractory patients switched from other anticonvulsants: Up to 2,400 mg daily.\n\nChild: >6 yr: 8-10 mg/kg daily in 2 divided doses; increase as necessary to max increments of 10 mg/kg daily at about wkly intervals to a max of 46 mg/kg daily. Maintenance in adjunctive therapy: 30 mg/kg daily.\n\nRenal impairment:\nCrCl (ml/min)	\n<30	       Initially, 300 mg daily or 50% of usual dose. Increase at wkly intervals or longer.\n\nContra-indication: Hypersensitivity. Lactation.\n\nSide effects: Dizziness, somnolence, headache, ataxia, fatigue, vertigo, nervousness, amnesia, abnormal thinking, insomnia, speech disorder, agitation, confusion; vomiting, nausea, abdominal pain, diarrhoea, dyspepsia, constipation, gastritis, wt gain; abnormal gait, tremor, weakness, back pain, abnormal coordination, dysmetria, sprains/strains, muscle weakness; diplopia, nystagmus, abnormal vision and accommodation; hypotension, leg oedema; rash, acne; hyponatraemia; rhinitis, chest infection, epistaxis, sinusitis.\nPotentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis. Anaphylaxis and angioedema.\n\nPrecaution: Cross-sensitivity to carbamazepine may occur. Do not discontinue abruptly. Renal and hepatic impairment. Patients at risk of hyponatraemia. May impair ability to drive or operate machinery. Pregnancy.\n\nMode of action:  	Reduced serum levels with carbamazepine, phenobarbitone, phenytoin, valproic acid. May reduce levels/effects of CYP3A4 substrates (e.g. benzodiazepines, calcium channel blockers, clarithromycin, ciclosporin, erythromycin, oestrogens, mirtazapine, nateglinide, nefazodone, nevirapine, protease inhibitors, tacrolimus, venlafaxine). May reduce efficacy of oral contraceptives. May reduce levels/effects of maraviroc. May increase levels of phenobarbitone, phenytoin.\n\nPregnancy category: C\n\nInteraction:  	Reduced serum levels with carbamazepine, phenobarbitone, phenytoin, valproic acid. May reduce levels/effects of CYP3A4 substrates (e.g. benzodiazepines, calcium channel blockers, clarithromycin, ciclosporin, erythromycin, oestrogens, mirtazapine, nateglinide, nefazodone, nevirapine, protease inhibitors, tacrolimus, venlafaxine). May reduce efficacy of oral contraceptives. May reduce levels/effects of maraviroc. May increase levels of phenobarbitone, phenytoin.
Oxiconazole 1% Topical	\n\n\tSquare\tOxifun Cream   10gm  tube 50.20\n\tIndication: Tinea pedis, Tinea cruris, Tinea corporis, Pityriasis versicolor\n\nDose: Tinea corporis\nAdult: Apply 1% cream or lotion once or bid. Duration of treatment: 2 wk for tinea corporis and tinea cruris or 1 mth for tinea pedis.\nElderly: Apply 1% cream or lotion once or bid. Duration of treatment: 2 wk for tinea corporis and tinea cruris or 1 mth for tinea pedis.\nPityriasis versicolor\nAdult: Apply 1% cream once daily for 2 wk.\nElderly: Apply 1% cream once daily for 2 wk.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Pruritus, burning, irritation, stinging, erythema, rash, folliculitis, nodules, pain, papules, maceration, fissuring, contact dermatitis, dyshidrotic eczema, tingling.\n\nPrecaution: Pregnancy and lactation. Avoid contact with eyes. Intravaginal preparation may damage latex contraceptives. Discontinue if irritation or sensitisation occurs. Cross-sensitisation with other imidazole derivatives may occur.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Oxybuprocaine Hydrochloride 0.4% Eye prep	\n\n\tGeneral\tBuprocane Eye Drops   10 ml drop 100\n\tOpso Saline Ltd.\tNovocaine Eye Drops   10 ml bot 42.16\n\tReman Drug Ltd.\tOxycaine Drops   10 ml bot 50.43\n\tIndication: Local occular anaesthesia\n\nDose:  Adult: Ophth As 0.4% soln: For short procedures: Instill 1 drop to allow tonometry after 60 sec; a further drop after a 90 sec interval produces sufficient anesth for contact lens fitting; 3 drops at 90 sec intervals produces sufficient anesth after 5 mins for a foreign body to be removed from the corneal epithelium or for incision of a meibomian cyst through the conjunctiva.\n\nContra-indication: Hypersensitivity\n\nSide effects: Hypersensitivity reactions; transient stinging and blurring of vision; excitation of CNS; muscle twitching and tremors; convulsions.\n\nPrecaution: Reduce systemic absorption by compressing the lacrimal sac at the medial canthus for a minute during and following instillation. Heart block; epilepsy, impaired cardiac conduction, myasthenia gravis; not to be applied to inflamed, infected tissues or damaged mucosa. Protect anaesthetised eye from dust and bacterial contamination; cornea may be damaged by prolonged application. Do not drive until normal vision restored.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Oxybutynin Hydrochloride	\n\n\tBeximco\tUricon CR TAB dr 5mg  30's pack 180.60\n\tIndication: Overactive bladder\n\nDose: Adult: PO 2.5-5 mg 2-3 times/day. Max: 5 mg 4 times/day if needed. Extended-release Initial: 5 mg once daily, increase slowly if needed. Max 30 mg/day. \n\nContra-indication: GI obstruction or atrophy, severe toxic megacolon, significant bladder outflow obstruction, glaucoma, urinary retention.\n\nSide effects: Dry mouth, constipation, nausea, abdominal pain; blurred vision; headache, dizziness, drowsiness; dry skin, rash; photosensitivity, diarrhoea, insomnia, palpitation, weakness, dry eyes, confusion, hypertension, UTI, dyspepsia.\n\nPrecaution: Elderly; hepatic or renal impairment; neuropathy; hyperthyroidism; prostatic hyperplasia; hiatus hernia; cardiac disease, reflux oesophagitis, ulcerative colitis, myasthenia gravis; pregnancy and lactation. High environmental temperature might cause heat prostration (fever with heat stroke due to decreased sweating).\n\nMode of action: Co-administration with other anticholinergic drugs may cause undesirable increased anticholinergic effects. Additive sedation with CNS depressants and alcohol. Concentration may be increased by CYP3A4 inhibitirs (e.g. imidazole antifungals, macrolide antibiotics).\n\nPregnancy category: B\n\nInteraction: Co-administration with other anticholinergic drugs may cause undesirable increased anticholinergic effects. Additive sedation with CNS depressants and alcohol. Concentration may be increased by CYP3A4 inhibitirs (e.g. imidazole antifungals, macrolide antibiotics).
Oxygen 99 % Gas	\n\n\tIndication: Anxiety disorders,Shock,Resuscitation,Cyanosis,Severe hemorrhage,Carbon monoxide poisoning,Major trauma,Artificially ventilated patients,COPD\n\nDose: \n\nContra-indication: \n\nSide effects: \n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Oxygenium	\n\n\tIndication: Anxiety disorders,Shock,Resuscitation,Cyanosis,Severe hemorrhage,Carbon monoxide poisoning,Major trauma,Artificially ventilated patients,COPD\n\nDose: \n\nContra-indication: \n\nSide effects: \n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Oxymetazoline Hydrochloride .025 % Nasal prep	\n\n\tAcme Ltd.\tAzolin Nasal Drops .025% 10ml bot \n\tAristopharma\tAfrin 0.025% Nasal Drops   10 ml drop 40\n\tGeneral\tNasalox 0.025% Nasal Drops 0.025% 10ml bot 45\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNatazol Paediatric Nasal Drops 0.025 %  \n\tIncepta\tRynex Nasal Drops 0.025mg 10 ml drop 40\n\tIncepta\tRynex Nasal Spray 25mcg 200 metered dose 80\n\tNavana\tCongenil Nasal Drops .025 %  10 ml bot \n\tNIPRO JMI Pharma\tOxydrop Nasal Drops 0.025 %  \n\tOpsonin Pharma\tOxynex 0.025% Nasal Drops   10ml bot 40\n\tSquare\tNocon 0.025% Nasal Drops   10 ml bot x 6's pack 180.66\n\tSquare\tXylocon Nasal Drops .025% 10ml bot 240\n\tIndication: Sinusitis, Hay fever, Common cold, Conjunctival decongestant, Acute or chronic rhinitis, Nasal congestion\n\nDose: Adults and children 6 yrs of age and older : 2-3 drops or sprays in each nostril twice daily for 3-5 days.\nChildren of age 2-6 : 2-3 drops in each nostril twice daily for 3-5 days. Sprays are generally unsuitable for young children because of the small size of their nostrils. The drug is not recommended in children under the age of 2.\n\nContra-indication: Contraindicated in patients hypersensitive to Oxymetazoine Hydrochloride.\n\nSide effects: * Transient burning, dryness of the nasal mucosa, sneezing.\n* Nervousness, dizziness, headache.\n* Hypertension, palpitation or reflex bradycardia.\n\nPrecaution: * Prolonged use may result in rebound congestion.\n* Since oxymetazoline has systemic adverse effects, it should be used with caution in patients with\n* hypertension, cardiovascular disease or hyperthyroidism or in those receiving MAO inhibitors.\n\nMode of action: Potentially Fatal: Hypertensive crisis with MAOIs.\n\nPregnancy category: C\n\nInteraction: Potentially Fatal: Hypertensive crisis with MAOIs.
Oxymetazoline Hydrochloride .05 % Nasal prep	\n\n\tAcme Ltd.\tAzolin NS 0.05% Drops   10 ml drop  45\n\tAcme Ltd.\tAzolin Paed Drops  10ml drop 40\n\tAristopharma\tAfrin 0.05% Drops   10 ml drop 45\n\tAsiatic Ltd.\tConfree Drops   10ml bot 45\n\tBeximco\tNazolin 0.05% Drops   1 spray unit of 200 doses 100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNatazol Nasal Drops 0.05%  \n\tIncepta\tRynex Nasal Drops 0.05mg 10ml 45\n\tKemiko\tG-Con Drops   10 ml drop 45\n\tNavana\tCongenil Nasal Drops .05 %  10 ml bot \n\tNIPRO JMI Pharma\tOxydrop Nasal Drops 0.05 %  \n\tOpsonin Pharma\tOxynex 0.5% Drops   10ml bot 45\n\tSquare\tNocon 0.05% Drops   10 ml bot x 6's pack 210.83\n\tSquare\tXylocon Drops .05% 10ml bot\n 270\n\tIndication: Sinusitis, Hay fever, Common cold, Acute or chronic rhinitis, Nasal congestion\n\nDose: Adults and children 6 yrs of age and older : 2-3 drops or sprays in each nostril twice daily for 3-5 days.\nChildren of age 2-6 : 2-3 drops in each nostril twice daily for 3-5 days. Sprays are generally unsuitable for young children because of the small size of their nostrils. The drug is not recommended in children under the age of 2.\n\nContra-indication: Contraindicated in patients hypersensitive to Oxymetazoine Hydrochloride.\n\nSide effects: * Transient burning, dryness of the nasal mucosa, sneezing.\n* Nervousness, dizziness, headache.\n* Hypertension, palpitation or reflex bradycardia.\n\nPrecaution: * Prolonged use may result in rebound congestion.\n* Since oxymetazoline has systemic adverse effects, it should be used with caution in patients with\n* hypertension, cardiovascular disease or hyperthyroidism or in those receiving MAO inhibitors.\n\nMode of action: Potentially Fatal: Hypertensive crisis with MAOIs.\n\nPregnancy category: C\n\nInteraction: Potentially Fatal: Hypertensive crisis with MAOIs.
Oxymorphone Hydrochloride	\n\n\tZiska\tO-morphon TAB dr 10 mg 20's pack 300\n\tZiska\tO-morphon Injection 1 mg/ml 5's pack 250\n\tIndication: Moderate to severe pain, Maintain anesthesia\n\nDose: Moderate-to-Severe Pain\nAcute pain\nImmediate-release tablets indicated for acute moderate-to-severe pain where opioid use is appropriate \nOpioid-naive patients (immediate-release): 10-20 mg PO 4-6hourly PRN initially, then titrated as warranted (may start with 5-mg increments).\n\nPreoperative Anesthesia/Analgesia\nAlso effective for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction\n1-1.5 mg IM/SC 4-6hourly PRN\nAnalgesia during labor: 0.5-1 mg IM\nIV: 0.5 mg, increased PRN\n\nElderly patients or those with renal or hepatic impairment: 5 mg PO q4-6hr initially.\n\n\nContra-indication:  Significant respiratory depression\nAcute or severe bronchial asthma or hypercarbia\nKnown or suspected paralytic ileus\nModerate and severe hepatic impairment \nHypersensitivity (e.g. anaphylaxis) to oxymorphone\n\nSide effects: The following serious adverse reactions are discussed elsewhere in the labeling:\n\n  -  Respiratory Depression \n   - Chronic Pulmonary Disease \n   - Head Injuries and Increased Intracranial Pressure \n    - Interactions with Other CNS Depressants \n    -Hypotensive Effect \n   -Gastrointestinal Effects \n   - Seizures \n\n\nPrecaution: Contains oxymorphone, an opioid agonist and a Schedule II controlled substance.  Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit.  Opioid agonists are sought by drug abusers and people with addiction disorders and are subject to criminal diversion.  Consider these risks when prescribing or dispensing   in situations where there is concern about increased risks of misuse, abuse, or diversion.  Concerns about abuse, addiction, and diversion should not, however, prevent the proper management of pain.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Oxyphencyclimine Hydrochloride	\n\n\tRenata\tRanicon TAB dr 5mg 100's pack \n\tIndication: Peptic ulcer disease,  smooth muscle spasms in gastrointestinal disorders, Familial hypophosphatemia\n\nDose: Adult: PO 10 mg 2 times/day.\n\nContra-indication: Closed-angle glaucoma; obstructive uropathy; GI obstruction, paralytic ileus, intestinal atony, ulcerative colitis; toxic megacolon; myasthenia gravis.\n\nSide effects: Xerostomia, decreased sweating, urinary hesitancy and retention, blurred vision, cycloplegia, increased ocular tension, loss of taste, headache, nervousness, mental confusion, impotence, suppression of lactation, urticaria, constipation.\n\nPrecaution: Elderly; autonomic neuropathy; hepatic or renal disease; hyperthyroidism, CHF, thyrotoxicosis, MI, tachyarrhythmias, hypertension, prostatic hypertrophy; hiatal hernia. May impair ability to drive or operate machinery. Pregnancy and lactation. Down's syndrome.\n\nMode of action: Enhanced effect with concurrent admin of other drugs with antimuscarinic properties and MAOIs. May affect absorption of other drugs. Antagonistic effect with parasympathomimetics.\n\nPregnancy category: Not Classified\n\nInteraction: Enhanced effect with concurrent admin of other drugs with antimuscarinic properties and MAOIs. May affect absorption of other drugs. Antagonistic effect with parasympathomimetics.
Oxyphenonium Bromide	\n\n\tAcme Ltd.\tA Spasm TAB dr 5mg 100's pack 143\n\tAmico Ltd.\tIsonil TAB dr 5mg 100's pack 141\n\tNovartis (Bangladesh) Ltd.\tAntrenyl TAB dr 5mg 100's pack 400\n\tOpsonin Pharma\tAntrenex TAB dr 5mg 100's pack 125\n\tIndication: Peptic ulcer, Gastrointestinal tract spasm, Visceral spasms\n\nDose: Adults: 1-2  tablets 3-4 times daily.\nChildren: 1/2-1 tablet 1-3 times daily.\n\nContra-indication: Intestinal obstruction, renal function impairment , appendicitis, chronic diarrhea, sensitivity to aluminium, magnesium and simethicone.\n\nSide effects: Constipation , diarrhea, intestinal pain.\n\nPrecaution: Should be caution , if allergic to any ingredient to  magaldrate and simethicone suspension, with a history of kidney problem or taking citrate salts ( found in some calcium supplements, antacids and laxative ) \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Oxyphenonium Bromide 1% Eye prep	\n\n\tOpso Saline Ltd.\tAntrenex 1% Eye Drops 10 mg/ml  \n\tIndication: Dilatation of pupil\n\nDose: 1-2 drops or as required.\n\n \n\nContra-indication: Patients with urinary obstruction, paralytic ileus and myasthenia gravis.\n\n   \n\n\nSide effects: Eye- Blurred vision and sensitivity to sunlight.\n\n\n \n\nPrecaution: Caution should be exercised in patients with history of high blood pressure, increased eye pressure, elderly, children, during pregnancy and breastfeeding.\n\n \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Oxytetracycline	\n\n\tACI\tImpetet CAP 250mg 100's pack \n\tAcme Ltd.\tOxecylin CAP 250mg 100's pack 110\n\tDesh\tOramycin CAP 250mg 60's pack 72\n\tDesh\tOramycin CAP 500 mg  100's pack 215\n\tDoctor's Chemicals Works Ltd.\tOxacin CAP 250mg 100's pack 115\n\tMedicon\tTeracin TAB dr 500mg 20's pack 46.20\n\tReliance\tOxytetracycline CAP 250mg 60's pack 90\n\tRenata\tRenamycin CAP 250mg 60's pack 73.80\n\tRenata\tRenamycin Injection 50 mg  10 ml vial 16.19\n\tSalton\tChemomycine CAP 250mg 100's pack 120\n\tIndication: Acne, Susceptible infections, Uncomplicated gonorrhoea, Gnathostomiasis, Superficial ophth infections\n\nDose: Adult: PO Susceptible infections 250-500 mg 4 times/day. Max: 4 g/day. Acne 250-500 mg twice daily. Uncomplicated gonorrhoea Initial: 1.5 g, then 0.5 g 4 times/day, up to a total of 9 g/treatment course. \n\nIM Susceptible infections 250 mg once daily.\n\nContra-indication: Hypersensitivity to tetracyclines, children <8 yr, renal damage. Pregnancy, lactation.\n\nSide effects: Anorexia, nausea, vomiting,diarrhoea, glossitis, dysphagia, photosensitivity, oesphageal irritation and ulceration, nephrotoxicity, enterocolitis, rash (rare), blood dyscrasias. Headache, visual disturbances; intracranial hypertension; bulging fontanelles (infants).\nPotentially Fatal: Rare. Fulminant diarrhoea in post operative patients.\n\nPrecaution: Elderly, renal or hepatic impairment; myasthenia gravis; lupus erythematosus, children <12 yr.\n\nMode of action: Antacids, iron, aluminum, calcium, magnesium, zinc salts reduce absorption. Concurrent use may cause increased levels of lithium, digoxin, halofantrine and theophylline; decreased concentrations of atovaquone. Increased risk of ergotism with ergot alkaloids. May cause failure of oral contraception.\nPotentially Fatal: Interferes with anticoagulant control. Nephrotoxic effects exacerbated by diuretics, methoxyflurane or other nephrotoxic drugs; avoid concurrent use with potentially hepatotoxic drugs. Increased incidence of benign intracranial hypertension with retinoids.\n\nPregnancy category: D\n\nInteraction: Antacids, iron, aluminum, calcium, magnesium, zinc salts reduce absorption. Concurrent use may cause increased levels of lithium, digoxin, halofantrine and theophylline; decreased concentrations of atovaquone. Increased risk of ergotism with ergot alkaloids. May cause failure of oral contraception.\nPotentially Fatal: Interferes with anticoagulant control. Nephrotoxic effects exacerbated by diuretics, methoxyflurane or other nephrotoxic drugs; avoid concurrent use with potentially hepatotoxic drugs. Increased incidence of benign intracranial hypertension with retinoids.
Oxytetracycline 0.5% + Polymixin B Sulphate E/E prep	\n\n\tRenata\tRenamycin Eye/Ear Ointment   3.5 gm tube 17.49\n\tIndication: Ocular infections, Aural infections, Trachoma\n\nDose: Adult & Child: As Eye ointment: Apply 2 hourly in acute infection.\nEar ointment: Small amount of ointment in the external auditory meatus 2-4 times daily.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Local irritation. Occular or Oto toxicity.\n\nPrecaution: Avoid prolonged use. Perforated ear drum.\n\nMode of action: Antacids, iron, aluminum, calcium, magnesium, zinc salts reduce absorption. Concurrent use may cause increased levels of lithium, digoxin, halofantrine and theophylline; decreased concentrations of atovaquone. Increased risk of ergotism with ergot alkaloids. May cause failure of oral contraception.\nPotentially Fatal: Interferes with anticoagulant control. Nephrotoxic effects exacerbated by diuretics, methoxyflurane or other nephrotoxic drugs; avoid concurrent use with potentially hepatotoxic drugs. Increased incidence of benign intracranial hypertension with retinoids.\n\nPregnancy category: A\n\nInteraction: Antacids, iron, aluminum, calcium, magnesium, zinc salts reduce absorption. Concurrent use may cause increased levels of lithium, digoxin, halofantrine and theophylline; decreased concentrations of atovaquone. Increased risk of ergotism with ergot alkaloids. May cause failure of oral contraception.\nPotentially Fatal: Interferes with anticoagulant control. Nephrotoxic effects exacerbated by diuretics, methoxyflurane or other nephrotoxic drugs; avoid concurrent use with potentially hepatotoxic drugs. Increased incidence of benign intracranial hypertension with retinoids.
Oxytetracycline 3% + Polymixin B Sulphate 0.013% Topical	\n\n\tPeoples Pharma Ltd.\tPetracin Ointment   5gm  tube 9.10\n\tPharmadesh Ltd.\tPolytetra Ointment 3% 5gm tube 25\n\tRenata\tRenamycin Ointment 3% 5gm tube 12.58\n\tIndication: Superficial skin infections\n\nDose: Adult & Child: Apply to the affected area on sterile gauze 2 or 3 times daily.\n\nContra-indication: Hypersensitivity. \n\nSide effects: Local skin irritation.\n\nPrecaution: Avoid prolonged use.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Oxytocin	\n\n\tChemist Ltd.\tPitocin Injection 5IU/ml 10 amps pack 160\n\tNovartis (Bangladesh) Ltd.\tSyntocinon Injection 5 IU/ml 5's pack \n\tNuvista Pharma Ltd\tLinda-S DS Injection 10 IU/ml 20 amp's pack 413.80\n\tOpsonin Pharma\tOcin Injection 5IU/ml 25 amps pack 232.02\n\tRenata\tOxyton Inj Injection 5IU/ml 10 amps pack 100\n\tTechno Drugs Ltd.\tSyntocin Injection 5IU/ml 10 amps pack 105\n\tIndication: Postpartum haemorrhage, Labour induction, Abortion, Facilitate lactation\n\nDose: Intravenous\nAdjunct in abortion\nAdult: 10-20 milliunits/minute. Max total dose: 30 units in a 12-hr period.\n\nPostpartum haemorrhage\nAdult: 10-40 units by infusion in 1000 mL of IV fluid at a rate sufficient to control uterine atony.\n\nLabour induction\nAdult: 1-2 milliunits/minute, may increase at intervals of at least 30 minutes until a max of 3-4 contractions occur every 10 minutes. Not to exceed 32 milliunits/minute and no more than a total of 5 units should be given in 1 day. Not to be given within 6 hr after admin of vaginal prostaglandins. Monitor uterine contractions and foetal heart rate continuously. Withdraw gradually once labour is progressing.\n\nOxytocin challenge test for evaluating of foetal distress\nAdult: Dilute 5-10 units in 1 L of 5% dextrose inj. Initially, administer the drug in the mother via IV infusion at a rate of 0.5 milliunits/minute. May gradually increase infusion rate at intervals of 15-30 minutes. Max: 20 milliunits/minute. Monitor foetal heart rate and uterine contractions immediately before and during infusion. Discontinue infusion when 3 moderate uterine contractions occur within one 10-minute interval. Compare baseline and oxytocin-induced foetal heart rates. If no change occurs, repeat the test in 1 wk. Termination of pregnancy may be required if a late deceleration in foetal heart rate occurs.\n\nContra-indication: Cephalopelvic disproportion; abnormal presentation of the foetus; hydraminios; multiparae; previous caesarian section or other uterine surgery; hyperactive or hypertonic uterus, uterine rupture; contraindicated vaginal delivery (invasive cervical cancer, active genital herpes, prolapse of the cord, cord presentation, total placenta previa or vasa previa); foetal distress where delivery is not imminent; severe pre-eclamptic toxaemia.\n\nSide effects: Foetus or neonate: Jaundice; arrhythmias, bradycardia; brain, CNS damage; seizure; retinal haemorrhage; low Apgar score. Mother: transient hypotension, reflex tachycardia; nasal irritation, rhinorrhoea, lachrymation (following nasal admin); uterine bleeding, violent contractions, hypertonicity; spasm; nausea, vomiting.\nPotentially Fatal: Maternal water intoxication (especially with slow infusion over 24 hr); prolonged uterine contractions causing foetal hypoxia and death; rupture of gravid uterus; afibrinogenaemia; subarachnoid haemorrhage\n\nPrecaution: CV disorders; >35 yr; lactation. Monitor foetal and maternal heart rate, maternal BP and uterine motility. Monitor fluid intake and output during treatment. Discontinute immediately if the uterus is hypertonic or hyperactive or if there is foetal distress. Use of nasal spray may produce maternal dependence on its effects. IM admin not regularly used due to unpredictable effects of oxytocin. Not to be used for prolonged periods in resistant uterine inertia, severe pre-eclampsia, or severe CV disorders. Risk of water intoxication when used at high doses for prolonged periods.\n\nMode of action: Possible severe hypertension if given within 3-4 hr of vasoconstrictor in association with a caudal block anaesthesia. Cyclopropane anaesthesia may increase risk of hypotension and maternal sinus bradycardia with abnormal AV rhythms. Dinoprostone and misoprostol may increase uterotonic effect of oxytocin, thus oxytocin should not be used within 6 hr after admin of vaginal prostaglandins. Concurrent use may increase the vasopressor effect of sympathomimetics.\n\nPotentially Fatal: Concomitant use with prostaglandins increases risk of uterine rupture and cervical lacerations.\n\nPregnancy category: X\n\nInteraction: Possible severe hypertension if given within 3-4 hr of vasoconstrictor in association with a caudal block anaesthesia. Cyclopropane anaesthesia may increase risk of hypotension and maternal sinus bradycardia with abnormal AV rhythms. Dinoprostone and misoprostol may increase uterotonic effect of oxytocin, thus oxytocin should not be used within 6 hr after admin of vaginal prostaglandins. Concurrent use may increase the vasopressor effect of sympathomimetics.\n\nPotentially Fatal: Concomitant use with prostaglandins increases risk of uterine rupture and cervical lacerations.
Paclitaxel	\n\n\tBeacon\tXelpac Injection 100mg/vial 1's pack 4500\n\tBeacon\tXelpac Injection 30mg/5ml 1's pack 1700\n\tBeacon\tXelpac Injection 300mg/50ml 1's pack 9900\n\tTechno Drugs Ltd.\tPaclitex Injection 30mg/5ml 1's pack 1700\n\tTechno Drugs Ltd.\tPaclitex Injection 300mg/50ml 1's pack 10000\n\tGosun Pharma Co. Ltd., China\tPXYJ Injection 30mg/ml 30 mg vial 3002.34\n\tGosun Pharma Co. Ltd., China\tPXJ-100 Injection 100mg 16.6ml vial 8359.20\n\tSandoz GmbH, Austria\tPaclitaxel SDZ Infusion 30mg/5ml 30mg/vial 	 1205\n\tIndication: Ovarian carcinoma, Breast cancer, Lung cancer, Kaposi's sarcoma \n\nDose: Adult: IV Ovarian carcinoma Primary treatment: 135 mg/m2, followed by cisplatin. Repeat 3 wkly. Secondary treatment: As single agent: 135 or 175 mg/m2 3 wkly. \n\nBreast cancer As adjunct therapy, 2nd line monotherapy or 1st line treatment w/ trastuzumab: 175 mg/m2 3 wkly for 4 courses. W/ trastuzumub, give dose one day after 1st dose of trastuzumab or immediately after subsequent doses if tolerated. 1st line treatment w/ doxorubicin: 220 mg/m2 3 wkly, give dose 24 hr after doxurubicin. \n\nAdvanced non-small cell lung cancer 135 mg/m2 over 24 hr, followed by cisplatin. Repeat 3 wkly. AIDS-related Kaposi's sarcoma 135 mg/m2 3 wkly.\n\nContra-indication: History of hypersensitivity (especially macrogol glycerol ricinolate). Patients with baseline neutropenia of <1500 cells/mm3 (<1000 cells/mm3 for kaposi's sarcoma). Pregnancy and lactation. In kaposi's sarcoma, contraindicated in patients with concurrent, serious, uncontrolled infections.\n\n\nSide effects: Neutropenia, leukopenia, thrombocytopenia, anaemia, bleeding; hypersensitivity reactions (dyspnoea, flushing, chest pain, tachycardia, rash, hypotension, hypertension); bradycardia, abnormal ECG; neurotoxicity (mainly peripheral neuropathy), myalgia, arthralgia; nausea, vomiting, diarrhoea; severe mucositis, alopecia; rarely hepatic necrosis and encephalopathy, inj site reactions e.g. erythema, tenderness, skin discolouration, swelling; interstitial pneumonitis; infections (mainly UTIs and upper respiratory tract); mucosal inflammation, severe elevation in LFTs (aspartate aminotransferase and alkaline phosphatase).\nPotentially Fatal: Infections and infestations leading to death e.g. pneumonia and peritonitis.\n\nPrecaution:  	Bone marrow suppression during therapy. Monitor cardiac function if conduction abnormalities result. Premedicaton (with corticosteroid, antihistamine and histamine H2-receptor antagonist) may be required to reduce risk of hypersensitivity reaction. Discontinue, if severe reactions e.g. hypotension, dyspnoea, angioedema or urticaria occur. Caution in patients with moderate hepatic impairment. Monitor for reactions of admin. Safety and efficacy in paediatric patients have not been established. Administer before platinum derivatives (cisplatin, carboplatin) if used in combination. Hazardous agent; use appropriate precautions for handling and disposal.\n\n\nMode of action: Myelosuppression was more profound when given after cisplatin than with the alternate sequence (e.g., paclitaxel before cisplatin). CYP2C8 inducers e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, rifapentine, and secobarbital may reduce levels or effects. CYP2C8 inhibitors e.g. gemfibrozil, ketoconazole, montelukast, and ritonavir may increase levels or effects. CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins may decrease the levels or effects. \n\nCYP3A4 inhibitors e.g. azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil may increase levels or effects. May increase anthracycline (eg doxorubicin, epirubicin) levels or toxicity; admin of anthracycline at least 24 hr prior to paclitaxel may reduce interaction. May decrease the absorption of cardiac glycosides (may only affect digoxin tablets); levels should be monitored.\n\nPregnancy category: D\n\nInteraction: Myelosuppression was more profound when given after cisplatin than with the alternate sequence (e.g., paclitaxel before cisplatin). CYP2C8 inducers e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, rifapentine, and secobarbital may reduce levels or effects. CYP2C8 inhibitors e.g. gemfibrozil, ketoconazole, montelukast, and ritonavir may increase levels or effects. CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins may decrease the levels or effects. \n\nCYP3A4 inhibitors e.g. azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil may increase levels or effects. May increase anthracycline (eg doxorubicin, epirubicin) levels or toxicity; admin of anthracycline at least 24 hr prior to paclitaxel may reduce interaction. May decrease the absorption of cardiac glycosides (may only affect digoxin tablets); levels should be monitored.
Palonosetron	\n\n\tBeacon\tPaloxi Injection .075mg/1.0ml 1's pack 75\n\tBeacon\tPaloxi TAB dr .5mg 20's pack 400\n\tBeacon\tPaloxi Injection .25mg/vial 5ml vial X 1's pack 100\n\tBeacon\tPaloxi CAP 500 mg  \n\tDrug International Ltd.\tPalnox Injection 0.075 mg/1.5 ml  \n\tDrug International Ltd.\tPalnox Injection 0.25 mg/vial  \n\tDrug International Ltd.\tPalnox TAB dr 0.5 mg  \n\tHealthcare\tPalzen Injection 0.075 mg/1.5 ml  \n\tHealthcare\tPalzen Injection 0.25 mg/vial  \n\tHealthcare\tPalzen TAB dr 0.5 mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tPalostat TAB dr 0.5mg  \n\tIncepta\tPaloxiron Injection .075mg/1.ml 5's pack 375\n\tIncepta\tPaloxiron Injection .25mg/vial 5's pack 500\n\tIncepta\tPaloxiron TAB dr .5mg 10's pack 200\n\tOpsonin Pharma\tPanoset Injection 0.25 mg 3's amps pack 263.90\n\tOpsonin Pharma\tPonoset TAB dr .5 mg 10's pack 200\n\tOpsonin Pharma\tPanoset 0.075 mg Injection .075 3 amps pack \n\tOpsonin Pharma\tPanoset 0.5 mg TAB dr .5mg 10's pack \n\tPharmasia Ltd.\tPalon TAB dr 0.5 mg  \n\tPharmasia Ltd.\tPalon IV/IM Injection 0.075 mg/1.5 ml  \n\tPharmasia Ltd.\tPalon IV/IM Injection 0.25 mg/vial  \n\tRAK\tPalorex TAB dr 0.5 mg  \n\tSquare\tPaloset Injection .5ml 2 amp's pack \n\tSquare\tPaloset Injection 2.5ml 5 amp's pack \n\tSquare\tPaloset TAB dr 0.5 mg  \n\tZiska\tPaloron TAB dr .5mg 20's pack 300\n\tZiska\tPaloron IV Injection .075mg/1.0ml 4's pack 300\n\tZiska\tPaloron IV Injection .25mg/vial 5ml vial X 4's pack 400\n\tIndication: Chemotherapy-induced nausea and vomiting, Postoperative nausea and vomiting\n\nDose: Adult: IV: Chemotherapy-induced nausea and vomiting 0.25 mg as a single dose 30 mins before chemotherapy. Do not repeat w/in 7 days. \n\nPrevention of post-op nausea and vomiting 0.075 mg as a single dose immediately before induction of anesth.\n\nPO: 0.5 mg tablet once daily. \n\nContra-indication: History of hypersensitivity.\n\nSide effects: Headache; flushing; fatigue, dizziness, drowsiness; hiccups; chest pain, tachycardia and bradycardia; diarrhoea, constipation, flatulence; dry mouth; urinary retention; dyspepsia, abdominal pain; changes in BP; asthenia; anxiety, euphoria, paraesthesia, peripheral neuropathy; anorexia; motion sickness; influenza-like symptoms; glycosuria, hyperglycaemia; electrolyte disturbance; arthralgia, eye irritation; amblyopia; tinnitus; rash, pruritus.\n\nPrecaution: Patients with intestinal obstruction or ileus. Rapid inj may lead to temporary visual changes e.g. blurred vision. Patients who have or may develop prolonged QT intervals. Safety and efficacy not established in children <18 yr. Counsel patients who handle skilled tasks e.g. driving may be impaired.\n\nMode of action: May have additive effect on prolonging QT with drugs e.g. moxifloxacin, erythromycin, antipsychotics and TCAs.\n\nPregnancy category: B\n\nInteraction: May have additive effect on prolonging QT with drugs e.g. moxifloxacin, erythromycin, antipsychotics and TCAs.
Pancreatin	\n\n\tAcme Ltd.\tA Zyme TAB dr 325mg 100's pack 173\n\tBeximco\tZymet TAB dr 325mg 100's pack 200\n\tOpsonin Pharma\tCrezyme TAB dr 325mg 100's pack 120\n\tSquare\tSuzyme TAB dr 325mg 100's pack 250\n\tIndication: Pancreatic insufficiency\n\nDose: Adult: PO 1-3 tablets daily with meal.\n\nContra-indication: Acute pancreatitis or acute exacerbation of chronic pancreatic disease.\n\nSide effects: GI effects e.g. abdominal discomfort, nausea and vomiting. Buccal and perianal irritation, particularly in infants. Colonic strictures may occur, mainly in children with cystic fibrosis receiving high doses of pancreatin preparations. Hyperuricaemia and hyperuricosuria may occur.\n\nPrecaution: Avoid high doses in patients with cystic fibrosis. Maintain adequate hydration. Some products contain pork protein. Inactivated by heat; do not mix with hot food or liquids. May irritate oral mucosa; should not be held in mouth. Pregnancy and lactation.\n\nMode of action: May impair the oral absorption of folic acid when taken together; antagonises hypoglycaemic effect of acarbose.\n\nPregnancy category: Not Classified\n\nInteraction: May impair the oral absorption of folic acid when taken together; antagonises hypoglycaemic effect of acarbose.
Pancuronium Bromide	\n\n\tTechno Drugs Ltd.\tPanalon Injection 4mg/2ml  2ml amp x 5's pack 275\n\tIndication: Adjunct to GA for Endotracheal intubation and to provide skeletal muscle ralaxation.\n\nDose: Intravenous\nFacilitate endotracheal intubation\nAdult: Initially, 50-100 mcg/kg. Maintenance: 10-20 mcg/kg. Can be administered undiluted by rapid IV inj.\nChild: Neonate:30-40 mcg/kg. Maintenance: 10-20 mcg/kg 4-6 hrly as necessary. 1 mth-18 yr: initially 60-100 mcg/kg, then 10-20 mcg/kg repeated as recquired.\n\nMuscle relaxant in general anaesthesia\nAdult: Initially, 50-100 mcg/kg. Maintenance: 10-20 mcg/kg. Can be administered undiluted by rapid IV inj.\nChild: Neonate:30-40 mcg/kg. Maintenance: 10-20 mcg/kg 4-6 hrly as necessary. 1 mth-18 yr: initially 60-100 mcg/kg, then 10-20 mcg/kg repeated as recquired.\n\nFacilitate mechanical ventilation in intensive care\nAdult: 60 mcg/kg every 60-90 min. May be administered undiliuted by rapid IV inj.\n\nRenal impairment:\nCrCl (ml/min)	\n10-50	50% dose\n<10 	avoid\n\nHepatic impairment: Hepatic impairment may result in a slower onset of action, higher initial dosage and longer neuromuscular blockade.\n\n\nContra-indication: Anuria. Relatively contraindicated in conditions of reduced airway control. Lactation.\n\nSide effects: Tachycardia may occur due to vagal blockade and especially during light anaesthesia. May decrease intra-ocular pressure and induce miosis; excessive salivation; transient rashes and itching; wheezing; elevation in pulse rate, BP, cardiac output; erythema; burning sensation along vein; profound muscle weakness; bronchospasm; hypersensitivity reaction; acute quadriplegic myopathy syndrome, myositis ossificans.\nPotentially Fatal: Rare anaphylactoid reactions; bradycardia, bronchospasm, hypotension and CV collapse; respiratory depression.\n\nPrecaution: Myasthenia gravis; severe electrolyte disorders; severe CV disease; pregnancy. Hepatic and renal function impairment. Hypothermia; jaundice; hypermagnesaemia, hypocalcaemia, hypokalaemia, hypoproteinaemia, acidosis, alkalosis, hypercalcemia. In obese patients, dose should be based on ideal body wt. Elderly; previous anaphylactic reactions to other neuromuscular-blocking agents. Burn patients (>30% of body) may be resistant to action for 5-70 days after injury. Demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and DM may antagonise the neuromuscular blockade effects of drug. Neuromuscular diseases, acute intermittent porphyria, Eaton-Lambert syndrome. Maintain adequate airway and respiratory support during use.\n\nMode of action: Neuroleptanalgaesia may decrease neuromuscular activity. Action may be prolonged and/or potentiated by aminoglycoside antibiotics, lithium, diazepam, lidocaine (high dose), quinidine, tetracyclines, propranolol, thiamine (high dose), parenteral magnesium sulphate, MAOIs, quinine, protamine, carbamazepine, donepezil and phenytoin (if pancuronium is given concurrently for <1 wk). Action may be decreased by neostigmine, edrophonium, high-dose or long term corticosteroids, adrenaline (may also potentiate effect), azathioprine, theophylline (high doses), clindamycin, nifedipine, piperacillin, polymixins, verapamil, procainamide. Furosemide may increase or decrease effects. TCAs may increase risk of arrhythmias and hypotension during anaesthesia.\n\nPotentially Fatal: Potentiated by volatile anaesthetics (isoflurane and enflurane) and local anaesthetics. Prior admin of suxamethonium can increase the intensity of neuromuscular block. Concomitant use with digoxin may increase risk of serious cardiac arrhythmias.\n\nPregnancy category: C\n\nInteraction: Neuroleptanalgaesia may decrease neuromuscular activity. Action may be prolonged and/or potentiated by aminoglycoside antibiotics, lithium, diazepam, lidocaine (high dose), quinidine, tetracyclines, propranolol, thiamine (high dose), parenteral magnesium sulphate, MAOIs, quinine, protamine, carbamazepine, donepezil and phenytoin (if pancuronium is given concurrently for <1 wk). Action may be decreased by neostigmine, edrophonium, high-dose or long term corticosteroids, adrenaline (may also potentiate effect), azathioprine, theophylline (high doses), clindamycin, nifedipine, piperacillin, polymixins, verapamil, procainamide. Furosemide may increase or decrease effects. TCAs may increase risk of arrhythmias and hypotension during anaesthesia.\n\nPotentially Fatal: Potentiated by volatile anaesthetics (isoflurane and enflurane) and local anaesthetics. Prior admin of suxamethonium can increase the intensity of neuromuscular block. Concomitant use with digoxin may increase risk of serious cardiac arrhythmias.
Pantoprazole Sodium Sesquihydrate	\n\n\tACI\tPantex TAB dr 40mg 30's pack 210.60\n\tACI\tPantex TAB dr 20mg 50's pack 251\n\tACI\tPantex IV Injection 40mg/vial 40mg amp X 1's pack 70.47\n\tACI\tPantex CAP 20mg 50's pack 200\n\tACI\tPantex CAP 40mg 40's pack 200.80\n\tACI\tPanz TAB dr 20mg 30's pack \n\tACI\tPanz TAB dr 40mg 30's pack \n\tAcme Ltd.\tProtocid TAB dr 20mg 50's pack 150\n\tAcme Ltd.\tProtocid TAB dr 40mg 30's pack 250\n\tAcme Ltd.\tProtocid IV Injection 40mg/vial 40mg amp X 1's pack 70.26\n\tAd-din\tNixpan TAB dr 20mg 30's pack/50's pack 90/150\n\tAexim\tPantaloc TAB dr 40mg 30's pack 105\n\tAlbion Ltd.\tPantoprazole TAB dr 40 mg/ 20 mg 50's pack \n\tAlco Pharma\tPantopra TAB dr 20mg 30's pack 90\n\tAlco Pharma\tPantopra TAB dr 40mg 30's pack 150\n\tAmico Ltd.\tPanzol TAB dr 20mg 30's pack 105\n\tAmico Ltd.\tPanzol TAB dr 40mg 30's pack 165\n\tApex\tPantrol TAB dr 40mg 30's pack 150\n\tApex\tPantrol TAB dr 20mg 50's pack 150\n\tApollo Pharmaceutical Ltd.\tProtopa TAB dr 20mg 30's pack 90\n\tAristopharma\tPronton-P IV Injection 40mg/vial 40mg amp X 1's pack 80\n\tAristopharma\tProton P TAB dr 20mg 50's pack 200\n\tAristopharma\tProton P TAB dr 40mg 50's pack 300\n\tAsiatic Ltd.\tP TAB dr 20mg 50's pack 200\n\tAsiatic Ltd.\tP TAB dr 40mg 50's pack 300\n\tAsiatic Ltd.\tP - 20 TAB dr 20mg  \n\tAsiatic Ltd.\tP - 40 TAB dr 40mg  \n\tAstra Biopharmaceuticals Ltd.\tPanoz TAB dr 20mg 30's pack 120\n\tBeacon\tProtoloc TAB dr 20mg 50's pack 150\n\tBeacon\tProtoloc TAB dr 40mg 50's pack 250\n\tBenham\tPantotop TAB dr 20mg  \n\tBenham\tPantotop TAB dr 40mg  \n\tBeximco\tPantobex TAB dr 20mg 100's pack 500\n\tBeximco\tPantobex TAB dr 40mg 100's pack 700\n\tBeximco\tPantobex IV Injection 40mg/vial 1's amps pack 110\n\tBio Pharma Ltd.\tPanpro TAB dr 20mg 50's pack 400\n\tBio Pharma Ltd.\tPanpro TAB dr 40mg 50's pack 300\n\tBio Pharma Ltd.\tPanpro Injection 40mg/vial 40mg amp X 1's pack 70\n\tBristol Pharma Ltd.\tPanton-AX TAB dr 20mg 50's pack 150\n\tCentral.\tPC TAB dr 20mg 50's pack 200\n\tCentral.\tPC-20 TAB dr 20mg  \n\tChemist Ltd.\tPantochem TAB dr 20mg 50's pack 150\n\tChemist Ltd.\tPantochem TAB dr 40mg 50's pack 250\n\tConcord\tPramax TAB dr 20mg 40's pack 120\n\tConcord\tPramax TAB dr 40mg 30's pack 180\n\tCosmo Pharma Ltd.\tCospra 20 TAB dr 20mg 50's pack 125\n\tDecent Pharma Ltd.\tAUP TAB dr 20mg 30's pack 90\n\tDecent Pharma Ltd.\tAUP TAB dr 40mg 30's pack 150\n\tDelta Pharma\tPelican TAB dr 20mg  \n\tDelta Pharma\tPelican TAB dr 40mg  \n\tDesh\tDetonix TAB dr 20mg 50's pack 200\n\tDoctor's Chemicals Works Ltd.\tPanprin TAB dr 20mg 50's pack 150\n\tDrug International Ltd.\tPansec TAB dr 20mg 100's pack 400\n\tDrug International Ltd.\tPansec TAB dr 40mg 100's pack 600\n\tDrug International Ltd.\tPansec Injection 40mg/vial 40mg amp X 1's pack 70\n\tEdruc Ltd.\tExopan TAB dr 20mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tPanoral TAB dr 20mg 40's pack 160\n\tEskayef Bangladesh Ltd.\tPanoral TAB dr 40mg 40's pack 240\n\tEthical Drug Ltd.\tGaspain TAB dr 20mg  \n\tEthical Drug Ltd.\tGaspain TAB dr 40mg  \n\tEuro Pharma Ltd.\tProtozin TAB dr 40mg 30's pack 90\n\tEuro Pharma Ltd.\tProtozin TAB dr 20mg 30's pack 150\n\tEverest\tPanzum TAB dr 20mg 50's pack 150\n\tEverest\tPanzum TAB dr 40mg 50's pack 250\n\tG. A. Company Ltd.\tPantozol TAB dr 20mg 20's pack 60\n\tG. A. Company Ltd.\tPantozol TAB dr 40mg 20's pack 100\n\tGeneral\tPantogen TAB dr 20mg 50's pack 150\n\tGeneral\tPantogen TAB dr 40mg 50's pack 251\n\tGlobe\tEuropan TAB dr 20mg 30's pack 90\n\tGlobe\tEuropan TAB dr 40mg 30's pack 150\n\tGlobe\tEuropan IV Injection 40mg/vial 40mg amp X 1's pack 70\n\tHealthcare\tPregel TAB dr 20mg 50's pack 200\n\tHealthcare\tPregel TAB dr 40mg 30's pack 180\n\tIbn Sina Pharmaceutical Ind. Ltd.\tPantolok TAB dr 20mg 100's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tPantolok TAB dr 40mg 50's pack 250\n\tIncepta\tPantonix 20 TAB dr 20mg 70's pack 350 	\n\tIncepta\tPantonix 40 TAB dr 40mg 70's pack 490 	\n\tIncepta\tPantonix 40 IV Injection 40mg 1's pack 90\n\tJayson\tTopra TAB dr 20mg 30's pack 90\n\tJayson\tTopra TAB dr 40mg 30's pack 150.60\n\tKemiko\tZopan TAB dr 20mg 50's pack 150\n\tKemiko\tZopan TAB dr 40mg 50's pack 250\n\tKumudini Pharma Ltd.\tPanloc TAB dr 20mg 50's pack 200\n\tKumudini Pharma Ltd.\tPanloc TAB dr 40mg 30's pack 180\n\tLeon\tExipro TAB dr 20mg  \n\tLeon\tExipro TAB dr 40mg  \n\tMedicon\tPamel TAB dr 20mg 50's pack 200\n\tMedicon\tPamel TAB dr 40mg 50's pack 250\n\tModern\tPz TAB dr 20mg 50's pack 200\n\tModern\tPz-40 TAB dr 40mg  \n\tNavana\tPantac TAB dr 20mg 60's pack 180\n\tNavana\tPantac TAB dr 40mg 30's pack 150\n\tNIPRO JMI Pharma\tPansos TAB dr 20mg 50's pack 150\n\tNIPRO JMI Pharma\tPansos TAB dr 40mg 50's pack 250\n\tNovus\tNovapan-20 TAB dr 20mg 30's pack 90\n\tOpsonin Pharma\tPantid Injection 40mg/vial 40mg amp X 1's pack 70\n\tOpsonin Pharma\tPantid TAB dr 20mg 100's pack 100\n\tOpsonin Pharma\tPantid TAB dr 40mg 50's pack 263\n\tOrganic Health Care\tPagerd TAB dr 20mg 50's pack 200\n\tOrganic Health Care\tPagerd TAB dr 40mg 50's pack 300\n\tOrion Pharma Ltd.\tTropaz TAB dr 40mg 50's pack \n\tPacific\tPanprazo TAB dr 20mg 50's pack 150\n\tPeoples Pharma Ltd.\tOtonix TAB dr 20mg 50's pack 150\n\tPeoples Pharma Ltd.\tOtonix TAB dr 40mg 50's pack 250\n\tPharmadesh Ltd.\tPretonix TAB dr 20mg 50's pack 150\n\tPharmadesh Ltd.\tPretonix TAB dr 40mg 30's pack 150.30\n\tPharmasia Ltd.\tPentosa TAB dr 20mg 30's pack 120\n\tPharmasia Ltd.\tPentosa TAB dr 40mg 30's pack 180\n\tPopular\tPantogut TAB dr 20mg 100's pack 400\n\tPopular\tPantogut TAB dr 40mg 50's pack 300\n\tPopular\tPantogut Injection 40mg/vial 40mg amp X 1's pack 70.26\n\tRadiant.\tPantium TAB dr 20mg 60's pack 420\n\tRadiant.\tPantium TAB dr 40mg 24's pack 240\n\tRenata\tProtonil TAB dr 20mg 50's pack 151\n\tRenata\tProtonil TAB dr 40mg 30's pack 150.30\n\tRephco\tPrazolin TAB dr 20mg 5x10's pack 200\n\tRephco\tPrazolin TAB dr 40mg 5x10's pack 300\n\tS. N.\tPantofast TAB dr 20mg 30's pack 90\n\tSeema\tPanto SP TAB dr 20mg 50's pack 150\n\tShamsul Al-Amin\tPropenta TAB dr 20mg 50's pack 150\n\tSilva\tPantosil TAB dr 20mg 50's pack 150.57\n\tSilva\tPantosil TAB dr 40mg 50's pack 250.94\n\tSomatec\tPanto TAB dr 20mg 50's pack 200\n\tSomatec\tPanto TAB dr 40mg 30's pack 150.60\n\tSquare\tTrupan TAB dr 20mg 60's pack 240\n\tSquare\tTrupan TAB dr 40mg 60's pack 360\n\tSquare\tTrupan Injection 40mg/vial 40mg amp X 1's pack 80\n\tSun Pharmaceutical (Bangladesh) Ltd.\tPanzer TAB dr 20mg 50's pack 150\n\tSun Pharmaceutical (Bangladesh) Ltd.\tPanzer TAB dr 40mg 50's pack 250\n\tSupreme\tNeopanta TAB dr 20mg 30's pack 120\n\tSupreme\tNeopanta TAB dr 40mg 50's pack 300\n\tTechno Drugs Ltd.\tPantosec Injection 40mg/vial 40mg amp X 1's pack 70\n\tUnimed & Unihealth Manufacturers Ltd.\tProtium TAB dr 40mg 28's pack 252\n\tUnimed & Unihealth Manufacturers Ltd.\tProtium 20 TAB dr 20mg 4x7's pack 240\n\tVeritas\tPantover TAB dr 20mg  \n\tVeritas\tPantover TAB dr 40mg  \n\tVeritas\tPantover Injection 40 mg/vial  \n\tZiska\tPantodac TAB dr 20mg 60's pack 240\n\tZiska\tPantodac TAB dr 40mg 30's pack 180\n\tMST Pharma and Healthcare Ltd.\tPansiv TAB dr 20mg  \n\tMST Pharma and Healthcare Ltd.\tPansiv TAB dr 40mg  \n\tIndication: Peptic ulcer disease, H. pylori infection, Gastro-oesophageal reflux disease, Zollinger-Ellison syndrome, Oesophagitis, Acid-related dyspepsia, NSAID-associated ulceration, ulcer resistant to H2 receptor antagonists, Gastrointestinal (GI) bleeding from stress, Prophylaxis for acid aspiration syndrome during induction of anaesthesia\n\nDose: Adult: PO The usual recommended adult oral dose is 40 mg given once daily, before breakfast. The duration of therapy is ranging from 2-8 weeks. \nPeptic ulcer: 40 mg/day in the morning. Duration: Duodenal ulceration: 2-4 wk; Benign gastric ulceration: 4-8 wk. \nGERD: 40 mg tablet, once daily in the morning for 4 to 8 weeks. In resistant ulcers: 40 mg tablet, once daily for 8 weeks. Ulcers induced by NSAIDs: 40 mg tablet once daily, in patients receiving continuous treatment with NSAIDs. \nGI bleeding from stress or acid peptic diseases: Usual adult oral dosage, if required the dosage may be increased. H. pylori infection: 40 mg twice daily w/ clarithromycin and either amoxicillin or metronidazole.\n Zollinger-Ellison syndrome: 160 mg tablets per day. Once control of acid secretion has been achieved, the dose should be gradually reduced. \nProphylaxis for acid aspiration syndrome during induction of anaesthesia: 40-80 mg tablet should be given the evening before surgery and repeated again the morning of surgery. \n\nIV Zollinger-Ellison syndrome and other hypersecretory states As Na salt: 80 mg/day. Max: 240 mg/day in divided doses if rapid control required. GERD; Peptic ulcer As Na salt: 40 mg/day until PO can be resumed. \n\nMaintenance therapy\nMaintenance treatment should involve the lowest dose of the drug. Both 20 and 40 mg doses of Pantoprazole are safe and effective in maintaining patients with healed reflux esophagitis and PUD in remission.\n\nElder patient: No problems with Pantoprazole have been encountered in clinical use in this patient group.\n\n\nContra-indication: Lactation. Delayed release tablets are contraindicated in patients with known hypersensitivity to any of the formulation.\n\nSide effects: Diarrhoea, dizziness, pruritus, skin rashes, GI tract infections, chest pain, headache, nausea, pain, anxiety, hyperglycaemia; malaise or lassitude; myalgia; oedema; insomnia; hyperlipidaemia; flatulence, abdominal pain, constipation, eructation, dyspepsia, rectal disorder; urinary frequency, UTI; abnormalities in liver function; local site reaction; hypertonia, neck pain, weakness; bronchitis, cough, dyspnoea, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, flu syndrome.\n\nPrecaution:  Long-term therapy may lead to bacterial overgrowth in the GI tract. Hepatic impairment; monitor liver function regularly (if enzymes increase, discontinue); pregnancy; not recommended in children <18 yr; long term use may lead to atrophic gastritis. Patients should be cautioned that Pantonix delayed release tablets should not be split, chewed or crushed.\n\nMode of action: Ketoconazole; phenprocoumon, warfarin; atazanavir. Concomitant use of proton pump inhibitors w/ methotrexate may elevate & prolong serum levels of methotrexate &/or its metabolite, possibly leading to methotrexate toxicities.\n\nPregnancy category: B\n\nInteraction: Ketoconazole; phenprocoumon, warfarin; atazanavir. Concomitant use of proton pump inhibitors w/ methotrexate may elevate & prolong serum levels of methotrexate &/or its metabolite, possibly leading to methotrexate toxicities.
Paracetamol	\n\n\tACI\tXcel Suspension 120mg/5ml 60ml bot 20.70\n\tACI\tXcel Syrup 120mg/5ml 60ml bot/100ml bot 20.70/31.87\n\tACI\tXcel TAB dr 500mg 500's pack 400\n\tACI\tXcel Paediatric Drops 80mg/ml 15 ml bot 12.35\n\tACI\tXcel Suppository 125mg 60ml 20\n\tACI\tXcel DISPERSABLE TAB dr 120mg 100's pack 128\n\tACI\tXcel ER TAB dr 665mg 120's pack 180\n\tAcme Ltd.\tFast Suspension 120mg/5ml 60ml bot 20.30\n\tAcme Ltd.\tFast TAB dr 500mg 500's pack 400\n\tAcme Ltd.\tFast Paediatric Drops 80mg/ml 15ml 12.27\n\tAcme Ltd.\tFast Suppository 125mg 10's pack 40.10\n\tAcme Ltd.\tFast Suppository 250mg 10's pack 50.10\n\tAcme Ltd.\tFast Suppository 500mg 10's pack 80.40\n\tAcme Ltd.\tFast XR TAB dr 665mg 100's pack 150\n\tAcme Ltd.\tFast Pad Suspension 80mg/ml 1's pack(15ml) 12.27\n\tAd-din\tFeva Suspension 120mg/5ml 60ml bot 18\n\tAd-din\tFeva TAB dr 500mg 200's pack 150\n\tAd-din\tFeva Paediatric Drops 80 mg/ml  \n\tAexim\tArchi Suspension 120mg/5ml 60ml bot 18\n\tAexim\tArchi TAB dr 500mg 200's pack 100\n\tAlbion Ltd.\tParacetamol TAB dr 500  250's pack \n\tAlbion Ltd.\tParacetamol Suspension 120 mg/5 ml 50 ml/ 100 ml \n\tAlbion Ltd.\tParacetamol Paediatric Drops 80 mg 15 ml \n\tAlbion Ltd.\tParacetamol Forte TAB dr 665 mg 100's pack \n\tAlco Pharma\tTempil Suspension 120mg 100ml bot 24.53\n\tAlco Pharma\tTempil TAB dr 500mg 200's pack /500's pack 160 / 400\n\tAlkad\tAlkaparol Suspension 120 mg/5 ml  \n\tAmbee\tAct Suspension 120mg/5ml 60ml bot 16.34\n\tAmbee\tAct TAB dr 500mg 250's pack 200\n\tAmbee\tAct Paediatric Drops 80mg/ml 15 ml bot 12.31\n\tAmbee\tAct Plus TAB dr 500mg  100's pack 151\n\tAmico Ltd.\tPara Suspension 120mg/5ml 60ml bot 16\n\tAmico Ltd.\tPara TAB dr 500mg 200's pack 160\n\tAmico Ltd.\tPara Paediatric Drops 80mg/ml 15 ml bot 12\n\tAmulet\tTempanil TAB dr 500mg 250's pack 200\n\tApex\tTamol Suspension 120mg/5ml 60ml bot 16.34\n\tApex\tTamol TAB dr 500mg 200's pack 160\n\tApollo Pharmaceutical Ltd.\tPromel Suspension 120mg/5ml 60ml bot 16\n\tAristopharma\tXpa Suspension 120mg/5ml 60ml bot/ 100ml bot 20.60 / 24.60\n\tAristopharma\tXpa TAB dr 500mg 250's pack 200\n\tAristopharma\tXpa Paediatric Drops 80mg/ml 15 ml bot 12.30\n\tAristopharma\tXpa Suppository 125mg 10''s pack 50\n\tAristopharma\tXpa Suppository 250mg 20's pack 120\n\tAristopharma\tXpa Suppository 500mg 20's pack 180\n\tAristopharma\tXpa XR TAB dr 665mg 100's pack 150\n\tAsiatic Ltd.\tTempol Suspension 120mg/5ml 100ml bot 16.34\n\tAsiatic Ltd.\tTempol Paediatric Drops 80mg/ml 15ml bot/30ml bot 12.31 / 15.73\n\tAsiatic Ltd.\tTempol TAB dr 500mg  \n\tBeacon\tFap TAB dr 500mg 200's pack 120\n\tBelsen\tOrpa TAB dr 500mg 100's pack 50\n\tBengal Drugs & Chemical Works Pharm. Ltd.\tBepol Suspension 120mg/5ml 60ml bot 18\n\tBeximco\tNapa Suspension 120mg/5ml  50ml bot/ 60ml bot 18.23 / 20.63\n\tBeximco\tNapa Syrup 120mg/5ml 50ml bot/60ml bot/100ml bot 18.24 / 20.63 / 31.77\n\tBeximco\tNapa TAB dr 500mg 500's pack 400\n\tBeximco\tNapa Paediatric Drops 80mg/ml 15 ml bot 12.30\n\tBeximco\tNapa Suppository 125mg 20's pack 80\n\tBeximco\tNapa Suppository 250mg 20's pack 100\n\tBeximco\tNapa Suppository 500mg 20's pack 160\n\tBeximco\tNapa Suppository 60mg 20's pack 70\n\tBeximco\tNapa DT TAB dr 500mg 200's pack 256\n\tBeximco\tNapa Extend TAB dr 665mg 120's pack 180\n\tBeximco\tNapa IV IV Infusion 1000mg 100ml bot 120\n\tBio Pharma Ltd.\tAceta Suspension 120mg/5ml 60ml bot 16.34\n\tBio Pharma Ltd.\tAceta Paediatric Drops 80mg/ml 15 ml bot 12.30\n\tBio Pharma Ltd.\tAceta TAB dr 500mg 200's pack 160\n\tBio Pharma Ltd.\tAceta Extend TAB dr 665mg  \n\tBristol Pharma Ltd.\tNeopara TAB dr 500mg 100's pack 50\n\tCentral.\tCentamol Suspension 120mg/5ml 60ml bot 16\n\tCentral.\tCentamol TAB dr 500mg 200's pack 160\n\tCosmic Chemical Industries Ltd.\tNova Suspension 120mg/5ml 60ml bot 20\n\tCosmic Chemical Industries Ltd.\tNova TAB dr 500mg 200's pack 160\n\tCosmo Pharma Ltd.\tCpmol TAB dr 500mg 250's pack 150\n\tDecent Pharma Ltd.\tD Cetamol Suspension 120mg/5ml 60ml bot 16\n\tDecent Pharma Ltd.\tD Cetamol TAB dr 500mg 250's pack 200\n\tDelta Pharma\tDepyrin Suspension 120mg/5ml 60ml bot 16.35\n\tDelta Pharma\tDepyrin TAB dr 500mg 200's pack 160\n\tDesh\tDepol Suspension 120mg/5ml 60ml bot 16\n\tDesh\tDepol TAB dr 500mg 400's pack 240\n\tDoctor's Chemicals Works Ltd.\tCetadol Suspension 120mg/5ml 60ml bot 16.28\n\tDoctor's Chemicals Works Ltd.\tCetadol TAB dr 500mg 200's pack 100\n\tEdruc Ltd.\tTydenol Suspension 120mg/5ml 60ml bot 21\n\tEdruc Ltd.\tTydenol TAB dr 500mg 200's pack 160\n\tEskayef Bangladesh Ltd.\tTamen Suspension 120mg/5ml 60ml bot 16.28\n\tEskayef Bangladesh Ltd.\tTamen Syrup 120mg/5ml 60ml bot / 100ml bot 20.56 / 31.66\n\tEskayef Bangladesh Ltd.\tTamen TAB dr 500mg 200's pack/400's pack 160/400\n\tEskayef Bangladesh Ltd.\tTamen Paediatric Drops 80mg/ml 15 ml bot 12.26\n\tEskayef Bangladesh Ltd.\tTamen Suppository 250mg  \n\tEskayef Bangladesh Ltd.\tTamen Suppository 500mg  \n\tEskayef Bangladesh Ltd.\tTamen DT TAB dr 120mg  \n\tEskayef Bangladesh Ltd.\tTamen XR Xr TAB dr 665mg  \n\tEuro Pharma Ltd.\tEnyl Suspension 120mg/5ml 60ml bot 20\n\tEuro Pharma Ltd.\tEnyl TAB dr 500mg 500's pack 400\n\tEverest\tPam Suspension 120mg/5ml 60ml bot 16\n\tG. A. Company Ltd.\tTimidal Suspension 120mg/5ml 60ml bot 20\n\tG. A. Company Ltd.\tTimidal TAB dr 500mg 250's pack 200\n\tGeneral\tATP Suspension 120mg/5ml 60ml bot 20.63\n\tGeneral\tATP TAB dr 500mg 250's pack 200\n\tGlaxoSmithKline Bangladesh Ltd.\tParapyrol Suspension 120mg/5ml 100ml bot 30\n\tGlaxoSmithKline Bangladesh Ltd.\tParapyrol TAB dr 500mg 500's pack 360.56\n\tGlobe\tPol TAB dr 500mg 200's pack 130\n\tGlobe\tPol Suspension 120mg/5ml 60ml bot 20.56\n\tGonoshasthaya\tG Paracetamol Syrup 120mg/5ml 50ml bot / 60ml bot / 100ml bot 15 / 16 / 27\n\tGonoshasthaya\tG Paracetamol TAB dr 500mg 100's pack/1000's pack 60 / 380\n\tHallmark\tTempac Suspension 120mg/5ml 60ml bot 20\n\tHallmark\tTempac TAB dr 500mg 200's pack 160\n\tHudson\tHepa Suspension 120mg/5ml 60ml bot 16.28\n\tHudson\tHepa TAB dr 500mg 500's pack 275\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLongpara TAB dr 665mg 120's pack 181.20\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinapol Suspension 120mg/5ml 60ml bot 20\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinapol TAB dr 500mg 250's pack 200\n\tIncepta\tReset Suspension 120mg/5ml 60ml bot 20.64\n\tIncepta\tReset Syrup 120mg/5ml 15ml 20\n\tIncepta\tReset TAB dr 500mg 200's pack 160\n\tIncepta\tReset Paediatric Drops 80mg/ml 15 ml bot 12.30\n\tIncepta\tReset IV Infusion 1gm  100 ml bot \n\tIndobangla Pharmaceuticals\tParacetamol Suspension 120mg 60ml bot 16\n\tJayson\tZerin Suspension 120mg/5ml 60ml bot 20\n\tJayson\tZerin TAB dr 500mg 500's pack 400\n\tJayson\tZerin Paediatric Drops 80mg/ml 15 ml bot 12.30\n\tKemiko\tAtopen Suspension 120mg/5ml 60ml bot / 100ml bot 20.63 / 24.62\n\tKemiko\tAtopen TAB dr 500mg 200's pack/400's pack 160 / 320\n\tKumudini Pharma Ltd.\tPainil TAB dr 500mg 500's pack 325\n\tKumudini Pharma Ltd.\tPainil Suspension 120mg 60ml bot 16.34\n\tMarksman.\tPrefer Suspension 120mg/5ml 60ml bot 12\n\tMarksman.\tPrefer TAB dr 500mg 300's pack 165\n\tMedicon\tTandamol Suspension 120mg/5ml 60ml bot 20\n\tMedicon\tTandamol TAB dr 500mg 300's pack 225\n\tMedimet\tPyrac Suspension 120mg/5ml 50ml bot / 60ml bot 18.25 / 20\n\tMedimet\tPyrac TAB dr 500mg 200's pack / 500's pack 160 / 400\n\tMillat\tDola Suspension 120mg/5ml 60ml bot 20\n\tMillat\tDola TAB dr 500mg 200's pack 160\n\tModern\tM-Pol Suspension 120mg/5ml 60ml bot 20\n\tModern\tM-Pol TAB dr 500mg 200's pack 160\n\tMystic\t2 A Suspension 120mg/5ml 60ml bot 16.28\n\tNavana\tFea Suspension 120mg/5ml 60ml bot 20\n\tNavana\tFea TAB dr 500mg 200's pack 160\n\tNavana\tFEA XR TAB dr 665mg 100's pack 150\n\tNipa\tNipa Suspension 120mg/5ml 60ml bot 12.66\n\tNipa\tNipa TAB dr 500mg 100's pack 65\n\tNipa\tNipa Paediatric Drops 80mg/ml 15 ml bot 10.87\n\tNIPRO JMI Pharma\tTamino Suspension 120mg/5ml 60ml bot 20.63\n\tNIPRO JMI Pharma\tTamino TAB dr 500mg 200's pack 160\n\tNIPRO JMI Pharma\tTamino ER TAB dr 665mg 100's pack 150\n\tNovartis (Bangladesh) Ltd.\tServigesic TAB dr 500mg 500's pack 400\n\tOpsonin Pharma\tRenova Suspension 120mg/5ml 60ml bot / 100ml bot 18.16 / 21.58\n\tOpsonin Pharma\tRenova Syrup 120mg/5ml 60ml bot /100ml bot 18.16 / 27.80\n\tOpsonin Pharma\tRenova TAB dr 500mg 250's pack 175.94\n\tOpsonin Pharma\tRenova Paediatric Drops 80mg/ml 15 ml bot 10.87\n\tOpsonin Pharma\tRenova Suppository 125mg 10's pack 35.35\n\tOpsonin Pharma\tRenova Suppository 250mg 10's pack 44.16\n\tOpsonin Pharma\tRenova Suppository 500mg 10's pack 70.64\n\tOpsonin Pharma\tRenova Suppository 60mg 10's pack 30.88\n\tOpsonin Pharma\tRenova XR TAB dr 665mg 100's pack 131.65\n\tOrion Pharma Ltd.\tFevac Suspension 120mg/5ml 60ml bot 20\n\tOrion Pharma Ltd.\tFevac TAB dr 500mg 250's pack \n\tOyster\tParet TAB dr 500mg 250's pack 200\n\tPacific\tCetam Suspension 120mg/5ml 60ml bot 20\n\tPacific\tCetam TAB dr 500mg 500's pack 300\n\tPeoples Pharma Ltd.\tPyramol TAB dr 500mg 250's pack 100\n\tPharmadesh Ltd.\tAnalpain Suspension 120mg/5ml 60ml bot 20.63\n\tPharmadesh Ltd.\tAnalpain Paediatric Drops 80mg/ml 15ml bot 12.25\n\tPharmadesh Ltd.\tAnalpain TAB dr 500mg 500's pack 375\n\tPharmasia Ltd.\tParaxia Suspension 120mg/5ml 60ml bot 20.50\n\tPharmasia Ltd.\tParaxia TAB dr 500mg 200's pack 160\n\tPharmik Ltd.\tAnapol Suspension 120 mg/5 ml  \n\tPharmik Ltd.\tAnapol TAB dr 500 mg  \n\tRAK\tTylen Suspension 120mg/5ml 60ml bot 20.63\n\tRAK\tTylen TAB dr 500mg 200's pack 160\n\tReliance\tAceto TAB dr 500mg 100's pack 79\n\tReliance\tAcetophane Suspension 120mg/5ml 60ml bot 13.25\n\tReman Drug Ltd.\tRemalgin Suspension 120mg/5ml 60ml bot 20\n\tReman Drug Ltd.\tRemalgin TAB dr 500mg 250's pack 200\n\tRenata\tPyralgin Suspension 120mg/5ml 60ml bot 20.64\n\tRenata\tPyralgin TAB dr 500mg 500's pack 400\n\tRephco\tAsta Suspension 120mg/5ml 60ml bot 18\n\tRephco\tAsta TAB dr 500mg 250's pack 200\n\tSalton\tTynol TAB dr 500mg 500's pack 325\n\tSalton\tTynol Suspension 120mg  60ml bot 16.35\n\tSeema\tParamol Suspension 120mg/5ml 60ml bot 20.90\n\tShamsul Al-Amin\tParacetamol TAB dr 500mg 200's pack/500's pack 160/300\n\tSharif\tAsmol Suspension 120mg/5ml 60ml bot 21\n\tSharif\tAsmol TAB dr 500mg 100's pack 80\n\tSilco Pharmaceuticlas Ltd.\tSilpol Suspension 120 mg/5 ml  \n\tSilco Pharmaceuticlas Ltd.\tSilpol TAB dr 500mg  \n\tSilva\tSilpa Suspension 120mg/5ml 60ml bot 16.35\n\tSilva\tSilpa TAB dr 500mg 250's pack 150.56\n\tSilva\tPreduet TAB dr 500mg 250's pack 200\n\tSilva\tPreduet Suspension 120mg 60ml bot 16.35\n\tSomatec\tActol Suspension 120mg/5ml 60ml bot 20.63\n\tSomatec\tActol TAB dr 500mg 200's pack 160\n\tSonear Ltd.\tSeridol TAB dr 500mg 100's pack 80\n\tSquare\tAce Suspension 120mg/5ml 60ml bot 16.35\n\tSquare\tAce Syrup 120mg/5ml 60ml bot/100ml bot 20.64 / 31.78\n\tSquare\tAce TAB dr 500mg 500's pack 400\n\tSquare\tAce Paediatric Drops 80mg/ml 15 ml bot/30ml bot 12.31 / 15.73\n\tSquare\tAce Suppository 125mg 20's pack 80.33\n\tSquare\tAce Suppository 250mg 20's pack 100.28\n\tSquare\tAce Suppository 500mg 20's pack 160.67\n\tSquare\tAce Suppository 60mg 10's pack 35.11\n\tSquare\tACE XR TAB dr 665mg 100's pack 150\n\tSupreme\tCetal Suspension 120mg/5ml 60ml bot 20.63\n\tSupreme\tCetal TAB dr 500mg 240's pack 192\n\tSyntho Ltd.\tFibi Suspension 120mg/5ml 60ml bot 12.10\n\tSyntho Ltd.\tFibi TAB dr 500mg 200's pack 160\n\tZenith\tAcep Suspension 120mg/5ml 60ml bot 16 \n\tZenith\tAcep TAB dr 500mg 200's pack 160\n\tZenith\tAcep Paediatric Drops 80mg/ml 15 ml bot 10.91\n\tZiska\tParafen Suspension 120mg 60ml bot 16.28\n\tIndication: Mild to moderate pain and fever\n\nDose: Tablet\nAdult: 1 - 2 tablets every 4 to 6 hours up to a maximum of 4 g (8 tablets) daily\nChildren (6 - 12 years) : 1/2 to 1 tablet 3 to 4 times daily\n\nSyrup\nChildren: 2 months: 60 mg (1/2 measuring spoonful) for post immunization pyrexia;\nUnder 3 months (on doctor's advice only) : 10 mg/kg (5 mg/kg if jaundiced)\n3 months - 1 year : 60 - 120 mg (1/2 - 1 measuring spoonful),\n1 - 5 years : 1 - 2 measuring spoonful\n6 - 12 years : 2 - 4 measuring spoonful\n\nPaediatric Drops\nChildren Up to 3 months: 0.5 ml (40 mg) \n4 to 11 months:  1.0 ml (80 mg) \n1 to 2 years: 1.5 ml (120 mg) \n2 to 3 years: 2 ml (160mg)\n4 to 5 years: 3 ml (240 mg)\nDose can be repeated, every 4 hours.\n\nFor Suppository: Suppository should be administered rectally.\nChildren: 3 months-1 year: 60-125 mg\n1-5 years: 125-250 mg\n5-12 years: 250-500 mg\nThese doses may be repeated every 4-6 hours as necessary (maximum 4 doses in 24 hours).\nAdults & children over 12 years: 500 mg-1 g every 4-6 hours to a maximum of 4 g daily.\n\nContra-indication: Hypersensitivity. \n\nSide effects: Nausea, allergic reactions, skin rashes, acute renal tubular necrosis.\nPotentially Fatal: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage.\n\nPrecaution: Renal or hepatic impairment; alcohol-dependent patients; G6PD deficiency.\n\nMode of action: May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.\n\nPregnancy category: B\n\nInteraction: May reduce serum levels w/ anticonvulsants (e.g. phenytoin, barbiturates, carbamazepine). May enhance the anticoagulant effect of warfarin and other coumarins w/ prolonged use. Accelerated absorption w/ metoclopramide and domperidone. May increase serum levels w/ probenecid. May increase serum levels of chloramphenicol. May reduce absorption w/ colestyramine w/in 1 hr of admin. May cause severe hypothermia w/ phenothiazine.
Paracetamol + Tramadol Hydrochloride	\n\n\tACI\tXcel Max TAB dr  325mg+37.5mg 30's pack 240.60\n\tAcme Ltd.\tFastdol TAB dr   30's pack 240\n\tBeacon\tFapdol TAB dr 325 mg + 37.5 mg  \n\tBeximco\tNapadol TAB dr  325 mg + 37.5 mg  30's pack 240\n\tBio Pharma Ltd.\tAceta-T TAB dr 325 mg + 37.5 mg  \n\tDelta Pharma\tPyredol TAB dr  30's pack 240\n\tEskayef Bangladesh Ltd.\tTamenol TAB dr   20's pack 160\n\tGeneral\tTramp TAB dr   50's pack 300\n\tHealthcare\tSyndol Plus TAB dr   30's pack 240\n\tIncepta\tResadol TAB dr   30's pack 240\n\tKemiko\tAtopen-X TAB dr   20's pack 160\n\tMundipharma (Bangladesh) Pvt. Ltd.\tTrd-P TAB dr  100's pack \n\tNavana\tAlkafen TAB dr   20's pack 180\n\tNovartis (Bangladesh) Ltd.\tDoloran Plus TAB dr   \n\tNovelta Bestway\tNorDol TAB dr   30's pack 240\n\tOpsonin Pharma\tTracet TAB dr   30's pack 211.13\n\tOrion Pharma Ltd.\tNovodol TAB dr   50's pack 400\n\tRenata\tSinergix TAB dr   30's pack 240\n\tSquare\tAcetram TAB dr  325 mg + 37.5 mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tUtracet TAB dr   50's pack 240\n\tIndication: Moderate to severe pain\n\nDose: Adult: PO >12 yr: Per tab contains tramadol HCl 37.5 mg and paracetamol 325 mg: 2 tab 6 hrly. Max: 8 tab/day.\n\nRenal impairment:\nCrCl (ml/min)	\n10-30	Increase dosing interva to 12 hr.ly\n<10	        Not recommended.\n\nContra-indication: Hypersensitivity to tramadol, paracetamol or opioids. Situations where opioid use may be contra-indicated (e.g. acute intoxication with alcohol, hypnotic drugs, centrally-acting analgesics, opioids or psychotropic drugs). Severe hepatic impairment, uncontrolled epilepsy. Concurrent use or within 2 wk of discontinuation from MAOIs.\n\nSide effects: Nausea, vomiting, constipation, diarrhoea, abdominal pain, dry mouth, dyspepsia, flatulence, dizziness, somnolence, headache, confusion, mood changes, nightmares, amnesia, sweating, pruritus.\nPotentially Fatal: Severe anaphylactic reactions.\n\nPrecaution: Not recommended in severe renal impairment (CrCl <10 ml/min), severe respiratory insufficiency, liver disease or opioid dependent patients. Increased intracranial pressure or head injury, patients at risk of seizures or on drugs that may lower the seizure threshold (e.g. SSRI, TCA, antipsychotics, centrally acting analgesics or local anaesthesia), biliary tract disorders, in a state of shock or unconsciousness. May impair ability to drive or operate machinery. Avoid abrupt withdrawal. May cause withdrawal symptoms, dependence and abuse. Elderly. Pregnancy, lactation.\n\nMode of action: Concomitant use is contraindicated w/ non-selective MAOIs, selective-A & B MAOIs; not recommend w/ alcohol, carbamazepine & other enzyme inducers, opioid agonists-antagonists; needs consideration w/ selective serotonin re-uptake inhibitors, triptans, other opioid derivatives & anxiolytics, barbiturates, benzodiazepines, hypnotics, sedative antidepressants & antihistamines, neuroleptics, centrally-acting antihypertensives, TCAs, thalidomide, baclofen, warfarin-like compd, ketoconazole, erythromycin, bupropion, ondansetron.\n\nPregnancy category: C\n\nInteraction: Concomitant use is contraindicated w/ non-selective MAOIs, selective-A & B MAOIs; not recommend w/ alcohol, carbamazepine & other enzyme inducers, opioid agonists-antagonists; needs consideration w/ selective serotonin re-uptake inhibitors, triptans, other opioid derivatives & anxiolytics, barbiturates, benzodiazepines, hypnotics, sedative antidepressants & antihistamines, neuroleptics, centrally-acting antihypertensives, TCAs, thalidomide, baclofen, warfarin-like compd, ketoconazole, erythromycin, bupropion, ondansetron.
Paracetamol 1%	\n\n\tEskayef Bangladesh Ltd.\tTamen IV Infusion  10mg/ml 100ml bot 120\n\tOpsonin Pharma\tRenova IV Infusion  10mg/ml 1x1's pack 120\n\tIndication: Mild to moderate pain and high fever\n\nDose: Intravenous route:\nParacetamol solution for infusion should not be mixed with other medicinal products.\nAdult >50 kg: 1g/100ml, up to 4 times a day.\nAdult 33 to 50 kg: 15 mg/kg body wt, up to 4 times a day\nNeonates, Infants and Children: up to 33 kg: 15 mg/kg body wt, up to 4 times a day.\nNeonates, Infants and Children: Less than 10 kg: 7.5 mg/kg body wt, up to 4 times a day.\n\nThe minimum interval between each administration must be 4 hours in patients without hepatic or renal impairment. In patients with renal and/or hepatic impairment the minimum interval between doses must not be less than 6 hours. \n\nContra-indication: Paracetamol is contraindicated in patients with severe renal function impairment and hepatic disease (Viral Hepatitis). Known hypersensitivity to paracetamol.\n\nSide effects: Side effects of paracetamol are usually mild, though haematological reactions including thrombocytopenia, leukopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.\n\nPrecaution: Paracetamol should be given with care to patients with impaired kidney or liver function. Paracetamol should be given with care to patients taking other drugs that affect the liver.\n\nMode of action: Hepatotoxic drugs, liver microsomal enzyme inducers. Metoclopramide. Probenecid. Colestyramine (w/in 1 hr of paracetamol administration).\n\nPregnancy category: B\n\nInteraction: Hepatotoxic drugs, liver microsomal enzyme inducers. Metoclopramide. Probenecid. Colestyramine (w/in 1 hr of paracetamol administration).
Paricalcitol	\n\n\tBeacon\tParicon 1 CAP 1mcg 10's pack 450\n\tIndication: Secondary hyperparathyroidism\n\nDose: Prevention & Treatment of Secondary Hyperparathyroidism\n\nAssociated with Chronic Kidney Disease (Stage 5)\n\n    Initial 0.04-0.1 mcg/kg IV (no more frequent than every other day) \n    Titrate up or down by 2-4 mcg q2-4Weeks\n    Up to 0.24 mcg/kg PO have been administered\n\nAssociated with Chronic Kidney Disease (Stage 3 & 4)\n\n    PTH <500 pg/mL: 1 mcg PO qDay OR 2 mcg PO 3 times/week\n    PTH >500 pg/mL: 2 mcg PO qDay OR 4 mcg PO 3 times/week\n    Do not administer 3 times/week dosing no more frequently than every other day\n    Titrate dose based on response\n\n Prevention & Treament of Secondary Hyperparathyroidism\n\nAssociated with Chronic Kidney Disease\n\n    >5 Years old with Stage 5\n    Initial 0.04-0.1 mcg/kg IV injection during dialysis (no more frequent than every other day) \n    Titrate up or down 2-4 mcg q2-4Weeks\n\n\n\nContra-indication: Hypersensitivity\n\nHypercalcemia, hypervitaminosis D\n\nSide effects: >10%\n\nNausea (13%)\n1-10%\n\nVomiting \n,\nEdema \n,\nPalpitation \n,\nChills \n,\nPneumonia \n,\nLightheadedness \n,\nGI bleeding \n,\nFlu\n,\nSepsis\n,\nHypokalemia\n,\nHypercalcemia\n.\n\nPrecaution: Monitor serum calcium and phosphorus frequently; reduce dose or stop the drug if calcium (in mg/dL) times phosphorus (in mg/dL) product >75\n\nPatients receiving digitalis; digitalis toxicity is potentiated by hypercalcemia\n\nStrong CYP3A4 inhibitors may increase paricalcitol AUC\n\nInjection solution doesn't contain preservatives; discard unused portions\n\nHepatic impairment\n\nMode of action: Doubled AUC w/ ketoconazole & other strong CYP3A4 inhibitors. Increased risk of hypercalcaemia & Ca x P product elevation w/ phosphate or vit D-related medicinal products, Ca-containing prep, thiazide diuretics; hypomagnesaemia w/ Mg-containing prep; blood levels of Al & risk of Al bone toxicity w/ Al-containing prep. Cholestyramine.\n\nPregnancy category: C\n\nInteraction: Doubled AUC w/ ketoconazole & other strong CYP3A4 inhibitors. Increased risk of hypercalcaemia & Ca x P product elevation w/ phosphate or vit D-related medicinal products, Ca-containing prep, thiazide diuretics; hypomagnesaemia w/ Mg-containing prep; blood levels of Al & risk of Al bone toxicity w/ Al-containing prep. Cholestyramine.
Paroxetine	\n\n\tACI\tParotin TAB dr 10mg 30's pack 181.20\n\tACI\tParotin TAB dr 20mg 30's pack 302.10\n\tBeximco\tMelev TAB dr 20mg 30's pack 286.20\n\tJayson\tParoxet TAB dr 20mg 30's pack 270.90\n\tSquare\tOxat TAB dr 20mg 30's pack 360\n\tIndication: Depression, Anxiety, Panic disorder, Obsessive-compulsive disorder, Posttraumatic stress disorder, Social anxiety disorder, Premenstrual dysmorphic disorder\n\nDose: Adult: PO Depression Initial: 20 mg/day. May increase if needed. Max: 50 mg/day. \nObsessive-compulsive disorder Initial: 20 mg/day. May increase if needed. Maintenance: 40-60 mg/day. \nPanic disorder Initial: 10 mg. May increase if needed. Maintenance: 40-60 mg/day. \nSocial anxiety disorder Initial: 20 mg/day. May increase if needed. Max: 50-60 mg/day. \nAnxiety; Posttraumatic stress disorder Initial: 20 mg/day. May increase if needed. Max: 50 mg/day. Premenstrual dysmorphic disorder As HCI: Extended release Initial: 12.5 mg once daily. May increase if needed. Take throughout menstrual cycle or limited to the luteal phase.\n\nContra-indication: Use with or within 14 days of MAOIs; concurrent use with thioridazine or pimozide.\n\nSide effects: Somnolence, insomnia, headache, dizziness; decreased libido; nausea, xerostomia, constipation, diarrhoea; ejaculatory disturbances; weakness, tremor, diaphoresis; vasodilation, chest pain, palpitation, hypertension, tachycardia, nervousness, anxiety , agitation, abnormal dreams, impaired concentration, yawning, depersonalisation, amnesia, emotional lability, vertigo, confusion, chills; rash, pruritus; orgasmic disturbance, dysmenorrhoea; anorexia, decreased appetite, dyspepsia, flatulence, abdominal pain, appetite increased, vomiting, taste perversion, weight gain; impotence, genital disorder, urinary frequency, UTI; paresthesia, myalgia, back pain, myoclonus, myopathy, myasthenia, arthralgia; blurred vision, abnormal vision; tinnitus; respiratory disorder, pharyngitis, sinusitis, rhinitis; infection.\n\nPrecaution: Epilepsy, glaucoma, history of mania, cardiac disease, DM, history of bleeding disorders, on drugs with increased risk of bleeding; renal and hepatic impairment; patients receiving electroconvulsive therapy; achlorhydria or high gastric pH (reduced absorption of oral suspension). Pregnancy and lactation. The risk of suicidal behaviour may be higher in young adults, closely monitor. May impair ability to drive or perform tasks. Avoid abrupt withdrawal.\n\nMode of action: Levels/effects inhibited by cyproheptadine, phenytoin. Levels/effects increased by carbamazepine, cimetidine, CYP2D6 inhibitors (e.g. chlorpromazine, delavirdine, fluoxetine, miconazole, pergolide, quinidine, quinine, ritonavir, ropinirole). Increases levels/effects of atomoxetine, carvedilol, clozapine, CYP2B6 substrates (e.g. bupropion, promethazine, propofol, selegiline, sertraline), CYP2D6 substrates (e.g. amphetamines, selected beta-blockers, dextromethorphan, fluoxetine, lidocaine, mirtazapine, nefazodone, risperidone, ritonavir, thioridazine, TCAs, venlafaxine), duloxetine, galantamine, mexilitine, pimozide, procyclidine, propafenone. Decreases levels/effects of CYP2D6 prodrug substrates (e.g. codeine, hydrocodone, oxycodone, tramadol). Inhibits the metabolism of dextromethorphan, haloperidol, thioridazine. Enhances bradycardic effect of beta-blockers. \n\nEnhances toxic effects of other CNS depressants. Increased risk of serotonin syndrome with amphetamines, SSRIs, meperidine, nefazodone, trazodone, serotonin agonists, sibutramine, sympathomimetics, tramadol, venlafaxine. Increases risk of bleeding with NSAIDs, aspirin, warfarin, or other drugs affecting coagulation. Increases sensitivity to amphetamines. Neurotoxicity with lithium. Additive hyponatraemia with loop diuretics. Mania or hypertension with selegiline.\n\nPotentially Fatal: Fatal reactions with nonselective MAOI.\n\nPregnancy category: D\n\nInteraction: Levels/effects inhibited by cyproheptadine, phenytoin. Levels/effects increased by carbamazepine, cimetidine, CYP2D6 inhibitors (e.g. chlorpromazine, delavirdine, fluoxetine, miconazole, pergolide, quinidine, quinine, ritonavir, ropinirole). Increases levels/effects of atomoxetine, carvedilol, clozapine, CYP2B6 substrates (e.g. bupropion, promethazine, propofol, selegiline, sertraline), CYP2D6 substrates (e.g. amphetamines, selected beta-blockers, dextromethorphan, fluoxetine, lidocaine, mirtazapine, nefazodone, risperidone, ritonavir, thioridazine, TCAs, venlafaxine), duloxetine, galantamine, mexilitine, pimozide, procyclidine, propafenone. Decreases levels/effects of CYP2D6 prodrug substrates (e.g. codeine, hydrocodone, oxycodone, tramadol). Inhibits the metabolism of dextromethorphan, haloperidol, thioridazine. Enhances bradycardic effect of beta-blockers. \n\nEnhances toxic effects of other CNS depressants. Increased risk of serotonin syndrome with amphetamines, SSRIs, meperidine, nefazodone, trazodone, serotonin agonists, sibutramine, sympathomimetics, tramadol, venlafaxine. Increases risk of bleeding with NSAIDs, aspirin, warfarin, or other drugs affecting coagulation. Increases sensitivity to amphetamines. Neurotoxicity with lithium. Additive hyponatraemia with loop diuretics. Mania or hypertension with selegiline.\n\nPotentially Fatal: Fatal reactions with nonselective MAOI.
Pefloxacin	\n\n\tBeximco\tIsofloxin TAB dr 400mg 50's pack 602.50\n\tDrug International Ltd.\tPeflox TAB dr 400mg 20's pack 220\n\tGlaxoSmithKline Bangladesh Ltd.\tPeflon TAB dr 400mg 50's pack 702.64\n\tGonoshasthaya\tG Pefloxacin TAB dr 400mg 30's pack 180\n\tGonoshasthaya\tG Pefloxacin Injection 400mg/5ml 5 amp's pack 150.55\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNobac TAB dr 400mg 20's pack 240\n\tSanofi Aventis (BD) Ltd.\tPleflacine TAB dr 400mg 30's pack 456.90\n\tSonear Ltd.\tPefla TAB dr 400mg 20's pack 307.60\n\tIndication: Susceptible infections, Gonococcal urethritis, Acute uncomplicated cystitis\n\nDose: Adult: PO Susceptible infections 400 mg twice daily. Acute uncomplicated cystitis in women; Gonococcal urethritis in men Single dose of 800 mg.\n\nContra-indication: Hypersensitivity to quinolones, children <12 yr, pregnancy, lactation.\n\nSide effects: Nausea, vomiting, gastric pain, dizziness, insomnia, allergic skin reactions, thrombocytopaenia, leukopenia/neutropenia, photosensitisation, arthropathy, muscular pain, headache, delusions, depression, hallucinations, hepatic dysfunction.\n\nPrecaution: Underlying CNS disease; hepatic disease; renal impairment. Avoid sun exposure, may cause severe sunburn.\n\nMode of action: Reduced absorption with antacids, didanosine (DDI), iron salts, pirenzepine, sucralfate, vincristine, zinc salts; increased levels with cimetidine, probenecid, theophylline; increases the levels of cyclosporine; causes seizures with foscarnet, NSAIDs, piroxicam; hypoglycemia with glimeperide; antagonistic with quercetin.\n\nPregnancy category: Not Classified\n\nInteraction: Reduced absorption with antacids, didanosine (DDI), iron salts, pirenzepine, sucralfate, vincristine, zinc salts; increased levels with cimetidine, probenecid, theophylline; increases the levels of cyclosporine; causes seizures with foscarnet, NSAIDs, piroxicam; hypoglycemia with glimeperide; antagonistic with quercetin.
Peginterferon Alfa-2a	\n\n\tBeacon\tPegin Injection 180mcg/vial 1 vial's pack 9800\n\tIncepta\tOptipeg-A 135 Injection 135mcg/vial 1's pack 8800\n\tIncepta\tOptipeg-A 180 Injection 180mcg/vial 1's pack 9800\n\tF.Hoffmann-La Roche Ltd.Germany\tPegasys Injection 135mcg/0.5ml 1 vial's pack 19597\n\tF.Hoffmann-La Roche Ltd.Germany\tPegasys Injection 180mcg/0.5ml 1 vial's pack 25425\n\tIndication: Chronic hepatitis C, Chronic hepatitis B\n\nDose: Adult: Chronic hepatitis C: The recommended dose of Peg interferon is 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thigh.\n\nChronic hepatitis B: The recommended dose of Peg interferon is 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thigh.\n\nHepatitis C (Genotype 1 & 4)\nMonotherapy: 180 mcg once weekly for 48 weeks\nDual therapy: Peginterferon Alfa-2a: 180 mcg once weekly for 48 weeks; : Ribavirin: < 75 kg= (400+0+600) mg, > 75 kg= (600+0+600) mg.\n\nHepatitis C (Genotype 2 & 3)\nMonotherapy: 180 mcg once weekly for 48 weeks.\nDual therapy: Peginterferon Alfa-2a: 180 mcg once weekly for 24 weeks;  Ribavirin: (400+0+400) mg.\n\nRenal impairment: ESRD requiring haemodialysis: 135 mcg/wk; monitor for toxicity.\n\nCrCl (ml/min)	\n<50 	Use caution; monitor for toxicity.\n\nHepatic impairment: Alanine transaminase (ALT) >5 times the upper limits of normal: Monitor LFTs more frequently; consider 135 mcg/wk or temporarily discontinuing (may resume after ALT flare subsides). ALT >10 times the upper limits of normal: Consider discontinuing.\n\n\nContra-indication: Hypersensitivity to any component of the product. Autoimmune hepatitis; decompensated liver disease in cirrhotic patients (Child-Pugh score >6); decompensated liver disease (Child-Pugh score ?6, class B and C) in chronic hepatitis C coinfected with HIV; neonates and infants; in combination with ribavirin in pregnant women.\n\nSide effects: â¢ Depression, suicide, relapse of drug abuse and bacterial infection â¢ Flu like symptoms: Fatigue, pyrexia, â¢ Gastrointestinal: Nausea/Vomiting, diarrhea, abdominal pain â¢ Metabolic and Nutritional: Anorexia â¢ Musculoskeletal: Myalgia, arthralgia â¢ Neurological: Headache, dizziness, insomnia â¢ Psychiatric reactions: Irritability, anxiety â¢ Injection site reaction, skin problems, hair loss â¢ Endocrine: Hypothyroidism.\n\nPrecaution: Neuropsychiatric disorders, discontinue treatment with worsening or persistently severe signs/symptoms; myelosuppresion; anemia (spherocytosis, history of GI bleeding); pulmonary disease; autoimmune disease; cardiovascular disease; DM; infectious disorders; ischaemic disorders; renal impairment; thyroid disorders; patients who have failed other alpha interferon therapy, received organ transplants, been coinfected with Hepatis B or C virus or HIV; or with Hepatitis C virus and HIV with a CD4+ cell count <100 cells/microliter, or been treated for >48 wk. Elderly. Safety and efficacy not been established in children. Do not change brands of interferon without the concurrence of healthcare provider (product variability). More frequent monitoring of LFTs and dose reduction in Hepatitis B. Hazardous agent, handle and dispose appropriately. May affect ability to drive or operate machinery.\n\nMode of action: Increased risk of haemolytic anemia, birth defects and/or foetal mortality, genotoxicity, mutagenicity, and may possibly be carcinogenic with ribavirin; decreases metabolism of theophylline; enhances adverse/toxic effects of zidovudine, decreases metabolism of zidovudine. Avoid ethanol in hepatitis C virus patients.\n\nPregnancy category: C\n\nInteraction: Increased risk of haemolytic anemia, birth defects and/or foetal mortality, genotoxicity, mutagenicity, and may possibly be carcinogenic with ribavirin; decreases metabolism of theophylline; enhances adverse/toxic effects of zidovudine, decreases metabolism of zidovudine. Avoid ethanol in hepatitis C virus patients.
Pemirolast Potassium 0.1% Eye prep	\n\n\tIncepta\tMirolast Eye Drops   10 ml drop 75\n\tOpso Saline Ltd.\tPemast Eye Drops  10 ml drop 75.28 	\n\tIndication: Allergic conjunctivitis\n\nDose: Ophthalmic\nProphylaxis of allergic conjunctivitis\nAdult: As 0.1% ophthalmic solution: Instill 1-2 drops into the affected eye(s) 4 times daily.\nChild: >3 yr: As 0.1% ophthalmic solution: Instill 1-2 drops into the affected eye(s) 4 times daily.\n\nContra-indication: Contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients of this product.\n\nSide effects: Headache, rhinitis, cold/flu symptoms, bronchitis, cough, sinusitis, sneezing/nasal congestion. Ocular application: Burning, dry eye, foreign body sensation and ocular discomfort.\n\nPrecaution:  	Not for treatment of contact lens-related irritation. Contact lens should be removed prior to drug admin and reinserted only at least 10 minutes after application. Safety and efficacy have not been established in children <3 yr. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Pentazocine Hydrochloride	\n\n\tBeximco\tStopain TAB dr 25mg 100's pack 500\n\tIndication: Moderate to severe pain\n\nDose: Adult: PO 50-100 mg 3-4 hrly. Max: 600 mg/day. IV/IM/SC 30-60 mg 3-4 hrly. Rectal As 50 mg supp: 1 supp ?4 times/day.\n\nContra-indication: Head injury; narcotic dependence; respiratory depression; raised intracranial pressure; MI; heart failure; arterial or pulmonary hypertension; porphyria; pregnancy (prolonged use or high doses at term).\n\nSide effects: Physical dependence; sedation, dizziness, euphoria, lightheadedness, alterations of mood; respiratory depression; visual hallucinations, disorientation, confusion; hypertension, tachycardia, circulatory depression; shock; hypotension; nausea, vomiting, constipation; seizures, diaphoresis; rash; blood dyscrasias; local tissue damages (SC), muscle fibrosis (IM).\nPotentially Fatal: Respiratory depression, hypotension, circulatory failure, deepening coma, convulsions.\n\nPrecaution:  	May precipitate withdrawal in narcotic addicts. Impaired respiratory, renal and hepatic function; morbidly obese patients; thyroid dysfunction; prostatic hyperplasia or urinary stricture; biliary tract impairment; adrenal insufficiency (including Addison's disease); abdominal conditions. Elderly or debilitated patients; seizure-prone patients; children and infants (safety and efficacy not established in <1 yr); lactation. May impair ability to drive or operate machinery. Administer IM rather than SC (when frequent inj are needed) and inj sites should be varied.\n\nMode of action: Depressant affects potentiated by alcohol, CNS depressants; concurrent use with fluoxetine may lead to diaphoresis, ataxia flushing and tremor associated with serotonin syndrome.\n\nPregnancy category: C\n\nInteraction: Depressant affects potentiated by alcohol, CNS depressants; concurrent use with fluoxetine may lead to diaphoresis, ataxia flushing and tremor associated with serotonin syndrome.
Pentoxifylline	\n\n\tBeximco\tVasolax TAB dr 400mg 30's pack 210\n\tSanofi Aventis (BD) Ltd.\tTrental TAB dr 400mg 30's pack 451.79\n\tSquare\tOxifyl CR TAB dr  400mg 30's pack 210.60\n\tIndication: Peripheral vascular disease\n\nDose: Adult: PO Extended release 400 mg 3 times/day (normally for at least 8 wk), may reduce to 400 mg twice daily if adverse effects occur.\n\nContra-indication: Previous hypersensitivity reactions to xanthine-related products e.g. caffeine, theophylline and theobromine. Recent cerebral and/or retinal haemorrhage. Porphyria.\n\nSide effects: Nausea, vomiting, dizziness, headache, flushing; angina, palpitations; occasional cardiac arrhythmias; hepatitis, jaundice; blood dyscrasias reported; agitation; sleep disturbances; hypotension; thrombocytopenia; intrahepatic cholestasis.\nPotentially Fatal: Fatal haemorrhage (cerebral and GI tract); anaphylactoid reaction.\n\nPrecaution: Avoid use in patients with severe cardiac arrhythmias or acute MI. Caution when used in patients with ischaemic heart disease or hypotension. Impaired renal or hepatic function. Start at lower dose in elderly; safety and efficacy not established in children. Tablets should not be chewed, crushed or broken; swallow whole. Pregnancy, lactation.\n\nMode of action: Concurrent use with ciprofloxacin may increase the adverse effect of pentoxifylline. Concurrent use may increase serum levels of theophylline derivatives.\nPotentially Fatal: May increase risk of adverse effect when used with ketorolac.\n\nPregnancy category: C\n\nInteraction: Concurrent use with ciprofloxacin may increase the adverse effect of pentoxifylline. Concurrent use may increase serum levels of theophylline derivatives.\nPotentially Fatal: May increase risk of adverse effect when used with ketorolac.
Peppermint Oil	\n\n\tBeacon\tLiqumint CAP .2ml 50's pack 200\n\tDrug International Ltd.\tMintek Soft Cap CAP 0.2ml 30's pack 180\n\tDrug International Ltd.\tMintex CAP 0.2ml 30's pack 180\n\tGeneral\tMintol CAP 0.2ml 30's pack 210.90\n\tSquare\tColmint CAP 187mg 30's pack 210\n\tIndication: Irritable bowel syndrome, GI tract spasm\n\nDose: Adult: PO Irritable bowel syndrome; GI tract spasm Peppermint oil: 0.2 mL 3 times/day, up to 0.4 mL 3 times/day if needed, for up to 3 mth. Peppermint spirit: (10% peppermint oil, 15% peppermint leaf extract): 1 mL (20 drops).\n\nContra-indication: Pregnancy; cholecystitis; hepatic damage; children.\n\nSide effects: Irritation; erythematous skin rash; headache; bradycardia; muscle tremors and ataxia; heartburn; exacerbation of asthma with wheezing and dypnoea; contact dermatitis, urticaria.\n\nPrecaution: Swallow capsules whole, some brands contain peanut oil, lactation.\n\nMode of action: Exacerbation of adverse effects if taken with alcohol; enteric-coated preparations containing peppermint oil should not be taken immediately with antacids.\n\nPregnancy category: Not Classified\n\nInteraction: Exacerbation of adverse effects if taken with alcohol; enteric-coated preparations containing peppermint oil should not be taken immediately with antacids.
Perindopril Erbumine	\n\n\tAcme Ltd.\tVersil TAB dr 4mg 30's pack 361.50\n\tAsiatic Ltd.\tPericard TAB dr 2mg 10's pack 70\n\tAsiatic Ltd.\tPericard TAB dr 4mg 10's pack 120\n\tEskayef Bangladesh Ltd.\tCoversyl TAB dr 4mg 30's pack 495\n\tEskayef Bangladesh Ltd.\tCoversyl TAB dr 8mg 30's pack 750\n\tIncepta\tPeripril TAB dr 2mg 20's pack 140\n\tIncepta\tPeripril TAB dr 4mg 20's pack 240\n\tIncepta\tPeripril TAB dr 8mg 20's pack 480\n\tRenata\tPendoril TAB dr 2mg 10's pack 70.20\n\tRenata\tPendoril TAB dr 4mg 20's pack 141\n\tRenata\tPendoril TAB dr 8mg 10's pack 240.90\n\tSquare\tCadnyl TAB dr 4mg 30's pack 361.49\n\tIndication: Heart failure, Hypertension, IHD\n\nDose: Adult: PO HTN As erbumine: Initial: 4 mg once daily. Patients w/ renovascular HTN, vol depletion, severe HTN: Initial: 2 mg once daily. Max: 8 mg/day. \n\nElderly: Initially, 2 mg (as erbumine) once daily. Dose may be increased to max 8 mg (erbumine)  after 1 mth if needed.\n\nPatients on diuretics: Withdraw diuretics 2 or 3 days before perindropil therapy. Resume later if required. If diuretic cannot be discontinued, an initial dose of 2 mg once daily. Max: 8 mg/day. \n\nHeart failure As erbumine: Initial: 2 mg in the morning. Increase slowly if needed. Maintenance: 4 mg/day.\n\n Stable ischaemic heart As erbumine: Initial: 4 mg once daily for 2 wk. Maintenance: 8 or 10 mg once daily.\n\nElderly: Initially, 2 mg mg (as erbumine) once daily on the 1st wk.\n\nRenal impairment:\nCrCl (ml/min)	\n<15 	2 mg (as erbumine) or 2.5 mg (as arginine) on dialysis days.\n15-30	2 mg (as erbumine) or 2.5 mg (as arginine) on alternate days.\n30-60	2 mg (as erbumine) or 2.5 mg (as arginine) daily.\n\nContra-indication: History of angioedema related to previous ACE inhibitor treatment. Pregnancy (2nd/3rd trimesters).\n\nSide effects: Headache, dizziness, sleep disorders, depression, fever, nervousness, somnolence; cough, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis; oedema, chest pain, abnormal ECG, palpitation; rash; hyperkalaemia, elevated triglycerides, menstrual disorder; nausea, diarrhoea, vomiting, dyspepsia, abdominal pain, flatulence: UTI, sexual dysfunction; increased LFTs; weakness, musculoskeletal pain, upper and lower extremity pain, hypertonia, paraesthesia; proteinuria; tinnitus, ear infection; viral infection, allergy.\nPotentially Fatal: Anaphylactoid reactions, angioedema.\n\nPrecaution: History of airway surgery. Withdraw if there is significant increase in LFTs. Risk factors for hyperkalaemia; monitor potassium closely. Patients dependent on renin-angiotensin-aldosterone system; consider withdrawal in patients with progressive deterioration in renal function. Collagen vascular disease. Hypovolaemia; monitor BP with the 1st dose. Unilateral renal artery stenosis and pre-existing renal insufficiency; valvular aortic stenosis. Before, during, or immediately after anaesthesia. May impair ability to drive or operate machinery. Lactation.\n\nMode of action: May enhance hypotensive effect w/ diuretics. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. ciclosporin, heparin, indometacin). May increase serum levels and toxicity of lithium. Antihypertensive effect may be reduced by aspirin or other NSAIDs. Coadministration w/ NSAIDs may also increase the risk of renal impairment. Increased risk of hypoglycaemia w/ antidiabetic agents. Rarely, nitritoid reactions occur w/ concomitant use of gold (sodium aurothiomalate).\nPotentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function (including acute renal failure) w/ aliskiren in patients w/ diabetes or renal impairment. \n\nPregnancy category: D\n\nInteraction: May enhance hypotensive effect w/ diuretics. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. ciclosporin, heparin, indometacin). May increase serum levels and toxicity of lithium. Antihypertensive effect may be reduced by aspirin or other NSAIDs. Coadministration w/ NSAIDs may also increase the risk of renal impairment. Increased risk of hypoglycaemia w/ antidiabetic agents. Rarely, nitritoid reactions occur w/ concomitant use of gold (sodium aurothiomalate).\nPotentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function (including acute renal failure) w/ aliskiren in patients w/ diabetes or renal impairment. 
Permethrin 5% Topical	\n\n\tACI\tPermisol 5% Cream   15gm  tube/ 30gm  tube 30.09 / 45.14\n\tAcme Ltd.\tPermin Cream 5% w/w 15gm  tube/ 30gm  tube 25.10 / 40.15\n\tAlco Pharma\tPerma Cream   15gm  tube/30gm  tube 24 / 35\n\tAmico Ltd.\tDelice Cream   15gm  tube/ 30gm  tube 25 / 40\n\tAristopharma\tArotrix Cream   15gm  tube/ 30gm  tube 28 / 50\n\tAsiatic Ltd.\tMecabis Cream   15gm tube 25\n\tBeximco\tNoscab Cream   25gm  tube 35 IP\n\tBio Pharma Ltd.\tScaper Cream   15gm  tube/ 30gm  tube 25.09 / 40.15\n\tChemist Ltd.\tScabid Cream   15gm  tube/ 30gm  tube 28.32 / 40.46\n\tCosmic Chemical Industries Ltd.\tFlorixe Cream   30gm  tube 40\n\tDrug International Ltd.\tLicerin Cream   15gm  tube 25\n\tEdruc Ltd.\tMithin Cream   15gm  tube/30gm  tube 25 / 40\n\tEskayef Bangladesh Ltd.\tPerosa Cream   30gm  tube 40\n\tG. A. Company Ltd.\tPermet Cream   15gm  tube 25\n\tGeneral\tSkilin Cream   15gm  tube / 30gm  tube 25.09 / 40.15\n\tGlaxoSmithKline Bangladesh Ltd.\tLotrix Cream 5% 30gm tube 55.21\n\tGlobe\tPerls Cream   30gm  tube 40\n\tIbn Sina Pharmaceutical Ind. Ltd.\tScarin Cream   15gm  tube / 30gm  tube 30 / 40\n\tIncepta\tElimate Cream  5% 30gm  tube 40\n\tJayson\tErmite Cream   30gm  tube 40.15\n\tKemiko\tNeeper Cream   15gm  tube/ 30gm  tube 28 / 40\n\tMedicon\tPermenin Cream   15gm  tube/ 30gm  tube 25 / 40\n\tMillat\tScameth Cream   30gm  tube 40\n\tNovo Healthcare and Pharma Ltd.\tDermanix Cream   30gm  tube 40\n\tOpsonin Pharma\tLorix Cream   30gm  tube 40\n\tPharmadesh Ltd.\tPesimex Cream   15gm  tube/ 30gm  tube 25.09 / 40.15\n\tPharmasia Ltd.\tPermethi Cream   15gm  tube 25\n\tReman Drug Ltd.\tRemathrin CR Cream   30gm  tube 40.50\n\tRephco\tZunex Cream   15gm  tube 28\n\tSquare\tScabex 5% Cream  5 gm/100 gm 15gm  tube/ 30gm  tube 25.10 / 40.15\n\tUnimed & Unihealth Manufacturers Ltd.\tUnix Cream   30gm  tube 40\n\tIndication: Scabies, Pediculosis pubis\n\nDose: Adults and children over 12 years(30 gm tube) : A full tube.\nChildren aged 6-12 years : Up to 1/2 of a tube.\nChildren aged 1-5 years : Up to 1/4 of a tube.\nChildren aged 2 months to 1 year: Up to 1/8 of a tube.\n\nScabies As 5% cream: Apply to skin surfaces from neck to toes. Wash off after 8-14 hr.\n\nAdult: Topical Pediculosis pubis As 5% cream: Apply and leave on for 10 mins before rinsing with water.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Mild and transient burning, stinging, pruritus, erythema, tingling, numbness, rash; difficulty in breathing; phototoxic or photosensitisation reactions.\n\nPrecaution: Avoid contact with eyes and mucous membranes. Cross-sensitivity may occur with ragweed or chrysanthemums. History of asthma. Pregnancy and lactation.\n\nMode of action: Mild and transient burning, stinging, pruritus, erythema, tingling, numbness, rash; difficulty in breathing; phototoxic or photosensitisation reactions.\n\nPregnancy category: B\n\nInteraction: Mild and transient burning, stinging, pruritus, erythema, tingling, numbness, rash; difficulty in breathing; phototoxic or photosensitisation reactions.
Pethidine Hydrochloride	\n\n\tGonoshasthaya\tG Pethidine Injection 100mg/2ml  2ml amp  x  5's pack 99.45\n\tRenata\tPethidine-R Injection 100mg/2ml 2ml amp  x  5's pack 99.05\n\tIndication: Anaesthesia, Postoperative pain, Moderate to severe acute pain, Obstetric analgesia\n\nDose: Adult:  IV Adjunct to anesth 10-25 mg. IV/IM/SC Moderate to severe acute pain 25-100 mg IM/SC inj or 25-50 mg by slow IV inj repeated after 4 hr. \n\nIM/SC Obstetric analgesia 50-100 mg as soon as contractions occur at regular intervals; repeat after 1-3 hr if needed. Max: 400 mg/24 hr. \n\nPre-op medication 25-100 mg 1 hr pre-op. Post-op pain25-100 mg 2-3 hrly if needed.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Hypotension; fatigue, drowsiness, dizziness, nervousness, headache, restlessness, malaise, confusion, depression, hallucinations, tremors, muscle twitches, increased intracranial pressure, seizure, serotonin syndrome; rash, urticaria; nausea, vomiting, constipation, anorexia, stomach cramps, xerostomia, biliary spasm, paralytic ileus, sphincter of Oddi spasm; ureteral spasms, decreased urination; pain at inj site; weakness; dyspnoea; histamine release, physical and psychological dependence.\n\nPrecaution: May impair ability to drive or operate machinery. Hypovolaemia, CV disease; adrenal insufficiency; biliary tract disorder; CNS depression or coma; history of drug abuse or acute alcoholism; head injury, intracranial lesions, elevated intracranial pressure; hepatic or renal impairment; morbidly obese; prostatic hyperplasia; toxic psychoses; pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive airway disease; sickle-cell disease; supraventricular tachycardia; thyroid dysfunction. Elderly and debilitated patients. Withdraw gradually. Pregnancy (avoid prolonged use or high doses at term) and lactation.\n\nMode of action: W/in 2 wk of MAOIs or moclobemide, selegiline, ritonavir, cimetidine, CNS depressants, barbiturate salts, aminophylline, heparin, methicillin, morphine, nitrofurantoin, phenytoin, sulphadiazine, Na iodide, sulphafurazole diethanolamine, acyclovir, imipenem, frusemide, idarubicin, minocycline, tetracycline, cefoperazone, mezlocillin, nafcillin, liposomal doxorubicin.\n\nPregnancy category: D\n\nInteraction: W/in 2 wk of MAOIs or moclobemide, selegiline, ritonavir, cimetidine, CNS depressants, barbiturate salts, aminophylline, heparin, methicillin, morphine, nitrofurantoin, phenytoin, sulphadiazine, Na iodide, sulphafurazole diethanolamine, acyclovir, imipenem, frusemide, idarubicin, minocycline, tetracycline, cefoperazone, mezlocillin, nafcillin, liposomal doxorubicin.
Pheniramine Maleate	\n\n\tBeximco\tAerovil Syrup 15mg/5ml 100ml bot 20.07\n\tIncepta\tAlervil Syrup 15mg/5ml 75ml bot 25\n\tOpsonin Pharma\tAmarin Syrup 15mg/5ml 100ml bot 20\n\tOpsonin Pharma\tAmarin TAB dr 22.7mg 100's pack 47\n\tOpsonin Pharma\tAmarin Injection 45.5mg 2ml amp x 25's pack 187\n\tSanofi Aventis (BD) Ltd.\tAvil Syrup 15mg/5ml 100ml bot 20.08\n\tSanofi Aventis (BD) Ltd.\tAvil TAB dr 22.7mg 500's pack 754.97\n\tSanofi Aventis (BD) Ltd.\tAvil Injection 45.5mg/2ml 2ml amp x 25's pack 201\n\tSanofi Aventis (BD) Ltd.\tAvil RETARD TAB dr 75mg 100's pack 200.75\n\tIndication: Allergic conjunctivitis, Allergic conditions, Motion sickness\n\nDose:  Adult: PO Allergic conditions; Prevention of motion sickness As maleate: \nSyr: 15-30 mg 2-3 times/day. \nTab: Up to 45 mg 3 times/day. Max: 3 mg/kg/day. \nFor motion sickness prevention: Take 1st dose at least 30 mins before travelling. \n\nChildren aged 1-3 years:  Half a measuring spoonful 2 or 3 times daily.\nChildren aged 4-12 years: 1 measuring spoonful 2 or 3 times daily.\n\n\nContra-indication: Symptomatic prostatic hypertrophy; neonates and premature infants.\n\nSide effects: Oral: Sedation. Hypersensitivity reactions. Lassitude, dizziness, tinnitus, inability to concentrate, incoordination, irritability, insomnia and tremors. Nausea, vomiting, diarrhoea, colic, epigastric pain, anorexia, dryness of mouth and constipation. Urinary retention. Palpitations, headache. Blurred vision, increased intraocular pressure. Muscular weakness. Rarely, blood dyscrasias e.g. agranulocytosis, haemolytic anaemia. Ophthalmic: Temporarily enlarged pupils, eye redness (overuse).\n\nPrecaution:  	May impair ability to drive or operate machinery. Has potential for abuse. Narrow angle glaucoma, asthma or severe CV disease. Antiemetic effect may mask signs of other conditions. Pregnancy and lactation. Elderly.\n\nMode of action: May mask ototoxicity produced by aminoglycoside antibiotics.\n\nPotentially Fatal: Potentiation of CNS depression by alcohol, sedatives, opioids, barbiturates, hypnotics, narcoleptics. May increase antimuscarinic effect of MAOIs, atropine and TCAs.\n\nPregnancy category: C\n\nInteraction: May mask ototoxicity produced by aminoglycoside antibiotics.\n\nPotentially Fatal: Potentiation of CNS depression by alcohol, sedatives, opioids, barbiturates, hypnotics, narcoleptics. May increase antimuscarinic effect of MAOIs, atropine and TCAs.
Phenobarbitone	\n\n\tBio Pharma Ltd.\tPhenoba TAB dr 30mg 100's pack 78\n\tBio Pharma Ltd.\tPhenoba TAB dr 60mg 100's pack 114\n\tDelta Pharma\tPheno TAB dr 15mg 100's pack 57\n\tDelta Pharma\tPheno TAB dr 60mg 100's pack 114\n\tDelta Pharma\tPheno TAB dr 30mg 100's pack 78\n\tG. A. Company Ltd.\tBerdinal TAB dr 30mg 100's pack 78\n\tIncepta\tBarbit Elixir 20mg/5ml 100ml bot 57\n\tIncepta\tBarbit TAB dr 30 mg 100's pack 78\n\tIncepta\tBarbit TAB dr 60 mg 100's pack 114\n\tJayson\tPhenoson TAB dr 30mg 100's pack 78\n\tOpsonin Pharma\tEmer Elixir 20mg/5ml 100ml bot 56\n\tOpsonin Pharma\tEmer TAB dr 30mg 100's pack 78\n\tOpsonin Pharma\tEmer TAB dr 60mg 100's pack 114\n\tOpsonin Pharma\tEmer TAB dr 15mg 100's pack 50\n\tSquare\tEpinal Elixir 20mg/5ml 100ml bot 56.20\n\tSquare\tEpinal TAB dr 30mg 100's pack 78.47\n\tSquare\tEpinal TAB dr 60mg 100's pack 114.38\n\tIndication: Status epilepticus, Partial seizures, Sedation, Generalised tonic-clonic seizures, Hypnotic, Preoperative sedation\n\nDose: Adult: PO Generalised tonic-clonic seizures; Partial seizures 60-180 mg/day at night. Adjust according to response. \nSedation 30-120 mg/day in 2-3 divided doses.\nHypnotic 100-320 mg at bedtime. \n\nPediatric Oral Dosage:\nPreoperative: 1 mg to 3 mg/kg.\nAnticonvulsant: 1 mg to 6 mg/kg per day \n\nRenal impairment:\nCrCl (ml/min)	\n<10	           Administer every 12-16 hr.\n\nHepatic impairment: Severe: Monitor plasma levels and adjust dose as necessary.\n\nContra-indication: Severe renal and hepatic disorders. Severe respiratory depression, dyspnoea or airway obstruction; porphyria. Pregnancy.\n\nSide effects: Bradycardia, hypotension, syncope; drowsiness, lethargy, CNS excitation or depression, impaired judgment, hangover effect, confusion, somnolence, agitation, hyperkinesia, ataxia, nervousness, headache, insomnia, nightmares, hallucinations, anxiety, dizziness; rash, exfoliative dermatitis; nausea, vomiting, constipation; agranulocytosis, thrombocytopenia, megaloblastic anaemia; pain at inj site, thrombophlebitis (IV); oliguria: laryngospasm, respiratory depression, apnoea (especially with rapid IV admin), hypoventilation.\nPotentially Fatal: Stevens-Johnson syndrome.\n\nPrecaution: Elderly or debilitated patients, children. Withdraw gradually. Impaired renal, hepatic and respiratory function. Patients with acute pain and depressive disorders. May impair ability to drive or operate machinery. Lactation.\n\nMode of action: May enhance the hepatotoxic potential of paracetemaol overdoses. May decrease levels/effects of various CYP isoenzyme substrates e.g. teniposide, methotrexate, antipsychotics, ?-blockers, calcium-channel blockers, other anticonvulsants, chloramphenicol, cimetidine, corticosteroids, ciclosporin, doxycycline, oestrogens, felbamate, griseofulvin, tacrolimus, furosemide, methadone, oral contraceptives, theophylline, TCAs, warfarin. May reduce effects of guanfacine. Reduced metabolism and or increased toxicity with chloramphenicol, felbamate, MAOIs, valproic acid. May enhance the nephrotoxic effects of methoxyflurane.\n\nPotentially Fatal: Additive sedation and/or respiratory depression with ethanol, sedatives, antidepressants, opioid analgesics, benzodiazepines and other CNS depressants. May decrease levels/effects of antiarrhythmic drugs e.g. disopyramide, propafenone, quinidine.\n\nPregnancy category: D\n\nInteraction: May enhance the hepatotoxic potential of paracetemaol overdoses. May decrease levels/effects of various CYP isoenzyme substrates e.g. teniposide, methotrexate, antipsychotics, ?-blockers, calcium-channel blockers, other anticonvulsants, chloramphenicol, cimetidine, corticosteroids, ciclosporin, doxycycline, oestrogens, felbamate, griseofulvin, tacrolimus, furosemide, methadone, oral contraceptives, theophylline, TCAs, warfarin. May reduce effects of guanfacine. Reduced metabolism and or increased toxicity with chloramphenicol, felbamate, MAOIs, valproic acid. May enhance the nephrotoxic effects of methoxyflurane.\n\nPotentially Fatal: Additive sedation and/or respiratory depression with ethanol, sedatives, antidepressants, opioid analgesics, benzodiazepines and other CNS depressants. May decrease levels/effects of antiarrhythmic drugs e.g. disopyramide, propafenone, quinidine.
Phenobarbitone Sodium	\n\n\tG. A. Company Ltd.\tBerdinal Injection 200mg/ml 1 amps pack 15.99\n\tIncepta\tBarbit Injection 200mg/ml 5 amps pack 80\n\tOpsonin Pharma\tEmer Injection 200mg/ml 5 amps pack 80\n\tSquare\tEpinal Injection 200mg/ml 5 amps pack 80\n\tIndication: Status epilepticus, Partial seizures, Sedation, Generalised tonic-clonic seizures, Hypnotic, Preoperative sedation\n\nDose: Adult: IV Status epilepticus Doses of 10-20 mg/kg. Max: 1 g. \n\nIV/IM/SC Hypnotic 100-320 mg/day at bedtime. \n\nIM Emergency management of acute seizures 200 mg repeated after 6 hr if needed. Sedation 30-120 mg/day in 2-3 divided doses. Pre-op sedation 100-200 mg 1-1.5 hr pre-op.\n\nChildren: Status epilepticus: IV 15-20 mg/Kg over 10-15 minutes\n\nContra-indication: Severe renal and hepatic disorders. Severe respiratory depression, dyspnoea or airway obstruction; porphyria. Pregnancy.\n\nSide effects: Bradycardia, hypotension, syncope; drowsiness, lethargy, CNS excitation or depression, impaired judgment, hangover effect, confusion, somnolence, agitation, hyperkinesia, ataxia, nervousness, headache, insomnia, nightmares, hallucinations, anxiety, dizziness; rash, exfoliative dermatitis; nausea, vomiting, constipation; agranulocytosis, thrombocytopenia, megaloblastic anaemia; pain at inj site, thrombophlebitis (IV); oliguria: laryngospasm, respiratory depression, apnoea (especially with rapid IV admin), hypoventilation.\nPotentially Fatal: Stevens-Johnson syndrome.\n\nPrecaution: Elderly or debilitated patients, children. Withdraw gradually. Impaired renal, hepatic and respiratory function. Patients with acute pain and depressive disorders. May impair ability to drive or operate machinery. Lactation.\n\nMode of action: May enhance the hepatotoxic potential of paracetemaol overdoses. May decrease levels/effects of various CYP isoenzyme substrates e.g. teniposide, methotrexate, antipsychotics, ?-blockers, calcium-channel blockers, other anticonvulsants, chloramphenicol, cimetidine, corticosteroids, ciclosporin, doxycycline, oestrogens, felbamate, griseofulvin, tacrolimus, furosemide, methadone, oral contraceptives, theophylline, TCAs, warfarin. May reduce effects of guanfacine. Reduced metabolism and or increased toxicity with chloramphenicol, felbamate, MAOIs, valproic acid. May enhance the nephrotoxic effects of methoxyflurane.\n\nPotentially Fatal: Additive sedation and/or respiratory depression with ethanol, sedatives, antidepressants, opioid analgesics, benzodiazepines and other CNS depressants. May decrease levels/effects of antiarrhythmic drugs e.g. disopyramide, propafenone, quinidine.\n\nPregnancy category: D\n\nInteraction: May enhance the hepatotoxic potential of paracetemaol overdoses. May decrease levels/effects of various CYP isoenzyme substrates e.g. teniposide, methotrexate, antipsychotics, ?-blockers, calcium-channel blockers, other anticonvulsants, chloramphenicol, cimetidine, corticosteroids, ciclosporin, doxycycline, oestrogens, felbamate, griseofulvin, tacrolimus, furosemide, methadone, oral contraceptives, theophylline, TCAs, warfarin. May reduce effects of guanfacine. Reduced metabolism and or increased toxicity with chloramphenicol, felbamate, MAOIs, valproic acid. May enhance the nephrotoxic effects of methoxyflurane.\n\nPotentially Fatal: Additive sedation and/or respiratory depression with ethanol, sedatives, antidepressants, opioid analgesics, benzodiazepines and other CNS depressants. May decrease levels/effects of antiarrhythmic drugs e.g. disopyramide, propafenone, quinidine.
Phenoxymethyl Penicillin	\n\n\tAlbion Ltd.\tAlbipen-V Dry Powder for Syrup 125 mg/5 ml  50 ml \n\tAlbion Ltd.\tRycin-K TAB dr 250 mg  200's pack \n\tAPC Pharma Ltd.\tPhenoxymethyl TAB dr 250mg 100's pack 150\n\tBio Pharma Ltd.\tBiopen VK Powder for Suspension 125mg/5ml 50ml bot/ 100ml bot 18.28/ 28.91\n\tBio Pharma Ltd.\tBiopen VK TAB dr 250mg 100's pack 151\n\tBristol Pharma Ltd.\tPenicillin TAB dr 250mg 100's  pack  140\n\tEdruc Ltd.\tCytapen V Powder for Suspension 125mg/5ml 100ml bot 22\n\tEdruc Ltd.\tCytapen V TAB dr 250mg 100's pack 230\n\tG. A. Company Ltd.\tEracillin K Powder for Suspension 125mg/5ml 50ml bot 18.21\n\tG. A. Company Ltd.\tEracillin K TAB dr 250mg 100's pack 148\n\tGonoshasthaya\tG Penicillin V Powder for Suspension 125mg/5ml 50ml bot 17.77\n\tGonoshasthaya\tG Penicillin V TAB dr 250mg 100's pack 200\n\tHudson\tH-Pen TAB dr 250mg 100's pack 135\n\tIndobangla Pharmaceuticals\tPenicillin V TAB dr 250mg 100's pack 140\n\tIndobangla Pharmaceuticals\tPenicillin-V Syrup 125mg 50ml bot  18\n\tNipa\tPencin V TAB dr 250mg 100's pack 152\n\tOpsonin Pharma\tOpen Powder for Suspension 125mg/5ml 50ml bot 18\n\tOpsonin Pharma\tOpen TAB dr 250mg 100'S pack 228\n\tOpsonin Pharma\tOpen TAB dr 500mg 100's  pack 268\n\tPharmadesh Ltd.\tPharmapen Powder for Suspension 125mg/5ml 60ml bot 18.4\n\tPharmadesh Ltd.\tPharmapen TAB dr 250mg 100's pack 220\n\tRenata\tPen VK TAB dr 250mg  \n\tSanofi Aventis (BD) Ltd.\tOracyn K Powder for Suspension 125mg/5ml 50ml bot 18.42\n\tSanofi Aventis (BD) Ltd.\tOracyn K TAB dr 250mg 500's pack 1130.5\n\tSanofi Aventis (BD) Ltd.\tOracyn K TAB dr 500mg 250's pack 1100.01\n\tSonear Ltd.\tPentab TAB dr 250mg 100's pack 229\n\tSquare\tPenvik TAB dr 250mg 100's pack 228.76\n\tSquare\tPenvik DS TAB dr 500mg 100's pack 443\n\tSquare\tPenvik FORTE Powder for Suspension 250mg/5ml 100ml bot 52.49\n\tSquare\tPenvik Syrup 125mg 50ml bot / 100ml bot  18.21 / 28.96\n\tZenith\tPacin-V TAB dr 250mg 80's pack/100's  pack 125 / 147\n\tIndication: Tonsillitis,Pharyngitis,Skin & soft tissue infections,Anthrax,Lyme disease,Rheumatic fever,Spleen disorders ,Dental Abscesses,gingivitis,upper respiratory tract, scarlet fever,erysipelas,otitis media,Vincent's infection\n\nDose: Adult: 250-500 mg 6 hourly\nChildren: 125-250 mg 6 hourly\nDry Syrup: 1-2 tea-spoonful (5-10ml) 6 hourly\nForte Syrup: Â½-1 tea-spoonful (2.5-5ml0 6 hourly\nInfants: 62.5-125 mg 6 hourly\n\nAdult: PO Prophylaxis of recurrent rheumatic fever 250 mg twice daily. Streptococcal infections of the upper respiratory tract, including scarlet fever and erysipelas 125-250 mg 6-8 hrly for 10 days. \n\nPneumococcal infections of the respiratory tract, including otitis media 250-500 mg 6 hrly until patient is afebrile for at least 2 days. \n\nFusospirochetosis (Vincent's infection) of the oropharynx; Staphylococcal infections of the skin and soft tissue 250-500 mg 6-8 hrly.\n\nContra-indication: Hypersensitivity to penicillins.\n\nSide effects: Nausea, vomiting, epigastric distress, diarrhoea, black hairy tongue; skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal oedema; fever, eosinophilia.\nPotentially Fatal: Anaphylaxis.\n\n\nPrecaution: Monitor renal and haematologic systems periodically during prolonged therapy or if high dose is used. Use may result in overgrowth of nonsusceptible organisms. Cross-sensitivity with cephalosporins may occur. History of significant allergies and/or asthma. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Phenylephrine 0.12% + Tetryzoline Hydrochloride 0.04% + Zinc Sulphate 0.1% Eye prep	\n\n\tIndication: Dry eye, Burning, Red eye, Eye irritation, Discomfort of the eye\n\nDose: Usual Adult Dose for:\n\n    Eye Redness/Itching\n\nUsual Pediatric Dose for:\n\n    Eye Redness/Itching\n\nAdditional dosage information:\n\n    Precautions\n\nUsual Adult Dose for Eye Redness/Itching\n\nInstill 1 to 2 drops in the affected eye(s) up to 4 times daily.\nUsual Pediatric Dose for Eye Redness/Itching\n\n>=6 years: Instill 1 to 2 drops in the affected eye(s) up to 4 times daily.\n\nContra-indication: \n\nSide effects:  Check with your doctor if any of these most COMMON side effects persist or become bothersome:\n\n    Blurred vision; minor stinging or tingling when the medicine is dropped into the eye.\n\nSeek medical attention right away if any of these SEVERE side effects occur while taking tetrahydrozoline / zinc sulfate ophthalmic:\n\n    Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); changes in vision; eye pain; worsening or persistent eye irritation or redness.\n\n\nPrecaution: Sympathomimetics are generally contraindicated in patients with narrow-angle glaucoma.\n\nContact lenses should be removed before use.\n\nPatients should be instructed to avoid allowing the tip of the container to contact the eye, eyelid, fingers or any other surface.\n\nOveruse may result in rebound congestion.\n\nPatients should be advised to discontinue use and notify their physician if their condition worsens or lasts for more than 72 hours.\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Phenylephrine Hydrochloride 5% + Tropicamide 0.8% Eye prep	\n\n\tAristopharma\tTrophen Eye Drops   5  ml drop 90\n\tDrug International Ltd.\tTrocane Eye Drops   5  ml drop 65\n\tG. A. Company Ltd.\tTrusil PLUS Eye Drops   5  ml drop 80\n\tGeneral\tTropigen Plus Eye Drops   5ml drop 80\n\tIncepta\tDilate Plus Eye Drops   5  ml drop 80\n\tOpso Saline Ltd.\tTropicamide PLUS Eye Drops   5  ml drop 80.30\n\tPopular\tTropidil PLUS Eye Drops  50 mg + 8 mg/ml 5  ml drop 80.30\n\tReman Drug Ltd.\tMydrimide PLUS Eye Drops   5  ml drop 80.50\n\tIndication: Uveal tract inflammation, Retinal photography, Refractive errors, Funduscopy, Slit lamp examination, Dilatation of the pupil\n\nDose: Therapeutic purpose:\nUveitis: 1-2 drops bid-qid or as required.\n\nDiagnostic purpose/Pre-operative purpose: Instill 1-2 drops in the eye(s) 15-20 minutes before examination. If examination is not conducted within 20â30 minutes, an additional drop may be placed in the eye(s) to prolong the effect. \n\nContra-indication: This medication is contraindicated in these following cases\n\n\n    Patients with hypersensitivity to any of the components and narrow angles or narrow angle glaucoma.\n\n    Low birth weight infants and some elderly adults with severe arteriosclerotic cardiovascular or cerebrovascular disease.\n\n    During intraocular operative procedures when the corneal epithelial barrier has been disturbed.\n\nSide effects: Elevated IOP (occasionally), stinging, blurred vision, tachycardia, photophobia, headache, parasympathetic stimulation and allergic reactions. Systemic effects include arrhythmias, hypertension and coronary artery spasm. \n\nPrecaution: Caution should be taken when administered with, or upto 21days after administration of monoamine oxidase (MAO) inhibitors as exaggerated adrenergic effects may result.\n\nThe possibility of psychotic reactions and behavioral disturbances should be considered in patients who are hypersensitive to anticholinergic drugs.\n\nUse with extreme caution in infants.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Phenytoin	\n\n\tAmbee\tDiphedan Suspension 30mg/5ml 100ml bot 31\n\tAmbee\tDiphedan Suspension 60mg/5ml 100ml bot 30.46\n\tNational Ltd.\tPhenyton Suspension 30 mg/5 ml  \n\tIndication: Epilepsy,Tonic-clonic status epilepticus\n\nDose: Adult: PO Epilepsy Initial: 3-4 mg/kg/day as single dose or in divided doses. Maintenance: 200-500 mg/day. \n\nChild: Initially, 5 mg/kg daily in 2-3 divided doses. Maintenance: 4-8 mg/kg daily in divided doses. Max dose: 300 mg daily.\n\nContra-indication: Pregnancy. \n\nSide effects: Hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, GI disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. Phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. Solutions for inj may cause local irritation or phlebitis. Prolonged use may produce subtle effects on mental function and cognition, especially in children.\nPotentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome.\n\nPrecaution: Cardiovascular disease, e.g. sinus bradycardia, heart blocks; DM; hepatic impairment; hypoalbuminemia; porphyria; seizures (may increase frequency of petit mal seizures); debilitated patients; elderly. Caution in IV admin in hypotension, heart failure or MI, monitor BP and ECG during therapy. IV must be given slowly (too rapid admin may cause hypotension, CNS depression, cardiac arrhythmias and impaired heart conduction). Extravasation and intra-arterial admin must be avoided. Do not discontinue abruptly (may increase seizure frequency), unless safety concerns require a more rapid withdrawal. May impair ability to drive or operate machinery.\n\nMode of action: Effects with other sedative drugs or ethanol may be potentiated. Enhances toxic effects of paracetamol, lithium. Increased risk of osteomalacia with acetazolamide. Decreased serum levels/effects with acyclovir, antineoplastics, benzodiazeines, ciprofloxacin, CYP2C9 inducers (e.g. carbamazepine), CYP2C19 inducers (e.g. rifampin), folic acid, vigabatrin. \n\nIncreased serum concentrations with allopurinol, capecitabine, cimetidine, CYP2C9 inhibitors (e.g. fluconazole), CYP2C19 inhibitors (e.g. delavirdine), disulfiram, methylphenidate, metronidazole, omeprazole, SSRI, trazodone, trimethoprim. Increases metabolism of antiarrhythmics, anticonvulsants, antipsychotics, beta-blockers, calcium channel blockers, chloramphenicol, corticosteroids, doxycycline, oestrogens, HMG-CoA reductase inhibitors, methadone, theophylline, TCAs. Decreases levels/effects of clozapine, ciclosporin, tacrolimus, CYP2B6 substrates (e.g. bupropion, selegiline), CYP2C8 substrates (e.g. amiodarone), CYP2C9 substrates (e.g. celecoxib), CYP2C19 substrates (e.g. citalopram), CYP3A4 substrates (e.g. benzodiazepines), digoxin, itraconazole, levodopa, neuromuscular-blocking agents, thyroid hormones, topiramate. \n\nIncreases levels/effect of dopamine, ticlopidine. Valproic acid may displace phenytoin from binding sites; and affect phenytoin serum concentrations. Transiently increases the hypothrombinaemia response to warfarin initially, followed by an inhibition of the response.\n\nPotentially Fatal: Enhances the hypotensive properties of dopamine and the cardiac depressant properties of lidocaine.\n\nPregnancy category: D\n\nInteraction: Effects with other sedative drugs or ethanol may be potentiated. Enhances toxic effects of paracetamol, lithium. Increased risk of osteomalacia with acetazolamide. Decreased serum levels/effects with acyclovir, antineoplastics, benzodiazeines, ciprofloxacin, CYP2C9 inducers (e.g. carbamazepine), CYP2C19 inducers (e.g. rifampin), folic acid, vigabatrin. \n\nIncreased serum concentrations with allopurinol, capecitabine, cimetidine, CYP2C9 inhibitors (e.g. fluconazole), CYP2C19 inhibitors (e.g. delavirdine), disulfiram, methylphenidate, metronidazole, omeprazole, SSRI, trazodone, trimethoprim. Increases metabolism of antiarrhythmics, anticonvulsants, antipsychotics, beta-blockers, calcium channel blockers, chloramphenicol, corticosteroids, doxycycline, oestrogens, HMG-CoA reductase inhibitors, methadone, theophylline, TCAs. Decreases levels/effects of clozapine, ciclosporin, tacrolimus, CYP2B6 substrates (e.g. bupropion, selegiline), CYP2C8 substrates (e.g. amiodarone), CYP2C9 substrates (e.g. celecoxib), CYP2C19 substrates (e.g. citalopram), CYP3A4 substrates (e.g. benzodiazepines), digoxin, itraconazole, levodopa, neuromuscular-blocking agents, thyroid hormones, topiramate. \n\nIncreases levels/effect of dopamine, ticlopidine. Valproic acid may displace phenytoin from binding sites; and affect phenytoin serum concentrations. Transiently increases the hypothrombinaemia response to warfarin initially, followed by an inhibition of the response.\n\nPotentially Fatal: Enhances the hypotensive properties of dopamine and the cardiac depressant properties of lidocaine.
Phenytoin Sodium	\n\n\tAmbee\tDiphedan TAB dr 100mg 100's pack 201\n\tBeacon\tXentoin TAB dr 100mg 50's pack 200.50\n\tDrug International Ltd.\tD-Toin TAB dr 100mg 100's pack 200\n\tIncepta\tSizatoin TAB dr 100mg  \n\tNational Ltd.\tPhenyton CAP 100mg  \n\tPopular\tFosfen IM/IV injection 2ml 5's pack 350\n\tTechno Drugs Ltd.\tEpilax Injection 50mg  \n\tIndication: Epilepsy, Tonic-clonic  status epilepticus\n\nDose: Epilepsy\nAdult: Initially, 3-4 mg/kg daily as single dose or in divided doses. Alternatively, 150-300 mg daily increased gradually to 600 mg daily if necessary. Maintenance: 200-500 mg daily.\n\nChild: Initially, 5 mg/kg daily in 2-3 divided doses. Maintenance: 4-8 mg/kg daily in divided doses. Max dose: 300 mg daily.\n\n\n\nContra-indication: Pregnancy. IV admin in sinus bradycardia, heart block, or Stokes-Adams syndrome.\n\nSide effects: Hypersensitivity, lack of appetite, headache, dizziness, tremor, transient nervousness, insomnia, GI disturbances (e.g. nausea, vomiting, constipation), tenderness and hyperplasia of the gums, acne, hirsutism, coarsening of the facial features, rashes, osteomalacia. Phenytoin toxicity as manifested as a syndrome of cerebellar, vestibular, ocular effects, notably nystagmus, diplopia, slurred speech, and ataxia; also with mental confusion, dyskinesias, exacerbations of seizure frequency, hyperglycaemia. Solutions for inj may cause local irritation or phlebitis. Prolonged use may produce subtle effects on mental function and cognition, especially in children.\nPotentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome.\n\nPrecaution: Cardiovascular disease, e.g. sinus bradycardia, heart blocks; DM; hepatic impairment; hypoalbuminemia; porphyria; seizures (may increase frequency of petit mal seizures); debilitated patients; elderly. Caution in IV admin in hypotension, heart failure or MI, monitor BP and ECG during therapy. IV must be given slowly (too rapid admin may cause hypotension, CNS depression, cardiac arrhythmias and impaired heart conduction). Extravasation and intra-arterial admin must be avoided. Do not discontinue abruptly (may increase seizure frequency), unless safety concerns require a more rapid withdrawal. May impair ability to drive or operate machinery.\n\nMode of action: Effects with other sedative drugs or ethanol may be potentiated. Enhances toxic effects of paracetamol, lithium. Increased risk of osteomalacia with acetazolamide. Decreased serum levels/effects with acyclovir, antineoplastics, benzodiazeines, ciprofloxacin, CYP2C9 inducers (e.g. carbamazepine), CYP2C19 inducers (e.g. rifampin), folic acid, vigabatrin. \n\nIncreased serum concentrations with allopurinol, capecitabine, cimetidine, CYP2C9 inhibitors (e.g. fluconazole), CYP2C19 inhibitors (e.g. delavirdine), disulfiram, methylphenidate, metronidazole, omeprazole, SSRI, trazodone, trimethoprim. Increases metabolism of antiarrhythmics, anticonvulsants, antipsychotics, beta-blockers, calcium channel blockers, chloramphenicol, corticosteroids, doxycycline, oestrogens, HMG-CoA reductase inhibitors, methadone, theophylline, TCAs. Decreases levels/effects of clozapine, ciclosporin, tacrolimus, CYP2B6 substrates (e.g. bupropion, selegiline), CYP2C8 substrates (e.g. amiodarone), CYP2C9 substrates (e.g. celecoxib), CYP2C19 substrates (e.g. citalopram), CYP3A4 substrates (e.g. benzodiazepines), digoxin, itraconazole, levodopa, neuromuscular-blocking agents, thyroid hormones, topiramate. \n\nIncreases levels/effect of dopamine, ticlopidine. Valproic acid may displace phenytoin from binding sites; and affect phenytoin serum concentrations. Transiently increases the hypothrombinaemia response to warfarin initially, followed by an inhibition of the response.\n\nPotentially Fatal: Enhances the hypotensive properties of dopamine and the cardiac depressant properties of lidocaine.\n\nPregnancy category: D\n\nInteraction: Effects with other sedative drugs or ethanol may be potentiated. Enhances toxic effects of paracetamol, lithium. Increased risk of osteomalacia with acetazolamide. Decreased serum levels/effects with acyclovir, antineoplastics, benzodiazeines, ciprofloxacin, CYP2C9 inducers (e.g. carbamazepine), CYP2C19 inducers (e.g. rifampin), folic acid, vigabatrin. \n\nIncreased serum concentrations with allopurinol, capecitabine, cimetidine, CYP2C9 inhibitors (e.g. fluconazole), CYP2C19 inhibitors (e.g. delavirdine), disulfiram, methylphenidate, metronidazole, omeprazole, SSRI, trazodone, trimethoprim. Increases metabolism of antiarrhythmics, anticonvulsants, antipsychotics, beta-blockers, calcium channel blockers, chloramphenicol, corticosteroids, doxycycline, oestrogens, HMG-CoA reductase inhibitors, methadone, theophylline, TCAs. Decreases levels/effects of clozapine, ciclosporin, tacrolimus, CYP2B6 substrates (e.g. bupropion, selegiline), CYP2C8 substrates (e.g. amiodarone), CYP2C9 substrates (e.g. celecoxib), CYP2C19 substrates (e.g. citalopram), CYP3A4 substrates (e.g. benzodiazepines), digoxin, itraconazole, levodopa, neuromuscular-blocking agents, thyroid hormones, topiramate. \n\nIncreases levels/effect of dopamine, ticlopidine. Valproic acid may displace phenytoin from binding sites; and affect phenytoin serum concentrations. Transiently increases the hypothrombinaemia response to warfarin initially, followed by an inhibition of the response.\n\nPotentially Fatal: Enhances the hypotensive properties of dopamine and the cardiac depressant properties of lidocaine.
Pholcodine	\n\n\tIndication: Unproductive coughs, Dry cough\n\nDose: Oral\nCough suppressant\nAdult: Symptomatic relief of non-productive cough: 5-10 mg 3-4 times daily.\nChild: 12-18 yr: 5-10 mg 3-4 times daily. 6-12 yr: 2-5 mg 3-4 times daily. Not to be used in children under the age of 6 yr.\n\nContra-indication: Hypersensitivity.\n\nSide effects:     Nausea (feeling sick)\n    Vomiting\n    Constipation\n    Drowsiness\n    Dizziness\n    Excitation\n    Confusion\n    Generalised rash\n    Excess mucus (phlegm)\n    Congestion (too much mucus / sputum staying in your airways)\n\n\n\nPrecaution: Long term lung/ breathing problems such as COPD; bronchitis (inflammation of the airways), bronchiectasis (abnormal widening of one or more airways) or damaged/ inflamed lungs caused by a build up of too much mucus (phlegm). Decreased kidney function.Decreased liver function.May affect ability to drive or operate machinery.\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Phytomenadione (Vitamin K1)	\n\n\tChemist Ltd.\tBabykion Injection  5 amps pack 100\n\tDrug International Ltd.\tDinakion Injection 10mg/ml 5 amps pack 225\n\tDrug International Ltd.\tDinakion MM Injection 2mg/.2ml 5 amps pack 99.45\n\tIncepta\tK MM Injection 2mg/0.2ml 5 amps pack 99.45\n\tIncepta\tKmm Injection 10mg/ml 5's pack 100\n\tRoche Bangladesh Pharmaceutical\tKonakion Injection  2mg (0.2ml) amp X 5's pack10mg (1ml) amp X 5's pack 551/575\n\tSquare\tK-One MM Injection 2mg/0.2ml 3 amps pack 59.46\n\tSquare\tK-One Injection 10 mg/ml  \n\tIndication: Vitamin K deficiency, Over-anticoagulation, Vitamin K deficiency bleeding\n\nDose: Intramuscular\nProphylaxis of vitamin K deficiency bleeding in neonates\nChild: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days.\n\nIntravenous\nOver-anticoagulation\nAdult: 0.5-5 mg via slow IV inj. Dose depends on INR and degree of haemorrhage.\n\nParenteral\nVitamin K deficiency bleeding in neonates\nChild: Infant: 1 mg by IV/IM/SC inj, further doses may be given if necessary\n\nContra-indication: Hypersensitivity.\n\nSide effects: Anaphylaxis, dyspnoea, cyanosis, pain, swelling, phloebitis at the Inj site, diaphoresis, dizziness, hypotension (rare), allergic reactions after SC and IM inj.\n\nPrecaution: Increased risk of severe haemolytic anaemia in neonates after large doses; severe hepatic impairment; pregnancy. Premature neonates weighing <2.5 kg.\n\nMode of action: Decreased effect of oral anticoagulants.\n\nPregnancy category: C\n\nInteraction: Decreased effect of oral anticoagulants.
Pilocarpine Hydrochloride	\n\n\tAristopharma\tPilogen TAB dr 5mg 30's pack 300\n\tIndication: Dry mouth, Sjogren's syndrome\n\nDose: Adult: PO Dry mouth after radiotherapy for malignant neoplasms of the head and neck Initial: 5 mg 3 times/day. Increase gradually after 4 wk if needed. Max: 10 mg 3 times/day. \n\nSjoren's syndrome 5 mg 4 times/day. Max: 30 mg/day. Stop treatment if no improvement after 3 mth. \n\nContra-indication: Angle-closure glaucoma; acute iritis, anterior uveitis; hypersensitivity. Pregnancy.\n\nSide effects: Ocular: Pain and irritation, blurred vision, lachrymation, browache, conjunctival vascular congestion, superficial keratitis, vitreous haemorrhage, increased pupillary block.\n\nPrecaution: Retinal detachment; corneal or conjunctival damage. Patients with cognitive or psychiatric disorders, renal impairment, biliary tract disorders. Prolonged use may lead to lens opacities. May impair ability to drive or operate machines. Lactation.\n\nMode of action: Concomitant admin of 2 miotics may increase risk of toxic reactions. Aminoglycosides, clindamycin, colistin, cyclopropane and halogenated inhalational anaesthetics, quinine, procainamide, lithium and beta-blockers may reduce the efficacy of pilacarpine. Concurrent use with beta-blockers may lead to bradycardia. May prolong the action of suxamethonium.\n\nPotentially Fatal: Miotic and ocular hypotensive effect antagonised by anticholinergics. Conduction disturbances with beta-blockers.\n\nPregnancy category: C\n\nInteraction: Concomitant admin of 2 miotics may increase risk of toxic reactions. Aminoglycosides, clindamycin, colistin, cyclopropane and halogenated inhalational anaesthetics, quinine, procainamide, lithium and beta-blockers may reduce the efficacy of pilacarpine. Concurrent use with beta-blockers may lead to bradycardia. May prolong the action of suxamethonium.\n\nPotentially Fatal: Miotic and ocular hypotensive effect antagonised by anticholinergics. Conduction disturbances with beta-blockers.
Pilocarpine Hydrochloride 1% Eye prep	\n\n\tAsiatic Ltd.\tAsipine 1% Eye Drops   10  ml drop 80\n\tOpso Saline Ltd.\tPilocarpine OSL 1% Eye Drops    10 ml drop 47.50\n\tReman Drug Ltd.\tPilo DROP Eye Drops   10 ml drop/10 ml drop/10 ml drop 74.20 / 172.25 / 212\n\tIndication: Open-angle glaucoma\n\nDose: Ophth: Open-angle glaucoma As HCl or nitrate: Instill a 0.5-4% soln 4 times/day. As modified release preparation which releases 20-40 mcg/hr for 7 days: Insert into the conjunctival sac. As 4% gel: Apply at bedtime.\n\nContra-indication: Angle-closure glaucoma; acute iritis, anterior uveitis; hypersensitivity. Pregnancy.\n\nSide effects: Ocular: Pain and irritation, blurred vision, lachrymation, browache, conjunctival vascular congestion, superficial keratitis, vitreous haemorrhage, increased pupillary block.\n\nPrecaution:  	Retinal detachment; corneal or conjunctival damage. Patients with cognitive or psychiatric disorders, renal impairment, biliary tract disorders. Prolonged use may lead to lens opacities. May impair ability to drive or operate machines. Lactation.\n\nMode of action: Concomitant admin of 2 miotics may increase risk of toxic reactions. Aminoglycosides, clindamycin, colistin, cyclopropane and halogenated inhalational anaesthetics, quinine, procainamide, lithium and beta-blockers may reduce the efficacy of pilacarpine. Concurrent use with beta-blockers may lead to bradycardia. May prolong the action of suxamethonium.\n\nPotentially Fatal: Miotic and ocular hypotensive effect antagonised by anticholinergics. Conduction disturbances with beta-blockers.\n\nPregnancy category: C\n\nInteraction: Concomitant admin of 2 miotics may increase risk of toxic reactions. Aminoglycosides, clindamycin, colistin, cyclopropane and halogenated inhalational anaesthetics, quinine, procainamide, lithium and beta-blockers may reduce the efficacy of pilacarpine. Concurrent use with beta-blockers may lead to bradycardia. May prolong the action of suxamethonium.\n\nPotentially Fatal: Miotic and ocular hypotensive effect antagonised by anticholinergics. Conduction disturbances with beta-blockers.
Pilocarpine Hydrochloride 2 % Eye prep	\n\n\tNipa\tPilomin 2% Eye Drops    10 ml drop 130\n\tOpso Saline Ltd.\tPilocarpine OSL 2% Eye Drops   10ml bot 74\n\tOpsonin Pharma\tPiloma Eye Drops  10 ml bot 200\n\tPopular\tOptacarpine 2% Eye Drops  2 %  5  ml drop 200\n\tIndication: Open-angle glaucoma\n\nDose: Ophth Open-angle glaucoma As HCl or nitrate: Instill a 0.5-4% soln 4 times/day. As modified release preparation which releases 20-40 mcg/hr for 7 days: Insert into the conjunctival sac. As 4% gel: Apply at bedtime.\n\nContra-indication: Angle-closure glaucoma; acute iritis, anterior uveitis; hypersensitivity. Pregnancy.\n\nSide effects: Ocular: Pain and irritation, blurred vision, lachrymation, browache, conjunctival vascular congestion, superficial keratitis, vitreous haemorrhage, increased pupillary block.\n\nPrecaution: Retinal detachment; corneal or conjunctival damage. Patients with cognitive or psychiatric disorders, renal impairment, biliary tract disorders. Prolonged use may lead to lens opacities. May impair ability to drive or operate machines. Lactation.\n\nMode of action: Concomitant admin of 2 miotics may increase risk of toxic reactions. Aminoglycosides, clindamycin, colistin, cyclopropane and halogenated inhalational anaesthetics, quinine, procainamide, lithium and beta-blockers may reduce the efficacy of pilacarpine. Concurrent use with beta-blockers may lead to bradycardia. May prolong the action of suxamethonium.\n\nPotentially Fatal: Miotic and ocular hypotensive effect antagonised by anticholinergics. Conduction disturbances with beta-blockers.\n\nPregnancy category: C\n\nInteraction: Concomitant admin of 2 miotics may increase risk of toxic reactions. Aminoglycosides, clindamycin, colistin, cyclopropane and halogenated inhalational anaesthetics, quinine, procainamide, lithium and beta-blockers may reduce the efficacy of pilacarpine. Concurrent use with beta-blockers may lead to bradycardia. May prolong the action of suxamethonium.\n\nPotentially Fatal: Miotic and ocular hypotensive effect antagonised by anticholinergics. Conduction disturbances with beta-blockers.
Pilocarpine Hydrochloride 4% Eye prep	\n\n\tNipa\tPilomin 4% Eye Drops   10 ml drop 175\n\tOpso Saline Ltd.\tPilocarpine OSL 4% Eye Drops   10ml drop 128\n\tIndication: Open-angle glaucoma\n\nDose: Ophth Open-angle glaucoma As HCl or nitrate: Instill a 0.5-4% soln 4 times/day. As modified release preparation which releases 20-40 mcg/hr for 7 days: Insert into the conjunctival sac. As 4% gel: Apply at bedtime.\n\nContra-indication: Angle-closure glaucoma; acute iritis, anterior uveitis; hypersensitivity. Pregnancy.\n\nSide effects: Ocular: Pain and irritation, blurred vision, lachrymation, browache, conjunctival vascular congestion, superficial keratitis, vitreous haemorrhage, increased pupillary block.\n\nPrecaution: Retinal detachment; corneal or conjunctival damage. Patients with cognitive or psychiatric disorders, renal impairment, biliary tract disorders. Prolonged use may lead to lens opacities. May impair ability to drive or operate machines. Lactation.\n\nMode of action: Concomitant admin of 2 miotics may increase risk of toxic reactions. Aminoglycosides, clindamycin, colistin, cyclopropane and halogenated inhalational anaesthetics, quinine, procainamide, lithium and beta-blockers may reduce the efficacy of pilacarpine. Concurrent use with beta-blockers may lead to bradycardia. May prolong the action of suxamethonium.\n\nPotentially Fatal: Miotic and ocular hypotensive effect antagonised by anticholinergics. Conduction disturbances with beta-blockers.\n\nPregnancy category: C\n\nInteraction: Concomitant admin of 2 miotics may increase risk of toxic reactions. Aminoglycosides, clindamycin, colistin, cyclopropane and halogenated inhalational anaesthetics, quinine, procainamide, lithium and beta-blockers may reduce the efficacy of pilacarpine. Concurrent use with beta-blockers may lead to bradycardia. May prolong the action of suxamethonium.\n\nPotentially Fatal: Miotic and ocular hypotensive effect antagonised by anticholinergics. Conduction disturbances with beta-blockers.
Pioglitazone	\n\n\tACI\tDiatag F/C 15 TAB dr 15mg 30's pack 240.90\n\tAcme Ltd.\tPidus TAB dr 15mg 30's pack 241.20\n\tAlco Pharma\tPiolit TAB dr 15mg 30's pack 240\n\tAristopharma\tGlucozon TAB dr 15mg 30's pack 240\n\tBeximco\tDiaglit TAB dr 15mg 30's pack 240\n\tDrug International Ltd.\tPiozena TAB dr 15mg 50's pack 400\n\tGeneral\tAdpas TAB dr 15mg 30's pack 240.90\n\tGeneral\tDianorm TAB dr 15mg 30's pack \n\tIbn Sina Pharmaceutical Ind. Ltd.\tGlitazon TAB dr 15mg 30's pack 240\n\tIncepta\tPiodar TAB dr 15mg 30's pack 240\n\tJayson\tPeegee TAB dr 15mg 30's pack 180.60\n\tKemiko\tOgli TAB dr 15mg 30's pack 240\n\tMedimet\tDiapiotab TAB dr 15mg 50's pack 400\n\tNational Ltd.\tPioglinet TAB dr 15mg 20's pack 300\n\tNavana\tDiatus TAB dr 15mg 30's pack 240\n\tOpsonin Pharma\tPiol TAB dr 15mg 30's pack 240\n\tPacific\tPiglit TAB dr 15mg 30's pack 240\n\tRenata\tPioglin TAB dr 15mg 30's pack 240.90\n\tSanofi Aventis (BD) Ltd.\tSaglit TAB dr 15mg 30's pack 240.90\n\tSquare\tTos TAB dr 15mg 30's pack 240.99\n\tWhite Horse Pharma\tLit TAB dr 15mg 30's pack 240\n\tIndication: Type 2 DM\n\nDose: Adult: PO 15 mg once daily. Please see the precaution.\n\n\n\nContra-indication: Hypersensitivity. Type 1 diabetes mellitus, symptomatic or history of heart failure, diabetic ketoacidosis, childn <18 yr. Lactation.\n\nSide effects: Pharyngitis, oedema, headache, upper resp tract infection, sinusitis, anaemia; GI disturbances, wt gain, visual disturbances, dizziness, arthralgia, haematuria, impotence.\n\nPrecaution: I. Liver Enzyme must be monitored regularly \nII. History of heart failure and MI should be verified \nIII. Incidence of bladder cancer should be verified \nIV. Not to be used for elderly patients \nV. Not to be used continuously more than one year \nVI. Use only by Specialist advice.\n\nIncreased risk of hypoglycaemia when used with insulin or oral hypoglycaemics. Oedema, congestive heart failure, hepatic dysfunction, jaundice, anaemia. May cause ovulation in premenopausal, anovulatory women. Monitor liver function before and during treatment. Monitor glycaemic control. Pregnancy. Caution when oral contraceptives or hormonal replacement therapy is used in diabetics due to increased risk of arterial diseases. Stop treatment if ALT increases and remains >3 times above the upper limit of normal or if jaundice develops.\n\nMode of action: Increased risk of oedema w/ insulin, metformin and sulfonylureas. Increased plasma levels w/ gemfibrozil and ketoconazole. Decreased plasma levels w/ rifampicin.\n\nPregnancy category: C\n\nInteraction: Increased risk of oedema w/ insulin, metformin and sulfonylureas. Increased plasma levels w/ gemfibrozil and ketoconazole. Decreased plasma levels w/ rifampicin.
Piperacillin + Tazobactam	\n\n\tACI\tTazosyn IV Infusion 2g+0.25g 1's pack 601.80\n\tACI\tTazosyn IV Infusion 4g+0.50g 1's pack 1003.01\n\tPopular\tMegacilin Injection  4 gm + .5 gm/vial 4.5gm combipack 1003.78\n\tRenata\tTazopen IV Injection   1's pack 1000\n\tSanofi Aventis (BD) Ltd.\tBrodactam IV Injection  1x1's Pack 1000\n\tSquare\tTazocil 4.5 IV Injection   1's pack 1000\n\tIndication: Septicaemia, Nosocomial pneumonia\n\nDose: Intravenous\nNosocomial pneumonia\nAdult: Initial dose: 4.5 g (piperacillin 4 g and tazobactam 0.5 g) every 6 hr for 7-14 days. When used empirically, combination with an aminoglycoside or antipseudomonal fluoroquinolone is recommended. May be given via infusion over 30 minutes. If Pseudomonas aeruginosa is not isolated, may discontinue aminoglycoside.\nChild: 2-8 mth: 80 mg of piperacillin/kg every 8 hr; >9 mth and >40 kg: 100 mg of piperacillin/kg every 8 hr. \n\nSevere infections\nAdult: 3.375 g (piperacillin 3 g and tazobactam 0.375 g) every 6 hr for 7-10 days. May be given via infusion over 30 minutes.\n\nRenal impairment: For haemodialysis, admin an additional dose of 0.75 g after each dialysis session on haemodialysis days.\n\nCrCl (ml/min)	\n>40 	3.375 g every 6 hr\n20-40	2.25 g every 6 hr\n<20	       2.25 g every 8 hr\nHaemodialysis	2.25 g every 12 hr\nCAPD	2.25 g every 12 hr\n\nContra-indication: Hypersensitivity.\n\nSide effects: Diarrhoea, skin rashes, occasionally platelet mediated bleeding, rigors, malaise, ulcerative stomatitis. Inj-site reactions such as pain, erythema, induration and thrombophlebitis.\nPotentially Fatal: Serious, anaphylactic reactions.\n\nPrecaution:  	Pregnancy and lactation, pseudomembranous colitis. Assess hematopoietic function periodically. Perform periodic electrolyte determinations in patients with low K reserves. Increased risk of fever and rash in patients with cystic fibrosis. Increased risk of bleeding manifestations. Prolonged treatment may increase risk of superinfections. Convulsions or neuromuscular excitability may occur when high doses are used, especially in renally impaired patients. Renal impairment.\n\nMode of action: Interacts w/ high doses of heparin, oral anticoagulants or other drugs that affect blood coagulation or thrombocyte function. Prolongs the neuromuscular blockade of vecuronium and non-depolarising muscle relaxants. Prolongs half-lives w/ probenecid. Increased risk of methotrexate toxicity.\n\nPregnancy category: B\n\nInteraction: Interacts w/ high doses of heparin, oral anticoagulants or other drugs that affect blood coagulation or thrombocyte function. Prolongs the neuromuscular blockade of vecuronium and non-depolarising muscle relaxants. Prolongs half-lives w/ probenecid. Increased risk of methotrexate toxicity.
Piracetam	\n\n\tACI\tMemopil Syrup 500mg/5ml 100ml bot 151.02\n\tACI\tMemopil TAB dr 1200mg 30's pack 270.90\n\tACI\tMemopil TAB dr 800mg 50's pack 302\n\tAristopharma\tPiramax TAB dr 800mg 30's pack 180\n\tGeneral\tPiratam Syrup 500mg/5ml 100ml bot 150.57\n\tGeneral\tPiratam TAB dr 800mg 40's pack 240.80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeuratam TAB dr 800mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeuratam Syrup 500 mg/5 ml  \n\tNovartis (Bangladesh) Ltd.\tEnmecon TAB dr 800mg 50's pack 455\n\tOpsonin Pharma\tJuvain Syrup 500mg/5ml 1's pack 132.46\n\tOpsonin Pharma\tJuvain TAB dr 800mg 50's pack 264.79\n\tSquare\tNeurolep Syrup 500mg/5ml 100ml bot 150.57\n\tSquare\tNeurolep TAB dr 800mg 40's pack 240.99\n\tEgis Pharmaceuticals, Hungary\tLucetum TAB dr 1200mg 20's pack 315\n\tIndication: Cortical myoclonus, Cognitive enhancer\n\nDose: Adult: PO Adjunct in treatment of cortical myoclonus 7.2 g/day in 2-3 divided doses, increase if needed. Max: 20 g/day. Cognitive enhancer 2.4 g/day in 2-3 divided doses. Severe: Up to 4.8 g/day.\n\nRenal impairment:\nCrCl (ml/min)	\n50-79	2/3 usual dose\n30-49	1/3 usual dose\n20-29	1/6 usual dose\n<20 	Contra-indicated\n\nContra-indication: Hepatic and severe renal impairment. Cerebral haemorrhage. Pregnancy and lactation.\n\nSide effects: Hyperkinesia, nervousness, depression, diarrhoea, rashes. CNS stimulation, sleep disturbances, dizziness, excitement, insomnia, somnolence, wt gain.\n\n\nPrecaution: Avoid abrupt withdrawal. Impaired renal function. Cardiac disorders. Haemostatic disorders. Patients who have recently undergone major surgery. Elderly.\n\nMode of action: May increase prothrombin time in patients who are on warfarin.\n\nPregnancy category: Not Classified\n\nInteraction: May increase prothrombin time in patients who are on warfarin.
Piroxicam	\n\n\tG. A. Company Ltd.\tRheudene CAP 10mg 100's pack 175\n\tRenata\tFlexicam CAP 10mg 100's pack 167\n\tRenata\tFlexicam IM Injection 40mg/2ml 2ml amp x 1's pack 14.72\n\tIndication: Acute gout, Rheumatic disorders, Postoperative pain, Acute musculoskeletal conditions, Juvenile idiopathic arthritis\n\nDose: Adult: PO Rheumatic disorders Initial: 20 mg/day as a single dose. Maintenance: 10-30 mg in single or divided doses. \nAcute gout 40 mg/day for 5-7 days. \nAcute musculoskeletal conditions; Post-op pain Initial: 40 mg/day for 2 days. Maintenance: 20 mg/day for 1-2 wk. \nJuvenile idiopathic arthritis\nChild: >6 yr: <15 kg: 5 mg, 16-25 kg: 10 mg, 26-45 kg: 15 mg, >46 kg: 20 mg. Doses to be taken once daily. \n\nContra-indication: Hypersensitivity, active peptic ulceration, porphyria, pregnancy (3rd trimester) and lactation.\n\nSide effects: GI disturbances, peptic ulcer, GI bleeding, headache, dizziness, blurred vision, tinnitus, skin rashes and pruritus. Haematological changes and photosensitivity.\nPotentially Fatal: Thrombocytopaenia and acute nephropathy. Toxic epidermal necrolysis and Stevens-Johnson syndrome.\n\nPrecaution: Elderly, childn <12 yr. Patients with infections, asthma, allergic disorders, haemorrhagic disorders or hypertension. Impaired renal, hepatic or cardiac function. Monitor for signs of liver, kidney, blood or eye disorders.\n\nMode of action: Increased risk of GI bleeding w/ anti-platelets and SSRIs. May exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels. Increased risk of nephrotoxicity w/ ciclosporin and tacrolimus. Increased absorption w/ cimetidine. Increased risk of GI ulceration w/ corticosteroids. May interfere w/ the natriuretic action of diuretics. May displace other highly protein-bound drugs. May increase steady state plasma lithium levels. May antagonise the effect of antihypertensives. May reduce the excretion of methotrexate, leading to acute toxicity. Increased risk of convulsions w/ quinolones. May interfere w/ mifepristone-mediated termination of pregnancy.\n\nPotentially Fatal: May enhance the effect of anticoagulants (e.g. warfarin). Increased risk of serious GI events w/ aspirin and other NSAIDs.\n\nPregnancy category: C\n\nInteraction: Increased risk of GI bleeding w/ anti-platelets and SSRIs. May exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels. Increased risk of nephrotoxicity w/ ciclosporin and tacrolimus. Increased absorption w/ cimetidine. Increased risk of GI ulceration w/ corticosteroids. May interfere w/ the natriuretic action of diuretics. May displace other highly protein-bound drugs. May increase steady state plasma lithium levels. May antagonise the effect of antihypertensives. May reduce the excretion of methotrexate, leading to acute toxicity. Increased risk of convulsions w/ quinolones. May interfere w/ mifepristone-mediated termination of pregnancy.\n\nPotentially Fatal: May enhance the effect of anticoagulants (e.g. warfarin). Increased risk of serious GI events w/ aspirin and other NSAIDs.
Pitavastatin	\n\n\tAcme Ltd.\tPavigard TAB dr 2mg 20's pack 200\n\tAristopharma\tPitavas TAB dr 2mg 30's pack 300\n\tDrug International Ltd.\tLip Loss TAB dr 2mg 20's pack 200\n\tDrug International Ltd.\tLiploss TAB dr 2mg 20's pack \n\tEskayef Bangladesh Ltd.\tPivasta TAB dr 2mg  \n\tSquare\tPivalo TAB dr 2mg 30's pack 300\n\tSquare\tPivalo TAB dr 4mg 20's pack \n\tIndication: Cardiovascular disease, Hypercholesterolaemia\n\nDose: The dose range for Pitavastatin is 1 to 4 mg orally once daily at any time of the day with or without food. The recommended starting dose is 2 mg and the maximum dose is 4 mg. \n\nThe starting dose and maintenance doses of Pitavastatin should be individualized according to patient characteristics, such as goal of therapy and response.\n\nContra-indication: Patients with a known hypersensitivity to any component of this products. Pitavastatin is contraindicated in patients with active liver disease , which may include unexplained persistent elevations of hepatic transaminase levels.\n\nSide effects: Pitavastatin is generally well tolerated . The common side effects are headache , myalgia , asthenia , constipation , dizziness , and abdominal pain. It may rarely cause rhabdomyolysis and hypersensitivity reaction , such as-rash , pruritus and urticaria.\n\nPrecaution: Use with caution in clients with predisposing factors\nto myopathy (e.g., >65 years of age, renal impairment,\ninadequately treated hypothyroidism)\n and in clients with impaired renal function, the elderly, or when used together with fibrates or lipid-modifying doses of niacin.\n\n? Elderly clients may manifest greater sensitivity to pitavastatin.\n\n? Safety and efficacy not determined in children.\n\nMode of action: Increased bioavailability w/ erythromycin and rifampicin. Increased risk of myopathy/rhabdomyolysis w/ gemfibrozil, colchicine, niacin and other fibrates.\nPotentially Fatal: Ciclosporin significantly increases pitavastatin exposure.\n\nPregnancy category: X\n\nInteraction: Increased bioavailability w/ erythromycin and rifampicin. Increased risk of myopathy/rhabdomyolysis w/ gemfibrozil, colchicine, niacin and other fibrates.\nPotentially Fatal: Ciclosporin significantly increases pitavastatin exposure.
Pivmecillinam	\n\n\tAristopharma\tAlexid TAB dr 200mg 50's pack 750\n\tGeneral\tPivicil TAB dr 200mg 20's pack 241\n\tKemiko\tPinam TAB dr 200mg 30's pack 360\n\tPharmadesh Ltd.\tBacilex TAB dr 200mg 20's pack 360\n\tRangs\tPivcilin TAB dr 200mg 20's pack 240\n\tRenata\tRelexid TAB dr 200mg 30's pack 360\n\tSquare\tEmcil TAB dr 200mg 30's pack 361.49\n\tTechno Drugs Ltd.\tLexipen TAB dr 200mg 30's pack 350\n\tIndication: Acute uncomplicated cystitis, Chronic or recurrent bacteriuria\n\nDose: Oral\nAcute uncomplicated cystitis\nAdult: Initially 400 mg followed by 200 mg tid for 8 doses.\nChild: <40 kg with UTI: 20-40 mg/kg/day in 3-4 divided doses.\n\nChronic or recurrent bacteriuria\nAdult: 400 mg 3-4 times daily.\nChild: <40 kg with UTI: 20-40 mg/kg/day in 3-4 divided doses.\n\nContra-indication: Hypersensitivity, porphyria.\n\nSide effects: Hypersensitivity reactions including uticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropaenia; thrombocytopaenia; CNS toxicity including convulsions; diarrhoea; antibiotic-associated colitis. Induction of carnitine deficiency.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum K concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route. May cause oesophageal injury.\n\nMode of action: Probenecid prolongs T1/2 of pivmecillinam. May cause prolonged bleeding when taken with anticoagulants. May decrease the efficacy of oral contraceptives. Increased risk of carnitine deficiency when used with valproate.\n\nPregnancy category: B\n\nInteraction: Probenecid prolongs T1/2 of pivmecillinam. May cause prolonged bleeding when taken with anticoagulants. May decrease the efficacy of oral contraceptives. Increased risk of carnitine deficiency when used with valproate.
Pizotifen	\n\n\tAcme Ltd.\tPizo A TAB dr 500mcg 100's pack 262\n\tAcme Ltd.\tPizo A TAB dr 1.5mg 50's pack 306\n\tApex\tZonil TAB dr 500mcg 50's pack 150\n\tApex\tZonil-TS TAB dr 1.5mg 30's pack 210\n\tAristopharma\tZofen TAB dr 500mcg 50's pack 155\n\tAristopharma\tZofen TS TAB dr 1.5mg 50's pack 360\n\tBeximco\tAvidro 0.5 TAB dr 0.5mg 100's pack 300\n\tBeximco\tAvidro TAB dr 1.5mg 50's pack 350\n\tDrug International Ltd.\tD Fen 0.5 TAB dr 500mcg 100's pack 150\n\tDrug International Ltd.\tD Fen TAB dr 1.5mg 50's pack 250\n\tEdruc Ltd.\tMigranex TAB dr 1.5mg 30's pack 210\n\tEdruc Ltd.\tMigranex TAB dr 500mcg 50's pack 150\n\tEskayef Bangladesh Ltd.\tZeromig 0.5 MG TAB dr 0.5mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tZeromig 1.5 MG TAB dr 1.5mg 30's pack 210\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAntigrain TAB dr 500mcg 50's pack 162.50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tAntigrain TS TAB dr 1.5mg 30's pack 217.50\n\tMedicon\tPitofen TAB dr 500mcg 100's pack 300\n\tNavana\tPizofen TAB dr 500mcg 100's pack 301\n\tNavana\tPizofen TS TAB dr 1.5mg 50's pack 351.50\n\tNipa\tPizotin TAB dr 500mcg 100's pack 300\n\tNipa\tPizotin TAB dr 1.5mg 30's pack 210\n\tNIPRO JMI Pharma\tDmigrain TAB dr 500mcg 50's pack 150\n\tNIPRO JMI Pharma\tDmigrain TAB dr 1.5mg 50's pack 350\n\tOpsonin Pharma\tPifen TAB dr 500mcg 50's pack 131.84\n\tOpsonin Pharma\tPifen TAB dr 1.5mg 30's pack 185.53\n\tSquare\tMigranil TAB dr 500mcg 50's pack 150.29\n\tSquare\tMigranil TAB dr 1.5mg 30's pack 210.67\n\tTechno Drugs Ltd.\tMigofen TAB dr 500mcg 30's pack 90\n\tTechno Drugs Ltd.\tMigofen TAB dr 1.5mg 30's pack 180\n\tIndication: Headache, Migraine\n\nDose: Oral\nProphylaxis of migraine, Prophylaxis of cluster headache\nAdult: 1.5 mg/day either in 3 divided doses or as a single dose at night. Gradual increase of 0.5 mg helps to avoid drowsiness. Max dose: 4.5 mg/day and 3 mg/dose.\n\nChild: >2 yr: Up to 1.5 mg daily in divided doses. Max dose: 1 mg/dose.\n\nContra-indication: Premature infants or neonates. Postural giddiness.\n\nSide effects: CNS depression; headache, psychomotor impairment, antimuscarinic effects; GI disturbances; increased appetite; wt gain; drowsiness; palpitations, arrhythmias; hypersensitivity reactions; blood disorders; convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, sleep disturbances, confusion, tinnitus, tremor, depression, hypotension, hair loss.\n\nPrecaution: Angle-closure glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction, epilepsy; hepatic impairment; elderly; young child. May affect ability to drive or operate machinery. Pregnancy, lactation.\n\nMode of action: Enhances sedative effects of CNS depressants. Additive antimuscarinic action with other antimuscarinic drugs. May mask warning signs of damage caused by ototoxic drugs eg, aminoglycosides.\n\nPregnancy category: B\n\nInteraction: Enhances sedative effects of CNS depressants. Additive antimuscarinic action with other antimuscarinic drugs. May mask warning signs of damage caused by ototoxic drugs eg, aminoglycosides.
Podophyllotoxin 0.15%	\n\n\tIndication: Anogenital warts\n\nDose: Topical/Cutaneous\nAnogenital warts\nAdult: On a wkly basis, apply 15% (Indian podophyllum) or up to 25% solution (American podophyllum) on the warts, leave for 1-6 hr then wash off. If there is no improvement after 6 wk, stop treatment. Alternatively, apply 0.5% alcoholic gel or 0.15% cream bid for 3 days but do not wash off. Repeat wkly for up to 5 wk.\n\nContra-indication: Hypersensitivity; pregnancy; lactation; child.\n\nSide effects: Irritating to the eyes and mucous membranes; GI disturbances; thrombocytopenia, leucopenia; renal failure; hepatotoxicity; CNS effects; EEG changes; peripheral and autonomic neuropathies; local reactions.\n\nPrecaution:  	Avoid excessive application. Avoid contact with eyes and inflamed skin. Not to be used on cervical or urethral warts.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Poly ethylene Glycol 3350 + Electrolytes	\n\n\tIncepta\tMovilax Dry Powder Sachet  20's 700\n\tIndication: Constipation, Fecal impaction\n\nDose: Constipation: The dose is 1 sachet daily. This may be increased to 2-3 sachets daily, if required.        \n\nFecal Impaction: 8 sachets daily, consumed within 6 hours. A course of treatment for fecal impaction does not normally exceed 3 days. \n\nContra-indication: Polyethylene glycol is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.\n\nSide effects: Nausea, abdominal bloating, cramping and flatulence may occur. High doses may produce diarrhea and excessive stool frequency, particularly in elderly nursing home patients. Patients taking other medications containing polyethylene glycol have occasionally developed urticaria suggestive of an allergic reaction.\n\nPrecaution: Patients with impaired cardiovascular function: For the treatment of faecal impaction the dose should be divided so that no more than two sachets are taken in any one hour. If patients develop any symptoms indicating shifts of fluid/electrolytes (e.g. edema, shortness of breath, increasing fatigue, dehydration, cardiac failure) It should be stopped immediately and any abnormality should be treated appropriately. Prolonged use with all laxatives is undesirable and may lead to dependence. \n\nPatients with symptoms suggestive of bowel obstruction (nausea, vomiting, abdominal pain or distention) should be evaluated to rule out this condition before initiating. \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Polyethylene Glycol 400 0.4% + Propylene Glycol 0.3% Eye prep	\n\n\tAcme Ltd.\tOpcol Eye Drops (400 mg + 300 mg)/100 ml  \n\tApex\tPolysol Eye Drops   10 ml drop 150\n\tAristopharma\tSystear Eye Drops   10 ml drop 150\n\tBeximco\tTearon Eye Drops   10 ml drop 150\n\tEskayef Bangladesh Ltd.\tFreshtear Eye Drops   10ml 150\n\tGeneral\tGlytear Eye Drops   10ml drop 150\n\tGlobe\tLubricol Eye Drops (400 mg + 300 mg)/100 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tPolygel Drops Eye Drops   10ml drop 150\n\tIncepta\tFiltear Eye Drops   10g 456\n\tPopular\tAutotear Lubricant Eye Drops  400 mg + 300 mg/100 ml 10 ml drop 150.57\n\tSquare\tOculant Eye Drops 0.4% + 0.3% 10ml bot 150\n\tIndication: Dry eye\n\nDose: For Adults and Children: Instill 1 or 2 drops in the affected eye(s) as needed. \n\nContra-indication: It is contraindicated in patients with known sensitivity to any ingredient in this formulation.\n\nSide effects: Generally well tolerated. A very serious allergic reaction to this drug is rare. It should not be used if allergic condition occurs to any ingredients of the product. \n\nPrecaution: Do not touch tip of container to any surface to avoid contamination. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Potassium Bicarbonate + Potassium Chloride	\n\n\tIndication: Hypokalemia\n\nDose: Usual Adult Dose for Hypokalemia\nOral:\n40 to 100 mEq orally once a day given in equally divided doses using formulations which include normal-release tablets or capsules, extended-release tablets or capsules, dissolvable tablets, oral solution or powder for dissolution mixed with an appropriate volume of water or juice.\n\nUsual Adult Dose for Prevention of Hypokalemia.\n\nOral:\n10 to 20 mEq orally once a day given in equally divided doses using formulations which include normal-release tablets or capsules, extended-release tablets or capsules, dissolvable tablets, oral solution or powder for dissolution mixed with an appropriate volume of water or juice.\nUsual Pediatric Dose for Hypokalemia\n\nTreatment of hypokalemia: Note: High variability exists in dosing/infusion rate recommendations; therapy should be guided by patient condition and specific institutional guidelines.\n\nInfants and Children:\n\nOral: 2 to 5 mEq/kg/day in divided doses; not to exceed 1 to 2 mEq/kg as a single dose; if deficits are severe or ongoing losses are great, IV route should be considered preferred route of administration.\n\nNormal daily requirements: Oral or IV:\nInfants: 2 to 6 mEq/kg/day\nChildren: 2 to 3 mEq/kg/day\n\nPrevention of hypokalemia during diuretic therapy:\nInfants and Children: 1 to 2 mEq/kg/day orally in 1 to 2 divided doses\n\nContra-indication: Hypersensitivity.\n\nSide effects: Metabolic\n\nMetabolic side effects have been reported rarely and have usually resulted from hyperkalemia. The risk of hyperkalemia is relatively high in patients with preexisting renal insufficiency.\n\nGastrointestinal\n\nGastrointestinal (GI) side effects have been reported from orally administered potassium chloride. They have included bad taste or aftertaste, nausea (10% to 30%), abdominal pain (20%), diarrhea (25%), dyspepsia or "heartburn" (5% to 20%) and GI ulceration. They have rarely included gastric or small bowel obstruction associated with the use of solid preparations.\n\nAll solid KCl preparations can cause erosive damage to the GI mucosa, especially when they are administered in high doses with an anticholinergic agent. Anticholinergic agents increase GI transit (and potassium-mucosa contact) time.\n\nPatients at higher risk of GI lesions include the elderly, the immobile and those with scleroderma, diabetes mellitus, mitral valve replacement, cardiomegaly or esophageal stricture. \n\nNearly half of all patients complain of a bad taste or aftertaste.\n\nLiquid KCl may be a better choice for patients with a history of esophageal stenosis or left atrial enlargement.\n\nHypersensitivity\n\nHypersensitivity side effects have been reported rarely. They have included a single case of contact dermatitis.\nDermatologic\n\nDermatologic side effects have rarely included skin rash.\n\nPrecaution: Potassium chloride (KCl) is contraindicated in the presence of hyperkalemia; renal failure and conditions in which potassium retention is present, including the concomitant use of potassium-sparing diuretics (such as triamterene, amiloride, or spironolactone); oliguria or azotemia; anuria; crush syndrome; severe hemolytic reactions; adrenocortical insufficiency (untreated Addison's disease); adynamical episodica hereditaria; acute dehydration; heat cramps; and early postoperative oliguria except during gastrointestinal drainage.\n\nPatients should not use potassium-rich salt substitutes without the advice of their healthcare professional during KCl therapy.\n\nIn patients with renal insufficiency, use of potassium chloride may cause potassium intoxication and life-threatening hyperkalemia.\n\nSolid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Potassium chloride should be discontinued immediately and the possibility of ulceration, obstruction, or perforation should be considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs.\n\nClinical evaluation and periodic laboratory evaluations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the administration of additional electrolyte supplements, or the administration of electrolyte-free dextrose solutions to which individualized electrolyte supplements may be added.\n\nCertain potassium chloride extended-release tablets contain a wax matrix. This matrix is not absorbed and is excreted in the feces. In some instances the empty matrices may be noticeable in the stool.\n\nDose selection in the elderly should be cautious and should start at the lower end of the dosing range.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Potassium Bicarbonate + Sodium Alginate	\n\n\tBeximco\tViscocid Solution 200ml 150 150\n\tBeximco\tViscocid Suspension (100 mg + 500 mg)/5 ml 200 ml bot \n\tEskayef Bangladesh Ltd.\tGelid Chewable TAB dr 100 mg + 500 mg  \n\tEskayef Bangladesh Ltd.\tGelid Suspension (100 mg + 500 mg) / 5 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tGerdex TAB dr 100 mg + 500 mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tGerdex Suspension (100 mg + 500 mg)/5 ml  \n\tIncepta\tAlgicid TAB dr   100's pack 350\n\tIncepta\tAlgicid Suspension   200ml bot 125\n\tLeon\tAlgicon TAB dr 100 mg + 500 mg  \n\tLeon\tAlgicon Suspension (100 mg + 500 mg)/5 ml  \n\tMonicopharma\tAlgerd Suspension (100 mg + 500 mg)/5 ml  \n\tNovelta Bestway\tXerocid TAB dr  50's pack 175\n\tNovelta Bestway\tXerocid Suspension   200ml bot 125\n\tOpsonin Pharma\tAlgisum TAB dr  10x5's pack 153.95\n\tOpsonin Pharma\tAlgisum Suspension 200ml 1's pack 109.96\n\tOrion Pharma Ltd.\tMarvelta Suspension (100 mg + 500 mg) / 5 ml  \n\tSquare\tAsynta Suspension 100 mg + 500 mg/5 ml 200ml bot 125\n\tSquare\tAsynta TAB dr 100 mg + 500 mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tGastrocon TAB dr  30's pack 135\n\tUnimed & Unihealth Manufacturers Ltd.\tGastrocon suspension  200 ml bot 155\n\tIndication: Heartburn, Indigestion, Gastro-oesophageal reflux, Acid regurgitation, Reflux esophagitis\n\nDose: Daily 4 times, after meals & before bedtime.\nTablet\nAdult and child over 12 years: 1-2 tablets.\nChild 6-12 years: 1 tablet.\n\nSuspension\nAdult and child over 12 years: 5-10 ml.\nChild 2-12 years: 2.5-5 ml.\nIt is not recommended for children under 2 years of age.\n\nContra-indication: Sodium alginate and potassium bicarbonate is contraindicated in patients with known hypersensitivity to these.\n\nSide effects: In addition to the desired effect of the drug, some side effects may appear such as: nausea, constipation, diarrhea or headache. In these cases consult a physician In case too big dosage has been taken, there might appear a sensation of swelling. In this case it is advisable to consult a physician.\n\nPrecaution: This should be prescribed with caution in patients with renal impairment and congestive cardiac failure.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Potassium Chloride	\n\n\tAcme Ltd.\tElectro K Syrup 500mg/5ml 100ml bot 25\n\tAcme Ltd.\tElectro K TAB dr 600mg 100's pack 60\n\tJayson\tK T Injection 1.5gm/10ml 10 amps pack 100\n\tJayson\tK T Syrup 540mg/5ml  100ml bot 25\n\tOpsonin Pharma\tKCL Injection 1.5gm/10ml 10ml x 5's pack 50\n\tOpsonin Pharma\tKCL Syrup 500mg/5ml 100ml bot 20.07\n\tIndication: Hypokalemia, Electrolyte replenisher\n\nDose: Oral\nProphylaxis of hypokalaemia and mild K deficiency\nAdult: Prevention of hypokalaemia: 20 mEq daily. Treatment of hypokalaemia: 40-100 mEq/day. Give in divided doses if >20 mEq/day.\n\nHypokalaemia\nAdult: Prevention of hypokalaemia: 20 mEq daily. Treatment of hypokalaemia: 40-100 mEq/day. Give in divided doses if >20 mEq/day.\n\nIntravenous\nSevere acute hypokalaemia\nAdult: If serum potassium level >2.5 mEq/L, give at a rate not exceeding 10 mEq/hr in a concentration of up to 40 mEq/L. Max dose: 200 mEq/24 hr. If serum potassium level <2 mEq/L, may infuse at a rate of up to 40 mEq/hr. Continuous cardiac monitoring is essential. Max dose: 400 mEq/24 hr.\nMax Dosage: 2-3 mmol potassium/kg body wt in 24 hrs.\n\nContra-indication: Hyperchloraemia, severe renal or adrenal insufficiency.\n\nSide effects: GI ulceration (sometimes with haemorrhage and perforation or with late formation of strictures) following the use of enteric-coated K chloride preparation; hyperkalaemia. Oral: Nausea, vomiting, diarrhoea and abdominal cramps. IV: Pain or phloebitis; cardiac toxicity.\n\nPrecaution: Renal or adrenocortical insufficiency; cardiac disease; acute dehydration; extensive tissue destruction. Pregnancy. Ensure adequate urine output; monitor plasma-potassium and other electrolyte concentrations. Discontinue treatment if severe nausea, vomiting or abdominal distress develops. Accumulation of potassium may occur in renal impairment.\n\nMode of action: Potassium-sparing diuretics, ACE inhibitors, ciclosporin and potassium-containing drugs. Antimuscarinics delay gastric emptying time consequently increasing risk of GI adverse effects esp of solid oral dosage forms.\n\nPregnancy category: C\n\nInteraction: Potassium-sparing diuretics, ACE inhibitors, ciclosporin and potassium-containing drugs. Antimuscarinics delay gastric emptying time consequently increasing risk of GI adverse effects esp of solid oral dosage forms.
Potassium Chloride + Rice powder + Sodium Chloride + Trisodium Citrate (Rice ORS)	\n\n\tEskayef Bangladesh Ltd.\tNeorice Oral Saline   1/2 liter x 10's pack 120\n\tGeneral\tRice Saline Oral Saline   1/4 liter x 20's pack1/4 liter x 12's pack 120.40 / 144.60\n\tSquare\tRice ORS Oral Saline   10's pack 60\n\tZenith\tRice Saline Oral Saline   1/4 liter x 20's pack 120\n\tIndication: Dehydration, Acute diarrhoea, Cholera, Vomiting, Acute fluid and electrolyte loss\n\nDose: 6 month to 23 months: 50 ml to 100 ml for each loose motion\n2 years to 9 years: 100 ml to 200 ml for each loose motion\n10 years or more: 200 ml to 500 ml for each loose motion \n\nContra-indication: Not to be used in -\nKidney failure resulting in diminished production of urine (oliguria)\nKidney failure, preventing production of urine (anuria)\nObstruction of the stomach or intestines\nReduced blood flow to vital internal organs (shock)\nSevere and continuous vomiting (intractable vomiting)\nSevere dehydration\nSevere diarrhoea in infants\n\nSide effects: Some studies have reported a slightly increased risk of hyponatraemia (low plasma sodium concentration) in patients who have received this ORS. However this decrease, which was very limited, was not associated with any clinical signs. \n\nPrecaution: Precautions should be taken in case of significant overdose, especially for the\nfollowing patients -\nChildren less than 1 year of age\nPatients with imbalance of salt concentrations in the blood (electrolyte\nimbalance)\nPatients with severely decreased kidney and liver function\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Potassium Chloride 0.003% + Sodium Chloride 0.004% + Sodium Lactate 0.007%	\n\n\tIndication: Surgery, Blood loss due to trauma, burn injury, Fluid and electrolyte loss, hypovolemic shock.\n\nDose: According to the requirements or as advised by the physician.The volume and rate of infusion will depend upon the requirements of the patients and the judgement of the physician. It usually varies with age, weight and clinical condition of the patient. The recommended flow rate is up to 100-drops/minute/70 kg body weight.\n\nContra-indication: Not to be used in -\nKidney failure resulting in diminished production of urine (oliguria)\nKidney failure, preventing production of urine (anuria)\n\n\nSide effects: \n\nPrecaution: It should not be administered rapidly or for prolonged periods. Since the solution contains different electrolytes, it should be infused with caution in patients where electrolyte imbalance may cause detrimental effects; e.g. in pregnancy, renal impairment, heart failure, pulmonary congestion, etc. or to patients receiving potassium.\nsparing diuretics \n\nMode of action: Potassium Chloride: Potassium-sparing diuretics, ACE inhibitors, ciclosporin and potassium-containing drugs. Antimuscarinics delay gastric emptying time consequently increasing risk of GI adverse effects esp of solid oral dosage forms.\n\nSodium Chloride: May affect serum concentrations of lithium.\n\nSodium Lactate: Caution when used in patients receiving corticosteroids or corticotropin.\n\nPregnancy category: Not Classified\n\nInteraction: Potassium Chloride: Potassium-sparing diuretics, ACE inhibitors, ciclosporin and potassium-containing drugs. Antimuscarinics delay gastric emptying time consequently increasing risk of GI adverse effects esp of solid oral dosage forms.\n\nSodium Chloride: May affect serum concentrations of lithium.\n\nSodium Lactate: Caution when used in patients receiving corticosteroids or corticotropin.
Potassium Chloride 0.1% + Sodium Acetate 0.65% + Sodium Chloride 0.5%	\n\n\tAcme Ltd.\tAcme's Cholera Saline IV Infusion  500 ml bag / 1000 ml bag \n\tBeximco\tKoloride IV Infusion   500 ml bag  / 1000 ml bag 69.93 / 91.72\n\tLibra Pharmaceuticls Ltd.\tDiasol IV Infusion   500 ml bag  / 1000 ml bag 69.93 / 91.72\n\tOpso Saline Ltd.\tCholera IV Infusion   500 ml bag  / 1000 ml bag 45 / 55\n\tOrion Pharma Ltd.\tDianak IV Infusion   500 ml bag  / 1000 ml bag 63 / 83\n\tPopular\tKolosal IV Infusion  100 mg + 650 mg + 500 mg 500 ml bag  / 1000 ml bag 52.80 / 66\n\tIPH\tCholera fluid saline   500ml bag / 1000ml bag \n\tIndication: Diarrhea, Dehydration, Cholera, Vomiting, Fluid and electrolyte loss\n\nDose: According to the requirements or as advised by the physician.The volume and rate of infusion will depend upon the requirements of the patients and the judgement of the physician. \n\nIt usually varies with age, weight and clinical condition of the patient. The recommended flow rate is up to 100-drops/minute/70 kg body weight.\n\nContra-indication: Not to be used in - Kidney failure resulting in diminished production of urine (oliguria) Kidney failure, preventing production of urine (anuria) \n\nSide effects: \n\nPrecaution: It should not be administered rapidly or for prolonged periods. Since the solution contains different electrolytes, it should be infused with caution in patients where electrolyte imbalance may cause detrimental effects; e.g. in pregnancy, renal impairment, heart failure, pulmonary congestion, etc. or to patients receiving potassium. sparing diuretics \n\nMode of action: Potassium Chloride: Potassium-sparing diuretics, ACE inhibitors, ciclosporin and potassium-containing drugs. Antimuscarinics delay gastric emptying time consequently increasing risk of GI adverse effects esp of solid oral dosage forms.\n\nSodium Chloride: May affect serum concentrations of lithium.\n\nSodium Acetate: May affect the absorption of certain drugs due to increased intra-gastric pH. May increase renal clearance of acidic drugs e.g. salicylates and barbiturates, and prolongs the half-life of basic drugs.\n\nPregnancy category: Not Classified\n\nInteraction: Potassium Chloride: Potassium-sparing diuretics, ACE inhibitors, ciclosporin and potassium-containing drugs. Antimuscarinics delay gastric emptying time consequently increasing risk of GI adverse effects esp of solid oral dosage forms.\n\nSodium Chloride: May affect serum concentrations of lithium.\n\nSodium Acetate: May affect the absorption of certain drugs due to increased intra-gastric pH. May increase renal clearance of acidic drugs e.g. salicylates and barbiturates, and prolongs the half-life of basic drugs.
Potassium Citrate	\n\n\tEskayef Bangladesh Ltd.\tUrokit TAB dr 1080mg  15's pack 150\n\tEskayef Bangladesh Ltd.\tUrokit ER TAB dr 540 mg  \n\tOpsonin Pharma\tUrilit TAB dr 1080mg  \n\tIndication: Urinary tract infections, Prevent kidney stone, Prevent gout, Acidosis\n\nDose: Alkalinizing Agent\n\nUrinary citrate <150 mg/day: 60 mEq/day PO (20 mEq with each meal) OR\n\nUrinary citrate >150 mg/day: 30 mEq/day PO (10 mEq with each meal)\n\nMaintenance\n\nTitrate dose to achieve urinary citrate 320-640 mg/day & urinary pH 6.0-7.0 (maximum dose 100 mEq/day)\n\n\n\nContra-indication: Hypersensitivity, hyperkalemia, Addison's disease, anuria, uncontrolled DM, acute dehydration, adrenal insufficiency, renal insufficiency (GFR <0.7ml/kg/min)\n\nDelayed gastric emptying, esophageal compression, GI obstruction, concomitant anticholinergic Rx, peptic ulcer dz, active UTI\n\nConcomitant K+-sparing agents (e.g., triamterene, spironolactone, amiloride)\n\nSide effects: Nausea, vomiting, diarrhea, and stomach pain may occur. Taking it after meals will help prevent these side effects.\nAn empty tablet shell may appear in your stool. This is harmless because your body has already absorbed the medication.\n\nThis drug may cause serious stomach or intestinal problems (e.g., bleeding, blockage, puncture). \nThis medication may cause high potassium levels in the blood (hyperkalemia). \n\nA very serious allergic reaction to this drug is rare. \n\nPrecaution:  This medication should not be used ifpatient have (Addison's disease), current bladder infection, uncontrolled diabetes, severe heart disease (e.g., recent heart attack, heart damage), certain stomach/intestinal problems (diabetic gastroparesis, conditions decreasing gut movement, peptic ulcer, blockage), severe kidney disease (e.g., inability to make urine), potassium-restricted diet, high potassium levels, severe loss of body water (dehydration).\n\nBefore using this medication, tell your doctor or pharmacist your medical history, especially of: low calcium levels, severe diarrhea, heart problems (e.g., irregular heartbeat, heart failure), kidney disease, stomach/gut problems (e.g., irritable bowel), severe tissue damage (e.g., severe burns).\n\nBefore having surgery, tell your doctor or dentist that you are taking this medication.\n\nMode of action: K-sparing diuretics, anticholinergics & other drugs which delay GI transit time.\n\nPregnancy category: A\n\nInteraction: K-sparing diuretics, anticholinergics & other drugs which delay GI transit time.
Potassium Guaiacol Sulphonate	\n\n\tDrug International Ltd.\tPotassium Guaiacol Syrup 125mg/5ml 100ml bot 18.40\n\tNipa\tN Potassium Syrup 125mg/5ml 100ml bot 20.23\n\tIndication: Hay fever, Cough, Flu, Common cold, Respiratory infections\n\nDose: PO: Adult: 1-2 tsf 2-4 times daily is the usual dose.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Mild irritation of the bronchial mucus membrane.\n\n\nPrecaution: Some medical conditions may interact with guaifenesin/potassium guaiacolsulfonate:\nPregnancy or  breast-feeding. If  chronic cough that occurs with smoking, asthma, chronic bronchitis, or emphysema, or if cough occurs with large amounts of mucus.\n\n\nMode of action: \n\nPregnancy category: C\n\nInteraction: 
Povidone 5%  Eye prep	\n\n\tACI\tRovidone Eye Drops  5% 10 ml drop 80.54\n\tAristopharma\tProtear Eye Drops  10 ml drop 90\n\tAsiatic Ltd.\tSolotear Eye Drops  10 ml drop  70\n\tBeximco\tTearex Eye Drops   10 ml drop 85\n\tGeneral\tTeargen Eye Drops  10 ml drop 85 	\n\tIbn Sina Pharmaceutical Ind. Ltd.\tOptear Eye Drops   10 ml drop 90\n\tJayson\tOptirex Eye Drops   10ml drop 80.30\n\tPopular\tArtear Eye Drops   10 ml drop 90\n\tIndication: Dry eye, Neonatal Conjunctivitis, Keratoconjunctivitis sicca\n\nDose:  Adult: 1 drop 4 times daily or as required, depending upon the severity of the disease, to be instilled into the conjunctival sac.\n\nContra-indication: Hypersensitivity; prolonged use in patients with thyroid disorders or on lithium therapy. Premature neonates or neonates weighing <1.5 kg.\n\nSide effects: Occasionally mild-transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions reported. Blurred vision after application may occur.\n\nPrecaution: Patients who experience blurred vision after application of the product should not drive or use machinery until their vision has cleared.\nContact lenses should not be worn during instillation of the product. After instillation there should be an interval of at least 30 minutes before reinsertion of contact lenses.\n\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Povidone Iodine 1%  Mouth-Wash	\n\n\tAristopharma\tArodin Mouthwash   100ml bot 26\n\tGeneral\tCleanser Mouth Wash & Gargle Mouthwash   100ml bot 25\n\tGreenland\tPoviclean Mouthwash 1 gm/100 ml  \n\tJayson\tPovisep Mouthwash   100ml bot 27\n\tMedicon\tHidin Mouthwash   100ml bot 25\n\tMundipharma (Bangladesh) Pvt. Ltd.\tBetadine Germicide Gargle Mouth Wash 1 gm/100 ml  \n\tOpsonin Pharma\tPovin Mouthwash   100ml bot 25\n\tSquare\tViodin Mouthwash   100ml bot 25.10\n\tIndication: Oral candidiasis\n\nDose: Adult: Mouth/Throat Oral hygiene As 0.1% soln: Rinse mouth w/ 10 mL undiluted soln or diluted w/ an equal amount of water 4 times/day for 14 days. Oral candidiasis As 1% soln: Rinse mouth as directed. \n\nContra-indication: Hypersensitivity; prolonged use in patients with thyroid disorders or on lithium therapy. Premature neonates or neonates weighing <1.5 kg.\n\nSide effects: Local irritation and sensitivity (rare). Idiosyncratic mucosal irritation and hypersensitivity reactions rarely, may interfere with thyroid-function tests.\n\nPrecaution: Avoid contact with eyes; should not be used under occlusive dressing. Pregnancy, lactation; neonates.\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Povidone Iodine 1.25% Eye prep	\n\n\tHealthcare\tBludrop Eye drops  10 ml bot \n\tJayson\tPovisep Eye Drops   5  ml drop 48.18\n\tIndication: Dry eye, Neonatal Conjunctivitis, Keratoconjunctivitis sicca, Bacterial  Conjunctivitis\n\nDose: Apply 1-2 drops in the affected eyes 3-4 times daily or as advised by the physician.\n\nContra-indication: Hypersensitivity; prolonged use. \n\nSide effects:  Local irritation and sensitivity. \n\nPrecaution: Pregnancy, lactation;\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Povidone Iodine 10% Topical	\n\n\tAmico Ltd.\tPovidone Topical Solution   100ml bot 44\n\tAristopharma\tArodin Topical Solution   100ml bot/1 liter pack/5  liter pack 60/450/1425\n\tAsiatic Ltd.\tProvia Topical Solution   100ml bot 30\n\tChemist Ltd.\tPolydin Topical Solution   100ml bot 36\n\tGeneral\tCleanser Antiseptic Solution Topical Solution   100ml bot 36\n\tGreenland\tPoviclean Topical Solution 10 gm/100 ml  \n\tJayson\tPovisep Topical Solution   30ml bot/100ml bot/1 liter bot/5 liter cont  23/44/341.28/1606\n\tJayson\tPovisep Gyno Gel Gel   30gm  tube x 1's pack 75.28\n\tMundipharma (Bangladesh) Pvt. Ltd.\tBetadine Standardised Topical Solution   100ml bot/ 500ml bot 190 / 550\n\tOpsonin Pharma\tPovin Topical Solution   100ml bot 38.70\n\tSquare\tViodin 10% Topical Solution   15ml bot x 12 's pack/100ml bot x 1 's pack/1000ml bot x 1 's pack 144.60/36.14/ 341.28\n\tUnimed & Unihealth Manufacturers Ltd.\tIosol Topical Solution   100ml bot/500ml bot 35/150\n\tZiska\tPovidone-I Solution  10% 100ml bot 36\n\tIndication:  Use as an antiseptic skin cleanser for major and minor surgical procedures, Skin infections, Wound infection, Decubitus ulcers, Candidal & Trichomonal vaginitis.\n\nDose: Treatment and prophylaxis of wound infection\nAdult: Apply 5-10% topical solutions on affected area. The site may be covered with gauze or adhesive bandage\nVaginal:.\nVaginal candidiasis\nAdult: 5 gm of   (10%) gel, one applicator full every night for up tp 14 days.\n\nContra-indication: Hypersensitivity; prolonged use in patients with thyroid disorders or on lithium therapy. \n\nSide effects: Local irritation and sensitivity to skin & mucus membrane. Application to large areas of denuded skin may produce systemic effects due to iodine absorption.\n\nPrecaution:  Pregnancy, lactation; neonates. Renal impairement.\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Povidone Iodine 5% Topical	\n\n\tAlco Pharma\tPovidine Ointment 5% 15gm 34 \n\tAristopharma\tArodin Ointment   10gm tube/20gm tube 20/30\n\tEdruc Ltd.\tPovigerm Ointment   20gm tube 25\n\tGlobe\tApodin Ointment   10gm tube 15\n\tJayson\tPovisep Powder  10gm 30\n\tMundipharma (Bangladesh) Pvt. Ltd.\tBetadine Ointment   15gm tube / 125gm tube 75 / 196\n\tMundipharma (Bangladesh) Pvt. Ltd.\tBetadine Sol Topical Solution   50ml bot / 100ml bot /500ml bot 100 /150 /450\n\tOpsonin Pharma\tPovin Ointment   10gm tube 79.17\n\tPacific\tTopidin Ointment 5 gm/100 gm  \n\tRephco\tPoviclean Ointment 5 gm/100 gm  \n\tSquare\tViodin Ointment   20gm tube 25.10\n\tIndication: Primary or secondary topical infections, infected surgical incisions, infected decubitus or stasis ulcers, pyodermas, secondarily infected dermatoses, and infected traumatic lesions. Prevention of infections in cuts and abrasions, wounds.\n\n\n\nDose: Adult: As Oinement: For the treatment of infection: Apply once or twice daily or at dressing changes for a maximum of 14 days.\nFor the prevention of infection: Apply once or twice a week for as long as necessary. Apply ointment directly to the affected area after being cleaned and dried. May be covered with a dressing or bandage.\n\n\nAs powd: Apply as often as required directed.May be covered with a dressing or bandage.\n\n\n\nContra-indication:  Regular use is contraindicated in patients or users with thyroid disorders (in particular nodular colloid goitre, endemic goiter and Hashimotos thyroiditis). Not for use in infants under 2 years. Special caution is needed when regular applications to broken skin are made to patients with pre-existing renal insufficiency. Regular use should be avoided in patients on concurrent lithium therapy.\n\nSide effects:  Local skin irritation and sensitivity. Application to large areas of denuded skin may produce systemic effects due to iodine absorption.The application of povidone iodine to large wounds or severe burns may producesystemic adverse effectssuch as metabolic acidosis, hypernatraemia and impairment of renal function.\n\nOccasionally mild-transient burning or sticky sensation and very rarely irritation or hypersensitivity reactions are reported. \n\n\nPrecaution: Pregnancy, lactation; neonates.\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Povidone Iodine 6% Topical	\n\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDonadin Cream   20gm tube 26\n\tJayson\tPovisep Cream   5gm tube/25gm tube 14/36\n\tJayson\tPiodin Ointment 0.6 gm/100 gm  \n\tIndication: Skin infections, Wound infection, Decubitus ulcers\n\nDose: Adult: As cream: For the treatment of infection: Apply once or twice daily or at dressing changes for a maximum of 14 days. For the prevention of infection: Apply once or twice a week for as long as necessary. Apply cream directly to the affected area after being cleaned and dried. May be covered with a dressing or bandage. \n\nContra-indication: Regular use is contraindicated in patients or users with thyroid disorders (in particular nodular colloid goitre, endemic goiter and Hashimotos thyroiditis). Not for use in infants under 2 years. Special caution is needed when regular applications to broken skin are made to patients with pre-existing renal insufficiency. Regular use should be avoided in patients on concurrent lithium therapy.\n\nSide effects:  Local skin irritation and sensitivity. Application to large areas of denuded skin may produce systemic effects due to iodine absorption.The application of povidone iodine to large wounds or severe burns may producesystemic adverse effectssuch as metabolic acidosis, hypernatraemia and impairment of renal function. \n\nPrecaution: Avoid contact with eyes; should not be used under occlusive dressing. Pregnancy, lactation;\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Povidone Iodine 7.5% Scrub	\n\n\tJayson\tPovisep Scrub   250ml bot/5 liter cont 325/ 3212.06\n\tMundipharma (Bangladesh) Pvt. Ltd.\tBetadine Surgical Scrub Scrub   50ml bot / 500ml bot 100 / 650\n\tUnimed & Unihealth Manufacturers Ltd.\tIosol Scrub   100ml bot/500ml bot 60/ 275\n\tIndication: Pre- and post-operative skin cleansing, pre-operative scrubbing & washing.\n\nDose:  Pre-operative scrubbing & washing: Wet hands with water, then pour 5 ml of solution onto the palm and spread over both the hands, rub the scrub over the entire area for about 2 mintues, add water to develope copious suds, rinse throughly under running water.\n\nPre- and post-operative skin cleansing: After the skin is shaved and wet with water, apply surgical scrub  & rub throughly for minimum 2 mintues, rinse of with the sterile gauze saturated with water.\n\nContra-indication:  	Hypersensitivity; prolonged use in patients with thyroid disorders or on lithium therapy. Special caution is needed when regular applications to broken skin are made to patients with pre-existing renal insufficiency. Regular use should be avoided in patients on concurrent lithium therapy.\n\nSide effects:  Local skin irritation and sensitivity. Application to large areas of denuded skin may produce systemic effects due to iodine absorption.The application of povidone iodine to large wounds or severe burns may producesystemic adverse effectssuch as metabolic acidosis, hypernatraemia and impairment of renal function.\n\nPrecaution: Avoid contact with eyes; should not be used under occlusive dressing. Pregnancy, lactation; \n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Pralidoxime Chloride	\n\n\tBeacon\tPradox Injection 1000mg/ml 1's pack 500\n\tIndication: Organophosphorous poisoning\n\nDose: Adult: IV/IM Used in combination w/ atropine. As Cl, iodide or mesilate: Upon atropinisation, administer 1-2 g, repeat dose after 1 hr, then 8-12 hrly if needed. Severe: 200-500 mg/hr via continuous infusion, titrate according to response. Max: 12 g/24 hr.\n\nChild: IV loading dose followed by continuous infusion\n\n    20-50 mg/kg/dose (not to exceed 2 g/dose) infused IV over 15-30 minutes\n    Maintenance: 10-20 mg/kg/hr IV continuous infusion.\n\nIM administration\n\n    <40 kg: 15 mg/kg/dose IM x3 doses \n    40 kg or greater: Administer as in adults; 600 mg/dose IM x3 doses.\n\n\nContra-indication: Carbamate pesticide poisoning, hypersensitivity.\n\nSide effects: Drowsiness, dizziness, visual disturbances, nausea, tachycardia, headache, hyperventilation and muscle weakness.\nPotentially Fatal: Rapid admin causes tachycardia, laryngospasm and rigidity. Large doses cause neuromuscular blockade.\n\nPrecaution: Renal dysfunction, myasthenia gravis. Atropinisation may occur faster when atropine and pralidoxime are used together. Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Pramipexol	\n\n\tACI\tParixol TAB dr 180mcg 30's pack 181.20\n\tACI\tParixol TAB dr 88mcg 30's pack 90.30\n\tIndication: Parkinson's disease, Restless leg syndrome\n\nDose: Adult: PO Parkinson's disease As adjunct to levodopa therapy: Initial: 125 mcg 3 times/day in the 1st wk, increase to 250 mcg 3 times/day in the 2nd wk and 500 mcg 3 times/day in the 3rd wk according to response. May further increase if needed. Max: 4.5 mg/day. \n\nRenal impairment:\nCrCl (ml/min)	\n20-50	125 mcg bid. Max: 2.25 mg/day.\n<20	        125 mcg once daily. Max: 1.5 mg/day.\n\nRestless leg syndrome Initial: 125 mcg/day, increase if needed. Max: 750 mcg/day.\n\nContra-indication: Lactation.\n\nSide effects: Sudden onset of sleep with or without any prior feeling of drowsiness. Nausea, constipation, confusion, drowsiness and insomnia, dizziness, hallucinations, dyskinesia and peripheral oedema.\n\nPrecaution: Renal and hepatic impairment, psychotic disorders; severe CV disease, pregnancy. Risk of neuroleptic malignant syndrome with abrupt withdrawal. Hypotensive reactions may be disturbing in some patients during initial treatment. Regular ophthalmological testing recommended due to risk of visual disorders. May impair ability to drive and operate machinery. May increase risk of rhabdomyolysis.\n\nMode of action: Inhibits active tubular secretion of basic cationic drugs eg, cimetidine. Reduced clearance w/ drugs eliminated by active renal tubular secretion eg, amantadine. Alcohol & other sedatives.\n\nPregnancy category: C\n\nInteraction: Inhibits active tubular secretion of basic cationic drugs eg, cimetidine. Reduced clearance w/ drugs eliminated by active renal tubular secretion eg, amantadine. Alcohol & other sedatives.
Prasugrel	\n\n\tACI\tHemagrel TAB dr 10mg 20's pack 400\n\tACI\tHemagrel TAB dr 5mg 30's pack 360\n\tBeacon\tPrasulet TAB dr 10mg 30's pack 599\n\tBeacon\tPrasulet TAB dr 5mg 30's pack 359\n\tBeximco\tPrasuva TAB dr 10mg 20's pack 400\n\tBeximco\tPrasuva TAB dr 5mg 30's pack 360\n\tDrug International Ltd.\tPrapid TAB dr 10mg 10's pack 200\n\tDrug International Ltd.\tPrapid TAB dr 5mg 20's pack\n 240\n\tHealthcare\tApagrel TAB dr 10mg 30's pack 600\n\tHealthcare\tApagrel TAB dr 5mg 30's pack 360\n\tIbn Sina Pharmaceutical Ind. Ltd.\tPsudex TAB dr 5mg 40's pack \n\tIncepta\tPrasurel TAB dr 10mg 20's pack 400\n\tIncepta\tPrasurel TAB dr 5mg 30's pack 360\n\tNavana\tAsurel TAB dr 10mg 20's pack 400\n\tNavana\tAsurel TAB dr 5mg 30's pack 360\n\tOpsonin Pharma\tEfirel TAB dr 10mg 10's pack 200\n\tOpsonin Pharma\tEfirel TAB dr 5mg 20's pack 240\n\tOrion Pharma Ltd.\tOpagrel TAB dr 10mg 30's pack 450\n\tOrion Pharma Ltd.\tOpagrel TAB dr 5mg 30's pack 240\n\tSquare\tEfigrel TAB dr 10mg 20's pack 400\n\tSquare\tEfigrel TAB dr 5mg 20's pack 240\n\tIndication: Acute coronary syndromes, thrombotic cardiovascular (CV) events, stent thrombosis, unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), Stroke\n\nDose: Treatment should be initiated with a single 60 mg oral loading dose.\nContinue at 10 mg once daily with or without food. Consider 5 mg once daily for patients < 60 kg. Patients should also take aspirin (75 mg to 325 mg) daily.\n\nPediatric Use: Safety and effectiveness in pediatric patients have not been established\nGeriatric Use: Patients > 75 years of age who received Prasugrel had an increased risk of fatal bleeding events (1.0%) compared to patients who received clopidogrel (0.1%).\n\nRenal Impairment: No dosage adjustment is necessary for patients with renal impairment. There is limited experience in patients with end-stage renal disease.\n\nHepatic Impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.\n\nContra-indication: Active pathological bleeding such as peptic ulcer or intracranial hamorrhage. Patient with a history of prior transient ischemic attack or stroke \n\nSide effects: - Bleeding\n- Thrombotic thrombocytopenic purpura\n- Other side effects ( Headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash etc)\n\nPrecaution: CABG-related bleeding: Risk increases in patients receiving Prasurel who undergo CABG.\n\nDiscontinuation of Prasugrel: Premature discontinuation increases risk of stent thrombosis, MI, and death \n\nMode of action: Increased risk of bleeding w/ oral anticoagulants (e.g. warfain), clopidogrel, NSAIDs and fibrinolytics.\n\nPregnancy category: B\n\nInteraction: Increased risk of bleeding w/ oral anticoagulants (e.g. warfain), clopidogrel, NSAIDs and fibrinolytics.
Prazosin	\n\n\tRenata\tAlphapress TAB dr 1mg 100's pack 302\n\tRenata\tAlphapress TAB dr 2mg 100's pack 501\n\tUnimed & Unihealth Manufacturers Ltd.\tPrazopress-1 TAB dr 1mg 30's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tPrazopress-2 TAB dr 2mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tPrazopress ER TAB dr 2.5mg/5mg 20's 200/300\n\tIndication: Hypertension, Heart failure, Benign prostatic hyperplasia; Raynaud's syndrome\n\nDose: Adult: PO HTN Initial: 500 mcg 2-3 times/day for 3-7 days, increase to 1 mg 2-3 times/day for the next 3-7 days if tolerated. May further increase if needed. Max: 20 mg/day. \nHeart failure Initial: 500 mcg 2-4 times/day, increase gradually when needed. Maintenance: 4-20 mg/day. \nBenign prostatic hyperplasia; Raynaud's syndrome Initial: 500 mcg twice daily. Maintenance: <2 mg twice daily.\n\nContra-indication: Congestive heart failure due to mechanical obstruction. Hypersensitivity. Pregnancy.\n\nSide effects: Postural hypotension, syncope, palpitations, lack of energy, nausea, oedema, chest pain, dyspnoea, constipation, diarrhoea, vomiting, depression, nervousness, sleep disturbances, headache, lassitude, drowsiness, loss of consciousness, dizziness, vertigo, hallucinations, paraesthesia, nasal congestion, epistaxis, dry mouth, urinary frequency and incontinence, pruritus, rash.\nPotentially Fatal: Rarely, hypotension may be life-threatening.\n\nPrecaution: Angina pectoris. Ability to drive or operate machinery may be impaired. Phaeochromocytoma, abrupt withdrawal, impaired renal and liver function. child <12 yr. Lactation. May develop tolerance in prolonged treatment. Intiate treatment with low doses.\n\nMode of action: Hypotensive effects may be enhanced w/ diuretics and other antihypertensives. Increased risk of 1st dose hypotension w/ ?-blockers or Ca channel blockers. Concomitant admin w/ phosphodiesterase type 5 (PDE5) inhibitors (e.g. sildenafil) may result in additive hypotensive effects and symptomatic hypotension.\n\nPregnancy category: C\n\nInteraction: Hypotensive effects may be enhanced w/ diuretics and other antihypertensives. Increased risk of 1st dose hypotension w/ ?-blockers or Ca channel blockers. Concomitant admin w/ phosphodiesterase type 5 (PDE5) inhibitors (e.g. sildenafil) may result in additive hypotensive effects and symptomatic hypotension.
Precipitated Sulpher 10% + Salicylic Acid 3%	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tSastid Bar cleanser 10 %, 3% 100gm 358.92\n\tIndication: Acne, Warts, Seborrheic dermatitis, Scalp disorders, Hyperkeratotic, Scaling skin conditions, Calluses, Dandruff\n\nDose: For bar dosage form\nUsing as a soap, wetting skin and washing face and other affected areas; rinsing thoroughly; patting dry\n\nProper dosing\nMissed dose: Using as soon as possible; not using if almost time for next dose\n\nContra-indication: Hyppersensitivity.\n\nSide effects: Signs of potential side effects, especially skin irritation not present before therapy\n\nPrecaution: Avoiding simultaneous use with other topical acne preparations or preparations containing peeling agents, alcohol-containing preparations, abrasive soaps or cleansers, cosmetics or soaps with drying effect, medicated cosmetics, or other topical skin medication, unless otherwise directed by physician. \n\nÂ» Avoiding concurrent use with topical mercury-containing preparations\n\nCaution if medications containing aspirin or other salicylates are used\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Prednisolone	\n\n\tACI\tSolone TAB dr 10mg 100's pack 207\n\tACI\tSolone TAB dr 20mg 50's pack 200\n\tACI\tSolone TAB dr 5mg 100's pack 172\n\tACI\tSolone Oral Sol Oral Solution 5mg/5ml 100ml bot/50ml bot 95/65\n\tAlbion Ltd.\tAltason TAB dr 20mg/10mg/5mg 200's pack \n\tAristopharma\tCortisol Solution 5mg/5ml 50ml bot 60\n\tAristopharma\tCortisol 10 TAB dr 10mg 100's pack 208\n\tAristopharma\tCortisol 20 TAB dr 20mg 50's pack 187.50\n\tAristopharma\tCortisol 5 TAB dr 5mg 200's pack 228\n\tBeximco\tBexipred TAB dr 20 mg  313\n\tBristol Pharma Ltd.\tDelta TAB dr 5mg 500's pack 350\n\tChemist Ltd.\tPrexan TAB dr 5mg 500's pack 350\n\tDesh\tDeltacort TAB dr 5mg 500's pack 310\n\tEdruc Ltd.\tEdruson TAB dr 5mg 100's pack 115\n\tEskayef Bangladesh Ltd.\tPred TAB dr 10mg 100's pack 200\n\tEskayef Bangladesh Ltd.\tPred TAB dr 20mg 50's pack 185\n\tEskayef Bangladesh Ltd.\tPred TAB dr 5mg 200's pack 228\n\tGeneral\tPredflam TAB dr 5mg  \n\tGeneral\tPredflam TAB dr 10mg  \n\tGeneral\tPredflam TAB dr 20mg  \n\tGlaxoSmithKline Bangladesh Ltd.\tPrednelan TAB dr 20mg 100's pack 320\n\tGlaxoSmithKline Bangladesh Ltd.\tPrednisolone TAB dr 5mg 500's pack 375\n\tGlaxoSmithKline Bangladesh Ltd.\tPrednelan TAB dr 5mg 500's pack 850\n\tGlobe\tP-Cort TAB dr 5mg  \n\tGlobe\tP-Cort Eye Drops 1 gm/100 ml  \n\tGonoshasthaya\tG-Prednisolone TAB dr 5mg 100's pack 114\n\tIncepta\tCortan Solution 5mg/5ml 50ml/100ml bot 60/95\n\tIncepta\tCortan TAB dr 10mg 100's pack 207\n\tIncepta\tCortan TAB dr 20mg 50's pack 186.50\n\tIncepta\tCortan TAB dr 5mg 200's pack 230\n\tIncepta\tCortan Solution 15 mg/5 ml  \n\tIncepta\tCortan TAB dr 2mg  \n\tNuvista Pharma Ltd\tAdam 33 TAB dr 20 mg 50's pack 314\n\tNuvista Pharma Ltd\tAdam 33 TAB dr 5mg 300's pack 519.00\n\tOpsonin Pharma\tPrecodil Solution 15mg/5ml 50ml bot/100ml bot 80/130\n\tOpsonin Pharma\tPrecodil Solution 5mg/5ml 50ml bot/100ml bot 65/95\n\tOpsonin Pharma\tPrecodil TAB dr 10mg 100's pack 207\n\tOpsonin Pharma\tPrecodil TAB dr 20mg 60's pack 223.80\n\tOpsonin Pharma\tPrecodil TAB dr 5mg 200's pack 230\n\tRenata\tDeltason TAB dr 1mg 100's pack 33\n\tRenata\tDeltason TAB dr 10mg 100's pack 207\n\tRenata\tDeltasone TAB dr 20mg 50's pack 186.50\n\tRenata\tDeltasone TAB dr 5mg 500's pack 570\n\tRenata\tDeltasone Oral Solution 5mg/5ml 1mg x100's, 5mg x500's, 10mg x100's, 20mg x50's 33/570/207/186.50\n\tSquare\tInflagic TAB dr 20mg 50's pack 150\n\tSquare\tInflagic TAB dr 5mg 100's pack 119\n\tZenith\tZenilon TAB dr 5mg 250's pack 185\n\tZiska\tDeltapred TAB dr 10mg 100's pack 200\n\tZiska\tDeltapred TAB dr 20mg 40's pack 148\n\tZiska\tPedipred 100 Oral Solution Solution 5mg/5ml 100 ml bot 95\n\tZiska\tDeltapred TAB dr 5mg 500's pack 550\n\tZiska\tPedipred 50 Oral Solution Solution 5 mg/ 5 ml  50ml 60\n\tIndication: Rheumatoid arthritis, Multiple sclerosis, Allergic and inflammatory disorders, Nephrotic syndrome, Idiopathic thrombocytopenic purpura, Joint inflammations, Moderate to severe asthma, Infantile spasms\n\nDose:  Oral\nAllergic and inflammatory disorders\nAdult: 5-60 mg daily in 2-4 divided doses. Maintenance: 2.5-15 mg daily. Withdrawal should be gradual after long-term therapy.\n\nChild: 1 mth-18 yr: Autoimmune inflammatory disorders: Initially, 1-2 mg/kg once daily; may reduce dose gradually after a few days if needed. Max: 60 mg daily. Autoimmune hepatitis: Initially, 2 mg/kg once daily, then reduce to minimum effective dose. Max: 40 mg daily.\n\nPoorly controlled, moderate to severe asthma\nAdult: Patients with at least 2 exacerbations/yr requiring oral corticosteroids: 40-60 mg daily in 1-2 divided doses; usually given as a short course treatment over 3-10 days until symptom resolution and patient achieves a peak expiratory flow (PEF) of at least 80% of his or her personal best. May be used with maintenance dosages of inhaled corticosteroid and a long-acting inhaled ?2-agonist bronchodilator.\n\nChild: Patients with >3 exacerbations/yr in children ?4 yr or at least 2 exacerbations/yr in children 5-11 yr: 1-2 mg/kg daily for 3-5 days may be used with existing asthma treatment; dose may be given in 1-2 divided doses. Max: 60 mg daily.\n\nNephrotic syndrome\nChild: 1 mth-18 yr: Initially, 60 mg/m2 (max: 80 mg) once daily for 4 wk until urine is protein-free followed by 40 mg/m2 every other day for 4 wk, then withdraw dose gradually. Prevention of relapse: 0.5-1 mg/kg once daily every other day for 3-6 mth.\n\nRheumatoid arthritis\nAdult: Initially, 5-7.5 mg daily, adjusted as necessary.\nElderly: 5 mg daily.\n\nMultiple sclerosis\nAdult: 200 mg daily for 1 wk followed by 80 mg every other day for 1 mth.\n\nInfantile spasms\nChild: 1 mth-2 yr: Initially, 10 mg 4 times daily for 14 days; increase to 20 mg 3 times daily for 7 days if seizures are not controlled after 7 days; reduce dose slowly over 15 days until therapy is stopped. For patients taking 40 mg daily, reduce dose in steps of 10 mg every 5 days, then stop; in patients taking 60 mg daily, reduce dose to 40 mg daily for 5 days, then 20 mg daily for 5 days, then 10 mg daily for 5 days, then stop.\n\nIdiopathic thrombocytopenic purpura\nChild: 1-10 yr: 1-2 mg/kg daily (max: 14 days) or 4 mg/kg daily (max: 4 days). \n\nContra-indication: Live vaccines; herpes simplex keratitis, systemic infections.\n\nSide effects: Cushing's syndrome and growth retardation in childn; osteoporosis, fractures. Peptic ulceration; glaucoma, cataracts; hyperglycaemia, pancreatitis; increased appetite, obesity. \n\nPotentially Fatal: Acute adrenal insufficiency precipitated by infection, trauma or surgery in patients on long-term therapy or following cessation of such therapy. CV collapse following rapid IV injection.\n\nPrecaution: Patients with hypothyroidism, cirrhosis, ulcerative colitis, CHF, convulsive disorders, thrombophlebitis, peptic ulcer, elderly. DM, hypertension, psychological disturbances, osteoporosis; pregnancy, lactation. Adrenal suppression and infection. May cause irreversible growth retardation, glaucoma, corneal perforation. \n\nMode of action: Efficacy may be reduced by phenytoin, phenobarb, rifampicin. Corticoids may reduce the effects of diuretics, hypoglycaemics, anticholinesterases, salicylates.\n\nPregnancy category: C\n\nInteraction: Efficacy may be reduced by phenytoin, phenobarb, rifampicin. Corticoids may reduce the effects of diuretics, hypoglycaemics, anticholinesterases, salicylates.
Prednisolone 1%  Eye prep	\n\n\tApex\tRenisol Eye Drops   5  ml drop 90\n\tAristopharma\tCortisol Eye Drops   5  ml drop 100\n\tAsiatic Ltd.\tPrednicort Eye Drops   5  ml drop 100\n\tDrug International Ltd.\tPednisol Eye Drops   5  ml drop 100\n\tGeneral\tPredflam Eye Drops 1 gm/100 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tIsolon Eye Drops   5  ml drop 100\n\tIncepta\tCortan Eye Drops 1 gm/100 ml 5  ml drop 100\n\tPopular\tOcusol Eye Drops  1 gm/100 ml 5  ml drop 100\n\tReman Drug Ltd.\tPrednol Eye Drops   5  ml drop 100\n\tIndication: Conjunctivitis, steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.\n\nDose: Conjunctivitis\nAdult: As 1% : Instill 1-2 drops into the affected eye(s) 2-4 times daily. Higher frequency may be used during the initial 24-48 hr, if needed. Re-evaluate if there is no improvement after 2 days of treatment.\n\n\n\nContra-indication: Live vaccines; herpes simplex keratitis, systemic infections.\n\nSide effects:  Ophthalmic: Raised IOP and reduced visual function  with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation and delayed wound healing.\nFungal and viral infections of the cornea are particularly may develop coincidentally with long-term applications of steroid.\n\n\nPrecaution: Prolonged use of corticosteroids may result in damage to the optic nerve and defects in vision. If this product is used for longer period of time, intraocular pressure should be routinely monitored.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Pregabalin	\n\n\tACI\tGabarol CAP 100mg 20's pack 443\n\tACI\tGabarol CAP 150mg 20's pack 604\n\tACI\tGabarol CAP 25mg 30's pack 240.60\n\tACI\tGabarol CAP 50mg 30's pack 361.20\n\tACI\tGabarol CAP 75mg 30's pack 483.30\n\tAcme Ltd.\tNeugalin CAP 150mg 30's pack 900\n\tAcme Ltd.\tNeugalin CAP 50mg 3x10's pack 330\n\tAcme Ltd.\tNeugalin CAP 75mg 3x10's pack 480\n\tAlbion Ltd.\tPregabid CAP 25mg  \n\tAlbion Ltd.\tPregabid CAP 50mg  \n\tAlbion Ltd.\tPregabid CAP 75mg  \n\tAlbion Ltd.\tPregabid CAP 100mg  \n\tAristopharma\tNeurovan CAP 150mg 20's pack 600\n\tAristopharma\tNeurovan CAP 50mg 30's pack 330\n\tAristopharma\tNeurovan CAP 75mg 30's pack 480\n\tAstra Biopharmaceuticals Ltd.\tPegamax CAP 75mg  \n\tAstra Biopharmaceuticals Ltd.\tPegamax CAP 50mg  \n\tBeacon\tRegab CAP 25mg 20's pack 160\n\tBeacon\tRegab CAP 50mg 20's pack 240\n\tBeacon\tRegab CAP 75mg 20's pack 320\n\tBeximco\tNervalin CAP 50mg 30's pack 330\n\tBeximco\tNervalin CAP 75mg 30's pack 440\n\tBeximco\tNervalin CAP 25mg  \n\tBio Pharma Ltd.\tLirica CAP 75mg 30's pack 480\n\tDelta Pharma\tPregadel CAP 75mg 16's pack/30's pack 240/480\n\tDelta Pharma\tPregadel CAP 50mg 24's pack 240\n\tDrug International Ltd.\tPrelin CAP 150mg 10's pack 300\n\tDrug International Ltd.\tPrelin CAP 50mg 20's pack 220\n\tDrug International Ltd.\tPrelin CAP 75mg 20's pack 320\n\tEskayef Bangladesh Ltd.\tPG CAP 150mg 12's pack 360\n\tEskayef Bangladesh Ltd.\tPG CAP 50mg 30's pack 330\n\tEskayef Bangladesh Ltd.\tPG CAP 75mg 30's pack 480\n\tGeneral\tPrebalin CAP 150mg 20's pack 602.20\n\tGeneral\tPrebalin CAP 50mg 30's pack 330\n\tGeneral\tPrebalin CAP 75mg 30's pack 481.80\n\tGlobe\tNeurica CAP 75mg  \n\tGlobe\tNeurica CAP 150mg  \n\tHealthcare\tLyric CAP 25mg 20's pack 160\n\tHealthcare\tLyric CAP 50mg 30's pack 420\n\tHealthcare\tLyric CAP 75mg 30's pack 540\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeurega CAP 100mg 12's pack 264\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeurega CAP 50mg 20's pack 260\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeurega CAP 75mg 20's pack 340\n\tIbn Sina Pharmaceutical Ind. Ltd.\tNeurega-25 CAP 25mg 20's Pack 160\n\tIncepta\tPregaben 150 CAP 150mg 20's pack 600\n\tIncepta\tPregaben 50 CAP 50mg 30's pack 360\n\tIncepta\tPregaben 75 CAP 75mg 30's pack 480\n\tIncepta\tPregaben CAP 25mg  \n\tIncepta\tPregaben CAP 300mg  \n\tLabaid\tGaba- Aid CAP 50mg 30's pack 360\n\tLabaid\tGaba- Aid CAP 75mg 30's pack 480\n\tMonicopharma\tPriga 75 CAP 75mg 30's pack 480\n\tNavana\tPregan CAP 50mg 30's pack 330\n\tNavana\tPregan CAP 75mg 30's pack 480\n\tNovartis (Bangladesh) Ltd.\tXablin CAP 150mg 30's pack 513\n\tNovartis (Bangladesh) Ltd.\tXablin CAP 75mg 30's pack 513\n\tOpsonin Pharma\tPregaba CAP 100mg 30's pack 660\n\tOpsonin Pharma\tPregaba CAP 150mg 30's pack 900\n\tOpsonin Pharma\tPregaba CAP 50mg 30's pack 360\n\tOpsonin Pharma\tPregaba CAP 75mg 30's pack 480\n\tOrion Pharma Ltd.\tXil CAP 50mg 30's pack 240\n\tOrion Pharma Ltd.\tXil CAP 75mg 30's pack 301.20\n\tPharmasia Ltd.\tPyrica CAP 75mg 30's pack 480\n\tPharmasia Ltd.\tPyrica CAP 50mg  \n\tPopular\tPegalin CAP 100mg 30's pack 662.42\n\tPopular\tPegalin CAP 75mg 30's pack 481.79\n\tPopular\tPegalin CAP 150mg 20's pack 602.20\n\tPopular\tPegalin CAP 25 mg 30's pack \n\tRadiant.\tPrelica CAP 25mg  \n\tRadiant.\tPrelica CAP 50mg  \n\tRadiant.\tPrelica CAP 75mg  \n\tRadiant.\tPrelica CAP 150mg  \n\tRAK\tPegaron CAP 50mg 30's pack 360\n\tRAK\tPegaron CAP 150mg 20's pack 602\n\tRAK\tPegaron CAP 75mg 30's pack 481.80\n\tRenata\tGABA-P CAP 50mg 30's pack 360\n\tRenata\tGABA-P CAP 75mg 30's pack 482.10\n\tRenata\tGABA-P CAP 100mg  \n\tRenata\tGABA-P CAP 25mg  \n\tRenata\tGapa-P CAP   \n\tSanofi Aventis (BD) Ltd.\tPretor CAP 50mg  \n\tSanofi Aventis (BD) Ltd.\tPretor CAP 75mg  \n\tSanofi Aventis (BD) Ltd.\tPretor CAP 150mg  \n\tSharif\tPregalex CAP 150mg 20's pack 600\n\tSharif\tPregalex CAP 75mg 30's pack 480\n\tSquare\tNeurolin CAP 150mg 10's pack 301.11\n\tSquare\tNeurolin CAP 50mg 30's pack 360\n\tSquare\tNeurolin CAP 75mg 30's pack 480\n\tSun Pharmaceutical (Bangladesh) Ltd.\tNeugaba CAP 150mg 30's pack 900\n\tSun Pharmaceutical (Bangladesh) Ltd.\tNeugaba CAP 75mg 30's pack 480\n\tSun Pharmaceutical (Bangladesh) Ltd.\tNeugaba CAP 25mg  \n\tSun Pharmaceutical (Bangladesh) Ltd.\tNeugaba CAP 50mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tMyrica CAP 50mg 28's pack 336\n\tUnimed & Unihealth Manufacturers Ltd.\tMyrica CAP 75mg 28's pack 448\n\tUnimed & Unihealth Manufacturers Ltd.\tMyrica CAP 100mg 28's pack 560\n\tWhite Horse Pharma\tNerfid CAP 50mg 30's pack 360\n\tWhite Horse Pharma\tNerfid CAP 75mg 50's pack 480\n\tIndication:  Anxiety, Fibromyalgia, Post herpetic Neuralgia, Partial seizures, Pain from diabetic neuropathy, Neuropathic pain associated with spinal cord injury\n\nDose: Oral\nNeuropathic pain\nAdult: Initially, 150 mg/day, may increase to 300 mg/day after 3-7 days. Max: 600 mg/day after a 7-day interval. All doses to be given in 2 or 3 divided doses.\n\nAdjunct in partial seizures\nAdult: Initially, 150 mg/day, may increase to 300 mg/day after a wk. Max: 600 mg/day. All doses to be given in 2 or 3 divided doses.\n\nFibromyalgia\nAdult: Initially, 150 mg/day, may increase to 300 mg/day after a wk. Max: 450 mg/day, if needed. All doses to be given in 2 or 3 divided doses.\n\nAnxiety\nAdult: Initially, 150 mg/day, may increase in increments of 150 mg wkly. Max: 600 mg/day. All doses to be given in 2 or 3 divided doses.\n\nPost herpetic neuralgia \nAdult: Initially, 150-300 mg/day in divided doses. Max: 600 mg/day in divded doses.\n\nRenal impairment: Haemodialysis: 25-100 mg immediately after each 4-hr haemodialysis session.\n\nCrCl (ml/min)	\n30 to <60	75 mg/day. Max: 300 mg/day. All doses to be given in 2 or 3 divided doses.\n15 to <30 	Initially, 25-50 mg/day. Max: 150 mg/day. All doses to be given as a single dose or in 2 divided doses.\n<15	                Initially, 25 mg/day. Max: 75 mg/day. All doses to be given as a single dose.\n\nContra-indication: Hypersensitivity. Pregnancy, lactation. Driving or working with machines, or do other dangerous activities.\n\nSide effects: Dizziness, drowsiness, visual disturbance (including blurred vision, diplopia), ataxia, dysarthria, tremor, lethargy, memory impairment, euphoria, wt gain, constipation, dry mouth, peripheral edema, depression, confusion, agitation, hallucinations, myoclonus, hypoaesthesia, hyperaesthesia, tachycardia, excessive salivation, sweating, flushing, rash, muscle cramp, myalgia, arthralgia, urinary incontinence, dysuria, thrombocytopenia, neutropenia, 1st Â° heart block, hypotension, hypertension, pancreatitis, dysphagia, oliguria, rhabdomyolysis.\n\nPrecaution: Abrupt or rapid discontinuation of Pregabalin may produce some symptoms including insomnia, nausea, headache and diarrhoea. So Pregabalin should be tapered gradually over a minimum of 1 week rather than discontinued abruptly. Pregabalin treatment may associate with creatine kinase elevations. It should be discontinued if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur. Discontinue treatment if patients develop severe angioedema. Withdraw treatment gradually over at least 1 wk. May cause peripheral oedema. Regular vision check is recommended. May decrease platelet count and prolong PR interval.\n\nMode of action: May potentiate the effects of lorazepam. Additive CNS depressant effects w/ opiates and benzodiazepines. May increase risk of angioedema w/ ACE inhibitors. May increase risk of wt gain and peripheral oedema w/ thiazolidinediones.\n\nPregnancy category: C\n\nInteraction: May potentiate the effects of lorazepam. Additive CNS depressant effects w/ opiates and benzodiazepines. May increase risk of angioedema w/ ACE inhibitors. May increase risk of wt gain and peripheral oedema w/ thiazolidinediones.
Primaquine	\n\n\tACI\tRemaquin TAB dr 15mg 100's pack 151\n\tGlobe\tKanaprim TAB dr 15mg 100's pack 62\n\tHudson\tP Phos TAB dr 15mg 100's pack 62\n\tJayson\tJasoprim TAB dr 15mg  100's pack 126\n\tIndication: Malaria\n\nDose: Oral\nRadical treatment of vivax or ovale malaria\nAdult: A course of treatment with a blood schizontocide should be given first to kill any erythrocytic parasites. 15 mg daily for 14 days, increased to higher doses or longer course if resistance in P.vivax occurs.\n\nChild: 250 mcg/kg daily for 14 days.\n\nProphylaxis of chloroquine-resistant malaria\nAdult: 30 mg once daily; to be started 1-2 days before travel and continue for 7 days after departure from the malaria-endemic area.\n\nChild: 0.5 mg/kg once daily for 14 days. Max: 30 mg/day. \n\nContra-indication: Hypersensitivity. Childn <1 yr. Acute flare-ups of systemic diseases (RA, SLE) having tendency for agranulocytopaenia, Pregnancy and lactation.\n\nSide effects: Nausea, vomiting, epigastric distress, abdominal cramps, leukopaenia, leucocytosis, agranulocytosis, methaemoglobinemia in NADH methaemoglobin reductase-deficient individuals.\nPotentially Fatal: Haemolytic anaemia (G6PD deficient), thrombocytopaenia, leucopaenia, AV block.\n\nPrecaution: G6PD deficiency; pregnancy; NADH methaemoglobin reductase deficient patients. Monitor Hb levels and blood counts routinely. Patients with systemic diseases that have an increased risk of granulocytopenia. Withdraw treatment if signs of haemolysis or methaemogloinaemia occur.\n\nMode of action: Primaquine may inhibit metabolism of chloroquine. Avoid ethanol.\n\nPotentially Fatal: Mepacrine may potentiate toxicity of primaquine. Potentially haemolytic drugs eg, sulphonamides, nitrofurans and bone marrow suppressants eg, methotrexate, phenylbutazone, chloramphenicol should not be co-admin with primaquine.\n\nPregnancy category: C\n\nInteraction: Primaquine may inhibit metabolism of chloroquine. Avoid ethanol.\n\nPotentially Fatal: Mepacrine may potentiate toxicity of primaquine. Potentially haemolytic drugs eg, sulphonamides, nitrofurans and bone marrow suppressants eg, methotrexate, phenylbutazone, chloramphenicol should not be co-admin with primaquine.
Primrose Oil	\n\n\tGeneral\tRose CAP 500mg 30's pack 240\n\tSquare\tEprim CAP 500mg 30's pack 150\n\tIndication: Premenstrual syndrome, acne & rosacea, mastalgia, eczema, rheumatoid arthritis, diabetic neuropathy, psoriasis, atherosclerosis. Naurish skin, scalp. hair & nail.\n\nDose: 2 capsules of 500 mg 2-3 times daily.\n\nContra-indication: \n\nSide effects: Upset stomach, nausea, soft stools, or headache may occur.\n\nPrecaution:  Before taking evening primrose oil, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.\n\nIf you have any of the following health problems, consult your doctor or pharmacist before using this product: bleeding or clotting problems.\n\nLiquid products may contain sugar and/or alcohol. Caution is advised if you have diabetes, alcohol dependence, or liver disease. Ask your doctor or pharmacist about using this product safely.\n\nMode of action: None\n\nPregnancy category: X\n\nInteraction: 
Prochlorperazine Maleate	\n\n\tAlbion Ltd.\tAlmetil TAB dr 5 mg 500's pack \n\tAristopharma\tAmetil TAB dr 5mg 500's pack 230\n\tG. A. Company Ltd.\tMelatil TAB dr 5mg 100's pack 27.83\n\tNavana\tPromat TAB dr 5mg 200's pack 58\n\tOpsonin Pharma\tVergon TAB dr 5mg 400's pack 184\n\tPharmadesh Ltd.\tVertigan TAB dr 5mg 500's pack 200\n\tRephco\tAvotil TAB dr 5mg 100's pack 30\n\tSanofi Aventis (BD) Ltd.\tStemetil TAB dr 5mg 500's pack 230.02\n\tSonear Ltd.\tEmitab TAB dr 5mg 100's pack 46\n\tSquare\tPromtil TAB dr 5mg 300's pack 138\n\tIndication: Vertigo, Psychoses, Nausea and vomiting, Severe anxiety disorders\n\nDose: Oral\nProphylaxis of nausea and vomitting\nAdult: As maleate : 5-10 mg bid/tid. \n\nNausea and vomiting\nAdult: As maleate : 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid.\n\nPsychoses\nAdult: As maleate : 12.5 mg bid for 7 days, adjusted gradually to 75-100 mg daily according to response. Usual maintenance dose: 25-50 mg daily.\n\nChild: 1-5 yr: 1.25-2.5 mg; 5-12 yr: 2.5-5 mg. May be given up to tid, if necessary.\n\nAdjunct in severe anxiety disorders\nAdult: As maleate: 5-10 mg, up to 3-4 times daily.\n\nVertigo\nAdult: As maleate : 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid.\n\n\n\nContra-indication: CNS depression, comatose patients. Bone marrow depression, phaechromocytoma, prolactin-dependent tumours, hypersensitivity. Childn <2 yr. Pregnancy and lactation.\n\nSide effects: Cholestatic jaundice, cardiac arrhythmias, orthostatic hypotension, leucopaenia, thrombocytopaenia, dry mouth, blurring of vision, glaucoma, urinary retention, constipation, galactorrhoea, gynaecomastia, amenorrhoea and impotence. Buccal: Transient numbness of gum and tongue.\nPotentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration.\n\nPrecaution: Extrapyramidal syndrome, hypotension, epilepsy, impaired hepatic, renal, CV, cerebrovascular or respiratory function, glaucoma. May impair ability to drive or perform tasks requiring mental alertness or physical coordination. Parenteral use in children is not recommended. History of jaundice, parkinsonism, diabetes mellitus, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia or urinary retention. Regular eye examinations are recommended in patients on long-term treatment.\n\nMode of action:  	Alcohol, antacids.\n\nPregnancy category: C\n\nInteraction:  	Alcohol, antacids.
Prochlorperazine Mesilate	\n\n\tG. A. Company Ltd.\tMelatil Injection 12.5mg/ml 1 amps pack 3.54\n\tOpsonin Pharma\tVergon Injection 12.5mg/ml 50 amps pack 250\n\tOpsonin Pharma\tVergon Syrup 5mg/5ml 100ml bot 68.79\n\tSanofi Aventis (BD) Ltd.\tStemetil Injection 12.5mg/ml 10 amps pack 50.27\n\tSquare\tPromtil Injection 12.5mg/ml 10 amps pack 50\n\tIndication: Vertigo, Psychoses, Nausea and vomiting, Severe anxiety disorders\n\nDose: IV/IM:\nNausea and vomiting\nAdult: As mesilate: 12.5 mg by deep IM. If required, may give further doses via oral admin.\nSevere nausea and vomiting\nAdult: 2.5-10 mg via slow IV inj or infusion at a rate not exceeding 5 mg/minute. Not to exceed 40 mg daily.\n\nPsychoses\nAdult: As mesilate: 12.5-25 mg by deep IM Inj bid/tid.\n\nOral\nProphylaxis of nausea and vomitting\nAdult: As mesilate: 5-10 mg bid/tid. May also be given rectally.\n\nNausea and vomiting\nAdult: As mesilate: 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid.\n\nPsychoses\nAdult: As mesilate: 12.5 mg bid for 7 days, adjusted gradually to 75-100 mg daily according to response. Usual maintenance dose: 25-50 mg daily.\nChild: 1-5 yr: 1.25-2.5 mg; 5-12 yr: 2.5-5 mg. May be given up to tid, if necessary.\n\nAdjunct in severe anxiety disorders\nAdult: As mesilate: 5-10 mg, up to 3-4 times daily.\n\nVertigo\nAdult: As mesilate: 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid. \n\n\nContra-indication:  CNS depression, comatose patients. Bone marrow depression, phaechromocytoma, prolactin-dependent tumours, hypersensitivity. Childn <2 yr. Pregnancy and lactation.\n\nSide effects: Cholestatic jaundice, cardiac arrhythmias, orthostatic hypotension, leucopaenia, thrombocytopaenia, dry mouth, blurring of vision, glaucoma, urinary retention, constipation, galactorrhoea, gynaecomastia, amenorrhoea and impotence. Buccal: Transient numbness of gum and tongue.\nPotentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration.\n\nPrecaution:  Extrapyramidal syndrome, hypotension, epilepsy, impaired hepatic, renal, CV, cerebrovascular or respiratory function, glaucoma. May impair ability to drive or perform tasks requiring mental alertness or physical coordination. Parenteral use in children is not recommended. History of jaundice, parkinsonism, diabetes mellitus, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia or urinary retention. Regular eye examinations are recommended in patients on long-term treatment.\n\nMode of action: Alcohol, antacids.\n\nPregnancy category: C\n\nInteraction: Alcohol, antacids.
Procyclidine Hydrochloride	\n\n\tGeneral\tExtranil TAB dr 5mg 100's pack 76\n\tGeneral\tExtranil IV/IM Injection 10mg/2ml 1's pack 30\n\tGlaxoSmithKline Bangladesh Ltd.\tKemadrin TAB dr 5mg 100's pack 186.20\n\tIncepta\tCyclid Injection 10mg/2ml 1 amps pack 30\n\tIncepta\tCyclid 5 TAB dr 5mg 100's pack 100\n\tOpsonin Pharma\tKdrine Injection 10mg/2ml 5's pack 150.55\n\tOpsonin Pharma\tKdrine TAB dr 5mg 100's pack 36.93\n\tSquare\tPerkinil Injection 10mg/2ml 1 amps pack 30.11\n\tSquare\tPerkinil TAB dr 5mg 200's pack 151.62\n\tSquare\tPerkinil TAB dr 2.5mg 10's pack 100.50\n\tIndication: Parkinsonism, Drug-induced extrapyramidal syndrome\n\nDose: Oral\nParkinsonism and drug-induced extrapyramidal syndrome\nAdult: As hydrochloride: Initially, 2.5 mg tid, increased gradually by 2.5-5 mg every 2-3 days if required. Maintenance: 10-30 mg/day in 3-4 divided doses. Up to 60 mg daily may be required in some cases.\nElderly: Lower doses are required.\n\nDystonia in children\nChild: 7-12 yr: 1.25 mg tid; 12-18 yr: 2.5 mg tid. For emergency cases, a single dose may be given via IM or IV inj: <2 yr: 0.5-2 mg; 2-10 yr: 2-5 mg and 10-18 yr: 5-10 mg.\n\nParenteral\nParkinsonism and drug-induced extrapyramidal syndrome\nAdult: Emergency cases: IV admin: 5-10 mg, higher doses may be needed; IM admin: 5-10 mg as a single dose, may repeat after 20 minutes if needed, to a max of 20 mg daily.\nElderly: Lower doses are required.\n\nContra-indication: Urinary outflow obstruction, prostatic hyperthrophy, narrow-angle glaucoma, paralytic ileus and pyloric stenosis.\n\nSide effects: Excitability, dizziness, hallucinations (seen on abuse), dry mouth, blurred vision, constipation, urinary retention, agitation, restlessness, confusion and convulsions.\n\nPrecaution: Patients with diarrhoea. May impair a patient's ability to perform skilled tasks e.g. driving. May precipitate psychotic episodes in patients with mental disorders. Thyrotoxicosis, heart failure, acute myocardial infarction, hypertension. Childn, elderly. Pregnancy and lactation. Avoid abrupt withdrawal.\n\nMode of action: Increased plasma concentrations w/ paroxetine. Enhanced anticholinergic action w/ MAOIs and other anticholinergic drugs. Reduced therapeutic effect w/ cholinergic drugs. May antagonise the effect of parasympathomimetic agents. May reduce the absorption and therapeutic effect of sublingual or buccal nitrate tab. May reduce the efficacy of levodopa. May antagonise the GI effects of cisapride, domperidone and metoclopramide. May potentiate the vagolytic effects of quinidine. May reduce the absorption of ketoconazole.\n\nPregnancy category: C\n\nInteraction: Increased plasma concentrations w/ paroxetine. Enhanced anticholinergic action w/ MAOIs and other anticholinergic drugs. Reduced therapeutic effect w/ cholinergic drugs. May antagonise the effect of parasympathomimetic agents. May reduce the absorption and therapeutic effect of sublingual or buccal nitrate tab. May reduce the efficacy of levodopa. May antagonise the GI effects of cisapride, domperidone and metoclopramide. May potentiate the vagolytic effects of quinidine. May reduce the absorption of ketoconazole.
Progesterone	\n\n\tRenata\tMicrogest CAP 100mg 30's pack 450\n\tRenata\tMicrogest CAP 200mg 30's pack 900\n\tSerono Pharma Ltd., UK\tCrinone 8% Gel 90mg 15's pack 4564.88\n\tIndication: Premenstrual syndrome, Contraception, Menopausal HRT, Amenorrhoea, Recurrent miscarriage\n\nDose: Oral \nProgestogen component of menopausal hormonal replacement therapy. Adult: 200 mg daily as a single daily dose at night for 12-14 days of each mth.\nAmenorrhoea Adult: 400 mg daily for 10 days.\nDysfunctional uterine bleeding. Adult: 400 mg daily for 10 days.\n\nVaginal Gel\nDysfunctional uterine bleeding. Adult: 45 mg every other day from the 15th-25th day of the cycle. May increase dose to 90 mg in non-responders.\n\nVaginal Gel\nAmenorrhoea. Adult: 45 mg every other day from the 15th-25th day of the cycle. May increase dose to 90 mg in non-responders.\n\n\n\nContra-indication: Hypersensitivity; thrombophloebitis; cerebral apoplexy; severe hepatic impairment; undiagnosed vag bleeding, incomplete abortion, hormone-dependent carcinoma, as a diagnostic test for pregnancy; pregnancy. History or current high risk of arterial disease.\n\nSide effects: GI disturbances, appetite/wt change, fluid retention, oedema, acne, skin rash, urticaria, depression, headache, fever, fatigue, breast changes, hirsutism, changes in libido, altered menstrual cycles or irregular menstrual bleeding (rare).\n\nPrecaution: Discontinue medications if there is sudden partial or complete loss of vision, proptosis or diplopia; migraine and embolic disorders; epilepsy, migraine, asthma, cardiac or renal dysfunction. History of depression, glucose tolerance and diabetic patients. May impair ability to drive or operate machinery. Avoid sudden withdrawal of progesterone; lactation.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Promethazine Hydrochloride	\n\n\tAlbion Ltd.\tMontil Syrup 0.10g/100 ml 100 ml \n\tAmbee\tProgan Syrup 5mg/5ml 100ml bot 15.50\n\tApollo Pharmaceutical Ltd.\tHistin Syrup 5mg/5ml  60ml bot / 100 ml bot 11 / 21.50\n\tBeximco\tPromezin Syrup 5mg/5ml   100 ml bot 15.50\n\tChemist Ltd.\tPromodin Syrup 5mg/5ml  100 ml bot 14.55\n\tCosmic Chemical Industries Ltd.\tFlumin Syrup 5mg/5ml  60ml bot / 100 ml bot 18.78 / 23.95\n\tEdruc Ltd.\tHisterzin Syrup 5mg/5ml  60ml bot   12\n\tG. A. Company Ltd.\tPromargan Syrup 5mg/5ml  60ml bot  12\n\tIndobangla Pharmaceuticals\tArromin Syrup 5mg/5ml  60ml bot / 100 ml bot 7 / 12\n\tJayson\tPhenerex Syrup 5mg/5ml 100ml bot 23.96\n\tJayson\tPhenerex Injection 25mg/1ml 1ml amp x 10's pack 33.70\n\tJayson\tPhenerex Injection 50mg/2ml 2ml amp x 10's pack 41.60\n\tMedimet\tAllphen Syrup 5mg/5ml  50ml bot / 100 ml bot 12 / 20\n\tMillat\tMitargan Syrup 5mg/5ml  100 ml bot 23.96\n\tModern\tPromalex M Syrup 5mg/5ml  60ml bot / 100 ml bot 18.70 / 23.95\n\tNorth Bengal\tMelin syrup 5mg/5ml 50 ml bot \n\tOpsonin Pharma\tOtosil Syrup 5mg/5ml  60ml bot / 100 ml bot 10 / 14\n\tOpsonin Pharma\tOtosil TAB dr 10mg 100's pack 30\n\tOpsonin Pharma\tOtosil TAB dr 25mg 100's pack 40\n\tOpsonin Pharma\tOtosil Syrup 5 mg/5 ml  \n\tPacific\tHistavil Syrup 5mg/5ml  60ml bot  10\n\tPharmadesh Ltd.\tPromestin Syrup 5mg/5ml  60ml bot / 100 ml bot 18 / 23\n\tSanofi Aventis (BD) Ltd.\tPhenergan Syrup 5mg/5ml 125ml bot 27.97\n\tSanofi Aventis (BD) Ltd.\tPhenergan TAB dr 10mg 500's pack 340\n\tSanofi Aventis (BD) Ltd.\tPhenergan TAB dr 25mg 250's pack 109.73\n\tSeema\tHistaphen Syrup 5mg/5ml  60ml bot   12\n\tTechno Drugs Ltd.\tFlugan Injection 50 mg/2 ml  \n\tZenith\tProzine TAB dr 25mg 500's pack 210\n\tIndication: Allergic conditions, Nausea and vomiting, Motion sickness, Insomnia\n\nDose: Oral\nAllergic conditions\nAdult: As hydrochloride: 25 mg at night inreased to 25 mg bid, if needed; alternatively, 10-20 mg bid or tid.\nChild: As hydrochloride: 5-10 yr: 10-25 mg daily; 2-5 yr: 5-15 mg daily. Doses are given in 1 or 2 divided doses.\nRenal impairment: Dose reduction may be required.\n\nProphylaxis of motion sickness\nAdult: As hydrochloride: 20 or 25 mg the night before travelling followed by a similar dose in the morning if needed. \n\nChild: As hydrochoride: 5-10 yr: 10 mg; 2-5 yr: 5 mg; doses are given at night before travelling, repeated the following morning if needed. As teoclate: 5-10 yr: 12.5 mg daily starting either on the night before long journeys or 1-2 hr before short journeys. \n\nRenal impairment: Dose reduction may be required.\n\nShort-term management of insomnia\nAdult: As hydrochloride: 20-50 mg at night.\nChild: As hydrochloride: 5-10 yr: 20-25 mg; 2-5 yr; 15-20 mg. Doses are taken at night. May also be given as suppository.\n\nRenal impairment: Dose reduction may be required.\n\nParenteral\nAllergic conditions\nAdult: As hydrochloride: 25-50 mg, given via IM or slow IV inj or injected into the tubing of a freely running infusion at a concentration of not >25 mg/ml and infused at a rate of not >25 mg/min. Max dose: 100 mg.\n\nChild: As hydrochloride: 5-10 yr: 6.25-12.5 mg by deep IM inj.\nRenal impairment: Dose reduction may be required. \n\nContra-indication: Hypersensitivity, coma, porphyria, cardiac disease, hypokalaemia, intra-arterial or SC inj, neonates and young children, pregnancy, lactation.\n\nSide effects: CNS depression, paradoxical excitation in childn, dryness of mouth, blurring of vision, retention of urine, constipation, glaucoma, tachycardia, headache, hypotension, tinnitus.\n\nPrecaution: Elderly, glaucoma, epilepsy, CVS disease, impaired liver function, asthma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction. May cause drowsiness. For parenteral admin: Drug must be administered carefully and slowly; incorrect admin can lead to severe tissue injury.\n\nMode of action: Masks ototoxicity of aminoglycoside antibiotics. May enhance the sedative effects of CNS depressants like alcohol, hypnotics, barbiturates and opioids.\nPotentially Fatal: Ventricular arrhythmias when used with drugs that prolong QT interval.\n\nPregnancy category: C\n\nInteraction: Masks ototoxicity of aminoglycoside antibiotics. May enhance the sedative effects of CNS depressants like alcohol, hypnotics, barbiturates and opioids.\nPotentially Fatal: Ventricular arrhythmias when used with drugs that prolong QT interval.
Promethazine Theoclate	\n\n\tSanofi Aventis (BD) Ltd.\tAvomine TAB dr 25mg 500's pack 285.95\n\tIndication: Nausea and vomiting, Motion sickness, Vertigo\n\nDose: Oral\nNausea and vomiting\nAdult: As teoclate: 25 mg at night, may be increased to 50 or 75 mg at night or to 25 mg bid/tid, if needed. Max: 100 mg daily.\n\nChild: As teoclate: 5-10 yr: 12.5-37.5 mg daily.\nRenal impairment: Dose reduction may be required.\n\nProphylaxis of motion sickness\nAdult: As teoclate: 25 mg at night or 25 mg 1-2 hr before travelling.\nChild: As teoclate: 5-10 yr: 12.5 mg daily starting either on the night before long journeys or 1-2 hr before short journeys.\n\n\n\nContra-indication: Hypersensitivity, coma, porphyria, cardiac disease, hypokalaemia, intra-arterial or SC inj.\n\nSide effects: CNS depression, paradoxical excitation in childn, dryness of mouth, blurring of vision, retention of urine, constipation, glaucoma, tachycardia, headache, hypotension, tinnitus.\n\nPrecaution: Elderly, glaucoma, epilepsy, CVS disease, impaired liver function, asthma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction. May cause drowsiness. For parenteral admin: Drug must be administered carefully and slowly; incorrect admin can lead to severe tissue injury.\n\nMode of action: Masks ototoxicity of aminoglycoside antibiotics. May enhance the sedative effects of CNS depressants like alcohol, hypnotics, barbiturates and opioids.\nPotentially Fatal: Ventricular arrhythmias when used with drugs that prolong QT interval.\n\nPregnancy category: C\n\nInteraction: Masks ototoxicity of aminoglycoside antibiotics. May enhance the sedative effects of CNS depressants like alcohol, hypnotics, barbiturates and opioids.\nPotentially Fatal: Ventricular arrhythmias when used with drugs that prolong QT interval.
Propafenone Hydrochloride	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tRythmosin TAB dr  150 mg 3x10's pack 450\n\tIndication: Supraventricular and ventricular arrhythmias\n\nDose: Oral\nSupraventricular and ventricular arrhythmias\nAdult: Doses should be started under close monitoring of ECG and BP. For immediate-release tablet: Usual initial doses: 150 mg tid, may increase at intervals of 3-4 days up to 300 mg tid. Dose reduction is recommended in patients weighing <70 kg. For extended-release capsule: Initial doses: 225 mg every 12 hr; may increase dose at intervals of at least 5 days, up to 325-425 mg every 12 hr\nElderly: Dose reduction is recommended.\nHepatic impairment: Dose reduction is recommended.\n\nSpecial Populations: Reduce dose in elderly, patients weighing <70 kg and in those with hepatic impairment.\n\nContra-indication: Uncontrolled heart failure, marked hypotension, severe bradycardia and heart block, conduction abnormalities, cardiogenic shock, myasthenia gravis.\n\nSide effects: Dizziness, headache, visual disturbances, vertigo, dry mouth, GI disturbances, alteration in taste, allergic skin rashes, leucopenia, bradycardia and bitter or metallic taste.\nPotentially Fatal: SA/AV or intraventricular blocks. Severe hypotension, especially in elderly.\n\nPrecaution: Severe pulmonary obstructive diseases, CHF, cardiac pacemaker, impaired renal/hepatic function, pregnancy, lactation, elderly. Correct electrolyte disturbances before starting treatment. May worsen heart failure in patients with preexisting organic heart disease. May worsen or cause new severe ventricular arrhythmias e.g. ventricular tachycardia or fibrillation. May aggravate electrically induced ventricular tachycardia in some patients.\n\nMode of action: Effect may be potentiated by local anesth, ?-blockers, TCA. May increase plasma level of propranolol, metoprolol, desipramine, cyclosporin, digoxin, theophylline. Plasma conc may rise when taken simultaneously w/ cimetidine or quinidine. May enhance effect of anticoagulant. Simultaneous administration w/ phenobarb or rifamycin may decrease propafenone plasma conc, possibly in sub-therapeutic levels.\n\nPregnancy category: C\n\nInteraction: Effect may be potentiated by local anesth, ?-blockers, TCA. May increase plasma level of propranolol, metoprolol, desipramine, cyclosporin, digoxin, theophylline. Plasma conc may rise when taken simultaneously w/ cimetidine or quinidine. May enhance effect of anticoagulant. Simultaneous administration w/ phenobarb or rifamycin may decrease propafenone plasma conc, possibly in sub-therapeutic levels.
Propantheline Bromide	\n\n\tBeacon\tProkind TAB dr 15mg 50's pack 175.50\n\tG. A. Company Ltd.\tPropanthene TAB dr 15mg 100's pack 130\n\tIndication: Hyperhidrosis, Peptic ulcer, Urinary incontinence, GI tract spasm, Adult enuresis\n\nDose: Oral\nAdjunct in peptic ulcer\nAdult: 15 mg tid and 30 mg at bedtime. Doses up to 120 mg daily may be needed.\nChild: For relief of GI spasm: 1 mth - 12 yr: 300 mcg/kg (max 15 mg), given 3-4 times daily.\nElderly: 7.5 mg tid. May increase to a max of 30 mg tid.\n\nGastrointestinal tract spasm\nAdult: 15 mg tid and 30 mg at bedtime. Doses up to 120 mg daily may be needed.\nChild: For relief of GI spasm: 1 mth - 12 yr: 300 mcg/kg (max 15 mg), given 3-4 times daily.\nElderly: 7.5 mg tid. May increase to a max of 30 mg tid.\n\nUrinary incontinence\nAdult: 15-30 mg bid/tid.\n\nAdult enuresis\nAdult: 15-30 mg bid/tid.\n\nHyperhidrosis\nAdult: 15-30 mg bid/tid.\n\nContra-indication: Glaucoma, obstructive diseases of GI or urinary tract, severe ulcerative colitis or toxic megacolon, intestinal atony, hiatus hernia associated with reflux oesophagitis, unstable cardiovascular adjustment in acute bleeding, prostatic enlargement, myasthenia gravis, paralytic ileus, pyloric stenosis, angle-closure glaucoma.\n\nSide effects: Dry mouth, thirst, difficulty in swallowing, skin dryness, flushing, reduced sweating, heat stroke, constipation, nausea and vomiting. Pupil dilatation with loss of accomodation and increased sensitivity to light; increased intra-ocular pressure. Bradycardia followed by tachycardia, arrhythmias and palpitations. Glaucoma, urinary hesitancy and retention, orthostatic hypotension especially in elderly.\nPotentially Fatal: Toxic megacolon due to preexisting ulcerative colitis.\n\nPrecaution: Hyperthyroidism, congestive heart failure, coronary heart disease, cardiac arrhythmias, acute MI, cardiac insufficiency, hypertension. Pregnancy and lactation; elderly. Patients with fever, diarrhoea, GI reflux disease or ulcerative colitis. Hepatic or renal impairment. Increased risk of fever or heat stroke in patients exposed to high environmental temperature. Caution when used in patients with Down's syndrome.\n\nMode of action: Additive anticholinergic effect with MAOIs, TCAs, phenothiazines, antihistamines and disopyramide. Delayed gastric emptying causes delayed absorption of other drugs. May antagonise the GI effects of domperidone, cisapride and metoclopramide. May reduce absorption of ketoconazole and levodopa. May increase absorption of nitrofurantoin. May increase serum levels of digoxin. May reduce effects of haloperidol and sublingual tablets of nitrates. May antagonise effects of parasympathomimetics.\n\nPregnancy category: C\n\nInteraction: Additive anticholinergic effect with MAOIs, TCAs, phenothiazines, antihistamines and disopyramide. Delayed gastric emptying causes delayed absorption of other drugs. May antagonise the GI effects of domperidone, cisapride and metoclopramide. May reduce absorption of ketoconazole and levodopa. May increase absorption of nitrofurantoin. May increase serum levels of digoxin. May reduce effects of haloperidol and sublingual tablets of nitrates. May antagonise effects of parasympathomimetics.
Proparacaine Hydrochloride 0.5%	\n\n\tAristopharma\tProcain Eye Drops   10ml bot 150\n\tPopular\tP-caine Eye Drops 0.5% 10 ml plastic dropper bottle \n\tIndication: Corneal anesthesia, Foreign Bodies & Suture Removal\n\nDose: Deep anesthesia as in cataract extraction:\n\nInstill 1 drop every 5 to 10 minutes for 5 to 7 doses.\n\nRemoval of sutures:\n\nInstill 1 or 2 drops 2 or 3 minutes before removal of stitches.\n\nRemoval of foreign bodies:\n\nInstill 1 or 2 drops prior to operating.\n\nTonometry:\n\nInstill 1 or 2 drops immediately before measurement.\n\n\nContra-indication: This preparation is contraindicated in patients with known hypersensitivity to any component of the solution. This product should never be prescribed for the patient's own use.\n\nSide effects: Pupillary dilatation or cycloplegic effects have rarely been observed with proparacaine hydrochloride. The drug appears to be safe for use in patients sensitive to other local anesthetics, but local or systemic sensitivity occasionally occurs. Instillation of proparacaine in the eye at recommended concentration and dosage usually produces little or no initial irritation, stinging, burning, conjunctival redness, lacrimation or increased winking. However, some local irritation and stinging may occur several hours after the instillation. Rarely, a severe immediate-type, apparently hyperallergic corneal reaction may occur which includes acute, intense and diffuse epithelial keratitis; a gray, ground-glass appearance; sloughing of large areas of necrotic epithelium; corneal filaments and, sometimes, iritis with descemetitis. Allergic contact dermatitis with drying and fissuring of the fingertips has been reported. Softening and erosion of the corneal epithelium and conjunctival congestion and hemorrhage have been reported.\n\nPrecaution: Proparacaine hydrochloride should be used cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism. The long-term toxicity of proparacaine is unknown, prolonged use may possibly delay wound healing. Although exceedingly rare with ophthalmic application of local anesthetics, it should be borne in mind that systemic toxicity (manifested by central nervous system stimulation followed by depression) may occur. Protection of the eye from irritating chemicals, foreign bodies and rubbing during the period of anesthesia is very important. Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water prior to use. Patients should be advised to avoid touching the eye until the anesthesia has worn off.\nCarcinogenesis, Mutagenesis, Impairment of Fertility\n\nLong-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment oi fertility in males or females.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Propofol	\n\n\tIncepta\tUfol Injection 20mg / ml  \n\tPopular\tPofol IV Injection 200mg/20ml  20 ml amp x 5's pack 1003.75\n\tB. Braun Melsungen Ag, Germany\tPropofol-Lipuro 1% Bandage 10mg/ml 5's pack 1400\n\tFresenius Kabi Austria GmbH,Austria\tFresofol 1% Injection 10mg/ml  20 ml amp x 1's pack 50 ml bot x 1's pack 1758 / 779\n\tAstrazeneca Pharmaceutical company\tDiprivan 1% Solution 10mg/ml 20mlx/1's pack \n\tIndication: General anaesthesia, Sedation\n\nDose: Adult: IV Induction and maintenance of general anesth Induction: 40 mg every 10 sec. Maintenance: 4-12 mg/kg/hr or intermittent boluses of 20-50 mg. \n\nChild: >8 yr: Induction dose of 2.5 mg/kg. Maintenance dose: 9-15 mg/kg/hr by IV infusion or intermittent bolus inj. \n\nSedation In diagnostic and surgical procedures: Initial: 6-9 mg/kg/hr by infusion. Maintenance: 1.5-4.5 mg/kg/hr. For ventilated patients: 0.3-4 mg/kg/hr. Monitor lipid concentrations if duration of sedation >3 days.\n\nContra-indication: Electroconvulsive therapy, obstetrics. Sedation in children ?16 yr. Pregnancy, lactation.\n\nSide effects: Involuntary muscle movements; nausea, vomiting, headache, fever; pain, burning or stinging at inj site.\nPotentially Fatal: Apnoea, bradycardia, hypotension, convulsions; anaphylaxis.\n\nPrecaution: Paediatrics, elderly, hypovolaemia, epilepsy, lipid disorders, patients with increased intracranial pressure. Avoid rapid bolus doses in high risk patients. Emulsion formulation of propofol 2% should only be used in children >3 yr.\n\nMode of action: Reduce dose if given with nitrous oxide or halogenated anaesthetics. Increased sedative, anaesthetic and cardiorespiratory effects when used with other CNS depressants.\n\nPregnancy category: B\n\nInteraction: Reduce dose if given with nitrous oxide or halogenated anaesthetics. Increased sedative, anaesthetic and cardiorespiratory effects when used with other CNS depressants.
Propranolol Hydrochloride	\n\n\tACI\tIndever TAB dr 10mg 100's pack 51\n\tACI\tIndever TAB dr 40mg 100's pack 150\n\tACI\tIndever SR CAP 40mg 100's pack 92\n\tACI\tIndever SR CAP 80mg 100's pack 155\n\tAlbion Ltd.\tPropranolol TAB dr 10 mg/ 40 mg 100's/ 100's pack \n\tGonoshasthaya\tG Propranolol TAB dr 40mg 100's pack 35\n\tOpsonin Pharma\tPropranol TAB dr 10mg 200's pack 42\n\tOpsonin Pharma\tPropranol TAB dr 40mg 100's pack 31\n\tSonear Ltd.\tAdlock TAB dr 10mg 100's pack 50\n\tSonear Ltd.\tAdlock TAB dr 40mg 100's pack 46\n\tSun Pharmaceutical (Bangladesh) Ltd.\tBetacap TR CAP 40mg 50's pack 125\n\tIndication: Tuberculosis, Hypertrophic cardiomyopathy, MI, Anxiety, Diabetic nephropathy, HTN, Cardiac arrhythmias, Angina pectoris, Phaeochromocytoma, Migraine prophylaxis, Essential tremor\n\nDose: Adults\nHypertension: As starting dose of 80mg twice a day may increased at weekly intervals according to response. The usual dose range is 160-320mg per day. With concurrentdiuretic or other antihypertensive drugs a further reduction of blood pressure is obtained.\n\nAngina, anxiety,migraine and essential tremor:\nA staring dose of 40mg two or three times daily may be increased by the same amount at weekly intervals according to patientsâ response. An adequate response in anxiety, migraine and essential tremor is usually seen in the range 80-160mg/day and an angina in the range 120-240mg/day.\n\nSituational and generalized anxiety:\nA dose of 40mg daily may provide short term relief of acute situational anxiety.\nGeneralized anxiety require long term therapy, usually responds adequately to 40mg twice daily which, which individual cases, may be increased to 40mg three times daily. Treatment should be continued according to responses. Patients shouldreviewed after 6 to12 months treatment.\n\nDysarhythmias, anxiety tachycardia, hypertrophic obstructive cardiomyopathy and thyrotoxicosis:\nA dosage range of 10-40mg three or four times a day usually achieves the required response.\n\nPost myocardial infarction:Treatment should be started between days 5 and after 21 after myocardial infarction,with an initial dose of 40mg four times a day for 2 or 3 days. In order to improve compliance the total daily doses three after be given as 80mg twice a day.\n\nPhaeochromocytoma (Used only with an alpha receptor blocking drug).\nPre-operative: 60mg daily for three days. Non-operable malignant cases: 30mg daily.\n\nChildren: Sysrhythmias, Phaeochromocytoma,Thyrotoxicisis: Dosage should be individually determined and the following is only a guide.0.25-0.5mg/kg three or four times daily as required.\n\nMigraine Under 12 years: 20mg two or three times daily.\nOver 12 years: The adult dose.\n\nAs Extended release Capsule:\nHypertension\nDosage Must Be Individualized. The usual initial dosage is 80 mg propranolol hydrochloride extended-release capsules once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks.\n\nAngina Pectoris\n\nDosage Must Be Individualized. Starting with 80 mg propranolol hydrochloride extended-release capsules once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established.\n\nIf treatment is to be discontinued, reduce dosage gradually over a period of a few weeks.\n\nMigraine\nDosage Must Be Individualized. The initial oral dose is 80 mg propranolol hydrochloride extended-release capsules once daily. The usual effective dose range is 160 to 240 mg once daily. The dosage may be increased gradually to achieve optimal migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximal dose, propranolol hydrochloride extended-release capsules therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks.\n\nHypertrophic Subaortic Stenosis\n80 mg to 160 mg propranolol hydrochloride extended-release capsules once daily.\n\n\n\nContra-indication: Propranolol hydrochloride is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3) bronchial asthma; 4) congestive heart failure (see WARNINGS), unless the failure is secondary to a tachyarrhythmia treatable with propranolol hydrochloride.\n\nSide effects: Most adverse effects have been mild and transient and have rarely required the withdrawal of therapy.\n\nCardiovascular: Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.\n\nCentral Nervous System: Lightheadedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate formulations, fatigue, lethargy, and vivid dreams appear dose related.\n\nGastrointestinal: Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, and ischemic colitis.\n\nAllergic: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, pharyngitis and agranulocytosis, erythematous rash, fever combined with aching and sore throat, laryngospasm, and respiratory distress.\n\nRespiratory: Bronchospasm.\n\nHematologic: Agranulocytosis, nonthrombocytopenic purpura, and thrombocytopenic purpura.\n\nSkin: Stevens-Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria.\n\nPrecaution: Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol is not indicated for the treatment of hypertensive emergencies.\n\nBeta-adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that propranolol may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.\n\nRisk of Anaphylactic Reaction\n\n\nWhile taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.\n\nMode of action: Antidiabetics, verapamil, diltiazem, lignocaine, ergotamine, dihydroergotamine, indomethacin, chlorpromazine, anaesth, disopyramide, quinidine, amiodarone, digitalis glycosides, cimetidine, hydralazine, adrenaline, alcohol.\n\nPregnancy category: D\n\nInteraction: Antidiabetics, verapamil, diltiazem, lignocaine, ergotamine, dihydroergotamine, indomethacin, chlorpromazine, anaesth, disopyramide, quinidine, amiodarone, digitalis glycosides, cimetidine, hydralazine, adrenaline, alcohol.
Protamin Sulphate	\n\n\tIndication: Heparin overdosage, Heparin neutralisation, Enoxaparin or dalteparin overdosage\n\nDose: Adult: IV Heparin overdosage Dosage depends heparin dose, its route of administration, time elapsed since heparin dose and blood coagulation studies. For heparin administered via IV inj: If only a few mins have elapsed since heparin dose, 1-1.5 mg per 100 u of heparin administered; if 30 mins have elapsed since heparin dose, 0.5 mg per 100 u of heparin and, if >2 hr have elapsed since heparin dose, 0.25-0.375 mg per 100 u of heparin; doses to be given via IV inj at rate >5 mg/minute. \n\nFor heparin administered via IV infusion: 25-50 mg via inj after stopping heparin infusion. For heparin administered via SC inj: 1-1.5 mg via inj per 100 u of heparin administered. Heparin neutralisation during extracorporeal circulation 1.5 mg per 100 u of heparin administered. \n\nEnoxaparin or dalteparin overdosage Dose depends on the administered dose of low molecular weight heparin (LMWH), time elapsed since drug was administered and blood coagulation tests. \n\nFor enoxaparin: If <8 hr since LMWH dose, dose should be equal to that of the administered enoxaparin dose; if >8 hr has elapsed since LMWH dose, infuse 0.5 mg per mg of enoxaparin Na administered; if >12 hr has elapsed since LMWH dose, protamine may not be needed.\n\n For dalteparin: 1 mg per 100 anti-Xa u of dalteparin administered. If aPTT remains prolonged 2-4 hr after the 1st infusion, a 2nd infusion may be given.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Hypotension, bradycardia, pulmonary and systemic hypertension, dyspnoea, warm sensation, transitory flushing, nausea and vomiting, lassitude.\nPotentially Fatal: Severe hypersensitivity reactions e.g. CV collapse, fatal anaphylactic reaction; noncardiogenic pulmonary oedema with prolonged hypotension (rare).\n\nPrecaution: Avoid rapid admin as this may cause severe hypotension and anaphylactoid reactions. Patients at risk of developing hypersensitivity to protamine (e.g previous history of procedures such as coronary angioplasty or cardio-pulmonary bypass which may include protamine, diabetics using protamine insulin, allergy to fish, vasectomised or infertile males who may have antibodies to protamine. Monitor aPTT or activated coagulation time, 5-15 minutes after protamine sulfate admin. Monitor clotting parameters closely especially in prolonged procedures as rebound bleeding may occur up to 18 hr after operation. Pregnancy, lactation, children.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Pseudoephedrine Hydrochloride	\n\n\tAlbion Ltd.\tPseudoephedring TAB dr 60 mg 100's pack \n\tGlaxoSmithKline Bangladesh Ltd.\tSudafed TAB dr 60mg 100's pack 202.16\n\tIncepta\tSudorin TAB dr 60mg 100's pack 200\n\tOpsonin Pharma\tSudotab TAB dr 60mg 100's pack 200\n\tIndication: Nasal congestion\n\nDose: As a decongestant and symptomatic treatment for upper respiratory tract infections the recommended dose is:\nAdults : 1  tablet every 4 to 6 hours, up to maximum of 240 mg in 24 hours\n\nChildren : (6 - 12 years of age) 1/2 tablet every 4 to 6 hours daily\n(2 - 5 years of age) 1/4  tablet every 4 to 6 hours daily\nFor children less than 2 years of age, the drug is not advised unless specifically recommended by a physician.\n\nContra-indication: Pseudoephedrine is contraindicated in\n* Hypersensitivity of individuals to this drug\n* Severe hypertension and coronary artery disease\n* Concurrent use of Mono Amine Oxidase Inhibitor (MAOI) drugs\n\nSide effects: Serious adverse effects associated with the use of Pseudoephedrine are rare. Symptoms of central nervous system excitation may occur, including sleep disturbances and, rarely, hallucinations have been reported. Skin rashes, with or without irritation, have occasionally been reported.\n\nPrecaution: Although Pseudoephedrine has virtually no pressor effects in normotensive patients, it should be used with caution in patients suffering mild to moderate hypertension. As with other sympathomimetic agents, Pseudoephedrine should be used with caution in patients with hypertension, heart disease, diabetes, hyperthyroidism, elevated intraocular pressure and prostatic enlargement. Caution should be exercised when using the product in the presence of severe hepatic impairment or moderate to severe renal impairment.\n\nMode of action: Increased risk of hypertension and arrhythmias if given with cardiac glycosides, quinidine or TCAs. Increased risk of vasoconstrictor effects if given with ergot alkaloids or oxytocin. Co-admin with MAOIs may cause hypertensive crisis. Anaesthetics e.g. cyclopropane, halothane and other halogenated anaesthestics; antihypertensive agents.\n\nPregnancy category: C\n\nInteraction: Increased risk of hypertension and arrhythmias if given with cardiac glycosides, quinidine or TCAs. Increased risk of vasoconstrictor effects if given with ergot alkaloids or oxytocin. Co-admin with MAOIs may cause hypertensive crisis. Anaesthetics e.g. cyclopropane, halothane and other halogenated anaesthestics; antihypertensive agents.
Pseudoephedrine Hydrochloride + Triprolidine Hydrochloride	\n\n\tOpsonin Pharma\tFrenos TAB dr   50's pack 175\n\tIndication: Pneumonia, Pharyngitis, Allergic rhinitis, Upper respiratory tract, Dry cough, Tracheolaryngitis\n\nDose: Oral\nAllergic rhinitis, Cold and flu\nAdult: Each tablet contains triprolidine HCl 2.5 mg and pseudoephedrine HCl 60 mg: 1 tablet 4-6 hrly, up to 4 times a day. \n\nAs syrup containing triprolidine HCl 1.25 mg and pseudoephedrine HCl 30 mg/5 ml: 10 ml 4-6 hrly, up to 4 times daily.\n\nChild: Each tablet contains triprolidine HCl 2.5 mg and pseudoephedrine HCl 60 mg: > 12 yr: 1 tablet 4-6 hrly, up to 4 times a day. \n\nAs syrup containing triprolidine HCl 1.25 mg and pseudoephedrine HCl 30 mg/5 ml: 6-12 yr: 5 ml 4-6 hrly, up to 4 times daily. 2-5 yr: 2.5 ml 4-6 hrly, up to 4 times daily; may be diluted 1:1-1:4 with syrup BP.\n\nContra-indication: Concurrent use or within 2 wk of stopping MAOIs. Severe hypertension or coronary artery disease.\n\nSide effects: Dry mouth, nose and throat; skin rashes, tachycardia, drowsiness, sleep disturbances, urinary retention. Rarely, hallucinations.\n\nPrecaution: Severe hepatic impairment. Moderate to severe renal impairment. DM, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, hypertension, heart disease. May affect ability to drive or operate machinery. Pregnancy and lactation.\n\nMode of action: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine.\n\nPotentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.\n\nPregnancy category: C\n\nInteraction: Increased BP with other sympathomimetic agents (e.g. decongestants, TCA, appetite suppressants). Reduced hypotensive effects of methyldopa, ?- and ?-adrenergic blockers. Increased side effects (e.g. somnolence, agitation) with atomoxetine.\n\nPotentially Fatal: Increased risk of hypertensive crisis with furazolidine, avoid concurrent use. Increased risk of hypertensive crisis with MAOIs; avoid concurrent use or within 2 wk after stopping MAOIs. Increased risk of psychosis with bromocriptine.
Pyrantel Pamoate	\n\n\tAlbion Ltd.\tMinisol Suspension 5 mg/100 ml 30 ml \n\tBeximco\tMelphin TAB dr 125mg 100's pack 166\n\tBeximco\tMelphin Suspension 500mg/10ml 10 ml bot 11.45\n\tHallmark\tWormex Suspension 500mg/10ml 10 ml bot 11\n\tOrganic Health Care\tPyropin Suspension 500mg/10ml 10ml bot 11.50\n\tRenata\tDelentin TAB dr 125mg 100's pack \n\tRenata\tDelentin Suspension 500mg/10ml 10 ml bot 16.05\n\tIndication: Enterobiasis, Ascariasis, Worm infections, Trichinosis\n\nDose: Adult: PO Susceptible single or mixed worm infections 10 mg/kg as a single dose. \nChild: 10 mg/kg as a single dose.\n\nAdult: Ascariasis 5 mg/kg as a single dose. Max: 1 g/dose. Mass treatment of ascariasis 2.5 mg/kg as a single dose given 3-4 times/yr. \nEnterobiasis 10 mg/kg repeated once after 2-4 wk. Max: 1 g/dose. \nTrichinosis 10 mg/kg/day for 5 days.\n\nContra-indication: Hypersensitivity\n\nSide effects: Anorexia, nausea, vomiting, abdominal cramps, drowsiness, insomnia, diarrhoea, tenesmus, SGOT elevations, headache, dizziness, rash.\n\nPrecaution: Liver dysfunction, anaemia or severe malnutrition. Treat members in close contact with the patient.\n\nMode of action: Potentially Fatal: Mutually antagonistic with piperazine.\n\nPregnancy category: C\n\nInteraction: Potentially Fatal: Mutually antagonistic with piperazine.
Pyrazinamide	\n\n\tNovartis (Bangladesh) Ltd.\tPza Ciba TAB dr 500mg 100's pack 235\n\tIndication: Tuberculosis\n\nDose: Oral\nTuberculosis\nAdult: As part of a multidrug regimen: For standard unsupervised 2-mth treatment: <50 kg: 1.5 g daily; >50 kg: 2 g daily. For intermittent supervised 2-mth treatment: <50 kg: 2 g 3 times wkly; <50 kg: 2.5 g 3 times wkly.\n\nChild: As part of a multidrug regimen: For standard unsupervised 2-mth treatment: 35 mg/kg daily. For intermittent supervised 2-mth treatment: 50 mg/kg 3 times wkly.\nHepatic impairment: Severe: Contraindicated.\n\nContra-indication: Hypersensitivity; existing liver disease; acute gout or hyperuricaemia. Porphyria. Pregnancy and lactation.\n\nSide effects: Hepatotoxicity (hepatomegaly, splenomegaly and jaundice may develop and in rare case fulminating acute yellow atrophy and death). Anorexia, nausea, vomiting, arthralgia, malaise, fever, hyperuricaemia, abnormal LFT, skin rashes.\nPotentially Fatal: Severe liver damage, fulminant hepatitis.\n\nPrecaution: Diabetes, renal failure, history of gout, children. Monitor liver function and serum uric acid regularly.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Pyridostigmine	\n\n\tPopular\tPyrostig TAB dr 60 mg 30's pack 752.71\n\tUnimed & Unihealth Manufacturers Ltd.\tDostimid TAB dr 60mg 14's pack 308\n\tIndication: Reversal of neuromuscular blockade,Myasthenia gravis,Paralytic ileus and post-operative urinary retention\n\nDose: Oral\nMyasthenia gravis\nAdult: 0.3-1.2 g daily in divided doses.\n\nChild: <6 yr: Initially, 30 mg, 6-12 yr: Initially, 60 mg. Dose may be gradually increased by 15-30 mg on a daily basis until a satisfactory response is observed.\n\nNeonatal myasthenia gravis\nChild: 5-10 mg given every 4-6 hr.\n\nParalytic ileus and postoperative urinary retention\nAdult: Doses of 60-240 mg.\n\nContra-indication: GI or urinary obstruction.\n\nSide effects: Muscarinic side effects e.g. nausea, vomiting, diarrhoea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects include muscle cramps, fasciculation and weakness.\n\nPrecaution: Renal impairment, pregnancy and lactation, epilepsy, bronchial asthma, bradycardia, cardiac arrhythmias, recent coronary occlusion, vagotonia, hyperthyroidism, peptic ulcer, recent bladder/intestinal surgery. Care should be taken in the use of atropine for counteracting side effects.\n\nMode of action: Excretion blocked by probenecid.\n\nPregnancy category: C\n\nInteraction: Excretion blocked by probenecid.
Pyridoxine Hydrochloride	\n\n\tBeacon\tSixvit TAB dr 20mg  \n\tGonoshasthaya\tG Vitamin B6 TAB dr 25mg 100'pack 18\n\tJayson\tPyrol TAB dr 25mg 100'pack 50\n\tPharmadesh Ltd.\tPyrovit TAB dr 20mg 250's pack 85\n\tIndication: Peripheral neuropathy,Vitamin B6 deficiency\n\nDose: Oral\nTreatment and prophylaxis of vitamin B6 deficiency states\nAdult: Up to 150 mg daily. May also be given via SC, IM or IV routes.\nOral\nSideroblastic anaemia\nAdult: Up to 400 mg daily. May also be given via SC, IM or IV routes.\n\nContra-indication: Patients receiving levodopa.\n\nSide effects: Severe peripheral neuropathies (with long-term admin of large doses).\n\n\nPrecaution: Drug interaction with Levodopa.\n\nMode of action: Isoniazid, penicillamine and oral contraceptives may result in greater requirement in pyridoxine dose. Reduces the effects of levodopa, phenobarbitone, altretamine and phenytoin.\n\nPregnancy category: C\n\nInteraction: Isoniazid, penicillamine and oral contraceptives may result in greater requirement in pyridoxine dose. Reduces the effects of levodopa, phenobarbitone, altretamine and phenytoin.
Pyridoxine Hydrochloride + Riboflavin + Vitamin B1	\n\n\tEdruc Ltd.\tTi Ediplex Injection   6 amps pack 43.20\n\tJayson\tNervin Injection   10'pack 45.20\n\tRephco\tReoplex Forte Injection   10 amps pack 55\n\tIndication: Trigeminal neuralgia, optic neuritis, lumbago sciatica, peripheral neuritis. Skin & nervous system, Neuritis of pregnancy, Fertility\n\nDose: Treatment and prophylaxis of vitamin B6 deficiency states\nAdult: 1 ampoule (2 ml) given via SC, IM or IV routes daily or can be given 1 ampoule 2-3 times a week..\n\nContra-indication: Contraindicated in patients with a known hypersensitivity to any of the ingredients. Patients receiving levodopa.\n\nSide effects: Generally well tolerated.\n\nPrecaution: Drug interaction with levodopa.\n\nMode of action: Pyridoxine: Isoniazid, penicillamine and oral contraceptives may result in greater requirement in pyridoxine dose. Reduces the effects of levodopa, phenobarbitone, altretamine and phenytoin.\n\nRiboflavin: Rate and extent of absorption may be affected by propantheline bromide.\n\nPregnancy category: X\n\nInteraction: Pyridoxine: Isoniazid, penicillamine and oral contraceptives may result in greater requirement in pyridoxine dose. Reduces the effects of levodopa, phenobarbitone, altretamine and phenytoin.\n\nRiboflavin: Rate and extent of absorption may be affected by propantheline bromide.
Pyrimethamine	\n\n\tJayson\tPyrison TAB dr 25mg 100's pack 28\n\tIndication: Acute malaria,Malaria prophylaxis,Toxoplasmosis\n\nDose: Oral\nAcute malaria\nAdult: As a single dose, in combination with a sulfonamide: 75 mg pyrimethamine with 1.5 g sulfadoxine.\n\nChild: 7-13 yr: 50 mg pyrimethamine with 1 g sulfadoxine; 1-6 yr: 25 mg pyrimethamine with 500 mg sulfadoxine; 5-11 mth: 12.5 mg pyrimethamine and 250 mg sulfadoxine. To be taken as a single dose, in combination with a sulfonamide.\n\nProphylaxis of malaria\nAdult: Pyrimethamine 25 mg as single dose once wkly. 1st dose should be taken 1-2 days before arrival in the endemic area, continue admin during stay and for 4-6 wk after leaving the area.\n\nChild: <4 yr: 6.25 mg once wkly; 4-10 yr: 12.5 mg once wkly; >10 yr: 25 mg once wkly. 1st dose should be taken 1-2 days before arrival in the endemic area, continue admin during stay and for 4-6 wk after leaving the area.\n\nToxoplasmosis\nAdult: 50-75 mg pyrimethamine daily with 1-4 g sulfadiazine daily. Continue at this dosage for 1-3 wk, depending on the patient's response and tolerance, then half the dosage and continue for another 4-5 wk.\n\nChild: 1 mg/kg daily 2-4 days then 0.5 mg/kg daily for another 4 wk with usual paediatric dose of sulfadiazine.\n\nContra-indication: Hypersensitivity, resistant malaria, megaloblastic anaemia secondary to folate deficiency. Pregnancy and lactation.\n\nSide effects: Rashes, macrocytic anaemia (high dose), leucopenia, thrombocytopenia, megaloblastic anaemia, pancytopenia, abdominal pain, vomiting, atrophic glossitis.\nPotentially Fatal: Cutaneous reactions e.g. erythema multiforme and Stevens-Johnson syndrome and toxic epidermal necrolysis with sulfadoxine at large doses.\n\nPrecaution: Renal or hepatic impairment; folate deficiency; monitor blood and platelet counts every 2 wk with prolonged treatment and large doses. Discontinue use if skin reactions, sore throats or shortness of breath occurs.\n\nMode of action: Lorazepam may induce hepatotoxicity. Increased risk of bone marrow suppression when used with agents that have myelosuppressive properties e.g. proguanil, sulfonamides, zidovudine and cytostatic agents. Increased risk of serious pancytopenia and megaloblastic anaemia when used with co-trimoxazole or other sulfonamides.\n\nPregnancy category: C\n\nInteraction: Lorazepam may induce hepatotoxicity. Increased risk of bone marrow suppression when used with agents that have myelosuppressive properties e.g. proguanil, sulfonamides, zidovudine and cytostatic agents. Increased risk of serious pancytopenia and megaloblastic anaemia when used with co-trimoxazole or other sulfonamides.
Pyrimethamine + Sulfadoxine	\n\n\tHudson\tMalason TAB dr   100's pack 380\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMalex TAB dr   30's pack 123\n\tJayson\tSulfamin TAB dr   30's pack 132.30\n\tSquare\tMalacide TAB dr  25 mg + 500 mg 60's pack 265.20\n\tIndication: Chloroquine-resistant falciparum malaria\n\nDose: Oral\nChloroquine resistant falciparum malaria acute attack\nAdult: Per tab contains pyrimethamine 25 mg and sulfadoxine 500 mg: 2-3 tabs as a single dose. Do not repeat for at least 7 days.\n\nChild: Pyrimethamine 25mg + Sulfadoxine 500mg (Tablet): <2 yr (5-10 kg): Â½ tab as a single dose; 2-5 yr (>10-20 kg): 1 tab as a single dose; 5-10 yr (< 20-30 kg): 1Â½ tab as a single dose; 10-14 yr (> 30-45 kg): 2 tab as a single dose. Do not repeat for at least 7 days.\nRenal impairment: Dose reduction may be needed. Severe: contra-indicated.\n\nContra-indication: Severe renal or hepatic impairment, blood dyscrasias, hypersensitivity to components, megaloblastic anaemia due to folate deficiency, pregnancy at term and during lactation, infants ? 2 mth old.\n\nSide effects: Urticaria, serum sickness, photosensitisation, arthralgia, nausea, vomiting, abdominal pain, diarrhoea, headache, peripheral neuritis, ataxia, tinnitus, vertigo, convulsions, toxic nephrosis and pulmonary infiltrates resembling eosinophilic or allergic alveolitis.\nPotentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, blood dyscrasias, anaphylactoid reactions.\n\nPrecaution: Impaired renal or hepatic function, folate deficiency, severe allergy or bronchial asthma, G6PD deficiency, pregnancy. Take with plenty of water to prevent crystalluria. Avoid excessive exposure to sun. Discontinue at the first sign of rash. Discontinue if signs of folic acid deficiency develops. Regular CBC monitoring, LFT, analysis of urine for crystalluria when admin for > 3 mth. Take with food to minimise Gi effects (e.g. anorexia and vomiting).\n\nMode of action: Increased halofantrine and chlorpromazine levels. Increased effects of warfarin.\nPotentially Fatal: Increased risk of myelosupression with zidovudine, clozapine.\n\nPregnancy category: C\n\nInteraction: Increased halofantrine and chlorpromazine levels. Increased effects of warfarin.\nPotentially Fatal: Increased risk of myelosupression with zidovudine, clozapine.
Quetiapine	\n\n\tACI\tQmax TAB dr 100mg 30's pack 300.90\n\tACI\tQmax TAB dr 25mg 30's pack 90.30\n\tGeneral\tTiapine TAB dr 25mg 50's pack 150\n\tGeneral\tTiapine TAB dr 100mg 30's pack 301.20\n\tIncepta\tQuiet 100 TAB dr 100mg 50's pack 500\n\tIncepta\tQuiet 25 TAB dr 25mg 50's pack 150\n\tSanofi Aventis (BD) Ltd.\tQpine TAB dr 100mg 30's pack 301.20\n\tSanofi Aventis (BD) Ltd.\tQpine TAB dr 25mg 100's pack 301.01\n\tSun Pharmaceutical (Bangladesh) Ltd.\tQutipin TAB dr 100mg 50's pack 502.50\n\tSun Pharmaceutical (Bangladesh) Ltd.\tQutipin TAB dr 25mg 50's pack 150\n\tSun Pharmaceutical (Bangladesh) Ltd.\tQutipin SR TAB dr 200mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tSeroquet-25 TAB dr 25mg 30's pack 90\n\tUnimed & Unihealth Manufacturers Ltd.\tSeroquet-100 TAB dr 100mg 30's pack 300\n\tIndication: Schizophrenia, Bipolar disorder\n\nDose: Adult: PO Schizophrenia Initial: 25 mg twice daily on day 1, increase to 50 mg twice daily on day 2, 100 mg twice daily on day 3 and 150 mg twice daily on day 4. Usual: 300-450 mg/day. Max: 750 mg/day.  \n\nBipolar disorder:  Manic phase: 50 mg twice daily, increase by 50 mg/dose for each subsequent day till 3rd day. Usual: 400-800 mg/day. Increase slowly if needed.  \n\nDepressive phase: Initial: 50 mg at bedtime on day 1, 100 mg on day 2, 200 mg on day 3, and 300 mg on day 4. May increase to 400 mg on day 5 and 600 mg on day 8 if needed. 	\n\nContra-indication: Quetiapine is contraindicated in individuals with a known hypersensitivity to this medication or any of its ingredients. Severe CNS depression, bone marrow suppression, coma.\n\nSide effects: Headache, asthenia, abdominal pain, back pain, fever, chest pain, postural and orthostatic hypotension, hypertension, constipation, dry mouth, dyspepsia, diarrhoea, leucopenia, elevations in serum transaminase level, weight gain, myalgia, somnolence, dizziness, anxiety, rhinitis, rash, dry skin, ear pain, UTI, syncope, neuroleptic malignant syndrome, variations in WBC count, neutropenia, eosinophilia, elevations in nonfasting serum triglyceride level and total cholesterol, decrease in thyroid hormone levels, prolongation of the QTc interval.\n\nPrecaution: Cerebrovascular disease or conditions that predispose to hypotension. History of seizures; neuroleptic malignant syndrome; tardive dyskinesia. Monitor glycaemic control, especially in diabetics. Hepatic or renal impairment. Gradual withdrawal is recommended. Monitor for signs of clinical worsening, suicidality or unusual changes in behaviour. Pregnancy and lactation.\n\nMode of action: Increased risk of drowsiness and postural hypotension when used with alcohol. CYP3A4 inducers eg. phenytoin and carbamazepine may decrease plasma levels of quetiapine while CYP3A4 inhibitors eg. ketoconazole and erythromycin may increase its plasma levels.\n\nPregnancy category: C\n\nInteraction: Increased risk of drowsiness and postural hypotension when used with alcohol. CYP3A4 inducers eg. phenytoin and carbamazepine may decrease plasma levels of quetiapine while CYP3A4 inhibitors eg. ketoconazole and erythromycin may increase its plasma levels.
Quinine Dihydrochloride	\n\n\tGonoshasthaya\tG Quinine Injection 300mg/5ml 10 amps pack 104.10\n\tJayson\tJasoquin Injection 300mg/5ml 10 amps pack 205.90\n\tIndication: Malaria, Nocturnal leg cramps\n\nDose: Malaria\nAdult: As dihydrochloride: Initially, 20 mg/kg (max: 1.4 g) given over 4 hr. Start maintenance doses 8 hr after the start of the initial infusion. Maintenance: 10 mg/kg (up to 700 mg) given over 4 hr every 8 hr. \n\nLoading dose should not be given if patient has received quinine, quinidine, mefloquine or halofantrine during the previous 24 hr. If parenteral treatment is required for >48 hr, maintenance dose should be reduced to 5-7 mg/kg.\n\nChild: ?5 mg/kg/hr by slow IV infusion.\nHepatic impairment: Mild to moderate (Child-Pugh class A and B): No dosage adjustment needed. Severe: Reduce maintenance dose to 5-7 mg/kg of quinine salt 8 hrly.\n\n\nContra-indication: Hypersensitivity to quinine or quinidine. Myasthaenia gravis; haemolytic anaemia; quinine-resistant falciparum; patients with tinnitus or optic neuritis; patients who have suffered an attack of blackwater fever. Prolonged QT interval. Pregnancy.\n\nSide effects: Cinchonism characterised by tinnitus, impaired hearing, headache, nausea, vomiting, disturbed vision, vertigo, abdominal pain and diarrhoea; urticaria, pruritus, fever, angioedema, asthma, dyspnoea, haemoglobinuria, thrombocytopenic purpura, hypoglycaemia, renal failure, hypoprothrombinaemia, agranulocytosis, Inj site irritation, pain and necrosis.\nPotentially Fatal: Sinus arrest, AV block, ventricular fibrillation and sudden death especially with IV use.\n\nPrecaution: Lactation. CV diseases; G6PD deficient individuals.\n\nMode of action: Reduced renal clearance of amantadine. Reduced clearance w/ cimetidine. Increased anticoagulant effect of warfarin and other anticoagulants. Reduced plasma levels of ciclosporin. Increased plasma levels of digoxin. Increased risk of myopathy and rhabdomyolysis w/ atorvastatin. May enhance hypoglycaemic effects of oral antidiabetics.\n\nPotentially Fatal: Increased risk of QT prolongation and torsade de pointes w/ mefloquine, class IA antiarrhythmic agents (e.g. quinidine, procainamide, disopyramide) and class III antiarrhythmic agents (e.g. amiodarone, sotalol, dofetilide) and other drugs known to cause QT prolongation (e.g. halofantrine, pimozide, thioridazine). Potentiates neuromuscular blockade w/ neuromascular blocking agents. Decreased plasma levels w/ rifampicin. Increased serum levels w/ ritonavir. May delay or decrease absorption w/ Al- and/or Mg-containing antacids.\n\nPregnancy category: C\n\nInteraction: Reduced renal clearance of amantadine. Reduced clearance w/ cimetidine. Increased anticoagulant effect of warfarin and other anticoagulants. Reduced plasma levels of ciclosporin. Increased plasma levels of digoxin. Increased risk of myopathy and rhabdomyolysis w/ atorvastatin. May enhance hypoglycaemic effects of oral antidiabetics.\n\nPotentially Fatal: Increased risk of QT prolongation and torsade de pointes w/ mefloquine, class IA antiarrhythmic agents (e.g. quinidine, procainamide, disopyramide) and class III antiarrhythmic agents (e.g. amiodarone, sotalol, dofetilide) and other drugs known to cause QT prolongation (e.g. halofantrine, pimozide, thioridazine). Potentiates neuromuscular blockade w/ neuromascular blocking agents. Decreased plasma levels w/ rifampicin. Increased serum levels w/ ritonavir. May delay or decrease absorption w/ Al- and/or Mg-containing antacids.
Quinine Sulphate	\n\n\tAlbion Ltd.\tAlbiquin TAB dr 300 mg 100's pack \n\tGlobe\tKanaquine TAB dr 300mg 100's pack 640\n\tHudson\tQuin-H TAB dr 300mg 100's pack 347\n\tJayson\tJasoquin TAB dr 300mg 100's pack 642\n\tOpsonin Pharma\tQuins TAB dr 300 mg 100's pack \n\tOpsonin Pharma\tQuins Injection 300 mg/5ml 10's pack \n\tIndication: Malaria, Nocturnal leg cramps\n\nDose: Malaria\nAdult: As sulfate: 648 mg given every 8 hr for 7 days.\nChild: 10 mg/kg given every 8 hr for 7 days.\n\nRenal impairment: Severe chronic renal failure (as sulfate): 648 mg followed 12 hr later by maintenance doses of 324 mg every 12 hr. \n\nBabesiosis\nAdult: As sulfate: 650 mg every 6-8 hr. To be taken with clindamycin for 7-10 days.\nChild: 8 mg/kg (up to 650 mg) every 8 hr. To be taken with clindamycin for 7-10 days.\n\nNocturnal leg cramps\nAdult: 200-300 mg once at night. \n\n\nContra-indication: Hypersensitivity to quinine or quinidine. Myasthaenia gravis; haemolytic anaemia; quinine-resistant falciparum; patients with tinnitus or optic neuritis; patients who have suffered an attack of blackwater fever. Prolonged QT interval. Pregnancy.\n\nSide effects: Cinchonism characterised by tinnitus, impaired hearing, headache, nausea, vomiting, disturbed vision, vertigo, abdominal pain and diarrhoea; urticaria, pruritus, fever, angioedema, asthma, dyspnoea, haemoglobinuria, thrombocytopenic purpura, hypoglycaemia, renal failure, hypoprothrombinaemia, agranulocytosis, Inj site irritation, pain and necrosis.\nPotentially Fatal: Sinus arrest, AV block, ventricular fibrillation and sudden death especially with IV use.\n\nPrecaution: Lactation. CV diseases; G6PD deficient individuals.\n\nMode of action: Reduced renal clearance of amantadine. Reduced clearance w/ cimetidine. Increased anticoagulant effect of warfarin and other anticoagulants. Reduced plasma levels of ciclosporin. Increased plasma levels of digoxin. Increased risk of myopathy and rhabdomyolysis w/ atorvastatin. May enhance hypoglycaemic effects of oral antidiabetics.\n\nPotentially Fatal: Increased risk of QT prolongation and torsade de pointes w/ mefloquine, class IA antiarrhythmic agents (e.g. quinidine, procainamide, disopyramide) and class III antiarrhythmic agents (e.g. amiodarone, sotalol, dofetilide) and other drugs known to cause QT prolongation (e.g. halofantrine, pimozide, thioridazine). Potentiates neuromuscular blockade w/ neuromascular blocking agents. Decreased plasma levels w/ rifampicin. Increased serum levels w/ ritonavir. May delay or decrease absorption w/ Al- and/or Mg-containing antacids.\n\nPregnancy category: C\n\nInteraction: Reduced renal clearance of amantadine. Reduced clearance w/ cimetidine. Increased anticoagulant effect of warfarin and other anticoagulants. Reduced plasma levels of ciclosporin. Increased plasma levels of digoxin. Increased risk of myopathy and rhabdomyolysis w/ atorvastatin. May enhance hypoglycaemic effects of oral antidiabetics.\n\nPotentially Fatal: Increased risk of QT prolongation and torsade de pointes w/ mefloquine, class IA antiarrhythmic agents (e.g. quinidine, procainamide, disopyramide) and class III antiarrhythmic agents (e.g. amiodarone, sotalol, dofetilide) and other drugs known to cause QT prolongation (e.g. halofantrine, pimozide, thioridazine). Potentiates neuromuscular blockade w/ neuromascular blocking agents. Decreased plasma levels w/ rifampicin. Increased serum levels w/ ritonavir. May delay or decrease absorption w/ Al- and/or Mg-containing antacids.
Rabeprazole	\n\n\tACI\tParicel TAB dr 20mg 100's pack 504\n\tACI\tParicel TAB dr 10mg 60's pack 210.60\n\tAcme Ltd.\tRabizol TAB dr 20mg 50's pack 250\n\tAlbion Ltd.\tRabeprazole TAB dr 20mg 50's pack \n\tAristopharma\tRabe TAB dr 20mg 60's pack 300\n\tBeacon\tRabepes TAB dr 20mg  \n\tBeximco\tAcifix TAB dr 20mg 50's pack 250\n\tBio Pharma Ltd.\tRabecon TAB dr 20mg 60's pack 300\n\tDelta Pharma\tRmax 20 CAP 20mg  \n\tDoctor Tims\tR-Proton TAB dr 20mg  \n\tDrug International Ltd.\tRabesec TAB dr 20mg 50's pack 250\n\tEskayef Bangladesh Ltd.\tRabifast 	 TAB dr  20mg 	 		 50's pack  250\n\tGlobe\tRP TAB dr 20mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tXorel TAB dr 20mg  \n\tIncepta\tRasonix 20 TAB dr 20mg 30's pack 150\n\tIncepta\tRasonix CAP 10mg 56's 196\n\tIncepta\tRasonix CAP 20mg  \n\tIncepta\tRasonix TAB dr 10mg  \n\tKemiko\tRazole TAB dr 20mg 50's pack 250\n\tKumudini Pharma Ltd.\tRubee TAB dr 20mg  \n\tLeon\tRaboz TAB dr 20mg  \n\tMedicon\tRapo TAB dr 20mg  \n\tNavana\tRabetac TAB dr 20mg 30's pack 150\n\tNIPRO JMI Pharma\tRablet TAB dr 20mg  \n\tOpsonin Pharma\tFinix TAB dr 20mg 100's pack 441\n\tPharmasia Ltd.\tRaha 20 TAB dr 20mg  \n\tPopular\tRabigut TAB dr 20mg 100's pack 500\n\tRadiant.\tPrompton CAP 20mg  \n\tRenata\tProfast TAB dr 20mg  \n\tSanofi Aventis (BD) Ltd.\tRespite TAB dr 10mg  \n\tSanofi Aventis (BD) Ltd.\tRespite TAB dr 20mg 50's pack 300\n\tSharif\tRabonac TAB dr 20mg 60's pack 300\n\tSomatec\tRabeprol TAB dr 20mg 50's pack 250\n\tSquare\tRabeca TAB dr 20mg 30's pack 150\n\tCosmic Pharma Ltd.\tRabium TAB dr 20mg  \n\tIndication: Peptic ulcer disease, H. pylori infection, Gastro-oesophageal reflux disease, Paediatric GERD\n\nDose: i) Duodenal ulcer: 20 mg tablet in the morning is indicated for 4 weeks treatment in the healing and symptomatic relief of duodenal ulcer. Most patients heal within 4 weeks.\nii) Benign gastric ulcer: 20 mg daily in the morning for 6 weeks, followed by a further 6 weeks if not fully cured.\niii) Duodenal ulcer and benign gastric ulcer associated with H. pylori infection: Rabeprazole in combination with Amoxicillin and Clarithromycin as a three drug regimen is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease. Rabeprazole offers a faster therapy option than other PPIs, up to 10 to 14 days 20 mg once daily.\niv) Healing of erosive or ulcerative Gastroesophageal Reflux Disease (GERD): 20 mg daily in the morning 4 to 8 weeks. Those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole may be considered.\nv) Treatment of symptomatic GERD: The recommended adult oral dose  is 20 mg once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered.\nvi) Maintenance of healing of erosive or ulcerative GERD: It is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative GERD maintenance. Controlled studies do not extend beyond 12 months.\nvii) Prevention or treatment of NSAID-induced ulcers: 20 mg tablet once daily, in patients receiving treatment with NSAIDs.\nviii) Zollinger-Ellison Syndrome: The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg once daily and 60 mg twice daily have been administered.\nix) Paediatric GERD: Treatment of GERD in Pediatric Patients 1 to 11 Years of Age: The recommended dosage for pediatric patients 1 to 11 years of age by body weight is:\nâ¢ Less than 15 kg: 5 mg once daily for up to 12 weeks with the option to increase to 10 mg if inadequate response.\nâ¢ 15 kg or more: 10 mg once daily for up to 12 weeks.\n\n\nContra-indication: Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, other PPIs or to any component of the formulation.\n\nSide effects: In general, Rabeprazole is well-tolerated in both short-term and long-term studies. Rabeprazole may some times cause headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, dizziness.\n\nPrecaution: Rabeprazole Sodium tablets should not be splited, chewed or crushed.\n\nMode of action: May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.\n\nPregnancy category: B\n\nInteraction: May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.
Raloxifene Hydrochloride	\n\n\tACI\tRolage TAB dr 60mg 30's pack 301.20\n\tIncepta\tAloxif TAB dr 60mg 30's pack 420\n\tOrion Pharma Ltd.\tRalox TAB dr 60mg 30's pack 301.20\n\tSquare\tOxilar TAB dr 60mg 10's pack 140.58\n\tIndication: Post-menopausal osteoporosis, Malignant gastrointestinal stromal tumours\n\nDose: One tablet (60 mg) once daily orally. It can be taken without regard to meal. High fat meal increases the absorption of Raloxifene.\n\nContra-indication: Hepatic & renal impairment.In active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis.Hypersensitivity to Raloxifene or any other constituents of the tablet.\n\nSide effects: Raloxifene is generally well tolerated. However, a few side effects like hot flushes, leg cramps, and influenza like symptoms, gastro-intestinal disturbances etc may be seen usually during first 6 months of treatment and were not different from placebo.\n\nPrecaution: Concurrent Estrogen Therapy: Concomitant use of Raloxifene with systemic estrogens is not recommended.Lipid Metabolism: Concurrent use of Raloxifene and lipid-lowering agents has not been studied.\n\nMode of action: Cholestyramine reduces the absorption of raloxifene. Raloxifene with warfarin may reduce the prothrombin response and time. Caution when used in hghly protein-bound drugs such as diazepam, lidocaine and diazoxide.\n\nPregnancy category: X\n\nInteraction: Cholestyramine reduces the absorption of raloxifene. Raloxifene with warfarin may reduce the prothrombin response and time. Caution when used in hghly protein-bound drugs such as diazepam, lidocaine and diazoxide.
Ramipril	\n\n\tAcme Ltd.\tUnipril TAB dr 2.5mg 30's pack 150.30\n\tAcme Ltd.\tUnipril TAB dr 5mg 30's pack 241.2\n\tAd-din\tCartace TAB dr 2.5mg 40's pack 184\n\tApex\tPril TAB dr 2.5mg 50's pack \n\tApex\tPril TAB dr 5mg 50's pack \n\tAristopharma\tRamilok TAB dr 2.5mg 50's pack 250\n\tAristopharma\tRamilok TAB dr 5mg 30's pack 240\n\tBeximco\tPrimace CAP 1.25mg 30's pack 75\n\tBeximco\tPrimace CAP 10mg 1's pack 12\n\tBeximco\tPrimace CAP 2.5mg 30's pack 150\n\tBeximco\tPrimace CAP 5mg 30's pack 240\n\tBio Pharma Ltd.\tR-Pil TAB dr 1.25mg 30's pack 90.30\n\tBio Pharma Ltd.\tR-Pil TAB dr 2.5mg 30's pack 150.60\n\tBio Pharma Ltd.\tR-Pil TAB dr 5mg 30's pack 240.90\n\tDrug International Ltd.\tRamicard TAB dr 2.5mg 50's pack 150\n\tDrug International Ltd.\tRamicard TAB dr 5mg 50's pack 350\n\tEskayef Bangladesh Ltd.\tMypril TAB dr 2.5mg 40's pack 200\n\tEskayef Bangladesh Ltd.\tMypril TAB dr 5mg 40's pack 320\n\tGeneral\tRamipro TAB dr 2.5mg 50's pack 151\n\tGeneral\tRamipro TAB dr 5mg 30's pack 240.90\n\tGlobe\tGepril TAB dr 5mg 30's pack 240\n\tHealthcare\tAcecard TAB dr 5mg 30's pack 240\n\tHealthcare\tAcecard TAB dr 1.25mg 30's pack 90\n\tHealthcare\tAcecard TAB dr 2.5mg 30's pack 150\n\tIncepta\tRamoril TAB dr 1.25mg 50's pack 125\n\tIncepta\tRamoril TAB dr 10mg 30's pack 360\n\tIncepta\tRamoril TAB dr 2.5mg 50's pack 250\n\tIncepta\tRamoril TAB dr 5mg 50's pack 400\n\tNovartis (Bangladesh) Ltd.\tPiramil TAB dr 2.5mg 28's pack 196\n\tNovartis (Bangladesh) Ltd.\tPiramil TAB dr 5mg 28's pack 280\n\tOpsonin Pharma\tRamace CAP 1.25mg 50's pack 125\n\tOpsonin Pharma\tRamace TAB dr 1.25mg 50's pack 125.50\n\tOpsonin Pharma\tRamace CAP 2.5mg 30's pack 150\n\tOpsonin Pharma\tRamace TAB dr 2.5mg 30's pack 150.60\n\tOpsonin Pharma\tRamace CAP 5mg 30's pack 240\n\tOpsonin Pharma\tRamace TAB dr 5mg 30's pack 240.90\n\tOrion Pharma Ltd.\tNuvace TAB dr 2.5mg 30's pack 150\n\tOrion Pharma Ltd.\tNuvace TAB dr 5mg 30's pack 240\n\tPacific\tRacard TAB dr 1.25mg 30's pack 75\n\tPacific\tRacard TAB dr 2.5mg 30's pack 138\n\tPacific\tRacard TAB dr 5mg 30's pack 240\n\tPopular\tRamil TAB dr 2.5mg 30's pack 251\n\tPopular\tRamil TAB dr 5mg 30's pack 401.50\n\tPopular\tRamil TAB dr 1.25mg 50's pack 125\n\tPopular\tRamil TAB dr 10mg 30's pack 360\n\tRangs\tRampril TAB dr 2.5mg 30's pack 120\n\tRangs\tRampril TAB dr 5mg 30's pack 180\n\tSanofi Aventis (BD) Ltd.\tTritace TAB dr 10mg 28's pack 505.95\n\tSanofi Aventis (BD) Ltd.\tTritace TAB dr 2.5mg 28's pack 241.92\n\tSanofi Aventis (BD) Ltd.\tTritace TAB dr 5mg 28's pack 354.20\n\tSilva\tRamipress TAB dr 1.25mg 30's pack 75.28\n\tSilva\tRamipress TAB dr 2.5mg 30's pack 150.57\n\tSilva\tRamipress TAB dr 5mg 30's pack 240.90\n\tSquare\tRipril TAB dr 1.25mg 30's pack 75.41\n\tSquare\tRipril TAB dr 2.5mg 30's pack 150.43\n\tSquare\tRipril TAB dr 5mg 30's pack 240.99\n\tTechno Drugs Ltd.\tHyopace CAP 5mg 30's pack 240\n\tTechno Drugs Ltd.\tHypace CAP 2.5mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tProtace CAP 2.5mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tProtace TAB dr 2.5mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tProtace TAB dr 5mg 30's pack 240\n\tVirgo\tRamilon TAB dr 2.5mg 30's pack 120\n\tVirgo\tRamilon TAB dr 5mg 30's pack 180\n\tWhite Horse Pharma\tPricard TAB dr 2.5mg 50's pack 200\n\tWhite Horse Pharma\tPricard TAB dr 5mg 30's pack 240\n\tSandoz GmbH, Austria\tPiramil TAB dr 5mg 30's pack 300\n\tIndication: Congestive heart failure, MI, HTN, CV events, Stroke\n\nDose: Adult: PO HTN Initial: 1.25 mg at bedtime. Maintenance: 2.5-5 mg/day as a single dose, up to 10 mg/day if needed. \nHeart failure Initial: 1.25 mg once daily. Max: 10 mg/day. \n\nMI Start 3-10 days after infarction. Initial: 2.5 mg twice daily after 2 days, then 5 mg twice daily. Maintenance: 2.5-5 mg twice daily. \nProphylaxis of CV events in high-risk patients Initial: 2.5 mg once daily for 1 wk, then increased if tolerated to 5 mg once daily for 3 wk, then maintenance: 10 mg once daily.\n\nRenal impairment:\nCrCl (ml/min)	\n10-30	Initially, 1.25 mg/day. Max: 5 mg/day.\n30-60	Not necessary to adjust the initial dose. Max: 5 mg/day.\nHepatic impairment: Max: 2.5 mg/day.\n\nContra-indication: Hypersensitivity, bilateral renal artery stenosis, or a single kidney with unilateral renal artery stenosis. Aortic stenosis or outflow tract obstruction. Pregnancy and lactation.\n\nSide effects: Nausea, vomiting, diarrhoea, dizziness, fatigue, headache, abdominal pain, cough. Rarely symptomatic hypotension. Angioneurotic oedema of face, lips, tongue, glottis and larynx, syncope, renal impairment, hypersensitivity reactions.\nPotentially Fatal: Severe hypotension and renal failure, angioedema.\n\nPrecaution: Renal impairment, hypovolaemia, hyperkalaemia, valvular stenosis; before, during or immediately after anaesthesia. Severe resistant hypertension, elderly, peripheral vascular disease or generalised atherosclerosis. Monitor renal function before and during treatment. Use with caution in patients with history of idiopathic or hereditary angioedema. Regular monitoring of WBC in patients with vascular collagen disorders is recommended.\n\nMode of action: May enhance hypotensive effect w/ diuretics and other antihypertensives. May increase risk of renal function deterioration w/ NSAIDs. May increase serum levels and toxicity of lithum. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.\n\nPotentially Fatal: Concomitant use w/ aliskiren aliskiren may increase the risk of hyperkalaemia, hypotension and nephrotoxicity in patients w/ diabetes or renal impairment\n\nPregnancy category: D\n\nInteraction: May enhance hypotensive effect w/ diuretics and other antihypertensives. May increase risk of renal function deterioration w/ NSAIDs. May increase serum levels and toxicity of lithum. May increase hyperkalaemic effect w/ K-sparing diuretics and supplements.\n\nPotentially Fatal: Concomitant use w/ aliskiren aliskiren may increase the risk of hyperkalaemia, hypotension and nephrotoxicity in patients w/ diabetes or renal impairment
Ranitidine	\n\n\tACI\tXantid Injection 50mg/2ml 2ml amp X 10's pack 75.50\n\tACI\tXantid TAB dr 150mg 100's pack/150's pack 201/376.50\n\tACI\tXantid HS TAB dr 300mg 100's pack 402\n\tAcme Ltd.\tRanidin Injection 50mg/2ml 10 amps pack 60.20\n\tAcme Ltd.\tRanidin Syrup 75mg/5ml 100ml bot 45.16\n\tAcme Ltd.\tRanidin TAB dr 150mg 100's pack/150's pack 201/301.50\n\tAcme Ltd.\tRanidin TAB dr 300mg 100's pack 401\n\tAexim\tUltac TAB dr 150mg 100's pack 150\n\tAlbion Ltd.\tRanitidine TAB dr 150 mg 100's pack \n\tAlco Pharma\tRani-150 TAB dr 150mg 100's pack 200\n\tAmbee\tAntac Injection 50mg/2ml 10 amps pack 53\n\tAmbee\tAntac Syrup 75mg/5ml 100ml bot 40.20\n\tAmbee\tAntac TAB dr 150mg 100's pack 181\n\tAmico Ltd.\tZorep TAB dr 150mg 100's pack 150\n\tAmulet\tAmuran TAB dr 150mg 100's pack 200\n\tAPC Pharma Ltd.\tRanitec TAB dr 150mg 100's pack 200\n\tApex\tRanul TAB dr 150mg 100's pack 100\n\tApollo Pharmaceutical Ltd.\tH2 TAB dr 150mg 100's pack 300\n\tAristopharma\tLumeran TAB dr 150mg 100's pack 200\n\tAristopharma\tLumeran TAB dr 300mg 50's pack 175\n\tAsiatic Ltd.\tAceptin-R TAB dr 150mg 100's pack 200\n\tAstra Biopharmaceuticals Ltd.\tAstac TAB dr 150mg 100's pack 200\n\tBeacon\tGastroloc TAB dr 150mg 100's pack 200\n\tBelsen\tJovran TAB dr 150mg 100's pack 200\n\tBenham\tBentid TAB dr 150mg 100's pack 141\n\tBeximco\tNeoceptin R IV Infusion 50mg/100ml 100ml bot 101\n\tBeximco\tNeoceptin R Injection 50mg/2ml 10 amps pack 60\n\tBeximco\tNeoceptin R TAB dr 150mg 150's pack 375\n\tBeximco\tNeoceptin R TAB dr 300mg 100's pack 400\n\tBeximco\tNeoceptrin R Syrup 75mg/5ml 100ml bot 45\n\tBio Pharma Ltd.\tAcin Syrup 75mg/5ml 100ml bot 45.17\n\tBio Pharma Ltd.\tAcin TAB dr 150mg 150's pack 301.50\n\tBio Pharma Ltd.\tAcin TAB dr 300mg 50's pack 175.50\n\tBristol Pharma Ltd.\tNeosetin R TAB dr 150mg 100's pack 150\n\tCentral.\tNeopep TAB dr 150mg 100's pack 200\n\tChemist Ltd.\tRanix Injection 50mg/2ml 10 amps pack 50\n\tConcord\tRicodin-150 TAB dr 150mg 100's pack 150\n\tConcord\tRecodin TAB dr 150mg 150's pack \n\tCosmic Chemical Industries Ltd.\tPeptidin TAB dr 150mg 100's pack 200\n\tCosmo Pharma Ltd.\tRani TAB dr 150mg 100's pack 202\n\tDecent Pharma Ltd.\tPeptonil TAB dr 150mg 100's pack 200\n\tDelta Pharma\tTinadin Syrup 75mg/5ml 100ml bot 40\n\tDelta Pharma\tTinadin TAB dr 150mg 100's pack 85\n\tDesh\tDetac Syrup 75mg/5ml 100ml bot 40\n\tDesh\tDetac TAB dr 150mg 150's pack 150\n\tDoctor's Chemicals Works Ltd.\tDenitine TAB dr 150mg 100's pack 200\n\tDrug International Ltd.\tUlcar TAB dr 150mg 100's pack 250\n\tDrug International Ltd.\tUlcar TAB dr 300mg 50's pack 200\n\tDrug International Ltd.\tUlcar Injection 50mg/5ml 1's pack \n\tEdruc Ltd.\tEditin R Injection 50mg/2ml 10 amps pack 120\n\tEdruc Ltd.\tEditin R TAB dr 150mg 100's pack 223\n\tEdruc Ltd.\tEditin-R TAB dr 300mg  \n\tEskayef Bangladesh Ltd.\tPeptil H Injection 50mg/2ml 10 amps pack 60\n\tEskayef Bangladesh Ltd.\tPeptil H Syrup 75mg/5ml 100ml bot 45\n\tEskayef Bangladesh Ltd.\tPeptil H TAB dr 150mg 150's pack 345\n\tEskayef Bangladesh Ltd.\tPeptil H TAB dr 300mg  \n\tEuro Pharma Ltd.\tRenete TAB dr 150mg 150's pack 375\n\tEverest\tEvran TAB dr 150mg 100's pack 150\n\tG. A. Company Ltd.\tUnitac TAB dr 150mg 100's pack 180\n\tGeneral\tGepin Syrup 75mg/5ml 100ml bot/200ml bot 45.17/80.30\n\tGeneral\tGepin TAB dr 150mg 100's pack 201\n\tGeneral\tGepin IM/IV Injection 50mg/2ml 10 amps pack 100\n\tGlaxoSmithKline Bangladesh Ltd.\tZantac TAB dr 150mg 100's pack 405.53\n\tGlobe\tUltradin TAB dr 150mg 100's pack 200\n\tGlobex\tProtec R TAB dr 150mg 100's pack 200\n\tGonoshasthaya\tG-Ranitidine TAB dr 150mg 100's pack 143\n\tHallmark\tExac TAB dr 150mg 100's pack 200\n\tHealthcare\tRhine TAB dr 150mg 60's pack/100's pack 150/300\n\tHudson\tHi Tac TAB dr 150mg 100's pack 200\n\tIbn Sina Pharmaceutical Ind. Ltd.\tInseac TAB dr 150mg 150's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tInseac TAB dr 300mg 48's pack 192\n\tIncepta\tNeofast-S TAB dr 150mg 100's pack \n\tIndobangla Pharmaceuticals\tNeostin-R TAB dr 150mg 100's pack 200\n\tJayson\tRanison Injection 50mg/2ml 10 amps pack 63.10\n\tJayson\tRanison TAB dr 150mg 100's pack 173\n\tKemiko\tNormacid Syrup 75mg/5ml 100ml bot 45\n\tKemiko\tNormacid TAB dr 150mg 100's pack 250\n\tKemiko\tNormacid IV/IM Injection 50mg/2ml 10 amps pack 60\n\tKumudini Pharma Ltd.\tRanitac TAB dr 150mg 300's pack 300\n\tKumudini Pharma Ltd.\tRaniloc TAB dr 150mg 150's pack 225\n\tLeon\tCeptin-R TAB dr 150mg  \n\tLibra Pharmaceuticls Ltd.\tLibret IV Infusion 50mg/100ml 100ml bot 55.21\n\tMarksman.\tUlcitid TAB dr 150mg 100's pack 200\n\tMedicon\tRenicon TAB dr 150mg 100's pack 200\n\tMedimet\tRantec TAB dr 150mg 100's pack 200\n\tMedimet\tRantec TAB dr 300mg 50's pack 175\n\tMillat\tRanidil TAB dr 150mg 100's pack 200\n\tMillat\tRanimil TAB dr 150mg 150's pack 250\n\tModern\tNeotid TAB dr 150mg 100's pack 200\n\tMonicopharma\tInran TAB dr 150mg 100's pack 200\n\tMonicopharma\tInran Injection 50mg/2ml 10 amps pack 60\n\tMystic\tMystin R TAB dr 150mg 100's pack 200\n\tNavana\tReetac R TAB dr 150mg 100's pack 201\n\tNavana\tReetac R TAB dr 300mg 50's pack 201\n\tNipa\tNeotin TAB dr 150mg 100's pack 250\n\tNIPRO JMI Pharma\tGastab TAB dr 150mg 100's pack 200\n\tNIPRO JMI Pharma\tGastab Syrup 75mg/5ml 100ml bot 45.17\n\tNovelta Bestway\tRanicare TAB dr 150mg 100's pack 200\n\tNovo Healthcare and Pharma Ltd.\tRanbex TAB dr 150mg 100's pack 125\n\tNovus\tRantop TAB dr 150mg 100's pack 200\n\tOpso Saline Ltd.\tPeptosol IV Infusion 50mg/100ml 100ml bot 35.13\n\tOpsonin Pharma\tRanitid Injection 50mg/2ml 50 amps pack 300\n\tOpsonin Pharma\tRanitid Syrup 75mg/5ml 100ml bot 45\n\tOpsonin Pharma\tRanitid TAB dr 150mg 150's pack 300\n\tOpsonin Pharma\tRanitid TAB dr 300mg 100's pack 400\n\tOrganic Health Care\tOff-H TAB dr 150mg 100's pack 250\n\tOrion Pharma Ltd.\tOrtac IV Infusion 50mg/100ml 100ml bot 60\n\tOrion Pharma Ltd.\tOrtac Injection 50mg/2ml 10 amps pack 60.20\n\tOrion Pharma Ltd.\tOrtac TAB dr 150mg 100's pack 201\n\tOrion Pharma Ltd.\tOrtac Syrup 75 mg/5 ml  \n\tPacific\tEucon TAB dr 150mg 100's pack 190\n\tPeoples Pharma Ltd.\tPeotid TAB dr 150mg 100's pack 120\n\tPharmadesh Ltd.\tRanit TAB dr 150mg 100's pack 200\n\tPharmasia Ltd.\tRavia TAB dr 150mg 100's pack/150's pack 100/150\n\tPopular\tRanitor TAB dr 150mg 150's pack 300\n\tPrime\tPritac TAB dr 150mg  \n\tRAK\tH-Blok TAB dr 150mg 100's pack 200\n\tRangs\tZenil TAB dr 150mg 100's pack 200\n\tRasa\tRostil TAB dr 150mg  \n\tReliance\tE Tack TAB dr 150mg 100's pack 200\n\tReman Drug Ltd.\tDugal TAB dr 150mg 100's pack 115\n\tRenata\tNorma H TAB dr 150mg 100's pack 219\n\tRephco\tAlin TAB dr 150mg 100's pack 200\n\tS. N.\tRanifast TAB dr 150mg 100's pack 200\n\tSalton\tMutac TAB dr 150mg 100's pack 203\n\tSanofi Aventis (BD) Ltd.\tAsinar TAB dr 150mg 100's pack 250\n\tSeema\tRantin TAB dr 150mg 150's pack 300\n\tShamsul Al-Amin\tSadin TAB dr 150mg 100's pack 200\n\tSharif\tXardin TAB dr 150mg 100's pack 200\n\tSilco Pharmaceuticlas Ltd.\tMucin R TAB dr 150mg  \n\tSilva\tRt TAB dr 150mg 100's pack 200.70\n\tSomatec\tZodin Syrup 75mg/5ml 100ml bot 40.15\n\tSomatec\tZodin TAB dr 150mg 100's pack 201\n\tSonear Ltd.\tRanitab TAB dr 150mg 100's pack 205\n\tSquare\tNeotack Injection 50mg/2ml 10 amps pack 100\n\tSquare\tNeotack Syrup 75mg/5ml 100ml bot 45.16\n\tSquare\tNeotack TAB dr 150mg 150's pack 375\n\tSquare\tNeotack TAB dr 300mg 100's pack 450\n\tSupreme\tSutac TAB dr 150mg 100's pack 200\n\tSyntho Ltd.\tRanisyn TAB dr 150mg 100's pack 210\n\tTechno Drugs Ltd.\tDuran IV Infusion 50mg/100ml 100ml bot 60\n\tTechno Drugs Ltd.\tDuran Syrup 75mg/5ml 100ml bot 45\n\tTechno Drugs Ltd.\tDuran TAB dr 150mg 100's pack 200\n\tTechno Drugs Ltd.\tDuran TAB dr 300mg 100's pack 400\n\tTechno Drugs Ltd.\tDuran Inj Injection 50mg/100ml 1's pack(100ml) 60\n\tVeritas\tVeridin TAB dr 150mg  \n\tWhite Horse Pharma\tWintack TAB dr 150mg 100's pack 200\n\tZenith\tZenidine TAB dr 150mg 100's pack 150\n\tZiska\tRanid Injection 50mg/2ml 10 amps pack 60\n\tZiska\tRanid TAB dr 150mg 100's pack 110\n\tIndication: Dyspepsia, H. pylori infection, Benign gastric and duodenal ulceration, GERD, Acid aspiration during general anesth, Prophylaxis during NSAID treatment, Stress ulceration of upper GI, Zollinger-Ellison syndrome\n\nDose: Adult: PO Benign gastric and duodenal ulceration Initial: 300 mg at bedtime or 150 mg twice daily for 4-8 wk depending on the condition. \nFor prevention of NSAID-associated ulceration: 150 mg bid. \nEradication of H. pylori infection 300 mg once daily or 150 mg twice daily w/ amoxicillin and metronidazole for 2 wk. May continue w/ ranitidine for a further 2 wk. \nGERD 150 mg twice daily or 300 mg at bedtime for up to 8 wk. Severe: 150 mg 4 times/day for 12 wk. Pathological hypersecretory conditions Initial: 150 mg 2-3 times/day, up to 6 g/day if needed.\n Acid aspiration during general anesth 150 mg 2 hr before induction of anesth and preferably, an additional dose on the previous evening. \nChronic episodic dyspepsia 150 mg twice daily for up to 6 wk. \nShort-term symptomatic dyspepsia 75 mg, up to 4 doses/day if needed. Max: 2 wk of continuous use at each time. \nProphylaxis during NSAID treatment 150 mg twice daily. \n\nIV Pathological hypersecretory conditions Initial: 1 mg/kg/hr, may increase slowly after 4 hr if needed. Stress ulceration of upper GI tract Priming dose: 50 mg via inj, then 125-250 mcg/kg/hr via infusion, then transfer to PO 150 mg twice daily once oral feeding is resumed. \n\nIV/IM Acid aspiration during general anesth 50 mg 45-60 mins before the induction of anasth.\n\nContra-indication: Porphyria.\n\nSide effects: Headache, dizziness. Rarely hepatitis, thrombocytopaenia, leucopaenia, hypersensitivity, confusion, gynaecomastia, impotence, somnolence, vertigo, hallucinations.\nPotentially Fatal: Anaphylaxis, hypersensitivity reactions.\n\nPrecaution: Exclude malignancy before treating gastric ulcer. Renal and hepatic impairment. Infants, pregnancy and lactation.\n\nMode of action: Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.\n\nPregnancy category: B\n\nInteraction: Delayed absorption and increased peak serum concentration w/ propantheline bromide. Ranitidine minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability w/ antacids.
Ranolazine	\n\n\tGeneral\tRanola ER TAB dr 500mg 20's pack 280\n\tGeneral\tRenola TAB dr 500mg 10's pack 500\n\tIncepta\tRalozine TAB dr 500mg 20's pack 320\n\tSquare\tRanolin XR 1g TAB dr 1g 10's pack 250\n\tSquare\tRanolin XR TAB dr 500mg 20's pack 320\n\tIndication: Chronic angina\n\nDose: Initiate Ranolazine dosing at 500 mg twice daily and increase to 1000 mg twice daily, if needed, based on clinical symptoms. \n\nThe maximum recommended daily dose of Ranolazine is 1000 mg twice daily. If a dose of Ranolazine is missed, take the prescribed dose at the next scheduled time; do not double the next dose.\n\nContra-indication: Taking strong inhibitors of CYP3A (e.g., ketoconazole, clarithromycin, nelfinavir) Taking inducers of CYP3A (e.g., phenobarbital, rifampicin)Significant hepatic impairment \n\nSide effects: Cardiac Disorders - bradycardia, palpitationsEar and Labyrinth Disorders - tinnitus, vertigoGastrointestinal Disorders - abdominal pain, dry mouth, vomitingGeneral Disorders and Administrative Site Adverse Events - peripheral edemaRespiratory, Thoracic, and Mediastinal Disorders - dyspneaVascular Disorders - hypotension, orthostatic hypotension \n\nPrecaution: Heart rhythm problems (e.g., bradycardia, QT prolongation, ventricular tachycardia), liver problems, certain uncorrected mineral imbalances (low potassium/magnesium levels), severe kidney problems. \n\nMode of action: Increased plasma levels w/ moderate CYP3A4 inhibitors (e.g. diltiazem, fluconazole, erythromycin), P-glycoprotein inhibitors (e.g. verapamil, ciclosporin) and CYP2D6 inhibitors (e.g. paroxetine). May increase plasma digoxin concentrations. May increase risk of rhabdomyolysis w/ simvastatin. May increase plasma concentrations of atorvastatin, other statins (e.g. lovastatin) and CYP3A4 substrates w/ narrow therapeutic range (e.g. tacrolimus, sirolimus, everolimus). May increase plasma exposure of metformin. Increased risk of ventricular arrhythmias w/ other drugs that prolong QT interval (e.g. terfenadine, astemizole, mizolastine).\n\nPotentially Fatal: Increased plasma concentrations leading to increased adverse effects w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone). Decreased plasma concentration w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine). Increased risk of QT interval prolongation w/ class 1A (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.\n\nPregnancy category: C\n\nInteraction: Increased plasma levels w/ moderate CYP3A4 inhibitors (e.g. diltiazem, fluconazole, erythromycin), P-glycoprotein inhibitors (e.g. verapamil, ciclosporin) and CYP2D6 inhibitors (e.g. paroxetine). May increase plasma digoxin concentrations. May increase risk of rhabdomyolysis w/ simvastatin. May increase plasma concentrations of atorvastatin, other statins (e.g. lovastatin) and CYP3A4 substrates w/ narrow therapeutic range (e.g. tacrolimus, sirolimus, everolimus). May increase plasma exposure of metformin. Increased risk of ventricular arrhythmias w/ other drugs that prolong QT interval (e.g. terfenadine, astemizole, mizolastine).\n\nPotentially Fatal: Increased plasma concentrations leading to increased adverse effects w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone). Decreased plasma concentration w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine). Increased risk of QT interval prolongation w/ class 1A (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.
Repaglinide	\n\n\tAlco Pharma\tRepaglid TAB dr 1mg 30's pack 90\n\tAlco Pharma\tRepaglid TAB dr 2mg 30's pack 150\n\tBeximco\tPremil TAB dr .5mg 30's pack 60\n\tBeximco\tPremil TAB dr 1mg 30's pack 90\n\tBeximco\tPremil TAB dr 2mg 30's pack 150\n\tDrug International Ltd.\tGlimet TAB dr 1mg 50's pack 150\n\tGeneral\tReglin TAB dr .5mg 45 90\n\tGeneral\tReglin TAB dr 1mg 20's pack 90\n\tIncepta\tNomopil TAB dr 0.5mg 100's pack 200\n\tIncepta\tNomopil TAB dr 1mg 100's pack 300\n\tIncepta\tNomopil TAB dr 2mg 50's pack 250\n\tOpsonin Pharma\tRepanid TAB dr .5mg 30's pack 60\n\tOpsonin Pharma\tRepanid TAB dr 1mg 30's pack 79\n\tOpsonin Pharma\tRepanid TAB dr 2mg 30's pack 132\n\tPacific\tGluretor TAB dr .5mg 30's pack 84\n\tPacific\tGluretor TAB dr 1mg 30's pack 120\n\tPacific\tGluretor TAB dr 2mg 30's pack 180\n\tRenata\tSinglin TAB dr .5mg 100's pack 200\n\tRenata\tSinglin TAB dr 1mg 100's pack 300\n\tRenata\tSinglin TAB dr 2mg 50's pack 250\n\tTechno Drugs Ltd.\tDiarepa TAB dr 1mg 30's pack 275\n\tUnimed & Unihealth Manufacturers Ltd.\tPrandil TAB dr 1mg 30's pack 90\n\tWhite Horse Pharma\tPrefid TAB dr 1mg 50's pack 150\n\tIndication: Type 2 DM\n\nDose: Adult: PO Initial: 0.5 mg before main meals. May adjust dose 1-2 wkly, up to 4 mg/dose. Max: 16 mg/day.\n\nContra-indication: Diabetic ketoacidosis; severe hepatic impairment, type 1 diabetes; hypersensitivity. Lactation.\n\nSide effects: Hypoglycaemia, nausea, diarrhoea, constipation, vomiting, dyspepsia, arthralgia, sinusitis, rhinitis, back pain; rash, pruritus, urticaria; visual disturbances.\n\nPrecaution: Myocardial infarction, coma, trauma during surgery, elderly, malnourished and debilitated patients. Hepatic or severe renal impairment. Pregnancy.\n\nMode of action: Cytochrome P450 3A4 inducers eg. rifampicin, barbiturates and carbamazepine may increase repaglinide metabolism. NSAIDs and other highly protein bound drugs eg, salicylates, sulphonamides, phenylbutazone, oral anticoagulants and hydantoins may potentiate action of repaglinide. Ketoconazole, fluconazole, itraconazole and erythromycin may increase plasma conc of repaglinide. Antagonistic effect with drugs causing hyperglycaemia. Concurrent use with gemfibrozil may lead to enhanced and prolonged blood glucose lowering effect.\n\nPotentially Fatal: Increased risk of myocardial infarction when used with isophane insulin.\n\nPregnancy category: C\n\nInteraction: Cytochrome P450 3A4 inducers eg. rifampicin, barbiturates and carbamazepine may increase repaglinide metabolism. NSAIDs and other highly protein bound drugs eg, salicylates, sulphonamides, phenylbutazone, oral anticoagulants and hydantoins may potentiate action of repaglinide. Ketoconazole, fluconazole, itraconazole and erythromycin may increase plasma conc of repaglinide. Antagonistic effect with drugs causing hyperglycaemia. Concurrent use with gemfibrozil may lead to enhanced and prolonged blood glucose lowering effect.\n\nPotentially Fatal: Increased risk of myocardial infarction when used with isophane insulin.
Retapamulin 1% Topical	\n\n\tIncepta\tRetapex Ointment 15gm 1's pack 300\n\tSquare\tRetabac Ointment 1 gm/100 gm  200\n\tIndication: Impetigo, Bacterial skin infections\n\nDose: Impetigo, Bacterial skin infections due to meticillin-susceptible Staphylococcus aureus and Streptococcus pyogenes\nAdult: As 1% ointment: Apply onto affected area bid for 5 days. Re-evaluate if there is no response after 3 days of treatment. Total treatment area: ?100 cm2 total body surface area.\n\nChild: As 1% ointment: ?9 mth: Apply onto affected area bid for 5 days. Total treatment area: ?2% of total body surface area.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Headache, pyrexia, pruritus, eczema, diarrhoea. Application site irritation, pain, erythema, contact dermatitis.\n\nPrecaution: Discontinue use if skin irritation occurs. Prolonged use may result in fungal or bacterial superinfection. Re-evaluate if there is no response within 3 days. Children <9 mth. Pregnancy, lactation.\n\nMode of action: Concurrent application w/ other topical products to the same skin area is not recommended.\n\nPregnancy category: B\n\nInteraction: Concurrent application w/ other topical products to the same skin area is not recommended.
Rhubarb 5%  +  Salicylic Acid 1%	\n\n\tOpsonin Pharma\tMeoral Oral Solution   10ml pack 79.17\n\tZiska\tOrofresh OS Oral Solution   10 ml bot 120\n\tIndication: Gingivitis, Pain or irritation of the mouth and throat, Apthous ulcer, Gum sore, Periodonitis\n\nDose: Mouth/Throat\nPain or irritation of the mouth and throat\nAdult: Per ml of solution containing 50 mg rhubarb extract (containing 5 mg of anthraquinone glycosides) and 10 mg salicylic acid: Apply onto the affected oral mucosal area 3-4 times daily using a brush applicator.\nChild: >12 yr: Per ml of solution containing 50 mg rhubarb extract (containing 5 mg of anthraquinone glycosides) and 10 mg salicylic acid: Apply onto the affected oral mucosal area 3-4 times daily using a brush applicator.\n\nContra-indication: Hypersensitivity to any of the constituents.\n\nSide effects: A transient local burning sensation at the site of application occurs very commonly. Temporary discoloration of teeth or oral mucosa has been described commonly following administration of oral solution.\n\nPrecaution: Each bottle of oral solution should be used by only one person.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ribavirin	\n\n\tBeacon\tCopeg CAP 200mg 20's pack 703\n\tIncepta\tCelbarin CAP 200mg 20's pack 700\n\tRAK\tRibacee CAP 200mg  \n\tIndication: Chronic hepatitis C\n\nDose: Adult: PO: Ribavirin + Interferon \nW/ interferon alfa-2a or interferon alpha-2b. Dosage depends on viral genotype. \nFor genotype 1 or 4: All < 75 kg= (400+600) mg 3 MIU 3 times weekly 48 weeks subcutaneously. or > 75 kg= (600+600) mg \nFor genotype 2 or 3: (400+400) mg/day.  \n\nRibavirin + Peg-Interferon\nW/ Peg-Interferon alpha-2a Duration or Peg-interferon alpha-2b\nFor genotype 1 or 4: < 75 kg= (400+600) mg, once weekly 48 weeks. > 75 kg= (600+600) mg subcutaneously.\nFor genotype 2 or 3:  (400+400) mg 24 weeks\nFor co-infection w/ HIV: 800 mg/day (regardless of viral genotype). \n\nTo be given in 2 divided doses for 48 wk (genotype 1 or 4 or HIV co-infection) or 24 wk (genotype 2 or 3). \nThe recommended duration of treatment for patients previously untreated with interferon is 24 to 48 weeks. After 24 weeks of treatment virologic response should be assessed. Treatment discontinuation should be considered in any patient who has not achieved an HCV RNA below the limit of detection of the assay by 24 weeks. \n\nThere are no safety and efficacy data on treatment for longer than 48 weeks in the previously untreated patient population. In patients who relapse following interferon therapy, the recommended duration of treatment is 24 weeks. There are no safety and efficacy data on treatment for longer than 24 weeks in the relapse patient populations. \n\nChild: >3 yr: recommended dosing regimen (Rebetol (Schering Plough)): 15 mg/kg daily, given in 2 divided doses. Used in combination with interferon alfa-2b. For patients <25 kg or unable to swallow capsules, oral solution should be used. Capsules should not be used in patients <5 yr. Usual treatment duration: 48 wk (treatment-naive patients) or 24 wk (patients who have failed interferon alfa-2b monotherapy).\n\nRenal impairment:\nCrCl (ml/min)	\n<50 	Avoid usage.\nHepatic impairment: Avoid in severe impairment.\n\n\nContra-indication: Hypersensitivity. Pregnancy and lactation. Unstable cardiac disease, haemoglobinopathies or CrCl <50 ml/min. Severe hepatic impairment or decompensated liver cirrhosis. Men whose female partners are pregnant. Children and adolescents with a history of, or existing psychiatric disorders.\n\nSide effects: Oral: Increased serum bilirubin and uric acid, haemolytic anaemia, reticulocytosis, anorexia, dyspepsia, nausea, irritability, dyspnoea, pharyngitis, skin rashes, pruritus and headache, abdominal cramps, fatigue, metallic taste, increased thirst, GI complaints, mood changes, insomnia. High dose may cause reduction in haemoglobin, haematocrit and RBC count. Aerosol: Deterioration in pulmonary function, bacterial pneumonia and pneumothorax, BP fall, cardiac arrest, anaemia, reticulocytosis, conjunctivitis, skin rash. Eye irritation due to deposited drug (infrequent).\n\nPrecaution: Patients with extensive hepatic fibrosis; renal impairment; anaemias. Monitor CBC at the start of, and regularly during treatment. Ensure contraception during treatment and for at least 6 mth after treatment cessation in women and female partners of male patients. Increased risk of fatal and nonfatal MI in patients with anaemia.\n\nMode of action: May worsen neutropenia induced by interferon alfa. May increase risk of adverse effects when used with nucleoside reverse transcriptase inhibitors.\n\nPotentially Fatal: Risk of fatal hepatic failure, peripheral neuropathy and pancreatitis when used with didanosine. Increased risk of severe neutropenia and anaemia when used with zidovudine.\n\nPregnancy category: X\n\nInteraction: May worsen neutropenia induced by interferon alfa. May increase risk of adverse effects when used with nucleoside reverse transcriptase inhibitors.\n\nPotentially Fatal: Risk of fatal hepatic failure, peripheral neuropathy and pancreatitis when used with didanosine. Increased risk of severe neutropenia and anaemia when used with zidovudine.
Riboflavin	\n\n\tAd-din\tRibomin TAB dr 5mg 100'pack 23\n\tAexim\tRibovit TAB dr 5mg 500'pack 100\n\tAmico Ltd.\tRiboflavine TAB dr 5mg 500'pack 65\n\tBristol Pharma Ltd.\tRiboflavine TAB dr 5mg 500's pack 105\n\tGonoshasthaya\tG Vitamin B2 TAB dr 5mg 100'pack 14\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRibosina TAB dr 5mg 500'pack 115\n\tIndobangla Pharmaceuticals\tRiboflavine TAB dr 5mg 500'pack 100\n\tJayson\tRiboson TAB dr 5mg 500'pack 115\n\tPharmadesh Ltd.\tRiboflavine TAB dr 5mg 500'pack/1000'pack 105/210\n\tSupreme\tRivin TAB dr 5mg 500'pack 50\n\tIndication: Riboflavin deficiency, Microcytic anaemia\n\nDose: Adult: PO Prophylaxis of riboflavin deficiency 5-10 mg/day. Riboflavin deficiency 30 mg/day in divided doses. \nChild: 3-10 mg daily. \n\nMicrocytic anaemia associated w/ splenomegaly and glutathione reductase deficiency 10 mg/day for 10 days.\n\nContra-indication: \n\nSide effects: Bright yellow disclouration of urine.\n\nPrecaution: Pregnancy (doses >RDA)\n\nMode of action: Rate and extent of absorption may be affected by propantheline bromide.\n\nPregnancy category: A\n\nInteraction: Rate and extent of absorption may be affected by propantheline bromide.
Rifampicin	\n\n\tGonoshasthaya\tG Rifampicin CAP 450mg 50's pack 304.50\n\tNovartis (Bangladesh) Ltd.\tRimactane TAB dr 450mg 50's pack 545\n\tPharmadesh Ltd.\tRifcin Syrup 100mg/5ml 60ml bot 80\n\tPharmadesh Ltd.\tRifcin CAP 150mg 40's pack 441.20\n\tIndication: Tuberculosis, Leprosy,  Brucellosis, Meningitis , Legionnaire's disease; Staphylococcal infections\n\nDose: Adult: PO Tuberculosis 10 mg/kg/day or 2-3 times/wk. Max: 600 mg/day. Leprosy 600 mg once mthly.\n\nProphylaxis against meningococcal meningitis 600 mg twice daily for 2 days. Prophylaxis against meningitis due to Haemophilus influenzae 600 mg/day for 4 days. \n\nPO/IV Brucellosis; Legionnaire's disease; Staphylococcal infections 600-1,200 mg/day in divided doses.\n\nContra-indication:  Hypersensitivity, jaundice, severe hepatic disease. IM/SC admin. Porphyria. Not to be used for treatment of meningococcal disease.\n\nSide effects: GI disturbances, pseudomembranous colitis (rare), abnormalities of liver function, fatalities in those with liver disorders, influenza-like symptoms, skin reactions, eosinophilia, transient leucopenia, thrombocytopenia, purpura, shock, drowsiness, headache, ataxia, visual disturbances, menstrual irregularities. Reddish coloured urine and tears. IV: Thrombophloebitis; extravasation following local irritation and inflammation.\nPotentially Fatal: Hepatitis or shock-like syndrome with hepatic involvement.\n\nPrecaution: Impaired hepatic or renal function. Elderly, malnourished or very young patients. Alcoholic patients. Monitor blood counts and liver function regularly. Body fluids may colour orange-red. Discontinue use if thrombocytopenia or purpura occurs. Pregnancy and lactation. Care should be taken during IV admin to prevent extravasation.\n\nMode of action: May accelerate the metabolism and reduce the effect of drugs that are metabolised by CYP450 enzymes (e.g. quinidine, phenytoin, theophylline). Decreased concentrations of atovaquone and increased concentrations of rifampicin when taken concomitantly. Concurrent use of ketoconazole and rifampicin may result in decreased serum concentrations of both drugs. May decrease serum concentrations of enalaprilat. Reduced absorption by antacids. Increased risk of hepatotoxicity w/ halothane or isoniazid.\n\nPotentially Fatal: Increased potential for hepatotoxicity when taken concomitantly w/ saquinavir/ritonavir combination.\n\nPregnancy category: C\n\nInteraction: May accelerate the metabolism and reduce the effect of drugs that are metabolised by CYP450 enzymes (e.g. quinidine, phenytoin, theophylline). Decreased concentrations of atovaquone and increased concentrations of rifampicin when taken concomitantly. Concurrent use of ketoconazole and rifampicin may result in decreased serum concentrations of both drugs. May decrease serum concentrations of enalaprilat. Reduced absorption by antacids. Increased risk of hepatotoxicity w/ halothane or isoniazid.\n\nPotentially Fatal: Increased potential for hepatotoxicity when taken concomitantly w/ saquinavir/ritonavir combination.
Rifaximin	\n\n\tACI\tHenlix TAB dr 200mg  \n\tACI\tHenlix TAB dr 550mg  \n\tAcme Ltd.\tAximin 200 TAB dr 200mg  \n\tAcme Ltd.\tAximin 550 TAB dr 550mg  \n\tAristopharma\tHepaximin TAB dr 200mg 20's pack 400\n\tAristopharma\tHepaximin TAB dr 550mg 10's pack 450\n\tDrug International Ltd.\tFaxan TAB dr 200mg 14's pack \n\tDrug International Ltd.\tFaxan TAB dr 550mg 7's pack \n\tIbn Sina Pharmaceutical Ind. Ltd.\tHepatab TAB dr 200mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tHepatab TAB dr 550mg  \n\tIncepta\tRifamax TAB dr 200mg 10's pack 650\n\tIncepta\tRifamax-550 TAB dr 550mg 10's pack 650\n\tNIPRO JMI Pharma\tXifamin TAB dr 200mg 10's pack 200\n\tOpsonin Pharma\tRifagut TAB dr 200mg 10's pack 175.94\n\tOpsonin Pharma\tRifagut TAB dr 550mg 10's pack 395.87\n\tPopular\tRifabac TAB dr 200mg  \n\tPopular\tRifabac TAB dr 550mg  \n\tSharif\tRifacol TAB dr 200mg 20's pack 400\n\tSharif\tRifacol TAB dr 550mg 10's pack 450\n\tZiska\tRefaxin TAB dr 200mg 2x8's pack 320\n\tZiska\tRifaxin TAB dr 550mg 8's pack 360\n\tIndication: Traveler's diarrhea, irritable bowel syndrome \n\nDose: Traveler's Diarrhea: For patients >12 years of age - 200 mg 3 times daily for 3 days.\nHepatic Encephalopathy: For patients >18 years of age - 550 mg 2 times daily.\nBacterial over growth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days.\n\n\nRenal Impairment: The pharmacokinetics of Rifaximin in patients with impaired renal function has not been studied.\nHepatic Impairment: The systemic exposure of Rifaximin was markedly elevated in patients with hepatic impairment compared to healthy subjects.\n\nContra-indication: Contraindicated in patients with a hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product.\n\nSide effects: Side effects include flatulence, headache, abdominal pain, rectal tenesmus, defecation urgency, nausea, constipation, pyrexia, vomiting. Reactions have been reported, including anaphylaxis, angioneurotic edema, and exfoliative dermatitis.\n\nPrecaution: Rifaximin is not found to be effective in patients with diarrhea complicated by fever and/or blood in the stools. Rifaximin therapy should be discontinued if diarrhea symptoms get worse or persist for more than 24-48 hours and an alternative antibiotic therapy should be considered. Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.\n\nMode of action: Although in vitro studies demonstrated the potential of rifaximin to interact with cytochrome P450 (CYP3A4), a clinical drug-drug interaction study demonstrated that rifaximin did not significantly affect the pharmacokinetics of midazolam. An additional clinical drug-drug interaction study showed no effect of rifaximin on the presystemic metabolism of an oral contraceptive containing ethinyl estradiol and norgestimate. Therefore, clinical interactions with drugs metabolized by human cytochrome P450 isozymes are not expected.\n\nPregnancy category: C\n\nInteraction: Although in vitro studies demonstrated the potential of rifaximin to interact with cytochrome P450 (CYP3A4), a clinical drug-drug interaction study demonstrated that rifaximin did not significantly affect the pharmacokinetics of midazolam. An additional clinical drug-drug interaction study showed no effect of rifaximin on the presystemic metabolism of an oral contraceptive containing ethinyl estradiol and norgestimate. Therefore, clinical interactions with drugs metabolized by human cytochrome P450 isozymes are not expected.
Rimexolone 1% Eye prep	\n\n\tIndication: Ocular inflammation\n\nDose: Adult: Ophth Post-op ocular inflammation As 1% susp: Apply 1-2 drops 4 times/day for 2 wk, starting 24 hr post-op. Anterior uveitis As 1% susp: Apply 1-2 drops hrly during waking hr for the 1st wk, followed by 2 hrly for 2nd wk, 4 times/day for 3rd wk, twice daily during the 1st 4 days of 4th wk and then once daily during the last 3 days of the 4th wk. Ocular inflammationAs 1% susp: Apply 1 drop 4 times/day for not >4 wk.\n\nContra-indication: Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, viral diseases of the cornea and conjunctiva, mycobacterial, fungal or amoebic infection of the eye; acute purulent untreated infections which may be masked or enhanced by the use of the steroid; undiagnosed red eye.\n\nSide effects: Blurring of vision, discharge, eye pain and discomfort, foreign body sensation, hyperaemia, pruritus, thinning of the cornea and sclera. Prolonged use may result in ocular hypertension, glaucoma, optic nerve damage, visual acuity and visual fields defects, formation of posterior subcapsular cataract and secondary ocular infections.\n\nPrecaution: Temporary, blurred vision may occur immediately after admin, do not drive or operate machinery if affected. Re-evaluate if sign and symptoms do not improve after 2 days and monitor intraocular pressure if used >10 days. For ophthalmic use only, not to be used as inj. Shake well before use. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Risperidone	\n\n\tACI\tRisolux TAB dr 1mg  \n\tACI\tRisolux TAB dr 2mg  \n\tACI\tRisolux TAB dr 4mg  \n\tDrug International Ltd.\tResco TAB dr 1mg 50's pack 75\n\tDrug International Ltd.\tResco TAB dr 2mg 50's pack 100\n\tGeneral\tRiscord TAB dr 2mg 30's pack 90\n\tGeneral\tRiscord TAB dr 4mg 30's pack 165\n\tGeneral\tRiscord 1 TAB dr 1mg 30's pack \n\tHealthcare\tResidone TAB dr 1mg  \n\tHealthcare\tResidone TAB dr 2mg  \n\tHealthcare\tResidone TAB dr 4mg  \n\tIncepta\tFrenia 1 TAB dr 1mg 50's pack 100\n\tIncepta\tFrenia 2 TAB dr 2mg 50's pack 150\n\tIncepta\tFrenia 4 TAB dr 4mg 30's pack 165\n\tNovartis (Bangladesh) Ltd.\tRispolux 1 TAB dr 1mg 100's pack 310\n\tNovartis (Bangladesh) Ltd.\tRispolux 2 TAB dr 2mg 100's pack 510\n\tNovartis (Bangladesh) Ltd.\tRispolux 4 TAB dr 4mg 30's pack 273\n\tOpsonin Pharma\tRisperdex 1 TAB dr 1mg 50's pack 75\n\tOpsonin Pharma\tRisperdex 2 TAB dr 2mg 50's pack 100\n\tOrion Pharma Ltd.\tRispa TAB dr 1mg 150's pack 75\n\tOrion Pharma Ltd.\tRispa TAB dr 2mg 50's pack 250\n\tRenata\tSperid TAB dr 1mg 50's pack 75\n\tRenata\tSperid TAB dr 2mg 50's pack 100\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSizodon TAB dr 1mg 50's pack 92.50\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSizodon TAB dr 2mg 100's pack 600\n\tSun Pharmaceutical (Bangladesh) Ltd.\tSizodon TAB dr 4mg 50's pack 450\n\tUnimed & Unihealth Manufacturers Ltd.\tRisdon TAB dr 1mg 30's pack 90\n\tUnimed & Unihealth Manufacturers Ltd.\tRisdon TAB dr 2mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tRisdon TAB dr 4mg 30's pack 270\n\tUnimed & Unihealth Manufacturers Ltd.\tRisperdal TAB dr 1mg 6's pack 192\n\tUnimed & Unihealth Manufacturers Ltd.\tRisperdal TAB dr 2mg 20's pack 1280\n\tIndication: Acute and chronic psychoses, Mania, Schizophrenia, Bipolar disorder.\n\nDose: Adult: PO: Schizophrenia Initial: 2 mg/day, up to 4 mg/day on the 2nd day if needed. May further adjust doses at wkly intervals. Maintenance: 4-6 mg/day. Max: 16 mg/day.  \nElderly: Initially, 0.5 mg bid gradually increased in increments of 0.5 mg bid. Maintenance: 1-2 mg bid. \n\nAcute manic episodes of bipolar disorder Initial: 2-3 mg once daily. May increase slowly if needed. Max: 6 mg/day.  \n\nPsychoses: 2 mg in 1-2 divided doses on 1st day then 4 mg in 1-2 divided doses on second day (Slower titration appropriate in some patients); usual dose range 4-6 mg daily\n\nContra-indication: Risperidone is contraindicated in patients with a known hypersensitivity to the product.\n\nSide effects: Agitation, anxiety, dizziness, headache, somnolence; orthostatic hypotension; constipation, dyspepsia, nausea, vomiting, abdominal pain, blurred vision, erectile dysfunction, priapism, rhinitis, rash and allergy, galactorrhoea, gynaecomastia, menstrual disorders, extrapyramidal symptoms (rarely). weight gain, oedema, tardive dyskinesia.Potentially Fatal: Neuroleptic malignant syndrome may occur rarely; seizures. May cause increased mortality in elderly with dementia-related psychosis.\n\nPrecaution: Preexisting CV diseases; discontinue use if signs and symptoms of tardive dyskinesia occur; renal and hepatic impairment, elderly, epilepsy; parkinsonism; pregnancy. May cause drowsiness and orthostatic hypotension. Gradual withdrawal is recommended. Monitor blood glucose in diabetics and patients at risk of developing diabetes.\n\nMode of action: May antagonise the effects of levodopa and dopamine agonists. May increase serum levels of clozapine when used together. Increased serum levels of carbamazepine when used concurrently. Carbamazepine may also decrease the serum levels of risperidone. Increased risk of neuroleptic malignant syndrome when used with indinavir and ritonavir.\n\nPotentially Fatal: Risperidone may enhance the hypotensive effect of certain antihypertensives.\n\nPregnancy category: C\n\nInteraction: May antagonise the effects of levodopa and dopamine agonists. May increase serum levels of clozapine when used together. Increased serum levels of carbamazepine when used concurrently. Carbamazepine may also decrease the serum levels of risperidone. Increased risk of neuroleptic malignant syndrome when used with indinavir and ritonavir.\n\nPotentially Fatal: Risperidone may enhance the hypotensive effect of certain antihypertensives.
Ritodrine Hydrochloride	\n\n\tACI\tRitopar Injection 10mg/ml 30's pack 350\n\tACI\tRitopar TAB dr 10mg 30's pack 240.60\n\tIndication: Premature labour\n\nDose: By intravenous infusion\nInitially 50 micrograms/minute, increased gradually according to response by 50 micrograms/minute every 10 minutes until contractions stop or maternal heart rate reaches 140 beats/minute; continue for 12â48 hours after contractions cease (usual rate 150â350 micrograms/minute); maximum rate 350 micrograms/minute.\n\nIntramuscular injection\n10 mg in every 3â8 hours continued for 12â48 hours after contractions have ceased; then by mouth.\n\nOral maintenance treatment\nOne tablet (10 mg) may be given approximately 30 minutes before termination of intravenous therapy, repeated every 2 hours for 24 hours, followed by 10â20 mg every 4â6 hours, maximum oral dose 120 mg daily.\n\nContra-indication: It is contraindicated in patients with known hypersensitivity to the active ingredient or any of the excipients of this component. ?2âagonists are contra-indicated in cardiac disease and in patients with significant risk factors for myocardial ischaemia; they should also be avoided in antepartum haemorrhage, intra-uterine infection, intra-uterine fetal death, placenta praevia, abruptio placenta, threatened miscarriage, cord compression, and eclampsia or severe pre-eclampsia.\n\nSide effects: The common side-effects of ritodrine hydrochloride are nausea, vomiting, flushing, sweating, tremor, hypokalaemia, tachycardia, palpitations, hypotension (left lateral position throughout infusion to minimize risk), uterine bleeding, pulmonary oedema; chest pain or tightness, arrhythmias and salivary gland enlargement. On prolonged administration for several weeks may cause leucopenia and agranulocytosis; liver function abnormalities including increased transaminases and hepatitis.\n\nPrecaution: It should be used cautiously in patient with suspected cardiac diseases, hypertension, hyperthyroidism, hypokalaemia, diabetes mellitus, mild to moderate preeclampsia, monitor blood pressure and pulse rate and avoid over-hydration during taking ritodrine hydrochloride.\n\nMode of action: May enhance neuromuscular blockade produced by pancuronium and vecuronium.\nPotentially Fatal: Potassium-depleting drugs may increase risk of hypokalaemia.\n\nPregnancy category: B\n\nInteraction: May enhance neuromuscular blockade produced by pancuronium and vecuronium.\nPotentially Fatal: Potassium-depleting drugs may increase risk of hypokalaemia.
Rivaroxaban	\n\n\tEskayef Bangladesh Ltd.\tRivarox TAB dr 10mg/15 mg  \n\tGeneral\tRoxaban TAB dr 10mg  \n\tSquare\tRivaXa TAB dr 2.5mg  \n\tIndication: Atrial fibrillation, Strokes, Deep venous thrombosis\n\nDose: Adult:\nDVT Prophylaxis (Orthopedic Surgery)\n\nKnee replacement: 10 mg PO qDay for 12 days; may take with or without food\n\nHip replacement: 10 mg PO qDay for 35 days; may take with or without food\n\nAdminister initial dose at least 6-10 hr after surgery once hemostasis has been established\nNonvalvular Atrial Fibrillation\n\n20 mg/day PO with the evening meal\nDVT or PE Treatment\n0 mg PO qDay for 6 months\n\nReduce risk for recurrent DVT or PE\n\n    20 mg PO qDay following initial 6 months of treatment for DVT and/or PE\n\nDosage Modifications\n\nRenal impairment (DVT)\n\n    Moderate (CrCl 30 to <50 mL/min): Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with moderate renal impairment\n    Severe (CrCl <30 mL/min): Avoid use, due to expected increase in rivaroxaban exposure and pharmacodynamic effects\n    If acute renal failure develops while on rivaroxaban, discontinue treatment\n\nRenal impairment (nonvalvular AF)\n\n    CrCl >50 mL/min: 20 mg/day PO with the evening meal\n    CrCl 15-50 mL/min: 15 mg/day PO with the evening meal\n    CrCl <15 mL/min: Avoid use\n    If acute renal failure develops while on rivaroxaban, discontinue treatment\n\nHepatic impairment\n\n    Moderate impairment: Clinical data show a significant increase in rivaroxaban exposure and pharmacodynamic effects\n    Avoid use in patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment or with any hepatic disease associated with coagulopathy\n\n\n\nContra-indication: Hypersensitivity, Active, Major bleeding.\n\nSide effects: Incidence of adverse effects was found not to differ significantly from that of enoxaparin\n1-10%\n\nAny bleeding event (5.8%)\n\nWound secretion (2.8%)\n\nPruritus (2.1%)\n\nExtremity pain (1.7%)\n\nBlister (1.4%)\n\nSyncope (1.2%)\n\nAtrial fibrillation\n\n    Major bleeding (5.6%)\n    Gastrointestinal bleeding (3.1%)\n    Bleeding resulting in transfusion (2.6%)\n    Bleeding into a critical organ (1.3%)\n\n<10%\n\nMuscle spasm (0.7%)\n\nAtrial fibrillation\n\n    Fatal bleeding (0.4%)\n\nDVT prophylaxis\n\n    Major bleeding (0.3%)\n    Bleeding requiring reoperation (0.2%)\n    Extra-surgical site bleeding requiring transfusion (0.1%)\n    Bleeding into a critical organ (<0.1%)\n    Fatal bleeding (<0.1%)\n\n\nPrecaution: Epidural or spinal hematomas\n\n    May occur in patients who are anticoagulated and are receiving neuraxial anesthesia or undergoing spinal puncture; consider the benefits and risks in anticoagulated patients who are candidates for neuraxial intervention\n    These hematomas may result in long-term or permanent paralysis; consider these risks when scheduling patients for spinal procedures\n    Factors increasing risk: Indwelling epidural catheters, coadministration with other drugs that affect hemostasis, history of traumatic or repeated epidural or spinal punctures, history of spinal deformity or spinal surgery\n    Monitor patients frequently for signs and symptoms of neurologic impairment; if neurologic compromise is noted, urgent treatment is necessary\n    Epidural catheters should not be removed earlier than 18 hours after the last administration of rivaroxaban; the next dose is not to be administered earlier than 6 hours after the removal of the catheter; if traumatic puncture occurs, delay rivaroxaban administration for 24 hours\n\nDiscontinuing use for atrial fibrillation\n\n    Premature discontinuation of anicoagulants, including rivaroxaban, places patients at increased risk for thrombotic events\n    If anticoagulation with rivaroxaban must be discontinued for a reason other than pathologic bleeding, consider administering another anticoagulant\n\n\nMode of action: Reduced hepatic & renal clearance w/ strong CYP3A4 inhibitors (clarithromycin, erythromycin, fluconazole). Increased bleeding risk w/ azole antimycotics (eg ketoconazole, itraconazole, voriconazole, posaconazole) or HIV-PIs (eg ritonavir); other anticoagulants; NSAIDs (including acetylsalicylic acid) & platelet aggregation inhibitors. Reduced plasma conc w/ CYP3A4 inducers (eg rifampicin, phenytoin, carbamazepine, phenobarb, St. John's wort). 20-mg FC tab: Increased prothrombin time/INR of warfarin.\n\nPregnancy category: C\n\nInteraction: Reduced hepatic & renal clearance w/ strong CYP3A4 inhibitors (clarithromycin, erythromycin, fluconazole). Increased bleeding risk w/ azole antimycotics (eg ketoconazole, itraconazole, voriconazole, posaconazole) or HIV-PIs (eg ritonavir); other anticoagulants; NSAIDs (including acetylsalicylic acid) & platelet aggregation inhibitors. Reduced plasma conc w/ CYP3A4 inducers (eg rifampicin, phenytoin, carbamazepine, phenobarb, St. John's wort). 20-mg FC tab: Increased prothrombin time/INR of warfarin.
Rizatriptan	\n\n\tAcme Ltd.\tRizat TAB dr 5mg 10's pack 162.60\n\tAcme Ltd.\tRizat TAB dr 5 mg 10's pack 301.10\n\tHealthcare\tRizamig TAB dr 5mg 10's pack 355\n\tIncepta\tRizagrin TAB dr 5mg 30's pack 240\n\tIndication: Acute migraine attacks\n\nDose: Adult: PO Initial: 10 mg. If ineffective, 2nd dose should not be taken for the same attack. If symptoms recur after initial response, a further dose of 10 mg may be given. Separate doses by at least 2 hr. Max: 20 mg/24 hr.\n\nHepatic impairment: For mild-moderate impairment, initate with 5 mg. Further dose of 5 mg may be taken after an interval of at least 2 hr. Max: 10 mg/24 hr. Avoid in severe impairment.\n\nContra-indication: History of MI, peripheral vascular disease, transient ishaemic attack, ischaemic heart disease or Prinzmetal's angina; uncontrolled hypertension; basilar or hemiplegic migraine; severe hepatic or renal impairment. Adolescent <18 yr.\n\nSide effects: Increased BP, chest pain, palpitation; skin flushing; dyspnoea; nausea, abdominal pain, dry mouth; dizziness, drowsiness, fatigue.\nPotentially Fatal: Toxic epidermal necrolysis.\n\nPrecaution: Elderly; mild to moderate hepatic or renal impairment; coronary artery disease; pregnancy, lactation. May cause drowsiness. History of seizures. Ensure an interval of at least 24 hr after stopping an ergotamine compound and starting a serotonin (5-HT1) agonist.\n\nMode of action: Increased serum concentrations with propranolol. Increased risk of vasospastic reactions when used with ergotamine and methysergide. Concurrent use with SSRIs may increase risk of serotonin syndrome.\nPotentially Fatal: Concurrent use with or within 2 wk of stopping MAOI treatment.\n\nPregnancy category: C\n\nInteraction: Increased serum concentrations with propranolol. Increased risk of vasospastic reactions when used with ergotamine and methysergide. Concurrent use with SSRIs may increase risk of serotonin syndrome.\nPotentially Fatal: Concurrent use with or within 2 wk of stopping MAOI treatment.
Roflumilast	\n\n\tAcme Ltd.\tMilast-A TAB dr 500 mcg 30's pack 450\n\tBeacon\tRoflast TAB dr 500mcg  \n\tDrug International Ltd.\tRofumil TAB dr 500mg 20's pack \n\tEskayef Bangladesh Ltd.\tRoflu Eye Drops  5ml bot 450\n\tIncepta\tRoxair TAB dr .5mg 30's pack 450\n\tSquare\tLumast TAB dr TAB dr 500mcg 5x6's Pack 450\n\tUnimed & Unihealth Manufacturers Ltd.\tDilarof TAB dr 500mg 200's pack 400\n\tIndication: Asthma, Chronic obstructive pulmonary disease\n\nDose: In adults (above 18 years of age), the recommended dose of Roflumilast is one 500 microgram (mcg) tablet per day with or without food for both asthma and COPD. \n\nAs there is lack of safety information of this drug in children so, it should be avoided in children and adolescent under 18 years of age.\n\nContra-indication: Roflumilast is contraindicated to patients with a history of hypersensitivity to Roflumilast or any of other ingredients of the tablet and if a patient has moderate to severe liver impairment.\n\nSide effects: Normally, Roflumilast is well tolerated. Common side-effects are Weight decrease, decreased appetite, sleeplessness, headache, diarrhoea, nausea, stomach ache etc. \n\nPrecaution: Roflumilast is not a bronchodilator and should not be used for the treatment of a sudden attack of breathlessness. Patients treated with this drug should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, this should be evaluated, and discontinuation of Roflumilast should be considered. Roflumilast should be given with caution in patients with severe immunological diseases (HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy and others), severe acute infectious diseases (tuberculosis or acute hepatitis), cancer (except basal-cell carcinoma), and severe impairment of the heart function.\n\nMode of action:  	Erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine; rifampicin, phenobarb, carbamazepine, phenytoin, theophylline, OC.\n\nPregnancy category: C\n\nInteraction:  	Erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine; rifampicin, phenobarb, carbamazepine, phenytoin, theophylline, OC.
Ropinirole	\n\n\tBeximco\tRepitol TAB dr .25mg 30's pack 60.30\n\tBeximco\tRepitol TAB dr 2mg 30's pack 301.20\n\tIncepta\tRopinol TAB dr .25mg 50's pack 100\n\tIncepta\tRopinol TAB dr 1mg 30's pack 120\n\tIncepta\tRopinol TAB dr 2mg 30's pack 180\n\tSquare\tPerkirol TAB dr .25mg 50's pack 100.41\n\tSquare\tPerkirol TAB dr 2mg 30's pack 180.74\n\tIndication: Parkinson's disease, Restless leg syndrome\n\nDose: Oral\nAs monotherapy in Parkinson's disease\nAdult: Initially, 250 mcg tid, may increase by 750 mcg at wkly intervals for the first 4 wk. Subsequent increments can be made in steps of 1.5 mg at wkly intervals up to 9 mg/day, then in steps of 3 mg at wkly intervals. Usual dose ranges from 3-9 mg daily. Max: 24 mg/day. Higher dose may be necessary if used in conjunction with levodopa. Gradual withdrawal is recommended.\n\nRestless leg syndrome\nAdult: Initially, 250 mcg daily for 2 days, taken 1-3 hr before bedtime. May increase to 500 mcg daily for the next few days. Subsequent increments may be made in steps of 500 mcg at wkly intervals until 3 mg daily is reached. Max: 4 mg daily.\n\nHepatic impairment: Dosing adjustments may be required.\n\nContra-indication: Lactation.\n\nSide effects: Sudden onset of sleep with or without any prior feeling of drowsiness. Nausea, abdominal pain; dizziness, somnolence, headache, hallucinations; dyskinesias.\n\nPrecaution: Pregnancy. May impair ability to drive or operate machinery. Withdrawal should be gradual. Hepatic or renal impairment. May cause daytime sleepiness or episodes of falling asleep during activities. May cause or worsen pre-existing dyskinesia.\n\nMode of action: Inhibitors of CYP1A2 e.g. cimetidine, ciprofloxacin, erythromycin, fluvoxamine, isoniazid, ritonavir and zileuton may increase serum concentrations of ropinirole. Oestrogens and tobacco smoking may decrease clearance of ropinirole. Efficacy may be reduced by dopamine antagonists such as phenothiazines and metoclopramide.\n\nPregnancy category: C\n\nInteraction: Inhibitors of CYP1A2 e.g. cimetidine, ciprofloxacin, erythromycin, fluvoxamine, isoniazid, ritonavir and zileuton may increase serum concentrations of ropinirole. Oestrogens and tobacco smoking may decrease clearance of ropinirole. Efficacy may be reduced by dopamine antagonists such as phenothiazines and metoclopramide.
Rosuvastatin	\n\n\tACI\tRosetor TAB dr 10mg 20's pack 361.20\n\tACI\tRosetor TAB dr 5mg 30's pack 300.90\n\tAcme Ltd.\tRostab TAB dr 10mg 20's pack 300\n\tAcme Ltd.\tRostab TAB dr 20mg 10's pack 250\n\tAlbion Ltd.\tRozavas TAB dr 10mg  \n\tAlbion Ltd.\tRozavas TAB dr 5mg  \n\tAlco Pharma\tRosvin TAB dr 10mg  \n\tAristopharma\tRuvastin TAB dr 10mg 20's pack 300\n\tAristopharma\tRuvastin TAB dr 5mg 30's pack 240\n\tBeximco\tRosutin TAB dr 5mg 30's pack 300\n\tBeximco\tRosutin TAB dr 10mg 20's pack 400\n\tBeximco\tRosutin TAB dr 40mg  \n\tBeximco\tRosutin TAB dr 20mg  \n\tBio Pharma Ltd.\tBestcol TAB dr 10mg  \n\tDelta Pharma\tRTV TAB dr 5mg  \n\tDelta Pharma\tRTV TAB dr 10mg  \n\tDrug International Ltd.\tRostatin TAB dr 10mg 20's pack 300\n\tDrug International Ltd.\tRostatin TAB dr 20mg 10's pack 250\n\tDrug International Ltd.\tRostatin TAB dr 5mg 20's pack 160\n\tEskayef Bangladesh Ltd.\tCreston TAB dr 10mg 20's pack 400\n\tGeneral\tRosugen TAB dr 10mg 20's pack 400\n\tGeneral\tRosugen TAB dr 5mg 30's pack 300\n\tHealthcare\tRovast TAB dr 10mg  \n\tHealthcare\tRovast TAB dr 5mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tRestat TAB dr 10mg  \n\tIncepta\tRocovas 5 TAB dr 5mg 30's pack 240\n\tIncepta\tRocovas 10 TAB dr 10 mg 10's pack 150\n\tIncepta\tRocovas TAB dr 20mg  \n\tNavana\tNestor TAB dr 10mg 20's pack 400\n\tNavana\tNestor TAB dr 5mg 30's pack 300\n\tOpsonin Pharma\tRopitor TAB dr 10mg 20's pack 400\n\tOpsonin Pharma\tRopitor TAB dr 20mg 10's pack 300\n\tOpsonin Pharma\tRopitor TAB dr 5mg 30's pack 300\n\tOrion Pharma Ltd.\tRovex TAB dr 5mg  \n\tOrion Pharma Ltd.\tRovex TAB dr 10mg  \n\tPopular\tRosu TAB dr 5mg/10mg/20mg 30/20/10's pack 264.02/316.82/264.02\n\tRenata\tRolip TAB dr  3x10's pack \n\tSquare\tRosuva TAB dr 10mg 30's pack 602.10\n\tSquare\tRosuva TAB dr 20mg 10's pack 300\n\tSquare\tRosuva TAB dr 5mg 30's pack 300\n\tSun Pharmaceutical (Bangladesh) Ltd.\tRozavel 10 TAB dr 10mg 30's pack 540\n\tWhite Horse Pharma\tRosicard TAB dr 10mg  \n\tIndication: Hyperlipidaemias, Primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia), mixed dyslipidaemia, homozygous familial hypercholesterolaemia, Stroke prevention\n\nDose: Adult: PO: Dose range: 5-40 mg once daily. Initially 5-10 mg once daily increased if necessary at intervals of at least 4 weeks to 20 mg once daily. Daily dose can be increased after further 4 weeks to 40 mg only in severe hypercholesterolaemia with high cardiovascular risk and under specialist supervision. \n\nElderly initially 5 mg once daily. \n\nHoFH: Starting dose 20 mg. \n\nChild: Heterozygous familial hypercholesterolaemia: >10 yr Initially, 5 mg once daily, may be adjusted at intervals of at least 4 wk. Max: 20 mg once daily. \n\nUse 40 mg dose only for patients not reaching LDL-C goal with 20 mg Rosuvastatin can be taken with or without food, at any time of day.\n\nRenal impairment:\nCrCl (ml/min)	\n30-60	Initially, 5 mg once daily to max 20 mg once daily\n<30	        Contraindicated.\n\n\nContra-indication: Severe renal impairment, active liver disease, unexplained persistent elevations of serum transaminases; hypersensitivity. Pregnancy, lactation.\n\nSide effects: Headache, dizziness, constipation, nausea, vomiting, abdominal pain, myalgia, chest pain, peripheral oedema, depression, insomnia, rash, paraesthesia, proteinuria and asthenia.Potentially Fatal: Rhabdomyolysis with acute renal failure.\n\nPrecaution:  Not to be used in patient with acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders or uncontrolled seizures and combination use with cyclosporine, lopinavir/ritonavir, atazanavir/ritonavir, or certain other lipid-lowering drugs. History of liver disease and alcoholism. Discontinue treatment if there is marked or persistent increase in serum aminotransferase concentrations, significant increase in creatinine phosphokinase or evidence of myopathy.\n\nMode of action: May increase serum levels of warfarin and oral contraceptives. May increase serum levels w/ itraconazole, HIV protease inhibitors. May decrease serum levels w/ erythromycin and antacids. May increase risk of myopathy w/ fenofibrate, niacin.\nPotentially Fatal: Increased risk of rhabdomyolysis w/ gemfibrozil and ciclosporin.\n\nPregnancy category: X\n\nInteraction: May increase serum levels of warfarin and oral contraceptives. May increase serum levels w/ itraconazole, HIV protease inhibitors. May decrease serum levels w/ erythromycin and antacids. May increase risk of myopathy w/ fenofibrate, niacin.\nPotentially Fatal: Increased risk of rhabdomyolysis w/ gemfibrozil and ciclosporin.
Roxatidine	\n\n\tIndication: Peptic ulcer, Gastritis, Zollinger-Ellison syndrome, GERD, Upper gastrointestinal haemorrhage\n\nDose: Adult: PO Peptic ulcer 150 mg at bedtime or 75 mg twice daily for 4-6 wk. Maintenance: 75 mg at bedtime. GERD 75 mg twice daily or 150 mg at bedtime for 6-8 wk. Gastritis 75 mg once daily in the evening. Zollinger-Ellison syndrome 75 mg twice daily. \n\nAnesth pre-med 75 mg in the evening one day pre-op and repeated 2 hr before induction of anesth. IV Upper GI haemorrhage 75 mg twice daily.\n\nRenal impairment:\nCrCl (ml/min)	\n20-50	75 mg at bedtime.\n<20	        75 mg every 2 days. \n\nContra-indication: Lactation. Porphyria.\n\nSide effects: Occasional headache, GI disturbances, gynaecomastia, alopecia, blood dyscrasias, pancreatitis, sleep disturbances, restlessness, rarely dizziness. Hypersensitivity reactions e.g. rash and itching reported occasionally. Changes in pulse rate and transient impairment of sexual drive. Possible increase in liver enzyme activity. May reduce leucocytes and/or thrombocytes.\n\n\nPrecaution: Renal and hepatic impairment, pregnancy. May mask the symptoms of gastric malignancy.\n\nMode of action: May affect serum levels of protease inhibitors.\n\nPregnancy category: Not Classified\n\nInteraction: May affect serum levels of protease inhibitors.
Roxithromycin	\n\n\tAlco Pharma\tRoxcin Powder for Suspension 50mg/5ml 50ml bot 45\n\tAlco Pharma\tRoxcin TAB dr 150mg 20's pack 120\n\tAlco Pharma\tRoxcin TAB dr 300mg 20's pack 240\n\tAmbee\tA Rox Powder for Suspension 50mg/5ml 50ml bot 45.17\n\tAmbee\tA Rox TAB dr 150mg 30's pack 195.90\n\tAmbee\tA Rox TAB dr 300mg 20's pack 220.80\n\tAmico Ltd.\tRocky Powder for Suspension 50mg/5ml 50ml bot 40\n\tBeximco\tPedrox Powder for Suspension 50mg/5ml 50ml bot 45\n\tBeximco\tPedrox TAB dr 150mg 30's pack 210\n\tBeximco\tPedrox TAB dr 300mg 20's pack 240\n\tGlobe\tRolid Powder for Suspension 50mg/5ml 50ml bot 45\n\tGlobe\tRolid TAB dr 150mg 50's pack 350\n\tGlobe\tRolid TAB dr 300mg 30's pack 420\n\tIncepta\tPedilid Powder for Suspension 50mg/5ml 50ml bot 50\n\tIncepta\tPedilid TAB dr 150mg 50's pack 350\n\tIncepta\tPedilid TAB dr 300mg 30's pack 420\n\tKemiko\tRotomycin TAB dr 300mg 30's pack 420\n\tNavana\tRyth Powder for Suspension 50mg/5ml 50ml bot 50.19\n\tNavana\tRyth TAB dr 150mg 18's pack 126.54\n\tNavana\tRyth TAB dr 300mg 18's pack 252.90\n\tIndication: Pneumonia, Pharyngitis, Susceptible infections, Sinusitis, Otitis media, Cellulitis,Tonsillitis, Folliculitis, Carbuncles, Prostatitis, Urethritis, Acute and chronic bronchitis, Bronchopneumonia, Furuncles, Pyoderma, Impetigo and infected dermatitis, Cervicitis and salpingitis\n\nDose: Adult: PO 150 mg twice daily or 300 mg once daily for 5-10 days.\n\nPaediatric dose: The dose for children is 2.5 to 5 mg/kg body weight twice a day. \n\n\nContra-indication: Hypersensitivity. Porphyria.\n\nSide effects: Nausea, vomiting, abdominal pain, diarrhoea, weakness, malaise, anorexia, constipation, dyspepsia, flatulence; hepatitis; rashes, headache, dizziness, weakness, changes in blood counts; increased liver enzyme values; eosinophilia; rarely, acute pancreatitis.\n\nPrecaution: Hepatic impairment. Monitor liver function. Prolonged treatment increases risk of hepatotoxicity. History of arrhythmias.\n\nMode of action: May raise serum levels of ciclosporin and digoxin. Increased risk of rhabdomyolysis when used with simvastatin.\n\nPregnancy category: B\n\nInteraction: May raise serum levels of ciclosporin and digoxin. Increased risk of rhabdomyolysis when used with simvastatin.
Rupatadine	\n\n\tAcme Ltd.\tRupastin-10 TAB dr 10mg 10's pack 80\n\tAlco Pharma\tRupaler TAB dr 10mg  \n\tAristopharma\tRupa TAB dr 10mg 30's pack / 50's pack 300 / 500\n\tBeacon\tRupadin TAB dr 10mg 30's pack 300\n\tBeximco\tDuvent Oral Solution 1mg/ml  \n\tBeximco\tDuvent TAB dr 10mg  \n\tBio Pharma Ltd.\tRufecta TAB dr 10mg  \n\tDrug International Ltd.\tDipa TAB dr 10mg 30's pack 180\n\tEskayef Bangladesh Ltd.\tRupaday TAB dr 10mg  \n\tHealthcare\tRosela TAB dr 10 mg  360\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRupamin 				 	 TAB dr 10mg  30's Pack 300 \n\tIncepta\tRupex TAB dr 10mg 30's pack 300\n\tLeon\tRupastar TAB dr 10mg  \n\tNavana\tPaftrol TAB dr 10mg 30's pack 300\n\tNIPRO JMI Pharma\tRupatid TAB dr 10mg 30's pack 300\n\tOpsonin Pharma\tRufast TAB dr 10mg  \n\tOrion Pharma Ltd.\tRupenta TAB dr 10mg  \n\tPharmasia Ltd.\tRunar TAB dr 10mg  \n\tPopular\tAlarup TAB dr 10mg  \n\tRadiant.\tMinista TAB dr 10mg  \n\tSharif\tRupanex TAB dr 10mg 30's pack 300\n\tSomatec\tRupafen TAB dr 10mg 30's pack 300\n\tSquare\tRupatrol TAB dr 10mg 10x3's Pack 300\n\tZiska\tRupin TAB dr 10mg 30's pack 300\n\tZiska\tRupin OS Oral Solution 100 mg/100 ml  \n\tIndication: Allergic rhinitis, Chronic idiopathic urticaria\n\nDose: Adults and adolescents (above 12 years): 10 mg (one tablet) once daily, with or without food. \n\nContra-indication: Hypersensitivity. Avoid alcohol.\n\nSide effects: Headache, somnolence, fatigue/asthenia.\n\nPrecaution: Renal or hepatic insufficiency. May impair ability to drive or operate machinery. Pregnancy, lactation. Elderly, children <12 yr.\n\nMode of action: Increased CNS depressant effects when used with CNS depressants or alcohol.\n\nPregnancy category: Not Classified\n\nInteraction: Increased CNS depressant effects when used with CNS depressants or alcohol.
Saccharin Sodium	\n\n\tSonear Ltd.\tSac Sweet TAB dr 12.5mg 200's pack/300's pack/500's pack 22/33/55\n\tIndication: Artificial sweetener usually used by diabetic patient.\n\nDose: As per advised by a the physician. 1 tab is equivalent in sweetners to 1 tespoon full of sugar.\n\nContra-indication: \n\nSide effects: Saccharin belongs to a class of compounds known as sulfonamides, which can cause allergic reactions in some individuals.\n\nReactions can include:\n\n    Headaches\n    Breathing difficulties\n    Diarrhoea and\n    Skin problems\n\n\nPrecaution: Possibility of allergic reactions. \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Salicylic Acid 0.5%	\n\n\tGeneral\tAcnecare Gel Gel 500 mg/100 gm  \n\tIndication: Acne, Hyperkeratotic and scaling skin conditions\n\nDose: Apply to affected area once daily. Hydrate area for 5 minutes prior to application if possible. Occlude the area at night. Wash off in morning. Salicylic Acid is used in children over 2 years.\n\nContra-indication: It should not be used in any patient known to be sensitive to Salicylic Acid or any other listed ingredients.\n\nSide effects: An allergic reaction (shortness of breath, closing of the throat, swelling of the lips, face or tongue or hives) or severe skin irritation.\n\nPrecaution: For external use only. Avoid contact with eyes and other mucous membranes.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Salicylic Acid 10% + Urea 10%	\n\n\tIndication: Psoriasis, Acne, Eczema, Warts, Dry skin, Keratosis, Xerosis, Corns, Callous\n\nDose: Usual Adult Dose for Foot Care\n\nApply to affected area on feet once or twice daily.\n\nMaximum benefit seen in 7 days.\n\nContra-indication: It should not be used in any patient known to be sensitive to Salicylic Acid or any other listed ingredients.\n\nSide effects:     Mild, temporary burning, itching, irritation, or stinging.\n\n    Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); excessive burning, irritation, itching, peeling, redness, stinging, or tenderness of your skin.\n\n\nPrecaution: For external use only. Avoid contact with eyes and other mucous membranes.\n\nMode of action: urea...Increased excretion of lithium.\n\nPregnancy category: C\n\nInteraction: urea...Increased excretion of lithium.
Salicylic Acid 6% & 12% Topical	\n\n\tEskayef Bangladesh Ltd.\tSalidex 	 Cream 6% 15g 42\n\tIncepta\tKerasol 6% Cream  6% 30g 50\n\tIncepta\tkerasol Cream 12% 20g tube 90\n\tIndication: As 6% Salicylic Acid: Psoriasis, Seborrhoeic dermatitis, Lichen simplex, Chronic atopic dermatitis, Ichthiosis.\n\nAs 12% Salicylic Acid: Warts,Verruca, Corns and Calluses\n\nDose: Apply to affected area once daily. Hydrate area for 5 minutes prior to application if possible. Occlude the area at night. Wash off in morning. Salicylic Acid is used in children over 2 years.\n\nContra-indication: It should not be used in any patient known to be sensitive to Salicylic Acid or any other listed ingredients.\n\nSide effects: An allergic reaction (shortness of breath, closing of the throat, swelling of the lips, face or tongue or hives) or severe skin irritation.\n\nPrecaution: For external use only. Avoid contact with eyes and other mucous membranes.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Salmeterol	\n\n\tAcme Ltd.\tAxinat Inhaler 25mcg 120 doses unit/200 doses unit 125/190\n\tAristopharma\tArobid HFA Inhaler 25mcg 120 inhalations unit 210\n\tBeximco\tBexitrol HFA Inhaler 25mcg 120 puffs 210\n\tBeximco\tBexitrol Inhaler 25mcg 120 inhalations unit 190\n\tDrug International Ltd.\tSeravent HFA Inhalation Aerosol 25 mcg  \n\tSquare\tSalmate 200 DOSE Inhaler 25mcg 200 doses unit 190.72\n\tSquare\tSalmete HFA Inhaler 25mcg 200puffs 210\n\tIndication: Chronic asthma, COPD\n\nDose: Adult: Inhalation Chronic asthma; COPD As metered-dose aerosol or dry powd inhalation:Adults and children over 4 years : 50 micrograms twice daily (two puffs with one minute gap in between every puff ) up to 100 mcg twice daily if needed.\n\nContra-indication: Contraindicated in patients with hypersensitivity to Salmeterol or to the any excipient of this preparation.\n\nSide effects: Fine skeletal muscle tremor especially hands, tachycardia, palpitations, muscle cramps, headache, paradoxical bronchospasm, angioedema, urticaria, hypotension and collapse.\n\nPrecaution: Pregnancy. Arrhythmias, hyperthyroidism, hypertension, DM, myocardial insufficiency, susceptibility to QT-interval prolongation. May cause paradoxical bronchospasm. Not to be used for treatment of acute bronchospasm or patients with deteriorating asthma. Monitor serum potassium concentrations in severe asthma.\n\nMode of action: Diuretics, corticosteroids and xanthines may augment hypokalaemia. Risk of severe hypertension when used with MAOIs, TCAs and other sympathomimetics. Increased susceptibility to cardiac arrhythmias caused by digoxin and other cardiac glycosides.\n\nPregnancy category: C\n\nInteraction: Diuretics, corticosteroids and xanthines may augment hypokalaemia. Risk of severe hypertension when used with MAOIs, TCAs and other sympathomimetics. Increased susceptibility to cardiac arrhythmias caused by digoxin and other cardiac glycosides.
Salmon Oil	\n\n\tIndication: Hypertriglyceridemia, Heart disease, Hyperlipidaemias, High blood pressure, rheumatoid arthritis, Skin healthness\n\nDose:     For high triglycerides: 1-4 grams/day of fish oil.\n    For high blood pressure: Either 4 grams of fish oil or fish oil providing 2.04 grams of EPA and 1.4 grams of DHA per day.\n   For kidney problems related to using cyclosporine to prevent organ transplant rejection: 12 grams/day containing 2.2 grams EPA and 1.4 grams DHA.\n    For reducing the overall risk of death and risk of sudden death in patients with coronary heart disease: Fish oil providing 0.3-6 grams of EPA with 0.6 to 3.7 grams of DHA.\n    For asthma in children: Fish oil providing 17-26.8 mg/kg EPA and 7.3-11.5 mg/kg DHA for reducing symptoms. Maternal ingestion of fish oil 4 grams daily, providing 32% EPA and 23% DHA with tocopherol, during late-phase pregnancy has been used for preventing the development of asthma in children.\n    For preventing childhood allergies: Maternal ingestion of fish oil 4 grams daily, providing 32% EPA and 23% DHA with tocopherol, during late-phase pregnancy.\n    For preventing childhood atopic dermatitis: Maternal ingestion of fish oil 4 grams daily, providing 32% EPA and 23% DHA with tocopherol, during late-phase pregnancy.\n    For treating asthma: 17-26.8 mg/kg EPA and 7.3-11.5 mg/kg DHA.\n    For preventing and reversing the progression of hardening of the arteries: 6 grams/day of fish oil for the first three months, followed by 3 grams/day thereafter.\n    For rheumatoid arthritis: Fish oil providing 3.8 grams/day of EPA and 2 grams/day DHA.\n    For attention deficit-hyperactivity disorder (ADHD): A specific supplement containing fish oil 400 mg and evening primrose oil 100 mg (Eye Q, Novasel) six capsules daily.\n    For preventing miscarriage in women with antiphospholipid antibody syndrome and a history of past miscarriage: 5.1 grams fish oil with a 1.5 EPA:DHA ratio.\n    For painful menstrual periods: A daily dose of EPA 1080 mg and DHA 720 mg.\n    For Raynaudâs syndrome: A daily dose of 3.96 grams EPA and 2.64 grams DHA.\n    For weight loss: A daily serving of 2-7 ounces of fish containing approximately 3.65 grams omega-3 fatty acids (0.66 gram from EPA and 0.60 gram from DHA).\n    For slowing weight loss in patients with cancer: 7.5 grams/day of fish oil providing EPA 4.7 grams and DHA 2.8 grams.\n    For improving movement disorders in children with poor coordination (dyspraxia): Fish oil providing DHA 480 mg combined with 35 mg arachidonic acid and 96 mg gamma-alpha linoleic acid from evening primrose oil, 24 mg thyme oil, and 80 mg vitamin E (Efalex).\n    For developmental coordination disorder in children: Fish oil providing EPA 558 mg and DHA 174 in 3 divided doses.\n    For depression along with conventional antidepressants: Fish oil 9.6 grams/day.\n    To prevent full psychosis from developing in people with mild symptoms: Fish oil 1.2 grams/day.\n    For keeping veins open after coronary bypass surgery: 4 grams/day of fish oil containing EPA 2.04 grams and DHA 1.3 grams.\n    For preventing the collapse of arteries opened by âballoonâ therapy (PTCA): 6 grams/day of fish oil starting one month before PTCA and continuing one month after PTCA, followed by 3 grams of fish oil daily thereafter for six months.\n    For reducing and preventing the long-term continuous rise in blood pressure and to preserve kidney function after heart transplantation: 4 grams/day of fish oil (46.5% EPA and 37.8% DHA).\n    For preventing clotting after placement of a tube for dialysis: 6 grams/day of fish oil.\n    For preserving kidney function in patients with severe IgA nephropathy: 4-8 grams/day of fish oil has been used.\n    For combined high triglycerides and high cholesterol: Fish oil providing EPA 1800-2160 mg and DHA 1200-1440 mg combined with garlic powder 900-1200 mg/day has been used to lower total cholesterol, LDL, triglycerides, and the ratios of total cholesterol to HDL, and LDL to HDL.\n    For salicylate intolerance: Fish oil 10 grams daily.\n\nContra-indication: Hypersensitivity\n\nSide effects:  High doses of fish oil might also reduce the immune systemâs activity, reducing the bodyâs ability to fight infection. This is a special concern for people taking medications to reduce their immune systemâs activity (organ transplant patients, for example) and the elderly.\n\nFish oil can cause side effects including belching, bad breath, heartburn, nausea, loose stools, rash, and nosebleeds. Taking fish oil supplements with meals or freezing them can often decrease these side effects.\nFish or seafood allergy: Some people who are allergic to seafood such as fish might also be allergic to fish oil supplements. There is no reliable information showing how likely people with seafood allergy are to have an allergic reaction to fish oil; however, until more is known advise patients allergic to seafood to avoid or use fish oil supplements cautiously.\n\nBipolar disorder: Taking fish oil might increase some of the symptoms of this condition.\n\nDepression: Taking fish oil might increase some of the symptoms of this condition.\n\nDiabetes: There is some concern that taking high doses of fish oil might make the control of blood sugar more difficult.\n\nHigh blood pressure: Fish oil can lower blood pressure and might cause blood pressure to drop too low in people who are being treated with blood pressure-lowering medications.\n\nHIV/AIDS and other conditions in which the immune system response is lowered: Higher doses of fish oil can lower the bodyâs immune system response. This could be a problem for people whose immune system is already weak.\n\nFamilial adenomatous polyposis: There is some concern that fish oil might further increase the risk of getting cancer in people with this condition.\n\nPrecaution: Liver disease: Fish oil might increase the risk of bleeding.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Salsalate	\n\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Pain and fever\n\nDose: Osteoarthritis, Rheumatoid arthritis, Pain and fever\nAdult: Up to 3 g daily in divided doses.\n\nContra-indication: Haemophilia, haemorrhagic disorders, gout, hypersensitivity to aspirin or NSAIDs. Children <12 yr. Pregnancy (3rd trimester) and lactation. Severe renal or hepatic impairment.\n\nSide effects: GI symptoms, hypersensitivity reactions, skin eruptions, angioedema, weakness, rhinitis and dyspnoea, hypoprothrombinaemia. Hepatotoxicity, renal impairment, iron-deficiency anaemia, occult bleeding. Local irritation (rectally); Reye's syndrome.\nPotentially Fatal: Paroxysmal bronchospasm, thrombocytopenia, leukopenia.\n\nPrecaution: Peptic ulcers; asthma, allergic disorders. Impaired hepatic or renal function. Dehydrated patients; uncontrolled hypertension. May cause acute haemolytic anaemia in patients with G6PD deficiency.\n\n\nMode of action: May increase risk of liver damage when used with gold compounds. GI effects may be enhanced with alcohol or concurrent use with corticosteroids. May increase activity of coumarin anticoagulants, sulfonylureas, zafirlukast, methotrexate, phenytoin and valproate. May decrease the activity of probenecid and sulfinpyrazone.\nPotentially Fatal: Increased risk of adverse effects when used with other NSAIDs.\n\nPregnancy category: D\n\nInteraction: May increase risk of liver damage when used with gold compounds. GI effects may be enhanced with alcohol or concurrent use with corticosteroids. May increase activity of coumarin anticoagulants, sulfonylureas, zafirlukast, methotrexate, phenytoin and valproate. May decrease the activity of probenecid and sulfinpyrazone.\nPotentially Fatal: Increased risk of adverse effects when used with other NSAIDs.
Saxagliptin	\n\n\tDrug International Ltd.\tSixtin TAB dr 2.5mg  \n\tDrug International Ltd.\tSixtin TAB dr 5mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tGlyza 2.5 TAB dr 2.5mg 30's pack 900\n\tIbn Sina Pharmaceutical Ind. Ltd.\tGlyza 5 TAB dr 5mg 30's pack 1500\n\tIndication: Type 2 diabetes\n\nDose: Diabetes Mellitus Type 2\n\n2.5-5 mg PO qDay\nDosage Modifications\n\nCombination therapy: May need to reduce dosage of sulfonylurea or other insulin secretagogues when administered in combination\n\nCoadministration with strong CYP450 3A4/5 inhibitors: Not to exceed 2.5 mg PO qDay\n\nRenal impairment\n\n    CrCl >50 mL/min: No dose adjustment required\n    CrCl <50 mL/min: Not to exceed 2.5 mg PO qDay\n    ESRD requiring hemodialysis: Not to exceed 2.5 mg PO qDay administered postdialysis\n    ESRD requiring peritoneal dialysis: Not studied\n\n\nContra-indication: Documented hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions)\n\nSide effects: 1-10% (selected)\n\nUrinary tract infection (7%)\n\nHeadache (7%)\n\nHypersensitivity-related events (<4%; eg, urticaria, facial edema)\n\nPeripheral edema (<4%; increased incidence when coadministered with thiazolidinediones)\n\nUpper respiratory tract infection (3%)\n\nGastroenteritis (2%)\n\nHypoglycemia (1.6%)\nFrequency Not Defined\n\nIncreased creatinine phosphokinase\n\nIncreased creatinine\n\nIdiopathic thrombocytopenic purpura rash\n\n\nPrecaution: Renal impairment\n\nDecrease dose with strong CYP450 3A4/5 inhibitors\n\nCoadministration with thiazolidinediones (eg, rosiglitazone, pioglitazone) increases risk for peripheral edema\n\nPancreatitis reported with saxagliptin; monitor for signs and symptoms and discontinue if pancreatitis suspected\n\nSerious hypersensitivity reactions with saxagliptin reported (typically within the first 3 months of therapy)\n\nHistory of angioedema\n\nCoadministration with a sulfonylurea or with insulin may increase hypoglycemia; monitor closely and adjust sulfonylurea and/or insulin dose accordingly\n\nCardiovascular risks\n\n    The FDA is investigating the risk of heart failure among patients with type 2 DM taking saxagliptin\n\nMode of action:  	Strong CYP3A4/5 inhibitors (eg ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir & telithromycin).\n\nPregnancy category: B\n\nInteraction:  	Strong CYP3A4/5 inhibitors (eg ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir & telithromycin).
Secnidazole	\n\n\tACI\tSezol DS TAB dr 1000mg 10's pack 170.50\n\tAcme Ltd.\tPronil TAB dr 500mg 8's pack 69.04\n\tAcme Ltd.\tPronil DS TAB dr 1gm 8's pack 128.48\n\tIncepta\tSecnizol DS TAB dr 1gm 6's pack 96\n\tSanofi Aventis (BD) Ltd.\tSecnidal DS TAB dr 1gm 10's pack 253.80\n\tSquare\tSecnid Suspension 500mg/10ml 500mg(10ml) bot 25.10\n\tSquare\tSecnid DS TAB dr 1gm 10's pack 160.67\n\tIndication: Giardiasis, Amoebiasis, Trichomoniasis\n\nDose: Adult: PO Invasive amoebiasis 1.5 g/day for 5 days. Amoebiasis; Giardiasis; Trichomoniasis Single dose of 2 g.\n\nContra-indication: Hypersensitivity; pregnancy (1st trimester) and lactation.\n\nSide effects: Nausea, gastralgia, change of taste, metallic taste, stomatitis, urticaria, rashes, leucopenia. Rarely vertigo, moderate neurological, digestive disturbances.\n\nPrecaution: Avoid alcohol and disulfiram. Avoid in patients with history of blood disorders.\n\nMode of action: Concurrent disulfiram admin may cause psychotic reactions. Disulfiram-like reactions with alcohol. Cimetidine may prolong half-life.\nPotentially Fatal: May potentiate anticoagulant effect of warfarin and increase risk of haemorrhage.\n\nPregnancy category: Not Classified\n\nInteraction: Concurrent disulfiram admin may cause psychotic reactions. Disulfiram-like reactions with alcohol. Cimetidine may prolong half-life.\nPotentially Fatal: May potentiate anticoagulant effect of warfarin and increase risk of haemorrhage.
Sennosides	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tLaxenna TAB dr 12mg 250's pack 313.68\n\tIndication: Constipation, Bowel evacuation\n\nDose: Constipation Adult: 15-30 mg (as total sennosides) 1-2 times daily.\nChild: 2-6 yr: 3.75-7.5 mg once daily in the morning; 6-12 yr: 7.5-15 mg once daily at night or in the morning; ?12 yr: 15-30 mg at bedtime.\n\nBowel evacuation Adult: 105-157.5 mg of sennosides on the day before the procedure. May be given as a liquid preparation.\n\nContra-indication: Nausea or vomiting, undiagnosed abdominal pain, intestinal obstruction.\n\nSide effects: Mild abdominal discomfort e.g. colic and cramps; diarrhoea, hypokalaemia and atonic non-functioning colon (prolonged use); reversible melanosis coli (chronic use). May colour the urine yellowish-brown at acidic pH or red at alkaline pH.\n\nPrecaution: Inflammatory bowel disease. Avoid prolonged use.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Sertraline Hydrochloride	\n\n\tACI\tChear TAB dr 100mg 30's pack 302.10\n\tACI\tChear TAB dr 25mg 100's pack 302\n\tACI\tChear TAB dr 50mg 50's pack 302\n\tAmbee\tSera TAB dr 25mg 50's pack 201\n\tBeximco\tAtralin TAB dr 50mg 50's pack 250\n\tDrug International Ltd.\tSertal TAB dr 50mg 50's pack 250\n\tGeneral\tSetra TAB dr 100mg 50's pack 301.20\n\tGeneral\tSetra TAB dr 25mg 50's pack 150.50\n\tGeneral\tSetra TAB dr 50mg 50's pack 301\n\tHealthcare\tAndep TAB dr 50mg 50's pack 275\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSerlin TAB dr 25mg 100's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSerlin TAB dr 50mg 30's pack 180\n\tIncepta\tRepose 25 TAB dr 25mg 50's pack 150\n\tIncepta\tRepose 50 TAB dr 50mg 50's pack 300\n\tIncepta\tRepose 100 TAB dr 100mg 30's pack 285\n\tNovartis (Bangladesh) Ltd.\tSerolux TAB dr 100mg 30's pack 333\n\tNovartis (Bangladesh) Ltd.\tSerolux TAB dr 25mg 50's pack 155\n\tNovartis (Bangladesh) Ltd.\tSerolux TAB dr 50mg 50's pack 305\n\tOpsonin Pharma\tMudiral TAB dr 100mg 30's pack 270\n\tOpsonin Pharma\tMudiral TAB dr 25mg 50's pack 150\n\tOpsonin Pharma\tMudiral TAB dr 50mg 50's pack 300\n\tPacific\tSartra TAB dr 50mg 50's pack 300\n\tRenata\tTraser TAB dr 100mg 50's pack 500\n\tRenata\tTraser TAB dr 25mg 50 150\n\tRenata\tTraser TAB dr 50mg 50's pack 250\n\tSilva\tTralin TAB dr 100mg 50's pack 351.32\n\tSilva\tTralin TAB dr 25mg 100's pack 250.94\n\tSilva\tTralin TAB dr 50mg 50's pack 200.75\n\tSun Pharmaceutical (Bangladesh) Ltd.\tZosert TAB dr 100mg 30's pack 300\n\tSun Pharmaceutical (Bangladesh) Ltd.\tZosert TAB dr 25mg 50's pack 150\n\tSun Pharmaceutical (Bangladesh) Ltd.\tZosert TAB dr 50mg 50's pack 277.50\n\tWhite Horse Pharma\tSelotin TAB dr 50mg 30's pack 150\n\tIndication: Depressive illness, Panic disorder, Premenstrual dysphoric disorder, Post-traumatic stress disorder, Obsessive-compulsive disorder, Social anxiety disorder\n\nDose: Depressive illness :Initially 50 mg daily, increased if necessary by increments of 50 mg over several weeks to maximum 200 mg daily. Usual maintenance dose is 50 mg daily. \n\nChild and adolescent less than 18 years are not recommended.\n\nObsessive-compulsive disorder :Adult and adolescent over 13 years- Initially 50 mg daily, increased if necessary in steps of 50 mg over several weeks. Usual dose range is 50-200 mg daily. \n\nChild (6-12 years) - Initially 25 mg daily, increased to 50 mg daily after 1 week, further increased if necessary in steps of 50 mg at intervals of at least 1 week (maximum 200 mg daily).\n\nPost-traumatic stress disorder: Initially 25 mg daily, increased after 1 week to 50 mg daily; if response is partial and if drug is tolerated, dose can be increased in steps of 50 mg over several weeks to maximum 200 mg daily. \n\nChild and adolescent less than 18 years are not recommended. \n\nContra-indication: Sertraline is contraindicated in patients with a known hypersensitivity to Sertraline or any of the excipients of drug.\n\nSide effects: Sertraline may cause side effects like upset stomach, diarrhoea, constipation, vomiting, dry mouth, loss of appetite, weight changes, drowsiness, dizziness, headache, pain, burning or tingling in the hands or feet, excitement, sore throat etc.\n\nPrecaution: Precaution should be taken in case of liver problems, kidney diseases, seizures, heart problems and any allergies. This drug may cause dizziness or drowsiness. Caution should be taken in activities requiring alertness such as driving or using machinery. Caution is advised while using this product in the elderly because they may be more sensitive to the effects of the drug. Do not take this drug if you have taken monoamine oxidase inhibitor in the last five weeks.\n\nMode of action: May increase risk of delirium when used with antimuscarinics. Increased risk of extrapyramidal symptoms and neuroleptic malignant syndrome when used with aripiprazole. Serum levels may be reduced by carbamazepine. Concurrent use with dihydroergotamine or linezolid may lead to serotonin syndrome. May increase serum levels of lamotrigine and risk of toxicity. May increase serum levels of olanzapine, pimozide, risperidone, methadone, clozapine and amiodarone. Plasma levels may be increased by cimetidine and ritonavir. May increase the anticoagulant activity of warfarin and acenocoumarol.\n\nPotentially Fatal: Concomitant admin with MAOIs can result in serious serotonin syndrome.\n\nPregnancy category: C\n\nInteraction: May increase risk of delirium when used with antimuscarinics. Increased risk of extrapyramidal symptoms and neuroleptic malignant syndrome when used with aripiprazole. Serum levels may be reduced by carbamazepine. Concurrent use with dihydroergotamine or linezolid may lead to serotonin syndrome. May increase serum levels of lamotrigine and risk of toxicity. May increase serum levels of olanzapine, pimozide, risperidone, methadone, clozapine and amiodarone. Plasma levels may be increased by cimetidine and ritonavir. May increase the anticoagulant activity of warfarin and acenocoumarol.\n\nPotentially Fatal: Concomitant admin with MAOIs can result in serious serotonin syndrome.
Sevelamer Hydrochloride/Carbonate	\n\n\tAcme Ltd.\tSevel TAB dr 400mg 6's pack 270\n\tIncepta\tRenophos TAB dr 400mg 20's pack 900\n\tSanofi Aventis (BD) Ltd.\tRenvela TAB dr 800 mg 30's pack 1850.10\n\tUnimed & Unihealth Manufacturers Ltd.\tRenosev TAB dr 800mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tRenosev Powder For Suspension 800mg  \n\tIndication: Hyperphosphataemia\n\nDose: Adult: PO: Patients not taking a Phosphate Binder: The recommended starting dose of Sevelamer is 800 to 1600 mg, which can be administered as two to four 400 mg Sevelamer tablets, with meals based on serum phosphorus level.\nRecommendation for the patients with hyperphosphatemia is given below-\n\nTable 1.  Starting dose for dialysis patients not taking any phosphate binder.\n\nSerum Phosphorus------------Sevelamer 400 mg\n> 5.5 and < 7.5 mg/dL ----2 tablets three times daily with meals\n7.5 and < 9.0 mg/dL ----3 tablets three times daily with meals\n>9.0 mg/dL-----------------4 tablets three times daily with meals\n\nTable 2.  Starting dose for dialysis patients switching from calcium acetate to Sevelamer.\n\nCalcium Acetate 667 mg---------- Sevelamer 400 mg\n(Tablets per meal)------------------ (Tablets per meal)\n1 tablet--------------------------------2 tablets\n2 tablets------------------------------3 tablets\n3 tablets-----------------------5 tablets\n\nDose titration for all patients taking Sevelamer:  Dosage should be adjusted based on the serum phosphorus concentration with a goal of lowering serum phosphorus to 5.5 mg/dl or less. The dose may be increased or decreased by one tablet per meal at two week intervals as necessary.\n\nTable 3. Dose titration guideline\nSerum Phosphorus -------------Sevelamer dose\n> 5.5 mg/dL ----------------------Increase 1 tablet per meal at 2 week intervals\n3.5 - 5.5 mg/dL ------------------Maintain current dose\n< 3.5 mg/dL ----------------------Decrease 1 tablet per meal\n\n\nContra-indication: Hypophosphatemia or bowel obstruction.\n\nSide effects: Dyspepsia, peritonitis, diarrhea, nausea, constipation, pruritus, abdominal distension, vomiting, fatigue, anorexia, arthralgia and less commonly ileus, bowel obstruction and bowel perforation.\n\nPrecaution: Dysphagia, swallowing disorders, severe GI motility disorders, or major GI tract surgery. Pregnancy and lactation. Monitor serum levels of calcium, bicarbonate and chloride. To be taken with meals and tablets should be swallowed intact.\n\nMode of action: May decrease absorption of ciprofloxacin, ciclosporin, mycophenolate, tacrolimus and levothyroxine. Sevelamer should be given 3 hr before or 1 hr after taking other drugs to minimise potential pharmacokinetic interaction.\n\nPregnancy category: C\n\nInteraction: May decrease absorption of ciprofloxacin, ciclosporin, mycophenolate, tacrolimus and levothyroxine. Sevelamer should be given 3 hr before or 1 hr after taking other drugs to minimise potential pharmacokinetic interaction.
Sevoflurane	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tSevorane Inhaler  250ml bot 14325.45\n\tIndication: General anaesthesia\n\nDose: Adult: Inhalation Via a calibrated vaporiser: Induction: Up to 5% v/v w/ oxygen or a mixture of oxygen and nitrous oxide. Maintenance: 0.5-3% v/v w/ or w/o nitrous oxide.\n\nContra-indication: Known or suspected susceptibility to malignant hyperthermia. Previous hypersensitivity.\n\nSide effects: Cardiorespiratory depression, hypotension, malignant hyperthermia, agitation, laryngospasm, increased cough, salivation, acute renal failure, shivering, nausea, vomiting; rarely, dystonic movements in children, postoperative hepatitis, and seizure-like activity.\n\n\nPrecaution: Raised intracranial pressure; cardiac, respiratory, renal, or hepatic impairment, elderly or obese patients. Maintenance of haemodynamic stability is important in patients with coronary artery disease. Concomitant use with adrenaline or other sympathomimetics. Pregnancy and lactation. May increase serum potassium levels.\n\nMode of action: May enhance effect and duration of competitive neuromuscular blockers. Metabolism and toxicity increased by cytochrome P450 isoenzyme CYP2E1 inducers including isoniazid and alcohol. Increased risk of cardiac arrhythmias when used with epinephrine or norepinephrine.\n\nPregnancy category: B\n\nInteraction: May enhance effect and duration of competitive neuromuscular blockers. Metabolism and toxicity increased by cytochrome P450 isoenzyme CYP2E1 inducers including isoniazid and alcohol. Increased risk of cardiac arrhythmias when used with epinephrine or norepinephrine.
Sibutramine Hydrochloride	\n\n\tACI\tSibuthin CAP 5mg 24's pack 120\n\tBeximco\tSibulin CAP 5mg 60's pack 301.20\n\tSquare\tObenil CAP 5mg 30's pack 150.43\n\tUnimed & Unihealth Manufacturers Ltd.\tRedux TAB dr 5mg 30's pack 150\n\tIndication: Obesity\n\nDose: The recommended starting dose of  (sibutramine hydrochloride monohydrate) is 10 mg administered once daily with or without food. \n\nIf there is inadequate weight loss, the dose may be titrated after four weeks to a total of 15 mg once daily. \n\nThe 5 mg dose should be reserved for patients who do not tolerate the 10 mg dose. Blood pressure and heart rate changes should be taken into account when making decisions regarding dose titration. \n\nDoses above 15 mg daily are not recommended. \n\n\n\nContra-indication:     With a history of coronary artery disease (e.g., angina, history of myocardial infarction), congestive heart failure, tachycardia, peripheral arterial occlusive disease, arrhythmia or cerebrovascular disease (stroke or transient ischemic attack (TIA)) (see WARNINGS).\n    with inadequately controlled hypertension > 145/90 mm Hg (see WARNINGS).\n    over 65 years of age.\n    receiving monoamine oxidase inhibitors (MAOIs) (see WARNINGS).\n    with hypersensitivity to sibutramine or any of the inactive ingredients of MERIDIA (sibutramine hydrochloride monohydrate) .\n    who have a major eating disorder (anorexia nervosa or bulimia nervosa).\n    taking other centrally acting weight loss drugs.\n\n\nSide effects: The most common events were dry mouth, anorexia, insomnia, constipation and headache. \n\nPrecaution: Pulmonary Hypertension\nSeizures\nBleeding\nGallstones\nRenal Impairment\nHepatic Dysfunction\nCarcinogenesis, Mutagenesis, Impairment of Fertility\nCarcinogenicity\nImpairment of Fertility\n\n\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Sildenafil	\n\n\tACI\tAdegra TAB dr 100mg 4's pack 200.60\n\tACI\tAdegra TAB dr 25mg 4's pack 80.24\n\tACI\tAdegra TAB dr 50mg 4's pack 120.36\n\tAcme Ltd.\tAcmegra TAB dr 25mg  \n\tAcme Ltd.\tAcmegra TAB dr 50mg  \n\tAcme Ltd.\tAcmegra TAB dr 100mg  \n\tAlco Pharma\tX-cite 50 TAB dr 50mg 4's pack 120\n\tAlco Pharma\tX-cite 100 TAB dr 100mg 4's pack 200\n\tApex\tSupergra-50 TAB dr 50mg 4's pack 120\n\tAristopharma\tV-Gra TAB dr 100mg 10's pack 500\n\tAristopharma\tV-Gra TAB dr 25mg 10's pack 160\n\tAristopharma\tV-Gra TAB dr 50mg 10's pack 300\n\tBeximco\tEnegra TAB dr 100mg 4's pack \n\tBeximco\tEnegra TAB dr 50mg 4's pack \n\tBio Pharma Ltd.\tImmense TAB dr 25mg 4's pack 72\n\tBio Pharma Ltd.\tImmense TAB dr 50mg 4's pack 100\n\tConcord\tPanagra TAB dr 50mg  \n\tConcord\tPanagra TAB dr 100mg  \n\tDelta Pharma\tNiagra TAB dr 100mg 8's pack 320\n\tDelta Pharma\tNiagra TAB dr 25mg 8's pack 120\n\tDelta Pharma\tNiagra TAB dr 50mg 8's pack 200\n\tEskayef Bangladesh Ltd.\tAggra TAB dr 100mg 100ml 200\n\tEskayef Bangladesh Ltd.\tAggra TAB dr 50mg 4's pack 120\n\tEuro Pharma Ltd.\tVegara TAB dr 50mg  \n\tEuro Pharma Ltd.\tVegara TAB dr 100mg  \n\tGeneral\tPeak TAB dr 100mg 4's pack 200\n\tGlobe\tTrigger DS TAB dr 100mg  \n\tHealthcare\tEnigma TAB dr 25mg  \n\tHealthcare\tEnigma TAB dr 100mg  \n\tHealthcare\tEnigma TAB dr 50mg  \n\tIncepta\tSilagra TAB dr 100mg 4's pack 200\n\tIncepta\tSilagra TAB dr 50mg 4's pack 120\n\tIncepta\tSilagra TAB dr 25mg  \n\tMedicon\tViara TAB dr 50mg 4's pack 120\n\tMedicon\tViara TAB dr 100mg 4's pack 200\n\tNavana\tEnjofil TAB dr 25mg 4's pack \n\tNavana\tEnjofil TAB dr 50mg 4's pack \n\tNavana\tEnjofil TAB dr 100mg 4's pack \n\tNIPRO JMI Pharma\tDanafil TAB dr 25mg  \n\tNIPRO JMI Pharma\tDanafil TAB dr 50mg  \n\tNIPRO JMI Pharma\tDanafil TAB dr 100mg  \n\tNovelta Bestway\tNovagra TAB dr 25mg  \n\tNovelta Bestway\tNovagra TAB dr 50mg  \n\tOpsonin Pharma\tViax TAB dr 50mg 4's pack 105.56\n\tOpsonin Pharma\tViax TAB dr 100mg 10x2's pack 175.92\n\tOrion Pharma Ltd.\tFulfeel TAB dr 50mg 8's pack 240\n\tPacific\tActiva TAB dr 100mg 4's pack 160\n\tPacific\tActiva TAB dr 50mg 4's pack 100\n\tRenata\tErecta TAB dr 100mg 4's pack 200\n\tRenata\tErecta TAB dr 50mg 4's pack 120\n\tSquare\tVigorex TAB dr 100mg 4's pack 200\n\tSquare\tVigorex TAB dr 50mg 20's pack 400\n\tSquare\tVigorex TAB dr 25mg  \n\tSun Pharmaceutical (Bangladesh) Ltd.\tEdegra 50 TAB dr 50mg  \n\tSun Pharmaceutical (Bangladesh) Ltd.\tEdegra 100 TAB dr 100mg 4 tab 200\n\tUnimed & Unihealth Manufacturers Ltd.\tViamax TAB dr 25mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tViamax TAB dr 50mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tViamax TAB dr 100mg  \n\tWhite Horse Pharma\tYogra TAB dr 50mg  \n\tWhite Horse Pharma\tYogra TAB dr 100mg  \n\tFaruk Pharmaceutical\tNufa TAB dr 40mg  \n\tIndication: Altitude sickness, Pulmonary arterial hypertension, Erectile dysfunction\n\nDose: Oral\nErectile dysfunction\nAdult: 50 mg about 1 hr before sexual intercourse. May adjust dose depending on penile response. Max: 100 mg/dose and not to be taken > once in 24 hr.\nElderly: >65 yr: Lower initial dose at 25 mg.\n\nRenal impairment:\nCrCl (ml/min)	\n<30	Initially, 25 mg.\n\nHepatic impairment: Initially, 25 mg.\n\nContra-indication: Hypersensitivity. Patients concurrently or intermittently using organic nitrates in any form.\n\nSide effects: Headache, flushing, respiratory tract infection, angina pectoris, AV block, migraine, syncope, tachycardia, postural hypotension, MI, cerebral thrombosis, cardiac arrest, paraesthesia, tremor, depression, herpes simplex, skin ulcer, oesophagitis, abnormal LFT, rectal haemorrhage, hypoglycaemic reaction, arthritis, deafness, retinal vascular disease, photosensitivity, accidental fall.\n\nPrecaution: Caution when used in patients with anatomical deformation of penis or conditions that may predispose them to priapism (e.g. sickle cell anaemia, myeloma, or leukaemia). Mild, transient, dose-related impairment of colour discrimination (blue/green) may occur. Hepatic or severe renal impairment, bleeding disorders, active peptic ulceration, hypotension, recent history of stroke, MI, arrhythmias, unstable angina, heart failure or retinal disorders. May cause sudden loss or decrease in hearing.\n\nMode of action: Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.\nPotentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.\n\nPregnancy category: B\n\nInteraction: Inhibitors of CYP3A4 such as cimetidine and erythromycin are likely to reduce sildenafil clearance. CYP3A4 inducers such as rifampicin may decrease the plasma concentrations of sildenafil. Symptomatic hypotension when used with ?-blockers. Plasma concentrations are increased by ritonavir.\nPotentially Fatal: May potentiate hypotensive effects of of organic nitrates and nicorandil.
Silver Sulphadiazine 1% Topical	\n\n\tACI\tSibalyn Cream  1% 25gm  tube/250gm  tube 40.12/225.85\n\tAlco Pharma\tDazine 1% Cream   25gm  tube250s pack500s pack 30 / 202.30 / 380\n\tAristopharma\tSilvadazin 1% Cream   25gm  tube/250gm  tube/500gm  tube 35 /225/ 425\n\tBeximco\tBurnsil 1% Cream   25gm  tube 35\n\tChemist Ltd.\tSilvazin 1% Cream   25gm  tube 24\n\tCosmic Chemical Industries Ltd.\tFlamzin 1% Cream   25gm  tube 25\n\tDoctor's Chemicals Works Ltd.\tBentol 1% Cream   20gm  tube 28\n\tG. A. Company Ltd.\tSilverzine 1% Cream   25gm  tube/250s pack  40 / 202.29\n\tGonoshasthaya\tG-Silver sulphadiazine Cream 1% 25 gm tube 20.08\n\tGonoshasthaya\tG-Silver sulphadiazine. Cream 1% 250 gm tube 196\n\tJayson\tSilcream 1% Cream   25gm  tube/250gm pot/500gm pot 35 /225 /425\n\tOpsonin Pharma\tNeozine 1% Cream   25gm  tube 30\n\tPacific\tEburn Cream 1 %  \n\tPharmadesh Ltd.\tSilburn 1% Cream   20gm  tube 31.26\n\tPharmasia Ltd.\tMedizen Cream   25gm  tube 35\n\tShamsul Al-Amin\tDersa 1% Cream   25gm  tube 24\n\tSquare\tBurna 1% Cream  1 % 25gm  tube 35.14\n\tLek dd Ljubljana Pharmaceutical &Chemical Co., Slovenia\tDermazin Cream 1gm/100gm 1's pack 35\n\tIndication: Cuts, Wounds, Severe burns, Post-operative wound dressing, Bed sores\n\nDose: Adult: Topical As 1% cream: Apply onto affected area 1-2 times/day.\n\nBurns: The burn wound should be cleaned and  cream applied over all the affected areas to a depth of 3-5mm.  Where necessary, the cream should be re-applied to any area from which it has been removed by patient activity. In burns,  cream should be re-applied at least every 24 hours or more frequently if the volume of exudate is large.\n\nHand burns: Before application of SibalynÂ® cream to the burn, the whole hand should be enclosed in a clear plastic bag or glove . The patient should be encouraged to move the hand and fingers. The dressing should be changed when an excessive amount of exudate has accumulated in the bag.\n\nLeg Ulcers/Pressure Sores: The cavity of the ulcer should be filled with  Cream to a depth of at least 3-5mm. As  Cream can cause maceration of normal skin on prolonged contact, care should be taken to prevent spread onto non-ulcerated areas. Application of Cream should be followed by an absorbent pad or gauze dressing, with further application of pressure bandaging as appropriate for the ulcer.The dressings should normally be changed daily but for wounds which are less exudative, less frequent changes (every 48 hours) may be acceptable. \n\nContra-indication: Silver sulfadiazine cream is contraindicated in patients known to be hypersensitivity to silver sulphonamide or to other components of the preparation such as cetyl alcohol or propylene glycol. Because sulphonamide therapy is known to increase the possibility of kernicterus, silver sulphadiazine cream should not be used in pregnant women at term, in premature infants or in infants during the first months of life. It should not be used if hepatic and renal functions become impaired or if the condition of porphyria is suspected.\n\nSide effects: The most common sides effects are allergic reactions including burning, itching and rashes; argyria reported following prolonged use. Transient leucopenia may occur in patients receiving silver sulfadiazine therapy.\n\nPrecaution: Silver sulfadiazine cream should be used with caution in the presence of significant hepatic or renal impairment or if the condition of porphyria is suspected. Caution of use is required in patients known to be sensitive to systemic sulphonamides and in individuals known to have glucose-6-phosphate dehydrogenase deficiency and concomitant use with topical proteolytic enzymes. Use of silver sulfadiazine cream may delay separation of burn eschar and may alter the appearance of the burn wounds.\n\nMode of action: Potentiates antidiabetic effect of sulphonylureas. Not antagonised by PABA.\n\nPregnancy category: B\n\nInteraction: Potentiates antidiabetic effect of sulphonylureas. Not antagonised by PABA.
Simethicone	\n\n\tACI\tSimet Paediatric Drops 67mg/ml 15ml drop 30.20\n\tAcme Ltd.\tFlatunil Paediatric Drops 67 mg/ml 15ml bot \n\tAlco Pharma\tSimecol Paediatric Drops 67mg/ml 15ml drop 28\n\tAmico Ltd.\tAeropac Paediatric Drops 67mg/ml 15ml drop 25\n\tBeximco\tNeodrop Paediatric Drops 67mg/ml 15ml drop 30\n\tDrug International Ltd.\tSemecon Paediatric Drops 67mg/ml 15ml drop 35\n\tEdruc Ltd.\tOro-Cure Paediatric Drops 67mg/ml 15ml drop 30\n\tEskayef Bangladesh Ltd.\tGasnil Paediatric Drops 67mg/ml 15ml drop 30\n\tGlobe\tPedigas Paediatric Drops 67mg/ml 15ml drop 30\n\tIncepta\tLefoam Paediatric Drops 67mg/ml 15ml drop 30\n\tNavana\tSimicon Paediatric Drops 67mg/ml 15ml drop 30.11\n\tOpsonin Pharma\tFlatulex Paediatric Drops 67mg/ml 15ml drop 26.49\n\tOrion Pharma Ltd.\tPedicon Paediatric Drops 67mg/ml 10ml drop/20ml drop 25.09/30.11\n\tSquare\tFlacol Paediatric Drops 67mg/ml 15ml drop 30.11\n\tSquare\tFlacol Chewable TAB dr 40mg 50's pack 35\n\tIndication: Peptic ulcer, Infantile colic, Upper GI bloating, Functional dyspepsia, Spastic or irritable colon\n\nDose: Simethicone drops should be taken after meals and at bedtime or as directed by the physician. \n\nChildren younger than 2 years of age: 20 mg (0.3 ml drops) 4 times daily up to 240 mg/day (3.6 ml drops).\nChildren 2 to12 years of age: 40 mg (0.6 ml drops) 4 times daily.\n\nAdults and children older than 12 years of age: 40 to 80 mg (0.6 to 1.2 ml drops) 4 times daily up to 500 mg/day (7.5 ml drops).\n\nContra-indication: There is no information about the contraindication of Simethicone.\n\nSide effects: Simethicone is physiologically inert and no adverse effect has been reported after oral ingestion.\n\nPrecaution: More than 12 doses per day should not be used, except under the advice and supervision of a physician. Keep the medicine out of the reach of children.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Simvastatin	\n\n\tACI\tRecol TAB dr 10mg 20's pack 200\n\tAcme Ltd.\tSimvatin TAB dr 10mg 20's pack 220.80\n\tAcme Ltd.\tSimvatin TAB dr 20mg 10's pack 180.60\n\tAlbion Ltd.\tSimvastatin TAB dr 10 mg 20's pack \n\tBeximco\tAvastin TAB dr 10mg 30's pack 451\n\tDrug International Ltd.\tNovastin TAB dr 10mg 30's pack 330\n\tIncepta\tVastocor TAB dr 10mg 30's pack 360\n\tNovartis (Bangladesh) Ltd.\tSimplaqor TAB dr 10mg 30's pack \n\tNovartis (Bangladesh) Ltd.\tSimplaqor TAB dr 20mg 30's pack \n\tRenata\tZostin TAB dr 10mg 30's pack 424.80\n\tSquare\tSimacor TAB dr 10mg 30's pack 301.24\n\tIndication: Hyperlipidaemias, stroke prevention\n\nDose: Adult: PO Hyperlipidaemias Initial: 10-20 mg/day. May adjust dose at intervals of at least 4 wk. Max: 80 mg/day. \n\nCV risk reduction In high-risk patients: 20-40 mg once daily. Moderate-risk patients: 10 mg once daily.\n\nContra-indication: Acute liver disease or unexplained persistent elevations of serum transaminases. Pregnancy, lactation. Porphyria. Patients of Chinese descent should not take 80 mg dose w/ lipid-modifying dose of niacin-containing products (?1 g/day).\n\nSide effects: Headache, nausea, flatulence, heartburn, abdominal pain, diarrhoea/constipation, dysgeusia; dose-related myopathy (e.g. myalgia, muscle weakness and dark urine); serum transaminases and CPK elevations; hypersensitivity; lens opacities; blurring of vision; dizziness; sexual dysfunction; insomnia; depression and upper respiratory symptoms.\nPotentially Fatal: Severe rhabdomyolysis with acute renal failure.\n\nPrecaution: History of liver disease. Increased risk of rhabdomyolysis in severe infection, hypotension, major surgical trauma, uncontrolled seizures or severe metabolic, endocrine and electrolyte disorder. Alcoholism; premenarcheal females; children <10 yr. Discontinue treatment if there is marked or persistent increase in serum-aminotransferase concentrations.\n\nMode of action: May increase bleeding risk w/ anticoagulants. Reduced serum levels w/ bosentan, efavirenz and rifampicin. Increased risk of myopathy and rhabdomyolysis w/ colchicine, amiodarone, verapamil and diltiazem. Increased risk of myopathy w/ amlodipine, fusidic acid. Potential reduction of cytotoxic effect of rituximab. Increased hepatotoxicity w/ ezetimibe.\n\nPotentially Fatal: Concurrent use w/ itraconazole, ketoconazole, posaconazole, clarithromycin, erythromycin, telithromycin, nefazodone, niacin, HIV protease inhibitors (e.g. nelfinavir), boceprivir, telaprevir, gemfibrozil, ciclosporin and danazol may increase the risk of myopathy, rhabdomyolysis and acute renal failure.\n\nPregnancy category: X\n\nInteraction: May increase bleeding risk w/ anticoagulants. Reduced serum levels w/ bosentan, efavirenz and rifampicin. Increased risk of myopathy and rhabdomyolysis w/ colchicine, amiodarone, verapamil and diltiazem. Increased risk of myopathy w/ amlodipine, fusidic acid. Potential reduction of cytotoxic effect of rituximab. Increased hepatotoxicity w/ ezetimibe.\n\nPotentially Fatal: Concurrent use w/ itraconazole, ketoconazole, posaconazole, clarithromycin, erythromycin, telithromycin, nefazodone, niacin, HIV protease inhibitors (e.g. nelfinavir), boceprivir, telaprevir, gemfibrozil, ciclosporin and danazol may increase the risk of myopathy, rhabdomyolysis and acute renal failure.
Sitagliptin	\n\n\tACI\tSitap 50 TAB dr 50mg 30's pack 451.50\n\tACI\tSitap 100 TAB dr 100mg 10's pack 280.80\n\tAcme Ltd.\tJanvia TAB dr 100mg 10's pack 280\n\tAcme Ltd.\tJanvia TAB dr 50mg 10's pack 150\n\tBeximco\tGlipita TAB dr 100mg 10's pack 470\n\tBeximco\tGlipita TAB dr 50mg 10's pack 240\n\tDelta Pharma\tSitalia TAB dr 50mg  \n\tDelta Pharma\tSitalia TAB dr 100mg  \n\tDrug International Ltd.\tSliptin TAB dr 100mg 10's pack 300\n\tDrug International Ltd.\tSliptin 25 TAB dr 25mg  \n\tDrug International Ltd.\tSliptin 50 TAB dr 50mg  \n\tHealthcare\tSilinor TAB dr 25 mg 50's pack \n\tHealthcare\tSilinor 100 TAB dr 100mg 50's pack \n\tHealthcare\tSilinor TAB dr 50mg 50's pack \n\tIncepta\tSitagil 100 TAB dr 100mg 10's pack 280\n\tIncepta\tSitagil 25 TAB dr 25mg 30's pack 240\n\tIncepta\tSitagil 50 TAB dr 50mg 20's pack 300\n\tPacific\tSGN 25 TAB dr 25mg 30's pack 240\n\tPacific\tSGN 50 TAB dr 50mg 30's pack 450\n\tPacific\tSGN 100 TAB dr 100mg 10's pack 350\n\tSanofi Aventis (BD) Ltd.\tIncrit TAB dr 50 mg  360\n\tSanofi Aventis (BD) Ltd.\tIncrit TAB dr 100 mg  \n\tSharif\tSitavia 50 TAB dr 50mg  \n\tSharif\tSitavia 100 TAB dr 100mg  \n\tSquare\tSiglita TAB dr 100mg 10's pack 300\n\tSquare\tSiglita TAB dr 50mg 10's pack 180\n\tWhite Horse Pharma\tSigtil TAB dr 50mg  \n\tWhite Horse Pharma\tSigtil TAB dr 25mg  \n\tWhite Horse Pharma\tSigtil TAB dr 100mg  \n\tIndication: Type 2 diabetes mellitus\n\nDose: The recommended dose of Sitagliptin is 100 mg once daily. Sitagliptin can be taken with or without food.     \n\nFor patients with mild renal insufficiency ( creatinine clearance [CrCl]>50ml/min), no dosage adjustment is required.     \n\nRenal impairment:\nCrCl (ml/min)	\n30-<50	50 mg daily.\n<30 	25 mg daily; may be given without regard to the timing of the haemodialysis. \n\nPediatric Use:  Safety and effectiveness of Sitagliptin in pediatric patients under 18 years of age have not been established.\n\nContra-indication: Hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome can occur. Type 1 diabetes. Diabetic ketoacidosis. \n\nSide effects: Headache, diarrhoea, upper respiratory tract infection, nasopharyngitis. Angioedema, exfoliative dermatitis. Hypoglycemia occurs in patients treated with the combination of Sitagliptin and sulfonylurea, with or without Metformin. Potentially Fatal: Anaphylaxis and/or severe dermatologic reactions such as Stevens-Johnson syndrome.\n\nPrecaution: Discontinue treatment if there are signs of hypersensitivity. Caution when used with sulphonylureas and/or other antidiabetic medications; monitor blood glucose regularly. Renal impairment; dose adjustment may be needed. Children <18 yr. Pregnancy, lactation.\n\nMode of action: Increased risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin.\n\nPregnancy category: B\n\nInteraction: Increased risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin.
Sodium Bicarbonate	\n\n\tJayson\tSodi bi carb Injection 7.5mg/100ml 25 amps x 10's pack 149.10\n\tJayson\tSodib Injection 7.5% 24's amps pack \n\tOpso Saline Ltd.\tSodium Bicarbonate IV Infusion 7.5% 25ml bot 7.03\n\tOpsonin Pharma\tSodinate TAB dr 600mg  \n\tPopular\tSodicarb TAB dr 600mg 60 tabs pack 361.20\n\tIndication: Dyspepsia,Urine alkalinisation,Severe metabolic acidosis\n\nDose: Adult: PO Urine alkalinisation Up to 10 g/day in divided doses w/ sufficient fluid intake. Chronic metabolic acidosis >4.8 g/day as needed. Dyspepsia 1-5 g when needed. \n\nIV Severe metabolic acidosis By slow inj of a hypertonic soln >8.4% or by continuous infusion of a weaker soln, usually 1.26% .\n\nContra-indication: Metabolic or respiratory alkalosis; hypernatraemia, severe pulmonary oedema; hypocalcaemia, hypochlorhydria.\n\nSide effects: Metabolic alkalosis; mood changes, tiredness, shortness of breath, muscle weakness, irregular heartbeat; muscle hypertonicity, twitching, tetany; hypernatraemia, hyperosmolality, hypocalcaemia, hypokalaemia; stomach cramps, flatulence. Tissue necrosis at inj site.\n\nPrecaution:  	Epilepsy, CHF, renal impairment, liver cirrhosis, hypertension, oedema, eclampsia, aldosteronism. Monitor serum electrolyte concentrations and acid-base status regularly during treatment of acidosis. Pregnancy; lactation.\n\nMode of action: Increases toxicity of amphetamines, ephedrine, pseudoephedrine, flecainide, quinidine and quinine. Decreases effects of lithium, chlorpropamide and salicylates due to increased clearance. May affect the absorption of certain drugs due to raised intra-gastric pH.\n\nPregnancy category: C\n\nInteraction: Increases toxicity of amphetamines, ephedrine, pseudoephedrine, flecainide, quinidine and quinine. Decreases effects of lithium, chlorpropamide and salicylates due to increased clearance. May affect the absorption of certain drugs due to raised intra-gastric pH.
Sodium Bicarbonate 6.6% + Sodium Chloride 3.1% + Highly purified water (Haemodialysis solutions)	\n\n\tPopular\tDialyte B	 Dialysis Solution  10liters containers 411.50\n\tIndication: Haemodialysis\n\nDose: 5 lit. Concentrate per dialysis or as required.\n\n\n\nContra-indication: Known hypersensitivity to any of the ingredients of this preparation.\n\nSide effects: \n\nPrecaution: Do not use sol A or sol B alone. It must be diluted immediately before use with water of suitable quality. Discard container in case of visible solid particles inside. It's not for IV injection or infusion.\n\nMode of action: sodium bicarbonate....Increases toxicity of amphetamines, ephedrine, pseudoephedrine, flecainide, quinidine and quinine. Decreases effects of lithium, chlorpropamide and salicylates due to increased clearance. May affect the absorption of certain drugs due to raised intra-gastric pH. \nsodium chloride ....May affect serum concentrations of lithium.\n\nPregnancy category: X\n\nInteraction: sodium bicarbonate....Increases toxicity of amphetamines, ephedrine, pseudoephedrine, flecainide, quinidine and quinine. Decreases effects of lithium, chlorpropamide and salicylates due to increased clearance. May affect the absorption of certain drugs due to raised intra-gastric pH. \nsodium chloride ....May affect serum concentrations of lithium.
Sodium Chloride 0.9%	\n\n\tACI\tSalinor 0.9% Normal Saline IV Infusion  0.9gm/100ml 100ml bot 50.14\n\tAcme Ltd.\tAcme's Normal saline IV Infusion  500 ml bag / 1000 ml bag \n\tBeacon\tXenosol 100 IV Infusion   100ml bag 74\n\tBeacon\tXenosol 250 IV Infusion   200ml bag 85\n\tBeximco\tSaloride Eye drops Eye Drops   10 ml ampoule 60\n\tBeximco\tSaloride IV Infusion   500 ml bag  / 1000 ml bag 67.64 / 87.13\n\tGeneral\tIsoline IV Infusion 0.9 gm/100 ml  \n\tLibra Pharmaceuticls Ltd.\tNormasol IV Infusion   500 ml bag  / 1000 ml bag 46.56/57.69\n\tOpso Saline Ltd.\tNormal Saline 0.9% IV Infusion   500 ml bag  / 1000 ml bag 47.85/60.40\n\tOpso Saline Ltd.\tNorsol Eye sol Solution   25 ml ampoule 25\n\tOpsonin Pharma\tNosomist Nasal Drops .9% 50ml bot 98\n\tOrion Pharma Ltd.\tSalpac IV Infusion   100ml bag / 500 ml bag  / 1000 ml bag 47 / 62 / 78\n\tPopular\tNormalin IV Infusion  .9 gm/100 ml 500 ml bag  / 1000 ml bag 46.57 /57.70\n\tPopular\tN-Sol Nasal Drops 0.9% Sodium Chloride 10ml 17.60\n\tSquare\tSolo Nasal Drops  10's pack 230\n\tIPH\tNormal saline saline   500ml bag Not for sale\n\tIndication: Dehydration, Excessive sweating, Water and electrolyte imbalance, Metabolic alkalosis, Diluting or dissolving drugs, Intra-ocular or topical irrigation during surgical procedure, dry nasal membranes including dry nose resulting from cold and allergy medications.\n\nDose: Adult: PO Chronic salt-losing conditions Extended release 2.4-4.8 g/day, up to 12 g/day. \n\nIV Replacement of fluid and electrolytes As 0.9, 3 or 5% soln: Dosage depends on age, wt, clinical condition and laboratory determinations of the patient. \n\nHypernatraemia As 0.9% soln: Dosage depends on age, wt, clinical condition and laboratory determinations of the patient. \n\nIrrigation Irrigation of the bladder, eye, general skin and wound cleansing As 0.9% soln: Use as directed. \n\nEye drop:1 drop in the affected eye (s) every 3 or 4 hours or as directed by a physician. \n\nNasal drop: Nasal congestion As 0.9% soln/spray: Infants, children & adults : 2-6 drops into each nostril as needed daily.Use as directed.\n\nContra-indication:  Conditions whereby admin of sodium chloride would be detrimental. Not to be used to induce emesis. Sustained release tablets: GI disorders associated with strictures or diverticula.\n\nSide effects: Hypernatraemia; thirst, reduced salivation and lachrymation, fever, tachycardia, hypertension, headache, dizziness, restlessness, irritability and weakness. Burning or irritation of the eye may occur temporarily when first applied. Other side effects are redness, pain, swelling in or around the eyes, sensitivity to light, and headache. Potentially Fatal: Intra-amniotic inj of hypertonic solutions: Disseminated intravascular coagulation, renal necrosis, cervical and uterine lesions, pulmonary embolism, pneumonia and death.\n\n\nPrecaution: Hypertension, heart failure, peripheral or pulmonary oedema, impaired renal function, liver cirrhosis, preeclampsia. Maintain adequate water intake. Pregnancy. Inj of 3 or 5% sodium chloride solution should be given via a large vein at a rate not exceeding 100 ml/hr. Monitor fluid balance, serum electrolytes and acid base balance espcially during prolonged treatment. Caution when used in patients who are receiving corticosteroids or corticotropin.\n\nMode of action: May affect serum concentrations of lithium.\n\nPregnancy category: Not Classified\n\nInteraction: May affect serum concentrations of lithium.
Sodium Chloride 5% Eye prep	\n\n\tAristopharma\tNCL Eye Drops   5  ml drop 70\n\tBeximco\tHypersol 5 Eye Drops   10 ml drop 70\n\tOpso Saline Ltd.\tI-Sol Eye Drops   10 ml drop 70\n\tIndication: Corneal Edema, Pain or swelling of the cornea, eye exams.\n\nDose: 1-2 drops in the affected eye (s) every 3 or 4 hours or as directed by a physician.\n\nContra-indication: Contraindicated in patients who develop allergic reactions to this medicine.\n\nSide effects: Vision may be temporarily blurred for a period after applying the drops. Burning or irritation of the eye may occur temporarily when first applied. Other side effects are redness, pain, swelling in or around the eyes, sensitivity to light, and headache.\n\nPrecaution: Precaution should be taken if patients have history of eye problems or allergies.\n\nMode of action: May affect serum concentrations of lithium.\n\nPregnancy category: Not Classified\n\nInteraction: May affect serum concentrations of lithium.
Sodium Cromoglycate 2%  Eye/Nasal prep	\n\n\tACI\tIcrom Drops   10 ml drop 65.25\n\tAristopharma\tAristocrom Drops   10 ml drop 65\n\tDrug International Ltd.\tNasochrom Drops   10 ml drop 60\n\tG. A. Company Ltd.\tItchin Drops   10 ml drop 60\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCromolin Drops 2% 10ml drop 80\n\tIncepta\tMastguard Drops 2% 10ml drop 60\n\tJayson\tOptipan 2% Drops   10 ml drop 50.77\n\tNavana\tNacrom Drops   10ml bot 65\n\tNovartis (Bangladesh) Ltd.\tNovacrom Drops   10ml drop 95\n\tOpso Saline Ltd.\tOpsocrom 2% Drops   10 ml drop 65\n\tPopular\tSodicrom Drops  2% 10 ml drop 60.23\n\tReman Drug Ltd.\tOptacrom Drops   10 ml drop 60.23\n\tSquare\tNacromin Drops  20mg/ml 10 ml drop 66.25\n\tIndication: Allergic rhinitis, Allergic conjuntivitis\n\nDose: For eyes:\nFor Child and Adult: 1 to 2 drops into each eye 2 to 3 times daily.\n\nFor nose:\nFor Child and Adult: 1-2 drop to each nostril 2 to 4 times daily.\n\nContra-indication: This drop is contraindicated in patient with hypersensitivity to Sodium Cromoglicate .\n\nSide effects: Mild throat irritation, coughing, & transient bronchospasm with a marked fall in pulmonary functions has been reported. In such cases treatment should be stopped and should not be re-introduced.Transient stinging and burning may occur after instillation of this drops. Other symptoms of local irritation have been reported rarely.\n\nPrecaution: As this drop contains benzalkonium chloride, patients should not wear contact lenses during treatment with this drop.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Sodium Cromoglycate +  Xylometazoline Hydrochloride	\n\n\tIncepta\tXylo Plus Nasal Spray    120 spray unit 110\n\tOpsonin Pharma\tXylomet Plus Nasal Spray  120 spray unit  110 	\n\tSquare\tAntazol PLUS Nasal Spray  2 gm + 25 mg/100 ml 120 spray unit 110.41\n\tIndication: Allergic rhinitis accompanied by nasal congestion\n\nDose: Adults (including the elderly) and children: One spray each nostril four times daily.\n\nContra-indication: Contraindicated in patients with a known hypersensitivity to any ingredients of the preparation.\n\nSide effects: No serious side effects have been reported. Occasional irritation of the nasal mucosa may occur during the first day of use. In rare cases with Sodium Cromoglicate solutions alone wheezing and tightness of the chest has been reported. Because a lower dose of Xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations.\n\nPrecaution: The prolonged use or abuse of decongestants in general may lead to rebound congestion or drug induced rhinitis.\n\nMode of action: xylometazoline hydrochloride....Increased heart rate or BP with sibutramine.\nPotentially Fatal: Hypertensive crisis with MAOIs.\n\nPregnancy category: Not Classified\n\nInteraction: xylometazoline hydrochloride....Increased heart rate or BP with sibutramine.\nPotentially Fatal: Hypertensive crisis with MAOIs.
Sodium Cromoglycate 3%  Nasal prep	\n\n\tIndication: Allergic rhinitis accompanied by nasal congestion\n\nDose: For nose:\nFor Child and Adult: 1 drop to each nostril 2 to 3 times daily.\n\nContra-indication: This drop is contraindicated in patient with hypersensitivity to Sodium Cromoglicate .\n\nSide effects: Transient stinging and burning may occur after instillation of this drops. Other symptoms of local irritation have been reported rarely.\n\nPrecaution: As this drop contains benzalkonium chloride, patients should not wear contact lenses during treatment with this drop.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Sodium Cromoglycate 4%  Eye/Nasal prep	\n\n\tG. A. Company Ltd.\tItchin DS Drops   10 ml drop 75\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCromolin 4% Drops    10 ml drop 80\n\tPopular\tSodicrom DS Eye Drops 4% 10 ml drop 75.28\n\tPopular\tSodicrom DS Nasal Drops 4% 10ml drop 50\n\tIndication: Allergic conjuntivitis, Allergic rhinitis accompanied by nasal congestion\n\nDose: For eyes:\nFor Child and Adult: 1 to 2 drops into each eye 2 to 3 times daily.\n\nFor nose:\nFor Child and Adult: 1 drop to each nostril 2 to 3 times daily.\n\nContra-indication: This drop is contraindicated in patient with hypersensitivity to Sodium Cromoglicate .\n\nSide effects: Transient stinging and burning may occur after instillation of this drops. Other symptoms of local irritation have been reported rarely.\n\nPrecaution: As this drop contains benzalkonium chloride, patients should not wear contact lenses during treatment with this drop.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Sodium Dichloroisocyanurate	\n\n\tSquare\tPeuritar 1 TAB dr 17mg 100's pack 50.54\n\tSquare\tPeuritar 3 TAB dr 51mg 30's pack 28.73\n\tIndication: Water purification, Effervescent water purification tablets make water safer by destroying harmful micro-organisms. It can also be used for washing fruits and vegetables and for cleaning teeth.\n\nDose: As 17 mg tab: For drinking water: 1 (one) tablet to 1 (one) liter of water. For fruits, vegetables washing water: 3 (three) tablets to 1 (one) liter of water. Double the amount of tablets if the water is heavily contaminated. Leave for 15 (fifteen) minutes before use.\n\nas 51 mg tab: For drinking water: 1 (one) tablet to 3 (three) liters of water. For fruits, vegetables washing water: 3 (three) tablets to 3 (three) liters of water. Double the amount of tablets if the water is heavily contaminated. Leave for 15 (fifteen) minutes before use.\n\nContra-indication: Do not use with other products. It may release dangerous gases (chlorine). It may react\nviolently with many substances, causing fire and explosion hazard\n\nSide effects: Skin contact: There may be irritation and redness at the site of contact. Repeated or\nprolo\nnged contact may cause dermatitis.\nEye contact: There may be severe pain, redness and irritation.\nIngestion: There may be nausea and vomiting, occasionally with abdominal pain.\nInhalation: Mild poisoning causes cough, irritation of the throat and shortness\nof breath.\nVery toxic to aquatic organisms, may cause long term adverse effects in the aquatic\nenvironment. \n\nPrecaution: Keep out of reach of children.Harmful if swallowed. If tablet is swallowed seek medical advice immediately.\nKeep away from other materials, especially from flammable materials\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: Cationic detergents, acids, metals.
Sodium Fluoride 0.022%	\n\n\tGeneral\tListacare Whitening Plus Mouthwash 0.022 gm/100 ml  \n\tIndication: Dental caries\n\nDose: Adult: PO Per loz contains 1 mg fluoride: 1 loz/day regardless of fluoride content of drinking water. \n\nTopical As 0.2% or 0.05% rinsing solutions: Rinse 10 mL once daily or wkly, preferably at bedtime after brushing the teeth. Rinse solution around and between teeth for 1 minute and spit after rinsing. \n\nAs gel containing 1.1% sodium fluoride: Apply a thin layer of the gel to the teeth daily (preferably at bedtime after brushing the teeth) for at least 1 minute and spit after application.\n\nContra-indication: Not to use 1 mg tablets in children <3 yr of age or when drinking water fluoride content is >0.3 ppm.\n\nSide effects: Hypersensitivity reactions, rash, nausea, vomiting. Products containing stannous fluoride may cause teeth staining.\n\nPrecaution: Prolonged treatment with large amounts of fluoride may result in dental fluorosis and osseous changes; do not exceed recommended dosage. Renal impairment. Pregnancy.\n\nMode of action: Absorption of fluoride may be reduced by aluminium, calcium and magnesium salts.\n\nPregnancy category: Not Classified\n\nInteraction: Absorption of fluoride may be reduced by aluminium, calcium and magnesium salts.
Sodium Fusidate	\n\n\tIndication: Treatment of infections caused by susceptible organisms, especially staphylococci eg, osteomyelitis, septicaemia, endocarditis, superinfected cystic fibrosis, pneumonia, Acne vulgaris, skin and soft tissue infections, surgical and traumatic wound infections.\n\nDose: Topical/Cutaneous\nSkin infections\nAdult: As a 2% ointment/cream/gel: Apply onto affected area 3-4 times daily until there is improvement. If gauze dressing is used, then frequency of application may be reduced to 1-2 times daily.\nChild: As a 2% ointment/cream/gel: Apply onto affected area 3-4 times daily until there is improvement. If gauze dressing is used, then frequency of application may be reduced to 1-2 times daily.\n\n\nContra-indication: Hypersensitivity to fusidic acid.\n\nSide effects: Fucidin given orally may cause gastrointestinal disturbances (dyspepsia, nausea, vomiting) which can normally be avoided by giving Fucidin with meals. Reversible increase of transaminases is reported at daily dosages of 1.5-3 g of Fucidin tablets. Reversible jaundice has been reported in some patients after administration of systemic Fucidin, most frequently in patients receiving IV Fucidin in high dosage and especially in serious Staphylococcus aureus bacteraemia. In some cases, instituting oral therapy may be beneficial. If the jaundice persists, Fucidin should be withdrawn, after which the serum bilirubin will return to normal. Allergic reactions are reported in very few cases.\n\nPrecaution: As fusidic acid is metabolized in the liver and excreted mainly through the bile, periodic liver function tests should be carried out in patients with liver dysfunction, abnormalities in the biliary pathway, when fusidic acid is given in high doses for prolonged periods, or when it is given in combination with other antibiotics which have similar excretion pathways eg, lincomycin and rifampicin. In vitro, fusidic acid displaces bilirubin from its albumin-binding site. The clinical significance of this finding is uncertain and kernicterus has not been observed in neonates receiving systemic Fucidin. However, this observation should be borne in mind when fusidic acid is given to preterm, jaundiced, acidotic or seriously ill neonates.\nUse in pregnancy & lactation: Animal studies and many years of clinical experience have suggested that Fucidin is devoid of teratogenic effects. Fusidic acid passes the placenta and should be avoided during the 3rd trimester of pregnancy due to the theoretical risk of kernicterus.\nConcentrations of fusidic acid found in breast milk are negligible and its use is not contraindicated in nursing mothers.\n\nMode of action: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.\n\nPregnancy category: Not Classified\n\nInteraction: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.
Sodium Hyaluronate	\n\n\tChemist Ltd.\tHelo Injection 20mg/2ml 2ml vial x 1's pack  1200\n\tHealthcare\tHyalgun Injection 20 mg/2 ml  \n\tIncepta\tHyronate Injection 20mg/2ml 2 ml prefilled  syringe  x 1's pack 1500\n\tIndication: Osteoarthritis\n\nDose: Adult: Intra-articular Osteoarthritis of the knee 20-25 mg once wkly for 5 wk, up to 30 mg once wkly for 3-4 wk. Not to repeat course w/in 6 mth for any individual joint.\n\nSodium Hyaluronate is administered by intra-articular injection. A treatment cycle consists of five injections given at weekly intervals. Some patients may experience benefit with three injections given at weekly intervals. Inject the full 2 ml in one knee only. If treatment is bilateral, a separate injection should be used for each knee.\n\nContra-indication: Hypersensitivity to sodium hyaluronate or avian proteins. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site.\n\nSide effects:  Intra-articular inj: Pain and inflammation at inj site. Hypersensitivity; anaphylaxis; hypotensive crisis.\nThe common side-effects include gastrointestinal complaints, knee swelling/effusion, local skin reactions (rash, ecchymosis), pruritus, and headache.\n\nPrecaution: Use caution when injecting Sodium Hyaluronate into patients who are allergic to avian proteins, feathers, and egg products. Strict aseptic administration technique must be followed. Remove joint effusion, if present, before injecting Sodium Hyaluronate. Do not use the same syringe for removing joint effusion and for injecting Sodium Hyaluronate. It is recommended that the patient avoid any strenuous activities or prolonged (i.e., more than 1 hour) weight-bearing activities such as jogging or tennis within 48 hours following the intra-articular injection.\n\nMode of action:  	The safety and effectiveness of the use of sodium hyaluronate concomitantly with other intra-articular injection has not yet been established.\nAs sodium hyaluronate is precipitated by quaternary amine bactericides or disinfectants eg, benzalkonium chloride and chlorhexidine, etc, adequate attention should be given.\n\nPregnancy category: Not Classified\n\nInteraction:  	The safety and effectiveness of the use of sodium hyaluronate concomitantly with other intra-articular injection has not yet been established.\nAs sodium hyaluronate is precipitated by quaternary amine bactericides or disinfectants eg, benzalkonium chloride and chlorhexidine, etc, adequate attention should be given.
Sodium Hyaluronate 0.1%, 0.2% Eye prep	\n\n\tAristopharma\tHyloron 0.1% Eye Drops   10 ml drop 220\n\tIncepta\tHyronate Eye Drops 0.1 gm/100 ml  \n\tIncepta\tHyronate DS Eye Drops 0.2 gm/100 ml  \n\tIndication: Cataract surgery, Cornea transplant surgery, Glaucoma surgery, Posterior segment surgery\n\nDose: Surgical aid in the anterior segment during cataract extraction and intraocular lens implantation\nAdult: Slowly admin a sufficient quantity into the eye.Instill 1 drop 3 times daily. If necessary this can be increased or as directed by a physician. \n\n\n\nContra-indication: Hypersensitivity to sodium hyaluronate or avian proteins.\n\nSide effects: Ophthalmic: Transient rise in intraocular pressure. Transient burning sensation, temporarily blurred vision.\n\nPrecaution: Monitor intraocular pressure. Pregnancy.\n\nMode of action:  	The safety and effectiveness of the use of sodium hyaluronate concomitantly with other intra-articular injection has not yet been established.\nAs sodium hyaluronate is precipitated by quaternary amine bactericides or disinfectants eg, benzalkonium chloride and chlorhexidine, etc, adequate attention should be given.\n\nPregnancy category: Not Classified\n\nInteraction:  	The safety and effectiveness of the use of sodium hyaluronate concomitantly with other intra-articular injection has not yet been established.\nAs sodium hyaluronate is precipitated by quaternary amine bactericides or disinfectants eg, benzalkonium chloride and chlorhexidine, etc, adequate attention should be given.
Sodium Hypochlorite 0.5%	\n\n\tIndication: Water purification, Root canal operation, infection of the skin and tissue, irrigate or cleanse a wound before and after surgery or to treat cuts, abrasions, and skin ulcers.\n\nDose: Pour sodium hypochlorite on or apply to the affected area as directed.Pour, apply or spray affected area as an irrigation or cleanser. It is also used to wet certain types of wound dressings (e.g., wet to moist dressing).\n\nContra-indication: Hypersensitivity to any ingredient in sodium hypochlorite or to chlorine compounds. Pregnancy, breast-feeding.\n\nSide effects: Skin irritation. Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).\n\nPrecaution: This product is for external use only. Avoid contact with the eyes, ears, nose, and mouth. If you get sodium hypochlorite in your eyes, rinse immediately with cool water.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Sodium Lactate 1.87%	\n\n\tIndication: Fluid and electrolyte imbalance\n\nDose: Fluid and electrolyte imbalance\nAdult: Dosage depends on the age, weight and clinical condition of the patient as well as laboratory determinations.\n\nRenal impairment: Dosage adjustments may be required.\n\n\nContra-indication: Treatment of lactic acidosis.\n\nSide effects:  Chest pain, confusion, difficulty breathing, muscle spasms or twitches, pain, redness, unusual swelling. Febrile response, venous thrombosis, extravasation or phlebitis at the site of inj.\n\nPrecaution: Heart failure, oedema, renal impairment, hypertension, eclampsia or aldosteronism. Patients who are taking corticosteroids or salt-retaining patients. Excessive admin may lead to hypokalaemia. Monitor fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy. Not to be used as IV infusion in the treatment of metabolic acidosis, especially in seriously ill patients with poor tissue perfusion or impaired hepatic function.\n\nMode of action: Caution when used in patients receiving corticosteroids or corticotropin.\n\nPregnancy category: C\n\nInteraction: Caution when used in patients receiving corticosteroids or corticotropin.
Sodium Nitroprusside Dihydrate	\n\n\tIndication: Heart failure, Severe hypertension, Hypertensive crises\n\nDose: Adult: IV Hypertensive crisis For patients not receiving any antihypertensives: Initial: 0.3-1.5 mcg/kg/min, adjust gradually as needed. Usual: 0.5-6 mcg/kg/min. Max rate: 8 mcg/kg/min, discontinue if there is no response after 10 mins. May continue for a few hr if there is response. \n\nIntroduce PO as soon as possible. Lower doses should be used in patients receiving antihypertensives. Induction of hypotension during anesth Recommended max: 1.5 mcg/kg/min. Heart failure Intial: 10-15 mcg/min, may increase if needed. Usual: 10-200 mcg/min. Max: 280 mcg/min.\n\nContra-indication: Hypersensitivity, compensatory hypertension.\n\nSide effects: Nausea, retching, apprehension, headache, restlessness, muscle twitching, retrosternal discomfort; palpitation, dizziness, abdominal discomfort. Cyanosis and hypothyroidism (rare).\n\nPrecaution: Hypothyroidism, renal and hepatic impairment, ischaemic heart disease, impaired cerebral circulation, elderly. Monitor blood thiocyanate concentration if treatment is longer than 3 days and should not exceed 100 mcg/ml. Monitor acid-base balance, venous oxygen concentration and BP. Caution to avoid extravasation. To be diluted with sterile dextrose 5% solution before infusion. Avoid sudden withdrawal. Leber's optic atrophy, low plasma-cobalamin concentrations, impaired pulmonary function. Pregnancy and lactation.\n\nMode of action: Additive effect when used with other antihypertensives. May prolong the fibrinolytic activity of alteplase. Risk of severe hypotension if used with phosphodiesterase inhibitors. May reduce serum digoxin levels.\n\nPregnancy category: C\n\nInteraction: Additive effect when used with other antihypertensives. May prolong the fibrinolytic activity of alteplase. Risk of severe hypotension if used with phosphodiesterase inhibitors. May reduce serum digoxin levels.
Sodium Stibogluconate	\n\n\tIndication: Leishmaniasis\n\nDose: Adult:\nLeishmaniasis\n\n20 mg Sb/kg/day (maximum 850 mg) IV/IM x20-28 days \n\nPediatric:\nLeishmaniasis\n\n20 mg Sb/kg/day (maximum 850 mg) IV/IM x20-28 day \n\n\n\n\nContra-indication: Significant renal impairment; breast-feeding\n\nSide effects: Anorexia\n\nNausea/vomiting\n\nAbdominal pain\n\nECG changes\n\nHeadache\n\nLethargy\n\nMyalgia\n\nRaised liver enzymes\n\nCoughing and substernal pain\n\nAnaphylaxis (rare)\n\nFever\n\nSweating\n\nFlushing\n\nVertigo\n\nBleeding from nose or gum\n\nJaundice\n\nRash\n\nPain and thrombosis on intravenous administration, intramuscular injection also painful\n\n\nPrecaution: \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Sodium Thiosulfate	\n\n\tSonear Ltd.\tThiotab TAB dr 15mg 100's pack 72\n\tSonear Ltd.\tThiotab TAB dr 7.5mg 100's pack 46\n\tIndication: Calcium urolithiasis, Cyanide poisoning, Secondary Preventive Treatment for Calciphylaxis in Dialysis Patients\n\nDose: Oral \nCodium thiosulfate has also been reported to suppress calciphylaxis, although or absorption may be poor. A 2 M (molar) solution can be prepared with 74.4 g in 150 mL free water; 2.6 g can be given orally daily or 3 times a week. Dose is limited by diarrhea. \n\nIntravenous\nCyanide poisoning\nAdult: To be given after 300 mg of sodium nitrite has been admin over 5-20 min: 12.5 g of sodium thiosulfate (50 ml of a 25% solution or 25 ml of a 50% solution) given over 10 min. Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses.\n\nChild: To be given after 4-10 mg/kg of sodium nitrite (max: 300 mg) has been admin: 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses.\n\nCalciphylaxis\n\n Intravenous doses have varied from 5-75 g after or during hemodialysis in adults. The most commonly reported dose has been 25 g after each dialysis. Some have used weight-based dosing (especially in children) at using 12 g/1.7 m2. Infusion times vary from 30-60 minutes.\n\nContra-indication: Oedematous sodium-retaining conditions.\n\nSide effects: Osmotic disturbances. Oral: catharsis (at high doses).\n\nPrecaution: May irritate eyes, skin and respiratory tract.\n\nMode of action: Decreases toxicity of cisplatin through rapid chemical inactivation of its platinum component.\n\nPregnancy category: C\n\nInteraction: Decreases toxicity of cisplatin through rapid chemical inactivation of its platinum component.
Sodium Valproate (valproic acid)	\n\n\tACI\tSodival TAB dr 200mg 50's pack 126\n\tACI\tSodival Syrup 200mg/5ml 100ml bot 80.24\n\tACI\tSodival CR Syrup 200mg5ml 100ml 80\n\tGeneral\tProval Syrup 200mg/5ml 100ml bot 75.28\n\tGeneral\tProval TAB dr 200mg 50's pack 125.50\n\tIncepta\tValex Syrup 200mg/5ml 100ml bot 80\n\tIncepta\tValex TAB dr 200mg 50's pack 150\n\tIncepta\tValex CR TAB dr 200mg 50's pack 225\n\tIncepta\tValex CR TAB dr 300mg 50's pack 350\n\tIncepta\tValex CR TAB dr 500mg 28's pack 308\n\tMedimet\tValepi TAB dr 200mg 50's pack 310\n\tMundipharma (Bangladesh) Pvt. Ltd.\tValcontin TAB dr 200mg 100's pack \n\tMundipharma (Bangladesh) Pvt. Ltd.\tValcontin TAB dr 300mg 100's pack \n\tMundipharma (Bangladesh) Pvt. Ltd.\tValcontin TAB dr 500mg 100's pack \n\tOpsonin Pharma\tConvules Syrup 200mg/5ml 100ml bot 75\n\tOpsonin Pharma\tConvules CR TAB dr 200mg 50's pack 176.82\n\tOpsonin Pharma\tConvules CR TAB dr 300mg 30's pack 158.87\n\tOpsonin Pharma\tConvules CR TAB dr 500mg 20's pack 176.65\n\tSanofi Aventis (BD) Ltd.\tEpilim Syrup 200mg/5ml 100ml bot 80.30\n\tSanofi Aventis (BD) Ltd.\tEpilim TAB dr 200mg 50's pack 200.50\n\tSanofi Aventis (BD) Ltd.\tEpilim TAB dr 300mg 50's pack 301\n\tSanofi Aventis (BD) Ltd.\tEpilim TAB dr 500mg 30's pack 301.20\n\tSanofi Aventis (BD) Ltd.\tEpilin TAB dr 200mg  \n\tSanofi Aventis (BD) Ltd.\tEpilin TAB dr 300mg  \n\tSanofi Aventis (BD) Ltd.\tEpilin TAB dr 500mg  \n\tSomatec\tValpro Syrup 200mg/5ml 100ml bot 75.28\n\tSomatec\tValpro TAB dr 200mg 50's pack 125.50\n\tSquare\tValoate Syrup 200mg/5ml 100ml bot 75\n\tSquare\tValoate CR TAB dr 200mg 50's pack 200\n\tSquare\tValoate CR TAB dr 300mg 50's pack 300\n\tSquare\tValoate CR TAB dr 500mg 30's pack 300\n\tSun Pharmaceutical (Bangladesh) Ltd.\tEncorate TAB dr 200mg 50's pack 150\n\tSun Pharmaceutical (Bangladesh) Ltd.\tEncorate Chrono TAB dr 500mg 30's pack 301.50\n\tSun Pharmaceutical (Bangladesh) Ltd.\tEncorate Chrono 300 TAB dr  50's pack 302\n\tUnimed & Unihealth Manufacturers Ltd.\tEpival 	 Syrup  250mg/5ml  1's pack(60ml) 122.18 \n\tWhite Horse Pharma\tVapo TAB dr 200mg 50's pack 200\n\tIndication: Epilepsy, e.g. Partial seizures, Absence seizures (petit mal), Generalized tonic-clonic seizures (grand mal), Myoclonic seizures, Atonic seizures, Mixed seizures, Anxiety disorder, Posttraumatic stress disorder, Febrile convulsion, Anorexia nervosa, Panic attack, Migraine and bipolar disorder.\n\nDose: Prolong release formulation of sodium Valproate may be given once or twice daily.  \n\nEpilepsy: Adults -Initially 600 mg daily given in 2 divided doses, preferably after food, increasing by 200 mg/day at 3-day intervals to a maximum of 2.5 g daily in divided doses until control of seizure is achieved. Usual maintenance dose is 1-2 g daily (20-30 mg/kg daily).  \n\nChildren Initially 20 mg/kg daily in divided doses, may be increased (up to 20 kg) provided plasma concentrations monitored (above 40 mg/kg daily also monitor clinical chemistry and hematological parameters). \n\nChildren Initially 400 mg daily in divided doses increased until control (0ver 20 kg) (usually in the range of 20-30 mg/kg daily); Maximum 35 mg/kg daily. \n\nFebrile convulsion20-30 mg/kg/day in 3 divided doses.  \n\nBipolar disorder initially 20-30 mg/kg/day in 2-3 divided doses; adjust dosage in 3-5 days. Maintenance dosage is 1000-2000 mg/day. \n\nProphylaxis of migraine 300 mg twice daily, although some may require 1000 mg daily.\n\nHepatic impairment: Contraindicated.\n\nContra-indication: Sodium Valproate is contraindicated to patients who have known hypersensitivity to the drug and liver dysfunction. Care should be exercised when prescribing Sodium Valproate in women of child bearing age.\n\nSide effects: The most common side effects are anorexia, nausea and vomiting. However, these side effects are minimized with the use of enteric coated tablets. Effects on the CNS include sedation, ataxia and tremor. These symptoms occur infrequently and usually respond to a decrease in doses. Rash, alopecia and stimulation of appetite have been observed occasionally. Sodium Valproate has several effects on hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. Rarely a fulminate hepatitis that may be fatal may develop. Children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are specially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of Sodium Valproate.\n\nPrecaution: Liver functions should be monitored before therapy and during first 6 months especially in patients most at risk, No undue potential for bleeding before starting and before major surgery must be ensured, Care should be taken in renal impairment, pregnancy, breast-feeding and systemic lupus erythematosus. Sodium Valproate is partially eliminated in the urine as a ketone metabolite, which may lead to a false interpretation of the urine ketone test. Sudden withdrawal of therapy should be avoided. \n\nMode of action: Increased risk of toxicity w/ bupropion. Increased risk of convulsions w/ mefloquine. Increased risk of carnitine deficiency w/ pivmecillinam and pivampicillin. Increased risk of hepatotoxicity and carbamazepine toxicity w/ a decrease in valproic acid levels w/ concurrent carbamazepine. Decreased valproic acid and increased ethosuximide serum levels w/ ethosuximide. \n\nDecreased valproic acid levels w/ carbapenems, rifampicin, phenytoin, phenobarbital (or primidone) and antineoplastic drug regimens. Increased valproic acid levels w/ felbamate and aspirin. Increased risk of hepatotoxicity w/ olanzepine. Concurrent use increased phenobarbital, nimodipine, nifedipine, lamotrigine, zidovudine, amitriptyline, nortriptyline and benzodiazepines levels. Concurrent use decreased tigabine and clozapine levels. Increased risk of absence status w/ clonazepam. Increased risk of hyperammonaemia w/ topiramate. Increased free valproic acid concentrations w/ highly protein bound drugs.\n\nPotentially Fatal: Concomitant carbapenem is not recommended as this may decrease valproate levels. Avoid concurrent salicylates in childn <3 yr due too risk of hepatotoxicity. Increased risk of hepatotoxicity w/ cosyntropin. Avoid ethanol as this may increase CNS depression.\n\nPregnancy category: D\n\nInteraction: Increased risk of toxicity w/ bupropion. Increased risk of convulsions w/ mefloquine. Increased risk of carnitine deficiency w/ pivmecillinam and pivampicillin. Increased risk of hepatotoxicity and carbamazepine toxicity w/ a decrease in valproic acid levels w/ concurrent carbamazepine. Decreased valproic acid and increased ethosuximide serum levels w/ ethosuximide. \n\nDecreased valproic acid levels w/ carbapenems, rifampicin, phenytoin, phenobarbital (or primidone) and antineoplastic drug regimens. Increased valproic acid levels w/ felbamate and aspirin. Increased risk of hepatotoxicity w/ olanzepine. Concurrent use increased phenobarbital, nimodipine, nifedipine, lamotrigine, zidovudine, amitriptyline, nortriptyline and benzodiazepines levels. Concurrent use decreased tigabine and clozapine levels. Increased risk of absence status w/ clonazepam. Increased risk of hyperammonaemia w/ topiramate. Increased free valproic acid concentrations w/ highly protein bound drugs.\n\nPotentially Fatal: Concomitant carbapenem is not recommended as this may decrease valproate levels. Avoid concurrent salicylates in childn <3 yr due too risk of hepatotoxicity. Increased risk of hepatotoxicity w/ cosyntropin. Avoid ethanol as this may increase CNS depression.
Solifenacin Succinate	\n\n\tAristopharma\tSolifen TAB dr 5mg 20's pack 400\n\tUnimed & Unihealth Manufacturers Ltd.\tUtrobin TAB dr 10mg 7's pack 210\n\tUnimed & Unihealth Manufacturers Ltd.\tUtrobin TAB dr 5mg 14's pack 210\n\tIndication: Overactive bladder\n\nDose: Overactive bladder\nAdult: 5 mg once daily. If well tolerated, may increase to 10 mg once daily if needed. For patients who are concurrently taking CYP3A4 inhibitors (e.g. ketoconazole, ritonavir): Max dose: 5 mg once daily. \n\nRenal impairment:\nCrCl (ml/min)	\n<30	          Max: 5 mg daily. \n\nHepatic impairment: Child-pugh class B: Max: 5 mg daily; Child-pugh class C: Use is not recommended.\n\n\nContra-indication: Uncontrolled narrow-angle glaucoma, urinary retention, gastric retention.\n\nSide effects: Constipation, dyspepsia, nausea, upper abdominal pain, xerostomia, hypertension, oedema, headache, depression, fatigue, urinary tract infection, blurred vision, cough, influenza.\n\n\nPrecaution: Increased risk of urinary retention in patients with bladder outflow obstruction. Caution in patients with decreased GI motility, GI obstructive diseases, controlled narrow-angle glaucoma, liver or kidney impairment, patients with known history of QT prolongation or other risk factors for QT prolongation. May cause drowsiness and/or blurred vision. Monitor serum creatinine clearance and liver function. Maintain adequate hydration. Increased susceptibility to heat prostration due to reduced ability to sweat. Pregnancy, lactation.\n\nMode of action:  May interfere with the prokinetic effects of cisapride and metoclopramide.\nPotentially Fatal: May reduce the stimulatory effect of secretin. Concurrent use with biperiden, orphenadrine, procyclidine or trihexyphenidyl may cause anticholinergic effects such as confusion and loss of bladder control; a washout period of 1 wk between using these drugs is recommended. May increase the ulcerogenic effect of potassium chloride. \n\nStrong CYP3A4 inhibitors (e.g. ketoconazole, fluconazole, itraconazole, erythromycin, telithromycin, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone, aprepitant, verapamil) may reduce the metabolism of solifenacin, thus increasing its plasma levels.\n\nPregnancy category: C\n\nInteraction:  May interfere with the prokinetic effects of cisapride and metoclopramide.\nPotentially Fatal: May reduce the stimulatory effect of secretin. Concurrent use with biperiden, orphenadrine, procyclidine or trihexyphenidyl may cause anticholinergic effects such as confusion and loss of bladder control; a washout period of 1 wk between using these drugs is recommended. May increase the ulcerogenic effect of potassium chloride. \n\nStrong CYP3A4 inhibitors (e.g. ketoconazole, fluconazole, itraconazole, erythromycin, telithromycin, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone, aprepitant, verapamil) may reduce the metabolism of solifenacin, thus increasing its plasma levels.
Sorafenib	\n\n\tBeacon\tSoranix TAB dr 200mg  \n\tRenata\tSofenib TAB dr 200mg  \n\tTechno Drugs Ltd.\tSorafen TAB dr 200mg  \n\tIndication: Renal cell carcinoma\n\nDose: Adult: PO 400 mg twice daily. Continue till patient is no longer responding or unacceptable toxicity occurs.\n\nContra-indication: Hypersensitivity\n\nSide effects: Rash and hand-foot skin reactions. Hypophosphataemia, hypertension, bleeding, tinnitus, depression and erectile dysfunction. Alopecia, pruritus, dry skin, erythema, acne, flushing, exfoliative dermatitis, hoarseness, GI disturbances, arthralgia, myalgia, asthenia, pain and peripheral neuropathy.\nPotentially Fatal: Bleeding fatalities. Hypertensive crisis.\n\nPrecaution: Interrupt teatment if patient develops cardiac infarction, ischaemia and/or bleeding fatalities. Regular monitoring of BP, CBC and platelet is recommended. Monitor INR in patients who are on treatment with warfarin. Adequate contraception should be used during and for at least 2 wk after stopping treatment. May need to discontinue treatment if severe or persistent hypertension occurs.\n\nMode of action: Inducers of isoenzyme CYP3A4 e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin may decrease sorafenib plasma concentration. Coadmin with sorafenib may increase the plasma concentration of doxorubicin and irinotecan.\n\nPregnancy category: D\n\nInteraction: Inducers of isoenzyme CYP3A4 e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin may decrease sorafenib plasma concentration. Coadmin with sorafenib may increase the plasma concentration of doxorubicin and irinotecan.
Sotalol Hydrochloride	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tSotalex TAB dr 80mg 30's pack 300\n\tIndication: Supraventricular and ventricular arrhythmias,Acute arrhythmias\n\nDose: Adult: PO Supraventricular and ventricular arrhythmias Initial: 80 mg/day in 1-2 divided doses, increase gradually every 2-3 days. Usual: 160-320 mg/day in 2 divided doses. Max: 640 mg/day. \n\nLife-threatening ventricular arrhythmias 480-640 mg/day. IV Acute arrhythmias 20-120 mg, may repeat 6 hrly if needed. For programmed electrical stimulation (to test antiarrhythmic efficacy) Initial: 1.5 mg/kg, then 0.2-0.5 mg/kg/hr infusion.\n\nContra-indication: Bronchospasm, asthma, history of obstructive airways disease, sinus bradycardia, cardiogenic shock. 2nd and 3rd degree AV block, uncontrolled cardiac failure, metabolic acidosis, hypotension, severe peripheral arterial disease.\n\nSide effects: Nausea, sleep disorders, lassitude, diarrhoea, palpitations, bradycardia, weakness, dyspnoea, decreased sexual activity, impotence, extremity pain, back pain, asthma, visual disturbances, cardiac arrhythmias. Rebound angina, arrhythmias and MI if withdrawn abruptly.\nPotentially Fatal: Polymorphic ventricular tachycardia (very rare). Rebound hypertension.\n\nPrecaution: Pregnancy and lactation. Renal insufficiency; preexisting sick sinus syndrome; compensated heart failure; gradual withdrawal is recommended. DM, 1st degree AV block. May mask the symptoms of hyperthyroidism and of hypoglycaemia. May unmask myasthenia gravis. May worsen psoriasis.\n\nMode of action: May increase risk of bradycardia w/ digoxin. May increase risk of arrhythmias w/ diuretics. May potentiate rebound HTN w/ clonidine. May prolong refractoriness w/ disopyramide, quinidine, procainamide, amiodarone and bepridil. May prolong QT interval w/ TCAs, phenothiazines, terfenadine and astemizole. Increased risk of torsades de pointes w/ K-depleting diuretics, erythromycin IV, halofantrine, pentamidine, and quinolones. May prolong neuromuscular blockade of tubocurarine. May reduce response to insulin and oral hypoglycaemics.\nPotentially Fatal: Additive effect on AV conduction and ventricular function w/ verapamil and diltiazem.\n\nPregnancy category: D\n\nInteraction: May increase risk of bradycardia w/ digoxin. May increase risk of arrhythmias w/ diuretics. May potentiate rebound HTN w/ clonidine. May prolong refractoriness w/ disopyramide, quinidine, procainamide, amiodarone and bepridil. May prolong QT interval w/ TCAs, phenothiazines, terfenadine and astemizole. Increased risk of torsades de pointes w/ K-depleting diuretics, erythromycin IV, halofantrine, pentamidine, and quinolones. May prolong neuromuscular blockade of tubocurarine. May reduce response to insulin and oral hypoglycaemics.\nPotentially Fatal: Additive effect on AV conduction and ventricular function w/ verapamil and diltiazem.
Sparfloxacin	\n\n\tACI\tAciflox TAB dr 200mg 10's pack 151.10\n\tAcme Ltd.\tFloxipar TAB dr 200mg 10's pack 155\n\tAlbion Ltd.\tSparfloxacin TAB dr 200 mg 10's pack \n\tAlco Pharma\tSparflox TAB dr 200mg 10's pack 160\n\tApollo Pharmaceutical Ltd.\tSpardon TAB dr 200mg 12's pack 192\n\tAristopharma\tOmniflox TAB dr 200mg 10's pack 180\n\tAsiatic Ltd.\tAsaf TAB dr 200mg 20's pack 375\n\tBeximco\tSparlin TAB dr 200mg 10's pack 150.60\n\tChemist Ltd.\tSparcin TAB dr 200mg 20's pack 300\n\tCosmic Chemical Industries Ltd.\tRoxipar TAB dr 200mg 10's pack 154\n\tDesh\tSparfloxin TAB dr 200mg 20's pack 320\n\tDrug International Ltd.\tSparoxen TAB dr 200mg 20's pack 360\n\tEdruc Ltd.\tSaplox TAB dr 200mg 10's pack 160\n\tEdruc Ltd.\tSpalox TAB dr 200mg 10's pack 160\n\tEskayef Bangladesh Ltd.\tParlox TAB dr 200mg 10's pack 150\n\tGlobe\tSpar TAB dr 200mg 10's pack 150\n\tHealthcare\tQuinoflox TAB dr 200mg 10's pack 150\n\tHudson\tMega Flox TAB dr 200mg 20's pack 300\n\tKemiko\tSalocin TAB dr 200mg 10's pack 170\n\tMillat\tPiocin TAB dr 200mg 6's pack 108\n\tNavana\tSpark TAB dr 200mg 10's pack 150\n\tNovartis (Bangladesh) Ltd.\tSpacin TAB dr 200mg 10's pack 260\n\tPacific\tSpalocin TAB dr 200mg 10's pack 200\n\tSomatec\tParflox TAB dr 200mg 10's pack 150.60\n\tSquare\tSaga TAB dr 200mg 15's pack 225.03\n\tUnimed & Unihealth Manufacturers Ltd.\tAnspar TAB dr 200mg 10's pack 120\n\tIndication: Chronic bronchitis, Community-acquired pneumonia\n\nDose: Adult: PO Acute bacterial exacerbation of chronic bronchitis; Community-acquired pneumonia 100-300 mg/day in 1-2 divided doses.\n\nContra-indication: Hypersensitivity; pregnancy and lactation; children <18 yr.\n\nSide effects: Diarrhoea, abdominal pain, nausea, vomiting; jaundice, renal failure, elevation of liver enzymes, BUN and creatinine; anaphylactoid reaction, headache, dizziness, convulsions; tremors, myalgia; rhabdomyolysis, thrombocytopenia and eosinophilia.\nPotentially Fatal: AV block; anaphylaxis.\n\nPrecaution: History of CNS disorders, pseudomembranous colitis, superinfection, severe renal dysfunction, epilepsy, G6PD deficiency, myasthenia gravis, patients with QT prolongation, uncorrected electrolyte disturbances, bradycardia, or pre-existing cardiac disease. Avoid exposure to strong sunlight or sunlamps during treatment. Discontinue treatment if patients experience tendon pain, inflammation or rupture; subsequent use of fluoroquinolones in these patients is not recommended. Avoid in MRSA infections due to high risk of resistance. Ensure adequate fluid intake to reduce risk of crystalluria.\n\nMode of action: Cations such as aluminum, magnesium, zinc and iron may reduce the bioavailability of sparfloxacin. May increase the plasma concentrations of theophylline and tizanidine. May enhance the effect of warfarin and glibenclamide. May decrease the renal clearance of methotrexate. Excretion may be reduced by probenecid. May alter serum levels of phenytoin.\nPotentially Fatal: Corticosteroids may increase risk of tendon rupture. Increased risk of seizures with NSAIDs. Risk of additive QT prolongation effect when used with class Ia or III antiarrhythmic drugs, astemizole, terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs.\n\nPregnancy category: C\n\nInteraction: Cations such as aluminum, magnesium, zinc and iron may reduce the bioavailability of sparfloxacin. May increase the plasma concentrations of theophylline and tizanidine. May enhance the effect of warfarin and glibenclamide. May decrease the renal clearance of methotrexate. Excretion may be reduced by probenecid. May alter serum levels of phenytoin.\nPotentially Fatal: Corticosteroids may increase risk of tendon rupture. Increased risk of seizures with NSAIDs. Risk of additive QT prolongation effect when used with class Ia or III antiarrhythmic drugs, astemizole, terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs.
Spectinomycin	\n\n\tIncepta\tTinobac Injection 2gm 2gm vial 250\n\tIndication: Gonorrhoea, Acute gonorrheal urethritis, Cervicitis  and proctitis\n\nDose: Adult: IM Gonorrhoea 2 g as single dose. In cases whereby antibiotic resistance is prevalent, 4 g may be used. Disseminated gonococcal infection 2 g 12 hrly.\n\nChild: Beyond newborn period and <45 kg: 40 mg/kg as a single dose. Max: 2 g.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Dizziness; nausea; urticaria; chills; fever; headache, insomnia, mild to moderate pain after inj.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Repeated doses may lead to changes in the kidney and liver function and a reduction in haemoglobin and haematocrit levels. Prolonged use may result in fungal or bacterial superinfection. All patients with gonorrhoea should be tested for syphilis at the time of diagnosis.\n\nMode of action: May result in lithium toxicity when used concurrently. May increase or prolong the neuromuscular blocking effect of atracurium.\n\nPregnancy category: B\n\nInteraction: May result in lithium toxicity when used concurrently. May increase or prolong the neuromuscular blocking effect of atracurium.
Spiramycine	\n\n\tDrug International Ltd.\tSpiracin TAB dr 1.5 MIU  \n\tDrug International Ltd.\tSpiracin TAB dr 3 MIU  \n\tSanofi Aventis (BD) Ltd.\tRovamycin TAB dr 3 MIU 20's pack 401.40\n\tIndication: Susceptible infections, Cryptosporidiosis, Toxoplasmosis, Protozoal infections\n\nDose: Adult: PO Cryptosporidiosis; Protozoal infections; Susceptible infections; Toxoplasmosis 6-9 million u/day in 2-3 divided doses. Severe: Up to 15 million u/day in divided doses. \n\nChild: and neonates: Chemoprophylaxis of congenital toxoplasmosis: 50 mg/kg bid. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea, vomiting, abdominal pain, diarrhoea; urticaria, pruritus, macular rashes. Transient paraesthesia may occur.\nPotentially Fatal: Pseudomembranous colitis; anaphylaxis; neuromuscular blockade; ventricular arrhythmias, prolongation of QT interval.\n\nPrecaution: Hepatic impairment; pregnancy and lactation. Monitor liver function. History of arrhythmias or predisposition to QT interval prolongation.\n\nMode of action:  Decreases carbidopa absorption and levodopa concentrations. Increased risk of ventricular arrhythmias when used with astemizole, cisapride and terfenadine. Risk of acute dystonia when used with fluphenazine.\n\nPregnancy category: C\n\nInteraction:  Decreases carbidopa absorption and levodopa concentrations. Increased risk of ventricular arrhythmias when used with astemizole, cisapride and terfenadine. Risk of acute dystonia when used with fluphenazine.
Spironolactone	\n\n\tAmbee\tVerospiron TAB dr 25mg 100's pack 501\n\tDrug International Ltd.\tSpiretic TAB dr 25mg 30's pack 150\n\tHealthcare\tAldactone TAB dr 25 mg 50's pack \n\tIncepta\tInospiron TAB dr 25mg 100's pack 500\n\tIncepta\tInospiron TAB dr 100mg  \n\tPopular\tSpirocard TAB dr 100mg 30's pack 542.10\n\tPopular\tSpirocard TAB dr 25mg 100's pack 502\n\tIndication: Oedema, Hirsutism, Hypertension, Hepatic cirrhosis w/ ascites and oedema, Hyperaldosteronism, Severe CHF, Hypokalaemia\n\nDose: Adult: PO Oedema Initial: 100 mg/day, up to 400 mg/day based on response. \nChild: Neonates: 1-2 mg/kg daily; 1 mth-12 yr: 1-3 mg/kg daily; 12-18 yr: 50-100 mg daily. To be given in 1-2 divided doses.\nElderly: Initially, 25-50 mg/day in 1-2 divided doses, may increase by 25-50 mg every 5 days when necessary. \n\nHepatic cirrhosis w/ ascites and oedema Depending on urinary Na/K ratio: If >1: Initial: 100 mg/day and if <1: Initial: 200-400 mg/day. \n\nDiagnosis of primary hyperaldosteronism 400 mg/day for 3-4 wk. Pre-op management of hyperaldosteronism 100-400 mg/day. \n\nHTN As monotherapy: 25-50 mg/day, up to 100 mg/day if needed. \n\nSevere CHF W/ ACE inhibitor and loop diuretic: Initial: 12.5-25 mg/day, up to 50 mg/day after 8 wk. \n\nDiuretic-induced hypokalaemia 25-100 mg/day. Hirsutism 50-200 mg/day.\n\nRenal impairment:\nCrCl (ml/min)	\n10-50	Recommended dosing interval: Every 12-24 hr.\n<10 	Avoid use.\n\nContra-indication: Anuria, hyperkalaemia, acute or progressive renal insufficiency. Addison's disease.\n\nSide effects: Fluid or electrolyte imbalance, gynaecomastia, GI upset, drowsiness, headache, hyponatraemia; tachycardia, hypotension, oliguria, hyperkalaemia; confusion, weakness, paraesthesia, hirsutism, mental disturbances, menstrual irregularities, loss of libido and impotence.\nPotentially Fatal: Fatal hyperkalaemia in combination with ACE inhibitors and previous renal impairment; agranulocytosis.\n\nPrecaution: Patients at risk of developing hyperkalaemia and acidosis; monitor serum electrolytes; renal and hepatic impairment; DM; elderly; pregnancy.\n\nMode of action: Sodium excretion effect may be inhibited by aspirin. May reduce ulcer-healing properties of carbenoxolone. Increased risk of nephrotoxicity when used with NSAIDs or ciclosporin. Hyperkalaemia may occur if given with potassium supplements, ACE inhibitors, angiotensin II antagonists, NSAIDs, ciclosporin or trilostane. May increase risk of orthostatic hypotension when used with barbiturates, narcotics or alcohol. May reduce vascular responsiveness to pressor amines. May increase half-life of digoxin.\n\nPotentially Fatal: Increased risk of lithium toxicity when used concurrently.\n\nPregnancy category: C\n\nInteraction: Sodium excretion effect may be inhibited by aspirin. May reduce ulcer-healing properties of carbenoxolone. Increased risk of nephrotoxicity when used with NSAIDs or ciclosporin. Hyperkalaemia may occur if given with potassium supplements, ACE inhibitors, angiotensin II antagonists, NSAIDs, ciclosporin or trilostane. May increase risk of orthostatic hypotension when used with barbiturates, narcotics or alcohol. May reduce vascular responsiveness to pressor amines. May increase half-life of digoxin.\n\nPotentially Fatal: Increased risk of lithium toxicity when used concurrently.
Streptokinase	\n\n\tBeacon\tEptase Injection 15 LacIU 1.5  million unit/vial 2690\n\tIncepta\tSTK Injection 1 500 000 IU 1's pack 3600\n\tPopular\tS-Kinase 0.75 Million Injection 15 LacIU 1.5  million unit/vial 3000\n\tSanofi Aventis (BD) Ltd.\tStreptase Injection  1.5  million unit/vial 3464\n\tCSL Behring GmbH, Germany\tStreptase Injection 1500000IU/vial 1's amps pack 3757.01\n\tIndication: Acute Evolving Myocardial Infarction, Acute Massive Pulmonary Embolism, Deep Vein Thrombosis, Arterial Thrombosis or Embolism, Arteriovenous Cannulae Occlusion.\n\nDose: Adult: IV infusion: Acute MI: 1.5 million u as a single dose immediately after onset of symptoms. \n\nTotal solution volume 45 ml. Infusion rate: Infuse 45 ml within 60 mins. \n\nPulmonary thromboembolism; Deep Vein Thrombosis, Arteriovenous occlusions Loading dose: 250,000 u via infusion. \n\nTotal solution volume 90 ml, Infusion rate: Infuse 30 ml/hour for 30 min. Maintenance: 100,000 u/hr for 24-72 hr depending on the condition treated. Duration for cerebral retinal thrombosis: 12 hr. Maintain thrombin clotting time at 2-4 times normal values. \n\nChild: Loading dose: 2500-4000 units/kg over 30 min, followed by infusion of 500-1000 units/kg/hr, continued until reperfusion occurs, up to 3 days. Initial dose may be estimated by streptokinase resistance test. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.\n\n\n\nContra-indication: Severe hypertension, recent stroke, cerebral neoplasm, recent history of peptic ulcer disease, ulcerative colitis, pancreatitis, subacute bacterial endocarditis, coagulation defects also due to liver or kidney disease, recent surgery, childbirth. Hypersensitivity, increased risk of cerebral bleeding, trauma. Pregnancy. Active internal bleeding, bleeding GI lesions. Arteriovenous malformation or aneurysm; recent (within 10 days) facial or head trauma, intracranial or intraspinal surgery, More than 5 days and less than 12 months since previous Streptokinase therapy.\n\nSide effects: Headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise. Gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis. Development of antistreptokinase antibodies. Hypotension, heart rate and rhythm disorders, angina pectoris. Recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema. Nausea, diarrhoea, epigastric pain and vomiting. Arrhythmia, bruising, rash, pruritus, acute renal failure due to embolism and haemorrhage. Cerebral, peripheral and pulmonary embolism. Allergic reactions, liver enzyme abnormalities, hypotension. Potentially Fatal: Haemorrhage; anaphylactic shock.\n\nPrecaution: Mitral stenosis associated with AF. Streptokinase treatment within last 12 mth, use after prolonged or traumatic CPR; diabetic retinopathy. Elderly. Because of the increased likelihood of resistance, due to antistreptokinase antibodies, retreatment with Streptokinase or Streptokinase-containing products may not be effective if administered between five days and twelve months of prior Streptokinase administration or Streptococcal infections, such as Streptococcal pharyngitis, acute rheumatic fever or acute glomerulonephritis secondary to a Streptococcal infection. In principle, no thrombolytic treatment should be commenced before the 10th postoperative day. However, in cases of pulmonary embolism, the indication for earlier treatment may be very strong and after careful consideration of all the risks, Streptokinase may be given before the tenth postoperative day. The danger of bleeding from the operative area must, of course, be taken into account. The danger of haemorrhage is increased by simultaneous or previous treatment with anticoagulants (e.g., Heparin) or substances which inhibit platelet formation or function. If the patient is under active heparinisation, it should be neutralised by the administration of protamine sulphate before the start of thrombolytic therapy.  Repeated Administration After administration of Streptokinase, the titre of antistreptokinase antibodies begins to rise after approximately one week, reaching a peak at 2 to 3 weeks and remains elevated for 8 to 12 months. Because of the increased likelihood of resistance, Streptokinase may not be effective if given during this period.\n\nMode of action: Antagonistic effects with antifibrinolytic agents e.g. aminocaproic acid.\nPotentially Fatal: Anticoagulants, heparin, antiplatelet agents e.g. aspirin and dipyridamole affect platelet function increasing the risk of haemorrhage.\n\nPregnancy category: C\n\nInteraction: Antagonistic effects with antifibrinolytic agents e.g. aminocaproic acid.\nPotentially Fatal: Anticoagulants, heparin, antiplatelet agents e.g. aspirin and dipyridamole affect platelet function increasing the risk of haemorrhage.
Streptomycin	\n\n\tRenata\tStreptomycin Injection 1gm/vial 1gm vial 9.19\n\tIndication: Tuberculosis, Bacterial endocarditis, Plague, Tularaemia, Brucellosis\n\nDose: Adult: IM Tuberculosis 15 mg/kg/day. Max: 1 g/day. For intermittent therapy: 25-30 mg/kg/day 2-3 times/wk. Max: 1.5 g/dose. \nChild: 20-40 mg/kg (max: 1 g) daily or 25-30 mg/kg (max: 1.5 g) 2-3 times wkly.\nElderly: >60 kg: Dosage reduction is required. \n\nMycobacterium avium complex infections As adjunct w/ macrolide, rifamycin and ethambutol: 15 mg/kg 3 times/wk for the 1st 2-3 mth for severe disease. \n\nBacterial endocarditis W/ penicillin: Streptococcal endocarditis: 1 g twice daily for the 1st wk, 500 mg twice daily for the 2nd wk; Enterococcal endocarditis: 1 g twice daily for 2 wk, then 500 mg twice daily for 4 wk. Terminate therapy if ototoxicity occurs. \n\nChild: To be used concurrently with penicillin. Enterococcal endocarditis: 20-30 mg/kg daily given in 2 divided doses. Recommended treatment duration: 4-6 wk for patients native valve endocarditis and at least 6 wk for patients with prosthetic valve or other prosthetic cardiac material.\n\nBrucellosis 1 g/day for 14-21 days, w/ oral doxycyline for 6 wk. Plague 2 g daily for at least 10 days. Tularaemia 1-2 g/day in divided doses for 7-14 days and until the patient is afebrile for 5-7 days.\n\nChild: 15 mg/kg bid (max: 2 g daily) for at least 10-14 days. \n\nRenal impairment: Modification in dose or dosing interval may be required.\nCrCl (ml/min)	\n10-50	Dosing interval: Every 24-72 hr.\n<10	        Dosing interval: Every 72-96 hr. \n\nContra-indication: Pregnancy; hypersensitivity.\n\nSide effects: Giddiness, vertigo, tinnitus, ataxia, hypersensitivity reactions, ototoxicity and nephrotoxicity.\nPotentially Fatal: Anaphylactic shock, aplastic anaemia and agranulocytosis. Stevens-Johnson syndrome and toxic epidermal necrolysis.\n\nPrecaution: Renal impairment. Lactation. Avoid topical and inhalational streptomycin. Regular audiometric tests are recommended for prolnoged therapy. Monitor renal function. Increased risk of neurotoxic effects when used in renally impaired patients. Neurotoxicity may cause respiratory paralysis especially if streptomycin is given soon after the use of anaesthesia or muscle relaxants.\n\n\nMode of action: H1-receptor blockers may mask early signs of ototoxicity. May reduce excretion of zalcitabine. May inhibit ?-galactosidase activity.\nPotentially Fatal: Potentiates nephrotoxicity produced by other aminoglycosides, vancomycin and some cephalosporins. Potentiates ototoxicity produced by other aminoglycosides, ethacrynic acid, mannitol, furosemide and other diuretics.\n\nPregnancy category: D\n\nInteraction: H1-receptor blockers may mask early signs of ototoxicity. May reduce excretion of zalcitabine. May inhibit ?-galactosidase activity.\nPotentially Fatal: Potentiates nephrotoxicity produced by other aminoglycosides, vancomycin and some cephalosporins. Potentiates ototoxicity produced by other aminoglycosides, ethacrynic acid, mannitol, furosemide and other diuretics.
Strontium Renalate	\n\n\tSquare\tStronel Sachet 2gm 7's pack 421.55\n\tIndication: Postmenopausal osteoporosis\n\nDose: Adult: PO 2 g/day.\n\nRenal impairment: No dosage adjustment needed.\nCrCl (ml/min)	\n<30	          Not recommended. \n\nContra-indication: Patients w/ current or previous venous thromboembolic events including deep vein thrombosis and pulmonary embolism; temporary or permanent immobilisation due to post-surgical recovery or prolonged bed rest; current or history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease; uncontrolled HTN. Lactation.\n\nSide effects: Nausea and diarrhoea. Headache, loose stools and eczema. Transient reversible increases in creatine kinase activity.\n\nPrecaution: Not recommended for use in patients with CrCl <30 ml/min. Patients at increased risk of venous thromboembolism. Pregnancy.\n\nMode of action: May reduce the absorption of oral tetracycline and quinolone antibiotics. Medicinal products containing Ca may reduce strontium ranelate bioavailability.\n\nPregnancy category: Not Classified\n\nInteraction: May reduce the absorption of oral tetracycline and quinolone antibiotics. Medicinal products containing Ca may reduce strontium ranelate bioavailability.
Sucralfate	\n\n\tAsiatic Ltd.\tUlsec TAB dr 1gm 24's pack 96\n\tBeximco\tGastalfet TAB dr 500mg 100's pack 402\n\tKemiko\tAntepsin TAB dr 1gm 100's pack 550\n\tIndication: Peptic ulcer, Chronic gastritis, GI haemorrhage from stress ulceration\n\nDose: Oral\nChronic gastritis\nAdult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Maintenance dose of 1 g bid may be given to prevent the recurrence of duodenal ulcers. Max: 8 g daily.\nChild: 1 mth-2 yr: 250 mg 4-6 times daily; 2-12 yr: 500 mg 4-6 times daily and 12-18 yr: 1 g 4-6 times daily.\n\nPeptic ulcer\nAdult: 1 g 4 times daily or 2 g bid for 4-8 wk, may extend up to 12 wk if necessary. Maintenance dose of 1 g bid may be given to prevent the recurrence of duodenal ulcers. Max: 8 g daily.\nChild: 1 mth-2 yr: 250 mg 4-6 times daily; 2-12 yr: 500 mg 4-6 times daily and 12-18 yr: 1 g 4-6 times daily.\n\nProphylaxis of gastrointestinal haemorrhage from stress ulceration\nAdult: 1 g 6 times daily. Not to exceed 8 g daily.\nChild: 1 mth-2 yr: 250 mg 4-6 times daily; 2-12 yr: 500 mg 4-6 times daily and 12-18 yr: 1 g 4-6 times daily.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Constipation, diarrhoea, nausea, dizziness, dry mouth. GI disturbances, rash, pruritus, headache, vertigo, back pain, drowsiness.\n\nPrecaution: Systemic aluminum toxicity may occur in patients with chronic renal failure. Neonates, children; pregnancy and lactation.\n\nMode of action: Avoid antacids within 30 min of sucralfate admin. May reduce absorption of tetracyclines, ranitidine, ketoconazole, theophylline, phenytoin, cimetidine and digoxin (ensure a dosing interval of at least 2 hr between admin of sucralfate and other non-antacid medications).\n\nPregnancy category: B\n\nInteraction: Avoid antacids within 30 min of sucralfate admin. May reduce absorption of tetracyclines, ranitidine, ketoconazole, theophylline, phenytoin, cimetidine and digoxin (ensure a dosing interval of at least 2 hr between admin of sucralfate and other non-antacid medications).
Sucralose	\n\n\tAcme Ltd.\tZero TAB dr 8mg 100's pack 100\n\tAd-din\tCalonil TAB dr 8mg 500's pack 500\n\tEskayef Bangladesh Ltd.\tKalfree TAB dr 8mg 100's pack 100\n\tEskayef Bangladesh Ltd.\tCal-x TAB dr 6.5g 100's pack 110\n\tEskayef Bangladesh Ltd.\tCalx Powder for suspension 10mg 25's pack 65\n\tIndication: Low calorie sweetner.\n\nDose: The acceptable daily intake of sucralose is 5-15 mg/kg body weight.\n\nNormally 1 tablet (8 mg) in a cup of tea or coffee is enough to sweeten the drink.\n\nContra-indication: No known contra indication.\n\nSide effects: No known side effects.\n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Sulfasalazine	\n\n\tAristopharma\tReumazin TAB dr 500mg 50's pack 260\n\tDrug International Ltd.\tSulfacol TAB dr 500mg 30's pack 150\n\tOpsonin Pharma\tSalazine TAB dr 500mg 50's pack 260\n\tPopular\tSulfazin TAB dr 500mg 30's pack 156.61\n\tUnimed & Unihealth Manufacturers Ltd.\tZulfidin-500 TAB dr 500 mg 30's pack 210\n\tIndication: Inflammatory bowel disease, Rheumatoid arthritis\n\nDose: Oral\nInflammatory bowel disease\nAdult: Initially, 1-2 g 4 times daily until remission occurs. Maintenance: 2 g/day in divided doses.\nChild: >2 yr: 40-60 mg/kg/day in divided doses. Maintenance: 20-30 mg/kg/day in divided doses.\n\nRheumatoid arthritis\nAdult: As enteric-coated tablet: Initially, 500 mg daily for the 1st wk increased by 500 mg every wk. Max: 3 g daily in 2-4 divided doses.\nChild: For polyarticular juvenile rheumatoid arthritis: >6 yr: As enteric-coated tablet: 30-50 mg/kg/day in 2 divided doses. Begin treatment with 1/4 to 2/3 of expected maintenance dose and increase wkly to reach maintenance dose in 1 mth. Max: 2 g daily. \n\nRenal impairment:\nCrCl (ml/min)	\n10-30 mL/min	Admin twice daily.\n<10ml/min	Admin once daily.\n\nHepatic impairment: Avoid use.\n\nContra-indication: Hypersensitivity to sulphonamides or salicylates, porphyria, <2 yr of age, intestinal or urinary obstruction, blood dycrasias, history of leucopenia with gold therapy.\n\nSide effects: Headache, anorexia, nausea, vomiting, diarrhoea, abdominal discomfort, photosensitivity, crystalluria, reversible oligospermia, yellow-orange staining of contact lens, skin, urine and other body fluids, alopoecia.\nPotentially Fatal: Severe hypersensitivity reactions, blood dyscrasias, renal and hepatic toxicity, fibrosing alveolitis.\n\nPrecaution: Hepatic/renal impairment, G6PD deficiency, allergic bronchial asthma, lactation.\n\nMode of action: Plasma levels reduced by rifampicin and ethambutol. Interferes with absorption of folic acid. Additive leucopaenia with gold therapy for rheumatoid arthritis. Increased haematological toxicity with azathioprine. Reduced serum levels of digoxin.\n\nPregnancy category: B\n\nInteraction: Plasma levels reduced by rifampicin and ethambutol. Interferes with absorption of folic acid. Additive leucopaenia with gold therapy for rheumatoid arthritis. Increased haematological toxicity with azathioprine. Reduced serum levels of digoxin.
Sulfinpyrazone	\n\n\tIncepta\tPyrazone TAB dr 200mg 20's pack 800\n\tIndication: Hyperuricaemia with gout\n\nDose: Oral\nHyperuricaemia with gout\nAdult: Initially, 100-200 mg bid, increased gradually over 1-3 wk to 600 mg/day, then maintain at 200 mg/day after the plasma-urate conc is controlled. Max: 800mg/day.\n\nRenal impairment:\nCrCl (ml/min)	\n<50ml/min	Avoid usage.\n\nContra-indication: Uric acid renal calculi; history or active peptic ulcer, GI inflammation; blood dyscrasias; blood coagulation disorders; porphyria; severe kidney or liver impairment. Hypersensitivity to pyrazole derivatives or provoked by drugs inhibiting prostaglandin synthesis.\n\nSide effects: Nausea, vomitting, diarrhoea, skin rashes, renal impairment or failure, salt and water retention, blood dyscrasia, jaundice, hepatitis, acute gout attacks, uric acid renal calculi development if inadequate fluid intake.\n\nPrecaution: Renal impairment, heart failure. May exacerbate and prolong acute attack of gout; start treatment only after acute attack has subsided. Not suitable for the control of hyperuricaemia associated w/ cancer or cancer chemotherapy. Lactation.\n\nMode of action: Reduced antihypertensive effect of oxprenolol. Concurrent use decreased plasma concentration of verapamil and ciclosporin. Concurrent use increased phenytoin and benzylpenicillin concentration. Increased risk of bleeding with fondaparinux and antiplatelet agents. Increased anticoagulant effect of warfarin and acenocoumarol. Reduced uricosuric effects with concurrent salicylate use.\nPotentially Fatal: Serious GI bleeding and decreased platelet aggregation when used with thrombolytic agents.\n\nPregnancy category: Not Classified\n\nInteraction: Reduced antihypertensive effect of oxprenolol. Concurrent use decreased plasma concentration of verapamil and ciclosporin. Concurrent use increased phenytoin and benzylpenicillin concentration. Increased risk of bleeding with fondaparinux and antiplatelet agents. Increased anticoagulant effect of warfarin and acenocoumarol. Reduced uricosuric effects with concurrent salicylate use.\nPotentially Fatal: Serious GI bleeding and decreased platelet aggregation when used with thrombolytic agents.
Sulindac	\n\n\tAlco Pharma\tSunil TAB dr 100mg 100's pack 250\n\tDrug International Ltd.\tSudac TAB dr 100mg  \n\tDrug International Ltd.\tSudac TAB dr 200mg  \n\tEskayef Bangladesh Ltd.\tSulidac TAB dr 100mg 50's pack 250\n\tEskayef Bangladesh Ltd.\tSulidac TAB dr 200mg  \n\tOpsonin Pharma\tClinorel TAB dr 100mg 50's pack 250\n\tOpsonin Pharma\tClinorel TAB dr 200mg 30's pack 286.20\n\tPopular\tLindac TAB dr 100mg 50's pack 251\n\tPopular\tLindac TAB dr 200mg 50's pack 477\n\tIndication: Rheumatoid arthritis, Osteoarthritis, Acute gouty arthritis, Ankylosing spondylitis, Acute painful shoulder\n\nDose: Adult: PO Symptomatic treatment of rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis 150 mg twice daily. \nAcute painful shoulder 200mg twice daily; usually for 7-14 days. \nAcute gouty arthritis200 mg twice daily; usually for 7 days. Max: 400mg/day.\n\nHepatic impairment: Acute and chronic hepatic disease: May need dosage reduction.\n\nContra-indication: Hypersensitivity. Pregnancy (3rd trimester), treatment of peri-operative pain in CABG surgery .\n\nSide effects: Headache, dizziness, nausea, vomiting, dyspepsia, GI cramps and pain, diarrhoea, constipation, flatulence, anorexia, tinnitus, rash, pruritus, erythema multiforme, nervousness, oedema, urine discoloration, muscle weakness, sore or dry mucous membranes, stomatitis, gastritis, peptic ulcer, GI bleeding, alopecia, photosensitivity, congestive heart failure, arrhythmia, hyperkalaemia, thrombocytopenia, leukopenia, agranulocytosis, liver function abnormalities, jaundice, cholestasis, hepatitis, hepatic failure, pancreatitis, proteinuria, renal calculi, interstitial nephritis, nephritic syndrome, renal failure, hypersensitivity reactions, and hypersensitivity vasculitis.\nPotentially Fatal: Anaphylaxis reactions; cross-sensitivity reactions in patients with known aspirin triad reactions; Steven-Johnson Syndrome and toxic epidermal necrolysis.\n\nPrecaution: Use at lowest effective dose for shortest duration possible. NSAIDs may increase risk of severe cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Risk may be increased with duration of use or pre-existing CV disease or risk factors. Treatment has been associated with new onset hypertension or worsening of pre-existing hypertension. May cause fluid retention and oedema; caution in heart failure. NSAIDs can cause serious GI adverse events including GI inflammation, ulceration, bleeding, and perforation. Caution in patients with history of GI disease; concomitant use of aspirin, anticoagulants and/or oral corticosteroids; smoking, use of alcohol, elderly or debilitated patients. Anaemia may occur, monitor CBC in patients who are on long term NSAIDs. May inhibit platelet aggregation and prolong bleeding in some patients. Rare cases of sever hepatotoxicity including jaundice, fatal fulminant hepatitis, liver necrosis and hepatic failure have been reported. May cause renal impairment; patients with pre-existing renal impairment, heart failure, liver dysfunction, concomitant use of diuretics and ACE inhibitors, volume-depleted and elderly are at greater risk. Use is not recommended in advance renal impairment. Caution in patients with pre-existing asthma; avoid in patients with history of aspirin-sensitive asthma. May cause serious skin reactions including exfoliative dermatitis, Steven-Johnson syndrome and toxic epidermal necrolysis. Aseptic meningitis in patients with SLE; pancreatitis have been reported. Pharmacokinetics has not been studied in paediatric patients. Should not be used during 3rd trimester of pregnancy. Lactation.\n\nMode of action: Concomittent use with dimethyl sulfoxide may result in peripheral neuropathy. Increased nephrotoxicity with ciclosporin; increased risk of methotrexate toxicity; increased risk of bleeding with other NSAIDs, warfarin and thrombolytic agents. Antagonises effect of antihypertensives. Unpredictable interactions with lithium.\n\nPregnancy category: D\n\nInteraction: Concomittent use with dimethyl sulfoxide may result in peripheral neuropathy. Increased nephrotoxicity with ciclosporin; increased risk of methotrexate toxicity; increased risk of bleeding with other NSAIDs, warfarin and thrombolytic agents. Antagonises effect of antihypertensives. Unpredictable interactions with lithium.
Sulphacetamide Sodium 10% Eye prep	\n\n\tNipa\tIcid 10% Eye Drops   10% x 10 ml 19.22\n\tIndication: Conjunctivitis, Blepharitis, Ocular infections\n\nDose: Ophthalmic\nOcular infections\nAdult: As sodium: Apply 10-30% eye drops or 10% ointment into the affected eye/s. May be used up to tid.\n\nContra-indication: Hypersensitivity; infants <2 mth.\n\nSide effects: Hypersensitivity skin reaction. Ophthalmic: Burning, stinging, conjunctivitis, corneal ulcers, irritation, conjunctival hyperaemia. Systemic absorption from inflamed conjunctiva.\nPotentially Fatal: Stevens-Johnson syndrome.\n\nPrecaution: Elderly. History of allergy or asthma; G6PD deficiency; renal and hepatic impairment. Prolonged therapy requires CBC and urinalysis with microscopic examination. Maintain adequate fluid intake. Pregnancy, lactation.\n\nMode of action:  Action antagonised by PABA and procaine group of local anaesthetics. PABA present in purulent eye exudates can competitively inhibit the action of sulphacetamide.\n\nPregnancy category: C\n\nInteraction:  Action antagonised by PABA and procaine group of local anaesthetics. PABA present in purulent eye exudates can competitively inhibit the action of sulphacetamide.
Sulphacetamide Sodium 20% Eye prep	\n\n\tNipa\tIcid 20% Eye Drops   20% x 10 ml 27\n\tReman Drug Ltd.\tOptacid 20% Eye Drops    20% x 10 ml 45\n\tIndication: Conjunctivitis, Blepharitis, Ocular infections\n\nDose: Ophthalmic\nOcular infections\nAdult: As sodium: Apply 10-30% eye drops or 10% ointment into the affected eye/s. May be used up to tid.\n\nContra-indication: Hypersensitivity; infants <2 mth.\n\nSide effects: Hypersensitivity skin reaction. Ophthalmic: Burning, stinging, conjunctivitis, corneal ulcers, irritation, conjunctival hyperaemia. Systemic absorption from inflamed conjunctiva.\nPotentially Fatal: Stevens-Johnson syndrome.\n\nPrecaution: Elderly. History of allergy or asthma; G6PD deficiency; renal and hepatic impairment. Prolonged therapy requires CBC and urinalysis with microscopic examination. Maintain adequate fluid intake. Pregnancy, lactation.\n\nMode of action: Action antagonised by PABA and procaine group of local anaesthetics. PABA present in purulent eye exudates can competitively inhibit the action of sulphacetamide.\n\nPregnancy category: C\n\nInteraction: Action antagonised by PABA and procaine group of local anaesthetics. PABA present in purulent eye exudates can competitively inhibit the action of sulphacetamide.
Sulphadiazine + Trimethoprim	\n\n\tIndication: UTI\n\nDose: Oral\nUrinary tract infections\nAdult: Per tablet contains sulfadiazine 410 mg and trimethoprim 90 mg or per 5 mL suspension contains sulfadiazine 205 mg and trimethoprim 45 mg: 2 tablets or 20 mL as a single dose every 24 hr.\n\nChild: >3 mth: Per day: 14 mg sulfadiazine/kg+3 mg trimethoprim/kg. Daily dose is divided into 2 equal doses given every 12 hr.\n\nContra-indication: Hypersensitivity; severe renal/hepatic impairment; blood dyscrasias, porphyrias, serious hematological disorders; megaloblastic anemia secondary to folate depletion. Infants <2 mth; pregnancy (at term), lactation.\n\nSide effects: Nausea, vomiting, anorexia and diarrhoea. Hypersensitivity, skin reactions; lumbar pain, haematuria, oliguria, anuria, crystallisation in urine, thrombocytopaenia, leucopaenia, eosinophilia, neonatal jaundice and kernicterus.\nPotentially Fatal: Stevens-Johnson syndrome; agranulocytosis, thrombocytopaenia, jaundice in new born. Mild GI disturbances; pruritus; skin rash; sulfonamide-like skin reactions; disturbances of liver enzyme values, cholestatic jaundice; raised serum creatinine and BUN; fever; anaphylaxis; aseptic meningitis; hematologic disturbances; photosensitivity; induce hyperkalemia particularly in HIV patients being treated for Pneumocystis carinii pneumonia or in the elderly.\n\nPrecaution: Elderly, adequate fluid intake, G6PD deficiency, AIDS; actual or possible folate deficiency, child with fragile X chromosome associated with mental retardation; discontinue in case of skin rash; perform regular hematological examination.\n\nMode of action: Sulphadiazine: Potentiates antidiabetic effect of sulphonylureas. Action antagonised by para-aminobenzoinc acid and procaine group of local anaesthetics.\n\nTrimethoprim: Potentiate effects of phenytoin, digoxin, procainamide, warfarin. Reduces renal excretion of zalcitabine, zidovudine and lamivudine. Dapsone; rifampicin; increase risk of nephrotoxicity when given with cyclosporin; severe hyperkalaemia when given with ACE inhibitor; depressants of bone marrow function; risk of megaloblastic anemia with other folate inhibitors eg pyrimethamine, methotrexate; hyponatraemia if receiving diuretics concurrently.\n\nPotentially Fatal: Potentiates oral anticoagulants, methotrexate and phenytoin. Ascorbic acid and hexamine may precipitate crystalluria; metabolism of oral hypoglycaemics may be inhibited.\n\nPregnancy category: A\n\nInteraction: Sulphadiazine: Potentiates antidiabetic effect of sulphonylureas. Action antagonised by para-aminobenzoinc acid and procaine group of local anaesthetics.\n\nTrimethoprim: Potentiate effects of phenytoin, digoxin, procainamide, warfarin. Reduces renal excretion of zalcitabine, zidovudine and lamivudine. Dapsone; rifampicin; increase risk of nephrotoxicity when given with cyclosporin; severe hyperkalaemia when given with ACE inhibitor; depressants of bone marrow function; risk of megaloblastic anemia with other folate inhibitors eg pyrimethamine, methotrexate; hyponatraemia if receiving diuretics concurrently.\n\nPotentially Fatal: Potentiates oral anticoagulants, methotrexate and phenytoin. Ascorbic acid and hexamine may precipitate crystalluria; metabolism of oral hypoglycaemics may be inhibited.
Sulphadimidine	\n\n\tIndication: UTI\n\nDose: Oral\nSusceptible infections\nAdult: Initially, 2 g then 0.5-1 g every 6-8 hr.\nRenal impairment: Dose reduction may be needed. Severe: Contraindicated.\nHepatic impairment: Dose reduction may be needed. Severe: Contraindicated.\n\nContra-indication: Severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; acute porphyria; SLE. Pregnancy (3rd trimester) and lactation; infants ?2 mth.\n\nSide effects: Nausea, vomiting, anorexia, diarrhoea, hypersensitivity reactions, SLE, serum sickness-like syndrome, liver necrosis and hepatomegaly, myocarditis, pulmonary eosinophilia and fibrosing alveolitis, vasculitis, hypoglycaemia, hypothyroidism, neurological reactions, jaundice and kernicterus in premature neonates. Pseudomembranous colitis.\nPotentially Fatal: Stevens-Johnson syndrome; toxic epidermal necrolysis; blood dyscrasias; anaphylaxis.\n\nPrecaution: Renal or hepatic impairment; history of allergy or asthma; AIDS; G6PD deficiency; elderly; ensure adequate fluid intake to reduce risk of crystalluria.\n\nMode of action: Potentiates effects of oral anticoagulants, methotrexate, phenytoin. Compounds that render the urine acidic increase risk of crystalluria.\nPotentially Fatal: Increased blood dyscrasias with clozapine\n\nPregnancy category: Not Classified\n\nInteraction: Potentiates effects of oral anticoagulants, methotrexate, phenytoin. Compounds that render the urine acidic increase risk of crystalluria.\nPotentially Fatal: Increased blood dyscrasias with clozapine
Sulphamethoxazole + Trimethoprim	\n\n\tACI\tAvlotrin Suspension  240mg/5ml 60ml bot 22.21\n\tACI\tAvlotrin DS TAB dr  960mg 100's pack 201\n\tAcme Ltd.\tPolitrim Suspension   60ml bot 21.58\n\tAcme Ltd.\tPolitrim TAB dr   100's pack 142\n\tAcme Ltd.\tPolitrim DS TAB dr   100's pack 264\n\tAd-din\tCo-try-DS TAB dr 960mg 100's pack 186\n\tAd-din\tCo-try Suspension 240mg 60ml bot 21.50\n\tAexim\tTrimetrin Suspension   60ml bot 21\n\tAlbion Ltd.\tAlbutrim Suspension (4g + 0.8g) /100ml 60 ml \n\tAlbion Ltd.\tAlbutrim-DS TAB dr 800 mg+ 160 mg 100's pack \n\tAlco Pharma\tMegaset TAB dr 960mg 100's pack 202\n\tAlco Pharma\tNeoset TAB dr 480mg 100's pack 142\n\tAlco Pharma\tNeoset Suspension 240mg 60ml bot 20.99\n\tAmbee\tSumetrolim Suspension   60ml bot 21.61\n\tAmbee\tSoma DS TAB dr 960mg 100's pack 203\n\tAmico Ltd.\tSulphatrim DS TAB dr   100's pack 250\n\tAmico Ltd.\tSulphatrim TAB dr   100's pack 149\n\tAmico Ltd.\tSulphatrim DS Suspension   60ml bot 22.10\n\tAPC Pharma Ltd.\tApcetrim Suspension   60ml bot 20\n\tApollo Pharmaceutical Ltd.\tAptrim Suspension   60ml bot 20.54\n\tAsiatic Ltd.\tSeptra Suspension   60ml bot 21.57\n\tAsiatic Ltd.\tSeptra TAB dr   100's pack 149\n\tBelsen\tPaba Suspension 240mg 60ml bot 20\n\tBeximco\tMegatrim Suspension   60ml bot 21.10\n\tBeximco\tMegatrim DS TAB dr 960mg 150's pack 390\n\tBeximco\tTrimoprim TAB dr 400 mg + 80 mg  \n\tBio Pharma Ltd.\tBiotrim Suspension   60ml bot 21.56\n\tBio Pharma Ltd.\tBiotrim TAB dr   100's pack 149\n\tBio Pharma Ltd.\tBiotrim DS TAB dr   100's pack 201\n\tCentral.\tCentrim Suspension   60ml bot 20\n\tCentral.\tCentrim DS TAB dr   100's pack 200\n\tDecent Pharma Ltd.\tDecatrim Suspension   60ml bot 21.83\n\tDecent Pharma Ltd.\tDecatrim DS TAB dr 960mg 100's pack 150\n\tDesh\tDeotrim Suspension   60ml bot 21.80\n\tDesh\tDeotrim TAB dr   100's pack 200\n\tDoctor's Chemicals Works Ltd.\tDoctrim Suspension   60ml bot 21\n\tDoctor's Chemicals Works Ltd.\tDoctrim TAB dr   100's pack 102\n\tDrug International Ltd.\tDitrim Suspension   100's pack 21.39\n\tDrug International Ltd.\tDitrim TAB dr  480 100's pack 201\n\tEdruc Ltd.\tEditrim Suspension   60ml bot 21.50\n\tEdruc Ltd.\tEditrim DS TAB dr   100's pack 202\n\tEskayef Bangladesh Ltd.\tCosat Suspension   60ml bot 22\n\tEskayef Bangladesh Ltd.\tCosat DS TAB dr   100's pack 202\n\tEskayef Bangladesh Ltd.\tCosat TAB dr   100's pack \n\tGeneral\tGentrim Suspension   60ml bot 22.13\n\tGeneral\tGentrim TAB dr   100's pack 149\n\tGlobe\tActrim Suspension   60ml bot 22\n\tGlobe\tActrim TAB dr   100's pack 90\n\tGlobe\tActrim DS TAB dr   100's pack 140\n\tGonoshasthaya\tG Cotrimoxazole Suspension   50ml bot/100ml bot 19/28.10\n\tGonoshasthaya\tG Cotrimoxazole TAB dr   100's pack/500's pack 121/605\n\tGonoshasthaya\tG-Cotrimoxazole DS TAB dr 960mg 100's pack 177\n\tHudson\tSeftrim Suspension   60ml bot 17\n\tHudson\tSeftrim DS Suspension 960mg 100's pack 150\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinatrim Suspension   60ml bot 22\n\tIbn Sina Pharmaceutical Ind. Ltd.\tSinatrim DS TAB dr   100's pack 210\n\tIncepta\tIncotim Suspension (200 mg + 40 mg)/5 ml  \n\tIncepta\tIncotim TAB dr 800 mg + 160 mg  \n\tIncepta\tIncotim TAB dr 400 mg + 80 mg  \n\tIndobangla Pharmaceuticals\tCotrimox Suspension   60ml bot 21\n\tIndobangla Pharmaceuticals\tCotrimox TAB dr   100's pack 135\n\tIndobangla Pharmaceuticals\tCotrimox DS TAB dr   100's pack 200\n\tJayson\tJasotrim Suspension   60ml bot 21.61\n\tJayson\tJasotrim TAB dr   100's pack 149\n\tKemiko\tK Trim Suspension   60ml bot 20\n\tMedicon\tNeotrim Suspension   60ml bot 22\n\tMedicon\tNeotrim TAB dr  480mg 100's pack 140\n\tMedicon\tNeotrim-DS TAB dr 960mg 100's pack 200\n\tMedimet\tMeditrim Suspension  240/5ml 60ml bot 20\n\tMedimet\tMeditrim TAB dr  480mg 100's pack 148\n\tMedimet\tMeditrim 960 TAB dr   50's pack 130\n\tMillat\tLitrim Suspension   60ml bot 21.05\n\tMillat\tLitrim TAB dr   100's pack 202\n\tModern\tM-Trim Suspension   60ml bot 21.24\n\tModern\tM-Trim TAB dr   100's pack 202\n\tNavana\tNavatrim Powder for Suspension   60ml bot 21.07\n\tNavana\tNavatrim TAB dr   100's pack \n\tNavana\tNavatrim DS TAB dr   100's pack 201\n\tNipa\tSuprim Suspension   60ml bot 20\n\tNipa\tSuprim DS TAB dr   50's pack 101\n\tNovartis (Bangladesh) Ltd.\tServitrim TAB dr   100's pack 142\n\tOpsonin Pharma\tCots Suspension   60ml bot 21.25\n\tOpsonin Pharma\tCots DS TAB dr  960mg 50's pack 100\n\tOrion Pharma Ltd.\tOctrim Suspension   60ml bot 21.08\n\tOrion Pharma Ltd.\tOctrim-DS TAB dr   100's pack \n\tPacific\tAlcot Suspension   60ml bot 20\n\tPacific\tAlcot TAB dr   100's pack 100\n\tPacific\tAlcot DS TAB dr   100's pack 200\n\tPharmadesh Ltd.\tPharmatrim Suspension   60ml bot 21.58\n\tPharmadesh Ltd.\tPharmatrim TAB dr   100's pack 219\n\tReliance\tSemotrim Suspension   60ml bot 22\n\tReliance\tSemotrim DS Suspension 960mg 100's pack 206\n\tReman Drug Ltd.\tTricot Suspension   60ml bot 21.50\n\tReman Drug Ltd.\tTricot-DS TAB dr 960mg 100's pack 210\n\tRenata\tBactipront Suspension   60ml bot 22.06\n\tRenata\tBactipront TAB dr   100's pack 148\n\tRenata\tBactipront DS TAB dr   100's pack 202\n\tRenata\tBactipront p-120 TAB dr 120mg 100's pack 48\n\tSalton\tSaltrim Suspension   60ml bot 21.08\n\tSalton\tSaltrim DS TAB dr   50's pack 100.50\n\tSanofi Aventis (BD) Ltd.\tFisat TAB dr   100's pack 151\n\tSeema\tSeematrin Suspension   60ml bot 24\n\tSilva\tSitrim Suspension   60ml bot 20.07\n\tSilva\tSitrim TAB dr   100's pack 200.75\n\tSomatec\tSulprim Suspension   60ml bot 21.07\n\tSomatec\tSulprim TAB dr   100's pack 201\n\tSquare\tCotrim DS TAB dr   100's pack 203.49\n\tSquare\tCotrim TAB dr   100's pack 203.49\n\tSquare\tCotrim Suspension 240mg 60ml bot 21.58\n\tSupreme\tTriprim Suspension   60ml bot 21\n\tSupreme\tTriprim DS TAB dr   100's pack 200\n\tSyntho Ltd.\tSytrim Suspension   60ml bot 21.25\n\tSyntho Ltd.\tSytrim DS TAB dr 960mg 50's pack 100\n\tZenith\tCotrazen Suspension   60ml bot 21.22\n\tZenith\tCotrazen TAB dr   100's pack 130\n\tZenith\tCotrazen DS TAB dr   100's pack 200\n\tIndication: Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias\n\nDose: Adult: PO Tablet : 2 tablet twice daily. In severe cases, 3 times/day. DS Tablet : 1 tablet twice daily. \nSuspension : 1-2 teaspoonful twice daily.\n\nGI infections; Resp and urinary tract infections; Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. \n\nPneumocystis (carinii) jiroveci pneumonia Up to 120 mg/kg/day in 2-4 divided doses for 14-21 days. Infection prophylaxis in AIDS patients 960 mg/day.\n\nChild: 6 wk-5 mth: 120 mg bid; 6 mth-5 yr: 240 mg bid; 6-12 yr: 480 mg bid.\n\nRenal impairment: Dosage reduction for adults and children >12 yr:\nCrCl (ml/min)	\n15-30	Half the standard dose.\n<15	        Not recommended.\n\nContra-indication: Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.\n\nSide effects: Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.\nPotentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.\n\nPrecaution: G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.\n\nMode of action: Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.\nPotentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.\n\nPregnancy category: D\n\nInteraction: Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.\nPotentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
Sumatriptan	\n\n\tAmbee\tNomigran TAB dr 50mg 4 tabs pack 180.60\n\tAmbee\tNomigran TAB dr 100mg 4 tabs pack 361.40\n\tGeneral\tSumigran TAB dr 50mg 4 tabs pack 120.44\n\tIndication: Migraine, Cluster headache\n\nDose: Adult: PO Migraine >18 yr: 50-100 mg, repeat 2 hrly if migraine recurs. Max: 300 mg/24 hr.  \n\nContra-indication: Not to be used prophylactically and in patients with basilar or hemiplegic or ophthalmoplegic migraine. History of MI or stroke, severe hepatic impairment, ischaemic heart disease, uncontrolled hypertension, peripheral vascular disease, hypersensitivity to sulfonamides.\n\nSide effects: Transient hypertension, hypotension, dizziness, flushing, fatigue, drowsiness, weakness, seizures, nausea and vomiting, heat, tightness in any part of body, paraesthesia, seizures, inj site reactions, irritation of nasal mucosa and epistaxis. Rebound headache with frequent use.\nPotentially Fatal: Cardiac arrhythmias, MI.\n\nPrecaution: Conditions predisposing to seizures, presence of coronary risk factors, cardiac arrhythmias, renal or hepatic impairment, elderly, pregnancy, lactation.\n\n\nMode of action: Concurrent use increased risk of vasospastic reaction with ergotamine and related compounds.\nPotentially Fatal: Increased risk of serotonin syndrome with concurrent use of SSRI, MAOIs or within 14 days of stopping MAOIs. Admin of ergotamine or related compounds within the previous 24 hr.\n\nPregnancy category: C\n\nInteraction: Concurrent use increased risk of vasospastic reaction with ergotamine and related compounds.\nPotentially Fatal: Increased risk of serotonin syndrome with concurrent use of SSRI, MAOIs or within 14 days of stopping MAOIs. Admin of ergotamine or related compounds within the previous 24 hr.
Sunitinib	\n\n\tBeacon\tSunitix CAP 50mg  \n\tIndication: Leukemia, Renal cell carcinoma, Gastrointestinal stromal tumor, Meningioma\n\nDose: GI Stromal Tumor, Metastatic Renal Cell Carcinoma\n\n50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle\n\nDose modification GI stromal tumor (GIST) or metastic renal cell carcinoma (MRCC)\n\n    Increase or reduce dose in 12.5-mg increments based on individual safety and tolerability\n   \nPancreatic Neuroendocrine Tumors\n\nIndicated for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease\n\nStandard dose: 37.5 mg PO qDay continuously without a scheduled off-treatment period\n\n\n\n\nContra-indication: Hypersensitivity\n\nRenal impairment\n\nSide effects: Dyspepsia \n\nAltered taste \n\nFatigue \n\nDiarrhea \n\nRash \n\nVomiting \n\nConstipation \n\nSkin discoloration\n\nAbdominal pain \n\nNausea \n\nAnorexia \n\nMucositis/stomatitis \n\nDyspnea \n\nHTN (MRCC 28%; GIST 15%)\n\nArthralgia\nBleeding \n\nHeadache \n\nAsthenia \n\nLymphopenia \n\nVenous thrombotic events\n\nHemorrhoids\n\nPancreatitis\n\nFlu-like syndrome\n\n\nHepatotoxicity\n\nAcute renal failure\n\nAdrenal dysfunction\n\n\nPrecaution: Hepatotoxicity has been observed in clinical trials (7/2281) and post-marketing experience (0.3%)\n\nHepatotoxicity may be severe and deaths have been reported\n\nMonitor liver function tests (ALT, AST, bilirubin) before treatment initiation, during each treatment cycle, and as clinically indicated\n\nInterrupted for Grade 3 or 4 drug-related hepatic related adverse events and discontinued if there is no resolution\n\nDo not restart if subsequently experience severe changes in liver function tests or other signs and symptoms of liver failure emerge\n\nSafety in patients with ALT or AST >2.5 x ULN or, if due to liver metastases, >5 x ULN has not been established\n\nUse and handle product with caution \n\nMode of action: Increased plasma conc w/ strong CYP3A4 inhibitors (eg ketoconazole, ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice). Decreased plasma conc w/ strong CYP3A4 inducers [eg rifampin, dexamethasone, phenytoin, carbamazepine, phenobarb, St. John's wort (Hypericum perforatum)]. Anticoagulants eg warfarin, acenocoumarol (periodically monitor platelets, prothrombin time/INR & physical exam).\n\nPregnancy category: D\n\nInteraction: Increased plasma conc w/ strong CYP3A4 inhibitors (eg ketoconazole, ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice). Decreased plasma conc w/ strong CYP3A4 inducers [eg rifampin, dexamethasone, phenytoin, carbamazepine, phenobarb, St. John's wort (Hypericum perforatum)]. Anticoagulants eg warfarin, acenocoumarol (periodically monitor platelets, prothrombin time/INR & physical exam).
Suxamethonium Chloride	\n\n\tACI\tRapilax Injection 100mg/2ml 2ml amp x 10's pack 84.30\n\tChemist Ltd.\tSuxa Injection 100mg/2ml 2ml amp x 5's pack 41.50\n\tPopular\tNeosuxa Injection 100mg/2ml 2ml amp x 10's pack 84\n\tTechno Drugs Ltd.\tSuxonium Injection 100mg/2ml 2ml amp x 10's pack 84\n\tIndication: Muscle relaxant\n\nDose: Intravenous\nMuscle relaxant in general anaesthesia\nAdult: As chloride: single dose of 0.3-1.1 mg/kg injected; supplementary doses of 50-100% of the initial dose may be given at 5-10 min intervals. Max dose (repeated IV injection or continuous infusion): 500 mg/hr\nChild: As chloride: <1 yr: 2 mg/kg; 1-12 yr: 1 mg/kg.\nIntramuscular\nMuscle relaxant in general anaesthesia\nAdult: As chloride: 3-4 mg/kg. Max total dose: 150 mg\nChild: As chloride: <1 yr: Up to 4-5 mg/kg; ?1 yr: Up to 4 mg/kg. Max dose: 150 mg.\n\nContra-indication: Genetic disorders of plasma pseudocholinesterase, personal/family history of malignant hyperthermia, hypersensitivity from previous neuromuscular drug, severe burns, massive trauma, extensive denervation of skeletal muscle, patients with risk of hyperkalaemia, renal impairment, angle closure glaucoma.\n\nSide effects: Bradycardia, tachycardia, hypotension, hyperpertension, raised intraocular pressure, hyperkalaemia, excessive salivation.\nPotentially Fatal: Respiratory depression, dysrhythmias, rhabdomyolsis, malignant hyperthermia.\n\nPrecaution: Bone fracture, raised intraocular pressure, neuromuscular disease, infants, childn, adolescents, pregnancy and lactation.\n\nMode of action: Concurrent use with anticholinesterases, cyclophosphamide, antiarrhythmics, aminoglycosides, lincosamides (clindamycin and lincomycin), anticonvulsants, phenelzine, magnesium, metoclopramide, inhalation anaesthetics, exposure to organophosphate insecticides may enhance neuromuscular block of suxamethonium. Increased risk of arrhythmias with cardiac glycosides.\n\nPregnancy category: C\n\nInteraction: Concurrent use with anticholinesterases, cyclophosphamide, antiarrhythmics, aminoglycosides, lincosamides (clindamycin and lincomycin), anticonvulsants, phenelzine, magnesium, metoclopramide, inhalation anaesthetics, exposure to organophosphate insecticides may enhance neuromuscular block of suxamethonium. Increased risk of arrhythmias with cardiac glycosides.
Tacrolimus 0.1%, 0.03% Topical	\n\n\tAcme Ltd.\tTacrol Ointment  0.03% 5gm tube/10gm tube 80.30/150.57\n\tBeximco\tAtolimus Ointment  0.03% 5gm tube  80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tDermus Ointment   5gm tube/10gm tube 80/150\n\tIncepta\tTacrolim Ointment 0.1%, 0.03%   5gm tube 80/200\n\tSquare\tRemus Ointment  0.1%, 0.03%  5gm tube / 5gm tube 80.30 / 200\n\tUnimed & Unihealth Manufacturers Ltd.\tVitilimus Ointment 100 mg/100 gm  \n\tUnimed & Unihealth Manufacturers Ltd.\tVitilimus Ointment 30 mg/100 gm  \n\tIndication: Atopic dermatitis, Allergic contact dermatitis, Severe eczema, Psoriasis, Alopecia areata, Pyoderma gangrenosum, Cutaneous lupus erythematosus, Dermatomyositis, Seborrheic dermatitis, Rosacea, Lichen Planus, Pemphigus Vulgaris, Vitiligo, Graft-Versus-Host Disease, Ichthyosis.\n\nDose: Apply a thin layer of Tacrolim ointment onto the affected skin areas twice daily and rub in gently and completely. Treatment should be continued for one week after clearing of signs and symptoms of atopic dermatitis. The safety of Tacrolim ointment under occlusion which may promote systemic exposure has not been evaluated. Tacrolim ointment should not be used with occlusive dressings. \n\nContra-indication: Tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to Tacrolimus or any other component of the preparation.\n\nSide effects: Topically applied Tacrolimus ointment have very few and rare type of side-effects including skin burning, pruritus, flu-like symptoms, allergic reactions, skin erythema, skin infections, headache, etc.\n\nPrecaution: Cautions should be exercised while treatment with Tacrolimus ointment in patients with atopic dermatitis predisposed to superficial skin infections. The safety of Tacrolimus ointment has not been established in patients with generalized erythroderma.\n\nMode of action: Increased nephrotoxicity with ciclosporin, aminoglycosides, amphotericin B, cisplatin, NSAIDs, vancomycin, co-trimoxazole, aciclovir, ganciclovir. Increased risk of hyperkalemia with potassium-sparing diuretics. Increased plasma concentrations and toxicity with azole antifungals, calcium-channel blockers, cimetidine, danazol, HIV-protease inhibitors, macrolide antibacterials and metoclopramide. Antacids, rifampin, rifabutin, casofungin, phenytoin, phenobarbital and carbamazepine decrease tacrolimus plasma concentrations. Concurrent admin of sirolimus and tacrolimus decrease levels of both.\n\nPregnancy category: C\n\nInteraction: Increased nephrotoxicity with ciclosporin, aminoglycosides, amphotericin B, cisplatin, NSAIDs, vancomycin, co-trimoxazole, aciclovir, ganciclovir. Increased risk of hyperkalemia with potassium-sparing diuretics. Increased plasma concentrations and toxicity with azole antifungals, calcium-channel blockers, cimetidine, danazol, HIV-protease inhibitors, macrolide antibacterials and metoclopramide. Antacids, rifampin, rifabutin, casofungin, phenytoin, phenobarbital and carbamazepine decrease tacrolimus plasma concentrations. Concurrent admin of sirolimus and tacrolimus decrease levels of both.
Tadalafil	\n\n\tACI\tCiaton TAB dr 10mg 4's pack 140.44\n\tACI\tCiaton TAB dr 20mg 4's pack 240.72\n\tACI\tCiaton TAB dr 5mg 4's pack 72.20\n\tAcme Ltd.\tMegafil TAB dr 10mg 10ml 350\n\tAlco Pharma\tViev TAB dr 10mg 4's pack 140\n\tAlco Pharma\tViev TAB dr 20mg 4's pack 240\n\tAristopharma\tPawar TAB dr 10mg 10's pack 350\n\tAristopharma\tPawar TAB dr 20mg 10's pack 600\n\tAristopharma\tPawar TAB dr 5mg 10's pack 180\n\tAstra Biopharmaceuticals Ltd.\tTadafil TAB dr 10mg 4's pack 140\n\tAstra Biopharmaceuticals Ltd.\tTadafil TAB dr 5mg 4's pack 72\n\tBeximco\tAdafil TAB dr 10mg 4's pack 140\n\tBeximco\tAdafil TAB dr 20mg 4's pack 240\n\tDelta Pharma\tFeel TAB dr 5mg  \n\tDelta Pharma\tFeel TAB dr 10mg  \n\tDelta Pharma\tFeel TAB dr 20mg  \n\tEskayef Bangladesh Ltd.\tTada TAB dr 10mg  \n\tEskayef Bangladesh Ltd.\tTada TAB dr 20mg  \n\tEuro Pharma Ltd.\tTopup TAB dr 10mg  \n\tEuro Pharma Ltd.\tTopup TAB dr 20mg  \n\tGeneral\tCeleste TAB dr 20mg 4's pack 240\n\tGeneral\tCeleste TAB dr 10mg 4's pack 140\n\tIncepta\tTadalis TAB dr 10mg 10's pack 350\n\tKemiko\tkTX TAB dr 10mg 5's pack 175\n\tKemiko\tkTX TAB dr 20mg 5's pack 300\n\tKemiko\tkTX TAB dr 5mg 5's pack 90\n\tNavana\tCiafil TAB dr 10mg 4's pack 140\n\tNavana\tCiafil TAB dr 20mg 4's pack 220\n\tNavana\tCiafil TAB dr 5mg 4's pack 72\n\tNIPRO JMI Pharma\tCialix TAB dr 10mg 4's pack 140\n\tNIPRO JMI Pharma\tCialix TAB dr 5mg  \n\tNIPRO JMI Pharma\tTadalafil TAB dr 20mg  \n\tOpsonin Pharma\tTealis TAB dr 10mg 4's pack 123.16\n\tOpsonin Pharma\tTealis TAB dr 5mg 4's pack 63.32\n\tOpsonin Pharma\tTealis TAB dr 20mg  \n\tOpsonin Pharma\tTealis TAB dr 40mg  \n\tOrion Pharma Ltd.\tRefeel TAB dr 10mg 8's pack 240\n\tOrion Pharma Ltd.\tRefeel TAB dr 20mg 8's pack 400\n\tPacific\tProlonga TAB dr 10mg 4's pack 100\n\tPacific\tProlonga TAB dr 20mg 4's pack 160\n\tSharif\tTafil TAB dr 10mg 4's pack 140\n\tSquare\tIntimate TAB dr 10mg 4's pack 140\n\tSquare\tIntimate TAB dr 5mg 4's pack 72\n\tUnimed & Unihealth Manufacturers Ltd.\tEdysta TAB dr 5mg 10's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tEdysta- TAB dr 10mg 4's pack 140\n\tUnimed & Unihealth Manufacturers Ltd.\tEdysta- TAB dr 20mg 4's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tEdysta TAB dr 2.5mg  \n\tZiska\tTiagra 5 TAB dr 5mg 4's pack/ 10's pack 72/180\n\tZiska\tTiagra 10 TAB dr 10mg 4's pack 120\n\tZiska\tTiagra 20 TAB dr 20mg 4's pack 200\n\tIndication: Erectile dysfunction, signs and symptoms of benign prostatic hyperplasia (BPH)\n\nDose: Oral\nErectile dysfunction\nAdult: Initially, 10 mg at least 30 min before sexual activity once daily, up to 20 mg as single dose. Max: Not more than once daily. If used with potent inhibitors of CYP3A4, e.g. azole antifungals or protease inhibitors: max 10 mg once every 72 hr.\n\nBenign Prostatic Hyperplasia\nThe recommended dose  is 5 mg, taken at approximately the same time every day.\n\nRenal impairment:\nCrCl (ml/min)	\n31-50	Initial dose at 5 mg/day. Max: 10 mg/48hr\n<30	        Max: 5 mg/24hr.\n\nHepatic impairment: Mild-moderate hepatic impairment (Child-Pugh category A or B): Max dose 10 mg. Severe hepatic impairment (Child-Pugh category C): Not recommended.\n\nContra-indication: Concurrent use of organic nitrates, nitrates and nitric oxide donors. Men with cardiac disease for whom sexual activity is inadvisable. Recent MI (within 90 days) or stroke (within last 6 mth), hypotension (<90/50 mm Hg), unstable angina, heart failure, uncontrolled arrhythmias or hypertension.\n\nSide effects: Headache, dyspepsia, dizziness, flushing, swelling of eyelids, eye pain, conjunctival hyperemia, back pain, myalgia, visual disturbances, nasal congestion, sudden decrease or loss of hearing, tinnitus.\nPotentially Fatal: Stevens-Johnson syndrome, exfoliative dermatitis, severe cardiovascular events e.g. MI, stroke, sudden cardiac death;\n\nPrecaution: Hepatic or renal impairment; CV diseases; anatomical penile deformation; predisposition to priapism; child <18 yr. Discontinue and seek medical advice if there is sudden vision loss or decreased vision in one or both eyes or tinnitus, dizziness or sudden loss or decrease in hearing, while taking Tadalafil. Seek immediate medical advice if erection last > 4 hr.\n\nMode of action: Concurrent use increased risk of hypotension with beta-blockers; increased risk of priapism with other drugs for erectile dysfunction, e.g. alprostadil; increased heart rate with theophylline; decreased tadalafil serum concentration with CYP 3A4 inducers e.g. rifampicin, efavirenz, carbamazepine, nevirapine, barbiturates, phenobarbital, phenytoin, ribabutin; increased tadalafil serum concentration with CYP3A4 inhibitors e.g. azole antifungals, protease inhibitors, cimetidine, macrolides.\n\nPotentially Fatal: Enhanced hypotensive effect with nitrates and nicorandil.\n\nPregnancy category: B\n\nInteraction: Concurrent use increased risk of hypotension with beta-blockers; increased risk of priapism with other drugs for erectile dysfunction, e.g. alprostadil; increased heart rate with theophylline; decreased tadalafil serum concentration with CYP 3A4 inducers e.g. rifampicin, efavirenz, carbamazepine, nevirapine, barbiturates, phenobarbital, phenytoin, ribabutin; increased tadalafil serum concentration with CYP3A4 inhibitors e.g. azole antifungals, protease inhibitors, cimetidine, macrolides.\n\nPotentially Fatal: Enhanced hypotensive effect with nitrates and nicorandil.
Tamoxifen	\n\n\tACI\tNolvadex D TAB dr 20mg 30's pack 720\n\tBeximco\tTamona TAB dr 10mg 30's pack 302.10\n\tBeximco\tTamona TAB dr 20mg 30's pack 482.10\n\tGeneral\tTamoxen TAB dr 10mg 30's pack 301.20\n\tGeneral\tTamoxen TAB dr 20mg 30's pack 481.80\n\tGonoshasthaya\tG Tamoxifen TAB dr 10mg 100's pack 600\n\tGonoshasthaya\tG Tamoxifen TAB dr 20mg 100's pack 1000\n\tTechno Drugs Ltd.\tTamoral TAB dr 10mg 30's pack 300\n\tTechno Drugs Ltd.\tTamoral TAB dr 20mg 30's pack 450\n\tIndication: Breast cancer\n\nDose: Adult: PO Breast cancer 20 mg in 1-2 divided doses. Max: 40 mg/day. Reduction of breast cancer incidence in high-risk women 20 mg/day for 5 yr. \n\nAnovulatory infertility 20 mg/day on days 2-5 of the menstrual cycle. Max: 80 mg/day.\n\nAdult: PO Breast cancer 20 mg in 1-2 divided doses. Max: 40 mg/day. Reduction of breast cancer incidence in high-risk women 20 mg/day for 5 yr. \n\nAnovulatory infertility 20 mg/day on days 2-5 of the menstrual cycle. Max: 80 mg/day.\n\nContra-indication: Pregnancy and lactation. History of thromboembolic events.\n\nSide effects: Hot flushes, oedema, fluid retention, dry skin, vaginal bleeding, vaginal discharge, pruritus vulvae, GI upsets, nausea, dizziness, rashes, blurred vision, loss of acuity, alopecia, increased liver enzymes, hypertriglyceridaemia, uterine fibroids and endometrial hyperplasia.\nPotentially Fatal: Blood dyscrasias, cholestasis, hepatitis, hypercalcaemia in patients with bone metastasis, thromboembolic events. Increased risk of endometrial cancer and uterine sarcoma.\n\nPrecaution: Perform routine haematological and liver function tests in long-term therapy. Gynaecological monitoring is necessary in women.\n\nMode of action: Aminoglutethimide reduces plasma-tamoxifen concentration.\nPotentially Fatal: Concurrent use increased anticoagulant effect of warfarin; increased risk of thromboembolic events with other cytotoxic drugs.\n\nPregnancy category: D\n\nInteraction: Aminoglutethimide reduces plasma-tamoxifen concentration.\nPotentially Fatal: Concurrent use increased anticoagulant effect of warfarin; increased risk of thromboembolic events with other cytotoxic drugs.
Tamsulosin Hydrochloride	\n\n\tACI\tSasolin CAP 400mcg 16's pack 161.12\n\tAcme Ltd.\tUropass CAP 400mcg 20's pack 200.80\n\tApex\tTamsol CAP 400mcg 20's pack 200\n\tAristopharma\tProstanil MR CAP 400mcg 30's pack 300\n\tBeximco\tUroflo CAP 400mcg 20's pack 200\n\tBio Pharma Ltd.\tEziflo TAB dr 400mcg  \n\tBio Pharma Ltd.\tEziflo CAP 400mcg  \n\tDelta Pharma\tTamsin CAP 400mcg 12's pack /30's pack 120 / 300\n\tDoctor Tims\tUrocare CAP 400 mcg  \n\tDrug International Ltd.\tProstam CAP 400mcg 30's pack 300\n\tEskayef Bangladesh Ltd.\tUrosin SR CAP 400mcg 30's pack 300\n\tGeneral\tUrolosin TAB dr 400mcg 28's pack 281.12\n\tGlobe\tTamuren CAP 0.4mg  \n\tHealthcare\tTamisol MR CAP 400mcg 30's pack 300\n\tIbn Sina Pharmaceutical Ind. Ltd.\tUrocap CAP 400mcg 30's pack 300\n\tIncepta\tProstacin CAP 400mcg 28's pack 280\n\tLeon\tEzipas CAP 400mcg  \n\tMundipharma (Bangladesh) Pvt. Ltd.\tTamcontin TAB dr .4mg 100's pack \n\tNavana\tUrotam CAP 400mcg 30's pack 300\n\tNovo Healthcare and Pharma Ltd.\tFlonor CAP 400mcg 16's pack 160\n\tOpsonin Pharma\tUrinom TAB dr 400mcg 20's pack 200\n\tOrion Pharma Ltd.\tTamlosin TAB dr 400mcg 20's pack 200.80\n\tRadiant.\tMictrol CAP 400mcg 30's pack 300\n\tRangs\tMaxflo U CAP 400mcg 28's pack 280\n\tSharif\tTamsule SR CAP 400mcg 20' pack 200\n\tSquare\tMaxrin CAP 400mcg 20's pack 200.83\n\tSupreme\tTamosin CAP 400mcg 20's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tUromax CAP 400mcg 28's pack 280\n\tWhite Horse Pharma\tUricare CAP 400mcg  \n\tIndication: Benign prostatic hyperplasia\n\nDose: Oral\nBenign prostatic hyperplasia\nAdult: As HCl: As modified-release preparation: 1 (one) capsule once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. \n\nFor those patients who fail to respond to the 0.4 mg dose after two to four weeks of dosing, the dose of capsules can be increased to 0.8 mg once daily. \n\nIf capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once daily dose.\n\nRenal impairment:\nCrCl (ml/min)	\n>10	No dose adjustment needed.\n<10	        Not studied.\n\nHepatic impairment: Moderate hepatic impairment (Child-Pugh classification A and B): No dose adjustment needed. Severe hepatic impairment: Avoid.\n\nContra-indication: Hypersensitivity to sulfonamide, severe hepatic impairment, lactation.\n\nSide effects: The following adverse reactions have been reported during the use of Tamsulosin: dizziness, abnormal ejaculation, and less frequently (1-2%) headache, asthenia, postural hypotension, palpitations and rhinitis. Gastrointestinal reactions such as nausea, vomiting, diarrhoea, and constipation can occasionally occur. Hypersensitivity reactions such as rash, pruritus, and urticaria can occur occasionally. As with other alpha-blockers, drowsiness, blurred vision, dry mouth or oedema can occur. Syncope has been reported rarely, and there have been very rare reports of angioedema and priapism.\n\nPrecaution: Hypersensitivity to Tamsulosin Hydrochloride. A history of orthostatic hypotension; severe hepatic insufficiency. As with other alpha1 blockers, a reduction in blood pressure can occur in individual cases during treatment with Tamsulosin, as a result of which, rarely, syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness) the patient should sit or lie down until the symptoms have disappeared. And they should be cautioned to avoid situations where injury could result (like driving, operating machinery or performing hazardous tasks). Before therapy with Tamsulosin is initiated the patient should be examined in order to exclude the presence of other conditions which can cause the same symptoms as Benign Prostatic Hyperplasia. Digital rectal examination and when necessary determination of Prostate Specific Antigen (PSA) should be performed before treatment and at regular intervals afterwards. The treatment of severely renal impaired patients (creatinine clearance is less than10ml/min) should be approached with caution as these patients have not been studied. Caution should be exercised in porphyria or allergic reaction to this or any other medicine.\n\nMode of action: Increased plasma concentration w/ strong CYP3A4 inhibitors (e.g. ketoconazole). Moderate CYP3A4 inhibitors (e.g. erythromycin), strong (e.g. paroxetine) or moderate (e.g. terbinafine) CYP2D6 inhibitors may increase exposure of tamsulosin. Increased plasma concentration w/ cimetidine. Additive effect w/ other ?-adrenergic blocking agents. Concomitant use w/ PDE5 inhibitors may lead to symptomatic hypotension. Decreased plasma concentration w/ furosemide.\n\nPregnancy category: B\n\nInteraction: Increased plasma concentration w/ strong CYP3A4 inhibitors (e.g. ketoconazole). Moderate CYP3A4 inhibitors (e.g. erythromycin), strong (e.g. paroxetine) or moderate (e.g. terbinafine) CYP2D6 inhibitors may increase exposure of tamsulosin. Increased plasma concentration w/ cimetidine. Additive effect w/ other ?-adrenergic blocking agents. Concomitant use w/ PDE5 inhibitors may lead to symptomatic hypotension. Decreased plasma concentration w/ furosemide.
Tapentadol	\n\n\tACI\tLopenta TAB dr 50mg  \n\tACI\tLopenta TAB dr 75mg  \n\tEskayef Bangladesh Ltd.\tTapenta TAB dr 100mg 10's pack 200\n\tEskayef Bangladesh Ltd.\tTapenta TAB dr 50mg 20's pack 240\n\tEskayef Bangladesh Ltd.\tTapenta TAB dr 75mg 10's pack 170\n\tHealthcare\tCynta TAB dr 50mg 20's pack 280\n\tHealthcare\tCynta TAB dr 75mg 10's pack 200\n\tOpsonin Pharma\tTapendol TAB dr 50mg 20's pack 211.13\n\tOpsonin Pharma\tTapendol TAB dr 75mg 20TAB dr 299.10\n\tSquare\tPentadol TAB dr 100mg 1x10's pack 250\n\tSquare\tPentadol TAB dr 50mg 20's pack 240\n\tSquare\tPentadol TAB dr 75mg 10's pack 170\n\tIndication: Diabetic neuropathy, Musculoskeletal pain\n\nDose: Moderate-to-Severe Pain\n\nAcute (immediate-release tablet or oral solution)\n\n50-100 mg PO q4-6hr PRN; not to exceed 700 mg on day 1 and 600 mg/day thereafter.\n\nChronic (extended-release tablet)\n\n50-250 mg PO q12hr PRN; not to exceed 500 mg/day.\nOpioid-naive patients: 50 mg PO q12hr; titrated to optimal dosage as needed; not to exceed 500 mg/day\n\nDiabetic Peripheral Neuropathy\n\nTreatment of pain associated with diabetic peripheral neuropathy when continuous, around-the-clock opioid analgesic is needed for extended period\n\nExtended release: 50 mg PO q12hr initially; titrated to balance individual tolerance with efficacy; typical range, 100-250 mg PO q12hr.\n\nRenal impairment\n\n    CrCl >30 mL/min : Dosage adjustment not required\n    CrCl <30 mL/min: Not recommended\n\nHepatic impairment\n\n    Mild: Dosage adjustment not required\n    Moderate: 50 mg immediate release q8hr initially; dosing frequency not to exceed 3 times daily; alternatively, 50 mg PO q24hr extended release; not to exceed 100 mg/day\n\nContra-indication: Hypersensitivity (eg, anaphylaxis, angioedema)\n\nSignificant respiratory depression\n\nAcute or severe asthma\n\nHypercarbia in unmonitored setting or in absence of resuscitative equipment\n\nParalytic ileus\n\nCoadministration with monoamine oxidase inhibitors (MAOIs) or use within 14 days\n\nSide effects: >10%\n\nNausea (30%)\n\nDizziness (24%)\n\nVomiting (18%)\n\nSomnolence (15%)\n1-10% (selected)\n\nConstipation (8%)\n\nPruritus (5%)\n\nXerostomia (4%)\n\nFatigue (3%)\n\nHyperhidrosis (3%)\n\nAnorexia (2%)\n\nDyspepsia (2%)\n\nInsomnia (2%)\nPostmarketing Reports\n\nAnaphylaxis, angioedema, anaphylactic shock\n\nPsychiatric disorders: Hallucinations, suicidal ideation, panic attack\n\nNervous system disorders: Headache\n\nGastrointestinal disorders: Diarrhea\n\nCardiac disorders: Palpitations\n\n\nPrecaution: Opioid REMS\n\n    FDA now requires risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid analgesics\n    REMS strongly encourages prescribers to complete REMS-compliant education program and to counsel patients regarding safe use, risks, storage, and disposal of ER/LA opioids\n\nLimitations of use\n\n    ER/LA opioids are intended only for management of moderate-to-severe pain when continuous, around-the-clock opioid analgesic is needed for extended period\n    ER/LA opioids are not intended for PRN use, acute pain, or postoperative pain (unless patient is already receiving long-term opioid therapy before surgery or postoperative pain is expected to persist for extended period\n\nAbuse potential\n\n    Druig is controlled substance with abuse potential; assess patientâs risk for opioid abuse or addiction (including alcohol) before prescribing\n    Assess mental illness (eg, major depressive disorder)\n    Routinely monitor for signs of misuse, abuse, and addiction during treatment\n\nLife-threatening respiratory depression\n\n    Respiratory depression, including fatal cases, may occur even when drug is used at recommended doses without misuse or abuse; proper dosing titration is essential and should be prescribed by healthcare providers knowledgeable in use of opioids and pain relief\n    Follow administration instructions for ER/LA opioids regarding swallowing whole (ie, do not chew, crush, or dissolve tablet) to avoid too-rapid release and absorption of potentially fatal dose\n\nAccidental exposure\n\n    Accidental ingestion, especially in children, can result in fatal overdose of opioid analgesic\n\nAlcohol interaction\n\n    Instruct patients not to consume alcoholic beverages or use alcohol-containing drug products while taking morphine\n    Coingestion of alcohol with opioid analgesics may increase plasma opioid levels and potentially result in fatal overdose\n\n\nMode of action: Potential severe adverse effects w/ MAOIs. CNS-active drugs; other serotonergic agents (including triptans, SSRIs, other SNRIs, lithium, sibutramine, fentanyl & its analogues, tramadol, dextromethorphan, tapentadol, meperidine, methadone, pentazocine or St. John's wort), drugs which impair serotonin (eg linezolid & methylene blue) or serotonin precursors (eg tryptophan supplements). Increased risk of QTc prolongation &/or ventricular arrhythmias w/ some antipsychotics & antibiotics. \n\nDecreased AUC & Cmax of indinavir. Increased AUC & Cmax of haloperidol. Increased plasma conc w/ ketoconazole. Increased plasma conc & reduced BP-lowering effect of metoprolol. Increased AUC of risperidone. Reduced metabolism w/ CYP2D6 inhibitors. Increased venlafaxine levels w/ CYP3A4 inhibitors.\n\nPregnancy category: C\n\nInteraction: Potential severe adverse effects w/ MAOIs. CNS-active drugs; other serotonergic agents (including triptans, SSRIs, other SNRIs, lithium, sibutramine, fentanyl & its analogues, tramadol, dextromethorphan, tapentadol, meperidine, methadone, pentazocine or St. John's wort), drugs which impair serotonin (eg linezolid & methylene blue) or serotonin precursors (eg tryptophan supplements). Increased risk of QTc prolongation &/or ventricular arrhythmias w/ some antipsychotics & antibiotics. \n\nDecreased AUC & Cmax of indinavir. Increased AUC & Cmax of haloperidol. Increased plasma conc w/ ketoconazole. Increased plasma conc & reduced BP-lowering effect of metoprolol. Increased AUC of risperidone. Reduced metabolism w/ CYP2D6 inhibitors. Increased venlafaxine levels w/ CYP3A4 inhibitors.
Tazarotene 0.1% Topical	\n\n\tBeximco\tSoritene Cream   25gm  tube 151\n\tIncepta\tTazoskin Cream   20gm tube 140\n\tIndication: Acne, Stable plaque psoriasis, Photo aging\n\nDose: For psoriasis: Apply once daily in the evening usually for up to twelve weeks. Use and dose must be determined by the doctor of children upto 12 years of age.\nFor acne: Cleanse the face gently. After the skin is dry, apply a thin layer of Tazarotene cream once per day, in the evening, to the skin areas where acne lesions appear. Use enough to cover the entire affeted area. \n\nContra-indication: It is contraindicated in patients with known hypersensitivity to any ingredients of Tazarotene cream.\n\nSide effects: Generally Tazarotene cream is well-tolerated .The most frequent adverse events related to treatment with Tazarotene are skin-related as for example pruritus, erythema, burning, irritation, desquamation, stinging, contact dermatitis, dermatitis, eczema, worsening of psoriasis, skin pain, rash, hypertriglyceridemia, dry skin, skin inflammation, and peripheral edema.\n\nPrecaution: Tazarotene cream should be applied only to the affected areas. It is for external use only. Avoid contact with eyes, eyelids, and mouth. If contact with eyes occurs, rinse thoroughly with water.\nRetinoid should not be used on eczematous skin, as they may cause severe irritation.\nBecause of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided unless deemed medically necessary and in such cases, exposure should be minimized during the use of Tazarotene cream. Tazarotene cream should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.\n\nMode of action: Increased drying effect effect with concomitant use of dermatologic medications and cosmetics that have irritant or strong drying effect. Increased risk of photosensitivity with drugs known to be photosensitisers.\n\nPregnancy category: X\n\nInteraction: Increased drying effect effect with concomitant use of dermatologic medications and cosmetics that have irritant or strong drying effect. Increased risk of photosensitivity with drugs known to be photosensitisers.
Tegaserod	\n\n\tEskayef Bangladesh Ltd.\tTibs TAB dr 6mg 50's pack 300\n\tIncepta\tDoresa TAB dr 6mg 50's pack 300\n\tKemiko\tZiled TAB dr 6mg 30's pack 180\n\tRenata\tTegarid TAB dr 6mg 30's pack 180\n\tSquare\tTesod TAB dr 6mg 30's pack 150.43\n\tIndication: Irritable bowel syndrome and constipation\n\nDose: Chronic idiopathic constipation, Constipation-predominant irritable bowel syndrome\nAdult: 6 mg taken bid for 4-6 wk continued for another 4-6 wk in responsive patients.\n\nRenal impairment: Severe impairment: Not recommended.\nHepatic impairment: Moderate to severe impairment: Not recommended.\n\nContra-indication: Severe renal or moderate to severe hepatic impairment; history of bowel obstruction or symptomatic gallbladder disease; suspected sphincter of Oddi dysfunction or abdominal adhesions; known hypersensitivity. Patients currently experiencing or who frequently experience diarrhoea. Lactation.\n\nSide effects: Diarrhoea, abdominal pain, nausea, flatulence, headache, dizziness, migraine, leg or back pain, arthropathy, insomnia, hypotension, arrhythmia, ischaemic colitis.\nPotentially Fatal: MI, stroke.\n\nPrecaution: Discontinue immediately if rectal bleeding, bloody diarrhoea, new or sudden worsening of abdominal pain occurs. Mild hepatic impairment; child <18 yr; pregnancy.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Teicoplanin	\n\n\tIncepta\tTergocin Injection 200mg/vial 1 vial's pack 1600\n\tIncepta\tTergocin Injection 400 mg/vial  \n\tGruppo Lepetit Srl, Italy\tTargocid Injection 400mg 3ml bot 1568.62\n\tGruppo Lepetit Srl, Italy\tTargocid Injection 200mg 3ml bot 872.08\n\tIndication: Gram-positive infection, CAPD-associated peritonitis\n\nDose: Parenteral\nSevere Gram-positive infections\nAdult: Initially, 6 mg/kg on first day, followed by 3 mg/kg/day. Severe infection: 6 mg/kg every 12 hr for the 1st 3 doses followed by 6 mg/kg/day. Doses may be given via IM inj, IV bolus or IV infusion over 30 minutes.\nChild: Loading dose: 10 mg/kg every 12 hr for 3 doses followed by 6-10 mg/kg/day depending on severity of the infection. Neonates: Loading dose: 16 mg/kg on the 1st day, followed by maintenance doses of 8 mg/kg/day by IV infusion.\n\n\nIntravenous\nProphylaxis of Gram-positive infection in high-risk patients undergoing surgery\nAdult: 400 mg as single dose at induction of anesth.\nIntravenous\nContinuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis\nAdult: If the patient is febrile, an initial loading dose of 400 mg may be given. Teicoplanin is added to the dialysis solution at a concentration of 20 mg/litre; dose is added into each bag of solution in the first wk, followed by alternate bags in the second wk and then in the overnight dwell bag in the third wk.\n\nRenal impairment: Usual dose to be given for first 3 days, thereafter adjust dose according to CrCl.\nCrCl (ml/min)	\n40-60	1/2 initial dose given daily or initial dose every 2 days.\n<40  	1/3 initial dose given daily or initial dose every 3 days.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Fever, chills, allergic reactions, GI disturbances, headache, dizziness, "red-man" syndrome, disturbances in liver enzymes, renal impairment, ototoxicity, blood dyscrasias. Pain, erythema, thrombophloebitis, abscess at site of admin.\nPotentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis.\n\nPrecaution: Preexisting renal insufficiency, hypersensitivity to vancomycin. Perform periodic haematological studies, renal, LFT. Pregnancy, lactation.\n\nMode of action: Other nephrotoxic and/or neurotoxic drugs.\n\nPregnancy category: B\n\nInteraction: Other nephrotoxic and/or neurotoxic drugs.
Telmisartan	\n\n\tNovartis (Bangladesh) Ltd.\tMitosan TAB dr 80mg 30's pack 630\n\tNovartis (Bangladesh) Ltd.\tMitosan TAB dr 40mg 30's pack 390\n\tOrion Pharma Ltd.\tTelsan TAB dr 40mg 30's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tTelcardis TAB dr 40mg 14's pack 175\n\tUnimed & Unihealth Manufacturers Ltd.\tTelcardis TAB dr 80mg 14's pack\n 280\n\tIndication: Hypertension, Diabetic nephropathy\n\nDose: Oral\nHypertension\nAdult: Initially, 40 mg once daily, may be adjusted to 20-80 mg once daily if needed.\nHepatic impairment: Mild to moderate: Max: 40 mg once daily. Severe: Contraindicated.\nOral\nCardiovascular risk reduction\nAdult: 80 mg once daily.\nHepatic impairment: Mild to moderate: Max: 40 mg once daily. Severe: Contraindicated.\n\nContra-indication: Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.\n\nSide effects: URTI, dizziness, back pain, sinusitis, pharyngitis and diarrhoea. Slight elevations in liver enzymes.\nPotentially Fatal: Rarely angioedema, rash, pruritus and urticaria.\n\nPrecaution: Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients.\n\nMode of action: May increase plasma levels of digoxin. May increase serum lithium levels and toxicity. May reduce plasma levels of warfarin. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs.\nPotentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).\n\nPregnancy category: D\n\nInteraction: May increase plasma levels of digoxin. May increase serum lithium levels and toxicity. May reduce plasma levels of warfarin. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs.\nPotentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Temazepam	\n\n\tIndication: Insomnia, Premedication in surgery\n\nDose: Oral\nShort-term management of insomnia\nAdult: 7.5-30 mg at bedtime for 7-10 days. Max: 40 mg.\nElderly: 5 mg at bedtime. May be increased to 10-20 mg in severe cases.\nHepatic impairment: 5 mg at bedtime. May be increased to 10-20 mg in severe cases. Severe: Contraindicated.\n\nPremedication in surgery\nAdult: 20-40 mg, 30 min to 1 hr before the procedure.\nElderly: 10-20 mg, 1 hr before the procedure.\nHepatic impairment: Severe: Contraindicated.\n\nContra-indication: Severe hepatic impairment. Pregnancy.\n\nSide effects: Confusion, dizziness, drowsiness, fatigue, headache, lethargy, hangover, euphoria, difficulty with coordination, ataxia, anorexia, tremor, vomiting and backache.\n\nPrecaution: Chronic pulmonary insufficiency, elderly or debilitated patients, impaired liver or kidney function, personality disorders or organic brain changes, history of alcohol or drug addiction, lactation.\n\nMode of action: May enhance CNS depressant effect w/ Na oxybate, antipsychotics, tranquilisers, neuroleptics, antidepressants, hypnotics, anaesth, analgesics, sedative antihistamines, barbiturates. Effect may be reduced w/ theophylline.\n\nPregnancy category: X\n\nInteraction: May enhance CNS depressant effect w/ Na oxybate, antipsychotics, tranquilisers, neuroleptics, antidepressants, hypnotics, anaesth, analgesics, sedative antihistamines, barbiturates. Effect may be reduced w/ theophylline.
Temozolomide Hydrochloride	\n\n\tTechno Drugs Ltd.\tZolomide CAP 100mg 5's pack 3250\n\tTechno Drugs Ltd.\tZolomide CAP 250mg 5's pack 6500\n\tIndication: Glioblastoma multiforme, Malignant gliomas, Metastatic melanoma\n\nDose: Adult: PO Glioblastoma multiforme Concomitant phase: 75 mg/m2 once daily for 42 days w/ focal radiotherapy. Initiate monotherapy 4 wk after completing concomitant phase: 150 mg/m2 once daily for 5 days followed by a 23 day break (1 cycle). Cycle 2: 200 mg/m2 once daily for 5 days. If dose cannot be increased in cycle 2, do not increase dose in subsequent cycles. Dose used in cycle 2 is given for the rest of the cycles, toxicity allowing, up to 6 cycles. \n\nRecurrent or progressive malignant gliomas Chemotherapy naive: 200 mg/m2 once daily for 5 days, followed by a 23 day break (1 cycle). Chemotherapy-experienced: 150 mg/m2/day for 5 days followed by 23 day break (1 cycle), increased to 200 mg/m2/day for the 2nd cycle if there is no haematological toxicity. \n\nChild: >3 yr: Previously untreated with chemotherapy: 200 mg/m2 once daily for 5 days, followed by a 23 day break (1 cycle). Previously treated with chemotherapy: 150 mg/m2 daily for 5 days followed by 23 day break (1 cycle) increased to 200 mg/m2 for the 2nd cycle if there is no haematological toxicity.\n\nMetastatic melanoma 200 mg/m2/day for 5 days every 28 days.\n\nContra-indication: Hypersensitivity to dacarbazine. Severe myelosupression. Pregnancy.\n\nSide effects: Nausea, vomiting, taste perversion, constipation, diarrhoea, abdominal pain, stomatitis, anorexia, headache, fatigue, convulsions, dizziness, memory impairment, impaired concentration, tremors, blurred vision, hearing impairment, speech disorder, rash, infection, oral candidiasis, dyspnoea, coughing, neutropenia, thrombocytopenia, leucopenia, anaemia, hyperglycemia, decreased wt, insomnia, anxiety, alopecia, muscle weakness, urinary incontinence, increased alanine aminotransferase. Rarely, myelodysplastic syndrome and secondary malignancies.\n\nPrecaution: Severe hepatic and renal impairment. Elderly >70 yr, children. Women of child bearing potential should avoid becoming pregnant during therapy. Males should be advised not to father a child up to 6 mth after treatment and to consider cryoconservation of sperms due to possibility of irreversible infertility. Unknown if distributed into breastmilk, discontinue nursing due to potential risk. May impair ability to drive or operate machinery. Swallow capsules whole with a full glass of water on an empty stomach or at bedtime. Do not take a 2nd dose if capsules are vomited. Monitor CBC wkly during concomitant therapy and on day 22 of each 28 day treatment cycle, followed by wkly blood count until recovery. Hepatitis screening and prophylactic therapy with antiviral agents as clinically indicated to be considered. Prophylaxis for Pneumocystis jiroveci (or Pneumocystis carinii) pneumonia (PCP) needed for all patients receiving concomitant temozolomide and radiation therapy for the 42-day regimen; if patients experience lymphocytopenia during the concomitant phase of therapy, PCP prophylaxis should be continued until recovery from lymphocytopenia. Monitor closely for PCP development in all patients. Anti-emetic prophylaxis recommended.\n\nMode of action: Valproic acid, other myelosuppressive agents.\n\nPregnancy category: D\n\nInteraction: Valproic acid, other myelosuppressive agents.
Tenofovir Disoproxil Fumarate	\n\n\tACI\tFoviral TAB dr 300mg 8's pack 682.08\n\tAristopharma\tTenvira TAB dr 300mg 10's pack 748.05\n\tBeacon\tBecovir TAB dr 300mg  \n\tDrug International Ltd.\tT-Fovir TAB dr 300mg 7's pack 595\n\tIncepta\tXynovir TAB dr 300mg 12's pack 1020\n\tOpsonin Pharma\tTenoviral TAB dr 300mg  \n\tPopular\tTafovir TAB dr 300mg 12's pack \n\tSquare\tProxivir TAB dr 300mg 12's pack 1020\n\tUnimed & Unihealth Manufacturers Ltd.\tVironil TAB dr 300 mg 10's pack 950\n\tIndication: HIV-1 infection, Chronic hepatitis B\n\nDose: Oral\nChronic hepatitis B, HIV infection\nAdult: >18 yr: 300 mg once daily.\n\nRenal impairment: Haemodialysis patients: 300 mg once every 7 days or 300 mg after a cumulative total of 12 hr of dialysis.\nCrCl (ml/min)	\n30-49	300 mg every 48 hr.\n10-29	300 mg every 72-96 hr\n\nContra-indication: Tenofovir is contraindicated in patients with previously demonstrated hypersensitivity to Tenofovir or any component of the product.\n\nSide effects: The most common side effects are nausea, vomiting, diarrhea and flatulence. \n\nPrecaution: Coadministration with other drugs: Tenofovir should not be administered concurrently with Emtricitabine & Tenofovir combination or Adefovir Dipivoxil.\nLactic Acidosis/Severe Hepatomegaly with Steatosis: Though the risk of occurrence of lactic acidosis is low for Tenofovir, treatment should be suspended in any patient who develops lactic acidosis or hepatotoxicity.\nExacerbation of Hepatitis after Discontinuation of Treatment: Discontinuation of Tenofovir therapy may be associated with severe acute exacerbations of hepatitis.\n\nMode of action: Decreased atazanavir concentration with tenofovir unless also co-administered with ritonavir. Increased serum concentration of tenofovir or co-administered drug if taken with drugs that are eliminated by active tubular secretion.\nPotentially Fatal: Increased risk of renal impairment with recent or concurrent use of nephrotoxic agents (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2); monitor renal function wkly if unavoidable. Increased didanosine levels and thereby increasing risk of pancreatitis and peripheral neuropathy, with a high treatment failure rate with concurrent use; avoid concurrent use. \n\nPregnancy category: B\n\nInteraction: Decreased atazanavir concentration with tenofovir unless also co-administered with ritonavir. Increased serum concentration of tenofovir or co-administered drug if taken with drugs that are eliminated by active tubular secretion.\nPotentially Fatal: Increased risk of renal impairment with recent or concurrent use of nephrotoxic agents (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2); monitor renal function wkly if unavoidable. Increased didanosine levels and thereby increasing risk of pancreatitis and peripheral neuropathy, with a high treatment failure rate with concurrent use; avoid concurrent use. 
Tenoxicam	\n\n\tACI\tOxicam TAB dr 20mg 	 30's pack  241.50\n\tAcme Ltd.\tEnocam TAB dr 20mg 30's pack 240\n\tApex\tTexicam TAB dr 20mg 20's pack 160\n\tAristopharma\tXicotil F/C TAB dr 20mg 30's pack 240\n\tBeacon\tTenoflex TAB dr 20mg 30's pack 240\n\tBeximco\tMobicam TAB dr 20mg 30's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tOxiflam TAB dr 20mg 30's Pack 240\n\tIncepta\tTenopain TAB dr 20mg 3x10's pack 240\n\tOpsonin Pharma\tInoten TAB dr 20mg 30's pack 240\n\tOrion Pharma Ltd.\tTenorix TAB dr 20mg 30's pack 240.90\n\tRadiant.\tTilkotil TAB dr 20mg 50's pack 850.50\n\tSquare\tXten TAB dr 20mg 30's pack 240\n\tIndication: Pain and inflammation associated w/ musculoskeletal and joint disorders\n\nDose: Adult: PO 20 mg/day as single dose for 7 days in acute disorders, up to 14 days in severe cases. Max: 40 mg/day (short term use). \n\nContra-indication: Active or history of recurrent GI bleed or peptic ulcer, hypersensitivity to NSAIDs, severe heart failure, haemorrhagic diathesis, asthma, pregnancy (3rd trimester).\n\nSide effects: GI upsets including epigastric pain and gastritis, nausea, hypersensitivity reactions, headache, dizziness, sleep disturbances.\nPotentially Fatal: CV thrombotic events, blood dyscrasias, nephrotoxicity, hepatotoxicity, toxic epidermal necrolysis, Stevens-Johnson syndrome.\n\nPrecaution: History of peptic ulceration, renal, cardiac or hepatic impairment, cerebovascular disease, fluid retention, inflammatory bowel disease, pregnancy, elderly.\n\nMode of action: Increased risk of adverse effects (particularly GI) w/ salicylates and other NSAIDs. May enhance the anticoagulant effect of warfarin and other anticoagulants. May reduce the effect of antihypertensive drugs. Increased risk of nephrotoxicity w/ ciclosporin. Increased risk of convulsions w/ quinolones. May decrease the elimination of lithium. May interfere w/ the natriuretic action of diuretics. May enhance the toxicity of methotrexate. May reduce the effects of mifepristone. Increased risk of GI bleeding w/ corticosteroids.\n\nPregnancy category: Not Classified\n\nInteraction: Increased risk of adverse effects (particularly GI) w/ salicylates and other NSAIDs. May enhance the anticoagulant effect of warfarin and other anticoagulants. May reduce the effect of antihypertensive drugs. Increased risk of nephrotoxicity w/ ciclosporin. Increased risk of convulsions w/ quinolones. May decrease the elimination of lithium. May interfere w/ the natriuretic action of diuretics. May enhance the toxicity of methotrexate. May reduce the effects of mifepristone. Increased risk of GI bleeding w/ corticosteroids.
Terazosin	\n\n\tDrug International Ltd.\tProstol CAP 1mg 50's pack 150\n\tDrug International Ltd.\tProstol CAP 2mg 50's pack 250\n\tIncepta\tTerazon TAB dr 2mg 50's pack 250\n\tIncepta\tTerazon TAB dr 5mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tHytrain TAB dr 1mg 30's pack 376.20\n\tUnimed & Unihealth Manufacturers Ltd.\tHytrain TAB dr 2mg 30's pack 691\n\tUnimed & Unihealth Manufacturers Ltd.\tHytrain TAB dr 5mg 30's pack 1600\n\tIndication: Hypertension, Benign prostatic hyperplasia\n\nDose: Adult: PO HTN; Benign prostatic hyperplasia Initial: 1 mg at bedtime, gradually increase if needed. Maintenance: 2-10 mg once daily (HTN); 5-10 mg once daily (benign prostatic hyperplasia). Max: 20 mg/day in 1-2 divided doses.\n\nContra-indication: Hypersensitivity to quinazoline derivatives.\n\nSide effects: Orthostatic hypotension, syncope, dizziness, fatigue, somnolence, peripheral oedema, headache, nasal congestion, nausea, blurred vision, postural hypotension, palpitations, priapism.\n\nPrecaution: Elderly. Syncope and orthostatic associated with first dose phenomenon. Pregnancy and lactation.\n\nMode of action: Concomitant admin w/ phosphodiesterase-5 (PDE-5) inhibitors (e.g. sildenafil) can result in additive BP lowering effects and symptomatic hypotension. Possible significant hypotension when admin w/ other antihypertensive agents e.g. verapamil.\n\nPregnancy category: C\n\nInteraction: Concomitant admin w/ phosphodiesterase-5 (PDE-5) inhibitors (e.g. sildenafil) can result in additive BP lowering effects and symptomatic hypotension. Possible significant hypotension when admin w/ other antihypertensive agents e.g. verapamil.
Terbinafine	\n\n\tAlbion Ltd.\tTerbinafine TAB dr 250 mg 10's pack \n\tAlco Pharma\tDerfin TAB dr 250mg 10's pack 350\n\tAristopharma\tTerbifin TAB dr 250mg 12's pack 600\n\tBeximco\tTerbex TAB dr 250mg 10's pack 500\n\tDrug International Ltd.\tMycofree TAB dr 250mg  \n\tEskayef Bangladesh Ltd.\tMycofin TAB dr 250mg 10's pack 400\n\tGeneral\tInfud TAB dr 250mg 4's pack 160\n\tNovartis (Bangladesh) Ltd.\tLamisil TAB dr 250mg 14's pack 2030\n\tSquare\tXfin TAB dr 250mg 5gm  tube 50.20\n\tUniDerma\tTelfin TAB dr 250mg 10's pack 300\n\tIndication: Tinea pedis, Tinea cruris, Tinea corporis, Dermatophytosis, Nail infections\n\nDose: Oral\nDermatophytosis\nAdult: 250 mg once daily for 2-4 wk in tinea cruris, 6 wk for tinea pedis, 4 wk for tinea corporis and 6-12 wk for nail infections.\n\nChild: 10-20 kg: 62.5 mg; 20-40 kg: 125 mg; >40 kg: 250 mg. Doses to be taken once daily. Treatment is usually given for 2 wk for tinea capitis; 2-4 wk for tinea cruris; 4 wk for tinea corporis; 6 wk in tinea pedis; 6-12 wk for nail infections.\n\nRenal impairment:\nCrCl (ml/min)	\n<50	        Half the usual oral dose.\n\nContra-indication: Hypersensitivity, active or chronic liver disease, lactation.\n\nSide effects: Anorexia, nausea, abdominal pain, taste disturbances, diarrhoea, rash, urticaria.\nPotentially Fatal: Liver failure, Stevens-Johnson syndrome, neutropaenia.\n\nPrecaution: Preexisting liver or renal impairment, pregnancy. Perform liver function tests prior to oral therapy.\n\nMode of action: Possible increase in levels in drugs metabolised by CYP450 2D6. Decreased terbinafine concentration with rifampicin; increased terbinafine concentration with cimetidine.\n\nPregnancy category: B\n\nInteraction: Possible increase in levels in drugs metabolised by CYP450 2D6. Decreased terbinafine concentration with rifampicin; increased terbinafine concentration with cimetidine.
Terbinafine Topical	\n\n\tACI\tSkinabin Cream  1% 15gm  tube 50.34\n\tAlco Pharma\tDerfin Cream   10gm  tube 30\n\tAristopharma\tTerbifin Cream   5gm  tube 52\n\tBeximco\tTerbex Cream   5gm tube /10gm tube \n\tBio Pharma Ltd.\tTarmider Cream  1% 10g 50.19\n\tBio Pharma Ltd.\tTermider Cream 1% 5 gm tube/ 10 gm tube 30.11 / 50.19\n\tDoctor's Chemicals Works Ltd.\tAnpar Cream   5gm  tube 35\n\tDrug International Ltd.\tMycofree Cream 1 gm/100 gm  \n\tEskayef Bangladesh Ltd.\tMycofin Cream   5gm  tube 50\n\tGeneral\tInfud Cream   5gm  tube 50.19\n\tIncepta\tDerbicil Cream   5gm  tube 50\n\tNovartis (Bangladesh) Ltd.\tLamisil Cream 1% 5g tube 95\n\tOpsonin Pharma\tTerbin Cream  10mg/gm 5gm tube 30\n\tSquare\tXfin Cream 1 gm/100 gm  \n\tUnimed & Unihealth Manufacturers Ltd.\tTelfin Cream  1 gm/100 gm 10gm  tube 40\n\tIndication: Tinea pedis, Tinea cruris, Tinea corporis, Dermatophytosis, Nail infections, Cutaneous candidiasis and Pityriasis versicolor\n\nDose: Dermatophytosis\nAdult: Apply  cream/solution/spray once or bid. 1-2 wk to treat tinea corporis and tinea cruris; 1-wk course is for tinea pedis; 2-wk course in cutaneous candidiasis and pityriasis versicolor\n\nContra-indication: Hypersensitivity, active or chronic liver disease, lactation.\n\nSide effects: Anorexia, nausea, abdominal pain, taste disturbances, diarrhoea, rash, urticaria.\nPotentially Fatal: Liver failure, Stevens-Johnson syndrome, neutropaenia.\n\nPrecaution: Preexisting liver or renal impairment, pregnancy. Perform liver function tests prior to oral therapy.\n\nMode of action: Possible increase in levels in drugs metabolised by CYP450 2D6. Decreased terbinafine concentration with rifampicin; increased terbinafine concentration with cimetidine.\n\nPregnancy category: B\n\nInteraction: Possible increase in levels in drugs metabolised by CYP450 2D6. Decreased terbinafine concentration with rifampicin; increased terbinafine concentration with cimetidine.
Terbutaline Sulphate	\n\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTerbulin Syrup 1.5mg/5ml 100ml bot 35.14\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTerbulin TAB dr 2.5mg 100's pack 100\n\tUnimed & Unihealth Manufacturers Ltd.\tTervent Syrup 1.5mg/5ml 100ml bot 25\n\tUnimed & Unihealth Manufacturers Ltd.\tTervent TAB dr 2.5mg 100's pack 50\n\tIndication: Acute bronchospasm, Uncomplicated premature labour\n\nDose: Adult: PO Acute bronchospasm Initial: 2.5 or 3 mg 3 times/day, up to 5 mg 3 times/day if needed. Extended release 7.5 mg twice daily. \n\nContra-indication: Hypersensitivity to sympathomimetics. Any condition of mother or foetus in which prolongation of pregnancy is dangerous.\n\nSide effects: Fine skeletal muscle tremor esp hands, dizziness, anxiety, flushes, sweating, nausea, vomiting, lethargy, tinnitus, tachycardia, palpitations, muscle cramps, headache, paradoxical bronchospasm. IV: Transient hyperglycemia, transient hypokaelemia.\nPotentially Fatal: (IV): MI, pulmonary oedema, ketoacidosis.\n\nPrecaution: Arrhythmias, hyperthyroidism, hypertension, diabetes, myocardial insufficiency, history of seizures, heart disease.\n\nMode of action: Antagonised effects of ?-blockers. Increased risk of hypokaelemia with xanthine derivatives, corticosteriods and diuretics; increased risk of arrhythmias with inhaled anaesthetics, sympathomimetics.\n\nPregnancy category: C\n\nInteraction: Antagonised effects of ?-blockers. Increased risk of hypokaelemia with xanthine derivatives, corticosteriods and diuretics; increased risk of arrhythmias with inhaled anaesthetics, sympathomimetics.
Terconazole 0.4% Vag prep	\n\n\tIndication: Vulvovaginal candidiasis\n\nDose: Adult: Vag Insert 40 mg (0.8% cream) or 80 mg pessary once at bedtime for 3 nights or 20 mg (0.4% cream) once at bedtime for 7 nights.\n\nContra-indication: Hypersensitivity. Lactation.\n\nSide effects: Vulvovaginal burning, vulvar itching, dysmenorrhoea, genital, body and abdominal pain. Flu-like syndrome with headache, fever, chills and hypotension with doses >80 mg.\n\nPrecaution: Discontinue if irritation or flu-like symptoms develop. May damage latex or rubber contraceptives. Patients <18 yrs. Pregnancy.\n\nMode of action: May decrease absorption of ciprofloxacin, ciclosporin, mycophenolate, tacrolimus and levothyroxine. Sevelamer should be given 3 hr before or 1 hr after taking other drugs to minimise potential pharmacokinetic interaction.\n\nPregnancy category: C\n\nInteraction: May decrease absorption of ciprofloxacin, ciclosporin, mycophenolate, tacrolimus and levothyroxine. Sevelamer should be given 3 hr before or 1 hr after taking other drugs to minimise potential pharmacokinetic interaction.
Testosterone 1% Topical	\n\n\tIncepta\tY 45 Gel  .01g 20g 200\n\tIndication: Hypogonadism, Testosterone replacement therapy\n\nDose: Adult: Testosterone gels: Take this medication by applying the gel to skin of lower abdomen, inner thighs or shoulders and upper arms, usually once daily. \n\nIt may take up to a few months before the full benefit of this drug takes effect.    \n\n\n\n\nContra-indication: Hypercalcaemia or hypercalciuria, males with breast or prostate carcinoma. Pregnancy and lactation.\n\nSide effects: Common side effects seen with the use of testosterone gels include:\n\n    Application site reactions including itching, rash and redness\n    High blood pressure\n    Headache\n    Acne\n    Increases in the blood of prostatic specific antigen (PSA) produced by the prostate gland\n    Large increases red blood cell count\n    Swelling of hands and feet\n    Loss of head hair\n    Increased body hair growth\n    Breast enlargement\n    Flushing\n    Women: Hair loss, enlargement of the clitoris, an increase in the amount of facial hair or your voice deepening or becoming hoarse with use of testosterone 300 Âµg patches.\n\n \nTransdermal: local irritation. Buccal: Gum irritation, bitter taste, gum pain, tenderness.\nPotentially Fatal: Peliosis hepatis, liver toxicity, malignant neoplasm.\n\nPrecaution: Cardiovascular disorders, skeletal metastases, renal or hepatic impairment, epilepsy, migraine, diabetes or other conditions which may be aggravated by fluid retention, eg heart failure. Elderly, prepubertal boys. Monitor signs of virilization (females) and development of priapism or excessive sexual stimulation (males). Periodic haemoglobin, lipid determinations and rectal prostate examination.\n\nMode of action: Enhance activities of ciclosporine, antidiabetics, thyroxine, anticoagulants. Long term use of testosterone may cause resistance to effects of neuromuscular blockers. Enhance fluid retention from corticosteroids.\n\nPregnancy category: X\n\nInteraction: Enhance activities of ciclosporine, antidiabetics, thyroxine, anticoagulants. Long term use of testosterone may cause resistance to effects of neuromuscular blockers. Enhance fluid retention from corticosteroids.
Testosterone Decanoate + Testosterone Isocaproate + Testosterone Phenyl propionate  + Testosterone Propionate	\n\n\tNuvista Pharma Ltd\tTestaton Injection  1 amp pack 162.19\n\tTechno Drugs Ltd.\tSustogen Injection   1 amps pack 95\n\tIndication: Testosterone replacement therapy\n\nDose: By deep IM injection 1 ml usually 1 to 4 weeks.  Dosage is based on your medical condition, testosterone blood levels, and response to treatment.\n\nContra-indication: Hypercalcaemia or hypercalciuria, males with breast or prostate carcinoma. Pregnancy and lactation.\n\nSide effects: Nausea, vomiting, headache, skin color changes, increased/decreased sexual interest, oily skin, hair loss, and acne may occur. Pain and redness at the injection site may also occur. Mental/mood changes (such as anxiety, depression, increased anger), trouble sleeping/snoring, signs of serious liver disease (such as persistent abdominal pain/nausea, unusual tiredness, yellowing eyes/skin, dark urine). Trouble urinating, breast swelling/tenderness, too frequent/prolonged erections. Rarely, males may have a painful or prolonged erection lasting 4 or more hours. If this occurs, stop using this drug and seek immediate medical attention, or permanent problems could occur. This medication can decrease sperm production, an effect that may lower male fertility. If you are female, tell your doctor immediately if any of these unlikely but serious side effects occur: deepening of the voice, hoarseness, unusual facial/body hair growth, enlarged clitoris, irregular menstrual periods. This medication can cause your body to hold on to extra body water (edema). A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.\n\n\nPrecaution: This product may contain inactive ingredients (such as sesame oil), which can cause allergic reactions or other problems. Before using this medicine, consult your doctor or pharmacist if you have: breast cancer in men, prostate cancer. Heart disease (such as heart failure, chest pain, heart attack), liver problems, kidney problems, other types of cancer, high cholesterol, high blood pressure, enlarged prostate, sleep apnea, diabetes. This product may decrease your blood sugar levels. This drug may affect your cholesterol and may increase your risk of heart or blood vessel problems (coronary artery disease). Your doctor will monitor your cholesterol level closely. Caution is advised when using this drug in children because bone growth may be affected, causing shorter adult height. Your child's doctor will monitor growth and bone development during treatment. This medication must not be used during pregnancy. It may harm an unborn baby. \n\nMode of action: Oral Anticoagulants: Testosterone and derivatives have been reported to increase the activity of oral anticoagulants. Patients receiving oral anticoagulants require close monitoring, especially at the beginning or end of androgen therapy. Increased monitoring of the prothrombin time, and INR determinations, are recommended.\n\nOther Interactions: The concurrent administration of testosterone with ACTH or corticosteroids may enhance edema formation; thus, these active substances should be administered cautiously, particularly in patients with cardiac or hepatic disease or in patients predisposed to edema.\n\nPregnancy category: X\n\nInteraction: Oral Anticoagulants: Testosterone and derivatives have been reported to increase the activity of oral anticoagulants. Patients receiving oral anticoagulants require close monitoring, especially at the beginning or end of androgen therapy. Increased monitoring of the prothrombin time, and INR determinations, are recommended.\n\nOther Interactions: The concurrent administration of testosterone with ACTH or corticosteroids may enhance edema formation; thus, these active substances should be administered cautiously, particularly in patients with cardiac or hepatic disease or in patients predisposed to edema.
Tetracycline Hydrochloride	\n\n\tAcme Ltd.\tA-Tetra CAP 500mg 100's pack 203\n\tAcme Ltd.\tA Tetra CAP 500mg 100's pack 203\n\tAcme Ltd.\tA Tetra TAB dr 500mg 100's pack 229\n\tAexim\tTetramin CAP 250mg 100's pack 100\n\tAlbion Ltd.\tTetra Cap CAP 250 mg 100's pack \n\tAmbee\tTetram CAP 250mg 100's pack 133\n\tAmico Ltd.\tMonatrex DS CAP 500mg 100's pack 200\n\tAsiatic Ltd.\tTetramycin CAP 250mg 100's pack 130\n\tBelsen\tTetralin CAP 250 mg  100's pack 75\n\tBeximco\tDecacycline CAP 250mg 100's pack 220\n\tBristol Pharma Ltd.\tBptetra CAP 250mg 100's pack 100\n\tDesh\tOmnimycin CAP 500mg 100's pack 215\n\tDesh\tRandamycin CAP 250mg 60's pack 72\n\tDoctor's Chemicals Works Ltd.\tTaracilin CAP 250mg 100's pack \n\tGeneral\tTetragen CAP 250mg 100's pack 136\n\tGonoshasthaya\tG Tetracycline CAP 250mg 100's pack 101\n\tHudson\tTetracycline H CAP 250mg 100's pack 100\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTetrasina CAP 250mg 100's pack 137\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTetrasina CAP 500mg 50's pack 112.50\n\tIncepta\tTetrafast CAP 250mg 100's pack 74.50\n\tIndobangla Pharmaceuticals\tIndotetra CAP 500mg 100's pack 150\n\tIndobangla Pharmaceuticals\tIndotetra CAP 250 mg  100's pack  80\n\tJayson\tJmycin CAP 250mg 100's pack 131\n\tMedicon\tBactocycline CAP 250mg 100's pack 130\n\tMedimet\tTetramet CAP 250mg 100's pack 137\n\tNovartis (Bangladesh) Ltd.\tServitet CAP 250mg 100's pack \n\tPacific\tTetclin CAP 250mg 100's pack 100\n\tPharmadesh Ltd.\tTetracycline CAP 250mg 100's pack 132\n\tReliance\tTetracycline CAP 500 mg  100's pack 228.76\n\tRenata\tTetracyn CAP 250mg 100's pack 122\n\tRenata\tTetracyn CAP 500mg 100's pack 202\n\tSquare\tTetrax CAP 500mg 100's pack 228.76\n\tSupreme\tTitacin CAP 250mg 100's pack 130\n\tSupreme\tTitacin CAP 500mg 100's pack 200\n\tZenith\tTetrazen CAP 250 mg  100's pack 100\n\tIndication: Acne, Lyme disease, Uncomplicated gonorrhea, Syphilis, Psittacosis, Q fever, Pleural effusions, Rocky Mountain spotted fever, Lymphogranuloma venereum, Mycoplasma pneumoniae, Trachoma, Nongonococcal urethritis\n\nDose: Adult: PO Susceptible infections As HCl: 250 or 500 mg 6 hrly, up to 4 g/day in severe infections. \n\nAcne As HCl: 0.5-1 g/day in 4 divided doses for 1-2 wk or till clinical improvement occurs. Maintenance: 125-500 mg/day till clinical improvement allows drug discontinuation. \n\nIntrapleural Pleural effusions As HCl: 500 mg dissolved in 0.9% NaCl and instilled into pleural spaces.\n\nChildren : 25-50 mg/kg daily.\n\nHepatic impairment: Max: 1 g daily.\n\n\nContra-indication: Hypersensitivity; pregnancy, lactation, children; renal impairment.\n\nSide effects: Oesophageal ulceration, nausea, vomiting, oral candidiasis, diarrhoea, epigastric burning, sore throat, black hairy tongue, pancreatitis, oncholysis, discolouration of tooth (children with developing teeth) and nails, tinnitus, visual disturbances, superinfections, photosensitivity, hypersensitivity,\nPotentially Fatal: Anaphylaxis, hepatotoxicity, nephrotoxicity, blood dyscrasias.\n\nPrecaution: Hepatic impairment. Myasthenia gravis, SLE. Should be administered with plenty of water, while sitting or standing, and well before going to bed to avoid oesophageal ulceration. Avoid exposure to sunlight. Periodic evaluation of renal, hepatic and haematological system during prolonged therapy.\n\nMode of action: Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.\n\nPotentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).\n\nPregnancy category: D\n\nInteraction: Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.\n\nPotentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).
Tetracycline Hydrochloride 1% Eye prep	\n\n\tAcme Ltd.\tA Tetra 1% Eye Ointment   3.5 gm tube/5 gm tube 8.50 / 11.55\n\tGonoshasthaya\tG Tetracycline Eye Ointment   5gm tube 8.03\n\tOpso Saline Ltd.\tTetracin 1% Eye Ointment   3gm tube 8.53\n\tIndication: Bacterial Conjunctivitis, trachoma.\n\nDose: Adult & Child: Apply 2 hourly in acute eye infection.\n\nContra-indication: Hypersensitivity; pregnancy, lactation, children; renal impairment.\n\nSide effects:  Burning, irritation, visual disturbances, superinfections, photosensitivity, hypersensitivity,\n\n\nPrecaution: Hepatic impairment. Avoid exposure to sunlight. Periodic evaluation of renal, hepatic and haematological system during prolonged therapy.\n\nMode of action: Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.\n\nPotentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).\n\nPregnancy category: D\n\nInteraction: Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.\n\nPotentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).
Tetracycline Hydrochloride 3% Eye prep	\n\n\tIndication: Bacterial Conjunctivitis\n\nDose: Adult & Child: Apply 2 hourly in acute eye infection.\n\nContra-indication: This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.\n\n\nSide effects: Burning, irritation, visual disturbances, superinfections, photosensitivity, hypersensitivity, \n\nPrecaution: Hepatic impairment. . Avoid exposure to sunlight. Periodic evaluation of renal, hepatic and haematological system during prolonged therapy.\n\nMode of action: Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.\n\nPotentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).\n\nPregnancy category: D\n\nInteraction: Impaired absorption w/ antacids containing divalent and trivalent cations (e.g. Al, Ca, Mg), Fe, Zn and Na bicarbonate preparations, kaolin-pectin, bismuth subsalicylate, sucralfate, strontium ranelate, colestipol and colestyramine. May interfere w/ the bactericidal action of penicillin. May potentiate the effect of anticoagulants. May decrease efficacy of oral contraceptives. Nephrotoxic effects may be exacerbated by diuretics or other nephrotoxic drugs. May increase the hypoglycaemic effect of insulin and sulfonylureas in patients w/ DM. May increase toxic effects of ergot alkaloids and methotrexate.\n\nPotentially Fatal: Concurrent methoxyflurane may result to fatal renal toxicity. Increased risk of benign intracranial HTN w/ vit A or retinoids (e.g. acitretin,isotretinoin, tretinoin).
Theophylline	\n\n\tACI\tTeolex CAP 400mg 100's pack 267\n\tACI\tTeolex SR TAB dr 200mg 100's pack 150\n\tACI\tTeolex CR CAP 300mg 100's pack 200\n\tACI\tTeolex SR TAB dr 300mg 100's pack 201\n\tACI\tTeolex SR TAB dr 400mg 100's pack 268\n\tAcme Ltd.\tThenglate Syrup 120mg/5ml 100ml bot 30.95\n\tAcme Ltd.\tThenglate SR TAB dr 250mg 50's pack 88\n\tAcme Ltd.\tThenglate SR TAB dr 400mg 50's pack 134\n\tAcme Ltd.\tThenglate TR CAP 300mg 100's pack 294\n\tAristopharma\tContine-200 TAB dr 200mg 100's pack 160\n\tAristopharma\tContine-300 TAB dr 300mg 100's pack 235\n\tAristopharma\tContine-400 TAB dr 400mg 100's pack 298\n\tAristopharma\tContine syrup 100ml 100ml bot 30\n\tBeximco\tBreathlin SR TAB dr 200mg 100's pack \n\tDoctor's Chemicals Works Ltd.\tTheonate Syrup 120mg/5ml 50ml bot/100ml bot 15/25\n\tDoctor's Chemicals Works Ltd.\tTheonate TAB dr 300mg 100's pack 131\n\tDoctor's Chemicals Works Ltd.\tTheonate SR TAB dr 300mg 40's pack 116\n\tDrug International Ltd.\tTheovent SR CAP 300mg 100's pack 292\n\tDrug International Ltd.\tTheovent SR TAB dr 300mg 100's pack 200\n\tDrug International Ltd.\tTheovent SR TAB dr 400mg 50's pack 134\n\tDrug International Ltd.\tTheovent SR 200 TAB dr 200mg 100's pack 159\n\tEdruc Ltd.\tAsmain Syrup 120mg/5ml 100ml bot 25\n\tGlobe\tTheofast Syrup 120 mg/5 ml  \n\tGlobe\tTheofast CR TAB dr 200mg  \n\tGlobe\tTheofast CR TAB dr 300mg  \n\tGlobe\tTheofast CR TAB dr 400mg  \n\tGonoshasthaya\tG Theophylline Syrup 120mg/5ml 100ml bot 15.05\n\tGonoshasthaya\tG Theophylline TAB dr 300mg 100's pack 82\n\tHealthcare\tFlumetol TAB dr 300mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tUnikon Syrup 120mg/5ml 100ml bot 26\n\tIbn Sina Pharmaceutical Ind. Ltd.\tUnikon SR TAB dr 400mg 100's pack 268\n\tIbn Sina Pharmaceutical Ind. Ltd.\tUnikon SR TAB dr 300mg  \n\tIncepta\tArofil 200 SR TAB dr 200mg 100's pack 160\n\tIncepta\tArofil 400 SR TAB dr 400mg 50's pack 149\n\tIncepta\tArofil 300 SR TAB dr 300mg 50's pack 117.50\n\tJayson\tJasophylin Syrup 120mg/5ml 100ml bot 25.10\n\tJayson\tJasophylin TAB dr 300mg 100's pack 131\n\tMundipharma (Bangladesh) Pvt. Ltd.\tUnicontin TAB dr 400mg 100's pack 768\n\tOpsonin Pharma\tUnilin Syrup 120mg/5ml 50ml bot/100ml bot 15.26/23.77\n\tOpsonin Pharma\tUnilin CR TAB dr 300mg 100's pack 200\n\tOpsonin Pharma\tUnilin CR TAB dr 400mg 100's pack 267\n\tOpsonin Pharma\tUnilin CR 200 TAB dr 200mg 100's pack 154\n\tOrion Pharma Ltd.\tNeulyn TAB dr 400mg 100's pack 251\n\tPacific\tAsmacon SR TAB dr 400mg 50's pack 133.50\n\tSharif\tAsmaloc SR TAB dr 300mg 50's pack 100\n\tSharif\tAsmaloc SR TAB dr 400mg 50's pack 133.50\n\tSquare\tContifil TAB dr 300mg 100's pack 196.84\n\tSquare\tContifil TAB dr 400mg 30's pack 79.80\n\tSun Pharmaceutical (Bangladesh) Ltd.\tOD Phylline TAB dr 400mg 50's pack 133.50\n\tIndication: Asthma, Chronic obstructive pulmonary disease, Bronchospasm, Apnoea\n\nDose: Adult: PO: usually controlled release tablet 12 hourly or as directed by the physicians.  10-15mg/Kg/day, 2 times daily.  \n\nChild:  \n1-6 months: 	10mg/Kg/day,   \n6 m-1 year: 	15mg/Kg/day,  \n1-9 years: 	        24mg/Kg/day,  \n10-l6 years: 	18mg/Kg/day, in divided doses.\n\nContra-indication: Hypersensitivity to xanthine derivatives, porphyria.\n\nSide effects: Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dizziness, anxiety, restlessness, tremor, palpitations.Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension and sudden death after too rapid IV inj.\n\nPrecaution: Smoking and alcohol consumption can increase the clearance of Theophylline and a higher dosage may be necessary.Careful monitoring is recommended for patients with congestive heart failure, chronic alcoholism, hepatic dysfunction or viral infections as they may have lower total clearance of Theophylline which could lead to higher than normal plasma levels.Caution should be exercised in patients with hyperthyroidism, cardiac arrhythmia, hypertension or other cardiovascular diseases.\n\nMode of action: Other xanthines. Theophylline clearance reduced by high dose allopurinol, some antiarrhythmics, cimetidine, disulfiram, propranolol, methotrexate, aciclovir, mexiletine, pentoxifylline, tacrine, ticlopidine, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Theophylline clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, aminoglutethimide, barbiturates, ipriflavone, cigarette smoking. Concurrent use decreased lithium, alprazolam levels. Increased risk of arrhythmias with ephedrine, sympathomimetic, general anaesthetics. Increased heart rate with tadalafil.\n\nPregnancy category: C\n\nInteraction: Other xanthines. Theophylline clearance reduced by high dose allopurinol, some antiarrhythmics, cimetidine, disulfiram, propranolol, methotrexate, aciclovir, mexiletine, pentoxifylline, tacrine, ticlopidine, fluvoxamine, interferon-?, macrolide antibiotics, quinolones, oral contraceptives, thiabendazole and viloxazine. Theophylline clearance increased by phenytoin, anticonvulsants, ritonavir, rifampicin, sulfinpyrazone, aminoglutethimide, barbiturates, ipriflavone, cigarette smoking. Concurrent use decreased lithium, alprazolam levels. Increased risk of arrhythmias with ephedrine, sympathomimetic, general anaesthetics. Increased heart rate with tadalafil.
Thiamine Hydrochloride	\n\n\tAcme Ltd.\tA B1 TAB dr 100mg 100'pack 74\n\tAd-din\tOnevit TAB dr 100mg 10 amps pack 74\n\tAlbion Ltd.\tVitaminI-B1 TAB dr 100mg 200's pack \n\tAlco Pharma\tB One TAB dr 100mg 100'pack 74\n\tAristopharma\tThiobion TAB dr 100mg 100's pack 72\n\tBeximco\tAvitron V TAB dr 100mg 250's pack 185\n\tBeximco\tBemin TAB dr 100mg 250's pack \n\tBristol Pharma Ltd.\tT-H TAB dr 100mg 100's pack 70\n\tChemist Ltd.\tVitamin B1 Injection 25mg/ml 50 amps pack 121\n\tEdruc Ltd.\tThia Injection 100mg/ml 10 amps pack 35\n\tGlaxoSmithKline Bangladesh Ltd.\tBerin TAB dr 100mg 250's pack 188.19\n\tGonoshasthaya\tG Vitamin B1 TAB dr 100mg 100'pack 62\n\tIbn Sina Pharmaceutical Ind. Ltd.\tThiosina TAB dr 100mg 200's pack 148\n\tJayson\tThiason Injection 100mg/ml 10 amps pack 35.50\n\tJayson\tThiason TAB dr 100mg  100'pack 74\n\tKemiko\tKvit TH TAB dr 100mg 100'pack 74\n\tMedicon\tThiabin TAB dr 100mg 200's pack 148\n\tMedimet\tNeurovit TAB dr 100mg 100'pack 74\n\tMedimet\tNeurovit Injection 25mg/ml 10 amps pack 40\n\tMystic\tThiatab TAB dr 100mg 100'pack 73\n\tOrion Pharma Ltd.\tTone TAB dr 100mg 100'pack 73\n\tPacific\tVita-1 TAB dr 100mg 100'pack 73\n\tPharmadesh Ltd.\tThiovit TAB dr 100mg 100'pack 80\n\tSquare\tBeovit TAB dr 100mg 250's pack 186.20\n\tStandard Ltd.\tStamurine TAB dr 100mg  \n\tIndication: Beriberi and Wernick's encephalopathy, neuritis associated with pregnancy and pellagra.\n\nDose: Treatment and prophylaxis of mild chronic thiamine deficiency\nAdult: 10-25 mg daily in single or divided doses.\n\nThiamine deficiency\nAdult: Up to 300 mg daily.\n\nWernicke-Korsakoff syndrome\nAdult: Initially, 100 mg by slow IV Inj over 10 min, then 50-100 mg/day IM or IV until the patient can take oral thiamine.\n\nIncompatibility: Alkaline or neutral solutions and with oxidizing and reducing agents.\n\nContra-indication: \n\nSide effects: IV: Warm sensation, tingling, pruritus, pain, urticaria, weakness, sweating, nausea, restlessness, tightness of the throat, angioedema, respiratory distress, cyanosis, pulmonary oedema, GI bleeding, transient vasodilation and hypotension, vascular collapse. IM: Tenderness and induration.\nPotentially Fatal: Very rarely, fatal anaphylactic shock.\n\nPrecaution: Parenteral admin. Increased daily requirements in pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Thiopental Sodium	\n\n\tACI\tThiopen IV Injection 500mg 1's pack 70.05\n\tACI\tThiopen IV Injection 1gm 1's pack 100.68\n\tGonoshasthaya\tG Thiopentone IV Injection 500mg 1's pack 60.23\n\tGonoshasthaya\tG Thiopentone IV Injection 1gm 1's pack 100.38\n\tIncepta\tAnestho IV 0.5gm Injection 500mg 1's pack 69.59\n\tIncepta\tAnestho IV 1gm Injection 1gm 1's pack 100\n\tPopular\tTPS IV Injection 500mg 1's pack 69.85\n\tPopular\tTPS IV Injection 1gm 1's pack 100.38\n\tSquare\tGenisia Injection 500mg 1's pack 69.59\n\tTechno Drugs Ltd.\tThioton IV Injection 500mg 1's pack 60\n\tTechno Drugs Ltd.\tThioton IV Injection 1gm 1's pack 100\n\tUnimed & Unihealth Manufacturers Ltd.\tPentothal Sodium 	 		 		 Injection  5's pack  1050\n\tIndication: Status epilepticus, Induction of anesthesia, Reduction of raised intracranial pressure\n\nDose: Intravenous\nInduction of anaesthesia\nAdult: 100-150 mg of a 2.5 or 5% solution injected over 10-15 sec repeated every 30-60 sec according to response or as a continuous infusion of a 0.2 or 0.4% solution. Max: 500mg. Max in pregnancy: 250mg.\nChild: 2-7 mg/kg over 10-15 seconds; repeated after 1 minute if needed..\n\nStatus epilepticus\nAdult: In conjunction with assisted ventilation: 75-125 mg as a 2.5% solution.\nChild: 5 mg/kg by slow IV inj followed by, neonates: continuous iv infusion of 2.5 mg/kg/hr; >1 month: 2-8 mg/kg/hr. Adjust infusion dose according to response.\n\nReduction of raised intracranial pressure\nAdult: Intermittent bolus inj of 1.5-3.5 mg/kg, if adequate ventilation is provided.\nChild: 3 mth-15 yr: initial 5-10-mg/kg IV followed by a continuous IV infusion at 1-4 mg/kg/hr.\nElderly: Dose reduction may be needed.\nHepatic impairment: Dose reduction may be needed.\n\nContra-indication: Thiopental Sodium for Injection is contraindicated in patients with severe respiratory embarrassment, hypersensitivity to barbiturates, status asthmaticus, variegate or acute intermittent porphyria, and inflammatory conditions of the mouth, jaw, and neck and in the absence of suitable veins for intravenous administration. Thiopental Sodium for Injection is also relatively contraindicated in severe cardiovascular disease, hypotension or shock, and conditions in which the hypnotic effect may be prolonged or potentiated, i.e. excessive premedication, Addison's disease, hepatic or renal dysfunction, myxedema, increased blood urea, severe anemia and myasthenia gravis.\n\nSide effects: Hypersensitivity reactions have been reported. Other adverse reactions to thiopental sodium include the followings: respiratory depression, myocardial depression, cardiac arrhythmias, prolonged somnolence and recovery, hypotension, tachycardia, sneezing, coughing, bronchospasm, laryngospasm and shivering. Anaphylactic reactions have been reported. Symptoms, e.g., urticaria, bronchospasm, vasodilation and edema.\n\nPrecaution: A person competent in anesthesia management should be in constant attendance and adequate facilities for support of respiration and circulation should be available when Thiopental Sodium for injection is being used. Thiopental Sodium for Injection should be administered with caution to patients with preexisting hypotension or in conditions where the hypnotic effect may be prolonged or intensified, such as in the presence of liver disease and renal disease.\n\nWarnings\nThis product may be habit forming. Keep resuscitative and endotracheal intubation equipment and oxygen readily available. Maintain patency of the airway at all times. Only persons qualified in the use of anesthetics should administer this drug. Avoid extravasations or intra-arterial injection.\n\nMode of action: Possible increase in difficulty in producing anaesthesia in patients taking alcohol or CNS depressants. Additive action with other CNS depressants including sedatives, hypnotics, nitrous oxide or alcohol. Increased hypotension and excitatory effects with phenothiazine antipsychotics. Increased hypnotic effect with antipsychotic. Decreased requirement of thiopental sodium with metoclopramide, sulfisoxazole, aspirin, meprobamate, probenecid and other highly protein bound drugs.\nPotentially Fatal: Increased resp depression with opioids.\n\nPregnancy category: C\n\nInteraction: Possible increase in difficulty in producing anaesthesia in patients taking alcohol or CNS depressants. Additive action with other CNS depressants including sedatives, hypnotics, nitrous oxide or alcohol. Increased hypotension and excitatory effects with phenothiazine antipsychotics. Increased hypnotic effect with antipsychotic. Decreased requirement of thiopental sodium with metoclopramide, sulfisoxazole, aspirin, meprobamate, probenecid and other highly protein bound drugs.\nPotentially Fatal: Increased resp depression with opioids.
Tibolone	\n\n\tACI\tTivion TAB dr 2.5mg 30's pack 601.80\n\tBeximco\tTibilon TAB dr 2.5 mg  \n\tEskayef Bangladesh Ltd.\tTibonor TAB dr 2.5mg 30's pack 600\n\tIncepta\tUbilon TAB dr 2.5mg 30's pack 600\n\tNuvista Pharma Ltd\tLenea TAB dr 2.5 mg 28's pack 603.68\n\tPopular\tTibo TAB dr 2.5mg 30's pack 602.40\n\tRenata\tMenorest TAB dr 2.5mg 28's pack 561.96\n\tSquare\tRenorma TAB dr 2.5mg 30's pack 602.09\n\tTechno Drugs Ltd.\tTibone TAB dr 2.5mg 30's pack 450\n\tIndication: Menopausal vasomotor symptoms [hot flushes, sweating, vaginal dryness & less elasticity, mood disorders, anxiety etc.], postmenopausal and post oophorectomy osteoporosis, improvement of bone-mineral density, Vaginal atrophy, Prevention of frequent UTI and urinary incontinence in postmenopausal women. \n\nDose: Adult: PO Climacteric symptoms & other post-menopausal problems in adults and elderly women: The dosage is 2.5 mg tablet per day, preferably at the same time of the day. Symptomatic relief occurs within few days, but optimal results are obtained minimum after 3 months. \n\nOsteoporosis: To prevent osteoporosis in post-menopausal women or after oophorectomy an uninterrupted longer (5-10 years) therapy of 2.5 mg daily is needed. \n\nStarting Tibolone: \nIn case of natural menopause: To avoid irregular & abnormal bleeding, Tibolone should be started at least 12 months after last natural bleeding.\n\n In case of artificial menopause: Treatment should be started immediately. \n\nIn case of switching over from other conventional HRT: If someone switches from estrogen-only preparation, she should start after a withdrawal bleeding. If someone switches from sequential HRT preparation she should wait for the completion of the progestogen phase. If someone switches from continuous combined HRT, she can start any time. \n\nIn case of missed pill: If no more than 12 hours have passed, the pill should be taken immediately. Otherwise the next dose should be continued as before.\n\n\nContra-indication: Known or suspected oestrogen dependent tumours in women, present or history of breast cancer, undiagnosed vaginal bleeding, severe liver disease, history or current CV or cerebrovascular disorders, untreated endometrial hyperplasia, porphyria, pregnancy and lactation, premenopausal women.\n\nSide effects: Weight gain; dizziness; rash; pruritus; headache; migraine; visual disturbances; GI symptoms; facial hair growth; altered liver function; ankle oedema; depression; arthralgia or myalgia; irregular vaginal bleeding.Potentially Fatal: Breast or endometrial cancer and stroke.\n\nPrecaution: Liver disease, history or risk factors of thromboembolic disorder, impaired glucose tolerance, hypercholesterolaemia, hypertriglyceridaemia, hypertension, cholelithiasis, SLE, uterine fibroids, endometriosis and history of endometrial hyperplasia. Disorders that may be worsened by fluid retention, eg. renal dysfunction, migraine, epilepsy. Discontinue in the event of thromboembolic or abnormal liver function results, significant increase in BP, new onset of migraine-type headache. Not recommended in women within 1 yr of menopause because of irregular vaginal bleeding. Stop tibolone 4 wk before elective surgery especially when prolonged immobilisation after surgery is expected. Adjustment of antidiabetic medications may be needed.\n\nMode of action: Enzyme inducers eg, barbiturates, phenytoin, carbamazepine and rifampicin may accelerate tibolone metabolism. Increased anticoagulant effects of warfarin.\n\nPregnancy category: D\n\nInteraction: Enzyme inducers eg, barbiturates, phenytoin, carbamazepine and rifampicin may accelerate tibolone metabolism. Increased anticoagulant effects of warfarin.
Ticlopidine Hydrochloride	\n\n\tIndication: Hereditary hemorrhagic telangiectasia, Intermittent claudication, Ischaemic heart disease\n\nDose: Prophylaxis of thrombotic stroke\nAdult: >18 yr: 250 mg bid.\n\nIschaemic heart disease\nAdult: >18 yr: 250 mg bid.\n\nIntermittent claudication\nAdult: >18 yr: 250 mg bid.\n\nProphylaxis of subacute stent occlusion after intracoronary stenting\nAdult: >18 yr: 250 mg bid for 4 wk, in conjunction with aspirin, starting at the time of stent placement.\n\nRenal impairment: Dose reduction or discontinuance if haemorrhagic or haematopoietic complications occur.\nHepatic impairment: Severe: contraindicated.\n\nContra-indication: Pre-existing or history of blood dyscrasias; haemostatic disorder or active pathological bleeding (eg. bleeding peptic ulcer, intracranial bleeding); severe hepatic dysfunction. Hypersensitivity. Lactation.\n\nSide effects: Diarrhoea, nausea, dyspepsia, bleeding, pupura, skin rash, increase in serum cholesterol concentration, elevation of LFTs, hepatitis, cholestatic jaundice.\nPotentially Fatal: Neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura and aplastic anaemia.\n\nPrecaution: Patients with increased risk of bleeding from trauma, surgery or pathological disorder. Moderate to severe renal impairment. May need to stop therapy 10-14 days before elective surgery. Full blood counts should be performed prior to therapy and every 2 wk during the first 3 mth of treatment. Pregnancy.\n\nMode of action: Reduced clearance with cimetidine; corticosteroid may antagonise effects on bleeding time. Avoid concurrent use with clopidogrel.\nPotentially Fatal: Risk of haemorrhage increased with NSAIDs and oral anticoagulants; decreased metabolism of theophylline, phenytoin and bupropion.\n\nPregnancy category: B\n\nInteraction: Reduced clearance with cimetidine; corticosteroid may antagonise effects on bleeding time. Avoid concurrent use with clopidogrel.\nPotentially Fatal: Risk of haemorrhage increased with NSAIDs and oral anticoagulants; decreased metabolism of theophylline, phenytoin and bupropion.
Tiemonium Methylsulphate	\n\n\tACI\tTynium Syrup 10mg/5ml 100ml bot/50ml bot 85.26/56.17\n\tACI\tTynium Injection 5mg/2ml 5 amps pack 75.55\n\tACI\tTynium TAB dr 50mg 50's pack 301\n\tAcme Ltd.\tTinium Injection 5mg/2ml 5 amps pack 75.25\n\tAcme Ltd.\tTinium TAB dr 50mg 50's pack 200.50\n\tAd-din\tTium TAB dr 50mg 30's pack 105\n\tAlco Pharma\tTiemo TAB dr 50mg 30's pack 120\n\tApex\tVisnor TAB dr 50mg 50's pack 200\n\tApex\tVisnor Injection 5mg/2ml 10 amps pack 150\n\tAristopharma\tVeralgin Injection 5mg/2ml 2ml amp X 10's pack 150\n\tAristopharma\tVeralgin TAB dr 50mg 50's pack 250\n\tBeacon\tTivis Injection 5 mg/2 ml  \n\tBeacon\tTivis TAB dr 50mg  \n\tBenham\tTimoben TAB dr 50mg 30's pack 120\n\tBeximco\tEmonium TAB dr 50mg 50's pack 250\n\tBeximco\tEmonium IM/IV Injection 5mg/2ml 5 amps pack 75\n\tBio Pharma Ltd.\tRelvis Inj Injection 5mg/2ml 10's pack 150\n\tBio Pharma Ltd.\tRelvis TAB dr 50mg 50's pack 250\n\tChemist Ltd.\tTienum TAB dr 50mg 50's pack 200\n\tChemist Ltd.\tTienum Injection 5mg/2ml 5 amps pack 75\n\tConcord\tTispa TAB dr 50mg 50's pack \n\tCosmic Chemical Industries Ltd.\tTimopa TAB dr 50mg 50's pack 200\n\tDelta Pharma\tTino TAB dr 50mg 30's pack 120\n\tDrug International Ltd.\tVisonium TAB dr 50mg 50's pack 200\n\tDrug International Ltd.\tParillex TAB dr 50mg 50's pack 200\n\tEdruc Ltd.\tTimeth TAB dr 50mg 50's pack 200\n\tEskayef Bangladesh Ltd.\tTimothy Injection 5mg/2ml 5 amps pack 75\n\tEskayef Bangladesh Ltd.\tTimothy TAB dr 50mg 50's pack 200\n\tEuro Pharma Ltd.\tSpazin TAB dr 50mg 50's pack 250\n\tGeneral\tPrevip TAB dr 50mg 50's pack 201\n\tGlobe\tVispazin Injection 5mg/2ml 10 amps pack 100\n\tGlobe\tVispazin TAB dr 50mg 50's pack 200\n\tHealthcare\tViset Injection 5mg/2ml 10 amps pack 160\n\tHealthcare\tViset TAB dr 50mg 50's pack 250\n\tHealthcare\tViset Syrup 25mg/5ml 100ml bot 50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVisceral Injection 5mg/2ml 10 amps pack 160\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVisceral TAB dr 50mg 50's pack 225\n\tIncepta\tTimozin Injection 5mg/2ml 5 amps pack 75\n\tIncepta\tTimozin TAB dr 50mg 50's pack 250\n\tKumudini Pharma Ltd.\tTimovis TAB dr 50mg 50's pack 200\n\tLeon\tVisalex TAB dr 50mg  \n\tMedicon\tTMS TAB dr 50mg 50's pack 200\n\tNavana\tPanium TAB dr 50mg 50's pack 250\n\tNIPRO JMI Pharma\tVisnil TAB dr 50mg  \n\tNovartis (Bangladesh) Ltd.\tZeum TAB dr 50mg 50's pack 325\n\tNovo Healthcare and Pharma Ltd.\tTitos TAB dr 50mg 30's pack 120\n\tNuvista Pharma Ltd\tVisceralgine Injection 5mg/2ml 10 amp's pack 395.70\n\tNuvista Pharma Ltd\tVisceralgine TAB dr 50 mg 50's pack 496.20\n\tOpsonin Pharma\tVisral Syrup 10mg/5ml 1x1's pack 85\n\tOpsonin Pharma\tVisral Injection 5mg/2ml 5 amps pack 75\n\tOpsonin Pharma\tVisral TAB dr 50mg 50's pack 250\n\tOpsonin Pharma\tSpasalgin TAB dr 50 mg 30's pack \n\tOpsonin Pharma\tSpasalgin Injection 5mg 5's pack \n\tOrion Pharma Ltd.\tOnium Syrup 10mg/5ml 50ml bot 50\n\tOrion Pharma Ltd.\tOnium Injection 10mg/5ml 5 amps pack 85\n\tOrion Pharma Ltd.\tOnium TAB dr 50mg 50's pack 251\n\tPharmasia Ltd.\tVisarin TAB dr 50mg 50's pack 201\n\tPharmasia Ltd.\tVisarin Syrup 200 mg/100 ml  \n\tPopular\tTimonil Injection 5mg/2ml 5 amps pack 75.30\n\tPopular\tTimonil TAB dr 50mg 50's pack 201.03\n\tRAK\tTimonac TAB dr 50mg 50's pack 200\n\tRangs\tDysma TAB dr 50mg 50's pack 200\n\tRenata\tAlgin Syrup 200mg/100ml 100ml bot 90\n\tRenata\tAlgin Injection 5mg/2ml 5 amps pack 125\n\tRenata\tAlgin TAB dr 50mg 50's pack 300\n\tRephco\tTinimet Injection 5mg/ml 2x5's pack 200\n\tRephco\tTinimet TAB dr 50mg 5x10's pack 250\n\tSeema\tSeemalgine TAB dr 50mg 30's pack 120\n\tShamsul Al-Amin\tTimolax TAB dr 50mg 50's pack 200\n\tSharif\tTinilux TAB dr 50mg 30's pack 120\n\tSilva\tTimem TAB dr 50mg 50's pack 200.75\n\tSomatec\tEmogin TAB dr 50mg 50's pack 250\n\tSquare\tNorvis Injection 5mg/2ml 10 amps pack 150.55\n\tSquare\tNorvis TAB dr 50mg 50's pack 250\n\tSquare\tNorvis Syrup 10mg/5ml 100ml bot 87\n\tSquare\tNorvis Suppository 20mg  \n\tTechno Drugs Ltd.\tViscer Injection 5mg/2ml 2ml amp X 10's pack 120\n\tTechno Drugs Ltd.\tViscer TAB dr 50mg 50's pack 175\n\tUnimed & Unihealth Manufacturers Ltd.\tVisegin TAB dr 50mg 30's pack 150\n\tVeritas\tSparel TAB dr 50mg  \n\tZiska\tSpanium Injection 5mg/2ml 5 amps pack 75\n\tZiska\tSpanium TAB dr 50mg 50's pack 200\n\tIndication: Dysentery, Diarrhoea, Gastroenteritis, Biliary colic, Enterocolitis, Cholecystitis, Colonopathies, Mild cystitis and spasmodic dysmenorrhoea, Visceral muscle spasm\n\nDose: Tablet: The usual dosages of Timozin are 2 to 6 tablets (100-300 mg) daily in divided doses as required.\nInjection: 1 ampoule by slow IV/IM injection 3 times daily.\n\nContra-indication: This drug must not be used in glaucoma (acute pain in the eyeball with disorders of vision), difficulties in urinating (disorders of the prostate or bladder).\n\nSide effects: Tiemonium Methylsulfate INN may have some undesirable effects in certain individuals like risk of hypotension and tachycardia especially in case of injection.\n\nPrecaution: Precautions should be exercised for treatment of patients with disorders of the prostate, serious diseases of the kidney or liver, cardiac disorders, thyroid disorders, chronic bronchitis and certain gastrointestinal diseases. The risks of visual disturbances can make it dangerous to drive or use machines.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Tigecycline	\n\n\tIncepta\tTigacil Infusion   1's pack 500\n\tIncepta\tWidebac IV Infusion 50 mg/vial  \n\tIndication: Skin and Skin structure Infections: Intra-Abdominal Infections: Community-Acquired Bacterial Pneumonia\n\nDose: The duration of therapy should be guided by the severity and site of the infection and the patient's clinical and bacteriological progress. The recommended duration of treatment with Tigecycline for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days and for community-acquired bacterial pneumonia is 7 to 14 days. The recommended daily dose is as follows:\n\nAdults: The recommended dosage regimen for Tigecycline is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous (IV) infusions of Tigecycline should be administered over approximately 30 to 60 minutes every 12 hours.\n\nPediatric use: Safety and effectiveness in pediatric patients below the age of 18 years have not been established.\n\nGeriatric use: No unexpected overall differences in safety or effectiveness were observed between these subjects and younger subjects.\n\n\nContra-indication: Tigecycline is contraindicated for use in patients who have known hypersensitivity to Tigecycline.\n\nSide effects: The most common treatment-emergent adverse events are nausea and vomiting which generally occurre during the first 1-2 days of therapy. The following drug-related adverse events are reported infrequently in patients receiving Tigecycline:\nInjection site inflammation & pain, septic shock, allergic reaction, chills, thrombophlebitis, bradycardia, tachycardia, vasodilatation, anorexia, dry mouth, hypoglycemia, hyponatremia, prolonged prothrombin time, eosinophilia, thrombocytopenia, vaginal moniliasis, vaginitis, leukorrhea.\n\nPrecaution: Tigecycline is structurally similar to Tetracycline-class antibiotics and should be administered with caution in patients with known hypersensitivity to Tetracycline-class antibiotics.\n\n\nMode of action: Increased warfarin serum levels. May decrease efficacy of oral contraceptives.\n\nPregnancy category: D\n\nInteraction: Increased warfarin serum levels. May decrease efficacy of oral contraceptives.
Timolol Maleate 0.25%  Eye prep	\n\n\tACI\tLotensin Eye Drops  .5% 5ml 67.25\n\tGlobe\tGlumol Eye Drops 0.25 %  \n\tIncepta\tTimopress .25% Eye Drops   1's pack 55\n\tOpso Saline Ltd.\tTimolol OSL Eye Drops  0.25% 5ml drop 43\n\tSquare\tTemlo .25% Eye Drops  5ml 70.26\n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: Ophth Open-angle glaucoma; Ocular HTN As eye drop soln: Initial: Instill 1 drop of 0.25% soln to affected eye(s) twice daily, increase to 1 drop of 0.5% soln twice daily if needed. Reduce to 1 drop/day if controlled. \n\nContra-indication: Present or history of bronchial asthma, severe COPD, sinus bradycardia, 2nd and 3rd degree heart block, sick sinus syndrome, overt heart failure, cardiogenic shock, severe peripheral vascular disease/Raynaud's disease), Prinzmetal angina, untreated pheochromocytoma, metabolic acidosis, hypotension.\n\nSide effects: Ophthalmic use: Burning, stinging, blurred vision, ocular irritation (e.g. conjunctivitis, blepharitis, crusting), decreased corneal sensitivity, visual disturbances, diplopia, ptosis, cystoid macular oedema, pseudopemphigoid, choroidal detachment following filtration surgery. Adverse reactions associated with systemic administration of beta-blocker may occur with ophthalmic use. Potentially Fatal: Heart failure, intensification of heart block, bronchospasm, respiratory failure.\n\nPrecaution: Due to systemic absorption of ophthalmic preparations, adverse reactions associated with systemic administration of beta-blockers may occur. Abrupt withdrawal of beta-blocker may cause exacerbation of angina, and myocardial infarctions have occurred in some cases. Ophthalmic Timolol should not be used alone for treatment of angle-closure glaucoma. beta-blocker therapy may increase sensitivity towards allergen in patients with history of atrophy or severe anaphylaxis reactions. Safety and efficacy have not been established in paediatric patients.\n\nMode of action: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).\n\nPregnancy category: C\n\nInteraction: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).
Timolol Maleate 0.5% Eye prep	\n\n\tApex\tTimolol 0.5% Eye Drops   5ml bot 70\n\tAristopharma\tAristomol 0.5% Eye Drops   5  ml drop 70\n\tAsiatic Ltd.\tAsinol 0.5% Eye Drops   5  ml drop 67\n\tBeximco\tIntramol Eye Drops   5  ml drop 70\n\tGeneral\tGemolol Eye Drops   5ml drop 70\n\tHealthcare\tTimocare Eye Drops   5ml drop 80\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTimolet 0.5% Eye Drops   5  ml drop 75 \n\tIncepta\tTimopress 0.5% Eye Drops   5  ml drop 70\n\tNipa\tTimomin 0.5% Eye Drops   5  ml drop 70\n\tOpso Saline Ltd.\tTimolol OSL Eye Drops  0.5% 5ml drop 62.75\n\tPopular\tOcupres 0.5% Eye Drops .5 % 5  ml drop 70.26\n\tReman Drug Ltd.\tTimodrop 0.5% Eye Drops   5  ml drop 75\n\tRephco\tTimosol Eye Drops   5ml drop 70\n\tSquare\tTemlo 0.5% Eye Drops   5  ml drop 70.26\n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: Adult: Ophth Open-angle glaucoma; Ocular HTN As eye drop soln: Initial: The usual starting dose is one drop of Timopress 0.5 in the affected eye(s) twice a day. Reduce to 1 drop/day if controlled. \n\nContra-indication: Present or history of bronchial asthma, severe COPD, sinus bradycardia, 2nd and 3rd degree heart block, sick sinus syndrome, overt heart failure, cardiogenic shock, severe peripheral vascular disease/Raynaud's disease), Prinzmetal angina, untreated pheochromocytoma, metabolic acidosis, hypotension.\n\nSide effects: Ophthalmic use: Burning, stinging, blurred vision, ocular irritation (e.g. conjunctivitis, blepharitis, crusting), decreased corneal sensitivity, visual disturbances, diplopia, ptosis, cystoid macular oedema, pseudopemphigoid, choroidal detachment following filtration surgery. Adverse reactions associated with systemic administration of beta-blocker may occur with ophthalmic use. Potentially Fatal: Heart failure, intensification of heart block, bronchospasm, respiratory failure.\n\nPrecaution: Due to systemic absorption of ophthalmic preparations, adverse reactions associated with systemic administration of beta-blockers may occur. Abrupt withdrawal of beta-blocker may cause exacerbation of angina, and myocardial infarctions have occurred in some cases. Ophthalmic Timolol should not be used alone for treatment of angle-closure glaucoma. beta-blocker therapy may increase sensitivity towards allergen in patients with history of atrophy or severe anaphylaxis reactions. Safety and efficacy have not been established in paediatric patients.\n\nMode of action: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).\n\nPregnancy category: C\n\nInteraction: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).
Timolol Maleate 0.5% + Travoprost 0.004% Eye prep	\n\n\tApex\tTravo Plus Eye Drops   3ml bot 500\n\tAristopharma\tAvatan-T Eye Drops   3ml drop 500\n\tIncepta\tTravast Plus Eye Drops   3  ml drop 500\n\tIndication: Open-angle glaucoma,Ocular hypertension\n\nDose: Use in adults:\nThe dose is one drop of  in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. It should be administered at the same time each day.\n\nPaediatric patients:\nThe efficacy and safety of Travast Plus in patients below the age of 18 years have not been established.\n\nContra-indication: Hypersensitivity to Travoprost, Timolol or to any of the excipients. \n\nSide effects: No serious ophthalmic or systemic undesirable effects  were reported. The most frequently reported treatment-related undesirable effect was ocular hyperaemia. Other common side-effects may be keratitis, anterior chamber flare, eye pain, photophobia, eye swelling, conjunctival haemorrhage, corneal staining, ocular discomfort, visual acuity reduced, visual disturbance, blurred vision etc.\n\nPrecaution: Like other topically applied ophthalmic agents, Travoprost and Timolol are absorbed systemically. Due to the beta-adrenergic component, timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta adrenergic blocking agents may occur. \n\nMode of action:  	Oral Ca channel blockers, guanethidine or ?-blockers, antiarrhythmics, digitalis glycosides, parasympathomimetics, antidiabetics. ?-blockers potentiate hypertensive reaction to clonidine w/drawal.\n\nPregnancy category: C\n\nInteraction:  	Oral Ca channel blockers, guanethidine or ?-blockers, antiarrhythmics, digitalis glycosides, parasympathomimetics, antidiabetics. ?-blockers potentiate hypertensive reaction to clonidine w/drawal.
Tinidazole	\n\n\tBeacon\tTinizol TAB dr 1gm 50's pack 285\n\tPopular\tT-Zol TAB dr 1gm 32's pack 183.36\n\tPopular\tT-Zol TAB dr 500mg 30's pack 82.80\n\tPopular\tT-Zol IV Infusion 400mg/100ml 100ml bot 120\n\tRenata\tProtogyn TAB dr 1gm 20's pack 120\n\tRenata\tProtogyn TAB dr 500mg 100's pack 400\n\tIndication: Giardiasis, H. pylori infection, Surgical Prophylaxis, Bacterial vaginosis, Intestinal amoebiasis, Trichomoniasis, Acute necrotising ulcerative gingivitis, Hepatic amoebiasis\n\nDose: Adult: PO Bacterial vaginosis; Acute necrotising ulcerative gingivitis; Giardiasis; Trichomoniasis 2 g as single dose. \nChild: >3 yr 50-75 mg/kg as single dose, repeat if necessary. Max: 2 g/day.\n\nBacterial vaginosis: May repeat the next day. \n\nSusceptible infections 2 g on 1st day, then 1 g once daily for 4-5 days. \n\nSurgical prophylaxis 2 g 12 hr pre-op. Eradication of H. pylori associated w/ peptic ulcer disease W/ clarithromycin and omeprazole: 500 mg twice daily for 7 days. \n\nIntestinal amoebiasis 2 g once daily for 2-3 days. Hepatic amoebiasis 1.5-2 g once daily for 3-6 days. \nChild: >3 yr 50-60 mg/kg daily for 3 consecutive days. Max: 2 g/day. \n\nIV Susceptible infections Initial: Infuse 800 mg, followed by 800 mg/day or 400 mg twice daily till PO can be given. \n\nSurgical prophylaxis 1.6 g as single infusion pre-op.\n\nContra-indication: Blood dyscrasias, organic neurologic disorders, hypersensitivity to 5-nitroimidazole derivatives, porphyria. Lactation, pregnancy (1st trimester).\n\nSide effects: Metallic taste, nausea, headache, vomiting, dark urine, flushing, anorexia, diarrhoea, tiredness, transient leucopenia.\nPotentially Fatal: Hypersensitivity.\n\nPrecaution: Alcohol should be avoided until 72 hr after stopping therapy. Discontinue if abnormal neurological signs (e.g. dizziness, incoordination, ataxia) develop. CNS diseases, pregnancy (2nd and 3rd trimester).\n\nMode of action: May potentiate the effects of oral anticoagulants resulting to prolonged prothrombin time.\n\nPregnancy category: C\n\nInteraction: May potentiate the effects of oral anticoagulants resulting to prolonged prothrombin time.
Tioconazole Vag prep	\n\n\tAcme Ltd.\tTycon Suppository 300mg  5's pack 301.10\n\tIndication: Vulbo-Vaginal candidiasis\n\nDose: Adult: Vag candidiasis As vaginal suppository: 300 mg as a single dose P/V. \n\nContra-indication: Hypersensitivity to imidazole-derivative azole antifungal. Self-medication in women with diabetes or HIV infection. Girls <12 yr.\n\nSide effects: Burning; itching; erythema; pain; rash; vaginitis; headache; infection; abdominal pain; transient small increase in LFT; paraesthesia.\n\nPrecaution: Avoid douching. Ointment: May damage rubber or latex contraceptives and additional contraceptive measures are necessary during first 72 hr after local admin. Do not use tampons if used during menstruation. Pregnancy. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Tioconazole 1% Topical	\n\n\tAcme Ltd.\tTycon Cream   10gm  tube 47.72\n\tRenata\tConasyd 1% Cream   10gm  tube 63\n\tIndication: Skin fungal infections, Pityriasis versicolor, Nail fungal infections\n\nDose: Adult: Topical Skin fungal infections As 1% cream: Apply 1-2 times/day. \nNail fungal infections As 28% w/w soln: Apply to the affected nails and immediately surrounding skin twice daily for up to 6-12 mth.\n\nContra-indication: Hypersensitivity to imidazole-derivative azole antifungal. Self-medication in women with diabetes or HIV infection. Girls <12 yr.\n\nSide effects: Burning; itching; erythema; pain; rash; vaginitis; headache; infection; abdominal pain; transient small increase in LFT; paraesthesia.\n\nPrecaution: Avoid douching. Ointment: May damage rubber or latex contraceptives and additional contraceptive measures are necessary during first 72 hr after local admin. Do not use tampons if used during menstruation. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Tiotropium	\n\n\tAcme Ltd.\tTopium DPI Dry powder inhalation capsule 18mcg 30 rotacaps pack 150.30\n\tBeximco\tTriomid Inhaler 9mcg 120 puffs unit 350\n\tBeximco\tTioriva Bexicap Dry Powder Inhaler 18mcg 30's pack 240\n\tSquare\tNorvent Inhaler 9mcg 200 puffs unit 351.31\n\tIndication: COPD\n\nDose: Maintenance therapy in chronic obstructive pulmonary disease\nAdults and adolescents 12 years and older : Inhaler \nThe recommended dosage of Tiotropium bromide is the inhalation of 2 puffs once daily.\n\nAdult: >18 yr: 1 cap (18 mcg of tiotropium) inhaled daily, with the inhalation device, at the same time of day.\n\n\nRenal impairment:\nCrCl (ml/min)	\n<50	           Use with caution and monitor closely.\n\nContra-indication: Hypersensitivity to atropine and its derivatives (e.g. ipratropium).\n\nSide effects: Dry mouth, constipation, cough and local irritation, tachycardia, urinary retention, UTI, upper respiratory tract infection, hypersensitivity reactions, pupil dilation, blurred vision, myalgia, dyspepsia, rash. Pharyngitis, sinusitis, rhinitis and epistaxis reported with the use of inhalation powder.\n\nPrecaution: Narrow-angle glaucoma; prostatic hypertrophy or bladder-neck obstruction; renal impairment. Pregnancy and lactation. Discontinue if immediate hypersensitivity (e.g. angioedema) or paradoxical bronchospasm occurs. Discontinue if eye pain, red eye, visual halos, and other signs of acute narrow-angle glaucoma.\n\nMode of action: Other anticholinergic agents.\n\nPregnancy category: C\n\nInteraction: Other anticholinergic agents.
Tizanidine	\n\n\tACI\tTizadin TAB dr 2mg 50's pack 252\n\tBeximco\tRelentus TAB dr 2mg 50's pack 250\n\tNovartis (Bangladesh) Ltd.\tSirdalud TAB dr 2mg 30's pack 300\n\tOpsonin Pharma\tTizalud TAB dr 2mg 30's pack 150\n\tIndication: Spasticity, Painful muscle spasm\n\nDose: Adult: PO Spasticity >18 yr: Initial: 2 mg once daily, increase slowly if needed, up to 24 mg/day in 3-4 divided doses. Max: 24 mg/day; 8 mg/dose. \n\nPainful muscle spasm associated w/ musculoskeletal conditions >18 yr: 2-4 mg 3 times/day.\n\nElderly: Not recommended.\n\nRenal impairment:\nCrCl (ml/min)	\n<25 	Initially, 2 mg once daily, gradually increasing the dose before increasing the frequency of admin.\n\nHepatic impairment: Avoid or use with extreme caution.\n\nContra-indication: Severe hepatic dysfunction.\n\nSide effects: Drowsiness, fatigue, dizziness, insomnia, headache, anxiety, nausea, dryness of mouth, GI disturbances, hypotension, bradycardia, muscle pain and weakness, transient increase in serum transaminases, hallucinations.\nPotentially Fatal: Hepatitis.\n\nPrecaution: Hepatic or renal insufficiency. Children, elderly, pregnancy and lactation. Monitor LFT regularly. Stop treatment if liver enzymes are raised persistently >3 times upper limit of normal range. Avoid abrupt withdrawal of therapy.\n\nMode of action: Potentiates hypotensive effect of antihypertensives. Increased CNS effects with alcohol and CNS depressants. Increased bradycardia with ?-blockers and digoxin. Increased serum concentration of tizanidine with CYP1A2 inhibitors e.g. zileuton, ciprofloxacin and other fluoroquinolones, antiarrhythmics, cimetidine, famotidine, oral contraceptives, aciclovir and ticlopidine. Decreased serum concentrations of tizanidine with rifampicin. Use with caution with drugs that may prolong QT interval.\n\nPregnancy category: C\n\nInteraction: Potentiates hypotensive effect of antihypertensives. Increased CNS effects with alcohol and CNS depressants. Increased bradycardia with ?-blockers and digoxin. Increased serum concentration of tizanidine with CYP1A2 inhibitors e.g. zileuton, ciprofloxacin and other fluoroquinolones, antiarrhythmics, cimetidine, famotidine, oral contraceptives, aciclovir and ticlopidine. Decreased serum concentrations of tizanidine with rifampicin. Use with caution with drugs that may prolong QT interval.
Tobramycin Eye prep	\n\n\tAristopharma\tT Mycin 0.3% Eye Drops   5  ml drop 90\n\tAristopharma\tT Mycin 0.3% Eye Ointment   3gm tube 60\n\tAsiatic Ltd.\tTobi 0.3% Eye Drops   5  ml drop 80\n\tBeximco\tCinarex Eye Drops   5  ml drop 85\n\tG. A. Company Ltd.\tTobirax 0.3% Eye Ointment   3.5 gm tube 50\n\tG. A. Company Ltd.\tTobirex 0.3% Eye Drops   5  ml drop 90\n\tGeneral\tGentob Eye Drops 3 mg/ml  \n\tGeneral\tGentob Eye Ointment 3 mg/gm  \n\tGlobe\tOcutob Eye Drops 3 mg/ml  \n\tHealthcare\tTobrel Eye Drops 3 mg/ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tTomycin Eye Ointment   3gm tube 55\n\tIbn Sina Pharmaceutical Ind. Ltd.\tTomycin 0.3% Eye Drops   5  ml drop 90\n\tIncepta\tIntobac 3% Eye Drops  5ml 85\n\tNipa\tTobramin 0.3% Eye Drops   5  ml drop 90\n\tOpso Saline Ltd.\tTobracin 0.3% Eye Ointment   3gm tube 30.11\n\tOpso Saline Ltd.\tTobracin 0.3% Eye Drops   5  ml drop 80.30\n\tOpsonin Pharma\tTorcin Eye Drops 3 mg/ml  \n\tPopular\tTobrabac Eye Drops  3 mg/ml 5  ml drop 85.32\n\tReman Drug Ltd.\tT Oint 0.3% Eye Ointment   3gm tube 50.50\n\tIndication: Ocular infection, bacterial eye infection\n\nDose: Ophthalmic Ocular infections Adult: As eye drop: Mild to moderate infections: Instill 1-2 drops into affected eye every 4 hr. Severe infections: Instill 2 drops into affected eye every 30-60 minutes initially until improvement, reduce treatment frequency before discontinuation. \n\nAs eye ointment: Mild to moderate infections: Apply a half-inch ribbon bid-tid into affected eye. Severe infections: Apply a half-inch ribbon into the affected eye every 3-4 hr until improvement, reduce treatment frequency before discontinuation.\n\nContra-indication: This eye drop is contraindicated in epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and other viral disease of the cornea and conjunctiva.It is contraindicated in mycobacterial infections of the eye caused by acid-fast bacilli such as Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium avium. Fungal diseases of eye, untreated purulent infection of the eye. Hypersensitivity to any component of the medication.\n\nSide effects: Tobramycin may cause hypersensitivity and localised ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than 4% of patients. The reactions due to dexdamethasone are: elevation of intraocular pressure (IOP), with possible development of glaucoma and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.\n\nPrecaution: Preexisting renal and auditory or vestibular impairment; dehydration; neuromuscular blockade, muscular disorders (e.g. myasthenia gravis, parkinsonism); neonates; elderly; lactation. \n\nMode of action: Increased nephrotoxicity or ototoxicity with etacrynic acid, furosemide, other aminoglycosides, cefalotin, cisplatin, vancomycin, piperacillin, ciclosporin, amphotericin B. Decrease serum tobramycin levels with miconazole.\nPotentially Fatal: Increased neuromuscular-blocking activity with magnesium and other neuromuscular-blocking agents. \n\nPregnancy category: B\n\nInteraction: Increased nephrotoxicity or ototoxicity with etacrynic acid, furosemide, other aminoglycosides, cefalotin, cisplatin, vancomycin, piperacillin, ciclosporin, amphotericin B. Decrease serum tobramycin levels with miconazole.\nPotentially Fatal: Increased neuromuscular-blocking activity with magnesium and other neuromuscular-blocking agents. 
Tolfenamic Acid	\n\n\tACI\tNamitol TAB dr 200mg 30's pack 240.60\n\tBeacon\tMigratol TAB dr 200mg  \n\tBeximco\tTolmic TAB dr 200mg 30's pack 240.90\n\tEskayef Bangladesh Ltd.\tTufnil TAB dr 200mg 40's pack 400\n\tIncepta\tMigrex 200 TAB dr 200mg 30's 300\n\tOpsonin Pharma\tArain TAB dr 200mg 30's pack 240\n\tIndication: Mild to moderate pain,  Acute migraine attacks\n\nDose: Adult: PO Acute migraine attacks Initial: 200 mg upon onset of symptoms. May repeat once after 1-2 hr. Mild to moderate pain 100-200 mg 3 times/day.\n\nRenal impairment: Dose adjustments may be needed\n\nContra-indication: Hypersensitivity to aspirin or other NSAID. Active peptic ulceration. Severe renal or hepatic impairment. Pregnancy (3rd trimester).\n\nSide effects: Dysuria especially in males; diarrhoea, nausea, epigastric pain, vomiting, dyspepsia, erythema, headache. Tremor, euphoria, fatigue, pulmonary infiltration.\nPotentially Fatal: Blood dyscrasias, toxic hepatitis.\n\nPrecaution: Asthma, bronchospasm, bleeding disorders, CV diseases, history of peptic ulceration, hypertension, patients with infections, liver, cardiac, or renal function impairment. Increase water intake or dose reduction to reduce dysuria. CHF; elderly; lactation.\n\nMode of action: Increased rate of absorption of tolfenamic acid with metoclopramide and magnesium hydroxide. Decreased rate of absorption of tolfenamic acid with aluminium hydroxide. Increased risk of bleeding with anticoagulants and other NSAIDs. Decreased antihypertensive response to loop diuretics, ?-blockers and ACE inhibitors. Coadmin increased plasma concentrations of lithium, methotrexate and cardiac glycosides. Increased risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus or diuretics.\n\nPregnancy category: C\n\nInteraction: Increased rate of absorption of tolfenamic acid with metoclopramide and magnesium hydroxide. Decreased rate of absorption of tolfenamic acid with aluminium hydroxide. Increased risk of bleeding with anticoagulants and other NSAIDs. Decreased antihypertensive response to loop diuretics, ?-blockers and ACE inhibitors. Coadmin increased plasma concentrations of lithium, methotrexate and cardiac glycosides. Increased risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus or diuretics.
Tolmetin	\n\n\tIndication: Rheumatoid arthritis, Osteoarthritis\n\nDose: Rheumatoid arthritis\nAdult: Initially, 400 mg tid. Maintenance: 600-1800 mg daily in 3 divided doses. Max: 1800 mg/day.\nRenal impairment: Dose adjustment may be needed.\n\nOsteoarthritis\nAdult: Initially, 400 mg tid. Maintenance: 600-1800 mg daily in 3 divided doses. Max: 1800 mg/day.\nRenal impairment: Dose adjustment may be needed.\n\nJuvenile idiopathic arthritis\nChild: >2 yr: Initially, 20 mg/kg daily in 3-4 divided doses. Maintenance: 15 mg/kg/day. Max: 30 mg/kg/day.\nRenal impairment: Dose adjustment may be needed.\n\nOsteoarthritis\nAdult: Apply 5% gel topically.\nRenal impairment: Dose adjustment may be needed.\n\nRheumatoid arthritis\nAdult: Apply 5% gel topically.\nRenal impairment: Dose adjustment may be needed.\n\nContra-indication: Pregnancy (3rd trimester), hypersensitivity to aspirin and NSAIDs, treatment of perioperative pain in CABG surgery.\n\nSide effects: Nausea, dyspepsia, diarrhoea, flatuence, vomiting, headache, GI bleed, hypersensitivity reactions, asthenia, hypertension, oedema, dizziness, weight gain, weight loss, visual disturbances, tinnitus, abnormal liver function. Erosive oesophagitis, interstitial nephritis and nephrotic syndrome.\nPotentially Fatal: Blood dyscrasias, serious CV thrombotic events, hepatitis, Stevens-Johnson syndrome.\n\nPrecaution: Lactation, elderly. Impaired renal and hepatic function. CV diseases, fluid retention, heart failure, history of GI bleed or gastric ulcer, dehydration, hypertension. Monitor renal function regularly.\n\n\nMode of action: Decreases the efficacy of mifepristone. Increased risk of bleeding with anticoagulants, other NSAIDs, antiplatelets, LMWH. Increased risk of convulsions with quinolones. Decreased antihypertensive response to loop diuretics, ?-blockers and ACE inhibitors. Coadmin increased plasma concentrations of lithium, methotrexate and cardiac glycosides. Increased risk of nephrotoxicity with ACE inhibitors, penicillamine, ciclosporin, tacrolimus or diuretics.\n\nPregnancy category: D\n\nInteraction: Decreases the efficacy of mifepristone. Increased risk of bleeding with anticoagulants, other NSAIDs, antiplatelets, LMWH. Increased risk of convulsions with quinolones. Decreased antihypertensive response to loop diuretics, ?-blockers and ACE inhibitors. Coadmin increased plasma concentrations of lithium, methotrexate and cardiac glycosides. Increased risk of nephrotoxicity with ACE inhibitors, penicillamine, ciclosporin, tacrolimus or diuretics.
Tolnaftate 1% Topical	\n\n\tPharmadesh Ltd.\tTinafate Cream   10gm pack 26.09\n\tIndication: Superficial dermatophyte infections and pityriasis versicolor\n\nDose: Superficial dermatophyte infections, Pityriasis versicolor\nAdult: Apply a 1% gel/solution/powder/cream bid for 2-6 wk; repeat if necessary. Continue treatment for 2 wk after disappearance of all symptoms to prevent recurrence of infection.\n\nContra-indication: Hypersensitivity. Nail and scalp infections.\n\nSide effects: Irritation, pruritus, contact dermatitis.\n\nPrecaution: Exposure to eyes. For external use only. Discontinue treatment if condition does not improve within 10 days.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Tolperisone Hydrochloride	\n\n\tAcme Ltd.\tA-calm TAB dr 50mg 50's pack 200\n\tAristopharma\tMusclex TAB dr 50mg 50's pack 250\n\tBeximco\tTolmus TAB dr 50mg  100 's pack 300\n\tBio Pharma Ltd.\tTolpa TAB dr 50mg 50's pack 200\n\tDrug International Ltd.\tLexaton TAB dr 50mg 50's pack 150\n\tEskayef Bangladesh Ltd.\tToperin TAB dr 50mg 60's pack 180\n\tGeneral\tTolcalm TAB dr 50mg 50's pack 200\n\tGlobe\tMyoxan TAB dr 100mg  \n\tGlobe\tMyoxan TAB dr 50mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tMyoson TAB dr 100mg 50's pack 250\n\tIbn Sina Pharmaceutical Ind. Ltd.\tMyoson TAB dr 50mg 50's pack 150\n\tIncepta\tMyolax TAB dr 100mg 50's pack 400\n\tIncepta\tMyolax TAB dr 50mg 100's pack 500\n\tIncepta\tMyolax Injection 100 mg/ml  \n\tKemiko\tRison TAB dr 50mg 50's pack 200\n\tKumudini Pharma Ltd.\tMyotol TAB dr 50mg  \n\tOpsonin Pharma\tTolson TAB dr 100mg 50's pack 250\n\tOpsonin Pharma\tTolson Injection 100mg/ml 1ml amp x 5's pack 150\n\tOpsonin Pharma\tTolson TAB dr 50mg 50's pack 175.94\n\tUnimed & Unihealth Manufacturers Ltd.\tMyoxant-50 TAB dr 50mg 30's pack 150\n\tChemial Works of Gedeon RichterLtd., Hungary\tMydocalm 	 				 TAB dr 50mg  30's pack 173\n\tIndication: Spasticity and muscle spasms\n\nDose: The recommended dose is as followings:\n\nTablet\nAdult: 50-150 mg three times daily according to the individual requirement and tolerance of the patient.\nChildren (from 3 months to 6 years): 5-10 mg/kg/day in three divided doses.\nChildren (from 6 to 14 years): 2-4 mg/kg/day in three divided doses.\n\nContra-indication: Hypersensitivity to any component of the product\nMyasthenia gravis\nNursing mother\n\nSide effects: Sometimes, muscular weakness, headache, nausea, vomiting and rarely hypersensitivity reactions may occur as side effects.\n\nPrecaution: In case of children, the prescribed dose and duration of treatment should closely be observed.\n\nMode of action: Methocarbamol. Tolperisone HCl.\n\nPregnancy category: Not Classified\n\nInteraction: Methocarbamol. Tolperisone HCl.
Tolterodine Tartrate	\n\n\tEskayef Bangladesh Ltd.\tUritol TAB dr 1mg 30's pack 60\n\tEskayef Bangladesh Ltd.\tUritol TAB dr 2mg 30's pack 90\n\tGeneral\tTolorin TAB dr 2mg 28's pack 84.28\n\tIncepta\tToltrex TAB dr 1mg 30's pack 90\n\tIncepta\tToltrex TAB dr 2mg 30's pack 90\n\tNavana\tTerodin TAB dr 2mg 30's pack 90\n\tRenata\tTolter TAB dr 1mg 30's pack 60\n\tRenata\tTolter TAB dr 2mg 30's pack 90\n\tSquare\tUcol TAB dr 2mg 60's pack 180.60\n\tUnimed & Unihealth Manufacturers Ltd.\tDetrusin LA CAP 2mg 20's pack 160\n\tUnimed & Unihealth Manufacturers Ltd.\tDetrusin LA CAP 4mg 20's pack 300\n\tIndication: Overactive bladder\n\nDose: Oral\nOveractive bladder\nAdult: >18 yr: As immediate release preparation: 2 mg bid, reduce to 1 mg bid if needed to reduce side effects. Reduce to 1 mg bid in patients concurrently taking CYP3A4 inhibitors. As extended release preparation: 4 mg once daily, may reduce to 2 mg daily if needed to reduce side effects. Reduce to 2 mg daily in patients concurrently taking CYP3A4 inhibitors.\n\nRenal impairment:\nCrCl (ml/min)	\n<30	1 mg bid (as immediate-release tablets) or 2 mg once daily (as extended-release capsules).\n\nHepatic impairment: 1 mg bid (as immediate-release tablets) or 2 mg once daily (as extended-release capsules).\n\nContra-indication: Tolterodine is contraindicated in patients with known hypersensitivity to tolterodine or any other component of the drug, urinary retention and uncontrolled narrow angle glaucoma.\n\nSide effects: Tolterodine may cause mild-to-moderate antimuscarinic effects, like dryness of the mouth, dyspepsia and reduced lacrimation.\n\nPrecaution: Tolterodine should be used with caution in the patients at risk for urinary retention & decreased gastrointestinal motility, with impaired renal & hepatic function and with myasthenia gravis.\n\nMode of action: Increased risk of overdosage with potent CYP3A4 inhibitors e.g. macrolide antibiotics (erythromycin and clarithromycin), azole antifungals (e.g. ketoconazole and itraconazole), protease inhibitors, ciclosporin or vinblastine. Increased risk of torsade de pointes with drugs that prolong the QT interval (e.g. class Ia and class III antiarrhythmics). Increased risk of 'cholinergic neurogenic hypersensitivity' with centrally acting anticholinesterases (e.g. donepezil, rivastigmine). Increased risk of antimuscarinic side effects with antimuscarinic drugs.\n\nPregnancy category: C\n\nInteraction: Increased risk of overdosage with potent CYP3A4 inhibitors e.g. macrolide antibiotics (erythromycin and clarithromycin), azole antifungals (e.g. ketoconazole and itraconazole), protease inhibitors, ciclosporin or vinblastine. Increased risk of torsade de pointes with drugs that prolong the QT interval (e.g. class Ia and class III antiarrhythmics). Increased risk of 'cholinergic neurogenic hypersensitivity' with centrally acting anticholinesterases (e.g. donepezil, rivastigmine). Increased risk of antimuscarinic side effects with antimuscarinic drugs.
Topiramate	\n\n\tIncepta\tTopirva 25 TAB dr 25mg 50's pack 150\n\tIncepta\tTopirva 50 TAB dr 50mg 50's pack 250\n\tRenata\tTopmate TAB dr 25mg 50's pack 150\n\tRenata\tTopmate TAB dr 50mg 50's pack 250\n\tSquare\tPiramed 200 TAB dr 200mg 20's pack 301.11\n\tSquare\tPiramed TAB dr 25mg 50's pack 150.29\n\tUnimed & Unihealth Manufacturers Ltd.\tEtopira TAB dr 25mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tEtopira TAB dr 50mg 30's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tEtopira Sprinkle CAP 25mg  \n\tIndication: Epilepsy, Migraine prophylaxis, Seizures associated w/ Lennox-gastaut syndrome\n\nDose: Adult: PO Adjunct in seizures associated w/ Lennox-gastaut syndrome Initial: 25 mg at night for 1 wk, then increase slowly. Usual: 200-400 mg/day in two divided doses. Max: 800 mg/day.  \n\nEpilepsy Monotherapy: Initial: 25 mg at night for 1 wk, then increase slowly. Usual: 100-400 mg/day in two divided doses. Max: 400 mg/day. Adjunct: Initial: 25 mg at night for 1 wk, then increase slowly. Usual: 200-400 mg/day. Max: 800 mg/day.  \n\nMigraine prophylaxis >16 yr: Initial: 25 mg at night for 1 wk, then increase slowly. Usual: 50-100 mg/day in 2 divided doses. \n\nChild: (Age 2 - 16 Years):  Partial Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome - The recommended total daily dose of Topiramate as adjunctive therapy is approximately  5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1 or 2 weeks intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response.  \n\nMigraine: The recommended total daily dose of Topiramate as treatment for prophylaxis of migraine headache is 100 mg/day administered in two divided doses.\n\n\nContra-indication: Contraindicated in persons showing hypersensitivity to any component of this preparation.\n\nSide effects: Confusion, dizziness, drowsiness, generalised slowing of mental and physical activity, difficulty with concentrations, ataxia, paresthesia, anorexia, weight loss, abnormal vision, metabolic acidosis, mood or mental changes, behavioural disturbances, depression, fatigue, agitation, nervousness, anxiety, oligohidrosis, hyperthermia and hyperammonaemic encephalopathy.\n\nPrecaution: Renal or hepatic impairment, pregnancy, lactation.  May impair ability to drive or operate machinery. Maintain adequate hydration to reduce the risk of renal calculi especially in predisposed patients. Measure serum bicarbonate at baseline and periodically during treatment. Avoid abrupt withdrawal; decrease dose by 100 mg daily at wkly intervals. Seek immediate medical attention if blurred vision or eye pain. Monitor closely for decreased sweating and increased body temperature, especially in hot weather. Ensure proper hydration before and during activities or exposure to warm temperatures.\n\nMode of action: Coadmin with antiepileptic drugs e.g. phenytoin, carbamazepine, phenobarbital decreases plasma concentration of topiramate. Possible increase in phenytoin levels. Increased risk of renal stone formation with carbonic anhydrase inhibitors e.g. acetazolamide. Increased risk of CNS depression with CNS depressants and alcohol. Increased risk of hyperammonaemia and encephalopathy with valproic acid. Increased risk of contraceptive failure in women taking combined oral contraceptives.\n\nPregnancy category: D\n\nInteraction: Coadmin with antiepileptic drugs e.g. phenytoin, carbamazepine, phenobarbital decreases plasma concentration of topiramate. Possible increase in phenytoin levels. Increased risk of renal stone formation with carbonic anhydrase inhibitors e.g. acetazolamide. Increased risk of CNS depression with CNS depressants and alcohol. Increased risk of hyperammonaemia and encephalopathy with valproic acid. Increased risk of contraceptive failure in women taking combined oral contraceptives.
Torasemide	\n\n\tAcme Ltd.\tTomide TAB dr 2.5mg 30's pack 60\n\tAcme Ltd.\tTomide TAB dr 2.5mg + 5mg 30's pack 60.00/105.00\n\tDrug International Ltd.\tLuretic TAB dr 2.5mg 50's pack 100\n\tDrug International Ltd.\tLuretic TAB dr 5mg 50's pack 175\n\tIncepta\tDilast TAB dr 20mg 30's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tDytor TAB dr 2.5mg 4x7's pack 168\n\tUnimed & Unihealth Manufacturers Ltd.\tDytor TAB dr 5 mg 4x7's pack 308\n\tIndication: Oedema, Hypertension, Chronic heart failure\n\nDose: Adult: PO HTN 2.5-5 mg once daily. Max: 5 mg/day. Oedema 5 mg once daily, up to 20 mg once daily if needed. Max: 40 mg/day. \n\nOedema in patients w/ hepatic cirrhosis Initial: 5-10 mg once daily, w/ an aldosterone antagonist or a K-sparing diuretic, titrate upwards till desired diuretic response. Max: 40 mg/day. \n\nIV Oedema 10-20 mg/day. Max: 200 mg/day.\n\nContra-indication: Hypersensitivity to sulfonylureas, renal failure with anuria, hepatic coma and pre-coma, hypotension, cardiac arrhythmias. Pregnancy and lactation.\n\nSide effects: Electrolyte disturbances e.g. hypokalaemia, dehydration, dry mouth, headache, dizziness, hypotension, weakness, drowsiness, confusional states, loss of appetite, cramps, increased serum uric acid, glucose, lipids, urea and creatinine, increase in LFT, metabolic alkalosis, tinnitus and hearing loss.\n\nPrecaution: Risk of hyperuricaemia, gout and DM. Correct electrolyte distubances and disorders of micturition before treatment. Monitor electrolyte balance, glucose, uric acid, creatinine and lipids regularly. May impair ability to drive or operate machinery.\n\nMode of action: Increased risk of severe hypokalaemia with amphotercin B, corticosteroids, carbenoxolone, hypokalaemia-causing medications. Increased risk of lithium toxicity. Increased potential for ototoxicity and nephrotoxicity with nephrotoxic or ototoxic medications e.g. aminoglycosides. High dose salicylates may increase the risk of salicylate toxicity. Increased risk of toxicity with digoxin. Reduced diuretic effect with NSAIDs. Increased risk of hypotension with antihypertensives.\n\nPregnancy category: B\n\nInteraction: Increased risk of severe hypokalaemia with amphotercin B, corticosteroids, carbenoxolone, hypokalaemia-causing medications. Increased risk of lithium toxicity. Increased potential for ototoxicity and nephrotoxicity with nephrotoxic or ototoxic medications e.g. aminoglycosides. High dose salicylates may increase the risk of salicylate toxicity. Increased risk of toxicity with digoxin. Reduced diuretic effect with NSAIDs. Increased risk of hypotension with antihypertensives.
Tramadol Hydrochloride	\n\n\tACI\tTendia ER CAP 100mg 30's pack 421.50\n\tACI\tTendia CAP 50mg  30's pack 225.90\n\tACI\tTendia IM/IV Injection 100mg/2ml 5's pack 100.65\n\tAcme Ltd.\tDolonil Injection 100mg/2ml 5 amps pack 100.35\n\tAcme Ltd.\tDolonil CAP 50mg  20's pack 150.60\n\tAcme Ltd.\tDolonil SR TAB dr 100mg 16's pack 400\n\tAd-din\tUltradol CAP 50mg 30's pack 225\n\tAlco Pharma\tPendol CAP 50mg 30's pack 180\n\tAmico Ltd.\tTramadol CAP 50mg 30's pack 180\n\tApex\tTrol CAP 50mg 30's pack 135\n\tAristopharma\tTramacap CAP 50mg 30's pack 225\n\tBeacon\tXtrapel Injection 100mg/2ml 5's pack 100.35\n\tBeacon\tXtrapel CAP 100mg 30's pack 360\n\tBeacon\tXtrapel CAP 50mg 20's pack 160\n\tBeximco\tLucidol Suppository 100mg  5's pack 75\n\tBeximco\tLucidol Injection 50mg/ml 5's pack 100\n\tBeximco\tLucidol TAB dr 50mg 30's pack 225\n\tBio Pharma Ltd.\tDolorex CAP 100mg 30's pack  225.90 \n\tBio Pharma Ltd.\tDolorex Injection 100mg/2ml 5 amps   pack 100.40\n\tBio Pharma Ltd.\tDolorex CAP 50mg 10's pack 130.50\n\tDelta Pharma\tImadol CAP 100mg 30's pack 225\n\tDelta Pharma\tImadol CAP 50mg 30's pack 225\n\tGeneral\tTrumen IV/IM Injection 100mg/2ml 5's pack 110\n\tGeneral\tTrumen CAP 50mg 30's pack 225.90\n\tGlobe\tReladol Injection 100mg/2ml 5 amps  pack 100\n\tGlobex\tTridol CAP 50mg 18's pack 135\n\tGlobex\tTridol Injection 100 mg/2 ml  \n\tHealthcare\tSyndol Injection 100mg/2ml 5 amps  pack 125\n\tHealthcare\tSyndol CAP 50mg 30's pack 255\n\tIncepta\tWinpain Injection 100mg/2ml 5's pack 100\n\tIncepta\tWinpain CAP 50mg 40's pack 300\n\tIncepta\tWinpain Injection 50mg/ml 5's pack 75\n\tIncepta\tWinpain ER CAP 100mg 20's pack 280\n\tKemiko\tKadol CAP 50mg 30's pack 240\n\tLeon\tLeotram CAP 50mg  \n\tMonicopharma\tMurtrum Injection 100mg/2ml 5  amps  pack 100\n\tMundipharma (Bangladesh) Pvt. Ltd.\tTrd-Contin TAB dr 100mg 50's pack \n\tMystic\tTamadol CAP 50mg 30's pack 217.50\n\tNavana\tOpidol CAP 100mg 20's pack 200.80\n\tNavana\tOpidol CAP 50mg  30's pack 180.60\n\tNovartis (Bangladesh) Ltd.\tDoloran Suppository 100mg 10's pack 200\n\tNovartis (Bangladesh) Ltd.\tDoloran Injection 100mg/2ml 5's pack 200\n\tNovartis (Bangladesh) Ltd.\tDoloran CAP 50mg 30's pack 255\n\tNovartis (Bangladesh) Ltd.\tDoloran PR TAB dr 100mg 30's pack 450\n\tNovo Healthcare and Pharma Ltd.\tZydol SR CAP 100mg 30's pack 360\n\tNovo Healthcare and Pharma Ltd.\tZydol CAP 50mg 30's pack 225\n\tNovo Healthcare and Pharma Ltd.\tZydol IV/IM Injection 100mg/2ml 2ml amp x 5's pack 90\n\tOpsonin Pharma\tTranal Suppository 100mg 10's pack 132.48\n\tOpsonin Pharma\tTranal Injection 100mg/2ml 5 amps  pack 88.32\n\tOpsonin Pharma\tTranal CAP 50mg 20's pack 132.48\n\tPharmasia Ltd.\tFudol CAP 50mg 30's pack 240\n\tRenata\tRapidol Injection 100mg/2ml 5 amps  pack 125\n\tRenata\tRapidol CAP 50mg 30's pack 210\n\tRephco\tRetram Injection 100mg/2ml 5amp's pack 125\n\tRephco\tRetram CAP 50mg 30's pack 240\n\tSquare\tAnadol Suppository 100mg  20's pack 301\n\tSquare\tAnadol Injection 100mg/2ml 10 amps  pack 200.69\n\tSquare\tAnadol SR CAP 100mg 30's pack 361.49\n\tSquare\tAnadol CAP 50mg 50's pack 321.60\n\tSun Pharmaceutical (Bangladesh) Ltd.\tDolotram CAP 50mg 30's pack 195\n\tTechno Drugs Ltd.\tDolan Injection 100mg/2ml 10 amps  pack 180\n\tTechno Drugs Ltd.\tDolan CAP 50mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tUtramal Suppository 100mg 5's pack 125\n\tUnimed & Unihealth Manufacturers Ltd.\tUtramal Injection 100mg/2ml 5 amps  pack 125\n\tUnimed & Unihealth Manufacturers Ltd.\tUtramal Retard TAB dr 100mg 10's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tUtramal Retard TAB dr 50mg 20's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tUtramal CAP 50mg 30's pack 255\n\tUnimed & Unihealth Manufacturers Ltd.\tTramal Rtd TAB dr 100mg  30's pack 791.50\n\tUnimed & Unihealth Manufacturers Ltd.\tTramal Suppository 100mg  5's pack 204.02\n\tVirgo\tTramavir TAB dr 100mg 30's pack 225\n\tIndication: Moderate to severe pain, Postoperative pain\n\nDose:  Adult: PO Moderate to severe pain 50-100 mg 4-6 hrly. Max: 400 mg/day. \n\nExtended-release 50-100 mg 1-2 times/day. Max: 300 mg/day. \n\nRenal impairment:\nCrCl (ml/min)	\n<10	                 Contraindicated.\n10 to <30	Increase dosing interval to 12hrly. Max: 200 mg/day; Contraindicated (extended-release tab).\nHepatic impairment: Severe: Increase dosing interval to 12 hrly; Contraindicated (extended-release). \n\nIV/IM Moderate to severe pain 50-100 mg 4-6 hrly. \n\nPost-op pain Initial: 100 mg, then 50 mg every 10-20 mins if needed, up to 250 mg for the 1st hr. Maintenance: 50-100 mg 4-6 hrly. Max: 600 mg/day. \n\nRectal Moderate to severe pain As 100 mg supp: 1 supp up to 4 times/day.\n\nElderly: >75 yr Increase dosing interval.\n\nRenal impairment:\nCrCl (ml/min)	\n10-30	Increase dosing interval to 12 hrly.\n<10 	Contraindicated.\n\nHepatic impairment: Severe: increase dosing interval to 12 hrly.\n\nContra-indication: Suicidal patients, acute alcoholism; head injuries; raised intracranial pressure; severe renal impairment; lactation.\n\nSide effects: Sweating, dizziness, nausea, vomiting, dry mouth, fatigue, asthenia, somnolence, confusion, constipation, flushing, headache, vertigo, tachycardia, palpitations, miosis, insomnia, orthostatic hypotension, seizures, CNS stimulation e.g. hallucinations.\nPotentially Fatal: Respiratory depression.\n\nPrecaution: Hypothyroidism; adrenocortical insufficiency; renal or hepatic impairment; history of epilepsy or increased risk of seizures; inflammatory or obstructive bowel disease; myasthaenia gravis; respiratory depression; prostatic hyperplasia. Pregnancy.\n\nMode of action: Increased risk of convulsions or serotonin syndrome w/ SSRI, serotonin-norepinephrine reuptake inhibitors (SNRI), TCA and other seizure threshold lowering drugs (e.g. bupropion, mirtazapine, tetrahydrocannabinol). Decreased serum concentrations w/ carbamazepine. May potentiate the anti-depressant effect of norepinephrine, 5-HT agonists or lithium. Increased INR and ecchymoses w/ coumarin derivatives (e.g. warfarin).\n\nPotentially Fatal: Increased risk of seizure and serotonin syndrome w/ MAOIs. \n\nPregnancy category: C\n\nInteraction: Increased risk of convulsions or serotonin syndrome w/ SSRI, serotonin-norepinephrine reuptake inhibitors (SNRI), TCA and other seizure threshold lowering drugs (e.g. bupropion, mirtazapine, tetrahydrocannabinol). Decreased serum concentrations w/ carbamazepine. May potentiate the anti-depressant effect of norepinephrine, 5-HT agonists or lithium. Increased INR and ecchymoses w/ coumarin derivatives (e.g. warfarin).\n\nPotentially Fatal: Increased risk of seizure and serotonin syndrome w/ MAOIs. 
Tranexamic Acid	\n\n\tACI\tAnaxyl CAP 500mg 20's pack 301.20\n\tACI\tAnaxyl Injection 500mg/5ml 5 amps pack 251.70\n\tACI\tAnaxyl TAB dr 500mg 20's pack 401.20\n\tAcme Ltd.\tTracid TAB dr 500mg 20's pack/30's pack 301/451\n\tAcme Ltd.\tTracid Injection 500mg/5ml 3 amps pack 150.60\n\tApex\tHemostop CAP 500mg 20's pack 240\n\tAristopharma\tHemostat CAP 500mg 20's pack 300\n\tAristopharma\tHemostat Injection 250mg/5ml 5 amps pack 150\n\tAristopharma\tHemostat TAB dr 500mg 20's pack 300\n\tBeacon\tTranex TAB dr 500mg 20's pack 320\n\tBeximco\tTranexil Injection 500mg/5ml 5's pack 250\n\tBeximco\tTranexil CAP 500mg 20's pack 447\n\tBio Pharma Ltd.\tBionex CAP 500mg 20's pack 320\n\tDrug International Ltd.\tBlock-T TAB dr 500 mg  \n\tDrug International Ltd.\tBlock-T IM/IV Injection 500 mg/5 ml  \n\tEskayef Bangladesh Ltd.\tFibrino CAP 500mg 18's pack 270\n\tEskayef Bangladesh Ltd.\tFibrino I.V Injection 500mg/5ml 5 amps pack 250\n\tGlobe\tFibrostat CAP 500mg 20's pack 300\n\tHealthcare\tTrexam TAB dr 500mg 30's pack 450\n\tIncepta\tIntrax CAP 500mg 20's pack 320\n\tIncepta\tIntrax Injection 500mg/5ml 5 amps pack 250\n\tNuvista Pharma Ltd\tTraxyl CAP 500 mg 20's pack 468.80\n\tNuvista Pharma Ltd\tCapilok Injection 500mg/5ml 10's pack 501.50\n\tOpsonin Pharma\tEnclot CAP 500mg 20's pack 300\n\tOpsonin Pharma\tEnclot Injection 500mg/5ml 5 amps pack 250\n\tOrion Pharma Ltd.\tOranex CAP 500mg 20's pack 300\n\tPacific\tTramic CAP 500mg 30's pack 570\n\tRenata\tXamic CAP 500mg 20's pack 301\n\tRenata\tXamic IV/IM Injection 500mg/5ml 5 amps pack 250.95\n\tSquare\tFrabex CAP 500mg 20's pack 240.99\n\tSquare\tFrabex Injection 250mg/5ml 5 amps pack 225\n\tSquare\tFrabex Injection 500mg/5ml 6 amps pack 240.91\n\tIndication: Haemorrhage, Hereditary angioedema\n\nDose: Adult: PO Short-term management of haemorrhage 1-1.5 g 2-3 times/day. Long-term management of hereditary angioedema 1-1.5 g 2-3 times/day. \nChild: 25 mg/kg bid or tid.\n\nIV Short-term management of haemorrhage 0.5-1 g 3 times/day.\nChild: 10 mg/kg bid or tid.\n\nContra-indication: Severe renal failure, active intravascular clotting, thromboembolic disease, colour vision disorders, subarachnoid bleeding.\n\nSide effects: Diarrhoea, nausea, vomiting, disturbances in colour vision, giddiness, hypotension (after rapid IV inj), thromboembolic events.\n\nPrecaution: Mild to moderate renal impairment, irregular menstrual bleeding, previous history of thromboembolic disease, haematuria. Monitor closely in disseminated intravascular coagulation. Monitor LFT and eye examination regularly during long-term use. Discontinue if disturbance in colour vision occurs. Avoid IV inj rate >1 ml/minute due to risk of hypotension. Pregnancy, lactation.\n\nMode of action: Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocytic leukaemia. \n\nPregnancy category: B\n\nInteraction: Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocytic leukaemia. 
Trastuzumab	\n\n\tBeacon\tTrastunix Injection 440mg  \n\tBeacon\tTrastunix Injection 150 mg/vial  \n\tRadiant.\tHerceptin Injection 440mg 1's pack 160000\n\tRoche Bangladesh Pharmaceutical\tHerceptin Injection   \n\tTechno Drugs Ltd.\tHertin Injection 440mg 1's pack 120000\n\tIndication: Breast cancer\n\nDose: Adult: IV Metastatic breast cancer Initial: 4 mg/kg via infusion, then 2 mg/kg/wk. Early breast cancer For treatment after surgery, radiation or chemotherapy. Initial: 8 mg/kg via infusion, then 6 mg/kg 3-wkly for a yr or until disease recurrence. \n\nIf patient misses a dose by >1 wk: Give 6 mg/kg immediately, then subsequent cycles according to the previous schedule; If the dose is missed by >1 wk: Re-load w/ 8 mg/kg, then maintain at 6 mg/kg 3 wkly.\n\nContra-indication: Lactation (start only 6 mth after last dose of drug). Do not admin by rapid IV or bolus inj.\n\nSide effects: Chills, fever, headache, dizziness, back pain, arthralgia, increased cough, infection, insomnia, oedema, tachycardia, diarrhoea, paresthesia and rashes.\nPotentially Fatal: Severe hypersensitivity (anaphylaxis) and infusion reactions; pulmonary events e.g. acute respiratory distress syndrome; cardiotoxicity. Neutropenia (especially when given with chemotherapy).\n\nPrecaution: Preexisting cardiac dysfunction and pulmonary disease (e.g. asthma, COPD), prior cardiotoxic therapy, extensive tumour involvement of lungs. Monitor cardiac function frequently and watch for signs of cardiotoxicity (ventricular dysfunction or CHF). Pregnancy, elderly.\n\nMode of action: Increased risk of severe cardiotoxicity with anthracyclines. Increased risk of leukopenia and anaemia in combination chemotherapy (e.g. paclitaxel). Paclitaxel may decrease the clearance of trastuzumab. Increased risk of bleeding with warfarin.\n\nPregnancy category: D\n\nInteraction: Increased risk of severe cardiotoxicity with anthracyclines. Increased risk of leukopenia and anaemia in combination chemotherapy (e.g. paclitaxel). Paclitaxel may decrease the clearance of trastuzumab. Increased risk of bleeding with warfarin.
Travoprost 0.004% Eye prep	\n\n\tApex\tTravotan Eye Drops   3ml bot 470\n\tAristopharma\tAvatan Eey Drop Eye Drops   3  ml drop 470\n\tDrug International Ltd.\tAvro Eye Drops 0.004% 3ml bot \n\tIbn Sina Pharmaceutical Ind. Ltd.\tAvost Eye Drops 3ml  470\n\tIncepta\tTravast Eye Drops   3  ml drop 470\n\tIndication: Open-angle glaucoma, Ocular HTN\n\nDose: Use in adults\nOne drop in the affected eye once-daily in the evening. The dosage of Travast should not exceed once daily since it has been shown that more frequent administration may decrease the normal intraocular pressure.\n\nPaediatric patients\nThe efficacy and safety of travoprost eye drops in patients below the age of 18 years have not been established.\n\nContra-indication: Hypersensitivity to travoprost or to any of the excipients.\n\nSide effects: The most common ocular adverse effect is ocular hyperemia. Ocular adverse events reported at an incidence of 5-10% included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus. Ocular adverse events reported at an incidence of 1-4% included, abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, dry eye, flare, iris discoloration, keratitis, lid margin crusting, photophobia, subconjunctival hemorrhage, and tearing.\n\nPrecaution: Travast eye drops should be used with caution in patients with active intraocular inflammation & macular edema. In case of patients with mild to severe hepatic impairment and renal impairment (creatinine clearance as low as 14 ml/min) no dosage adjustment is necessary. Travast should not be administered while wearing contact lenses. Lenses may be reinserted 15 minutes following administration of Travast eye drop.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Tretinoin Topical	\n\n\tACI\tTrena Gel  .025% 10g 45\n\tBeximco\tCosmotrin Cream   10gm tube 45\n\tRenata\tTrinon 0.025% Cream   10gm tube 46.52\n\tRenata\tTrinon Cream 0.05% 10gm tube  48 	\n\tSanofi Aventis (BD) Ltd.\tRetin A Cream 0.05% 5gm tube/15gm tube/30gm tube  26.40/ 55.21/ 85.28\n\tSquare\tNilac Gel  25 mg/100 gm 10gm tube 45.16\n\tIndication: Acne, Mottled hyperpigmentation, Roughness and fine wrinkling of photodamaged skin\n\nDose: Adult: Topical Acne As 0.01-0.1% cream/gel/alcoholic soln: Apply 1-2 times/day. \n\nMottled hyperpigmentation, roughness and fine wrinkling of photodamaged skin As 0.02-0.05% preparation: Apply once daily at night.\n\nContra-indication: Hypersensitivity to retinoids. Application to eczematous, sunburnt or abraded skin. Pregnancy, lactation.\n\nSide effects: Initial exacerbation of symptoms, skin irritation, stinging on application, oedema, blistering, crusting of the skin, erythema, scaling, photosensitivity, temporary hypo/hyperpigmentation. \n\nPrecaution: Topical: avoid concomitant topical applications, esp keratolytic agents. Avoid exposure to sunlight, UV light and weather extremes (e.g. cold). Keep away from eyes, mouth, angles of nose, mucous membranes or open wounds. In case of severe local erythema, oedema, blistering or crusting, use less frequently or discontinue. Avoid medicated or drying soaps, abrasive soaps and cleansers, frequent washing and harsh scrubbing. Avoid use of topical preparations with high concentrations of alcohol, menthol, spices or lime. \n\nMode of action: Enhances percutaneous absorption of minoxidil. Increased risk of fatal thrombotic complications with antifibrinolytic. Increased tretinoin concentrations with azole antifungals. Enhances peeling action of sulphur, resorcinol, benzoyl peroxide, salicylic acid. Increased photosensitivity with photosensitising medications eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides.\nPotentially Fatal: Increased risk of intracranial pressure with tetracyclines.\n\nPregnancy category: C\n\nInteraction: Enhances percutaneous absorption of minoxidil. Increased risk of fatal thrombotic complications with antifibrinolytic. Increased tretinoin concentrations with azole antifungals. Enhances peeling action of sulphur, resorcinol, benzoyl peroxide, salicylic acid. Increased photosensitivity with photosensitising medications eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides.\nPotentially Fatal: Increased risk of intracranial pressure with tetracyclines.
Triamcinolone Acetonide	\n\n\tAristopharma\tAristocort 				 Injection 40 mg/ml 2 amps pack  120 	\n\tChemist Ltd.\tTrimcort Injection 40mg/ml 1ml amp x 2's pack / 1ml amp x 20's pack 120 / 1200\n\tDrug International Ltd.\tTrialon S Injection 40 mg/ml 3 amps pack  180 	\n\tGlobe\tTriamon Injection 40 mg/ml  \n\tIncepta\tCenolon Injection Injection 40mg/ml 1's pack 75\n\tKemiko\tTriacin Injection 40mg/ml 1ml amp x 1's pack 60\n\tTechno Drugs Ltd.\tCyanocort Injection 40mg/ml 1ml amp 60\n\tTechno Drugs Ltd.\tCynocort Injection 40mg/ml 1's pack 60\n\tZiska\tAlfacort Injection 40mg/ml 4amps pack 240\n\tIndication: Allergic and inflammatory responses, Inflammatory joint disease, Inflammatory skin conditions\n\nDose: Adult: IM Allergic and inflammatory responses As acetonide: 20-80 mg. Hay fever As acetonide: 40-100 mg.  \n\nIntra-articular Inflammatory joint disease As acetonide: Smaller joints: 2.5-5 mg (up to 10 mg), larger joints: 5-15 mg (up to 40 mg). Max: 20-80 mg/treatment. \n\nChildren 6 to 12 years: initial dose is 40 mg. Adults and children over 12 years of age: initial dose is 60 mg. Dosage is usually adjusted within the range of 40 to 80 mg. For local areas, dose for adults is up to 10 mg for smaller areas and up to 40 mg for larger areas.\n\nContra-indication: Triamcinolone Acetonide  is contraindicated in patients with a sensitivity to the active or inactive ingredients. Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. Neonates (Parenteral)\n\nSide effects: Cushingoid syndrome, weakness, bruising or purpura, aggravation of infections, peptic ulcer, glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changesm activation of latent or aggravation of existing diabetes, altered menstrual cycle, hirsutism.\n\nPrecaution: Triamcinolone Acetonide should be used cautiously in patients with ocular herpes simplex, nonspecific ulcerative colitis, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, Cushing's syndrome, diabetes mellitus, congestive heart failure, chronic nephritis.\n\nMode of action: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.\n\nPregnancy category: C\n\nInteraction: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
Triamcinolone Acetonide 0.1% Topical	\n\n\tACI\tCortefin Cream  Cortefin Crm 10gm tube 25.17\n\tACI\tCortefin Ointment  0.1% 10gm tube 25.08\n\tAristopharma\tAristocort Ointment   10gm tube 20\n\tAristopharma\tAristocort 0.1% Cream   10gm tube 20\n\tDrug International Ltd.\tTrialon Cream 5mg  100\n\tDrug International Ltd.\tTrialon Ointment 1 mg/gm  \n\tGeneral\tStelone Ointment   10gm tube 25.09\n\tKemiko\tSkinaderm Ointment   10gm tube 20\n\tIndication: Inflammatory skin conditions\n\nDose: Inflammatory skin conditions\nAdult: As acetonide: Apply a 0.025-0.5% cream/lotion/ointment sparingly onto affected area 2-3 times daily. Lower concentrations may be used up to 4 times daily.\n\n\nContra-indication: Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. \n\nSide effects:  Topical: Systemic absorption if applied to large areas, broken skin or under occlusive dressing.\n\n\nPrecaution: Diabetes; hypertension, renal and liver impairment; glaucoma; psychosis; delayed tissue healing; cirrhosis; heart failure; recent MI; hypothyroidism; osteoporosis; peptic ulceration; thromboembolic disorders. Monitor height in children on prolonged therapy. Avoid rapid drug withdrawal. Elderly, children, pregnancy, lactation.\n\nMode of action: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.\n\nPregnancy category: C\n\nInteraction: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
Trifluoperazine	\n\n\tDelta Pharma\tStela TAB dr 1mg 50's pack 75\n\tDelta Pharma\tStela TAB dr 5mg 50's pack 125\n\tEskayef Bangladesh Ltd.\tTelazine TAB dr 1mg 100's pack 150\n\tEskayef Bangladesh Ltd.\tTelazine TAB dr 5mg 100's pack 250\n\tHealthcare\tSizonil TAB dr 1mg 100's pack 175\n\tHealthcare\tSizonil TAB dr 5mg 100's pack 300\n\tIncepta\tFlurazine TAB dr 1mg 100's pack 150\n\tIncepta\tFlurazine TAB dr 5mg 100's 250\n\tIndication: Anxiety, Psychoses, Nausea and vomiting, Schizophrenia\n\nDose: Adult: PO Psychoses 2-5 mg twice daily, up to 15-20 mg/day. Severe or resistant: 40 mg/day. \nNausea and vomiting; Short-term management of anxiety 1-2 mg twice daily. Max: 6 mg/day. \nFor anxiety: Max duration: 12 wk. \n\nContra-indication: Preexisting CNS depression and coma; bone marrow depression, blood dyscrasias, liver disease, hypersensitivity to phenothiazines, prolactin dependent tumours. Pregnancy (1st trimester), lactation.\n\nSide effects: Drowsiness, dry mouth, blurred vision, dizziness, sedation, antimuscarinic affects, postural hypotension, akathisia, muscle weakness, anorexia, insomnia, rash, amenorrhoea, fatigue, increased prolactin levels, extrapyramidal side effects.\nPotentially Fatal: Neuroleptic malignant syndrome, blood dyscrasias.\n\nPrecaution: Cardiovascular disease, epilepsy, angle-closure glaucoma, exposure to extreme temperatures, elderly, parkinson's disease, myasthenia gravis, benign prostatic hyperplasia, DM, renal amd hepatic impairment. Discontinue trifluoperazine at least 48 hr before myelography and do not resume for at least 24 hr after procedure. Do not use trifluoperazine in control of nausea and vomiting occurring either prior to myelography or postprocedure with metrizamide. Pregnancy.\n\nMode of action: Increased CNS depression with CNS depressants such as opiates or other analgesics, barbiturates or other sedatives, general anaesthetics, or alcohol. Increased risk of side effects with drugs with antimuscarinic properties e.g. TCA, antiparkinsonian drugs. Antagonised effects of dopaminergic drugs such as levodopa. Increased risk of hypotension with antihypertensives, trazodone. Reverses antihypertensive effect of guanethidine. Increased risk of severe extrapyramidal side-effects or severe neurotoxicity with lithium. Possible decrease in absorption with antacids.\n\nPregnancy category: C\n\nInteraction: Increased CNS depression with CNS depressants such as opiates or other analgesics, barbiturates or other sedatives, general anaesthetics, or alcohol. Increased risk of side effects with drugs with antimuscarinic properties e.g. TCA, antiparkinsonian drugs. Antagonised effects of dopaminergic drugs such as levodopa. Increased risk of hypotension with antihypertensives, trazodone. Reverses antihypertensive effect of guanethidine. Increased risk of severe extrapyramidal side-effects or severe neurotoxicity with lithium. Possible decrease in absorption with antacids.
Trifluridine 1% Eye prep	\n\n\tAristopharma\tFludin Eye Drops   5ml bot 950\n\tIndication: Keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex viruses\n\nDose: Adult: Ophth As 1% soln: Instill 1 drop 2 hrly, up to 9 times/day till complete re-epithelialization, then reduce to 1 drop 4 hrly during wake hr to a min of 5 drops/day for 7 days. \n\nRe-evaluate if there is no improvement after 7 days or complete re-epithelialization has not occurred after 14 days.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Transient burning or stinging upon instillation, irritation, hyperemia, palpebral oedema, dry eye, superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction and increased intraocular pressure.\n\nPrecaution: Pregnancy; child <6 yr. Use under close supervision of ophthalmologist. Continuous admin >21 days to be avoided due to risk of ocular toxicity.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Trihexyphenidyl Hydrochloride	\n\n\tACI\tTricalm TAB dr 2 mg  \n\tACI\tTricalm 5 TAB dr 5 mg  \n\tBeacon\tHexinor TAB dr 2mg 50's pack 250\n\tBeacon\tHexinor 5 TAB dr 5 mg  250\n\tIncepta\tTrihexy 2 TAB dr 2mg 30's pack 150\n\tIncepta\tTrihexy 5 TAB dr 5mg 30's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tParkinfen TAB dr 2mg 30's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tParkinfen TAB dr 5mg 30's pack 360\n\tIndication: Extrapyramidal symptoms, Parkinsonism (postencephalitic, arteriosclerotic & idiopathic)\n\nDose: Prophylaxis of drug-induced extrapyramidal symptoms: Adult: Initially, 1 mg daily, increased gradually to usual maintenance dose of 5-15 mg daily in 3-4 divided doses. Max dose: 15 mg daily. \nElderly: May require smaller doses.  \n\nIdiopathic Parkinsonism: Adult: Initially, 1 mg daily, increased gradually over a period of several days in steps of 2 mg, up to 6-10 mg daily in 3-4 divided doses according to response.  For advanced cases: 12-15 mg daily in 3-4 divided doses.  \n\nFor postencephalitic patients: Larger doses may be required. Elderly: May require smaller doses. Max Dosage: 15 mg daily. \n\nConcomitant Use with Levodopa: When trihexyphenidyl HCl is used concomitantly with levodopa, the usual dose is 3-6 mg daily.\n\nContra-indication: Patients with closed-angle glaucoma, chronic pulmonary disease, sick sinus syndrome, thyrotoxicosis, cardiac failure with tachycardia.\n\nSide effects: Dry mouth, blurring of vision, constipation, urinary retention, glaucoma, confusion, drowsiness, restlessness, hallucinations.Potentially Fatal: Arrhythmias, AV dissociation, multiple ventricular ectopics.\n\nPrecaution: Glaucoma, obstructive disease of GI or genitourinary tracts. In elderly males with possible prostatic hypertrophy. Liver and renal disorders. Pregnancy and lactation.\n\nMode of action: Increased antimuscarinic side effects w/ phenothiazines, clozapine, antihistamines, disopyramide, nefopam and amantadine. Synergistic effect when concomitantly used w/ TCAs. Concurrent admin w/ MAOIs may cause dry mouth, blurred vision, urinary hesitancy or retention and constipation. May antagonise effect of metoclopramide and domperidone on GI function. Reduced absorption of levodopa. May antagonise effect of parasympathomimetics.\n\nPregnancy category: C\n\nInteraction: Increased antimuscarinic side effects w/ phenothiazines, clozapine, antihistamines, disopyramide, nefopam and amantadine. Synergistic effect when concomitantly used w/ TCAs. Concurrent admin w/ MAOIs may cause dry mouth, blurred vision, urinary hesitancy or retention and constipation. May antagonise effect of metoclopramide and domperidone on GI function. Reduced absorption of levodopa. May antagonise effect of parasympathomimetics.
Trimebutine Maleate	\n\n\tIncepta\tTrimotil TAB dr 100mg 50's pack 250\n\tRenata\tTritin TAB dr 100mg 30's pack \n\tSquare\tTimotor TAB dr 100mg 50's pack 250.70\n\tIndication: Irritable bowel syndrome, Chronic gastritis\n\nDose: Oral\nIrritable bowel syndrome\nAdult: 300-600 mg/day in 3 divided doses.\n\nChronic gastritis\nAdult: 300 mg/day in 3 divided doses.\nElderly: Use with caution.\n\nUse in children: Trimebutine is not recommended for use in children under 12 years of age.\n\nContra-indication: Patients with known hypersensitivity to trimebutine maleate or any excipient.\n\nSide effects: Trimebutine Maleate is generally well tolerated. The infrequently reported adverse effects are as follows: a) Gastrointestinal: Dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation, b) CNS: Drowsiness, fatigue, dizziness, hot/cold sensations, headache etc.\n\nPrecaution: Elderly; pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Trimetazidine Dihydrochloride	\n\n\tAcme Ltd.\tAngirid MR TAB dr 35mg 30's pack 150.30\n\tAristopharma\tMetacard MR TAB dr 35mg 50's pack 300\n\tBeximco\tMetazine MR TAB dr 35mg 30's pack 180\n\tDrug International Ltd.\tTrimet TAB dr 20mg 50's pack 150\n\tDrug International Ltd.\tTrimet MR TAB dr 35mg 30's pack 150\n\tEskayef Bangladesh Ltd.\tVastarel MR TAB dr 35mg 30's pack 250\n\tEskayef Bangladesh Ltd.\tCardimet CR CAP 60mg  \n\tGeneral\tAnginox TAB dr 20mg 30's pack 90.30\n\tHealthcare\tVestar MR TAB dr 35mg  \n\tIncepta\tFeelnor TAB dr 20mg 30's pack 90\n\tIncepta\tFeelnor MR TAB dr 35mg 30's pack 150\n\tNIPRO JMI Pharma\tMetavas MR TAB dr 35mg 30's pack 150\n\tOpsonin Pharma\tAntoris MR TAB dr 35mg 30's pack 158\n\tOrion Pharma Ltd.\tAngimet TAB dr 20mg 50's pack 150.50\n\tOrion Pharma Ltd.\tAngimet MR TAB dr 35mg 30's pack 150.30\n\tPopular\tAngivas TAB dr 20mg  \n\tPopular\tAngivas TAB dr 35mg  \n\tSharif\tVastadin MR TAB dr 35mg 30's pack 150\n\tSquare\tAngivent MR TAB dr 35mg 30's pack 150.43\n\tIndication: Ischaemic heart disease, Angina pectoris; Meniere's disease, Coronary heart disease\n\nDose: One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.\n\nOne 35 mg MR tablet twice daily at mealtimes in the morning and evening.\n\nContra-indication: Hypersensitivity to Trimetazidine Dihydrochloride.\n\nSide effects: (Trimetazidine) is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.\n\nPrecaution: Although teratological studies have not shown any drug related adverse effects on the course and outcome of pregnancy, the use  in pregnant women is not recommended.It is not known whetherTrimetazidine passes into breast milk or not. This medication should be used while breast feeding only if the potential benefits outweigh risks to the nursing infants.\n\nMode of action: MAOIs, nifedipine. May potentiate the effects of other antianginals.\n\nPregnancy category: Not Classified\n\nInteraction: MAOIs, nifedipine. May potentiate the effects of other antianginals.
Trimethoprim	\n\n\tIndication: Urinary tract infections,Gastroenteritis,Pneumocystis jiroveci pneumonia,Resp tract infections\n\nDose: Adult: PO Susceptible infections Acute infections: 100 or 200 mg twice daily. UTI 100 mg 12 hrly for 10 days. Pneumocystis jiroveci pneumonia W/ dapsone: 5 mg/kg 3 times/day for 21 days. Max: 20 mg/kg/day. \n\nIV Gastroenteritis; Resp tract infections; Treatment and prophylaxis of UTI 200 mg 12 hrly.\n\nChild: 6-8 mg/kg/day in 2 divided doses. Alternatively, 6 wk-5 mth: 25 mg bid, 6 mth-5 yr: 50 mg bid, 6-12 yr: 100 mg bid.\n\nRenal impairment:\nCrCl (ml/min)\n15-27	Normal dose for 3 days, thereafter half the normal doses.\n<15	        Half the normal dose from the start of the treatment. \n\nContra-indication: Hypersensitivity, serious haematological disorders, severe renal impairment, megaloblastic anaemia secondary to folate depletion.\n\nSide effects: Nausea, vomiting, glossitis, pruritus, skin rash, fever, hyponatremia, hyperkalaemia, photosensitivity, liver enzyme elevation, , raised serum creatinine and BUN, blood dyscrasias, cholestatic jaundice, anaphylaxis, aseptic meningitis.\nPotentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis.\n\nPrecaution: Renal and hepatic impairment, porphyria, patients with potential folate deficiency, elderly, pregnancy, lactation, children with fragile X chromosome associated with mental retardation. Perform regular haematological examination.\n\nMode of action: Concurrent use increased risk of blood dyscrasias with azathioprine, methotrexate, pyrimethamine; increased risk of hyperkalaemia with ACE inhibitors; increased risk of hyponatraemia when used with both potassium-sparing diuretics and thiazides; increased risk of bleeding with warfarin; increased risk of lithium toxicity; increased digoxin, phenytoin, procainamide, lamivudine, stavudine, repaglinide, rosiglitazone, dofetilide serum levels; decreased ciclosporin levels. Concurrent use with dapsone increased serum levels of both and increased risk of dapsone toxicity.\n\nPregnancy category: C\n\nInteraction: Concurrent use increased risk of blood dyscrasias with azathioprine, methotrexate, pyrimethamine; increased risk of hyperkalaemia with ACE inhibitors; increased risk of hyponatraemia when used with both potassium-sparing diuretics and thiazides; increased risk of bleeding with warfarin; increased risk of lithium toxicity; increased digoxin, phenytoin, procainamide, lamivudine, stavudine, repaglinide, rosiglitazone, dofetilide serum levels; decreased ciclosporin levels. Concurrent use with dapsone increased serum levels of both and increased risk of dapsone toxicity.
Trimipramine	\n\n\tIndication: Depression\n\nDose: Depression\nAdult: Initially 50-75 mg daily, increased gradually as necessary to 150-300 mg daily. May be given in divided doses during the day or as a single dose at night.\nElderly: Initial 50-75 mg daily, increased gradually if necessary. Max: 100 mg daily.\n\nContra-indication: Recent MI, cardiac arrhythmias, heart block; mania; porphyria, severe liver disease. Neonates and children. Lactation.\n\nSide effects: Dry mouth, accommodation disturbances, tachycardia, constipation, hesitancy of micturation, drowsiness, sweating, postural hypotension, skin rashes, cholestatic jaundice, hypomania, convulsions, cardiac arrhythmias and peripheral neuropathy. Agitation, confusion (elderly).\nPotentially Fatal: Agranulocytosis and thrombocytopenia.\n\nPrecaution: Narrow-angle glaucoma; prostatic hypertrophy; history of epilepsy; hyperthyroidism; patients requiring anaesthesia. Pregnancy. Withdraw gradually to decrease risk of withdrawal symptoms. Monitor liver function in long term treatment. May impair ability to drive or operate machinery.\n\nMode of action: Decreased antihypertensive effects of guanethidine, guanfacine, debrisoquine, betanidine and possibly clonidine. Increased CNS depression with CNS depressants such as alcohol, sedatives, hypnotics or barbiturates. Increased trimipramine levels with protease inhibitors, SSRIs, selegiline, tramadol, quinidine, diltiazem and verapamil. Decreased trimipramine levels with barbiturates. Increased risk of arrhythmias with drugs that prolong QT intervals. Increased risk of serotonin syndrome with linezolid. Increased antimuscarinic adverse effects with nefopam. Risk of neurotoxicity and serotonin syndrome with lithium.\n\nPotentially Fatal: Not to be given concurrently with, or within 2 wk of cessation of, therapy with MAOI and MAOI should be restarted at least 7-14 days after trimipramine has been stopped. Exaggerated response such as hypertension, cardiac arrhythmias with sympathomimetic drugs.\n\nPregnancy category: C\n\nInteraction: Decreased antihypertensive effects of guanethidine, guanfacine, debrisoquine, betanidine and possibly clonidine. Increased CNS depression with CNS depressants such as alcohol, sedatives, hypnotics or barbiturates. Increased trimipramine levels with protease inhibitors, SSRIs, selegiline, tramadol, quinidine, diltiazem and verapamil. Decreased trimipramine levels with barbiturates. Increased risk of arrhythmias with drugs that prolong QT intervals. Increased risk of serotonin syndrome with linezolid. Increased antimuscarinic adverse effects with nefopam. Risk of neurotoxicity and serotonin syndrome with lithium.\n\nPotentially Fatal: Not to be given concurrently with, or within 2 wk of cessation of, therapy with MAOI and MAOI should be restarted at least 7-14 days after trimipramine has been stopped. Exaggerated response such as hypertension, cardiac arrhythmias with sympathomimetic drugs.
Tropicamide 0.5% Eye prep	\n\n\tApex\tEyetrop 0.5% Eye Drops   5ml bot 60\n\tAristopharma\tTropicam 0.5% Eye Drops   5  ml drop 60\n\tG. A. Company Ltd.\tTrusil 0.5% Eye Drops   5  ml drop 55.63\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCamide 0.5% Eye Drops   5  ml drop 60.22\n\tIncepta\tDilate 0.5% Eye Drops   1's pack 76\n\tNipa\tTropicamin  0.5% Eye Drops   5  ml drop 60\n\tOpso Saline Ltd.\tTropicamide OSL 0.5% Eye Drops   5  ml drop/ 10  ml drop 55.21 / 75\n\tReman Drug Ltd.\tMydrimide 0.5% Eye Drops   5  ml drop 70.26\n\tIndication: Uveitis, Production of mydriasis\n\nDose: For examination of fundus, instill one or two drops of 0.5% solution 15 to 20 minutes prior to examination. Individuals with heavily pigmented irides may require higher strength or more doses. \n\nContra-indication: Contraindicated in persons showing hypersensitivity to any component of this preparation.\n\nSide effects: Transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. Increased intraocular pressure has been reported following the use of mydriatics.\nDryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide.\n\nPrecaution: The lacrimal sac should be compressed by digital pressure for 2-3 minutes after instillation to avoid excessive systemic absorption.\n\nMode of action: May antagonise effects of ophthalmic carbachol, pilocarpine, or cholinesterase inhibitors.\n\nPregnancy category: C\n\nInteraction: May antagonise effects of ophthalmic carbachol, pilocarpine, or cholinesterase inhibitors.
Tropicamide 1% Eye prep	\n\n\tApex\tEyetrop 1% Eye Drops   5  ml drop 80\n\tAristopharma\tTropicam 1% Eye Drops   5  ml drop 85\n\tG. A. Company Ltd.\tTrusil 1% Eye Drops   5  ml drop 75.86\n\tGeneral\tTropigen Eye Drops 1 gm/100 ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tCamide 1% Eye Drops   5  ml drop 80.31\n\tIncepta\tDilate 1% Eye Drops   5  ml drop 80\n\tNipa\tTropicamin 1% Eye Drops   5  ml drop 85\n\tOpso Saline Ltd.\tTropicamide OSL 1% Eye Drops   5  ml drop 80.30\n\tPopular\tTropidil 1% Eye Drops 1 gm/100 ml 5  ml drop 85.32\n\tReman Drug Ltd.\tMydrimide 1% Eye Drops   5  ml drop 85.23\n\tIndication: Iridocyclitis, Production of cycloplegia\n\nDose: For refraction, instill one or two drops of 1% solution in the eye(s), repeated in five minutes. If patient is not seen within 20 to 30 minutes, an additional drop may be instilled to prolong mydriatic effect. \n\nContra-indication: Contraindicated in persons showing hypersensitivity to any component of this preparation.\n\nSide effects: Transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. Increased intraocular pressure has been reported following the use of mydriatics.\nDryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide.\n\nPrecaution: The lacrimal sac should be compressed by digital pressure for 2-3 minutes after instillation to avoid excessive systemic absorption.\n\nMode of action: May antagonise effects of ophthalmic carbachol, pilocarpine, or cholinesterase inhibitors.\n\nPregnancy category: C\n\nInteraction: May antagonise effects of ophthalmic carbachol, pilocarpine, or cholinesterase inhibitors.
Tulobuterol Hydrochloride	\n\n\tDrug International Ltd.\tBreton Syrup 1mg/5ml 60ml bot 35\n\tDrug International Ltd.\tBreton TAB dr 2mg 100's pack 250\n\tUnimed & Unihealth Manufacturers Ltd.\tBremax Syrup 1mg/5ml 1's pack(60ml) 66.50\n\tUnimed & Unihealth Manufacturers Ltd.\tBremax Tab TAB dr 2mg/5ml 100's pack 372\n\tIndication: Chronic obstructive pulmonary disease\n\nDose: Adult: PO Bronchodilator Initial: 1-2 mg twice daily, up to 2 mg 3 times/day if needed. \n\nContra-indication: Phaeochromocytoma.\n\nSide effects: Fine tremor of skeletal muscle, palpitations, muscle cramps, tachycardia, nervous tension, headache, peripheral vasodilatation, hypersensitivity reactions.\n\nPrecaution: Hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation, hypertension and DM.\n\nMode of action: Increased risk of arrhythmia with digoxin. Hypokalaemia with concomitant admin of xanthines, corticosteroids and diuretics.\n\nPregnancy category: Not Classified\n\nInteraction: Increased risk of arrhythmia with digoxin. Hypokalaemia with concomitant admin of xanthines, corticosteroids and diuretics.
Ulipristal Acetate	\n\n\tSquare\tTulip TAB dr 30mg 30's pack 300\n\tZiska\tPeuli TAB dr 30 mg 1's pack 195\n\tZiska\tUliroid TAB dr 5mg  800\n\tIndication: Emergency contraception, For pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age\n\nDose: Emergency Contraception: \nInstruct patients to take one tablet orally as soon as possible within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure.\nIf vomiting occurs within 3 hours of Ulipristal Acetate intake, consideration should be given to repeating the dose.\n\nUterine Fibroids: \nThe treatment consists of 1 tablet of 5 mg to be taken orally once daily for up to 3 months. This 3-month treatment course can be repeated once. Re-treatment should start at the earliest during the second menstruation following the 1st treatment course completion.\nTreatments should always be started during the 1st week of menstruation.\n\nIf a patient misses a dose, the patient should take ulipristal acetate as soon as possible.\nIf the dose was missed by >12 hrs, the patient should not take the missed dose and simply resume the usual dosing schedule.\n\nContra-indication: Ulipristal Acetate is contraindicated for use in the case of known or suspected pregnancy. \nHypersensitivity to ulipristal acetate or to any of the excipients.\nGenital bleedng or unknown aetiology or for reasons other than uterine fibroids.\nUterine, cervical, ovarian or breast cancer. \nBreastfeeding. \n\n\nSide effects: Side effects are mild to moderate. Most common side effects are:\nHeadache; Vertigo\nDizziness, tired feeling;\nNausea, stomach pain; \nMenstrual pain, acne\nExcessive sweating, hot flushes,\nMuscle or bone pain.\n\n\nPrecaution: Existing Pregnancy\nNot indicated for termination of an existing pregnancy. Pregnancy should be excluded before prescribing Ulipristal Acetate.\n\nEctopic Pregnancy\nA history of ectopic pregnancy is not a contraindication to use of this emergency contraceptive method. \n\nRepeated Use\nUlipristal Acetate is for occasional use as an emergency contraceptive. It should not replace a regular method of contraception. Repeated use of Ulipristal Acetate within the same menstrual cycle is not recommended, as safety and efficacy of repeat use within the same cycle has not been evaluated.\n\nFertility Following Use\nA rapid return of fertility is likely following treatment with Ulipristal Acetate for emergency contraception; therefore, routine contraception should be continued or initiated as soon as possible following use of Ulipristal Acetate to ensure ongoing prevention of pregnancy. \nEffect on Menstrual Cycle\n\nAfter Ulipristal Acetate intake, menses sometimes occur earlier or later than expected by a few days. \n\nContraception\nConcomitant use of progestagen only pills, a progestagen releasing intrauterine device or combined oral contraceptive pills is not recommended (see Interactions). Although a majority of women taking a therapeutic dose of ulipristal acetate have anovulation, a non hormonal contraceptive method is recommended during treatment.\n\nSexually Transmitted Infections/HIV\nThis does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs).\n\nEndometrial Changes\nChanges in the histology of the endometrium may be observed in patients treated with ulipristal acetate. These changes are reversible after treatment cessation. These histological changes should not be mistaken for endometrial hyperplasia .\n\nMode of action: Concomitant administration of medicinal products containing progestagen is not recommended. \nAlso concomitant use of ulipristal acetate and potent CYP3A4 inducers (eg, rifampicin, rifabutin, carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, primidone, St JohnÂ´s wort, efzvirenz, nevirapine, long term use of ritonavir) is not recommended. \n\nPregnancy category: X\n\nInteraction: Concomitant administration of medicinal products containing progestagen is not recommended. \nAlso concomitant use of ulipristal acetate and potent CYP3A4 inducers (eg, rifampicin, rifabutin, carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, primidone, St JohnÂ´s wort, efzvirenz, nevirapine, long term use of ritonavir) is not recommended. 
Urea 10%	\n\n\tBeximco\tEukrim 10% Cream   15gm tube 30\n\tDrug International Ltd.\tAqua Care Cream 10 gm/100 gm  \n\tIncepta\tEudrate Cream 10gm 1's pack 30\n\tSquare\tEqura Cream 10% 1's pack(15g) 30.11\n\tUnimed & Unihealth Manufacturers Ltd.\tEucera Cream   30gm tube 75\n\tIndication: Psoriasis, Ichthyosis, hyperkeratotic and dry skin conditions, Eczemas\n\nDose: Urea 10%  cream is applied topically. Wash affected areas well, rinse off all traces of soap, dry, and apply sparingly twice daily.\n\nContra-indication: Individuals who have hypersensitivity to any of its components.\n\nSide effects: May produce local irritations (including erythema, burning or pruritus) and oedema when applied to sensitive, moist or fissured skin.\n\nPrecaution: Avoid application to moist or broken skin.\n\nMode of action: Increased excretion of lithium.\n\nPregnancy category: C\n\nInteraction: Increased excretion of lithium.
Urokinase	\n\n\tIndication: Acute MI, Pulmonary embolism, Thromboembolism, Deep vein thrombosis\n\nDose: Adult: IV Deep vein thrombosis; Pulmonary embolism Initial: 4,400 u/kg over 10 mins, then 4,400 u/kg/hr for 12-24 hr (deep vein thrombosis) or 12 hr (pulmonary embolism). \n\nAcute MI 2-3 million u as infusion. Peripheral arterial thromboembolism As 2,000 u/ml soln: Infuse into a clot via a catheter at a rate of 4,000 u/min for 2 hr. Monitor response using angiography. If clot is not removed, the catheter is advanced into the occluded vessel and continue infusion for another 2 hr. May repeat procedure up to 4 times if needed. If blood flow is re-established, partially remove cathether and infuse at 1,000 u/min till remaining clot has lysed. Inj Clearance of occluded catheters and shunts Instill 5,000 - 25,000 u into affected IV catheter or shunt and clamped for up to 4 hr. Aspirate the lysate and repeat the procedure if needed. \n\nIrrigation Break down of clots in hyphaema Dissolve 5,000 u in 2 mL of sterile distilled water. Irrigate the anterior chamber with 0.3 mL of the prepared soln and leave it in situ for 3 mins before washing out w/ saline. Repeat 5 times. May leave 0.3 mL in the anterior chamber for 24-48 hr if residual clot is still present at the end.\n\nContra-indication: Active internal bleeding; history of cerebrovascular accident; recent (within 2 mth) trauma of any kind including surgery; aneurysm; known bleeding diathesis; severe uncontrolled hypertension. Recent history of peptic ulcer disease, oesophageal varices, ulcerative colitis or other bleeding GI lesions; pancreatitis; subacute bacterial endocarditis; coagulation defects including those due to liver or kidney disease, or after recent surgery, childbirth or trauma. Increased risk of cerebral bleeding e.g. recent stroke or cerebral neoplasm. Pregnancy.\n\nSide effects: Bleeding, pyrexia, haematuria, thromboembolic episodes, hypersensitivity reactions.\nPotentially Fatal: Severe bleeding, anaphylaxis.\n\nPrecaution: Any vascular punctures or invasive procedures should be avoided as far as possible during, and immediately before and after urokinase therapy and if unavoidable done with great care. External chest compression. Caution in conditions eg, possibility of left heart thrombus, subacute bacterial endocarditis, coagulation defects, cerebrovascular disease, diabetic retinopathy and any conditions in which bleeding could be dangerous. Monitor for reperfusion arrhythmias when used in MI.\n\nMode of action: Reduced thrombolytic effect when given again some time later due to development of high levels of antibodies.\nPotentially Fatal: Platelet inhibitors eg, aspirin and indometacin can potentiate the action of urokinase and cause haemorrhage. Heparin and oral anticoagulants may increase risk of bleeding.\n\nPregnancy category: B\n\nInteraction: Reduced thrombolytic effect when given again some time later due to development of high levels of antibodies.\nPotentially Fatal: Platelet inhibitors eg, aspirin and indometacin can potentiate the action of urokinase and cause haemorrhage. Heparin and oral anticoagulants may increase risk of bleeding.
Ursodeoxycholic Acid	\n\n\tACI\tBilicir TAB dr 300mg  \n\tACI\tBilicir TAB dr 150mg  \n\tAcme Ltd.\tUliv TAB dr 150mg 20's pack 241\n\tAcme Ltd.\tUliv TAB dr 300mg 10's pack 200.70\n\tAlbion Ltd.\tLivacor TAB dr 150mg  \n\tAlbion Ltd.\tLivacor TAB dr 300mg  \n\tBeximco\tLiveric Suspension 250 mg/5 ml  \n\tBeximco\tLiveric 150 TAB dr 150 mg  \n\tBeximco\tLiveric 300 TAB dr 300 mg  \n\tBio Pharma Ltd.\tUDCA TAB dr 300mg  \n\tDrug International Ltd.\tUrsolic TAB dr 150mg 20's pack 220\n\tDrug International Ltd.\tUrsolic TAB dr 300mg 10's pack 200\n\tGeneral\tUrsodil TAB dr 150mg 30's pack 380\n\tGeneral\tUrsodil TAB dr 300mg 10's pack 200.70\n\tHealthcare\tStener TAB dr 150mg  \n\tHealthcare\tStener TAB dr 300mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tUrsodex TAB dr 150mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tUrsodex TAB dr 300mg  \n\tMundipharma (Bangladesh) Pvt. Ltd.\tUdihep TAB dr 150mg  \n\tMundipharma (Bangladesh) Pvt. Ltd.\tUdihep Forte TAB dr 300mg  \n\tOpsonin Pharma\tLiconor Suspension 250mg/5ml 50ml bot 158.94\n\tOpsonin Pharma\tLiconor TAB dr 150mg 30's pack 330\n\tOpsonin Pharma\tLiconor TAB dr 300mg 10's pack 200\n\tSun Pharmaceutical (Bangladesh) Ltd.\tUrsocal TAB dr 300mg 30's pack 603\n\tSun Pharmaceutical (Bangladesh) Ltd.\tUrsocol TAB dr 150mg 50's pack 552.50\n\tUnimed & Unihealth Manufacturers Ltd.\tOxycol TAB dr 150mg 20's pack 400\n\tUnimed & Unihealth Manufacturers Ltd.\tOxycol TAB dr 300mg 20's pack 720\n\tIndication: Dissolution of cholesterol-rich gallstones, Primary biliary cirrhosis, Prevention of gallstones\n\nDose: Adult: PO Dissolution of cholesterol-rich gallstones 6-12 mg/kg/day as a single dose at bedtime after radiological disappearance of stones. Max: 15 mg/kg. \n\nPrimary biliary cirrhosis 10-15 mg/kg/day in 2-4 divided doses. Prevention of gallstones in patients undergoing rapid wt loss 300 mg twice daily.\n\nContra-indication: Calcified and pigment gallstones, radio opaque gallstones. Nonfunctioning gall bladders; chronic liver and peptic ulcer disease. Inflammatory disease of colon and small intestine. Pregnancy.\n\nSide effects: Diarrhoea, pruritus, nausea, vomiting, gallstone calcification.\n\nPrecaution: 50% of successfully treated patients will develop further gallstones within 10 yr. Lactation.\n\nMode of action: Cholestyramine, charcoal and antacids may reduce effectiveness. Aluminum-based antacids may reduce absorption. Oestrogens and clofibrate may counteract effectiveness of ursodeoxycholic acid by increasing cholesterol elimination in bile. Possible increase in ciclosporin serum concentration. Decreased effectiveness of dapsone. Possible decrease in serum ciprofloxacin and nitrendipine.\n\nPregnancy category: B\n\nInteraction: Cholestyramine, charcoal and antacids may reduce effectiveness. Aluminum-based antacids may reduce absorption. Oestrogens and clofibrate may counteract effectiveness of ursodeoxycholic acid by increasing cholesterol elimination in bile. Possible increase in ciclosporin serum concentration. Decreased effectiveness of dapsone. Possible decrease in serum ciprofloxacin and nitrendipine.
Valacyclovir	\n\n\tACI\tAlaclov TAB dr 500mg 10's pack 402.70\n\tBeximco\tOvalac TAB dr 500mg 10's pack 1500\n\tIncepta\tValovir TAB dr 1gm 8's pack 600\n\tIncepta\tValovir TAB dr 500mg 10's pack 400\n\tSquare\tRevira TAB dr 500mg 10's pack 401.52\n\tSquare\tRevira TAB dr 1gm 12's pack 900\n\tUnimed & Unihealth Manufacturers Ltd.\tZostiva TAB dr 1gm  \n\tUnimed & Unihealth Manufacturers Ltd.\tZostiva TAB dr 500mg  \n\tIndication: Genital herpes, Herpes zoster, Herpes labialis, CMV infections\n\nDose: Oral\nHerpes zoster (shingles)\nAdult: 1 g tid for 7 days; commence within 72 hr of rash.\nRenal impairment: Patients on haemodialysis: 1 g daily after haemodialysis.\nCrCl (ml/min)	\n15-30	1 g bid.\n<15 	1 g daily.\n\n\nGenital herpes\nAdult: Initial episode: 1 g bid for up to 10 days, begin course within 72 hr of symptom onset.\nRenal impairment:\nCrCl (ml/min)	\n10-29	1 g once daily.\n<10	        500 mg once daily.\n\n\nProphylaxis of herpes simplex infections\nAdult: Immunocompetent patients: 500 mg daily in 1-2 divided doses. Immunocompromised patients: 500 mg bid.\nRenal impairment: Patients on haemodialysis: immunocompetent patients: 250 mg once daily after haemodialysis; immunocompromised patients: 500 mg once daily after haemodialysis\nCrCl (ml/min)	\n<15 	Immunocompetent patients: 250 mg once daily; immunocompromised patients: 500 mg once daily .\n\n\nHerpes simplex infections of skin and mucous membranes\nAdult: Initial episode: 500 mg bid for up to 10 days, start treatment as early as possible. For recurrent episodes, 500 mg bid for 5 days, begin during prodromal period or as soon as symptoms appear.\nRenal impairment: Patients on haemodialysis: 500 mg daily after haemodialysis.\nCrCl (ml/min)	\n<15	           500 mg once daily.\n\nRecurrent genital herpes\nAdult: 500 mg bid for 3 days within 24 hr of first sign or symptom.\nRenal impairment:\nCrCl (ml/min)	\n<29 	500 mg once daily.\n\nSuppression of recurrent episodes of genital herpes\nAdult: Immunocompetent patients: 1 g once daily or 500 mg once daily for patients with ?9 recurrences per year; HIV infected patients with CD4 cells count ?100 cells/mm3: 500 mg bid up to 6 mth.\nRenal impairment:\nCrCl (ml/min)	\n<29	500 mg once daily if normal dose is 1 g once daily or HIV infected patients; 500 mg every 48 hr if normal dose is 500 mg once daily.\n\nReduction of transmission of genital herpes\nAdult: In combination with safer sex practices and abstinence when lesions are present, 500 mg once daily for infected partner with history of ?9 recurrences per yr.\nRenal impairment:\nCrCl (ml/min)	\n<15	         250 mg once daily.\n\nProphylaxis of cytomegaloviral infections in immunocompromised patients\nAdult: 2 g 4 times daily for 90 days, started within 72 hr after transplant.\nChild: >12 yr: 2 g 4 times daily for 90 days, started within 72 hr after transplant.\nRenal impairment: Patients on haemodialysis: 1.5 g once daily after haemodialysis.\nCrCl (ml/min)	\n50 to <75	1.5 g four times daily\n25 to <50	1.5 g tid\n10 to <25	1.5 g bid\n<10           	1.5 g once daily.\n\nHerpes labialis\nAdult: 2 g 12 hrly for 1 day, admin at earliest symptom of cold sore (e.g. tingling, itching or burning).\nRenal impairment:\nCrCl (ml/min)	\n30-49	1 g 12 hrly for 1 day.\n10-29	500 mg 12 hrly for 1 day.\n<10	        500 mg as a single dose.\nHepatic impairment: Use with caution.\n\nContra-indication: Hypersensitvity to valaciclovir, aciclovir.\n\nSide effects: Headache, nausea, vomiting, diarrhoea, rash, photosensitivity, LFT abnormalities, psychiatric reactions (e.g. confusion, hallucinations and thinking disorders) especially at high doses.\nPotentially Fatal: Hepatitis; renal failure; blood dyscrasias; thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.\n\nPrecaution: Dehydration; renal or hepatic impairment, pregnancy, lactation. Maintain adequate hydration. Monitor renal function daily especially during first 10 days post transplant.\n\nMode of action: Increased risk of renal failure w/ nephrotoxic drugs (e.g. aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, tacrolimus). Probenecid and cimetidine may increase peak plasma concentrations and AUC of aciclovir.\n\nPregnancy category: B\n\nInteraction: Increased risk of renal failure w/ nephrotoxic drugs (e.g. aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, tacrolimus). Probenecid and cimetidine may increase peak plasma concentrations and AUC of aciclovir.
Valsartan	\n\n\tAcme Ltd.\tValtin TAB dr 80mg  \n\tAcme Ltd.\tValtin TAB dr 160mg  \n\tAristopharma\tArovan CAP 80mg 30's pack 300\n\tBeximco\tValcap CAP 160mg 20's pack 320\n\tBeximco\tValcap CAP 80mg 20's pack 196\n\tConcord\tValosan 80 TAB dr 80mg 30's pack \n\tDrug International Ltd.\tCardival TAB dr 80mg 30's pack 210\n\tHealthcare\tDisys TAB dr 160mg 30's pack 510\n\tHealthcare\tDisys TAB dr 80mg 30's pack 273\n\tHealthcare\tDysis TAB dr 160mg 30's pack 480\n\tIncepta\tValsartil TAB dr 160mg 30's pack 480\n\tIncepta\tValsartil TAB dr 40mg 30's pack 150\n\tIncepta\tValsartil TAB dr 80mg 30's pack 270\n\tMystic\tValsan CAP 80mg 30's pack 240.90\n\tNovartis (Bangladesh) Ltd.\tDiovan TAB dr 160mg 28's pack 1848\n\tNovartis (Bangladesh) Ltd.\tDiovan TAB dr 80mg 28's pack 1344\n\tOrion Pharma Ltd.\tValset TAB dr 80mg 30's pack 180.60\n\tRAK\tReovan TAB dr 80mg 30's pack 300\n\tSilva\tValpress CAP 80mg 30's pack 300\n\tNovartis Pharma Switzerland\tDiovan TAB dr 40mg 28's pack 952\n\tIndication: Heart failure, Hypertension, Post myocardial infarction\n\nDose: Adult: PO HTN Initial: 80 mg once daily, up to 160 mg once daily. Max: 320 mg/day. \nHeart failure 40 mg twice daily, up to 160 mg twice daily if tolerated. \nPost-MI Initial: 20 mg twice daily, up to 160 mg bid if tolerated.\n\nElderly: No dosage adjustment needed.\nHepatic impairment: Mild to moderate: Max: 80 mg once daily. Severe: Contraindicated.\n\nContra-indication: Hypersensitivity; severe hepatic impairment, cirrhosis or biliary obstruction; primary hyperaldosteronism. Pregnancy (2nd and 3rd trimesters) and lactation.\n\nSide effects: Dizziness; headache; dose-related orthostatic hypotension; rash; angioedema; hyperkalaemia; myalgia; resp tract disorders; back pain; GI disturbances; fatigue; increase in BUN and serum creatinine; abdominal pain; dry cough; LFT elevations.\nPotentially Fatal: Blood dyscrasias (e.g. neutropenia).\n\nPrecaution: Volume depletion; renal artery stenosis; monitor serum potassium concentrations; severe CHF; renal impairment; mild to moderate hepatic impairment. Elderly.\n\nMode of action: May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.\nPotentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).\n\nPregnancy category: D\n\nInteraction: May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.\nPotentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Vancomycin	\n\n\tIncepta\tVanmycin Injection 1gm 1gm vial X 1's pack 480\n\tIncepta\tVanmycin Injection 500mg 500mg vial X 1's pack 250\n\tOpsonin Pharma\tVancomin Injection 1gm 1gm vial X 1's pack 480\n\tOpsonin Pharma\tVancomin Injection 500mg 500mg vial X 1's pack 250\n\tPopular\tVancobac Injection 1gm 1gm vial X 1's pack 552.08\n\tPopular\tVancobac Injection 500mg 500mg vial X 1's pack 321.21\n\tRenata\tCovan Injection 500mg 1's pack 250\n\tRenata\tCovan Injection 1gm 1's pack 480\n\tTechno Drugs Ltd.\tVancard Injection 1gm 1gm vial X 1's pack 460\n\tTechno Drugs Ltd.\tVancard Injection 500mg 500mg vial X 1's pack 245\n\tIndication: Septicaemia, Soft tissue infections, Osteomyelitis, Enterocolitis, Colitis, Serious staphylococcal or other Gm +ve infections, Bacterial endocarditis\n\nDose: Adult:  IV Osteomyelitis; Septicaemia; Endocarditis, Soft tissue infections; Serious staphylococcal or other Gm +ve infections 500 mg 6 hrly.\n\nChildren: Total daily dose is 40 mg/Kg (in 4 divided doses).\n\nInfants and Neonates: <1 month:  An initial dose of 15 mg/Kg is suggested followed by 10 mg/Kg every 12 hours in the first week, then every 8 hours up to 1 month.\n\n>1 month: 10 mg/kg/day IV divided q6hr; individual dose not to exceed 1 g.\n\n\nContra-indication: Hypersensitivity to the drug; history of impaired hearing; IM administration.\n\nSide effects: Ototoxicity, nephrotoxicity, eosinophilia, "red-man" syndrome (e.g. flushing, hypotension, erythema), urticaria, thrombophloebitis, hypersensitivity reactions.\nPotentially Fatal: Stevens-Johnson syndrome; toxic epidermal necrolysis, blood dyscrasias such as neutropenia or thrombocytopenia.\n\nPrecaution: Renal impairment; neonates, elderly, pregnancy and lactation. Administer by slow IV only. Decrease thrombophlebitis by giving vancomycin slowly as a dilute solution (2.5-5 mg/ml) and rotate infusion sites frequently. Keep rate of infusion ?10 mg/min. Serum trough vancomycin levels to be kept at 5-20 mcg/ml depending on severity of infections and sites of infection. Monitor renal function, blood counts and auditory functions regularly. Discontinue if tinnitus develops.\n\nMode of action: General anaesth may enhance the adverse effects of vancomycin. Increased risk of ototoxicity and nephrotoxicity w/ aminoglycosides, polymyxins, ciclosporin, cisplatin and loop diuretics. Increased potential of neuromuscular blockade w/ suxamethonium or vecuronium.\n\nPregnancy category: C\n\nInteraction: General anaesth may enhance the adverse effects of vancomycin. Increased risk of ototoxicity and nephrotoxicity w/ aminoglycosides, polymyxins, ciclosporin, cisplatin and loop diuretics. Increased potential of neuromuscular blockade w/ suxamethonium or vecuronium.
Vecuronium Bromide	\n\n\tACI\tVecuron Injection 4mg/ml 5's pack 410\n\tHealthcare\tSurvec Injection 10 mg/ml  \n\tIncepta\tNor Q Injection 10mg/ml 10ml vial x 1's pack 185\n\tPopular\tVencur Injection 10mg  1 's pack 200\n\tTechno Drugs Ltd.\tCuron Injection 10mg/ml 4ml vial x 5's pack/10ml vial x1's pack 400 / 185\n\tTechno Drugs Ltd.\tVencuron Injection 10mg 1's pack 185\n\tIndication: General anaesthesia, Skeletal muscle relaxation\n\nDose: Intravenous\nMuscle relaxant in general anaesthesia, Facilitate endotracheal intubation\nAdult: Initially, 80-100 mcg/kg given as inj (reduced doses at 30-50 mcg/kg have been suggested after use of suxamethonium; not to exceed 100 mcg/kg in caesarean and neonatal surgery). Maintenance in prolonged procedure: 20-30 mcg/kg, adjust according to response. Alternatively, as continuous infusion: 0.8-1.4 mcg/kg/minute after initial IV dose of 40-100 mcg/kg.\n\nChild: < 5 mth: Initially, 10-20 mcg/kg, increased if necessary according to response. > 5 mth: initially, 80-100 mcg/kg given as inj; alternatively, 30-50 mcg/kg after clinical recovery from neuromuscular blockade of suxamethonium. Max in caesarean and neonatal surgery: 100 mcg/kg. Maintenance in prolonged procedure: 10-15 mcg/kg.\n\nElderly: Dose reduction may be needed.\nHepatic impairment: Dose adjustments may be needed.\n\n\nContra-indication: Hypersensitivity to vecuronium or bromide.\n\nSide effects: Muscle weakness, paralysis, muscle atrophy (after long term use), hypersensitivity reactions e.g urticaria and erythema.\nPotentially Fatal: Anaphylaxis, respiratory failure, apnoea.\n\nPrecaution: Pregnancy, lactation, elderly. Renal and hepatic impairment. Increase in onset time in conditions associated with prolonged circulation time (e.g. CV disease, oedema). Neuromuscular disease e.g. myasthenia gravis, Eaton-Lambert syndrome or after poliomyelitis. Hypothermia, burns patients. Decrease dose in obese patients, taking into account lean body-mass. Correct severe electrolyte disturbances, altered blood pH, dehydration where possible before vecuronium admin. Do not use potentially dangerous machinery or drive a car within 24 hr after full recovery from the neuromuscular blocking action of vecuronium. Do not admin vecuronium unless facilities for intubation, artificial respiration, oxygen therapy and agents for neuromuscular reversal are immediately available.\n\nMode of action: Increases neuromuscular blockade with volatile anaesthetic agents (halothane, ether, enflurane, isoflurane, methoxyflurane, propofol and cyclopropane), fentanyl, other non-depolarising muscle relaxants, prior admin of succinylcholine, tetracyclines, polymyxins, diuretics, thiamine, MAOIs, bacitracin, colistin, sodium colistimethate, acylaminopenicillins, aminoglycoside antibiotics, high dose metronidazole, protamine, beta-adrenergic blocking agents, calcium antagonists e.g. verapamil, and Mg. Decreased neuromuscular blockade with anticholinesterases, prior chronic admin of corticosteroids, phenytoin, carbamazepine, noradrenaline, azathioprine, theophylline, calcium chloride.\n\nPregnancy category: C\n\nInteraction: Increases neuromuscular blockade with volatile anaesthetic agents (halothane, ether, enflurane, isoflurane, methoxyflurane, propofol and cyclopropane), fentanyl, other non-depolarising muscle relaxants, prior admin of succinylcholine, tetracyclines, polymyxins, diuretics, thiamine, MAOIs, bacitracin, colistin, sodium colistimethate, acylaminopenicillins, aminoglycoside antibiotics, high dose metronidazole, protamine, beta-adrenergic blocking agents, calcium antagonists e.g. verapamil, and Mg. Decreased neuromuscular blockade with anticholinesterases, prior chronic admin of corticosteroids, phenytoin, carbamazepine, noradrenaline, azathioprine, theophylline, calcium chloride.
Venlafaxine	\n\n\tAcme Ltd.\tVenaxin SR CAP 75mg  \n\tGeneral\tVenlax TAB dr 37.5mg 30's pack 165.60\n\tGeneral\tVenlax TAB dr 75mg 20's pack 200.80\n\tOrion Pharma Ltd.\tVenlaf TAB dr 25mg 50's pack \n\tOrion Pharma Ltd.\tVenlaf TAB dr 75mg 30's pack \n\tRenata\tVenax TAB dr 37.5mg 20's pack 80\n\tRenata\tVenax TAB dr 75mg 20's pack 120\n\tSun Pharmaceutical (Bangladesh) Ltd.\tVeniz XR CAP 75mg 30's pack 241.50\n\tIndication: Depression, Anxiety, Panic disorder, Social anxiety disorder\n\nDose: Adult: PO Depression Initial: 75 mg/day in 2-3 divided doses, increase slowly if needed. Max: 375 mg/day. \n\nAnxiety; Social anxiety disorder Extended release Initial: 75 mg once daily, may increase slowly if needed. Max: 225 mg/day. \n\nPanic disorder 37.5 mg once daily for 1st 7 days, may increase slowly if needed. Max: 225 mg/day.\n\nHepatic impairment: Mild to moderate: Reduce dose by 50%.\n\nContra-indication: <18 yr. Lactation. Uncontrolled hypertension; high risk of serious ventricular arrhythmia.\n\nSide effects: Nausea, vomiting, anorexia, dry mouth, constipation, orthostatic hypotension, tremour, sweating, rash, anxiety, dizziness, fatigue, headache, syncope, insomnia, somnolence, constipation, hyponatraemia, sexual dysfunction, dyspepsia, visual disturbances, mydriasis, increased cholesterol concentrations, increased LFT. Aggressive behaviour (especially at the start and when stoppping therapy).\nPotentially Fatal: Blood dyscrasias, Stevens-Johnson syndrome, hepatitis.\n\nPrecaution: Moderate to severe renal or hepatic impairment. Conditions which may be worsened by increase in heart rate. History of MI, bleeding disorder, epilepsy, hypomania or mania. Raised Intraocular pressure or risk at angle-closure glaucoma. May impair performance of skilled tasks, driving or machinery operation. Monitor BP and serum cholesterol regularly. Monitor closely during early therapy until depression improves due to increased risk of suicide. Avoid abrupt withdrawal. Withdraw gradually over at least 1-2 wk and monitor for withdrawal symptoms e.g. fatigue, headache, nausea, vomiting, palpitations. Discontinue if seizure develops or increase in seizure frequency. Elderly, pregnancy.\n\nMode of action: Increased risk of serotonin syndrome w/ TCA, SSRI, SNRI, lithium, sibutramine, tramadol. May increase serum levels w/ CYP3A4 inhibitors (e.g. ketoconazole, atazanavir, clarithromycin). May increase serum levels of haloperidol. May decrease serum levels of indinavir. May increase bleeding risk w/ aspirin, NSAIDs, warfarin and other anticoagulants.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.\n\nPregnancy category: C\n\nInteraction: Increased risk of serotonin syndrome w/ TCA, SSRI, SNRI, lithium, sibutramine, tramadol. May increase serum levels w/ CYP3A4 inhibitors (e.g. ketoconazole, atazanavir, clarithromycin). May increase serum levels of haloperidol. May decrease serum levels of indinavir. May increase bleeding risk w/ aspirin, NSAIDs, warfarin and other anticoagulants.\nPotentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
Verapamil Hydrochloride	\n\n\tAlbion Ltd.\tVerapamil TAB dr 80mg 30's pack 150\n\tAlbion Ltd.\tVerapamil TAB dr 40 mg/ 80 mg 50's / 50's pack \n\tIncepta\tVeracal Injection 5mg/2ml 5 amps pack 150\n\tIncepta\tVeracal 80 TAB dr 80mg 50's pack 150\n\tIncepta\tVeracal SR 180 TAB dr 180mg 30's pack 180\n\tIncepta\tVeracal SR TAB dr 240mg 30's pack 210\n\tIncepta\tVeracal 40 TAB dr 40mg 50's pack 112.50\n\tKemiko\tMil TAB dr 80mg 50's pack 150\n\tMedimet\tAngimil TAB dr 40mg 100's pack 225\n\tMedimet\tAngimil TAB dr 80mg 100's pack 425\n\tMedimet\tAngimil SR TAB dr 240mg 15's pack 105\n\tRangs\tVeramil SR TAB dr 240mg 30's pack 210\n\tRangs\tVeramil TAB dr 80mg 50's pack 150\n\tIndication: Essential hypertension, Angina pectoris and prevention of re-infarction, Supraventricular arrhythmias. Paroxysmal supraventricular tachycardias, Atrial fibrillation with rapid ventricular response (except WPWS) , Atrial flutter with rapid conduction,  Extrasystoles, Acute hypertension, Acute coronary insufficiency, For the prophylaxis and / or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia respectively.\n\nDose: Oral: The dose of Verapamil should be individualized by titration and the drug should be administered with food.\n\nFor essential hypertension the initial dose should be given 180 mg in the morning. If adequate response is not obtained with 180 mg of Verapamil then the dose may be titrated by following manner:\n240 mg each morning.\n180 mg each morning plus 180 mg each evening.\n240 mg every 12 hourly.\n\nFor angina the usual dose is 80 mg to 120 mg three times a day.\n\nFor arrythmias in digitalized patients, Verapamil should be given 240 mg to 360 mg in divided doses, depending on the severity of the condition. Divided doses up to 180 mg/day may occasionally be needed.\n\nIntravenous: Adults: 5mg slowly intravenously, in tachycardias and hypertensive crises, if necessary repeat after 5 to 10 minutes. \n\nDrip infusion to maintain the therapeutic effect: 5-10 mg/hour in physiological saline, glucose, laevulose or similar solutions, on average up to a total dose of 100mg/day.   \n\nChildren: Newborn 0.75-1mg (= 0.3-0.4ml) \nInfants 0.75-2mg (= 0.3-0.8ml) \nChildren age 1-5 years: 2-3mg (= 0.8-1.2ml) \nage 6-14 years: 2.5-5mg (= 1-2ml) of Verapamil, given intravenously, depending on age and action. \n\nThe injection should be made slowly under electrocardiographic control and only until onset of the effect. \n\nIntravenous infusion in hypertensive crises: initially 0.05-0.1mg/kg/hour; if the effect proves to be insufficient, the dose is increased at 30-60 minute intervals until twice the dose or more is reached. Average total dose up to 1.5mg/kg/day.\n\nContra-indication: Severe left ventricular dysfunction, hypotension or cardiogenic shockSick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker)Second or third-degree atrioventricular (AV) block (except in patients with a functioning artificial pacemaker)Patients with atrial flutter or atrial fibrillation and an accessory by pass tract(eg. Wolff-Parkinson-White, Lown-Ganong-Levine syndrome)Patients with known hypersensitivity to verapamil hydrochlorideVerapamil injection should not be administered intravenously to patients on beta-blockers (except in an intensive care setting) and known hypersensitivity to Verapamil hydrochloride.\n\nSide effects: Verapamil is generally well tolerated. The following reaction to orally administered Verapamil appeared clearly drug related or occurred at rates greater than 1% in clinical trials with approximately 5000 patients.Digestive system: Constipation, nausea;Cardiovascular system: Hypotension, edema, CHF, pulmonary edema, bradycardia, AV block;Respiratory system: Upper respiratory tract infections;Nervous system: Dizziness, headache, fatigue;Skin: Rash, flashing;Hepatic: Elevated liver enzyme.\n\nPrecaution: Care should be taken in 1st degree AV block, bradycardia <50 beats/minutes, hypotension <90 mm Hg systolic pressure, atrial fibrillation/flutter and simultaneous pre-excitation syndrome e.g. WPW syndrome, heart failure (previous compensation with cardiac glycosides/diuretics required).Verapamil may impair ability to drive or operate machinery, particularly in the initial stages of treatment and with concomitant consumption of alcohol. \n\nVerapamil markedly slows down the elimination of alcohol and prolongs the duration of the effects of alcohol.Verapamil should be given as a slow intravenous injection over at least 2 minutes under continuous ECG and blood pressure monitoring. Intravenous injection should only be given by the physician.In atrial fibrillation and simultaneous WPW syndrome there is a risk of inducing ventricular fibrillation\n\nMode of action: Increased cardiac depressant effects with ?-blockers and flecainide. Increased risk of additive bradycardia, conduction disturbances and digoxin toxicity with digoxin. Increased risk of bradycardia and hypotension with remifentanil and sufentanil. Increased levels of both everolimus and verapamil on concurrent use. May increase doxorubicin, buspirone, carbamazepine, ciclosporin, epirubicin, eplerenone, quinidine, statins, sirolimus, tacrolimus, quinupristin/dalfopristin levels. Verapamil increase blood alcohol levels. Unpredictable interactions with lithium. Decreased verapamil concentrations with phenobarbital, sulfinpyrazone, rifampicin, rifabutin and rifapentine. Increased verapamil concentrations with protease inhibitors and cimetidine.\n\nPotentially Fatal: Increased cardiac depressant effects with amiodarone. Increased risk of QT prolongation with dofetilide, ranolazine, sertindole. Additive bradycardia with ivabradine. Increased risk of heart block with clonidine. Increased risk of acute hyperkalaemia and CV collapse with dantrolene.\n\nPregnancy category: C\n\nInteraction: Increased cardiac depressant effects with ?-blockers and flecainide. Increased risk of additive bradycardia, conduction disturbances and digoxin toxicity with digoxin. Increased risk of bradycardia and hypotension with remifentanil and sufentanil. Increased levels of both everolimus and verapamil on concurrent use. May increase doxorubicin, buspirone, carbamazepine, ciclosporin, epirubicin, eplerenone, quinidine, statins, sirolimus, tacrolimus, quinupristin/dalfopristin levels. Verapamil increase blood alcohol levels. Unpredictable interactions with lithium. Decreased verapamil concentrations with phenobarbital, sulfinpyrazone, rifampicin, rifabutin and rifapentine. Increased verapamil concentrations with protease inhibitors and cimetidine.\n\nPotentially Fatal: Increased cardiac depressant effects with amiodarone. Increased risk of QT prolongation with dofetilide, ranolazine, sertindole. Additive bradycardia with ivabradine. Increased risk of heart block with clonidine. Increased risk of acute hyperkalaemia and CV collapse with dantrolene.
Vildagliptin	\n\n\tAcme Ltd.\tVildapin TAB dr 50mg 2x10's pack 300\n\tAlbion Ltd.\tReclevus TAB dr 50 mg 30's pack \n\tAlco Pharma\tGluvil TAB dr 50 mg  \n\tAristopharma\tGalvan TAB dr 50mg 20's pack 400\n\tAristopharma\tGluvan TAB dr 50mg 20's pack 400\n\tDrug International Ltd.\tDialiptin TAB dr 50mg 20's pack 300\n\tEskayef Bangladesh Ltd.\tVigatin TAB dr 50 mg  \n\tGeneral\tViptin TAB dr 50mg 30's pack 450\n\tHealthcare\tRedia TAB dr 50mg 30's pack 60\n\tOpsonin Pharma\tVildus TAB dr 50mg 10x2's pack 351.88\n\tPacific\tVida TAB dr 50mg 20's pack 400\n\tPacific\tVida 50 TAB dr 50 mg  400\n\tSharif\tVildagil TAB dr 50mg 20's pack 360\n\tSquare\tViglita TAB dr 50mg 20's pack 400\n\tWhite Horse Pharma\tGalet TAB dr 50mg 20's pack \n\tNovartis Pharma AG, Switzerland\tGalvus TAB dr 50mg 28's pack 784\n\tIndication: Type 2 DM\n\nDose: Adult: PO W/ metformin or a thiazolidinedione: 50 mg twice daily; w/ a sulfonylurea: 50 mg/day in the morning. Not recommended to use >100 mg/day.\n\nContra-indication: Hypersensitivity to vildagliptin\n\nSide effects: Hypoglycaemia, delayed gastric emptying, nausea and vomiting. Flu-like symptoms, headache and dizziness may occur.\nPotentially Fatal: Stevens-Johnson syndrome.\n\nPrecaution: Renal impairment.\n\nMode of action: Decreased hypoglycaemic effect w/ thiazides, corticosteroids, thyroid products and sympathomimetics.\n\nPregnancy category: Not Classified\n\nInteraction: Decreased hypoglycaemic effect w/ thiazides, corticosteroids, thyroid products and sympathomimetics.
Vinorelbine	\n\n\tIndication: Breast cancer, Ovarian cancer, Cervical cancer, Non-small cell lung cancer\n\nDose: Adult: PO Non-small cell lung cancer 60 mg/m2/wk for 3 wk, up to 80 mg/m2/wk depending on neutrophil count. IV Non-small cell lung cancer As single agent: 30 mg/m2/wk. Delay treatment if neutrophil count is <2000 cells/mm3 until recovery. As combination therapy w/ cisplatin: 25-30 mg/m2 every 7 days. Cervical cancer 30 mg/m2/dose on days 1 and 8 of a 21-day treatment cycle. Breast cancer; Ovarian cancer 25 mg/m2/dose every 7 days.\n\nContra-indication: Hypersensitivity to vinorelbine or other vinca alkaloids; severe current or recent infection (within last 2 wk); neutropenia; thrombocytopenia; severe hepatic impairment. Intrathecal admin. Do not give concomitantly with radiotherapy if liver is in treatment field. Pregnancy, lactation.\n\nSide effects: Neurotoxicity, peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, severe constipation, diarrhoea, alopecia, severe local irritation. Dose limiting granulocytopenia, leukopenia and anaemia. Intestinal obstruction, paralytic ileus, nausea, vomitinh, increased in LFT, chest pain, fatigue. Local pain and thrombophlebitis with repeated Inj.\n\nPrecaution:  Hepatic impairment. Compromised bone marrow reserve due to prior irradiation or chemotherapy; recovering marrow function from the effects of previous chemotherapy. Prior radiation therapy; past history or pre-existing neuropathy. CBC with differentials to be monitored prior to admin of subsequent doses. Delay subsequent doses, if neutrophil count < 2000 cells/mm3. Each admin to be followed by at least 250 ml of normal saline to flush the vein. Avoid extravasation. If extravasation occurs, stop infusion immediately, and flush the vein with normal saline solution; admin the remaining solution in another vein. Do not father a child during and up to six mth after treatment and females of childbearing potential to use effective method of contraception during treatment and three mth thereafter. When admin orally, capsules must be swallowed whole with water and not chewed or sucked.\n\nMode of action: Increased risk of granulocytopenia with cisplatin. Increased risk of neurotoxicity with paclitaxel, itraconazole, ketoconazole. Increased radiosensitising effects with prior or concomitant radiation therapy. Increased pulmonary toxicity with mitomycin. Increased myelotoxicity with zidovudine. Earlier onset and/or an increased severity of side effects with CYP3A inhibitors. Possible increase in vincristine levels with aprepitant. Possible infection with live vaccines.\n\nPregnancy category: D\n\nInteraction: Increased risk of granulocytopenia with cisplatin. Increased risk of neurotoxicity with paclitaxel, itraconazole, ketoconazole. Increased radiosensitising effects with prior or concomitant radiation therapy. Increased pulmonary toxicity with mitomycin. Increased myelotoxicity with zidovudine. Earlier onset and/or an increased severity of side effects with CYP3A inhibitors. Possible increase in vincristine levels with aprepitant. Possible infection with live vaccines.
Vinpocetine	\n\n\tACI\tAvintol TAB dr 5mg 50's pack 200.50\n\tAcme Ltd.\tVinpoton TAB dr 5mg  \n\tAmbee\tCerenin TAB dr 5mg 50's pack 177.50\n\tAristopharma\tVinton TAB dr 5mg 100's pack 400\n\tBeximco\tCerivin TAB dr 5mg 100's pack 402\n\tDrug International Ltd.\tCamiton TAB dr 5mg 100's pack 400\n\tEskayef Bangladesh Ltd.\tVincet TAB dr 5mg 50's pack 200\n\tGeneral\tCereton Injection 10mg/2ml 5's pack 200\n\tGeneral\tCereton TAB dr 5mg 50's pack 175.50\n\tIncepta\tVinsetine TAB dr 5mg 100's pack 400\n\tOpsonin Pharma\tCaviton TAB dr 5mg 50's pack 132.40\n\tSquare\tCerevas TAB dr 5mg 50's pack 200.83\n\tSun Pharmaceutical (Bangladesh) Ltd.\tCognitol TAB dr 5mg 50's pack 203\n\tCity overseas\tCavinton TAB dr 5mg 50's pack 360\n\tCity overseas\tCavinton Injection 10mg/2ml 10 amps pack 502\n\tIndication: Dementia, Cerebrovascular disorders, Stroke\n\nDose: Adult: PO Cerebrovascular disorders; Dementia 15-30 mg/day in 3 divided doses.\n\nContra-indication: Pregnancy; lactation.\n\nSide effects: Transient hypotension, tachycardia.\n\nPrecaution: Hypertension or cardiac dysfunction.\n\nMode of action: Possible decrease in anticoagulation effect with warfarin.\n\nPregnancy category: Not Classified\n\nInteraction: Possible decrease in anticoagulation effect with warfarin.
Vitamin A (Retinol)	\n\n\tDrug International Ltd.\tRatinol FORTE CAP 50000IU 120'pack 240\n\tDrug International Ltd.\tVitamin A FORTE CAP 2 LacIU 50's pack 150\n\tDrug International Ltd.\tVitamin A FORTE CAP 1 Lac IU 50's pack \n\tGlobe\tA FORTE CAP 50000IU 100'pack 190\n\tOpsonin Pharma\tOvit A CAP 2 LacIU 100'pack 633\n\tOpsonin Pharma\tOvit A CAP 50000IU 100'pack 193\n\tPacific\tVis A CAP 50000IU 100'pack 190\n\tIndication: Vitamin A deficiency, Night blindness, Xerophthalmia\n\nDose: Adult: PO Vitamin A deficiency For severe deficiency w/ corneal changes: 500,000 u/day for 3 days, followed by 50,000 u/day for 2 wk and then 10,000-20,000 u/day for 2 mth as follow-up therapy. \n\nFor cases w/o corneal changes: 10,000-25,000 u/day until clinical improvement occurs (usually 1-2 wk). \n\n\n\nContra-indication: Hypervitaminosis A; pregnancy (dose exceeding RDA).\n\nSide effects: Hypervitaminosis A characterised by fatigue, irritability, anorexia, weight loss, vomiting and other GI disturbances, low-grade fever, hepatosplenomegaly, skin changes, alopoecia, dry hair, cracking and bleeding lips, SC swelling, nocturia, pains in bones and joints.\n\nPrecaution:  	Cholestatic jaundice; fat-malabsorption conditions. Monitor patients closely for toxicity. Liver impairment and children.\n\nMode of action: Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.\n\nPregnancy category: A\n\nInteraction: Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.
Vitamin A + D + C + Vitamin B-complex Paediatric prep	\n\n\tAcme Ltd.\tV-plex Paediatric Drops  15ml bot 22\n\tCipla Ltd.\tPentavit Paediatric Drops   \n\tOpsonin Pharma\tVita-M Paediatric Drops  15ml bot 14.81\n\tIndication: For prevention and treatment of vitamin deficiency in children and infants.\n\nDose: Below 1 year : 9-10 drops (0.3 ml), 1 year and above : 23-25 drops (1.0 ml) once daily or as advised by the physicians.\n\nContra-indication: Supplemental vitamins should not be prescribed for patients with haemochromatosis or Wilsonâs disease.\nHypersensitivity to any of the ingredients is contraindicated. Excessive doses of vitamin A and D can lead to hypervitaminosis. When multivitamin preparations are prescribed allowance must be made for vitamins from other sources. \n\nSide effects: Multivitamin preparation with ordinary doses of component are usually\nnontoxic.\n\nPrecaution: \n\nMode of action: vitamin a.....Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.\n\nPregnancy category: Not Classified\n\nInteraction: vitamin a.....Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.
Vitamin C (Ascorbic Acid)	\n\n\tACI\tNutrivit C TAB dr 1000mg 10's pack 120.40\n\tACI\tNutrivit C TAB dr 250mg 200's pack 264\n\tACI\tNutrivit-C Syrup 100mg/5ml 100ml bot 33.45\n\tACI\tNutrivit-C Paediatric Drops 100mg/ml 15ml bot 30.11\n\tAcme Ltd.\tCecon TAB dr 250mg 100's pack 132\n\tAmbee\tC Bon TAB dr 250mg 100'pack 130\n\tAmico Ltd.\tSuvic TAB dr 250mg 200's pack 150\n\tApex\tAscorbic TAB dr 250mg 100'pack 130\n\tAristopharma\tVC-250 TAB dr 250mg 200's pack 260\n\tBeximco\tAscobex TAB dr 250mg 200's pack 264\n\tBeximco\tC Gum TAB dr 250mg 30's pack 113.70\n\tBio Pharma Ltd.\tCevalin TAB dr 250mg 200's pack 262\n\tBristol Pharma Ltd.\tAscorin TAB dr 250mg 100'pack 130\n\tCentral.\tVita C TAB dr 250mg 200's pack 260\n\tEdruc Ltd.\tMega C Injection 500mg/5ml 5ml amp x 10's pack 50\n\tEdruc Ltd.\tMega C TAB dr 250mg 200's pack 262\n\tEskayef Bangladesh Ltd.\tHI-C TAB dr 1gm 200's pack 160\n\tEskayef Bangladesh Ltd.\tHI-C Syr Syrup 100mg/5ml 100ml 33.22\n\tEskayef Bangladesh Ltd.\tJuci Sachet 500mg  \n\tGlobe\tGevit TAB dr 250mg 200's pack 260\n\tGonoshasthaya\tG Vitamin C TAB dr 250mg 100'pack 132\n\tHallmark\tVigor C TAB dr 250mg  \n\tHealthcare\tCevion TAB dr 1000mg 10's pack 80.82\n\tHealthcare\tCivion T TAB dr 250mg 10's pack \n\tHealthcare\tCivion TAB dr 250 10's pack \n\tIbn Sina Pharmaceutical Ind. Ltd.\tVeesina TAB dr 250mg 100'pack 132\n\tIncepta\tCeegram TAB dr 1gm 10's pack 100\n\tJayson\tAscoson Syrup 100mg/5ml 100ml bot 33.34\n\tJayson\tAscoson Injection 500mg/5ml 5ml amp x 10's pack 49.50\n\tJayson\tAscoson TAB dr 250mg 200's pack 264\n\tKemiko\tKvit C TAB dr 250mg 50's pack 65\n\tMedicon\tC-Med TAB dr 250mg 200's pack 262\n\tMedimet\tCeemet TAB dr 250mg 250's pack 300\n\tMillat\tC-Vitera TAB dr 250mg 100'pack 130\n\tNavana\tChewce Syrup 100mg/5ml 60ml bot 25.09\n\tNavana\tChewce TAB dr 250mg 200's pack 262\n\tOpsonin Pharma\tVasco Syrup 100mg/5ml 100ml bot 33.22\n\tOpsonin Pharma\tVasco TAB dr 250mg 200's pack 262\n\tOrion Pharma Ltd.\tLivit-C Syrup 100mg/5ml 100ml bot 33.34\n\tPeoples Pharma Ltd.\tPpvit C TAB dr 250mg 200's pack 138\n\tPharmadesh Ltd.\tAscovit TAB dr 250mg 200's pack 260\n\tPopular\tRapid C Syrup 100mg/5ml 100ml bot 33.35\n\tPopular\tRapid C TAB dr 1gm 9's pack 90.36\n\tSilva\tCapcee TR CAP 500mg 48's pack 186.94\n\tSquare\tCeevit TAB dr 250mg 200's pack 263.34\n\tSquare\tCeevit Forte Orange TAB dr 1gm 10's pack 100.41\n\tSquare\tCevit TAB dr 250mg  \n\tSquare\tCevit Gum Gum 125mg  \n\tSyntho Ltd.\tCeeta TAB dr 250mg 200's pack 164\n\tZenith\tVita Cee TAB dr 250mg 200's pack 227.47\n\tZiska\tLemovit C TAB dr 250mg 200's pack 262\n\tIndication: Treatment or prevention of Vitamin C Deficiency, Scurvy, Infection, Trauma, Burns, Cold exposure, Following Surgery, common cold, Fever, scurvy, Stress, Cancer, Methaemoglobinaemia and Children receiving unfortified formulas. Also indicated in Hematuria, Dental Caries, Gum Diseases, Pyorrhea, Acne, Infertility, Atherosclerosis, Fractures, Leg ulcers, Hay fever, Vascular thrombosis prevention, Levodopa toxicity, Arsenic toxicity and etc.\n\nDose: Oral\nScurvy\nAdult: Prevention: 25-75 mg daily. 4 tablets 2 to 3 times daily. Treatment: >250 mg daily, given in divided doses. May also be given via IM/IV/SC admin. 250-500mg IV qDay/BID  for at least 2 weeks.\n\nChild: 1 mth-4 yr: 125-250 mg daily; 4-12 yr: 250-500 mg daily; 12-18 yr: 500 mg-1 g daily. Doses to be given in 1-2 divided doses.\n\nThalassaemia\nAdult: 100-200 mg daily, to be given with desferrioxamine.\nChild: 100-200 mg daily, to be given with desferrioxamine.\n\nMetabolic disorders\nChild: Neonate: 50-200 mg daily, adjust if needed; 1 mth-18 yr: 200-400 mg daily in 1-2 divided doses, up to 1 g daily may be needed.\n\nAdult:\nCommon cold: 1 gm or more daily in divided doses, i.e. 4 tablets daily.\nIn wound healing: 2-4 tablets 2 to 3 times daily\nIn other conditions: 1-2 tablets daily\n\nChildren: < 4 years: 1/4 adult dose, 4-12 years: 1/2 of the adult dose.\n\n1 effervescent tablet daily with a meal or as directed by physician. Dissolve one tablet in half glass (100 ml) of water and drink instantly.\n\n\n\nContra-indication: \n\nSide effects: Ascorbic acid does not seem to have any important adverse effects at dosages less than 4 mg/day. Larger dose may cause diarrhoea or formation of renal calculi of calcium oxalate in patients with renal impairment. Ingestion of more than 600 mg daily have a diuretic action.\n\nPrecaution: Should be given with caution to patient with hyperoxaluria. \n\nMode of action: Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\nPregnancy category: A\n\nInteraction: Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.
Vitamin C + Vitamin E	\n\n\tDelta Pharma\tCarv TAB dr   15's pack 60\n\tDrug International Ltd.\tE Cap PLUS CAP   40's pack 240\n\tEuro Pharma Ltd.\tAntage TAB dr   15's pack/30's pack 60/120\n\tOpsonin Pharma\tProtecor TAB dr   30's pack 120\n\tOrion Pharma Ltd.\tEC TAB dr  200/50mg 20's pack \n\tOrion Pharma Ltd.\tEC PLUS TAB dr  200/200mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tVital E+C TAB dr   28's pack 112\n\tIndication: Keratosis, Rough skin,Wrinkles associated with aging, Alzheimer's disease, Cancer Prevention, dementia, degenerative diseases, coronary heart diseases, end stage renal disease, growth and repair of body tissue, bone, skin, teeth and hair. \n\nDose: One tablet/capsule daily or as directed by a physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally, this preparation is well-tolerated. Diarrhea may occasionally occur during treatment with beta carotene and the skin may assume a slightly yellow discoloration. The side-effects of vitamin A are reversible. Vitamin C and vitamin E may cause diarrhea and other gastrointestinal disturbances.\n\nPrecaution: Hypervitaminosis. Avoid use in early pregnancy. Patients on anti coagulant therapy should not use ascorbic acid prolonged period of time.\n\nMode of action: Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\nVit E: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.\n\nPregnancy category: A\n\nInteraction: Vit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\nVit E: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.
Vitamin E  (Alpha-tocopherol)	\n\n\tACI\tNutrivit E TAB dr 200mg 50's pack 191\n\tAcme Ltd.\tE Tab TAB dr 200mg 100'pack 326\n\tAcme Ltd.\tLifil-E CAP 200mg  \n\tAcme Ltd.\tLifil-E CAP 400mg  \n\tAlbion Ltd.\tPolyvit TAB dr 200 mg 15's pack \n\tAristopharma\tAlfa E TAB dr 200mg 15's pack 75\n\tBeacon\tLiqu - E CAP 200mg 30's pack/50's pack 120.30 / 200.50\n\tBeximco\tFormula E TAB dr 200mg 15's pack 57.30\n\tBio Pharma Ltd.\tBiovit E TAB dr 200mg 15's pack 45.15\n\tBristol Pharma Ltd.\tE-200 TAB dr  30's pack/100's pack 100/ 333\n\tBristol Pharma Ltd.\tE-400 TAB dr  30's pack/50's pack 150/250\n\tCosmo Pharma Ltd.\tCpvit E TAB dr 200mg 50's pack 100\n\tDoctor's Chemicals Works Ltd.\tEvidon TAB dr 200mg 25's pack 162.50\n\tDrug International Ltd.\tE-Cap CAP 200mg 100'pack 400\n\tDrug International Ltd.\tE-Cap CAP 400mg 50's pack 300\n\tDrug International Ltd.\tE-Cap-Plus CAP  60's pack 211\n\tEdruc Ltd.\tVita E TAB dr 200mg 15's pack 55\n\tEskayef Bangladesh Ltd.\tVanila TAB dr 200mg 15's pack 57\n\tGeneral\tE-Fill CAP 200mg 50's pack 201\n\tGeneral\tE-Fill CAP 400mg 30's pack 180.60\n\tGlobe\tEcovit S CAP 200mg 100'pack 400\n\tGlobe\tEcovit S Soft Gelatine CAP 400mg 50's pack 300\n\tHealthcare\tEfynal TAB dr 200mg 25's pack 162.50\n\tIncepta\tInovit E CAP 200mg 30's pack 120\n\tIncepta\tInovit E CAP 400mg 30's pack 180\n\tKemiko\tKvit E TAB dr 200mg 20's pack 70\n\tMedicon\tE-Fil Chewable TAB dr 200mg 50's pack / 30's pack 210 / 180\n\tNavana\tPlacent E TAB dr 200mg 15's pack 51.15\n\tNIPRO JMI Pharma\tVegecap-E CAP 200mg  \n\tNIPRO JMI Pharma\tVegecap-E CAP 400mg  \n\tNovartis (Bangladesh) Ltd.\tRenbo E TAB dr 200mg 100's pack 380\n\tNovartis (Bangladesh) Ltd.\tRenbo E TAB dr 400mg 50's pack 312.50\n\tOpsonin Pharma\tOvit E CAP 200mg 100'pack 250\n\tOpsonin Pharma\tOvit-E CAP 400mg 50's pack 250\n\tOrion Pharma Ltd.\tTocovit TAB dr 200mg 15's pack \n\tPacific\tE-Soft CAP 200mg 100'pack 400\n\tPacific\tE-Soft CAP 400mg 50's pack 300\n\tPharmadesh Ltd.\tE V V TAB dr 200mg 15's pack 82.82\n\tRangs\tE-Gold CAP 200mg 30's pack/ 50's pack 105 / 175\n\tRenata\tE-gel 200 CAP  100's pack  401\n\tRenata\tE-gel 400 CAP  50's pack   301\n\tSquare\tEvit TAB dr 200mg 15's pack 50.07\n\tSquare\tEvit Chewable TAB dr 200mg 15's pack 50.10\n\tSquare\tEvit Licap CAP 200mg 30's pack 120.30\n\tSquare\tEvit Licap CAP 400mg 30's pack 180.60\n\tIndication: Cardiovascular disease,Male infertility,Diabetes,Obesity,Vitamin E deficiency and peripheral neuropathy,Macular Degeneration\n\nDose: Adult: Betterment of Cardiovascular health: 400 mg - 800 mg / day Deficiency syndrome in adults: 200 mg - 400 mg / day Deficiency syndrome in children: 200 mg / day Thalassemia: 800 mg / day Sickle-cell anemia: 400 mg / day Betterment of Skin & Hair: 200 mg - 400 mg / day. Chronic cold in adults: 200 mg / day \n\nContra-indication: There is no absolute contraindication except known hypersensitivity to vitamin E.\n\nSide effects: Vitamin E is usually well tolerated. Large doses (more than 400 mg/day) for prolonged period have been associated with a variety of less serious side effects including fatigue, weakness, headache, nausea, blurred vision, flatulence or diarrhoea.\n\nPrecaution: Vitamin E may enhance the anticoagulant activity of anticoagulant drugs.\n\nMode of action: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.\n\nPregnancy category: A\n\nInteraction: Colestyramine, colestipol, and orlistat may interfere with vitamin E absorption. High doses of vitamin E potentiates the anticoagulant action of warfarin. Large doses of vitamin E may impair response to iron supplementation.
Voriconazole	\n\n\tIndication: Candidemia, Deep tissue Candida infections, Invasive aspergillosis, Scedosporiosis and Fusariosis\n\nDose: Adult: PO Candidemia; Deep tissue Candida infections; Invasive aspergillosis; Scedosporiosis and Fusariosis >40 kg: 400 mg 12 hrly for the 1st 24 hr. Maintenance: 200 mg 12 hrly, up to 300 mg 12 hrly if needed. <40 kg: 200 mg 12 hrly for the 1st 24 hr. Maintenance: 100 mg 12 hrly, up to 150 mg 12 hrly if needed. \n\nFor oesophageal candidiases: Loading dose is not recommended and treatment is for at least 14 days and continued for 7 days after symptoms resolved. \n\nIV Candidemia; Deep tissue Candida infections; Invasive aspergillosis; Scedosporiosis and Fusariosis Loading dose: 6 mg/kg 12 hrly for the 1st 24 hr. Maintenance: 4 mg/kg 12 hrly (3-4 mg/kg 12 hrly for candidemia in non-neutropenic patients or patients intolerant of high doses). Max duration: 6 mth.Max infusion rate: 3 mg/kg/hr over 1-2 hr.\n\nChild: 2-14 yr <50 kg: 9 mg/kg 12 hrly for the 1st 24 hr, then 8 mg/kg 12 hrly. Max infusion rate: 3 mg/kg/hr. May switch to oral therapy once patient is able to tolerate oral admin.\n\nRenal impairment:\nCrCl (ml/min)	\n<50	       Use oral voriconazole when possible.\n\nHepatic impairment: Mild to moderate (Child-Pugh category A and B): Standard loading dose but maintenance doses should be reduced by 50%.\n\nContra-indication: Hypersensitivity. Lactation.\n\nSide effects: Transient and reversible visual disturbances; fever; headache; abdominal pain; chills; asthenia; back pains; chest pain; face oedema; flu-like syndrome; hypotension; thrombophloebitis; phloebitis; GI disturbances (eg, nausea, vomiting, diarrhoea); jaundice; cheilitis; cholestatic jaundice; gastroenteritis; blood dyscrasias; purpura; peripheral oedema; facial oedema; hypokalaemia; hypoglycaemia; dizziness; hallucinations; confusion; depression; anxiety; tremor; agitation; paraesthesia; respiratory distress syndrome; sinusitis; rash; pruritus; photosensitivity; alopecia; exfoliative dermatitis; acute kidney failure; haematuria; infusion-related reactions. Increased LFT and serum creatinine; prolongation of QT interval.\nPotentially Fatal: Stevens-Johnson Syndrome, toxic epidermal necrolysis.\n\nPrecaution: Monitor renal and hepatic function before and during treatment. Monitor visual function if used >28 days. Monitor pancreatic function in patients at risk of acute pancreatitis. Haematological malignancy; patients with proarrhythmic conditions; hepatic and renal impairment. Use in pregnancy not recommended, ensure effective contraception during treatment. Avoid exposure to sunlight. Correct electrolyte abnormalities before treatment initiation. May affect ability to drive or operate machinery and do not drive at nght.\n\nMode of action: Increased prothrombin time w/ oral anticoagulants. May increase plasma concentrations of ciclosporin and tacrolimus, long-acting opiates (e.g. oxycodone, methadone), NSAIDs (e.g. ibuprofen, diclofenac), omeprazole, short-acting opiates (e.g. alfentanil, fentanyl). Decreased voriconazole plasma concentration and increased phenytoin plasma concentrations when used concomitantly. May increase plasma concentration w/ oral contraceptives.\n\nPotentially Fatal: May increase risk of QT prolongation or torsades de pointes w/ astemizole, cisapride, pimozide, quinidine and terfenadine. May increase risk of ergotism w/ ergot alkaloids (e.g. ergotamine and dihydroergotamine). May significantly increase plasma concentrations of sirolimus. Decreased plasma concentrations w/ rifampicin, carbamazepine, long-acting barbiturates (e.g. phenobarbital, mephobarbital), efavirenz (?400 mg once daily), ritonavir (?400 mg bid). Concomitant use may significantly increase rifabutin and decrease voriconazole plasma concentration.\n\nPregnancy category: D\n\nInteraction: Increased prothrombin time w/ oral anticoagulants. May increase plasma concentrations of ciclosporin and tacrolimus, long-acting opiates (e.g. oxycodone, methadone), NSAIDs (e.g. ibuprofen, diclofenac), omeprazole, short-acting opiates (e.g. alfentanil, fentanyl). Decreased voriconazole plasma concentration and increased phenytoin plasma concentrations when used concomitantly. May increase plasma concentration w/ oral contraceptives.\n\nPotentially Fatal: May increase risk of QT prolongation or torsades de pointes w/ astemizole, cisapride, pimozide, quinidine and terfenadine. May increase risk of ergotism w/ ergot alkaloids (e.g. ergotamine and dihydroergotamine). May significantly increase plasma concentrations of sirolimus. Decreased plasma concentrations w/ rifampicin, carbamazepine, long-acting barbiturates (e.g. phenobarbital, mephobarbital), efavirenz (?400 mg once daily), ritonavir (?400 mg bid). Concomitant use may significantly increase rifabutin and decrease voriconazole plasma concentration.
Warfarin Sodium	\n\n\tG. A. Company Ltd.\tFarevan TAB dr 5mg 100's pack 304\n\tIncepta\tWarin TAB dr 5mg 100's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tUnifarin-1 TAB dr 1mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tUnifarin-2 TAB dr 2mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tUnifarin-2.5 TAB dr 2.5mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tUnifarin-5 TAB dr 5mg  \n\tIndication: Venous thromboembolism, Stroke prevention\n\nDose: Oral\nTreatment and prophylaxis of venous thromboembolism\nAdult: Initially, 5 mg daily. Rapid anti-coagulation: Initially, 10 mg daily for 2 days. Adjust subsequent doses based on PT/INR. Usual maintenance dose: 2-10 mg daily.\nElderly: Lower initial dose.\nHepatic impairment: Severe: Avoid.\n\n\n\nContra-indication: 1. Actual or potential haemorrhagic conditions, eg. Peptic ulcer, or to patients with uncontrolled hypertension\n2. Severe hepatic or renal disease\n3. Pregnancy\n4. Known hypersensitivity to warfarin\n5. Bacterial endocarditis\nIts use within 24 hours following surgery or labour should be undertaken with caution, if at all.\n\nSide effects: Hemorrhage is the principal adverse effect of oral anticoagulants. Other adverse reactions include nausea, vomiting, diarrhea, hypersensitivity, rash, alopecia, and unexplained drop in haematocrit, "purple toes", skin necrosis, jaundice, and hepatic dysfunction.\n\nPrecaution: Periodic determination of prothrombin time (PT)/international normalized ratio (INR) or other suitable coagulation test is essential. Numerous factors, alone or in combination, including travel, changes in diet, environment, physical state and medication may influence response of the patient to anticoagulants. It is generally good practice to monitor the patient's response with additional PT/INR determination in the period immediately after discharge from the hospital, and whenever other medications are initiated, discontinued or taken irregularly. \n\nThe following factors may exaggerate the effects of warfarin and necessitate a reduction in dosage; loss of weight, elderly subject, acute illness, deficient renal function, decreased dietary intake of vitamin K, administration of certain drugs (see drug interaction). Factors which may call for an increase in maintenance dosage include weight gain, diarrhea and vomiting, increased intake of vitamin K, fats and oils, and the administration of certain drugs (see drug interaction). Careful additional laboratory control is necessary if the patient is to be changed from one formulation to another. Reversal of warfarin anticoagulation by vitamin K takes several days. In emergency situations fresh frozen plasma should be given.\n\nMode of action: Cholestatic hepatitis may occur when taken concomitantly w/ ticlopidine. Increased risk of bleeding w/ other anticoagulants (e.g. argatroban, dabigatran, heparin), antiplatelet agents (e.g. aspirin, cilostazol, clopidogrel), NSAIDs (e.g. celecoxib, diclofenac, ibuprofen), serotonin reuptake inhibitors (e.g. citalopram, paroxetine, venlafaxine). Increased INR w/ CYP2C9 (e.g. amiodarone, capecitabine, cotrimoxazole), CYP1A2 (e.g. aciclovir, allopurinol, ciprofloxacin) and CYP3A4 (e.g. alprazolam, amlodipine, atorvastatin) inhibitors. Decreased INR w/ CYP2C9, CYP1A2 and CYP3A4 inducers.\n\nPotentially Fatal: Increased risk of bleeding w/ fibrinolytic drugs (e.g. streptokinase and alteplase).\n\nPregnancy category: X\n\nInteraction: Cholestatic hepatitis may occur when taken concomitantly w/ ticlopidine. Increased risk of bleeding w/ other anticoagulants (e.g. argatroban, dabigatran, heparin), antiplatelet agents (e.g. aspirin, cilostazol, clopidogrel), NSAIDs (e.g. celecoxib, diclofenac, ibuprofen), serotonin reuptake inhibitors (e.g. citalopram, paroxetine, venlafaxine). Increased INR w/ CYP2C9 (e.g. amiodarone, capecitabine, cotrimoxazole), CYP1A2 (e.g. aciclovir, allopurinol, ciprofloxacin) and CYP3A4 (e.g. alprazolam, amlodipine, atorvastatin) inhibitors. Decreased INR w/ CYP2C9, CYP1A2 and CYP3A4 inducers.\n\nPotentially Fatal: Increased risk of bleeding w/ fibrinolytic drugs (e.g. streptokinase and alteplase).
Xylometazoline Hydrochloride 0.05% Nasal prep	\n\n\tAcme Ltd.\tRhinozol 0.05% Nasal Drops  0.5 mg / ml 15 ml drop 11.01\n\tG. A. Company Ltd.\tNovin 0.05% Nasal Drops   10 ml drop 82.69\n\tOpso Saline Ltd.\tXylovin 0.05% Nasal Drops   10 ml drop 7.28\n\tSquare\tAntazol 0.05% Nasal Drops   12's pack 132.12\n\tSquare\tAntazol 0.05% Nasal Spray   120 sprays 110.41\n\tIndication: Sinusitis, Nasal congestion, Seasonal & perennial allergic rhinitis\n\nDose: Adults (including the elderly) and children: One spray each nostril four times daily.\n\nContra-indication: Contraindicated in patients with a known hypersensitivity to any ingredients of the preparation.\n\nSide effects: No serious side effects have been reported. Occasional irritation of the nasal mucosa may occur during the first day of use. In rare cases with Sodium Cromoglicate solutions alone wheezing and tightness of the chest has been reported. Because a lower dose of Xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations.\n\nPrecaution: The prolonged use or abuse of decongestants in general may lead to rebound congestion or drug induced rhinitis.\n\nMode of action: Increased heart rate or BP with sibutramine.\nPotentially Fatal: Hypertensive crisis with MAOIs.\n\nPregnancy category: C\n\nInteraction: Increased heart rate or BP with sibutramine.\nPotentially Fatal: Hypertensive crisis with MAOIs.
Xylometazoline Hydrochloride 0.1% Nasal prep	\n\n\tAcme Ltd.\tRhinozol 0.1% Drops  1.0 mg / ml 15 ml drop 11.51\n\tG. A. Company Ltd.\tNovin 0.1% Drops   10 ml drop 90\n\tOpso Saline Ltd.\tXylovin 0.1% Drops   10 ml drop 7.28\n\tOpsonin Pharma\tXylomet 0.1% Drops   10 ml drop 7.62\n\tSquare\tAntazol Nasal Spray   15 ml drop x 12's pack 91.44\n\tSquare\tAntazol 0.1% Drops   12's pack 138.12\n\tIndication: Sinusitis, Nasal congestion, Seasonal & perennial allergic rhinitis\n\nDose: Adults (including the elderly) and children: One spray each nostril four times daily.\n\nContra-indication: Contraindicated in patients with a known hypersensitivity to any ingredients of the preparation.\n\nSide effects: No serious side effects have been reported. Occasional irritation of the nasal mucosa may occur during the first day of use. In rare cases with Sodium Cromoglicate solutions alone wheezing and tightness of the chest has been reported. Because a lower dose of Xylometazoline is employed in this preparation it causes mild side effects such as nasal irritation, dryness of the nose, sneezing, headache, insomnia, drowsiness and palpitations.\n\nPrecaution: The prolonged use or abuse of decongestants in general may lead to rebound congestion or drug induced rhinitis.\n\nMode of action: Increased heart rate or BP with sibutramine.\nPotentially Fatal: Hypertensive crisis with MAOIs.\n\nPregnancy category: C\n\nInteraction: Increased heart rate or BP with sibutramine.\nPotentially Fatal: Hypertensive crisis with MAOIs.
Zafirlukast	\n\n\tBeximco\tZukast TAB dr 20mg 10's pack \n\tGeneral\tZafnil TAB dr 20mg 20's pack \n\tRenata\tZaft TAB dr 20mg 10's pack 260\n\tAstrazeneca Pharmaceutical company\tAccolate TAB dr 20mg 30's pack \n\tIndication: Chronic asthma\n\nDose: Oral\nChronic asthma\nAdult: 20 mg bid.\nChild: 5-11 yr: 10 mg bid. >12 yr: 20 mg bid.\n\nContra-indication: Hypersensitivity, hepatic impairment, cirrhosis, acute asthmatic attacks. Lactation.\n\nSide effects: GI disturbances, headache, myalgia, generalised pain, fever, dizziness, raised LFT, respiratory tract infections, hypersensitivity reactions, Churg-Strauss syndrome.\nPotentially Fatal: Severe hepatotoxicity.\n\nPrecaution: Elderly, pregnancy, moderate or severe renal impairment. Discontinue if patient develops systemic eosinophilia, eosinophilic pneumonia, or clinical features consistent with Churg-Strauss syndrome. Patients to watch out for signs of hepatic dysfunction.\n\nMode of action: May enhance anticoagulant activity of warfarin resulting to increased prothrombin time. Decreased plasma levels w/ theophylline, terfenadine and erythromycin. Increased plasma levels w/ fluconazole and high dose aspirin.\n\nPregnancy category: B\n\nInteraction: May enhance anticoagulant activity of warfarin resulting to increased prothrombin time. Decreased plasma levels w/ theophylline, terfenadine and erythromycin. Increased plasma levels w/ fluconazole and high dose aspirin.
Zaleplone	\n\n\tBeximco\tEplon CAP 10mg 30's pack \n\tBeximco\tEplon CAP 5mg 30's pack \n\tSquare\tSomna CAP 10mg 12's pack 84\n\tSquare\tSomna CAP 5mg 12's pack 48\n\tIndication: Insomnia\n\nDose: Insomnia Adult: 10 mg before bedtime. Max: 20 mg daily.\nElderly: >65 yr: 5 mg before bedtime. Max: 10 mg daily.\nRenal impairment: Severe: No studies done.\nHepatic impairment: Mild to moderate: 5 mg at bedtime. Severe: Contra-indicated.\n\nContra-indication: Hypersensitivity. Severe hepatic impairment. Lactation.\n\nSide effects: Headache, light headedness, asthenia, dizziness, nausea, somnolence, rash, myalgia, back pain, chest pain, taste perversion, fever, migraine, constipation, dry mouth, dyspepsia, arthralgia, anxiety, depression, difficulty concentrating, amnesia, confusion, hallucinations. Transient impairment of memory and psychomotor function. Decreased inhibition, behavioural changes (e.g. bizarre behaviour, depersonalisation), complex sleep related behaviour (e.g. sleep driving).\n\nPrecaution: May precipitate new psychiatric abnormalities. Depression; hepatic impairment. History of drug or alcohol dependence or abuse, elderly and debilitated patients. Childn <18 yr. Pregnancy. May impair ability to drive or operate machinery. Do not take zaleplon if there is <4 hr of sleep. Dose reduction or withdrawal of drug should be done gradually.\n\nMode of action: Additive CNS effects may occur with CNS depressants e.g. TCA, alcohol, antihistamines, narcotic analgesics, thioridazine and diphenhydramine. Cytochrome P450 CYP3A4 inducers e.g. rifampicin, phenytoin, carbamazepine and phenobarbital decrease zaleplon concentrations. Increased zaleplon concentration with cimetidine and CYP 3A4 inhibitors e.g. erythromycin, ketoconazole.\n\nPregnancy category: C\n\nInteraction: Additive CNS effects may occur with CNS depressants e.g. TCA, alcohol, antihistamines, narcotic analgesics, thioridazine and diphenhydramine. Cytochrome P450 CYP3A4 inducers e.g. rifampicin, phenytoin, carbamazepine and phenobarbital decrease zaleplon concentrations. Increased zaleplon concentration with cimetidine and CYP 3A4 inhibitors e.g. erythromycin, ketoconazole.
Zidovudine	\n\n\tIndication: Cancer therapy-induced hyperuricaemia, HIV infection\n\nDose: Adult: PO HIV infection 600 mg/day in divided doses, w/ other anti-retrovirals. \nChild: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals.\n\nRenal impairment: Haemodialysis or peritoneal dialysis: 100 mg every 6-8 hr.\nCrCl (ml/min)	\n<10	      100 mg every 6-8 hr.\n\nPrevention of maternal-foetal HIV transmission 100 mg 5 times/day given after 14 wk of pregnancy until start of labour. \n\nIV HIV infection 1-2 mg/kg 4 hrly. \nChild: As continuous infusion: 20 mg/m2/hr. Alternatively, as intermittent infusion: 120 mg/m2 every 6 hr.\nRenal impairment: Haemodialysis or peritoneal dialysis: 1 mg/kg every 6-8 hr.\nCrCl (ml/min)	\n<10  	1 mg/kg every 6-8 hr. \n\nPrevention of maternal-foetal HIV transmission during labour and delivery Loading dose: 2 mg/kg, then 1 mg/kg/hr until the umbilical cord is clamped.\n\nHepatic impairment: Dose reduction may be needed.\n\nContra-indication: Lactation.\n\nSide effects: Nausea, severe headache, myalgia, insomnia, vomiting, anorexia, diarrhoea, asthenia, dizziness, taste perversion, convulsions, myopathy, nail, skin and oral mucosa pigmentation, raised LFT, pancreatitis, fat redistribution.\nPotentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis, hepatotoxicity. Blood dyscrasias, e.g. serious anaemia (may require transfusion), neutropenia, leucopenia.\n\nPrecaution: Anaemia or myelosuppression, renal and hepatic impairment, elderly, pregnancy. Monitor patients with risk factors for liver disease. Blood tests should be carried out regularly, reduce dose if neutrophil or haemoglobin count is low. Monitor serum CK concentration every 3 mth in patients who have received >6 mth of treatment. Patients to contact doctor if they experience muscle weakness, shortness of breath, symptoms of hepatitis or pancreatitis.\n\nMode of action: Decreased zidovudine concentration with tipranavir. Increased risk of peripheral neuropathy with bortezomib. Increased haematological toxicity with IV pentamidine, lamivudine, dapsone, vancomycin flucytosine, amphotericin, ganciclovir, interferon alfa, cyclophosphamide and other bone marrow suppressive or cytotoxic agents Increased risk of zidovudine toxicity with atovaquone, chloramphenicol, fluconazole, valproate. Decreased absorption with clarithromycin, minimise interactions by admin at least 2 hours apart. Increased zidovudine concentration and increased potential for hypersensitivity reactions with probenecid. Increased zidovudine clearance and haematological toxicity with rifampicin. Increased bioavailability of zidovudine with nimodipine. Increased incidences of headache with benzodiazepines. Possible increase in zidovudine concentration with methadone.\n\nPotentially Fatal: Avoid stavudine (due to inhibition of activation of stavudine), didanosine, ribavirin (antagonize effect of zidovudine), zalcitabine (inferior virological activity and a higher rate of side effects) with zidovudine. Increased risk of toxicity (e.g. hepatic decompensation, neutropenia) in patients with interferon alfa with or without ribavirin.\n\nPregnancy category: C\n\nInteraction: Decreased zidovudine concentration with tipranavir. Increased risk of peripheral neuropathy with bortezomib. Increased haematological toxicity with IV pentamidine, lamivudine, dapsone, vancomycin flucytosine, amphotericin, ganciclovir, interferon alfa, cyclophosphamide and other bone marrow suppressive or cytotoxic agents Increased risk of zidovudine toxicity with atovaquone, chloramphenicol, fluconazole, valproate. Decreased absorption with clarithromycin, minimise interactions by admin at least 2 hours apart. Increased zidovudine concentration and increased potential for hypersensitivity reactions with probenecid. Increased zidovudine clearance and haematological toxicity with rifampicin. Increased bioavailability of zidovudine with nimodipine. Increased incidences of headache with benzodiazepines. Possible increase in zidovudine concentration with methadone.\n\nPotentially Fatal: Avoid stavudine (due to inhibition of activation of stavudine), didanosine, ribavirin (antagonize effect of zidovudine), zalcitabine (inferior virological activity and a higher rate of side effects) with zidovudine. Increased risk of toxicity (e.g. hepatic decompensation, neutropenia) in patients with interferon alfa with or without ribavirin.
Zinc Sulphate Monohydrate	\n\n\tACI\tDispazinc 20 Disp TAB dr    50's pack 88\n\tAcme Ltd.\tBaby Zinc TAB dr 20mg 100's pack 176\n\tAcme Ltd.\tZis DS Syrup 20mg/5ml 100ml bot 30.11\n\tAd-din\tJ Zinc Syrup 10mg/5ml 100ml bot 30\n\tAlbion Ltd.\tMisole Syrup 10 mg/ 5 ml 100 ml bot \n\tAlco Pharma\tZep Syrup 10mg/5ml 100ml bot 30\n\tAlco Pharma\tZep JUNIOR Syrup 4.05mg/5ml 100ml bot 27\n\tAlco Pharma\tZinc -DT TAB dr   10's pack 17.50\n\tAmbee\tZinc S Syrup 10mg/5ml 100ml bot 25.10\n\tAmico Ltd.\tZn Syrup 10mg/5ml 100ml bot 35\n\tAPC Pharma Ltd.\tZinc Sulphate Syrup 10mg/5ml 100ml bot 30\n\tApex\tZipol Syrup 10mg/5ml 100ml bot 30\n\tApex\tZipol-DT 		 		 TAB dr 20mg 50's  75 	\n\tApollo Pharmaceutical Ltd.\tZinca Syrup   100ml bot 35\n\tAristopharma\tOralzin Syrup 10mg/5ml 100ml bot 30\n\tAristopharma\tOralzin TAB dr 20mg 50's pack 75\n\tAsiatic Ltd.\tSyrup Zinc Syrup   100ml bot 30\n\tBeacon\tZT TAB dr 20mg 60's pack 90\n\tBenham\tB Zn Syrup 10mg/5ml 100ml bot 25\n\tBeximco\tZedex TAB dr 20mg 30's pack 45\n\tBeximco\tZedex DS Syrup 10mg/5ml 100ml bot 30\n\tBeximco\tZedex Max Syrup 20mg/5ml 100ml bot 55\n\tBio Pharma Ltd.\tZinga TAB dr 20mg 50's pack 100.50\n\tBio Pharma Ltd.\tZinga Syrup 4.05mg/5ml 100ml bot 35\n\tBristol Pharma Ltd.\tBP Zinc TAB dr 20mg 100'pack 175\n\tCentral.\tC-zinc Syrup   100ml bot 30\n\tChemist Ltd.\tZeenee Syrup 10mg/5ml 100ml bot 30\n\tConcord\tConzi Syrup 10mg/5ml 100ml bot 30\n\tCosmic Chemical Industries Ltd.\tZeenk Syrup 10mg/5ml 100ml bot 26\n\tDecent Pharma Ltd.\tZs Syrup 10mg/5ml 100ml bot 30\n\tDelta Pharma\tZnkid Syrup 10mg/5ml 100ml bot 30\n\tDelta Pharma\tZnkid Dispersible TAB dr 20mg 30's pack 60\n\tDesh\tZincep Syrup 10mg/5ml 100ml bot 30\n\tDoctor's Chemicals Works Ltd.\tZinsul Syrup 10mg/5ml 100ml bot 28\n\tDrug International Ltd.\tZiton Syrup 10mg/5ml 100ml bot 30\n\tEdruc Ltd.\tGrow Syrup 10mg/5ml 100ml bot 26\n\tEdruc Ltd.\tGrow TAB dr 125mg/2ml 100ml 26\n\tEskayef Bangladesh Ltd.\tEZY Xinc TAB dr 20mg 100'pack 175\n\tEskayef Bangladesh Ltd.\tXinc Syrup 10mg/5ml 100ml bot/200ml bot 35 / 55\n\tEskayef Bangladesh Ltd.\tXinc TAB dr 20mg 60's pack 90\n\tEskayef Bangladesh Ltd.\tXinc DS Syrup   100ml bot 55\n\tEuro Pharma Ltd.\tZemin Syrup 10mg/5ml 100ml bot 30\n\tEuro Pharma Ltd.\tZemin DS Syrup 20mg/5ml 100ml bot 55\n\tEverest\tZicat TAB dr 20mg 100ml bot 30\n\tG. A. Company Ltd.\tKids B Syrup 10mg/5ml 100ml bot 30\n\tGeneral\tZico Syrup 10mg/5ml 100ml bot 26.10\n\tGlobe\tZikid Syrup 10mg/5ml 100ml bot 25\n\tGonoshasthaya\tG Zinc Syrup 10mg/5ml 100ml bot 24\n\tGonoshasthaya\tG Zinc TAB dr 20mg 60's pack 60.60\n\tHallmark\tZym Syrup 10mg/5ml 100ml bot 30\n\tHallmark\tZym DS Syrup 4.05mg/5ml 100ml bot 35\n\tHudson\tZee 1 Syrup 4.05mg/5ml 100ml bot 30\n\tHudson\tZee 2 Syrup 10mg/5ml 100ml bot 50\n\tIbn Sina Pharmaceutical Ind. Ltd.\tBiozinc Syrup 10mg/5ml 100ml bot 35\n\tIncepta\tZiflu Syrup 10mg/5ml 100ml bot 30\n\tIncepta\tZiflu TAB dr 20mg 100'pack 150\n\tIncepta\tZiflu Syrup 4.05mg/5ml 1's pack 30\n\tIndobangla Pharmaceuticals\tZins Syrup 10mg/5ml 100ml bot 26\n\tJayson\tZeal Syrup 10mg/5ml 100ml bot 30\n\tKemiko\tZismo Syrup 10mg/5ml 100ml bot 35\n\tKumudini Pharma Ltd.\tZinpro Syrup 4.05mg/5ml 100ml bot 30\n\tLeon\tLeozinc Syrup 4.05 mg/5 ml  \n\tLeon\tLeozinc DS Syrup 10 mg/5 ml  \n\tMarksman.\tZisul Syrup 10mg/5ml 100ml bot 25\n\tMedicon\tZinon Syrup 10mg/5ml 100ml bot 30\n\tMedicon\tZinon TAB dr 20mg 30's pack 45\n\tMedimet\tZisulmet Syrup 10mg/5ml 100ml bot 30\n\tMillat\tZinton Syrup 10mg/5ml 100ml bot 35\n\tModern\tZinofa Syrup 10mg/5ml 100ml bot 30\n\tMonicopharma\tZiqui Syrup 10mg/5ml 100ml bot 30\n\tNavana\tOrazinc Syrup 10mg/5ml 50ml bot/100ml bot 20.08 / 30.11\n\tNavana\tOrazinc TAB dr 20mg 30's pack 45.30\n\tNipa\tPeptin Syrup 4.05mg/5ml 100ml bot 25.28\n\tNipa\tPeptin DS Syrup 10mg/5ml 100ml bot 26\n\tNIPRO JMI Pharma\tNipozin Syrup 10 mg/5 ml  \n\tNovo Healthcare and Pharma Ltd.\tNovo Zinc Dispersible TAB dr 20mg 50's pack 100\n\tNovo Healthcare and Pharma Ltd.\tZido Syrup 10mg/5ml 100ml bot 35\n\tOpsonin Pharma\tNid Syrup 10mg/5ml 100ml bot 30\n\tOpsonin Pharma\tNid TAB dr 20mg 30's pack 45\n\tOpsonin Pharma\tXinadal TAB dr 20mg 30's pack \n\tOrion Pharma Ltd.\tPep TAB dr 20mg 30's pack 45.30\n\tOrion Pharma Ltd.\tPep Syrup 20mg/5ml 100ml bot 55\n\tOrion Pharma Ltd.\tPep Syrup 4.05mg/5ml 100ml bot 27.10\n\tOrion Pharma Ltd.\tPep DT TAB dr 20mg 10's pack 200\n\tOrion Pharma Ltd.\tPep-2 Syrup 10mg/5ml 100ml bot 30.11\n\tPacific\tBimuty DS Syrup 10mg/5ml 100ml bot 29.80\n\tPacific\tBimuty Disp TAB dr   30's pack 60\n\tPharmadesh Ltd.\tSyrup zp Syrup   100ml bot 30\n\tPharmasia Ltd.\tTiny-Z Syrup 20mg/5ml 100ml bot 30.11\n\tPopular\tSoluzinc Syrup 10mg/5ml 100ml bot 30.11\n\tRAK\tDZ 20 Syrup 20mg/5ml 100ml bot 50\n\tRangs\tPedizinc Syrup 10mg/5ml 100ml bot  30\n\tReliance\tZincase Syrup 10mg/5ml 100ml bot 27\n\tRenata\tMazic Syrup 10mg/5ml 100ml bot 30.11\n\tRenata\tMazic TAB dr 20mg 30's pack 45.30\n\tRenata\tMazic DS Syrup 20mg/5ml 100ml bot 50.19\n\tRenata\tMazic JR Syrup 4.05mg/5ml 100ml bot 27.10\n\tRenata\tPustikona Sachet   30 sachets  pack 75.30\n\tSeema\tZMS Syrup 10mg/5ml 100ml bot 35\n\tSharif\tKidzin Syrup 10mg/5ml 100ml bot 30\n\tSilva\tZ Sil Syrup 10mg/5ml  100ml bot/  200 ml bot 25.10 / 48.19\n\tSilva\tZ Sil DT TAB dr 20mg  100's pack 190.92\n\tSocial Marketing Company\tSMC Zinc TAB dr 20mg 10's pack 17.50\n\tSomatec\tZincol Syrup 10mg/5ml 100ml bot 30\n\tSquare\tSquare Zinc TAB dr 20mg 30's pack 60.25\n\tSquare\tZ-DT TAB dr 10mg 100's pack 150\n\tSquare\tZesup Syrup 10mg/5ml 100ml bot 35\n\tSquare\tZesup Forte Syrup 20mg/5ml 100ml bot 50.20\n\tSupreme\tPedi Z Syrup 10mg/5ml 100ml bot 25\n\tUnimed & Unihealth Manufacturers Ltd.\tZixol Syrup 10mg/5ml 100ml bot 30\n\tVirgo\tKidizinc Syrup 10mg/5ml 100ml bot 35\n\tZenith\tZimon Syrup 10mg/5ml 100ml bot 30\n\tZenith\tZimon TAB dr 20mg 100's 175\n\tZiska\tZincoral Syrup 10 mg/ 5 ml 100 ml bot 30\n\tIndication: Zinc deficiency, Severe diarrhea, Liver cirrhosis,  immune deficiency, age related blindness, prevention and treatment of colds, maintenance of taste and smell, male potency and sex drive, infertility, prostate problem, hair loss and diabetes & rheumatoid arthritis. \n\nDose: Tablet: For infants between 2 to 6 months of age: 10 mg Zinc once daily for 10-14 days. For children between 6 months to 5 years of age: 20 mg Zinc once daily for 10-14 days. For other indications The recommended dose for children is 2 to 2.5 mg/kg/day. Children under 10 kg: 10 mg Zinc 2 times daily. Children within 10 to 30 kg: 20 mg Zinc 1-3 times daily. Adults and children over 30 kg body weight: 40 mg Zinc 1-3 times daily.\n\nSyrup: Child under 10 kg : 5 ml (1 teaspoonful) 2 times daily. Child between 10 - 30 kg : 10 ml (2 teaspoonful) 1-3 times daily. Adults and child over 30 kg : 20 ml (4 teaspoonful) 1-3 times daily. \n\n\n\nContra-indication: It is contraindicated in patients with hypersensitivity to Zinc.\n\nSide effects: Most of the supplements including Zinc are considered to be safe. However, few mild side effects such as nausea, vomiting, headache, drowsiness, gastric ulcer, metallic taste may be occurred. \n\nPrecaution: Accumulation of Zinc may occur in case of renal failure. Food may decrease the absorption of Zinc. Hence the patients are advised to take the preparation at least 1 hour before or 2 hours after meal. \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Zinc Oxide 40% Topical	\n\n\tBeximco\tQ Rash Ointment   25gm pack 50\n\tIncepta\tNapguard Ointment   25gm pack 50\n\tSquare\tDe-Rash Ointment  40 gm/100 gm 25gm pack 50.20\n\tIndication: Diaper rash, Burns, Poison ivy, Cuts, Bed sore,\n\nDose: Apply thin layer topically every 8 hourly. \n\nChange wet and soiled diapers, promptly cleans the diaper area, allow to dry and apply ointment liberally as often as necessary, with each diaper change, especially at bedtime or any time when exposure to wet diapers may be prolonged.\n\nContra-indication: Known hypersensitivity to any component of the preparation\n\nSide effects: Usually well tolerated. Extremely low frequency of hypersensitivity reaction.\n\nPrecaution: For external use only. Avoid contact with the eyes. Stop use and ask a doctor if condition worsens or does not improve within 7 days. Keep out of the reach of children. If swallowed, get medical help or contact a poison control center right away\n\nMode of action: Zinc oxide reduce therapeutic efficacy of hydroxyquinoline.\n\nPregnancy category: Not Classified\n\nInteraction: Zinc oxide reduce therapeutic efficacy of hydroxyquinoline.
Zinc Oxide + Castor oil Topical	\n\n\tEskayef Bangladesh Ltd.\tSofti Ointment   15gm pack/50gm pack 35/90\n\tIndication: Burns, Bed sore, Diaper rash, Skin irritations and abrasions, Haemorrhoids, vulvo-vaginitis, Eczema\n\nDose: Haemorrhoids, vulvo-vaginitis & Eczema Adult: As ointment: Use 3 times daily or as required in a thin layer to protect the skin. \n\nNappy rash Child: Apply thin layer topically every 8 hourly. \n\nChange wet and soiled diapers, promptly cleans the diaper area, allow to dry and apply ointment liberally as often as necessary, with each diaper change, especially at bedtime or any time when exposure to wet diapers may be prolonged.\n\nContra-indication: Known hypersensitivity to any component of the preparation\n\nSide effects: Usually well tolerated. Extremely low frequency of hypersensitivity reaction.\n\nPrecaution: For external use only. Avoid contact with the eyes. Stop use and ask a doctor if condition worsens or does not improve within 7 days. Keep out of the reach of children. If swallowed, get medical help or contact a poison control center right away.\n\nMode of action:  	Zinc oxide reduce therapeutic efficacy of hydroxyquinoline.\n\nPregnancy category: X\n\nInteraction:  	Zinc oxide reduce therapeutic efficacy of hydroxyquinoline.
Ziprasidone	\n\n\tDrug International Ltd.\tZipradon CAP 20mg 50's pack 250\n\tDrug International Ltd.\tZipradon CAP 40mg 30's pack 300\n\tSun Pharmaceutical (Bangladesh) Ltd.\tZipsydon CAP 20mg 50's pack 302\n\tIndication: Schizophrenia, Bipolar Disorder, Mania\n\nDose: Adult: PO Schizophrenia As HCl: >18 yr: Initial: 20 mg twice daily, may increase slowly to 80 mg twice daily, if needed. Maintenance: 20 mg twice daily. \n\nMania As HCl: Initial: 40 mg twice daily, increase to 60-80 mg twice daily on the 2nd day. Subsequent doses based on patient's response. \n\n\n\nContra-indication: Concomitant use of oral and IM ziprasidone. Recent acute MI, decompensated heart failure, cardiac arrhythmias, conditions that may increase QT interval eg, QT-interval prolongation or history of QT prolongation; prolactin dependent tumours. Lactation. Not for treatment of behavioural disorders in elderly with dementia.\n\nSide effects: Somnolence, respiratory tract infections, akathisia, extrapyramidal syndrome, tardive dyskinesia, hyperglycaemia, dizziness, dystonia, headache, GI disturbances, asthenia, agitation, rash, urticaria, visual disturbances, prolonged QT interval, orthostatic hypotension, increased prolactin levels, weight gain, sexual dysfunction, hyperlipidaemia, seizures.\nPotentially Fatal: Blood dyscrasias, neuroleptic malignant syndrome.\n\nPrecaution: Patients predisposed to significant electrolyte disturbances, esp hypokalaemia, should have a baseline serum potassium and magnesium screening performed and corrected before treatment. CNS depression; cerebrovascular disease and significant CV illness; history of seizures; conditions that decrease seizue threshold; predisposition to hypotension; patients at risk of aspiration pneumonia; Parkinson's disease; renal impairment (IM); hepatic impairment; pregnancy. Discontinue if persistent QTc measurements >500 msec. May impair ability to drive or operate machinery. Monitor ECG in patients who shows symptoms of torsades de pointes (e.g. syncope, dizziness, palpitations). Monitor serum electrolytes if on concurrent diuretic therapy. Monitor glucose levels in DM or patient at risk of developing DM.\n\nMode of action: Antagonistic effect with levodopa and dopamine antagonists. Additive hypotensive effect with antihypertensives. Additive sedative effects with other CNS agents, alcohol.\nPotentially Fatal: Increased risk of torsades de pointes with drugs that prolong QT interval e.g. dofetilide, quinidine, sotalol, and other Class Ia and III antiarrhythmics, moxifloxacin, pimozide, sparfloxacin, thioridazine.\n\nPregnancy category: C\n\nInteraction: Antagonistic effect with levodopa and dopamine antagonists. Additive hypotensive effect with antihypertensives. Additive sedative effects with other CNS agents, alcohol.\nPotentially Fatal: Increased risk of torsades de pointes with drugs that prolong QT interval e.g. dofetilide, quinidine, sotalol, and other Class Ia and III antiarrhythmics, moxifloxacin, pimozide, sparfloxacin, thioridazine.
Zolendronic Acid	\n\n\tHealthcare\tZoclast Injection 4 mg/5 ml  \n\tIncepta\tDrometa Injection 4mg/5ml 5ml amp x 1 's pack 5000\n\tIncepta\tZolenic Solution for Infusion 5mg/100ml 5 mg in 100 ml bot x 1's pack 5947\n\tOpsonin Pharma\tZoledron IV Infusion 5 mg/100 ml  \n\tTechno Drugs Ltd.\tOstometa Injection 4 mg/5 ml  \n\tNovartis Pharma Switzerland\tZometa 	 Infusion 4mg/5ml vial 			 4 mg (5ml ) amp x 1's pack  26122\n\tNovartis Pharma Switzerland\tAclasta 		 Infusion 5mg/100ml 	 1's pack 32500\n\tIndication: Hypercalcaemia of malignancy, Bone malignancies , Paget's disease of bone, Postmenopausal osteoporosis\n\nDose: Intravenous\nHypercalcaemia of malignancy\nAdult: 4 mg as a single dose by infusion over at least 15 minutes. Retreatment in patients who relapse or who are refractory to initial treatment: 4 mg as an infusion over at least 15 minutes, after at least 1 wk from initial dose.\n\n\nBone metastases associated with solid tumours\nAdult: 4 mg infusion over at least 15 minutes every 3-4 wk, in conjunction with 500 mg calcium and 400 IU vitamin D oral supplement.\n\nRenal impairment:\nCrCl (ml/min)	\n50-60	3.5 mg every 3-4 wk\n40-49	3.3 mg every 3-4 wk\n30-39	3 mg every 3-4 wk\n<30	        Not recommended.\n\nPaget's disease of bone\nAdult: Single 5 mg IV infusion over 15 minutes, in conjunction with 1500 mg elemental calcium daily in divided doses and 800 IU vitamin D daily, especially in the 2 wk following zoledronic acid admin.\n\nOsteoporosis in postmenopausal women\nAdult: Single 5 mg IV infusion over at least 15 minutes, once a year.\n\nRenal impairment:\nCrCl (ml/min)	\n<40 	Not recommended.\n\nPatients with renal impairment\nThe use of Zolenic in patients with creatinine clearance <35 mL/min is not recommended due to limited clinical safety data in such patients. No dose adjustment is necessary in patients with creatinine clearance >35 mL/min.\n\nPatients with hepatic impairment\nNo dose adjustment is required for patients with hepatic impairment.\n\n\n\nContra-indication: The drug is contraindicated if patients have hypersensitivity to the active substance or to any of the excipients or to any bisphosphonates, hypocalcaemia, renal impairment (creatinine clearance <35 mL/min), current or recent uveitis, or a history of bisphosphonate-associated uveitis, pregnancy and lactation. \n\nSide effects: The post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia and headache, the majority of which occur within the first 3 days following Zolenic administration. The majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. The incidence of these symptoms occurring within the first 3 days after administration of Zolenic, can be reduced with the administration of Paracetamol or Ibuprofen shortly following Zolenic administration. Severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking Zolenic.\n\nPrecaution: Patients must be appropriately hydrated prior to administration of Zolenic. This is especially important in the elderly and for patients receiving diuretic therapy. Adequate hydration can be achieved by the patient drinking two glasses of fluid (such as water) before and after the infusion. Pre-existing hypocalcaemia must be treated by adequate intake of Calcium and Vitamin-D before initiating therapy with Zolenic. Other disturbances of mineral metabolism must also be effectively treated (e.g. diminished parathyroid reserve, thyroid surgery, parathyroid surgery, intestinal Calcium malabsorption). Physicians should consider clinical monitoring for these patients.\n\nMode of action: Increased risk of hypocalcaemia with aminoglycosides and loop diuretics. Increased risk renal dysfunction with nephrotoxic agents.\n\nPregnancy category: D\n\nInteraction: Increased risk of hypocalcaemia with aminoglycosides and loop diuretics. Increased risk renal dysfunction with nephrotoxic agents.
Zolmitriptan	\n\n\tBeximco\tZolmit TAB dr 2.5mg 20's pack 500\n\tDrug International Ltd.\tMiotrol TAB dr 2.5mg 50's pack 750\n\tIncepta\tZomitan TAB dr 2.5mg 10's pack 250\n\tSquare\tNomi TAB dr 2.5mg 12's pack 301.16\n\tIndication: Acute migraine attacks\n\nDose: Oral\nAcute migraine attacks\nAdult: Initially, 2.5 mg. A 2nd dose may be taken at least 2 hr after the 1st dose if symptoms recur within 24 hr. Max dose: 10 mg in 24 hr. Safety of treating > three headaches in a 30-day period has not been established.\nHepatic impairment: Dose reduction may be needed with BP monitoring. Moderate to severe: Max dose: 5 mg/24 hr \n\nContra-indication: Patients at risk of coronary artery disease (post-menopausal women, men >40 yr, hypertension, hypercholesterolemia, smoking, obesity, DM, family history of coronary artery disease) unless evaluated. Wolff-Parkinson-White syndrome; arrhythmias associated with accessory cardiac conduction pathways; previous cerebrovascular accident; uncontrolled or severe hypertension; ischaemic heart disease, history of MI, coronary vasospasm, transient ischaemic attack. Basilar or hemiplegic migraine.\n\nSide effects: Dizziness, asthenia, dry mouth, hyperesthesia, paresthesia, drowsiness, nausea, pain or sensations of tingling, heaviness, pressure or tightness in any part of the body including throat/chest; cerebrovascular events; transient increases in blood pressure; hypotension, ischaemic colitis, GI infarction, hypersensitivity reactions, coronary vasospasm.\nPotentially Fatal: Cardiac arrhythmias, MI, subarachnoid haemorrhage.\n\nPrecaution: Use only if there is a clear diagnosis of migraine; exclude other potentially serious neurological conditions. Monitor BP closely. May impair ability to drive or operate machinery. Pregnancy and lactation. Child. Moderate to severe hepatic impairment. Prior CV evaluation for patients with risk factors of coronary heart disease; admin of first dose under close supervision and ECG if satisfactory CV assessment in these patients. Periodic CV evaluation for patients with risk factors of coronary arteries on zolmitriptan. Avoid oral disintegrating formulation for patients with phenylketouria. Long term use may cause accumulation of zolmitriptan in melanin rich tissue (e.g. eye).\n\nMode of action: Increased risk of serotonin syndrome with SSRI, selective serotonin- and norepinephrine-reuptake inhibitors (SNRI). Increased zolmitriptan concentrations with cimetidine, quinolone antibacterials and drugs that inhibit the cytochrome P450 isoenzyme CYP1A2.\n\nPotentially Fatal: Increased risk of fatal serotonin syndrome with sibutramine. Increased risk of serotonin syndrome with MAOI and reversible inhibitors of monoamine oxidase type-A (RIMA); do not use zolmitriptan during and for 2 wk after the use of MAOI and RIMAs Do not use within 24 hr of treatment with another 5-HT1 agonist. Increased risk of additive vasoconstriction with ergot alkaloids; zolmitriptan should not be taken within 24 hr of any ergotamine or ergot-type medication.\n\nPregnancy category: C\n\nInteraction: Increased risk of serotonin syndrome with SSRI, selective serotonin- and norepinephrine-reuptake inhibitors (SNRI). Increased zolmitriptan concentrations with cimetidine, quinolone antibacterials and drugs that inhibit the cytochrome P450 isoenzyme CYP1A2.\n\nPotentially Fatal: Increased risk of fatal serotonin syndrome with sibutramine. Increased risk of serotonin syndrome with MAOI and reversible inhibitors of monoamine oxidase type-A (RIMA); do not use zolmitriptan during and for 2 wk after the use of MAOI and RIMAs Do not use within 24 hr of treatment with another 5-HT1 agonist. Increased risk of additive vasoconstriction with ergot alkaloids; zolmitriptan should not be taken within 24 hr of any ergotamine or ergot-type medication.
Zolmitriptan 5% Nasal prep	\n\n\tIndication: Acute migraine attacks\n\nDose: Acute migraine attacksAdult: 5 mg (1 spray) into 1 nostril as soon as possible after onset of symptoms, repeated at least 2 hr after the 1st dose if symptoms recur w/in 24 hr. Max: 10 mg/day.\n\nSafety of treating >4 headaches in a 30 day period is not established.\n\nHepatic impairment: Avoid use.Special Populations: Concurrent use with cimetidine, quinolone antibacterials: Max dose: 5 mg in 24 hr.\n\nContra-indication: Patients at risk of coronary artery disease (post-menopausal women, men >40 yr, hypertension, hypercholesterolemia, smoking, obesity, DM, family history of coronary artery disease) unless evaluated. Wolff-Parkinson-White syndrome; arrhythmias associated with accessory cardiac conduction pathways; previous cerebrovascular accident; uncontrolled or severe hypertension; ischaemic heart disease, history of MI, coronary vasospasm, transient ischaemic attack. Basilar or hemiplegic migraine.\n\nSide effects: Dizziness, asthenia, dry mouth, hyperesthesia, paresthesia, drowsiness, nausea, pain or sensations of tingling, heaviness, pressure or tightness in any part of the body including throat/chest; cerebrovascular events; transient increases in blood pressure; hypotension, ischaemic colitis, GI infarction, hypersensitivity reactions, coronary vasospasm.\nPotentially Fatal: Cardiac arrhythmias, MI, subarachnoid haemorrhage.\n\nPrecaution: Use only if there is a clear diagnosis of migraine; exclude other potentially serious neurological conditions. Monitor BP closely. May impair ability to drive or operate machinery. Pregnancy and lactation. Child. Moderate to severe hepatic impairment. Prior CV evaluation for patients with risk factors of coronary heart disease; admin of first dose under close supervision and ECG if satisfactory CV assessment in these patients. Periodic CV evaluation for patients with risk factors of coronary arteries on zolmitriptan. Avoid oral disintegrating formulation for patients with phenylketouria. Long term use may cause accumulation of zolmitriptan in melanin rich tissue (e.g. eye).\n\nMode of action: Increased risk of serotonin syndrome with SSRI, selective serotonin- and norepinephrine-reuptake inhibitors (SNRI). Increased zolmitriptan concentrations with cimetidine, quinolone antibacterials and drugs that inhibit the cytochrome P450 isoenzyme CYP1A2.\n\nPotentially Fatal: Increased risk of fatal serotonin syndrome with sibutramine. Increased risk of serotonin syndrome with MAOI and reversible inhibitors of monoamine oxidase type-A (RIMA); do not use zolmitriptan during and for 2 wk after the use of MAOI and RIMAs Do not use within 24 hr of treatment with another 5-HT1 agonist. Increased risk of additive vasoconstriction with ergot alkaloids; zolmitriptan should not be taken within 24 hr of any ergotamine or ergot-type medication.\n\nPregnancy category: C\n\nInteraction: Increased risk of serotonin syndrome with SSRI, selective serotonin- and norepinephrine-reuptake inhibitors (SNRI). Increased zolmitriptan concentrations with cimetidine, quinolone antibacterials and drugs that inhibit the cytochrome P450 isoenzyme CYP1A2.\n\nPotentially Fatal: Increased risk of fatal serotonin syndrome with sibutramine. Increased risk of serotonin syndrome with MAOI and reversible inhibitors of monoamine oxidase type-A (RIMA); do not use zolmitriptan during and for 2 wk after the use of MAOI and RIMAs Do not use within 24 hr of treatment with another 5-HT1 agonist. Increased risk of additive vasoconstriction with ergot alkaloids; zolmitriptan should not be taken within 24 hr of any ergotamine or ergot-type medication.
Zolpidem Tartrate	\n\n\tSun Pharmaceutical (Bangladesh) Ltd.\tNitrest TAB dr 10mg 30's pack 148.50\n\tIndication: Insomnia\n\nDose: Short-term management of insomnia Adult: As immediate release tab: 5-10 mg immediately before bedtime. Max: 10 mg/day. \n\nAs extended release tab: 6.25-12.5 mg immediately before bedtime. Max: 12.5 mg/day. Max duration of treatment: 4 wk including tapering.\n\nElderly: As immediate release tab: 5 mg immediately before bedtime. As extended release tab: 6.25 mg immediately before bedtime. Max duration of treatment: 4 wk including tapering.\n\nRenal impairment: No dosage adjustment needed. \n\nHepatic impairment: As immediate release tab: 5 mg immediately before bedtime. As extended release tab: 6.25 mg immediately before bedtime. Max duration of treatment: 4 wk including tapering. Severe: Contraindicated.\n\nContra-indication: Severe hepatic impairment.\n\nSide effects: Atypical thinking and behaviour, hallucination, nightmare, somnolence, somnambulism, headache, nausea, vomiting, dizziness, vertigo, drowsiness, asthenia, ataxia, rebound insomnia, amnesia, GI disturbances, upper and lower respiratory tract infection, fatigue, visual disturbances, increased ALT serum concentrations, abnormal LFT.\nPotentially Fatal: Hepatitis, anaphylactic reactions, angioedema, sleep-driving (driving while not fully awake after drug intake, w/ no recollection of the event).\n\nPrecaution: Obstructive sleep apnoea, myasthenia gravis, compromised respiratory function. Patients exhibiting symptoms of depression. History of drug or alcohol abuse. Avoid abrupt withdrawal and rapid dose reduction after prolonged therapy. Re-evaluate if insomnia fail to remit after 7-10 days as this may indicate the presence of underlying psychiatric and/or medical condition. Pregnancy, lactation, childn <18 yr. Patient Counseling Patients should be warned about performing activities involving mental alertness or physical coordination after drug intake.\n\nMode of action: Flumazenil reverses the sedative/hypnotic effect of zolpidem. Increased depressant effects w/ CNS depressants (e.g. sedatives, antihistamines, alcohol). Additive effect on decreased alertness and psychomotor performance w/ imipramine and chlorpromazine. Increased plasma concentration w/ itraconazole, ketoconazole and other CYP3A4 inhibitors. May decrease plasma concentration w/ CYP3A4 inducers (e.g. carbamazepine). Reduced hypnotic effect w/ rifampicin.\nPotentially Fatal: Increased risk of prolonged sedation and respiratory depression w/ ritonavir.\n\nPregnancy category: C\n\nInteraction: Flumazenil reverses the sedative/hypnotic effect of zolpidem. Increased depressant effects w/ CNS depressants (e.g. sedatives, antihistamines, alcohol). Additive effect on decreased alertness and psychomotor performance w/ imipramine and chlorpromazine. Increased plasma concentration w/ itraconazole, ketoconazole and other CYP3A4 inhibitors. May decrease plasma concentration w/ CYP3A4 inducers (e.g. carbamazepine). Reduced hypnotic effect w/ rifampicin.\nPotentially Fatal: Increased risk of prolonged sedation and respiratory depression w/ ritonavir.
Zopiclone	\n\n\tACI\tHypnoclone TAB dr 7.5mg 20's pack 90.57\n\tSanofi Aventis (BD) Ltd.\tImovane TAB dr 7.5mg 30's pack 228.60\n\tIndication: Insomnia\n\nDose: Adult: 7.5 mg at bed time. Increased to 15 mg in severe insomnia.\nElderly: 3.75 mg at bed time.\nChild: Not recommended. \n\nContra-indication: Myasthenia gravis; respiratory failure; severe sleep apnoea syndrome; severe hepatic impairment; pregnancy, lactation.\n\nSide effects: Metallic or bitter aftertaste; irritability, confusion, depressed mood, aggressiveness, incoordination, anterograde amnesia, mild increase in LFTs, drowsiness, lightheadedness, nausea, vomiting, urticaria, rashes.\n\nPrecaution: Hepatic and renal insufficiency; elderly; psychiatric disorders; history of drug abuse. May impair ability to drive or operate machinery. Limit treatment duration to <4 wk to minimise risk of dependence and tolerance. Avoid abrupt discontinuation of therapy.\n\nMode of action: Reduced hypnotic effect with phenytoin and carbamazepine. Increased drowsiness and incoordination with TCAs. Increased CNS depressant effect with alcohol and other CNS depressants. Decreased zopiclone concentration with rifampicin. Possible increase in zopiclone concentration with CYP3A4 inhibitors e.g. erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir.\n\nPregnancy category: Not Classified\n\nInteraction: Reduced hypnotic effect with phenytoin and carbamazepine. Increased drowsiness and incoordination with TCAs. Increased CNS depressant effect with alcohol and other CNS depressants. Decreased zopiclone concentration with rifampicin. Possible increase in zopiclone concentration with CYP3A4 inhibitors e.g. erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir.
Alpha Ketoanalogues & essential amino acids (Isoleucine, leucine, phenylalanine, valine, methionine, L-lysine, L-threonine, L-tryptophan, L-histidine, L-tyrosine, nitrogen)	\n\n\tIndication: Prevention and therapy of damages due to faulty or deficient protein metabolism in chronic renal insufficiency in connection with limited protein in food of <40 g/day (for adults) ie, generally in patients with a glomerular filtration rate (GFR) <25 mL/min.  \n\nCKD and diabetic nephropathy patients with proteinuria, creatininie clearance less than 50ml/min.\n\nChronic renal insufficiency in compensated or decompensated retention.\n\nDose: For oral use. Swallow whole.\nAdults (70 kg body weight): If not otherwise prescribed take 4-8 tablets 3 times a day during meals.\nIt is given as long as the GFR is <25 mL/min and a diet with an intake of maximum 40 g protein/day (for adults) is followed.\n\nContra-indication: Hypercalcaemia, disturbed amino acid metabolism.\nIn case of hereditary phenylketonuria, it has to be taken into account that it contains phenylalanine.\n\nSide effects: Hypercalcaemia may develop. In this case, it is recommended to decrease vitamin D intake.\nIf the hypercalcaemia persists, reduce the dosage as well as any other source of calcium.\n\nPrecaution: It should be taken during meals to allow proper absorption and metabolism into the corresponding amino acids. The serum calcium level should be monitored regularly.\nEnsure the sufficient supply with calories.\n\nUse in pregnancy & lactation: No experience has been made so far with the application in pregnancy and lactation.\nUse in children: No experience has been made so far with the application in paediatric.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
5-Fluorouracil (5-FU)	\n\n\tChoongwae Pharma Corporation,Korea\t5-Fu Injection 250mg 5 ml vial x 1's pack 38.80\n\tChoongwae Pharma Corporation,Korea\t5-Fu Injection 500mg 10 ml vial x 1's pack 75.52\n\tIndication: Palliation of malignant neoplasms, Superficial basal cell carcinoma, Oesophageal carcinoma\n\nDose: Adult: IV Palliation of malignant neoplasms 12 mg/kg/day (max: 0.8-1g/day) for 3-4 days, if no toxicity occurs, may be followed after 1 day w/ 6 mg/kg on alternate days for another 3-4 doses. May repeat course 4-6 wk later or maintenance doses of 5-15 mg/kg (max: 1 g) may be given wkly. \n\nAs an infusion: 15 mg/kg/day (max: 1 g/day), continue until toxicity occurs or a total of 12-15 g is given. May repeat course 4-6 wk later. Intra-arterial Palliation of malignant neoplasms 5-7.5 mg/kg/day as continuous infusion (regional perfusion). \n\nChild: Safety & efficacy not established.\n\nContra-indication: Topical application on mucous membranes, exposure to sunlight, hypersensitivity. Depressed bone marrow function, poor nutritional status, potentially serious infections. Pregnancy and lactation.\n\nSide effects: Leucopenia, thrombocytopaenia, stomatitis, GI ulceration, bleeding and diarrhoea, haemorrhage from any site (stop treatment). Nausea, vomiting, rashes, hyperpigmentation, alopecia. Topical: Local inflammatory and photosensitivity reactions. Dermatitis and erythema multiforme (rare).\nPotentially Fatal: Central neurotoxicity, myocardial ischaemia.\n\nPrecaution: Regular monitoring of blood counts. History of heart disease, hepatic or renal insufficiency, weak or malnourished patients, patients who with history of high-dose pelvic radiation or use of alkylating agents. Patients with widespread metastases to the bone marrow.\n\nMode of action: May increase warfarin effects. May reduce response to vaccines; possibility of generalized infection with live vaccines. Action may be modified by allopurinol. Leucovorin calcium may enhance the toxicity of fluorouracil.\n\nPregnancy category: D\n\nInteraction: May increase warfarin effects. May reduce response to vaccines; possibility of generalized infection with live vaccines. Action may be modified by allopurinol. Leucovorin calcium may enhance the toxicity of fluorouracil.
Influenza vaccine inactivated (split virion)	\n\n\tIncepta\tInfluvax Injection 15 mcg / 0.5 ml  \n\tGlaxoSmithKline Biologicals,Germany\tFluarix Vaccine 	 		 Injection  0.5 ml prefilled syringe x 1's pack 	 \n\tNovartis Vaccines & DiagnosticsS.r.l Italy\tAgrippal S1 	 		 Injection  0.5 ml prefilled syringe x 1's pack 	 650\n\tSanofi Pasteur S A ,France\tVaxigrip Injection    0.5 ml prefilled  syringe  x 1's pack 508.74\n\tIndication: Prevention of influenza caused by Influenza Virus types A and B in adults and children aged 6 months and over. \n\nDose: Adults and Children >36 months: One 0.5-mL dose.\nChildren 6-35 months: One 0.25-mL dose.\nFor children (<8 years) who have not previously been vaccinated, a 2nd dose should be given after an interval of at least 4 weeks.\nAdministration: IM route or deep SC injection. \n\nContra-indication: Known anaphylactic hypersensitivity reactions to egg proteins (eggs or egg products), chicken proteins, or any other component of the vaccine including traces (formaldehyde, octoxino\nl 9 (Triton X-100) and neomycin).\nImmunisation should not be performed during a febrile or acute illness. \n\nSide effects: In children under 5 years of age, systemic reactions (e.g. fever, malaise, myalgia) may be more pronounced. \nLocal Reactions: Erythema (redness), swelling, pain, ecchymosis, induration.\n\nSystemic Reactions: Fever, malaise, shivering, fatigue, headache, sweating, joint and muscular pain. These reactions usually disappear within 1-2 days without treatment.\n\nRarely: Neuralgia, paresthesia, convulsions and transient thrombocytopenia Allergic reactions leading to shock in rare cases. Vasculitis with transient renal involvement, in very rare cases.\n\n\n\nPrecaution: Since this vaccine contains traces of formaldehyde, octoxinol 9 (Triton X-100) and neomycin due to the use of these substances during production, it should be used with caution in subjects with a hypersensitivity to any of these substances.\nPatients with a history of Guillain-BarrÃ© Syndrome (GBS) with an onset related in time to influenza vaccination may be at increased risk of again developing GBS if given influenza vaccine.\nUse in pregnancy & lactation: Safety of use during pregnancy has not been\nestablished; benefits of vaccination should be weighed against potential risks. However, as an inactivated vaccine, it does not share the theoretical risks associated with live vaccines. \n\nIt is not known if this is excreted in human milk; hence, caution should used when administering vaccine to breastfeed ing women. However, as an inactivated vaccine, it does not share the theoretical risks associated with live vaccines. \n\nMode of action: Reduced immunological response w/ immunosuppressants.\n\nPregnancy category: C\n\nInteraction: Reduced immunological response w/ immunosuppressants.
Daclizumab	\n\n\tIndication: Acute graft rejection in renal transplantation\n\nDose: Adult and pediatric patients is 1.0 mg/kg  . The calculated volume   should be mixed with 50 mL of sterile 0.9% sodium chloride solution and administered via a peripheral or central vein over a 15-minute period.  Based on the clinical trials, the standard course   therapy is five doses. The first dose should be given no more than 24 hours before transplantation. The four remaining doses should be given at intervals of 14 days.\n\nContra-indication: Patients with known hypersensitivity to daclizumab or to any components of this product.\n\nSide effects:  Gastrointestinal System: constipation, nausea, diarrhea, vomiting, abdominal pain, pyrosis, dyspepsia, abdominal distention, epigastric pain not food-related; Metabolic and Nutritional: edema extremities, edema; Central and Peripheral Nervous System: tremor, headache, dizziness; Urinary System: oliguria, dysuria, renal tubular necrosis; Body as a Whole - General: posttraumatic pain, chest pain, fever, pain, fatigue; Autonomic Nervous System: hypertension, hypotension, aggravated hypertension; Respiratory System: dyspnea, pulmonary edema, coughing; Skin and Appendages: impaired wound healing without infection, acne; Psychiatric: insomnia; Musculoskeletal System: musculoskeletal pain, back pain; Heart Rate and Rhythm: tachycardia; Vascular Extracardiac: thrombosis; Platelet, Bleeding and Clotting Disorders: bleeding; Hemic and Lymphatic: lymphocele.\n\nPrecaution: It is not known whether  use will have a long-term effect on the ability of the immune system to respond to antigens first encountered during  induced immunosuppression.\n\nRe-administration   after an initial course of therapy has not been studied in humans. The potential risks of such re-administration, specifically those associated with immunosuppression and/or the occurrence of anaphylaxis/anaphylactoid reactions, are not known.\n\nMode of action: Increased risk of mortality when used with anti-lymphocyte antibody therapy.\n\nPregnancy category: C\n\nInteraction: Increased risk of mortality when used with anti-lymphocyte antibody therapy.
Albumin Human 5%	\n\n\tGrifols Biologicals Inc, USA\tAlbutein 5% Solution Injection   250ml 4000\n\tIndication: Burns, Hypovolemia, Hypoalbuminemia, Adult Respiratory Distress Syndrome, Nephrosis, Cardiopulmonary Bypass Surgery, Hemolytic Disease of the Newborn, Ovarian Hyperstimulation Syndrome\n\nDose: Adult: Initially, 25 g of albumin, adjusted according to patient's response. Usual rates of infusion: Up to 5 ml/minute (5% solution). \nChild: Up to 1 g/kg, adjusted according to patient's response. Usual rates of infusion: Up to 5 ml/minute (5% solution). \n\nIntravenous Hypoproteinaemia Adult: Up to 2 g/kg daily. Usual rates of infusion: Up to 5 ml/minute (5% solution). \n\nIntravenous Neonatal hyperbilirubinaemia Child: 1 g/kg of albumin before exchange transfusion. Usual rates of infusion: Up to 5 ml/minute (5% solution). \n\nSpecial Populations: Volume admin and rate of infusion must always be individualised according to situation and response. Usual rates of infusion are up to 5 ml/min (5% soln).\n\nContra-indication: Cardiac failure, severe anaemia, history of hypersensitivity, parenteral nutrition.\n\nSide effects: Allergic reactions, nausea, vomiting, increased salivation, fever and chills; vascular overload, haemodilution and pulmonary oedema.\nPotentially Fatal: Anaphylactic shock.\n\nPrecaution: Hypertension or low cardiac reserve; additional fluids for dehydrated patients. Monitor for signs of cardiac overload in injured or postoperative patients. May carry risk of viral transmission. Volume admin and rate of infusion must always be individualised according to situation and response. Pregnancy, lactation.\n\nMode of action: Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.\n\nPregnancy category: C\n\nInteraction: Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.
Albumin Human 20%	\n\n\tOctapharma Pharmazeutika mbH,Germany\tAlbumin Human 20% Infusion   50ml bot / 100ml bot 3609 / 7218\n\tIndication: Burns, Hypovolemia, Hypoalbuminemia, Hypoproteinaemia, Adult Respiratory Distress Syndrome, Nephrosis, Cardiopulmonary Bypass Surgery, Hemolytic Disease of the Newborn, Ovarian Hyperstimulation Syndrome, Acute hypovolaemic shock, Neonatal hyperbilirubinaemia\n\nDose: Adult: Initially, 25 g of albumin, adjusted according to patient's response. Usual rates of infusion: Up to 5 ml/minute (5% solution) or 1-2 ml/minute (20% solution). \nChild: Up to 1 g/kg, adjusted according to patient's response. Usual rates of infusion: Up to 5 ml/minute (5% solution) or 1-2 ml/minute (20% solution). \n\nIntravenous Hypoproteinaemia Adult: Up to 2 g/kg daily. Usual rates of infusion: Up to 5 ml/minute (5% solution) or 1-2 ml/minute (20% solution). \nIntravenous Neonatal hyperbilirubinaemia Child: 1 g/kg of albumin before exchange transfusion. Usual rates of infusion: Up to 5 ml/minute (5% solution) or 1-2 ml/minute (20% solution).\n\nSpecial Populations: Volume admin and rate of infusion must always be individualised according to situation and response. Usual rates of infusion are up to 5 ml/min (5% soln) or 1-2 ml/min (20% soln).\n\nContra-indication: Cardiac failure, severe anaemia, history of hypersensitivity, parenteral nutrition.\n\nSide effects: Allergic reactions, nausea, vomiting, increased salivation, fever and chills; vascular overload, haemodilution and pulmonary oedema.\nPotentially Fatal: Anaphylactic shock.\n\nPrecaution: Hypertension or low cardiac reserve; additional fluids for dehydrated patients. Monitor for signs of cardiac overload in injured or postoperative patients. May carry risk of viral transmission. Volume admin and rate of infusion must always be individualised according to situation and response. Pregnancy, lactation.\n\nMode of action: Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.\n\nPregnancy category: C\n\nInteraction: Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.
Albumin Human 25%	\n\n\tGrifols Biologicals Inc, USA\tAlbutein 25% Solution Injection  25% 100ml \n\tIndication: Burns, Hypovolemia, Hypoalbuminemia, Adult Respiratory Distress Syndrome, Nephrosis, Cardiopulmonary Bypass Surgery, Hemolytic Disease of the Newborn, Ovarian Hyperstimulation Syndrome, Acute hypovolaemic shock, Neonatal hyperbilirubinaemia\n\nDose: Adult: Initially, 25 g of albumin, adjusted according to patient's response. Usual rates of infusion:  1-2 ml/minute. \nChild: Up to 1 g/kg, adjusted according to patient's response. Usual rates of infusion: 1-2 ml/minute. \n\n\n\nContra-indication: Cardiac failure, severe anaemia, history of hypersensitivity, parenteral nutrition.\n\nSide effects: Allergic reactions, nausea, vomiting, increased salivation, fever and chills; vascular overload, haemodilution and pulmonary oedema.\nPotentially Fatal: Anaphylactic shock.\n\nPrecaution: Hypertension or low cardiac reserve; additional fluids for dehydrated patients. Monitor for signs of cardiac overload in injured or postoperative patients. May carry risk of viral transmission. Volume admin and rate of infusion must always be individualised according to situation and response. Pregnancy, lactation.\n\nMode of action: Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.\n\nPregnancy category: C\n\nInteraction: Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.
Alfacalcidol	\n\n\tLeo Pharmaceutical Products,Denmark\tOne Alpha CAP 0.25mcg 100'pack 1252\n\tIndication: Hypoparathyroidism, Hypocalcaemia, Renal osteodystrophy, Hypophosphataemia, Rickets or osteomalacia\n\nDose: Adult: PO Hypocalcaemia; Hypoparathyroidism; Hypophosphataemia; Renal osteodystrophy; Rickets or osteomalacia Initial: 1 mcg/day. Maintenance: 0.25-1 mcg/day.\n\nChild: Premature infants and neonates: 0.05-0.1 mcg/kg daily; <20 kg: 0.05 mcg/kg daily.\nElderly: 0.5 mcg daily.\n\nContra-indication:  Hypercalcaemia, metastatic calcification, hyperphosphataemia (except when occurring with hypoparathyroidism), hypermagnesaemia.\n\nSide effects: Anorexia, nausea, vomiting, diarrhoea, lassitude, polyuria, sweating, headache, thirst, vertigo, pruritus, rash, urticaria. Hypercalcaemia, hypercalciuria and ectopic calcification. In case of renal impairment, hyperphosphataemia. In hypercalcaemic dialysis patients, possibility of calcium influx from the dialysate should be considered.\n\nPrecaution: Pregnancy, lactation, renal impairment, infants, elderly. Monitor serum levels of calcium in patients with renal failure. Caution in hypercalciuria esp in those with history of renal calculi. Avoid in patients with hypersensitivity to inj. containing propylene glycol.\n\nMode of action: Thiazides may increase the risk of hypercalcaemia. Some antiepileptics e.g. carbamazepine, phenobarbital, phenytoin and primidone may increase vitamin D requirements. Rifampicin, isoniazid and corticosteroids may reduce the efficacy of vitamin D.\n\nPregnancy category: Not Classified\n\nInteraction: Thiazides may increase the risk of hypercalcaemia. Some antiepileptics e.g. carbamazepine, phenobarbital, phenytoin and primidone may increase vitamin D requirements. Rifampicin, isoniazid and corticosteroids may reduce the efficacy of vitamin D.
Aliskiren Hemifumarate + Hydrochlorothiazide	\n\n\tNovartis Farma SpA, Italy\tRasilez HCT 150/12.5 TAB dr   28's pack 1750\n\tIndication: Hypertension\n\nDose: Adult: PO 150 mg once daily, increased to 300 mg once daily if needed.\n\nContra-indication: History of angioedema; severe renal impairment. Concomitant use w/ ACE inhibitors or angiotensin II receptor antagonists in patients w/ DM and renal impairment (GFR <60 mL/min). Concomitant use w/ ciclosporin, itraconazole and quinidine. Pregnancy.\n\nSide effects: Diarrhoea, dyspepsia, GERD, abdominal pain, hypotension, headache, fatigue, dizziness, back pain, cough, rashes, hyperuricaemia, gout, renal calculi, hyperkalaemia, decreases in Hb levels (dose-related), angioedema and seizures.\nPotentially Fatal: Anaphylactic reactions.\n\nPrecaution: Serious CHF, sodium or volume depletion. Discontinue if diarrhoea is severe and persistent. Lactation. Monitoring Parameters Periodically monitor serum potassium concentration and renal function.\n\nMode of action: Aliskiren increased risk of hypotension w/ other antihypertensives. Increased risk of acute renal failure w/ ACE inhibitors, angiotensin II receptor antagonists or NSAIDs. Antihypertensive effect may be reduced w/ NSAIDs. Increased serum levels w/ atorvastatin, itraconazole, ketoconazole, verapamil. Significant decrease in furosemide concentrations w/ aliskiren. Increased risk of hyperkalaemia w/ potassium-sparing diuretics, potassium supplements or any substances that may increase serum potassium levels.\nPotentially Fatal: Increased risk of renal impairment, hypotension and hyperkalaemia w/ ACE inhibitors or angiotensin II receptor antagonists. Markedly increased plasma concentration w/ ciclosporin, itraconazole and quinidine.\n\nHydrochlorothiazide  increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.\n\nPregnancy category: D\n\nInteraction: Aliskiren increased risk of hypotension w/ other antihypertensives. Increased risk of acute renal failure w/ ACE inhibitors, angiotensin II receptor antagonists or NSAIDs. Antihypertensive effect may be reduced w/ NSAIDs. Increased serum levels w/ atorvastatin, itraconazole, ketoconazole, verapamil. Significant decrease in furosemide concentrations w/ aliskiren. Increased risk of hyperkalaemia w/ potassium-sparing diuretics, potassium supplements or any substances that may increase serum potassium levels.\nPotentially Fatal: Increased risk of renal impairment, hypotension and hyperkalaemia w/ ACE inhibitors or angiotensin II receptor antagonists. Markedly increased plasma concentration w/ ciclosporin, itraconazole and quinidine.\n\nHydrochlorothiazide  increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
Amino acids	\n\n\tAcme Ltd.\tAminoplex IV Infusion 5 %  \n\tIndication: Parenteral nutrition\n\nDose: Adults: The nitrogen requirement for maintenance of body protein mass depends on the patient's condition (nutritional state and degree of metabolic stress). No or minor metabolic stress and normal nutritional state: 0.10-0.15 g nitrogen/kg/day, Moderate metabolic stress with or without malnutrition: 0.15-0.20 g nitrogen/kg/day, Severe catabolism as in burns, sepsis and trauma: up to 0.20-0.25 g nitrogen/kg/day. The dosage range 0.10-0.25 g nitrogen/kg/day corresponds to 15-35 ml amino acid IV/kg/day. In obese patients, the dose should be based on the estimated ideal weight. Depending upon patients requirements, 1000-2000 ml amino acid may be infused intravenously per 24 hours. It should be infused slowly, at rates 1.4-2.8 ml (30-60 drops) per minute. Infants and Children: In children and infants, the rate of infusion is 28-35 ml/kg body wt/day is recommended, with a stepwise increment in the rate of administration during the first week of treatment.\n\nContra-indication: contraindicated in patients with inborn errors of amino acids metabolism. Moreover, amino acid should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.\n\nSide effects: It is usually well tolerated. Yet nausea, vomiting, flushing and sweating have been observed during infusion of amino acid IV at rates exceeding the recommended maximal rate. Hypersensitivity reactions have been reported. Like all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. The incidence may be reduced by the simultaneous infusion of 10% fat emulsion. If it is infused to severely ill patients, premature infants, hyperphenylalaninemia may occur.\n\nPrecaution: Hyperphenylalaninemia has been noted in severely ill, premature infants. In these patients, monitoring of the phenylalanine levels is recommended and the infusion rate adjusted as needed. Do not use if the solution is turbid or contains particles. Discard any unused portion.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Methoxsalen	\n\n\tZiska\tVitilen Lotion 10 mg/ml 1's pack 300\n\tIndication: Psoriasis, Vitiligo, Eczema, T-Cell Lymphoma\n\nDose: For topical solution dosage form:\n\nFor vitiligo:  Adults and children 12 years of age and overâApply to the affected area of the skin and allow to dry for one to two minutes, then apply again within two to two and one-half hours before UVA exposure.\n\nMethoxsalen lotion is applied only in small well-defined lesions and preferably on lesions that can be protected by clothing or sunscreen from later exposure to UVA.\n\nDo not sunbathe for 24 hours before taking methoxsalen and having the UVA light treatment.Take this medication by mouth with food or milk, usually 2 to 4 hours before your UVA light treatment or as directed by your doctor. \n\nThe dosage of methoxsalen is based on  weight, medical condition, and response to treatment. The amount and time of UVA light for each treatment is based on  skin type and response to treatment. patient may have UVA light treatments 2 to 4 times a week when first start and then less frequently as  condition improves.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea or trouble sleeping may occur with methoxsalen. Mild itching/drying/reddening/darkening of skin may occur when methoxsalen is used along with UVA light treatment.\n\nUnlikely but serious side effects occur: severe reddening of skin, blistering/peeling/burning of skin, thinning/wrinkling skin, painful browning/whitening/yellowing of nails, swelling ankles, mental/mood changes (such as depression, nervousness).\n\nPrecaution: For the treatment of psoriasis, this medication should only be used for severe psoriasis that has not responded well to other treatments since this medication may cause serious side effects (such as cataracts, skin cancer/aging).\n\nPatients must not sunbathe during the 24 hours prior to methoxsalen ingestion and UV exposure. The presence of a sunburn may prevent an accurate evaluation of the patient's response to photochemotherapy.\n\nMode of action: Additive effects with drugs known to cause photosensitisation e.g. anthralin, coal tar or derivatives, griseofulvin, phenothiazines, nalidixic acid, sulfonamides., tetracyclines and thiazide diuretics. May increase the levels/effects of aminophylline, fluvoxamine, mexiletine, mirtazapine, ropinirole, theophylline, trifluoperazine, dexmedetomidine and ifosfamide.\n\nPregnancy category: C\n\nInteraction: Additive effects with drugs known to cause photosensitisation e.g. anthralin, coal tar or derivatives, griseofulvin, phenothiazines, nalidixic acid, sulfonamides., tetracyclines and thiazide diuretics. May increase the levels/effects of aminophylline, fluvoxamine, mexiletine, mirtazapine, ropinirole, theophylline, trifluoperazine, dexmedetomidine and ifosfamide.
Anti-Rho(D) Immunoglobulin 250mcg	\n\n\tIndication: Hemolytic disease of newborn\n\nDose: For intramuscular use only. Do not inject. \nIn the case of postpartum use, the product is intended for maternal administration. Do not inject the newborn infant. Inject the entire contents of the syringe(s). For single use only.\n\nContra-indication: Contraindicated in Rh-positive individuals.\n\nSide effects: The most frequently reported AEs are anti-D formation and injection site reactions, such as swelling, induration, redness and mild pain or warmth. Possible systemic reactions are skin rash, body aches or a slight elevation in temperature. Severe systemic allergic reactions are extremely rare. Patients should be observed for at least 20 minutes after administration.\nPatients who are Rh-positive or have received Rh-positive red blood cells may result in signs and symptoms of a hemolytic reaction, including fever, back pain, nausea and vomiting, hypo- or hypertension, hemoglobinuria/emia, elevated bilirubin and creatinine and decreased haptoglobin.\n\nPrecaution: For intramuscular use only, do not inject intravenously.\nIn the case of postpartum use, the product is intended for maternal administration.\nDo not inject the newborn infant.\nPatients should be observed for at least 20 minutes after administration.\nAdminister with caution to patients who have had prior severe systemic allergic reactions to human immune globulin.\nRhoGAM / MICRhoGAM contain a small quantity og IgA. There is a potential risk of hypersensitivity in IgA deficient individuals.\nPatients treated for Rh-incompatible transfusion should be monitored by clinical and laboratory means for signs and symptoms of a hemolytic reaction.\n\nMode of action: \n\nPregnancy category: C\n\nInteraction: 
Antihemophilic Factor VIII	\n\n\tGrifols Biologicals Inc, USA\tAlphanate Injection 200-300IU 250 i. u vial 7300\n\tGrifols Biologicals Inc, USA\tAlphanate Injection 400-600IU 1's pack \n\tIndication: Hemophilia A\n\nDose: Minor hemorrhage:( Early joint or muscle bleed,Severe epistaxis)\nLoading dose 15 IU FVIII:C/kg to achieve a FVIII:C plasma level of approximately 30% of normal; one infusion may be sufficient. If needed, half of the loading dose may be given once or twice daily for 1-2 days.\n\nModerate hemorrhage:(Advanced joint or muscle bleed,Neck, tongue, or pharyngeal hematoma (without airway compromise), Tooth extraction, Severe abdominal pain )\n\nLoading dose 25 IU FVIII:C/kg to achieve a FVIII:C plasma level of approximately 50% of normal, followed by 15 IU FVIII:C/kg every 8-12 hours for the first 1-2 days to maintain the FVIII:C plasma level at 30% of normal. Continue the same dose once or twice daily for up to 7 days or until adequate wound healing is achieved.\n\nLife-threatening hemorrhage:(Major surgery, Gastrointestinal bleeding, Neck, tongue, or pharyngeal hematoma (with potential for airway compromise) , Intracranial, intraabdominal, or intrathoracic bleeding, Fractures)\n\nInitially 40-50 IU FVIII:C/kg, followed by 20-25 IU FVIII:C/kg every 8 hours to maintain the FVIII:C plasma level at 80-100% of normal for 7 days. Continue the same dose once or twice daily for another 7 days to maintain the FVIII:C level at 30-50% of normal.\n\n\nContra-indication: In individuals who have had an anaphylactic or severe systemic reaction to antihemophilic factor or von Willebrand factor preparations.\n\nSide effects: The most serious adverse reaction observed in patients receiving Antihemophilic Factor VIII is anaphylaxis. Thromboembolic events have also been observed in patients receiving Antihemophilic Factor VIII for the treatment of VWD . Reports of thromboembolic events in VWD patients with other thrombotic risk factors receiving coagulation factor replacement therapy have been obtained from spontaneous reports, published literature, and a European clinical study. In some cases, inhibitors to coagulation factors may occur. However, no inhibitor formation was observed in any of the clinical studies.\n\nIn patients receiving Antihemophilic Factor VIII in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions (including urticaria, chest tightness, rash, pruritus, and edema). For patients undergoing surgery, the most common adverse reactions are postoperative wound and injection-site bleeding, and epistaxis.\n\nPrecaution: 5.1 Thromboembolic Events (VWD Patients)\n\nThromboembolic events have been reported in VWD patients receiving Antihemophilic Factor/von Willebrand Factor Complex replacement therapy, especially in the setting of known risk factors for thrombosis.3,4 Early reports indicate a higher incidence may occur in females. Endogenous high levels of FVIII have also been associated with thrombosis, but no causal relationship has been established. Exercise caution and consider antithrombotic measures in all at-risk VWD patients who are receiving coagulation factor replacement therapy.\n\n5.2 Monitoring for Intravascular Hemolysis\n\nThis contains blood group isoagglutinins (anti-A and anti-B). When doses are very large or need to be repeated frequently (for example, when inhibitors are present or when pre- and post-surgical care is involved), monitor patients of blood groups A, B, and AB for signs of intravascular hemolysis and decreasing hematocrit values and treat appropriately.\n\n5.3 Monitoring VWF:RCo and FVIII Levels\n\nMonitor the VWF: RCo and FVIII levels of VWD patients receiving this medicine using standard coagulation tests, especially in cases of surgery. It is advisable to monitor trough VWF:RCo and FVIII:C levels at least once a day in order to adjust the dosage of this as needed to avoid excessive accumulation of coagulation factors \n\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Azathioprine	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tImuran TAB dr 50mg 100's pack  1394\n\tIndication: Rheumatoid arthritis, Prevention of rejection in organ and tissue transplantation, Auto-immune diseases, Renal homotransplantation\n\nDose: Adult: PO Rheumatoid arthritis Initial: 1 mg/kg/day for 6-8 wk. May adjust dose gradually to 2.5 mg/kg/day if needed. \nPrevention of rejection in organ and tissue transplantation 1-5 mg/kg/day. \nAuto-immune diseases 1-3 mg/kg/day.\n\nContra-indication: Hypersensitivity; previous treatment with alkylating agents; pregnancy, lactation.\n\nSide effects: Fever, chills; bone marrow depression characterised by leucopenia, thrombocytopenia or anaemia; anorexia, nausea, diarrhoea; arthralgias; secondary infections; hepatotoxicity, rash, alopoecia.\nPotentially Fatal: Myelosuppression, mutagenicity and carcinogenicity; veno-occlussive liver disease.\n\nPrecaution: Increased risk of serious infections and neoplasia in chronic immunosuppression; leucopenia, thrombocytopenia, renal or hepatic impairment. Increased risk of haematologic toxicity in patients with thiopurine methyltransferase deficiency. Monitor CBC (including platelet count) wkly during 1st mth, twice mthly for 2nd and 3rd mth, then mthly; monitor more frequently if there are dosage adjustments. Monitor LFT periodically; discontinue treatment if jaundice occurs. Reduce dose promptly or withdraw drug temporary if there is rapid decrease/persistently low WBC or signs of bone marrow depression. Dose reduction may be necessary in patients with reduced TPMT (thiopurine methyltransferase) activity.\n\nMode of action: Increased risk of haematotoxicity with aminosalicylates, drugs that affect myelopoesis e.g. co-trimoxazole or trimethoprim. Increased risk of infections with intra-uterine devices and live vaccines. Increased risk of leucopenia with ACE inhibitors. Concurrent use may reduce the anticoagulant effect of vitamin K antagonists e.g. warfarin. Increased risk of myelosuppressive effects when used with drugs that inhibit TPMT (thiopurine methyltransferase) or xanthine oxidase e.g. olsalazine, allopurinol.\nPotentially Fatal: Increased risk of serious haematotoxicity or hepatotoxicity with leflunomide. Increased risk of bone marrow suppression with mycophenolate mofetil. Increased risk of infections and malignancies with efalizumab.\n\nPregnancy category: D\n\nInteraction: Increased risk of haematotoxicity with aminosalicylates, drugs that affect myelopoesis e.g. co-trimoxazole or trimethoprim. Increased risk of infections with intra-uterine devices and live vaccines. Increased risk of leucopenia with ACE inhibitors. Concurrent use may reduce the anticoagulant effect of vitamin K antagonists e.g. warfarin. Increased risk of myelosuppressive effects when used with drugs that inhibit TPMT (thiopurine methyltransferase) or xanthine oxidase e.g. olsalazine, allopurinol.\nPotentially Fatal: Increased risk of serious haematotoxicity or hepatotoxicity with leflunomide. Increased risk of bone marrow suppression with mycophenolate mofetil. Increased risk of infections and malignancies with efalizumab.
Bacillus calmette-Guerin strain (BCG vaccine)	\n\n\tIndication: Prevention of tuberculosis, Urothelial bladder carcinoma, Carcinoma in situ\n\nDose: Intradermal\nActive immunisation against tuberculosis\nAdult: 0.2-0.3 ml (full strength dilution); conduct postvaccinal tuberculin test (5 TU of PPD) 2-3 mth later; if test is negative, repeat vaccination. Dose to be given via intradermal inj.\n\nChild: <1 mth: 0.2-0.3 ml (half-strength dilution). Conduct tuberculin test (5 TU of PPD) 2-3 mth later; repeat vaccination after 1 yr of age for negative tuberculin test if indications persist. >1 mth: 0.2-0.3 ml (full strength dilution); conduct postvaccinal tuberculin test (5 TU of PPD) 2-3 mth later; if test is negative, repeat vaccination. Dose to be given via intradermal inj. \n\nIntravesical\nImmunotherapy of bladder cancer\nDosage: The content of 1 vial is required for 1 bladder instillation.\nDuration: A standard treatment schedule consists of 1 intravesical instillation of BCG-Medac per week for 6 consecutive weeks as induction therapy. BCG treatment must not start until 2-3 weeks after transurethral resection (TUR). After a treatment-free interval of 4 weeks, intravesical administration should continue using maintenance therapy for at least 1 year. \n\nInduction Therapy (Prophylactic Treatment of Recurrence): BCG therapy should begin about 2-3 weeks after TUR or bladder biopsy, and without traumatic catheterisation, and be repeated at weekly intervals for 6 weeks. In intermediate and high-risk tumours, this should be followed by maintenance therapy.\n\nMaintenance Therapy: One schedule consists of a 12-month therapy with treatments at monthly intervals. Another maintenance scheme consists of 3 instillations at weekly intervals at month 3, 6, 12, 18, 24, 30 and 36. In this scheme, a total of 27 instillations are administered during a period of 3 years.\n\nAdministration: BCG-Medac should be administered in the conditions required for intravesical endoscopy.  The bladder must be emptied before BCG instillation. BCG-Medac is introduced into the bladder by means of a catheter and at low pressure. \n\n\nContra-indication: Hypersensitivity to any of the ingredients of BCG-Medac.\nBCG-Medac should not be used in immunosuppressed patients or persons with congenital or acquired immune deficiencies, whether due to concurrent disease (eg, positive HIV serology, leukaemia, lymphoma), cancer therapy (eg, cytostatic drugs, radiation) or immunosuppressive therapy (eg, corticosteroids).\nBCG-Medac should not be administered to persons with active tuberculosis. Active tuberculosis should be ruled out in individuals by anamnesis.\nPast history of radiotherapy of the bladder.\nBCG-Medac must not be instilled before 2-3 weeks after a TUR, a bladder biopsy or a traumatic catheterisation. Perforation of the bladder. Acute urinary tract infection (UTI) (see Precautions).\nUse in lactation: There are no adequate data from the excretion of these bacteria in breastmilk. This treatment is contraindicated in nursing women.\n\nSide effects: Side effects of BCG treatment are frequent but generally mild and transient. Adverse reactions usually increase with the number of BCG instillations.\nIn uncommon cases of arthritis/arthralgias, skin rash may occur. In most cases of arthritis, arthralgias and skin rash, these can be attributed to hypersensitivity reactions of the patient to BCG. It may be necessary in some cases to discontinue the administration of BCG-Medac.\nLocal Adverse Reactions: Discomfort and pain when urinating and frequent urination occur in up to 90% of the patients. The cystitis and inflammatory reaction (granulomata) may be an essential part of the antitumour activity.\nFurther local side effects which are uncommonly observed: Macroscopic haematuria, UTI, bladder retraction, urinary obstruction, bladder contracture, symptomatic granulomatous prostatitis, orchitis and epididymitis. Renal abscess is rarely observed. Furthermore, genital disorders (eg, vaginal pain, dyspareunia) may occur with an unknown frequency.\nTransient Systemic BCG Reaction: Low grade fever, flu-like symptoms and general discomfort may occur. These symptoms usually subside within 24-48 hrs and should be managed by standard symptomatic treatment. These reactions are signs of a starting immune reaction. All patients receiving BCG-Medac should be carefully monitored and advised to report all incidences of fever and other events outside the urinary tract.\nSevere Systemic Adverse Reactions/Infections: Systemic adverse reactions/infections are defined as: Fever >39.5Â°C during at least 12 hrs, fever >38.5Â°C during at least 48 hrs, miliary pneumonia due to BCG, granulomatous hepatitis, liver function test abnormalities, organic dysfunction (other than genitourinary tract) with granulomatous inflammation at biopsy, Reiter's syndrome. Severe systemic BCG reaction/infection can lead to BCG sepsis which is a life-threatening situation.\n\nPrecaution: BCG-Medac may not be used for SC, intradermal, IM or IV administration or vaccination.\nTreatment of Symptoms, Signs or Syndrome: See Adverse Reactions.\nNumber of BCG instillations: Side effects of BCG-treatment are frequent but generally mild and transient. Adverse reactions usually increase with the number of BCG instillations.\nSevere Systemic BCG Infection/Reaction: Systemic BCG infections/reactions have been rarely reported and are described as fever >39.5Â°C during at least 12 hrs, fever >38.5Â°C during at least 48 hrs, miliary pneumonia, granulomatous hepatitis, liver function test abnormalities, organic dysfunction (other than genitourinary tract) with granulomatous inflammation at biopsy. Reiter's syndrome. The possibility of severe systemic BCG infections has to be considered before starting the therapy.\n\nMode of action: Concurrent use with antimicrobials may interfere with efficacy of intravesicular BCG and suppress the immune response to BCG vaccination. Immune globulins may reduce the therapeutic effect of live organism vaccines. Increased risk of infections associated with vaccines (live organism) when used with immunosuppressants. Immune response of BCG vaccination may be compromised when used within 30 days of another live organism vaccine.\n\nPregnancy category: C\n\nInteraction: Concurrent use with antimicrobials may interfere with efficacy of intravesicular BCG and suppress the immune response to BCG vaccination. Immune globulins may reduce the therapeutic effect of live organism vaccines. Increased risk of infections associated with vaccines (live organism) when used with immunosuppressants. Immune response of BCG vaccination may be compromised when used within 30 days of another live organism vaccine.
Basiliximab	\n\n\tNovartis Pharma AG, Switzerland\tSimulect Injection 20mg/vial  1's pack 102884\n\tIndication: Acute graft rejection in renal transplantation\n\nDose: Intravenous\nProphylaxis of acute graft rejection in renal transplantation\nAdult: 20 mg dose given by IV bolus or infusion over 20-30 min within 2 hr prior to transplantation surgery. Repeat once 4 days later. Withhold 2nd dose if graft loss or severe hypersensitivity reaction occurs.\n\nChild: <35 kg: 10 mg dose 2 hr before surgery, repeated once 4 days later; >35 kg: same as adult dosing. Withhold 2nd dose if graft loss or severe hypersensitivity reaction occurs.\n\nContra-indication: Hypersensitivity to basiliximab and murine proteins.\n\nSide effects: Peripheral oedema, hypertension, atrial fibrillation; fever, headache, insomnia, pain; wound complication, acne; hypokalaemia, hyperglycaemia, hyperuricaemia, hypophosphataemia, hypercholesterolaemia; GI effects; UTI; anaemia; tremor; dyspnoea, infection. Rarely, hypersensitivity and anaphylactoid-type reactions.\n\nPrecaution: Pregnancy and lactation. Re-exposure to a subsequent course of therapy of basiliximab.\n\nMode of action: Immunosuppressives other than ciclosporin and corticosteroids may increase the potential for over-immunosuppression.\n\nPregnancy category: B\n\nInteraction: Immunosuppressives other than ciclosporin and corticosteroids may increase the potential for over-immunosuppression.
Benzalkonium Chloride 0.5%	\n\n\tIndication: Wound cleansing, antiseptic, disinfectant, minor cuts, scrapes, and burns, \n\nDose: Apply Dettol Anti- Septic Liquid to clean bruises or cuts before applying the medicated plaster for personal hygiene. \n\nContra-indication:  Hyper-sensitivity to any of the components.\n\nSide effects: Repeated application may cause hypersensitivity reactions. Brief stinging at the application site.\n\nPrecaution: \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Benzoyl Peroxide 4%	\n\n\tDrug International Ltd.\tBenzac Cream 4% 15gm tube 150\n\tStiefel Ptd Ltd.,Singapore\tBrevoxyl 4% Cream   40ml tube 372.30\n\tIndication: Acne vulgaris\n\nDose: Adult: Topical Acne cream: Apply 1-2 times/day. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Excessive drying of skin, allergic dermatitis. May bleach fabrics or hair. Skin discoloration; skin rash, peeling, transient local oedema.\n\nPrecaution: Discontinue if severe irritation develops. Restart with tolerable levels of treatment after irritiation has cleared. Do not use occlusive dressing. May cause dermatitis in allergic patients. Apply carefully near the eyes, mouth, neck and other mucous membranes as well as other sensitive areas.\n\nMode of action: PABA sunscreens may transiently discolour fabric.\n\nPregnancy category: C\n\nInteraction: PABA sunscreens may transiently discolour fabric.
Betahistine Dihydrochloride	\n\n\tIncepta\tMenaril 8 TAB dr 8mg 100's pack 200\n\tIncepta\tMenaril 16 TAB dr 16 mg 50's 200\n\tOpsonin Pharma\tTiniril TAB dr 8mg 100's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tVeserc TAB dr 8mg 50's pack 150\n\tUnimed & Unihealth Manufacturers Ltd.\tVeserc TAB dr 16mg 50's pack 250\n\tIndication: Meniere's disease, tinnitus and/or progressive loss of hearing, vertigo, dizziness.\n\nDose: Adult: Initially, 8-16 mg tid. Maintenance: 24-48 mg daily.\n\nContra-indication: Phaeochromocytoma. Porphyria.\n\nSide effects: Rash, pruritus, urticaria, dyspepsia, nausea, peptic ulcer disease, headache, dizziness, insomnia.\n\nPrecaution: Active peptic ulcer, bronchial asthma, pregnancy and lactation.\n\nMode of action: May antagonise antihistamines. May decrease bronchodilator effects of ?-2 agonists.\n\nPregnancy category: C\n\nInteraction: May antagonise antihistamines. May decrease bronchodilator effects of ?-2 agonists.
Bevacizumab	\n\n\tBeacon\tBevastim Injection 400 mg/16 ml  \n\tMade for F. Hoffmann-La RocheLtd. Switzerland By RocheDiagnostic GmbH Germany\tAvastin Injection 100mg/4ml 4ml amp x 1's pack 54731\n\tIndication: Colo-rectal cancer, Lung cancers, Renal cancers, Ovarian cancers, Breast cancers and glioblastoma multiforme of the brain, Exudative ARMD\n\nDose: General: Avastin should be prepared by a healthcare professional using aseptic technique. The initial Avastin dose should be delivered over 90 min as an IV infusion. If the 1st infusion is well tolerated, the 2nd infusion may be administered over 60 min. If the 60-min infusion is well tolerated, all subsequent infusions may be administered over 30 min.\nDose reduction of Avastin for adverse events is not recommended. If indicated, Avastin should either be permanently discontinued or temporarily suspended (see Precautions).\nMetastatic Colorectal Cancer (mCRC): The recommended dose of Avastin, administered as an IV infusion, is as follows: First-line Treatment: 5 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg of body weight given once every 3 weeks. Second-line Treatment: 10 mg/kg of body weight given every 2 weeks or 15 mg/kg of body weight given once every 3 weeks.\nIt is recommended that Avastin treatment be continued until progression of the underlying disease.\nLocally Recurrent or Metastatic Breast Cancer (mBC): The recommended dose of Avastin is 10 mg/kg of body weight given once every 2 weeks or 15 mg/kg of body weight given once every 3 weeks as an IV infusion. Clinical benefit in mBC patients has also been demonstrated at a dose of 7.5 mg/kg of body weight given once every 3 weeks as an IV infusion. For details refer to Locally Recurrent or Metastatic Breast Cancer (mBC) under Pharmacology under Actions.\nIt is recommended that Avastin treatment be continued until progression of the underlying disease.\nAdvanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC): Avastin is administered in addition to platinum-based chemotherapy for up to 6 cycles of treatment followed by Avastin as a single agent until disease progression.\nThe recommended dose of Avastin when used in addition to cisplatin-based chemotherapy is 7.5 mg/kg of body weight given once every 3 weeks as an IV infusion.\nThe recommended dose of Avastin when used in addition to carboplatin-based chemotherapy is 15 mg/kg of body weight given once every 3 weeks as an IV infusion.\nAdvanced and/or Metastatic Renal Cell Cancer (mRCC): The recommended dose of Avastin is 10 mg/kg of body weight given once every 2 weeks as an IV infusion.\nIt is recommended that Avastin treatment be continued until progression of the underlying disease.\nMalignant Glioma (WHO Grade IV)-Glioblastoma: The recommended dose of Avastin is 10 mg/kg of body weight given once every 2 weeks or 15 mg/kg of body weight given once every 3 weeks as an IV infusion.\nEpithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer: The recommended dose is 15 mg/kg of body weight given once every 3 weeks.\n\nExudative age-related macular degeneration\n\n1.25 mg (in 0.05mL of solution) administered by intravitreal injection once monthly \n\n\nContra-indication: Hypersensitivity to any component\n\nRecent hemoptysis \n\nSide effects: Weakness (73-74%)\n\nHypertension (23-67%; grades 3/4: 8-18%)\n\nPain (61-62%)\n\nAbdominal pain (50-61%; grades 3/4: 8%)\n\nVomiting (47-52%, grades 3/4:6-11%)\n\nURI (40-47%)\n\nConstipation (29-40%)\n\nLeukopenia (grades 3/4: 37%)\n\nProteinuria (36%, grades 3/4: 3%)\n\nEpistaxis (32-35%)\n\nOvarian failure (with mFolfox) (34%)\n\nDiarrhea (grades 3/4: 2-34%)\n\nStomatitis (30-32%)\n\nAlopecia (6-32%)\n\nNeutropenia (grades 3/4: 6-27%)\n\nHeadache (26%; grades 3/4: 2-4%)\n\nDyspnea (25-26%)\n\nDizziness (19-26%)\n\nGI hemorrhage (19-24%)\n\nDyspepsia (17-24%)\n\nTaste alteration (14-21%)\n\nDry skin (7-20%)\n\nExfoliative dermatitis (3-19%)\n\nFatigue (grades 3/4: 5-19%)\n\nFlatulence (11-19%)\n\nLacrimation disorder (6-18%)\n\nNeuropathy (grades 3/4: 1-17%)\n\nWeight loss (15-16%)\n\nHypokalemia (12-16%)\n\nSkin discoloration (2-16%)\n\nThromboembolic events (grades 3/4: 15%)\n\nMyalgia (8-15%)\n\nHypotension (7-15%)\n\nNausea (grades 3/4: 4-12%)\n\nBack pain (undefined)\n\nPrecaution: Gastrointestinal perforations\n\n    Gastrointestinal (GI) perforation, fistula formation, and/or intra-abdominal abscess unrelated to therapy duration reported in patients with colorectal cancer as well as other types of cancers\n    Typical presentation reported as abdominal pain associated with symptoms such as constipation and vomiting\n    Include GI perforation in the differential diagnosis of patients presenting with abdominal pain\n    Discontinue therapy permanently in patients with GI perforation\n\nWound healing complications\n\n    Administration may result in the development of fatal wound dehiscence\n    Discontinue therapy in patients with wound dehiscence requiring medical intervention\n\nHemorrhage\n\n    Fatal pulmonary hemorrhage can occur in patients with non-small cell lung cancer treated with chemotherapy and bevacizumab\n    Do not administer the drug to patients with recent hemoptysis (at least 2.5 mL of red blood)\n\n\nMode of action: Irinotecan/5âfluorouracil/leucovorin\nThe incidence of epistaxis and grade 1 or 2 hemorrhage (including GI hemorrhage, minor gum bleeding, vaginal hemorrhage) was greater in patients receiving bevacizumab plus irinotecan/5-fluorouracil/leucovorin compared with patients receiving irinotecan/5-fluorouracil/leucovorin plus placebo. Closely monitor the patient during coadministration.\n\nLive vaccines\nThe administration of live vaccines to patients receiving bevacizumab may result in a reduced immune response. Avoid coadministration.\n\nPaclitaxel\nDecreased paclitaxel exposure was seen when paclitaxel/carboplatin was given in combination with bevacizumab. Closely monitor the patient during coadministration.\n\nSunitinib\nCoadministration of bevacizumab and sunitinib has been reported to cause unexpected severe toxicity (eg, microangiopathic hemolytic anemia). Coadministration of sunitinib and bevacizumab is not recommended.\n\nPregnancy category: C\n\nInteraction: Irinotecan/5âfluorouracil/leucovorin\nThe incidence of epistaxis and grade 1 or 2 hemorrhage (including GI hemorrhage, minor gum bleeding, vaginal hemorrhage) was greater in patients receiving bevacizumab plus irinotecan/5-fluorouracil/leucovorin compared with patients receiving irinotecan/5-fluorouracil/leucovorin plus placebo. Closely monitor the patient during coadministration.\n\nLive vaccines\nThe administration of live vaccines to patients receiving bevacizumab may result in a reduced immune response. Avoid coadministration.\n\nPaclitaxel\nDecreased paclitaxel exposure was seen when paclitaxel/carboplatin was given in combination with bevacizumab. Closely monitor the patient during coadministration.\n\nSunitinib\nCoadministration of bevacizumab and sunitinib has been reported to cause unexpected severe toxicity (eg, microangiopathic hemolytic anemia). Coadministration of sunitinib and bevacizumab is not recommended.
Bisoprolol	\n\n\tACI\tProbis TAB dr 2.5mg 30's pack 180.60\n\tACI\tProbis TAB dr 5mg 30's pack 300.90\n\tAcme Ltd.\tBetabis TAB dr 2.5mg 30's pack 180\n\tAcme Ltd.\tBetabis TAB dr 5mg 30's pack 300\n\tAristopharma\tAncor F/C TAB dr 2.5mg 30's pack 180\n\tAristopharma\tAncor F/C TAB dr 5mg 30's pack 300\n\tAristopharma\tAncor TAB dr 10mg 10's pack 160\n\tBeximco\tBetapro TAB dr 2.5mg  \n\tBeximco\tBetapro TAB dr 5mg  \n\tBeximco\tBetapro TAB dr 10mg  \n\tBio Pharma Ltd.\tMyocor TAB dr 2.5mg 3x10's pack 158.35\n\tConcord\tAcubis 5 TAB dr 5mg 30's pack \n\tConcord\tAcubis 2.5 TAB dr 2.5mg 30's pack \n\tDrug International Ltd.\tTenobis TAB dr 2.5mg 50's pack 300\n\tDrug International Ltd.\tTenobis TAB dr 5mg 30's pack 300\n\tEskayef Bangladesh Ltd.\tCardobis TAB dr 2.5mg  \n\tEskayef Bangladesh Ltd.\tCardobis TAB dr 5mg  \n\tGeneral\tMyocard TAB dr 2.5mg  \n\tGeneral\tMyocard TAB dr 5mg  \n\tGeneral\tMyocard TAB dr 10mg  \n\tHealthcare\tBetafix TAB dr 2.5mg  \n\tHealthcare\tBetafix TAB dr 5mg  \n\tHealthcare\tBetafix TAB dr 10mg  \n\tIncepta\tBisopro TAB dr 2.5mg 30's pack 180\n\tIncepta\tBisopro TAB dr 5mg 30's pack 300\n\tLabaid\tCardinor TAB dr 2.5mg 30's pack 180\n\tLabaid\tCardinor-5 TAB dr 5mg 3x10's pack 300\n\tNavana\tTabis TAB dr 2.5mg 30's pack \n\tNavana\tTabis TAB dr 5mg 30's pack \n\tNIPRO JMI Pharma\tBisopress TAB dr 2.5mg 30's pack 180\n\tOpsonin Pharma\tBislol TAB dr 10mg 30's pack 480\n\tOpsonin Pharma\tBislol TAB dr 2.5mg 30's pack 180\n\tOpsonin Pharma\tBislol TAB dr 5mg 30's pack 300\n\tOrion Pharma Ltd.\tBisoloc TAB dr 2.5mg 30's pack 180\n\tOrion Pharma Ltd.\tBisoloc TAB dr 5mg 30's pack 300\n\tPharmasia Ltd.\tBisotab TAB dr 2.5mg  \n\tPharmasia Ltd.\tBisotab TAB dr 5mg  \n\tPharmasia Ltd.\tBisotab TAB dr 10mg  \n\tPopular\tBisu TAB dr 10mg 30's pack 780\n\tPopular\tBisu TAB dr 2.5mg 30's pack 369\n\tPopular\tBisu TAB dr 5mg 30's pack 492.30\n\tPopular\tBetacor 2.5 TAB dr 2.5 mg 3x10's pack 180\n\tPopular\tBetacor 5 TAB dr 5 mg 3x10's pack 300\n\tPopular\tBetacorÂ 10 TAB dr 10mg 3x10's pack \n\tRAK\tConbis TAB dr 2.5mg 30's pack 180\n\tRAK\tConbis TAB dr 5mg 30's pack 300\n\tRenata\tBisoren TAB dr 2.5mg 30's pack 180\n\tRenata\tBisoren TAB dr 5mg 30's pack\n 300\n\tSharif\tB-Prolol TAB dr 2.5mg 30's pack 180\n\tSharif\tB-prolol TAB dr 5mg 30's pack 300\n\tSquare\tBisocor TAB dr 10mg 10's pack 160.67\n\tSquare\tBisocor TAB dr 2.5mg 30's pack 180.74\n\tSquare\tBisocor TAB dr 5mg 30's pack 301.24\n\tUnimed & Unihealth Manufacturers Ltd.\tCardicor TAB dr 2.5mg 30's pack 180\n\tUnimed & Unihealth Manufacturers Ltd.\tCardicor TAB dr 5mg 30's pack 300\n\tWhite Horse Pharma\tBisonat TAB dr 2.5mg  \n\tMerck KGaA, Germany\tConcor TAB dr 10mg 30's pack 780\n\tIndication: Hypertension, Angina pectoris;  Congestive heart failure					\n\n\nDose: The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.\n\nFor heart failure: Initially 1.25 mg once daily (in the morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily; max. 10 mg daily. \n\nRenal impairment:\nCrCl (ml/min)	\n<40	Initial: 2.5 mg/day.\n\nHepatic impairment: Severe: Initially, 2.5 mg/day. Max: 10 mg/day.\n\nContra-indication: Patients with cardiogenic shock, overt cardiac failure, second or third degree AV block and marked sinus bradycardia.\n\nSide effects: Diarrhoea, dizziness, drowsiness, fatigue, headache, lightheadedness, nausea, sleeplessness, unusual tiredness, weakness, Severe allergic reactions (rash, hives, itching, difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue), chest pain, difficulty breathing, lightheadedness or dizziness when rising from a lying or sitting position, very slow heartbeat.\n\nPrecaution: Impaired Renal or Hepatic Function.\n\nMode of action: May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.\n\nPregnancy category: D\n\nInteraction: May potentiate AV conduction time and may increase negative inotropic effect w/ class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive sympathetic activity. May exacerbate rebound HTN upon discontinuance of clonidine treatment. Increased risk of bradycardia w/ digitalis glycosides. Reduced hypotensive effect w/ NSAIDs.
Bleomycin	\n\n\tNippon Kayaku Co Ltd,.Japan\tBleocin Injection 15mg/vial 1 amps pack 1121.75\n\tIndication: Lymphoma, Squamous cell or Testicular tumours, Malignant effusions\n\nDose: Parenteral\nSquamous cell or testicular tumours\nAdult: 15,000 IU 3 times a wk or 30,000 IU twice a wk IM/IV, repeated at usual intervals of 3-4 wk up to a total cumulative dose of 500,000 IU.\nElderly: Dose reduction is necessary.\nIntramuscular\nLymphoma\nAdult: 15,000 IU once or twice a wk, up to a total cumulative dose of 225,000 IU.\nElderly: Dose reduction is necessary.\nInjection\nMalignant effusions\nAdult: 60,000 IU in 100 ml of 0.9% sodium chloride instilled into the affected serous cavity, may be repeated up to a total cumulative dose of 500,000 IU.\nElderly: Dose reduction is necessary.\n\nContra-indication:  	Hypersensitivity. Severe pulmonary disease; pregnancy and lactation.\n\nSide effects: Fever, thrombophloebitis (inj). Acute anaphylactoid reactions, hyperpyrexia. Rash, erythema, pruritus, vesiculation, hyperkeratosis, nail changes, alopecia, hyperpigmentation, striae, stomatitis.\nPotentially Fatal: Pulmonary toxicity, interstitial pneumonitis, fibrosis, cardiorespiratory collapse in patients with lymphoma.\n\nPrecaution: Pulmonary infection, preexisting pulmonary function impairment, renal impairment. Patients who received radiotherapy, particularly to the thorax. Regular chest x-rays should be done. Elderly. Discontinue treatment if chest x-rays show infiltrates or breathlessness occurs.\n\nMode of action: Increased incidence and severity of lung toxicity w/ previous or concurrent radiotherapy to the chest. Combination w/ vinca alkaloids may result to a syndrome corresponding to morbus Raynaud, ischaemia which can lead to necrosis of peripheral parts of the body (fingers, toes, nose tip). May reduce the absorption of phenytoin. Increased risk of agranulocytosis w/ clozapine.\nPotentially Fatal: Increased pulmonary toxicity w/ oxygen, cisplatin or brentuximab.\n\nPregnancy category: D\n\nInteraction: Increased incidence and severity of lung toxicity w/ previous or concurrent radiotherapy to the chest. Combination w/ vinca alkaloids may result to a syndrome corresponding to morbus Raynaud, ischaemia which can lead to necrosis of peripheral parts of the body (fingers, toes, nose tip). May reduce the absorption of phenytoin. Increased risk of agranulocytosis w/ clozapine.\nPotentially Fatal: Increased pulmonary toxicity w/ oxygen, cisplatin or brentuximab.
Brimonidine Tartrate  +  Benzalkonium Chloride	\n\n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: The recommended dose is one drop   in the affected eye(s) three times daily. Shake well before use.Ophthalmic suspension may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.\n\nContra-indication: Hypersensitivity. Patients receiving MAO inhibitor therapy.\n\nSide effects: Oral dryness; ocular hyperaemia, burning and stinging; headache, blurring of vision; foreign body sensation, fatigue or drowsiness; conjunctival follicles, ocular allergic reactions and ocular pruritus. Corneal staining or erosion, photophobia, eyelid erythema, ocular ache and pain, ocular dryness, tearing; upper respiratory symptoms; eyelid oedema, conjunctival oedema, dizziness, blepharitis, ocular irritation; GI symptoms; asthaenia; conjunctival blanching, abnormal vision and muscular pain.\n\nPrecaution: Patients wearing soft contact lenses should wait for at least 15 min after instilling brimonidine tartrate before inserting soft contact lenses. Renal or hepatic impairment. CV disease. Use with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangitis obliterans. Pregnancy, lactation.\n\nMode of action: Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with beta-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.\n\nPregnancy category: B\n\nInteraction: Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with beta-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.
Brinzolamide 1%  Eye prep	\n\n\tAristopharma\tBrinzopt Eye Drops 1% 5  ml drop 500\n\tOpso Saline Ltd.\tBrinz Eye Drops 10 mg/ml  \n\tPopular\tBenozol Eye Drops 1% 5 ml drop 500\n\tIndication: Open-angle glaucoma , ocular hypertension				\n\n\nDose: Adult: Ophth Open-angle glaucoma; Ocular HTN As 1% susp: Instill 1 drop 2-3 times/day.\n\nContra-indication: Brinzolamide 1% ophthalmic suspension is contraindicated in patients who are hypersensitive to any component of this product.\n\nSide effects: Conjunctivitis; keratitis; burning or stinging; eyelid inflammation or irritation; blurred vision; corneal erosion; headache; dizziness; paraesthesia; nausea; bitter taste; epistaxis; fatigue; dyspepsia; dry mouth; chest pain; haemoptysis; dyspnoea; rhinitis; pharyngitis; bronchitis; depression; dermatitis; alopoecia.\n\nPrecaution: Hepatic and renal impairment; pregnancy. Efficacy has not been established in angle-closure glaucoma. Ensure an interval of at least 10 minutes between admin of different ophthalmic solutions.\n\nMode of action: Brinzolamide: Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.\n\nPregnancy category: C\n\nInteraction: Brinzolamide: Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.
Bromocriptine	\n\n\tNovartis (Bangladesh) Ltd.\tBromergon TAB dr 2.5mg 60's pack 840\n\tNovartis (Bangladesh) Ltd.\tParlodel TAB dr 2.5mg 30's pack \n\tNuvista Pharma Ltd\tBromotine TAB dr 2.5mg 30's pack 330.90\n\tOpsonin Pharma\tBromodel TAB dr 2.5mg 30's pack 265\n\tRenata\tCriptine TAB dr 2.5mg 30's pack 360\n\tSquare\tBromolac TAB dr 2.5mg 30's pack 360\n\tChemial Works of Gedeon RichterLtd., Hungary\tBromocriptin -Richter TAB dr  2.5 30's pack 636\n\tIndication:  Parkinson's disease, Galactorrhoea; Hypogonadism; Infertility, acromegaly, Lactation suppression, benign breast and menstrual disorders, Amenorrhea, hyperprolactinaemia							\n.\n\nDose: Adult: PO Parkinson's disease As adjunct to levodopa: 1st wk: 1-1.25 mg at night, 2nd wk: 2-2.5 mg at night; 3rd wk: 2.5 mg twice daily; 4th wk: 2.5 mg 3 times/day, then increase as needed. \n\nMaintenance: 10-40 mg/day. Galactorrhoea; Hypogonadism; Infertility 1-1.25 mg at bedtime, increase gradually. Max: 30 mg/day. \n\nAdjunct to surgery and radiotherapy in patients w/ acromegaly Initial: 2.5 mg twice daily, increase slowly, up to 5 mg 6 hrly if needed. Lactation suppression 2.5 mg/day for 2-3 days, up to 2.5 mg twice daily for 14 days. \n\nPrevention of puerperal lactation 2.5 mg on the day of delivery, then 2.5 mg twice daily for 14 days. Cyclical benign breast and menstrual disorders 2.5 mg twice daily.\n\nContra-indication: Breast carcinoma, hypersensitivity to ergot alkaloids, uncontrolled hypertension, severe ischaemic heart disease. Pregnancy and lactation.\n\nSide effects: Nausea, vomiting, gastric haemorrhage (acromegaly), dizziness, headache, drowsiness, depression, postural hypotension, nasal congestion, pleural effusion, mania, ataxia. High doses produce confusion, hallucinations, delirium, psychosis.\n\nPrecaution: Increased risk of conception, patients with peptic ulcer, diabetes, diabetic retinopathy, impaired hepatic or renal function, pleuropulmonary signs and symptoms, history of psychosis, CV disease, dementia or concurrent antihypertensive therapy, ability to drive vehicles or operating machinery may be impaired.\n\nMode of action: Bioavailability increased if given along with erythromycin. Alcohol reduces tolerance to bromocriptine and vice-versa. Effects of antihypertensives may be potentiated. Avoid concurrent psychotropics.\n\nPregnancy category: B\n\nInteraction: Bioavailability increased if given along with erythromycin. Alcohol reduces tolerance to bromocriptine and vice-versa. Effects of antihypertensives may be potentiated. Avoid concurrent psychotropics.
Busulphan	\n\n\tExcella, Germany\tMyleran TAB dr 2mg 100's pack 1030\n\tIndication: Chronic myeloid leukaemia,  Bone marrow transplantation, Polycythemia vera, Essential thrombocythemia, \n\nDose: Oral\nPalliative treatment of chronic myeloid leukemia\nAdult: 60 mcg/kg daily. Maintenance: 0.5-2 mg daily. Max: 4 mg daily.\n\nPolycythemia vera\nAdult: 4-6 mg daily continued for 4-6 wk with blood counts monitoring.\n\nEssential thrombocythemia\nAdult: 2-4 mg daily.\n\nConditioning regimens for bone marrow transplantation\nAdult: 3.5-4 mg/kg daily in divided doses for 4 days up to a total dose of 14-16 mg/kg. Usually used with cyclophosphamide for ablation of recipient's bone marrow.\n\nContra-indication: Pregnancy and lactation. Hypersensitivity.\n\nSide effects: GI symptoms, anorexia, wt loss, weakness, hyperpigmentation, amenorrhoea, cataracts, cough or hoarseness, impaired fertility and gonadal function, dry skin, liver damage, gynaecomastia.\nPotentially Fatal: Bone marrow depression manifesting as thrombocytopaenia, leucopaenia, anaemia. Interstitial pulmonary fibrosis (known as "busulfan lung" on prolonged treatment).\n\nPrecaution: Prior treatment with other myelosuppressive drugs, patients predisposed to seizures. May cause secondary malignancies (tumors, acute leukaemias, ovarian failure). Previous irradiation/therapy. Monitor blood counts carefully during therapy. Discontinue if lung toxicity develops.\n\nMode of action:  	Decreased clearance when used with cyclophosphamide and itraconazole. Increased clearance by phenytoin. May reduce response to vaccines, possibility of generalized infections with live vaccines. Combination with thioguanine results in oesophageal varices and abdominal liver function tests.\nPotentially Fatal: Cytotoxic agents may increase risk of pulmonary toxicity.\n\nPregnancy category: D\n\nInteraction:  	Decreased clearance when used with cyclophosphamide and itraconazole. Increased clearance by phenytoin. May reduce response to vaccines, possibility of generalized infections with live vaccines. Combination with thioguanine results in oesophageal varices and abdominal liver function tests.\nPotentially Fatal: Cytotoxic agents may increase risk of pulmonary toxicity.
Cabazitaxel accton solvate	\n\n\tIndication: Metastatic prostate cancer\n\nDose: The individual dosage  is based on calculation of the Body Surface Area (BSA) and is 25 mg/mÂ² administered as a one-hour intravenous infusion every three weeks in combination with oral prednisone 10 mg administered daily throughout treatment.\n\nProlonged grade ? 3 neutropenia  : Delay treatment until neutrophil count is\n> 1,500 cells/mm3, then reduce dosage  to 20 mg/m2.\n\nFebrile neutropenia : Delay treatment until improvement or resolution, and until neutrophil count is\n> 1,500 cells/mm3, then reduce dosage  to 20 mg/m2. \n\nGrade  3 diarrhea or persisting diarrhea despite appropriate medication, fluid and electrolytes replacement : Delay treatment until improvement or resolution, then reduce dosageto 20 mg/m2.\n\nContra-indication: -Patients with neutrophil counts of  > 1,500/mm3.\n\n-Patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.\n\nSide effects: Most common all grades adverse reactions (>10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.\n\nPrecaution:     Neutropenia, febrile neutropenia: Neutropenic deaths have been reported. Monitor blood counts frequently to determine if initiation of G-CSF and/or dosage modification is needed. Primary prophylaxis with G-CSF should be considered in patients with high-risk clinical features. \n    Hypersensitivity: Severe hypersensitivity reactions can occur. Premedicate with corticosteroids and H2 antagonists. Discontinue infusion immediately if hypersensitivity is observed and treat as indicated. \n    Gastrointestinal disorders: Nausea, vomiting, and diarrhea may occur. Mortality related to diarrhea has been reported. Rehydrate and treat with anti-emetics and anti-diarrheals as needed. If experiencing Grade  3 diarrhea, dosage should be modified. Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis. Delay or discontinue.\n    Renal failure, including cases with fatal outcomes, has been reported. Identify cause and manage aggressively. \n    Elderly patients: Patients > 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia. Monitor closely.\n    Hepatic impairment: Patients with impaired hepatic function were excluded from the randomized clinical trial. Hepatic impairment is likely to increase the cabazitaxel concentrations. It should not be given to patients with hepatic impairment. \nIt can cause fetal harm when administered to a pregnant woman. \n\n\nMode of action: Increased conc w/ strong CYP3A inhibitors (eg ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) & decreased conc w/ CYP3A inducers (eg phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarb). Serious or fatal infections w/ live or live attenuated vaccines. Risk of interaction w/ OATP1B1 substrates (eg statins, valsartan, repaglinide) during 1-hr & 20 min after infusion.\n\nPregnancy category: D\n\nInteraction: Increased conc w/ strong CYP3A inhibitors (eg ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) & decreased conc w/ CYP3A inducers (eg phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarb). Serious or fatal infections w/ live or live attenuated vaccines. Risk of interaction w/ OATP1B1 substrates (eg statins, valsartan, repaglinide) during 1-hr & 20 min after infusion.
Calcipotriol	\n\n\tIncepta\tPlanex Ointment 0.05mg/gm 10 gm tube 200\n\tSquare\tDyvon Cream 0.001%  20gm pack  350\n\tSquare\tDyvon Ointment 0.005%  20gm pack  350\n\tLeo Pharmaceutical Products,Denmark\tDaivonex Ointment Ointment 50mcg 30gm pack 1377.98\n\tLeo Pharmaceutical Products,Denmark\tDaivonex Cream 50mcg/gm 30gm pack 1377.98\n\tLeo Pharmaceutical Products,Denmark\tDaivonex Scalp Solution 50mcg/ml 30ml bot 1377.88\n\tIndication: Plaque psoriasis, Scalp  psoriasis, Alopecia areata\n\nDose: Adult: Topical Plaque psoriasis As 0.005% cream/oint: Apply 1-2 times/day. Max: 100 g per wk. \n\nScalp psoriasis As 0.005% soln: Apply 1-2 times/day. Max: 60 mL per week.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Skin irritation, erythema, scaling; hypercalcemia w/ high doses.\n\nPrecaution: Not to be applied on the face; pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Certoparin	\n\n\tIndication: Pulmonary embolism, Thromboembolism, Deep venous thrombosis\n\nDose: Adult: IV Unstable angina; Venous thromboembolism; Peripheral arterial embolism Loading dose: 5,000 u, then 1,000-2,000 u/hr. \n\nPrevention of re-occlusion of the coronary arteries following thrombolytic therapy in MI 5,000 u, then 1,000 u/hr w/ alteplase. SC Venous thromboembolism 15,000 u 12 hrly. \n\nPrevention of post-op venous thromboembolism 5,000 u 2 hr before surgery, then 8-12 hrly for 7 days or until patient is ambulant. Prevention of mural thrombosis 12,500 u 12 hrly for at least 10 days.\n\nContra-indication: Patients predisposed to active bleeding including thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, haemorrhagic blood disorders, bacterial endocarditis, severe hypertension, oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage, abdominal or thoracic bleeding into closed space, severe traumatic bleed, hepatic, renal, splenic or arterial injury, severe haemostatic defect, arterial thrombosis with heparin-associated thrombocytopenia. IM admin.\n\nSide effects: Slight fever, headache, chills, nausea, vomiting, constipation, epistaxis, bruising, slight haematuria, skin necrosis (SC inj), osteoporosis, alopecia. Hypersensitivity reactions include urticaria, conjunctivitis, rhinitis, asthma, angioedema and anaphylactic shock. Priapism.\nPotentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding.\n\nPrecaution: Monitor platelet counts. Discontinue treatment if thrombocytopenia occurs. Hypersensitivity, elderly, pregnancy.\n\nMode of action: Enhanced anticoagulant effect w/ other drugs affecting platelet function or the coagulation system (e.g. platelet aggregation inhibitors, thrombolytic agents, salicylates, NSAIDs, vit K antagonists, dextrans, activated protein C). Decreased anticoagulant effect w/ gyceryl trinitrate infusion. Increased risk of hyperkalaemia w/ ACE inhibitors or angiotensin II antagonists.\n\nPregnancy category: C\n\nInteraction: Enhanced anticoagulant effect w/ other drugs affecting platelet function or the coagulation system (e.g. platelet aggregation inhibitors, thrombolytic agents, salicylates, NSAIDs, vit K antagonists, dextrans, activated protein C). Decreased anticoagulant effect w/ gyceryl trinitrate infusion. Increased risk of hyperkalaemia w/ ACE inhibitors or angiotensin II antagonists.
Cetrorelix	\n\n\tJanata Pharma\tCetrotide Injection 0.25mg 7's pack 22958.95\n\tIndication: Assisted reproductive technologies, In-vitro fertilization\n\nDose: Adult: SC 250 mcg/day, given either in the morning beginning on the day 5 or 6 of ovarian stimulation or in the evening beginning on day 5, and continued until ovulation induction.\n\nContra-indication: Hypersensitivity. Moderate to severe renal or hepatic impairment. Women with severe allergic conditions. Pregnancy and lactation;\n\nSide effects: Mild and transient reactions at Inj site, nausea, headache, ovarian hyperstimulation syndrome, systemic hypersensitivity reactions.\n\nPrecaution: Women with active allergic conditions or a history of allergies; childn; elderly >65 yrs\n\nMode of action: In vitro investigations have shown that interactions are unlikely with medications that are metabolised by cytochrome P-450 or glucuronised or conjugated in some other way. However, the possibility of interactions with commonly used medicinal products can not entirely be excluded.\n\nPregnancy category: X\n\nInteraction: In vitro investigations have shown that interactions are unlikely with medications that are metabolised by cytochrome P-450 or glucuronised or conjugated in some other way. However, the possibility of interactions with commonly used medicinal products can not entirely be excluded.
Chlorambucil	\n\n\tExcella, Germany\tLeukeran TAB dr 2mg 25's pack 1137\n\tIndication: Lymphocytic leukemia, non-Hodgkin lymphoma, Waldenstrm macroglobulinemia, polycythemia vera, trophoblastic neoplasms, ovarian carcinoma, nephrotic syndrome, Hodgkin's disease 							\n\n\nDose: Adult: PO Hodgkin's disease 200 mcg/kg/day. Maintenance: 30-100 mcg/kg/day. Non-Hodgkin's lymphoma 100 mcg/kg/day. Maintenance: 30-100 mcg/kg/day. \n\nChronic lymphocytic leukaemia 100-200 mcg/kg/day for 3-8 wk. Maintenance: 30-100 mcg/kg/day. Waldenstrom's macroglobulinaemia Initial: 6-12 mg/day until leucopenia develops. Maintenance: 2-8 mg/day.\n\nContra-indication: Hypersensitivity. Pregnancy and lactation. Porphyria.\n\nSide effects: Reversible progressive lymphocytopenia and neutropenia; GI disturbances; hepatotoxicity; skin rashes; peripheral neuropathy; central neurotoxicity including seizures; interstitial pneumonia, pulmonary fibrosis. High doses may produce azoospermia and amenorrhoea. Sterility when given to boys at or before puberty.\nPotentially Fatal: Severe bone marrow suppression, carcinogenic and human infertility.\n\nPrecaution: Renal or hepatic dysfunction. Perform blood counts regularly. Seizure disorder, bone marrow suppression. Patient who has received radiation therapy, myelosuppressive drugs or has a depressed baseline leukocyte/platelet count within the previous 4 wk. Increased incidence of acute leukaemias and other secondary malignancies.\n\nMode of action: Impairs immune response to vaccines, possible infection after admin of live vaccines.\n\nPregnancy category: D\n\nInteraction: Impairs immune response to vaccines, possible infection after admin of live vaccines.
Chlorhexidine Tulle gras Dressing 0.5% w/w	\n\n\tIndication: Burns, Wound dressing for preventing excessive wound dryness and the prevention of infection in minor skin, Scalds abrasions, Lacerations, Crush injuries, Diabetic ulcers, Skin Grafting, Pressure sores, Colostomies, Surgical wounds\n\nDose: The dressing is for administration to adults, children and infants; it may be changed daily but frequency of application will depend upon the clinical circumstances. It is intended that the dressing be used principally on body wounds covering up to ten percent surface area. There is however no contraindication for use on larger area wounds.\n\nContra-indication: Should not be used in known cases of sensitivity or allergy to chlorhexidine\n\nSide effects: Chlorhexidine is well tolerated topically with minimal absorption. Sensitivity reaction is extremely rare.\n\nPrecaution: Avoid contact with eyes, middle ear, meninges and brain\nDo not use with oxidising wound cleaning agents, soap, other anionic materials, or potassium iodide\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Choriogonadotropin Alfa	\n\n\tIndication: Anovulatory infertility, Adjunct to IVF procedures and other assisted conception techniques\n\nDose: Adult: SC Anovulatory infertility; Adjunct to IVF procedures and other assisted conception techniques 250 mcg as a single dose when optimal stimulation of follicular growth in achieved.\n\nContra-indication:  	Ovarian enlargement or cyst (unless caused by polycystic ovarian disease); ectopic pregnancy in previous 3 months; active thromboembolic disorders; hypothalamus, pituitary, ovarian, uterine or mammary malignancy; gynaecological haemorrhage of unknown etiology; primary ovarian failure; sexual organ malformations and fibroid uterine tumors incompatible with pregnancy; postmenopausal women. Uncontrolled thyroid or adrenal dysfunction. Pregnancy and lactation.\n\nSide effects: Nausa, vomiting, abdominal pain; headache, tiredness; Inj site reactions; ovarian hyperstimulation syndrome; rarely diarrhoea, depression, irritability, breast pain. Ectopic pregnancy, ovarian torsion and other complications in some patients after hCG administration.\n\nPrecaution: Asthma, epilepsy, migraine, CV disorders, renal disorders; infertility caused by hyperprolactinaemia, pituitary or hypothalamic tumors; clinically significant systemic diseases where pregnancy could exacerbate the condition. Monitor carefully estradiol levels and ovarian response based on ultrasound prior to and during stimulation therapy. Multiple pregnancy.\n\nMode of action: None\n\nPregnancy category: X\n\nInteraction: 
Chorionic Gonadotrophin	\n\n\tPopular\tHcg 5000 Injection 5000 i.u 5000 i.u amp's pack 1300\n\tIndication: Anovulatory infertility, Adjunct to IVF procedures and other assisted conception techniques\n\nDose: Adult: IM Prepubertal cryptorchidism in males 500-4,000 u 3 times/wk. Continue for 1-2 mth after testicular descent. \nMale infertility due to hypogonadotrophic hypogonadism 500-4,000 u 2-3 times/wk. \nDelayed puberty due to hypogonadism in males Initial: 500-1,500 u twice wkly. \nAnovulatory infertility 5,000-10,000 u as a single dose. May repeat inj (up to 5,000 u/inj) up to 3 times w/in the next 9 days.\n\nContra-indication: Hypersensitivity; precocious puberty, prostatic carcinoma or other androgenic dependent neoplasm. Pregnancy and lactation.\n\nSide effects: Headache, irritability, restlessness, depression, fatigue, oedema; precocious puberty, gynaecomastia; pain at Inj site; enlargement of preexisting ovarian cysts and possible rupture; arterial thromboembolism; shock; abdominal pain.\nPotentially Fatal: Ovarian hyperstimulation syndrome (OHSS).\n\nPrecaution: Discontinue therapy if signs of precocious puberty are seen in patients treated for cryptorchidism. Patients with cardiac or renal disease, epilepsy, migraine or asthma.\n\nMode of action: No specific interaction studies with Chorionic Gonadotrophin  and other medicines have been performed; however, no clinically significant drug interactions have been reported during hCG therapy.\nFollowing administration, Chorionic Gonadotrophin  may interfere for up to 10 days with the immunological determination of serum/urinary hCG, leading to a false-positive pregnancy test.\nIncompatibilities: In the absence of incompatibility studies, Chorionic Gonadotrophin must not be mixed with other medicinal products.\n\n\nPregnancy category: X\n\nInteraction: No specific interaction studies with Chorionic Gonadotrophin  and other medicines have been performed; however, no clinically significant drug interactions have been reported during hCG therapy.\nFollowing administration, Chorionic Gonadotrophin  may interfere for up to 10 days with the immunological determination of serum/urinary hCG, leading to a false-positive pregnancy test.\nIncompatibilities: In the absence of incompatibility studies, Chorionic Gonadotrophin must not be mixed with other medicinal products.\n
Clarithromycin	\n\n\tAcme Ltd.\tClaricin TAB dr 250mg 8's pack 200.80\n\tAcme Ltd.\tClaricin TAB dr 500mg 8's pack 321.20\n\tBio Pharma Ltd.\tClamycin TAB dr 500mg 12's pack 480\n\tDesh\tClarocin TAB dr 500mg 12's pack 360\n\tDrug International Ltd.\tClarin TAB dr 250mg 10's pack 250\n\tDrug International Ltd.\tClarin TAB dr 500mg 10's pack 400\n\tGeneral\tMacrobid TAB dr 500mg 4's pack 200.76\n\tHudson\tClarison TAB dr 500mg 10's pack 450\n\tIncepta\tKlarix TAB dr 250mg 10's pack 25\n\tIncepta\tKlarix TAB dr 500mg 6's pack 40\n\tIncepta\tKlarix Granules for Suspension 125mg/5ml 1's pack 340\n\tMedimet\tClacin TAB dr 500mg 4's pack 160\n\tNovartis (Bangladesh) Ltd.\tBinoclar Powder for Suspension 125mg/5ml 60ml bot 395\n\tNovartis (Bangladesh) Ltd.\tBinoclar TAB dr 250mg 14's pack 495.60\n\tNovartis (Bangladesh) Ltd.\tBinoclar TAB dr 500mg 14's pack 924\n\tNovartis (Bangladesh) Ltd.\tBinoclar SR TAB dr 500mg 10's pack 780\n\tOpsonin Pharma\tKlabex TAB dr 500mg 6's pack 211.13\n\tOpsonin Pharma\tKlabex SR TAB dr 500mg 6's pack 468\n\tOpsonin Pharma\tKlabex TAB dr 250mg 12's pack 263.90\n\tRenata\tClarox TAB dr 250mg 20's pack 500\n\tRenata\tClarox TAB dr 500mg 12's pack 480\n\tSquare\tRemac TAB dr 500mg 6's pack 240.91\n\tTechno Drugs Ltd.\tMaclar Powder for Suspension 125mg/5ml 60ml bot 330\n\tTechno Drugs Ltd.\tMaclar IV Injection 500mg 1 vial pack 300\n\tTechno Drugs Ltd.\tMaclar TAB dr 250mg 6's pack 180\n\tTechno Drugs Ltd.\tMaclar TAB dr 500mg 6's pack 240\n\tTechno Drugs Ltd.\tMaclar SR TAB dr 500mg 6's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tKlaricid TAB dr 250mg 10's pack 420\n\tUnimed & Unihealth Manufacturers Ltd.\tKlaricid TAB dr 500mg 10's pack 690\n\tUnimed & Unihealth Manufacturers Ltd.\tKlaricid Powder for suspension 125mg/5ml 1's pack(60ml) 451.70\n\tUnimed & Unihealth Manufacturers Ltd.\tKlaricid Injection 500mg 1's pack 623.73\n\tUnimed & Unihealth Manufacturers Ltd.\tKlaricid Xl TAB dr 500mg 5's pack 464.15\n\tUnimed & Unihealth Manufacturers Ltd.\tKlabid TAB dr 250mg 8's pack 240\n\tUnimed & Unihealth Manufacturers Ltd.\tKlabid TAB dr 500mg 4's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tKlabid ER TAB dr 500mg 7's pack 455\n\tUnimed & Unihealth Manufacturers Ltd.\tKlabid Paediatric Suspension 125mg/5ml 70ml bot 340\n\tAbbott Ltd., Pakistan\tKlaricid I.V. Injection 500mg 1 vial pack 464.15\n\tIndication: Respiratory tract infections, Skin and soft tissue infections, Leprosy, peptic ulcer disease, pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia, legionellosis, Helicobacter pylori, lyme disease, Community-Acquired Pneumonia							\n\n\nDose: Adult: PO Resp tract infections; Skin and soft tissue infections; Susceptible infections 250 mg twice daily, up to 500 mg twice daily for severe infections, for 7-14 days. \n\nMycobacterium avium complex infections W/ other antimycobacterials: 500 mg twice daily. Leprosy As part of multidrug therapy: 500 mg/day. \n\nH. pylori infection W/ another antibacterial and either a proton pump inhibitor or H2 antagonist: 500 mg twice daily for 7-14 days. \n\nIV Resp tract infections; Skin and soft tissue infections; Susceptible infections 500 mg twice daily for 2-5 days.\n\nChild: 7.5 mg/kg bid for 5-10 days.\nRenal impairment:\nCrCl (ml/min)	\n<30 	Half the dosage or double dosing interval.\n\nContra-indication: Hypersensitivity. Patients receiving terfenadine, astemizole, pimozide, cisapride and ergot derivatives. Pregnancy; history of acute porphyria.\n\nSide effects: GI upset, glossitis, stomatitis, altered taste; headache, dizziness, hallucinations, insomnia, other CNS effects; rash; hepatic dysfunction,\nPotentially Fatal: Pseudomembranous colitis, anaphylaxis, Stevens-Johnson syndrome.\n\nPrecaution: Renal and hepatic impairment; macrolide cross-resistance; lactation, children.\n\nMode of action: Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine. Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam).\nPotentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.\n\nPregnancy category: C\n\nInteraction: Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine. Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam).\nPotentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.
Clindamycin	\n\n\t\tEndamycin 150 CAP 150 mg 3X10 8.00\n\t\tAdiz CAP 150 mg 30's pack 8.00\n\t\tCephracap DS CAP 150 mg 30's pack 8.00\n\tACI\tDaclin CAP 300mg 30's pack 451.50\n\tACI\tDaclin CAP 150mg 30's pack 240.60\n\tAcme Ltd.\tLincocin CAP 150mg 3x10's pack 240\n\tAcme Ltd.\tLincocin CAP 300mg 3x10's pack 450\n\tAristopharma\tClinex CAP 300mg 30's pack 450\n\tAristopharma\tClinex CAP 150mg 30's pack 240\n\tAsiatic Ltd.\tAsiclin CAP 150mg  \n\tBeximco\tClinacyn 150 CAP 150mg 30's Pack 240\n\tBeximco\tClinacyn 300 CAP 300mg 30's Pack 450\n\tBeximco\tClinacyn Injection 300 mg/2 ml  \n\tBeximco\tClinacyn Injection 600 mg/4 ml  \n\tBeximco\tClinacyn Lotion 10 mg/ml  \n\tBio Pharma Ltd.\tRiboclin CAP 150mg  \n\tBio Pharma Ltd.\tRiboclin CAP 300mg 30's pack 450\n\tDrug International Ltd.\tDalacin CAP 300mg 14's pack 210\n\tDrug International Ltd.\tDalacin Injection 300mg/2ml 5's pack 200\n\tDrug International Ltd.\tDalacin Injection 600mg/4ml 3's pack 210\n\tEskayef Bangladesh Ltd.\tLindamax CAP 150mg 30's pack 240\n\tEskayef Bangladesh Ltd.\tLindamax CAP 300mg 30's pack 450\n\tEuro Pharma Ltd.\tEndamycin CAP 150mg  \n\tEuro Pharma Ltd.\tEndamycin CAP 300mg  \n\tGeneral\tCleodin CAP 150mg 30's pack 240\n\tGeneral\tCleodin CAP 300mg 30's pack 450\n\tGeneral\tCleodin IV/IM Injection 300mg/2ml 5's pack 200\n\tGeneral\tCleodin IV/IM Injection 600mg/4ml 5's pack 350\n\tGlobe\tAnobac CAP 150mg  \n\tGlobe\tAnobac CAP 300mg  \n\tHealthcare\tCleocin CAP 150mg  \n\tHealthcare\tCleocin CAP 300mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tCinamycin CAP 150mg 30's pack 240\n\tIbn Sina Pharmaceutical Ind. Ltd.\tCinamycin CAP 300mg 30's pack 450\n\tIncepta\tClindacin Soln Powder for Suspension 75mg/5ml 100ml 280\n\tIncepta\tClindacin CAP 150mg 30's pack 240\n\tIncepta\tClindacin CAP 300mg 30's pack 450\n\tIncepta\tClindacin Injection 300mg/2ml 5 amp's pack 350\n\tIncepta\tClindacin Injection 600mg/4ml 5 amp's pack 350\n\tLeon\tClimed CAP 150mg  \n\tLeon\tClimed CAP 300mg  \n\tNavana\tClincin CAP 150mg 30's pack 240\n\tNavana\tClincin CAP 300mg 30's pack 450\n\tOpsonin Pharma\tClindax Powder for Suspension 75mg/5ml 100ml bot 250\n\tOpsonin Pharma\tClindax CAP 150mg 30's pack 211.92\n\tOpsonin Pharma\tClindax CAP 300mg 30's pack 397.45\n\tOpsonin Pharma\tClindax Injection 300mg/2ml 5 amp's pack 176.60\n\tOpsonin Pharma\tClindax Injection 600mg/4ml 5 amp's pack 309.04\n\tOrion Pharma Ltd.\tXindal CAP 150mg 30's pack 240\n\tOrion Pharma Ltd.\tXindal CAP 300mg 30's pack 450\n\tPopular\tClindabac CAP 150mg 3x30's pack \n\tRangs\tCleomycin CAP 300mg  \n\tRenata\tQcin CAP 150mg 30's pack 240\n\tRenata\tQcin Injection 300mg/2ml 5's pack 200\n\tRenata\tQcin CAP 300mg 30's pack 450\n\tRenata\tQcin Injection 600mg/4ml 5's pack 350\n\tSharif\tLinacin CAP 150mg 30's pack 240\n\tSquare\tClimycin CAP 150mg 30's pack 240.99\n\tSquare\tClimycin CAP 300mg 30's pack 451.67\n\tVeritas\tClindaver CAP 300mg  \n\tPfizer PGM, France\tDalacin C CAP 300mg 16's pack 848.16\n\tPfizer Puus SP.A,., Belgium\tDalacin CTM CAP 300mg 		 14's pack 210\n\tJanata Pharma\tDalacin Injection  600mg amp x 1's pack 332.03\n\tIndication: Dental infections, Respiratory tract infections, Skin and soft tissue infections, peritonitis, acne, anaerobic infections, endocarditis, Toxic shock syndrome, Bacterial vaginosis, Pelvic inflammatory disease							\n\n\nDose: Adult: PO Serious anaerobic infections 150-300 mg 6 hrly, up to 450 mg 6 hrly for severe infections. Max: 1.8 g/day. Prophylaxis of endocarditis 600 mg 1 hr before dental procedure. \n\nIV Serious anaerobic infections 0.6-2.7 g/day in divided does, up to 4.8 g/day for severe infections. Toxic shock syndrome W/ penicillin G or ceftriaxone: 900 mg 8 hrly. Pelvic inflammatory disease W/ gentamicin: 900 mg 8 hrly. \n\nNeonates (less than 1 month): 15 to 20 mg/kg/day in 3 to 4 equal doses. The lower effective dosage may be adequate for small prematures.\n\nPediatric patients (1 month of age to 16 years)\nParenteral (IV/IM) administration: 20 to 40 mg/kg/day in 3 or 4 equal doses. The higher doses would be used for more severe infections. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Diarrhoea, nausea, vomiting, abdominal pain; erythema multiforme, contact dermatitis, exfoliative and vesiculous dermatitis, urticaria; eosinophilia; local irritation, thrombophloebitis.\nPotentially Fatal: Gasping syndrome (neonates); pseudomembranous colitis.\n\nPrecaution: Renal and hepatic diseases; pregnancy and lactation; GI disease; elderly, females, neonates, atopic patients. Regular monitoring of blood counts, liver and kidney functions.\n\nMode of action:  	May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).\n\nPregnancy category: B\n\nInteraction:  	May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).
Clostridium Botulinum Toxin Type A Neurotoxin	\n\n\tAllergan,Ireland\tBotox Injection 100 Units 100 units vial 26815.28\n\tIndication: Muscle spasm, Strabismus, Blepharospasm, Achalasia, Cervical dystonia, Limb spasticity, Overactive bladder, Chronic migraine, Severe Primary Axillary Hyperhidrosis, Glabellar and lateral Canthal lines (cosmetic purpose)\n\nDose: Glabellar lines: Inject 4 units (0.1 mL) into each of 5 sites, 2 in each corrugator muscle and 1 in procerus muscle for a total dose of 20 units\n\nCanthal lines: Inject 4 units (0.1 mL) into 3 sites per side (6 total injection points) in the lateral orbicularis oculi muscle for a total of 24 units/0.6 mL (12 units per side)\n\nDuration of activity is approximately 3-4 months. More frequent dosing not recommended.\n\nBlepharospasm\n1.25-2.5 units IM; not to exceed 200 units in 30 days.\n\nStrabismus\n1.25-5 units IM; <25 units per injection .\n\nChronic Migraine\nRecommended total dose 155 units, as 0.1 mL (5 units) IM injections per each site divided across 7 head/neck muscles q12wk.\n\nOveractive Bladder\nIndicated for adults with overactive bladder symptoms (urge incontinence, urgency, frequency) who cannot use or do not adequately respond to anticholinergic medication.\n\n100 units (divided into 20 intradetrusor injections of 5 units each) administered using cystoscopy.\n\nContra-indication:     As with other immunoglobulin preparations, it should not be used in individuals with a prior history of severe reaction to other human immunoglobulin preparations.\n    Individuals with selective immunoglobulin A deficiency have the potential for developing antibodies to immunoglobulin A and could have anaphylactic reactions to the subsequent administration of blood products that contain immunoglobulin A.\n\n\nSide effects:     Serious adverse reactions were not observed in clinical trials.\n    The most common adverse reaction was skin rash.\n    Other reactions such as chills, muscle cramps, back pain, fever, nausea, vomiting, and wheezing were the most frequent adverse reactions observed during the clinical trials of similarly-prepared human IGIV products. \n\nPrecaution:   Patient Monitoring for Administration\n\n    Patients should be well hydrated prior to the initiation.\n    Assess renal function, including the measurement of blood urea nitrogen (BUN) or serum creatinine prior to the initial infusion.  Periodic monitoring of renal function tests and urine output is particularly important in patients judged to have a potential risk for developing acute renal failure.  Increases in serum creatinine and BUN have been observed as soon as one to two days following treatment with other IGIV products.\n    During administration, monitor the patient's vital signs continuously and observe the patient carefully for any associated symptoms.\n    DO NOT EXCEED THE RECOMMENDED INFUSION RATE of 1 mL/kg/hour (50 mg/kg/h), and follow the infusion schedule closely  . If a patient develops an infusion reaction, slow the rate of infusion immediately or temporarily interrupt the infusion.\n\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Coagulation Factor IX Human USP	\n\n\tIndication: Hemophilia B or Christmas disease\n\nDose: In adult PTPs, on average, one international unit of coagulation factor ix recombinant per kilogram of body weight increased the circulating activity of factor IX by 0.8 Â± 0.2 (range 0.4 to 1.4) IU/dL. \n\nIn pediatric patients, on average, one international unit of coagulation factor ix recombinant per kilogram of body weight increased the circulating activity of factor IX by 0.7 Â± 0.3 (range 0.2 to 2.1 IU/dL; median of 0.6 IU/dL per IU/kg). \n\nContra-indication:  patients with a known history of hypersensitivity to hamster protein.\n\nSide effects:     fever or chills;\n    continued bleeding after treatment;\n    feeling like you might pass out;\n    sudden numbness or weakness, especially on one side of the body;\n    sudden headache, confusion, problems with vision, speech, or balance; or\n    swelling in your feet or ankles, weight gain, loss of appetite.\n\nLess serious side effects may be more likely to occur, such as:\n\n    headache;\n    warmth, redness, or tingly feeling under your skin;\n    nausea, vomiting;\n    dizziness; or\n    pain, redness, or swelling where the medicine was injected.\n\nPrecaution: Activity-neutralizing antibodies (inhibitors) have been detected in patients receiving factor IXcontaining products. As with all factor IX products, patients using  (coagulation factor ix recombinant) should be monitored for the development of factor IX inhibitors . Patients with factor IX inhibitors may be at an increased risk of anaphylaxis upon subsequent challenge with factor IX.\n\n Patients experiencing allergic reactions should be evaluated for the presence of inhibitor. Preliminary information suggests a relationship may exist between the presence of major deletion mutations in a patient's factor IX gene and an increased risk of inhibitor formation and of acute hypersensitivity reactions. \n\nPatients known to have major deletion mutations of the factor IX gene should be observed closely for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of initial exposure to product. In view of the potential for allergic reactions with factor IX concentrates, the initial (approximately 10 - 20) administrations of factor IX should be performed under medical supervision where proper medical care for allergic reactions could be provided.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Colistin Sulfate	\n\n\tIndication:  Bowel sterilization, gastrointestinal tract infections, respiratory tract infections							\n\n\nDose: Adult: PO GI infections; Bowel sterilisation 1.5-3 million units 3 times/day. \n\nIV/IM GI infections; Bowel sterilisation As colistimethate Na: 6 million units/day in 3 divided doses. Max: 6 million units/24 hr. \n\nInhalation Adjunct to antimicrobial therapy in resp infections As colistimethate Na: 1-2 million units twice daily. Max: 2 million units 3 times/day for up to 3 mth in frequent recurrent infections.\n\nRenal impairment:\nCrCl (ml/min)	\n20-50	1-2 million units every 8 hr.\n10-20	1 million units every 12-18 hr.\n<10  	1 million units every 18-24 hr \n\nContra-indication: Hypersensitivity. Anuria; porphyria; myasthenia gravis. Pregnancy and lactation.\n\nSide effects: Superinfection; renal damage; visual disturbances; GI disturbances, dizziness, nausea, vomiting; confusion, peripheral neuropathy; respiratory insufficiency and muscle weakness.\nPotentially Fatal: Acute tubular necrosis, neurotoxicity; nephrotoxicity. The neuromuscular blockade is potentially fatal, when associated with use of curariform muscle relaxants.\n\nPrecaution: Preexisting renal impairment; disorders of neuromuscular transmission. Monitor serum creatinine and BUN regularly while on treatment.\n\nMode of action: Potentiates chloramphenicol and trimethoprim.\nPotentially Fatal: Potentiates action of curariform muscle relaxants. Potentiates nephrotoxicity of aminoglycosides and cephalothin.\n\nPregnancy category: C\n\nInteraction: Potentiates chloramphenicol and trimethoprim.\nPotentially Fatal: Potentiates action of curariform muscle relaxants. Potentiates nephrotoxicity of aminoglycosides and cephalothin.
Crystalline Mitomycin-C	\n\n\tKyowa Hakko Kogyo Co., Ltd.,Japan\tMitomycin Injection 2mg 2ml vial 51.25\n\tIndication: Diabetic foot infections, Chronic lymphatic leukaemia, Chronic myelogenous leukaemia, Gastric, Colorectal, Lung, Pancreatic, Cervix, Endometrium, Breast, Bladder, Head & neck carcinoma.\n\nDose: Adult: IV Solid tumours Suggested regimen: Initial: 10-20 mg/m2; may repeat 6-8 wkly depending on blood count. Do not repeat if leucocyte and platelet counts are below acceptable levels. Do not re-administer if the nadir of the leucocyte count is <2,000 cells/mm3.\n\n Intravesical Superficial bladder tumours Instill 10-40 mg 1-3 times/wk for a total of 20 doses. Prevention of recurrent bladder tumours Instill 20 mg 2 wkly or 40 mg 1-3-mthly.\n\nContra-indication: Thrombocytopenia, coagulation disorders, increase in bleeding tendency due to other causes. Renal impairment, potentially severe infections. Pregnancy and lactation.\n\nSide effects: CHF; fever; alopecia, nail banding/discolouration; nausea, vomiting, anorexia; anaemia; rash; stomatitis; paraesthesia; increased creatinine; interstitial pneumonitis, infiltrates, dyspnoea, cough; malaise, pruritus, extravasation, bladder fibrosis/contraction (intravesical admin).\nPotentially Fatal: Myelosuppression, haemolytic-uraemic syndrome.\n\nPrecaution: Repeated haematologic studies are necessary during treatment and for at least 7 wk after discontinuation of the drug. Discontinue use when the leucocyte count decreases to <4000/mm3 or the platelet count decreases to <150,000/mm3 or if a progressive decline in either occurs. Monitor patient for signs of renal or pulmonary toxicity.\n\nMode of action: Increased incidence of cardiotoxicity w/ doxorubicin.\nPotentially Fatal: Increased risk of intravascular haemolysis and renal failure w/ fluorouracil. Increased risk of haemolytic uraemic syndrome w/ tamoxifen. Acute pulmonary toxicity w/ vinca alkaloids (e.g. vinblastine, vinorelbine). Increased bone marrow depressant effects of aclarubicin.\n\nPregnancy category: Not Classified\n\nInteraction: Increased incidence of cardiotoxicity w/ doxorubicin.\nPotentially Fatal: Increased risk of intravascular haemolysis and renal failure w/ fluorouracil. Increased risk of haemolytic uraemic syndrome w/ tamoxifen. Acute pulmonary toxicity w/ vinca alkaloids (e.g. vinblastine, vinorelbine). Increased bone marrow depressant effects of aclarubicin.
Cyclophosphamide	\n\n\tBeacon\tCyclotox Injection 1000mg/vial 1's pack 650\n\tBeacon\tCyclotox Injection 200mg/vial 1's pack  180\n\tSanofi Aventis (BD) Ltd.\tEndoxan Injection 200mg 10's pack 3114.20\n\tSanofi Aventis (BD) Ltd.\tEndoxan Coated TAB dr 50mg 50's pack 1718\n\tSanofi Aventis (BD) Ltd.\tEndoxan Injection 500mg 1's pack 720.53\n\tSanofi Aventis (BD) Ltd.\tEndoxan Injection 1 Gram 1's pack 1374.56\n\tTechno Drugs Ltd.\tCyclomid Injection 200mg/vial 1's pack 150\n\tTechno Drugs Ltd.\tCyclomide 1G Injection 1g 1'a pack 700\n\tIndication: Bone marrow transplantation, malignancies, lymphomas, brain cancer, leukemia, systemic lupus erythematosus, minimal change disease, severe rheumatoid arthritis, wegener's granulomatosis, multiple sclerosis, multiple myeloma, carcinoma of the breast, ovarian carcinoma, neuroblastoma, retinoblastoma.							\n\n\nDose: Adult: PO Part of the conditioning regimen in patients undergoing bone marrow transplantation 60 mg/kg/day for 2 days. Malignancies Low dose regimen: 2-6 mg/kg/wk in divided doses. \n\nIV Malignancies Moderate dose regimen: 10-15 mg/kg/wk; high dose regimen: 20-40 mg/kg given every 10-20 days.\n\nContra-indication: Bladder haemorrhage. Patients with bone-marrow aplasia, acute infection, drug- or radiation-induced urothelial toxicity. Porphyria. Pregnancy and lactation.\n\nSide effects: Congestive heart failure; leucopenia; poor wound healing; anorexia. Nausea, vomiting; alopoecia; oral mucosal ulceration; thrombocytopenia, anaemia; nonhaemorrhagic cystitis and/or fibrosis of the bladder; gonadal suppression, ovarian or skin and nail pigmentation, dermatitis, jaundice.\nPotentially Fatal: Myelosuppression; haemorrhagic cystitis; interstitial pulmonary fibrosis; tachyarrhythmias and intractable heart failure (high doses). Increased risk of developing acute leukaemias.\n\nPrecaution: Blood disorders. Elderly or debilitated patients. Diabetic patients. Renal or hepatic impairment or who have gone adrenaloctomy. Previous treatment with x-ray or cytotoxic agents. Monitor haematological profile and presence of RBCs in urine regularly. Maintain adequate hydration and frequent micturition to reduce the risk of cystitis.\n\nMode of action:  	Chronic high-dose administration of phenobarbital can increase the metabolism and leukopaenic activity of cyclophosphamide. Doxorubicin and daunorubicin increase risk of cardiotoxicity. Allopurinol may increase risk of bone marrow toxicity while chloramphenicol may increase the serum T1/2 of cyclophosphamide.\nPotentially Fatal: Serious toxicity when combined with other myelotoxic drugs or radiotherapy.\n\nPregnancy category: D\n\nInteraction:  	Chronic high-dose administration of phenobarbital can increase the metabolism and leukopaenic activity of cyclophosphamide. Doxorubicin and daunorubicin increase risk of cardiotoxicity. Allopurinol may increase risk of bone marrow toxicity while chloramphenicol may increase the serum T1/2 of cyclophosphamide.\nPotentially Fatal: Serious toxicity when combined with other myelotoxic drugs or radiotherapy.
Cytarabine	\n\n\tBeacon\tCytabin Injection 100 mg/vial  \n\tChoongwae Pharma Corporation,Korea\tCytarabine 5ml Injection 100mg/5ml 1's pack 116.42\n\tIndication: Acute myeloid leukaemia, acute lymphocytic leukaemia (ALL), lymphomas, Leukaemic meningitis							\n\n\nDose: Adult: 100 mg/m2 BSA bid by rapid IV inj or 100 mg/m2 BSA daily by continuous IV infusion. Continue treatment for 5-10 days depending on therapeutic response and toxicity. Maintenance: 1-1.5 mg/kg 1-2 times wkly via IV or SC admin. \nFor refractory disease: High dose regimen is used: Up to 3 g/m2 BSA every 12 hr for up to 6 days, given as an IV infusion over at least 1 hr. \nChild: 100 mg/m2 BSA bid by rapid inj or 100 mg/m2 BSA daily by continuous infusion given for 5-10 days. \nIntrathecal\nLeukaemic meningitis\nAdult: 10-30 mg/m2 BSA every 2-4 days. For lymphomatous meningitis: 50 mg every 2 wk for 5 doses, then every 4 wk for 5 doses.\n\nContra-indication: Hypersensitivity; pregnancy and lactation.\n\nSide effects: Dementia, GI disturbances, hepatic and renal dysfunction, neurotoxicity, rashes, oral and anal ulceration, GI haemorrhage, oesophagitis, conjunctivitis, flu-like syndrome, anaphylactoid reactions.\nPotentially Fatal: Convulsions. Cerebellar dysfunction, respiratory distress syndrome, GI perforation, bone marrow suppression.\n\nPrecaution: Hepatic and renal dysfunction, severe infections, preexisting drug-induced bone marrow suppression. Monitor WBC, platelet counts and blood uric acid frequently. Assess renal and hepatic function periodically.\n\nMode of action:  	May reduce efficacy of gentamicin, digoxin and flucytosine.\nPotentially Fatal: Potentiates bone marrow depression with radiotherapy and other myelotoxic drugs.\n\nPregnancy category: D\n\nInteraction:  	May reduce efficacy of gentamicin, digoxin and flucytosine.\nPotentially Fatal: Potentiates bone marrow depression with radiotherapy and other myelotoxic drugs.
Dalteparin Sodium	\n\n\tPfizer Manufacturing, Belgium\tFragmin Injection 7500IU/0.3ml 7500 i.u prefilled syringe 6314\n\tPfizer Manufacturing, Belgium\tFragmin Injection 5000IU/0.2ml 5000 i.u prefilled syringe 3375\n\tIndication: Unstable angina, Pulmonary embolism, Deep-vein thrombosis, Prophylaxis of clotting in extracorporeal circulation in haemodialysis or haemofiltration, Prophylaxis of venous thromboembolism during surgery\n\nDose: Adult: IV Prophylaxis of clotting in extracorporeal circulation in haemodialysis or haemofiltration 30-40 u/kg via inj, then infuse at 10-15 u/kg/hr. \n\nSC Deep-vein thrombosis; Pulmonary embolism 200 u/kg/day in 1-2 divided doses. Max: 18,000 u/day. Prophylaxis of venous thromboembolism during surgery High-risk: 2,500 u 1-2 hr before and 8-12 hr after procedure followed by 5,000 u/day. Moderate-risk: 2,500 u 1-2 hr before procedure, then 2,500 u/day for 5-7 days or until patient is ambulant. \n\nUnstable angina 120 u/kg 12 hrly for 5-8 days w/ low-dose aspirin. Max: 10,000 u 12 hrly.\n\nContra-indication: Hypersensitivity. Active major bleeding, severe coagulation disorders; lumbar puncture; sympathetic block; brain, spinal cord, eye or ear surgery; severe hypertension.\n\nSide effects: Hypersensitivity reactions; thrombocytopenia; inj site pain and tenderness; ecchymoses; haematoma. Prolonged use may lead to alopecia and osteoporosis\nPotentially Fatal: Severe haemorrhage.\n\nPrecaution: Preexisting thrombocytopenia, recent childbirth, DM, subacute bacterial endocarditis, pericarditis, recent lumbar puncture, vasculitis. Monitor coagulation time. Hepatic or renal dysfunction; high doses; osteoporosis; familial antithrombin III deficiency; elderly; children; platelet count and stool occult blood test recommended during treatment; GI ulceration. Pregnancy and lactation.\n\nMode of action: Increased risk of haemorrhage w/ other anticoagulant/antiplatelet agents (e.g. aspirin/dipyridamole, glycoprotein IIb/IIIa receptor antagonists, vit K antagonists, NSAIDs, cytostatics, dextran, thrombolytics, sulfinpyrazone, probenecid, etacrynic acid). Reduced anticoagulant effect w/ antihistamines, cardiac glycosides, tetracycline and ascorbic acid.\n\nPregnancy category: B\n\nInteraction: Increased risk of haemorrhage w/ other anticoagulant/antiplatelet agents (e.g. aspirin/dipyridamole, glycoprotein IIb/IIIa receptor antagonists, vit K antagonists, NSAIDs, cytostatics, dextran, thrombolytics, sulfinpyrazone, probenecid, etacrynic acid). Reduced anticoagulant effect w/ antihistamines, cardiac glycosides, tetracycline and ascorbic acid.
Dacarbazine	\n\n\tIndication:  Metastatic melanoma,  Hodgkin's disease ,  Soft tissue sarcoma\n\nDose: Adult: IV Metastatic melanoma 2-4.5 mg/kg/day for 10 days, repeat at 4-wkly intervals. Hodgkin's disease 150 mg/m2/day for 5 days, repeat at 4-wkly intervals. Soft tissue sarcoma 250 mg/m2/day for 5 days, repeat at 3-wkly intervals.\n\nContra-indication: Bone marrow suppression; hypersensitivity.\n\nSide effects: Leucopenia, thrombocytopenia, anorexia, nausea, diarrhoea, vomiting; flu-like syndrome, myalgia, malaise, facial flushing, paraesthesia, skin reactions, rashes; alopoecia, photosensitivity reactions.\nPotentially Fatal: Myelosuppression; hepatotoxicity, anaphylaxis.\n\nPrecaution: Hepatic or renal impairment. Pregnancy, lactation.\n\nMode of action: Impairs immune response to vaccines; possible infection after admin of live vaccines. Effect increased by CYP1A2 inhibitors e.g. amiodarone, ciprofloxacin, fluvoxamine, ketoconazole, lomefloxacin, ofloxacin and rofecoxib. Effect decreased by CYP1A2 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital and rifampicin.\n\nPregnancy category: C\n\nInteraction: Impairs immune response to vaccines; possible infection after admin of live vaccines. Effect increased by CYP1A2 inhibitors e.g. amiodarone, ciprofloxacin, fluvoxamine, ketoconazole, lomefloxacin, ofloxacin and rofecoxib. Effect decreased by CYP1A2 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital and rifampicin.
Deferasirox	\n\n\tCipla Ltd.\tDesirox Dis TAB dr 250mg 30's pack 1500\n\tCipla Ltd.\tDesirox Dis TAB dr 500mg 30's pack 2700\n\tUnimed & Unihealth Manufacturers Ltd.\tFerasirrox 250 TAB dr 250mg 10's pack 800\n\tNovartis Pharma AG, Switzerland\tAsunra TAB dr 100mg 100mg x 30's pack/400mg x 30's pack 1239 / 4963\n\tIndication: Chronic iron overload.\n\nDose: Oral\nChronic iron overload\nAdult: 20 mg/kg once daily. Adjust dose every 3-6 mth when needed. Max: 30 mg/kg daily.\nChild: >2 yr: 20 mg/kg once daily. Max: 30 mg/kg daily.\n\nContra-indication: Hypersensitivity.\n\nSide effects: GI disorders, such as nausea, vomiting, diarrhoea and abdominal pain; headache, pyrexia and cough. May increase LFT.\nPotentially Fatal: Acute renal failure, serious hypersensitivity reactions such as angioedema and anaphylaxis.\n\nPrecaution: Monitor renal function and CBC before starting treatment and regularly during treatment; may need to reduce dose or stop treatment if serum creatinine levels are persistently elevated. May increase LFTs. Perform audiological and ophthamological tests before starting treatment and yrly thereafter. Pregnancy.\n\nMode of action: Not to be used with aluminium-containing antacids as it may chelate aluminium.\n\nPregnancy category: C\n\nInteraction: Not to be used with aluminium-containing antacids as it may chelate aluminium.
Desogestrel	\n\n\tIncepta\tPop-D TAB dr 75mcg 28's pack 60.20\n\tRenata\tBredicon TAB dr 75mcg 28's pack 60.20\n\tIndication: Oral contraception\n\nDose: Oral\nOral contraception\nAdult: 75 mcg daily when used alone. For monophasic combined oral contraceptives: Typically, 150 mcg daily; for triphasic combined oral contraceptives: 50-150 mcg daily.\n\nContra-indication: Pregnancy, undiagnosed vaginal bleeding, severe arterial disease; liver adenoma, porphyria; after evacuation of hydatidiform mole; history of breast cancer.\n\nSide effects: Menstrual irregularities; nausea, vomiting, headache, dizziness, breast discomfort, gynecomastia, depression, skin disorders, disturbance of appetite, wt changes, fluid retention, oedema, changes in libido, cholestatic jaundice, hair loss or hirsutism.\n\nPrecaution: Heart disease, sex-steroid dependent cancer, past ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy, history of CV or renal impairment, DM, asthma, epilepsy, migraine, depression and thromboembolism; lactation.\n\nMode of action: Reduced efficacy with enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism.\n\nPregnancy category: X\n\nInteraction: Reduced efficacy with enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism.
Dexamethasone	\n\n\tACI\tDexcor TAB dr 0.5mg 100's pack \n\tAcme Ltd.\tSteron TAB dr 0.5mg 100's pack 45\n\tAlbion Ltd.\tDexamethason TAB dr 0.5mg 100's pack 42\n\tAlbion Ltd.\tDexamethasone TAB dr 0.5 mg 200's pack \n\tAmbee\tAmason TAB dr 0.5mg 100's pack 100\n\tBelsen\tB-Dexa TAB dr 0.5mg 100's pack 50\n\tBeximco\tOdeson TAB dr 0.5mg 200's pack 230\n\tChemist Ltd.\tDexan TAB dr 0.5mg 250's pack 105\n\tEdruc Ltd.\tDexison TAB dr 0.5mg 100's pack 90\n\tEskayef Bangladesh Ltd.\tDextor TAB dr 0.5mg 200's pack 200\n\tGeneral\tDexagen TAB dr 0.5mg  \n\tGlobe\tD Cort TAB dr 0.5mg 100's pack 38\n\tIncepta\tMetadaxan TAB dr 0.5 mg  \n\tIndobangla Pharmaceuticals\tDextrin TAB dr 0.5mg 100's pack 40\n\tJayson\tDexamin TAB dr 0.5mg 100's pack 55\n\tKemiko\tGludex TAB dr .5mg 100's pack 60\n\tMedimet\tDexam TAB dr 0.5mg 100's pack 100\n\tNuvista Pharma Ltd\tOradexon TAB dr 0.5mg 500's pack 575\n\tOpsonin Pharma\tDecason TAB dr 0.5mg 200's pack 200\n\tPharmadesh Ltd.\tDexasone TAB dr 0.5mg 100's pack 50\n\tRenata\tDexatab TAB dr 0.5mg 250's pack 150\n\tRephco\tDexamet TAB dr 0.5mg 200's pack 140\n\tSquare\tDexonex TAB dr 0.5mg 100's pack 89.11\n\tTechno Drugs Ltd.\tDexavet Injection 2 mg/ml  \n\tZenith\tDeson TAB dr 0.5mg 250's pack 125\n\tZiska\tDextason TAB dr 0.5mg 100's pack 60\n\tIndication:  Shock, Bronchial asthma, Status asthmaticus, Rheumatoid arthritis, Gout, Severe allergies, Skin diseases, Hyperpyrexia, Bacteraemia, Toxaemia, Acute adrenocortical insufficiency, Cortisosteroid-responsive dermatoses, Eczema, Urticaria, Cerebral oedema, other indications where glucocorticoid therapy is required.,\n\nDose: Usual oral dosage range is 0.5-10 mg daily. \n\nDexamethasone can be given parenterally at doses of 0.5-20 mg daily, either as a single IV/IM injection or by IV infusion. \n\nChild: 200-500 mcg/kg daily. Cerebral oedema: 10 mg IV initially, then 4 mg IM every 6 hours as required for 2-10 days. Large IV doses should be given slowly to reduce the possibility of cardiovascular collapse.\n\nShock: By intravenous or intramascular injection or infusion 2-6 mg/kg, repeated if necessary after 2-6 hours.\n\nThe total daily intake of Dexamethasone, even in acute conditions should not exceed 80 mg except in certain very special circumstances.\n\nContra-indication: Ocular herpes simplex is an example of absolute contraindication to corticosteroid therapy. Relative contraindications are:\nGastrointestinal ulcer, acute or chronic infections, osteoporosis, pregnancy, diabetes mellitus, renal insufficiency, hypertension, history of psychotic illness, immediate before prophylactic immunization and finally hypersensitivity to Dexamethasone.\n\nSide effects: Hypersensitivity including anaphylaxis and allergic skin reactions has been reported. The incidence of predictable undesirable effects of glucocoticoids correlates with the dosage timing of administration and duration of treatment. Patients on prolonged Dexamethasone therapy are at risk of collapse and possibly death if their daily dose is not increased at times of severe physical stress e.g. injury, surgery or infections. The somatic manifestations include growth retardation in children, osteoporosis and aseptic bone necrosis, peptic ulceration, ocular hypertension, subcapsular cataract, pancreatic disturbances and myopathy. Other Cushing-like features characteristic of glucocorticoid excess includes truncal obesity, moon-face, oedema, delayed wound healing, glaucoma and various psychiatric syndromes. These are all generally reversible with discontinuation of Dexamethasone treatment.\n\nPrecaution: Dexamethasone should be used with caution in the presence of congestive heart failure or hypertension, in patients with diabetes mellitus, epilepsy, glaucoma, infectious disease, chronic renal failure and uraemia and in elderly persons.\n\nMode of action:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\n\nPregnancy category: C\n\nInteraction:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.
Dextrose Hydrous + Sodium Chloride + Sodium Lactate + Calcium chloride + Magnesium chloride (Peritoneal dialysis solution)	\n\n\tIndication: Acute renal failure, Chronic renal failure. Peritoneal dialysis,\n\nDose:  Solutions are provided for intraperitoneal administration only. The mode of therapy, frequency of treatment, formulation, exchange volume, duration of dwell, and length of dialysis should be selected by the physician responsible for the treatment of the individual patient.\n\nIn case of IPD: Usually  2 litres of peritoneal dialysis solutiion is instill into the abdominal cavity and dwell over a period of an hour then drained from the cavity. Exchange should be continued for 8-36 hours.\n\nTo avoid the risk of severe dehydration or hypovolemia and to minimize the loss of protein, it is advisable to select the peritoneal dialysis solution with lowest level of osmolarity consistent with the fluid removal requirements for that exchange.\n\nContra-indication: Patient with excessive obesity and pregnancy.\n\nSide effects: Adverse reactions occurring with administration of peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around a peritoneal catheter, catheter blockage, difficulty in fluid removal, and ileus are among the complications of the procedure. Solution related adverse reactions may include peritonitis, catheter site infection, electrolyte and fluid imbalances, hypovolemia, hypervolemia, hypertension, hypotension, disequilibrium syndrome and muscle cramping.\n\nIf an adverse reaction does occur, institute appropriate therapeutic procedures according to the patient's needs and conditions, and save the remainder of the fluid in the bag for evaluation if deemed necessary.\n\nPrecaution: Solution should not be administered unless it is clear, all seals are intact, and there is no evidence of leaking.\n\nCare should be taken to see that the catheter is inserted completely, since leakage around the catheter, if not controlled, can create edema from subcutaneous infiltration of the dialysis solution. This will also create an inaccurate fluid balance measurement.\n\nChronic patients that have been stabilized on peritoneal dialysis therapy should have routine evaluation of electrolyte blood chemistries and hematologic factors measured in order to determine the patient's ongoing condition.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Diphtheria Toxoid 30IU + Tetanus Toxoid 60IU + Pertusis + Hepatitis B (Vaccine)	\n\n\tGlaxo SmithKline Biological S.A.,Belgium\tTritanrix HB Injection   0.5 ml vial 393\n\tIndication: Diphtheria, Tetanus, Pertussis & Hepatitis B in infants.\n\nDose: Deep IM inj Primary vaccination 3 doses of 0.5 mL w/in the 1st 6 mth of life at intervals of at least 4 wk. \nBooster dose: Administer during the 2nd yr of life.\n\nContra-indication: Previous encephalopathy after pertussis vaccine; acute severe febrie illness.Hypersensitivity to any component of the vaccine. Childn w/ history of encephalopathy of unknown etiology occurring w/in 7 days following previous vaccination. Do not administer IV.\n\nSide effects: Redness, swelling & severe pain at inj site. Unusual crying, drowsiness, irritability, GI symptoms, feeding problems & fever. Collapse or shock-like state.\n\nPrecaution: Previous reaction to DTP vaccine; family history of convulsions, SIDS; bleeding disÂ­orders;   immunosuppression /deficiency;  pregÂ­nancy, lactation. Postpone vaccination in patients w/ acute severe febrile illness. Should be administered SC in patients w/ thrombocytopenia or bleeding disorders. Syncope, risk of apnea. Temp >40Â°C, persistent crying lasting >3 hr & collapse or shock-like state w/in 48 hrs; convulsions w/ or w/o fever w/in 3 days. High incidence of pertussis. Childn w/ progressive neurological disorders including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Consider potential risk of apnea & need for resp monitoring for 48-72 hr to very premature infants (>28 wk of gestation) particularly those w/ previous history of resp immaturity. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Diphtheria Toxoid 30 IU + Tetanus Toxoid 40 IU	\n\n\tIndication: Diphtheria, tetanus\n\nDose: Children >2 months: Primary vaccination: The course of vaccination is 3 successive doses of 0.5 mL given at 1-2 month intervals.\nBooster: 1 injection 1 year after primary vaccination eg, generally between 16-18 months.\n\nFor primary vaccination and for the 1st booster dose, vaccine may be administered by reconstituting the conjugated Haemophilus influenzae type b vaccine (Act-HIB) or administered at the same time as this vaccine, at 2 separate injection sites.\n\n5-11 or 11-13 years: Late booster: 1 booster injection according to national official recommendations.\nAdministration: administered IM. \n\nContra-indication: A severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine or any component of this vaccine is a contraindication to administration. \n\nProgressive encephalopathies, with or without convulsions.\nA severe reaction occurring within 48 hrs of a previous vaccine injection: Fever ?40Â°C; persistent crying syndrome; febrile or afebrile convulsions; hypotonic-hyporesponsive syndrome.\n\nSide effects: Local reactions eg, pain, erythema or induration may occur at the injection site within the 48 hrs following vaccination.\nSystemic reactions eg, fever occasionally >40Â°C, irritability, drowsiness, eating and sleeping disturbances, diarrhea, vomiting, and inconsolable prolonged crying.\nMore rarely urticaria, rash, convulsions with or without fever have been observed within 48 hrs following vaccination.\nHypotonic or hypotonic-hyporesponsive episodes have been reported.\nEdematous reactions of the lower limbs have been reported following administration of vaccines containing the Haemophilus influenzae type b valence. These reactions consist of edema with cyanosis or transient purpura affecting all of the vaccinated limb and sometimes the contralateral limb, appearing during the hrs following immunization, possibly lasting several hrs and resolving spontaneously without sequelae. These reactions are sometimes accompanied by fever, pain and crying.\n\nPrecaution:  A history of febrile convulsions not related to a previous vaccination does not constitute per se sufficient grounds for contraindication to immunization. \nAs with all injectable vaccines, appropriate medical treatment and supervision should be readily available for immediate use in case of a rare anaphylactic reaction following the administration of vaccine.\nHaemophilus influenzae type b valence, the 2 vaccines, diphtheria-tetanus-pertussis-poliomyelitis and the H. influenzae type b conjugate vaccine, should be administered at 2 separate injection sites and on 2 different days.\n\nMode of action: Immune response to vaccines may be reduced in patients who are receiving immunosuppressive treatment e.g. cytotoxics, high dose corticosteroids, irradiation.\n\nPregnancy category: Not Classified\n\nInteraction: Immune response to vaccines may be reduced in patients who are receiving immunosuppressive treatment e.g. cytotoxics, high dose corticosteroids, irradiation.
Diptheria + tetanus + pertussis + hepatitis B + inactivated polio vaccine + Haemophilus influenza type B (HIB) Vaccine	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tInfanrix Hexa IM Injection .5 ml 1's pack 1559.89\n\tGlaxoSmithkline Biologicals S.A,Belgium\tInfanrix hexa Injection    0.5 ml prefilled  syringe  x 1's pack 1737\n\tIndication: Diphtheria, Tetanus,  Pertussis, Hepatitis B, Poliomyelitis & HIB.\n\nDose: Deep IM inj Primary vaccination 3 or 2 doses of 0.5 mL w/ at least 1-mth interval between doses. \n\nReplacement for hepatitis B vaccine in infants who received 1st dose at birth, supplementary doses given from >6 wk. \n\nBooster vaccination Given at least 6 mth after last priming dose between 11 & 13 mth of age (after 2 doses) or before 18 mth of age (after 3 doses).\n\nContra-indication: Hypersensitivity. Encephalopathy of unknown etiology occurring w/in 7 days following previous vaccination w/ pertussis-containing vaccine.\n\nSide effects:  Loss of appetite; irritability, abnormal crying, restlessness, nervousness; vomiting, diarrhea; pruritus. Fever, fatigue, inj site reactions including pain, redness, local swelling & induration.\n\nPrecaution: Hypersensitivity to neomycin & polymyxin. Do not administer intravascularly or intradermally. Postpone vaccination in patients w/ acute severe febrile illness. Temp >40Â°C, collapse or shock-like state, persistent & inconsolable crying lasting >3 hr w/in 48 hr of vaccination. Convulsions w/ or w/o fever w/in 3 days of vaccination. Progressive neurological disorders including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Anaphylactic event & syncope may occur. Thrombocytopenia or bleeding disorder. History of febrile convulsions. Consider risk of apnea & resp monitoring for 48-72 hr in very premature infants (>28 wk of gestation) & those w/ history of resp immaturity. False +ve urine tests for HIB infection w/in 1-2 wk after vaccination.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Diphtheria toxoids + tetanus toxoids + pertussis toxoid + inactivated Poliomyelitis virus + Haemophilus influenzae type b Vaccine	\n\n\tSanofi Pasteur S A ,France\tPentaxim Injection    0.5 ml prefilled  syringe  x 1's pack 1390.63\n\tIndication: Haemophilus influenzae type B, diphtheria, tetanus, pertussis and poliomyelitis.\n\nDose: Primary Vaccination: 3 doses given at an interval of 1-2 months with booster 1 year after the primary vaccination around 16-18 months of age.\n\nContra-indication: Progressive encephalopathies with or without convulsions.\n\nSide effects: Pain, erythema, induration, fever, irritability.\n\nPrecaution:  Fever, acute illness, progressive chronic disease.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Doxorubicin Hydrochloride	\n\n\tBeacon\tXorubin Injection 50mg/vial 1's pack 1000\n\tBeacon\tXorubin Injection 10mg/vial 1's pack 300\n\tNovartis (Bangladesh) Ltd.\tDoxorubicin Hexal Injection  200mg/100ml 1's pack 3423\n\tNovartis (Bangladesh) Ltd.\tDoxorubicin Hexal Injection  100mg/50ml 1's pack 1836\n\tNovartis (Bangladesh) Ltd.\tDoxorubicin Hexal Injection  50mg/25ml 1's pack 1166\n\tTechno Drugs Ltd.\tDoxorub Injection 50mg/vial 1's pack 950\n\tTechno Drugs Ltd.\tDoxorub Injection 10mg/vial 1's pack 350\n\tIndication: AIDS-related Kaposi's sarcoma, Ovarian carcinoma, Metastatic breast carcinoma, bladder carcinoma\n\nDose: Adult: IV AIDS-related Kaposi's sarcoma As pegylated liposome: 20 mg/m2 once 2-3 wkly. \n\nOvarian carcinoma As pegylated liposome: 50 mg/m2 once 4 wkly. Metastatic breast carcinoma w/ cyclophosphamide: 60-75 mg/m2 once 3 wkly. \n\nIrrigation Local malignant neoplasms in the bladder As 1 mg/mL soln: Instill 50 mL into the bladder for 1 hr once mthly.\n\nContra-indication: Cardiac disease, neonates, pregnancy and lactation, prior irradiation to mediastinum. IM/SC admin. Severe myelosuppression due to previous treatment with antitumour agents or radiotherapy.\n\nSide effects: Leucopenia, thrombocytopenia, nausea, vomiting, diarrhoea. Rarely facial flushing, rash, alopecia. Blurred vision, headache, seizures, paraesthesia, confusion, malaise, lethargy, skin pigmentation.\nPotentially Fatal: Bone marrow suppression, cardiotoxicity.\n\nPrecaution: Elderly, children, hepatic impairment. Monitor blood counts and ECG.\n\nMode of action: Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.\nPotentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.\n\nPregnancy category: D\n\nInteraction: Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.\nPotentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.
Dydrogesterone	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tDuphaston TAB dr 10mg 20's pack 598.73\n\tSolvay Pharmaceuticals,Netherlands\tDuphaston TAB dr 10mg 10mg x 20's pack 596.20\n\tIndication: Endometriosis, Miscarriage, Menstrual disorders, Infertility, Dysmenorrhea, Dysfunctional uterine bleeding, Premenstrual syndrome, Hormone replacement therapy							\n\n\nDose: Adult: PO Endometriosis 10 mg 2-3 times/day in a cyclical or continuous regimen. \n\nRecurrent miscarriage 10 mg twice daily cyclically until conception, then continuously until wk 20 of pregnancy, then reduce dose slowly. \n\nMenstrual disorders 10 mg twice daily in a cyclical regimen. \n\nThreatened miscarriage Initial: 40 mg followed by >10 mg 8 hrly, continue for a wk after symptoms cease. Infertility 10 mg twice daily. \n\nEndometrial protection during menopausal HRT 10 mg 1-2 times/day in a cyclical regimen or 5 mg/day..\n\nContra-indication: Hypersensitivity; pregnancy. Undiagnosed abnormal vag bleeding, thromboembolic disorders, history or existing cerebrovascular or coronary artery disease, missed or incomplete abortion, known or suspected carcinoma of the breast or genital organs, severe hepatic dysfunction, as a diagnostic test for pregnancy.\n\nSide effects: Dizziness, nausea, headache, fatigue, emotional lability, irritability; abdominal pain and distention; muskuloskeletal pain.\n\nPrecaution: Monitor closely for loss of vision, proptosis, diplopia, migraine, signs and symptoms of embolic disorders. CVD or renal impairment, epilepsy, asthma, other conditions which may be aggravated by fluid retention. Lactation.\n\nMode of action: Carbamazepine, griseofulvin, phenobarbital, rifampicin enhances the clearance of progestogens.\n\nPregnancy category: Not Classified\n\nInteraction: Carbamazepine, griseofulvin, phenobarbital, rifampicin enhances the clearance of progestogens.
Efalizumab	\n\n\tIndication: Psoriasis\n\nDose: Adult: SC Initial: 0.7 mg/kg, then 1 mg/kg/wk. Usual duration: 12 wk. Max: 200 mg/dose.\n\nContra-indication: Known hypersensitivity. Should not be used in patients with clinically important infections.\n\nSide effects: Headache, fever, nausea, vomiting.\n\n\nPrecaution: Monitor platelet counts before and during treatment. Acellular, live and live-attenuated vaccines should not be given during treatment. Pregnancy and lactation.\n\nMode of action: Avoid concurrent admin of other immunosuppressive agents or with phototherapy.\n\nPregnancy category: C\n\nInteraction: Avoid concurrent admin of other immunosuppressive agents or with phototherapy.
Emtricitabine + Tenofovir disoproxil	\n\n\tIncepta\tEmtifovir TAB dr 200mg + 300mg 8's pack \n\tIndication: HIV-1 infection, Reduce the risk of getting HIV-1 infection\n\nDose: Adult: One tablet once daily taken orally with or without food.\n\nRenal impairment: Patient on haemodialysis: Not recommended.\nCrCl (ml/min)	\n30-49	1 tablet every 48 hr.\n<30	        Not recommended.\n\nContra-indication: Lactation. Not to be used for treatment of chronic hepatitis B virus (HBV) infection.\n\nSide effects: Renal impairment, acute renal failure, Fanconi syndrome.\nPotentially Fatal: Lactic acidosis and severe hepatomegaly with steatosis. \n\nNausea, vomiting, diarrhoea, abdominal pain, dyspepsia, flatulence, pain, hypersensitivity, increased pigmentation, asthenia, osteonecrosis, osteomalacia, metabolic abnormalities (e.g. hyperglycaemia, insulin resistance, hypercholesterolaemia, hypertriglyceridaemia, hyperlactataemia), lipodystrophy, elevated lipase, amylase, creatine kinase or transaminases levels, hyperbilirubinaemia, insomnia, abnormal dreams. Neutropenia, anaemia, Immune Reactivation Syndrome. \n\nPrecaution: Lactic Acidosis/Severe Hepatomegaly With Steatosis. Liver impairment. Renal impairment; avoid in CrCl <30ml/min and in patients on dialysis. Pregnancy. Not to be used with other emtricitabine, tenofovir disoproxil fumarate or other cytidine analogues (e.g. lamivudine and zalcitabine) preparations. \n\n Increased risk for severe and potentially fatal hepatic adverse reactions in patients with HIV and hepatitis B or C virus co-infection treated with antiretroviral agents. If combination drug is discontinued in patients co-infected with HIV and HBV, monitor hepatic function for several months for acute exacerbation of hepatitis. Discontinue therapy if there is a rapid rise in aminotransferase concentrations, progressive hepatomegaly or steatosis, metabolic or lactic acidosis of unknown cause. Test for presence of chronic HBV before initiating therapy. \n\nCheck CrCl before initiation of therapy and monitor renal function (CrCl and serum phosphate) every 4 wkly during the 1st year and then every 3 mthly (more frequently in patients at risk for renal impairment). Bone monitoring needed for patient with history of pathologic bone fracture or at risk of osteopenia. Monitor child exposed in utero to combination drug for possible mitochondrial dysfunction.\n\nMode of action: Decreased atazanavir concentration with tenofovir unless also co-administered with ritonavir. Increased serum concentration of both tenofovir and emtricitabine or co-administered drug if taken with drugs that are eliminated by active tubular secretion.\nPotentially Fatal: Increased risk of renal impairment with recent or concurrent use of nephrotoxic agents (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2); monitor renal function wkly if unavoidable. Increased didanosine levels and thereby increasing risk of pancreatitis and peripheral neuropathy, with a high treatment failure rate with concurrent use; avoid concurrent use. Do not use emtricitabine with lamivudine due to similar resistance profile. Increased risk of lactic acidosis with ?-interferon.\n\nPregnancy category: B\n\nInteraction: Decreased atazanavir concentration with tenofovir unless also co-administered with ritonavir. Increased serum concentration of both tenofovir and emtricitabine or co-administered drug if taken with drugs that are eliminated by active tubular secretion.\nPotentially Fatal: Increased risk of renal impairment with recent or concurrent use of nephrotoxic agents (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2); monitor renal function wkly if unavoidable. Increased didanosine levels and thereby increasing risk of pancreatitis and peripheral neuropathy, with a high treatment failure rate with concurrent use; avoid concurrent use. Do not use emtricitabine with lamivudine due to similar resistance profile. Increased risk of lactic acidosis with ?-interferon.
Enoxaparin Sodium	\n\n\tBristol Myers Squibb Pvt. Ltd.,USA\tClexane Injection 100mg/1ml  600\n\tSanofi Winthrop Industries,France\tClexane 2000 anti-xaIU/0.2ml Injection 20mg/0.2ml 1's pack 425.06\n\tSanofi Winthrop Industries,France\tClexane 4000 anti-xaIU/0.4ml Injection 40mg/0.4ml 1's pack 743.06\n\tSanofi Winthrop Industries,France\tClexane 6000 anti-xaIU/0.6ml Injection 60mg/0.6ml 1's pack 1049.52\n\tSanofi Winthrop Industries,France\tClexane 8000 anti-xaIU /0.8ml Injection 80mg/0.8ml 1's pack 1343.38\n\tIndication: Myocardial infarction, Unstable angina, Venous thromboembolism, Deep vein thrombosis\n\nDose: Adult: SC Prophylaxis of venous thromboembolism during surgery Low-moderate risk: 20 mg once daily, start 2 hr before start of procedure. High risk: 40 mg once daily, start 12 hr before start of procedure. \n\nChild: <2 mth 750 mcg/kg (75 u/kg) 12 hrly; >2 mth 500 mcg/kg (50 u/kg) 12 hrly.\n\nFor hip replacement surgery: 40 mg once daily for a further 3 wk. For immobilised patients: 40 mg once daily for at least 6 days or until patient is ambulant, up to a max of 14 days. \n\nDeep vein thrombosis 1 mg/kg 12 hrly for 5 days and until oral anticoagulation is established. \n\nPrevention of clotting in extracorporeal circulation during haemodialysis 1 mg/kg into the arterial line of the circuit at the start of the dialysis session. Give a further dose of 0.5-1 mg/kg if needed. \n\nUnstable angina 1 mg/kg 12 hrly for 2-8 days w/ low dose aspirin.\n\nParenteral\nAcute ST-elevation myocardial infarction\nAdult: Initially, 30 mg (3000 u) via IV w/ 1 mg/kg (100 u/kg) via SC given at the same time. Dose should be followed by 1 mg/kg (100 u/kg) via SC 12 hrly for 8 days or until hospital discharge. The 1st 2 SC doses should not exceed 100 mg (10,000 u) each. \nPatients who undergo PCI: An additional 300 mcg/kg (30 u/kg) via IV given at the time of the procedure if the last SC dose was given >8 hr ago.\n\nElderly: >75 yr SC: 750 mcg/kg (75 u/kg) 12 hrly, w/ max 75 mg (7500 u) for each of the 1st 2 doses.\n\n\nContra-indication: Hypersensitivity, acute bacterial endocarditis; major bleeding disorder, haemorrhagic stroke, drug-induced thrombocytopenia.\n\nSide effects: Thrombocytopenia, mild bleeding, inj site irritation, pain and ecchymoses, hypersensitivity and erythema.\nPotentially Fatal: Haemorrhagic complications.\n\nPrecaution: Renal or hepatic impairment, history of GI ulceration, uncontrolled hypertension, spinal or epidural anaesthesia; lactation and pregnancy; elderly. Periodic blood counts, platelet count and stool occult blood test recommended.\n\nMode of action: Increased risk of bleeding w/ anticoagulants, platelet aggregation inhibitors (e.g. dipyridamole, salicylates, NSAIDs, sulfinpyrazone). May increase bleeding w/ vit E.\n\nPregnancy category: B\n\nInteraction: Increased risk of bleeding w/ anticoagulants, platelet aggregation inhibitors (e.g. dipyridamole, salicylates, NSAIDs, sulfinpyrazone). May increase bleeding w/ vit E.
Epidoxorubicin HCl	\n\n\tIndication: AIDS-related Kaposi's sarcoma, ovarian carcinoma, breast carcinoma, malignant neoplasms in the bladder \n\nDose: Adult: IV AIDS-related Kaposi's sarcoma As pegylated liposome: 20 mg/m2 once 2-3 wkly. \nOvarian carcinoma As pegylated liposome: 50 mg/m2 once 4 wkly. \nMetastatic breast carcinoma w/ cyclophosphamide: 60-75 mg/m2 once 3 wkly. \nIrrigation Local malignant neoplasms in the bladder As 1 mg/mL soln: Instill 50 mL into the bladder for 1 hr once mthly.\n\nContra-indication: Cardiac disease, neonates, pregnancy and lactation, prior irradiation to mediastinum. IM/SC admin. Severe myelosuppression due to previous treatment with antitumour agents or radiotherapy.\n\nSide effects: Leucopenia, thrombocytopenia, nausea, vomiting, diarrhoea. Rarely facial flushing, rash, alopecia. Blurred vision, headache, seizures, paraesthesia, confusion, malaise, lethargy, skin pigmentation.\nPotentially Fatal: Bone marrow suppression, cardiotoxicity.\n\nPrecaution: Elderly, children, hepatic impairment. Monitor blood counts and ECG.\n\nMode of action: Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.\nPotentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.\n\nPregnancy category: D\n\nInteraction: Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.\nPotentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.
Epirubicin Hydrochloride	\n\n\tPfizer Italia Srl, Italy\tFarmorubicin Injection 50mg 50mg vial 3704.60\n\tIndication: Acute leukaemias; Lymphoma; Multiple myeloma, Breast cancer, Bladder carcinoma\n\nDose: Adult: IV Acute leukaemias; Lymphoma; Multiple myeloma; Solid tumours As a single agent: 60-90 mg/m2 3-4 wkly. Max (total cumulative dose): 0.9-1 g/m2. \nPalliative care: 12.5-25 mg/m2 once wkly. \n\nAdjuvant treatment in axillary-node positive breast cancer Recommended starting doses: 100-120 mg/m2 as a single dose on day 1 or as 2 divided doses on days 1 and 8 of each 28-day cycle. Repeat for 6 cycles. \nIntravesical Local treatment of bladder carcinoma As 0.1% soln: 50 mg/wk for 8 wk; reduce dose if chemical cystitis develops. \n\nFor carcinoma in-situ: 80 mg in 50 mL wkly. For prevention of recurrence in patients who have undergone transurethral resection: 50 mg/wk for 4 wk, followed by 50 mg/mth for 11 mth; retain soln in the bladder for 1 hr during each administration.\n\nContra-indication: Cardiac impairment, severe or recent MI; previous full cumulative doses of anthracyclines. Hypersensitivity; severe hepatic dysfunction. Not for intravesical use where invasive tumours have penetrated the bladder wall; urinary infections, bladder inflammation or catheterisation problems. Pregnancy, lactation.\n\nSide effects: Myelosuppression; cardiotoxicity, alopoecia; mucositis; hyperpyrexia; lethargy; amenorrhoea; nausea and vomiting; diarrhoea; fever; rash, skin changes, anorexia; anaphylaxis; photosensitivity; premature menopause; skin and nail hyperpigmentation; harmless reddish appearance of urine for 1-2 days.\n\nPrecaution: Previous extensive radiotherapy, bone infiltration by tumour, severe renal and hepatic dysfunction. May cause tumor lysis syndrome or radiation recall. Elderly women >70 yr. CV disease, hypertensive cardiomyopathy; monitor hematological and cardiac function regularly. Extravasation during IV admin may result in severe local tissue necrosis. Do not give via IM/SC routes as extravasation can lead to severe local necrosis.\n\nMode of action: Paclitaxel and other anthracyclines. Cimetidine, heparin. Antineoplastic drugs, cardiotoxic drugs, radiation, hepatoactive drugs.\n\nPregnancy category: D\n\nInteraction: Paclitaxel and other anthracyclines. Cimetidine, heparin. Antineoplastic drugs, cardiotoxic drugs, radiation, hepatoactive drugs.
Epoetin alfa (Recombinant Human Erythropoietin)	\n\n\tCilag AG, Switzerland\tEPREX Injection 2000IU/0.5ml pre-filled syringe x 1's 1524.90\n\tCilag AG, Switzerland\tEPREX Injection 4000IU/0.4ml pre-filled syringe x 1's 2809\n\tCilag AG, Switzerland\tEPREX Liquid for Intraaocular Application 10000IU/1ml pre-filled syringe x 1's 5250.60\n\tIndication: Anaemia of chronic renal failure, Anaemia in zidovudine-treated HIV-infected patients, Anemia related to non-myeloid malignant disease chemotherapy, To reduce the need for allogenic blood tranfusion, Anaemia of prematurity.\n\nDose: Adult: IV Increase yield of autologous blood 600 u/kg twice wkly starting 3 wk before surgery. \n\nIV/SC Anaemia of chronic renal failure Predialysis and haemodialysis: Initial: 50 iu/kg 3 times/wk. May increase slowly. \n\nPeritoneal dialysis: Initial: 50 u/kg twice wkly. Total maintenance dose/wk: Predialysis: 50-100 u/kg in 3 divided doses; \n\nHaemodialysis: 75-300 u/kg in 3 divided doses; Peritoneal dialysis: 50-100 u/kg in 2 divided doses. \n\nAnaemia in zidovudine-treated HIV-infected patients Initial: 100 u/kg 3 times/wk for 8 wk. May increase slowly. Not >300 u/kg 3 times/wk.\n\n SC Anemia related to non-myeloid malignant disease chemotherapy Initial: 150 u/kg 3 times/wk, up to 300 u/kg 3 times/wk after 4-8 wk if needed. To reduce the need for allogenic blood tranfusion 600 u/kg once wkly starting 3 wk before surgery w/ the 4th dose given on the day of surgery.\n\nContra-indication: Hypersensitivity to albumin (human) or mammalian cell-derived products; uncontrolled hypertension.\n\nSide effects: Headache, hypertension and seizures. Hypertensive crisis with encephalopathy-like symptoms; thrombosis at vascular access sites and clotting in the dialyser. Transient increases in the platelet count. Flu-like symptoms including chills and myalgia; hyperkalaemia and skin rashes; anaphylactoid reactions. Rarely, pure red cell aplasia after prolonged treatment in patients with prolonged renal failure.\n\nPrecaution: Hypertension; history of seizures; thrombocytosis; chronic liver failure; poor renal function; ischaemic vascular disease; malignant tumours. Increased risk of thrombotic events. Monitor BP during treatment. Regularly monitor platelet counts and serum-potassium concentration. Iron deficiency, infection or inflammatory disorders, haemolysis, or aluminium intoxication will reduce efficacy. Proper dosage control is required to prevent to rapid increase in the haematocrit and haemoglobin levels. Pregnancy; lactation.\n\nMode of action: Cyclosporine, hematinic agents, drugs that decrease erythropoiesis. Potentiated by hematinic agents.\n\n\n\nPregnancy category: C\n\nInteraction: Cyclosporine, hematinic agents, drugs that decrease erythropoiesis. Potentiated by hematinic agents.\n\n
Epoetin beta	\n\n\tRoche Bangladesh Pharmaceutical\tRecormon Injection 2000, 5000, 10000 IU pre-filled syringe x 1's 1250, 2995, 6300\n\tIndication: Anaemia of chronic renal failure, Anaemia in zidovudine-treated HIV-infected patients, Anemia related to non-myeloid malignant disease chemotherapy, To reduce the need for allogenic blood tranfusion, Anaemia of prematurity.\n\nDose: Adult: IV Anaemia of chronic renal failure40 u/kg 3 times/wk for 4 wk via IV admin, up to 80 u/kg 3 times/wk. Increase yield of autologous blood Up to 800 u/kg twice wkly for 4 wk pre-op. \n\nSC Anaemia of chronic renal failure60 u/kg/wk for 4 wk. Increase yield of autologous blood Up to 600 u/kg twice wkly for 4 wk pre-op. \n\nAnaemia of prematurity 250 u/kg 3 times/wk. Start as early as possible and continue for 6 wk. Anemia related to non-myeloid malignant disease chemotherapy 450 u/kg/wk. May double dose after 4 wk if needed. May continue for up to a mth after chemotherapy\n\nContra-indication: Uncontrolled hypertension. Neonates: injections containing benzyl alcohol.\n\nSide effects: Headache, seizures; hypertension; thrombosis at vascular access sites, clotting in the dialyser, transient increases in platelet count, flu-like symptoms including chills, myalgia, hyperkalaemia, skin rashes; hypertensive crisis with encephalopathy-like symptoms, including headache and confusion, generalised seizures (patients with normal or low blood pressure). Rarely, anaphylactoid reactions.\n\nPrecaution: Hypertension, history of seizure, thrombocytosis, chronic hepatic impairment, ischaemic vascular disease, malignant tumours, epilepsy; recent MI or CVA. Fe deficiency, infection, inflammatory disorders, haemolysis and aluminium intoxication may decrease response to epoetin beta. Regularly monitor platelet counts and serum-potassium concentrations. Control haematocrit levels. Poorly-controlled hypertension: Monitor BP, Hb and electrolytes. Anaemia (eg, megaloblastic or folic acid): Give Fe supplements when needed. Thromobocytosis: monitor platelet count for 1st 8 wk. Lactation.\n\nMode of action: Antagonises the hypotensive effects of ACE inhibitors and angiotensin-II receptor antagonists and increases risk of hyperkalaemia\n\nPregnancy category: C\n\nInteraction: Antagonises the hypotensive effects of ACE inhibitors and angiotensin-II receptor antagonists and increases risk of hyperkalaemia
Eptacog Alfa	\n\n\tIndication: Hemophilia, bleeding episodes\n\nDose: The recommended initial dose administered by IV bolus is 90 mcg/kg body wt over 2-5 mins. Further inj may be repeated. Dose range: 3-6 KIU (60-120 mcg)/kg body wt/single dose. Dose interval initially 2-3 hr to obtain haemostasis. Duration of treatment & interval between inj will vary w/ the severity of haemorrhage, invasive procedures or surgery performed. Treatment may be continued for 2-3 wk for serious bleeding or surgery.      \n\nContra-indication: Hypersensitivity to the active substance, the excipients, or to mouse, hamster or bovine protein.\n\nSide effects: Undesirable effects, Blood and lymphatic system disorders ,Immune system disorders ,Nervous system disorders ,Vascular disorders ,Gastrointestinal disorders ,Skin and subcutaneous disorders, \n\nPrecaution: There may be a potential risk of development of thrombotic events or induction of\nDisseminated Intravascular Coagulation (DIC).\n Because the risk of thromboembolic complications, caution should be exercised  to patients with a history of coronary heart disease, to patients with liver disease, to patients\nundergoing major surgery, to neonates, or to patients at risk of thromboembolic phenomena or disseminated intravascular coagulation. In each of these situations, the potential benefit of treatment should be weighed against the risk of these complications.\n\nIf allergic or anaphylactic-type reactions occur, the administration should be discontinued\nimmediately. In case of anaphylactic shock, standard medical treatment for shock should be\nimplemented. \n\nPatients with rare hereditary problems of fructose intolerance, glucose malabsorption or\nsucrose-isomaltase insufficiency should not take this medicine.\n\nMode of action: Risk of potential DI w/ coagulation factor conc unknown. Avoid simultaneous use of prothrombin complex conc, activated or not. Not recommended to combine rFVIIa & rFXIII.\n\nPregnancy category: C\n\nInteraction: Risk of potential DI w/ coagulation factor conc unknown. Avoid simultaneous use of prothrombin complex conc, activated or not. Not recommended to combine rFVIIa & rFXIII.
Estrogens	\n\n\tPfizer Pharmaceuticals, Ireland\tPremarin TAB dr 0.625mg 0.625mg x 100's pack 202.60\n\tIndication: Breast cancer, Prostate cancer, Hormone replacement therapy, Oral contraceptives\n\nDose: Adult: PO Menopausal vasomotor symptoms 0.45 mg/day, up to 1.25 mg/day. Attempt to discontinue medication at 3-6-mth intervals. \n\nVulvular and vag atrophy 0.3 mg/day. Female hypogonadism 0.3-0.625 mg/day in a cyclical regimen. Add progestin treatment once skeletal maturity is achieved. \n\nFemale castration; Primary ovarian failure 1.25 mg/day in a cyclical regimen. \n\nPalliation in prostate carcinoma 1.25-2.5 mg 3 times/day. \n\nOsteoporosis prophylaxis in postmenopausal women Initial: 0.3 mg/day in a cyclical or continuous regimen depending on patient's condition.\n\nContra-indication: Severe liver impairment; breast carcinoma; thromboembolic disorders; CV disease; undiagnosed vag bleeding; estrogen-dependent neoplasms; hypersensitivity; pregnancy.\n\nSide effects: Abnormal bleeding; vomiting, nausea; tender breasts, wt gain, fluid retention; headache, depression. Males: Gynaecomastia, impotence.\nPotentially Fatal: Unopposed replacement therapy in postmenopausal women associated with increased risk of endometrial and breast cancer.\n\nPrecaution: Asthma, epilepsy, migraine; heart or kidney dysfunction; CV disease; cerebrovascular disorders; diabetes, hypercalcaemia; gall bladder disease; porphyria. Childn. Lactation.\n\nMode of action: Rifampicin, barbiturates increase rate of metabolism.\nPotentially Fatal: May reduce the efficacy of anticoagulants.\n\nPregnancy category: Not Classified\n\nInteraction: Rifampicin, barbiturates increase rate of metabolism.\nPotentially Fatal: May reduce the efficacy of anticoagulants.
Ethyl Chloride	\n\n\tIndication: Local anesthesia\n\nDose: Adult: Topical As spray containing 88 g/100 mL: Spray at a distance of 30 cm from skin surface until a fine white film is produced.\n\nContra-indication: Hypersensitivity; porphyria. Application on broken skin or mucous membranes.\n\nSide effects: Thawing of frozen tissue after surgery may be painful. Chemical frostbite may occur following prolonged spraying onto the skin. Nephrotoxicity or hepatotoxicity (long-term exposure).\n\nPrecaution: To protect against tissue sloughing, cover the skin adjacent to the area being treated with petrolatum. Avoid spilling the liquid on the skin. Freezing may also distort the histological structure of biopsy specimens. Highly flammable. Avoid inhalation when used as local anaesthesia.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Etonogestrel	\n\n\tIndication: Contraception\n\nDose: Adult: Vag Per vag ring delivers etonorgestrel 120 mcg and ethinylestradiol 15 mcg daily. Insert 1 ring into the vagina on the 1st day of menstruation. Leave the ring in place for 3 wk, then allow for 1 wk break. Insert a new ring 1 wk after removal of the previous ring. Subdermal Per implant contains 68 mg of etonorgestrel: Insert 1 implant during the 1st 5 days of menstruation. Remove no later than 3 yr after date of insertion.\n\nContra-indication: Pregnancy, undiagnosed vag bleeding, severe arterial disease; liver adenoma; active liver disease; current or history of thromboembolic disorders; porphyria; after evacuation of hydatidiform mole; history of breast cancer.\n\nSide effects: Menstrual irregularities; nausea, vomiting, headache, dizziness, breast discomfort, gynaecomastia, depression, skin disorders, disturbance of appetite, wt changes, fluid retention, oedema, changes in libido, cholestatic jaundice, hair loss or hirsutism.\n\nPrecaution: Heart disease, sex-steroid dependent cancer, history of ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, recurrent cholestatic jaundice, history of jaundice in pregnancy; history of pruritus during pregnancy or of deterioration of otosclerosis; disturbances of lipid metabolism; history of CV or renal impairment, DM, asthma, epilepsy, migraine, depression; lactation. May develop bleeding irregularities.\n\nMode of action: Reduced efficacy with hepatic enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism. Changes in efficacy and safety of treatment when used in combination with protease inhibitors.\n\nPregnancy category: Not Classified\n\nInteraction: Reduced efficacy with hepatic enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism. Changes in efficacy and safety of treatment when used in combination with protease inhibitors.
Etonogestrel + Ethinylestradiol	\n\n\tIndication: Contraception\n\nDose: Adult: Vag Per vag ring delivers etonorgestrel 120 mcg and ethinylestradiol 15 mcg daily. Insert 1 ring into the vagina on the 1st day of menstruation. Leave the ring in place for 3 wk, then allow for 1 wk break. Insert a new ring 1 wk after removal of the previous ring. Subdermal Per implant contains 68 mg of etonorgestrel: Insert 1 implant during the 1st 5 days of menstruation. Remove no later than 3 yr after date of insertion.\n\nContra-indication: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:\n\n    Smoke, if over age 35 \n    Have deep vein thrombosis or pulmonary embolism, now or in the past \n    Have cerebrovascular disease  \n    Have coronary artery disease  \n    Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) \n    Have inherited or acquired hypercoagulopathies \n    Have uncontrolled hypertension  \n    Have diabetes mellitus with vascular disease \n    Have headaches with focal neurological symptoms or migraine headaches with aura \n        Women over age 35 with any migraine headaches \n\nLiver tumors, benign or malignant or liver disease \nUndiagnosed abnormal uterine bleeding \nPregnancy, because there is no reason to use CHCs during pregnancy \nBreast cancer or other estrogen- or progestin-sensitive cancer, now or in the past  \nHypersensitivity \n\nSide effects: The following serious adverse reactions with the use of CHCs are discussed elsewhere in the labeling.\n\n    -Serious cardiovascular events and stroke \n   - Vascular events \n   - Liver disease \n\nAdverse reactions commonly reported by CHC users are:\n\n   - Irregular uterine bleeding\n    -Nausea\n   - Breast tenderness\n    -Headache\n\n\nPrecaution:   1 Thromboembolic Disorders and Other Vascular Problems\n 2 Toxic Shock Syndrome (TSS)\n 3 Liver Disease\n 4 High Blood Pressure\n 5 Vaginal Use\n 6 Gallbladder Disease\n 7 Carbohydrate and Lipid Metabolic Effects\n 8 Headache\n 9 Bleeding Irregularities and Amenorrhea\n 10 Inadvertent Urinary Bladder Insertion\n 11 CHC Use Before or During Early Pregnancy\n 12 Depression\n 13 Carcinoma of the Breasts and Cervix\n 14 Effect on Binding Globulins\n 15 Monitoring\n 16 Hereditary Angioedema\n 17 Chloasma \n\nMode of action:  	CYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol.\nPotentially Fatal: Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs.\nReduced efficacy with hepatic enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism. Changes in efficacy and safety of treatment when used in combination with protease inhibitors.\n\nPregnancy category: X\n\nInteraction:  	CYP1A2 and CYP3A4 inducers such as aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together. Altered anticoagulant effect when used with dicoumarol.\nPotentially Fatal: Antibiotics (ampicillin, tetracycline, sulphonamides and chloramphenicol) can cause intermenstrual bleeding or failure of contraception. Reduced efficacy of antihypertensives or hypoglycaemic drugs.\nReduced efficacy with hepatic enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism. Changes in efficacy and safety of treatment when used in combination with protease inhibitors.
Exemestane	\n\n\tIndication: Breast cancer in postmenopausal women\n\nDose: Adult: PO 25 mg once daily.\n\nContra-indication: Hypersensitivity. Premenopausal women. Pregnancy and lactation.\n\nSide effects: Hot flushes; nausea; fatigue; increased sweating; dizziness; headache; insomnia; skin rash; abdominal pain; anorexia, vomiting (less frequently), dyspepsia, depression, alopoecia, peripheral oedema, constipation, dyspepsia. Rarely thrombocytopaenia, leucopaenia.\n\nPrecaution: Hepatic and renal impairment. Monitor bone mineral density at regular intervals especially in patients at risk of osteoporosis.\n\nMode of action: May result in reduced plasma levels of exemestane when used with CYP3A4 enzyme inducers. Oestrogen-containing drugs; St. John's wort, black cohosh, dong quai.\n\nPregnancy category: X\n\nInteraction: May result in reduced plasma levels of exemestane when used with CYP3A4 enzyme inducers. Oestrogen-containing drugs; St. John's wort, black cohosh, dong quai.
Factor IX Complex	\n\n\tIndication: Haemophilia B\n\nDose: Adult: IV Replacement therapy in haemophilia B Dosage is individualised dependng on the preparation used, severity of the disease and type of surgery. Suggested target factor IX concentrations: To be raised to 20-30% of normal for mild-moderate haemorrhage; 30-60% of normal for more serious haemorrhage or minor surgery and 60-100% of normal for severe haemorrhage or major surgery. Prophylaxis in severe haemophilia B 20-40 IU/kg every 3-4 days as needed.\n\nContra-indication: Hypersensitivity to mouse or hamster protein.\n\nSide effects: Nausea and vomiting, headache, and flushing particularly after rapid infusion. Hypersensitivity reactions such as chills and urticaria.\nPotentially Fatal: Severe allergic reactions.\n\nPrecaution: Caution when used in patients at risk of thromboembolism or disseminated intravascular coagulation. May cause increased risk of intravascular coagulation and thrombosis in patients with hepatic impairment. Risk of viral infection transmission as factor IX complex is a plasma-derived product. Vaccination against hepatitis A and B are recommended in haemophilic patients. Safety and efficacy have not been demostrated in patients < 16 yr. Pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Factor VIII	\n\n\tGrifols Biologicals Inc, USA\tAphanate 		 		 	 Injection 250IU, 500IU 1's pack \n\tIndication: Haemophilia A, Haemorrhage \n\nDose: Adult: IV Replacement therapy in patients w/ haemophilia A Dosage is individualised based on coagulation test results. Recommended doses vary according to preparation used. \n\nSuggested doses: Mild-moderate haemorrhage (increase to 20-30% of normal): 10-15 u/kg as a single dose; \n\nMore serious haemorrhage or minor surgery (increase to 30-50% of normal): Initial: 15-25 u/kg followed by 10-15 u/kg 8-12 hrly if required; severe haemorrhage or major surgery (increase to 80-100% of normal): Initial: 40-50 u/kg followed by 20-25 u/kg 8-12 hrly. Refer to individual product information for further dosing details. \n\nProphylaxis in severe haemophilia A 10-50 u/kg every 2-3 days, as needed.\n\nContra-indication: Hypersensitivity\n\nSide effects: Allergic reactions e.g. chills, chest tightness, fever, headache, hyperfibrinogenaemia, jittery feeling, lethargy, nausea, vomiting, somnolence, stinging at infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion.\n\nPrecaution: Risk of intravascular haemolysis in patients with blood groups A, B, or AB receiving high doses or repeated doses of factor VIII preparations. Risk of transmission of some viral infections especially hepatitis B and C. Dose requirement may vary in patients with factor VIII inhibitors; thus optimal treatment should be based on clinical response. Monitor platelet counts regularly during treatment. Pregnancy, lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Famciclovir INN	\n\n\tNovartis Farmaceutica S.A., Spain\tFamvir TAB dr 125mg 10's pack 1310\n\tNovartis Farmaceutica S.A., Spain\tFamvir TAB dr 250mg 21's pack 4263\n\tIndication: Genital herpes, Herpes zoster, Herpes labialis, CMV infections, Mucocutaneous herpes\n\nDose: Adult: PO Herpes zoster 250 mg 3 times/day for 7 days. \n\nRenal impairment: For immunocompromised patients: CrCl >40 ml/min: 500 mg tid; 30-39 ml/min: 250 mg tid; 10-29 ml/min: 125 mg tid.\nCrCl (ml/min)	\n30-59	 For immunocompetent patients: 250 mg bid.\n10-29	 For immunocompetent patients: 250 mg once daily. \n\nRecurrent episodes of genital herpes 125 mg twice daily for 5 days. \n\nRenal impairment:\nCrCl (ml/min)	\n10-29	For immunocompetent patients: 125 mg once daily. \n\nSuppression of recurrent episodes of genital herpes 250 mg twice daily. Recurrent mucocutaneous herpes in HIV-infected patients 500 mg twice daily for 7 days. \n\nRenal impairment:\nCrCl (ml/min)	\n>30	         For immunocompetent patients: 250 mg bid.\n10-29	For immunocompetent patients: 125 mg bid\n\nGenital herpes For 1st episodes: 250 mg 3 times/day for 5 days. \n\nRenal impairment:\nCrCl (ml/min)	\n30-59	For immunocompetent patients: 250 mg bid.\n10-29	For immunocompetent patients: 250 mg once daily. \n\nRecurrent herpes labialis 1.5 g as a single dose at the 1st sign or symptom.\n\nContra-indication: Hypersensitivity. Lactation.\n\nSide effects: Dizziness, headache, diarrhoea, constipation, nausea, vomiting, hallucinations, confusion, pruritus, abdominal pain, fever.\n\nPrecaution: Renal impairment. Pregnancy.\n\nMode of action: Reduced renal excretion resulting to increased plasma concentration w/ probenecid. Raloxifen may reduce the formation of penciclovir, the active metabolite of famciclovir.\n\nPregnancy category: B\n\nInteraction: Reduced renal excretion resulting to increased plasma concentration w/ probenecid. Raloxifen may reduce the formation of penciclovir, the active metabolite of famciclovir.
Filgrastim	\n\n\tBeacon\tFilgrast Injection 30 MIU/0.5ml 30 MIU (0.5ml) amp x 1's pack 2750\n\tHealthcare\tNeufil Injection 30 MIU/0.5 ml  \n\tHealthcare\tNeufil Injection 120 mcg/0.2 ml  \n\tIncepta\tFilastin Injection 30 MIU/ml 30 MIU (0.5ml) amp x 1's pack 2890\n\tSquare\tGrastim prefield syrige Injection 30 MIU / 0.5 ml  \n\tTechno Drugs Ltd.\tNeugrastim Injection 30 MIU/.5 ml  \n\tF. Hoffmann La Roche,Switzerland\tNeupogen Injection 30 Mio U 30 MIU ( 1ml) amp x 1's pack 7194\n\tIndication: Myelosuppressive chemotherapy, Acute Myeloid Leukemia receiving induction or consolidation chemotherapy, Peripheral blood progenitor cell collection and therapy, Severe Neutropenia, Bone marrow transplantation, HIV infection.						\n\nDose: Cancer patients receiving myelosuppressive chemotherapy: The recommended starting dose of Filgrastim is 5 mcg/kg/day. Doses may be increased in increments of 5 mcg/kg for each chemotherapy cycle. \n\nCancer patients receiving bone marrow transplant: The recommended dose of Filgrastim following bone marrow transplantation is 10 mcg/kg/day. During the period of neutrophil recovery, the daily dose should be titrated against the neutrophil response as follows: \n\nAbsolute Neutrophil Count (ANC): Dose adjustment ANC>1000/mm3 for consecutive 3 days Reduces to 5 mcg/kg/day. Then, If ANC remains >1000/mm3 for consecutive 3 days Discontinue drug. Then, If ANC remains <1000/mm3 for consecutive 3 days Resume at 5 mcg/kg/day. \n\nPatients with chronic neutropenia: The recommended daily starting dose is 5 mcg/kg/day in idiopathic neutropenia. \n\nPeripheral blood progenitor cell collection and therapy: The recommended starting dose is 10 mcg/kg/day. Dose may be adjusted as required. \n\nHIV infection and persistent neutropenia Initial: 1 mcg/kg/day, up to 4 mcg/kg/day until neutrophil count is normalized. Maintenance: 300 mcg/day. Max: 4 mcg/kg/day.\n\n\nContra-indication: Hypersensitivity to E. coli derived proteins, Filgrastim or any component of the product. Myeloid malignancies. Not to be used within 24 hr of cytotoxic chemotherapy admin due to the sensitivity of rapidly dividing myeloid cells. Severe congenital neutropaenia (Kostman's syndrome) with abnormal cytogenetics.\n\nSide effects: Musculoskeletal pain, bone pain, hypersensitivity reactions, splenic rupture, acute respiratory distress syndrome, alveolar hemorrhage and haemoptysis, sickle cell crisis, splenic enlargement, hepatomegaly, thrombocytopaenia, anaemia, epistaxis, headache, nausea, vomiting, diarrhoea, urinary abnormalities (dysuria, proteinuria, haematuria), osteoporosis, exacerbation of rheumatoid arthritis, transient decrease in blood glucose, raised uric acid, cutaneous vasculitis, transient hypotension.Potentially Fatal: Pulmonary infiltrates leading to resp failure or acute resp distress syndrome.\n\nPrecaution: Filgrastim should not be administered within 24 hours before and after chemotherapy. Premalignant or malignant myeloid condition; sickle-cell disease; osteoporotic bone disease; withdraw treatment if there are signs of pulmonary infiltrates. Fluid retention or heart failure. Monitor CBC and platelet count during therapy. Monitor bone density in patients with osteoporosis (long-term treatment). Regular morphological and cytogenic bone-marrow examinations in severe congenital neutropenia. Pregnancy and lactation.\n\nMode of action: Myelosuppressive antineoplastic agents. Drugs which may potentiate the release of neutrophils e.g. lithium.\n\nPregnancy category: C\n\nInteraction: Myelosuppressive antineoplastic agents. Drugs which may potentiate the release of neutrophils e.g. lithium.
Fludarabin Phosphate	\n\n\tIndication: Chronic lymphocytic leukaemia\n\nDose: Adult: PO 40 mg/m2/day for 5 consecutive days. May repeat course every 28 days, usually for up to 6 cycles. IV 25 mg/m2/day for 5 consecutive days. May repeat course every 28 days, usually for up to 6 cycles.\n\nRenal impairment: Avoid in severe impairment.\nCrCl (ml/min)	\n30-70	May reduce doses by up to 50%. \n\nContra-indication: Renal impairment (CrCl <30 mL/min); decompensated haemolytic anaemia. Pregnancy and lactation. Concomitant use of live vaccines.\n\nSide effects: Fever, chills, cough, dyspnoea, pneumonia; GI disturbances, stomatitis; oedema; tumour lysis syndrome; skin rashes; haemolytic anaemia, haemorrhagic cystitis; neurological disturbances including peripheral neuropathy, agitation, confusion, visual disturbances and coma. Progressive encephalopathy and blindness (high doses).\nPotentially Fatal: Myelosuppression. Fatal autoimmune haemolytic anemia.\n\nPrecaution: Routine monitoring of blood counts and Hb conc. Monitor for signs of autoimmune haemolytic anaemia; elderly. Avoid contact with skin and eyes; avoid inhalation. Myelosuppression may be cumulative and severe increasing risk of opportunistic infections. Increased risk of tumour lysis syndrome in patients with high tumour burden.\n\nMode of action: Co-administration with pentostatin may lead to pulmonary toxicity. Reduced metabolic activation of fludarabine with cytarabine. Reduced therapeutic efficacy with dipyridamole and other adenosine uptake inhibitors.\n\nPregnancy category: D\n\nInteraction: Co-administration with pentostatin may lead to pulmonary toxicity. Reduced metabolic activation of fludarabine with cytarabine. Reduced therapeutic efficacy with dipyridamole and other adenosine uptake inhibitors.
Flumazenil	\n\n\tF.Hoffmann La Roche, Switzerland\tAnexate Injection 0.5mg/5ml  5ml amp x 1's pack 1631.25\n\tIndication: Benzodiazepine-induced sedation,Benzodiazepine overdose\n\nDose: Adult: IV Benzodiazepine-induced sedation Initial: 200 mcg followed by 100-200 mcg at intervals of 60 seconds to a max total of 1 mg if needed. Usual range: 0.3-1 mg. \nChild: 10 mcg/kg (up to 200mcg) over 15 sec, repeated at 60-sec intervals, if necessary, up to a max of 50 mcg/kg or 1 mg, whichever is lower. \n\nBenzodiazepine overdose Initial: 200 mcg; an additional dose of 300 mcg can be given 30 sec later followed by doses of 500 mcg at 1-min intervals if needed, up to a total dose of 3 mg.\n\nContra-indication: Hypersensitivity. Patients receiving benzodiazepines for control of a potentially life-threatening condition such as status epilepticus and control of intracranial pressure. Severe intoxication with tricyclic and related antidepressants.\n\nSide effects: Nausea, vomiting, dizziness, blurred vision, headache, flushing; anxiety, fear and agitation (following too rapid reversal of sedation); seizures (especially in epileptics); transient increases in BP and heart rate.\n\nPrecaution: Should only be used until the effects of neuromuscular blockade have been fully reversed. Risk of raising intracranial pressure, precipitating convulsions or altering cerebral blood flow in patients with head injuries. Increased risk of seizures in high-risk patients. May provoke panic attacks in patient with a history of panic disorder. Hepatic impairment. Pregnancy and lactation.\n\nMode of action: Toxic effects with cyclic antidepressants. Reverses effects of benzodiazepines.\n\nPregnancy category: C\n\nInteraction: Toxic effects with cyclic antidepressants. Reverses effects of benzodiazepines.
Fluorouracil	\n\n\tBeacon\tFluroxan Injection 250mg/10ml 5 ml vial x 1's pack 60\n\tBeacon\tFluroxan Injection 500mg/10ml 10 ml vial x 1's pack 100\n\tTechno Drugs Ltd.\t5-Fluril Injection 500mg/10ml 1's pack 95\n\tPharmachemie B. V. Netherlands\tFluracedyl Injection 50mg/ml 10 ml amp x 1's pack 450\n\tIndication: Malignant neoplasm, Basal cell carcinoma, Oesophageal carcinoma\n\nDose: Adult: IV Palliation of malignant neoplasms 12 mg/kg/day (max: 0.8-1g/day) for 3-4 days, if no toxicity occurs, may be followed after 1 day w/ 6 mg/kg on alternate days for another 3-4 doses. May repeat course 4-6 wk later or maintenance doses of 5-15 mg/kg (max: 1 g) may be given wkly. \n\nAs an infusion: 15 mg/kg/day (max: 1 g/day), continue until toxicity occurs or a total of 12-15 g is given. May repeat course 4-6 wk later. Intra-arterial Palliation of malignant neoplasms 5-7.5 mg/kg/day as continuous infusion (regional perfusion).  \n\nChild: Safety & efficacy not established.\n\nContra-indication: Hypersensitivity. Depressed bone marrow function, poor nutritional status, potentially serious infections. Pregnancy and lactation.\n\nSide effects: Leucopenia, thrombocytopaenia, stomatitis, GI ulceration, bleeding and diarrhoea, haemorrhage from any site (stop treatment). Nausea, vomiting, rashes, hyperpigmentation, alopecia. Topical: Local inflammatory and photosensitivity reactions. Dermatitis and erythema multiforme (rare).\nPotentially Fatal: Central neurotoxicity, myocardial ischaemia.\n\nPrecaution: Regular monitoring of blood counts. History of heart disease, hepatic or renal insufficiency, weak or malnourished patients, patients who with history of high-dose pelvic radiation or use of alkylating agents. Patients with widespread metastases to the bone marrow.\n\nMode of action:  	May increase warfarin effects. May reduce response to vaccines; possibility of generalized infection with live vaccines. Action may be modified by allopurinol. Leucovorin calcium may enhance the toxicity of fluorouracil.\n\nPregnancy category: D\n\nInteraction:  	May increase warfarin effects. May reduce response to vaccines; possibility of generalized infection with live vaccines. Action may be modified by allopurinol. Leucovorin calcium may enhance the toxicity of fluorouracil.
Flupentixol	\n\n\tSquare\tAnxit TAB dr  50's pack \n\tH. Lundbeck & Co., A/S, Denmark\tFluanxol TAB dr 0.5mg 100's pack 981\n\tH. Lundbeck & Co., A/S, Denmark\tFluanxol TAB dr 1.0mg 50's pack 792\n\tH. Lundbeck & Co., A/S, Denmark\tFluanxol depot Injection 20mg/ml 10 amps pack 3045.50\n\tH. Lundbeck & Co., A/S, Denmark\tFluanxol depot Injection 40mg/2ml 10 amps pack 5769.20\n\tIndication: Schizophrenia, Psychoses, Depression			\n\n\nDose: Adult: PO Psychoses Initial: 3-9 mg twice daily. Max: 18 mg/day. Depression Initial: 1 mg/day, increase to 2 mg/day after 1 wk, then to 3 mg/day. Max: 3 mg/day. \n\nIM Psychoses As decanoate: Initial: 20 mg as a test dose. After at least 7 days and depending on response: Subsequent doses of 20-40 mg may be given 2-4 wkly. Usual maintenance: 50 mg 4 wkly to 300 mg 2 wkly, up to 400 mg/wk in severe cases.\n\nContra-indication: Hypersensitivity. Extremely excitable and overactive patients; mania; porphyria; coma; preexisting CNS depression; bone-marrow supression; phaeochromocytoma. Lactation.\n\nSide effects: Rigidity, tremors, restlessness, tardive dyskinesia, insomnia, dryness of mouth, wt gain, sexual dysfunction, galactorrhoea and menstrual disturbances.\nPotentially Fatal: Neuroleptic malignant syndrome (hyperthermia, hypertonicity of skeletal muscles, unconsciousness and autonomic nervous system instability).\n\nPrecaution: Patients with convulsive disorders; advanced hepatic, renal, CV or resp disease; tasks requiring mental alertness; elderly (especially with dementia), and debilitated patients; neuroleptics with sedative effect must be withdrawn gradually; history of angle-closure glaucoma; urinary retention; prostatic hyperplasia; breast cancer, prolactin dependent tumours; parkinsonism; myasthenia gravis; pregnancy; Avoid direct sunlight.\n\nMode of action:  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).\nPotentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.\n\nPregnancy category: C\n\nInteraction:  	May potentiate the adverse effects of drugs with antimuscarinic effects e.g. TCAs. Reduced efficacy of levodopa. Increases adverse extrapyramidal symptoms with dopamine antagonists (metoclopramide and prochlorperazine).\nPotentially Fatal: Potentiates CNS effects of alcohol, general anaesthetics, hypnotics, anxiolytics and opioids. Blocks antihypertensive effect of guanethidine.
Fluphenazine Decanoate	\n\n\tIncepta\tFenazine Injection 25mg/ml 5 amps pack 375\n\tRotexmedica GmbH, Germany\tFluphenazine Injection 1ml & 10ml Vial 1ml X 10 amps pack/ 10ml X 1 vials pack 960/700\n\tIndication: In the long-term management of psychotic disorders including:SchizophreniaMania andOrganic brain syndrome.\n\nDose: Fluphenazine Decanoate by deep intramuscular injection into the gluteal muscle, test dose 12.5 mg (6.25 mg in elderly), then after 4-7 days 12.5-100 mg repeated at intervals of 14-35 days, adjusted according to response; it is not recommended for children. \n\nContra-indication: Fluphenazine Decanoate oily Injection is contraindicated in patients with hypersensitivity to the drug. Also contraindicated in comatose or severely depressed states, blood dyscrasias, liver disease, pregnancy (3rd trimester), lactation.\n\nSide effects: The side effects include tardive dyskinesia, sedation, mental confusion; hypotension; hyperprolactinaemia leading to galactorrhoea and amenorrhoea in women; loss of libido, impotence and sterility in males. Also include allergic reactions, cholestatic jaundice, corneal and lens deposists, skin pigmentation. Other potential adverse reactions are agranulocytosis; neuroleptic syndrome.\n\nPrecaution: Special precaution should be practiced in presence of convulsive disorders; hepatic, renal, cerebrovascular, respiratory and cardiovascular diseases. Also precaution should be observed in case of phenochromocytoma; bone marrow suppression; elderly or debilitated patients.\n\nMode of action: Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics.\nPotentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.\n\nPregnancy category: C\n\nInteraction: Reduces antihypertensive effects of guanethidine, methyldopa and clonidine. Lithium toxicity. Reduced bioavailability with antacids. Increased risk of arrhythmia when used with drugs that prolong QT interval. May cause electrolyte disturbance when used with diuretics.\nPotentially Fatal: Additive CNS depressant effects with alcohol, barbiturates, hypnotics, sedatives, opiates and antihistamines.
Fluvastatin	\n\n\tNovartis (Bangladesh) Ltd.\tLescol XL CAP 80mg 28's pack 1092\n\tOpsonin Pharma\tLesterol CAP 20mg 10's pack 120\n\tOpsonin Pharma\tLesterol CAP 40mg 10's pack 200\n\tSilva\tFluvas CAP 20mg 12's pack 144.54\n\tNovartis Farmaceutica S.A., Spain\tLescol CAP 20mg 28's pack 840\n\tNovartis Farmaceutica S.A., Spain\tLescol CAP 40mg 28's pack 1204\n\tIndication: Hyperlipidaemias, Hypercholesterolemia\n\nDose: Adult: PO Initial: 20-40 mg/day in the evening, may increase slowly. Max: 80 mg/day.\n\nChild: Heterozygous familial hypercholesterolaemia: 9-16 yr 20 mg once daily. If necessary, may increase dose at 6-wkly intervals to 40 mg bid or 80 mg once daily as modified-release.\n\nContra-indication: Acute liver disease; unexplained persistently raised serum aminotransferase concentrations; porphyria; pregnancy; lactation.\n\nSide effects: GI disturbances; headache; skin rashes; dizziness; blurred vision; insomnia; dysgeusia; hepatitis; pancreatitis; hypersensitivity syndrome; myopathy; rhabdomyolysis with acute renal failure.\n\nPrecaution: History of liver disease; high alcohol intake. Manage hypothyroidism adequately before starting treatment. Report unexplained muscle pain. Monitor LFTs. Discontinue in case of marked or persistent increase in serum aminotransferase or creatine phosphokinase. Severe renal impairment.\n\nMode of action:  	Bleeding and increased prothrombin time w/ coumarin anticoagulants. May increase the risk of myopathy and rhabdomyolysis w/ HIV protease inhibitors, colchicine, bezafibrate, ciprofibrate or niacin (nicotinic acid), ciclosporin and fluconazole. Reduced bioavailability w/ concomitant rifampicin.\n\nPregnancy category: X\n\nInteraction:  	Bleeding and increased prothrombin time w/ coumarin anticoagulants. May increase the risk of myopathy and rhabdomyolysis w/ HIV protease inhibitors, colchicine, bezafibrate, ciprofibrate or niacin (nicotinic acid), ciclosporin and fluconazole. Reduced bioavailability w/ concomitant rifampicin.
Follitropin Alfa	\n\n\tMerck Serono S.A., Switzerland\tGonal-F 75IU (5.5mcg) Injection   75 i.u amp with solvent 1789.64\n\tIndication: Female infertility, Assisted reproductive technologies, Spermatogenesis induction\n\nDose: Adult: SC Female infertility Dose should be individualised. Recommended initial: 75 IU/day; may increase by up to 37.5 IU after 14 days; further increases of the same magnitude may be made every 7 days, if needed. Max: 300 IU/day. If response is appropriate, administer hCG 1 day after the last dose. \n\nAssisted reproductive technologies Initial: 150-225 IU/day for at least 4 days, to be started on day 2 or 3 of cycle, until follicular development is adequate. Adjust dose based on ovarian response. Usual max: 450 IU/day. Once follicular development is adequate, administer hCG to induce final follicular maturation. Withhold hCG if ovaries are abnormally enlarged. \n\nSpermatogenesis induction 150 IU 3 times/wk w/ continued chorionic gonadotrophin for at least 4 mth. Max: 300 IU 3 times/wk.\n\nContra-indication: Hypersensitivity. Abnormal genital bleeding of undetermined origin, sex hormone sensitive malignancies of the reproductive tract and accessory organs, an organic intracranial lesion e.g. pituitary tumor, ovarian cysts or enlargement of undetermined origin, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, pregnancy, lactation.\n\nSide effects: Ovarian cysts, mild to severe Inj site reactions, headache, mild to moderate ovarian hyperstimulation syndrome (OHSS), abdominal pain, GI disturbances. Rarely, severe OHSS, ovarian torsion, thromboembolism, mild systemic allergic reactions.\n\nPrecaution: May result in multiple births. Ovarian hyperstimulation syndrome, serious pulmonary conditions and thromboembolic events may occur. Evaluate patients for hypothyroidism, adrenocortical deficiency, hyperprolactinaemia, pituitary and hypothalamic tumors before starting therapy.\n\nMode of action: Other ovulation stimulating agents (eg hCG, clomiphene citrate) may potentiate the follicular response, concurrent use of GnRH agonist-induced pituitary desensitisation may increase the dosage of Gonal-f needed to elicit an adequate ovarian response.\n\nPregnancy category: X\n\nInteraction: Other ovulation stimulating agents (eg hCG, clomiphene citrate) may potentiate the follicular response, concurrent use of GnRH agonist-induced pituitary desensitisation may increase the dosage of Gonal-f needed to elicit an adequate ovarian response.
Follitropin Beta	\n\n\tNuvista Pharma Ltd\tPuregon Injection 50 IU 1 vial pack 2300\n\tNuvista Pharma Ltd\tPuregon Injection 100 IU 1 vial pack 4600\n\tIndication: Ovulation induction, Assisted reproductive technologies\n\nDose: Adult: IM/SC Ovulation induction Initial: 75 IU/day for up to 14 days, may increase by 37.5 IU/wk. Max: 300 IU/day. If follicular growth or serum estradiol levels indicates an adequate response, administer hCG after the last dose. Withhold hCG if the ovaries are abnormally enlarged or if abdominal pain occurs. Max: 300 IU/day. \n\nAssisted reproductive technologies 150-225 IU/day for at least 1st 4 days, adjust dose based on ovarian response. Maintenance: 75-300 IU/day for 6-12 days. Max: 600 IU/day. If response is adequate, administer hCG after the last dose. Withhold hCG if ovaries are abnormally enlarged on the last day of follicular treatment.\n\nContra-indication: Abnormal genital bleeding of undetermined origin, hormone sensitive malignancies; ovary, breast, uterus, hypothalamus, testes or pituitary gland tumor; ovarian cysts or enlargement not due to the polycystic ovary syndrome; high levels of FSH indicating primary gonadal failure (ovarian or testicular); uncontrolled thyroid or adrenal dysfunction; presence of any cause of infertility other than anovulation; hypersensitivity; pregnancy, lactation.\n\nSide effects: Ovarian cysts, mild to severe inj site reactions, headache, mild to moderate OHSS, abdominal pain, GI disturbances. Rarely, severe OHSS, ovarian torsion, thromboembolism, mild systemic allergic reactions.\n\nPrecaution: May result in multiple births. Ovarian hyperstimulation syndrome (OHSS), serious pulmonary conditions and thromboembolic events may occur. Evaluate patients for hypothyroidism, adrenocortical deficiency, hyperprolactinaemia, pituitary and hypothalamic tumors before starting therapy.\n\nMode of action: Concomitant use w/ clomiphene citrate may enhance the follicular response. A higher dose may be needed after pituitary desensitisation induced by a GnRH agonist.\n\nPregnancy category: X\n\nInteraction: Concomitant use w/ clomiphene citrate may enhance the follicular response. A higher dose may be needed after pituitary desensitisation induced by a GnRH agonist.
Fosinopril Sodium	\n\n\tIndication: Hypertension, Congestive heart failure\n\nDose: Adult: PO HTN Initial: 10 mg/day at bedtime. Maintenance: 10-40 mg oce daily. Heart failure Initial: 10 mg once daily. May increase slowly. Max: 40 mg once daily.\n\nContra-indication: Hypersensitivity, idiopathic or hereditary angioedema, history of angioedema related to previous treatment with an ACE inhibitor. Bilateral renal artery stenosis. Pregnancy (2nd and 3rd trimesters), lactation.\n\nSide effects: Dizziness, orthostatic hypotension, palpitation, headache, weakness, fatigue, hyperkalaemia, chest pain, musculoskeletal pain, dry cough, nausea, vomiting, dyspepsia, diarrhoea.\nPotentially Fatal: Cerebrovascular accident, rhythm disturbances, palpitations, hypotension, syncope, rashes, oedema, hypersensitivity reactions, angioedema.\n\nPrecaution: Severely impaired renal function; hyperkalaemia, hypovolaemia, collagen vascular diseases, valvular stenosis; before, during or immediately after anaesthesia, unilateral renal artery stenosis.\n\nMode of action: Additive hyperkalaemic effect w/ K-sparing diuretics and K supplements. May increase lithium serum levels and toxicity. May decrease serum level w/ antacids. May increase risk of renal function deterioration w/ NSAIDs. May increase nitritoid reactions of gold (Na aurothiomalate).\n\nPregnancy category: D\n\nInteraction: Additive hyperkalaemic effect w/ K-sparing diuretics and K supplements. May increase lithium serum levels and toxicity. May decrease serum level w/ antacids. May increase risk of renal function deterioration w/ NSAIDs. May increase nitritoid reactions of gold (Na aurothiomalate).
Fucidic Acid + Betamethasone Topical	\n\n\tPfizer Puus SP.A,., Belgium\tFucidin-H Cream  1's pack 80\n\tIndication: Corticosteriod-responsive dermatoses w/ secondary infection\n\nDose: Adult: Topical As cream containing fusidic acid 2% and betamethasone valerate 0.1%: Apply twice daily. Usual duration: Up to 2 wk/course.\n\nContra-indication: Skin lesions of viral, fungal or bacterial origin, acne rosacea and perioral dermatitis.\n\nSide effects:  Prolonged intensive treatment may cause local atrophic changes in the skin e.g. striae, thining and dilatation of superficial blood vessels. Dryness, itching, irritation, hypopigmentation, burning sensation at the site of application or miliaria.\n\nPrecaution: Avoid prolonged continuous treatment especially in infants and children. Extended treatment may increase the risk of contact sensitisation and development of antibiotic resistance. Not to be used for >7 days if there is no clinical improvement. Increased risk of glaucoma if preparation enters the eye(s). Pregnancy and lactation.\n\nMode of action: Fucidic Acid: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.\n\nBetamethasone : Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents.\nPotentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.\n\n\n\nPregnancy category: Not Classified\n\nInteraction: Fucidic Acid: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.\n\nBetamethasone : Increased hyperglycaemia and hypokalaemia with thiazide diuretics. Increased incidence of peptic ulcer or GI bleeding with concurrent NSAIDs admin. Response to anticoagulants altered. Dose of antidiabetics and antihypertensives needs to be increased. Decreases serum conc of salicylates and antimuscarinic agents.\nPotentially Fatal: Reduced efficacy with concurrent use of carbamazepine, phenytoin, primidone, barbiturates and rifampicin. Enhanced effect in women taking oestrogens or oral contraceptives.\n\n
Fusidic Acid	\n\n\tLeo Pharmaceutical Products,Denmark\tFucithalmic viscous Eye Drops Eye Drops 10mg/ml 5gm tube 249.78\n\tLeo Pharmaceutical Products,Denmark\tFucidin TAB dr  20's pack 1966.40\n\tIndication: Acne vulgaris, Skin infections, Conjunctivitis, staphylococcal infections						\n\n\nDose: Susceptible infections Adult: 500 mg tid. May increase to 1 g tid in fulminating infections. \nChild: <1 yr: About 15 mg/kg; 1-5 yr: 250 mg; 5-12 yr: 500 mg. Doses to be taken tid.\n\nOphthalmic Conjunctivitis Adult: As 1% eye drops: Instill 1 drop into the affected eye every 12 hr for 7 days. Child: >2 yr: As 1% eye drops: Instill 1 drop into the affected eye every 12 hr for 7 days. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Jaundice and liver dysfunction (reversible); GI disturbances. IV: Venospasm, thrombophloebitis and haemolysis; hypocalcaemia. SC/IM: Tissue necrosis. Topical: Rashes and irritation.\n\nPrecaution: Hepatic disease; monitor liver function. Neonates; pregnancy, lactation.\n\nMode of action: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.\n\nPregnancy category: C\n\nInteraction: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.
Gadodiamide	\n\n\tPopular\tGadoscan Injection 287 mg 200's pack 500\n\tTechno Drugs Ltd.\tDiascan Injection 370mg/ml 1's pack(370) 590\n\tIndication:  Indicated for intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues\n\nDose: Adults: The recommended dose  is 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection. Pediatric Patients (2-16 years): The recommended dose  is 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.\n\nContra-indication: Chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73mÂ²), or\nacute kidney injury\nprior hypersensitivity reaction\n\nSide effects:    1. Nephrogenic systemic fibrosis  .\n  2.  Hypersensitivity reactions .\n\nBecause clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.\n\nPrecaution: Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast enhanced MRI or other modalities. \n\nThe GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73mÂ²) as well as patients with acute kidney injury. \n\nScreen patients for acute kidney injury and other conditions that may reduce renal function. \n\nMode of action: \n\nPregnancy category: C\n\nInteraction: 
Gadoversetamide	\n\n\tIndication:  Injection is indicated for use with magnetic resonance imaging (MRI) in patients with abnormal blood-brain barrier or abnormal vascularity of the brain, spine and associated tissues.\n It also indicated for use with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography.\n\nDose: Kilograms (kg)  40 	Pounds (lb)88 	Volume (mL)8.0\n\n\nKilograms (kg) 50 	Pounds (lb)110 	Volume (mL)10.0\n\n\nKilograms (kg) 60 	Pounds (lb)132 	Volume (mL)12.0\n\n\nKilograms (kg) 70 	Pounds (lb)154 	Volume (mL)14.0\n\n\nKilograms (kg) 80 	Pounds (lb)176 	Volume (mL)16.0\n\n\nKilograms (kg) 90 	Pounds (lb)198 	Volume (mL)18.0\n\n\nKilograms (kg) 100 Pounds (lb)	220 Volume (mL)	20.0\n\n\nKilograms (kg) 110 	Pounds (lb)242 	Volume (mL)22.0\n\n\nKilograms (kg) 120 	Pounds (lb)264 	Volume (mL)24.0\n\n\nKilograms (kg)  130 	vPounds (lb)286 	Volume (mL)26.0\n\n\nKilograms (kg) 140 	 Pounds (lb) 308 Volume (mL)	28.0\n\n\nKilograms (kg) 150  Pounds (lb)330 	Volume (mL)30.0\n\nContra-indication:  - chronic, severe kidney disease (glomerular filtration rate, GFR <30 mL/min/1.73m2), or\n-  acute kidney injury, or\n - known allergic or hypersensitivity reactions to gadolinium, versetamide or any of the inert ingredients.\n\n\nSide effects:   Body as a Whole: allergic reaction, edema face, fever, flu-like syndrome, malaise, mucous membrane discharge, neck rigidity, neck pain, pelvic pain, increased sweating\n\nCardiovascular: arrhythmia, chest pain, hypertension, hypotension, pallor, palpitation, syncope, tachycardia, vasospasm\n\nDigestive: anorexia, increased appetite, constipation, dry mouth, dysphagia, eructation, flatulence, increased salivation, thirst, vomiting\n\nHemic and Lymphatic: thrombocytopenia\n\nMetabolic and Nutritional: increased creatinine, edema, hypercalcemia, hyperglycemia, hypoglycemia, hyponatremia\n\nMusculoskeletal: arthralgia, leg cramps, myalgia, myasthenia, spasm\n\nNervous System: agitation, anxiety, confusion, depersonalization, diplopia, dystonia, hallucinations, hypertonia, hypesthesia, nervousness, somnolence, tremor, vertigo\n\nRespiratory System: asthma, cough, dyspnea, epistaxis, hemoptysis, laryngismus, pharyngitis, sinusitis, voice alteration\n\nSkin and Appendages: application site reaction, edema injection site, erythema multiforme, pruritus, rash macular-papular and vesicullous bullous, skin dry, thrombophlebitis, inflammation injection site, urticaria\n\nSpecial Senses: amblyopia, conjunctivitis, hyperacusis, parosmia, tinnitus\n\nUrogenital: dysuria, oliguria, urine frequency\n\nPrecaution: Diagnostic procedures that involve the use of contrast agents should be carried out under direction of a physician with the prerequisite training and a thorough knowledge of the procedure to be performed.\n\nPersonnel trained in resuscitation techniques and resuscitation equipment should be available.\n\nThe possibility of a reaction, including serious, life threatening, fatal, anaphylactoid or cardiovascular reactions or other idiosyncratic reactions should always be considered especially in those patients with a known clinical hypersensitivity, a history of asthma, or other respiratory disorders .\n\nSome paramagnetic contrast agents may impair the visualization of existing lesions, which are seen on the unenhanced, non-contrast MRI. This may be due to effects of the paramagnetic contrast agent, imaging parameters, misregistration, etc. CAUTION SHOULD BE EXERCISED WHEN A CONTRAST ENHANCED INTERPRETATION IS MADE IN THE ABSENCE OF A COMPANION UNENHANCED MRI.\n\nMode of action: \n\nPregnancy category: C\n\nInteraction: 
Ganciclovir	\n\n\tAristopharma\tXoviral Eye gel 150mg/100ml 5 gm tube 200\n\tGeneral\tGenclovir Eye Gel 150 mg/100 gm  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tZirgan 0.15% Eye gel 150mg/100ml 5 gm tube 200\n\tF. Hoffmann La Roche,Switzerland\tCymevene Vials Injection 500mg 1 vial 4849\n\tIndication: CMV retinitis, Pneumonitis, Cytomegaloviral infections						\n\n\nDose: Adult: IV Cytomegaloviral infections Induction: 5 mg/kg 12 hrly for 14-21 days. Maintenance: 5 mg/kg once daily for 7 days/wk or 6 mg/kg once daily for 5 days/wk. \n\nPrevention of cytomegaloviral infections in immunocompromised patients Initial: 5 mg/kg 12 hrly for 7-14 days. Maintenance: 5 mg/kg once daily for 7 days/wk or 6 mg/kg once daily for 5 days/wk. \n\nRenal impairment: For dialysis patients: 1.25 mg/kg for induction or 0.625 mg/kg for maintenance, to be given postdialysis on days when dialysis is performed.\n\nCrCl (ml/min)	\n10-24	1.25 mg/kg 24 hrly for induction, then 0.625 mg/kg 24 hrly for maintenance.\n25-49	2.5 mg/kg 24 hrly for induction, then 1.25 mg/kg 24 hrly for maintenance.\n50-69	2.5 mg/kg 12 hrly for induction, then 2.5 mg/kg 24 hrly for maintenance.\n>70	5 mg/kg 12 hrly for induction, then 5 mg/kg 24 hrly for maintenance.\n\nOphth: Cytomegaloviral retinitis As intravitreal implant which can last for 5-8 mth: Use as directed.\n\nEye Gel: Instill 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals and then 1 drop 3 times per day for 7 days.\n\nContra-indication: Hypersensitivity; absolute neutrophil count <500 cells/mm3; platelet count <25,000/mm3; pregnancy, lactation. Not to be used as a bolus inj.\n\nSide effects: Haematolgical disturbances; marrow depression; GI disturbances; fever, rash and abnormal LFTs; irritation and phlebitis at inj site. Less frequent: CV, CNS, metabolic, musculoskeletal, respiratory, urogenital, ocular effects, cutaneous symptoms and increased serum-creatinine and BUN concentration. Potential risk of testicular effects and female fertility.\n\nPrecaution: Renal impairment; preexisting cytopenias or history of cytopenic reactions to drugs; child; contraceptive precautions to be followed during and at least 90 days thereafter; care in administering only into veins with good blood flow. Avoid contact with the skin and eyes. Maintain adequate hydration during infusion. Monitor WBC and platelet counts regularly during treatment. Eye examinations should be conducted at least once every 4-6 wk during treatment for CMV retinitis.\n\nMode of action: Increased risk of haematologic toxicity w/ zidovudine. May increase serum levels of didanosine. Increased serum concentration w/ probenecid and other drugs that inhibit renal tubular secretion and resorption. Use of IV ganciclovir w/ oral mycophenolate mofetil may result in increased plasma concentrations of both drugs due to competition for renal tubular secretion. Concomitant use w/ immunosuppressive agents (e.g. azathioprine, ciclosporin, corticosteroids) may result in excessive suppression of bone marrow or the immune system. Generalised seizure may occur when taken w/ imipenem and cilastatin. Concurrent use w/ drugs that inhibit replication of rapidly dividing cells (e.g. dapsone, pentamidine, pyrimethamine, flucytosine, cytotoxic antineoplastic agents, amphotericin B, co-trimoxazole, other nucleoside analogues) may result in additive toxicity.\n\nPregnancy category: C\n\nInteraction: Increased risk of haematologic toxicity w/ zidovudine. May increase serum levels of didanosine. Increased serum concentration w/ probenecid and other drugs that inhibit renal tubular secretion and resorption. Use of IV ganciclovir w/ oral mycophenolate mofetil may result in increased plasma concentrations of both drugs due to competition for renal tubular secretion. Concomitant use w/ immunosuppressive agents (e.g. azathioprine, ciclosporin, corticosteroids) may result in excessive suppression of bone marrow or the immune system. Generalised seizure may occur when taken w/ imipenem and cilastatin. Concurrent use w/ drugs that inhibit replication of rapidly dividing cells (e.g. dapsone, pentamidine, pyrimethamine, flucytosine, cytotoxic antineoplastic agents, amphotericin B, co-trimoxazole, other nucleoside analogues) may result in additive toxicity.
Ganirelix Ph. Eur	\n\n\tIndication: Ovarian stimulation, Assisted reproduction\n\nDose: Subcutaneous\nOvarian stimulation regimens for assisted reproduction in infertility\nAdult: As acetate: 250 mcg once daily, starting on day 6 of ovarian stimulation and continued until ovulation induction.\n\nContra-indication: Hypersensitivity, pregnancy, lactation, moderate to severe renal or hepatic impairment.\n\nSide effects: Nausea, headache, inj site reactions, ovarian hyperstimulation syndrome, abdominal pain, vag bleeding, dizziness, malaise, congenital abnormalities.\n\nPrecaution: Women with active allergic conditions or a history of allergies.\n\nMode of action: None\n\nPregnancy category: X\n\nInteraction: 
Gemcitabine	\n\n\tACI\tGemzar Injection 1g 1's pack 13210\n\tACI\tGemzar Injection 200mg 1's pack 2770\n\tBeacon\tGemoxen Injection 1gm/vial 1's pack 5000\n\tBeacon\tGemoxen Injection 200mg/vial 1's pack 1400\n\tTechno Drugs Ltd.\tGemcetin Injection 1gm/vial 1's pack 5000\n\tTechno Drugs Ltd.\tGemcetin Injection 200mg/vial 1's pack 1400\n\tLilly France SA, France\tGemzar Injection 1gm 1's pack 12210\n\tIndication: Lung cancer, pancreatic cancer, bladder cancer, breast cancer, ovarian carcinoma							\n\n\nDose: Adult: IV Advanced non-small cell lung cancer 1 g/m2 on days 1, 8 and 15 of each 28-day cycle. \nPancreatic cancer 1 g/m2 once wkly for up to 7 wk followed by 1 wk of rest. Continue thereafter w/ once wkly infusions for 3 consecutive wk out of 4. \nBladder cancer 1 g/m2 on days 1, 8 and 15 of each 28-day cycle. To be given before cisplatin. \nBreast cancer 1.25 g/m2 on days 1 and 8 of each 21-day cycle. \nOvarian carcinoma 1 g/m2 on days 1 and 8 of each 21-day cycle. To be given before carboplatin.\n\nContra-indication: Concurrent radical radiotherapy; pregnancy, lactation; hypersensitivity.\n\nSide effects: Bone marrow suppression as manifested by leukopenia, thrombocytopenia, anaemia and myelosuppression. Mild GI effects; rashes; renal impairment, pulmonary toxicity, influenza-like symptoms; interstitial pneumonia, pulmonary oedema. Proteinuria, haematuria and haemolytic uraemic syndrome. Elevation of serum transaminase.\nPotentially Fatal: Oesophagitis and pneumonitis when given with radical radiotherapy to the thorax.\n\nPrecaution: Children, hepatic and renal impairment. May impair ability to drive or operate machinery. Discontinue on 1st sign of microangiopathic haemolytic anaemia. Prolonged infusion time (>60 minutes) and more frequent than wkly dosing may increase toxicity. Monitor CBC before every dose. Increased risk of haemolytic uraemic syndrome and/or thrombocytcpenic purpura which may lead to irreversible renal failure.\n\nMode of action: May increase the anticoagulant effect of warfarin when used together.\n\nPregnancy category: D\n\nInteraction: May increase the anticoagulant effect of warfarin when used together.
Gonadotrophin	\n\n\tIndication: Infertility, Stimulate ovulation, Sperm production\n\nDose: Adult: IM Prepubertal cryptorchidism in males 500-4,000 u 3 times/wk. Continue for 1-2 mth after testicular descent. Male infertility due to hypogonadotrophic hypogonadism 500-4,000 u 2-3 times/wk. Delayed puberty due to hypogonadism in males Initial: 500-1,500 u twice wkly. Anovulatory infertility 5,000-10,000 u as a single dose. May repeat inj (up to 5,000 u/inj) up to 3 times w/in the next 9 days.\n\nContra-indication: Hypersensitivity; precocious puberty, prostatic carcinoma or other androgenic dependent neoplasm. Pregnancy and lactation.\n\nSide effects: Headache, irritability, restlessness, depression, fatigue, oedema; precocious puberty, gynaecomastia; pain at Inj site; enlargement of preexisting ovarian cysts and possible rupture; arterial thromboembolism; shock; abdominal pain.\nPotentially Fatal: Ovarian hyperstimulation syndrome (OHSS).\n\nPrecaution: Discontinue therapy if signs of precocious puberty are seen in patients treated for cryptorchidism. Patients with cardiac or renal disease, epilepsy, migraine or asthma.\n\nMode of action: Interactions of Human chorionic gonadotrophin  with other medicines have not been investigated; interactions with commonly used medicinal products cannot be excluded.\nFollowing administration, Human chorionic gonadotrophin  may interfere for up to 10 days with the immunological determination of serum/urinary human chorionic gonadotropin (hCG), leading to a false positive pregnancy test.\n\nIncompatibilities: In the absence of compatibility studies, Pregnyl must not be mixed with other medicinal products.\n\nPregnancy category: X\n\nInteraction: Interactions of Human chorionic gonadotrophin  with other medicines have not been investigated; interactions with commonly used medicinal products cannot be excluded.\nFollowing administration, Human chorionic gonadotrophin  may interfere for up to 10 days with the immunological determination of serum/urinary human chorionic gonadotropin (hCG), leading to a false positive pregnancy test.\n\nIncompatibilities: In the absence of compatibility studies, Pregnyl must not be mixed with other medicinal products.
Haemophilus Influenzae Type B Polysaccharide Vaccine	\n\n\tRenata\tVaxem Injection  1's amps pack 425.77\n\tGlaxoSmithkline Biologicals S.A,Belgium\tHiberix Vaccine Injection  0.5 ml 0.5 ml amp x 1's pack  180.60 \n\tNovartis Vaccines & DiagnosticsS.r.l Italy\tVaxem HIB Injection  0.5 ml 0.5 ml amp x 1's pack  180.60 \n\tSanofi Pasteur S A ,France\tAct-HIB Injection 10 ug/dose 10 vials pack with diluent 5400\n\tIndication: Haemophilus influenzae  type b infection (meningitis, septicemia, cellulitis, arthritis).\n\nDose: Primary vaccination: From 2 months: 3 injections at 1 or 2 months intervals followed by a booster 12 months after the 3rd dose. \nPreviously unvaccinated children between 6-12 months: 2 injections at 1 or 2 months intervals followed by a booster 12 months after the 2nd dose. \n\nFrom 1-5 years: 1 single injection.\n\nContra-indication: HIB VACCINE IS CONTRAINDICATED IN CHILDREN WITH A HISTORY OF HYPERSENSITIVITY TO ANY COMPONENT OF THE VACCINE.\n\nSide effects:  Adverse reactions commonly associated with a first HIB vaccine immunization of children 12 to 15 months of age who were previously unimmunized with any Haemophilus b conjugate vaccine, include local pain, redness and swelling at the injection site. Systemic reactions include fever, irritability and lethargy.\n\nPrecaution: Minor illnesses such as upper respiratory infection with or without low-grade fever are not contraindications for use of HIB vaccine. As reported with Haemophilus b polysaccharide vaccines, cases of H influenzae type b disease may occur subsequent to vaccination and prior to the onset of protective effects of the vaccine. Medical supervision is needed.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Hepatits A Vaccine (HAV Antigen)	\n\n\tGlaxo Smith Kline Biological S.A.,Belgium\tHavrix 1440 Injection   1.0 ml prefilled  syringe  x 1's pack 1189.90\n\tGlaxo Smith Kline Biological S.A.,Belgium\tHavrix 720 Injection    0.5 ml prefilled  syringe  x 1's pack 755.66\n\tIndication: Hepatitis A virus\n\nDose: Adult: IM Single dose of 0.5 or 1 mL depending on the product and patient's age. Give booster dose 6-12 mth after the initial dose. Give via SC administration in haemophiliacs.\n\nChild: Same as adult.\n\nContra-indication: Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.\n\nSide effects: Transient soreness, erythema, induration at inj site. Fever, malaise,\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation.\n\nMode of action: Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.\n\nPregnancy category: C\n\nInteraction: Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.
Hepatitis B Vaccine (rDNA) BP	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tEngerix-B Injection  10 mcg 0.5 ml vial /  0.5 ml prefilled  syringe    298.81 / 386.40\n\tGlaxoSmithKline Bangladesh Ltd.\tEngerix-B Injection  20 mcg 1.0 ml vial / 1.0 ml prefilled  syringe    531.22 / 608\n\tIncepta\tHepa-B for Adult Injection 20 Âµg/ml 1's 500\n\tIncepta\tHepa-B for Pediatric Injection 10 Âµg/ml 1's 400\n\tPopular\tHepavax-B Injection  1's amps pack 431\n\tSanofi Aventis (BD) Ltd.\tEuvax-B Injection 0.5ml 0.5 ml vial 263.10\n\tSanofi Aventis (BD) Ltd.\tEuvax-B Injection 1.0ml 1.0 ml vial  383.70\n\tIndication: To prevent Hepatiis B virus\n\nDose: Adult: IM Basic course consists of 3(1 ml each) doses: 2nd and 3rd doses given 1 and 6 mth after the 1st dose respectively. More rapid immunization 3rd dose can be given 2 months after initial dose with booster at 12 months.Dose depends on the product used. Typical doses: 10 or 20 mcg. Given via SC administration in haemophiliacs.\n\nChild: 0.5 ml each 3 doses should be injected as same manner as adult.\n\nContra-indication: Previous confirmed anaphylactic reaction to a previous dose of a vaccine containing the same antigens. Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.\n\nSide effects: Abdominal pain and GI disturbance, and musculoskeletal and joint pain and inflammation. Dizziness and sleep disturbance. CV effects include occasional hypotension and, rarely, tachycardia. Dysuria, visual disturbances and earache.\n\nPrecaution: If any alcohol or disinfectant is used for cleansing the skin it should be allowed to evaporate before vaccination otherwise inactivation of live vaccines may occur.\n\nMode of action: Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.\n\nPregnancy category: C\n\nInteraction: Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.
Human 1gG Proteins with Rabies	\n\n\tIndication: Postexposure prophylaxis of Rabies\n\nDose: Recommended Dose: Adults and Children: 40 IU/kg of body weight. However, for children, particularly in the case of multiple wounds, it has been proposed to dilute the dose 2-3 times in a 0.9% sodium chloride solution to obtain a sufficient quantity of equine rabies immune globulin to infiltrate the wound(s) correctly.\n\nIt must be injected slowly by the IM route.\nIf anatomically feasible, as much as possible of the dose should be infiltrated around and into the wounds. The remainder of the dose should be administered IM (into the gluteal region) in a single injection.\n\nAs a general rule, 1 IU of Factor IX activity per kg can be expected to increase the circulating level of Factor IX by 1% [IU/dL] of normal.\n\nContra-indication: Known history of allergic symptoms to horse proteins.\n\nSide effects: Do not administer the vaccine IV due to the risk of shock ie, sudden collapse with drop in blood pressure. \n\nPrecaution: Administered intravenously at a rate that will permit observation of the patient for any immediate reaction. Rates of infusion of up to 225 IU per minute have been regularly tolerated with no adverse reactions. If any reaction takes place that is thought to be related to the administration   , the rate of infusion should be decreased or the infusion stopped, as dictated by the response of the patient. The infusion should be stopped promptly and appropriate countermeasures and supportive therapy should be administered should evidence of an acute hypersensitivity reaction be observed. Patients known to have major deletion mutations of the factor IX gene may be at increased risk for inhibitor formation and acute hypersensitivity reactions.\n\nMode of action: Decreased response to live virus vaccine (e.g. measles, mumps, rubella and varicella), admin at least 4 mth after human rabies immunoglobulin admin.\n\nPregnancy category: C\n\nInteraction: Decreased response to live virus vaccine (e.g. measles, mumps, rubella and varicella), admin at least 4 mth after human rabies immunoglobulin admin.
Human Albumin	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tBiotest Human Albumin Solution For Infusion 20% 1's pack(50ml) 2802\n\tAlpha Therapeutic Corporation,USA\tAlbutein 5% Injection   250ml bot  3800\n\tAlpha Therapeutic Corporation,USA\tAlbutein 25% Injection   50ml bot / 100ml bot  3700 / 7500\n\tCity overseas\tHuman albumin 20% Injection   50ml bot / 100ml bot  2750 / 5350\n\tIndication: Acute hypovolaemic shock, Hypoproteinaemia\n\nDose: Intravenous\nAcute hypovolaemic shock\nAdult: Initially, 25 g of albumin, adjusted according to patient's response. Usual rates of infusion: Up to 5 ml/minute (5% solution) or 1-2 ml/minute (20% solution).\nChild: Up to 1 g/kg, adjusted according to patient's response. Usual rates of infusion: Up to 5 ml/minute (5% solution) or 1-2 ml/minute (20% solution).\n\nHypoproteinaemia\nAdult: Up to 2 g/kg daily. Usual rates of infusion: Up to 5 ml/minute (5% solution) or 1-2 ml/minute (20% solution).\n\nNeonatal hyperbilirubinaemia\nChild: 1 g/kg of albumin before exchange transfusion. Usual rates of infusion: Up to 5 ml/minute (5% solution) or 1-2 ml/minute (20% solution).\n\nContra-indication: Cardiac failure, severe anaemia, history of hypersensitivity, parenteral nutrition.\n\nSide effects: Allergic reactions, nausea, vomiting, increased salivation, fever and chills; vascular overload, haemodilution and pulmonary oedema.\nPotentially Fatal: Anaphylactic shock.\n\nPrecaution: Hypertension or low cardiac reserve; additional fluids for dehydrated patients. Monitor for signs of cardiac overload in injured or postoperative patients. May carry risk of viral transmission. Volume admin and rate of infusion must always be individualised according to situation and response. Pregnancy, lactation.\n\nMode of action: Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.\n\nPregnancy category: C\n\nInteraction: Albumin solution should not be mixed by protein hydrolysates or alcoholic solutions. Risk of atypical reactions to ACE inhibitors in patients undergoing therapeutic plasma exchange with albumin human replacement.
Human Anti-D Immunoglobulin	\n\n\tCSL Behring Ag, Switzeland\tRhophylac 300 Infusion   2 ml prefilled  syringe   3395\n\tIndication: Hemolytic disease of newborn, Rhesus disease\n\nDose: 1 dose 250 mcg should be given IM immediately or as soon as possible after delivery or abortion of a Rh positive child, preferably within 48 hours but not later than 72 hours post partum.\n\nFor antenatal prophylaxis 250 mcg should be given in week 28 & week 34 of pregnancy.\n\nContra-indication: Patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.\n\nSide effects: The most serious adverse reactions in patients receiving Rh0(D) Immune Globulin Intravenous (Human) have been observed in the treatment of ITP and include intravascular hemolysis, clinically compromising anemia, acute renal insufficiency, and, very rarely, DIC and death\nThe most common adverse reactions observed in the use  for suppression of Rh isoimmunization (?0.5% of subjects) are nausea, dizziness, headache, injection-site pain, and malaise.\nThe most common adverse reactions observed in the treatment of ITP (>14% of subjects) are chills, pyrexia/increased body temperature, and headache. Mild hemolysis (manifested by an increase in bilirubin, a decrease in hemoglobin, or a decrease in haptoglobin) was also observed.\n\nPrecaution: IgA deficient patients with known antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions .\n It is made from human blood; therefore it may contain infectious agents; e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent\n\nMode of action: May interfere with the immune response to live measles vaccine, live mumps vaccine, live rubella vaccine and live varicella vaccine, therefore these vaccines should be given at least 3 wk before or 3 mth after the admin of the immunoglobulins.\n\nPregnancy category: C\n\nInteraction: May interfere with the immune response to live measles vaccine, live mumps vaccine, live rubella vaccine and live varicella vaccine, therefore these vaccines should be given at least 3 wk before or 3 mth after the admin of the immunoglobulins.
Tetanus (Human Anti-tetanus) Immunoglobulin	\n\n\tCSL Behring GmbH, Germany\tTetagam(R) P Injection 250IU 250 IU prefilled syringe  1023\n\tCSL Behring GmbH, Germany\tHuman Anti-tetanus Immuno Globulin Injection 250 IU  1200\n\tIndication: Passive immunisation against Tetanus\n\nDose: Adults and children 7 years and older: 250 units(1 ml) should be given by deep intramuscular injection . \nAt the same time, but in a different extremity and with a separate syringe, active immunization with adsorved tetanus vaccine should be administered. \n\nChildren less than 7 years old: In small children the routine prophylactic dose  may be calculated by the body weight (4.0 units/kg). \n\nContra-indication: Hypersensitivity homologous Ig-containing medicinal products particularly in patients w/ IgA deficiency & concurrent presence of Ab to IgA.\n\nSide effects: Slight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare.\n\nIn the course of routine injections of large numbers of persons with immunoglobulin there have been a few isolated occurrences of angioneurotic edema, nephrotic syndrome, and anaphylactic shock after injection.\n\nPrecaution: Intravenous injection of immunoglobulin intended for intramuscular use can, on occasion, cause a precipitous fall in blood pressure, and a picture not unlike anaphylaxis. Injections should only be made intramuscularly and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel. Intramuscular injections are preferably administered in the deltoid muscle of the upper arm or lateral thigh muscle. The gluteal region should not be used as an injection site because of the risk of injury to the sciatic nerve.\n\nChemoprophylaxis against tetanus is neither practical nor useful in managing wounds. Wound cleaning, debridement when indicated, and proper immunization are important. The need for tetanus toxoid (active immunization), with or without TIG (passive immunization), depends on both the condition of the wound and the patientâs vaccination history. Rarely has tetanus occurred among persons with documentation of having received a primary series of toxoid injections.\n\nMode of action: May reduce the efficacy of live vaccines.\n\nPregnancy category: C\n\nInteraction: May reduce the efficacy of live vaccines.
Human Papilloma virus Bivalent (Types 16 and 18) Vaccine, Recombinant	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tCervarix Injection 0.5ml 1's pack 1903\n\tIndication: Human Papillomavirus infection, Premalignant cervical lesions and cervical cancer, Adenocarcinoma in situ, Cervical intraepithelial neoplasia\n\nDose: Intramuscular\nAdult: Females 10-25 yr (or between 10-45 yr in some countries): 3 doses of 0.5 mL each  given at 0, 1 and 6 mth, preferably administered into deltoid muscle.\nChild: Not recommended for use in girls below 10 yr of age.\n\nContra-indication: Known hypersensitivity to any component. \n\nSide effects: The most common reaction observed after vaccine administration was injection site pain, which occurred after 78% of all doses. The majority of these reactions were of mild to moderate severity and were not long lasting.\nAdverse reactions considered as being at least possibly related to vaccination have been categorized by frequency.\n\nInfections and Infestations: Uncommon: Upper respiratory tract infection.\nBlood and Lymphatic System Disorders: Uncommon: Lymphadenopathy.\nNervous System Disorders: Very Common: Headache. Uncommon: Dizziness.\nGastrointestinal Disorders: Common: Gastrointestinal disturbances including nausea, vomiting, diarrhea and abdominal pain.\n\nSkin and Subcutaneous Tissue Disorders: Common: Itching/pruritus, rash, urticaria.\nMusculoskeletal and Connective Tissue and Bone Disorders: Very Common: Myalgia. Common: Arthralgia.\nGeneral Disorders and Administration Site Conditions: Very Common: Injection site reactions including pain, redness, swelling, fatigue. Common: Fever (?38Â°C). Uncommon: Other injection site reactions eg, induration, local paresthesia.\n Immune System Disorders: Rare: Allergic reactions (including anaphylactic and anaphylactoid reactions), angioedema.\nNervous System Disorders: Rare: Syncope or vasovagal responses to injection, sometimes accompanied by tonic-clonic movements.\n\nPrecaution: Do not administer this product intravenously, intradermally, or subcutaneously.\nAs with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of Cervarix.\nAs with other vaccines, the administration of Cervarix should be postponed in subjects suffering from acute severe febrile illness. However, the presence of a minor infection eg, a cold should not result in the deferral of vaccination.\nUse in lactation: The effect on breastfed infants of the administration of Cervarix to their mothers has not been evaluated in clinical studies.\nCervarix should only be used during breastfeeding when the possible advantages outweigh the possible risks.\nSerological data suggest a transfer of anti-HPV-16 and anti-HPV-18 antibodies via the milk during the lactation period in rats. However, it is unknown whether vaccine-induced antibodies are excreted in human breast milk.\n\nMode of action: Immunosuppressive therapies e.g. irradiation, cytotoxic drugs and corticorsteroids may reduce a patient's immune response to the vaccine.\n\nPregnancy category: B\n\nInteraction: Immunosuppressive therapies e.g. irradiation, cytotoxic drugs and corticorsteroids may reduce a patient's immune response to the vaccine.
Human Rota Virus, Live attenuated Vaccine	\n\n\tGlaxoSmithkline Biologicals S.A,Belgium\tRotarix Oral Vaccine  1.5 ml  1 ml vial with oral applicator 1548.50\n\tIndication: Prevention of Rotavirus diarrhea\n\nDose: The vaccination course consists of two doses. The first dose should be given between 6 and 14 weeks of age. The interval between the two doses should not be less than 4 weeks. The vaccine course should be completed by the age of 24 weeks as safety has not been assessed in older children. In clinical trials, spitting or regurgitation of the vaccine has rarely been observed and, under such circumstances, a replacement dose was not given. However, in the unlikely event that an infant spits out or regurgitates most of the vaccine dose, a single replacement dose may be given at the same vaccination visit.\n\nContra-indication: Subjects with history of intussusception. Subjects with Severe Combined Immunodeficiency (SCID) disorder The presence of a minor infection, such as a cold, is not a contraindication for immunisation.\n\nSide effects: Risk of intussusception has not been established. The overall incidence of intussusception remains rare.\n\nPrecaution: It is good clinical practice that vaccination should be preceded by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination. Parents/guardians should be advised to seek medical advice promptly where these signs/symptoms are evident. There is a potential risk for transmission to non-vaccinated contacts. It should be administered with caution to infants with close contacts who are immunodeficient, such as household members with malignancies or who are otherwise immunocompromised or receiving immunosuppressive therapy. Contacts of recent vaccinees should be advised to observe personal hygiene (e.g. washing their hands when changing childrenÃ¢â¬â¢s nappies).\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Hyaluronic Acid Sodium Salt P.F.S	\n\n\tF.Hoffmann La Roche, Switzerland\tHyalgan Injection 20mg/2ml  4000\n\tIndication: Osteoarthritis\n\nDose: Intra-articular\nOsteoarthritis of the knee\nAdult: 20-25 mg once wkly for 5 wk or up to 30 mg once wkly for 3-4 wk. Not to repeat treatment course within 6 mth for any individual joint. \n\nContra-indication: Do not administer to patients with known hypersensitivity to this product.\n\nSide effects: Common adverse events reported for the (hyaluronate) -treated subjects were gastrointestinal complaints, injection site pain, knee swelling/effusion, local skin reactions (rash, ecchymosis), pruritus, and headache. Swelling and effusion, local skin reactions (ecchymosis and rash), and headache may occur.\n\nPrecaution: Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronic acid can precipitate in their presence.\n\nInject subcutaneous lidocaine or similar local anesthetic prior to injection of hyaluronate.\nRemove joint effusion, if present, before injection. Do not use the same syringe for removing joint effusion and for injecting hyaluronate.The vial/syringe is intended for single use.\n\nMode of action: The safety and effectiveness of the use of sodium hyaluronate concomitantly with other intra-articular injection has not yet been established.\nAs sodium hyaluronate is precipitated by quaternary amine bactericides or disinfectants eg, benzalkonium chloride and chlorhexidine, etc, adequate attention should be given.\n\nPregnancy category: Not Classified\n\nInteraction: The safety and effectiveness of the use of sodium hyaluronate concomitantly with other intra-articular injection has not yet been established.\nAs sodium hyaluronate is precipitated by quaternary amine bactericides or disinfectants eg, benzalkonium chloride and chlorhexidine, etc, adequate attention should be given.
Hyaluronidase	\n\n\tIndication: Hypodermoclysis, Facilitate SC/IM inj, Aid in dispersal of extravasated fluids or blood, Aid in diffusion of local anesthesia in ophthalmology\n\nDose: Adult: Parenteral Adjunct in hypodermoclysis 1,500 u for every 500-1,000 mL of fluid for SC administration. \n\nFacilitate SC/IM inj 1,500 u added directly into the inj. Aid in dispersal of extravasated fluids or blood 1,500 u into the affected area. \n\nAid in diffusion of local anesth in ophthalmology 15 u/mL of local anesth soln.\n\nContra-indication: Hypersensitivity, malignancy. Direct application to the cornea, reduction of swelling of bites or stings. Inj into or around infected area. IV admin; unexplained premature labour.\n\nSide effects: Urticaria, occasional severe allergy.\nPotentially Fatal: Hypersensitivity and anaphylaxis.\n\nPrecaution: Impaired renal function. Infants, elderly. Patients with infections. Pregnancy, lactation.\n\nMode of action: Action potentiated by urokinase especially in the treatment of MI. May increase absorption and toxicity of local anaesthetics. Heparin, salicylates and NSAIDs may inhibit the spreading action and efficacy of hyaluronidase.\n\nPregnancy category: C\n\nInteraction: Action potentiated by urokinase especially in the treatment of MI. May increase absorption and toxicity of local anaesthetics. Heparin, salicylates and NSAIDs may inhibit the spreading action and efficacy of hyaluronidase.
Hypochlorous Acid (Sodium Hypochlorite)	\n\n\tIndication: Diabetic foot ulcer, necrotic wound infections, post-surgical wounds, first, second and third degree burns, pressure ulcer, and grafted and donor sites. Solution is safe to use around the eyes, nose and mouth.\n\nDose: Use as required. This may require a secondary cover dressing.\n\nContra-indication: No known contraindications.\n\nSide effects: \n\nPrecaution: Wound healing rates and characteristics will vary significantly with patient age, nutritional status, metabolic status, immunologic status and compliance.\nIn the presence of vascular compromise, care must be taken to avoid circumferential bandage compression pressures in excess of arterial perfusion pressures. \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Immune Serum Globulin Human	\n\n\tPlasmapharm Sera GmbH & Co.,Austria\tImmune Serum Globulin Human Injection   3000\n\tIndication: Chickenpox, Hepatitis A, Measles, Rubella, Immunodeficiency, Wiskott-Aldrich syndrome\n\nDose: Adult: IV Prevention of infections after bone marrow transplantation 500 mg/kg/wk. Increase platelet count in patients w/ idiopathic thrombocytopenic purpura 400 mg/kg/day for 2-5 consecutive days. \n\nKawasaki disease 1.6-2 g/kg in divided doses over 2-5 days. Guillain-Barre syndrome 400 mg/kg/day for 5 consecutive days, repeat 4 wkly if needed. Allogenic bone marrow transplantation 500 mg/kg/wk, starting 7 days before transplantation and for up to 3 mth after transplantation. \n\nPrimary antibodies deficiency Initial: 400-800 mg/kg, then 200 mg/kg 3 wkly. Maintenance: 200-800 mg/kg/mth. For secondary immunodeficiency syndromes: 200-400 mg/kg 3-4 wkly. \n\nIM Hepatits A 500 mg. Measles attack in immunocompromised patients Prevention: 750 mg w/in 6 days after exposure. To modify an attack: 250 mg. Primary rubella in pregnant women 750 mg.\n\nContra-indication: Patients with selective immunoglobulin A deficiency. Prior anaphylactic reactions to immunoglobulin, blood or other blood-derived preparations.\n\nSide effects: Dizziness, light-headedness, nausea, vomiting, allergic and cutaneous reactions. Local pain and tenderness at the site of inj. IV admin may lead to systemic effects such as headache, chills and fever.\n\nPrecaution: Increased risk of acute renal failure in patients with renal impairment, DM, hypovolaemia, overweight, concomitant nephrotoxic medicinal products or >65 yr. High infusion rate may increased risk of adverse reactions. Ensure adequate hydration prior to IV infusion of immunoglobulin. Monitor urine output and serum creatinine levels during treatment. Avoid concurrent use of loop diuretics during IV infusion of immunoglobulin. Live vaccines should generally be given 3 wk before or 3 mth after admin of normal immunoglobulin. Different formulations and brands of human normal immunoglobulins may not be equivalent, thus individual literature should be consulted. Pregnancy and lactation.\n\nMode of action: May interfere with the immune response to live measles vaccine, live mumps vaccine, live rubella vaccine and live varicella vaccine, therefore these vaccines should be given at least 3 wk before or 3 mth after the admin of the immunoglobulins.\n\nPregnancy category: C\n\nInteraction: May interfere with the immune response to live measles vaccine, live mumps vaccine, live rubella vaccine and live varicella vaccine, therefore these vaccines should be given at least 3 wk before or 3 mth after the admin of the immunoglobulins.
Immunoglobulin-G Human + Maltose	\n\n\tIndication: Replacement therapy in primary immunodeficiency syndromes eg congenital agammaglobulinaemia & hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, Wiskott Aldrich syndrome; myeloma or chronic lymphocytic leukaemia w/ severe secondary hypogammaglobulinaemia & recurrent infections; childn w/ congenital AIDS & recurrent infections. Immunomodulation of idiopathic thrombocytopenic purpura (ITP), in childn or adults at high risk of bleeding or prior surgery to correct the platelet count; Guillain-Barre syndrome; Kawasaki disease. Allogeneic bone marrow transplantation.\n\nDose: Replacement therapy in primary immunodeficiency syndromes Starting dose: 0.4-0.8 g/kg followed by 0.2-0.8 g/kg 2-4 wkly to achieve IgG trough level of 4.6 g/L. \n\nReplacement therapy in myeloma or chronic lymphotic leukaemia w/ severe secondary hypogammaglobulinaemia & recurrent infections; replacement therapy in childn w/ AIDS & recurrent infections 0.2-0.4 g/kg 3-4 wk. \n\nITP 0.8-1 g/kg on day 1, may be repeated once w/in 3 days, or 0.4 g/kg daily for 2-5 days. Guillain-BarrÃ© syndrome 0.4 g/kg daily for 3-7 days. Kawasaki disease 1.6-2 g/kg in divided doses over 2-5 days or 2 g/kg as a single-dose in combination w/ acetylsalicylic acid. \n\nAllogeneic bone marrow transplantation 0.5 g/kg wkly starting 7 days before & up to 3 mth after transplantation for the treatment of infections & prophylaxis of graft versus host disease, & mthly until Ab levels return to normal in persistent lack of Ab production.\n\nContra-indication: Hypersensitivity to homologous Ig esp in IgA deficiency due to Ab against Ig (rare). Fructose intolerance.\n\nSide effects: Headache, cough, inj site reaction, nausea, pharyngitis & urticaria; fatigue, arthralgia & pyrexia; vomiting, fever, back pain & rash; chills, HTN, asthenia.\n\nPrecaution: High rate of infusion; patients w/ hypo- or agammaglobulinaemia w/ or w/o IgA deficiency, receiving human normal Ig therapy for the 1st time, or when human normal Ig is switched or during a long interval since the previous infusion (rare). Obese patients; preexisting risk for thrombotic events. Discontinue use in case of renal impairment. Maintain adequate hydration prior to initiation; monitor urine output & serum creatinine levels; avoid concomitant use w/ loop diuretics. Perform appropriate tests for the presence of antineutrophil Ab if transfusion-related acute lung injury (TRALI) is suspected. May interfere w/ serological test for red cell Ab eg Coomb's test. May impair ability to drive or operate machinery. Pregnancy & lactation.\n\nMode of action: May interfere with the immune response to live measles vaccine, live mumps vaccine, live rubella vaccine and live varicella vaccine, therefore these vaccines should be given at least 3 wk before or 3 mth after the admin of the immunoglobulins.\n\nPregnancy category: C\n\nInteraction: May interfere with the immune response to live measles vaccine, live mumps vaccine, live rubella vaccine and live varicella vaccine, therefore these vaccines should be given at least 3 wk before or 3 mth after the admin of the immunoglobulins.
Hepatitis A Virus (Inactivated) Vaccine	\n\n\tSanofi Aventis Pasteur SA, France\tAvaxim Pediatric 	 Injection  80IU 	 avaxim 80 amp x 1's pack 753.55 	 	\n\tSanofi Pasteur S A ,France\tAvaxim Injection  160IU avaxim 160 amp x 1's pack 1275.55\n\tIndication: Active immunisation against Hepatitis A\n\nDose: Adult: IM Single dose of 0.5 or 1 mL depending on the product and patient's age. Give booster dose 6-12 mth after the initial dose. Give via SC administration in haemophiliacs.\n\nContra-indication: Hypersensitivity. Vaccines prepared in egg cultures are contraindicated in patients with hypersensitivity reactions to egg. Severe immunodeficiency. Malignant disease being treated with chemotherapy or radiotherapy and for at least 6 mth after stopping treatment. Patients with compromised immune system such as those on high-dose systemic corticosteroids, immunosuppressants or HIV positive.\n\nSide effects: Transient soreness, erythema, induration at inj site. Fever, malaise,\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Alcohol or disinfectant used for cleaning the skin prior to inj should be allowed to evaporate completely before vaccination to prevent vaccine inactivation.\n\nMode of action: Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.\n\nPregnancy category: C\n\nInteraction: Reduced response to vaccination when used concurrently with immunosuppressants such as corticosteroids or antineoplastics.
Indacaterol	\n\n\tBeximco\tOnriva Dry powder inhalation capsule 75mcg  \n\tNovartis (Bangladesh) Ltd.\tOnbrez Breezhaler 150mg CAP 150mg 30's pack 2808\n\tNovartis (Bangladesh) Ltd.\tOnbrez Breezhaler 300mg CAP 300mg 30's pack 3811\n\tIndication: Asthma, Chronic obstructive pulmonary disease\n\nDose: The recommended dosage  is the once-daily inhalation of the contents of one 75 mcg   capsule using the  inhaler. \n\nContra-indication: Patients with asthma without use of a long-term asthma control medication\nPatients with a history of hypersensitivity to indacaterol or to any of the ingredients.\n\nSide effects:   1     Clinical Trials Experience in Chronic Obstructive Pulmonary Disease\n 2     Clinical Trials Experience in Asthma\n 3     Postmarketing Experience \n\nPrecaution:  Data from a large placebo-controlled study in asthma patients showed that long-acting beta2-adrenergic agonists may increase the risk of asthma-related death. Data are not available to determine whether the rate of death in patients with COPD is increased by long-acting beta2-adrenergic agonists.\nA 28-week, placebo-controlled US study comparing the safety of another long-acting beta2-adrenergic agonist (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34). The increased risk of asthma-related death is considered a class effect of the long-acting beta2-adrenergic agonists, including  . No study adequate to determine whether the rate of asthma-related death is increased in patients treated     has been conducted. The safety and efficacy  patients with asthma have not been established. It is not indicated for the treatment of asthma. \nSerious asthma-related events, including death   . The sizes of these studies were not adequate to precisely quantify the differences in serious asthma exacerbation rates between treatment groups.\n\nMode of action: Potentiated adverse effects w/ other sympathomimetic agents; possible hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics. Other long-acting ?2-adrenergic agonists or medicinal products containing long-acting ?2-adrenergic agonists. Inhibition of the key contributors of indacaterol clearance, CYP3A4 and P-gp.\n\nPregnancy category: C\n\nInteraction: Potentiated adverse effects w/ other sympathomimetic agents; possible hypokalaemic effect w/ methylxanthine derivatives, steroids or non-K-sparing diuretics. Other long-acting ?2-adrenergic agonists or medicinal products containing long-acting ?2-adrenergic agonists. Inhibition of the key contributors of indacaterol clearance, CYP3A4 and P-gp.
Insulin Aspart	\n\n\tACI\tAcilog SC Injection 100IU/ml 1pc 450\n\tAristopharma\tInsulet ASP Injection 3.5 3ml bot \n\tAristopharma\tInsulet ASP 30/70 Injection 3.5mg 3ml bot 415\n\tIncepta\tGlyset R Injection 300 IU/3 ml  \n\tNovo Nordisk A/S Denmark\tNovoRapid Penfill Injection 100IU/ml  3ml cartridge with penfill X 5's pack  3650\n\tNovo Nordisk A/S Denmark\tNovoRapid Flexpen Injection 100IU/ml 3ml pre-filled pen X 1's pack 860\n\tIndication: Diabetes mellitus\n\nDose: Adult: SC Usual range: 0.5-1 u/kg/day. Dosage should be individualised and adjusted based on patient's glycaemic response.\n\nContra-indication: Hypoglycaemia. Hypersensitivity to any of the components. \n\nSide effects: Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatrophy or lipohypertrophy with SC Inj (rotate Inj site).\n\nPrecaution: Renal or hepatic impairment; pregnancy; lactation. Transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections; hypokalaemia.\n\nMode of action: Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by ?-blockers, clonidine.\n\nPregnancy category: B\n\nInteraction: Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by ?-blockers, clonidine.
Insulin Aspart Biphasic	\n\n\tACI\tAcilog Mix SC Injection 100IU/ml 1's pack 450\n\tIncepta\tGlyset Mix Injection 100 IU/ml  \n\tNovo Nordisk A/S Denmark\tNovoMix 30 Penfill Injection 100IU/ml 3ml x 5's pack 3850\n\tNovo Nordisk A/S Denmark\tNovoMix 30 FlexPen Injection 100IU/ml 3ml x 1's pack 860\n\tIndication: Diabetes mellitus\n\nDose: Combination rapid-onset (faster than regular insulin) and intermediate-acting insulins in fixed dose.\nAdult: SC DM Dosage should be individualised and adjusted based on patient's glycaemic response. Usual range: 0.5-1 u/kg/day.\n\nContra-indication: Hypoglycaemia.Hypersensitivity to any of the components. \n\nSide effects: Adverse events commonly associated with human insulin therapy include the following: Allergic reactions. Injection site reaction, lipodystrophy, pruritus, rash, lipoatrophy, hypokalaemia, blurred vision. Hypoglycaemia, insulin resistance.\n\nPrecaution: Pregnancy (insulin requirements tend to fall during the 1st trimester, increase during the 2nd and 3rd) and lactation. Regular monitoring of HbA1c and blood glucose concentrations.\n\nMode of action: Reduce insulin requirements w/ oral hypoglycemics, octreotide, MAOIs, nonselective ?-adrenergic blockers, ACE inhibitors, salicylates, alcohol, anabolic steroids & sulfonamides; increase insulin requirements w/ OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics & danazol. ?-blocking agents may mask the symptoms of hypoglycaemia. Alcohol may intensify & prolong the glucose lowering effect of insulin.\n\nPregnancy category: B\n\nInteraction: Reduce insulin requirements w/ oral hypoglycemics, octreotide, MAOIs, nonselective ?-adrenergic blockers, ACE inhibitors, salicylates, alcohol, anabolic steroids & sulfonamides; increase insulin requirements w/ OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics & danazol. ?-blocking agents may mask the symptoms of hypoglycaemia. Alcohol may intensify & prolong the glucose lowering effect of insulin.
Insulin Detemir	\n\n\tNovo Nordisk A/S Denmark\tLevemir Penfill Injection 100IU/ml 10ml ot 542\n\tNovo Nordisk A/S Denmark\tLevemir Flexpen Injection 100IU/ml 1's pack 1300\n\tIndication: Diabetes mellitus\n\nDose: Adult: SC In insulin-naive patients w/ type 2 DM who are not well controlled on oral antidiabetic drugs: Initial: 0.1-0.2 u/kg once daily in the evening or 10 u 1-2 times/day, adjust subsequently based on glycaemic control. \n\nIn patients on basal insulin only: May substitute w/ insulin detemir on a unit-for-unit basis based on the current basal insulin dosage, adjust subsequently to achieve glycaemic targets.\n\nContra-indication: Do not admin by IV, IM or via insulin infusion pump.\n\nSide effects: Hypoglycaemia, lipodystrophy, pruritus, rash, wt gain, sodium retention and oedema. Inj site reactions e.g. pain, itching, hives, swelling and inflammation.\n\nPrecaution: Renal or hepatic impairment. Regular monitoring of blood glucose and HbA1c. Continuous rotation of the inj site within a given area to reduce inj site reactions. Pregnancy, lactation\n\nMode of action: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Increased blood sugar with thiazide diuretics, corticosteriods, chlorpromazine, tibolone, isoniazid, niacin, some calcium-channel blockers such as diltiazem or nifedipine, diazoxide, lithium and thyroid hormones. Increased risk of hypoglycemia with disopyramide, larges doses of aspirin, gatifloxacin, MAOIs, mebanazine, nandrolone, pegvisomant, testosterone. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.\n\nPregnancy category: B\n\nInteraction: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Increased blood sugar with thiazide diuretics, corticosteriods, chlorpromazine, tibolone, isoniazid, niacin, some calcium-channel blockers such as diltiazem or nifedipine, diazoxide, lithium and thyroid hormones. Increased risk of hypoglycemia with disopyramide, larges doses of aspirin, gatifloxacin, MAOIs, mebanazine, nandrolone, pegvisomant, testosterone. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
Insulin Glargine	\n\n\tACI\tGlarin Injection 100IU/ml  3ml 600\n\tACI\tGlarine SC Injection 100 IU/ml 3ml bot 600\n\tAristopharma\tInsulet GN Injection 100IU/ml  3ml bot 600\n\tIncepta\tVibrenta Injection 100IU/ml 3ml vial x 1's pack 600\n\tPopular\tInsul Glargine Injection 100 IU/ml 3 ml vial x 1's pack 600\n\tPopular\tInsul Glargine Cartridge Injection  100 IU/ml 3ml x 3's pack 1800\n\tSanofi Aventis (BD) Ltd.\tLantus SoloStar Injection  100IU/ml 3ml x 5's pack 5588\n\tSanofi-aventis DeutschlandGmbH, Germany\tLantus Optiset Injection 100IU/ml 3ml x 5's pack 5395.76\n\tIndication: Diabetes mellitus\n\nDose: Adult: SC For insulin-naive patients: May initiate w/ 10 IU once daily, adjust subsequently based on glycaemic response. Usual range: 2-100 IU/day.\nChild: >6 yr: According to requirements; administer once daily at the same time each day.\n\nContra-indication: Hypoglycaemia; IV route.\n\nSide effects: Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatrophy or lipohypertrophy with SC Inj (rotate Inj site).\n\nPrecaution: Renal or hepatic impairment; pregnancy; lactation; child <6 yrs. Transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections; hypokalaemia.\n\nMode of action: Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g. octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by ?-blockers, clonidine.\n\nPregnancy category: C\n\nInteraction: Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g. octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by ?-blockers, clonidine.
Insulin Glulisine	\n\n\tSanofi-aventis DeutschlandGmbH, Germany\tApidra Solostar Injection  100 IU/ml 3ml SoloStar prefilled pen X 5's pack 4673\n\tIndication: Diabetes mellitus\n\nDose: Adult: Dose should be individualised and depends on patient's needs. Usual range: 0.5-1 u/kg/day. \n\nBy Inj: Admin within 15 minutes before a meal or within 20 minutes after starting a meal into the abdominal wall, thigh, or upper arm. \n\nBy continuous infusion: Admin into the abdominal wall. To be used in conjunction with a longer-acting insulin or basal insulin analogue. \n\nRenal impairment: Dose reduction may be needed. \nHepatic impairment: Dose reduction may be needed.\n\n\nContra-indication: Hypoglycaemia.Hypersensitivity to any of the components. \n\nSide effects: Hypoglycaemia, Inj site reactions, lipodystrophy, local and systemic hypersensitivity reactions.\n\nPrecaution: Renal or hepatic impairment. Regular monitoring of blood glucose and HbA1c. Rotate Inj sites to reduce lipodystrophy . Pregnancy, lactation.\n\nMode of action: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotics (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.\n\nPregnancy category: C\n\nInteraction: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotics (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
Interferon Beta 1a	\n\n\tIndication: Relapsing multiple sclerosis\n\nDose: Dosages   shown to be safe and effective are 22 mcg and 44 mcg injected subcutaneously three times per week. if possible, at the same time (preferably in the late afternoon or evening) on the same three days (e.g., Monday, Wednesday, and Friday) at least 48 hours apart each week . Generally, patients should be started at 20% of the prescribed dose three times per week and increased over a 4-week period to the targeted dose, either 22 mcg three times per week   or 44 mcg three times per week  . Patients prescribed a targeted dose of 22 mcg three times per week should use the pre-filled syringes for titration. Following the administration of each dose, any residual product remaining in the syringe should be discarded in a safe and proper manner.\n\nContra-indication: Patients with a history of hypersensitivity to natural or recombinant interferon, human albumin, or any other component of the formulation.\n\nSide effects: The most commonly reported adverse reactions were injection site disorders, influenza-like symptoms (headache, fatigue, fever, rigors, chest pain, back pain, myalgia), abdominal pain, depression, elevation of liver enzymes and hematologic abnormalities. The most frequently reported adverse reactions resulting in clinical intervention   were injection site disorders, influenza-like symptoms, depression and elevation of liver enzymes\n\nPrecaution: Caution should be exercised when administering  to patients with pre-existing seizure disorders. Seizures have been associated with the use of beta interferons. Leukopenia and new or worsening thyroid abnormalities have developed in some patients treated . Regular monitoring for these conditions is recommended\n\nMode of action: Drugs w/ narrow therapeutic index eg antiepileptics & some classes of antidepressants.\n\nPregnancy category: Not Classified\n\nInteraction: Drugs w/ narrow therapeutic index eg antiepileptics & some classes of antidepressants.
Ioversol	\n\n\tIndication: Peripheral and coronary arteriography and left ventriculography,Intravenous excretory urography,Angiography\n\nDose: As with all radiopaque contrast agents, only the lowest dose necessary to obtain adequate visualization should be used. A lower dose may reduce the possibility of an adverse reaction. Most procedures do not require use of either the maximum volume or the highest concentration . The combination of volume and concentration  to be used should be carefully individualized accounting for factors such as age, body weight, size of the vessel and the rate of blood flow within the vessel. Other factors such as anticipated pathology, degree and extent of opacification required, structure(s) or area to be examined, disease processes affecting the patient, and equipment and technique to be employed should be considered.\n\nIt is desirable that intravascularly administered iodinated contrast agents be at or close to body temperature when injected.\n\nIf during administration a reaction occurs, the injection should be stopped until the reaction has subsided.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Usually mild to moderate, of short duration and resolve spontaneously (without treatment). However, serious, life-threatening and fatal reactions, mostly of cardiovascular origin, have been associated with the administration of iodine-containing contrast media.\n\nInjections of contrast media are often associated with sensations of warmth and pain. In controlled double-blind clinical studies, significantly less warmth and pain were associated with the injection   than with iothalamate meglumine, diatrizoate meglumine, and diatrizoate meglumine and diatrizoate sodium.\n\nPrecaution: Diagnostic procedures which involve the use of iodinated intravascular contrast agents should be carried out under the direction of personnel skilled and experienced in the particular procedure to be performed. A fully equipped emergency cart, or equivalent supplies and equipment, and personnel competent in recognizing and treating adverse reactions of all types should always be available. Since severe delayed reactions have been known to occur, emergency facilities and competent personnel should be available for at least 30 to 60 minutes after administration.\n\nMode of action: \n\nPregnancy category: B\n\nInteraction: 
Irinotecan Hydrochloride Trihydrate	\n\n\tEbew Pharma,Austria\tIrinotecan Infusion 20mg/ml 	 100mg/vial 	 \n\tPfizer (perth) Pty. Ltd. Australia\tCampto Infusion 100mg/5ml 100mg vial 11957.63\n\tPfizer (perth) Pty. Ltd. Australia\tCampto Infusion 40mg/2ml 40mg vial 4985.59\n\tS.C Sindan Pharma S.R.l,Romania\tIrinotesin Injection 20mg/ml 	 5ml Vial  \n\tIndication: Carcinoma of the colon or rectum\n\nDose: Administer as a 90-minute intravenous infusion followed by LV and 5-FU. A reduction in the starting dose by one dose level may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels.\n\nAdult: IV Refractory colorectal malignancies 125 mg/m2 once wkly for 4 wk, followed by a 2 wk rest period. Metastatic colorectal cancer As 1st line treatment: 125 mg/m2 on days 1, 8, 15 and 22 of a 6-wk cycle.\n\nContra-indication: Patients with a known hypersensitivity to the drug or its excipients.\n\nSide effects: Neutropenia, anaemia, thrombocytopenia; acute diarrhoea, sweating, hypersalivation, abdominal cramps, lachrymation, miosis, weakness; nausea, vomiting, alopecia and skin reactions; cardiovascular toxicity. Potentially Fatal: Fatal sepsis due to myelosuppression; severe, chronic diarrhoea. 	\n\nPrecaution: Early diarrhea is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Bradycardia may also occur.\n\nLate diarrhea can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis.Late diarrhea can be complicated by colitis, ulceration, bleeding, ileus, obstruction, and infection. Cases of megacolon and intestinal perforation have been reported.\n\n\nMode of action: Diuretics increase risks of dehydration secondary to vomiting/diarrhoea; prophylactic dexamethasone as an antiemetic may enhance lymphocytopenia; prochlorperazine may increase incidence of akathisia; antineoplastic agents (myelosuppression and diarrhoea). St John's wort, ketoconazole may reduce irinotecan exposure.\n\nPregnancy category: D\n\nInteraction: Diuretics increase risks of dehydration secondary to vomiting/diarrhoea; prophylactic dexamethasone as an antiemetic may enhance lymphocytopenia; prochlorperazine may increase incidence of akathisia; antineoplastic agents (myelosuppression and diarrhoea). St John's wort, ketoconazole may reduce irinotecan exposure.
Iron (III)-Hydroxide Dextran Complex	\n\n\tChemist Ltd.\tNefrofer Injection 100 mg/5 ml  \n\tNovo Nordisk A/S Denmark\tCosmoFer Infusion   570\n\tIndication:  Iron deficiency anaemia\n\n\n\nDose: Parenteral\nIron-deficiency anaemia\nAdult: As a preparation containing the equivalent of 50 mg/ml of iron. Total dose (ml) = 0.0442 (desired haemoglobin - observed haemoglobin) x LBW + (0.26 x LBW) (Note: LBW = Lean body weight(kg)) A test dose of 0.5 ml should be given and observe patient for at least 1 hr for signs for hypersensitivity. Usual daily max: 2 ml (100 mg). Total dose may be given in divided doses on a daily or twice wkly basis via IM inj (into the upper outer quadrant of the buttock); may also be given intravenously by total-dose infusion or as divided inj.\n\nChild: As a preparation containing the equivalent of 50 mg/ml of iron. Total dose (ml) = 0.0442 (desired haemoglobin - observed haemoglobin) x LBW + (0.26 x LBW) (Note: LBW = Lean body weight(kg)) A test dose (<10 kg: 0.2 ml; 10-20 kg: 0.3 ml) should be given and observe the patient for at least 1 hr for signs of hypersensitivity. Usual daily max: <5 kg: Up to 0.5 ml (25 mg); 5-9 kg: Up to 1 ml (50 mg); larger children: 2 ml (100 mg). Total dose may be given in divided doses on a daily or twice wkly basis via IM inj (into the upper outer quadrant of the buttock); may also be given intravenously by total-dose infusion or as divided inj.\n\n\n\nIntravenous drip infusion:\n\nIt must be diluted only in 0.9% sodium chloride solution (normal saline) or in 5% glucose solution. In a dose of 100-200 mg iron (2-4ml) may be diluted in 100 ml. On each occasion the first 25 mg of iron should be infused over a period of 15 minutes. If no adverse reactions occur during this time the remaining portion of the infusion should be given at an infusion rate of not more than 100 ml in 30 minutes.\n\nIntravenous injection:\n\nIt may be administered in a dose of 100 â 200 mg iron (2-4 ml) by slow intravenous injection (0.2 ml/min) preferably diluted in 10 â 20 ml 0.9% sodium chloride or 5% glucose solution. On each occasion before administering a slow intravenous injection, 25 mg of iron should be injected slowly over a period of 1 to 2 minutes. If no adverse reactions occur within 15 minutes, the remaining portion of the injection may be given. \n\nContra-indication: Known serious hypersensitivity to other parenteral iron products.\n\nNon-iron deficiency anaemia (e.g. haemolytic anaemia).\n\nIron overload or disturbances in utilisation of iron (e.g. haemochromatosis, haemosiderosis).\n\nDecompensated liver cirrhosis and hepatitis.\n\nAcute or chronic infection, because parenteral iron administration may exacerbate bacterial or viral infections.\n\nAcute renal failure. \n\nSide effects: Anaphylactoid reactions are uncommon and include urticaria, rashes, itching, nausea and shivering. Administration must be stopped immediately when signs of an anaphylactoid reaction are observed.\n\nAcute, severe anaphylactoid reactions are very rare. They usually occur within the first few minutes of administration and are generally characterised by the sudden onset of respiratory difficulty and / or cardiovascular collapse; fatalities have been reported.\n\nDelayed reactions are well described and may be severe. They are characterised by arthralgia, myalgia and sometimes fever. The onset varies from several hours up to four days after administration. Symptoms usually last two to four days and settle spontaneously or following the use of simple analgesics.\n\nExacerbation of joint pain in rheumatoid arthritis can occur. Local reactions reported are soreness and inflammation at or near injection site and local phlebitic reaction.\n\nLocal complications at the injection site after intramuscular injection such as staining of the skin, bleeding, formation of sterile abscesses, tissue necrosis or atrophy and pain are observed.\n\nPrecaution: Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes.\n\nThe risk is enhanced for patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy.\n\nHypotensive episodes may occur if intravenous injection is administered too rapidly.\n\nMode of action: Reduced Fe absorption upon oral Fe administration earlier than 5 days after the last inj. Reduced effect when used with chloramphenicol.\n\nPregnancy category: C\n\nInteraction: Reduced Fe absorption upon oral Fe administration earlier than 5 days after the last inj. Reduced effect when used with chloramphenicol.
Isotretinoin	\n\n\tF. Hoffmann-La Roche Ltd.Switzerland\tRoaccutane CAP 10 mg, 20 mg 30 's pack  \n\tLes Servier Industrie,France\tIsotretinion CAP 10mg  120\n\tLes Servier Industrie,France\tIsotretinion CAP 20mg  130\n\tIndication: Acne\n\nDose: Oral\nAcne\nAdult: Initially, 0.5-1 mg/kg daily in 2 divided doses. Usual duration of treatment: 15-20 wk; may be discontinued if number of cysts is reduced by >70% (whichever is sooner). Patients intolerant to initial dose: Continue treatment at a lower dose. Patients with very severe acne or acne evident on the body instead of face: Up to 2 mg/kg daily. There should be a 2-mth drug-free interval if a 2nd course is necessary.\nHepatic impairment: Dose reduction may be needed.\n\n\nContra-indication: Pregnancy, lactation.\n\nSide effects: Dryness of mucous membranes, dryness of skin with scaling, fragility, erythema, cheilitis, pruritus, epistaxis, conjunctivitis, dry sore mouth and palmo-plantar exfoliation. Corneal opacities, dry eyes, visual disturbances, skeletal hyperostosis and musculoskeletal symptoms. Elevation of serum triglycerides, LFTs, ESR and blood glucose. Hair thinning, photosensitivity, changes in skin pigmentation, paronychia. GI disturbances, hepatitis. Headache, drowsiness, sweating, mood changes, psychotic symptoms, depression, suicidal tendencies, benign intracranial hypertension, seizures. Vasculitis, hypersensitivity reactions, IBS.\nPotentially Fatal: Anaphylaxis. Haemorrhagic pancreatitis.\n\nPrecaution: Preexisting or predisposition to hypertriglyceridaemia (e.g. DM, obesity or increased alcohol intake). Monitor triglyceride levels. Monitor blood lipids and LFTs at wkly or bi-wkly intervals. Monitor blood glucose in known or suspected DM patients. Genetic predisposition for age-related osteoporosis, history of childhood osteoporosis, osteomalacia or other bone metabolism disorders. Anorexia nervosa. History of psychiatric disorder. May impair night vision. Avoid wax epilation and skin resurfacing procedures for at least 6 mth. Avoid prolonged exposure to UV light or sunlight. Discontinue if hearing impairment, abdominal pain, rectal bleeding, severe diarrhoea or adverse ocular effects occur. Patient should not donate blood during therapy and for at least 1 mth following drug discontinuation.\n\nMode of action: Additive toxicity with vitamin A or its derivatives. Decreased efficacy of microdosed progesterone (use 2 forms of contraception). May increase risk of bone loss with phenytoin. May increase risk of osteoporosis with systemic corticosteroids. Reduces plasma levels of carbamazepine.\nPotentially Fatal: Increased risk of pseudotumor cerebri with tetracyclines.\n\nPregnancy category: X\n\nInteraction: Additive toxicity with vitamin A or its derivatives. Decreased efficacy of microdosed progesterone (use 2 forms of contraception). May increase risk of bone loss with phenytoin. May increase risk of osteoporosis with systemic corticosteroids. Reduces plasma levels of carbamazepine.\nPotentially Fatal: Increased risk of pseudotumor cerebri with tetracyclines.
Ketamine	\n\n\tACI\tPentyl Injection 50mg/ml 1's pack 115.78\n\tGonoshasthaya\tG Ketamine Injection 50mg/ml 10 ml vial x 1's pack 101.18\n\tIncepta\tKetaride Injection 500mg/10ml 1's pack 115\n\tPopular\tKetalar Injection 50mg/ml 10 ml vial x 1's pack 115.43\n\tRenata\tKain Injection 50mg/ml 10 ml vial x 1's pack 100\n\tChemial Works of Gedeon RichterLtd., Hungary\tCalypsol Injection 500mg  1200\n\tGrifols Biologicals Inc, USA\tKetmine Injection 50mg/ml 10ml ampule  400\n\tIndication: Induction of anesthesia.\n\nDose: Intravenous\nInduction of anaesthesia\nAdult: 1-4.5 mg/kg via slow IV inj over 60 sec. A dose of 2 mg/kg produces surgical anaesthesia w/in 30 sec after inj lasting for 5-10 min. Increments of half to the full induction dose may be repeated as needed for maintenance of anesth. Alternatively, a total induction dose of 0.5-2 mg/kg via infusion, given at an appropriate rate, and maintained at a rate of 10-45 mcg/kg/min, adjusted according to response.\nIntramuscular\nInduction of anaesthesia\nAdult: 6.5-13 mg/kg. A dose of 10 mg/kg produces surgical anaesthesia w/in 3-4 min after inj lasting for 12-25 min. Increments of half to the full induction dose may be repeated as needed for maintenance of anesth. For diagnostic or other procedures not involving intense pain: 4 mg/kg as initial dose.\n\nContra-indication: Hypertension, history of cerebrovascular accident. Eye injury, raised ocular and intracranial pressure. Psychotic disorders.\n\nSide effects: Emergence reactions e.g. vivid dreams, hallucinations, confusion, irrational behaviour. Increased muscle tone sometimes resembling seizures. Temporary hypertension and tachycardia. Hypotension, bradycardia, arrhythmias. Respiratory depression, apnoea, laryngospasm, diplopia, nystagmus, nausea, vomiting, lachrymation, hypersalivation, raised intraocular and CSF pressure, skin rash and pain at inj site.\n\nPrecaution: Minimise verbal and tactile stimulation during recovery period. Chronic alcoholic and alcohol-intoxicated patients. Preanaesthetic elevated CSF pressure. Dependence and tolerance may develop. May impair ability to drive or operate machinery. Monitor cardiac function in patients with hypertension or cardiac decompensation. Pregnancy and lactation.\n\nMode of action: Prolonged recovery time w/ barbiturates or narcotics. May potentiate neuromuscular blocking effects of atracurium and tubocurarine including resp depression w/ apnoea. May increase risk of bradycardia, hypotension or decreased cardiac output w/ halogenated anaesth. May potentiate CNS depression and risk of resp depression w/ CNS depressants (e.g. phenothiazines, sedating H1-blockers, skeletal muscle relaxants). May antagonise hypnotic effect of thiopental. May increase risk of HTN w/ thyroid hormones. May increase risk of hypotension w/ antihypertensive agents. Reduction in seizure threshold resulting in unpredictable extensor-type seizures when given concurrently w/ theophylline.\n\nPregnancy category: B\n\nInteraction: Prolonged recovery time w/ barbiturates or narcotics. May potentiate neuromuscular blocking effects of atracurium and tubocurarine including resp depression w/ apnoea. May increase risk of bradycardia, hypotension or decreased cardiac output w/ halogenated anaesth. May potentiate CNS depression and risk of resp depression w/ CNS depressants (e.g. phenothiazines, sedating H1-blockers, skeletal muscle relaxants). May antagonise hypnotic effect of thiopental. May increase risk of HTN w/ thyroid hormones. May increase risk of hypotension w/ antihypertensive agents. Reduction in seizure threshold resulting in unpredictable extensor-type seizures when given concurrently w/ theophylline.
Ketoprofen	\n\n\tACI\tKetron SR CAP 100mg 50's pack 351.50\n\tAcme Ltd.\tKeto A Injection 100mg/2ml 10 amps pack 195.80\n\tAcme Ltd.\tKeto A Suppository 100mg 10 amps pack 120.50\n\tAcme Ltd.\tKeto A TAB dr 100mg 50's pack 276\n\tAcme Ltd.\tKeto A TAB dr 50mg 50's pack 175.50\n\tApex\tKetronil TAB dr 100mg 50's pack 175\n\tApex\tKetronil TAB dr 50mg 50's pack 100\n\tBeximco\tXynofen SR CAP 100mg 50's pack 377\n\tBio Pharma Ltd.\tTop TAB dr 100mg 30's pack 180.60\n\tBio Pharma Ltd.\tTop TAB dr 50mg 50's pack 175.50\n\tBristol Pharma Ltd.\tTramp CR CAP 100 mg 50's pack 505.50\n\tEskayef Bangladesh Ltd.\tKetofen TR TAB dr 100mg 100's pack \n\tEskayef Bangladesh Ltd.\tKynol TR CAP 100mg 50's pack 350\n\tEskayef Bangladesh Ltd.\tKynol TR CAP 200mg 30's pack 300\n\tHudson\tKeto SR CAP 100mg 100's pack 350\n\tNavana\tKetonac TAB dr 100mg 50's pack 251\n\tNavana\tKetonac TAB dr 50mg 50's pack 125.50\n\tOrion Pharma Ltd.\tOrket Injection 100mg/2ml 5  amps pack 75.30\n\tSanofi Aventis (BD) Ltd.\tProfenid Injection 100mg/2ml 10 amps pack 500\n\tSanofi Aventis (BD) Ltd.\tProfenid CR CAP 100mg 50's pack 550\n\tSanofi Aventis (BD) Ltd.\tProfenid CR CAP 200mg 50's pack 1000\n\tSanofi Aventis (BD) Ltd.\tProfenid E TAB dr 100mg 50's pack 450\n\tSanofi Aventis (BD) Ltd.\tProfenid E TAB dr 50mg 50's pack 300\n\tSilva\tKontrol TR CAP 100mg 30's pack 180.68\n\tSquare\tKop IM Injection 100mg/2ml 10 amps pack 200.69\n\tSquare\tKop TAB dr 50mg 50's pack 175.56\n\tSquare\tKop SR CAP 100mg 50's pack 351.12\n\tSquare\tKop SR CAP 200mg 30's pack 301.24\n\tTechno Drugs Ltd.\tKefen Injection 100mg/2ml 10 amps pack 150\n\tIndication: Rheumatic disorders, Pain and inflammation, Musculoskeletal and joint disorders,							\n\n\nDose: Adult: PO Rheumatic disorders 100-200 mg/day in 2-4 divided doses. Max: 300 mg/day in divided doses. Pain and inflammation 25-50 mg 6-8 hrly. Max: 300 mg/day. \n\nIM Pain and inflammation associated w/ musculoskeletal and joint disorders; Pain following orthopaedic surgery 50-100 mg by deep inj into the gluteal muscle 4 hrly. Max: 200 mg/24 hr for up to 3 days. \n\nRectal Rheumatic disorders 100 mg at night. Recommended total dose (combined oral and rectal): Not to exceed 200 mg/day. \n\nContra-indication: For all routes: Hypersensitivity to aspirin or other NSAIDs or those suffering from asthma, angioedema, urticaria or rhinitis. Active GI disease (e.g. bleeding or ulcer). Severe heart failure, and renal insufficiency. Treatment of perioperative pain in the setting CABG surgery. Rectal: Patients w/ history of proctitis or haemorrhoids.\n\nSide effects: HTN; GI symptoms e.g. dyspepsia, discomfort, nausea, diarrhoea; pain and tissue damage at inj site (IM). Cardiovascular toxicity (chest pain, dyspnea, weakness, slurred speech). May mask the usual signs and symptoms of infection. NSAID-induced liver dysfunction, anaphylactoid reaction (e.g. difficulty breathing, swelling of the face or throat); photosensitivity reactions (topical).\nPotentially Fatal: Anaphylaxis, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis.\n\nPrecaution: History of GI disease (e.g. bleeding or ulcer). Hypertensive patients; renal or hepatic impairment. Pregnancy, lactation, elderly. Monitoring Parameters Close monitoring of BP during initiation and throughout the therapy. Complete blood cell count, chemistry profile, liver and renal function test performed periodically for patients receiving long-term ketoprofen therapy.\n\nMode of action: Increases plasma concentrations of lithium and methotrexate. Reduces effects of antihypertensives (e.g. ACE inhibitors, angiotensin II receptor antagonists). Increased risk of GI bleeding w/ warfarin. Decreased protein binding of ketoprofen and increased risk for serious GI events w/ aspirin and other NSAIDs. Increased risk of developing renal failure w/ diuretics. Increased risk of GI bleeding and ulceration w/ corticosteroids. Increased plasma levels w/ probenecid. Salicylate reduces conjugation and renal elimination of ketoprofen.\n\nPregnancy category: D\n\nInteraction: Increases plasma concentrations of lithium and methotrexate. Reduces effects of antihypertensives (e.g. ACE inhibitors, angiotensin II receptor antagonists). Increased risk of GI bleeding w/ warfarin. Decreased protein binding of ketoprofen and increased risk for serious GI events w/ aspirin and other NSAIDs. Increased risk of developing renal failure w/ diuretics. Increased risk of GI bleeding and ulceration w/ corticosteroids. Increased plasma levels w/ probenecid. Salicylate reduces conjugation and renal elimination of ketoprofen.
L-Asparaginase	\n\n\tIndication: Acute Lymphocytic Leukemia\n\nDose: 6,000 International Units/m2 intramuscularly (IM) or intravenously (IV) three times a week  \nReconstitute in volume appropriate for the intended route of administration:\nFor IM administration, reconstitute in 2 mL \nFor IV administration, reconstitute in 5 mL \nFor IM administration, limit the volume at a single injection site to 2 mL; if greater than 2 mL, use multiple injection sites.  \nFor IV administration, give over ? 30 min through side arm of an infusion of Sodium Chloride Injection or Dextrose Injection 5% (D5W) .\nUse reconstituted Elspar within eight hours. \n\nContra-indication: Serious allergic reactions to Elspar or other Escherichia coli-derived L-asparaginases  \nSerious thrombosis with prior L-asparaginase therapy  \nPancreatitis with prior L-asparaginase therapy  \nSerious hemorrhagic events with prior L-asparaginase therapy\n\nSide effects: Most common adverse reactions are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases \n\nPrecaution: Anaphylaxis and other serious allergic reactions can occur. Observe patients for one hour after administration. Discontinue Elspar in patients with serious allergic reactions. \nSerious thrombotic events, including sagittal sinus thrombosis, can occur. Discontinue Elspar in patients with serious thrombotic events.  \nPancreatitis, in some cases fulminant or fatal, can occur. Evaluate patients with abdominal pain for pancreatitis. Discontinue Elspar in patients with pancreatitis.  \nGlucose intolerance, in some cases irreversible, can occur. Monitor serum glucose.  \nCoagulopathy can occur. Perform appropriate monitoring. \nHepatotoxicity including hepatic failure can occur. Perform appropriate monitoring. \nPosterior Reversible Encephalopathy Syndrome (PRES).  \nDo not interchange Elspar with Erwinia asparaginase or pegylated E. coli asparaginase [polyethylene glycol (PEG) asparaginase].\n\nMode of action: Activity of methotrexate may be reduced if L-asparaginase is given before hand.\nPotentially Fatal: IV admin of asparaginase may increase vincristine neurotoxicity.\n\nPregnancy category: C\n\nInteraction: Activity of methotrexate may be reduced if L-asparaginase is given before hand.\nPotentially Fatal: IV admin of asparaginase may increase vincristine neurotoxicity.
L-Norgestral +Ethinyloestradiol	\n\n\tWyeth Pharma GmbH, Germany\tNordette-28 TAB dr  150/30 mcg 28's pack \n\tIndication: Contraception\n\nDose: To achieve maximum contraceptive effectiveness, levonorgestrel and ethinyl estradiol tablets must be taken exactly as directed and at intervals not exceeding 24 hours.\n\nThe dosage of levonorgestrel and ethinyl estradiol tablets is one white tablet daily for 21 consecutive days, followed by one orange inert tablet daily for 7 consecutive days, according to the prescribed schedule.\n\nIt is recommended that levonorgestrel and ethinyl estradiol tablets be taken at the same time each day.\n\nContra-indication: Combination oral contraceptives should not be used in women with any of the following conditions:\n\nThrombophlebitis or thromboembolic disorders\n\nA history of deep-vein thrombophlebitis or thromboembolic disorders\n\nCerebrovascular or coronary artery disease (current or past history)\n\nValvular heart disease with thrombogenic complications\n\nThrombogenic rhythm disorders\n\nHereditary or acquired thrombophilias\n\nMajor surgery with prolonged immobilization\n\nDiabetes with vascular involvement\n\nHeadaches with focal neurological symptoms\n\nUncontrolled hypertension\n\nKnown or suspected carcinoma of the breast or personal history of breast cancer\n\nCarcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia\n\nUndiagnosed abnormal genital bleeding\n\nCholestatic jaundice of pregnancy or jaundice with prior pill use\n\nHepatic adenomas or carcinomas, or active liver disease Known or suspected pregnancy\n\nHypersensitivity to any of the components of levonorgestrel and ethinyl estradiol tablets.\n\nSide effects: Thromboembolic and thrombotic disorders and other vascular problems (including thrombophlebitis and venous thrombosis with or without pulmonary embolism, mesenteric thrombosis, arterial thromboembolism, myocardial infarction, cerebral hemorrhage, cerebral thrombosis), carcinoma of the reproductive organs and breasts, hepatic neoplasia (including hepatic adenomas or benign liver tumors), ocular lesions (including retinal vascular thrombosis), gallbladder disease, carbohydrate and lipid effects, elevated blood pressure, and headache including migraine.\n\nThe following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug related (alphabetically listed):\n\nAcne\n\nAmenorrhea\n\nAnaphylactic/anaphylactoid reactions, including urticaria, angioedema, and severe reactions with respiratory and circulatory symptoms\n\nBreast changes: tenderness, pain, enlargement, secretion\n\nBudd-Chiari syndrome\n\nCervical erosion and secretion, change in\n\nCholestatic jaundice\n\nChorea, exacerbation of\n\nColitis\n\nContact lenses, intolerance to\n\nCorneal curvature (steepening), change in\n\nDizziness\n\nEdema/fluid retention\n\nErythema multiforme\n\nErythema nodosum\n\nGastrointestinal symptoms (such as abdominal pain, cramps, and bloating) Hirsutism\n\nInfertility after discontinuation of treatment, temporary\n\nLactation, diminution in, when given immediately postpartum\n\nLibido, change in\n\nMelasma/chloasma which may persist Menstrual flow, change in\n\nMood changes, including depression\n\nNausea\n\nNervousness\n\nPancreatitis\n\nPorphyria, exacerbation of\n\nRash (allergic)\n\nScalp hair, loss of\n\nSerum folate levels, decrease in\n\nSpotting\n\nSystemic lupus erythematosus, exacerbation of\n\nUnscheduled bleeding\n\nVaginitis, including candidiasis\n\nVaricose veins, aggravation of\n\nVomiting Weight or appetite (increase or decrease), change in\n\nThe following adverse reactions have been reported in users of oral contraceptives:\n\nCataracts\n\nCystitis-like syndrome\n\nDysmenorrhea\n\nHemolytic uremic syndrome\n\nHemorrhagic eruption\n\nOptic neuritis, which may lead to partial or complete loss of vision\n\nPremenstrual syndrome\n\nRenal function, impaired\n\nPrecaution: Patients should be counseled that oral contraceptives do not protect against transmission of HIV (AIDS) and other sexually transmitted diseases (STDs) such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.\n\nMode of action: CYP3A4 inducers may decrease levels/effects eg aminoglutethimide, carbamazepine, nafcillin, nevirapine, atazanavir, nelfinavir, phenobarbital, phenytoin, lamotrigine, rifamycins, griseofulvin and ritonavir; ampicillin, tetracycline and other antibiotics may reduce efficacy; oestrogens may antagonise anticoagulant effect of coumarins; may inhibit metabolism of prednisolone and ciclosporin; may reduce clearance of alprazolam, chlordiazepoxide, diazepam; may increase clearance of lorazepam, oxazepam, temazepam.\n\nPregnancy category: X\n\nInteraction: CYP3A4 inducers may decrease levels/effects eg aminoglutethimide, carbamazepine, nafcillin, nevirapine, atazanavir, nelfinavir, phenobarbital, phenytoin, lamotrigine, rifamycins, griseofulvin and ritonavir; ampicillin, tetracycline and other antibiotics may reduce efficacy; oestrogens may antagonise anticoagulant effect of coumarins; may inhibit metabolism of prednisolone and ciclosporin; may reduce clearance of alprazolam, chlordiazepoxide, diazepam; may increase clearance of lorazepam, oxazepam, temazepam.
Lapatinib	\n\n\tGlaxo Operations UK Ltd., UK\tTykerb TAB dr 250mg 250 mg x 70's pack 24961.30\n\tIndication: Breast cancer\n\nDose: HER2 positive metastatic breast cancer 1, 250 mg (5 tab) daily on days 1-21 continuously in combination w/ capecitabine. 2,000 mg/m2/day (orally in 2 doses approx 12 hr apart) on days 1-14 in a repeating 21-day cycle. \n\nHormone receptor positive, HER2 positive metastatic breast cancer Recommended dose: 1,500 mg (6 tab) continuously in combination w/ letrozole. All doses to be given once daily as a single dose.\n\nContra-indication: Hypersensitivity to lapatinib ditosylate\n\nSide effects: Anorexia, diarrhea, nausea, vomiting, rash, fatigue, dyspepsia, dry skin, stomatitis, constipation, abdominal pain, palmar-plantar erythrodysesthesia, mucosal inflammation, pain in extremity, back pain, insomnia, epistaxis, alopecia; decreased LVEF, nail disorders, headache.\n\nPrecaution: Evaluate left ventricular ejection fraction (LVEF) prior to treatment. Moderate or severe hepatic impairment. Patients who have or may develop QTc prolongation, including those w/ hypokalaemia or hypomagnesemia. Monitor liver function & pulmonary symptoms indicative of interstitial lung disease/pneumonitis. Pregnancy & lactation.\n\nMode of action: Increased conc w/ CYP3A4 inhibitors (eg ketoconazole, itraconazole or grapefruit juice), midazolam, irinotecan & digoxin. Decreased conc w/ CYP3A4 inducers (eg rifampin, carbamazepine, phenytoin) & proton-pump inhibitors (eg esomeprazole). Altered pharmacokinetics w/ P-glycoprotein, breast cancer resistance protein (BCRP) inhibitors & inducers, topotecan & rosuvastation. Increased incidence & severity of adverse events w/ paclitaxel & docetaxel. CYP3A4 or CYP2C8 substrates.\n\nPregnancy category: D\n\nInteraction: Increased conc w/ CYP3A4 inhibitors (eg ketoconazole, itraconazole or grapefruit juice), midazolam, irinotecan & digoxin. Decreased conc w/ CYP3A4 inducers (eg rifampin, carbamazepine, phenytoin) & proton-pump inhibitors (eg esomeprazole). Altered pharmacokinetics w/ P-glycoprotein, breast cancer resistance protein (BCRP) inhibitors & inducers, topotecan & rosuvastation. Increased incidence & severity of adverse events w/ paclitaxel & docetaxel. CYP3A4 or CYP2C8 substrates.
Lenograstrim	\n\n\tAventis Pharma, France\tGranocyte 34 Injection 33.6 MIU 34 million units vial 7355\n\tIndication: Neutropenia, Reduce the risk of life-threatening infection in patients with neutropenia after cytotoxic chemotherapy.\n\nDose:  The recommended dose is 150 mcg/m2/day starting from day 2 of transplantation for max of 28 consecutive days.\n\nContra-indication: Contraindicated in patients with bone marrow cancer, children less than 2 years, and hypersensitivity. \n\nSide effects: Musculoskeletal - Musculoskeletal pain, bone pain, splenic enlargement and osteoporosis.\nGastrointestinal - Nausea, diarrhea and loss of appetite.\nBlood - Anemia and decrease in platelet counts.\nSkin - Painful skin condition, skin death and skin inflammation.\nMiscellaneous - Fever, headache and painful urination. \n\nPrecaution:  Caution should be exercised in patients with history of bone marrow cancer, sickle-cell anemia, osteoporosis, lung infection, during pregnancy and breastfeeding.\nMonitor complete blood count regularly while taking this medication.\nIt may reduce platelet counts; avoid injury or bruising. \n\nMode of action: Increased risk of myelosuppression with myelosuppressive antineoplastic agents; increased pulmonary toxicity with bleomycin and cyclophosphamide.\n\nPregnancy category: Not Classified\n\nInteraction: Increased risk of myelosuppression with myelosuppressive antineoplastic agents; increased pulmonary toxicity with bleomycin and cyclophosphamide.
Letrozole	\n\n\tBeacon\tLexel TAB dr 2.5mg  \n\tBeximco\tFemzole TAB dr 2.5mg  5's pack 200\n\tEskayef Bangladesh Ltd.\tLenor TAB dr 2.5mg 10's pack 400\n\tIbn Sina Pharmaceutical Ind. Ltd.\tLetrogen TAB dr 2.5mg  \n\tIncepta\tEndofree TAB dr 2.5mg 5's pack 200\n\tNuvista Pharma Ltd\tZoleta TAB dr 2.5 mg  5's pack 200.6\n\tPopular\tLoreta TAB dr 2.5mg 10's pack 400\n\tRenata\tLetrol TAB dr 2.5mg 5's pack 200.76\n\tSquare\tLerozol TAB dr 2.5mg  5's pack 200.75\n\tNovartis Pharma AG, Switzerland\tFemara TAB dr 2.50mg 30's pack 10223\n\tIndication: Breast cancer	\n\n\nDose: Adult: PO Adjuvant therapy for post menopausal women with hormone receptor positive early breast cancer; Advanced breast cancer in postmenopausal women 2.5 mg once daily.\n\nHepatic impairment: Reduce dose by 50% in patients with cirrhosis and severe hepatic impairment; recommended dose: 2.5 mg on alternate days.\n\nContra-indication: Premenopausal women and children; hypersensitivity.\n\nSide effects: Hot flushes, arthralgia, nausea, vomiting, fatigue, dizziness, headache, dyspepsia, constipation, diarrhoea, anorexia, alopoecia, increased sweating, rash, peripheral oedema, osteoporosis, musculoskeletal pain, vaginal irritation.\nPotentially Fatal: Thromboembolic events.\n\nPrecaution: Severe renal impairment; severe hepatic impairment; osteoporosis. Caution when driving or operating machinery.\n\nMode of action: Plasma levels reduced by tamoxifen.\n\nPregnancy category: X\n\nInteraction: Plasma levels reduced by tamoxifen.
Leuprolide acetate 3.75mg + Gelatin 0.65mg + dl-lactic	\n\n\tTakeda Pharmaceutical Companyltd., Japan\tLucrin Depot Injection 3.75mg 1's pack 11649.65\n\tIndication: Uterine fibroids, Endometriosis, Prostate cancer\n\nDose: Recommended Dose: 1 mg (0.2 mL) administered as a single daily SC injection. The injection sites should be varied periodically.\nLucrin Depot PDS: 1-Month (3.75 mg)/3-Month (11.25 mg): As with other drugs administered by injection, the injection site should be varied periodically.\n\n1-Month (3.75 mg): Prostate Cancer, Endometriosis, Endometriosis with Add-back, Uterine Fibroids, Breast Cancer: Recommended Dose: 3.75 mg administered monthly as a single IM or SC injection.\n\nCentral Precocious Puberty (CPP): The dose must be individualized for each child. The dose is based on a mg/kg ratio of Lucrin Depot PDS to body weight. Younger children require higher doses on a mg/kg ratio.\n\nContra-indication: Hypersensitivity to GnRH, GnRH agonist analogs or any of the excipients\nUndiagnosed abnormal vaginal bleeding.\n The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by the drug. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.\nUse in women who are breast-feeding. \nNorethindrone acetate is contraindicated in women with the following conditions:\n\n    Thrombophlebitis, thromboembolic disorders, cerebral apoplexy, or a past history of these conditions\n    Markedly impaired liver function or liver disease\n    Known or suspected carcinoma of the breast\n\n\n\nSide effects: The following adverse reactions are commonly associated with the pharmacological actions of leuprorelin acetate on steroidogenesis: Men: Benign, Malignant and Unspecified Neoplasm (Including Cysts and Polyps): Prostate tumor flare, aggravation of prostate cancer.\nMetabolism and Nutrition Disorders: Weight gain/loss.\nPsychiatric Disorders: Loss or decreased libido, increased libido.\nNervous System Disorders: Headache, muscular weakness.\nVascular Disorders: Vasodilatation, hot flushes, hypotension, orthostatic hypotension.\nSkin and Subcutaneous Tissue Disorders: Dry skin, hyperhydrosis, rash, urticaria, abnormal hair growth, hair disorder, night sweats, hypotrichosis, pigmentation disorder, cold sweats, hirsutism.\nReproductive System and Breast Disorders: Gynaecomastia, breast tenderness, erectile dysfunction, testicular pain, breast enlargement and pain, prostate pain, penile swelling, penis disorder, testis atrophy.\nGeneral Disorders and Administration Site Conditions: Mucosal dryness.\nInvestigations: Increased PSA, decreased bone density.\nLong Exposure (6-12 Months): Diabetes mellitus, impaired glucose tolerance, osteoporosis; increased total cholesterol, low-density lipoprotein and triglycerides.\n\nPrecaution: Safe use of leuprolide acetate or norethindrone acetate in pregnancy has not been established clinically. Before starting treatment with LUPRON DEPOT, pregnancy must be excluded.\n\nWhen used monthly at the recommended dose, LUPRON DEPOT usually inhibits ovulation and stops menstruation. Contraception is not insured, however, by taking LUPRON DEPOT. Therefore, patients should use non-hormonal methods of contraception.\n\nPatients should be advised to see their physician if they believe they may be pregnant. If a patient becomes pregnant during treatment, the drug must be discontinued and the patient must be apprised of the potential risk to the fetus.\n\nDuring the early phase of therapy, sex steroids temporarily rise above baseline because of the physiologic effect of the drug. Therefore, an increase in clinical signs and symptoms may be observed during the initial days of therapy, but these will dissipate with continued therapy.\nNorethindrone acetate treatment should be discontinued if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be withdrawn.\n\n\nMode of action: None\n\nPregnancy category: X\n\nInteraction: 
Levonorgestrel 0.15mg + Ethinylestradiol 0.03mg	\n\n\tSchering A.G, Germany\tCombination-3 TAB dr  10's pack 260\n\tScheringOy,Pansiontie,47,20210Turku, Finland\tNorplant Injection 36mg  250\n\tIndication: Contraception\n\nDose: Adult: PO Monophasic combined OC: As tab containing levonogestrel 150-250 mcg and ethinylestradiol 30 mcg: 1 tab once daily. Triphasic combined OC: Levonorgestrel 50-125 mcg + ethinylestradiol 30-40 mcg: 1 tab once daily.\n\nContra-indication: Pregnancy, undiagnosed vaginal bleeding, severe arterial disease (or family history of atherogenic lipid profile); liver adenoma; porphyria; after evacuation of hydatidiform mole; history of breast cancer; hepatic impairment; thrombophloebitis or thromboembolic disorders; breast carcinoma except in selected patients being treated for metastatic disease; oestrogen-dependent tumour; smoking ?40 cigarettes daily; >50 yr; diabetes complications present; BMI >39 kg/m2; migraine with typical focal aura, lasting >72 hr despite treatment or migraine treated with ergot derivatives; BP >160 mmHg systolic and 100 mmHg diastolic; transient ischaemic attacks without headaches; SLE; gallstones; history of haemolytic uraemic syndrome, pruritis during pregnancy; cholestatic jaundice; chorea or deterioration of otosclerosis pemphigoid; breast feeding during 1st 6 mth after delivery.\n\nSide effects: Menstrual irregularities; headache, dizziness; breast discomfort; gynaecomastia; depression; disturbance of appetite; wt changes; fluid retention; oedema; changes in libido; hair loss or hirsutism; GI disturbances (nausea and vomiting); genitourinary changes; haematologic disorders; endocrine and metabolic disorders; cholestatic jaundice; local skin reactions; chorea; contact lens intolerance; steeping of corneal curvature; pulmonary thromboembolism; carbohydrate and/or glucose intolerance; depression; chloasma; BP increase, liver impairment; reduced menstrual loss, 'spotting' in early cycles, absence of withdrawal bleeding; rarely photosensitivity; increased risk in breast cancer; elevation of plasma bound iodine, cortisol and thyroid binding, erythrocyte sedimentation may be accelerated; increases in plasma copper, iron and alkaline phosphatase; may affect serum triglyceride and lipoprotein levels; retinal vascular thrombosis.\nPotentially Fatal: Hepatic tumours; increased risk of thromboembolism.\n\nPrecaution: Sex-steroid dependent cancer; past ectopic pregnancy; malabsorption syndromes; functional ovarian cysts; active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy; history of CV or renal impairment; DM; asthma; epilepsy; migraine; depression; lactation; conditions exacerbated by fluid retention; hypercalcaemia; CV and gall bladder diseases; lipid effects; familial defects of lipoprotein metabolism; patients at risk of venous thromboembolism, breast cancer, preexisting uterine leiomyomata and benign hepatic adenoma; family history of arterial disease in 1st degree relative <45 yr; BP > systolic 140 mmHg and diastolic 90 mmHg; >35 yr; BMI 30-39 kg/m2; migraine without focal aura, controlled with 5HT1; GI upset (vomiting and diarrhoea), missed pills and interaction with other drugs may require additional contraceptive precautions. Should be taken at same time each day.\n\nMode of action: CYP3A4 inducers may decrease levels/effects eg aminoglutethimide, carbamazepine, nafcillin, nevirapine, atazanavir, nelfinavir, phenobarbital, phenytoin, lamotrigine, rifamycins, griseofulvin and ritonavir; ampicillin, tetracycline and other antibiotics may reduce efficacy; oestrogens may antagonise anticoagulant effect of coumarins; may inhibit metabolism of prednisolone and ciclosporin; may reduce clearance of alprazolam, chlordiazepoxide, diazepam; may increase clearance of lorazepam, oxazepam, temazepam.\n\nPregnancy category: X\n\nInteraction: CYP3A4 inducers may decrease levels/effects eg aminoglutethimide, carbamazepine, nafcillin, nevirapine, atazanavir, nelfinavir, phenobarbital, phenytoin, lamotrigine, rifamycins, griseofulvin and ritonavir; ampicillin, tetracycline and other antibiotics may reduce efficacy; oestrogens may antagonise anticoagulant effect of coumarins; may inhibit metabolism of prednisolone and ciclosporin; may reduce clearance of alprazolam, chlordiazepoxide, diazepam; may increase clearance of lorazepam, oxazepam, temazepam.
Liraglutide	\n\n\tNovo Nordisk\tVictoza Injection 3ml 1's  pack 7850\n\tIndication: Type 2 diabetes\n\nDose: It can be administered once daily at any time of day, independently of meals, and can be injected subcutaneously in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment.\n\nFor all patients  should be initiated with a dose of 0.6 mg per day for one week. The 0.6 mg dose is a starting dose intended to reduce gastrointestinal symptoms during initial titration, and is not effective for glycemic control. After one week at 0.6 mg per day, the dose should be increased to 1.2 mg. If the 1.2 mg dose does not result in acceptable glycemic control, the dose can be increased to 1.8 mg.\n\nWhen initiating , consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycemia\n\nContra-indication: Do not use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).\n\nDo not use in patients with a prior serious hypersensitivity reaction to   any of the product components.\n\nSide effects: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n\nPrecaution: In the clinical trials, there have been 6 reported cases of thyroid C-cell hyperplasia among Victoza-treated patients and 2 cases in comparator-treated patients (1.3 vs. 1.0 cases per 1000 patient-years). One comparator-treated patient with MTC had pre-treatment serum calcitonin concentrations >1000 ng/L suggesting pre-existing disease. All of these cases were diagnosed after thyroidectomy, which was prompted by abnormal results on routine, protocol-specified measurements of serum calcitonin. Five of the six Victoza-treated patients had elevated calcitonin concentrations at baseline and throughout the trial. One Victoza and one non-Victoza-treated patient developed elevated calcitonin concentrations while on treatment. \n\nMode of action: Oral Contraceptives: Liraglutide lowered ethinyloestradiol and levonorgestrel Cmax by 12% and 13%, respectively, following administration of a single dose of an oral contraceptive product. Tmax was delayed by 1.5 hrs with liraglutide for both compounds. There was no clinically relevant effect on the overall exposure of either ethinyloestradiol or levonorgestrel. The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide.\n\nWarfarin: No interaction study has been performed. Upon initiation of Liraglutide treatment in patients on warfarin more frequent monitoring of International Normalised Ratio (INR) is recommended.\n\nInsulin: Combination of Liraglutide with insulin has not been evaluated.\n\nIncompatibilities: Substances added to Liraglutide may cause degradation of liraglutide. In the absence of compatibility studies, Liraglutide must not be mixed with other medicinal products.\n\nPregnancy category: C\n\nInteraction: Oral Contraceptives: Liraglutide lowered ethinyloestradiol and levonorgestrel Cmax by 12% and 13%, respectively, following administration of a single dose of an oral contraceptive product. Tmax was delayed by 1.5 hrs with liraglutide for both compounds. There was no clinically relevant effect on the overall exposure of either ethinyloestradiol or levonorgestrel. The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide.\n\nWarfarin: No interaction study has been performed. Upon initiation of Liraglutide treatment in patients on warfarin more frequent monitoring of International Normalised Ratio (INR) is recommended.\n\nInsulin: Combination of Liraglutide with insulin has not been evaluated.\n\nIncompatibilities: Substances added to Liraglutide may cause degradation of liraglutide. In the absence of compatibility studies, Liraglutide must not be mixed with other medicinal products.
Mumps, Rubella, Measles (Live Attenuated) Vaccine	\n\n\tGlaxo Smith Kline Biological S.A.,Belgium\tPriorix Vaccine Injection   0.5 ml vial ( mono dose with diluent) 529\n\tGlaxoSmithKline Biologicals,Germany\tPriorix Injection  .5ml 471\n\tSanofi Pasteur S A ,France\tTrimovax Injection   0.5 ml vial with   diluent x 10's pack 4127\n\tIndication: Measles, Mumps, Rubella, Multiple myeloma, \n\nDose: The dose for any age is 0.5 mL administered subcutaneously, preferably into the outer aspect of the upper arm.\n\nThe recommended age for primary vaccination is 12 to 15 months.\n\nParenteral\nActive immunisation against measles, mumps and rubella\nAdult: Given by SC (if there is bleeding disorder). A complete course consists of 2 doses of 0.5 ml; ensure an interval of 3 mth between the 2 doses. If protection against measles is needed urgently, the 2nd dose may be given 1 mth after the 1st dose. For protection against measles after exposure, doses should be given within 72 hr of contact.\n\nChild: Given by SC (if there is bleeding disorder). >12 mth: A complete course consists of 2 doses of 0.5 ml; 1st dose to be given ahortly after 1 yr old and the 2nd dose to be given before school entry. \n\nDoses may be given at any age, allowing an interval of 3 mth between the 2 doses. If the vaccine is administered before the child is 1 yr old, re-immunisation with the standard 2 doses is necessary when the child is >12 mth old. If protection against measles is needed urgently, the 2nd dose may be given 1 mth after the 1st dose; if the 2nd dose is given before the child is 18 mths old, the child should receive the routine dose before starting school at 3-5 yr old. \n\nFor protection against measles after exposure: MMR vaccine may be used in susceptible children >6 mths old and doses should be given within 72 hr of contact; these children should still receive the routine MMR vaccine at the recommended ages.\n\nContra-indication: Hypersensitivity to any component of the vaccine, including gelatin.\n\nSide effects: The following adverse reactions are listed in decreasing order of severity, without regard to causality, within each body system category and have been reported during clinical trials, with use of the marketed vaccine, or with use of monovalent or bivalent vaccine containing measles, mumps, or rubella:\n\nBody as a Whole\n\nPanniculitis; atypical measles; fever; syncope; headache; dizziness; malaise; irritability.\n\nCardiovascular System\n\nVasculitis.\n\nDigestive System\n\nPancreatitis; diarrhea; vomiting; parotitis; nausea.\n\nEndocrine System\n\nDiabetes mellitus.\n\nHemic and Lymphatic System\n\nThrombocytopenia\n Immune System\n\nAnaphylaxis and anaphylactoid reactions have been reported as well as related phenomena such as angioneurotic edema (including peripheral or facial edema) and bronchial spasm in individuals with or without an allergic history.\n\nMusculoskeletal System\n\nArthritis; arthralgia; myalgia.\n\nPrecaution: Adequate treatment provisions, including epinephrine injection (1:1000), should be available for immediate use should an anaphylactic or anaphylactoid reaction occur.\n\nSpecial care should be taken to ensure that the injection does not enter a blood vessel.\n\nChildren and young adults who are known to be infected with human immunodeficiency viruses and are not immunosuppressed may be vaccinated. However, vaccinees who are infected with HIV should be monitored closely for vaccine-preventable diseases because immunization may be less effective than for uninfected persons\n\nMode of action: Affected by Ig.\n\nPregnancy category: C\n\nInteraction: Affected by Ig.
Varicella Virus Vaccine (Live Attenuated OKA Strain)	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tVarilrix Injection  0.5ml 1487.39\n\tIndication: Chickenpox\n\nDose: Adults\nIndicated for all adults without evidence of immunity to varicella.\n\n2 dose series: 0.5 mL SC, repeat at least 4 weeks later.\n\nRoutine vaccination\n\n    2 dose series: 0.5 mL SC\n    1st dose: 12-15 months\n    2nd dose: 4-6 years; may be administered before age 4 yr, provided at least 3 months have elapsed since the first dose\n\nContra-indication: Do not administer  to individuals with a history of anaphylactic or severe allergic reaction to any component of the vaccine (including neomycin and gelatin) or to a previous dose of a varicella-containing vaccine.\n\nSide effects: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in clinical practice.\n\nPrecaution: 5.1 Management of Allergic Reactions\n\nAdequate treatment provisions, including epinephrine injection (1:1000), should be available for immediate use should anaphylaxis occur.\n\n5.2 Family History of Immunodeficiency\n\nVaccination should be deferred in patients with a family history of congenital or hereditary immunodeficiency until the patient's immune status has been evaluated and the patient has been found to be immunocompetent.\n\n5.3 Use in HIV-Infected Individuals\n\nThe Advisory Committee for Immunization Practices (ACIP) has recommendations on the use of varicella vaccine in HIV-infected individuals.\n\n5.4 Risk of Vaccine Virus Transmission\n\nPost-marketing experience suggests that transmission of vaccine virus may occur rarely between healthy vaccinees who develop a varicella-like rash and healthy susceptible contacts. Transmission of vaccine virus from a mother who did not develop a varicella-like rash to her newborn infant has been reported.\n\nMode of action: Concurrent use may interfere with the immune response to certain live vaccines.\n\nPregnancy category: X\n\nInteraction: Concurrent use may interfere with the immune response to certain live vaccines.
Lodoxamide	\n\n\tIndication: Allergic conjunctivitis\n\nDose: Adult: Ophth As 0.1% soln: Instill 1-2 drops 4 times/day.\n\nContra-indication: Hypersensitivity to the drug \n\nSide effects: May cause local irritation including burning, stinging and itching. Flushing and dizziness may also occur.\n\nPrecaution: Contact lenses should be removed prior to admin and can only be reinserted at least 15 min after drug admin as it contains benzalkonium chloride. Pregnancy.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Levodopa 200mg + Carbidopa 50mg + Entacapone 200mg	\n\n\tOrion Corporation Finland\tStalevo TAB dr  200mg 30's pack 2115\n\tIndication: Parkinson's disease and 'end of dose' motor fluctuations not controlled by levodopa/dopa decarboxylase inhibitor combinations.\n\nDose: Adult: PO Per tab contains levodopa and carbidopa in a ratio of 4:1 w/ entacapone 200 mg. Initial: 1 tab/day. Titrate dose according to patient's response. Recommended to take only 1 tab per dose administration. Max: 8 tabs/day.\n\nContra-indication: Hypersensitivity. Narrow angle glaucoma. Should not be used in patients with suspicious, undiagnosed skin lesions or a history ot melanoma.\n\nSide effects: Diarrhoea, nausea, vomiting, hypotension, hallucinations, hyperpyrexia and confusion. Fibrotic complications. Dark colour (red, brown or black) may appear in bodily secretions such as sweat, saliva and urine. Possible increase in dyskinesia. Chest pain, asthenia, cardiac irregularities, angioedema, urticaria, pruritus, back pain, shoulder pain and muscle cramps.\nPotentially Fatal: Rhabdomyolysis.\n\nPrecaution: Periodic monitoring of hepatic, renal, haematopoietic and CV functions in patients on prolonged therapy. Monitor for changes in IOP in patients with chronic wide-angle glaucoma. Caution when used in patients with biliary obstruction. Caution when interpreting plasma and urine levels of catecholamines and their metabolites. Withdrawal should be gradual.\n\nMode of action: Increased risk of postural hypotension when used concurrently with hypotensive drugs. Severe orthostatic hypotension may result from concurrent usage with MAOIs. Dopamine D2 receptor antagonists, phenytoin or papaverine may reduce the efficacy of levodopa. Iron salts may reduce the bioavailability. Concurrent usage with drugs that interfere with biliary excretion may lead to increased plasma levels of entacapone. May depress prolactin secretion and increase growth hormone levels.\n\nPregnancy category: C\n\nInteraction: Increased risk of postural hypotension when used concurrently with hypotensive drugs. Severe orthostatic hypotension may result from concurrent usage with MAOIs. Dopamine D2 receptor antagonists, phenytoin or papaverine may reduce the efficacy of levodopa. Iron salts may reduce the bioavailability. Concurrent usage with drugs that interfere with biliary excretion may lead to increased plasma levels of entacapone. May depress prolactin secretion and increase growth hormone levels.
Meningococcal polysaccharide  ACWY Vaccine	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tMencevax ACWY Injection .5ml 1's pack 535.71\n\tIncepta\tIngovax ACWY Vaccine 50 mcg / 0.5 ml  \n\tSanofi Aventis (BD) Ltd.\tMeningococcal( A+C) Injection 1.0ml 1.0 ml vial  580\n\tIndication: Pneumonia, Meningitis, Septicemia, Septic Arthritis, Meningococcemia, Carditis\n\nDose: The recommended dose for vaccines in all age groups is 0.5mL, administered as a single dose. Administer a 0.5 mL dose vaccine by subcutaneous injection.  \n\nWithdraw the 0.5 mL dose of vaccine from the single-dose vial using a sterile needle and syringe.\n\nContra-indication: Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine, or to any component of Menactra vaccine\n\nSide effects: Local and systemic adverse reactions especially febrile reactions may be encountered more frequently in children than in adults.Irritability, drowsiness, headache, gastrointestinal symptoms e.g. nau sea, vomiting and diarrhoea, local axillary lymphadenopathy. Very common: erythema, induration, tenderness, pain and redness at the injection site, fatigue, malaise. \n\nPrecaution:  1. Guillain-BarrÃ© Syndrome\n\nPersons previously diagnosed with Guillain-BarrÃ© syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. The decision to give Menactra vaccine should take into account the potential benefits and risks.\n\nGBS has been reported in temporal relationship following administration of Menactra vaccine.  The risk of GBS following Menactra vaccination was evaluated in a post-marketing retrospective cohort study .\n\n 2. Preventing and Managing Allergic Vaccine Reactions\n\nPrior to administration, the healthcare provider should review the immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions to allow an assessment of benefits and risks. Epinephrine and other appropriate agents used for the control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur.\n\n 3. Altered Immunocompetence\n\nImmunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Menactra vaccine.\n\n 4. Limitations of Vaccine Effectiveness\n\nThis vaccine may not protect all recipients.\n\n\nMode of action: This can be administered at the same time as other vaccines. Different injectable vaccines should always be administered at a different injection site.\nIncompatibilities: In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.\n\nPregnancy category: C\n\nInteraction: This can be administered at the same time as other vaccines. Different injectable vaccines should always be administered at a different injection site.\nIncompatibilities: In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.
Maraviroc	\n\n\tIndication: HIV infection, Allogeneic bone marrow transplantation\n\nDose: [Potent CYP3A inhibitors (with or without a potent CYP3A inducer) including:\n\n    protease inhibitors (except tipranavir/ritonavir)\n    delavirdine\n    ketoconazole, itraconazole, clarithromycin\n    other potent CYP3A inhibitors (e.g., nefazodone, telithromycin)]\n:150 mg twice daily.\n\n\n[Other concomitant medications, including tipranavir/ritonavir, nevirapine, raltegravir all NRTIs and enfuvirtide ] : 300 mg twice daily\n\n\n[Potent CYP3A inducers (without a potent CYP3A inhibitor) including:\n\n    efavirenz\n    rifampin\n    etravirine\n    carbamazepine, phenobarbital, and phenytoin] : 600 mg twice daily\n\n\nContra-indication: Patients with severe renal impairment or end-stage renal disease (ESRD) (CrCl < 30 mL/min) who are taking potent CYP3A inhibitors or inducers.\n\nSide effects: The following adverse reactions are discussed in other sections of the labeling:\n\n -   Hepatotoxicity \n  -  Cardiovascular events\n\nPrecaution: 1 Hepatotoxicity\n2 Cardiovascular Events\n3 Immune Reconstitution Syndrome\n4 Potential Risk of Infection\n5 Potential Risk of Malignancy\n\nMode of action: Increased or decreased conc w/ CYP3A inhibitors &/or inducers, respectively. Increased metabolic ratio of debrisoquine. Increased conc w/ elvitegravir/ritonavir, delavirdine, boceprevir, telaprevir, HIV PIs (except tipranavir/ritonavir), NNRTI + PI, rifabutin + PI, clarithromycin, telithromycin, ketoconazole, itraconazole. Decreased conc w/ efavirenz, etravirine, rifampicin, St. John's wort.\n\nPregnancy category: B\n\nInteraction: Increased or decreased conc w/ CYP3A inhibitors &/or inducers, respectively. Increased metabolic ratio of debrisoquine. Increased conc w/ elvitegravir/ritonavir, delavirdine, boceprevir, telaprevir, HIV PIs (except tipranavir/ritonavir), NNRTI + PI, rifabutin + PI, clarithromycin, telithromycin, ketoconazole, itraconazole. Decreased conc w/ efavirenz, etravirine, rifampicin, St. John's wort.
Medroxyprogesterone Acetate	\n\n\tACI\tMovera TAB dr 10mg 30's pack 300.90\n\tACI\tMovera TAB dr 5mg 60's pack 324\n\tBeacon\tMedrina TAB dr 5mg 30's pack 141\n\tEskayef Bangladesh Ltd.\tProvenor TAB dr 10mg 30's pack 150\n\tEskayef Bangladesh Ltd.\tProvenor TAB dr 5mg 45's pack 225\n\tIncepta\tMedogen TAB dr 5mg 60"s 322.8\n\tIncepta\tMedogen TAB dr 10mg 30's pack 300\n\tIncepta\tMedogen Injection 150 mg/ml 1's pack 38\n\tNuvista Pharma Ltd\tMedora TAB dr 10mg 30's pack 262.20\n\tPopular\tMedroxy TAB dr 10mg 30's pack 301.20\n\tPopular\tMedroxy TAB dr 5mg 30's pack/60's pack 161.40/322.80\n\tRenata\tMedrogest TAB dr 5mg 30's pack 160.80\n\tRenata\tMedrogest TAB dr 10mg 30's pack 300\n\tLeo Pharmaceutical Products,Denmark\tPerlutex TAB dr 5mg 20's pack 212.40\n\tIndication: Menorrhagia, endometriosis, menopausal HRT, breast cancer, endometrial and renal carcinoma, prostatic carcinoma, secondary amenorrhoea, contraception, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer, to reduce the incidence of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets						\n\n\nDose: Adult: PO Menorrhagia 2.5-10 mg/day for 5-10 days on days 16-21 of the menstrual cycle. Repeat for 2 cycles. \nMild to moderate endometriosis 10 mg 3 times/day for 90 consecutive days, beginning on the first day of the menstrual cycle. \nAs progestogen component in menopausal HRT Dosage depends on oestrogen component of therapy, several regimens are used: 1.5 mg, 2.5 mg or 5 mg/day; 5 or 10 mg/day for 12-14 days of a 28-day cycle; 20 mg/day for 14 days of a 91-day cycle. \n\nAbnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: Beginning on the calculated 16th or 21st day of the menstrual cycle, 5 or 10 mg of Medroxyprogesterone acetate may be given daily for 5 to 10 days. \n\nReduction of endometrial hyperplasia in postmenopausal women receiving daily 0.625 mg conjugated estrogens :  Medroxyprogesterone acetate tablets may be given in dosages of 5 or 10 mg daily for 12 to 14 consecutive days per month, in postmenopausal women receiving daily 0.625 mg conjugated estrogens, either beginning on the 1st day of the cycle or the 16th day of the cycle. \n\nBreast cancer 0.4-1.5 g/day. Max: 2 g/day. \nPalliation of endometrial and renal carcinoma 200-600 mg/day. \nPalliation of prostatic carcinoma 100-600 mg/day. \nSecondary amenorrhoea 5-10 mg/day for 5-10 days. Repeat for 3 cycles. \n\n\nContra-indication: Thromboembolic disorders; cerebral apoplexy; severe hepatic dysfunction; incomplete abortion, hormone-dependent carcinoma; Undiagnosed vaginal bleeding, Undiagnosed urinary tract bleeding, Known or suspected pregnancy, Undiagnosed breast pathology, Missed abortion, Active thromboembolic disorders, Markedly impaired liver function, \n\nSide effects: Depression, fluid retention. Fatigue, insomnia, dizziness, headache, nausea; breast tenderness; wt gain/loss, anorexia; cholestatic jaundice; pain at Inj site.\nPotentially Fatal: Thrombophlebitis and pulmonary embolism.\n\nPrecaution: Breakthrough bleeding is likely to occur in patients being treated for endometriosis. May cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, asthma, or cardiac or renal dysfunction, require careful observation. A decrease in glucose tolerance has been observed in some patients. Patients with depression, DM, epilepsy, asthma, migraine, hypertension, renal or cardiac dysfunction. Monitor patient closely for loss of vision, proptosis, diplopia and thromboembolic disorders. Lactation.\n\nMode of action: Aminoglutethimide and enzyme-inducing drugs (e.g. carbamazepine, griseofulvin, phenobarbital, rifampicin, phenytoin) may reduce plasma concentrations leading to reduced efficacy. Additional measures required when medroxyprogesterone is used for contraception during coadministration with these drugs.\n\nPregnancy category: X\n\nInteraction: Aminoglutethimide and enzyme-inducing drugs (e.g. carbamazepine, griseofulvin, phenobarbital, rifampicin, phenytoin) may reduce plasma concentrations leading to reduced efficacy. Additional measures required when medroxyprogesterone is used for contraception during coadministration with these drugs.
Megestrol Acetate	\n\n\tTechno Drugs Ltd.\tApegestrol TAB dr 160mg  \n\tLaboratorio Varifarma, Argentina\tVarigestrol TAB dr 160 mg 30's pack 1800\n\tIndication: Contraception, Breast carcinoma, Endometrial carcinoma, Anorexia and Cachexia\n\nDose: Adult: PO Palliation of breast carcinoma 40 mg 4 times/day. Palliation of endometrial carcinoma 40-320 mg/day in divided doses. Anorexia and cachexia in patients w/ cancer or AIDS Initial: 800 mg/day. Usual: 400-800 mg/day.\n\nContra-indication: Pregnancy and lactation. Severe hepatic impairment.\n\nSide effects: Acne, urticaria, fluid retention, wt gain, heart failure, nausea, vomiting, GI disturbances, changes in libido, breast discomfort, premenstrual symptoms, irregular menstrual cycles, depression, insomnia, somnolence, alopoecia, hirsutism, anaphylactoid-like reaction, jaundice, hot flushes, adrenocortical suppression, nausea, carpal tunnel syndrome, hypercalcaemia, tumour flare, hypertension.\n\nPrecaution: History of thrombophlebitis, mild to moderate hepatic impairment, risk of fluid retention, history of depression, diabetes, hypertension, renal or cardiac dysfunction.\n\nMode of action: Concentrations of indinavir may be reduced. Possible reduced efficacy of cisplatin. Warfarin half life may be increased. Megestrol concentration may be decreased by aminoglutethimide and enzyme-inducing drugs.\n\nPregnancy category: X\n\nInteraction: Concentrations of indinavir may be reduced. Possible reduced efficacy of cisplatin. Warfarin half life may be increased. Megestrol concentration may be decreased by aminoglutethimide and enzyme-inducing drugs.
Melphanlan	\n\n\tIndication: Breast cancer, Ovarian cancer, Multiple myeloma, Neuroblastoma, Soft tissue sarcoma, Malignant melanoma, Retinoblastoma, Polycythaemia vera\n\nDose: Adult: PO Multiple myeloma 150 mcg/kg/day in divided doses for 4-7 days, followed by rest period (for haematologic recovery) up to 6 wk, then repeat the course or start maintenance w/ 1-3 mg/day. Breast cancer 150 mcg/kg/day, repeat 6 wkly. Ovarian carcinoma 200 mcg/kg/day for 5 days 4-8 wkly. Polycythaemia vera 6-10 mg/day for 5-7 days; 2-4 mg/day for remission induction. Maintenance: 2-6 mg/wk. IV Ovarian adenocarcinoma 1 mg/kg as a single dose, repeat in 4 wk if platelet and neutrophil counts permit. Multiple myeloma 400 mcg/kg /m2 via infusion, 1st 4 doses may be given 2 wkly; further doses given 4 wkly depending on toxicity. Neuroblastoma 100-240 mg/m2 followed by autologous stem cell rescue if doses are >140 mg/m2. Intra-arterial Melanoma; Soft tissue sarcoma Upper extremity perfusions: 0.6-1 mg/kg. Lower extremity perfusions: 0.8-1.5 mg/kg (melanoma) or 1-1.4 mg/kg (sarcoma).\n\nContra-indication: Hypersensitivity. Severe bone marrow suppression. Pregnancy.\n\nSide effects: Diarrhoea, stomatitis, vomiting; haemolytic anaemia, vasculitis, pulmonary fibrosis, hepatic disorders, suppression of ovarian function in premenopausal women, temporary or permanent sterility in male patients. Allergic reactions.\nPotentially Fatal: Bone marrow suppression. Secondary malignancy, cardiac arrest. Anaphylaxis.\n\nPrecaution: Renal impairment. Lactation. Prior bone marrow suppression, prior chemotherapy or irradiation. May mask signs of infection e.g. fever and increased WBC. Elderly.\n\nMode of action: Potentially Fatal: Fatal haemorrhagic enterocolitis with concurrent nalidixic acid in children. Potentiates risk of renal damage with ciclosporin.\n\nPregnancy category: D\n\nInteraction: Potentially Fatal: Fatal haemorrhagic enterocolitis with concurrent nalidixic acid in children. Potentiates risk of renal damage with ciclosporin.
Meningococcal group A oligosaccharide Diphtheria Conjugate Vaccine	\n\n\tRenata\tMenveo Injection  1's amps pack 2650\n\tIndication: Meningococcal infection\n\nDose:  The dosing schedule for individuals initiating vaccination is as follows:\n\nInfants 2 Months of Age :\nadministered as a four-dose series at 2, 4, 6, and 12 months of age.\n\nChildren 7 Months through 23 Months of Age : administered as a two-dose series with the second dose administered in the second year of life and at least three months after the first dose. \n\nChildren 2 Years through 10 Years of Age : administered as a single dose. For children 2 years through 5 years of age at continued high risk of meningococcal disease, a second dose may be administered 2 months after the first dose. \n\nAdolescents and Adults 11 Years through 55 Years of Age :  administered as a single dose. \n\nContra-indication: Severe allergic reaction (e.g., anaphylaxis) after a previous dose  , any component of this vaccine, or any other CRM197, diphtheria toxoid or meningococcal-containing vaccine is a contraindication to administration\n\nSide effects: Common solicited adverse reactions (> 10%) among children initiating vaccination at 2 months of age and receiving the four-dose series were tenderness (24-41%) and erythema at injection site (11-15%), irritability (42-57%), sleepiness (29-50%), persistent crying (21-41%), change in eating habits (17-23%), vomiting (5-11%) and diarrhea (8-16%). \nCommon solicited adverse reactions (?>10%) among children initiating vaccination at 7 months through 23 months of age and receiving the two-dose series were tenderness (10-16%) and erythema at injection site (12-15%), irritability (27-40%), sleepiness (17-29%), persistent crying (12-21%), change in eating habits (12-20%) and diarrhea (10-16%). \nCommon solicited adverse reactions (> 10%) among children 2 years through 10 years of age who received     injection site pain (31%), erythema (23%), irritability (18%), induration (16%), sleepiness (14%), malaise (12%), and headache (11%).  \nCommon solicited adverse reactions (> 10%) among adolescents and adults who received   were pain at the injection site (41%), headache (30%), myalgia (18%), malaise (16%) and nausea (10%). \n\nPrecaution:  1 Management of Acute Allergic Reactions\n\nAppropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration  .\n\n 2 Syncope\n\nSyncope, sometimes resulting in falling injury associated with seizure-like movements has been reported following vaccination   . Vaccinees should be observed for at least 15 minutes after vaccine administration to prevent and manage syncopal reactions.\n\n 3.  Altered Immunocompetence\n\nSafety and effectiveness of  have not been evaluated in immunocompromised persons. If  is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.\n\n 4 . Guillain-BarrÃ© Syndrome\n\nGuillain-BarrÃ© syndrome (GBS) has been reported in temporal relationship following administration of another U.S.-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer   to subjects with a known history of Guillain-BarrÃ© Syndrome should take into account the potential benefits and risks.\n\n 5 . Apnea in Premature Infants\n\nApnea following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including  , to an infant born prematurely should be based on consideration of the individual infant's medical status, and the potential benefits and possible risks of vaccination.\n\n\nMode of action: Live vaccines. Reduced immunological response w/ immunosuppresants.\n\nPregnancy category: C\n\nInteraction: Live vaccines. Reduced immunological response w/ immunosuppresants.
Meningococcal polysaccharide Serogroup ACWY Vaccine	\n\n\tGlaxo SmithKline Biological S.A.,Belgium\tMencevax ACWY Injectable Vaccine Injection   1 vial + diluent 600\n\tIndication: Meningococcal meningitis and septicaemia\n\nDose: The recommended dose for vaccines in all age groups is 0.5mL, administered as a single dose. Administer a 0.5 mL dose vaccine by subcutaneous injection.  \n\nContra-indication: Hypersensitivity to the active substances or to any of the excipients. Do not administer to anyone with a history of a severe allergic reaction.\n\nSide effects: Local and systemic adverse reactions especially febrile reactions may be encountered more frequently\nin children than in adults.Irritability, drowsiness, headache, gastrointestinal symptoms e.g. nau\nsea, vomiting and diarrhoea, local axillary lymphadenopathy. Very common: erythema, induration, tenderness, pain and redness at the injection site, fatigue, malaise.\n\n\n\nPrecaution: Vaccine is for subcutaneous use only, and should under no circumstances be administered\nintravascularly or by intradermal injection.\n\nMode of action: This can be administered at the same time as other vaccines. Different injectable vaccines should always be administered at a different injection site.\nIncompatibilities: In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.\n\nPregnancy category: C\n\nInteraction: This can be administered at the same time as other vaccines. Different injectable vaccines should always be administered at a different injection site.\nIncompatibilities: In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.
Menotrophin 75 IU FSH + 75 IU LH	\n\n\tIndication: Infertility, Assisted reproductive technologies, Polycystic ovarian disease, In vitro fertilisation procedures\n\nDose: Unless prescribed otherwise, doses are as follows: Sterility in Females: The dosage of HMG for the induction of follicle growth in normo- or hypogonadotrophic women varies according to the individual. The amount depends on ovarian reaction and should be checked by ultrasound examinations of the ovaries and measuring estradiol levels. If the HMG dosage is too high for the treated individual, multiple uni- and bilateral follicle growth can occur. HMG is administered IM or SC and in general, the therapy is begun with a daily dosage corresponding to 75-150 IU FSH + 75-150 IU LH daily. If the ovaries do not respond, the dosage can slowly be increased until a rise in estradiol secretion and follicle growth is evident. Treatment with the same dosage of HMG continues until the preovulatory estradiol serum level is attained. If the level rises too quickly, the dosage should be reduced. To induce ovulation, hCG 5000 or 10,000 IU are injected IM 1-2 days after the last HMG administration. Note: After administering a HMG dosage which is too high for the corresponding individual, a subsequent hCG administration can cause an unintentional hyperstimulation of the ovaries. Sterility in Males: Initially, 3 x 1000 and 3000 IU hCG a week are administered until a normal testosterone serum level is reached. Then, an additional dose of HMG 3 x (75-150 IU FSH + 75-150 IU LH)/week is administered IM for a few months.\n\nContra-indication: Females: Pregnancy, enlargement of the ovaries or cysts that is not caused by polycystic ovarian syndrome, gynaecological bleeding of unknown cause and tumors in the uterus, ovaries and breasts.\nMales: Carcinoma of the prostate and tumors in the testes.\nThe following conditions must be properly treated before therapy with HMG is begun: Dysfunctions of the thyroid gland and of the cortex of the suprarenal gland, a rise in the serum level of prolactin with different causes (hyperprolactinaemia), tumors in the pituitary gland (hypophysis) or in part of the diencephalon (hypothalamus).\n\nSide effects: Occasionally, nausea and vomiting can occur.\nIn single cases, hypersensitivity reactions and fever can occur during treatment with HMG. The administration of Menogon may lead to reactions at the injection site: Reddening, pain, swelling and itching. In very rare cases, long-term usage can lead to the formation of antibodies, making the therapy ineffective.\nTreatment with HMG can often lead to ovarian hyperstimulation that first becomes clinically relevant after the administration of hCG (pregnancy hormone) to induce ovulation. This can lead to the formation of large ovarian cysts that tend to rupture and to intra-abdominal bleeding.\nIn addition, the accumulation of fluids in the abdominal cavity (ascites), the accumulation of fluids in the chest cavity (hydrothorax), a decrease in the excretion of urine (oliguria), lowering of the blood pressure (hypotension), and occlusion of blood vessels by blood clots (thromboembolic phenomena) can occur. Treatment should be immediately discontinued when the first signs of hyperstimulation appear: Abdominal pain and a palpable (by the physician) enlargement in the lower abdomen, which can be detected sonographically.\nIf abdominal pain occurs, see the doctor.\nWith pregnancy, these side effects can intensify, continue over a long period of time, and be life threatening.\nUnintentional multiple pregnancies occur more often during treatment with HMG.\n\nPrecaution: hCG should not be administered to induce ovulation in females whose ovaries have unintentionally been hyperstimulated.\nWhen treating sterile women, ovarian activity should be checked (ultrasound and estradiol levels in serum response) prior to HMG administration. During treatment, these tests should be carried out every 1-2 days until stimulation occurs. Ovarian reaction can also be measured using a cervix index. Close supervision is imperative during treatment. Treatment should be immediately discontinued if unintentional hyperstimulation occurs.\nFurther remarks concerning the steps to be taken when ovarian hyperstimulation has occurred can be found under Actions.\n\nMode of action: Increased follicular response with clomiphene citrate. Higher dose of menotrophin needed when gonadotropin-releasing hormone agonist is used for pituitary desensitisation.\n\nPregnancy category: X\n\nInteraction: Increased follicular response with clomiphene citrate. Higher dose of menotrophin needed when gonadotropin-releasing hormone agonist is used for pituitary desensitisation.
Methotrexate	\n\n\tBeacon\tTrexonate Injection 50mg/ml 1's pack 130\n\tBeacon\tTrexonate TAB dr 10mg 30's pack 450\n\tBeacon\tTrexonate TAB dr 2.5mg 30's pack 150\n\tDelta Pharma\tMethotrax TAB dr 10mg 20's pack 300\n\tDelta Pharma\tMethotrax TAB dr 2.5mg 30's pack 150\n\tGonoshasthaya\tG-Methotrexate TAB dr   18's  pack 72.36\n\tPopular\tMethox TAB dr 2.5mg 30's pack 165.59\n\tPopular\tMethox TAB dr 10mg 10's pack 451.79\n\tRenata\tMetorax TAB dr 2.5mg 30's pack 165\n\tRenata\tMetorax F. C TAB dr 10mg  \n\tTechno Drugs Ltd.\tMtrex Injection 50mg/vial 5's pack 550\n\tChoongwae Pharma Corporation,Korea\tMTX TAB dr 2.5mg 100's pack 539\n\tChoongwae Pharma Corporation,Korea\tMTX Injection 50mg/vial 2ml  x 1's pack 129.47\n\tPharmachemie B. V. Netherlands\tEmthexate Injection   25's  pack 3250\n\tIndication: Burkitt's lymphoma, Choriocarcinoma, Mycosis fungoides, Crohn's disease, Psoriasis, Osteosarcoma, Breast cancer, lymphosarcoma, Acute lymphoblastic leukaemia,  Rheumatoid arthritis							\n\n\nDose: Adult: PO Burkitt's lymphoma 10-25 mg/day for 4-8 days, repeat after 7-10 days. Choriocarcinoma 15-30 mg/day for 5 days, repeat after an interval of at least 1 wk for 3-5 courses. Mycosis fungoides 2.5-10 mg/day to induce remission. Rheumatoid arthritis 7.5 mg once wkly, adjust if needed. Up to 20 mg/wk. Crohn's disease 12.5-22.5 mg once wkly for up to 1 yr. \n\nPO/IV/IM Psoriasis 10-25 mg once wkly, adjust subsequent doses if needed. IV Osteosarcoma 12-15 g/m2 as infusion, followed by folinic acid. Breast cancer 10-60 mg/m2 often w/ cyclophosphamide and fluorouracil. Advanced lymphosarcoma Up to 30 mg/kg, followed by folinic acid rescue. Acute lymphoblastic leukaemia Maintenance: 2.5 mg/kg every 14 days. \n\nPO/IM Acute lymphoblastic leukaemia Maintenance: 15 mg/m2 1-2 times/wk w/ other agents. IM Choriocarcinoma 15-30 mg/day for 5 days. Repeat after at least 1 wk for 3-5 courses. Mycosis fungoides 50 mg/wk in 1-2 divided doses. Crohn's disease 25 mg once wkly for 16 wk. Maintenance: 15 mg/wk. Intrathecal Meningeal leukaemia 12 mg/m2 (Max: 15 mg) once wkly for 2-3 wk, then once mthly.\n\nRenal impairment:\nCrCl (ml/min)	\n61-80	75% of dose\n51-60	70% of dose\n10-50	30-50% of dose\n<10	        Avoid use\n\nHepatic impairment: Bilirubin 3.1-5 mg/dl: Administer 75% of dose; Bilirubin >5 mg/dl: Avoid use.\n\nContra-indication: Severe renal or hepatic impairment, pre-existing profound bone marrow suppression in patients with psoriasis or rheumatoid arthritis, alcoholic liver disease, AIDS, pre-existing blood dyscrasias, pregnancy (in patients with psoriasis or rheumatoid arthritis), breast-feeding.\n\nSide effects: Ulceration of the mouth and GI disturbances (e.g. stomatitis and diarrhoea), bone marrow depression, hepatotoxicity, renal failure, skin reactions, alopecia, ocular irritation, arachnoiditis in intrathecal use, megaloblastic anaemia, osteoporosis, precipitation of diabetes, arthralgias, necrosis of soft tissue and bone, anaphylaxis, impaired fertility.\nPotentially Fatal: Pulmonary reactions (e.g. interstitial lung disease); neurotoxicity (e.g. leukoencephalopathy, paresis, demyelination) with intrathecal use; foetal deaths.\n\nPrecaution: Hepatic or renal impairment, bone marrow depression, elderly, neonates. Ulcerative disorders of the GI tract. Monitor haematological, renal and hepatic function, and GI toxicity regularly.\n\nMode of action: Decreased effectiveness with folic acid and its derivatives.\nPotentially Fatal: Increased toxicity with NSAIDs and salicylates; probenecid; some penicillins; aminoglycosides neomycin and paromomycin; sulfonamides such as sulfafurazole and sulfamethoxazole; co-trimoxazole or trimethoprim; nephrotoxic agents (e.g. cisplatin); ciclosporin; etretinate. Synergistic enhancement of effects with fluorouracil. Increased bioavailability of mercaptopurine. Reduces serum-valproate concentrations. Reduced serum concentrations with colestyramine. Increased serum concentrations with omeprazole.\n\nPregnancy category: X\n\nInteraction: Decreased effectiveness with folic acid and its derivatives.\nPotentially Fatal: Increased toxicity with NSAIDs and salicylates; probenecid; some penicillins; aminoglycosides neomycin and paromomycin; sulfonamides such as sulfafurazole and sulfamethoxazole; co-trimoxazole or trimethoprim; nephrotoxic agents (e.g. cisplatin); ciclosporin; etretinate. Synergistic enhancement of effects with fluorouracil. Increased bioavailability of mercaptopurine. Reduces serum-valproate concentrations. Reduced serum concentrations with colestyramine. Increased serum concentrations with omeprazole.
Methoxy Polyethyelene Glycol-Epoetin Beta	\n\n\tRadiant.\tMircera 50 Injection  50mcg x 1's pack 6950\n\tRadiant.\tMircera 75 Injection  75mcg x 1's pack 10425\n\tRadiant.\tMircera100 Injection  100mcg x 1's pack 13900\n\tRadiant.\tMircera120 Injection  120mcg x 1's pack 20138\n\tIndication: Anaemia associated with chronic kidney disease\n\nDose: Anemia Associated with Chronic Renal Failure\n\nDo not increase dose more frequently than q4weeks; decreases in dose can occur more frequently; avoid frequent dose adjustments\n\nIf hemoglobin rises rapidly (e.g., > 1 g/dL in any 2-week period), reduce dose by 25% or more as needed to reduce rapid responses\n\nFor patients who do not respond adequately, if hemoglobin has not increased by >1 g/dL after 4 weeks of therapy, increase dose by 25%\n\nFor patients who do not respond adequately over a 12-week escalation period, increasing Mircera dose further is unlikely to improve response and may increase risks; use lowest dose that will maintain a hemoglobin level sufficient to reduce need for RBC transfusions; evaluate other causes of anemia; discontinue Mircera if responsiveness does not improve\n\nPatients with chronic renal failure on dialysis\n\n    Initiate Mircera treatment when hemoglobin level < 10 g/dL\n    If hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose of Mircera\n    Dose if not currently on ESA therapy: 0.6 mcg/kg IV/SC q2week initially \n    Once hemoglobin has been stabilized, dose may be administered once monthly using a dose that is twice that of every-two-week dose and subsequently titrated as necessary\n\nPatients with chronic renal failure not on dialysis\n\n    Consider initiating treatment only when hemoglobin level is < 10 g/dL and the following considerations apply. Rate of hemoglobin decline indicates likelihood of requiring a RBC transfusion and reducing risk of alloimmunization and/or other RBC transfusion-related risks is a goal\n\n    If hemoglobin level >10 g/dL, reduce or interrupt dose, and use lowest dose sufficient to reduce need for RBC transfusions\n    Dose if not currently on ESA therapy: 0.6 mcg/kg IV/SC q2week initially \n    Once hemoglobin has been stabilized, Mircera may be administered once monthly using a dose that is twice that of the every-two-week dose and subsequently titrated as necessary\n\nSwitching Patients Currently on Other ESA\n\n    Receiving epoetin <8000 units/week or darbepoetin <40 mcg/week: 120 mcg/qmonth or 60 mcg/q2week IV/SC\n    Receiving epoetin 8000-16000 units/week or darbepoetin 40-80 mcg/week: 200 mcg/qmonth or 100 mcg/q2week IV/SC\n    Receiving epoetin >16000 units/week or darbepoetin >80 mcg/week:360 mcg/qmonth or 180 mcg/q2week IV/SC\n\n\n\n\n\nContra-indication: Uncontrolled HTN.\n\nSide effects: HTN.\n\nPrecaution: Discontinue if pure red cell aplasia. Adequate control of BP. Hemoglobinopathies, seizures, platelet level >500 x 109/L. Patients <18 yr.\n\nMode of action: No interaction studies have been performed. There is no evidence that Mircera alters the metabolism of other medicinal products.\n\nPregnancy category: C\n\nInteraction: No interaction studies have been performed. There is no evidence that Mircera alters the metabolism of other medicinal products.
Miltefosine	\n\n\tIndication: Visceral leishmaniasis,Mycosis fungoides,Skin metastases of breast cancer\n\nDose: Adult: PO Visceral Leishmaniasis 100-150 mg/day for 28 days. Topical Mycosis fungoides; Skin metastases of breast cancer As 6% soln: Apply 1-2 times/day.\n\nContra-indication: Pregnancy, lactation, concurrent radiation therapy.\n\nSide effects: Oral: leukocytosis; thrombocytosis; GI irritation, nausea, vomiting, diarrhoea, constipation; ocular, hepatic, renal toxicity. Topical: pruritis; erythema; scaling; xerosis; tightness of the skin; dermatitis; pain; ulceration; necrosis.\n\nPrecaution: Metastases grown over breast implants.\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Mineral Oil	\n\n\tIndication:  Constipation and bowel irregularity\n\nDose: Do not take with meals  take only at bedtime  may be taken as a single daily dose or in divided doses. Adults and children over 12 years: 1 to 3 tablespoons (15 to 45ml)                                             maximum3 tablespoons (45mL) in 24 hours.   \n\nChildren 6 years to under 12 years:  1 to 3 tablespoons (15 to 45 ml)  maximum3 tablespoons (45mL) in 24 hours. \n\nChildren under 6 years: Do not use, consult a doctor\n\nContra-indication: Rectal bleeding or failure to have a bowel movement after use these could be signs of a serious condition\n\nSide effects: Abdominal pain, nausea or vomiting\n\nPrecaution: Do not use\n\nif you have difficulty swallowing\n\nin children under 6 years of age\n\nif you are pregnant\n\nfor a period longer than one week\n\nif you are bedridden or aged\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Mitomycin	\n\n\tKyowa Hakko Kogyo Co., Ltd.,Japan\tMitomycin Injection 10mg 1's pack 230.55\n\tKyowa Hakko Kogyo Co., Ltd.,Japan\tMitomycin-C TAB dr   1000 tabs  pack 1607\n\tIndication: Solid tumours, bladder tumours, stomach cancer, pancreas cancer			\n\n\nDose: Adult: IV: Solid tumours Suggested regimen: Initial: 10-20 mg/m2; may repeat 6-8 wkly depending on blood count. Do not repeat if leucocyte and platelet counts are below acceptable levels. Do not re-administer if the nadir of the leucocyte count is <2,000 cells/mm3. \n\nIntravesical Superficial bladder tumours Instill 10-40 mg 1-3 times/wk for a total of 20 doses. Prevention of recurrent bladder tumours Instill 20 mg 2 wkly or 40 mg 1-3-mthly.\n\nRenal Impairment\n\nSerum creatinine >1.7 mg/dL: Avoid use\nCrCl <10 mL/min: Decrease dose by 25%\nCAPD: Decrease dose by 25%\n\n\nContra-indication: Thrombocytopenia, coagulation disorders, increase in bleeding tendency due to other causes. Renal impairment, potentially severe infections. Pregnancy and lactation.\n\nSide effects: CHF; fever; alopecia, nail banding/discolouration; nausea, vomiting, anorexia; anaemia; rash; stomatitis; paraesthesia; increased creatinine; interstitial pneumonitis, infiltrates, dyspnoea, cough; malaise, pruritus, extravasation, bladder fibrosis/contraction (intravesical admin).\nPotentially Fatal: Myelosuppression, haemolytic-uraemic syndrome.\n\nPrecaution: Repeated haematologic studies are necessary during treatment and for at least 7 wk after discontinuation of the drug. Discontinue use when the leucocyte count decreases to <4000/mm3 or the platelet count decreases to <150,000/mm3 or if a progressive decline in either occurs. Monitor patient for signs of renal or pulmonary toxicity.\n\nMode of action: Increased incidence of cardiotoxicity w/ doxorubicin.\nPotentially Fatal: Increased risk of intravascular haemolysis and renal failure w/ fluorouracil. Increased risk of haemolytic uraemic syndrome w/ tamoxifen. Acute pulmonary toxicity w/ vinca alkaloids (e.g. vinblastine, vinorelbine). Increased bone marrow depressant effects of aclarubicin.\n\nPregnancy category: D\n\nInteraction: Increased incidence of cardiotoxicity w/ doxorubicin.\nPotentially Fatal: Increased risk of intravascular haemolysis and renal failure w/ fluorouracil. Increased risk of haemolytic uraemic syndrome w/ tamoxifen. Acute pulmonary toxicity w/ vinca alkaloids (e.g. vinblastine, vinorelbine). Increased bone marrow depressant effects of aclarubicin.
Monobasic Sodium Phosphate + Diabasic Sodium Phosphate	\n\n\tIndication: Cleansing of the colon as a preparation for colonoscopy, Foods and water treatment\n\nDose: The recommended dose of monobasic sodium phosphate and dibasic sodium phosphate tablets for colon cleansing for adult patients is 32 tablets (48 grams of sodium phosphate) taken orally with a total of 2 quarts of clear liquids in the following manner: \n\nThe evening before the colonoscopy procedure: Take 4 monobasic sodium phosphate and dibasic sodium phosphate tablets with 8 ounces of clear liquids every 15 minutes for a total of 20 tablets.                     \n\nOn the day of the colonoscopy procedure: Starting 3-5 hours before the procedure, take 4 monobasic sodium phosphate and dibasic sodium phosphate tablets with 8 ounces of clear liquids every 15 minutes for a total of 12 tablets. \n\nPatients should be advised of the importance of taking the recommended fluid regimen. It is recommended that patients receiving monobasic sodium phosphate and dibasic sodium phosphate tablets be advised to adequately hydrate before, during, and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets.  \n\nPatients should not use monobasic sodium phosphate and dibasic sodium phosphate tablets for colon cleansing within seven days of previous administration. No additional enema or laxative is required, and patients should be advised NOT to take additional agents, particularly those containing sodium phosphate\n\nContra-indication: Monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in patients with biopsy-proven acute phosphate nephropathy.\n\nMonobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients.\n\nSide effects: Abdominal bloating, abdominal pain, nausea, and vomiting were the most common adverse events reported with the use of monobasic sodium phosphate and dibasic sodium phosphate tablets. Dizziness and headache were reported less frequently. Since diarrhea was considered as a part of the efficacy of monobasic sodium phosphate and dibasic sodium phosphate tablets, diarrhea was not defined as an adverse event in the clinical studies. Table 2 shows the most common adverse events associated with the use of 48 grams of monobasic sodium phosphate and dibasic sodium phosphate tablets, 60 grams of monobasic sodium phosphate and dibasic sodium phosphate tablets, and 60 grams of Visicol in the colon preparation trials (n=931).\n\nPrecaution: Patients should be instructed to drink 8 ounces of clear liquids with each 4-tablet dose of monobasic sodium phosphate and dibasic sodium phosphate tablets. Patients should take a total of 2 quarts of clear liquids with monobasic sodium phosphate and dibasic sodium phosphate tablets. Inadequate fluid intake, as with any effective purgative, may lead to excessive fluid loss, hypovolemia, and dehydration. Dehydration from purgation may be exacerbated by inadequate oral fluid intake, vomiting, and/or use of diuretics.\n\nPatients should be instructed not to administer additional laxative or purgative agents, particularly additional sodium phosphate-based purgative or enema products.\n\nProlongation of the QT interval has been observed in some patients who were dosed with sodium phosphate colon preparations. QT prolongation with sodium phosphate tablets has been associated with electrolyte imbalances, such as hypokalemia and hypocalcemia. Monobasic sodium phosphate and dibasic sodium phosphate tablets should be used with caution in patients who are taking medications known to prolong the QT interval, since serious complications may occur. Pre-dose and post-colonoscopy ECGs should be considered in patients with known prolonged QT.\n\nAdministration of monobasic sodium phosphate and dibasic sodium phosphate tablets may induce colonic mucosal aphthous ulcerations, since this endoscopic finding was observed with other sodium phosphate cathartic preparations. In the monobasic sodium phosphate and dibasic sodium phosphate tablets clinical program, aphthous ulcers were observed in 3% of patients who took the 48 gram monobasic sodium phosphate and dibasic sodium phosphate tablets dosing regimen. This colonoscopic finding should be considered in patients with known or suspected inflammatory bowel disease.\n\nBecause published data suggest that sodium phosphate absorption may be enhanced in patients experiencing an acute exacerbation of chronic inflammatory bowel disease, monobasic sodium phosphate and dibasic sodium phosphate tablets should be used with caution in such patients.\n\nMode of action: \n\nPregnancy category: C\n\nInteraction: 
Mycophenolate Mofetil	\n\n\tRenata\tPhenocept TAB dr 500mg  1's pack 1950\n\tTechno Drugs Ltd.\tMycotil TAB dr 500mg 30's pack 1650\n\tNovartis Pharma Switzerland\tMyfortic 	 TAB dr 360mg / 180mg 120's pack / 12's pack 18840 / 9480\n\tRoche Spa, ItalyF. Hoffmann La Roche,Switzerland\tCellcept TAB dr 500mg 500 mg pack x  1's pack 186\n\tSandoz Private Ltd. India\tMycophenolat-Mofetil sandoz TAB dr 500mg 50's pack 3375\n\tIndication:  Prophylaxis of acute renal graft rejection\n\nDose: Adult: PO Prophylaxis of acute renal graft rejection As mycophenolate mofetil (MMF): 1 g twice daily starting w/in 72 hr of transplantation. Max: 2 g/day. As mycophenolic acid: 720 mg twice daily.\n\nProphylaxis of cardiac graft rejection As MMF: 1.5 g twice daily starting w/in 5 days after transplantation. \n\n\n\nContra-indication: Pregnancy, lactation. Rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), including Kelley-Seegmiller or Lesch-Nyhan syndrome.\n\nSide effects: Diarrhoea, vomiting, GI haemorrhage and perforation; leucopenia; asthenia, pain, headache, anaemia, thrombocytopenia, renal tubular necrosis, haematuria, BP changes, hyperglycaemia, disturbances of electrolytes and blood lipids, peripheral oedema, dyspnoea, cough, acne, rash, alopecia, dizziness, insomnia, paraesthesia, tremor, hypersensitivity reactions, pancreatitis, hepatitis.\nPotentially Fatal: Angioedema, anaphylaxis, fatal pulmonary fibrosis.\n\nPrecaution: Teratogenic in animals; avoid inhalation or direct skin contact. Monitor patients for lymphoproliferative disorders; advise patient to limit exposure to sunlight/UV light. Active peptic ulcer disease. Severe renal impairment. Mycophenolate mofetil and mycophenolate sodium are not interchangeable. Perform CBCs; monitor for neutropenia.\n\nMode of action: Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.\n\nPregnancy category: D\n\nInteraction: Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.
Nedocromil sodium	\n\n\tSanofi Aventis (BD) Ltd.\tTilade CFC Free Inhaler 2mg 112 actuations unit 900\n\tIndication: Chronic asthma\n\nDose: Adult: Inhalation Chronic asthma As Na: Inhale 4 mg 4 times/day; reduce to twice daily once desired clinical achieved. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Inhalation: Unpleasant taste, headache, fatigue, nausea, vomiting, dyspepsia, diarrhoea, abdominal pain, conjunctivitis, cough, pharyngitis, rhinitis, upper respiratory infection. \n\nPrecaution: Pregnancy and lactation. Not for use in acute asthma attacks; acute bronchospasm. Children <6 yr; monitor closely.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Neostigmine Methyl Sulphate	\n\n\tACI\tStignal Injection 500mcg/ml 10's pack 30.15\n\tChemist Ltd.\tProstig Injection 500mcg/ml 10 amps pack 80\n\tGonoshasthaya\tG-Neostigmine Injection 500mcg/ml 5 amps pack 30.25\n\tPopular\tNeostig Injection 500mcg/ml 1ml amp x 5's pack 30.25\n\tRenata\tNeos-R Injection 500mcg/ml 1ml amp x 5's pack 175\n\tSquare\tVersia Injection 500mcg/ml 1ml amp x 10's pack 70\n\tTechno Drugs Ltd.\tStigmin Injection 500mcg/ml 1ml amp x 10's pack 60\n\tIndication:  Myasthenia gravis, Paralytic ileus; Post-op urinary retention, Reversal of nondepolarising neuromuscular blockade					\n\n\nDose: Adult:  IV Reversal of non depolarising neuromuscular blockade As metilsulfate: 50-70 mcg/kg via inj. \nChild: As metilsulfate: Children: 0.025-0.08 mg/kg/dose. Infants: 0.025-0.1 mg/kg/dose.\n\nIM Diagnosis of myasthenia gravis As metilsulfate: 0.02 mg/kg as a single dose. Discontinue all anticholinesterase medications for at least 8 hr prior to administration. \n\nIM/SC Myasthenia gravis As metilsulfate: 0.5-2.5 mg at intervals, up to a total dose of 5-20 mg/day. \n\nParalytic ileus; Post-op urinary retention As metilsulfate: 0.5 mg. \n\nRenal impairment:\nCrCl (ml/min)	\n10-50	50% of normal dose.\n<10	        25% of normal dose.\n\n\n\nContra-indication: Mechanical GI or urinary tract obstruction, peritonitis.\n\nSide effects: Increased salivation and sweating, nausea and vomiting, abdominal cramps, diarrhoea, allergic reactions, rash (bromide salt), miosis, increased bronchial secretions, bradycardia, bronchospasm, weakness, muscle cramps, fasciculation, hypotension.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Patients with epilepsy, bronchial asthma, bradycardia, recent MI, hypotension, vagotonia, hyperthyroidism, recent intestinal or bladder surgery, renal impairment, arrhythmias, peptic ulcer. Distinguish cholinergic crisis due to overdosage from myasthenic crisis. Pregnancy and lactation. Atropine should always be available when given by inj.\n\nMode of action: May reduce effects of anticholinergics. May increase effects of cholinergic agonists. Increased risk of bradycardia with digoxin, diltiazem, verapamil or beta-blockers without intrinsic sympathomimetic activity. Increased muscle weakness and decreased response to anticholinesterases with corticosteroids. May increase effects of depolarising neuromuscular blockers. Effects may be antagonised by drugs with neuromuscular blocking activity e.g. aminoglycosides, clindamycin, colistin, cyclopropane, halogenated inhalational anaesthetics. Effects may be reduced by quinine, chloroquine, hydroxychloroquine, quinidine, procainamide, propafenone, lithium, ?-blockers. Possible additive toxicity with ophthalmic use of anticholinesterases e.g. ecothiopate.\n\nPregnancy category: C\n\nInteraction: May reduce effects of anticholinergics. May increase effects of cholinergic agonists. Increased risk of bradycardia with digoxin, diltiazem, verapamil or beta-blockers without intrinsic sympathomimetic activity. Increased muscle weakness and decreased response to anticholinesterases with corticosteroids. May increase effects of depolarising neuromuscular blockers. Effects may be antagonised by drugs with neuromuscular blocking activity e.g. aminoglycosides, clindamycin, colistin, cyclopropane, halogenated inhalational anaesthetics. Effects may be reduced by quinine, chloroquine, hydroxychloroquine, quinidine, procainamide, propafenone, lithium, ?-blockers. Possible additive toxicity with ophthalmic use of anticholinesterases e.g. ecothiopate.
Nilotinib	\n\n\tNovartis (Bangladesh) Ltd.\tTasigna CAP 200mg 28's pack 78204\n\tIndication: Chronic myelogenous leukaemia\n\nDose: Adult: PO 400 mg 12 hrly. May continue until patient shows unacceptable toxicity or evidence of progression.\n\nContra-indication: Patients with hypokalaemia, hypomagnaesemia or long QT syndrome. Pregnancy.\n\nSide effects: Nausea, diarrhoea, vomiting, abdominal pain, headache, fatigue, pyrexia, asthenia, cough, dyspnoea, peripheral oedema. Arthralgia, myalgia, bone pain and muscle spasms. Myelosuppression. May increase LFTs. Hepatotoxicity, hypophosphataemia, hypokalaemia, hypocalcaemia and hyponatraemia.\nPotentially Fatal: QT prolongation and sudden deaths.\n\n\nPrecaution: Hepatic impairment. Monitor ECG, CBC and hepatic function regularly. Monitor serum lipase regularly in patients with a history of pancreatitis. Electrolyte abnormalities should be corrected prior to initiating therapy. Not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption as capsules contain lactose. Lactation.\n\nMode of action: Drugs that inhibit gastric acid secretion (e.g. PPIs) may reduce solubility and bioavailability of nilotinib.\nPotentially Fatal: Concomitant use w/ potent CYP3A4 inhibitors or antiarrhythmics (e.g. amiodarone, disopyramide, quinidine, sotalol, ketoconazole, clarithromycin, atazanavir) and other QT prolonging drugs (e.g. chloroquine, haloperidol, methadone, moxifloxacin, pimozide) may increase nilotinib serum levels and/or increase the risk of QT prolongation. Concomitant use w/ potent CYP3A4 inducers (e.g. rifampcin, phenobarbital, carbamazepine, phenytoin) may decrease nilotinib serum levels.\n\nPregnancy category: D\n\nInteraction: Drugs that inhibit gastric acid secretion (e.g. PPIs) may reduce solubility and bioavailability of nilotinib.\nPotentially Fatal: Concomitant use w/ potent CYP3A4 inhibitors or antiarrhythmics (e.g. amiodarone, disopyramide, quinidine, sotalol, ketoconazole, clarithromycin, atazanavir) and other QT prolonging drugs (e.g. chloroquine, haloperidol, methadone, moxifloxacin, pimozide) may increase nilotinib serum levels and/or increase the risk of QT prolongation. Concomitant use w/ potent CYP3A4 inducers (e.g. rifampcin, phenobarbital, carbamazepine, phenytoin) may decrease nilotinib serum levels.
Norfloxacin	\n\n\tIndication: Uncomplicated urinary tract infections (including cystitis), Uncomplicated urethral and cervical gonorrhea, Prostatitis, Gastroenteritis\n\nDose: Adult: PO Uncomplicated gonorrhoea 800 mg once daily. Susceptible infections 400 mg twice daily. Duration: Chronic bacterial prostatitis: 28 days; Complicated UTI: 10-21 days; Gastroenteritis: 3-5 days; \n\nUncomplicated UTI caused by susceptible Escherichia coli, Klebsiella pneumoniae, roteus mirabilis species: 3 days; Uncomplicated UTI caused by other susceptible bacteria: 7-10 days. Chronic relapsing UTI 400 mg twice daily, up to 12 wk, may reduce to once daily if adequate suppression w/in 1st 4 wk. \n\nRenal impairment:\nCrCl (ml/min)	\n<30	400 mg once daily\n\nContra-indication: Hypersensitivity to quinolones; children <18 yr. Lactation.\n\nSide effects: Nausea, vomiting, heartburn, constipation, diarrhoea, abdominal cramping, anorexia; headache, dizziness; depression, insomnia; phototoxicity; rash, fever, arthralgia; elevated liver enzymes, urea and creatinine. Eosinophilia, neutropenia, thrombocytopenia and anaemia; hyperhidris; tendon rupture; QT prolongation.\nPotentially Fatal: Anaphylaxis, acute renal failure, seizures.\n\nPrecaution: Renal impairment; history of CNS disorders; myasthaenia gravis. Pregnancy. QT prolongation; discontinue if signs of neuropathy occur.\n\nMode of action: Additive effect on QT interval prolongation w/ class IA (e.g. quinidine) or class III (e.g. amiodarone) antiarrhythmics and other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Increased serum concentrations of theophylline. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn) and antacids containing Al or Mg, sucralfate, buffered didanosine. \n\nProlonged prothrombin time w/ concomitant coumarin anticoagulant. Increased risk of severe tendon disorders w/ corticosteroids. Concurrent use w/ NSAIDs may increase the risk of CNS stimulation and convulsive seizures.\n\nPregnancy category: C\n\nInteraction: Additive effect on QT interval prolongation w/ class IA (e.g. quinidine) or class III (e.g. amiodarone) antiarrhythmics and other drugs that prolong QT interval (e.g. erythromycin, TCAs, antipsychotic agents). Increased serum concentrations of theophylline. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn) and antacids containing Al or Mg, sucralfate, buffered didanosine. \n\nProlonged prothrombin time w/ concomitant coumarin anticoagulant. Increased risk of severe tendon disorders w/ corticosteroids. Concurrent use w/ NSAIDs may increase the risk of CNS stimulation and convulsive seizures.
Norgestrel + Ethinyl Estradiol	\n\n\tIndication: Contraception\n\nDose:  	Oral\nOral contraception\nAdult: As combination containing 0.3 mg norgestrel and 0.03 mg ethinyl estradiol per tablet: Starting on day 1 of the menstrual cycle, take 1 tablet daily at the same time for 21 days, then stop for 7 days or take the placebo tablet for 7 days. Breakthrough bleeding should occur within 3 days following discontinuation. Start the 2nd cycle on the 8th day regardless whether the menstruation has occurred or still in progress. \n\nIf >2 tablets are missed or in newly started patients, non-hormonal birth control method should be used until the active tablet has been taken consecutively for 7 days.\n\nContra-indication: Thrombophlebitis or thromboembolic disorders\nA history of deep-vein thrombophlebitis or thromboembolic disorders\nCerebrovascular or coronary artery disease (current or past history)\nValvular heart disease with thrombogenic complications\nThrombogenic rhythm disorders\nHereditary or acquired thrombophilias\nMajor surgery with prolonged immobilization\nDiabetes with vascular involvement\nHeadaches with focal neurological symptoms\nUncontrolled hypertension\nKnown or suspected carcinoma of the breast or personal history of breast cancer\nCarcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia\nUndiagnosed abnormal genital bleeding\nCholestatic jaundice of pregnancy or jaundice with prior pill use\nHepatic adenomas or carcinomas, or active liver disease\nKnown or suspected pregnancy\nHypersensitivity to any of the components of NORGESTREL/ETHINYL ESTRADIOL\n\nSide effects: The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related (alphabetically listed):\n\nAcne\nAmenorrhea\nAnaphylactic/anaphylactoid reactions, including urticaria, angioedema, and severe reactions with respiratory and circulatory symptoms\nBreast changes: tenderness, pain, enlargement, secretion\nBudd-Chiari syndrome\nCervical erosion and secretion, change in\nCholestatic jaundice\nChorea, exacerbation of\nColitis\nDizziness\nEdema/fluid retention\nErythema multiforme\nErythema nodosum\nGastrointestinal symptoms (such as abdominal pain, cramps, and bloating)\nHirsutism\nMelasma/chloasma which may persist\nMenstrual flow, \nMood changes, including depression\nNausea\nNervousness\nPancreatitis\nPorphyria, exacerbation of\nRash (allergic)\nScalp hair, loss of\nSerum folate levels, decrease in\nSpotting\nSystemic lupus erythematosus, \nUnscheduled bleeding\nVaginitis, including candidiasis\nVaricose veins, aggravation of\nVomiting\nWeight or appetite (increase or decrease), change in\n\n\n\nPrecaution: 1. General\n\nPatients should be counseled that oral contraceptives do not protect against transmission of HIV (AIDS) and other sexually transmitted diseases (STDs) such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.\n2. Physical Examination and Follow-Up\n\nA periodic personal and family medical history and complete physical examination are appropriate for all women, including women using oral contraceptives. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care.\n3. Lipid Disorders\n\nWomen who are being treated for hyperlipidemias should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult.\n\n\n4. Liver Function\n\nIf jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function.\n5. Fluid Retention\n\nOral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention.\n6. Emotional Disorders\n\nPatients becoming significantly depressed while taking oral contraceptives should stop the medication and use an alternate method of contraception in an attempt to determine whether the symptom is drug-related. Women with a history of depression should be carefully observed and the drug discontinued if depression recurs to a significant degree.\n7. Contact Lenses\n\nContact-lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.\n8. Gastrointestinal\n\nDiarrhea and/or vomiting may reduce hormone absorption resulting in decreased serum concentrations\n\nMode of action: None\n\nPregnancy category: X\n\nInteraction: 
Octreotide	\n\n\tNovartis (Bangladesh) Ltd.\tSandostatin SC Injection 50mcg/1ml 5's pack 6226\n\tNovartis (Bangladesh) Ltd.\tSandostatin Lar Injection  20mg (large dose) 20mg vial x 1's pack 79240\n\tNovartis Pharma AG, Switzerland\tSandostatin Injection 0.05mg/ml 5 amps pack 6226\n\tIndication: Acromegaly, Variceal haemorrhage, Secretory neoplasms, Following pancreatic surgery, HIV-associated diarrhoea\n\nDose: Adult: IV Variceal haemorrhage in patients w/ cirrhosis 25 mcg/hr for 48 hr (up to 5 days in patients at high risk of re-bleeding). \n\nIM Acromegaly Following initial control w/ SC therapy: Depot Initial: 20 mg 4 wkly. Adjust if required after 3 mth to 10-30 mg 4 wkly. Max: 40 mg 4 wkly. \n\nIM/SC Secretory neoplasms As SC: Initial: 50 mcg 1-2 times/day, up to 600 mcg/day in 2-4 divided doses based on response. Maintenance: Depot 10-30 mg 4 wkly via IM inj. \n\nSC Acromegaly Initial: 50 mcg 3 times/day, increase if needed. Usual dose: 100-200 mcg 3 times/day. Max: 500 mcg 3 times/day. Prevention of complications following pancreatic surgery 100 mcg 3 times/day of a rapid-acting preparation for 7 days, starting at least 1 hr pre-op. \n\nHIV-associated diarrhoea Initial: 100 mcg 3 times/day. If symptoms are not controlled after 1 wk, increase to 250 mcg 3 times/day. Secretory neoplasms Initial: 50 mcg 1-2 times/day, up to 600 mcg/day in 2-4 divided doses based on response.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Local pain, stinging, tingling at site of inj; anorexia, nausea, vomiting, abdominal pain, bloating, flatulence, loose stools, steatorrhoea; biliary tract abnormalities. Hypoglycaemia and hyperglycaemia, hypothyroidism, cardiac conduction abnormalitles, pancreatitis.\n\nPrecaution: Renal disease; risk of gall bladder disease; DM; hypothyroidism. Pregnancy, lactation, children, elderly. Monitor levels of vitamin B12 during long term therapy.\n\nMode of action: Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, ?-blockers, diuretics. May increase concentration of bromocriptine.\n\nPotentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.\n\nPregnancy category: B\n\nInteraction: Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, ?-blockers, diuretics. May increase concentration of bromocriptine.\n\nPotentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.
Varicella Zoster Virus (live attenuated)  Vaccine	\n\n\tIndication: Varicella infection\n\nDose:  Usually, 1 dose (0.5 mL) is injected SC. Adults and adolescents: 0.5 mL dose administered SC at elected date then a 2nd 0.5 mL dose 4-8 weeks later. \n\nChildren 12 months-12 years: 0.5 mL as a single dose to be administered SC. \n\nContra-indication:  A history of hypersensitivity to any component of the vaccine; individuals with blood dyscrasias, leukonia, lymphomas of any type, or other malignant neoplasma affecting the bone marrow or lymphatic systems; individuals receiving immunosuppressive therapy.\n\n\nSide effects: Hemic and Lymphatic System: Thrombocytopenia, nervous, encephalitic, respiratory skin (Stevens-Johnson syndrome, secondary bacterial infections of skin and soft tissue including impetigo and cellulitis, herpes zoster).\nFever and rash occasionally appear in healthy children and adults 1-3 weeks after vaccination.  Anaphylactoid symptoms eg, urticaria, dyspnea, lip edema or laryngeal edema may appear rarely. A hypersensitivity reaction may rarely occur immediately after vaccination by the day following vaccination, with the appearance of rash, urticaria, erythema, pruritus, and fever. A local reaction eg, redness, swelling and induration may rarely occur at the injection site.\n\n\nPrecaution: General: \nBefore vaccination, the general health condition of the vaccine recipient should be evaluated clinically by taking their temperature and being examined (inspection, auscultation, etc) by a physician.\nAdequate treatment provisions including epinephrine injection (1:1000), should be available for immediate use should an anaphylactoid reaction occur.\nVaccination should be deferred to at least 5 months following blood or plasma transfusion, or administration of immunoglobulin or varicella-zoster immunoglobulin (VZIG).\nVaccine recipients should avoid use of salicylate for 6 weeks after vaccination as rege's syndrome has been reported following the use of salicylate during varicella infection.\nVaccination should be deferred in patients with a family history of congenital or hereditary immunodeficiency until the patient's own immune system has been evaluated.\nCases Requiring Careful Consideration Before Vaccination: The decision for vaccination is to be made carefully in the following categories, those having a history of seizures; those previously diagnosed with an immunodeficiency; those suffering from diseases accompanied by abnormal immune system function or those receiving immunosuppressive therapy (see Dosage & Administration); and those suspected of being allergic to any of the components of Okavax.\nUse in pregnancy: Women of childbearing age are to be warned to practice appropriate birth control for approximately 1 month before vaccination and to avoid becoming pregnant for at least 2 months after vaccination.\nUse in children: No clinical data are available on the safety or efficacy of Okavax vaccine in children <1 year, therefore, administration in infants <12 months is not recommended.\nUse in the elderly: Since the elderly frequently have decreased physiologic function, it is advisable to carefully evaluate the health condition before vaccination.\n\nMode of action: Concurrent use may interfere with the immune response to certain live vaccines.\n\nPregnancy category: C\n\nInteraction: Concurrent use may interfere with the immune response to certain live vaccines.
Omalizumab	\n\n\tNovartis (Bangladesh) Ltd.\tXolair Injection 150mg 1 amps pack 33654\n\tIndication: Severe allergic asthma\n\nDose: Adult: SC Dose depends on patients wt and pre-treatment serum IgE levels. Dose may range from 75-300 mg 4 wkly to 225-375 mg 2 wkly. Not >150 mg/inj site.\n\nContra-indication: Previous severe hypersensitivity reaction, acute bronchospasm, status asthmaticus.\n\nSide effects: Headache; upper respiratory tract infection, sinusitis, pharyngitis; viral infection; pain, fatigue, dizziness; dermatitis, pruritus; arthralgia; earache; inj site reaction.\nPotentially Fatal: Anaphylactic reactions including bronchospasm, hypotension, syncope, dyspnoea and/or angioedema of the throat or tongue.\n\nPrecaution: Children <12 yr; pregnancy; lactation; patients at risk for parasitic infections. Corticosteriod therapy should not be stopped abruptly. Delayed-onset anaphylaxis has been reported; reactions usually occur within 2 hr of admin, but may occur up to 24 hr to >1 yr after initiation of regular treatment. Treatment should only be under direct medical supervision and be observed for a min of 2 hr following admin. May increase risk of malignancy in some patients.\n\nMode of action: Cytochrome P-450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of omalizumab; thus, there is little potential for drug-drug interactions. No formal drug or vaccine interaction studies have been performed with Omalizumab. There is no pharmacological reason to expect that commonly prescribed medications used in the treatment of asthma will interact with omalizumab.\n\nIn clinical studies, Omalizumab was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short- and long-acting beta-agonists, leukotriene modifiers, theophyllines and oral antihistamines. There was no indication that the safety of Omalizumab was altered with these other commonly used asthma medications. Limited data are available on the use of Xolair in combination with specific immunotherapy (hyposensitisation therapy).\n\nOmalizumab may indirectly reduce the efficacy of medicinal products for the treatment of helminthic or other parasitic infections.\nIncompatibilities: Omalizumab should not be mixed with any medication or diluents other than water for injections.\n\nPregnancy category: B\n\nInteraction: Cytochrome P-450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of omalizumab; thus, there is little potential for drug-drug interactions. No formal drug or vaccine interaction studies have been performed with Omalizumab. There is no pharmacological reason to expect that commonly prescribed medications used in the treatment of asthma will interact with omalizumab.\n\nIn clinical studies, Omalizumab was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short- and long-acting beta-agonists, leukotriene modifiers, theophyllines and oral antihistamines. There was no indication that the safety of Omalizumab was altered with these other commonly used asthma medications. Limited data are available on the use of Xolair in combination with specific immunotherapy (hyposensitisation therapy).\n\nOmalizumab may indirectly reduce the efficacy of medicinal products for the treatment of helminthic or other parasitic infections.\nIncompatibilities: Omalizumab should not be mixed with any medication or diluents other than water for injections.
Pegfilgrastim	\n\n\tHealthcare\tPegneufil Injection 6 mg/0.6 ml  \n\tIndication: Chemotherapy induced-neutropenia, Bone marrow stimulation\n\nDose: Adult: SC To reduce incidence of infection in patients w/ non-myeloid malignancies receiving myelosuppressive chemotherapy that is associated w/ a clinically significant risk of febrile neutropenia: >18 yr: 6 mg once/chemotherapy cycle. Do not administer between 14 days before and 24 hr after administration of cytotoxic chemotherapy.\n\nContra-indication: Hypersensitivity to Pegfilgrastim or filgrastim; or to any ingredients in the formulation.\n\nSide effects: Bone pain, pain in extremity, myalgia, arthralgia, headache, nausea, vomiting , constipation, peripheral oedema, inj site reactions, skin rash, urticaria, erythema, flushing, splenomegaly, splenic rupture, sickle cell crises, ARDS, thrombocytopenia, leukocytosis, antibody formation, Sweet's syndrome; elevations in uric acid, alkaline phosphatase, lactate dehydrogenase, ALT and AST.\nPotentially Fatal: Anaphylaxis.\n\nPrecaution: Splenic rupture (including fatal cases) or enlarged spleen have been reported following admin of Pegfilgrastim; patients who reported left upper abdominal or shoulder tip pain should be evaluated for development of splenomegaly or splenic rupture. Acute respiratory distress syndrome (ARDS) may occur; monitor patients for pulmonary symptoms e.g. cough, fever, lung infiltrates, or respiratory distress. Discontinue or withhold Pegfilgrastim in patients with confirmed ARDS. Caution in patients with existing sickle cell disorders; as severe sickle cell crisis may occur. Possibility of Pegfilgrastim acting as a growth factor for any tumor type cannot be excluded. Not approved for myeloid malignancies and myelodysplasia. Monitor platelet count and haematocrit regularly. Do not administer Pegfilgrastim during the 14 days before and 24 hr after chemotherapy admin due to the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy. Safety and efficacy in paediatric patients have not been established. Pregnancy and lactation.\n\nMode of action: Colony-stimulating factors such as Pegfilgrastim should not be given at the same time as cytotoxic chemotherapy due to the increased risk of myelosuppression.\n\nPregnancy category: C\n\nInteraction: Colony-stimulating factors such as Pegfilgrastim should not be given at the same time as cytotoxic chemotherapy due to the increased risk of myelosuppression.
Peginterferon Alfa-2b	\n\n\tJanata Pharma\tPeg-intron Injection  1's pack 17728.90\n\tIndication: Chronic hepatitis C, Chronic hepatitis B\n\nDose: Adult: SC Chronic hepatitis C:  >18 yr: Monotherapy: Initial: 1 mcg/kg/wk for 24-48 wk. W/ ribavirin: 1.5 mcg/kg/wk for 24-48 wk. Duration: 48 wk (genotype 1); 24 wk (genotype 2 and 3).\n\nRenal impairment: Haemodialysis: Reduce dose by 50%. Discontinue if renal function declines. Combination therapy with ribavirin is not recommended in patients with CrCl <50 ml/min.\n\nCrCl (ml/min)	\n30-50	Reduce dose by 25%.\n10-29	Reduce dose by 50%.\n\nContra-indication: Autoimmune hepatitis; decompensated liver disease; in combination with ribavirin in pregnant women.\n\nSide effects: Headache, fatigue, depression/anxiety/emotional liability/irritability, insomnia, fever, dizziness; alopecia, pruritus, dry skin; nausea, anorexia, diarrhoea, abdominal pain, wt loss; neutropenia, thrombocytopenia; inj site inflammation/reaction; myalgia, weakness, musculoskeletal pain, arthralgia, rigors; viral infection. Rarely: Chest pain, flushing, concentration impaired, malaise, nervousness, agitation; rash; hypothyroidism, menstrual disorder, hyperthyroidism; vomiting, dyspepsia, xerostomia, constipation, taste perversion; increased transaminases, hepatomegaly; inj site pain; conjunctivitis, blurred vision; pharyngitis, cough, sinusitis, dyspnoea, rhinitis; diaphoresis, neutralising antibodies.\n\nPrecaution: Neuropsychiatric disorders, discontinue treatment with worsening or persistently severe signs/symptoms; chronically immunosuppressed and myelosuppresion; pulmonary disease; autoimmune disease; cardiovascular disease; DM; infectious disorders; ischaemic disorders; renal impairment; thyroid disorders; failed other alfa interferon therapy, received organ transplants, coinfected with HIV or hepatitis B, or received treatment for >1 yr. Elderly. Safety and efficacy not been established in children. Do not change brands of interferon without the concurrence of healthcare provider (product variability). Hazardous agent, handle and dispose appropriately. May affect ability to drive or operate machinery.\n\nMode of action: Increased risk of haemolytic anemia, birth defects and/or foetal mortality, genotoxicity, mutagenicity, and may possibly be carcinogenic with ribavirin; decreases metabolism of theophylline; enhances adverse/toxic effects of zidovudine, decreases metabolism of zidovudine. Avoid ethanol in hepatitis C virus patients.\n\nPregnancy category: C\n\nInteraction: Increased risk of haemolytic anemia, birth defects and/or foetal mortality, genotoxicity, mutagenicity, and may possibly be carcinogenic with ribavirin; decreases metabolism of theophylline; enhances adverse/toxic effects of zidovudine, decreases metabolism of zidovudine. Avoid ethanol in hepatitis C virus patients.
Pemetrexed	\n\n\tBeacon\tPemetrex Injection 500 mg/5 ml  \n\tBeacon\tPemetrex Injection 100 mg/ml  \n\tLilly, France\tAlimta Injection 500mg 500 mg vial x 1's pack 119720\n\tIndication: Non-small cell lung cancer, Malignant pleural mesothelioma\n\nDose: Adult: IV Non-small cell lung cancer; Malignant pleural mesothelioma 500 mg/m2 on day 1 of each 21-day cycle. After the 1st treatment cycle, adjust subsequent doses based on nadir haematologic counts and max non-haematologic toxicity. Malignant pleural mesothelioma: Used w/ cisplatin\n\nContra-indication: Hypersensitivity.\n\nSide effects: Stomatitis, pharyngitis, dyspnoea and neuropathy. Chest pain, oedema, hypertension, fatigue, fever, anorexia, nausea, vomiting, constipation, depression. Rash/desquamation and alopecia. Anaemia, leukopenia and neutropenia. Neuropathy and myalgia.\nPotentially Fatal: Acute renal failure.\n\nPrecaution: Monitor CBC. Premedication with folate and vitamin B12 are recommended as prophylaxis against haematological and GI toxicity during treatment. Pre-treatment with a corticosteroid also reduces the incidence and severity of skin reactions. Caution when used in renal or hepatic impairment. Not recommended for use in pregnancy and lactation.\n\nMode of action: High doses of NSAIDs and aspirin may reduce the elimination of pemetrexed; avoid usage 2 days (5 days for longer-acting NSAIDs) before, during and 2 days after treatment with pemetrexed in patients with impaired renal function. Additive GI side effects when used with SSRIs, acetylcholinesterase inhibitors, aripiprazole or ziprasidone. Additive sedation when used with psychotropics. Concurrent use with nephrotoxic drugs (e.g. aminoglycosides, loop diuretics, platinum compounds and ciclosporin) may decrease pemetrexed clearance, thus increasing the risk of toxicity. Clearance may be reduced when used with drugs that are cleared by tubular secretion e.g. probenecid and penicillin.\n\nPregnancy category: D\n\nInteraction: High doses of NSAIDs and aspirin may reduce the elimination of pemetrexed; avoid usage 2 days (5 days for longer-acting NSAIDs) before, during and 2 days after treatment with pemetrexed in patients with impaired renal function. Additive GI side effects when used with SSRIs, acetylcholinesterase inhibitors, aripiprazole or ziprasidone. Additive sedation when used with psychotropics. Concurrent use with nephrotoxic drugs (e.g. aminoglycosides, loop diuretics, platinum compounds and ciclosporin) may decrease pemetrexed clearance, thus increasing the risk of toxicity. Clearance may be reduced when used with drugs that are cleared by tubular secretion e.g. probenecid and penicillin.
Pentosan Polysulphate Sodium	\n\n\tIndication: Interstitial cystitis, Nocturia, Painful bladder syndrome, Dyspareunia\n\nDose: Adult: PO 100 mg 3 times/day.\n\nContra-indication: Patients who are haemorrhaging. Serious renal or hepatic impairment. Not to be given via IM inj.\n\nSide effects: Local irritation, skin necrosis; alopecia and osteoporosis may occur upon prolonged treatment; hyperkalaemia and bleeding; nausea, diarrhoea, headache, fatigue, drowsiness, pelvic pain, rectal haemorrhage, dyspepsia, abdominal pain; LFT abnormalities.\n\nPrecaution: Patients with spleen disorders, hepatic or renal impairment. Monitor platelet counts during treatment. To discontinue treatment if thrombocytopenia occurs. Caution when used in patients with haemorrhagic blood disorders, thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, bacterial endocarditis, severe hypertension or oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Safety not established in children <16 yr. Patients should be monitored every 3 mth; risks and benefits after 6 mth of treatment not known. Pregnancy; lactation.\n\nMode of action: Increased risk of bleeding when used with oral anticoagulants or drugs that affect platelet function. Concurrent admin with glyceryl trinitrate via IV route may reduce the efficacy of pentosan.\n\nPregnancy category: B\n\nInteraction: Increased risk of bleeding when used with oral anticoagulants or drugs that affect platelet function. Concurrent admin with glyceryl trinitrate via IV route may reduce the efficacy of pentosan.
Perindopril + Indapamide	\n\n\tGeneral\tAldoc TAB dr  30's pack \n\tGeneral\tAldoc DS TAB dr  20's pack \n\tLes Servier Industrie,France\tCoversyl Plus TAB dr  30's pack 630\n\tIndication: Heart failure, Hypertension, IHD\n\nDose: Adult: PO 1 tab once daily in the morning.\n\nRenal impairment:\nCrCl (ml/min)	\n<30	        Avoid use.\n30-60	Dose adjustment may be needed. \n\nContra-indication: Hypersensitivity. Severe renal impairment (CrCl <30 ml/min), hypokalaemia, severe hepatic impairment or hepatic encephalopathy, history of angioedema associated with treatment with an ACE inhibitor, children. Dialysis patients or patients with untreated decompensated heart failure. Hereditary/idiopathic angioneurotic oedema. Pregnancy and lactation.\n\nSide effects: Dry cough, headache, bradycardia, dizziness, asthenia, hypokalaemia and orthostatic hypotension. GI effects such as constipation, dry mouth, nausea, epigastric pain, anorexia, abdominal pain and taste disturbance.\n\nPrecaution: Impaired renal function, risk of hypotension and electrolyte imbalance. Regular monitoring of renal function and plasma levels of potassium are recommended. Blood glucose levels should be monitored in diabetic patients especially in those with low serum potassium levels. Increased risk of neutropenia/agranulocytosis in immunosuppressed patients. Treatment should be discontinued immediately if there is angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx.\n\nMode of action: Increased risk of lithium toxicity. May cause and potentiate orthostatic hypotension when used with alcohol, barbiturates, neuroleptics, narcotics or other antihypertensives. Increased risk of acute renal insufficiency in dehydrated patients when used with systemic NSAIDs or high dose salicylates. May increase risk of hypoglycaemia in patients on concurrent treatment with hypoglycaemic sulfonamides/insulin. Concurrent use with baclofen may potentiate antihypertensive effect. May reduce antihypertensive effect when used with corticosteroids or tetracosactide. Increased risk of hyperkalaemia when used with potassium-sparing diuretics or potassium supplements. May increase hypotensive effect of certain anaesthetic drugs. Increased risk of leucopenia when used with allopurinol, immunosuppressants, procainamide or systemic corticosteoids. Additive hypotensive effect when used with other antihypertensives.\n\nPregnancy category: A\n\nInteraction: Increased risk of lithium toxicity. May cause and potentiate orthostatic hypotension when used with alcohol, barbiturates, neuroleptics, narcotics or other antihypertensives. Increased risk of acute renal insufficiency in dehydrated patients when used with systemic NSAIDs or high dose salicylates. May increase risk of hypoglycaemia in patients on concurrent treatment with hypoglycaemic sulfonamides/insulin. Concurrent use with baclofen may potentiate antihypertensive effect. May reduce antihypertensive effect when used with corticosteroids or tetracosactide. Increased risk of hyperkalaemia when used with potassium-sparing diuretics or potassium supplements. May increase hypotensive effect of certain anaesthetic drugs. Increased risk of leucopenia when used with allopurinol, immunosuppressants, procainamide or systemic corticosteoids. Additive hypotensive effect when used with other antihypertensives.
Pheniramine Maleate + Naphazoline HCl Eye prep	\n\n\tIndication: Itchy, Red eyes\n\nDose: Adult: Ophth As soln containing naphazoline HCl 0.025% and pheniramine maleate 0.3%: Instill 1-2 drops up to 4 times/day.\n\nContra-indication: Angle closure glaucoma.\n\nSide effects: Blurring of vision, mild stinging and/or irritation, mydriasis and increased or decreased intraocular pressure. When used in high doses in elderly, naphazoline may liberate pigment granules from the iris.\n\nPrecaution:  	Glaucoma, hypertension, CV abnormalities, DM, hyperthyroidism, infection, or injury. Pregnancy and lactation. Avoid in infants and young children <6 yr. Rebound congestion may occur with prolonged use or overuse. Patient to seek medical advice if there is ocular pain, vision changes, worsening of redness or irritation of the eye or symptoms lasts >72 hr. Remove contact lens before use.\n\nMode of action: Increased pressor effects with maprotiline or TCA. Possibility of severe hypertensive reaction with MAOI.\n\nPregnancy category: C\n\nInteraction: Increased pressor effects with maprotiline or TCA. Possibility of severe hypertensive reaction with MAOI.
Phospolipids	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tSurvanta Suspension (Intra-tracheal) 25mg/ml  4ml / 8ml 20814.61/24356.88\n\tAbbott Ltd., USA\tSurvanta Intratracheal suspension 25mg/ml 4ml vial/8ml vial 20726.73/24254.05\n\tIndication: Resp distress syndrome (RDS) in premature infants.\n\nDose: 4 mL/kg birth wt(100 mg of phospholipids/kg birth wt) intratracheally up to 4 doses in 1st 48 hr. Doses should not be given more frequently than 6 hrly. To be administered as soon as possible. Prevention in premature infant <1250 g birthwt or w/ evidence of surfactant deficiency Preferably w/in 15 mins of birth. Rescue Preferably by 8 hr of age.\n\nContra-indication: None known.\n\nSide effects: Transient bradycardia. O2 desaturation, endotracheal tube reflux & blockage, pallor, vasoconstriction, hypotension, HTN, hypocarbia, hypercarbia & apnea.\n\nPrecaution: Infants <600 g birth wt. For intratracheal use only.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Pimecrolimus 1% Topical	\n\n\tNovartis Pharma GmbH, Germany\tElidel Cream   15gm tube 1213\n\tIndication: Atopic dermatitis, Eczema\n\nDose: Adult: Topical As 1% cream: Apply twice daily. Stop treatment if there is no improvement after 6 wk or if there is worsening of condition.\n\nContra-indication: Hypersensitivity; children <2 yr; immunocompromised patients. Patients with Netherton's syndrome.\n\nSide effects: Application-site reactions, upper respiratory tract infection, cough, nasopharyngitis and headache. Increased incidence of impetigo; skin infections and superinfection; rhinitis and urticaria with combined topical corticosteroids.\n\nPrecaution: Avoid use in areas affected by active, cutaneous viral infections. Avoid contact with the eyes and mucous membranes. Immunosuppression may increase risk of lymphoma and other malignancies. Limit exposure to sunlight or other UV light. Mild to moderate sensation of warmth and/or burning may occur at the treatment site within 1-5 days of initiation. Safety of usage beyond 1 yr is not established. Renal or hepatic impairment. Monitor renal, hepatic, cardiac and visual functions, BP, serum glucose and electrolytes regularly. Pregnancy, lactation.\n\nMode of action: Inhibitors of cytochrome P450 3A4 isoenzyme in patients with widespread and/or erythrodermic disease.\nPotentially Fatal: Increased risk of infections when used with live vaccines.\n\nPregnancy category: C\n\nInteraction: Inhibitors of cytochrome P450 3A4 isoenzyme in patients with widespread and/or erythrodermic disease.\nPotentially Fatal: Increased risk of infections when used with live vaccines.
Piperazine Citrate	\n\n\tIndication: Enterobiasis, Ascariasis\n\nDose: Ascariasis Adult: As hydrate: 4.5 g as a single dose repeated once after 14 days. Alternatively, may be given as a preparation with senna in a single dose of 4 g of the phosphate, repeat dose mthly for up to 3 mth if needed; same dosage regimen may also be used to prevent ascariasis.\n\nChild: As a single dose, repeated once after 14 days. <1 yr: 120 mg/kg (only upon medical advice), 1-3 yr: 1.5 g, 4-5 yr: 2.25 g, 6-8 yr: 3 g, 9-12 yr: 3.75 g. Alternatively, may be given as a preparation with senna in a single dose of 4 g of the phosphate, repeat dose mthly for up to 3 mth if needed; same dosage regimen may also be used to prevent ascariasis.\n\nEnterobiasisAdult: As hydrate: 2.25 g once daily for 7 days, 2nd course may be repeated after an interval of 7 days. Alternatively, may be given as a preparation with senna in a single dose of 4 g of the phosphate, repeat dose after 14 days.\n\nChild: <1 yr: 45-75 mg/kg (only upon medical advice), 1-3 yr: 750 mg, 4-6 yr: 1.125 g, 7-12 yr: 1.5 g, >12 yr: same as adult dose. To be taken once daily for 7 days, 2nd course may be repeated after an interval of 7 days. Alternatively, for children >6 yr: May be given as a preparation with senna in a single dose of 4 g of the phosphate; repeat dose after 14 days.\n\nContra-indication: Severe renal impairment, epilepsy. Pregnancy.\n\nSide effects:  	Nausea, vomiting, colic, abdominal pain, diarrhoea, urticaria, skin rashes, headache, bronchospasm, dizziness, nystagmus, ataxia, paraesthesia, myoclonic contractions, choreiform movements, muscular incoordination (worm wobble), confusion, EEG abnormalities, blurred vision.\nPotentially Fatal: Stevens-Johnson syndrome, bronchospasm and angioedema.\n\nPrecaution: Hepatic impairment, neurological conditions, mild to moderate renal impairment. Lactation.\n\nMode of action: Antagonism if pyrantel and piperazine are used together. Piperazine may potentiate extrapyramidal effects of chlorpromazine and other phenothiazines.\n\nPregnancy category: B\n\nInteraction: Antagonism if pyrantel and piperazine are used together. Piperazine may potentiate extrapyramidal effects of chlorpromazine and other phenothiazines.
Plasma Volume Substitute	\n\n\tIndication: Dehydration, Fluid replacement, Hypovolemic shock, loss of blood & plasma eg due to trauma, burns, autologous blood or plasma donation before an operation. For filling the heart-lung machine.\n\nDose: Adult Shock prophylaxis 500-1,500 mL, approx 20 mL/kg/day. Vol-deficiency shock Max: 2,000 mL. In emergencies: Vol as required. \n\nIn case of long-term maintenance of plasma vol, infusion should not cause the hematocrit to fall below 30 vol % (max. 25 vol %). In case of lower values the infusion should be supplemented w/ erythrocyte concentrate whole blood.\n\nContra-indication: Existing anaphylactoid reaction.\n\nSide effects: Wheals, transient urticarial skin reactions, temporary hypotension, rise in temp &/or shivering.\n\nPrecaution: Cardiac insufficiency, fixed HTN, cardiogenic shock.\n\nMode of action: \n\nPregnancy category: D\n\nInteraction: 
Pnenmococcal Polysaccharide Conjugated Vaccine	\n\n\tGlaxoSmithkline Biologicals S.A,Belgium\tSynflorix Injection   .5ml 1936.49\n\tIndication: Active immunization for the prevention of pneumococcal disease, Meningitis, Sepsis, Bacteraemic pneumonia, Pleural empyema, Bacteraemia, Pneumococcal pneumonia\n\nDose: Infants from 6 weeks to 6 months of age:\nThree-dose primary series\nThe recommended immunisation series to ensure optimal protection consists of four doses, each of 0.5 ml. The primary infant series consists of three doses with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses. The first dose may be given as early as six weeks of age.\nA booster dose is recommended at least 6 months after the last priming dose.\n\nTwo-dose primary series\nAlternatively, when it is given as part of a routine infant immunisation programme, a series consisting of three doses, each of 0.5 ml may be given. The first dose may be administered from the age of 2 months, with a second dose 2 months later. A booster dose is recommended at least 6 months after the last primary dose.\n\nPreviously unvaccinated older infants and children:\nInfants aged 7-11 months: The vaccination schedule consists of two doses of 0.5 ml with an interval of at least 1 month between doses. A third dose is recommended in the second year of life with an interval of at least 2 months between doses.\n\nChildren aged 12-23 months: The vaccination schedule consists of two doses of 0.5 ml with an interval of at least 2 months between doses. The need for a booster dose after this immunization schedule has not been established.\n\n\nContra-indication: Hypersensitivity to any component of the vaccine. Epinephrine injection (1:1000) must be immediately available should an acute anaphylactoid reaction occur due to any component of the vaccine.\n\nSide effects: The most common adverse experiences reported with(pneumococcal vaccine )  in clinical trials were: Local reaction at injection site including soreness, erythema, warmth, swelling and induration Fever > 102Â°F\n\n\n\nPrecaution: Severe renal, hepatic, cardiac, vascular &/or pulmonary dysfunction. Patients on immunosuppressants may be unable to attain required antibody titres. Pregnancy & lactation. Efficacy may be reduced in multiple myeloma, Hodgkin's and non-Hogkin's lymphoma, especially during treatment and in chronic alcoholism. Vaccine should be given 2 wk before starting immunosuppressive treatment or at least 3 mth after treatment completion.\n\nMode of action: Adequate response may not be elicited w/ immunosuppressants.\n\nPregnancy category: C\n\nInteraction: Adequate response may not be elicited w/ immunosuppressants.
Poly (0-2 hydroxyethyl) Starch (Molar Substitution)	\n\n\tIndication: Hypovolaemia and shock, Surgery (haemorrhagic shock), Injuries (traumatic shock), Burns Therapeutic dilution of blood\n\nDose: Adult Dose\n\nUp to 50 mL of  (hydroxyethyl starch in sodium chloride injection) per kg of body weight per day (equivalent to 3 g hydroxyethyl starch and 7.7 mEq sodium per kg of body weight). This dose is equivalent to 3500 mL of  (hydroxyethyl starch in sodium chloride injection) for a 70 kg patient.\nPediatric Dose\n\n\n\nContra-indication:     Known hypersensitivity to hydroxyethyl starch \n    fluid overload (hyperhydration) and especially in \n\ncases of pulmonary edema and congestive heart failure\n    renal failure with oliguria or anuria not related \n\nto hypovolemia\n    patients receiving dialysis treatment\n    severe hypernatremia or severe hyperchloremia\n    intracranial bleeding.\n\n\nSide effects: From the accumulated clinical development experience, \n\nexpected adverse reactions after administration of \n\n (hydroxyethyl starch in sodium chloride injection) occurring in less than 10% of patients are as follows:\n\nImmune system disorders (Rare, > 0.01% to < 0.1%): \n\nanaphylactoid reactions (hypersensitivity, mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema). In the event of an intolerance reaction, the infusion should be discontinued immediately and the appropriate emergency medical treatment initiated. \n\nSkin and subcutaneous tissue disorders (Common, > 1 to < 10%, dose dependent): Prolonged administration of high dosages of hydroxyethyl starch may cause pruritus (itching) which is an undesirable effect observed with all hydroxyethyl starches.\n\n\n\nPrecaution: Anaphylactoid reactions (mild influenza-like symptoms, \n\nbradycardia, tachycardia, bronchospasm, non-cardiac \n\npulmonary edema) have been reported with solutions \n\ncontaining hydroxyethyl starch. If a hypersensitivity \n\nreaction occurs, administration of the drug should be \n\ndiscontinued immediately and the appropriate treatment \n\nand supportive measures should be undertaken until \n\nsymptoms have resolved. \n\nFluid status and rate of infusion should be assessed \n\nregularly during treatment, especially in patients with \n\ncardiac insufficiency or severe kidney dysfunction.\n\nIn cases of severe dehydration, a crystalloid solution \n\nshould be given first. Generally, sufficient fluid \n\nshould be administered in order to avoid dehydration.\n\nCaution should be observed before administering \n\n(hydroxyethyl starch in sodium chloride \n\ninjection) to patients with severe liver disease or \n\nsevere bleeding disorders (e.g., severe cases of von \n\nWillebrandÂ´s disease).\n\n\nMode of action: \n\nPregnancy category: C\n\nInteraction: 
Poly (0-2-hydroxyethyl) starch 60g + Sodium Chloride	\n\n\tBeacon\tPlasmex IV Solution For Infusion (60 gm + 9 gm)/1000 ml  \n\tFresenius Kabi DeutschlandGmbH, Germany\tVoluven 	 Solution for Infusion  6% x 500ml bot  601.77\n\tOrion Infusion Ltd.\tPlasmasol Solution for infusion   \n\tIndication: Prophylaxis of Hypovolaemia and shock, Surgery (haemorrhagic shock), Injuries (traumatic shock), Burns, Therapeutic dilution of blood\n\nDose: Adult Dose Up to 50 mL of (hydroxyethyl starch in sodium chloride injection) per kg of body weight per day (equivalent to 3 g hydroxyethyl starch and 7.7 mEq sodium per kg of body weight). This dose is equivalent to 3500 mL of (hydroxyethyl starch in sodium chloride injection) for a 70 kg patient. \n\nPediatric Dose \nDosage in children should be adapted to the individual patient colloid needs, taking into account the disease state, as well as the hemodynamic and hydration status\n\nNewborns and infants\n\n<2 yr: Mean dose of 16 mL/kg IV\n\n2-12 years: Mean dose of 36 mL/kg IV\n\nGive initial 10-20 mL by slow IV infusion and monitor for anaphylactoid reaction\n\nContra-indication: Known hypersensitivity to hydroxyethyl starch fluid overload (hyperhydration) and especially in cases of pulmonary edema and congestive heart failure renal failure with oliguria or anuria not related to hypovolemia patients receiving dialysis treatment severe hypernatremia or severe hyperchloremia intracranial bleeding. \n\n\n\nSide effects: From the accumulated clinical development experience, expected adverse reactions after administration of (hydroxyethyl starch in sodium chloride injection) occurring in less than 10% of patients are as follows: Immune system disorders (Rare, > 0.01% to < 0.1%): anaphylactoid reactions (hypersensitivity, mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema). In the event of an intolerance reaction, the infusion should be discontinued immediately and the appropriate emergency medical treatment initiated. Skin and subcutaneous tissue disorders (Common, > 1 to < 10%, dose dependent): Prolonged administration of high dosages of hydroxyethyl starch may cause pruritus (itching) which is an undesirable effect observed with all hydroxyethyl starches. \n\n\n\nPrecaution: Anaphylactoid reactions (mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch. If a hypersensitivity reaction occurs, administration of the drug should be discontinued immediately and the appropriate treatment and supportive measures should be undertaken until symptoms have resolved. Fluid status and rate of infusion should be assessed regularly during treatment, especially in patients with cardiac insufficiency or severe kidney dysfunction. In cases of severe dehydration, a crystalloid solution should be given first. Generally, sufficient fluid should be administered in order to avoid dehydration. Caution should be observed before administering (hydroxyethyl starch in sodium chloride injection) to patients with severe liver disease or severe bleeding disorders (e.g., severe cases of von WillebrandÂ´s disease). \n\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Poly (O-2-hydroxyethyl) starch 100gm + Sodium Chlorride	\n\n\tFresenius Kabi DeutschlandGmbH, Germany\tHaes Steril 10% Infusion   10% x 500ml bot 744\n\tIndication: Hypovolaemia and shock, Surgery (haemorrhagic shock), Injuries (traumatic shock), Burns, Therapeutic dilution of blood\n\nDose: Adult Dose Up to 50 mL of (hydroxyethyl starch in sodium chloride injection) per kg of body weight per day (equivalent to 3 g hydroxyethyl starch and 7.7 mEq sodium per kg of body weight). This dose is equivalent to 3500 mL of (hydroxyethyl starch in sodium chloride injection) for a 70 kg patient. \n\nPediatric Dose \nDosage in children should be adapted to the individual patient colloid needs, taking into account the disease state, as well as the hemodynamic and hydration status\n\nNewborns and infants\n\n<2 yr: Mean dose of 16 mL/kg IV\n\n2-12 years: Mean dose of 36 mL/kg IV\n\nGive initial 10-20 mL by slow IV infusion and monitor for anaphylactoid reaction.\n\n\nContra-indication: Known hypersensitivity to hydroxyethyl starch fluid overload (hyperhydration) and especially in cases of pulmonary edema and congestive heart failure renal failure with oliguria or anuria not related to hypovolemia patients receiving dialysis treatment severe hypernatremia or severe hyperchloremia intracranial bleeding. \n\n\nSide effects: From the accumulated clinical development experience, expected adverse reactions after administration of (hydroxyethyl starch in sodium chloride injection) occurring in less than 10% of patients are as follows: Immune system disorders (Rare, > 0.01% to < 0.1%): anaphylactoid reactions (hypersensitivity, mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema). In the event of an intolerance reaction, the infusion should be discontinued immediately and the appropriate emergency medical treatment initiated. Skin and subcutaneous tissue disorders (Common, > 1 to < 10%, dose dependent): Prolonged administration of high dosages of hydroxyethyl starch may cause pruritus (itching) which is an undesirable effect observed with all hydroxyethyl starches. injection) group. \n\n\nPrecaution: Anaphylactoid reactions (mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch. If a hypersensitivity reaction occurs, administration of the drug should be discontinued immediately and the appropriate treatment and supportive measures should be undertaken until symptoms have resolved. Fluid status and rate of infusion should be assessed regularly during treatment, especially in patients with cardiac insufficiency or severe kidney dysfunction. In cases of severe dehydration, a crystalloid solution should be given first. Generally, sufficient fluid should be administered in order to avoid dehydration. Caution should be observed before administering (hydroxyethyl starch in sodium chloride injection) to patients with severe liver disease or severe bleeding disorders (e.g., severe cases of von WillebrandÂ´s disease). \n\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Polytar 1.0 %	\n\n\tSanofi Winthrop Industries,France\tPolyter Liquid 1.0% 1's pack \n\tIndication: Psoriasis, Eczema, Itchy, Flaking scalps, Seborrhoea, Dandruff\n\nDose: Scalp Psoriasis & Seborrhea\n\nApply to wet hair/scalp, lather for several minutes, then rinse thoroughly & repeat.\n\nApplication frequency depends on severity (two times/week to qDay) .\n\n\n\nContra-indication: Hypersensitivity\n\nSide effects:  Skin/scalp irritation or staining of skin/hair (especially in patients with blonde, bleached, dyed, or gray hair) may occur. If skin irritation develops or worsens, stop using this product and tell your doctor or pharmacist promptly.\n\nIf your doctor has directed you to use this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.\n\nLong-term use of this product can cause hair follicle problems (tar acne). Contact your doctor if you notice new skin bumps and/or acne in the treated area.\n\nA very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.\n\nThis is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.\n\nPrecaution:  Before using coal tar shampoo, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.\n\nThis medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: current severe flare-up of psoriasis.\n\nYour doctor may direct you to use another medication such as a steroid cream (for example, triamcinolone) before using this product.\n\nBefore using this medication, tell your doctor or pharmacist your medical history, especially of: skin conditions (such as psoriasis or seborrheic dermatitis) that cover a large area of the body.\n\nThis medication may make you more sensitive to the sun. Be sure to completely wash off the medication before going out into the sun. Avoid sun exposure, tanning booths, and sunlamps for at least 24 hours after using this medication unless your doctor directs you otherwise. Other medications may also increase your sun sensitivity. Ask your doctor or pharmacist for more details.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Polyvinyl Alcohol	\n\n\tIndication: Dry, Irritated eyes\n\nDose: Adult: Ophth As 0.5-1.4% soln w/ or w/o povidone: Instill 1-2 drops up to 3- 4 times/day when needed.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Mild stinging/burning/irritation in the eye; temporary blurred vision.\n\nPrecaution: Not to be used with soft contact lens.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Prednisolone Acetate + Sulfacetamide Sodium	\n\n\tIndication: Steroid-responsive inflammatory ocular conditions, Inflammatory conditions of the palpebral and bulbar conjunctiva, Cornea, Chronic anterior uveitis and corneal injury, Conjunctivitis;\n\nDose: Adult:\nInflammation/Infection\n\nAs eye drop: 1-2 drops 3-4 times or as required.\n\n\nContra-indication: Allergies to sulfa, glaucoma, Herpes, vaccinia, varicella, & other viral diseases of cornea or conjunctiva, mycobacterial infection of eye, fungal diseases of ocular structures, hypersensitivity to any ingredients.\n\nAfter uncomplicated removal of corneal foreign body. \n\nSide effects:  This medication may temporarily sting or burn your eyes for a minute or two when applied. Eye discomfort, dry eyes, tearing, itching, or redness may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.\n\nAdverse reactions have occurred with corticosteroid/antibacterial combination drugs which can be attributed to the corticosteroid component, the antibacterial component, or the combination.\n\nUse of this medication for prolonged or repeated periods may result in a new type of eye infection (e.g., viral, fungal). Do not use it for longer than prescribed. Contact your doctor if you notice new or worsening symptoms.\n\nTell your doctor immediately if any of these unlikely but serious side effects occur: vision changes, eye pain, staining of the eyes.\n\nA very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing, signs of infection (e.g., fever, persistent sore throat), easy bleeding/bruising, yellowing of the eyes/skin, dark urine.\n\nPrecaution: Use for short term only because of steroid concerns. Watch for hypersensitivity to sulfas & steroid side effects (superinfection, glaucoma, etc). The possibility of fungal infections of the cornea should be considered after prolonged corticosteroid dosing. Use with caution in patients with severe dry eye. \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Prednisolone Acetate  + Neomycin Sulphate E/E prep	\n\n\tRenata\tDeltasone-N E/E drop Eye/Ear Drops  5 ml drop \n\tIndication: Allergic and inflammatory conditions of the eye & ear.\n\nDose: Conjunctivitis\nAdult & Child:  Instill 1-2 drops into the affected eye(s) 2-4 times daily. \nOtic/Aural\nAllergic and inflammatory conditions of the ear\nAdult & Child:1-2 drops into the affected ear 3-4 times daily. \n\n\nContra-indication: Live vaccines; herpes simplex keratitis, systemic infections.\n\nSide effects: Ophthalmic: Raised IOP and reduced visual function.\nEar: Discomfort & pain in ear.\n\n\nPrecaution: Patients with hypothyroidism, cirrhosis, ulcerative colitis, CHF, convulsive disorders, thrombophlebitis, peptic ulcer, elderly. DM, hypertension, psychological disturbances, osteoporosis; pregnancy, lactation. Adrenal suppression and infection. May cause irreversible growth retardation, glaucoma, corneal perforation. Topical: Broken or infected skin. Not to be applied over large areas under occlusive dressings.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Urofollitropin	\n\n\tIndication: Female infertility, Hypogonadotrophic hypogonadism\n\nDose: Injection\nPolycystic ovarian syndrome\nAdult: Initially, 150 IU daily SC/IM for the first 5 days. Adjust subsequent dosing based on clinical monitoring (e.g. serum oestradiol levels and vaginal ultrasound). Dose adjustments should not be made more frequently than once every 2 days and be <75-150 units per adjustment. Max dose: 450 units daily and max course of treatment: 12 days. \n\nStop treatment when adequate response obtained as determined by oestrogen monitoring or ultrasonic visualisation of follicles. A single dose of chorionic gonadotrophin 5000 to 10 000 units is given to induce ovulation after 1-2 days. Urofollitropin treatment may be tried again in future cycles.\n\nFemale infertility\nAdult: Initially, 150 IU daily SC/IM for the first 5 days. Adjust subsequent dosing based on clinical monitoring (e.g. serum oestradiol levels and vaginal ultrasound). Dose adjustments should not be made more frequently than once every 2 days and be <75-150 units per adjustment. Max dose: 450 units daily and max course of treatment: 12 days. Stop treatment when adequate response obtained as determined by oestrogen monitoring or ultrasonic visualisation of follicles. A single dose of chorionic gonadotrophin 5000 to 10 000 units is given to induce ovulation after 1-2 days. Urofollitropin treatment may be tried again in future cycles.\n\nIn vitro fertilisation procedures or other assisted conception techniques\nAdult: In conjunction with other agents: 150-225 units of FSH daily SC/IM from day 2 or 3 of menstrual cycle. Alternatively, begin therapy with clomifene citrate and continue with urofollitropin; or urofollitropin may be given after gonadorelin analogue is given to suppress gonadotrophin release. Continue treatment until an adequate response is obtained and admin 5000 to 10 000 units of chorionic gonadotrophin 1-2 days after final injection of urofollitropin. Oocyte retrieval is performed 34-35 hr later.\n\nMale infertility\nAdult: In conjunction with chorionic gonadotrophin, 150 units of FSH SC/IM 3 times a wk, continue for at least 4 mth.\n\nContra-indication: Pregnancy, ovarian cysts or enlargement not due to polycystic ovary syndrome, primary ovarian failure, organic intracranial lesion e.g. pituitary tumour, uncontrolled thyroid and adrenal dysfunction, presence of any cause of infertility other than anovulation, abnormal bleeding of undetermined origin.\n\nSide effects: Nausea, vomiting, joint pain, ovarian hyperstimulation syndrome, adnexal torsion, mild to moderate ovarian enlargement, abdominal pain, ovarian cysts, local reaction at inj site, headaches, haemoperitoneum, benign and malignant ovarian neoplasms, ascites, pleural effusion, hypovolaemia, thromboembolic disorders. Weight gain, acne and gynaecomastia in men.\nPotentially Fatal: Ovarian cysts rupture, intraperitoneal haemorrhage.\n\nPrecaution: May result in multiple pregnancies. Abnormal genital bleeding, hormone sensitive malignancies, ovarian cysts not caused by polycystic ovary syndrome. Exclude and treat other causes of infertility e.g. pituitary or hypothalamic lesions, adrenal or thyroid disorders and hyperprolactinaemia.\n\nMode of action: Increased risk of ovarian hyperstimulation syndrome with drugs with luteinising hormone activity.\n\nPregnancy category: X\n\nInteraction: Increased risk of ovarian hyperstimulation syndrome with drugs with luteinising hormone activity.
Pneumococcal polysaccharide unconjugated Vaccine	\n\n\tSanofi Pasteur S A ,France\tPneumo-23 Injection    0.5 ml prefilled  syringe  x 1's pack 982.76\n\tIndication: Prevention of pneumococcal disease\n\nDose: Pneumococcal polysaccharide vaccine (PPSV23) is recommended for all adults 65 years or older. People 2 years through 64 years of age who are at high risk of pneumococcal disease (e.g., those with sickle cell disease, HIV infection, or other immunocompromising conditions) should also receive PPSV23.\n\nPrimary Immunization: One 0.5 mL inj is sufficient to provide protection against the pneumococcal serotypes contained in the vaccine.\n\nRevaccination: One 0.5 mL inj must not be given within 5 years except in very high-risk subjects or patients under immunosuppressive treatment.\n\nAdministered intramuscularly or subcutaneously only.\n\n\n\nContra-indication: A known allergy to one of the components of the vaccine. Fever or acute disease or a relapse of a chronic disease: It is preferable to postpone vaccination. Vaccination is not recommended for subjects who have been vaccinated within the previous 3 years, unless indicated otherwise. A confirmed or suspected episode of pneumococcal infection is not a contraindication and vaccination should be considered according to the underlying risk status.\n\nSide effects: Local Reactions at the Injection Site: Pain, erythema (redness), induration and oedema (swelling). These reactions are mild and transient. Rare reactions eg, Arthus phenomenon (severe local reactions) are reversible without after-effects; they mainly occur in subjects with high initial levels of pneumococcal antibody. Moderate and transient hyperthermia (fever) sometimes >39Â°C which generally occurs very shortly after vaccination and resolves within 24 hrs.\nOther General Reactions: Adenopathy (inflammation of the lymph nodes), rashes, arthralgia (pain in the joints) and allergic reactions [urticaria, Quincke'soedema (type of urticaria with sudden swelling of the face and neck), anaphylactoid reactions (severe allergic reaction)], headache, muscle pain, malaise, and fatigue have exceptionally been reported.\n\nPrecaution:  Use in pregnancy: It should only be used during pregnancy on medical advice.\n\nMode of action: Reduce immune response to Zostavax. Immunosuppressives.\n\nPregnancy category: C\n\nInteraction: Reduce immune response to Zostavax. Immunosuppressives.
Purified Soybean Oil	\n\n\tIndication: Parenteral fat emulsions, essential fatty acid deficiency, Parenteral nutrition.\n\nDose: 1g triglycerides corresponds to 10 ml Intralipid 10%.\n\nAdults. The recommended maximum dosage is 3 g triglycerides/kg body weight/day. Within this upper limit, Intralipid can be given to contribute up to 70% of the energy requirements, also in patients with highly increased energy requirements. The infusion rate for Intralipid 10% should not exceed 500 ml in 5 hours.\n\nNeonates and infants. The recommended dosage range in neonates and infants is 0.5-4 g triglycerides/ kg bw/day. The rate of infusion should not exceed 0.17 g triglycerides/kg bw/hour (4 g in 24 hours). In prematures and low birthweight neonates, Intralipid should preferably be infused continuously over 24 hours. The initial dosage should be 0.5-1 g/kg bw/day followed by a successive increase by 0.5-1 g/kg bw/day up to 2g/kg bw/day. Only with close monitoring of serum triglyceride concentration, liver tests and oxygen saturation may the dosage be increased to 4 g/kg bw/day. The rates given are maximum rates and no attempt should be made to exceed these in order to compensate for missed doses.\n\nContra-indication: Intralipid is contraindicated in patients with acute shock and in patients with severe hyperlipemia. Severe liver insufficiency. Hemophagocytotic syndrome. Hypersensitivity to egg-, soya- or peanut protein or to any of the active substances or excipients.\n\nSide effects: Intralipid infusion may cause a rise in body temperature and, less frequently, shivering, chills and nausea/vomiting (incidence<1%).\n\nPrecaution: Intralipid should be given with caution in conditions of impaired lipid metabolism as in renal insufficiency, uncompensated diabetes mellitus, pancreatitis, impaired liver function, hypothyroidism (if hypertri-glyceridemic) and sepsis. If Intralipid is given to patients with these conditions, close monitoring of the serum triglyceride concentration is obligatory.\n\nThis medicinal product contains soya-bean oil and egg phospholipids, which may rarely cause allergic reactions. Cross allergic reactions have been observed between soybean and peanut.\n\nIntralipid should be given with caution to neonates and prematures with hyperbilirubinemia and cases with suspected pulmonary hypertension. In neonates, particularly prematures on long term parenteral nutrition, platelet count, liver tests and serum triglyceride concentration should be monitored.\n\nIntralipid may interfere with certain laboratory measurements (bilirubin, lactate dehydrogenase, oxygen saturation, Hb etc) if blood is sampled before fat has been adequately cleared from the blood stream. Fat is cleared after a fat free interval of 5-6 hours in most patients.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Tetanus toxoid (Absorbed Tetanus) Vaccine	\n\n\tIncepta\tVaxitet Injection  40 i.u / 0.5ml 1's pack/10 ampoule pack 80/600\n\tPopular\tTT vax Injection  40 i.u / 0.5ml 5 amps pack 500\n\tPopular\tTTvax Injection  0.5ml \n\tNovartis Pharma Ag. Germany\tTetanol Pur Injection 40IU/0.5ml 1's pack 280\n\tSanofi Pasteur Lyon, France\tTetavax Injection 0.5ml 20 amps / 1 amps pack 3596.80 / 240\n\tIndication: Active immunisation against tetanus, Postexposure prophylaxis of tetanus\n\nDose: Primary immunization for persons 7 years of age and older: A series of three doses of 0.5 ml each, of adsorbed tetanus vaccine should be given intramuscularly; First dose: At appropriate date, Second dose: 4 to 8 weeks after the first dose, Third dose: 6 to 12 months after the second dose.\n\nChildren older than 7 years who did not complete primary immunization series (e.g., previously received only two doses of DTaP or DTP) need to receive only one dose of tetanus toxoid adsorbed vaccine to complete the primary series of tetanus.\nInterruption of the recommended schedule with a delay between doses does not interfere with the final immunity achieved with adsorbed tetanus vaccine. There is no need to start the series over again, regardless of the time elapsed between doses.\n\nRoutine booster injections: To maintain adequate protection, a booster dose of 0.5 ml of adsorbed tetanus vaccine every 10 years thereafter is recommended.\n\nVaccination of injured persons:\nClean and minor wound: \nâ¢	If primary immunization confirmed and receiving booster dose within previous 5 years, no need of additional vaccine.\nâ¢	If primary immunization confirmed and receiving booster dose more than previous 5 years, 1 dose of 0.5 ml required.\n\nAll other dirty wounds (contaminated with feces, soil, and saliva): \nâ¢	If primary immunization confirmed and receiving booster dose within previous 5 years, 1 dose of 0.5 ml required.\nâ¢	If primary immunization confirmed and receiving booster dose more than previous 5 years, 1 dose of 0.5 ml along with tetanus immunoglobulin required.\n\nIf a person has no previous vaccination or uncertain, the primary series of 3 doses of 0.5ml adsorbed tetanus vaccine should be given along with tetanus immunoglobulin with 1st dose.\nProtection of neonatal tetanus\nFor prevention of neonatal tetanus, adsorbed tetanus vaccine is recommended for immunization of women of childbearing age.\n \nFor pregnant woman who have not had previous immunization, 2 doses of tetanus toxoid at four weeks interval preferably during the last two trimester or at least 2 weeks before delivery should be given during pregnancy so that protective antibody would be transferred to the infant in order to prevent neonatal tetanus. e.g. 1 dose of 0.5 ml at 6th month of pregnancy and 1 dose of 0.5 ml at 7th month of pregnancy.\n\nPregnant woman who have completed the course of tetanus, next 10 years no need of additional dose during pregnancy. Thereafter a single booster dose would be sufficient to extend immunity.\n\n\nContra-indication: It is a contraindication to use this or any other related vaccine after a serious adverse event temporally associated with a previous dose including an anaphylactic reaction. A history of systemic allergic or neurologic reactions following a previous dose of Tetanus Toxoid is an absolute contraindication for further use. \n\nIf a contraindication to using tetanus toxoid -containing preparations exists in a person who has not completed a primary immunizing course of tetanus toxoid and other than a clean, minor wound is sustained; only passive immunization should be given using TIG (Human). \n\nElective immunization should be deferred during the course of any febrile illness or acute infection. A minor afebrile illness such as a mild upper respiratory infection should not preclude immunization. Elective immunization procedures should be deferred during an outbreak of poliomyelitis. \n\n\nSide effects: Mild inj site reactions eg transient swelling, rash, fever, malaise, tiredness, nausea, vomiting, arthralgias, pruritus, dizziness.Potentially Fatal: Anaphylactic reactions. \n\nPrecaution: Do not administer IV. Use subcutaneous route in bleeding disorders. Withhold vaccination in moderate or severe febrile illness. Pregnancy, lactation, history of Guillian-Barre syndrome.\n\nMode of action: Decreased immunologic response with concurrent immunosuppressants. Neutralisation of tetanus immune globulin and tetanus toxoid adsorbed if not given at different sites using different syringes.\n\nPregnancy category: C\n\nInteraction: Decreased immunologic response with concurrent immunosuppressants. Neutralisation of tetanus immune globulin and tetanus toxoid adsorbed if not given at different sites using different syringes.
Typhoid polysaccharide Vaccine	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tTypherix Injection 0.5 ml 	 1's pack 394\n\tIncepta\tVaxphoid Injection 25 Âµg/0.5 ml	 1's pack 300\n\tGlaxo SmithKline Biological S.A.,Belgium\tTypherix Injection 25ug/0.5ml  0.5 ml prefilled  syringe    394\n\tSanofi Pasteur S A ,France\tTyphim VI Injection 0.025mg  0.5 ml prefilled  syringe  x 1's pack 444.17\n\tIndication: Prevention of typhoid, Active immunisation against typhoid fever caused by Salmonella typhi.\n\n\nDose: Intramuscular\nActive immunisation against typhoid fever caused by Salmonella typhi\nAdult:  Initial: 0.5 ml, to be given at least 2 wk before expected exposure. Booster immunisation: Repeat dose every 3 yr if exposure continues.\n\nChild: >2 yr: Initial: 0.5 ml, to be given at least 2 wk before expected exposure. Booster immunisation: Repeat dose every 3 yr if exposure continues.\n\nElderly: Initial: 0.5 ml, to be given at least 2 wk before expected exposure. Booster immunisation: Repeat dose every 3 yr if exposure continues.\n\nContra-indication: The vaccine protects against typhoid fever caused by Salmonella typhi. Protection is not conferred against paratyphoid fever or illness caused by non-invasive Salmonella. Typhoid vaccine should not be administered to subjects with known hypersensitivity to any component of the vaccine or to subjects having shown signs of hypersensitivity after previous Typhoid vaccine administration, or after any other vaccine containing Vi polysaccharide Salmonella typhi antigens. \nIt may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate response may not be achieved. The administration of Typhoid vaccine should be postponed in subjects suffering from acute severe febrile illness.\n\n\nSide effects: Most recepients of Typhoid vaccine experience some reactions upon vaccination. These are generally moderate and short in duration. They mainly consist of local reactions at the injection site (erythema, induration and tenderness). Systemic reactions (malaise, headache, diarrhea, vomiting, myalgia and elevated temperature) are reported less commonly. In very rare cases allergic type reactions (pruritus, rash, urticaria) may be observed.\n\nPrecaution: Not for treatment of typhoid fever. Vaccination may not provide full proetction thus, travellers should be advised to take all necessary precautions to avoid contact or ingestion of potentially contaminated food or water sources. IM admin: Caution when used in patients with a history of bleeding disorders, patients on anticoagulant treatment or severely immunocompromised patients. Pregnancy, lactation.\n\nMode of action: Concurrent use with antibiotics or immunoglobulins may reduce the efficacy of typhoid vaccine. Mefloquine may increase the efficacy of typhoid vaccine. May reduce the diagnostic effect of tuberculin tests.\nPotentially Fatal: Concurrent use with immunosuppressants may increase the adverse effects of live vaccines.\n\nPregnancy category: C\n\nInteraction: Concurrent use with antibiotics or immunoglobulins may reduce the efficacy of typhoid vaccine. Mefloquine may increase the efficacy of typhoid vaccine. May reduce the diagnostic effect of tuberculin tests.\nPotentially Fatal: Concurrent use with immunosuppressants may increase the adverse effects of live vaccines.
Rabies Vaccine (Human) BP	\n\n\tIncepta\tRabix-VC Injection  2.5 IU/ml 1's  500\n\tRenata\tRabipur Injection 2.5IU 1 ml vial 640\n\tSanofi Pasteur S A ,France\tVerorab Injection  2.5 IU/0.5ml  1 vial + diluent 648.69\n\tIndication: To prevent Rabies virus\n\nDose: Adult: 1 ml for children and adults:\n\n a) Pre-exposure immunization Primary-vaccination: According to the WHO recommendations 1 injection by the intramuscular route on days D0, D7, D21 or D28, followed by a booster dose one year later. Boosters Thereafter, one injection every 5 years or when the titre is found to be less than 0.5 I.U./ml. \n\nb) Post-exposure treatment Intramuscular schedule: \nNon-vaccinated individuals: Treatment consists of 5 injections. Intramuscular injections to be given on Day 0, D3, D7, D14 and D28 subsequent to contact with an animal confirmed or suspected of being rabid. In case of severe (WHO category 3) wounds, immunoglobulin should be administered as soon as possible. \n\nFully vaccinated individuals: If vaccine administered in less than 5 years of exposure (cell culture rabies vaccine): 2 injections on D0, D3. If vaccine administered in more than 5 years of exposure or incomplete vaccination: 5 injections on D0, D3, D7, D14 and D28 with administration of immunoglobulin if required. Post exposure vaccination must be administered on the basis of severity under medical supervision.\n\nIntradermal schedules: One intradermal (ID) dose is comprised of 0.1 ml.\nWHO Modified Thai Red Cross (2-2-2-0-2) schedule: Day 0: 2 injections each of 0.1 ml at separate sites, Day 3: 2 injections each of 0.1 ml at separate sites, Day 7: 2 injections each of 0.1 ml at separate sites, Day 28: 2 injections each of 0.1 ml at separate sites.\n\nTo reconstitute the vaccine, transfer content of supplied diluent into the vial containing freeze-dried preparation. Do not shake. After reconstitution the solution should be homogeneous, clear and free from any particles. Vaccine must be injected immediately after reconstitution and the syringe should be destroyed after use. \n\n\nContra-indication: Pre-exposure\nSevere fever, febrile infection, acute disease, progressive chronic diseases. Known hypersensitivity reactions to rabies vaccine or any of its components.\n\nPost-exposure\nNo contraindication to post-exposure treatment, because rabies is lethal disease, any  contraindication to exposure, treatment should be considered carefully before disqualifying an individual for anti-rabies treatment.\n\nSide effects: Minor local  reactions like pain, erythema, oedema, pruritus and induration at the injection site and lasting to 24-48 hours. Moderate fever, shivering, fainting, asthenia, dizziness, respiratory manifestations (dyspnoea, wheezing), fever, abdominal pain, vomiting and allergic skin reactions (urticaria, rash, itching). \n\nPrecaution:  Possibility of immune complex reaction 2-21 days after booster doses of HDCV (Human diploid cell cultures rabies vaccine); symptoms include arthralgia, arthritis, nausea, malaise, angioedema, fever and vomiting. Caution when used in patients with bleeding disorders, patients on anticoagulant treatment, severely immunocompromised patients. Not to be used in patients with confirmed diagnosis of rabies. Postexposure prophylaxis may be started regardless of the length of time from likely exposure, as long as clinical signs of rabies infection are not present. Pregnancy, lactation.\n\nMode of action: Concurrent use with immunosuppressants may reduce the efficacy of vaccines.\n\nPregnancy category: C\n\nInteraction: Concurrent use with immunosuppressants may reduce the efficacy of vaccines.
Racepinephrine HCl	\n\n\tIndication: Asthma, Stridor, Wheezing\n\nDose: Do not use more than directed    The ingredient is used in an aqueous solution at a concentration equivalent to 1 percent epinephrine    For use in a Hand-held Bulb Nebulizer:    Racepinephrine inhalation solution does not require dilution    For use in a Jet Nebulizer:    One 0.5 mL vial should be diluted to a volume of 3 to 5 mL with sterile 0.9% sodium chloride solution?    Adults and children 4 years of age and over:        Hand-held Bulb Nebulizer: 1 to 3 inhalations not more often than every 3 hours        Jet Nebulizer: Administer for fifteen minutes every 3 to 4 hours?    Do not use more than 12 inhalations in 24 hours. The use of this product by children should be supervised by an adult.?    Children under 4 years of age: ask a doctor. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Cardiovascular\n\nCardiovascular side effects have included elevations of heart rate and blood pressure. In smaller doses, racepinephrine has caused peripheral coronary arterial vasodilation, but in larger doses, racepinephrine has caused diffuse vasoconstriction. This has caused increased peripheral vascular resistance, which was important in patients with coronary artery disease (worsened myocardial ischemia/angina) or hypertension (risk of emergent hypertension/stroke).\n\nArrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease. Rapid rises in blood pressure have produced cerebral hemorrhage, particularly in elderly patients with cardiovascular disease. Angina may occur in patients with coronary artery disease.\nGastrointestinal\n\nGastrointestinal side effects have included nausea and vomiting.\nNervous system\n\nNervous system side effects have included fear, agitation, anxiety, tenseness, restlessness, headache, tremor, dizziness, lightheadedness, nervousness, sleeplessness, excitability, weakness, and increased parkinsonian tremors.\nPsychiatric\n\nPsychiatric side effects have included agitation, disorientation, impaired memory, aggressive or assautive behavior, hallucinations, and psychosis.\n\nPrecaution:  Asthma alert: Because asthma may be life threatening, see a doctor if you:\n\n    Are not better in 20 minutes\n    Get worse\n    Need more than 12 inhalations in 24 hours\n    Use more than 9 inhalations in 24 hours for 3 or more days a week\n    Have more than 2 asthma attacks in a week\n\nThese may be signs that your asthma is getting worse.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ranibizumab	\n\n\tNovartis Pharma AG, Switzerland\tLucentis Injection 10mg/ml 0.3 ml (3.0 mg ) vial x 1's pack 100000\n\tIndication: Wet ARMD, Central retinal vein occlusion, Diabetic macular edema\n\nDose: Neovascular (Wet) Age-Related Macular Degeneration (AMD):0.5 mg (0.05 mL of 10 mg/mL) administered by intravitreal injection once a month (approximately every 28 days).\n\nUsual Adult Dose for Macular EdemaMacular Edema Following Retinal Vein Occlusion (RVO):0.5 mg (0.05 mL of 10 mg/mL) administered by intravitreal injection once a month (approximately every 28 days).\n\nDiabetic Macular Edema (DME):0.3 mg (0.05 mL of 6 mg/mL) administer by intravitreal injection once a month (approximately every 28 days).\n\nContra-indication: Hypersensitivity.\n\nSide effects: Along with its needed effects, ranibizumab ophthalmic may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.\n\nCheck with your doctor or nurse immediately if any of the following side effects occur while taking ranibizumab ophthalmic:\nMore common\n\n    Blindness\n    bloody eye\n    blurred vision or loss of vision\n    decreased vision or other changes in vision\n    disturbed color perception\n    dizziness\n    double vision\n    dry eye\n    eye pain\n    fainting\n    feeling of having something in the eye\n    halos around lights\n    headache\n    night blindness\n    overbright appearance of lights\n    pain or tenderness around the eyes and cheekbones\n    red, sore eyes\n    redness of the white part of the eyes or inside of the eyelids\n    redness, swelling, or itching of the eyelid\n    seeing flashes or sparks of light\n    seeing floating spots before the eyes, or a veil or curtain appearing across part of vision\n    sensitivity of the eye to light\n    tearing of the eyes\n    tunnel vision\n    watering of the eyes\n\nLess common\n\n    Body aches or pain\n    chest pain\n    chills\n    cough\n    difficulty with breathing\n    dry mouth\n    fainting\n    fast, slow, or irregular heartbeat\n    general feeling of discomfort or illness\n    head congestion\n    hoarseness, loss of voice, or other voice changes\n    loss of consciousness\n    muscle aches and pains\n    nasal congestion\n    pain in the chest, groin, or legs, especially the calves\n    painful blisters on the trunk of the body\n    pale skin\n    runny nose\n    severe, sudden headache\n    shivering\n    shortness of breath\n    slurred speech\n    sneezing\n    sore throat\n    sudden loss of coordination\n    sudden, severe weakness or numbness in the arm or leg\n    sudden, unexplained shortness of breath\n    sweating\n    tightness in the chest\n    trouble sleeping\n    troubled breathing\n    unexplained weight loss\n    unusual tiredness or weakness\n\nSome side effects of ranibizumab ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:\nMore common\n\n    Back pain\n    difficulty having a bowel movement (stool)\n    difficulty with moving\n    muscle stiffness\n    swelling or redness in the joints\n\n\nPrecaution: Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection, and patients should be instructed to report any symptoms of endophthalmitis (red eyes, sensitivity to light, pain, or vision changes).\n\nIncreases in intraocular pressure have been noted both pre- and post-injection (at 60 minutes), patients should be monitored prior to and 30 minutes following the intravitreal injection.\n\nSafety and effectiveness have not been established in pediatric patients (less than 18 years old).\n\n\nMode of action: No formal interaction studies have been performed.\nFor the adjunctive use of verteporfin photodynamic therapy (PDT) and Lucentis in wet age-related macular edema (AMD) and pathological myopia (PM) (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).\n\nFor the adjunctive use of laser photocoagulation and Lucentis in diabetic macular edema (DME) and branch retinal vein occlusion (BRVO) (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions and Dosage & Administration).\n\nIncompatibilities: In the absence of compatibility studies, Lucentis must not be mixed with other medicinal products.\n\nPregnancy category: C\n\nInteraction: No formal interaction studies have been performed.\nFor the adjunctive use of verteporfin photodynamic therapy (PDT) and Lucentis in wet age-related macular edema (AMD) and pathological myopia (PM) (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).\n\nFor the adjunctive use of laser photocoagulation and Lucentis in diabetic macular edema (DME) and branch retinal vein occlusion (BRVO) (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions and Dosage & Administration).\n\nIncompatibilities: In the absence of compatibility studies, Lucentis must not be mixed with other medicinal products.
Recombinant Somatropin	\n\n\tIndication: Children's growth disorders, growth hormone deficiency,Turner syndrome, chronic renal failure, Prader-Willi syndrome, intrauterine growth retardation,  severe idiopathic short stature\n\nDose: Pediatric Growth Hormone Deficiency (GHD)\n\nGenerally, a dosage of 0.16 to 0.24 mg/kg body weight /week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.\n\nPrader-Willi Syndrome (PWS)\n\nGenerally, a dosage of 0.24 mg/kg body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.\n\nSmall for Gestational Age (SGA)\n\nGenerally, a dosage of up to 0.48 mg/kg body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.\n\nIdiopathic Short Stature (ISS)\n\nGenerally, a dose up to 0.47 mg/kg of body weight/week is recommended. The weekly dose should be divided over 6 or 7 days of subcutaneous injections.\nDosing of Adult Patients\nAdult Growth Hormone Deficiency (GHD)\n\nBased on the weight-based dosing utilized in clinical studies with another somatropin product, the recommended dosage at the start of therapy is not more than 0.04 mg/kg/week given as a daily subcutaneous injection. The dose may be increased at 4- to 8-week intervals according to individual patient requirements to not more than 0.08 mg/kg/week. Clinical response, side effects, and determination of age- and gender-adjusted serum IGF-I levels may be used as guidance in dose titration.\n\nAlternatively, taking into account recent literature, a starting dose of approximately 0.2 mg/day (range, 0.15-0.30 mg/day) may be used without consideration of body weight. This dose can be increased gradually every 1-2 months by increments of approximately 0.1 to 0.2 mg/day, according to individual patient requirements based on the clinical response and serum IGF-I concentrations. During therapy, the dose should be decreased if required by the occurrence of adverse events and/or serum IGF-I levels above the age- and gender-specific normal range. Maintenance dosages vary considerably from person to person.\n\nA lower starting dose and smaller dose increments should be considered for older patients, who are more prone to the adverse effects of somatropin than younger individuals. In addition, obese individuals are more likely to manifest adverse effects when treated with a weight-based regimen. In order to reach the defined treatment goal, estrogen-replete women may need higher doses than men. Oral estrogen administration may increase the dose requirements in women.\n\nContra-indication:     Acute Critical Illness\n    Children with Prader-Willi Syndrome who are severely obese or have severe respiratory impairmentâreports of sudden death\n    Active Malignancy\n    Active Proliferative or Severe Non-Proliferative Diabetic Retinopathy\n    Children with closed epiphyses\n    Known hypersensitivity to somatropin or excipients\n\n\nSide effects: Injection site reactions/rashes and lipoatrophy and headaches.\nSudden death in pediatric patients with Prader-Willi Syndrome with risk factors including severe obesity, history of upper airway obstruction or sleep apnea and unidentified respiratory infection\nIntracranial tumors, in particular meningiomas, in teenagers/young adults treated with radiation to the head as children for a first neoplasm and somatropin.\nGlucose intolerance including impaired glucose tolerance/impaired fasting glucose as well as overt diabetes mellitus.\nIntracranial hypertension.\nFluid retention manifested by edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel syndrome/paraesthesias.\nPancreatitis.\n\nPrecaution:     Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk\n    Prader-Willi Syndrome in children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment. Discontinue treatment if these signs occur\n    Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropinâin particular meningiomas in patients treated with radiation to the head for their first neoplasm\n    Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked. Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment\n    Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction\n    Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome, especially in adults): May occur frequently. Reduce dose as necessary\n    Hypopituitarism: Closely monitor other hormone replacement therapies\n    Hypothyroidism: May first become evident or worsen\n    Slipped Capital Femoral Epiphysis: May develop. Evaluate children with the onset of a limp or hip/knee pain\n    Progression of Preexisting Scoliosis: May develop\n    Otitis Media and Cardiovascular Disorders in Turner syndrome: Patients with Turner syndrome should be evaluated for otitis media and other ear disorders and monitored for cardiovascular disorders\n    Pancreatitis: Consider pancreatitis in patients with persistent severe abdominal pain, especially children\n    Adverse events and death associated with benzyl alcohol: Formulations containing benzyl alcohol (5 mg/1.5 mL Omnitrope Cartridges and the Bacteriostatic Water for Injection diluent for the O\n\nMode of action: Concomitant corticosteroid therapy may inhibit the effect of somatropin. Gonadotropins, oestrogens, androgens & anabolic agents.\n\nPregnancy category: B\n\nInteraction: Concomitant corticosteroid therapy may inhibit the effect of somatropin. Gonadotropins, oestrogens, androgens & anabolic agents.
Recombinent Human Luteinising Hormone (Lutropin alpha)	\n\n\tIndication: Female infertility,  (LH) and FSH deficiency\n\nDose: Treatment should be tailored to the individual patient's response as assessed by measuring follicle size by ultrasound and estrogen response. A recommended regimen commences at lutropinalpha 75 IU (ie, 1 vial of Luveris) daily with FSH 75-150 IU.\n\nIf an FSH, dose increase is deemed appropriate; dose adaptation should preferably be after 7- to 14-day intervals and preferably by 37.5-75 IU increments. It may be acceptable to extend the duration of stimulation in any 1 cycle to up to 5 weeks.\n\nWhen an optimal response is obtained, a single injection of 5000-10,000 IU hCG should be administered 24-48 hrs after the last Luveris and FSH injections. The patient is recommended to have coitus on the day of, and on the day following, hCG administration.\n\nContra-indication: Hypersensitivity to gonadotropins or to any of the excipients of Luveris.\nOvarian, uterine or mammary carcinoma; active, untreated tumors of the hypothalamus and pituitary gland; ovarian enlargement or cyst not due to polycystic ovarian disease; gynecological hemorrhages of unknown origin.\nUse in pregnancy & lactationThis should not be administered during pregnancy and lactation.\n\nSide effects: General Description: Lutropin alpha is used for the stimulation of follicular development in association with follitropin alpha. In this context, it is difficult to attribute adverse reactions to any one of the substances used.\nThere is considerable post-marketing safety experience with human luteinizing hormone (hLH)-containing medicinal products of urinary origin. The safety profile of Luveris is expected to be very similar to that of urine-derived hLH, with the exception of hypersensitivity reactions and application site disorders.\nIn a clinical trial, mild and moderate injection site reactions (bruising, pain, redness, itching or swelling) were reported in 7.4% and 0.9% of the injections, respectively. No severe injection site reactions were reported. To date, no systemic allergic reactions have been reported following Luveris administration.\nOvarian hyperstimulation syndrome was observed in <6% of patients treated with Luveris. No severe OHSS was reported.\nEctopic pregnancy may also occur, especially in women with a history of prior tubal disease.\n\nPrecaution: Before starting treatment, the couple's infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated.\nIt should not be used when an effective response cannot be obtained eg, ovarian failure, malformation of the sexual organs incompatible with pregnancy or fibroid tumors of the uterus incompatible with pregnancy.\nIn addition, patients should be evaluated for hypothyroidism, adrenocortical deficiency and hyperprolactinemia and, pituitary or hypothalmic tumors, and appropriate specific treatment given.\nPatients undergoing follicular growth stimulation are at increased risk of developing hyperstimulation in view of possible excessive oestrogen response and multiple follicular development.\nOvarian hyperstimulation syndrome can become a serious medical event characterised by large ovarian cysts which are prone to rupture. Excessive ovarian response seldom gives rise to significant hyperstimulation unless hCG is administered to induce ovulation. It is therefore prudent to withhold hCG in such cases and advise the patient to refrain from coitus or use barrier methods for at least 4 days.\nCareful monitoring of ovarian response, based on ultrasound is recommended prior to and during stimulation therapy, especially in patients with polycystic ovaries.\nIn patients undergoing induction of ovulation, the incidence of multiple pregnancies and births is increased compared with natural conception.\n\nMode of action: Luveris should not be administered as a mixture with other medicinal products, in the same injection, except follitropin ? for which studies have shown that co-administration does not significantly alter the activity, stability, pharmacokinetic nor pharmacodynamic properties of the active substances.\n\nIncompatibilities: Luveris must not be mixed with other medicinal products except follitropin ?.\n\nPregnancy category: Not Classified\n\nInteraction: Luveris should not be administered as a mixture with other medicinal products, in the same injection, except follitropin ? for which studies have shown that co-administration does not significantly alter the activity, stability, pharmacokinetic nor pharmacodynamic properties of the active substances.\n\nIncompatibilities: Luveris must not be mixed with other medicinal products except follitropin ?.
Risedronate Sodium	\n\n\tGeneral\tSedron-35 TAB dr 35mg 10's pack 350\n\tGeneral\tSedron TAB dr 5mg 20's pack 160.60\n\tOpsonin Pharma\tRisonet TAB dr 35mg  \n\tOpsonin Pharma\tRisonet TAB dr 150mg  \n\tSquare\tRisedon TAB dr 150mg 1's pack 120\n\tUnimed & Unihealth Manufacturers Ltd.\tSalost TAB dr 150mg 1's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tSalost TAB dr 35mg 4's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tSalost TAB dr 5mg 28's pack 224\n\tProcter & Gumble, Germany\tActonel TAB dr 5mg 28's pack 1618.79\n\tIndication: Paget's disease of bone,  postmenopausal or corticosteroid-induced osteoporosis, increase bone mass in men with osteoporosis\n\nDose: Adult: PO Paget's disease of bone 30 mg once daily for 2 mth, repeat if needed after 2 mth interval. \n\nTreatment or prevention of postmenopausal or corticosteroid-induced osteoporosis 5 mg/day. \n\nFor postmenopausal osteoporosis, 35 mg once wkly may be given. Increase bone mass in men w/ osteoporosis 35 mg once wkly.\n\nIncrease bone mass in men with osteoporosis\nAdult: 35 mg once wkly.\n\nRenal impairment:\nCrCl (ml/min)	\n<30 	Avoid use.\n\nContra-indication: Acute upper GI inflammation, pregnancy, hypocalcaemia and CrCl <30 ml/min.\n\nSide effects: Electrolyte disturbances; GI disturbances; musculoskeletal pain; headache; hypersensitivity reactions; blood disorders; liver enzyme disturbances. Bone, joint and/or muscle pain.\n\nPrecaution: Correct hypocalcaemia prior to therapy. Monitor hepatic and renal function and WBC. Renal impairment; inability to remain in an upright position for at least 30 min after oral intake.\n\nMode of action: Co-admin with calcium, antacids or oral medications containing divalent cations may affect the absorption of risedronate. May have additive calcium lowering effects when used with aminoglycosides.\n\nPregnancy category: C\n\nInteraction: Co-admin with calcium, antacids or oral medications containing divalent cations may affect the absorption of risedronate. May have additive calcium lowering effects when used with aminoglycosides.
Ritonavir	\n\n\tIndication: HIV infection, AIDS\n\nDose: Adult: PO HIV infection Combined w/ other antiretrovirals: Initial: 300 mg twice daily for 1 day. May increase gradually over a period of up to 14 days to 600 mg twice daily. As a pharmacokinetic enhancer 100-200 mg 1-2 times/day.\n\nContra-indication: Hypersensitivity; lactation; severe hepatic impairment.\n\nSide effects: Syncope, orthostatic hypotension; dry mouth, mouth ulcers, throat irritation, cough; dyspepsia, nausea, vomiting, diarrhoea, taste disturbance, seizures, anxiety, sweating, fever, asthenia, fatigue, headache, dizziness, paraesthesia, myalgia, skin rashes, pruritus, renal insufficiency, anaemia, raised WBC, raised prothrombin time, lipodystrophy, pancreatitis, electrolyte imbalance.\nPotentially Fatal: Hypersensitivity, anaphylaxis and Stevens-Johnson syndrome.\n\nPrecaution:  	Pregnancy; child; hepatic impairment; DM; haemophilia; pancreatitis. Monitor glucose, lipid, uric acid and blood counts. Ensure adequate hydration to reduce risk of nephrolithiasis. Discontinue treatment if patient develops haemolytic anaemia.\n\nMode of action: Decreased plasma conc with phenobarbital, carbamazepine, dexamethasone, phenytoin, rifabutin and rifampicn. Increased plasma conc of certain drugs highly metabolized by CYP3A. May increase serum levels of sildenafil.\nPotentially Fatal: Avoid concurrent admin of oral solution (contains alcohol) with disulfiram or metronidazole. Increased risk of myopathy when used with simvastatin or lovastatin. Concurrent use with alfuzosin may lead to serious hypotension. Increased risk of cardiac arrhythmias when used with amiodarone, cisapride, propafenone, quinidine, flecainide and pimozide. Risk of acute ergot toxicity when used with ergot derivatives. Increased risk of serious adverse reactions when used with midazolam or triazolam.\n\nPregnancy category: B\n\nInteraction: Decreased plasma conc with phenobarbital, carbamazepine, dexamethasone, phenytoin, rifabutin and rifampicn. Increased plasma conc of certain drugs highly metabolized by CYP3A. May increase serum levels of sildenafil.\nPotentially Fatal: Avoid concurrent admin of oral solution (contains alcohol) with disulfiram or metronidazole. Increased risk of myopathy when used with simvastatin or lovastatin. Concurrent use with alfuzosin may lead to serious hypotension. Increased risk of cardiac arrhythmias when used with amiodarone, cisapride, propafenone, quinidine, flecainide and pimozide. Risk of acute ergot toxicity when used with ergot derivatives. Increased risk of serious adverse reactions when used with midazolam or triazolam.
Ritonavir + Lopinavir	\n\n\tIndication: HIV infection\n\nDose: Adult: PO Per cap contains lopinavir 133.3 mg and ritonavir 33.3 mg. Treatment-naive patients: 3 cap twice daily or 6 cap once daily. Treatment-experienced patients: 3 cap twice daily. W/ efavirenz, nevirapine, amprenavir or nelfinavir: 4 cap twice daily.\n\nOral solution 800/200 mg (10 mL) once daily in patients with less than three lopinavir resistance-associated substitutions. A dose increase is recommended for all patients who use oral solution. The recommended dose of oral solution is 533/133 mg (6.5 mL) twice daily when used in combination with efavirenz, nevirapine, or nelfinavir.\n\nPediatric Patients: Tablets and oral solution should not be administered once daily in pediatric patients < 18 years of age. Thids oral solution should not be administered to neonates before a postmenstrual age (first day of the mother's last menstrual period to birth plus the time elapsed after birth) of 42 weeks and a postnatal age of at least 14 days has been attained \n\nContra-indication: Hypersensitivity. Avoid concomitant use with ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, pimozide, and sedatives (midazolam, triazolam).\n\nSide effects: Diarrhoea, vomiting, headache, asthenia, abdominal pain, and nausea ; elevations in liver enzymes, total cholesterol and triglycerides.\n\nPrecaution: Pancreatitis, hepatic impairment, haemophilia. Pregnancy, lactation, elderly, child <6 mth.\n\nMode of action: ritonvir ....Decreased plasma conc with phenobarbital, carbamazepine, dexamethasone, phenytoin, rifabutin and rifampicn. Increased plasma conc of certain drugs highly metabolized by CYP3A. May increase serum levels of sildenafil.\n\nPotentially Fatal: Avoid concurrent admin of oral solution (contains alcohol) with disulfiram or metronidazole. Increased risk of myopathy when used with simvastatin or lovastatin. Concurrent use with alfuzosin may lead to serious hypotension. Increased risk of cardiac arrhythmias when used with amiodarone, cisapride, propafenone, quinidine, flecainide and pimozide. Risk of acute ergot toxicity when used with ergot derivatives. Increased risk of serious adverse reactions when used with midazolam or triazolam.\n\nlopinavir....Most interactions reported with lopinavir are due to its combination with the potent inhibitor of CYP3A4 ritonavir. Lopinavir levels may be decreased by CYP3A4 inducers such as efavirenz, nevirapine, amprenavir, nelfinavir, rifampicin, phenytoin. Lopinavir level are increased by CYP3A4 inhibitors such as valproate and rifabutin.\nPotentially Fatal: Severe myelosuppression reported with paclitaxel.\n\nPregnancy category: A\n\nInteraction: ritonvir ....Decreased plasma conc with phenobarbital, carbamazepine, dexamethasone, phenytoin, rifabutin and rifampicn. Increased plasma conc of certain drugs highly metabolized by CYP3A. May increase serum levels of sildenafil.\n\nPotentially Fatal: Avoid concurrent admin of oral solution (contains alcohol) with disulfiram or metronidazole. Increased risk of myopathy when used with simvastatin or lovastatin. Concurrent use with alfuzosin may lead to serious hypotension. Increased risk of cardiac arrhythmias when used with amiodarone, cisapride, propafenone, quinidine, flecainide and pimozide. Risk of acute ergot toxicity when used with ergot derivatives. Increased risk of serious adverse reactions when used with midazolam or triazolam.\n\nlopinavir....Most interactions reported with lopinavir are due to its combination with the potent inhibitor of CYP3A4 ritonavir. Lopinavir levels may be decreased by CYP3A4 inducers such as efavirenz, nevirapine, amprenavir, nelfinavir, rifampicin, phenytoin. Lopinavir level are increased by CYP3A4 inhibitors such as valproate and rifabutin.\nPotentially Fatal: Severe myelosuppression reported with paclitaxel.
Rituximab	\n\n\tBeacon\tRituxim Injection 100 mg/10 ml  \n\tBeacon\tRituxim Injection 500 mg/50 ml  \n\tMade for F. Hoffmann-La RocheLtd. Switzerland By RocheDiagnostic GmbH Germany\tMabthera Injection 100mg/10ml  1's pack 35888\n\tMade for F. Hoffmann-La RocheLtd. Switzerland By RocheDiagnostic GmbH Germany\tMabthera Injection 500mg/50ml  1's pack 161945\n\tIndication: Non-Hodgkin's lymphoma; follicular lymphoma\n\nDose: Adult: IV Non-Hodgkin's lymphoma; Refractory or relapsed follicular lymphoma As a single agent: 375 mg/m2 via infusion at 50 mg/hr once wkly for 4 doses. May increase rate slowly. If tolerated, may start subsequent infusions at 100 mg/hr and increase slowly. Max rate: 400 mg/hr. \n\nW/ cyclophosphamide, vincristine, and prednisolone for follicular lymphoma (CVP) or w/ cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for diffuse large B-cell lymphoma: 375 mg/m2 on day 1 of each 21-day cycle for 8 doses. Patients who were treated w/ 6-8 cycles of CVP chemotherapy and have not progressed: May give 375 mg/m2 once wkly for 4 doses, may repeat 6 mthly up to 16 doses. Maintenance for responders to induction chemotherapy: 375 mg/m2 once 3 mthly until disease progression or a max period of 2 yr. Rheumatoid arthritis Two 1g infusion doses, separated by 2 wk.\n\nContra-indication: Lactation. Type I hypersensitivity or anaphylactic reactions to murine proteins or component of the formulation.\n\nSide effects: Fever and rigors. Pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, tumor lysis syndrome, respiratory failure, thrombocytopenia, neutropenia, anaemia. Hypersensitivity reactions.\nPotentially Fatal: Pulmonary or cardiac toxicity during infusion; severe mucocutaneous reactions; severe cytokine release syndrome associated with tumor lysis syndrome. Toxic epidermal necrolysis.\n\nPrecaution: Extensive tumor burden, pulmonary tumor infiltration or pulmonary insufficiency; history of cardiac disease; effective contraception during and up to 12 mth after treatment; pregnancy. Monitor CBC and platelet counts regularly. Premedication with analgesics, antihistamines and corticosteroids may be recommended. Monitor for signs of active infection or hepatitis in hepatitis B carriers. Discontinue treatment if viral hepatitis develops.\n\nMode of action: Increased risk of renal toxicity w/ cisplatin.\nPotentially Fatal: May decrease the efficacy of vaccines and increase the risk of infections in patients immunised w/ live vaccines.\n\nPregnancy category: C\n\nInteraction: Increased risk of renal toxicity w/ cisplatin.\nPotentially Fatal: May decrease the efficacy of vaccines and increase the risk of infections in patients immunised w/ live vaccines.
Rivastigmine	\n\n\tIbn Sina Pharmaceutical Ind. Ltd.\tRovacap CAP 6mg  \n\tNovartis (Bangladesh) Ltd.\tExelon 10 cm Patch 10 cm 30's pack 6146\n\tNovartis (Bangladesh) Ltd.\tExelon 5cm Patch 5cm 30's pack 6146\n\tSun Pharmaceutical (Bangladesh) Ltd.\tRivamer CAP 1.5mg 30's pack 423\n\tSun Pharmaceutical (Bangladesh) Ltd.\tRivamer CAP 4.5mg 30's pack 840\n\tUnimed & Unihealth Manufacturers Ltd.\tDemelon-1.5 TAB dr 1.5mg 28's pack 560\n\tUnimed & Unihealth Manufacturers Ltd.\tDemelon-3 TAB dr 3mg 14's pack 560\n\tNovartis Farmaceutica S.A., Spain\tExelon CAP 1.5mg 60's pack 6420\n\tNovartis Farmaceutica S.A., Spain\tExelon CAP 3mg 60's pack 6420\n\tNovartis Farmaceutica S.A., Spain\tExelon CAP 4.5mg 60's pack 6420\n\tNovartis Farmaceutica S.A., Spain\tExelon CAP 6mg 60's pack 6420\n\tIndication: Severe dementia in Alzheimer's disease.\n\nDose: Oral\nMild to moderately severe dementia in Alzheimer's disease\nAdult: Initially, 1.5 mg bid, increased according to response by 1.5 mg bid at intervals of at least 2 wk. If treatment is interrupted for >a few days, restart at 1.5 mg bid and increase dose accordingly, if required. Max: 6 mg bid.\n\nTransdermal\n\n    Indicated for mild, moderate, and severe dementia of the Alzheimer's type\n    Initial: Apply 4.6 mg q24hr\n    Dose titration: May increase dose to 9.5 mg q24hr after a minimum 4 weeks if well tolerated; after an additional 4 weeks, may further increase to 13.3 mg patch if needed\n    Mild-to-moderate Alzheimer disease: Effective dosage range is 9.5-13.3 mg/24 hr\n    Moderate-to-severe Alzheimer disease: Effective dose is 13.3 mg/24 hr\n    Replace with new patch q24hr\n\n\nContra-indication: Hypersensitivity to other carbamate derivatives. Severe hepatic impairment.\n\nSide effects: Accidental trauma, fatigue, asthenia, dizziness, headache, somnolence, agitation, insomnia, confusion, depression, nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, dyspepsia, upper respiratory tract infection, urinary tract infection. Rarely, angina pectoris, gastric and duodenal ulcers, GI haemorrhage; bradycardia, seizures, rashes and syncope.\nPotentially Fatal: Serious GI reactions such as anorexia, vomiting and weight loss.\n\nPrecaution: Patients with sick sinus syndrome or conduction defects, resp diseases. Cholinergic stimulation may increase gastric acid secretion. May exacerbate urinary obstruction and seizures. Pregnancy. Renal impairment, mild to moderate hepatic impairment. Monitor body wt. Asthma or obstructive pulmonary disease. May worsen extrapyramidal symptoms. Lactation.\n\nMode of action: Not to be used with other cholinomimetic drugs that might interfere with the activity of anticholinergic medications. May exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. Tobacco smoking may increase its clearance.\n\nPregnancy category: B\n\nInteraction: Not to be used with other cholinomimetic drugs that might interfere with the activity of anticholinergic medications. May exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. Tobacco smoking may increase its clearance.
Rocuronium Bromide	\n\n\tIncepta\tRocuron IV Injection 1 gm/100 ml 1's pack 300\n\tNuvista Pharma Ltd\tEsmeron Injection 50 mg 10 amp's pack 4000\n\tN. V. Organon, Netherlands\tEsmeron Injection 100mg/10ml 10's pack 4000\n\tIndication: Endotracheal intubation, Aid controlled ventilation, Muscle relaxant in general anesthesia\n\nDose: Intravenous\nMuscle relaxant in general anaesthesia, Endotracheal intubation, Aid controlled ventilation\nAdult: Initially, 600 mcg/kg by inj. Higher doses of 1 mg/kg may be used for intubation during rapid sequence induction of anaesthesia. Maintenance: 150 mcg/kg by inj (may reduce to 75-100 mcg/kg if inhalational anaesthesia is used) or by infusion at a rate of 300-600 mcg/kg/hr. Doses should be based on lean body weight for obese patients weighing >30% above the ideal body weight.\nChild: Infants and children >1 mth: Initially, 600 mcg/kg by inj. Maintenance: 150 mcg/kg by inj or by infusion at a rate of 300-600 mcg/kg/hr, maintenance doses may be required more frequently than in adult patients.\nElderly: Reduced maintenance doses: 75-100 mcg/kg.\nHepatic impairment: or biliary tract disease: Initially, 600 mcg/kg by inj. Maintenance: 75-100 mcg/kg.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Itching and erythematous reactions at the inj site and/or generalised histaminoid reactions. CV changes. Tachycardia and increase in BP.\nPotentially Fatal: Abnormal ECG, arrhythmia, bronchospasm, anaphylaxis and malignant hyperthermia.\n\nPrecaution: Pulmonary disease, hepatic, renal impairment, biliary disease, electrolyte/acid-base abnormalities, neuromuscular diseases, DM, dehydrated or severely-ill patients, patients with >40% burns. Ventilation must be supported during neuromuscular blockade. Pregnancy and lactation. Doses >900 mcg/kg may have vagolytic activity.\n\nMode of action: May cause enhanced block when used with lidocaine, procainamide, quinidine, verapamil, aminoglycosides, inhalational anaesthetics and vancomycin. May cause prolonged paralysis when used with clindamycin. Anticholinesterases such as pyridostigmine and galantamine may antagonise the effect of rocuronium. Chronic use of carbamazepine or phenytoin may lead to resistance to rocuronium.\n\nPregnancy category: C\n\nInteraction: May cause enhanced block when used with lidocaine, procainamide, quinidine, verapamil, aminoglycosides, inhalational anaesthetics and vancomycin. May cause prolonged paralysis when used with clindamycin. Anticholinesterases such as pyridostigmine and galantamine may antagonise the effect of rocuronium. Chronic use of carbamazepine or phenytoin may lead to resistance to rocuronium.
Salbutamol	\n\n\tACI\tBrodil Syrup 2mg/5ml 100ml bot 23\n\tACI\tBrodil TAB dr 4mg 500's pack 230\n\tACI\tBrodil Acucap Dry powder inhalation capsule 200mcg 32's pack 43.20\n\tACI\tBrodil HFA Inhaler 100mcg/puff 1s 195.59\n\tACI\tBrodil Respiratory Solution Nebuliser Solution 5mg/ml 20ml 120.36\n\tACI\tBrodil TAB dr 2mg 500's pack 130\n\tACI\tBrodil-Hfa Refill Inhaler 100mcg/puff 1s 170.51\n\tAcme Ltd.\tSalmolin Syrup 2mg/5ml 60ml bot/100ml bot 10.83/22.93\n\tAcme Ltd.\tSalmolin Dry powder inhalation capsule 200mcg 30's pack/100's pack 37/125\n\tAcme Ltd.\tSalmolin TAB dr 4mg 100's pack 34\n\tAcme Ltd.\tSalmolin Inhaler 100mcg 200 doses unit 180\n\tAcme Ltd.\tSalmolin Nebuliser Solution 5mg/ml 20ml pack 120\n\tAd-din\tVentosol Syrup 2mg/5ml 100ml bot 20\n\tAlbion Ltd.\tSalbutamol TAB dr 2 mg/ 4 mg 500's/ 500's pack \n\tAlbion Ltd.\tSalbutamol Syrup 2.4 mg/ 5 ml 100 ml \n\tAmico Ltd.\tSalbutamol Syrup 2mg/5ml 100ml bot 21.75\n\tAristopharma\tAsmalin HFA Inhaler 100mcg 200 doses unit 175\n\tAristopharma\tAsmolex Syrup 2mg/5ml 100ml bot 22.92\n\tAsiatic Ltd.\tAsul Syrup 2mg/5ml 100ml bot 22.92\n\tAsiatic Ltd.\tAsul TAB dr 4mg 100's pack 34\n\tBeximco\tAzmasol TAB dr 2mg 500's pack 130\n\tBeximco\tAzmasol Bexicap Dry powder inhalation capsule 200mcg 30 caps pack 40.50\n\tBeximco\tAzmasol HFA Inhaler 100mcg 200 doses unit/300 doses unit 180/240\n\tBeximco\tBronkolax Syrup 2mg/5ml 100ml bot 22.93\n\tBeximco\tAzmasol TAB dr 4mg 500's pack 200\n\tBeximco\tAzmasol Nebuliser Solution 5mg/ml 20ml pack 120\n\tBio Pharma Ltd.\tSalbu Syrup 2mg/5ml 60ml bot/100ml bot 11.04/22.93\n\tBio Pharma Ltd.\tSalbu TAB dr 2mg 100's pack 26\n\tBio Pharma Ltd.\tSalbu TAB dr 4mg 100's pack 34\n\tCentral.\tVentol Syrup 2mg/5ml 60ml bot/100ml bot 10.50/15\n\tChemist Ltd.\tSabul Nebuliser Solution 5mg/ml 20ml bot 110\n\tCosmic Chemical Industries Ltd.\tSalol Syrup 2mg/5ml 100ml bot 22\n\tCosmo Pharma Ltd.\tResdil TAB dr 4mg 200's pack 66\n\tDecent Pharma Ltd.\tDecabutamol Syrup 2mg/5ml 60ml bot/100ml bot 12/21.83\n\tDesh\tVentolex Syrup 2mg/5ml 100ml bot 16\n\tDesh\tVentolex TAB dr 4mg 500's pack 170\n\tDoctor's Chemicals Works Ltd.\tD Butamol Syrup 2mg/5ml 100ml bot 22.80\n\tDoctor's Chemicals Works Ltd.\tD Butamol TAB dr 2mg 100's pack 26\n\tDoctor's Chemicals Works Ltd.\tD Butamol TAB dr 4mg 100's pack 33\n\tDrug International Ltd.\tVentil Inhalation Aerosol 100 mcg/Metered Inhalatio  \n\tEdruc Ltd.\tEtol Syrup 2mg/5ml 100ml bot 22\n\tEskayef Bangladesh Ltd.\tSalomax Inhaler 100mcg 200 doses unit 160\n\tEuro Pharma Ltd.\tAzmarel Syrup 2mg/5ml 100ml bot 22\n\tEuro Pharma Ltd.\tAzmarel TAB dr 2mg 100's pack 26\n\tEuro Pharma Ltd.\tAzmarel TAB dr 4mg 100's pack 34\n\tGeneral\tSalbut Syrup 2mg/5ml 100ml bot 22.90\n\tGeneral\tSalbut TAB dr 2mg 100ml \n\tGeneral\tSalbut TAB dr 4mg 100's pack \n\tGlaxoSmithKline Bangladesh Ltd.\tVentolin Inhaler 100mcg 200 doses unit 230\n\tGlaxoSmithKline Bangladesh Ltd.\tVentolin Syrup 2mg/5ml 100ml bot 22.93\n\tGlaxoSmithKline Bangladesh Ltd.\tVentolin Nebuliser Solution 5mg/ml 20ml pack 173\n\tGlaxoSmithKline Bangladesh Ltd.\tVentolin TAB dr 2mg 500's pack 131.67\n\tGlaxoSmithKline Bangladesh Ltd.\tVentolin TAB dr 4mg 500's pack 230\n\tGlaxoSmithKline Bangladesh Ltd.\tVentolin SR TAB dr 8mg 250's pack 194.84\n\tGlaxoSmithKline Bangladesh Ltd.\tVentolin Nebules Nebuliser Solution 2.5 mg/2.5 ml 30 doses  803.40\n\tGlobe\tActolin Syrup 2mg/5ml 100ml bot 15\n\tGonoshasthaya\tG Salbutamol Syrup 2mg/5ml 100ml bot 15.05\n\tGonoshasthaya\tG-Salbutamol Injection 50mcg/ml 20ml vial 101.53\n\tHealthcare\tPulmocare TAB dr 4mg  \n\tHealthcare\tPulmocare Inhaler 100 mcg/Spray  \n\tHudson\tH Selax Syrup 2mg/5ml 60ml bot/100ml bot 10.80/15\n\tHudson\tH Selax TAB dr 4mg 100's pack 34\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVentisal Syrup 2mg/5ml 100ml bot 22.92\n\tIbn Sina Pharmaceutical Ind. Ltd.\tVentisal TAB dr 4mg 100's pack 34\n\tIncepta\tWindel Nebuliser Solution 1mg/ml 10's pack 14\n\tIncepta\tWindel Syrup 2mg/5ml 100ml bot 22.90\n\tIncepta\tWindel Nebuliser Solution 5mg/ml 20ml pack 120\n\tIncepta\tWindel TAB dr 2mg 200's pack 52\n\tIncepta\tWindel TAB dr 4mg 200's pack 68\n\tIncepta\tWindel DPI Dry powder inhalation capsule 200mcg 30's pack 75\n\tIncepta\tWindel ConviCap Dry powder inhalation capsule 200mcg 30's pack 75\n\tIndobangla Pharmaceuticals\tSalbumol Syrup 2mg/5ml 100ml bot 22.90\n\tJayson\tRespolin Syrup 2mg/5ml 100ml bot 22.92\n\tJayson\tRespolin TAB dr 4mg 100's pack 25\n\tKemiko\tDilatol Syrup 2mg/5ml 100ml bot 22.84\n\tKumudini Pharma Ltd.\tSulbion Syrup 2mg/5ml 100ml bot 20\n\tLeon\tSaltamol Syrup 2 mg/5 ml  \n\tMedicon\tAzmet Syrup 2mg/5ml 60ml bot/100ml bot 15/22\n\tMedimet\tSalmol Syrup 2mg/5ml 60ml bot/100ml bot 13/20\n\tMedimet\tSalmol TAB dr 4mg 100's pack 34\n\tMillat\tBrondyl Syrup 2mg/5ml 100ml bot 22.80\n\tModern\tSalix Syrup 2mg/5ml 60ml bot/100ml bot 10.80/22.90\n\tModern\tSalix TAB dr 4mg 100's pack 34\n\tMystic\tTolin Syrup 2mg/5ml 100ml bot 15\n\tMystic\tTolin TAB dr 4mg 100's pack 34\n\tNipa\tBroad Syrup 2mg/5ml 100ml bot 15\n\tOpsonin Pharma\tPulmolin Syrup 2mg/5ml 60ml bot/100ml bot 10.45/22.85\n\tOpsonin Pharma\tPulmolin TAB dr 4mg 100's pack 33\n\tOpsonin Pharma\tPulmolin TAB dr 2mg  \n\tOrion Pharma Ltd.\tOrsal Syrup 2mg/5ml 100ml bot 22.85\n\tPacific\tBroncotrol Syrup 2mg/5ml 100ml bot 16.11\n\tPacific\tBroncotrol TAB dr 4mg 200's pack 68\n\tPharmaco International Ltd.\tAsthmanil TAB dr 4mg 10's pack 155\n\tPharmadesh Ltd.\tAsthmolin Syrup 2mg/5ml 60ml bot/100ml bot 11.38/21.08\n\tPharmadesh Ltd.\tAsthmolin TAB dr 2mg 100's pack 28\n\tRephco\tAsmatol Syrup 2mg/5ml 60ml bot 14.45\n\tSanofi Aventis (BD) Ltd.\tSalbutal Syrup 2mg/5ml 100ml bot 22.89\n\tSanofi Aventis (BD) Ltd.\tSalbutal TAB dr 2mg 500's pack 130.31\n\tSanofi Aventis (BD) Ltd.\tSalbutal TAB dr 4mg 500's pack 169.97\n\tSeema\tBronil-S Syrup 2mg/5ml 100ml bot 22\n\tSilva\tAlvolex Syrup 2mg/5ml 100ml bot 16.07\n\tSomatec\tBrolax Syrup 2mg/5ml 100ml bot 15.06\n\tSomatec\tBrolax TAB dr 2mg 100's pack 25\n\tSomatec\tBrolax TAB dr 4mg 100's pack 33\n\tSquare\tSultolin Syrup 2mg/5ml 100ml bot 22.93\n\tSquare\tSultolin Dry powder inhalation capsule 200mcg 30's pack 40\n\tSquare\tSultolin Nebuliser Solution 5mg/ml 20ml pack 120.50\n\tSquare\tSultolin Inhaler 100mcg 200 doses unit 180.69\n\tSquare\tSultolin TAB dr 4mg 200's pack 69.16\n\tSquare\tSultolin SR TAB dr 8mg 100's pack 156.94\n\tZenith\tZentolin Syrup 2mg/5ml 60ml bot/100ml bot 10/15.60\n\tZiska\tAsnil Syrup 2mg/5ml 100ml bot 16\n\tGlaxo Smith Klin ,Australia\tVentolin Nebules Nebuliser Solution 2.5mg 30's pack 803.40\n\tIndication: Acute severe asthma, Severe bronchospasm\n\nDose: Adult: PO Acute bronchospasm 2-4 mg (up to 8 mg) 3-4 times/day. Extended release 8 mg twice daily. \n\nChildren\n2 - 6 years: 2.5 ml syrup, 3-4 times daily\n6-12 years: 5 ml syrup, 3-4 times daily\nOver 12 years: 5-10 ml syrup, 3-4 times daily (2-4 mg tablet, 3-4 times daily) \n\nInhalation Capsule: Adults:\nFor the relief of acute asthma or before exercise 400 Âµg (2 ConviCaps). The recommended dose for maintenance treatment or prophylactic therapy is 400 Âµg (2 ConviCaps) three to four times a day. Maximum dose is 1600 Âµg/day.\n\nChildren:\nIn the treatment of episodic asthma or before exercise 200 Âµg (1 ConviCap). The recommended dose for maintenance treatment or prophylactic treatment is 200 Âµg (1 ConviCap) three to four times a day. Maximum dose is 800 Âµg/day.\n\nAs aerosol: Inhalation Acute bronchospasm 100 or 200 mcg 3-4 times/day. 2 puffs may be given prior to exertion to prevent exercise-induced bronchospasm. \n\nAcute severe asthma As MDI: 4-6 inhalations every 10-20 mins. Severe bronchospasm Via nebuliser: 2.5-5 mg up to 4 times/day.\n\nChildren For relief of acute bronchospasm in the maintenance of episodic asthma or before exercise: one 1 puff may be administered as a single dose. \n\nFor routine maintenance and prophylaxis therapy: one 1 puff three or four times daily, increasing if necessary to two puffs three or four times daily. \nElderly The dosage is the same as that for adults.\n\nNebuliser Solution\nNebuliser Solution is for inhalation use only, to be breathed in through the mouth, under the direction of a physician, using a suitable nebuliser. The solution should not be injected or swallowed.\nAdults (including the elderly): 2.5 mg to 5 mg salbutamol up to four times a day. Up to 40 mg per day can be given under strict medical supervision in hospital.\n\nChildren 4 years and above: 2.5 mg to 5 mg up to four times a day.\nChildren 18 months to 4 years: 2.5 mg up to four times a day.The dose may be increased to 5 mg if necessary.\nInfants under 18 months old: 1.25 mg (0.25 mg/kg) to 2.5 mg up to four times a day.\n\nRespirator Solution\nBy Intermittent Administration : Adult : Respirator Solution 0.5-1.0 ml should be diluted to final volume of 2.0-4.0 ml with normal saline for injection. The resulting solution is inhaled from a suitably driven nebulizer until aerosol generation ceases. Should take about 10 minutes. \nRespirator Solution may be used undiluted for intermittent administration. For this 2.0 ml of the solution is placed in the nebulizer and the patient allowed to inhale until bronchodilatation is achieved. This usually takes 3-5 minutes. \n\nChildren under 12 years age: 0.5 ml of the solution diluted to 2.0-4.0 ml with normal saline. Intermittent treatment may be repeated four times a day. \n\nBy Continuous Administration :  Respirator Solution is diluted with normal saline for injection, 1-2 ml solution made upto 100 ml with diluent. The diluted solution is administered as an aerosol by a suitably driven nebulizer. The usual rate of administration is 1-2 mg/hour.\n\nContra-indication: Salbuatmol inhaler is contraindicated in patients with a history of hypersensitivity to any of its components. Although intravenous Salbutamol, and occasionally Salbutamol tablets, is used in the management of premature labour uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage or toxaemia of pregnancy, Salbutamol inhaler preparations are not appropriate for managing premature labour. Salbutamol preparation should not be used for threatened abortion during the first or second trimesters of pregnancy.\n\nSide effects: Fine skeletal muscle tremor especially hands, tachycardia, palpitations, muscle cramps, headache, paradoxical bronchospasm, angioedema, urticaria, hypotension and collapse.\nPotentially Fatal: Potentially serious hypokalaemia after large doses.\n\nPrecaution: Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. In the event of previously effective dose of Salbuatmol inhaler failing to give relief for at least three hours, the patient should be advised to seek medical advice in order that any necessary additional steps may be taken.\n\nMode of action: Diuretics, corticosteroids and xanthines may augment hypokalaemia. CV effects potentiated by MAOIs, TCAs, sympathomimetics. Increases absorption of sulfamethoxazole when used together. May markedly increase heart rate and BP when used with atomoxetine. Reduces serum levels of digoxin. Hypokalaemia induced by salbutamol increases the risk of digitalis toxicity. BP should be closely monitored if linezolid is used concurrently with salbutamol.\n\nPregnancy category: C\n\nInteraction: Diuretics, corticosteroids and xanthines may augment hypokalaemia. CV effects potentiated by MAOIs, TCAs, sympathomimetics. Increases absorption of sulfamethoxazole when used together. May markedly increase heart rate and BP when used with atomoxetine. Reduces serum levels of digoxin. Hypokalaemia induced by salbutamol increases the risk of digitalis toxicity. BP should be closely monitored if linezolid is used concurrently with salbutamol.
Salicylic Acid 16.7% + Lactic Acid 16.7%	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tDuoflam Liquid  1's pack(15ml) 265.13\n\tStiefel Ptd Ltd.,Ireland\tDuofilm Solution  15ml bot 296.94\n\tIndication: Warts\n\nDose: i. Wash your hands thoroughly with soap and water before and after using this medication.ii. Soak the wart in hot water for at least five minutes.iii. Use an emery board or pumice stone to rub off the dead skin in the affected area (avoid sharing this board/ stone with others).iv. Dry the area thoroughly.v. Use the applicator to apply 2 to 4 drops of the medication directly to the wart once a day. Note: Allow each drop to dry before the next is applied. DO NOT apply the medication to surrounding healthy skin.vi. Cover the treated area with a plaster or adhesive tape.\n\nContra-indication: Not for prolonged use in high concentrations and on large areas of the body. Impaired peripheral circulation or diabetes. Avoid broken skin, mouth, eyes, mucous membranes and anogenital region.\n\nSide effects: Possible side effects:\nStinging, burning, or irritation of the skin\nItching\nProlonged use over a large skin area may cause salicylate toxicity. \nRinging sound in the ears (tinnitus)\nDiarrhoea\nVomiting\n\nPrecaution:  	Not for prolonged use in high concentrations and on large areas of the body. Impaired peripheral circulation or diabetes. Avoid broken skin, mouth, eyes, mucous membranes and anogenital region.\n\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Salmeterol +  Fluticasone	\n\n\tACI\tSeroxyn HFA 25/125 Inhaler 25mcg+125mcg/puff 120 doses x 1's pack 596.79\n\tACI\tSeroxyn HFA 25/250 Inhaler 25mcg+250mcg/puff 120 doses x 1's pack 797.39\n\tACI\tSeroxyn 50/100 Acucap Dry Powder Inhaler 50Âµg+100Âµg/Cap 32's pack 155.52\n\tACI\tSeroxyn 50/250 Acucap Dry Powder Inhaler 50Âµg+250Âµg/Cap 32's pack 295.36\n\tACI\tSeroxyn 50/500 Acucap Dry Powder Inhaler 50Âµg+500Âµg/Cap 32's pack 481.60\n\tAcme Ltd.\tSalfu 100 Rotacap Dry powder inhalation capsule  30's pack 142.80\n\tAcme Ltd.\tSalfu 250 Rotacap Dry powder inhalation capsule  30's pack 271.20\n\tAcme Ltd.\tSalfu 500 Rotacap Dry powder inhalation capsule  30's pack 451.50\n\tAcme Ltd.\tSalflu Dry Powder Inhaler (DPI) 50 mcg +100 mcg  30âs in a plastic conatiner 142.80\n\tAcme Ltd.\tSalflu Dry Powder Inhaler (DPI) 50 mcg +250 mcg 30âs in a plastic conatiner 271.20\n\tAcme Ltd.\tSalflu Dry Powder Inhaler (DPI) 50 mcg +500 mcg 30âs in a plastic conatiner 451.50\n\tAristopharma\tAroflo 50 HFA Inhaler  120 doses x 1's pack 520\n\tAristopharma\tAroflo 125 HFA Inhaler  120 doses x 1's pack 595\n\tAristopharma\tAroflo 250 HFA Inhaler  60 /120 doses x 1's pack 430/795\n\tBeximco\tBexitrol F 25/50 Inhaler  120 doses x 1's pack 520\n\tBeximco\tBexitrol F 25/125 Inhaler  120 doses x 1's pack 595\n\tBeximco\tBexitrol F 25/250 Inhaler  120 doses x 1's pack 795\n\tDrug International Ltd.\tSeraflo HFA Inhalation Aerosol 25 mcg + 250 mcg/Metered   \n\tEskayef Bangladesh Ltd.\tArotide 25/125 Inhaler  120 doses x 1's pack 575\n\tEskayef Bangladesh Ltd.\tArotide 25/250 Inhaler  120 doses x 1's pack 750\n\tGlaxoSmithKline Bangladesh Ltd.\tSeretide 100 Accuhaler Dry powder inhalation capsule  60 doses x 1's pack 1086.51\n\tGlaxoSmithKline Bangladesh Ltd.\tSeretide 250 Accuhaler Dry powder inhalation capsule  60 doses x 1's pack 1238.12\n\tGlaxoSmithKline Bangladesh Ltd.\tSeretide 500 Accuhaler Dry powder inhalation capsule  60 doses x 1's pack 1440.26\n\tGlaxoSmithKline Bangladesh Ltd.\tSeretide 50 Evohaler Inhaler  120 doses x 1's pack 750\n\tGlaxoSmithKline Bangladesh Ltd.\tSeretide 125 Evohaler Inhaler  120 doses x 1's pack 1474.69\n\tGlaxoSmithKline Bangladesh Ltd.\tSeretide 250 Evohaler Inhaler  120 doses x 1's pack 1250\n\tHealthcare\tFlumetol Inhalation Aerosol (25 mcg + 250 mcg) / Mete  \n\tHealthcare\tFlumetol Inhalation Aerosol (25 mcg + 125 mcg) / Mete  \n\tIncepta\tFlutisal 100 Convicap Dry powder inhalation capsule 100/50 mcg 30's pack 150\n\tIncepta\tFlutisal 250 Convicap Dry powder inhalation capsule 250/50 mcg 30's pack 300\n\tIncepta\tFlutisal 500 Convicap Dry powder inhalation capsule 500/50 mcg 30's pack 450\n\tSquare\tTicamet 50 Inhaler Inhaler  120 doses x 1's pack 526.99\n\tSquare\tTicamet 250 Inhaler Inhaler  120 doses x 1's pack 752.83\n\tSquare\tTicamet HFC 25/125 Inhaler  120 doses x 1's pack 595\n\tSquare\tTicamet HFC 25/250 Inhaler  120 doses x 1's pack 795\n\tSquare\tTicamet 100 cozycap Cozycap  30's pack 145.64\n\tSquare\tTicamet 250 cozycap Cozycap  30's pack 752.83	\n\tIndication: Chronic Asthma, COPD\n\nDose: Adult: Inhalation Asthma: Per powd inhalation dose contains salmeterol 50 mcg and fluticasone propionate 100/250/500 mcg: 1 inhalation twice daily.  Per pressurized inhalation contains salmeterol 25 mcg and fluticasone propionate 50/125/250 mcg: 2 inhalations twice daily.\n \nCOPD: Per powd inhalation dose contains salmeterol 50 mcg and fluticasone propionate 500 mcg: 1 inhalation twice daily.  \n\nChild: 4-12 yr: As combination containing salmeterol 50 mcg and fluticasone propionate 100 mcg/ dose of inhalation powder: 1 inhalation bid; as combination containing salmeterol 25 mcg and fluticasone propionate 50 mcg/dose of pressurized inhalation: 2 inhalation bid.  \n\nChild: >12 yr: As combination containing salmeterol 50 mcg and fluticasone propionate 100/250/500 mcg/dose of inhalation powder: 1 inhalation bid; as combination containing salmeterol 50/125/250 mcg and fluticasone propionate 50 mcg/dose of pressurized inhalation: 2 inhalation bid.\n\nContra-indication: Not for primary treatment of status asthmaticus or other acute attacks of asthma. Severe hypersensitivity to milk proteins.\n\nSide effects: Mouth and throat candidiasis, throat irritation, hoarseness/dysphonia, nasopharyngitis, lower respiratory tract infections (e.g. pneumonia and bronchitis), hypokalaemia, headache, tremors, palpitation, muscle cramps. Prolonged high dose use may cause Cushing's syndrome, Cushingoid features, adrenal suppression, retardation of growth in children and adolescents, bone mineral density decrease, cataract and glaucoma. Potentially Fatal: Paradoxical bronchospasm.\n\nPrecaution: Pulmonary TB, severe cardiovascular disorders, heart rhythm abnormalities, DM, thyrotoxicosis, hypokalaemia. Patients at risk of decreased bone mineral content (e.g. smoking, old age, sedentary lifestyle, poor nutrition, family history of osteoporosis or long term use of drugs that may decrease bone mass (e.g. anticonvulsants and corticosteroids). Do not stop therapy abruptly; therapy should be down titrated. Advise patient to rinse mouth after inhalation. Monitor height of children on prolonged therapy. Pregnancy, lactation.\n\nMode of action: Increased fluticasone levels with CYP 3A4 inhibitors e.g ritonavir, ketoconazole, itraconazole. Additive effects with other ?-agonist.\n\nPregnancy category: C\n\nInteraction: Increased fluticasone levels with CYP 3A4 inhibitors e.g ritonavir, ketoconazole, itraconazole. Additive effects with other ?-agonist.
Salmon Calcitonin	\n\n\tNovartis Pharma AG, Switzerland\tMiacalcic Injection 100IU 1ml amp x 5's pack 2375\n\tNovartis Pharma, France\tMiacalcic Nasal Spray 200IU/ml 22 inhalations (2ml) unit 2375\n\tRotexmedica GmbH, Germany\tCalcitonin Injection 100IU 1ml amp x 10's pack 1450\n\tIndication: Hypercalcaemia, Paget's disease of bone, Postmenopausal osteoporosis.\n\nDose: Adult: IV Emergency treatment of hypercalcaemia 5-10 u/kg/day via infusion. \n\nIM/SC Paget's disease of bone Initial: 100 u/day. Maintenance: 50 u 3 times/wk to 100 u/day. Adjunct in hypercalcaemia 100 u 6-8 hrly. Max: 400 u 6-8 hrly. Postmenopausal osteoporosis 100 u/day or every other day. Bone pain due to malignant neoplasms 200 u 4 times/day, up to 48 hr. \n\nNasal Postmenopausal osteoporosis 200 u/day, alternating nostrils everyday.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nausea, vomiting, tingling of hands; Inj site inflammatory reactions, rashes, facial flushing, bronchospasm, headache, unusual taste, abdominal pain, anorexia. Nasal: Local irritation, ulceration, rhinitis, sinusitis, epistaxis.\nPotentially Fatal: Anaphylactic shock.\n\nPrecaution: Prior intradermal test preferably done. Children <18 yr, renal impairment. Pregnancy, lactation.\n\nMode of action:  	Concurrent use w/ cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.\n\nPregnancy category: C\n\nInteraction:  	Concurrent use w/ cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.
Sodium Alginate 5%	\n\n\tIndication: Gastroesophageal reflux (GERD), Indigestion\n\nDose: Chewable Tablet: Adults and Children >12 years: 2-4 tablets. The tablet must be chewed thoroughly before swallowing.\nOral Liquid: Adults and Children >12 years: Take 10-20 mL (two to four 5 mL spoonfuls). Children 6-12 years: Take 5-10 mL (one to two 5 mL spoonfuls). Administered after meals and at bedtime.\n\nContra-indication: Hypersensitivity\n\nSide effects: Gastrointestinal\n\nGastrointestinal side effects have been reported the most frequently. These have included constipation (secondary to aluminum hydroxide therapy) and diarrhea (secondary to magnesium carbonate therapy). \n\nPatients with renal failure may be at risk of aluminum toxicity because of ingestion of aluminum hydroxide and because of exposure to aluminum-containing water used for dialysate solutions. Adverse effects of aluminum accumulation in these patients has led to monitoring of water source aluminum content by dialysis units and periodic measurements of serum aluminum in patients undergoing chronic dialysis.\n\nConcurrent administration of aluminum hydroxide with citrate containing products has been associated with unusually high serum concentrations of aluminum and, especially in cases of renal failure, severe toxicity. Citrate may increase aluminum solubility and absorption.\n\nDuring long-term use, aluminum has been shown to deposit in bone, joint, and brain.\n\nSigns and symptoms of hypermagnesemia may include hypotension, nausea, vomiting, EKG changes, respiratory depression, loss of deep tendon reflex, dilated pupils, altered mental status, and coma.\n\nMetabolic\n\nMetabolic side effects have included hypophosphatemia with the use of aluminum hydroxide. In patients on long-term aluminum hydroxide therapy, especially in association with poor diets, hypophosphatemia may result in muscle weakness, rhabdomyolysis, hemolysis, and encephalopathy.\n\nOsteomalacia due to aluminum deposition in bone is generally only seen in patients with chronic renal failure. Bone formation slows in response to aluminum bone deposits. Aluminum may also deposit in joint tissue, resulting in arthropathy and hydrarthrosis.\n\nMusculoskeletal side effects have included osteomalacia, due to aluminum hydroxide, which may occur by two different mechanisms. Osteomalacia may occur due to hypophosphatemia or due to aluminum accumulation in bone. Osteomalacia due to hypophosphatemia is often accompanied by malaise, bone pain, muscular weakness, and bone fractures. Osteomalacia due to aluminum deposition may present in a similar fashion and occurs predominately in patients with chronic renal failure. Aluminum deposits typically can be observed on bone biopsy.\nNervous system\n\nEncephalopathy associated with aluminum accumulation is characterized by speech disorders, dysarthria, dyspraxia, dysphasia, tremor, myoclonus, seizures, coma, and ultimately death. EEG of patients with aluminum encephalopathy may show paroxysmal slowing and diffuse rhythmical bursts of delta activity.\nRenal\n\nRenal side effects have rarely included formation of renal calculi, most probably due to hypercalciuria, with the use of aluminum hydroxide.\n\n\nPrecaution: Magnesium carbonate, aluminum hydroxide and alginic acid have not been formally assigned to a pregnancy category by the FDA. There are no controlled data in human pregnancy.  Magnesium carbonate, aluminum hydroxide and alginic acid should only be given in pregnancy when benefit outweighs risk.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Sodium Carboxymethyl-cellulose 10 mg/ml	\n\n\tIndication: Tear substitute for the treatment of dry eye syndrome, relief from burning & irritation, discomfort due to exposure to sun & wind.\n\nDose: Adults and Children's Dose:\n\nMild dry eye : 1-4 applications/day. Moderate dry eye: 1-6 applications/day. Severe dry eye: hourly doses or as required.\n\nContra-indication: Hypersensitivity\n\nSide effects: Tinging/redness in the eye, widened pupils, or blurred vision may occur. \n    \n    eye pain\n    worsening redness/itching/swelling in or around the eyes\n    other vision problems\n\n\n\nPrecaution: Reevaluate if irritation, eye pain, or visual changes persist beyond 72 hours or worsen.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Sodium Chloride + Sodium Lactate + Calcium chloride + Magnesium chloride (CAPD solutions)	\n\n\tIndication: Continuous ambulatory peritoneal dialysis (CAPD)\n\nDose: Adults: As CAPD:\nThe usual dose is 2,000 ml solution four times daily depending on body weight and kidney function. Smaller or larger doses can be administered as appropriate (dose given merely as a guide, dosage must be adjusted for the individual patient). Bags are exchanged over 24 hours. After 4 â8 hours retention time the solution is drained off. \n\nContra-indication: Patients with excessive obesity and in pregnancy. \n\nSide effects: During dialysis amino acids and water soluble vitamins may be lost. Fluid and electrolyte imbalance, hypovolemia, hypotension or muscle cramping may occur.\n\nPrecaution: It is used for peritoneal dialysis purposes only.\n\nMode of action: Sodium Chloride: May affect serum concentrations of lithium.\n\nSodium Lactate:  Caution when used in patients receiving corticosteroids or corticotropin.\n\nCalcium chloride: Co-administration of high Ca doses with thiazide diuretics may result in milk-alkali syndrome and hypercalcaemia. May potentiate digoxin toxicity. Decreases effects of calcium-channel blockers. Enhanced absorption with calcitriol (a vit D metabolite).\n\nMagnesium chloride: Oral magnesium salts may decrease absorption of bisphosphonates, quinolone antibiotics and tetracycline derivatives; admin should be separated apart if concomitant use is required. Magnesium-containing products may reduce absorption of eltrombopag by 70%; separate admin by at least 4 hr. Calcitriol may increase serum concentrations of Magnesium salts. Magnesium salts may decrease serum concentrations of mycophenolate if used concurrently; monitor for reduced effects of mycophenolate. Concomitant use of trientine and magnesium salt may reduce serum concentrations of both agents.\n\nPregnancy category: Not Classified\n\nInteraction: Sodium Chloride: May affect serum concentrations of lithium.\n\nSodium Lactate:  Caution when used in patients receiving corticosteroids or corticotropin.\n\nCalcium chloride: Co-administration of high Ca doses with thiazide diuretics may result in milk-alkali syndrome and hypercalcaemia. May potentiate digoxin toxicity. Decreases effects of calcium-channel blockers. Enhanced absorption with calcitriol (a vit D metabolite).\n\nMagnesium chloride: Oral magnesium salts may decrease absorption of bisphosphonates, quinolone antibiotics and tetracycline derivatives; admin should be separated apart if concomitant use is required. Magnesium-containing products may reduce absorption of eltrombopag by 70%; separate admin by at least 4 hr. Calcitriol may increase serum concentrations of Magnesium salts. Magnesium salts may decrease serum concentrations of mycophenolate if used concurrently; monitor for reduced effects of mycophenolate. Concomitant use of trientine and magnesium salt may reduce serum concentrations of both agents.
Sodium Chloride + Potassium Chloride + Calcium chloride + Magnesium Chloride + Sodium Acetate + Sodium Citrate + Sodium Hydroxide + Hydrochloric Acid (Balanced Salt Solution)	\n\n\tBeximco\tNavsol Solution (0.640gm + 0.075gm + 0.04 500ml bot 250\n\tIndication: For irrigation during various surgical procedures of the eyes, ears, nose and/or throat.\n\nDose: This ocular irrigating solution should be used according to standard format for each surgical procedure. Note: Use an administration set with an air inlet in the plastic spike since the bottle does not contain a separate airway tube. Follow directions of the particular administration set to be used.\n\nGrasp plastic ring on top of bottle and pull down along scored area. Then pull radially around the cap and remove. Remove the spike port protective cover by lifting up on the finger grip tab. Insert spike aseptically into the bottle through the center target area of the recessed membrane. Allow the fluid to flow and remove air from the tubing before irrigation begins.\n\nContra-indication: Contraindicated in patients with known hypersensitivity to the products.\n\nSide effects: When the corneal endothelium is abnormal, irrigation or any other trauma may result in bullous keratopathy. Postoperative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported. Their relationship to the use of BSS has not been established.\n\nPrecaution: Not for injection or IV infusion.This solution contains no preservative and should not be used for more than one patient. Use only if vacuum is present, and if container and seal are undamaged and solution is clear.\nThe addition of any medication to BSS may result in damage to intraocular tissue. There have been rare reports of corneal clouding or edema following ocular surgery in which BSS was used as an irrigating solution. As in all surgical procedures appropriate measures should be taken to minimize trauma to the cornea and other ocular tissues.\n\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Sodium Cromoglycate	\n\n\tIndication: Asthma, Asthma propylaxis\n\nDose:  Adults: Inhalation Asthma prophylaxis As dry powd/ nebulising soln: 20 mg 4 times/day or as aerosol:10 mg 4 times/day, up to 6-8 times/day if needed, reduced to 5 mg 4 times/day once asthma has stabilised. Additional doses may be taken before exercise. \n\nContra-indication:  Hypersensitivity.\n\nSide effects: Nausea, headache, dizziness, unpleasant taste, joint pain and swelling, skin rashes, aggravation of asthma, pulmonary infiltrates with eosinophilia, urticaria. Bronchospasm, wheezing, cough, nasal congestion and throat irritation following inhalation of dry powder.\n\nPrecaution: Lactation, cardiac arrhythmias, hepatic or renal dysfunction.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Sodium Fusidate 2% Topical	\n\n\tAristopharma\tFusidate Ointment  20gm tube 85\n\tLeo Pharmaceutical Products,Denmark\tFucidin Leo Cream 20mg 15gm tube 303.90\n\tLeo Pharmaceutical Products,Denmark\tFucidin Leo Ointment   15gm  tube 275.94\n\tIndication: Fusidate Ointment is indicated for treatment of skin infections caused by Staphylococci, Streptococci, Corynebacterium minutissimum and other Fusidate sensitive organisms. The most important indications being: impetigo, boils, abscess, varicose ulcers, skin grafts, hidradenitis, infected wounds, sycosis barbae, paronychia, folliculitis, carbuncles and erythrasma.\n\nDose: Topical/Cutaneous\nSkin infections\nAdult: As a 2% ointment/cream/gel: Apply onto affected area 3-4 times daily until there is improvement. If gauze dressing is used, then frequency of application may be reduced to 1-2 times daily.\nChild: As a 2% ointment/cream/gel: Apply onto affected area 3-4 times daily until there is improvement. If gauze dressing is used, then frequency of application may be reduced to 1-2 times daily.\n\nContra-indication: Known hypersensitivity to Fusidic acid, severe hepatic failure.\n\nSide effects: Fusidate Ointment is remarkably well tolerated, and there is an extremely low frequency of hypersensitivity reactions.\n\nPrecaution: Prolonged treatment should be avoided. Liver impairment. Pregnancy. Caution should be observed when applying Fusidate Ointment near the eye region as this preparation may cause irritation if it gets into the eye.\n\nMode of action: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.\n\nPregnancy category: Not Classified\n\nInteraction: Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin.
Sodium Hyaluronate + Sodium Chondroitin Sulfate Eye drop	\n\n\tIndication: Cataract extraction and intraocular lens implantation. Anterior segment surgery, Cornea transplant surgery, Glaucoma surgery.\n\nDose: Depending on surgical procedure used. Recommended for single use. Inj into the chamber prior to or following delivery of the crystalline lens.\n\nContra-indication: There are no known contraindications.\n\nSide effects: Transient rise in IOP.\n\nPrecaution: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material.\n\nMode of action:  spdium hyaluronate.......	The safety and effectiveness of the use of sodium hyaluronate concomitantly with other intra-articular injection has not yet been established.\nAs sodium hyaluronate is precipitated by quaternary amine bactericides or disinfectants eg, benzalkonium chloride and chlorhexidine, etc, adequate attention should be given.Sodium Chondroitin Sulfate..........Low potential for interactions. Cumarinic anticoagulants eg warfarin, platelet antiaggregant; tetracyclines\n\nPregnancy category: Not Classified\n\nInteraction:  spdium hyaluronate.......	The safety and effectiveness of the use of sodium hyaluronate concomitantly with other intra-articular injection has not yet been established.\nAs sodium hyaluronate is precipitated by quaternary amine bactericides or disinfectants eg, benzalkonium chloride and chlorhexidine, etc, adequate attention should be given.Sodium Chondroitin Sulfate..........Low potential for interactions. Cumarinic anticoagulants eg warfarin, platelet antiaggregant; tetracyclines
Somatostatin	\n\n\tMerck Serono S.A., Switzerland\tStilamin Injection 3mg/amp 1 amps pack 4405\n\tIndication: GI haemorrhage\n\nDose: Adult: IV 250 mcg as a bolus inj, then infuse at 3.5 mcg/kg/hr until bleeding has ceased. May continue for a further 48-72 hr to prevent recurrent bleeding.\n\nContra-indication: \n\nSide effects: Rapid infusion may lead to abdominal discomfort, nausea, flushing, bradycardia.\n\nPrecaution: Monitor blood glucose levels. May inhibit intestinal absorption thus concomitant parenteral nutrition may be recommended.\n\nMode of action: Lengthens the time of hexobarbital-induced sleep & potentiates the action of pentetrazol.\n\nPregnancy category: B\n\nInteraction: Lengthens the time of hexobarbital-induced sleep & potentiates the action of pentetrazol.
Somatropin	\n\n\tNovartis (Bangladesh) Ltd.\tOmnitrope Injection 3mg/ vial 1ml vial x 2's pack 45000\n\tNovo Nordisk A/S Denmark\tNorditropin Simplexx Injection 3.3mg/ml 1.5ml vial X 1's pack 10900\n\tNovo Nordisk A/S Denmark\tNorditropin Simplexx Injection 5mg/1.5ml 1's pack 11000\n\tIndication: Growth hormone deficiency, HIV-associated wasting or cachexia, Short bowel syndrome\n\nDose:  Adult: Subcutaneous: Growth hormone deficiency Initial: 6 mcg/kg/day. May increase dose gradually. Max: 12.5 mcg/kg/day. \nChild: 25-35 mcg/kg daily. Reassess 9 mth after starting treatment. \n\nHIV-associated wasting or cachexia 0.1 mg/kg/day at bedtime. May take on alternate days for patients at increased risk of adverse effects. Max: 6 mg/day.\n\nShort bowel syndrome100 mcg/kg/day for 4 wk. Max: 8 mg/day.\n\nGrowth retardation in children who were born small for gestational age\nChild: 35 mcg/kg or 1 mg/m2 daily. Max: 2.7 mg daily.\n\nTurner's syndrome\nChild: 45-50 mcg/kg or 1.4 mg/m2 daily. \n\nContra-indication: Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.\n\nSide effects: Hypothyroidism, peripheral oedema; headache; muscle and joint pain; benign intracranial hypertension. Loss of glycaemic control in diabetics.\n\nPrecaution: Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis.\n\nMode of action: High doses of corticosteroid may inhibit growth-promoting effects of somatropin.\n\nPregnancy category: B\n\nInteraction: High doses of corticosteroid may inhibit growth-promoting effects of somatropin.
Sulphamethoxazole 200 mg +Trimethoprim 40 mg/ml	\n\n\tIndication: Bacterial infections, Upper and lower respiratory tract infections, Gastrointestinal tract infections, Renal and urinary tract infections, Skin and wound infections, Septicaemias\n\nDose: Adult:IV or IM: Susceptible infections 960 mg twice daily, up to 2.88 g/day in 2 divided doses for severe cases. \n\nContra-indication: Hypersensitivity; severe renal or hepatic insufficiency; infants <4 wk; megaloblastic anaemia; pregnancy and lactation.\n\nSide effects: Renal failure, nausea, vomiting, diarrhoea, anorexia; skin rashes, urticaria.\nPotentially Fatal: Stevens-Johnson syndrome, agranulocytosis, toxic epidermal necrolysis, hepatic necrosis.\n\nPrecaution: G6PD deficiency; potential folate deficiency; hepatic and renal impairment; elderly; porphyria; thyroid dysfunction; maintain adequate hydration.\n\nMode of action: Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.\nPotentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.\n\nPregnancy category: D\n\nInteraction: Reduced ciclosporin concentrations in blood when used concurrently. Increases toxicity of methotrexate. Inhibits phenytoin clearance. Potentiates warfarin and oral hypoglycaemics.\nPotentially Fatal: Co-admin with pyrimethamine causes megaloblastic anaemia. Enhancement of renal damage by ciclosporin.
Telbivudine	\n\n\tNovartis Pharma AG, Switzerland\tSebivo TAB dr 600mg 28's pack 7308\n\tIndication: Chronic hepatitis B\n\nDose: Oral\nChronic hepatitis B\nAdult: 600 mg once daily.\nChild: >16 yr: 600 mg once daily.\n\nRenal impairment: Haemodialysis: Administer dose after dialysis session.\nCrCl (ml/min)	\n30-49	600 mg every 48 hr.\n<30         (not requiring dialysis)	600 mg every 72 hr.\nEnd stage renal disease	                600 mg every 96 hr. \n\nContra-indication: Hypersensitivity.\n\nSide effects: Fatigue, malaise, headache, abdominal pain. Dizziness, insomnia, fever, rash, increased lipase, nausea and vomiting, diarrhoea, dyspepsia, cough, flu-like symptoms.\nPotentially Fatal: Lactic acidosis and severe hepatomegaly.\n\nPrecaution: Patients with risk factors for liver disease (especially in female gender, obesity, pregnancy or prolonged exposure). Discontinue treatment in patients who develop clinical/laboratory findings suggestive of lactic acidosis or hepatotoxicity. Interrupt therapy if myopathy is suspected; discontinue if myopathy is diagnosed. Monitor LFTs several mth after discontinuation of treatment due to risk of severe acute exacerbation of hepatitis B. Renal impairment. Safety and efficacy have not been established in patients <16 yr, liver transplant patients or those coinfected with HIV, hepatitis C virus or hepatitis D virus. Caution in patients who have failed previous lamivudine treatment due to risk of cross-resistance development. Pregnancy, lactation.\n\nMode of action: Increased risk of peripheral neuropathy when used with peginterferon alfa-2a.\n\nPregnancy category: B\n\nInteraction: Increased risk of peripheral neuropathy when used with peginterferon alfa-2a.
Testosterone Enanthate	\n\n\tRotexmedica GmbH, Germany\tTestosterone Enanthate Injection 250mg/ml 10 amps pack 1400\n\tIndication: Inoperable metastatic breast cancer, Delayed puberty, Male hypogonadism\n\nDose:  By deep IM injection 1 ml usually 1 to 4 weeks.\n\nDosage is based on your medical condition, testosterone blood levels, and response to treatment.\n\nContra-indication: Hypercalcaemia or hypercalciuria, males with breast or prostate carcinoma. Pregnancy and lactation.\n\nSide effects: Nausea, vomiting, headache, skin color changes, increased/decreased sexual interest, oily skin, hair loss, and acne may occur. Pain and redness at the injection site may also occur. \n\nMental/mood changes (such as anxiety, depression, increased anger), trouble sleeping/snoring, signs of serious liver disease (such as persistent abdominal pain/nausea, unusual tiredness, yellowing eyes/skin, dark urine).\n\nTrouble urinating, breast swelling/tenderness, too frequent/prolonged erections.\n\nRarely, males may have a painful or prolonged erection lasting 4 or more hours. If this occurs, stop using this drug and seek immediate medical attention, or permanent problems could occur.\n\nThis medication can decrease sperm production, an effect that may lower male fertility. \n\nIf you are female, tell your doctor immediately if any of these unlikely but serious side effects occur: deepening of the voice, hoarseness, unusual facial/body hair growth, enlarged clitoris, irregular menstrual periods.\n\nThis medication can cause your body to hold on to extra body water (edema). \n\nA very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.\n\nPrecaution: This product may contain inactive ingredients (such as sesame oil), which can cause allergic reactions or other problems. \n\n Before using this medicine, consult your doctor or pharmacist if you have: breast cancer in men, prostate cancer.\n\n Heart disease (such as heart failure, chest pain, heart attack), liver problems, kidney problems, other types of cancer, high cholesterol, high blood pressure, enlarged prostate, sleep apnea, diabetes.\n\nThis product may decrease your blood sugar levels. \n\nThis drug may affect your cholesterol and may increase your risk of heart or blood vessel problems (coronary artery disease). Your doctor will monitor your cholesterol level closely.\n\nCaution is advised when using this drug in children because bone growth may be affected, causing shorter adult height. Your child's doctor will monitor growth and bone development during treatment.\n\nThis medication must not be used during pregnancy. It may harm an unborn baby. \n\nMode of action: Enhance activities of ciclosporine, antidiabetics, thyroxine, anticoagulants. Long term use of testosterone may cause resistance to effects of neuromuscular blockers. Enhance fluid retention from corticosteroids\n\nPregnancy category: X\n\nInteraction: Enhance activities of ciclosporine, antidiabetics, thyroxine, anticoagulants. Long term use of testosterone may cause resistance to effects of neuromuscular blockers. Enhance fluid retention from corticosteroids
Testosterone Undecanoate	\n\n\tNuvista Pharma Ltd\tAndriol Testocaps CAP 40mg 625 30's pack\n\tRenata\tAndrocap CAP 40mg  \n\tIndication: Male hypogonadism\n\nDose: Testosterone undecanoate capsules: Initially 12-160 mg daily for 2-3 weeks followed by maintenance dosage of 40-120 mg daily. \n\nTake this medication by mouth, usually twice daily with food. It is best to take half of the daily dose in the morning and the other half in the evening.   \n\nContra-indication: Hypercalcaemia or hypercalciuria, males with breast or prostate carcinoma. Pregnancy and lactation.\n\nSide effects:  Testosterone capsules:\n    Prostate problems including enlarged prostate and prostate cancer\n    Headache\n    Depression\n    Blood in faeces due to intestinal bleeding\n    Increased body hair\n    Loss of head hair - male pattern baldness\n    Oily skin\n    Acne\n    Frequent and prolonged erections of the penis\n    Yellowing of skin and whites of the eyes (due to cholestatic jaundice)\n    Changes in sexual desire (libido)\n    Nausea\n    Anxiety\n    Tingling feeling\n    Abnormal blood tests - changes in electrolytes e.g. sodium, chloride, potassium, calcium, inorganic phosphates\n\n\n\n\n\nPrecaution:  Before taking testosterone, tell your doctor or pharmacist if you are allergic to it; or to other androgens; or if you have any other allergies.\n\nThis medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist in case of:\n\n    Hypersensitivity (allergy) to testosterone or to any of the ingredients in the medication\n    Peanut allergy (IM injection- Sustanon only)\n    Male breast cancer\n    Known or suspected prostate cancer\n    Rare hereditary problems of galactose intolerance such as the Lapp lactase deficiency or glucose-galactose malabsorption (buccal tablets only)\n\nFor some formulations if you have:\n\n    Or have had liver tumours\n    High blood or urine calcium levels (hypercalcaemia or hypercalciuria)\n    Kidney damage (nephrotic syndrome)\n    Enlarged prostate gland\n\nBefore using this medication tell your doctor or pharmacist your medical history, especially any of the following\n\n    Bone cancer\n    Lung cancer\n    High blood pressure, heart problems and heart blood flow problems (ischaemic heart disease)\n    Kidney or liver problems\n    Difficulties in urinating\n    Epilepsy (fits)\n    Migraine\n    Diabetes\n    Long standing lung diseases such as chronic bronchitis or emphysema or are overweight\n    Interrupted breathing during sleep known as sleep apnoea\n    Dry mouth due to a lack of saliva (xerostomia)\n    Any skin problems (if testosterone is applied to the skin)\n\nBefore having surgery, tell your doctor or dentist that you are taking this medication.\n\nDoes alcohol intake affect this drug?\n\n    Alcohol is not known to affect testosterone.\n\nThe elderly: testosterone should be used with caution in elderly males as they are at a higher risk of developing prostate problems and swelling due to fluid retention (oedema). Testosterone 300 Âµg patches (Intrinsa) are only to be used in surgically menopausal women up to the age of 60. \n\nMode of action: Enhance activities of ciclosporine, antidiabetics, thyroxine, anticoagulants. Long term use of testosterone may cause resistance to effects of neuromuscular blockers. Enhance fluid retention from corticosteroids\n\nPregnancy category: X\n\nInteraction: Enhance activities of ciclosporine, antidiabetics, thyroxine, anticoagulants. Long term use of testosterone may cause resistance to effects of neuromuscular blockers. Enhance fluid retention from corticosteroids
Tetanus Antitoxin (Equine) BP	\n\n\tIncepta\tVaxitet-IG Injection 3000 IU/ml 1's pack 408\n\tFisons, UK\tTetabulin Injection  10's amps pack 7500\n\tIndication: Immediate protection against Tetanus\n\nDose: Prophylaxis of tetanus: Tetanus Antitoxin (equine) should not be used in the routine treatment of traumatic wounds. It is given prophylactically to persons at the risk of tetanus infection by infected wounds or severe wounds. \n\nFor prophylaxis after injury, non-immune or partially immune persons may be given 3,000 to 5,000 units of tetanus antitoxin subcutaneously or intramuscularly. If 24 hours have passed since the wound occurred, the dose is 3,000 IU. \n\nIn crush wounds or wounds contaminated with soil or other foreign bodies, the dose is 10,000 to 20,000 IU. For persons below 30 kg the dosage is 1,500 IU. \n\nActive immunization with Adsorbed Tetanus vaccine should be given simultaneously with the use of this preparation or a booster injection of Adsorbed Tetanus vaccine should be given if the patient has previously been immunized. \n\nTreatment: Therapy should be given as soon as possible after the appearance of symptoms of the disease. Therapeutic dose not less than 3000 IU. Depending on the severity, the dose may vary from 50,000 to 100,000 IU of tetanus antitoxin for hospitalized patients given partially by intravenous route and the rest of the dose intramuscularly.\n\n\n\nContra-indication: Should be used with great caution if patient is subject to allergic disease such as asthma or infantile eczema, or was allergic to any previous antiserum injection.\n\n\nSide effects: Reactions are liable to occur after the injection of any serum of animal origin. Anaphylaxis may occur in rare cases, with hypotension, dyspnoea, urticaria, and shock. Anaphylactic reactions should be treated with adrenalin, possibly in association with antihistamine and corticosteroid therapy. Serum sickness may occur 7 to 10 days after injection of serum of animal origin; symptoms include fever, vomiting, diarrhoea, bronchospasm, and urticaria; nephritis, myocarditis, neuritis, polyarthritis, and uveitis have been reported as rare complications of serum sickness.\n\n\nPrecaution: If there is no history of previous serum injection or allergic reaction, the dose of serum may be given intramuscularly. If the patient is subject to allergic diseases, a trial dose of 0,2 mL (diluted 1:10 if preferred) of the serum should be given subcutaneously; if no general reaction develops during an interval of 30 minutes, the main dose may be given intramuscularly. The patient must be kept under observation for at least 30 minutes after the injection and adrenaline kept in readiness for emergency use. In all urgent cases, the intravenous route is indicated, but should never be used unless a preliminary intramuscular injection, given at least 30 minutes beforehand, has been tolerated. For intravenous use, the serum should be at room temperature, the injection should be given very slowly, and the patient should be recumbent during the injection, and for at least an hour afterwards.\n\n\nMode of action: Decreased immunologic response with concurrent immunosuppressants. Neutralisation of tetanus immune globulin and tetanus toxoid adsorbed if not given at different sites using different syringes.\n\nPregnancy category: Not Classified\n\nInteraction: Decreased immunologic response with concurrent immunosuppressants. Neutralisation of tetanus immune globulin and tetanus toxoid adsorbed if not given at different sites using different syringes.
Thioridazine hydrochloride	\n\n\tNovartis (Bangladesh) Ltd.\tMelleril TAB dr 10mg 30's pack 135.70\n\tNovartis Pharmaceuticals, UK\tMelleril TAB dr 25mg 30's pack 162.10\n\tIndication: Depression, Schizophrenia\n\nDose: Schizophrenia Adult: Initially, 50-100 tid daily and slowly titrated upwards at no more than 100 mg wkly. Max: 800 mg daily in 2-4 divided doses.\n\nChild: 2-12 yr: Initially, 0.5 mg/kg daily in divided doses, increased gradually until optimum effect obtained. Max: 3 mg/kg daily. \n\nDepressionAdult: Initially, 25 mg tid, titrated to 20-200 mg daily.\n\nRenal impairment: Lower initial doses and more gradual dosage increase.Hepatic impairment: Lower initial doses and more gradual dosage increase.\n\nContra-indication: Hypersensitivity to phenothiazines, comatose states, pre-exisitng CNS depression, severe CVS disorders, uncorrected hypokalaemia or any electrolyte imbalance, known or suspected QT prolongation, history of ventricular arrhythmias including torsades de pointes and porphyria. Bone-marrow suppression, phaeochromocytoma, or prolactin-dependent tumours, angle-closure glaucoma, history of jaundice, parkinsonism, DM, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia, or urinary retention. Patients with reduced activity of cytochrome P450 isoenzyme CYP2D6.\n\nSide effects: Drowsiness, sedation, dry mouth, nasal congestion, blurring of vision, tremor, mydriasis, constipation, urinary retention, tachycardia, postural hypotension, sexual dysfunction, pigmentary retinopathy (high doses and prolonged therapy), contact dermatitis, tardive dyskinesias.\nPotentially Fatal: Neuroleptic malignant syndrome. Sudden deaths due to cardiac arrhythmias and arrest.\n\nPrecaution: Pregnancy, lactation; renal or hepatic impairment, epilepsy. Perform ECG screening and electrolyte measurement before therapy, after each dose increase and at 6-mthly intervals. Monitor for visual defects on long-term therapy. May impair ability to perform skilled tasks. Withdrawal of drug to be carried out gradually over 1-2 wk.\n\nMode of action: Potentiates adverse effects of anticholinergics. Concurrent use of TCAs leads to raised blood levels of both drugs. May antagonise effects of levodopa, bromocriptine and other dopamine agonists. Avoid co-admin with drugs that cause electrolyte imbalance. Monitor phenytoin therapy due to inconsistent effects of thioridazine on phenytoin levels.\n\nPotentially Fatal: Increased risk of QT prolongation with class IA and class II antiarrhythmics, astemizole, cisapride, pimozide, droperidol, erythromycin IV, sparfloxacin, terfenadine, clarithromycin and other drugs that may prolong QT interval. Potentiates CNS depression with opioids. Increased risk of arrhythmias with ephedrine-like drugs e.g. phenylpropanolamine. Increased thioridazone levels with fluovoxamine, pindolol, propranolol, ritonavir and other CYP2D6 isoenzymes inhibitors (e.g. fluoxetine, paroxetine).\n\nPregnancy category: C\n\nInteraction: Potentiates adverse effects of anticholinergics. Concurrent use of TCAs leads to raised blood levels of both drugs. May antagonise effects of levodopa, bromocriptine and other dopamine agonists. Avoid co-admin with drugs that cause electrolyte imbalance. Monitor phenytoin therapy due to inconsistent effects of thioridazine on phenytoin levels.\n\nPotentially Fatal: Increased risk of QT prolongation with class IA and class II antiarrhythmics, astemizole, cisapride, pimozide, droperidol, erythromycin IV, sparfloxacin, terfenadine, clarithromycin and other drugs that may prolong QT interval. Potentiates CNS depression with opioids. Increased risk of arrhythmias with ephedrine-like drugs e.g. phenylpropanolamine. Increased thioridazone levels with fluovoxamine, pindolol, propranolol, ritonavir and other CYP2D6 isoenzymes inhibitors (e.g. fluoxetine, paroxetine).
Thiotepa	\n\n\tIndication: Breast cancer,Ovarian carcinoma,Bladder cancer,Malignant effusions,Condylomata acuminata\n\nDose: Adult: IV Breast cancer; Ovarian carcinoma Dosage must be individualised. Usual range: 0.3-0.4 mg/kg 1-4 wkly. \n\nOphth Reduction of recurrence following surgical removal of pterygium As 0.05% soln in sterile Ringer's solution: Instill every 3 hrly, for up to 6 wk. Intravesical Bladder cancer Instill 60 mg into the bladder of patient previously dehydrated for 8-12 hr and retained for 2 hr. May repeat wkly, for up to 4 wk. \n\nIntracavitary Malignant effusions Up to 60 mg in 20-60 mL of sterile water may be instilled after aspiration. Urethral Condylomata acuminata Instill 60 mg/wk into urethra.\n\nContra-indication: Pregnancy; lactation; hypersensitivity; severe myelosuppression with leukocyte count <3000 cells/mm3 or platelet count <150,000 cells/mm3.\n\nSide effects: GI disturbances; fatigue, weakness, headache and dizziness; hypersensitivity reactions; blurred vision and conjunctivitis; amenorrhoea, impaired fertility; local irritation, frank chemical or haemorrhagic cystitis; depigmentation of periorbital skin (eye drops).\nPotentially Fatal: Bone marrow depression, mutagenesis, teratogenesis and carcinogenesis.\n\nPrecaution: Elderly; child; preexisting renal, hepatic and bone marrow function impairment. Monitor for fever, chills, sore throat, discoloration of urine, black stools or unusual bleeding or easy bruising. Monitor blood counts before initiation, at least wkly during and at least 3 wk after discontinuation of therapy; monitor hepatic and renal function.\n\nMode of action: Concomitant use of other alkylating agents or irradiation enhance effect. Prolongs action of succinylcholine and other neuromuscular-blocking agents due to inhibition of plasma pseudocholinesterase. Increased risk of myelosuppression when used with colony-stimulating factors (such as filgrastim, lenograstim) 24 hr before to 24 hr after admin of cytotoxic chemotherapy. Coadmin with cyclophosphamide inhibit the metabolism of cyclophosphamide to its active metabolite and decrease both its efficacy and toxicity.\n\nPregnancy category: D\n\nInteraction: Concomitant use of other alkylating agents or irradiation enhance effect. Prolongs action of succinylcholine and other neuromuscular-blocking agents due to inhibition of plasma pseudocholinesterase. Increased risk of myelosuppression when used with colony-stimulating factors (such as filgrastim, lenograstim) 24 hr before to 24 hr after admin of cytotoxic chemotherapy. Coadmin with cyclophosphamide inhibit the metabolism of cyclophosphamide to its active metabolite and decrease both its efficacy and toxicity.
Timolol Maleate Eye prep	\n\n\tNovartis (Bangladesh) Ltd.\tNyolol 0.5% Eye Gel   249\n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: Adult:  As 0.25 or 0.5% gel-forming eyedrop: Instill 1 drop once daily.\n\nContra-indication: Present or history of bronchial asthma, severe COPD, sinus bradycardia, 2nd and 3rd degree heart block, sick sinus syndrome, overt heart failure, cardiogenic shock, severe peripheral vascular disease/Raynaud's disease), Prinzmetal angina, untreated pheochromocytoma, metabolic acidosis, hypotension.\n\nSide effects: Ophthalmic use: Burning, stinging, blurred vision, ocular irritation (e.g. conjunctivitis, blepharitis, crusting), decreased corneal sensitivity, visual disturbances, diplopia, ptosis, cystoid macular oedema, pseudopemphigoid, choroidal detachment following filtration surgery. Adverse reactions associated with systemic administration of beta-blocker may occur with ophthalmic use.\nPotentially Fatal: Heart failure, intensification of heart block, bronchospasm, respiratory failure.\n\nPrecaution: Due to systemic absorption of ophthalmic preparations, adverse reactions associated with systemic administration of beta-blockers may occur. Abrupt withdrawal of beta-blocker may cause exacerbation of angina, and myocardial infarctions have occurred in some cases. \n\nOphthalmic Timolol should not be used alone for treatment of angle-closure glaucoma. beta-blocker therapy may increase sensitivity towards allergen in patients with history of atrophy or severe anaphylaxis reactions. \n\nSafety and efficacy have not been established in paediatric patients.\n\nMode of action: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).\n\nPregnancy category: C\n\nInteraction: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).
Tobramycin Sulphate	\n\n\tBeximco\tTobasol Solution 300 mg/5 ml 50's pack 500\n\tIndication: Cystic fibrosis\n\nDose: Inhalation\nCystic fibrosis\nAdult: 300 mg every 12 hr inhaled from a suitable nebuliser for 28 days, then stop for 28 days and repeat in cycles of 28 days as needed. Do not give doses <6 hr apart. \n\nContra-indication: Hypersensitivity to aminoglycosides; pregnancy.\n\nSide effects: Nausea, vomiting, dizziness or vertigo, acute renal failure, interstitial nephritis, acute tubular necrosis, electrolyte imbalances, purpura, encephalopathy, convulsions, mental depression, hallucinations, ototoxicity, blood dyscrasias, increased LFT and bilirubin concentrations.\n\nPrecaution: Preexisting renal and auditory or vestibular impairment; dehydration; neuromuscular blockade, muscular disorders (e.g. myasthenia gravis, parkinsonism); neonates; elderly; lactation. \n\nMode of action: Increased nephrotoxicity or ototoxicity with etacrynic acid, furosemide, other aminoglycosides, cefalotin, cisplatin, vancomycin, piperacillin, ciclosporin, amphotericin B. Decrease serum tobramycin levels with miconazole.\nPotentially Fatal: Increased neuromuscular-blocking activity with magnesium and other neuromuscular-blocking agents.\n\nPregnancy category: D\n\nInteraction: Increased nephrotoxicity or ototoxicity with etacrynic acid, furosemide, other aminoglycosides, cefalotin, cisplatin, vancomycin, piperacillin, ciclosporin, amphotericin B. Decrease serum tobramycin levels with miconazole.\nPotentially Fatal: Increased neuromuscular-blocking activity with magnesium and other neuromuscular-blocking agents.
Tocilizumab	\n\n\tF.Hoffmann La Roche, Switzerland\tActemra Injection 80mg/4ml 1's pack 12938\n\tF.Hoffmann La Roche, Switzerland\tActemra Injection 200mg/10ml 1's pack 32344\n\tIndication: Juvenile idiopathic arthritis, Rheumatoid Arthritis (RA)\n\nDose: Adult:\nRheumatoid Arthritis\n\nIV infusion: \n\n4 mg/kg IV q4wk initially; may increase to 8 mg/kg q4wk based on clinical response \n    Not to exceed 800 mg/dose q4wk\n\nSC injection\n\n    Weight <100 kg: 162 mg SC every other week, followed by an increase to every week based on clinical response\n    Weight >100 kg: 162 mg SC every week\n\nDosage Modifications\n\nRenal impairment\n\n    Mild: No dosage adjustment required\n    Moderate-to-severe: Has not been studied\n\nHepatic impairment\n\n    Not recommended with active hepatic disease or hepatic impairment.\n\nPediatric:\n\nSystemic Juvenile Idiopathic Arthritis (SJIA, Still's Disease)\n\n<2 years: Safety and efficacy not established\n\n2 years or older (<30 kg): 12 mg/kg IV q2weeks \n\n2 years or older (>30 kg): 8 mg/kg IV q2weeks\nPolyarticular Juvenile Idiopathic Arthritis (PJIA)\n\n<2 years: Safety and efficacy not established\n\n2 years or older (<30 kg): 10 mg/kg IV q4weeks \n\n2 years or older (>30 kg or more): 8 mg/kg IV q4weeks\n\nMonitor neutrophils, platelets, ALT and AST at the time of the second infusion and thereafter every 4-8 weeks for PJIA and every 2-4 weeks for SJIA\n\nMonitor lipids 4-8 weeks following initiation of therapy and then at ~24 week intervals\n\nGeriatric:\n\nIncreased risk of serious infections in patient >65 years of age; caution should be used when treating the elderly\n\nContra-indication: Hypersensitivity\n\nSide effects: SC injection site reactions \n\nUpper respiratory tract infections\n\nNasopharyngitis\n\nHeadache\n\nHypertension\n\nIncreased ALT\n\nInfusion related skin reactions (eg, rash, pruritus, urticaria)\n\nDose related adverse reactions including decreased neutrophil count <1000/cu.mm, decreased platelets <100,000/cu.mm\n\nLipid elevations\n\nMouth ulcerations\n\nGastritis\n\nUpper abdominal pain\n\n\nPrecaution: Serious infections leading to hospitalization or death (ie, tuberculosis; bacterial, invasive fungal, viral, or other opportunistic infections) have occurred with use\n\nStop therapy if serious infection occurs; can restart if infection is controlled\n\nTest for latent tuberculosis before initiating; if positive, initiate tuberculosis therapy before starting tocilizumab\n\nContinue to monitor all patients for active tuberculosis during therapy\n\nMode of action: Interactions with Other Medications and Other Forms of Interaction: Population pharmacokinetic analyses did not detect any effect of MTX, nonsteroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance.\n\nTocilizumab has not been studied in combination with other biological DMARDs.\n\nThe expression of hepatic CYP450 enzymes is suppressed by cytokines, eg, IL-6, that stimulate chronic inflammation. Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, eg, tocilizumab is introduced.\n\nIn vitro studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19, and CYP3A4 enzyme expression. Tocilizumab normalizes expression of these enzymes.\n\nThe effect of tocilizumab on CYP enzymes (except CYP2C19 and CYP2D6) is clinically relevant for CYP450 substrates with a narrow therapeutic index, and/or where the dose is individually adjusted.\n\nIn a study in RA patients, levels of simvastatin (CYP3A4) were decreased by 57% one week following a single dose of tocilizumab, to the level similar or slightly higher than those observed in healthy subjects.\n\nWhen starting or stopping therapy with tocilizumab, patients taking medications, which are individually dose-adjusted and are metabolised via CYP450 3A4, 1A2, or 2C9 (eg, atorvastatin, calcium channel blockers, theophylline, warfarin, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses of these products may need to be adjusted to maintain their therapeutic effect. Given its long elimination tÂ½, the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.\n\nPregnancy category: C\n\nInteraction: Interactions with Other Medications and Other Forms of Interaction: Population pharmacokinetic analyses did not detect any effect of MTX, nonsteroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance.\n\nTocilizumab has not been studied in combination with other biological DMARDs.\n\nThe expression of hepatic CYP450 enzymes is suppressed by cytokines, eg, IL-6, that stimulate chronic inflammation. Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, eg, tocilizumab is introduced.\n\nIn vitro studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19, and CYP3A4 enzyme expression. Tocilizumab normalizes expression of these enzymes.\n\nThe effect of tocilizumab on CYP enzymes (except CYP2C19 and CYP2D6) is clinically relevant for CYP450 substrates with a narrow therapeutic index, and/or where the dose is individually adjusted.\n\nIn a study in RA patients, levels of simvastatin (CYP3A4) were decreased by 57% one week following a single dose of tocilizumab, to the level similar or slightly higher than those observed in healthy subjects.\n\nWhen starting or stopping therapy with tocilizumab, patients taking medications, which are individually dose-adjusted and are metabolised via CYP450 3A4, 1A2, or 2C9 (eg, atorvastatin, calcium channel blockers, theophylline, warfarin, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses of these products may need to be adjusted to maintain their therapeutic effect. Given its long elimination tÂ½, the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.
Tretinoin	\n\n\tAlbion Ltd.\tTretinoin Cream 0.025g/100g 100g \n\tAsiatic Ltd.\tAcnetrin Cream 25 mg/100 gm  \n\tR. P. Scherer GmbH, Germany\tVesanoid CAP 10mg 100's pack 31011\n\tIndication: Acute promyelocytic leukaemia\n\nDose: Oral\nAcute promyelocytic leukaemia\nAdult: A daily dose of 45 mg/m2 daily in 2 divided doses, continue treatment until 30 days after complete remission or 90 days of treatment given, whichever occurs first. To increase duration of remission, consolidation therapy, usually with an anthracycline- and cytarabine-based regimen, is given concurrently or subsequently, depending on the leukocyte count.\n\nChild: A daily dose of 45 mg/m2 daily in 2 divided doses, continue treatment until 30 days after complete remission or 90 days of treatment given, whichever occurs first. To increase duration of remission, consolidation therapy, usually with an anthracycline- and cytarabine-based regimen, is given concurrently or subsequently, depending on the leukocyte count. Reduce dose if serious or intolerable drug toxicity. However, the safety and efficacy < 45 mg/m2 daily in paediatric patients have not been established.\nHepatic impairment: Decrease to 25 mg/m2 daily.\n\nContra-indication: Hypersensitivity to retinoids. Application to eczematous, sunburnt or abraded skin. Pregnancy, lactation.\n\nSide effects:  Oral: Haemorrhage, reversible hypercholesterolemia and/or hypertriglyceridemia, acidosis, hypothermia, pseudotumour cerebri, infection, dizziness, paresthesias, anxiety, dryness of skin and mucous membranes, nausea, vomiting, GI haemorrhage, mucositis, decreased appetite, rash, pruritus, increased sweating, alopecia, bone pain, peripheral oedema, renal insufficiency, earache, visual disturbances, neurotoxicity.\n\nPotentially Fatal: Retinoic acid syndrome, cardiac arrthythmia, disseminated intravascular coagulation, blood dyscrasias, cardiac arrest, cerebral haemorrhage.\n\nPrecaution: Oral: Children, hepatic or renal impairment. Reduce dose if intractable headache occurs. Discontinue temporarily if LFT exceed 5 times upper limit of normal. Monitor closely for leukocytosis or respiratory compromise. Monitor haematologic profile, coagulation parameters, LFT, serum triglyceride and cholesterol concentrations regularly.\n\nMode of action: Enhances percutaneous absorption of minoxidil. Increased risk of fatal thrombotic complications with antifibrinolytic. Increased tretinoin concentrations with azole antifungals. Enhances peeling action of sulphur, resorcinol, benzoyl peroxide, salicylic acid. Increased photosensitivity with photosensitising medications eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides.\nPotentially Fatal: Increased risk of intracranial pressure with tetracyclines.\n\nPregnancy category: D\n\nInteraction: Enhances percutaneous absorption of minoxidil. Increased risk of fatal thrombotic complications with antifibrinolytic. Increased tretinoin concentrations with azole antifungals. Enhances peeling action of sulphur, resorcinol, benzoyl peroxide, salicylic acid. Increased photosensitivity with photosensitising medications eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides.\nPotentially Fatal: Increased risk of intracranial pressure with tetracyclines.
Triptorelin Acetate	\n\n\tIndication: Uterine fibroids, Female infertility, Endometriosis, Prostate cancer\n\nDose: Prostate cancer. Adult: 3 or 3.75 mg by IM Inj every 4 wk using 1 mth depot preparation. The 1st dose may be preceded with 0.1 mg daily for 7 days by SC inj. Alternatively, 11.25 mg IM every 12 wk using the 3 mth depot formulation.\n\nIntramuscular Endometriosis. Adult: 3 or 3.75 mg by IM Inj every 4 wk for up to 6 mth. Begin treatment during the 1st 5 days of the menstrual cycle.IntramuscularUterine fibroidsAdult: 3 or 3.75 mg by IM Inj every 4 wk for up to 6 mth. Begin treatment during the 1st 5 days of the menstrual cycle.\n\nSubcutaneous Female infertility Adult: In conjunction with gonadotrophins, 0.1 mg daily by SC Inj starting from the 2nd day of the menstrual cycle for 10-12 days.\n\nParenteral Precocious puberty Child: 50 mcg/kg, using the 3 mg depot preparation by IM Inj every 4 wk. Alternatively, using the 3.75 mg depot preparation, <20 kg 1.875 mg, 20-30 kg 2.5 mg, >30 kg 3.75 mg by IM or SC inj; first 3 doses to be given at 14 day intervals with further doses given every 4 wk.\n\nContra-indication: Hypersensitivity to triptorelin and other luteinising hormone-releasing hormone (LHRH) or LHRH agonists; as sole treatment in prostate cancer patients with spinal cord compression or evidence of spinal metastases; progressive brain tumours in children. Pregnancy; lactation.\n\nSide effects: Hot flushes, weight gain, sleep disturbances, headache, hypertension, weight gain, decreased libido, abnormal vision, mood disorders, nausea, abdominal pain or discomfort, rash and impotence. Transient pain, redness or local inflammation at the inj site may occur. Prostate cancer: During first few wk, bone pain, worsening of urinary obstruction symptoms and/or worsening of neurological signs of vertebral metastases (back pain, weakness or paresthesia of the lower limbs). Gynaecomastia, vertigo and dizziness. Endometriosis: Initial worsening of pelvic pain, dysmenorrhoea with heavy menstrual bleeding or spotting. Sweating, vaginal dryness, dyspareunia, breast pain, hair loss, small loss in bone density. Precocious puberty: Mild or moderate withdrawal bleeding in the first mth of treatment.\nPotentially Fatal: Anaphylactic shock.\n\nPrecaution: Patients with pituitary adenoma; weight-related amenorrhoea until weight corrected; polycystic ovary disease or endometriotic cysts; metabolic bone disease. Monitor closely as there may be initial worsening of signs and symptoms during first few wk of therapy. Contraceptive measures to be taken to protect against unwanted ovulation in females.\n\nMode of action: Decrease in LHRH receptors in pituitary with hyperprolactinaemic drugs antagonises effects of triptorelin.\n\nPregnancy category: X\n\nInteraction: Decrease in LHRH receptors in pituitary with hyperprolactinaemic drugs antagonises effects of triptorelin.
Valganciclovir	\n\n\tIndication: Cytomegalovirus infections\n\nDose: Adult:\nCytomegalovirus Retinitis in Patients with AIDS, Treatment\n\nInduction dose: 900 mg PO q12hr for 21 days\n\nMaintenance dose: 900 mg PO qDay\nCMV Prevention in Solid Organ Transplant\n\nKidney transplantation\n\n    900 mg PO qDay\n    Begin within 10 days of transplant until 200 days post-transplant\n\nKidney-pancreas transplantation\n\n    900 mg PO qDay\n    Begin within 10 days of transplant until 100 days posttransplant\n\nHeart transplantation\n\n    900 mg PO qDay\n    Begin within 10 days of transplant until 100 days posttransplant\n\nRenal Impairment\n\nCrCl 40-59 mL/min: 450 mg PO q12hr (induction), THEN 450 mg qDay\n\nCrCl 25-39 mL/min: 450 mg PO qDay (induction), THEN 450 mg q2days\n\nCrCl <25 mL/min: 450 mg PO q2days (induction), THEN 450 mg 2 times/week\n\nHD: Give ganciclovir instead\nOther Information\n\nAdministration: take with food\n\nMonitor: CBC\n\nPediatric:\nCMV Prevention in Kidney & Heart Transplant\n\n<4 months: Safety and efficacy not established\n\n4 months -16 years: Daily dose = 7 mg x BSA x CrCl; not to exceed 900 mg/day \n\nBegin within 10 days of transplant until 100 days post-transplant\n\nCalculate BSA by Mosteller equation\n\n    BSA (sq.meter) = height (cm) X weight (kg) divided by 3600 \n\nCalculate CrCl by Schwartz equation\n\n    CrCl (mL/min/1.73 sq.meter) = K x height (cm) divided by serum Cr (mg/dL)\n    If CrCl exceeds 150 mL/min/1.73 sq.meter, then use maximum value of 150 mL/min/1.73 sq.meter; an upper limit of 150 mL/min/1.73 sq. meter helps prevent the potential for over dosing\n    If the calculated pediatric dose exceeds 900 mg, a dose of 900 mg should be given to the child\n    Where K =\n    0.45 for aged 4 months to <2 yr\n    0.45 for boys aged 2 -12 yr and girls aged 2-16 yr\n    0.7 for boys aged 13-16 yr\n\nGeriatric:\n\nCytomegalovirus Retinitis in Patients with AIDS, Treatment\n\nInduction dose: 900 mg PO q12hr for 21 days\n\nMaintenance dose: 900 mg PO qDay\nCMV Prevention in Solid Organ Transplant\n\nKidney transplantation\n\n- 900 mg PO qDay\n\n- Begin within 10 days of transplant until 200 days post-transplant\n\nKidney-pancreas transplantation\n\n- 900 mg PO qDay\n\n- Begin  within 10 days of transplant until 100 days posttransplant\n\nHeart transplantation\n\n- 900 mg PO qDay\n\n- Begin  within 10 days of transplant until 100 days posttransplant\n\n\nContra-indication: Hypersensitivity to valganciclovir, ganciclovir\n\nHemodialysis patients (use ganciclovir instead)\n\nANC <500/cu.mm, Patients <25,000/cu.mm, Hgb <8 g/dL\n\nLiver transplant patients\n\nConcomitant zidovudine: increases hematological toxicity\n\nSide effects: Abdominal pain \n\nAnemia\n\nDiarrhea\n\nFever\n\nGranulocytopenia \n\nHeadache\n\nInsomnia \n\nNausea \n\nRetinal detachment \n\nVomiting\n\nPeripheral neuropathy \n\nParesthesia \n\nSeizures \n\nPsychosis, hallucinations \n\nConfusion \n\nAgitation \n\nThrombocytopenia \n\nPancytopenia \n\nBone marrow depression \n\nAplastic anemia \n\nBleeding, potentially life-threatening due to thrombocytopenia \n\nDecr renal function \n\nLocal & systemic infections, incl sepsis \n\nAllergic reaction \n\n\nPrecaution: Valganciclovir metabolized to ganciclovir\n\nGranulocytopenia, anemia, and thrombocytopenia reported\n\nAnimal studies showed cidofovir was carcinogenic, teratogenic, and caused hypospermia\n\nMode of action: Imipenem-cilastatin, probenecid, zidovudine, didanosine, mycophenolate mofetil, zalcitabine, trimethoprim, cyclosporin.\n\nPregnancy category: C\n\nInteraction: Imipenem-cilastatin, probenecid, zidovudine, didanosine, mycophenolate mofetil, zalcitabine, trimethoprim, cyclosporin.
Valsartan + Hydrochlorothiazide	\n\n\tIndication: Hypertension\n\nDose: Adult: PO Per tab contains valsartan (mg)/hydrochlorothiazide (mg): 80/12.5; 160/12.5; 160/25; 320/12.5; 320/25: Initial: 80/12.5 mg once daily, up to 320/25 mg if needed.\n\nRenal impairment:\nCrCl (ml/min)	\n<30 	Not recommended. \n\nContra-indication: Hypersensitivity to valsartan, hydrochlorothiazide or sulphonamides. Severe hepatic impairment, creatinine clearance <30ml/min, anuria, cirrhosis, biliary obstruction, conditions where there is increased potassium loss (e.g. salt losing nephropathies and pre-renal impairment of kidney function), refractory hypokalaemia, hyponatraemia, hypercalcaemia, hyperuricaemia, history of gout and uric acid stones, untreated Addison's disease. Pregnancy and lactation.\n\nSide effects: Headache, asthenia, fatigue, dizziness, somnolence, insomnia, orthostatic hypotension, paraesthesia, nasopharyngitis, tachycardia, palpitations, tinnitus, vertigo, dyspepsia, diarrhoea, flatulence, dry mouth, nausea, vomiting, abdominal pain, peripheral oedema, pyrexia, increased BUN, elevated LFT, anxiety, erectile dysfunction, glucose intolerance, increased serum cholesterol, triglycerides, uric acid. Electrolyte imbalances e.g. hypomagnesaemia, hypercalcaemia, hyponatraemia, hypochloraemic alkalosis.\n\nPrecaution: DM, postsympathectomy patients. May exacerbate SLE. Monitor serum potassium regularly. Observe for signs of fluid or electrolyte imbalance. Discontinue before testing for parathyroid function. May affect ability to drive or operate machinery. Elderly.\n\nMode of action: Valsartan: May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.\nPotentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).\n\nHydrochlorothiazide: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.\n\nPregnancy category: D\n\nInteraction: Valsartan: May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes.\nPotentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).\n\nHydrochlorothiazide: Increases toxicity of lithium. May potentiate orthostatic hypotension w/ barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect w/ corticosteroids, corticotropin, ?2 agonists (e.g. salbutamol). Additive effect w/ other antihypertensives. Potentiation of orthostatic hypotension w/ barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
Varenicline Tartrate	\n\n\tMonicopharma\tVarni TAB dr 0.5 mg  \n\tIndication: Smoking cessation aid\n\nDose: Adult: PO 0.5 mg once daily for 1st 3 days, followed by 0.5 mg twice daily for the next 4 days. Maintenance (wk 2-12): 1 mg twice daily. Initiate dose 1-2 wk before target quit date. \n\nUsual treatment duration: 12 wk. May continue for another 12 wk to reduce relapse in patients who have successfully quitted after the initial treatment course.\n\nContra-indication: \n\nSide effects: Nausea, headache, dizziness, somnolence, fatigue, sleep disturbances, increased appetite and GI disturbances including vomiting, constipation and flatulence.\n\nPrecaution: Monitor for signs of suicidal ideation or behaviour, or changes in behaviour. May affect performance of skilled tasks. Not recommended for use in children <18 yr. Pregnancy, lactation.\n\nMode of action: Increased incidence of adverse effects (nausea, vomiting) w/ transdermal nicotine. Increased exposure w/ cimetidine.\n\nPregnancy category: C\n\nInteraction: Increased incidence of adverse effects (nausea, vomiting) w/ transdermal nicotine. Increased exposure w/ cimetidine.
Verteporfin	\n\n\tJHP Pharmaceuticals, USA\tVisudyne Injection 15mg/vial 15 mg ( in singel- use glass ) vial 137280\n\tIndication: Neovascular age-related macular degeneration\n\nDose: Adult: IV 6 mg/m2, followed by activation using laser (at a wavelength of 689 nm) 15 mins after starting infusion. Recommended light dose: 50 J/cm2 over 83 sec. Repeat 3 mthly for recurrent choroidal neovascular leakage.\n\nContra-indication: Porphyria; lactation.\n\nSide effects: Visual disturbances; severe vision loss with or without subretinal or vitreous bleeding; inj site reactions; nausea; photosensitivity; asthenia; cataracts; blepharitis; conjunctivitis; dry eyes; ocular itching; flu-like syndrome; atrial fibrillation; hypertension; peripheral vascular disorder; varicose veins; eczema; constipation; GI cancers; fever; lachrymation disorder; hypersensitivity reactions; increased LFT.\n\nPrecaution: Moderate to severe hepatic disorders; biliary disorders. Pregnancy. Use the largest arm vein possible (e.g. antecubital) especially in elderly and avoid small veins in the back of the hand. Stop infusion if extravasation occurs and protect extravasation area from direct light and apply cold compresses. Patient to be under close monitoring during verteporfin infusion and exercise caution when general anaesthesia is considered. Avoid exposure of unprotected skin, eyes or other body organs to direct sunlight or bright indoor light for 5 days after treatment. Protect all parts of skin and eyes by wearing protective clothing and dark sunglasses (sunscreens are ineffective) if going outdoors in daylight is necessary. Exposure to ambient indoor light is encouraged as it helps in gradual inactivation of any remaining drug.\n\nMode of action: Increased rate of verteporfin uptake by the vascular endothelium with calcium channel blockers, polymyxin B or radiation therapy. Increased photosensitivity with photosensitizing agents (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycaemic agents, thiazide diuretics and griseofulvin). Decreased verteporfin efficacy with compounds that quench active oxygen species or scavenge radicals e.g. dimethyl sulfoxide, betacarotene, ethanol, formate and mannitol. Decreased verteporfin efficacy with drugs that decrease clotting, vasoconstriction or platelet aggregation e.g. thromboxane A2 inhibitors. Anaesthetics may cause haemodynamic effects.\n\nPregnancy category: C\n\nInteraction: Increased rate of verteporfin uptake by the vascular endothelium with calcium channel blockers, polymyxin B or radiation therapy. Increased photosensitivity with photosensitizing agents (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycaemic agents, thiazide diuretics and griseofulvin). Decreased verteporfin efficacy with compounds that quench active oxygen species or scavenge radicals e.g. dimethyl sulfoxide, betacarotene, ethanol, formate and mannitol. Decreased verteporfin efficacy with drugs that decrease clotting, vasoconstriction or platelet aggregation e.g. thromboxane A2 inhibitors. Anaesthetics may cause haemodynamic effects.
Typhoid Vaccine  (live attenuated)	\n\n\tIndication: Prophylaxis of Typhoid fever \n\nDose: Indicated for selective immunization against typhoid fever for people traveling to endemic areas\n\n1 capsule PO every other day x 4 doses (days 1, 3, 5, and 7)\n\nSwallow 1 hr before meal with cold or luke-warm drink\n\nBooster: Repeat same regimen every 5 yr \n\nContra-indication: Congenital and acquired immune deficiency, including treatment with immunosuppressive and antimitotic drugs, acute febrile illness and acute intestinal infection. Safety of the vaccination during pregnancy has not yet been established.\n\nSide effects: In very rare cases, mild gastrointestinal disturbances or a transitory exanthema may occur.\n\nPrecaution: Certain antibiotics as well as sulfonamides are active against Salmonellae. These products should not be given simultaneously with Vivotif.\nOther inoculations, including live vaccines, may be administered at the same time.\n\nMode of action: Concurrent use with antibiotics or immunoglobulins may reduce the efficacy of typhoid vaccine. Mefloquine may increase the efficacy of typhoid vaccine. May reduce the diagnostic effect of tuberculin tests.\nPotentially Fatal: Concurrent use with immunosuppressants may increase the adverse effects of live vaccines.\n\nPregnancy category: C\n\nInteraction: Concurrent use with antibiotics or immunoglobulins may reduce the efficacy of typhoid vaccine. Mefloquine may increase the efficacy of typhoid vaccine. May reduce the diagnostic effect of tuberculin tests.\nPotentially Fatal: Concurrent use with immunosuppressants may increase the adverse effects of live vaccines.
Oral Cholera Vaccine (Vibrio cholerae 01 Inaba & Ogawa strains)	\n\n\tSBL Vaccin AB, Sweden\tDukoral Oral Vaccine   2doses pack 2398\n\tIndication: Cholera,  Protection against cholera in adult & children >2 yr.\n\nDose: Oral\nActive immunisation against cholera\nAdult: For primary vaccination schedule: Given as a suspension (in doses of 3 ml, mixed with sodium hydrogen carbonate solution): 2 doses, at wkly intervals. \n\nComplete immunisation 1 wk prior to potential exposure. If >6 wk have elapsed between doses, primary immunisation course should be re-initiated. \n\nA single booster dose may be given after 2 yr to maintain protection.\n\nChild: For primary vaccination schedule: Given as a suspension (in doses of 3 ml, mixed with sodium hydrogen carbonate solution): 2-6 yr: 3 doses, at wkly intervals; >6 yr: 2 doses, at wkly intervals. \n\nComplete immunisation 1 wk prior to potential exposure. If >6 wk have elapsed between doses, primary immunisation course should be re-initiated. \n\nA single booster dose may be given after 6 mth (2-6 yr) or 2 yr (>6 yr), depending on the age of the patient to maintain protection.\n\nContra-indication: Hypersensitivity. Acute stomach disorder or infection w/ fever (postpone vaccination).\n\nSide effects:  GI disturbances, headache.\n\nPrecaution: There are only limited data on safety and immunogenicity of the vaccine in children aged 1 to 2 years\nand protective efficacy has not been studied. Therefore, this is not recommended to be used in\nchildren less than 2 years of age.\nThere are only very limited data on protective efficacy of the vaccine in subjects aged 65 years and\nmore.\nNo clinical data on protective efficacy of this vaccine against cholera after administration of booster doses\nare available.\nThis vaccine confers protection specific to Vibrio cholerae serogroup O1. Immunisation does not protect\nagainst V. cholerae serogroup O139 or other species of Vibrio.\nIn subjects infected with HIV, limited data are available on immunogenicity and safety of the vaccine.\nVaccine protective efficacy has not been studied. Immunisation of HIV infected subjects could result\nin transient increases of viral load. Dukoral may not induce protective antibody levels in subjects with\nadvanced HIV disease.\nFormaldehyde is used during the manufacturing process and trace amounts may be present in the final\nproduct. Caution should be taken in subjects with known hypersensitivity to formaldehyde.\nThe vaccine does not provide complete protection and it is important to adhere to standard protective\nmeasures to avoid cholera.\n\nMode of action: Not to be used within 3 wk of immunoglobulin admin. Reduced response may occur in patients who are concurrently receiving immunosuppressant treatment e.g. antineoplastics, corticosteroids at therapeutic doses. Oral, encapsulated typhoid vaccine should not be admin within 8 hr of cholera vaccine admin.\n\nPregnancy category: Not Classified\n\nInteraction: Not to be used within 3 wk of immunoglobulin admin. Reduced response may occur in patients who are concurrently receiving immunosuppressant treatment e.g. antineoplastics, corticosteroids at therapeutic doses. Oral, encapsulated typhoid vaccine should not be admin within 8 hr of cholera vaccine admin.
Vincristine Sulphate	\n\n\tBeacon\tCriston 1 Injection 1 mg/vial  \n\tBeacon\tCriston 2 Injection 2 mg/vial  \n\tTechno Drugs Ltd.\tVincrist Injection 2mg/vial 1's pack 550\n\tTechno Drugs Ltd.\tVincrist Injection 1mg/vial 1's pack 300\n\tTechno Drugs Ltd.\tVincristin Injection 1 mg/vial  \n\tPharmachemie B. V. Netherlands\tVincristine PCH Injection 1mg/ml 10 amps pack 2650\n\tIndication: Acute lymphoblastic leukaemia; Acute myeloid leukaemia; AIDS-related Kaposi's sarcoma; Brain tumours; Hodgkin's disease; Neuroblastoma; Non-Hodgkin's lymphoma; Small cell lung cancer; Wilm's tumour \n\nDose: Intravenous\nAcute lymphoblastic leukaemia, AIDS-related Kaposi's sarcoma, Hodgkin's disease, Neuroblastoma, Small cell lung cancer, Wilm's tumour, Brain tumours, Non-Hodgkin's lymphoma, Acute myeloid leukaemia\nAdult: Usual recommended dosage: 1.4-1.5 mg/m2 once wkly. Max: 2 mg wkly. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of admin.\n\nChild: Usual recommended dosage: 1.5-2 mg/m2 once wkly; for patients ?10 kg: Initiate at 0.05 mg/kg once wkly. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of admin.\n\nHepatic impairment: Dose adjustment may be needed. Serum bilirubin >3 mg/100ml: Reduce dose by 50%.\n\nContra-indication: Patients with demyelinating form of Charcot-Marie-Tooth syndrome. Pregnancy and lactation. Intrathecal admin (may be fatal). Patients receiving radiation therapy through ports which include liver.\n\nSide effects:  Dose limiting neurotoxicity (e.g. motor function impairment, gait abnormalities), hyperuricaemia, bronchospasm, azospermia, amenorrhoea, alopoecia, leucopenia, urinary dysfunction, abdominal cramps, vomiting, diarrhoea, severe constipation, paralytic ileus, convulsions, hypertension, orthostatic hypotension, ptosis, hoarseness, optic neuropathies, hallucinations, blindness, neurological deafness, difficulty in walking, syndrome of inappropriate ADH secretion.\nPotentially Fatal: Myelosuppression.\n\nPrecaution: Elderly. Preexisting pulmonary dysfunction or neuromuscular disease; leucopenia or a complicating infection; impaired liver function; obstructive jaundice. Routine prophylactic laxative needed to ensure regular bowel movement. Discontinue immediately if extravasation occurs, and inj any remaining drug into another vein, followed by local Inj of hyaluronidase and topical heat application to the affected area to aid in drug removal and reduce discomfort. Discontinue in patients who develop progressive dyspnea. CBC to be checked before each dose admin. Frequent monitoring of uric acid during first 3-4 wk of treatment and watch out for uric acid nephropathy.\n\nMode of action: Decreased digoxin (tablets) and verapamil absorption with antineoplastic regimens. Increased etoposide serum levels with vincristine. Increased toxicity when ganciclovir given with, immediately before or after vincristine. Reduced vincristine metabolism with miconazole. Increased neurotoxicity with isoniazid, itraconazole, voriconazole, posaconazole and nifedipine. Decreased immune response when used concurrently with vaccines. Increased myelotoxicity with zidovudine. \n\nIncreased risk of thromboembolic complications with tamoxifen. Increased risk of ototoxicity with ototoxic drugs (e.g. platinum-containing antineoplastic agents). Possible risk of earlier onset and/or increased severity of adverse effects with macrolides. Possible increase in vincristine levels with aprepitant. Possible decrease in antiepileptic levels with vincristine, monitor serum antiepileptic levels and effectiveness of chemotherapy.\n\nPotentially Fatal: Increased risk of bronchospasm with mitomycin C. Reduced vincristine clearance and increased toxicity with asparaginase, minimise toxicity by giving vincristine 12-24 hr before L-asparaginase admin.\n\nPregnancy category: D\n\nInteraction: Decreased digoxin (tablets) and verapamil absorption with antineoplastic regimens. Increased etoposide serum levels with vincristine. Increased toxicity when ganciclovir given with, immediately before or after vincristine. Reduced vincristine metabolism with miconazole. Increased neurotoxicity with isoniazid, itraconazole, voriconazole, posaconazole and nifedipine. Decreased immune response when used concurrently with vaccines. Increased myelotoxicity with zidovudine. \n\nIncreased risk of thromboembolic complications with tamoxifen. Increased risk of ototoxicity with ototoxic drugs (e.g. platinum-containing antineoplastic agents). Possible risk of earlier onset and/or increased severity of adverse effects with macrolides. Possible increase in vincristine levels with aprepitant. Possible decrease in antiepileptic levels with vincristine, monitor serum antiepileptic levels and effectiveness of chemotherapy.\n\nPotentially Fatal: Increased risk of bronchospasm with mitomycin C. Reduced vincristine clearance and increased toxicity with asparaginase, minimise toxicity by giving vincristine 12-24 hr before L-asparaginase admin.
Yellow fever Virus (Live attenuated) Vaccine	\n\n\tSanofi Pasteur S A ,France\tStamaril Injection  1000u/0.5ml 1's pack 1000.63\n\tIndication: Yellow fever infection\n\nDose: Primary Vaccination: Adults and Children >9 months: 0.5 mL of reconstituted vaccine administered as a single dose.\n\nChildren <9 months: The vaccine must not be given to children <6 months. Vaccination against yellow fever is not usually recommended in children aged from 6 months up to 9 months except in specific circumstances and in accordance with available official recommendations, in which case, the dose is the same as in older children and adults.\n\nThe vaccine should be given at least 10 days before entering an endemic area since protective immunity may not be achieved until at least this time has elapsed.\n\nElderly: The dose is the same as for adults. However, due to a higher risk of yellow fever vaccine-associated severe and potentially fatal disease in persons from 60 years of age, the vaccine should only be given when it is considered that there is a considerable and unavoidable risk of acquiring yellow fever infection.\n\nRe-Vaccination: Re-vaccination with 1 dose of 0.5mL is recommended every 10 years in persons considered to be at risk of exposure. International Health Regulations (IHR) require re-vaccination, using the same dose as for primary vaccination, at intervals of 10 years in order to retain a valid certificate.\n\nFor IM use, the recommended injection sites are the anterolateral aspect of the thigh in the infants and toddlers (6 months up to 2 years of age) and the deltoid muscle in older children and adults.\n\n\nContra-indication: Hypersensitivity reaction to eggs, chicken proteins or to any component of this vaccine.\nSerious hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any yellow fever vaccine.\nImmunosuppression, whether congenital, idiopathic or as a result of treatment with systemic steroids (greater than the standard dose of topical or inhaled steroids), radiotherapy or cytotoxic drugs.\nHistory of thymus dysfunction (including thymoma, thymectomy).\nSymptomatic HIV infection.\nAsymptomatic HIV infection when accompanied by evidence of impaired immune function (see Precautions).\nAge <6 months (see Dosage & Administration and Precautions).\nCurrent severe febrile illness.\n\nSide effects:  Hypersensitivity. The most common adverse reactions occurring after vaccine administration were local reactions. Nervous System Disorders: Very Common: Headache.\nGastrointestinal System Disorders: Common: Nausea, diarrhoea, vomiting. Uncommon: Abdominal pain.\nMusculoskeletal and Connective Tissue Disorders: Common: Myalgia. Uncommon: Arthralgia.\nGeneral Disorders and Administration Site Conditions: Very Common: Local reactions (including pain, redness, hematoma, induration, swelling). Common: Pyrexia, asthenia.\n\nPrecaution: As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of anaphylaxis or other severe hypersensitivity reaction following administration of the vaccine.\nStamaril should be administered only to persons who are or will be at risk of infection with yellow fever virus or who must be vaccinated to comply with IHR.\nImmunosuppressed Persons:It must not be administered to immunosuppressed persons.\nChildren Born to HIV Positive Mothers: Children aged at least 6 months may be vaccinated if it is confirmed that they are not infected with HIV.\nHIV-infected children aged at least 6 months who are potentially in need of protection against yellow fever should be referred to a specialist paediatric team for advice on whether or not to vaccinate.\n This vaccine must not be administered to children before the age of 6 months.\n\nSixty Years and Older: Some serious and potentially fatal adverse reactions (including systemic and neurological reactions persisting >48 hrs, YEL-AVD and YEL-AND) appear to occur at higher frequencies after the age of 60 years. Therefore, the vaccine should only be given to those who have a considerable risk of acquiring yellow fever.\nBecause IM injection can cause injection site haematoma, Stamaril should not be given by the IM route to persons with any bleeding disorder, eg, haemophilia or thrombocytopenia, or to persons on anticoagulant therapy. The subcutaneous route of administration should be used instead.\nPatients with rare hereditary problems of fructose intolerance should not take this vaccine.\n\n\n\nMode of action: Immunosuppressants eg cytotoxic agents, systemic steroids.\n\nPregnancy category: D\n\nInteraction: Immunosuppressants eg cytotoxic agents, systemic steroids.
Zannamivir	\n\n\tIndication: Influenza A and B\n\nDose: Inhalation\nInfluenza A and B\nAdult: 10 mg (2 inhalations) bid for 5 days, admin as soon as possible (within 48 hr) after the onset of symptoms. 2 doses should be taken on 1st day of treatment provided there is at least an interval of at least 2 hr between doses, subsequent doses to be given every 12 hr.\n\nChild: >7 yr: 10 mg (2 inhalations) bid for 5 days, admin as soon as possible (within 48 hr) after the onset of symptoms. 2 doses should be taken on 1st day of treatment, if possible, provided there is at least an interval of at least 2 hr between doses, subsequent doses to be given every 12 hr.\n\nProphylaxis of influenza A and B\nAdult: For community outbreak: 10 mg (2 inhalations) once daily for 28 days, to be started within 5 days of outbreak. For prophylaxis in household setting: 10 mg (2 inhalations) once daily for 10 days, to be started within 36 hr of exposure.\n\nChild: For community outbreak: >12 yr: 10 mg (2 inhalations) once daily for 28 days, started within 5 days of outbreak. For prophylaxis in household setting: >5 yr: 10 mg (2 inhalations) once daily for 10 days, to be started within 36 hr of exposure.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Nasal symptoms, headache, dizziness, GI disturbances, cough, infection, rash, bronchitis. Rarely, hypersensitivity reactions, arrhythmias, bronchospasm, dyspnoea, facial oedema, seizures and syncope.\n\nPrecaution: Pregnancy, lactation. High risk of bronchospasm in chronic respiratory diseases. Fast-acting bronchodilator should be readily available for asthma/COPD patients; avoid in severe asthma. Bronchodilators to be inhaled before zanamivir admin. Discontinue if bronchospasm develops or there is decrease in respiratory function.\n\nMode of action: Do not admin live attenuated influenza vaccine intranasal within 2 wk before or 48 hr after zanamivir admin to improve response to vaccine.\n\nPregnancy category: C\n\nInteraction: Do not admin live attenuated influenza vaccine intranasal within 2 wk before or 48 hr after zanamivir admin to improve response to vaccine.
Zinc Pyrithione 1% + Polytar 1%	\n\n\tIndication: Psoriasis, Dandruff, Scaly, itchy scalps caused by conditions such as Dermatitis,Pruritus and Eczema\n\nDose: Polytar AF (Salicylic Acid) is applied to the skin surface 2-3 times / day.\n\nContra-indication:  Hypersensitivity to salicylic acid, renal failure, infancy.\n\n\nSide effects:  Rarely: local reactions such as itching, burning, skin rashes, allergic reactions.\n\nPrecaution: Avoid contact with eyes.\n\nAvoid inflamed or broken skin.\n\nAvoid exposure to sunlight .\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Zuclopenthixol	\n\n\tA/S Lundbeck Export DivisionLtd., Denmark\tClopixol Acuphase Injection 50mg/ml 5 amp's pack 2607\n\tH. Lundbeck & Co., A/S, Denmark\tClopixol 	 TAB dr 10mg 	 	 100's pack  1593\n\tH. Lundbeck & Co., A/S, Denmark\tClopixol Depot 	 Injection 200mg/ml 	 10 amp's pack   4333.10 		\n\tIndication: Schizophrenia, Psychoses, Bipolar mania\n\nDose: Adult: PO Psychoses Initial: 20-30 mg/day in divided doses. Maintenance: 20-50 mg/day. Max: 150 mg/day. \n\nIM Acute psychosis As acetate ester: 150 mg, repeat if needed 2-3 days later. Max cumulative dose: 400 mg/course. Max number of inj: 4/course. Max duration: 2 wk. \n\nChronic psychosis As decanoate ester: Initial: 100 mg as test dose, followed after at least 1 wk by 200-500 mg or more, repeated at 1-4 wkly if needed. Max: 600 mg/wk. Inj >2 mL to be distributed between 2 inj sites.\n\nContra-indication: Hypersensitivity. Comatose states e.g. alcohol, barbiturate and opiate intoxications; porphyria. children.\n\nSide effects: Drowsiness, blurred vision, tachycardia, nausea, dizziness, headache, excitement, postural hypotension, hyperprolactinaemia, sexual dysfunction, ECG changes (prolongation of QT interval and T wave changes), hyperthermia. Extrapyramidal symptoms may occur, especially during the early phase of treatment; urinary frequency or incontinence; tardive dyskinesia.\nPotentially Fatal: Neuroleptic malignant syndrome, blood dyscrasias.\n\nPrecaution: Hepatic and renal impairment, heart disease, recent acute MI, arrhythmias, significant bradycardia (<50 beats/min), severe respiratory disease, epilepsy (and conditions at risk of epilepsy, e.g. alcohol withdrawal or brain damage), Parkinson's disease, acute angle glaucoma, prostatic hypertrophy, hypothyroidism, hyperthyroidism, myasthenia gravis, phaeochromocytoma. Patients at risk of stroke and QT interval prolongation. Avoid abrupt withdrawal. Ability to drive a car or operate machinery may be impaired.\n\nMode of action: Zuclopenthixol may enhance the sedative effects of alcohol and the effects of barbiturates and other CNS depressants. Zuclopenthixol reduces the antihypertensive effect of guanethidine. Concomitant use of metoclopramide and piperazine with zuclopenthixol increases the risk of extrapyramidal symptoms. Increased risk of severe neurotoxicity with lithium and sibutramine. Increased anticholinergic side effects with drugs with anticholinergic properties.\n\nPotentially Fatal: Antagonises effect of apomorphine, levodopa and other dopamine agonists. Increased risk of blood dyscrasias with clozapine. Increased risk of arrhythmias with dugs that prolong QT interval e.g. class Ia and III antiarrhythmics, erythromycin or cause electrolyte disturbances e.g. thiazide diuretics.\n\nPregnancy category: C\n\nInteraction: Zuclopenthixol may enhance the sedative effects of alcohol and the effects of barbiturates and other CNS depressants. Zuclopenthixol reduces the antihypertensive effect of guanethidine. Concomitant use of metoclopramide and piperazine with zuclopenthixol increases the risk of extrapyramidal symptoms. Increased risk of severe neurotoxicity with lithium and sibutramine. Increased anticholinergic side effects with drugs with anticholinergic properties.\n\nPotentially Fatal: Antagonises effect of apomorphine, levodopa and other dopamine agonists. Increased risk of blood dyscrasias with clozapine. Increased risk of arrhythmias with dugs that prolong QT interval e.g. class Ia and III antiarrhythmics, erythromycin or cause electrolyte disturbances e.g. thiazide diuretics.
Hydrocolloid + moisture-retentive wound dressing	\n\n\tIndication: Dermal ulcers including full-thickness wounds, pressure ulcers (Stage II-IV), Diabetic Ulcers, leg ulcers, superficial wounds, Surgical Wounds, partial thickness burns and donor sites. Also lacerations, skin tears, and minor abrasions, cuts, scalds. \n\nDose: Before using the dressing, clean the wound area with a wound cleansing agent or normal saline and dry the surrounding skin.\n\nThe size of the dressing to be applied to the wound should extend at least 1(1/4)" (3.2cm) beyond the edges of the wound. \n\nDressing can be worn for up to seven days.\n\nContra-indication: Should not be used on individuals who are sensitive to or who have had an allergic reaction to the dressing or its components.\n\nSide effects: Local skin irritation.\n\nPrecaution: During the body's normal healing process, unnecessary material is removed from the wound, which could make the wound appear larger after the first few dressing changes. If the wound continues to get larger after the first few dressing changes, consult a health care professional. \n\nFrequent dressing changes on wounds with damaged or delicate skin surrounding the wound is not recommended. The wound should be inspected during dressing changes. \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Salicylic acid 2%	\n\n\tIndication: Acne; Hyperkeratotic and scaling skin conditions\n\nDose: Adult: Topical Acne; Hyperkeratotic and scaling skin conditions As 2-6% preparation: Apply >3 times/day. Warts and calluses As 60% preparation: Apply as directed.\n\nContra-indication: Hypersensitivity\n\nSide effects: Irritation, sensitivity, excessive drying; systemic effects on prolonged use.\n\nPrecaution: Not for prolonged use in high concentrations and on large areas of the body. Impaired peripheral circulation or diabetes. Avoid broken skin, mouth, eyes, mucous membranes and anogenital region.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Clofazimine	\n\n\tIndication: Leprosy\n\nDose: Adult: PO Multibacillary leprosy 300 mg (w/ rifampicin 600 mg) once mthly combined w/ 50 mg (w/ dapsone 100 mg) daily for 12 mth. Erythema nodosum leprosum (Type 2) Treatment depends on severity. 100-200 mg/day for up to 3 mth. Doses >200 mg/day are not recommended. Gradually taper the dose to 100 mg/day as soon as the reactive episode is controlled. Dapsone-resistant leprosy 100 mg/day w/ 1 or more other antileprosy drugs for 3 yr, then continue as a monotherapy at 100 mg/day.\n\nContra-indication: Hypersensitivity. Lactation.\n\nSide effects: Red-brownish black discolouration of skin especially areas exposed to sunlight, hair, sweat, sputum, urine, faeces. Rash, pruritus, photosensitivity, diarrhoea, nausea, abdominal pain, vomiting, weight loss, headache, drowsiness, dizziness, taste disorders, dryness of the skin, ichthyosis, decreased tear and sweat production.\nPotentially Fatal: Crystal depletion in the wall of small bowel mesenteric lymph nodes, liver and spleen. Severe abdominal symptoms including bowel obstruction, GI bleeding and splenic infarction.\n\nPrecaution: Pregnancy. Patients with GI symptoms.\n\nMode of action: Dapsone\nConcomitant use of dapsone and clofazimine does not have a clinically important effect on dapsone pharmacokinetics.\nSome evidence suggests dapsone may decrease or nullify some anti-inflammatory effects of clofazimine and theoretically might adversely affect clofazimineâs efficacy in patients with ENL reactions; several borderline leprosy and lepromatous leprosy patients with severe, recurrent ENL reactions reportedly required higher clofazimine dosage to control these reactions when dapsone therapy was given concomitantly than when clofazimine was given alone.\n\nIsoniazid\nPossible increased clofazimine plasma and urine concentrations and decreased clofazimine skin concentrations.\n\nRifampin\nAlthough one study indicated that concomitant use of clofazimine in leprosy patients receiving rifampin alone or in conjunction with dapsone may decrease plasma concentrations and AUC of rifampin, concomitant use of clofazimine in another study in lepromatous leprosy patients receiving dapsone (100 mg daily) and rifampin (600 mg daily) did not affect rifampin pharmacokinetics.\n\n\nPregnancy category: C\n\nInteraction: Dapsone\nConcomitant use of dapsone and clofazimine does not have a clinically important effect on dapsone pharmacokinetics.\nSome evidence suggests dapsone may decrease or nullify some anti-inflammatory effects of clofazimine and theoretically might adversely affect clofazimineâs efficacy in patients with ENL reactions; several borderline leprosy and lepromatous leprosy patients with severe, recurrent ENL reactions reportedly required higher clofazimine dosage to control these reactions when dapsone therapy was given concomitantly than when clofazimine was given alone.\n\nIsoniazid\nPossible increased clofazimine plasma and urine concentrations and decreased clofazimine skin concentrations.\n\nRifampin\nAlthough one study indicated that concomitant use of clofazimine in leprosy patients receiving rifampin alone or in conjunction with dapsone may decrease plasma concentrations and AUC of rifampin, concomitant use of clofazimine in another study in lepromatous leprosy patients receiving dapsone (100 mg daily) and rifampin (600 mg daily) did not affect rifampin pharmacokinetics.\n
Potassium Iodide	\n\n\tIndication: Diabetic nephropathy, Thyrotoxicosis, Erythema nodosum, Iodine deficiency, Radiation emergency\n\nDose: Adult: PO Pre-op reduction of the vascularity of the thyroid gland 250 mg 3 times/day for 10-14 days pre-op. Thyrotoxicosis 500 mg 4 hrly. Given 1 hr after an antithyroid agent. \n\nCutaneous or lymphocutaneous sporotrichosis As 1 g/mL soln: 1 mL 3 times/day. Duration: >1 mth after the disappearance or stabilisation of the lesions. \nChild: Max of 1.25-2 g tid. Usual duration of therapy is 3-6 months. \n\nRadiation emergency >40 yr w/ a predicted thyroid exposure of >500 centigrays (cGy), 18-40 yr w/ a predicted exposure of >10 cGy, pregnant or lactating women w/ a predicted exposure of >5 cGy, adolescents approaching adult size (>70 kg) w/ a predicted exposure of >5 cGy: 130 mg/day until the risk of significant exposure to radioiodides no longer exists. Cough 300-650 mg 3-4 times/day.\n\nChild: 3-18 yr (except adolescents approaching adult size) with a predicted exposure of ?5 cGy: 65 mg; 1 mth-3 yr with a predicted exposure of >5 cGy: 32 mg; infants from birth-1 mth with a predicted exposure of >5 cGy: 16 mg. Doses to be taken daily until the risk of significant exposure to radioiodides no longer exists.\n\nContra-indication: Hypersensitivity. Acute bronchitis.\n\nSide effects: Hypersensitivity reactions, gastric irritation, diarrhoea. Iodism (large doses).\nPotentially Fatal: Periarteritis.\n\nPrecaution: Pregnancy, lactation. Hyperkalaemia, hyperthyroidism, myotonia congenita, renal function impairment, tuberculosis, hypocomplementemic vasculitis, goiter, autoimmune thyroid disease. Child. Repeated admin not recommended in neonatesdue to risk of hypothyroidism.\n\nMode of action: Concurrent use with antithyroid agents may lead additional hypothyroid effect. Concurrent use with potassium-containing drugs or potassium-sparing diuretics may lead to hyperkalaemia.\nPotentially Fatal: Concurrent use with lithium salts may lead to additive hypothyroid effect.\n\nPregnancy category: D\n\nInteraction: Concurrent use with antithyroid agents may lead additional hypothyroid effect. Concurrent use with potassium-containing drugs or potassium-sparing diuretics may lead to hyperkalaemia.\nPotentially Fatal: Concurrent use with lithium salts may lead to additive hypothyroid effect.
Podophyllin 25% in Tincture of Benzoin	\n\n\tIndication: Genital warts\n\nDose: Thoroughly cleanse affected area. Use supplied applicator to apply (podophyllin) sparingly to lesion. Avoid contact with healthy tissue. Allow to dry thoroughly. Only intact (no bleeding) lesions should be treated. As podophyllin is a powerful caustic and severe irritant, it is recommended the first application of (podophyllin) be left in contact for only a short time (30-40 minutes) to determine patient's sensitivity. \n\nTo avoid systemic absorption, time of contact should be minimum time necessary to produce the desired result (1 to 4 hours, depending on condition of lesion and of patient), the physician developing his/her own experience and technique. Large areas or numerous warts should not be treated at once.\n\nContra-indication: Podophyllin is contraindicated in diabetics, patients using steroids or with poor blood circulation.  (podophyllin) should not be used on bleeding warts, moles, birthmarks or unusual warts with hair growing from them. It is recommended that Podocon-25Â® (podophyllin) not be used during pregnancy\n\nSide effects: The use of topical podophyllin has been known to result in paresthesia, polyneuritis, paralytic ileus, pyrexia, leukopenia, thrombocytopenia, coma and death.\n\nPrecaution: Do not use  (podophyllin) if wart or surrounding tissue is inflamed or irritated. Do not use on bleeding warts, moles, birthmarks or unusual warts with hair growing from them.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Vitamin B7 (Biotin)	\n\n\tIndication: Biotin deficiency,  tissue maintenance, healthy skin, nails & hairs, weight loss,  Hairfall, premature greying, neuropathy, relief from heart problems, alopecia, Parkinsonâs disease, Rett syndrome and vaginal candidiasis.\n\nDose: An adequate amount of biotin is about 30 to 100 mcg daily. The biotin,  used for nutritional supplement and food labeling purposes, is 300 micrograms/day. \n\nDoses of up to 2,500 mcg have been used safely to treat hair and nail problems. Higher intakes have been recommended for reducing blood sugar levels in diabetics (5-15 mg/d). Vitamin B 7 works best when combined with B-vitamins. \n\nContra-indication: \n\nSide effects: No side effects have been reported for biotin in amounts up to 10 milligrams a day. Like other water soluble B-vitamins, excess biotin is excreted in the urine. Even when taken in high doses (2,500 mcg to treat hair and nail problems), there are no known side effects. In people without disorders of biotin metabolism, doses of up to 5 mg/day for two years were not associated with adverse effects.\n\nPrecaution: Biotin deficiency can be induced in humans by feeding them raw egg whites, which contain a protein that binds biotin and prevents its absorption. Long-term antibiotic use can interfere with biotin production in the intestine and increase the risk of deficiency symptoms, such as dermatitis, depression, hair loss, anemia, and nausea. Long-term use of anti-seizure medications may also lead to biotin deficiency. Biotin deficiency results in fatigue, depression, nausea, muscle pains, hair loss, and anemia. Biotin is necessary for both metabolism and growth in humans, particularly with reference to production of fatty acids, antibodies, digestive enzymes, and in niacin (vitamin B3) metabolism. \n\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Emollient	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tOilatum Emollient  Bottle of 150 ml 672\n\tMundipharma (Bangladesh) Pvt. Ltd.\tMederma Gel  10gm tube \n\tUnimed & Unihealth Manufacturers Ltd.\tOilatum Bar cleanser   100gm bar(soap) 258\n\tUnimed & Unihealth Manufacturers Ltd.\tOilatum Cream   40gm tube  306\n\tUnimed & Unihealth Manufacturers Ltd.\tOilatum Liquid   150ml bot 560\n\tMerz Pharmaceuticals\tMederma Gel  20gm tube 910\n\tIndication: Contact dermatitis, atopic eczema, senile pruritus, ichthyosis, eczema, dry skin, protect sensitive skin, improve skin tone and texture\n\nDose: Parents of children with eczema should try to bathe their child in an emollient wash product once a day.\nEmollient creams should be used frequently; the weekly recommended amount for children is 250 g per week.    On a day to day basis, it is recommended to apply an emollient cream at least 3 to 4 times a day. \nAdd a bath emollient to the water to help prevent the skin from drying out.After bathing, apply an emollient cream to all areas of the skin to lock in the moisture\n\nApply an emollient cream about 20 minutes before bedtime to allow it to soak in to the skin\n\n\n\nContra-indication:  Patients with a history of hypersensitivity to any of the components of the preparation.\n\nSide effects:  Skin irritation in people hypersensitive to any of the ingredients.\n\nPrecaution:     This preparation is for external use only.\n    Avoid contact with the eyes.\n    This preparation contains cetostearyl alcohol and potassium sorbate which may cause skin irritation.\n    \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Microfine zinc oxide 15%	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tSpectraban 19 Cream 15% 1's pack(50g) 660\n\tStiefel Ptd Ltd.,Ireland\tSpectraban 19 Cream  50gm  tube 660\n\tStiefel Ptd Ltd.,Ireland\tSpectraban 28 Cream  60ml bot 552\n\tIndication: Protection from harmful UV rays. Ideal for those with photodermatoses & reduced skin pigmentation, Sun block.\n\nDose: Apply on the area exposed to sunlight (such as face, neck & body) atleast 30 min before exposure and whenever necessary. Massage on to skin until absorbed.\n\nTo ensure maximum protection, we recommend repeating the application every two hours after continuous exposure to the sun and after swimming, physical exercise (sweat or dry with towel). \n\nContra-indication: Hypersensitivity to any ingredient in zinc oxide cream, lotion.\n\nSide effects: Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).\n\nPrecaution: Zinc oxide cream may be harmful if swallowed. Pregnancy & Lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Coal Tar	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tSoritar Cream 10% 50mg tube 300\n\tIndication: Psoriasis, Seborrhoeic dermatitis\n\nDose: Apply sparingly to affected area up to 4 times/day; decrease frequency to 2-3 times/week once improvement observed  	\n\nContra-indication: Application to inflamed or broken skin.\n\nSide effects: Skin irritation and acne-like skin eruptions. Photosensitivity.\n\nPrecaution: Use with caution on the face, near eyes and mucous membranes. Do not apply to genital or rectal areas. Avoid use in patient with exacerbation of psoriasis. Avoid exposure to direct sunlight and sunlamps for at least 24-72 hr after application. May stain clothes and hair. If undergoing Goeckerman treatment, all coal tar preparation should be removed from skin before exposure to radiation. Pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Betamethasone valerate 0.05%  Topical	\n\n\tSquare Cephalosporins Ltd.\tDiprobet Cream  15gm  tube 33.56\n\tSquare Cephalosporins Ltd.\tDiprobet Ointment  15gm  tube 35.14\n\tIndication: Eczema, atopic dermatitis, contact dermatitis, , systemic lupus erythematosus, lichen planus, lichen simplex, psoriasis, prurigo nodularis, plaque psoriasis							\n\n\nDose: As  valerate (0.05%): Apply sparingly 2-3 times daily. Cream for moist & ointment for dry surface.\n\nContra-indication: Underlying infection\n\nHypersensitivity\n\nOphthalmic use \n\nSide effects: Skin atrophy\n\nStriae\n\nAcneform lesions\n\nPigmentation changes\n\nHPA suppression (with higher potency used >2 wk)\n\nPrecaution: Chronic topical corticosteroid therapy may interfere with growth and development in children\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Calcipotriene 0.005%	\n\n\tIndication: Plaque psoriasis, Scalp psoriasis\n\nDose: Apply a thin layer of ointment once or twice daily and rub in gently and completely. \n\nContra-indication:  Patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.\n\nSide effects: In controlled clinical trials, the most frequent adverse reactions reported  were burning, itching and skin irritation, which occurred in approximately 10-15% of patients. Erythema, dry skin, peeling, rash, dermatitis, worsening of psoriasis including development of facial/scalp psoriasis were reported in 1 to 10% of patients. Other experiences reported in less than 1% of patients included skin atrophy, hyperpigmentation, hypercalcemia, and folliculitis. Once daily dosing has not been shown to be superior in safety to twice daily dosing.\n\nPrecaution: For external use only. Keep out of the reach of children. Always wash hands thoroughly after use.\n\nTransient, rapidly reversible elevation of serum calcium has occurred with use  . If elevation in serum calcium outside the normal range should occur, discontinue treatment until normal calcium levels are restored.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Clotrimazole 1%  Topical	\n\n\tACI\tDermasim Solution 1% 20ml 68\n\tAcme Ltd.\tClotrim Cream   10gm  tube 28.60\n\tAd-din\tLoderm Cream   10gm  tube 23\n\tAlco Pharma\tClosten Cream   10gm  tube 25\n\tBeximco\tNeosten VT Cream   20gm tube \n\tBeximco\tNeosten Cream  20gm  tube 40\n\tDoctor's Chemicals Works Ltd.\tZenestrim Cream   10gm  tube/20gm  tube 25 / 31.27\n\tG. A. Company Ltd.\tKanis Cream   10gm  tube 30\n\tGeneral\tCloderm Cream   10gm  tube 35.10\n\tGlaxoSmithKline Bangladesh Ltd.\tTinatrim Cream   10gm  tube 35.10\n\tGlobe\tClodal Cream   10gm  tube 25\n\tHealthcare\tTriderm Cream   10gm  tube/20gm  tube 26 / 40\n\tIbn Sina Pharmaceutical Ind. Ltd.\tFungin Cream   10gm  tube 35\n\tIncepta\tClarizol Solution  20ml 1's pack 50\n\tKumudini Pharma Ltd.\tFusten Cream   10gm  tube 25\n\tMystic\tMaret Cream   10gm  tube 30\n\tOpsonin Pharma\tTrimazole Cream   10gm  tube 25\n\tPharmadesh Ltd.\tCanten Cream   10gm  tube 29\n\tReman Drug Ltd.\tClotrizole Cream   10gm  tube 30.11\n\tRephco\tCantrim Cream   10gm  tube 28\n\tSharif\tClotzol Cream   10gm  tubex1 's pack 29\n\tSquare\tAfun Cream  10 mg/gm 10gm  tube 29.11\n\tSquare\tCanesten Cream   10gm tube \n\tUnimed & Unihealth Manufacturers Ltd.\tClozox Cream   10gm  tubex1 's pack 25\n\tIndication: Skin and nail fungal infections, Tinea pedis, Tinea cruris, Tinea corporis, Candidiasis, Pityriasis versicolor \n\nDose: Topical/Cutaneous Skin  and nail fungal infections: Adult: Apply 2 or 3 times daily. Onychomycosis: for 6 months.Tinea pedis & Dermatomycoses: for 4 weeks.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Topical: Erythema, stinging, irritation; hypersensitivity reactions; contact dermatitis. \n\nPrecaution: Avoid contact with eyes upon topical application. Childn <3 yrs. Pregnancy, lactation.If local intolerance develops, consider withdrawal of the medicine and institution of appropriate therapy. \n\nMode of action: Antagonism with polyene antibiotics.\n\nPregnancy category: B\n\nInteraction: Antagonism with polyene antibiotics.
Cholestyramine	\n\n\tIndication:  Bile acid-induced diarrhoea; Hyperlipidaemias, Pruritus associated w/ partial biliary obstruction or primary biliary cirrhosis\n\nDose: Hyperlipidaemias\nAdult: 12-24 g daily in single dose or up to 4 divided doses.\nChild: >6 yr: 240 mg/kg daily in divided doses.\n\nBile acid-induced diarrhoea\nAdult: 12-24 g daily in single dose or up to 4 divided doses.\nChild: >6 yr: 240 mg/kg daily in divided doses.\n \nPruritus associated with partial biliary obstruction or primary biliary cirrhosis\nAdult: 4-8 g daily.\nChild: >6 yr: 240 mg/kg daily in divided doses.\n\nContra-indication: Complete biliary obstruction; hypersensitivity.\n\nSide effects: Constipation; faecal impaction; haemorrhoids; abdominal discomfort or pain; heartburn; flatulence; nausea; vomiting; diarrhoea; increased bleeding tendency (chronic use); osteoporosis; steatorrhoea (high doses); skin rashes; pruritus of the tongue, skin and perianal region; hyperchloraemic acidosis.\n\nPrecaution: Admin as a suspension in water or a flavored vehicle to minimise risk of oesophageal obstruction. May interfere with absorption of fat-soluble vitamins and folic acid and prolonged use may be associated with an increased bleeding tendency. Pregnancy; lactation.\n\nMode of action:  	Delayed or reduced absorption of folic acid, thiazide diuretics, propranolol, digoxin and related glycosides, loperamide, phenylbutazone, barbiturates, oestrogens, progestogens, thyroid hormones, warfarin and other coumarin-derivative anticoagulants, iron salts, deferasirox and some antibacterials (e.g. tetracycline, penicillin G). May prevent absorption of fat-soluble vit. Slightly decreased rate of absorption of clofibrate. May interfere w/ absorption of oral phosphate supplements.\n\nPregnancy category: C\n\nInteraction:  	Delayed or reduced absorption of folic acid, thiazide diuretics, propranolol, digoxin and related glycosides, loperamide, phenylbutazone, barbiturates, oestrogens, progestogens, thyroid hormones, warfarin and other coumarin-derivative anticoagulants, iron salts, deferasirox and some antibacterials (e.g. tetracycline, penicillin G). May prevent absorption of fat-soluble vit. Slightly decreased rate of absorption of clofibrate. May interfere w/ absorption of oral phosphate supplements.
Stanozolol	\n\n\tIndication: Behcet's syndrome , Hereditary angioedema, Anaemia; Breast cancer in postmenopausal women; Catabolic disorders; Osteoporosis\n\nDose: Adult: PO Vascular manifestations of Behcet's syndrome 10 mg/day. Hereditary angioedema Initial: 2.5-10 mg/day. Maintenance: 2 mg/day or on alternate days or 2.5 mg 3 times/wk. \n\nIM Anaemia; Breast cancer in postmenopausal women; Catabolic disorders; Osteoporosis 50 mg 2-3 wkly.\n\nContra-indication: Pregnancy and lactation; carcinoma of prostate or breast in men, hypercalcaemia, hypercalciuria, porphyria, severe hepatic impairment.\n\nSide effects: Peliosis hepatis, premature epiphyseal closure, cholestatic jaundice, virilism, impotence, priapism, testicular atrophy, gynaecomastia, prostatic hyperplasia, decreased libido, hirsutism, menstrual irregularities; oedema, acne.\nPotentially Fatal: Hepatic necrosis, hepatocellular carcinoma.\n\nPrecaution: Patients with cardiac, renal or hepatic disease, epilepsy or DM. Children, elderly. Monitor liver function, haematocrit and haemoglobin concentrations. Not recommended for treatment of hereditary angioedema in premenopausal women.\n\nMode of action: Enhances activity of insulin, sulfonylureas, levothyroxine and anticoagulants e.g. warfarin. May cause resistance to the effects of neuromuscular blockers.\n\nPregnancy category: X\n\nInteraction: Enhances activity of insulin, sulfonylureas, levothyroxine and anticoagulants e.g. warfarin. May cause resistance to the effects of neuromuscular blockers.
Methylcobalamin + Selenium + Vitamin A+E + Zinc	\n\n\tIndication: Nutritional supplementation\n\nDose: Nutritional Supplement\nGeneral dosage range 1 to 2 capsules 3 times a day with meals\n\n\n\nContra-indication: Hypersensitivity to drug or fish or soybeans.\n\nSide effects: 1.Back pain\n2.Unusual or unpleasant taste in your mouth\n3.Upset stomach, belching\n4.Mild skin rash \n\nPrecaution: 1.Diabetes\n2.Liver disease\n3.Pancreas disorder\n4.Underactive thyroid\n5.If drink more than 2 alcoholic beverages per day \n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Sulphar +  salicylic acid (10%  & 3% ) Topical	\n\n\tIndication: Acne vulgaris, Dandruff, Seborrheic dermatitis of the scalp\n\nDose: Usual adult and adolescent dose:\nAntiacne agent:\nTopical, to the affected skin, 2 or3 times a day.\n\nDandruff or Dermatitis, seborrheic, of scalp:\nTopical, to the affected skin of the scalp, once a day at least two times a week to maintain control or as directed by physician. Apply after wetting hair, lather, massage into affected scalp, leave on scalp for five minutes, rinse, and repeat. May be used once a day if needed.\n\nPediatric dose same as adult dose.\n\nContra-indication: Sensitivity to salicylic acid and sulphar.\n\nSide effects: Skin irritation. Redness and peeling of skin may occur after a few days.\n\nPrecaution: Pregnancy/Reproduction, Breast-feeding, young children may be at increased risk of toxicity because of increased absorption of salicylic acid through the skin.Salicylic acid should not be applied to large areas of the body, for prolonged periods of time.\nElderly patients are more likely to have age-related peripheral vascular disease and, therefore, may be more prone to acute inflammation or ulceration of the extremities. \nAvoiding contact with the eyes. Washing hands immediately after application to remove any medication. Avoiding concurrent use with topical mercury-containing preparations.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Ketoconazole	\n\n\tAmico Ltd.\tKetofun TAB dr 200mg 30's pack 249.90\n\tOpsonin Pharma\tKetocon TAB dr 200mg 30's pack 240\n\tSquare\tKetoral TAB dr 200mg 40's pack 361.20\n\tIndication: Candidiasis, Fungal infections, Pityriasis versicolor, Seborrhoeic dermatitis							\n\n\nDose: Adult: PO Fungal infections 200 mg once daily, up to 400 mg once daily if needed. Usual duration: 14 days and for at least 1 wk after symptoms have cleared and cultures have become negative. \n\nChronic vag candidiasis 400 mg once daily for 5 days. \n\nContra-indication: Hypersensitivity; preexisting liver disease, porphyria. Concurrent use with cisapride, terfenadine or astemizole.\n\nSide effects: GI disturbances e.g. nausea and vomiting; rash, dermatitis, burning sensation, pruritus; headache, dizziness, somnolence, fever and chills; thrombocytopenia; gynaecomastia, impotence; raised intracranial pressure; photophobia; transient elevations in LFTs.\nPotentially Fatal: Hepatotoxicity.\n\nPrecaution: Hepatic impairment; monitor liver function regularly. Pregnancy, lactation. Predisposition to adrenocortical insufficiency. Discontinue treatment if there is persistent or worsening of liver enzyme elevation.\n\nMode of action: Reduced absorption w/ antimuscarinics, antacids, H2-blockers, PPIs, sucralfate. Reduced plasma concentrations w/ rifampicin, isoniazid, efavirenz, nevirapine, phenytoin. May also reduce concentrations of isoniazid and rifampicin. May reduce efficacy of oral contraceptives. May increase serum levels of CYP3A4 substrates e.g. digoxin, oral anticoagulants, sildenafil, tacrolimus.\nPotentially Fatal: May potentiate and prolong sedative and hypnotic effects of midazolam and triazolam. Increased plasma levels and prolonged QT intervals of astemizole, cisapride, dofetilide, pimozide, quinidine and terfenadine which may lead to torsade de pointes. Increased risk of myopathy w/ HMG-CoA reductase inhibitors (e.g. lovastatin, simvastatin). Markedly increased plasma levels of nisoldipine. Increased risk of hyperkalaemia and hypotension w/ eplerenone. Increased risk of vasospasm potentially leading to cerebral ischaemia w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine).\n\nPregnancy category: C\n\nInteraction: Reduced absorption w/ antimuscarinics, antacids, H2-blockers, PPIs, sucralfate. Reduced plasma concentrations w/ rifampicin, isoniazid, efavirenz, nevirapine, phenytoin. May also reduce concentrations of isoniazid and rifampicin. May reduce efficacy of oral contraceptives. May increase serum levels of CYP3A4 substrates e.g. digoxin, oral anticoagulants, sildenafil, tacrolimus.\nPotentially Fatal: May potentiate and prolong sedative and hypnotic effects of midazolam and triazolam. Increased plasma levels and prolonged QT intervals of astemizole, cisapride, dofetilide, pimozide, quinidine and terfenadine which may lead to torsade de pointes. Increased risk of myopathy w/ HMG-CoA reductase inhibitors (e.g. lovastatin, simvastatin). Markedly increased plasma levels of nisoldipine. Increased risk of hyperkalaemia and hypotension w/ eplerenone. Increased risk of vasospasm potentially leading to cerebral ischaemia w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine).
Lactic acid 5% + Sodium PCA 2.5% Topical	\n\n\tStiefel Ptd Ltd.,Ireland\tLacticare Lotion  100gm  tube 455\n\tIndication: Skin care, skin moisturization		\n\n\nDose: For external use only . Use as required on affected areas .\n\nContra-indication: Hypersensitivity\n\nSide effects:  Most emollients can be used safely and effectively with no side effects. However, burning, stinging, redness, or irritation may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.\n\nA very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.\n\nPrecaution: This product may contain inactive ingredients, which can cause allergic reactions or other problems. \n\nSome ingredients (e.g., preservatives, fragrance) may make more sensitive to the sun. using a sunscreen, wearing protective clothing when outdoors, and avoiding prolonged sun exposure, tanning booths, and sunlamps.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Framycetin sulfate (Dressing)	\n\n\tSanofi Aventis (BD) Ltd.\tSofra-Tulle Wound Dressing Bandage 1% 10 pcs 165\n\tIndication: Wounds dressings. Thermal: Light, and not too extensive burns or scalds. Traumatic: Lacerations, abrasions, bites, wounds, crash injuries. Miscellaneous: Secondary infected skin condition (eg, eczema, dermatitis, herpes zoster).\n\nDose:  A lightweight, lano-paraffin (anhydrous lanolin 10%) & white soft paraffin 90%  gauze dressing impregnated with 1% framycetin sulfate BP. Apply a single layer on the lesion & cover w/ a suitable dressing. For wounds w/ profuse exudate change the dressing once daily.\n\nContra-indication: Known allergy to lanolin or framycetin, or where organisms are known to be resistant to framycetin.\n\nSide effects: Possible ototoxicity (open wounds, large areas, renal impairment on prolonged use).\n\nPrecaution: Allergy to Streptomyces-derived antibiotics. Large-scale burns.\n\nMode of action: Co-admin of gramicidin with framycetin reduces the risk of selecting resistant bacteria.\n\nPregnancy category: C\n\nInteraction: Co-admin of gramicidin with framycetin reduces the risk of selecting resistant bacteria.
Anti Recurrence Emollient Balm	\n\n\tIndication: Skin moisturization,Very dry reactive skin\n\nDose: Apply once or twice a day to cleansed skin.\n\nContra-indication: Hypersensitivity.\n\nSide effects: \n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Aprepitant	\n\n\tIncepta\tEmestop CAP 40mg 4's 200\n\tOpsonin Pharma\tEmend CAP 40mg  \n\tIndication: Prevent nausea and vomiting caused by certain types of cancer medicines (chemotherapy),  prevent nausea and vomiting after surgery.\n\nDose: Prevention of Postoperative Nausea and Vomiting\nAdults\n\nPO 40 mg within 3 h prior to induction of anesthesia.\nPrevention of ChemotherapyâInduced Nausea and Vomiting\nAdults\n\nPO 125 mg 1 h prior to chemotherapy treatment on day 1 and 80 mg/day in the morning on days 2 and 3. Administer in combination with a corticosteroid and 5-HT 3 antagonist.\n\nContra-indication: Coadministration of astemizole, cisapride, pimozide, or terfenadine; hypersensitivity to any component of the product.\n\nSide effects:  To prevent nausea and vomiting caused by chemotherapy, the most common side effects include: Tiredness, nausea, hiccups, constipation, diarrhea, loss of appetite, headache, hair loss.\nTo prevent nausea and vomiting after surgery, the most common side effects are: Constipation, nausea, itch, fever, low blood pressure, headache.\n\n\nPrecaution: This medicine could make hormonal contraceptives, eg the pill, mini-pill or patch less effective at preventing pregnancy. If you are using hormonal contraceptives, you should use an extra back-up method of contraception, eg condoms, to prevent pregnancy, both during treatment with this medicine and for two months after the last dose.\nUse with caution in\nModerate to severely decreased liver function.\n\n\nMode of action: Concurrent use with CYP3A4 inhibitors (e.g. clarithromycin, troleandomycin, diltiazem, verapamil, itraconazole, ketoconazole, nefazodone, ritonavir, nelfinavir) may lead to increased plasma levels of Aprepitant; concurrent use with CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin, primidone, phenobarbital) may lead to reduced efficacy of Aprepitant. May decrease concentrations of CYP2C9 substrates e.g. phenytoin, tolbutamide, warfarin. May increase plasma levels of dexamethasone and methylprednisolone. May increase plasma levels of benzodiazepine (e.g. midazolam, diazepam, alprazolam). Serum concentrations of colchicine may increase with Aprepitant. May increase toxicity of chemotherapy drug metabolised by CYP3A4 e.g. docetaxel, etoposide, ifosfamide, imatinib, paclitaxel, vincristine, vinblastin. May increase levels of ergot derivatives resulting in ergotism. May reduce efficacy of oral contraceptives, use additional methods of contraception during treatment and for at least 1 mth following the last dose of Aprepitant.\nPotentially Fatal: May result in increased serum levels of astemizole, cisapride, pimozide and terfenadine which can lead to life-threatening torsade de pointes arrhythmias.\n\nPregnancy category: B\n\nInteraction: Concurrent use with CYP3A4 inhibitors (e.g. clarithromycin, troleandomycin, diltiazem, verapamil, itraconazole, ketoconazole, nefazodone, ritonavir, nelfinavir) may lead to increased plasma levels of Aprepitant; concurrent use with CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin, primidone, phenobarbital) may lead to reduced efficacy of Aprepitant. May decrease concentrations of CYP2C9 substrates e.g. phenytoin, tolbutamide, warfarin. May increase plasma levels of dexamethasone and methylprednisolone. May increase plasma levels of benzodiazepine (e.g. midazolam, diazepam, alprazolam). Serum concentrations of colchicine may increase with Aprepitant. May increase toxicity of chemotherapy drug metabolised by CYP3A4 e.g. docetaxel, etoposide, ifosfamide, imatinib, paclitaxel, vincristine, vinblastin. May increase levels of ergot derivatives resulting in ergotism. May reduce efficacy of oral contraceptives, use additional methods of contraception during treatment and for at least 1 mth following the last dose of Aprepitant.\nPotentially Fatal: May result in increased serum levels of astemizole, cisapride, pimozide and terfenadine which can lead to life-threatening torsade de pointes arrhythmias.
Trypan Blue 0.06%	\n\n\tIncepta\tTrypan Blue Solution 0.6mg 1ml bot \n\tIndication: Aid in ophthalmic surgery by staining the anterior capsule of the lens.\n\nDose: Trypan blue is packaged in a 2.25 mL syringe to which a blunt cannula has to be attached.\n\nAfter opening the eye, an air bubble is injected into the anterior chamber of the eye in order to minimize dilution of  (trypan blue) by the aqueous.  (trypan blue) is carefully applied onto the anterior lens capsule using a blunt cannula. Sufficient staining is achieved as soon as the dye has contacted the capsule. The anterior chamber is then irrigated with balanced salt solution to remove all excess dye. An anterior capsulotomy can then be performed.\n\nContra-indication:  (Trypan blue) is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL) is planned to be inserted into the eye because the dye may be absorbed by the IOL and stain the IOL.\n\nSide effects: Adverse reactions reported following use of  (trypan blue) include discoloration of high water content hydrogen intraocular lenses and inadvertent staining of the posterior lens capsule and vitreous face.\n\nPrecaution: General: It is recommended that after injection all excess (trypan blue) be immediately removed from the eye by thorough irrigation of the anterior chamber.\nCarcinogenesis, mutagenesis, impairment of fertility\n\nMode of action: \n\nPregnancy category: C\n\nInteraction: 
Cyproheptadine HCI	\n\n\tAexim\tPerictol TAB dr 4mg 100's pack 200\n\tAristopharma\tArictin TAB dr 4mg 100's pack 200\n\tEskayef Bangladesh Ltd.\tProactin TAB dr 2mg 50's pack 50\n\tEskayef Bangladesh Ltd.\tProactin TAB dr 4mg 50's pack 100\n\tOrion Pharma Ltd.\tReactin TAB dr 4mg 100's pack 200\n\tRenata\tXcitin TAB dr 4mg 30's pack 60\n\tIndication: Rash and pruritus in a variety of condition; appetite stimulation , anorexia nervosa ; cushing's and Nelson's syndrome, acromegaly and hyperprolactinemia ; migraine; antidepressant-induced inorgasmia .\n\nDose: Adult: PO Allergic conditions As HCl: 4 mg 3 times/day. Usual: 12-16 mg/day in 3-4 divided doses, up to 32 mg/day if needed. \n\nPrevention and treatment of migraine and other vascular headaches As HCl: 4 mg, may repeat 30 mins later. Not to exceed 8 mg w/in a 4-6-hr period. Maintenance: 4 mg 4-6 hrly.\n\nContra-indication: Narrow-angle glaucoma; acute asthmatic attack; bladder neck obstruction; stenosing peptic ulcer; GIT obstruction; MAOIs therapy; hypersensitivity; neonates, lactation.\n\nSide effects: Slight to moderate drowsiness, fatigue; dry mouth, GI upsets, nausea; appetite increase, wt gain and impaired alertness.\n\nPrecaution: Elderly; epilepsy; tasks requiring mental alertness; symptomatic prostate hypertrophy; epilepsy; alcoholism; pregnancy.\n\nMode of action: May have additive effects w/ CNS depressants e.g. hypnotics, sedatives, tranquilizers, antianxiety agents.\nPotentially Fatal: MAOIs prolong and intensify the anticholinergic effects of antihistamines.\n\nPregnancy category: B\n\nInteraction: May have additive effects w/ CNS depressants e.g. hypnotics, sedatives, tranquilizers, antianxiety agents.\nPotentially Fatal: MAOIs prolong and intensify the anticholinergic effects of antihistamines.
Pipecuronium bromide	\n\n\tTechno Drugs Ltd.\tArduan Injection 4mg/2ml 5's pack 680\n\tTechno Drugs Ltd.\tPycuron Injection 4mg/2ml 2.5ml amp x 5's pack 475\n\tIndication: Muscle relaxant in general anaesthesia, Facilitate endotracheal intubation\n\nDose: Intravenous\nMuscle relaxant in general anaesthesia, Facilitate endotracheal intubation\nAdult: Initial dose: 80-100 mcg/kg. Subsequent doses: 10-20 mcg/kg. Initial dose following suxamethonium admin or in patients at high risk: 50-60 mcg/kg. Initial dose for caesarean section: 35 mcg/kg.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Transient hypotension, bradycardia, reduced cardiac output.\nPotentially Fatal: Anaphylactic reactions and malignant hyperthermia.\n\nPrecaution: Pulmonary disease, respiratory insufficiency, asthma, neuromuscular disease, dehydration, severely ill patients, hepatic or renal impairment. Doses in obese patients should be based on patient's ideal body weight. Pregnancy, lactation.\n\nMode of action: Actions antagonised by cholinesterases and long term carbamazepine, phenytoin or corticosteroids usage. Enhanced block when used with drugs that have neuromuscular blocking activity such as lidocaine, quinidine, verapamil and aminoglycosides.\n\nPotentially Fatal: Effects enhanced by volatile inhalational anaesthetics, ketamine (IV), antiarrhythmics, antibacterials, K depleting diuretics, parenteral Mg salts.\n\nPregnancy category: C\n\nInteraction: Actions antagonised by cholinesterases and long term carbamazepine, phenytoin or corticosteroids usage. Enhanced block when used with drugs that have neuromuscular blocking activity such as lidocaine, quinidine, verapamil and aminoglycosides.\n\nPotentially Fatal: Effects enhanced by volatile inhalational anaesthetics, ketamine (IV), antiarrhythmics, antibacterials, K depleting diuretics, parenteral Mg salts.
Vinblastine	\n\n\tCity overseas\tVinblastin Injection  10mg 1's  pack  720\n\tIndication: Histiocytic lymphoma; Hodgkin's disease; Kaposi's sarcoma; Letterer-Siwe disease; Lymphocytic lymphoma; Mycosis fungoides; Testicular cancer\n\nDose: Intravenous\nHodgkin's disease, Mycosis fungoides, Testicular cancer, Lymphocytic lymphoma, Histiocytic lymphoma, Kaposi's sarcoma, Letterer-Siwe disease\nAdult: Initially, 3.7 mg/m2, increase dose wkly based on WBC counts in increments of about 1.8 mg/m2 until leukocyte count decreases to about 3000/mm3, or max wkly dose of 18.5 mg/m2 reached. Do not increase dose if leukocyte count is reduced to approximately 3000 cells/mm3; administer the max dose that does not cause leucopenia for maintenance. Do not increase subsequent doses if onolytic activity occurs before leucopenic effect. Usual dose: 5.5-7.4 mg/m2 per wk. Do not admin next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3.\n\n\nChild: Initial 2.5 mg/m2 of BSA, increased dose at wkly intervals in increments of about 1.25 mg/m2 until leukocyte count decreases to about 3000/ mm3, or max wkly dose of 12.5 mg/m2 reached. Do not increase dose once leukocyte count reaches approximately 3000 cells/mm3, instead, a dose of 1 increment smaller to be admin at wkly intervals for maintenance i.e. patient receives the max dose that does not cause leucopenia. If onolytic activity is encountered before leucopenic effect, then there is no need to increase subsequent doses. Do not admin next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3. Duration of maintenance therapy depends on disease state and the antineoplastic agent combination.\n\nHepatic impairment: Serum bilirubin >3 mg/100ml: Reduce dose by 50%.\n\n\nContra-indication: Severe bone marrow suppression; presence of bacterial infection; maglignant cell infiltration of bone marrow; Inj into extremity with poor circulation; porphyria; granulocytopenia. Elderly with cachexia or extreme skin ulcerations. Pregnancy; lactation. Intrathecal use may result in death.\n\nSide effects: Alopecia, constipation, malaise, stomatitis, dose-limiting bone marrow suppression (e.g. granulocytopenia, thrombocytopenia, anaemia), hypertension, central and peripheral neurotoxicity, 8th cranial nerve damage resulting in vestibular and auditory toxicity, ischaemic cardiac toxicity, breathlessness, bone, tumour or jaw pain. Nausea, vomiting, GI bleed, syndrome of inappropriate antidiuretic hormone. Necrosis, cellulitis if extravasation occurs.\n\nPrecaution: Hepatic impairment; neurotoxicity; ischemic heart disease; preexisting pulmonary dysfunction; extravasation may cause tissue damage and pain. Discontinue immediately if extravasation occurs, with local Inj of hyaluronidase and local heat application to decrease discomfort and risk of cellulitis; remaining Inj to be injected into another vein. Routine prophylaxis against constipation recommended especially in high doses. Nadir in leukocyte count occur 4-10 days after vinblastine admin; recovery observed 7-14 days after treatment.\n\nMode of action: Possible increase in vinblastine levels with aprepitant. Reduced vinblastine metabolism with miconazole. Variable interactions with phenytoin, monitor serum phenytoin levels. Reduced immune response with vaccines. Additive myelotoxicity with zidovudine. Concurrent admin of vinblastine with CYP3A inhibitors may cause an earlier onset and/or an increased severity of side effects.\n\nPotentially Fatal: Increased toxicity of vinblastine with erythromycin. Increased neurotoxicity and myelotoxicity with azole antifungals e.g. itraconazole and posaconazole. Increased risk of severe neutropenia with ritonavir. Increased risk of acute pulmonary toxicity with mitomycin. Increased toxicity when ganciclovir is given with, immediately before or after vinblastine.\n\nPregnancy category: D\n\nInteraction: Possible increase in vinblastine levels with aprepitant. Reduced vinblastine metabolism with miconazole. Variable interactions with phenytoin, monitor serum phenytoin levels. Reduced immune response with vaccines. Additive myelotoxicity with zidovudine. Concurrent admin of vinblastine with CYP3A inhibitors may cause an earlier onset and/or an increased severity of side effects.\n\nPotentially Fatal: Increased toxicity of vinblastine with erythromycin. Increased neurotoxicity and myelotoxicity with azole antifungals e.g. itraconazole and posaconazole. Increased risk of severe neutropenia with ritonavir. Increased risk of acute pulmonary toxicity with mitomycin. Increased toxicity when ganciclovir is given with, immediately before or after vinblastine.
Fondaparinux	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tArixtra 2.5 Injection 2.5mg/0.5ml 10's pack \n\tIndication: Venous thromboembolic events, acute DVT, pulmonary embolism (PE), unstable angina or non-ST segment elevation MI\n\nDose: Adult Prevention of VTE in orthopedic & abdominal surgery 2.5 mg SC once daily, starting not <6 hr post-op & after hemostasis is established for at least 5-9 days, up to an additional 24 days in hip fracture. \n\nPatients at risk of thromboembolic complications 2.5 mg SC once daily for 6-14 days. \n\nDVT & PE >100 kg body wt 10 mg, 50-100 kg body wt 7.5 mg, <50 kg body wt 5 mg. Doses to be administered SC once daily for at least 5 days & until adequate oral anticoagulant is established (INR 2-3). Initiate concomitant treatment w/ vit K antagonists w/in 72 hr. Duration: 5-9 days. \n\nUA/NSTEMI 2.5 mg SC once daily for up to 8 days or until hospital discharge. STEMI 2.5 mg once daily, 1st dose to be given IV & subsequent doses given SC for up to 8 days or until hospital discharge.\n\nRenal impairment:\nCrCl (ml/min)	\n20-50	1.5 mg once daily.\n<20 	Contra-indicated. \n\nContra-indication: Hypersensitivity. Active clinically significant bleeding, acute bacterial endocarditis.\n\nSide effects: Anemia, bleeding, purpura; edema.\n\nPrecaution: Do not administer IM. Do not give 24 hr prior to CABG surgery & may be restarted 48 hr post-op. STEMI patients undergoing primary PCI for reperfusion. Monotherapy in UA/NSTEMI & STEMI patients undergoing non-primary PCI. Increased risk of hemorrhage eg congenital or acquired bleeding disorders, active ulcerative GI disease, recent intracranial hemorrhage, shortly after brain, spinal or ophth surgery. Low body wt <50 kg; spinal/epidural anesth or spinal puncture. History of heparin-induced thrombocytopenia & latex allergy. Renal (CrCl <20 or 30 mL/min) or severe hepatic impairment. Close monitoring is recommended in patients concomitantly taking products enhancing the risk of hemorrhage. Pregnancy & lactation. Childn <17 yr. Elderly >75 yr.\n\nMode of action: Increased risk of bleeding w/ (e.g. desirudin, fibrinolytic drugs, glycoprotein IIb/IIIa-receptor antagonists, heparin, heparinoids or LMWH).\n\nPregnancy category: B\n\nInteraction: Increased risk of bleeding w/ (e.g. desirudin, fibrinolytic drugs, glycoprotein IIb/IIIa-receptor antagonists, heparin, heparinoids or LMWH).
Clindamycin + Benzoyl Peroxide	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tDuac GEL 1% / 5% 25gm Tube 623.08\n\tOpsonin Pharma\tClindax-B Gel  10 gm tube 150\n\tIndication:  Acne vulgaris.\n\nDose: Apply once daily in the evening to the affected areas.\n\nContra-indication: History of regional enteritis or ulcerative colitis or history of antibiotic-associated colitis.\n\nSide effects: May cause slight itching & burning, may also notice flaking & redness of skin during the 1st few wk of use.\n\nPrecaution: Avoid contact w/ mouth, eyes, lips & mucous membranes; abraded or eczematous skin. May discolor hair & dyed fabrics. Pregnancy & lactation.\n\nMode of action:  	May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).\nPABA sunscreens may transiently discolour fabric.\n\nPregnancy category: A\n\nInteraction:  	May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).\nPABA sunscreens may transiently discolour fabric.
Caprylic + Capric Triglyceride	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tPhysiogel cream Cream  75ml Tube 499\n\tGlaxoSmithKline Bangladesh Ltd.\tPhysiogel lotion Lotion  200ml Bottle 750\n\tIndication: Repairs, restores & protects dry skin & sensitive skin conditions\n\nDose: Cream Apply a thin film once or bd on hands, face & particularly dry areas. Lotion Apply once or bd. Ideal for the entire body.\n\nContra-indication: Hypersensitivity.\n\nSide effects: \n\nPrecaution: Discontinue use and consult a dermatologist if undue irritation develops or increases. Avoid contact with eyes or mucous membranes. In case of contact, rinse thoroughly with water.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Denosumab	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tProlia Injection 60mg/ml 1's Pack \n\tIndication: Postmenopausal Osteoporosis\n\nDose: Recommended Dose: 60 mg single SC injection administered once every 6 months.\nPatients should receive calcium and vitamin D supplements whilst undergoing treatment.\n\nElderly: Based on the available safety and efficacy data in the elderly, no dosage adjustment is required.\nRenal Impairment: Based on the available safety and efficacy data in the elderly, no dosage adjustment is required in patients with renal impairment.\n\nPatients with severe renal impairment [creatinine clearance (CrCl) <30 mL/min] or receiving dialysis are at greater risk of developing hypocalcemia. Adequate intake of calcium and vitamin D is important in patients with severe renal impairment or receiving dialysis.\n\nHepatic Impairment: The safety and efficacy have not been studied in patients with hepatic impairment.\n\nContra-indication: Clinically significant hypersensitivity to denosumab or to any of the components. Hypocalcemia.\n\nSide effects: Cataracts; pain in extremity.\n\nPrecaution: Correct hypocalcemia prior to initiation of therapy. Patients should receive Ca & vit D supplements during treatment (unless hypercalcemia is present). Skin infections predominantly cellulitis may develop. Osteonecrosis of the jaw in patients w/ advanced cancer. Atypical femoral fracture. Severe renal impairment or undergoing dialysis. Pregnancy & lactation. Childn.\n\nMode of action: Increased risk of serious infections w/ immunosuppressive agents.Denosumab did not affect the pharmacokinetics of midazolam, a drug metabolised by cytochrome P450 3A4 (CYP3A4).\nIncompatibilities:Denosumab must not be mixed with other medicinal products.\n\nPregnancy category: X\n\nInteraction: Increased risk of serious infections w/ immunosuppressive agents.Denosumab did not affect the pharmacokinetics of midazolam, a drug metabolised by cytochrome P450 3A4 (CYP3A4).\nIncompatibilities:Denosumab must not be mixed with other medicinal products.
Human Milk Based Amino Acid	\n\n\tEskayef Bangladesh Ltd.\tProtinex Kidz Infusion 6.53gm/100ml 100ml 280\n\tIndication: Surgery, Trauma, Burn injury, GI disease, Protein deficiency or Sarcopenia, Cancer, Hepatic insufficiency, Renal insufficiency, Malnutrition\n\n\nDose: Infants and Children: The recommended rate of infusion is 28-35 ml/kg body weight per day. It should be infused slowly, at rates 1.4- 2.8 ml (30-60 drops) per minute.\n\nContra-indication: Contraindicated in patients with inborn errors of amino acids metabolism. Moreover, amino acid should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.\n\nSide effects: It is usually well tolerated. Yet nausea, vomiting, flushing and sweating have been observed during infusion of amino acid IV at rates exceeding the recommended maximal rate. Hypersensitivity reactions have been reported. Like all hypertonic infusion solution, thrombophlebitis may occur when peripheral veins are used. The incidence may be reduced by the simultaneous infusion of 10% fat emulsion. If it is infused to severely ill patients, premature infants, hyperphenylalaninemia may occur.\n\nPrecaution: Hyperphenylalaninemia has been noted in severely ill, premature infants. In these patients, monitoring of the phenylalanine levels is recommended and the infusion rate adjusted as needed. Do not use if the solution is turbid or contains particles. Discard any unused portion.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Eltrombopag Olamine	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tRevolade TAB dr 25mg 28's pack 25666\n\tIndication: Adult chronic immune (idiopathic) thrombocytopenic purpura (ITP), Hepatitis C  Virus (HCV) related Thrombocytopenia.\n\nDose: Adult Initially 50 mg once daily. East Asian patient 25 mg once daily. Then, adjust dose to maintain platelet count >50,000/microliter. Max: 75 mg daily.\n\nShould be taken on an empty stomach.Take at least 4 hr before or after antacids, dairy products or other Ca-containing food products or mineral supplements containing polyvalent cations. After adjustment, platelet counts should be monitored at least weekly for 2-3 weeks. Wait for at least 2 weeks to see the effect of any dose adjustment on the patientâs platelet response prior to considering another dose adjustment.\n\nRenal Impairment: No dose adjustment is necessary in ITP patients with renal impairment.\n\nHepatic Impairment: Should not be used in ITP patients with liver cirrhosis (hepatic impairment unless the expected benefit outweighs the identified risk of portal venous thrombosis.\n\nContra-indication:  Eltrombopag is contraindicated in patients with severe hepatic impairment and who are hypersensitive to any of its excipients.\n\nSide effects: Insomnia; headache, paraesthesia; cataract, dry eye; nausea; GI & hepatobiliary disorders; rash, pruritus, alopecia; arthralgia, myalgia, muscle spasm, bone pain; fatigue, peripheral oedema; thromboembolic events.\n\nPrecaution: Not established for use in other thrombocytopenic conditions. Regularly monitor clinical haematology, platelet counts & serum liver test throughout therapy. Renal & hepatic impairment; hepatic disease. Thrombotic/thromboembolic complications. Increased risk of bleeding upon discontinuation of treatment. Bone marrow reticulin formation & risk of bone marrow fibrosis. Malignancies & progression of malignancies. Pregnancy & lactation. Childn <18 yr, elderly.\n\nMode of action: Increased plasma Cmax & AUC of HMG-CoA reductase inhibitors. Caution w/ methotrexate, topotecan. Increased conc w/ fluvoxamine; decreased conc w/ rifampicin & lopinavir/ritonavir. Reduced absorption by antacids, dairy products & other products containing polyvalent cations (eg Fe, Ca, Mg, Al, Se, Zn). Reduced plasma AUC & Cmax w/ high-calorie & -fat meal. Monitor platelet counts when used in combination w/ lopinavir/ritonavir & other drugs for treatment of idiopathic thrombocytopenic purpura (ITP).\n\nPregnancy category: C\n\nInteraction: Increased plasma Cmax & AUC of HMG-CoA reductase inhibitors. Caution w/ methotrexate, topotecan. Increased conc w/ fluvoxamine; decreased conc w/ rifampicin & lopinavir/ritonavir. Reduced absorption by antacids, dairy products & other products containing polyvalent cations (eg Fe, Ca, Mg, Al, Se, Zn). Reduced plasma AUC & Cmax w/ high-calorie & -fat meal. Monitor platelet counts when used in combination w/ lopinavir/ritonavir & other drugs for treatment of idiopathic thrombocytopenic purpura (ITP).
Pazopanib Hydrochloride	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tVotrient TAB dr 200mg 30's pack 18770.70\n\tIndication: Renal cell carcinoma, soft tissue sarcoma \n\nDose: Advanced Renal Cell Carcinoma\n800 mg PO qDay on empty stomach (at least 1 hr ac or 2 hr pc).\n\nIn RCC, the initial dose reduction should be 400 mg, and additional dose decrease or increase should be in 200 mg steps based on individual tolerability.\n\nIn STS, a decrease or increase should be in 200 mg steps based on individual tolerability.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Common side effects may include:\n\n    mild nausea or vomiting, diarrhea;\n\n    weight loss;\n\n    changes in hair or skin color;\n\n    joint or muscle pain;\n\n    tumor pain, mild headache; or\n\n    unusual or unpleasant taste in your mouth.\n\n\nPrecaution: Hepatic Toxicity and Hepatic Impairment, QT Prolongation, Cardiac Dysfunction, Hemorrhagic Events, Thromboembolic Events, Gastrointestinal Perforation and Fistula, Hypertension, Hypothyroidism, Pregnancy.\n\nMode of action:  	Co-administration w/ CYP3A4 (eg, itraconazole, clarithromycin, atazanavir, idinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice), P-gp & BCRP inhibitors, high-/low-fat food increases exposure & conc of pazopanib. Co-administration w/ CYP3A4 (eg, rifampicin) inducers may decrease plasma pazopanib conc. P-gp & BCRP inducers may alter exposure & distribution of pazopanib. Pazopanib may alter exposure &/or distribution of CYP3A4 substrates (eg, midazolam), CYP2C8 substrates (eg, paclitaxel) & UGT1A1 substrates (eg, irinotecan & its active metabolite SN-38). Pazopanib may increase the ratio of dextrometrophan to dextrophan conc after administration of dextrometrophan. Proton-pump inhibitors (eg, esomeprazole) & other agents that increase gastric pH may decrease bioavailability of pazopanib. Concomitant use w/ simvastatin & other statins may lead to ALT elevations.\n\nPregnancy category: D\n\nInteraction:  	Co-administration w/ CYP3A4 (eg, itraconazole, clarithromycin, atazanavir, idinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice), P-gp & BCRP inhibitors, high-/low-fat food increases exposure & conc of pazopanib. Co-administration w/ CYP3A4 (eg, rifampicin) inducers may decrease plasma pazopanib conc. P-gp & BCRP inducers may alter exposure & distribution of pazopanib. Pazopanib may alter exposure &/or distribution of CYP3A4 substrates (eg, midazolam), CYP2C8 substrates (eg, paclitaxel) & UGT1A1 substrates (eg, irinotecan & its active metabolite SN-38). Pazopanib may increase the ratio of dextrometrophan to dextrophan conc after administration of dextrometrophan. Proton-pump inhibitors (eg, esomeprazole) & other agents that increase gastric pH may decrease bioavailability of pazopanib. Concomitant use w/ simvastatin & other statins may lead to ALT elevations.
Silymarin	\n\n\tDrug International Ltd.\tHepanor CAP 500mg 20's Pack 400\n\tRadiant.\tRadisyl CAP 140mg  \n\tSquare\tSilybin CAP 70mg 30's pack 180\n\tSquare\tSilybin CAP 140mg 30's pack 170\n\tIndication: Chronic inflammatory diseases of the liver & hepatic cirrhosis.\n\nDose: Oral\nHepatic diseases\nAdult: Initially and In Serious Cases: 70-mg capsule: 2 caps 3 times daily.\n140-mg capsule: 1 cap 3 times daily.\nShould be taken with food. Take after meals.\n\nContra-indication: Hypersensitivity, pregnancy, lactation.\n\nSide effects: Occasional laxative effects. Abdominal bloating, diarrhoea, flatulence, loss of appetite, anorexia, nausea, stomach upset.\n\nPrecaution: Children.\n\nMode of action: Reduced lipid peroxidation w/ butyrophenones or phenothiazine. Antagonistic effect w/ yohimbine & phentolamine.\n\nPregnancy category: Not Classified\n\nInteraction: Reduced lipid peroxidation w/ butyrophenones or phenothiazine. Antagonistic effect w/ yohimbine & phentolamine.
Rabies Immunoglobulin USP	\n\n\tIncepta\tRabix-IG Injection 1000 IU/5 ml 1's Pack 1000\n\tSanofi Aventis (BD) Ltd.\tFavirab Solution 1000 IU/5ml 1's pack 1758\n\tIndication: Postexposure prophylaxis of rabies.\n\nDose: Injection\nPost exposure prophylaxis of rabies: The recommended dose for both adults and children is 40 IU/kg of body weight.\nAdult: In conjunction with rabies vaccine in previously unvaccinated individuals: admin as soon as possible at the same time as vaccine, or up to 7 days after vaccine inj. Recommended dose to be infiltrated thoroughly in and around the cleansed wound; any remainder to be injected via IM inj in area distant to that of vaccine inoculation e.g. anterior thigh. If calculated dose is not enough to infiltrate all wounds, dilute 2-3 folds with sterile saline to allow thorough infiltration. Previously vaccinated individuals with adequate rabies antibody titer: Rabies immunoglobulin should not be admin; only vaccine should be given.\n\nChild: In conjunction with rabies vaccine in previously unvaccinated individuals: admin as soon as possible at the same time as vaccine, or up to 7 days after vaccine inj. Recommended dose to be infiltrated thoroughly in and around the cleansed wound; any remainder to be injected via IM inj in area distant to that of vaccine inoculation e.g. anterior thigh. If calculated dose is not enough to infiltrate all wounds, dilute 2-3 folds with sterile saline to allow thorough infiltration. Previously vaccinated individuals with adequate rabies antibody titer: Rabies immunoglobulin should not be admin; only vaccine should be given.\n\n\nContra-indication: Known history of allergic symptoms to horse proteins. Do not give repeated doses of rabies immunoglobulin once rabies vaccine is given as this may reduce the immunologic response to the vaccine.\n\nSide effects: Soreness at inj site, fever, chest or joint pain, dyspnoea, tremor, dizziness, oedema of the face, glossitis, buccal ulceration. The observed immediate reactions are hypotension, dyspnoea, and urticaria. Delayed reactions consist of inflammatory reaction, fever, pruritis, rash or urticaria, adenopathy and arthralgia. Rare risk of disease transmission by infective agents.\nPotentially Fatal: Anaphylactic reactions.\n\nPrecaution: Hypersensitivity to human immune globulin preparations, increased risk of hypersensitivity with specific immunoglobulin A deficiency; epinephrine should be available for management of possible anaphylactic reactions. Thrombocytopenia or bleeding disorders. If IM inj is contra-indicated, inj may be given by SC with pressure and compress applied to site after inj. \n\nDo not exceed recommended doses as this may reduce the immune response to rabies vaccine. Patients preciously immunised with rabies vaccine and have adequate rabies antibody titer should receive rabies vaccine without the rabies immunoglobulin. Avoid IV admin, and IM inj into central region of gluteal area. Admin rabies immunoglobulin and vaccine in separate syringes and to different sites with different lymphatic drainage. Pregnancy and lactation.\n\nMode of action: Decreased response to live virus vaccine (e.g. measles, mumps, rubella and varicella), admin at least 4 mth after human rabies immunoglobulin admin.\n\nPregnancy category: C\n\nInteraction: Decreased response to live virus vaccine (e.g. measles, mumps, rubella and varicella), admin at least 4 mth after human rabies immunoglobulin admin.
Human chorionic gonadotropin	\n\n\tNuvista Pharma Ltd\tPregnyl Injection 5000 IU 1 + 1 amp's pack (powder + water for injection) 2050\n\tIndication: Female infertility, Male Hypogonadotrophic hypogonadism, Delayed puberty, Cryptorchidism\n\nDose: Female Ovulation induction in infertility due to anovulation or impaired follicle-ripening & in controlled hyperstimulation regimens to prepare the follicles for puncture Usually 1 inj of 5,000-10,000 IU to complete treatment w/ FSH-containing prep. Luteal phase support 2-3 repeat inj of 1,000-3,000 IU each may be given w/in 9 days following ovulation or embryo transfer. \n\nMale Hypogonadotrophic hypogonadism 1,000-2,000 IU 2-3 times wkly for at least 3 mth. \nDelayed puberty associated w/ insufficient gonadotrophic pituitary function 1,500 IU 2-3 times wkly for at least 6 mth. \nCryptorchidism, not due to anatomical obstruction >6 yr 1,500 IU twice wkly for 6 wk, &lt;6 yr 500-1,000 IU twice wkly for 6 wk, &lt;2 yr 250 IU twice wkly for 6 wk. If necessary, this treatment can be repeated.\n\nContra-indication:  Hypersensitivity. Known or suspected androgen-dependent tumors. Malformation of the sexual organs & fibroid tumors of the uterus incompatible w/ pregnancy.\n\nSide effects: Local reactions at inj site: Bruising, pain, redness, swelling, itching, allergic reactions eg rash. Female: Thromboembolism, hydrothorax, GI symptoms (nausea, diarrhea), unwanted ovarian hyperstimulation, OHSS, painful breasts, ovarian cyst enlargement. Males: Water & Na retention, gynecomastia.\n\nPrecaution: Females: Multiple pregnancy, ectopic pregnancy, pregnancy loss, unwanted ovarian hyperstimulation, increased risk of venous/arterial thromboembolic events. Presence of uncontrolled non-gonadal endocrinopathies (eg thyroid, adrenal, pituitary disorders) should be excluded. May lead to false +ve pregnancy test. Males: Latent or overt cardiac failure, renal dysfunction, HTN, epilepsy, migraine, premature epiphyseal closure in prepubertal boys.\n\nMode of action: No specific interaction studies with Chorionic Gonadotrophin  and other medicines have been performed; however, no clinically significant drug interactions have been reported during hCG therapy.\nFollowing administration, Chorionic Gonadotrophin  may interfere for up to 10 days with the immunological determination of serum/urinary hCG, leading to a false-positive pregnancy test.\nIncompatibilities: In the absence of incompatibility studies, Chorionic Gonadotrophin must not be mixed with other medicinal products.\n\nPregnancy category: X\n\nInteraction: No specific interaction studies with Chorionic Gonadotrophin  and other medicines have been performed; however, no clinically significant drug interactions have been reported during hCG therapy.\nFollowing administration, Chorionic Gonadotrophin  may interfere for up to 10 days with the immunological determination of serum/urinary hCG, leading to a false-positive pregnancy test.\nIncompatibilities: In the absence of incompatibility studies, Chorionic Gonadotrophin must not be mixed with other medicinal products.
Bupropion Hydrochloride	\n\n\tBeximco\tZybex SR TAB dr 150mg 30's pack 300\n\tJayson\tDepnox SR TAB dr 150mg 30's pack 300.90\n\tJayson\tbupropion TAB dr 150mg 30's pack 300\n\tIndication: Depression, smoking cessation\n\nDose: Oral\nSmoking cessation\nAdult: Modified-release preparation: Initially, 150 mg once daily for 6 days then increased to 150 mg bid. Period of treatment: 7-12 wk. To discontinue treatment if abstinence is not achieved by 7th wk. Max: 300 mg/day.\nElderly: 150 mg/day.\n\nDepression\nAdult: Initially, 100 mg bid increased to 100 mg tid after 3 days if necessary. Increased further to 150 mg tid if no improvement has been observed after several wk of therapy. Max: 150 mg tid. As a modified-release preparation: 150 mg once daily in the morning, increased to 150 mg bid after 3 days if necessary, may further increase to 200 mg bid after several wk if needed. Max: 450 mg as a single dose.\n\nContra-indication: It is contraindicated in patients with a seizure disorder. Bupropion Hydrochloride is contraindicated in patients treated with other medications that contain Bupropion because the incidence of seizure is\ndose dependent. Bupropion may induce seizure and consequently its use is contraindicated in patients with epilepsy. The drug is also contraindicated in patients with a current or prior diagnosis of bulimia or\nanorexia nervosa because of a higher incidence of seizures noted in such patients treated for bulimia with Bupropion Hydrochloride. The concurrent administration of Bupropion Hydrochloride and\na monoamine oxidase (MAO) inhibitor is contraindicated. At least 14 days should elapse between discontinuation of MAO inhibitor and initiation of treatment with Bupropion Hydrochloride. Bupropion Hydrochloride is contraindicated in patients who have shown an allergic response to\nBupropion or the other ingredients that make up Bupropion Hydrochloride.\n\nSide effects: Agitation, anxiety, and insomnia often occur during the initial stages of Bupropion therapy. Other relatively common side effects reported with Bupropion include fever, dry mouth, headache or migraine, dizziness, nausea and vomiting, constipation, tremor, sweating, and skin rashes.\nHypersensitivity reactions, ranging from pruritus and urticaria, less commonly, angio-oedema, dyspnoea, and anaphylactoid reactions have been reported.\n\nPrecaution: It should be used with extreme caution, in patients with history of seizure disorders or in patients with other predisposing factors such as severe hepatic cirrhosis or a CNS tumour, and in those undergoing abrupt withdrawal from alcohol or Benzodiazepines. The use of Bupropion in patients with other risk factors for seizures (for example, alcohol abuse, a history of head trauma, diabetes, and drugs known to lower the seizure threshold) should only be undertaken when there are compelling clinical\nreasons. Bupropion should be used with caution in patients with bipolar depression or psychoses and in patients with a recent history of myocardial infarction or unstable heart disease and in hepatic or renal\nimpairment. \n\nMode of action: Neuroleptics, lithium and TCAs, benzodiazepine, alcohol, drugs that lower seizure threshold. Increased risk of side effects when co-admin with levodopa. Reduced hepatic clearance with fluoxetine. Caution when administering with agents that will affect hepatic drug metabolizing enzymes. Increased risk of toxicity when used with ritonavir.\nPotentially Fatal: Concurrent use with MAO inhibitors may cause acute toxicity symptoms and increased risk of fatality.\n\nPregnancy category: C\n\nInteraction: Neuroleptics, lithium and TCAs, benzodiazepine, alcohol, drugs that lower seizure threshold. Increased risk of side effects when co-admin with levodopa. Reduced hepatic clearance with fluoxetine. Caution when administering with agents that will affect hepatic drug metabolizing enzymes. Increased risk of toxicity when used with ritonavir.\nPotentially Fatal: Concurrent use with MAO inhibitors may cause acute toxicity symptoms and increased risk of fatality.
Omeprazole + Metronidazole + Clarithromycin	\n\n\tBeximco\tNeokit Kit  14's pack 770\n\tIndication: H-pylori infection.\n\nDose: Each kit twice daily for 7-14 days. \n\nContra-indication: Known hypersensitivity to any of its component.\n\nSide effects: Nausea, vomiting, diarrhoea, dark stools, dry mouth, stomatitis, myalgia, confusion, headache, dizziness, vaginitis.\n\nPrecaution: Serious and occasional hypersensitivity reactions have been reported in patients on amoxycillin therapy. Elderly patients may suffer from hepatic and renal impairment.\n\nMode of action: Omeprazole: Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.\n\nMetronidazole: Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.\n\nClarithromycin: Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine. Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam).\nPotentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.\n\nPregnancy category: C\n\nInteraction: Omeprazole: Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.\n\nMetronidazole: Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.\n\nClarithromycin: Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine. Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam).\nPotentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.
Dapoxetine	\n\n\tACI\tDaxetin TAB dr 30mg  \n\tACI\tDaxetin TAB dr 60mg  \n\tBeacon\tDapotin TAB dr 30mg 20's pack 600\n\tDelta Pharma\tPlezer 30 TAB dr 30mg 2 x 4 tab 165\n\tDrug International Ltd.\tEjalong TAB dr 30mg  \n\tDrug International Ltd.\tEjalong TAB dr 60mg  \n\tEskayef Bangladesh Ltd.\tDumax TAB dr 30mg 8's pack 240\n\tEskayef Bangladesh Ltd.\tDumax TAB dr 60mg 4's pack 200\n\tGlobe\tDejac TAB dr 30mg  \n\tGlobe\tDejac TAB dr 60mg  \n\tIncepta\tMaturex 30 TAB dr 30 mg 20âs pack 600\n\tIncepta\tMaturex 60 TAB dr 60 mg 10âs pack 500\n\tIncepta\tDepotin TAB dr 30mg  \n\tIncepta\tDepotin TAB dr 60mg  \n\tOpsonin Pharma\tDapoxen TAB dr 30mg 4's 120\n\tRadiant.\tDulong TAB dr 30mg  \n\tRadiant.\tDulong TAB dr 60mg  \n\tSharif\tXtreme TAB dr 30mg  \n\tSharif\tXtreme TAB dr 60mg  \n\tSomatec\tX-Ride TAB dr 30mg  \n\tSomatec\tX-Ride TAB dr 60mg  \n\tSquare\tSusten TAB dr 30mg  \n\tSquare\tSusten TAB dr 60mg  \n\tSun Pharmaceutical (Bangladesh) Ltd.\tDuralast TAB dr 30mg 4's pack 96\n\tSun Pharmaceutical (Bangladesh) Ltd.\tDuralast TAB dr 60mg 4's pack 200\n\tUnimed & Unihealth Manufacturers Ltd.\tImpreja TAB dr 30mg 4's 120\n\tZiska\tProlong TAB dr 30mg 4's pack 120\n\tZiska\tProlong TAB dr 60 mg  4's pack 200\n\tIndication: Premature ejaculation \n\nDose: Recommended Starting Dose: 30 mg, taken as needed approximately 1-3 hrs prior to sexual activity.\nMaximum Recommended Dosing Frequency: Once every 24 hrs. If the effect of 30 mg is insufficient and the side effects are acceptable, the dose may be increased to the maximum recommended dose of 60 mg.\n\nElderly (>65 years): Safety and efficacy of Dapoxetine have not been established in patients >65 years as limited data are available in this population.\n\nChildren and Adolescents: Dapoxetine should not be used in individuals <18 years.\n\nPatients with Renal Impairment: No dose adjustment is required but caution is advised in patients with mild or moderate renal impairment. Dapoxetine is not recommended for use in the patients with severe renal impairment.\n\nPatients with Hepatic Impairment: No dose adjustment is required in patients with mild hepatic impairment. Dapoxetine is contraindicated in patients with moderate and severe hepatic impairment.\n\nBefore treatment is initiated, the physician should obtain a careful medical history focusing on past orthostatic events and also perform an orthostatic test (blood pressure and pulse rate, supine and standing). If the patient discloses a history suggestive of orthostatic reactions or an orthostatic test shows this kind of reaction, treatment with Dapoxetine should be avoided.\n\nContra-indication: Known hypersensitivity to dapoxetine HCl or to any of the excipients.\nPatients with significant pathological cardiac conditions [eg, heart failure (NYHA class II-IV), conduction abnormalities (2nd- or 3rd-degree AV block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease or significant valvular disease].\nConcomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with a MAOI. Similarly, a MAOI should not be administered within 7 days after Dapoxetine has been discontinued.\n\nConcomitant treatment with thioridazine, or within 14 days of discontinuing treatment with thioridazine. Similarly, thioridazine should not be administered within 7 days after Dapoxetine has been discontinued.\n\nConcomitant treatment with serotonin re-uptake inhibitors [selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine re-uptake inhibitors (SNRIs), tricyclic antidepressants (TCAs)] or other medicinal/herbal products with serotonergic effects or within 14 days of discontinuing treatment with these medicinal/herbal products. Similarly these medicinal/herbal products should not be administered within 7 days after Dapoxetine has been discontinued.\n\nSide effects: Syncope characterized as loss of consciousness has been reported.The majority of cases occurred during the first 3 hrs after dosing, after the 1st dose or associated with study-related procedures in the clinic setting (eg, blood draw and orthostatic maneuvers and blood pressure measurements). Prodromal symptoms often preceded the syncope.\nOrthostatic hypotension has been reported in clinical trials.\n\nThe most common adverse drug reactions (5%) reported during clinical trials were headache, dizziness, nausea, diarrhea, insomnia and fatigue. The most common events leading to discontinuation were nausea and dizziness.\n\nPrecaution: General: Dapoxetine is only indicated in men with PE. Safety has not been established and there are no data on the ejaculation-delaying effects in men without PE.\n\nUse with Recreational Drugs: Patients should be advised not to use Dapoxetine in combination with recreational drugs. Recreational drugs with serotonergic activity eg, ketamine, methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) may lead to potentially serious reactions if combined with Dapoxetine. These reactions include, but are not limited to, arrhythmia, hyperthermia and serotonin syndrome. \n\nUse of Dapoxetine with recreational drugs with sedative properties eg, narcotics and benzodiazepines may further increase somnolence and dizziness.\n\nEthanol: Combining alcohol with Dapoxetine may increase alcohol-related neurocognitive effects and may also enhance neurocardiogenic adverse events eg, syncope, thereby increasing the risk of accidental injury; therefore, patients should be advised to avoid alcohol while taking Dapoxetine.\n\nPossibly prodromal symptoms eg, nausea, dizziness/lightheadedness and diaphoresis were reported more frequently among patients treated with Dapoxetine compared to placebo.\n\nOrthostatic Hypotension: An orthostatic test should be performed before initiating therapy. In case of a history of documented or suspected orthostatic reaction, treatment with Dapoxetine should be avoided.\n\nDapoxetine is not indicated for psychiatric disorders and should not be used in men with these disorders eg, schizophrenia, or in those suffering with co-morbid depression, as worsening of symptoms associated with depression cannot be excluded.\n\nWithdrawal Effects: Abrupt discontinuation of chronically administered SSRIs used to treat chronic depressive disorders has been reported to result in the following symptoms: Dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, paresthesias, electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia and hypomania.\n\nMode of action: Potential serious reactions w/ MAOIs. Inhibits metabolism of thioridazine. Risk of serotonergic-associated effects w/ serotonergic medicinal/herbal products (including L-tryptophan, triptans, tramadol, linezolid, SSRIs, SNRIs, lithium & St. John's wort prep). CNS-active medicinal products. \n\nPossible reduction of clearance w/ CYP2D6, CYP3A4 & flavin monooxygenase 1 inhibitors. Increased exposure w/ potent (eg ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir & atazanavir) & moderate (eg erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem) CYP3A4 inhibitors; potent CYP2D6 inhibitors. \n\nPossible reduced orthostatic tolerance w/ PDE-5 inhibitors & ?-adrenergic receptor antagonists. Increases plasma conc of desipramine & other drugs metabolized by CYP2D6. Decreases AUCinf of midazolam. Warfarin (chronic therapy). Alcohol.\n\nPregnancy category: Not Classified\n\nInteraction: Potential serious reactions w/ MAOIs. Inhibits metabolism of thioridazine. Risk of serotonergic-associated effects w/ serotonergic medicinal/herbal products (including L-tryptophan, triptans, tramadol, linezolid, SSRIs, SNRIs, lithium & St. John's wort prep). CNS-active medicinal products. \n\nPossible reduction of clearance w/ CYP2D6, CYP3A4 & flavin monooxygenase 1 inhibitors. Increased exposure w/ potent (eg ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir & atazanavir) & moderate (eg erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem) CYP3A4 inhibitors; potent CYP2D6 inhibitors. \n\nPossible reduced orthostatic tolerance w/ PDE-5 inhibitors & ?-adrenergic receptor antagonists. Increases plasma conc of desipramine & other drugs metabolized by CYP2D6. Decreases AUCinf of midazolam. Warfarin (chronic therapy). Alcohol.
Aluminium Hydroxide	\n\n\tACI\tLocid TAB dr 400mg 200's pack \n\tACI\tLocid TAB dr 250mg 200's pack \n\tACI\tLocid Liquid Liquid  1's pack  \n\tEskayef Bangladesh Ltd.\tStoma Suspension Suspension  1's pack(200) \n\tIndication: Heartburn, Indigestion, Gastric Hyperacidity, Peptic ulcer disease,\n\nDose: Oral\nAntacid\nAdult: Up to 1 g daily.\nOral\nHyperphosphataemia in patients with chronic renal failure\nAdult: Dose is adjusted to the individual patient's requirement. Up to 10 g/day may be given in divided doses with meals.\nMax Dosage: 10 g daily in divided doses.\n\nMay be taken with or without food.\n\nContra-indication: Hypersensitivity to aluminium salts.\n\nSide effects: Constipation; intestinal obstruction (with large doses); phosphate depletion may occur with prolonged admin or large doses.\n\nPrecaution: Chronic renal impairment; CHF; oedema; cirrhosis and low Na diets; patients with recent GI haemorrhage. Administer 2-3 hrs before/after another medication to minimise drug interactions. Pregnancy and lactation.\n\nMode of action: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.\n\nPregnancy category: C\n\nInteraction: Enhanced absorption with citrates or ascorbic acid. Decreases absorption of allopurinol, tetracyclines, quinolones, cephalosporins, biphosphonate derivatives, corticosteroids, cyclosporin, delavirdine, Fe salts, imidazole antifungals, isoniazid, mycophenolate, penicillamine, phosphate supplements, phenytoin, phenothiazines, trientine.
Valdecoxib	\n\n\tACI\tValiflex tablet 10mg 50's pack 150\n\tACI\tValiflex tablet 20mg 30's pack 150\n\tAcme Ltd.\tVib TAB dr 10mg 5x10's pack 150\n\tAcme Ltd.\tVib TAB dr 20mg 3x10's pack 150\n\tNavana\tValdol TAB dr 10mg 10's pack \n\tNavana\tValdol TAB dr 20mg 10's pack \n\tNovartis (Bangladesh) Ltd.\tVaxib TAB dr 10mg 50's pack 250\n\tNovartis (Bangladesh) Ltd.\tVaxib TAB dr 20mg 30's pack 240\n\tOpsonin Pharma\tValcox TAB dr 10mg 50's pack 150\n\tOpsonin Pharma\tValcox TAB dr 20mg 30's pack 150\n\tOrion Pharma Ltd.\tVextra TAB dr 10mg 50's pack \n\tOrion Pharma Ltd.\tVextra TAB dr 20mg 50's pack \n\tIndication: Osteoarthritis; Rheumatoid arthritis, Dysmenorrhoea\n\nDose: Adult: PO Osteoarthritis; Rheumatoid arthritis 10 mg once daily. Dysmenorrhoea 20 mg twice daily.\n\nContra-indication: Hypersensitivity to sulfonamides, NSAIDs and other COX 2 inhibitors; asthma, urticaria; severe hepatic impairment; pregnancy (third trimester); lactation. Active GI bleed or ulceration, severe CHF, inflammatory bowel disease.\n\nSide effects: Hypertension, back pain, myalgia, peripheral oedema, influenza-like symptoms, dizziness, headache, abdominal fullness, abdominal pain, diarrhoea, dyspepsia, flatulence, nausea, myalgia, sinusitis.\nPotentially Fatal: Toxic epidermal necrolysis, exfoliative dermatitis.\n\nPrecaution: Mild to moderate hepatic impairment; history of ulcer disease or GI bleeding; dehydration, hypertension, history of heart failure, left ventricular dysfunction, pre-existing oedema. Monitor Hb or haematocrit values for signs and symptoms of anaemia.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Human normal Immunoglobulin	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tIntraglobin Liquid  1's pack(50ml) 6020.06\n\tUnimed & Unihealth Manufacturers Ltd.\tPentaglobin Injection  10ml bot 4478.28\n\tIndication: Immunocompromised patients or patients with primary antibodies deficiency, Prophylaxis of infections after bone marrow transplantation, Allogenic bone marrow transplantation.\n\nDose: Adult & child: Therapy of severe bacterial infection 5 mL/kg body wt daily on 3 consecutive days. Further infusion may be needed. Ig substitution 3-5 mL/kg body wt. Repeat at wkly intervals if needed. Neonate & infant 5 mL/kg body wt daily on 3 consecutive days.\n\nIntramuscular\nControl outbreaks of hepatitis A\nAdult: Recommended dose: 500 mg via deep IM inj.\nChild: Recommended dose: <10 yr: 250 mg; >10 yr: 500 mg, to be given as deep IM inj.\n\nProphylaxis against hepatitis A in immunocompromised patients\nAdult: Recommended dose: 500 mg via deep IM inj.\nChild: Recommended dose: <10 yr: 250 mg; >10 yr: 500 mg, to be given as deep IM inj.\n\nPrevent or modify measles attack in immunocompromised patients\nAdult: For prevention of an attack: 750 mg as an IM inj; to be given within 6 days after exposure (better efficacy if given within 72 hr). To modify an attack: 250 mg as an IM inj.\nChild: For prevention of an attack: <1 yr: 250 mg; 1-2 yr: 500 mg; >3 yr: 750 mg, as a single IM inj. Dose should be given within 6 days after exposure (better efficacy if given within 72 hr). To modify an attack: <1 yr: 100 mg and >1 yr: 250 mg, as a single IM inj.\n\nPrimary rubella in pregnant women whereby pregnancy termination is unacceptable\nAdult: 750 mg as an IM inj.\n\nParenteral\nImmunocompromised patients or patients with primary antibodies deficiency\nAdult: IV admin: Initially, 400-800 mg/kg, then 200 mg/kg every 3 wk, adjust according to trough-immunoglobulin levels; maintenance dose: 200-800 mg/kg/mth. In patients with secondary immunodeficiency syndromes: 200-400 mg/kg every 3-4 wk may be used. Alternatively, dose may be given via SC admin: Initial loading dose of 200-500 mg/kg (divided over several days), followed by maintenance doses at repeated intervals to achieve a cumulative mthly dose of 400-800 mg/kg.\n\nIntravenous\nProphylaxis of infections after bone marrow transplantation\nAdult: 500 mg/kg/wk, adjust dose according to response.\n\nRaise platelet count in patients with idiopathic thrombocytopenic purpura\nAdult: 400 mg/kg/day for 2-5 consecutive days. Alternatively, a dose of 800-1000 mg/kg may be given on day 1 and repeated on day 3 if needed. Doses to be given via IV infusion. Treatment may be repeated if relapse occurs.\n\nKawasaki disease\nAdult: 1.6-2 g/kg in divided doses over 2-5 days, or 2 g/kg given as a single dose. To be used in conjunction with acetylsalicylic acid.\n\nGuillain-Barre syndrome\nAdult: 400 mg/kg daily for 5 consecutive days, may repeat every 4 wk if needed.\n\nAllogenic bone marrow transplantation\nAdult: As part of the conditioning regimen and after transplantation: 500 mg/kg/wk, starting 7 days before transplantation and for up to 3 mth after transplantation. In cases of persistent lack of antibody production, 500 mg/kg/mth may be used to normalise the antibody level.\n\nContra-indication: Hypersensitivity to human Ig, circulating Abs to IgA.\n\nSide effects: Occasionally, chills, headache, fever, allergic reactions, nausea, arthralgia & mild back pain. In particular cases & esp after high IV doses, reversible aseptic meningitis & impaired renal function (dose-dependent) may occur. Rarely, fall in BP. In isolated cases, anaphylactic shock.\n\nPrecaution: For IV use only. Pregnancy, lactation.\n\nMode of action: May interfere with the immune response to live measles vaccine, live mumps vaccine, live rubella vaccine and live varicella vaccine, therefore these vaccines should be given at least 3 wk before or 3 mth after the admin of the immunoglobulins.\n\nPregnancy category: C\n\nInteraction: May interfere with the immune response to live measles vaccine, live mumps vaccine, live rubella vaccine and live varicella vaccine, therefore these vaccines should be given at least 3 wk before or 3 mth after the admin of the immunoglobulins.
Vitamin B1 + Vitamin B2 + Nicotinamide + Vitamin B6 + Pantothenic Acid + Vitamin C + Biotin + Folic Acid + Vitamin B12 Inj	\n\n\tAristopharma\tArovital Injection  1's vial 200\n\tIndication: It is intended as a supplement for intravenous nutrition in order to meet the daily requirements of the water-soluble vitamins in infants, children and adults. \n\nDose: Adults: For adult patients and children weighing 10 kg or more, the recommended daily doses are the content of 1 vial (10 ml).\n\nChildren: Children weighing less than 10 kg should be given 1/10 of the content of one vial i.e. 1 ml per kg body weight per day.\n\nContra-indication: Hypersensitivity to any of the ingredients of the preparation. \n\nSide effects: The unwanted effects of nutrient solutions are a rise in the body temperature, shivering, chills and nausea and vomiting. Other rare unwanted effects include: allergic reactions; breathing difficulties (rapid breathing, shortness of breath); effects on blood pressure, abdominal pain, tiredness, headaches, flushing, slight pressure over the eyes and dizziness. \n\nPrecaution: Administering folic acid may obscure pernicious anemia. In patients receiving total parenteral nutrition (TPN), routine supplementation with both fat-soluble and water-soluble vitamins is recommended to prevent deficiency states and to obviate the need to speculate on individual vitamin status. Daily vitamin requirements must be calculated to avoid over dosage and toxic effects, especially with regards to vitamins A & D and particularly in pediatric patients. In patients for whom total parenteral nutrition is continued for prolonged periods (months or years), periodic monitoring of blood vitamin levels should be considered. To prevent excessive excretion of water-soluble vitamins and for reasons of safety, daily dosage should be administered over a number of hours. \n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Clarithromycin + Metronidazole + Lansoprazol	\n\n\tBeximco\tPylopac TAB dr  7's pack 315\n\tIndication: H. pylori infection, Peptic ulcer disease\n\nDose: One strip lansoprazole, 30 mg; clarithromycin, 500 mg; and metronidazole, 500 mg twice daily for 7-14 days or as per the physicians advice. \n\nContra-indication: Contraindicated in patients with known severe hypersensitivity to any component. Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes. \n\nSide effects: Adverse reactions which were reported as possibly or probably related to treatment (<3%) in clinical trials when all three components of this therapy were given concomitantly are listed below and divided by body systems. Digestive system : nausea, vomiting, diarrhoea, dark stool, glossitis, oral moniliasis, stomatitis, tongue discoloration, Musculoskeletal System : myalgia, Nervous System : confusion, headache, dizziness, Skin : skin reactions, Urological System : vaginitis, vaginal moniliasis. \n\nPrecaution: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.\n\nMode of action: Clarithromycin: Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine. Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam).\nPotentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.\n\nMetronidazole: Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.\n\nLansoprazole: Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.\nPotentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.\n\n\nPregnancy category: Not Classified\n\nInteraction: Clarithromycin: Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine. Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam).\nPotentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.\n\nMetronidazole: Concurrent use w/ disulfiram may produce psychotic reactions. May potentiate the effect of oral anticoagulants. May increase risk of lithium toxicity. May reduce the renal clearance resulting to increased toxicity of 5-fluorouracil. May increase serum levels of ciclosporin. May increase plasma levels of busulfan resulting to severe busulfan toxicity. Enhanced metabolism w/ phenobarbital and phenytoin resulting to decreased serum concentrations.\n\nLansoprazole: Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.\nPotentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.\n
Rofecoxib	\n\n\tBeximco\tRecox TAB dr 12.5mg 50's pack \n\tBeximco\tRecox TAB dr 25mg 50's pack \n\tBeximco\tRecox TAB dr 50mg 50's pack \n\tDrug International Ltd.\tPantrol TAB dr 12.5mg 100's pack 250\n\tDrug International Ltd.\tPantrol TAB dr 25mg 100's pack 300\n\tRenata\tFexib TAB dr 25mg 50's pack \n\tRenata\tFexib TAB dr 12.5mg 50's pack \n\tIndication: Osteoarthritis, Rheumatoid arthritis, Pain\n\nDose: Adult: PO Osteoarthritis Initial: 12.5 mg once daily. Max: 25 mg/day. Rheumatoid arthritis 25 mg/day. Max: 25 mg/day. Pain relief Initial: 50 mg once daily, then 25-50 mg/day. Max: 50 mg/day. Treatment duration >5 days is not recommended.\n\nContra-indication: Hypersensitivity. Severe renal impairment.\n\nSide effects: Mouth ulcers, chest pain, weight gain, atopic eczema, muscle cramps, diarrhoea, headache, nausea; upper respiratory tract infection, hypertension, ischaemia, dyspepsia, epigastric discomfort, heart burn, nausea, sinusitis, back pain, headache, bronchitis, urinary tract infections.\nPotentially Fatal: Renal failure; nephrotoxicity; MI.\n\nPrecaution: Hepatic dysfunction, pregnancy and lactation. History of ulcer disease or GI bleeding. Elderly or debilitated patients. Prolonged treatment, smoking and alcoholism may increase risk of GI bleeding. Ischaemic heart disease.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Nimesulide	\n\n\tEskayef Bangladesh Ltd.\tNimex TAB dr 100mg 100's pack \n\tGeneral\tFeverein TAB dr 100mg 100's pack \n\tNavana\tSumo TAB dr 100mg 100's pack \n\tOrion Pharma Ltd.\tNibid TAB dr 100mg 100's pack \n\tIndication: Acute pain; Extra-articular disorders; Osteoarthritis; Post-op pain; Primary dysmenorrhoea\n\nDose: Adult: PO Acute pain; Extra-articular disorders; Osteoarthritis; Post-op pain; Primary dysmenorrhoea 100 mg twice daily. \n\n\n\nContra-indication: Hypersensitivity; GI bleeding, active peptic ulcer disease; severe renal and heart failure; hepatic impairment or known liver disease; coagulation disorders; pregnancy; children <12 yr.\n\nSide effects: Epigastric discomfort, heartburn or abdominal cramps, nausea, vomiting and diarrhoea; skin rash, pruritus, oedema, headache, dizziness, drowsiness; hypersensitivity reactions (e.g. bronchospasm, rhinitis, angioedema urticaria); GI haemorrhage/perforation; bullous/erosive stomatitis, purpura, thrombocytopenia, toxic epidermal necrolysis, haematuria, oliguria, and renal failure; increases in liver enzymes.\nPotentially Fatal: Fatal hepatitis, Stevens Johnson syndrome.\n\nPrecaution: History of GI tract disease, infections, oedema, hypertension, elderly, lactation.\n\nMode of action: Additive hepatotoxic effects with known hepatotoxins: anti-convulsants (e.g. valproic acid), anti-fungals (e.g. ketoconazole), anti-tuberculous drugs (e.g. isoniazid), tacrine, pemoline, amiodarone, methotrexate, methyldopa, amoxicillin/clavulanic acid. May decrease the oral bioavailability of furosemide and the natriuretic and diuretic response to furosemide. Increased risks of GI and hepatic adverse effects with other NSAIDs, including aspirin. May increase anti-coagulant effect of warfarin. Potentiates the action of phenytoin. May be displaced from binding sites with fenofibrate, salicylic acid, and tolbutamide. Interactions between NSAIDs and lithium, probenecid and ciclosporin, have been documented.\n\nPregnancy category: Not Classified\n\nInteraction: Additive hepatotoxic effects with known hepatotoxins: anti-convulsants (e.g. valproic acid), anti-fungals (e.g. ketoconazole), anti-tuberculous drugs (e.g. isoniazid), tacrine, pemoline, amiodarone, methotrexate, methyldopa, amoxicillin/clavulanic acid. May decrease the oral bioavailability of furosemide and the natriuretic and diuretic response to furosemide. Increased risks of GI and hepatic adverse effects with other NSAIDs, including aspirin. May increase anti-coagulant effect of warfarin. Potentiates the action of phenytoin. May be displaced from binding sites with fenofibrate, salicylic acid, and tolbutamide. Interactions between NSAIDs and lithium, probenecid and ciclosporin, have been documented.
Coenzyme Q 10	\n\n\tBeacon\tCoQ 30 CAP 30mg  \n\tBeacon\tCoQ 60 CAP 60mg  \n\tDrug International Ltd.\tCozyme Cream 30mg 30's pack \n\tDrug International Ltd.\tCozyme CAP 60mg 20's pack \n\tGeneral\tQ10 CAP 30mg 30's pack 240\n\tGeneral\tQ10 CAP 60mg 20's pack 300\n\tRadiant.\tUbi Q CAP 30mg  \n\tRadiant.\tUbi Q CAP 60mg  \n\tSquare\tResQ 60 TAB dr  18's pack \n\tSquare\tResQ 30 TAB dr  30's pack \n\tIndication: A natural catalyst for energy release from food; an antioxidant.\nâ¢ HMG CoA reductase inhibitor mediated decreased level of Coenzyme Q10 in blood\nâ¢ Drug induced Myopathy\nâ¢ Protects body against free radial damage with its antioxidant property\nâ¢ Adjuvant therapy in cardiovascular disease especially in angina and congestive heart failure\nâ¢ Immune system depression\nâ¢ Cognitive decline\nâ¢ Useful in the management of Periodontal Disease\nâ¢ Intensive moisturizer fights visible skin lines and wrinkles\nâ¢ Helps keep skin moisturized\n\nDose: Oral: 1 cap daily, may be increased up to 3 cap daily if high dose is required.\nDaily doses of Coenzyme Q10 range from 5 to 300 milligrams. Effectiveness is thought to be obtained with doses of 50 to 200 milligrams daily. \n\nCream: After cleansing and before bed, apply to face and neck.\n\n\n\nContra-indication: Not known\n\nSide effects: Generally, Coenzyme Q10 is well tolerated and having no significant side effects. Mild gastro-intestinal symptoms such as nausea, diarrhea and epigastric distress have been reported, particularly with higher doses (200 mg or more daily).\n\nPrecaution: Supplemental Coenzyme Q10 may improve beta-cell function and glycemic control in type II diabetics. Therefore, those diabetics who do use supplemental Coenzyme Q10 should determine by appropriate monitoring if they need to make any adjustments in their diabetic medications. \n\nCream for external use only. Avoid contact with eyes. Keep out of reach of children.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Hypromellose 0.3% + Carbomer 0.22% Eye prep	\n\n\tNovartis (Bangladesh) Ltd.\tGenTeal Eye gel  10gm tube 456\n\tIndication: Dry eye conditions, management of stable tear film, lubricant eye gel for wearers of all types of contact lenses.\n\nDose: Adult & elderly Apply in each eye as needed.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Burning, stinging, allergic reactions, red eyes.\n\nPrecaution: Not to be used during surgery,  use of other eye medications.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Vitamin A palmitate Carbomer 980 Eye prep	\n\n\tNovartis (Bangladesh) Ltd.\tHypro Tears Gel Eye Gel  10gm tube 158.79\n\tIndication: Dry eyes, irritated eyes\n\nDose: Apply 1 to 2 times daily as needed.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Vision may be temporarily blurred when this product is first used. Also, minor burning/stinging/irritation may temporarily occur.\n\nPrecaution: Not to be used during surgery, use of other eye medications\n\nMode of action: Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.\n\nPregnancy category: Not Classified\n\nInteraction: Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.
Vitamin A palmitate Carbomer 980 + Polyvidone + Electrolytes Eye prep	\n\n\tNovartis (Bangladesh) Ltd.\tHypro Tears Plus Eye drops  10ml bot 136.24\n\tIndication: Dry eye, Corneal protection\n\nDose: 1 drop in each eye as needed.\n\nContra-indication: Known hypersensitivity or allergy to any ingredient of the product.\n\nSide effects: Vision may be temporarily blurred when this product is first used. Also, minor burning/stinging/irritation may temporarily occur.\n\nPrecaution: Not to be used during surgery, use of other eye medications\n\nMode of action: vitamin a....Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.\n\nPregnancy category: Not Classified\n\nInteraction: vitamin a....Decreased absorption with neomycin. Increased risk of hypervitaminosis A with synthetic retinoids eg, acitretin, isotretinoin and tretinoin. Increased risk of toxicity when used with alcohol.
Immuno booster	\n\n\tNovartis (Bangladesh) Ltd.\tImpact Powder for Suspension  61gx4's pack 480\n\tIndication: Nutritionally complete enteral supplement for the preoperative preparation of malnourished patients.\n\nDose: Individualized dosage.\nDissolve contents of 1 sachet in 250 mL of cold water. Use shaker, whisk or fork to mix. Consume immediately.\n\nContra-indication: \n\nSide effects: \n\nPrecaution: Do not administer simultaneously with or mix with drugs or other foodstuffs. Food for special medical purposes. Suitable for use as the sole source of nourishment.\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Isradipine	\n\n\tNovartis (Bangladesh) Ltd.\tLomir TAB dr 2.5mg 28's pack \n\tIndication: Hypertension\n\nDose: Oral\nHypertension\nAdult: Initially, 2.5 mg bid, increase if necessary after 3-4 wk to 5 mg bid, or 10 mg bid as required.\nElderly: Initially, 1.25 mg bid. Maintenance: 2.5 or 5 mg once or twice daily.\nHepatic impairment: Initially 1.25 mg bid titrated slowly to maintenance: 2.5 or 5 mg once or twice daily.\n\nContra-indication: Cardiogenic shock; recent MI or acute unstable angina; severe aortic stenosis; lactation; porphyria.\n\nSide effects: Dizziness; flushing; headache; hypotension; peripheral oedema; tachycardia; palpitations; GI disturbances; increased micturition frequency; lethargy; eye pain; depression; ischaemic chest pain; cerebral or myocardial ischaemia; transient blindness; rashes; fever; abnormal liver function; gingival hyperplasia; myalgia; tremor; impotence; dyspnea.\n\nPrecaution: Hypotension, poor cardiac reserve, heart failure. Pregnancy.\n\nMode of action: Concurrent admin w/ enzyme-inducing drugs (e.g. rifampicin, phenobarbital, carbamazepine) reduced plasma concentrations of isradipine. Increased bioavailability w/ cimetidine. May increase serum levels w/ CYP3A4 inhibitors (e.g. macrolides, HIV protease inhibitors, azole antifungals, delavirdine).\n\nPregnancy category: C\n\nInteraction: Concurrent admin w/ enzyme-inducing drugs (e.g. rifampicin, phenobarbital, carbamazepine) reduced plasma concentrations of isradipine. Increased bioavailability w/ cimetidine. May increase serum levels w/ CYP3A4 inhibitors (e.g. macrolides, HIV protease inhibitors, azole antifungals, delavirdine).
Cinchocaine Hydrochloride 1%	\n\n\tNovartis (Bangladesh) Ltd.\tNupercainal Ointment  20gm tube \n\tIndication: Surface anaesthesia\n\nDose: Topical/Cutaneous\nSurface anaesthesia\nAdult: Up to 1% in cream and ointment. Use as directed.\n\nContra-indication: Complete heart block; pyogenic infection at or near the skin. Application to inflamed or infected tissues or to damaged skin mucosa; instillation into the middle ear.\n\nSide effects: Restlessness; excitement; nervousness; paraesthesias; dizziness; tinnitus; blurred vision; nausea; vomiting; muscle twitching; tremors; convulsions; hypotension; bradycardia; arrhythmias; cardiac arrest.\n\nPrecaution: Elderly; debilitated patients; child; epilepsy; impaired cardiac conduction or respiratory function; shock; hepatic impairment; myasthenia gravis. Do not to rub or touch the eye while anaesthesia persists. Avoid application for prolonged periods and to extensive areas. Pregnancy, lactation.\n\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Terfenadine	\n\n\tNovartis (Bangladesh) Ltd.\tServinin TAB dr 60mg 100's pack \n\tIndication: Allergic conditions.\n\nDose:  Adult: PO >12 yr and >50 kg: 60-120 mg/day in the morning or 60 mg twice daily. Max: 120 mg/day.\n\nContra-indication: Porphyria.\n\nSide effects: Anxiety, palpitations, insomnia, mild GI distubances, erythema multiforme and galactorrhoea.\nPotentially Fatal: Ventricular arrhythmias including torsades de pointes. Palpitations, dizziness, syncope or convulsions may indicate arrhythmias. Hepatitis.\n\nPrecaution: Child and elderly. Avoid in patients with cardiac or significant hepatic disease, electrolyte imbalance, or known or suspected prolongation of the QT interval. Lactation, pregnancy.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Halometasone	\n\n\tNovartis (Bangladesh) Ltd.\tSicorten Cream/Ointment 0.05% 5g tube 77\n\tIndication: Corticosteroid-responsive dermatoses.\n\nDose: Topical/Cutaneous\nCorticosteroid-responsive dermatoses\nAdult: Apply as a 0.05% cream or ointment on affected areas.\n\nContra-indication: Hypersensitivity. Not to be applied with an occlusive dressing and to large areas of the body. Rosaceae, leg ulcers, long-term topical treatment esp in child.\n\nSide effects: Bone disorders; muscle fractures; muscle wasting; Na depletion; hyperglycaemia; impaired tissue repair; susceptibility to infections; menstrual irregularities; hyperhydrosis; skin thinning.\nPotentially Fatal: Hypersensitivity reactions.\n\nPrecaution: Risk of systemic absorption when applied to large areas, broken skin or under occlusive dressings.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Halometasone 0.05% + Triclosan 1%	\n\n\tNovartis (Bangladesh) Ltd.\tSicorten Plus Cream  5g tube 83\n\tIndication: Acne, Corticosteroid-responsive dermatoses \n\nDose: Topical/Cutaneous\nAcne,  Corticosteroid-responsive dermatoses \nApply on affected areas as directed.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Contact dermatitis.\n\nPrecaution: Risk of systemic absorption when applied to large areas, broken skin or under occlusive dressings.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Omeprazole 20mg + Sodium bicarbonate 1100mg	\n\n\tOpsonin Pharma\tOmetid IR CAP  60's pack 240\n\tIndication: Peptic ulcer disease, Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis \n\nDose: Usually once daily on an empty stomach, at least 1 hour before a meal. The powder form of this medication may also be given through a tube into the stomach (nasogastric or gastric tube). \n\nContra-indication: Patients with known hypersensitivity to any components of the formulation.\n\nSide effects: Diarrhoea, nausea, fatigue, constipation, vomiting, flatulence, acid regurgitation, taste perversion, arthralgia, myalgia, urticaria, dry mouth, dizziness, headache, paraesthesia, abdominal pain, skin rashes, weakness, back pain, upper respiratory infection, cough. Potentially Fatal: Anaphylaxis.\n\nPrecaution:  Exclude malignancy, prolonged use, hepatic impairment. Pregnancy, lactation, children <1 yr. \n\nMode of action: Omeprazole: Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.\n\nSodium bicarbonate: Increases toxicity of amphetamines, ephedrine, pseudoephedrine, flecainide, quinidine and quinine. Decreases effects of lithium, chlorpropamide and salicylates due to increased clearance. May affect the absorption of certain drugs due to raised intra-gastric pH.\n\nPregnancy category: C\n\nInteraction: Omeprazole: Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel.\nPotentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.\n\nSodium bicarbonate: Increases toxicity of amphetamines, ephedrine, pseudoephedrine, flecainide, quinidine and quinine. Decreases effects of lithium, chlorpropamide and salicylates due to increased clearance. May affect the absorption of certain drugs due to raised intra-gastric pH.
Carbonyl Iron + Folic acid + Vitamin B complex + Vitamin C + Zinc	\n\n\tAcme Ltd.\tMomneed CAP 50mg + 0.5mg + 61.8mg + 5 50's pack 175\n\tApex\tMaxiron CAP  30's pack 105\n\tBeacon\tXvit CAP   50's pack 175\n\tBeximco\tOmnivit CAP  50's pack 175\n\tCentral.\tKarbon-5 CAP  100's pack 350\n\tEskayef Bangladesh Ltd.\tZilvit CAP   60's pack 210\n\tGlobe\tEPL plus CAP  30's pack 105\n\tKumudini Pharma Ltd.\tCivic-ZF CAP  50's pack 175\n\tNovelta Bestway\tFemavit Forte CAP   60's pack 210\n\tNovo Healthcare and Pharma Ltd.\tFeocron PLUS CAP   30's pack 105\n\tOrganic Health Care\tFer-V CAP  30's pack 105\n\tSilva\tFamina Z CAP   60's pack 210.79\n\tSomatec\tCarbomet CAP   60's pack 180.60\n\tSquare\tZif Forte TR CAP    30's pack 	 105.33 	\n\tSyntho Ltd.\tSyn-Z CAP   50's pack 175\n\tIndication: Iron, Folic acid, Zinc, vitamins B and Vitamin C deficiency during pregnancy and lactation\n\nDose: One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: \nCarbonyl iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\nPregnancy category: Not Classified\n\nInteraction: \nCarbonyl iron: Antacids may decrease the absorption of carbonyl iron.\n\nFolic acid: Antiepileptics, oral contraceptives, anti-TB drugs, alcohol, aminopterin, methotrexate, pyrimethamine, trimethoprim and sulphonamides may result to decrease in serum folate contrations. Decreases serum phenytoin concentrations.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n
Esomeprazole Sodium INN	\n\n\tACI\tEsomep Injection 40mg/vial 1's 90\n\tAcme Ltd.\tMaxima Injection 40mg/vial 1's 70\n\tAlbion Ltd.\tEsofour CAP 20 mg 30's pack \n\tAlbion Ltd.\tEsofour TAB dr 20 mg 50's pack \n\tAlbion Ltd.\tEsofour TAB dr 40mg  \n\tAristopharma\tEmep IV Injection 40mg/vial 1's 90\n\tBeximco\tOpton Injection 20mg, 40mg/vial 1's 100\n\tBio Pharma Ltd.\tEsocon 40 IV Injection 40mg/vial 1's 65\n\tDrug International Ltd.\tPronex Injection 40mg/vial 1's 70\n\tEskayef Bangladesh Ltd.\tEsoral IV Injection 40mg/vial 1's 70\n\tEthical Drug Ltd.\tGaspro Injection 40 mg/vial  \n\tGlobe\tEma IV Injection 40mg/vial 1's 70\n\tHealthcare\tSergel Injection 40mg/vial 1's 90\n\tIncepta\tEsonix 40 IV injection Injection 40mg 1's pack 90\n\tIncepta\tEsonix Injection 20 mg/vial  \n\tIncepta\tEsonix Granules for suspension 20mg  \n\tMonicopharma\tNuloc Injection 40 mg/vial  \n\tNovo Healthcare and Pharma Ltd.\tAsector Injection 40mg/vial 1's 90\n\tNuvista Pharma Ltd\tGerdo CAP 20 mg 49's pack 342.98\n\tOpsonin Pharma\tEsotid Injection 40mg/vial 1's 70\n\tPharmasia Ltd.\tXelpro IV Injection 40 mg/vial  \n\tPopular\tProgut Injection 40mg/vial 1's 90\n\tRadiant.\tExium 40 IV IV Injection 40 mg/vial  \n\tRenata\tMaxpro Injection 20mg, 40mg/vial 1's 90\n\tSquare\tNexum IV Injection 20mg, 40mg/vial 1's 70.26\n\tIndication: Heartburn, Acid Related Dyspepsia, Peptic ulcer disease, Zollinger-Ellison syndrome, Gastroesophageal reflux disease (GERD), Helicobacter pylori infection, Erosive Esophagitis, Gouty arthritis.\n\nDose: IV: Gastro-oesophageal reflux disease 20 or 40 mg once daily for 10 days. Convert to oral therapy as soon as possible. \n\n\n\nContra-indication: Esomeprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted Benzimidazoles.\n\nSide effects: The most frequently occurring adverse events ( >1%) are headache, diarrhoea, abdominal pain, nausea, flatulence, dry mouth, constipation.\n\nPrecaution: Paediatric; pregnancy, lactation. Malignancy and hepatic impairment. Increased risk of developing certain infections such as community-acquired pneumonia. For patients with severe liver impairment, a dose of 20 mg should not be exceeded.\n\nMode of action:  	Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.\nPotentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.\n\nPregnancy category: C\n\nInteraction:  	Increased risk of digoxin-induced cardiotoxic effects. Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. May increase serum concentration of tacrolimus, saquinavir, methotrexate. May interfere the elimination of drugs metabolised by CYP2C19 (e.g. diazepam). May decrease the bioavailability of ketoconazole, erlotinib and Fe salts.\nPotentially Fatal: May decrease serum concentration and pharmacological effects of rilpivirine, atazanavir and nelfinavir. May decrease the antiplatelet effects of clopidogrel.
Hyoscine Hydro Bromide	\n\n\tNavana\tJoytrip Chewable TAB dr 150 mcg 30's pack 150\n\tIndication: Motion sickness\n\nDose: Adult & Children over 12 years: Motion sickness As hydrobromide: 300 mcg 30 mins before journey, then 300 mcg 6 hrly if needed. Max: 3 doses in 24 hr.\n\nChildren 4-12 years: 1 tablet 30 mins before journey. Maximum 2 tablet in 24 hours.\nChidren 3-4 years: 1/2 tab 30 mins before journey. Maximum 1 tablet in 24 hours.\n\nContra-indication: Narrow-angle glaucoma, acute haemorrhage, paralytic ileus, tachycardia due to cardiac insufficiency, myasthenia gravis.\n\nSide effects: Flushing, postural hypotension, tachycardia, fibrillation. Rarely psychotic reactions. Dizziness, drowsiness, fatigue, headache, memory loss. Dry skin, erythema, increased sensitivity to light, rash. Bloatedness, constipation, dry throat, dysphagia, nausea, vomiting, xerostomia. Dysuria, urinary retention. Tremor, weakness. Impaired accommodation, blurred vision, cycloplegia, dryness, narrow-angle glaucoma, increased intraocular pain, itching, photophobia, pupil dilation. Dry nose. Decreased diaphoresis, heat intolerance. Ophthalmic: Somnolence, dermatitis, oedema, exudate, follicular conjunctivitis, increased IOP, local irritation, photophobia, vascular and respiratory congestion. Potentially Fatal: CNS depression, coma, circulatory and respiratory failure.\n\nPrecaution: Hepatic/renal disease, pyloric stenosis, urinary retention, prostatic hyperplasia, psychosis, seizure disorders, ulcerative colitis, coronary artery disease, tachyarrhythmias, heart failure, hypertension. Elderly, children, pregnancy, lactation\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Protein, fat, carbohydrate, vitamins & minerals	\n\n\tAbbott HealthcareProducts,Netherlands\tEnsure Powder Powder milk  400gm, 1000gm 950, 1700\n\tAbbott HealthcareProducts,Netherlands\tGlucerna SR Powder Powder milk  400gm, 1000gm 1100, 2100\n\tAbbott HealthcareProducts,Netherlands\tPediasure Powder Powder milk  400gm, 1000gm \n\tIndication: Total diet replacement or supplement in anorexia, illness, convalescence, pregnancy, lactation, old age, weight loss, fatigue, pre- & post-surgical conditions, oral pathology, cancer, transition from TPN & tube feeding for adults & older persons. Specialized nutrition with fiber for diabetic patients.\n\n\n\nDose: To prepare a 250ml feeding, put 200ml of cold water in a glass_ Gradually add 6 level scoops (enclosed) of powder while stirring and mix until dissolved_ When mixed as directed powder provides approx_ 1 kcal per ml.\n\nContra-indication: \n\nSide effects: \n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Sulphonated Surfactant	\n\n\tGlaxoSmithKline Bangladesh Ltd.\tAcne-Aid Bar Bar cleanser  100gm bar 310\n\tGlaxoSmithKline Bangladesh Ltd.\tAcne-Aid Liquid Liquid cleanser  150 ml bot 649\n\tIndication: Bar Cleanser for acne & greasy skin. Liquid cleanser Soap-free cleanser for acne prone and oily skin conditions.\n\nDose: Use on the face or other affected areas. Wash as with an ordinary soap and massage the creamy lather into the skin. Wet skin, apply & rinse off w/ water once or bid. Using warm water, gently rub the soap on the skin until a rich lather is formed. Massage briskly and rinse thoroughly. \n\nThis Liquid cleanser can be used both with water and without water for face. If the cleanser is used with water, apply liberal amount of cleanser to the skin. Massage gently in circular motion. Rinse with water. In case it is used without water, apply cleanser to the skin and massage gently in circular motion, remove excess with soft tissue or cotton wool.\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: Mild irritation, skin sensitization\n\nPrecaution: Avoid contact with eyes. Flush with water if lather enters the eyes.\n\n\n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Clotrimazole 1%  Eye prep	\n\n\tAristopharma\tAristen 	 Eye Ointment    4 gm tube 55 	\n\tReman Drug Ltd.\tFungizol Eye Ointment    4 gm tube 55.50\n\tReman Drug Ltd.\tFungizol Eye Drops   10 ml drop 	  80 		\n\tIndication: Fungal keratitis, Fungal eye infections\n\nDose: Opthalmic: It should be applied thinly and evenly to the conjunctival sac every 4 hours daily \n\nContra-indication: Hypersensitivity\n\nSide effects: \n\nPrecaution: Childn <3 yrs. Pregnancy, lactation.If local intolerance develops, consider withdrawal of the medicine and institution of appropriate therapy. \n\nMode of action: Antagonism with polyene antibiotics.\n\nPregnancy category: B\n\nInteraction: Antagonism with polyene antibiotics.
Clotrimazole 1%  Ear prep	\n\n\tG. A. Company Ltd.\tKanis 	 Ear Drops   10 ml drop 80 	 	\n\tIncepta\tClarizol Ear Drops   10 ml drop 80 	 	\n\tIndication: Fungal otitis externa\n\nDose: Otic/Aural Fungal otitis externa Adult: Apply 2-3 drops in the affected ear two or three times daily. \n\nContra-indication: Hypersensitivity\n\nSide effects: \n\nPrecaution: Childn <3 yrs. Pregnancy, lactation.If local intolerance develops, consider withdrawal of the medicine and institution of appropriate therapy. Clotrimazole ear drop is not intended for ophthalmic use.\n\nMode of action: Antagonism with polyene antibiotics.\n\nPregnancy category: B\n\nInteraction: Antagonism with polyene antibiotics.
Gentamicin 0.3% Topical	\n\n\tAmico Ltd.\tMonamycin 			 Cream   15gm tube  16.75 	\n\tBeximco\tGentosep 	 Cream   15gm tube  18.45 \n\tG. A. Company Ltd.\tGento Ointment   5gm tube 	 9.10 	\n\tGonoshasthaya\tG-Gentamicin Ointment   25gm tube  19.72 	\n\tOpsonin Pharma\tGentin Cream   10gm tube  11.30 \n\tIndication: Bacterial skin infections, Burns, eczema, seborrheic dermatitis, ecthyma, excoriation, folliculitis, furunculosis, insect bites and stings, lacerations and abrasions, paronychia, pyoderma gangrenosum, skin cysts and abscesses, stasis ulcers and infected skin ulcers, bacterial, fungal or viral superinfection, sycosis barbae, minor surgical wounds, infected contact dermatitis caused by susceptible organisms. \n\nDose: Adult & Child: Apply to the affected area 3-4 times daily.\n\n\nContra-indication: History of hypersensitivity to aminoglycoside; pregnancy; hepatic impairment.\n\nSide effects: Dizziness or vertigo; acute renal failure, interstitial nephritis, acute tubular necrosis; electrolyte imbalances; transient elevation of serum bilirubin and aminotransferases; purpura; nausea, vomiting; convulsions, mental depression, hallucinations. Atrophy or rat necrosis at inj sites. \nPotentially Fatal: Nephrotoxicity, ototoxicity and neuromuscular blockade (may unmask or aggravate myasthaenia gravis).\n\nPrecaution: Concurrent use of neuromuscular blocking agents; myasthenia gravis, parkinsonism; conditions predisposing to ototoxicity and nephrotoxicity; lactation. Monitor plasma concentrations of gentamicin in patients receiving high doses or prolonged courses, in infants, elderly, patients with renal impairment, cystic fibrosis or significant obesity. Monitor auditory and renal functions.\n\nMode of action: Synergistic with ampicillin, benzylpenicillin and other ?-lactam antibiotics. Increased risk of severe respiratory depression when used concurrently with anaesthetics or opioids. May reduce renal clearance of zalcitabine and induce hypocalcaemia when used with biphosphonates. Not to be used with agalsidase alfa or beta as it may inhibit ?-galactosidase activity.\nPotentially Fatal: Increased incidence of ototoxicity when combined with ethacrynic acid and furosemide. Cephalosporins, ciclosporin, cisplatin, vancomycin, hydrocortisone and indometacin potentiate nephrotoxicity. Potentiates neuromuscular blocking agents.\n\nPregnancy category: C\n\nInteraction: Synergistic with ampicillin, benzylpenicillin and other ?-lactam antibiotics. Increased risk of severe respiratory depression when used concurrently with anaesthetics or opioids. May reduce renal clearance of zalcitabine and induce hypocalcaemia when used with biphosphonates. Not to be used with agalsidase alfa or beta as it may inhibit ?-galactosidase activity.\nPotentially Fatal: Increased incidence of ototoxicity when combined with ethacrynic acid and furosemide. Cephalosporins, ciclosporin, cisplatin, vancomycin, hydrocortisone and indometacin potentiate nephrotoxicity. Potentiates neuromuscular blocking agents.
Bacitracin Zinc + Neomycin Sulphate + Polymixin B Eye prep	\n\n\tG. A. Company Ltd.\tBoxitrol Eye Ointment   5gm tube 20.62\n\tG. A. Company Ltd.\tBoxitrol Eye Drops   5  ml drop 30\n\tIndication: Bacterial ocular infections\n\nDose: Adult & Child: Eye Drop: 1-2 drops 3-4 times daily.\nEye ointment: Apply 2 or more times daily. \n\nContra-indication: Hypersensitivity\n\nSide effects: Rash, itching, burning, anaphylactic reactions, swelling, conjunctival erythema.\n\nPrecaution: Excessive use of the topical preparation may lead to substantial systemic absorption which may lead to nephrotoxicity (polymyxin B sulfate) and neurotoxicity (bacitracin). Prolonged use of the antibacterial preparation may cause overgrowth of non-susceptible organisms, including fungi. Pregnancy and lactation.\n\nMode of action: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\nNeomycin Sulphate: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\nPolymixin B: Potentially Fatal: Additive neurotoxic or nephrotoxic effect w/ bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, colistin. Increased risk of resp paralysis w/ neuromuscular blockers (e.g. anaesthetics, muscle relaxants).\n\nPregnancy category: C\n\nInteraction: Bacitracin Zinc: Increased risk of nephrotoxicity when used with other nephrotoxic drugs. May enhance the action of neuromuscular-blocking agents.\n\nNeomycin Sulphate: Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.\n\nPolymixin B: Potentially Fatal: Additive neurotoxic or nephrotoxic effect w/ bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, colistin. Increased risk of resp paralysis w/ neuromuscular blockers (e.g. anaesthetics, muscle relaxants).
Dexamethasone 0.1%   Eye prep	\n\n\tAcme Ltd.\tSteron Eye Drops   5 ml bot 70\n\tApex\tApidex Eye Drops   5 ml bot 60\n\tAristopharma\tSonexa Eye Drops   5 ml bot 70\n\tAsiatic Ltd.\tOcudex Eye Drops   5ml bot 70\n\tBio Pharma Ltd.\tInfladex Eye Drops 1 mg/ml  \n\tChemist Ltd.\tDexan Eye Drops   4 ml bot 60\n\tGeneral\tDexagen Eye Drops   5ml drop 70\n\tGlobe\tD-Cort Eye Drops 1 mg/ml  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tDexon Eye Drops   5 ml bot 70\n\tPopular\tOrbidex Eye Drops  0.1% 5 ml bot 61.60\n\tRephco\tDexamet Eye Drops   5ml drop 60\n\tIndication: Allergic conjunctivitis, Ocular inflammation, Superficial punctate keratitis , Herpes zoster keratitis, Iritis , Cyclitis. \n\nDose: Eye: 1 or 2 drops in conjunctival sac. Severe or acute inflammation: Every 30 to 60 minutes as initial therapy, reducing the dosage when favourable response is observed to every two to four hours. Further reduction may be made to one drop three or four times daily if sufficient to control inflammation. Chronic inflammation: Every three to six hours, or as necessary. Allergic inflammation: Every three to four hours until the desired response is obtained. \n\nContra-indication: Hypersensitivity; Contraindicated in epithelial herpes simplex, vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; tuberculosis of the eye; fungal disease of ocular structures; other diseases caused by micro-organisms, may be enhanced by the presence of the steroid. It is contraindicated in patients with perforated ear drum membrane.\n\nSide effects: Topical application to eye: Corneal ulcers, glaucoma and reduced visual ability. The following side effects are common for patients taking Dexamethasone Ã¢â¬Â¢ Increased appetite Ã¢â¬Â¢ Insomnia Ã¢â¬Â¢ Fluid retention Ã¢â¬Â¢ Heartburn Ã¢â¬Â¢ Muscle weakness.\n\nPrecaution: Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity, and posterior subcapsular cataract formation.Elderly, children and adolescent; pregnancy and lactation.\n\nMode of action:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.\n\nPregnancy category: C\n\nInteraction:  	Increased risk of hypokalaemia when used concurrently with potassium-depleting drugs such as amphotericin B and loop diuretics. Reduces efficacy of isoniazid, salicylates, vaccines and toxoids. Increased activity of dexamethasone and cyclosporin when used together. Concurrent use with aspirin or ethanol may lead to increased GI side effects.\nPotentially Fatal: Reduced efficacy in combination with ephedrine, cholestyramine, phenytoin, phenobarbital and rifampicin.
Ipratropium Bromide Nasal prep	\n\n\tACI\tRinase Nasal Spray 20mcg/ Sp 120 sprays 148.56\n\tSquare\tRynaspray Nasal Spray 20mcg/ Sp 120 sprays unit 148.56\n\tIndication: Allergic rhinitis, Rhinorrhoea\n\nDose: Adults : Nasal Rhinorrhoea associated w/ rhinitis; Seasonal allergic rhinitis As metered dose nasal spray (0.06%): 42 mcg into each nostril 2-3 times/day, up to 84 mcg into each nostril 3-4 times/day.\n\nContra-indication: Hypersensitivity\n\nSide effects: Acute angle-closure glaucoma, nasal dryness and epistaxis (nasal spray). Potentially Fatal: Anaphylactic reactions, atrial fibrillation, supraventricular tachycardia.\n\nPrecaution: Narrow-angle glaucoma or patients susceptible to glaucoma, Renal and hepatic impairment. Pregnancy, lactation, children, elderly.\n\nMode of action: Increased toxicity with other anticholinergic drugs.\n\nPregnancy category: B\n\nInteraction: Increased toxicity with other anticholinergic drugs.
Triamcinolone Acetonide Nasal prep	\n\n\tIncepta\tCenolon Nasal Spray 55mcg 1's pack 200\n\tOpsonin Pharma\tT-Cort Nasal Spray 55mcg 150 metered dose 200\n\tSquare\tTrispray Nasal Spray 55mcg 120 dose ( spray) unit 200.75\n\tFisons, UK\tNasacort AQ Nasal Spray    100 dose ( spray) unit 523.72\n\tIndication: Allergic rhinitis, Hay fever, Allergic and inflammatory responses.\n\nDose:  Nasal Treatment and prophylaxis of allergic rhinitis Adult: As acetonide: Initially, 2 sprays (110 mcg) into each nostril once daily, reduced to 1 spray (55 mcg) when under control. \n\nChild: 6-12 yr: as acetonide: 1 spray (55 mcg) into each nostril once daily. Increased to 220 mcg daily in severe cases.Hay fever As acetonide: 40-100 mg\n\nContra-indication: Triamcinolone Acetonide is contraindicated in patients with a sensitivity to the active or inactive ingredients. Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity\n\nSide effects: Sneezing, headache, sore throat, dry mouth, nausea etc. have been reported as the common side effects.\n\nPrecaution: Triamcinolone Acetonide should be used cautiously in patients with ocular herpes simplex, nonspecific ulcerative colitis, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, Cushing's syndrome, diabetes mellitus, congestive heart failure, chronic nephritis.\n\nMode of action: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.\n\nPregnancy category: C\n\nInteraction: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
Triamcinolone Acetonide Mouth prep	\n\n\tAristopharma\tAristocort Oral Paste   5g tube / 10ml tube 60 / 100\n\tChemist Ltd.\tTrimcort Oral Paste  10gm tube 100\n\tDrug International Ltd.\tTrialon Oral Paste   10gm tube 25.09\n\tIndication: Mouth ulceration\n\nDose: Mouth ulceration Adult: A small amount (about 0.6 cm) of the 0.1% paste is pressed onto the lesion without rubbing until a thin film develops. Apply 2 or 3 times daily, preferably after meals. Re-evaluate if recovery does not occur after 7 days of treatment.\n\nContra-indication: Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity.\n\nSide effects: \n\nPrecaution: Diabetes; hypertension, renal and liver impairment; glaucoma; psychosis; delayed tissue healing; cirrhosis; heart failure; recent MI; hypothyroidism; osteoporosis; peptic ulceration; thromboembolic disorders. Monitor height in children on prolonged therapy. Avoid rapid drug withdrawal. Elderly, children, pregnancy, lactation.\n\nMode of action: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.\n\nPregnancy category: C\n\nInteraction: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
Triamcinolone Acetonide Inhalation	\n\n\tSanofi Aventis (BD) Ltd.\tAzmacort Inhaler 200mcg	 240 doses unit 498	\n\tIndication: Prophylaxis treatment of Asthma\n\nDose: Adults: The usual recommended dosage is two inhalations (150 mcg) given three to four times a day or four inhalations (300 mcg) given twice daily. \n\nThe maximal daily intake should not exceed 16 inhalations (1200 mcg) in adults. Higher initial doses (12 to 16 inhalations per day) may be considered in patients with more severe asthma.  \n\nChildren 6 to 12 Years of Age: The usual recommended dosage is one or two inhalations (75 to 150 mcg) given three to four times a day or two to four inhalations (150 to 300 mcg) given twice daily. The maximal daily intake should not exceed 12 inhalations (900 mcg) in children 6 to 12 years of age.\n\nContra-indication: Triamcinolone acetonide (inhalation aerosol) Inhalation Aerosol is not to be regarded as a bronchodilator and is not indicated for rapid relief of bronchospasm. Triamcinolone Acetonide is contraindicated in patients with a sensitivity to the active or inactive ingredients. Untreated systemic fungal, bacterial, viral or parasitic infection. \n\nSide effects: Localized infections with Candida albicans have occurred infrequently in the mouth and pharynx. \n\nPrecaution: Triamcinolone Acetonide should be used cautiously in patients with ocular herpes simplex, nonspecific ulcerative colitis, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, Cushing's syndrome, diabetes mellitus, congestive heart failure, chronic nephritis. Particular care is needed in patients who are transferred from systemically active corticosteroids to Azmacort (triamcinolone acetonide (inhalation aerosol)) Inhalation Aerosol because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to aerosolized steroids in recommended doses. Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients.  \n\nMode of action: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.\n\nPregnancy category: C\n\nInteraction: Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, ? agonists, ?-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines.
Miconazole Nitrate 2% Topical	\n\n\tACI\tMiconex Cream  2% 10gm  tube 35.24\n\tAd-din\tMitigal Cream   10gm  tube 30\n\tGlobe\tMIC Cream   10gm  tube 35\n\tIncepta\tTopicazole Cream   10gm  tube 35\n\tKumudini Pharma Ltd.\tFungimin Cream   10gm  tube 30\n\tOpsonin Pharma\tUnigal Cream  20mg/1gm 1's pack 35.27\n\tPacific\tSkimico Cream 20 mg/gm  \n\tSquare\tFungidal Cream   10gm  tube 35.14\n\tIndication: Skin and nail infections due to dermatophytes, yeasts and other fungi such as: Tinea capitis, corporis, manuum, pedis, barbae, cruris, unguium or onychomycosis. Pityriasis versicolor, candidiasis of skin and nails, stomatitis angularis, otitis externa, mycoses secondarily infected with bacteria.\n\nDose: Sufficient Miconazole Cream should be applied to cover affected areas twice daily (morning and evening) in patients with tinea pedis, tinea cruris, tinea corporis and cutaneous candidiasis and once daily in patients with tinea versicolor. \n\nAll lesions usually disappear after 2 to 5 weeks.Prolong treatment for 10 days to prevent relapse. However, Candida infections, tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence.\n\nContra-indication: History of sensitivity reactions to Miconazole or any of the components of the preparation.\n\nSide effects: Irritation, burning, maceration and allergic contact dermatitis may occur. \n\nPrecaution: For external use only. Avoid introduction into the eyes.\n\nMode of action: May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.\nPotentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.\n\nPregnancy category: C\n\nInteraction: May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine.\nPotentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.
Bromelain + Trypsin	\n\n\tCity overseas\tKontab TAB dr 50 mg/1mg 50s pack 285\n\tIndication: Inflammatory pains, soft tissue inflammation, edema associated with trauma and surgery such as in Gynaecological conditions , breast engorgement , fractures , sprains , injuries , hemorrhoid, anal prolapse\n\nDose: Initially 2 tabs 3 times daily. Maintenance 1 tab 3 times daily preferably before meals. \n\nContra-indication: Hypersensitivity.\n\nSide effects: \n\nPrecaution: \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Framycetin sulfate Eye prep	\n\n\tSanofi Aventis (BD) Ltd.\tSoframycin Eye drops 5mg/ml 8ml bot \n\tIndication: Conjunctivitis, blepharitis, blepharoconjunctivitis\n\nDose: Apply 2-3 times daily into the affected eyes.\n\nContra-indication: Known allergy to lanolin or framycetin. Fungal/viral or resistant bacterial eye infections \n\nSide effects: Sensitisation, contact dermatitis, local irritation and itching.\n\nPrecaution: Pregnancy.\n\nMode of action: Co-admin of gramicidin with framycetin reduces the risk of selecting resistant bacteria.\n\nPregnancy category: X\n\nInteraction: Co-admin of gramicidin with framycetin reduces the risk of selecting resistant bacteria.
Deflazacort	\n\n\tAristopharma\tFlacort TAB dr 6mg  \n\tBeacon\tDefacort TAB dr 6mg 30's pack 240\n\tBeacon\tXalcort TAB dr 6mg  \n\tBeximco\tCortiflo TAB dr 6mg  \n\tIncepta\tDeflazit TAB dr 6mg  \n\tRAK\tRefla TAB dr 6mg  \n\tSquare\tDeflacort TAB dr 6mg 30's pack 240\n\tSquare\tDaflacort TAB dr 5mg 30's pack 240\n\tIndication: Allergic and inflammatory disorders\n\nDose: Oral\nAllergic and inflammatory disorders\nAdult: Initially, up to 120 mg daily. Maintenance: 3-18 mg/day.\n\nChild: 0.25-1.5 mg/kg/day given on alternate days.\nHepatic impairment: Dose reductions may be needed.\n\nContra-indication: Systemic infection; live virus vaccines in those receiving immunosuppressive doses.\n\nSide effects: GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.\n\nPrecaution: Adrenal suppression and infection, child, adolescents, elderly, history of TB and steroid myopathy, hypertension, recent MI, CHF, liver failure, renal impairment, DM and glaucoma (including family history), osteoporosis, corneal perforation, severe affective disorders, epilepsy, peptic ulcer, hypothyroidism, pregnancy and lactation.\n\nMode of action: Antacids, ACE inhibitors, acetazolamide, adrenergic neuron blockers, antidiabetics, aspirin, barbiturate, ?-blockers, calcium-channel blockers, carbamazepine, carbenoxolone, cardiac glycosides, clonidine, coumarins, diazoxide, diuretics, erythromycin, hydralazine, ketoconazole, methotrexate, methyldopa, mifepristone, minoxidil, moxonidine, nitrates, nitroprusside, NSAIDs, oestrogens, phenytoin, primidone, rifamycins, ritonavir, somatropin, ?2 sympathomimetics, theophylline, vaccines.\n\nPregnancy category: Not Classified\n\nInteraction: Antacids, ACE inhibitors, acetazolamide, adrenergic neuron blockers, antidiabetics, aspirin, barbiturate, ?-blockers, calcium-channel blockers, carbamazepine, carbenoxolone, cardiac glycosides, clonidine, coumarins, diazoxide, diuretics, erythromycin, hydralazine, ketoconazole, methotrexate, methyldopa, mifepristone, minoxidil, moxonidine, nitrates, nitroprusside, NSAIDs, oestrogens, phenytoin, primidone, rifamycins, ritonavir, somatropin, ?2 sympathomimetics, theophylline, vaccines.
Vitamin A + Vitamin-B complex + Vitamin-C + Vitamin-D + Vitamin E IV prep	\n\n\tIncepta\tProviten IV Injection/ Infusion  1's 330\n\tIndication: Daily multivitamin maintenance dosage for adults and children aged 11 years and above receiving parenteral nutrition. It is also indicated in other situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases and comatose states, which may provoke a "stress" situation with profound alterations in the body's metabolic demands and consequent tissue depletion of nutrients.\n\nDose: Adults and children aged 11 years and above: 1 vial/day \n\nAdministration procedure: The single dose vial is reconstituted by adding 5ml of sterile Water for injection or other intravenous fluids like 0.9% Sodium Chloride injection or 5% Glucose injection. 5 ml of diluent should be added by means of sterile syringe into the vial and gently mixed to dissolve the lyophilized powder. The entire volume of the resultant solution should then be administered by slow Intravenous injection (at least over 10 minutes) or further diluted for intravenous infusion. To minimize vitamin losses in parenteral nutrition admixtures, add the vitamins immediately prior to administration and complete administration within 24 hours.\n\nContra-indication: This is contraindicated in patients with pre-existing hypervitaminosis or known hypersensitivity to any of the active ingredients. This product should not be injected to patients with pre-existing intolerance to thiamine. \n\nSimilarly, this product should not be administered to patients with impaired hepatic function. This preparation should not be administered to those suffering from hyperparathyroidism due to hypercalcaemic complications.\n\nSide effects: Anaphylactic reactions have been reported following large intravenous doses of Thiamine. Urticaria and rash have also been associated with this preparation. There have been very rare reports of anaphylactic reactions following IV injection/infusion with this preparation over 1-4 minutes.\n\nPrecaution: Anaphylactic reactions may occur in allergic subjects who are susceptible to Thiamine (Vitamin B1) and nicotinamide components of this product. Mild allergic reactions such as sneezing or mild asthma are warning signs that further injection/infusion may give rise to anaphylactic shock. Due to glychocolic acid content, repeated and prolonged administration in patients with jaundice of hepatic origin or severe biochemical evidence of cholestatis requires careful monitoring of liver function. Also in the case of impaired kidney function, fat-soluble vitamin levels should be carefully monitored.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Racecadotril	\n\n\tIncepta\tRacetril CAP 100 mg  30's 180\n\tIncepta\tRacetril Granules For Suspension 10mg  \n\tIncepta\tRacetril Granules For Suspension 30mg  \n\tNIPRO JMI Pharma\tRececa CAP 100mg 30's pack 180\n\tIndication: Acute diarrhoea\n\nDose: Adults: PO: 1 capsule initially, regardless of the time of day. Then 1capsule 3 times daily preferably before the main meals up to 7 days. \n\nChildren: The recommended dose is determined according to body weight: 1.5 mg/kg per administration, three times daily.\n\nContra-indication: Hypersensitivity to Racecadotril, or to any of the excipients. \n\nSide effects: Headache, erythema multiforme, urticaria, angioedema, vomiting, nausea, constipation, abdominal pain, thirst, vertigo.\n\nPrecaution: Chronic & antibiotic-associated diarrhoea, bloddy or purulent stools & fever, patients w/ diabetes, renal or liver impairment, cases of prolonged or uncontrolled vomiting. Pregnancy, lactation.\n\nMode of action: No interactions with other drugs have been described in humans to date.\nIn humans, the concomitant treatment of Hidrasec with loperamide or nifuroxazide does not modify the kinetics of Hidrasec.\nIncompatibilities: Not applicable.\n\nPregnancy category: Not Classified\n\nInteraction: No interactions with other drugs have been described in humans to date.\nIn humans, the concomitant treatment of Hidrasec with loperamide or nifuroxazide does not modify the kinetics of Hidrasec.\nIncompatibilities: Not applicable.
Multivitamin & Multimineral prep for Nursing mother	\n\n\tAristopharma\tAristo Mom TAB dr   50's pack 150\n\tBeximco\tMomvit Plus TAB dr   60's pack 180\n\tBeximco\tMomvit TAB dr  30's pack 60\n\tNovelta Bestway\tVitora Mom TAB dr  60's pack 180\n\tOpsonin Pharma\tNatal-16 TAB dr   30's pack 90\n\tRadiant.\tFormum CAP  50's pack 250\n\tIndication: Improving the nutritional status of women throughout the pregnancy and for lactating mothers. \n\nDose: 1-2 tablet daily or as recommended by the physician.\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. \n\nPrecaution: Should not use in over dosage.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ciclopirox Olamine Topical	\n\n\tIncepta\tCandirox Cream 10 mg/gm 1's pack 110\n\tSquare\tClopirox Cream 1% 10gm Tube \n\tIndication: Tineapedis, Tineacruris, Tineacorporis, Candidiasis (moniliasis), Tinea (pityriasis) versicolor, Skin fungal infections.\n\nDose: Cream should be gently massaged onto the affected and surrounding skin areas twice daily for four weeks. \n\nContra-indication: Hypersensitivity; occlusive wrappings/dressings.\n\nSide effects: Pruritus, burning sensation; headache, rash, irritation, dryness.\n\nPrecaution: Children <10 yr; pregnancy, lactation. Avoid contact with eyes. For external use only.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Risedronate Sodium  +  Calcium	\n\n\tSquare\tRisedon Plus TAB dr   220\n\tIndication: Treatment and prevention of osteoporosis in postmenopausal women. It can be also used to increase bone mass in men with osteoporosis,  Pagetâs disease of bone.\n\nDose: Adult: PO: 1  tablet should be taken orally once a week (Day 1 of the 7-day treatment cycle) then 01 Calcium 500 mg tablet should be taken orally with food daily on each of the remaining 6 days (Days 2 through 7 of the 7-day treatment cycle).\n\nContra-indication: Risedronate Sodium is not recommended for use in patients with severe renal impairment\n(creatinine clearance <30 ml/min). Pregnancy & Lactation.\n\nSide effects: Chest pain, difficulty or pain when swallowing, pain or burning under the ribs or in the back, new or worsening heartburn, severe joint, bone, or muscle pain, jaw pain, numbness, or swelling, mild heartburn or stomach upset, diarrhea, gas, or constipation, mild joint or back pain, headache.\n\nPrecaution: Take special care if:\nâ¢ have low blood calcium (hypocalcemia).\nâ¢ cannot sit or stand up for 30 minutes.\nâ¢ have kidneys that work poorly.\nâ¢ have an allergy to Risedronate Sodium.\nâ¢ are pregnant or may become pregnant.\nâ¢ are breast-feeding or plan to breast-feed.\nâ¢ have kidney problems.\n\nMode of action: Risedronate Sodium: Co-admin with calcium, antacids or oral medications containing divalent cations may affect the absorption of risedronate. May have additive calcium lowering effects when used with aminoglycosides.\n\nCalcium: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nPregnancy category: Not Classified\n\nInteraction: Risedronate Sodium: Co-admin with calcium, antacids or oral medications containing divalent cations may affect the absorption of risedronate. May have additive calcium lowering effects when used with aminoglycosides.\n\nCalcium: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.
Calcium 600 mg + Vitamin D 400 IU	\n\n\tSquare\tCalbo-D Vita TAB dr 600 mg + 400 IU  150\n\tIndication: Calcium and vitamin D deficiency, Calcium and vitamin D supplement, Osteoporosis.\n\nDose: 1 -2 tablets per day, preferably one tablet each morning and evening or as directed by the physician\n\n\nContra-indication: Hypercalcemia and hyperparathyroidism\nHypercalciuria and nephrolithiasis\nHypersensitivity to the component of this preparation\nSevere renal insufficiencies\n\nSide effects: Orally administered Calcium Carbonate may be irritating to the GI tract. It may also cause constipation. Hypercalcemia is rarely produced by administration of Calcium alone, but may occur when large doses are given to patients with chronic renal failure. Also there may be allergic reactions, irregular heartbeats, nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash.\n\nPrecaution: When hypercalcemia occurs discontinuation of the drug is usually sufficient to return serum calcium concentrations to normal. Calcium salts should be used cautiously in patients with sarcoidosis, renal or cardiac disease and in patients receiving cardiac glycosides. Patients with a history of stone formation should also be recommended to increase their fluid intake.\n\nMode of action: May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.\n\nPregnancy category: C\n\nInteraction: May affect the absorption of tetracycline when used together. Concurrent use with systemic corticosteroids may reduce calcium absorption. Thiazide diuretics may decrease urinary excretion of calcium. Concurrent use with ion-exchange resins may reduce GI absorption of vitamin D. Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D, monitor ECG and serum calcium levels. Bisphosphonate or sodium fluoride should be given at least 3 hr before calcium-containing preparations.
Ceftibuten	\n\n\tEskayef Bangladesh Ltd.\tCefaten CAP 400mg  \n\tEskayef Bangladesh Ltd.\tCefaten Powder For Suspension 1.8 gm/100 ml  \n\tOpsonin Pharma\tOditen suspension 120 ml 1's pack 800\n\tOpsonin Pharma\tOditen CAP 400mg  \n\tRenata\tCebuten CAP 400mg  960\n\tIndication: Respiratory tract infections, Urinary tract infections\n\nDose: Oral\nRespiratory tract infections, Urinary tract infections\nAdult: As dihydrate: 400 mg once daily.\nChild: >6 mth and ?45 kg: 9 mg/kg/day as a single dose.\n\nRenal impairment:\nCrCl (ml/min)	\n30-49	200 mg once daily.\n5-29	100 mg once daily. \n\nContra-indication: Hypersensitivity to cephalosporins.\n\nSide effects: Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction; haematologic disorders; pain at Inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use. Headache.\nPotentially Fatal: Pseudomembranous colitis.\n\nPrecaution: Hypersensitivity to penicillins; renal impairment; Porphyria. Monitor renal and haematologic status.\n\nMode of action:  	Enhanced nephrotoxicity of aminoglycosides. Increased serum concentration w/ probenecid. Decreased serum concentration w/ zinc salts.\n\nPregnancy category: B\n\nInteraction:  	Enhanced nephrotoxicity of aminoglycosides. Increased serum concentration w/ probenecid. Decreased serum concentration w/ zinc salts.
Mifepristone + Misoprostol	\n\n\tSharif\tMTP kit TAB dr  2 strips (1+4 tabs) pack 300\n\tSquare\tTerminex TAB dr   \n\tZiska\tMM-kit TAB dr  2 strips (1+4 tabs) pack 300\n\tIndication: Termination of pregnancy upto 9th week(63 days) of gestation, Early menstrual regulation.\n\nDose: Day 1: 1 tablet of mifepristone (200mg) is taken in a single oral dose. \n\nDay 2: 24-48 hours after ingesting the mifepristone tablet, patient takes 4, 200 mcg (800 mcg) tablets of misoprostol buccally or sublingually. Place 2 tablets on each side of cheeck & gum or under the tongue.\n\nDay 10-14: Patient must return to the doctor office or hospital within 10-14 days after the administration of mifepristone. \n\nThe visit is important to confirm by clinical examination or usg that a complete termination of pregnancy has occured. \n\nContra-indication: Confirmed or suspected ectopic pregnancy, chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, misoprostol or other prostaglandin, haemorrhagic disorders or concurrent anticoagulant therapy, porphyria, hepatic or renal impairment; pregnancy and lactation; IUD in place; undiagnosed adnexal mass.\n\nSide effects: Excessive vaginal bleeding; UTI; uterine cramping, uterine haemorrhage; uterine infections; unusual tiredness or weakness; back pain; diarrhoea, nausea, vomiting; fever; dizziness; headache; anxiety; GI cramps.\n\nPrecaution: Mifepristone must not be administered if there is doubt as to the existence or age of the pregnancy or if an extra-uterine pregnancy is suspected. An ultrasound scan and/or measurement of Beta-hCG must be performed before administration. For first trimester abortions, Mifepristone is contraindicated if the pregnancy is beyond 49 days of amenorrhoea when used with Misoprostol. Mifepristone should never be prescribed in patients with chronic adrenal failure, known allergy to Mifepristone or to any component of the product, severe asthma uncontrolled by corticosteroid therapy, porphyrias and renal failure, liver failure or malnutrition, or during breast feeding. Mifepristone is a lipophilic compound and may theoretically be excreted in the mother's breast milk, however no data is available.\n\nMode of action: Decreased efficacy with aspirin and NSAIDs. Efficacy of corticosteroids (including inhaled) decreased, monitor patients during co-admin and for several days afterwards.\nMay increase effects of oxytocin. Increased risk of misoprostol-induced diarrhoea with magnesium-containing antacids.\n\nPregnancy category: X\n\nInteraction: Decreased efficacy with aspirin and NSAIDs. Efficacy of corticosteroids (including inhaled) decreased, monitor patients during co-admin and for several days afterwards.\nMay increase effects of oxytocin. Increased risk of misoprostol-induced diarrhoea with magnesium-containing antacids.
Calcium Citrate + Calcitriol	\n\n\tOpsonin Pharma\tCitritol TAB dr  30's pack 180\n\tIndication: Calcium calcium and vitamin D3 supplement, Osteoporosis.\n\nDose: Adult: PO: 1 tablet twice daily or as prescribed by the physician.\n\nContra-indication: Patients with hypercalcaemia, hypercalciuria or hypophosphatemia. Nephrolithiasis, hypervitaminosis D.\n\nSide effects: Constipation, nausea, abdominal pain, hypercalcaemia, hypercalciuria, headache, muscle weakness.\n\nPrecaution: Impaired calcium absorption in achlorhydria which is common in elderly. Increased risk of hypercalcaemia and hypercalciuria in hypoparathyroid patients on high doses of vitamin D. History of kidney stones. Renal impairment.\n\nMode of action:  	Reduced absorption of tetracyclines, quinolones and oral biphosphates with concurrent calcium use. Calcium absorption may be reduced by corticosteriods. Increased risk of hypercalcemia and metabolic alkalosis with thiazide diuretics. High blood calcium level may increase the effect of caridac glycosides. Reduced erlotinib efficacy with calcium. Increased risk of hypercalaemia with paricalcitol. Enzyme-inducing antiepileptics increases the metabolism of Vit D.\nPotentially Fatal: Fatal encephalopathy can occur in patients with renal failure when given calcium citrate and aluminium products concurrently due to marked rise in aluminium levelCalcium salt can be used in the prevention and treatment of calcium deficiency states or negative calcium balance. It is also used as an adjunct in the prevention and treatment of osteoporosis.\n\nPregnancy category: C\n\nInteraction:  	Reduced absorption of tetracyclines, quinolones and oral biphosphates with concurrent calcium use. Calcium absorption may be reduced by corticosteriods. Increased risk of hypercalcemia and metabolic alkalosis with thiazide diuretics. High blood calcium level may increase the effect of caridac glycosides. Reduced erlotinib efficacy with calcium. Increased risk of hypercalaemia with paricalcitol. Enzyme-inducing antiepileptics increases the metabolism of Vit D.\nPotentially Fatal: Fatal encephalopathy can occur in patients with renal failure when given calcium citrate and aluminium products concurrently due to marked rise in aluminium levelCalcium salt can be used in the prevention and treatment of calcium deficiency states or negative calcium balance. It is also used as an adjunct in the prevention and treatment of osteoporosis.
Dantrolene Sodium	\n\n\tZiska\tRelaxo 25 CAP 50 gm  \n\tZiska\tRelaxo 25 CAP 25mg 4x7's pack 280\n\tIndication: Muscle tightness, muscle cramping (spasms), muscle pain caused by spinal cord injury, stroke, cerebral palsy, and multiple sclerosis. \n\nDose: Oral\nSpasticity\nAdult: Initially, 25 mg daily increased gradually at 7-day intervals over 7 wk. Discontinue if no response after 45 days of treatment. Max: 100 mg 4 times daily.\n\nChild: Initially, 0.5 mg/kg once daily, may increase gradually to 2 mg/kg 3-4 times daily. Max: 100 mg 4 times daily. \n\nContra-indication: Active liver disease; acute muscle spasm; patients who use their spasticity to maintain posture or function. Lactation.\n\nSide effects: Fatigue, muscle weakness/pain. GI disturbances, CNS effects, tachycardia, unstable BP, dyspnoea, drowsiness, rashes, pruritus, chills and fever, visual disturbances, dysphagia, speech disturbances; haematuria, crystalluria, urinary frequency, retention and incontinence.\nPotentially Fatal: Hepatotoxicity, pleural effusion with pericarditis.\n\nPrecaution: Perform LFTs before and during treatment. Increased risk of liver injury in patients >30 yr, female patients especially those on oestrogen therapy, history of liver disease or patients with daily dose >400 mg. Cardiac or pulmonary disorders. Pregnancy.\n\nMode of action:  	CNS depressants; oestrogens; calcium-channel blockers. CNS effects enhanced by alcohol or CNS depressants.\n\nPregnancy category: C\n\nInteraction:  	CNS depressants; oestrogens; calcium-channel blockers. CNS effects enhanced by alcohol or CNS depressants.
Docusate Sodium	\n\n\tOpsonin Pharma\tDocuset TAB dr 120mg 30's pack 60\n\tIndication: Constipation\n\nDose: Oral\nConstipation\nAdult: 50-500 mg/day in 1-4 divided doses.\nChild: 6-12 yr: 40-120 mg/day; 3-6 yr: 20-60 mg/day. To be given in 1-4 divided doses. \n\nContra-indication: Intestinal obstruction or undiagnosed abdominal symptoms. Prolonged use. Concurrent use with liqd paraffin. \n\nSide effects: GI effects; skin rash;\n\nPrecaution: Pregnancy, lactation.\n\nMode of action: Enhances GI uptake of other drugs. Increases effect of anthraquinone laxatives. Increases incidence of adverse effects when given concurrently with aspirin.\n\nPregnancy category: C\n\nInteraction: Enhances GI uptake of other drugs. Increases effect of anthraquinone laxatives. Increases incidence of adverse effects when given concurrently with aspirin.
Desvenlafaxine	\n\n\tZiska\tNevola 100 TAB dr 100mg 2x10's pack 300\n\tZiska\tNevola 50 TAB dr 50mg 3x10's pack 300\n\tIndication: Depression\n\nDose: Oral\nDepression\nAdult: 50 mg once daily. Doses up to 400 mg once daily have been studied and shown to be effective, but no additional benefit was observed with doses >50 mg once daily.\n\nRenal impairment:\nCrCl (ml/min)	\n30-50 mL/min	  50 mg once daily.\n<30 mL/min or ESRD	  50 mg every other day. Additional doses should not be given after dialysis.\n\nHepatic impairment: 50 mg once daily. Doses >100 mg/day are not advised.\n\nContra-indication: Hypersensitivity to Desvenlafaxine, venlafaxine or any component of the formulation. Concomitant/recent (within preceeding 14 days) use of MAOI. Do not initiate MAOI at least 7 days after discontinuing Desvenlafaxine.\n\nSide effects: Dizziness, nausea, vomiting, dry mouth, headache, tinnitus, insomnia, abnormal dreams, fatigue, constipation, diarrhoea, somnolence, decreased appetite, irritability, anxiety, tremor, paresthesia, male sexual function disorders (e.g. decreased libido, delayed ejaculation, erectile dysfunction), urinary hesitancy, hyperhidrosis, blurred vision, mydriasis, palpitations, hypertension, orthostatic hypotension, dyslipidemia, proteinuria, and abnormal liver function test.\nPotentially Fatal: Serotonin syndrome or neuroleptic malignant syndrome-like reactions.\n\nPrecaution: May be associated with increased risk of suicidal thinking and behaviour in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Monitor patients for clinical worsening of depression, emergence of suicidality, unusual changes in behaviour particularly during initiation of therapy and during dosage adjustments. Serotonin syndrome or neuroleptic malignant syndrome (NMS) have occurred with selective serotonin reuptake inhibitor (SSRI) or SNRI treatment alone; and particularly with concomitant use of MAOI, serotogenic agents (e.g. triptans), antipsychotics or dopamine antagonists. \n\nGradually taper dose if discontinuing to reduce risk of withdrawal symptoms. May activate mania/hypomania, caution in patients with history or family history of mania or hypomania. Caution in patients with pre-existing glaucoma, hypertension, cardiovascular, cerebrovascular, or lipid metabolism and seizure disorders. Sustained elevations in blood pressure have been reported. May be associated with dose-related increase in serum total cholesterol, LDL, triglycerides. May increase risk of bleeding. \n\nMay be associated with development of syndrome of inappropriate antidiuretic hormone (SIADH) and Hyponatraemia, elderly and patients who are taking diuretics or with volume depletion may be at greater risk. Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of desvenlafaxine) have been reported. Medications containing venlafaxine should not be used concomitantly. Renal and hepatic impairment. Safety and efficacy have not been established in paediatrics. Elderly. Pregnancy. Not recommended in lactation.\n\nMode of action: Desvenlafaxine may diminish the therapeutic effect of Iobenguane I-123. May enhance adverse effects of other CNS depressants. Sibutramine and MAOI may enhance the serotonergic effect of Desvenlafaxine; increase risk of development of serotonin syndrome. Concomitant use with alpha-/beta-agonists may enhance tachycardic and vasopressor effect. Desvenlafaxine may increase concentration of CYP2D6 substrates (e.g. desipramine); decrease exposure of CYP3A4 substrates (e.g. midazolam). CYP3A4 inhibitors (e.g. ketoconazole) may increase concentration of desvenlafaxine. May enhance the antiplatelet effect of nonselective NSAIDs, aspirin; and anticoagulant effect of warfarin.\nPotentially Fatal: Concurrent use with MAOIs may lead to fatal serotonin syndrome or NMS-like reactions. Do not use within at least 14 days of discontinuing MAOI treatment and start MAOI at least 7 days after stopping desvenlafaxine. Increased risk of serotonin syndrome with sibutramine.\n\nPregnancy category: C\n\nInteraction: Desvenlafaxine may diminish the therapeutic effect of Iobenguane I-123. May enhance adverse effects of other CNS depressants. Sibutramine and MAOI may enhance the serotonergic effect of Desvenlafaxine; increase risk of development of serotonin syndrome. Concomitant use with alpha-/beta-agonists may enhance tachycardic and vasopressor effect. Desvenlafaxine may increase concentration of CYP2D6 substrates (e.g. desipramine); decrease exposure of CYP3A4 substrates (e.g. midazolam). CYP3A4 inhibitors (e.g. ketoconazole) may increase concentration of desvenlafaxine. May enhance the antiplatelet effect of nonselective NSAIDs, aspirin; and anticoagulant effect of warfarin.\nPotentially Fatal: Concurrent use with MAOIs may lead to fatal serotonin syndrome or NMS-like reactions. Do not use within at least 14 days of discontinuing MAOI treatment and start MAOI at least 7 days after stopping desvenlafaxine. Increased risk of serotonin syndrome with sibutramine.
Eslicarbazepine	\n\n\tSquare\tEslicar TAB dr 400mg 10's pack \n\tIndication: Partial-onset seizures\n\nDose: Adult: PO: The recommended starting dose is 400 mg once daily which should be increased to 800 mg once daily after one or two weeks. Based on individual response, the dose may be increased to 1,200 mg once daily.\n\nPaediatric population\nThe safety and efficacy of eslicarbazepine acetate in children and adolescents below 18 years has not yet been established.\n\nContra-indication: Hypersensitivity to the active substance, to other carboxamide derivatives (e.g. carbamazepine, oxcarbazepine) or to any of the excipients. Second or third degree atrioventricular (AV) block.\n\nSide effects: Allergic reactions: May cause serious skin rash or other serious allergic reactions\nVery common (may affect more than 1 in 10 people) side effects are:\nâ¢ Feeling dizzy or sleepy.\nCommon (may affect up to 1 in 10 people) side effects are:\nâ¢ Feeling unsteady or having a sensation of spinning or floating;\nâ¢ Feeling sick or vomiting;\nâ¢ Headache;\nâ¢ Diarrhoea;\nâ¢ Seeing double or blurred vision;\nâ¢ Difficulty in concentration;\nâ¢ Feeling low in energy or tired;\nâ¢ Shaking;\nâ¢ Skin rash;\nâ¢ Blood tests showing that you have low levels of sodium in your blood;\nâ¢ Decrease of appetite;\nâ¢ Difficulty in sleeping;\nâ¢ Difficulty in coordinating movements (ataxia).\n\nPrecaution: Suicidal ideation\nSuicidal ideation and behaviour have been reported in patients treated with anti-epileptic active substances in several indications. A meta-analysis of randomised placebo-controlled trials of anti-epileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.\nNervous system disorders\nEslicarbazepine acetate has been associated with some central nervous system adverse reactions, such as dizziness and somnolence, which could increase the occurrence of accidental injury.\nOral contraceptives\nEslicarbazepine acetate may decrease the effectiveness of hormonal contraceptives. Additional non-hormonal forms of contraception are recommended\nOther warnings and precautions\nIf Eslicarbazepine is to be discontinued it is recommended to withdraw it gradually to minimise the potential of increased seizure frequency.\nConcomitant use of eslicarbazepine acetate with oxcarbazepine is not recommended because this may cause overexposure to the active metabolites.\nHyponatraemia\nHyponatraemia has been reported as an adverse reaction in 1.2% of patients treated with Eslicarbazepine. Hyponatraemia is asymptomatic in most cases, however, it may be accompanied by clinical symptoms like worsening of seizures, confusion, decreased consciousness. Frequency of hyponatraemia increased with increasing eslicarbazepine acetate dose. In patients with pre-existing renal disease leading to hyponatraemia, or in patients concomitantly treated with medicinal products which may themselves lead to hyponatraemia (e.g. diuretics, desmopressin, carbamazepine), serum sodium levels should be examined before and during treatment with eslicarbazepine acetate. Furthermore, serum sodium levels should be determined if clinical signs of hyponatraemia occur. Apart from this, sodium levels should be determined during routine laboratory examination. If clinically-relevant hyponatraemia develops, eslicarbazepine acetate should be discontinued.\nPR interval\nProlongations in PR interval have been observed in clinical studies with eslicarbazepine acetate.\nCaution should be exercised in patients with medical conditions (e.g. low levels of thyroxine, cardiac conduction abnormalities), or when taking concomitant medicinal products known to be associated with PR prolongation.\nRenal impairment\nCaution should be exercised in the treatment of patients with renal impairment and the dose should be adjusted according to creatinine clearance. In patients with CLCR <30 ml/min use is not recommended due to insufficient data.\nHepatic impairment\nAs clinical data are limited in patients with mild to moderate hepatic impairment and pharmacokinetic and clinical data are missing in patients with severe hepatic impairment, eslicarbazepine acetate should be used with caution in patients with mild to moderate hepatic impairment and is not recommended in patients with severe hepatic impairment.\n\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Insulin Degludec	\n\n\tNovo Nordisk A/S Denmark\tTresiba FlexTouch Injection 100IU/ml 3ml(300IU) Cartridge 2490\n\tIndication: Diabetes Mellitus\n\nDose: Adult: S/C: Insulin Degludec is ultra long-acting basal insulin for once-daily at any time of the day, preferably at the same time every day.\nInitiation:\nPatients with type 2 diabetes mellitus:\nThe recommended daily starting dose is 10 units followed by individual dosage adjustments.\n\nPatients with type 1 diabetes mellitus:\nInsulin Degludec is to be used once-daily with meal-time insulin and requires subsequent individual dosage adjustments.\n\n\nIn patients with type 2 diabetes mellitus, Insulin Degludec can be administered alone or in any combination with oral anti-diabetic medicinal products, GLP-1 receptor agonists and bolus insulin.\n\nIn type 1 diabetes mellitus, Insulin Degludec must be combined with short-/rapid-acting insulin to cover mealtime insulin requirements.\n\nOn occasions when administration at the same time of the day is not possible, Insulin Degludec allows for flexibility in the timing of insulin administration. A minimum of 8 hours between injections should always be ensured.\n\nPatients who forget a dose, are advised to take it upon discovery and then resume their usual once-daily dosing schedule.\n\nSpecial populations:\n\nElderly patients (> 65 years old):\n\nInsulin Degludec can be used in elderly patients. Glucose-monitoring is to be intensified and the insulin dose adjusted on an individual basis.\n\nRenal and hepatic impairment:\n\nDegludec can be used in renal and hepatic impaired patients. Glucose-monitoring is to be intensified and the insulin dose adjusted on an individual basis.\n\nPaediatric population:\n\nThe safety and efficacy of Insulin Degludec in children and adolescents below 18 years of age have not been established.\n\n\n\n\nContra-indication: Hypersensitivity to the active substance or to any of the excipients.Hypoglycaemia, Hyperglycaemia, Eye disorder.\n\nSide effects: Hypoglycemia, Lipodystrophy & Reactions at the site of injection may occur. \nRarer side effects include: Hypersensitivity, Urticaria, Peripheral oedema\n\n\nPrecaution: Insulin Degludecs must not be injected into a vein (intravenously) or a muscle (intramuscularly) and must not be used in infusion pumps.\n\nThere is no experience with Insulin Degludec in children and adolescents under 18 years of age.\n\nMode of action: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.\n\nPregnancy category: B\n\nInteraction: Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
Macrogol + Potassium Chloride  + Sodium Bicarbonate  + Sodium Chloride	\n\n\tZiska\tMovicol Sachet  1's 280\n\tIndication: Constipation, faecal impaction.\n\nDose: ADULTS AND CHILDREN OVER 12 YEARS OF AGE:\n\nConstipation: 1 sachet daily, increasing to 2 or 3 sachets daily if necessary.\n\nFaecal impaction: 8 sachets a day for no more than 3 days.\n\nDirections for use:\n\nDissolve the contents of one sachet in 125 mL of water then drink it. Do not exceed the stated dose. Not recommended for children less than 12 years of age.\n\nContra-indication: GI obstruction or perforation, paralytic ileus, gastric retention, severe inflammatory conditions of the intestinal tract (eg, Crohn's disease, ulcerative colitis, toxic megacolon).\n\nSide effects: Abdominal pain or distension, nausea, vomiting, diarrhoea, dyspepsia, borborygmi, flatulence, anal discomfort, headache. Rarely, allergic reactions.\n\nPrecaution: Impaired gag reflex, reflux oesophagitis, impaired consciousness. Discontinue if symptoms of fluid or electrolyte disturbance occur. pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Insulin Lispro (25%/50%) + Insulin Lispro Protamine (75%+50%) mix	\n\n\tEli Lilly France SA, France\tHumalog Mix 50 Kwikpen Injection 100u/ml 3ml 540\n\tEli Lilly France SA, France\tHumalog Mix 25 Kwikpen Injection 100u/ml 3ml 540\n\tIndication: Diabetes mellitus\n\nDose: Combination rapid-onset (faster than regular insulin) and intermediate-acting insulins in fixed dose\nAdult:\nDose regimen varies among patients depending on metabolic needs; typical daily insulin requirements range between 0.5-1 unit/kg \n\nContra-indication: Hypoglycaemia. Hypersensitivity to any of the components.\n\nSide effects: Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj.\n\nPrecaution: Renal or hepatic impairment; pregnancy, lactation; transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections.\n\nMode of action: Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by ?-blockers, clonidine.\n\nPregnancy category: B\n\nInteraction: Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by ?-blockers, clonidine.
Tamsulosin + Dutasteride	\n\n\tAcme Ltd.\tUropass D CAP 0.4mg  \n\tDelta Pharma\tTamsin D CAP 400/500mcg  \n\tDrug International Ltd.\tCombomax CAP 400/500mcg  280\n\tUnimed & Unihealth Manufacturers Ltd.\tUromax D CAP  0.4 mg/0.5 mg  320\n\tIndication: Benign prostatic hyperplasia\n\nDose: Oral\nBenign prostatic hyperplasia\nAdult: Per tab contains tamsulosin 0.4 mg and dutasteride 0.5 mg: 1 tab once daily.\n\nContra-indication: Hypersensitivity, severe liver impairment. Pregnancy, lactation, child, adolescent.\n\nSide effects: Impotence, decreased libido, ejaculation disorders, breast tenderness and enlargement, postural hypotension, dizziness and vertigo, headache, infection, asthenia, back pain, chest pain, somnolence, insomnia, rhinitis, pharyngitis, cough, sinusitis, diarrhoea, nausea, tooth disorder, blurred vision.\n\nPrecaution: Excreted in semen therefore use of condom is recommended. Women of childbearing potential should avoid handling leaking capsules of dutasteride. Prostate carcinoma should be ruled out before starting the therapy. Blood donation to be avoided during and at least 6 mths after discontinuance of drug.\n\nMode of action: Concomitant admin with moderate or strong inhibitors of CYP2D6 (eg. fluoxetine) or CYP34A (eg. ketoconazole, cimetidine) increases tamsulosin serum concentration; increase in blood concentrations of dutasteride in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, and ciprofloxacin.\n\nPregnancy category: X\n\nInteraction: Concomitant admin with moderate or strong inhibitors of CYP2D6 (eg. fluoxetine) or CYP34A (eg. ketoconazole, cimetidine) increases tamsulosin serum concentration; increase in blood concentrations of dutasteride in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, and ciprofloxacin.
Ticagrelor	\n\n\tACI\tAcora TAB dr 90mg  \n\tIncepta\tTicarel 90 TAB dr 90mg 20's 1500\n\tZiska\tBrilinta TAB dr 90mg 10's 750\n\tIndication: Prevention of thrombotic events [cardiovascular death (CV), myocardial infarction (MI) and stroke] in patients with acute coronary syndromes (ACS) [unstable angina, non-ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI)]; including patients managed with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).\n\nDose: Initiate treatment with 180 mg (two 90 mg tablets) oral loading dose. Continue treatment with 90 mg twice daily. \n\n After the initial loading dose of Aspirin (usually 325 mg), use Ticagrelor with a daily maintenance dose of Aspirin should be of 75-100 mg. \n\nACS patients who have received a loading dose of Clopidogrel, may be started on Ticagrelor. Ticagrelor can be administered with or without food. A patient who misses a dose of Ticagrelor should take one 90 mg tablet (next dose) at its scheduled time.\n\nContra-indication: History of Intracranial Hemorrhage: Ticagrelor is not recommended in patients with a history of intracranial hemorrhage (ICH) due to a high risk of recurrent ICH in this population.\n\nActive Bleeding: Patients with active pathological bleeding eg, peptic ulcer or intracranial hemorrhage.\n\nSevere Hepatic Impairment: Patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins. \n\nHypersensitivity (eg, angioedema) to ticagrelor or to any of the components.\n\nSide effects: Bleeding, Dyspnea, Other side effects (Headache, back pain, nausea, dizziness, cough, hypotension, fatigue, Atrial fibrillation). \n\nPrecaution: General Risk of Bleeding: Drugs that inhibit platelet function including Ticagrelor increase the risk of bleeding. \nConcomitant Aspirin Maintenance Dose: Use of Ticagrelor with maintenance doses of aspirin above 100 mg decreased the effectiveness of Ticagrelor. Therefore, after the initial loading dose of aspirin (usually 325 mg), use Ticagrelor with a maintenance dose of aspirin of 75-100 mg. \n\nModerate Hepatic Impairment: Ticagrelor has not been studied in patients with moderate hepatic impairment. \n\nDiscontinuation of Ticagrelor: Discontinuation of Ticagrelor will increase the risk of myocardial infarction, stent thrombosis, and death. \n\nMode of action: Aminocaproic acid or tranexamic acid &/or recombinant clotting factor VIIa may augment haemostatis. NSAIDs, oral anticoagulants &/or fibrinolytics, ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir, rifampin, dexamethasone, phenytoin, carbamazepine, phenobarb, simvastatin >40 mg, digoxin. Increased Cmax & AUC w/ cyclosporine.\n\nPregnancy category: C\n\nInteraction: Aminocaproic acid or tranexamic acid &/or recombinant clotting factor VIIa may augment haemostatis. NSAIDs, oral anticoagulants &/or fibrinolytics, ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir, rifampin, dexamethasone, phenytoin, carbamazepine, phenobarb, simvastatin >40 mg, digoxin. Increased Cmax & AUC w/ cyclosporine.
Doxofylline	\n\n\tACI\tDoximar TAB dr 400mg  \n\tApex\tXiva Syrup 100 mg/5 ml  \n\tAristopharma\tDocopa TAB dr 400 mg 30's pack 180\n\tBeacon\tDoxoven TAB dr 400mg  \n\tBeximco\tDoxovent TAB dr 400mg  \n\tBeximco\tFixolin Syrup 100 mg/5 ml  \n\tBeximco\tFixolin TAB dr 400mg  \n\tDelta Pharma\tDoxobid TAB dr 400mg  \n\tDrug International Ltd.\tDoxoma TAB dr 400mg  \n\tIncepta\tBrezofil TAB dr 400mg 30's 240\n\tNIPRO JMI Pharma\tDoxiva TAB dr 400mg 30's pack 300\n\tUnimed & Unihealth Manufacturers Ltd.\tPulmodox TAB dr 400mg  \n\tUnimed & Unihealth Manufacturers Ltd.\tPulmodox Syrup 100 mg/5 ml  \n\tJulphar Bangladesh Ltd.\tDoxair TAB dr 400mg  \n\tIndication: COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma\n\nDose: Adults: 1 to 3 times a day.Dosage of Doxofylline depends on patientâs response to the medication. If a patient has been advised to dose once a day, he or she may be directed to do so in the evenings to reduce nocturnal symptoms.\n\nElderly: The dosage may be decreased according to medical prescription in the very elderly patients with concomitant cardiovascular, hepatic, renal and gastric disease, to Â½ tablet b.i.d/ t.i.d.\n\nChild: Children >12 years â 200 mg 2 or 3 times daily. (Â½ tablet b.i.d/ t.i.d) \n\nContra-indication: This is contraindicated for individuals who have shown hypersensitivity to Doxofylline and its components. It is also contraindicated in patients with acute myocardial infarction, hypotension, and in lactating women.\n\nSide effects: After xanthine administration, nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia, tachycardia, extrasystole, tachypnea and occasionally, hyperglycemia and albuminuria, may occur. If a potential oral overdose is established, the patient may present with severe arrhythmias and seizure; these symptoms could be the first sign of an intoxication. Adverse reactions may cause the withdrawal from treatment; a lower dose rechallenge may start only after the advice of a physician.\n\nPrecaution: Use with caution in patients with hypoxemia, hyperthyroidism, liver disease, renal disease, in those with history of peptic ulcer and in elderly. Frequently, patients with Congestive Heart Failure (CHF) have markedly prolonged drug serum levels following discontinuation of Doxofylline.\n\nMode of action: Other xanthine derivatives, ephedrine, phenytoin & other anticonvulsants, erythromycin, troleandomycin, lincomycin, clindamycin, allopurinol, cimetidine, ranitidine, propranolol, flu vaccine.\n\nPregnancy category: Not Classified\n\nInteraction: Other xanthine derivatives, ephedrine, phenytoin & other anticonvulsants, erythromycin, troleandomycin, lincomycin, clindamycin, allopurinol, cimetidine, ranitidine, propranolol, flu vaccine.
Sofosbuvir	\n\n\tBeximco\tSofovir-C TAB dr 400mg 14's 8400\n\tEskayef Bangladesh Ltd.\tSoventa TAB dr 400mg  \n\tIncepta\tHopetavir TAB dr 400mg 6's 4800\n\tRAK\tHepcee TAB dr 400mg  \n\tIndication: Chronic Hepatitis C, Patients with hepatocellular carcinoma awaiting liver transplantation\n\nDose: One 400 mg tablet taken once daily with or without food\n- Should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC.\n\nRecommended combination therapy:\n(HCV Mono-infected and HCV/HIV-1 Co-infected )\n\nGenotype 1 or 4 : Sofosbuvir + Peginterferon alfa + Ribavirin for 12 weeks\nGenotype 2:            Sofosbuvir + Ribavirin for 12 weeks\nGenotype 3:            Sofosbuvir + Ribavirin for 24 weeks\n\n- Sofosbuvir in combination with Ribavirin for 24 weeks can be considered for CHC patients with genotype 1 infection who are Interferon ineligible\n- Should be used in combination with Ribavirin for treatment of CHC in patients with hepatocellular carcinoma awaiting liver transplantation for up to 48 weeks or until liver transplantation whichever occurs first\n- A dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease\n\nContra-indication: When Sofosbivur is used in combination with Ribavirin or Peginterferon alfa/Ribavirin, the contraindications applicable to those agents are applicable to combination therapies. Sofosbuvir combination treatment with Ribavirin or Peginterferon alfa/Ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant, because of the risks for birth defects and fetal death associated with Ribavirin.\n\nSide effects: The most common adverse events observed with Sofosbuvir in combination with Ribavirin were fatigue and headache. The most common adverse events observed with Sofosbuvir in combination with Peginterferon alfa and Ribavirin were fatigue, headache, nausea, insomnia and anemia.\n\nPrecaution: Pregnancy: Ribavirin may cause birth defects and fetal death and animal studies have shown interferons have abortifacient effects; avoid pregnancy in female patients and female partners of male patients. Patients must have a negative pregnancy test prior to initiating therapy, use at least 2 effective methods of contraception and have monthly pregnancy tests.\n\nMode of action: Reduced therapeutic effect w/ drugs that are potent P-gp inducers in the intestine (eg rifampicin, St. John's wort, carbamazepine & phenytoin), modafinil, phenobarb/oxcarbazepine, rifabutin/rifapentine. P-gp &/or BCRP inhibitors. May result in serious symptomatic bradycardia when co-administered w/ amiodarone in combination w/ another direct acting antiviral.\n\nPregnancy category: B\n\nInteraction: Reduced therapeutic effect w/ drugs that are potent P-gp inducers in the intestine (eg rifampicin, St. John's wort, carbamazepine & phenytoin), modafinil, phenobarb/oxcarbazepine, rifabutin/rifapentine. P-gp &/or BCRP inhibitors. May result in serious symptomatic bradycardia when co-administered w/ amiodarone in combination w/ another direct acting antiviral.
Polyethylene Glycol	\n\n\tIncepta\tAqualax Powder 3350  85gm bot 120\n\tIndication: Constipation, faecal impaction.\n\nDose: The usual dose  is 17 gm of powder per day (or as directed by physician) in a glass of water, juice, coke, coffee or tea. \nEach bottle  is supplied with a cup that is used to measure 17 gm or 8.5 gm of laxative powder when filled upto the marked line. \n\nContra-indication: Polyethylene glycol is contraindicated in patients with known or suspected bowel obstruction and patients known to be allergic to polyethylene glycol.\n\nSide effects: Nausea, abdominal bloating, cramping and flatulence may occur. High doses may produce diarrhea and excessive stool frequency, particularly in elderly nursing home patients. Patients taking other medications containing polyethylene glycol have occasionally developed urticaria suggestive of an allergic reaction.\n\nPrecaution: Patients with symptoms suggestive of bowel obstruction (nausea, vomiting, abdominal pain or distention) should be evaluated to rule out this condition before initiating therapy.It should be administered after being dissolved in water, juice, coke, coffee or tea.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Carboxymethylcellulose Sodium 0.25% + Hypromellose 0.3% Eye prep	\n\n\tIncepta\tLubric Extra Eye Drops  1's pack 150\n\tOpso Saline Ltd.\tAqua Eye Drops (250 mg + 300 mg) / 100 m  \n\tIndication: Relieve the dryness and pain associated with reduced or abnormal tear production.\n\nDose: For Adults and Children: Instill 1 or 2 drops in the affected eye(s) as needed.\n\nContra-indication: Known sensitivity or allergy to any ingredient of the formulation.\n\nSide effects: - Blurred vision.\n- Matting or stickiness of eyelashes.\n\nPrecaution: If you experience eye pain, changes in vision, continued redness or irritation of the eye or if your symptoms continue for more than 3 days or become worse, check with your doctor .\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Alcaftadine	\n\n\tAristopharma\tCaftadin Eye Drops 250 mg/100 ml  \n\tGeneral\tGenacaft Eye Drops 250 mg/100 ml  \n\tIncepta\tAlcafta Eye Drops  5ml bot 400\n\tPopular\tAlcadin Eye Drops 0.25% 5 ml plastic dropper bottle 400\n\tIndication: Prevention of itching associated with allergic conjunctivitis. \n\nDose: Instill one drop in each eye once daily. \n\nContra-indication: Alcaftadine eye drop is contraindicated in patients who are hypersensitive to any component of this product.\n\nSide effects: Reported side effects are irritation, burning, eye redness, itching etc. Other side effects are headache, ocular pruritus and nasopharyngitis.\n\nPrecaution: The drug should not be instilled while wearing contact lenses. If hypersensitivity reaction occurs after instillation patients should be advised to discontinue the use of Alcaftadine and consult with physicians.\n\nMode of action: None well documented.\n\nPregnancy category: B\n\nInteraction: None well documented.
Insulin degludec + Insulin aspart 70/30 premixed	\n\n\tNovo Nordisk\tRyzodeg FlexTouch Injection 100IU/ml  \n\tIndication: Treatment of diabetes mellitus in adults.\n\nDose: Adult: SC: This is a soluble insulin product consisting of the basal insulin degludec and the rapid-acting prandial insulin aspart.\nThis can be administered once- or twice-daily with the main meal(s). When needed, the patient can change the time of administration as long as this insulin is dosed with the largest meal when taken once daily.\nIn patients with type 2 diabetes mellitus this insulin can be administered alone, in combination with oral anti-diabetic medicinal products, and in combination with bolus insulin.\nIn type 1 diabetes mellitus, this insulin is combined with short-/rapid-acting insulin at the remaining meals.\nThis is to be dosed in accordance with the individual patientâs needs. Dose-adjustments are recommended to be primarily based on fasting plasma glucose measurements.\n\nInitiation\nPatients with type 2 diabetes mellitus\nThe recommended total daily starting dose is 10 units with meal(s) followed by individual dosage adjustments.\nPatients with type 1 diabetes mellitus\nThe recommended starting dose is 60â70% of the total daily insulin requirements. This is to be used once-daily at meal-time in combination.\n\nRenal and hepatic impairment\nThiss insulin can be used in renal and hepatic impaired patients. Glucose-monitoring is to be intensified and the insulin dose adjusted on an individual basis.\n\n\nContra-indication: Hypersensitivity to the active substances or to any of the excipients.\n\nSide effects: The most frequently reported adverse reaction during treatment is hypoglycaemia.  \nImmune system disorders\nWith insulin preparations, allergic reactions may occur. Immediate-type allergic reactions to either insulin itself or the excipients may potentially be life-threatening.\nWith Ryzodeg, hypersensitivity (manifested with swelling of tongue and lips, diarrhoea, nausea, tiredness and itching) and urticaria were reported rarely.\n\nLipodystrophy\nLipodystrophy (including lipohypertrophy, lipoatrophy) may occur at the injection site. Continuous rotation of the injection site within the particular injection area may help to reduce the risk of developing these reactions.\nInjection site reactions\nInjection site reactions (including injection site haematoma, pain, haemorrhage, erythema, nodules, swelling, discolouration, pruritus, warmth and injection site mass) occurred in patients treated with\nRyzodeg. These reactions are usually mild and transitory and they normally disappear during continued treatment.\n\n\n\nPrecaution: Hypoglycaemia\nOmission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia. Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. Concomitant illness, especially infections and fever, usually increases the patient's insulin requirement. Concomitant diseases in the kidney, liver or diseases affecting the adrenal, pituitary or thyroid gland may require changes in the insulin dose.\n\n\nHyperglycaemia\nAdministration of rapid-acting insulin is recommended in situations with severe hyperglycaemia. Inadequate dosing and/or discontinuation of treatment in patients requiring insulin may lead to hyperglycaemia and potentially to diabetic ketoacidosis. Furthermore, concomitant illness, especially infections, may lead to hyperglycaemia and thereby cause an increased insulin requirement.\n\nEye disorder\nIntensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.\n\nAvoidance of accidental mix-ups\nPatients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Ryzodeg and other insulin products.\n\nOlder patients (? 65 years old)\nRyzodeg can be used in older patients. Glucose-monitoring is to be intensified and the insulin dose adjusted on an individual basis.\n\nPaediatric population\nRyzodeg has been administered to children and adolescents up to 18 years of age for the investigation of pharmacokinetic properties. Safety and efficacy have not been investigated in children and adolescents.\n\n\n\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Indacaterol + Glycopyrronium	\n\n\tNovartis (Bangladesh) Ltd.\tUltibro Breezhaler Dry powder inhalation capsule 110/50 mcg  \n\tIndication: Bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).\n\nDose: (Indacaterol maleate and glycopyrronium bromide) is a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).\nRecommeded Dose: One capsule once daily.\nIndacaterol + Glycopyrronium Breezhaler is recommended to be administered at the same time of the day each day. If a dose is missed, it should be taken as soon as possible on the same day. Patients should be instructed not to take >1 dose in a day.\nSpecial Populations: Renal Impairment: This Breezhaler can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or end-stage renal disease requiring dialysis it should be used only if the expected benefit outweighs the potential risk. \nHepatic Impairment: This Breezhaler can be used at the recommended dose in patients with mild and moderate hepatic impairment. There are no data available for the use of Indacaterol + Glycopyrronium Breezhaler in patients with severe hepatic impairment, therefore caution should be observed in these patients.\nElderly: Indacaterol + Glycopyrronium Breezhaler can be used at the recommended dose in elderly patients (?75 years).\nAdministration: For inhalation use only. The capsules must not be swallowed.\n\n\nContra-indication: Hypersensitivity to indacaterol, glycopyrronium or to any of the excipients of  Indacaterol + Glycopyrronium Breezhaler.\nUse in children: This should not be used in patients <18 years.\n\nSide effects: Upper resp tract infection; nasopharyngitis, UTI, sinusitis, rhinitis; dizziness, headache, cough, oropharyngeal pain including throat irritation, dyspepsia, dental carries, gastroenteritis, musculoskeletal pain, pyrexia & chest pain.\n\nPrecaution: Concomitant use w/ long-acting ?-agonists or long-acting muscarinic antagonists. Not for the treatment of asthma. Immediately discontinue use if hypersensitivity & paradoxical bronchospasm occurs. Narrow-angle glaucoma, urinary retention, CV disorders (CAD, acute MI, cardiac arrhythmia, HTN), convulsive disorders or thyrotoxicosis, severe renal impairment; hypokalaemia; hyperglycaemia. Pregnancy & lactation.\n\nMode of action: Decreases levodopa effects. Effects may be enhanced by using drugs with antimuscarinic properties or MAOIs concurrently. May antagonise the GI effects of cisapride, metoclopramide and dompeidone.\nPotentially Fatal: IV admin in the presence of cyclopropane anesth can result in ventricular arrhythmias.\n\nPregnancy category: A\n\nInteraction: Decreases levodopa effects. Effects may be enhanced by using drugs with antimuscarinic properties or MAOIs concurrently. May antagonise the GI effects of cisapride, metoclopramide and dompeidone.\nPotentially Fatal: IV admin in the presence of cyclopropane anesth can result in ventricular arrhythmias.
Methyl Salicylate 30% + Menthol 10% + Camphor 4% Topical	\n\n\tDrug International Ltd.\tChampion Cream 30% + 10% + 4% 15gm tube \n\tIncepta\tMooverix Cream  1's 130\n\tPacific\tFrefast Cream (4 gm + 10 gm + 30 gm)/10  \n\tSharif\tBangay Ultra Cream  (30 gm + 10 gm + 4 gm)/1 15gm tube 95\n\tIndication: Back pain, shoulder pain, neck pain,  joint pain, arthritis, strains\n\nDose: Only for topical use. Adults and children 12 years of age and older: apply on affected area not more than 3 to 4 times daily. \nChildren under 12 years of age:Â  use on advice of a doctor.\n\nContra-indication: Hypersensitivity to salicylate or any of its ingredients\n\nSide effects: Redness or irritation may occur, especially in persons with sensitive skin. Adverse reactions possibly involved are mild to moderate local irritation, erythema, rash, desquamation, pruritis and relative local reaction at the application site.\n\nPrecaution: Avoid contact with the eyes and mucous membranes. Do not bandage tightly, wrap or cover until washing the area. It should not be applied to wounds or damaged skin. It should not be used immediately after bath. Wash hand thoroughly after applying.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Iron Polymaltose Complex (Elemental Iron) + Folic Acid + Zinc	\n\n\tAristopharma\tIpec PLUS TAB dr   100'pack 350\n\tConcord\tHemax- TR CAP  30's pack 90\n\tDrug International Ltd.\tFerotab TAB dr 48 mg + 500 mcg + 61.8 mg  \n\tIbn Sina Pharmaceutical Ind. Ltd.\tZepiron TAB dr  30's pack 90\n\tNIPRO JMI Pharma\tIrobest TAB dr 48 mg + 500 mcg + 61.8 mg  \n\tReman Drug Ltd.\tRefol Z TR CAP   30's pack 87.30\n\tSquare\tZiliron TAB dr  60's pack 180\n\tIndication: Dietary supplement, Iron, Folic Acid and Zinc deficiency especially during pregnancy and lactation.\n\nDose: One capsule daily. In more severe cases, 2 capsules a day may be required or as directed by the physician.\n\nContra-indication: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Care should be taken in patients who may develop iron overload, such as those with haemochromatosis, haemolytic anaemia or red cell aplasia. Iron chelates with tetracycline and absorption may be impaired.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Brinzolamide 1%  +  Brimonidine Tartrate 0.2%	\n\n\tAristopharma\tZoladin Eye Drops (10mg + 2mg)/ml 5ml bot 484.03\n\tGeneral\tGenazopt Plus Eye Drops 1 gm + 200 mg /100 ml  \n\tPopular\tBenozol BR Eye drops 1% + 0.2% 5ml bot 484.03\n\tIndication: Open-angle glaucoma, Ocular hypertension\n\nDose: The recommended dose is one drop in the affected eye(s) 2-3 times daily.\n\nContra-indication: This eye drops are contraindicated in patients who are hypersensitive to any component of this product.\n\nSide effects: Conjunctivitis; keratitis; burning or stinging; eyelid inflammation or irritation; blurred vision; corneal erosion; headache; dizziness; paraesthesia; nausea; bitter taste; epistaxis; fatigue; dyspepsia; dry mouth; chest pain; haemoptysis; dyspnoea; rhinitis; pharyngitis; bronchitis; depression; dermatitis; alopoecia.\n\nPrecaution: Hepatic and renal impairment; pregnancy. Efficacy has not been established in angle-closure glaucoma. Ensure an interval of at least 10 minutes between admin of different ophthalmic solutions. Patients wearing soft contact lenses should wait for at least 15 min after instilling brimonidine tartrate before inserting soft contact lenses. \n\nGeneral Brimonidine ophthalmic solution 0.2% should be used with caution in patients with known hypersensitivity to other alpha-adrenoceptor agonists. Although brimonidine had minimal effect on blood pressure and heart rate of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. \n\nMode of action: Brinzolamide: Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.\n\nBrimonidine Tartrate: Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with ?-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.\n\n\nPregnancy category: A\n\nInteraction: Brinzolamide: Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.\n\nBrimonidine Tartrate: Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with ?-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.\n
Refined Soyabean Oil + Purified Egg Lecithin + Glycerol (10% fat emulsion)	\n\n\tPopular\tFatisol IV injection 10g+1.2g+2.25g 100ml/250ml/500ml tube 800.85/510.43/334.42\n\tIndication:     Parenteral nutrition\n    Preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required;\n    Nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis);\n    Burns, to reduce the frequently excessive nitrogen losses; Prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible;\n    Impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown;\n    Cachexia and Patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.\n\n\nDose: Total Parenteral nutrition: As a part of TPN, administer IV via a peripheral vein or by central venous catheter. Fat emulsion should comprise no more than 60% of the patient's total caloric intake, with carbohydrates and amino acids comprising the remaining 40% or more of caloric intake. \n\nAdult: Initial infusion rate is 1ml/min for the first 15 to 30 mins. If no adverse reactions occur, the infusion rate can be increased to 2 ml/min. Infuse only 500 ml the first day and increase dose the following day. Do not exceed a daily dosage of 2.5 g/kg. \nChildren: Initial infusion rate is 0.1ml/min for the first 10 to 15 mins. If no adverse reactions occur, the infusion rate can be increased to 1g/kg in 4 hours. Do not exceed a daily dosage of 3 g/kg. \nInfants: Starts at 0.5g/kg/24 hours and may be increased in relation to the infant's ability to eliminate fat. The maximum recommended dosage is 3g/kg/24 hours. \nFatty acid deficiency: To correct EFAD, supply 8% to 10% of the caloric intake by IV fat emulsion to provide an adequate amount of linoleic acid. \n\nContra-indication: It is contraindicated in conditions with severely disordered fat metabolism, such as in severe liver damage and acute shock. Hypersensitivity to egg-, soya- or peanut protein or to any of active substances or excipients.\n\nSide effects: This may cause a rise in body temperature (incidence <3%) and, less frequently, shivering, chills and nausea/vomiting (incidence <1%). Reports of other adverse events in conjunction with 10% fat emulsion infusion are extremely rare, less than one report of certain events per one million infusions. Hypersensitivity reactions (anaphylactic reaction, skin rash, urticaria), respiratory symptoms (tachypnoea) and circulatory effects (hypertension, hypotension) have been described. \nThrombosis, haemolysis, reticulocytosis, abdominal pain, tiredness, priapism and neurological adverse reactions including headaches, flushing, dyspnoea, slight pressure over the eyes and dizziness have been reported.\n\nPrecaution: This contains soya oil and egg lecithin which may rarely cause allergic reactions. Cross allergic reaction has been observed between soya-bean and peanut. Fat metabolism may be disturbed in conditions such as renal insufficiency, uncompensated diabetes, pancreatitis, certain forms of liver insufficiency, metabolic disorders and sepsis. Fatisol should be administered with caution as a strong correlation exists between C-reactive protein and the agglutination of Fatisol in seriously ill patients. \n\nIt should be given with caution to neonates and premature infants with hyperbilirubinaemia and in cases with suspected pulmonary hypertension. In low birthweight infants, the risk of lipid infusions may outweigh potential benefits due to further diminution of defences against infection. In infants, metabolism of lipids in peripheral tissues may be diminished by infection and heparin administration. In neonates receiving long term parenteral nutrition, particularly premature neonates, platelet count, liver function tests and serum triglyceride concentration should be monitored. Use in Pregnancy & Lactation: Absolute safety of the foetus and the nursing infant has not been established. Therefore,it should be administered with caution during pregnancy and lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Carboxymethylcellulose Sodium	\n\n\tAristopharma\tDrylief Eye Drops 10mg 10ml bot \n\tAsiatic Ltd.\tRefresh Tear Eye Drops 10 mg/ml 15ml 255\n\tEskayef Bangladesh Ltd.\tRefresh Liquigel Eye Drops 1% 15ml bot 504\n\tIbn Sina Pharmaceutical Ind. Ltd.\tI-Fresh Eye Drops 10 mg/ml  \n\tIndication: For the temporary relief of burning, irritation and discomfort due to dryness of the eye or exposure to wind or sun.\nMay be used as a protectant against further irritation.\n\n\nDose:  For drops/gels: Instill 1 or 2 drops in the affected eye(s) as needed.\n\nContra-indication: It is contraindicated in patients with known hypersensitivity to any ingredient of this formulation.\n\nSide effects: Vision may be temporarily blurred when this product is first used. Also, minor burning/stinging/irritation may temporarily occur.\n\nPrecaution: For external use only.  If you experience eye pain, changes in vision, continued redness or irritation of the eye or if your symptoms continue for more than 3 days or become worse, check with your doctor .\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Eucalyptol + Menthol + Methyl Salicylate + Thymol + Sodium Fluoride	\n\n\tSquare\tOrostar Plus Mouthwash 120ml/250ml 120ml/250ml 85/150\n\tIndication: Dental cavities/Tooth decay, Bad breath, Dental plaque, Gingivitis\n\n\nDose: Adults and children 6 years of age and older: Rinse full strength for 1 minute with 10 ml in morning and night. Do not swallow. Children under 6 years of age: Consult a dentist or doctor.\n\nContra-indication: Hypersensitivity;\n\nSide effects: Do not rinse, eat, or smoke for thirty minutes after using a mouthwash. Doing so will diminish the effects of the mouthwash.\n\nPrecaution: Do not swallow. It is not indicated below 12 years of age. Keep out of the reach of children. Keep in a cool and dry palace. Do not use if cap seal is broken. \n\nMode of action: \n\nPregnancy category: Not Classified\n\nInteraction: 
Multivitamin with L-Lysine	\n\n\tOpsonin Pharma\tFirmvit TAB dr   \n\tIndication: Improve appetite and growth of children, Promotes muscle growth, weight gain and calcium retention, Ensures good eye sight, Necessary for the normal process in protein, fat carbohydrate metabolism, RBC formation and proper cell functioning, Increases the carnitine which is responsible of energy production\n\nDose: Children: 1-3 Tablet daily. Adult: 2-3 Tablet daily\n\nContra-indication: This is contraindicated in patients with pre-existing hypervitaminosis or known hypersensitivity to any of the active ingredients.\n\nSide effects: Generally well tolerated. \n\nPrecaution: Anaphylactic reactions may occur in allergic subjects who are susceptible to Thiamine (Vitamin B1) and nicotinamide components of this product. Due to glychocolic acid content, repeated and prolonged administration in patients with jaundice of hepatic origin or severe biochemical evidence of cholestatis requires careful monitoring of liver function. Also in the case of impaired kidney function, fat-soluble vitamin levels should be carefully monitored.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Ambrisentan	\n\n\tSquare\tAmbrisan TAB dr 5mg  \n\tSquare\tAmbrisan TAB dr 10mg  \n\tIndication: Pulmonary Arterial Hypertension\n\nDose: Initiate treatment at 5 mg once daily, and consider increasing the dose to 10 mg once daily if 5 mg is tolerated. \n\nDose adjustment of Letairis in patients with mild or moderate renal impairment is therefore not required. There is no information on the exposure to ambrisentan in patients with severe renal impairment.\n\nIt is not recommended in patients with moderate or severe hepatic impairment.\n\n\nContra-indication: Ambrisentan  may  cause  fetal  harm  when  administered  to  a  pregnant  woman.  Ambrisentan  is  contraindicated  in  women  who  are  or  may  become  pregnant.  If  this  drug  is  used  during  pregnancy,  or  if  the  patient  becomes  pregnant  while  taking this drug, the patient should be apprised of the potential hazard to a fetus.  Pregnancy must be excluded before the initiation of treatment with Ambrisentan  and  prevented  during  treatment  and  for  one  month  after  stopping  treatment. Ambrisentan is contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF) including IPF patients with pulmonary hypertension (WHO Group 3).\n\nSide effects: Most common adverse reactions are peripheral edema, nasal congestion, sinusitis, and flushing. Decreases  in  hemoglobin  concentration  and  hematocrit  have  followed  administration  of  other endothelin  receptor  antagonists  and  were  observed  in  clinical studies with Ambrisentan.\n\n\n\nPrecaution: Fluid Retention: Peripheral edema is a known class eÂ¬ect of endothelin receptor antagonists, and is also a clinical consequence of PAH and worsening PAH. \nPulmonary Veno-occlusive Disease: If patients develop acute pulmonary edema during initiation of therapy with vasodilating agents such as Ambrisentan, the possibility of pulmonary veno-occlusive disease should be considered, and if confirmed. Ambrisentan should be discontinued. \nHematological Changes: Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Ambrisentan. \nHepatic impairment: Ambrisentan is not recommended in patients with moderate or severe hepatic impairment.\n\n\n\n\nMode of action: Cyclosporine\nExposure to ambrisentan may be increased (approximately 2-fold). Limit the dosage of ambrisentan to 5 mg daily with coadministration.\n\nRifampin\nCoadministration was associated with a 2-fold increase in ambrisentan AUC. Use with caution.\n\nPregnancy category: X\n\nInteraction: Cyclosporine\nExposure to ambrisentan may be increased (approximately 2-fold). Limit the dosage of ambrisentan to 5 mg daily with coadministration.\n\nRifampin\nCoadministration was associated with a 2-fold increase in ambrisentan AUC. Use with caution.
Hydralazine	\n\n\tIndication: Severe Essential Hypertension, Hypertensive Crisis, \n\nDose: Severe Essential Hypertension\n20-40 mg IM/IV; repeat as necessary\n\nHypertensive Crisis\n20-40 mg IV/IM; repeat PRN\n\nPregnancy-associated\n 5-10 mg IV/IM initially, THEN 5-10 mg q20-30min PRN, OR\n 0.5-10 mg/hr IV infusion\n\n\nContra-indication: Hypersensitivity to hydralazine, Coronary artery disease, Mitral valve rheumatic heart disease.\n\nSide effects: Common\n\nHeadache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris.\nLess Frequent\n\nDigestive: constipation, paralytic ileus.\n\nCardiovascular: hypotension, paradoxical pressor response, edema.\n\nRespiratory: dyspnea.\n\nNeurologic: peripheral neuritis evidenced by paresthesia, numbness, and tingling, dizziness: tremors; muscle cramps; psychotic reactions characterized by depression, disorientation, or anxiety.\n\nGenitourinary: difficulty in urination.\n\nHematologic: blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura, lymphadenopathy; splenomegaly.\n\nHypersensitive Reactions: rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and, rarely, hepatitis.\n\nOther: nasal congestion, flushing, lacrimation, conjunctivitis.\n\nPrecaution: May induce SLE-type syndrome (usually at >200 mg/day); instruct patients to report joint/chest pain or fever; consider discontinuation if occurs\n\nUse caution in CVA, severe renal impairment, volume depletion, preexisting hypotension, concurrency with other hypotensive agents, CAD (potential contraindication)\n\nDiscontinue slowly to avoid rapid rise in blood pressure\n\nIncreases fluid and sodium retention; may require treatment or increase in diutretic dose\n\nPeripheral neuritis reported; treat symptoms with pyridoxine\n\nMode of action: Hypotensives, diazoxide, NSAIDs, oestrogens, sympathomimetics.\n\nPregnancy category: C\n\nInteraction: Hypotensives, diazoxide, NSAIDs, oestrogens, sympathomimetics.
Multivitamin-Multimineral A-Z preparations for Juniors	\n\n\tIncepta\tProviten JR Syrup  100ml /200ml 100ml /200ml bot 90/160\n\tOpsonin Pharma\tZovia Jr Chewable TAB dr   \n\tIndication: Vitamin/mineral supplement \n\nDose: One chewable tablet daily or as recommended by the physician.\nInfants up to 1 year: 1 tea-spoon daily Children 1-4 years: 1-2 tea-spoons daily Children 4-12 years: 2-3 tea-spoons daily Adult : 3-4 tea-spoons daily\n\n\nContra-indication: Patients with a known hypersensitivity to any of the ingredients.\n\nSide effects: Generally well tolerated. However, a few allergic reactions may be seen.\n\nPrecaution: Supplement should not be used in over dosage or continiously except reccomended by the physicians.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Silodosin	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tRapasin CAP 4mg  \n\tIndication: Treating the signs and symptoms of enlarged prostate (benign prostatic hyperplasia [BPH]). \n\nDose: Adults\nPO 8 mg once daily with a meal.\n\nAdults Renal impairment (CrCl 30 to 50 mL/min)\n\nPO 4 mg once daily with a meal.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Retrogade ejaculation, thirst, diarrhea, orthostatic hypotension, dizziness, headache, asthenia, insomnia, nasal congestion, nasopharyngitis, rhinorrhea, sinusitis and abdominal pain.\n\nPrecaution: Impaired hepatic & renal function. Start treatment w/ a low dose (2 mg/dose).\n\nMode of action:  	Ketoconazole, digoxin.\n\nPregnancy category: B\n\nInteraction:  	Ketoconazole, digoxin.
Dapagliflozin propanediol	\n\n\tConcord\tDapazin TAB dr 5mg 20âs pack \n\tIncepta\tDapaglip 5 TAB dr 5mg  \n\tIndication: Type 2 diabetes mellitus\n\nDose: Initial dose: 5 mg orally once a day\nMaximum dose: May increase to 10 mg orally once a day in patients tolerating therapy with 5 mg and requiring additional glycemic control\n\nRenal Impairment: No dosage adjustment is indicated based on renal function.\nThe efficacy  is dependent on renal function.It is not recommended for use in patients with moderate to severe renal impairment (patients with CrCl <60 mL/min or eGFR <60 mL/min/1.73 m2).\n\nContra-indication: Hypersensitivity to dapagliflozin propanediol or to any of the excipients. Moderate to severe renal impairment; end-stage renal disease; active bladder cancer. Pregnancy (2nd & 3rd trimester) & lactation.\n\nSide effects: Hypoglycemia, genital infections, UTI, back pain, dysuria, polyuria, dyslipidemia.\n\nPrecaution: CV disease; history of hypotension. Monitor vol status & electrolytes. UTI. Childn. Elderly.\n\nMode of action: Hypoglycemia may occur w/ concomitant use w/ insulin & insulin secretagogues eg sulfonylureas. Decrease in Cmax & AUC w/ rifampin. Increase in Cmax & AUC w/ mefenamic acid. Increased thiazide & loop diuretic effects; may increase risk of dehydration & hypotension. Pioglitazone.\n\n\n\nPregnancy category: C\n\nInteraction: Hypoglycemia may occur w/ concomitant use w/ insulin & insulin secretagogues eg sulfonylureas. Decrease in Cmax & AUC w/ rifampin. Increase in Cmax & AUC w/ mefenamic acid. Increased thiazide & loop diuretic effects; may increase risk of dehydration & hypotension. Pioglitazone.\n\n
Lurasidone	\n\n\tSquare\tLuraprex TAB dr 40mg  \n\tIndication: Schizophrenia & bipolar depression.\n\nDose: Schizophrenia 	40 mg â 160 mg once daily\nBipolar depression 	20 mg once daily 	\n\nModerate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum \nrecommended dose is 80 mg per day.\n . \n\nContra-indication: Hypersensitivity. Concurrent administration of strong CYP3A4 inhibitors (eg, Ketoconazole). Concurrent \nadministration of strong CYP3A4 inducers (eg, Rifampin). Dementia-related psychosis.\n\nSide effects: Somnolence, akathisia, extrapyramidal symptoms, parkinsonism; insomnia; dizziness, dystonia; agitation, anxiety; fatigue, restlessness (4%).and nausea.\n\nPrecaution: Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis: Increased incidence of  cerebrovascular adverse events (e.g., stroke, transient ischemic attack). \n\nNeuroleptic malignant syndrome: Manage with immediate discontinuation and close monitoring. \n\nTardive dyskinesia: Discontinue if clinically appropriate. \n\nMetabolic changes:  Atypical antipsychotic drugs have been associated with metabolic changes that may \nincrease cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain.  \n\nHyperglycemia and diabetes mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, \npolyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes.\n\nDyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.\n\nWeight Gain: Gain in body weight has been observed. Monitor weight. \n\nHyperprolactinemia: Prolactin elevations may occur. \n\nLeukopenia, neutropenia and agranulocytosis:  Perform complete blood counts (CBC) in patients with a \npre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider discontinuing Lurasidone if a clinically significant decline in WBC occurs in the absence of other causative factors. \n\nOrthostatic hypotension and syncope: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.  In patients with known cardiovascularor cerebrovascular disease, and in antipsychotic-naÃ¯ve patients, consider a lower starting dose and slower titration.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Sertaconazole	\n\n\tIndication: Tinea pedis\n\nDose: Topical/Cutaneous\nTinea pedis\nAdult: As 2% cream: Apply to affected area bid for 4 wk.\n\nContra-indication: Hypersensitivity.\n\nSide effects: Contact dermatitis, dry skin, burning skin, application site reaction, skin tenderness, erythema, pruritus, vesiculation, desquamation, hyperpigmentation.\n\nPrecaution: Discontinue if irritation or sensitivity develop. Pregnancy and lactation. Monitoring Parameters Reassess diagnosis if no clinical improvement after 2 wk.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Estradiol	\n\n\tRenata\tGynova TAB dr 2mg  \n\tIndication: Moderate to severe vasomotor symptoms associated with menopause, Prophylaxis of osteoporosis in postmenopausal women, Hypogonadism, Atrophic vaginitis\n\nDose: Oral\nModerate to severe vasomotor symptoms associated with menopause\nAdult: 1-2 mg/day adjusted as necessary; admin can be cyclical (3 wk on, 1 wk off) or continuous. In conjunction with a progestogen in women with uterus. \n\nProphylaxis of osteoporosis in postmenopausal women\nAdult: 0.5 mg/day in cyclic regimen (23 days on and 5 days off). \n\nHypogonadism\nAdult: 1-2 mg/day in a cyclic regimen for 3 wk on drug, followed by 1 wk drug-free.\n\nVaginal\nAtrophic vaginitis\nAdult: Initial: Insert 1 tab (20 mcg) once daily for 2 wk. Maintenance: Insert 1 tab twice wkly. Attempt to discontinue or taper medication at 3-6 mthly intervals.\n\n\nContra-indication: Hypersensitivity; undiagnosed vag bleeding; thrombophloebitis or thromboembolic disorders; breast carcinoma except in selected patients being treated for metastatic disease; oestrogen-dependent tumor; porphyria; pregnancy.\n\nSide effects: GI disturbances, genitourinary changes, haematologic disorders, CV and CNS effects, endocrine and metabolic disorders, cholestatic jaundice, local skin reactions, chorea, contact lens intolerance, steeping of corneal curvature, pulmonary thromboembolism, carbohydrate intolerance.\n\nPrecaution: Conditions exacerbated by fluid retention; hypercalcaemia, cerebrovascular diorders, coronary artery disease, gall bladder diseases; lipid effects; familial defects of lipoprotein metabolism. May increase BP, risk of venous thromboembolism, breast cancer, benign hepatic adenoma, endometrial cancer and size of preexisting uterine leiomyomata. Dosage should be reduced in hepatic impairment. Lactation. Child.\n\nMode of action: CYP1A2 and CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together.\n\nPregnancy category: X\n\nInteraction: CYP1A2 and CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital, and rifampin may decrease the effects of estradiol. May enhance the effects of hydrocortisone and prednisolone when used together.
Calcium Carbonate + Calcium Lactate + Vitamin-C	\n\n\tIndication: Osteoporosis, Calcium and vitamin C deficiency, Hypocalcaemia, Calcium supplement, Osteomalacia\n\nDose: Adults and children above 7 years: 1 effervescent tablet daily.\nChildren 3 to 7 years : 1/2 effervescent tablet daily, \nInfants : As prescribed by the physician. Dissolve one tablet in half glass (100 ml) of water.\n\nContra-indication: Absolute contraindications are hypercalcaemia resulting from myeloma, bone metastases or other malignant bone disease, sarcoidosis; primary hyperparathyroidism and Vitamin-D overdosage. It is also contraindicated in severe renal failure and hypersensitivity to any of the tablet ingredients.\n\nSide effects: The use of Calcium supplements has rarely given rise to mild gastrointestinal disturbances, such as constipation, flatulence, nausea, gastric pain and diarrhoea.\n\nPrecaution: Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. Periodic checks of plasma Calcium levels and urinary Calcium excretion should be made in patients with mild to moderate renal failure or mild hypercalciuria. In patients with a history of renal stones urinary Calcium excretion should be measured to exclude hypercalciuria. \nWith long-term treatment it is advisable to monitor serum and urinary Calcium levels and kidney function, and reduce or stop treatment temporarily if urinary Calcium exceeds 7.5 mmol/24 hours. \n\nMode of action: Calcium Carbonate: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nCalcium Lactate: May reduce the efficacy of calcium-channel blockers. Concurrent admin of IV calcium salt with cardiac glycosides may lead to serious adverse events. Increased risk of hypercalcaemia when used with thiazide diuretics. May reduce absorption of tetracycline, alendronate, atenolol, iron, quinolone antibiotics, sodium fluoride and zinc.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n\n\nPregnancy category: C\n\nInteraction: Calcium Carbonate: Co-administration with thiazide diuretics or vit D may lead to milk-alkali syndrome and hypercalcaemia. Decreased absorption with corticosteroids. Decreases absorption of tetracyclines, atenolol, iron, quinolones, alendronate, Na fluoride, Zn and calcium-channel blockers. Enhances cardiac effects of digitalis glycosides and may precipitate digitalis intoxication.\n\nCalcium Lactate: May reduce the efficacy of calcium-channel blockers. Concurrent admin of IV calcium salt with cardiac glycosides may lead to serious adverse events. Increased risk of hypercalcaemia when used with thiazide diuretics. May reduce absorption of tetracycline, alendronate, atenolol, iron, quinolone antibiotics, sodium fluoride and zinc.\n\nVit C: Deferroxamine, hormonal contraceptives, flufenazine, warfarin, elemental iron, salicylates, warfarin, fluphenazine, disulfiram, mexiletine, vitamin B12.\n
Iloperidone	\n\n\tBeacon\tIlodon TAB dr 2mg  \n\tBeacon\tIlodon TAB dr 6mg  \n\tIndication: Schizophrenia\n\nDose: Schizophrenia\n\nDay 1: 1 mg PO q12hr; increase qDay to effective dose of 6-12 mg PO q12hr\n\nDay 2: 2 mg PO q12hr, THEN increase qDay by 2 mg/day to effective dose of 6-12 mg PO q12hr; not to exceed 24 mg/day\n\nMust gradually increase dose to avoid orthostatic hypotension\n\nRenal impairment: Unlikely to have a significant impact since <1% of drug is excreted unchanged in urine\n\nContra-indication: Hypersensitivity.\n\nSide effects: >10%\nDizziness (20%), Dry mouth (15%), Nausea (10%), Somnolence (10%), Tachycardia (12%)\n1-10% (selected)\nDiarrhea, Ejaculation failure, Myalgia, Nasal congestion, Orthostatic hypotension, Palpitations, Urinary incontinence, Weight gain \n\n\nPrecaution: This drug is not approved for the treatment of patients with dementia-related psychosis. \nProlongs QT interval; caution with other drugs/conditions that increase QTc.\nNot recommended in hepatic impairment.\nRisk of neuroleptic malignant syndrome and extrapyramidal symptoms.\nMay cause anticholinergic side effects (eg., confusion, agitation).\nBlood dyscrasias (leukopenia, neutropenia, agranulocytosis) may occur.\nOrthostatic hypotension may occur.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
lactase	\n\n\tAristopharma\tLaczyme Chewable TAB dr 300mg  \n\tIndication: Lactose Intolerance, Infant Colic\n\nDose: Adult:\nLactose Intolerance\n\nTake 3,000-9,000 units PO with meals or dairy\n\nChild:\n\nLactose Intolerance\n\nTake 3,000-9,000 units PO with meals or dairy\n\nInfant Colic\n\nBreast milk\n\n    Express a few tablespoons of breast milk into a sterilized container\n    Add 4 drops of lactase infant drops\n    Give mixture to infant on a spoon or oral syringe before initiating breastfeeding\n    Breast feed as normal\n\n\nContra-indication: \n\nSide effects: \n\nPrecaution: Some products may contain aspartame and should be avoided in patients with phenylketonuria.\n\nHas not been evaluated by the FDA, but is generally recognized as safe (GRAS) for human consumption.\n\nMode of action: None\n\nPregnancy category: A\n\nInteraction: 
Ledipasvir + Sofosbuvir	\n\n\tBeximco\tLesovir-C TAB dr 90 mg + 400 mg  \n\tIncepta\tTwinvir TAB dr 90/400mg 6's \n\tIndication: Chronic hepatitis C (CHC) genotype 1, 4 & 6 infection in adults.\n\nDose: Recommended dosage: One tablet (90 mg of Ledipasvir and 400 mg of Sofosbuvir) taken orally once daily with or without food.\n\nRecommended treatment duration:\nTreatment-naÃ¯ve with or without cirrhosis: 12 weeks\nTreatment-experienced without cirrhosis: 12 weeks\nTreatment-experienced with cirrhosis: 24 weeks\n\nA dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease.\n\n\nContra-indication: Hypersensitivity.\n\nSide effects: The most common adverse reactions with treatment with Ledipasvir and Sofosbuvir combination for 8, 12, or 24 weeks are fatigue and headache.\n\nPrecaution: Bradycardia with Amiodarone coadministration: Serious symptomatic bradycardia may occur in patients taking Amiodarone, particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. Coadministration of Amiodarone with Ledipasvir and Sofosbuvir combination is not recommended. In patients without viable treatment options, cardiac monitoring is recommended.\n\nUse with other drugs containing sofosbuvir, is not recommended.\n\n\nMode of action: Reduced therapeutic effect w/ drugs that are potent P-gp inducers in the intestine (eg rifampicin, St. John's wort, carbamazepine & phenytoin), modafinil, phenobarb/oxcarbazepine, rifabutin/rifapentine. P-gp &/or BCRP inhibitors. May result in serious symptomatic bradycardia when co-administered w/ amiodarone in combination w/ another direct acting antiviral.\n\nPregnancy category: B\n\nInteraction: Reduced therapeutic effect w/ drugs that are potent P-gp inducers in the intestine (eg rifampicin, St. John's wort, carbamazepine & phenytoin), modafinil, phenobarb/oxcarbazepine, rifabutin/rifapentine. P-gp &/or BCRP inhibitors. May result in serious symptomatic bradycardia when co-administered w/ amiodarone in combination w/ another direct acting antiviral.
Snake Venom Antiserum	\n\n\tIncepta\tAntivenom Injection  10ml vial 1000\n\tIndication: Snake Venom Antiserum  is  indicated  for  bites  caused  by  Cobra,  Common  Krait,  Russell's  Viper  and  Saw-Scaled \nViper, where the patient presents with one or more of fallowing visible clinical signs and symptoms of \nenvenomation â \n\n1. Local envenomation-\na) Presence of bite marks with or without oozing of blood, blistering and change in color of skin.\nb) Rapidly progressive or massive swelling involving more than half of the bitten limb within few hours \nof bite (without tourniquet)\nc) Development of enlarged tender lymph nodes draining the bitten part within couple of hours after \nbite\n\n2. Systemic envenomation-\na) Neurotoxic syndrome- signs of neuro-paralysis like blurring of vision, double vision, and difficulty in \nswallowing, sleepy feeling, drooping of head, slurring of speech and the voice may become indistinct \nwith shallow breathing, ptosis, ataxia, respiratory paralysis and generalized flaccid paralysis.\n\nb)  Hemotoxic  syndrome-  spontaneous  systemic  bleeding,  nausea,  vomiting,  abdominal  pain  and \nabdominal tenderness suggestive of gastro-intestinal or retro-peritoneal bleed and/or renal damage, \ncoagulopathy detected by 20 min WBCT with or without external bleeding and shock.\n\nDose: Initial dose depends upon an estimate of the amount of envenomation as mentioned below:\n1. Minimal Envenomation -Progressive local swelling but no systemic symptoms.  5 vials (50ml) is recommended to be administered.\n2. Moderate  Envenomation -Swelling  beyond  the  site  of  the  bite,  mild  systemic  symptoms,  and/or hematologic and coagulation abnormalities are present. 5 to 10 vials (50 to 100ml) is recommended to be administered.\n3. Severe  Envenomation -Rapidly  progressive  and  extensive  local  effects,  systemic  symptoms  and evidence  of  hemolysis  or  coagulopathy.  10  to  20  vials  (100 -200ml)  or  more  is  recommended  to  be administered.\n\nIn  children  and  small  adults  (body  weight  less  than  40kg)  upto  50%  more  doses  of  Snake    Venom Antiserum is recommended to be administered.\n\nADMINISTRATION:\nSnake Venom Antiserum is administered intravenously either  undiluted at the rate of not more than 1ml per  minute  or  is  diluted  in  500ml  of  intravenous  fluid  (either  Sodium  Chloride  Injection  or  5%  Dextrose Injection) and  administered  as  rapidly  as  tolerated  over  1-2  hours.  While diluting the Snake Venom Antiserum, mix by gentle swirling rather than shaking to avoid foaming.\nAdditional  infusions  should  be  repeated  hourly  until  progressive  swelling  in  the  bitten  part  ceases  and systemic  signs  and  symptoms  disappear.  When an adequate dosage is achieved, the improvement in patient's clinical signs are often seen.\n\n\nContra-indication: There are no known contraindications for the administration of Antivenom. Person who is proven to be allergic to equine antisera.\n\nSide effects: a) The immediate reaction (shock & anaphylaxis) usually occurs within 30 minutes. Symptoms and signs may develop before the needle is withdrawn and include urticaria, itching, fever, chills or rigor, nausea, vomiting, diarrhoea, abdominal cramps, tachycardia, hypotension, bronchospasm, and angioedema.\n\nb)  Serum sickness usually occurs 5 to 24 days after administration.  The  usual symptoms  and  signs  are  fever,  urticaria,  edema,  nausea  and  vomiting.  Occasionally neurological manifestations develop. Pain and muscle weakness are frequently present.\n\n\nPrecaution: Proper  precautions  are  necessary  while  dealing  with  persons  with  a  known  hypersensitivity  to \nconstituents of product. Few doctors prefer to premedicate patients with Inj. Adrenaline 0.25 ml s/c to \nprevent  possibility  of  adverse  reactions.  In  haemotoxic  bites,  IM  injections  should  be  avoided  till \ncorrection of coagulopathy to avoid formation of haematoma and oozing of blood.\n\nNot for local administration on bitten area.\n\nIn   patients   having   tourniquet,   it   should   be   released   slowly   only   after   start   of  Antivenom \nadministration.\n\nMode of action: Increased risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin.\n\nPregnancy category: Not Classified\n\nInteraction: Increased risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin.
Brinzolamide + Timolol	\n\n\tGeneral\tGenazopt Eye Drops (1 gm + 500 mg)/100 ml  \n\tIndication: Treatment of elevated IOP in open-angle glaucoma or ocular HTN when monotherapy is insufficient.\n\nDose: 1 drop into the affected eye(s) twice daily.\n\nContra-indication: Bronchial asthma, severe COPD, sinus bradycardia, 2nd or 3rd degree AV block, overt cardiac failure, cardiogenic shock, severe allergic rhinitis, bronchial hyperreactivity, hyperchloraemic acidosis, severe renal impairment.\n\nSide effects: Dysgeusia, blurred vision, eye pain & irritation, foreign body sensation.\n\nPrecaution: Control cardiac failure prior to therapy. History of severe cardiac & resp disease. Patients subject to hypoglycemia or labile insulin-dependent diabetes. May mask hyperthyroidism or worsen Prinzmetal's angina, severe peripheral & central circulatory disorders & hypotension. \n\nHistory of atopy or severe anaphylactic reaction to a variety of allergens. Avoid concomitant use of 2 local ?-adrenergic blockers or 2 local carbonic anhydrase inhibitors. Close monitoring of IOP in patients w/ pseudoexfoliative or pigmentary glaucoma. Narrow-angle glaucoma. Monitor patients w/ compromised corneas eg patients w/ DM or corneal dystrophies. \n\nRemove contact lenses prior to application; reinsert after 15 min. May impair ability to drive or operate machinery. Pregnancy. Childn <18 yr.\n\nMode of action: Brinzolamide: Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.\n\nTimolol: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).\n\n\nPregnancy category: A\n\nInteraction: Brinzolamide: Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.\n\nTimolol: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).\n
Hydrocortisone  + Lidocaine rectal prep	\n\n\tIncepta\tAnacaine HC Cream (5 mg + 30 mg)/gm  \n\tIndication: Relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area.\n\nDose: Apply BID in and around the anal opening in a thin layer using an applicator.\n\nContra-indication: Patients with a history of hypersensitivity to any of its ingredients.\n\nSide effects: Rare side effects like Rectal bleeding, Swelling of the skin, Adrenal suppression, Anaphylaxis , Angioedema, Cushing syndrome, Hirsutism, Acne, Cutaneous and subcutaneous atrophy , Dry scaly skin, Urticaria.\n\n\nPrecaution: If extensive areas are treated, the possibility of systemic absorption exists. Systemic absorption of topical steroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushingâs syndrome, hyperglycemia, and glycosuria in some patients. If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy.\n\nMode of action: This cream should be used with caution together with dental injection anaesthesia, other local anaesthetics or agents structurally related to local anaesthetics of amide type eg, antiarrhythmic drugs (eg, mexiletine), as the toxic effects of these drugs are additive.\nPatients treated with class III antiarrhythmic drugs (eg, amiodarone) should be closely observed and ECG monitoring should be considered, as the cardiac effects of lidocaine and class III antiarrhythmic drugs can be additive.\nDrugs that inhibit the metabolism of lidocaine (eg, cimetidine or ?-blockers) may cause potentially toxic plasma concentrations when lidocaine is given in repeated high doses over a long time period. Such interactions are of no clinical importance following short-term treatment with lidocaine at recommended doses.\n\n\nPregnancy category: C\n\nInteraction: This cream should be used with caution together with dental injection anaesthesia, other local anaesthetics or agents structurally related to local anaesthetics of amide type eg, antiarrhythmic drugs (eg, mexiletine), as the toxic effects of these drugs are additive.\nPatients treated with class III antiarrhythmic drugs (eg, amiodarone) should be closely observed and ECG monitoring should be considered, as the cardiac effects of lidocaine and class III antiarrhythmic drugs can be additive.\nDrugs that inhibit the metabolism of lidocaine (eg, cimetidine or ?-blockers) may cause potentially toxic plasma concentrations when lidocaine is given in repeated high doses over a long time period. Such interactions are of no clinical importance following short-term treatment with lidocaine at recommended doses.\n
Carbetocin	\n\n\tRenata\tArbecin Injection 100 mcg/ml  \n\tIndication: Prophylaxis of uterine atony and excessive bleeding after caesarean section\n\nDose: Intravenous\nProphylaxis of uterine atony and excessive bleeding after caesarean section\nAdult: Single dose of 100 mcg given over 1 min after delivery.\n\nContra-indication: Do not administer before delivery. Vascular disease esp coronary artery disease; hepatic or renal disease.\n\nSide effects: Nausea; vomiting; abdominal pain; pruritus; flushing; feeling of warmth; hypotension; headache; tremor; back pain; dizziness; metallic taste; anaemia; sweating; chest pain; dyspnoea; chills; tachycardia; anxiety.\n\nPrecaution: Monitor BP in eclampsia and preeclampsia for up to 8 hrs. Inadequate uterine contraction (do not repeat treatment). Epilepsy; migraine; asthma.\n\nMode of action: Vasoconstrictors in conjunction with caudal block anaesthesia; cyclopropane anaesthesia.\n\nPregnancy category: Not Classified\n\nInteraction: Vasoconstrictors in conjunction with caudal block anaesthesia; cyclopropane anaesthesia.
Canagliflozin	\n\n\tDrug International Ltd.\tCanarol TAB dr 100mg  \n\tNIPRO JMI Pharma\tInvocana TAB dr 100mg  \n\tSquare\tCanaglif TAB dr 100mg 10's pack 600\n\tZiska\tCanaflo TAB dr 100mg  \n\tIndication: Type 2 diabetes mellitus\n\nDose: Adults ?18 years: Recommended Dose: 100 mg PO once daily taken before the first meal of the day\n\nMay increase dose to 300 mg once daily in patients tolerating 100 mg/day who have an eGFR ?60 mL/min/1.73 mÂ² and require additional glycemic control.\n\nRenal impairment\n\n    eGFR ?60 mL/min/1.73 mÂ²: No dosage adjustment required\n    eGFR 45 to <60 mL/min/1.73 mÂ²: Do not exceed 100 mg/day\n    eGFR <45 mL/min/1.73 mÂ²: Do not initiate canagliflozin\n    Discontinue if eGFR declines below 45 mL/min/1.73 mÂ²\n\n\nContra-indication: History of a serious hypersensitivity reaction and hypersensitivity to canagliflozin.\nSevere renal impairment (eGFR <30 mL/min/1.73 m2), end stage renal disease or patients on dialysis.\n\nSide effects: Female genital mycotic infections (10.4-11.4%)\n\nIncreased urination (4.6-5.3%)\n\nMale genital mycotic infections (3.7-4.2%)\n\nVulvovaginal pruritus (1.6-3%)\n\nThirst (2.3-2.8%)\n\nConstipation (1.8-2.3%)\n\nNausea (2.2-2.3%)\n\nAbdominal pain (1.7-1.8%)\n\nVolume depletion\n\nOverall population (2.3-3.4%)\nAge >75 yr (4.9-8.7%)\neGFR <60/mL/min/1.73 mÂ³ (4.7-8.1%)\nUse of loop diuretic (3.2-8.8%)\n\n\n\nPrecaution: Causes intravascular volume contraction and symptomatic hypotension can occur, particularly if eGFR <60 mL/min/1.73 mÂ²2, advance age, existing low systolic BP, or taking either diuretics or drugs that interfere with renin-angiotensin-aldosterone system (RAS) (eg, ACE inhibitors, ARBs).\n\nDrug increases serum creatinine and decreases eGFR, patients with hypovolemia are more susceptible to renal function impairment.\n\nHyperkalemia reported; patients with moderate renal impairment who take potassium-sparing diuretics or drugs that alter RAS are more likely to develop hyperkalemia.\n\nHypoglycemia risk increased with insulin and insulin secretagogues, adjust dose.\n\nGenital mycotic infections may occur, patients with history of genital mycotic infections and uncircumcised males are more susceptible.\n\nHypersensitivity reactions (eg, generalized urticaria), some serious, were reported during clinical trials.\n\nDose-related increases in LDL-C reported.\n\nNo conclusive evidence of macrovascular risk reduction with canagliflozin or any other antidiabetic agent.\n\nSGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests; use alternative methods to monitor glycemic control.\n\nThe FDA continues to investigate reports of ketoacidosis associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors (ie, canagliflozin, dapagliflozin, empagliflozin); monitor for signs of ketoacidosis and advise patients to seek immediate medical attention for symptoms (eg, difficulty breathing, nausea, vomiting, abdominal pain, confusion, unusual fatigue or sleepiness).\n\nIncreased risk of bone fracture, occurring as early as 12 weeks after treatment initiation, reported; consider factors that contribute to fracture risk prior to initiating therapy.\n\nHigher risk of falls for patients treated within first few weeks of treatment reported.\n\nMode of action: Decreased efficacy w/ rifampicin. Increase AUC & Cmax of digoxin (not clinically meaningful).\n\nPregnancy category: C\n\nInteraction: Decreased efficacy w/ rifampicin. Increase AUC & Cmax of digoxin (not clinically meaningful).
Thalidomide	\n\n\tIncepta\tMidothal CAP 50mg  \n\tIndication: Multiple myeloma, Erythema nodosum leprosum\n\nDose: Oral\nErythema nodosum leprosum (Type 2)\nAdult: 100-300 mg once daily at bedtime, reduced gradually by 50 mg every 2-4 wk once a satisfactory reponse is achieved. Not for monotherapy if moderate or severe neuritis present. Max: 400 mg/day. Patients < 50 kg: Initially, 100 mg daily.\n\nMultiple myeloma\nAdult: Initial dose of 200 mg once daily, increased by 100 mg at wkly intervals according to patient tolerance. Max: 800 mg daily.\n\nContra-indication: Hypersensitivity. Pregnancy and lactation.\n\nSide effects: Severe and irreversible peripheral neuropathy, constipation, dizziness, orthostatic hypotension, drowsiness, somnolence, bradycardia, increase of viral load in HIV-infected patients, hypersensitivity reaction.\n\nPotentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis and blood dyscrasias.\n\nPrecaution: All females of childbearing potential must use 2 reliable forms of contraception simultaneously 4 wk before starting therapy, during and 4 wk after therapy is discontinued. Therapy to be stopped immediately if pregnancy occurs. \n\nMale: Use of barrier methods of contraception if partner is of child-bearing potential. Do not donate blood or sperm during therapy. Patient should not drive or operate machinery. Discontinue therapy if any skin rash develops. Do not resume therapy if the rash is exfoliative, purpuric, or bullous, or if Stevens-Johnson syndrome or toxic epidermal necrolysis suspected.\n\nMode of action: Thalidomide enhances sedative activity of barbiturates, alcohol, chlorpromazine and reserpine. Avoid use of other drugs that have the potential to cause peripheral neuropathy. Increased risk of thromboembolic events with darbepoetin-alfa and doxorubicin.\nPotentially Fatal: Increased risk of bone marrow supression with peg interferon alfa.\n\nPregnancy category: X\n\nInteraction: Thalidomide enhances sedative activity of barbiturates, alcohol, chlorpromazine and reserpine. Avoid use of other drugs that have the potential to cause peripheral neuropathy. Increased risk of thromboembolic events with darbepoetin-alfa and doxorubicin.\nPotentially Fatal: Increased risk of bone marrow supression with peg interferon alfa.
Azilsartan Medoxomil	\n\n\tNIPRO JMI Pharma\tAzisart TAB dr 40mg  \n\tNIPRO JMI Pharma\tAdarbi TAB dr 40mg  \n\tRenata\tAzisan TAB dr 40mg  \n\tRenata\tAzisan TAB dr 80mg  \n\tIndication: Treatment of Hypertension, alone or in combination w/ other antihypertensive agents.\n\nDose: Adult: Initially 40 mg once daily. May be increased to a max of 80 mg once daily as necessary.\n\nRenal Impairment\n\nNo dose adjustment is required with mild-to-severe renal impairment or end-stage renal disease.\nPatients with moderate-to-severe renal impairment are more likely to report high serum creatinine values.\n\n\nContra-indication: Hypersensitivity. Pregnancy (2nd & 3rd trimester).\n\nSide effects: Hypotension/orthostatic hypotension. Diarrhea. Nausea; asthenia, fatigue; muscle spasm; dizziness, postural dizziness; cough.\n\nPrecaution: Correct vol or salt depletion prior to administration. Renal (moderate to severe) & hepatic (severe) impairment. Pregnancy (1st trimester) & lactation. Childn <18 yr.\n\nMonitor serum K in patients taking K-sparing diuretics, salt substitutes containing K & drugs that increase K levels (eg heparin) & creatinine levels in patients w/ renal impairment & type 2 DM. Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy.\n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Daclatasvir	\n\n\tBeacon\tDaclavir TAB dr 60mg  \n\tIncepta\tVirodacla TAB dr 60mg  \n\tJulphar Bangladesh Ltd.\tDaclacee TAB dr 60mg  \n\tIndication: Chronic hepatitis C virus infection in adults.\n\nDose: Adult: Indicated for use with sofosbuvir for chronic hepatitis C virus (HCV) genotype 3 infection: 60 mg (plus sofosbuvir 400 mg) PO qDay for 12 weeks.\n\nMay take with or without food.\n\nRenal impairment (any degree): No dose adjustment required.\n\nContra-indication: Hypersensitivity. Co-administration w/ strong CYP3A4 inducers & P-gp eg phenytoin, carbamazepine, oxcarbazepine, phenobarb, rifampicin, rifabutin, rifapentine, systemic dexamethasone, St. John's wort.\n\nSide effects: Fatigue, headache, nausea.\n\nPrecaution: Patients w/ genotype 1 infection & compensated cirrhosis; receiving amiodarone; decompensated liver disease; prior exposure to a NS5A inhibitor; pre-, peri- or post-liver transplant or other organ transplant; HIV/HCV, HBV co-infected patients. \nRare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May impair ability to drive or operate machinery. Women of childbearing potential. Pregnancy & lactation. Childn & adolescents <18 yr.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Vardenafil	\n\n\tEskayef Bangladesh Ltd.\tValenty TAB dr 10mg  \n\tEskayef Bangladesh Ltd.\tValenty TAB dr 20mg  \n\tIndication: Erectile dysfunction\n\nDose: Oral\nErectile dysfunction\nAdult: Initially, 10 mg taken 60 minutes before sexual activity. Adjust subsequent doses according to response. Max: 20 mg as a single dose. Max frequency: Once daily. Sexual stimulation needed for response to therapy.\n\nElderly: ?65 yr: Initially 5 mg 60 minutes before sexual activity, increased to 10 mg then 20 mg if needed.\n\nRenal impairment: Haemodialysis: Avoid.\nCrCl (ml/min)	Dosage Recommendation\n<30	Initial dose 5 mg, increased to 10 mg then 20 mg if needed.\n\nHepatic impairment: Child Pugh A-B (mild to moderate) impairment: Initiate with 5 mg. Max dose in moderate impairment: 10 mg. Child-Pugh C (severe impairment): No studies done.\n\nSpecial Populations: Patients stabilised on alpha-blocker therapy: max daily dose 5 mg and not to be taken within 6 hr of the ?-blocker (except tamsulosin). Patients on erythromycin: Max: 5 mg daily.\n\nContra-indication: Known prolongation of QT interval (congenital or acquired); men for whom sexual intercourse is inadvisable due to CV risk factors; hypotension (systolic <90 mm Hg); hypertension (systolic >170 mm Hg or diastolic >110 mm Hg); recent stroke or MI (within last 6 mth); unstable angina; severe heart failure; end-stage renal disease requiring dialysis; severe hepatic impairment; known degenerative retinal disorders e.g. retinitis pigmentosa. Women, child.\n\nSide effects: Dyspepsia, vomiting, headache, flushing, dizziness, visual disturbances, colour vision changes, raised intra-ocular pressure, nasal congestion, hypersensitivity reactions, nausea, photosensitivity reactions, hypotension, hypertension, priapism, palpitations, myalgia, increased creatinine kinase, sudden decrease or loss of hearing, tinnitus.\n\nPrecaution: Anatomical deformation of the penis; predisposition to priapism e.g. sickle cell anaemia, multiple myeloma, or leukaemia; bleeding disorders or active peptic ulceration; left ventricular outflow obstruction; elderly (? 65 yr). \n\nDiscontinue and seek medical advice if there is sudden vision loss or decreased vision in one or both eyes or tinnitus, dizziness or sudden loss or decrease in hearing, while taking vardenafil. May cause dizziness or abnormal vision so avoid driving or operating machinery until effects of vardenafil is known. Seek immediate medical advice if erection last > 4 hr.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Betamethasone + Clotrimazole + Gentamicin Topical	\n\n\tAristopharma\tAristoderm Cream (50 mg + 1 gm + 100 mg)/1  \n\tIndication: Allergic inflammatory skin disease (acute & chronic eczema, contact dermatitis, atopic dermatitis, seborrheic dermatitis, chronic simple lichen, intertrigo, exfoliative dermatitis, papular urticaria, psoriasis, pruritus vulvae, pruritus ani, dermatitis solaris; skin mycosis (athlete's foot, trichophytia); tinea versicolor; insect bite and skin disease by secondary bacterial infection.\n\nDose: Apply thin film to affected skin areas  2 times daily. Limit treatment to less than 45g per week.\n\nDuration of therapy varies depending upon the extent and location of disease and patient response. However, if clinical improvement is not achieved by 3-4 weeks, diagnosis should be reviewed.\n\nContra-indication: Hypersensitivity to any of the ingredients.\nTuberculosis and most viral lesion of the skin, particularly herpes simplex, vaccinia and varicella.\n\nSide effects: Continuous application without interruption may result in local atrophy of the skin, striae and superficial vascular dilation. Rarely, patients may experience local mild burning or irritation.\n\nTopical use of gentamicin may cause ototoxicity and/or nephrotoxicity when Gentriderm is applied to large burned areas or for extended periods of time, especially in patients with renal insufficiency or when administered concurrently with other drugs that are potentially ototoxic or nephrotoxic.\n\nPrecaution: Similar effect to systemic steroid therapy may occur in large amount use or long-term therapy by occlusive dressing technique (ODT). Local adverse effect eg, skin atrophy, facial erythema may occur. Manifestations hypersensitivity eg, itching, flare, vesicle and urticaria may occur. Discontinue using  if these reactions occur. Do not use in overdosage or ODT in prolonged period of therapy.\n\nDo not use in the eyes. Propyleneglycol, which is an inactive ingredient of Gentriderm, can cause allergic reaction.\n\nDiscontinue use in case of no improvements or condition worsens; as soon as possible improvements happen.\n\nUse in pregnancy & lactation.\n\nMode of action: None\n\nPregnancy category: Not Classified\n\nInteraction: 
Bismuth subsalicylate	\n\n\tUnimed & Unihealth Manufacturers Ltd.\tPepto-Care Suspension 1.75 gm/100 ml  \n\tZiska\tPink-Bismol Suspension 17.5 mg/ml 1's (200 ml) 95\n\tIndication: Diarrhea, nausea, heartburn, indigestion, and upset stomach.\n\nDose: Adult: 300 ml 3-4 times daily 30 mintues before meal.\nChild: 3-12 years: 5-15 ml\n\nContra-indication: Hypersensitivity to bismuth, aspirin, other salicylates.\n\nInfectious diarrhea, high fever, von Willebrand disease, hemorrhage, ulcer or GI bleeding with black or bloody stool, hemophilia.\n\nIn pediatric patients, chicken pox or influenza (risk of Reye syndrome); changes in behavior with nausea and vomiting may be early sign of Reye syndrome.\n\nSide effects: Nausea, Diarrhea, Abdominal pain, Melena, Constipation, Anorexia, Vomiting, Asthenia, Discolored tongue, Headache, Dyspepsia, Dizziness, Stool abnormality.\n\nPrecaution: May cause black tongue and/or black stool. \n\nMode of action: None\n\nPregnancy category: D\n\nInteraction: 
Norepinephrine (Noradrenaline)	\n\n\tBeacon\tLevofed Injection 2 mg/2 ml  \n\tIndication: Acute Hypotension, Cardiac Arrest, Sepsis & Septic Shock\n\nDose: Adult:\nAcute Hypotension\nInitial: 8-12 mcg/min IV infusion; titrate to effect\n\nMaintenance: 2-4 mcg/min IV infusion\n\nCardiac Arrest\nInitial: 8-12 mcg/min IV infusion; titrate to effect\n\nMaintenance: 2-4 mcg/min IV infusion\n\nSepsis & Septic Shock\n0.01-3 mcg/kg/min IV infusion\n\nChild:\nAcute Hypotension\nInitial: 0.05-0.1 mcg/kg/min IV infusion; titrate to effect \n\nMaximum: 1-2 mcg/kg/min\n\nCardiac Arrest\nInitial: 0.05-0.1 mcg/kg/min IV infusion; titrate to effect \n\nMaximum: 1-2 mcg/kg/min\n\nShock\n0.05-0.1 mcg/kg/min IV infusion; titrate to effect; not to exceed 2 mcg/kg/min\n\n\n\nContra-indication: Hypersensitivity\n\nHypotension due to blood volume deficit\n\nPeripheral vascular thrombosis (except for lifesaving procedures)\n\nConcomitant use with some general anesthetics: Chloroform, trichloroethylene, cyclopropane, halothane\n\nSide effects: Hypertension, headache, peripheral ischaemia, bradycardia, arrhythmias, anxiety, skin necrosis (with extravasation), dyspnoea, respiratory difficulty.\n\nPrecaution: Not a substitute for replacement of blood, plasma, fluids, and/or electrolytes; correct volume depletion prior to admin. Identify and correct hypoxia, hypercapnia and acidosis prior to or during admin. Avoid extravasation as tissue necrosis may occur. Avoid inj into leg veins, especially in elderly or those with occlusive vascular diseases, arteriosclerosis, DM or Buerger's disease. Hypertensive or hyperthyroid patients. In conjunction with local anaesthetics, do not use in fingers, toes, ears, nose or genitalia. Lactation.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Mirabegron	\n\n\tGeneral\tMirabeg Er TAB dr 25mg  \n\tIndication: Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency\n\nDose: Adults (Including Elderly): Recommended Starting Dose: 25 mg once daily with or without food. Based on individual patient efficacy and tolerability the dose may be increased to 50 mg once daily.\n\nRenal impairment\nSevere (CrCl 15-29 mL/min): Not to exceed 25 mg/day\nESRD: Not recommended\n\nContra-indication: Hypersensitivity\n\nSide effects: Elevated BP, UTI, Tachycardia, Dry mouth, Nasopharyngitis .\n\nPrecaution: End-stage renal disease, severe renal impairment; moderate (Child-Pugh Class B) & severe hepatic impairment (Child-Pugh Class C); severe uncontrolled HTN. Known history of QT prolongation or taking medicines known to prolong QT interval; bladder outlet obstruction & taking antimuscarinic medications for OAB. Women of childbearing potential not using contraception. Pregnancy & lactation. Childn <18 yr.\n\nMode of action: None\n\nPregnancy category: C\n\nInteraction: 
Lymecycline	\n\n\tIncepta\tLymeclin CAP 408mg 12's pack 360\n\tIndication: Treatment of acne vulgaris, brucella, pasteurella, pulmonary, genitourinary, ophth, gonococcal & resp infections, syphilis, Lyme disease, leptospirosis, cholera.\n\nDose: Adult: 1 cap twice daily. Acne 1 cap daily for 15 days. Maintenance: 1 cap every other day.\n\nContra-indication: Hypersensitivity to tetracyclines. Concurrent treatment w/ oral retinoids. Pregnancy & lactation. Childn &lt;12 yr.\n\nSide effects: Dental dyschromia &/or enamel hypoplasia especially in childn &lt;12 yr. GI disturbances; hypersensitivity & photosensitivity reactions; haemolytic anaemia, thrombocytopenia, neutropenia, eosinophilia & other hematologic disorders; extra-renal hyperazotemia.\n\nPrecaution: Avoid exposure to direct sunlight & UV light. Renal & hepatic impairment.\n\nMode of action: Oral retinoids (risk of intracranial HTN). Reduced absorption by Fe prep & antacids. Increased risk of haemorrhage w/ coumarin anticoagulants. Decreased digestive absorption w/ didanosine.\n\nPregnancy category: Not Classified\n\nInteraction: Oral retinoids (risk of intracranial HTN). Reduced absorption by Fe prep & antacids. Increased risk of haemorrhage w/ coumarin anticoagulants. Decreased digestive absorption w/ didanosine.
Aciclovir 5% + Hydrocortisone 1%  Topical	\n\n\tSquare\tVirux HC Cream (5 gm + 1 gm)/100 gm  \n\tIndication: Recurrent herpes labialis (cold sores)\n\nDose: Adults and children >6 years :\nThe cream should be topically applied 5 times per day for 5 days. Therapy should be initiated as early as possible after the first signs and symptoms.\n\nContra-indication: Hypersensitivity.\n\nSide effects: The following most common adverse reactions (&lt; 1%) were local skin reactions like drying or flaking of the skin; burning or tingling, erythema; pigmentation changes, application site reactions including signs and symptoms of inflammation.\n\nPrecaution: Aciclovir and Hydrocortisone should not be used in the eye, inside the mouth or nose, or on the genitals. Patients should seek medical advice when a cold sore fails to heal within 2 weeks.\n\nMode of action: None\n\nPregnancy category: B\n\nInteraction: 
Tetrabenazine	\n\n\tBeacon\tTetrazin TAB dr 12.5mg  \n\tIndication: Movement disorders, Moderate to severe tardive dyskinesia\n\nDose: Oral\nMovement disorders\nAdult: Initially 12.5 mg bid, increased gradually to 12.5-25 mg tid. Max: 200mg daily. If no improvement at max dose for 7 days, drug unlikely to be of benefit.\nElderly: Initially 12.5 mg daily, increased gradually.\n\nOral\nModerate to severe tardive dyskinesia\nAdult: Initially 12.5 mg daily increased gradually according to response.\n\nContra-indication: Hypersensitivity. Lactation.\n\nSide effects: Drowsiness, extrapyramidal symptoms, parkinsonism, depression, orthostatic hypotension, GI disturbances.\nPotentially Fatal: Neuroleptic malignant syndrome (NMS).\n\nPrecaution: May exacerbate symptoms of parkinsonism. Caution to be exercised when driving or performing skilled tasks. Pregnancy.\n\nMode of action: Tetrabenazine should not be given with or within 14 days of discontinuation of MAOI therapy. Blocks action of reserpine. Decreases effects of levodopa and worsen parkinsonism. Increased risk of extrapyramidal side effects when given with amantadine, metoclopramide, antipsychotics.\n\nPregnancy category: C\n\nInteraction: Tetrabenazine should not be given with or within 14 days of discontinuation of MAOI therapy. Blocks action of reserpine. Decreases effects of levodopa and worsen parkinsonism. Increased risk of extrapyramidal side effects when given with amantadine, metoclopramide, antipsychotics.
